FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Ghislin, S
   Deshayes, F
   Middendorp, S
   Boggetto, N
   Alcaide-Loridan, C
AF Ghislin, Stephanie
   Deshayes, Frederique
   Middendorp, Sandrine
   Boggetto, Nicole
   Alcaide-Loridan, Catherine
TI PHF19 and Akt control the switch between proliferative and invasive
   states in melanoma
SO CELL CYCLE
LA English
DT Article
DE melanoma; PHF19; Akt; Oct4; nanog; transmigration
ID GROUP PROTEIN EZH2; BREAST-CANCER; CELL-LINES; EXPRESSION; GENE;
   RECEPTOR; PHOSPHORYLATION; METHYLATION; MIGRATION; ESTROGEN
AB Melanoma tumor cells shift between proliferative and invasive states based on their plasticity and microenvironmental conditions. Our team has shown that melanoma cells, grown as spheroids in a neural cell crest medium, polarize toward an invasive phenotype, characterized by a higher motility, a poor proliferation rate and a gain of pluripotency gene expression (Nanog and Oct4) when compared with cells grown in two dimensions in a serum-contaning medium. In agreement with the phenotypic switching hypothesis, most of these features are reversible. Microarray studies comparing two- vs. three-dimensional cultures revealed the downregulation of a polycomb-like protein, PHF19 (PHD finger protein 19), in the spheroids. As Polycomb proteins are involved in the epigenetic control of gene expression, we hypothesized that PHF19 might play a role in the switch between proliferative and invasive phenotypes. In this report, we show that PHF19 silencing reduces the cell proliferation rate and increases the transendothelial migration capacities of melanoma cell lines. However, PHF19 does not modulate the transcription level of Oct4 and Nanog. In the search of an upstream transcriptional regulator of the above genes, we identified the Akt signaling cascade as an inhibitor of Oct4 and Nanog expression and an activator for PHF19 expression. Through chromatin immunoprecipitation, we further provide evidence that phospho-Akt is part of the transcriptional complex associated to the promoters of all three genes. Our data therefore indicate the role of PHF19 and its upstream regulator, Akt, in the phenotype switch of melanoma cells from proliferative to invasive states.
C1 [Ghislin, Stephanie; Deshayes, Frederique; Middendorp, Sandrine; Alcaide-Loridan, Catherine] Univ Paris Diderot, Team Regulat Reponses Immunitaires, CNRS UMR 7592, Inst Jacques Monod, Paris, France.
C3 Universite Paris Cite; Centre National de la Recherche Scientifique
   (CNRS); CNRS - National Institute for Biology (INSB)
RP Alcaide-Loridan, C (通讯作者)，Univ Paris Diderot, Team Regulat Reponses Immunitaires, CNRS UMR 7592, Inst Jacques Monod, Paris, France.
EM alcaide@ijm.univ-paris-diderot.fr
OI GHISLIN, Stephanie/0000-0001-9456-6782
CR Abdullah C, 2011, CELL CYCLE, V10, P977, DOI 10.4161/cc.10.6.15079
   [Anonymous], MEL RES
   Bhatia S, 2009, ONCOLOGY-NY, V23, P488
   Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018
   Bordonaro M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027308
   Boulay G, 2011, BIOCHEM J, V434, P333, DOI 10.1042/BJ20100944
   Bryant RJ, 2008, PROSTATE, V68, P255, DOI 10.1002/pros.20705
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Caputo E, 2011, CELL CYCLE, V10, P2924, DOI 10.4161/cc.10.17.17068
   Chawla R, 2010, CELL CYCLE, V9, P3305, DOI 10.4161/cc.9.16.12632
   Cheli Y, 2011, ONCOGENE, V30, P2307, DOI 10.1038/onc.2010.598
   Coles AH, 2009, J CELL PHYSIOL, V218, P45, DOI 10.1002/jcp.21583
   Eichhoff OM, 2011, PIGM CELL MELANOMA R, V24, P631, DOI 10.1111/j.1755-148X.2011.00871.x
   Ghislin S, 2011, PIGM CELL MELANOMA R, V24, P504, DOI 10.1111/j.1755-148X.2011.00856.x
   Gonzalez ME, 2009, ONCOGENE, V28, P843, DOI 10.1038/onc.2008.433
   Haqq C, 2005, P NATL ACAD SCI USA, V102, P6092, DOI 10.1073/pnas.0501564102
   Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x
   Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491
   Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x
   Hu TH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-236
   Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222
   Javelaud D, 2011, PIGM CELL MELANOMA R, V24, P932, DOI 10.1111/j.1755-148X.2011.00893.x
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Li J, 2008, CARCINOGENESIS, V29, P1373, DOI 10.1093/carcin/bgn086
   Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433
   Liu Y, 2006, J BIOL CHEM, V281, P31359, DOI 10.1074/jbc.M604478200
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Madhunapantula SV, 2009, PIGM CELL MELANOMA R, V22, P400, DOI 10.1111/j.1755-148X.2009.00585.x
   Martins I, 2007, EUR J IMMUNOL, V37, P788, DOI 10.1002/eji.200636620
   Mitchison TJ, 2012, MOL BIOL CELL, V23, P1, DOI 10.1091/mbc.E10-04-0335
   Monzani E, 2007, EUR J CANCER, V43, P935, DOI 10.1016/j.ejca.2007.01.017
   Mukhopadhyay A, 2008, NAT PROTOC, V3, P698, DOI 10.1038/nprot.2008.38
   Ramgolam K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018784
   Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020
   Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07
   Sun LD, 2007, CELL SIGNAL, V19, P2255, DOI 10.1016/j.cellsig.2007.06.014
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Villares GJ, 2011, ONCOTARGET, V2, P8
   Wang RW, 2006, CELL SIGNAL, V18, P1722, DOI 10.1016/j.cellsig.2006.01.020
   Wang SW, 2004, GENE, V343, P69, DOI 10.1016/j.gene.2004.09.006
   Wei YK, 2011, NAT CELL BIOL, V13, P87, DOI 10.1038/ncb2139
   Wong CE, 2006, J CELL BIOL, V175, P1005, DOI 10.1083/jcb.200606062
NR 43
TC 41
Z9 45
U1 0
U2 14
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4101
EI 1551-4005
J9 CELL CYCLE
JI Cell Cycle
PD APR 15
PY 2012
VL 11
IS 8
BP 1634
EP 1645
DI 10.4161/cc.20095
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 930TC
UT WOS:000303162100026
PM 22487681
OA Bronze
DA 2025-01-12
ER

PT J
AU Ben Gacem, R
   Hachana, M
   Ziadi, S
   Amara, K
   Ksia, F
   Mokni, M
   Trimeche, M
AF Ben Gacem, R.
   Hachana, M.
   Ziadi, S.
   Amara, K.
   Ksia, F.
   Mokni, M.
   Trimeche, M.
TI Contribution of epigenetic alteration of <i>BRCA1</i> and <i>BRCA2</i>
   genes in breast carcinomas in Tunisian patients
SO CANCER EPIDEMIOLOGY
LA English
DT Article
DE Breast cancer; BRCA1; BRCA2; Methylation; Tunisia
ID MAMMARY EPITHELIAL-CELLS; DNA-REPAIR DEFECT; SPORADIC BREAST; PROMOTER
   METHYLATION; OVARIAN-CANCER; CHROMOSOME 13Q12-Q13; HEREDITARY BREAST;
   ESTROGEN-RECEPTOR; TUMORS; HYPERMETHYLATION
AB Objective: The aim of this study was to evaluate the contribution of the BRCA1 and BRCA2 promoter methylation in the pathogenesis of sporadic breast cancer in Tunisian patients. Methods: Breast carcinoma tissues (n = 117) and available paired normal breast tissues (n = 65) from Tunisian women who had no family history were investigated for the methylation status of BRCA1 and BRCA2 promoters using methylation-specific PCR. Breast specimens from women without carcinoma (16 fibroadenomas and 5 mastopathies) were used as control. Results: Hypermethylation of BRCA1 and BRCA2 promoters was detected respectively in 60.7% and 69.2% of the carcinoma tissues, and in only 7.7% and 4.6% of the paired normal breast tissues. None of the fibroadenomas and mastopathies showed hypermethylation. Correlations were found between BRCA1 and BRCA2 hypermethylation and decrease in their mRNA expression (p = 0.02 and p = 0.009, respectively). Moreover, BRCA1 methylation correlates with patients age (p = 0.01) and triple negative (ER-, PR-, HER2-) tumors (p = 0.01). Patients with methylated BRCA1 and/or BRCA2 had a significant prolonged survivals compared to those with unmethylated tumors (p = 0.002). Conclusion: Our results suggest an important role of BRCA1 and BRCA2 promoter methylation in breast cancer development in the Tunisian population. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Ben Gacem, R.; Hachana, M.; Ziadi, S.; Amara, K.; Ksia, F.; Mokni, M.; Trimeche, M.] Farhat Hached Hosp, Dept Pathol, Sousse 4000, Tunisia.
C3 Universite de Sousse; Hopital Farhat Hached
RP Trimeche, M (通讯作者)，Farhat Hached Hosp, Dept Pathol, Sousse 4000, Tunisia.
EM m_trimech@yahoo.fr
OI HACHANA, Mohamed Ridha/0000-0003-0991-8857; Amara,
   Khaled/0000-0002-5584-4441
FU Ministere de l'Enseignement Superieur, de la Recherche Scientifique et
   Technologie; "Ministere de la Sante Publique" of Tunisia
FX This work was supported by the "Ministere de l'Enseignement Superieur,
   de la Recherche Scientifique et Technologie" and the "Ministere de la
   Sante Publique" of Tunisia.
CR Arver B, 2000, SEMIN CANCER BIOL, V10, P271, DOI 10.1006/scbi.2000.0325
   Baranovskaya S, 2001, P NATL ACAD SCI USA, V98, P15107, DOI 10.1073/pnas.251234498
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Ben Ahmed S, 2004, SANTE PUBLIQUE, V14, P231
   Bièche I, 1999, ONCOGENE, V18, P5232, DOI 10.1038/sj.onc.1202903
   Bieche I, 1997, BRIT J CANCER, V76, P1416, DOI 10.1038/bjc.1997.572
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Butcher DT, 2007, EUR J CANCER, V43, P210, DOI 10.1016/j.ejca.2006.09.002
   Catteau A, 2002, SEMIN CANCER BIOL, V12, P359, DOI 10.1016/S1044-579X(02)00056-1
   Charef-Hamza S, 2005, CANCER LETT, V224, P185, DOI 10.1016/j.canlet.2004.11.001
   Chen YL, 2009, CANCER SCI, V100, P1663, DOI 10.1111/j.1349-7006.2009.01225.x
   CLETONJANSEN AM, 1995, BRIT J CANCER, V72, P1241, DOI 10.1038/bjc.1995.493
   Collins N, 1997, BRIT J CANCER, V76, P1150, DOI 10.1038/bjc.1997.526
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445
   Feng Jing, 2009, Ai Zheng, V28, P436
   FERLAY J, 2000, IARC CANCERBASE, V5
   Foulkes WD, 2006, FAM CANCER, V5, P135, DOI 10.1007/s10689-005-2832-5
   FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399
   FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630
   Goodheart MJ, 2009, CLIN GENET, V76, P161, DOI 10.1111/j.1399-0004.2009.01207.x
   Gras E, 2001, CANCER-AM CANCER SOC, V92, P787, DOI 10.1002/1097-0142(20010815)92:4<787::AID-CNCR1384>3.0.CO;2-4
   Hachana M, 2009, BREAST CANCER RES TR, V113, P43, DOI 10.1007/s10549-008-9901-z
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hilton JL, 2002, JNCI-J NATL CANCER I, V94, P1396
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Khoo US, 1999, ONCOGENE, V18, P4643, DOI 10.1038/sj.onc.1202847
   Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238
   Lord CJ, 2008, CURR OPIN PHARMACOL, V8, P363, DOI 10.1016/j.coph.2008.06.016
   Lux MP, 2006, J MOL MED, V84, P16, DOI 10.1007/s00109-005-0696-7
   Ma YX, 2006, MOL ENDOCRINOL, V20, P14, DOI 10.1210/me.2004-0488
   Ma YX, 2005, ONCOGENE, V24, P1831, DOI 10.1038/sj.onc.1208190
   Maalej M, 1999, B CANCER, V86, P302
   Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630
   Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8
   Miki Y, 1996, NAT GENET, V13, P245, DOI 10.1038/ng0696-245
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Mirza S, 2007, LIFE SCI, V81, P280, DOI 10.1016/j.lfs.2007.05.012
   Miyamoto K, 2002, JPN J CLIN ONCOL, V32, P79, DOI 10.1093/jjco/hyf020
   [Parkin D.M. International Agency for Research on Cancer International Agency for Research on Cancer], 2003, Cancer in Africa, Epidemiology and Prevention
   Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078
   Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086
   Rosell R, 2006, Bull Cancer, V93, pE101
   SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0
   Schmutzler RK, 1997, INT J CANCER, V74, P322, DOI 10.1002/(SICI)1097-0215(19970620)74:3<322::AID-IJC15>3.3.CO;2-J
   Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725
   Singal R, 2004, ONCOL REP, V12, P631
   Snell C, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1858
   Suijkerbuijk KPM, 2008, ANN ONCOL, V19, P1870, DOI 10.1093/annonc/mdn409
   Swisher EM, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-48
   Tripathi MK, 2005, J BIOL CHEM, V280, P17163, DOI 10.1074/jbc.M501375200
   Troudi W, 2008, CANCER BIOMARK, V4, P11, DOI 10.3233/CBM-2008-4102
   Turner N, 2005, CURR OPIN PHARMACOL, V5, P388, DOI 10.1016/j.coph.2005.03.006
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457
   vandenBerg J, 1996, BRIT J CANCER, V74, P1615, DOI 10.1038/bjc.1996.597
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0
   Xu XR, 2010, BREAST CANCER RES TR, V121, P685, DOI 10.1007/s10549-009-0628-2
   Xu XR, 2009, BREAST CANCER RES TR, V115, P397, DOI 10.1007/s10549-008-0075-5
NR 61
TC 19
Z9 20
U1 0
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1877-7821
EI 1877-783X
J9 CANCER EPIDEMIOL
JI Cancer Epidemiol.
PD APR
PY 2012
VL 36
IS 2
BP 190
EP 197
DI 10.1016/j.canep.2011.09.001
PG 8
WC Oncology; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Public, Environmental & Occupational Health
GA 931SY
UT WOS:000303240800029
PM 21978880
DA 2025-01-12
ER

PT J
AU Song, LB
   Dai, T
   Xie, YJ
   Wang, CJ
   Lin, CY
   Wu, ZQ
   Ying, Z
   Wu, JH
   Li, MF
   Li, J
AF Song, Libing
   Dai, Ting
   Xie, Yingjun
   Wang, Chanjuan
   Lin, Chuyong
   Wu, Zhiqiang
   Ying, Zhe
   Wu, Jueheng
   Li, Mengfeng
   Li, Jun
TI Up-regulation of miR-1245 by c-myc targets BRCA2 and impairs DNA repair
SO JOURNAL OF MOLECULAR CELL BIOLOGY
LA English
DT Article
DE BRCA2; miR-1245; DNA damage; c-myc
ID SPORADIC BREAST-TUMORS; GENOMIC INSTABILITY; MESSENGER-RNAS;
   GENE-EXPRESSION; CANCER; MUTATIONS; PROTEIN; OVEREXPRESSION;
   RECOMBINATION; POPULATIONS
AB BRCA2, a clinical prognostic factor, is significantly up-regulated in mRNA level, while its protein expression is often decreased in sporadic breast cancer. However, how BRCA2 protein expressions are suppressed in these tumors remains unknown. In this study, we demonstrated that miR-1245 directly suppressed BRCA2 3'-UTR and translation, impaired homologous recombination (HR)-mediated repair, reduced DNA damage-induced Rad51 nuclear foci, and rendered cells hypersensitive to gamma-irradiation (IR), ultimately inducing high chromosomal abnormalities in normal breast cells and breast cancer cells. Conversely, inhibiting miR-1245 in breast cancer cells enhanced BRCA2 levels and induced resistance to IR. Furthermore, we demonstrated that c-myc up-regulated miR-1245 expression via direct binding to the miR-1245 promoter, which led to down-regulation of BRCA2 and reduction in HR efficiency. Significantly, miR-1245 levels in primary breast tumors correlated with c-myc overexpression and BRCA2 suppression. These findings uncover a BRCA2 regulatory and signaling pathway in sporadic breast cancer and support a functionally and clinically relevant epigenetic mechanism in cancer pathogenesis.
C1 [Dai, Ting; Wang, Chanjuan; Lin, Chuyong; Wu, Zhiqiang; Li, Jun] Sun Yat Sen Univ, Dept Biochem, Zhongshan Sch Med, Guangzhou 510080, Guangdong, Peoples R China.
   [Song, Libing] Sun Yat Sen Univ, State Key Lab Oncol So China, Dept Expt Res, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China.
   [Xie, Yingjun] Sun Yat Sen Univ, Dept Obstet & Gynecol, Fetal Med Ctr, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China.
   [Ying, Zhe; Wu, Jueheng; Li, Mengfeng] Sun Yat Sen Univ, Dept Microbiol, Zhongshan Sch Med, Guangzhou 510080, Guangdong, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University;
   Sun Yat Sen University
RP Li, J (通讯作者)，Sun Yat Sen Univ, Dept Biochem, Zhongshan Sch Med, Guangzhou 510080, Guangdong, Peoples R China.
EM lijun37@mail.sysu.edu.cn
RI Wang, Shiyao/JLL-7826-2023; Song, LB/AAL-1968-2020; Lin,
   Chuyong/AAA-9931-2020
OI Lin, Chuyong/0000-0003-4887-5386; , Zhe/0000-0002-0080-5402
FU National Natural Science Foundation of China [81071647, 81071762,
   30872930, 81071780, 81030048, 30870963, 30831160517]; Science and
   Technology Department of Guangdong Province, China [S2011020002757];
   Fundamental Research Funds for the Central Universities [10ykzd03]
FX This work was supported by the National Natural Science Foundation of
   China (Nos. 81071647, 81071762, 30872930, 81071780, 81030048, 30870963,
   and 30831160517), the Science and Technology Department of Guangdong
   Province, China (No. S2011020002757), and the Fundamental Research Funds
   for the Central Universities (No. 10ykzd03).
CR Aly A, 2011, J MOL CELL BIOL, V3, P66, DOI 10.1093/jmcb/mjq055
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Bartel DP, 2004, NAT REV GENET, V5, P396, DOI 10.1038/nrg1328
   Bièche I, 1999, ONCOGENE, V18, P5232, DOI 10.1038/sj.onc.1202903
   Brooks TA, 2009, NAT REV CANCER, V9, P849, DOI 10.1038/nrc2733
   Crosby ME, 2009, CANCER RES, V69, P1221, DOI 10.1158/0008-5472.CAN-08-2516
   Egawa C, 2002, INT J CANCER, V98, P879, DOI 10.1002/ijc.10231
   Fackenthal JD, 2007, NAT REV CANCER, V7, P937, DOI 10.1038/nrc2054
   FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749
   Greene F.L., 2002, TNM CLASSIFICATION M, P255
   GUDMUNDSSON J, 1995, CANCER RES, V55, P4830
   Karlsson A, 2003, P NATL ACAD SCI USA, V100, P9974, DOI 10.1073/pnas.1732638100
   King M, 2004, NEW ENGL J MED, V350, P1252, DOI 10.1056/NEJMcibr033528
   Kuttler F, 2006, GENOME DYN, V1, P171, DOI 10.1159/000092507
   Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238
   Li J, 2006, ONCOGENE, V25, P1186, DOI 10.1038/sj.onc.1209153
   Li YJ, 2007, P NATL ACAD SCI USA, V104, P3490, DOI 10.1073/pnas.0610163104
   Li ZD, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-98
   Lio YC, 2004, J BIOL CHEM, V279, P42313, DOI 10.1074/jbc.M405212200
   LOEB LA, 1991, CANCER RES, V51, P3075
   Ludwig T, 2001, ONCOGENE, V20, P3937, DOI 10.1038/sj.onc.1204512
   Luoto KR, 2010, CANCER RES, V70, P8748, DOI 10.1158/0008-5472.CAN-10-0944
   Malone JL, 2009, J PATHOL, V217, P380, DOI 10.1002/path.2458
   Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231
   Moore MJ, 2005, SCIENCE, V309, P1514, DOI 10.1126/science.1111443
   Moskwa P, 2011, MOL CELL, V41, P210, DOI 10.1016/j.molcel.2010.12.005
   Murga M, 2007, CLIN TRANSL ONCOL, V9, P216, DOI 10.1007/s12094-007-0042-3
   Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431
   Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858
   NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840
   Peto J, 1999, J NATL CANCER I, V91, P943, DOI 10.1093/jnci/91.11.943
   Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144
   Prochownik EV, 2008, CURR MOL MED, V8, P446, DOI 10.2174/156652408785747988
   Prochownik EV, 2007, CELL CYCLE, V6, P1024, DOI 10.4161/cc.6.9.4161
   Rahman N, 1998, ANNU REV GENET, V32, P95, DOI 10.1146/annurev.genet.32.1.95
   Ricke RM, 2008, TRENDS GENET, V24, P457, DOI 10.1016/j.tig.2008.07.002
   Sakai W, 2008, NATURE, V451, P1116, DOI 10.1038/nature06633
   Sandberg R, 2008, SCIENCE, V320, P1643, DOI 10.1126/science.1155390
   Schoenfeld AR, 2004, MOL CELL BIOL, V24, P7444, DOI 10.1128/MCB.24.17.7444-7455.2004
   Teng DHF, 1996, NAT GENET, V13, P241, DOI 10.1038/ng0696-241
   Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8
   Valeri N, 2010, P NATL ACAD SCI USA, V107, P6982, DOI 10.1073/pnas.1002472107
   Wang SC, 2001, CANCER RES, V61, P2838
   Wang WX, 2008, CANCER BIOL THER, V7, P1004, DOI 10.4161/cbt.7.7.6409
   Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498
NR 47
TC 39
Z9 44
U1 0
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1674-2788
J9 J MOL CELL BIOL
JI J. Mol. Cell Biol.
PD APR
PY 2012
VL 4
IS 2
BP 108
EP 117
DI 10.1093/jmcb/mjr046
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 930SZ
UT WOS:000303161600007
PM 22158906
OA Bronze
DA 2025-01-12
ER

PT J
AU Ye, M
   Li, DQ
   Zhou, F
   Guo, QS
   Xia, B
AF Ye, Mei
   Li, Dongqing
   Zhou, Feng
   Guo, Qiusha
   Xia, Bing
TI Epigenetic regulation of death-associated protein kinase expression in
   primary gastric cancers from Chinese patients
SO EUROPEAN JOURNAL OF CANCER PREVENTION
LA English
DT Article
DE DAPK; epigenetics; gastric cancer; methylation
ID CPG ISLAND METHYLATION; DAP-KINASE; PROMOTER METHYLATION;
   DOWN-REGULATION; HELICOBACTER-PYLORI; HOMOZYGOUS DELETION;
   BREAST-CANCER; HYPERMETHYLATION; GENE; CARCINOGENESIS
AB Death-associated protein kinase (DAPK) is a novel serine/threonine kinase involved in apoptosis and tumor suppression. Promoter methylation is an important mechanism by which tumor suppressor gene transcription is repressed in cancer cells. Although reduced expression and aberrant methylation of DAPK has been reported in various human cancers, including gastric cancer (GC), the results remain discrepant. We aimed to investigate DAPK mRNA and protein expression in primary GC tissues from Chinese patients and establish a possible relationship between the promoter methylation status and the decreased expression of DAPK. The mRNA level, protein expression, and promoter methylation of DAPK were examined, in the cancer tissues and the corresponding, adjacent nontumor tissues of the 62 GC cases, by RT-PCR, western blotting and methylation-specific PCR, respectively. DAPK mRNA and protein expression in GC tissues was significantly reduced compared with corresponding nontumor tissues (P<0.0001). The methylation frequency of the DAPK promoter in primary GC tissues is significantly higher than in the corresponding nontumor tissues (54.8 vs. 17.7%, P<0.0001). Furthermore, DAPK mRNA expression in tissues containing aberrant promoter methylation was significantly reduced compared with GC tissues with unmethylated DAPK promoter (P<0.0001). Moreover, a significant correlation was demonstrated between the TNM stage and the degree of DAPK promoter methylation in primary GCs (P=0.04). DAPK protein and mRNA expression was reduced in GC tissues of Chinese patients. Diminished expression of DAPK was associated with promoter methylation. European Journal of Cancer Prevention 21:241-246 (C) 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins.
C1 [Ye, Mei; Zhou, Feng; Guo, Qiusha; Xia, Bing] Wuhan Univ, Zhongnan Hosp, Dept Gastroenterol, Hubei Clin Ctr,Sch Med, Wuhan 430071, Hubei Province, Peoples R China.
   [Ye, Mei; Zhou, Feng; Guo, Qiusha; Xia, Bing] Wuhan Univ, Zhongnan Hosp, Key Lab Intestinal & Colorectal Dis, Sch Med, Wuhan 430071, Hubei Province, Peoples R China.
   [Li, Dongqing] Wuhan Univ, Dept Microbiol, Sch Basic Med Sci, Wuhan 430071, Hubei Province, Peoples R China.
C3 Wuhan University; Wuhan University; Wuhan University
RP Xia, B (通讯作者)，Wuhan Univ, Zhongnan Hosp, Dept Gastroenterol, Hubei Clin Ctr,Sch Med, Wuhan 430071, Hubei Province, Peoples R China.
EM bingxia2004@yahoo.com.cn
RI YE, Mei/V-2483-2019; Liu, Dongming/IVH-1284-2023
FU Hubei Science and Technology Foundation [2004AA301C91]; Hubei Nature
   Science Foundation [2007ABA261]; Hubei Clinical Center & Key Laboratory
   of Intestinal and Colorectal Diseases [2008BCC002]
FX This study was supported by a grant (No: 2004AA301C91) from Hubei
   Science and Technology Foundation to Mei Ye and a grant (No: 2007ABA261)
   from Hubei Nature Science Foundation to Mei Ye and Grants from Hubei
   Clinical Center & Key Laboratory of Intestinal and Colorectal Diseases
   (2008BCC002). The authors thank staff members of the Key Laboratory of
   Allergy and Immune-Related Diseases in Wuhan University School of
   Medicine for technical assistance.
CR Chan AWH, 2005, ONCOL REP, V13, P937
   Christoph F, 2006, BRIT J CANCER, V95, P1701, DOI 10.1038/sj.bjc.6603482
   Correa P, 2007, GASTROENTEROLOGY, V133, P659, DOI 10.1053/j.gastro.2007.06.026
   Crew KD, 2006, WORLD J GASTROENTERO, V12, P354, DOI 10.3748/wjg.v12.i3.354
   Dansranjavin T, 2006, ONCOL REP, V15, P1125
   Farinati F, 2008, EUR J CANCER PREV, V17, P195, DOI 10.1097/CEJ.0b013e3282f0bff5
   Gozuacik D, 2006, AUTOPHAGY, V2, P74, DOI 10.4161/auto.2.2.2459
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kang GH, 2003, AM J PATHOL, V163, P1551, DOI 10.1016/S0002-9440(10)63511-0
   Kang GH, 2003, LAB INVEST, V83, P519, DOI 10.1097/01.LAB.0000064704.53132.65
   Kang GH, 2001, CANCER RES, V61, P2847
   Kato K, 2008, INT J CANCER, V122, P603, DOI 10.1002/ijc.23143
   Kawaguchi K, 2004, HUM PATHOL, V35, P1266, DOI 10.1016/j.humpath.2004.07.007
   Kim HC, 2005, J CANCER RES CLIN, V131, P733, DOI 10.1007/s00432-005-0017-0
   Kim WS, 2003, INT J MOL MED, V12, P827
   Kögel D, 2001, BIOESSAYS, V23, P352, DOI 10.1002/bies.1050
   Kuester D, 2007, NEOPLASIA, V9, P236, DOI 10.1593/neo.06802
   Lehmann U, 2002, CANCER RES, V62, P6634
   Lévy D, 2004, CLIN CANCER RES, V10, P3124, DOI 10.1158/1078-0432.CCR-03-0213
   Nuñez F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018562
   Raval A, 2007, CELL, V129, P879, DOI 10.1016/j.cell.2007.03.043
   Satoh A, 2002, BRIT J CANCER, V86, P1817, DOI 10.1038/sj.bjc.6600319
   Schneider-Stock R, 2006, J PATHOL, V209, P95, DOI 10.1002/path.1951
   Simpson DJ, 2002, ONCOGENE, V21, P1217, DOI 10.1038/sj.onc.1205195
   Stevens C, 2007, J BIOL CHEM, V282, P13791, DOI 10.1074/jbc.M605649200
   Sun J, 2001, EUR J CANCER PREV, V10, P61, DOI 10.1097/00008469-200102000-00007
   Tang LP, 2006, DIGESTION, V74, P85, DOI 10.1159/000097623
   Toyooka S, 2003, CLIN CANCER RES, V9, P3034
   Waki T, 2003, CANCER SCI, V94, P360, DOI 10.1111/j.1349-7006.2003.tb01447.x
NR 32
TC 12
Z9 13
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0959-8278
EI 1473-5709
J9 EUR J CANCER PREV
JI Eur. J. Cancer Prev.
PD MAY
PY 2012
VL 21
IS 3
BP 241
EP 246
DI 10.1097/CEJ.0b013e32834c9caa
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 922QW
UT WOS:000302564000005
PM 21979297
DA 2025-01-12
ER

PT J
AU de Volo, CPB
   Alfonsi, M
   Gatta, V
   Novelli, A
   Bernardini, L
   Fantasia, D
   Antonucci, I
   Angelucci, D
   Zori, R
   Stuppia, L
   Chiarelli, F
   Calabrese, G
AF de Volo, Chiara Palka Bayard
   Alfonsi, Melissa
   Gatta, Valentina
   Novelli, Antonio
   Bernardini, Laura
   Fantasia, Donatella
   Antonucci, Ivana
   Angelucci, Domenico
   Zori, Robert
   Stuppia, Liborio
   Chiarelli, Francesco
   Calabrese, Giuseppe
TI 16q22.1 microdeletion detected by array-CGH in a family with mental
   retardation and lobular breast cancer
SO GENE
LA English
DT Article
DE ZFP90; CDH1; Array-CGH
ID DIFFUSE GASTRIC-CANCER; E-CADHERIN; GERMLINE MUTATIONS; UNIPARENTAL
   DISOMY; CDH1; EXPRESSION; GENES; DIAGNOSIS
AB We describe the case of a boy with psychomotor delay and dysmorphic features, with a germline 16q22.1 microdeletion identified by array-CGH. The deletion spans 0.24 Mb and encompasses three genes (ZFP90, CDH3 and CDH1). The deletion has been demonstrated to be inherited from his mother who was affected by lobular breast cancer (LBC) without any other apparently phenotypic features. We suppose that the microdeletion, in particular ZFP90 which is cerebrally expressed, is causative for the boy's phenotype. Mental retardation in the affected boy can recognize several mechanisms such as variable expressivity, non-penetrance, multifactorial/polygenic inheritance, recessive inheritance, a second rearrangement event and epigenetics. Furthermore, we suggest that the deletion of the CDH1, a tumor suppressor gene, involved in hereditary diffuse gastric cancer (HDGC) and LBC predisposed the mother to the carcinoma. (C) 2012 Elsevier B.V. All rights reserved.
C1 [de Volo, Chiara Palka Bayard; Chiarelli, Francesco] Univ G DAnnunzio, Dept Pediat, I-66100 Chieti, Italy.
   [Alfonsi, Melissa; Gatta, Valentina; Fantasia, Donatella; Antonucci, Ivana; Stuppia, Liborio; Calabrese, Giuseppe] Univ G DAnnunzio, Dept Oral Sci Nano & Biotechnol, I-66100 Chieti, Italy.
   [Novelli, Antonio; Bernardini, Laura] IRCCS Casa Sollievo Sofferenza, San Giovanni Rotondo, Italy.
   [Angelucci, Domenico] Univ G DAnnunzio, Unit Pathol, I-66100 Chieti, Italy.
   [Zori, Robert] Univ Florida, Dept Pediat, Div Clin Genet & Metab, Gainesville, FL USA.
   [Stuppia, Liborio] IGM CNR IOR, Bologna, Italy.
   [Calabrese, Giuseppe] Med Genet Spirito Santo Hosp, Pescara, Italy.
C3 G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of
   Chieti-Pescara; IRCCS Casa Sollievo Della Sofferenza; G d'Annunzio
   University of Chieti-Pescara; State University System of Florida;
   University of Florida; Consiglio Nazionale delle Ricerche (CNR);
   Istituto di Genetica Molecolare (IGM-CNR)
RP de Volo, CPB (通讯作者)，Univ G DAnnunzio, Dept Pediat, Via Vestini 31, I-66100 Chieti, Italy.
EM chiarapalka@libero.it
RI Gatta, Valentina/G-5765-2014; Novelli, Antonio/K-4035-2016; Bernardini,
   Laura/H-5360-2016
OI angelucci, domenico/0000-0003-2132-3362; GATTA,
   Valentina/0000-0002-9999-5823; Novelli, Antonio/0000-0002-9037-4297;
   Stuppia, Liborio/0000-0002-6232-0996; Bernardini,
   Laura/0000-0002-3554-2817; palka bayard de volo,
   chiara/0000-0003-3927-6277
CR Bernardini L, 2005, PRENATAL DIAG, V25, P283, DOI 10.1002/pd.1095
   Bertucci F, 2008, ONCOGENE, V27, P5359, DOI 10.1038/onc.2008.158
   Blair V, 2006, CLIN GASTROENTEROL H, V4, P262, DOI 10.1016/j.cgh.2005.12.003
   Fitzgerald RC, 2010, J MED GENET, V47, P436, DOI 10.1136/jmg.2009.074237
   Green AR, 2009, BREAST CANCER RES TR, V113, P59, DOI 10.1007/s10549-008-9905-8
   Guilford P, 2010, GASTRIC CANCER, V13, P1, DOI 10.1007/s10120-009-0531-x
   Hannes FD, 2009, J MED GENET, V46, P223, DOI 10.1136/jmg.2007.055202
   Kaurah P, 2007, JAMA-J AM MED ASSOC, V297, P2360, DOI 10.1001/jama.297.21.2360
   Kohlhase J, 2000, AM J MED GENET, V91, P190, DOI 10.1002/(SICI)1096-8628(20000320)91:3<190::AID-AJMG6>3.0.CO;2-I
   Krepischi-Santos ACV, 2009, CYTOGENET GENOME RES, V125, P1, DOI 10.1159/000218743
   Luedi PP, 2007, GENOME RES, V17, P1723, DOI 10.1101/gr.6584707
   Masciari S, 2007, J MED GENET, V44, P726, DOI 10.1136/jmg.2007.051268
   Nagase T, 2001, DNA RES, V8, P319, DOI 10.1093/dnares/8.6.319
   Oliveira C, 2009, HUM MOL GENET, V18, P1545, DOI 10.1093/hmg/ddp046
   Palacios J, 2008, PATHOBIOLOGY, V75, P85, DOI 10.1159/000123846
   Pharoah PDP, 2001, GASTROENTEROLOGY, V121, P1348, DOI 10.1053/gast.2001.29611
   Sarrió D, 2003, INT J CANCER, V106, P208, DOI 10.1002/ijc.11197
   Schrader KA, 2011, J MED GENET, V48, P64, DOI 10.1136/jmg.2010.079814
   Schwarzbraun T, 2009, J MED GENET, V46, P341, DOI 10.1136/jmg.2008.064972
   Shaffer LG, 2004, HUM REPROD UPDATE, V10, P221, DOI 10.1093/humupd/dmh022
   Slavotinek AM, 2008, HUM GENET, V124, P1, DOI 10.1007/s00439-008-0513-9
   Vissers LELM, 2004, NAT GENET, V36, P955, DOI 10.1038/ng1407
   Yong PJ, 2002, AM J MED GENET, V112, P123, DOI 10.1002/ajmg.10702
NR 23
TC 9
Z9 9
U1 1
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD MAY 1
PY 2012
VL 498
IS 2
BP 328
EP 331
DI 10.1016/j.gene.2012.01.028
PG 4
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 927EA
UT WOS:000302888700028
PM 22326525
DA 2025-01-12
ER

PT J
AU Greathouse, KL
   Bredfeldt, T
   Everitt, JI
   Lin, K
   Berry, T
   Kannan, K
   Mittelstadt, ML
   Ho, SM
   Walker, CL
AF Greathouse, K. Leigh
   Bredfeldt, Tiffany
   Everitt, Jeffrey I.
   Lin, Kevin
   Berry, Tia
   Kannan, Kurunthachalam
   Mittelstadt, Megan L.
   Ho, Shuk-mei
   Walker, Cheryl L.
TI Environmental Estrogens Differentially Engage the Histone
   Methyltransferase EZH2 to Increase Risk of Uterine Tumorigenesis
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID PRENATAL DIETHYLSTILBESTROL EXPOSURE; BISPHENOL-A; NEONATAL EXPOSURE;
   RECEPTOR-ALPHA; REPRODUCTIVE-TRACT; BREAST-CANCER; FEMALE RATS;
   DEVELOPMENTAL EXPOSURE; EARLY-LIFE; METHYLATION
AB Environmental exposures during sensitive windows of development can reprogram normal physiologic responses and alter disease susceptibility later in life in a process known as developmental reprogramming. For example, exposure to the xenoestrogen diethylstilbestrol during reproductive tract development can reprogram estrogen-responsive gene expression in the myometrium, resulting in hyperresponsiveness to hormone in the adult uterus and promotion of hormone-dependent uterine leiomyoma. We show here that the environmental estrogens genistein, a soy phytoestrogen, and the plasticizer bisphenol A, differ in their pattern of developmental reprogramming and promotion of tumorigenesis (leiomyomas) in the uterus. Whereas both genistein and bisphenol A induce genomic estrogen receptor (ER) signaling in the developing uterus, only genistein induced phosphoinositide 3-kinase (PI3K)/AKT nongenomic ER signaling to the histone methyltransferase enhancer of zeste homolog 2 (EZH2). As a result, this pregenomic signaling phosphorylates and represses EZH2 and reduces levels of H3K27me3 repressive mark in chromatin. Furthermore, only genistein caused estrogen-responsive genes in the adult myometrium to become hyperresponsive to hormone; estrogen-responsive genes were repressed in bisphenol A-exposed uteri. Importantly, this pattern of EZH2 engagement to decrease versus increase H3K27 methylation correlated with the effect of these xenoestrogens on tumorigenesis. Developmental reprogramming by genistein promoted development of uterine leiomyomas, increasing tumor incidence and multiplicity, whereas bisphenol A did not. These data show that environmental estrogens have distinct nongenomic effects in the developing uterus that determines their ability to engage the epigenetic regulator EZH2, decrease levels of the repressive epigenetic histone H3K27 methyl mark in chromatin during developmental reprogramming, and promote uterine tumorigenesis. Mol Cancer Res; 10(4); 546-57. (C)2012 AACR.
C1 [Mittelstadt, Megan L.; Walker, Cheryl L.] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Ctr Translat Canc Res, Houston, TX 77030 USA.
   [Everitt, Jeffrey I.] GlaxoSmithKline Inc, Res Triangle Pk, NC USA.
   [Kannan, Kurunthachalam] SUNY Albany, Sch Publ Hlth, New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA.
   [Kannan, Kurunthachalam] SUNY Albany, Sch Publ Hlth, Dept Environm Hlth Sci, Albany, NY USA.
   [Greathouse, K. Leigh; Bredfeldt, Tiffany; Lin, Kevin; Berry, Tia; Walker, Cheryl L.] Univ Texas MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, Smithville, TX USA.
   [Ho, Shuk-mei] Univ Cincinnati, Med Ctr, Dept Environm Hlth, Ctr Environm Genet, Cincinnati, OH 45267 USA.
C3 Texas A&M University System; Texas A&M University College Station; Texas
   A&M Health Science Center; GlaxoSmithKline; Wadsworth Center; State
   University of New York (SUNY) System; University at Albany, SUNY; State
   University of New York (SUNY) System; University at Albany, SUNY;
   University of Texas System; UTMD Anderson Cancer Center; University
   System of Ohio; University of Cincinnati
RP Walker, CL (通讯作者)，Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Ctr Translat Canc Res, 2121 W Holcombe Blvd, Houston, TX 77030 USA.
EM cwalker@ibt.tamhsc.edu
RI Greathouse, Leigh/S-6612-2018; Kannan, Kayambu/I-6919-2016; Lin,
   Kevin/JFS-1634-2023; Kannan, Kurunthachalam/ACA-0037-2022
OI Everitt, Jeffrey/0000-0003-0273-6284; Lin, Kevin/0000-0002-1236-9847;
   Kannan, Kurunthachalam/0000-0002-1926-7456
FU National Institute of Environmental Health Sciences [P30ES006096,
   RC2ES018789, P30ES007784, R01ES008263, 1F32ES016509]; National Institute
   of Child Health and Development [HD046282]; National Cancer Institute
   [P30CA016672]; Graduate School of Biomedical Sciences, University of
   Texas (Smithville, TX)
FX The support for this work was funded by grants from the National
   Institute of Environmental Health Sciences (P30ES006096, RC2ES018789,
   P30ES007784, R01ES008263, and 1F32ES016509), National Institute of Child
   Health and Development (HD046282), and the National Cancer Institute
   (P30CA016672). K. L. Greathouse was supported by the Schissler
   Foundation Fellowship in Human Genetics and Cancer from the Graduate
   School of Biomedical Sciences, University of Texas (Smithville, TX).
CR Adachi T, 2004, FOOD CHEM TOXICOL, V42, P445, DOI 10.1016/j.fct.2003.10.012
   Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367
   Bredfeldt TG, 2010, MOL ENDOCRINOL, V24, P993, DOI 10.1210/me.2009-0438
   BURROUGHS CD, 1990, REPROD TOXICOL, V4, P127, DOI 10.1016/0890-6238(90)90007-I
   Camp EA, 2009, J WOMENS HEALTH, V18, P547, DOI 10.1089/jwh.2007.0580
   Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947
   Chen JR, 2005, J BIOL CHEM, V280, P4632, DOI 10.1074/jbc.M411530200
   Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347
   Choi Kyung-Chul, 2006, Immunology Endocrine & Metabolic Agents in Medicinal Chemistry, V6, P3
   Cook JD, 2005, P NATL ACAD SCI USA, V102, P8644, DOI 10.1073/pnas.0503218102
   Cook JD, 2007, REPROD SCI, V14, P121, DOI 10.1177/1933719106298401
   Couse JF, 2004, TOXICOLOGY, V205, P55, DOI 10.1016/j.tox.2004.06.046
   D'Aloisio AA, 2010, ENVIRON HEALTH PERSP, V118, P375, DOI 10.1289/ehp.0901423
   Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104
   Estève PO, 2006, GENE DEV, V20, P3089, DOI 10.1101/gad.1463706
   FABER KA, 1993, REPROD TOXICOL, V7, P35, DOI 10.1016/0890-6238(93)90007-T
   Fernández M, 2009, ENVIRON HEALTH PERSP, V117, P757, DOI 10.1289/ehp.0800267
   Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200
   Glidewell-Kenney C, 2007, P NATL ACAD SCI USA, V104, P8173, DOI 10.1073/pnas.0611514104
   Greathouse KL, 2008, REPROD SCI, V15, P765, DOI 10.1177/1933719108322440
   Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516
   Howdeshell KL, 1999, NATURE, V401, P763, DOI 10.1038/44517
   Hugo ER, 2008, ENVIRON HEALTH PERSP, V116, P1642, DOI 10.1289/ehp.11537
   Jefferson WN, 2007, REPROD TOXICOL, V23, P308, DOI 10.1016/j.reprotox.2006.11.012
   Kato H, 2003, REPROD TOXICOL, V17, P283, DOI 10.1016/S0890-6238(03)00002-9
   Katsuda S, 2000, TOXICOL APPL PHARM, V165, P217, DOI 10.1006/taap.2000.8940
   Kim MS, 2009, NATURE, V461, P1007, DOI 10.1038/nature08456
   Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Li SF, 1997, CANCER RES, V57, P4356
   Li XR, 2006, J STEROID BIOCHEM, V98, P122, DOI 10.1016/j.jsbmb.2005.08.018
   Mowa CN, 2000, J ENDOCRINOL, V167, P363, DOI 10.1677/joe.0.1670363
   Müller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5
   Newbold RR, 2007, REPROD TOXICOL, V24, P253, DOI 10.1016/j.reprotox.2007.07.006
   Newbold RR, 2009, ENVIRON HEALTH PERSP, V117, P879, DOI 10.1289/ehp.0800045
   Newbold RR, 2001, CANCER RES, V61, P4325
   Nikaido Y, 2005, IN VIVO, V19, P487
   Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109
   Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274
   Prins GS, 2011, REPROD TOXICOL, V31, P1, DOI 10.1016/j.reprotox.2010.09.009
   Prins Gail S, 2008, Fertil Steril, V89, pe41, DOI 10.1016/j.fertnstert.2007.12.023
   Prins GS, 2001, CANCER RES, V61, P6089
   Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200
   Rubin BS, 2001, ENVIRON HEALTH PERSP, V109, P675, DOI 10.2307/3454783
   Sarraf SA, 2004, MOL CELL, V15, P595, DOI 10.1016/j.molcel.2004.06.043
   Schönfelder G, 2004, NEOPLASIA, V6, P584, DOI 10.1593/neo.04217
   Setchell KDR, 1998, AM J CLIN NUTR, V68, p1453S, DOI 10.1093/ajcn/68.6.1453S
   Walker CL, 2005, SCIENCE, V308, P1589, DOI 10.1126/science.1112063
   Walker CL, 2003, GENE CHROMOSOME CANC, V38, P349, DOI 10.1002/gcc.10281
   Walker CL, 2001, CARCINOGENESIS, V22, P2049, DOI 10.1093/carcin/22.12.2049
   Watson CS, 2007, STEROIDS, V72, P124, DOI 10.1016/j.steroids.2006.11.002
   Wise LA, 2005, OBSTET GYNECOL, V105, P167, DOI 10.1097/01.AOG.0000147839.74848.7c
NR 52
TC 120
Z9 135
U1 0
U2 13
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD APR
PY 2012
VL 10
IS 4
BP 546
EP 557
DI 10.1158/1541-7786.MCR-11-0605
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA 925WL
UT WOS:000302792600007
PM 22504913
OA Green Submitted, Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Sharif, T
   Alhosin, M
   Auger, C
   Minker, C
   Kim, JH
   Etienne-Selloum, N
   Bories, P
   Gronemeyer, H
   Lobstein, A
   Bronner, C
   Fuhrmann, G
   Schini-Kerth, VB
AF Sharif, Tanveer
   Alhosin, Mahmoud
   Auger, Cyril
   Minker, Carole
   Kim, Jong-Hun
   Etienne-Selloum, Nelly
   Bories, Pierre
   Gronemeyer, Hinrich
   Lobstein, Annelise
   Bronner, Christian
   Fuhrmann, Guy
   Schini-Kerth, Valerie B.
TI <i>Aronia melanocarpa</i> Juice Induces a Redox-Sensitive p73-Related
   Caspase 3-Dependent Apoptosis in Human Leukemia Cells
SO PLOS ONE
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; BREAST-CANCER CELLS; COLON-CANCER;
   LYMPHOBLASTIC-LEUKEMIA; SRA DOMAIN; IN-VITRO; INDUCTION; EXTRACTS;
   PATHWAY; PROTEIN
AB Polyphenols are natural compounds widely present in fruits and vegetables, which have antimutagenic and anticancer properties. The aim of the present study was to determine the anticancer effect of a polyphenol-rich Aronia melanocarpa juice (AMJ) containing 7.15 g/L of polyphenols in the acute lymphoblastic leukemia Jurkat cell line, and, if so, to clarify the underlying mechanism and to identify the active polyphenols involved. AMJ inhibited cell proliferation, which was associated with cell cycle arrest in G(2)/M phase, and caused the induction of apoptosis. These effects were associated with an upregulation of the expression of tumor suppressor p73 and active caspase 3, and a downregulation of the expression of cyclin B1 and the epigenetic integrator UHRF1. AMJ significantly increased the formation of reactive oxygen species (ROS), decreased the mitochondrial membrane potential and caused the release of cytochrome c into the cytoplasm. Treatment with intracellular ROS scavengers prevented the AMJ-induced apoptosis and upregulation of the expression of p73 and active caspase 3. The fractionation of the AMJ and the use of identified isolated compounds indicated that the anticancer activity was associated predominantly with chlorogenic acids, some cyanidin glycosides, and derivatives of quercetin. AMJ treatment also induced apoptosis of different human lymphoblastic leukemia cells (HSB-2, Molt-4 and CCRF-CEM). In addition, AMJ exerted a strong pro-apoptotic effect in human primary lymphoblastic leukemia cells but not in human normal primary T-lymphocytes. Thus, the present findings indicate that AMJ exhibits strong anticancer activity through a redox-sensitive mechanism in the p53-deficient Jurkat cells and that this effect involves several types of polyphenols. They further suggest that AMJ has chemotherapeutic properties against acute lymphoblastic leukemia by selectively targeting lymphoblast-derived tumor cells.
C1 [Sharif, Tanveer; Alhosin, Mahmoud; Auger, Cyril; Kim, Jong-Hun; Etienne-Selloum, Nelly; Bronner, Christian; Fuhrmann, Guy; Schini-Kerth, Valerie B.] Univ Strasbourg, CNRS, UMR 7213, Lab Biophoton & Pharmacol,Fac Pharm, Illkirch Graffenstaden, France.
   [Minker, Carole; Lobstein, Annelise] Univ Strasbourg, CNRS, UMR 7200, Lab Innovat Therapeut,Fac Pharm, Illkirch Graffenstaden, France.
   [Bories, Pierre; Gronemeyer, Hinrich] Univ Strasbourg, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire,UMR 7104,U964, Illkirch Graffenstaden, France.
C3 Universites de Strasbourg Etablissements Associes; Universite de
   Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS -
   National Institute for Biology (INSB); Centre National de la Recherche
   Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Universites de
   Strasbourg Etablissements Associes; Universite de Strasbourg; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Universites
   de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre
   National de la Recherche Scientifique (CNRS); CNRS - National Institute
   for Biology (INSB)
RP Sharif, T (通讯作者)，Univ Strasbourg, CNRS, UMR 7213, Lab Biophoton & Pharmacol,Fac Pharm, Illkirch Graffenstaden, France.
EM valerie.schini-kerth@unistra.fr
RI Auger, Cyril/N-4702-2016; Alhosin, Mahmoud/H-8101-2017; Gronemeyer,
   Hinrich/G-6240-2011; BRONNER, Christian/R-8488-2016
OI Gronemeyer, Hinrich/0000-0001-9454-2449; Bories,
   Pierre/0000-0002-2252-0395; Kim, Jong Hun/0000-0002-9431-9906; Alhosin,
   Mahmoud/0000-0003-2147-1445; BRONNER, Christian/0000-0002-3101-9279;
   Sharif, Tanveer/0000-0003-3269-8100; Auger, Cyril/0000-0003-0695-3841
FU Higher Education Commission of Pakistan; Association pour la Recherche
   sur le Cancer (ARC); Syrian Higher Education Ministry
FX TS is supported by a fellowship from the Higher Education Commission of
   Pakistan and from the Association pour la Recherche sur le Cancer (ARC).
   MA is supported by a fellowship from the Syrian Higher Education
   Ministry. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Achour M, 2008, ONCOGENE, V27, P2187, DOI 10.1038/sj.onc.1210855
   Aiyer HS, 2010, CANCER PREV RES, V3, P727, DOI 10.1158/1940-6207.CAPR-09-0260
   Alhosin M, 2010, BIOCHEM PHARMACOL, V79, P1251, DOI 10.1016/j.bcp.2009.12.015
   Avvakumov GV, 2008, NATURE, V455, P822, DOI 10.1038/nature07273
   Azam S, 2004, TOXICOL IN VITRO, V18, P555, DOI 10.1016/j.tiv.2003.12.012
   Bermúdez-Soto MJ, 2004, EUR FOOD RES TECHNOL, V219, P133, DOI 10.1007/s00217-004-0940-3
   Bermúndez-Soto MJ, 2007, J NUTR BIOCHEM, V18, P259, DOI 10.1016/j.jnutbio.2006.05.003
   Boominathan L, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-27
   Bostick M, 2007, SCIENCE, V317, P1760, DOI 10.1126/science.1147939
   Bronner C, 2007, PHARMACOL THERAPEUT, V115, P419, DOI 10.1016/j.pharmthera.2007.06.003
   Chen W, 2008, FREE RADICAL BIO MED, V45, P60, DOI 10.1016/j.freeradbiomed.2008.03.013
   CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502
   Chung FL, 2003, J NUTR, V133, p3268S, DOI 10.1093/jn/133.10.3268S
   Das A, 2010, CANCER-AM CANCER SOC, V116, P164, DOI 10.1002/cncr.24699
   DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104
   Duvoix A, 2005, CANCER LETT, V223, P181, DOI 10.1016/j.canlet.2004.09.041
   Juan ME, 2008, J AGR FOOD CHEM, V56, P4813, DOI 10.1021/jf800175a
   Feng RT, 2007, J BIOL CHEM, V282, P13468, DOI 10.1074/jbc.M610616200
   Fuhrmann G, 1999, CELL MOL BIOL, V45, P717
   Gusman J, 2001, CARCINOGENESIS, V22, P1111, DOI 10.1093/carcin/22.8.1111
   Hakimuddin F, 2006, J AGR FOOD CHEM, V54, P7912, DOI 10.1021/jf060834m
   HSIAO MH, 1994, BLOOD, V83, P2922, DOI 10.1182/blood.V83.10.2922.2922
   Jeanblanc M, 2005, ONCOGENE, V24, P7337, DOI 10.1038/sj.onc.1208878
   Jenkins Y, 2005, MOL BIOL CELL, V16, P5621, DOI 10.1091/mbc.E05-03-0194
   Jeong JC, 2010, NUTR CANCER, V62, P402, DOI 10.1080/01635580903441287
   Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298
   Kulling SE, 2008, PLANTA MED, V74, P1625, DOI 10.1055/s-0028-1088306
   Kwan ML, 2004, AM J EPIDEMIOL, V160, P1098, DOI 10.1093/aje/kwh317
   Lala G, 2006, NUTR CANCER, V54, P84, DOI 10.1207/s15327914nc5401_10
   Li GX, 2010, CARCINOGENESIS, V31, P902, DOI 10.1093/carcin/bgq039
   Liu CY, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-15
   Malik M, 2003, NUTR CANCER, V46, P186, DOI 10.1207/S15327914NC4602_12
   Miller PE, 2010, NUTR CANCER, V62, P413, DOI 10.1080/01635580903407114
   Misikangas M, 2007, J NUTR, V137, P2285, DOI 10.1093/jn/137.10.2285
   Mousli M, 2003, BRIT J CANCER, V89, P120, DOI 10.1038/sj.bjc.6601068
   Murias M, 2008, TOXICOL IN VITRO, V22, P1361, DOI 10.1016/j.tiv.2008.03.002
   Porter Lisa A, 2003, Prog Cell Cycle Res, V5, P335
   Poyton RO, 2009, TRENDS ENDOCRIN MET, V20, P332, DOI 10.1016/j.tem.2009.04.001
   Rigas B, 2008, BRIT J CANCER, V98, P1157, DOI 10.1038/sj.bjc.6604225
   Sánchez-Duffhues G, 2009, BIOCHEM PHARMACOL, V77, P1401, DOI 10.1016/j.bcp.2009.01.004
   Sharif T, 2011, INVEST NEW DRUG, V29, P239, DOI 10.1007/s10637-009-9352-3
   Sharif T, 2010, EUR J CANCER, V46, P983, DOI 10.1016/j.ejca.2009.12.029
   SINGLETON V. L., 1965, AMER J ENOL VITICULT, V16, P144
   Skupien K, 2008, PHYTOTHER RES, V22, P689, DOI 10.1002/ptr.2411
   Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189
   Tien AL, 2011, BIOCHEM J, V435, P175, DOI 10.1042/BJ20100840
   Walter A, 2010, FASEB J, V24, P3360, DOI 10.1096/fj.09-149419
   Warburg O., 1925, KLIN WOCHENSCHR, V4, P534
NR 48
TC 48
Z9 52
U1 1
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 8
PY 2012
VL 7
IS 3
AR e32526
DI 10.1371/journal.pone.0032526
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 929KT
UT WOS:000303062000012
PM 22412883
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Kim, JH
   Kang, S
   Kim, TW
   Yin, LH
   Liu, R
   Kim, SJ
AF Kim, Ju Hee
   Kang, Seongeun
   Kim, Tae Woo
   Yin, Lihong
   Liu, Ran
   Kim, Sun Jung
TI Expression Profiling after Induction of Demethylation in MCF-7 Breast
   Cancer Cells Identifies Involvement of TNF-α Mediated Cancer Pathways
SO MOLECULES AND CELLS
LA English
DT Article
DE 5-Aza-2 '-deoxycytidine; breast cancer; genome-wide expression; MCF-7;
   TNF-alpha
ID TUMOR-NECROSIS-FACTOR; DNA METHYLATION; PROMOTER METHYLATION;
   GENE-EXPRESSION; CPG ISLAND; HYPERMETHYLATION; SUPPRESSOR; CARCINOMA;
   FREQUENT; TISSUE
AB Epigenetic methylation change is a major process that occurs during cancer development. Even though many tumor-related genes have been identified based on their relationship between methylation and expression, few studies have been conducted to investigate the relevant biological pathways involved in these changes. To identify essential pathways likely to be affected by methylation in breast cancer, we examined a pool of genes in which expression was upregulated after induction of demethylation by 5-Aza-2'-deoxycytidine (Aza) in the MCF-7 breast cancer cell line. Genome-wide demethylation was confirmed by monitoring the demethylation of a previously known gene, SULT1A1. Overall, 210 and 213 genes were found to be upregulated and downregulated (fold change >= 2), respectively, in common in cells treated with 5 and 10 mu M of Aza. Network analysis of these 423 genes with altered expression patterns identified the involvement of a cancer related network of genes that were heavily regulated by TNF-alpha in breast tumorigenesis. Our results suggest that epigenetic dysregulation of cellular processes relevant to TNF-alpha-dependent apoptosis may be intimately involved in tumorigenesis in MCF-7 cells.
C1 [Kim, Ju Hee; Kang, Seongeun; Kim, Tae Woo; Kim, Sun Jung] Dongguk Univ Seoul, Dept Life Sci, Seoul 100715, South Korea.
   [Yin, Lihong; Liu, Ran] Southeast Univ, Key Lab Environm Med Engn, Minist Educ, Sch Publ Hlth, Nanjing 210009, Peoples R China.
C3 Dongguk University; Southeast University - China
RP Kim, SJ (通讯作者)，Dongguk Univ Seoul, Dept Life Sci, Seoul 100715, South Korea.
EM ranliu@seu.edu.cn; sunjungk@dongguk.edu
RI Kim, Dokyun/IYJ-2278-2023; kim, sun/T-1013-2019
FU National Research Foundation of Korea (NRF) [NRF-2011-C00056]; National
   Science Foundation of China (NSFC) [30800891, 81111140396]
FX This study was supported by the National Research Foundation of Korea
   (NRF) Grant (NRF-2011-C00056) and by the National Science Foundation of
   China (NSFC) Grant (30800891 & 81111140396).
CR Ando K, 2003, ONCOGENE, V22, P7796, DOI 10.1038/sj.onc.1206965
   Bonazzi VF, 2009, GENE CHROMOSOME CANC, V48, P10, DOI 10.1002/gcc.20615
   Budinsky AC, 1997, INT J CANCER, V71, P1086, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1086::AID-IJC27>3.0.CO;2-A
   Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985
   Chambers AF, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2197
   Dempsey PW, 2003, CYTOKINE GROWTH F R, V14, P193, DOI 10.1016/S1359-6101(03)00021-2
   Kim SJ, 2011, CANCER LETT, V302, P47, DOI 10.1016/j.canlet.2010.12.010
   Kim TW, 2010, INT J ONCOL, V36, P1105, DOI 10.3892/ijo_00000592
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   Kwon MS, 2006, ONCOL REP, V15, P27
   Laux DE, 1999, BREAST CANCER RES TR, V56, P35, DOI 10.1023/A:1006222803788
   Li LA, 2010, HUM MOL GENET, V19, P4273, DOI 10.1093/hmg/ddq351
   Liu B, 2010, SCIENCE, V330, P521, DOI 10.1126/science.1193787
   Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544
   Lui ELH, 2005, BIOMED PHARMACOTHER, V59, pS363, DOI 10.1016/S0753-3322(05)80079-4
   Maegawa S, 2010, GENOME RES, V20, P332, DOI 10.1101/gr.096826.109
   Malumbres M, 1999, ONCOGENE, V18, P385, DOI 10.1038/sj.onc.1202299
   Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8
   Politi K, 2004, SEMIN CANCER BIOL, V14, P341, DOI 10.1016/j.semcancer.2004.04.013
   Rivenbark AG, 2006, EPIGENETICS-US, V1, P32, DOI 10.4161/epi.1.1.2358
   Rodenhiser DI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2121
   Ruan K, 2009, CELL MOL LIFE SCI, V66, P2219, DOI 10.1007/s00018-009-0013-7
   Shao L, 2007, CLIN CANCER RES, V13, P5756, DOI 10.1158/1078-0432.CCR-06-3082
   Shivapurkar N, 2004, INT J CANCER, V109, P786, DOI 10.1002/ijc.20041
   Sohn BH, 2010, GASTROENTEROLOGY, V138, P1898, DOI 10.1053/j.gastro.2009.12.044
   Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233
   Van der Auwera I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012616
   van Horssen R, 2006, ONCOLOGIST, V11, P397, DOI 10.1634/theoncologist.11-4-397
   Weng WH, 2011, BIOCHEM BIOPH RES CO, V405, P278, DOI 10.1016/j.bbrc.2011.01.028
   Wolf I, 2006, CANCER RES, V66, P7818, DOI 10.1158/0008-5472.CAN-05-4368
   Xiong HH, 2009, J HUAZHONG U SCI-MED, V29, P498, DOI 10.1007/s11596-009-0421-9
   Xiong JB, 2009, MOL CANCER THER, V8, P779, DOI 10.1158/1535-7163.MCT-08-0926
   Yan PS, 2003, CANCER RES, V63, P6178
   Yin YM, 2009, BIOMED PHARMACOTHER, V63, P421, DOI 10.1016/j.biopha.2009.04.032
   Zhang Q, 2009, P NATL ACAD SCI USA, V106, P15843, DOI 10.1073/pnas.0907070106
   Zhang Y, 2010, J SURG RES, V160, P102, DOI 10.1016/j.jss.2008.12.042
NR 36
TC 10
Z9 10
U1 0
U2 6
PU KOREAN SOC MOLECULAR & CELLULAR  BIOLOGY
PI SEOUL
PA 635-4, YUCKSAM-DONG, GANGNAM-GU, SEOUL 135-703, SOUTH KOREA
SN 1016-8478
J9 MOL CELLS
JI Mol. Cells
PD FEB
PY 2012
VL 33
IS 2
BP 127
EP 133
DI 10.1007/s10059-012-2182-8
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 926GE
UT WOS:000302818500004
PM 22228181
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Chen, KG
   Sikic, BI
AF Chen, Kevin G.
   Sikic, Branimir I.
TI Molecular Pathways: Regulation and Therapeutic Implications of Multidrug
   Resistance
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; PHASE-I TRIAL; HUMAN MDR1 GENE; P-GLYCOPROTEIN
   EXPRESSION; BREAST-CANCER CELLS; TRANSCRIPTIONAL REGULATION;
   LYMPHOCYTIC-LEUKEMIA; EPIGENETIC CHANGES; DRUG-RESISTANCE; PROMOTER
   REGION
AB Multidrug transporters constitute major mechanisms of MDR in human cancers. The ABCB1 (MDR1) gene encodes a well-characterized transmembrane transporter, termed P-glycoprotein (P-gp), which is expressed in many normal human tissues and cancers. P-gp plays a major role in the distribution and excretion of drugs and is involved in intrinsic and acquired drug resistance of cancers. The regulation of ABCB1 expression is complex and has not been well studied in a clinical setting. In this review, we elucidate molecular signaling and epigenetic interactions that govern ABCB1 expression and the development of MDR in cancer. We focus on acquired expression of ABCB1 that is associated with genomic instability of cancer cells, including mutational events that alter chromatin structures, gene rearrangements, and mutations in tumor suppressor proteins (e. g., mutant p53), which guard the integrity of genome. In addition, epigenetic modifications of the ABCB1 proximal and far upstream promoters by either demethylation of DNA or acetylation of histone H3 play a pivotal role in inducing ABCB1 expression. We describe a molecular network that coordinates genetic and epigenetic events leading to the activation of ABCB1. These mechanistic insights provide additional translational targets and potential strategies to deal with clinical MDR. Clin Cancer Res; 18(7); 1863-9. (C) 2012 AACR.
C1 [Chen, Kevin G.; Sikic, Branimir I.] Stanford Univ, Dept Med, Div Oncol, Sch Med, Stanford, CA 94305 USA.
   [Chen, Kevin G.] Natl Inst Neurol Disorders & Stroke, NIH Stem Cell Unit, NIH, Bethesda, MD USA.
C3 Stanford University; National Institutes of Health (NIH) - USA; NIH
   National Institute of Neurological Disorders & Stroke (NINDS)
RP Sikic, BI (通讯作者)，Stanford Univ, Dept Med, Div Oncol, Sch Med, CCSR 1105, Stanford, CA 94305 USA.
EM brandy@stanford.edu
RI Chen, Kevin/D-6769-2011
OI Chen, Kevin/0000-0003-2983-6330
FU National Cancer Institute [CA09302]; NIH [R01 CA52168, R01 CA92474];
   General Clinical Research Center, Stanford University [M01 RR0070]
FX This work was supported by National Cancer Institute grant CA09302 (K.G.
   Chen), NIH grants R01 CA52168 and R01 CA92474 (B. I. Sikic), and M01
   RR0070 (General Clinical Research Center, Stanford University).
CR Advani R, 2005, ANN ONCOL, V16, P1968, DOI 10.1093/annonc/mdi396
   Advani R, 2001, CLIN CANCER RES, V7, P1221
   Allen JD, 2000, CANCER RES, V60, P5761
   Baer MR, 2002, BLOOD, V100, P1224, DOI 10.1182/blood.V100.4.1224.h81602001224_1224_1232
   Baker EK, 2005, ONCOGENE, V24, P8061, DOI 10.1038/sj.onc.1208955
   Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447
   BARTLETT NL, 1994, J CLIN ONCOL, V12, P835, DOI 10.1200/JCO.1994.12.4.835
   Calcagno AM, 2008, BRIT J CANCER, V98, P1515, DOI 10.1038/sj.bjc.6604334
   CHEN G, 1994, CANCER RES, V54, P4980
   Chen GK, 2000, BRIT J CANCER, V83, P892, DOI 10.1054/bjoc.2000.1371
   Chen GK, 2004, MOL PHARMACOL, V65, P906, DOI 10.1124/mol.65.4.906
   Chen KG, 2005, CANCER RES, V65, P9388, DOI 10.1158/0008-5472.CAN-04-4133
   CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476
   Clarke R, 2005, SEMIN ONCOL, V32, pS9, DOI 10.1053/j.seminoncol.2005.09.009
   COMBATES NJ, 1994, J BIOL CHEM, V269, P29715
   Conze D, 2001, CANCER RES, V61, P8851
   CORNWELL MM, 1993, J BIOL CHEM, V268, P15347
   Cripe LD, 2010, BLOOD, V116, P4077, DOI 10.1182/blood-2010-04-277269
   David GL, 2004, CANCER BIOL THER, V3, P540, DOI 10.4161/cbt.3.6.845
   Desiderato L, 1997, SOMAT CELL MOLEC GEN, V23, P391, DOI 10.1007/BF02673749
   Dumontet C, 1996, CANCER RES, V56, P1091
   El-Osta A, 2002, MOL CELL BIOL, V22, P1844, DOI 10.1128/MCB.22.6.1844-1857.2002
   Garcia-Manero G, 2002, CLIN CANCER RES, V8, P1897
   Gottesman MM, 2006, FEBS LETT, V580, P998, DOI 10.1016/j.febslet.2005.12.060
   Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706
   Gryshchenko I, 2008, J CLIN ONCOL, V26, P2252, DOI 10.1200/JCO.2007.11.5212
   Harikrishnan KN, 2005, NAT GENET, V37, P254, DOI 10.1038/ng1516
   Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X
   Heist RS, 2007, J CLIN ONCOL, V25, P2243, DOI 10.1200/JCO.2006.08.8914
   Huff LM, 2006, J BIOL CHEM, V281, P36501, DOI 10.1074/jbc.M602998200
   JAFFREZOU JP, 1994, J NATL CANCER I, V86, P1152, DOI 10.1093/jnci/86.15.1152
   Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377
   Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200
   Kantharidis P, 1997, CLIN CANCER RES, V3, P2025
   Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6
   Lancet JE, 2009, LEUKEMIA RES, V33, P1055, DOI 10.1016/j.leukres.2008.09.015
   List AF, 2001, BLOOD, V98, P3212, DOI 10.1182/blood.V98.12.3212
   LUM BL, 1992, J CLIN ONCOL, V10, P1635, DOI 10.1200/JCO.1992.10.10.1635
   Mahadevan D, 2004, BLOOD, V104, P1940, DOI 10.1182/blood-2003-07-2490
   Marcelletti JF, 2009, LEUKEMIA RES, V33, P769, DOI 10.1016/j.leukres.2008.09.020
   Matsubara H, 2009, J PHARMACOL EXP THER, V328, P839, DOI 10.1124/jpet.108.147462
   Michaelis M, 2009, CANCER RES, V69, P416, DOI 10.1158/0008-5472.CAN-08-1856
   Mickley LA, 1998, BLOOD, V91, P1749, DOI 10.1182/blood.V91.5.1749.1749_1749_1756
   Nakayama M, 1998, BLOOD, V92, P4296, DOI 10.1182/blood.V92.11.4296.423k25_4296_4307
   Oda Y, 1998, CLIN CANCER RES, V4, P2273
   Qadir M, 2005, CLIN CANCER RES, V11, P2320, DOI 10.1158/1078-0432.CCR-04-1725
   Raaijmakers MHGP, 2006, CLIN CANCER RES, V12, P3452, DOI 10.1158/1078-0432.CCR-05-1945
   Robey RW, 2006, CLIN CANCER RES, V12, P1547, DOI 10.1158/1078-0432.CCR-05-1423
   Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200
   Scotto KW, 2003, ONCOGENE, V22, P7496, DOI 10.1038/sj.onc.1206950
   Sikic BI, 1999, ONCOLOGY-NY, V13, P183
   Sikic BI, 1997, CANCER CHEMOTH PHARM, V40, pS13, DOI 10.1007/s002800051055
   Sikic BI, 2006, CLIN CANCER RES, V12, P3231, DOI 10.1158/1078-0432.CCR-06-0655
   Smit JW, 1998, HEPATOLOGY, V27, P1056, DOI 10.1002/hep.510270422
   Tabe Y, 2006, BLOOD, V107, P1546, DOI 10.1182/blood-2004-10-4126
   Tada Y, 2000, CLIN CANCER RES, V6, P4618
   Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025
   Thottassery JV, 1997, P NATL ACAD SCI USA, V94, P11037, DOI 10.1073/pnas.94.20.11037
   To KKW, 2008, MOL CANCER RES, V6, P151, DOI 10.1158/1541-7786.MCR-07-0175
   van den Heuvel-Eibrink MM, 2002, LEUKEMIA, V16, P833, DOI 10.1038/sj.leu.2402496
   van der Kolk DM, 2002, BLOOD, V99, P3763, DOI 10.1182/blood.V99.10.3763
   van der Kolk DM, 2001, LEUKEMIA, V15, P1544, DOI 10.1038/sj.leu.2402236
   van der Kolk DM, 2000, BLOOD, V95, P3514, DOI 10.1182/blood.V95.11.3514.011k50_3514_3519
   Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541
   Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529
   YAHANDA AM, 1992, J CLIN ONCOL, V10, P1624, DOI 10.1200/JCO.1992.10.10.1624
   Yang JM, 2001, MOL PHARMACOL, V60, P674
   Yin JAL, 2001, BRIT J HAEMATOL, V113, P713
NR 68
TC 159
Z9 184
U1 1
U2 33
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD APR 1
PY 2012
VL 18
IS 7
BP 1863
EP 1869
DI 10.1158/1078-0432.CCR-11-1590
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 922LX
UT WOS:000302549900008
PM 22344233
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Candelaria, M
   de la Cruz-Hernandez, E
   Taja-Chayeb, L
   Perez-Cardenas, E
   Trejo-Becerril, C
   Gonzalez-Fierro, A
   Chavez-Blanco, A
   Soto-Reyes, E
   Dominguez, G
   Trujillo, JE
   Diaz-Chavez, J
   Duenas-Gonzalez, A
AF Candelaria, Myrna
   de la Cruz-Hernandez, Erick
   Taja-Chayeb, Lucia
   Perez-Cardenas, Enrique
   Trejo-Becerril, Catalina
   Gonzalez-Fierro, Aurora
   Chavez-Blanco, Alma
   Soto-Reyes, Ernesto
   Dominguez, Guadalupe
   Trujillo, Jaenai E.
   Diaz-Chavez, Jose
   Duenas-Gonzalez, Alfonso
TI DNA Methylation-Independent Reversion of Gemcitabine Resistance by
   Hydralazine in Cervical Cancer Cells
SO PLOS ONE
LA English
DT Article
ID EQUILIBRATIVE NUCLEOSIDE TRANSPORTER-1; TUMOR-SUPPRESSOR GENES; RNA
   EXPRESSION LEVELS; DEOXYCYTIDINE KINASE; HISTONE METHYLTRANSFERASE;
   RIBONUCLEOTIDE REDUCTASE; EPIGENETIC THERAPY; IN-VITRO; CHEMOTHERAPY
   RESISTANCE; MAGNESIUM VALPROATE
AB Background: Down regulation of genes coding for nucleoside transporters and drug metabolism responsible for uptake and metabolic activation of the nucleoside gemcitabine is related with acquired tumor resistance against this agent. Hydralazine has been shown to reverse doxorubicin resistance in a model of breast cancer. Here we wanted to investigate whether epigenetic mechanisms are responsible for acquiring resistance to gemcitabine and if hydralazine could restore gemcitabine sensitivity in cervical cancer cells.
   Methodology/Principal Findings: The cervical cancer cell line CaLo cell line was cultured in the presence of increasing concentrations of gemcitabine. Down-regulation of hENT1 & dCK genes was observed in the resistant cells (CaLoGR) which was not associated with promoter methylation. Treatment with hydralazine reversed gemcitabine resistance and led to hENT1 and dCK gene reactivation in a DNA promoter methylation-independent manner. No changes in HDAC total activity nor in H3 and H4 acetylation at these promoters were observed. ChIP analysis showed H3K9m2 at hENT1 and dCK gene promoters which correlated with hyper-expression of G9A histone methyltransferase at RNA and protein level in the resistant cells. Hydralazine inhibited G9A methyltransferase activity in vitro and depletion of the G9A gene by iRNA restored gemcitabine sensitivity.
   Conclusions/Significance: Our results demonstrate that acquired gemcitabine resistance is associated with DNA promoter methylation-independent hENT1 and dCK gene down-regulation and hyper-expression of G9A methyltransferase. Hydralazine reverts gemcitabine resistance in cervical cancer cells via inhibition of G9A histone methyltransferase.
C1 [Candelaria, Myrna] Inst Nacl Cancerol, Div Clin Res, Mexico City, DF, Mexico.
   [de la Cruz-Hernandez, Erick; Taja-Chayeb, Lucia; Perez-Cardenas, Enrique; Trejo-Becerril, Catalina; Gonzalez-Fierro, Aurora; Chavez-Blanco, Alma; Soto-Reyes, Ernesto; Dominguez, Guadalupe; Trujillo, Jaenai E.; Diaz-Chavez, Jose] Inst Nacl Cancerol, Basic Res Div, Mexico City, DF, Mexico.
   [Duenas-Gonzalez, Alfonso] Inst Invest Biomed UNAM, Inst Nacl Cancerol, Unit Biomed Res Canc, Mexico City, DF, Mexico.
C3 Instituto Nacional de Cancerologia (INCAN); Instituto Nacional de
   Cancerologia (INCAN); Instituto Nacional de Cancerologia (INCAN);
   Universidad Nacional Autonoma de Mexico
RP Candelaria, M (通讯作者)，Inst Nacl Cancerol, Div Clin Res, Mexico City, DF, Mexico.
EM alfonso_duenasg@yahoo.com
RI De la Cruz-Hernandez, Erick/E-1487-2019; Díaz-Chávez,
   José/HGU-7481-2022; Perez-Cardenas, Enrique/JPW-9339-2023; Velasco,
   Iván/D-3593-2014
OI Soto-Reyes, Ernesto/0000-0002-4219-6406; Perez-Cardenas,
   Enrique/0000-0002-4896-4111; Diaz-Chavez, Jose/0000-0001-9583-3790;
   Dominguez-Gomez, Guadalupe/0000-0003-3906-4493
FU Psicofarma S.A. de C.V
FX This work was partly supported by Psicofarma S.A. de C.V. The funders
   had a role in data collection, but not in study design, data analysis,
   decision to publish, or preparation of the manuscript. No additional
   external funding received for this study.
CR Abdulla P, 2007, NUCLEOS NUCLEOT NUCL, V26, P99, DOI 10.1080/15257770601052331
   Achiwa H, 2004, CANCER SCI, V95, P753, DOI 10.1111/j.1349-7006.2004.tb03257.x
   ANTONSSON BE, 1987, CANCER RES, V47, P3672
   Arce C, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000098
   AVRAMIS VI, 1989, CANCER CHEMOTH PHARM, V24, P203
   Barnes K, 2006, CIRC RES, V99, P510, DOI 10.1161/01.RES.0000238359.18495.42
   Bergman AM, 2005, CANCER RES, V65, P9510, DOI 10.1158/0008-5472.CAN-05-0989
   Boukovinas I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003695
   Caceres-Cortes JR, 2001, CANCER RES, V61, P6281
   Candelaria M, 2007, ANN ONCOL, V18, P1529, DOI 10.1093/annonc/mdm204
   Candelaria M, 2010, MED ONCOL, V27, P1133, DOI 10.1007/s12032-009-9349-y
   Candelaria M, 2007, EJC SUPPL, V5, P37, DOI 10.1016/S1359-6349(07)70014-9
   Chávez-Blanco A, 2011, INT J ONCOL, V39, P1491, DOI 10.3892/ijo.2011.1144
   CHEN EH, 1995, J CLIN INVEST, V95, P1660, DOI 10.1172/JCI117841
   De la Cruz-Hernández E, 2011, ONCOL REP, V25, P399, DOI 10.3892/or.2010.1086
   Duenas-Gonzalez A, 2011, EXPERT OPIN DRU 0928, P28
   Galmarini Carlos Maria, 2004, BMC Pharmacology, V4, P8, DOI 10.1186/1471-2210-4-8
   Gati WP, 1997, BLOOD, V90, P346
   Giovannetti E, 2006, CANCER RES, V66, P3928, DOI 10.1158/0008-5472.CAN-05-4203
   Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739
   Huang Y, 2007, P NATL ACAD SCI USA, V104, P8023, DOI 10.1073/pnas.0700720104
   Huo HR, 2010, CANCER RES, V70, P8726, DOI 10.1158/0008-5472.CAN-10-0755
   Inoue T, 2009, CELL CYCLE, V8, P1279, DOI 10.4161/cc.8.8.8245
   Jiang ZP, 2010, MED HYPOTHESES, V74, P92, DOI 10.1016/j.mehy.2009.07.036
   Jordheim LP, 2005, MOL CANCER THER, V4, P1268, DOI 10.1158/1535-7163.MCT-05-0121
   Kikuchi R, 2006, MOL PHARMACOL, V70, P887, DOI 10.1124/mol.106.025494
   KONG XB, 1991, MOL PHARMACOL, V39, P250
   Kroep JR, 2002, MOL CANCER THER, V1, P371
   Law AYS, 2008, EXP CELL RES, V314, P1823, DOI 10.1016/j.yexcr.2008.03.001
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Liu F, 2010, J MED CHEM, V53, P5844, DOI 10.1021/jm100478y
   Ma J, 2010, CANCER GENE THER, V17, P523, DOI 10.1038/cgt.2010.18
   Manome Y, 1996, NAT MED, V2, P567, DOI 10.1038/nm0596-567
   Mini E, 2006, ANN ONCOL, V17, pV7, DOI 10.1093/annonc/mdj941
   NYCE J, 1989, CANCER RES, V49, P5829
   Nyce JW, 1997, MUTAT RES-REV MUTAT, V386, P153, DOI 10.1016/S1383-5742(96)00051-8
   Oguri T, 2007, CANCER LETT, V256, P112, DOI 10.1016/j.canlet.2007.06.012
   Ohhashi S, 2008, ANTICANCER RES, V28, P2205
   Ougolkov AV, 2008, CLIN CANCER RES, V14, P6790, DOI 10.1158/1078-0432.CCR-08-1013
   Park JY, 2008, PANCREAS, V36, pE32, DOI 10.1097/MPA.0b013e3181630ffe
   Peters GJ, 2010, NUCLEOS NUCLEOT NUCL, V29, P408, DOI 10.1080/15257771003730078
   Provenzano MJ, 2007, OTOLARYNG HEAD NECK, V137, P722, DOI 10.1016/j.otohns.2007.07.030
   Schroder JK, 1996, LEUKEMIA, V10, P1919
   Sebastiani V, 2006, CLIN CANCER RES, V12, P2492, DOI 10.1158/1078-0432.CCR-05-2655
   Segura-Pacheco B, 2003, CLIN CANCER RES, V9, P1596
   Segura-Pacheco B, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-32
   Shutoh M, 2005, CANCER-AM CANCER SOC, V104, P1609, DOI 10.1002/cncr.21392
   Singh N, 2009, CHEMMEDCHEM, V4, P792, DOI 10.1002/cmdc.200900017
   Song YH, 2009, CANCER CHEMOTH PHARM, V63, P605, DOI 10.1007/s00280-008-0773-z
   Souglakos J, 2008, BRIT J CANCER, V98, P1710, DOI 10.1038/sj.bjc.6604344
   Spratlin J, 2004, CLIN CANCER RES, V10, P6956, DOI 10.1158/1078-0432.CCR-04-0224
   Wang X, 2009, TUMOR BIOL, V30, P8, DOI 10.1159/000197911
   Wong A, 2009, DRUG METAB REV, V41, P77, DOI 10.1080/03602530902741828
   Worm J, 2001, J BIOL CHEM, V276, P39990, DOI 10.1074/jbc.M103181200
   Wozniak RJ, 2007, ONCOGENE, V26, P77, DOI 10.1038/sj.onc.1209763
   Wu H, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0008570, 10.1371/journal.pone.0013316]
   Yoshida T, 2010, DRUG METAB DISPOS, V38, P1814, DOI 10.1124/dmd.110.034397
   Zambrano P, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-44
NR 58
TC 40
Z9 42
U1 0
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 12
PY 2012
VL 7
IS 3
AR e29181
DI 10.1371/journal.pone.0029181
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 920DF
UT WOS:000302381500002
PM 22427797
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Polakis, P
AF Polakis, Paul
TI Wnt Signaling in Cancer
SO COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY
LA English
DT Article
ID WNT/BETA-CATENIN PATHWAY; TUMOR-SUPPRESSOR GENES; FREQUENT EPIGENETIC
   INACTIVATION; BETA-CATENIN; STEM-CELLS; COLORECTAL-CANCER; THERAPEUTIC
   TARGET; BREAST-CANCER; CYCLIN D1; EXPRESSION
AB Aberrant regulation of the Wnt signaling pathway is a prevalent theme in cancer biology. From the earliest observation that Wnt overexpression could lead to malignant transformation of mouse mammary tissue to the most recent genetic discoveries gleaned from tumor genome sequencing, the Wnt pathway continues to evolve as a central mechanism in cancer biology. This article summarizes the evidence supporting a role for Wnt signaling in human cancer. This includes a review of the genetic mutations affecting Wnt pathway components, as well as some of epigenetic mechanisms that alter expression of genes relevant to Wnt. I also highlight some research on the cooperativity of Wnt with other signaling pathways in cancer. Finally, some emphasis is placed on laboratory research that provides a proof of concept for the therapeutic inhibition of Wnt signaling in cancer.
C1 Genentech Inc, San Francisco, CA 94608 USA.
C3 Roche Holding; Genentech
RP Polakis, P (通讯作者)，Genentech Inc, San Francisco, CA 94608 USA.
EM polakis.paul@gene.com
CR Abrahamsson AE, 2009, P NATL ACAD SCI USA, V106, P3925, DOI 10.1073/pnas.0900189106
   Akiri G, 2009, ONCOGENE, V28, P2163, DOI 10.1038/onc.2009.82
   Angus-Hill ML, 2011, P NATL ACAD SCI USA, V108, P4914, DOI 10.1073/pnas.1102300108
   Araki Y, 2003, CANCER RES, V63, P728
   Ashihara E, 2009, CLIN CANCER RES, V15, P2731, DOI 10.1158/1078-0432.CCR-08-1350
   Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032
   Bass AJ, 2011, NAT GENET, V43, P964, DOI 10.1038/ng.936
   Björklund P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004243
   Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221
   Chan AT, 2007, NEW ENGL J MED, V356, P2131, DOI 10.1056/NEJMoa067208
   Cheng ASL, 2011, CANCER RES, V71, P4028, DOI 10.1158/0008-5472.CAN-10-3342
   Cheng CK, 2011, BLOOD, V118, P6638, DOI 10.1182/blood-2011-05-354712
   Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734
   Chung GG, 2004, CANCER, V100, P2084, DOI 10.1002/cncr.20232
   Clements Wilson M, 2003, Clin Colorectal Cancer, V3, P113, DOI 10.3816/CCC.2003.n.018
   Cong F, 2003, BMC MOL BIOL, V4, DOI 10.1186/1471-2199-4-10
   Cuilliere-Dartigues P, 2006, ONCOGENE, V25, P4441, DOI 10.1038/sj.onc.1209471
   DeAlmeida VI, 2007, CANCER RES, V67, P5371, DOI 10.1158/0008-5472.CAN-07-0266
   Ekström EJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018674
   Fre S, 2005, NATURE, V435, P964, DOI 10.1038/nature03589
   Fre S, 2009, P NATL ACAD SCI USA, V106, P6309, DOI 10.1073/pnas.0900427106
   Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205
   Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049
   Green DW, 2001, J SURG RES, V101, P16, DOI 10.1006/jsre.2001.6241
   Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561
   Hu TH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-236
   Huff V, 2011, NAT REV CANCER, V11, P111, DOI 10.1038/nrc3002
   Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258
   Jiang X, 2008, CANCER CELL, V13, P529, DOI 10.1016/j.ccr.2008.04.019
   Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125
   Kim JS, 2002, MOL CANCER THER, V1, P1355
   Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389
   Kongkham PN, 2010, ONCOGENE, V29, P3017, DOI 10.1038/onc.2010.32
   Kwon C, 2011, NAT CELL BIOL, V13, P1244, DOI 10.1038/ncb2313
   LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1
   Lammi L, 2004, AM J HUM GENET, V74, P1043, DOI 10.1086/386293
   Lilien J, 2005, CURR OPIN CELL BIOL, V17, P459, DOI 10.1016/j.ceb.2005.08.009
   Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397
   Mahmoudi T, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000539
   Major MB, 2007, SCIENCE, V316, P1043, DOI 10.1126/science/1141515
   Malanchi I, 2008, NATURE, V452, P650, DOI 10.1038/nature06835
   Malanchi I, 2009, CURR OPIN ONCOL, V21, P41, DOI 10.1097/CCO.0b013e32831d1faf
   Marvin ML, 2011, AM J MED GENET A, V155A, P898, DOI 10.1002/ajmg.a.33927
   Matsuda Y, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2317
   McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481
   Moisan A, 2011, DEV CELL, V20, P583, DOI 10.1016/j.devcel.2011.03.013
   Mologni L, 2010, CANCER RES, V70, P7253, DOI 10.1158/0008-5472.CAN-10-1108
   Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950
   Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518
   Mullighan CG, 2011, NATURE, V471, P235, DOI 10.1038/nature09727
   Myung SJ, 2006, P NATL ACAD SCI USA, V103, P12098, DOI 10.1073/pnas.0603235103
   Nguyen DX, 2009, CELL, V138, P51, DOI 10.1016/j.cell.2009.04.030
   Ni M, 2011, CANCER CELL, V20, P119, DOI 10.1016/j.ccr.2011.05.026
   Oshima M, 2002, CURR PHARM DESIGN, V8, P1021, DOI 10.2174/1381612023394953
   Pasqualucci L, 2011, NATURE, V471, P189, DOI 10.1038/nature09730
   Phesse TJ, 2008, MOL CELL BIOL, V28, P6094, DOI 10.1128/MCB.00539-08
   Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Roh H, 2001, CANCER RES, V61, P6563
   Ruteshouser EC, 2008, GENE CHROMOSOME CANC, V47, P461, DOI 10.1002/gcc.20553
   Salahshor S, 2005, J CLIN PATHOL, V58, P225, DOI 10.1136/jcp.2003.009506
   Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155
   Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448
   Sjöblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427
   Smartt HJM, 2012, GUT, V61, P1306, DOI 10.1136/gutjnl-2011-300817
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Takagi H, 2008, J GASTROENTEROL, V43, P378, DOI 10.1007/s00535-008-2170-0
   Tang W, 2008, P NATL ACAD SCI USA, V105, P9697, DOI 10.1073/pnas.0804709105
   Teo JL, 2010, ADV DRUG DELIVER REV, V62, P1149, DOI 10.1016/j.addr.2010.09.012
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0
   van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659
   van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349
   van Veelen W, 2011, GUT, V60, P1204, DOI 10.1136/gut.2010.233460
   Verma UN, 2003, CLIN CANCER RES, V9, P1291
   Vincent A, 2011, CLIN CANCER RES, V17, P4341, DOI 10.1158/1078-0432.CCR-10-3431
   Wang DZ, 2004, CELL CYCLE, V3, P1512, DOI 10.4161/cc.3.12.1288
   Wang YZ, 2010, SCIENCE, V327, P1650, DOI 10.1126/science.1186624
   Willert K, 2006, GENE DEV, V20, P1394, DOI 10.1101/gad.1424006
   Yang L, 2011, ONCOGENE, V30, P4437, DOI 10.1038/onc.2011.145
   Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598
   You L, 2004, ONCOGENE, V23, P6170, DOI 10.1038/sj.onc.1207844
   Zeng G, 2007, NEOPLASIA, V9, P951, DOI 10.1593/neo.07469
   Zhao C, 2007, CANCER CELL, V12, P528, DOI 10.1016/j.ccr.2007.11.003
NR 87
TC 572
Z9 692
U1 1
U2 59
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1943-0264
J9 CSH PERSPECT BIOL
JI Cold Spring Harbor Perspect. Biol.
PD MAY
PY 2012
VL 4
IS 5
AR a008052
DI 10.1101/cshperspect.a008052
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 995PV
UT WOS:000308024100010
PM 22438566
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Fürst, RW
   Kliem, H
   Meyer, HHD
   Ulbrich, SE
AF Fuerst, Rainer W.
   Kliem, Heike
   Meyer, Heinrich H. D.
   Ulbrich, Susanne E.
TI A differentially methylated single CpG-site is correlated with estrogen
   receptor alpha transcription
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article
DE Estrogen receptor alpha; Epigenetics; Methylation-specific
   high-resolution melting; Pyrosequencing; Chromatin immunoprecipitation
ID FACTOR-BINDING SITES; HUMAN BREAST-CANCER; GENE-EXPRESSION; DNA
   METHYLATION; EPIGENETIC REGULATION; TARGET GENES; BISPHENOL-A; PROMOTER;
   MECHANISMS; ESTRADIOL
AB DNA methylation of the promoter region of estrogen receptor alpha (ESR1) is recognized as an epigenetic mechanism that regulates its mRNA abundance. We questioned whether tissues in male growing piglets were influenced in terms of DNA methylation by the developmentally occurring distinct plasma estradiol-17 beta (E2) concentrations. Additionally, we aimed at broadening the currently limited understanding of the epigenetic regulation of ESR1 in physiological settings. Three distinct genetic regions of ESR1 were analyzed using a combination of methylation-sensitive high resolution melting (MS-HRM) and pyrosequencing. Unexpectedly, major E2 concentration differences were only marginally associated with minor variations in DNA methylation and mRNA abundance. However, by analyzing two tissues showing the greatest differences in transcript abundance, we were able to find one single CpG site in the +1 kb intragenic region of ESR1 strikingly differently methylated between heart vs. epididymis. Interestingly, this single CpG-site was identified as a putative binding site for the transcriptional repressor TG-interacting factor 1 (TGIF) which can recruit histone deacetylase 1 (HDAC1) leading to chromatin condensation. Indeed, chromatin immunoprecipitation confirmed a reduced histone H3 presence at the specific ESR1 location in case of higher DNA methylation. We therefore hypothesize that ESR1 expression may be manifested by a single-CpG-site based methylation difference impairing transcription factor binding. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Fuerst, Rainer W.] Tech Univ Munich, Grad Sch Epigenet Imprinting & Nutr, D-85354 Freising Weihenstephan, Germany.
C3 Technical University of Munich
RP Ulbrich, SE (通讯作者)，Weihenstephaner Berg 3, D-85354 Freising Weihenstephan, Germany.
EM ulbrich@wzw.tum.de
RI Ulbrich, Susanne E/D-1815-2014
OI Ulbrich, Susanne E/0000-0003-0355-3869
FU ZIEL PhD Graduate school 'Epigenetics, Imprinting and Nutrition',
   Technische Universitat-Munchen
FX This study was partially funded by the ZIEL PhD Graduate school
   'Epigenetics, Imprinting and Nutrition', Technische Universitat-Munchen.
CR Björnström L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486
   Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473
   Choy MK, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-519
   Cornwall GA, 2009, HUM REPROD UPDATE, V15, P213, DOI 10.1093/humupd/dmn055
   Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358
   Delbès G, 2006, REPRODUCTION, V132, P527, DOI 10.1530/rep.1.01231
   Donaghue C, 1999, MOL ENDOCRINOL, V13, P1934, DOI 10.1210/me.13.11.1934
   Flanagan JM, 2010, AM J HUM GENET, V86, P420, DOI 10.1016/j.ajhg.2010.02.008
   Fürst RW, 2012, MOL CELL ENDOCRINOL, V348, P67, DOI 10.1016/j.mce.2011.07.032
   GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487
   Giacinti L, 2006, ONCOLOGIST, V11, P1, DOI 10.1634/theoncologist.11-1-1
   Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485
   Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200
   Ing NH, 1997, BIOL REPROD, V56, P1205, DOI 10.1095/biolreprod56.5.1205
   Joseph A, 2011, BIOL REPROD, V84, P207, DOI 10.1095/biolreprod.110.087353
   Kos M, 2001, MOL ENDOCRINOL, V15, P2057, DOI 10.1210/me.15.12.2057
   Kurian JR, 2010, ENDOCRINOLOGY, V151, P2297, DOI 10.1210/en.2009-0649
   Levin ER, 2005, MOL ENDOCRINOL, V19, P1951, DOI 10.1210/me.2004-0390
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Marino M, 2006, CURR GENOMICS, V7, P497, DOI 10.2174/138920206779315737
   Maunakea AK, 2010, NATURE, V466, P253, DOI 10.1038/nature09165
   Mccarthy MM, 2008, PHYSIOL REV, V88, P91, DOI 10.1152/physrev.00010.2007
   McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4
   Meyer H.H.D., 1999, HDB EXPT PHARM
   MEYER HHD, 1990, J STEROID BIOCHEM, V35, P263, DOI 10.1016/0022-4731(90)90283-X
   Nadal A, 2001, NEWS PHYSIOL SCI, V16, P251
   Nielsen M, 2001, HISTOCHEM CELL BIOL, V115, P521
   Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535
   Pfaffl MW, 2004, BIOTECHNOL LETT, V26, P509, DOI 10.1023/B:BILE.0000019559.84305.47
   PIVA R, 1989, BIOCHEM INT, V19, P267
   Prins GS, 2008, BASIC CLIN PHARMACOL, V102, P134, DOI 10.1111/j.1742-7843.2007.00166.x
   Prins GS, 2006, ANN NY ACAD SCI, V1089, P1, DOI 10.1196/annals.1386.009
   Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878
   ROBERTSON HA, 1974, J REPROD FERTIL, V40, P133, DOI 10.1530/jrf.0.0400133
   Sato K, 2006, ENDOCR J, V53, P331, DOI 10.1507/endocrj.K06-009
   Schug J, 2002, CURRENT PROTOCOLS BI
   Segars JH, 2002, TRENDS ENDOCRIN MET, V13, P349, DOI 10.1016/S1043-2760(02)00633-1
   Shiota K, 2002, GENES CELLS, V7, P961, DOI 10.1046/j.1365-2443.2002.00574.x
   Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023
   Tan GH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni124
   TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M
   Tierney RJ, 2000, J VIROL, V74, P10468, DOI 10.1128/JVI.74.22.10468-10479.2000
   Ulbrich SE, 2009, REPRODUCTION, V138, P371, DOI 10.1530/REP-09-0081
   Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021
   Verdel A, 2004, SCIENCE, V303, P672, DOI 10.1126/science.1093686
   Wagner A, 2008, REPROD FERT DEVELOP, V20, P505, DOI 10.1071/RD07136
   WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136
   Westberry JM, 2010, ENDOCRINOLOGY, V151, P731, DOI 10.1210/en.2009-0955
   Wilson ME, 2008, FRONT NEUROENDOCRIN, V29, P375, DOI 10.1016/j.yfrne.2008.03.002
   Wotton D, 1999, J BIOL CHEM, V274, P37105, DOI 10.1074/jbc.274.52.37105
   Yang XW, 2000, CANCER RES, V60, P6890
   Yoshida T, 2000, CARCINOGENESIS, V21, P2193, DOI 10.1093/carcin/21.12.2193
   Zaratiegui M, 2007, CELL, V128, P763, DOI 10.1016/j.cell.2007.02.016
   Zhang DP, 2006, COMP BIOCHEM PHYS A, V144, P306, DOI 10.1016/j.cbpa.2006.01.025
   Zhou Q, 2001, P NATL ACAD SCI USA, V98, P14132, DOI 10.1073/pnas.241245898
NR 55
TC 43
Z9 46
U1 1
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0760
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD MAY
PY 2012
VL 130
IS 1-2
BP 96
EP 104
DI 10.1016/j.jsbmb.2012.01.009
PG 9
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 931NH
UT WOS:000303226100012
PM 22342840
DA 2025-01-12
ER

PT J
AU Bosviel, R
   Dumollard, E
   Déchelotte, P
   Bignon, YJ
   Bernard-Gallon, D
AF Bosviel, Remy
   Dumollard, Elise
   Dechelotte, Pierre
   Bignon, Yves-Jean
   Bernard-Gallon, Dominique
TI Can Soy Phytoestrogens Decrease DNA Methylation in <i>BRCA1</i> and
   <i>BRCA2</i> Oncosuppressor Genes in Breast Cancer?
SO OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
LA English
DT Article
ID ESTROGEN-RECEPTOR MODULATORS; SPORADIC BREAST; CELL LINE; PROMOTER
   HYPERMETHYLATION; HISTONE-MODIFICATION; MBD2 EXPRESSION; MESSENGER-RNA;
   GENISTEIN; ISOFLAVONES; BINDING
AB Although soy phytoestrogens have been postulated to exert a protective effect against breast cancer, the attendant mechanisms, in particular epigenetics underpinnings, have remained elusive. We investigated the putative effects on DNA methylation by two naturally occurring isoflavones, genistein and daidzein, in a study of the BRCA1 and BRCA2 oncosuppressor genes in breast cancer cell lines (MCF-7, MDA-MB 231, and MCF10a). A demethylant agent, the 5-azacytidine, and a methylant, the budesonide, were used as treatment controls. DNA methylation of BRCA1 and BRCA2 was investigated with methylated DNA immunoprecipitation coupled with PCR. In parallel, protein expression was determined by Western blot, immunohistochemistry, and confocal microscopy. Our results suggest that treatment with 18.5 mu M Genistein or 78.5 mu M Daidzein might reverse DNA hypermethylation and restore the expression of the oncosuppressor genes BRCA1 and BRCA2. 5-Azacitydine also enhanced the re-expression of these genes while budesonide had an opposite effect. To the best of our knowledge, these observations, while requiring replication, provide new evidence on potential epigenetic mechanisms by which genistein and daidzein might contribute to regulation of the BRCA1 and BRCA2. Future studies are warranted on whether the demethylating effect of genistein and daidzein is global or focused on select candidate genes.
C1 [Bosviel, Remy; Dumollard, Elise; Bignon, Yves-Jean; Bernard-Gallon, Dominique] Ctr Jean Perrin, Dept Oncogenet, CBRV, F-63011 Clermont Ferrand, France.
   [Bosviel, Remy; Dumollard, Elise; Dechelotte, Pierre; Bignon, Yves-Jean; Bernard-Gallon, Dominique] Univ Auvergne, Clermont Ferrand, France.
   [Dechelotte, Pierre] CHU, Nouvel Hop Estaing, Serv Anat Pathol, Clermont Ferrand, France.
C3 UNICANCER; Centre Jean Perrin; Universite Clermont Auvergne (UCA); CHU
   Clermont Ferrand
RP Bignon, YJ (通讯作者)，Ctr Jean Perrin, Dept Oncogenet, CBRV, 58 Rue Montalembert,BP 392, F-63011 Clermont Ferrand, France.
EM Yves-Jean.BIGNON@cjp.fr
RI Bernard-Gallon, Dominique/L-6079-2015
FU Auvergne Regional Council/CPER [32316-0930FDBG-106NL]
FX We gratefully acknowledge the engaged help of Caroline Vachias and
   Jean-Louis Couderc from the ICCF (Imagerie confocale de
   Clermont-Ferrand) platform for confocal microscopy use. We thank the
   technical assistance of Christelle Picard, Nicolas Sonnier, Elodie
   Heinry, Sinda Mabouli, Julie Durif, and Marine Gueugneau. We also thank
   "La ligue contre le Cancer, comites de la region Auvergne.'' Remy
   Bosviel received a grant from the Auvergne Regional Council/CPER
   2008+FEDER no. 32316-0930FDBG-106NL.
CR Adlercreutz H, 1997, ANN MED, V29, P95, DOI 10.3109/07853899709113696
   Billard LM, 2002, ONCOGENE, V21, P2704, DOI 10.1038/sj/onc/1205357
   Brzezinski A, 1999, EUR J OBSTET GYN R B, V85, P47, DOI 10.1016/S0301-2115(98)00281-4
   CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661
   Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509
   Cucer N, 2008, J GENET, V87, P155, DOI 10.1007/s12041-008-0023-5
   Day JK, 2002, J NUTR, V132, p2419S, DOI 10.1093/jn/132.8.2419S
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700
   Elsheikh SE, 2009, CANCER RES, V69, P3802, DOI 10.1158/0008-5472.CAN-08-3907
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fang MZ, 2007, J NUTR, V137, p223S, DOI 10.1093/jn/137.1.223S
   Fang MZ, 2005, CLIN CANCER RES, V11, P7033, DOI 10.1158/1078-0432.CCR-05-0406
   Ferlay J, 2010, EUR J CANCER, V46, P765, DOI 10.1016/j.ejca.2009.12.014
   Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801
   King-Batoon A, 2008, ENVIRON MOL MUTAGEN, V49, P36, DOI 10.1002/em.20363
   Koch C, 2004, BIOCHEMISTRY-US, V43, P5011, DOI 10.1021/bi0359271
   Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252
   Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863
   Lee MN, 2007, CLIN CANCER RES, V13, P832, DOI 10.1158/1078-0432.CCR-05-2694
   Li Y, 2010, CURR MED CHEM, V17, P2141, DOI 10.2174/092986710791299966
   Li YY, 2009, INT J CANCER, V125, P286, DOI 10.1002/ijc.24398
   Liu ZH, 2010, WATER RES, V44, P567, DOI 10.1016/j.watres.2009.03.025
   LYNCOOK BD, 1995, P SOC EXP BIOL MED, V208, P116
   Majid S, 2009, CARCINOGENESIS, V30, P662, DOI 10.1093/carcin/bgp042
   Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630
   Messina M, 2009, AM J CLIN NUTR, V89, pS1673, DOI 10.3945/ajcn.2009.26736V
   MILLER OJ, 1974, NATURE, V251, P636, DOI 10.1038/251636a0
   Mirza S, 2010, MOL CELL BIOCHEM, V342, P101, DOI 10.1007/s11010-010-0473-y
   Müller HM, 2003, BRIT J CANCER, V89, P1934, DOI 10.1038/sj.bjc.6601392
   Oseni T, 2008, PLANTA MED, V74, P1656, DOI 10.1055/s-0028-1088304
   Pfitscher A, 2008, J STEROID BIOCHEM, V112, P87, DOI 10.1016/j.jsbmb.2008.08.007
   Qin WY, 2009, NUTR CANCER, V61, P238, DOI 10.1080/01635580802404196
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086
   Rossetto D, 2010, CLIN CANCER RES, V16, P4543, DOI 10.1158/1078-0432.CCR-10-0513
   Setchell KD, 2001, J AM COLL NUTR, V20, p381S, DOI DOI 10.1080/07315724.2001.107
   Setchell KDR, 2001, J AM COLL NUTR, V20, p354S, DOI 10.1080/07315724.2001.10719168
   SOULE HD, 1990, CANCER RES, V50, P6075
   SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409
   Takeuchi S, 2009, BIOL PHARM BULL, V32, P195, DOI 10.1248/bpb.32.195
   Tost J, 2010, MOL BIOTECHNOL, V44, P71, DOI 10.1007/s12033-009-9216-2
   Vissac-Sabatier C, 2003, NUTR CANCER, V45, P247, DOI 10.1207/S15327914NC4502_15
   Wessels LFA, 2002, CANCER RES, V62, P7110
   Wu CT, 2001, SCIENCE, V293, P1103, DOI 10.1126/science.293.5532.1103
   Zhao Y, 2004, INFLAMM RES, V53, P664, DOI 10.1007/s00011-004-1309-6
NR 47
TC 51
Z9 56
U1 0
U2 18
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1536-2310
J9 OMICS
JI OMICS
PD MAY
PY 2012
VL 16
IS 5
BP 235
EP 244
DI 10.1089/omi.2011.0105
PG 10
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 937IX
UT WOS:000303653300002
PM 22339411
DA 2025-01-12
ER

PT J
AU Tserga, A
   Michalopoulos, NV
   Levidou, G
   Korkolopoulou, P
   Zografos, G
   Patsouris, E
   Saetta, AA
AF Tserga, Aggeliki
   Michalopoulos, Nicolaos V.
   Levidou, Georgia
   Korkolopoulou, Penelope
   Zografos, George
   Patsouris, Efstratios
   Saetta, Angelica A.
TI Association of aberrant DNA methylation with clinicopathological
   features in breast cancer
SO ONCOLOGY REPORTS
LA English
DT Article
DE breast cancer; methylation; methylation-sensitive high-resolution
   melting analysis; methylation-specific-PCR; pyrosequencing
ID PROMOTER HYPERMETHYLATION; TUMOR-SUPPRESSOR; GENE; RASSF1A; PATHWAY;
   DEATH; CARCINOGENESIS; INACTIVATION; EPIGENETICS; PROGRESSION
AB Aberrant DNA methylation is responsible for the epigenetic silencing of genes associated with tumourigenesis and progression of cancer. In this study, we assessed the methylation status of eight genes in 49 snap-frozen primary breast tumours. Epigenetic alterations of 8 genes were analysed with methylation-specific polymerase chain reaction (MS-PCR) (DCR1, DAPK1, RASSF1A and DCR2) or methylation-sensitive high-resolution melting analysis (MS-HRM) (APC, mGmT, GSTP1 and PTEN). MS-HRM performance was validated by bisulfite pyrosequencing regarding the methylation levels of MGMT. Promoter methylation was observed in APC 54.34%, 40.4% DCR1, 37.5% DAPK1, 33.3% RASSF1A, 22.44% MGMT, 16.6% GSTP1, 6% PTEN and 0% DCR2 promoters, respectively. Interestingly, 37 out of 49 cases (75.5%) displayed aberrant promoter methylation in at least one gene. An association of MGMT promoter methylation with age and tumour grade was recorded. Moreover, a correlation with advanced T-category was elicited for GSTP1, RASSF1 and DAPK1 promoter methylation. Finally, concurrent methylation of several genes showed a marginal statistical relationship with N-category. We conclude that APC, DCR1, DAPK I and RASSF1A promoter methylation represents a common event in breast cancer tumourigenesis. Our results suggest that GSTP1, RASSF1, DAPK1 and MGMT may be implicated in the acquisition of a more aggressive phenotype in breast cancer.
C1 [Tserga, Aggeliki; Levidou, Georgia; Korkolopoulou, Penelope; Patsouris, Efstratios; Saetta, Angelica A.] Univ Athens, Dept Pathol 1, Sch Med, Athens 11527, Greece.
   [Michalopoulos, Nicolaos V.; Zografos, George] Univ Athens, Propaedeut Dept Surg 1, Hippocrat Univ Hosp, Athens 11527, Greece.
C3 National & Kapodistrian University of Athens; Athens Medical School;
   National & Kapodistrian University of Athens
RP Tserga, A (通讯作者)，Univ Athens, Dept Pathol 1, Sch Med, Mikras Assias 75, Goudi 11527, Greece.
EM atserga@gmail.com
OI Saetta, Angelica A./0000-0002-4862-3413; Tserga,
   Aggeliki/0000-0002-5531-2111
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Ahuja N, 2000, HISTOL HISTOPATHOL, V15, P835, DOI 10.14670/HH-15.835
   Arai T, 2006, BREAST CANCER RES TR, V100, P169, DOI 10.1007/s10549-006-9241-9
   Brooks J, 2009, CANCER CAUSE CONTROL, V20, P1539, DOI 10.1007/s10552-009-9415-y
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Buyru N, 2009, CANCER INVEST, V27, P307, DOI 10.1080/07357900802350814
   Candiloro ILM, 2011, EPIGENETICS-US, V6, P501, DOI 10.4161/epi.6.4.14853
   Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311
   Cho YH, 2010, ANTICANCER RES, V30, P2489
   Colella S, 2003, BIOTECHNIQUES, V35, P146, DOI 10.2144/03351md01
   Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007
   Esteller M, 2001, CANCER RES, V61, P3225
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hoque MO, 2009, CANCER EPIDEM BIOMAR, V18, P2694, DOI 10.1158/1055-9965.EPI-08-0821
   Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10
   Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Kang GH, 2003, LAB INVEST, V83, P635, DOI 10.1097/01.LAB.0000067481.08984.3F
   Karray-Chouayekh S, 2010, J CANCER RES CLIN, V136, P203, DOI 10.1007/s00432-009-0649-6
   Kioulafa M, 2009, CLIN BIOCHEM, V42, P970, DOI 10.1016/j.clinbiochem.2009.04.003
   Laborde E, 2010, CELL DEATH DIFFER, V17, P1373, DOI 10.1038/cdd.2010.80
   Lee JS, 2007, VIRCHOWS ARCH, V450, P637, DOI 10.1007/s00428-007-0421-8
   Lehmann U, 2002, CANCER RES, V62, P6634
   Levy-Strumpf N, 1998, ONCOGENE, V17, P3331, DOI 10.1038/sj.onc.1202588
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466
   Orlando FA, 2009, ANN SURG ONCOL, V16, P2270, DOI 10.1245/s10434-009-0500-y
   Park SY, 2011, VIRCHOWS ARCH, V458, P73, DOI 10.1007/s00428-010-1013-6
   Pegg AE, 2000, MUTAT RES-REV MUTAT, V462, P83, DOI 10.1016/S1383-5742(00)00017-X
   Sharma G, 2010, LIFE SCI, V87, P83, DOI 10.1016/j.lfs.2010.05.001
   Sharma G, 2009, CELL ONCOL, V31, P487, DOI 10.3233/CLO-2009-0507
   Shivapurkar N, 2004, INT J CANCER, V109, P786, DOI 10.1002/ijc.20041
   Sobin LH, 2011, TNM CLASSIFICATION M
   Tavassoli FA., 2003, WHO CLASSIFICATION T
   Wojdacz TK, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm013
   Wojdacz Tomasz K., 2009, V507, P229, DOI 10.1007/978-1-59745-522-0_17
NR 41
TC 45
Z9 48
U1 0
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
J9 ONCOL REP
JI Oncol. Rep.
PD MAY
PY 2012
VL 27
IS 5
BP 1630
EP 1638
DI 10.3892/or.2011.1576
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 917TX
UT WOS:000302202600050
PM 22159596
OA Bronze
DA 2025-01-12
ER

PT J
AU Pawlik, P
   Mostowska, A
   Lianeri, M
   Sajdak, S
   Kedzia, H
   Jagodzinski, PP
AF Pawlik, Piotr
   Mostowska, Adrianna
   Lianeri, Margarita
   Sajdak, Stefan
   Kedzia, Helena
   Jagodzinski, Pawel P.
TI Folate and choline metabolism gene variants in relation to ovarian
   cancer risk in the Polish population
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Ovarian cancer; Polymorphism; Choline; Folate metabolism
ID ONE-CARBON METABOLISM; METHIONINE-SYNTHASE-REDUCTASE; SQUAMOUS-CELL
   CARCINOMA; ACUTE LYMPHOBLASTIC-LEUKEMIA; METHYLENETETRAHYDROFOLATE
   REDUCTASE; DNA METHYLATION; BREAST-CANCER; COLORECTAL-CANCER;
   ALCOHOL-DRINKING; LUNG-CANCER
AB Data indicates that genetic factors alone do not account for ovarian tumorigenesis, suggesting that epigenetic status additionally affects this process. Therefore, we assessed the possible contribution of polymorphic variants of genes that may affect DNA methylation to the risk of ovarian cancer incidence in the Polish population. Using PCR-RFLP and HRM analyses, we studied the distribution of BHMT (rs3733890), MTHFD1 (rs2236225), MTHFR (rs1801133), MTR (rs1805087), MTRR (rs1801394) and TCN2 (rs1801198) genotypes and alleles in patients with ovarian cancer (n = 136) and controls (n = 160). Moreover, using DNA and methylation-specific PCR (MSP) we also determined the methylation of the Cadherin 13 (CDH13) promoter in cancerous tissue from these patients. We did not observe a significant association between all studied gene variants and the incidence of ovarian cancer. The lowest P (trend) = 0.1226 was observed for the MTHFR Ala222Val polymorphism. Moreover, the lowest P = 0.0772 was found in the comparison of MTHFR Ala/Ala versus Val/Val and Val/Ala genotypes in patients and control groups. The multifactor dimensionality reduction analysis also did not indicate a significant interactive genetic effect on ovarian cancer incidence for all analyzed SNPs. However, we observed frequent methylation of the CDH13 promoter in approximately 21% (29/136) patients with ovarian carcinomas. Our results might suggest that the selected polymorphic gene variants may not contribute to ovarian cancer incidence.
C1 [Mostowska, Adrianna; Lianeri, Margarita; Jagodzinski, Pawel P.] Poznan Univ Med Sci, Dept Biochem & Mol Biol, PL-60781 Poznan, Poland.
   [Pawlik, Piotr; Sajdak, Stefan] Poznan Univ Med Sci, Clin Gynecol Surg, PL-60781 Poznan, Poland.
   [Kedzia, Helena] Poznan Univ Med Sci, Dept Pathol, PL-60781 Poznan, Poland.
C3 Poznan University of Medical Sciences; Poznan University of Medical
   Sciences; Poznan University of Medical Sciences
RP Jagodzinski, PP (通讯作者)，Poznan Univ Med Sci, Dept Biochem & Mol Biol, 6 Swiecickiego St, PL-60781 Poznan, Poland.
EM pjagodzi@um.poznan.pl
RI Mostowska, Adrianna/J-6719-2012; Jagodzinski, Pawel/KWV-0637-2024
OI Mostowska, Adrianna/0000-0003-4181-9402; Sajdak,
   Stefan/0000-0002-8641-4188; Jagodzinski, Pawel/0000-0002-9046-6802
FU Poznan University of Medical Sciences [502-01-01124182-07474]
FX Supported by grant No. 502-01-01124182-07474, Poznan University of
   Medical Sciences. The technical assistance of Ms. Joanna Grzelczak and
   Longina Nowak is gratefully acknowledged.
CR Arslan S, 2011, MOL BIOL REP, V38, P991, DOI 10.1007/s11033-010-0194-z
   Balch C, 2009, ENDOCRINOLOGY, V150, P4003, DOI 10.1210/en.2009-0404
   Barton CA, 2008, GYNECOL ONCOL, V109, P129, DOI 10.1016/j.ygyno.2007.12.017
   Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644
   Batch C, 2004, AM J OBSTET GYNECOL, V191, P1552, DOI 10.1016/j.agoj.2004.05.025
   Bethke L, 2008, CANCER EPIDEM BIOMAR, V17, P1195, DOI 10.1158/1055-9965.EPI-07-2733
   Bol GM, 2010, HISTOPATHOLOGY, V57, P363, DOI 10.1111/j.1365-2559.2010.03642.x
   CANTONI GL, 1953, J BIOL CHEM, V204, P403
   Cho KR, 2009, ANNU REV PATHOL-MECH, V4, P287, DOI 10.1146/annurev.pathol.4.110807.092246
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fasching PA, 2009, MOL ONCOL, V3, P171, DOI 10.1016/j.molonc.2009.01.008
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Ferlay J, 2007, ANN ONCOL, V18, P581, DOI 10.1093/annonc/mdl498
   FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111
   Garrow TA, 1996, J BIOL CHEM, V271, P22831, DOI 10.1074/jbc.271.37.22831
   Gershoni-Baruch R, 2000, EUR J CANCER, V36, P2313, DOI 10.1016/S0959-8049(00)00306-3
   HAKAMI N, 1971, NEW ENGL J MED, V285, P1163, DOI 10.1056/NEJM197111182852103
   Hazra A, 2007, CARCINOGENESIS, V28, P1510, DOI 10.1093/carcin/bgm062
   Hazra A, 2010, CANCER CAUSE CONTROL, V21, P331, DOI 10.1007/s10552-009-9464-2
   HUM DW, 1988, J BIOL CHEM, V263, P15946
   Iacopetta B, 2009, INT J CANCER, V125, P84, DOI 10.1002/ijc.24324
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kang S, 2005, GYNECOL ONCOL, V96, P173, DOI 10.1016/j.ygyno.2004.09.031
   Kelemen LE, 2008, CANCER RES, V68, P2498, DOI 10.1158/0008-5472.CAN-07-5165
   Kotsopoulos J, 2010, EUR J CLIN NUTR, V64, P111, DOI 10.1038/ejcn.2009.109
   Kotsopoulos J, 2010, INT J CANCER, V126, P2191, DOI 10.1002/ijc.24723
   Krajinovic M, 2004, PHARMACOGENOMICS J, V4, P66, DOI 10.1038/sj.tpj.6500224
   Kwon MJ, 2011, INT J MOL SCI, V12, P983, DOI 10.3390/ijms12020983
   Lacasaña-Navarro M, 2006, EUR J CANCER, V42, P528, DOI 10.1016/j.ejca.2005.10.020
   Leclerc D, 1998, P NATL ACAD SCI USA, V95, P3059, DOI 10.1073/pnas.95.6.3059
   Li YN, 1996, HUM MOL GENET, V5, P1851, DOI 10.1093/hmg/5.12.1851
   Lima CSP, 2008, LEUKEMIA RES, V32, P401, DOI 10.1016/j.leukres.2007.06.001
   Liu HL, 2008, LUNG CANCER, V61, P21, DOI 10.1016/j.lungcan.2007.12.001
   Liu YX, 2011, ASIAN PAC J CANCER P, V12, P247
   Ma E, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-122
   Maruti SS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2462
   Matsuo K, 2005, CARCINOGENESIS, V26, P2164, DOI 10.1093/carcin/bgi196
   Matsuo Keitaro, 2002, Asian Pac J Cancer Prev, V3, P353
   Mostowska A, 2011, CLIN BIOCHEM, V44, P596, DOI 10.1016/j.clinbiochem.2011.02.007
   Neumann AS, 2005, INT J CANCER, V115, P131, DOI 10.1002/ijc.20888
   Paz MF, 2002, CANCER RES, V62, P4519
   da Silva LMRB, 2011, REV ASSOC MED BRAS, V57, P194, DOI 10.1590/S0104-42302011000200018
   de Lima ELS, 2010, PEDIATR BLOOD CANCER, V54, P904, DOI 10.1002/pbc.22472
   Schickel R, 2008, ONCOGENE, V27, P5959, DOI 10.1038/onc.2008.274
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Skibola CF, 2004, BLOOD, V104, P2155, DOI 10.1182/blood-2004-02-0557
   Sood S, 2010, LEUKEMIA LYMPHOMA, V51, P928, DOI 10.3109/10428191003719023
   Stolzenberg-Solomon RZ, 2003, CANCER EPIDEM BIOMAR, V12, P1222
   Sueblinvong T, 2009, CURR TREAT OPTION ON, V10, P67, DOI 10.1007/s11864-009-0108-2
   Suzuki T, 2008, CANCER EPIDEM BIOMAR, V17, P2742, DOI 10.1158/1055-9965.EPI-08-0470
   Suzuki T, 2008, CARCINOGENESIS, V29, P356, DOI 10.1093/carcin/bgm295
   Suzuki T, 2007, CARCINOGENESIS, V28, P1718, DOI 10.1093/carcin/bgm104
   Suzuki T, 2007, CANCER SCI, V98, P1439, DOI 10.1111/j.1349-7006.2007.00533.x
   Terry KL, 2010, GYNECOL ONCOL, V119, P319, DOI 10.1016/j.ygyno.2010.08.007
   Turek-Plewa J, 2005, CELL MOL BIOL LETT, V10, P631
   Wu Q, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-45
   Xu XR, 2008, CANCER EPIDEM BIOMAR, V17, P2109, DOI 10.1158/1055-9965.EPI-07-2900
   Xu XR, 2009, FASEB J, V23, P4022, DOI 10.1096/fj.09-136507
   Zhang ZD, 2005, CANCER EPIDEM BIOMAR, V14, P1188, DOI 10.1158/1055-9965.EPI-04-0501
NR 60
TC 29
Z9 31
U1 0
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD MAY
PY 2012
VL 39
IS 5
BP 5553
EP 5560
DI 10.1007/s11033-011-1359-0
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 917BU
UT WOS:000302147800057
PM 22183302
DA 2025-01-12
ER

PT J
AU Minocherhomji, S
   Tollefsbol, TO
   Singh, KK
AF Minocherhomji, Sheroy
   Tollefsbol, Trygve O.
   Singh, Keshav K.
TI Mitochondrial regulation of epigenetics and its role in human diseases
SO EPIGENETICS
LA English
DT Article
DE DNA methylation; mitocheckpoint; OXPHOS; mitochondria; epigenome;
   epigenetics
ID DNA G10398A POLYMORPHISM; AFRICAN-AMERICAN WOMEN; BREAST-CANCER; HISTONE
   METHYLATION; H3K27 DEMETHYLASES; DAMAGE CHECKPOINT; CPG METHYLATION;
   GENE-REGULATION; GENOME; TRANSCRIPTION
AB Most pathogenic mitochondrial DNA (mtDNA) mutations induce defects in mitochondrial oxidative phosphorylation (OXPHOS). However, phenotypic effects of these mutations show a large degree of variation depending on the tissue affected. These differences are difficult to reconcile with OXPHOS as the sole pathogenic factor suggesting that additional mechanisms contribute to the lack of genotype and clinical phenotype correlationship. An increasing number of studies have identified a possible effect on the epigenetic landscape of the nuclear genome as a consequence of mitochondrial dysfunction. In particular, these studies demonstrate reversible or irreversible changes in genomic DNA methylation profiles of the nuclear genome. Here we review how mitochondria damage checkpoint (mitocheckpoint) induces epigenetic changes in the nucleus. Persistent pathogenic mutations in mtDNA may also lead to epigenetic changes causing genomic instability in the nuclear genome. We propose that "mitocheckpoint" mediated epigenetic and genetic changes may play key roles in phenotypic variation related to mitochondrial diseases or host of human diseases in which mitochondrial defect plays aprimary role.
C1 [Minocherhomji, Sheroy] Univ Copenhagen, Wilhelm Johannsen Ctr Funct Genome Res, Inst Cellular & Mol Med, Copenhagen, Denmark.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Ctr Aging, Birmingham, AL USA.
   [Singh, Keshav K.] Univ Alabama Birmingham, Sch Med, Dept Genet, UAB Comprehens Canc Ctr, Birmingham, AL USA.
C3 University of Copenhagen; University of Alabama System; University of
   Alabama Birmingham; University of Alabama System; University of Alabama
   Birmingham; University of Alabama System; University of Alabama
   Birmingham
RP Minocherhomji, S (通讯作者)，Univ Copenhagen, Wilhelm Johannsen Ctr Funct Genome Res, Inst Cellular & Mol Med, Copenhagen, Denmark.
EM sheroy@sund.ku.dk; kksingh@uab.edu
OI Minocherhomji, Sheroy/0000-0002-1101-4761
FU National Institutes of Health [RO1 CA121904, 113655]; Marie Curie
   Research Training Network, "Chromatin Plasticity" (EU)
FX This work was supported in part by a National Institutes of Health RO1
   CA121904 and 113655 (K. K. S.). S. M. is a Marie Curie Early Stage
   Research (ESR) fellow funded by the Marie Curie Research Training
   Network, "Chromatin Plasticity" (EU FP6). The Wilhelm Johannsen Centre
   for Functional Genome Research is established by the Danish National
   Research Foundation, Denmark.
CR Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145
   Alberio S, 2007, MITOCHONDRION, V7, P6, DOI 10.1016/j.mito.2006.11.010
   Astuti D, 2005, BRIT J CANCER, V92, P1574, DOI 10.1038/sj.bjc.6602478
   Bai RK, 2007, CANCER RES, V67, P4687, DOI 10.1158/0008-5472.CAN-06-3554
   Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5
   Barile M, 2000, EUR J BIOCHEM, V267, P4888, DOI 10.1046/j.1432-1327.2000.01552.x
   Barrès R, 2009, CELL METAB, V10, P189, DOI 10.1016/j.cmet.2009.07.011
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946
   Bergman Y, 2004, NAT REV IMMUNOL, V4, P753, DOI 10.1038/nri1458
   Berkich DA, 2005, J NEUROSCI RES, V79, P106, DOI 10.1002/jnr.20325
   Bianchi NO, 2001, MUTAT RES-REV MUTAT, V488, P9, DOI 10.1016/S1383-5742(00)00063-6
   Booker LM, 2006, J UROLOGY, V175, P468, DOI 10.1016/S0022-5347(05)00163-1
   Canter JA, 2005, CANCER RES, V65, P8028, DOI 10.1158/0008-5472.CAN-05-1428
   Chandra D., 2010, Biochim Biophys Acta
   Chatterjee A, 2006, ONCOGENE, V25, P4663, DOI 10.1038/sj.onc.1209604
   Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346
   CLAYTON DA, 1967, NATURE, V216, P652, DOI 10.1038/216652a0
   Collado M, 2005, CELL CYCLE, V4, P1722, DOI 10.4161/cc.4.12.2260
   Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902
   Dakubo GD, 2010, MITOCHONDRIAL GENETICS AND CANCER, P213, DOI 10.1007/978-3-642-11416-8_9
   Darvishi K, 2007, CANCER LETT, V249, P249, DOI 10.1016/j.canlet.2006.09.005
   Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655
   De Smet C, 1999, MOL CELL BIOL, V19, P7327
   Delsite RL, 2003, MUTAGENESIS, V18, P497, DOI 10.1093/mutage/geg027
   Delsite Robert, 2002, Mol Cancer, V1, P6, DOI 10.1186/1476-4598-1-6
   Desler C, 2007, MUTAT RES-FUND MOL M, V625, P112, DOI 10.1016/j.mrfmmm.2007.06.002
   Dimri GP, 2005, CANCER CELL, V7, P505, DOI 10.1016/j.ccr.2005.05.025
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Ezzeldin HH, 2005, CLIN CANCER RES, V11, P8699, DOI 10.1158/1078-0432.CCR-05-1520
   FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Furuta M, 2010, CARCINOGENESIS, V31, P766, DOI 10.1093/carcin/bgp250
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Gibson GE, 2010, BBA-MOL BASIS DIS, V1802, P122, DOI 10.1016/j.bbadis.2009.08.010
   Hall IJ, 2005, AM J EPIDEMIOL, V161, P40, DOI 10.1093/aje/kwh331
   Iijima-Ando K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008310
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303
   JACKY PB, 1983, SCIENCE, V220, P69, DOI 10.1126/science.6828880
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Koehntop KD, 2005, J BIOL INORG CHEM, V10, P87, DOI 10.1007/s00775-005-0624-x
   Kriaucionis S, 2009, SCIENCE, V324, P929, DOI 10.1126/science.1169786
   Kulawiec M, 2006, CANCER BIOL THER, V5, P967, DOI 10.4161/cbt.5.8.2880
   Kulawiec M, 2009, J HUM GENET, V54, P647, DOI 10.1038/jhg.2009.89
   Kulawiec Mariola, 2009, J Carcinog, V8, P8, DOI 10.4103/1477-3163.50893
   KUNZ BA, 1991, ANNU REV GENET, V25, P339, DOI 10.1146/annurev.ge.25.120191.002011
   Langevin SM, 2010, CARCINOGENESIS, V31, P864, DOI 10.1093/carcin/bgq051
   Lee JT, 2009, GENE DEV, V23, P1831, DOI 10.1101/gad.1811209
   Lee JS, 2010, CELL, V142, P682, DOI 10.1016/j.cell.2010.08.011
   Lee MS, 2005, CANCER BIOL THER, V4, P1248, DOI 10.4161/cbt.4.11.2136
   Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887
   Li XY, 2008, PLANT CELL, V20, P259, DOI 10.1105/tpc.107.056879
   Lin JC, 2007, CANCER CELL, V12, P432, DOI 10.1016/j.ccr.2007.10.014
   Liu L., 2011, Communications and Photonics Conference and Exhibition, P1
   Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890
   Minocherhomji S, 2010, OBSTET GYNECOL INT, V2010, DOI 10.1155/2010/198709
   Modica-Napolitano JS, 2004, MITOCHONDRION, V4, P755, DOI 10.1016/j.mito.2004.07.027
   Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7
   Nagano T, 2008, SCIENCE, V322, P1717, DOI 10.1126/science.1163802
   Naviaux RK, 2008, CANCER BIOL THER, V7, P1191, DOI 10.4161/cbt.7.8.6741
   Park SY, 2004, J BIOL CHEM, V279, P7512, DOI 10.1074/jbc.M307677200
   Pello R, 2008, HUM MOL GENET, V17, P4001, DOI 10.1093/hmg/ddn303
   Rasmussen AK, 2003, NUCLEIC ACIDS RES, V31, P3909, DOI 10.1093/nar/gkg446
   Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905
   REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8
   Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81
   Schatz G, 1996, J BIOL CHEM, V271, P31763, DOI 10.1074/jbc.271.50.31763
   Schones DE, 2008, NAT REV GENET, V9, P179, DOI 10.1038/nrg2270
   Selvanayagam P, 1996, LAB INVEST, V74, P592
   Shahbazian MD, 2007, ANNU REV BIOCHEM, V76, P75, DOI 10.1146/annurev.biochem.76.052705.162114
   Sharpless NE, 2005, NATURE, V436, P636, DOI 10.1038/436636a
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Shock LS, 2011, P NATL ACAD SCI
   Singh K., 1998, Mitochondrial DNA Mutations in Aging, Disease and Cancer
   Singh KK, 2006, ANN NY ACAD SCI, V1067, P182, DOI 10.1196/annals.1354.022
   Singh KK, 2005, GENE, V354, P140, DOI 10.1016/j.gene.2005.03.027
   Singh KK, 2004, FEMS YEAST RES, V5, P127, DOI 10.1016/j.femsyr.2004.04.008
   Singh KK, 2008, MITOCHONDRIA HUMAN C
   Sisková Z, 2010, AM J PATHOL, V177, P1411, DOI 10.2353/ajpath.2010.091037
   Smiraglia DJ, 2008, CANCER BIOL THER, V7, P1182, DOI 10.4161/cbt.7.8.6215
   Smiraglia DJ, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-446
   Stumpf J.D., 2010, CELL MOL LIFE SCI
   Suissa S, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000474
   Swigut T, 2007, CELL, V131, P29, DOI 10.1016/j.cell.2007.09.026
   Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3
   Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116
   Takasugi M, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-481
   Tseng LM, 2006, GENE CHROMOSOME CANC, V45, P629, DOI 10.1002/gcc.20326
   Ulrey CL, 2005, HUM MOL GENET, V14, pR139, DOI 10.1093/hmg/ddi100
   Verma M, 2007, CLIN CHIM ACTA, V383, P41, DOI 10.1016/j.cca.2007.04.018
   Verma Mukesh, 2007, Cancer Res, V67, P437, DOI 10.1158/0008-5472.CAN-06-4119
   Wallace DC, 2010, MITOCHONDRION, V10, P12, DOI 10.1016/j.mito.2009.09.006
   Wang L, 2007, CANCER EPIDEM BIOMAR, V16, P1455, DOI 10.1158/1055-9965.EPI-07-0119
   Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050
   Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154
   Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097
   Williams K, 2011, NATURE, V473, P343, DOI 10.1038/nature10066
   Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007
   Wu HJ, 2005, NATURE, V438, P981, DOI 10.1038/nature04225
   Xie CH, 2007, BIOCHEM BIOPH RES CO, V364, P656, DOI 10.1016/j.bbrc.2007.10.047
   Xu YF, 2011, MOL CELL, V42, P451, DOI 10.1016/j.molcel.2011.04.005
   Yin PH, 2004, BRIT J CANCER, V90, P2390, DOI 10.1038/sj.bjc.6601838
NR 106
TC 111
Z9 127
U1 0
U2 33
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD APR
PY 2012
VL 7
IS 4
BP 326
EP 334
DI 10.4161/epi.19547
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 921QX
UT WOS:000302493300002
PM 22419065
OA Green Published
DA 2025-01-12
ER

PT J
AU Boulay, G
   Dubuissez, M
   Van Rechem, C
   Forget, A
   Helin, K
   Ayrault, O
   Leprince, D
AF Boulay, Gaylor
   Dubuissez, Marion
   Van Rechem, Capucine
   Forget, Antoine
   Helin, Kristian
   Ayrault, Olivier
   Leprince, Dominique
TI Hypermethylated in Cancer 1 (HIC1) Recruits Polycomb Repressive Complex
   2 (PRC2) to a Subset of Its Target Genes through Interaction with Human
   Polycomb-like (hPCL) Proteins
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; DNA-BINDING; TRANSCRIPTIONAL REPRESSION; MICE
   DEFICIENT; BREAST-CANCER; TUDOR DOMAIN; DROSOPHILA; METHYLATION;
   RECEPTOR; EZH2
AB HIC1 (hypermethylated in cancer 1) is a tumor suppressor gene epigenetically silenced or deleted in many human cancers. HIC1 is involved in regulatory loops modulating p53- and E2F1-dependent cell survival, growth control, and stress responses. HIC1 is also essential for normal development because Hic1-deficient mice die perinatally and exhibit gross developmental defects throughout the second half of development. HIC1 encodes a transcriptional repressor with five C2H2 zinc fingers mediating sequence-specific DNA binding and two repression domains: an N-terminal BTB/POZ domain and a central region recruiting CtBP and NuRD complexes. By yeast two-hybrid screening, we identified the Polycomb-like protein hPCL3 as a novel corepressor for HIC1. Using multiple biochemical strategies, we demonstrated that HIC1 interacts with hPCL3 and its paralog PHF1 to form a stable complex with the PRC2 members EZH2, EED, and Suz12. Confirming the implication of HIC1 in Polycomb recruitment, we showed that HIC1 shares some of its target genes with PRC2, including ATOH1. Depletion of HIC1 by siRNA interference leads to a partial displacement of EZH2 from the ATOH1 promoter. Furthermore, in vivo, ATOH1 repression by HIC1 is associated with Polycomb activity during mouse cerebellar development. Thus, our results identify HIC1 as the first transcription factor in mammals able to recruit PRC2 to some target promoters through its interaction with Polycomb-like proteins.
C1 [Boulay, Gaylor; Dubuissez, Marion; Van Rechem, Capucine; Leprince, Dominique] Univ Lille Nord France, Inst Biol Lille, CNRS, UMR8161,Inst Pasteur Lille, F-59021 Lille, France.
   [Forget, Antoine; Ayrault, Olivier] Ctr Univ Orsay, INSERM, U1005, CNRS,UMR 3306,Inst Curie, F-91405 Orsay, France.
   [Helin, Kristian] Univ Copenhagen, BRIC, DK-2200 Copenhagen, Denmark.
C3 Pasteur Network; Universite de Lille; Institut Pasteur Lille; Centre
   National de la Recherche Scientifique (CNRS); CNRS - National Institute
   for Biology (INSB); Universite PSL; UNICANCER; Institut Curie; Centre
   National de la Recherche Scientifique (CNRS); Institut National de la
   Sante et de la Recherche Medicale (Inserm); Universite Paris Saclay;
   University of Copenhagen
RP Leprince, D (通讯作者)，Univ Lille Nord France, Inst Biol Lille, CNRS, UMR8161,Inst Pasteur Lille, 1 Rue Prof Calmette,BP 447, F-59021 Lille, France.
EM dominique.leprince@ibl.fr
RI Forget, Antoine/AAA-4967-2020; Helin, Kristian/HDM-8306-2022
OI Van Rechem, Capucine/0000-0002-5408-6124; Helin,
   Kristian/0000-0003-1975-6097
FU CNRS; Ligue Nationale contre le Cancer (Comite Interregional du
   Septentrion); Fondation pour la Recherche Medicale (Comite du Nord);
   Association pour la Recherche contre le Cancer; CNRS/Region Nord-Pas de
   Calais; AVENIR/INSERM/Inca
FX This work was supported in part by grants from the CNRS, the Ligue
   Nationale contre le Cancer (Comite Interregional du Septentrion), the
   Fondation pour la Recherche Medicale (Comite du Nord), and the
   Association pour la Recherche contre le Cancer (to D. L.).Supported by
   fellowships from the CNRS/Region Nord-Pas de Calais and the Association
   pour la Recherche contre le Cancer.Supported by a AVENIR/INSERM/Inca
   grant.
CR Adams-Cioaba MA, 2009, BIOCHEM CELL BIOL, V87, P93, DOI 10.1139/O08-129
   ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193
   Ayrault O, 2010, CANCER RES, V70, P5618, DOI 10.1158/0008-5472.CAN-09-3740
   Bienz M, 2006, TRENDS BIOCHEM SCI, V31, P35, DOI 10.1016/j.tibs.2005.11.001
   Boldajipour B, 2008, CELL, V132, P463, DOI 10.1016/j.cell.2007.12.034
   Boukarabila H, 2009, GENE DEV, V23, P1195, DOI 10.1101/gad.512009
   Boulay G, 2012, J BIOL CHEM, V287, P5379, DOI 10.1074/jbc.M111.304287
   Boulay G, 2011, BIOCHEM J, V434, P333, DOI 10.1042/BJ20100944
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Bracken AP, 2009, NAT REV CANCER, V9, P773, DOI 10.1038/nrc2736
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Briggs KJ, 2008, CANCER RES, V68, P8654, DOI 10.1158/0008-5472.CAN-08-1904
   Briggs KJ, 2008, GENE DEV, V22, P770, DOI 10.1101/gad.1640908
   Cao R, 2008, MOL CELL BIOL, V28, P1862, DOI 10.1128/MCB.01589-07
   Carter MG, 2000, HUM MOL GENET, V9, P413, DOI 10.1093/hmg/9.3.413
   Casanova M, 2011, DEVELOPMENT, V138, P1471, DOI 10.1242/dev.053652
   Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011
   Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077
   Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030
   Corsini L, 2007, NAT STRUCT MOL BIOL, V14, P98, DOI 10.1038/nsmb0207-98
   Coulson M, 1998, GENOMICS, V48, P381, DOI 10.1006/geno.1997.5201
   Dahl JA, 2007, STEM CELLS, V25, P1037, DOI 10.1634/stemcells.2006-0430
   Dehennaut V, 2009, B CANCER, V96, pE66, DOI 10.1684/bdc.2009.0959
   Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831
   Deltour S, 2002, MOL CELL BIOL, V22, P4890, DOI 10.1128/MCB.22.13.4890-4901.2002
   Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856
   Fleuriel C, 2009, INT J BIOCHEM CELL B, V41, P26, DOI 10.1016/j.biocel.2008.05.028
   Foveau B, 2012, J BIOL CHEM, V287, P5366, DOI 10.1074/jbc.M111.329466
   Friberg A, 2010, PROTEIN SCI, V19, P1906, DOI 10.1002/pro.476
   Grimmer MR, 2008, GENE DEV, V22, P693, DOI 10.1101/gad.1657808
   Hansen KH, 2008, NAT CELL BIOL, V10, P1291, DOI 10.1038/ncb1787
   Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08
   Huang Y, 2006, SCIENCE, V312, P748, DOI 10.1126/science.1125162
   Jenal M, 2009, MOL CANCER RES, V7, P916, DOI 10.1158/1541-7786.MCR-08-0359
   Laible G, 1997, EMBO J, V16, P3219, DOI 10.1093/emboj/16.11.3219
   Li G, 2010, GENE DEV, V24, P368, DOI 10.1101/gad.1886410
   Long JY, 2004, P NATL ACAD SCI USA, V101, P99, DOI 10.1073/pnas.0307598100
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Mellor J, 2006, CELL, V126, P22, DOI 10.1016/j.cell.2006.06.028
   Mohammad HP, 2011, ONCOGENE, V30, P2659, DOI 10.1038/onc.2010.633
   Morey L, 2008, MOL CELL BIOL, V28, P5912, DOI 10.1128/MCB.00467-08
   Morey L, 2010, TRENDS BIOCHEM SCI, V35, P323, DOI 10.1016/j.tibs.2010.02.009
   Nekrasov M, 2007, EMBO J, V26, P4078, DOI 10.1038/sj.emboj.7601837
   Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402
   Pasini D, 2007, MOL CELL BIOL, V27, P3769, DOI 10.1128/MCB.01432-06
   Pasini D, 2010, NUCLEIC ACIDS RES, V38, P4958, DOI 10.1093/nar/gkq244
   Pasini D, 2010, NATURE, V464, P306, DOI 10.1038/nature08788
   Pinte S, 2004, J BIOL CHEM, V279, P38313, DOI 10.1074/jbc.M401610200
   Pospichalova V, 2011, GENESIS, V49, P142, DOI 10.1002/dvg.20719
   Reynolds N, 2012, EMBO J, V31, P593, DOI 10.1038/emboj.2011.431
   Rood BR, 2002, CANCER RES, V62, P3794
   Sarma K, 2008, MOL CELL BIOL, V28, P2718, DOI 10.1128/MCB.02017-07
   Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002
   Savla U, 2008, DEVELOPMENT, V135, P813, DOI 10.1242/dev.016006
   Schuettengruber B, 2009, DEVELOPMENT, V136, P3531, DOI 10.1242/dev.033902
   Sierro F, 2007, P NATL ACAD SCI USA, V104, P14759, DOI 10.1073/pnas.0702229104
   Sing A, 2009, CELL, V138, P885, DOI 10.1016/j.cell.2009.08.020
   Srinivasan L, 2004, GENE DEV, V18, P2596, DOI 10.1101/gad.1228204
   Stankovic-Valentin N, 2007, MOL CELL BIOL, V27, P2661, DOI 10.1128/MCB.01098-06
   Stankovic-Valentin N, 2006, FEBS J, V273, P2879, DOI 10.1111/j.1742-4658.2006.05301.x
   Stogios PJ, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-10-r82
   Tie F, 2003, MOL CELL BIOL, V23, P3352, DOI 10.1128/MCB.23.9.3352-3362.2003
   Van Rechem C, 2010, MOL CELL BIOL, V30, P4045, DOI 10.1128/MCB.00582-09
   Van Rechem C, 2009, J BIOL CHEM, V284, P20927, DOI 10.1074/jbc.M109.022350
   Van Rechem C, 2009, BIOCHEM BIOPH RES CO, V385, P586, DOI 10.1016/j.bbrc.2009.05.115
   Villa R, 2007, CANCER CELL, V11, P513, DOI 10.1016/j.ccr.2007.04.009
   WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570
   Walker E, 2010, CELL STEM CELL, V6, P153, DOI 10.1016/j.stem.2009.12.014
   Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468
   Wang SW, 2004, GENE, V343, P69, DOI 10.1016/j.gene.2004.09.006
   Woo CJ, 2010, CELL, V140, P99, DOI 10.1016/j.cell.2009.12.022
   Zhang W, 2010, ONCOGENE, V29, P2467, DOI 10.1038/onc.2010.12
NR 73
TC 40
Z9 44
U1 0
U2 9
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAR 23
PY 2012
VL 287
IS 13
BP 10509
EP 10524
DI 10.1074/jbc.M111.320234
PG 16
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 917IN
UT WOS:000302167200077
PM 22315224
OA Green Published
DA 2025-01-12
ER

PT J
AU Huqun
   Ishikawa, R
   Zhang, JL
   Miyazawa, H
   Goto, Y
   Shimizu, Y
   Hagiwara, K
   Koyama, N
AF Huqun
   Ishikawa, Rinako
   Zhang, Jialing
   Miyazawa, Hitoshi
   Goto, Yoshiya
   Shimizu, Yoshihiko
   Hagiwara, Koichi
   Koyama, Nobuyuki
TI Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall
   cell lung cancer
SO CANCER
LA English
DT Article
DE EZH2; nonsmall cell lung cancer; prognostic biomarker; tumor size; tumor
   progression; tumor invasion
ID GROUP PROTEIN EZH2; HISTONE METHYLTRANSFERASE ACTIVITY; EMBRYONIC
   STEM-CELLS; BREAST-CANCER; PROMOTER HYPERMETHYLATION; DEVELOPMENTAL
   REGULATORS; SOMATIC MUTATIONS; DNA METHYLATION; PROSTATE-CANCER;
   E-CADHERIN
AB BACKGROUND: Enhancer of zeste homolog 2 (EZH2) epigenetically silences many genes through the trimethylation of histone H3 lysine 27 and is implicated in tumor growth, invasion, and metastasis. However, its role in lung cancer has not been well characterized. The objective of the current study was to elucidate the role of EZH2 in nonsmall cell lung cancer (NSCLC) by investigating both clinical samples and cell lines. METHODS: An immunohistochemical analysis of EZH2 expression was performed in samples from patients with stage I NSCLC to investigate the association of EZH2 expression levels with clinicopathologic variables. An in vitro cell growth assay and a Matrigel invasion assay also were conducted in the EZH2-expressing NSCLC cell lines A549 and H1299 after knocking down EZH2 expression by using an EZH2-specific short-hairpin RNA. RESULTS: The immunohistochemical analysis classified stage I NSCLC samples (n 106) into a negative EZH2 expression group (n 40; 37.7%) and a positive EZH2 expression group (n 66; 62.3%). Positive EZH2 expression was associated significantly with larger tumor size (P.014). Kaplan-Meier survival analyses and log-rank tests demonstrated that patients whose samples were classified into the positive EZH2 expression group had a significantly shorter overall survival (P.015). Experiments in the NSCLC cell lines revealed that the knockdown of EZH2 expression reduced the tumor growth rate and invasive activity. CONCLUSIONS: The current results indicated that EZH2 promotes progression and invasion of NSCLC, and its expression is a novel prognostic biomarker in NSCLC. Cancer 2012; 118: 1599-606. VC 2011 American Cancer Society.
C1 [Huqun; Ishikawa, Rinako; Zhang, Jialing; Koyama, Nobuyuki] Saitama Med Univ, Int Med Ctr, Dept Resp Med, Hidaka, Saitama 3501298, Japan.
   [Huqun] Affiliated Hosp Inner Mongolia, Coll Med, Dept Med Oncol, Hohhot, Peoples R China.
   [Zhang, Jialing] Affiliated Hosp Inner Mongolia, Coll Med, Clin Res Ctr, Hohhot, Peoples R China.
   [Goto, Yoshiya] Saitama Med Univ, Int Med Ctr, Dept Pathol, Hidaka, Saitama 3501298, Japan.
   [Shimizu, Yoshihiko] Saitama Prefectural Cardiopulm Ctr, Dept Pathol, Saitama, Japan.
C3 Saitama Medical University; Saitama Medical University
RP Koyama, N (通讯作者)，Saitama Med Univ, Int Med Ctr, Dept Resp Med, 1397-1 Yamane, Hidaka, Saitama 3501298, Japan.
EM nkoyama@saitama-med.ac.jp
RI Carrot-Zhang, Jian/K-8618-2019
OI Zhang, Jialing/0009-0007-8596-8449
FU Japan Society for the Promotion of Science [21591001]; Takeda Science
   Foundation; Daiwa Securities Health Foundation; Saitama Medical
   University [20-2-2-04]; Ishidsu Shun Memorial Scholarship; Grants-in-Aid
   for Scientific Research [21591001, 22659163] Funding Source: KAKEN
FX This study was supported in part by Grants-in-Aid for Scientific
   Research (grant 21591001) from the Japan Society for the Promotion of
   Science, Grants-in-Aid for Encouragement for Medical Research from
   Takeda Science Foundation, an investigative research grant from Daiwa
   Securities Health Foundation, Saitama Medical University Internal Grant
   20-2-2-04, and an Ishidsu Shun Memorial Scholarship.
CR Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Erhardt S, 2003, DEVELOPMENT, V130, P4235, DOI 10.1242/dev.00625
   Ezhkova E, 2009, CELL, V136, P1122, DOI 10.1016/j.cell.2008.12.043
   Fujii S, 2008, CANCER SCI, V99, P738, DOI 10.1111/j.1349-7006.2008.00743.x
   Goya T, 2005, LUNG CANCER, V50, P227, DOI 10.1016/j.lungcan.2005.05.021
   He LR, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-461
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Keedy VL, 2011, J CLIN ONCOL, V29, P2121, DOI 10.1200/JCO.2010.31.8923
   Kikuchi J, 2010, CANCER-AM CANCER SOC, V116, P3015, DOI 10.1002/cncr.25128
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Kuroki T, 2003, CANCER RES, V63, P3352
   Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Merola E, 2006, J CELL PHYSIOL, V207, P512, DOI 10.1002/jcp.20590
   Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518
   Müller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5
   Nikoloski G, 2010, NAT GENET, V42, P665, DOI 10.1038/ng.620
   Reijm EA, 2011, BREAST CANCER RES TR, V125, P387, DOI 10.1007/s10549-010-0836-9
   Rodenhuis S, 1997, J CLIN ONCOL, V15, P285, DOI 10.1200/JCO.1997.15.1.285
   SAKAI T, 1991, AM J HUM GENET, V48, P880
   Samaratunga H, 2008, WORLD J UROL, V26, P431, DOI 10.1007/s00345-008-0260-5
   Santos-Rosa H, 2005, EUR J CANCER, V41, P2381, DOI 10.1016/j.ejca.2005.08.010
   Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07
   Tonini T, 2004, ONCOGENE, V23, P4930, DOI 10.1038/sj.onc.1207608
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087
   Yang XJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005011
NR 33
TC 55
Z9 57
U1 0
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD MAR 15
PY 2012
VL 118
IS 6
BP 1599
EP 1606
DI 10.1002/cncr.26441
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 901NE
UT WOS:000300973000016
PM 21837672
DA 2025-01-12
ER

PT J
AU Qin, XY
   Fukuda, T
   Yang, LQ
   Zaha, H
   Akanuma, H
   Zeng, Q
   Yoshinaga, J
   Sone, H
AF Qin, Xian-Yang
   Fukuda, Tomokazu
   Yang, Linqing
   Zaha, Hiroko
   Akanuma, Hiromi
   Zeng, Qin
   Yoshinaga, Jun
   Sone, Hideko
TI Effects of bisphenol A exposure on the proliferation and senescence of
   normal human mammary epithelial cells
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
ID BREAST-CANCER CELLS; DNA METHYLATION; GENE-EXPRESSION; CYCLIN-E;
   CELLULAR SENESCENCE; IN-SITU; ESTROGEN; HYPERMETHYLATION;
   PHOSPHORYLATION; XENOESTROGENS
AB The carcinogenic activity of bisphenol A (BPA) is responsible for stimulating growth in estrogen-dependent breast cancer tissues, cell lines and rodent studies. However, it is not fully understood how this compound promotes mammary carcinogenesis. In our study, we examined the effect of BPA on cellular proliferation and senescence in human mammary epithelial cells (HMEC). Exposure to BPA for 1 week at the early stage at passage 8 increased the proliferation and sphere size of HMEC at the later stage up to passage 16, suggesting that BPA has the capability to modulate cell growth in breast epithelial cells. Interestingly, the number of human heterochromatin protein-1. positive cells, which is a marker of senescence, was also increased among BPA-treated cells. Consistent with these findings, the protein levels of both p16 and cyclin E, which are known to induce cellular senescence and promote proliferation, respectively, were increased in BPA-exposed HMEC. Furthermore, DNA methylation levels of genes related to development of most or all tumor types, such as BRCA1, CCNA1, CDKN2A (p16), THBS1, TNFRSF10C and TNFRSF10D, were increased in BPA-exposed HMEC. Our findings in the HMEC model suggested that the genetic and epigenetic alterations by BPA might damage HMEC function and result in complex activities related to cell proliferation and senescence, playing a role in mammary carcinogenesis. This manuscript has been published online, prior to printing. Once the issue is complete and page numbers have been assigned, the citation will change accordingly.
C1 [Qin, Xian-Yang; Yang, Linqing; Zaha, Hiroko; Akanuma, Hiromi; Zeng, Qin; Sone, Hideko] Natl Inst Environm Studies, Hlth Risk Res Sect, Tsukuba, Ibaraki, Japan.
   [Qin, Xian-Yang; Yoshinaga, Jun] Univ Tokyo, Grad Sch Frontier Sci, Dept Environm Studies, Kashiwa, Chiba, Japan.
   [Fukuda, Tomokazu] Tohoku Univ, Grad Sch Agr Sci, Lab Anim Breeding & Genet, Sendai, Miyagi 980, Japan.
   [Yang, Linqing] Shenzhen Ctr Dis Control & Prevent, Shenzhen, Guangdong, Peoples R China.
C3 National Institute for Environmental Studies - Japan; University of
   Tokyo; Tohoku University; Shenzhen Center for Disease Control &
   Prevention (SZCDC)
RP Sone, H (通讯作者)，Natl Inst Environm Studies, Hlth Risk Res Sect, Tsukuba, Ibaraki, Japan.
EM hsone@nies.go.jp
RI Qin, Xian-Yang/AAB-5628-2020; Fukuda, Tomokazu/O-1257-2018
OI Fukuda, Tomokazu/0000-0001-8456-0483
FU Ministry of the Health and Labor, Japan
FX This study was supported in part by a Grant-in-Aid for Scientific
   Research from the Ministry of the Health and Labor, Japan. The authors
   gratefully acknowledge the critical advice of Dr. Tohru Inoue ( National
   Institute of Health Sciences, Japan), and the technical support of Ms.
   Noriko Oshima (GE Healthcare Japan Corporation) in the analysis using
   the IN Cell Analyzer 1000. The authors also thank Ms. Yumi Matsumoto for
   her technical assistance.
CR Bandyopadhyay D, 2007, AGING CELL, V6, P577, DOI 10.1111/j.1474-9726.2007.00308.x
   Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367
   BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439
   Bruder ED, 2007, PHYSIOL GENOMICS, V29, P193, DOI 10.1152/physiolgenomics.00245.2006
   Buterin T, 2006, CARCINOGENESIS, V27, P1567, DOI [10.1093/carcin/bci339, 10.1093/carcin/bgi339]
   Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391, DOI 10.1289/ehp.7534
   Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003
   Dairkee SH, 2008, CANCER RES, V68, P2076, DOI 10.1158/0008-5472.CAN-07-6526
   de Waard WJ, 2008, TOXICOL IN VITRO, V22, P396, DOI 10.1016/j.tiv.2007.10.007
   Dejeux E, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-68
   Diel P, 2002, J STEROID BIOCHEM, V80, P61, DOI 10.1016/S0960-0760(01)00173-X
   Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Fleming JM, 2010, J CELL PHYSIOL, V224, P795, DOI 10.1002/jcp.22190
   Garbe JC, 2007, CELL CYCLE, V6, P1927, DOI 10.4161/cc.6.15.4519
   Hao B, 2007, MOL CELL, V26, P131, DOI 10.1016/j.molcel.2007.02.022
   Hayakawa T, 2003, J CELL SCI, V116, P3327, DOI 10.1242/jcs.00635
   Iso T, 2007, BIOL PHARM BULL, V30, P266, DOI 10.1248/bpb.30.266
   Jenkins S, 2011, ENVIRON HEALTH PERSP, V119, P1604, DOI 10.1289/ehp.1103850
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004
   Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008
   Kitagawa K, 2009, CANCER SCI, V100, P1374, DOI 10.1111/j.1349-7006.2009.01196.x
   Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203
   KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279
   Lamartiniere CA, 2011, HORM MOL BIOL CLIN I, V5, P45, DOI 10.1515/HMBCI.2010.075
   Lee JS, 2008, CANCER BIOL THER, V7, P1400
   Li H, 2009, NATURE, V460, P1136, DOI 10.1038/nature08290
   Lozada KW, 2011, BIOL REPROD, V85, P490, DOI 10.1095/biolreprod.110.090431
   Malyavantham KS, 2008, J CELL BIOCHEM, V105, P391, DOI 10.1002/jcb.21834
   Markey CM, 2001, BIOL REPROD, V65, P1215, DOI 10.1093/biolreprod/65.4.1215
   Minc E, 1999, CHROMOSOMA, V108, P220, DOI 10.1007/s004120050372
   Minella AC, 2005, CELL CYCLE, V4, P1356, DOI 10.4161/cc.4.10.2058
   Minella AC, 2008, GENE DEV, V22, P1677, DOI 10.1101/gad.1650208
   Moelans CB, 2011, J PATHOL, V225, P222, DOI 10.1002/path.2930
   Moral R, 2008, J ENDOCRINOL, V196, P101, DOI 10.1677/JOE-07-0056
   Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X
   Nijjar T, 2005, ONCOGENE, V24, P3369, DOI 10.1038/sj.onc.1208482
   Pal R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-303
   Ptak A, 2011, TOXICOL LETT, V202, P30, DOI 10.1016/j.toxlet.2011.01.015
   Qin XY, 2011, TOXICOL LETT, V206, P152, DOI 10.1016/j.toxlet.2011.07.007
   Radpour R, 2009, ONCOGENE, V28, P2969, DOI 10.1038/onc.2009.149
   Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579
   Roussel-Gervais A, 2010, MOL ENDOCRINOL, V24, P1835, DOI 10.1210/me.2010-0091
   Salvesen HB, 2000, CLIN CANCER RES, V6, P153
   Sarkar P, 2006, INT J ONCOL, V28, P43
   Serrano M, 2007, NAT REV MOL CELL BIO, V8, P715, DOI 10.1038/nrm2242
   Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672
   Shim YH, 2000, LAB INVEST, V80, P689, DOI 10.1038/labinvest.3780072
   Singleton DW, 2006, ENVIRON RES, V100, P86, DOI 10.1016/j.envres.2005.05.004
   Sudo H, 2008, RADIAT RES, V170, P23, DOI 10.1667/RR1317.1
   Taghavi N, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-138
   Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010
   Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x
   Weng YI, 2010, TOXICOL APPL PHARM, V248, P111, DOI 10.1016/j.taap.2010.07.014
   Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010
   Zang JJ, 2011, WORLD J GASTROENTERO, V17, P3043, DOI 10.3748/wjg.v17.i25.3043
NR 59
TC 78
Z9 82
U1 0
U2 22
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD MAR 1
PY 2012
VL 13
IS 5
BP 296
EP 306
DI 10.4161/cbt.18942
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 905VY
UT WOS:000301305500008
PM 22258036
OA Bronze
DA 2025-01-12
ER

PT J
AU Lodha, RS
   Nandeshwar, S
   Pal, DK
   Shrivastav, A
   Lodha, KM
   Bhagat, VK
   Bankwar, VV
   Nandeshwar, S
   Saxena, DM
AF Lodha, Rama S.
   Nandeshwar, Sunil
   Pal, D. K.
   Shrivastav, Atul
   Lodha, K. M.
   Bhagat, Vimal K.
   Bankwar, Vishal V.
   Nandeshwar, Sunil
   Saxena, D. M.
TI Risk Factors for Breast Cancer among Women in Bhopal Urban Agglomerate:
   A Case-Control Study
SO ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
LA English
DT Article
DE Breast cancer; breast feeding; oral contraceptive pills; reproductive;
   AORs
ID FEMALE BREAST; TURKISH WOMEN; DISEASE
AB Background: Breast cancer is the most common cancer in females worldwide, and the second leading cause of cancer deaths in women. The incidence is on the rise in India, and breast cancer is the second most common malignancy in Indian women. Objective: To assess the risk factors for breast cancer patients living in Bhopal. Study Design and Method: This case-control study was conducted in Bhopal urban agglomerate for a period of a year from October 2008 to August 2009. Demographic data and reproductive risk factor related information was collected using a structured questionnaire with analyses by Epi-info and SPSS 16. Results: A history of oral contraceptive pill use (OR=2.77, 95% CI: 1.15-6.65), history of not having breastfeeding (OR=3.49, 95% CI: 1.22-9.97), over weight (OR=0.11, 95% CI: 0.02-0.49), obese women (OR=0.24, 95% CI: 0.06-0.88) and family history of breast cancer (OR=3.89, 95% CI: 1.01-14.92) were associated significantly with the occurrence of breast cancer on multivariate analysis. Conclusions: The findings of the present study suggests that positive family history of breast cancer and history of using OCP may be the epigenetic factors promoting the occurrence of breast cancer while breastfeeding reduces the possibility of acquiring breast cancer.
C1 [Lodha, Rama S.; Bhagat, Vimal K.; Bankwar, Vishal V.; Saxena, D. M.] LN Med Coll, Bhopal, Madhya Pradesh, India.
   [Shrivastav, Atul] Populat Based Canc Registry, Bhopal, Madhya Pradesh, India.
   [Lodha, K. M.] Gandhi Med Coll, Bhopal, Madhya Pradesh, India.
RP Lodha, RS (通讯作者)，LN Med Coll, Bhopal, Madhya Pradesh, India.
EM drramalodha@gmail.com
CR A Wilder-Smith, 2009, BODY SIZE BREAST CAN
   Ahmad M., 2003, NCD Malaysia, V2, P23
   Al-Saad S, 2009, BAHRAIN MED B, V31
   Anderson WF, 2007, CANCER CAUSE CONTROL, V18, P439, DOI 10.1007/s10552-006-0092-9
   [Anonymous], 2004, ANTHROPOLOGIST, DOI DOI 10.1080/09720073.2005.11890889
   Beji NK, 2007, EUR J CANCER CARE, V16, P178, DOI 10.1111/j.1365-2354.2006.00711.x
   BRINTON LA, 1982, JNCI-J NATL CANCER I, V69, P817
   Carmichael AR, 2004, BREAST, V13, P85, DOI 10.1016/j.breast.2003.03.001
   Deo Deepali S, 2004, Indian J Pediatr, V71, P565, DOI 10.1007/BF02724307
   Ebrahimi M, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr454
   Fioretti F, 1999, BRIT J CANCER, V79, P1923, DOI 10.1038/sj.bjc.6690306
   Friedenreich CM, 2001, EUR J CANCER PREV, V10, P15, DOI 10.1097/00008469-200102000-00003
   GAJALAKSHMI CK, 1991, ACTA ONCOL, V30, P569, DOI 10.3109/02841869109092419
   Gupta Padmini, 2002, J Indian Med Assoc, V100, P282
   I Romieu, 1996, AM J EPIDEMIOL, V132, P17
   Iwasaki M, 2007, EUR J CANCER PREV, V16, P116, DOI 10.1097/01.cej.0000228410.14095.2d
   JICK H, 1980, AM J EPIDEMIOL, V112, P577, DOI 10.1093/oxfordjournals.aje.a113030
   K Zhu, 2003, ANN EPIDEMIOL, V15, P123
   M Sivkami, 2005, EC POLIT WKLY, V40, P282
   Mathew A, 2008, BRIT J CANCER, V99, P207, DOI 10.1038/sj.bjc.6604423
   McPherson K, 2000, BMJ-BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624
   Meshram II, 2009, ONLINE J HLTH ALLIED, V8, P5
   Must A, 1999, JAMA-J AM MED ASSOC, V282, P1523, DOI 10.1001/jama.282.16.1523
   NA Daud, 2004, NCD MALAYSIA, V3, P51
   Naieni KH, 2007, ASIAN PAC J CANCER P, V8, P395
   Newcomb PA, 1999, AM J EPIDEMIOL, V150, P174, DOI 10.1093/oxfordjournals.aje.a009977
   Norsa'adah B., 2005, SMJ Singapore Medical Journal, V46, P698
   Oran B, 2004, MED ONCOL, V21, P31, DOI 10.1385/MO:21:1:31
   Pakseresht S., 2009, Indian Journal of Cancer, V46, P132, DOI 10.4103/0019-509X.49151
   Palmer JR, 1997, CANCER CAUSE CONTROL, V8, P841, DOI 10.1023/A:1018408211089
   Reid RL, 2007, J OBSTET GYNAECOL CA, V29, P207, DOI 10.1016/S1701-2163(16)32418-5
   Russo J, 2001, Breast J, V7, P278, DOI 10.1046/j.1524-4741.2001.21033.x
   SS Parashar, 2009, TEXT BOOK PUBLIC HLT
   Vainio H, 2002, EUR J CANCER PREV, V11, pS94
   WILLETT WC, 2000, DIS BREAST, pCH15
   Yavari P, 2005, Asian Pac J Cancer Prev, V6, P370
   Yeole BB, 2008, ASIAN PAC J CANCER P, V9, P119
   Zeleniuch-Jacquotte Anne., 2005, BREAST CANCER-TOKYO, V2nd, P3
NR 38
TC 19
Z9 21
U1 0
U2 7
PU ASIAN PACIFIC ORGANIZATION CANCER PREVENTION
PI GYEONGGI-DO
PA APJCP HEAD OFFICE, KOREAN NATL CANCER CENTER, 323 ILAN -RO,
   ILSANDONG-GU, GOYANG-SI, GYEONGGI-DO, 410-769, SOUTH KOREA
SN 1513-7368
J9 ASIAN PAC J CANCER P
JI Asian Pac. J. Cancer Prev.
PY 2011
VL 12
IS 8
BP 2111
EP 2115
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 915FK
UT WOS:000302009300043
PM 22292661
DA 2025-01-12
ER

PT J
AU Nazir, M
   Kayani, MR
   Malik, FA
   Masood, N
   Kayani, MA
AF Nazir, M.
   Kayani, M. R.
   Malik, Faraz Arshad
   Masood, Nosheen
   Kayani, Mahmood Akhtar
TI Lack of Germ Line Changes in KISS1 and KAI1 Genes in Sporadic Head and
   Neck Cancer Patients of Pakistani Origin
SO ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
LA English
DT Article
DE PTEN; breast cancer; germline mutations; PCR; SSCPS
ID METASTASIS-SUPPRESSOR GENE; PROTEIN-COUPLED RECEPTOR;
   MESSENGER-RNA-EXPRESSION; SQUAMOUS-CELL CARCINOMA; BREAST-CANCER;
   DECREASED EXPRESSION; PANCREATIC-CANCER; PROSTATIC-CANCER;
   DOWN-REGULATION; MUTATION
AB Background: Head and neck cancer is included among the top five most commonly prevailing cancers worldwide. Abnormalities of either genetic or epigenetic factors are found responsible for the development and progression of head and neck cancer. Metastasis is the leading cause of death in patients with head and neck cancer. Down regulation of metastasis suppressor genes (MSGs) expression have been frequently observed in advanced tumours. Methodology: The present study was designed to screen two of the most frequently down-regulated MSGs (KISS1 and KAI1) for mutations in 120 diagnosed head and neck cancer affected Pakistani patients. The questionnaire was filled for basic information about age, gender, smoking habits and area of cancer affected and other relevant details. Primers for both genes were designed using "Primer 3" software in such a way that both intron exon boundaries were included in this region. DNA isolation and estimation was done by using organic method and agarose gel electrophoresis. Single Strand conformational polymorphism technique was used after amplification of the respective genes. Mobility patterns were analyzed using BioDoc Analyzer. Results: Data of patients were analyzed on the basis of age, sex and type of cancer as variables. The mean age of patients and controls was 44 years. There were 53% females and 47% males in this group of study, 63% nonsmokers and 37% smokers and larynx cancer was found to be most frequent type of cancer with a percentage of 64. Lack of germ line mutation was observed in the entire coding region in both coding regions as well as splice sites of the respective genes. Conclusion: Germ line mutations in KISS1 and KAI1 are thus considered to be a less frequent event in head and neck cancer patients. However, two polymorphisms in intronic region of exon 3 and exon 9 of KAI1 gene were observed in 1% of patients. In non coding region downstream of exon 3 (KAI1), there was a C 29166 T substitution and in intronic region upstream exon 9 of KAI1 gene, a C 52840 A substitution was observed. Both patients were females with ages 47 and 50 years respectively. A detailed analysis of regulatory mechanism is required to explore the genetic basis of down regulation of these MSGs for a better understanding of head and neck cancer progression.
C1 [Nazir, M.; Kayani, M. R.; Malik, Faraz Arshad; Masood, Nosheen; Kayani, Mahmood Akhtar] COMSATS Inst Informat & Technol, Canc Genet Lab, Islamabad, Pakistan.
C3 COMSATS University Islamabad (CUI)
RP Kayani, MA (通讯作者)，COMSATS Inst Informat & Technol, Canc Genet Lab, Islamabad, Pakistan.
EM mkay-ani@comsats.edu.pk
RI malik, Faraz./AFQ-1839-2022; Masood, Nosheen/ADW-3220-2022; Kayani,
   Mahmood/I-7760-2015
OI Masood, Nosheen/0000-0001-8909-6587; Kayani, Mahmood/0000-0001-9886-180X
CR Adeyemi BF, 2008, J NATL MED ASSOC, V100, P690, DOI 10.1016/S0027-9684(15)31343-2
   Akhtar N, 2007, PROFESSIONAL MED J, V14, P300
   Anderson D, 1997, TERATOGEN CARCIN MUT, V17, P115, DOI 10.1002/(SICI)1520-6866(1997)17:3<115::AID-TCM3>3.3.CO;2-F
   Bhurgri Yasmin, 2006, Asian Pac J Cancer Prev, V7, P195
   COMEY CT, 1994, J FORENSIC SCI, V39, P1254
   Dong JT, 1996, CANCER RES, V56, P4387
   Ferlito A, 2001, ORL-J OTO-RHIN-LARYN, V63, P202, DOI 10.1159/000055740
   Guo XZ, 1996, CANCER RES, V56, P4876
   Ha PK, 2009, ORAL ONCOL, V45, P335, DOI 10.1016/j.oraloncology.2008.05.015
   Higashiyama M, 1998, CANCER, V83, P466, DOI 10.1002/(SICI)1097-0142(19980801)83:3<466::AID-CNCR15>3.0.CO;2-U
   Hinoda Y, 1998, CANCER LETT, V129, P229, DOI 10.1016/S0304-3835(98)00112-8
   ICHIKAWA T, 1991, CANCER RES, V51, P3788
   Ikeguchi M, 2004, CLIN CANCER RES, V10, P1379, DOI 10.1158/1078-0432.CCR-1519-02
   Lallas TA, 1998, MOL GENET METAB, V64, P173, DOI 10.1006/mgme.1998.2713
   Lee JH, 1997, INT J CANCER, V71, P1035, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1035::AID-IJC20>3.0.CO;2-B
   Lee JH, 1996, JNCI-J NATL CANCER I, V88, P1731, DOI 10.1093/jnci/88.23.1731
   Lv Zhiqiang, 2009, CHINESE GERMAN J CLI, V8, P336
   Macfarlane GJ, 1996, BRIT J CANCER, V73, P805, DOI 10.1038/bjc.1996.141
   Mäkitie A, 1999, EUR ARCH OTO-RHINO-L, V256, P277, DOI 10.1007/s004050050245
   Malik FA, 2008, GENE THER MOL BIOL, V12B, P239
   Marcu LG, 2009, J CANCER RES CLIN, V135, P1303, DOI 10.1007/s00432-009-0648-7
   Masui T, 2004, BIOCHEM BIOPH RES CO, V315, P85, DOI 10.1016/j.bbrc.2004.01.021
   Miyazaki T, 2000, CANCER-AM CANCER SOC, V89, P955, DOI 10.1002/1097-0142(20000901)89:5<955::AID-CNCR3>3.0.CO;2-Z
   Muir AI, 2001, J BIOL CHEM, V276, P28969, DOI 10.1074/jbc.M102743200
   Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135
   Stadler ME, 2008, HEMATOL ONCOL CLIN N, V22, P1099, DOI 10.1016/j.hoc.2008.08.007
   Stark AM, 2005, J CANCER RES CLIN, V131, P191, DOI 10.1007/s00432-004-0629-9
   STEEG PS, 1988, JNCI-J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200
   Titcomb Jr CP, 2001, J INSUR MED, V3, P236
   Uzawa K, 2002, CLIN CANCER RES, V8, P828
   White A, 1998, ONCOGENE, V16, P3143, DOI 10.1038/sj.onc.1201852
   Yang XH, 1997, CANCER LETT, V119, P149, DOI 10.1016/S0304-3835(97)00273-5
   Yu GZ, 2006, CHINESE GERMAN J CLI, V5, P388
   Yu Y, 1997, CLIN CANCER RES, V3, P1045
NR 34
TC 5
Z9 6
U1 0
U2 0
PU ASIAN PACIFIC ORGANIZATION CANCER PREVENTION
PI GYEONGGI-DO
PA APJCP HEAD OFFICE, KOREAN NATL CANCER CENTER, 323 ILAN -RO,
   ILSANDONG-GU, GOYANG-SI, GYEONGGI-DO, 410-769, SOUTH KOREA
SN 1513-7368
J9 ASIAN PAC J CANCER P
JI Asian Pac. J. Cancer Prev.
PY 2011
VL 12
IS 10
BP 2767
EP 2771
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 915HD
UT WOS:000302013900056
PM 22320990
DA 2025-01-12
ER

PT J
AU Knower, KC
   To, SQ
   Takagi, K
   Miki, Y
   Sasano, H
   Simpson, ER
   Clyne, CD
AF Knower, Kevin C.
   To, Sarah Q.
   Takagi, Kiyoshi
   Miki, Yasuhiro
   Sasano, Hironobu
   Simpson, Evan R.
   Clyne, Colin D.
TI Melatonin suppresses aromatase expression and activity in breast cancer
   associated fibroblasts
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Melatonin; Aromatase; Postmenopause; Breast cancer; Epigenetic;
   Prostaglandin E-2
ID ADIPOSE STROMAL CELLS; RECEPTOR; GROWTH; BIOSYNTHESIS; MECHANISMS;
   TUMOR; ALPHA; LIGHT; AMP
AB The main biological active substance secreted by the pineal gland, melatonin (MLT), counteracts the effects of estrogens in breast cancer via exerting a number of its own oncostatic properties. Recent studies of postmenopausal women have identified that the major metabolite of MLT is statistically significantly associated with a lower risk of developing breast cancer. While MLT production decreases with age, breast cancer risk, however, increases with age and obesity. We hypothesize that MLT inhibits estrogen production in breast adipose fibroblasts (BAFs), the main local source of estrogen in breast tumors of postmenopausal women, by inhibiting transcription of the CYP19A1 gene that encodes the key enzyme aromatase. Normal BAFs were cultured from women undergoing breast reduction surgery, while breast cancer-associated fibroblasts (CAFs) were isolated from three women with estrogen receptor (ER) positive invasive ductal carcinomas. MTNR1A and MTNR1B receptor expression and CYP19A1 mRNA expression following MLT treatments were determined by qRT-PCR. BAFs express the G-protein coupled MLT receptors MTNR1A and MTNR1B with elevated levels of MTNR1A found in CAFs. Treatment of BAFs and CAFs with MLT resulted in significant suppression of CYP19A1 transcription and aromatase activity at pharmacological, physiological and sub-physiological concentrations. MLT suppression occurred through promoter-specific PI.4-, PI.3- and PII-derived CYP19A1 mRNA. Stimulation of CYP19A1 PII-mRNA and aromatase activity by prostaglandin E-2 (PGE(2)) were significantly attenuated by physiological doses of MLT. Lower levels of MLT in aging women may increase the risk of progressing ER-positive breast cancer through a decreased ability to suppress CYP19A1 expression and subsequent local estrogen production in BAFs/CAFs.
C1 [Knower, Kevin C.; To, Sarah Q.; Clyne, Colin D.] Prince Henrys Inst Med Res, Canc Drug Discovery Lab, Clayton, Vic 3168, Australia.
   [Takagi, Kiyoshi; Miki, Yasuhiro; Sasano, Hironobu] Tohoku Univ, Dept Pathol, Grad Sch Med, Sendai, Miyagi 980, Japan.
   [Simpson, Evan R.] Prince Henrys Inst, Metab & Canc Lab, Clayton, Vic, Australia.
   [Simpson, Evan R.; Clyne, Colin D.] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic, Australia.
C3 Prince Henry's Institute of Medical Research; Tohoku University; Prince
   Henry's Institute of Medical Research; Monash University
RP Knower, KC (通讯作者)，Prince Henrys Inst Med Res, Canc Drug Discovery Lab, POB 5152, Clayton, Vic 3168, Australia.
EM kevin.knower@princehenrys.org
RI Miki, Yasuhiro/AFQ-3410-2022; Takagi, Kiyoshi/ABJ-3265-2022; Knower,
   Kevin/C-2869-2014
OI To, Sarah Quynh Giao/0000-0002-7198-484X
FU U.S. Department of Defense [W81XWH-08-BCRP-POSTDOC]; National Health and
   Medical Research Council of Australia [338518, 550900]; Victoria Breast
   Cancer Research Consortium Inc.; Victorian Government
FX KCK was supported by a U.S. Department of Defense Post-doctoral Training
   Award (W81XWH-08-BCRP-POSTDOC). This work was supported by the National
   Health and Medical Research Council of Australia through fellowships to
   CDC (#338518) and ERS (#550900); the Victoria Breast Cancer Research
   Consortium Inc.; and the Victorian Government's Operational
   Infrastructure Support Program. PHI Data Audit #11-17.
CR ACKERMAN GE, 1981, J CLIN ENDOCR METAB, V53, P412, DOI 10.1210/jcem-53-2-412
   Allred DC, 1998, MODERN PATHOL, V11, P155
   Anisimov VN, 2010, CELL CYCLE, V9, P188, DOI 10.4161/cc.9.1.10407
   Anisimov VN, 2002, NEUROENDOCRINOL LETT, V23, P28
   Blask DE, 2011, J PINEAL RES, V51, P259, DOI 10.1111/j.1600-079X.2011.00888.x
   Brown KA, 2010, BREAST CANCER RES TR, V123, P591, DOI 10.1007/s10549-010-0834-y
   BULUN SE, 1993, J CLIN ENDOCR METAB, V77, P1622, DOI 10.1210/jc.77.6.1622
   Chen D, 2009, CANCER LETT, V273, P15, DOI 10.1016/j.canlet.2008.05.038
   Chen S, 2005, J STEROID BIOCHEM, V95, P17, DOI 10.1016/j.jsbmb.2005.04.002
   CORBIN CJ, 1988, P NATL ACAD SCI USA, V85, P8948, DOI 10.1073/pnas.85.23.8948
   Cos S, 2006, INT J CANCER, V118, P274, DOI 10.1002/ijc.21401
   Cos S, 2005, J PINEAL RES, V38, P136, DOI 10.1111/j.1600-079X.2004.00186.x
   Gonzalez A, 2008, J PINEAL RES, V45, P86, DOI 10.1111/j.1600-079X.2008.00559.x
   González A, 2007, ONCOL REP, V17, P947
   Gonzalez A, 2011, J PINEAL RES
   Grant SG, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409000982
   Hill SM, 2011, BREAST CANCER RES TR, V127, P91, DOI 10.1007/s10549-010-0958-0
   IGUCHI H, 1982, J CLIN ENDOCR METAB, V55, P27, DOI 10.1210/jcem-55-1-27
   Kiefer TL, 2005, J PINEAL RES, V38, P231, DOI 10.1111/j.1600-079X.2004.00198.x
   Martínez-Campa C, 2005, BREAST CANCER RES TR, V94, P249, DOI 10.1007/s10549-005-9006-x
   Martínez-Campa C, 2009, BRIT J CANCER, V101, P1613, DOI 10.1038/sj.bjc.6605336
   Mediavilla MD, 2010, CURR MED CHEM, V17, P4462, DOI 10.2174/092986710794183015
   Negi G, 2011, J PINEAL RES, V50, P124, DOI 10.1111/j.1600-079X.2010.00821.x
   ROBBINS P, 1995, HUM PATHOL, V26, P873, DOI 10.1016/0046-8177(95)90010-1
   Schernhammer ES, 2009, CANCER EPIDEM BIOMAR, V18, P74, DOI 10.1158/1055-9965.EPI-08-0637
   Shibuya R, 2008, ENDOCR-RELAT CANCER, V15, P113, DOI 10.1677/ERC-07-0092
   TAMARKIN L, 1982, SCIENCE, V216, P1003, DOI 10.1126/science.7079745
   Wolff AC, 2007, ARCH PATHOL LAB MED, V131, P18, DOI 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2
   Zhao Y, 1996, ENDOCRINOLOGY, V137, P5739, DOI 10.1210/en.137.12.5739
   Zhao Y, 1996, MOL ENDOCRINOL, V10, P1350, DOI 10.1210/me.10.11.1350
NR 30
TC 37
Z9 39
U1 1
U2 7
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD APR
PY 2012
VL 132
IS 2
BP 765
EP 771
DI 10.1007/s10549-012-1953-4
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 909ER
UT WOS:000301545900041
PM 22237979
DA 2025-01-12
ER

PT J
AU Lindqvist, BM
   Farkas, SA
   Wingren, S
   Nilsson, TK
AF Lindqvist, Breezy Malakkaran
   Farkas, Sanja A.
   Wingren, Sten
   Nilsson, Torbjorn K.
TI DNA methylation pattern of the <i>SLC25A43</i> gene in breast cancer
SO EPIGENETICS
LA English
DT Article
DE breast cancer; CpG island; CpG shore; gene inactivation; HER2 receptor;
   methylation; SLC25A43 gene
ID PROMOTER HYPERMETHYLATION; CPG ISLANDS; EARLY EVENT; HYPOMETHYLATION;
   EXPRESSION; TISSUE; TAMOXIFEN; TUMORS; GRADE; HMLH1
AB Solute carrier family 25A member 43 (SLC25A43) gene is a putative tumor suppressor gene that undergoes loss of heterozygosity (LOH) in human epidermal growth factor receptor 2 (HER2) positive breast cancer. Also, knockdown of SLC25A43 in cell lines influences cell turnover and metabolism. Absence of mutations in this gene in breast cancers prompted us to study methylation as an alternate mechanism for gene inactivation of this X encoded gene. Quantification of CpG site methylation using pyrosequencing was performed upstream of the SLC25A43 gene and at its 5' end in a cohort of breast tumor tissues (n = 80, HER2 positive or negative) with different SLC25A43 gene deletion status. Compared with control tissue, cancer tissues had lower levels of methylation at the 5' and 3' shores of the gene. Cancer tissues with no deletion in the SLC25A43 gene (Del(-)) had higher methylation in the CpG island (CGI) of the gene than cancers carrying the deletion (Del(+)). Methylation in the CGI of the SLC25A43 gene was negatively correlated with age at diagnosis. In HER2 positive breast cancer, ER negativity and lymph node positivity was associated with higher methylation in the CGI and in the adjacent shores of this gene. Our results suggest that methylation in the CGI of the SLC25A43 gene could be an alternate mechanism of gene silencing in the absence of LOH. Also, associations between site-specific methylation and clinicopathological parameters suggest that epigenetic changes in SLC25A43 gene could be of importance in breast carcinogenesis.
C1 [Lindqvist, Breezy Malakkaran; Wingren, Sten; Nilsson, Torbjorn K.] Univ Orebro, Sch Hlth & Med Sci, Orebro, Sweden.
   [Farkas, Sanja A.; Nilsson, Torbjorn K.] Orebro Univ Hosp, Dept Lab Med, Orebro, Sweden.
C3 Orebro University; Orebro University
RP Lindqvist, BM (通讯作者)，Univ Orebro, Sch Hlth & Med Sci, Orebro, Sweden.
EM breezy.malakkaran-lindqvist@orebroll.se
RI Farkas, Sanja/AAF-6190-2020
OI Farkas, Sanja/0000-0002-0418-7779
FU Swedish Cancer Society; Nyckelfonden Orebro, Sweden; Lions Cancer
   Foundation, Sweden
FX This study was supported by the grants from the Swedish Cancer Society,
   Nyckelfonden Orebro, Sweden and Lions Cancer Foundation, Sweden.
CR Baylin SB, 1998, ADV CANCER RES, V72, P141
   Bettstetter M, 2005, J PATHOL, V205, P606, DOI 10.1002/path.1732
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Carey LA, 2010, CLIN BREAST CANCER, V10, P188, DOI 10.3816/CBC.2010.n.026
   Chien J, 2005, ONCOGENE, V24, P5089, DOI 10.1038/sj.onc.1208700
   Cotton AM, 2011, HUM GENET, V130, P187, DOI 10.1007/s00439-011-1007-8
   Dewdney SB, 2011, CLIN CANCER RES, V17, P2120, DOI 10.1158/1078-0432.CCR-10-2668
   Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471
   Esteller M, 1999, CANCER RES, V59, P67
   Esteller M, 1998, CANCER RES, V58, P4515
   Esteva FJ, 2002, ONCOLOGY-NY, V16, P17
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Futscher BW, 2004, NEOPLASIA, V6, P380, DOI 10.1593/neo.04115
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435
   Goossens E, 2009, HUM REPROD, V24, P2255, DOI 10.1093/humrep/dep213
   GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709
   Haitina T, 2006, GENOMICS, V88, P779, DOI 10.1016/j.ygeno.2006.06.016
   Hellman A, 2007, SCIENCE, V315, P1141, DOI 10.1126/science.1136352
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Jackson K, 2004, CANCER BIOL THER, V3, P1225, DOI 10.4161/cbt.3.12.1222
   Ji H, 2010, NATURE, V467, P338, DOI 10.1038/nature09367
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jordan VC, 2007, CANCER EPIDEM BIOMAR, V16, P2207, DOI 10.1158/1055-9965.EPI-07-0629
   Kane MF, 1997, CANCER RES, V57, P808
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lee JS, 2007, VIRCHOWS ARCH, V450, P637, DOI 10.1007/s00428-007-0421-8
   Löf-Öhlin ZM, 2011, INT J ONCOL, V38, P685, DOI 10.3892/ijo.2011.895
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Lin CH, 2001, CANCER RES, V61, P4238
   Lorincz MC, 2004, NAT STRUCT MOL BIOL, V11, P1068, DOI 10.1038/nsmb840
   Milani L, 2009, GENOME RES, V19, P1, DOI 10.1101/gr.083931.108
   Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465
   Palmieri F, 2004, PFLUG ARCH EUR J PHY, V447, P689, DOI 10.1007/s00424-003-1099-7
   Piotrowski A, 2006, GENE CHROMOSOME CANC, V45, P656, DOI 10.1002/gcc.20331
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776
   SAKAI T, 1991, AM J HUM GENET, V48, P880
   Schmitt F., 2009, ADV THER, V26, P1
   Schulz WA, 2002, GENE CHROMOSOME CANC, V35, P58, DOI 10.1002/gcc.10092
   Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Strathdee G, 2004, CARCINOGENESIS, V25, P693, DOI 10.1093/carcin/bgh066
   Subramaniam MM, 2009, BREAST CANCER RES TR, V113, P113, DOI 10.1007/s10549-008-9917-4
   Tusnády GE, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni012
   Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007
NR 50
TC 12
Z9 14
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD MAR
PY 2012
VL 7
IS 3
BP 300
EP 306
DI 10.4161/epi.7.3.19064
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 907PC
UT WOS:000301428800011
PM 22430806
OA Bronze
DA 2025-01-12
ER

PT J
AU Shore, AN
   Herschkowitz, JI
   Rosen, JM
AF Shore, Amy N.
   Herschkowitz, Jason I.
   Rosen, Jeffrey M.
TI Noncoding RNAs Involved in Mammary Gland Development and Tumorigenesis:
   There's a Long Way to Go
SO JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
LA English
DT Article
DE Noncoding RNA; Mammary gland development; Alveologenesis; Epigenetics;
   Breast cancer
ID EPITHELIAL-MESENCHYMAL TRANSITION; X-CHROMOSOME INACTIVATION;
   GENE-EXPRESSION; POTENTIAL MARKER; ACTIVATOR SRA; TARGET GENE; KEY
   STAGES; BC200 RNA; CELL FATE; BREAST
AB The mammalian genome encodes thousands of noncoding RNAs. These noncoding transcripts are broadly categorized into short noncoding RNAs, such as microRNAs (miRNAs), and long noncoding RNAs (lncRNAs) of greater than 200 nt. While the role of miRNAs in development and cancer biology has been extensively studied, much less is known about the vast majority of noncoding transcripts represented by lncRNAs. LncRNAs are emerging as key regulators of developmental processes and as such, their frequent misregulation in tumorigenesis and disease in not unexpected. The role of lncRNAs in mammary gland development and breast cancer is just beginning to be elucidated. This review will discuss the role of lncRNAs in mammalian and mammary gland development. In addition, we will review the contributions of lncRNAs to the stepwise progression of tumorigenesis, highlighting the role of lncRNAs in breast cancer.
C1 [Shore, Amy N.; Rosen, Jeffrey M.] Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA.
   [Herschkowitz, Jason I.; Rosen, Jeffrey M.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
C3 Baylor College of Medicine; Baylor College of Medicine
RP Rosen, JM (通讯作者)，Baylor Coll Med, Program Dev Biol, 1 Baylor Plaza, Houston, TX 77030 USA.
EM jrosen@bcm.edu
FU Department of Defense [W81XWH-06-1-0717]; National Cancer Institute
   (NCI) [CA-16303, CA148761]
FX ANS was supported by a Department of Defense Pre-doctoral Fellowship
   Award (W81XWH-06-1-0717). This work was supported by National Cancer
   Institute (NCI) Grants CA-16303 and CA148761.
CR Adriaenssens E, 1998, AM J PATHOL, V153, P1597, DOI 10.1016/S0002-9440(10)65748-3
   Adriaenssens E, 1999, ONCOGENE, V18, P4460, DOI 10.1038/sj.onc.1202819
   Amaral PP, 2008, MAMM GENOME, V19, P454, DOI 10.1007/s00335-008-9136-7
   Anderson AE, 2011, DEVELOPMENT, V138, P1957, DOI 10.1242/dev.058461
   Anderson SM, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1653
   Askarian-Amiri ME, 2011, RNA, V17, P878, DOI 10.1261/rna.2528811
   Bartolomei MS, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a002592
   Benetatos L, 2010, LEUKEMIA RES, V34, P148, DOI 10.1016/j.leukres.2009.06.019
   Bertani S, 2011, MOL CELL, V43, P1040, DOI 10.1016/j.molcel.2011.08.019
   Berteaux N, 2005, J BIOL CHEM, V280, P29625, DOI 10.1074/jbc.M504033200
   Bertone P, 2004, SCIENCE, V306, P2242, DOI 10.1126/science.1103388
   Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874
   Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214
   Bond AM, 2009, NAT NEUROSCI, V12, P1020, DOI 10.1038/nn.2371
   Braconi C, 2011, ONCOGENE, V30, P4750, DOI 10.1038/onc.2011.193
   Brisken C, 2006, J MAMMARY GLAND BIOL, V11, P239, DOI 10.1007/s10911-006-9026-0
   Brockdorff N, 2011, DEVELOPMENT, V138, P5057, DOI 10.1242/dev.065276
   Bussemakers MJG, 1999, CANCER RES, V59, P5975
   Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611
   Calin GA, 2007, CANCER CELL, V12, P215, DOI 10.1016/j.ccr.2007.07.027
   Candeias MM, 2008, NAT CELL BIOL, V10, P1098, DOI 10.1038/ncb1770
   Caretti G, 2006, DEV CELL, V11, P547, DOI 10.1016/j.devcel.2006.08.003
   Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014
   Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028
   Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173
   Chen W, 1997, J PATHOL, V183, P345, DOI 10.1002/(SICI)1096-9896(199711)183:3<345::AID-PATH930>3.0.CO;2-8
   Cheng J, 2005, SCIENCE, V308, P1149, DOI 10.1126/science.1108625
   Chu C, 2011, MOL CELL, V44, P667, DOI 10.1016/j.molcel.2011.08.027
   Clemson CM, 2009, MOL CELL, V33, P717, DOI 10.1016/j.molcel.2009.01.026
   Cooper C, 2009, NUCLEIC ACIDS RES, V37, P4518, DOI 10.1093/nar/gkp441
   Day JR, 2011, CANCER LETT, V301, P1, DOI 10.1016/j.canlet.2010.10.019
   Dinger ME, 2008, GENOME RES, V18, P1433, DOI 10.1101/gr.078378.108
   Feng JC, 2006, GENE DEV, V20, P1470, DOI 10.1101/gad.1416106
   Foulds Charles E, 2010, Mol Endocrinol, V24, P1090, DOI 10.1210/me.2009-0427
   Gabory A, 2010, BIOESSAYS, V32, P473, DOI 10.1002/bies.200900170
   Gee HE, 2011, BRIT J CANCER, V104, P1168, DOI 10.1038/sj.bjc.6606076
   Gibb EA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025915
   Gibb EA, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-38
   Ginger MR, 2006, P NATL ACAD SCI USA, V103, P5781, DOI 10.1073/pnas.0600745103
   Ginger MR, 2001, MOL ENDOCRINOL, V15, P1993, DOI 10.1210/me.15.11.1993
   Guan LS, 1998, J BIOL CHEM, V273, P27047, DOI 10.1074/jbc.273.42.27047
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398
   Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672
   Hah N, 2011, CELL, V145, P622, DOI 10.1016/j.cell.2011.03.042
   Hansen TB, 2011, EMBO J, V30, P4414, DOI 10.1038/emboj.2011.359
   He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939
   Hennighausen L, 2005, NAT REV MOL CELL BIO, V6, P715, DOI 10.1038/nrm1714
   Hu WQ, 2011, GENE DEV, V25, P2573, DOI 10.1101/gad.178780.111
   Huarte M, 2010, HUM MOL GENET, V19, pR152, DOI 10.1093/hmg/ddq353
   Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040
   Hube F, 2006, DNA CELL BIOL, V25, P418, DOI 10.1089/dna.2006.25.418
   Hung T, 2011, NAT GENET, V43, P621, DOI 10.1038/ng.848
   Iacoangeli A, 2004, CARCINOGENESIS, V25, P2125, DOI 10.1093/carcin/bgh228
   Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609
   Jin GF, 2011, CARCINOGENESIS, V32, P1655, DOI 10.1093/carcin/bgr187
   Karreth FA, 2011, CELL, V147, P382, DOI 10.1016/j.cell.2011.09.032
   Katayama S, 2005, SCIENCE, V309, P1564, DOI 10.1126/science.1112009
   Khalil AM, 2011, SEMIN CELL DEV BIOL, V22, P359, DOI 10.1016/j.semcdb.2011.02.016
   Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106
   Kim T, 2011, J EXP MED, V208, P875, DOI 10.1084/jem.20110235
   Kino T, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000568
   Kohtz JD, 2004, GENE EXPR PATTERNS, V4, P407, DOI 10.1016/j.modgep.2004.01.007
   Kotake Y, 2011, ONCOGENE, V30, P1956, DOI 10.1038/onc.2010.568
   Kretz M, 2012, GENE DEV, V26, P338, DOI 10.1101/gad.182121.111
   Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902
   Lanz RB, 2003, MOL CELL BIOL, V23, P7163, DOI 10.1128/MCB.23.20.7163-7176.2003
   Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4
   Lee GL, 2011, NAT REV UROL, V8, P123, DOI 10.1038/nrurol.2011.10
   Lee JT, 2011, NAT REV MOL CELL BIO, V12, P815, DOI 10.1038/nrm3231
   Lemay DG, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-4-r43
   Leygue E, 1999, CANCER RES, V59, P4190
   Maruyama R, 2012, P NATL ACAD SCI USA, V109, P2820, DOI 10.1073/pnas.1010559107
   Matouk IJ, 2010, BBA-MOL CELL RES, V1803, P443, DOI 10.1016/j.bbamcr.2010.01.010
   Mazo A, 2007, J CELL SCI, V120, P2755, DOI 10.1242/jcs.007633
   Meola N, 2012, RNA, V18, P111, DOI 10.1261/rna.029454.111
   Mercer TR, 2008, P NATL ACAD SCI USA, V105, P716, DOI 10.1073/pnas.0706729105
   Mohamed JS, 2010, RNA, V16, P324, DOI 10.1261/rna.1441510
   Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518
   Moskalev EA, 2012, GENE CHROMOSOME CANC, V51, P105, DOI 10.1002/gcc.20943
   Mourtada-Maarabouni M, 2009, ONCOGENE, V28, P195, DOI 10.1038/onc.2008.373
   Nagano T, 2008, SCIENCE, V322, P1717, DOI 10.1126/science.1163802
   Ng SY, 2012, EMBO J, V31, P522, DOI 10.1038/emboj.2011.459
   Oakes SR, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1411
   Orom UA, 2010, CELL, V143, P46, DOI 10.1016/j.cell.2010.09.001
   Pandey RR, 2008, MOL CELL, V32, P232, DOI 10.1016/j.molcel.2008.08.022
   Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056
   Pasmant E, 2007, CANCER RES, V67, P3963, DOI 10.1158/0008-5472.CAN-06-2004
   Pasmant E, 2011, FASEB J, V25, P444, DOI 10.1096/fj.10-172452
   Pauli A, 2011, NAT REV GENET, V12, P136, DOI 10.1038/nrg2904
   Perez DS, 2008, HUM MOL GENET, V17, P642, DOI 10.1093/hmg/ddm336
   Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144
   Ponjavic J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000617
   Prasanth KV, 2007, GENE DEV, V21, P11, DOI 10.1101/gad.1484207
   Qureshi IA, 2010, BRAIN RES, V1338, P20, DOI 10.1016/j.brainres.2010.03.110
   Rapicavoli NA, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-49
   Ravasi T, 2006, GENOME RES, V16, P11, DOI 10.1101/gr.4200206
   Rijnkels M, 2010, J MAMMARY GLAND BIOL, V15, P85, DOI 10.1007/s10911-010-9170-4
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Rotblat B, 2011, MED HYPOTHESES, V77, P962, DOI 10.1016/j.mehy.2011.08.020
   Schwartz JC, 2008, NAT STRUCT MOL BIOL, V15, P842, DOI 10.1038/nsmb.1444
   Siegel PM, 2010, ONCOGENE, V29, P2753, DOI 10.1038/onc.2010.43
   Silva JM, 2011, RNA BIOL, V8, P496, DOI 10.4161/rna.8.3.14800
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199
   Takeda K, 1998, J BIOL CHEM, V273, P17079, DOI 10.1074/jbc.273.27.17079
   Tay Y, 2011, CELL, V147, P344, DOI 10.1016/j.cell.2011.09.029
   Tripathi V, 2010, MOL CELL, V39, P925, DOI 10.1016/j.molcel.2010.08.011
   Tsai MC, 2011, CANCER RES, V71, P3, DOI 10.1158/0008-5472.CAN-10-2483
   Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002
   Tsutsumi M, 2007, GENE EXPR PATTERNS, V7, P227, DOI 10.1016/j.modgep.2006.10.002
   Tursun B, 2011, SCIENCE, V331, P304, DOI 10.1126/science.1199082
   Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509
   Vorbach C, 2006, BIOESSAYS, V28, P606, DOI 10.1002/bies.20423
   Wagner LA, 2007, BLOOD, V109, P5191, DOI 10.1182/blood-2006-06-027987
   Wang JY, 2010, NUCLEIC ACIDS RES, V38, P5366, DOI 10.1093/nar/gkq285
   Wang XT, 2008, NATURE, V454, P126, DOI 10.1038/nature06992
   Wapinski O, 2011, TRENDS CELL BIOL, V21, P354, DOI 10.1016/j.tcb.2011.04.001
   Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341
   Watson CJ, 2008, DEVELOPMENT, V135, P995, DOI 10.1242/dev.005439
   Willingham AT, 2005, SCIENCE, V309, P1570, DOI 10.1126/science.1115901
   Wilusz JE, 2008, CELL, V135, P919, DOI 10.1016/j.cell.2008.10.012
   Yang LQ, 2011, CELL, V147, P773, DOI 10.1016/j.cell.2011.08.054
   Yang RX, 2008, CARCINOGENESIS, V29, P351, DOI 10.1093/carcin/bgm290
   Yap KL, 2010, MOL CELL, V38, P662, DOI 10.1016/j.molcel.2010.03.021
   Yochum GS, 2007, J BIOL CHEM, V282, P871, DOI 10.1074/jbc.M609391200
   Young TL, 2005, CURR BIOL, V15, P501, DOI 10.1016/j.cub.2005.02.027
   Younger ST, 2011, NUCLEIC ACIDS RES, V39, P5682, DOI 10.1093/nar/gkr155
   Zhang X, 2003, J CLIN ENDOCR METAB, V88, P5119, DOI 10.1210/jc.2003-030222
   Zhang XQ, 2009, BLOOD, V113, P2526, DOI 10.1182/blood-2008-06-162164
   Zhang X, 2010, CANCER RES, V70, P2350, DOI 10.1158/0008-5472.CAN-09-3885
   Zhao J, 2008, SCIENCE, V322, P750, DOI 10.1126/science.1163045
   Zhao J, 2010, MOL CELL, V40, P939, DOI 10.1016/j.molcel.2010.12.011
   Zhou Y, 2007, J BIOL CHEM, V282, P24731, DOI 10.1074/jbc.M702029200
NR 135
TC 47
Z9 53
U1 0
U2 16
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1083-3021
EI 1573-7039
J9 J MAMMARY GLAND BIOL
JI J. Mammary Gland Biol. Neoplasia
PD MAR
PY 2012
VL 17
IS 1
BP 43
EP 58
DI 10.1007/s10911-012-9247-3
PG 16
WC Oncology; Endocrinology & Metabolism; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Endocrinology & Metabolism; Physiology
GA 913AZ
UT WOS:000301845000006
PM 22402938
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Peters, KM
   Edwards, SL
   Nair, SS
   French, JD
   Bailey, PJ
   Salkield, K
   Stein, S
   Wagner, S
   Francis, GD
   Clark, SJ
   Brown, MA
AF Peters, Kate M.
   Edwards, Stacey L.
   Nair, Shalima S.
   French, Juliet D.
   Bailey, Peter J.
   Salkield, Kathryn
   Stein, Sandra
   Wagner, Sarah
   Francis, Glenn D.
   Clark, Susan J.
   Brown, Melissa A.
TI Androgen receptor expression predicts breast cancer survival: the role
   of genetic and epigenetic events
SO BMC CANCER
LA English
DT Article
DE Androgen receptor; Prognostic biomarker; Breast cancer; Gene regulation;
   Promoter methylation; Regulatory mutation; MiRNA
ID PROMOTER; IDENTIFICATION; TRANSCRIPTION; METHYLATION; MUTATIONS; GROWTH
AB Background: Breast cancer outcome, including response to therapy, risk of metastasis and survival, is difficult to predict using currently available methods, highlighting the urgent need for more informative biomarkers. Androgen receptor (AR) has been implicated in breast carcinogenesis however its potential to be an informative biomarker has yet to be fully explored. In this study, AR protein levels were determined in a cohort of 73 Grade III invasive breast ductal adenocarcinomas.
   Methods: The levels of Androgen receptor protein in a cohort of breast tumour samples was determined by immunohistochemistry and the results were compared with clinical characteristics, including survival. The role of defects in the regulation of Androgen receptor gene expression were examined by mutation and methylation screening of the 5' end of the gene, reporter assays of the 5' and 3' end of the AR gene, and searching for miRNAs that may regulate AR gene expression.
   Results: AR was expressed in 56% of tumours and expression was significantly inversely associated with 10-year survival (P = 0.004). An investigation into the mechanisms responsible for the loss of AR expression revealed that hypermethylation of the AR promoter is associated with loss of AR expression in breast cancer cells but not in primary breast tumours. In AR negative breast tumours, mutation screening identified the same mutation (T105A) in the 5' UTR of two AR negative breast cancer patients but not reported in the normal human population. Reporter assay analysis of this mutation however found no evidence for a negative impact on AR 5' UTR activity. The role of miR-124 in regulating AR expression was also investigated, however no evidence for this was found.
   Conclusion: This study highlights the potential for AR expression to be an informative biomarker for breast cancer survival and sets the scene for a more comprehensive investigation of the molecular basis of this phenomenon.
C1 [Peters, Kate M.; Edwards, Stacey L.; French, Juliet D.; Bailey, Peter J.; Salkield, Kathryn; Brown, Melissa A.] Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld 4072, Australia.
   [Nair, Shalima S.; Clark, Susan J.] Garvan Inst Med Res, Epigenet Grp, Sydney, NSW 2010, Australia.
   [Stein, Sandra; Wagner, Sarah; Francis, Glenn D.] Princess Alexandra Hosp, Dept Pathol, Woolloongabba, Qld 4102, Australia.
C3 University of Queensland; Garvan Institute of Medical Research; Princess
   Alexandra Hospital
RP Brown, MA (通讯作者)，Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld 4072, Australia.
EM melissa.brown@uq.edu.au
RI Brown, Melissa/F-1451-2010; Edwards, Stacey/A-4980-2011; French,
   Juliet/A-4982-2011; Bailey, Peter/E-9877-2011; Clark, Susan/B-2272-2008
OI Peters, Kate/0000-0002-5982-4448; French, Juliet/0000-0002-9770-0198;
   Brown, Melissa/0000-0002-2830-9259; Edwards, Stacey/0000-0001-7428-4139;
   Bailey, Peter/0000-0002-0857-2041; Clark, Susan/0000-0001-5925-5030
FU National Breast Cancer Foundation (NBCF); Cancer Australia; National
   Health and Medical Research Council (NHMRC)
FX This project was funded by grants from the National Breast Cancer
   Foundation (NBCF), Cancer Australia and National Health and Medical
   Research Council (NHMRC). SE was supported by an NHMRC CJ Martin
   Fellowship.
CR Agoff SN, 2003, AM J CLIN PATHOL, V120, P725, DOI 10.1309/42F00D0DJD0J5EDT
   BIRRELL SN, 1995, J STEROID BIOCHEM, V52, P459, DOI 10.1016/0960-0760(95)00005-K
   BRYAN RM, 1984, CANCER-AM CANCER SOC, V54, P2436, DOI 10.1002/1097-0142(19841201)54:11<2436::AID-CNCR2820541121>3.0.CO;2-H
   Bryne JC, 2008, NUCLEIC ACIDS RES, V36, pD102, DOI 10.1093/nar/gkm955
   Castellano I, 2010, BREAST CANC RES TREA
   Chen S, 1997, MOL ENDOCRINOL, V11, P3, DOI 10.1210/me.11.1.3
   Coolen MW, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm662
   Cox DG, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1602
   Crocitto LE, 1997, J UROLOGY, V158, P1599, DOI 10.1016/S0022-5347(01)64287-3
   Doane AS, 2006, ONCOGENE, V25, P3994, DOI 10.1038/sj.onc.1209415
   FABER PW, 1991, J BIOL CHEM, V266, P10743
   FABER PW, 1993, J BIOL CHEM, V268, P9296
   Francis GD, 2009, DIAGN MOL PATHOL, V18, P88, DOI 10.1097/PDM.0b013e31816f6374
   Gonzalez-Angulo AM, 2009, CLIN CANCER RES, V15, P2472, DOI 10.1158/1078-0432.CCR-08-1763
   Hurst DR, 2009, CANCER RES, V69, P7495, DOI 10.1158/0008-5472.CAN-09-2111
   Jarrard DF, 1998, CANCER RES, V58, P5310
   Karlsson C, 2009, CANCER EPIDEM BIOMAR, V18, P2014, DOI 10.1158/1055-9965.EPI-08-0743
   Kinoshita H, 2000, CANCER RES, V60, P3623
   Korhonen J, 2009, BIOINFORMATICS, V25, P3181, DOI 10.1093/bioinformatics/btp554
   Kyndi M, 2008, ACTA ONCOL, V47, P591, DOI 10.1080/02841860701851871
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li SJ, 2010, J HISTOCHEM CYTOCHEM, V58, P509, DOI 10.1369/jhc.2009.954644
   Liao DJ, 2002, J STEROID BIOCHEM, V80, P175, DOI 10.1016/S0960-0760(01)00185-6
   Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031
   MIZOKAMI A, 1994, MOL ENDOCRINOL, V8, P77, DOI 10.1210/me.8.1.77
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Ni M, 2011, CANCER CELL, V20, P119, DOI 10.1016/j.ccr.2011.05.026
   Park S., 2011, Ann Oncol
   Rakha EA, 2010, BREAST CANCER RES TR, V120, P293, DOI 10.1007/s10549-010-0746-x
   Sikand K, 2010, INT J CANC
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Takane KK, 1996, MOL CELL ENDOCRINOL, V119, P83, DOI 10.1016/0303-7207(96)03800-2
   Valastyan S, 2009, GENE DEV, V23, P2592, DOI 10.1101/gad.1832709
   Waltering KK, 2006, PROSTATE, V66, P1585, DOI 10.1002/pros.20387
   Wojdacz Tomasz K, 2008, BMC Res Notes, V1, P54, DOI 10.1186/1756-0500-1-54
   Yeap BB, 2004, BIOESSAYS, V26, P672, DOI 10.1002/bies.20051
   Yeh SY, 2003, J EXP MED, V198, P1899, DOI 10.1084/jem.20031233
NR 37
TC 51
Z9 61
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD APR 2
PY 2012
VL 12
AR 132
DI 10.1186/1471-2407-12-132
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 940MT
UT WOS:000303894400001
PM 22471922
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Hoyo, C
   Fortner, K
   Murtha, AP
   Schildkraut, JM
   Soubry, A
   Demark-Wahnefried, W
   Jirtle, RL
   Kurtzberg, J
   Forman, MR
   Overcash, F
   Huang, ZQ
   Murphy, SK
AF Hoyo, Cathrine
   Fortner, Kimberly
   Murtha, Amy P.
   Schildkraut, Joellen M.
   Soubry, Adelheid
   Demark-Wahnefried, Wendy
   Jirtle, Randy L.
   Kurtzberg, Joanne
   Forman, Michele R.
   Overcash, Francine
   Huang, Zhiqing
   Murphy, Susan K.
TI Association of cord blood methylation fractions at imprinted
   insulin-like growth factor 2 (<i>IGF2</i>), plasma IGF2, and birth
   weight
SO CANCER CAUSES & CONTROL
LA English
DT Article
DE IGF2; H19; ELISA; DNA methylation; Epigenetics; Epidemiology
ID FACTOR-II GENE; CTCF-BINDING SITES; BREAST-CANCER RISK; FOLIC-ACID USE;
   COLORECTAL-CANCER; PROSTATE-CANCER; DNA-METHYLATION; ALTERED
   METHYLATION; TEMPORAL STABILITY; OVARIAN-CANCER
AB Purpose Altered methylation at Insulin-like Growth Factor 2 (IGF2) regulatory regions has previously been associated with obesity, and several malignancies including colon, esophageal, and prostate adenocarcinomas, presumably via changes in expression and/or loss of imprinting, but the functional significance of these DNA methylation marks have not been demonstrated in humans. We examined associations among DNA methylation at IGF2 differentially methylated regions (DMRs), circulating IGF2 protein concentrations in umbilical cord blood (UCB) and birth weight in newborns.
   hods Questionnaire data were obtained from 300 pregnant women recruited between 2005 and 2009. UCB DNA methylation was measured by bisulfite pyrosequencing. UCB plasma concentrations of soluble IGF2 were measured by ELISA assays. Generalized linear regression models were used to examine the relationship between DMR methylation and IGF2 levels.
   Results Lower IGF2 DMR methylation was associated with elevated plasma IGF2 protein concentrations (beta = -9.87, p < 0.01); an association that was stronger in infants born to obese women (pre-pregnancy BMI >30 kg/m(2), beta = -20.21, p < 0.0001). Elevated IGF2 concentrations were associated with higher birth weight (p < 0.0001) after adjusting for maternal race/ethnicity, pre-pregnancy BMI, cigarette smoking, gestational diabetes, and infant sex. These patterns of association were not apparent at the H19 DMR.
   Conclusion Our data suggest that variation in IGF2 DMR methylation is an important mechanism by which circulating IGF2 concentrations, a putative risk factor for obesity and cancers of the colon, esophagus, and prostate, are modulated; associations that may depend on pre-pregnancy obesity.
C1 [Hoyo, Cathrine] Duke Univ, Sch Med, Div Clin Epidemiol, Dept Obstet & Gynecol, Durham, NC 27705 USA.
   [Hoyo, Cathrine; Schildkraut, Joellen M.; Overcash, Francine] Duke Univ, Med Ctr, Dept Community & Family Med, Durham, NC 27705 USA.
   [Hoyo, Cathrine; Schildkraut, Joellen M.; Soubry, Adelheid; Murphy, Susan K.] Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC 27710 USA.
   [Fortner, Kimberly; Murtha, Amy P.] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Div Maternal Fetal Med, Durham, NC 27710 USA.
   [Demark-Wahnefried, Wendy] Univ Texas MD Anderson Canc Ctr, Dept Behav Sci, Houston, TX 77030 USA.
   [Jirtle, Randy L.] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA.
   [Kurtzberg, Joanne] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27705 USA.
   [Forman, Michele R.] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA.
   [Huang, Zhiqing; Murphy, Susan K.] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Durham, NC 27708 USA.
   [Huang, Zhiqing; Murphy, Susan K.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27708 USA.
C3 Duke University; Duke University; Duke University; Duke University;
   University of Texas System; UTMD Anderson Cancer Center; Duke
   University; Duke University; University of Texas System; UTMD Anderson
   Cancer Center; Duke University; Duke University
RP Hoyo, C (通讯作者)，Duke Univ, Sch Med, Div Clin Epidemiol, Dept Obstet & Gynecol, 2200 W Main St,Suite 600, Durham, NC 27705 USA.
EM cathrine.hoyo@duke.edu
RI Soubry, Adelheid/LWI-5218-2024; Murphy, Susan/R-3903-2019
OI Hoyo, Cathrine/0000-0002-2466-8617; Murphy, Susan/0000-0001-8298-7272;
   Demark-Wahnefried, Wendy/0000-0001-5241-932X
FU American Cancer Society [ACS-IRG-83-006]; Fred and Alice Stanback
   Foundation; Duke Comprehensive Cancer Center; Duke Environmental Health
   Sciences Research Center;  [R21ES014947];  [R01ES016772]; 
   [R01DK085173];  [K01CA104517]
FX We thank the parents and children of the Newborn Epigenetics Study,
   research nurse Tammy Bishop, and research personnel: Stacy Murray,
   Carole Grenier, Darby Kroyer, Natasha Duggan, Suba Narasimhan, and James
   Nathan Yarnall for enrolling and tracing participants, and processing
   the specimens; and the obstetrics faculty and staff at Duke University
   and Durham regional Hospitals, Durham, NC. This work was supported in
   part by R21ES014947, R01ES016772, R01DK085173, K01CA104517 the American
   Cancer Society (grant number ACS-IRG-83-006) and the Fred and Alice
   Stanback Foundation. Dr. Susan Murphy was also supported by the Duke
   Comprehensive Cancer Center and Duke Environmental Health Sciences
   Research Center.
CR Akre O, 2006, CANCER EPIDEM BIOMAR, V15, P867, DOI 10.1158/1055-9965.EPI-05-0590
   Bagchi S, 2005, LANCET ONCOL, V6, P70, DOI 10.1016/S1470-2045(05)01724-9
   Bateson P, 2004, NATURE, V430, P419, DOI 10.1038/nature02725
   Bhusari S, 2011, PROSTATE, V71, P1621, DOI 10.1002/pros.21379
   Cruz-Correa M, 2004, GASTROENTEROLOGY, V126, P964, DOI 10.1053/j.gastro.2003.12.051
   Cruz-Correa M, 2009, EPIGENETICS-US, V4, P114, DOI 10.4161/epi.4.2.7954
   Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902
   Cui HM, 2001, CANCER RES, V61, P4947
   Cui HM, 2002, CANCER RES, V62, P6442
   Dammann RH, 2010, INT J ONCOL, V36, P171, DOI 10.3892/ijo_00000488
   Edwards CA, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-157
   Eriksson M, 2007, PROSTATE, V67, P1247, DOI 10.1002/pros.20428
   Feinberg AP, 2007, CANCER J, V13, P70, DOI 10.1097/PPO.0b013e31803c6e3b
   Forman MR, 2005, CANCER INVEST, V23, P609, DOI 10.1080/07357900500283093
   Fowke JH, 2010, ENDOCR-RELAT CANCER, V17, P51, DOI 10.1677/ERC-09-0023
   Gronbæk H, 2004, CANCER EPIDEM BIOMAR, V13, P1759
   Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105
   Heijmans BT, 2009, EPIGENETICS-US, V4, P526, DOI 10.4161/epi.4.8.10265
   Hoyo C, 2011, EPIGENETICS-US, V6, P928, DOI 10.4161/epi.6.7.16263
   Hoyo C, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-46
   Hoyo C, 2009, J EPIDEMIOL COMMUN H, V63, P683, DOI 10.1136/jech.2009.090803
   Huang ZQ, 2006, NUCLEIC ACIDS RES, V34, P555, DOI 10.1093/nar/gkj468
   Jarrard DF, 1995, CLIN CANCER RES, V1, P1471
   Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045
   Johnsen SP, 2004, EUR J EPIDEMIOL, V19, P41, DOI 10.1023/B:EJEP.0000013396.40006.8f
   Kaijser M, 2005, GASTROENTEROLOGY, V128, P607, DOI 10.1053/j.gastro.2004.11.049
   Murphy SK, 2006, MOL CANCER RES, V4, P283, DOI 10.1158/1541-7786.MCR-05-0138
   Murphy SK, 2003, HUM MUTAT, V22, P92, DOI 10.1002/humu.10237
   Murphy SK, 2003, BIOESSAYS, V25, P577, DOI 10.1002/bies.10277
   Murrell A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001849
   Nakagawa H, 2001, P NATL ACAD SCI USA, V98, P591, DOI 10.1073/pnas.011528698
   Nilsen TIL, 2005, INT J CANCER, V113, P1002, DOI 10.1002/ijc.20674
   Nowakowska-Zajdel E, 2011, INT J IMMUNOPATH PH, V24, P781, DOI 10.1177/039463201102400324
   Paradowska A, 2009, INT J ONCOL, V35, P87, DOI 10.3892/ijo_00000316
   Schlinzig T, 2009, ACTA PAEDIATR, V98, P1096, DOI 10.1111/j.1651-2227.2009.01371.x
   Shetty PJ, 2011, J CANCER RES CLIN, V137, P339, DOI 10.1007/s00432-010-0890-z
   Steegers-Theunissen RP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007845
   Strathdee G, 2004, BIOCHEM SOC T, V32, P913, DOI 10.1042/BST0320913
   Sullivan MJ, 1999, ONCOGENE, V18, P7527, DOI 10.1038/sj.onc.1203096
   Takai D, 2001, HUM MOL GENET, V10, P2619, DOI 10.1093/hmg/10.23.2619
   Talens RP, 2010, FASEB J, V24, P3135, DOI 10.1096/fj.09-150490
   Turan N, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001033
   Umbers AJ, 2011, J INFECT DIS, V203, P561, DOI 10.1093/infdis/jiq080
   Varrault A, 2006, DEV CELL, V11, P711, DOI 10.1016/j.devcel.2006.09.003
   Waterland RA, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001252
   Woodfine K, 2011, EPIGENET CHROMATIN, V4, DOI 10.1186/1756-8935-4-1
   Wu AH, 2011, BREAST CANCER RES TR, V130, P917, DOI 10.1007/s10549-011-1640-x
   Xu W, 2006, J EXP CLIN CANC RES, V25, P543
   Yang Rong, 2009, Wei Sheng Yan Jiu, V38, P423
   Zhao RH, 2009, CARCINOGENESIS, V30, P2117, DOI 10.1093/carcin/bgp254
   Zuo QS, 2011, MOL CARCINOGEN, V50, P390, DOI 10.1002/mc.20731
NR 51
TC 89
Z9 96
U1 1
U2 29
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957-5243
J9 CANCER CAUSE CONTROL
JI Cancer Causes Control
PD APR
PY 2012
VL 23
IS 4
BP 635
EP 645
DI 10.1007/s10552-012-9932-y
PG 11
WC Oncology; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Public, Environmental & Occupational Health
GA 931QE
UT WOS:000303233600012
PM 22392079
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Rivenbark, AG
   Stolzenburg, S
   Beltran, AS
   Yuan, XN
   Rots, MG
   Strahl, BD
   Blancafort, P
AF Rivenbark, Ashley G.
   Stolzenburg, Sabine
   Beltran, Adriana S.
   Yuan, Xinni
   Rots, Marianne G.
   Strahl, Brian D.
   Blancafort, Pilar
TI Epigenetic reprogramming of cancer cells via targeted DNA methylation
SO EPIGENETICS
LA English
DT Article
DE DNA methylation; artificial transcription factors (ATFs); zinc finger
   proteins (ZFPs); epigenetics; cancer cell reprogramming; epigenetic
   reprogramming; breast cancer; Maspin; SOX2
ID ZINC-FINGER DOMAINS; CONTROLLING GENE-EXPRESSION; TRANSCRIPTIONAL
   REPRESSION; TUMOR PROGRESSION; RNA INTERFERENCE; MASPIN GENE; SELECTION;
   RECOGNITION; SEQUENCES; CONSTRUCTION
AB An obstacle in the treatment of human diseases such as cancer is the inability to selectively and effectively target historically undruggable targets such as transcription factors. Here, we employ a novel technology using artificial transcription factors (ATFs) to epigenetically target gene expression in cancer cells. We show that site-specific DNA methylation and long-term stable repression of the tumor suppressor Maspin and the oncogene SOX2 can be achieved in breast cancer cells via zinc-finger ATFs targeting DNA methyltransferase 3a (DNMT3a) to the promoters of these genes. Using this approach, we show Maspin and SOX2 downregulation is more significant as compared with transient knockdown, which is also accompanied by stable phenotypic reprogramming of the cancer cell. These findings indicate that multimodular Zinc Finger Proteins linked to epigenetic editing domains can be used as novel cell resources to selectively and heritably alter gene expression patterns to stably reprogram cell fate.
C1 [Rivenbark, Ashley G.; Stolzenburg, Sabine; Beltran, Adriana S.; Yuan, Xinni; Blancafort, Pilar] Univ Groningen, Univ Med Ctr Groningen, Dept Pharmacol, Groningen, Netherlands.
   [Rivenbark, Ashley G.; Strahl, Brian D.] Univ Groningen, Univ Med Ctr Groningen, Dept Biochem & Biophys, Groningen, Netherlands.
   [Stolzenburg, Sabine; Rots, Marianne G.] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Lab Med, Groningen, Netherlands.
   [Rivenbark, Ashley G.; Beltran, Adriana S.; Yuan, Xinni; Strahl, Brian D.; Blancafort, Pilar] Univ N Carolina, Sch Med, UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA.
C3 University of Groningen; University of Groningen; University of
   Groningen; University of North Carolina; University of North Carolina
   Chapel Hill; University of North Carolina School of Medicine
RP Blancafort, P (通讯作者)，Univ Groningen, Univ Med Ctr Groningen, Dept Pharmacol, Groningen, Netherlands.
EM pilar_blancafort@med.unc.edu
RI Blancafort, Pilar/K-9029-2012; Strahl, Brian D/C-7601-2012
OI Blancafort, Pilar/0000-0002-3881-7396; Strahl, Brian
   D/0000-0002-4947-6259
FU American Cancer Society [116066-PF-08-166-01-GMC]; National Cancer
   Institute/National Institutes of Health [1R01CA125273,
   3R01CA125273-03S1]; Department of Defense (DoD) [W81XWH-10-1-0265,
   W81XWH-10-1-0266]
FX We thank Drs. Lee M. Graves and William B. Coleman at the University of
   North Carolina School of Medicine for critical reading and scientific
   discussions of this manuscript. This work was supported by Postdoctoral
   Fellowship 116066-PF-08-166-01-GMC from the American Cancer Society
   awarded to A. G. R. and from National Cancer Institute/National
   Institutes of Health grants 1R01CA125273, 3R01CA125273-03S1 and
   Department of Defense (DoD) awards W81XWH-10-1-0265 (to P.B.) and
   W81XWH-10-1-0266 (to B.D.S.).
CR Beerli RR, 1998, P NATL ACAD SCI USA, V95, P14628, DOI 10.1073/pnas.95.25.14628
   Beltran A, 2007, ONCOGENE, V26, P2791, DOI 10.1038/sj.onc.1210072
   Beltran AS, 2008, MOL CANCER THER, V7, P1080, DOI 10.1158/1535-7163.MCT-07-0526
   Beltran AS, 2011, EPIGENETICS-US, V6, P224, DOI 10.4161/epi.6.2.13700
   Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Blancafort P, 2004, MOL PHARMACOL, V66, P1361, DOI 10.1124/mol.104.002758
   Blancafort P, 2008, COMB CHEM HIGH T SCR, V11, P146, DOI 10.2174/138620708783744453
   Bostick M, 2007, SCIENCE, V317, P1760, DOI 10.1126/science.1147939
   Campbell TN, 2005, CURR ISSUES MOL BIOL, V7, P1
   Chen YP, 2008, J BIOL CHEM, V283, P17969, DOI 10.1074/jbc.M802917200
   Cher ML, 2003, P NATL ACAD SCI USA, V100, P7847, DOI 10.1073/pnas.1331360100
   CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168
   Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5
   Dreier B, 2005, J BIOL CHEM, V280, P35588, DOI 10.1074/jbc.M506654200
   Dreier B, 2001, J BIOL CHEM, V276, P29466, DOI 10.1074/jbc.M102604200
   Dreier B, 2000, J MOL BIOL, V303, P489, DOI 10.1006/jmbi.2000.4133
   Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886
   Groner AC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000869
   Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65
   Hashimoto H, 2010, EPIGENOMICS-UK, V2, P657, DOI 10.2217/EPI.10.44
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Isalan M, 2001, NAT BIOTECHNOL, V19, P656, DOI 10.1038/90264
   JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004
   Jin Bilian, 2011, Genes Cancer, V2, P607, DOI 10.1177/1947601910393957
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jurkowska RZ, 2011, CHEMBIOCHEM, V12, P206, DOI 10.1002/cbic.201000195
   Kim VN, 2003, J KOREAN MED SCI, V18, P309, DOI 10.3346/jkms.2003.18.3.309
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lengerke C, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-42
   Li FY, 2007, NUCLEIC ACIDS RES, V35, P100, DOI 10.1093/nar/gkl1035
   Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478
   MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509
   Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256
   REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274
   Rivenbark AG, 2006, EPIGENETICS-US, V1, P32, DOI 10.4161/epi.1.1.2358
   Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15
   Segal DJ, 1999, P NATL ACAD SCI USA, V96, P2758, DOI 10.1073/pnas.96.6.2758
   Segal DJ, 2003, BIOCHEMISTRY-US, V42, P2137, DOI 10.1021/bi026806o
   Sharif J, 2007, NATURE, V450, P908, DOI 10.1038/nature06397
   Shi HY, 2002, MOL THER, V5, P755, DOI 10.1006/mthe.2002.0602
   Sikorska M, 2008, J NEUROSCI RES, V86, P1680, DOI 10.1002/jnr.21635
   Takahashi K, 2007, NAT PROTOC, V2, P3081, DOI 10.1038/nprot.2007.418
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tan SY, 2003, P NATL ACAD SCI USA, V100, P11997, DOI 10.1073/pnas.2035056100
   Watanabe M, 2005, HUM GENE THER, V16, P699, DOI 10.1089/hum.2005.16.699
   Zhang M, 2000, ONCOGENE, V19, P6053, DOI 10.1038/sj.onc.1204006
NR 50
TC 171
Z9 212
U1 0
U2 21
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD APR
PY 2012
VL 7
IS 4
BP 350
EP 360
DI 10.4161/epi.19507
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 921QX
UT WOS:000302493300006
PM 22419067
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Dong, CF
   Wu, YD
   Yao, J
   Wang, YF
   Yu, YH
   Rychahou, PG
   Evers, BM
   Zhou, BP
AF Dong, Chenfang
   Wu, Yadi
   Yao, Jun
   Wang, Yifan
   Yu, Yinhua
   Rychahou, Piotr G.
   Evers, B. Mark
   Zhou, Binhua P.
TI G9a interacts with Snail and is critical for Snail-mediated E-cadherin
   repression in human breast cancer
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTION FACTOR SNAIL;
   GENE-EXPRESSION; DNA METHYLATION; STEM-CELLS; BASAL-LIKE; HISTONE
   METHYLATION; TUMOR-CELLS; CLAUDIN-LOW; PHENOTYPE
AB Breast cancers are highly heterogeneous but can be grouped into subtypes based on several criteria, including level of expression of certain markers. Claudin-low breast cancer (CLBC) is associated with early metastasis and resistance to chemotherapy, while gene profiling indicates it is characterized by the expression of markers of epithelial-mesenchymal transition (EMT) - a phenotypic conversion linked with metastasis. Although the epigenetic program controlling the phenotypic and cellular plasticity of EMT remains unclear, one contributor may be methylation of the E-cadherin promoter, resulting in decreased E-cadherin expression, a hallmark of EMT. Indeed, reduced E-cadherin often occurs in CLBC and may contribute to the early metastasis and poor patient survival associated with this disease. Here, we have determined that methylation of histone H3 on lysine 9 (H3K9me2) is critical for promoter DNA methylation of E-cadherin in three TGF-beta-induced EMT model cell lines, as well as in CLBC cell lines. Further, Snail interacted with G9a, a major euchromatin methyltransferase responsible for H3K9me2, and recruited G9a and DNA methyltransferases to the E-cadherin promoter for DNA methylation. Knockdown of G9a restored E-cadherin expression by suppressing H3K9me2 and blocking DNA methylation. This resulted in inhibition of cell migration and invasion in vitro and suppression of tumor growth and lung colonization in in vivo models of CLBC metastasis. Our study not only reveals a critical mechanism underlying the epigenetic regulation of EMT but also paves a way for the development of new treatment strategies for CLBC.
C1 [Zhou, Binhua P.] Univ Kentucky, Sch Med, Breast Canc Res Program, Markey Canc Ctr,Coll Med, Lexington, KY 40506 USA.
   [Dong, Chenfang; Wang, Yifan; Evers, B. Mark; Zhou, Binhua P.] Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40506 USA.
   [Wu, Yadi] Univ Kentucky, Coll Med, Dept Mol & Biomed Pharmacol, Lexington, KY 40506 USA.
   [Yao, Jun] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA.
   [Yu, Yinhua] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA.
   [Rychahou, Piotr G.; Evers, B. Mark] Univ Kentucky, Coll Med, Dept Surg, Lexington, KY 40506 USA.
C3 University of Kentucky; University of Kentucky; University of Kentucky;
   University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; University of Kentucky
RP Zhou, BP (通讯作者)，Univ Kentucky, Sch Med, Breast Canc Res Program, Markey Canc Ctr,Coll Med, BBSRB Room B336,741 S Limestone, Lexington, KY 40506 USA.
EM peter.zhou@uky.edu
RI Dong, Chenfang/B-1164-2013; WANG, YIFAN/AAW-1973-2021
OI Rychahou, Piotr/0000-0001-7352-9122
FU NIH [R01CA125454]; Susan G. Komen Foundation [KG081310]; Mary Kay Ash
   Foundation
FX We thank Nathan L. Vanderford for critical reading and editing of the
   manuscript. This work was supported by grants from the NIH
   (R01CA125454), the Susan G. Komen Foundation (KG081310), and the Mary
   Kay Ash Foundation (to B.P. Zhou).
CR Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034
   Bindels S, 2006, ONCOGENE, V25, P4975, DOI 10.1038/sj.onc.1209511
   Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74
   Caldeira JRF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-48
   Campos EI, 2009, ANNU REV GENET, V43, P559, DOI 10.1146/annurev.genet.032608.103928
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505
   Cheng XD, 2010, BIOCHEMISTRY-US, V49, P2999, DOI 10.1021/bi100213t
   Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872
   Collins R, 2010, NUCLEIC ACIDS RES, V38, P3503, DOI 10.1093/nar/gkq081
   Epsztejn-Litman S, 2008, NAT STRUCT MOL BIOL, V15, P1176, DOI 10.1038/nsmb.1476
   Estève PO, 2006, GENE DEV, V20, P3089, DOI 10.1101/gad.1463706
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   Grewal SIS, 2007, NAT REV GENET, V8, P35, DOI 10.1038/nrg2008
   Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010
   Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76
   Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108
   Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96
   Ikegami K, 2007, GENES CELLS, V12, P1, DOI 10.1111/j.1365-2443.2006.01029.x
   Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356
   Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kreike B, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1771
   Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017
   Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123
   Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63
   Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996
   Mahler-Araujo B, 2008, J CLIN PATHOL, V61, P615, DOI 10.1136/jcp.2007.053991
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   McCabe MT, 2009, CLIN CANCER RES, V15, P3927, DOI 10.1158/1078-0432.CCR-08-2784
   McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481
   MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021
   López-Novoa JM, 2009, EMBO MOL MED, V1, P303, DOI 10.1002/emmm.200900043
   Mohn F, 2009, TRENDS GENET, V25, P129, DOI 10.1016/j.tig.2008.12.005
   Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888
   Nabel CS, 2011, SCIENCE, V333, P1229, DOI 10.1126/science.1211917
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757
   Ooi L, 2007, NAT REV GENET, V8, P544, DOI 10.1038/nrg2100
   Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918
   Reiman JM, 2010, CANCER RES, V70, P3005, DOI 10.1158/0008-5472.CAN-09-4041
   Rudolph T, 2007, MOL CELL, V26, P103, DOI 10.1016/j.molcel.2007.02.025
   Sarrió D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017
   Shi Y, 2007, NAT REV GENET, V8, P829, DOI 10.1038/nrg2218
   Smallwood A, 2007, GENE DEV, V21, P1169, DOI 10.1101/gad.1536807
   Storci G, 2008, J PATHOL, V214, P25, DOI 10.1002/path.2254
   Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116
   Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509
   Wu SC, 2010, NAT REV MOL CELL BIO, V11, P607, DOI 10.1038/nrm2950
   Wu YD, 2010, CELL ADHES MIGR, V4, P199, DOI 10.4161/cam.4.2.10943
   Wu Y, 2009, CELL CYCLE, V8, P3267, DOI 10.4161/cc.8.20.9699
   Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016
   Wu YD, 2009, J BIOL CHEM, V284, P640, DOI 10.1074/jbc.M806916200
   Xie L, 2003, BREAST CANCER RES, V5, pR187, DOI 10.1186/bcr640
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
   Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173
NR 66
TC 376
Z9 412
U1 1
U2 60
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD APR
PY 2012
VL 122
IS 4
BP 1469
EP 1486
DI 10.1172/JCI57349
PG 18
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 918WJ
UT WOS:000302281800038
PM 22406531
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Taniguchi, H
   Jacinto, FV
   Villanueva, A
   Fernandez, AF
   Yamamoto, H
   Carmona, FJ
   Puertas, S
   Marquez, VE
   Shinomura, Y
   Imai, K
   Esteller, M
AF Taniguchi, H.
   Jacinto, F. V.
   Villanueva, A.
   Fernandez, A. F.
   Yamamoto, H.
   Carmona, F. J.
   Puertas, S.
   Marquez, V. E.
   Shinomura, Y.
   Imai, K.
   Esteller, M.
TI Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2
   in human cancer
SO ONCOGENE
LA English
DT Article
DE epigenetics; histone methyltransferase; EZH2; KLF2
ID TRANSCRIPTION FACTORS; CELL-GROWTH; POLYCOMB; REPRESSION; PROGRESSION;
   EXPRESSION; COMPLEX; TARGET
AB The Kruppel-like factor (KLF) proteins are multitasked transcriptional regulators with an expanding tumor suppressor function. KLF2 is one of the prominent members of the family because of its diminished expression in malignancies and its growth-inhibitory, pro-apoptotic and anti-angiogenic roles. In this study, we show that epigenetic silencing of KLF2 occurs in cancer cells through direct transcriptional repression mediated by the Polycomb group protein Enhancer of Zeste Homolog 2 (EZH2). Binding of EZH2 to the 5'-end of KLF2 is also associated with a gain of trimethylated lysine 27 histone H3 and a depletion of phosphorylated serine 2 of RNA polymerase. Upon depletion of EZH2 by RNA interference, short hairpin RNA or use of the small molecule 3-Deazaneplanocin A, the expression of KLF2 was restored. The transfection of KLF2 in cells with EZH2-associated silencing showed a significant anti-tumoral effect, both in culture and in xenografted nude mice. In this last setting, KLF2 transfection was also associated with decreased dissemination and lower mortality rate. In EZH2-depleted cells, which characteristically have lower tumorigenicity, the induction of KLF2 depletion 'rescued' partially the oncogenic phenotype, suggesting that KLF2 repression has an important role in EZH2 oncogenesis. Most importantly, the translation of the described results to human primary samples demonstrated that patients with prostate or breast tumors with low levels of KLF2 and high expression of EZH2 had a shorter overall survival. Oncogene (2012) 31, 1988-1994; doi:10.1038/onc.2011.387; published online 5 September 2011
C1 [Taniguchi, H.; Jacinto, F. V.; Fernandez, A. F.; Carmona, F. J.; Esteller, M.] Hosp Duran & Reynals, Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona 08908, Catalonia, Spain.
   [Taniguchi, H.; Yamamoto, H.; Shinomura, Y.] Sapporo Med Univ, Sch Med, Dept Internal Med 1, Sapporo, Hokkaido, Japan.
   [Taniguchi, H.] Sapporo Med Univ, Sch Med, Tumor Med Examinat & Treatment Ctr, Sapporo, Hokkaido, Japan.
   [Jacinto, F. V.] Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA.
   [Villanueva, A.; Puertas, S.] Bellvitge Biomed Res Inst IDIBELL, ICO, Barcelona, Spain.
   [Marquez, V. E.] NCI, Biol Chem Lab, Ctr Canc Res, NIH, Frederick, MD 21701 USA.
   [Imai, K.] Univ Tokyo, Inst Med Sci, Tokyo, Japan.
   [Esteller, M.] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Spain.
   [Esteller, M.] ICREA, Barcelona, Spain.
C3 Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran
   i Reynals; Sapporo Medical University; Sapporo Medical University; Salk
   Institute; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL);
   National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); University of Tokyo; University of Barcelona; ICREA
RP Esteller, M (通讯作者)，Hosp Duran & Reynals, Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, 3rd Floor,Avda Gran Via LHosp 199-203, Barcelona 08908, Catalonia, Spain.
EM mesteller@idibell.cat
RI Marquez, Victor/KWD-9188-2024; Taniguchi, Hiroaki/AGB-3012-2022;
   Esteller, Manel/L-5956-2014; Fernandez, Agustin/N-7302-2014
OI Carmona Sanz, F Javier/0000-0001-7904-8493; Taniguchi,
   Hiroaki/0000-0003-0494-5290; Esteller, Manel/0000-0003-4490-6093;
   Fernandez, Agustin/0000-0002-3792-4085
FU Lilly Foundation; Dr Josef Steiner Cancer Research Foundation; NIH,
   National Cancer Institute and Center for Cancer Research; 
   [SAF2007-00027-65134];  [Consolider CSD2006-49]; ICREA Funding Source:
   Custom; Grants-in-Aid for Scientific Research [23240129, 24650632,
   23701063] Funding Source: KAKEN
FX We thank O Dominguez for help with the microarray procedures and
   analysis, F Setien for technical assistance and Miki Kojiya for the flow
   cytometry analysis. This work was supported by Grants
   SAF2007-00027-65134, Consolider CSD2006-49, and Lilly Foundation and Dr
   Josef Steiner Cancer Research Foundation to ME, and the Intramural
   Research Program of the NIH, National Cancer Institute and Center for
   Cancer Research to VEM. HT is supported by the Uehara Memorial
   Foundation and Pancreas Research Foundation of Japan. ME is an ICREA
   Research Professor.
CR Beke L, 2007, ONCOGENE, V26, P4590, DOI 10.1038/sj.onc.1210248
   Bhattacharya R, 2005, J BIOL CHEM, V280, P28848, DOI 10.1074/jbc.C500200200
   Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Buckley AF, 2001, NAT IMMUNOL, V2, P698, DOI 10.1038/90633
   Bureau C, 2009, CURR GENOMICS, V10, P353, DOI 10.2174/138920209788921010
   Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200
   Duhagon MA, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-324
   Fernandez-Zapico ME, 2011, BIOCHEM J, V435, P529, DOI 10.1042/BJ20100773
   Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200
   Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206
   Kannan-Thulasiraman P, 2010, J BIOL CHEM, V285, P19106, DOI 10.1074/jbc.M109.099770
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761
   Pasini D, 2004, CELL CYCLE, V3, P396
   Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907
   Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Wang F, 2005, ONCOGENE, V24, P3875, DOI 10.1038/sj.onc.1208546
   Wu JH, 2004, ONCOGENE, V23, P8088, DOI 10.1038/sj.onc.1207996
   Yap DB, 2011, BLOOD, V117, P2451, DOI 10.1182/blood-2010-11-321208
   Yu J, 2010, ONCOGENE, V29, P5370, DOI 10.1038/onc.2010.269
   Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016
   Zhao CT, 2005, DEV GROWTH DIFFER, V47, P201
NR 26
TC 88
Z9 101
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD APR
PY 2012
VL 31
IS 15
BP 1988
EP 1994
DI 10.1038/onc.2011.387
PG 7
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 926CW
UT WOS:000302809900010
PM 21892211
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Kristensen, LS
   Raynor, M
   Candiloro, I
   Dobrovic, A
AF Kristensen, Lasse Sommer
   Raynor, Michael
   Candiloro, Ida
   Dobrovic, Alexander
TI Methylation profiling of normal individuals reveals mosaic promoter
   methylation of cancer-associated genes.
SO ONCOTARGET
LA English
DT Article
DE DNA methylation; epigenetics; biomarkers; high-resolution melting (HRM);
   methylation-specific PCR (MSP); constitutional methylation
ID SINGLE-NUCLEOTIDE POLYMORPHISMS; DNA METHYLATION; MELTING ANALYSIS;
   LUNG-CANCER; HIGH-THROUGHPUT; BREAST-CANCER; CPG ISLANDS; SMART-MSP;
   PCR; CELLS
AB Epigenetic silencing by promoter methylation of genes associated with cancer initiation and progression is a hallmark of tumour cells. As a consequence, testing for DNA methylation biomarkers in plasma or other body fluids shows great promise for detection of malignancies at early stages and/or for monitoring response to treatment. However, DNA from normal leukocytes may contribute to the DNA in plasma and will affect biomarker specificity if there is any methylation in the leukocytes. DNA from 48 samples of normal peripheral blood mononuclear cells was evaluated for the presence of methylation of a panel of DNA methylation biomarkers that have been implicated in cancer. SMART-MSP, a methylation specific PCR (MSP) methodology based on real time PCR amplification, high-resolution melting and strategic primer design, enabled quantitative detection of low levels of methylated DNA. Methylation was observed in all tested mononuclear cell DNA samples for the CDH1 and HIC1 promoters and in the majority of DNA samples for the TWIST1 and DAPK1 promoters. APC and RARB promoter methylation, at a lower average level, was also detected in a substantial proportion of the DNA samples. We found no BRCA1, CDKN2A, GSTP1 and RASSF1A promoter methylation in this sample set. Several individuals had higher levels of methylation at several loci suggestive of a methylator phenotype. In conclusion, methylation of many potential DNA methylation biomarkers can be detected in normal peripheral blood mononuclear cells, and is likely to affect their specificity for detecting low level disease. However, we found no evidence of promoter methylation for other genes indicating that panels of analytically sensitive and specific methylation biomarkers in body fluids can be obtained.
C1 [Kristensen, Lasse Sommer; Candiloro, Ida; Dobrovic, Alexander] Peter MacCallum Canc Ctr, Dept Pathol, Mol Pathol Res & Dev Lab, Melbourne, Vic, Australia.
   [Kristensen, Lasse Sommer] Aarhus Univ, Dept Biomed, DK-8000 Aarhus C, Denmark.
   [Raynor, Michael] Queen Elizabeth Hosp, Dept Haematol Oncol, Adelaide, SA, Australia.
   [Candiloro, Ida; Dobrovic, Alexander] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia.
   [Dobrovic, Alexander] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3052, Australia.
C3 Peter Maccallum Cancer Center; Aarhus University; University of
   Melbourne; University of Melbourne; Peter Maccallum Cancer Center
RP Dobrovic, A (通讯作者)，Peter MacCallum Canc Ctr, Dept Pathol, Mol Pathol Res & Dev Lab, Melbourne, Vic, Australia.
EM alexander.dobrovic@petermac.org
RI Kristensen, Lasse Sommer/G-6042-2016
OI Kristensen, Lasse Sommer/0000-0002-5980-7939; Dobrovic,
   Alexander/0000-0003-3414-112X
FU Department of Defense [W81XWH-05-1-0500]; Cancer Council of Victoria;
   Victorian Cancer Agency; National Breast Cancer Foundation of Australia
FX This study was supported by grants to AD from the Department of Defense
   Breast Cancer Research Program under award number W81XWH-05-1-0500, the
   Cancer Council of Victoria, the Victorian Cancer Agency and the National
   Breast Cancer Foundation of Australia. Views and opinions of, and
   endorsements by the author(s) do not reflect those of the US Army or the
   Department of Defense. We thank Thomas Mikeska and Hongdo Do for
   critical comments on the manuscript.
CR Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891
   Bhatia K, 2003, CANCER EPIDEM BIOMAR, V12, P165
   Candiloro ILM, 2008, EPIGENET CHROMATIN, V1, DOI 10.1186/1756-8935-1-7
   Cottrell SE, 2003, ANN NY ACAD SCI, V983, P120, DOI 10.1111/j.1749-6632.2003.tb05967.x
   Dobrovic A, 2005, MOL DIAGNOSTICS CLIN, P149
   Dobrovic A, 2009, INT J BIOCHEM CELL B, V41, P34, DOI 10.1016/j.biocel.2008.09.006
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Gudnason H, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm671
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hochedlinger K, 2004, GENE DEV, V18, P1875, DOI 10.1101/gad.1213504
   Hoque MO, 2005, J CLIN ONCOL, V23, P6569, DOI 10.1200/JCO.2005.07.009
   Kristensen LS, 2008, CANCER EPIDEM BIOMAR, V17, P1240, DOI 10.1158/1055-9965.EPI-07-2531
   Kristensen LS, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-453
   Kristensen LS, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn113
   Kristensen LS, 2009, CLIN CHEM, V55, P1471, DOI 10.1373/clinchem.2008.121962
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Liew M, 2004, CLIN CHEM, V50, P1156, DOI 10.1373/clinchem.2004.032136
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lombaerts M, 2004, BIOCHEM BIOPH RES CO, V319, P697, DOI 10.1016/j.bbrc.2004.05.041
   Mikeska T, EXPERT REV MOL UNPUB
   Mikeska T, 2010, EPIGENOMICS-UK, V2, P561, DOI 10.2217/EPI.10.32
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Palmisano WA, 2000, CANCER RES, V60, P5954
   Pedersen KS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018223
   Rand K, 2002, METHODS, V27, P114, DOI 10.1016/S1046-2023(02)00062-2
   Reddy AN, 2003, CANCER RES, V63, P7694
   Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157
   Shaw RJ, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl424
   Shi H, 2007, EXPERT REV MOL DIAGN, V7, P519, DOI 10.1586/14737159.7.5.519
   Taylor KH, 2007, CANCER RES, V67, P8511, DOI 10.1158/0008-5472.CAN-07-1016
   Teschendorff AE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008274
   Ushijima T, 2010, CANCER SCI, V101, P300, DOI 10.1111/j.1349-7006.2009.01434.x
   Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340
   Wang L, 2010, J THORAC ONCOL, V5, P778, DOI 10.1097/JTO.0b013e3181d6e0b3
   Wang YC, 2008, WORLD J GASTROENTERO, V14, P3074, DOI 10.3748/wjg.14.3074
   Weisenberger DJ, 2008, NUCLEIC ACIDS RES, V36, P4689, DOI 10.1093/nar/gkn455
   Wittwer CT, 2003, CLIN CHEM, V49, P853, DOI 10.1373/49.6.853
   Wong EM, 2011, CANCER PREV RES, V4, P23, DOI 10.1158/1940-6207.CAPR-10-0212
NR 40
TC 29
Z9 32
U1 0
U2 12
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD APR
PY 2012
VL 3
IS 4
BP 450
EP 461
DI 10.18632/oncotarget.480
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA 948SK
UT WOS:000304522700011
PM 22570110
OA Green Published, hybrid, Green Accepted, Green Submitted
DA 2025-01-12
ER

PT J
AU Prabhu, JS
   Wahi, K
   Korlimarla, A
   Correa, M
   Manjunath, S
   Raman, N
   Srinath, BS
   Sridhar, TS
AF Prabhu, Jyothi S.
   Wahi, Kanu
   Korlimarla, Aruna
   Correa, Marjorrie
   Manjunath, Suraj
   Raman, N.
   Srinath, B. S.
   Sridhar, T. S.
TI The epigenetic silencing of the estrogen receptor (ER) by
   hypermethylation of the ESR1 promoter is seen predominantly in
   triple-negative breast cancers in Indian women
SO TUMOR BIOLOGY
LA English
DT Article
DE Quantitative methylation; Estrogen receptor promoter; Triple-negative
   breast cancer; Epigenetic; FFPE
ID POLYMERASE-CHAIN-REACTION; DNA METHYLATION; MOLECULAR SUBTYPES;
   GENE-EXPRESSION; PROGNOSTIC FACTORS; CPG ISLANDS; ALPHA GENE; TUMORS;
   BRCA1; ASSAY
AB The proportion of estrogen receptor (ER)-negative and triple-negative (TN) breast cancer in Indian women is higher than that reported in the West, and this difference persists even after their migration to the West. The causes for this significant difference are not entirely clear. Hypermethylation of the ER promoter, an epigenetic alteration, is known to be one of the mechanisms by which the expression of ER is suppressed. Two thirds of breast cancer specimens from an Indian center tested, using the highly sensitive, methylation-specific polymerase chain reaction (MSP) technique, were reported positive. We have used a quantitative assay, the MethyLight, to better assess the extent of methylation in the ESR1 promoter region in 98 breast cancer tumor specimens from Indian women. In addition, the amount of ER transcripts was determined by quantitative reverse transcriptase polymerase chain reaction. Using the stringent cutoff of at least 4% of the target sequence being methylated, 27% of TN tumors were methylated. In addition they demonstrated the highest levels of methylation. In contrast less than 2% ER-positive tumors were hypermethylated. While the proportion of hypermethylated tumors are lower in this study than that estimated using MSP, our results support the notion of increased epigenetic deregulations in ER-negative tumors in general and TN tumors in particular. The development of this assay also permits a rational approach to the selection of patients for clinical trials examining the efficacy of demethylating agents in the treatment of ER-negative breast cancer.
C1 [Prabhu, Jyothi S.; Wahi, Kanu; Korlimarla, Aruna; Sridhar, T. S.] St Johns Res Inst, Div Mol Med, Bangalore, Karnataka, India.
   [Correa, Marjorrie] St Johns Med Coll & Hosp, Dept Pathol, Bangalore, Karnataka, India.
   [Manjunath, Suraj] St Johns Med Coll & Hosp, Dept Surg Oncol, Bangalore, Karnataka, India.
   [Raman, N.; Srinath, B. S.] Rangadore Mem Hosp, Bangalore, Karnataka, India.
C3 St. John's National Academy of Health Sciences; St. John's Research
   Institute; St. John's National Academy of Health Sciences; St. John's
   Medical College; St. John's National Academy of Health Sciences; St.
   John's Medical College
RP Prabhu, JS (通讯作者)，St Johns Res Inst, Div Mol Med, Bangalore, Karnataka, India.
EM jyothisprabhu@gmail.com
RI Prabhu, Jyothi/AAW-6361-2020; Wahi, Kanu/JCE-1249-2023
OI Prabhu, Jyothi/0000-0002-2269-3704; Wahi, Kanu/0000-0003-1114-6075;
   Manjunath, Suraj/0000-0002-4760-7366
FU Nadathur Holdings, Bangalore; Bagaria Education Trust, Bangalore
FX This work was funded by the Nadathur Holdings, Bangalore and the Bagaria
   Education Trust, Bangalore. The patient enrolment, sample collection,
   and patient follow-up were coordinated by Ms. Annie Alexander of
   "Aadhara", our patient support group. We would also like to acknowledge
   the excellent technical support provided by Mr. Raju and Ms. Anupama as
   well as the meticulous collation of clinical information by Ms. Rohini
   our clinical research associate. Dr Tinku Thomas of the Epidemiology and
   Biostatistics division of SJRI reviewed the statistical analysis.
CR Agarwal G, 2007, WORLD J SURG, V31, P1031, DOI 10.1007/s00268-005-0585-9
   Ambroise M, 2011, ASIAN PAC J CANCER P, V12, P625
   Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109
   CLARK GM, 1988, SEMIN ONCOL, V15, P20
   Cronin M, 2004, AM J PATHOL, V164, P35, DOI 10.1016/S0002-9440(10)63093-3
   Desai SB, 2000, BREAST, V9, P267, DOI 10.1054/brst.2000.0134
   Eads CA, 2001, CANCER RES, V61, P3410
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   FALETTE NS, 1990, CANCER RES, V50, P3974
   Gaudet MM, 2009, CANCER EPIDEM BIOMAR, V18, P3036, DOI 10.1158/1055-9965.EPI-09-0678
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hicks DG, 2006, AM J SURG PATHOL, V30, P1097
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Iwase H, 1999, BRIT J CANCER, V80, P1982, DOI 10.1038/sj.bjc.6690631
   Kakarala M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-191
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   MCGUIRE WL, 1990, J NATL CANCER I, V82, P1006, DOI 10.1093/jnci/82.12.1006
   Mirza S, 2007, LIFE SCI, V81, P280, DOI 10.1016/j.lfs.2007.05.012
   Mirza S, 2010, CLIN BIOCHEM, V43, P380, DOI 10.1016/j.clinbiochem.2009.11.016
   Moran MS, 2011, BREAST CANCER RES TR, V128, P543, DOI 10.1007/s10549-011-1362-0
   Murthy NS, 2007, EUR J CANCER CARE, V16, P185, DOI 10.1111/j.1365-2354.2006.00761.x
   National Cancer Registry Programme, 2001, CONS REP POP BAS CAN
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Perou CM, 2010, ONCOLOGIST, V15, P39, DOI 10.1634/theoncologist.2010-S5-39
   Raina V, 2000, INDIAN PRACT, V53, P405
   Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421
   Shet T, 2009, INDIAN J PATHOL MICR, V52, P171, DOI 10.4103/0377-4929.48909
   Singh AK, 2011, EUR J CANCER PREV, V20, P478, DOI 10.1097/CEJ.0b013e32834761a6
   Stark A, 2010, CANCER-AM CANCER SOC, V116, P4926, DOI 10.1002/cncr.25276
   Stead LA, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2242
   Veeck J, 2010, J CLIN ONCOL, V28, pE563, DOI 10.1200/JCO.2010.30.1010
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Yan L, 2001, J MAMMARY GLAND BIOL, V6, P183, DOI 10.1023/A:1011308707512
   Yoshida T, 2000, CARCINOGENESIS, V21, P2193, DOI 10.1093/carcin/21.12.2193
   Zhao L, 2009, BREAST CANCER RES TR, V117, P253, DOI 10.1007/s10549-008-0192-1
NR 39
TC 25
Z9 29
U1 0
U2 12
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1010-4283
J9 TUMOR BIOL
JI Tumor Biol.
PD APR
PY 2012
VL 33
IS 2
SI SI
BP 315
EP 323
DI 10.1007/s13277-012-0343-1
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 904IX
UT WOS:000301189400006
PM 22362381
DA 2025-01-12
ER

PT J
AU Katsios, C
   Ziogas, DE
   Liakakos, T
   Zoras, O
   Roukos, DH
AF Katsios, Christos
   Ziogas, Dimosthenis E.
   Liakakos, Theodore
   Zoras, Odysseas
   Roukos, Dimitrios H.
TI Translating Cancer Genomes Sequencing Revolution into Surgical Oncology
   Practice
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE cancer; genome sequencing; drugs; surgical oncology
ID GENOTYPE-PHENOTYPE MAP; BREAST-CANCER; MOLECULAR NETWORKS;
   NEXT-GENERATION; TRASTUZUMAB; CHALLENGES; CHEMOTHERAPY; ASSOCIATION;
   RESISTANCE; THERAPY
AB Background. Ten years after the first complete human genome sequencing, next-generation sequencing (NGS) technology has revolutionized genomics and biomedical research. Here we discuss potential emerging and future applications of NGS platforms and how cancer genome advances may change current surgical oncology practice.
   Materials and Methods. Publications in PubMed with partial or complete human and cancer genome sequencing over the last decade have been retrieved and analyzed. Recently launched international large-scale consortiums for systematic study of causal (driver) mutations underlying common complex diseases such as cancer and more recent opinion articles by leading scientists have been considered to predict the prospects of integration genomics data into surgical oncology.
   Results. Two dozen complete human genome sequences, and three full-genome sequencing in three cancer patients have recently been published. These studies and other cancer genome systematic studies evaluating genomic rearrangements and copy-number changes consistently reveal that cancer initiation and metastasis are much more complex than we thought. This high complexity and widespread variability of cancer genes, mutations, and deregulated signaling pathways among patients with the same cancer type, tumor stage, and clinicopathologic features explains the limited effectiveness of currently used biologically targeted agents.
   Conclusions. Yet the impact of genomics explosion in surgical oncology is little. Nevertheless, "big" biology consortiums such as the International Cancer Genome Project and other systematic studies in the areas of genetics, genomics, and epigenetics are now providing in-depth understanding of cancer, and shape new more rational ways towards novel therapeutics for improving oncologic outcomes of millions of patients worldwide. At the beginning of the second post-genomic decade, an explosion in genomic technology has revolutionized biomedical sciences. The ability of latest DNA sequencing technology to identify, in an unprecedented level, causal mutations driving cancer initiation and metastasis raises significant expectations for improving oncologic outcomes. Which are the challenges and perspectives to translate this genomic revolution into a surgical oncology-changing era? (C) 2012 Elsevier Inc. All rights reserved.
C1 [Katsios, Christos; Ziogas, Dimosthenis E.; Roukos, Dimitrios H.] Univ Ioannina, Sch Med, Dept Surg, Ioannina 45110, Greece.
   [Liakakos, Theodore] Univ Athens, Sch Med, Attikon Univ Hosp, Dept Surg 3, GR-11527 Athens, Greece.
   [Zoras, Odysseas] Univ Crete Heraklion, Sch Med, Univ Hosp Heraklion, Dept Gen Surg, Iraklion, Greece.
   [Roukos, Dimitrios H.] Univ Ioannina, Biobank, Ioannina 45110, Greece.
C3 University of Ioannina; National & Kapodistrian University of Athens;
   Athens Medical School; University Hospital Attikon; University Hospital
   of Heraklion; University of Crete; University of Ioannina
RP Roukos, DH (通讯作者)，Univ Ioannina, Sch Med, Dept Surg, Ioannina 45110, Greece.
EM droukos@uoi.gr
RI Liakakos, Theodore/A-2779-2011; Ziogas, Demosthenes/D-7973-2011
OI Liakakos, Theodore/0000-0003-2289-6242; Roukos,
   Dimitrios/0000-0002-6210-5065; Ziogas, Demosthenes/0000-0003-2234-8393
CR [Anonymous], 2010, Nature, V464, P670, DOI 10.1038/464670a
   [Anonymous], NATURE
   [Anonymous], MED DEV LETT IND
   [Anonymous], N ENGL J ME IN PRESS
   [Anonymous], GUID TREATM CANC SIT
   [Anonymous], NATURE
   Bang YJ, 2010, LANCET, V376, P687, DOI 10.1016/S0140-6736(10)61121-X
   Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656
   Beaudet AL, 2010, NATURE, V466, P816, DOI 10.1038/466816a
   Birney E., 2007, NATURE, V447, P799, DOI [10.1038/nature05874, DOI 10.1038/NATURE05874]
   Bohman T, 2009, SCIENCE, V323, P1438, DOI 10.1126/science.1171297
   Breitkreutz A, 2010, SCIENCE, V328, P1043, DOI 10.1126/science.1176495
   Collins F, 2010, NATURE, V464, P674, DOI 10.1038/464674a
   Dahabreh IJ, 2008, ONCOLOGIST, V13, P620, DOI 10.1634/theoncologist.2008-0001
   Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989
   Donnelly P, 2008, NATURE, V456, P728, DOI 10.1038/nature07631
   Ellis LM, 2009, NATURE, V458, P290, DOI 10.1038/458290a
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Evans JP, 2010, NEW ENGL J MED, V363, P1099, DOI 10.1056/NEJMp1006202
   Goldhirsch A, 2009, ANN ONCOL, V20, P1319, DOI 10.1093/annonc/mdp322
   Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795
   Hortobagyi GN, 2005, NEW ENGL J MED, V353, P1734, DOI 10.1056/NEJMe058196
   Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987
   Katsios C, 2010, PERS MED, V7, P347, DOI [10.2217/pme.10.30, 10.2217/PME.10.30]
   Katsnelson A, 2010, NATURE, V465, P145, DOI 10.1038/465145a
   Ledford H, 2010, NATURE, V464, P972, DOI 10.1038/464972a
   Lee W, 2010, NATURE, V465, P473, DOI 10.1038/nature09004
   Manolio TA, 2010, NEW ENGL J MED, V363, P166, DOI 10.1056/NEJMra0905980
   Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699
   Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658
   Rockman MV, 2008, NATURE, V456, P738, DOI 10.1038/nature07633
   Roukos DH, 2011, PHARMACOGENOMICS J, V11, P81, DOI 10.1038/tpj.2010.81
   Roukos DH, 2010, PHARMACOGENOMICS, V11, P1039, DOI [10.2217/pgs.10.104, 10.2217/PGS.10.104]
   Roukos DH, 2010, BIOMARK MED, V4, P583, DOI 10.2217/BMM.10.70
   Roukos DH, 2010, EXPERT REV MOL DIAGN, V10, P541, DOI [10.1586/erm.10.49, 10.1586/ERM.10.49]
   Roukos DH, 2010, ANN SURG ONCOL, V17, P14, DOI 10.1245/s10434-009-0766-0
   Roukos DH, 2010, EXPERT REV MOL DIAGN, V10, P33, DOI [10.1586/erm.09.69, 10.1586/ERM.09.69]
   Roukos DH, 2009, EXPERT REV ANTICANC, V9, P1413, DOI [10.1586/era.09.116, 10.1586/ERA.09.116]
   Schadt EE, 2009, NATURE, V461, P218, DOI 10.1038/nature08454
   Shendure J, 2008, NAT BIOTECHNOL, V26, P1135, DOI 10.1038/nbt1486
   Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101
   Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943
   Van Cutsem E, 2009, J CLIN ONCOL, V27, P2231, DOI 10.1200/JCO.2008.20.0238
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   Venter JC, 2010, NATURE, V464, P676, DOI 10.1038/464676a
   Wheeler DL, 2010, NAT REV CLIN ONCOL, V7, P493, DOI 10.1038/nrclinonc.2010.97
   Wood SN, 2010, NATURE, V466, P1102, DOI 10.1038/nature09319
NR 47
TC 6
Z9 8
U1 0
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
EI 1095-8673
J9 J SURG RES
JI J. Surg. Res.
PD APR
PY 2012
VL 173
IS 2
BP 365
EP 369
DI 10.1016/j.jss.2010.10.038
PG 5
WC Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Surgery
GA 906IQ
UT WOS:000301339100033
PM 21195428
DA 2025-01-12
ER

PT J
AU Wei, J
   Han, B
   Mao, XY
   Wei, MJ
   Yao, F
   Jin, F
AF Wei, Jing
   Han, Bing
   Mao, Xiao-yun
   Wei, Min-jie
   Yao, Fan
   Jin, Feng
TI Promoter methylation status and expression of estrogen receptor alpha in
   familial breast cancer patients
SO TUMOR BIOLOGY
LA English
DT Article
DE ER alpha; Methylation; Familial breast cancer; Chinese women
ID ER-ALPHA; TP53 MUTATIONS; CHINESE WOMEN; CPG ISLANDS; GENE; P53;
   HYPERMETHYLATION; CARCINOMA; IMMUNOHISTOCHEMISTRY; ACCUMULATION
AB The hypermethylation of estrogen receptor alpha (ER alpha) promoter is a common molecular alteration in sporadic breast cancer (BC), but its involvement in familial BC remains largely unknown. In the present study, we analyzed the methylation statuses of four regions (ER1, ER3, ER4, and ER5) of the ER alpha promoter and the ER alpha expression levels of 113 familial BC patients in a Han Chinese Population from northeastern China and evaluated the association between major clinicopathological features and the hypermethylation statuses of the ER alpha gene. Tumor samples were analyzed for ER alpha methylation status by the methylation-specific polymerase chain reaction for ER alpha, PR, p53, BRCA-1, and BRCA-2 by immunohistochemical (IHC) staining and for Her-2 status by IHC and fluorescence in situ hybridization (FISH). ER alpha methylation was observed in tumor tissues in 47/113 (41.6%) familial BC patients. There were no significant differences in the methylation statuses among ER1 (20.4%), ER3 (18.6%), ER4 (17.7%), and ER5 (19.5%; chi (2) = 3.89, p > 0.05). An association between ER alpha expression level and its promoter methylation level was found. In addition, ER alpha methylation was significantly correlated with tumor size, PR expression, p53 nuclear accumulation, and BRCA-1 and BRCA-2 statuses. In conclusion, in familial BC patients, the level of ER alpha gene promoter methylation correlates with ER alpha expression, PR, p53 nuclear accumulation, and BRCA-1 and BRCA-2 statuses. Epigenetic alteration of ER alpha gene may play an important role in the pathogenesis of familial BC.
C1 [Wei, Jing; Mao, Xiao-yun; Yao, Fan; Jin, Feng] China Med Univ, Dept Breast Surg, Res Unit Gen Surg, Affiliated Hosp 1, Shenyang 110001, Liaoning, Peoples R China.
   [Wei, Jing; Mao, Xiao-yun; Yao, Fan; Jin, Feng] China Med Univ, Dept Surg Oncol, Res Unit Gen Surg, Affiliated Hosp 1, Shenyang 110001, Liaoning, Peoples R China.
   [Han, Bing] China Med Univ, Dept Minimal Invas Surg & Bile Duct & Vasc Surg 1, Sheng Jing Hosp, Shenyang 110003, Liaoning, Peoples R China.
   [Wei, Min-jie] China Med Univ, Dept Pharmacol, Shenyang 110001, Liaoning, Peoples R China.
C3 China Medical University; China Medical University; China Medical
   University; China Medical University
RP Jin, F (通讯作者)，China Med Univ, Dept Breast Surg, Res Unit Gen Surg, Affiliated Hosp 1, Shenyang 110001, Liaoning, Peoples R China.
EM jinfeng66cn@hotmail.com
RI xiao, ming/KHT-1774-2024
CR Ahmad Z, 2009, INDIAN J PATHOL MICR, V52, P477, DOI 10.4103/0377-4929.56123
   Alsner J, 2008, ACTA ONCOL, V47, P600, DOI 10.1080/02841860802047411
   [Anonymous], J SURG RES
   Asada H, 2008, MOL HUM REPROD, V14, P539, DOI 10.1093/molehr/gan045
   Brinkman JA, 2009, J MAMMARY GLAND BIOL, V14, P67, DOI 10.1007/s10911-009-9113-0
   Burkadze G, 2010, Georgian Med News, P51
   Dunnwald LK, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1639
   Duss S, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1734
   Flanagan JM, 2010, BREAST CANCER RES, V12, pS2, DOI 10.1186/bcr2495
   Flanagan JM, 2010, AM J HUM GENET, V86, P420, DOI 10.1016/j.ajhg.2010.02.008
   Gasco M, 2003, HUM MUTAT, V21, P301, DOI 10.1002/humu.10173
   Hatanaka Y, 2001, PATHOL INT, V51, P33, DOI 10.1046/j.1440-1827.2001.01162.x
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hockings JK, 2006, CANCER RES, V66, P2224, DOI 10.1158/0008-5472.CAN-05-1619
   Hoff ER, 2002, AM J CLIN PATHOL, V117, P916, DOI 10.1309/4NTU-N6K4-F8JF-EWRX
   Hosey AM, 2007, J NATL CANCER I, V99, P1683, DOI 10.1093/jnci/djm207
   Huang Yu-Shan, 2009, Pathophysiology, V16, P259, DOI 10.1016/j.pathophys.2009.02.010
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kok LF, 2010, ARCH GYNECOL OBSTET, V281, P293, DOI 10.1007/s00404-009-1094-0
   Koo CL, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-25
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Mao XY, 2010, J EXP CLIN CANC RES, V29, P1, DOI 10.1186/1756-9966-29-112
   Mirza S, 2007, LIFE SCI, V81, P280, DOI 10.1016/j.lfs.2007.05.012
   Murff HJ, 2005, J GEN INTERN MED, V20, P75, DOI 10.1111/j.1525-1497.2004.40112.x
   Narod SA, 2010, LANCET, V375, P2123, DOI 10.1016/S0140-6736(10)60876-8
   Nass SJ, 2000, CANCER RES, V60, P4346
   Pharoah PDP, 1997, INT J CANCER, V71, P800, DOI 10.1002/(SICI)1097-0215(19970529)71:5<800::AID-IJC18>3.0.CO;2-B
   Pirouzpanah S, 2010, CANCER CAUSE CONTROL, V21, P2101, DOI 10.1007/s10552-010-9629-z
   Rossner P, 2009, J CELL MOL MED, V13, P3847, DOI 10.1111/j.1582-4934.2008.00553.x
   Sayeed A, 2007, CANCER RES, V67, P7746, DOI 10.1158/0008-5472.CAN-06-3724
   Shirley SH, 2009, CANCER RES, V69, P3405, DOI 10.1158/0008-5472.CAN-08-3628
   Tavassoli FA, 2005, NAT CLIN PRACT ONCOL, V2, P116, DOI 10.1038/ncponc0109
   Wirtenberger M, 2007, CARCINOGENESIS, V28, P423, DOI 10.1093/carcin/bgl164
   Wirtenberger M, 2006, CARCINOGENESIS, V27, P2201, DOI 10.1093/carcin/bgl067
   Yehiely F, 2006, TRENDS MOL MED, V12, P537, DOI 10.1016/j.molmed.2006.09.004
   Yoshida T, 2000, CARCINOGENESIS, V21, P2193, DOI 10.1093/carcin/21.12.2193
   Zhao L, 2009, BREAST CANCER RES TR, V117, P253, DOI 10.1007/s10549-008-0192-1
NR 37
TC 20
Z9 20
U1 0
U2 17
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1010-4283
J9 TUMOR BIOL
JI Tumor Biol.
PD APR
PY 2012
VL 33
IS 2
SI SI
BP 413
EP 420
DI 10.1007/s13277-011-0234-x
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 904IX
UT WOS:000301189400015
PM 21922275
DA 2025-01-12
ER

PT J
AU Pasquier, J
   Galas, L
   Boulangé-Lecomte, C
   Rioult, D
   Bultelle, F
   Magal, P
   Webb, G
   Le Foll, F
AF Pasquier, Jennifer
   Galas, Ludovic
   Boulange-Lecomte, Celine
   Rioult, Damien
   Bultelle, Florence
   Magal, Pierre
   Webb, Glenn
   Le Foll, Frank
TI Different Modalities of Intercellular Membrane Exchanges Mediate
   Cell-to-cell P-glycoprotein Transfers in MCF-7 Breast Cancer Cells
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID ACQUIRED MULTIDRUG-RESISTANCE; EPIGENETIC CHANGES; DRUG-RESISTANCE; BCRP
   ABCG2; EXPRESSION; AMPLIFICATION; GENE; MDR1; DOXORUBICIN; INDUCTION
AB Multi-drug resistance (MDR) is a phenomenon by which tumor cells exhibit resistance to a variety of chemically unrelated chemotherapeutic drugs. The classical form of multidrug resistance is connected to overexpression of membrane P-glycoprotein (P-gp), which acts as an energy dependent drug efflux pump. P-glycoprotein expression is known to be controlled by genetic and epigenetic mechanisms. Until now processes of P-gp gene up-regulation and resistant cell selection were considered sufficient to explain the emergence of MDR phenotype within a cell population. Recently, however, "non-genetic" acquisitions of MDR by cell-to-cell P-gp transfers have been pointed out. In the present study we show that intercellular transfers of functional P-gp occur by two different but complementary modalities through donor-recipient cells interactions in the absence of drug selection pressure. P-glycoprotein and drug efflux activity transfers were followed over 7 days by confocal microscopy and flow cytometry in drug-sensitive parental MCF-7 breast cancer cells co-cultured with P-gp overexpressing resistant variants. An early process of remote transfer was established based on the release and binding of P-gp-containing microparticles. Microparticle-mediated transfers were detected after only 4 h of incubation. We also identify an alternative mode of transfer by contact, consisting of cell-to-cell P-gp trafficking by tunneling nanotubes bridging neighboring cells. Our findings supply new mechanistic evidences for the extragenetic emergence of MDR in cancer cells and indicate that new treatment strategies designed to overcome MDR may include inhibition of both microparticles and Tunneling nanotube-mediated intercellular P-gp transfers.
C1 [Pasquier, Jennifer; Boulange-Lecomte, Celine; Rioult, Damien; Bultelle, Florence; Le Foll, Frank] Univ Le Havre, Lab Ecotoxicol, F-76058 Le Havre, France.
   [Pasquier, Jennifer; Galas, Ludovic] Univ Rouen, IRIB, INSERM, PRIMACEN, F-76821 Mont St Aignan, France.
   [Magal, Pierre] Univ Bordeaux, UMR CNRS 5251, IMB, F-33076 Bordeaux, France.
   [Magal, Pierre] Univ Bordeaux, INRIA Sud Ouest Anubis, F-33076 Bordeaux, France.
   [Webb, Glenn] Vanderbilt Univ, Stevenson Ctr, Dept Math, Nashville, TN 37240 USA.
C3 Universite de Reims Champagne-Ardenne; Universite Le Havre Normandie;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Rouen Normandie; Universite de Bordeaux; Universite de
   Bordeaux; Vanderbilt University
RP Le Foll, F (通讯作者)，Univ Le Havre, Lab Ecotoxicol, F-76058 Le Havre, France.
EM frank.lefoll@univ-lehavre.fr
RI Magal, Pierre/HLG-7279-2023; Webb, Glenn/AAW-7228-2021; galas,
   ludovic/A-2500-2014; Boulangé-Lecomte, Céline/HNR-2154-2023
OI Boulange-Lecomte, Celine/0000-0002-2461-7473; Pasquier,
   Jennifer/0000-0002-2465-7942; magal, pierre/0000-0002-4776-0061; Le
   Foll, Frank/0000-0002-9585-9250
FU European Regional Development Fund
FX This work was supported by European Regional Development Fund as part of
   the Interreg IVA project Admin (Trans-Channel Advanced Microscopy
   network).
CR Ambudkar SV, 2003, ONCOGENE, V22, P7468, DOI 10.1038/sj.onc.1206948
   Baker EK, 2005, ONCOGENE, V24, P8061, DOI 10.1038/sj.onc.1208955
   Bebawy M, 2009, LEUKEMIA, V23, P1643, DOI 10.1038/leu.2009.76
   BELLI JA, 1990, CANCER RES, V50, P2191
   Callaghan R, 2008, J CLIN PHARMACOL, V48, P365, DOI 10.1177/0091270007311568
   Chekhun VF, 2006, CANCER LETT, V231, P87, DOI 10.1016/j.canlet.2005.01.038
   Choi CH, 1999, MOL CELLS, V9, P314
   Demeule M, 1999, AM J PHYSIOL-RENAL, V277, pF832, DOI 10.1152/ajprenal.1999.277.6.F832
   Fojo T, 2007, DRUG RESIST UPDATE, V10, P59, DOI 10.1016/j.drup.2007.02.002
   Geick A, 2001, J BIOL CHEM, V276, P14581, DOI 10.1074/jbc.M010173200
   Gerdes HH, 2008, CURR OPIN CELL BIOL, V20, P470, DOI 10.1016/j.ceb.2008.03.005
   GOLDSTEIN LJ, 1989, JNCI-J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116
   Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135
   Gurke S, 2008, HISTOCHEM CELL BIOL, V129, P539, DOI 10.1007/s00418-008-0412-0
   Hawkins BT, 2010, J CEREBR BLOOD F MET, V30, P1593, DOI 10.1038/jcbfm.2010.117
   Hawkins BT, 2010, J NEUROSCI, V30, P1417, DOI 10.1523/JNEUROSCI.5103-09.2010
   JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7
   KLIMECKI WT, 1994, BLOOD, V83, P2451
   Kovalchuk O, 2008, MOL CANCER THER, V7, P2152, DOI 10.1158/1535-7163.MCT-08-0021
   LEIGHTON JC, 1995, HEMATOL ONCOL CLIN N, V9, P251, DOI 10.1016/S0889-8588(18)30095-9
   Leslie EM, 2005, TOXICOL APPL PHARM, V204, P216, DOI 10.1016/j.taap.2004.10.012
   Levchenko A, 2005, P NATL ACAD SCI USA, V102, P1933, DOI 10.1073/pnas.0401851102
   Marin M, 2005, BIOCHEM BIOPH RES CO, V334, P1266, DOI 10.1016/j.bbrc.2005.07.010
   Meesungnoen J, 2002, CAN J PHYSIOL PHARM, V80, P1054, DOI 10.1139/Y02-132
   Mizutani T, 2008, CURR DRUG METAB, V9, P167, DOI 10.2174/138920008783571756
   Nieth C, 2005, J CHEMOTHERAPY, V17, P215, DOI 10.1179/joc.2005.17.2.215
   Oleinikov VA, 2006, FEBS LETT, V580, P4953, DOI 10.1016/j.febslet.2006.07.069
   Pajic M, 2004, ONCOL REP, V11, P1091
   Pasquier J, 2011, BIOL DIRECT, V6, DOI 10.1186/1745-6150-6-5
   PASTAN I, 1987, NEW ENGL J MED, V316, P1388
   Rafii A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003894
   Reed K, 2008, EPIGENETICS-US, V3, P270, DOI 10.4161/epi.3.5.6868
   RIORDAN JR, 1985, NATURE, V316, P817, DOI 10.1038/316817a0
   Rosenberg MF, 2005, J BIOL CHEM, V280, P2857, DOI 10.1074/jbc.M410296200
   Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133
   Safaei R, 2005, MOL CANCER THER, V4, P1595, DOI 10.1158/1535-7163.MCT-05-0102
   Seelig A, 2000, EUR J PHARM SCI, V12, P31, DOI 10.1016/S0928-0987(00)00177-9
   Shedden K, 2003, CANCER RES, V63, P4331
   Simpson RJ, 2008, PROTEOMICS, V8, P4083, DOI 10.1002/pmic.200800109
   Staubach S, 2009, PROTEOMICS, V9, P2820, DOI 10.1002/pmic.200800793
   Synold TW, 2001, NAT MED, V7, P584, DOI 10.1038/87912
   Théry C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567
   Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30
   Zhou SF, 2008, XENOBIOTICA, V38, P802, DOI [10.1080/00498250701867889, 10.1080/00498250701867889 ]
NR 44
TC 115
Z9 120
U1 0
U2 15
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAR 2
PY 2012
VL 287
IS 10
BP 7374
EP 7387
DI 10.1074/jbc.M111.312157
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 902SL
UT WOS:000301060200039
PM 22228759
OA Green Published
DA 2025-01-12
ER

PT J
AU Liu, Y
   Mayo, MW
   Nagji, AS
   Smith, PW
   Ramsey, CS
   Li, D
   Jones, DR
AF Liu, Y.
   Mayo, M. W.
   Nagji, A. S.
   Smith, P. W.
   Ramsey, C. S.
   Li, D.
   Jones, D. R.
TI Phosphorylation of RelA/p65 promotes DNMT-1 recruitment to chromatin and
   represses transcription of the tumor metastasis suppressor gene
   <i>BRMS1</i>
SO ONCOGENE
LA English
DT Article
DE DNMT-1; phosphorylation; RelA/p65; TNF; transcription
ID NF-KAPPA-B; CELL LUNG-CANCER; BREAST-CANCER; INDUCED APOPTOSIS;
   METHYLTRANSFERASE RECRUITMENT; DNA METHYLTRANSFERASES; TARGET PROMOTERS;
   DOWN-REGULATION; EXPRESSION; ACTIVATION
AB The majority of patients with lung cancer present with metastatic disease. Chronic inflammation and subsequent activation of nuclear factor-kappa B (NF-kappa B) have been associated with the development of cancers. The RelA/p65 subunit of NF-kappa B is typically associated with transcriptional activation. In this report we show that RelA/p65 can function as an active transcriptional repressor through enhanced methylation of the BRMS1 (breast cancer metastasis suppressor 1) metastasis suppressor gene promoter via direct recruitment of DNMT-1 (DNA (cytosine-5)-methyltransferase 1) to chromatin in response to tumor necrosis factor (TNF). TNF-mediated phosphorylation of S276 on RelA/p65 is required for RelA/p65-DNMT-1 interactions, chromatin loading of DNMT-1 and subsequent BRMS1 promoter methylation and transcriptional repression. The ability of RelA/p65 to function as an active transcriptional repressor is promoter specific, as the NF-kappa B-regulated gene cIAP2 (cellular inhibitor of apoptosis 2) is transcriptionally activated whereas BRMS1 is repressed under identical conditions. Small-molecule inhibition of either of the minimal interacting domains between RelA/p65-DNMT-1 and RelA/p65-BRMS1 promoter abrogates BRMS1 methylation and its transcriptional repression. The ability of RelA/p65 to directly recruit DNMT-1 to chromatin, resulting in promoter-specific methylation and transcriptional repression of tumor metastasis suppressor gene BRMS1, highlights a new mechanism through which NF-kappa B can regulate metastatic disease, and offers a potential target for newer-generation epigenetic oncopharmaceuticals. Oncogene (2012) 31, 1143-1154; doi:10.1038/onc.2011.308; published online 18 July 2011
C1 [Liu, Y.; Nagji, A. S.; Smith, P. W.; Jones, D. R.] Univ Virginia, Dept Surg, Charlottesville, VA 22908 USA.
   [Mayo, M. W.; Ramsey, C. S.; Li, D.] Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.
C3 University of Virginia; University of Virginia
RP Jones, DR (通讯作者)，Univ Virginia, Dept Surg, Box 800679, Charlottesville, VA 22908 USA.
EM djones@virginia.edu
RI Smith, Philip/P-7736-2019
OI Jones, David/0000-0002-3318-0146
FU  [R01 CA136705];  [R01 CA104397];  [R01 CA132580]
FX This work was supported by grants R01 CA136705 (to DRJ), R01 CA104397
   (to MWM) and R01 CA132580 (to MWM). In addition, this project was
   supported in part by a gift provided to the University of Virginia by
   Philip Morris USA. The review and approval process was overseen by an
   independent National External Advisory Board without any affiliation
   with the University, Philip Morris USA or any other tobacco company.
CR Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   Bobrovnikova-Marjon EV, 2004, CANCER RES, V64, P4858, DOI 10.1158/0008-5472.CAN-04-0682
   BOURS V, 1994, BIOCHEM PHARMACOL, V47, P145, DOI 10.1016/0006-2952(94)90448-0
   Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5
   Ceribelli M, 2008, MOL CELL BIOL, V28, P2047, DOI 10.1128/MCB.01861-07
   Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000
   Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956
   Chen LF, 2005, MOL CELL BIOL, V25, P7966, DOI 10.1128/MCB.25.18.7966-7975.2005
   Chen YQ, 2000, STRUCT FOLD DES, V8, P419, DOI 10.1016/S0969-2126(00)00123-4
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Denlinger Chadrick E, 2004, Semin Thorac Cardiovasc Surg, V16, P28, DOI 10.1053/j.semtcvs.2003.12.004
   Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173
   Dong J, 2008, GENE DEV, V22, P1159, DOI 10.1101/gad.1657408
   Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029
   Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013
   Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200
   Hicks DG, 2006, CLIN CANCER RES, V12, P6702, DOI 10.1158/1078-0432.CCR-06-0635
   Hoberg JE, 2006, MOL CELL BIOL, V26, P457, DOI 10.1128/MCB.26.2.457-471.2006
   Hodge DR, 2005, CANCER RES, V65, P6255, DOI 10.1158/0008-5472.CAN-04-4482
   Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200
   Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358
   Jones DR, 2000, ANN THORAC SURG, V70, P930, DOI 10.1016/S0003-4975(00)01635-0
   Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703
   Kim S, 2004, J BIOL CHEM, V279, P4285, DOI 10.1074/jbc.M308383200
   Kouba DJ, 1999, J IMMUNOL, V162, P4226
   Liu Y, 2006, MOL CELL BIOL, V26, P8683, DOI 10.1128/MCB.00940-06
   Liu Y, 2006, J BIOL CHEM, V281, P31359, DOI 10.1074/jbc.M604478200
   Mayo MW, 2000, BBA-REV CANCER, V1470, pM55, DOI 10.1016/S0304-419X(00)00002-0
   Meehan WJ, 2003, CLIN EXP METASTAS, V20, P45, DOI 10.1023/A:1022542519586
   Mottet D, 2009, ONCOGENE, V28, P243, DOI 10.1038/onc.2008.371
   Nagji AS, 2010, J PATHOL, V221, P229, DOI 10.1002/path.2707
   NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924
   Puto LA, 2008, GENE DEV, V22, P998, DOI 10.1101/gad.1632208
   Romano A, 2010, MOL CELL ENDOCRINOL, V314, P90, DOI 10.1016/j.mce.2009.08.008
   Sankpal NV, 2009, CANCER RES, V69, P753, DOI 10.1158/0008-5472.CAN-08-2708
   Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7
   Shaw J, 2006, CIRC RES, V99, P1347, DOI 10.1161/01.RES.0000251744.06138.50
   Smith PW, 2009, CANCER LETT, V276, P196, DOI 10.1016/j.canlet.2008.11.024
   Snyder M, 2010, J BIOL CHEM, V285, P23639, DOI 10.1074/jbc.M110.101063
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Takada Y, 2005, ONCOGENE, V24, P6957, DOI 10.1038/sj.onc.1208845
   Ushijima T, 2005, CANCER SCI, V96, P206, DOI 10.1111/j.1349-7006.2005.00035.x
   Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139
   Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784
   Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680
   Wehbe H, 2006, CANCER RES, V66, P10517, DOI 10.1158/0008-5472.CAN-06-2130
   Xia DR, 2007, J BIOL CHEM, V282, P3507, DOI 10.1074/jbc.M610141200
   Zhang Q, 2005, P NATL ACAD SCI USA, V102, P6948, DOI 10.1073/pnas.0501959102
   Zhang ZH, 2006, CLIN CANCER RES, V12, P6410, DOI 10.1158/1078-0432.CCR-06-1347
   Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6
   Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X
NR 54
TC 65
Z9 74
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD MAR
PY 2012
VL 31
IS 9
BP 1143
EP 1154
DI 10.1038/onc.2011.308
PG 12
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 901EW
UT WOS:000300945900007
PM 21765477
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Zänker, KS
AF Zaenker, K. S.
TI Primary cancer prevention
SO ONKOLOGE
LA German
DT Article
DE Metabolic syndrome; Chronic inflammation; Infection; Vaccination;
   Psychooncology
ID ALL-CAUSE MORTALITY; BREAST-CANCER; DIABETES-MELLITUS;
   COLORECTAL-CANCER; THERAPY; RISK; PATHWAYS
AB The approach to winning the war against cancer has scientific, political and public health dimensions. In order to reduce cancer mortality in the future primary prevention is a major goal. Primary prevention can be achieved through the reduction of identified risk factors, such as smoking, uncontrolled alcohol consumption, poor nutrition and caloric imbalance, insufficient physical activity, obesity, metabolic syndrome, chronic inflammation, virus and bacterial infections and psychosocial stress. Progress can be made by the use of the new concept of personalized medicine where the genetic and epigenetic make-up of an individual in health and disease is used as a diagnostic and therapeutic fundament for targeted preventive therapy. Ingredients of plants, vegetables and herbs with scientifically proven preventive properties (nutriceuticals), second generation NSAIDs, COX-2 inhibitors, pharmacological chaperone-like molecules, sirtuin and kinase inhibitors can be applied alone or within a cocktail to support primary cancer prevention. The development of prophylactic vaccination strategies against virus and bacteria-induced tumors are promising investments in primary cancer preventions and all efforts are accompanied and complemented by supportive psychooncological care giving.
C1 Univ Witten Herdecke, Inst Immunol & Expt Onkol, D-58448 Witten, Germany.
C3 Witten Herdecke University
RP Zänker, KS (通讯作者)，Univ Witten Herdecke, Inst Immunol & Expt Onkol, Stockumerstr 10, D-58448 Witten, Germany.
EM ksz@uni-wh.de
CR Al-Wadei HA, 2009, ANTI-CANCER DRUG, V20, P477, DOI 10.1097/CAD.0b013e32832bd1e3
   [Anonymous], METABOLISM
   [Anonymous], ANN ONCOL
   Bonecchi R, 2011, CANCER CELL, V19, P434, DOI 10.1016/j.ccr.2011.03.017
   Borena W, 2011, CANCER CAUSE CONTROL, V22, P291, DOI 10.1007/s10552-010-9697-0
   Chaturvedi P, 2010, J MED FOOD, V13, P520, DOI 10.1089/jmf.2009.0151
   Coughlin SS, 2004, AM J EPIDEMIOL, V159, P1160, DOI 10.1093/aje/kwh161
   Cuzick J, 2011, LANCET ONCOL, V12, P496, DOI 10.1016/S1470-2045(11)70030-4
   Frieden TR, ONCOLOGIST, V13, P1306
   Fuangchan A, 2011, J ETHNOPHARMACOL, V134, P422, DOI 10.1016/j.jep.2010.12.045
   Giovannucci E, 2010, CA-CANCER J CLIN, V60, P207, DOI 10.3322/caac.20078
   Gissmann L, 2011, HAUTARZT
   Goossens MCM, 2010, EUR J CANCER PREV, V19, P485, DOI 10.1097/CEJ.0b013e32833b4886
   Hoffken K, 2002, GERIATRISCHE ONKOLOG
   Holleczek B, 2011, CANC EPIDEMIOL
   Khaw KT, 2004, CANCER EPIDEM BIOMAR, V13, P915
   Li N, 2011, CANCER CELL, V19, P429, DOI 10.1016/j.ccr.2011.03.018
   Luciani S, 2009, TUMORI J, V95, P597
   Masur K, 2008, FRONTIERS DIABETES, V19
   McCullough ML, 2011, CANCER EPIDEM BIOMAR, V20, P1089, DOI 10.1158/1055-9965.EPI-10-1173
   Meyer-Abich KM, 2010, PHILOS MED, P276
   Miller SM, 2008, CANCER-AM CANCER SOC, V113, P3484, DOI 10.1002/cncr.23945
   Morena JM, 2010, EUR J CANCER, V46, P2525
   Pitchakam P, 2010, CANCER SCI, V10, P2234
   Powe DG, 2010, ONCOTARGET, V1, P628, DOI 10.18632/oncotarget.197
   Ray RB, 2010, CANCER RES, V70, P1925, DOI 10.1158/0008-5472.CAN-09-3438
   Schuller HM, 2007, PROG EXP TUMOR RES, V39, P45, DOI 10.1159/000100045
   Schussler CH, 2011, PSYCHONEUROIMMUNOLOG
   Spalding MC, 2008, AM FAM PHYSICIAN, V78, P206
   Stocks T, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000201
   Tan AC, 2011, NUTR CANCER, V63, P495, DOI 10.1080/01635581.2011.538953
   Teucher B, 2010, MATURITAS, V65, P112, DOI 10.1016/j.maturitas.2009.11.018
   Weikert S, 2010, WORLD J UROL, V28, P247, DOI 10.1007/s00345-010-0555-1
   Xu Li, 2011, Cancer Prev Res (Phila), V4, P616, DOI 10.1158/1940-6207.CAPR-11-0018
   Yang YX, 2004, GASTROENTEROLOGY, V127, P1044, DOI 10.1053/j.gastro.2004.07.011
   Zaenker KS, 2011, TRANSL ONCOL, V4, P198, DOI 10.1593/tlo.11142
   Zanker KS, 2007, PROG EXP TUMOR RES, V39, P1
   Zanker KS, 1998, NOVA ACTA LEOPOLDINA, V78, P21
NR 38
TC 0
Z9 0
U1 0
U2 15
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0947-8965
J9 ONKOLOGE
JI Onkologe
PD MAR
PY 2012
VL 18
IS 3
BP 198
EP +
DI 10.1007/s00761-011-2088-7
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 904HA
UT WOS:000301183900003
DA 2025-01-12
ER

PT J
AU Pyne, NJ
   Tonelli, F
   Lim, KG
   Long, JS
   Edwards, J
   Pyne, S
AF Pyne, Nigel J.
   Tonelli, Francesca
   Lim, Keng Gat
   Long, Jaclyn S.
   Edwards, Joanne
   Pyne, Susan
TI Sphingosine 1-phosphate signalling in cancer
SO BIOCHEMICAL SOCIETY TRANSACTIONS
LA English
DT Article
DE cancer; FTY720; G-protein-coupled receptor; metastasis; sphingosine
   kinase; sphingosine 1-phosphate
ID POSITIVE BREAST-CANCER; KINASE 1; MAMMALIAN-CELLS;
   PROTEASOMAL-DEGRADATION; TAMOXIFEN RESISTANCE; REGULATED KINASE-1/2;
   GENE-EXPRESSION; SMOOTH-MUSCLE; G-PROTEIN; RECEPTOR
AB There is an increasing body of evidence demonstrating a critical role for the bioactive lipid SIP (sphingosine 1-phosphate) in cancer. S1P is synthesized and metabolized by a number of enzymes, including sphingosine kinase, S1P lyase and SIP phosphatases. SIP binds to cell-surface G-protein-coupled receptors (S1P(1)-S1P(5)) to elicit cell responses and can also regulate, by direct binding, a number of intracellular targets such as HDAC (histone deacetylase) 1/2 to induce epigenetic regulation. S1P is involved in cancer progression including cell transformation/oncogenesis, cell survival/apoptosis, cell migration/metastasis and tumour microenvironment neovascularization. In the present paper, we describe our research findings regarding the correlation of sphingosine kinase 1 and S1P receptor expression in tumours with clinical outcome and we define some of the molecular mechanisms underlying the involvement of sphingosine kinase 1 and SIP receptors in the formation of a cancer cell migratory phenotype. The role of sphingosine kinase 1 in the acquisition of chemotherapeutic resistance and the interaction of S1P receptors with oncogenes such as HER2 is also reviewed. We also discuss novel aspects of the use of small-molecule inhibitors of sphingosine kinase 1 in terms of allosterism, ubiquitin-proteasomal degradation of sphingosine kinase 1 and anticancer activity. Finally, we describe how S1P receptor-modulating agents abrogate SIP receptor-receptor tyrosine kinase interactions, with potential to inhibit growth-factor-dependent cancer progression.
C1 [Pyne, Nigel J.; Tonelli, Francesca; Lim, Keng Gat; Long, Jaclyn S.; Pyne, Susan] Univ Strathclyde, Cell Biol Grp, Strathclyde Inst Pharm & Biomed Sci, Glasgow G4 0RE, Lanark, Scotland.
   [Edwards, Joanne] Univ Glasgow, Sect Surg, Div Canc Studies & Mol Pathol, Fac Med, Glasgow G11 6NT, Lanark, Scotland.
C3 University of Strathclyde; University of Glasgow
RP Pyne, NJ (通讯作者)，Univ Strathclyde, Cell Biol Grp, Strathclyde Inst Pharm & Biomed Sci, 161 Cathedral St, Glasgow G4 0RE, Lanark, Scotland.
EM n.j.pyne@strath.ac.uk
RI Pyne, Susan/AAF-5001-2019; Edwards, Joanne/J-1903-2015
OI Pyne, Nigel/0000-0002-5657-4578; Long, Jaclyn/0000-0002-6644-542X; Pyne,
   Susan/0000-0002-6608-9584; Tonelli, Francesca/0000-0002-4600-6630;
   Edwards, Joanne/0000-0002-7192-6906
FU Cancer Research UK [C23158/A7536]
FX This work was funded by the Cancer Research UK [grant number
   C23158/A7536 (to N.J.P./S.P.)].
CR Akao Y, 2006, BIOCHEM BIOPH RES CO, V342, P1284, DOI 10.1016/j.bbrc.2006.02.070
   Alderton F, 2001, J BIOL CHEM, V276, P28578, DOI 10.1074/jbc.M102771200
   Bergelin N, 2010, ENDOCRINOLOGY, V151, P2994, DOI [10.1210/en.2009-1387, 10.1210//en.2009-1387]
   Bernardini M, 2005, NEOPLASIA, V7, P603, DOI 10.1593/neo.04760
   BORG A, 1990, CANCER RES, V50, P4332
   Brinkmann V, 2010, NAT REV DRUG DISCOV, V9, P883, DOI 10.1038/nrd3248
   Cattoretti G, 2009, CANCER RES, V69, P8686, DOI 10.1158/0008-5472.CAN-09-1110
   Dawson G, 2011, BIOCHEM BIOPH RES CO, V404, P321, DOI 10.1016/j.bbrc.2010.11.115
   Dayon A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008048
   Fisher KE, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-69
   Hibbs K, 2004, AM J PATHOL, V165, P397, DOI 10.1016/S0002-9440(10)63306-8
   Johnson KR, 2003, J BIOL CHEM, V278, P34541, DOI 10.1074/jbc.M301741200
   Kihara A, 2006, J BIOL CHEM, V281, P4532, DOI 10.1074/jbc.M510308200
   Lahiri S, 2009, J BIOL CHEM, V284, P16090, DOI 10.1074/jbc.M807438200
   Leclercq TM, 2011, ONCOGENE, V30, P372, DOI 10.1038/onc.2010.420
   Lim KG, 2011, J BIOL CHEM, V286, P18633, DOI 10.1074/jbc.M111.220756
   Long JS, 2010, J BIOL CHEM, V285, P35957, DOI 10.1074/jbc.M110.117945
   Long JS, 2010, MOL CELL BIOL, V30, P3827, DOI 10.1128/MCB.01133-09
   Loveridge C, 2010, J BIOL CHEM, V285, P38841, DOI 10.1074/jbc.M110.127993
   Malchnkhuu E, 2008, BIOCHEM BIOPH RES CO, V366, P963, DOI 10.1016/j.bbrc.2007.12.054
   Min JX, 2005, MOL CANCER RES, V3, P287, DOI 10.1158/1541-7786.MCR-04-0197
   Nagaoka Y, 2008, BIOL PHARM BULL, V31, P1177, DOI 10.1248/bpb.31.1177
   Nava VE, 2000, CANCER RES, V60, P4468
   Oskouian B, 2006, P NATL ACAD SCI USA, V103, P17384, DOI 10.1073/pnas.0600050103
   Paugh SW, 2008, BLOOD, V112, P1382, DOI 10.1182/blood-2008-02-138958
   Payne SG, 2007, BLOOD, V109, P1077, DOI 10.1182/blood-2006-03-011437
   Pchejetski D, 2005, CANCER RES, V65, P11667, DOI 10.1158/0008-5472.CAN-05-2702
   Pchejetski D, 2008, MOL CANCER THER, V7, P1836, DOI 10.1158/1535-7163.MCT-07-2322
   Pyne NJ, 2008, BBA-MOL CELL BIOL L, V1781, P467, DOI 10.1016/j.bbalip.2008.05.004
   Pyne NJ, 2010, NAT REV CANCER, V10, P489, DOI 10.1038/nrc2875
   Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385
   Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060
   Rayala SK, 2007, BIOMED PHARMACOTHER, V61, P408, DOI 10.1016/j.biopha.2007.05.006
   Shida D, 2005, BIOCHEM BIOPH RES CO, V327, P907, DOI 10.1016/j.bbrc.2004.12.088
   Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166
   Tonelli F, 2010, CELL SIGNAL, V22, P1536, DOI 10.1016/j.cellsig.2010.05.022
   Vadas M, 2008, BBA-MOL CELL BIOL L, V1781, P442, DOI 10.1016/j.bbalip.2008.06.007
   Valentine WJ, 2010, CELL SIGNAL, V22, P1543, DOI 10.1016/j.cellsig.2010.05.023
   Waters C, 2003, J BIOL CHEM, V278, P6282, DOI 10.1074/jbc.M208560200
   Waters CM, 2005, CELL SIGNAL, V17, P263, DOI 10.1016/j.cellsig.2004.07.011
   Waters D, 2006, FASEB J, V20, pA1058
   Watson C, 2010, AM J PATHOL, V177, P2205, DOI 10.2353/ajpath.2010.100220
   Woodcock JM, 2010, CELL SIGNAL, V22, P1291, DOI 10.1016/j.cellsig.2010.04.004
   Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4
   Yamashita H, 2006, J SURG RES, V130, P80, DOI 10.1016/j.jss.2005.08.004
NR 45
TC 111
Z9 127
U1 0
U2 12
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0300-5127
EI 1470-8752
J9 BIOCHEM SOC T
JI Biochem. Soc. Trans.
PD FEB
PY 2012
VL 40
BP 94
EP 100
DI 10.1042/BST20110602
PN 1
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 890HV
UT WOS:000300136600017
PM 22260672
DA 2025-01-12
ER

PT J
AU Mostovich, LA
   Prudnikova, TY
   Kondratov, AG
   Loginova, D
   Vavilov, PV
   Rykova, VI
   Sidorov, SV
   Pavlova, TV
   Kashuba, VI
   Zabarovsky, ER
   Grigorieva, EV
AF Mostovich, Luydmila A.
   Prudnikova, Tatiana Y.
   Kondratov, Aleksandr G.
   Loginova, Dina
   Vavilov, Pavel V.
   Rykova, Valentina I.
   Sidorov, Sergei V.
   Pavlova, Tatiana V.
   Kashuba, Vladimir I.
   Zabarovsky, Eugene R.
   Grigorieva, Elvira V.
TI Integrin alpha9 (ITGA9) expression and epigenetic silencing in human
   breast tumors
SO CELL ADHESION & MIGRATION
LA English
DT Article
DE integrin alpha9; ITGA9; breast cancer; expression; methylation;
   bisulfite sequencing
ID NERVE GROWTH-FACTOR; CELL-ADHESION; ALPHA-9-BETA-1 INTEGRIN;
   PROGNOSTIC-SIGNIFICANCE; NEUTROPHIL MIGRATION; UP-REGULATION;
   ANGIOGENESIS; INTEGRIN-ALPHA-9-BETA-1; ALPHA(9)BETA(1); FIBRONECTIN
AB Integrin alpha9 (ITGA9) is one of the less studied integrin subunits that facilitates accelerated cell migration and regulates diverse biological functions such as angiogenesis, lymphangiogenesis, cancer cell proliferation and migration. In this work, integrin alpha9 expression and its epigenetic regulation in normal human breast tissue, primary breast tumors and breast cancer cell line MCF7 were studied. It was shown that integrin alpha9 is expressed in normal human breast tissue. In breast cancer, ITGA9 expression was downregulated or lost in 44% of tumors while another 45% of tumors showed normal or increased ITGA9 expression level (possible aberrations in the ITGA9 mRNA structure were supposed in 11% of tumors). Methylation of ITGA9 CpG-island located in the first intron of the gene was shown in 90% of the breast tumors with the decreased ITGA9 expression while no methylation at 5'-untranslated region of ITGA9 was observed. 5-aza-dC treatment restored integrin alpha9 expression in ITGA9-negative MCF7 breast carcinoma cells, Trichostatin A treatment did not influenced it but a combined treatment of the cells with 5-aza-dC/Trichostatin A doubled the ITGA9 activation. The obtained results suggest CpG methylation as a major mechanism of integrin alpha9 inactivation in breast cancer with a possible involvement of other yet unidentified molecular pathways.
C1 [Mostovich, Luydmila A.; Prudnikova, Tatiana Y.; Vavilov, Pavel V.; Grigorieva, Elvira V.] Inst Mol Biol & Biophys SD RAMS, Novosibirsk, Russia.
   [Kondratov, Aleksandr G.; Rykova, Valentina I.; Kashuba, Vladimir I.] UNAS, Inst Mol Biol & Genet, Kiev, Ukraine.
   [Loginova, Dina] Inst Cytol & Genet SD RAS, Novosibirsk, Russia.
   [Sidorov, Sergei V.] Cent Municipal Hosp N1, Novosibirsk, Russia.
   [Pavlova, Tatiana V.; Kashuba, Vladimir I.; Zabarovsky, Eugene R.; Grigorieva, Elvira V.] Karolinska Inst, MTC, Stockholm, Sweden.
   [Zabarovsky, Eugene R.] Linkoping Univ, Inst Clin & Expt Med, Linkoping, Sweden.
C3 Russian Academy of Medical Sciences; National Academy of Sciences
   Ukraine; Institute of Molecular Biology & Genetics of NASU; Russian
   Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS;
   Karolinska Institutet; Linkoping University
RP Grigorieva, EV (通讯作者)，Inst Mol Biol & Biophys SD RAMS, Novosibirsk, Russia.
EM elv_grig@yahoo.com
RI Kashuba, Vladimir/AAO-7742-2020; Zabarovsky, Eugene/A-6645-2010;
   Kashuba, Vladimir/N-3732-2017; Grigorieva, Elvira/A-4937-2010
OI Kondratov, Oleksandr/0000-0001-8305-2989; Pavlova,
   Tatiana/0000-0002-2857-5696; Kashuba, Vladimir/0000-0001-9416-8282;
   Grigorieva, Elvira/0000-0003-2457-9179
FU Russian Foundation for Basic Research (RFBR) [09-04-01599a]; Karolinska
   Institute; Swedish Institute; Swedish Cancer Society; Swedish Research
   Council; Concern Foundation in Los Angeles; Cancer Research Institute in
   New York
FX We thank Drs. A. Proskura, O. Goldinshtein, V. Titova for the assistance
   with the clinical tissue samples collecting, Dr. Z. Shevchuk for her
   help with bisulfite sequencing, A. Grigoriev for the help with the
   manuscript preparation. The work was supported by the research grant
   from Russian Foundation for Basic Research (RFBR 09-04-01599a);
   Karolinska Institute; ERZ was supported by the Swedish Institute, the
   Swedish Cancer Society and the Swedish Research Council. EVG was
   recipient of fellowship from the Concern Foundation in Los Angeles and
   the Cancer Research Institute in New York.
CR Arihiro K, 2000, Breast Cancer, V7, P19, DOI 10.1007/BF02967183
   Arnaout MA, 2007, CURR OPIN CELL BIOL, V19, P495, DOI 10.1016/j.ceb.2007.08.002
   Barczyk M, 2010, CELL TISSUE RES, V339, P269, DOI 10.1007/s00441-009-0834-6
   Basora N, 1998, INT J CANCER, V75, P738, DOI 10.1002/(SICI)1097-0215(19980302)75:5<738::AID-IJC12>3.0.CO;2-2
   Bazigou E, 2009, DEV CELL, V17, P175, DOI 10.1016/j.devcel.2009.06.017
   Brown MC, 2008, NEURO-ONCOLOGY, V10, P968, DOI 10.1215/15228517-2008-047
   Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748
   Eto B, 2000, J BIOL CHEM, V275, P34922, DOI 10.1074/jbc.M001953200
   Fiorilli P, 2008, LAB INVEST, V88, P1143, DOI 10.1038/labinvest.2008.89
   Gerashchenko G V, 2009, Ukr Biokhim Zh (1999), V81, P81
   Ghosh A, 2010, CANCER SCI, V101, P1511, DOI 10.1111/j.1349-7006.2010.01551.x
   Gupta SK, 2010, CELL ADHES MIGR, V4, P194, DOI 10.4161/cam.4.2.10900
   HIBI K, 1994, ONCOGENE, V9, P611
   Huang XZ, 2000, MOL CELL BIOL, V20, P5208, DOI 10.1128/MCB.20.14.5208-5215.2000
   Liao YF, 2002, J BIOL CHEM, V277, P14467, DOI 10.1074/jbc.M201100200
   Lin KT, 2005, J BIOMED SCI, V12, P803, DOI 10.1007/s11373-005-9005-2
   Luo BH, 2007, ANNU REV IMMUNOL, V25, P619, DOI 10.1146/annurev.immunol.25.022106.141618
   Lydolph MC, 2009, EXP CELL RES, V315, P3312, DOI 10.1016/j.yexcr.2009.09.022
   Mambole A, 2010, J LEUKOCYTE BIOL, V88, P321, DOI 10.1189/jlb.1009704
   Mitra S, 2010, GENE CHROMOSOME CANC, V49, P155, DOI 10.1002/gcc.20726
   Ortega P, 2010, INT J ONCOL, V36, P1209, DOI 10.3892/ijo_00000604
   PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289
   Park J, 2004, ONCOGENE, V23, P3474, DOI 10.1038/sj.onc.1207470
   Pavlova TV, 2009, MOL BIOL+, V43, P313, DOI 10.1134/S0026893309020137
   Rathinam R, 2010, CANCER METAST REV, V29, P223, DOI 10.1007/s10555-010-9211-x
   Rüegg C, 2010, RECENT RESULTS CANC, V180, P83, DOI 10.1007/978-3-540-78281-0_6
   Schreiber TD, 2009, HAEMATOL-HEMATOL J, V94, P1493, DOI 10.3324/haematol.2009.006072
   Shang T, 1999, J LEUKOCYTE BIOL, V66, P809, DOI 10.1002/jlb.66.5.809
   Soung YH, 2010, BMB REP, V43, P311, DOI 10.5483/BMBRep.2010.43.5.311
   Staniszewska I, 2008, J CELL SCI, V121, P504, DOI 10.1242/jcs.000232
   Staniszewska I, 2007, CIRC RES, V100, P1308, DOI 10.1161/01.RES.0000266662.98355.66
   Stupack DG, 2004, CURR TOP DEV BIOL, V64, P207, DOI 10.1016/S0070-2153(04)64009-9
   Taooka Y, 1999, J CELL BIOL, V145, P413, DOI 10.1083/jcb.145.2.413
   Uhm KO, 2010, J CANCER RES CLIN, V136, P187, DOI 10.1007/s00432-009-0646-9
   Vlahakis NE, 2005, J BIOL CHEM, V280, P4544, DOI 10.1074/jbc.M412816200
   Vlahakis NE, 2007, J BIOL CHEM, V282, P15187, DOI 10.1074/jbc.M609323200
   Wang Z, 2010, EXPERT OPIN DRUG DEL, V7, P159, DOI 10.1517/17425240903468696
   YOKOSAKI Y, 1994, J BIOL CHEM, V269, P26691
   Yokosaki Y, 1999, J BIOL CHEM, V274, P36328, DOI 10.1074/jbc.274.51.36328
   Young BA, 2001, MOL BIOL CELL, V12, P3214, DOI 10.1091/mbc.12.10.3214
NR 40
TC 37
Z9 41
U1 0
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
EI 1933-6926
J9 CELL ADHES MIGR
JI Celll Adhes. Migr.
PD SEP-OCT
PY 2011
VL 5
IS 5
BP 395
EP 401
DI 10.4161/cam.5.5.17949
PG 7
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 898CT
UT WOS:000300713700004
PM 21975548
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Stefanska, B
   Salamé, P
   Bednarek, A
   Fabianowska-Majewska, K
AF Stefanska, Barbara
   Salame, Patrick
   Bednarek, Andrzej
   Fabianowska-Majewska, Krystyna
TI Comparative effects of retinoic acid, vitamin D and resveratrol alone
   and in combination with adenosine analogues on methylation and
   expression of phosphatase and tensin homologue tumour suppressor gene in
   breast cancer cells
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE Vitamins; Phyto-oestrogens; Promoter methylation; Chemoprevention;
   Epigenetic therapy
ID CHRONIC LYMPHOCYTIC-LEUKEMIA; DNA METHYLATION;
   1-ALPHA,25-DIHYDROXYVITAMIN D-3; RECEPTOR-BETA; TRANSCRIPTIONAL
   REGULATION; PROMOTER HYPERMETHYLATION; PTEN; PATHWAY; APOPTOSIS;
   5-AZA-2'-DEOXYCYTIDINE
AB Aberrations in DNA methylation patterns have been reported to be involved in driving changes in the expression of numerous genes during carcinogenesis and have become promising targets for chemopreventive action of natural compounds. In the present study, we investigated the effects of all-trans retinoic acid (ATRA), vitamin D-3 and resveratrol alone and in combination with adenosine analogues, 2-chloro-2'-deoxyadenosine (2CdA) and 9-beta-D-arabinosyl-2-fluoroadenine (F-ara-A), on the methylation and expression of phosphatase and tensin homologue (PTEN) tumour suppressor gene in MCF-7 and MDA-MB-231 breast cancer cells. The present results showed that in non-invasive MCF-7 cells, ATRA, vitamin D-3 and resveratrol possess high efficacy in the reduction of PTEN promoter methylation. It was associated with PTEN induction as well as DNA methyltransferase down-regulation and p21 up-regulation after treatments with vitamin D-3 and resveratrol, suggesting a complex regulation of the DNA methylation machinery. Vitamin D-3 and resveratrol improved the inhibitory effects of 2CdA and F-ara-A on PTEN methylation in MCF-7 cells; however, only the combined action of vitamin D-3 and 2CdA boosted the induction of PTEN expression, suggesting a cooperation of these compounds in additional processes driving changes in PTEN expression. In contrast, in highly invasive MDA-MB-231 cells, only vitamin D-3 reduced PTEN methylation and induced its expression without notable effects in combined treatments. The present results suggest that natural compounds can find application in epigenetic anticancer therapy aimed at inhibition of promoter methylation of tumour suppressor genes and induction of their expression at early stages of carcinogenesis.
C1 [Stefanska, Barbara; Fabianowska-Majewska, Krystyna] Med Univ Lodz, Dept Biomed Chem, PL-92215 Lodz, Poland.
   [Salame, Patrick] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada.
   [Bednarek, Andrzej] Med Univ Lodz, Dept Mol Carcinogenesis, PL-92215 Lodz, Poland.
C3 Medical University Lodz; McGill University; Medical University Lodz
RP Stefanska, B (通讯作者)，Med Univ Lodz, Dept Biomed Chem, 6-8 Mazowiecka St, PL-92215 Lodz, Poland.
EM barbara.stefanska@mail.mcgill.ca
RI Stefańska, Barbara/ABD-1161-2021; Bednarek, Andrzej/S-9664-2016
OI Bednarek, Andrzej/0000-0002-4570-4154
FU Medical University of Lodz, Poland [502-12-302]; Ministry of Science and
   Higher Education, Poland [2 P05A 036 30]
FX The present study was supported by grants from the Medical University of
   Lodz, Poland (no. 502-12-302, to K. F.-M.) and the Ministry of Science
   and Higher Education, Poland (no. 2 P05A 036 30, to K. F.-M.). The
   authors are grateful to Dr Marek Rozanski (Department of Biology and
   Biotechnology, Medical University of Lodz, Poland) for the MCF-7 cell
   line. The authors' contributions were as follows: B. S. conducted the
   study and was involved in the study design, data interpretation,
   statistical analysis and wrote the manuscript; P. S. edited the
   manuscript and was involved in the statistical analysis and writing the
   manuscript; A. B. was involved in the real-time PCR data analysis; K.
   F.-M. designed and supervised the study and was involved in the data
   interpretation. All authors read and approved the final manuscript. The
   authors declare that there are no conflicts of interest.
CR Arany I, 2003, ANTICANCER RES, V23, P495
   Balch C, 2005, FRONT BIOSCI-LANDMRK, V10, P1897, DOI 10.2741/1668
   Besson A, 1999, EUR J BIOCHEM, V263, P605, DOI 10.1046/j.1432-1327.1999.00542.x
   Bigey P, 2000, GENE, V242, P407, DOI 10.1016/S0378-1119(99)00501-6
   Bowers JL, 2000, ENDOCRINOLOGY, V141, P3657, DOI 10.1210/en.141.10.3657
   Campbell PM, 2003, CARCINOGENESIS, V24, P17, DOI 10.1093/carcin/24.1.17
   Chandra J, 2002, BLOOD, V99, P655, DOI 10.1182/blood.V99.2.655
   Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699
   Chung JH, 2006, HUM MOL GENET, V15, P2553, DOI 10.1093/hmg/ddl177
   Fabianowska-Majewska K, 1998, ADV EXP MED BIOL, V431, P531
   Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4
   García JM, 2004, GENE CHROMOSOME CANC, V41, P117, DOI 10.1002/gcc.20062
   Goel A, 2004, CANCER RES, V64, P3014, DOI 10.1158/0008-5472.CAN-2401-2
   Hisatake J, 2001, BLOOD, V97, P2427, DOI 10.1182/blood.V97.8.2427
   Iida T, 2002, GENES CELLS, V7, P997, DOI 10.1046/j.1365-2443.2002.00584.x
   Iwase H, 1999, BRIT J CANCER, V80, P1982, DOI 10.1038/sj.bjc.6690631
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Khan S, 2004, INT J CANCER, V112, P407, DOI 10.1002/ijc.20447
   Krawczyk Barbara, 2006, Postepy Biologii Komorki, V33, P365
   Manna SK, 2000, J IMMUNOL, V164, P6509, DOI 10.4049/jimmunol.164.12.6509
   McCabe MT, 2005, CANCER RES, V65, P3624, DOI 10.1158/0008-5472.CAN-04-2158
   Milutinovic S, 2000, J BIOL CHEM, V275, P6353, DOI 10.1074/jbc.275.9.6353
   Mongan NP, 2005, MOL CANCER THER, V4, P477
   Montiel-Duarte C, 2008, LEUKEMIA RES, V32, P709, DOI 10.1016/j.leukres.2007.09.005
   Narvaez CJ, 2001, J BIOL CHEM, V276, P9101, DOI 10.1074/jbc.M006876200
   Niitsu N, 2001, BRIT J HAEMATOL, V112, P315, DOI 10.1046/j.1365-2141.2001.02523.x
   Niu MY, 2001, ONCOGENE, V20, P3506, DOI 10.1038/sj.onc.1204453
   Pethe V, 1999, J BIOL CHEM, V274, P30969, DOI 10.1074/jbc.274.43.30969
   Pettitt AR, 2003, BRIT J HAEMATOL, V121, P692, DOI 10.1046/j.1365-2141.2003.04336.x
   Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36
   Pogribny IP, 2009, MUTAT RES-FUND MOL M, V669, P56, DOI 10.1016/j.mrfmmm.2009.05.003
   Pratt MAC, 1996, J BIOL CHEM, V271, P20346, DOI 10.1074/jbc.271.34.20346
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   Saramäki A, 2009, J BIOL CHEM, V284, P8073, DOI 10.1074/jbc.M808090200
   Stefanska B, 2010, EUR J PHARMACOL, V638, P47, DOI 10.1016/j.ejphar.2010.04.032
   Swami S, 2000, CLIN CANCER RES, V6, P3371
   Szyf M, 2005, BIOCHEMISTRY-MOSCOW+, V70, P533, DOI 10.1007/s10541-005-0147-7
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Tili E, 2010, BIOCHEM PHARMACOL, V80, P2057, DOI 10.1016/j.bcp.2010.07.003
   Vladusic EA, 2000, ONCOL REP, V7, P157
   Waite KA, 2005, HUM MOL GENET, V14, P1457, DOI 10.1093/hmg/ddi155
   Wang Q, 2001, BREAST CANCER RES TR, V67, P157, DOI 10.1023/A:1010643323268
   Warzocha K, 1997, EUR J CANCER, V33, P170, DOI 10.1016/S0959-8049(96)00347-4
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Wu Q, 2002, INT J BIOCHEM CELL B, V34, P1102, DOI 10.1016/S1357-2725(02)00030-4
   Wyczechowska D, 2003, BIOCHEM PHARMACOL, V65, P219, DOI 10.1016/S0006-2952(02)01486-7
NR 46
TC 86
Z9 95
U1 0
U2 18
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
J9 BRIT J NUTR
JI Br. J. Nutr.
PD MAR
PY 2012
VL 107
IS 6
BP 781
EP 790
DI 10.1017/S0007114511003631
PG 10
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 896IO
UT WOS:000300559100003
PM 21801466
OA Bronze
DA 2025-01-12
ER

PT J
AU Foveau, B
   Boulay, G
   Pinte, S
   Van Rechem, C
   Rood, BR
   Leprince, D
AF Foveau, Benedicte
   Boulay, Gaylor
   Pinte, Sebastien
   Van Rechem, Capucine
   Rood, Brian R.
   Leprince, Dominique
TI The Receptor Tyrosine Kinase EphA2 Is a Direct Target Gene of
   Hypermethylated in Cancer 1 (<i>HIC1</i>)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; HUMAN BREAST-CANCER; CLINICAL-SIGNIFICANCE;
   CARCINOMA-CELLS; LIGAND-BINDING; EXPRESSION; GROWTH; METHYLATION;
   INVASION; MICE
AB The tumor suppressor gene hypermethylated in cancer 1 (HIC1), which encodes a transcriptional repressor, is epigenetically silenced in many human tumors. Here, we show that ectopic expression of HIC1 in the highly malignant MDA-MB-231 breast cancer cell line severely impairs cell proliferation, migration, and invasion in vitro. In parallel, infection of breast cancer cell lines with a retrovirus expressing HIC1 also induces decreased mRNA and protein expression of the tyrosine kinase receptor EphA2. Moreover, chromatin immunoprecipitation (ChIP) and sequential ChIP experiments demonstrate that endogenous HIC1 proteins are bound, together with the MTA1 corepressor, to the EphA2 promoter in WI38 cells. Taken together, our results identify EphA2 as a new direct target gene of HIC1. Finally, we observe that inactivation of endogenous HIC1 through RNA interference in normal breast epithelial cells results in the up-regulation of EphA2 and is correlated with increased cellular migration. To conclude, our results involve the tumor suppressor HIC1 in the transcriptional regulation of the tyrosine kinase receptor EphA2, whose ligand ephrin-A1 is also a HIC1 target gene. Thus, loss of the regulation of this Eph pathway through HIC1 epigenetic silencing could be an important mechanism in the pathogenesis of epithelial cancers.
C1 [Foveau, Benedicte; Boulay, Gaylor; Pinte, Sebastien; Van Rechem, Capucine; Leprince, Dominique] Univ Lille 2, Univ Lille 1, CNRS, UMR 8161,Inst Pasteur Lille,Inst Biol Lille, F-59021 Lille, France.
   [Rood, Brian R.] George Washington Univ, Childrens Natl Med Ctr, Sch Med, Washington, DC 20010 USA.
C3 Pasteur Network; Universite de Lille; Institut Pasteur Lille; Centre
   National de la Recherche Scientifique (CNRS); CNRS - National Institute
   for Biology (INSB); Children's National Health System; George Washington
   University
RP Leprince, D (通讯作者)，Univ Lille 2, Univ Lille 1, CNRS, UMR 8161,Inst Pasteur Lille,Inst Biol Lille, BP 447, F-59021 Lille, France.
EM dominique.leprince@ibl.fr
OI Van Rechem, Capucine/0000-0002-5408-6124; Leprince,
   Dominique/0000-0002-1999-0775
FU National Institutes of Health from NINDS [1K08NS051477]; CNRS;
   Association for International Cancer Research; Association pour la
   Recherche Contre le Cancer [ARC 3983, ARC 1081]; CNRS/Region Nord-Pas de
   Calais
FX This work was supported, in whole or in part, by National Institutes of
   Health Grant 1K08NS051477 from NINDS (for work performed in the
   laboratory of B. R. R.). This work was also supported by CNRS, the
   Association for International Cancer Research), and the Association pour
   la Recherche Contre le Cancer Grants ARC 3983 and ARC 1081 (to D. L.).
   Supported by fellowships from the CNRS/Region Nord-Pas de Calais and
   from the Association pour la Recherche Contre le Cancer. Present
   address: Harvard Medical School and Massachusetts General Hospital
   Cancer Center, Charlestown, MA 02129.
CR ANDRES AC, 1994, ONCOGENE, V9, P1461
   Annamalai B, 2009, MOL CANCER RES, V7, P1021, DOI 10.1158/1541-7786.MCR-08-0582
   BAE SN, 1993, BREAST CANCER RES TR, V24, P241, DOI 10.1007/BF01833264
   Beauchamp A., 2011, SEMIN CELL IN PRESS
   Bin Fang W, 2008, J BIOL CHEM, V283, P16017, DOI 10.1074/jbc.M709934200
   Boulay G, 2012, J BIOL CHEM, V287, P5379, DOI 10.1074/jbc.M111.304287
   Brantley-Sieders D, 2004, CURR PHARM DESIGN, V10, P3431, DOI 10.2174/1381612043383160
   Brantley-Sieders DM, 2008, J CLIN INVEST, V118, P64, DOI 10.1172/JCI33154
   Brantley-Sieders Dana M., 2004, Angiogenesis, V7, P17, DOI 10.1023/B:AGEN.0000037340.33788.87
   Brieger J, 2010, ORAL ONCOL, V46, P678, DOI 10.1016/j.oraloncology.2010.06.016
   Briggs KJ, 2008, CANCER RES, V68, P8654, DOI 10.1158/0008-5472.CAN-08-1904
   Briones VR, 2006, BIOCHEM BIOPH RES CO, V345, P595, DOI 10.1016/j.bbrc.2006.04.052
   Carles-Kinch K, 2002, CANCER RES, V62, P2840
   Chen Jin, 2008, Cancer Res, V68, P10031, DOI 10.1158/0008-5472.CAN-08-3010
   Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011
   Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077
   Dahl JA, 2007, STEM CELLS, V25, P1037, DOI 10.1634/stemcells.2006-0430
   Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831
   Deltour S, 2002, MOL CELL BIOL, V22, P4890, DOI 10.1128/MCB.22.13.4890-4901.2002
   Dohn M, 2001, ONCOGENE, V20, P6503, DOI 10.1038/sj.onc.1204816
   Eguchi K, 1997, CANCER RES, V57, P4913
   Fang BW, 2008, J CELL SCI, V121, P358, DOI 10.1242/jcs.017145
   Fleuriel C, 2009, INT J BIOCHEM CELL B, V41, P26, DOI 10.1016/j.biocel.2008.05.028
   Fox BP, 2004, BIOCHEM BIOPH RES CO, V318, P882, DOI 10.1016/j.bbrc.2004.04.102
   Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976
   Giunciuglio D, 1995, INT J CANCER, V63, P815, DOI 10.1002/ijc.2910630612
   Han LQ, 2005, GYNECOL ONCOL, V99, P278, DOI 10.1016/j.ygyno.2005.06.036
   Hayashi M, 2001, ANTICANCER RES, V21, P535
   Ireton RC, 2005, CURR CANCER DRUG TAR, V5, P149, DOI 10.2174/1568009053765780
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kawabe M, 2009, CANCER RES, V69, P6995, DOI 10.1158/0008-5472.CAN-08-4511
   Kinch MS, 2003, CLIN EXP METASTAS, V20, P59, DOI 10.1023/A:1022546620495
   Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856
   Larsen AB, 2007, MOL CANCER RES, V5, P283, DOI 10.1158/1541-7786.MCR-06-0321
   Larsen AB, 2010, CELL SIGNAL, V22, P636, DOI 10.1016/j.cellsig.2009.11.018
   Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183
   Macrae M, 2005, CANCER CELL, V8, P111, DOI 10.1016/j.ccr.2005.07.005
   Miao H., 2011, SEMIN CELL IN PRESS
   Miao H, 2009, CANCER CELL, V16, P9, DOI 10.1016/j.ccr.2009.04.009
   Mohammad HP, 2011, ONCOGENE, V30, P2659, DOI 10.1038/onc.2010.633
   Morton RA, 1996, J UROLOGY, V156, P512, DOI 10.1016/S0022-5347(01)65916-0
   Nicoll G, 2001, BRIT J CANCER, V85, P1878, DOI 10.1054/bjoc.2001.2163
   Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011
   Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806
   Pinte S, 2004, J BIOL CHEM, V279, P38313, DOI 10.1074/jbc.M401610200
   Pratt RL, 2003, MOL CANCER RES, V1, P1070
   Ramnarain DB, 2006, CANCER RES, V66, P867, DOI 10.1158/0008-5472.CAN-05-2753
   Rood BR, 2002, CANCER RES, V62, P3794
   Stankovic-Valentin N, 2006, FEBS J, V273, P2879, DOI 10.1111/j.1742-4658.2006.05301.x
   Taddei ML, 2009, AM J PATHOL, V174, P1492, DOI 10.2353/ajpath.2009.080473
   Tandon M, 2011, EXPERT OPIN THER TAR, V15, P31, DOI 10.1517/14728222.2011.538682
   Van Rechem C, 2010, MOL CELL BIOL, V30, P4045, DOI 10.1128/MCB.00582-09
   Van Rechem C, 2009, J BIOL CHEM, V284, P20927, DOI 10.1074/jbc.M109.022350
   Vaught D, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2207
   Vilgelm A, 2008, ONCOGENE, V27, P2170, DOI 10.1038/sj.onc.1210862
   Waha A, 2004, INT J CANCER, V110, P542, DOI 10.1002/ijc.20165
   WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570
   Walker-Daniels J, 2002, MOL CANCER RES, V1, P79
   Wykosky J, 2008, MOL CANCER RES, V6, P1795, DOI 10.1158/1541-7786.MCR-08-0244
   Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629
   Zantek ND, 2001, CLIN CANCER RES, V7, P3640
   Zelinski DP, 2002, J CELL BIOCHEM, V85, P714, DOI 10.1002/jcb.10186
   Zelinski DP, 2001, CANCER RES, V61, P2301
   Zhang GQ, 2008, CANCER RES, V68, P1691, DOI 10.1158/0008-5472.CAN-07-2372
   Zhang W, 2010, ONCOGENE, V29, P2467, DOI 10.1038/onc.2010.12
   Zhou N, 2011, MICROVASC RES, V82, P113, DOI 10.1016/j.mvr.2011.06.005
NR 66
TC 30
Z9 30
U1 0
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 17
PY 2012
VL 287
IS 8
BP 5366
EP 5378
DI 10.1074/jbc.M111.329466
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 897HE
UT WOS:000300638000018
PM 22184117
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Joung, KE
   Min, KN
   Kim, DK
   Sheen, YY
AF Joung, Ki Eun
   Min, Kyung Nan
   Kim, Dae-Kee
   Sheen, Yhun Yhong
TI Anti-Cancer Effect of IN-2001 in T47D Human Breast Cancer
SO BIOMOLECULES & THERAPEUTICS
LA English
DT Article
DE IN-2001; T47D; HDAC
ID HISTONE DEACETYLASE INHIBITORS; SUBEROYLANILIDE HYDROXAMIC ACID;
   WAF1/CIP1 GENE PROMOTER; COLON-CANCER; IN-VIVO; ANTITUMOR-ACTIVITY;
   CELL-LINES; SP1 SITES; ACETYLATION; EXPRESSION
AB Histone deacetylases (HDACs) are enzymes involved in the remodelling of chromatin, and have a key role in the epigenetic regulation of gene expression. Histone deacetylase (HDAC) inhibitors are emerging as an exciting new class of potential anti-cancer agents. In recent years, a number of structurally diverse HDAC inhibitors have been identified and these HDAC inhibitors induce growth arrest, differentiation and/or apoptosis of cancer cells in vitro and in vivo. However, the underlying molecular mechanisms remain unclear. This study aimed at investigating the anti-tumor activity of various HDAC inhibitors, IN-2001, using T47D human breast cancer cells. Moreover, the possible mechanism by which HDAC inhibitors exhibit anti-tumor activity was also explored. In estrogen receptor positive T47D cells, IN-2001, HDAC inhibitor showed anti-proliferative effects in dose-and time-dependent manner. In T47D human breast cancer cells showed anti-tumor activity of IN-2001 and the growth inhibitory effects of IN-2001 were related to the cell cycle arrest and induction of apoptosis. Flow cytometry studies revealed that IN-2001 showed accumulation of cells at G(2)/M phase. At the same time, IN-2001 treatment time-dependently increased sub-G(1) population, representing apoptotic cells. IN-2001-mediated cell cycle arrest was associated with induction of cdk inhibitor expression. In T47D cells, IN-2001 as well as other HDAC inhibitors treatment significantly increased p21(WAF1) and p27(KIP1), expression. In addition, thymidylate synthase, an essential enzyme for DNA replication and repair, was down-regulated by IN-2001 and other HDAC inhibitors in the T47D human breast cancer cells. In summary, IN-2001 with a higher potency than other HDAC inhibitors induced growth inhibition, cell cycle arrest, and eventual apoptosis in human breast cancer possibly through modulation of cell cycle and apoptosis regulatory proteins, such as cdk inhibitors, cyclins, and thymidylate synthase.
C1 [Joung, Ki Eun; Min, Kyung Nan; Kim, Dae-Kee; Sheen, Yhun Yhong] Ewha Womans Univ, Coll Pharm, Seoul 120750, South Korea.
C3 Ewha Womans University
RP Sheen, YY (通讯作者)，Ewha Womans Univ, Coll Pharm, Seoul 120750, South Korea.
EM yysheen@ewha.ac.kr
FU KOSEF [2006-KRF-531-E00112]
FX This work was supported by grant 2006-KRF-531-E00112 from KOSEF.
CR Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791
   Banwell CM, 2003, RECENT RESULTS CANC, V164, P83
   Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018
   Biswas S, 2006, CLIN CANCER RES, V12, P4142, DOI 10.1158/1078-0432.CCR-06-0952
   Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755
   Brown R, 2002, TRENDS MOL MED, V8, pS43, DOI 10.1016/S1471-4914(02)02314-6
   Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317
   Butler LM, 2000, CANCER RES, V60, P5165
   Carron JA, 1997, BRIT J CANCER, V76, P1095, DOI 10.1038/bjc.1997.513
   Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062
   Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825
   Furumai R, 2001, P NATL ACAD SCI USA, V98, P87, DOI 10.1073/pnas.011405598
   Gartel A L, 1998, Prog Mol Subcell Biol, V20, P43
   Glaser KB, 2003, MOL CANCER THER, V2, P151
   Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100
   Hortobagyi GN, 1998, NEW ENGL J MED, V339, P974, DOI 10.1056/NEJM199810013391407
   Johnstone RW, 2003, CANCER CELL, V4, P13, DOI 10.1016/S1535-6108(03)00165-X
   Joung KE, 2006, CANCER RES, V66, P5394, DOI 10.1158/0008-5472.CAN-05-3835
   Kim MS, 2003, CANCER RES, V63, P7291
   Kim YB, 1999, ONCOGENE, V18, P2461, DOI 10.1038/sj.onc.1202564
   Komatsu Y, 2001, CANCER RES, V61, P4459
   Mariadason JM, 2000, CANCER RES, V60, P4561
   Marks P., 2011, NAT REV CANCER, V1, P194
   Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199
   Papeleu P, 2005, CRIT REV TOXICOL, V35, P363, DOI 10.1080/10408440590935639
   Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197
   Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592
   Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940
   Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786
   Suzuki T, 1999, J MED CHEM, V42, P3001, DOI 10.1021/jm980565u
   VanLint C, 1996, GENE EXPRESSION, V5, P245
   Villar-Garea A, 2004, INT J CANCER, V112, P171, DOI 10.1002/ijc.20372
   Vrana JA, 1999, ONCOGENE, V18, P7016, DOI 10.1038/sj.onc.1203176
   Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693
   Wittich S, 2002, J MED CHEM, V45, P3296, DOI 10.1021/jm0208119
   Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252
   Zhou Q, 2000, J BIOL CHEM, V275, P35256, DOI 10.1074/jbc.M003106200
NR 37
TC 4
Z9 4
U1 0
U2 1
PU KOREAN SOC APPLIED PHARMACOLOGY
PI SEOUL
PA RM 805, KOREAN FEDERATION SCIENCE & TECHNOLOGY B/D, 635-4 YEOKSAM-DONG,
   KANGNAM-GU, SEOUL, 135-703, SOUTH KOREA
SN 1976-9148
EI 2005-4483
J9 BIOMOL THER
JI Biomol. Ther.
PD JAN 31
PY 2012
VL 20
IS 1
BP 81
EP 88
DI 10.4062/biomolther.2012.20.1.081
PG 8
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 895AR
UT WOS:000300469100011
PM 24116279
OA Bronze, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Artacho-Cordón, A
   Artacho-Cordón, F
   Ríos-Arrabal, S
   Calvente, I
   Núñez, MI
AF Artacho-Cordon, Antonia
   Artacho-Cordon, Francisco
   Rios-Arrabal, Sandra
   Calvente, Irene
   Isabel Nunez, Maria
TI Tumor microenvironment and breast cancer progression A complex scenario
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE breast cancer; tumor microenvironment; tumor progression; matrix
   metalloproteinases; inflammation; angiogenesis; epigenetic
ID GENE-EXPRESSION; EXTRACELLULAR-MATRIX; LYMPHOVASCULAR INVASION;
   ANGIOGENIC SWITCH; OXIDATIVE STRESS; EPITHELIAL-CELLS; DNA METHYLATION;
   TGF-BETA; HOST MICROENVIRONMENT; HISTONE MODIFICATIONS
AB It is now widely accepted that the development and progression of a tumor toward the malignant phenotype is highly dependent on interactions between tumor cells and the tumor microenvironment. Different components of the tumor microenvironment may have stimulatory or inhibitory effects on tumor progression by regulating the gene expression repertoire in tumor cells and stromal cells.
   This review analyzes novel research findings on breast cancer progression, discussing acquisition of the metastatic phenotype in breast disease in relation to different aspects of cross-talk among components of the tumor microenvironment. Knowledge of the interaction of all of these factors would contribute to elucidating the mechanisms that disrupt regulatory/signaling cascades and downstream effects in breast cancer.
C1 [Artacho-Cordon, Antonia; Artacho-Cordon, Francisco; Rios-Arrabal, Sandra; Calvente, Irene; Isabel Nunez, Maria] Univ Granada, Dept Radiol & Med Phys, San Cecilio Univ Hosp, Lab Med Invest, Granada, Spain.
C3 Hospital Universitario San Cecilio; University of Granada
RP Núñez, MI (通讯作者)，Univ Granada, Dept Radiol & Med Phys, San Cecilio Univ Hosp, Lab Med Invest, Granada, Spain.
EM isabeln@ugr.es
RI Núñez, María/L-9924-2014; Cordon, Antonia/Z-1233-2019; Artacho-Cordon,
   Francisco/A-3166-2015
OI Artacho, Antonia/0000-0001-5495-9389; Artacho-Cordon,
   Francisco/0000-0003-3850-6173
FU Instituto de Salud Carlos III [PI 080728]; Fundacion Benefica San
   Francisco Javier y Santa Candida, University of Granada; Spanish
   Ministry of Science and Education; San Cecilio University Hospital,
   Granada
FX This study was supported by the Instituto de Salud Carlos III, PI 080728
   to M.I.N. S.R. is supported by the Fundacion Benefica San Francisco
   Javier y Santa Candida, University of Granada. A grant from the Spanish
   Ministry of Science and Education to F.A. greatly aided this work. This
   research was also funded by the San Cecilio University Hospital,
   Granada. The authors thank Richard Davies for improving the English
   style of the manuscript. We are also indebted to Juan Jesus Priego
   Cordoba for his assistance in designing the figure.
CR Acevedo VD, 2009, CELL CYCLE, V8, P580, DOI 10.4161/cc.8.4.7657
   Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429
   Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010
   Allred DC, 2001, ENDOCR-RELAT CANCER, V8, P47, DOI 10.1677/erc.0.0080047
   Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639
   Barcellos-Hoff MH, 1998, J MAMMARY GLAND BIOL, V3, P165, DOI 10.1023/A:1018794806635
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Ben-Baruch A, 2003, BREAST CANCER RES, V5, P31, DOI 10.1186/bcr554
   Bergamaschi A, 2008, J PATHOL, V214, P357, DOI 10.1002/path.2278
   Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093
   Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374
   Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003
   Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059
   BISSELL MJ, 1987, J CELL SCI, P327
   BISSELL MJ, 1989, ENVIRON HEALTH PERSP, V80, P61, DOI 10.2307/3430732
   BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5
   Bussard KM, 2010, CANCER RES, V70, P6336, DOI 10.1158/0008-5472.CAN-10-0591
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007
   Chin K, 2004, NAT GENET, V36, P984, DOI 10.1038/ng1409
   Ciruna B, 2001, DEV CELL, V1, P37, DOI 10.1016/S1534-5807(01)00017-X
   Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127
   Corcoran KE, 2007, MOL CANCER RES, V5, P373, DOI 10.1158/1541-7786.MCR-06-0396
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Cunha GR, 2002, DIFFERENTIATION, V70, P473, DOI 10.1046/j.1432-0436.2002.700902.x
   Curtis CD, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-9
   Curtis CD, 2009, MOL ENDOCRINOL, V23, P1346, DOI 10.1210/me.2009-0093
   Dalmay T, 2006, ONCOGENE, V25, P6170, DOI 10.1038/sj.onc.1209911
   Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105
   Dvorak HF, 2011, J SURG ONCOL, V103, P468, DOI 10.1002/jso.21709
   DVORAK HF, 1986, NEW ENGL J MED, V315, P1650
   Ejlertsen B, 2009, JNCI-J NATL CANCER I, V101, P729, DOI 10.1093/jnci/djp090
   El-Gohary YM, 2008, AM J CLIN PATHOL, V129, P578, DOI 10.1309/2HGNJ1GU57JMBJAQ
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Farmer P, 2009, NAT MED, V15, P68, DOI 10.1038/nm.1908
   Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508
   Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764
   Fisher ER, 2001, CANCER-AM CANCER SOC, V91, P1679, DOI 10.1002/1097-0142(20010415)91:8+<1679::AID-CNCR1183>3.0.CO;2-8
   Florin L, 2005, J CELL SCI, V118, P1981, DOI 10.1242/jcs.02303
   Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017
   Fukino K, 2004, CANCER RES, V64, P7231, DOI 10.1158/0008-5472.CAN-04-2866
   Fukino K, 2007, JAMA-J AM MED ASSOC, V297, P2103, DOI 10.1001/jama.297.19.2103
   Gajdos C, 1999, ANN SURG, V230, P692, DOI 10.1097/00000658-199911000-00012
   Gehler S, 2009, MOL BIOL CELL, V20, P3224, DOI 10.1091/mbc.E08-12-1186
   Giacinti L, 2006, ONCOLOGIST, V11, P1, DOI 10.1634/theoncologist.11-1-1
   Goetz JG, 2011, CELL, V146, P148, DOI 10.1016/j.cell.2011.05.040
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   Hitchiler MJ, 2008, FREE RADICAL BIO MED, V45, P1573, DOI 10.1016/j.freeradbiomed.2008.09.005
   Hoda SA, 2006, ADV ANAT PATHOL, V13, P308, DOI 10.1097/01.pap.0000213048.69564.26
   Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596
   Hu M, 2008, CURR OPIN GENET DEV, V18, P27, DOI 10.1016/j.gde.2007.12.006
   Hu M, 2008, CANCER CELL, V13, P394, DOI 10.1016/j.ccr.2008.03.007
   Hunter Kent W, 2008, Breast Cancer Res, V10 Suppl 1, pS2, DOI 10.1186/bcr1988
   Hunter KW, 2004, BRIT J CANCER, V90, P752, DOI 10.1038/sj.bjc.6601590
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jeon HW, 2010, MOL CANCER THER, V9, P1361, DOI 10.1158/1535-7163.MCT-09-0717
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015
   Klaunig JE, 2004, ANNU REV PHARMACOL, V44, P239, DOI 10.1146/annurev.pharmtox.44.101802.121851
   Köhrmann A, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-188
   Kurose K, 2001, HUM MOL GENET, V10, P1907, DOI 10.1093/hmg/10.18.1907
   Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Lerwill MF, 2004, AM J SURG PATHOL, V28, P1076, DOI 10.1097/01.pas.0000126780.10029.f0
   Lewis CE, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1679
   Li Jing-ruo, 2008, Zhonghua Yi Xue Za Zhi, V88, P2278
   Lin EY, 2007, CANCER RES, V67, P5064, DOI 10.1158/0008-5472.CAN-07-0912
   Lin HJL, 2008, CANCER RES, V68, P10257, DOI 10.1158/0008-5472.CAN-08-0288
   Lohela M, 2009, CURR OPIN CELL BIOL, V21, P154, DOI 10.1016/j.ceb.2008.12.012
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   Ma XJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2222
   Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100
   Maffini MV, 2005, AM J PATHOL, V167, P1405, DOI 10.1016/S0002-9440(10)61227-8
   Maffini MV, 2004, J CELL SCI, V117, P1495, DOI 10.1242/jcs.01000
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Maruyama R, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001369
   Mezquita B, 2010, J CELL BIOCHEM, V110, P732, DOI 10.1002/jcb.22584
   Moinfar F, 2000, CANCER RES, V60, P2562
   Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346
   Murdoch C, 2004, BLOOD, V104, P2224, DOI 10.1182/blood-2004-03-1109
   Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002
   Nelson CM, 2006, ANNU REV CELL DEV BI, V22, P287, DOI 10.1146/annurev.cellbio.22.010305.104315
   Nguyen DH, 2011, CANCER CELL, V19, P640, DOI 10.1016/j.ccr.2011.03.011
   Olumi AF, 1999, CANCER RES, V59, P5002
   Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112
   Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125
   Patel SA, 2008, J ONCOL, V2008, DOI 10.1155/2008/425895
   Patocs A, 2007, NEW ENGL J MED, V357, P2543, DOI 10.1056/NEJMoa071825
   Plachot C, 2004, EXP CELL RES, V298, P122, DOI 10.1016/j.yexcr.2004.04.024
   Polyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295
   Polyak K, 2009, TRENDS GENET, V25, P30, DOI 10.1016/j.tig.2008.10.012
   Qiu W, 2008, NAT GENET, V40, P650, DOI 10.1038/ng.117
   Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688
   Rajski M, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-1
   Rao AK, 2008, MOL ENDOCRINOL, V22, P1113, DOI 10.1210/me.2007-0381
   Rao AK, 2009, J MOL ENDOCRINOL, V43, P251, DOI 10.1677/JME-09-0053
   Roberts RA, 2009, TOXICOL SCI, V112, P4, DOI 10.1093/toxsci/kfp179
   Ruan K, 2009, CANCER LETT, V285, P116, DOI 10.1016/j.canlet.2009.04.031
   Saharinen P, 2010, CURR OPIN HEMATOL, V17, P198, DOI 10.1097/MOH.0b013e3283386673
   Sandal T, 2007, AM J PATHOL, V170, P1739, DOI 10.2353/ajpath.2007.060922
   Schäfer M, 2008, NAT REV MOL CELL BIO, V9, P628, DOI 10.1038/nrm2455
   Schedin P, 2004, BREAST CANCER RES, V6, P93, DOI 10.1186/bcr772
   Schoppmann SF, 2004, ANN SURG, V240, P306, DOI 10.1097/01.sla.0000133355.48672.22
   Schultz-Norton JR, 2006, MOL ENDOCRINOL, V20, P1982, DOI 10.1210/me.2006-0006
   Sgroi DC, 2010, ANNU REV PATHOL-MECH, V5, P193, DOI 10.1146/annurev.pathol.4.110807.092306
   Sharma M, 2010, BREAST CANCER RES TR, V123, P397, DOI 10.1007/s10549-009-0654-0
   Shekhar MPV, 2003, BREAST CANCER RES, V5, P130, DOI 10.1186/bcr580
   Shibuya M, 2006, J BIOCHEM MOL BIOL, V39, P469
   Sibilia M, 2007, DIFFERENTIATION, V75, P770, DOI 10.1111/j.1432-0436.2007.00238.x
   Soares J, 1999, CANCER, V85, P112, DOI 10.1002/(SICI)1097-0142(19990101)85:1<112::AID-CNCR16>3.0.CO;2-T
   Soucek L, 2007, NAT MED, V13, P1211, DOI 10.1038/nm1649
   Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224
   Vakkila J, 2004, NAT REV IMMUNOL, V4, P641, DOI 10.1038/nri1415
   Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009
   Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3
   Weber F, 2005, BRIT J CANCER, V92, P1922, DOI 10.1038/sj.bjc.6602557
   Weber F, 2006, AM J HUM GENET, V78, P961, DOI 10.1086/504090
   Weiser MR, 2001, ANN SURG ONCOL, V8, P145, DOI 10.1007/s10434-001-0145-y
   Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835
   Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153
   Woo CS, 2002, AM J SURG, V184, P337, DOI 10.1016/S0002-9610(02)00950-9
   Yu JL, 2003, BREAST CANCER RES, V5, P83, DOI 10.1186/bcr573
   Yu Q, 2000, GENE DEV, V14, P163
   Zong WX, 2006, GENE DEV, V20, P1, DOI 10.1101/gad.1376506
NR 133
TC 42
Z9 49
U1 0
U2 32
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD JAN 1
PY 2012
VL 13
IS 1
BP 14
EP 24
DI 10.4161/cbt.13.1.18869
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 893LH
UT WOS:000300356900002
PM 22336584
OA Bronze
DA 2025-01-12
ER

PT J
AU Dong, SW
   Zhang, P
   Liu, YM
   Cui, YT
   Wang, S
   Liang, SJ
   He, Z
   Sun, P
   Wang, YG
AF Dong, Shang-Wen
   Zhang, Peng
   Liu, Yi-Mei
   Cui, Yuan-Tao
   Wang, Shuo
   Liang, Shao-Jie
   He, Zhun
   Sun, Pei
   Wang, Yuan-Guo
TI Study on <i>RIZ1</i> gene promoter methylation status in human
   esophageal squamous cell carcinoma
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Retinoblastoma protein-interacting zinc finger gene 1; Tumor suppressor
   genes; Esophageal squamous cell carcinoma; Promoter methylation;
   Methylation-specific polymerase chain reaction
ID HUMAN HEPATOCELLULAR-CARCINOMA; DNA METHYLATION; BREAST-CANCER;
   HYPERMETHYLATION; INACTIVATION; EXPRESSION; BINDING; REGION; MEMBER
AB AIM: To investigate the promoter region methylation status of retinoblastoma protein-interacting zinc finger gene 1 (RIZ1) in the human esophageal squamous cell carcinoma (ESCC) cell lines and tissues and verify the relationship between methylation of RIZ1 and oncogenesis, tumor progression and metastasis etc of ESCC.
   METHODS: Methylation-specific polymerase chain reaction (MSP) was used to investigate the promoter region methylation status of RIZ1 in 6 ESCC cell lines. One cell line where RIZ1 promoter region methylation was detected was selected for the next study, where the cell line was treated with 5-aza-CdR. Real-time polymerase chain reaction was used to investigate its influence on the transcription of RIZ1. Experiments using frozen pathological specimens from 47 ESCC patients were performed using the same MSP methodology.
   RESULTS: Promoter methylation of RIZ1 gene was detected in TE13, CaEs17 and EC109 cell lines and the cell line TE13 was chosen for further study. The expression of RIZ1 mRNA in TE-13 was up-regulated after treatment with 5-aza-CdR. The rate of methylation in carcinomas tissues was significantly higher than those in matched neighboring normal and distal ending normal tissue, and the deviation of data was statistically significant (chi(2) = 24.136, P < 0.01). Analysis of the gender, age familial history, tumour deviation, tumour saturation, lymph gland displacement and clinical staging of 47 samples from ESCC patients showed that the fluctuation of data was not statistically significant.
   CONCLUSION: Promoter methylation may play an important role in the epigenetic silencing of RIZ1 gene expression in human ESCC. RIZ1 is considered to be a potential tumor suppressor gene and may be a biological parameter for testing early stage human ESCC. (C) 2012 Baishideng. All rights reserved.
C1 [Dong, Shang-Wen; Zhang, Peng; Liu, Yi-Mei; Cui, Yuan-Tao; Wang, Shuo; Liang, Shao-Jie; He, Zhun; Wang, Yuan-Guo] Tianjin Med Univ Gen Hosp, Dept Cardiothorac Surg, Tianjin 300052, Peoples R China.
   [Sun, Pei] Tianjin Med Univ, Tianjin Inst Endocrinol, Tianjin 300070, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University
RP Zhang, P (通讯作者)，TianJin Med Univ, Tianjin Med Univ Gen Hosp, Dept Cardiothorac Surg, Qixiangtai Rd 22, Tianjin 300070, Peoples R China.
EM zhang_peng6036@yeah.net
RI Zhang, Zhen/GXH-3666-2022; Dong, Shangwen/G-6083-2014
OI Dong, Shangwen/0000-0003-4272-9572; Zhang, Peng/0000-0003-3481-9439
FU Specialized Research Fund for the Doctoral Program of Higher Education
   [20091202110009]; Natural Science Foundation of Tianjin [10JCYBJC11300]
FX Supported by Grant-in-aid from Specialized Research Fund for the
   Doctoral Program of Higher Education, No. 20091202110009; and
   Grant-in-aid from Natural Science Foundation of Tianjin, No.
   10JCYBJC11300
CR Chen BS, 2000, INT J CANCER, V88, P862, DOI 10.1002/1097-0215(20001215)88:6<862::AID-IJC4>3.0.CO;2-L
   Dong SW, 2011, NEOPLASMA, V58, P89, DOI 10.4149/neo_2011_01_89
   Du Y, 2001, CANCER RES, V61, P8094
   Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010
   Esteller M, 2001, CANCER RES, V61, P3225
   Fang W, 2000, GENE CHROMOSOME CANC, V28, P269, DOI 10.1002/1098-2264(200007)28:3<269::AID-GCC4>3.0.CO;2-K
   Fang W, 2001, BRIT J CANCER, V84, P743, DOI 10.1054/bjoc.2000.1667
   Gazzerro P, 2006, EXP CELL RES, V312, P340, DOI 10.1016/j.yexcr.2005.11.002
   Hasegawa Y, 2007, CANCER SCI, V98, P32, DOI 10.1111/j.1349-7006.2006.00338.x
   He LS, 1998, CANCER RES, V58, P4238
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634
   Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7
   Lal G, 2006, CANCER, V107, P2752, DOI 10.1002/cncr.22325
   Liu LB, 1997, J BIOL CHEM, V272, P1997, DOI 10.1074/jbc.272.3.1997
   Ma L, 2010, CLIN LAB, V56, P407
   Metzger R, 2004, ONKOLOGIE, V27, P200, DOI 10.1159/000076913
   Montesano R, 1996, INT J CANCER, V69, P225, DOI 10.1002/(SICI)1097-0215(19960621)69:3<225::AID-IJC13>3.0.CO;2-6
   Oshimo Y, 2004, INT J CANCER, V110, P212, DOI 10.1002/ijc.20090
   Qin YR, 2008, WORLD J GASTROENTERO, V14, P1828, DOI 10.3748/wjg.14.1828
   RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991
   Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101
   Tokumaru Y, 2003, ONCOGENE, V22, P6954, DOI 10.1038/sj.onc.1206403
NR 23
TC 16
Z9 20
U1 0
U2 9
PU BAISHIDENG PUBL GRP CO LTD
PI BEIJING
PA RM 903, BLDG D, OCEAN INTERNATIONAL CTR, NO 62 DONGSIHUAN ZHONGLU,
   BEIJING, CHAOYANG DISTRICT 100025, PEOPLES R CHINA
SN 1007-9327
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD FEB 14
PY 2012
VL 18
IS 6
BP 576
EP 582
DI 10.3748/wjg.v18.i6.576
PG 7
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 892HN
UT WOS:000300277400013
PM 22363126
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Chen, M
   Shabashvili, D
   Nawab, A
   Yang, SX
   Dyer, LM
   Brown, KD
   Hollingshead, M
   Hunter, KW
   Kaye, FJ
   Hochwald, SN
   Marquez, VE
   Steeg, P
   Zajac-Kaye, M
AF Chen, Min
   Shabashvili, Daniel
   Nawab, Akbar
   Yang, Sherry X.
   Dyer, Lisa M.
   Brown, Kevin D.
   Hollingshead, Melinda
   Hunter, Kent W.
   Kaye, Frederic J.
   Hochwald, Steven N.
   Marquez, Victor E.
   Steeg, Patricia
   Zajac-Kaye, Maria
TI DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and
   Induces Apoptosis in a Genetically Engineered Mouse Model of Breast
   Cancer
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID FREQUENT EPIGENETIC INACTIVATION; P53-MEDIATED G(1) ARREST; CYCLIN D2
   EXPRESSION; TRANSGENIC MICE; PROMOTER HYPERMETHYLATION; P53-DEPENDENT
   APOPTOSIS; EPITHELIAL-CELLS; MAMMARY-TUMORS; SFRP GENES; IN-VITRO
AB Zebularine is a novel potent inhibitor of both cytidine deaminase and DNA methylation. We examined the effect of zebularine on mammary tumor growth in genetically engineered MMTV-PyMT transgenic mice that develop mammary tumors at 60 days of age with 100% penetrance. The MMTV-PyMT transgenic mice were randomized at 46 days of age into control (n = 25) and zebularine (n = 25) treatment groups and monitored for parameters of tumor growth. Zebularine was administered at 5 mg/mL in drinking water. We observed a significant delay in the growth of mammary tumors in zebularine-treated mice with a statistically significant reduction (P = 0.0135) in total tumor burden at 94 days of age when the mice were sacrificed. After 48 days of zebularine treatment, the tumors were predominantly necrotic compared with untreated animals. In addition, a high apoptotic index by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay was observed as early as 13 days following treatment. Immunoblot analysis showed depletion of DNMT1 and partial depletion of DNMT3b after zebularine treatment. Microarray analyses of global gene expression identified upregulation of twelve methylation-regulated genes as well as a set of candidate cancer genes that participate in cell growth and apoptosis. In summary, zebularine inhibits the growth of spontaneous mammary tumors and causes early onset of tumor cell necrosis and apoptosis in a genetically engineered mouse model of breast cancer. Defining the parameters of zebularine-mediated tumor inhibition may advance the future development of DNA methyltransferase inhibitors as an effective cancer treatment. Mol Cancer Ther; 11(2); 370-82. (C) 2011 AACR.
C1 [Zajac-Kaye, Maria] Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA.
   [Chen, Min; Kaye, Frederic J.; Zajac-Kaye, Maria] Univ Florida, Dept Med, Gainesville, FL 32610 USA.
   [Dyer, Lisa M.; Brown, Kevin D.] Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA.
   [Hochwald, Steven N.] Univ Florida, Dept Surg, Gainesville, FL 32610 USA.
   [Yang, Sherry X.] NCI Frederick, Natl Clin Target Validat Lab, Frederick, MD USA.
   [Hollingshead, Melinda] NCI Frederick, Dev Therapeut Program, Frederick, MD USA.
   [Hunter, Kent W.] NCI, Lab Canc Biol & Genet, Bethesda, MD 20892 USA.
   [Marquez, Victor E.] NCI, Med Chem Lab, Bethesda, MD 20892 USA.
   [Steeg, Patricia] NCI, Mol Pharmacol Lab, Bethesda, MD 20892 USA.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida; State University
   System of Florida; University of Florida; State University System of
   Florida; University of Florida; National Institutes of Health (NIH) -
   USA; NIH National Cancer Institute (NCI); Science Applications
   International Corporation (SAIC); Science Applications International
   Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH
   National Cancer Institute (NCI); National Institutes of Health (NIH) -
   USA; NIH National Cancer Institute (NCI); National Institutes of Health
   (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of
   Health (NIH) - USA; NIH National Cancer Institute (NCI)
RP Zajac-Kaye, M (通讯作者)，Univ Florida, Coll Med, Dept Anat & Cell Biol, Canc & Genet Res Complex,Room 360,2033 Mowry Rd, Gainesville, FL 32610 USA.
EM mzajackaye@ufl.edu
RI kaye, frederic/E-2437-2011; Marquez, Victor/KWD-9188-2024
FU National Cancer Institute; Department of Medicine at the University of
   Florida; Department of Anatomy and Cell Biology at the University of
   Florida
FX This work was supported by National Cancer Institute intramural program
   and by the Department of Medicine and Department of Anatomy and Cell
   Biology at the University of Florida.
CR Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379
   Asch HL, 1996, CANCER RES, V56, P4841
   Beaulieu N, 2002, J BIOL CHEM, V277, P28176, DOI 10.1074/jbc.M204734200
   BEISLER JA, 1978, J MED CHEM, V21, P204, DOI 10.1021/jm00200a012
   Billam M, 2010, BREAST CANCER RES TR, V120, P581, DOI 10.1007/s10549-009-0420-3
   Bodine PVN, 2005, J CELL BIOCHEM, V96, P1212, DOI 10.1002/jcb.20599
   Bradbury C, 2005, LEUKEMIA, V19, P1751, DOI 10.1038/sj.leu.2403910
   Castaneda CA, 2010, CANCER METAST REV, V29, P751, DOI 10.1007/s10555-010-9261-0
   Chen M, 2010, INT J ONCOL, V37, P963, DOI 10.3892/ijo_00000747
   Cheng JC, 2003, J NATL CANCER I, V95, P399, DOI 10.1093/jnci/95.5.399
   Cheng JC, 2004, MOL CELL BIOL, V24, P1270, DOI 10.1128/MCB.24.3.1270-1278.2004
   Cheng JC, 2004, CANCER CELL, V6, P151, DOI 10.1016/j.ccr.2004.06.023
   Choi EJ, 2009, J NUTR BIOCHEM, V20, P285, DOI 10.1016/j.jnutbio.2008.03.005
   Chopin V, 2004, EXP CELL RES, V298, P560, DOI 10.1016/j.yexcr.2004.04.038
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Dote H, 2005, CLIN CANCER RES, V11, P4571, DOI 10.1158/1078-0432.CCR-05-0050
   ELDEIRY WS, 1994, CANCER RES, V54, P1169
   Evron E, 2001, CANCER RES, V61, P2782
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Fischer HN, 2002, ONCOL REP, V9, P1157
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   Gopinathan A, 2008, DIS MODEL MECH, V1, P83, DOI 10.1242/dmm.000570
   GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954
   HERMAN JG, 1995, CANCER RES, V55, P4525
   Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730
   JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lo PK, 2006, CANCER BIOL THER, V5, P281, DOI 10.4161/cbt.5.3.2384
   MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935
   Maroulakou IG, 2007, CANCER RES, V67, P167, DOI 10.1158/0008-5472.CAN-06-3782
   Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636
   Nagler RM, 2003, ONCOLOGY-BASEL, V64, P389, DOI 10.1159/000070298
   Neureiter D, 2007, SCAND J GASTROENTERO, V42, P103, DOI 10.1080/00365520600874198
   Nojima M, 2007, ONCOGENE, V26, P4699, DOI 10.1038/sj.onc.1210259
   Olive KP, 2006, CLIN CANCER RES, V12, P5277, DOI 10.1158/1078-0432.CCR-06-0436
   Pedersen TX, 2005, CARCINOGENESIS, V26, P1233, DOI 10.1093/carcin/bgi065
   Periyasamy S, 2000, ONCOGENE, V19, P4660, DOI 10.1038/sj.onc.1203822
   Qiu TH, 2004, CANCER RES, V64, P5973, DOI 10.1158/0008-5472.CAN-04-0242
   Ramachandran C, 2005, ANTICANCER RES, V25, P3293
   Scott SA, 2007, EXP HEMATOL, V35, P263, DOI 10.1016/j.exphem.2006.10.005
   Singh M, 2010, NAT BIOTECHNOL, V28, P585, DOI 10.1038/nbt.1640
   SORM F, 1968, NEOPLASMA, V15, P339
   SRINIVAS S, 1994, P NATL ACAD SCI USA, V91, P10064, DOI 10.1073/pnas.91.21.10064
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Sweeney KJ, 1997, ONCOGENE, V14, P1329, DOI 10.1038/sj.onc.1200951
   Thor AD, 2001, CLIN CANCER RES, V7, P2415
   VANDEKERCKHOVE J, 1990, J CELL BIOL, V111, P95, DOI 10.1083/jcb.111.1.95
   WALDMAN T, 1995, CANCER RES, V55, P5187
   Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344
   WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849
   WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0
   Yang SX, 2008, CLIN CANCER RES, V14, P5893, DOI 10.1158/1078-0432.CCR-07-4762
   Yang ZQ, 2009, INT J CANCER, V125, P1613, DOI 10.1002/ijc.24518
   Yoo CB, 2004, BIOCHEM SOC T, V32, P910, DOI 10.1042/BST0320910
   Yoo CB, 2008, CANCER PREV RES, V1, P233, DOI 10.1158/1940-6207.CAPR-07-0008
   Zou HZ, 2005, INT J CANCER, V116, P584, DOI 10.1002/ijc.21045
NR 58
TC 45
Z9 53
U1 0
U2 15
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD FEB
PY 2012
VL 11
IS 2
BP 370
EP 382
DI 10.1158/1535-7163.MCT-11-0458
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 894GO
UT WOS:000300415300012
PM 22203734
OA Green Submitted, Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Dong, SW
   Cui, YT
   Zhong, RR
   Liang, DC
   Liu, YM
   Wang, YG
   He, Z
   Wang, S
   Liang, SJ
   Zhang, P
AF Dong, Shang-Wen
   Cui, Yuan-Tao
   Zhong, Rong-Rong
   Liang, Dong-Chun
   Liu, Yi-Mei
   Wang, Yuan-Guo
   He, Zhun
   Wang, Shuo
   Liang, Shao-Jie
   Zhang, Peng
TI Decreased Expression of Retinoblastoma Protein-Interacting Zinc-Finger
   Gene 1 in Human Esophageal Squamous Cell Cancer by DNA Methylation
SO CLINICAL LABORATORY
LA English
DT Article
DE RIZ1; TSG; ESCC; promoter methylation; MSP; 5-aza-2 '-deoxycytidine
ID HUMAN HEPATOCELLULAR-CARCINOMA; PROMOTER HYPERMETHYLATION;
   BREAST-CANCER; RIZ1 GENE; INACTIVATION; BINDING; MEMBER
AB Background: To study the expression of the RIZ1 (Retinoblastoma protein-interacting zinc-finger gene 1) gene and investigate the promoter region methylation status of RIZ1 gene in the human esophageal squamous cell carcinoma (ESCC) cell lines of KYSE150, KYSE510, TE13, EC9706, CaEs17, and EC109. To investigate the influence of DNMT (DNA methyltransferase) 5-aza-CdR(5-aza-2'-deoxycytidine) on the transcription of the RIZ1 gene in one cell line whose RIZ1 gene promoter region methylation was detected, and to investigate its influence on the cell proliferation.
   Methods: Real-time PCR (Real-time quantitative PCR) and an immunohistochemistry technique was used to get the expression of RIZ1 in specimens from 6 human ESCC cell lines and 28 ESCC patients (tumor tissues and adjacent non-cancerous tissues). MSP (Methylation-specific PCR) was used to investigate the promoter region methylation status of the RIZ1 gene in the 6 ESCC cell lines. One cell line, whose RIZ1 gene promoter region methy-lation was detected, was chosen for the next studies in which it was treated it by with 5-aza-CdR. Real-time PCR was used to investigate its influence on the transcription of RIZ1 gene and MTT (methyl thiazolyl tetrazolium) was used to detect if 5-aza-CdR inhibits the proliferation of the cell line.
   Results: In the 28 ESCC patient samples, RIZ1 expression was significantly lower in the tumor tissues than that in their adjacent non-cancerous tissues (p<0.05). Consistently, immunohistochemistry analyses of RIZ1 protein expression showed that in the ESCC tissues RIZ1 protein expression was also significantly lower than in the adjacent tissues. In the human ESCC tissues the rate of expression accounts for 0% (0/12), and in the adjacent non-cancerous tissues the rate of expression was 66.7% (8/12), the correlation was highly significant (chi(2) = 12.000, p<0.05). Promoter methylation of the RIZ1 gene was detected in TE13, CaEs17, EC109. The cell line TE13 was chosen for the next studies. The expression of RIZ1 mRNA in TE-13 was up-regulated after having been treated with 5-aza-CdR. 5-aza-CdR inhibited cell proliferation of TE-13 in a time and concentration-dependent manner.
   Conclusions: Promoter methylation may play an important role in the epigenetic silencing of RIZ1 gene expression. Methylation of the RIZ1 promoter and loss of RIZ1 expression in human ESCC are independent biomarkers. Their determination may offer guidance for selecting appropriate diagnoses and treatments. RIZ1 may be a potential tumor suppressor in human ESCC. (Clin. Lab. 2012;58:41-51)
C1 [Dong, Shang-Wen; Cui, Yuan-Tao; Zhong, Rong-Rong; Liu, Yi-Mei; Wang, Yuan-Guo; He, Zhun; Wang, Shuo; Liang, Shao-Jie; Zhang, Peng] Tianjin Med Univ Gen Hosp, Dept Cardiothorac Surg, Tianjin 300052, Peoples R China.
   [Liang, Dong-Chun] TianJin Med Univ, Tianjin Inst Endocrinol, Tianjin 300070, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University
RP Zhang, P (通讯作者)，TianJin Med Univ, Tianjin Med Univ Gen Hosp, Dept Cardiothorac Surg, Qixiangtai Rd 22, Tianjin 300070, Peoples R China.
EM zhang_peng6036@yeah.net
RI zhang, zhilong/JHS-5747-2023; Dong, Shangwen/G-6083-2014
OI Zhang, Peng/0000-0003-3481-9439
FU Doctoral Program of Higher Education Research Fund [20091202110009];
   Natural Science Foundation of Tianjin [10JCYBJC11 300]
FX This work was supported in part by a grant-in-aid from the Doctoral
   Program of Higher Education Research Fund (20091202110009) and a
   grant-in-aid from the Natural Science Foundation of Tianjin (10JCYBJC11
   300). We thank Dr. Si-cheng Zhao for verbal changes in the material.
CR Chen BS, 2000, INT J CANCER, V88, P862, DOI 10.1002/1097-0215(20001215)88:6<862::AID-IJC4>3.0.CO;2-L
   Du Y, 2001, CANCER RES, V61, P8094
   Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010
   Esteller M, 2001, CANCER RES, V61, P3225
   Fang W, 2000, GENE CHROMOSOME CANC, V28, P269, DOI 10.1002/1098-2264(200007)28:3<269::AID-GCC4>3.0.CO;2-K
   Fang W, 2001, BRIT J CANCER, V84, P743, DOI 10.1054/bjoc.2000.1667
   Gazzerro P, 2006, EXP CELL RES, V312, P340, DOI 10.1016/j.yexcr.2005.11.002
   Hasegawa Y, 2007, CANCER SCI, V98, P32, DOI 10.1111/j.1349-7006.2006.00338.x
   He LS, 1998, CANCER RES, V58, P4238
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634
   Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7
   Lal G, 2006, CANCER, V107, P2752, DOI 10.1002/cncr.22325
   Liu LB, 1997, J BIOL CHEM, V272, P1997, DOI 10.1074/jbc.272.3.1997
   Metzger R, 2004, ONKOLOGIE, V27, P200, DOI 10.1159/000076913
   Montesano R, 1996, INT J CANCER, V69, P225, DOI 10.1002/(SICI)1097-0215(19960621)69:3<225::AID-IJC13>3.0.CO;2-6
   Oshimo Y, 2004, INT J CANCER, V110, P212, DOI 10.1002/ijc.20090
   Qin YR, 2008, WORLD J GASTROENTERO, V14, P1828, DOI 10.3748/wjg.14.1828
   RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991
   Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101
   Tokumaru Y, 2003, ONCOGENE, V22, P6954, DOI 10.1038/sj.onc.1206403
NR 21
TC 14
Z9 19
U1 0
U2 8
PU CLIN LAB PUBL
PI HEIDELBERG
PA IM BREITSPIEL 15, HEIDELBERG, D-69126, GERMANY
SN 1433-6510
J9 CLIN LAB
JI Clin. Lab.
PY 2012
VL 58
IS 1-2
BP 41
EP 51
PG 11
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA 893EU
UT WOS:000300339200005
PM 22372344
DA 2025-01-12
ER

PT J
AU Raynal, NJM
   Si, J
   Taby, RF
   Gharibyan, V
   Ahmed, S
   Jelinek, J
   Estécio, MRH
   Issa, JPJ
AF Raynal, Noel J. -M.
   Si, Jiali
   Taby, Rodolphe F.
   Gharibyan, Vazganush
   Ahmed, Saira
   Jelinek, Jaroslav
   Estecio, Marcos R. H.
   Issa, Jean-Pierre J.
TI DNA Methylation Does Not Stably Lock Gene Expression but Instead Serves
   as a Molecular Mark for Gene Silencing Memory
SO CANCER RESEARCH
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITOR; ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER;
   PROMOTER; CELLS; 5-AZA-2'-DEOXYCYTIDINE; DEMETHYLATION; REACTIVATION;
   CPG; HYPERMETHYLATION
AB DNA methylation is commonly thought of as a "molecular lock" that leads to permanent gene silencing. To investigate this notion, we tested 24 different histone deacetylase inhibitors (HDACi) on colon cancer cells that harbor a GFP locus stably integrated and silenced by a hypermethylated cytomegalovirus (CMV) promoter. We found that HDACi efficiently reactivated expression of GFP and many other endogenous genes silenced by DNA hypermethylation. After treatment, all promoters were marked with active chromatin, yet DNA hypermethylation did not change. Thus, DNA methylation could not prevent gene reactivation by drug-induced resetting of the chromatin state. In evaluating the relative contribution of DNA methylation and histone modifications to stable gene silencing, we followed expression levels of GFP and other genes silenced by DNA hypermethylation over time after treatment with HDACi or DNA-demethylating drugs. Reactivation of methylated loci by HDACi was detectable for only 2 weeks, whereas DNA-demethylating drugs induced permanent epigenetic reprogramming. Therefore, DNA methylation cannot be considered as a lock for gene expression but rather as a memory signal for long-term maintenance of gene silencing. These findings define chromatin as an important druggable target for cancer epigenetic therapy and suggest that removal of DNA methylation signals is required to achieve long-term gene reactivation. Cancer Res; 72(5); 1170-81. (C) 2012 AACR.
C1 [Raynal, Noel J. -M.; Jelinek, Jaroslav; Issa, Jean-Pierre J.] Temple Univ, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA.
   [Raynal, Noel J. -M.; Si, Jiali; Taby, Rodolphe F.; Gharibyan, Vazganush; Ahmed, Saira; Jelinek, Jaroslav; Estecio, Marcos R. H.; Issa, Jean-Pierre J.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple
   University; University of Texas System; UTMD Anderson Cancer Center
RP Issa, JPJ (通讯作者)，Temple Univ, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA.
EM jpissa@temple.edu
RI ; Jelinek, Jaroslav/D-2282-2012
OI Si, Jiali/0009-0003-2046-5374; Estecio, Marcos/0000-0002-6874-7413;
   Jelinek, Jaroslav/0000-0002-2533-0220; Issa,
   Jean-Pierre/0000-0003-2258-5030
FU NIH [CA100632, CA121104, CA16672]; Stand Up to Cancer Dream Team;
   Entertainment Industry Foundation [SU2C-AACR-DT0109]; F. M. Kirby
   Foundation
FX This work was supported by NIH grants CA100632 and CA121104. J.-P.J.
   Issa and J. Jelinek are supported by a Stand Up to Cancer Dream Team
   Translational Cancer Research Grant, a Program of the Entertainment
   Industry Foundation (SU2C-AACR-DT0109). J.-P.J. Issa is an American
   Cancer Society Clinical Research professor supported by a generous gift
   from the F. M. Kirby Foundation. DNA sequencing and Flow Cytometry in
   the respective cores at the MD Anderson Cancer Center is supported by
   Core Grant CA16672 from the NIH.
CR Belinsky SA, 2003, CANCER RES, V63, P7089
   Bender CM, 1998, CANCER RES, V58, P95
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Bovenzi V, 2001, CANCER CHEMOTH PHARM, V48, P71, DOI 10.1007/s002800100294
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825
   Egger G, 2007, CANCER RES, V67, P346, DOI 10.1158/0008-5472.CAN-06-2845
   Estécio MRH, 2007, GENOME RES, V17, P1529, DOI 10.1101/gr.6417007
   Fujii S, 2003, HUM MOL GENET, V12, P1791, DOI 10.1093/hmg/ddg204
   Kagey JD, 2010, MOL CANCER RES, V8, P1048, DOI 10.1158/1541-7786.MCR-10-0189
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Meng CF, 2009, ONCOL REP, V22, P1221, DOI 10.3892/or_00000558
   Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013
   Peart MJ, 2005, P NATL ACAD SCI USA, V102, P3697, DOI 10.1073/pnas.0500369102
   Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Si J, 2010, CANCER RES, V70, P6968, DOI 10.1158/0008-5472.CAN-09-4474
   Siegfried Z, 1997, CURR BIOL, V7, pR305, DOI 10.1016/S0960-9822(06)00144-8
   Sirchia SM, 2002, CANCER RES, V62, P2455
   Sproul D, 2011, P NATL ACAD SCI USA, V108, P4364, DOI 10.1073/pnas.1013224108
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Taby R, 2010, CA-CANCER J CLIN, V60, P376, DOI 10.3322/caac.20085
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Wu LP, 2008, MOL CELL BIOL, V28, P3219, DOI 10.1128/MCB.01516-07
   Xiong YN, 2005, CANCER RES, V65, P2684, DOI 10.1158/0008-5472.CAN-04-2843
   Yang XW, 2000, CANCER RES, V60, P6890
   You JS, 2008, ONCOGENE, V27, P1376, DOI 10.1038/sj.onc.1210776
   Zhou Q, 2007, CANCER BIOL THER, V6, P64, DOI 10.4161/cbt.6.1.3549
NR 29
TC 109
Z9 122
U1 0
U2 20
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD MAR 1
PY 2012
VL 72
IS 5
BP 1170
EP 1181
DI 10.1158/0008-5472.CAN-11-3248
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 901TG
UT WOS:000300989100016
PM 22219169
OA Green Submitted, Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Jiang, LY
   Lian, M
   Wang, H
   Fang, JG
   Wang, Q
AF Jiang, Ling-yan
   Lian, Meng
   Wang, Hong
   Fang, Ju-gao
   Wang, Qi
TI Inhibitory Effects of 5-Aza-2′-Deoxycytidine and Trichostatin A in
   Combination with <i>p53</i>-Expressing Adenovirus on Human
   Laryngocarcinoma Cells
SO CHINESE JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE 5-Aza-2 '-deoxycytidine; trichostatin A; p53-expressing adenovirus;
   Hep-2 cell line
ID TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; BREAST-CANCER;
   HEPATOCELLULAR-CARCINOMA; PROSTATE-CANCER; GENE-THERAPY; FOLLOW-UP;
   IN-VIVO; P53; EPIGENOMICS; APOPTOSIS
AB Objective: To investigate the effects of 5-Aza-2'-deoxycytidine (5-Aza-Cdr) and trichostatin A (TSA) combined with p53-expressing adenovirus (Ad-p53) on Hep-2 cell line in vivo and in vitro, in order to explore its possibility in biological treatment of laryngocarcinoma.
   Methods: Effects of 5-Aza-Cdr and TSA in combination with Ad-p53 on Hep-2 cell line in vivo were determined by Cell Counting Kit-8 (CCK-8) assay. The effect of drug combination was calculated by Jin's formula. Effects on the cell line in vitro were investigated by establishing the nude mice model.
   Results: 5-Aza-Cdr and TSA showed inhibitory effects on the proliferation of Hep-2 cells in dose-and time-dependent manner. Ad-p53 can inhibit the growth of Hep-2 cells in vivo and in vitro. However, the combination of epigenetic reagents (5-Aza-Cdr/TSA) and Ad-p53 was less effective than individual use of Ad-p53. 5-Aza-Cdr and Ad-p53 inhibited the growth of transplanted tumors and reduced the volume of tumors, and the tumor volume of Ad-p53 group was significantly smaller than that of the control group (P<0.05).
   Conclusion: Both epigenetic reagents (5-Aza-Cdr/TSA) and Ad-p53 can suppress cell proliferation on Hep-2 in vivo and in vitro and there may be some antagonistic mechanism between Ad-p53 and epigenetic reagents (5-Aza-Cdr/TSA).
C1 [Jiang, Ling-yan; Lian, Meng; Wang, Hong; Fang, Ju-gao; Wang, Qi] Beijing Inst Otorhinolaryngol, Minist Educ, Key Lab Otorhinolaryngol Head & Neck Surg, Beijing 100005, Peoples R China.
   [Jiang, Ling-yan; Lian, Meng; Fang, Ju-gao; Wang, Qi] Capital Med Univ, Beijing Tongren Hosp, Dept Otorhinolaryngol Head & Neck Surg, Beijing 100730, Peoples R China.
C3 Capital Medical University
RP Fang, JG (通讯作者)，Beijing Inst Otorhinolaryngol, Minist Educ, Key Lab Otorhinolaryngol Head & Neck Surg, Beijing 100005, Peoples R China.
EM fangjugao@vip.sohu.com; qiwang121@yahoo.com.cn
FU National Natural Science Foundation of China [30772407]
FX This work was supported by the National Natural Science Foundation of
   China (No. 30772407).
CR Achison M, 2003, ONCOGENE, V22, P3431, DOI 10.1038/sj.onc.1206434
   Akkiprik M, 2009, PATHOL ONCOL RES, V15, P359, DOI 10.1007/s12253-008-9129-6
   Allegrucci C, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-7
   [Anonymous], 2011, GENES CANC
   Brooks WH, 2010, J AUTOIMMUN, V34, pJ207, DOI 10.1016/j.jaut.2009.12.006
   Chen GX, 2011, WORLD J GASTROENTERO, V17, P4289, DOI 10.3748/wjg.v17.i38.4289
   Cho HS, 2007, J BIOCHEM MOL BIOL, V40, P151
   Cillessen SAGM, 2010, J PATHOL, V220, P509, DOI 10.1002/path.2670
   Francisco R, 2012, CANCER LETT, V318, P42, DOI 10.1016/j.canlet.2011.11.036
   Guan YS, 2011, WORLD J GASTROENTERO, V17, P2143, DOI 10.3748/wjg.v17.i16.2143
   Guan YS, 2009, J ZHEJIANG UNIV-SC B, V10, P331, DOI 10.1631/jzus.B0820248
   Huang HY, 2012, J SCI FOOD AGR, V92, P135, DOI 10.1002/jsfa.4551
   Jin Z J, 1980, Zhongguo Yao Li Xue Bao, V1, P70
   Khan SI, 2012, CHEM RES TOXICOL, V25, P61, DOI 10.1021/tx200378c
   Li Gui-deng, 2011, Clinical Oncology and Cancer Research, V8, P191, DOI 10.1007/s11805-011-0580-x
   Li XQ, 2010, BRIT J HAEMATOL, V148, P69, DOI 10.1111/j.1365-2141.2009.07920.x
   Lu C, 2009, APOPTOSIS, V14, P597, DOI 10.1007/s10495-009-0330-1
   Lu P, 2011, CELL BIOCHEM BIOPHYS, V59, P147, DOI 10.1007/s12013-010-9122-z
   Majid S, 2010, CANCER-AM CANCER SOC, V116, P66, DOI 10.1002/cncr.24662
   Mani S, 2010, ADV GENET, V70, P327, DOI [10.1016/B978-0-12-380866-0.60012-5, 10.1016/S0065-2660(10)70012-2]
   Oyer JA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004832
   Pandey M, 2010, INT J CANCER, V126, P2520, DOI 10.1002/ijc.24988
   Roth JA, 1999, ONCOLOGY-NY, V13, P148
   Sandoval J, 2012, CURR OPIN GENET DEV, V22, P50, DOI 10.1016/j.gde.2012.02.008
   Shao Y, 2010, CANCER GENE THER, V17, P844, DOI 10.1038/cgt.2010.41
   Suzuki K, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/978312
   Tambunan USF, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-S7-S16
   Tian G, 2009, ANTI-CANCER DRUG, V20, P389, DOI 10.1097/CAD.0b013e32832a2df9
   Verma B, 2010, J IMMUNOL, V184, P2156, DOI 10.4049/jimmunol.0902414
   Yang ZX, 2010, J CANCER RES CLIN, V136, P625, DOI 10.1007/s00432-009-0701-6
   Zeng X, 2010, BIOMATERIALS, V31, P4771, DOI 10.1016/j.biomaterials.2010.02.039
NR 31
TC 12
Z9 14
U1 0
U2 17
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1000-9604
J9 CHINESE J CANCER RES
JI Chin. J. Cancer Res.
PD MAR
PY 2012
VL 24
IS 3
BP 232
EP 237
DI 10.1007/s11670-012-0232-6
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 080YE
UT WOS:000314279500010
PM 23359343
OA Green Published
DA 2025-01-12
ER

PT J
AU Shimada, S
   Mimata, A
   Sekine, M
   Mogushi, K
   Akiyama, Y
   Fukamachi, H
   Jonkers, J
   Tanaka, H
   Eishi, Y
   Yuasa, Y
AF Shimada, Shu
   Mimata, Ayako
   Sekine, Masaki
   Mogushi, Kaoru
   Akiyama, Yoshimitsu
   Fukamachi, Hiroshi
   Jonkers, Jos
   Tanaka, Hiroshi
   Eishi, Yoshinobu
   Yuasa, Yasuhito
TI Synergistic tumour suppressor activity of E-cadherin and p53 in a
   conditional mouse model for metastatic diffuse-type gastric cancer
SO GUT
LA English
DT Article
ID GERMLINE MUTATIONS; GENE-MUTATIONS; BREAST-CANCER; MICE LACKING;
   EXPRESSION; ADHESION; CELLS; ACTIVATION; CARCINOMA; FAMILY
AB Background Gastric cancer is the second most frequent cause of death from cancer in the world, diffuse-type gastric cancer (DGC) exhibiting a poor prognosis. Germline mutations of CDH1, encoding E-cadherin, have been reported in hereditary DGC, and genetic and/or epigenetic alterations of CDH1 are frequently detected in sporadic DGC. Genetic alterations of TP53 are also frequently found in DGC. To examine the synergistic effect of the loss of E-cadherin and p53 on gastric carcinogenesis, a mouse line was established in which E-cadherin and p53 are specifically inactivated in the stomach parietal cell lineage.
   Methods Atp4b-Cre mice were crossed with Cdh1(loxP/loxP) and Trp53(loxP/loxP) mice, and the gastric phenotype of Atp4b-Cre(+); Cdh1(loxP/loxP); Trp53(loxP/loxP) double conditional knockout (DCKO) mice was examined.
   Results Non-polarised E-cadherin-negative parietal cells and proton pump-negative atypical foci were observed in DCKO mice. Intramucosal cancers and invasive cancers composed of poorly differentiated carcinoma cells and signet ring cells, histologically very similar to those in humans, were found from 6 to 9 months, respectively. Fatal DGC developed at 100% penetrance within a year, frequently metastasised to lymph nodes, and had tumourigenic activity in immunodeficient mice. Gene expression profiles of DGC in DCKO mice also resembled those of human DGC, and mesenchymal markers and epithelial-mesenchymal transition-related genes were highly expressed in mouse DGC as in human DGC.
   Conclusion This mouse line is the first genetically engineered mouse model of DGC and is very useful for clarifying the mechanism underlying gastric carcinogenesis, and provides a new approach to the treatment and prevention of DGC.
C1 [Yuasa, Yasuhito] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Mol Oncol, Bunkyo Ku, Tokyo 1138519, Japan.
   [Sekine, Masaki; Eishi, Yoshinobu] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Human Pathol, Tokyo 1138519, Japan.
   [Mogushi, Kaoru; Tanaka, Hiroshi] Tokyo Med & Dent Univ, Grad Sch Biomed Sci, Dept Syst Biol, Tokyo 1138519, Japan.
   [Jonkers, Jos] Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Netherlands Cancer Institute
RP Yuasa, Y (通讯作者)，Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Mol Oncol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.
EM yuasa.monc@tmd.ac.jp
RI Jonkers, Jos/AAG-3246-2019; Eishi, Yoshinobu/N-3602-2017
OI Mogushi, Kaoru/0000-0002-2618-8684; Jonkers, Jos/0000-0002-9264-9792
FU Ministry of Education, Culture, Sports, Science and Technology, Japan
   [17015013]; JSPS; Princess Takamatsu Cancer Research Fund; Grants-in-Aid
   for Scientific Research [21590396, 17015013, 22501005] Funding Source:
   KAKEN
FX This work was supported by a grant-in-aid for scientific research on
   priority areas cancer 17015013 from the Ministry of Education, Culture,
   Sports, Science and Technology, Japan, by the JSPS A3 Foresight Program
   and by a research grant from the Princess Takamatsu Cancer Research
   Fund.
CR Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013
   BECKER KF, 1994, CANCER RES, V54, P3845
   Boussadia O, 2002, MECH DEVELOP, V115, P53, DOI 10.1016/S0925-4773(02)00090-4
   Chen X, 2003, MOL BIOL CELL, V14, P3208, DOI 10.1091/mbc.E02-12-0833
   Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013
   Donehower LA, 2009, NAT REV CANCER, V9, P830, DOI 10.1038/nrc2731
   Ebert MPA, 2003, J CLIN ONCOL, V21, P1708, DOI 10.1200/JCO.2003.10.017
   FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173
   Giannakis M, 2006, J BIOL CHEM, V281, P11292, DOI 10.1074/jbc.M512118200
   Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049
   Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Humar B, 2007, CANCER RES, V67, P2480, DOI 10.1158/0008-5472.CAN-06-3021
   Humar B, 2009, CANCER RES, V69, P2050, DOI 10.1158/0008-5472.CAN-08-2457
   Itadani H, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-615
   Japanese Gastric Cancer Association, 1998, Gastric Cancer, V1, P10
   Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437
   Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747
   Judd LM, 2004, GASTROENTEROLOGY, V126, P196, DOI 10.1053/j.gastro.2003.10.066
   Keller G, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.015594
   KEMLER R, 1977, P NATL ACAD SCI USA, V74, P4449, DOI 10.1073/pnas.74.10.4449
   Kim IJ, 2004, J HUM GENET, V49, P591, DOI 10.1007/s10038-004-0193-9
   LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263
   LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31
   Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259
   MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   MAYER B, 1993, CANCER RES, V53, P1690
   Mimata A, 2011, CANCER SCI, V102, P942, DOI 10.1111/j.1349-7006.2011.01890.x
   Ohta H, 2009, BRIT J CANCER, V100, P389, DOI 10.1038/sj.bjc.6604846
   OKA H, 1993, CANCER RES, V53, P1696
   Oshima H, 2006, GASTROENTEROLOGY, V131, P1086, DOI 10.1053/j.gastro.2006.07.014
   Quante M, 2010, GASTROENTEROLOGY, V139, P2018, DOI 10.1053/j.gastro.2010.08.003
   RANZANI GN, 1995, CANCER EPIDEM BIOMAR, V4, P223
   Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1
   SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0
   Syder AJ, 2004, P NATL ACAD SCI USA, V101, P4471, DOI 10.1073/pnas.0307983101
   Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Tinkle CL, 2004, P NATL ACAD SCI USA, V101, P552, DOI 10.1073/pnas.0307437100
   UCHINO S, 1993, INT J CANCER, V54, P759, DOI 10.1002/ijc.2910540509
   Wang TC, 2000, GASTROENTEROLOGY, V118, P36, DOI 10.1016/S0016-5085(00)70412-4
   Yuasa Y, 2003, NAT REV CANCER, V3, P592, DOI 10.1038/nrc1141
NR 43
TC 92
Z9 104
U1 0
U2 13
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD MAR
PY 2012
VL 61
IS 3
BP 344
EP 353
DI 10.1136/gutjnl-2011-300050
PG 10
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 889FH
UT WOS:000300058500005
PM 21865403
DA 2025-01-12
ER

PT J
AU Howe, EN
   Cochrane, DR
   Richer, JK
AF Howe, Erin N.
   Cochrane, Dawn R.
   Richer, Jennifer K.
TI The miR-200 and miR-221/222 microRNA Families: Opposing Effects on
   Epithelial Identity
SO JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
LA English
DT Article
DE miR-200; miR-221; miR-222; EMT; MET; Breast cancer
ID BREAST-CANCER CELLS; ESTROGEN-RECEPTOR-ALPHA; TO-MESENCHYMAL TRANSITION;
   TUMOR-SUPPRESSOR GENE; E-CADHERIN; DOWN-REGULATION;
   HEPATOCELLULAR-CARCINOMA; REGULATES PROLIFERATION; TAMOXIFEN RESISTANCE;
   DNA METHYLATION
AB Carcinogenesis is a complex process during which cells undergo genetic and epigenetic alterations. These changes can lead tumor cells to acquire characteristics that enable movement from the primary site of origin when conditions become unfavorable. Such characteristics include gain of front-rear polarity, increased migration/invasion, and resistance to anoikis, which facilitate tumor survival during metastasis. An epithelial to mesenchymal transition (EMT) constitutes one way that cancer cells can gain traits that promote tumor progression and metastasis. Two microRNA (miRNA) families, the miR-200 and miR-221 families, play crucial opposing roles that affect the differentiation state of breast cancers. These two families are differentially expressed between the luminal A subtype of breast cancer as compared to the less well-differentiated triple negative breast cancers (TNBCs) that exhibit markers indicative of an EMT. The miR-200 family promotes a well-differentiated epithelial phenotype, while high miR-221/222 results in a poorly differentiated, mesenchymal-like phenotype. This review focuses on the mechanisms (specific proven targets) by which these two miRNA families exert opposing effects on cellular plasticity during breast tumorigenesis and metastasis.
C1 [Howe, Erin N.; Cochrane, Dawn R.; Richer, Jennifer K.] Univ Colorado, Dept Pathol, Aurora, CO 80045 USA.
   [Howe, Erin N.; Richer, Jennifer K.] Univ Colorado, Program Canc Biol, Aurora, CO 80045 USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus; University of Colorado System; University of Colorado Anschutz
   Medical Campus
RP Richer, JK (通讯作者)，Univ Colorado, Dept Pathol, Anschutz Med Campus,12800 E 19th Ave,MS 8104 RC1, Aurora, CO 80045 USA.
EM jennifer.richer@ucdenver.edu
OI Howe, Erin/0000-0003-0314-6999
FU DOD [W81XWH-09-1-0124]; Susan G. Koman foundation [KG090415]
FX We thank Nicole Spoelstra for IHC and Dicer staining. The Richer lab is
   supported by DOD W81XWH-09-1-0124 and Susan G. Koman foundation KG090415
   to JKR.
CR Adam L, 2009, CLIN CANCER RES, V15, P5060, DOI 10.1158/1078-0432.CCR-08-2245
   Ahmad A, 2011, CANCER RES, V71, P3400, DOI 10.1158/0008-5472.CAN-10-0965
   Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508
   [Anonymous], NUCL ACIDS RES  0914
   [Anonymous], P NATL ACAD SCI 0601
   [Anonymous], MED ONCOLOGY NO 1119
   [Anonymous], ONCOGENE        0829
   [Anonymous], BREAST CANC RES 0507
   [Anonymous], RADIAT PROT DOSIM
   [Anonymous], MED ONCOLOGY NO 0413
   Baffa R, 2009, J PATHOL, V219, P214, DOI 10.1002/path.2586
   Bao B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017850
   Bao JJ, 2002, CANCER RES, V62, P7264
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312
   Bhat-Nakshatri P, 2009, NUCLEIC ACIDS RES, V37, P4850, DOI 10.1093/nar/gkp500
   Blakaj A, 2008, J BIOL CHEM, V283, P9505, DOI 10.1074/jbc.R800002200
   Bockmeyer CL, 2011, BREAST CANCER RES TR, V130, P735, DOI 10.1007/s10549-010-1303-3
   Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942
   Brioschi M, 2010, NEOPLASIA, V12, P866, DOI 10.1593/neo.10482
   Buffa FM, 2011, CANCER RES, V71, P5635, DOI 10.1158/0008-5472.CAN-11-0489
   Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Cameron HL, 2008, REPROD TOXICOL, V25, P256, DOI 10.1016/j.reprotox.2007.11.013
   Cammarata G, 2010, AM J HEMATOL, V85, P331, DOI 10.1002/ajh.21667
   Ceppi P, 2010, MOL CANCER RES, V8, P1207, DOI 10.1158/1541-7786.MCR-10-0052
   Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173
   Chen Y, 2011, CANCER PREV RES, V4, P76, DOI 10.1158/1940-6207.CAPR-10-0167
   Chou CK, 2010, THYROID, V20, P489, DOI 10.1089/thy.2009.0027
   Cochrane Dawn R., 2010, Hormones & Cancer, V1, P306, DOI 10.1007/s12672-010-0043-5
   Cochrane DR, 2010, J ONCOL, V2010, DOI 10.1155/2010/821717
   Cochrane DR, 2009, MOL CANCER THER, V8, P1055, DOI 10.1158/1535-7163.MCT-08-1046
   Di Leva G, 2010, JNCI-J NATL CANCER I, V102, P706, DOI 10.1093/jnci/djq102
   Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765
   Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181
   Eades G, 2011, J BIOL CHEM, V286, P25992, DOI 10.1074/jbc.M111.229401
   Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429
   Fan MY, 2006, CANCER RES, V66, P11954, DOI 10.1158/0008-5472.CAN-06-1666
   Felicetti F, 2004, ONCOGENE, V23, P4567, DOI 10.1038/sj.onc.1207597
   Felicetti F, 2008, CANCER RES, V68, P2745, DOI 10.1158/0008-5472.CAN-07-2538
   Fontemaggi G, 2005, ONCOGENE, V24, P7273, DOI 10.1038/sj.onc.1208891
   Fornari F, 2008, ONCOGENE, V27, P5651, DOI 10.1038/onc.2008.178
   Frenquelli M, 2010, BLOOD, V115, P3949, DOI 10.1182/blood-2009-11-254656
   Fu XH, 2011, MOL BIOL REP, V38, P3029, DOI 10.1007/s11033-010-9969-5
   Gai ZB, 2009, J AM SOC NEPHROL, V20, P2403, DOI 10.1681/ASN.2008091020
   Galardi S, 2007, J BIOL CHEM, V282, P23716, DOI 10.1074/jbc.M701805200
   Geiger TR, 2007, CANCER RES, V67, P6221, DOI 10.1158/0008-5472.CAN-07-0121
   Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209
   Gill JG, 2011, STEM CELLS, V29, P764, DOI 10.1002/stem.628
   Gottardo F, 2007, UROL ONCOL-SEMIN ORI, V25, P387, DOI 10.1016/j.urolonc.2007.01.019
   Gramantieri L, 2009, CLIN CANCER RES, V15, P5073, DOI 10.1158/1078-0432.CCR-09-0092
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103
   Grelier G, 2009, BRIT J CANCER, V101, P673, DOI 10.1038/sj.bjc.6605193
   Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200
   Howe EN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2867
   Hu MH, 2010, DIGEST DIS SCI, V55, P2365, DOI 10.1007/s10620-009-1008-9
   Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001
   Hui ABY, 2009, LAB INVEST, V89, P597, DOI 10.1038/labinvest.2009.12
   Hurteau GJ, 2007, CANCER RES, V67, P7972, DOI 10.1158/0008-5472.CAN-07-1058
   Hurteau GJ, 2009, CELL CYCLE, V8, P2064, DOI 10.4161/cc.8.13.8883
   Hyun S, 2009, CELL, V139, P1096, DOI 10.1016/j.cell.2009.11.020
   Iliopoulos D, 2010, MOL CELL, V39, P761, DOI 10.1016/j.molcel.2010.08.013
   Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356
   Janssen EAM, 2009, CELL ONCOL, V31, P335, DOI 10.3233/CLO-2009-0479
   KALKHOVEN E, 1995, INT J CANCER, V61, P80, DOI 10.1002/ijc.2910610114
   Kavallaris M, 2010, NAT REV CANCER, V10, P194, DOI 10.1038/nrc2803
   Kenney PA, 2011, BJU INT, V107, P656, DOI 10.1111/j.1464-410X.2010.09489.x
   Kim T, 2011, J EXP MED, V208, P875, DOI 10.1084/jem.20110235
   Kong DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012445
   Kong DJ, 2009, STEM CELLS, V27, P1712, DOI 10.1002/stem.101
   Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200
   Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401
   le Sage C, 2007, EMBO J, V26, P3699, DOI 10.1038/sj.emboj.7601790
   Li XH, 2011, MOL CANCER RES, V9, P824, DOI 10.1158/1541-7786.MCR-10-0529
   Li YW, 2009, CANCER RES, V69, P6704, DOI 10.1158/0008-5472.CAN-09-1298
   Lin CH, 2009, EMBO J, V28, P3157, DOI 10.1038/emboj.2009.254
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lu XM, 2009, MOL MED REP, V2, P651, DOI 10.3892/mmr_00000152
   Lu YZ, 2011, J BIOL CHEM, V286, P42292, DOI 10.1074/jbc.M111.270926
   Luo YP, 2010, ONCOGENE, V29, P662, DOI 10.1038/onc.2009.308
   Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017
   Medina R, 2008, CANCER RES, V68, P2773, DOI 10.1158/0008-5472.CAN-07-6754
   Mercatelli N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004029
   Micalizzi DS, 2010, J MAMMARY GLAND BIOL, V15, P117, DOI 10.1007/s10911-010-9178-9
   Miller TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200
   Mozzetti S, 2005, CLIN CANCER RES, V11, P298
   Ndlovu MN, 2009, MOL CELL BIOL, V29, P5488, DOI 10.1128/MCB.01657-08
   Neveu P, 2010, CELL STEM CELL, V7, P671, DOI 10.1016/j.stem.2010.11.012
   Paradiso A, 2005, ANN ONCOL, V16, P14, DOI 10.1093/annonc/mdi902
   Park JK, 2011, CANCER RES, V71, P7608, DOI 10.1158/0008-5472.CAN-11-1144
   Park JK, 2009, PANCREAS, V38, pE190, DOI 10.1097/MPA.0b013e3181ba82e1
   Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608
   Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131
   Piccart M, 2001, ONCOLOGY-BASEL, V61, P73, DOI 10.1159/000055405
   Pillai RS, 2007, TRENDS CELL BIOL, V17, P118, DOI 10.1016/j.tcb.2006.12.007
   Pogribny IP, 2010, INT J CANCER, V127, P1785, DOI 10.1002/ijc.25191
   Radojicic J, 2011, CELL CYCLE, V10, P507, DOI 10.4161/cc.10.3.14754
   Rao X, 2011, ONCOGENE, V30, P1082, DOI 10.1038/onc.2010.487
   Remacle JE, 1999, EMBO J, V18, P5073, DOI 10.1093/emboj/18.18.5073
   Samavarchi-Tehrani P, 2010, CELL STEM CELL, V7, P64, DOI 10.1016/j.stem.2010.04.015
   Schickel R, 2010, MOL CELL, V38, P908, DOI 10.1016/j.molcel.2010.05.018
   Shah MY, 2011, GENOME MED, V3, DOI 10.1186/gm272
   Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011
   Shirakihara T, 2007, MOL BIOL CELL, V18, P3533, DOI 10.1091/mbc.E07-03-0249
   Slabáková E, 2011, PROSTATE, V71, P1332, DOI 10.1002/pros.21350
   Smit MA, 2009, MOL CELL BIOL, V29, P3722, DOI 10.1128/MCB.01164-08
   Sossey-Alaoui K, 2009, J BIOL CHEM, V284, P33019, DOI 10.1074/jbc.M109.034553
   Sovak MA, 1999, CELL GROWTH DIFFER, V10, P537
   Stefani G, 2008, NAT REV MOL CELL BIO, V9, P219, DOI 10.1038/nrm2347
   Stengel C, 2010, BRIT J CANCER, V102, P316, DOI 10.1038/sj.bjc.6605489
   Stinson S, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001538
   Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459
   Sun K, 2011, ACTA PHARMACOL SIN, V32, P375, DOI 10.1038/aps.2010.206
   Sun Y, 2009, BREAST CANCER RES TR, V118, P185, DOI 10.1007/s10549-008-0171-6
   Tellez CS, 2011, CANCER RES, V71, P3087, DOI 10.1158/0008-5472.CAN-10-3035
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835
   Tommasi S, 2007, INT J CANCER, V120, P2078, DOI 10.1002/ijc.22557
   Tryndyak VP, 2010, INT J CANCER, V126, P2575, DOI 10.1002/ijc.24972
   Uhlmann S, 2010, ONCOGENE, V29, P4297, DOI 10.1038/onc.2010.201
   Umezu T, 2008, INT J GYNECOL PATHOL, V27, P207, DOI 10.1097/PGP.0b013e318156c838
   Vallejo DM, 2011, EMBO J, V30, P756, DOI 10.1038/emboj.2010.358
   Veerla S, 2009, INT J CANCER, V124, P2236, DOI 10.1002/ijc.24183
   Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697
   Wang R, 2010, J CELL MOL MED, V14, P206, DOI 10.1111/j.1582-4934.2009.00964.x
   Wang ZS, 2011, TOXICOL SCI, V121, P110, DOI 10.1093/toxsci/kfr029
   Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998
   Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461
   Williams AE, 2007, DEV DYNAM, V236, P572, DOI 10.1002/dvdy.21047
   Xia W, 2010, MOL CELL BIOCHEM, V344, P261, DOI 10.1007/s11010-010-0550-2
   Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009
   Yang YN, 2011, J CLIN INVEST, V121, P1373, DOI 10.1172/JCI42579
   Yoshimoto N, 2011, BREAST CANCER RES TR, V130, P331, DOI 10.1007/s10549-011-1672-2
   Yuan JH, 2003, CANCER RES, V63, P4174
   Yuan JH, 2011, HEPATOLOGY, V54, P2025, DOI 10.1002/hep.24606
   Zhang CZ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-367
   Zhang CZ, 2009, INT J ONCOL, V34, P1653, DOI 10.3892/ijo_00000296
   Zhang JX, 2010, INT J ONCOL, V36, P913, DOI 10.3892/ijo_00000570
   Zhao JJ, 2008, J BIOL CHEM, V283, P31079, DOI 10.1074/jbc.M806041200
   Zhou M, 2010, J BIOL CHEM, V285, P21496, DOI 10.1074/jbc.M109.083337
   Zhu L, 2004, CLIN CANCER RES, V10, P4639, DOI 10.1158/1078-0432.CCR-04-0057
NR 142
TC 109
Z9 125
U1 0
U2 15
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1083-3021
EI 1573-7039
J9 J MAMMARY GLAND BIOL
JI J. Mammary Gland Biol. Neoplasia
PD MAR
PY 2012
VL 17
IS 1
BP 65
EP 77
DI 10.1007/s10911-012-9244-6
PG 13
WC Oncology; Endocrinology & Metabolism; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Endocrinology & Metabolism; Physiology
GA 913AZ
UT WOS:000301845000008
PM 22350980
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Molina, JR
   Agarwal, NK
   Morales, FC
   Hayashi, Y
   Aldape, KD
   Cote, G
   Georgescu, MM
AF Molina, J. R.
   Agarwal, N. K.
   Morales, F. C.
   Hayashi, Y.
   Aldape, K. D.
   Cote, G.
   Georgescu, M-M
TI PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled
   in glioblastoma
SO ONCOGENE
LA English
DT Article
DE glioblastoma; PTEN; NHERF1; PHLPP; Akt
ID MEMBRANE ASSOCIATION; BREAST-CANCER; PDZ DOMAIN; PROTEIN; BINDING;
   GROWTH; AKT; PHOSPHATASE; RECEPTOR; CELLS
AB The phosphatidylinositol-3-OH kinase (PI3K)-Akt pathway is activated in cancer by genetic or epigenetic events and efforts are under way to develop targeted therapies. phosphatase and tensin homolog deleted on chromosome 10 (PTEN) tumor suppressor is the major brake of the pathway and a common target for inactivation in glioblastoma, one of the most aggressive and therapy-resistant cancers. To achieve potent inhibition of the PI3K-Akt pathway in glioblastoma, we need to understand its mechanism of activation by investigating the interplay between its regulators. We show here that PTEN modulates the PI3K-Akt pathway in glioblastoma within a tumor suppressor network that includes Na+/H+ exchanger regulatory factor 1 (NHERF1) and pleckstrin-homology domain leucine-rich repeat protein phosphatases 1 (PHLPP1). The NHERF1 adaptor, previously characterized by our group as a PTEN ligand and regulator, shows also PTEN-independent Akt-modulating effects that led us to identify the PHLPP1/PHLPP2 Akt phosphatases as NHERF1 ligands. NHERF1 interacts via its PDZ domains with PHLPP1/PHLPP2 and scaffolds heterotrimeric complexes with PTEN. Functionally, PHLPP1 requires NHERF1 for membrane localization and growth-suppressive effects. PHLPP1 loss boosts Akt phosphorylation only in PTEN-negative cells and cooperates with PTEN loss for tumor growth. In a panel of low-grade and high-grade glioma patient samples, we show for the first time a significant disruption of all three members of the PTEN-NHERF1-PHLPP1 tumor suppressor network in high-grade tumors, correlating with Akt activation and patient's abysmal survival. We thus propose a PTEN-NHERF1-PHLPP PI3K-Akt pathway inhibitory network that relies on molecular interactions and can undergo parallel synergistic hits in glioblastoma. Oncogene (2012) 31, 1264-1274; doi:10.1038/onc.2011.324; published online 1 August 2011
C1 [Molina, J. R.; Agarwal, N. K.; Morales, F. C.; Hayashi, Y.; Georgescu, M-M] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA.
   [Aldape, K. D.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
   [Cote, G.] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; University of Texas System;
   UTMD Anderson Cancer Center
RP Georgescu, MM (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, 6767 Bertner Ave, Houston, TX 77030 USA.
EM mgeorges@mdanderson.org
RI Aldape, Kenneth/ADV-7384-2022
FU  [NCI-CA107201];  [NCI-CA16672]
FX We thank NCI-CA107201 and the corresponding ARRA supplement (M-M.
   Georgescu), and NCI-CA16672 that partially supported the DNA sequencing
   and animal breeding.
CR Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5
   Barrett T, 2007, NUCLEIC ACIDS RES, V35, pD760, DOI 10.1093/nar/gkl887
   Brognard J, 2008, TRENDS ENDOCRIN MET, V19, P223, DOI 10.1016/j.tem.2008.04.001
   Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017
   Cardone RA, 2007, MOL BIOL CELL, V18, P1768, DOI 10.1091/mbc.E06-07-0617
   Carnero A, 2008, CURR CANCER DRUG TAR, V8, P187, DOI 10.2174/156800908784293659
   Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641
   Fouassier L, 2000, J BIOL CHEM, V275, P25039, DOI 10.1074/jbc.C000092200
   Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313
   Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008
   Georgescu MM, 2008, CURR MOL MED, V8, P459, DOI 10.2174/156652408785748031
   Georgescu Maria-Magdalena, 2010, Genes Cancer, V1, P1170, DOI 10.1177/1947601911407325
   Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182
   Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496
   Hayashi Y, 2010, NEOPLASIA, V12, P1013, DOI 10.1593/neo.10780
   Kreimann EL, 2007, ONCOGENE, V26, P5290, DOI 10.1038/sj.onc.1210336
   Lazar CS, 2004, MOL BIOL CELL, V15, P5470, DOI 10.1091/mbc.E04-03-0239
   Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   Liu J, 2009, ONCOGENE, V28, P994, DOI 10.1038/onc.2008.450
   Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375
   Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000
   Molina JR, 2010, CANCER RES, V70, P6697, DOI 10.1158/0008-5472.CAN-10-1271
   Molina JR, 2010, NEOPLASIA, V12, P453, DOI 10.1593/neo.10126
   Morales FC, 2007, MOL CELL BIOL, V27, P2527, DOI 10.1128/MCB.01372-06
   Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273
   Pan Y, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1846
   Qiao M, 2010, MOL CELL, V38, P512, DOI 10.1016/j.molcel.2010.03.017
   Rahdar M, 2009, P NATL ACAD SCI USA, V106, P480, DOI 10.1073/pnas.0811212106
   Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Shenolikar S, 2001, FEBS LETT, V489, P233, DOI 10.1016/S0014-5793(01)02109-3
   Shibata T, 2003, HEPATOLOGY, V38, P178, DOI 10.1053/jhep.2003.50270
   Shimizu K, 1999, FEBS LETT, V458, P363, DOI 10.1016/S0014-5793(99)01190-4
   Song J, 2007, HISTOPATHOLOGY, V51, P40, DOI 10.1111/j.1365-2559.2007.02730.x
   Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356
   Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003
   Takahashi Y, 2006, EMBO J, V25, P910, DOI 10.1038/sj.emboj.7600979
   Walker SM, 2004, BIOCHEM J, V379, P301, DOI 10.1042/BJ20031839
   Weinman EJ, 1998, J CLIN INVEST, V101, P2199, DOI 10.1172/JCI204
NR 40
TC 139
Z9 153
U1 0
U2 19
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD MAR
PY 2012
VL 31
IS 10
BP 1264
EP 1274
DI 10.1038/onc.2011.324
PG 11
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 906KS
UT WOS:000301344600006
PM 21804599
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Singh, KP
   Treas, J
   Tyagi, T
   Gao, WM
AF Singh, Kamaleshwar P.
   Treas, Justin
   Tyagi, Tulika
   Gao, Weimin
TI DNA demethylation by 5-aza-2-deoxycytidine treatment abrogates 17
   beta-estradiol-induced cell growth and restores expression of DNA repair
   genes in human breast cancer cells
SO CANCER LETTERS
LA English
DT Article
DE Breast cancer; Epigenetics; DNA methylation; DNA repair; Estrogen; Cell
   survival
ID INDUCED KIDNEY TUMORS; PROMOTER HYPERMETHYLATION; SPORADIC BREAST;
   RETINOIC ACID; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; STILBENE
   ESTROGEN; SYRIAN-HAMSTERS; METHYLATION; HMLH1; MUTATIONS
AB Prolonged exposure to elevated levels of estrogen is a risk factor for breast cancer. Though increased cell growth and loss of DNA repair capacity is one of the proposed mechanisms for estrogen-induced cancers, the mechanism through which estrogen induces cell growth and decreases DNA repair capacity is not clear. DNA hypermethylation is known to inactivate DNA repair genes and apoptotic response in cancer cells. Therefore, the objective of this study was to determine the role of DNA hypermethylation in estrogen-induced cell growth and regulation of DNA repair genes expression in breast cancer cells. To achieve this objective, the estrogen-responsive MCF-7 cells either pretreated with 5-aza-2-deoxycytidine (5-aza-dC) or untreated (as control) were exposed to 17 beta-estradiol (E2), and its effect on cell growth and expression of DNA repair genes were measured. The result revealed that 5-aza-dC abrogates the E2-induced growth in MCF-7 cells. An increased expression of OGG1, MSH4, and MLH1 by 5-aza-dC treatment alone, suggest the DNA hypermethylation as a potential cause for decreased expression of these genes in MCF-7 cells. The decreased expression of ERCC1, XPC, OGG1, and MLH1 by E2 alone and its restoration by co-treatment with 5-aza-dC further suggest that E2 reduces the expression of these DNA repair genes potentially through promoter hypermethylation. Reactivation of mismatch repair (MMR) gene MLH1 and abrogation of E2-induced cell growth by 5-aza-dC treatment suggest that estrogen causes increased growth in breast cancer cells potentially through the inhibition of MMR-mediated apoptotic response. In summary, this study suggests that estrogen increases cell growth and decreases the DNA repair capacity in breast cancer cells, at least in part, through epigenetic mechanism. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Singh, Kamaleshwar P.; Treas, Justin; Tyagi, Tulika; Gao, Weimin] Texas Tech Univ, Inst Environm & Human Hlth TIEHH, Dept Environm Toxicol, Lubbock, TX 79409 USA.
C3 Texas Tech University System; Texas Tech University
RP Singh, KP (通讯作者)，Texas Tech Univ, Inst Environm & Human Hlth TIEHH, Dept Environm Toxicol, Lubbock, TX 79409 USA.
EM kamaleshwar.singh@tiehh.ttu.edu
RI Singh, Kamaleshwar/AAE-9166-2020
CR Al-Salihi M., 2011, EPIGENETICS, V6
   Arapshian A, 2000, ONCOGENE, V19, P4066, DOI 10.1038/sj.onc.1203734
   Bellacosa A, 2001, CELL DEATH DIFFER, V8, P1076, DOI 10.1038/sj.cdd.4400948
   Bock N, 2000, ANTICANCER RES, V20, P119
   Cejka P, 2003, EMBO J, V22, P2245, DOI 10.1093/emboj/cdg216
   Chintamani, 2007, Int Semin Surg Oncol, V4, P5, DOI 10.1186/1477-7800-4-5
   Dhénaut A, 2000, MUTAT RES-DNA REPAIR, V461, P109, DOI 10.1016/S0921-8777(00)00042-2
   Dickson RB., 1989, Recent Progress in Hormone Research, V45, P383
   Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895
   DuMond JW, 2001, MUTAT RES-FUND MOL M, V483, P27, DOI 10.1016/S0027-5107(01)00222-6
   Espada J, 2004, J BIOL CHEM, V279, P37175, DOI 10.1074/jbc.M404842200
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2001, CANCER RES, V61, P4689
   Esteller M, 2005, EMBO REP, V6, P624, DOI 10.1038/sj.embor.7400456
   Esteller M, 1999, CANCER RES, V59, P793
   Fernandez SV, 2006, INT J CANCER, V118, P1862, DOI 10.1002/ijc.21590
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   Hodgson AV, 1998, CARCINOGENESIS, V19, P2169, DOI 10.1093/carcin/19.12.2169
   Hsu MS, 2010, ANN SURG ONCOL, V17, P760, DOI 10.1245/s10434-009-0802-0
   *IARC, 1999, IARC MON EV CARC RIS, V72, P399
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kagey JD, 2010, MOL CANCER RES, V8, P1048, DOI 10.1158/1541-7786.MCR-10-0189
   Kane MF, 1997, CANCER RES, V57, P808
   Kutanzi KR, 2010, CELL CYCLE, V9, P3078, DOI 10.4161/cc.9.15.12516
   Latimer JJ, 2010, P NATL ACAD SCI USA, V107, P21725, DOI 10.1073/pnas.0914772107
   Li JJ, 2002, MOL CARCINOGEN, V33, P56, DOI 10.1002/mc.10022
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Löf-Öhlin ZM, 2009, ONCOL REP, V21, P721, DOI 10.3892/or_00000277
   Martin L, 2010, CANCER LETT, V291, P142, DOI 10.1016/j.canlet.2009.10.007
   Mirza S, 2010, MOL CELL BIOCHEM, V342, P101, DOI 10.1007/s11010-010-0473-y
   Momparler RL, 2005, SEMIN ONCOL, V32, P443, DOI 10.1053/j.seminoncol.2005.07.008
   Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V
   Mongan NP, 2005, MOL CANCER THER, V4, P477
   Munot K, 2006, HUM PATHOL, V37, P989, DOI 10.1016/j.humpath.2006.04.013
   Murata H, 2005, CANCER LETT, V223, P143, DOI 10.1016/j.canlet.2004.09.039
   Murata H, 2002, ONCOGENE, V21, P5696, DOI 10.1038/sj.onc.1205683
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Naqvi RA, 2008, HUM PATHOL, V39, P672, DOI 10.1016/j.humpath.2007.09.011
   Narine KAD, 2010, DNA REPAIR, V9, P161, DOI 10.1016/j.dnarep.2009.11.010
   Patel RK, 1997, INT J CANCER, V73, P20, DOI 10.1002/(SICI)1097-0215(19970926)73:1<20::AID-IJC4>3.0.CO;2-3
   Pattarozzi A, 2008, MOL PHARMACOL, V73, P191, DOI 10.1124/mol.107.039974
   Platet N, 2004, CRIT REV ONCOL HEMAT, V51, P55, DOI 10.1016/j.critrevonc.2004.02.001
   Roy D, 2004, CURR GENOMICS, V5, P245, DOI 10.2174/1389202043349471
   Sanders SL, 2004, CELL, V119, P603, DOI 10.1016/j.cell.2004.11.009
   Segura-Pacheco B, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-32
   Singh KP, 2008, GENE, V408, P18, DOI 10.1016/j.gene.2007.10.022
   Singh KP, 2004, MUTAGENESIS, V19, P67, DOI 10.1093/mutage/geh003
   Son Byung Ho, 2004, Breast J, V10, P20, DOI 10.1111/j.1524-4741.2004.09609.x
   Spagnoletti I, 2004, ONCOL REP, V11, P845
   Stefanska B, 2010, EUR J PHARMACOL, V638, P47, DOI 10.1016/j.ejphar.2010.04.032
   van Engeland M, 2003, CANCER RES, V63, P3133
   Wu YY, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-32
   Yan ZJ, 1995, BIOCHEM MOL BIOL INT, V37, P175
NR 54
TC 52
Z9 59
U1 0
U2 17
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD MAR
PY 2012
VL 316
IS 1
BP 62
EP 69
DI 10.1016/j.canlet.2011.10.022
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 884MO
UT WOS:000299712400009
PM 22082530
DA 2025-01-12
ER

PT J
AU Zhu, QS
   Huang, Y
   Marton, LJ
   Woster, PM
   Davidson, NE
   Casero, RA
AF Zhu, Qingsong
   Huang, Yi
   Marton, Laurence J.
   Woster, Patrick M.
   Davidson, Nancy E.
   Casero, Robert A., Jr.
TI Polyamine analogs modulate gene expression by inhibiting lysine-specific
   demethylase 1 (LSD1) and altering chromatin structure in human breast
   cancer cells
SO AMINO ACIDS
LA English
DT Article
DE Epigenetics; Chromatin; Histone methylation; Acetylation; Gene silencing
ID HUMAN GENOME; MURINE SKIN; HISTONE ACETYLTRANSFERASE; DNA
   METHYLTRANSFERASE; SILENCED GENES; TUMORS; GROWTH; REEXPRESSION;
   ACETYLATION; METHYLATION
AB Aberrant epigenetic repression of gene expression has been implicated in most cancers, including breast cancer. The nuclear amine oxidase, lysine-specific demethylase 1 (LSD1) has the ability to broadly repress gene expression by removing the activating mono- and di-methylation marks at the lysine 4 residue of histone 3 (H3K4me1 and me2). Additionally, LSD1 is highly expressed in estrogen receptor alpha negative (ER-) breast cancer cells. Since epigenetic marks are reversible, they make attractive therapeutic targets. Here we examine the effects of polyamine analog inhibitors of LSD1 on gene expression, with the goal of targeting LSD1 as a therapeutic modality in the treatment of breast cancer. Exposure of the ER-negative human breast cancer cells, MDA-MB-231 to the LSD1 inhibitors, 2d or PG11144, significantly increases global H3K4me1 and H3K4me2, and alters gene expression. Array analysis indicated that 98 (75 up and 23 down) and 477 (237 up and 240 down) genes changed expression by at least 1.5-fold or greater after treatment with 2d and PG11144, respectively. The expression of 12 up-regulated genes by 2d and 14 up-regulated genes by PG11144 was validated by quantitative RT-PCR. Quantitative chromatin immunoprecipitation (ChIP) analysis demonstrated that up-regulated gene expression by polyamine analogs is associated with increase of the active histone marks H3K4me1, H3K4me2 and H3K9act, and decrease of the repressive histone marks H3K9me2 and H3K27me3, in the promoter regions of the relevant target genes. These data indicate that the pharmacologic inhibition of LSD1 can effectively alter gene expression and that this therapeutic strategy has potential.
C1 [Casero, Robert A., Jr.] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21231 USA.
   [Zhu, Qingsong; Casero, Robert A., Jr.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Sch Med, Baltimore, MD 21231 USA.
   [Huang, Yi; Davidson, Nancy E.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Inst Canc, Pittsburgh, PA 15232 USA.
   [Marton, Laurence J.] Univ Calif San Francisco, Dept Lab Med, San Francisco Sch Med, San Francisco, CA 94143 USA.
   [Woster, Patrick M.] Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Charleston, SC 29425 USA.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE);
   University of Pittsburgh; University of California System; University of
   California San Francisco; Medical University of South Carolina
RP Casero, RA (通讯作者)，Johns Hopkins Univ, Dept Oncol, Bunting Blaustein Canc Res Bldg 1,Room 551,1650 O, Baltimore, MD 21231 USA.
EM rcasero@jhmi.edu
RI Woster, Patrick/A-5604-2010; Huang, Yi/AAW-7892-2021
OI Huang, Yi/0000-0002-9982-117X; Casero, Robert/0000-0001-5653-3306;
   Woster, Patrick/0000-0002-9471-1916
FU NIH [CA51085, CA98454, CA149095]; Susan G. Komen for the Cure
   [KG088923]; Samuel Waxman Cancer Research Foundation; Office Of The
   Director; EPSCoR [0919440] Funding Source: National Science Foundation
FX This work was funded by NIH grants CA51085, CA98454, and CA149095, Susan
   G. Komen for the Cure KG088923, and the Samuel Waxman Cancer Research
   Foundation.
CR Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   BASU HS, 1993, CANCER RES, V53, P3948
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001
   Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109
   Carruthers LM, 2007, BIOCHEM J, V405, P541, DOI 10.1042/BJ20061347
   Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260
   FEUERSTEIN BG, 1991, J CELL BIOCHEM, V46, P37, DOI 10.1002/jcb.240460107
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Hobbs CA, 2000, J CELL BIOCHEM, V77, P345, DOI 10.1002/(SICI)1097-4644(20000601)77:3<345::AID-JCB1>3.3.CO;2-G
   Hobbs CA, 2003, EXP CELL RES, V290, P427, DOI 10.1016/S0014-4827(03)00352-5
   Hobbs CA, 2002, CANCER RES, V62, P67
   Hobbs CA, 2006, CANCER RES, V66, P8116, DOI 10.1158/0008-5472.CAN-06-0359
   Huang Y, 2004, MOL CANCER RES, V2, P81
   Huang Y, 2003, CLIN CANCER RES, V9, P2769
   Huang Y, 2007, P NATL ACAD SCI USA, V104, P8023, DOI 10.1073/pnas.0700720104
   Huang Y, 2009, CLIN CANCER RES, V15, P7217, DOI 10.1158/1078-0432.CCR-09-1293
   KABRA PM, 1986, J CHROMATOGR, V380, P19, DOI 10.1016/S0378-4347(00)83621-X
   Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003
   Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324
   McGarvey KM, 2008, CANCER RES, V68, P5753, DOI 10.1158/0008-5472.CAN-08-0700
   McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481
   Mitchell JLA, 2002, BIOCHEM J, V366, P663, DOI 10.1042/BJ20011612
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Putti TC, 2005, MODERN PATHOL, V18, P26, DOI 10.1038/modpathol.3800255
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Roh TY, 2005, GENE DEV, V19, P542, DOI 10.1101/gad.1272505
   Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Snowden AW, 2002, CURR BIOL, V12, P2159, DOI 10.1016/S0960-9822(02)01391-X
   Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154
   Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049
   Wei G, 2007, MOL CARCINOGEN, V46, P611, DOI 10.1002/mc.20350
   Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481
   Yan L, 2003, CANCER BIOL THER, V2, P552, DOI 10.4161/cbt.2.5.469
   Yang XW, 2001, CANCER RES, V61, P7025
NR 36
TC 71
Z9 86
U1 0
U2 20
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0939-4451
J9 AMINO ACIDS
JI Amino Acids
PD FEB
PY 2012
VL 42
IS 2-3
BP 887
EP 898
DI 10.1007/s00726-011-1004-1
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 881RT
UT WOS:000299506000046
PM 21805138
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Arriaga, JM
   Levy, EM
   Bravo, AI
   Bayo, SM
   Amat, M
   Aris, M
   Hannois, A
   Bruno, L
   Roberti, MP
   Loria, FS
   Pairola, A
   Huertas, E
   Mordoh, J
   Bianchini, M
AF Martin Arriaga, Juan
   Mariel Levy, Estrella
   Ines Bravo, Alicia
   Morales Bayo, Sergio
   Amat, Mora
   Aris, Mariana
   Hannois, Adrian
   Bruno, Luisina
   Roberti, Maria Paula
   Sanchez Loria, Fernando
   Pairola, Alejandro
   Huertas, Eduardo
   Mordoh, Jose
   Bianchini, Michele
TI Metallothionein expression in colorectal cancer: relevance of different
   isoforms for tumor progression and patient survival
SO HUMAN PATHOLOGY
LA English
DT Article
DE Metallothioneins; Colorectal cancer; Biomarker; Oncogenesis;
   Hypermethylation; Survival
ID PAPILLARY THYROID-CARCINOMA; 2 GENE-EXPRESSION; MT1G HYPERMETHYLATION;
   PROMOTER METHYLATION; PROSTATE-CANCER; CELL CARCINOMA; BREAST-CANCER;
   PROFILES; STAGE; ADENOCARCINOMA
AB Metallothioneins are a family of small, cysteine-rich proteins with many functions. Immunohistochemical evaluation of all metallothionein 1 + 2 isoforms in colorectal tumors has demonstrated an important down-regulation compared with normal tissue, although its prognostic significance is unclear. Moreover, the contribution of individual isoforms to overall metallothionein down-regulation is not known. To address these important issues, we analyzed the messenger RNA expression levels of all functional metallothionein 1 + 2 isoforms by quantitative reverse transcription polymerase chain reaction in 22 pairs of normal and tumor-microdissected epithelia and correlated these to the overall immunohistochemical protein expression. Our results showed that 5 isoforms (MT1G, 1E, 1F, 1H, and 1M) were lost during the transition from normal mucosa to tumor, whereas MT1X and MT2A were less down-regulated, and their expression was correlated with overall protein positivity. Second, we showed that MT1G hypermethylation occurred in cell lines and in 29% of tumor samples, whereas histone deacetylase inhibitors are able to induce most isoforms. Furthermore, we analyzed by immunohistochemistry 107 normal mucosae, 25 adenomas, 81 carcinomas, and 19 lymph node metastases to evaluate metallothionein expression during different stages of cancer development and to assess its relationship to patient survival. A lower immunohistochemical expression was associated with poorer survival, although it was not an independent predictor. Overall, this study identifies for the first time the relevant metallothionein isoforms for colorectal cancer progression, supports the concept that their loss is associated with worse prognosis, and suggests 2 mechanisms for epigenetic repression of metallothionein expression in colorectal tumors. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Amat, Mora; Bruno, Luisina; Sanchez Loria, Fernando; Pairola, Alejandro; Huertas, Eduardo; Mordoh, Jose; Bianchini, Michele] Inst Med Especializado Alexander Fleming, RA-1426 Buenos Aires, DF, Argentina.
   [Martin Arriaga, Juan; Mariel Levy, Estrella; Roberti, Maria Paula; Mordoh, Jose; Bianchini, Michele] Ctr Ivest Oncol Fdn Canc, RA-1426 Buenos Aires, DF, Argentina.
   [Ines Bravo, Alicia; Hannois, Adrian] Hosp Interzonal Gen Agudos Eva Peron, RA-1650 San Martin, Argentina.
   [Morales Bayo, Sergio] Hosp Municipal Prof Dr Houssay, RA-1638 Vicente Lopez, Argentina.
   [Aris, Mariana; Mordoh, Jose] Fdn Inst Leloir, IIBBA CONICET, Inst Invest Bioquim Buenos Aires, RA-1405 Buenos Aires, DF, Argentina.
C3 Leloir Institute; Consejo Nacional de Investigaciones Cientificas y
   Tecnicas (CONICET)
RP Bianchini, M (通讯作者)，Inst Med Especializado Alexander Fleming, Zabala 2836, RA-1426 Buenos Aires, DF, Argentina.
EM mbianchini@conicet.gov.ar
RI Arriaga, Juan Martin/HMD-3283-2023
OI Bayo, Sergio/0000-0001-7007-0694; Bruno, Luisina/0000-0003-4901-1627;
   Aris, Mariana/0000-0002-9404-5845; Arriaga, Juan
   Martin/0000-0001-7523-2955
FU Fundacion Cancer; Consejo Nacional de Investigaciones Cientificas y
   Tecnicas (CONICET) [845-10]; ANPCyT; Fundacion P. Mosoteguy; Fundacion
   Sales; Fundacion Maria Calderon de la Barca
FX This work was funded by Fundacion Cancer, Consejo Nacional de
   Investigaciones Cientificas y Tecnicas (CONICET) (PIP No. 845-10),
   ANPCyT, Fundacion P. Mosoteguy, Fundacion Sales, and Fundacion Maria
   Calderon de la Barca. M.B., J.M., and E.M.L. are members of CONICET, and
   J.M.A., M.A., and M.P.R. are fellows of the same institution.
CR Adams L, 2008, CANCER PREV RES, V1, P357, DOI 10.1158/1940-6207.CAPR-08-0061
   Bell SG, 2009, CHEMBIOCHEM, V10, P55, DOI 10.1002/cbic.200800511
   Bianchini M, 2006, INT J ONCOL, V29, P83
   Bouzourene H, 2002, CANCER-AM CANCER SOC, V95, P1003, DOI 10.1002/cncr.10780
   Cunningham D, 2007, LANCET, V370, P1980, DOI 10.1016/S0140-6736(07)61841-8
   Dutsch-Wicherek M, 2008, FRONT BIOSCI-LANDMRK, V13, P4029, DOI 10.2741/2991
   Dziegiel P, 2003, HISTOL HISTOPATHOL, V18, P401, DOI 10.14670/HH-18.401
   Ferrario C, 2008, LAB INVEST, V88, P474, DOI 10.1038/labinvest.2008.17
   Garrett SH, 2000, PROSTATE, V43, P125
   Henrique R, 2005, CANCER EPIDEM BIOMAR, V14, P1274, DOI 10.1158/1055-9965.EPI-04-0659
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hishikawa Y, 2001, ONCOLOGY-BASEL, V61, P162, DOI 10.1159/000055368
   Huang Y, 2003, INT J CANCER, V104, P735, DOI 10.1002/ijc.11006
   Janssen AML, 2000, J PATHOL, V192, P293, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH712>3.0.CO;2-Z
   Jasani B, 1997, HISTOPATHOLOGY, V31, P211, DOI 10.1046/j.1365-2559.1997.2140848.x
   Jin RX, 2002, CARCINOGENESIS, V23, P81, DOI 10.1093/carcin/23.1.81
   Kanda M, 2009, INT J ONCOL, V35, P477, DOI 10.3892/ijo_00000359
   Kang GH, 2008, LAB INVEST, V88, P161, DOI 10.1038/labinvest.3700707
   Klaassen CD, 2009, TOXICOL APPL PHARM, V238, P215, DOI 10.1016/j.taap.2009.03.026
   Koga Y, 2009, GENOME RES, V19, P1462, DOI 10.1101/gr.091447.109
   Kuroda K, 2002, EUR J CANCER, V38, P1879, DOI 10.1016/S0959-8049(02)00233-2
   Laukens D, 2009, CRIT REV EUKAR GENE, V19, P301, DOI 10.1615/CritRevEukarGeneExpr.v19.i4.40
   Majumder S, 2010, CANCER RES, V70, P10265, DOI 10.1158/0008-5472.CAN-10-2839
   MARGOSHES M, 1957, J AM CHEM SOC, V79, P4813, DOI 10.1021/ja01574a064
   McDonald SAC, 2006, NAT CLIN PRACT GASTR, V3, P267, DOI 10.1038/ncpgasthep0473
   MULDER TPJ, 1990, FREE RADICAL BIO MED, V9, P501, DOI 10.1016/0891-5849(90)90128-6
   Nguyen A, 2000, CANCER LETT, V160, P133, DOI 10.1016/S0304-3835(00)00534-6
   Nielsen AE, 2006, BIOMARK INSIGHTS, V1, P99
   Notterman DA, 2001, CANCER RES, V61, P3124
   OFNER D, 1994, VIRCHOWS ARCH, V425, P491
   Pedersen MO, 2009, PROG HISTOCHEM CYTO, V44, P29, DOI 10.1016/j.proghi.2008.10.001
   REMMELE W, 1987, PATHOLOGE, V8, P138
   Sakamoto LHT, 2010, PEDIATR RES, V67, P387, DOI 10.1203/PDR.0b013e3181d01863
   Schmitz KJ, 2009, INT J COLORECTAL DIS, V24, P1287, DOI 10.1007/s00384-009-0753-8
   Somji S, 2001, CANCER DETECT PREV, V25, P62
   Sutoh I, 2000, DIS COLON RECTUM, V43, P221, DOI 10.1007/BF02236987
   Suzuki JS, 2003, CARCINOGENESIS, V24, P1123, DOI 10.1093/carcin/bgg052
   Tokumaru Y, 2004, CANCER RES, V64, P5982, DOI 10.1158/0008-5472.CAN-04-0993
   Türeci Ö, 2003, FASEB J, V17, P376, DOI 10.1096/fj.02-0478com
   UDOM AO, 1980, BIOCHEM J, V187, P329, DOI 10.1042/bj1870329
   WEST AK, 1990, GENOMICS, V8, P513, DOI 10.1016/0888-7543(90)90038-V
   ZENG J, 1991, FEBS LETT, V279, P310, DOI 10.1016/0014-5793(91)80175-3
NR 42
TC 48
Z9 55
U1 0
U2 18
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0046-8177
J9 HUM PATHOL
JI Hum. Pathol.
PD FEB
PY 2012
VL 43
IS 2
BP 197
EP 208
DI 10.1016/j.humpath.2011.04.015
PG 12
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 885GL
UT WOS:000299766600006
PM 21820154
OA Green Published
DA 2025-01-12
ER

PT J
AU Fang, YC
   Lai, PT
   Dai, HJ
   Hsu, WL
AF Fang, Yu-Ching
   Lai, Po-Ting
   Dai, Hong-Jie
   Hsu, Wen-Lian
TI MeInfoText 2.0: gene methylation and cancer relation extraction from
   biomedical literature
SO BMC BIOINFORMATICS
LA English
DT Article
ID HUMAN BREAST-CANCER; NAMED ENTITY RECOGNITION; DNA METHYLATION;
   EPIGENETIC INACTIVATION; BINDING-PROTEINS; TEXT; PATTERNS;
   METHYLTRANSFERASE; NORMALIZATION; EXPRESSION
AB Background: DNA methylation is regarded as a potential biomarker in the diagnosis and treatment of cancer. The relations between aberrant gene methylation and cancer development have been identified by a number of recent scientific studies. In a previous work, we used co-occurrences to mine those associations and compiled the MeInfoText 1.0 database. To reduce the amount of manual curation and improve the accuracy of relation extraction, we have now developed MeInfoText 2.0, which uses a machine learning-based approach to extract gene methylation-cancer relations.
   Description: Two maximum entropy models are trained to predict if aberrant gene methylation is related to any type of cancer mentioned in the literature. After evaluation based on 10-fold cross-validation, the average precision/recall rates of the two models are 94.7/90.1 and 91.8/90% respectively. MeInfoText 2.0 provides the gene methylation profiles of different types of human cancer. The extracted relations with maximum probability, evidence sentences, and specific gene information are also retrievable. The database is available at http://bws.iis.sinica.edu.tw:8081/MeInfoText2/.
   Conclusion: The previous version, MeInfoText, was developed by using association rules, whereas MeInfoText 2.0 is based on a new framework that combines machine learning, dictionary lookup and pattern matching for epigenetics information extraction. The results of experiments show that MeInfoText 2.0 outperforms existing tools in many respects. To the best of our knowledge, this is the first study that uses a hybrid approach to extract gene methylation-cancer relations. It is also the first attempt to develop a gene methylation and cancer relation corpus.
C1 [Dai, Hong-Jie; Hsu, Wen-Lian] Acad Sinica, Inst Informat Sci, Taipei, Taiwan.
   [Fang, Yu-Ching] Natl Taiwan Univ, Inst Mol & Cellular Biol, Taipei 10764, Taiwan.
   [Lai, Po-Ting] Natl Chengchi Univ, Dept Comp Sci, Taipei 11623, Taiwan.
C3 Academia Sinica - Taiwan; National Taiwan University; National Chengchi
   University
RP Hsu, WL (通讯作者)，Acad Sinica, Inst Informat Sci, Taipei, Taiwan.
EM hsu@iis.sinica.edu.tw
RI Lai, Poting/JGM-5295-2023; Hsu, Wen-Lian/ABB-2851-2020; Dai,
   Hong-Jie/C-2526-2013
OI Lai, Po-Ting/0000-0003-2025-318X
FU National Science Council [NSC99-3112-B-001-005]; Academia Sinica
   [95-02]; research center for Humanities and Social Sciences [IIS-50-23]
FX This research was supported in part by the National Science Council
   under grant NSC99-3112-B-001-005, the Academia Sinica Investigator Award
   95-02 and the research center for Humanities and Social Sciences under
   grant IIS-50-23. The authors thank Chi-Yang Wu for annotating the subset
   of the corpus for the inter-annotator agreement analysis.
CR [Anonymous], MAXENT TOOLKIT
   [Anonymous], P 2 BIOCREATIVE CHAL
   Berger AL, 1996, COMPUT LINGUIST, V22, P39
   Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Chim CS, 2010, CARCINOGENESIS, V31, P745, DOI 10.1093/carcin/bgq033
   Cohen A.M., 2005, ACL ISMB WORKSHOP LI, P17
   Cohen AM, 2005, BRIEF BIOINFORM, V6, P57, DOI 10.1093/bib/6.1.57
   Dai HJ, 2010, IEEE ACM T COMPUT BI, V7, P412, DOI 10.1109/TCBB.2010.45
   Esteller M, 2001, CANCER RES, V61, P3225
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fang YC, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-22
   Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750
   Hashimoto Y, 2010, CARCINOGENESIS, V31, P777, DOI 10.1093/carcin/bgq013
   Kim MS, 2010, CANCER METAST REV, V29, P181, DOI 10.1007/s10555-010-9207-6
   Kristensen LS, 2009, EUR J PHARMACOL, V625, P131, DOI 10.1016/j.ejphar.2009.10.011
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Ohta Tomoko, 2011, J Biomed Semantics, V2 Suppl 5, pS2, DOI 10.1186/2041-1480-2-S5-S2
   Ongenaert M, 2008, NUCLEIC ACIDS RES, V36, pD842, DOI 10.1093/nar/gkm788
   Rosario Barbara, 2004, P 42 ANN M ASS COMP
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5
   Spasic I, 2005, BRIEF BIOINFORM, V6, P239, DOI 10.1093/bib/6.3.239
   Sung CL, 2009, INTEGR COMPUT-AID E, V16, P259, DOI 10.3233/ICA-2009-0313
   Tost Joerg, 2009, V507, P3, DOI 10.1007/978-1-59745-522-0_1
   Tryndyak VP, 2006, CANCER BIOL THER, V5, P65, DOI 10.4161/cbt.5.1.2288
   Tsai RTH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-S5-S11
   Tsai RTH, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-S15-S9
   Tsai RTH, 2006, BMC BIOINFORMATICS, V7, P1, DOI 10.1186/1471-2105-7-92
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   Weeber M, 2000, J AM MED INFORM ASSN, P903
NR 31
TC 19
Z9 21
U1 0
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PD DEC 14
PY 2011
VL 12
AR 471
DI 10.1186/1471-2105-12-471
PG 8
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
GA 886AW
UT WOS:000299823700001
PM 22168213
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Prando, ED
   Cavalli, LR
   Rainho, CA
AF Prando, Erika da Costa
   Cavalli, Luciane Regina
   Rainho, Claudia Aparecida
TI Evidence of epigenetic regulation of the tumor suppressor gene cluster
   flanking <i>RASSF1</i> in breast cancer cell lines
SO EPIGENETICS
LA English
DT Article
DE DNA methylation; histone modification; gene expression; breast cancer
   cell lines; tumor suppressor genes; RASSF1
ID COLORECTAL-CANCER; ALLELE LOSS; DNA METHYLATION; LUNG-CANCER; 3P21.3;
   INACTIVATION; PROMOTER; REGION; BLU; HYPERMETHYLATION
AB Epigenetic mechanisms are frequently deregulated in cancer cells and can lead to the silencing of genes with tumor suppressor activities. The isoform A of the Ras-association domain family member 1 (RASSF1A) gene is one of the most frequently silenced transcripts in human tumors; however, few studies have simultaneously investigated epigenetic abnormalities associated with the 3p21.3 tumor suppressor gene cluster flanking RASSF1 (i.e., SEMA3B, HYAL3, HYAL2, HYAL1, TUSC2, RASSF1, ZMYND10, NPRL2, TMEM115 and CACNA2D2). This study aimed to investigate the role of epigenetic changes to these genes in 17 breast cancer cell lines and in three non-tumorigenic epithelial breast cell lines (184A1, 184B5 and MCF 10A) and to evaluate the effect on gene expression of treatment with the demethylating agent 5-Aza -2'-deoxycytidine and/or Trichostatin A (TSA), a histone deacetylase inhibitor. We report that, although the RASSF1A isoform was determined to be epigenetically silenced in 15 of the 17 breast cancer cell lines, all the cell lines expressed the RASSF1C isoform. Five breast cancer cell lines overexpressed RASSF1C when compared with the normal epithelial cell line 184A1. Furthermore, the genes HYAL1 and CACNA2D2 were significantly overexpressed after the treatments. After the combined treatment, RASSF1A re-expression was accompanied by an increase in expression levels of the flanking genes. The Spearman's correlation coefficient indicated a positive co-regulation of the following gene pairs: RASSF1 and TUSC2 (r = 0.64, p = 0.002), RASSF1 and ZMYND10 (r = 0.58, p = 0.07), RASSF1 and NPRL2 (r = 0.48, p = 0.03), ZMYND10 and NPRL2 (r = 0.71; p = 0.0004) and NPRL2 and TMEM115 (r = 0.66, p = 0.001). Interestingly, the genes TUSC2, NPRL2 and TMEM115 were found to be unmethylated in each of the untreated cell lines. Chromatin immunoprecipitation using antibodies against the acetylated and trimethylated lysine 9 of histone H3 demonstrated low levels of histone methylation in these genes, which are located closest to RASSF1. These results provide evidence that epigenetic repression is involved in the downregulation of multiple genes at 3p21.3 in breast cancer cells.
C1 [Prando, Erika da Costa; Rainho, Claudia Aparecida] Sao Paulo State Univ UNESP, Lab Epigenet, Dept Genet, Biosci Inst, Sao Paulo, Brazil.
   [Cavalli, Luciane Regina] Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20007 USA.
C3 Universidade Estadual Paulista; Georgetown University
RP Rainho, CA (通讯作者)，Sao Paulo State Univ UNESP, Lab Epigenet, Dept Genet, Biosci Inst, Sao Paulo, Brazil.
EM rainho@ibb.unesp.br
RI Cavalli, Luciane/J-6100-2012; Rainho, Claudia Aparecida/B-7567-2012;
   Prando Munhoz, Erika/J-7886-2015
OI Cavalli, Luciane Regina/0000-0001-5619-9037; Rainho, Claudia
   Aparecida/0000-0002-0285-1162; Prando Munhoz, Erika/0000-0002-1561-5070
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [07/59110-9]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior-Capes, Brazil; NIH/NCI [P30-CA51008]
FX This study was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP grant# 07/59110-9) and Coordenacao de Aperfeicoamento
   de Pessoal de Nivel Superior-Capes, Brazil. We are grateful to the
   Natallia Carrion Teodoro for her technical assistance. The Tissue
   Culture Shared Resource (TCSR) of Georgetown University Lombardi
   Comprehensive Cancer Center is partially supported by NIH/NCI Cancer
   Center Support Grant (CCSG) Grant P30-CA51008, to the Lombardi
   Comprehensive Cancer Center.
CR Bertrand P, 1997, INT J CANCER, V73, P327, DOI 10.1002/(SICI)1097-0215(19971104)73:3<327::AID-IJC4>3.0.CO;2-1
   Carboni GL, 2003, ONCOGENE, V22, P615, DOI 10.1038/sj.onc.1206134
   Chari R, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-67
   Chari R, 2010, CANCER METAST REV, V29, P73, DOI 10.1007/s10555-010-9199-2
   Chow LSN, 2004, INT J CANCER, V109, P839, DOI 10.1002/ijc.20079
   Clark SJ, 2007, HUM MOL GENET, V16, pR88, DOI 10.1093/hmg/ddm051
   Coolen MW, 2010, NAT CELL BIOL, V12, P235, DOI 10.1038/ncb2023
   Dallosso AR, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000745
   Devaney J, 2011, CANCER EPIDEM BIOMAR, V20, P148, DOI 10.1158/1055-9965.EPI-10-0719
   Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Estrabaud E, 2007, CANCER RES, V67, P1054, DOI 10.1158/0008-5472.CAN-06-2530
   Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781
   Hesson L, 2004, ONCOGENE, V23, P2408, DOI 10.1038/sj.onc.1207407
   Hesson LB, 2007, ONCOGENE, V26, P7283, DOI 10.1038/sj.onc.1210547
   Hitchins MP, 2007, CANCER RES, V67, P9107, DOI 10.1158/0008-5472.CAN-07-0869
   Hsu PY, 2010, GENOME RES, V20, P733, DOI 10.1101/gr.101923.109
   Ito M, 2005, CANCER LETT, V225, P131, DOI 10.1016/j.canlet.2004.10.041
   Ji Lin, 2005, Future Oncol, V1, P79, DOI 10.1517/14796694.1.1.79
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Karpinski P, 2008, MOL CANCER RES, V6, P585, DOI 10.1158/1541-7786.MCR-07-2158
   Komashko Vitalina M, 2010, Epigenetics, V5, P229
   Kondo Y, 2009, YONSEI MED J, V50, P455, DOI 10.3349/ymj.2009.50.4.455
   Lai HC, 2007, GYNECOL ONCOL, V104, P629, DOI 10.1016/j.ygyno.2006.10.003
   Lerman MI, 2000, CANCER RES, V60, P6116
   Lokeshwar VB, 2008, J BIOL CHEM, V283, P29215, DOI 10.1074/jbc.M801101200
   Lokeshwar VB, 2008, SEMIN CANCER BIOL, V18, P281, DOI 10.1016/j.semcancer.2008.03.008
   Maitra A, 2001, AM J PATHOL, V159, P119, DOI 10.1016/S0002-9440(10)61679-3
   Martinez A, 2001, J CLIN PATHOL-MOL PA, V54, P300, DOI 10.1136/mp.54.5.300
   Mayor R, 2009, BRIT J CANCER, V100, P1534, DOI 10.1038/sj.bjc.6605045
   Mayor R, 2011, EPIGENETICS-US, V6, P1138, DOI 10.4161/epi.6.9.16066
   Nguyen CT, 2002, CANCER RES, V62, P6456
   Novak P, 2008, CANCER RES, V68, P8616, DOI 10.1158/0008-5472.CAN-08-1419
   Novak P, 2006, CANCER RES, V66, P10664, DOI 10.1158/0008-5472.CAN-06-2761
   Reeves ME, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-562
   Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004
   Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858
   Senchenko VN, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-75
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Stransky N, 2006, NAT GENET, V38, P1386, DOI 10.1038/ng1923
   Tan JX, 2011, INT J CANCER, V128, P1303, DOI 10.1002/ijc.25460
   Udabage L, 2005, EXP CELL RES, V310, P205, DOI 10.1016/j.yexcr.2005.07.026
   van der Weyden L, 2007, BBA-REV CANCER, V1776, P58, DOI 10.1016/j.bbcan.2007.06.003
NR 43
TC 32
Z9 39
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD DEC
PY 2011
VL 6
IS 12
BP 1413
EP 1424
DI 10.4161/epi.6.12.18271
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 886CI
UT WOS:000299828200002
PM 22139571
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Huang, WC
   Chen, WS
   Chen, YJ
   Wang, LY
   Hsu, SC
   Chen, CC
   Hung, MC
AF Huang, Wei-Chien
   Chen, Wen-Shu
   Chen, Yun-Ju
   Wang, Li-Yun
   Hsu, Sheng-Chieh
   Chen, Ching-Chow
   Hung, Mien-Chie
TI Hepatitis B virus X protein induces IKKa nuclear translocation via
   Akt-Dependent phosphorylation to promote the motility of hepatocarcinoma
   cells
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID NF-KAPPA-B; KINASE-ALPHA; BREAST-CANCER; UBIQUITINATION; ACTIVATION;
   TRANSCRIPTION; EXPRESSION; P53; PROLIFERATION; DEREPRESSION
AB Hepatitis B virus (HBV) X protein (HBx) has been implicated in HBV-associated carcinogenesis through activation of I?B kinase (IKK)/nuclear factor kappa B (NF-?B) signaling pathway. Besides activating NF-?B in the cytoplasm, IKKa was found in the nucleus to regulate gene expression epigenetically in response to various stimuli. However, it is unknown whether nuclear IKKa plays a role in HBx-associated tumor progression. Moreover, the molecular mechanism underlying IKKa nuclear transport also remains to be elucidated. Here, we disclosed HBx as a new inducer of IKKa nuclear transport in hepatoma cells. HBx induced IKKa nuclear transport in an Akt-dependent manner. HBx-activated Akt promoted IKKa nuclear translocation via phosphorylating its threonine-23 (Thr23). In addition, IKKa ubiquitination enhanced by HBx and Akt also contributed to the IKKa accumulation in the nucleus, indicating the involvement of ubiquitination in Akt-increased IKKa nuclear transport in response to HBx. Furthermore, inhibition of IKKa nuclear translocation by mutation of its nuclear localization signal and Thr23 diminished IKKa-dependent cell migration. Taken together, our findings shed light on the molecular mechanism of IKKa nuclear translocation and provide a potential role of nuclear IKKa in HBx-mediated hepatocellular carcinoma (HCC) progression. J. Cell. Physiol. 227: 1446-1454, 2012. (C) 2011 Wiley Periodicals, Inc.
C1 [Huang, Wei-Chien; Chen, Wen-Shu; Wang, Li-Yun] China Med Univ & Hosp, Grad Inst Canc Biol, Taichung 404, Taiwan.
   [Huang, Wei-Chien] China Med Univ & Hosp, PhD Program Canc Biol & Drug Discovery, Taichung 404, Taiwan.
   [Huang, Wei-Chien; Chen, Yun-Ju; Hsu, Sheng-Chieh; Hung, Mien-Chie] China Med Univ Hosp, Ctr Mol Med, Taichung, Taiwan.
   [Huang, Wei-Chien] Asia Univ, Dept Biotechnol, Taichung 413, Taiwan.
   [Chen, Ching-Chow] Natl Taiwan Univ, Dept Pharmacol, Taipei 10764, Taiwan.
   [Hung, Mien-Chie] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.
C3 China Medical University Taiwan; China Medical University Hospital -
   Taiwan; China Medical University Taiwan; China Medical University
   Hospital - Taiwan; China Medical University Taiwan; China Medical
   University Hospital - Taiwan; Asia University Taiwan; National Taiwan
   University; University of Texas System; UTMD Anderson Cancer Center
RP Huang, WC (通讯作者)，China Med Univ & Hosp, Grad Inst Canc Biol, 9F,6th Hsueh Shih Rd, Taichung 404, Taiwan.
EM whuang@mail.cmu.edu.tw
RI Chen, Honglei/ABG-8632-2021; Hung, Mien-Chie/ABD-5911-2021; Huang,
   Wei-Chien/H-3126-2019; Huang, Wei-Chien/D-1740-2012
OI CHEN, CHING-CHOW/0000-0002-7810-0939; Huang,
   Wei-Chien/0000-0001-6467-8716; Hung, Mien-Chie/0000-0003-4317-4740
FU National Science Council of Taiwan [NSC-97-2320-B-039-033-MY3,
   NSC-99-3112-B-039-002, NSC-2632-B-039-001-MY3]; National Health Research
   Institutes of Taiwan [NHRI-EX-98-9812BC]
FX Contract grant sponsor: National Science Council of Taiwan;Contract
   grant numbers: NSC-97-2320-B-039-033-MY3, NSC-99-3112-B-039-002,
   NSC-2632-B-039-001-MY3.Contract grant sponsor: National Health Research
   Institutes of Taiwan;Contract grant number: NHRI-EX-98-9812BC.
CR Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648
   Arsura M, 2005, CANCER LETT, V229, P157, DOI 10.1016/j.canlet.2005.07.008
   Birbach A, 2002, J BIOL CHEM, V277, P10842, DOI 10.1074/jbc.M112475200
   Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101
   Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4
   Carter RS, 2003, J BIOL CHEM, V278, P48903, DOI 10.1074/jbc.M310686200
   Chen Bojiang, 2010, Zhongguo Fei Ai Za Zhi, V13, P1059, DOI 10.3779/j.issn.1009-3419.2010.11.12
   Cher ML, 2003, P NATL ACAD SCI USA, V100, P7847, DOI 10.1073/pnas.1331360100
   Chung TW, 2004, FASEB J, V18, P1123, DOI 10.1096/fj.03-1429fje
   Fernández-Majada V, 2007, P NATL ACAD SCI USA, V104, P276, DOI 10.1073/pnas.0606476104
   Geetha T, 2005, EMBO J, V24, P3859, DOI 10.1038/sj.emboj.7600845
   He XC, 2007, NAT GENET, V39, P189, DOI 10.1038/ng1928
   Hirata Y, 2006, INFECT IMMUN, V74, P1452, DOI 10.1128/IAI.74.3.1452-1461.2006
   Hoberg JE, 2006, MOL CELL BIOL, V26, P457, DOI 10.1128/MCB.26.2.457-471.2006
   Hoberg JE, 2004, MOL CELL, V16, P245, DOI 10.1016/j.molcel.2004.10.010
   Huang WC, 2007, MOL CELL, V26, P75, DOI 10.1016/j.molcel.2007.02.019
   Huang WC, 2009, J FORMOS MED ASSOC, V108, P180, DOI 10.1016/S0929-6646(09)60051-6
   Jiang X, 2003, BIOCHEM BIOPH RES CO, V301, P583, DOI 10.1016/S0006-291X(03)00011-1
   Johnstone PAS, 2002, CURR PROB CANCER, V26, P282, DOI 10.1067/mcn.2002.129997
   Lara-Pezzi E, 2002, J CLIN INVEST, V110, P1831, DOI 10.1172/JCI200215887
   Lara-Pezzi E, 2001, HEPATOLOGY, V33, P1270, DOI 10.1053/jhep.2001.1270
   Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001
   Luo JL, 2007, NATURE, V446, P690, DOI 10.1038/nature05656
   Marotta F, 2004, Clin Ter, V155, P187
   Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041
   Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629
   Ohata K, 2003, FEBS LETT, V553, P304, DOI 10.1016/S0014-5793(03)01034-2
   Ozes ON, 1999, NATURE, V401, P82
   Park GY, 2006, CURR DRUG TARGETS, V7, P661, DOI 10.2174/138945006777435317
   Shambharkar PB, 2007, EMBO J, V26, P1794, DOI 10.1038/sj.emboj.7601622
   Sil AK, 2004, NATURE, V428, P660, DOI 10.1038/nature02421
   Tang ED, 2003, J BIOL CHEM, V278, P37297, DOI 10.1074/jbc.M303389200
   Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741
   Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040
   Tu Z, 2006, J BIOL CHEM, V281, P6699, DOI 10.1074/jbc.M512439200
   Wang T, 2004, WORLD J GASTROENTERO, V10, P356
   Wolfrum C, 2003, P NATL ACAD SCI USA, V100, P11624, DOI 10.1073/pnas.1931483100
   Xia LM, 2009, VIROLOGY, V385, P335, DOI 10.1016/j.virol.2008.11.042
   Xie XX, 2003, CLIN CANCER RES, V9, P167
   Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576
   Yuan ZQ, 2010, J BIOL CHEM, V285, P3815, DOI 10.1074/jbc.M109.059675
   Zhang XY, 2009, HEPATOLOGY, V50, P490, DOI 10.1002/hep.23008
   Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973
NR 43
TC 22
Z9 26
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD APR
PY 2012
VL 227
IS 4
BP 1446
EP 1454
DI 10.1002/jcp.22860
PG 9
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA 874VL
UT WOS:000298986100018
PM 21618535
DA 2025-01-12
ER

PT J
AU Balestrieri, ML
   Dicitore, A
   Benevento, R
   Di Maio, M
   Santoriello, A
   Canonico, S
   Giordano, A
   Stiuso, P
AF Balestrieri, Maria Luisa
   Dicitore, Alessandra
   Benevento, Raffaella
   Di Maio, Massimo
   Santoriello, Antonio
   Canonico, Silvestro
   Giordano, Antonio
   Stiuso, Paola
TI Interplay between membrane lipid peroxidation, transglutaminase
   activity, and Cyclooxygenase 2 expression in the tissue adjoining to
   breast cancer
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID OXIDATIVE STRESS; ANTIOXIDANT STATUS; EPIGENETIC ALTERATIONS; CELLS;
   UBIQUITIN; INHIBITION; ACTIVATION; DAMAGE; COX-2; GENE
AB Breast cancer, a leading cause of cancer related deaths worldwide, is one of the most common neoplasms in women. The increased generation of reactive oxygen species (ROS) in breast lesion is critically involved in the mutagenic processes that drive to breast carcinoma initiation and progression. To date, the molecular events occurring in the tissue adjoin the cancer lesion have not been elucidated. Here, we investigated the role of excess ROS generation during human breast carcinogenesis by evaluating oxidative stress biomarkers, tissue transglutaminase (t-TGase) activity, and expression levels of ubiquitin and cyclooxygenase-2 (COX-2) in the normal tissue adjoin to fibroadenoma (nFA), atypical ductal hyperplasia (nADH), and invasive ductal carcinoma (nIDC) from 45 breast cancer patients. We found that lipid peroxidation and nitric oxide production significantly increased in nIDC respect to nFA and nADH (P<0.005) whereas the 4-hydroxy-2-nonenal (HNE) protein-adducts increased only in nADH (P<0.005). The increased lipid damage observed in nIDC correlates with estrogen receptor exposure in IDC (R2=0.89). Moreover, nIDC and invasive ductal carcinoma (IDC) showed a 10-fold higher t-TGase activity compared to nFA and nADH. Contrary, COX-2 expression levels significantly decreased nIDC and IDC respect to the nFA and nADH (P<0.001). The analysis of the free ubiquitin expression revealed equal levels in nADH and nIDC samples whereas high molecular weight-ubiquitin conjugate increased about fivefold only in nIDC (P<0.01 vs. nADH). These novel findings reveal an interplay between membrane lipid peroxidation, t-TGase activity, and COX-2 expression levels in the tissue adjoining to neoplastic lesion during breast cancer progression. J. Cell. Physiol. 227: 1577-1582, 2012. (C) 2011 Wiley Periodicals, Inc.
C1 [Balestrieri, Maria Luisa; Dicitore, Alessandra; Stiuso, Paola] Univ Naples 2, Dept Biochem & Biophys, Sch Med, I-80138 Naples, Italy.
   [Benevento, Raffaella; Santoriello, Antonio; Canonico, Silvestro] Univ Naples 2, Sch Med, Unit Gen & Geriatr Surg, I-80138 Naples, Italy.
   [Di Maio, Massimo] Local Hlth Author Naples ASL NA I, Naples, Italy.
   [Giordano, Antonio] Temple Univ, Coll Sci & Technol, Sbarro Res Inst, Philadelphia, PA 19122 USA.
   [Giordano, Antonio] Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy.
C3 Universita della Campania Vanvitelli; Universita della Campania
   Vanvitelli; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); Temple University; University of Siena
RP Balestrieri, ML (通讯作者)，Univ Naples 2, Dept Biochem & Biophys, Sch Med, Via Crecchio 7, I-80138 Naples, Italy.
EM marialuisa.balestrieri@unina2.it
RI Giordano, Antonio/F-1927-2010; DI MAIO, Massimo/K-9990-2016
OI Giordano, Antonio/0000-0002-5959-016X; Canonico,
   Silvestro/0000-0003-4010-5205; Stiuso, Paola/0000-0001-5096-7488; DI
   MAIO, Massimo/0000-0001-8906-3785; Balestrieri, Maria
   Luisa/0000-0001-6001-1789
FU PRIN [2008X2PNYX_002]
FX Contract grant sponsor: PRIN 2008;Contract grant number: 2008X2PNYX_002.
CR Albright CD, 2005, EXP MOL PATHOL, V79, P118, DOI 10.1016/j.yexmp.2005.05.005
   Antonyak MA, 2009, J BIOL CHEM, V284, P17914, DOI 10.1074/jbc.M109.013037
   Balestrieri ML, 2008, CARDIOVASC RES, V78, P250, DOI 10.1093/cvr/cvn029
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Caraglia M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.34
   Crawford YG, 2004, CANCER CELL, V5, P263, DOI 10.1016/S1535-6108(04)00023-6
   Dalle-Donne I, 2006, CLIN CHEM, V52, P601, DOI 10.1373/clinchem.2005.061408
   Davies G, 2002, ANN ONCOL, V13, P669, DOI 10.1093/annonc/mdf125
   Carneiro JLD, 2009, J CANCER RES CLIN, V135, P997, DOI 10.1007/s00432-008-0535-7
   Felty Q, 2005, ONCOGENE, V24, P4883, DOI 10.1038/sj.onc.1208667
   Fésüs L, 2005, FEBS LETT, V579, P3297, DOI 10.1016/j.febslet.2005.03.063
   Fucito A, 2008, INT J BIOCHEM CELL B, V40, P565, DOI 10.1016/j.biocel.2007.10.018
   Gago-Dominguez M, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1628
   Gönenç A, 2001, J CLIN PHARM THER, V26, P141, DOI 10.1046/j.1365-2710.2001.00334.x
   Hicke L, 2005, NAT REV MOL CELL BIO, V6, P610, DOI 10.1038/nrm1701
   Hristozov D, 2001, Arch Physiol Biochem, V109, P331, DOI 10.1076/apab.109.4.331.4248
   Ientile R, 2007, AMINO ACIDS, V33, P385, DOI 10.1007/s00726-007-0517-0
   Jiang WG, 2003, PROSTAG LEUKOTR ESS, V69, P275, DOI 10.1016/S0952-3278(03)00110-8
   Kedzierska M, 2010, GEN PHYSIOL BIOPHYS, V29, P208, DOI 10.4149/gpb_2010_02_208
   Kumagai T, 2000, BIOCHEM BIOPH RES CO, V273, P437, DOI 10.1006/bbrc.2000.2967
   Kumar A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013390
   Kumaraguruparan R, 2002, CLIN CHIM ACTA, V325, P165, DOI 10.1016/S0009-8981(02)00292-9
   Lari SA, 2011, J CANCER, V2, P232, DOI 10.7150/jca.2.232
   Mangala LS, 2007, ONCOGENE, V26, P2459, DOI 10.1038/sj.onc.1210035
   Marques C, 2004, FASEB J, V18, P1424, DOI 10.1096/fj.04-1743fje
   Mittal MK, 2011, J BIOL CHEM, V286, P469, DOI 10.1074/jbc.M110.164384
   Mobley JA, 2004, CARCINOGENESIS, V25, P3, DOI 10.1093/carcin/bgg175
   Nikseresht M, 2010, CANCER GENET CYTOGEN, V197, P101, DOI 10.1016/j.cancergencyto.2009.11.020
   Park KS, 2009, FRONT BIOSCI-LANDMRK, V14, P1945, DOI 10.2741/3354
   Pervin S, 2010, CURR PHARM DESIGN, V16, P451, DOI 10.2174/138161210790232130
   Piacentini M, 2005, PROG EXP TUMOR RES, V38, P58
   Ralph SJ, 2010, MOL ASPECTS MED, V31, P145, DOI 10.1016/j.mam.2010.02.008
   Ray G, 2000, BREAST CANCER RES TR, V59, P163, DOI 10.1023/A:1006357330486
   Sener DE, 2007, CELL BIOCHEM FUNCT, V25, P377, DOI 10.1027/cbf.1308
   Servillo L, 2006, FASEB J, V20, P1015, DOI 10.1096/fj.05-5059fje
   Shabek N, 2007, BIOCHEM BIOPH RES CO, V363, P425, DOI 10.1016/j.bbrc.2007.08.185
   Shim V, 2003, CANCER RES, V63, P2347
   Singer CF, 2006, CLIN EXP METASTAS, V23, P33, DOI 10.1007/s10585-006-9015-0
   Steiner C, 2007, CARCINOGENESIS, V28, P738, DOI 10.1093/carcin/bgl180
   Stiuso P, 2010, AMINO ACIDS, V39, P661, DOI 10.1007/s00726-010-0487-5
   Tas F, 2005, MED ONCOL, V22, P11, DOI 10.1385/MO:22:1:011
   Witton CJ, 2004, HISTOPATHOLOGY, V45, P47, DOI 10.1111/j.1365-2559.2004.01898.x
   You JC, 2009, ENDOCRINOLOGY, V150, P1607, DOI 10.1210/en.2008-0616
   Zhao D, 2010, CANCER RES, V70, P4728, DOI 10.1158/0008-5472.CAN-10-0040
   Ziech D, 2011, MUTAT RES-FUND MOL M, V711, P167, DOI 10.1016/j.mrfmmm.2011.02.015
NR 45
TC 11
Z9 11
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD APR
PY 2012
VL 227
IS 4
BP 1577
EP 1582
DI 10.1002/jcp.22874
PG 6
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA 874VL
UT WOS:000298986100032
PM 21678409
DA 2025-01-12
ER

PT J
AU Yu, SC
   Xiao, HL
   Jiang, XF
   Wang, QL
   Li, Y
   Yang, XJ
   Ping, YF
   Duan, JJ
   Jiang, JY
   Ye, XZ
   Xu, SL
   Xin, YH
   Yao, XH
   Chen, JH
   Chu, WH
   Sun, W
   Wang, B
   Wang, JM
   Zhang, X
   Bian, XW
AF Yu, Shi-Cang
   Xiao, Hua-Liang
   Jiang, Xue-Feng
   Wang, Qing-Liang
   Li, Yan
   Yang, Xiao-Jun
   Ping, Yi-Fang
   Duan, Jiang Jie
   Jiang, Jian-Yong
   Ye, Xian-Zong
   Xu, Sen-Lin
   Xin, Yang-Hong
   Yao, Xiao-Hong
   Chen, Jian-Hong
   Chu, Wei-Hua
   Sun, Wei
   Wang, Bing
   Wang, Ji Ming
   Zhang, Xia
   Bian, Xiu-Wu
TI Connexin 43 Reverses Malignant Phenotypes of Glioma Stem Cells by
   Modulating E-Cadherin
SO STEM CELLS
LA English
DT Article
DE Connexin 43; Glioma stem cells; E-Cadherin; Gap junctional intercellular
   communication; Invasiveness; Tumorigenicity
ID JUNCTIONAL INTERCELLULAR COMMUNICATION; HUMAN GLIOBLASTOMA CELLS;
   BREAST-CANCER CELLS; BETA-CATENIN; GAP-JUNCTIONS; EPIGENETIC REGULATION;
   GENE-EXPRESSION; LUNG-CANCER; GROWTH; CX43
AB Malfunctioned gap junctional intercellular communication (GJIC) has been thought associated with malignant transformation of normal cells. However, the role of GJIC-related proteins such as connexins in sustaining the malignant behavior of cancer stem cells remains unclear. In this study, we obtained tumorspheres formed by glioma stem cells (GSCs) and adherent GSCs and then examined their GJIC. All GSCs showed reduced GJIC, and differentiated glioma cells had more gap junction-like structures than GSCs. GSCs expressed very low level of connexins, Cx43 in particular, which are key components of gap junction. We observed hypermethylation in the promoter of gap junction protein a1, which encodes Cx43 in GSCs. Reconstitution of Cx43 in GSCs inhibited their capacity of self-renewal, invasiveness, and tumorigenicity via influencing E-cadherin and its coding protein, which leads to changes in the expression of Wnt/beta-catenin targeting genes. Our results suggest that GSCs require the low expression of Cx43 for maintaining their malignant phenotype, and upregulation of Cx43 might be a potential strategy for treatment of malignant glioma. STEM CELLS 2012; 30:108-120.
C1 [Yu, Shi-Cang; Xiao, Hua-Liang; Jiang, Xue-Feng; Wang, Qing-Liang; Yang, Xiao-Jun; Ping, Yi-Fang; Duan, Jiang Jie; Jiang, Jian-Yong; Ye, Xian-Zong; Xu, Sen-Lin; Xin, Yang-Hong; Yao, Xiao-Hong; Chen, Jian-Hong; Wang, Bing; Zhang, Xia; Bian, Xiu-Wu] Third Mil Med Univ, Inst Pathol, Southwest Hosp, Chongqing 400038, Peoples R China.
   [Yu, Shi-Cang; Xiao, Hua-Liang; Jiang, Xue-Feng; Wang, Qing-Liang; Yang, Xiao-Jun; Ping, Yi-Fang; Duan, Jiang Jie; Jiang, Jian-Yong; Ye, Xian-Zong; Xu, Sen-Lin; Xin, Yang-Hong; Yao, Xiao-Hong; Chen, Jian-Hong; Wang, Bing; Zhang, Xia; Bian, Xiu-Wu] Third Mil Med Univ, SW Canc Ctr, Southwest Hosp, Chongqing 400038, Peoples R China.
   [Li, Yan] Third Mil Med Univ, Cent Lab, Southwest Hosp, Chongqing 400038, Peoples R China.
   [Chu, Wei-Hua] Third Mil Med Univ, Dept Neurosurg, Southwest Hosp, Chongqing 400038, Peoples R China.
   [Sun, Wei] Third Mil Med Univ, Cent Lab, Chongqing 400038, Peoples R China.
   [Wang, Ji Ming] NCI, Mol Immunoregulat Lab, Canc & Inflammat Program, Ctr Canc Res, Frederick, MD 21701 USA.
C3 Army Medical University; Army Medical University; Army Medical
   University; Army Medical University; Army Medical University; National
   Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
RP Bian, XW (通讯作者)，Third Mil Med Univ, Inst Pathol, Southwest Hosp, Chongqing 400038, Peoples R China.
EM bianxiuwu@263.net
RI Bian, Xiu-Wu/D-4736-2017; Li, Yan/O-7342-2016; Zhang, Xia/B-8152-2008;
   Jiang, Xuefeng/AAP-3315-2020; ye, xianzong/G-6079-2011; Wang,
   Binghui/Y-8424-2019
OI Li, Yan/0000-0002-2091-7313
FU National Basic Research Program of China (973 Program) [2010CB529403];
   National Natural Science Foundation of China (NSFC) [30725035, 30700863]
FX This study was supported by grants from National Basic Research Program
   of China (973 Program, No. 2010CB529403) and the National Natural
   Science Foundation of China (NSFC, Nos. 30725035 and 30700863).
CR Ale-Agha N, 2009, HEPATOLOGY, V50, P1567, DOI 10.1002/hep.23146
   Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717
   Avizienyte E, 2002, NAT CELL BIOL, V4, P632, DOI 10.1038/ncb829
   Baba T, 2009, ONCOGENE, V28, P209, DOI 10.1038/onc.2008.374
   Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694
   Chen JT, 2003, CLIN CANCER RES, V9, P4200
   Do JT, 2009, TRENDS PHARMACOL SCI, V30, P296, DOI 10.1016/j.tips.2009.03.003
   Eramo A, 2006, CELL DEATH DIFFER, V13, P1238, DOI 10.1038/sj.cdd.4401872
   Fearon ER, 2009, CANCER CELL, V16, P366, DOI 10.1016/j.ccr.2009.10.007
   Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007
   Fujimoto K, 1997, J CELL SCI, V110, P311
   Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364
   Giepmans BNG, 2004, CARDIOVASC RES, V62, P233, DOI 10.1016/j.cardiores.2003.12.009
   Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355
   Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100
   Hernandez-Blazquez FJ, 2001, EXP CELL RES, V270, P235, DOI 10.1006/excr.2001.5342
   Hervé JC, 2004, EUR BIOPHYS J BIOPHY, V33, P201, DOI 10.1007/s00249-003-0381-0
   Huang RP, 1998, CANCER RES, V58, P5089
   Huang RP, 1999, J SURG ONCOL, V70, P21, DOI 10.1002/(SICI)1096-9098(199901)70:1<21::AID-JSO4>3.3.CO;2-S
   Huang RP, 2001, INT J CANCER, V92, P130, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1165>3.3.CO;2-7
   Iacobas DA, 2003, PHYSIOL GENOMICS, V15, P177, DOI 10.1152/physiolgenomics.00062.2003
   Jean-Marc M, 2007, DRUG DISCOV TODAY, V4, P285
   Jinn Y, 2010, ANTICANCER RES, V30, P2271
   KANNO Y, 1984, EXP CELL RES, V152, P270, DOI 10.1016/0014-4827(84)90253-2
   Kardami E, 2007, PROG BIOPHYS MOL BIO, V94, P245, DOI 10.1016/j.pbiomolbio.2007.03.009
   Kase S, 2000, CLIN CANCER RES, V6, P4789
   Klarmann GJ, 2009, CLIN EXP METASTAS, V26, P433, DOI 10.1007/s10585-009-9242-2
   Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100
   Langlois S, 2010, CANCER RES, V70, P4222, DOI 10.1158/0008-5472.CAN-09-3281
   LAU AF, 1992, MOL BIOL CELL, V3, P865, DOI 10.1091/mbc.3.8.865
   Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030
   Lewis-Tuffin LJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013665
   Lin JHC, 2002, J NEUROSCI, V22, P4302, DOI 10.1523/JNEUROSCI.22-11-04302.2002
   Liu C, 2011, CLIN EXP MED, V11, P105, DOI 10.1007/s10238-010-0110-9
   LOEWENSTEIN WR, 1966, NATURE, V209, P1248, DOI 10.1038/2091248a0
   McDonough WS, 1999, INT J DEV NEUROSCI, V17, P601, DOI 10.1016/S0736-5748(99)00024-6
   McLachlan E, 2006, CANCER RES, V66, P9886, DOI 10.1158/0008-5472.CAN-05-4302
   Mesnil M, 2005, BBA-BIOMEMBRANES, V1719, P125, DOI 10.1016/j.bbamem.2005.11.004
   Mesnil M, 2002, BIOL CELL, V94, P493, DOI 10.1016/S0248-4900(02)00025-4
   Mosimann C, 2009, NAT REV MOL CELL BIO, V10, P276, DOI 10.1038/nrm2654
   Nambara C, 2007, J MEMBRANE BIOL, V217, P63, DOI 10.1007/s00232-007-9032-1
   Neijssen J, 2005, NATURE, V434, P83, DOI 10.1038/nature03290
   Neijssen J, 2007, PROG BIOPHYS MOL BIO, V94, P207, DOI 10.1016/j.pbiomolbio.2007.03.008
   Nicholson BJ, 2003, J CELL SCI, V116, P4479, DOI 10.1242/jcs.00821
   Orsulic S, 1999, J CELL SCI, V112, P1237
   Ping YF, 2011, STEM CELLS, V29, P888, DOI 10.1002/stem.650
   Pollard SM, 2009, CELL STEM CELL, V4, P568, DOI 10.1016/j.stem.2009.03.014
   Polyak K, 2006, NAT MED, V12, P296, DOI 10.1038/nm1379
   Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626
   Qin H, 2002, J BIOL CHEM, V277, P29132, DOI 10.1074/jbc.M200797200
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Ruch RJ, 1998, EXP LUNG RES, V24, P523, DOI 10.3109/01902149809087384
   Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339
   Salmaggi A, 2006, GLIA, V54, P850, DOI 10.1002/glia.20414
   Sawada K, 2008, CANCER RES, V68, P2329, DOI 10.1158/0008-5472.CAN-07-5167
   SCHMIDT R, 1989, J CELL PHYSIOL, V140, P281, DOI 10.1002/jcp.1041400213
   Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610
   Soroceanu L, 2001, GLIA, V33, P107, DOI 10.1002/1098-1136(200102)33:2<107::AID-GLIA1010>3.0.CO;2-4
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tabu K, 2008, CELL RES, V18, P1037, DOI 10.1038/cr.2008.270
   Tang B, 2011, MED ONCOL, V28, P502, DOI 10.1007/s12032-010-9492-5
   Trosko JE, 2004, ANN NY ACAD SCI, V1028, P192, DOI 10.1196/annals.1322.023
   Westhoff MA, 2008, ONCOGENE, V27, P5169, DOI 10.1038/onc.2008.148
   White TW, 2000, CURR BIOL, V10, pR685, DOI 10.1016/S0960-9822(00)00689-8
   Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076
   Yang BF, 2007, NAT MED, V13, P486, DOI 10.1038/nm1569
   Yi L, 2007, MODERN PATHOL, V20, P1061, DOI 10.1038/modpathol.3800942
   You HN, 2010, HEPATOLOGY, V51, P1635, DOI 10.1002/hep.23544
   Yu SC, 2008, CANCER LETT, V265, P124, DOI 10.1016/j.canlet.2008.02.010
   Yu SC, 2009, STEM CELL REV REP, V5, P66, DOI 10.1007/s12015-008-9047-8
   Yuan XP, 2004, ONCOGENE, V23, P9392, DOI 10.1038/sj.onc.1208311
   ZHU D, 1991, P NATL ACAD SCI USA, V88, P1883, DOI 10.1073/pnas.88.5.1883
   ZHU DG, 1992, P NATL ACAD SCI USA, V89, P10218, DOI 10.1073/pnas.89.21.10218
NR 76
TC 72
Z9 80
U1 0
U2 28
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1066-5099
J9 STEM CELLS
JI Stem Cells
PD FEB
PY 2012
VL 30
IS 2
BP 108
EP 120
DI 10.1002/stem.1685
PG 13
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 877UW
UT WOS:000299209200003
PM 22131169
OA Bronze
DA 2025-01-12
ER

PT J
AU Chang, J
   Varghese, DS
   Gillam, MC
   Peyton, M
   Modi, B
   Schiltz, RL
   Girard, L
   Martinez, ED
AF Chang, J.
   Varghese, D. S.
   Gillam, M. C.
   Peyton, M.
   Modi, B.
   Schiltz, R. L.
   Girard, L.
   Martinez, E. D.
TI Differential response of cancer cells to HDAC inhibitors trichostatin A
   and depsipeptide
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE trichostatin A; depsipeptide; HDAC inhibitors; cancer cell viability;
   drug sensitivity
ID HISTONE DEACETYLASE INHIBITORS; BRONCHIAL EPITHELIAL-CELLS; REFRACTORY
   SOLID TUMORS; LUNG-CANCER; ANTITUMOR-ACTIVITY; BREAST-CANCER; PHASE-I;
   EPIGENETIC THERAPY; UVEAL MELANOMA; ACETYLATION
AB BACKGROUND: Over the last decade, several drugs that inhibit class I and/or class II histone deacetylases (HDACs) have been identified, including trichostatin A, the cyclic depsipeptide FR901228 and the antibiotic apicidin. These compounds have had immediate application in cancer research because of their ability to reactivate aberrantly silenced tumour suppressor genes and/or block tumour cell growth. Although a number of HDAC inhibitors are being evaluated in preclinical cancer models and in clinical trials, little is known about the differences in their specific mechanism of action and about the unique determinants of cancer cell sensitivity to each of these inhibitors.
   METHODS: Using a combination of cell viability assays, HDAC enzyme activity measurements, western blots for histone modifications, microarray gene expression analysis and qRT-PCR, we have characterised differences in trichostatin A vs depsipeptide-induced phenotypes in lung cancer, breast cancer and skin cancer cells and in normal cells and have then expanded these studies to other HDAC inhibitors.
   RESULTS: Cell viability profiles across panels of lung cancer, breast cancer and melanoma cell lines showed distinct sensitivities to the pan-inhibitor TSA compared with the class 1 selective inhibitor depsipeptide. In several instances, the cell lines most sensitive to one inhibitor were most resistant to the other inhibitor, demonstrating these drugs act on at least some non-overlapping cellular targets. These differences were not explained by the HDAC selectivity of these inhibitors alone since apicidin, which is a class 1 selective compound similar to depsipeptide, also showed a unique drug sensitivity profile of its own. TSA had greater specificity for cancer vs normal cells compared with other HDAC inhibitors. In addition, at concentrations that blocked cancer cell viability, TSA effectively inhibited purified recombinant HDACs 1, 2 and 5 and moderately inhibited HDAC8, while depsipeptide did not inhibit the activity of purified HDACs in vitro but did in cellular extracts, suggesting a potentially indirect action of this drug. Although both depsipeptide and TSA increased levels of histone acetylation in cancer cells, only depsipeptide decreased global levels of transcriptionally repressive histone methylation marks. Analysis of gene expression profiles of an isogenic cell line pair that showed discrepant sensitivity to depsipeptide, suggested that resistance to this inhibitor may be mediated by increased expression of multidrug resistance genes triggered by exposure to chemotherapy as was confirmed by verapamil studies.
   CONCLUSION: Although generally thought to have similar activities, the HDAC modulators trichostatin A and depsipeptide demonstrated distinct phenotypes in the inhibition of cancer cell viability and of HDAC activity, in their selectivity for cancer vs normal cells, and in their effects on histone modifications. These differences in mode of action may bear on the future therapeutic and research application of these inhibitors. British Journal of Cancer (2012) 106, 116-125. doi:10.1038/bjc.2011.532 www.bjcancer.com Published online 8 December 2011 (C) 2012 Cancer Research UK
C1 [Chang, J.; Varghese, D. S.; Gillam, M. C.; Peyton, M.; Modi, B.; Girard, L.; Martinez, E. D.] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA.
   [Schiltz, R. L.] NCI, Lab Receptor Biol & Gene Express, NIH, Bethesda, MD 20892 USA.
   [Girard, L.; Martinez, E. D.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center Dallas; National Institutes of Health (NIH) - USA; NIH National
   Cancer Institute (NCI); University of Texas System; University of Texas
   Southwestern Medical Center Dallas
RP Martinez, ED (通讯作者)，Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.
EM elisabeth.martinez@utsouthwestern.edu
FU NCI [K22CA11871703, R01CA12526901]; Galderma; Doctors Cancer Foundation
FX We are grateful to Drs John Minna and Adi Gazdar for sharing a large
   collection of non- small cell lung cancer cells and bronchial epithelial
   cells, and to Shelley Sheridan for immortalising epithelial cells. We
   thank MK Hyland for technical assistance with MDR western blots. We are
   indebted to Dr David Schrump for the generous gift of depsipeptide.
   Human breast cancer cells and immortalised mammary epithelial cells were
   the kind gift of Drs Cheryl Lewis and David Euhus. Melanoma cell lines
   were received from the NCI and uveal melanoma lines were generously
   provided by Jerry Niederkorn. This study was supported by the NCI
   (K22CA11871703 and R01CA12526901 to EDM), by Galderma (grant to EDM) and
   by the Doctors Cancer Foundation (Nolan Miller Lung Cancer grant to
   EDM).
CR Arce C, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000098
   Bieliauskas AV, 2008, CHEM SOC REV, V37, P1402, DOI 10.1039/b703830p
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Candelaria M, 2007, ANN ONCOL, V18, P1529, DOI 10.1093/annonc/mdm204
   Cantor JP, 2007, INT J CANCER, V120, P24, DOI 10.1002/ijc.22073
   Chen CS, 2005, J BIOL CHEM, V280, P38879, DOI 10.1074/jbc.M505733200
   Clapier CR, 2009, ANNU REV BIOCHEM, V78, P273, DOI 10.1146/annurev.biochem.77.062706.153223
   Crabb SJ, 2008, BIOCHEM PHARMACOL, V76, P463, DOI 10.1016/j.bcp.2008.06.004
   Di Gennaro E, 2004, AMINO ACIDS, V26, P435, DOI 10.1007/s00726-004-0087-3
   Duvic M, 2007, EXPERT OPIN INV DRUG, V16, P1111, DOI 10.1517/13543784.16.7.1111
   Ekwall K, 2005, TRENDS GENET, V21, P608, DOI 10.1016/j.tig.2005.08.009
   Facchetti F, 2004, APOPTOSIS, V9, P573, DOI 10.1023/B:APPT.0000038036.31271.50
   Fischle W, 2001, BIOCHEM CELL BIOL, V79, P337, DOI 10.1139/bcb-79-3-337
   Forbes SA, 2010, NUCLEIC ACIDS RES, V38, pD652, DOI 10.1093/nar/gkp995
   Furumai R, 2002, CANCER RES, V62, P4916
   Itoh Y, 2008, CURR PHARM DESIGN, V14, P529
   Jones P, 2008, CURR PHARM DESIGN, V14, P545, DOI 10.2174/138161208783885317
   Kelly WK, 2005, NAT CLIN PRACT ONCOL, V2, P150, DOI 10.1038/ncponc0106
   Klisovic DD, 2005, MELANOMA RES, V15, P147, DOI 10.1097/00008390-200506000-00002
   Lee KW, 2006, ANTICANCER RES, V26, P3429
   Lin HY, 2006, MED RES REV, V26, P397, DOI 10.1002/med.20056
   Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938
   Marshall JC, 2009, MOL CELL BIOCHEM, V329, P115, DOI 10.1007/s11010-009-0116-3
   McLaughlin F, 2004, BIOCHEM PHARMACOL, V68, P1139, DOI 10.1016/j.bcp.2004.05.034
   Miyanaga A, 2008, MOL CANCER THER, V7, P1923, DOI 10.1158/1535-7163.MCT-07-2140
   Mukhopadhyay NK, 2006, ANN THORAC SURG, V81, P1034, DOI 10.1016/j.athoracsur.2005.06.059
   Peart MJ, 2003, CANCER RES, V63, P4460
   Phelps RM, 1996, J CELL BIOCHEM, P32
   Prince HM, 2009, CLIN CANCER RES, V15, P3958, DOI 10.1158/1078-0432.CCR-08-2785
   Qiu Y, 2006, MOL CELL, V22, P669, DOI 10.1016/j.molcel.2006.04.019
   Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703
   Ren DH, 2004, INVEST OPHTH VIS SCI, V45, P1162, DOI 10.1167/iovs.03-1285
   Riester D, 2007, APPL MICROBIOL BIOT, V75, P499, DOI 10.1007/s00253-007-0912-1
   Rocca A, 2009, BRIT J CANCER, V100, P28, DOI 10.1038/sj.bjc.6604817
   Ryan QC, 2005, J CLIN ONCOL, V23, P3912, DOI 10.1200/JCO.2005.02.188
   Sadoul K, 2008, BIOCHIMIE, V90, P306, DOI 10.1016/j.biochi.2007.06.009
   Sandor V, 2002, CLIN CANCER RES, V8, P718
   Sato M, 2006, CANCER RES, V66, P2116, DOI 10.1158/0008-5472.CAN-05-2521
   Schrump David S, 2002, Clin Lung Cancer, V4, P186, DOI 10.3816/CLC.2002.n.027
   Schultz BE, 2004, BIOCHEMISTRY-US, V43, P11083, DOI 10.1021/bi0494471
   Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486
   Stimson L, 2009, CANCER LETT, V280, P177, DOI 10.1016/j.canlet.2009.03.016
   Takai N, 2010, J ONCOL, V2010, DOI 10.1155/2010/458431
   Vigushin DM, 2001, CLIN CANCER RES, V7, P971
   Villar-Garea A, 2004, INT J CANCER, V112, P171, DOI 10.1002/ijc.20372
   Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016
   Wu LP, 2008, MOL CELL BIOL, V28, P3219, DOI 10.1128/MCB.01516-07
   Xiao JJ, 2003, RAPID COMMUN MASS SP, V17, P757, DOI 10.1002/rcm.976
   Zhang W, 2009, J THORAC ONCOL, V4, P161, DOI 10.1097/JTO.0b013e318194fae7
   Zhang XH, 2008, CANCER BIOL THER, V7, P1390, DOI 10.4161/cbt.7.9.6415
   Zhao Y, 2006, MOL CELL BIOL, V26, P2782, DOI 10.1128/MCB.26.7.2782-2790.2006
   Zhong S, 2007, ONCOGENE, V26, P2621, DOI 10.1038/sj.onc.1210041
NR 52
TC 74
Z9 90
U1 0
U2 22
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD JAN 3
PY 2012
VL 106
IS 1
BP 116
EP 125
DI 10.1038/bjc.2011.532
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 877HL
UT WOS:000299168300017
PM 22158273
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Helbing, CC
   Wagner, MJ
   Pettem, K
   Johnston, J
   Heimeier, RA
   Veldhoen, N
   Jirik, FR
   Shi, YB
   Browder, LW
AF Helbing, Caren C.
   Wagner, Mary J.
   Pettem, Katherine
   Johnston, Jill
   Heimeier, Rachel A.
   Veldhoen, Nik
   Jirik, Frank R.
   Shi, Yun-Bo
   Browder, Leon W.
TI Modulation of Thyroid Hormone-Dependent Gene Expression in <i>Xenopus
   laevis</i> by INhibitor of Growth (ING) Proteins
SO PLOS ONE
LA English
DT Article
ID PHD FINGER; BREAST-CANCER; PLANT HOMEODOMAIN; TUMOR-SUPPRESSOR; AXIS
   DISRUPTION; HISTONE H3; METAMORPHOSIS; RECEPTOR; FAMILY; CHROMATIN
AB Background: INhibitor of Growth (ING) proteins belong to a large family of plant homeodomain finger-containing proteins important in epigenetic regulation and carcinogenesis. We have previously shown that ING1 and ING2 expression is regulated by thyroid hormone (TH) during metamorphosis of the Xenopus laevis tadpole. The present study investigates the possibility that ING proteins modulate TH action.
   Methodology/Principal Findings: Tadpoles expressing a Xenopus ING2 transgene (Trans(ING2)) were significantly smaller than tadpoles not expressing the transgene (Trans(GFP)). When exposed to 10 nM 3,5,3'-triiodothyronine (T(3)), premetamorphic Trans(ING2) tadpoles exhibited a greater reduction in tail, head, and brain areas, and a protrusion of the lower jaw than T(3)-treated Trans(GFP) tadpoles. Quantitative real time polymerase chain reaction (QPCR) demonstrated elevated TH receptor beta (TR beta) and TH/bZIP transcript levels in Trans(ING2) tadpole tails compared to Trans(GFP) tadpoles while TR alpha mRNAs were unaffected. In contrast, no difference in TR alpha, TR beta or insulin-like growth factor (IGF2) mRNA abundance was observed in the brain between Trans(ING2) and Trans(GFP) tadpoles. All of these transcripts, except for TR alpha mRNA in the brain, were inducible by the hormone in both tissues. Oocyte transcription assays indicated that ING proteins enhanced TR-dependent, T(3)-induced TR beta gene promoter activity. Examination of endogenous T(3)-responsive promoters (TR beta and TH/bZIP) in the tail by chromatin immunoprecipitation assays showed that ING proteins were recruited to TRE-containing regions in T(3)-dependent and independent ways, respectively. Moreover, ING and TR proteins coimmunoprecipitated from tail protein homogenates derived from metamorphic climax animals.
   Conclusions/Significance: We show for the first time that ING proteins modulate TH-dependent responses, thus revealing a novel role for ING proteins in hormone signaling. This has important implications for understanding hormone influenced disease states and suggests that the induction of ING proteins may facilitate TR function during metamorphosis in a tissue-specific manner.
C1 [Helbing, Caren C.; Wagner, Mary J.; Pettem, Katherine; Veldhoen, Nik] Univ Victoria, Dept Biochem & Microbiol, Victoria, BC, Canada.
   [Johnston, Jill; Jirik, Frank R.; Browder, Leon W.] Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB, Canada.
   [Heimeier, Rachel A.; Shi, Yun-Bo] NICHHD, Sect Mol Morphogenesis, Lab Gene Regulat & Dev, Program Cell Regulat & Metab,NIH, Bethesda, MD 20892 USA.
   [Jirik, Frank R.] Univ Calgary, McCaig Inst Bone & Joint Hlth, Calgary, AB, Canada.
C3 University of Victoria; University of Calgary; National Institutes of
   Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of
   Child Health & Human Development (NICHD); University of Calgary
RP Helbing, CC (通讯作者)，Univ Victoria, Dept Biochem & Microbiol, Victoria, BC, Canada.
EM chelbing@uvic.ca
RI Shi, Yubing/AAG-8554-2019
OI Helbing, Caren/0000-0002-8861-1070; Shi, Yun-Bo/0000-0002-6330-0639
FU Natural Sciences and Engineering Research Council (NSERC); National
   Institute of Child Health and Human Development, NIH; NSERC-PGSM;
   Michael Smith Foundation for Health Research (MSFHR); PGSD
FX This work was funded by Natural Sciences and Engineering Research
   Council (NSERC) Discovery grants to CCH and LWB, and also in part by the
   Intramural Research Program of the National Institute of Child Health
   and Human Development, NIH (YBS). MJW was recipient of NSERC-PGSM and
   PGSD scholarships and a Michael Smith Foundation for Health Research
   (MSFHR) trainee award. CCH is a past MSFHR scholar and recipient of a
   NSERC University Faculty Award; and FRJ held a Canada Tier I Research
   Chair Award. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR ALMOUZNI G, 1990, NUCLEIC ACIDS RES, V18, P5767, DOI 10.1093/nar/18.19.5767
   Amaya E, 1999, METH MOL B, V97, P393, DOI 10.1385/1-59259-270-8:393
   [Anonymous], 2000, Amphibian Metamorphosis: From Morphology to Molecular biology
   [Anonymous], 1956, NORMAL TABLE XENOPUS
   Bartke T, 2010, CELL, V143, P470, DOI 10.1016/j.cell.2010.10.012
   Bienz M, 2006, TRENDS BIOCHEM SCI, V31, P35, DOI 10.1016/j.tibs.2005.11.001
   Bilesimo P, 2011, MOL ENDOCRINOL, V25, P225, DOI 10.1210/me.2010-0269
   Boland D, 2000, HYBRIDOMA, V19, P161, DOI 10.1089/02724570050031202
   Bua DJ, 2009, CURR DRUG TARGETS, V10, P418, DOI 10.2174/138945009788185112
   Buchholz DR, 2005, J BIOL CHEM, V280, P41222, DOI 10.1074/jbc.M509593200
   Champagne KS, 2009, CURR DRUG TARGETS, V10, P432, DOI 10.2174/138945009788185040
   Cordera F, 2006, SEMIN ONCOL, V33, P631, DOI 10.1053/j.seminoncol.2006.08.020
   Das B, 2006, DEV BIOL, V291, P342, DOI 10.1016/j.ydbio.2005.12.032
   ELICEIRI BP, 1994, J BIOL CHEM, V269, P24459
   Ellerhorst JA, 2003, ONCOL REP, V10, P1317
   Garske AL, 2010, NAT CHEM BIOL, V6, P283, DOI [10.1038/NCHEMBIO.319, 10.1038/nchembio.319]
   González-Sancho JM, 2003, CANCER LETT, V192, P121, DOI 10.1016/S0304-3835(02)00614-6
   Gunduz M, 2009, CURR DRUG TARGETS, V10, P465, DOI 10.2174/138945009788185086
   Havis E, 2003, EMBO REP, V4, P883, DOI 10.1038/sj.embor.embor908
   He GHY, 2005, MOL BIOL EVOL, V22, P104, DOI 10.1093/molbev/msh256
   Helbing CC, 2007, AQUAT TOXICOL, V82, P227, DOI 10.1016/j.aquatox.2007.02.013
   Helbing CC, 2007, AQUAT TOXICOL, V82, P215, DOI 10.1016/j.aquatox.2007.02.014
   Helbing CC, 1997, CANCER RES, V57, P1255
   Kataoka H, 2003, CANCER RES, V63, P5785
   Kichina JV, 2006, ONCOGENE, V25, P857, DOI 10.1038/sj.onc.1209118
   LELOUP J, 1977, CR ACAD SCI D NAT, V284, P2261
   Maher Stacey K, 2009, Curr Drug Targets, V10, P392
   Martin DGE, 2006, MOL CELL BIOL, V26, P7871, DOI 10.1128/MCB.00573-06
   Menéndez C, 2009, CURR DRUG TARGETS, V10, P406, DOI 10.2174/138945009788185077
   Peña PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814
   Peña PV, 2009, MAGN RESON CHEM, V47, P352, DOI 10.1002/mrc.2390
   Rotondi M, J CLIN ENDOCRINOL ME, V96, P344
   Russo J, 2006, J STEROID BIOCHEM, V102, P89, DOI 10.1016/j.jsbmb.2006.09.004
   Saksouk N, 2009, MOL CELL, V33, P257, DOI 10.1016/j.molcel.2009.01.007
   Shah S, 2009, CURR DRUG TARGETS, V10, P385, DOI 10.2174/138945009788185103
   Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835
   Soliman MA, 2007, TRENDS BIOCHEM SCI, V32, P509, DOI 10.1016/j.tibs.2007.08.006
   Sparrow D B, 2000, Nucleic Acids Res, V28, pE12, DOI 10.1093/nar/28.4.e12
   Tomita A, 2004, MOL CELL BIOL, V24, P3337, DOI 10.1128/MCB.24.8.3337-3346.2004
   Toyama T, 2003, J STEROID BIOCHEM, V87, P57, DOI 10.1016/S0960-0760(03)00388-1
   Turken O, 2003, BREAST CANCER RES, V5, pR110, DOI 10.1186/bcr609
   Unoki M, 2009, CURR DRUG TARGETS, V10, P442, DOI 10.2174/138945009788185059
   Unoki M, 2009, CANCER SCI, V100, P1173, DOI 10.1111/j.1349-7006.2009.01183.x
   Veldhoen N, 2002, DEV DYNAM, V225, P457, DOI 10.1002/dvdy.10175
   Wagner MJ, 2008, BBA-GENE REGUL MECH, V1779, P152, DOI 10.1016/j.bbagrm.2007.12.002
   Wagner MJ, 2005, GEN COMP ENDOCR, V144, P38, DOI 10.1016/j.ygcen.2005.04.008
   Wagner MJ, 2001, J BIOL CHEM, V276, P47013, DOI 10.1074/jbc.M106965200
   Walzak AA, 2008, EXP CELL RES, V314, P273, DOI 10.1016/j.yexcr.2007.07.029
   Wang GG, 2009, NATURE, V459, P847, DOI 10.1038/nature08036
   WONG JM, 1995, J BIOL CHEM, V270, P18479, DOI 10.1074/jbc.270.31.18479
   WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696
   Yen PM, 2006, MOL CELL ENDOCRINOL, V246, P121, DOI 10.1016/j.mce.2005.11.030
NR 52
TC 4
Z9 6
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 5
PY 2011
VL 6
IS 12
AR e28658
DI 10.1371/journal.pone.0028658
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 863NX
UT WOS:000298172800054
PM 22163049
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Parasramka, MA
   Ho, E
   Williams, DE
   Dashwood, RH
AF Parasramka, Mansi A.
   Ho, Emily
   Williams, David E.
   Dashwood, Roderick H.
TI MicroRNAs, diet, and cancer: New mechanistic insights on the epigenetic
   actions of phytochemicals
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE microRNA; chemoprevention; epigenetics; natural agents
ID POLYUNSATURATED FATTY-ACIDS; TO-MESENCHYMAL TRANSITION; HUMAN
   BREAST-CANCER; PROSTATE-CANCER; DOWN-REGULATION; HISTONE DEACETYLASE;
   GENE-EXPRESSION; MESSENGER-RNAS; LUNG-CANCER; COLORECTAL-CANCER
AB There is growing interest in the epigenetic mechanisms that impact human health and disease, including the role of microRNAs (miRNAs). These small (1825 nucleotide), evolutionarily conserved, non-coding RNA molecules regulate gene expression in a post-transcriptional manner. Several well-orchestered regulatory mechanisms involving miRNAs have been identified, with the potential to target multiple signaling pathways dysregulated in cancer. Since the initial discovery of miRNAs, there has been progress towards therapeutic applications, and several natural and synthetic chemopreventive agents also have been evaluated as modulators of miRNA expression in different cancer types. This review summarizes the most up-to-date information related to miRNA biogenesis, and critically evaluates proposed miRNA regulatory mechanisms in relation to cancer signaling pathways, as well as other epigenetic modifications (DNA methylation patterns, histone marks) and their involvement in drug resistance. We also discuss the mechanisms by which dietary factors regulate miRNA expression, in the context of chemoprevention versus therapy. (c) 2011 Wiley Periodicals, Inc.
C1 [Parasramka, Mansi A.; Williams, David E.; Dashwood, Roderick H.] Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA.
   [Parasramka, Mansi A.; Ho, Emily; Williams, David E.; Dashwood, Roderick H.] Oregon State Univ, Linus Pauling Inst, Corvallis, OR 97331 USA.
   [Ho, Emily] Oregon State Univ, Dept Nutr & Exercise Sci, Corvallis, OR 97331 USA.
C3 Oregon State University; Oregon State University; Oregon State
   University
RP Parasramka, MA (通讯作者)，503 Weniger Hall,Monroe St, Corvallis, OR 97331 USA.
RI Dashwood, Roderick/AAF-2025-2020
OI Dashwood, Roderick/0000-0003-0351-4034
FU National Cancer Institute [CA090890, CA122959, CA65525, CA122906,
   CA80176]; National Institute of Environmental Health Sciences [T32
   ES007060]
FX We thank Mr. Animesh Koya for assistance with the art work. Studies in
   the authors' laboratories are supported by National Cancer Institute
   grants CA090890, CA122959, CA65525, CA122906, and CA80176, and by Award
   T32 ES007060 from the National Institute of Environmental Health
   Sciences. The content of this review is solely the responsibility of the
   authors and does not necessarily represent the official views of the
   National Institutes of Health.
CR Aagaard L, 2007, ADV DRUG DELIVER REV, V59, P75, DOI 10.1016/j.addr.2007.03.005
   Adam L, 2009, CLIN CANCER RES, V15, P5060, DOI 10.1158/1078-0432.CCR-08-2245
   Akao Y, 2006, BIOL PHARM BULL, V29, P903, DOI 10.1248/bpb.29.903
   Ali S, 2010, CANCER RES, V70, P3606, DOI 10.1158/0008-5472.CAN-09-4598
   Babiarz JE, 2008, GENE DEV, V22, P2773, DOI 10.1101/gad.1705308
   Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242
   Bandres E, 2009, INT J CANCER, V125, P2737, DOI 10.1002/ijc.24638
   Bao B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017850
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Berezikov E, 2005, CELL, V120, P21, DOI 10.1016/j.cell.2004.12.031
   Berezikov E, 2007, MOL CELL, V28, P328, DOI 10.1016/j.molcel.2007.09.028
   Berezikov E, 2006, NAT GENET, V38, pS2, DOI 10.1038/ng1794
   Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995
   Bhattacharyya SN, 2006, CELL, V125, P1111, DOI 10.1016/j.cell.2006.04.031
   Boese Q, 2005, METHOD ENZYMOL, V392, P73, DOI 10.1016/S0076-6879(04)92005-8
   Bohnsack MT, 2004, RNA, V10, P185, DOI 10.1261/rna.5167604
   Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068
   Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880
   Borchert GM, 2006, NAT STRUCT MOL BIOL, V13, P1097, DOI 10.1038/nsmb1167
   Bourguignon LYW, 2009, J BIOL CHEM, V284, P26533, DOI 10.1074/jbc.M109.027466
   Boyerinas B, 2010, ENDOCR-RELAT CANCER, V17, pF19, DOI 10.1677/ERC-09-0184
   Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085
   Brower V, 2011, NATURE, V471, pS12, DOI 10.1038/471S12a
   Brueckner B, 2007, CANCER RES, V67, P1419, DOI 10.1158/0008-5472.CAN-06-4074
   Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800
   Caudy AA, 2003, NATURE, V425, P411, DOI 10.1038/nature01956
   Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010
   Cheloufi S, 2010, NATURE, V465, P584, DOI 10.1038/nature09092
   Chiarantini L, 2005, J CONTROL RELEASE, V109, P24, DOI 10.1016/j.jconrel.2005.09.013
   Chirila TV, 2002, BIOMATERIALS, V23, P321, DOI 10.1016/S0142-9612(01)00125-9
   Choi WY, 2007, SCIENCE, V318, P271, DOI 10.1126/science.1147535
   Chuang CK, 2007, CANCER DETECT PREV, V31, P59, DOI 10.1016/j.cdp.2006.11.001
   Chuang JC, 2007, PEDIATR RES, V61, p24R, DOI 10.1203/pdr.0b013e3180457684
   Clarke JD, 2008, CANCER LETT, V269, P291, DOI 10.1016/j.canlet.2008.04.018
   Cochrane DR, 2009, MOL CANCER THER, V8, P1055, DOI 10.1158/1535-7163.MCT-08-1046
   Corney DC, 2007, CANCER RES, V67, P8433, DOI 10.1158/0008-5472.CAN-07-1585
   Czech B, 2009, MOL CELL, V36, P445, DOI 10.1016/j.molcel.2009.09.028
   Dashwood RH, 1999, ONCOL REP, V6, P277
   Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655
   David L, 2008, CIRC RES, V102, P914, DOI 10.1161/CIRCRESAHA.107.165530
   Davidson LA, 2009, CARCINOGENESIS, V30, P2077, DOI 10.1093/carcin/bgp245
   Davis CD, 2008, NUTR REV, V66, P477, DOI 10.1111/j.1753-4887.2008.00080.x
   Denli AM, 2004, NATURE, V432, P231, DOI 10.1038/nature03049
   Dias N, 2002, MOL CANCER THER, V1, P347
   Duursma AM, 2008, RNA, V14, P872, DOI 10.1261/rna.972008
   Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079
   Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Eulalio A, 2007, MOL CELL BIOL, V27, P3970, DOI 10.1128/MCB.00128-07
   Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104
   Fish JE, 2008, DEV CELL, V15, P272, DOI 10.1016/j.devcel.2008.07.008
   Forman JJ, 2008, P NATL ACAD SCI USA, V105, P14879, DOI 10.1073/pnas.0803230105
   Friedman JM, 2009, CANCER RES, V69, P2623, DOI 10.1158/0008-5472.CAN-08-3114
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08
   Gaedicke S, 2008, FEBS LETT, V582, P3542, DOI 10.1016/j.febslet.2008.09.032
   Garofalo M, 2008, ONCOGENE, V27, P3845, DOI 10.1038/onc.2008.6
   Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014
   Garzon R, 2007, ONCOGENE, V26, P4148, DOI 10.1038/sj.onc.1210186
   Garzon R, 2009, BLOOD, V114, P5331, DOI 10.1182/blood-2009-03-211938
   Gaur A, 2007, CANCER RES, V67, P2456, DOI 10.1158/0008-5472.CAN-06-2698
   Ghildiyal M, 2010, RNA, V16, P43, DOI 10.1261/rna.1972910
   Giovannetti E, 2010, CANCER RES, V70, P4528, DOI 10.1158/0008-5472.CAN-09-4467
   Gopinath B, 2011, AM J CLIN NUTR, V93, P1073, DOI 10.3945/ajcn.110.009977
   Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120
   Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952
   Gumireddy K, 2008, ANGEW CHEM INT EDIT, V47, P7482, DOI 10.1002/anie.200801555
   Hatley ME, 2010, CANCER CELL, V18, P282, DOI 10.1016/j.ccr.2010.08.013
   Hatziapostolou M, 2011, CELL MOL LIFE SCI, V68, P1681, DOI 10.1007/s00018-010-0624-z
   Hausser J, 2009, GENOME RES, V19, P2009, DOI 10.1101/gr.091181.109
   He L, 2007, NAT REV CANCER, V7, P819, DOI 10.1038/nrc2232
   Higdon JV, 2007, PHARMACOL RES, V55, P224, DOI 10.1016/j.phrs.2007.01.009
   Huang J, 2010, CURR DRUG TARGE 1215, pEpub
   Huse JT, 2009, GENE DEV, V23, P1327, DOI 10.1101/gad.1777409
   Hutvágner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961
   Hwang JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010630
   Iorio MV, 2009, CANCER RES, V69, P2195, DOI 10.1158/0008-5472.CAN-08-2920
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Izzotti A, 2010, CARCINOGENESIS, V31, P894, DOI 10.1093/carcin/bgq037
   Izzotti A, 2010, CANCER PREV RES, V3, P62, DOI 10.1158/1940-6207.CAPR-09-0202
   Izzotti A, 2009, FASEB J, V23, P806, DOI 10.1096/fj.08-121384
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Ji JF, 2010, J HEPATOL, V52, P690, DOI 10.1016/j.jhep.2009.12.025
   Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014
   Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678
   Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801
   Kim J, 2007, SCIENCE, V317, P1220, DOI 10.1126/science.1140481
   Kiriakidou M, 2007, CELL, V129, P1141, DOI 10.1016/j.cell.2007.05.016
   Kotani A, 2009, BLOOD, V114, P4169, DOI 10.1182/blood-2008-12-191619
   Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536
   Kumar A, 2010, CRIT REV THER DRUG, V27, P279, DOI 10.1615/CritRevTherDrugCarrierSyst.v27.i4.10
   Kumar MS, 2008, P NATL ACAD SCI USA, V105, P3903, DOI 10.1073/pnas.0712321105
   Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003
   Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209
   Kutay H, 2006, J CELL BIOCHEM, V99, P671, DOI 10.1002/jcb.20982
   Lambert JD, 2010, ARCH BIOCHEM BIOPHYS, V501, P65, DOI 10.1016/j.abb.2010.06.013
   Lambertz I, 2010, CELL DEATH DIFFER, V17, P633, DOI 10.1038/cdd.2009.202
   Lanford RE, 2010, SCIENCE, V327, P198, DOI 10.1126/science.1178178
   Larsen CA, 2010, PHARMACOL RES, V62, P457, DOI 10.1016/j.phrs.2010.07.010
   Le XF, 2010, CANCER MICROENVIRON, V3, P137, DOI 10.1007/s12307-010-0037-4
   Lee DY, 2007, P NATL ACAD SCI USA, V104, P20350, DOI 10.1073/pnas.0706901104
   Lee JI, 2009, CANCER PREV RES, V2, P683, DOI 10.1158/1940-6207.CAPR-09-0047
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957
   Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385
   Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3
   Li Cheng-Mei, 2004, Yichuan, V26, P133
   Li Y, 2009, BRAIN RES, V1286, P13, DOI 10.1016/j.brainres.2009.06.053
   Li YW, 2010, CANCER RES, V70, P1486, DOI 10.1158/0008-5472.CAN-09-2792
   Li YW, 2009, CANCER RES, V69, P6704, DOI 10.1158/0008-5472.CAN-09-1298
   Liu JD, 2005, NAT CELL BIOL, V7, P719, DOI 10.1038/ncb1274
   Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lu M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003420
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   Lujambio A, 2007, CELL CYCLE, V6, P1455
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024
   Majid S, 2010, CANCER RES, V70, P2809, DOI 10.1158/0008-5472.CAN-09-4176
   Maniataki E, 2005, GENE DEV, V19, P2979, DOI 10.1101/gad.1384005
   Marsit CJ, 2006, CANCER RES, V66, P10843, DOI 10.1158/0008-5472.CAN-06-1894
   Mathonnet G, 2007, SCIENCE, V317, P1764, DOI 10.1126/science.1146067
   Mavrakis KJ, 2010, NAT CELL BIOL, V12, P372, DOI 10.1038/ncb2037
   Michelfelder S, 2009, ADV GENET, V67, P29, DOI 10.1016/S0065-2660(09)67002-4
   Mohri T, 2009, INT J CANCER, V125, P1328, DOI 10.1002/ijc.24459
   Moriyama T, 2009, MOL CANCER THER, V8, P1067, DOI 10.1158/1535-7163.MCT-08-0592
   Motoyama K, 2008, CLIN CANCER RES, V14, P2334, DOI 10.1158/1078-0432.CCR-07-4667
   Nian H, 2009, CARCINOGENESIS, V30, P1416, DOI 10.1093/carcin/bgp147
   Noonan EJ, 2009, ONCOGENE, V28, P1714, DOI 10.1038/onc.2009.19
   O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677
   Okamura K, 2009, MOL CELL, V36, P431, DOI 10.1016/j.molcel.2009.09.027
   OKUDA T, 1989, PLANTA MED, P117, DOI 10.1055/s-2006-961902
   Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001
   Pan XA, 2010, CANCER BIOL THER, V10, P1224, DOI 10.4161/cbt.10.12.14252
   Pappa G, 2006, MUTAT RES-FUND MOL M, V599, P76, DOI 10.1016/j.mrfmmm.2006.01.007
   Parker LP, 2009, EUR J GYNAECOL ONCOL, V30, P616
   Peng XJ, 2010, J CELL BIOCHEM, V110, P1324, DOI 10.1002/jcb.22646
   Persson H, 2011, CANCER RES, V71, P78, DOI 10.1158/0008-5472.CAN-10-1869
   Peter ME, 2010, CELL STEM CELL, V6, P4, DOI 10.1016/j.stem.2009.12.006
   Pillai RS, 2007, TRENDS CELL BIOL, V17, P118, DOI 10.1016/j.tcb.2006.12.007
   Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076
   Preall JB, 2005, CELL, V123, P543, DOI 10.1016/j.cell.2005.11.006
   Reuter S, 2011, GENES NUTR, V6, P93, DOI 10.1007/s12263-011-0222-1
   Roccaro AM, 2009, BLOOD, V113, P6669, DOI 10.1182/blood-2009-01-198408
   Rosi NL, 2006, SCIENCE, V312, P1027, DOI 10.1126/science.1125559
   Rossi Annalisa, 2010, BMC Res Notes, V3, P24, DOI 10.1186/1756-0500-3-24
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Sang S, 2011, PHARM RES       0301
   Sarkar FH, 2010, DRUG RESIST UPDATE, V13, P57, DOI 10.1016/j.drup.2010.02.001
   Sarveswaran S, 2010, INT J ONCOL, V36, P1419, DOI 10.3892/ijo_00000627
   Sato F, 2011, FEBS J, V278, P1598, DOI 10.1111/j.1742-4658.2011.08089.x
   Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425
   Scott GK, 2006, CANCER RES, V66, P1277, DOI 10.1158/0008-5472.CAN-05-3632
   Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228
   Shan SW, 2009, NAT CELL BIOL, V11, P1031, DOI 10.1038/ncb1917
   Shao NY, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-409
   Shin S, 2009, INT J ONCOL, V35, P1343, DOI 10.3892/ijo_00000452
   Slattery ML, 2011, GENE CHROMOSOME CANC, V50, P196, DOI 10.1002/gcc.20844
   Stark A, 2007, NATURE, V450, P219, DOI 10.1038/nature06340
   Sun M, 2008, MOL CANCER THER, V7, P464, DOI 10.1158/1535-7163.MCT-07-2272
   Sun QM, 2009, ONCOL REP, V22, P563, DOI 10.3892/or_00000472
   Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5
   Tagawa H, 2005, LEUKEMIA, V19, P2013, DOI 10.1038/sj.leu.2403942
   Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Taylor CK, 2009, NUTR REV, V67, P398, DOI 10.1111/j.1753-4887.2009.00213.x
   Thakur VS, 2011, CURR PHARM BIOT 0405
   Tili E, 2010, BIOCHEM PHARMACOL, V80, P2057, DOI 10.1016/j.bcp.2010.07.003
   Tili E, 2010, CARCINOGENESIS, V31, P1561, DOI 10.1093/carcin/bgq143
   Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325
   Tsai KW, 2011, INT J CANC      0106
   Tsang WP, 2010, J NUTR BIOCHEM, V21, P140, DOI 10.1016/j.jnutbio.2008.12.003
   Tzur G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003726
   Wakiyama M, 2007, GENE DEV, V21, P1857, DOI 10.1101/gad.1566707
   Wang B, 2010, ONCOGENE, V29, P1787, DOI 10.1038/onc.2009.468
   Wang H, 2008, CANCER CELL, V14, P369, DOI 10.1016/j.ccr.2008.10.006
   Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002
   Wang XN, 2009, CELL CYCLE, V8, P736, DOI 10.4161/cc.8.5.7870
   Weiler J, 2006, GENE THER, V13, P496, DOI 10.1038/sj.gt.3302654
   Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998
   Wen XY, 2009, PHYTOTHER RES, V23, P778, DOI 10.1002/ptr.2616
   White RWD, 2009, UROL ONCOL-SEMIN ORI, V27, P307, DOI 10.1016/j.urolonc.2009.01.004
   WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4
   Williams CD, 2011, NUTR RES, V31, P1, DOI 10.1016/j.nutres.2011.01.002
   Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228
   Xia HP, 2009, BRAIN RES, V1269, P158, DOI 10.1016/j.brainres.2009.02.037
   Xiao JN, 2007, J CELL PHYSIOL, V212, P285, DOI 10.1002/jcp.21062
   Xiong YJ, 2010, HEPATOLOGY, V51, P836, DOI 10.1002/hep.23380
   Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025
   Yang N, 2008, CANCER RES, V68, P10307, DOI 10.1158/0008-5472.CAN-08-1954
   Yu B, 2008, P NATL ACAD SCI USA, V105, P10073, DOI 10.1073/pnas.0804218105
   Yu SL, 2008, CANCER CELL, V13, P48, DOI 10.1016/j.ccr.2007.12.008
   Zhang J, 2010, BIOCHEM BIOPH RES CO, V399, P1, DOI 10.1016/j.bbrc.2010.07.013
   Zhang LL, 2008, ACTA PHARMACOL SIN, V29, P1060, DOI 10.1111/j.1745-7254.2008.00831.x
   Zhang YQ, 2009, WORLD J SURG, V33, P698, DOI 10.1007/s00268-008-9833-0
   Zhao JJ, 2008, J BIOL CHEM, V283, P31079, DOI 10.1074/jbc.M806041200
   Zheng TS, 2010, INT J CANCER, V126, P2, DOI 10.1002/ijc.24782
   Zuhorn IS, 2007, EUR BIOPHYS J BIOPHY, V36, P349, DOI 10.1007/s00249-006-0092-4
NR 201
TC 81
Z9 100
U1 0
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
EI 1098-2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD MAR
PY 2012
VL 51
IS 3
BP 213
EP 230
DI 10.1002/mc.20822
PG 18
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 875LT
UT WOS:000299032100001
PM 21739482
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Rathore, K
   Wang, HCR
AF Rathore, Kusum
   Wang, Hwa-Chain Robert
TI Green tea catechin extract in intervention of chronic breast cell
   carcinogenesis induced by environmental carcinogens
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE breast cancer; dietary prevention; reactive oxygen species; ERK; DNA
   damage
ID POLYCYCLIC AROMATIC-HYDROCARBONS; TOBACCO-SMOKE CARCINOGENS;
   4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE NNK; EPITHELIAL-CELLS;
   CIGARETTE-SMOKING; CANCER CELLS; PROLIFERATION; MIGRATION; PROTEIN;
   GROWTH
AB Sporadic breast cancers are mainly attributable to long-term exposure to environmental factors, via a multi-year, multi-step, and multi-path process of tumorigenesis involving cumulative genetic and epigenetic alterations in the chronic carcinogenesis of breast cells from a non-cancerous stage to precancerous and cancerous stages. Epidemiologic and experimental studies have suggested that green tea components may be used as preventive agents for breast cancer control. In our research, we have developed a cellular model that mimics breast cell carcinogenesis chronically induced by cumulative exposures to low doses of environmental carcinogens. In this study, we used our chronic carcinogenesis model as a target system to investigate the activity of green tea catechin extract (GTC) at non-cytotoxic levels in intervention of cellular carcinogenesis induced by cumulative exposures to pico-molar 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and benzo[a]pyrene (B[a]P). We identified that GTC, at a non-cytotoxic, physiologically achievable concentration of 2.5 mu g/mL, was effective in suppressing NNK- and B[a]P-induced cellular carcinogenesis, as measured by reduction of the acquired cancer-associated properties of reduced dependence on growth factors, anchorage-independent growth, increased cell mobility, and acinar-conformational disruption. We also detected that intervention of carcinogen-induced elevation of reactive oxygen species (ROS), increase of cell proliferation, activation of the ERK pathway, DNA damage, and changes in gene expression may account for the mechanisms of GTC's preventive activity. Thus, GTC may be used in dietary and chemoprevention of breast cell carcinogenesis associated with long-term exposure to low doses of environmental carcinogens. (c) 2011 Wiley Periodicals, Inc.
C1 [Rathore, Kusum; Wang, Hwa-Chain Robert] Univ Tennessee, Coll Vet Med, Dept Biomed & Diagnost Sci, Knoxville, TN 37996 USA.
   [Rathore, Kusum; Wang, Hwa-Chain Robert] Univ Tennessee, Grad Sch Genome Sci & Technol, Knoxville, TN 37996 USA.
C3 University of Tennessee System; University of Tennessee Knoxville; UT
   Institute of Agriculture; University of Tennessee System; University of
   Tennessee Knoxville
RP Wang, HCR (通讯作者)，Univ Tennessee, Coll Vet Med, Dept Biomed & Diagnost Sci, 2407 River Dr, Knoxville, TN 37996 USA.
RI Wang, Hwa-Chain/L-5646-2015
OI Wang, Hwa-Chain/0000-0001-5836-4120
FU University of Tennessee, College of Veterinary Medicine, Center of
   Excellence in Livestock Diseases and Human Health; National Institutes
   of Health [CA125795, CA129772]; Direct For Biological Sciences; Div Of
   Biological Infrastructure [1300426] Funding Source: National Science
   Foundation
FX We are grateful to Ms. M. Bailey for textual editing of the manuscript.
   We thank Ms. DJ Trent for technique support in flow cytometric analysis
   of ROS and apoptosis. This study was supported by a grant from the
   University of Tennessee, College of Veterinary Medicine, Center of
   Excellence in Livestock Diseases and Human Health (to H-C.R. W.) and the
   National Institutes of Health (CA125795 and CA129772 [H-C.R. W.]).
CR [Anonymous], 2009, COCHRANE DATABASE SY
   Bagchi D., 2005, Phytopharmaceuticals in cancer chemoprevention
   CAMPISI J, 1984, EXP CELL RES, V152, P459, DOI 10.1016/0014-4827(84)90647-5
   Caruso JA, 2001, MUTAT RES-FUND MOL M, V473, P85, DOI 10.1016/S0027-5107(00)00140-8
   Chhabra SK, 2000, TOXICOL APPL PHARM, V169, P191, DOI 10.1006/taap.2000.9068
   Choudhary S, 2011, J CANCER RES CLIN, V137, P471, DOI 10.1007/s00432-010-0910-z
   COBB MH, 1994, SEMIN CANCER BIOL, V5, P261
   Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev
   Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   DeBruin LS, 2002, ENVIRON HEALTH PERSP, V110, P119, DOI 10.1289/ehp.02110s1119
   Fuentes MK, 2007, DIS COLON RECTUM, V50, P1230, DOI 10.1007/s10350-006-0850-5
   Gery S, 2006, MOL CELL, V22, P375, DOI 10.1016/j.molcel.2006.03.038
   Grover PL, 2002, CARCINOGENESIS, V23, P1095, DOI 10.1093/carcin/23.7.1095
   Guengerich FP, 2000, CARCINOGENESIS, V21, P345, DOI 10.1093/carcin/21.3.345
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194
   Hecht SS, 2002, ENVIRON MOL MUTAGEN, V39, P119, DOI 10.1002/em.10071
   Hecht SS, 1996, CRIT REV TOXICOL, V26, P163, DOI 10.3109/10408449609017929
   Ho YS, 2005, TOXICOL APPL PHARM, V205, P133, DOI 10.1016/j.taap.2004.09.019
   Johnson KC, 2011, TOB CONTROL, V20, DOI 10.1136/tc.2010.035931
   Kasai T, 2004, PROTEIN SCI, V13, P545, DOI 10.1110/ps.03401004
   Kavanagh KT, 2001, J CELL BIOCHEM, V82, P387, DOI 10.1002/jcb.1164
   Kelloff GJ, 2005, CANC CHEMOPREVENTION, V2
   Lambert JD, 2006, DRUG METAB DISPOS, V34, P8, DOI 10.1124/dmd.104.003434
   LARSSON O, 1985, J CELL SCI, V75, P259
   Lee MJ, 2002, CANCER EPIDEM BIOMAR, V11, P1025
   Li SG, 2004, J NEUROSCI, V24, P3104, DOI 10.1523/JNEUROSCI.4444-03.2004
   LIPTON A, 1971, P NATL ACAD SCI USA, V68, P2799, DOI 10.1073/pnas.68.11.2799
   Luo J, 2010, BMJ-BRIT MED J, V342, P1
   Madsen CD, 2010, DEV CELL, V19, P13, DOI 10.1016/j.devcel.2010.06.013
   Maiani G, 1997, J CHROMATOGR B, V692, P311, DOI 10.1016/S0378-4347(97)00009-1
   Mehta RG, 2000, EUR J CANCER, V36, P1275, DOI 10.1016/S0959-8049(00)00100-3
   Mei JX, 2003, BREAST CANCER RES TR, V79, P95, DOI 10.1023/A:1023326121951
   MORRIS JJ, 1992, MED HYPOTHESES, V38, P177, DOI 10.1016/0306-9877(92)90090-Y
   Nishikori M, 2005, CANCER SCI, V96, P487, DOI 10.1111/j.1349-7006.2005.00078.x
   Prescott J, 2007, CANCER EPIDEM BIOMAR, V16, P620, DOI 10.1158/1055-9965.EPI-06-0873
   PRESTONMARTIN S, 1993, ENVIRON HEALTH PERSP, V101, P137, DOI 10.2307/3431856
   Reddig PJ, 2005, CANCER METAST REV, V24, P425, DOI 10.1007/s10555-005-5134-3
   Reddy SPM, 2002, AM J RESP CELL MOL, V27, P64, DOI 10.1165/ajrcmb.27.1.20020003oc
   Remacle C, 2010, PLANT MOL BIOL, V74, P223, DOI 10.1007/s11103-010-9668-6
   Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858
   Roomi MW, 2005, BREAST CANCER RES, V7, pR291, DOI 10.1186/bcr989
   Rubin H, 2001, CARCINOGENESIS, V22, P1903, DOI 10.1093/carcin/22.12.1903
   Rundle A, 2000, CARCINOGENESIS, V21, P1281, DOI 10.1093/carcin/21.7.1281
   Sartippour MR, 2001, NUTR CANCER, V40, P149, DOI 10.1207/S15327914NC402_11
   Seely Dugald, 2005, Integr Cancer Ther, V4, P144, DOI 10.1177/1534735405276420
   Shi HL, 2005, ARCH BIOCHEM BIOPHYS, V437, P59, DOI 10.1016/j.abb.2005.02.028
   SHOU M, 1993, CARCINOGENESIS, V14, P475, DOI 10.1093/carcin/14.3.475
   SIMES RJ, 1986, BIOMETRIKA, V73, P751, DOI 10.2307/2336545
   Siriwardhana N, 2008, BREAST CANCER RES TR, V109, P427, DOI 10.1007/s10549-007-9666-9
   Siriwardhana N, 2008, MOL CARCINOGEN, V47, P338, DOI 10.1002/mc.20392
   Song XY, 2010, MOL CARCINOGEN, V49, P450, DOI 10.1002/mc.20616
   Terry PD, 2002, CANCER EPIDEM BIOMAR, V11, P953
   Thangapazham RL, 2007, CANCER LETT, V245, P232, DOI 10.1016/j.canlet.2006.01.027
   Trabosh VA, 2009, EXP DERMATOL, V18, P387, DOI 10.1111/j.1600-0625.2008.00801.x
   Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009
   Valentijn AJ, 2004, BIOCHEM SOC T, V32, P421, DOI 10.1042/BST0320421
   van het Hof KH, 1998, EUR J CLIN NUTR, V52, P356, DOI 10.1038/sj.ejcn.1600568
   Wang DY, 2004, MOL ENDOCRINOL, V18, P402, DOI 10.1210/me.2003-0202
   Wogan GN, 2004, SEMIN CANCER BIOL, V14, P473, DOI 10.1016/j.semcancer.2004.06.010
   Wu Y, 2008, ONCOGENE, V27, P6679, DOI 10.1038/onc.2008.264
   Wu Z, 2002, CARCINOGENESIS, V23, P171, DOI 10.1093/carcin/23.1.171
   Yoo YA, 2005, MOL CELL BIOL, V25, P6603, DOI 10.1128/MCB.25.15.6603-6616.2005
   Zaveri NT, 2006, LIFE SCI, V78, P2073, DOI 10.1016/j.lfs.2005.12.006
NR 65
TC 24
Z9 28
U1 0
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
EI 1098-2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD MAR
PY 2012
VL 51
IS 3
BP 280
EP 289
DI 10.1002/mc.20844
PG 10
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 875LT
UT WOS:000299032100006
PM 21882252
OA Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Bai, L
   Deng, XL
   Li, Q
   Wang, M
   An, W
   Deli, A
   Gao, Z
   Xie, YT
   Dai, YF
   Cong, YS
AF Bai, Lin
   Deng, Xiaoli
   Li, Qian
   Wang, Miao
   An, Wei
   Deli, A.
   Gao, Zhuo
   Xie, Yuntao
   Dai, Yifan
   Cong, Yu-Sheng
TI Down-regulation of the cavin family proteins in breast cancer
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Caveolae; PTRF; SRBC; SDPR; Caveolin-1; Methylation
ID CAVEOLIN-1 GENE; EXPRESSIONAL ANALYSES; LUNG CANCERS; INACTIVATION;
   HSRBC; CELLS
AB Caveolae are abundant membrane domain on the cell surface of many mammalian cell types and are implicated in a wide range of physiological processes. The caveolae structural protein caveolin-1 is often mutated or deregulated in cancer, and cavin family protein serum deprivation response factor-related gene product that binds to C-kinase (SRBC) has been found to be epigenetically inactivated in lung, breast, and gastric cancer. Both caveolin-1 and SRBC have been proposed to function as tumor suppressors. Polymerase 1 and transcript release factor (PTRF) is the essential component for caveolae formation. The regulation of PTRF expression in cancer has not been characterized. We report here that the cavin family protein PTRF, SRBC and serum deprivation response protein were down regulated in breast cancer cell lines and breast tumor tissue. We further show that down-regulation of PTRF in breast cancer cells was associated with the promoter methylation. As caveolin-1 and cavin family proteins are required for caveolae formation and function, the reported tumor suppression function of caveolin-1 and SRBC may be due to the deregulation of caveolae and its down-stream signaling. Thus, the caveolae is a potential therapeutic target and the expression of cavin family proteins could be a useful prognostic indicator of breast cancer progression. J. Cell. Biochem. 113: 322328, 2012. (C) 2011 Wiley Periodicals, Inc.
C1 [Bai, Lin; Deng, Xiaoli; Li, Qian; Wang, Miao; An, Wei; Deli, A.; Cong, Yu-Sheng] Beijing Normal Univ, Key Lab Cell Proliferat & Regulat Biol, Minist Educ, Inst Cell Biol, Beijing 100875, Peoples R China.
   [Gao, Zhuo; Dai, Yifan] Nanjing Med Univ, Ctr Metab Dis Res, Nanjing 210029, Jiangsu, Peoples R China.
   [Xie, Yuntao] Peking Univ, Canc Hosp, Breast Ctr, Beijing Canc Hosp & Inst, Beijing 100142, Peoples R China.
C3 Beijing Normal University; Nanjing Medical University; Peking University
RP Cong, YS (通讯作者)，Beijing Normal Univ, Key Lab Cell Proliferat & Regulat Biol, Minist Educ, Inst Cell Biol, 19 Xin Jie Kou Wai Ave, Beijing 100875, Peoples R China.
EM yscong@bnu.edu.cn
RI An, wei/AGZ-8037-2022; Xie, Yuntao/KPB-0391-2024
FU National Natural Science Foundation of China [30671065, 31171320];
   Ministry of Science and Technology [2007CB507402, 2007CB914402,
   2009CB18904, 2011CB911203]
FX Grant sponsor: National Natural Science Foundation of China; Grant
   numbers: 30671065, 31171320; Grant sponsor: "973" Project of the
   Ministry of Science and Technology; Grant numbers: 2007CB507402,
   2007CB914402, 2009CB18904.This work was supported in part by grants from
   the National Natural Science Foundation of China [30671065,31171320] and
   grants from the "973" Project of the Ministry of Science and Technology
   [2007CB507402, 2007CB914402, 2009CB18904, 2011CB911203].
CR Bai L, 2011, CELL RES, V21, P1088, DOI 10.1038/cr.2011.56
   Bastiani M, 2010, J CELL SCI, V123, P3831, DOI 10.1242/jcs.070102
   Chan TF, 2003, INT J ONCOL, V23, P599
   Chen ST, 2004, INT J MOL MED, V14, P577
   Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300
   Hansen CG, 2010, TRENDS CELL BIOL, V20, P177, DOI 10.1016/j.tcb.2010.01.005
   Hayashi YK, 2009, J CLIN INVEST, V119, P2623, DOI 10.1172/JCI38660
   Hill MM, 2008, CELL, V132, P113, DOI 10.1016/j.cell.2007.11.042
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Lee JH, 2008, INT J CANCER, V122, P1573, DOI 10.1002/ijc.23166
   Li X, 2008, CANCER SCI, V99, P1326, DOI 10.1111/j.1349-7006.2008.00816.x
   Liu LB, 2008, CELL METAB, V8, P310, DOI 10.1016/j.cmet.2008.07.008
   Liu LB, 2008, J BIOL CHEM, V283, P4314, DOI 10.1074/jbc.M707890200
   Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200
   Nabi IR, 2009, NAT CELL BIOL, V11, P789, DOI 10.1038/ncb0709-789
   Parton RG, 2007, NAT REV MOL CELL BIO, V8, P185, DOI 10.1038/nrm2122
   Rajab A, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000874
   Sotgia F, 2006, CANCER RES, V66, P10647, DOI 10.1158/0008-5472.CAN-06-2805
   Tong SY, 2010, ACTA OBSTET GYN SCAN, V89, P629, DOI 10.3109/00016341003678443
   Williams TM, 2005, AM J PHYSIOL-CELL PH, V288, pC494, DOI 10.1152/ajpcell.00458.2004
   Williams TM, 2004, J BIOL CHEM, V279, P24745, DOI 10.1074/jbc.M402064200
   Williams TM, 2003, MOL BIOL CELL, V14, P1027, DOI 10.1091/mbc.E02-08-0503
   Xu XL, 2001, CANCER RES, V61, P7943
   Zöchbauer-Müller S, 2005, ONCOGENE, V24, P6249, DOI 10.1038/sj.onc.1208775
NR 24
TC 61
Z9 68
U1 0
U2 23
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JAN
PY 2012
VL 113
IS 1
BP 322
EP 328
DI 10.1002/jcb.23358
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 869LB
UT WOS:000298598300035
PM 21913217
DA 2025-01-12
ER

PT J
AU Hao, XW
   Zhu, ST
   He, YL
   Li, P
   Wang, YJ
   Zhang, ST
AF Hao, Xiao-Wen
   Zhu, Sheng-Tao
   He, Yuan-Long
   Li, Peng
   Wang, Yong-Jun
   Zhang, Shu-Tian
TI Epigenetic inactivation of secreted frizzled-related protein 2 in
   esophageal squamous cell carcinoma
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Esophageal squamous cell carcinoma; Secreted frizzled-related protein 2;
   Methylation; Tumor suppressor gene; Wnt signaling pathway
ID COLORECTAL-CANCER; SFRP GENES; GASTRIC-CANCER; BREAST-CANCER; FECAL DNA;
   PATHWAY; METHYLATION; MARKER; HYPERMETHYLATION; ACTIVATION
AB AIM: To investigate the expression and methylation status of the secreted frizzled-related protein 2 (SFRP2) in esophageal squamous cell carcinoma (ESCC) and explore its role in ESCC carcinogenesis.
   METHODS: Seven ESCC cell lines (KYSE 30, KYSE150, KYSE410, KYSE510, EC109, EC9706 and TE-1) and one immortalized human esophageal epithelial cell line (Het-1A), 20 ESCC tissue samples and 20 paired adjacent non-tumor esophageal epithelial tissues were analyzed in this study. Reverse-transcription polymerase chain reaction (RT-PCR) was employed to investigate the expression of SFRP2 in cell lines, primary ESCC tumor tissue, and paired adjacent normal tissue. Methylation status was evaluated by methylation-specific PCR and bisulfite sequencing. The correlation between expression and promoter methylation of the SFRP2 gene was confirmed with treatment of 5-aza-2'-deoxycytidine. To assess the potential role of SFRP2 in ESCC, we established stable SFRP2-transfected cells and examined them with regard to cell proliferation, colony formation, apoptosis and cell cycle in vivo and in vitro.
   RESULTS: SFRP2 mRNA was expressed in the immortalized normal esophageal epithelial cell line but not in seven ESCC cell lines. By methylation-specific PCR, complete methylation was detected in three cell lines with silenced SFRP2 expression, and extensive methylation was observed in the other four ESCC cell lines. 5-aza-2'-deoxycytidine could restore the expression of SFRP2 mRNA in the three ESCC cell lines lacking SFRP2 expression. SFRP2 mRNA expression was obviously lower in primary ESCC tissue than in adjacent normal tissue (0.939 +/- 0.398 vs 1.51 +/- 0.399, P < 0.01). SFRP2 methylation was higher in tumor tissue than in paired normal tissue (95% vs 65%, P < 0.05). The DNA methylation status of the SFRP2 correlated inversely with the SFRP2 expression. To assess the potential role of SFRP2 in ESCC, we established stable SFRP2 transfectants and control counterparts by introducing pcDNA3.1/v5 hisA -SFRP2 or pcDNA3.1/v5 hisA -empty vector into KYSE30 cells lacking SFRP2 expression. After transfection, the forced-expression of SFRP2 was confirmed by the RT-PCR. In comparison with the control groups, stably-expressed SFRP2 in KYSE 30 cells significantly reduced colony formation in vitro (47.17% +/- 15.61% vs 17% +/- 3.6%, P = 0.031) and tumor growth in nude mice (917.86 +/- 249.35 mm(3) vs 337.23 +/- 124.43 mm(3), P < 0.05). Using flow cytometry analysis, we found a significantly higher number of early apoptotic cells in SFRP2-transfected cells than in the control cells (P = 0.025). The mean cell number in the S and G2-M phases of the cell cycle was also significantly lower in SFRP2-transfected KYSE30 cells compared with mock transfected counterparts.
   CONCLUSION: Silencing of SFRP2 expression through promoter hypermethylation may be a factor in ESCC carcinogenesis through loss of its tumor-suppressive activity. (C) 2012 Baishideng. All rights reserved.
C1 [Hao, Xiao-Wen; Zhu, Sheng-Tao; He, Yuan-Long; Li, Peng; Wang, Yong-Jun; Zhang, Shu-Tian] Capital Med Univ, Beijing Friendship Hosp, Dept Gastroenterol, Beijing 100050, Peoples R China.
C3 Capital Medical University
RP Zhang, ST (通讯作者)，Capital Med Univ, Beijing Friendship Hosp, Dept Gastroenterol, 95 Yongan Rd, Beijing 100050, Peoples R China.
EM zst1964@126.com
FU National Natural Science Foundation of China [81050016]; Research Fund
   for the Doctoral Program of Higher Education of China [200800250003]
FX Supported by National Natural Science Foundation of China, No. 81050016;
   Research Fund for the Doctoral Program of Higher Education of China, No.
   200800250003
CR Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Cheng YY, 2007, BRIT J CANCER, V97, P895, DOI 10.1038/sj.bjc.6603968
   Chung MT, 2009, GYNECOL ONCOL, V112, P646, DOI 10.1016/j.ygyno.2008.10.026
   Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Feng QH, 2005, JNCI-J NATL CANCER I, V97, P273, DOI 10.1093/jnci/dji041
   Huang ZH, 2007, DIGEST DIS SCI, V52, P2287, DOI 10.1007/s10620-007-9755-y
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389
   Kolligs FT, 2002, DIGESTION, V66, P131, DOI 10.1159/000066755
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lee JL, 2006, BREAST CANCER RES TR, V100, P49, DOI 10.1007/s10549-006-9233-9
   Müller HM, 2004, LANCET, V363, P1283, DOI 10.1016/S0140-6736(04)16002-9
   Nojima M, 2007, ONCOGENE, V26, P4699, DOI 10.1038/sj.onc.1210259
   PALOMAKI GE, 1990, AM J OBSTET GYNECOL, V162, P317, DOI 10.1016/0002-9378(90)90377-J
   Ramírez N, 2008, EUR J CANCER, V44, P2689, DOI 10.1016/j.ejca.2008.09.004
   Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859
   Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783
   Sogabe Y, 2008, INT J ONCOL, V32, P1253
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Takagi H, 2008, J GASTROENTEROL, V43, P378, DOI 10.1007/s00535-008-2170-0
   Tamoto E, 2004, CLIN CANCER RES, V10, P3629, DOI 10.1158/1078-0432.CCR-04-0048
   Veeck J, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-83
   Wang DR, 2008, WORLD J GASTROENTERO, V14, P524, DOI 10.3748/wjg.14.524
   Workman P, 2010, BRIT J CANCER, V102, P1555, DOI 10.1038/sj.bjc.6605642
   Yamamura S, 2010, MOL CANCER THER, V9, P1680, DOI 10.1158/1535-7163.MCT-10-0012
   Yu J, 2009, GASTROENTEROLOGY, V136, P640
NR 28
TC 14
Z9 14
U1 0
U2 12
PU BAISHIDENG PUBL GRP CO LTD
PI BEIJING
PA RM 903, BLDG D, OCEAN INTERNATIONAL CTR, NO 62 DONGSIHUAN ZHONGLU,
   BEIJING, CHAOYANG DISTRICT 100025, PEOPLES R CHINA
SN 1007-9327
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD FEB 14
PY 2012
VL 18
IS 6
BP 532
EP 540
DI 10.3748/wjg.v18.i6.532
PG 9
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 892HN
UT WOS:000300277400006
PM 22363119
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Essa, S
   Reichrath, S
   Mahlknecht, U
   Montenarh, M
   Vogt, T
   Reichrath, J
AF Essa, Salma
   Reichrath, Sandra
   Mahlknecht, Ulrich
   Montenarh, Mathias
   Vogt, Thomas
   Reichrath, Joerg
TI Signature of VDR miRNAs and Epigenetic Modulation of Vitamin D Signaling
   in Melanoma Cell Lines
SO ANTICANCER RESEARCH
LA English
DT Article
DE Vitamin D receptor; malignant melanoma; TsA,5-Aza; microRNA antisense;
   MeWo; SK-Me128; SK-Me15; IGR; epigenetic silencing; miR-125b; miR-27b
ID CANCER-CELLS; D-RECEPTOR; DNA METHYLATION; BREAST-CANCER; TRICHOSTATIN;
   PROGRESSION; EXPRESSION; MICRORNAS; GENES
AB Background: Melanoma cells express the nuclear vitamin D receptor (VDR), indicating that malignant melanoma represents a promising target for treatment with 1,25-dihydroxyvitamin D3 (1,25(OH)(2)D-3) or its analogs. We previously showed that some melanoma cell lines are resistant to the antiproliferative effects of 1,25(OH)(2)D-3 and that 1,25(OH)(2)D-3-sensitivity can, at least in part, be restored by co-treatment with the histone deacetylase inhibitor (HDACI) Trichostatin A (TSA) or with the DNA methyltransferase inhibitor (DNMTI), 5-azacytidine (5-Aza). This study aimed at gaining further insights into the molecular mechanisms that underlie the epigenetic modulation of 1,25(OH)(2)D-3-sensitivity in melanoma cells. Materials and Methods: The expression of VDR mRNA, protein and two candidates of VDR microRNAs (miR-125b, miR-27b) were compared in 1,25(OH)(2)D-3-responsive (MeWo, SK-Mel28) and -resistant (SK-Mel5, IGR) melanoma cell lines and in normal human melanocytes (NHM) using real time PCR and western blot analysis. Additionally, the effect of 1,25(OH)(2)D-3, epigenetic modulating drugs (TSA, 5-Aza) and miR-125b antisense on the expression of VDR messenger RNA (mRNA)1protein, miR-125b and miR-27b was investigated. Results: Treatment with 1,25(OH)(2)D-3 and/or epigenetic drugs (5-Aza, TSA) modulated the VDR mRNA expression in the 1,25(OH)(2)D-3-responsive and - resistant melanoma cell lines and in the NHM. Treatment with 5-Aza, but not with TSA, reduced the expression of miR-125b in the 1,25(OH)(2)D-3-responsive and -resistant thelanoma cell lines and in the NHM. Treatment with I,25(OH)(2)D-3 and/or epigenetic drugs (5-Aza,TSA) reduced the miR-27b expression in three out of four melanoma cell lines. Moreover, no difference was observed in VDR protein expression in the 1,25(OH)(2)D-3-responsive as compared to the 1,25(OH)(2)D-3-resistant melanoma cell lines. Transfection with miR-125b antisense did not affect the VDR mRNA/protein expression in the IGR cells. Conclusion: Responsiveness to 1,25(OH)(2)D-3 corresponds to the expression level of VDR mRNA which in turn might be regulated by VDR microRNAs or epigenetic modulating drugs.
C1 [Essa, Salma; Reichrath, Sandra; Vogt, Thomas; Reichrath, Joerg] Univ Saarland, Dept Dermatol, D-6650 Homburg, Germany.
C3 Saarland University
RP Essa, S (通讯作者)，Saarland Univ Hosp, Dept Dermatol, Kirrbcrgerstr, D-66421 Homburg, Germany.
EM ssessa77@hotmail.com
RI Montenarh, Mathias/AAB-6689-2020
FU Syrian Government from the Ministry of Higher Education
FX This work was supported in part by Syrian Government from the Ministry
   of Higher Education. We thank Nathaniel Saidu for his help in editing
   this manuscript.
CR BURAS RR, 1994, BREAST CANCER RES TR, V31, P191, DOI 10.1007/BF00666153
   Carlberg C, 2009, ANTICANCER RES, V29, P3485
   Essa S, 2010, J STEROID BIOCHEM, V121, P110, DOI 10.1016/j.jsbmb.2010.02.003
   Essa S, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0001-7
   Gallagher WM, 2005, CARCINOGENESIS, V26, P1856, DOI 10.1093/carcin/bgi152
   Goetz C, 2007, PROSTATE, V67, P125, DOI 10.1002/pros.20471
   Gommersall LM, 2004, J STEROID BIOCHEM, V89-90, P251, DOI 10.1016/j.jsbmb.2004.03.080
   Guil S, 2009, INT J BIOCHEM CELL B, V41, P87, DOI 10.1016/j.biocel.2008.09.005
   Howell PM, 2009, CANCER CONTROL, V16, P200, DOI 10.1177/107327480901600302
   Malinen M, 2008, NUCLEIC ACIDS RES, V36, P121, DOI 10.1093/nar/gkm913
   Marik R, 2010, CANCER BIOL THER, V10, P44, DOI 10.4161/cbt.10.1.11994
   Mohri T, 2009, INT J CANCER, V125, P1328, DOI 10.1002/ijc.24459
   Mueller DW, 2009, J INVEST DERMATOL, V129, P1740, DOI 10.1038/jid.2008.452
   Pan YZ, 2009, DRUG METAB DISPOS, V37, P2112, DOI 10.1124/dmd.109.027680
   Philippidou D, 2010, CANCER RES, V70, P4163, DOI 10.1158/0008-5472.CAN-09-4512
   Plum LA, 2010, NAT REV DRUG DISCOV, V9, P941, DOI 10.1038/nrd3318
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Wang YJ, 2010, ARCH BIOCHEM BIOPHYS, V494, P166, DOI 10.1016/j.abb.2009.11.029
   Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103
   Zhang S., 2008, Experimental Oncology, V30, P265
NR 20
TC 37
Z9 42
U1 0
U2 12
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD JAN
PY 2012
VL 32
IS 1
SI SI
BP 383
EP 389
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 872BF
UT WOS:000298780700022
PM 22213330
DA 2025-01-12
ER

PT J
AU Sandhu, R
   Rivenbark, AG
   Coleman, WB
AF Sandhu, Rupninder
   Rivenbark, Ashley G.
   Coleman, William B.
TI Enhancement of chemotherapeutic efficacy in hypermethylator breast
   cancer cells through targeted and pharmacologic inhibition of DNMT3b
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer; Chemotherapy; Hypermethylation defect; DNA
   methyltransferase 3B; Doxorubicin; Paclitaxel; 5-Fluorouracil;
   Basal-like breast cancer
ID DNA METHYLTRANSFERASE INHIBITORS; TUMOR-SUPPRESSOR GENES;
   MONOCLONAL-ANTIBODY; EXPRESSION PROFILES; METHYLATION; TRASTUZUMAB;
   SUBTYPES; PATTERNS; SURVIVAL; THERAPY
AB A subset of primary breast cancers and breast cancer cell lines express a hypermethylation defect (characterized by DNMT hyperactivity and DNMT3b overexpression) which contributes to chemotherapy resistance and provides a target for development of new treatment strategies. The objective of the current study was to determine if targeting the epigenome enhances the sensitivity of breast cancer cells to cytotoxic chemotherapy. Hypermethylator breast cancer cell lines (MDA-MB-453, BT549, and Hs578T) were treated with 250 or 500 nM 5-aza-2'-deoxycytidine (5-aza) and/or were subjected to RNAi-mediated DNMT3b knockdown (KD), and then tested for sensitivity to doxorubicin hydrochloride (DOX), paclitaxel (PAX), and 5-fluorouracil (5-FU). In MDA-MB-453 cells, DNMT3b KD reduces the IC50 for DOX from 0.086 to 0.048 mu M (44% reduction), for PAX from 0.497 to 0.376 nM (24%), and for 5-FU from 0.817 to 0.145 mM (82%). Treatment with 250 nM 5-aza for 7 days did not increase the efficacy of DOX, PAX, or 5-FU, but 7-day treatment with 500 nM 5-aza sensitized cells, reducing the IC50 for DOX to 0.035 mu M (60%), PAX to 0.311 nM (37%), and 5-FU to 0.065 mM (92%). 5-aza treatment of DNMT3b KD cells reduced the IC50 for DOX to 0.036 mu M (59%), for PAX to 0.313 nM (37%) and for 5-FU to 0.067 (92%). Similar trends of enhancement of cell kill were seen in BT549 (13-60%) and Hs578T (29-70%) cells after RNAi-mediated DNMT3b KD and/or treatment with 5-aza. The effectiveness of DOX, PAX, and 5-FU is enhanced through targeted and/or pharmacological inhibition of DNMT3b, strongly suggesting that combined epigenetic and cytotoxic treatment will improve the efficacy of breast cancer chemotherapy.
C1 [Sandhu, Rupninder; Coleman, William B.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA.
   [Rivenbark, Ashley G.] Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.
   [Sandhu, Rupninder; Rivenbark, Ashley G.; Coleman, William B.] Univ N Carolina, Sch Med, UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine; University of North
   Carolina; University of North Carolina Chapel Hill; University of North
   Carolina; University of North Carolina Chapel Hill; University of North
   Carolina School of Medicine
RP Coleman, WB (通讯作者)，Univ N Carolina, Dept Pathol & Lab Med, 515 Brinkhous Bullitt Bldg,CB 7525, Chapel Hill, NC 27599 USA.
EM wbcolemn@med.unc.edu
FU UNC Lineberger Comprehensive Cancer Center, University of North Carolina
   School of Medicine; American Cancer Society [PF-08-166-01-GMC]
FX This study was supported by a University Cancer Research Fund grant from
   the UNC Lineberger Comprehensive Cancer Center, University of North
   Carolina School of Medicine. AGR is supported by a Postdoctoral
   Fellowship grant from the American Cancer Society (PF-08-166-01-GMC).
CR Ai LB, 2006, CANCER RES, V66, P7899, DOI 10.1158/0008-5472.CAN-06-0576
   [Anonymous], DEV BIOL BASEL
   Bardou VJ, 2003, J CLIN ONCOL, V21, P1973, DOI 10.1200/JCO.2003.09.099
   Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737
   Baselga J, 2006, ONCOLOGIST, V11, P4, DOI 10.1634/theoncologist.11-90001-4
   Baylin S, 2001, Dev Biol (Basel), V106, P85
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Bergamaschi A, 2006, GENE CHROMOSOME CANC, V45, P1033, DOI 10.1002/gcc.20366
   Brenton JD, 2005, J CLIN ONCOL, V23, P7350, DOI 10.1200/JCO.2005.03.3845
   Brueckner B, 2004, TRENDS PHARMACOL SCI, V25, P551, DOI 10.1016/j.tips.2004.09.004
   Brueckner B, 2007, CANCER J, V13, P17, DOI 10.1097/PPO.0b013e31803c7245
   Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109
   Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
   CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Clarke M, 1998, LANCET, V351, P1451
   Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639
   Demonty G, 2007, EUR J CANCER, V43, P497, DOI 10.1016/j.ejca.2006.10.020
   Duffy MJ, 2006, CRIT REV CL LAB SCI, V43, P325, DOI 10.1080/10408360600739218
   Esteller M, 2005, J PATHOL, V205, P172, DOI 10.1002/path.1707
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Gansler T, 2010, CA-CANCER J CLIN, V60, P1, DOI [10.3322/caac.20073, 10.3322/caac.20049]
   Grunau C, 2001, NUCLEIC ACIDS RES, V29, P270, DOI 10.1093/nar/29.1.270
   Herman JG, 1999, SEMIN CANCER BIOL, V9, P359, DOI 10.1006/scbi.1999.0138
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Leone G, 2003, CLIN IMMUNOL, V109, P89, DOI 10.1016/S1521-6616(03)00207-9
   Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147
   Lyko F, 2005, JNCI-J NATL CANCER I, V97, P1498, DOI 10.1093/jnci/dji311
   Mielnicki LM, 2001, J MAMMARY GLAND BIOL, V6, P169, DOI 10.1023/A:1011356623442
   Millikan RC, 2008, BREAST CANCER RES TR, V109, P123, DOI 10.1007/s10549-007-9632-6
   Mirza S, 2010, MOL CELL BIOCHEM, V342, P101, DOI 10.1007/s11010-010-0473-y
   Miyamoto K, 2005, INT J CANCER, V116, P407, DOI 10.1002/ijc.21054
   Moasser MM, 2007, ONCOGENE, V26, P6577, DOI 10.1038/sj.onc.1210478
   Mund C, 2006, EPIGENETICS-US, V1, P7
   Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207
   Osborne CK, 2000, J CLIN ONCOL, V18, P3172, DOI 10.1200/JCO.2000.18.17.3172
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Pegram MD, 2004, JNCI-J NATL CANCER I, V96, P739, DOI 10.1093/jnci/djh131
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306
   Puppe J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2354
   Rakha EA, 2008, J CLIN ONCOL, V26, P2568, DOI 10.1200/JCO.2007.13.1748
   Rivenbark AG, 2006, EPIGENETICS-US, V1, P32, DOI 10.4161/epi.1.1.2358
   Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15
   Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421
   Schneider BP, 2008, CLIN CANCER RES, V14, P8010, DOI 10.1158/1078-0432.CCR-08-1208
   Segura-Pacheco B, 2003, CLIN CANCER RES, V9, P1596
   Segura-Pacheco B, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-32
   Slamon D, 2001, SEMIN ONCOL, V28, P13, DOI 10.1053/sonc.2001.22812
   Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100
   Sotiriou C, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr433
   Sowinska A, 2007, CANCER LETT, V255, P153, DOI 10.1016/j.canlet.2007.04.004
   Troester MA, 2004, CANCER RES, V64, P4218, DOI 10.1158/0008-5472.CAN-04-0107
   Troester MA, 2004, ENVIRON HEALTH PERSP, V112, P1607, DOI [10.1289/txg.7204, 10.1289/ehp.7204]
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Yoo CB, 2004, BIOCHEM SOC T, V32, P910, DOI 10.1042/BST0320910
NR 66
TC 37
Z9 44
U1 0
U2 13
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JAN
PY 2012
VL 131
IS 2
BP 385
EP 399
DI 10.1007/s10549-011-1409-2
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 871QG
UT WOS:000298752200003
PM 21359954
DA 2025-01-12
ER

PT J
AU Yu, V
   Fisch, T
   Long, AM
   Tang, J
   Lee, JH
   Hierl, M
   Chen, H
   Yakowec, P
   Schwandner, R
   Emkey, R
AF Yu, Violeta
   Fisch, Tanja
   Long, Alexander M.
   Tang, Jin
   Lee, Josie Han
   Hierl, Markus
   Chen, Hao
   Yakowec, Peter
   Schwandner, Ralf
   Emkey, Renee
TI High-Throughput TR-FRET Assays for Identifying Inhibitors of LSD1 and
   JMJD2C Histone Lysine Demethylases
SO JOURNAL OF BIOMOLECULAR SCREENING
LA English
DT Article
DE cancer and cancer drugs; enzyme assays or enzyme kinetics; epigenetics;
   fluorescence methods
ID BREAST-CANCER; PROTEIN; FAMILY; DOMAIN; GASC1; PLU-1
AB Lysine demethylase 1 (LSD1) and Jumonji C domain-containing oxygenase D2C (JMJD2C) participate in regulating the methylation status of histone H3 lysine residues. In some contexts, LSD1 and JMJD2C activity causes enhanced cellular proliferation, which may lead to tumorigenesis. The authors explored the utility of time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassays, which employed peptides consisting of the first 21 amino acids of histone H3 in which lysine 4 (H3K4) or lysine 9 (H3K9) was methylated (me) to quantify LSD1 and JMJD2C activity. The LSD1 assay monitored demethylation of the H3K4me1 peptide using an antibody that recognizes H3K4me1 but not the unmethylated peptide product. The JMJD2C assay measured demethylation of H3K9me3 with an antibody that selectively recognizes H3K9me2. The optimized conditions resulted in robust assays (Z'>0.7) that required only 3 to 6 nM of enzyme in a reaction volume of 6 to 10 mu L. These assays were used to compare the activity of different LSD1 constructs and to determine the apparent K-m of each JMJD2C substrate. Finally, both assays were used in a high-throughput setting for identifying demethylase inhibitors. Compounds discovered by these TR-FRET methods may lead to powerful tools for ascertaining the roles of demethylases in a cellular context and ultimately for potential cancer treatments.
C1 [Yu, Violeta; Long, Alexander M.; Tang, Jin; Lee, Josie Han; Chen, Hao; Yakowec, Peter; Emkey, Renee] Amgen Inc, Cambridge, MA 02142 USA.
   [Fisch, Tanja; Hierl, Markus; Schwandner, Ralf] Amgen Res GmbH, Regensburg, Germany.
C3 Amgen; Amgen; Amgen Research Munich GmbH
RP Yu, V (通讯作者)，Amgen Inc, 360 Binney St, Cambridge, MA 02142 USA.
EM vyu@amgen.com
CR Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Barrett A, 2002, INT J CANCER, V101, P581, DOI 10.1002/ijc.10644
   Blair Lauren P, 2011, Cancers (Basel), V3, P1383, DOI 10.3390/cancers3011383
   Chen Y, 2006, P NATL ACAD SCI USA, V103, P13956, DOI 10.1073/pnas.0606381103
   Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837
   Degorce Francois, 2009, Curr Chem Genomics, V3, P22, DOI 10.2174/1875397300903010022
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Forneris F, 2007, J BIOL CHEM, V282, P20070, DOI 10.1074/jbc.C700100200
   Fortschegger K, 2011, EPIGENETICS-US, V6, P4, DOI 10.4161/epi.6.1.13297
   Glickman JF, 2002, J BIOMOL SCREEN, V7, P3, DOI 10.1177/108705710200700102
   Hemmilä I, 2005, J FLUORESC, V15, P529, DOI 10.1007/s10895-005-2826-6
   Huang F, 2010, J BIOL CHEM, V285, P24548, DOI 10.1074/jbc.M110.117333
   Huang Y, 2007, P NATL ACAD SCI USA, V104, P8023, DOI 10.1073/pnas.0700720104
   Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570
   Kawamura A, 2010, ANAL BIOCHEM, V404, P86, DOI 10.1016/j.ab.2010.04.030
   King ONF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015535
   Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   Rose NR, 2010, J MED CHEM, V53, P1810, DOI 10.1021/jm901680b
   Sakurai M, 2010, MOL BIOSYST, V6, P357, DOI 10.1039/b912993f
   Schmidt DMZ, 2007, BIOCHEMISTRY-US, V46, P4408, DOI 10.1021/bi0618621
   Shi Y, 2007, NAT REV GENET, V8, P829, DOI 10.1038/nrg2218
   Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Tan HD, 2008, MOL BIOL REP, V35, P551, DOI 10.1007/s11033-007-9121-3
   Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433
   Ueda R, 2009, J AM CHEM SOC, V131, P17536, DOI 10.1021/ja907055q
   Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028
   Yamane K, 2007, MOL CELL, V25, P801, DOI 10.1016/j.molcel.2007.03.001
   Yang ZQ, 2000, CANCER RES, V60, P4735
NR 30
TC 29
Z9 34
U1 0
U2 11
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1087-0571
EI 1552-454X
J9 J BIOMOL SCREEN
JI J. Biomol. Screen
PD JAN
PY 2012
VL 17
IS 1
SI SI
BP 27
EP 38
DI 10.1177/1087057111418228
PN 2
PG 12
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Chemistry
GA 873MH
UT WOS:000298886900004
PM 21859682
OA hybrid
DA 2025-01-12
ER

PT J
AU Patani, N
   Jiang, WG
   Newbold, RF
   Mokbel, K
AF Patani, Neill
   Jiang, Wen G.
   Newbold, Robert F.
   Mokbel, Kefah
TI Histone-modifier Gene Expression Profiles Are Associated with
   Pathological and Clinical Outcomes in Human Breast Cancer
SO ANTICANCER RESEARCH
LA English
DT Article
DE Breast cancer; epigenetic regulation; histone-modifier genes; histone
   acetyltransferases; histone methyltransferases
ID ESTROGEN-RECEPTOR-ALPHA; DEACETYLASE INHIBITION; PROGNOSTIC-FACTORS;
   EPITHELIAL-CELLS; ACETYLATION; EPIGENETICS; TRANSCRIPTION; METHYLATION;
   PROGRESSION; ACTIVATION
AB Background: Epigenetic regulation of gene expression is under normal circumstances tightly controlled by the specific methylation of cytosine residues in CpG dinucleotides and coordinated by adjustments in the histone-dependent configuration of chromatin. Following our original report, providing the first description of potential tumor suppressor function associated with the hi stone methyltransferase SET domain containing 2 (SETD2) in breast cancer, the objective of this study was to determine the expression profiles of 16 further histone-modifier genes in a well annotated cohort of patients with primary operable breast cancer. Materials and Methods: Breast cancer tissues (n=127) and normal tissues (n=33) underwent RNA extraction and reverse transcription, and hi stone-modifier gene transcript levels were determined using real-time quantitative PCR. The histone-modifier genes included: hi stone acetyltransferases (cAMP response element-binding protein-binding protein (CREBBP)); class I (histone deacetylase 1 (HDAC1) and histone deacetylase 2 (HDAC2)), II (histone deacetylase 5 (HDAC5)) and 111 (sirtuin 1 (SIRT1))histone deacetylases; and histone methyltransferases (SET domain containing suppressor of variegation 3-9 homolog I (SUV39H1) and suppressor of variegation 3-9 homolog 2 (SUV39H2)) amongst others. Expression levels were analysed against tumor size, grade, nodal involvement, histological subtype, receptor status, TNM stage, Nottingham Prognostic Index, and disease-free and overall survival over a 10-year follow-up period. Results: Expression of histone-modifier genes in breast cancer differed significantly from those in normal tissue (HDAC5, HDAC1, lysine (K)-specific demethylase 4A (KDM4A) and lysine (K)specific demethylase 6A (KDM6A)). Differences in expression profiles were also found to exist between individual breast tumors and, in some cases, were significantly associated with conventional pathological parameters and prognostic indices: tumor grade (K (lysine) acetyltransferase 5 (KAT5), HDAC1, KDM4A, SUV39H1 and KDM6A)); TNM stage (SUV39H1, K (lysine) acetyltransferase 28 (KAT2B), lysine (K)-specific demethylase 1A (KDM1A), KDM4A, lysine (K)-specific demethylase 5C (KDM5C), K (lysine) acetyltransferase 8 (KAT8), HDAC5 and KAT5)); Nottingham Prognostic Index (KDM5C, myeloid/lymphoid or mixed-lineage leukemia (MLL), KAT8 and SET and MYND domain containing 3 (SMYD3)); receptor status (KAT5, SMYD3 and KDM1A); histological type (KAT5, KDM5C, KAT8, KDM4A and MU); disease-free survival (SUV39H1, SMYD3, HDAC5, KDM6A, HDAC1, KDM1A, KDM4A, KAT8, KDM5C, KAT5 and MLL) and overall survival (KAT8). Significant correlations were identified between the differential expression profiles of particular histone-modifying genes. Conclusion: Expression levels of histone-modifier genes in breast cancer differ significantly from normal tissue. Differences in expression profiles exist between breast tumors and are significantly associated with conventional pathological parameters and clinical outcomes. Further study is warranted to determine the consequences of altered expression for each specific histone-modifier gene and the biological and clinical implications of combinatorial variations in expression profiles. Histone-modifier enzymes offer utility as biomarkers and potential for targeted therapeutic strategies.
C1 [Patani, Neill; Mokbel, Kefah] Princess Grace Hosp, London Breast Inst, Dept Breast Surg, London W1U 5NY, England.
   [Jiang, Wen G.] Cardiff Univ, Sch Med, Univ Dept Surg, Metastasis & Angiogenesis Res Grp, Cardiff, S Glam, Wales.
   [Newbold, Robert F.; Mokbel, Kefah] Brunel Univ, Brunel Inst Canc Genet & Pharmacogenom, Dept Biosci, Sch Hlth Sci & Social Care, London, England.
C3 Cardiff University; Brunel University
RP Mokbel, K (通讯作者)，Princess Grace Hosp, London Breast Inst, Dept Breast Surg, 45 Nottingham Pl, London W1U 5NY, England.
EM kefahmokbel@hotmail.com
RI Newbold, Robert/JDN-0280-2023; Jiang, Wen/AAF-1876-2020; Jiang, Wen
   G./B-1293-2010
OI Jiang, Wen G./0000-0002-3283-1111; Mokbel, Kefah/0000-0001-7255-7850;
   Patani, Neill/0000-0002-9591-8636
FU Cancer Research Wales; The Fong Family Foundation
FX The Authors wish to thank Cancer Research Wales and The Fong Family
   Foundation for supporting this work.
CR Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923
   Al Sarakbi W, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-290
   Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4
   Bradley C, 2007, CARCINOGENESIS, V28, P2184, DOI 10.1093/carcin/bgm100
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Claus R, 2003, ONCOGENE, V22, P6489, DOI 10.1038/sj.onc.1206814
   Conway KE, 2000, CANCER RES, V60, P6236
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Elsheikh SE, 2009, CANCER RES, V69, P3802, DOI 10.1158/0008-5472.CAN-08-3907
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536
   Hu Q, 2008, P NATL ACAD SCI USA, V105, P19199, DOI 10.1073/pnas.0810634105
   Huang J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092
   Huang Y, 2011, BREAST CANC RES TREA
   Issa JPJ, 2007, CLIN CANCER RES, V13, P1634, DOI 10.1158/1078-0432.CCR-06-2076
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jiang WG, 2003, CLIN CANCER RES, V9, P6432
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Kapoor-Vazirani P, 2008, CANCER RES, V68, P6810, DOI 10.1158/0008-5472.CAN-08-0141
   Kawai H, 2003, INT J CANCER, V107, P353, DOI 10.1002/ijc.11403
   Khorasanizadeh S, 2004, CELL, V116, P259, DOI 10.1016/S0092-8674(04)00044-3
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kurdistani SK, 2007, BRIT J CANCER, V97, P1, DOI 10.1038/sj.bjc.6603844
   Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493
   Leader JE, 2006, ANN NY ACAD SCI, V1089, P73, DOI 10.1196/annals.1386.047
   Li SY, 2006, CANCER LETT, V237, P272, DOI 10.1016/j.canlet.2005.06.011
   Li XZ, 2009, MOL CELL, V36, P290, DOI 10.1016/j.molcel.2009.07.031
   Li ZY, 2009, J BIOL CHEM, V284, P10361, DOI 10.1074/jbc.M900956200
   Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324
   Liu XF, 2004, J BIOL CHEM, V279, P15050, DOI 10.1074/jbc.M311932200
   Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504
   Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578
   Mann BS, 2007, CLIN CANCER RES, V13, P2318, DOI 10.1158/1078-0432.CCR-06-2672
   Marchion DC, 2009, MOL CANCER THER, V8, P794, DOI 10.1158/1535-7163.MCT-08-0985
   Munster P, 2009, CLIN CANCER RES, V15, P2488, DOI 10.1158/1078-0432.CCR-08-1930
   Özdag H, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-90
   Parsons MJ, 2009, CANCER RES, V69, P1706, DOI 10.1158/0008-5472.CAN-08-2351
   Pfister S, 2008, INT J CANCER, V122, P1207, DOI 10.1002/ijc.23283
   Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506
   Ronneberg JA, 2011, MOL ONCOL, V5, P61, DOI 10.1016/j.molonc.2010.11.004
   Santos-Rosa H, 2005, EUR J CANCER, V41, P2381, DOI 10.1016/j.ejca.2005.08.010
   Soares J, 1999, CANCER, V85, P112, DOI 10.1002/(SICI)1097-0142(19990101)85:1<112::AID-CNCR16>3.0.CO;2-T
   Sun JM, 2001, J BIOL CHEM, V276, P49435, DOI 10.1074/jbc.M108364200
   Suzuki J, 2009, CLIN CANCER RES, V15, P3163, DOI 10.1158/1078-0432.CCR-08-2319
   Taipale M, 2005, MOL CELL BIOL, V25, P6798, DOI 10.1128/MCB.25.15.6798-6810.2005
   Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x
   Vaquero A, 2007, NATURE, V450, P440, DOI 10.1038/nature06268
   Wang GG, 2007, TRENDS MOL MED, V13, P363, DOI 10.1016/j.molmed.2007.07.003
   Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049
   Yang XW, 2001, CANCER RES, V61, P7025
   Yang XW, 2000, CANCER RES, V60, P6890
NR 52
TC 87
Z9 97
U1 0
U2 17
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
J9 ANTICANCER RES
JI Anticancer Res.
PD DEC
PY 2011
VL 31
IS 12
BP 4115
EP 4125
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 868HM
UT WOS:000298514300009
PM 22199269
DA 2025-01-12
ER

PT J
AU Nebbioso, A
   Pereira, R
   Khanwalkar, H
   Matarese, F
   García-Rodríguez, J
   Miceli, M
   Logie, C
   Kedinger, V
   Ferrara, F
   Stunnenberg, HG
   de Lera, AR
   Gronemeyer, H
   Altucci, L
AF Nebbioso, Angela
   Pereira, Raquel
   Khanwalkar, Harshal
   Matarese, Filomena
   Garcia-Rodriguez, Jose
   Miceli, Marco
   Logie, Colin
   Kedinger, Valerie
   Ferrara, Felicetto
   Stunnenberg, Hendrik G.
   de Lera, Angel R.
   Gronemeyer, Hinrich
   Altucci, Lucia
TI Death Receptor Pathway Activation and Increase of ROS Production by the
   Triple Epigenetic Inhibitor UVI5008
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID TUMOR-SUPPRESSOR GENES; HISTONE DEACETYLASE; HDAC INHIBITORS;
   CATALYTIC-ACTIVITY; CELL-CYCLE; ACETYLATION; CANCER; SIRT1; APOPTOSIS;
   STRESS
AB Deregulation of the epigenome is recognized as cause of cancer and epigenetic factors are receiving major attention as therapeutic targets; yet, the molecular mode of action of existing epi-drugs is largely elusive. Here, we report on the decryption of the mechanism of action of UVI5008, a novel epigenetic modifier, that inhibits histone deacetylases, sirtuins, and DNA methyltransferases. UVI5008 highly efficiently induces cancer cell-selective death in a variety of models and exerts its activities in several human tumor xenografts and genetic mouse models of human breast cancer in vivo. Its anticancer activity involves independent activation of death receptors and reactive oxygen species production. Importantly, UVI5008 action is not critically dependent on p53, Bcl-2 modifying factor, and/or TNF-related apoptosis-inducing ligand as cell death is efficiently induced in cells mutated or deficient for these factors limiting the risk of drug resistance development and maximizing its application spectrum. The simultaneous modulation of multiple (epigenetic) targets promises to open new avenues with unanticipated potential against cancer. Mol Cancer Ther; 10(12); 2394-404. (C)2011 AACR.
C1 [Nebbioso, Angela; Miceli, Marco; Altucci, Lucia] Univ Naples 2, Dipartimento Patol Gen, I-80138 Naples, Italy.
   [Ferrara, Felicetto] Osped Cardarelli, Naples, Italy.
   [Altucci, Lucia] CNR IGB, Naples, Italy.
   [Pereira, Raquel; Garcia-Rodriguez, Jose; de Lera, Angel R.] Univ Vigo, Dept Quim Organ, Fac Quim, Vigo 36310, Spain.
   [Khanwalkar, Harshal; Kedinger, Valerie; Gronemeyer, Hinrich] Inst Genet & Biol Mol & Cellulaire, Dept Canc Biol, Strasbourg, France.
   [Matarese, Filomena; Logie, Colin; Stunnenberg, Hendrik G.] Radboud Univ Nijmegen, NCMLS, Dept Mol Biol, Ga Nijmegen, Netherlands.
C3 Universita della Campania Vanvitelli; Antonio Cardarelli Hospital;
   Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e
   Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Universidade de Vigo;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Radboud University Nijmegen
RP Altucci, L (通讯作者)，Univ Naples 2, Dipartimento Patol Gen, Vico L De Crecchio 7, I-80138 Naples, Italy.
EM lucia.altucci@unina2.it
RI Stunnenberg, Hendrik/D-6875-2012; Logie, Colin/A-1528-2010; Altucci,
   Lucia/S-8031-2019; Miceli, Marco/AAG-4627-2019; NEBBIOSO,
   ANGELA/GVS-1294-2022; NEBBIOSO, Angela/C-3566-2016; Gronemeyer,
   Hinrich/G-6240-2011
OI miceli, marco/0000-0001-5806-1488; NEBBIOSO, Angela/0000-0001-5374-3527;
   Rodriguez de Lera, Angel/0000-0001-6896-9078; ,
   Raquel/0000-0003-2634-9799; Gronemeyer, Hinrich/0000-0001-9454-2449;
   altucci, lucia/0000-0002-7312-5387; Logie, Colin/0000-0002-8534-6582
FU Associazione Italiana ricerca contro il cancro (AIRC); MIUR; Association
   for International Cancer Research (AICR) [00-108]; Ligue National Contre
   le Cancer [ANR-07-EMPB-012-01]; MEC [SAF2010-17935]; Programmi di
   Ricerca Scientifica di Rilevante Interesse Nazionale [PRIN2009PX2T2E];
   EU [LSHC-CT-2005-518417, HEALTH-F4-2007-200767, HEALTH-F2-2007-200620,
   HEALTH-F4-2009-221952]
FX The study was supported by Associazione Italiana ricerca contro il
   cancro (AIRC; L. Altucci), MIUR ('EpiGen' Italian IHEC Flag project) to
   L. Altucci, Association for International Cancer Research (AICR 00-108;
   H. Gronemeyer), Ligue National Contre le Cancer (H. Gronemeyer),
   ANR-07-EMPB-012-01 "EPI_DRUG", MEC (SAF2010-17935 FEDER; A.R. de Lera),
   Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale
   (PRIN2009PX2T2E; L. Altucci), EU LSHC-CT-2005-518417 (EPITRON),
   HEALTH-F4-2007-200767 (APO-SYS), HEALTH-F2-2007-200620 (CAN-CERDIP),
   HEALTH-F4-2009-221952 (ATLAS).
CR Ahn MY, 2008, GYNECOL ONCOL, V108, P27, DOI 10.1016/j.ygyno.2007.08.098
   Akkers RC, 2009, DEV CELL, V17, P425, DOI 10.1016/j.devcel.2009.08.005
   Altucci L, 2007, NAT REV DRUG DISCOV, V6, P793, DOI 10.1038/nrd2397
   Avalos JL, 2002, MOL CELL, V10, P523, DOI 10.1016/S1097-2765(02)00628-7
   Bai YX, 2007, WORLD J GASTROENTERO, V13, P3883
   Bantscheff M, 2011, NAT BIOTECHNOL, V29, P255, DOI 10.1038/nbt.1759
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Brinkman AB, 2010, METHODS, V52, P232, DOI 10.1016/j.ymeth.2010.06.012
   Brueckner B, 2005, CANCER RES, V65, P6305, DOI 10.1158/0008-5472.CAN-04-2957
   Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637
   Cardellini M, 2009, DIABETES, V58, P2396, DOI 10.2337/db09-0280
   Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876
   Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2
   Das C, 2009, NATURE, V459, P113, DOI 10.1038/nature07861
   Datta J, 2009, CANCER RES, V69, P4277, DOI 10.1158/0008-5472.CAN-08-3669
   Denissov S, 2007, EMBO J, V26, P944, DOI 10.1038/sj.emboj.7601550
   Durr ML, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010828
   Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197
   García J, 2011, BIOORGAN MED CHEM, V19, P3637, DOI 10.1016/j.bmc.2010.12.026
   Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901
   Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085
   Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Lahm A, 2007, P NATL ACAD SCI USA, V104, P17335, DOI 10.1073/pnas.0706487104
   Lane AA, 2009, J CLIN ONCOL, V27, P5459, DOI 10.1200/JCO.2009.22.1291
   Lee MW, 2002, CANCER LETT, V182, P75
   Maas NL, 2006, MOL CELL, V23, P109, DOI 10.1016/j.molcel.2006.06.006
   Mai A, 2009, INT J BIOCHEM CELL B, V41, P199, DOI 10.1016/j.biocel.2008.08.020
   Martens JHA, 2010, FEBS LETT, V584, P2662, DOI 10.1016/j.febslet.2010.04.002
   Martens JHA, 2010, CANCER CELL, V17, P173, DOI 10.1016/j.ccr.2009.12.042
   Matsushita H, 2006, J EXP MED, V203, P821, DOI 10.1084/jem.20050616
   Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6
   Myatt SS, 2011, ANTIOXID REDOX SIGN, V14, P675, DOI 10.1089/ars.2010.3383
   Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161
   Nebbioso A, 2009, EMBO REP, V10, P776, DOI [10.1038/embor.2009.88, 10.15252/embr.202051028]
   Ooi SKT, 2008, CELL, V133, P1145, DOI 10.1016/j.cell.2008.06.009
   Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199
   Ozdemir A, 2005, J BIOL CHEM, V280, P25949, DOI 10.1074/jbc.C500181200
   Piña IC, 2003, J ORG CHEM, V68, P3866, DOI 10.1021/jo034248t
   Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Solomon JM, 2006, MOL CELL BIOL, V26, P28, DOI 10.1128/MCB.26.1.28-38.2006
   Szyf M, 2009, ANNU REV PHARMACOL, V49, P243, DOI 10.1146/annurev-pharmtox-061008-103102
   Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025
   van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200
   Zhang Y, 2006, CELL DEATH DIFFER, V13, P129, DOI 10.1038/sj.cdd.4401686
NR 50
TC 45
Z9 46
U1 0
U2 15
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD DEC
PY 2011
VL 10
IS 12
BP 2394
EP 2404
DI 10.1158/1535-7163.MCT-11-0525
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 865XO
UT WOS:000298344400018
PM 21980132
OA Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Tao, YG
   Liu, S
   Briones, V
   Geiman, TM
   Muegge, K
AF Tao, Yongguang
   Liu, Shuang
   Briones, Victorino
   Geiman, Theresa M.
   Muegge, Kathrin
TI Treatment of breast cancer cells with DNA demethylating agents leads to
   a release of Pol II stalling at genes with DNA-hypermethylated regions
   upstream of TSS
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID RNA-POLYMERASE-II; POLYCOMB-REPRESSIVE COMPLEX-2; TUMOR-SUPPRESSOR
   GENES; TRANSCRIPTION ELONGATION; CHROMATIN PATTERN; SILENCED GENES; SNF2
   FAMILY; METHYLATION; LSH; EXPRESSION
AB Inactivation of tumor suppressor genes plays an important role in tumorigenesis, and epigenetic modifications such as DNA methylation are frequently associated with transcriptional repression. Here, we show that gene silencing at selected genes with signs of DNA hypermethylation in breast cancer cells involves Pol II stalling. We studied several repressed genes with DNA hypermethylation within a region 1-kb upstream of the transcriptional start site that were upregulated after treatment with DNA demethylating agents, such as Azacytidine and several natural products. All those selected genes had stalled Pol II at their transcriptional start site and showed enhanced ser2 phosphorylated Pol II and elevated transcripts after drug treatment indicating successful elongation. In addition, a decrease of the epigenetic regulator LSH in a breast cancer cell line by siRNA treatment reduced DNA methylation and overcame Pol II stalling, whereas overexpression of LSH in a normal breast epithelial cell line increased DNA methylation and resulted in repression. Decrease of LSH was associated with reduced DNMT3b binding to promoter sequences, and depletion of DNMT3b by siRNA could release Pol II suggesting that DNMT3b is functionally involved. The release of paused Pol II was accompanied by a dynamic switch from repressive to active chromatin marks. Thus release of Pol II stalling can act as a mechanism for gene reactivation at specific target genes after DNA demethylating treatment in cancer cells.
C1 [Tao, Yongguang; Briones, Victorino; Geiman, Theresa M.; Muegge, Kathrin] NCI, Lab Canc Prevent, SAIC Frederick, Frederick, MD 21701 USA.
   [Tao, Yongguang] Cent S Univ, Xiangya Sch Med, Canc Res Inst, Changsha 410078, Hunan, Peoples R China.
   [Liu, Shuang] NCI, Expt Immunol Lab, Canc & Inflammat Program, Frederick, MD 21701 USA.
C3 Science Applications International Corporation (SAIC); SAIC-Frederick;
   National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); Central South University; National Institutes of Health (NIH) -
   USA; NIH National Cancer Institute (NCI)
RP Muegge, K (通讯作者)，NCI, Lab Canc Prevent, SAIC Frederick, Frederick, MD 21701 USA.
EM Kathrin.Muegge@nih.gov
FU National Institutes of Health, National Cancer Institute (NCI), Center
   for Cancer Research; National Cancer Institute, National Institutes of
   Health [N01-C0-12400]; NCI, NIH
FX Intramural Research Program of National Institutes of Health, National
   Cancer Institute (NCI), Center for Cancer Research; Federal funds from
   the National Cancer Institute, National Institutes of Health [under
   Contract No. N01-C0-12400]. Funding for open access charge: NCI, NIH.
CR Aravin AA, 2008, MOL CELL, V31, P785, DOI 10.1016/j.molcel.2008.09.003
   Bilodeau S, 2009, GENE DEV, V23, P2484, DOI 10.1101/gad.1837309
   Cairns BR, 2009, NATURE, V461, P193, DOI 10.1038/nature08450
   Christensen J, 2007, CELL, V128, P1063, DOI 10.1016/j.cell.2007.02.003
   Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228
   Das R, 2009, MAMM GENOME, V20, P563, DOI 10.1007/s00335-009-9229-y
   Datta J, 2009, CANCER RES, V69, P4277, DOI 10.1158/0008-5472.CAN-08-3669
   De la Fuente R, 2006, NAT CELL BIOL, V8, P1448, DOI 10.1038/ncb1513
   Dennis K, 2001, GENE DEV, V15, P2940, DOI 10.1101/gad.929101
   Duss S, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1734
   Einbond LS, 2007, ANTICANCER RES, V27, P697
   Erfurth FE, 2008, P NATL ACAD SCI USA, V105, P7517, DOI 10.1073/pnas.0800090105
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fan T, 2005, DEVELOPMENT, V132, P635, DOI 10.1242/dev.01612
   Fan T, 2003, CANCER RES, V63, P4677
   Fang MZ, 2003, CANCER RES, V63, P7563
   Flanagan JF, 2005, NATURE, V438, P1181, DOI 10.1038/nature04290
   Fuda NJ, 2009, NATURE, V461, P186, DOI 10.1038/nature08449
   Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200
   Gal-Yam EN, 2008, P NATL ACAD SCI USA, V105, P12979, DOI 10.1073/pnas.0806437105
   Gaspar-Maia A, 2009, NATURE, V460, P863, DOI 10.1038/nature08212
   Gemenetzidis E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004849
   Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042
   Hargreaves DC, 2009, CELL, V138, P129, DOI 10.1016/j.cell.2009.05.047
   Hawkins RD, 2010, CELL STEM CELL, V6, P479, DOI 10.1016/j.stem.2010.03.018
   Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803
   Jin BL, 2008, HUM MOL GENET, V17, P690, DOI 10.1093/hmg/ddm341
   Jin BL, 2009, CANCER RES, V69, P7412, DOI 10.1158/0008-5472.CAN-09-0116
   Keyes WM, 2011, CELL STEM CELL, V8, P164, DOI 10.1016/j.stem.2010.12.009
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   Klose RJ, 2007, CELL, V128, P889, DOI 10.1016/j.cell.2007.02.013
   Lee DW, 2000, CANCER RES, V60, P3612
   Lin JC, 2007, CANCER CELL, V12, P432, DOI 10.1016/j.ccr.2007.10.014
   Liu ZF, 2009, J PHARMACOL EXP THER, V329, P505, DOI 10.1124/jpet.108.147934
   Lopez-Bigas N, 2008, MOL CELL, V31, P520, DOI 10.1016/j.molcel.2008.08.004
   McGarvey KM, 2008, CANCER RES, V68, P5753, DOI 10.1158/0008-5472.CAN-08-0700
   Métivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Ooi SKT, 2009, J CELL SCI, V122, P2787, DOI 10.1242/jcs.015123
   Ostrow KL, 2009, CLIN CANCER RES, V15, P1184, DOI 10.1158/1078-0432.CCR-08-1304
   Pasini D, 2008, GENE DEV, V22, P1345, DOI 10.1101/gad.470008
   Pennings Sari, 2005, Briefings in Functional Genomics & Proteomics, V3, P351, DOI 10.1093/bfgp/3.4.351
   Rahl PB, 2010, CELL, V141, P432, DOI 10.1016/j.cell.2010.03.030
   Ramirez-Carrozzi VR, 2009, CELL, V138, P114, DOI 10.1016/j.cell.2009.04.020
   Rodriguez J, 2008, P NATL ACAD SCI USA, V105, P19809, DOI 10.1073/pnas.0810133105
   Ryu B, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000594
   Saunders A, 2006, NAT REV MOL CELL BIO, V7, P557, DOI 10.1038/nrm1981
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Schones DE, 2008, CELL, V132, P887, DOI 10.1016/j.cell.2008.02.022
   Simic R, 2003, EMBO J, V22, P1846, DOI 10.1093/emboj/cdg179
   Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763
   Sims RJ, 2007, MOL CELL, V28, P665, DOI 10.1016/j.molcel.2007.11.010
   Stock JK, 2007, NAT CELL BIOL, V9, P1428, DOI 10.1038/ncb1663
   Suzuki T, 2008, EPIGENETICS-US, V3, P281, DOI 10.4161/epi.3.5.6914
   Tao YG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009163
   Terranova R, 2006, P NATL ACAD SCI USA, V103, P6629, DOI 10.1073/pnas.0507425103
   Villa R, 2007, CANCER CELL, V11, P513, DOI 10.1016/j.ccr.2007.04.009
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Xi SC, 2007, P NATL ACAD SCI USA, V104, P14366, DOI 10.1073/pnas.0703669104
   Xi SC, 2009, STEM CELLS, V27, P2691, DOI 10.1002/stem.183
   Yan QS, 2003, EMBO J, V22, P5154, DOI 10.1093/emboj/cdg493
   Zeitlinger J, 2007, NAT GENET, V39, P1512, DOI 10.1038/ng.2007.26
   Zhu HM, 2006, EMBO J, V25, P335, DOI 10.1038/sj.emboj.7600925
NR 63
TC 34
Z9 39
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD DEC
PY 2011
VL 39
IS 22
BP 9508
EP 9520
DI 10.1093/nar/gkr611
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 863RT
UT WOS:000298186000012
PM 21880597
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Wu, XW
   Patterson, S
   Hawk, E
AF Wu, Xiangwei
   Patterson, Sherri
   Hawk, Ernest
TI Chemoprevention - History and general principles
SO BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY
LA English
DT Article
DE Cancer; Chemoprevention
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SURGICAL ADJUVANT BREAST; DIETARY
   VITAMIN-A; CANCER PREVENTION; PROSTATE-CANCER; LUNG-CANCER;
   COLORECTAL-CANCER; BETA-CAROTENE; DOUBLE-BLIND; CHEMICAL CARCINOGENESIS
AB Our current understanding of tumourigenesis suggests that cancer develops as a series of cumulative genetic and epigenetic derangements across time culminating in a clone of cells differing from its population of origin in terms of cellular identity, growth control, and its contextual relationship to its environment. Our increasing knowledge of the timing, sequence, frequency, and specific implications of these changes provides unique opportunities for earlier identification of aberrations and preventive interventions. Here we discuss the fundamentals of cancer prevention including the targets, cohorts, agents, endpoints, mechanistic biomarkers, designs, and strategies employed in preventive drug development. There have been many notable successes in this field such as the identification and development of tamoxifen and raloxifene for breast cancer risk reduction, instillational BCG and valrubicin for treatment of preinvasive bladder cancer, and a variety of topical and systemic agents that effectively treat preinvasive neoplastic lesions of the skin. A variety of null or negative developmental endeavours have occurred as well, including trials of beta-carotene for lung cancer prevention, nutritional modifications for colorectal adenoma prevention, and most recently, selenium and alpha-tocopherol for prostate cancer prevention. A third category of prevention trials can be summarized as investigationally successful, but not achieving regulatory success. The development of finasteride and dutasteride for prostate cancer prevention, and celecoxib for colorectal neoplasia prevention fall into this category. In less than four decades, cancer chemoprevention has transformed from a concept to an achievable reality. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Patterson, Sherri; Hawk, Ernest] Univ Texas MD Anderson Canc Ctr, Div Canc Prevent & Populat Sci, Unit 1370, Houston, TX 77030 USA.
   [Wu, Xiangwei] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Unit 1360, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center
RP Hawk, E (通讯作者)，Univ Texas MD Anderson Canc Ctr, Div Canc Prevent & Populat Sci, Unit 1370, POB 301439, Houston, TX 77030 USA.
EM xwwu@mdanderson.org; spatterson@mdanderson.org; ehawk@mdanderson.org
CR Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Andriole GL, 2010, NEW ENGL J MED, V362, P1192, DOI 10.1056/NEJMoa0908127
   [Anonymous], 1994, Ann Epidemiol, V4, P1, DOI 10.1016/1047-2797(94)90036-1
   Arber N, 2006, NEW ENGL J MED, V355, P885, DOI 10.1056/NEJMoa061652
   Bach PB, 2003, JNCI-J NATL CANCER I, V95, P470, DOI 10.1093/jnci/95.6.470
   BALMAIN A, 1988, BRIT J CANCER, V58, P72
   Baron JA, 1999, NEW ENGL J MED, V340, P101, DOI 10.1056/NEJM199901143400204
   Baron JA, 1998, J NATL CANCER I, V90, P57, DOI 10.1093/jnci/90.1.57
   Baron JA, 2003, NEW ENGL J MED, V348, P891, DOI 10.1056/NEJMoa021735
   Baron JA, 2008, LANCET, V372, P1756, DOI 10.1016/S0140-6736(08)61490-7
   Barthelman M, 1998, CANCER RES, V58, P711
   Beatson GT., 1896, LANCET, V148, P104
   Benamouzig R, 2003, GASTROENTEROLOGY, V125, P328, DOI 10.1016/S0016-5085(03)00887-4
   Bertagnolli MM, 2006, NEW ENGL J MED, V355, P873, DOI 10.1056/NEJMoa061355
   Bertagnolli MM, 2009, CANCER PREV RES, V2, P310, DOI 10.1158/1940-6207.CAPR-08-0206
   BJELKE E, 1975, INT J CANCER, V15, P561, DOI 10.1002/ijc.2910150405
   BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483
   Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103
   Boone CW, 1997, J CELL BIOCHEM, P1
   Chan AT, 2005, JAMA-J AM MED ASSOC, V294, P914, DOI 10.1001/jama.294.8.914
   Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602
   Clark LC, 1998, BRIT J UROL, V81, P730
   Coogan PF, 2000, CANCER CAUSE CONTROL, V11, P249, DOI 10.1023/A:1008931708716
   Cook NR, 2005, JAMA-J AM MED ASSOC, V294, P47, DOI 10.1001/jama.294.1.47
   Cooper K, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI [10.3310/hta14320, 10.3310/hta.14320]
   Corley DA, 2003, GASTROENTEROLOGY, V124, P47, DOI 10.1053/gast.2003.50008
   Cuzick J, 2009, LANCET ONCOL, V10, P501, DOI 10.1016/S1470-2045(09)70035-X
   DOBZHANSKY T, 1946, GENETICS, V31, P269
   Duffield-Lillico AJ, 2003, BJU INT, V91, P608, DOI 10.1046/j.1464-410X.2003.04167.x
   Erdelyi I, 2009, J NUTR, V139, P2072, DOI 10.3945/jn.108.104125
   *FDA, 2008, HLTH CLAIMS CALC VIT
   Fisher B, 2005, JNCI-J NATL CANCER I, V97, P1652, DOI 10.1093/jnci/dji372
   Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371
   Flossmann E, 2007, LANCET, V369, P1603, DOI 10.1016/S0140-6736(07)60747-8
   GAIL MH, 1989, JNCI-J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879
   GANN PH, 1993, CANCER, V85, P1220
   GIARDIELLO FM, 1994, CANCER METAST REV, V13, P279, DOI 10.1007/BF00666098
   Goodman GE, 2004, J NATL CANCER I, V96, P1743, DOI 10.1093/jnci/djh320
   Goss PE, 2011, NEW ENGL J MED, V364, P2381, DOI 10.1056/NEJMoa1103507
   Grau MV, 2007, JNCI-J NATL CANCER I, V99, P129, DOI 10.1093/jnci/djk016
   Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014
   Greenwald P, 1996, SCI AM, V275, P96, DOI 10.1038/scientificamerican0996-96
   GUARENTE L, 1993, TRENDS GENET, V9, P362, DOI 10.1016/0168-9525(93)90042-G
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Harris R. E., 2009, Inflammopharmacology, V17, P55, DOI 10.1007/s10787-009-8049-8
   Hawk E, 2005, CANCER EPIDEM BIOMAR, V14, P297, DOI 10.1158/1055-9965.EPI-14-2-EDA
   Hawk ET, 2005, RECENT RESULTS CANC, V166, P71
   Hawkey CJ, 2009, CLIN DRUG INVEST, V29, P677, DOI 10.2165/11317830-000000000-00000
   Heinonen OP, 1998, J NATL CANCER I, V90, P440, DOI 10.1093/jnci/90.6.440
   Huang K, 2011, FAM CANCER, V10, P303, DOI 10.1007/s10689-011-9423-4
   Huang SY, 2011, CANCER PREV RES, V4, P666, DOI 10.1158/1940-6207.CAPR-10-0235
   JANKOWSKI JA, 2010, GASTROINTEST ENDOSC, V21, P155
   Johnson JR, 2011, J NATL CANCER I, V103, P636, DOI 10.1093/jnci/djr062
   Jordan V C, 1980, Recent Results Cancer Res, V71, P30
   Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691
   KELLOFF GJ, 1995, CANCER EPIDEM BIOMAR, V4, P1
   KELLOFF GJ, 2002, CHEMOPREVENTION CANC
   Klein EA, 2003, WORLD J UROL, V21, P21, DOI 10.1007/s00345-002-0314-z
   Klein EA, 2011, JAMA-J AM MED ASSOC, V306, P1549, DOI 10.1001/jama.2011.1437
   Koutsky LA, 2002, NEW ENGL J MED, V347, P1645, DOI 10.1056/NEJMoa020586
   Kristal AR, 2009, J NATL CANCER I, V101, P363, DOI 10.1093/jnci/djp029
   KVALE G, 1983, INT J CANCER, V31, P397, DOI 10.1002/ijc.2910310402
   Lamm DL, 2000, CLIN INFECT DIS, V31, pS86, DOI 10.1086/314064
   Lanza FL, 2009, AM J GASTROENTEROL, V104, P728, DOI 10.1038/ajg.2009.115
   Lathrop A E, 1916, J Cancer Res, V1, P1
   Lippman SM, 2009, JAMA-J AM MED ASSOC, V301, P39, DOI 10.1001/jama.2008.864
   LUCCHESI JC, 1968, GENETICS, V59, P37
   Lynch PM, 2010, AM J GASTROENTEROL, V105, P1437, DOI 10.1038/ajg.2009.758
   Metcalfe KA, 2005, FAM CANCER, V4, P97, DOI 10.1007/s10689-005-4215-3
   Meyskens FL, 2008, CANCER PREV RES, V1, P32, DOI 10.1158/1940-6207.CAPR-08-0042
   O'Shaughnessy JA, 2002, CLIN CANCER RES, V8, P314
   Omenn GS, 1996, J NATL CANCER I, V88, P1550, DOI 10.1093/jnci/88.21.1550
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Patrono C, 2008, CHEST, V133, p199S, DOI 10.1378/chest.08-0672
   PETO R, 1981, NATURE, V290, P201, DOI 10.1038/290201a0
   Phillips RKS, 2002, GUT, V50, P857, DOI 10.1136/gut.50.6.857
   Redman MW, 2008, CANCER PREV RES, V1, P174, DOI 10.1158/1940-6207.CAPR-08-0092
   Reinhardt HC, 2009, CELL CYCLE, V8, P3112, DOI 10.4161/cc.8.19.9626
   Rothwell PM, 2010, LANCET, V376, P1741, DOI 10.1016/S0140-6736(10)61543-7
   Sandler RS, 2003, NEW ENGL J MED, V348, P883, DOI 10.1056/NEJMoa021633
   Scheiman JM, 2010, CLIN THER, V32, P667, DOI 10.1016/j.clinthera.2010.04.009
   Serebruany VL, 2005, AM J CARDIOL, V95, P1218, DOI 10.1016/j.amjcard.2005.01.049
   SHEKELLE RB, 1981, LANCET, V2, P1185
   Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247
   SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q
   *SOC AC, HIST CANC
   Solomon SD, 2008, CIRCULATION, V117, P2104, DOI 10.1161/CIRCULATIONAHA.108.764530
   Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405
   Spitz MR, 2007, JNCI-J NATL CANCER I, V99, P715, DOI 10.1093/jnci/djk153
   SPORN MB, 1976, FED PROC, V35, P1332
   Squires H, 2011, CLIN THER, V33, P1289, DOI 10.1016/j.clinthera.2011.07.009
   Steele VE, 1998, HEMATOL ONCOL CLIN N, V12, P943, DOI 10.1016/S0889-8588(05)70035-6
   Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603
   Theoret MR, 2011, NEW ENGL J MED, V365, P97, DOI 10.1056/NEJMp1106783
   Thompson IM, 2003, NEW ENGL J MED, V349, P215, DOI 10.1056/NEJMoa030660
   Vane JR, 1998, INT J TISSUE REACT, V20, P3
   Viner JL., 2006, CANC EPIDEMIOLOGY PR, P1318
   Vogel VG, 2006, JAMA-J AM MED ASSOC, V295, P2727, DOI 10.1001/jama.295.23.joc60074
   VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901
   Wen CP, 2011, LANCET, V378, P1244, DOI 10.1016/S0140-6736(11)60749-6
   William WN, 2009, NAT REV DRUG DISCOV, V8, P213, DOI 10.1038/nrd2663
   WU X, NAT REV CAN IN PRESS
   YUSPA SH, 1988, ADV CANCER RES, V50, P25, DOI 10.1016/S0065-230X(08)60434-0
   Yuspa SH, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P147
   Zhang L, 2010, NATURE, V464, P1058, DOI 10.1038/nature08871
   ZIEGLER RG, 1989, J NUTR, V119, P116, DOI 10.1093/jn/119.1.116
NR 107
TC 38
Z9 43
U1 0
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1521-6918
EI 1532-1916
J9 BEST PRACT RES CL GA
JI Best Pract. Res. Clin. Gastroenterol.
PD AUG-OCT
PY 2011
VL 25
IS 4-5
BP 445
EP 459
DI 10.1016/j.bpg.2011.10.012
PG 15
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 868OL
UT WOS:000298532500002
PM 22122762
DA 2025-01-12
ER

PT J
AU Byun, HM
   Heo, K
   Mitchell, KJ
   Yang, AS
AF Byun, Hyang-Min
   Heo, Kyu
   Mitchell, Kasey J.
   Yang, Allen S.
TI Mono-allelic retrotransposon insertion addresses epigenetic
   transcriptional repression in human genome
SO JOURNAL OF BIOMEDICAL SCIENCE
LA English
DT Article
DE Epigenetics; Retrotransposons; Long interspersed elements; Alu
ID PROGESTERONE-RECEPTOR GENE; BREAST-CANCER; IN-VIVO; POLYMORPHISM;
   EXPRESSION; ELEMENTS; PROGINS; RISK; TRANSPOSITION; ENDOMETRIOSIS
AB Background: Retrotransposons have been extensively studied in plants and animals and have been shown to have an impact on human genome dynamics and evolution. Their ability to move within genomes gives retrotransposons to affect genome instability.
   Methods: we examined the polymorphic inserted AluYa5, evolutionary young Alu, in the progesterone receptor gene to determine the effects of Alu insertion on molecular environment. We used mono-allelic inserted cell lines which carry both Alu-present and Alu-absent alleles. To determine the epigenetic change and gene expression, we performed restriction enzyme digestion, Pyrosequencing, and Chromatin Immunoprecipitation.
   Results: We observed that the polymorphic insertion of evolutionally young Alu causes increasing levels of DNA methylation in the surrounding genomic area and generates inactive histone tail modifications. Consequently the Alu insertion deleteriously inactivates the neighboring gene expression.
   Conclusion: The mono-allelic Alu insertion cell line clearly showed that polymorphic inserted repetitive elements cause the inactivation of neighboring gene expression, bringing aberrant epigenetic changes.
C1 [Byun, Hyang-Min; Yang, Allen S.] Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Jane Anne Nohl Div Hematol, Los Angeles, CA 90033 USA.
   [Heo, Kyu] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA.
   [Mitchell, Kasey J.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
   [Heo, Kyu] Dongnam Inst Radiol & Med Sci, Res Ctr, Pusan 619953, South Korea.
   [Yang, Allen S.] Amgen Inc, Thousand Oaks, CA 91320 USA.
C3 University of Southern California; University of Southern California;
   Harvard University; Harvard T.H. Chan School of Public Health; Korea
   Institute of Radiological & Medical Sciences; Amgen
RP Byun, HM (通讯作者)，Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Jane Anne Nohl Div Hematol, Los Angeles, CA 90033 USA.
EM hmbyun@hsph.harvard.edu
RI ; Byun, Hyang-Min/X-2843-2018
OI Heo, Kyu/0000-0001-8833-4731; Byun, Hyang-Min/0000-0002-6278-3165
CR Agoulnik IU, 2004, J CLIN ENDOCR METAB, V89, P6340, DOI 10.1210/jc.2004-0114
   Arnaud P, 2000, MOL CELL BIOL, V20, P3434, DOI 10.1128/MCB.20.10.3434-3441.2000
   BRANCIFORTE D, 1994, MOL CELL BIOL, V14, P2584, DOI 10.1128/MCB.14.4.2584
   Brouha B, 2003, P NATL ACAD SCI USA, V100, P5280, DOI 10.1073/pnas.0831042100
   Byun HM, 2007, CANCER RES, V67, P10753, DOI 10.1158/0008-5472.CAN-07-0329
   Byun HM, 2009, HUM MOL GENET, V18, P4808, DOI 10.1093/hmg/ddp445
   De Vivo I, 2002, P NATL ACAD SCI USA, V99, P12263, DOI 10.1073/pnas.192172299
   Deininger PL, 1999, MOL GENET METAB, V67, P183, DOI 10.1006/mgme.1999.2864
   Engehausen DG, 2000, ANTICANCER RES, V20, P5145
   Ergün S, 2004, J BIOL CHEM, V279, P27753, DOI 10.1074/jbc.M312985200
   Hollister JD, 2009, GENOME RES, V19, P1419, DOI 10.1101/gr.091678.109
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Lattuada D, 2004, CLIN ENDOCRINOL, V61, P190, DOI 10.1111/j.1365-2265.2004.02076.x
   Li WL, 2004, PLANT J, V40, P500, DOI 10.1111/j.1365-313X.2004.02228.x
   Li XM, 2001, HUM MUTAT, V17, P511, DOI 10.1002/humu.1134
   Miki Y, 1998, J HUM GENET, V43, P77, DOI 10.1007/s100380050045
   Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202
   Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032
   ROWE SM, 1995, CANCER RES, V55, P2743
   SanMiguel P, 1998, NAT GENET, V20, P43, DOI 10.1038/1695
   Symer DE, 2002, CELL, V110, P327, DOI 10.1016/S0092-8674(02)00839-5
   Wang-Gohrke S, 2000, CANCER RES, V60, P2348
   Wasserman L, 2004, INT J OBESITY, V28, P49, DOI 10.1038/sj.ijo.0802481
   Wieser F, 2002, FERTIL STERIL, V77, P309, DOI 10.1016/S0015-0282(01)02984-3
   Wolff EM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000917
   Xing JC, 2009, GENOME RES, V19, P1516, DOI 10.1101/gr.091827.109
NR 27
TC 14
Z9 16
U1 0
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1021-7770
J9 J BIOMED SCI
JI J. Biomed. Sci.
PD FEB 2
PY 2012
VL 19
AR 13
DI 10.1186/1423-0127-19-13
PG 8
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 921MX
UT WOS:000302482800001
PM 22300442
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Yamamoto, N
   Nakayama, T
   Kajita, M
   Miyake, T
   Iwamoto, T
   Kim, SJ
   Sakai, A
   Ishihara, H
   Tamaki, Y
   Noguchi, S
AF Yamamoto, Noriaki
   Nakayama, Takahiro
   Kajita, Masahiro
   Miyake, Tomohiro
   Iwamoto, Takashi
   Kim, Seung Jin
   Sakai, Ayako
   Ishihara, Hideki
   Tamaki, Yasuhiro
   Noguchi, Shinzaburo
TI Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2
   in serum DNA of patients with breast cancer by a newly established
   one-step methylation-specific PCR assay
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer; Methylation; DNA; Serum
ID MULTIPLE GENES; HYPERMETHYLATION; EPIGENOMICS; BIOMARKERS; MARKERS;
   EPIGENETICS; DISEASE
AB Aberrant promoter methylation of genes is a common molecular event in breast cancer. Thus, DNA methylation analysis is expected to be a new tool for cancer diagnosis. In this article, we have established a new, high-performance DNA methylation assay, the one-step methylation-specific polymerase chain reaction (OS-MSP) assay, which is optimized for analyzing gene methylation in serum DNA. The OS-MSP assay is designed to detect aberrant promoter methylation of GSTP1, RASSF1A, and RAR beta 2 genes in serum DNA. Moreover, two quality control markers were designed for monitoring the bisulfite conversion efficiency and measuring the DNA content in the serum. Serum samples were collected from patients with primary (n = 101, stages I-III) and metastatic breast cancers (n = 58) as well as from healthy controls (n = 87). If methylation of at least one of the three genes was observed, the OS-MSP assay was considered positive. The sensitivity of this assay was significantly higher than that of the assay involving conventional tumor markers (CEA and/or CA15-3) for stages I (24 vs. 8%) and II (26 vs. 8%) breast cancer and similar to that of the assay involving the conventional tumor markers for stage III (18 vs. 19%) and metastatic breast cancers (55 vs. 59%). The results of the OS-MSP assay and those of the assay involving CEA and/or CA15-3 seemed to compensate for each other because sensitivity of these assays increased to 78% when used in combination for metastatic breast cancer. In conclusion, we have developed a new OS-MSP assay with improved sensitivity and convenience; thus, this assay is more suitable for detecting aberrant promoter methylation in serum DNA. Moreover, the combination of the OS-MSP assay and the assay involving CEA and/or CA15-3 is promising for enhancing the sensitivity of diagnosis of metastatic breast cancer.
C1 [Yamamoto, Noriaki; Nakayama, Takahiro; Miyake, Tomohiro; Iwamoto, Takashi; Kim, Seung Jin; Tamaki, Yasuhiro; Noguchi, Shinzaburo] Osaka Univ, Grad Sch Med, Dept Breast & Endocrine Surg, Suita, Osaka 5650871, Japan.
   [Yamamoto, Noriaki; Kajita, Masahiro; Sakai, Ayako; Ishihara, Hideki] Sysmex Corp, Cent Res Labs, Nishi Ku, Kobe, Hyogo 6512271, Japan.
C3 Osaka University; Sysmex Corporation
RP Noguchi, S (通讯作者)，Osaka Univ, Grad Sch Med, Dept Breast & Endocrine Surg, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM noguchi@onsurg.med.osaka-u.ac.jp
RI Nakayama, Takahiro/AAE-8953-2019
OI MIYAKE, TOMOHIRO/0000-0002-9362-9822
FU Promotion of Cancer Research (Japan)
FX This research was supported by Promotion of Cancer Research (Japan) for
   the 3rd Term Comprehensive 10-Year Strategy for Cancer Control. The
   authors thank Noriko Oka and Kaya Tai for their assistance during the
   assay development.
CR Baylin SB, 1998, ADV CANCER RES, V72, P141
   BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I
   Brock MV, 2008, NEW ENGL J MED, V358, P1118, DOI 10.1056/NEJMoa0706550
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Fiegl H, 2005, CANCER RES, V65, P1141, DOI 10.1158/0008-5472.CAN-04-2438
   Grunau C, 2001, NUCLEIC ACIDS RES, V29, P270, DOI 10.1093/nar/29.1.270
   Hayatsu Hikoya, 2008, Curr Protoc Nucleic Acid Chem, VChapter 6, DOI 10.1002/0471142700.nc0610s33
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kim MS, 2010, CANCER METAST REV, V29, P181, DOI 10.1007/s10555-010-9207-6
   Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879
   Lofton-Day C, 2008, CLIN CHEM, V54, P414, DOI 10.1373/clinchem.2007.095992
   Ludwig JA, 2005, NAT REV CANCER, V5, P845, DOI 10.1038/nrc1739
   Martens JWM, 2009, FUTURE ONCOL, V5, P1245, DOI [10.2217/fon.09.89, 10.2217/FON.09.89]
   Mehrotra J, 2004, CLIN CANCER RES, V10, P2052, DOI 10.1158/1078-0432.CCR-03-0514
   Mulero-Navarro S, 2008, CRIT REV ONCOL HEMAT, V68, P1, DOI 10.1016/j.critrevonc.2008.03.001
   Müller HM, 2003, CANCER RES, V63, P7641
   ROBBINS P, 1995, HUM PATHOL, V26, P873, DOI 10.1016/0046-8177(95)90010-1
   Stearns V, 1998, BREAST CANCER RES TR, V52, P239, DOI 10.1023/A:1006137619153
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
NR 28
TC 69
Z9 76
U1 0
U2 15
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD FEB
PY 2012
VL 132
IS 1
BP 165
EP 173
DI 10.1007/s10549-011-1575-2
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 892HX
UT WOS:000300278400016
PM 21594664
DA 2025-01-12
ER

PT J
AU Huang, Y
   Vasilatos, SN
   Boric, L
   Shaw, PG
   Davidson, NE
AF Huang, Yi
   Vasilatos, Shauna N.
   Boric, Lamia
   Shaw, Patrick G.
   Davidson, Nancy E.
TI Inhibitors of histone demethylation and histone deacetylation cooperate
   in regulating gene expression and inhibiting growth in human breast
   cancer cells
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Histone demethylase; Histone deacetylase; Epigenetics; Breast cancer;
   Growth inhibition; Gene expression
ID ESTROGEN-RECEPTOR-ALPHA; POLYAMINE ANALOGS; SILENCED GENES;
   REEXPRESSION; ER; COMBINATION; REPRESSION; APOPTOSIS; LINES; LSD1
AB Abnormal activities of histone lysine demethylases (KDMs) and lysine deacetylases (HDACs) are associated with aberrant gene expression in breast cancer development. However, the precise molecular mechanisms underlying the crosstalk between KDMs and HDACs in chromatin remodeling and regulation of gene transcription are still elusive. In this study, we showed that treatment of human breast cancer cells with inhibitors targeting the zinc cofactor dependent class I/II HDAC, but not NAD(+) dependent class III HDAC, led to significant increase of H3K4me2 which is a specific substrate of histone lysine-specific demethylase 1 (LSD1) and a key chromatin mark promoting transcriptional activation. We also demonstrated that inhibition of LSD1 activity by a pharmacological inhibitor, pargyline, or siRNA resulted in increased acetylation of H3K9 (AcH3K9). However, siRNA knockdown of LSD2, a homolog of LSD1, failed to alter the level of AcH3K9, suggesting that LSD2 activity may not be functionally connected with HDAC activity. Combined treatment with LSD1 and HDAC inhibitors resulted in enhanced levels of H3K4me2 and AcH3K9, and exhibited synergistic growth inhibition of breast cancer cells. Finally, microarray screening identified a unique subset of genes whose expression was significantly changed by combination treatment with inhibitors of LSD1 and HDAC. Our study suggests that LSD1 intimately interacts with histone deacetylases in human breast cancer cells. Inhibition of histone demethylation and deacetylation exhibits cooperation and synergy in regulating gene expression and growth inhibition, and may represent a promising and novel approach for epigenetic therapy of breast cancer.
C1 [Huang, Yi; Vasilatos, Shauna N.; Boric, Lamia; Shaw, Patrick G.; Davidson, Nancy E.] Univ Pittsburgh Canc Inst, Pittsburgh, PA 15260 USA.
   [Huang, Yi; Davidson, Nancy E.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA.
   [Shaw, Patrick G.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Johns Hopkins University; Johns
   Hopkins Bloomberg School of Public Health
RP Huang, Y (通讯作者)，Univ Pittsburgh Canc Inst, Pittsburgh, PA 15260 USA.
EM yih26@pitt.edu
RI Huang, Yi/AAW-7892-2021
OI Huang, Yi/0000-0002-9982-117X
FU NIH [CA88843]; Breast Cancer Research Foundation
FX This work was funded in part by NIH grant CA88843 and the Breast Cancer
   Research Foundation.
CR Alexopoulou AN, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2610
   Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651
   Bradley C, 2007, CARCINOGENESIS, V28, P2184, DOI 10.1093/carcin/bgm100
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Ciccone DN, 2009, NATURE, V461, P415, DOI 10.1038/nature08315
   Ficner R, 2009, CURR TOP MED CHEM, V9, P235, DOI 10.2174/156802609788085304
   Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080
   Hahm HA, 2001, CLIN CANCER RES, V7, P391
   Ho TF, 2007, TOXICOL APPL PHARM, V225, P318, DOI 10.1016/j.taap.2007.08.007
   Huang Y, 2004, MOL CANCER RES, V2, P81
   Huang Y, 2003, CLIN CANCER RES, V9, P2769
   Huang Y, 2007, P NATL ACAD SCI USA, V104, P8023, DOI 10.1073/pnas.0700720104
   Huang Y, 2009, ESSAYS BIOCHEM, V46, P95, DOI [10.1042/BSE0460007, 10.1042/bse0460007]
   Huang Y, 2009, CLIN CANCER RES, V15, P7217, DOI 10.1158/1078-0432.CCR-09-1293
   Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570
   Karytinos A, 2009, J BIOL CHEM, V284, P17775, DOI 10.1074/jbc.M109.003087
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   Lan F, 2007, NATURE, V448, P718, DOI 10.1038/nature06034
   Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021
   Liang GQ, 2009, J BIOL CHEM, V284, P21719, DOI 10.1074/jbc.M109.028407
   Marks PA, 2004, ADV CANCER RES, V91, P137, DOI 10.1016/S0065-230X(04)91004-4
   Novak P, 2008, CANCER RES, V68, P8616, DOI 10.1158/0008-5472.CAN-08-1419
   Rao R, 2010, MOL CANCER THER, V9, P942, DOI 10.1158/1535-7163.MCT-09-0988
   Scoumanne A, 2007, J BIOL CHEM, V282, P15471, DOI 10.1074/jbc.M701023200
   Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402
   Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Stearns V, 2007, CANCER INVEST, V25, P659, DOI 10.1080/07357900701719234
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Wu Q, 1997, MOL CELL BIOL, V17, P6598, DOI 10.1128/MCB.17.11.6598
   Yang XW, 2000, CANCER RES, V60, P6890
   Yang Z, 2010, CELL RES, V20, P276, DOI 10.1038/cr.2010.12
   Zhou Q, 2007, CANCER BIOL THER, V6, P64, DOI 10.4161/cbt.6.1.3549
NR 34
TC 101
Z9 119
U1 1
U2 35
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD FEB
PY 2012
VL 131
IS 3
BP 777
EP 789
DI 10.1007/s10549-011-1480-8
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 879QE
UT WOS:000299346100005
PM 21452019
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Kim, J
   Hwang, J
   Jeong, H
   Song, HJ
   Shin, J
   Hur, G
   Park, YW
   Lee, SH
   Kim, J
AF Kim, Jeeyeon
   Hwang, Junha
   Jeong, Hyeseon
   Song, Hee-Jung
   Shin, Jieun
   Hur, Gangmin
   Park, Young Woo
   Lee, Suk Hoon
   Kim, Jei
TI Promoter methylation status of VEGF receptor genes A possible epigenetic
   biomarker to anticipate the efficacy of intracellular-acting
   VEGF-targeted drugs in cancer cells
SO EPIGENETICS
LA English
DT Article
DE vascular endothelial growth factor (VEGF); VEGF receptor (VEGFR); Flt1;
   KDR; promoter hypermethylation; epigenetic change; VEGF-targeted drug;
   VEGF-specific tyrosine kinase inhibitor; VEGF-specific antibody;
   VEGFR2-specific antibody
ID ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE INHIBITOR; TUMOR
   ANGIOGENESIS; BREAST-CANCER; EXPRESSION; AUTOCRINE; SUNITINIB;
   BEVACIZUMAB; RESISTANCE; MECHANISMS
AB We evaluated whether the inhibitory effects of vascular endothelial growth factor (VEGF)-targeted drugs on the proliferation of cancer cells differed according to VEGF receptor (VEGFR) genes, Flt1 and KDR, promoter methylation status. Five hyper-VEGFR-methylation and six no-VEGFR-methylation cancer cells were used for the present study, together with human umbilical endothelial cells (HUVECs) as a control. No-VEGFR-methylation cancer cells showed higher expression of Flt1 and KDR than hyper-VEGFR-methylation cancer cells. Hyper-VEGFR-methylation cancer cells only showed increased expression and protein levels of Flt1 and KDR after treatment with the demethylase 5-aza-2'-deoxycytidine. Two drugs (a VEGF-specific-antibody, bevacizumab and a KDR-specific-antibody) targeting extracellular VEGF-VEGFR signaling and two VEGF-specific-tyrosine kinase inhibitors (PTK/ZK and sunitinib) targeting intracellular VEGFR signaling were used in the cell proliferation assay. HUVECs showed dose-and time-dependent proliferation decrease with all tested drugs over a 72 h incubation period. No-or hyper-VEGFR-methylation cancer cells showed no significant proliferation differences after treatment with VEGF-specific-antibody or VEGFR2-specific-antibody. After PTK/ZK or sunitinib treatment, no-VEGFR-methylation cancer cells showed dose-or time-dependent decreases in proliferation. Hyper-VEGFR-methylation cancer cells also showed proliferation inhibition by VEGF-specific-tyrosine kinase inhibitors after demethylation of Flt1 and KDR. Proliferation inhibition synergistically increased after combination of demethylation with PTK/ZK in hyper-VEGF-methylation cancer cells. We observed that intracellular targeting of VEGF-VEGFR signaling could be more effective than extracellular targeting of the pathway in the suppression of proliferation of some cancer cells. In particular, the efficacy of intracellular targeting of VEGF-specific-tyrosine kinase inhibitors might be influenced by the epigenetic alteration of VEGFRs.
C1 [Kim, Jeeyeon; Hwang, Junha; Jeong, Hyeseon; Song, Hee-Jung; Kim, Jei] Chungnam Natl Univ, Hosp & Sch Med, Neurogenet Lab, Taejon, South Korea.
   [Kim, Jeeyeon; Hwang, Junha; Jeong, Hyeseon; Song, Hee-Jung; Kim, Jei] Chungnam Natl Univ, Hosp & Sch Med, Dept Neurol, Taejon, South Korea.
   [Shin, Jieun; Lee, Suk Hoon] Chungnam Natl Univ, Coll Nat Sci, Dept Informat & Stat, Taejon, South Korea.
   [Hur, Gangmin] Chungnam Natl Univ, Dept Pharmacol, Sch Med, Taejon, South Korea.
   [Park, Young Woo] Korea Res Inst Biosci & Biotechnol, Integrat Omics Res Ctr, Taejon, South Korea.
C3 Chungnam National University; Chungnam National University; Chungnam
   National University; Chungnam National University; Korea Research
   Institute of Bioscience & Biotechnology (KRIBB)
RP Kim, J (通讯作者)，Chungnam Natl Univ, Hosp & Sch Med, Neurogenet Lab, Taejon, South Korea.
EM jeikim@cnu.ac.kr
RI Hur, Gang-min/ABF-9263-2021; lee, jung/H-8107-2018; lee,
   hy/GRS-0797-2022; Kim, Beom Joon/C-2904-2011
OI Song, Hee-Jung/0000-0001-9572-4105; hur, gang min/0000-0003-4870-6574
FU Ministry of Knowledge Economy (MKE) of Korea [B0009735]
FX This work was financially supported by the Regional Research and
   Development Cluster Project (B0009735) funded by the Ministry of
   Knowledge Economy (MKE) of Korea.
CR Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442
   BOOCOCK CA, 1995, JNCI-J NATL CANCER I, V87, P506, DOI 10.1093/jnci/87.7.506
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005
   Colella S, 2003, BIOTECHNIQUES, V35, P146, DOI 10.2144/03351md01
   De Jong JS, 1998, J PATHOL, V184, P44
   de Jonge MJA, 2006, EUR J CANCER, V42, P1351, DOI 10.1016/j.ejca.2006.02.013
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   Dias S, 2001, P NATL ACAD SCI USA, V98, P10857, DOI 10.1073/pnas.191117498
   Dias S, 2000, J CLIN INVEST, V106, P511, DOI 10.1172/JCI8978
   Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403
   Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Ferrara N, 2005, ONCOLOGY-BASEL, V69, P11, DOI 10.1159/000088479
   Ferrer FA, 1999, UROLOGY, V54, P567, DOI 10.1016/S0090-4295(99)00156-9
   Hess-Stumpp H, 2005, CHEMBIOCHEM, V6, P550, DOI 10.1002/cbic.200400305
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kim JY, 2009, EPIGENETICS-US, V4, P313, DOI 10.4161/epi.4.5.9160
   Kobayashi H, 2008, ANN SURG ONCOL, V15, P1232, DOI 10.1245/s10434-008-9811-7
   LoRusso PM, 2008, EXPERT OPIN INV DRUG, V17, P1013, DOI [10.1517/13543784.17.7.1013, 10.1517/13543784.17.7.1013 ]
   Masood R, 2001, BLOOD, V98, P1904, DOI 10.1182/blood.V98.6.1904
   Mendel DB, 2003, CLIN CANCER RES, V9, P327
   Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113
   Miller KD, 2005, CLIN CANCER RES, V11, P3369, DOI 10.1158/1078-0432.CCR-04-1923
   Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
   Nia PS, 2007, HISTOPATHOLOGY, V51, P354, DOI 10.1111/j.1365-2559.2007.02800.x
   Nishida T, 2009, INT J CLIN ONCOL, V14, P143, DOI 10.1007/s10147-008-0822-y
   Passalidou E, 2002, BRIT J CANCER, V86, P244, DOI 10.1038/sj.bjc.6600015
   Prewett M, 1999, CANCER RES, V59, P5209
   Roskoski R, 2007, BIOCHEM BIOPH RES CO, V356, P323, DOI 10.1016/j.bbrc.2007.02.156
   Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884
   Takahama M, 1999, MOL CARCINOGEN, V24, P287, DOI 10.1002/(SICI)1098-2744(199904)24:4<287::AID-MC6>3.0.CO;2-T
   Von Marschall Z, 2000, GASTROENTEROLOGY, V119, P1358, DOI 10.1053/gast.2000.19578
   Wang WL, 2011, CANCER CHEMOTH PHARM, V67, P15, DOI 10.1007/s00280-010-1513-8
   Wedge SR, 2005, CANCER RES, V65, P4389, DOI 10.1158/0008-5472.CAN-04-4409
   Young E, 2010, CANCER BIOL THER, V10, P703, DOI 10.4161/cbt.10.7.12904
NR 38
TC 27
Z9 28
U1 0
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD FEB
PY 2012
VL 7
IS 2
BP 191
EP 200
DI 10.4161/epi.7.2.18973
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 890OR
UT WOS:000300154600011
PM 22395469
OA Bronze
DA 2025-01-12
ER

PT J
AU Hon, GC
   Hawkins, RD
   Caballero, OL
   Lo, C
   Lister, R
   Pelizzola, M
   Valsesia, A
   Ye, Z
   Kuan, S
   Edsall, LE
   Camargo, AA
   Stevenson, BJ
   Ecker, JR
   Bafna, V
   Strausberg, RL
   Simpson, AJ
   Ren, B
AF Hon, Gary C.
   Hawkins, R. David
   Caballero, Otavia L.
   Lo, Christine
   Lister, Ryan
   Pelizzola, Mattia
   Valsesia, Armand
   Ye, Zhen
   Kuan, Samantha
   Edsall, Lee E.
   Camargo, Anamaria Aranha
   Stevenson, Brian J.
   Ecker, Joseph R.
   Bafna, Vineet
   Strausberg, Robert L.
   Simpson, Andrew J.
   Ren, Bing
TI Global DNA hypomethylation coupled to repressive chromatin domain
   formation and gene silencing in breast cancer
SO GENOME RESEARCH
LA English
DT Article
ID NUCLEAR LAMINA INTERACTIONS; BODY-SPECIFIC METHYLATION; COLORECTAL
   CANCERS; PROMOTER HYPERMETHYLATION; SOMATIC MUTATIONS; SATELLITE
   REPEATS; EPITHELIAL-CELLS; RENAL-CARCINOMA; COMMON EVENT; HUMAN GENOME
AB While genetic mutation is a hallmark of cancer, many cancers also acquire epigenetic alterations during tumorigenesis including aberrant DNA hypermethylation of tumor suppressors, as well as changes in chromatin modifications as caused by genetic mutations of the chromatin-modifying machinery. However, the extent of epigenetic alterations in cancer cells has not been fully characterized. Here, we describe complete methylome maps at single nucleotide resolution of a low-passage breast cancer cell line and primary human mammary epithelial cells. We find widespread DNA hypomethylation in the cancer cell, primarily at partially methylated domains (PMDs) in normal breast cells. Unexpectedly, genes within these regions are largely silenced in cancer cells. The loss of DNA methylation in these regions is accompanied by formation of repressive chromatin, with a significant fraction displaying allelic DNA methylation where one allele is DNA methylated while the other allele is occupied by histone modifications H3K9me3 or H3K27me3. Our results show a mutually exclusive relationship between DNA methylation and H3K9me3 or H3K27me3. These results suggest that global DNA hypomethylation in breast cancer is tightly linked to the formation of repressive chromatin domains and gene silencing, thus identifying a potential epigenetic pathway for gene regulation in cancer cells.
C1 [Hon, Gary C.; Hawkins, R. David; Ye, Zhen; Kuan, Samantha; Edsall, Lee E.; Ren, Bing] Ludwig Inst Canc Res, La Jolla, CA 92093 USA.
   [Caballero, Otavia L.; Strausberg, Robert L.; Simpson, Andrew J.] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Ludwig Collaborat Lab Canc Biol & Therapy, Baltimore, MD 21231 USA.
   [Lo, Christine; Bafna, Vineet] Univ Calif San Diego, Dept Comp Sci, La Jolla, CA 92093 USA.
   [Lister, Ryan; Pelizzola, Mattia; Ecker, Joseph R.] Salk Inst Biol Studies, Howard Hughes Med Inst, Genom Anal Lab, La Jolla, CA 92037 USA.
   [Valsesia, Armand; Stevenson, Brian J.] Univ Lausanne, Ludwig Inst Canc Res, Swiss Inst Bioinformat, CH-1011 Lausanne, Switzerland.
   [Camargo, Anamaria Aranha] Ludwig Inst Canc Res, BR-01323903 Sao Paulo, Brazil.
   [Strausberg, Robert L.; Simpson, Andrew J.] Ludwig Inst Canc Res Ltd, New York, NY 10017 USA.
   [Ren, Bing] Univ Calif San Diego, Moores Canc Ctr, Dept Cellular & Mol Med, La Jolla, CA 92093 USA.
   [Ren, Bing] Univ Calif San Diego, Inst Genom Med, La Jolla, CA 92093 USA.
C3 Ludwig Institute for Cancer Research; Johns Hopkins University;
   University of California System; University of California San Diego;
   Howard Hughes Medical Institute; Salk Institute; Swiss Institute of
   Bioinformatics; University of Lausanne; Ludwig Institute for Cancer
   Research; Ludwig Institute for Cancer Research; Ludwig Institute for
   Cancer Research; University of California System; University of
   California San Diego; University of California System; University of
   California San Diego
RP Ren, B (通讯作者)，Ludwig Inst Canc Res, La Jolla, CA 92093 USA.
EM biren@ucsd.edu
RI YE, Zhen/IYS-1774-2023; Pelizzola, Mattia/AFG-8416-2022; Bafna,
   Vineet/LTF-6857-2024; Valsesia, Armand/F-1724-2010; Aranha Camargo,
   Anamaria/E-9388-2012; Lister, Ryan/B-5168-2012; Ecker,
   Joseph/B-9144-2008
OI Aranha Camargo, Anamaria/0000-0002-6076-9597; Edsall,
   Lee/0000-0002-0326-2829; Lister, Ryan/0000-0001-6637-7239; Bafna,
   Vineet/0000-0002-5810-6241; Valsesia, Armand/0000-0003-0746-9664; Ecker,
   Joseph/0000-0001-5799-5895; Pelizzola, Mattia/0000-0001-6672-9636
FU Ludwig Institute for Cancer Research; Mary K. Chapman Foundation; Howard
   Hughes Medical Institute; Gordon and Betty Moore foundation; NSF
   [NSF-CCF-1115206]; NIH [5RO1-HG004962]; Division of Computing and
   Communication Foundations; Direct For Computer & Info Scie & Enginr
   [1115206] Funding Source: National Science Foundation
FX This work was supported by the Ludwig Institute for Cancer Research and
   the Mary K. Chapman Foundation (J.R.E.). Work in the laboratory of
   J.R.E. is supported by the Howard Hughes Medical Institute and the
   Gordon and Betty Moore foundation. J.R.E. is a HHMI-GBMF Investigator.
   C.L. and V.B. were supported by an NSF fellowship, and grants
   5RO1-HG004962 (NIH), and NSF-CCF-1115206 to V.B.
CR Alvarez-Díaz S, 2009, J CLIN INVEST, V119, P2343, DOI 10.1172/JCI37205
   Aran D, 2011, HUM MOL GENET, V20, P670, DOI 10.1093/hmg/ddq513
   Ball MP, 2009, NAT BIOTECHNOL, V27, P361, DOI 10.1038/nbt.1533
   Bansal V, 2008, BIOINFORMATICS, V24, pI153, DOI 10.1093/bioinformatics/btn298
   Bansal V, 2008, GENOME RES, V18, P1336, DOI 10.1101/gr.077065.108
   Barreto G, 2007, NATURE, V445, P671, DOI 10.1038/nature05515
   Bartke T, 2010, CELL, V143, P470, DOI 10.1016/j.cell.2010.10.012
   Bhutani N, 2010, NATURE, V463, P1042, DOI 10.1038/nature08752
   Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874
   Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035
   Cortellino S, 2011, CELL, V146, P67, DOI 10.1016/j.cell.2011.06.020
   Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Ding Y, 2006, MOL CELL BIOL, V26, P1979, DOI 10.1128/MCB.26.5.1979-1996.2006
   Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007
   Egelhofer TA, 2011, NAT STRUCT MOL BIOL, V18, P91, DOI 10.1038/nsmb.1972
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 1999, CANCER RES, V59, P793
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Everhard S, 2009, NEURO-ONCOLOGY, V11, P348, DOI 10.1215/15228517-2009-001
   FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Florl AR, 1999, BRIT J CANCER, V80, P1312, DOI 10.1038/sj.bjc.6690524
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883
   Garbe JC, 2009, CANCER RES, V69, P7557, DOI 10.1158/0008-5472.CAN-09-0270
   Guelen L, 2008, NATURE, V453, P948, DOI 10.1038/nature06947
   Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865
   Hansen RS, 2010, P NATL ACAD SCI USA, V107, P139, DOI 10.1073/pnas.0912402107
   Hawkins RD, 2010, CELL STEM CELL, V6, P479, DOI 10.1016/j.stem.2010.03.018
   Hellman A, 2007, SCIENCE, V315, P1141, DOI 10.1126/science.1136352
   Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441
   Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76
   Herschkowitz JI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2142
   Hibi K, 2009, ANTICANCER RES, V29, P5053
   Hibi K, 2009, HEPATO-GASTROENTEROL, V56, P1642
   Hinshelwood RA, 2008, J MOL MED, V86, P1315, DOI 10.1007/s00109-008-0386-3
   Hoadley KA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-258
   HOLLIDAY R, 1979, BRIT J CANCER, V40, P513, DOI 10.1038/bjc.1979.216
   Hsu F, 2006, BIOINFORMATICS, V22, P1036, DOI 10.1093/bioinformatics/btl048
   Hu ZY, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-9
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Ishii H, 1999, P NATL ACAD SCI USA, V96, P3928, DOI 10.1073/pnas.96.7.3928
   Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303
   Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609
   Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9
   JONES PA, 1983, RECENT RES CANCER, V84, P202
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Kaminskas E, 2005, ONCOLOGIST, V10, P176, DOI 10.1634/theoncologist.10-3-176
   Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kohonen-Corish MRJ, 2007, ONCOGENE, V26, P4435, DOI 10.1038/sj.onc.1210210
   Komashko Vitalina M, 2010, Epigenetics, V5, P229
   Laird PW, 2010, NAT REV GENET, V11, P191, DOI 10.1038/nrg2732
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lakshmikuttyamma A, 2010, ONCOGENE, V29, P576, DOI 10.1038/onc.2009.361
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9
   Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Lindroth AM, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000145
   Lister R, 2008, CELL, V133, P523, DOI 10.1016/j.cell.2008.03.029
   Lister R, 2011, NATURE, V471, P68, DOI 10.1038/nature09798
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Maunakea AK, 2010, NATURE, V466, P253, DOI 10.1038/nature09165
   Menendez L, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-12
   MOIR RD, 1994, J CELL BIOL, V125, P1201, DOI 10.1083/jcb.125.6.1201
   Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518
   Mullins M, 2007, CLIN CHEM, V53, P1273, DOI 10.1373/clinchem.2006.083725
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Novak P, 2008, CANCER RES, V68, P8616, DOI 10.1158/0008-5472.CAN-08-1419
   Oh DS, 2006, J CLIN ONCOL, V24, P1656, DOI 10.1200/JCO.2005.03.2755
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Parkhomchuk D, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp596
   Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056
   Peric-Hupkes D, 2010, MOL CELL, V38, P603, DOI 10.1016/j.molcel.2010.03.016
   Perreard L, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1399
   Prak ETL, 2000, NAT REV GENET, V1, P134
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Pruitt KD, 2005, NUCLEIC ACIDS RES, V33, pD501, DOI 10.1093/nar/gki025
   Rolny C, 2011, CANCER CELL, V19, P31, DOI 10.1016/j.ccr.2010.11.009
   Ruike Y, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-137
   Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704
   Schulz WA, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/83672
   Sjöblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427
   Stephens PJ, 2009, NATURE, V462, P1005, DOI 10.1038/nature08645
   Streit M, 1999, P NATL ACAD SCI USA, V96, P14888, DOI 10.1073/pnas.96.26.14888
   Tapia T, 2008, EPIGENETICS-US, V3, P157, DOI 10.4161/epi.3.3.6387
   Teer JK, 2010, GENOME RES, V20, P1420, DOI 10.1101/gr.106716.110
   Ting DT, 2011, SCIENCE, V331, P593, DOI 10.1126/science.1200801
   Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621
   Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120
   van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349
   Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639
   Völkel P, 2007, BIOCHIMIE, V89, P1, DOI 10.1016/j.biochi.2006.07.009
   Weigelt B, 2005, CANCER RES, V65, P9155, DOI 10.1158/0008-5472.CAN-05-2553
   Wild L, 2010, BBA-REV CANCER, V1806, P50, DOI 10.1016/j.bbcan.2010.03.003
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Wu H, 2010, SCIENCE, V329, P444, DOI 10.1126/science.1190485
   Yap DB, 2011, BLOOD, V117, P2451, DOI 10.1182/blood-2010-11-321208
   Yuan BZ, 1998, CANCER RES, V58, P2196
NR 103
TC 400
Z9 479
U1 1
U2 47
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1088-9051
EI 1549-5469
J9 GENOME RES
JI Genome Res.
PD FEB
PY 2012
VL 22
IS 2
BP 246
EP 258
DI 10.1101/gr.125872.111
PG 13
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 883BA
UT WOS:000299606400008
PM 22156296
OA Green Published, hybrid, Green Submitted
DA 2025-01-12
ER

PT J
AU Naushad, SM
   Prayaga, A
   Digumarti, RR
   Gottumukkala, SR
   Kutala, VK
AF Naushad, Shaik Mohammad
   Prayaga, Aruna
   Digumarti, Raghunadha Rao
   Gottumukkala, Suryanarayana Raju
   Kutala, Vijay Kumar
TI Bcl-2/adenovirus E1B 19 kDa-interacting protein 3 (BNIP3) expression is
   epigenetically regulated by one-carbon metabolism in invasive duct cell
   carcinoma of breast
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE BNIP3; One-carbon metabolism; CpG island methylator phenotype; 8-Oxo-2
   '-deoxyguanosine
ID CANCER; METHYLATION; GENE; DNA
AB In view of recent studies highlighting the prognostic relevance of expression and CpG island methylator phenotype (CIMP) of Bcl-2/adenovirus E1B 19 kDa-interacting protein 3 (BNIP3) in invasive duct cell carcinoma (IDC), we hypothesized in this article that impaired one-carbon metabolism might influence CIMP phenotype of BNIP3. In order to substantiate the prognostic relevance of BNIP3, we explored its association with 8-oxo-2'deoxyguanosine (8-oxodG), a marker of oxidative stress with prognostic relevance. BNIP3 expression and CIMP phenotype were studied using semi-quantitative RT-PCR and combined bisulfite restriction analysis (COBRA), respectively, in 56 IDC tumors. Eight polymorphisms in one-carbon metabolism were studied using PCR-RFLP and PCR-AFLP approaches. 8-oxodG was measured using competitive ELISA kit. BNIP3 was found to be upregulated in IDC (cases vs. controls: 0.94 +/- A 0.05 vs. 0.18 +/- A 0.08, P < 0.0001). COBRA analysis confirmed hypomethylation of BNIP3 promoter CpG island in these cases. CIMP phenotype of BNIP3 showed positive association with tubule formation (P = 0.034) and methionine synthase reductase (MTRR) A66G (P = 0.002); inverse association with cytosolic serine hydroxyl methyltransferase (cSHMT) C1420T (P < 0.005) and 8-oxodG (< 10% vs. > 10% methylation: 7.24 +/- A 2.77 ng/ml vs. 4.42 +/- A 2.93 ng/ml, P < 0.0005); and no association with nuclear pleomorphism or mitotic index or ER, PR, and HER statuses. Synergistic effect of MTR A2756G and MTRR A66G variants on BNIP3 hypermethylator phenotype was clearly evident (P < 0.0007). MTRR A66G and cSHMT C1420T polymorphisms influence CIMP phenotype of BNIP3, thus epigenetically regulating BNIP3 in breast cancer. The linear association between BNIP3 and 8-oxodG substantiates the role of BNIP3 as redox sensor as well as prognostic marker in breast cancer.
C1 [Naushad, Shaik Mohammad; Kutala, Vijay Kumar] Nizams Inst Med Sci, Dept Clin Pharmacol & Therapeut, Hyderabad 500082, Andhra Pradesh, India.
   [Prayaga, Aruna] Nizams Inst Med Sci, Dept Pathol, Hyderabad 500082, Andhra Pradesh, India.
   [Digumarti, Raghunadha Rao] Nizams Inst Med Sci, Dept Med Oncol, Hyderabad 500082, Andhra Pradesh, India.
   [Gottumukkala, Suryanarayana Raju] Nizams Inst Med Sci, Dept Surg Oncol, Hyderabad 500082, Andhra Pradesh, India.
C3 Nizam's Institute of Medical Sciences; Nizam's Institute of Medical
   Sciences; Nizam's Institute of Medical Sciences; Nizam's Institute of
   Medical Sciences
RP Kutala, VK (通讯作者)，Nizams Inst Med Sci, Dept Clin Pharmacol & Therapeut, Hyderabad 500082, Andhra Pradesh, India.
EM vijaykutala@gmail.com
RI Digumarti, Raghunadharao/H-4075-2019; Naushad, Shaik
   Mohammad/C-3094-2012
OI Digumarti, Raghunadharao/0000-0003-2876-3475; Naushad, Shaik
   Mohammad/0000-0001-8952-9581; Kutala, Vijay Kumar/0000-0002-7253-8999
FU Indian Council of Medical Research (ICMR), New Delhi [5/13/32/2007];
   Department of Science and Technology, Government of India
FX This study was supported by the grant funded by Indian Council of
   Medical Research (ICMR), New Delhi (Ref No. 5/13/32/2007). Vijay Kumar
   Kutala is a recipient of Ramanujan Fellowship awarded by Department of
   Science and Technology, Government of India.
CR An HJ, 2011, MOL CELLS
   Friso S, 2002, J NUTR, V132, p2382S, DOI 10.1093/jn/132.8.2382S
   Koop EA, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-175
   Kubli DA, 2008, AM J PHYSIOL-HEART C, V295, pH2025, DOI 10.1152/ajpheart.00552.2008
   Manka D, 2005, CANCER RES, V65, P11689, DOI 10.1158/0008-5472.CAN-05-3091
   Mohammad NS, 2011, MOL CELL BIOCHEM, V349, P159, DOI 10.1007/s11010-010-0670-8
   Murai M, 2005, BRIT J CANCER, V92, P1165, DOI 10.1038/sj.bjc.6602422
   Murai M, 2005, CLIN CANCER RES, V11, P1021
   Naushad SM., 2010, Molecular Biology Reports
   Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591
   Rossner P, 2006, CANCER EPIDEM BIOMAR, V15, P639, DOI 10.1158/1055-9965.EPI-05-0554
   Soliman AS, 2004, INT J ENVIRON HEAL R, V14, P121, DOI 10.1080/0960312042000209534
   Sova H, 2010, BRIT J CANCER, V102, P1018, DOI 10.1038/sj.bjc.6605565
   Tan EY, 2007, CLIN CANCER RES, V13, P467, DOI 10.1158/1078-0432.CCR-06-1466
   van Diest PJ, 2010, ANAL CELL PATHOL, V33, P175, DOI [10.1155/2010/852197, 10.3233/ACP-CLO-2010-0543]
   Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000
   Xu XR, 2008, CANCER EPIDEM BIOMAR, V17, P2109, DOI 10.1158/1055-9965.EPI-07-2900
   Xu XR, 2009, J GENET GENOMICS, V36, P203, DOI 10.1016/S1673-8527(08)60108-3
   Yamada K, 2006, P NATL ACAD SCI USA, V103, P9476, DOI 10.1073/pnas.0603694103
NR 19
TC 15
Z9 16
U1 0
U2 11
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300-8177
EI 1573-4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD FEB
PY 2012
VL 361
IS 1-2
BP 189
EP 195
DI 10.1007/s11010-011-1103-z
PG 7
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 869OM
UT WOS:000298607600022
PM 21987236
DA 2025-01-12
ER

PT J
AU Blank, M
   Tang, Y
   Yamashita, M
   Burkett, SS
   Cheng, SY
   Zhang, YE
AF Blank, Michael
   Tang, Yi
   Yamashita, Motozo
   Burkett, Sandra S.
   Cheng, Steven Y.
   Zhang, Ying E.
TI A tumor suppressor function of Smurf2 associated with controlling
   chromatin landscape and genome stability through RNF20
SO NATURE MEDICINE
LA English
DT Article
ID UBIQUITIN LIGASE SMURF2; BREAST-CANCER CELLS; HISTONE H2B; DEPENDENT
   DEGRADATION; H3 METHYLATION; UBIQUITYLATION; DNA; MONOUBIQUITINATION;
   ELONGATION; EXPRESSION
AB In addition to allelic mutations, cancers are known to harbor alterations in their chromatin landscape. Here we show that genomic ablation of Smad ubiquitin regulatory factor 2 (Smurf2), a HECT-domain E3 ubiquitin ligase, results in dysregulation of both the DNA damage response and genomic stability, culminating in increased susceptibility to various types of cancers in aged mice. We show that Smurf2 regulates the monoubiquitination of histone H2B as well as the trimethylation of histone H3 at Lys4 and Lys79 by targeting ring finger protein 20 (RNF20) for proteasomal degradation in both mouse and human cells. We also show that Smurf2 and RNF20 are colocalized at the gamma-H2AX foci of double-stranded DNA breaks in the nucleus. Thus, Smurf2 has a tumor suppression function that normally maintains genomic stability by controlling the epigenetic landscape of histone modifications through RNF20.
C1 [Blank, Michael; Tang, Yi; Yamashita, Motozo; Zhang, Ying E.] NCI, Cellular & Mol Biol Lab, Ctr Canc Res, Bethesda, MD 20892 USA.
   [Burkett, Sandra S.] NCI, Mouse Canc Genet Program, Frederick, MD 21701 USA.
   [Cheng, Steven Y.] Nanjing Med Univ, Dept Dev Genet, Sch Basic Med Sci, Nanjing, Jiangsu, Peoples R China.
C3 National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer
   Institute (NCI); Nanjing Medical University
RP Zhang, YE (通讯作者)，NCI, Cellular & Mol Biol Lab, Ctr Canc Res, Bldg 37, Bethesda, MD 20892 USA.
EM zhangyin@mail.nih.gov
RI Yamashita, Motozo/JUF-6473-2023; Zhang, Ying/G-3657-2015
OI Burkett, Sandra/0000-0002-5476-4028; Zhang, Ying/0000-0003-2753-7601
FU US National Cancer Institute, US National Institutes of Health, Center
   for Cancer Research; Japan Society for the Promotion of Science
   [21689053]; Grants-in-Aid for Scientific Research [21689053] Funding
   Source: KAKEN
FX We thank M. Anver for pathology services, V. Barr for assistance with
   microscope, X. Wu for assistance with the microarray experiments, N.
   Morris for the animal husbandry and N. Teja for assistance with cell
   culture. We also thank K. Sixt for comments on the manuscript. This
   research is supported by the Intramural Research Program of the US
   National Cancer Institute, US National Institutes of Health, Center for
   Cancer Research. M.Y. was partially supported by the Japan Society for
   the Promotion of Science grant 21689053.
CR Berglund L, 2008, MOL CELL PROTEOMICS, V7, P2019, DOI 10.1074/mcp.R800013-MCP200
   Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523
   Falk M, 2008, BBA-MOL CELL RES, V1783, P2398, DOI 10.1016/j.bbamcr.2008.07.010
   Fierz B, 2011, NAT CHEM BIOL, V7, P113, DOI 10.1038/NCHEMBIO.501
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339
   Fukuchi M, 2002, CANCER RES, V62, P7162
   Fukunaga E, 2008, J BIOL CHEM, V283, P35660, DOI 10.1074/jbc.M710496200
   Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320
   HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375
   Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425
   Izzi L, 2004, ONCOGENE, V23, P2071, DOI 10.1038/sj.onc.1207412
   Jin CY, 2009, CANCER RES, V69, P735, DOI 10.1158/0008-5472.CAN-08-1463
   Johnstone SE, 2010, NAT REV GENET, V11, P806, DOI 10.1038/nrg2881
   Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9
   Kim J, 2005, MOL CELL, V20, P759, DOI 10.1016/j.molcel.2005.11.012
   Kim J, 2009, CELL, V137, P459, DOI 10.1016/j.cell.2009.02.027
   Kizer KO, 2005, MOL CELL BIOL, V25, P3305, DOI 10.1128/MCB.25.8.3305-3316.2005
   Laribee RN, 2005, CURR BIOL, V15, P1487, DOI 10.1016/j.cub.2005.07.028
   Lee JS, 2007, CELL, V131, P1084, DOI 10.1016/j.cell.2007.09.046
   Li HX, 2004, ONCOGENE, V23, P1801, DOI 10.1038/sj.onc.1207319
   Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200
   Lönn P, 2009, CELL RES, V19, P21, DOI 10.1038/cr.2008.308
   Minsky N, 2008, NAT CELL BIOL, V10, P483, DOI 10.1038/ncb1712
   Montecucco A, 2007, CANCER LETT, V252, P9, DOI 10.1016/j.canlet.2006.11.005
   Moyal L, 2011, MOL CELL, V41, P529, DOI 10.1016/j.molcel.2011.02.015
   Murga M, 2007, J CELL BIOL, V178, P1101, DOI 10.1083/jcb.200704140
   Nakamura K, 2011, MOL CELL, V41, P515, DOI 10.1016/j.molcel.2011.02.002
   Narimatsu M, 2009, CELL, V137, P295, DOI 10.1016/j.cell.2009.02.025
   Schwamborn JC, 2007, EMBO J, V26, P1410, DOI 10.1038/sj.emboj.7601580
   Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984
   Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422
   Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883
   Tang LY, 2011, EMBO J, V30, P4777, DOI 10.1038/emboj.2011.393
   TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299
   Weake VM, 2008, MOL CELL, V29, P653, DOI 10.1016/j.molcel.2008.02.014
   Zhang H, 2004, GENE DEV, V18, P3028, DOI 10.1101/gad.1253004
   Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974
   Zhu B, 2005, MOL CELL, V20, P601, DOI 10.1016/j.molcel.2005.09.025
NR 38
TC 129
Z9 143
U1 0
U2 21
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD FEB
PY 2012
VL 18
IS 2
BP 227
EP 234
DI 10.1038/nm.2596
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 890JG
UT WOS:000300140300036
PM 22231558
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Augoff, K
   McCue, B
   Plow, EF
   Sossey-Alaoui, K
AF Augoff, Katarzyna
   McCue, Brian
   Plow, Edward F.
   Sossey-Alaoui, Khalid
TI miR-31 and its host gene lncRNA LOC554202 are regulated by promoter
   hypermethylation in triple-negative breast cancer
SO MOLECULAR CANCER
LA English
DT Article
DE miR-31; LOC554202; Triple-negative breast cancer; lncRNA; CpG
   hypermethylation; Invasion-metastasis cascade
ID EPITHELIAL-MESENCHYMAL TRANSITION; FULL-LENGTH HUMAN; DOWN-REGULATION;
   STEM-CELLS; METASTASIS; MICRORNA; EXPRESSION; INVASION; WAVE3;
   SUPPRESSOR
AB Background: microRNAs have been established as powerful regulators of gene expression in normal physiological as well as in pathological conditions, including cancer progression and metastasis. Recent studies have demonstrated a key role of miR-31 in the progression and metastasis of breast cancer. Downregulation of miR-31 enhances several steps of the invasion-metastasis cascade in breast cancer, i.e., local invasion, extravasation and survival in the circulation system, and metastatic colonization of distant sites. miR-31 exerts its metastasis-suppressor activity by targeting a cohort of pro-metastatic genes, including RhoA and WAVE3. The molecular mechanisms that lead to the loss of miR-31 and the activation of its pro-metastatic target genes during these specific steps of the invasion-metastasis cascade are however unknown.
   Results: In the present report, we identify promoter hypermethylation as one of the major mechanisms for silencing miR-31 in breast cancer, and in the triple-negative breast cancer (TNBC) cell lines of basal subtype, in particular. miR-31 maps to the intronic sequence of a novel long non-coding (lnc)RNA, LOC554202 and the regulation of its transcriptional activity is under control of LOC554202. Both miR-31 and the host gene LOC554202 are down-regulated in the TNBC cell lines of basal subtype and over-expressed in the luminal counterparts. Treatment of the TNBC cell lines with either a de-methylating agent alone or in combination with a de-acetylating agent resulted in a significant increase of both miR-31 and its host gene, suggesting an epigenetic mechanism for the silencing of these two genes by promoter hypermethylation. Finally, both methylation-specific PCR and sequencing of bisulfite-converted DNA demonstrated that the LOC554202 promoter-associated CpG island is heavily methylated in the TNBC cell lines and hypomethylated in the luminal subtypes.
   Conclusion: Loss of miR-31 expression in TNBC cell lines is attributed to hypermethylation of its promoter-associated CpG island. Together, our results provide the initial evidence for a mechanism by which miR-31, an important determinant of the invasion metastasis cascade, is regulated in breast cancer.
C1 [Augoff, Katarzyna; McCue, Brian; Plow, Edward F.; Sossey-Alaoui, Khalid] Cleveland Clin, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation
RP Sossey-Alaoui, K (通讯作者)，Cleveland Clin, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA.
EM sosseyk@ccf.org
OI Augoff, Katarzyna/0000-0002-6133-3621
FU DOD [W81XWH0810236]; NIH [P01HL073311, P50HL077107]; European Social
   Fund, Human Capital, national Cohesion Strategy
   [UDA-POKL.04.01.01-00-010/08-00]; U.S. Department of Defense (DOD)
   [W81XWH0810236] Funding Source: U.S. Department of Defense (DOD)
FX DOD Breast Cancer Idea Award grant W81XWH0810236 (K. Sossey-Alaoui), NIH
   grants P01HL073311 and P50HL077107 (E. F. Plow). K. Augoff is funded in
   part by a research fellowship "Development program of Wroclaw Medical
   University" from the European Social Fund, Human Capital, national
   Cohesion Strategy" (contract # UDA-POKL.04.01.01-00-010/08-00)".
CR Akao Y, 2006, BIOL PHARM BULL, V29, P903, DOI 10.1248/bpb.29.903
   Anders C, 2008, ONCOLOGY-NY, V22, P1233
   Anders CK, 2009, CLIN BREAST CANCER, V9, pS73, DOI 10.3816/CBC.2009.s.008
   Andorfer CA, 2011, TRENDS MOL MED, V17, P313, DOI 10.1016/j.molmed.2011.01.006
   [Anonymous], UROL ONCOL
   Augoff K, 2011, MOL CANCER RES, V9, P1500, DOI 10.1158/1541-7786.MCR-11-0311
   Bachour Tarek, 2011, J Assoc Genet Technol, V37, P21
   Berx G, 2007, CLIN EXP METASTAS, V24, P587, DOI 10.1007/s10585-007-9114-6
   Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Carey L, 2010, NAT REV CLIN ONCOL, V7, P683, DOI 10.1038/nrclinonc.2010.154
   Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239
   Corcoran DL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005279
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Fernando HS, 2007, ONCOLOGY-BASEL, V73, P376, DOI 10.1159/000136157
   Finnegan Timothy J, 2007, Future Oncol, V3, P55, DOI 10.2217/14796694.3.1.55
   Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389
   Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001
   He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277
   Jiang Z, 2011, CELL CYCLE, V10, P1563, DOI 10.4161/cc.10.10.15703
   Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083
   Li F, 2007, CELL RES, V17, P3, DOI 10.1038/sj.cr.7310118
   May CD, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2789
   Nagano T, 2009, MAMM GENOME, V20, P557, DOI 10.1007/s00335-009-9218-1
   Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622
   Ota T, 2004, NAT GENET, V36, P40, DOI 10.1038/ng1285
   Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Schneider BP, 2008, CLIN CANCER RES, V14, P8010, DOI 10.1158/1078-0432.CCR-08-1208
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sossey-Alaoui K, 2005, EXP CELL RES, V308, P135, DOI 10.1016/j.yexcr.2005.04.011
   Sossey-Alaoui K, 2002, GENOMICS, V80, P5, DOI 10.1006/geno.2002.6792
   Sossey-Alaoui K, 2007, J BIOL CHEM, V282, P26257, DOI 10.1074/jbc.M701484200
   Sossey-Alaoui K, 2007, AM J PATHOL, V170, P2112, DOI 10.2353/ajpath.2007.060975
   Sossey-Alaoui K, 2011, INT J CANCER, V129, P1331, DOI 10.1002/ijc.25793
   Sossey-Alaoui K, 2009, J BIOL CHEM, V284, P33019, DOI 10.1074/jbc.M109.034553
   Spaderna S, 2007, Verh Dtsch Ges Pathol, V91, P21
   Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899
   Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637
   Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040
   Taylor MA, 2010, J MAMMARY GLAND BIOL, V15, P169, DOI 10.1007/s10911-010-9181-1
   Valastyan S, 2011, GENE DEV, V25, P646, DOI 10.1101/gad.2004211
   Valastyan S, 2010, CELL CYCLE, V9, P2124, DOI 10.4161/cc.9.11.11843
   Valastyan S, 2009, GENE DEV, V23, P2592, DOI 10.1101/gad.1832709
   Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047
   Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037
   Wang WG, 2004, CANCER RES, V64, P8585, DOI 10.1158/0008-5472.CAN-04-1136
   Wapinski O, 2011, TRENDS CELL BIOL, V21, P354, DOI 10.1016/j.tcb.2011.04.001
   Weigel MT, 2010, ENDOCR-RELAT CANCER, V17, pR245, DOI 10.1677/ERC-10-0136
   Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025
   Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009
NR 53
TC 312
Z9 334
U1 1
U2 102
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD JAN 30
PY 2012
VL 11
AR 5
DI 10.1186/1476-4598-11-5
PG 12
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 909YS
UT WOS:000301604300001
PM 22289355
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Soto-Reyes, E
   González-Barrios, R
   Cisneros-Soberanis, F
   Herrera-Goepfert, R
   Pérez, V
   Cantú, D
   Prada, D
   Castro, C
   Recillas-Targa, F
   Herrera, LA
AF Soto-Reyes, Ernesto
   Gonzalez-Barrios, Rodrigo
   Cisneros-Soberanis, Fernanda
   Herrera-Goepfert, Roberto
   Perez, Victor
   Cantu, David
   Prada, Diddier
   Castro, Clementina
   Recillas-Targa, Felix
   Herrera, Luis A.
TI Disruption of CTCF at the miR-125b1 locus in gynecological cancers
SO BMC CANCER
LA English
DT Article
DE CTCF; miR-125b1; Epigenetic; Cancer; Promoter; MicroRNA; Breast cancer
ID TUMOR-SUPPRESSOR; EPIGENETIC INACTIVATION; GENE PROMOTER; MICRORNAS;
   METHYLATION; BOUNDARIES; EXPRESSION; BINDING; BRCA1
AB Background: In cancer cells, transcriptional gene silencing has been associated with genetic and epigenetic defects. The disruption of DNA methylation patterns and covalent histone marks has been associated with cancer development. Until recently, microRNA (miRNA) gene silencing was not well understood. In particular, miR-125b1 has been suggested to be an miRNA with tumor suppressor activity, and it has been shown to be deregulated in various human cancers. In the present study, we evaluated the DNA methylation at the CpG island proximal to the transcription start site of miR-125b1 in cancer cell lines as well as in normal tissues and gynecological tumor samples. In addition, we analyzed the association of CTCF and covalent histone modifications at the miR-125b1 locus.
   Methods: To assess the DNA methylation status of the miR-125b1, genomic DNA was transformed with sodium bisulfite, and then PCR-amplified with modified primers and sequenced. The miR-125b1 gene expression was analyzed by qRT-PCR using U6 as a control for constitutive gene expression. CTCF repressive histone marks abundance was evaluated by chromatin immunoprecipitation assays.
   Results: The disruption of CTCF in breast cancer cells correlated with the incorporation of repressive histone marks such H3K9me3 and H3K27me3 as well as with aberrant DNA methylation patterns. To determine the effect of DNA methylation at the CpG island of miR-125b1 on the expression of this gene, we performed a qRT-PCR assay. We observed a significant reduction on the expression of miR-125b1 in cancer cells in comparison with controls, suggesting that DNA methylation at the CpG island might reduce miR-125b1 expression. These effects were observed in other gynecological cancers, including ovarian and cervical tumors.
   Conclusions: A reduction of miR-125b1 expression in cancers, correlated with methylation, repressive histone marks and loss of CTCF binding at the promoter region.
C1 [Soto-Reyes, Ernesto; Gonzalez-Barrios, Rodrigo; Cisneros-Soberanis, Fernanda; Cantu, David; Prada, Diddier; Castro, Clementina; Herrera, Luis A.] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Inst Nacl Cancerol INCan, Unidad Invest Biomed Canc, Mexico City 04510, DF, Mexico.
   [Herrera-Goepfert, Roberto; Perez, Victor] INCan, Dept Patol, Mexico City, DF, Mexico.
   [Recillas-Targa, Felix] Univ Nacl Autonoma Mexico, Dept Mol Genet, Inst Fisiol Celular, Mexico City 04510, DF, Mexico.
C3 Universidad Nacional Autonoma de Mexico; Instituto Nacional de
   Cancerologia (INCAN); Instituto Nacional de Cancerologia (INCAN);
   Universidad Nacional Autonoma de Mexico
RP Herrera, LA (通讯作者)，Univ Nacl Autonoma Mexico, Inst Invest Biomed, Inst Nacl Cancerol INCan, Unidad Invest Biomed Canc, Mexico City 04510, DF, Mexico.
EM herreram@biomedicas.unam.mx
RI Herrera, Luis/GOV-3311-2022; Velasco, Iván/D-3593-2014; Cantu-de Leon,
   David/P-7930-2017
OI Soto-Reyes, Ernesto/0000-0002-4219-6406; Cantu-de Leon,
   David/0000-0002-0229-7931; Herrera-Goepfert,
   Roberto/0000-0001-7901-2378; Gonzalez Barrios,
   Rodrigo/0000-0001-8982-6586; Cisneros-Soberanis,
   Fernanda/0000-0003-1120-1695
FU Consejo Nacional de Ciencia y Tecnologia (CONACyT) [83959]; Universidad
   Nacional Autonoma de Mexico [PAPIIT, IN213311]
FX This work was supported by the Consejo Nacional de Ciencia y Tecnologia
   (CONACyT: 83959) and Programa de Apoyo a Proyectos de Investigacion e
   Innovacion Tecnologica of the Universidad Nacional Autonoma de Mexico
   (PAPIIT, IN213311). In loving memory of Carlos Hesselbart, "Carlitos".
CR Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Butcher DT, 2007, EUR J CANCER, V43, P210, DOI 10.1016/j.ejca.2006.09.002
   Butcher DT, 2004, INT J CANCER, V111, P669, DOI 10.1002/ijc.20324
   De la Rosa-Velázquez IA, 2007, CANCER RES, V67, P2577, DOI 10.1158/0008-5472.CAN-06-2024
   Espinoza CA, 2011, NAT GENET, V43, P615, DOI 10.1038/ng.869
   Feng JJ, 2012, CANCER-AM CANCER SOC, V118, P232, DOI 10.1002/cncr.26250
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Handoko L, 2011, NAT GENET, V43, P630, DOI 10.1038/ng.857
   Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936
   Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204
   Laganà A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011166
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   Ma L, 2008, CELL CYCLE, V7, P570, DOI 10.4161/cc.7.5.5547
   Medina PP, 2008, CELL CYCLE, V7, P2485, DOI 10.4161/cc.7.16.6453
   Melo SA, 2011, FEBS LETT, V585, P2087, DOI 10.1016/j.febslet.2010.08.009
   Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001
   Recillas-Targa F, 2006, J CELL MOL MED, V10, P554, DOI 10.1111/j.1582-4934.2006.tb00420.x
   Recillas-Targa F, 2011, BIOCHEM CELL BIOL, V89, P479, DOI [10.1139/O11-031, 10.1139/o11-031]
   Sato F, 2011, FEBS J, V278, P1598, DOI 10.1111/j.1742-4658.2011.08089.x
   Scott GK, 2007, J BIOL CHEM, V282, P1479, DOI 10.1074/jbc.M609383200
   Shi M, 2010, CANCER METAST REV, V29, P785, DOI 10.1007/s10555-010-9265-9
   Simonini PDR, 2010, CANCER RES, V70, P9175, DOI 10.1158/0008-5472.CAN-10-1318
   Soto-Reyes E, 2010, ONCOGENE, V29, P2217, DOI 10.1038/onc.2009.509
   Tolmachev V, 2008, CURR PHARM DESIGN, V14, P2999, DOI 10.2174/138161208786404290
   Visone R, 2009, AM J PATHOL, V174, P1131, DOI 10.2353/ajpath.2009.080794
   Witcher M, 2009, MOL CELL, V34, P271, DOI 10.1016/j.molcel.2009.04.001
   Zhang Y, 2011, CANCER RES, V71, P3552, DOI 10.1158/0008-5472.CAN-10-2435
   Zhou M, 2010, J BIOL CHEM, V285, P21496, DOI 10.1074/jbc.M109.083337
NR 29
TC 27
Z9 31
U1 1
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JAN 25
PY 2012
VL 12
AR 40
DI 10.1186/1471-2407-12-40
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 907NK
UT WOS:000301424400001
PM 22277129
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Xiang, TX
   Li, LL
   Yin, XD
   Yuan, CF
   Tan, C
   Su, XW
   Xiong, L
   Putti, TC
   Oberst, M
   Kelly, K
   Ren, GS
   Tao, Q
AF Xiang, Tingxiu
   Li, Lili
   Yin, Xuedong
   Yuan, Chenfu
   Tan, Cui
   Su, Xianwei
   Xiong, Lei
   Putti, Thomas C.
   Oberst, Michael
   Kelly, Kathleen
   Ren, Guosheng
   Tao, Qian
TI The Ubiquitin Peptidase UCHL1 Induces G0/G1 Cell Cycle Arrest and
   Apoptosis Through Stabilizing p53 and Is Frequently Silenced in Breast
   Cancer
SO PLOS ONE
LA English
DT Article
ID CANDIDATE TUMOR-SUPPRESSOR; TERMINAL HYDROLASE L1; DNA METHYLATION;
   PROMOTER METHYLATION; MULTIPLE CARCINOMAS; PROTEASOME PATHWAY; GENE;
   ESOPHAGEAL; DISEASE; NASOPHARYNGEAL
AB Background: Breast cancer (BrCa) is a complex disease driven by aberrant gene alterations and environmental factors. Recent studies reveal that abnormal epigenetic gene regulation also plays an important role in its pathogenesis. Ubiquitin carboxyl-terminal esterase L1 (UCHL1) is a tumor suppressor silenced by promoter methylation in multiple cancers, but its role and alterations in breast tumorigenesis remain unclear.
   Methodology/Principal Findings: We found that UCHL1 was frequently downregulated or silenced in breast cancer cell lines and tumor tissues, but readily expressed in normal breast tissues and mammary epithelial cells. Promoter methylation of UCHL1 was detected in 9 of 10 breast cancer cell lines (90%) and 53 of 66 (80%) primary tumors, but rarely in normal breast tissues, which was statistically correlated with advanced clinical stage and progesterone receptor status. Pharmacologic demethylation reactivated UCHL1 expression along with concomitant promoter demethylation. Ectopic expression of UCHL1 significantly suppressed the colony formation and proliferation of breast tumor cells, through inducing G0/G1 cell cycle arrest and apoptosis. Subcellular localization study showed that UCHL1 increased cytoplasmic abundance of p53. We further found that UCHL1 induced p53 accumulation and reduced MDM2 protein level, and subsequently upregulated the expression of p21, as well as cleavage of caspase3 and PARP, but not in catalytic mutant UCHL1 C90S-expressed cells.
   Conclusions/Significance: UCHL1 exerts its tumor suppressive functions by inducing G0/G1cell cycle arrest and apoptosis in breast tumorigenesis, requiring its deubiquitinase activity. Its frequent silencing by promoter CpG methylation may serve as a potential tumor marker for breast cancer.
C1 [Xiang, Tingxiu; Yin, Xuedong; Yuan, Chenfu; Tan, Cui; Ren, Guosheng; Tao, Qian] Chongqing Med Univ, Affiliated Hosp 1, Mol Oncol & Epigenet Lab, Chongqing, Peoples R China.
   [Li, Lili; Su, Xianwei; Xiong, Lei; Tao, Qian] Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci,Canc Epigenet Lab, Dept Clin Oncol,Sir YK Pao Ctr Canc, Hong Kong, Hong Kong, Peoples R China.
   [Putti, Thomas C.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pathol, Singapore 117595, Singapore.
   [Oberst, Michael; Kelly, Kathleen] NCI, Signal Transduct Sect, NIH, Bethesda, MD 20892 USA.
C3 Chongqing Medical University; Chinese University of Hong Kong; CUHK
   Shenzhen Research Institute; National University of Singapore; National
   Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
RP Ren, GS (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Mol Oncol & Epigenet Lab, Chongqing, Peoples R China.
EM rgs726@163.com; qtao@clo.cuhk.edu.hk
RI Xiang, Tingxiu/E-6157-2016; Li, Lili/Q-5750-2018; Tao, Qian/T-4743-2018
OI Li, Lili/0000-0002-0292-5889; Tao, Qian/0000-0001-5383-4808
FU Chongqing Health Bureau; National Natural Science Foundation of China
   [31171243, 81072148, 81172582]; Shenzhen Science Fund for Distinguished
   Young Scholars [JC201005270328A]
FX This study was supported by the Chongqing Health Bureau grant, National
   Natural Science Foundation of China (#31171243, 81072148 and 81172582)
   and Shenzhen Science Fund for Distinguished Young Scholars
   (#JC201005270328A). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Brait M, 2008, CANCER EPIDEM BIOMAR, V17, P2786, DOI 10.1158/1055-9965.EPI-08-0192
   Brooks J, 2009, CANCER CAUSE CONTROL, V20, P1539, DOI 10.1007/s10552-009-9415-y
   Cheng YD, 2010, CANCER RES, V70, P6516, DOI 10.1158/0008-5472.CAN-09-4566
   Cui Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002990
   Dehan P, 2009, EXPERT REV MOL DIAGN, V9, P651, DOI [10.1586/erm.09.53, 10.1586/ERM.09.53]
   EDWARDS YH, 1991, ANN HUM GENET, V55, P273, DOI 10.1111/j.1469-1809.1991.tb00853.x
   Fujikane T, 2010, BREAST CANCER RES TR, V122, P699, DOI 10.1007/s10549-009-0600-1
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hu XT, 2009, ONCOGENE, V28, P2466, DOI 10.1038/onc.2009.92
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kuperwasser C, 2000, CANCER RES, V60, P2723
   Li LL, 2010, CLIN CANCER RES, V16, P2949, DOI 10.1158/1078-0432.CCR-09-3178
   Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7
   Loyo M, 2011, INT J CANCER, V128, P1393, DOI 10.1002/ijc.25443
   Mandelker DL, 2005, CANCER RES, V65, P4963, DOI 10.1158/0008-5472.CAN-04-3923
   Mani A, 2005, J CLIN ONCOL, V23, P4776, DOI 10.1200/JCO.2005.05.081
   Meray RK, 2007, J BIOL CHEM, V282, P10567, DOI 10.1074/jbc.M611153200
   Miasari M, 2008, CURR CANCER DRUG TAR, V8, P118
   Miyoshi Y, 2006, CANCER SCI, V97, P523, DOI 10.1111/j.1349-7006.2006.00202.x
   Mizukami H, 2008, ANTICANCER RES, V28, P2697
   MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262
   Oka D, 2009, CANCER-AM CANCER SOC, V115, P3412, DOI 10.1002/cncr.24394
   Okochi-Takada E, 2006, INT J CANCER, V119, P1338, DOI 10.1002/ijc.22025
   Orlowski RZ, 2003, BREAST CANCER RES, V5, P1, DOI 10.1186/bcr460
   Osaka H, 2003, HUM MOL GENET, V12, P1945, DOI 10.1093/hmg/ddg211
   Parrella P, 2010, BREAST CARE, V5, P66, DOI 10.1159/000309138
   Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632
   Seliger B, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-90
   Seng TJ, 2007, ONCOGENE, V26, P934, DOI 10.1038/sj.onc.1209839
   Shivapurkar N, 2010, CURR MOL MED, V10, P123, DOI 10.2174/156652410790963303
   Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7
   Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091
   Wang WJ, 2008, INT J ONCOL, V33, P1037, DOI 10.3892/ijo_00000092
   Wang Y, 2009, CANCER RES, V69, P5194, DOI 10.1158/0008-5472.CAN-08-3694
   Xavier LL, 2005, BRAIN RES PROTOC, V16, P58, DOI 10.1016/j.brainresprot.2005.10.002
   Xiang TX, 2010, CANCER BIOL THER, V10, DOI 10.4161/cbt.10.5.12726
   Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154
   Yu J, 2008, HEPATOLOGY, V48, P508, DOI 10.1002/hep.22343
   Yuan J, 2010, CELL, V140, P384, DOI 10.1016/j.cell.2009.12.032
NR 39
TC 115
Z9 130
U1 0
U2 20
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 18
PY 2012
VL 7
IS 1
AR e29783
DI 10.1371/journal.pone.0029783
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 885IH
UT WOS:000299771900023
PM 22279545
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Yamagishi, M
   Nakano, K
   Miyake, A
   Yamochi, T
   Kagami, Y
   Tsutsumi, A
   Matsuda, Y
   Sato-Otsubo, A
   Muto, S
   Utsunomiya, A
   Yamaguchi, K
   Uchimaru, K
   Ogawa, S
   Watanabe, T
AF Yamagishi, Makoto
   Nakano, Kazumi
   Miyake, Ariko
   Yamochi, Tadanori
   Kagami, Yayoi
   Tsutsumi, Akihisa
   Matsuda, Yuka
   Sato-Otsubo, Aiko
   Muto, Satsuki
   Utsunomiya, Atae
   Yamaguchi, Kazunari
   Uchimaru, Kaoru
   Ogawa, Seishi
   Watanabe, Toshiki
TI Polycomb-Mediated Loss of miR-31 Activates NIK-Dependent NF-κB Pathway
   in Adult T Cell Leukemia and Other Cancers
SO CANCER CELL
LA English
DT Article
ID HISTONE METHYLTRANSFERASE EZH2; GROUP PROTEIN EZH2; VIRUS TYPE-I;
   PROSTATE-CANCER; BREAST-CANCER; KINASE; MICRORNAS; PROGRESSION;
   EXPRESSION; INHIBITOR
AB Constitutive NF-kappa B activation has causative roles in adult T cell leukemia (ATL) caused by HTLV-1 and other cancers. Here, we report a pathway involving Polycomb-mediated miRNA silencing and NF-kappa B activation. We determine the miRNA signatures and reveal miR-31 loss in primary ATL cells. MiR-31 negatively regulates the noncanonical NF-kappa B pathway by targeting NF-kappa B inducing kinase (NIK). Loss of miR-31 therefore triggers oncogenic signaling. In ATL cells, miR-31 level is epigenetically regulated, and aberrant upregulation of Polycomb proteins contribute to miR-31 downregulation in an epigenetic fashion, leading to activation of NF-kappa B and apoptosis resistance. Furthermore, this emerging circuit operates in other cancers and receptor-initiated NF-kappa B cascade. Our findings provide a perspective involving the epigenetic program, inflammatory responses, and oncogenic signaling.
C1 [Yamagishi, Makoto; Nakano, Kazumi; Miyake, Ariko; Yamochi, Tadanori; Kagami, Yayoi; Tsutsumi, Akihisa; Matsuda, Yuka; Muto, Satsuki; Watanabe, Toshiki] Univ Tokyo, Grad Sch Frontier Sci, Tokyo 1088639, Japan.
   [Uchimaru, Kaoru] Univ Tokyo, Inst Med Sci, Tokyo 1088639, Japan.
   [Yamagishi, Makoto] Japan Fdn AIDS Prevent, Tokyo 1010061, Japan.
   [Sato-Otsubo, Aiko; Muto, Satsuki; Ogawa, Seishi] Univ Tokyo, Grad Sch Med, Canc Genom Project, Tokyo 1138655, Japan.
   [Utsunomiya, Atae] Imamura Hosp, Dept Haematol, Kagoshima 8900064, Japan.
   [Yamaguchi, Kazunari] NIID, Dept Safety Res Blood & Biol, Tokyo 2080611, Japan.
C3 University of Tokyo; University of Tokyo; University of Tokyo; National
   Institute of Infectious Diseases (NIID)
RP Watanabe, T (通讯作者)，Univ Tokyo, Grad Sch Frontier Sci, Tokyo 1088639, Japan.
EM tnabe@ims.u-tokyo.ac.jp
RI Ogawa, Seishi/AAE-7088-2019; Watanabe, Toshiki/AAX-2230-2020
FU Ministry of Education, Culture, Sports, Science, and Technology of Japan
   [23390250]; Ministry of Health, Labour and Welfare [H21-G-002,
   H22-AIDS-I-002]; Grants-in-Aid for Scientific Research [22591028,
   24790436, 22134006, 23249052, 23390250] Funding Source: KAKEN
FX We thank Dr. M. Iwanaga, Mr. M. Nakashima, and Ms. T. Akashi for support
   and maintenance of JSPFAD. We thank Drs. H. Miyoshi and A. Miyawaki for
   providing the Venus-encoding lentivirus vectors. We also thank Dr. R.
   Hone for experimental advices, and Drs. T. Kanno and T. Ishida for
   providing the MDA-MB-453. Grant support: Grants-in-Aid for Scientific
   Research from Ministry of Education, Culture, Sports, Science, and
   Technology of Japan to T.W. (No. 23390250) and by Grants-in-Aid from the
   Ministry of Health, Labour and Welfare to T.W. (H21-G-002 and
   H22-AIDS-I-002).
CR Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bellon M, 2009, BLOOD, V113, P4914, DOI 10.1182/blood-2008-11-189845
   Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904
   Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399
   Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086
   Fiskus W, 2009, BLOOD, V114, P2733, DOI 10.1182/blood-2009-03-213496
   Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020
   Hironaka N, 2004, NEOPLASIA, V6, P266, DOI 10.1593/neo.03388
   Horie R, 2004, CANCER CELL, V5, P353, DOI 10.1016/S1535-6108(04)00084-4
   Iwanaga M, 2010, BLOOD, V116, P1211, DOI 10.1182/blood-2009-12-257410
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Liao GX, 2004, J BIOL CHEM, V279, P26243, DOI 10.1074/jbc.M403286200
   Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0
   Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100
   Prasad S, 2010, MOL CELL BIOCHEM, V336, P25, DOI 10.1007/s11010-009-0267-2
   Ramakrishnan P, 2004, IMMUNITY, V21, P477, DOI 10.1016/j.immuni.2004.08.009
   Saitoh Y, 2008, BLOOD, V111, P5118, DOI 10.1182/blood-2007-09-110635
   Sander S, 2008, BLOOD, V112, P4202, DOI 10.1182/blood-2008-03-147645
   Schaefer A, 2010, INT J CANCER, V126, P1166, DOI 10.1002/ijc.24827
   Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Su I, 2005, CELL, V121, P425, DOI 10.1016/j.cell.2005.02.029
   Su IH, 2003, NAT IMMUNOL, V4, P124, DOI 10.1038/ni876
   Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729
   Thu YM, 2010, CYTOKINE GROWTH F R, V21, P213, DOI 10.1016/j.cytogfr.2010.06.002
   Trabucchi M, 2009, NATURE, V459, P1010, DOI 10.1038/nature08025
   Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395
   Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005
   Watanabe M, 2005, BLOOD, V106, P2462, DOI 10.1182/blood-2004-09-3646
   Yamagishi M, 2009, MICROBES INFECT, V11, P500, DOI 10.1016/j.micinf.2009.02.003
   Yamaguchi K, 2002, INT J HEMATOL, V76, P240, DOI 10.1007/BF03165123
   Yeung ML, 2008, CANCER RES, V68, P8976, DOI 10.1158/0008-5472.CAN-08-0769
   Zarnegar B, 2008, P NATL ACAD SCI USA, V105, P3503, DOI 10.1073/pnas.0707959105
   Zarnegar BJ, 2008, NAT IMMUNOL, V9, P1371, DOI 10.1038/ni.1676
NR 37
TC 267
Z9 289
U1 0
U2 22
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1535-6108
J9 CANCER CELL
JI Cancer Cell
PD JAN 17
PY 2012
VL 21
IS 1
BP 121
EP 135
DI 10.1016/j.ccr.2011.12.015
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA 879XA
UT WOS:000299365000013
PM 22264793
OA Bronze
DA 2025-01-12
ER

PT J
AU Nelson, HH
   Marsit, CJ
   Kelsey, KT
AF Nelson, Heather H.
   Marsit, Carmen J.
   Kelsey, Karl T.
TI Global Methylation in Exposure Biology and Translational Medical Science
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article
DE ALU; biomarker; epigenetic; exposure biology; LINE-1; methylation
ID HUMAN ENDOGENOUS RETROVIRUS; GENOMIC DNA HYPOMETHYLATION; EMBRYONAL
   CARCINOMA-CELLS; ISCHEMIC-HEART-DISEASE; BREAST-CANCER;
   CARDIOVASCULAR-DISEASE; L1 RETROTRANSPOSITION; TRANSPOSABLE ELEMENTS;
   PROMOTER METHYLATION; COLORECTAL-CANCER
AB BACKGROUND: Many groups are actively investigating how the epigenetic state relates to environmental exposures and development of disease, including cancer. There are myriad choices for capturing and measuring the epigenetic state of a tissue, ranging from assessing the total methyl-CpG content to array-based platforms that simultaneously probe hundreds of thousands of CpG loci. There is an emerging literature that uses CpG methylation at repetitive sequences, including LINE-1 (long interspersed nuclear element-1)elements, to capture the epigenomic state.
   OBJECTIVES: We explored the complexity of using CpG methylation at repetitive sequences in epidemiology and translational medical research and suggest needed avenues of research to clarify its meaning and utility.
   CONCLUSIONS: Among the most urgent avenues of research is the need for prospective studies to eliminate the possibilities of reverse causality, and development of new LINE-1 assays that capture both class of LINE-1 element and copy number.
C1 [Nelson, Heather H.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA.
   [Nelson, Heather H.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN 55455 USA.
   [Marsit, Carmen J.] Brown Univ, Dept Pathol, Providence, RI 02912 USA.
   [Marsit, Carmen J.; Kelsey, Karl T.] Brown Univ, Ctr Environm Hlth & Technol, Providence, RI 02912 USA.
   [Kelsey, Karl T.] Brown Univ, Dept Epidemiol, Providence, RI 02912 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   Brown University; Brown University; Brown University
RP Nelson, HH (通讯作者)，Univ Minnesota, Masonic Canc Ctr, MMC806,8806A,420 Delaware St SE, Minneapolis, MN 55455 USA.
EM hhnelson@umn.edu
RI Kelsey, Karl/I-1252-2014
OI Nelson, Heather/0000-0003-1901-9513; Marsit, Carmen/0000-0003-4566-150X
CR Alexander RP, 2010, NAT REV GENET, V11, P559, DOI 10.1038/nrg2814
   An WF, 2008, GENESIS, V46, P373, DOI 10.1002/dvg.20407
   Babushok DV, 2006, GENOME RES, V16, P240, DOI 10.1101/gr.4571606
   Baccarelli A, 2010, EPIDEMIOLOGY, V21, P819, DOI 10.1097/EDE.0b013e3181f20457
   Baccarelli A, 2009, AM J RESP CRIT CARE, V179, P572, DOI 10.1164/rccm.200807-1097OC
   Balada E, 2009, REV MED VIROL, V19, P273, DOI 10.1002/rmv.622
   BARKER DJP, 1989, LANCET, V2, P577
   Barker DJP, 2005, J AM SOC NEPHROL, V16, P2537, DOI 10.1681/ASN.2005020160
   BARKER DJP, 1988, BRIT MED J, V297, P134, DOI 10.1136/bmj.297.6641.134-b
   Belancio VP, 2009, GENOME MED, V1, DOI 10.1186/gm97
   Bennett KL, 2010, JAMA-J AM MED ASSOC, V304, P2724, DOI 10.1001/jama.2010.1877
   Bollati V, 2007, CANCER RES, V67, P876, DOI 10.1158/0008-5472.CAN-06-2995
   Bollati V, 2009, MECH AGEING DEV, V130, P234, DOI 10.1016/j.mad.2008.12.003
   BRANCIFORTE D, 1994, MOL CELL BIOL, V14, P2584, DOI 10.1128/MCB.14.4.2584
   Cash HL, 2012, INT J CANCER, V130, P1151, DOI 10.1002/ijc.26098
   Chalitchagorn K, 2004, ONCOGENE, V23, P8841, DOI 10.1038/sj.onc.1208137
   Cho YH, 2010, ANTICANCER RES, V30, P2489
   Choi JY, 2009, CARCINOGENESIS, V30, P1889, DOI 10.1093/carcin/bgp143
   Choi SH, 2009, INT J CANCER, V125, P723, DOI 10.1002/ijc.24384
   Christensen BC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000602
   Cordaux R, 2009, NAT REV GENET, V10, P691, DOI 10.1038/nrg2640
   Davis CD, 2000, J NUTR, V130, P2903, DOI 10.1093/jn/130.12.2903
   Dean Wendy, 2005, Birth Defects Res C Embryo Today, V75, P98, DOI 10.1002/bdrc.20037
   Dewannieux M, 2003, NAT GENET, V35, P41, DOI 10.1038/ng1223
   Dion V, 2008, DNA REPAIR, V7, P313, DOI 10.1016/j.dnarep.2007.11.002
   Dobrovic A, 2009, INT J BIOCHEM CELL B, V41, P34, DOI 10.1016/j.biocel.2008.09.006
   Ergün S, 2004, J BIOL CHEM, V279, P27753, DOI 10.1074/jbc.M312985200
   Ewing AD, 2010, GENOME RES, V20, P1262, DOI 10.1101/gr.106419.110
   Florl AR, 1999, BRIT J CANCER, V80, P1312, DOI 10.1038/sj.bjc.6690524
   Gimenez J, 2009, DNA RES, V16, P195, DOI 10.1093/dnares/dsp011
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hitchins MP, 2010, ADV GENET, V70, P201, DOI [10.1016/S0065-2660(10)70008-0, 10.1016/B978-0-12-380866-0.60008-3]
   Hou LF, 2010, INT J CANCER, V127, P1866, DOI 10.1002/ijc.25190
   Hsiung DT, 2007, CANCER EPIDEM BIOMAR, V16, P108, DOI 10.1158/1055-9965.EPI-06-0636
   Huh JW, 2008, PLACENTA, V29, P602, DOI 10.1016/j.placenta.2008.04.002
   Januchowski Radoslaw, 2004, Journal of Applied Genetics, V45, P237
   Jintaridth P, 2010, PHYSIOL GENOMICS, V41, P194, DOI 10.1152/physiolgenomics.00146.2009
   Jordan IK, 2003, TRENDS GENET, V19, P68, DOI 10.1016/S0168-9525(02)00006-9
   Kano H, 2009, GENE DEV, V23, P1303, DOI 10.1101/gad.1803909
   Kile ML, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013730
   Kim KY, 2010, ENVIRON HEALTH PERSP, V118, P370, DOI 10.1289/ehp.0901131
   Kim M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009692
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Largaespada David A., 2009, V530, P379, DOI 10.1007/978-1-59745-471-1_20
   Maksakova IA, 2006, PLOS GENET, V2, P1, DOI 10.1371/journal.pgen.0020002
   MARTIN SL, 1993, MOL CELL BIOL, V13, P5383, DOI 10.1128/MCB.13.9.5383
   MARTIN SL, 1991, MOL CELL BIOL, V11, P4804, DOI 10.1128/MCB.11.9.4804
   Menendez L, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-12
   Miki Y, 1998, J HUM GENET, V43, P77, DOI 10.1007/s100380050045
   Mirabello L, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-77
   Moore LE, 2008, LANCET ONCOL, V9, P359, DOI 10.1016/S1470-2045(08)70038-X
   Muotri AR, 2010, NATURE, V468, P443, DOI 10.1038/nature09544
   Ogasawara H, 2003, CLIN EXP RHEUMATOL, V21, P733
   Okada M, 2002, J RHEUMATOL, V29, P1678
   Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032
   Pavanello S, 2009, INT J CANCER, V125, P1692, DOI 10.1002/ijc.24492
   Pilsner JR, 2011, ENVIRON HEALTH PERSP, V119, P113, DOI 10.1289/ehp.1001937
   Pufulete M, 2003, GASTROENTEROLOGY, V124, P1240, DOI 10.1016/S0016-5085(03)00279-8
   Ruprecht K, 2008, CELL MOL LIFE SCI, V65, P3366, DOI 10.1007/s00018-008-8496-1
   Rusiecki JA, 2008, ENVIRON HEALTH PERSP, V116, P1547, DOI 10.1289/ehp.11338
   Schulz WA, 2006, CURR TOP MICROBIOL, V310, P211
   Smolarek I, 2010, MED SCI MONITOR, V16, pCR149
   Stacey KJ, 2010, CELL RES, V20, P869, DOI 10.1038/cr.2010.96
   Starr TK, 2009, SCIENCE, V323, P1747, DOI 10.1126/science.1163040
   Stengel S, 2010, GENE CHROMOSOME CANC, V49, P401, DOI 10.1002/gcc.20751
   Suter CM, 2004, INT J COLORECTAL DIS, V19, P95, DOI 10.1007/s00384-003-0539-3
   Tamashiro KLK, 2010, PHYSIOL BEHAV, V100, P560, DOI 10.1016/j.physbeh.2010.04.008
   Tarantini L, 2009, ENVIRON HEALTH PERSP, V117, P217, DOI 10.1289/ehp.11898
   Terry MB, 2008, CANCER EPIDEM BIOMAR, V17, P2306, DOI 10.1158/1055-9965.EPI-08-0312
   Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003
   Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262
   Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987
   Wilhelm CS, 2010, CLIN CANCER RES, V16, P1682, DOI 10.1158/1078-0432.CCR-09-2983
   Wolff GL, 1998, FASEB J, V12, P949, DOI 10.1096/fasebj.12.11.949
   Wong EM, 2010, CANCER PREV RES, V4, P23
   Wright RO, 2010, ENVIRON HEALTH PERSP, V118, P790, DOI 10.1289/ehp.0901429
   Wu HC, 2011, EPIGENETICS-US, V6, P29, DOI 10.4161/epi.6.1.13393
   Wu HC, 2011, EPIGENETICS-US, V6, P76, DOI 10.4161/epi.6.1.13391
   Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032
   Zhao CQ, 1997, P NATL ACAD SCI USA, V94, P10907, DOI 10.1073/pnas.94.20.10907
   Zhu ZZ, 2012, INT J EPIDEMIOL, V41, P126, DOI 10.1093/ije/dyq154
NR 82
TC 78
Z9 86
U1 0
U2 5
PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE
PI RES TRIANGLE PK
PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
   RES TRIANGLE PK, NC 27709-2233 USA
SN 0091-6765
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD NOV
PY 2011
VL 119
IS 11
BP 1528
EP 1533
DI 10.1289/ehp.1103423
PG 6
WC Environmental Sciences; Public, Environmental & Occupational Health;
   Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health; Toxicology
GA 844XL
UT WOS:000296785900017
PM 21669556
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Ebert, MPA
   Tänzer, M
   Balluff, B
   Burgermeister, E
   Kretzschmar, AK
   Hughes, DJ
   Tetzner, R
   Lofton-Day, C
   Rosenberg, R
   Reinacher-Schick, AC
   Schulmann, K
   Tannapfel, A
   Hofheinz, R
   Röcken, C
   Keller, G
   Langer, R
   Specht, K
   Porschen, R
   Stöhlmacher-Williams, J
   Schuster, T
   Ströbel, P
   Schmid, RM
AF Ebert, Matthias P. A.
   Taenzer, Marc
   Balluff, Benjamin
   Burgermeister, Elke
   Kretzschmar, Antje Karen
   Hughes, David J.
   Tetzner, Reimo
   Lofton-Day, Catherine
   Rosenberg, Robert
   Reinacher-Schick, Anke C.
   Schulmann, Karsten
   Tannapfel, Andrea
   Hofheinz, Ralf
   Roecken, Christoph
   Keller, Gisela
   Langer, Rupert
   Specht, Katja
   Porschen, Rainer
   Stoehlmacher-Williams, Jan
   Schuster, Tibor
   Stroebel, Philipp
   Schmid, Roland M.
TI <i>TFAP2E</i>-<i>DKK4</i> and Chemoresistance in Colorectal Cancer
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID THYMIDYLATE SYNTHASE; GENE-EXPRESSION; BREAST-CANCER; PHASE-III;
   METHYLATION; MUTATIONS; 5-FLUOROURACIL; IDENTIFICATION; INSTABILITY;
   CARCINOMA
AB BACKGROUND
   Chemotherapy for advanced colorectal cancer leads to improved survival; however, predictors of response to systemic treatment are not available. Genomic and epigenetic alterations of the gene encoding transcription factor AP-2 epsilon (TFAP2E) are common in human cancers. The gene encoding dickkopf homolog 4 protein (DKK4) is a potential downstream target of TFAP2E and has been implicated in chemotherapy resistance. We aimed to further evaluate the role of TFAP2E and DKK4 as predictors of the response of colorectal cancer to chemotherapy.
   METHODS
   We analyzed the expression, methylation, and function of TFAP2E in colorectal-cancer cell lines in vitro and in patients with colorectal cancer. We examined an initial cohort of 74 patients, followed by four cohorts of patients (total, 220) undergoing chemotherapy or chemoradiation.
   RESULTS
   TFAP2E was hypermethylated in 38 of 74 patients (51%) in the initial cohort. Hyper-methylation was associated with decreased expression of TFAP2E in primary and metastatic colorectal-cancer specimens and cell lines. Colorectal-cancer cell lines overexpressing DKK4 showed increased chemoresistance to fluorouracil but not irinotecan or oxaliplatin. In the four other patient cohorts, TFAP2E hypermethylation was significantly associated with nonresponse to chemotherapy (P<0.001). Conversely, the probability of response among patients with hypomethylation was approximately six times that in the entire population (overall estimated risk ratio, 5.74; 95% confidence interval, 3.36 to 9.79). Epigenetic alterations of TFAP2E were independent of mutations in key regulatory cancer genes, microsatellite instability, and other genes that affect fluorouracil metabolism.
   CONCLUSIONS
   TFAP2E hypermethylation is associated with clinical nonresponsiveness to chemotherapy in colorectal cancer. Functional assays confirm that TFAP2E-dependent resistance is mediated through DKK4. In patients who have colorectal cancer with TFAP2E hypermethylation, targeting of DKK4 may be an option to overcome TFAP2E-mediated drug resistance. (Funded by Deutsche Forschungsgemeinschaft and others.)
C1 [Ebert, Matthias P. A.; Burgermeister, Elke] Univ Heidelberg, Univ Med Mannheim, Dept Med 2, D-68167 Mannheim, Germany.
   [Hofheinz, Ralf] Univ Heidelberg, Univ Med Mannheim, Dept Med 3, D-68167 Mannheim, Germany.
   [Stroebel, Philipp] Univ Heidelberg, Univ Med Mannheim, Inst Pathol, D-68167 Mannheim, Germany.
   [Taenzer, Marc; Balluff, Benjamin; Kretzschmar, Antje Karen; Schmid, Roland M.] Tech Univ Munich, Klinikum Rechts Isar, Dept Med 2, D-8000 Munich, Germany.
   [Rosenberg, Robert] Tech Univ Munich, Klinikum Rechts Isar, Chirurg Klin & Poliklin, D-8000 Munich, Germany.
   [Keller, Gisela; Specht, Katja] Tech Univ Munich, Klinikum Rechts Isar, Inst Pathol, D-8000 Munich, Germany.
   [Schuster, Tibor] Tech Univ Munich, Klinikum Rechts Isar, Inst Med Stat & Epidemiol, D-8000 Munich, Germany.
   [Balluff, Benjamin] Tech Univ Munich, Inst Pathol, D-8000 Munich, Germany.
   [Balluff, Benjamin] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Pathol, Munich, Germany.
   [Reinacher-Schick, Anke C.; Schulmann, Karsten] Ruhr Univ Bochum, Knappschafts Krankenhaus, Dept Med, Bochum, Germany.
   [Tannapfel, Andrea] Ruhr Univ Bochum, Dept Pathol, Bochum, Germany.
   [Roecken, Christoph] Univ Kiel, Inst Pathol, Kiel, Germany.
   [Porschen, Rainer] Bremen Ost Hosp, Dept Med, Bremen, Germany.
   [Stoehlmacher-Williams, Jan] Tech Univ Dresden, Univ Hosp, Dept Med 1, D-01062 Dresden, Germany.
   [Hughes, David J.] Royal Coll Surgeons Ireland, Ctr Syst Med, Dept Physiol & Med Phys, Dublin 2, Ireland.
   [Tetzner, Reimo] Epigenomics, Berlin, Germany.
   [Lofton-Day, Catherine] Epigenomics, Seattle, WA USA.
C3 Ruprecht Karls University Heidelberg; Ruprecht Karls University
   Heidelberg; Ruprecht Karls University Heidelberg; Technical University
   of Munich; Technical University of Munich; University of Munich;
   Technical University of Munich; Technical University of Munich;
   Technical University of Munich; Helmholtz Association; Helmholtz-Center
   Munich - German Research Center for Environmental Health; Ruhr
   University Bochum; Ruhr University Bochum; University of Kiel;
   Technische Universitat Dresden; Carl Gustav Carus University Hospital;
   Royal College of Surgeons - Ireland
RP Ebert, MPA (通讯作者)，Univ Heidelberg, Univ Med Mannheim, Dept Med 2, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM matthias.ebert@umm.de
RI Reinacher-Schick, Anke/F-2722-2012; Hughes, David/K-8960-2019;
   Schulmann, Karsten/N-2230-2016; Langer, Rupert/AAU-1174-2021; Schuster,
   Tibor/LQJ-4546-2024; Rocken, Christoph/A-9239-2010; Peters, Godefridus
   J/C-7562-2013
OI Rocken, Christoph/0000-0002-6989-8002; Peters, Godefridus
   J/0000-0002-5447-2877; Hughes, David John/0000-0003-1668-8770; Langer,
   Rupert/0000-0001-9491-3609
FU Deutsche Krebshilfe [107885, 108096]; Deutsche Forschungsgemeinschaft
   [SFB 824]; Else Kroner Stiftung [P14/07//A104/06]; Bundesministerium fur
   Bildung und Forschung [01EZ0802, 0315116B]; Academy of Finland (AKA)
   [107885] Funding Source: Academy of Finland (AKA)
FX Supported by grants from Deutsche Krebshilfe (107885 and 108096),
   Deutsche Forschungsgemeinschaft (SFB 824), Else Kroner Stiftung (Nr
   P14/07//A104/06), and Bundesministerium fur Bildung und Forschung
   (01EZ0802 and 0315116B).
CR Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116
   Boland CR, 1998, CANCER RES, V58, P5248
   Chung W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002079
   Dalgin GS, 2008, J UROLOGY, V180, P1126, DOI 10.1016/j.juro.2008.04.137
   Ebert MPA, 2006, GASTROENTEROLOGY, V131, P1418, DOI 10.1053/j.gastro.2006.08.034
   Eckert D, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-13-246
   Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Giaretti W, 2004, CELL ONCOL, V26, P301
   Guler G, 2007, CLIN CANCER RES, V13, P6115, DOI 10.1158/1078-0432.CCR-07-1282
   Heinrich MC, 2008, J CLIN ONCOL, V26, P5360, DOI 10.1200/JCO.2008.17.4284
   Hirsch FR, 2006, J CLIN ONCOL, V24, P5034, DOI 10.1200/JCO.2006.06.3958
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Lièvre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906
   Maeda S, 2005, J HUM GENET, V50, P283, DOI 10.1007/s10038-005-0253-9
   Maehata T, 2008, WORLD J GASTROENTERO, V14, P2702, DOI 10.3748/wjg.14.2702
   Orso F, 2007, ADV EXP MED BIOL, V604, P87, DOI 10.1007/978-0-387-69116-9_6
   Porschen R, 2007, J CLIN ONCOL, V25, P4217, DOI 10.1200/JCO.2006.09.2684
   Prix L, 2002, CLIN CHEM, V48, P428
   Rosenberg R, 2008, J SURG ONCOL, V97, P8, DOI 10.1002/jso.20844
   Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990
   Wojdacz TK, 2008, NAT PROTOC, V3, P1903, DOI 10.1038/nprot.2008.191
   Woodfield GW, 2007, CANCER RES, V67, P8439, DOI 10.1158/0008-5472.CAN-07-2293
   Xi Y, 2008, ONCOL REP, V19, P257
   Xi YG, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-68
   You J, 2008, DIGEST DIS SCI, V53, P1013, DOI 10.1007/s10620-007-9973-3
NR 26
TC 143
Z9 161
U1 3
U2 15
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JAN 5
PY 2012
VL 366
IS 1
BP 44
EP 53
DI 10.1056/NEJMoa1009473
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 887XY
UT WOS:000299968800006
PM 22216841
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Yang, F
   Sun, LY
   Li, Q
   Han, X
   Lei, LD
   Zhang, H
   Shang, YF
AF Yang, Fen
   Sun, Luyang
   Li, Qian
   Han, Xiao
   Lei, Liandi
   Zhang, Hua
   Shang, Yongfeng
TI SET8 promotes epithelial-mesenchymal transition and confers TWIST dual
   transcriptional activities
SO EMBO JOURNAL
LA English
DT Article
DE breast cancer; EMT; metastasis; SET8; TWIST
ID HISTONE METHYLTRANSFERASE SET8; BREAST-CANCER; GENE-EXPRESSION; S-PHASE;
   NUCLEAR TRANSLOCATION; CELL-PROLIFERATION; RECEPTOR-ALPHA; METASTASIS;
   MONOMETHYLATION; ACTIVATION
AB SET8 is implicated in transcriptional regulation, heterochromatin formation, genomic stability, cell-cycle progression, and development. As such, it is predicted that SET8 might be involved in the development and progression of tumour. However, whether and how SET8 might be implicated in tumourigenesis is currently unknown. Here, we report that SET8 is physically associated with TWIST, a master regulator of epithelial-mesenchymal transition (EMT). We demonstrated that SET8 and TWIST are functionally interdependent in promoting EMT and enhancing the invasive potential of breast cancer cells in vitro and in vivo. We showed that SET8 acts as a dual epigenetic modifier on the promoters of the TWIST target genes E-cadherin and N-cadherin via its H4K20 monomethylation activity. Significantly, in breast carcinoma samples, SET8 expression is positively correlated with metastasis and the expression of TWIST and N-cadherin and negatively correlated with E-cadherin. Together, our experiments revealed a novel role for SET8 in tumour invasion and metastasis and provide a molecular mechanism underlying TWIST-promoted EMT, suggesting SET8 as a potential target for intervention of the metastasis of breast cancer. The EMBO Journal (2012) 31, 110-123. doi: 10.1038/emboj.2011.364; Published online 7 October 2011
C1 [Yang, Fen; Zhang, Hua] China Astronaut Res & Training Ctr, Dept Biochem & Mol Biol, State Key Lab Space Med Fundamentals & Applicat, Beijing 100193, Peoples R China.
   [Yang, Fen; Sun, Luyang; Li, Qian; Han, Xiao; Shang, Yongfeng] Peking Univ, Dept Biochem & Mol Biol, Key Lab Carcinogenesis & Translat Res, Hlth Sci Ctr,Minist Educ, Beijing 100191, Peoples R China.
   [Lei, Liandi] Peking Univ, Hlth Sci Ctr, Lab Mol Imaging, Hlth Sci Anal Ctr, Beijing 100871, Peoples R China.
   [Shang, Yongfeng] Tianjin Med Univ, Dept Biochem & Mol Biol, Tianjin Key Lab Med Epigenet, Tianjin, Peoples R China.
C3 Peking University; Peking University; Tianjin Medical University
RP Zhang, H (通讯作者)，China Astronaut Res & Training Ctr, Dept Biochem & Mol Biol, State Key Lab Space Med Fundamentals & Applicat, Beijing 100193, Peoples R China.
EM hzhang@hsc.pku.edu.cn; yshang@hsc.pku.edu.cn
RI Han, Xiao/A-1109-2017; Li, Qian/KIE-2130-2024
OI Li, Qian/0000-0003-0359-5604; Han, Xiao/0000-0002-6024-6286
FU National Natural Science Foundation of China [30830032, 30921062,
   30671076, 30771104]; Ministry of Science and Technology of China
   [2011CB504204]; State Key Laboratory of Space Medicine Fundamentals and
   Application of China [KC1001, SMFA09A11, 2010SY5403002]
FX This work was supported by grants (30830032 and 30921062 to YS; 30671076
   and 30771104 to HZ) from the National Natural Science Foundation of
   China, by grants (973 Program: 2011CB504204 to YS and HZ) from the
   Ministry of Science and Technology of China, and by grants (KC1001,
   SMFA09A11, and 2010SY5403002 to HZ) from State Key Laboratory of Space
   Medicine Fundamentals and Application of China.
CR Abbas T, 2010, MOL CELL, V40, P9, DOI 10.1016/j.molcel.2010.09.014
   Acevedo VD, 2007, CANCER CELL, V12, P559, DOI 10.1016/j.ccr.2007.11.004
   Alexander NR, 2006, CANCER RES, V66, P3365, DOI 10.1158/0008-5472.CAN-05-3401
   Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005
   Castanon I, 2001, DEVELOPMENT, V128, P3145
   Centore RC, 2010, MOL CELL, V40, P22, DOI 10.1016/j.molcel.2010.09.015
   Cheng GZ, 2008, J BIOL CHEM, V283, P14665, DOI 10.1074/jbc.M707429200
   Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479
   Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876
   Congdon LM, 2010, J CELL BIOCHEM, V110, P609, DOI 10.1002/jcb.22570
   Dalton TP, 1997, MOL CELL BIOL, V17, P2781, DOI 10.1128/MCB.17.5.2781
   Fang J, 2002, CURR BIOL, V12, P1086, DOI 10.1016/S0960-9822(02)00924-7
   Fu JJ, 2011, CELL RES, V21, P275, DOI 10.1038/cr.2010.118
   Hasselblatt M, 2009, CANCER RES, V69, P2219, DOI 10.1158/0008-5472.CAN-08-3176
   Horikawa T, 2007, CANCER RES, V67, P1970, DOI 10.1158/0008-5472.CAN-06-3933
   Houston SI, 2008, J BIOL CHEM, V283, P19478, DOI 10.1074/jbc.M710579200
   Jorgensen S, 2007, J CELL BIOL, V179, P1337, DOI 10.1083/jcb.200706150
   Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618
   Kalakonda N, 2008, ONCOGENE, V27, P4293, DOI 10.1038/onc.2008.67
   Klein CA, 2009, NAT REV CANCER, V9, P302, DOI 10.1038/nrc2627
   Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253
   Kudo-Saito C, 2009, CANCER CELL, V15, P195, DOI 10.1016/j.ccr.2009.01.023
   Kwok WK, 2005, CANCER RES, V65, P5153, DOI 10.1158/0008-5472.CAN-04-3785
   Li RF, 2009, EMBO J, V28, P2763, DOI 10.1038/emboj.2009.211
   Li YY, 2011, J BIOL CHEM, V286, P13925, DOI 10.1074/jbc.M111.223198
   Li ZF, 2011, P NATL ACAD SCI USA, V108, P3116, DOI 10.1073/pnas.1009353108
   Lu CH, 2010, CANCER CELL, V18, P185, DOI 10.1016/j.ccr.2010.06.016
   Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Mironchik Y, 2005, CANCER RES, V65, P10801, DOI 10.1158/0008-5472.CAN-05-0712
   Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518
   Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622
   Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619
   Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8
   Oda H, 2009, MOL CELL BIOL, V29, P2278, DOI 10.1128/MCB.01768-08
   Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7
   Pan DN, 2009, CELL, V137, P73, DOI 10.1016/j.cell.2009.01.051
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Psaila B, 2009, NAT REV CANCER, V9, P285, DOI 10.1038/nrc2621
   Radisky DC, 2007, NAT CELL BIOL, V9, P361, DOI 10.1038/ncb0407-361
   Rayasam GV, 2003, EMBO J, V22, P3153, DOI 10.1093/emboj/cdg288
   Richter GHS, 2009, P NATL ACAD SCI USA, V106, P5324, DOI 10.1073/pnas.0810759106
   Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704
   Shi L, 2011, P NATL ACAD SCI USA, V108, P7541, DOI 10.1073/pnas.1017374108
   Shi XB, 2007, MOL CELL, V27, P636, DOI 10.1016/j.molcel.2007.07.012
   Shiota M, 2008, CANCER RES, V68, P98, DOI 10.1158/0008-5472.CAN-07-2981
   Smirnova IV, 2000, J BIOL CHEM, V275, P9377, DOI 10.1074/jbc.275.13.9377
   Subramanian K, 2008, MOL CELL, V30, P336, DOI 10.1016/j.molcel.2008.03.022
   Talasz H, 2005, J BIOL CHEM, V280, P38814, DOI 10.1074/jbc.M505563200
   Tardat M, 2007, J CELL BIOL, V179, P1413, DOI 10.1083/jcb.200706179
   Tardat M, 2010, NAT CELL BIOL, V12, P1086, DOI 10.1038/ncb2113
   Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107
   Trojer P, 2007, CELL, V129, P915, DOI 10.1016/j.cell.2007.03.048
   Wakabayashi K, 2009, MOL CELL BIOL, V29, P3544, DOI 10.1128/MCB.01856-08
   Wang GG, 2009, NATURE, V459, P847, DOI 10.1038/nature08036
   Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050
   Wu HJ, 2005, NATURE, V438, P981, DOI 10.1038/nature04225
   Wu SM, 2010, GENE DEV, V24, P2531, DOI 10.1101/gad.1984210
   Yamane K, 2007, MOL CELL, V25, P801, DOI 10.1016/j.molcel.2007.03.001
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
   Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691
   Zhang H, 2004, GENE DEV, V18, P1753, DOI 10.1101/gad.1194704
   Zhang H, 2006, EMBO J, V25, P4223, DOI 10.1038/sj.emboj.7601306
NR 63
TC 207
Z9 253
U1 0
U2 32
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0261-4189
J9 EMBO J
JI Embo J.
PD JAN 4
PY 2012
VL 31
IS 1
BP 110
EP 123
DI 10.1038/emboj.2011.364
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 885YM
UT WOS:000299817400010
PM 21983900
OA Green Published
DA 2025-01-12
ER

PT J
AU Yu, FY
   Jiao, Y
   Zhu, YH
   Wang, Y
   Zhu, JD
   Cui, XY
   Liu, YJ
   He, YH
   Park, EY
   Zhang, HY
   Lv, XB
   Ma, KL
   Su, FX
   Park, JH
   Song, EW
AF Yu, Fengyan
   Jiao, Yu
   Zhu, Yinghua
   Wang, Ying
   Zhu, Jingde
   Cui, Xiuying
   Liu, Yujie
   He, Yinghua
   Park, Eun-Young
   Zhang, Hongyu
   Lv, Xiaobin
   Ma, Kelong
   Su, Fengxi
   Park, Jong Hoon
   Song, Erwei
TI MicroRNA 34c Gene Down-regulation via DNA Methylation Promotes
   Self-renewal and Epithelial-Mesenchymal Transition in Breast
   Tumor-initiating Cells
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID CANCER STEM-CELLS; CPG METHYLATION; EPIGENETIC INACTIVATION; EXPRESSION;
   TRANSCRIPTION; BINDING; MIR-34; SITE; DEMETHYLATION; ACTIVATION
AB Tumor-initiating cells (T-ICs), a subpopulation of cancer cells with stem cell-like properties, are related to tumor relapse and metastasis. Our previous studies identified a distinct profile of microRNA (miRNA) expression in breast T-ICs (BT-ICs), and the dysregulated miRNAs contribute to the self-renewal and tumorigenesis of these cells. However, the underlying mechanisms for miRNA dysregulation in BT-ICs remain obscure. In the present study, we demonstrated that the expression and function of miR-34c were reduced in the BT-ICs of MCF-7 and SK-3rd cells, a breast cancer cell line enriched for BT-ICs. Ectopic expression of miR-34c reduced the self-renewal of BT-ICs, inhibited epithelial-mesenchymal transition, and suppressed migration of the tumor cells via silencing target gene Notch4. Furthermore, we identified a single hypermethylated CpG site in the promoter region of miR-34c gene that contributed to transcriptional repression of miR-34c in BT-ICs by reducing DNA binding activities of Sp1. Therefore, miR-34c reduction in BT-ICs induced by a single hypermethylated CpG site in the promoter region promotes self-renewal and epithelial-mesenchymal transition of BT-ICs.
C1 [Park, Eun-Young; Park, Jong Hoon] Sookmyung Womens Univ, Dept Biol Sci, Seoul 140742, South Korea.
   [Yu, Fengyan; Wang, Ying; Liu, Yujie; Su, Fengxi; Song, Erwei] Sun Yat Sen Univ, Dept Breast Surg, Sun Yat Sen Mem Hosp, Guangzhou 510120, Guangdong, Peoples R China.
   [Jiao, Yu; Zhu, Yinghua; Song, Erwei] Sun Yat Sen Univ, Sch Life Sci, Guangzhou 510006, Guangdong, Peoples R China.
   [Zhu, Jingde; He, Yinghua; Zhang, Hongyu; Ma, Kelong] Shanghai Jiao Tong Univ, Canc Epigenet & Gene Therapy Grp, Shanghai Canc Inst, Shanghai 200032, Peoples R China.
   [Cui, Xiuying; Lv, Xiaobin] Sun Yat Sen Univ, Med Res Ctr, Sun Yat Sen Mem Hosp, Guangzhou 510120, Guangdong, Peoples R China.
C3 Sookmyung Women's University; Sun Yat Sen University; Sun Yat Sen
   University; Shanghai Jiao Tong University; Sun Yat Sen University
RP Park, JH (通讯作者)，Sookmyung Womens Univ, Dept Biol Sci, 52 Hyochangwonro, Seoul 140742, South Korea.
EM parkjh@sookmyung.ac.kr; songerwei02@yahoo.com.cn
RI Lv, Xiao-Bin/T-7607-2019
FU Natural Science Foundation of China [30921140312, 30831160515, 30830110,
   30973396, 30972785]; Ministry of Science and Technology of China
   [2010CB912800, 2011CB504203, 2009CB521706, 2009CB825606, 2009CB825607];
   Public Health Administration of China; Ministry of Health of China
   [2011ZX09102-010-02]; Key Laboratory of Malignant Tumor Gene Regulation
   and Target Therapy of Guang-dong Higher Education Institutes,
   Sun-Yat-Sen University [KLB09001]; HuoYingdong Educational Foundation
   [121042]; National Research Foundation of Korea [2011-0001382]; Korea
   government
FX This work was supported by Grant 30921140312 from the A3 program of the
   Natural Science Foundation of China; 973 Projects 2010CB912800,
   2011CB504203, 2009CB521706, 2009CB825606, and 2009CB825607 from the
   Ministry of Science and Technology of China; Grants 30831160515,
   30830110, 30973396, and 30972785 from the Natural Science Foundation of
   China; a Clinical Key Project of the Public Health Administration of
   China; Grant 2011ZX09102-010-02 for the Development of Important New
   Drugs from the Ministry of Health of China; Grant KLB09001 from the Key
   Laboratory of Malignant Tumor Gene Regulation and Target Therapy of
   Guang-dong Higher Education Institutes, Sun-Yat-Sen University; Young
   Teacher Grant 121042 from the HuoYingdong Educational Foundation; and
   National Research Foundation of Korea Grant 2011-0001382 funded by the
   Korea government.
CR BENHATTAR J, 1988, GENE, V65, P219, DOI 10.1016/0378-1119(88)90458-1
   Cai KM, 2010, INT J MOL MED, V25, P565, DOI 10.3892/ijmm_00000378
   Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173
   COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975
   Corney DC, 2010, CLIN CANCER RES, V16, P1119, DOI 10.1158/1078-0432.CCR-09-2642
   Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854
   Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086
   Friso S, 2008, ATHEROSCLEROSIS, V199, P323, DOI 10.1016/j.atherosclerosis.2007.11.029
   Furuta T, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-39
   He CL, 2009, BIOCHEM BIOPH RES CO, V388, P35, DOI 10.1016/j.bbrc.2009.07.101
   Honda H, 2006, J BIOL CHEM, V281, P21433, DOI 10.1074/jbc.M603767200
   Ji Q, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006816
   Ji Q, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-266
   Klopp AH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012180
   Kong DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012445
   Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284
   Liu Y, 2009, CLIN IMMUNOL, V130, P213, DOI 10.1016/j.clim.2008.08.009
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Meng FY, 2012, J CELL MOL MED, V16, P160, DOI 10.1111/j.1582-4934.2011.01282.x
   Michelotti GA, 2007, FASEB J, V21, P1979, DOI 10.1096/fj.06-7118com
   Murayama A, 2006, EMBO J, V25, P1081, DOI 10.1038/sj.emboj.7601012
   Norton L, 2011, ONCOLOGY-NY, V25, P30
   Noseda M, 2004, CIRC RES, V94, P910, DOI 10.1161/01.RES.0000124300.76171.C9
   Ozsolak F, 2008, GENE DEV, V22, P3172, DOI 10.1101/gad.1706508
   PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636
   Ren JQ, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-20
   ROBERTSON KD, 1995, MOL CELL BIOL, V15, P6150
   Rokhlin OW, 2008, CANCER BIOL THER, V7, P1288, DOI 10.4161/cbt.7.8.6284
   Sato H, 2007, CARCINOGENESIS, V28, P2459, DOI 10.1093/carcin/bgm178
   Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011
   Torng PL, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-120
   Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325
   Vogt M, 2011, VIRCHOWS ARCH, V458, P313, DOI 10.1007/s00428-010-1030-5
   Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312
   Wenger RH, 1998, EUR J BIOCHEM, V253, P771, DOI 10.1046/j.1432-1327.1998.2530771.x
   Wicha MS, 2006, CLIN CANCER RES, V12, P5606, DOI 10.1158/1078-0432.CCR-06-1537
   Wilting SM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-167
   Xu J, 2002, CELL RES, V12, P177, DOI 10.1038/sj.cr.7290124
   Yu F, 2010, ONCOGENE, V29, P4194, DOI 10.1038/onc.2010.167
   Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054
   Zhang H, 2004, CELL RES, V14, P283, DOI 10.1038/sj.cr.7290229
   Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003
   Zou B, 2006, GASTROENTEROLOGY, V131, P1835, DOI 10.1053/j.gastro.2006.09.050
NR 45
TC 122
Z9 131
U1 1
U2 33
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 2
PY 2012
VL 287
IS 1
BP 465
EP 473
DI 10.1074/jbc.M111.280768
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 870PW
UT WOS:000298682400045
PM 22074923
OA Green Published
DA 2025-01-12
ER

PT J
AU Addou-Klouche, L
   Adélaïde, J
   Cornen, S
   Bekhouche, I
   Finetti, P
   Guille, A
   Sircoulomb, F
   Raynaud, S
   Bertucci, F
   Birnbaum, D
   Chaffanet, M
AF Addou-Klouche, L.
   Adelaide, J.
   Cornen, S.
   Bekhouche, I
   Finetti, P.
   Guille, A.
   Sircoulomb, F.
   Raynaud, S.
   Bertucci, F.
   Birnbaum, D.
   Chaffanet, M.
TI INTEGRATED GENOMIC ANALYSIS OF BREAST CANCERS
SO BALKAN JOURNAL OF MEDICAL GENETICS
LA English
DT Article
DE Breast cancers; Genome; Transcriptome; Epigenome; Oncogenes; Tumor
   suppressor genes
ID GENE-EXPRESSION SIGNATURES; DNA METHYLATION; CELL-LINES; PROTEIN
   EXPRESSION; HYBRIDIZATION; DEREGULATION; CHEMOTHERAPY; BREAKPOINT;
   FREQUENCY; PATTERNS
AB Breast cancer is the most frequent and the most deadly cancer in women in Western countries. Different classifications of disease (anatomoclinical, pathological, prognostic, genetic) are used for guiding the management of patients. Unfortunately, they fail to reflect the whole clinical heterogeneity of the disease. Consequently, molecularly distinct diseases are grouped in similar clinical classes, likely explaining the different clinical outcome between patients in a given class, and the fact that selection of the most appropriate diagnostic or therapeutic strategy for each patient is not done accurately. Today, treatment is efficient in only 70.0-75.0% of cases overall. Our repertoire of efficient drugs is limited but is being expanded with the discovery of new molecular targets for new drugs, based on the identification of candidate oncogenes and tumor suppressor genes (TSG) functionally relevant in disease. Development of new drugs makes therapeutical decisions even more demanding of reliable classifiers and prognostic/predictive tests. Breast cancer is a complex, heterogeneous disease at the molecular level. The combinatorial molecular origin and the heterogeneity of malignant cells, and the variability of the host background, create distinct subgroups of tumors endowed with different phenotypic features such as response to therapy and clinical outcome. Cellular and molecular analyses can identify new classes biologically and clinically relevant, as well as provide new clinically relevant markers and targets.
   The various stages of mammary tumorigenesis are not clearly defined and the genetic and epigenetic events critical to the development and aggressiveness of breast cancer are not precisely known. Because the phenotype of tumors is dependent on many genes, a large-scale and integrated molecular characterization of the genetic and epigenetic alterations and gene expression deregulation should allow the identification of new molecular classes clinically relevant, as well as among the altered genes and/or pathways, the identification of more accurate molecular diagnostic, prognostic/predictive factors, and for some of them, after functional validation, the identification of new therapeutic targets.
C1 [Addou-Klouche, L.; Adelaide, J.; Cornen, S.; Bekhouche, I; Finetti, P.; Guille, A.; Sircoulomb, F.; Raynaud, S.; Bertucci, F.; Birnbaum, D.; Chaffanet, M.] INSERM, Marseille Canc Res Ctr, Dept Mol Oncol, UMR891, F-13258 Marseille, France.
   [Addou-Klouche, L.; Adelaide, J.; Cornen, S.; Bekhouche, I; Finetti, P.; Guille, A.; Sircoulomb, F.; Raynaud, S.; Bertucci, F.; Birnbaum, D.; Chaffanet, M.] Inst J Paoli I Calmettes, F-13009 Marseille, France.
   [Addou-Klouche, L.] Univ Djillali Liabes Sidi Bel Abbes, Biotoxicol Lab, Sidi Bel Abbes, Algeria.
   [Bertucci, F.; Chaffanet, M.] Inst J Paoli I Calmettes, Dept Mol Oncol, F-13009 Marseille, France.
   [Bertucci, F.] Univ Mediterranee, Marseille, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UNICANCER; Institut Paoli-Calmette (IPC); University Djillali Liabes
   Sidi Bel Abbes; UNICANCER; Institut Paoli-Calmette (IPC); Aix-Marseille
   Universite
RP Chaffanet, M (通讯作者)，Inst J Paoli I Calmettes, Dept Mol Oncol, 232 Blvd St Marguerite, F-13009 Marseille, France.
EM CHAFFANETM@ipc.unicancer.fr
RI Guille, Arnaud/GZG-1785-2022; CHAFFANET, Max/AAU-5743-2020; ADELAIDE,
   José/O-4390-2017; Finetti, Pascal/O-8669-2017
OI Finetti, Pascal/0000-0002-2674-3123; CHAFFANET, Max/0000-0002-2344-1488;
   Guille, Arnaud/0000-0001-5747-562X
CR Addou-Klouche L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-213
   Adélaïde J, 2003, GENE CHROMOSOME CANC, V37, P333, DOI 10.1002/gcc.10218
   Adélaide J, 2007, CANCER RES, V67, P11565, DOI 10.1158/0008-5472.CAN-07-2536
   Andre F, 2009, CLIN CANCER RES, V15, P441, DOI 10.1158/1078-0432.CCR-08-1791
   Ayers M, 2004, J CLIN ONCOL, V22, P2284, DOI 10.1200/JCO.2004.05.166
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Bekhouche I, 2011, PLOS ONE, V6
   Bergamaschi A, 2006, GENE CHROMOSOME CANC, V45, P1033, DOI 10.1002/gcc.20366
   Bernard-Pierrot I, 2008, CANCER RES, V68, P7165, DOI 10.1158/0008-5472.CAN-08-1360
   Bertucci F, 2001, LANCET ONCOL, V2, P674, DOI 10.1016/S1470-2045(01)00557-5
   Bonnefoi Herve, 2007, Lancet Oncol, V8, P1071, DOI 10.1016/S1470-2045(07)70345-5
   Chang JC, 2003, LANCET, V362, P362, DOI 10.1016/S0140-6736(03)14023-8
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009
   Chin SF, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r215
   Curtis C, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-588
   Dunn L, 2009, MOL DIAGN THER, V13, P73, DOI 10.2165/01250444-200913020-00002
   Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Farmer P, 2009, NAT MED, V15, P68, DOI 10.1038/nm.1908
   Gelsi-Boyer V, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-299
   Ginestier C, 2003, INT J CANCER, V107, P854, DOI 10.1002/ijc.11462
   Goll MG, 2002, GENE DEV, V16, P1739, DOI 10.1101/gad.1013902
   Hill VK, 2011, CANCER RES, V71, P2988, DOI 10.1158/0008-5472.CAN-10-4026
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Horlings HM, 2010, CLIN CANCER RES, V16, P651, DOI 10.1158/1078-0432.CCR-09-0709
   Huang HE, 2004, CANCER RES, V64, P6840, DOI 10.1158/0008-5472.CAN-04-1762
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   Letessier A, 2007, ONCOGENE, V26, P298, DOI 10.1038/sj.onc.1209772
   Letessier A, 2005, GENE CHROMOSOME CANC, V44, P103, DOI 10.1002/gcc.20200
   Letessier A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-245
   Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504
   Mulero-Navarro S, 2008, CRIT REV ONCOL HEMAT, V68, P1, DOI 10.1016/j.critrevonc.2008.03.001
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Ordway JM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001314
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524
   Popovici C, 2002, GENE CHROMOSOME CANC, V35, P204, DOI 10.1002/gcc.10107
   Rice KL, 2007, ONCOGENE, V26, P6697, DOI 10.1038/sj.onc.1210755
   Sircoulomb F, 2011, EMBO MOL MED, V3, P153, DOI 10.1002/emmm.201100121
   Sircoulomb F, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-539
   SolinasToldo S, 1997, GENE CHROMOSOME CANC, V20, P399, DOI 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289
   Stransky N, 2006, NAT GENET, V38, P1386, DOI 10.1038/ng1923
   van Beers EH, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1510
   Van der Auwera I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012616
   Vincent-Salomon A, 2008, CLIN CANCER RES, V14, P1956, DOI 10.1158/1078-0432.CCR-07-1465
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
NR 49
TC 1
Z9 2
U1 0
U2 2
PU MACEDONIAN ACAD SCIENCES ARTS
PI SKOPJE
PA BULEVAR KRSTE MISIRKOV 2, P. O. B. 428, SKOPJE, 1000, MACEDONIA
SN 1311-0160
J9 BALK J MED GENET
JI Balk. J. Med. Gen.
PY 2012
VL 15
SU S
BP 71
EP 74
DI 10.2478/v10034-012-0023-x
PG 4
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 080LT
UT WOS:000314244600013
PM 24052748
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Batarseh, A
   Barlow, KD
   Martinez-Arguelles, DB
   Papadopoulos, V
AF Batarseh, Amani
   Barlow, Keith D.
   Martinez-Arguelles, Daniel B.
   Papadopoulos, Vassilios
TI Functional characterization of the human translocator protein (18 kDa)
   gene promoter in human breast cancer cell lines
SO BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS
LA English
DT Article
DE TSPO; Breast cancer; Metastasis; Sp1; Sp3; Epigenetics
ID PERIPHERAL BENZODIAZEPINE-RECEPTOR; DIAZEPAM-BINDING INHIBITOR;
   IN-VITRO; DNA-SYNTHESIS; EXPRESSION; SP1; TRANSCRIPTION; LIGAND; GROWTH;
   PROLIFERATION
AB The translocator protein (18 kDa; TSPO) is a mitochondrial drug- and cholesterol-binding protein that has been implicated in several processes, including steroidogenesis, cell proliferation, and apoptosis. Expression of the human TSPO gene is elevated in several cancers. To understand the molecular mechanisms that regulate TSPO expression in human breast cancer cells, the TSPO promoter was identified, cloned, and functionally characterized in poor-in-TSPO hormone-dependent, non-aggressive MCF-7 cells and rich-in-TSPO hormone-independent, aggressive, and metastatic MDA-MB-231 breast cancer cells. RNA ligase-mediated 5'-rapid amplification of cDNA ends analysis indicated transcription initiated at multiple sites downstream of a GC-rich promoter that lacks functional TATA and CCAAT boxes. Deletion analysis indicated that the region from -121 to +66, which contains five putative regulatory sites known as GC boxes, was sufficient to induce reporter activity up to 24-fold in MCF-7 and nearly 120-fold in MDA-MB-231 cells. Electrophoretic mobility shift and chromatin immunoprecipitation assays indicated that Sp1, Sp3 and Sp4 bind to these GC boxes in vitro and to the endogenous TSPO promoter. Silencing of Sp1, Sp3 and Sp4 gene expression reduced TSPO levels. In addition. TSPO expression was epigenetically regulated at one or more of the identified GC boxes. Disruption of the sequence downstream of the main start site of TSPO differentially regulated TSPO promoter activity in MCF-7 and MDA-MB-231 cells, indicating that essential elements contribute to its differential expression in these cells. Taken together, these experiments constitute the first in-depth functional analysis of the human TSPO gene promoter and its transcriptional regulation. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Batarseh, Amani; Martinez-Arguelles, Daniel B.; Papadopoulos, Vassilios] McGill Univ, Res Inst, Ctr Hlth, Montreal, PQ H3G 1A4, Canada.
   [Batarseh, Amani; Martinez-Arguelles, Daniel B.; Papadopoulos, Vassilios] McGill Univ, Dept Med, Montreal, PQ H3G 1A4, Canada.
   [Barlow, Keith D.; Papadopoulos, Vassilios] Georgetown Univ, Med Ctr, Dept Biochem & Mol & Cellular Biol, Washington, DC 20057 USA.
   [Papadopoulos, Vassilios] McGill Univ, Dept Biochem, Montreal, PQ H3G 1A4, Canada.
   [Papadopoulos, Vassilios] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1A4, Canada.
C3 McGill University; McGill University; Georgetown University; McGill
   University; McGill University
RP Papadopoulos, V (通讯作者)，McGill Univ, Res Inst, Ctr Hlth, Montreal Gen Hosp, 1650 Cedar Ave,C10-148, Montreal, PQ H3G 1A4, Canada.
EM amani.batarseh@childrens.harvard.edu; kdbarlow@mindspring.com;
   dan.martinez@mail.mcgill.ca; vassilios.papadopoulos@mcgill.ca
RI Papadopoulos, Vassilios/AAI-2613-2019
OI Papadopoulos, Vassilios/0000-0002-1183-8568; Batarseh,
   Amani/0000-0002-7020-2498
FU National Institutes of Health [R01 ES07747]; Susan G. Komen Breast
   Cancer Foundation; Canada Research Chair in Biochemical Pharmacology; Le
   Fonds de la recherche en sante du Quebec
FX This work was supported by grants from the National Institutes of Health
   (R01 ES07747), the Susan G. Komen Breast Cancer Foundation, and a Canada
   Research Chair in Biochemical Pharmacology to V.P. The Research
   Institute of MUHC is supported by a Center grant from Le Fonds de la
   recherche en sante du Quebec.
CR Ammanamanchi S, 2001, J BIOL CHEM, V276, P3348, DOI 10.1074/jbc.M002462200
   ANHOLT RRH, 1986, J BIOL CHEM, V261, P576
   Batarseh A, 2010, MOL CELL ENDOCRINOL, V327, P1, DOI 10.1016/j.mce.2010.06.013
   Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994
   BRUCE JH, 1991, BRAIN RES, V564, P167, DOI 10.1016/0006-8993(91)91369-C
   CAMINS A, 1995, EUR J PHARMACOL, V272, P289, DOI 10.1016/0014-2999(94)00652-N
   Carr IM, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm330
   Culty M, 1999, J STEROID BIOCHEM, V69, P123, DOI 10.1016/S0960-0760(99)00056-4
   Delavoie F, 2003, BIOCHEMISTRY-US, V42, P4506, DOI 10.1021/bi0267487
   Discher DJ, 1998, J BIOL CHEM, V273, P26087, DOI 10.1074/jbc.273.40.26087
   Drews VL, 2005, GENOMICS, V85, P245, DOI 10.1016/j.ygeno.2004.09.002
   Galiègue S, 2004, CLIN CANCER RES, V10, P2058, DOI 10.1158/1078-0432.CCR-03-0988
   GARNIER M, 1994, MOL PHARMACOL, V45, P201
   GARNIER M, 1993, ENDOCRINOLOGY, V132, P444, DOI 10.1210/en.132.1.444
   Gavish M, 1999, PHARMACOL REV, V51, P629
   Giatzakis C, 2004, ENDOCRINOLOGY, V145, P1113, DOI 10.1210/en.2003-1330
   Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010
   Han ZQ, 2003, J RECEPT SIG TRANSD, V23, P225, DOI 10.1081/RRS-120025210
   Hardwick M, 2002, CANCER GENET CYTOGEN, V139, P48, DOI 10.1016/S0165-4608(02)00604-0
   Hardwick M, 1999, CANCER RES, V59, P831
   Higgins KJ, 2006, ENDOCRINOLOGY, V147, P3285, DOI 10.1210/EN.2006-0081
   Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084
   Hoo RLC, 2003, ENDOCRINOLOGY, V144, P518, DOI 10.1210/EN.2002-220591
   Hung JJ, 2006, MOL CELL BIOL, V26, P1770, DOI 10.1128/MCB.26.5.1770-1785.2006
   IKEZAKI K, 1990, CANCER LETT, V49, P115, DOI 10.1016/0304-3835(90)90146-O
   Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249
   KITADAI Y, 1992, BIOCHEM BIOPH RES CO, V189, P1342, DOI 10.1016/0006-291X(92)90221-6
   KupczykSubotkowska L, 1997, J MED CHEM, V40, P1726, DOI 10.1021/jm960592p
   Kwon HS, 1999, J BIOL CHEM, V274, P20, DOI 10.1074/jbc.274.1.20
   Lacapère JJ, 2003, STEROIDS, V68, P569, DOI 10.1016/S0039-128X(03)00101-6
   Maaser K, 2001, BRIT J CANCER, V85, P1771, DOI 10.1054/bjoc.2001.2181
   MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170
   Mertens-Talcott SU, 2007, CANCER RES, V67, P11001, DOI 10.1158/0008-5472.CAN-07-2416
   Mullan PB, 2006, ONCOGENE, V25, P5854, DOI 10.1038/sj.onc.1209872
   NEARY JT, 1995, BRAIN RES, V675, P27, DOI 10.1016/0006-8993(95)00031-K
   PAPADOPOULOS V, 1993, ENDOCR REV, V14, P222, DOI 10.1210/er.14.2.222
   PAPADOPOULOS V, 1994, MOL CELL ENDOCRINOL, V104, pR5, DOI 10.1016/0303-7207(94)90061-2
   Papadopoulos V, 2006, TRENDS PHARMACOL SCI, V27, P402, DOI 10.1016/j.tips.2006.06.005
   Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878
   Sänger N, 2000, EUR J CANCER, V36, P2157, DOI 10.1016/S0959-8049(00)00298-7
   Takai Daiya, 2003, In Silico Biology, V3, P235
   Wierstra I, 2008, BIOCHEM BIOPH RES CO, V372, P1, DOI 10.1016/j.bbrc.2008.03.074
   Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.3.CO;2-X
   Xu Y, 1997, J COMPUT BIOL, V4, P325, DOI 10.1089/cmb.1997.4.325
   ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A
NR 45
TC 24
Z9 26
U1 0
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1874-9399
EI 1876-4320
J9 BBA-GENE REGUL MECH
JI Biochim. Biophys. Acta-Gene Regul. Mech.
PD JAN
PY 2012
VL 1819
IS 1
BP 38
EP 56
DI 10.1016/j.bbagrm.2011.09.001
PG 19
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 889JG
UT WOS:000300069400004
PM 21958735
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Stefansson, OA
   Esteller, M
AF Stefansson, Olafur Andri
   Esteller, Manel
TI BRCA1 as a tumor suppressor linked to the regulation of epigenetic
   states: keeping oncomiRs under control
SO BREAST CANCER RESEARCH
LA English
DT Article
ID CPG ISLAND HYPERMETHYLATION; BREAST-CANCER; POLYMERASE INHIBITORS;
   SPORADIC BREAST; GENE
AB BRCA1 is a tumor suppressor gene known to be implicated in the development of a subset of breast and ovarian cancers. The tumor suppressor properties of BRCA1 are generally thought to be linked to the gene's critical roles in the network of DNA damage response. In a recent report, BRCA1-mediated epigenetic repression at the promoter region of miRNA-155 was identified as a novel mechanism by which BRCA1 carries out its tumor suppressor functions.
C1 [Stefansson, Olafur Andri; Esteller, Manel] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona 08908, Catalonia, Spain.
   [Esteller, Manel] Univ Barcelona, Dept Physiol Sci 2, Sch Med, E-08036 Barcelona, Catalonia, Spain.
   [Esteller, Manel] ICREA, Barcelona 08010, Catalonia, Spain.
C3 Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of
   Barcelona; ICREA
RP Esteller, M (通讯作者)，Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona 08908, Catalonia, Spain.
EM mesteller@idibell.cat
RI Esteller, Manel/L-5956-2014
OI Esteller, Manel/0000-0003-4490-6093
FU ICREA Funding Source: Custom
CR Ashworth A, 2008, J CLIN ONCOL, V26, P3785, DOI 10.1200/JCO.2008.16.0812
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Chang SH, 2011, NAT MED, V17, P1275, DOI 10.1038/nm.2459
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630
   Krutovskikh VA, 2010, BIOESSAYS, V32, P894, DOI 10.1002/bies.201000040
   Lopez-Serra P., 2011, Oncogene
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181
   SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128
   Stefansson OA, 2011, EPIGENETICS-US, V6, P638, DOI 10.4161/epi.6.5.15667
   Stefansson OA, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2334
   Stephens PJ, 2009, NATURE, V462, P1005, DOI 10.1038/nature08645
   Veeck J, 2010, J CLIN ONCOL, V28, pE563, DOI 10.1200/JCO.2010.30.1010
NR 16
TC 6
Z9 8
U1 0
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1465-542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2012
VL 14
IS 2
AR 304
DI 10.1186/bcr3119
PG 2
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 952DZ
UT WOS:000304771800006
PM 22423979
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Agostini, M
   Enzo, MV
   Bedin, C
   Belardinelli, V
   Goldin, E
   Del Bianco, P
   Maschietto, E
   D'Angelo, E
   Izzi, L
   Saccani, A
   Zavagno, G
   Nitti, D
AF Agostini, M.
   Enzo, M. V.
   Bedin, C.
   Belardinelli, V.
   Goldin, E.
   Del Bianco, P.
   Maschietto, E.
   D'Angelo, E.
   Izzi, Leo
   Saccani, A.
   Zavagno, G.
   Nitti, D.
TI Circulating cell-free DNA: A promising marker of regional lymphonode
   metastasis in breast cancer patients
SO CANCER BIOMARKERS
LA English
DT Article
DE Breast cancer; regional LN metastasis; cfDNA
ID TUMOR-SUPPRESSOR GENE; PLASMA DNA; PROMOTER HYPERMETHYLATION; ABERRANT
   METHYLATION; EPIGENETIC INACTIVATION; NUCLEIC-ACIDS; BLOOD-PLASMA; SERUM
   DNA; INTEGRITY; EXPRESSION
AB Purpose: We undertook the current study with untreated breast cancer to (1) role the variations in the plasma levels of cfDNA and the size distribution in early stage, (2) determine the frequency in plasma of methylation of three candidate genes, RASSF1A, MAL, and SFRP1, and (3) to determine whether detection of cfDNA variations and methylation changes in plasma might have specific clinical utility.
   Methods and materials: Thirty-nine patients woman patients (median age 64 years; range, 36-90 years) who underwent surgery for primary BR and 49 healthy females' subjects (control group without any breast lesion) were evaluated. The cfDNA levels were analyzed using quantitative real-time polymerase chain reaction of beta-globin. Based on the ALU repeats, the cfDNA was considered as either total (fragments of 115 bp, ALU115) or tumoral (fragments of 247 bp, ALU247). The association between the levels of the ALU247, ALU115 repeat, and ALU 247/115 and the pathologic tumor characteristics was analyzed. Used methylight qPCR method, cfDNA from plasma samples of healthy donors and patients with breast cancer were evaluated for the diagnotic value of the methylation status of three genes (RASSF1A, MAL, SFRP1) frequently methylated in breast cancer.
   Results: The baseline levels of cfDNA were significantly higher in the patients with cancer, and the level of ALU247 was the most accurate circulating cfDNA marker in discriminating the cancer from non-cancer subjects. A high statistical significance was found by considering the T stage and patients with regional LN metastasis positive cancers showed significantly higher cfDNA level of ALU247. Moreover, patients with methylation of at least one of the gene under investigate showed a higher quantity of cfDNA ALU115 (p < 0.0001) and ALU247 level (p < 0.0001).
   Conclusions: We observed that necrosis could be a potential source of circulating tumour-specific cfDNA ALU247; and that cfDNA ALU247 and methylated cfDNA (RASSF1A, MAL and SFRP1) are both a phenotypic feature of tumour biology.
C1 [Agostini, M.; Enzo, M. V.; Bedin, C.; Belardinelli, V.; Goldin, E.; Maschietto, E.; D'Angelo, E.; Zavagno, G.; Nitti, D.] 2nd Surg Clin, Dept Surg Oncol & Gastroenterol Sci, Padua, Italy.
   [Agostini, M.] Methodist Hosp, Res Inst, Dept Nanomed, Houston, TX 77030 USA.
   [Agostini, M.; Enzo, M. V.; Bedin, C.; Maschietto, E.; D'Angelo, E.] Ist Ric Pediat Citta Speranza, Padua, Italy.
   [Del Bianco, P.] IRCCS, Veneto Oncol Inst, Clin Trials & Biostat Unit, Padua, Italy.
   [Izzi, Leo; Saccani, A.] Euroclone Spa, Pero, MI, Italy.
C3 Houston Methodist; Fondazione Citta della Speranza; IRCCS Istituto
   Oncologico Veneto (IOV)
RP Agostini, M (通讯作者)，Univ Padua, Dept Oncol & Surg Gastroenterol Sci, Surg Clin 2, Via Giustiniani 2, I-35128 Padua, Italy.
EM m.agostini@unipd.it
RI Del Bianco, Paola/IUM-9339-2023; Del Bianco, Paola/F-4655-2014; Bedin,
   Chiara/K-8619-2016; agostini, marco/K-2449-2018; D'Angelo,
   Edoardo/P-1668-2014
OI Del Bianco, Paola/0000-0002-6597-0265; Bedin,
   Chiara/0000-0001-7872-9828; agostini, marco/0000-0001-7578-1233;
   D'Angelo, Edoardo/0000-0002-4554-2140
FU Euroclone; Banca AntonVeneta; CARIPARO; AIRC Foundation; Euroclone
   S.p.a.
FX This study was supported in part by grants from the Euroclone, Banca
   AntonVeneta, CARIPARO and AIRC Foundation, and Euroclone S.p.a.
CR Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088
   Agostini M., ANN SURG ONCOL
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Chen XQ, 1999, CLIN CANCER RES, V5, P2297
   Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Ehrlich M, 2002, J NUTR, V132, p2424S, DOI 10.1093/jn/132.8.2424S
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Evron E, 2001, CANCER RES, V61, P2782
   Fujimoto A, 2004, CANCER RES, V64, P4085, DOI 10.1158/0008-5472.CAN-04-0957
   Giacona MB, 1998, PANCREAS, V17, P89, DOI 10.1097/00006676-199807000-00012
   Goessl C, 2000, CANCER RES, V60, P5941
   Gormally E, 2007, MUTAT RES-REV MUTAT, V635, P105, DOI 10.1016/j.mrrev.2006.11.002
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Holdenrieder S, 2008, ANN NY ACAD SCI, V1137, P180, DOI 10.1196/annals.1448.012
   Holdenrieder S, 2009, CRIT REV CL LAB SCI, V46, P1, DOI [10.1080/10408360802485875, 10.1080/10408360802485875 ]
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   Huang ZH, 2006, CANCER LETT, V243, P64, DOI 10.1016/j.canlet.2005.11.027
   Jahr S, 2001, CANCER RES, V61, P1659
   Jiang WW, 2006, INT J CANCER, V119, P2673, DOI 10.1002/ijc.22250
   Kamat AA, 2006, ANN NY ACAD SCI, V1075, P230, DOI 10.1196/annals.1368.031
   KATTLOVE H, 1995, JAMA-J AM MED ASSOC, V273, P142, DOI 10.1001/jama.273.2.142
   Leonhardt H, 2000, J CELL BIOCHEM, P78
   Lo PK, 2006, CANCER BIOL THER, V5, P281, DOI 10.4161/cbt.5.3.2384
   Martens JWM, 2009, FUTURE ONCOL, V5, P1245, DOI [10.2217/fon.09.89, 10.2217/FON.09.89]
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   Mimori K, 2003, ONCOGENE, V22, P3463, DOI 10.1038/sj.onc.1206378
   Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774
   Müller HM, 2003, CANCER RES, V63, P7641
   Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461
   Silva JM, 1999, BRIT J CANCER, V80, P1262, DOI 10.1038/sj.bjc.6690495
   Stroun M, 2000, ANN NY ACAD SCI, V906, P161
   Stroun M, 2001, ANN NY ACAD SCI, V945, P258
   Stroun M, 2001, CLIN CHIM ACTA, V313, P139, DOI 10.1016/S0009-8981(01)00665-9
   Taback B, 2004, ANN NY ACAD SCI, V1022, P1, DOI 10.1196/annals.1318.002
   Taback B, 2004, CURR OPIN MOL THER, V6, P273
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Umetani N, 2006, J CLIN ONCOL, V24, P4270, DOI 10.1200/JCO.2006.05.9493
   Umetani N, 2006, CLIN CHEM, V52, P1062, DOI 10.1373/clinchem.2006.068577
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Wang BG, 2003, CANCER RES, V63, P3966
   Wang W., CANC PREV RES PHILA, V3, P16
   Wong IHN, 1999, CANCER RES, V59, P71
   Yazici H, 2009, CANCER EPIDEM BIOMAR, V18, P2723, DOI 10.1158/1055-9965.EPI-08-1237
   Zanetti-Dällenbach RA, 2007, INT J BIOL MARKER, V22, P95, DOI 10.1177/172460080702200202
NR 48
TC 57
Z9 67
U1 2
U2 19
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1574-0153
EI 1875-8592
J9 CANCER BIOMARK
JI Cancer Biomark.
PY 2012
VL 11
IS 2-3
BP 89
EP 98
DI 10.3233/CBM-2012-0263
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 016KZ
UT WOS:000309518400003
PM 23011155
DA 2025-01-12
ER

PT J
AU Ling, C
   Su, VMT
   Zuo, DM
   Muller, WJ
AF Ling, Chen
   Vi-Minh-Tri Su
   Zuo, Dongmei
   Muller, William J.
TI Loss of the 14-3-3σ Tumor Suppressor Is a Critical Event in
   ErbB2-Mediated Tumor Progression
SO CANCER DISCOVERY
LA English
DT Article
ID HUMAN-BREAST-CANCER; SALIVARY-GLAND TUMORS; TRANSGENIC MICE; CELL
   POLARITY; NEU ONCOGENE; MAMMARY TUMORIGENESIS; PROTEOMIC ANALYSIS;
   CHROMOSOME 1P; MOUSE MODEL; TGF-ALPHA
AB 14-3-3 sigma is a putative tumor suppressor involved in cell-cycle progression and epithelial polarity. We demonstrate that loss of one or both copies of the conditional 14-3-3 sigma allele results in accelerated mammary and salivary tumorigenesis in mice expressing an activated erbB2 oncogene under the endogenous erbB2 promoter. Significantly, the majority of tumors bearing a single conditional 14-3-3 sigma allele lose expression of the remaining 14-3-3 sigma allele, which is associated with epigenetic methylation of the 14-3-3 sigma locus. In addition to accelerated tumor onset, in a mouse mammary tumor virus-driven ErbB2 tumor model, loss of 14-3-3 sigma results in enhanced metastatic phenotype that is correlated with loss of cellular junctions. Taken together, these results provide compelling evidence that 14-3-3 sigma is a potent tumor suppressor involved in ErbB2-driven breast cancer initiation and metastasis.
   SIGNIFICANCE: 14-3-3 sigma has been identified as a normal mammary epithelial cell marker frequently downregulated during neoplastic development. Consistent with its potential role as a tumor suppressor, we demonstrate that targeted disruption of 14-3-3 sigma in a number of epithelial tissues can profoundly impact both the initiation and metastatic phases of ErbB2-mediated tumor progression through modulation of a number of distinct signaling networks. Cancer Discovery; 2(1); 68-81. (C) 2011 AACR.
C1 [Ling, Chen; Vi-Minh-Tri Su; Zuo, Dongmei; Muller, William J.] McGill Univ, Dept Biochem, Montreal, PQ H3A 1A3, Canada.
   [Ling, Chen; Vi-Minh-Tri Su; Zuo, Dongmei; Muller, William J.] McGill Univ, Rosalind & Morris Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada.
   [Muller, William J.] McGill Univ, Dept Med, Montreal, PQ H3A 1A3, Canada.
C3 McGill University; McGill University; McGill University
RP Muller, WJ (通讯作者)，McGill Univ, Dept Biochem, Canc Pavill,Room 516,1160 Pine Ave W, Montreal, PQ H3A 1A3, Canada.
EM william.muller@mcgill.ca
RI Zuo, Dongmei/KXS-2151-2024
FU Department of Defense [W81XWH-06-1-0700]; Canadian Institute of Health
   Research (CIHR) [MOP-10594]; Terry Fox Foundation [NCIC 020002]
FX C. Ling received a scholarship from the Department of Defense Breast
   Cancer Research Program (W81XWH-06-1-0700). All authors were supported
   by grants by the Canadian Institute of Health Research (CIHR MOP-10594)
   and the Terry Fox Foundation (NCIC 020002).
CR Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497
   Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340
   Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485
   Benzinger A, 2005, MOL CELL PROTEOMICS, V4, P785, DOI 10.1074/mcp.M500021-MCP200
   BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0
   Brandt R, 2000, ONCOGENE, V19, P2129, DOI 10.1038/sj.onc.1203520
   Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188
   COHEN JA, 1989, ONCOGENE, V4, P81
   Cullere X, 1998, J VIROL, V72, P558
   Dillon RL, 2007, MOL CELL BIOL, V27, P8648, DOI 10.1128/MCB.00866-07
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Fischer A, 2009, J BIOL CHEM, V284, P3183, DOI 10.1074/jbc.M804795200
   Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673
   HAINSWORTH PJ, 1992, BRIT J CANCER, V66, P131, DOI 10.1038/bjc.1992.229
   Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7
   Herron BJ, 2005, NAT GENET, V37, P1210, DOI 10.1038/ng1652
   Hodgson JG, 2005, CANCER RES, V65, P9695, DOI 10.1158/0008-5472.CAN-05-0755
   Hurd TW, 2003, CURR BIOL, V13, P2082, DOI 10.1016/j.cub.2003.11.020
   KERNOHAN NM, 1991, J PATHOL, V163, P77, DOI 10.1002/path.1711630113
   KNUDSON AG, 1993, MED PEDIATR ONCOL, V21, P193, DOI 10.1002/mpo.2950210308
   LEMOINE NR, 1990, ONCOGENE, V5, P237
   Li QT, 2005, P NATL ACAD SCI USA, V102, P15977, DOI 10.1073/pnas.0508310102
   Ling C, 2010, GENE DEV, V24, P947, DOI 10.1101/gad.1896810
   Lodygin D, 2005, CELL RES, V15, P237, DOI 10.1038/sj.cr.7290292
   Lodygin D, 2006, SEMIN CANCER BIOL, V16, P214, DOI 10.1016/j.semcancer.2006.03.008
   Lu J, 2009, CANCER CELL, V16, P195, DOI 10.1016/j.ccr.2009.08.010
   LUCCHINI F, 1992, CANCER LETT, V64, P203, DOI 10.1016/0304-3835(92)90044-V
   MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R
   Montagna C, 2002, ONCOGENE, V21, P890, DOI 10.1038/sj.onc.1205146
   MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5
   NAGAI H, 1995, CANCER RES, V55, P1752
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507
   SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P
   SANDGREN EP, 1995, CANCER RES, V55, P3915
   SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497
   Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149
   SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1
   SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152
   SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
   STENMAN G, 1991, GENE CHROMOSOME CANC, V3, P128, DOI 10.1002/gcc.2870030208
   Uchida D, 2004, BRIT J CANCER, V91, P1131, DOI 10.1038/sj.bjc.6602004
   Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826
   Ursini-Siegel J, 2008, EMBO J, V27, P910, DOI 10.1038/emboj.2008.22
   Vercoutter-Edouart AS, 2001, CANCER RES, V61, P76
   Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045
NR 46
TC 26
Z9 28
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
J9 CANCER DISCOV
JI Cancer Discov.
PD JAN
PY 2012
VL 2
IS 1
BP 68
EP 81
DI 10.1158/2159-8290.CD-11-0189
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 883LR
UT WOS:000299636100033
PM 22585169
OA Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Lo, PK
   Lee, JS
   Sukumar, S
AF Lo, Pang-Kuo
   Lee, Ji Shin
   Sukumar, Saraswati
TI The p53-p21 <SUP>WAF1</SUP> checkpoint pathway plays a protective role
   in preventing DNA rereplication induced by abrogation of FOXF1 function
SO CELLULAR SIGNALLING
LA English
DT Article
DE FOXF1; Tumor suppressor gene; DNA rereplication; p53; p21(WAF1)
ID CANCER CELL-LINES; FORKHEAD BOX F1; BREAST-CANCER; TRANSCRIPTION
   FACTORS; GENE FOXF1; P53; REPLICATION; EXPRESSION; PROTEINS; DAMAGE
AB We previously identified FOXF1 as a potential tumor suppressor gene with an essential role in preventing DNA rereplication to maintain genomic stability, which is frequently inactivated in breast cancer through the epigenetic mechanism. Here we further addressed the role of the p53-p21(WAF1) checkpoint pathway in DNA rereplication induced by silencing of FOXF1. Knockdown of FOXF1 by small interference RNA (siRNA) rendered colorectal p53-null and p21(wAF1)-null HCT116 cancer cells more susceptible to rereplication and apoptosis than the wild-type parental cells. In parental HCT116 cells with a functional p53 checkpoint, the p53-p21(WAF1) checkpoint pathway was activated upon FOXF1 knockdown, which was concurrent with suppression of the CDK2-Rb cascade and induction of G(1) arrest In contrast, these events were not observed in FOXF1-depleted HCT116-p53-/- and HCT116-p21-/- cells, indicating that the p53-dependent checkpoint function is vital for inhibiting CDK2 to induce G(1) arrest and protect cells from rereplication. The pharmacologic inhibitor (caffeine) of ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3 related (ATR) protein kinases abolished activation of the p53-p21 (WAF1) pathway upon FOXF1 knockdown, suggesting that suppression of FOXF1 function triggered the ATM/ATR-mediated DNA damage response. Cosilencing of p53 by siRNA synergistically enhanced the effect of FOXF1 depletion on the stimulation of DNA rereplication and apoptosis in wild-type HCT116. Finally, we show that FOXF1 expression is predominantly silenced in breast and colorectal cancer cell lines with inactive p53. Our study demonstrated that the p53-p21 (WAF1) checkpoint pathway is an intrinsically protective mechanism to prevent DNA rereplication induced by silencing of FOXF1. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Lo, Pang-Kuo] Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA.
   [Lee, Ji Shin] Chonnam Natl Univ, Hwasun Hosp, Dept Pathol, Jeollanam Do, South Korea.
   [Sukumar, Saraswati] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.
C3 University of South Carolina System; University of South Carolina
   Columbia; Chonnam National University; Johns Hopkins University
RP Lo, PK (通讯作者)，Univ S Carolina, Dept Biol Sci, 715 Sumter St,PSC621, Columbia, SC 29208 USA.
EM LOP@mailbox.sc.edu; saras@jhmi.edu
FU National Institutes of Health [P50-CA 88843]
FX We thank Dr. B. Vogelstein for kindly providing the colorectal cancer
   cell line HCT116 and its derivative cell lines p53-/- and p21-/-. This
   work was supported by the National Institutes of Health SPORE Grant
   P50-CA 88843 to SS.
CR Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493
   Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663
   Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497
   Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780
   Chung JH, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000863
   Davidson IF, 2006, MOL CELL, V24, P433, DOI 10.1016/j.molcel.2006.09.010
   Hannenhalli S, 2009, NAT REV GENET, V10, P233, DOI 10.1038/nrg2523
   HARPER JW, 1993, CELL, V75, P805
   Hellqvist M, 1996, J BIOL CHEM, V271, P4482
   Hook SS, 2007, CURR OPIN CELL BIOL, V19, P663, DOI 10.1016/j.ceb.2007.10.007
   Kalinichenko VV, 2003, HEPATOLOGY, V37, P107, DOI 10.1053/jhep.2003.50005
   Kalinichenko VV, 2002, J BIOL CHEM, V277, P12369, DOI 10.1074/jbc.M112162200
   Katoh M, 2004, INT J ONCOL, V25, P1495
   Kearsey SE, 2003, MOL CELL, V12, P1067, DOI 10.1016/S1097-2765(03)00441-6
   LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421
   Le Gac G, 2006, J BIOL CHEM, V281, P24161, DOI 10.1074/jbc.M603724200
   Leach SD, 1998, CANCER RES, V58, P3231
   Liu Y, 2006, P NATL ACAD SCI USA, V103, P976, DOI 10.1073/pnas.0510146103
   Lo PK, 2006, CANCER BIOL THER, V5, P281, DOI 10.4161/cbt.5.3.2384
   Lo PK, 2010, CANCER RES, V70, P6047, DOI 10.1158/0008-5472.CAN-10-1576
   Madison BB, 2009, J BIOL CHEM, V284, P5936, DOI 10.1074/jbc.M808103200
   Mahlapuu M, 2001, DEVELOPMENT, V128, P2397
   Malin D, 2007, MOL CELL BIOL, V27, P2486, DOI 10.1128/MCB.01736-06
   McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342
   Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3
   Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Nishitani H, 2004, FRONT BIOSCI-LANDMRK, V9, P2115
   Ormestad M, 2006, DEVELOPMENT, V133, P833, DOI 10.1242/dev.02252
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   Saito RA, 2010, CANCER RES, V70, P2644, DOI 10.1158/0008-5472.CAN-09-3644
   Samuel T, 2002, CELL CYCLE, V1, P162, DOI 10.4161/cc.1.3.118
   Tsuyama T, 2005, NUCLEIC ACIDS RES, V33, P765, DOI 10.1093/nar/gki226
   van der Horst A, 2007, NAT REV MOL CELL BIO, V8, P440, DOI 10.1038/nrm2190
   Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6
   Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675
   Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627
   Watson JEV, 2004, ONCOGENE, V23, P3487, DOI 10.1038/sj.onc.1207474
   Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677
   Zhu WG, 2004, MOL CELL BIOL, V24, P7140, DOI 10.1128/MCB.24.16.7140-7150.2004
NR 40
TC 28
Z9 30
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0898-6568
J9 CELL SIGNAL
JI Cell. Signal.
PD JAN
PY 2012
VL 24
IS 1
BP 316
EP 324
DI 10.1016/j.cellsig.2011.09.017
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 852YH
UT WOS:000297392900035
PM 21964066
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Chmelarová, M
   Krepinská, E
   Spacek, J
   Laco, J
   Nekvindová, J
   Palicka, V
AF Chmelarova, M.
   Krepinska, E.
   Spacek, J.
   Laco, J.
   Nekvindova, J.
   Palicka, V.
TI Methylation Analysis of Tumour Suppressor Genes in Ovarian Cancer Using
   MS-MLPA
SO FOLIA BIOLOGICA
LA English
DT Article
DE MS-MLPA; DNA methylation; ovarian cancer; CDH13; epigenetics
ID PROMOTER HYPERMETHYLATION; BREAST-CANCER; CPG ISLAND; CARCINOGENESIS;
   BRCA2; WT1
AB Epigenetic changes are considered to be a frequent event during tumour development. Hyper-methylation of promoter CpG islands represents an alternative mechanism for inactivation of tumour suppressor genes, DNA repair genes, cell cycle regulators and transcription factors. The aim of this study was to investigate promoter methylation of specific genes in ovarian cancer by comparison with normal ovarian tissue. To search for epigenetic events we used methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) to compare the methylation status of 69 tissue samples of ovarian cancer with 40 control samples. Using a 15% cut-off for methylation, we observed significantly higher methylation in genes MGMT, PAX5, CDH13, WT1, THBS1, GATA5 in the ovarian cancer group, while in the ESR1 gene we observed significantly higher methylation in the control group compared with the ovarian cancer group. These findings could potentially be used in screening of ovarian cancer and may have implications for future chemotherapy based on epigenetic changes.
C1 [Chmelarova, M.; Nekvindova, J.; Palicka, V.] Charles Univ Prague, Fac Med Hradec Kralove, Dept Clin Biochem & Diagnost, Prague, Czech Republic.
   [Krepinska, E.; Spacek, J.] Charles Univ Prague, Fac Med Hradec Kralove, Dept Obstet & Gynaecol, Prague, Czech Republic.
   [Laco, J.] Charles Univ Prague, Fac Med Hradec Kralove, Fingerland Dept Pathol, Prague, Czech Republic.
   [Chmelarova, M.] Fac Hosp Hradec Kralove, Dept Clin Biochem & Diagnost, Hradec Kralove 50005, Czech Republic.
C3 University Hospital Hradec Kralove; Charles University Prague;
   University Hospital Hradec Kralove; Charles University Prague;
   University Hospital Hradec Kralove; Charles University Prague;
   University Hospital Hradec Kralove
RP Chmelarová, M (通讯作者)，Fac Hosp Hradec Kralove, Dept Clin Biochem & Diagnost, Sokolska 581, Hradec Kralove 50005, Czech Republic.
EM ChmelarovaMarcela@seznam.cz
RI ; Laco, Jan/L-9715-2017; Palicka, Vladimir/N-1802-2017; Nekvindova,
   Jana/B-9292-2012
OI /0000-0002-7891-9979; Laco, Jan/0000-0002-9602-7501; Palicka,
   Vladimir/0000-0001-7236-1647; Nekvindova, Jana/0000-0002-2861-5483
FU Ministry of Health of the Czech Republic [MZO 00179906]; SVV UK
   [262902/2011]; GA UK [157310]
FX This study was supported by research project MZO 00179906 from the
   Ministry of Health of the Czech Republic, by Grant SVV UK 262902/2011
   and by Grant GA UK No. 157310.
CR [Anonymous], 2003, PATHOLOGY GENETICS T
   Asadollahi R, 2010, GYNECOL ONCOL, V118, P81, DOI 10.1016/j.ygyno.2010.03.015
   Bol GM, 2010, HISTOPATHOLOGY, V57, P363, DOI 10.1111/j.1365-2559.2010.03642.x
   Bonazzi VF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026121
   Chan KYK, 2002, CANCER RES, V62, P4151
   Chmelarova Marcela, 2011, Cas Lek Cesk, V150, P442
   Feng WW, 2008, CANCER-AM CANCER SOC, V112, P1489, DOI 10.1002/cncr.23323
   Gaudet MM, 2009, CANCER EPIDEM BIOMAR, V18, P3036, DOI 10.1158/1055-9965.EPI-09-0678
   Gras E, 2001, CANCER-AM CANCER SOC, V92, P2829, DOI 10.1002/1097-0142(20011201)92:11<2829::AID-CNCR10094>3.0.CO;2-3
   Ibanez de Caceres I, 2004, CANCER RES, V64, P6476
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kaneuchi M, 2005, CANCER-AM CANCER SOC, V104, P1924, DOI 10.1002/cncr.21397
   Karlan-Beth Y, 2009, CLIN OVARIAN CANC, V2, P83, DOI 10.3816/COC.2009.n.015
   Mei FC, 2005, FASEB J, V19, P497, DOI 10.1096/fj.05-4586fje
   Moelans CB, 2011, J PATHOL, V225, P222, DOI 10.1002/path.2930
   Montavon C, 2012, GYNECOL ONCOL, V124, P582, DOI 10.1016/j.ygyno.2011.11.026
   Nygren AOH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni127
   Palmisano WA, 2003, CANCER RES, V63, P4620
   Roh HJ, 2011, J OBSTET GYNAECOL RE, V37, P851, DOI 10.1111/j.1447-0756.2010.01452.x
   van Vlodrop IJH, 2011, CLIN CANCER RES, V17, P4225, DOI 10.1158/1078-0432.CCR-10-3394
   Wakana K, 2006, CANCER LETT, V241, P281, DOI 10.1016/j.canlet.2005.10.039
   Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466
NR 22
TC 23
Z9 26
U1 0
U2 14
PU CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE
PI PRAGUE 6
PA FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLIC
SN 0015-5500
J9 FOLIA BIOL-PRAGUE
JI Folia Biol.-Prague
PY 2012
VL 58
IS 6
BP 246
EP 250
PG 5
WC Biochemistry & Molecular Biology; Biology; Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Oncology; Cell Biology
GA 075XL
UT WOS:000313920400004
PM 23438850
DA 2025-01-12
ER

PT J
AU Lovato, A
   Panasci, L
   Witcher, M
AF Lovato, Amanda
   Panasci, Lawrence
   Witcher, Michael
TI Is there an epigenetic component underlying the resistance of
   triple-negative breast cancers to Parp inhibitors?
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE Pap inhibitors; epigenetics; breast cancer; transcription factors;
   therapeutic resistance
ID POLY(ADP-RIBOSE) POLYMERASE PARP; GENE-EXPRESSION PROFILE; REFRACTORY
   SOLID TUMORS; PHASE-I; CHROMATIN-STRUCTURE; DNA-DAMAGE; GLYCOHYDROLASE
   REVEALS; SYNTHETIC LETHALITY; B-MYB; TRANSCRIPTION
AB Poly(ADP-ribose) polymerase (Parp) is an enzyme responsible for catalyzing post-translational modifications through the addition of poly(ADP-ribose) chains (known as PARylation). Modification by PARylation modulates numerous cellular processes including transcription, chromatin remodeling, apoptosis, and DNA damage repair. In particular, the role of Parp activation in response to DNA damage has been intensely studied. Tumors bearing mutations of the breast cancer susceptibility genes, Brca1/2, are prone to DNA breakages whose restoration into functional double-strand DNA is Parp dependent. This concept has been exploited therapeutically in Brca mutated breast and ovarian tumors, where acute sensitivity to Parp inhibitors is observed. Based on in vitro and clinical studies it remains unclear to what extent Parp inhibitors can be utilized beyond treating Brca mutated tumors. This review will focus on the often overlooked roles of PARylation in chromatin remodeling, epigenetics, and transcription to explain why some cancers may be unresponsive to Parp inhibition. We predict that understanding the impact of PARylation on gene expression will lead to alternative approaches to manipulate the Parp pathway for therapeutic benefit.
C1 [Witcher, Michael] McGill Univ, Jewish Gen Hosp, Lady Davis Inst, Dept Oncol, Montreal, PQ H3T 1E2, Canada.
   McGill Univ, Jewish Gen Hosp, Lady Davis Inst, Dept Expt Med, Montreal, PQ H3T 1E2, Canada.
   McGill Univ, Jewish Gen Hosp, Segal Canc Ctr, Montreal, PQ H3T 1E2, Canada.
C3 Lady Davis Institute; McGill University; Lady Davis Institute; McGill
   University; McGill University
RP Witcher, M (通讯作者)，McGill Univ, Jewish Gen Hosp, Lady Davis Inst, Dept Oncol, Montreal, PQ H3T 1E2, Canada.
EM michael.witcher@mcgill.ca
CR Aly A, 2011, J MOL CELL BIOL, V3, P66, DOI 10.1093/jmcb/mjq055
   Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8
   Boyle F, 2012, J CLIN ONCOL, V30
   Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443
   Butler AJ, 1999, MOL CELL BIOL, V19, P296
   Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692
   Chuang HC, 2012, BREAST CANCER RES TR, V134, P649, DOI 10.1007/s10549-012-2106-5
   Cohen-Armon M, 2007, MOL CELL, V25, P297, DOI 10.1016/j.molcel.2006.12.012
   Corona DFV, 2007, PLOS BIOL, V5, P2011, DOI 10.1371/journal.pbio.0050232
   Cuddapah S, 2009, GENOME RES, V19, P24, DOI 10.1101/gr.082800.108
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249
   Dávalos-Salas M, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-232
   Di Cosimo S, 2010, NAT REV CLIN ONCOL, V7, P139, DOI 10.1038/nrclinonc.2009.234
   Nguyen D, 2011, CELL CYCLE, V10, P4074, DOI 10.4161/cc.10.23.18170
   DING RC, 1994, CANCER RES, V54, P4627
   Donawho CK, 2007, CLIN CANCER RES, V13, P2728, DOI 10.1158/1078-0432.CCR-06-3039
   FARAONEMENNELLA MR, 1993, BIOCHEM MOL BIOL INT, V31, P373
   Farrar D, 2010, MOL CELL BIOL, V30, P1199, DOI 10.1128/MCB.00827-09
   Fathers C, 2012, CELL CYCLE, V11, P990, DOI 10.4161/cc.11.5.19482
   Fauzee NJS, 2012, PATHOL ONCOL RES, V18, P191, DOI 10.1007/s12253-011-9428-1
   Feng XX, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-48
   Fisher AEO, 2007, MOL CELL BIOL, V27, P5597, DOI 10.1128/MCB.02248-06
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749
   Frizzell KM, 2009, J BIOL CHEM, V284, P33926, DOI 10.1074/jbc.M109.023879
   Gagné JP, 2012, NUCLEIC ACIDS RES, V40, P7788, DOI 10.1093/nar/gks486
   Gagné JP, 2008, NUCLEIC ACIDS RES, V36, P6959, DOI 10.1093/nar/gkn771
   Gamble MJ, 2007, NAT STRUCT MOL BIOL, V14, P548, DOI 10.1038/nsmb1248
   Gelmon KA, 2011, LANCET ONCOL, V12, P852, DOI 10.1016/S1470-2045(11)70214-5
   Gonzalez-Angulo AM, 2011, CLIN CANCER RES, V17, P1082, DOI 10.1158/1078-0432.CCR-10-2560
   Gusterson BA, 2005, BREAST CANCER RES, V7, P143, DOI 10.1186/bcr1041
   Hang CT, 2010, NATURE, V466, P62, DOI 10.1038/nature09130
   Hassa PO, 2003, J BIOL CHEM, V278, P45145, DOI 10.1074/jbc.M307957200
   Helleday T, 2011, MOL ONCOL, V5, P387, DOI 10.1016/j.molonc.2011.07.001
   Huang D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027123
   HULETSKY A, 1989, J BIOL CHEM, V264, P8878
   Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196
   Ju BG, 2006, CELL CYCLE, V5, P2557, DOI 10.4161/cc.5.22.3497
   Kaur H, 2006, DIABETES, V55, P3104, DOI 10.2337/db06-0519
   Khan OA, 2011, BRIT J CANCER, V104, P750, DOI 10.1038/bjc.2011.8
   Kim IK, 2012, NAT STRUCT MOL BIOL, V19, P653, DOI 10.1038/nsmb.2305
   Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805
   Kim MY, 2004, CELL, V119, P803, DOI 10.1016/j.cell.2004.11.002
   Konstantinopoulos PA, 2010, J CLIN ONCOL, V28, P3555, DOI 10.1200/JCO.2009.27.5719
   Krishnakumar R, 2008, SCIENCE, V319, P819, DOI 10.1126/science.1149250
   Krishnakumar R, 2010, MOL CELL, V39, P736, DOI 10.1016/j.molcel.2010.08.014
   Kumari SR, 1998, CANCER RES, V58, P5075
   Kummar S, 2012, CLIN CANCER RES, V18, P1726, DOI 10.1158/1078-0432.CCR-11-2821
   Kummar S, 2011, CANCER RES, V71, P5626, DOI 10.1158/0008-5472.CAN-11-1227
   Kun E, 2002, J BIOL CHEM, V277, P39066, DOI 10.1074/jbc.C200410200
   Kurian AW, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2780
   Li M, 2004, BIOCHEM J, V382, P323, DOI 10.1042/BJ20040593
   Li QZ, 2012, CELL PHYSIOL BIOCHEM, V29, P361, DOI 10.1159/000338491
   Liu XS, 2008, MOL CANCER RES, V6, P1621, DOI 10.1158/1541-7786.MCR-08-0240
   Liu XS, 2012, CLIN CANCER RES, V18, P510, DOI 10.1158/1078-0432.CCR-11-1973
   Lönn P, 2010, MOL CELL, V40, P521, DOI 10.1016/j.molcel.2010.10.029
   Lonskaya I, 2005, J BIOL CHEM, V280, P17076, DOI 10.1074/jbc.M413483200
   Lu H, 2011, J BIOL CHEM, V286, P20335, DOI 10.1074/jbc.M110.215632
   Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839
   Marienfeld C, 2003, HEPATOLOGY, V37, P1097, DOI 10.1053/jhep.2003.50192
   Martinez-Zamudio R, 2012, MOL CELL BIOL, V32, P2490, DOI 10.1128/MCB.06667-11
   Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261
   Mendoza-Alvarez H, 2000, IUBMB LIFE, V50, P145, DOI 10.1080/15216540050212187
   Mortusewicz O, 2011, NUCLEIC ACIDS RES, V39, P5045, DOI 10.1093/nar/gkr099
   O'Shaughnessy J, 2009, J CLIN ONCOL, V27
   O'Shaughnessy J, 2011, NEW ENGL J MED, V364, P205, DOI 10.1056/NEJMoa1011418
   Ogino H, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-41
   Okada H, 2008, J AM SOC NEPHROL, V19, P933, DOI 10.1681/ASN.2007060648
   Olabisi OA, 2008, MOL CELL BIOL, V28, P2860, DOI 10.1128/MCB.01746-07
   Oonk AMM, 2012, ANN ONCOL, V23, P2301, DOI 10.1093/annonc/mdr621
   Pan J, 2012, CANCER GENE THER, V19, P715, DOI 10.1038/cgt.2012.48
   Pant V, 2004, MOL CELL BIOL, V24, P3497, DOI 10.1128/MCB.24.8.3497-3504.2004
   Patel AG, 2012, CLIN CANCER RES, V18, P1655, DOI 10.1158/1078-0432.CCR-11-2890
   Pavri R, 2005, MOL CELL, V18, P83, DOI 10.1016/j.molcel.2005.02.034
   Pern F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047993
   Petesch SJ, 2008, CELL, V134, P74, DOI 10.1016/j.cell.2008.05.029
   Phuah SY, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3347
   Pinnola A, 2007, J BIOL CHEM, V282, P32511, DOI 10.1074/jbc.M705989200
   Plummer R, 2008, CLIN CANCER RES, V14, P7917, DOI 10.1158/1078-0432.CCR-08-1223
   POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Rajan A, 2012, CLIN CANCER RES, V18, P2344, DOI 10.1158/1078-0432.CCR-11-2425
   Ratner ES, 2012, CURR OPIN ONCOL, V24, P564, DOI 10.1097/CCO.0b013e3283564230
   Reale A, 2005, ONCOGENE, V24, P13, DOI 10.1038/sj.onc.1208005
   Sala A, 2008, PLOS BIOL, V6, P2329, DOI 10.1371/journal.pbio.0060252
   Santilli G, 2001, ONCOGENE, V20, P8167, DOI 10.1038/sj.onc.1204943
   Slade D, 2011, NATURE, V477, P616, DOI 10.1038/nature10404
   SLATTERY E, 1983, J BIOL CHEM, V258, P5955
   Talbert PB, 2006, NAT REV GENET, V7, P793, DOI 10.1038/nrg1920
   Tulin A, 2003, SCIENCE, V299, P560, DOI 10.1126/science.1078764
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457
   Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6
   Wacker DA, 2007, MOL CELL BIOL, V27, P7475, DOI 10.1128/MCB.01314-07
   Witcher M, 2009, MOL CELL, V34, P271, DOI 10.1016/j.molcel.2009.04.001
   Yu WQ, 2004, NAT GENET, V36, P1105, DOI 10.1038/ng1426
   Zampieri M, 2012, BIOCHEM J, V441, P645, DOI 10.1042/BJ20111417
   Zampieri M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004717
   Zaniolo K, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-96
   Zhang T, 2012, J BIOL CHEM, V287, P12405, DOI 10.1074/jbc.M111.304469
   Ziegler M, 2001, BIOESSAYS, V23, P543, DOI 10.1002/bies.1074
   Zobeck KL, 2010, MOL CELL, V40, P965, DOI 10.1016/j.molcel.2010.11.022
NR 102
TC 3
Z9 3
U1 0
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PY 2012
VL 3
AR 202
DI 10.3389/fphar.2012.00202
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA V35XE
UT WOS:000209177700194
PM 23293602
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Akalin, A
   Kormaksson, M
   Li, S
   Garrett-Bakelman, FE
   Figueroa, ME
   Melnick, A
   Mason, CE
AF Akalin, Altuna
   Kormaksson, Matthias
   Li, Sheng
   Garrett-Bakelman, Francine E.
   Figueroa, Maria E.
   Melnick, Ari
   Mason, Christopher E.
TI methylKit: a comprehensive R package for the analysis of genome-wide DNA
   methylation profiles
SO GENOME BIOLOGY
LA English
DT Article
ID SINGLE-BASE RESOLUTION; BREAST-CANCER; CELLS; 5-HYDROXYMETHYLCYTOSINE;
   HYPERMETHYLATION; PLURIPOTENT; ARABIDOPSIS; CHROMATIN; MAPS
AB DNA methylation is a chemical modification of cytosine bases that is pivotal for gene regulation, cellular specification and cancer development. Here, we describe an R package, methylKit, that rapidly analyzes genome-wide cytosine epigenetic profiles from high-throughput methylation and hydroxymethylation sequencing experiments. methylKit includes functions for clustering, sample quality visualization, differential methylation analysis and annotation features, thus automating and simplifying many of the steps for discerning statistically significant bases or regions of DNA methylation. Finally, we demonstrate methylKit on breast cancer data, in which we find statistically significant regions of differential methylation and stratify tumor subtypes. methylKit is available at http://code.google.com/p/methylkit.
C1 [Akalin, Altuna; Li, Sheng; Mason, Christopher E.] Weill Cornell Med Coll, Dept Physiol & Biophys, New York, NY 10065 USA.
   [Akalin, Altuna; Li, Sheng; Mason, Christopher E.] Weill Cornell Med Coll, HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsau, New York, NY 10065 USA.
   [Kormaksson, Matthias] Weill Cornell Med Coll, Dept Publ Hlth, New York, NY 10065 USA.
   [Garrett-Bakelman, Francine E.; Melnick, Ari] Weill Cornell Med Coll, Div Hematol Oncol, Dept Med, New York, NY 10065 USA.
   [Figueroa, Maria E.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
   [Melnick, Ari] Weill Cornell Med Coll, Dept Pharmacol, New York, NY 10065 USA.
C3 Cornell University; Weill Cornell Medicine; Cornell University; Weill
   Cornell Medicine; Cornell University; Weill Cornell Medicine; Cornell
   University; Weill Cornell Medicine; University of Michigan System;
   University of Michigan; Cornell University; Weill Cornell Medicine
RP Akalin, A (通讯作者)，Weill Cornell Med Coll, Dept Physiol & Biophys, 1305 York Ave, New York, NY 10065 USA.
EM ala2027@med.cornell.edu; chm2042@med.cornell.edu
RI Li, Sheng/A-1964-2014; Melnick, Ari/AAA-5763-2020; Figueroa,
   Maria/AAE-8662-2019; Mason, Christopher/HCH-3977-2022; AKALIN,
   ALTUNA/A-4424-2012
OI AKALIN, ALTUNA/0000-0002-0468-0117; Figueroa, Maria
   Eugenia/0000-0003-4887-4981
FU Leukemia & Lymphoma Society Special Fellow Award; Doris Duke Clinical
   Scientist Development Award; Sass Foundation Judah Folkman Fellowship;
   LLS SCOR grant [7132-08]; Burroughs Wellcome Clinical Translational
   Scientist Award; Starr Cancer Consortium grant [I4-A442]; National
   Institutes of Health [I4-A442, I4-A411, 1R01NS076465-01]
FX We wish to acknowledge the invaluable contribution of the WCMC
   Epigenomics Core Facility. MEF is supported by the Leukemia & Lymphoma
   Society Special Fellow Award and a Doris Duke Clinical Scientist
   Development Award. FGB is supported by a Sass Foundation Judah Folkman
   Fellowship. AM is supported by an LLS SCOR grant (7132-08) and a
   Burroughs Wellcome Clinical Translational Scientist Award. AM and CEM
   are supported by a Starr Cancer Consortium grant (I4-A442). CEM is
   supported by the National Institutes of Health (I4-A411, I4-A442, and
   1R01NS076465-01).
CR Adams D, 2012, NAT BIOTECHNOL, V30, P224, DOI 10.1038/nbt.2153
   Akalin A, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002781
   Ball MP, 2009, NAT BIOTECHNOL, V27, P361, DOI 10.1038/nbt.1533
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   Booth MJ, 2012, SCIENCE, V336, P934, DOI 10.1126/science.1220671
   Branco MR, 2012, NAT REV GENET, V13, P7, DOI 10.1038/nrg3080
   Cherf GM, 2012, NAT BIOTECHNOL, V30, P344, DOI 10.1038/nbt.2147
   Cokus SJ, 2008, NATURE, V452, P215, DOI 10.1038/nature06745
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471
   Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI [10.2217/epi.09.33, 10.2217/EPI.09.33]
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Esteller M, 2001, CANCER RES, V61, P3225
   Fernandez AF, 2012, GENOME RES, V22, P407, DOI 10.1101/gr.119867.110
   Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015
   Flusberg BA, 2010, NAT METHODS, V7, P461, DOI [10.1038/NMETH.1459, 10.1038/nmeth.1459]
   Frith MC, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks275
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865
   Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538
   Huang Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008888
   Joliffe I.T., 2002, Principal Component Analysis
   Krueger F, 2012, NAT METHODS, V9, P145, DOI [10.1038/nmeth.1828, 10.1038/NMETH.1828]
   Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167
   LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0
   Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352
   Lister R, 2008, CELL, V133, P523, DOI 10.1016/j.cell.2008.03.029
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107
   Rodriguez J, 2008, NUCLEIC ACIDS RES, V36, P770, DOI 10.1093/nar/gkm1105
   Smith ZD, 2012, NATURE, V484, P339, DOI 10.1038/nature10960
   Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100
   Stadler MB, 2011, NATURE, V480, P490, DOI 10.1038/nature10716
   Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346
   Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100
   Sun ZF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017490
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Wang HQ, 2011, BIOINFORMATICS, V27, P225, DOI 10.1093/bioinformatics/btq650
   Wiench M, 2011, EMBO J, V30, P3028, DOI 10.1038/emboj.2011.210
   Yu M, 2012, CELL, V149, P1368, DOI 10.1016/j.cell.2012.04.027
NR 43
TC 1313
Z9 1495
U1 11
U2 106
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1474-760X
J9 GENOME BIOL
JI Genome Biol.
PY 2012
VL 13
IS 10
SI SI
AR R87
DI 10.1186/gb-2012-13-10-R87
PG 9
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 065XQ
UT WOS:000313183900006
PM 23034086
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Sproul, D
   Kitchen, RR
   Nestor, CE
   Dixon, JM
   Sims, AH
   Harrison, DJ
   Ramsahoye, BH
   Meehan, RR
AF Sproul, Duncan
   Kitchen, Robert R.
   Nestor, Colm E.
   Dixon, J. Michael
   Sims, Andrew H.
   Harrison, David J.
   Ramsahoye, Bernard H.
   Meehan, Richard R.
TI Tissue of origin determines cancer-associated CpG island promoter
   hypermethylation patterns
SO GENOME BIOLOGY
LA English
DT Article
ID X-CHROMOSOME INACTIVATION; NOVO DNA METHYLATION; COLORECTAL-CANCER;
   NONCODING RNAS; HUMAN GENOME; HEMATOPOIETIC DIFFERENTIATION;
   BREAST-CANCER; COLON-CANCER; PHENOTYPE; GENE
AB Background: Aberrant CpG island promoter DNA hypermethylation is frequently observed in cancer and is believed to contribute to tumor progression by silencing the expression of tumor suppressor genes. Previously, we observed that promoter hypermethylation in breast cancer reflects cell lineage rather than tumor progression and occurs at genes that are already repressed in a lineage-specific manner. To investigate the generality of our observation we analyzed the methylation profiles of 1,154 cancers from 7 different tissue types.
   Results: We find that 1,009 genes are prone to hypermethylation in these 7 types of cancer. Nearly half of these genes varied in their susceptibility to hypermethylation between different cancer types. We show that the expression status of hypermethylation prone genes in the originator tissue determines their propensity to become hypermethylated in cancer; specifically, genes that are normally repressed in a tissue are prone to hypermethylation in cancers derived from that tissue. We also show that the promoter regions of hypermethylation-prone genes are depleted of repetitive elements and that DNA sequence around the same promoters is evolutionarily conserved. We propose that these two characteristics reflect tissue-specific gene promoter architecture regulating the expression of these hypermethylation prone genes in normal tissues.
   Conclusions: As aberrantly hypermethylated genes are already repressed in pre-cancerous tissue, we suggest that their hypermethylation does not directly contribute to cancer development via silencing. Instead aberrant hypermethylation reflects developmental history and the perturbation of epigenetic mechanisms maintaining these repressed promoters in a hypomethylated state in normal cells.
C1 [Sproul, Duncan; Kitchen, Robert R.; Nestor, Colm E.; Dixon, J. Michael; Sims, Andrew H.; Harrison, David J.; Ramsahoye, Bernard H.; Meehan, Richard R.] Univ Edinburgh, Western Gen Hosp, Breakthrough Breast Canc Res Unit, Edinburgh EH4 2XU, Midlothian, Scotland.
   [Sproul, Duncan; Kitchen, Robert R.; Nestor, Colm E.; Dixon, J. Michael; Sims, Andrew H.; Harrison, David J.; Ramsahoye, Bernard H.; Meehan, Richard R.] Univ Edinburgh, Western Gen Hosp, Div Pathol, Edinburgh EH4 2XU, Midlothian, Scotland.
   [Sproul, Duncan; Nestor, Colm E.; Meehan, Richard R.] Univ Edinburgh, Western Gen Hosp, Inst Genet & Mol Med, MRC Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland.
   [Kitchen, Robert R.] Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06511 USA.
   [Kitchen, Robert R.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06511 USA.
   [Harrison, David J.] Univ St Andrews, Sch Med, St Andrews KY16 9TF, Fife, Scotland.
   [Ramsahoye, Bernard H.] Univ Edinburgh, Western Gen Hosp, Inst Genet & Mol Med, Ctr Mol Med, Edinburgh EH4 2XU, Midlothian, Scotland.
C3 University of Edinburgh; University of Edinburgh; University of
   Edinburgh; Yale University; Yale University; University of St Andrews;
   University of Edinburgh
RP Meehan, RR (通讯作者)，Univ Edinburgh, Western Gen Hosp, Breakthrough Breast Canc Res Unit, Edinburgh EH4 2XU, Midlothian, Scotland.
EM Richard.Meehan@igmm.ed.ac.uk
RI ; Sims, Andrew/E-4819-2012
OI harrison, david/0000-0001-9041-9988; Meehan,
   Richard/0000-0001-6471-6882; Sims, Andrew/0000-0001-9082-3665
FU Breakthrough Breast Cancer; Medical Research Council; MRC
   [MC_PC_U127574433, MC_U127574433] Funding Source: UKRI
FX This work was funded by Breakthrough Breast Cancer and the Medical
   Research Council. We thank Professor WA Bickmore, Dr JG Prendergast, J
   Reddington (MRC Human Genetics Unit, University of Edinburgh), Professor
   CP Ponting and Dr C Nellaker (MRC Functional Genomics Unit, Oxford) for
   discussion of results and the manuscript.
CR Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166
   Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bestor TH, 2003, ANN NY ACAD SCI, V983, P22, DOI 10.1111/j.1749-6632.2003.tb05959.x
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x
   Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509
   Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611
   Calvanese V, 2012, NUCLEIC ACIDS RES, V40, P116, DOI 10.1093/nar/gkr685
   Cimmino L, 2011, CELL STEM CELL, V9, P193, DOI 10.1016/j.stem.2011.08.007
   Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179
   De Gobbi M, 2011, EPIGENET CHROMATIN, V4, DOI 10.1186/1756-8935-4-9
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   Estécio MRH, 2010, GENOME RES, V20, P1369, DOI 10.1101/gr.107318.110
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   Fearon ER, 2000, JNCI-J NATL CANCER I, V92, P515, DOI 10.1093/jnci/92.7.515
   Feldman N, 2006, NAT CELL BIOL, V8, P188, DOI 10.1038/ncb1353
   Ferguson-Smith AC, 2011, NAT REV GENET, V12, P565, DOI 10.1038/nrg3032
   Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015
   Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929
   Ge XJ, 2005, GENOMICS, V86, P127, DOI 10.1016/j.ygeno.2005.04.008
   Gebhard C, 2010, CANCER RES, V70, P1398, DOI 10.1158/0008-5472.CAN-09-3406
   Gusterson B, 2009, NAT REV CANCER, V9, P128, DOI 10.1038/nrc2571
   Habegger L, 2011, BIOINFORMATICS, V27, P281, DOI 10.1093/bioinformatics/btq643
   Haber DA, 2007, NATURE, V446, P145, DOI 10.1038/446145a
   Haffner MC, 2011, ONCOTARGET, V2, P627
   HANSON I, 1995, TRENDS GENET, V11, P268, DOI 10.1016/S0168-9525(00)89073-3
   Hekimoglu B, 2009, RNA BIOL, V6, P129, DOI 10.4161/rna.6.2.8178
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Hervouet E, 2009, EPIGENETICS-US, V4, P487, DOI 10.4161/epi.4.7.9883
   Hinoue T, 2012, GENOME RES, V22, P271, DOI 10.1101/gr.117523.110
   Hosoya K, 2009, CANCER LETT, V285, P182, DOI 10.1016/j.canlet.2009.05.016
   Ibrahim AEK, 2011, GUT, V60, P499, DOI 10.1136/gut.2010.223602
   Illingworth, 2010, 2010 PUBLICATION SUP
   Illingworth RS, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001134
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Jin SG, 2011, CANCER RES, V71, P7360, DOI 10.1158/0008-5472.CAN-11-2023
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Karsunky H, 2002, NAT GENET, V30, P295, DOI 10.1038/ng831
   Kleinjan DA, 2005, AM J HUM GENET, V76, P8, DOI 10.1086/426833
   Kobayashi Y, 2011, GENOME RES, V21, P1017, DOI 10.1101/gr.119487.110
   Kriaucionis S, 2009, SCIENCE, V324, P929, DOI 10.1126/science.1169786
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Levanon D, 2011, EMBO MOL MED, V3, P593, DOI 10.1002/emmm.201100168
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   Linhart HG, 2007, GENE DEV, V21, P3110, DOI 10.1101/gad.1594007
   LOCK LF, 1987, CELL, V48, P39, DOI 10.1016/0092-8674(87)90353-9
   Lunter G, 2006, PLOS COMPUT BIOL, V2, P2, DOI 10.1371/journal.pcbi.0020005
   Martinez O, 2008, P NATL ACAD SCI USA, V105, P9709, DOI 10.1073/pnas.0803479105
   Nestor C, 2010, BIOTECHNIQUES, V48, P317, DOI 10.2144/000113403
   Nestor CE, 2012, GENOME RES, V22, P467, DOI 10.1101/gr.126417.111
   Nosho K, 2009, CLIN CANCER RES, V15, P3663, DOI 10.1158/1078-0432.CCR-08-2383
   Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017
   Ogino S, 2006, J MOL DIAGN, V8, P582, DOI 10.2353/jmoldx.2006.060082
   Ogino S, 2009, GUT, V58, P90, DOI 10.1136/gut.2008.155473
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Okamoto I, 2009, CHROMOSOME RES, V17, P659, DOI 10.1007/s10577-009-9057-7
   Person RE, 2003, NAT GENET, V34, P308, DOI 10.1038/ng1170
   Ponting CP, 2011, GENOME RES, V21, P1769, DOI 10.1101/gr.116814.110
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Ringnér M, 2008, NAT BIOTECHNOL, V26, P303, DOI 10.1038/nbt0308-303
   Sado T, 2000, DEV BIOL, V225, P294, DOI 10.1006/dbio.2000.9823
   Sado T, 2004, DEVELOPMENT, V131, P975, DOI 10.1242/dev.00995
   Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157
   Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826
   Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170
   Siepel A, 2005, GENOME RES, V15, P1034, DOI 10.1101/gr.3715005
   Simons C, 2006, GENOME RES, V16, P164, DOI 10.1101/gr4624306
   Sproul D, 2011, P NATL ACAD SCI USA, V108, P4364, DOI 10.1073/pnas.1013224108
   Teodoridis JM, 2008, CANCER LETT, V268, P177, DOI 10.1016/j.canlet.2008.03.022
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Van der Auwera I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012616
   Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509
   Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018
   Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
   Wild L, 2010, BBA-REV CANCER, V1806, P50, DOI 10.1016/j.bbcan.2010.03.003
   Wutz A, 2011, NAT REV GENET, V12, P542, DOI 10.1038/nrg3035
   Xu YM, 2012, GENOME RES, V22, P283, DOI 10.1101/gr.122788.111
NR 80
TC 127
Z9 150
U1 0
U2 13
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1474-760X
J9 GENOME BIOL
JI Genome Biol.
PY 2012
VL 13
IS 10
SI SI
AR R84
DI 10.1186/gb-2012-13-10-R84
PG 16
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 065XQ
UT WOS:000313183900003
PM 23034185
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Lee, YJ
   Won, AJ
   Lee, J
   Jung, JH
   Yoon, S
   Lee, BM
   Kim, HS
AF Lee, Young Ju
   Won, A. Jin
   Lee, Jaewon
   Jung, Jee H.
   Yoon, Sungpil
   Lee, Byung Mu
   Kim, Hyung Sik
TI Molecular Mechanism of SAHA on Regulation of Autophagic Cell Death in
   Tamoxifen-Resistant MCF-7 Breast Cancer Cells
SO INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE HDAC inhibitor; tamoxifen-resistant; breast cancer; apoptosis; autophagy
ID HISTONE DEACETYLASE INHIBITORS; ENDOCRINE THERAPY; ACQUIRED-RESISTANCE;
   PHASE-II; APOPTOSIS; EPIGENETICS; APICIDIN; VORINOSTAT; TARGET
AB Objective: Tamoxifen is currently used for the treatment of estrogen receptor-positive breast cancer patients, but acquired resistance to tamoxifen is a critical problem in breast cancer therapy. Suberoylanilide hydroxamic acid (SAHA) is a prototype of the newly developed HDAC inhibitor. The aim of this study is to investigate the anticancer effects of SAHA in tamoxifen-resistant MCF-7 (TAMR/MCF-7) cells.
   Methods: Cytotoxicity, apoptosis and autophagic cell death induced by SAHA were studied. A TAMR/MCF-7 cells xenograft model was established to investigate the inhibitory effect of SAHA on tumor growth in vivo.
   Results: SAHA inhibited the proliferation of TAMR/MCF-7 cells in a dose-dependent manner. SAHA significantly reduced the expression of HDAC1, 2, 3, 4 and 7 and increased acetylated histone H3 and H4. Although SAHA induced G2/M phase arrest of cell cycle, apoptotic cell death was very low, which is correlated with the slight change in the activation of caspases and PARP cleavage. Interestingly, expression of the autophagic cell death markers, LC3-II and beclin-1, was significantly increased in TAMR/MCF-7 cells treated with SAHA. Autophagic cell death induced by SAHA was confirmed by acridine orange staining and transmission electron microscopy (TEM) in TAMR/MCF-7 cells. In mice bearing the TAMR/MCF-7 cell xenografts, SAHA significantly reduced the tumor growth and weight, without apparent side effects.
   Conclusion: These results suggest that SAHA can induce caspase-independent autophagic cell death rather than apoptotic cell death in TAMR/MCF-7 cells. SAHA-mediated autophagic cell death is a promising new strategy to treatment of tamoxifen-resistant human breast cancer.
C1 [Lee, Young Ju; Won, A. Jin; Lee, Jaewon; Jung, Jee H.; Kim, Hyung Sik] Pusan Natl Univ, Coll Pharm, Mol Toxicol Lab, Pusan 609735, South Korea.
   [Yoon, Sungpil] Natl Canc Ctr, Res Inst, Goyang Si, Gyeonggi Do, South Korea.
   [Lee, Byung Mu] Sungkyunkwan Univ, Div Toxicol, Coll Pharm, Suwon, Gyeonggi Do, South Korea.
C3 Pusan National University; National Cancer Center - Korea (NCC);
   Sungkyunkwan University (SKKU)
RP Kim, HS (通讯作者)，Pusan Natl Univ, Coll Pharm, Mol Toxicol Lab, San 30, Pusan 609735, South Korea.
EM hkims@pusan.ac.kr
RI Yoon, Sungpil/Q-7338-2019; Lee, Suhyun/HOF-4644-2023; Lee,
   Jaewon/N-9064-2013
OI Lee, Jaewon/0000-0003-3203-2130
FU National Research Foundation of Korea (NRF); Korea Government
   [2010-0023750, KRF-2010-314-E00292]
FX This work was supported by National Research Foundation of Korea (NRF)
   grants funded by the Korea Government (No. 2010-0023750 and
   KRF-2010-314-E00292).
CR Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
   Aguilar H, 2010, ONCOGENE, V29, P6071, DOI 10.1038/onc.2010.333
   Ahn MY, 2009, CHEM-BIOL INTERACT, V179, P169, DOI 10.1016/j.cbi.2008.11.011
   Ahn MY, 2011, ORAL ONCOL, V47, P1032, DOI 10.1016/j.oraloncology.2011.07.027
   [Anonymous], J HYDRO ENVIRON RES
   [Anonymous], 2008, World Cancer Report
   Bachelot T, 2012, J CLIN ONCOL, V30, P2718, DOI 10.1200/JCO.2011.39.0708
   Carew JS, 2007, BLOOD, V110, P313, DOI 10.1182/blood-2006-10-050260
   Castro-Galache MD, 2003, INT J CANCER, V104, P579, DOI 10.1002/ijc.10998
   Chavan AV, 2010, MINI-REV MED CHEM, V10, P1263
   Cook KL, 2011, EXPERT REV ANTICANC, V11, P1283, DOI [10.1586/ERA.11.111, 10.1586/era.11.111]
   DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9
   Dietrich CS, 2010, GYNECOL ONCOL, V116, P126, DOI 10.1016/j.ygyno.2009.09.039
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Esteve Juan M, 2011, World J Biol Chem, V2, P232, DOI 10.4331/wjbc.v2.i10.232
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Hrzenjak A, 2008, J PATHOL, V216, P495, DOI 10.1002/path.2434
   Kim DH, 2003, J BIOCHEM MOL BIOL, V36, P110
   Kim JS, 2001, BIOCHEM BIOPH RES CO, V281, P866, DOI 10.1006/bbrc.2001.4434
   Lee JH, 2010, P NATL ACAD SCI USA, V107, P14639, DOI 10.1073/pnas.1008522107
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Long J, 2009, INT J CANCER, V124, P1235, DOI 10.1002/ijc.24074
   Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504
   Mai A, 2005, MED RES REV, V25, P261, DOI 10.1002/med.20024
   Marks PA, 2009, J CELL BIOCHEM, V107, P600, DOI 10.1002/jcb.22185
   Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010
   Marks PA, 2004, ADV CANCER RES, V91, P137, DOI 10.1016/S0065-230X(04)91004-4
   MCGUIRE WL, 1977, CANCER-AM CANCER SOC, V39, P2934, DOI 10.1002/1097-0142(197706)39:6<2934::AID-CNCR2820390680>3.0.CO;2-P
   Miller TA, 2003, J MED CHEM, V46, P5097, DOI 10.1021/jm0303094
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Mouridsen H, 2009, NEW ENGL J MED, V361, P766, DOI 10.1056/NEJMoa0810818
   Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156
   MUSS HB, 1992, BREAST CANCER RES TR, V21, P15, DOI 10.1007/BF01811960
   Mutze K, 2010, ANN SURG ONCOL, V17, P3336, DOI 10.1245/s10434-010-1182-1
   Nguyen TTP, 2011, BREAST CANCER RES TR, V130, P73, DOI 10.1007/s10549-010-1304-2
   Notte A, 2011, BIOCHEM PHARMACOL, V82, P427, DOI 10.1016/j.bcp.2011.06.015
   Oh M, 2008, BIOCHEM BIOPH RES CO, V369, P1179, DOI 10.1016/j.bbrc.2008.03.019
   Paglin S, 2001, CANCER RES, V61, P439
   Park JH, 2012, INVEST NEW DRUG, V30, P1887, DOI 10.1007/s10637-011-9752-z
   Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776
   Schaefer EW, 2009, HAEMATOL-HEMATOL J, V94, P1375, DOI 10.3324/haematol.2009.009217
   Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102
   Yamamoto S, 2008, ANTICANCER RES, V28, P1585
   Yue W, 2007, J STEROID BIOCHEM, V106, P102, DOI 10.1016/j.jsbmb.2007.05.008
NR 45
TC 96
Z9 117
U1 1
U2 12
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449-1907
J9 INT J MED SCI
JI Int. J. Med. Sci.
PY 2012
VL 9
IS 10
BP 881
EP 893
DI 10.7150/ijms.5011
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 070RS
UT WOS:000313529000007
PM 23155362
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Hauser, AT
   Bissinger, EM
   Metzger, E
   Repenning, A
   Bauer, UM
   Mai, A
   Schüle, R
   Jung, M
AF Hauser, Alexander-Thomas
   Bissinger, Elisabeth-Maria
   Metzger, Eric
   Repenning, Antje
   Bauer, Uta-Maria
   Mai, Antonello
   Schuele, Roland
   Jung, Manfred
TI Screening Assays for Epigenetic Targets Using Native Histones as
   Substrates
SO JOURNAL OF BIOMOLECULAR SCREENING
LA English
DT Article
DE epigenetics; histone modifications; in vitro assays; histone
   demethylases; arginine methyltransferases
ID ARGININE METHYLTRANSFERASES; CELL-PROLIFERATION; BREAST-CANCER; PROTEIN;
   LSD1; DEMETHYLATION; INHIBITORS; IDENTIFICATION; METHYLATION;
   TRANSCRIPTION
AB In the past years, a lot of attention has been given to the identification and characterization of selective and potent inhibitors of chromatin-modifying enzymes to better understand their specific role in transcriptional regulation. As aberrant histone methylation is involved in different pathological processes, the search for methyltransferase and demethylase inhibitors has emerged as a crucial issue in current medicinal chemistry research. High-throughput in vitro assays are important tools for the identification of new methyltransferase or demethylase inhibitors. These usually use oligopeptide substrates derived from histone sequences, although in many cases, they are not good substrates for these enzymes. Here, the authors report about the setup and establishment of in vitro assays that use native core histones as substrates, enabling an assay environment that better resembles native conditions. They have applied these substrates for the known formaldehyde dehydrogenase assay for the histone demethylase LSD1 and have established two new antibody-based assays. For LSD1, a heterogeneous assay format was set up, and a homogeneous assay was used for the characterization of the arginine methyltransferase PRMT1. Validation of the system was achieved with reference inhibitors in each case.
C1 [Hauser, Alexander-Thomas; Bissinger, Elisabeth-Maria; Jung, Manfred] Univ Freiburg, Inst Pharmaceut Sci, D-79104 Freiburg, Germany.
   [Metzger, Eric; Schuele, Roland] Univ Freiburg, Med Ctr, Womens Hosp, Dept Urol, D-79104 Freiburg, Germany.
   [Metzger, Eric; Schuele, Roland] Univ Freiburg, Med Ctr, Clin Res Ctr, D-79104 Freiburg, Germany.
   [Repenning, Antje; Bauer, Uta-Maria] Univ Marburg, Inst Mol Biol & Tumor Res, Marburg, Germany.
   [Mai, Antonello] Univ Roma La Sapienza, Pasteur Inst Cenci Bolognetti Fdn, Dept Drug Chem & Technol, Rome, Italy.
C3 University of Freiburg; University of Freiburg; University of Freiburg;
   Philipps University Marburg; Fondazione Cenci Bolognetti; Sapienza
   University Rome
RP Jung, M (通讯作者)，Univ Freiburg, Inst Pharmaceut Sci, Albertstr 25, D-79104 Freiburg, Germany.
EM manfred.jung@pharmazie.uni-freiburg.de
RI Schüle, Rebecca/B-5763-2019; Mai, Antonello/AAC-2144-2019; Jung,
   Manfred/Q-8029-2016
OI Mai, Antonello/0000-0001-9176-2382; Jung, Manfred/0000-0002-6361-7716
FU Deutsche Krebshilfe (PRMT) [107898]; Deutsche Forschungsgemeinschaft
   (LSD1) [Ju 295/7-1, Schu 688/11-1]; Academy of Finland (AKA) [107898]
   Funding Source: Academy of Finland (AKA)
FX The authors thank the Deutsche Krebshilfe (PRMT, Nr. 107898) and the
   Deutsche Forschungsgemeinschaft (LSD1, Ju 295/7-1, Schu 688/11-1) for
   funding.
CR Aherne GW, 2002, METHODS, V26, P245, DOI 10.1016/S1046-2023(02)00028-2
   Barrett A, 2002, INT J CANCER, V101, P581, DOI 10.1002/ijc.10644
   Bedford MT, 2005, MOL CELL, V18, P263, DOI 10.1016/j.molcel.2005.04.003
   Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   Binda C, 2010, J AM CHEM SOC, V132, P6827, DOI 10.1021/ja101557k
   Bissinger EM, 2010, MEDCHEMCOMM, V1, P114, DOI 10.1039/c0md00062k
   Bradley C, 2007, CARCINOGENESIS, V28, P2184, DOI 10.1093/carcin/bgm100
   Chang MJ, 2010, CANCER RES, V70, P10234, DOI 10.1158/0008-5472.CAN-10-3294
   Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200
   Chen ZZ, 2007, P NATL ACAD SCI USA, V104, P10818, DOI 10.1073/pnas.0704525104
   Cheung N, 2007, NAT CELL BIOL, V9, P1208, DOI 10.1038/ncb1642
   Collazo E, 2005, ANAL BIOCHEM, V342, P86, DOI 10.1016/j.ab.2005.04.007
   Couture JF, 2007, NAT STRUCT MOL BIOL, V14, P689, DOI 10.1038/nsmb1273
   Dorgan KM, 2006, ANAL BIOCHEM, V350, P249, DOI 10.1016/j.ab.2006.01.004
   Forneris F, 2005, FEBS LETT, V579, P2203, DOI 10.1016/j.febslet.2005.03.015
   Fuchs SM, 2011, CURR BIOL, V21, P53, DOI 10.1016/j.cub.2010.11.058
   HEMMILA I, 1984, ANAL BIOCHEM, V137, P335, DOI 10.1016/0003-2697(84)90095-2
   Holliday R, 2006, EPIGENETICS-US, V1, P76, DOI 10.4161/epi.1.2.2762
   Infantino S, 2010, J EXP MED, V207, P711, DOI 10.1084/jem.20091303
   Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570
   Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017
   Li Y, 2009, J BIOL CHEM, V284, P34283, DOI 10.1074/jbc.M109.034462
   Lizcano JM, 2000, ANAL BIOCHEM, V286, P75, DOI 10.1006/abio.2000.4782
   Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444
   Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416
   Nishioka K, 2003, METHODS, V31, P49, DOI 10.1016/S1046-2023(03)00087-2
   Qi C, 2002, J BIOL CHEM, V277, P28624, DOI 10.1074/jbc.M201053200
   Quinn AM, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkp899
   Schmidt DMZ, 2007, BIOCHEMISTRY-US, V46, P4408, DOI 10.1021/bi0618621
   Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190
   Scoumanne A, 2007, J BIOL CHEM, V282, P15471, DOI 10.1074/jbc.M701023200
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Simon MD, 2007, CELL, V128, P1003, DOI 10.1016/j.cell.2006.12.041
   Sneeringer CJ, 2010, P NATL ACAD SCI USA, V107, P20980, DOI 10.1073/pnas.1012525107
   Spannhoff A, 2007, J MED CHEM, V50, P2319, DOI 10.1021/jm061250e
   Spannhoff A, 2009, CHEMMEDCHEM, V4, P1568, DOI 10.1002/cmdc.200900301
   Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433
   Ullman EF, 1996, CLIN CHEM, V42, P1518
   Wagner S, 2006, J BIOL CHEM, V281, P27242, DOI 10.1074/jbc.M605172200
   Wang YL, 2003, BIOCHEM BIOPH RES CO, V304, P605, DOI 10.1016/S0006-291X(03)00636-3
   Wigle TJ, 2010, CHEM BIOL, V17, P695, DOI 10.1016/j.chembiol.2010.04.014
   Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546
   Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481
   Yamane K, 2007, MOL CELL, V25, P801, DOI 10.1016/j.molcel.2007.03.001
   Yang ZQ, 2001, JPN J CANCER RES, V92, P423, DOI 10.1111/j.1349-7006.2001.tb01112.x
NR 46
TC 16
Z9 22
U1 0
U2 10
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1087-0571
J9 J BIOMOL SCREEN
JI J. Biomol. Screen
PD JAN
PY 2012
VL 17
IS 1
SI SI
BP 18
EP 26
DI 10.1177/1087057111423968
PN 2
PG 9
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Chemistry
GA 873MH
UT WOS:000298886900003
PM 21965113
OA hybrid
DA 2025-01-12
ER

PT J
AU Kwon, YJ
   Lee, SJ
   Koh, JS
   Kim, SH
   Lee, HW
   Kang, MC
   Bae, JB
   Kim, YJ
   Park, JH
AF Kwon, Yong-Jae
   Lee, Seog Joo
   Koh, Jae Soo
   Kim, Sung Han
   Lee, Hae Won
   Kang, Moon Chul
   Bae, Jae Bum
   Kim, Young-Joon
   Park, Jong Ho
TI Genome-Wide Analysis of DNA Methylation and the Gene Expression Change
   in Lung Cancer
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Article
DE Lung cancer; DNA methylation; Pyrosequencing; Microarray
ID CPG-ISLAND METHYLATION; FREQUENT EPIGENETIC INACTIVATION; BREAST-CANCER;
   PROMOTER METHYLATION; SLIT2 GENE; TRANSCRIPTION FACTOR; POOR-PROGNOSIS;
   CELLS; BINDING; CARCINOMA
AB Introduction: The recent DNA methylation studies on cancers have revealed the necessity of profiling an entire human genome and not to restrict the profiling to specific regions of the human genome. It has been suggested that genome-wide DNA methylation analysis enables us to identify the genes that are regulated by DNA methylation in carcinogenesis.
   Methods: So, we performed whole-genome DNA methylation analysis for human lung squamous cell carcinoma (SCC), which is strongly related with smoking. We also performed microarrays using 21 pairs of normal lung tissues and tumors from patients with SCC. By combining these data, 30 hypermethylated and down-regulated genes, and 22 hypomethylated and up-regulated genes were selected. The gene expression level and DNA methylation pattern were confirmed by semiquantitative reverse-transcriptase polymerase chain reaction and pyrosequencing, respectively.
   Results: By these validations, we selected five hypermethylated and down-regulated genes and one hypomethylated and up-regulated gene. Moreover, these six genes were proven to be actually regulated by DNA methylation by confirming the recovery of their DNA methylation pattern and gene expression level using a demethylating agent. The DNA methylation pattern of the CYTL1 promoter region was significantly different between early and advanced stages of SCC.
   Conclusion: In conclusion, by combining the whole-genome DNA methylation pattern and the gene expression profile, we identified the six genes (CCDC37, CYTL1, CDO1, SLIT2, LMO3, and SERPINB5) that are regulated by DNA methylation, and we suggest their value as target molecules for further study of SCC.
C1 [Lee, Hae Won; Kang, Moon Chul; Park, Jong Ho] Korea Canc Ctr Hosp, Korea Inst Radiol & Med Sci, Dept Thorac Surg, Seoul 139706, South Korea.
   [Kwon, Yong-Jae; Lee, Seog Joo] Korea Canc Ctr Hosp, Korea Inst Radiol & Med Sci, Dept Translat Res, Seoul 139706, South Korea.
   [Koh, Jae Soo] Korea Canc Ctr Hosp, Korea Inst Radiol & Med Sci, Dept Pathol, Seoul 139706, South Korea.
   [Kim, Sung Han] Digital Genom Inc, Seoul, South Korea.
   [Bae, Jae Bum; Kim, Young-Joon] Yonsei Univ, Dept Biochem, Seoul 120749, South Korea.
C3 Korea Institute of Radiological & Medical Sciences; National Cancer
   Center - Korea (NCC); Korea Institute of Radiological & Medical
   Sciences; National Cancer Center - Korea (NCC); Korea Institute of
   Radiological & Medical Sciences; National Cancer Center - Korea (NCC);
   Yonsei University
RP Park, JH (通讯作者)，Korea Canc Ctr Hosp, Korea Inst Radiol & Med Sci, Dept Thorac Surg, 215-4 Gongneung Dong, Seoul 139706, South Korea.
EM jhpark@kcch.re.kr
FU National Research Foundation; Korea government (MEST) [2010-0020534,
   2010020536]; Korea Cancer Center Hospital
FX Supported by National Research Foundation grant funded by the Korea
   government (MEST) (2010-0020534) and (2010020536). The management of
   clinical data used in this article was supported by Registration of
   Cancer Patients and Establishment of Clinical Database grant of Korea
   Cancer Center Hospital.
CR Agrelo R, 2006, P NATL ACAD SCI USA, V103, P8822, DOI 10.1073/pnas.0600645103
   Andrews J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008665
   Aoyama M, 2005, CANCER RES, V65, P4587, DOI 10.1158/0008-5472.CAN-04-4630
   Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706
   Brell M, 2005, CLIN CANCER RES, V11, P5167, DOI 10.1158/1078-0432.CCR-05-0230
   Brena RM, 2007, PLOS MED, V4, P572, DOI 10.1371/journal.pmed.0040108
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Cheung HH, 2010, BRIT J CANCER, V102, P419, DOI 10.1038/sj.bjc.6605505
   Cokus SJ, 2008, NATURE, V452, P215, DOI 10.1038/nature06745
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Dallol A, 2003, ONCOGENE, V22, P4611, DOI 10.1038/sj.onc.1206687
   Dallol A, 2003, CANCER RES, V63, P1054
   Dallol A, 2002, CANCER RES, V62, P5874
   Dammann R, 2005, EUR J CANCER, V41, P1223, DOI 10.1016/j.ejca.2005.02.020
   Dietrich D, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-247
   Dunwell TL, 2009, EPIGENETICS-US, V4, P265, DOI 10.4161/epi.9137
   Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   GASTON K, 1995, NUCLEIC ACIDS RES, V23, P901, DOI 10.1093/nar/23.6.901
   Hecht SS, 2003, NAT REV CANCER, V3, P733, DOI 10.1038/nrc1190
   Hegi ME, 2004, CLIN CANCER RES, V10, P1871, DOI 10.1158/1078-0432.CCR-03-0384
   Heller G, 2010, CANCER METAST REV, V29, P95, DOI 10.1007/s10555-010-9203-x
   Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714
   Jiang CL, 2004, J BIOL CHEM, V279, P52456, DOI 10.1074/jbc.M409149200
   Jin J, 2009, BIOCHEM BIOPH RES CO, V379, P86, DOI 10.1016/j.bbrc.2008.12.022
   Jones PL, 1999, SEMIN CANCER BIOL, V9, P339, DOI 10.1006/scbi.1999.0134
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Kauder SE, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000495
   Kim JS, 2007, J BIOL CHEM, V282, P29359, DOI 10.1074/jbc.M700965200
   Kim SN, 2009, MOL CANCER RES, V7, P735, DOI 10.1158/1541-7786.MCR-08-0296
   Kwon YJ, 2009, IN VITRO CELL DEV-AN, V45, P496, DOI 10.1007/s11626-009-9229-y
   Larsen S, 2010, BIOCHEM BIOPH RES CO, V392, P252, DOI 10.1016/j.bbrc.2009.12.010
   Lonardo F, 2010, CURR PHARM DESIGN, V16, P1877, DOI 10.2174/138161210791208974
   Molina JR, 2008, MAYO CLIN PROC, V83, P584, DOI 10.4065/83.5.584
   Morris MR, 2011, ONCOGENE, V30, P1390, DOI 10.1038/onc.2010.525
   Nam E, 2010, CANCER RES TREAT, V42, P42, DOI 10.4143/crt.2010.42.1.42
   Rauch T, 2007, P NATL ACAD SCI USA, V104, P5527, DOI 10.1073/pnas.0701059104
   Rauch T, 2006, CANCER RES, V66, P7939, DOI 10.1158/0008-5472.CAN-06-1888
   Rauch TA, 2009, P NATL ACAD SCI USA, V106, P671, DOI 10.1073/pnas.0812399106
   Ruike Y, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-137
   Seng TJ, 2008, BRIT J CANCER, V99, P375, DOI 10.1038/sj.bjc.6604452
   Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486
   Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000
   Tellez CS, 2009, MELANOMA RES, V19, P146, DOI 10.1097/CMR.0b013e32832b274e
   Toyota M, 2009, CANCER SCI, V100, P787, DOI 10.1111/j.1349-7006.2009.01095.x
   Tseng RC, 2010, CANCER RES, V70, P543, DOI 10.1158/0008-5472.CAN-09-2084
   VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x
   Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598
   Woenckhaus M, 2006, J PATHOL, V210, P192, DOI 10.1002/path.2039
   Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845
NR 50
TC 73
Z9 80
U1 0
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JAN
PY 2012
VL 7
IS 1
BP 20
EP 33
DI 10.1097/JTO.0b013e3182307f62
PG 14
WC Oncology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Respiratory System
GA 892SJ
UT WOS:000300305600006
PM 22011669
OA Bronze
DA 2025-01-12
ER

PT J
AU Bozkurt, E
   Atmaca, H
   Kisim, A
   Uzunoglu, S
   Uslu, R
   Karaca, B
AF Bozkurt, Emir
   Atmaca, Harika
   Kisim, Asli
   Uzunoglu, Selim
   Uslu, Ruchan
   Karaca, Burcak
TI Effects of <i>Thymus serpyllum</i> Extract on Cell Proliferation,
   Apoptosis and Epigenetic Events in Human Breast Cancer Cells
SO NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
LA English
DT Article
ID DNA METHYLATION; HISTONE; THERAPY
AB Thymus (T.) serpyllum (wild thyme) is an aromatic medicinal plant due to its several biological properties, including anticancer activity. Breast cancer is one of the most common malignancies and increasing evidence supports that it is not only a genetic but also an epigenetic disease. Epigenetics investigates changes in gene expression caused by mechanisms that do not involve alterations in DNA sequence. DNA methylation and histone acetylation are the most widely studied epigenetic changes in cancer cells. This study evaluated the effects of T. serpyllum on apoptosis and epigenetic events in breast cancer cells. XTT cell viability assay was used to determine cytotoxicity. DNA fragmentation and caspase 3/7 activity assays were used in the assesment of apoptosis. DNA methyltransferase (DNMT) and histone deacetylase (HDAC) activities were evaluated by ELISA and verified by qRT-PCR. T. serpyllum extract induced significant cytotoxicity in breast cancer cells (MCF-7 and MDA-MB-231) but not in normal cells. It also induced apoptosis and inhibited the DNMT and HDAC activities in MDA-MB-231 cells. In the present study, the first preliminary data on the effects of the methanolic extract of T. serpyllum in normal and breast cancer cells were obtained and suggest that T. serpyllum may be a promising candidate in the development of novel therapeutic drugs for breast cancer treatment.
C1 [Uslu, Ruchan; Karaca, Burcak] Ege Univ, Sch Med, Tulay Aktas Oncol Hosp, Div Med Oncol, TR-35100 Izmir, Turkey.
   [Bozkurt, Emir; Atmaca, Harika; Kisim, Asli; Uzunoglu, Selim] Celal Bayar Univ, Fac Sci & Arts, Mol Biol Sect, Dept Biol, Manisa, Turkey.
C3 Ege University; Celal Bayar University
RP Karaca, B (通讯作者)，Ege Univ, Sch Med, Tulay Aktas Oncol Hosp, Div Med Oncol, TR-35100 Izmir, Turkey.
EM burcak.karaca@ege.edu.tr
RI Atmaca, Harika/C-7096-2008; Uzunoglu, Selim/Y-9285-2019; Bozkurt,
   Emir/B-9734-2013; Uslu, Ruchan/C-6855-2008; atmaca, harika/AAX-8164-2021
OI Bozkurt, Emir/0000-0003-4703-397X; Uslu, Ruchan/0000-0002-9584-6134;
   Karaca, Burcak/0000-0003-2638-1625; atmaca, harika/0000-0002-8459-4373;
   Kisim, Asli/0000-0002-5245-1706
FU Medical Oncology Clinics
FX This research was done at Medical Oncology Research Laboratories, School
   of Medicine, Tulay Aktas Oncology Hospital, Ege University. We thank
   Naturin Natural Products Ltd. (Izmir, Turkey) for supplying the plant
   material (T. serpyllum) and also thank Ruchan Uslu, M.D., who funded
   this research as the chairman of Medical Oncology Clinics.
CR [Anonymous], 2010, CUMHUR MED J
   Ateeq-ur-Rehman, 2009, PHARM BIOL, V47, P628, DOI 10.1080/13880200902915622
   Badisa RB, 2003, PHYTOTHER RES, V17, P472, DOI 10.1002/ptr.1175
   Butler KV, 2008, CURR PHARM DESIGN, V14, P505
   Cai FF, 2011, INT J MOL SCI, V12, P4465, DOI 10.3390/ijms12074465
   Chaouki W, 2010, PHARM BIOL, V48, P269, DOI 10.3109/13880200903096588
   Elisabeth SB, 2002, THYME
   Ganesan A, 2009, CURR CANCER DRUG TAR, V9, P963, DOI 10.2174/156800909790192428
   Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200
   Javad SG, 2009, DIG J NANOMATER BIOS, V4, P835
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Kaileh M, 2007, J ETHNOPHARMACOL, V113, P510, DOI 10.1016/j.jep.2007.07.008
   Mulero-Navarro S, 2008, CRIT REV ONCOL HEMAT, V68, P1, DOI 10.1016/j.critrevonc.2008.03.001
   Özdag H, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-90
   Raal Ain, 2004, Medicina (Kaunas), V40, P795
   Ropero S, 2007, MOL ONCOL, V1, P19, DOI 10.1016/j.molonc.2007.01.001
   Sporn MB, 2000, CARCINOGENESIS, V21, P525, DOI 10.1093/carcin/21.3.525
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   Xu X, 2012, DIAGN PATHOL, V7
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Yu Xiao-Dan, 2010, Biomol Concepts, V1, P239, DOI 10.1515/bmc.2010.020
NR 21
TC 34
Z9 37
U1 0
U2 32
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0163-5581
EI 1532-7914
J9 NUTR CANCER
JI Nutr. Cancer
PY 2012
VL 64
IS 8
BP 1245
EP 1250
DI 10.1080/01635581.2012.719658
PG 6
WC Oncology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Nutrition & Dietetics
GA 042FS
UT WOS:000311457700015
PM 23163852
DA 2025-01-12
ER

PT J
AU Wu, J
   Liu, S
   Liu, G
   Dombkowski, A
   Abrams, J
   Martin-Trevino, R
   Wicha, MS
   Ethier, SP
   Yang, ZQ
AF Wu, J.
   Liu, S.
   Liu, G.
   Dombkowski, A.
   Abrams, J.
   Martin-Trevino, R.
   Wicha, M. S.
   Ethier, S. P.
   Yang, Z-Q
TI Identification and functional analysis of 9p24 amplified genes in human
   breast cancer
SO ONCOGENE
LA English
DT Article
DE chromosome 9p24; GASC1; UHRF2; gene amplification
ID HISTONE LYSINE METHYLATION; TUMOR-SUPPRESSOR GENE; CELL-LINES; JMJD2
   FAMILY; DNA METHYLATION; AMPLICON; PROTEIN; AMPLIFICATION; PTPRD;
   DEMETHYLATION
AB Previously, our group identified a novel amplicon at chromosome 9p24 in human esophageal and breast cancers, and cloned the novel gene, GASC1 (gene amplified in squamous cell carcinoma 1, also known as JMJD2C/KDM4C), from this amplicon. GASC1 is a histone demethylase involved in the deregulation of histone methylation in cancer cells. In the current study, we aimed to comprehensively characterize the genes in the 9p24 amplicon in human breast cancer. We performed extensive genomic analyses on a panel of cancer cell lines and narrowed the shortest region of overlap to approximately 2 Mb. Based on statistical analysis of copy number increase and overexpression, the 9p24 amplicon contains six candidate oncogenes. Among these, four genes (GASC1 UHRF2, KIAA1432 and C9orf123) are overexpressed only in the context of gene amplification while two genes (ERMP1 and IL33) are overexpressed independent of the copy number increase. We then focused our studies on the UHRF2 gene, which has a potential involvement in both DNA methylation and histone modification. Knocking down UHRF2 expression inhibited the growth of breast cancer cells specifically with 9p24 amplification. Conversely, ectopic overexpression of UHRF2 in non-tumorigenic MCF10A cells promoted cell proliferation. Furthermore, we demonstrated that UHRF2 has the ability to suppress the expression of key cell-cycle inhibitors, such as p16(INK4a), p21(Waf1/Cip1) and p27(Kip1). Taken together, our studies support the notion that the 9p24 amplicon contains multiple oncogenes that may integrate genetic and epigenetic codes and have important roles in human tumorigenesis. Oncogene (2012) 31, 333-341; doi:10.1038/onc.2011.227; published online 13 June 2011
C1 [Wu, J.; Liu, G.; Ethier, S. P.; Yang, Z-Q] Wayne State Univ, Breast Canc Program, Detroit, MI 48201 USA.
   [Liu, S.; Martin-Trevino, R.; Wicha, M. S.] Univ Michigan, Dept Internal Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
   [Dombkowski, A.] Wayne State Univ, Dept Pediat, Detroit, MI 48201 USA.
   [Abrams, J.; Yang, Z-Q] Wayne State Univ, Karmanos Canc Inst, Dept Oncol, Detroit, MI 48201 USA.
C3 Wayne State University; University of Michigan System; University of
   Michigan; Wayne State University; Barbara Ann Karmanos Cancer Institute;
   Wayne State University
RP Yang, ZQ (通讯作者)，Wayne State Univ, Karmanos Canc Inst, Dept Oncol, 4100 John R St,HWCRC 815, Detroit, MI 48201 USA.
EM yangz@karmanos.org
RI LIU, GANG/AAR-4584-2021; Liu, Suling/N-2796-2013; Wicha,
   Max/AAE-7268-2019
OI liu, suling/0000-0002-0475-0242; Dombkowski, Alan/0000-0002-0312-8750
FU Department of Defense [BC086177, BC083945]; National Institutes of
   Health [RO1 CA100724, P30-CA022453-29]; Taubman Institute
FX This work was supported by Grants from the Department of Defense Breast
   Cancer Program (BC086177 and BC083945) to Zeng-Quan Yang, a grant from
   the National Institutes of Health grant RO1 CA100724 to Stephen P.
   Ethier, and the Taubman Scholar Award from Taubman Institute to Max S.
   Wicha. The Biostatistics Core of the Karmanos Cancer Institute is
   supported by the National Institutes of Health Grant P30-CA022453-29. We
   thank Michele L. Dziubinski for technical assistance on the cell
   culture. We thank Dr Steve Guest, Dr Aliccia Bollig-Fischer and Kimberly
   Lyons for discussions and careful reading of a draft manuscript.
CR Akiyama M, 2005, BIOCHEM BIOPH RES CO, V335, P1264, DOI 10.1016/j.bbrc.2005.08.019
   Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215
   Albertson DG, 2006, TRENDS GENET, V22, P447, DOI 10.1016/j.tig.2006.06.007
   Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822
   Bronner C, 2007, PHARMACOL THERAPEUT, V115, P419, DOI 10.1016/j.pharmthera.2007.06.003
   Chan DW, 2009, PROTEOMICS, V9, P2343, DOI 10.1002/pmic.200800600
   Chan TA, 2008, PLOS MED, V5, P823, DOI 10.1371/journal.pmed.0050114
   Chen ZZ, 2006, CELL, V125, P691, DOI 10.1016/j.cell.2006.04.024
   Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837
   Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989
   ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955
   Garcia MJ, 2005, ONCOGENE, V24, P5235, DOI 10.1038/sj.onc.1208741
   Garcia-Rudaz C, 2007, DEVELOPMENT, V134, P945, DOI 10.1242/dev.02795
   Gelsi-Boyer W, 2005, MOL CANCER RES, V3, P655, DOI 10.1158/1541-7786.MCR-05-0128
   Giefing M, 2011, GENE CHROMOSOME CANC, V50, P154, DOI 10.1002/gcc.20840
   Han W, 2008, GENE CHROMOSOME CANC, V47, P490, DOI 10.1002/gcc.20550
   He XY, 2009, FEBS LETT, V583, P3501, DOI 10.1016/j.febslet.2009.10.007
   Hopfner R, 2000, CANCER RES, V60, P121
   Ishimura A, 2009, BIOCHEM BIOPH RES CO, V389, P366, DOI 10.1016/j.bbrc.2009.08.155
   Italiano A, 2006, CANCER GENET CYTOGEN, V167, P122, DOI 10.1016/j.cancergencyto.2006.01.004
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Katoh M, 2004, INT J ONCOL, V24, P1623
   Kim JK, 2009, NUCLEIC ACIDS RES, V37, P493, DOI 10.1093/nar/gkn961
   Klose RJ, 2007, NAT REV MOL CELL BIO, V8, P307, DOI 10.1038/nrm2143
   Kohno T, 2010, GENE CHROMOSOME CANC, V49, P342, DOI 10.1002/gcc.20746
   Kurowska-Stolarska M, 2011, J INTERN MED, V269, P29, DOI 10.1111/j.1365-2796.2010.02316.x
   Liu G, 2009, ONCOGENE, V28, P4491, DOI 10.1038/onc.2009.297
   Loh YH, 2007, GENE DEV, V21, P2545, DOI 10.1101/gad.1588207
   Mori T, 2002, BIOCHEM BIOPH RES CO, V296, P530, DOI 10.1016/S0006-291X(02)00890-2
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Natrajan R, 2009, CLIN CANCER RES, V15, P2711, DOI 10.1158/1078-0432.CCR-08-1878
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Northcott PA, 2009, NAT GENET, V41, P465, DOI 10.1038/ng.336
   Östman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837
   Pole JCM, 2006, ONCOGENE, V25, P5693, DOI 10.1038/sj.onc.1209570
   Qian CM, 2008, J BIOL CHEM, V283, P34490, DOI 10.1074/jbc.C800169200
   Rottach A, 2010, NUCLEIC ACIDS RES, V38, P1796, DOI 10.1093/nar/gkp1152
   Rui LX, 2010, CANCER CELL, V18, P590, DOI 10.1016/j.ccr.2010.11.013
   Santarius T, 2010, NAT REV CANCER, V10, P59, DOI 10.1038/nrc2771
   Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010
   SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C
   Sjöblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427
   Solomon DA, 2008, CANCER RES, V68, P10300, DOI 10.1158/0008-5472.CAN-08-3272
   Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433
   Unoki M, 2009, BIOCHEM PHARMACOL, V78, P1279, DOI 10.1016/j.bcp.2009.05.035
   Veeriah S, 2009, P NATL ACAD SCI USA, V106, P9435, DOI 10.1073/pnas.0900571106
   Vinatzer U, 2008, CLIN CANCER RES, V14, P6426, DOI 10.1158/1078-0432.CCR-08-0702
   Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087
   Wang JL, 2010, BIOL REPROD, V82, P105, DOI 10.1095/biolreprod.109.078055
   Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028
   Yang ZQ, 2006, CANCER RES, V66, P11632, DOI 10.1158/0008-5472.CAN-06-2946
   Yang ZQ, 2010, CANCER RES, V70, P8487, DOI 10.1158/0008-5472.CAN-10-1013
   Yang ZQ, 2004, CANCER GENET CYTOGEN, V155, P57, DOI 10.1016/j.cancergencyto.2004.03.013
   Yang ZQ, 2000, CANCER RES, V60, P4735
NR 56
TC 68
Z9 77
U1 0
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD JAN
PY 2012
VL 31
IS 3
BP 333
EP 341
DI 10.1038/onc.2011.227
PG 9
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 882DQ
UT WOS:000299542100006
PM 21666724
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Fonseca-Silva, T
   de Oliveira, MVM
   Fraga, CAD
   Farias, LC
   Gomes, EPP
   Barros, LO
   Roy, A
   Gomez, RS
   De Paula, AMB
   Guimaraes, ALS
AF Fonseca-Silva, Thiago
   Macedo de Oliveira, Marcos Vinicius
   de Carvalho Fraga, Carlos Alberto
   Farias, Lucyana Conceicao
   Pereira Gomes, Erika Patricia
   Barros, Lucas Oliveira
   Roy, Ashbeel
   Gomez, Ricardo Santiago
   Batista De Paula, Alfredo Mauricio
   Sena Guimaraes, Andre Luiz
TI DNMT3B (C46359T) Polymorphisms and Immunoexpression of DNMT3b and DNMT1
   Proteins in Oral Lichen Planus
SO PATHOBIOLOGY
LA English
DT Article
DE Oral lichen planus; Oral inflammatory fibrous hyperplasia; DNA
   methylation; DNMT3b polymorphism
ID GIANT-CELL FIBROMA; DNA METHYLTRANSFERASES; MALIGNANT-TRANSFORMATION;
   GENE POLYMORPHISMS; BREAST-CANCER; EXPRESSION; METHYLATION; RISK; 3B; 3A
AB Objective: To investigate the DNMT3B (C46359T) polymorphism and immunoexpression of DNMT3b and DNMT1 in oral lichen planus (OLP) compared to a control group. Methods: We aimed to investigate the DNMT3B (C46359T) polymorphism and immunoexpression of DNMT3b and DNMT1 in OLP (n = 32), comparing it with oral mucosa (control; n = 24). The DNMT3B (C46359T) polymorphism was analyzed using the RFLP- PCR and DNMT1, and DNMT3a proteins were identified using immunohistochemistry. We also compared the DNMT3B expression in OLP and oral inflammatory fibrous hyperplasia (OIFH), another oral inflammatory disease. Differences between the groups were determined by specific statistical analyses. Results: The CT genotype of DNMT3B was associated with OLP development (p = 0.012). Increased expression of DNMT3B and DNMT1 was observed in OLP compared to the control group (p = 0.014 and p = 0.001, respectively). A significant increase in DNMT3B(C46359T) polymorphisms (p = 0.045). No DNMT3B expression differences between OLP and OIFH were observed. Conclusions: Our data show that the DNMT3B (C46359T) polymorphism is associated with OLP development. Furthermore, increased expression of the enzyme DNMT3B, an epigenetic- associated protein, is present in OLP. Copyright (C) 2012 S. Karger AG, Basel
C1 [Fonseca-Silva, Thiago; Macedo de Oliveira, Marcos Vinicius; de Carvalho Fraga, Carlos Alberto; Farias, Lucyana Conceicao; Pereira Gomes, Erika Patricia; Barros, Lucas Oliveira; Batista De Paula, Alfredo Mauricio; Sena Guimaraes, Andre Luiz] Univ Estadual Montes Claros, Dept Dent, BR-39401001 Montes Claros, MG, Brazil.
   [Farias, Lucyana Conceicao; Gomez, Ricardo Santiago] Univ Fed Minas Gerais, Dept Oral Pathol & Surg, Belo Horizonte, MG, Brazil.
   [Roy, Ashbeel] Univ Western Ontario, Schulich Sch Med & Dent, Dept Physiol & Pharmacol, London, ON, Canada.
C3 Universidade Estadual de Montes Claros; Universidade Federal de Minas
   Gerais; Western University (University of Western Ontario)
RP Guimaraes, ALS (通讯作者)，Univ Estadual Montes Claros, Hosp Univ Clemente Faria, Lab Pesquisa Saude, Ave Cula Mangabeira 562, BR-39401001 Montes Claros, MG, Brazil.
EM andreluizguimaraes@gmail.com
RI De Paula, Alfredo/K-3015-2012; barros, lucas/GXG-6687-2022; de Carvalho
   Fraga, Carlos Alberto/C-1328-2013; Gomez, Ricardo/G-1976-2012;
   Fonseca-Silva, Thiago/D-1627-2015; Guimaraes, Andre/D-8122-2011
OI Alberto de Carvalho Fraga, Carlos/0000-0002-9564-9595; Gomez,
   Ricardo/0000-0001-8770-8009; C.Farias, Lucyana/0000-0002-5379-361X;
   Guimaraes, Andre/0000-0002-3162-3206; De Paula,
   Alfredo/0000-0002-8715-0030
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq);
   Fundaao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)
FX This study was supported by grants from Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq) and Fundaao de Amparo a
   Pesquisa do Estado de Minas Gerais (FAPEMIG). Dr. Guimaraes and Dr.
   Gomez are research fellows of CNPq. Dr. De Paula is a research fellow of
   FAPEMIG.
CR Anuradha Ch, 2008, N Y State Dent J, V74, P66
   Baba S, 2009, CANCER SCI, V100, P1186, DOI 10.1111/j.1349-7006.2009.01171.x
   Barish GD, 2010, GENE DEV, V24, P2760, DOI 10.1101/gad.1998010
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   Cao J, 2009, CLIN CANCER RES, V15, P5178, DOI 10.1158/1078-0432.CCR-09-0580
   Cebrian A, 2006, CARCINOGENESIS, V27, P1661, DOI 10.1093/carcin/bgi375
   Dan HX, 2010, INFLAMMATION, V33, P76, DOI 10.1007/s10753-009-9160-0
   Santos PPD, 2011, ARCH ORAL BIOL, V56, P231, DOI 10.1016/j.archoralbio.2010.09.020
   Ducasse M, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-60
   Dutra WO, 2009, CYTOKINE GROWTH F R, V20, P223, DOI 10.1016/j.cytogfr.2009.05.005
   Eisen D, 2002, J AM ACAD DERMATOL, V46, P207, DOI 10.1067/mjd.2002.120452
   Eisen D, 2003, DERMATOL CLIN, V21, P79, DOI 10.1016/S0733-8635(02)00067-0
   Epstein JB, 2003, ORAL SURG ORAL MED O, V96, P32, DOI 10.1016/S1079-2104(03)00161-6
   Fang MX, 2009, QUINTESSENCE INT, V40, P235
   Farias LC, 2010, INT J ONCOL, V37, P167, DOI 10.3892/ijo_00000664
   Fazzari MJ, 2004, NAT REV GENET, V5, P446, DOI 10.1038/nrg1349
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   Gonzalez-Moles MA, 2008, ORAL DIS, V14, P229, DOI 10.1111/j.1601-0825.2008.01441.x
   Guimaraes ALS, 2007, ARCH ORAL BIOL, V52, P268, DOI 10.1016/j.archoralbio.2006.08.008
   Guz Jolanta, 2010, Postepy Biochem, V56, P7
   Januchowski Radoslaw, 2004, Journal of Applied Genetics, V45, P237
   Jones JS, 2006, CANCER EPIDEM BIOMAR, V15, P886, DOI 10.1158/1055-9965.EPI-05-0644
   JUNGELL P, 1991, INT J ORAL MAX SURG, V20, P129, DOI 10.1016/S0901-5027(05)80001-3
   Lanfranchi-Tizeira Hector Eduardo, 2003, Med Oral, V8, P2
   Larsson Å, 2003, ORAL ONCOL, V39, P630, DOI 10.1016/S1368-8375(03)00051-4
   Liu Hong-wei, 2005, Zhonghua Kou Qiang Yi Xue Za Zhi, V40, P94
   Liu ZS, 2008, CANCER LETT, V268, P158, DOI 10.1016/j.canlet.2008.03.034
   MAGNUSSON BC, 1995, ACTA ODONTOL SCAND, V53, P293, DOI 10.3109/00016359509005990
   Mignogna MD, 2007, EJSO-EUR J SURG ONC, V33, P383, DOI 10.1016/j.ejso.2006.09.028
   Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172
   Mollaoglu N, 2000, BRIT J ORAL MAX SURG, V38, P370, DOI 10.1054/bjom.2000.0335
   Montgomery KG, 2004, BREAST CANCER RES, V6, pR390, DOI 10.1186/bcr807
   Parra FC, 2003, P NATL ACAD SCI USA, V100, P177, DOI 10.1073/pnas.0126614100
   Perdigao PF, 2007, ARCH ORAL BIOL, V52, P889, DOI 10.1016/j.archoralbio.2007.02.001
   Resende RG, 2010, J CLIN IMMUNOL, V30, P465, DOI 10.1007/s10875-010-9377-6
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   Scully C, 2008, BRIT J ORAL MAX SURG, V46, P15, DOI 10.1016/j.bjoms.2007.07.199
   Andre LGS, 2007, J ORAL PATHOL MED, V36, P533, DOI 10.1111/j.1600-0714.2007.00559.x
   Guimaraes ALS, 2006, J PAIN, V7, P654, DOI 10.1016/j.jpain.2006.02.011
   Simao TDA, 2006, HUM EXP TOXICOL, V25, P515, DOI 10.1191/0960327106het649oa
   Singal R, 2005, ONCOL REP, V14, P569
   Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059
   Sousa Fernando Augusto Cervantes Garcia de, 2008, Rev. Bras. Otorrinolaringol., V74, P284, DOI 10.1590/S0034-72992008000200021
   Su Yu, 2009, Yichuan, V31, P1087, DOI 10.3724/SP.J.1005.2009.01087
   Szarka K, 2009, ORAL MICROBIOL IMMUN, V24, P314, DOI 10.1111/j.1399-302X.2009.00516.x
   Teodoridis JM, 2004, DRUG RESIST UPDATE, V7, P267, DOI 10.1016/j.drup.2004.06.005
   Xavier GM, 2007, J ORAL PATHOL MED, V36, P476, DOI 10.1111/j.1600-0714.2007.00560.x
   Yarom N, 2009, J DENT RES, V88, P427, DOI 10.1177/0022034509337089
NR 48
TC 21
Z9 24
U1 0
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-2008
EI 1423-0291
J9 PATHOBIOLOGY
JI Pathobiology
PY 2012
VL 79
IS 1
BP 18
EP 23
DI 10.1159/000330171
PG 6
WC Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Pathology
GA 879IG
UT WOS:000299322300003
PM 22236544
OA Bronze
DA 2025-01-12
ER

PT J
AU Bulun, SE
   Monsavais, D
   Pavone, ME
   Dyson, M
   Xue, Q
   Attar, E
   Tokunaga, H
   Su, EJ
AF Bulun, Serdar E.
   Monsavais, Diana
   Pavone, Mary Ellen
   Dyson, Matthew
   Xue, Qing
   Attar, Erkut
   Tokunaga, Hideki
   Su, Emily J.
TI Role of Estrogen Receptor-β in Endometriosis
SO SEMINARS IN REPRODUCTIVE MEDICINE
LA English
DT Article
DE ER-beta; nuclear receptor; estrogen; DNA methylation; epigenetic;
   promoter; ER-alpha; PR
ID HUMAN PROGESTERONE-RECEPTOR; MESSENGER-RIBONUCLEIC-ACID; STEROIDOGENIC
   FACTOR-I; BREAST-CANCER CELLS; ELEMENT HALF-SITE; GENE-EXPRESSION;
   STROMAL CELLS; PELVIC PAIN; AROMATASE EXPRESSION; ACTIVATOR PROTEIN-1
AB Endometriosis is an estrogen-dependent disease. The biologically active estrogen, estradiol, aggravates the pathological processes (e. g., inflammation and growth) and the symptoms (e. g., pain) associated with endometriosis. Abundant quantities of estradiol are available for endometriotic tissue via several mechanisms including local aromatase expression. The question remains, then, what mediates estradiol action. Because estrogen receptor (ER)beta levels in endometriosis are >100 times higher than those in endometrial tissue, this review focuses on this nuclear receptor. Deficient methylation of the ER beta promoter results in pathological overexpression of ER beta in endometriotic stromal cells. High levels of ER beta suppress ER alpha expression. A severely high ER beta-to-ER alpha ratio in endometriotic stromal cells is associated with suppressed progesterone receptor and increased cyclo-oxygenase-2 levels contributing to progesterone resistance and inflammation. ER beta-selective estradiol antagonists may serve as novel therapeutics of endometriosis in the future.
C1 [Bulun, Serdar E.; Monsavais, Diana; Pavone, Mary Ellen; Dyson, Matthew; Su, Emily J.] Northwestern Univ, Feinberg Sch Med, Dept Obstet & Gynecol, Div Reprod Biol Res, Chicago, IL 60611 USA.
   [Xue, Qing] Peking Univ, Hosp 1, Dept Obstet & Gynecol, Beijing 100871, Peoples R China.
   [Attar, Erkut] Istanbul Univ, Capa Sch Med, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, Istanbul, Turkey.
   [Tokunaga, Hideki] Tohoku Univ, Sch Med, Dept Obstet & Gynecol, Sendai, Miyagi 980, Japan.
C3 Northwestern University; Feinberg School of Medicine; Peking University;
   Istanbul University; Tohoku University
RP Bulun, SE (通讯作者)，Northwestern Univ, Feinberg Sch Med, Dept Obstet & Gynecol, Div Reprod Biol Res, 303 E Super St,4-123, Chicago, IL 60611 USA.
EM s-bulun@northwestern.edu
RI Tokunaga, Hideki/H-1672-2014
OI Dyson, Matthew/0000-0003-3596-5753; Pavone, Mary
   Ellen/0000-0001-9682-6381
FU NICHD [R37-HD37691]; Grants-in-Aid for Scientific Research [23791805]
   Funding Source: KAKEN
FX This manuscript was supported by a grant from the NICHD (R37-HD37691, to
   SEB).
CR Abushahin F, 2011, FERTIL STERIL, V96, P939, DOI 10.1016/j.fertnstert.2011.07.1136
   Attar E, 2009, J CLIN ENDOCR METAB, V94, P623, DOI 10.1210/jc.2008-1180
   Attia GR, 2000, J CLIN ENDOCR METAB, V85, P2897, DOI 10.1210/jc.85.8.2897
   BERGMAN MD, 1992, ENDOCRINOLOGY, V130, P1923, DOI 10.1210/en.130.4.1923
   Bonéy-Montoya J, 2010, MOL ENDOCRINOL, V24, P346, DOI 10.1210/me.2009-0429
   Brandenberger AW, 1999, MOL HUM REPROD, V5, P651, DOI 10.1093/molehr/5.7.651
   Bulun SE, 2006, MOL CELL ENDOCRINOL, V248, P94, DOI 10.1016/j.mce.2005.11.041
   Bulun SE, 2005, PHARMACOL REV, V57, P359, DOI 10.1124/pr.57.3.6
   Bulun SE, 2009, MOL CELL ENDOCRINOL, V300, P104, DOI 10.1016/j.mce.2008.12.012
   Bulun SE, 2009, NEW ENGL J MED, V360, P268, DOI 10.1056/NEJMra0804690
   Burney RO, 2007, ENDOCRINOLOGY, V148, P3814, DOI 10.1210/en.2006-1692
   DMOWSKI WP, 1981, AM J OBSTET GYNECOL, V141, P377, DOI 10.1016/0002-9378(81)90598-6
   Donaghue C, 1999, MOL ENDOCRINOL, V13, P1934, DOI 10.1210/me.13.11.1934
   Eskenazi B, 1997, OBSTET GYN CLIN N AM, V24, P235, DOI 10.1016/S0889-8545(05)70302-8
   Fujimoto J, 1999, MOL HUM REPROD, V5, P742, DOI 10.1093/molehr/5.8.742
   Giudice LC, 2004, LANCET, V364, P1789, DOI 10.1016/S0140-6736(04)17403-5
   Giudice LC, 2010, NEW ENGL J MED, V362, P2389, DOI 10.1056/NEJMcp1000274
   Grandien K, 1996, MOL CELL ENDOCRINOL, V116, P207, DOI 10.1016/0303-7207(95)03716-0
   GRANDIEN K, 1995, ENDOCRINOLOGY, V136, P2223, DOI 10.1210/en.136.5.2223
   GRANDIEN KFH, 1993, J MOL ENDOCRINOL, V10, P269, DOI 10.1677/jme.0.0100269
   GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0
   HALME J, 1988, J CLIN ENDOCR METAB, V66, P1044, DOI 10.1210/jcem-66-5-1044
   HALME J, 1983, AM J OBSTET GYNECOL, V145, P333, DOI 10.1016/0002-9378(83)90720-2
   Harris HA, 2007, MOL ENDOCRINOL, V21, P1, DOI 10.1210/me.2005-0459
   Hewitt SC, 2005, ANNU REV PHYSIOL, V67, P285, DOI 10.1146/annurev.physiol.67.040403.115914
   Hornung D, 1997, J CLIN ENDOCR METAB, V82, P1621, DOI 10.1210/jc.82.5.1621
   Kao LC, 2003, ENDOCRINOLOGY, V144, P2870, DOI 10.1210/en.2003-0043
   Kao LC, 2002, ENDOCRINOLOGY, V143, P2119, DOI 10.1210/en.143.6.2119
   KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x
   KENNEDY S, 1995, J ASSIST REPROD GEN, V12, P32, DOI 10.1007/BF02214126
   Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925
   Lin ZH, 2007, CANCER RES, V67, P5017, DOI 10.1158/0008-5472.CAN-06-3696
   Matthews J, 2006, MOL ENDOCRINOL, V20, P534, DOI 10.1210/me.2005-0140
   Montano MM, 1997, MOL ENDOCRINOL, V11, P330, DOI 10.1210/me.11.3.330
   Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X
   NARDULLI AM, 1988, ENDOCRINOLOGY, V122, P935, DOI 10.1210/endo-122-3-935
   Noble LS, 1997, J CLIN ENDOCR METAB, V82, P600, DOI 10.1210/jc.82.2.600
   Osteen KG, 2005, FERTIL STERIL, V83, P529, DOI 10.1016/j.fertnstert.2004.11.026
   Osteen KG, 2002, ANN NY ACAD SCI, V955, P37, DOI 10.1111/j.1749-6632.2002.tb02764.x
   OSTEEN KG, 2002, ANN NY ACAD SCI, V955, P396
   OSTEEN KG, 2002, ANN NY ACAD SCI, V955, P86
   Petz LN, 2002, ENDOCRINOLOGY, V143, P4583, DOI 10.1210/en.2002-220369
   Petz LN, 2004, J STEROID BIOCHEM, V88, P113, DOI 10.1016/j.jsbmb.2003.11.008
   Petz LN, 2004, MOL ENDOCRINOL, V18, P521, DOI 10.1210/me.2003-0105
   Petz LN, 2000, MOL ENDOCRINOL, V14, P972, DOI 10.1210/me.14.7.972
   READ LD, 1988, MOL ENDOCRINOL, V2, P263, DOI 10.1210/mend-2-3-263
   SAVOURET JF, 1991, EMBO J, V10, P1875, DOI 10.1002/j.1460-2075.1991.tb07713.x
   Schulke L, 2009, HUM REPROD, V24, P1695, DOI 10.1093/humrep/dep071
   Schultz JR, 2005, J BIOL CHEM, V280, P347, DOI 10.1074/jbc.M407879200
   Schultz JR, 2003, MOL CELL ENDOCRINOL, V201, P165, DOI 10.1016/S0303-7207(02)00415-X
   Scott REM, 1997, MOL ENDOCRINOL, V11, P1581, DOI 10.1210/me.11.11.1581
   SIMPSON JL, 1980, AM J OBSTET GYNECOL, V137, P327, DOI 10.1016/0002-9378(80)90917-5
   Su EJ, 2011, J CLIN ENDOCR METAB, V96, pE1558, DOI 10.1210/jc.2011-1084
   Su EJ, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2009.01.025
   Trukhacheva E, 2009, J CLIN ENDOCR METAB, V94, P615, DOI 10.1210/jc.2008-1466
   Vercellini P, 1996, FERTIL STERIL, V65, P299, DOI 10.1016/S0015-0282(16)58089-3
   Vercellini P, 1997, FERTIL STERIL, V68, P393, DOI 10.1016/S0015-0282(97)00193-3
   VERCELLINI P, 1993, FERTIL STERIL, V60, P75
   WEI LL, 1988, MOL ENDOCRINOL, V2, P62, DOI 10.1210/mend-2-1-62
   Xue Q, 2007, BIOL REPROD, V77, P681, DOI 10.1095/biolreprod.107.061804
   Zeitoun K, 1998, J CLIN ENDOCR METAB, V83, P4474, DOI 10.1210/jc.83.12.4474
   Zeitoun KM, 1999, FERTIL STERIL, V72, P961, DOI 10.1016/S0015-0282(99)00393-3
NR 62
TC 220
Z9 247
U1 3
U2 27
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 1526-8004
EI 1526-4564
J9 SEMIN REPROD MED
JI Semin. Reprod. Med.
PD JAN
PY 2012
VL 30
IS 1
BP 39
EP 45
DI 10.1055/s-0031-1299596
PG 7
WC Obstetrics & Gynecology; Reproductive Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Obstetrics & Gynecology; Reproductive Biology
GA 891ZO
UT WOS:000300255900007
PM 22271293
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Ramos, EAS
   Grochoski, M
   Braun-Prado, K
   Seniski, GG
   Cavalli, IJ
   Ribeiro, EMSF
   Camargo, AA
   Costa, FF
   Klassen, G
AF Ramos, Edneia A. S.
   Grochoski, Mariana
   Braun-Prado, Karin
   Seniski, Gerusa G.
   Cavalli, Iglenir J.
   Ribeiro, Enilze M. S. F.
   Camargo, Anamaria A.
   Costa, Fabricio F.
   Klassen, Giseli
TI Epigenetic Changes of <i>CXCR4</i> and Its Ligand <i>CXCL12</i> as
   Prognostic Factors for Sporadic Breast Cancer
SO PLOS ONE
LA English
DT Article
ID CHEMOKINE RECEPTOR CXCR4; LYMPH-NODE METASTASIS; CPG ISLAND
   HYPERMETHYLATION; DNA METHYLATION; UP-REGULATION; EXPRESSION
AB Chemokines and their receptors are involved in the development and cancer progression. The chemokine CXCL12 interacts with its receptor, CXCR4, to promote cellular adhesion, survival, proliferation and migration. The CXCR4 gene is upregulated in several types of cancers, including skin, lung, pancreas, brain and breast tumors. In pancreatic cancer and melanoma, CXCR4 expression is regulated by DNA methylation within its promoter region. In this study we examined the role of cytosine methylation in the regulation of CXCR4 expression in breast cancer cell lines and also correlated the methylation pattern with the clinicopathological aspects of sixty-nine primary breast tumors from a cohort of Brazilian women. RT-PCR showed that the PMC-42, MCF7 and MDA-MB-436 breast tumor cell lines expressed high levels of CXCR4. Conversely, the MDA-MB-435 cell line only expressed CXCR4 after treatment with 5-Aza-CdR, which suggests that CXCR4 expression is regulated by DNA methylation. To confirm this hypothesis, a 184 bp fragment of the CXCR4 gene promoter region was cloned after sodium bisulfite DNA treatment. Sequencing data showed that cell lines that expressed CXCR4 had only 15% of methylated CpG dinucleotides, while the cell line that not have CXCR4 expression, had a high density of methylation (91%). Loss of DNA methylation in the CXCR4 promoter was detected in 67% of the breast cancer analyzed. The absence of CXCR4 methylation was associated with the tumor stage, size, histological grade, lymph node status, ESR1 methylation and CXCL12 methylation, metastasis and patient death. Kaplan-Meier curves demonstrated that patients with an unmethylated CXCR4 promoter had a poorer overall survival and disease-free survival. Furthermore, patients with both CXCL12 methylation and unmethylated CXCR4 had a shorter overall survival and disease-free survival. These findings suggest that the DNA methylation status of both CXCR4 and CXCL12 genes could be used as a biomarker for prognosis in breast cancer.
C1 [Ramos, Edneia A. S.; Grochoski, Mariana; Braun-Prado, Karin; Seniski, Gerusa G.; Klassen, Giseli] Univ Fed Parana, Dept Basic Pathol, Epigenet & Mol Biol Lab, BR-80060000 Curitiba, Parana, Brazil.
   [Costa, Fabricio F.] Northwestern Univ, Canc Biol & Epigen Program, Childrens Mem Res Ctr, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Cavalli, Iglenir J.; Ribeiro, Enilze M. S. F.] Univ Fed Parana, Dept Genet, BR-80060000 Curitiba, Parana, Brazil.
   [Camargo, Anamaria A.] Ludwig Inst Canc Res, Lab Mol Biol & Genom, Sao Paulo, Brazil.
C3 Universidade Federal do Parana; Northwestern University; Feinberg School
   of Medicine; Universidade Federal do Parana; Ludwig Institute for Cancer
   Research
RP Ramos, EAS (通讯作者)，Univ Fed Parana, Dept Basic Pathol, Epigenet & Mol Biol Lab, BR-80060000 Curitiba, Parana, Brazil.
EM fcosta@childrensmemorial.org; giseli@ufpr.br
RI Braun-Prado, Karin/C-4282-2014; Cavalieri, Edneia/Q-9636-2019; Costa,
   Fabricio/M-5309-2017; Ribeiro, Enilze/K-7319-2012; Aranha Camargo,
   Anamaria/E-9388-2012; Klassen, Giseli/F-8753-2012
OI ASR Cavalieri, Edneia/0000-0002-8855-5988; Aranha Camargo,
   Anamaria/0000-0002-6076-9597; Klassen, Giseli/0000-0001-5336-6178; braun
   prado, Karin/0000-0002-9652-0566
FU Brazilian Research Council (CNPq); Coordination of Improvement of Higher
   Education Personnel (CAPES); Maeve McNicholas Memorial Foundation; Avon
   Foundation [01-2009-037]
FX This work was supported by the Brazilian Research Council (CNPq) and
   Coordination of Improvement of Higher Education Personnel (CAPES). Dr.
   Costa is supported by the Maeve McNicholas Memorial Foundation and the
   Avon Foundation (grant # 01-2009-037). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Andre F, 2006, ANN ONCOL, V17, P945, DOI 10.1093/annonc/mdl053
   Cabioglu N, 2005, CLIN CANCER RES, V11, P5686, DOI 10.1158/1078-0432.CCR-05-0014
   Costa Fabricio F, 2010, Cancer Manag Res, V2, P255, DOI 10.2147/CMR.S7280
   Costa FF, 2006, CANCER GENET CYTOGEN, V165, P135, DOI 10.1016/j.cancergencyto.2005.07.023
   Dumitrescu RG, 2005, J CELL MOL MED, V9, P208, DOI 10.1111/j.1582-4934.2005.tb00350.x
   Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007
   Furusato B, 2010, PATHOL INT, V60, P497, DOI 10.1111/j.1440-1827.2010.02548.x
   Hamm CA, 2011, DRUG DISCOV TODAY, V16, P626, DOI 10.1016/j.drudis.2011.04.007
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hassan S, 2008, CLIN CANCER RES, V14, P446, DOI 10.1158/1078-0432.CCR-07-1189
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hiller DJ, 2011, J SURG RES, V166, P14, DOI 10.1016/j.jss.2010.04.045
   Holm NT, 2007, J SURG RES, V141, P53, DOI 10.1016/j.jss.2007.03.015
   INCA, 2012, INC CANC BRAS, P100
   Jemal A, 2010, CANC STAT 2010
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Kang H, 2005, BREAST, V14, P360, DOI 10.1016/j.breast.2004.12.007
   Kato M, 2003, BREAST CANCER RES, V5, pR144, DOI 10.1186/bcr627
   Kubarek L, 2007, FEBS LETT, V581, P1441, DOI 10.1016/j.febslet.2007.02.070
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Meier R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001016
   Montero AJ, 2006, CANCER BIOL THER, V5, P1494, DOI 10.4161/cbt.5.11.3299
   Mori T, 2005, CANCER RES, V65, P1800, DOI 10.1158/0008-5472.CAN-04-3531
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Pathiraja TN, 2010, J MAMMARY GLAND BIOL, V15, P35, DOI 10.1007/s10911-010-9166-0
   Ramos EAS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-23
   Sambrook J, 2001, Molecular Cloning: a Laboratory Manual, Vthird
   Sato N, 2005, CANCER BIOL THER, V4, P70, DOI 10.4161/cbt.4.1.1378
   Shim H, 2006, BIOCHEM BIOPH RES CO, V346, P252, DOI 10.1016/j.bbrc.2006.05.110
   Singh S, 2004, LAB INVEST, V84, P1666, DOI 10.1038/labinvest.3700181
   Su YC, 2006, BREAST, V15, P533, DOI 10.1016/j.breast.2005.08.034
   Veronesi U, 2006, BREAST, V15, P3, DOI 10.1016/j.breast.2005.11.011
   Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670
   Wendt MK, 2006, ONCOGENE, V25, P4986, DOI 10.1038/sj.onc.1209505
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Woo SU, 2008, ANN SURG ONCOL, V15, P281, DOI 10.1245/s10434-007-9595-1
NR 37
TC 51
Z9 58
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 29
PY 2011
VL 6
IS 12
AR e29461
DI 10.1371/journal.pone.0029461
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 897SP
UT WOS:000300677000036
PM 22220212
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Gumy-Pause, F
   Pardo, B
   Khoshbeen-Boudal, M
   Ansari, M
   Gayet-Ageron, A
   Sappino, AP
   Attiyeh, EF
   Ozsahin, H
AF Gumy-Pause, Fabienne
   Pardo, Bruno
   Khoshbeen-Boudal, Mary
   Ansari, Marc
   Gayet-Ageron, Angele
   Sappino, Andre-Pascal
   Attiyeh, Edward F.
   Ozsahin, Hulya
TI GSTP1 hypermethylation is associated with reduced protein expression,
   aggressive disease and prognosis in neuroblastoma
SO GENES CHROMOSOMES & CANCER
LA English
DT Article
ID GLUTATHIONE-S-TRANSFERASE; CPG ISLAND HYPERMETHYLATION; TUMOR-SUPPRESSOR
   GENES; PROMOTER HYPERMETHYLATION; MULTIPLE GENES; CELL-LINES;
   METHYLATION PROFILES; ABERRANT METHYLATION; PROSTATE-CANCER;
   BREAST-CANCER
AB Epigenetic modifications such as methylation of CpG islands in tumor-suppressor gene promoter regions have been associated with tumor development in many human cancers. Using methylation specific multiplex ligation-dependent probe amplification method, we analyzed the methylation status of 35 different genes in 16 neuroblastoma (NB) cell lines and 50 NB tumor samples (NBs), and investigated whether specific hypermethylation was associated with biological and/or clinical parameters. Among the genes found hypermethylated, the effect of GSTP1 hypermethylation on mRNA and protein expression was also explored. The median number of hypermethylated genes was higher in cell lines compared to NBs (5.5 vs. 2). For eight genes, aberrant methylation of CpG-islands in NB was not (ESR1, PAX5, WT1, CADM1, MSH6, and CDKN2B) or very rarely (CDH13 and GSTP1) reported in literature. GSTP1 was found hypermethylated in 44% of the NB cell lines and in 33% of the stage 4-11qLOH -non MYCN-amplified high risk NBs. Hypermethylation was correlated with reduced mRNA and protein expression. In the whole NBs cohort, GSTP1 hypermethylation was less frequently detected (8%), but found to be associated with lower event-free (EFS) and overall survival. Hypermethylation of GSTP1 showed also association with lower EFS in high risk subgroups as stage 4 and older patients (=547 days). Our results suggest that, as in several adult cancers, aberrant methylation of GSTP1 may contribute to the carcinogenetic process in NB and could be potentially used as a new marker leading to define an ultra-high risk subgroup. (C) 2011 Wiley Periodicals, Inc.
C1 [Gumy-Pause, Fabienne; Ansari, Marc; Ozsahin, Hulya] Univ Hosp Geneva, Dept Pediat, Geneva, Switzerland.
   [Pardo, Bruno; Khoshbeen-Boudal, Mary] Univ Hosp Geneva, Dept Genet & Lab Med, Geneva, Switzerland.
   [Gayet-Ageron, Angele] Univ Hosp Geneva, Dept Community Hlth & Med, Div Clin Epidemiol, Clin Res Ctr, Geneva, Switzerland.
   [Sappino, Andre-Pascal] Clin Grangettes, Geneva, Switzerland.
   [Attiyeh, Edward F.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA.
C3 University of Geneva; University of Geneva; University of Geneva;
   University of Pennsylvania
RP Gumy-Pause, F (通讯作者)，Hop Enfants 6, Dept Pediat, Oncohematol Unit, Rue Willy Donze, CH-1211 Geneva 14, Switzerland.
EM fabienne.gumypause@unige.ch
RI Gayet-Ageron, Angèle/JAX-9530-2023; ANSARI, Marc/V-3334-2017; Ozsahin,
   Hulya/FSE-2148-2022
OI ansari, marc/0000-0002-9649-6498; Gayet-Ageron,
   Angele/0000-0002-6164-9693
FU Geneva Cancer League; CARIGEST SA; La Fondation pour la Lutte contre le
   Cancer et pour des Recherches Medico-biologiques; L'association "Le
   Printemps des Enfants" (Geneva, Switzerland)
FX Supported by: Geneva Cancer League, CARIGEST SA, La Fondation pour la
   Lutte contre le Cancer et pour des Recherches Medico-biologiques,
   L'association "Le Printemps des Enfants" (Geneva, Switzerland).
CR Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321
   Alaminos M, 2004, JNCI-J NATL CANCER I, V96, P1208, DOI 10.1093/jnci/djh224
   Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968
   Banelli B, 2005, ONCOGENE, V24, P5619, DOI 10.1038/sj.onc.1208722
   Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014
   Buyru N, 2009, CANCER INVEST, V27, P307, DOI 10.1080/07357900802350814
   Carén H, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-66
   Castro-Caldas M, 2009, NEUROSCI LETT, V451, P241, DOI 10.1016/j.neulet.2009.01.017
   Chan QKY, 2005, J MOL DIAGN, V7, P8, DOI 10.1016/S1525-1578(10)60003-7
   Chen KM, 2007, ARCH OTOLARYNGOL, V133, P1131, DOI 10.1001/archotol.133.11.1131
   CHOW NWI, 1988, J BIOL CHEM, V263, P12797
   Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785
   Duffy MJ, 2009, EUR J CANCER, V45, P335, DOI 10.1016/j.ejca.2008.12.008
   Enokida H, 2005, CLIN CANCER RES, V11, P6582, DOI 10.1158/1078-0432.CCR-05-0658
   Esteller M, 1998, CANCER RES, V58, P4515
   Gonzalez-Gomez P, 2003, EUR J CANCER, V39, P1478, DOI 10.1016/S0959-8049(03)00312-5
   Grau E, 2010, J CANCER RES CLIN, V136, P1415, DOI 10.1007/s00432-010-0796-9
   Grau E, 2011, MOL CARCINOGEN, V50, P153, DOI 10.1002/mc.20700
   Harada K, 2002, ONCOGENE, V21, P4345, DOI 10.1038/sj.onc.1205446
   Hoebeeck J, 2009, CANCER LETT, V273, P336, DOI 10.1016/j.canlet.2008.08.019
   Hoque MO, 2004, CANCER RES, V64, P5511, DOI 10.1158/0008-5472.CAN-04-0799
   Jakoby W B, 1978, Adv Enzymol Relat Areas Mol Biol, V46, P383
   Jeuken JW, 2007, LAB INVEST, V87, P1055, DOI 10.1038/labinvest.3700664
   Karius T, 2011, BIOCHEM PHARMACOL, V81, P1329, DOI 10.1016/j.bcp.2011.03.014
   Ketterer B, 1998, FREE RADICAL RES, V28, P647, DOI 10.3109/10715769809065820
   Lanciotti M, 2005, PHARMACOGENET GENOM, V15, P423, DOI 10.1097/01213011-200506000-00008
   Lazcoz P, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-254
   Leong KJ, 2011, BRIT J SURG, V98, P724, DOI 10.1002/bjs.7422
   Mandriota SJ, 2010, J BIOL CHEM, V285, P13092, DOI 10.1074/jbc.M109.078360
   Margetts CDE, 2005, ENDOCR-RELAT CANCER, V12, P161, DOI 10.1677/erc.1.00865
   Michalowski MB, 2008, PEDIATR BLOOD CANCER, V50, P29, DOI 10.1002/pbc.21279
   Moribe T, 2009, INT J CANCER, V125, P388, DOI 10.1002/ijc.24394
   Nakayama M, 2004, J CELL BIOCHEM, V91, P540, DOI 10.1002/jcb.10740
   Nygren AOH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni127
   Paulsson K, 2009, BRIT J HAEMATOL, V144, P838, DOI 10.1111/j.1365-2141.2008.07523.x
   Sharma G, 2010, LIFE SCI, V87, P83, DOI 10.1016/j.lfs.2010.05.001
   Spitz R, 2006, CANCER GENET CYTOGEN, V167, P51, DOI 10.1016/j.cancergencyto.2005.09.001
   Spitz R, 2006, GENE CHROMOSOME CANC, V45, P1130, DOI 10.1002/gcc.20376
   Suijkerbuijk KPM, 2010, ANAL CELL PATHOL, V33, P133, DOI [10.1155/2010/185219, 10.3233/ACP-CLO-2010-0542]
   Taby R, 2010, CA-CANCER J CLIN, V60, P376, DOI 10.3322/caac.20085
   Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007
   TERRIER P, 1990, AM J PATHOL, V137, P845
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Yang QW, 2007, CLIN CANCER RES, V13, P3191, DOI 10.1158/1078-0432.CCR-06-2846
   Yang QW, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-286
   Yang QW, 2004, CLIN CANCER RES, V10, P8493, DOI 10.1158/1078-0432.CCR-04-1331
   Yuan YF, 2008, MODERN PATHOL, V21, P856, DOI 10.1038/modpathol.2008.60
NR 47
TC 16
Z9 17
U1 0
U2 5
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1045-2257
J9 GENE CHROMOSOME CANC
JI Gene Chromosomes Cancer
PD FEB
PY 2012
VL 51
IS 2
BP 174
EP 185
DI 10.1002/gcc.20941
PG 12
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA 857QS
UT WOS:000297734400007
PM 22045684
DA 2025-01-12
ER

PT J
AU Rhodes, LV
   Nitschke, AM
   Segar, HC
   Martin, EC
   Driver, JL
   Elliott, S
   Nam, SY
   Li, M
   Nephew, KP
   Burow, ME
   Collins-Burow, BM
AF Rhodes, Lyndsay V.
   Nitschke, Ashley M.
   Segar, H. Chris
   Martin, Elizabeth C.
   Driver, Jennifer L.
   Elliott, Steven
   Nam, Seung Yoon
   Li, Meng
   Nephew, Kenneth P.
   Burow, Matthew E.
   Collins-Burow, Bridgette M.
TI The histone deacetylase inhibitor trichostatin A alters microRNA
   expression profiles in apoptosis-resistant breast cancer cells
SO ONCOLOGY REPORTS
LA English
DT Article
DE microRNA; trichostatin A; histone deacetylase; MCF-7; breast cancer;
   drug resistance
ID TUMOR-SUPPRESSOR MICRORNAS; TARGETING TAGLN2; DOWN-REGULATION;
   ACTIVATION; INVOLVEMENT; METASTASIS; MARKER; MIR-1; SAHA
AB The development of drug resistance represents a major complication in the effective treatment of breast cancer. Epigenetic therapy, through the use of histone deacetylase inhibitors (HDACi) or demethylation agents, is an emerging area of therapeutic targeting in a number of ontological entities, particularly in the setting of aggressive therapy-resistant disease. Using the well-described HDAC inhibitor trichostatin A (TSA) we demonstrate the suppression of in vitro clonogenicity in the previously described apoptosis-resistant MCF-7TN-R breast carcinoma cell line. Additionally, recent work has demonstrated that these agents can alter the expression profile of microRNA signatures in malignant cells. Using an unbiased microRNA microarray analysis, changes in miRNA expression of MCF-7TN-R cells treated with TSA for 24 h were analyzed. We observed significant up-regulation of 22 miRNAs and down-regulation of 10 miRNAs in response to TSA treatment. Our results demonstrate that the HDACi, TSA, exerts anticancer activity in the apoptosis-resistant MCF-7TN-R breast carcinoma cell line. This activity is correlated with TSA alteration of microRNA expression profiles indicative of a less aggressive phenotype.
C1 [Rhodes, Lyndsay V.; Nitschke, Ashley M.; Segar, H. Chris; Martin, Elizabeth C.; Driver, Jennifer L.; Elliott, Steven; Burow, Matthew E.; Collins-Burow, Bridgette M.] Tulane Univ, Hlth Sci Ctr, Dept Med, Sect Hematol & Med Oncol, New Orleans, LA 70112 USA.
   [Burow, Matthew E.] Tulane Univ, Hlth Sci Ctr, Dept Pharmacol, New Orleans, LA 70112 USA.
   Tulane Univ, Hlth Sci Ctr, Dept Pathol & Lab Med, New Orleans, LA 70112 USA.
   [Burow, Matthew E.; Collins-Burow, Bridgette M.] Tulane Univ, Hlth Sci Ctr, Ctr Bioenvironm Res, New Orleans, LA 70112 USA.
   [Burow, Matthew E.; Collins-Burow, Bridgette M.] Tulane Univ, Hlth Sci Ctr, Tulane Canc Ctr, New Orleans, LA 70112 USA.
   [Nam, Seung Yoon; Li, Meng; Nephew, Kenneth P.] Indiana Univ Sch Med, Dept Cellular & Integrat Physiol, Bloomington, IN 47405 USA.
C3 Tulane University; Tulane University; Tulane University; Tulane
   University; Tulane University; Indiana University System; Indiana
   University Bloomington
RP Collins-Burow, BM (通讯作者)，Tulane Univ, Hlth Sci Ctr, Dept Med, Sect Hematol & Med Oncol, 1430 Tulane Ave SL 78, New Orleans, LA 70112 USA.
EM bcollin1@tulane.edu
RI Burow, Matthew/D-6351-2013; Rhodes, Lyndsay/AAC-4989-2020
OI Rhodes, Lyndsay/0000-0001-7672-2059
FU Department of Defense [BC085426]; National Institutes of Health/National
   Center for Research Resources [P20RR020152]; NIH/NCI [U54CA113001];
   Walther Cancer Foundation, Indianapolis, IN
FX This research was supported by The Department of Defense Breast Cancer
   Research Program BC085426 (B.M. Collins-Burow); The National Institutes
   of Health/National Center for Research Resources P20RR020152 (B.M.
   Collins-Burow); The Integrated Cancer Biology Program: Centers for
   Cancer Systems Biology NIH/NCI U54CA113001 (K. Nephew); and The Walther
   Cancer Foundation, Indianapolis, IN (S.Y. Nam). The funders did not have
   any involvement in study design; the collection, analysis, or
   interpretation of the data; the writing of the manuscript; or the
   decision to submit the manuscript for publication.
CR Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X
   Antoon JW, 2009, J MED CHEM, V52, P5748, DOI 10.1021/jm9009668
   Atadja PW, 2011, PROG DRUG RES, V67, P175, DOI 10.1007/978-3-7643-8989-5_9
   Bandres E, 2009, INT J CANCER, V125, P2737, DOI 10.1002/ijc.24638
   Boumber Y, 2011, ONCOLOGY-NY, V25, P220
   Chen F, 2010, ONCOL REP, V23, P1457, DOI 10.3892/or_00000784
   Chen H, 2009, BIOCHEM BIOPH RES CO, V385, P596, DOI 10.1016/j.bbrc.2009.05.113
   Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937
   Di Leva G, 2010, JNCI-J NATL CANCER I, V102, P706, DOI 10.1093/jnci/djq102
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Foekens JA, 2008, P NATL ACAD SCI USA, V105, P13021, DOI 10.1073/pnas.0803304105
   GARCIA M, 1992, P NATL ACAD SCI USA, V89, P11538, DOI 10.1073/pnas.89.23.11538
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Jiang SA, 2010, CANCER RES, V70, P3119, DOI 10.1158/0008-5472.CAN-09-4250
   Kato M, 2007, P NATL ACAD SCI USA, V104, P3432, DOI 10.1073/pnas.0611192104
   Kong W, 2010, J BIOL CHEM, V285, P17869, DOI 10.1074/jbc.M110.101055
   Lee EM, 2009, INT J MOL MED, V24, P45, DOI 10.3892/ijmm_00000204
   Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879
   Lujambio A, 2007, CELL CYCLE, V6, P1455
   Lv K, 2008, BIOCHEM BIOPH RES CO, V374, P101, DOI 10.1016/j.bbrc.2008.06.102
   Ma L, 2008, CELL CYCLE, V7, P570, DOI 10.4161/cc.7.5.5547
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Meacham WD, 2009, EXP BIOL MED, V234, P1253, DOI 10.3181/0902-MR-77
   Mees ST, 2009, ANN SURG ONCOL, V16, P2339, DOI 10.1245/s10434-009-0531-4
   Meng ZP, 2010, HEPATOLOGY, V52, P2148, DOI 10.1002/hep.23915
   Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156
   Nana-Sinkam SP, 2011, TRANSL RES, V157, P216, DOI 10.1016/j.trsl.2011.01.013
   Nohata N, 2011, ONCOTARGET, V2, P29
   Ou ZM, 2011, MOL ENDOCRINOL, V25, P584, DOI 10.1210/me.2010-0360
   Rao X, 2011, ONCOGENE, V30, P1082, DOI 10.1038/onc.2010.487
   Sabnis GJ, 2011, CANCER RES, V71, P1893, DOI 10.1158/0008-5472.CAN-10-2458
   Saito Y, 2009, ONCOGENE, V28, P2738, DOI 10.1038/onc.2009.140
   Saito Y, 2006, CELL CYCLE, V5, P2220, DOI 10.4161/cc.5.19.3340
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Scarola M, 2010, CANCER RES, V70, P6925, DOI 10.1158/0008-5472.CAN-10-0141
   Scott GK, 2006, CANCER RES, V66, P1277, DOI 10.1158/0008-5472.CAN-05-3632
   Shankar S, 2008, ADV EXP MED BIOL, V615, P261, DOI 10.1007/978-1-4020-6554-5_13
   Shenouda SK, 2009, CANCER METAST REV, V28, P369, DOI 10.1007/s10555-009-9188-5
   Shih KK, 2011, GYNECOL ONCOL, V121, P444, DOI 10.1016/j.ygyno.2011.01.025
   Shin S, 2009, INT J ONCOL, V35, P1343, DOI 10.3892/ijo_00000452
   Sureban SM, 2011, CANCER RES, V71, P2328, DOI 10.1158/0008-5472.CAN-10-2738
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Thomson JM, 2004, NAT METHODS, V1, P47, DOI 10.1038/NMETH704
   Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082
   Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906
   van Agthoven T, 2009, J CLIN ONCOL, V27, P542, DOI 10.1200/JCO.2008.17.1462
   Weldon CB, 2004, INT J ONCOL, V24, P1473
   Wilkes Gail, 2007, Oncology (Williston Park), V21, P39
   Wong CCL, 2011, GASTROENTEROLOGY, V140, P322, DOI 10.1053/j.gastro.2010.10.006
   Xin FX, 2009, BIOINFORMATICS, V25, P430, DOI 10.1093/bioinformatics/btn646
   Xu B, 2011, MOL CELL BIOCHEM, V350, P207, DOI 10.1007/s11010-010-0700-6
   Xu JZ, 2010, INT J CANCER, V126, P1029, DOI 10.1002/ijc.24823
   Yamamoto Y, 2009, BIOMARKERS, V14, P529, DOI 10.3109/13547500903150771
   Yan D, 2009, J BIOL CHEM, V284, P29596, DOI 10.1074/jbc.M109.020511
   Yoshino H, 2011, BRIT J CANCER, V104, P808, DOI 10.1038/bjc.2011.23
   Zhang H, 2010, ONCOL REP, V24, P1363, DOI 10.3892/or_00000994
   Zhang S., 2008, Experimental Oncology, V30, P265
   Zhou CH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2210
NR 58
TC 57
Z9 65
U1 0
U2 10
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD JAN
PY 2012
VL 27
IS 1
BP 10
EP 16
DI 10.3892/or.2011.1488
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 853AB
UT WOS:000297397500002
PM 21971930
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Dedeurwaerder, S
   Desmedt, C
   Calonne, E
   Singhal, SK
   Haibe-Kains, B
   Defrance, M
   Michiels, S
   Volkmar, M
   Deplus, R
   Luciani, J
   Lallemand, F
   Larsimont, D
   Toussaint, J
   Haussy, S
   Rothé, F
   Rouas, G
   Metzger, O
   Majjaj, S
   Saini, K
   Putmans, P
   Hames, G
   van Baren, N
   Coulie, PG
   Piccart, M
   Sotiriou, C
   Fuks, F
AF Dedeurwaerder, Sarah
   Desmedt, Christine
   Calonne, Emilie
   Singhal, Sandeep K.
   Haibe-Kains, Benjamin
   Defrance, Matthieu
   Michiels, Stefan
   Volkmar, Michael
   Deplus, Rachel
   Luciani, Judith
   Lallemand, Francoise
   Larsimont, Denis
   Toussaint, Jerome
   Haussy, Sandy
   Rothe, Francoise
   Rouas, Ghizlane
   Metzger, Otto
   Majjaj, Samira
   Saini, Kamal
   Putmans, Pascale
   Hames, Gerald
   van Baren, Nicolas
   Coulie, Pierre G.
   Piccart, Martine
   Sotiriou, Christos
   Fuks, Francois
TI DNA methylation profiling reveals a predominant immune component in
   breast cancers
SO EMBO MOLECULAR MEDICINE
LA English
DT Article
DE breast cancer; DNA methylation; epigenetics; epigenomics;
   microenvironment
ID GENE-EXPRESSION PROFILES; POPULATION; CARCINOMAS; SIGNATURES; METHYLOME;
   SUBTYPES; OPINION
AB Breast cancer is a molecularly, biologically and clinically heterogeneous group of disorders. Understanding this diversity is essential to improving diagnosis and optimizing treatment. Both genetic and acquired epigenetic abnormalities participate in cancer, but the involvement of the epigenome in breast cancer and its contribution to the complexity of the disease are still poorly understood. By means of DNA methylation profiling of 248 breast tissues, we have highlighted the existence of previously unrecognized breast cancer groups that go beyond the currently known expression subtypes. Interestingly, we showed that DNA methylation profiling can reflect the cell type composition of the tumour microenvironment, and in particular a T lymphocyte infiltration of the tumours. Further, we highlighted a set of immune genes having high prognostic value in specific tumour categories. The immune component uncovered here by DNA methylation profiles provides a new perspective for the importance of the microenvironment in breast cancer, holding implications for better management of breast cancer patients.
C1 [Dedeurwaerder, Sarah; Calonne, Emilie; Defrance, Matthieu; Volkmar, Michael; Deplus, Rachel; Luciani, Judith; Putmans, Pascale; Fuks, Francois] Univ Libre Bruxelles, Fac Med, Lab Canc Epigenet, Brussels, Belgium.
   [Desmedt, Christine; Singhal, Sandeep K.; Haibe-Kains, Benjamin; Michiels, Stefan; Lallemand, Francoise; Toussaint, Jerome; Haussy, Sandy; Rothe, Francoise; Rouas, Ghizlane; Metzger, Otto; Majjaj, Samira; Saini, Kamal; Sotiriou, Christos] Univ Libre Bruxelles, Inst Jules Bordet, Breast Canc Translat Res Lab JC Heuson, Brussels, Belgium.
   [Haibe-Kains, Benjamin] Univ Libre Bruxelles, Machine Learning Grp, Dept Comp Sci, Brussels, Belgium.
   [Larsimont, Denis] Inst Jules Bordet, Dept Pathol, B-1000 Brussels, Belgium.
   [Hames, Gerald; Coulie, Pierre G.] Catholic Univ Louvain, de Duve Inst, B-1200 Brussels, Belgium.
   [van Baren, Nicolas] Ludwig Inst Canc Res, Brussels Branch, Brussels, Belgium.
   [Piccart, Martine] Univ Libre Bruxelles, Inst Jules Bordet, Dept Med, Brussels, Belgium.
C3 Universite Libre de Bruxelles; Institut Jules Bordet; Universite Libre
   de Bruxelles; Universite Libre de Bruxelles; Universite Catholique
   Louvain; Cliniques Universitaires Saint-Luc; Institut Jules Bordet;
   Universite Catholique Louvain; Ludwig Institute for Cancer Research;
   Institut Jules Bordet; Universite Libre de Bruxelles
RP Fuks, F (通讯作者)，Univ Libre Bruxelles, Fac Med, Lab Canc Epigenet, Brussels, Belgium.
EM christos.sotiriou@bordet.be; ffuks@ulb.ac.be
RI Saini, Kamal S./ABD-5499-2021; Fuks, Francois/HJY-8201-2023; Deplus,
   Rachel/LPP-7920-2024; Haibe-Kains, Benjamin/D-3702-2011; Michiels,
   Stefan/L-1516-2013; Desmedt, Christine/P-7438-2017
OI Haibe-Kains, Benjamin/0000-0002-7684-0079; Saini, Kamal
   S./0000-0001-6301-3309; Michiels, Stefan/0000-0002-6963-2968; Desmedt,
   Christine/0000-0002-5223-5579; Volkmar, Michael/0000-0001-5970-1053;
   Defrance, Matthieu/0000-0002-3090-3142
FU Belgian F.N.R.S.; Brussels Region; F.N.R.S.; Televie; Plan National
   Cancer; Brussels Region 'BruBreast'; Interuniversity Attraction Poles
   [IAP P6/28]; E.U [FP7-200620]; European Molecular Biology Organization
   (EMBO)
FX We thank Michel Georges, Nadine Cambisano, Naima Ahariz and Latifa Karim
   for technical assistance and for their helpful advices. SD, EC, JL and
   JT were supported by the Belgian F.N.R.S. CS and FF are 'Chercheur
   Qualifie' and 'Maitre de Recherche' from the F.N.R.S., respectively. CD
   and SKS were supported by the Brussels Region. This work was funded by
   grants from the F.N.R.S. and Televie, the 'Plan National Cancer', the
   Brussels Region 'BruBreast' and the 'Interuniversity Attraction Poles'
   (IAP P6/28), by the E.U. grant CANCERDIP FP7-200620 and by a European
   Molecular Biology Organization Young Investigator Programme (EMBO YIP).
CR Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Bibikova M, 2009, EPIGENOMICS-UK, V1, P177, DOI 10.2217/EPI.09.14
   Bock C, 2005, BIOINFORMATICS, V21, P4067, DOI 10.1093/bioinformatics/bti652
   Bock C, 2007, PLOS COMPUT BIOL, V3, P1055, DOI 10.1371/journal.pcbi.0030110
   Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370
   Desmedt C, 2008, CLIN CANCER RES, V14, P5158, DOI 10.1158/1078-0432.CCR-07-4756
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Flanagan JM, 2010, AM J HUM GENET, V86, P420, DOI 10.1016/j.ajhg.2010.02.008
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Liedtke C, 2009, J CLIN ONCOL, V27, P3185, DOI 10.1200/JCO.2008.18.5934
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   Lusa L, 2007, JNCI-J NATL CANCER I, V99, P1715, DOI 10.1093/jnci/djm216
   Pathiraja TN, 2010, J MAMMARY GLAND BIOL, V15, P35, DOI 10.1007/s10911-010-9166-0
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Prat A, 2009, NAT MED, V15, P842, DOI 10.1038/nm0809-842
   Ronneberg JA, 2011, MOL ONCOL, V5, P61, DOI 10.1016/j.molonc.2010.11.004
   Salmond RJ, 2009, IMMUNOL REV, V228, P9, DOI 10.1111/j.1600-065X.2008.00745.x
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100
   Sotiriou C, 2007, NAT REV CANCER, V7, P545, DOI 10.1038/nrc2173
   Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289
   Stingl J, 2007, NAT REV CANCER, V7, P791, DOI 10.1038/nrc2212
   Sun ZF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017490
   Van der Auwera I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012616
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509
   Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
   Wirapati P, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2124
   Wu JS, 2006, J BIOL CHEM, V281, P11002, DOI 10.1074/jbc.M600498200
NR 35
TC 180
Z9 198
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1757-4676
EI 1757-4684
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD DEC
PY 2011
VL 3
IS 12
BP 726
EP 741
DI 10.1002/emmm.201100801
PG 16
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 857DG
UT WOS:000297694500005
PM 21910250
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Ge, MH
   Chen, C
   Xu, JJ
   Ling, ZQ
AF Ge, Ming-Hua
   Chen, Chao
   Xu, Jia-Jie
   Ling, Zhi-Qiang
TI Critical regions and spreading of runt-related transcription factor-3
   C-phosphate-G (CpG) island methylation in human salivary gland adenoid
   cystic carcinoma
SO HUMAN PATHOLOGY
LA English
DT Article
DE RUNX3; Human salivary gland adenoid cystic carcinoma (ACC); Methylation;
   Real-time methylation-specific PCR (real-time MSP); Western blotting
ID NONNEOPLASTIC GASTRIC EPITHELIA; SQUAMOUS-CELL CARCINOMAS;
   TUMOR-SUPPRESSOR GENES; PROMOTER HYPERMETHYLATION; PROTEIN
   MISLOCALIZATION; EPIGENETIC INACTIVATION; DNA METHYLATION;
   CANCER-PATIENTS; BREAST-CANCER; DAP-KINASE
AB We investigated the spreading pattern of runt-related transcription factor-3 (RUNX3) C-phosphate-G (CpG) island (3478 base pairs) methylation in salivary gland adenoid cystic carcinoma. The methylation status of multiple regions within the runt-related transcription factor-3 promoter CpG island (3478 base pairs) was detected by real-time methylation-specific polymerase chain reaction, and the runt-related transcription factor-3 protein was detected with a Western blot in 19 salivary gland adenoid cystic carcinoma samples and the corresponding nonneoplastic salivary glands. The risk ratio between runt-related transcription factor-3 CpG island methylation and salivary gland adenoid cystic carcinoma progression was analyzed by the logistic analysis of variance model. A possible association between runt-related transcription factor-3 methylation, clinicopathologic parameters, and runt-related transcription factor-3 protein was analyzed. Hypermethylation initially occurs the most at the 5' region of runt-related transcription factor-3 CpG island before spreading to the transcription start site. The extent of methylation was found to be the highest in region nos. 1 and 2 among the successive 10 regions, which extend from the 5' region to the transcription start site within the runt-related transcription factor-3 CpG island. The extent of methylation is lowest at the transcription start site, both in salivary gland adenoid cystic carcinoma and in normal salivary glands. No methylation in the transcription start site was found in normal salivary glands. Logistic analysis of variance model indicates that the transcription start site within the runt-related transcription factor-3 promoter CpG island is critical for gene silencing. Western blots revealed that levels of the runt-related transcription factor-3 protein in adenoid cystic carcinoma samples are significantly lower than those in normal salivary glands (P < .001). Methylation of the runt-related transcription factor-3 CpG island spreads the most from 5' region to the transcription start site in adenoid cystic carcinoma tissues, and the transcription start site may be a critical region for the runtrelated transcription factor-3 methylation. The spreading pattern of the runt-related transcription factor-3 methylation may play an a role in the progression of adenoid cystic carcinoma. Crown Copyright (C) 2011 Published by Elsevier Inc. All rights reserved.
C1 [Chen, Chao; Ling, Zhi-Qiang] Zhejiang Prov Canc Hosp, Zhejiang Canc Res Inst, Zhejiang Canc Ctr, Hangzhou 310022, Zhejiang, Peoples R China.
   [Ge, Ming-Hua; Chen, Chao; Xu, Jia-Jie] Zhejiang Prov Canc Hosp, Dept Surg Oncol, Zhejiang Canc Ctr, Hangzhou 310022, Zhejiang, Peoples R China.
C3 Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
RP Ling, ZQ (通讯作者)，Zhejiang Prov Canc Hosp, Zhejiang Canc Res Inst, Zhejiang Canc Ctr, 38 Guangji Rd, Hangzhou 310022, Zhejiang, Peoples R China.
EM lingzq@hotmail.com
FU Natural Science Foundation of Zhejiang Province, China [Y2080660];
   Zhejiang Provincial Program for the Cultivation of High-level Innovative
   Health talents; Science and Technology General Project of Zhejiang
   Province [2009C33116]
FX This research was supported by a grant from the Natural Science
   Foundation of Zhejiang Province, China (No. Y2080660), a grant from the
   Zhejiang Provincial Program for the Cultivation of High-level Innovative
   Health talents, and a grant from the Science and Technology General
   Project of Zhejiang Province (No. 2009C33116).
CR Araki K, 2005, CANCER SCI, V96, P227, DOI 10.1111/j.1349-7006.2005.00033.x
   Bangsow C, 2001, GENE, V279, P221, DOI 10.1016/S0378-1119(01)00760-0
   Gao F, 2009, J CANCER RES CLIN, V135, P739, DOI 10.1007/s00432-008-0508-x
   Guo CC, 2005, INT J CANCER, V116, P155, DOI 10.1002/ijc.20919
   Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037
   He JF, 2008, CANCER SCI, V99, P1334, DOI 10.1111/j.1349-7006.2008.00826.x
   Homma N, 2006, CANCER SCI, V97, P51, DOI 10.1111/j.1349-7006.2005.00133.x
   Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743
   Jiang Y, 2008, PATHOBIOLOGY, V75, P244, DOI 10.1159/000132385
   KIM EJ, 2008, J UROLOGY, V180, P806
   Kim TY, 2004, LAB INVEST, V84, P479, DOI 10.1038/labinvest.3700060
   Kim WJ, 2005, CANCER RES, V65, P9347, DOI 10.1158/0008-5472.CAN-05-1647
   Lau QC, 2006, CANCER RES, V66, P6512, DOI 10.1158/0008-5472.CAN-06-0369
   Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6
   Long CZ, 2007, CANCER INVEST, V25, P685, DOI 10.1080/07357900701561131
   Nomoto S, 2008, BRIT J CANCER, V98, P1690, DOI 10.1038/sj.bjc.6604333
   Roa JC, 2005, REV MED CHILE, V133, P874
   Salto-Tellez M, 2006, ONCOGENE, V25, P7646, DOI 10.1038/sj.onc.1209739
   Sato K, 2006, ONCOL REP, V15, P129
   Satoh A, 2002, BRIT J CANCER, V86, P1817, DOI 10.1038/sj.bjc.6600319
   So KJ, 2006, CANCER SCI, V97, P1155, DOI 10.1111/j.1349-7006.2006.00302.x
   Stewart M, 2002, J VIROL, V76, P4364, DOI 10.1128/JVI.76.9.4364-4369.2002
   Tan SH, 2007, ONCOL REP, V18, P1225
   Tanji Y, 2007, ORAL ONCOL, V43, P88, DOI 10.1016/j.oraloncology.2006.01.009
   Waki T, 2003, CANCER SCI, V94, P360, DOI 10.1111/j.1349-7006.2003.tb01447.x
   Wei DY, 2005, CANCER RES, V65, P4809, DOI 10.1158/0008-5472.CAN-04-3741
   Wittekind C, 2002, CANCER-AM CANCER SOC, V94, P2511, DOI 10.1002/cncr.10492.abs
NR 27
TC 13
Z9 17
U1 0
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0046-8177
J9 HUM PATHOL
JI Hum. Pathol.
PD DEC
PY 2011
VL 42
IS 12
BP 1862
EP 1872
DI 10.1016/j.humpath.2011.02.003
PG 11
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 853SI
UT WOS:000297445600006
PM 21658745
DA 2025-01-12
ER

PT J
AU Ramachandran, K
   Gordian, E
   Singal, R
AF Ramachandran, Kavitha
   Gordian, Edna
   Singal, Rakesh
TI 5-Azacytidine Reverses Drug Resistance in Bladder Cancer Cells
SO ANTICANCER RESEARCH
LA English
DT Article
DE Epigeneties; bladder cancer; DNA methylation; chemotherapy;
   chemoresistance; 5-azacytidine
ID RECRUITMENT DOMAIN PROTEIN; PHASE-II TRIAL; ABERRANT METHYLATION;
   OVARIAN-CANCER; BREAST-CANCER; POTENTIAL CONTRIBUTION; PROMOTER
   METHYLATION; DOCETAXEL TAXOTERE; UROTHELIAL CANCER; PROSTATE-CANCER
AB Background: Patients with metastatic and muscle-invasive bladder cancer are commonly treated with cisplatin. A significant proportion of patients develop disease progression after an initial response to chemotherapy. Presently there is no standard of care for such patients. We examined whether pretreatment with an epigenetic agent would result in reversal of drug resistance. Materials and Methods: Methylation of proapoptotic and cell cycle genes in bladder cancer cells was examined. Cisplatin- and docetaxel-resistant cells were generated. The effect of target of methylation-induced silencing (TMSI) expression and pretreatment of wild-type and drug-resistant cells with 5-azacytidine on chemosensitivity was determined. Results: Unidirectional crossresistance of cisplatin-resistant UMUC3 cells to docetaxel was observed. Recombinant expression of TMSI or pre-treatment of wild-type and drug-resistant cells with 5-azacytidine resulted in enhanced sensitivity to cisplatin and docetaxel. Conclusion: Our results indicate that epigenetic therapy may restore sensitivity to chemotherapeutic agents in bladder cancer cells.
C1 [Ramachandran, Kavitha; Gordian, Edna; Singal, Rakesh] Univ Miami, Sylvester Canc Ctr, Coral Gables, FL 33124 USA.
C3 University of Miami
RP Singal, R (通讯作者)，1550 NW 10th Ave,PAP 219,M877, Miami, FL 33136 USA.
EM rsingal@med.miami.edu
FU Celgene Corporation
FX This work was supported by funding from Celgene Corporation to RS.
CR CHRISTEN RD, 1993, J CLIN INVEST, V92, P431, DOI 10.1172/JCI116585
   Conway KE, 2000, CANCER RES, V60, P6236
   Cookson MS, 1997, J UROLOGY, V158, P62, DOI 10.1097/00005392-199707000-00017
   de Wit R, 1998, BRIT J CANCER, V78, P1342, DOI 10.1038/bjc.1998.681
   Fabbri F, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-6
   Friedrich MG, 2004, CLIN CANCER RES, V10, P7457, DOI 10.1158/1078-0432.CCR-04-0930
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Gallagher DJ, 2008, CANCER-AM CANCER SOC, V113, P1284, DOI 10.1002/cncr.23692
   Gonzalez VM, 2001, MOL PHARMACOL, V59, P657, DOI 10.1124/mol.59.4.657
   Gordian E, 2009, ANTICANCER RES, V29, P3207
   Hasegawa M, 2007, ONCOGENE, V26, P1748, DOI 10.1038/sj.onc.1209965
   Henkels KM, 1999, CANCER RES, V59, P3077
   HENNEQUIN C, 1995, BRIT J CANCER, V71, P1194, DOI 10.1038/bjc.1995.232
   Jones PA, 2001, NATURE, V409, P141, DOI 10.1038/35051677
   Levine JJ, 2003, ONCOGENE, V22, P3475, DOI 10.1038/sj.onc.1206430
   Li M, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-34
   Marsit CJ, 2007, CARCINOGENESIS, V28, P1745, DOI 10.1093/carcin/bgm116
   Maruyama R, 2001, CANCER RES, V61, P8659
   Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835
   Masumoto J, 2003, BIOCHEM BIOPH RES CO, V303, P69, DOI 10.1016/S0006-291X(03)00309-7
   McCaffrey JA, 1997, J CLIN ONCOL, V15, P1853, DOI 10.1200/JCO.1997.15.5.1853
   McConnell BB, 2000, CANCER RES, V60, P6243
   McConnell BB, 2004, APOPTOSIS, V9, P5, DOI 10.1023/B:APPT.0000012117.32430.0c
   Parsons MJ, 2006, ONCOGENE, V25, P6948, DOI 10.1038/sj.onc.1209684
   Pizzi S, 2005, J PATHOL, V206, P409, DOI 10.1002/path.1784
   Pu YS, 2001, J UROLOGY, V165, P2082, DOI 10.1016/S0022-5347(05)66298-2
   Ramachandran K, 2010, ANTICANCER RES, V30, P3919
   Ramachandran K, 2009, CANCER RES, V69, P1527, DOI 10.1158/0008-5472.CAN-08-3609
   Saxman SB, 1997, J CLIN ONCOL, V15, P2564, DOI 10.1200/JCO.1997.15.7.2564
   Shivapurkar N, 2004, INT J CANCER, V109, P786, DOI 10.1002/ijc.20041
   Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121
   Singal R, 1997, P NATL ACAD SCI USA, V94, P13724, DOI 10.1073/pnas.94.25.13724
   Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606
   Sonpavde G, 2010, LANCET ONCOL, V11, P861, DOI 10.1016/S1470-2045(10)70086-3
   Sternberg CN, 2006, EUR J CANCER, V42, P50, DOI 10.1016/j.ejca.2005.08.032
   Stordal B, 2007, CANCER TREAT REV, V33, P688, DOI 10.1016/j.ctrv.2007.07.013
   Suzuki M, 2006, CANCER LETT, V242, P222, DOI 10.1016/j.canlet.2005.11.002
   Takahashi T, 2005, INT J CANCER, V115, P503, DOI 10.1002/ijc.20910
   Terasawa K, 2004, CLIN CANCER RES, V10, P2000, DOI 10.1158/1078-0432.CCR-0932-03
   Vanaja DK, 2006, CLIN CANCER RES, V12, P1128, DOI 10.1158/1078-0432.CCR-05-2072
   Vaughn DJ, 2002, J CLIN ONCOL, V20, P937, DOI 10.1200/JCO.20.4.937
   Virmani A, 2003, INT J CANCER, V106, P198, DOI 10.1002/ijc.11206
   von der Maase H, 2005, J CLIN ONCOL, V23, P4602, DOI 10.1200/JCO.2005.07.757
NR 43
TC 22
Z9 26
U1 0
U2 7
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
J9 ANTICANCER RES
JI Anticancer Res.
PD NOV
PY 2011
VL 31
IS 11
BP 3757
EP 3766
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 854GC
UT WOS:000297482000015
PM 22110197
DA 2025-01-12
ER

PT J
AU Almendro, V
   Fuster, G
AF Almendro, Vanessa
   Fuster, Gemma
TI Heterogeneity of breast cancer: etiology and clinical relevance
SO CLINICAL & TRANSLATIONAL ONCOLOGY
LA English
DT Article
DE Breast cancer; Heterogeneity; Stem-like cells; Chemotherapy
ID STEM-CELL; INTRATUMORAL HETEROGENEITY; MOLECULAR CHARACTERIZATION;
   EXPRESSION PATTERNS; TUMOR SUBTYPES; BRCA1; IDENTIFICATION; POPULATION;
   PHENOTYPE; CARCINOMA
AB Cancer progression is a dynamic process of clonal adaptation to changing microenvironments. From the single founder cell until the clinical detection of tumours, there are consecutive clonal expansions and a constant acquisition of genetic and epigenetic alterations, events that contribute to the generation of intra-tumor heterogeneity. In breast cancer intra-tumor heterogeneity can arise from the differentiation of stem-like cells along with the clonal selection during tumor progression, and represents a major challenge for the design of effective therapies. To infer breast cancer progression and its response to particular treatments it is important to understand the origins of the inter- and intra-tumor heterogeneity and the forces that control tumor evolution. Insights about the evolution of breast cancer heterogeneity would contribute to the design of most effective therapeutic strategies to target the tumors at single clon level. This review is intended to give a general overview about the origins of breast cancer heterogeneity and its impact in the clinical management of the disease.
C1 [Almendro, Vanessa; Fuster, Gemma] Univ Barcelona, Inst Invest Biomed Agusti Pi & Sunyer IDIBAPS, CEK, Serv Oncol Med,Hosp Clin, ES-08036 Barcelona, Spain.
C3 University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS
RP Almendro, V (通讯作者)，Univ Barcelona, Inst Invest Biomed Agusti Pi & Sunyer IDIBAPS, CEK, Serv Oncol Med,Hosp Clin, C Rossello 153, ES-08036 Barcelona, Spain.
EM almendro@clinic.ub.es
RI Fuster, Gemma/ACH-5814-2022; Fuster Orellana, Gemma/B-5468-2019
OI Fuster Orellana, Gemma/0000-0002-4501-2422
FU Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III
   [PI080022]; Fundacion Cellex; Redes Tematicas de Investigacion en Cancer
   (RTICC) [RD07/0020/2014]
FX This work has been partially funded by a grant from the Fondo de
   Investigacion Sanitaria, Instituto de Salud Carlos III (PI080022), by a
   grant from the Fundacion Cellex, and by Redes Tematicas de Investigacion
   en Cancer (RTICC, RD07/0020/2014).
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   [Anonymous], 4 WHO IARC
   Benetkiewicz M, 2006, INT J ONCOL, V29, P935
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Broeks A, 2011, HUM MOL GENET, V20, P3289, DOI 10.1093/hmg/ddr228
   Brunelli M, 2009, AM J CLIN PATHOL, V131, P678, DOI 10.1309/AJCP09VUTZWZXBMJ
   Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108
   Clayton H, 2004, EXP CELL RES, V297, P444, DOI 10.1016/j.yexcr.2004.03.029
   Cohnheim J., 1875, VIRCHOWS ARCH, V65, P64
   Cottu PH, 2008, ANN ONCOL, V19, P596, DOI 10.1093/annonc/mdn021
   Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106
   Foulkes WD, 2004, CANCER RES, V64, P830, DOI 10.1158/0008-5472.CAN-03-2970
   Gerlinger M, 2010, BRIT J CANCER, V103, P1139, DOI 10.1038/sj.bjc.6605912
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Hanna W, 2007, BREAST J, V13, P122, DOI 10.1111/j.1524-4741.2007.00396.x
   Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76
   Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108
   Hu M, 2008, CANCER CELL, V13, P394, DOI 10.1016/j.ccr.2008.03.007
   Hu M, 2008, EUR J CANCER, V44, P2760, DOI 10.1016/j.ejca.2008.09.038
   Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108
   Kalinsky K, 2011, BREAST CANCER RES TR, V129, P635, DOI 10.1007/s10549-011-1601-4
   Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Korsching E, 2002, LAB INVEST, V82, P1525, DOI 10.1097/01.LAB.0000038508.86221.B3
   Lee HE, 2011, BRIT J CANCER, V104, P1730, DOI 10.1038/bjc.2011.159
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   Liu S, 2008, P NATL ACAD SCI USA, V105, P1680, DOI 10.1073/pnas.0711613105
   Louie E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2773
   MAKINO S, 1956, ANN NY ACAD SCI, V63, P818, DOI 10.1111/j.1749-6632.1956.tb50894.x
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745
   Marusyk A, 2010, BBA-REV CANCER, V1805, P105, DOI 10.1016/j.bbcan.2009.11.002
   Mathieu J, 2011, CANCER RES, V71, P4640, DOI 10.1158/0008-5472.CAN-10-3320
   Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013
   Meyer MJ, 2010, CANCER RES, V70, P4624, DOI 10.1158/0008-5472.CAN-09-3619
   Michor F, 2010, CANCER PREV RES, V3, P1361, DOI 10.1158/1940-6207.CAPR-10-0234
   Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010
   Palacios J, 2005, BREAST CANCER RES TR, V90, P5, DOI 10.1007/s10549-004-1536-0
   Park SY, 2010, CLIN CANCER RES, V16, P876, DOI 10.1158/1078-0432.CCR-09-1532
   Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Polyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295
   Polyak K, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003244
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007
   Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029
   Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457
   Villadsen R, 2007, J CELL BIOL, V177, P87, DOI 10.1083/jcb.200611114
   Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781
   Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509
   Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705
NR 56
TC 47
Z9 54
U1 0
U2 19
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 1699-048X
EI 1699-3055
J9 CLIN TRANSL ONCOL
JI Clin. Transl. Oncol.
PD NOV
PY 2011
VL 13
IS 11
BP 767
EP 773
DI 10.1007/s12094-011-0731-9
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 854TZ
UT WOS:000297518700002
PM 22082639
DA 2025-01-12
ER

PT J
AU Corver, WE
   ter Haar, NT
   Fleuren, GJ
   Oosting, J
AF Corver, Willem Ernst
   ter Haar, Natalja Tatjana
   Fleuren, Gert Jan
   Oosting, Jan
TI Cervical carcinoma-associated fibroblasts are DNA diploid and do not
   show evidence for somatic genetic alterations
SO CELLULAR ONCOLOGY
LA English
DT Article
DE Cervical cancer; Formalin-fixed; paraffin-embedded; Carcinoma-associated
   fibroblast; Vimentin; Smooth-muscle actin; Fluorescence activated cell
   sorter; SNP-array
ID TRANSFORMING GROWTH FACTOR-BETA(1); CANCER-ASSOCIATED FIBROBLASTS;
   WHOLE-GENOME AMPLIFICATION; TUMOR-SUPPRESSOR GENES; CLASS-I LOSS;
   BREAST-CANCER; CHROMOSOMAL-ABERRATIONS; STROMAL CELLS; HETEROZYGOSITY;
   INSTABILITY
AB Background Cancer-associated fibroblasts (CAFs) have been recognized as important contributors to cancer development and progression. However, opposing evidence has been published whether CAFs, in addition to epigenetic, also undergo somatic genetic alterations and whether these changes contribute to carcinogenesis and tumour progression.
   Methods We combined multiparameter DNA flow cytometry, flow-sorting and 6K SNP-arrays to study DNA aneuploidy, % S-phase, loss of heterozygosity (LOH) and copy number alterations (CNAs) in cervical cancer-associated stromal cell fractions (n = 57) from formalin-fixed, paraffin-embedded (FFPE) samples. Tissue sections were examined for the presence of CAFs. Microsatellite analysis was used to confirm LOH findings.
   Results Smooth muscle actin and vimentin immunohistochemistry verified the presence of CAFs in all cases tested. However, we found no evidence for DNA aneuploidy, somatic genetic alterations in the vimentin-positive stromal cell fractions of any samples, while high frequencies of DNA content abnormalities (43/57) and substantial numbers of CNAs and LOH were identified in the keratin-positive epithelial cell fractions. LOH hot-spots on chromosomes 3p, 4p and 6p found were confirmed by microsatellite analysis.
   Conclusion From our study we conclude that stromal cell fractions from cervical carcinomas are DNA diploid, have a genotype undistinguishable from patient-matched normal tissue and are genetically stable. Using flow cytometry and SNP-arrays, stromal genetic changes do not seem to play a role during cervical carcinogenesis and progression. In addition, the stromal cell fraction of cervical carcinomas can be used as reference allowing large retrospective studies of archival FFPE tissues for which no normal reference tissue is available.
C1 [Corver, Willem Ernst; ter Haar, Natalja Tatjana; Fleuren, Gert Jan; Oosting, Jan] Leiden Univ Med Ctr, Dept Pathol, NL-2300 RC Leiden, Netherlands.
C3 Leiden University; Leiden University Medical Center (LUMC)
RP Corver, WE (通讯作者)，Leiden Univ Med Ctr, Dept Pathol, Bldg 1,L1-Q,POB 9600, NL-2300 RC Leiden, Netherlands.
EM w.e.corver@lumc.nl
RI Corver, Willem/T-6576-2018
OI Corver, Willem/0000-0001-8313-3658
CR ABELN ECA, 1994, BRIT J CANCER, V70, P255, DOI 10.1038/bjc.1994.289
   Allen M, 2011, J PATHOL, V223, P162, DOI 10.1002/path.2803
   Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010
   [Anonymous], CURR PROTOC CYTOM
   Arriola E, 2007, LAB INVEST, V87, P75, DOI 10.1038/labinvest.3700495
   Campbell I, 2011, J PATHOL, V223, P450, DOI 10.1002/path.2842
   Campbell I, 2009, CANCER RES, V69, P6765, DOI 10.1158/0008-5472.CAN-08-4253
   Choi CH, 2007, CANCER LETT, V255, P26, DOI 10.1016/j.canlet.2007.03.015
   Corver WE, 2005, J PATHOL, V206, P233, DOI 10.1002/path.1765
   Corver WE, 2000, CYTOMETRY, V39, P96, DOI 10.1002/(SICI)1097-0320(20000201)39:2<96::AID-CYTO2>3.3.CO;2-O
   Corver WE, 2008, CANCER RES, V68, P10333, DOI 10.1158/0008-5472.CAN-08-2665
   de Boer MA, 2007, CLIN CANCER RES, V13, P132, DOI 10.1158/1078-0432.CCR-06-1568
   Direkze NC, 2004, CANCER RES, V64, P8492, DOI 10.1158/0008-5472.CAN-04-1708
   Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764
   Fukino K, 2004, CANCER RES, V64, P7231, DOI 10.1158/0008-5472.CAN-04-2866
   Fukino K, 2007, JAMA-J AM MED ASSOC, V297, P2103, DOI 10.1001/jama.297.19.2103
   Gius D, 2007, CANCER RES, V67, P7113, DOI 10.1158/0008-5472.CAN-07-0260
   Glogovac JK, 1996, CYTOMETRY, V24, P260, DOI 10.1002/(SICI)1097-0320(19960701)24:3<260::AID-CYTO9>3.0.CO;2-L
   Hazelbag S, 2002, HUM PATHOL, V33, P1193, DOI 10.1053/hupa.2002.130109
   Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718
   Hosein AN, 2010, CANCER RES, V70, P5770, DOI 10.1158/0008-5472.CAN-10-0673
   Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596
   Ishiguro K, 2006, GUT, V55, P695, DOI 10.1136/gut.2005.079459
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   KIMMIG R, 1995, J CANCER RES CLIN, V121, P107, DOI 10.1007/BF01202222
   Koopman LA, 2000, J EXP MED, V191, P961, DOI 10.1084/jem.191.6.961
   Lim KP, 2011, J PATHOL, V223, P459, DOI 10.1002/path.2841
   Lips EH, 2005, CANCER RES, V65, P10188, DOI 10.1158/0008-5472.CAN-05-2486
   Luft F, 1999, INT J GYNECOL PATHOL, V18, P374, DOI 10.1097/00004347-199910000-00013
   Marsh D, 2011, J PATHOL, V223, P470, DOI 10.1002/path.2830
   Massagué J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5
   Matsumoto N, 2003, BRIT J CANCER, V89, P707, DOI 10.1038/sj.bjc.6601141
   Moinfar F, 2000, CANCER RES, V60, P2562
   Nakamura N, 2004, CANCER SCI, V95, P226, DOI 10.1111/j.1349-7006.2004.tb02207.x
   Oosting J, 2007, GENOME RES, V17, P368, DOI 10.1101/gr.5686107
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Paterson RF, 2003, CANCER, V98, P1830, DOI 10.1002/cncr.11747
   Patocs A, 2007, NEW ENGL J MED, V357, P2543, DOI 10.1056/NEJMoa071825
   Paulson TG, 1999, GENOME RES, V9, P482
   Petrov VV, 2002, HYPERTENSION, V39, P258, DOI 10.1161/hy0202.103268
   Qiu W, 2008, NAT GENET, V40, P650, DOI 10.1038/ng.117
   Rabinovitch PS., 1993, Clinical flow cytometry: Principles and application, P117
   Rader JS, 1998, GENE CHROMOSOME CANC, V22, P57, DOI 10.1002/(SICI)1098-2264(199805)22:1<57::AID-GCC8>3.0.CO;2-6
   Ried T, 2009, ENVIRON MOL MUTAGEN, V50, P593, DOI 10.1002/em.20526
   Sahebali S, 2010, EUR J CANCER PREV, V19, P204, DOI 10.1097/CEJ.0b013e32833720de
   Sherwood JB, 2000, GYNECOL ONCOL, V79, P90, DOI 10.1006/gyno.2000.5922
   Sieben NLG, 2000, HUM PATHOL, V31, P1414, DOI 10.1053/hupa.2000.20381
   Singh RK, 2007, HUM GENET, V122, P71, DOI 10.1007/s00439-007-0375-6
   Vermeulen CFW, 2005, HUM IMMUNOL, V66, P1167, DOI 10.1016/j.humimm.2005.10.011
   Weber F, 2006, AM J HUM GENET, V78, P961, DOI 10.1086/504090
   Weber F, 2007, JAMA-J AM MED ASSOC, V297, P187, DOI 10.1001/jama.297.2.187
   Yagishita H, 2008, SCAND J GASTROENTERO, V43, P559, DOI 10.1080/00365520701817419
NR 52
TC 23
Z9 24
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 2211-3428
J9 CELL ONCOL
JI Cell. Oncol.
PD DEC
PY 2011
VL 34
IS 6
BP 553
EP 563
DI 10.1007/s13402-011-0061-5
PG 11
WC Oncology; Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology; Pathology
GA 852MQ
UT WOS:000297362500005
PM 22042555
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Sun, JY
   Xu, X
   Liu, JT
   Liu, H
   Fu, L
   Gu, L
AF Sun, Jingyan
   Xu, Xu
   Liu, Juntian
   Liu, Hong
   Fu, Li
   Gu, Lin
TI Epigenetic regulation of retinoic acid receptor β2 gene in the
   initiation of breast cancer
SO MEDICAL ONCOLOGY
LA English
DT Article
DE Breast neoplasms; Retinoic acid receptors; DNA methylation;
   Methylation-specific polymerase chain reaction
ID CARCINOMA CELL-LINES; LUNG-CANCER; DIFFERENTIAL EXPRESSION;
   UP-REGULATION; CHEMOPREVENTION; SUPPRESSION; ADJACENT; TISSUE
AB In order to investigate the methylation status of the retinoic acid receptor beta 2 gene (RAR-beta 2) in breast carcinoma in relation to gene expression and clinicopathological parameters of patients with breast cancer, expression of RAR-beta 2 gene and methylation status were analyzed in invasive carcinoma, atypical ductal hyperplasia, fibroadenoma specimens, and normal tissues. Our findings showed that RAR-beta 2 expression was lower in the breast cancer compared to normal tissue and fibroadenoma. The methylation rate of RAR-beta 2 in breast cancer and precancerous lesions of breast cancer were higher than that of normal tissues. Hypermethylation may be an initial step in breast carcinogenesis.
C1 [Sun, Jingyan; Xu, Xu; Liu, Juntian; Liu, Hong; Gu, Lin] Tianjin Med Univ Canc Inst & Hosp, Dept Breast Oncol, Key Lab Canc Prevent & Therapy, Tianjin 300060, Peoples R China.
   [Fu, Li] Tianjin Med Univ Canc Inst & Hosp, Dept Breast Pathol, Key Lab Canc Prevent & Therapy, Tianjin 300060, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University
RP Gu, L (通讯作者)，Tianjin Med Univ Canc Inst & Hosp, Dept Breast Oncol, Key Lab Canc Prevent & Therapy, Tianjin 300060, Peoples R China.
EM gulindr@yahoo.com
RI FU, Li/AAD-4775-2019
CR Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172
   Bix M, 1998, SCIENCE, V281, P1352, DOI 10.1126/science.281.5381.1352
   Brtko Julius, 2007, Central European Journal of Public Health, V15, P3
   Cote S, 1997, ANTI-CANCER DRUG, V8, P56
   Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057
   DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x
   HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727
   Holländer GA, 1998, SCIENCE, V279, P2118, DOI 10.1126/science.279.5359.2118
   HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985
   HU L, 1991, CANCER RES, V51, P3972
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Karamouzis MV, 2007, CELL ONCOL, V29, P183
   LEE XH, 1995, EXP CELL RES, V218, P296, DOI 10.1006/excr.1995.1158
   Liu FF, 2009, HISTOPATHOLOGY, V54, P741, DOI 10.1111/j.1365-2559.2009.03289.x
   Liu Y, 1996, MOL CELL BIOL, V16, P1138
   López-Otín C, 1998, ENDOCR REV, V19, P365, DOI 10.1210/er.19.4.365
   LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103
   Minna JD, 1997, J NATL CANCER I, V89, P602, DOI 10.1093/jnci/89.9.602
   Minucci S, 1996, CURR OPIN GENET DEV, V6, P567, DOI 10.1016/S0959-437X(96)80085-2
   Pavan B, 2006, CURR MED CHEM, V13, P3553, DOI 10.2174/092986706779026183
   Sabichi AL, 1998, J NATL CANCER I, V90, P597, DOI 10.1093/jnci/90.8.597
   Sirchia SM, 2002, CANCER RES, V62, P2455
   SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133
   VANDERLEEDE BM, 1992, BIOCHEM BIOPH RES CO, V188, P695, DOI 10.1016/0006-291X(92)91112-4
   Veronesi U, 1999, J NATL CANCER I, V91, P1847, DOI 10.1093/jnci/91.21.1847
   WIDSCHWENDTER M, 1995, CANCER RES, V55, P2135
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Widschwendter M, 1997, CANCER RES, V57, P4158
   XU XC, 1994, CANCER RES, V54, P3580
   Yang QF, 2001, AM J PATHOL, V158, P299, DOI 10.1016/S0002-9440(10)63969-7
   ZHANG XK, 1994, CANCER RES, V54, P5663
NR 32
TC 7
Z9 8
U1 0
U2 6
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1357-0560
J9 MED ONCOL
JI Med. Oncol.
PD DEC
PY 2011
VL 28
IS 4
BP 1311
EP 1318
DI 10.1007/s12032-010-9685-y
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 851GM
UT WOS:000297256400056
PM 20865461
DA 2025-01-12
ER

PT J
AU Mitra, D
   Das, PM
   Huynh, FC
   Jones, FE
AF Mitra, Doyel
   Das, Partha M.
   Huynh, Felicia C.
   Jones, Frank E.
TI Jumonji/ARID1 B (JARID1B) Protein Promotes Breast Tumor Cell Cycle
   Progression through Epigenetic Repression of MicroRNA let-7e
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID DOWN-REGULATION; GENE-EXPRESSION; MAMMARY-GLAND; CANCER; PROLIFERATION;
   RECEPTOR; PLU-1; DIFFERENTIATION; ACTIVATION; RESISTANCE
AB MicroRNAs (miRs) function as tumor suppressors or oncogenes in multiple tumor types. Although miR expression is tightly regulated, the molecular basis of miR regulation is poorly understood. Here, we investigated the influence of the histone demethylase Junionji/ARID1 B (JARID1B) on miR regulation in breast tumor cells. In MCF-7 cells with stable RNAi-mediated suppression of JARID1B expression we identified altered regulation of multiple miRs including let-7e, a member of the let-7 family of tumor suppressor miRs. Chromatin immunoprecipitation analysis demonstrated JARID1B binding to the let-7e promoter region as well as removal of the of H3K4me3 histone mark associated with active gene expression. These results suggest that JARID1B epigenetically represses let-7e expression. JARID1B stimulates tumor cell proliferation by promoting the G, to S transition. As predicted, suppression of JARID1B resulted in an accumulation of MCF-7 cells in G We confirmed that cyclin D1, which also promotes G, progression, is a direct target of let-7e, and we show that cydin D1 expression is suppressed in JARID1B knockdown cells. Cyclin D1 expression and cell cycle progression were restored following inhibition of let-7e, suggesting that JARID1B repression of let-7e contributes to cydin D1 expression and JARID1B-mediated cell cycle progression. Our results indicate that the JARID1B demethylase contributes to tumor cell proliferation through the epigenetic repression of a tumor suppressor miR.
C1 [Mitra, Doyel] Univ Colorado Denver, Dept Pathol, Aurora, CO 80045 USA.
   [Das, Partha M.; Huynh, Felicia C.; Jones, Frank E.] Tulane Univ, Dept Cell & Mol Biol, New Orleans, LA 70118 USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus; Children's Hospital Colorado; Tulane University
RP Jones, FE (通讯作者)，6400 Freret St, New Orleans, LA 70118 USA.
EM fjones3@tulane.edu
RI Das, Partha/C-6898-2012
FU United States Army Medical Research and Materiel Command
   [W81XWH-08-1-0506]
FX This work was supported by United States Army Medical Research and
   Materiel Command Grant W81XWH-08-1-0506 (to D. M. and F. E. J.).
CR Barrett A, 2002, INT J CANCER, V101, P581, DOI 10.1002/ijc.10644
   Barrett A, 2007, INT J CANCER, V121, P265, DOI 10.1002/ijc.22673
   Boyerinas B, 2010, ENDOCR-RELAT CANCER, V17, pF19, DOI 10.1677/ERC-09-0184
   Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
   Catchpole S, 2011, INT J ONCOL, V38, P1267, DOI 10.3892/ijo.2011.956
   Cittelly DM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-317
   Cittelly DM, 2010, CARCINOGENESIS, V31, P2049, DOI 10.1093/carcin/bgq192
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fabbri M, 2008, CANCER J, V14, P1, DOI 10.1097/PPO.0b013e318164145e
   Hoadley KA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-258
   Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083
   Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77
   Lan FF, 2011, INT J CANCER, V128, P319, DOI 10.1002/ijc.25336
   Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000
   Lu PJ, 1999, J BIOL CHEM, V274, P15633, DOI 10.1074/jbc.274.22.15633
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   Miller TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Schultz J, 2008, CELL RES, V18, P549, DOI 10.1038/cr.2008.45
   Scibetta AG, 2007, MOL CELL BIOL, V27, P7220, DOI 10.1128/MCB.00274-07
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Verghese ET, 2008, J PATHOL, V215, P214, DOI 10.1002/path.2359
   Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155
   Xiang Y, 2007, P NATL ACAD SCI USA, V104, P19226, DOI 10.1073/pnas.0700735104
   Yamane K, 2007, MOL CELL, V25, P801, DOI 10.1016/j.molcel.2007.03.001
   Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054
   Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500
   Yu ZR, 2008, J CELL BIOL, V182, P509, DOI 10.1083/jcb.200801079
   Zhao C, 2010, P NATL ACAD SCI USA, V107, P1876, DOI 10.1073/pnas.0908750107
   Zhu Y, 2006, CANCER RES, V66, P7991, DOI 10.1158/0008-5472.CAN-05-4397
NR 33
TC 75
Z9 83
U1 0
U2 15
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 25
PY 2011
VL 286
IS 47
BP 40531
EP 40535
DI 10.1074/jbc.M111.304865
PG 5
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 852AN
UT WOS:000297315400012
PM 21969366
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Eades, G
   Yang, MH
   Yao, Y
   Zhang, YS
   Zhou, Q
AF Eades, Gabriel
   Yang, Muhua
   Yao, Yuan
   Zhang, Yongshu
   Zhou, Qun
TI miR-200a Regulates Nrf2 Activation by Targeting <i>Keap1</i> mRNA in
   Breast Cancer Cells
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID MESENCHYMAL TRANSITION; OXIDATIVE STRESS; POSTTRANSCRIPTIONAL
   REGULATION; DNA METHYLATION; FEEDBACK LOOP; EXPRESSION; MICRORNAS;
   PROLIFERATION; MECHANISMS; CARCINOGENESIS
AB NE-E2-related factor 2 (Nrf2) is an important transcription factor that activates the expression of cellular detoxifying enzymes. Nrf2 expression is largely regulated through the association of Nrf2 with Kelch-like ECH-associated protein 1 (Keap1), which results in cytoplasmic Nrf2 degradation. Conversely, little is known concerning the regulation of Keap1 expression. Until now, a regulatory role for microRNAs (miRs) in controlling Keap1 gene expression had not been characterized. By using miR array-based screening, we observed miR-200a silencing in breast cancer cells and demonstrated that upon re-expression, miR-200a targets the Keap1 3'-untranslated region (3'-UTR), leading to Keap1 mRNA degradation. Loss of this regulatory mechanism may contribute to the dysregulation of Nrf2 activity in breast cancer. Previously, we have identified epigenetic repression of miR-200a in breast cancer cells. Here, we find that treatment with epigenetic therapy, the histone deacetylase inhibitor suberoylanilide hydroxamic acid, restored miR-200a expression and reduced Keap1 levels. This reduction in Keap1 levels corresponded with Nrf2 nuclear translocation and activation of Nrf2-dependent NAD(P)H-quinone oxidoreductase 1 (NQO1) gene transcription. Moreover, we found that Nrf2 activation inhibited the anchorage-independent growth of breast cancer cells. Finally, our in vitro observations were confirmed in a model of carcinogen-induced mammary hyperplasia in vivo. In conclusion, our study demonstrates that miR-200a regulates the Keap1/Nrf2 pathway in mammary epithelium, and we find that epigenetic therapy can restore miR-200a regulation of Keap1 expression, therefore reactivating the Nrf2-dependent antioxidant pathway in breast cancer.
C1 [Eades, Gabriel; Yang, Muhua; Yao, Yuan; Zhang, Yongshu; Zhou, Qun] Univ Maryland, Dept Biochem & Mol Biol, Sch Med, Baltimore, MD 21201 USA.
C3 University System of Maryland; University of Maryland Baltimore
RP Zhou, Q (通讯作者)，Univ Maryland, Dept Biochem & Mol Biol, Sch Med, Baltimore, MD 21201 USA.
EM qzhou@som.umaryland.edu
RI yao, yuan/AHB-5578-2022
FU National Institutes of Health, NCI [NCI T32]; FAMRI; Maryland Stem Cell
   Fund
FX This work was supported, in whole or in part, by National Institutes of
   Health, NCI, Training Grant NCI T32 in cancer biology (to G. E.). This
   work was also supported by grants from FAMRI (to Q. Z.) and the Maryland
   Stem Cell Fund (to Q. Z.).
CR Acharya A, 2010, OXID MED CELL LONGEV, V3, P23, DOI 10.4161/oxim.3.1.10095
   Ahmad A, 2011, CANCER RES, V71, P3400, DOI 10.1158/0008-5472.CAN-10-0965
   Aoki Y, 2007, CANCER RES, V67, P5643, DOI 10.1158/0008-5472.CAN-06-3355
   Bagchi A, 2008, CANCER RES, V68, P2551, DOI 10.1158/0008-5472.CAN-07-2095
   Bandres E, 2009, INT J CANCER, V125, P2737, DOI 10.1002/ijc.24638
   Bolton JL, 2008, CHEM RES TOXICOL, V21, P93, DOI 10.1021/tx700191p
   Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942
   Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899
   Eades G, 2011, J BIOL CHEM, V286, P25992, DOI 10.1074/jbc.M111.229401
   Fields WR, 1999, CARCINOGENESIS, V20, P1121, DOI 10.1093/carcin/20.6.1121
   Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290
   Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Havens CG, 2006, MOL CELL BIOL, V26, P4701, DOI 10.1128/MCB.00303-06
   Hsieh TC, 2010, ANTICANCER RES, V30, P4169
   Iida K, 2004, CANCER RES, V64, P6424, DOI 10.1158/0008-5472.CAN-04-1906
   Kaspar JW, 2009, FREE RADICAL BIO MED, V47, P1304, DOI 10.1016/j.freeradbiomed.2009.07.035
   Kensler TW, 2010, CARCINOGENESIS, V31, P90, DOI 10.1093/carcin/bgp231
   Khor TO, 2008, CANCER PREV RES, V1, P187, DOI 10.1158/1940-6207.CAPR-08-0028
   Kobayashi M, 2006, ADV ENZYME REGUL, V46, P113, DOI 10.1016/j.advenzreg.2006.01.007
   Kovalchuk O, 2007, CELL CYCLE, V6, P2010, DOI 10.4161/cc.6.16.4549
   Lee S, 2011, CELL MOL LIFE SCI, V68, P325, DOI 10.1007/s00018-010-0457-9
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Lister A, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-37
   Loignon M, 2009, MOL CANCER THER, V8, P2432, DOI 10.1158/1535-7163.MCT-08-1186
   Mense SM, 2008, TOXICOL APPL PHARM, V232, P78, DOI 10.1016/j.taap.2008.06.007
   Muscarella LA, 2011, EPIGENETICS-US, V6, P317, DOI 10.4161/epi.6.3.14408
   Niture SK, 2010, TOXICOL APPL PHARM, V244, P37, DOI 10.1016/j.taap.2009.06.009
   O'Day E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2484
   Ohtsuji M, 2008, J BIOL CHEM, V283, P33554, DOI 10.1074/jbc.M804597200
   Rachakonda G, 2010, ONCOGENE, V29, P3703, DOI 10.1038/onc.2010.118
   Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798
   Santini V, 2007, CURR DRUG METAB, V8, P383, DOI 10.2174/138920007780655397
   Sarkar S, 2011, ANTICANCER RES, V31, P2723
   Sato Y, 2001, LEUKEMIA, V15, P1193, DOI 10.1038/sj.leu.2402188
   Shin DH, 2010, FREE RADICAL BIO MED, V48, P1051, DOI 10.1016/j.freeradbiomed.2010.01.021
   Simonini PDR, 2010, CANCER RES, V70, P9175, DOI 10.1158/0008-5472.CAN-10-1318
   Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420
   Tellez CS, 2011, CANCER RES, V71, P3087, DOI 10.1158/0008-5472.CAN-10-3035
   Tsai KW, 2009, EPIGENETICS-US, V4, P587, DOI 10.4161/epi.4.8.10230
   Uhlmann S, 2010, ONCOGENE, V29, P4297, DOI 10.1038/onc.2010.201
   Voorhoeve PM, 2007, BBA-REV CANCER, V1775, P274, DOI 10.1016/j.bbcan.2006.11.003
   Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697
   Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101
   Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228
   Yang MH, 2011, BREAST CANCER RES TR, V129, P983, DOI 10.1007/s10549-011-1604-1
   Yao YA, 2010, BREAST CANCER RES TR, V124, P585, DOI 10.1007/s10549-010-1023-8
   Yao Y, 2010, CARCINOGENESIS, V31, P382, DOI 10.1093/carcin/bgp308
   Yu SW, 2007, CURR CANCER DRUG TAR, V7, P416
   Zhang P, 2010, MOL CANCER THER, V9, P336, DOI 10.1158/1535-7163.MCT-09-0589
   Zhou H, 2010, NUCLEIC ACIDS RES, V38, P3619, DOI 10.1093/nar/gkq084
   Zimmerman AL, 2011, CANCER LETT, V300, P10, DOI 10.1016/j.canlet.2010.09.019
NR 52
TC 258
Z9 288
U1 0
U2 28
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 25
PY 2011
VL 286
IS 47
BP 40725
EP 40733
DI 10.1074/jbc.M111.275495
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 852AN
UT WOS:000297315400033
PM 21926171
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Indra, DM
   Mitra, S
   Roy, A
   Mondal, RK
   Basu, PS
   Roychoudhury, S
   Chakravarty, R
   Panda, CK
AF Indra, Dipanjana Mazumder
   Mitra, Sraboni
   Roy, Anup
   Mondal, Ranajit Kumar
   Basu, Partha Sarathi
   Roychoudhury, Susanta
   Chakravarty, Runu
   Panda, Chinmay Kumar
TI Alterations of ATM and CADM1 in chromosomal 11q22.3-23.2 region are
   associated with the development of invasive cervical carcinoma
SO HUMAN GENETICS
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; TUMOR-SUPPRESSOR GENE; COMPLEX-II GENE;
   PROMOTER METHYLATION; PPP2R1B GENE; NUCLEAR-LOCALIZATION; ADHESION
   MOLECULE; BREAST-CANCER; CYTOCHROME-B; TSLC1 GENE
AB To understand the importance of chr11q22.3-23.2 region in the development of cervical cancer, we have studied the genetic and epigenetic alterations of the candidate genes ATM, PPP2R1B, SDHD and CADM1 in cervical intraepithelial neoplasia (CIN) and cervical carcinoma (CACX) samples. Our study revealed low expression and high alterations (methylation/deletion) (55-59%) of ATM and CADM1 genes along with poor patient outcome. The alterations of ATM and CADM1 are associated with the progression of tumor from CIN to Stage I/II, thus implying their role in early invasiveness. The two genes, PPP2R1B and SDHD, lying in between ATM and CADM1, have low frequency of alterations, and majority of the alterations are in CACX samples, indicating that their alterations might be associated with disease progression. Expressions (mRNA/protein) of the genes showed concordance with their molecular alterations. Significant co-alteration of ATM and CADM1 points to their synergic action for the development of CACX. Mutation is, however, a rare phenomenon for inactivation of ATM. Association between the alteration of ATM and CHEK1 and poor survival of the patients having co-alterations of ATM and CHEK1 points to the DNA damage response pathway disruption in development of CACX. Thus, our data suggest that inactivation of ATM-CHEK1-associated DNA damage response pathway and CADM1-associated signaling network might have an important role in the development of CACX.
C1 [Indra, Dipanjana Mazumder; Mitra, Sraboni; Panda, Chinmay Kumar] Chittaranjan Natl Canc Inst, Dept Oncogene Regulat, Kolkata 700026, India.
   [Roy, Anup] Midnapore Med Coll & Hosp, Dept Pathol, Paschim Medinipur, India.
   [Mondal, Ranajit Kumar; Basu, Partha Sarathi] Chittaranjan Natl Canc Inst, Dept Gynaecol Oncol, Kolkata, India.
   [Roychoudhury, Susanta] CSIR, Mol & Human Genet Div, Indian Inst Chem Biol, Kolkata, India.
   [Chakravarty, Runu] ICMR Virus Unit, Kolkata, India.
C3 Midnapore Medical College; Council of Scientific & Industrial Research
   (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB);
   Indian Council of Medical Research (ICMR); ICMR - National Institute of
   Cholera & Enteric Diseases (NICED); ICMR - Virus Unit, Kolkata
RP Panda, CK (通讯作者)，Chittaranjan Natl Canc Inst, Dept Oncogene Regulat, 37 SP Mukherjee Rd, Kolkata 700026, India.
EM ckpanda.cnci@gmail.com
RI Roychoudhury, Susanta/AAD-7946-2021
FU Council of Scientific and Industrial Research (CSIR), Government of
   India [27 (0111)/00/EMR-II]; CSIR-JRF/NET; CSIR [IAP-001];  [no
   9/30(44)/2005-EMR-I]
FX We are thankful to The Director, Chittaranjan National Cancer Institute,
   Kolkata, India for active encouragement during this work. We extend our
   gratitude to Professors H. zur Hausen and E. M. de Villiers for their
   generous gifts of HPV16/18 plasmids. Financial support for this work was
   provided by grants [no. 27 (0111)/00/EMR-II] from Council of Scientific
   and Industrial Research (CSIR), Government of India to Dr. C. K. Panda,
   CSIR-JRF/NET and Fellowship grant (no 9/30(44)/2005-EMR-I) to Ms. D.
   Indra and CSIR-Project (IAP-001) to Dr. S. Roychoudhury.
CR Ai LB, 2004, CANCER EPIDEM BIOMAR, V13, P150, DOI 10.1158/1055-9965.EPI-082-3
   [Anonymous], 1989, Molecular Cloning, A Laboratory Manual
   Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848
   Carpenter G, 2003, CURR OPIN CELL BIOL, V15, P143, DOI 10.1016/S0955-0674(03)00015-2
   Chakrabarti S, 2001, INT J CANCER, V92, P555, DOI 10.1002/ijc.1233
   Chou HC, 2007, CANCER LETT, V253, P138, DOI 10.1016/j.canlet.2007.01.016
   Chunder N, 2004, DIAGN MOL PATHOL, V13, P172, DOI 10.1097/01.pas.0000124337.49401.0b
   Davis M, 1996, CANCER RES, V56, P741
   De Preter K, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-55
   Fukami T, 2003, INT J CANCER, V107, P53, DOI 10.1002/ijc.11348
   Gentile M, 2001, ONCOGENE, V20, P7753, DOI 10.1038/sj.onc.1204993
   Ghosh S, 2008, INT J CANCER, V123, P2594, DOI 10.1002/ijc.23834
   Gimm O, 2000, CANCER RES, V60, P6822
   Goodarzi AA, 2004, EMBO J, V23, P4451, DOI 10.1038/sj.emboj.7600455
   Habano W, 2003, ONCOL REP, V10, P1375
   HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953
   Hemmer S, 2002, CANCER GENET CYTOGEN, V134, P13, DOI 10.1016/S0165-4608(01)00597-0
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hirawake H, 1997, CYTOGENET CELL GENET, V79, P132, DOI 10.1159/000134700
   Hirawake H, 1999, BBA-BIOENERGETICS, V1412, P295, DOI 10.1016/S0005-2728(99)00071-7
   Huang Katie T, 2009, BMC Res Notes, V2, P194, DOI 10.1186/1756-0500-2-194
   Hui ABY, 2002, INT J CANCER, V97, P875, DOI 10.1002/ijc.10066
   Khanna KK, 2000, JNCI-J NATL CANCER I, V92, P795, DOI 10.1093/jnci/92.10.795
   Kim WJ, 2002, ONCOGENE, V21, P3864, DOI 10.1038/sj.onc.1205485
   KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103
   Kozlov SV, 2006, EMBO J, V25, P3504, DOI 10.1038/sj.emboj.7601231
   Laake K, 1997, GENE CHROMOSOME CANC, V18, P175, DOI 10.1002/(SICI)1098-2264(199703)18:3<175::AID-GCC4>3.3.CO;2-R
   Lazo PA, 1999, BRIT J CANCER, V80, P2008, DOI 10.1038/sj.bjc.6690635
   Lee ASG, 2000, BRIT J CANCER, V83, P750, DOI 10.1054/bjoc.2000.1366
   Li JD, 2005, GYNECOL ONCOL, V96, P150, DOI 10.1016/j.ygyno.2004.08.050
   Li W, 2006, INT J GYNECOL CANCER, V16, P1620, DOI 10.1111/j.1525-1438.2006.00636.x
   Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Loginov VI, 2004, MOL BIOL+, V38, P549, DOI 10.1023/B:MBIL.0000037007.71787.b9
   Masuda M, 2002, J BIOL CHEM, V277, P31014, DOI 10.1074/jbc.M203620200
   Mazumder D, 2011, INT J CANCER, V129, P1859, DOI 10.1002/ijc.25849
   MISRA BC, 1989, AM J HUM GENET, V45, P565
   Mitra S, 2010, GENE CHROMOSOME CANC, V49, P155, DOI 10.1002/gcc.20726
   Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886
   Moody CA, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000605
   Murakami Y, 2005, CANCER SCI, V96, P543, DOI 10.1111/j.1349-7006.2005.00089.x
   NEGRINI M, 1995, CANCER RES, V55, P3003
   Overmeer RM, 2008, J PATHOL, V215, P388, DOI 10.1002/path.2367
   Perrone F, 2006, CLIN CANCER RES, V12, P6643, DOI 10.1158/1078-0432.CCR-06-1759
   Pisani P, 2002, INT J CANCER, V97, P72, DOI 10.1002/ijc.1571
   Pugh TJ, 2009, CLIN CANCER RES, V15, P5008, DOI 10.1158/1078-0432.CCR-08-3357
   Pulido HA, 2000, CANCER RES, V60, P6677
   SCHIFFMAN MH, 1995, CANCER-AM CANCER SOC, V76, P1888, DOI 10.1002/1097-0142(19951115)76:10+<1888::AID-CNCR2820761305>3.0.CO;2-H
   Shingai T, 2003, J BIOL CHEM, V278, P35421, DOI 10.1074/jbc.M305387200
   Singh RK, 2005, J CANCER RES CLIN, V131, P395, DOI 10.1007/s00432-004-0655-7
   Steenbergen RDM, 2004, JNCI-J NATL CANCER I, V96, P294, DOI 10.1093/jnci/djh031
   Takagi M, 1998, CANCER RES, V58, P4923
   Takagi Y, 2000, GUT, V47, P268, DOI 10.1136/gut.47.2.268
   Thorstenson YR, 2003, CANCER RES, V63, P3325
   Tripathi A, 2003, J CANCER RES CLIN, V129, P642, DOI 10.1007/s00432-003-0485-z
   WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W
   Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284
   Wang SSQ, 1999, GENE CHROMOSOME CANC, V25, P154, DOI 10.1002/(SICI)1098-2264(199906)25:2<154::AID-GCC11>3.3.CO;2-N
   Watabe K, 2003, HISTOL HISTOPATHOL, V18, P1321, DOI 10.14670/HH-18.1321
   Wu Rong, 1999, Neoplasia (New York), V1, P311, DOI 10.1038/sj.neo.7900042
   Xia M.H. P., 2008, J CANC MOL, V4, P79
   Zhang PL, 2003, CANCER BIOL THER, V2, P87
   Zhang ZY, 2005, GENE CHROMOSOME CANC, V43, P95, DOI 10.1002/gcc.20151
   zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690
NR 64
TC 8
Z9 9
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0340-6717
EI 1432-1203
J9 HUM GENET
JI Hum. Genet.
PD DEC
PY 2011
VL 130
IS 6
BP 735
EP 748
DI 10.1007/s00439-011-1015-8
PG 14
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 849MW
UT WOS:000297130600004
PM 21643982
DA 2025-01-12
ER

PT J
AU Radpour, R
   Barekati, Z
   Kohler, C
   Schumacher, MM
   Grussenmeyer, T
   Jenoe, P
   Hartmann, N
   Moes, S
   Letzkus, M
   Bitzer, J
   Lefkovits, I
   Staedtler, F
   Zhong, XY
AF Radpour, Ramin
   Barekati, Zeinab
   Kohler, Corina
   Schumacher, Martin M.
   Grussenmeyer, Thomas
   Jenoe, Paul
   Hartmann, Nicole
   Moes, Suzette
   Letzkus, Martin
   Bitzer, Johannes
   Lefkovits, Ivan
   Staedtler, Frank
   Zhong, Xiao Yan
TI Integrated Epigenetics of Human Breast Cancer: Synoptic Investigation of
   Targeted Genes, MicroRNAs and Proteins upon Demethylation Treatment
SO PLOS ONE
LA English
DT Article
ID DNA METHYLATION; TUMOR-SUPPRESSOR; MYELODYSPLASTIC SYNDROMES;
   POOR-PROGNOSIS; LUNG-CANCER; CELL-LINES; PHASE-III; IN-VIVO; EXPRESSION;
   METASTASIS
AB Background: The contribution of aberrant DNA methylation in silencing of tumor suppressor genes (TSGs) and microRNAs has been investigated. Since these epigenetic alterations are reversible, it became of interest to determine the effects of the 5-aza-2'-deoxycytidine (DAC) demethylation therapy in breast cancer at different molecular levels.
   Methods and Findings: Here we investigate a synoptic model to predict complete DAC treatment effects at the level of genes, microRNAs and proteins for several human breast cancer lines. The present study assessed an effective treatment dosage based on the cell viability, cytotoxicity, apoptosis and methylation assays for the investigated cell lines. A highly aggressive and a non-aggressive cell line were investigated using omics approaches such as MALDI-TOF MS, mRNA- and microRNA expression arrays, 2-D gel electrophoresis and LC-MS-MS. Complete molecular profiles including the biological interaction and possible early and late systematic stable or transient effects of the methylation inhibition were determined. Beside the activation of several epigenetically suppressed TSGs, we also showed significant dysregulation of some important oncogenes, oncomiRs and oncosuppressors miRNAs as well as drug tolerance genes/miRNAs/proteins.
   Conclusions: In the present study, the results denote some new molecular DAC targets and pathways based on the chemical modification of DNA methylation in breast cancer. The outlined approach might prove to be useful as an epigenetic treatment model also for other human solid tumors in the management of cancer patients.
C1 [Radpour, Ramin; Barekati, Zeinab; Kohler, Corina; Zhong, Xiao Yan] Univ Basel, Lab Gynecol Oncol, Womens Hosp, Dept Biomed, Basel, Switzerland.
   [Schumacher, Martin M.; Hartmann, Nicole; Letzkus, Martin; Staedtler, Frank] Novartis Pharma AG, Biomarker Dev, Novartis Inst BioMed Res, Basel, Switzerland.
   [Grussenmeyer, Thomas; Lefkovits, Ivan] Univ Basel Hosp, Dept Biomed, CH-4031 Basel, Switzerland.
   [Grussenmeyer, Thomas; Lefkovits, Ivan] Univ Basel Hosp, Dept Cardiac Surg, CH-4031 Basel, Switzerland.
   [Jenoe, Paul; Moes, Suzette] Univ Basel, Biozentrum, Basel, Switzerland.
   [Bitzer, Johannes] Univ Basel, Dept Obstet & Gynecol, Womens Hosp, Basel, Switzerland.
C3 University of Basel; Novartis; University of Basel; University of Basel;
   University of Basel; University of Basel
RP Radpour, R (通讯作者)，Univ Basel, Lab Gynecol Oncol, Womens Hosp, Dept Biomed, Basel, Switzerland.
EM ivan.lefkovits@unibas.ch; frank.staedtler@novartis.com; zhongx@uhbs.ch
RI Kohler, Corina/KTH-9502-2024; Grussenmeyer, Thomas/B-9859-2009; Scholz,
   Nicole/LMO-5798-2024; Radpour, PD Dr. Ramin/J-4949-2014; Lefkovits,
   Ivan/B-9777-2009
OI Radpour, PD Dr. Ramin/0000-0002-5632-7833; Schumacher, Martin
   Max/0000-0001-9538-8682; Lefkovits, Ivan/0000-0003-1783-8881
FU Swiss National Science Foundation Basel, Switzerland [320000-119722/1,
   320030_124958/1]; Swiss National Science Foundation (SNF)
   [320030_124958] Funding Source: Swiss National Science Foundation (SNF)
FX This work was supported in part by Swiss National Science Foundation
   (320000-119722/1 and 320030_124958/1) Basel, Switzerland. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Bachmeier BE, 2008, CARCINOGENESIS, V29, P779, DOI 10.1093/carcin/bgm248
   Barekati Z, 2010, HUM MOL GENET, V19, P2936, DOI 10.1093/hmg/ddq199
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   BERDICHEVSKY F, 1994, J CELL SCI, V107, P3557
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263
   Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137
   CHANDRASEKARAN EV, 1979, CANCER RES, V39, P870
   Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036
   Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Fabbri M, 2007, EXPERT OPIN BIOL TH, V7, P1009, DOI 10.1517/14712598.7.7.1009
   Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104
   Fenaux P, 2009, LANCET ONCOL, V10, P223, DOI 10.1016/S1470-2045(09)70003-8
   Frank NY, 2010, J CLIN INVEST, V120, P41, DOI 10.1172/JCI41004
   Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200
   Fujita T, 2006, CYTOKINE, V34, P271, DOI 10.1016/j.cyto.2006.06.002
   Garzon R, 2009, BLOOD, V113, P6411, DOI 10.1182/blood-2008-07-170589
   Gatlin CL, 2000, ANAL CHEM, V72, P757, DOI 10.1021/ac991025n
   Gumireddy K, 2007, P NATL ACAD SCI USA, V104, P6696, DOI 10.1073/pnas.0701145104
   Han HJ, 2008, NATURE, V452, P187, DOI 10.1038/nature06781
   Hong DS, 2007, CANCER-AM CANCER SOC, V110, P1911, DOI 10.1002/cncr.22999
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Issa Jean-Pierre, 2003, Current Opinion in Oncology, V15, P446, DOI 10.1097/00001622-200311000-00007
   Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640
   Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1794, DOI 10.1002/cncr.21792
   Kishimoto T, 2005, ANNU REV IMMUNOL, V23, P1, DOI 10.1146/annurev.immunol.23.021704.115806
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lal A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001864
   Li JP, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-354
   Li Min, 2005, Archives of Gynecology and Obstetrics, V272, P48, DOI 10.1007/s00404-004-0708-9
   Lin RK, 2007, LUNG CANCER, V55, P205, DOI 10.1016/j.lungcan.2006.10.022
   LittlewoodEvans AJ, 1997, CANCER RES, V57, P5386
   Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   Ma J, 2010, CANCER GENE THER, V17, P523, DOI 10.1038/cgt.2010.18
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200
   Mertens-Talcott SU, 2007, CANCER RES, V67, P11001, DOI 10.1158/0008-5472.CAN-07-2416
   Métivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544
   Moggs JG, 2004, TOXICOL APPL PHARM, V196, P422, DOI 10.1016/j.taap.2004.01.009
   Momparler RL, 2005, SEMIN ONCOL, V32, P443, DOI 10.1053/j.seminoncol.2005.07.008
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   MUSGROVE EA, 1995, INT J CANCER, V63, P584, DOI 10.1002/ijc.2910630420
   Plante I., 2010, ONCOGENE
   POLLACK MS, 1981, JNCI-J NATL CANCER I, V66, P1003, DOI 10.1093/jnci/66.6.1003
   Radpour R, 2009, ONCOGENE, V28, P2969, DOI 10.1038/onc.2009.149
   Radpour R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016080
   Radpour R, 2009, J PROTEOME RES, V8, P5264, DOI 10.1021/pr900591w
   Radpour R, 2009, GENET TEST MOL BIOMA, V13, P565, DOI 10.1089/gtmb.2009.0060
   Redmond KM, 2008, FRONT BIOSCI-LANDMRK, V13, P5138, DOI 10.2741/3070
   Rivenbark AG, 2007, EXP MOL PATHOL, V83, P188, DOI 10.1016/j.yexmp.2007.03.008
   Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1
   Rubin I, 2001, ANN ONCOL, V12, P3, DOI 10.1023/A:1011195320446
   Savarese F, 2009, GENE DEV, V23, P2625, DOI 10.1101/gad.1815709
   Schafer ZT, 2007, J CLIN INVEST, V117, P3660, DOI 10.1172/JCI34237
   Scott GK, 2007, J BIOL CHEM, V282, P1479, DOI 10.1074/jbc.M609383200
   Shi LM, 2010, NAT BIOTECHNOL, V28, P827, DOI 10.1038/nbt.1665
   Simstein R, 2003, EXP BIOL MED, V228, P995, DOI 10.1177/153537020322800903
   SMITH HS, 1979, JNCI-J NATL CANCER I, V62, P225
   Subramaniam Deepa S, 2005, Curr Treat Options Oncol, V6, P147, DOI 10.1007/s11864-005-0022-1
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329
   Tsuchiya Y, 2006, CANCER RES, V66, P9090, DOI 10.1158/0008-5472.CAN-06-1403
   Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675
   Wu BL, 2010, SCIENCE, V330, P1066, DOI 10.1126/science.1194396
   Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973
   Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24
NR 70
TC 41
Z9 45
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 4
PY 2011
VL 6
IS 11
AR e27355
DI 10.1371/journal.pone.0027355
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 850MH
UT WOS:000297198200068
PM 22076154
OA gold, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Meng, Y
   Wang, QG
   Wang, JX
   Zhu, ST
   Jiao, Y
   Li, P
   Zhang, ST
AF Meng, Ying
   Wang, Qing-Gang
   Wang, Jun-Xiong
   Zhu, Sheng-tao
   Jiao, Yue
   Li, Peng
   Zhang, Shu-tian
TI Epigenetic Inactivation of the SFRP1 Gene in Esophageal Squamous Cell
   Carcinoma
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Esophageal squamous cell carcinoma; DNA methylation; SFRP1; Acetylation
ID CANDIDATE TUMOR-SUPPRESSOR; WNT ANTAGONIST SFRP1; DNA METHYLATION;
   HEPATOCELLULAR-CARCINOMA; HISTONE DEACETYLATION; PROMOTER METHYLATION;
   BARRETTS-ESOPHAGUS; CPG METHYLATION; BREAST-CANCER; LUNG-CANCER
AB Introduction The secreted frizzled-related protein 1 (SFRP1) gene, as a Wnt signaling modulator, is frequently inactivated by promoter methylation in many tumors including gastric cancer, breast cancer, oral squamous cell carcinoma, and esophageal adenocarcinoma. However, the role of SFRP1 in esophageal squamous cell carcinoma (ESCC) is not clear. In this study, we investigated the epigenetic inactivation of the SFRP1 gene in ESCC.
   Methods Nine ESCC cell lines, two immortalized human esophageal epithelial cell lines, twenty ESCC tissues, and paired adjacent nontumor tissues were analyzed in the study. Methylation-specific polymerase chain reaction (PCR), bisulfite sequencing, reverse-transcription PCR, immunohistochemistry, and chromatin immunoprecipitation assay were used to detect SFRP1 promoter methylation, expression of the SFRP1 gene, and histone modification in the SFRP1 promoter region.
   Results The SFRP1 promoter was found to be highly methylated in 95% (19/20) of the ESCC tissues and in nine ESCC cell lines, compared with 65% (13/20) of the paired nontumor tissues. Moreover, we confirmed that complete methylation of the SFRP1 gene promoter was correlated with its greatly reduced expression level. After individual treatment with 5-aza-2'-deoxycytidine (DAC) and trichostatin A (TSA), the messenger RNA (mRNA) level of the SFRP1 gene was not obviously rescued in the EC9706 cell line. Combined incubation with DAC and TSA can, however, substantially increase the SFRP1 mRNA expression level in the EC9706 cell line. Chromatin immunoprecipitation assay showed that acetylated histone H3 and H4 were found in the SFRP1 promoter region.
   Conclusion Promoter hypermethylation of SFRP1 is a frequent event in ESCC. Promoter methylation and histone acetylation may cooperatively regulate expression of the SFRP1 gene.
C1 [Meng, Ying; Wang, Qing-Gang; Wang, Jun-Xiong; Zhu, Sheng-tao; Jiao, Yue; Li, Peng; Zhang, Shu-tian] Capital Med Univ, Dept Gastroenterol, Beijing Friendship Hosp, Beijing 100050, Peoples R China.
C3 Capital Medical University
RP Zhang, ST (通讯作者)，Capital Med Univ, Dept Gastroenterol, Beijing Friendship Hosp, 95 Yongan Rd, Beijing 100050, Peoples R China.
EM zhang-2288@163.com
FU National Natural Science Foundation of China [81050016]; Ph.D. Programs
   Foundation of the Ministry of Education of China [200800250003]; Beijing
   Municipal Science and Technology Commission [Z101100055610031]
FX This work was supported by the National Natural Science Foundation of
   China (81050016), the Ph.D. Programs Foundation of the Ministry of
   Education of China (200800250003), and the Beijing Municipal Science and
   Technology Commission Project (Z101100055610031).
CR Ali I, 2009, J CLIN GASTROENTEROL, V43, P327, DOI 10.1097/MCG.0b013e31816256ff
   Aragonés N, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-3
   Armes JE, 2004, ONCOGENE, V23, P5697, DOI 10.1038/sj.onc.1207740
   Awakura Y, 2008, ONCOL REP, V20, P1257, DOI 10.3892/or_00000138
   Baylin SB, 2002, SEMIN CANCER BIOL, V12, P331, DOI 10.1016/S1044-579X(02)00053-6
   Belinsky SA, 2003, CANCER RES, V63, P7089
   Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   Brock MV, 2008, NEW ENGL J MED, V358, P1118, DOI 10.1056/NEJMoa0706550
   Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286
   Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200
   Chiurazzi P, 1999, HUM MOL GENET, V8, P2317, DOI 10.1093/hmg/8.12.2317
   Chung MT, 2009, GYNECOL ONCOL, V112, P301, DOI 10.1016/j.ygyno.2008.10.004
   Clément G, 2006, ONCOGENE, V25, P3084, DOI 10.1038/sj.onc.1209338
   Corrao G, 2004, PREV MED, V38, P613, DOI 10.1016/j.ypmed.2003.11.027
   Egger G, 2007, CANCER RES, V67, P346, DOI 10.1158/0008-5472.CAN-06-2845
   Engel LS, 2003, J NATL CANCER I, V95, P1404, DOI 10.1093/jnci/djg047
   Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770
   Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536
   Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750
   Guo MZ, 2006, CLIN CANCER RES, V12, P4515, DOI 10.1158/1078-0432.CCR-05-2858
   He J, 2006, J BIOL CHEM, V281, P35598, DOI 10.1074/jbc.C600200200
   He YL, 2011, DIGEST DIS SCI, V56, P681, DOI 10.1007/s10620-010-1369-0
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hu J, 2009, CANCER RES, V69, P6951, DOI 10.1158/0008-5472.CAN-09-0541
   Huang J, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-126
   Ishii T, 2007, GUT, V56, P13, DOI 10.1136/gut.2005.089813
   Kapoor-Vazirani P, 2008, CANCER RES, V68, P6810, DOI 10.1158/0008-5472.CAN-08-0141
   Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602
   Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407
   Marsit CJ, 2006, INT J CANCER, V119, P1761, DOI 10.1002/ijc.22051
   Milde-Langosch K, 2001, BREAST CANCER RES TR, V67, P61, DOI 10.1023/A:1010623308275
   Nojima M, 2007, ONCOGENE, V26, P4699, DOI 10.1038/sj.onc.1210259
   Plumb JA, 2004, BIOCHEM SOC T, V32, P1095, DOI 10.1042/BST0321095
   Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124
   Smith E, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-75
   Steele N, 2009, BRIT J CANCER, V100, P758, DOI 10.1038/sj.bjc.6604932
   Sundararaj KP, 2004, J BIOL CHEM, V279, P6152, DOI 10.1074/jbc.M310549200
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Ushijima T, 2007, J BIOCHEM MOL BIOL, V40, P142
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Wang Y, 2009, CANCER RES, V69, P5194, DOI 10.1158/0008-5472.CAN-08-3694
   Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154
   Yokokawa Y, 1999, INT J CANCER, V83, P620, DOI 10.1002/(SICI)1097-0215(19991126)83:5<620::AID-IJC9>3.0.CO;2-W
   Yu J, 2008, HEPATOLOGY, V48, P508, DOI 10.1002/hep.22343
   Zhang C, 2007, J PATHOL, V212, P134, DOI 10.1002/path.2173
   Zhang WM, 2005, ONCOL REP, V13, P1095
NR 48
TC 26
Z9 28
U1 0
U2 10
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD NOV
PY 2011
VL 56
IS 11
BP 3195
EP 3203
DI 10.1007/s10620-011-1734-7
PG 9
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 843AE
UT WOS:000296643400013
PM 21567192
DA 2025-01-12
ER

PT J
AU Katoh, H
   Qin, ZHS
   Liu, RH
   Wang, LZ
   Li, WQ
   Li, XZ
   Wu, LP
   Du, ZW
   Lyons, R
   Liu, CG
   Liu, XP
   Dou, YL
   Zheng, P
   Liu, Y
AF Katoh, Hiroto
   Qin, Zhaohui S.
   Liu, Runhua
   Wang, Lizhong
   Li, Weiquan
   Li, Xiangzhi
   Wu, Lipeng
   Du, Zhanwen
   Lyons, Robert
   Liu, Chang-Gong
   Liu, Xiuping
   Dou, Yali
   Zheng, Pan
   Liu, Yang
TI FOXP3 Orchestrates H4K16 Acetylation and H3K4 Trimethylation for
   Activation of Multiple Genes by Recruiting MOF and Causing Displacement
   of PLU-1
SO MOLECULAR CELL
LA English
DT Article
ID HISTONE ACETYLTRANSFERASE; BREAST-CANCER; TARGET GENES; H4-K16
   ACETYLATION; SUPPRESSOR GENE; PROTEIN; METHYLATION; H4; REPRESSOR;
   LYSINE-4
AB Both H4K16 acetylation and H3K4 trimethylation are required for gene activation. However, it is still largely unclear how these modifications are orchestrated by transcriptional factors. Here, we analyzed the mechanism of the transcriptional activation by FOXP3, an X-linked suppressor of autoimmune diseases and cancers. FOXP3 binds near transcriptional start sites of its target genes. By recruiting MOF and displacing histone H3K4 demethylase PLU-1, FOXP3 increases both H4K16 acetylation and H3K4 trimethylation at the FOXP3-associated chromatins of multiple FOXP3-activated genes. RNAi-mediated silencing of MOF reduced both gene activation and tumor suppression by FOXP3, while both somatic mutations in clinical cancer samples and targeted mutation of FOXP3 in mouse prostate epithelial cells disrupted nuclear localization of MOF. Our data demonstrate a pull-push model in which a single transcription factor orchestrates two epigenetic alterations necessary for gene activation and provide a mechanism for somatic inactivation of the FOXP3 protein function in cancer cells.
C1 [Katoh, Hiroto; Liu, Runhua; Wang, Lizhong; Li, Weiquan; Zheng, Pan; Liu, Yang] Univ Michigan, Sch Med, Dept Surg, Div Immunotherapy, Ann Arbor, MI 48109 USA.
   [Katoh, Hiroto; Liu, Runhua; Wang, Lizhong; Li, Weiquan; Zheng, Pan; Liu, Yang] Univ Michigan, Ctr Canc, Ann Arbor, MI 48109 USA.
   [Qin, Zhaohui S.] Emory Univ, Ctr Comprehens Informat, Rollins Sch Publ Hlth, Dept Biostat & Bioinformat, Atlanta, GA 30329 USA.
   [Li, Xiangzhi; Wu, Lipeng; Dou, Yali; Zheng, Pan; Liu, Yang] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.
   [Lyons, Robert; Dou, Yali] Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.
   [Liu, Yang] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA.
   [Du, Zhanwen] Chinese Acad Sci, Inst Biophys, State Key Lab Macromol, Beijing 100080, Peoples R China.
   [Du, Zhanwen] Chinese Acad Sci, Inst Biophys, Key Lab Infect & Immun, Beijing 100080, Peoples R China.
   [Lyons, Robert] Univ Michigan, DNA Sequencing Core, Ann Arbor, MI 48109 USA.
   [Liu, Chang-Gong; Liu, Xiuping] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; Emory University; Rollins
   School Public Health; University of Michigan System; University of
   Michigan; University of Michigan System; University of Michigan;
   University of Michigan System; University of Michigan; Chinese Academy
   of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences;
   Institute of Biophysics, CAS; University of Michigan System; University
   of Michigan; University of Texas System; UTMD Anderson Cancer Center
RP Zheng, P (通讯作者)，Univ Michigan, Sch Med, Dept Surg, Div Immunotherapy, Ann Arbor, MI 48109 USA.
EM panz@med.umich.edu; yangl@med.umich.edu
RI Li, Weiquan/B-4897-2011; Liu, Yang/HNJ-6693-2023; Liu,
   Runhua/K-2388-2019; Liu, Chang-Gong/O-6585-2014; Wang,
   Lizhong/J-4268-2019; Qin, Zhaohui/Q-3133-2019; Du, Zhanwen/H-9903-2016;
   Katoh, Hiroto/ADO-8117-2022; Qin, Zhaohui/E-8196-2011; Zheng,
   Pan/E-8691-2011
OI Qin, Zhaohui/0000-0002-1583-146X; Liu, Yang/0000-0002-9442-700X; Zheng,
   Pan/0000-0003-2598-3544
FU Department of Defense; National Institutes of Health; U.S. Department of
   Defense; Ministry of Sciences and Technology of China [2009DFB30310]
FX H.K. is a recipient of a Postdoctoral Fellowship Award from the Breast
   Cancer Research Program, Department of Defense. This work has been
   supported by grants from the National Institutes of Health and the U.S.
   Department of Defense and a grant from the Ministry of Sciences and
   Technology of China (2009DFB30310). We are grateful to Jindan Yu for
   critical reading of the manuscript and Chun-Shu Wong for editorial
   assistance.
CR Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713
   Birzele F, 2011, NUCLEIC ACIDS RES, V39, P7946, DOI 10.1093/nar/gkr444
   Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784
   Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473
   Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679
   Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876
   Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672
   Dion MF, 2005, P NATL ACAD SCI USA, V102, P5501, DOI 10.1073/pnas.0500136102
   Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031
   Duns G, 2010, CANCER RES, V70, P4287, DOI 10.1158/0008-5472.CAN-10-0120
   Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Katoh H, 2010, INT J BIOCHEM CELL B, V42, P1784, DOI 10.1016/j.biocel.2010.07.015
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kwon SY, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000574
   Ladoire S, 2011, BREAST CANCER RES TR, V125, P65, DOI 10.1007/s10549-010-0831-1
   Lee JS, 2010, CELL, V142, P682, DOI 10.1016/j.cell.2010.08.011
   Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145
   Levy D, 2010, CELL, V142, P844, DOI 10.1016/j.cell.2010.08.032
   Li B, 2007, P NATL ACAD SCI USA, V104, P4571, DOI 10.1073/pnas.0700298104
   Li XZ, 2010, MOL CELL BIOL, V30, P5335, DOI 10.1128/MCB.00350-10
   Li XZ, 2010, EPIGENETICS-US, V5
   Liu RH, 2009, CANCER RES, V69, P2252, DOI 10.1158/0008-5472.CAN-08-3717
   Liu Y, 2010, TRENDS GENET, V26, P260, DOI 10.1016/j.tig.2010.03.004
   Lu CH, 2010, CANCER CELL, V18, P185, DOI 10.1016/j.ccr.2010.06.016
   Marson A, 2007, NATURE, V445, P931, DOI 10.1038/nature05478
   Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Mosammaparast N, 2010, ANNU REV BIOCHEM, V79, P155, DOI 10.1146/annurev.biochem.78.070907.103946
   Pan F, 2009, SCIENCE, V325, P1142, DOI 10.1126/science.1176077
   Pan GJ, 2007, CELL STEM CELL, V1, P299, DOI 10.1016/j.stem.2007.08.003
   Pfister S, 2008, INT J CANCER, V122, P1207, DOI 10.1002/ijc.23283
   Qin ZHS, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-369
   Robinson PJJ, 2008, J MOL BIOL, V381, P816, DOI 10.1016/j.jmb.2008.04.050
   Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014
   Ruthenburg AJ, 2011, CELL, V145, P692, DOI 10.1016/j.cell.2011.03.053
   Sadlon TJ, 2010, J IMMUNOL, V185, P1071, DOI 10.4049/jimmunol.1000082
   Sawasdichai A., 2010, JoVE, V41, pe1958
   Scibetta AG, 2007, MOL CELL BIOL, V27, P7220, DOI 10.1128/MCB.00274-07
   Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000
   Smith ER, 2005, MOL CELL BIOL, V25, P9175, DOI 10.1128/MCB.25.21.9175-9188.2005
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Taipale M, 2005, MOL CELL BIOL, V25, P6798, DOI 10.1128/MCB.25.15.6798-6810.2005
   Vastenhouw NL, 2010, NATURE, V464, P922, DOI 10.1038/nature08866
   Vermeulen M, 2010, CELL, V142, P967, DOI 10.1016/j.cell.2010.08.020
   Wang LZ, 2010, DISCOV MED, V10, P322
   Wang LZ, 2009, CANCER CELL, V16, P336, DOI 10.1016/j.ccr.2009.08.016
   Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049
   Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707
   Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815
   Yamane K, 2007, MOL CELL, V25, P801, DOI 10.1016/j.molcel.2007.03.001
   Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018
   Zheng Y, 2007, NATURE, V445, P936, DOI 10.1038/nature05563
   Zuo T, 2007, J CLIN INVEST, V117, P3765, DOI 10.1172/JCI32538
   Zuo T, 2007, CELL, V129, P1275, DOI 10.1016/j.cell.2007.04.034
NR 60
TC 60
Z9 63
U1 0
U2 23
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1097-2765
EI 1097-4164
J9 MOL CELL
JI Mol. Cell
PD DEC 9
PY 2011
VL 44
IS 5
BP 770
EP 784
DI 10.1016/j.molcel.2011.10.012
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 860QK
UT WOS:000297962600012
PM 22152480
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Wrzeszczynski, KO
   Varadan, V
   Byrnes, J
   Lum, E
   Kamalakaran, S
   Levine, DA
   Dimitrova, N
   Zhang, MQ
   Lucito, R
AF Wrzeszczynski, Kazimierz O.
   Varadan, Vinay
   Byrnes, James
   Lum, Elena
   Kamalakaran, Sitharthan
   Levine, Douglas A.
   Dimitrova, Nevenka
   Zhang, Michael Q.
   Lucito, Robert
TI Identification of Tumor Suppressors and Oncogenes from Genomic and
   Epigenetic Features in Ovarian Cancer
SO PLOS ONE
LA English
DT Article
ID OLIGONUCLEOTIDE MICROARRAY ANALYSIS; CIRCULAR BINARY SEGMENTATION;
   HIGH-RESOLUTION METHOD; COPY-NUMBER; BREAST-CANCER; DNA METHYLATION;
   GENE-EXPRESSION; HYPERMETHYLATION; HYBRIDIZATION; CARCINOMAS
AB The identification of genetic and epigenetic alterations from primary tumor cells has become a common method to identify genes critical to the development and progression of cancer. We seek to identify those genetic and epigenetic aberrations that have the most impact on gene function within the tumor. First, we perform a bioinformatic analysis of copy number variation (CNV) and DNA methylation covering the genetic landscape of ovarian cancer tumor cells. We separately examined CNV and DNA methylation for 42 primary serous ovarian cancer samples using MOMA-ROMA assays and 379 tumor samples analyzed by The Cancer Genome Atlas. We have identified 346 genes with significant deletions or amplifications among the tumor samples. Utilizing associated gene expression data we predict 156 genes with altered copy number and correlated changes in expression. Among these genes CCNE1, POP4, UQCRB, PHF20L1 and C19orf2 were identified within both data sets. We were specifically interested in copy number variation as our base genomic property in the prediction of tumor suppressors and oncogenes in the altered ovarian tumor. We therefore identify changes in DNA methylation and expression for all amplified and deleted genes. We statistically define tumor suppressor and oncogenic features for these modalities and perform a correlation analysis with expression. We predicted 611 potential oncogenes and tumor suppressors candidates by integrating these data types. Genes with a strong correlation for methylation dependent expression changes exhibited at varying copy number aberrations include CDCA8, ATAD2, CDKN2A, RAB25, AURKA, BOP1 and EIF2C3. We provide copy number variation and DNA methylation analysis for over 11,500 individual genes covering the genetic landscape of ovarian cancer tumors. We show the extent of genomic and epigenetic alterations for known tumor suppressors and oncogenes and also use these defined features to identify potential ovarian cancer gene candidates.
C1 [Wrzeszczynski, Kazimierz O.; Byrnes, James; Lum, Elena; Zhang, Michael Q.; Lucito, Robert] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA.
   [Varadan, Vinay; Kamalakaran, Sitharthan; Dimitrova, Nevenka] Philips Res N Amer, Briarcliff Manor, NY USA.
   [Levine, Douglas A.] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, New York, NY 10021 USA.
   [Zhang, Michael Q.] Univ Texas Dallas, Dept Mol & Cell Biol, Richardson, TX 75083 USA.
C3 Cold Spring Harbor Laboratory; Philips; Philips Research; Memorial Sloan
   Kettering Cancer Center; University of Texas System; University of Texas
   Dallas
RP Wrzeszczynski, KO (通讯作者)，Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.
EM kwrzesz@cshl.edu
RI Lucito, Robert/AID-7159-2022; Varadan, Vinay/AAC-2520-2020
OI Byrnes, James/0000-0002-4906-0640; Levine, Douglas/0000-0003-1038-8232
FU Department of Defense [W81XWH-05-1-0068]; Starr Foundation; Philips
   Research North America
FX This work was supported by Department of Defense W81XWH-05-1-0068, The
   Starr Foundation (http://www.starrcancer.org) and Philips Research North
   America. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Agarwal R, 2009, TRAFFIC, V10, P1561, DOI 10.1111/j.1600-0854.2009.00969.x
   Andrews J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008665
   Bapat SA, 2010, CANCER RES, V70, P4809, DOI 10.1158/0008-5472.CAN-10-0447
   Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644
   Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166
   Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822
   Bohnert KA, 2009, MOL BIOL CELL, V20, P3646, DOI 10.1091/mbc.E09-04-0289
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
   Bowtell DD, NAT REV CANC, V10, P803
   Burrows JF, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-250
   Carden CP, 2010, DRUG DISCOV TODAY, V15, P88, DOI 10.1016/j.drudis.2009.11.006
   Cerami E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008918
   Chari R, 2010, CANCER METAST REV, V29, P73, DOI 10.1007/s10555-010-9199-2
   Chen S., 2008, CANC BIOL THER, V7
   Cheng KW, 2004, NAT MED, V10, P1251, DOI 10.1038/nm1125
   Ciró M, 2009, CANCER RES, V69, P8491, DOI 10.1158/0008-5472.CAN-09-2131
   de Pontual L, 2007, EUR J CANCER, V43, P2366, DOI 10.1016/j.ejca.2007.07.016
   Degenhardt YY, 2008, CURR OPIN GENET DEV, V18, P68, DOI 10.1016/j.gde.2008.01.005
   Delcuve GP, 2009, J CELL PHYSIOL, V219, P243, DOI 10.1002/jcp.21678
   Despierre E, 2010, GYNECOL ONCOL, V117, P358, DOI 10.1016/j.ygyno.2010.02.012
   Ehrlich M, 2006, CURR TOP MICROBIOL, V310, P251
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Haller F, 2005, CLIN CANCER RES, V11, P6589, DOI 10.1158/1078-0432.CCR-05-0329
   Hansen KD., 2011, Nature Genetics
   Hao M, 2009, J OBSTET GYNAECOL RE, V35, P918, DOI 10.1111/j.1447-0756.2009.01045.x
   Hastings PJ, 2009, NAT REV GENET, V10, P551, DOI 10.1038/nrg2593
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Hicks J, 2006, GENOME RES, V16, P1465, DOI 10.1101/gr.5460106
   Iacobuzio-Donahue CA, 2009, ANNU REV PATHOL-MECH, V4, P229, DOI 10.1146/annurev.pathol.3.121806.151442
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kamalakaran S, 2011, MOL ONCOL, V5, P77, DOI 10.1016/j.molonc.2010.11.002
   Kamalakaran S, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp413
   Kiechle M, 2001, CANCER, V91, P534, DOI 10.1002/1097-0142(20010201)91:3<534::AID-CNCR1031>3.3.CO;2-K
   Laird PW, 2010, NAT REV GENET, V11, P191, DOI 10.1038/nrg2732
   Leary RJ, 2008, P NATL ACAD SCI USA, V105, P16224, DOI 10.1073/pnas.0808041105
   Li ZY, 2010, INT J GYNECOL CANCER, V20, P9, DOI 10.1111/IGC.0b013e3181a9026d
   Lucito R, 2003, GENOME RES, V13, P2291, DOI 10.1101/gr.1349003
   Lucito R, 1998, P NATL ACAD SCI USA, V95, P4487, DOI 10.1073/pnas.95.8.4487
   Lucito R, 2009, METHODS MOL BIOL, V556, P33, DOI 10.1007/978-1-60327-192-9_4
   McDermott U, 2011, NEW ENGL J MED, V364, P340, DOI 10.1056/NEJMra0907178
   Meinhold-Heerlein I, 2005, ONCOGENE, V24, P1053, DOI 10.1038/sj.onc.1208298
   Nakayama K, 2007, INT J CANCER, V120, P2613, DOI 10.1002/ijc.22609
   Narayan G, 2009, GENE CHROMOSOME CANC, V48, P983, DOI 10.1002/gcc.20703
   Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858
   Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017
   Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008
   Pereg Y, 2010, NAT CELL BIOL, V12, P400, DOI 10.1038/ncb2041
   Pinkel D, 2005, NAT GENET, V37, pS11, DOI 10.1038/ng1569
   Ramakrishna M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009983
   Reitman ZJ, 2010, J NATL CANC I
   Sadikovic B, 2008, CURR GENOMICS, V9, P394, DOI 10.2174/138920208785699580
   Santarius T, 2010, NAT REV CANCER, V10, P59, DOI 10.1038/nrc2771
   Sawyers CL, 2008, NATURE, V452, P548, DOI 10.1038/nature06913
   Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918
   Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943
   Taylor BS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003179
   Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906
   Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571
   Vang R, 2009, ADV ANAT PATHOL, V16, P267, DOI 10.1097/PAP.0b013e3181b4fffa
   Vaske CJ, 2010, BIOINFORMATICS, V26, pi237, DOI 10.1093/bioinformatics/btq182
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   Venkatraman ES, 2007, BIOINFORMATICS, V23, P657, DOI 10.1093/bioinformatics/btl646
   Wimmer K, 2002, GENE CHROMOSOME CANC, V33, P285, DOI 10.1002/gcc.10030
   Yap TA, 2009, NAT REV CANCER, V9, P167, DOI 10.1038/nrc2583
   Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275
   Yu JS, 2008, ONCOGENE, V27, P4657, DOI 10.1038/onc.2008.101
NR 70
TC 81
Z9 94
U1 0
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 8
PY 2011
VL 6
IS 12
AR e28503
DI 10.1371/journal.pone.0028503
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 863KY
UT WOS:000298163600029
PM 22174824
OA gold, Green Submitted, Green Accepted, Green Published
DA 2025-01-12
ER

PT J
AU Xu, XR
   Gammon, MD
   Jefferson, E
   Zhang, YJ
   Cho, YH
   Wetmur, JG
   Teitelbaum, SL
   Bradshaw, PT
   Terry, MB
   Garbowski, G
   Hibshoosh, H
   Neugut, AI
   Santella, RM
   Chen, J
AF Xu, Xinran
   Gammon, Marilie D.
   Jefferson, Elizabeth
   Zhang, Yujing
   Cho, Yoon Hee
   Wetmur, James G.
   Teitelbaum, Susan L.
   Bradshaw, Patrick T.
   Terry, Mary Beth
   Garbowski, Gail
   Hibshoosh, Hanina
   Neugut, Alfred I.
   Santella, Regina M.
   Chen, Jia
TI The influence of one-carbon metabolism on gene promoter methylation in a
   population-based breast cancer study
SO EPIGENETICS
LA English
DT Article
DE epigenetics; DNA methylation; one-carbon; B vitamins; genetic
   polymorphism
ID CPG ISLAND HYPERMETHYLATION; SPORADIC COLORECTAL-CANCER; MODERATE
   FOLATE-DEPLETION; GENOMIC DNA METHYLATION; GERM-LINE VARIANTS; REDUCTASE
   GENE; LONG-ISLAND; EXPRESSION; TUMORS; WOMEN
AB Abnormal methylation in gene promoters is a hallmark of the cancer genome; however, factors that may influence promoter methylation have not been well elucidated. As the one-carbon metabolism pathway provides the universal methyl donor for methylation reactions, perturbation of this pathway might influence DNA methylation and, ultimately, affect gene functions. Utilizing approximately 800 breast cancer tumor tissues from a large population-based study, we investigated the relationships between dietary and genetic factors involved in the one-carbon metabolism pathway and promoter methylation of a panel of 13 breast cancer-related genes. We found that CCND2, HIN1 and CHD1 were the most "dietary sensitive" genes, as methylation of their promoters was associated with intakes of at least two out of the eight dietary methyl factors examined. On the other hand, some micronutrients (i.e., B-2 and B-6) were more "epigenetically active" as their intake levels correlated with promoter methylation status in 3 out of the 13 breast cancer genes evaluated. Both positive (hypermethylation) and inverse (hypomethylation) associations with high micronutrient intake were observed. Unlike what we saw for dietary factors, we did not observe any clear patterns between one-carbon genetic polymorphisms and the promoter methylation status of the genes examined. Our results provide preliminary evidence that one-carbon metabolism may have the capacity to influence the breast cancer epigenome. Given that epigenetic alterations are thought to occur early in cancer development and are potentially reversible, dietary modifications may offer promising venues for cancer intervention and prevention.
C1 [Xu, Xinran] Tongji Univ, Res Ctr Translat Med, Shanghai E Hosp, Sch Med, Shanghai 200092, Peoples R China.
   [Xu, Xinran] Tongji Univ, Sch Med, Shanghai E Hosp, Key Lab Arrhythmias,Minist Educ, Shanghai 200092, Peoples R China.
   [Gammon, Marilie D.; Bradshaw, Patrick T.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA.
   [Jefferson, Elizabeth; Teitelbaum, Susan L.; Chen, Jia] Mt Sinai Sch Med, Dept Prevent Med, New York, NY USA.
   [Zhang, Yujing; Cho, Yoon Hee; Garbowski, Gail; Santella, Regina M.] Columbia Univ, Dept Environm Hlth Sci, New York, NY USA.
C3 Tongji University; Tongji University; University of North Carolina;
   University of North Carolina Chapel Hill; Icahn School of Medicine at
   Mount Sinai; Columbia University
RP Xu, XR (通讯作者)，Tongji Univ, Res Ctr Translat Med, Shanghai E Hosp, Sch Med, Shanghai 200092, Peoples R China.
EM xu_xinran@hotmail.com; jia.chen@mssm.edu
RI Zhang, Yujing/ABB-3590-2021; Bradshaw, Patrick/AAJ-7529-2021; Cho,
   Yoon/AAN-6560-2021
OI Xu, Xinran/0000-0001-6435-8181; Cho, Yoon Hee/0000-0002-4290-7140;
   Terry, Mary Beth/0000-0002-4106-5033
FU National Cancer Institutes [R01CA109753, 3R01CA109753-04S1]; Department
   of Defense [BC031746, W81XWH-06-1-0298]; National Cancer Institute and
   National Institutes of Environmental Health and Sciences [UO1CA/ES66572,
   UO1CA66572, P30CA013696, P30ES009089, P30ES10126]
FX This work was supported by grants from the National Cancer Institutes
   (R01CA109753 and 3R01CA109753-04S1) and in part by grants from
   Department of Defense (BC031746 and W81XWH-06-1-0298) and National
   Cancer Institute and National Institutes of Environmental Health and
   Sciences (UO1CA/ES66572, UO1CA66572, P30CA013696, P30ES009089 and
   P30ES10126).
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416
   Chen J, 2005, CANCER RES, V65, P1606, DOI 10.1158/0008-5472.CAN-04-2630
   Chen J, 2010, ADV GENET, V71, P237, DOI [10.1016/S0065-2660(10)71009-9, 10.1016/B978-0-12-380864-6.00008-0]
   Cho YH, BREAST CANC IN PRESS
   CHRISTMAN JK, 1993, CARCINOGENESIS, V14, P551, DOI 10.1093/carcin/14.4.551
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Eads CA, 1999, CANCER RES, V59, P2302
   Eads CA, 2000, CANCER RES, V60, P5021
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Estécio MRH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000399
   Esteller M, 1998, CANCER RES, V58, P4515
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Evron E, 2001, CANCER RES, V61, P2782
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Fowler BM, 1998, CANCER EPIDEM BIOMAR, V7, P901
   Friso S, 2002, P NATL ACAD SCI USA, V99, P5606, DOI 10.1073/pnas.062066299
   Gammon MD, 2002, BREAST CANCER RES TR, V74, P235, DOI 10.1023/A:1016387020854
   Gammon MD, 2002, CANCER EPIDEM BIOMAR, V11, P677
   Gaudet MM, 2004, CANCER EPIDEM BIOMAR, V13, P1485
   Gort EH, 2008, CANCER EPIDEM BIOMAR, V17, P3325, DOI 10.1158/1055-9965.EPI-08-0472
   Jacob RA, 1998, J NUTR, V128, P1204, DOI 10.1093/jn/128.7.1204
   Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853
   Kim YI, 2004, CANCER EPIDEM BIOMAR, V13, P511
   Li SY, 2006, ONCOL REP, V15, P221
   Liu ZJ, 2003, LIFE SCI, V73, P1963, DOI 10.1016/S0024-3205(03)00544-7
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Michels KB, 1996, LANCET, V348, P1152, DOI 10.1016/S0140-6736(96)05418-9
   Mokarram P, 2008, WORLD J GASTROENTERO, V14, P3662, DOI 10.3748/wjg.14.3662
   Nass SJ, 2000, CANCER RES, V60, P4346
   Ogino S, 2006, J MOL DIAGN, V8, P209, DOI 10.2353/jmoldx.2006.050135
   Paz MF, 2002, CANCER RES, V62, P4519
   Potischman N, 1997, CANCER CAUSE CONTROL, V8, P713, DOI 10.1023/A:1018475203820
   Rampersaud GC, 2000, AM J CLIN NUTR, V72, P998
   Rossner P, 2009, J CELL MOL MED, V13, P3847, DOI 10.1111/j.1582-4934.2008.00553.x
   Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010
   Rothman K.J., 1998, Modern Epidemiology, P2
   Silva JM, 1999, BRIT J CANCER, V80, P1262, DOI 10.1038/sj.bjc.6690495
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Stern LL, 2000, CANCER EPIDEM BIOMAR, V9, P849
   Stidley CA, 2010, CANCER RES, V70, P568, DOI 10.1158/0008-5472.CAN-09-3410
   Tao MH, 2009, CANCER EPIDEM BIOMAR, V18, P998, DOI 10.1158/1055-9965.EPI-08-0916
   Ulrich CM, 2010, CANCER PREV RES, V3, P1505, DOI 10.1158/1940-6207.CAPR-10-0298
   van Engeland M, 2003, CANCER RES, V63, P3133
   Wacholder S, 2004, J NATL CANCER I, V96, P434, DOI 10.1093/jnci/djh075
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Xu XR, 2008, CANCER EPIDEM BIOMAR, V17, P2109, DOI 10.1158/1055-9965.EPI-07-2900
   Xu XR, 2008, FASEB J, V22, P2045, DOI 10.1096/fj.07-101279
   Xu XR, 2007, CARCINOGENESIS, V28, P1504, DOI 10.1093/carcin/bgm061
   Xu XR, 2010, BREAST CANCER RES TR, V121, P685, DOI 10.1007/s10549-009-0628-2
   Xu XR, 2009, BREAST CANCER RES TR, V115, P397, DOI 10.1007/s10549-008-0075-5
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Zeisel SH, 2003, J NUTR, V133, P1302
NR 54
TC 14
Z9 17
U1 0
U2 11
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD NOV
PY 2011
VL 6
IS 11
BP 1276
EP 1283
DI 10.4161/epi.6.11.17744
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 849ZD
UT WOS:000297163200001
PM 22048254
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Ari, F
   Napieralski, R
   Ulukaya, E
   Dere, E
   Colling, C
   Honert, K
   Krüger, A
   Kiechle, M
   Schmitt, M
AF Ari, Ferda
   Napieralski, Rudolf
   Ulukaya, Engin
   Dere, Egemen
   Colling, Christoph
   Honert, Katja
   Krueger, Achim
   Kiechle, Marion
   Schmitt, Manfred
TI Modulation of protein expression levels and DNA methylation status of
   breast cancer metastasis genes by anthracycline-based chemotherapy and
   the demethylating agent decitabine
SO CELL BIOCHEMISTRY AND FUNCTION
LA English
DT Article
DE apoptosis; breast cancer; decitabine; DNA methylation; M30-antigen;
   PAI-1; uPA
ID UROKINASE UPA PROMOTER; PLASMINOGEN-ACTIVATOR; LUMINESCENCE ASSAY;
   CLINICAL UTILITY; TUMOR INVASION; INHIBITOR; PAI-1; HYPOMETHYLATION;
   EPIGENETICS; RELEVANCE
AB Epigenetic drugs are promising add-ons to cancer treatment; still, adverse effects concerning tumour promotion have been reported occasionally. In this in vitro study, we investigated the effect of combination treatment of decitabine with anthracycline-based chemotherapy [5-fluorouracil plus epirubicine plus cyclophosphamide (FEC)] on viability and metastatic activity of breast cancer cell lines, MDA-MB-231 (estrogen receptor-negative) and MCF-7 (estrogen receptor-positive). The effect of decitabine and its combined treatment with FEC on viability of both cancer cell lines was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide and adenosine triphosphate (ATP) cell survival assays. DNA methylation specific real-time polymerase chain reaction (PCR) (Methylight (R)) was employed to document the methylation status of the metastasis-relevant urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-I (PAI-1) genes. Additionally, protein expression levels of uPA and PAI-1 were determined using enzyme-linked immunosorbent assays. Invasion capacity of cells was assayed using Matrigel (R) invasion assay. Decitabine lowered the viability of MCF-7 cells, although MDA-MB-231 cells were not affected. Decitabine did not augment FEC-mediated cytotoxicity in both cell lines. In MCF-7 cells, methylation of the uPA and PAI-1 gene promoter was significantly reduced by decitabine or decitabine plus FEC. Protein levels of uPA and PAI-1 were induced by all treatments. Decitabine significantly induced the invasion capacity of MCF-7 cells, whereas all of the drugs resulted in decreased invasion capacity of MDA-MB-231. Our results suggest differential effects of single-dose decitabine and its combination with FEC on the metastatic capacity and survival of breast cancer cell lines endowed with different metastatic behaviour. Copyright (c) 2011 John Wiley & Sons, Ltd.
C1 [Ulukaya, Engin] Uludag Univ, Sch Med, Dept Med Biochem, TR-16059 Gorukle, Bursa, Turkey.
   [Ari, Ferda; Dere, Egemen] Uludag Univ, Fac Sci & Art, Dept Biol, TR-16059 Gorukle, Bursa, Turkey.
   [Napieralski, Rudolf; Colling, Christoph; Kiechle, Marion; Schmitt, Manfred] Tech Univ Munich, Klinikum Rechts Isar, Dept Obstet & Gynecol, D-8000 Munich, Germany.
   [Honert, Katja; Krueger, Achim] Tech Univ Munich, Klinikum Rechts Isar, Inst Expt Oncol & Therapy Res, D-8000 Munich, Germany.
C3 Uludag University; Uludag University; Technical University of Munich;
   Technical University of Munich
RP Ulukaya, E (通讯作者)，Uludag Univ, Sch Med, Dept Med Biochem, TR-16059 Gorukle, Bursa, Turkey.
EM eulukaya@uludag.edu.tr
RI Arı, Ferda/AAG-7012-2021; Ulukaya, Engin/K-5792-2018; DERE,
   Egemen/AAH-5068-2021
OI Ulukaya, Engin/0000-0003-4875-5472
FU TUBITAK (The Scientific and Technical Research Council of Turkey)
   [106S349]; STFC [ST/I002200/1, ST/I005912/1, ST/I000410/1, ST/F006748/1,
   ST/G502347/1] Funding Source: UKRI
FX We thank TUBITAK (The Scientific and Technical Research Council of
   Turkey) for supporting project 106S349.
CR Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
   ANDREOTTI PE, 1995, CANCER RES, V55, P5276
   Annecke K, 2008, ADV CLIN CHEM, V45, P31, DOI 10.1016/S0065-2423(07)00002-9
   Benson JR, 2009, LANCET, V373, P1463, DOI 10.1016/S0140-6736(09)60316-0
   Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5
   Chai YB, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2634
   Chen MY, 2011, CANCER-AM CANCER SOC, V117, P4424, DOI 10.1002/cncr.26073
   Cortez CC, 2008, MUTAT RES-FUND MOL M, V647, P44, DOI 10.1016/j.mrfmmm.2008.07.006
   Dellas C, 2005, THROMB HAEMOSTASIS, V93, P631, DOI 10.1160/TH05-01-0033
   Duffy MJ, 2002, BIOCHEM SOC T, V30, P207, DOI 10.1042/bst0300207
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Gao S, 2005, THROMB HAEMOSTASIS, V94, P651, DOI 10.1160/TH05-02-0114
   Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200
   Harbeck N, 2004, THROMB HAEMOSTASIS, V91, P450, DOI 10.1160/TH03-12-0798
   Harbeck N, 2007, CRIT REV CL LAB SCI, V44, P179, DOI 10.1080/10408360601040970
   Kannappan R, 2010, MOL CANCER THER, V9, P2196, DOI 10.1158/1535-7163.MCT-10-0277
   Kurbacher CM, 1998, ANTI-CANCER DRUG, V9, P51, DOI 10.1097/00001813-199801000-00006
   Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879
   Lopez J, 2009, BRIT J CANCER, V100, P571, DOI 10.1038/sj.bjc.6604930
   Mirza S, 2010, MOL CELL BIOCHEM, V342, P101, DOI 10.1007/s11010-010-0473-y
   Napieralski R, 2007, CLIN CANCER RES, V13, P5095, DOI 10.1158/1078-0432.CCR-07-0241
   Nguyen DX, 2011, J PATHOL, V223, P195, DOI 10.1002/path.2801
   Pakneshan P, 2005, CURR CANCER DRUG TAR, V5, P471, DOI 10.2174/156800905774574011
   Pakneshan P, 2004, J BIOL CHEM, V279, P31735, DOI 10.1074/jbc.M401669200
   Pakneshan P, 2004, CLIN CANCER RES, V10, P3035, DOI 10.1158/1078-0432.CCR-03-0545
   Rabbani SA, 2008, NEOPLASIA, V10, P266, DOI 10.1593/neo.07947
   SCHMITT M, 1992, BIOL CHEM H-S, V373, P611, DOI 10.1515/bchm3.1992.373.2.611
   Schmitt M, 1997, THROMB HAEMOSTASIS, V78, P285
   Schmitt M, 2010, EXPERT REV MOL DIAGN, V10, P1051, DOI [10.1586/erm.10.71, 10.1586/ERM.10.71]
   Suh I, 2010, ARCH SURG-CHICAGO, V145, P226, DOI 10.1001/archsurg.2009.292
   Ulukaya E, 2008, TOXICOL IN VITRO, V22, P232, DOI 10.1016/j.tiv.2007.08.006
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987
   Witzel ID, 2010, J CANCER RES CLIN, V136, P1709, DOI 10.1007/s00432-010-0829-4
   Xu J, 2007, CANCER RES, V67, P1203, DOI 10.1158/0008-5472.CAN-06-2310
   Yi Xiao-ming, 2011, Zhonghua Nan Ke Xue, V17, P247
NR 36
TC 10
Z9 11
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0263-6484
EI 1099-0844
J9 CELL BIOCHEM FUNCT
JI Cell Biochem. Funct.
PD DEC
PY 2011
VL 29
IS 8
BP 651
EP 659
DI 10.1002/cbf.1801
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 856II
UT WOS:000297632400005
PM 21887697
DA 2025-01-12
ER

PT J
AU Bao, W
   Fu, HJ
   Xie, QS
   Wang, L
   Zhang, R
   Guo, ZY
   Zhao, J
   Meng, YL
   Ren, XL
   Wang, T
   Li, Q
   Jin, BQ
   Yao, LB
   Wang, RA
   Fan, DM
   Chen, SY
   Jia, LT
   Yang, AG
AF Bao, Wei
   Fu, Hai-Jing
   Xie, Qiao-Sheng
   Wang, Lei
   Zhang, Rui
   Guo, Zhang-Yan
   Zhao, Jing
   Meng, Yan-Ling
   Ren, Xin-Ling
   Wang, Tao
   Li, Qing
   Jin, Bo-Quan
   Yao, Li-Bo
   Wang, Rui-An
   Fan, Dai-Ming
   Chen, Si-Yi
   Jia, Lin-Tao
   Yang, An-Gang
TI HER2 Interacts With CD44 to Up-regulate CXCR4 via Epigenetic Silencing
   of <i>microRNA</i>-<i>139</i> in Gastric Cancer Cells
SO GASTROENTEROLOGY
LA English
DT Article
DE Trastuzumab/Herceptin; Cancer Cell Signaling; Histone Deacetylase;
   Metastasis-Associated Protein-1
ID SMALL INTERFERING RNA; TUMOR-GROWTH; BREAST-CANCER; METASTASIS;
   EXPRESSION; THERAPY; CARCINOMAS; INVASION; ERBB2; OVEREXPRESSION
AB BACKGROUND & AIMS: Human epidermal growth factor receptor 2 (HER2) (neu/ERBB2) is overexpressed on many types of cancer cells, including gastric cancer cells; HER2 overexpression has been associated with metastasis and poor prognosis. We investigated the mechanisms by which HER2 regulates cell migration and invasion. METHODS: HER2 expression or activity was reduced in gastric cancer cell lines using small interfering RNAs or the monoclonal antibody, trastuzumab. We identified proteins that interact with HER2 or microRNAs (miRNAs) involved in HER2 signaling. We used various software programs to identify miRNAs that regulate factors in the HER2 signaling pathway. We analyzed expression patterns of these miRNAs in gastric cancer cell lines and tumor samples from patients. RESULTS: We found that CD44 binds directly to HER2, which up-regulates the expression of metastasis-associated protein-1, induces deacetylation of histone H3 lysine 9, and suppresses transcription of microRNA139 (miR-139) to inhibit expression of its target gene, C-X-C chemokine receptor type 4 (CXCR4). Knockdown of HER2 and CD44 reduced invasive activity of cultured gastric cancer cells and suppressed tumor growth in nude mice. Lymph node metastasis was associated with high levels of HER2, CD44, and CXCR4, and reduced levels of miR-139 in human metastatic gastric tumors. Cultures of different types of metastatic cancer cells with histone deacetylase inhibitors and/or DNA methyltransferase resulted in up-regulation of miR-139. CONCLUSIONS: HER2 interaction with CD44 up-regulates CXCR4 by inhibiting expression of miR-139, at the epigenetic level, in gastric cancer cells. These findings indicate how HER2 signaling might promote gastric tumor progression and metastasis.
C1 [Bao, Wei; Xie, Qiao-Sheng; Guo, Zhang-Yan; Meng, Yan-Ling; Jin, Bo-Quan; Yang, An-Gang] Fourth Mil Med Univ, Dept Immunol, State Key Lab Canc Biol, Xian 710032, Shaanxi, Peoples R China.
   [Fu, Hai-Jing; Wang, Lei; Zhang, Rui; Zhao, Jing; Ren, Xin-Ling; Wang, Tao; Yao, Li-Bo; Jia, Lin-Tao] Fourth Mil Med Univ, Dept Biochem & Mol Biol, Xian 710032, Shaanxi, Peoples R China.
   [Li, Qing; Wang, Rui-An] Fourth Mil Med Univ, Dept Pathol, Xian 710032, Shaanxi, Peoples R China.
   [Fan, Dai-Ming] Fourth Mil Med Univ, Xijing Hosp, Inst Digest Dis, Xian 710032, Shaanxi, Peoples R China.
   [Bao, Wei] Nanjing Bayi Hosp, Nanjing, Peoples R China.
   [Chen, Si-Yi] Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA.
C3 Air Force Military Medical University; Air Force Military Medical
   University; Air Force Military Medical University; Air Force Military
   Medical University; Nanjing University of Chinese Medicine; University
   of Southern California
RP Yang, AG (通讯作者)，Fourth Mil Med Univ, Dept Immunol, State Key Lab Canc Biol, 169 Changle W Rd, Xian 710032, Shaanxi, Peoples R China.
EM jialth@fmmu.edu.cn; agyang@fmmu.edu.cn
RI chen, siyi/KXR-2904-2024; Wang, Tao/AEN-3843-2022; meng,
   yan/GSE-2653-2022; Wang, Brian/HGA-9535-2022; Yao, Libo/AHA-0939-2022
OI Jia, Lintao/0000-0002-0907-6429; Jia, Lintao/0000-0001-6329-0453
FU National Basic Research Program of China [2010CB529905]; National
   Natural Sciences Foundation of China [81030045]
FX This work was supported by grants from the National Basic Research
   Program of China (no. 2010CB529905) and the National Natural Sciences
   Foundation of China (no. 81030045).
CR Bang YJ, 2010, LANCET, V376, P687, DOI 10.1016/S0140-6736(10)61121-X
   Bao W, 2010, ARCH BIOCHEM BIOPHYS, V499, P49, DOI 10.1016/j.abb.2010.05.009
   Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656
   Bertolini F, 2002, CANCER RES, V62, P3106
   Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200
   Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010
   Carl-McGrath S, 2007, CANCER BIOL THER, V6, P1218
   CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285
   Davalos V, 2010, CURR OPIN ONCOL, V22, P35, DOI 10.1097/CCO.0b013e328333dcbb
   DAVID L, 1992, MODERN PATHOL, V5, P384
   Dinarello CA, 2010, CELL, V140, P935, DOI 10.1016/j.cell.2010.02.043
   Ganesan A, 2009, CURR CANCER DRUG TAR, V9, P963, DOI 10.2174/156800909790192428
   Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186
   Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868
   Jackson JG, 2004, CANCER RES, V64, P2601, DOI 10.1158/0008-5472.CAN-03-3106
   JAEHNE J, 1992, J CANCER RES CLIN, V118, P474, DOI 10.1007/BF01629433
   Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014
   Lane AA, 2009, J CLIN ONCOL, V27, P5459, DOI 10.1200/JCO.2009.22.1291
   Lapteva N, 2005, CANCER GENE THER, V12, P84, DOI 10.1038/sj.cgt.7700770
   Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027
   Lin WC, 2000, ONCOGENE, V19, P5680, DOI 10.1038/sj.onc.1203924
   Mariani G, 2009, NAT CLIN PRACT ONCOL, V6, P93, DOI 10.1038/ncponc1298
   Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Muscolini M, 2008, MOL CANCER THER, V7, P1410, DOI 10.1158/1535-7163.MCT-08-0299
   Nawrocki ST, 2007, CANCER RES, V67, P6987, DOI 10.1158/0008-5472.CAN-07-0812
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004
   Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060
   Spector NL, 2009, J CLIN ONCOL, V27, P5838, DOI 10.1200/JCO.2009.22.1507
   Taichman RS, 2002, CANCER RES, V62, P1832
   Toh Y, 1997, INT J CANCER, V74, P459, DOI 10.1002/(SICI)1097-0215(19970822)74:4<459::AID-IJC18>3.3.CO;2-H
   Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037
   Yang G, 2004, J BIOL CHEM, V279, P4339, DOI 10.1074/jbc.M311153200
   You Y, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl175
   Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972
   Yu Q, 2000, GENE DEV, V14, P163
   Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702
   Zhang H, 2010, ONCOGENE, V29, P937, DOI 10.1038/onc.2009.406
   Zhu ZB, 2004, GENE THER, V11, P645, DOI 10.1038/sj.gt.3302089
NR 40
TC 138
Z9 148
U1 0
U2 39
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD DEC
PY 2011
VL 141
IS 6
BP 2076
EP U210
DI 10.1053/j.gastro.2011.08.050
PG 18
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 852DQ
UT WOS:000297329000029
PM 21925125
OA Bronze
DA 2025-01-12
ER

PT J
AU Tsai, KW
   Wu, CW
   Hu, LY
   Li, SC
   Liao, YL
   Lai, CH
   Kao, HW
   Fang, WL
   Huang, KH
   Chan, WC
   Lin, WC
AF Tsai, Kuo-Wang
   Wu, Chew-Wun
   Hu, Ling-Yueh
   Li, Sung-Chou
   Liao, Yu-Lun
   Lai, Chun-Hung
   Kao, Hsiao-Wei
   Fang, Wen-Liang
   Huang, Kuo-Hung
   Chan, Wen-Ching
   Lin, Wen-Chang
TI Epigenetic regulation of miR-34b and miR-129 expression in gastric
   cancer
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE miR-34b; miR-129; tumor-specific methylation; CpG islands; 5-Aza-dC
ID DNA HYPERMETHYLATION; METHYLATION STATUS; COLORECTAL-CANCER;
   DOWN-REGULATION; BREAST-CANCER; MICRORNA; CELLS; FAMILY; HMLH1
AB MicroRNAs (miRNAs) are small noncoding RNAs that play fundamental roles in diverse biological and pathological processes by targeting the expression of specific genes. Here, we identified 38 methylation-associated miRNAs, the expression of which could be epigenetically restored by cotreatment with 5-aza-20-deoxycytidine and trichostatin A. Among these 38 miRNAs, we further analyzed miR-34b, miR-127-3p, miR-129-3p and miR-409 because CpG islands are predicted adjacent to them. The methylation-silenced expression of these miRNAs could be reactivated in gastric cancer cells by treatment with demethylating drugs in a time-dependent manner. Analysis of the methylation status of these miRNAs showed that the upstream CpG-rich regions of mir-34b and mir-129-2 are frequently methylated in gastric cancer tissues compared to adjacent normal tissues, and their methylation status correlated inversely with their expression patterns. The expression of miR-34b and miR-129-3p was downregulated by DNA hypermethylation in primary gastric cancers, and the low expression was associated with poor clinicopathological features. In summary, our study shows that tumor-specific methylation silences miR-34b and miR-129 in gastric cancer cells.
C1 [Hu, Ling-Yueh; Li, Sung-Chou; Liao, Yu-Lun; Lai, Chun-Hung; Kao, Hsiao-Wei; Chan, Wen-Ching; Lin, Wen-Chang] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan.
   [Tsai, Kuo-Wang] Kaohsiung Vet Gen Hosp, Dept Med Educ & Res, Kaohsiung, Taiwan.
   [Wu, Chew-Wun; Fang, Wen-Liang; Huang, Kuo-Hung] Vet Gen Hosp, Dept Surg, Taipei 11217, Taiwan.
   [Li, Sung-Chou; Chan, Wen-Ching; Lin, Wen-Chang] Natl Yang Ming Univ, Inst Biomed Informat, Taipei 112, Taiwan.
   [Li, Sung-Chou; Chan, Wen-Ching] Acad Sinica, Bioinformat Program, Taiwan Int Grad Program, Taipei 115, Taiwan.
   [Fang, Wen-Liang; Huang, Kuo-Hung] Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan.
C3 Academia Sinica - Taiwan; Kaohsiung Veterans General Hospital; National
   Yang Ming Chiao Tung University; Academia Sinica - Taiwan; National Yang
   Ming Chiao Tung University
RP Lin, WC (通讯作者)，Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan.
EM wenlin@ibms.sinica.edu.tw
RI Lin, Wen-chang/ABH-7976-2020; Lin, Wen-chang/B-3100-2011; Tsai,
   Kuo-Wang/AFS-8885-2022; Li, Sung-Chou/AGZ-8626-2022
OI Lin, Wen-chang/0000-0003-0194-1745; Tsai, Kuo-Wang/0000-0002-9028-9834;
   Li, Sung-Chou/0000-0002-3016-9718; CHAN, WEN-CHING/0000-0003-0034-7277
FU Center of Excellence for Cancer Research at Taipei Veterans General
   Hospital [DOH99-TD-C-111-007]; Academia Sinica
FX Grant sponsor: Center of Excellence for Cancer Research at Taipei
   Veterans General Hospital; Grant number: DOH99-TD-C-111-007; Grant
   sponsor: Academia Sinica
CR Bandres E, 2009, INT J CANCER, V125, P2737, DOI 10.1002/ijc.24638
   Bortolin-Cavaillé ML, 2009, NUCLEIC ACIDS RES, V37, P3464, DOI 10.1093/nar/gkp205
   Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406
   Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178
   Chen JG, 2006, INT J CANCER, V119, P1447, DOI 10.1002/ijc.21952
   Corney DC, 2010, CLIN CANCER RES, V16, P1119, DOI 10.1158/1078-0432.CCR-09-2642
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Gallardo E, 2009, CARCINOGENESIS, V30, P1903, DOI 10.1093/carcin/bgp219
   Grady WM, 2008, ONCOGENE, V27, P3880, DOI 10.1038/onc.2008.10
   Huang YW, 2009, CANCER RES, V69, P9038, DOI 10.1158/0008-5472.CAN-09-1499
   Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317
   Ji Q, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-266
   Kim TY, 2004, ALIMENT PHARM THER, V20, P131, DOI 10.1111/j.1365-2036.2004.01984.x
   Kim VN, 2005, MOL CELLS, V19, P1
   Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   Meola Nicola, 2009, Pathogenetics, V2, P7, DOI 10.1186/1755-8417-2-7
   Oue N, 2001, ONCOL REP, V8, P1085
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Shen RZ, 2010, BIOCHEM BIOPH RES CO, V394, P1047, DOI 10.1016/j.bbrc.2010.03.121
   Tsai KW, 2009, EPIGENETICS-US, V4, P587, DOI 10.4161/epi.4.8.10230
   Waki T, 2002, AM J PATHOL, V161, P399, DOI 10.1016/S0002-9440(10)64195-8
   Wang Y, 2004, BIOINFORMATICS, V20, P1170, DOI 10.1093/bioinformatics/bth059
   Zhang R, 2008, MOL BIOL EVOL, V25, P1493, DOI 10.1093/molbev/msn094
NR 26
TC 163
Z9 177
U1 0
U2 7
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD DEC 1
PY 2011
VL 129
IS 11
BP 2600
EP 2610
DI 10.1002/ijc.25919
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 840OK
UT WOS:000296449900007
PM 21960261
DA 2025-01-12
ER

PT J
AU Peng, LR
   Yuan, ZG
   Ling, HB
   Fukasawa, K
   Robertson, K
   Olashaw, N
   Koomen, J
   Chen, JD
   Lane, WS
   Seto, E
AF Peng, Lirong
   Yuan, Zhigang
   Ling, Hongbo
   Fukasawa, Kenji
   Robertson, Keith
   Olashaw, Nancy
   Koomen, John
   Chen, Jiandong
   Lane, William S.
   Seto, Edward
TI SIRT1 Deacetylates the DNA Methyltransferase 1 (DNMT1) Protein and
   Alters Its Activities
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
ID BREAST-CANCER CELLS; ESTROGEN-RECEPTOR-ALPHA; CPG ISLAND
   HYPERMETHYLATION; LYSINE ACETYLATION; METHYLATION PATTERNS;
   CHROMATIN-STRUCTURE; BINDING PROTEIN; GENE-EXPRESSION; STEADY-STATE;
   INHIBITION
AB DNA methylation and histone acetylation/deacetylation are distinct biochemical processes that control gene expression. While DNA methylation is a common epigenetic signal that inhibits gene transcription, histone deacetylation similarly represses transcription but can be both an epigenetic and nonepigenetic phenomenon. Here we report that the histone deacetylase SIRT1 regulates the activities of DNMT1, a key enzyme responsible for DNA methylation. In mass spectrometry analysis, 12 new acetylated lysine sites were identified in DNMT1. SIRT1 physically associates with DNMT1 and can deacetylate acetylated DNMT1 in vitro and in vivo. Interestingly, deacetylation of different lysines on DNMT1 has different effects on the functions of DNMT1. For example, deacetylation of Lys1349 and Lys1415 in the catalytic domain of DNMT1 enhances DNMT1's methyltransferase activity, while deacetylation of lysine residues in the GK linker decreases DNMT1's methyltransferase-independent transcriptional repression function. Furthermore, deacetylation of all identified acetylated lysine sites in DNMT1 abrogates its binding to SIRT1 and impairs its capability to regulate cell cycle G(2)/M transition. Finally, inhibition of SIRT1 strengthens the silencing effects of DNMT1 on the expression of tumor suppressor genes ER-alpha and CDH1 in MDA-MB-231 breast cancer cells. Together, these results suggest that SIRT1-mediated deacetylation of DNMT1 is crucial for DNMT1's multiple effects in gene silencing.
C1 [Peng, Lirong; Yuan, Zhigang; Ling, Hongbo; Fukasawa, Kenji; Olashaw, Nancy; Koomen, John; Chen, Jiandong; Seto, Edward] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA.
   [Robertson, Keith] Med Coll Georgia, Mol Oncol Program, Augusta, GA 30912 USA.
   [Lane, William S.] Harvard Univ, Dept Mol & Cellular Biol, Microchem & Prote Anal Facil, Cambridge, MA 02138 USA.
C3 H Lee Moffitt Cancer Center & Research Institute; State University
   System of Florida; University of South Florida; University System of
   Georgia; Augusta University; Harvard University
RP Seto, E (通讯作者)，H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, SRB 23011,12902 Magnolia Dr, Tampa, FL 33612 USA.
EM ed.seto@moffitt.org
RI Koomen, John/D-1844-2013
OI Robertson, Keith/0000-0002-7508-3328
FU NIH [GM081650]; AHA [0755298]; Kaul Foundation
FX This work was supported by grants to E. S. from the NIH (GM081650), the
   AHA (0755298), and the Kaul Foundation. L. P. was supported by a
   postdoctoral fellowship from the AHA.
CR ADAMS RLP, 1991, J BIOCHEM BIOPH METH, V22, P19, DOI 10.1016/0165-022X(91)90077-A
   Aizawa H, 2004, SCIENCE, V303, P197, DOI 10.1126/science.1089845
   Aoki A, 2001, NUCLEIC ACIDS RES, V29, P3506, DOI 10.1093/nar/29.17.3506
   BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325
   Bender CM, 1998, CANCER RES, V58, P95
   BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2
   BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Chen T, 2006, CURR TOP MICROBIOL, V301, P179
   Chen TP, 2007, NAT GENET, V39, P391, DOI 10.1038/ng1982
   Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371
   Damelin M, 2007, MOL CELL BIOL, V27, P3891, DOI 10.1128/MCB.00036-07
   Desplats P, 2011, J BIOL CHEM, V286, P9031, DOI 10.1074/jbc.C110.212589
   Du ZW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001462
   Eads CA, 1999, CANCER RES, V59, P2302
   Egger G, 2006, P NATL ACAD SCI USA, V103, P14080, DOI 10.1073/pnas.0604602103
   Espada J, 2007, NUCLEIC ACIDS RES, V35, P2191, DOI 10.1093/nar/gkm118
   Estève PO, 2009, P NATL ACAD SCI USA, V106, P5076, DOI 10.1073/pnas.0810362106
   Fan J, 2008, J CANCER RES CLIN, V134, P883, DOI 10.1007/s00432-008-0354-x
   Flynn J, 1996, BIOCHEMISTRY-US, V35, P7308, DOI 10.1021/bi9600512
   Flynn J, 1998, BIOCHEMISTRY-US, V37, P15162, DOI 10.1021/bi9810609
   Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750
   Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506
   Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1
   ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235
   Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730
   Jeong YS, 2009, DEV DYNAM, V238, P1666, DOI 10.1002/dvdy.21975
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570
   KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594
   Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026
   Kimura H, 2003, J BIOL CHEM, V278, P4806, DOI 10.1074/jbc.M209923200
   Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176
   Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383
   Lee B, 2009, BIOCHEM J, V421, P449, DOI 10.1042/BJ20090142
   Leonhardt H., 1993, Experientia Supplementum (Basel), V64, P109
   LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P
   Leonhardt H, 2000, J CELL BIOCHEM, P78
   LEWIS J, 1991, FEBS LETT, V285, P155, DOI 10.1016/0014-5793(91)80795-5
   LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F
   LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0
   Lodde V, 2009, EUR J HISTOCHEM, V53, P199, DOI 10.4081/ejh.2009.e24
   Lundberg J, 2009, NEUROSCI LETT, V457, P8, DOI 10.1016/j.neulet.2009.03.105
   Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578
   Michishita E, 2005, MOL BIOL CELL, V16, P4623, DOI 10.1091/mbc.E05-01-0033
   Milutinovic S, 2000, J BIOL CHEM, V275, P6353, DOI 10.1074/jbc.275.9.6353
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040
   Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000
   Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124
   Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023
   Sato M, 2002, ONCOGENE, V21, P4822, DOI 10.1038/sj.onc.1205581
   Saunders LR, 2007, ONCOGENE, V26, P5489, DOI 10.1038/sj.onc.1210616
   Spada F, 2007, J CELL BIOL, V176, P565, DOI 10.1083/jcb.200610062
   Sugiyama Y, 2010, BIOCHEM J, V427, P489, DOI 10.1042/BJ20091856
   TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G
   Ting AH, 2004, NAT GENET, V36, P582, DOI 10.1038/ng1365
   Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008
   Turek-Plewa J, 2005, CELL MOL BIOL LETT, V10, P631
   Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031
   Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X
   Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468
   Wei MJ, 2008, BREAST CANCER RES TR, V111, P113, DOI 10.1007/s10549-007-9766-6
   WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891
   Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001
   Yang XJ, 2008, MOL CELL, V31, P449, DOI 10.1016/j.molcel.2008.07.002
   Yang XJ, 2008, NAT REV MOL CELL BIO, V9, P206, DOI 10.1038/nrm2346
   Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0
   Yang XW, 2001, CANCER RES, V61, P7025
   Yang XW, 2000, CANCER RES, V60, P6890
   Yokochi T, 2002, J BIOL CHEM, V277, P11735, DOI 10.1074/jbc.M106590200
   Yuan Z, 2007, MOL CELL, V27, P149, DOI 10.1016/j.molcel.2007.05.029
   Zhou Q, 2008, MOL CANCER RES, V6, P873, DOI 10.1158/1541-7786.MCR-07-0330
NR 81
TC 169
Z9 184
U1 1
U2 17
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD DEC
PY 2011
VL 31
IS 23
BP 4720
EP 4734
DI 10.1128/MCB.06147-11
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 844ZF
UT WOS:000296791900006
PM 21947282
OA Green Published
DA 2025-01-12
ER

PT J
AU Kokcu, A
AF Kokcu, Arif
TI Relationship between endometriosis and cancer from current perspective
SO ARCHIVES OF GYNECOLOGY AND OBSTETRICS
LA English
DT Article
DE Endometriosis; Cancer; Genetic; Epigenetic; Hormone
ID CLEAR-CELL CARCINOMA; OVARIAN-CANCER; GENE-EXPRESSION; BREAST-CANCER;
   ADENOCARCINOMA; WOMEN; RISK; ASSOCIATION; PATHOGENESIS; EPIGENETICS
AB To examine the current mechanisms of the increased incidence of cancer in women with endometriosis.
   The synthesis and review of the relevant current literature in English language.
   Compared with general population, women with endometriosis have two times higher risk for developing ovarian cancer, 30% higher risk for developing breast cancer, and 40% higher risk for developing hematopoietic malignancies, mainly non-Hodgkin lymphoma.
   Endometriosis comprises many predisposing factors including genetic, epigenetic, local environmental, hormonal, inflammatory and immunologic changes, for the development of some cancers.
C1 [Kokcu, Arif] Ondokuz Mayis Univ, Dept Obstet & Gynecol, Sch Med, Samsun, Turkey.
C3 Ondokuz Mayis University
RP Kokcu, A (通讯作者)，Abdulhakhamid Cad,Onursal Ap 19-4, TR-55070 Samsun, Turkey.
EM arifkokcu@yahoo.com
RI Kokcu, Arif/D-3662-2013
CR Agrawal A, 2009, J OBSTET GYNAECOL CA, V31, P538, DOI 10.1016/S1701-2163(16)34217-7
   Ali-Fehmi R, 2006, INT J GYNECOL PATHOL, V25, P223, DOI 10.1097/01.pgp.0000192274.44061.36
   Aris A, 2010, J OVARIAN RES, V3, DOI 10.1186/1757-2215-3-2
   Barros SP, 2009, J DENT RES, V88, P400, DOI 10.1177/0022034509335868
   Beebe-Dimmer JL, 2010, PROSTATE CANCER P D, V13, P362, DOI 10.1038/pcan.2010.27
   Benoit L, 2006, EJSO-EUR J SURG ONC, V32, P6, DOI 10.1016/j.ejso.2005.08.011
   Bertelsen L, 2007, INT J CANCER, V120, P1372, DOI 10.1002/ijc.22490
   Borghese B, 2008, MOL ENDOCRINOL, V22, P2557, DOI 10.1210/me.2008-0322
   Boruban MC, 2008, EUR J GYNAECOL ONCOL, V29, P393
   Brinton LA, 1997, AM J OBSTET GYNECOL, V176, P572, DOI 10.1016/S0002-9378(97)70550-7
   Bulun SE, 2006, MOL CELL ENDOCRINOL, V248, P94, DOI 10.1016/j.mce.2005.11.041
   Depalo R, 2009, REPROD BIOMED ONLINE, V19, P808, DOI 10.1016/j.rbmo.2009.09.024
   Efthymiou CA, 2009, ANN ROY COLL SURG, V91, P259, DOI 10.1308/003588409X391848
   Gemmill JAL, 2010, FERTIL STERIL, V94, P1627, DOI 10.1016/j.fertnstert.2009.07.1698
   Götte M, 2008, J PATHOL, V215, P317, DOI 10.1002/path.2364
   Govindan S., 2007, Cancer Biomarkers, V3, P73
   Grammatikakis Ioannis, 2010, J Med Life, V3, P76
   Guo SW, 2009, MOL HUM REPROD, V15, P587, DOI 10.1093/molehr/gap064
   Hirabayashi K, 2009, INT J GYNECOL PATHOL, V28, P262, DOI 10.1097/PGP.0b013e31818e101f
   Hiromura T, 2009, Br J Radiol, V82, pe20, DOI 10.1259/bjr/75304693
   Hudelist G, 2009, FERTIL STERIL, V92, P1536, DOI 10.1016/j.fertnstert.2008.08.086
   Karanjgaokar VC, 2009, FERTIL STERIL, V92, DOI 10.1016/j.fertnstert.2009.08.012
   Karita M, 2011, FERTIL STERIL, V95, P889, DOI 10.1016/j.fertnstert.2010.12.026
   Kauppila S, 2008, APMIS, V116, P842, DOI 10.1111/j.1600-0463.2008.00806.x
   Keita M, 2010, J OVARIAN RES, V3, DOI 10.1186/1757-2215-3-3
   Khan KN, 2008, AM J REPROD IMMUNOL, V60, P383, DOI 10.1111/j.1600-0897.2008.00643.x
   Kobayashi H, 2009, GYNECOL ENDOCRINOL, V25, P39, DOI 10.1080/09513590802366204
   Kobayashi H, 2009, ONCOL REP, V22, P233, DOI 10.3892/or_00000429
   Kobayashi S, 2010, DIGEST ENDOSC, V22, P59, DOI 10.1111/j.1443-1661.2009.00925.x
   Kondi-Pafiti A, 2008, EUR J GYNAECOL ONCOL, V29, P256
   Kondi-Paphitis A, 1998, EUR J GYNAECOL ONCOL, V19, P588
   Konishi I, 2009, INT J CLIN ONCOL, V14, P377, DOI 10.1007/s10147-009-0930-3
   Mach P, 2010, AM J REPROD IMMUNOL, V63, P387, DOI 10.1111/j.1600-0897.2009.00806.x
   Mandai M, 2009, INT J CLIN ONCOL, V14, P383, DOI 10.1007/s10147-009-0935-y
   Manipadam MT, 2008, INT J GYNECOL PATHOL, V27, P398, DOI 10.1097/PGP.0b013e318165e2d0
   Massuger L, 2010, MED HYPOTHESES, V74, P859, DOI 10.1016/j.mehy.2009.11.029
   Matalliotakis I, 2009, J BUON, V14, P699
   Mataltiotakis IM, 2008, SURG ONCOL, V17, P289, DOI 10.1016/j.suronc.2008.01.002
   Matsuo K, 2009, ARCH GYNECOL OBSTET, V280, P637, DOI 10.1007/s00404-009-0962-y
   Mhawech P, 2002, INT J GYNECOL PATHOL, V21, P401, DOI 10.1097/00004347-200210000-00010
   Nagle CM, 2008, EUR J CANCER, V44, P2477, DOI 10.1016/j.ejca.2008.07.009
   Nezhat F, 2008, FERTIL STERIL, V90, P1559, DOI 10.1016/j.fertnstert.2008.08.007
   Nyiraneza C, 2010, FAM CANCER, V9, P383, DOI 10.1007/s10689-010-9321-1
   Oppelt P, 2010, FERTIL STERIL, V93, P1778, DOI 10.1016/j.fertnstert.2008.12.061
   Orezzoli JP, 2008, GYNECOL ONCOL, V110, P336, DOI 10.1016/j.ygyno.2008.05.025
   Park HM, 2009, J KOREAN MED SCI, V24, P767, DOI 10.3346/jkms.2009.24.4.767
   Peiretti M, 2008, FERTIL STERIL, V90, DOI 10.1016/j.fertnstert.2007.06.054
   Shaco-Levy R, 2008, EUR J OBSTET GYN R B, V139, P226, DOI 10.1016/j.ejogrb.2008.01.004
   Staats PN, 2007, AM J SURG PATHOL, V31, P1490, DOI 10.1097/PAS.0b013e31804a7e9a
   Swiersz LM, 2002, ANN NY ACAD SCI, V955, P281, DOI 10.1111/j.1749-6632.2002.tb02788.x
   Sznurkowski JJ, 2008, ACTA OBSTET GYN SCAN, V87, P104, DOI 10.1080/00016340701671929
   Takemura Y, 2005, HUM REPROD, V20, P3510, DOI 10.1093/humrep/dei233
   Tariverdian N, 2007, SEMIN IMMUNOPATHOL, V29, P193, DOI 10.1007/s00281-007-0077-0
   Vaissière T, 2008, MUTAT RES-REV MUTAT, V659, P40, DOI 10.1016/j.mrrev.2008.02.004
   Van Patten K, 2010, MODERN PATHOL, V23, P38, DOI 10.1038/modpathol.2009.127
   Vlahos NF, 2010, BEST PRACT RES CL OB, V24, P39, DOI 10.1016/j.bpobgyn.2009.08.004
   Vlahos NF, 2010, GYNECOL ENDOCRINOL, V26, P213, DOI [10.1080/09513590903184050, 10.3109/09513590903184050]
   Wilson AG, 2008, J PERIODONTOL, V79, P1514, DOI 10.1902/jop.2008.080172
   Wu WC, 2009, EUR J GYNAECOL ONCOL, V30, P563
   Yap OWS, 2009, ANTICANCER RES, V29, P139
NR 60
TC 30
Z9 34
U1 0
U2 14
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0932-0067
EI 1432-0711
J9 ARCH GYNECOL OBSTET
JI Arch. Gynecol. Obstet.
PD DEC
PY 2011
VL 284
IS 6
BP 1473
EP 1479
DI 10.1007/s00404-011-2047-y
PG 7
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Obstetrics & Gynecology
GA 842WM
UT WOS:000296632500023
PM 21837422
DA 2025-01-12
ER

PT J
AU Doshi, T
   Mehta, SS
   Dighe, V
   Balasinor, N
   Vanage, G
AF Doshi, Tanvi
   Mehta, Smita Salian
   Dighe, Vikas
   Balasinor, Nafisa
   Vanage, Geeta
TI Hypermethylation of estrogen receptor promoter region in adult testis of
   rats exposed neonatally to bisphenol A
SO TOXICOLOGY
LA English
DT Article
DE Bisphenol A; Estrogen receptor; DNA methylation; Neonatal exposure
ID HUMAN BREAST-CANCER; DNA METHYLTRANSFERASES; DIETHYLSTILBESTROL ALTERS;
   GENE-EXPRESSION; BETA EXPRESSION; GENOMIC DNA; METHYLATION; MOUSE;
   ALPHA; ENVIRONMENT
AB Background: Bisphenol A (BPA) is an estrogenic endocrine disruptor commonly used in manufacture of polycarbonate plastics and epoxy resins. Due to its ubiquitous presence in the environment, health concerns are increasing. Earlier studies from our group have shown that neonatal exposure of male rats to BPA affected spermatogenesis leading to impairment in fertility during adulthood. Further we also observed an altered gene expression of ER alpha and ER beta in adult testis upon BPA exposure. Based on these results, we hypothesized that apart from endocrine action, BPA might mediate perturbations in expression of ERs via epigenetic mechanism.
   Objectives: The present study was undertaken to determine the effect of exposure of neonatal male rats to BPA on DNA methylation profile of estrogen receptor promoter region and on DNA methylation machinery.
   Methods: In order to test this hypothesis, neonatal male rats were subcutaneously injected with 2.4 mu g of BPA/day for the first five days of life, i.e., on postnatal days (PND) 1-5, while control group received vehicle (sesame oil). Animals were sacrificed during adulthood (PND-125) and testes were dissected out for analysis. Methylation pattern of promoter region of ER alpha and ER beta was analyzed in the testis by bisulfite sequencing and expression levels of DNA methyltransferases by quantitative RT-PCR and Western blotting respectively.
   Results: Bisulfite sequencing revealed significant hypermethylation of ER alpha promoter to varying extents from 40% to 60%, and ER beta promoter region with varying extent from 20% to 65%. Approximately 2-fold increase in Dnmt3a and Dnmt3b expression at transcript and protein level was also observed.
   Conclusion: The experimental evidence demonstrated that the neonatal exposure of rats to BPA led to aberrant DNA methylation in testis, indicating methylation mediated epigenetic changes as one of the possible mechanisms of BPA induced adverse effects on spermatogenesis and fertility. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Doshi, Tanvi; Mehta, Smita Salian; Dighe, Vikas; Balasinor, Nafisa; Vanage, Geeta] Natl Inst Res Reprod Hlth ICMR, Natl Ctr Preclin Reprod & Genet Toxicol, Mumbai 400012, Maharashtra, India.
C3 Indian Council of Medical Research (ICMR); ICMR - National Institute for
   Research in Reproductive & Child Health (NIRRCH)
RP Vanage, G (通讯作者)，Natl Inst Res Reprod Hlth ICMR, Natl Ctr Preclin Reprod & Genet Toxicol, JM St, Mumbai 400012, Maharashtra, India.
EM vanageg@nirrh.res.in
RI Salian-Mehta, Smita/AAE-4677-2021
OI DIGHE, VIKAS/0000-0001-9718-7358
FU Department of Science and Technology [100/IFD/6122/2010-2011]; Indian
   Council of Medical Research
FX The author would like to acknowledge the Department of Science and
   Technology (100/IFD/6122/2010-2011) for financial support and Indian
   Council of Medical Research for fellowship to Ms. Tanvi Doshi. The
   authors are grateful to Dr. A. Maitra, Mr. Saravanan and Ms. Nanda for
   technical assistance with DNA sequencing. The author would like to
   acknowledge the technical and animal experimentation assistance of Mr.
   S. Bhagat, Mr. D. Tiwari, Mr. S. Kadam, Mr. P. Salunke, Mr. J. Tare, Mr.
   M. Mali and Mr. S. Bavdane.
CR [Anonymous], 2001, NAT TOX PROGR REP EN
   [Anonymous], NTP NTP CERHR MON PO
   Anway MD, 2006, J ANDROL, V27, P868, DOI 10.2164/jandrol.106.000349
   Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190
   Baccarelli A, 2009, CURR OPIN PEDIATR, V21, P243, DOI 10.1097/MOP.0b013e32832925cc
   BARKER E, 1992, FETAL INFANT ORIGINS
   Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533
   Bromer JG, 2009, ENDOCRINOLOGY, V150, P3376, DOI 10.1210/en.2009-0071
   BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439
   Carwile JL, 2009, ENVIRON HEALTH PERSP, V117, P1368, DOI 10.1289/ehp.0900604
   Cui M, 2009, MOL BIOL REP, V36, P2201, DOI 10.1007/s11033-008-9435-9
   Delbès G, 2006, REPRODUCTION, V132, P527, DOI 10.1530/rep.1.01231
   DODDS E. C, 1936, NATURE [LONDON], V137, P996, DOI 10.1038/137996a0
   Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104
   Dolinoy DC, 2007, REPROD TOXICOL, V23, P297, DOI 10.1016/j.reprotox.2006.08.012
   Eddy EM, 1996, ENDOCRINOLOGY, V137, P4796, DOI 10.1210/en.137.11.4796
   Fukata Hideki, 2004, Reprod Med Biol, V3, P115, DOI 10.1111/j.1447-0578.2004.00066.x
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   Goyal HO, 2003, BIOL REPROD, V68, P2081, DOI 10.1095/biolreprod.102.010637
   He YH, 2009, J OCCUP HEALTH, V51, P432, DOI 10.1539/joh.O9006
   HO S, 2006, CANCER RES, V11, P5624
   JINAWANTH A, 2005, BIOCHEM J, V15, P557
   Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045
   Khurana S, 2000, ENDOCRINOLOGY, V141, P4512, DOI 10.1210/en.141.12.4512
   KIM D, 2001, CANCER RES, V15, P3419
   KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279
   Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887
   Li SF, 1997, CANCER RES, V57, P4356
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033
   Matthews Jason, 2003, Mol Interv, V3, P281, DOI 10.1124/mi.3.5.281
   Matthews JB, 2001, CHEM RES TOXICOL, V14, P149, DOI 10.1021/tx0001833
   Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172
   Newbold RR, 2006, ENDOCRINOLOGY, V147, pS11, DOI 10.1210/en.2005-1164
   O'Donnell L, 2001, ENDOCR REV, V22, P289, DOI 10.1210/er.22.3.289
   Olea N, 1996, ENVIRON HEALTH PERSP, V104, P298, DOI 10.2307/3432888
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Pathak S, 2009, FERTIL STERIL, V91, P2253, DOI 10.1016/j.fertnstert.2008.07.1709
   Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443
   Rody A, 2005, ENDOCR-RELAT CANCER, V12, P903, DOI 10.1677/erc.1.01088
   Salian S, 2009, LIFE SCI, V85, P742, DOI 10.1016/j.lfs.2009.10.004
   Salian S, 2009, TOXICOLOGY, V265, P56, DOI 10.1016/j.tox.2009.09.012
   Sato K, 2006, ENDOCR J, V53, P331, DOI 10.1507/endocrj.K06-009
   Sato K, 2009, ENDOCR J, V56, P131, DOI 10.1507/endocrj.K08E-239
   Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059
   Szyf M, 2009, BBA-GEN SUBJECTS, V1790, P878, DOI 10.1016/j.bbagen.2009.01.009
   Takao T, 2003, LIFE SCI, V72, P1159, DOI 10.1016/S0024-3205(02)02364-0
   Toyama Y, 2004, ARCH HISTOL CYTOL, V67, P373, DOI 10.1679/aohc.67.373
   Toyama Y, 2004, REPROD TOXICOL, V19, P181, DOI 10.1016/j.reprotox.2004.08.003
   Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010
   Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716
   Yamagata Y, 2009, MOL HUM REPROD, V15, P259, DOI 10.1093/molehr/gap010
   Yaoi T, 2008, BIOCHEM BIOPH RES CO, V376, P563, DOI 10.1016/j.bbrc.2008.09.028
   Yap OWS, 2009, ANTICANCER RES, V29, P139
   Yoshida T, 2000, CARCINOGENESIS, V21, P2193, DOI 10.1093/carcin/21.12.2193
   Zama AM, 2009, ENDOCRINOLOGY, V150, P4681, DOI 10.1210/en.2009-0499
   Zhu XG, 2004, AM J PATHOL, V164, P2003, DOI 10.1016/S0002-9440(10)63760-1
NR 57
TC 132
Z9 148
U1 0
U2 33
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0300-483X
J9 TOXICOLOGY
JI Toxicology
PD NOV 18
PY 2011
VL 289
IS 2-3
BP 74
EP 82
DI 10.1016/j.tox.2011.07.011
PG 9
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA 833OS
UT WOS:000295895400002
PM 21827818
DA 2025-01-12
ER

PT J
AU Zhang, Y
   Chen, FQ
   Sun, YH
   Zhou, SY
   Li, TY
   Chen, R
AF Zhang, Yi
   Chen, Fu-qiang
   Sun, Ye-hong
   Zhou, Shu-yan
   Li, Ti-yuan
   Chen, Rui
TI Effects of DNMT1 silencing on malignant phenotype and methylated gene
   expression in cervical cancer cells
SO JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
LA English
DT Article
ID INTERFERENCE-MEDIATED KNOCKDOWN; DNA METHYLATION; PROMOTER METHYLATION;
   EPIGENETIC INACTIVATION; BREAST-CANCER; CARCINOMA; METHYLTRANSFERASE-1;
   HYPERMETHYLATION; CONTRIBUTES; MARKERS
AB Background: DNA methylation has been widely used in classification, early diagnosis, therapy and prediction of metastasis as well as recurrence of cervical cancer. DNMT methyltransferase 1 (DNMT1), which plays a significant role in maintaining DNA methylation status and regulating the expression of tumor suppressor genes. The aim of this research was to investigate the relationship between DNMT1 and abnormal methylation of tumor suppressor genes and malignant phenotype in cervical cancer.
   Methods: Levels of DNMT1 mRNA and protein were detected using qPCR and Western blot, respectively. Cell proliferation was analyzed by MTT and apoptosis was performed by Annexin V-FITC/PI double staining flow cytometry, respectively. MeDIP-qPCR and qPCR were performed to measure demethylation status and mRNA re-expression level of 7 tumor-suppressor genes (CCNA1, CHFR, FHIT, PAX1, PTEN, SFRP4, TSLC1) in Hela and Siha cells after silencing DNMT1.
   Results: The average expression levels of DNMT1 mRNA and protein in Hela and Siha cells were decreased significantly compared with control group. The flow cytometry and MTT results showed that Hela and Siha cells apoptosis rates and cell viabilities were 19.4 +/- 2.90%, 25.7 +/- 3.92% as well as 86.7 +/- 3.12%, 84.16 +/- 2.67% respectively 48 h after transfection (P < 0.01). Furthermore, the promoter methylation of five tumor suppressor genes was decreased with the increased mRNA expression after silencing DNMT1, whereas there were no significant changes in PTEN and FHIT genes in Hela cells, and CHFR and FHIT genes in Siha cells.
   Conclusions: Our experimental results demonstrate that methylation status of DNMT1 can influence several important tumor suppressor genes activity in cervical tumorigenesis and may have the potential to become an effective target for treatment of cervical cancer.
C1 [Zhang, Yi; Chen, Fu-qiang; Sun, Ye-hong; Zhou, Shu-yan; Li, Ti-yuan; Chen, Rui] Jinan Univ, Coll Med 2, Shenzhen Clin Med Res Ctr, Shenzhen Peoples Hosp, Shenzhen 518020, Peoples R China.
   [Zhang, Yi; Chen, Rui] Jinan Univ, Coll Pharm, Guangzhou 510632, Guangdong, Peoples R China.
C3 Jinan University; Jinan University
RP Li, TY (通讯作者)，Jinan Univ, Coll Med 2, Shenzhen Clin Med Res Ctr, Shenzhen Peoples Hosp, Shenzhen 518020, Peoples R China.
EM tiyuan_li@163.com
FU Shenzhen major research projects of healthy department
FX This study was supported by the Shenzhen major research projects of
   healthy department.
CR Banno K, 2007, INT J ONCOL, V31, P713
   Cheung HW, 2005, MOL CARCINOGEN, V43, P237, DOI 10.1002/mc.20106
   Chung MT, 2009, GYNECOL ONCOL, V112, P301, DOI 10.1016/j.ygyno.2008.10.004
   Hsieh SM, 2007, ADV EXP MED BIOL, V599, P31
   Kitkumthorn N, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-55
   Lai HC, 2008, INT J CANCER, V123, P161, DOI 10.1002/ijc.23519
   Ongenaert M, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-57
   Peng DF, 2006, CARCINOGENESIS, V27, P1160, DOI 10.1093/carcin/bgi361
   Qi M, 2005, MOL MED, V11, P59, DOI 10.2119/2006-00007.Auborn
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   ROBERT SM, 2002, NAT GENET, V33, P61
   Shi HD, 2003, CANCER RES, V63, P2164
   Sowinska A, 2007, CANCER LETT, V255, P153, DOI 10.1016/j.canlet.2007.04.004
   Steenbergen RDM, 2004, JNCI-J NATL CANCER I, V96, P294, DOI 10.1093/jnci/djh031
   Suzuki M, 2004, CANCER RES, V64, P3137, DOI 10.1158/0008-5472.CAN-03-3046
   Szyf M, 2001, FRONT BIOSCI-LANDMRK, V6, pD599, DOI 10.2741/szyf
   Ting AH, 2004, NAT GENET, V36, P582, DOI 10.1038/ng1365
   Wu Y, 2006, ONCOL REP, V16, P625
   Ye CZ, 2006, ONCOL REP, V16, P429
NR 19
TC 39
Z9 50
U1 1
U2 29
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-9966
J9 J EXP CLIN CANC RES
JI J. Exp. Clin. Cancer Res.
PD OCT 17
PY 2011
VL 30
AR 98
DI 10.1186/1756-9966-30-98
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 841MO
UT WOS:000296516600001
PM 21999220
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Brody, JP
AF Brody, James P.
TI Age-Specific Incidence Data Indicate Four Mutations Are Required for
   Human Testicular Cancers
SO PLOS ONE
LA English
DT Article
ID GERM-CELL TUMORS; MULTISTAGE CARCINOGENESIS; TEMPORAL VARIATION;
   BREAST-CANCER; COHORT MODELS; IN-UTERO; DISEASE; GENOME; TRENDS; PERIOD
AB Normal human cells require a series of genetic alterations to undergo malignant transformation. Direct sequencing of human tumors has identified hundreds of mutations in tumors, but many of these are thought to be unnecessary and a result of, rather than a cause of, the tumor. The exact number of mutations to transform a normal human cell into a tumor cell is unknown. Here I show that male gonadal germ cell tumors, the most common form of testicular cancers, occur after four mutations. I infer this by constructing a mathematical model based upon the multi-hit hypothesis and comparing it to the age-specific incidence data. This result is consistent with the multi-hit hypothesis, and implies that these cancers are genetically or epigenetically predetermined at birth or an early age.
C1 Univ Calif Irvine, Dept Biomed Engn, Ctr Complex Biol Syst, Irvine, CA 92717 USA.
C3 University of California System; University of California Irvine
RP Brody, JP (通讯作者)，Univ Calif Irvine, Dept Biomed Engn, Ctr Complex Biol Syst, Irvine, CA 92717 USA.
EM jpbrody@uci.edu
RI Brody, Jim/KMY-3269-2024
OI Brody, James/0000-0002-7995-5197
FU University of California
FX This research was supported by the University of California. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR [Anonymous], SEER*Stat Software
   ARMITAGE P, 1954, BRIT J CANCER, V8, P1, DOI 10.1038/bjc.1954.1
   Arnheim N, 2009, NAT REV GENET, V10, P478, DOI 10.1038/nrg2529
   Brody JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007053
   Byrne HM, 2010, NAT REV CANCER, V10, P221, DOI 10.1038/nrc2808
   Calabrese P, 2004, AM J PATHOL, V164, P1337, DOI 10.1016/S0002-9440(10)63220-8
   Chanock S, 2009, NAT GENET, V41, P765, DOI 10.1038/ng0709-765
   Chia VM, 2010, CANCER EPIDEM BIOMAR, V19, P1151, DOI 10.1158/1055-9965.EPI-10-0031
   CLAYTON D, 1987, STAT MED, V6, P449, DOI 10.1002/sim.4780060405
   CLAYTON D, 1987, STAT MED, V6, P469, DOI 10.1002/sim.4780060406
   Czene K, 2002, INT J CANCER, V99, P260, DOI 10.1002/ijc.10332
   Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423
   Ekbom A, 1998, SEMIN CANCER BIOL, V8, P237, DOI 10.1006/scbi.1998.0073
   FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Frank S. A., 2007, Dynamics of cancer: incidence, inheritance and evolution
   Frank SA, 2004, CURR BIOL, V14, P242, DOI 10.1016/j.cub.2003.12.026
   Gordon RA, 2003, TOXICOL IND HEALTH, V19, P125, DOI 10.1191/0748233703th195oa
   Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795
   Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780
   Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Harding C, 2008, CANCER RES, V68, P4465, DOI 10.1158/0008-5472.CAN-07-1670
   Houldsworth J, 2006, J CLIN ONCOL, V24, P5512, DOI 10.1200/JCO.2006.08.4285
   Johnson NL, 2005, WILEY SER PROBAB ST, P1, DOI 10.1002/0471715816
   Kanetsky PA, 2009, NAT GENET, V41, P811, DOI 10.1038/ng.393
   Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100
   Looijenga LHJ, 1999, REV REPROD, V4, P90, DOI 10.1530/ror.0.0040090
   Luebeck EG, 2002, P NATL ACAD SCI USA, V99, P15095, DOI 10.1073/pnas.222118199
   Manecksha RP, 2009, BJU INT, V104, P1329, DOI 10.1111/j.1464-410X.2009.08854.x
   Mdzinarishvili T, 2010, CANCER INFORM, V9, P179
   Meza R, 2008, P NATL ACAD SCI USA, V105, P16284, DOI 10.1073/pnas.0801151105
   Moger TA, 2004, BIOSTATISTICS, V5, P1, DOI 10.1093/biostatistics/5.1.1
   Moolgavkar SH, 2004, INT J EPIDEMIOL, V33, P1182, DOI 10.1093/ije/dyh288
   Moolgavkar SH, 2003, GENE CHROMOSOME CANC, V38, P302, DOI 10.1002/gcc.10264
   Myrup C, 2007, NEW ENGL J MED, V357, P825
   Oosterhuis JW, 2005, NAT REV CANCER, V5, P210, DOI 10.1038/nrc1568
   Pettersson A, 2007, NEW ENGL J MED, V356, P1835, DOI 10.1056/NEJMoa067588
   Pompei F, 2002, TOXICOL IND HEALTH, V18, P365, DOI 10.1191/0748233702th164oa
   Rapley EA, 2009, NAT GENET, V41, P807, DOI 10.1038/ng.394
   Rothman N, 2001, BBA-REV CANCER, V1471, pC1, DOI 10.1016/S0304-419X(00)00021-4
   Shah MN, 2007, INT J ANDROL, V30, P206, DOI 10.1111/j.1365-2605.2007.00795.x
   Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943
   Surveillance Epidemiology and End Results (SEER) Program, 2010, SEER STAT DAT INC SE
   Thilly WG, 2003, NAT GENET, V34, P255, DOI 10.1038/ng1205
   Thornburg KL, 2010, ADV GENET, V71, P57, DOI [10.1016/S0065-2660(10)71003-8, 10.1016/B978-0-12-380864-6.00003-1]
   TRICHOPOULOS D, 1990, LANCET, V335, P939, DOI 10.1016/0140-6736(90)91000-Z
   VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z
   Westergaard T, 1996, INT J CANCER, V66, P627, DOI 10.1002/(SICI)1097-0215(19960529)66:5<627::AID-IJC8>3.0.CO;2-V
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Zhang XN, 2005, BREAST CANCER RES TR, V91, P121, DOI 10.1007/s10549-004-5782-y
NR 51
TC 6
Z9 6
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 6
PY 2011
VL 6
IS 10
AR e25978
DI 10.1371/journal.pone.0025978
PG 5
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 834NO
UT WOS:000295968700029
PM 21998737
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Gambari, R
   Fabbri, E
   Borgatti, M
   Lampronti, I
   Finotti, A
   Brognara, E
   Bianchi, N
   Manicardi, A
   Marchelli, R
   Corradini, R
AF Gambari, Roberto
   Fabbri, Enrica
   Borgatti, Monica
   Lampronti, Ilaria
   Finotti, Alessia
   Brognara, Eleonora
   Bianchi, Nicoletta
   Manicardi, Alex
   Marchelli, Rosangela
   Corradini, Roberto
TI Targeting microRNAs involved in human diseases: A novel approach for
   modification of gene expression and drug development
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE MicroRNAs; Erythroid differentiation; Epigenetics; Gene transcription;
   Gene regulation; Peptide nucleic acids
ID PEPTIDE-NUCLEIC-ACIDS; DOUBLE-STRANDED DNA; BREAST-CANCER;
   MESSENGER-RNA; IN-VIVO; TUMOR-SUPPRESSOR; CELL-SURVIVAL;
   BIOLOGICAL-ACTIVITY; UP-REGULATION; HOST GENE
AB The identification of all epigenetic modifications (i.e. DNA methylation, histone modifications and expression of noncoding RNAs such as microRNAs) involved in gene regulation is one of the major steps forward for understanding human biology in both normal and pathological conditions and for development of novel drugs. In this context, microRNAs play a pivotal role. This review article focuses on the involvement of microRNAs in the regulation of gene expression, on the possible role of microRNAs in the onset and development of human pathologies, and on the pharmacological alteration of the biological activity of microRNAs. RNA and DNA analogs, which can selectively target microRNAs using Watson-Crick base pairing schemes, provide a rational and efficient way to modulate gene expression. These compounds, termed antago-miR or anti-miR have been described in many examples in the recent literature and have proved to be able to perform regulatory as well as therapeutic functions. Among these, a still not fully exploited class is that of peptide nucleic acids (PNAs), promising tools for the inhibition of miRNA activity, with important applications in gene therapy and in drug development. PNAs targeting miR-122, miR-155 and miR-210 have already been developed and their biological effects studied both in vitro and in vivo. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Gambari, Roberto] Univ Ferrara, Dept Biochem & Mol Biol, I-44100 Ferrara, Italy.
   [Gambari, Roberto; Fabbri, Enrica; Borgatti, Monica; Lampronti, Ilaria; Finotti, Alessia; Brognara, Eleonora; Bianchi, Nicoletta] Univ Ferrara, Lab Dev Pharmacol & Pharmacogen Therapy Thalassae, Ctr Biotechnol, I-44100 Ferrara, Italy.
   [Manicardi, Alex; Marchelli, Rosangela; Corradini, Roberto] Univ Ferrara, Dept Organ & Ind Chem, I-44100 Ferrara, Italy.
C3 University of Ferrara; University of Ferrara; University of Ferrara
RP Gambari, R (通讯作者)，Univ Ferrara, Dept Biochem & Mol Biol, Via Fossato Mortara 74, I-44100 Ferrara, Italy.
EM gam@unife.it
RI Lampronti, Ilaria/F-5522-2016; Bianchi, Nicoletta/H-1902-2015; Gambari,
   Roberto/F-9555-2015; Fabbri, Enrica/O-8059-2015; Corradini,
   Roberto/K-4791-2015; Finotti, Alessia/C-6268-2012; Manicardi,
   Alex/I-8370-2012; Borgatti, Monica/G-2611-2015
OI Lampronti, Ilaria/0000-0002-1972-7766; Bianchi,
   Nicoletta/0000-0001-9280-6017; Gambari, Roberto/0000-0001-9205-6033;
   Fabbri, Enrica/0000-0002-9836-8262; Corradini,
   Roberto/0000-0002-8026-0923; Brognara, Eleonora/0000-0002-7845-5895;
   Finotti, Alessia/0000-0002-7638-515X; Manicardi,
   Alex/0000-0003-0083-1392; Borgatti, Monica/0000-0001-8470-2496
FU MIUR (Italian Ministry of University and Research); Fondazione Cariparo
   (Cassa di Risparmio di Padova e Rovigo); CIB; UE ITHANET Project
   (Infrastructure for the Thalassaemia Research Network); Telethon
   [GGP10124, FIRB-2007]; Associazione Veneta per la Lotta alla Talassemia
   (AVLT), Rovigo
FX This work was supported by a grant by MIUR (Italian Ministry of
   University and Research, PRIN-2007). RG is granted by Fondazione
   Cariparo (Cassa di Risparmio di Padova e Rovigo), CIB, by UE ITHANET
   Project (Infrastructure for the Thalassaemia Research Network), by
   Telethon GGP10124 and by FIRB-2007. This research is also supported by
   Associazione Veneta per la Lotta alla Talassemia (AVLT), Rovigo. We
   thank Dr. Amanda Julie Neville for her help in producing the English
   text.
CR Abes R, 2008, J PEPT SCI, V14, P455, DOI 10.1002/psc.979
   Abu-Elneel K, 2008, NEUROGENETICS, V9, P153, DOI 10.1007/s10048-008-0133-5
   ALTER BP, 1979, EXP HEMATOL, V7, P200
   Alvarez-Garcia I, 2005, DEVELOPMENT, V132, P4653, DOI 10.1242/dev.02073
   Bader AG, 2010, CANCER RES, V70, P7027, DOI 10.1158/0008-5472.CAN-10-2010
   Berezikov E, 2007, MOL CELL, V28, P328, DOI 10.1016/j.molcel.2007.09.028
   Bianchi N, 2009, BMB REP, V42, P493, DOI 10.5483/BMBRep.2009.42.8.493
   Björk JK, 2010, DEVELOPMENT, V137, P3177, DOI 10.1242/dev.050955
   Borgatti M, 2003, J BIOL CHEM, V278, P7500, DOI 10.1074/jbc.M206780200
   Borgatti M, 2002, BIOCHEM PHARMACOL, V64, P609, DOI 10.1016/S0006-2952(02)01188-7
   Bracken CP, 2011, NUCLEIC ACIDS RES, V39, P5658, DOI 10.1093/nar/gkr110
   Bravo JA, 2011, CURR PHARM DESIGN, V17, P176
   Brown BD, 2009, NAT REV GENET, V10, P578, DOI 10.1038/nrg2628
   Bruchova H, 2007, EXP HEMATOL, V35, P1657, DOI 10.1016/j.exphem.2007.08.021
   Büssing I, 2008, TRENDS MOL MED, V14, P400, DOI 10.1016/j.molmed.2008.07.001
   Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995
   Calin GA, 2008, P NATL ACAD SCI USA, V105, P5166, DOI 10.1073/pnas.0800121105
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Camps C, 2008, CLIN CANCER RES, V14, P1340, DOI 10.1158/1078-0432.CCR-07-1755
   Cao GJ, 2010, BIOCHEM BIOPH RES CO, V396, P978, DOI 10.1016/j.bbrc.2010.05.037
   Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137
   Cho WCS, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-60
   Choe J, 2010, EMBO REP, V11, P380, DOI 10.1038/embor.2010.44
   Choong ML, 2007, EXP HEMATOL, V35, P551, DOI 10.1016/j.exphem.2006.12.002
   Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102
   Cordes KR, 2009, NATURE, V460, P705, DOI 10.1038/nature08195
   Corradini R, 2007, CURR TOP MED CHEM, V7, P681, DOI 10.2174/156802607780487759
   Corsten MF, 2007, CANCER RES, V67, P8994, DOI 10.1158/0008-5472.CAN-07-1045
   Costa Fabricio F, 2010, Cancer Manag Res, V2, P255, DOI 10.2147/CMR.S7280
   Cuccato G, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-19
   Czech MP, 2006, NEW ENGL J MED, V354, P1194, DOI 10.1056/NEJMcibr060065
   Dai R, 2011, TRANSL RES, V157, P163, DOI 10.1016/j.trsl.2011.01.007
   Daisy Narayan A, 2005, BRIT J HAEMATOL, V128, P562, DOI 10.1111/j.1365-2141.2004.05336.x
   Demidov VV, 2001, METHODS, V23, P108, DOI 10.1006/meth.2000.1112
   Dragulescu-Andrasi A, 2005, CHEM COMMUN, P244, DOI 10.1039/b412522c
   Edmonds MD, 2009, CELL CYCLE, V8, P2673, DOI 10.4161/cc.8.17.9303
   El Ouaamari A, 2008, DIABETES, V57, P2708, DOI 10.2337/db07-1614
   Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783
   Elmen J, 2008, NUCLEIC ACIDS RES, V36, P1153, DOI 10.1093/nar/gkm1113
   Fabani MM, 2008, RNA, V14, P336, DOI 10.1261/rna.844108
   Fabani MM, 2010, NUCLEIC ACIDS RES, V38, P4466, DOI 10.1093/nar/gkq160
   Fabbri E, 2010, INT J MOL MED, V26, pS61
   Fasanaro P, 2008, J BIOL CHEM, V283, P15878, DOI 10.1074/jbc.M800731200
   Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102
   Fibach E, 2003, BLOOD, V102, P1276, DOI 10.1182/blood-2002-10-3096
   Filipowicz W, 2005, CURR OPIN STRUC BIOL, V15, P331, DOI 10.1016/j.sbi.2005.05.006
   Fiore R, 2007, EXPERT OPIN BIOL TH, V7, P1823, DOI 10.1517/14712598.7.12.1823
   Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200
   Friedman JM, 2009, AM ASS CANC RES AACR, V69, P2623
   Fu SW, 2011, J CANCER, V2, P116, DOI 10.7150/jca.2.116
   Gabbianelli M, 2010, HAEMATOL-HEMATOL J, V95, P1253, DOI 10.3324/haematol.2009.018259
   Gambari R, 2004, CURR MED CHEM, V11, P1253, DOI 10.2174/0929867043365242
   Gambari R, 2001, CURR PHARM DESIGN, V7, P1839, DOI 10.2174/1381612013397087
   Gambari R, 2007, CURR MED CHEM, V14, P199, DOI 10.2174/092986707779313318
   Gandellini P, 2009, CANCER RES, V69, P2287, DOI 10.1158/0008-5472.CAN-08-2894
   Garzon R, 2008, CURR OPIN HEMATOL, V15, P352, DOI 10.1097/MOH.0b013e328303e15d
   Garzon R, 2008, BLOOD, V111, P3183, DOI 10.1182/blood-2007-07-098749
   Georgantas RW, 2007, P NATL ACAD SCI USA, V104, P2750, DOI 10.1073/pnas.0610983104
   Gerin I, 2010, J BIOL CHEM, V285, P33652, DOI 10.1074/jbc.M110.152090
   Giannakakis A, 2008, CANCER BIOL THER, V7, P255, DOI 10.4161/cbt.7.2.5297
   Good L, 1997, ANTISENSE NUCLEIC A, V7, P431, DOI 10.1089/oli.1.1997.7.431
   Grabher C, 2011, LEUKEMIA, V25, P506, DOI 10.1038/leu.2010.280
   Gramantieri L, 2007, CANCER RES, V67, P6092, DOI 10.1158/0008-5472.CAN-06-4607
   Guglielmelli P, 2011, BLOOD, V117, P6923, DOI 10.1182/blood-2010-09-306506
   Hansen T, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000873
   Hariharan M, 2005, BIOCHEM BIOPH RES CO, V337, P1214, DOI 10.1016/j.bbrc.2005.09.183
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   Hemida MG, 2010, MOL DIAGN THER, V14, P271, DOI 10.2165/11539540-000000000-00000
   Heneghan HM, 2010, OBES REV, V11, P354, DOI 10.1111/j.1467-789X.2009.00659.x
   Hinske LCG, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-533
   Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681
   Huang XQ, 2011, BLOOD, V117, P2157, DOI 10.1182/blood-2010-08-302711
   Huntzinger E, 2011, NAT REV GENET, V12, P99, DOI 10.1038/nrg2936
   Hurst DR, 2009, CANCER RES, V69, P7495, DOI 10.1158/0008-5472.CAN-09-2111
   Iguchi Haruhisa, 2010, Curr Drug Discov Technol, V7, P95
   Ishihara T, 2010, J CONTROL RELEASE, DOI [10.1016/1.contel.2010.10.014, DOI 10.1016/1.CONTEL.2010.10.014]
   Jiang SA, 2010, CANCER RES, V70, P3119, DOI 10.1158/0008-5472.CAN-09-4250
   Joergensen M, 2011, OLIGONUCLEOTIDES, V21, P29, DOI 10.1089/oli.2010.0266
   Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329
   Jordan SD, 2011, NAT CELL BIOL, V13, P434, DOI 10.1038/ncb2211
   Kano M, 2010, INT J CANCER, V127, P2804, DOI 10.1002/ijc.25284
   Kapinas K, 2010, J BIOL CHEM, V285, P25221, DOI 10.1074/jbc.M110.116137
   Karkare S, 2006, APPL MICROBIOL BIOT, V71, P575, DOI 10.1007/s00253-006-0434-2
   Kerr TA, 2011, TRANSL RES, V157, P241, DOI 10.1016/j.trsl.2011.01.008
   Kheir TB, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-29
   Kolfschoten IGM, 2009, DIABETES OBES METAB, V11, P118, DOI 10.1111/j.1463-1326.2009.01118.x
   Kosaka N, 2008, BRIT J HAEMATOL, V142, P293, DOI 10.1111/j.1365-2141.2008.07151.x
   Kosaka N, 2010, CANCER SCI, V101, P2087, DOI 10.1111/j.1349-7006.2010.01650.x
   Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821
   Kota SK, 2010, DRUG DISCOV TODAY, V15, P733, DOI 10.1016/j.drudis.2010.07.003
   Kozomara A, 2011, NUCLEIC ACIDS RES, V39, pD152, DOI 10.1093/nar/gkq1027
   Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843
   Krützfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303
   Krützfeldt J, 2007, NUCLEIC ACIDS RES, V35, P2885, DOI 10.1093/nar/gkm024
   Kuhn S, 2011, P NATL ACAD SCI USA, V108, P2355, DOI 10.1073/pnas.1016646108
   Kulshreshtha R, 2008, CELL DEATH DIFFER, V15, P667, DOI 10.1038/sj.cdd.4402310
   Lampronti I, 2003, EUR J HAEMATOL, V71, P189, DOI 10.1034/j.1600-0609.2003.00113.x
   Larsen HJ, 1996, NUCLEIC ACIDS RES, V24, P458, DOI 10.1093/nar/24.3.458
   le Sage C, 2007, EMBO J, V26, P3699, DOI 10.1038/sj.emboj.7601790
   Lee DY, 2007, P NATL ACAD SCI USA, V104, P20350, DOI 10.1073/pnas.0706901104
   Leivonen SK, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.005322
   Levy C, 2010, MOL CELL, V40, P841, DOI 10.1016/j.molcel.2010.11.020
   Lewis MA, 2009, NAT GENET, V41, P614, DOI 10.1038/ng.369
   Li JYZ, 2010, NEPHROLOGY, V15, P599, DOI 10.1111/j.1440-1797.2010.01363.x
   Linsley PS, 2007, MOL CELL BIOL, V27, P2240, DOI 10.1128/MCB.02005-06
   Liu W, 2010, ONCOGENE, V29, P4914, DOI 10.1038/onc.2010.237
   Lopez-Fraga M., 2008, Infectious Disorders - Drug Targets, V8, P262
   Lu M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003420
   Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024
   Ma N, 2011, MOL CELL ENDOCRINOL, V333, P96, DOI 10.1016/j.mce.2010.11.027
   Macadangdang B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017981
   Mack GS, 2007, NAT BIOTECHNOL, V25, P631, DOI 10.1038/nbt0607-631
   Marchetti R, GENE MODULATION PEPT
   Marin VL, 2004, EXPERT OPIN BIOL TH, V4, P337, DOI 10.1517/14712598.4.3.337
   Martinelli R, 2010, OBESITY, V18, P2170, DOI 10.1038/oby.2009.474
   McCullough DF, 2010, BIOCHEM SOC T, V38, P1565, DOI 10.1042/BST0381565
   Mencía A, 2009, NAT GENET, V41, P609, DOI 10.1038/ng.355
   Moser JJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013445
   Nana-Sinkam SP, 2009, AM J RESP CRIT CARE, V179, P4, DOI 10.1164/rccm.200807-1042PP
   Nastruzzi C, 2000, J CONTROL RELEASE, V68, P237, DOI 10.1016/S0168-3659(00)00273-X
   Nielsen PE, 2000, CURR OPIN MOL THER, V2, P282
   NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210
   Nielsen PE, 2001, CURR MED CHEM, V8, P545
   Nohata N, 2011, ONCOTARGET, V2, P29
   Noorbakhsh F, 2010, FASEB J, V24, P1799, DOI 10.1096/fj.09-147819
   Ofir M, 2011, MOL CANCER RES, V9, P440, DOI 10.1158/1541-7786.MCR-10-0344
   Oh SY, 2009, MOL CELLS, V28, P341, DOI 10.1007/s10059-009-0134-8
   Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305
   Park JK, 2011, BIOCHEM BIOPH RES CO, V406, P518, DOI 10.1016/j.bbrc.2011.02.065
   Paulasova P, 2004, ANN GENET-PARIS, V47, P349, DOI 10.1016/j.anngen.2004.07.001
   Rainer J, 2009, LEUKEMIA, V23, P746, DOI 10.1038/leu.2008.370
   Rasmussen FW, 2006, OLIGONUCLEOTIDES, V16, P43, DOI 10.1089/oli.2006.16.43
   Ray A, 2000, FASEB J, V14, P1041, DOI 10.1096/fasebj.14.9.1041
   Rogers HM, 2008, EXP HEMATOL, V36, P17, DOI 10.1016/j.exphem.2007.08.014
   Romanelli A, 2001, EUR J BIOCHEM, V268, P6066, DOI 10.1046/j.0014-2956.2001.02549.x
   Sankaran VG, 2011, P NATL ACAD SCI USA, V108, P1519, DOI 10.1073/pnas.1018384108
   Saugstad JA, 2010, J CEREBR BLOOD F MET, V30, P1564, DOI 10.1038/jcbfm.2010.101
   Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106
   Sforza S, 2000, EUR J ORG CHEM, V2000, P2905
   Sforza S, 2007, EUR J ORG CHEM, V2007, P5879, DOI 10.1002/ejoc.200700644
   Sforza S, 2010, EUR J ORG CHEM, V2010, P2441, DOI 10.1002/ejoc.201000123
   Shafi G, 2010, CAN J NEUROL SCI, V37, P177, DOI 10.1017/S0317167100009902
   Shi W, 2011, CANCER RES, V71, P2926, DOI 10.1158/0008-5472.CAN-10-3369
   Shiraishi T, 2011, METHODS MOL BIOL, V683, P391, DOI 10.1007/978-1-60761-919-2_28
   Sibley CR, 2010, MOL THER, V18, P466, DOI 10.1038/mt.2009.306
   Sonkoly E, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000610
   Sontheimer EJ, 2005, CELL, V122, P9, DOI 10.1016/j.cell.2005.06.030
   Soomets U., 1999, FRONT BIOSCI, V4, pd782, DOI [10.2741/Soomets, DOI 10.2741/SOOMETS]
   Sredni ST, 2010, CHILD NERV SYST, V26, P279, DOI 10.1007/s00381-009-1028-y
   Stenvang J, 2008, EXPERT OPIN BIOL TH, V8, P59, DOI 10.1517/14712598.8.1.59
   Subramanian S, 2010, J CELL PHYSIOL, V223, P289, DOI 10.1002/jcp.22066
   Sugatani T, 2011, BLOOD, V117, P3648, DOI 10.1182/blood-2010-10-311415
   Sun YQ, 2010, BIOCHEM BIOPH RES CO, V391, P1483, DOI 10.1016/j.bbrc.2009.12.098
   Taccioli C, 2009, NUCLEIC ACIDS RES, V37, pD41, DOI 10.1093/nar/gkn702
   Taft RJ, 2010, J PATHOL, V220, P126, DOI 10.1002/path.2638
   Tan S, 2011, FEBS LETT, V585, P2229, DOI 10.1016/j.febslet.2011.05.042
   Tedeschi T, 2005, TETRAHEDRON LETT, V46, P8395, DOI 10.1016/j.tetlet.2005.09.157
   Thum T, 2008, NATURE, V456, P980, DOI 10.1038/nature07511
   Tian YY, 2010, J BIOL CHEM, V285, P7986, DOI 10.1074/jbc.M109.062877
   Tie J, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000879
   Tiscornia G, 2010, GENE DEV, V24, P2732, DOI 10.1101/gad.1982910
   Torres AG, 2011, RNA, V17, P933, DOI 10.1261/rna.2533811
   Tsai LM, 2010, CLIN EXP PHARMACOL P, V37, P102, DOI 10.1111/j.1440-1681.2009.05269.x
   Tsang WP, 2010, CARCINOGENESIS, V31, P350, DOI 10.1093/carcin/bgp181
   Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047
   van Almen GC, 2011, AGING CELL, DOI [10.1111/1.1474-9726.2011.00714.x, DOI 10.1111/1.1474-9726.2011.00714.X]
   Visone R, 2011, BLOOD, V118, P3072, DOI 10.1182/blood-2011-01-333484
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Voorhoeve PM, 2007, ADV EXP MED BIOL, V604, P17, DOI 10.1007/978-0-387-69116-9_2
   Wahid F, 2010, BBA-MOL CELL RES, V1803, P1231, DOI 10.1016/j.bbamcr.2010.06.013
   Wang D, 2010, BIOINFORMATICS, V26, P1644, DOI 10.1093/bioinformatics/btq241
   Wang K, 2010, J BIOL CHEM, V285, P16958, DOI 10.1074/jbc.M109.093005
   Wang WX, 2008, J NEUROSCI, V28, P1213, DOI 10.1523/JNEUROSCI.5065-07.2008
   Wang YM, 2009, CANCER RES, V69, P4093, DOI 10.1158/0008-5472.CAN-09-0309
   Wang Z., 2011, Journal of Biological Medicine, V1, P1
   Woods K, 2007, J BIOL CHEM, V282, P2130, DOI 10.1074/jbc.C600252200
   Wu WKK, 2011, CARCINOGENESIS, V32, P247, DOI 10.1093/carcin/bgq243
   Würdinger T, 2008, CANCER CELL, V14, P382, DOI 10.1016/j.ccr.2008.10.005
   Xi SC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013764
   Xiao CC, 2008, NAT IMMUNOL, V9, P405, DOI 10.1038/ni1575
   Xie HM, 2009, EXPERT OPIN THER TAR, V13, P1227, DOI 10.1517/14728220903190707
   Xu N, 2011, J INVEST DERMATOL, V131, P1521, DOI 10.1038/jid.2011.55
   Xu YJ, 2011, EXPERT OPIN THER TAR, V15, P961, DOI 10.1517/14728222.2011.581232
   Yan LX, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2803
   Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488
   Yoda M, 2010, NAT STRUCT MOL BIOL, V17, P17, DOI 10.1038/nsmb.1733
   Zhang CZ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-229
   Zhou P, 2003, J AM CHEM SOC, V125, P6878, DOI 10.1021/ja029665m
   Zhou P, 2006, BIOORG MED CHEM LETT, V16, P4931, DOI 10.1016/j.bmcl.2006.06.052
NR 189
TC 90
Z9 109
U1 0
U2 36
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
EI 1873-2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD NOV 15
PY 2011
VL 82
IS 10
SI SI
BP 1416
EP 1429
DI 10.1016/j.bcp.2011.08.007
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 840BX
UT WOS:000296414400017
PM 21864506
DA 2025-01-12
ER

PT J
AU Ashktorab, H
   Nguza, B
   Fatemi, M
   Nouraie, M
   Smoot, DT
   Schäffer, AA
   Kupfer, SS
   Camargo, CA
   Brim, H
AF Ashktorab, Hassan
   Nguza, Bijou
   Fatemi, Mehrnaz
   Nouraie, Mehdi
   Smoot, Duane T.
   Schaeffer, Alejandro A.
   Kupfer, Sonia S.
   Camargo, Carlos A., Jr.
   Brim, Hassan
TI Case-Control Study of Vitamin D, <i>dickkopf homolog 1</i> (<i>DKK1</i>)
   Gene Methylation, <i>VDR</i> Gene Polymorphism and the Risk of Colon
   Adenoma in African Americans
SO PLOS ONE
LA English
DT Article
ID D-RECEPTOR GENE; BREAST-CANCER RISK; COLORECTAL-CANCER; RECTAL-CANCER;
   CIRCULATING 25-HYDROXYVITAMIN-D; D DEFICIENCY; PREVENTION; POPULATION;
   ASSOCIATIONS; METAANALYSIS
AB Background: There are sparse data on genetic, epigenetic and vitamin D exposure in African Americans (AA) with colon polyp. Consequently, we evaluated serum 25(OH) D levels, vitamin D receptor (VDR) polymorphisms and the methylation status of the tumor suppressor gene dickkopf homolog 1 (DKK1) as risk factors for colon polyp in this population.
   Methods: The case-control study consisted of 93 patients with colon polyp (cases) and 187 healthy individuals (controls) at Howard University Hospital. Serum levels of 25(OH)D (including D3, D2, and total) were measured by liquid chromatography-mass spectrometry. DNA analysis focused on 49 single nucleotide polymorphisms (SNPs) in the VDR gene. Promoter methylation analysis of DKK1 was also performed. The resulting data were processed in unadjusted and multivariable logistic regression analyses.
   Results: Cases and controls differed in vitamin D status (D-3 < 50 nmol/L: Median of 35.5 in cases vs. 36.8 in controls nmol/L; P = 0.05). Low levels of 25(OH)D-3 (< 50 nmol/L) were observed in 86% of cases and 68% of controls and it was associated with higher risks of colon polyp (odds ratio of 2.7, 95% confidence interval 1.3-3.4). The SNP analysis showed no association between 46 VDR polymorphisms and colon polyp. The promoter of the DKK1 gene was unmethylated in 96% of the samples.
   Conclusion: We found an inverse association between serum 25(OH)D-3 and colon polyp in AAs. VDR SNPs and DKK1 methylation were not associated with colon polyp. Vitamin D levels may in part explain the higher incidence of polyp in AAs.
C1 [Ashktorab, Hassan; Nguza, Bijou; Fatemi, Mehrnaz; Smoot, Duane T.] Howard Univ, Coll Med, Dept Med, Washington, DC 20059 USA.
   [Ashktorab, Hassan; Nguza, Bijou; Fatemi, Mehrnaz; Smoot, Duane T.] Howard Univ, Ctr Canc, Coll Med, Washington, DC 20059 USA.
   [Nouraie, Mehdi] Howard Univ, Coll Med, Ctr Sickle Cell Dis, Washington, DC USA.
   [Brim, Hassan] Howard Univ, Coll Med, Dept Pathol, Washington, DC USA.
   [Schaeffer, Alejandro A.] NIH, Natl Ctr Biotechnol Informat, Dept Hlth & Human Serv, Bethesda, MD 20892 USA.
   [Kupfer, Sonia S.] Univ Chicago, Dept Med, Gastroenterol Sect, Chicago, IL 60637 USA.
   [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA.
C3 Howard University; Howard University; Howard University; Howard
   University; National Institutes of Health (NIH) - USA; University of
   Chicago; Harvard University; Massachusetts General Hospital; Harvard
   Medical School
RP Ashktorab, H (通讯作者)，Howard Univ, Coll Med, Dept Med, Washington, DC 20059 USA.
EM hashktorab@howard.edu
RI Kupfer, Sonia/ABD-9416-2021; Schaffer, Alejandro/N-1222-2019; Ashktorab,
   hassan/AAJ-2908-2020; , fatemi/AAF-5319-2021; Nouraie, Seyed
   Mehdi/GPW-8812-2022; Camargo, Carlos/C-2145-2008
OI Camargo, Carlos/0000-0002-5071-7654; Nouraie, Seyed
   Mehdi/0000-0001-7465-0581
FU National Institutes of Health [CA102681]; Massachusetts General Hospital
   Center for D-receptor Activation Research; NIH, NLM
FX This work was supported in part by a PHS grant from the National
   Institutes of Health CA102681, (H.A) and by the Massachusetts General
   Hospital Center for D-receptor Activation Research (C.A.C). The Cancer
   Research Foundation (S.S.K.) and the Digestive Disease Research Core
   Center (P30 DK42086). This work was also supported by the Intramural
   Research Program of the NIH, NLM (A.A.S.). No additional external
   funding received for this study. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Adams SV, 2011, NUTR CANCER, V63, P319, DOI 10.1080/01635581.2011.535960
   Ashktorab H, 2003, CLIN CANCER RES, V9, P1112
   Ashktorab H, 2009, DIGEST DIS SCI, V54, P1985, DOI 10.1007/s10620-009-0866-5
   Barroso E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-385
   Botella-Carretero JI, 2007, CLIN NUTR, V26, P573, DOI 10.1016/j.clnu.2007.05.009
   Bronowski C, 2008, MICROBIOL-SGM, V154, P571, DOI 10.1099/mic.0.2007/013086-0
   Chan AT, 2010, GASTROENTEROLOGY, V138, P2029, DOI 10.1053/j.gastro.2010.01.057
   Chen QY, 2005, P NATL ACAD SCI USA, V102, P14142, DOI 10.1073/pnas.0505018102
   Davis CD, 2008, AM J CLIN NUTR, V88, p565S, DOI 10.1093/ajcn/88.2.565S
   Dong LM, 2009, CANCER EPIDEM BIOMAR, V18, P2540, DOI 10.1158/1055-9965.EPI-09-0228
   Engelman CD, 2008, J CLIN ENDOCR METAB, V93, P3381, DOI 10.1210/jc.2007-2702
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Fedirko V, 2010, AM J EPIDEMIOL, V172, P489, DOI 10.1093/aje/kwq157
   Gandini S, 2011, INT J CANCER, V128, P1414, DOI 10.1002/ijc.25439
   Gao L, 2010, INT J TUBERC LUNG D, V14, P15
   Garland CF, 2009, ANN EPIDEMIOL, V19, P468, DOI 10.1016/j.annepidem.2009.03.021
   GARLAND CF, 1980, INT J EPIDEMIOL, V9, P227, DOI 10.1093/ije/9.3.227
   Houghton LA, 2006, AM J CLIN NUTR, V84, P694, DOI 10.1093/ajcn/84.4.694
   Howie BN, 2006, HUM GENET, V120, P58, DOI 10.1007/s00439-006-0182-5
   Jemal A, 2009, CANCER EPIDEM BIOMAR, V18, P3349, DOI 10.1158/1055-9965.EPI-09-0740
   Jenab M, 2009, CANCER EPIDEM BIOMAR, V18, P2485, DOI 10.1158/1055-9965.EPI-09-0319
   Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105
   Lee JE, 2011, CANCER PREV RES, V4, P735, DOI 10.1158/1940-6207.CAPR-10-0289
   Li C, 2009, DIGEST DIS SCI, V54, P634, DOI 10.1007/s10620-008-0375-y
   Looker AC, 2008, J BONE MINER RES, V23, P143, DOI 10.1359/JBMR.071003
   Lorente A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-61
   Mai V, 2009, NUTR J, V8, DOI 10.1186/1475-2891-8-49
   Mckay JD, 2009, CANCER EPIDEM BIOMAR, V18, P297, DOI 10.1158/1055-9965.EPI-08-0539
   Mohr SB, 2009, ANN EPIDEMIOL, V19, P79, DOI 10.1016/j.annepidem.2008.10.003
   Murtaugh MA, 2006, NUTR CANCER, V55, P35, DOI 10.1207/s15327914nc5501_5
   Newmark HL, 2009, CARCINOGENESIS, V30, P88, DOI 10.1093/carcin/bgn229
   Nouraie M, 2010, DIGEST DIS SCI, V55, P1442, DOI 10.1007/s10620-010-1133-5
   Pendás-Franco N, 2008, ANTICANCER RES, V28, P2613
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Roth HJ, 2008, ANN CLIN BIOCHEM, V45, P153, DOI 10.1258/acb.2007.007091
   Sharma N, 2004, J CLIN GASTROENTEROL, V38, P844, DOI 10.1097/00004836-200411000-00003
   Singh RJ, 2006, J CLIN ENDOCR METAB, V91, P3055, DOI 10.1210/jc.2006-0710
   Slattery ML, 2007, NUTR REV, V65, pS102, DOI 10.1111/j.1753-4887.2007.tb00332.x
   Slattery ML, 2009, MUTAT RES-FUND MOL M, V660, P12, DOI 10.1016/j.mrfmmm.2008.10.001
   Slattery ML, 2006, INT J CANCER, V118, P3140, DOI 10.1002/ijc.21791
   Tangpricha V, 2005, J NUTR, V135, P2350, DOI 10.1093/jn/135.10.2350
   Touvier M, 2011, CANCER EPIDEM BIOMAR, V20, P1003, DOI 10.1158/1055-9965.EPI-10-1141
   Trabert B, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1833
   Wei MY, 2008, CANCER EPIDEM BIOMAR, V17, P2958, DOI 10.1158/1055-9965.EPI-08-0402
   Zhang CL, 2008, CLIN CHIM ACTA, V395, P111, DOI 10.1016/j.cca.2008.05.019
NR 45
TC 16
Z9 17
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 13
PY 2011
VL 6
IS 10
AR e25314
DI 10.1371/journal.pone.0025314
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 834QT
UT WOS:000295978600012
PM 22022386
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Bi, CL
   Chng, WJ
AF Bi Chong Lei
   Chng Wee Joo
TI miRNA deregulation in multiple myeloma
SO CHINESE MEDICAL JOURNAL
LA English
DT Article
DE miRNA; multiple myeloma; pathogenesis; genetics; chromosome 13
ID CHRONIC LYMPHOCYTIC-LEUKEMIA; MICRORNA EXPRESSION; DOWN-REGULATION;
   PHARMACOLOGICAL ACTIVATION; UNDETERMINED SIGNIFICANCE; MONOCLONAL
   GAMMOPATHY; GENETIC EVENTS; BREAST-CANCER; CELL-LINES; PROFILES
AB Multiple myeloma (MM) is an incurable plasma cell malignancy and is the second most common hematological cancer. It is characterized by complex, recurrent genetic and epigenetic abnormalities. Recent publications have linked miRNAs, a novel class of gene regulators to cancer including MM. miRNAs are about 20 nucleotide, single strand, non-coding RNAs that repress gene expression by mRNA degradation or translational repression. Aberrant miRNA expression profiles have been described in MM, and their functional roles in MM pathogenesis are being increasingly recognized. This review summarizes the current literature on the role of miRNAs in MM and offers perspectives on future research and utilization of miRNAs in MM management. Chin Med J 2011;124(19):3164-3169
C1 [Chng Wee Joo] Natl Univ Hlth Syst, Natl Univ Canc Inst Singapore, Dept Hematol Oncol, Singapore 119228, Singapore.
   [Bi Chong Lei; Chng Wee Joo] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117548, Singapore.
   [Chng Wee Joo] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore 117595, Singapore.
C3 National University of Singapore; National University of Singapore;
   National University of Singapore
RP Chng, WJ (通讯作者)，Natl Univ Hlth Syst, Natl Univ Canc Inst Singapore, Dept Hematol Oncol, Singapore 119228, Singapore.
EM mdccwj@nus.edu.sg
RI Bi, Chonglei/D-2158-2011
CR Agnelli L, 2005, J CLIN ONCOL, V23, P7296, DOI 10.1200/JCO.2005.01.3870
   Ballabio E, 2010, BLOOD, V116, P1105, DOI 10.1182/blood-2009-12-256719
   Bandres E, 2009, INT J CANCER, V125, P2737, DOI 10.1002/ijc.24638
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   BI CL, 2010, MOL GENETICS MULTIPL, DOI DOI 10.1002/9780470015902.A0022446
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Chesi M, 2010, CANCER CELL, V18, P299, DOI 10.1016/j.ccr.2010.10.004
   Chng WJ, 2007, BEST PRACT RES CL HA, V20, P571, DOI 10.1016/j.beha.2007.08.004
   Chng Wee Joo, 2005, Cancer Control, V12, P91
   Feng DD, 2011, J CELL MOL MED, V15, P2164, DOI 10.1111/j.1582-4934.2010.01213.x
   Gutiérrez NC, 2010, LEUKEMIA, V24, P629, DOI 10.1038/leu.2009.274
   He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552
   Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868
   Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632
   Kozomara A, 2011, NUCLEIC ACIDS RES, V39, pD152, DOI 10.1093/nar/gkq1027
   Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843
   Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746
   Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003
   Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209
   Kumar S, 2010, CANCER TREAT REV, V36, pS3, DOI 10.1016/S0305-7372(10)70006-2
   Kyle RA, 2002, NEW ENGL J MED, V346, P564, DOI 10.1056/NEJMoa01133202
   Kyle RA, 2006, NEW ENGL J MED, V354, P1362, DOI 10.1056/NEJMoa054494
   Kyle RA, 2008, BLOOD, V111, P2962, DOI 10.1182/blood-2007-10-078022
   Lionetti M, 2009, BLOOD, V114, pE20, DOI 10.1182/blood-2009-08-237495
   Lionetti M, 2009, GENE CHROMOSOME CANC, V48, P521, DOI 10.1002/gcc.20660
   Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101
   Löffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood-2007-03-081133
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Melo SA, 2011, FEBS LETT, V585, P2087, DOI 10.1016/j.febslet.2010.08.009
   Mi SL, 2007, P NATL ACAD SCI USA, V104, P19971, DOI 10.1073/pnas.0709313104
   Munker R, 2010, ACTA HAEMATOL-BASEL, V123, P201, DOI 10.1159/000302889
   Muralidhar B, 2007, J PATHOL, V212, P368, DOI 10.1002/path.2179
   Pichiorri F, 2008, P NATL ACAD SCI USA, V105, P12885, DOI 10.1073/pnas.0806202105
   Pichiorri F, 2010, CANCER CELL, V18, P367, DOI 10.1016/j.ccr.2010.09.005
   Raab MS, 2009, LANCET, V374, P324, DOI 10.1016/S0140-6736(09)60221-X
   Rao X, 2011, ONCOGENE, V30, P1082, DOI 10.1038/onc.2010.487
   Roccaro AM, 2009, BLOOD, V113, P6669, DOI 10.1182/blood-2009-01-198408
   Roldo C, 2006, J CLIN ONCOL, V24, P4677, DOI 10.1200/JCO.2005.05.5194
   Ronchetti D, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-37
   Saha MN, 2010, J CLIN PATHOL, V63, P204, DOI 10.1136/jcp.2009.070961
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Sato F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005540
   Spizzo R, 2009, CELL, V137, P586, DOI 10.1016/j.cell.2009.04.040
   Stühmer T, 2006, CELL CYCLE, V5, P39, DOI 10.4161/cc.5.1.2281
   Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637
   Unno K, 2009, LEUKEMIA LYMPHOMA, V50, P1865, DOI 10.3109/10428190903221010
   Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Wang ZW, 2011, NAT REV GASTRO HEPAT, V8, P27, DOI 10.1038/nrgastro.2010.188
   Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025
   Zhou YM, 2010, P NATL ACAD SCI USA, V107, P7904, DOI 10.1073/pnas.0908441107
NR 58
TC 7
Z9 9
U1 0
U2 2
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0366-6999
J9 CHINESE MED J-PEKING
JI Chin. Med. J.
PD OCT 5
PY 2011
VL 124
IS 19
BP 3164
EP 3169
DI 10.3760/cma.j.issn.0366-6999.2011.19.037
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 838QP
UT WOS:000296307600038
PM 22040573
DA 2025-01-12
ER

PT J
AU Svotelis, A
   Bianco, S
   Madore, J
   Huppé, G
   Nordell-Markovits, A
   Mes-Masson, AM
   Gévry, N
AF Svotelis, Amy
   Bianco, Stephanie
   Madore, Jason
   Huppe, Gabrielle
   Nordell-Markovits, Alexei
   Mes-Masson, Anne-Marie
   Gevry, Nicolas
TI H3K27 demethylation by JMJD3 at a poised enhancer of anti-apoptotic gene
   <i>BCL2</i> determines ERα ligand dependency
SO EMBO JOURNAL
LA English
DT Article
DE BCL2; H3K27me3; JMJD3; oestrogen receptors
ID ESTROGEN-RECEPTOR-ALPHA; HISTONE METHYLTRANSFERASE ACTIVITY; POSITIVE
   BREAST-CANCER; ENDOCRINE RESISTANCE; TAMOXIFEN RESISTANCE;
   CELL-PROLIFERATION; EZH2; EXPRESSION; LYSINE-27; MECHANISMS
AB Chromatin represents a repressive barrier to the process of ligand-dependent transcriptional activity of nuclear receptors. Here, we show that H3K27 methylation imposes ligand-dependent regulation of the oestrogen receptor a (ER alpha)-dependent apoptotic response via Bcl-2 in breast cancer cells. The activation of BCL2 transcription is dependent on the simultaneous inactivation of the H3K27 methyltransferase, EZH2, and the demethylation of H3K27 at a poised enhancer by the ER alpha-dependent recruitment of JMJD3 in hormone-dependent breast cancer cells. We also provide evidence that this pathway is modified in cells resistant to anti-oestrogen (AE), which constitutively express BCL2. We show that the lack of H3K27 methylation at BCL2 regulatory elements due to the inactivation of EZH2 by the HER2 pathway leads to this constitutive activation of BCL2 in these AE-resistant cells. Our results describe a mechanism in which the epigenetic state of chromatin affects ligand dependency during ER alpha-regulated gene expression. The EMBO Journal (2011) 30, 3947-3961. doi:10.1038/emboj.2011.284; Published online 12 August 2011
C1 [Svotelis, Amy; Bianco, Stephanie; Huppe, Gabrielle; Nordell-Markovits, Alexei; Gevry, Nicolas] Univ Sherbrooke, Dept Biol, Fac Sci, Sherbrooke, PQ J1K 2R1, Canada.
   [Madore, Jason; Mes-Masson, Anne-Marie] CR CHUM, Inst Canc Montreal, Montreal, PQ, Canada.
C3 University of Sherbrooke; Universite de Montreal
RP Gévry, N (通讯作者)，Univ Sherbrooke, Dept Biol, Fac Sci, 2500 Blvd Univ, Sherbrooke, PQ J1K 2R1, Canada.
EM nicolas.gevry@usherbrooke.ca
OI Madore, Jason/0000-0002-3499-474X; Mes-Masson,
   Anne-Marie/0000-0002-6498-266X
FU Canadian Institute of Health Research (CIHR); FRSQ; NSERC; Reseau
   Quebecois en reproduction
FX We thank Alain Lavigueur, Viktor Steimle, Bruce Murphy, and Mylene
   Brunelle for critical comments on the manuscript and Benoit Leblanc for
   the artwork included in Figure 7. We thank Liette Laflamme and Luc
   Gaudreau for advice with the immunoprecipitation and GST pull-down
   assays and providing reagents. We are also grateful to Robert Clark,
   Mien-Chie Hung, and Didier Trono for providing reagents. We would also
   like to thank Viktor Steimle for the use of the FACS and important
   advice concerning the analysis, and Luc Paquette for advice on
   statistical analysis of the breast TMA. This work was supported with
   fund from the Canadian Institute of Health Research (CIHR) to NG. NG
   holds a Chercheur boursier (junior 1) award from the FRSQ. AS was the
   recipient of a doctoral fellowship from NSERC and Reseau Quebecois en
   reproduction.
CR Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145
   Agger K, 2009, GENE DEV, V23, P1171, DOI 10.1101/gad.510809
   Anderton JA, 2011, ONCOGENE, V30, P2037, DOI 10.1038/onc.2010.579
   Arold ST, 2001, J BIOL CHEM, V276, P17199, DOI 10.1074/jbc.M011185200
   Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Badia E, 2007, CURR MED CHEM, V14, P3035, DOI 10.2174/092986707782794023
   Badve S, 2009, J CLIN PATHOL, V62, P6, DOI 10.1136/jcp.2008.059899
   Barradas M, 2009, GENE DEV, V23, P1177, DOI 10.1101/gad.511109
   Benevolenskaya EV, 2007, BIOCHEM CELL BIOL, V85, P435, DOI 10.1139/O07-057
   BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bhat-Nakshatri P, 2008, MOL CELL BIOL, V28, P7487, DOI 10.1128/MCB.00799-08
   Blazejczyk M., 2007, FlexArray: A statistical data analysis software for gene expression microarrays
   Bredfeldt TG, 2010, MOL ENDOCRINOL, V24, P993, DOI 10.1210/me.2009-0438
   BRUNNER N, 1993, CANCER RES, V53, P3229
   Brunner N, 1997, CANCER RES, V57, P3486
   Burgold T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003034
   Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Castaneda CA, 2010, CANCER METAST REV, V29, P751, DOI 10.1007/s10555-010-9261-0
   Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050
   Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947
   Cloos PAC, 2008, GENE DEV, V22, P1115, DOI 10.1101/gad.1652908
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Cooper CS, 2009, BRIT J CANCER, V100, P240, DOI 10.1038/sj.bjc.6604771
   Creyghton MP, 2008, CELL, V135, P649, DOI 10.1016/j.cell.2008.09.056
   Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3
   De Santa F, 2007, CELL, V130, P1083, DOI 10.1016/j.cell.2007.08.019
   Ding L, 2006, CANCER RES, V66, P4095, DOI 10.1158/0008-5472.CAN-05-4300
   Ding L, 2006, CANCER RES, V66, P9352, DOI 10.1158/0008-5472.CAN-06-2384
   Eeckhoute J, 2009, GENOME RES, V19, P372, DOI 10.1101/gr.084582.108
   Fan MY, 2003, MOL ENDOCRINOL, V17, P356, DOI 10.1210/me.2002-0323
   FERGUSON DJP, 1981, BRIT J CANCER, V44, P177, DOI 10.1038/bjc.1981.168
   Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497
   Gevry N, 2007, GENE DEV, V21, P1869, DOI 10.1101/gad.1545707
   Gévry N, 2009, GENE DEV, V23, P1522, DOI 10.1101/gad.1787109
   Gonzalez ME, 2009, ONCOGENE, V28, P843, DOI 10.1038/onc.2008.433
   He HSHS, 2010, NAT GENET, V42, P343, DOI 10.1038/ng.545
   Jones RS, 2007, NATURE, V450, P357, DOI 10.1038/450357a
   Jorgensen HF, 2006, CELL CYCLE, V5, P1411, DOI 10.4161/cc.5.13.2927
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kumar R, 1996, CLIN CANCER RES, V2, P1215
   Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902
   KYPRIANOU N, 1991, CANCER RES, V51, P162
   Lan F, 2007, NATURE, V449, P689, DOI 10.1038/nature06192
   Luger K, 2003, CURR OPIN GENET DEV, V13, P127, DOI 10.1016/S0959-437X(03)00026-1
   Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504
   Mattera L, 2009, ONCOGENE, V28, P1506, DOI 10.1038/onc.2008.499
   Mattera L, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000983
   McClelland RA, 1996, BREAST CANCER RES TR, V41, P31, DOI 10.1007/BF01807034
   Mellor J, 2005, MOL CELL, V19, P147, DOI 10.1016/j.molcel.2005.06.023
   Métivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Müller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5
   Naughton C, 2007, MOL ENDOCRINOL, V21, P2615, DOI 10.1210/me.2007-0110
   Normanno N, 2005, ENDOCR-RELAT CANCER, V12, P721, DOI 10.1677/erc.1.00857
   Ordóñez-Morán P, 2009, CELL CYCLE, V8, P1675, DOI 10.4161/cc.8.11.8579
   Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917
   Park S, 2008, CELL SIGNAL, V20, P1368, DOI 10.1016/j.cellsig.2008.03.004
   Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402
   Pearce ST, 2004, CRIT REV ONCOL HEMAT, V50, P3, DOI 10.1016/j.critrevonc.2003.09.003
   Perillo B, 2008, SCIENCE, V319, P202, DOI 10.1126/science.1147674
   Pietras RJ, 2007, CLIN CANCER RES, V13, P4672, DOI 10.1158/1078-0432.CCR-07-1373
   Raaphorst FM, 2003, NEOPLASIA, V5, P481, DOI 10.1016/S1476-5586(03)80032-5
   Rada-Iglesias A, 2011, NATURE, V470, P279, DOI 10.1038/nature09692
   Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100
   Riggins RB, 2007, CANCER LETT, V256, P1, DOI 10.1016/j.canlet.2007.03.016
   Russell KS, 2000, P NATL ACAD SCI USA, V97, P5930, DOI 10.1073/pnas.97.11.5930
   Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349
   Schiff R, 2004, CLIN CANCER RES, V10, p331S, DOI 10.1158/1078-0432.CCR-031212
   Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672
   Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4
   Sharov AA, 2007, CELL STEM CELL, V1, P237, DOI 10.1016/j.stem.2007.08.015
   Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166
   Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763
   Sommer S, 2001, SEMIN CANCER BIOL, V11, P339, DOI 10.1006/scbi.2001.0389
   Stoica GE, 2003, ONCOGENE, V22, P7998, DOI 10.1038/sj.onc.1206769
   Sun M, 2001, CANCER RES, V61, P5985
   Swigut T, 2007, CELL, V131, P29, DOI 10.1016/j.cell.2007.09.026
   TEIXEIRA C, 1995, CANCER RES, V55, P3902
   Wang LH, 2006, CANCER CELL, V10, P487, DOI 10.1016/j.ccr.2006.09.015
   Wei YK, 2008, MOL CARCINOGEN, V47, P701, DOI 10.1002/mc.20413
   Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88
   Xiang Y, 2007, CELL RES, V17, P850, DOI 10.1038/cr.2007.83
   Zhou VW, 2011, NAT REV GENET, V12, P7, DOI 10.1038/nrg2905
NR 87
TC 72
Z9 87
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
PD OCT 5
PY 2011
VL 30
IS 19
BP 3947
EP 3961
DI 10.1038/emboj.2011.284
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 834ND
UT WOS:000295967300010
PM 21841772
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Di, JZ
   Han, XD
   Gu, WY
   Wang, Y
   Zheng, Q
   Zhang, P
   Wu, HM
   Zhu, ZZ
AF Di, Jian-zhong
   Han, Xiao-dong
   Gu, Wen-ye
   Wang, Yu
   Zheng, Qi
   Zhang, Pin
   Wu, Hui-min
   Zhu, Zhong-zheng
TI Association of hypomethylation of LINE-1 repetitive element in blood
   leukocyte DNA with an increased risk of hepatocellular carcinoma
SO JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B
LA English
DT Article
DE Cancer risk; Epigenetics; Global hypomethylation; Hepatocellular
   carcinoma; LINE-1 repetitive element
ID GENOMIC HYPOMETHYLATION; METHYLATION PATTERNS; COLORECTAL ADENOMA;
   BREAST-CANCER; HYPERMETHYLATION; BIOMARKER; RETROTRANSPOSONS; EXPOSURE;
   DISEASE; TUMORS
AB Global DNA hypomethylation has been associated with increased risk for cancers of the colorectum, bladder, breast, head and neck, and testicular germ cells. The aim of this study was to examine whether global hypomethylation in blood leukocyte DNA is associated with the risk of hepatocellular carcinoma (HCC). A total of 315 HCC cases and 356 age-, sex- and HBsAg status-matched controls were included. Global methylation in blood leukocyte DNA was estimated by analyzing long interspersed element-1 (LINE-1) repeats using bisulfite-polymerase chain reaction (PCR) and pyrosequencing. We observed that the median methylation level in HCC cases (percentage of 5-methylcytosine (5mC)=77.7%) was significantly lower than that in controls (79.5% 5mC) (P=0.004, Wilcoxon rank-sum test). The odds ratios (ORs) of HCC for individuals in the third, second, and first (lowest) quartiles of LINE-1 methylation were 1.1 (95% confidence interval (CI) 0.7-1.8), 1.4 (95% CI 0.8-2.2), and 2.6 (95% CI 1.7-4.1) (P for trend <0.001), respectively, compared to individuals in the fourth (highest) quartile. A 1.9-fold (95% CI 1.4-2.6) increased risk of HCC was observed among individuals with LINE-1 methylation below the median compared to individuals with higher (>median) LINE-1 methylation. Our results demonstrate for the first time that individuals with global hypomethylation measured in LINE-1 repeats in blood leukocyte DNA have an increased risk for HCC. Our data provide the evidence that global hypomethylation detected in the easily obtainable DNA source of blood leukocytes may help identify individuals at risk of HCC.
C1 [Di, Jian-zhong; Han, Xiao-dong; Wang, Yu; Zheng, Qi; Zhang, Pin] Shanghai Jiao Tong Univ, Dept Gen Surg, Peoples Hosp 6, Shanghai 200233, Peoples R China.
   [Gu, Wen-ye] Shanghai Guanghua Hosp, Dept Gastroenterol, Shanghai 200052, Peoples R China.
   [Wu, Hui-min] Tongji Univ, Dept Gen Surg, Tongji Hosp, Shanghai 200065, Peoples R China.
   [Zhu, Zhong-zheng] 113 Hosp Peoples Liberat Army, Dept Oncol, Ningbo 315040, Zhejiang, Peoples R China.
C3 Shanghai Jiao Tong University; Tongji University
RP Zhang, P (通讯作者)，Shanghai Jiao Tong Univ, Dept Gen Surg, Peoples Hosp 6, Shanghai 200233, Peoples R China.
EM zhangpindjz@163.com
RI han, xiao/HDN-9782-2022
CR Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877
   Bjornsson HT, 2004, TRENDS GENET, V20, P350, DOI 10.1016/j.tig.2004.06.009
   Bollati V, 2007, CANCER RES, V67, P876, DOI 10.1158/0008-5472.CAN-06-2995
   Breton CV, 2009, AM J RESP CRIT CARE, V180, P462, DOI 10.1164/rccm.200901-0135OC
   Burden AF, 2005, J BIOL CHEM, V280, P14413, DOI 10.1074/jbc.M413836200
   Cho NY, 2007, J PATHOL, V211, P269, DOI 10.1002/path.2106
   Cho YH, 2010, ANTICANCER RES, V30, P2489
   Choi JY, 2009, CARCINOGENESIS, V30, P1889, DOI 10.1093/carcin/bgp143
   Cordaux R, 2009, NAT REV GENET, V10, P691, DOI 10.1038/nrg2640
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Dhanasekaran R, 2012, HEPATIC MED-EVID RES, V4, P19, DOI [10.1586/egh.09.35, 10.2147/HMER.S16316]
   El-Maarri O, 2007, HUM GENET, V122, P505, DOI 10.1007/s00439-007-0430-3
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Formeister EJ, 2010, MUTAT RES-FUND MOL M, V692, P26, DOI 10.1016/j.mrfmmm.2010.07.013
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Gluckman PD, 2008, NEW ENGL J MED, V359, P61, DOI 10.1056/NEJMra0708473
   Gomaa AI, 2008, WORLD J GASTROENTERO, V14, P4300, DOI 10.3748/wjg.14.4300
   Hillemacher T, 2008, EUR NEUROPSYCHOPHARM, V18, P295, DOI 10.1016/j.euroneuro.2007.12.005
   Hsieh CL, 2000, CURR OPIN GENET DEV, V10, P224, DOI 10.1016/S0959-437X(00)00064-2
   Hsiung DT, 2007, CANCER EPIDEM BIOMAR, V16, P108, DOI 10.1158/1055-9965.EPI-06-0636
   Iskow RC, 2010, CELL, V141, P1253, DOI 10.1016/j.cell.2010.05.020
   Kim YJ, 2005, INTERVIROLOGY, V48, P10, DOI 10.1159/000082089
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Lee HS, 2009, CLIN CANCER RES, V15, P812, DOI 10.1158/1078-0432.CCR-08-0266
   Lei HJ, 2006, J AM COLL SURGEONS, V203, P426, DOI 10.1016/j.jamcollsurg.2006.06.030
   Lim U, 2008, GASTROENTEROLOGY, V134, P47, DOI 10.1053/j.gastro.2007.10.013
   Liu F, 2010, ONCOGENE, V29, P3650, DOI 10.1038/onc.2010.129
   Mirabello L, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-77
   Moore LE, 2008, LANCET ONCOL, V9, P359, DOI 10.1016/S1470-2045(08)70038-X
   Morgan TR, 2004, GASTROENTEROLOGY, V127, pS87, DOI 10.1053/j.gastro.2004.09.020
   Ogino S, 2008, INT J CANCER, V122, P2767, DOI 10.1002/ijc.23470
   Okuda H, 2007, BEST PRACT RES CL GA, V21, P161, DOI 10.1016/j.bpg.2006.07.002
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Pufulete M, 2003, GASTROENTEROLOGY, V124, P1240, DOI 10.1016/S0016-5085(03)00279-8
   Rusiecki JA, 2008, ENVIRON HEALTH PERSP, V116, P1547, DOI 10.1289/ehp.11338
   Schernhammer ES, 2010, GUT, V59, P794, DOI 10.1136/gut.2009.183707
   Suzuki Hiromu, 2006, Asian Pac J Cancer Prev, V7, P177
   Tangkijvanich P, 2007, CLIN CHIM ACTA, V379, P127, DOI 10.1016/j.cca.2006.12.029
   Tarantini L, 2009, ENVIRON HEALTH PERSP, V117, P217, DOI 10.1289/ehp.11898
   THOMAS GA, 1992, CARCINOGENESIS, V13, P1039, DOI 10.1093/carcin/13.6.1039
   Wan YJ, 2010, TOXICOLOGY, V274, P57, DOI 10.1016/j.tox.2010.05.006
   Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987
   WILSON MJ, 1984, BIOCHEM J, V218, P987, DOI 10.1042/bj2180987
   Wolff EM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000917
   Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032
   Zhu ZZ, 2011, CANCER CAUSE CONTROL, V22, P437, DOI 10.1007/s10552-010-9715-2
NR 47
TC 21
Z9 21
U1 0
U2 10
PU ZHEJIANG UNIV
PI HANGZHOU
PA EDITORIAL BOARD, 20 YUGU RD, HANGZHOU, 310027, PEOPLES R CHINA
SN 1673-1581
J9 J ZHEJIANG UNIV-SC B
JI J. Zhejiang Univ.-SCI. B
PD OCT
PY 2011
VL 12
IS 10
BP 805
EP 811
DI 10.1631/jzus.B1000422
PG 7
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Research & Experimental Medicine
GA 837YX
UT WOS:000296251900003
PM 21960343
OA Green Published
DA 2025-01-12
ER

PT J
AU Chang, SH
   Wang, RH
   Akagi, K
   Kim, KA
   Martin, BK
   Cavallone, L
   Haines, DC
   Basik, M
   Mai, P
   Poggi, E
   Isaacs, C
   Looi, LM
   Mun, KS
   Greene, MH
   Byers, SW
   Teo, SH
   Deng, CX
   Sharan, SK
AF Chang, Suhwan
   Wang, Rui-Hong
   Akagi, Keiko
   Kim, Kyung-Ae
   Martin, Betty K.
   Cavallone, Luca
   Haines, Diana C.
   Basik, Mark
   Mai, Phuong
   Poggi, Elizabeth
   Isaacs, Claudine
   Looi, Lai M.
   Mun, Kein S.
   Greene, Mark H.
   Byers, Stephen W.
   Teo, Soo H.
   Deng, Chu-Xia
   Sharan, Shyam K.
CA Kathleen Cuningham Fdn Consortium
TI Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155
SO NATURE MEDICINE
LA English
DT Article
ID CELL-CYCLE CHECKPOINT; DNA-DAMAGE RESPONSE; BREAST-CANCER; LIGASE
   ACTIVITY; HIGH EXPRESSION; STEM-CELLS; IN-VIVO; C-MYC; PROTEIN; GENE
AB BRCA1, a well-known tumor suppressor with multiple interacting partners, is predicted to have diverse biological functions. However, so far its only well-established role is in the repair of damaged DNA and cell cycle regulation. In this regard, the etiopathological study of low-penetrant variants of BRCA1 provides an opportunity to uncover its other physiologically important functions. Using this rationale, we studied the R1699Q variant of BRCA1, a potentially moderate-risk variant, and found that it does not impair DNA damage repair but abrogates the repression of microRNA-155 (miR-155), a bona fide oncomir. Mechanistically, we found that BRCA1 epigenetically represses miR-155 expression via its association with HDAC2, which deacetylates histones H2A and H3 on the miR-155 promoter. We show that overexpression of miR-155 accelerates but the knockdown of miR-155 attenuates the growth of tumor cell lines in vivo. Our findings demonstrate a new mode of tumor suppression by BRCA1 and suggest that miR-155 is a potential therapeutic target for BRCA1-deficient tumors.
C1 [Sharan, Shyam K.; Kathleen Cuningham Fdn Consortium] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
   [Chang, Suhwan; Kim, Kyung-Ae] NCI, Mouse Canc Genet Program, Ctr Canc Res, Frederick, MD 21701 USA.
   [Wang, Rui-Hong; Deng, Chu-Xia] NIDDK, Genet Dev & Dis Branch, Bethesda, MD USA.
   [Akagi, Keiko] Ohio State Univ, Human Canc Genet Program, Dept Mol Virol, Columbus, OH 43210 USA.
   [Akagi, Keiko] Ohio State Univ, Human Canc Genet Program, Dept Immunol, Columbus, OH 43210 USA.
   [Akagi, Keiko] Ohio State Univ, Human Canc Genet Program, Dept Med Genet, Columbus, OH 43210 USA.
   [Martin, Betty K.] NCI, Sci Applicat Int Corp SAIC Frederick, Frederick, MD 21701 USA.
   [Cavallone, Luca; Basik, Mark] McGill Univ, Jewish Gen Hosp, Lady Davis Inst, Montreal, PQ H3T 1E2, Canada.
   [Cavallone, Luca] McGill Univ, Dept Oncol, Program Canc Genet, Montreal, PQ, Canada.
   [Cavallone, Luca] McGill Univ, Dept Human Genet, Program Canc Genet, Montreal, PQ, Canada.
   [Haines, Diana C.] NCI, Pathol Histotechnol Lab, SAIC Frederick, Frederick, MD 21701 USA.
   [Mai, Phuong; Greene, Mark H.] NCI, Clin Genet Branch, Rockville, MD USA.
   [Poggi, Elizabeth; Isaacs, Claudine; Byers, Stephen W.] Georgetown Univ, Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA.
   [Looi, Lai M.; Mun, Kein S.] Univ Malaya, Dept Pathol, Med Ctr, Kuala Lumpur, Malaysia.
   [Teo, Soo H.] Univ Malaya, Med Ctr, Dept Surg, Univ Malaya Canc Res Inst, Kuala Lumpur, Malaysia.
   [Teo, Soo H.] Sime Darby Med Ctr, Canc Res Initiat Fdn, Kuala Lumpur, Malaysia.
C3 Peter Maccallum Cancer Center; National Institutes of Health (NIH) -
   USA; NIH National Cancer Institute (NCI); National Institutes of Health
   (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney
   Diseases (NIDDK); University System of Ohio; Ohio State University;
   University System of Ohio; Ohio State University; University System of
   Ohio; Ohio State University; National Institutes of Health (NIH) - USA;
   NIH National Cancer Institute (NCI); Science Applications International
   Corporation (SAIC); SAIC-Frederick; McGill University; Lady Davis
   Institute; McGill University; McGill University; National Institutes of
   Health (NIH) - USA; NIH National Cancer Institute (NCI); Science
   Applications International Corporation (SAIC); SAIC-Frederick; National
   Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI);
   Georgetown University; Universiti Malaya; Universiti Malaya
RP Sharan, SK (通讯作者)，Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
EM sharans@mail.nih.gov
RI deng, chuxia/N-6713-2016; Looi, Lai Meng/AAB-9403-2019; Mun,
   Kein/E-4155-2010; Teo, Soo-hwang/H-2353-2014; Kim, Jong/I-3135-2019;
   Looi, Lai Meng/A-3382-2009
OI Thorne, Heather/0000-0003-3610-2511; Chang, Suhwan/0000-0002-0282-0120;
   Teo, Soo/0000-0002-0444-590X; Looi, Lai Meng/0000-0001-8325-0117
FU Center for Cancer Research, US National Cancer Institute; US National
   Institutes of Health; National Cancer Institute [ZIACP010144] Funding
   Source: NIH RePORTER
FX We thank J. Acharya, K. Biswas, R. Chittela, I. Daar, K. Reilly and A.
   Spurdle for helpful discussions and critical review of the manuscript.
   We also thank D. M. Livingston (Dana-Farber Cancer Institute) and D. L.
   Turner (University of Michigan) for providing DNA constructs; D. Swing
   for help with BAC transgenic mice and allograft experiment; W. D.
   Foulkes, A. Spurdle, H. Thorne, Y.C. Har, P.S. Yee, A. Saleh, the
   Georgetown-Lombardi Comprehensive Cancer Center, Familial Cancer and
   Histopathology and Tissue Share Resources, who helped with the human
   tumor samples; S. Burkett for cytogenetic analysis; C. H. Kim for
   microarray analysis, and A. Kane and R. Frederickson for illustrations.
   The research was sponsored by the Center for Cancer Research, US
   National Cancer Institute and US National Institutes of Health.
CR Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808
   Aiyar SE, 2007, INT J BIOL SCI, V3, P486
   Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168
   Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929
   Cable PL, 2003, MOL CARCINOGEN, V38, P85, DOI 10.1002/mc.10148
   Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X
   Chang SW, 2009, J CLIN INVEST, V119, P3160, DOI 10.1172/JCI39836
   Chen JJ, 2000, CANCER RES, V60, P5037
   Clapperton JA, 2004, NAT STRUCT MOL BIOL, V11, P512, DOI 10.1038/nsmb775
   Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162
   Costinean S, 2006, P NATL ACAD SCI USA, V103, P7024, DOI 10.1073/pnas.0602266103
   Deffenbaugh AM, 2002, GENET TEST, V6, P119, DOI 10.1089/10906570260199375
   Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010
   García EBG, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2223
   Gironella M, 2007, P NATL ACAD SCI USA, V104, P16170, DOI 10.1073/pnas.0703942104
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Jiang SA, 2010, CANCER RES, V70, P3119, DOI 10.1158/0008-5472.CAN-09-4250
   Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505
   Kluiver J, 2005, J PATHOL, V207, P243, DOI 10.1002/path.1825
   Kong W, 2010, J BIOL CHEM, V285, P17869, DOI 10.1074/jbc.M110.101055
   Lee MS, 2010, CANCER RES, V70, P4880, DOI 10.1158/0008-5472.CAN-09-4563
   Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334
   Liu X, 2007, P NATL ACAD SCI USA, V104, P12111, DOI 10.1073/pnas.0702969104
   Lovelock PK, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1826
   Metzler M, 2004, GENE CHROMOSOME CANC, V39, P167, DOI 10.1002/gcc.10316
   O'Connell RM, 2008, J EXP MED, V205, P585, DOI 10.1084/jem.20072108
   O'Donovan PJ, 2010, CARCINOGENESIS, V31, P961, DOI 10.1093/carcin/bgq069
   Ouchi M, 2004, J BIOL CHEM, V279, P19643, DOI 10.1074/jbc.M311780200
   Rowling PJE, 2010, J BIOL CHEM, V285, P20080, DOI 10.1074/jbc.M109.088922
   Ruffner H, 1999, MOL CELL BIOL, V19, P4843
   Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4
   SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811
   Tam W, 2002, J VIROL, V76, P4275, DOI 10.1128/JVI.76.9.4275-4286.2002
   van den Berg A, 2003, GENE CHROMOSOME CANC, V37, P20, DOI 10.1002/gcc.10186
   Venkitaraman AR, 2009, ANNU REV PATHOL-MECH, V4, P461, DOI 10.1146/annurev.pathol.3.121806.151422
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403
   Wang RH, 2008, MOL CELL, V32, P11, DOI 10.1016/j.molcel.2008.09.011
   Williams RS, 2004, NAT STRUCT MOL BIOL, V11, P519, DOI 10.1038/nsmb776
   Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200
   Yamamoto M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016841
   Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983
   Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388
   Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753
NR 46
TC 182
Z9 204
U1 0
U2 19
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD OCT
PY 2011
VL 17
IS 10
BP 1275
EP U308
DI 10.1038/nm.2459
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 835FW
UT WOS:000296022100046
PM 21946536
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Tao, MH
   Marian, C
   Shields, PG
   Nie, J
   McCann, SE
   Millen, A
   Ambrosone, C
   Hutson, A
   Edge, SB
   Krishnan, SS
   Xie, B
   Winston, J
   Vito, D
   Russell, M
   Nochajski, TH
   Trevisan, M
   Freudenheim, JL
AF Tao, Meng Hua
   Marian, Catalin
   Shields, Peter G.
   Nie, Jing
   McCann, Susan E.
   Millen, Amy
   Ambrosone, Christine
   Hutson, Alan
   Edge, Stephen B.
   Krishnan, Shiva S.
   Xie, Bin
   Winston, Janet
   Vito, Dominica
   Russell, Marcia
   Nochajski, Thomas H.
   Trevisan, Maurizio
   Freudenheim, Jo L.
TI Alcohol consumption in relation to aberrant DNA methylation in breast
   tumors
SO ALCOHOL
LA English
DT Article
DE Alcohol consumption; Breast cancer; Epidemiology; Epigenetics; Promoter
   methylation; Postmenopause
ID SQUAMOUS-CELL CARCINOMA; SPORADIC COLORECTAL-CANCER; LIFETIME DRINKING
   HISTORY; PROMOTER METHYLATION; POSTMENOPAUSAL WOMEN; HYPERMETHYLATION
   PROFILE; DIETARY-FOLATE; GENES; HEAD; NECK
AB The mechanism for the observed association of alcohol consumption breast cancer risk is not known; understanding that mechanism could improve understanding of breast carcinogenesis and optimize prevention strategies. Alcohol may impact breast malignancies or tumor progression by altering DNA methylation. We examined promoter methylation of three genes, the E-cadherin, pl6, and retinoic acid-binding receptor-beta 2 (RAR-beta(2)) genes in archived breast tumor tissues from participants in a population-based case-control study. Real time methylation-specific PCR was performed on 803 paraffin-embedded samples, and lifetime alcohol consumption was queried. Unordered polytomous and unconditional logistic regression were used to derive adjusted odds ratios (ORs) and 95% confidence intervals (CIs). RAR-beta(2) methylation was not associated with drinking. Among premenopausal women, alcohol consumption was also not associated with promoter methylation for E-cadherin and pl6 genes. In case-case comparisons of postmenopausal breast cancer, compared with lifetime never drinkers, promoter methylation likelihood was increased for higher alcohol intake for E-cadherin (OR = 2.39; 95% CI, 1.15-4.96), in particular for those with estrogen receptor-negative tumors (OR = 4.13; 95% CI, 1.16-14.72), and decreased for pl6 (OR = 0.52; 95% CI, 0.29-0.92). There were indications that the association with pl6 was stronger for drinking at younger ages. Methylation was also associated with drinking intensity independent of total consumption for both genes. We found alcohol consumption was associated with DNA methylation in postmenopausal breast tumors, suggesting that the association of alcohol and breast cancer may be related, at least in part, to altered methylation, and may differ by drinking pattern. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Tao, Meng Hua] Mt Sinai Sch Med, Dept Hematol & Med Oncol, New York, NY 10029 USA.
   [Tao, Meng Hua; Nie, Jing; Millen, Amy; Vito, Dominica; Trevisan, Maurizio; Freudenheim, Jo L.] SUNY Buffalo, Dept Social & Prevent Med, Sch Publ Hlth & Hlth Profess, Buffalo, NY 14260 USA.
   [Marian, Catalin; Shields, Peter G.; Krishnan, Shiva S.; Xie, Bin] Georgetown Univ, Lombardi Canc Ctr, Washington, DC USA.
   [McCann, Susan E.; Ambrosone, Christine] Roswell Pk Canc Inst, Dept Canc Prevent & Control, Buffalo, NY 14263 USA.
   [Hutson, Alan] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Biostat, Buffalo, NY 14260 USA.
   [Edge, Stephen B.] Roswell Pk Canc Inst, Dept Surg, Buffalo, NY 14263 USA.
   [Winston, Janet] Potomac Hosp, Woodbridge, VA USA.
   [Russell, Marcia] Prevent Res Ctr, Berkeley, CA USA.
   [Trevisan, Maurizio] Univ Nevada Hlth Sci Syst, Las Vegas, NV USA.
C3 Icahn School of Medicine at Mount Sinai; State University of New York
   (SUNY) System; University at Buffalo, SUNY; Georgetown University;
   Roswell Park Comprehensive Cancer Center; State University of New York
   (SUNY) System; University at Buffalo, SUNY; Roswell Park Comprehensive
   Cancer Center; Pacific Institute for Research & Evaluation (PIRE);
   Nevada System of Higher Education (NSHE); University of Nevada Las Vegas
RP Tao, MH (通讯作者)，Mt Sinai Sch Med, Dept Hematol & Med Oncol, New York, NY 10029 USA.
EM menghua.tao@mssm.edu
RI Millen, Amy/JJC-1611-2023; Marian, Catalin/KHU-8477-2024; Shields,
   Peter/I-1644-2012; Marian, Catalin/P-2885-2019
OI Marian, Catalin/0000-0002-7749-1384; Freudenheim, Jo/0000-0002-9301-0499
FU National Institute on Alcohol Abuse and Alcoholism [P50-AA09802];
   Department of Defense [DAMD 179616202, DAMD 17030446]; National Cancer
   Institute [R01CA 092040]
FX This study would not have been possible without the support of all the
   study participants and the research staff of the Western New York
   Exposures and Breast Cancer Study. This work was supported in part by
   the National Institute on Alcohol Abuse and Alcoholism (P50-AA09802),
   the Department of Defense (DAMD 179616202 and DAMD 17030446), and the
   National Cancer Institute (R01CA 092040).
CR Beral V, 2002, BRIT J CANCER, V87, P1234, DOI 10.1038/sj.bjc.6600596
   Castro GD, 2006, TOXICOLOGY, V219, P208, DOI 10.1016/j.tox.2005.11.019
   Choi SW, 2002, J NUTR, V132, p2413S, DOI 10.1093/jn/132.8.2413S
   de Vogel S, 2008, CARCINOGENESIS, V29, P1765, DOI 10.1093/carcin/bgn074
   Dorgan JF, 2001, JNCI-J NATL CANCER I, V93, P710, DOI 10.1093/jnci/93.9.710
   Durnitrescu RG, 2005, ALCOHOL, V35, P213, DOI 10.1016/j.alcohol.2005.04.005
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Esteller M, 2001, CANCER RES, V61, P3225
   Fernandez SV, 2010, TOXICOL PATHOL, V38, P110, DOI 10.1177/0192623309354108
   Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508
   Friedenreich C M, 1991, Ann Epidemiol, V1, P439
   GIOVANNUCCI E, 1993, CANCER CAUSE CONTROL, V4, P441, DOI 10.1007/BF00050863
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Hasegawa M, 2002, ONCOGENE, V21, P4231, DOI 10.1038/sj.onc.1205528
   Homann N, 2005, ALCOHOL CLIN EXP RES, V29, P1317, DOI 10.1097/01.ALC.0000171892.09367.6F
   Jerónimo C, 2001, J NATL CANCER I, V93, P1747, DOI 10.1093/jnci/93.22.1747
   Ke ZJ, 2006, INT J CANCER, V119, P8, DOI 10.1002/ijc.21769
   Key J, 2006, CANCER CAUSE CONTROL, V17, P759, DOI 10.1007/s10552-006-0011-0
   Krassenstein R, 2004, CLIN CANCER RES, V10, P28, DOI 10.1158/1078-0432.CCR-0410-3
   Kraunz KS, 2006, INT J CANCER, V119, P1553, DOI 10.1002/ijc.22013
   Lee ES, 2008, CLIN CANCER RES, V14, P2664, DOI 10.1158/1078-0432.CCR-07-1232
   Li SY, 2006, CANCER LETT, V237, P272, DOI 10.1016/j.canlet.2005.06.011
   Ma CL, 2003, ONCOGENE, V22, P5281, DOI 10.1038/sj.onc.1206675
   Marsit CJ, 2006, INT J CANCER, V119, P1761, DOI 10.1002/ijc.22051
   Mason JB, 2005, ALCOHOL, V35, P235, DOI 10.1016/j.alcohol.2005.03.012
   Mehrotra J, 2004, CLIN CANCER RES, V10, P3104, DOI 10.1158/1078-0432.CCR-03-0118
   Meng QH, 2000, BIOCHEM BIOPH RES CO, V273, P448, DOI 10.1006/bbrc.2000.2942
   Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Petri AL, 2004, ALCOHOL CLIN EXP RES, V28, P1084, DOI 10.1097/01.ALC.0000130812.85638.E1
   Puri SK, 2005, AM J OTOLARYNG, V26, P12, DOI 10.1016/j.amjoto.2004.06.007
   Rinaldi S, 2006, CANCER CAUSE CONTROL, V17, P1033, DOI 10.1007/s10552-006-0041-7
   Russell M, 1998, DRUG ALCOHOL REV, V17, P377, DOI 10.1080/09595239800187221
   Russell M, 1997, AM J EPIDEMIOL, V146, P975
   Sauer J, 2010, BRIT J NUTR, V104, P24, DOI 10.1017/S0007114510000322
   Shames DS, 2007, CANCER LETT, V251, P187, DOI 10.1016/j.canlet.2006.10.014
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   SINGLETARY KW, 2004, JAMA-J AM MED ASSOC, V286, P2143
   Slattery ML, 2007, INT J CANCER, V120, P656, DOI 10.1002/ijc.22342
   Smith-Warner SA, 1998, JAMA-J AM MED ASSOC, V279, P535, DOI 10.1001/jama.279.7.535
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Tao MH, 2009, BREAST CANCER RES TR, V114, P559, DOI 10.1007/s10549-008-0028-z
   van Engeland M, 2003, CANCER RES, V63, P3133
   Wajed SA, 2001, ANN SURG, V234, P10, DOI 10.1097/00000658-200107000-00003
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yan PS, 2000, CLIN CANCER RES, V6, P1432
   Zhu KM, 2003, CANCER CAUSE CONTROL, V14, P827, DOI 10.1023/B:CACO.0000003823.97506.be
NR 47
TC 26
Z9 32
U1 1
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-8329
EI 1873-6823
J9 ALCOHOL
JI Alcohol
PD NOV
PY 2011
VL 45
IS 7
BP 689
EP 699
DI 10.1016/j.alcohol.2010.11.006
PG 11
WC Substance Abuse; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Substance Abuse; Pharmacology & Pharmacy; Toxicology
GA 834IC
UT WOS:000295952000008
PM 21168302
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Park, ES
   Kim, SJ
   Kim, SW
   Yoon, SL
   Leem, SH
   Kim, SB
   Kim, SM
   Park, YY
   Cheong, JH
   Woo, HG
   Mills, GB
   Fidler, IJ
   Lee, JS
AF Park, Eun Sung
   Kim, Sun Jin
   Kim, Seung Wook
   Yoon, Se-Lyun
   Leem, Sun-Hee
   Kim, Sang-Bae
   Kim, Soo Mi
   Park, Yun-Yong
   Cheong, Jae-Ho
   Woo, Hyun Goo
   Mills, Gordon B.
   Fidler, Isaiah J.
   Lee, Ju-Seog
TI Cross-species hybridization of microarrays for studying tumor
   transcriptome of brain metastasis
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE genomics; tumor microenvironment; stromal cells; DNA methylation
ID BREAST-CANCER; CELLS; DIFFERENTIATION; CHEMOTHERAPY; DISSEMINATION; CDNA
AB Although the importance of the cellular microenvironment (soil) during invasion and metastasis of cancer cells (seed) has been well-recognized, technical challenges have limited the ability to assess the influence of the microenvironment on cancer cells at the molecular level. Here, we show that an experimental strategy, competitive cross-species hybridization of microarray experiments, can characterize the influence of different microenvironments on cancer cells by independently extracting gene expression data of cancer and host cells when human cancer cells were xenografted into different organ sites of immunocompromised mice. Surprisingly, the analysis of gene expression data showed that the brain microenvironment induces complete reprogramming of metastasized cancer cells, resulting in a gain of neuronal cell characteristics and mimicking neurogenesis during development. We also show that epigenetic changes coincide with transcriptional reprogramming in cancer cells. These observations provide proof of principle for competitive cross-species hybridization of microarray experiments to characterize the effect of the microenvironment on tumor cell behavior.
C1 [Kim, Sun Jin; Kim, Seung Wook; Fidler, Isaiah J.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA.
   [Park, Eun Sung; Kim, Sang-Bae; Park, Yun-Yong; Cheong, Jae-Ho; Mills, Gordon B.; Lee, Ju-Seog] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA.
   [Yoon, Se-Lyun; Leem, Sun-Hee] Dong A Univ, Dept Biol, Pusan 604714, South Korea.
   [Kim, Soo Mi] Chonbuk Natl Univ Med Sch & Hosp, Dept Physiol, Jeonju 561180, South Korea.
   [Woo, Hyun Goo] Ajou Univ, Sch Med, Dept Physiol, Suwon 443721, South Korea.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; Dong A University; Jeonbuk
   National University; Jeonbuk National University Hospital; Ajou
   University
RP Fidler, IJ (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA.
EM ifidler@mdanderson.org; jlee@mdanderson.org
RI Park, Jun Won/KSM-8932-2024; Park, Eun Sung/ABD-2500-2022; Kim,
   Seung-Hyung/AAA-4707-2020; Woo, Hyun/I-8954-2019; Mills,
   Gordon/L-5416-2014; Kim, You Sun/B-2881-2015; Woo, Hyun
   Goo/AEJ-7372-2022; Lee, Ju-Seog/X-1786-2018
OI Woo, Hyun Goo/0000-0002-0916-893X; Lee, Ju-Seog/0000-0002-5666-9753;
   Cheong, Jae-Ho/0000-0002-1703-1781
FU University of Texas M.D. Anderson Cancer Center [CA016672,
   1U54CA143834-01, 5P50CA140388-02(PP-CDP2), CA99031]; National Cancer
   Institute/National Institutes of Health [PC073184]; Congressionally
   Directed Medical Research Programs; Farmer Foundation; Polo on the
   Prairie; Vivian L. Smith Foundation; National Research Foundation of
   Korea [2011-0001047]; Korean government
FX This project was funded by an intramural fund from the University of
   Texas M.D. Anderson Cancer Center, M. D. Anderson's Cancer Center
   Support Grants CA016672, 1U54CA143834-01, 5P50CA140388-02(PP-CDP2), and
   CA99031 from the National Cancer Institute/National Institutes of
   Health, Grant PC073184 from the Congressionally Directed Medical
   Research Programs, the Farmer Foundation, Polo on the Prairie, the
   Vivian L. Smith Foundation, and National Research Foundation of Korea
   Grant 2011-0001047 funded by the Korean government.
CR Afra D, 2002, LANCET, V359, P1011
   Altrock WD, 2003, NEURON, V37, P787, DOI 10.1016/S0896-6273(03)00088-6
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
   Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865
   de Bruin EC, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-142
   Fenner MH, 2002, ONKOLOGIE, V25, P474, DOI 10.1159/000067443
   Fields RD, 2002, SCIENCE, V298, P556, DOI 10.1126/science.298.5593.556
   Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764
   Flora A, 2007, P NATL ACAD SCI USA, V104, P15382, DOI 10.1073/pnas.0707456104
   FREILICH RJ, 1995, CANCER, V76, P232, DOI 10.1002/1097-0142(19950715)76:2<232::AID-CNCR2820760212>3.0.CO;2-0
   Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075
   Hamby ME, 2008, BBA-GENE REGUL MECH, V1779, P432, DOI 10.1016/j.bbagrm.2008.07.006
   Kim SJ, 2011, NEOPLASIA, V13, P286, DOI 10.1593/neo.11112
   Lin NU, 2004, J CLIN ONCOL, V22, P3608, DOI 10.1200/JCO.2004.01.175
   Lotem J, 2006, ONCOGENE, V25, P7663, DOI 10.1038/sj.onc.1209816
   Mohn F, 2009, TRENDS GENET, V25, P129, DOI 10.1016/j.tig.2008.12.005
   Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622
   Nygaard V, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-11
   Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Surani MA, 2001, NATURE, V414, P122, DOI 10.1038/35102186
   Yao PJ, 2003, NEUROBIOL AGING, V24, P173, DOI 10.1016/S0197-4580(02)00055-6
   ZHAO ND, 1994, GENE, V145, P313
NR 23
TC 93
Z9 108
U1 0
U2 18
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 18
PY 2011
VL 108
IS 42
BP 17456
EP 17461
DI 10.1073/pnas.1114210108
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 834PP
UT WOS:000295975300048
PM 21987811
OA Green Published
DA 2025-01-12
ER

PT J
AU Kwon, MJ
   Kim, SH
   Jeong, HM
   Jung, HS
   Kim, SS
   Lee, JE
   Gye, MC
   Erkin, ÖC
   Koh, SS
   Choi, YL
   Park, CK
   Shin, YK
AF Kwon, Mi Jeong
   Kim, Seok-Hyung
   Jeong, Hae Min
   Jung, Hun Soon
   Kim, Sung-Su
   Lee, Jae Eun
   Gye, Myung Chan
   Erkin, Oezguer Cem
   Koh, Sang Seok
   Choi, Yoon-La
   Park, Cheol Keun
   Shin, Young Kee
TI Claudin-4 overexpression is associated with epigenetic derepression in
   gastric carcinoma
SO LABORATORY INVESTIGATION
LA English
DT Article
DE claudin-4; DNA methylation; epigenetic derepression; gastric carcinoma;
   histone modification
ID CLOSTRIDIUM-PERFRINGENS ENTEROTOXIN; JUNCTION PROTEINS CLAUDIN-3;
   OVARIAN-CANCER; GENE-EXPRESSION; PROGNOSTIC CORRELATION;
   PANCREATIC-CANCER; EPITHELIAL-CELLS; DNA-METHYLATION; DOWN-REGULATION;
   BREAST-CANCER
AB The tight junction (TJ) protein claudin-4 is aberrantly upregulated in gastric cancer, but its clinical significance and the molecular mechanisms underlying claudin-4 overexpression in gastric cancer remain unclear. Here, we investigated its roles and epigenetic mechanisms regulating CLDN4 expression in gastric cancer. We show that increased membranous expression of claudin-4 in gastric carcinoma is associated with better patient prognosis, whereas cytoplasmic claudin-4 expression did not show a significant association with prognosis. Consistent with the correlation of increased membranous claudin-4 with favorable clinicopathological factors, claudin-4 overexpression inhibited the migration and invasion of gastric cancer cells; in contrast, it did not affect cell growth. Claudin-4 expression also increased the barrier function of TJs. Claudin-4 upregulation was strongly correlated with DNA hypomethylation in both gastric tissues and gastric cancer cells. Moreover, CLDN4 expression was repressed in normal gastric tissues in association with bivalent histone modifications, and loss of repressive histone methylations and gain of active histone modifications were associated with CLDN4 overexpression in gastric cancer cells. Interestingly, CLDN4 repression could be markedly derepressed by combined treatments that simultaneously target both histone modifications and DNA demethylation in CLDN4-hypermethylated cells, whereas concomitant changes in histone methylations and acetylations are required for CLDN4 induction in CLDN4-repressed cells with low DNA methylation. Taken together, this study reveals that membranous claudin-4 expression is associated with gastric cancer progression and that it is an independent positive prognosis marker in gastric carcinoma. Furthermore, our findings suggest that epigenetic derepression may be a possible mechanism underlying CLDN4 overexpression in gastric cancer and that claudin-4 may have potential as a promising target for the treatment of gastric cancer. Laboratory Investigation (2011) 91, 1652-1667; doi:10.1038/labinvest.2011.117; published online 15 August 2011
C1 [Shin, Young Kee] Seoul Natl Univ, Lab Mol Pathol & Canc Genom, Dept Pharm, Coll Pharm, Seoul 151742, South Korea.
   [Kim, Seok-Hyung; Choi, Yoon-La; Park, Cheol Keun] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, Seoul, South Korea.
   [Lee, Jae Eun; Gye, Myung Chan] Hanyang Univ, Dept Life Sci, Seoul 133791, South Korea.
   [Koh, Sang Seok] Korea Res Inst Biosci & Biotechnol, Therapeut Antibody Res Ctr, Taejon, South Korea.
   [Shin, Young Kee] Adv Inst Convergence Technol, Suwon, Kyeonggi Do, South Korea.
C3 Seoul National University (SNU); Sungkyunkwan University (SKKU); Samsung
   Medical Center; Hanyang University; Korea Research Institute of
   Bioscience & Biotechnology (KRIBB)
RP Shin, YK (通讯作者)，Seoul Natl Univ, Lab Mol Pathol & Canc Genom, Dept Pharm, Coll Pharm, 599 Gwanak Ro, Seoul 151742, South Korea.
EM ykeeshin@snu.ac.kr
RI Shin, Young/C-8929-2011; Park, Keunchil/ABD-5852-2021; Erkin,
   Ozgur/ABE-6436-2020
OI Kwon, Mi Jeong/0000-0002-7599-878X; Shin, Young Kee/0000-0003-0896-718X;
   Gye, Myung Chan/0000-0001-5682-3709
FU Ministry of Health, Welfare Family Affairs [A084366]; National Research
   Foundation of Korea (NRF) by the Korea government (MEST) [20090083533];
   MKE/KEIT [10035329]
FX We thank Dr Victor E Marquez for DZNep and we are grateful to Si Eun Kim
   for her technical assistance. This study was supported by grants from
   the Korea Healthcare Technology R&D project of the Ministry of Health,
   Welfare & Family Affairs (A084366), the National Research Foundation of
   Korea (NRF) by the Korea government (MEST) (No. 20090083533) and the R&D
   program of MKE/KEIT (10035329, Development of Antibody drug for new
   target protein related with ovarian cancer).
CR Agarwal R, 2005, CANCER RES, V65, P7378, DOI 10.1158/0008-5472.CAN-05-1036
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Boireau S, 2007, CARCINOGENESIS, V28, P246, DOI 10.1093/carcin/bgl120
   Chang TL, 2010, GASTROENTEROLOGY, V138, P255, DOI 10.1053/j.gastro.2009.08.044
   Choi IS, 2005, CELL RES, V15, P247, DOI 10.1038/sj.cr.7290293
   Choi YL, 2007, HISTOL HISTOPATHOL, V22, P1185, DOI 10.14670/HH-22.1185
   Cunningham SC, 2006, CANCER EPIDEM BIOMAR, V15, P281, DOI 10.1158/1055-9965.EPI-05-0539
   Darido C, 2008, CANCER RES, V68, P4258, DOI 10.1158/0008-5472.CAN-07-5805
   De Craene B, 2005, CANCER RES, V65, P6237, DOI 10.1158/0008-5472.CAN-04-3545
   Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200
   Fujii S, 2008, CANCER SCI, V99, P738, DOI 10.1111/j.1349-7006.2008.00743.x
   Hewitt KJ, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-186
   Honda H, 2006, J BIOL CHEM, V281, P21433, DOI 10.1074/jbc.M603767200
   Ikenouchi J, 2003, J CELL SCI, V116, P1959, DOI 10.1242/jcs.00389
   Johnson AH, 2005, AM J PATHOL, V167, P577, DOI 10.1016/S0002-9440(10)62999-9
   Kang GH, 2001, CANCER RES, V61, P2847
   Kominsky Scott L., 2006, Expert Reviews in Molecular Medicine, V8, P1, DOI 10.1017/S1462399406000056
   Kominsky SL, 2004, AM J PATHOL, V164, P1627, DOI 10.1016/S0002-9440(10)63721-2
   Kuo WL, 2006, ONCOL REP, V16, P729
   Kwon MJ, 2010, CARCINOGENESIS, V31, P974, DOI 10.1093/carcin/bgp336
   Kwon MJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006162
   Lal-Nag M, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-8-235
   Lanigan F, 2009, INT J CANCER, V124, P2088, DOI 10.1002/ijc.24159
   Lee SK, 2005, ONCOL REP, V13, P193
   Li JH, 2009, CANCER BIOL THER, V8, P1806, DOI 10.4161/cbt.8.19.9427
   Lioni M, 2007, AM J PATHOL, V170, P709, DOI 10.2353/ajpath.2007.060343
   Litkouhi B, 2007, NEOPLASIA, V9, P304, DOI 10.1593/neo.07118
   Long HY, 2001, CANCER RES, V61, P7878
   Matsuda Y, 2007, CANCER SCI, V98, P1014, DOI 10.1111/j.1349-7006.2007.00490.x
   Michl P, 2003, CANCER RES, V63, P6265
   Michl P, 2001, GASTROENTEROLOGY, V121, P678, DOI 10.1053/gast.2001.27124
   Mima S, 2005, CANCER RES, V65, P1868, DOI 10.1158/0008-5472.CAN-04-2770
   Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013
   Mironchik Y, 2005, CANCER RES, V65, P10801, DOI 10.1158/0008-5472.CAN-05-0712
   Morin PJ, 2005, CANCER RES, V65, P9603, DOI 10.1158/0008-5472.CAN-05-2782
   Ohtani S, 2009, GASTRIC CANCER, V12, P43, DOI 10.1007/s10120-008-0497-0
   Oku N, 2006, CANCER RES, V66, P5251, DOI 10.1158/0008-5472.CAN-05-4478
   Rangel LBA, 2003, CLIN CANCER RES, V9, P2567
   Resnick MB, 2005, HUM PATHOL, V36, P886, DOI 10.1016/j.humpath.2005.05.019
   Sanada Y, 2006, J PATHOL, V208, P633, DOI 10.1002/path.1922
   Satake S, 2008, PATHOL INT, V58, P156, DOI 10.1111/j.1440-1827.2007.02204.x
   Shin K, 2006, ANNU REV CELL DEV BI, V22, P207, DOI 10.1146/annurev.cellbio.22.010305.104219
   SINICROPE FA, 1995, CANCER RES, V55, P237
   Soini Y, 2006, VIRCHOWS ARCH, V448, P52, DOI 10.1007/s00428-005-0011-6
   Takehara M, 2009, BIOL PHARM BULL, V32, P825, DOI 10.1248/bpb.32.825
   Van Itallie C, 2001, J CLIN INVEST, V107, P1319, DOI 10.1172/JCI12464
   Wang LH, 2007, CLIN CANCER RES, V13, P102, DOI 10.1158/1078-0432.CCR-06-1467
   Yuasa Y, 2003, NAT REV CANCER, V3, P592, DOI 10.1038/nrc1141
NR 51
TC 63
Z9 67
U1 0
U2 12
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD NOV
PY 2011
VL 91
IS 11
BP 1652
EP 1667
DI 10.1038/labinvest.2011.117
PG 16
WC Medicine, Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pathology
GA 842MK
UT WOS:000296603400011
PM 21844869
OA Bronze
DA 2025-01-12
ER

PT J
AU Balasubramanian, S
   Chew, YC
   Eckert, RL
AF Balasubramanian, Sivaprakasam
   Chew, Yap Ching
   Eckert, Richard L.
TI Sulforaphane Suppresses Polycomb Group Protein Level via a
   Proteasome-Dependent Mechanism in Skin Cancer Cells
SO MOLECULAR PHARMACOLOGY
LA English
DT Article
ID DEMETHYLASE JMJD3 CONTRIBUTES; HISTONE DEACETYLASE; EPITHELIAL-CELLS;
   BREAST-CANCER; CYCLE ARREST; EZH2; APOPTOSIS; EXPRESSION; BMI-1; GENE
AB The polycomb group (PcG) genes encode a family of proteins that methylate and ubiquitinate histones to close chromatin and suppress gene expression. PcG proteins are present at elevated levels in cancer cells, and this is associated with reduced tumor suppressor protein level and enhanced cell survival. Agents that reduce PcG protein level are regarded as potentially cancer-preventative agents. Sulforaphane (SFN) is a biologically important isothiocyanate found in cruciferous vegetables that is an important candidate chemopreventive agent. However, the impact of SFN on the level and function of PcG proteins in skin cancer cells has not been assessed. We show that SFN treatment causes a concentration-dependent reduction in PcG protein (Bmi-1, Ezh2) expression in SCC-13 skin cancer cells and also reduces trimethylation of lysine 27 of histone H3. This is associated with accumulation of cells in G(2)/M phase; reduced levels of cyclin B1, cyclin A, cyclin dependent kinases 1 and 2; and increased p21(Cip1) expression. Sulforaphane treatment also increases cleavage of procaspase 3, 8, and 9 and enhances PARP cleavage and apoptosis. Similar results are observed in other skin-derived cell immortalized and transformed cell lines. Forced expression of the Bmi-1 polycomb protein in SCC-13 cells reverses these effects. The SFN-dependent loss of Bmi-1 and Ezh2 is due to proteasome-associated degradation. These results suggest that dietary isothiocyanates may suppress cancer progression by reducing PcG protein level via a proteasome-dependent mechanism, thereby inhibiting PcG-dependent pro-survival epigenetic events.
C1 [Balasubramanian, Sivaprakasam; Chew, Yap Ching; Eckert, Richard L.] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA.
   [Eckert, Richard L.] Univ Maryland, Sch Med, Dept Dermatol, Baltimore, MD 21201 USA.
   [Eckert, Richard L.] Univ Maryland, Sch Med, Dept Obstet & Gynecol, Baltimore, MD 21201 USA.
C3 University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore
RP Eckert, RL (通讯作者)，Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.
EM reckert@umaryland.edu
OI Chew, Yap Ching/0000-0002-1686-6541
FU National Institutes of Health National Cancer Institute [R01-CA131074];
   National Institutes of Health National Institute of Arthritis,
   Musculoskeletal and Skin Diseases [R01-AR053851]
FX This work was supported by the National Institutes of Health National
   Cancer Institute [Grant R01-CA131074]; and the National Institutes of
   Health National Institute of Arthritis, Musculoskeletal and Skin
   Diseases [Grant R01-AR053851].
CR Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145
   Agger K, 2009, GENE DEV, V23, P1171, DOI 10.1101/gad.510809
   Alajez NM, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.64
   Balasubramanian S, 2010, CARCINOGENESIS, V31, P496, DOI 10.1093/carcin/bgp314
   Barradas M, 2009, GENE DEV, V23, P1177, DOI 10.1101/gad.511109
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Brooks JD, 2001, CANCER EPIDEM BIOMAR, V10, P949
   Cannell IG, 2008, BIOCHEM SOC T, V36, P1224, DOI 10.1042/BST0361224
   Chen YC, 2007, HEPATOLOGY, V46, P200, DOI 10.1002/hep.21668
   Clarke JD, 2008, CANCER LETT, V269, P291, DOI 10.1016/j.canlet.2008.04.018
   Dimri M, 2010, CARCINOGENESIS, V31, P489, DOI 10.1093/carcin/bgp305
   Dinkova-Kostova AT, 2006, CANCER LETT, V240, P243, DOI 10.1016/j.canlet.2005.09.012
   Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887
   Eckert RL, 2011, J INVEST DERMATOL, V131, P295, DOI 10.1038/jid.2010.318
   Gamet-Payrastre L, 2000, CANCER RES, V60, P1426
   Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412
   Herman-Antosiewicz A, 2007, MOL CANCER THER, V6, P1673, DOI 10.1158/1535-7163.MCT-06-0807
   Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678
   Kisliouk T, 2011, EUR J NEUROSCI, V33, P224, DOI 10.1111/j.1460-9568.2010.07493.x
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kwak MK, 2003, MOL CELL BIOL, V23, P8786, DOI 10.1128/MCB.23.23.8786-8794.2003
   Lee K, 2008, J INVEST DERMATOL, V128, P9, DOI 10.1038/sj.jid.5700949
   Li J, 2010, AM J PATHOL, V176, P699, DOI 10.2353/ajpath.2010.090502
   Li ZZ, 2006, J BIOL CHEM, V281, P20643, DOI 10.1074/jbc.M602461200
   LIU S, 1992, ANTIVIR RES, V19, P247, DOI 10.1016/0166-3542(92)90083-H
   Mills AA, 2010, NAT REV CANCER, V10, P669, DOI 10.1038/nrc2931
   Myzak MC, 2006, CARCINOGENESIS, V27, P811, DOI 10.1093/carcin/bgi265
   Myzak MC, 2006, CURR DRUG TARGETS, V7, P443, DOI 10.2174/138945006776359467
   Myzak MC, 2004, CANCER RES, V64, P5767, DOI 10.1158/0008-5472.CAN-04-1326
   Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402
   Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763
   Singh AV, 2004, CARCINOGENESIS, V25, P83, DOI 10.1093/carcin/bgg178
   Singh SV, 2004, J BIOL CHEM, V279, P25813, DOI 10.1074/jbc.M313538200
   Smits M, 2010, ONCOTARGET, V1, P710, DOI 10.18632/oncotarget.205
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Tang XH, 2004, ONCOGENE, V23, P5759, DOI 10.1038/sj.onc.1207706
   van Poppel G, 1999, ADV EXP MED BIOL, V472, P159
   Wang LG, 2004, INT J ONCOL, V24, P187
   Xu CJ, 2006, CANCER RES, V66, P8293, DOI 10.1158/0008-5472.CAN-06-0300
   Xu ZS, 2011, ONCOL REP, V25, P409, DOI 10.3892/or.2010.1078
NR 40
TC 59
Z9 68
U1 0
U2 3
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0026-895X
J9 MOL PHARMACOL
JI Mol. Pharmacol.
PD NOV
PY 2011
VL 80
IS 5
BP 870
EP 878
DI 10.1124/mol.111.072363
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 842CC
UT WOS:000296563700011
PM 21807989
OA Green Accepted, Green Published
DA 2025-01-12
ER

PT J
AU Magnani, L
   Ballantyne, EB
   Zhang, XY
   Lupien, M
AF Magnani, Luca
   Ballantyne, Elizabeth B.
   Zhang, Xiaoyang
   Lupien, Mathieu
TI PBX1 Genomic Pioneer Function Drives ERα Signaling Underlying
   Progression in Breast Cancer
SO PLOS GENETICS
LA English
DT Article
ID ESTROGEN-RECEPTOR-ALPHA; GENE-EXPRESSION PATTERNS; INDEPENDENT
   PROSTATE-CANCER; EMBRYONIC STEM-CELLS; TRANSCRIPTION FACTORS;
   HOMEODOMAIN PROTEINS; ENDOCRINE RESISTANCE; RETINOIC ACID;
   BINDING-SITES; DNA-BINDING
AB Altered transcriptional programs are a hallmark of diseases, yet how these are established is still ill-defined. PBX1 is a TALE homeodomain protein involved in the development of different types of cancers. The estrogen receptor alpha (ER alpha) is central to the development of two-thirds of all breast cancers. Here we demonstrate that PBX1 acts as a pioneer factor and is essential for the ER alpha-mediated transcriptional response driving aggressive tumors in breast cancer. Indeed, PBX1 expression correlates with ER alpha in primary breast tumors, and breast cancer cells depleted of PBX1 no longer proliferate following estrogen stimulation. Profiling PBX1 recruitment and chromatin accessibility across the genome of breast cancer cells through ChIP-seq and FAIRE-seq reveals that PBX1 is loaded and promotes chromatin openness at specific genomic locations through its capacity to read specific epigenetic signatures. Accordingly, PBX1 guides ER alpha recruitment to a specific subset of sites. Expression profiling studies demonstrate that PBX1 controls over 70% of the estrogen response. More importantly, the PBX1-dependent transcriptional program is associated with poor-outcome in breast cancer patients. Correspondingly, PBX1 expression alone can discriminate a priori the outcome in ER alpha-positive breast cancer patients. These features are markedly different from the previously characterized ER alpha-associated pioneer factor FoxA1. Indeed, PBX1 is the only pioneer factor identified to date that discriminates outcome such as metastasis in ER alpha-positive breast cancer patients. Together our results reveal that PBX1 is a novel pioneer factor defining aggressive ER alpha-positive breast tumors, as it guides ER alpha genomic activity to unique genomic regions promoting a transcriptional program favorable to breast cancer progression.
C1 [Magnani, Luca; Ballantyne, Elizabeth B.; Zhang, Xiaoyang; Lupien, Mathieu] Dartmouth Med Sch, Norris Cotton Canc Ctr, Inst Quantitat Biomed Sci, Lebanon, NH 03756 USA.
C3 Norris Cotton Cancer Center; Dartmouth College
RP Magnani, L (通讯作者)，Dartmouth Med Sch, Norris Cotton Canc Ctr, Inst Quantitat Biomed Sci, Lebanon, NH 03756 USA.
EM Mathieu.Lupien@Dartmouth.edu
RI Lupien, Mathieu/KFB-6691-2024; magnani, luca/N-1094-2015
OI Lupien, Mathieu/0000-0003-0929-9478; magnani, luca/0000-0002-7534-0785
FU NCI [2P30CA023108-32]; ACS [IRG-82-003-27]; Div Of Biological
   Infrastructure; Direct For Biological Sciences [0923008] Funding Source:
   National Science Foundation
FX This work was supported by NCI (2P30CA023108-32) and the ACS
   (IRG-82-003-27). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Allison KH, 2011, BREAST CANC RES TREA
   Badve S, 2007, CLIN CANCER RES, V13, P4415, DOI 10.1158/1078-0432.CCR-07-0122
   Barrero MJ, 2010, CELL STEM CELL, V7, P565, DOI 10.1016/j.stem.2010.10.009
   Berkes CA, 2004, MOL CELL, V14, P465, DOI 10.1016/S1097-2765(04)00260-6
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bhandare R, 2010, GENOME RES, V20, P428, DOI 10.1101/gr.102038.109
   Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874
   Bittner M, EXPRESSION IN PRESS
   Blankenberg Daniel, 2010, Curr Protoc Mol Biol, VChapter 19, DOI 10.1002/0471142727.mb1910s89
   Brykczynska U, 2010, NAT STRUCT MOL BIOL, V17, P679, DOI 10.1038/nsmb.1821
   Burda P, 2010, LEUKEMIA, V24, P1249, DOI 10.1038/leu.2010.104
   Butt AJ, 2005, ENDOCR-RELAT CANCER, V12, pS47, DOI 10.1677/erc.1.00993
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008
   CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663
   Choe SK, 2009, DEV CELL, V17, P561, DOI 10.1016/j.devcel.2009.08.007
   Cicatiello L, 2010, AM J PATHOL, V176, P2113, DOI 10.2353/ajpath.2010.090837
   Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8
   Crijns APG, 2007, EUR J CANCER, V43, P2495, DOI 10.1016/j.ejca.2007.08.025
   Cuesta I, 2007, MOL CELL BIOL, V27, P7302, DOI 10.1128/MCB.00758-07
   Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765
   Duan R, 1998, ENDOCRINOLOGY, V139, P1981, DOI 10.1210/en.139.4.1981
   Eeckhoute J, 2006, J MOL BIOL, V364, P567, DOI 10.1016/j.jmb.2006.07.096
   Eeckhoute J, 2009, GENOME RES, V19, P372, DOI 10.1101/gr.084582.108
   Giresi PG, 2007, GENOME RES, V17, P877, DOI 10.1101/gr.5533506
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Habashy HO, 2008, EUR J CANCER, V44, P1541, DOI 10.1016/j.ejca.2008.04.020
   Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829
   Hess KR, 2006, J CLIN ONCOL, V24, P4236, DOI 10.1200/JCO.2006.05.6861
   Hoffman BG, 2010, GENOME RES, V20, P1037, DOI 10.1101/gr.104356.109
   Hu M, 2010, NUCLEIC ACIDS RES, V38, P2154, DOI 10.1093/nar/gkp1180
   Hua S, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.25
   Hua SJ, 2009, CELL, V137, P1259, DOI 10.1016/j.cell.2009.04.043
   Hurtado A, 2008, NATURE, V456, P663, DOI 10.1038/nature07483
   Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730
   Inoue A, 2004, J MOL ENDOCRINOL, V32, P649, DOI 10.1677/jme.0.0320649
   Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008-5472.CAN-05-4414
   Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134
   Joseph R, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.109
   Julka PK, 2008, BRIT J CANCER, V98, P1327, DOI 10.1038/sj.bjc.6604322
   KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2
   Kao KJ, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-143
   Kikugawa T, 2006, PROSTATE, V66, P1092, DOI 10.1002/pros.20443
   Kim SK, 2002, NAT GENET, V30, P430, DOI 10.1038/ng860
   Korkola JE, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-61
   Kreike B, 2006, CLIN CANCER RES, V12, P5705, DOI 10.1158/1078-0432.CCR-06-0805
   Laganière J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102
   Laurent A, 2008, INT J DEV BIOL, V52, P9, DOI 10.1387/ijdb.072304al
   Laurent A, 2007, MECH DEVELOP, V124, P364, DOI 10.1016/j.mod.2007.01.008
   Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087
   Liu DB, 2005, WORLD J GASTROENTERO, V11, P1562
   Liu Y, 2008, P NATL ACAD SCI USA, V105, P2604, DOI 10.1073/pnas.0712085105
   Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522
   Loi S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-239
   Lu XS, 2008, BREAST CANCER RES TR, V108, P191, DOI 10.1007/s10549-007-9596-6
   Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018
   Lupien M, 2010, GENE DEV, V24, P2219, DOI 10.1101/gad.1944810
   Magnani L, 2011, TRENDS GENE IN PRESS
   Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3
   Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107
   Meissner A, 2010, NAT BIOTECHNOL, V28, P1079, DOI 10.1038/nbt.1684
   Mikkelsen TS, 2008, NATURE, V454, P49, DOI 10.1038/nature07056
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Moens CB, 2006, DEV BIOL, V291, P193, DOI 10.1016/j.ydbio.2005.10.032
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Orford K, 2008, DEV CELL, V14, P798, DOI 10.1016/j.devcel.2008.04.002
   Park JT, 2008, CANCER RES, V68, P8852, DOI 10.1158/0008-5472.CAN-08-0517
   Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325
   Payne SJL, 2008, HISTOPATHOLOGY, V52, P82, DOI 10.1111/j.1365-2559.2007.02897.x
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013
   Ross-Innes CS, 2010, GENE DEV, V24, P171, DOI 10.1101/gad.552910
   Schmidt D, 2010, GENOME RES, V20, P578, DOI 10.1101/gr.100479.109
   Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206
   Schnabel CA, 2003, GENESIS, V37, P123, DOI 10.1002/gene.10235
   Schnabel CA, 2003, DEV BIOL, V254, P262, DOI 10.1016/S0012-1606(02)00038-6
   Selleri L, 2001, DEVELOPMENT, V128, P3543
   Sérandour AA, 2011, GENOME RES, V21, P555, DOI 10.1101/gr.111534.110
   Smale ST, 2010, CURR OPIN GENET DEV, V20, P519, DOI 10.1016/j.gde.2010.06.010
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100
   Specchia G, 2001, J CLIN ONCOL, V19, P4023, DOI 10.1200/JCO.2001.19.20.4023
   Stack G, 1988, Cancer Treat Res, V40, P185
   Subramaniam N, 1998, J BIOL CHEM, V273, P23567, DOI 10.1074/jbc.273.36.23567
   Swanton C, 2008, CANCER CELL, V13, P83, DOI 10.1016/j.ccr.2008.01.021
   Thorat MA, 2008, J CLIN PATHOL, V61, P327, DOI 10.1136/jcp.2007.052431
   Toi M, 2010, CANCER-AM CANCER SOC, V116, P3112, DOI 10.1002/cncr.25206
   Tsai WW, 2010, NATURE, V468, P927, DOI 10.1038/nature09542
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Wang K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010622
   Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056
   Wang YT, 2001, J BIOL CHEM, V276, P23838, DOI 10.1074/jbc.M102166200
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L
   Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88
   Wu C, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r130
   Yeh HY, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-70
   Yu K, 2006, CLIN CANCER RES, V12, P3288, DOI 10.1158/1078-0432.CCR-05-1530
   Zaret KS, 2008, COLD SH Q B, V73, P119, DOI 10.1101/sqb.2008.73.040
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
   Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786
NR 103
TC 156
Z9 170
U1 1
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD NOV
PY 2011
VL 7
IS 11
AR e1002368
DI 10.1371/journal.pgen.1002368
PG 15
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 851JM
UT WOS:000297264500022
PM 22125492
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Kim, HM
   Kim, CS
   Lee, JH
   Jang, SJ
   Hwang, JJ
   Ro, S
   Hyun, YL
   Choi, J
AF Kim, Hyun Mi
   Kim, Choung-Soo
   Lee, Je-Hwan
   Jang, Se Jin
   Hwang, Jung Jin
   Ro, Seonggu
   Hyun, Young-Lan
   Choi, Jene
TI CG0006, a novel histone deacetylase inhibitor, induces breast cancer
   cell death via histone-acetylation and chaperone-disrupting pathways
   independent of ER status
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE CG0006; Histone deacetylase inhibitor; Tamoxifen; Breast cancer; Hsp90;
   HDAC6
ID ESTROGEN-RECEPTOR-ALPHA; SUBEROYLANILIDE HYDROXAMIC ACID; PHASE-I TRIAL;
   VALPROIC ACID; POOR-PROGNOSIS; TRICHOSTATIN-A; EXPRESSION; TAMOXIFEN;
   PROMOTER; HEAT-SHOCK-PROTEIN-90
AB We previously reported that CG0006, a novel hydroxamate-based pan-histone deacetylase inhibitor (HDACI), suppresses the growth of human cancer cells. Here, we tested the ability of CG0006 to inhibit breast cancer cell proliferation in relation to estrogen receptor (ER) status, and examined changes in the expression of cell-cycle regulatory proteins. CG0006 effects on the proliferation of multiple human cancer cell lines were tested using MTT and MTS assays. Changes in estrogen-signaling proteins and cell-cycle regulatory proteins were examined by western blotting and quantitative RT-PCR, and cell-cycle effects were tested using flow cytometry. CG0006 increased histone H3 and H4 acetylation, up-regulated p21 protein, and promoted cell-cycle arrest, inducing G(2)/M-phase accumulation in ER-positive MCF7 cells, and G(1)- and G(2)/M-phase accumulation in ER-negative MDA-MB-231 cells. In both cell types, CG0006 treatment (1 mu M) reduced the levels of the estrogen-signaling proteins ER alpha and cyclin D1, and promoted massive degradation of cell-cycle regulatory proteins. CG0006 down-regulated the histone deacetylase HDAC6 at the protein level in association with a subsequent increase in Hsp90 and alpha-tubulin acetylation. HDAC6 depletion using small interfering RNA produced a protein-degradation phenotype similar to that of CG0006 treatment. These findings suggest that CG0006 inhibits breast cancer cell growth by two different pathways: a histone acetylation-dependent pathway, and a non-epigenetic pathway that disrupts chaperone function.
C1 [Kim, Hyun Mi; Jang, Se Jin; Choi, Jene] Univ Ulsan, Dept Pathol, Coll Med, Seoul 138736, South Korea.
   [Kim, Choung-Soo] Univ Ulsan, Dept Urol, Coll Med, Seoul 138736, South Korea.
   [Lee, Je-Hwan] Univ Ulsan, Dept Hematol, Coll Med, Seoul 138736, South Korea.
   [Hwang, Jung Jin] Univ Ulsan, Asan Inst Life Sci, Coll Med, Asan Med Ctr, Seoul 138736, South Korea.
   [Kim, Hyun Mi; Kim, Choung-Soo; Lee, Je-Hwan; Jang, Se Jin; Hwang, Jung Jin; Choi, Jene] Asan Med Ctr, Inst Innovat Canc Res, Seoul 138736, South Korea.
   [Ro, Seonggu; Hyun, Young-Lan] Crystal Genom Inc, Seoul 138736, South Korea.
C3 University of Ulsan; University of Ulsan; University of Ulsan;
   University of Ulsan; University of Ulsan; Asan Medical Center
RP Choi, J (通讯作者)，Univ Ulsan, Dept Pathol, Coll Med, 388-1 Pungnap 2 Dong, Seoul 138736, South Korea.
EM jenec@amc.seoul.kr
RI Kim, Sun-Ouck/HKE-9385-2023; Hwang, Jung/F-3424-2014; Lee, Jae
   Lyun/AGI-4843-2022; Kim, Soo/P-7880-2016
FU Ministry of Health, Welfare and Family Affairs, Republic of Korea
   [A062254]; MEST [2009-0081016]; Asan Institute for Life Science
   [2006-309]
FX This work was supported by a grant (A062254) from the Korea Health 21
   R&D Project, Ministry of Health, Welfare and Family Affairs, Republic of
   Korea. This research was also supported by the Mid-career Researcher
   Program through an NRF grant funded by the MEST (No. 2009-0081016), and
   a grant from the Asan Institute for Life Science (2006-309).
CR Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721
   Balasubramanian S, 2009, CANCER LETT, V280, P211, DOI 10.1016/j.canlet.2009.02.013
   Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200
   Blagg BSJ, 2006, MED RES REV, V26, P310, DOI 10.1002/med.20052
   Chang J, 2000, CLIN CANCER RES, V6, P616
   Chiba T, 2004, J HEPATOL, V41, P436, DOI 10.1016/j.jhep.2004.05.018
   Fiskus W, 2007, CLIN CANCER RES, V13, P4882, DOI 10.1158/1078-0432.CCR-06-3093
   Fortunati N, 2010, MOL CELL ENDOCRINOL, V314, P17, DOI 10.1016/j.mce.2009.09.011
   Fortunati N, 2008, CANCER LETT, V259, P156, DOI 10.1016/j.canlet.2007.10.006
   Huang LL, 2000, MOL MED, V6, P849, DOI 10.1007/BF03401823
   Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a
   Hwang JJ, 2009, ANTI-CANCER DRUG, V20, P815, DOI 10.1097/CAD.0b013e3283300a0f
   Jang ER, 2004, ONCOGENE, V23, P1724, DOI 10.1038/sj.onc.1207315
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021
   Lin YC, 2008, CANCER RES, V68, P2375, DOI 10.1158/0008-5472.CAN-07-5807
   Ma XJ, 2009, DRUGS, V69, P1911, DOI 10.2165/11315680-000000000-00000
   Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247
   Margueron R, 2004, BIOCHEM PHARMACOL, V68, P1239, DOI 10.1016/j.bcp.2004.04.031
   Margueron R, 2003, J ENDOCRINOL, V179, P41, DOI 10.1677/joe.0.1790041
   Münster P, 2007, J CLIN ONCOL, V25, P1979, DOI 10.1200/JCO.2006.08.6165
   Munster PN, 2001, CANCER RES, V61, P8492
   Park WC, 2002, TRENDS MOL MED, V8, P82, DOI 10.1016/S1471-4914(02)02282-7
   Rae JM, 2007, BREAST CANCER RES TR, V104, P13, DOI 10.1007/s10549-006-9392-8
   Reid G, 2005, ONCOGENE, V24, P4894, DOI 10.1038/sj.onc.1208662
   Roy PG, 2010, INT J CANCER, V127, P355, DOI 10.1002/ijc.25034
   Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   Sowa Y, 1999, ANN NY ACAD SCI, V886, P195, DOI 10.1111/j.1749-6632.1999.tb09415.x
   Thomas S, 2009, CANCER LETT, V280, P184, DOI 10.1016/j.canlet.2008.12.026
   Umekita Y, 2002, INT J CANCER, V98, P415, DOI 10.1002/ijc.10151
   Viale G, 2007, J CLIN ONCOL, V25, P3846, DOI 10.1200/JCO.2007.11.9453
   Watanabe T, 2010, CANCER SCI, V101, P196, DOI 10.1111/j.1349-7006.2009.01360.x
   Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016
   Xia QH, 2006, CANCER RES, V66, P7237, DOI 10.1158/0008-5472.CAN-05-0487
   Yang XW, 2001, CANCER RES, V61, P7025
   Zhou Q, 2008, MOL CANCER RES, V6, P873, DOI 10.1158/1541-7786.MCR-07-0330
NR 37
TC 8
Z9 8
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD NOV
PY 2011
VL 130
IS 2
BP 365
EP 375
DI 10.1007/s10549-010-1310-4
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 830RY
UT WOS:000295675700001
PM 21184271
DA 2025-01-12
ER

PT J
AU Singh, AK
   Pandey, A
   Tewari, M
   Shukla, HS
   Pandey, HP
AF Singh, Alok Kumar
   Pandey, Anjita
   Tewari, Mallika
   Shukla, Hari Shankar
   Pandey, Hausila Prasad
TI Epigenetic silencing of BRCA1 gene associated with demographic and
   pathologic factors in sporadic breast cancer: a study of an Indian
   population
SO EUROPEAN JOURNAL OF CANCER PREVENTION
LA English
DT Article
DE BRCA1; breast cancer; epigenetic; metastasis; promoter methylation
ID DNA METHYLATION; PROMOTER HYPERMETHYLATION; TUMOR DNA; SERUM;
   CARCINOGENESIS; CARCINOMA; REGION; MARKER
AB Breast cancer (BC) is a leading cause of cancer-related deaths among women worldwide, and this study further demonstrates that the women of Varanasi (north India) are not untouched by this fatal disease. During BC development, epigenetic activity plays a key role in silencing gene expression. Its widespread occurrence in the cancer genome could inactivate many cellular pathways including DNA repair, cell cycle control, apoptosis, cell adherence, and detoxification. In this study, our aim was to determine the penetrance of BRCA1 promoter methylation and its correlation with pathological and demographic factors in sporadic BC in an Indian population. Our analysis included 127 patients who were diagnosed with sporadic BC. Methylation-specific PCR for the BRCA1 promoter was used during the study and correlated with pathological and demographic factors. Methylation of the BRCA1 promoter was detected in 8.7% (11/127) of the tumors. Correlation of promoter methylation with demographic factors and clinicopathological markers revealed the following data: (i) BRCA1 methylation was more frequently observed in tumor samples taken from premenopausal or perimenopausal women (P=0.026), (ii) methylation of the BRCA1 promoter negatively correlated with estrogen receptor (P=0.040), progesterone receptor (P=0.013), and epidermal growth factor receptor-2 (P=0.002), (iii) the overall promoter methylation was higher in more advanced stages (P=0.036) of the disease. This study has immense implications for understanding epigenetic mechanisms in BC development. The result suggests that the epigenetic silencing of BRCA1 is uncommon and is associated with the triple-negative phenotype. European Journal of Cancer Prevention 20:478-483 (C) 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
C1 [Pandey, Hausila Prasad] Banaras Hindu Univ, Fac Sci, Dept Biochem, Varanasi 221005, Uttar Pradesh, India.
   [Singh, Alok Kumar] Amity Univ, Amity Inst Biotechnol, Lucknow, Uttar Pradesh, India.
   [Pandey, Anjita; Tewari, Mallika; Shukla, Hari Shankar] Banaras Hindu Univ, Inst Med Sci, Dept Surg Oncol, Varanasi 221005, Uttar Pradesh, India.
C3 Banaras Hindu University (BHU); Banaras Hindu University (BHU)
RP Pandey, HP (通讯作者)，Banaras Hindu Univ, Fac Sci, Dept Biochem, Varanasi 221005, Uttar Pradesh, India.
EM dr.pandeyhp@gmail.com
RI Singh, Alok/AAY-9909-2021
FU University Grants Commission
FX The authors declare that all of them have made substantial contributions
   toward the writing of this article. The data presented are accurate.
   This study was supported by a research Grant from the University Grants
   Commission, availed through Banaras Hindu University JRF contingency.
CR Agrawal A, 2007, MODERN PATHOL, V20, P711, DOI 10.1038/modpathol.3800822
   Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   Baldwin RL, 2000, CANCER RES, V60, P5329
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Brown MA, 1996, ONCOGENE, V12, P2507
   Catteau A, 2002, SEMIN CANCER BIOL, V12, P359, DOI 10.1016/S1044-579X(02)00056-1
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Clark SJ, 2007, HUM MOL GENET, V16, pR88, DOI 10.1093/hmg/ddm051
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Esteller M, 2000, EUR J CANCER, V36, P2294, DOI 10.1016/S0959-8049(00)00303-8
   Fiegl H, 2005, CANCER RES, V65, P1141, DOI 10.1158/0008-5472.CAN-04-2438
   Georgiou E, 2007, EUR J CANCER PREV, V16, P396, DOI 10.1097/01.cej.0000236260.26265.d6
   Grushko TA, 2002, CANCER RES, V62, P1481
   Grushko Tatyana A., 2004, P151
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kim SJ, 2008, ONCOL REP, V19, P663
   Mirza S, 2007, LIFE SCI, V81, P280, DOI 10.1016/j.lfs.2007.05.012
   Müller HM, 2003, CANCER RES, V63, P7641
   Pandey A, 2009, J SURG ONCOL, V99, P386, DOI 10.1002/jso.21249
   Rosen EM, 2003, J CELL PHYSIOL, V196, P19, DOI 10.1002/jcp.10257
   Sharma G, 2007, LIFE SCI, V80, P1873, DOI 10.1016/j.lfs.2007.02.026
   Shukla S, 2006, EPIGENETICS-US, V1, P88, DOI 10.4161/epi.1.2.2679
   Staff S, 2003, CANCER RES, V63, P4978
   STEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P61, DOI 10.1073/pnas.79.1.61
   Suijkerbuijk KPM, 2008, ANN ONCOL, V19, P1870, DOI 10.1093/annonc/mdn409
   Turner N, 2005, CURR OPIN PHARMACOL, V5, P388, DOI 10.1016/j.coph.2005.03.006
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994
   XU X, 2008, BREAST CANC RES TREA, V115, P397
NR 31
TC 13
Z9 13
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0959-8278
J9 EUR J CANCER PREV
JI Eur. J. Cancer Prev.
PD NOV
PY 2011
VL 20
IS 6
BP 478
EP 483
DI 10.1097/CEJ.0b013e32834761a6
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 826MM
UT WOS:000295358300006
PM 21572332
DA 2025-01-12
ER

PT J
AU Geng, CZ
   Sang, MX
   Yang, RL
   Gao, W
   Zhoui, T
   Wang, SJ
AF Geng, Cuizhi
   Sang, Meixiang
   Yang, Ruiling
   Gao, Wei
   Zhoui, Tao
   Wang, Shijie
TI Overexpression of 14-3-3σ counteracts tumorigenicity by positively
   regulating p73 <i>in vivo</i>
SO ONCOLOGY LETTERS
LA English
DT Article
DE breast cancer; 14-3-3 sigma; p53; p73
ID SUPPRESSES TUMOR-GROWTH; BREAST-CANCER CELLS; EPIGENETIC INACTIVATION;
   SIGMA GENE; P53; HYPERMETHYLATION; EXPRESSION; CARCINOMA; PROTEINS;
   14-3-3-PROTEINS
AB 14-3-3 sigma, one of the 14-3-3 family members, was initially identified as a human mammary epithelium-specific marker I. The expression of 14-3-3 sigma is directly regulated by p53. It has been demonstrated that 14-3-3 sigma stabilizes p53 and enhances its transcriptional activity through the interaction with p53, suggesting that 14-3-3 sigma has a positive feedback effect on p53. Our previous study showed that 14-3-3 sigma is a direct transcriptional target of p73 and enhances the p73-mediated transcriptional as well as pro-apoptotic activity in vitro. In the present study, we explored the tumor-suppressive effect of 14-3-3 sigma by establishing a breast cancer xenograft nude mouse model with an inducible expression of 14-3-3 sigma or with an inducible expression of p53/p73 plus 14-3-3 sigma with ADR treatment. Tumor formation was then assayed. Moreover, 66 primary breast cancer specimens and paired tumor-free breast specimens obtained from the female patients were examined. Results showed that the expression of p73 and 14-3-3 sigma in breast cancer specimens was significantly lower than the tumor-free breast specimens and that 14-3-3 sigma expression was positively correlated with the expression of p73. Furthermore, overexpression of 14-3-3 sigma counteracts tumorigenicity by positively regulating p73 in p53-mutated or -deficient cancers in vivo. Therefore, our results may lead to the use of 14-3-3 sigma in the therapeutic application for the p53-mutated and p73-expressed breast cancer patients.
C1 [Geng, Cuizhi; Yang, Ruiling; Gao, Wei; Zhoui, Tao] Hebei Med Univ, Hosp 4, Breast Ctr, Shijiazhuang 050017, Hebei, Peoples R China.
   [Sang, Meixiang; Wang, Shijie] Hebei Med Univ, Hosp 4, Tumor Res Inst, Shijiazhuang 050017, Hebei, Peoples R China.
C3 Hebei Medical University; Hebei Medical University
RP Geng, CZ (通讯作者)，Hebei Med Univ, Hosp 4, Breast Ctr, Shijiazhuang 050017, Hebei, Peoples R China.
EM cuizhigeng@hotmail.com
FU National Nature Science Foundation of China [81001178]
FX This study was supported by the National Nature Science Foundation of
   China (No. 81001178). We thank Dr Nakagawara of the Chiba Cancer Center
   for the p53, p73 and 14-3-3 sigma expression plasmids. We would also
   like to extend our thanks to Dr Qianglin Duan, a skilled English
   proofreader from Tongji University for revision of this study.
CR CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617
   Gasco M, 2002, CANCER RES, V62, P2072
   Gasco M, 2002, ONCOGENE, V21, P1876, DOI 10.1038/sj.onc.1205256
   Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230
   Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7
   Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631
   Ikeda K, 2004, ARCH HISTOL CYTOL, V67, P435, DOI 10.1679/aohc.67.435
   Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898
   Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199
   Lodygin D, 2005, CELL RES, V15, P237, DOI 10.1038/sj.cr.7290292
   Mhawech P, 2005, CELL RES, V15, P228, DOI 10.1038/sj.cr.7290291
   MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262
   Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5
   PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507
   Rosenquist M, 2003, BRAZ J MED BIOL RES, V36, P403, DOI 10.1590/S0100-879X2003000400001
   Sang MX, 2006, BIOCHEM BIOPH RES CO, V347, P327, DOI 10.1016/j.bbrc.2006.06.079
   Suzuki H, 2000, CANCER RES, V60, P4353
   Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252
   van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134
   Vayssade M, 2005, INT J CANCER, V116, P860, DOI 10.1002/ijc.21033
   Vercoutter-Edouart AS, 2001, CANCER RES, V61, P76
   Yang HL, 2006, MOL CANCER THER, V5, P253, DOI 10.1158/1535-7163.MCT-05-0395
   Yang HY, 2003, MOL CELL BIOL, V23, P7096, DOI 10.1128/MCB.23.20.7096-7107.2003
NR 25
TC 4
Z9 4
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
J9 ONCOL LETT
JI Oncol. Lett.
PD NOV-DEC
PY 2011
VL 2
IS 6
BP 1177
EP 1182
DI 10.3892/ol.2011.401
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 826YF
UT WOS:000295390800026
PM 22848285
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Inoue, H
   Sakamoto, Y
   Kangawa, N
   Kimura, C
   Ogata, T
   Fujieda, K
   Qian, ZR
   Sano, T
   Itakura, M
AF Inoue, Hiroshi
   Sakamoto, Yukiko
   Kangawa, Natsumi
   Kimura, Chizuko
   Ogata, Tsutomu
   Fujieda, Kenji
   Qian, Zhi Rong
   Sano, Toshiaki
   Itakura, Mitsuo
TI Analysis of expression and structure of the rat
   <i>GH</i>-<i>secretagogue</i>/<i>ghrelin receptor</i> (<i>Ghsr</i>)
   gene: Roles of epigenetic modifications in transcriptional regulation
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE Growth hormone secretagogue receptor; Ghrelin receptor; Gene expression;
   CpG island; Promoter methylation
ID SEABREAM ACANTHOPAGRUS-SCHLEGELI; TRUNCATED GHRELIN RECEPTOR;
   GROWTH-HORMONE; MESSENGER-RNA; CELL-LINE; 5'-FLANKING REGION; DNA
   METHYLATION; BREAST-CANCER; FOOD-INTAKE; PITUITARY
AB In the current study, to elucidate the molecular basis of cell type-specific expression of the GH-secretagogue/ghrelin receptor type 1A (GHSR1A), we characterized the structure and putative promoter region of the rat Ghsr gene. We identified an alternative 5'-untranslated first exon that contains multiple transcription start sites, and confirmed a 200-bp sequence proximal to this exon to be sufficient for basal promoter activity. A promoter-associated CpG island conserved across different species was found to be hypomethylated in Ghsr1a-expressing cell lines, while being heavily methylated in non-expressing cells. In cells with low or absent Ghsr1a expression, treatment with demethylating agents activated Ghsr1a transcription. Chromatin immunoprecipitation assays demonstrated Ghsr1a-expressing cells to display active histone modifications, whereas repressive modifications were present exclusively in other cell types. These results suggest epigenetic modifications at GHSR to play important roles in determining GHSR1A expression and abundance, and therefore the consequent sensitivity of cells to ghrelin. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Inoue, Hiroshi; Sakamoto, Yukiko; Kangawa, Natsumi; Kimura, Chizuko; Itakura, Mitsuo] Univ Tokushima, Div Genet Informat, Inst Genome Res, Tokushima 7708503, Japan.
   [Inoue, Hiroshi] Univ Tokushima, Diabet Therapeut & Res Ctr, Tokushima 7708503, Japan.
   [Ogata, Tsutomu] Natl Res Inst Child Hlth & Dev, Dept Endocrinol & Metab, Tokyo, Japan.
   [Fujieda, Kenji] Asahikawa Med Univ, Dept Pediat, Asahikawa, Hokkaido, Japan.
   [Qian, Zhi Rong; Sano, Toshiaki] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Human Pathol, Tokushima 7708503, Japan.
C3 Tokushima University; Tokushima University; National Center for Child
   Health & Development - Japan; Asahikawa Medical College; Tokushima
   University
RP Inoue, H (通讯作者)，Univ Tokushima, Div Genet Informat, Inst Genome Res, Kuramoto 3-18-15, Tokushima 7708503, Japan.
EM hinoue@genome.tokushima-u.ac.jp
OI Qian, Zhi rong/0000-0003-1633-4120
FU Ministry of Education, Science and Technology (Knowledge Cluster
   Initiative); Grants-in-Aid for Scientific Research [22227002, 23591499]
   Funding Source: KAKEN
FX Grant support: This study was partially funded by Grants from the
   Ministry of Education, Science and Technology (Knowledge Cluster
   Initiative).
CR Adams EF, 1998, J CLIN ENDOCR METAB, V83, P638, DOI 10.1210/jc.83.2.638
   Baldanzi G, 2002, J CELL BIOL, V159, P1029, DOI 10.1083/jcb.200207165
   Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023
   Chan CB, 2004, MOL CELL ENDOCRINOL, V214, P81, DOI 10.1016/j.mce.2003.11.020
   Chen CY, 2009, PHARMACOL REV, V61, P430, DOI 10.1124/pr.109.001958
   Chu KM, 2007, INT J BIOCHEM CELL B, V39, P752, DOI 10.1016/j.biocel.2006.11.007
   Davenport AP, 2005, PHARMACOL REV, V57, P541, DOI 10.1124/pr.57.4.1
   Dixit VD, 2005, EXP GERONTOL, V40, P900, DOI 10.1016/j.exger.2005.09.003
   Doi A, 2006, P NATL ACAD SCI USA, V103, P885, DOI 10.1073/pnas.0502470102
   Dunn GA, 2009, ENDOCRINOLOGY, V150, P4999, DOI 10.1210/en.2009-0500
   Falls HD, 2006, J MOL ENDOCRINOL, V37, P51, DOI 10.1677/jme.1.01943
   Gnanapavan S, 2002, J CLIN ENDOCR METAB, V87, P2988, DOI 10.1210/jc.87.6.2988
   Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362
   Hewson AK, 2000, J NEUROENDOCRINOL, V12, P1047, DOI 10.1046/j.1365-2826.2000.00584.x
   Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974
   HURBAINKOSMATH I, 1990, IN VITRO CELL DEV B, V26, P431
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jeffery PL, 2005, ENDOCR-RELAT CANCER, V12, P839, DOI 10.1677/erc.1.00984
   Kaji H, 1998, J BIOL CHEM, V273, P33885, DOI 10.1074/jbc.273.51.33885
   Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230
   Kojima M, 2005, PHYSIOL REV, V85, P495, DOI 10.1152/physrev.00012.2004
   KOMORI T, 2008, 38 ANN M SOC NEUR WA
   Kumaki Y, 2008, NUCLEIC ACIDS RES, V36, pW170, DOI 10.1093/nar/gkn294
   Lai JKC, 2005, INT J BIOCHEM CELL B, V37, P887, DOI 10.1016/j.biocel.2004.11.012
   Lande-Diner L, 2007, J BIOL CHEM, V282, P12194, DOI 10.1074/jbc.M607838200
   Leung PK, 2007, CELL SIGNAL, V19, P1011, DOI 10.1016/j.cellsig.2006.11.011
   Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mousseaux D, 2006, BRIT J PHARMACOL, V148, P350, DOI 10.1038/sj.bjp.0706727
   Murata M, 2002, J BIOL CHEM, V277, P5667, DOI 10.1074/jbc.M103898200
   Ordway JM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001314
   Perdonà E, 2011, EUR J PHARMACOL, V650, P178, DOI 10.1016/j.ejphar.2010.10.042
   Petersenn S, 2001, ENDOCRINOLOGY, V142, P2649, DOI 10.1210/en.142.6.2649
   Povey S, 2001, HUM GENET, V109, P678, DOI 10.1007/s00439-001-0615-0
   Rando OJ, 2007, CURR OPIN GENET DEV, V17, P94, DOI 10.1016/j.gde.2007.02.006
   Robertson KD, 1997, J VIROL, V71, P6445, DOI 10.1128/JVI.71.9.6445-6454.1997
   SCHUG J, 1997, CBILTR19971001V00
   Smith RG, 1997, ENDOCR REV, V18, P621, DOI 10.1210/er.18.5.621
   Sun YX, 2007, ENDOCRINOLOGY, V148, P1323, DOI 10.1210/en.2006-0782
   Takahashi K, 2006, CANCER RES, V66, P9408, DOI 10.1158/0008-5472.CAN-06-1349
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Tanaka M, 2003, GEN COMP ENDOCR, V134, P198, DOI 10.1016/S0016-6480(03)00247-8
   Thielemans L, 2007, J RECEPT SIG TRANSD, V27, P309, DOI 10.1080/10799890701519587
   Toshinai K, 2006, ENDOCRINOLOGY, V147, P2306, DOI 10.1210/en.2005-1357
   Tritos NA, 2006, MAYO CLIN PROC, V81, P653, DOI 10.4065/81.5.653
   Umetani N, 2005, BIOCHEM BIOPH RES CO, V329, P219, DOI 10.1016/j.bbrc.2005.01.088
   Untergasser A, 2007, NUCLEIC ACIDS RES, V35, pW71, DOI 10.1093/nar/gkm306
   van der Lely AJ, 2004, ENDOCR REV, V25, P426, DOI 10.1210/er.2002-0029
   Yang H, 2008, BRAIN BEHAV IMMUN, V22, P1138, DOI 10.1016/j.bbi.2008.06.003
   Yeung CM, 2004, MOL CELL ENDOCRINOL, V223, P5, DOI 10.1016/j.mce.2004.06.005
   Zigman JM, 2006, J COMP NEUROL, V494, P528, DOI 10.1002/cne.20823
NR 52
TC 11
Z9 13
U1 0
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303-7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD OCT 15
PY 2011
VL 345
IS 1-2
BP 1
EP 15
DI 10.1016/j.mce.2011.06.034
PG 15
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA 833PE
UT WOS:000295896600001
PM 21756973
DA 2025-01-12
ER

PT J
AU Lodha, R
   Joshi, A
   Paul, D
   Lodha, KM
   Nahar, N
   Shrivastava, A
   Bhagat, VK
   Nandeshwar, S
AF Lodha, R.
   Joshi, A.
   Paul, D.
   Lodha, K. M.
   Nahar, N.
   Shrivastava, A.
   Bhagat, V. K.
   Nandeshwar, S.
TI Association between reproductive factors and breast cancer in an urban
   set up at central India: A case-control study
SO INDIAN JOURNAL OF CANCER
LA English
DT Article
DE Adjusted odd ratios; breast cancer; breastfeeding; oral contraceptive
   pills; reproductive
ID RISK-FACTORS; ORAL-CONTRACEPTIVES; WOMEN; EPIDEMIOLOGY
AB BACKGROUND: Epigenetic changes, geography and environmental factors do surpass the genetic factors in the development of breast cancer. This study investigates the association of reproductive factors with the breast cancer in this context. OBJECTIVE: To detect the association of reproductive risk factors with breast cancer in an urban set up at central India. STUDY DESIGN: Matched paired community-based case-control study. MATERIALS AND METHODS: The study was conducted for a period of a year from October 2008 to August 2009 in Bhopal (MP). Demographic data and reproductive risk factor related information were collected using structured questionnaire. Data analysis was done by Epi-info and SPSS 16. RESULTS: History of using oral contraceptive pills (OR = 3.02, 95% CI: 1.28-7.11), history of not having breastfeeding (OR = 3.62, 95% CI: 1.29-10.16) and family history of breast cancer (OR = 3.98, 95% CI: 1.06-14.826) were associated significantly with the occurrence of breast cancer in multivariate analysis. CONCLUSIONS: The findings of the present study suggests that positive family history of breast cancer and history of using OCP may be the epigenetic factors promoting the occurrence of breast cancer while breastfeeding reduces the possibility of acquiring breast cancer.
C1 [Lodha, R.; Bhagat, V. K.] LN Med Coll & Res Ctr, Dept Community Med, Bhopal, India.
   [Joshi, A.] Peoples Coll Med Coll & Res Ctr, Bhopal, India.
   [Shrivastava, A.] Indian Council Med Res, Gandhi Med Coll, Population Based Canc Registry, Bhopal, India.
C3 People's College of Medical Sciences & Research Centre; Indian Council
   of Medical Research (ICMR)
RP Lodha, R (通讯作者)，LN Med Coll & Res Ctr, Dept Community Med, Bhopal, India.
EM drramalodha@gmail.com
CR Ahmad M., 2003, NCD Malaysia, V2, P23
   [Anonymous], CONS REP POP BAS CAN
   [Anonymous], 2004, ANTHROPOLOGIST, DOI DOI 10.1080/09720073.2005.11890889
   Asch BB, 2001, J MAMMARY GLAND BIOL, V6, P151, DOI 10.1023/A:1011306222533
   BRINTON LA, 1982, INT J EPIDEMIOL, V11, P316, DOI 10.1093/ije/11.4.316
   Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5
   Colditz GA, 2005, CANCER EPIDEM BIOMAR, V14, P768, DOI 10.1158/1055-9965.EPI-04-0157
   Deo Deepali S, 2004, Indian J Pediatr, V71, P565, DOI 10.1007/BF02724307
   Ebrahimi M, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr454
   Freund C, 2005, Gynecol Obstet Fertil, V33, P739, DOI 10.1016/j.gyobfe.2005.07.030
   Gajalakshmi V, 2009, INT J CANCER, V125, P662, DOI 10.1002/ijc.24429
   Hankinson SE, 1997, CANCER CAUSE CONTROL, V8, P65, DOI 10.1023/A:1018435205695
   HELEWA M, 2002, 111 SOC OBST GYN CAN, P2
   JICK H, 1980, AM J EPIDEMIOL, V112, P577, DOI 10.1093/oxfordjournals.aje.a113030
   KELSEY JL, 1993, EPIDEMIOL REV, V15, P36, DOI 10.1093/oxfordjournals.epirev.a036115
   LESTER SC, 2004, ROBBINS COTRAN PATHO, P1133
   M Sivkami, 2005, EC POLIT WKLY, V40, P282
   Marchbanks PA, 2002, NEW ENGL J MED, V346, P2025, DOI 10.1056/NEJMoa013202
   McPherson K, 2000, BMJ-BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624
   MESHRAM, 2009, ONLINE J HLTH ALLIED, V8, P5
   Nair MK., CANC CURRENT SCENARI
   Okobia M, 2006, INT J CANCER, V119, P2179, DOI 10.1002/ijc.22102
   Pakseresht S., 2009, Indian Journal of Cancer, V46, P132, DOI 10.4103/0019-509X.49151
   PARASHAR SS, 2009, TXB PUBLIC HLTH COMM
   Pharoah PDP, 1997, INT J CANCER, V71, P800, DOI 10.1002/(SICI)1097-0215(19970529)71:5<800::AID-IJC18>3.0.CO;2-B
   Reid RL, 2007, J OBSTET GYNAECOL CA, V29, P207, DOI 10.1016/S1701-2163(16)32418-5
   Yavari P, 2005, Asian Pac J Cancer Prev, V6, P370
   2007, IVANHOE BROADCAST NE
NR 28
TC 8
Z9 10
U1 0
U2 10
PU INDIAN CANCER SOC
PI MUMBAI
PA C/O DR D J JUSSAWALLA, EDITOR-IN-CHIEF, 74 JERBAI WADIA RD, PAREL,
   MUMBAI, 00000, INDIA
SN 0019-509X
J9 INDIAN J CANCER
JI Indian J. Cancer
PD JUL-SEP
PY 2011
VL 48
IS 3
BP 303
EP 307
DI 10.4103/0019-509X.84928
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 830IU
UT WOS:000295651500007
PM 21921328
DA 2025-01-12
ER

PT J
AU Martín-Guerrero, I
   Enjuanes, A
   Richter, J
   Ammerpohl, O
   Colomer, D
   Ardanaz, M
   Marco, F
   Salas, A
   Campo, E
   Siebert, R
   García-Orad, A
AF Martin-Guerrero, Idoia
   Enjuanes, Anna
   Richter, Julia
   Ammerpohl, Ole
   Colomer, Dolors
   Ardanaz, Maite
   Marco, Fernando
   Salas, Antonio
   Campo, Elias
   Siebert, Reiner
   Garcia-Orad, Africa
TI A Putative "hepitype" in the <i>ATM</i> Gene Associated with Chronic
   Lymphocytic Leukemia Risk
SO GENES CHROMOSOMES & CANCER
LA English
DT Article
ID DNA METHYLATION; DOWN-REGULATION; BREAST-CANCER; VARIANTS; CELL; GENOME;
   HYPERMETHYLATION; HAPLOTYPES; LYMPHOMA; TRANSCRIPTION
AB Chronic lymphocytic leukemia (CLL) cells are characterized by several chromosomal lesions. Some of these aberrations imply chromosome breaks as a result of unrepaired double strand breaks (DSBs) in the DNA. The ATM (ataxia telangiectasia-mutated) protein is the principal integrator of cellular responses to DSBs. ATM deletion is also an adverse prognostic factor in CLL. Taking this into account, we evaluated if genetic and/or epigenetic variation in the ATM gene may modulate the individual susceptibility to develop CLL. Our case-control association study was performed in a large Spanish population of 1,503 individuals, including 742 patients with CLL and 761 controls. We identified one haplotype within the ATM gene that confers an increased risk of CLL development (OR = 1.33; 95% Cl: 1.10-1.60). Two polymorphisms of this ATM haplotype eliminated one CpG site each in Introns 15 and 61, causing changes in DNA methylation pattern. These data provide the first evidence for the existence of a putative "hepitype" in the ATM gene associated with CLL risk. (C) 2011 Wiley-Liss, Inc.
C1 [Martin-Guerrero, Idoia; Garcia-Orad, Africa] Univ Basque Country, Dept Genet Phys Anthropol & Anim Physiol, Leioa 48940, Bizkaia, Spain.
   [Enjuanes, Anna; Colomer, Dolors; Campo, Elias] Univ Barcelona, Hosp Clin, Dept Anat Pathol, Inst Invest Biomed August Pi & Sunyer,Hematopatho, Barcelona, Spain.
   [Richter, Julia; Ammerpohl, Ole; Siebert, Reiner] Univ Kiel, Inst Human Genet, Kiel, Germany.
   [Richter, Julia; Ammerpohl, Ole; Siebert, Reiner] Univ Hosp Schleswig Holstein, Campus Kiel, Germany.
   [Ardanaz, Maite] Hosp Txagorritxu, Vitoria, Alava, Spain.
   [Marco, Fernando] Hosp Basurto, Bilbao, Vizcaya, Spain.
   [Salas, Antonio] Univ Santiago Compostela, Fac Med, Inst Med Legal, Unidade Xenet, Galicia, Spain.
   [Salas, Antonio] Univ Santiago Compostela, Fac Med, Dept Anat Patolox Ciencias Forenses, Galicia, Spain.
C3 University of Basque Country; University of Barcelona; Hospital Clinic
   de Barcelona; IDIBAPS; University of Kiel; University of Kiel; Schleswig
   Holstein University Hospital; University Hospital of Araba; Basurto
   Hospital; Universidade de Santiago de Compostela; Universidade de
   Santiago de Compostela
RP García-Orad, A (通讯作者)，Univ Basque Country, Dept Genet Phys Anthropol & Anim Physiol, Barrio Sarriena Sn, Leioa 48940, Bizkaia, Spain.
EM africa.garciaorad@ehu.es
RI MARCO, FERNANDO/H-6086-2013; Siebert, Reiner/A-8049-2010;
   Martin-Guerrero, Idoia/AAF-3446-2020; COLOMER, DOLORS/ABG-6894-2020;
   Campo, Elias/AAC-5593-2019; Ammerpohl, Ole/G-2691-2010; Salas,
   Antonio/E-3977-2012; Enjuanes, Anna/H-3245-2015; Campo,
   Elias/O-7192-2016
OI Martin-Guerrero, Idoia/0000-0002-0098-1908; Salas,
   Antonio/0000-0002-2336-702X; COLOMER, DOLORS/0000-0001-7486-8484;
   Enjuanes, Anna/0000-0002-4679-6687; Garcia.Orad,
   Africa/0000-0002-5575-3080; Campo, Elias/0000-0001-9850-9793
FU Red Tematicade Investigacion Cooperativa de Cancer del Instituto de
   Salud Carlos III [RD06/0020/0048, 2006-RET2039-O]; die Basque Government
   [IT-463-07]; Medical Faculty, Kiel; University of the Basque Country
FX Supported by: Red Tematicade Investigacion Cooperativa de Cancer del
   Instituto de Salud Carlos III. Grant numbers: RD06/0020/0048,
   2006-RET2039-O; die Basque Government, Grant number: IT-463-07; Medical
   Faculty, Kiel; University of the Basque Country.
CR Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Bell CG, 2009, GENOME MED, V1, DOI 10.1186/gm56
   Bose S, 2007, J PATHOL, V213, P329, DOI 10.1002/path.2232
   Buetow KH, 2001, P NATL ACAD SCI USA, V98, P581, DOI 10.1073/pnas.021506298
   Cheung HH, 2010, BRIT J CANCER, V102, P419, DOI 10.1038/sj.bjc.6605505
   Cheung HH, 2009, BIRTH DEFECTS RES C, V87, P335, DOI 10.1002/bdrc.20163
   Chim CS, 2002, HEMATOL ONCOL, V20, P167, DOI 10.1002/hon.694
   Chim CS, 2005, LEUKEMIA, V19, P880, DOI 10.1038/sj.leu.2403676
   Choudhury A, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-69
   Conde L, 2005, NUCLEIC ACIDS RES, V33, pW501, DOI 10.1093/nar/gki476
   Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655
   Döhner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602
   Dudbridge F, 2003, GENET EPIDEMIOL, V25, P115, DOI 10.1002/gepi.10252
   Einarsdóttir K, 2007, HUM MOL GENET, V16, P154, DOI 10.1093/hmg/ddl451
   Enjuanes A, 2008, CANCER RES, V68, P10178, DOI 10.1158/0008-5472.CAN-08-2221
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Ghia P, 2005, BLOOD, V105, P1678, DOI 10.1182/blood-2004-07-2606
   Goldin LR, 2004, BLOOD, V104, P1850, DOI 10.1182/blood-2004-01-0341
   Gumy-Pause F, 2006, LEUKEMIA RES, V30, P335, DOI 10.1016/j.leukres.2005.07.012
   Jaffe E.S., 2001, PATHOLOGY GENETICS T, V3
   Kastan MB, 2000, COLD SPRING HARB SYM, V65, P521, DOI 10.1101/sqb.2000.65.521
   Kerkel K, 2008, NAT GENET, V40, P904, DOI 10.1038/ng.174
   Khanna KK, 2001, CELL DEATH DIFFER, V8, P1052, DOI 10.1038/sj.cdd.4400874
   Koren M, 2006, BRIT J CANCER, V94, P1537, DOI 10.1038/sj.bjc.6603062
   Laayouni H, 2010, HUM GENET, V127, P455, DOI 10.1007/s00439-010-0798-3
   Lee PH, 2008, NUCLEIC ACIDS RES, V36, pD820, DOI 10.1093/nar/gkm904
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Murrell A, 2004, HUM MOL GENET, V13, P247, DOI 10.1093/hmg/ddh013
   Raval A, 2006, SEMIN ONCOL, V33, P157, DOI 10.1053/j.seminoncol.2005.12.011
   Roman-Gomez J, 2007, LEUKEMIA LYMPHOMA, V48, P1269, DOI 10.1080/10428190701344899
   Rudd MF, 2006, BLOOD, V108, P638, DOI 10.1182/blood-2005-12-5022
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Schaffner C, 1999, BLOOD, V94, P748, DOI 10.1182/blood.V94.2.748.414k02_748_753
   Schwindt H, 2009, LEUKEMIA, V23, P1875, DOI 10.1038/leu.2009.120
   Stankovic T, 1999, LANCET, V353, P26, DOI 10.1016/S0140-6736(98)10117-4
   Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378
   Stevenson FK, 2004, BLOOD, V103, P4389, DOI 10.1182/blood-2003-12-4312
   Tapper W, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2213
   Tong Wei-Gang, 2010, Epigenetics, V5, P499
   Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413
   Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281
   Yang HS, 2007, INT J CANCER, V121, P2254, DOI 10.1002/ijc.22918
   Zilberman D, 2007, NAT GENET, V39, P61, DOI 10.1038/ng1929
NR 43
TC 4
Z9 5
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1045-2257
J9 GENE CHROMOSOME CANC
JI Gene Chromosomes Cancer
PD NOV
PY 2011
VL 50
IS 11
BP 887
EP 895
DI 10.1002/gcc.20912
PG 9
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA 824NO
UT WOS:000295208800004
PM 21910157
DA 2025-01-12
ER

PT J
AU Samaiya, M
   Bakhshi, S
   Shukla, AA
   Kumar, L
   Chauhan, SS
AF Samaiya, Misti
   Bakhshi, Sameer
   Shukla, Abhay A.
   Kumar, Lalit
   Chauhan, Shyam S.
TI Epigenetic regulation of cathepsin L expression in chronic myeloid
   leukaemia
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE cathepsin L (CTSL); chronic myeloid leukaemia (CML); vascular
   endothelial growth factor (VEGF); promoter methylation; K562 cells
ID CHRONIC MYELOGENOUS LEUKEMIA; ENDOTHELIAL GROWTH-FACTOR; HUMAN
   BREAST-CANCER; BONE-MARROW; CYSTATIN-C; PHILADELPHIA-CHROMOSOME;
   GLIOBLASTOMA CELLS; ANGIOGENIC FACTORS; EPITHELIAL-CELLS; UP-REGULATION
AB The expression and significance of cathepsin L (CTSL) has been extensively studied in solid tumours. However no such information in chronic myeloid leukaemia (CML) was available. We investigated the activity and expression of this protease in peripheral blood mononuclear cells (PBMCs) of 47 adult CML patients. Thirty adults suffering from systemic diseases and 50 healthy volunteers served as controls. The mRNA levels of CTSL, its specific endogenous inhibitor cystatin C and transcriptional up-regulator vascular endothelial growth factor (VEGF) were quantitated by real-time qPCR. CTSL protease activity and its mRNA expression were significantly higher in CML chronic phase (CP) patients compared to CML accelerated phase/blast crisis (AP/BC) patients and controls (P <= 0.001). VEGF whose expression was most pronounced in CP and declined (P <= 0.001) in the advanced phases of the malignancy exhibited a strong positive correlation with CTSL expression (r = 0.97; P <= 0.001). Cystatin C expression was significantly lower (P <= 0.001) in CML and displayed inverse correlation with CTSL (r - -0.713; P <= 0.001) activity. CTSL promoter was significantly hypomethylated in CML CP compared to CML AP/BC patients as well as controls. K562, a BC CML cell line displayed CTSL activity, expression and methylation status of CTSL promoter that was comparable to CML AP/BC patients. Treatment of these cells or PBMCs isolated from CML AP/BC patients with 5'-aza-cytidine resulted in a dramatic increase in CSTL activity and/or expression thereby demonstrating the role of promoter methylation in the stage specific expression of CTSL in CML. Differential expression of CTSL in CML at various stages of malignancy may prove useful in identification of the high-risk patients thereby facilitating better management of disease.
C1 [Samaiya, Misti; Shukla, Abhay A.; Chauhan, Shyam S.] All India Inst Med Sci, Dept Biochem, New Delhi 110029, India.
   [Bakhshi, Sameer; Kumar, Lalit] All India Inst Med Sci, Dr BRA Inst Rotary Canc Hosp, Dept Med Oncol, New Delhi 110029, India.
C3 All India Institute of Medical Sciences (AIIMS) New Delhi; All India
   Institute of Medical Sciences (AIIMS) New Delhi; DR. B.R.A. Institute
   Rotary Cancer Hospital
RP Chauhan, SS (通讯作者)，All India Inst Med Sci, Dept Biochem, Room 3009, New Delhi 110029, India.
EM s_s_chauhan@hotmail.com
RI Kumar, Lalit/JFK-9602-2023
FU University Grants Commission; Council of Scientific and Industrial
   Research, Government of India
FX M.J. and A.A.S. were the recipients of junior and senior research
   fellowship from University Grants Commission and Council of Scientific
   and Industrial Research, Government of India, respectively.
CR Aguayo A, 2000, BLOOD, V96, P2240, DOI 10.1182/blood.V96.6.2240.h8002240_2240_2245
   Albano F, 2003, GENE CHROMOSOME CANC, V36, P353, DOI 10.1002/gcc.10183
   Arora S, 2002, GENE, V293, P123, DOI 10.1016/S0378-1119(02)00700-X
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653
   CHAUHAN SS, 1993, J BIOL CHEM, V268, P1039
   CHAUHAN SS, 1991, CANCER RES, V51, P1478
   Chauhan SS, 1998, BIOCHEMISTRY-US, V37, P8584, DOI 10.1021/bi972251z
   Collette J, 2004, INT J CANCER, V112, P190, DOI 10.1002/ijc.20398
   DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902
   Dennemärker J, 2010, ONCOGENE, V29, P1611, DOI 10.1038/onc.2009.466
   Di Raimondo F, 2001, ACTA HAEMATOL-BASEL, V106, P177, DOI 10.1159/000046614
   Divya, 2002, Placenta, V23, P59
   Faderl S, 1999, ANN INTERN MED, V131, P207, DOI 10.7326/0003-4819-131-3-199908030-00008
   Foekens JA, 1998, J CLIN ONCOL, V16, P1013, DOI 10.1200/JCO.1998.16.3.1013
   Gallardo E, 2001, J NEUROPATH EXP NEUR, V60, P847, DOI 10.1093/jnen/60.9.847
   Gerber A, 2001, J INTERF CYTOK RES, V21, P11, DOI 10.1089/107999001459114
   Gocheva V, 2007, CELL CYCLE, V6, P60, DOI 10.4161/cc.6.1.3669
   GOTTESMAN MM, 1980, CELL, V19, P449, DOI 10.1016/0092-8674(80)90519-X
   Hagiwara H, 2008, BRIT J PHARMACOL, V153, P1373, DOI 10.1038/bjp.2008.17
   He R, 2003, CANCER GENE THER, V10, P879, DOI 10.1038/sj.cgt.7700645
   HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0
   Janowska-Wieczorek A, 2002, LEUKEMIA, V16, P1160, DOI 10.1038/sj.leu.2402486
   Janssen JJWM, 2005, LEUKEMIA, V19, P998, DOI 10.1038/sj.leu.2403735
   Jean D, 2006, ONCOGENE, V25, P1474, DOI 10.1038/sj.onc.1209196
   Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094
   Kane S E, 1990, Semin Cancer Biol, V1, P127
   Kayser K, 2003, ANTICANCER RES, V23, P2767
   Keerthivasan S, 2007, GENE, V399, P129, DOI 10.1016/j.gene.2007.05.002
   KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649
   Kim K, 1998, INT J CANCER, V79, P324, DOI 10.1002/(SICI)1097-0215(19980821)79:4<324::AID-IJC4>3.0.CO;2-X
   Konduri SD, 2002, ONCOGENE, V21, P8705, DOI 10.1038/sj.onc.1205949
   Korkolopoulou P, 2003, LEUKEMIA, V17, P89, DOI 10.1038/sj.leu.2402769
   Krauth MT, 2004, AM J CLIN PATHOL, V121, P473, DOI 10.1039/3JLTFNNEDQHB4A0P
   Lankelma JM, 2010, LIFE SCI, V86, P225, DOI 10.1016/j.lfs.2009.11.016
   LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321
   LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149
   Mayerhofer M, 2002, BLOOD, V100, P3767, DOI 10.1182/blood-2002-01-0109
   MULLERESTERL W, 1985, FEBS LETT, V191, P221, DOI 10.1016/0014-5793(85)80012-0
   Musolino C, 2002, AM J HEMATOL, V69, P159, DOI 10.1002/ajh.10020
   Niedergethmann M, 2004, PANCREAS, V29, P204, DOI 10.1097/00006676-200410000-00005
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Rebbaa A, 2009, ANTICANCER RES, V29, P4473
   Rivenbark AG, 2007, EXP MOL PATHOL, V83, P188, DOI 10.1016/j.yexmp.2007.03.008
   Sato N, 2003, CANCER RES, V63, P4158
   Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706
   Shimada N, 2010, AM J PATHOL, V176, P2571, DOI 10.2353/ajpath.2010.091027
   SHIN TH, 1992, MOL CELL BIOL, V12, P3998, DOI 10.1128/MCB.12.9.3998
   Sun X, 2008, LEUKEMIA, V22, P1053, DOI 10.1038/sj.leu.2404990
   Trinkaus M, 2005, INT J BIOL MARKER, V20, P50, DOI 10.1177/172460080502000108
   Vidovic A, 2008, HEMATOLOGY, V13, P34, DOI 10.1179/102453308X315807
   Vigneswaran N, 2005, PATHOL RES PRACT, V200, P753, DOI 10.1016/j.prp.2004.09.005
NR 52
TC 17
Z9 19
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD OCT
PY 2011
VL 15
IS 10
BP 2189
EP 2199
DI 10.1111/j.1582-4934.2010.01203.x
PG 11
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 824RD
UT WOS:000295218800016
PM 21496199
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Bendinelli, P
   Maroni, P
   Matteucci, E
   Desiderio, MA
AF Bendinelli, Paola
   Maroni, Paola
   Matteucci, Emanuela
   Desiderio, Maria Alfonsina
TI Comparative role of acetylation along c-SRC/ETS1 signaling pathway in
   bone metastatic and invasive mammary cell phenotypes
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
LA English
DT Article
DE c-Src; HDACs; CXCR4; Breast cancer; Bone metastasis
ID BREAST-CANCER METASTASIS; HEPATOCYTE GROWTH-FACTOR; HISTONE DEACETYLASE
   INHIBITORS; NF-KAPPA-B; C-SRC; TRANSCRIPTIONAL REGULATION;
   NUCLEAR-LOCALIZATION; CHEMOKINE RECEPTORS; CXCR4 EXPRESSION; CARCINOMA
   CELLS
AB Metastatic cells switch between different modes of migration through supramolecular plasticity mechanism(s) still largely unknown. The aim of the present paper was to clarify some molecular aspects of the epigenetic control of migration of 1833-bone metastatic cells compared to MDA-MB231-parental mammary carcinoma cells. Active c-Src overexpression enhanced 1833-cell spontaneous migration and CXCR4-mediated chemoinvasion toward CXCL12 ligand. Only in metastatic cells, in fact, c-Src seemed to stabilize nuclear CXCR4-protein receptor possibly due to tyrosine phosphotylation, by impairing protein-degradative smear and causing instead an electrophoretic-mobility shift; the cytosolic steady-state level of CXCR4 was enhanced, and the protein appeared also phosphorylated. These findings suggested the triggering of unique signaling pathways in metastasis for homing of breast-cancer cells to congenial environment of specific organs. Microenvironmental stimuli activating c-Src might influence Ets1 binding to CXCR4 promoter and consequent transactivation, as well as CXCR4 post-translational regulatory mechanisms such as phosphorylation. Enhancement of Ets1 activity and CXCR4 induction by c-Src overexpression were prevented by histone deacetylase (HDAC) blockade. In contrast, HDAC inhibition with trichostatin A increased cytosolic phosphorylated CXCR4 expression in MDA-MB231 cells, but Ets1 involvement was practically unneeded. c-Src might be suggested as a bio-marker predicting metastasis sensitivity patterns to HDAC inhibitors. Rationally designed and individualized therapy may become possible as more is learned about the target molecules of HDAC's inhibitory agents and their roles, as undertaken for CXCR4 that is likely to be crucial for homing, angiogenesis and survival in a c-Src-dependent manner in bone-metastatic mammary cells. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Bendinelli, Paola; Matteucci, Emanuela; Desiderio, Maria Alfonsina] Univ Milan, Dipartimento Morfol Umana & Sci Biomed Citta Stud, Mol Pathol Lab, I-20133 Milan, Italy.
   [Maroni, Paola] Ist Ortoped Galeazzi, Milan, Italy.
C3 University of Milan; IRCCS Istituto Ortopedico Galeazzi
RP Desiderio, MA (通讯作者)，Univ Milan, Dipartimento Morfol Umana & Sci Biomed Citta Stud, Mol Pathol Lab, Via Luigi Mangiagalli 31, I-20133 Milan, Italy.
EM a.desiderio@unimi.it
RI Desiderio, Maria/M-8870-2016; Bendinelli, Paola/M-7324-2016; Maroni,
   Paola/B-1366-2017
OI Maroni, Paola/0000-0002-3444-9338
FU Ministero Salute; Ricerca Corrente [4029]; Fondazione Cariplo
   [2010-0737]
FX This study was supported by funds from Ministero Salute, Ricerca
   Corrente-4029 and Fondazione Cariplo-2010-0737.
CR Allgayer H, 2002, CANCER, V94, P344, DOI 10.1002/cncr.10221
   Araujo J, 2009, INT J CANCER, V124, P1, DOI 10.1002/ijc.23998
   Balkwill F, 2004, SEMIN CANCER BIOL, V14, P171, DOI 10.1016/j.semcancer.2003.10.003
   Bendinelli P, 2009, MOL CANCER RES, V7, P1328, DOI 10.1158/1541-7786.MCR-08-0548
   Berlin I, 2010, J BIOL CHEM, V285, P37895, DOI 10.1074/jbc.M110.129411
   BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Buggy Y, 2004, BRIT J CANCER, V91, P1308, DOI 10.1038/sj.bjc.6602128
   Busillo JM, 2010, J BIOL CHEM, V285, P7805, DOI 10.1074/jbc.M109.091173
   Cabioglu N, 2005, CANCER RES, V65, P6493, DOI 10.1158/0008-5472.CAN-04-1303
   Cabioglu N, 2009, ANN ONCOL, V20, P1013, DOI 10.1093/annonc/mdn740
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000
   Chetram MA, 2011, MOL CANCER RES, V9, P90, DOI 10.1158/1541-7786.MCR-10-0235
   Dittmer J, 2003, MOL CANCER, V2, P1
   Forsberg EC, 2001, BIOESSAYS, V23, P820, DOI 10.1002/bies.1117
   Fry CJ, 1999, J BIOL CHEM, V274, P29583, DOI 10.1074/jbc.274.42.29583
   Furlan A, 2008, J CELL PHYSIOL, V215, P782, DOI 10.1002/jcp.21360
   Furusato B, 2010, PATHOL INT, V60, P497, DOI 10.1111/j.1440-1827.2010.02548.x
   Gimona M, 2008, CURR OPIN CELL BIOL, V20, P235, DOI 10.1016/j.ceb.2008.01.005
   Gobeil F, 2006, CAN J PHYSIOL PHARM, V84, P287, DOI 10.1139/Y05-127
   Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200
   Hassan S, 2009, AM J PATHOL, V175, P66, DOI 10.2353/ajpath.2009.080948
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6
   Katoh M, 2010, INT J ONCOL, V36, P415, DOI 10.3892/ijo_00000514
   Kim TY, 2006, EPIGENETICS-US, V1, P14
   Kostyniuk CL, 2002, ONCOGENE, V21, P6340, DOI 10.1038/sj.onc.1205787
   Kumar A, 2011, J IMMUNOL, V186, P951, DOI 10.4049/jimmunol.1002019
   Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027
   Liang ZX, 2004, CANCER RES, V64, P4302, DOI 10.1158/0008-5472.CAN-03-3958
   Liang ZX, 2005, CANCER RES, V65, P967
   Malik R, 2010, MOL BIOL CELL, V21, P2529, DOI 10.1091/mbc.E10-02-0169
   Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496
   MARONI P, 2011, BREAST CANC RES TREA, DOI DOI 10.1007/S10549-010-1240
   Maroni P, 2007, CARCINOGENESIS, V28, P267, DOI 10.1093/carcin/bgl129
   Matteucci E, 2006, CELL MOL LIFE SCI, V63, P2016, DOI 10.1007/s00018-006-6137-0
   Matteucci E, 2005, EXP CELL RES, V310, P176, DOI 10.1016/j.yexcr.2005.07.008
   Matteucci E, 2007, MOL CANCER RES, V5, P833, DOI 10.1158/1541-7786.MCR-07-0054
   Matteucci E, 2009, CARCINOGENESIS, V30, P937, DOI 10.1093/carcin/bgp080
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Nelson ML, 2010, P NATL ACAD SCI USA, V107, P10026, DOI 10.1073/pnas.0915137107
   Previdi S, 2010, EUR J CANCER, V46, P1679, DOI 10.1016/j.ejca.2010.02.036
   RIDOLFI E, 2008, BRIT J CANCER, V99, P1323
   Ropero S, 2007, MOL ONCOL, V1, P19, DOI 10.1016/j.molonc.2007.01.001
   Rucci N, 2006, J PHARMACOL EXP THER, V318, P161, DOI 10.1124/jpet.106.102004
   Salvucci O, 2006, BREAST CANCER RES TR, V97, P275, DOI 10.1007/s10549-005-9121-8
   Scita G, 2010, NATURE, V463, P464, DOI 10.1038/nature08910
   Shim H, 2006, BIOCHEM BIOPH RES CO, V346, P252, DOI 10.1016/j.bbrc.2006.05.110
   Smith MCP, 2004, CANCER RES, V64, P8604, DOI 10.1158/0008-5472.CAN-04-1844
   Smith-Pearson PS, 2010, J BIOL CHEM, V285, P40201, DOI 10.1074/jbc.M110.147330
   Stresemann C, 2008, INT J CANCER, V123, P8, DOI 10.1002/ijc.23607
   TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200
   Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329
   Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693
   Wang LH, 2009, ONCOL REP, V22, P1333, DOI 10.3892/or_00000572
   Woerner BM, 2005, CANCER RES, V65, P11392, DOI 10.1158/0008-5472.CAN-05-0847
   Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006
   Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366
   Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017
NR 60
TC 8
Z9 8
U1 0
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-4889
EI 0006-3002
J9 BBA-MOL CELL RES
JI Biochim. Biophys. Acta-Mol. Cell Res.
PD OCT
PY 2011
VL 1813
IS 10
BP 1767
EP 1776
DI 10.1016/j.bbamcr.2011.06.004
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 822QB
UT WOS:000295063600009
PM 21741415
OA Bronze
DA 2025-01-12
ER

PT J
AU Chen, MY
   Liao, WSL
   Lu, Z
   Bornmann, WG
   Hennessey, V
   Washington, MN
   Rosner, GL
   Yu, YH
   Ahmed, AA
   Bast, RC
AF Chen, Min-Yu
   Liao, Warren S. -L.
   Lu, Zhen
   Bornmann, William G.
   Hennessey, Violeta
   Washington, Michele N.
   Rosner, Gary L.
   Yu, Yinhua
   Ahmed, Ahmed Ashour
   Bast, Robert C., Jr.
TI Decitabine and Suberoylanilide Hydroxamic Acid (SAHA) Inhibit Growth of
   Ovarian Cancer Cell Lines and Xenografts While Inducing Expression of
   Imprinted Tumor Suppressor Genes, Apoptosis, G2/M Arrest, and Autophagy
SO CANCER
LA English
DT Article
DE ovarian cancer; autophagy; decitabine; suberoylanilide hydroxamic acid;
   imprinted tumor suppressor genes; ARHI; PEG3
ID HISTONE DEACETYLASE INHIBITORS; EPITHELIAL OVARIAN; DNA METHYLATION;
   PHASE-II; MYELODYSPLASTIC SYNDROME; DEMETHYLATING AGENTS; ARHI;
   COMBINATION; 5-AZA-2'-DEOXYCYTIDINE; ACETYLATION
AB BACKGROUND: Epigenetic therapy has had a significant impact on the management of hematologic malignancies, but its role in the treatment of ovarian cancer remains to be defined. The authors previously demonstrated that treatment of ovarian and breast cancer cells with DNA methyltransferase and histone deacetylase (HDAC) inhibitors can up-regulate the expression of imprinted tumor suppressors. In this study, demethylating agents and HDAC inhibitors were tested for their ability to induce re-expression of tumor suppressor genes, inhibiting growth of ovarian cancer cells in culture and in xenografts. METHODS: Ovarian cancer cells (Hey and SKOv3) were treated with demethylating agents (5-aza-2'-deoxycytidine [DAC] or 5-azacitidine [AZA]) or with HDAC inhibitors (suberoylanilide hydroxamic acid [SAHA] or trichostatin A [TSA]) to determine their impact on cellular proliferation, cell cycle regulation, apoptosis, autophagy, and re-expression of 2 growth inhibitory imprinted tumor suppressor genes: guanosine triphosphate-binding Di-RAS-like 3 (ARHI) and paternally expressed 3 (PEG3). The in vivo activities of DAC and SAHA were assessed in a Hey xenograft model. RESULTS: The combination of DAC and SAHA produced synergistic inhibition of Hey and SKOv3 cell growth by apoptosis and cell cycle arrest. DAC induced autophagy in Hey cells that was enhanced by SAHA. Treatment with both agents induced re-expression of ARHI and PEG3 in cultured cells and in xenografts, correlating with growth inhibition. Knockdown of ARHI decreased DAC-induced autophagy. DAC and SAHA inhibited the growth of Hey xenografts and induced autophagy in vivo. CONCLUSIONS: A combination of DAC and SAHA inhibited ovarian cancer growth while inducing apoptosis, G2/M arrest, autophagy, and re-expression of imprinted tumor suppressor genes. Cancer 2011; 117: 4424-38. (C) 2011 American Cancer Society.
C1 [Chen, Min-Yu; Liao, Warren S. -L.; Lu, Zhen; Bornmann, William G.; Washington, Michele N.; Yu, Yinhua; Ahmed, Ahmed Ashour; Bast, Robert C., Jr.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA.
   [Chen, Min-Yu] Chang Gung Mem Hosp, Dept Obstet & Gynecol, Tao Yuan, Taiwan.
   [Chen, Min-Yu] Chang Gung Univ, Coll Med, Tao Yuan, Taiwan.
   [Hennessey, Violeta; Rosner, Gary L.] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA.
   [Rosner, Gary L.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Oncol Biostat & Bioinformat Div, Baltimore, MD USA.
C3 University of Texas System; UTMD Anderson Cancer Center; Chang Gung
   Memorial Hospital; Chang Gung University; University of Texas System;
   UTMD Anderson Cancer Center; Johns Hopkins University; Johns Hopkins
   Medicine
RP Bast, RC (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA.
EM rbast@mdanderson.org
RI Lu, Zhen/E-5221-2015; Rosner, Gary/ABG-8161-2021; ahmed,
   ahmed/JZD-7597-2024; Bast, Robert/E-6585-2011
FU National Cancer Institute; University of Texas MD Anderson Cancer Center
   from the National Cancer Institute (NCI) [P50 CA83639]; National
   Foundation for Cancer Research; Zarrow Foundation; NCI Cancer Center
   [CA016672]
FX We acknowledge support from the National Cancer Institute for our
   Translational Chemistry Core Facility.This work was supported in part
   with funds from The University of Texas MD Anderson Cancer Center
   Specialized Programs of Research Excellence (SPORE) in Ovarian Cancer
   from the National Cancer Institute (NCI) (P50 CA83639), the National
   Foundation for Cancer Research, the Zarrow Foundation, and Mr. Stuart
   Zarrow. The University of Texas MD Anderson Cancer Center Translational
   Chemistry Core Facility also is supported by NCI Cancer Center Support
   Grant CA016672.
CR Adair SJ, 2009, CANCER IMMUNOL IMMUN, V58, P589, DOI 10.1007/s00262-008-0582-6
   Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Berek JS, 2010, HOLLAND FREI CANC ME, P1344
   Cashen AF, 2008, CANCER CHEMOTH PHARM, V61, P759, DOI 10.1007/s00280-007-0531-7
   Chou T.C., 1991, MEDIAN EFFECT PRINCI
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Dietrich CS, 2010, GYNECOL ONCOL, V116, P126, DOI 10.1016/j.ygyno.2009.09.039
   Dokmanovic M, 2007, MOL CANCER RES, V5, P981, DOI 10.1158/1541-7786.MCR-07-0324
   EFRON B, 1977, J AM STAT ASSOC, V72, P557, DOI 10.2307/2286217
   Fandy TE, 2007, CANCER J, V13, P40, DOI 10.1097/PPO.0b013e31803c7359
   Feng WW, 2008, CANCER-AM CANCER SOC, V112, P1489, DOI 10.1002/cncr.23323
   FU S, CANCER IN PRESS
   Fujii S, 2003, HUM MOL GENET, V12, P1791, DOI 10.1093/hmg/ddg204
   Garcia-Manero G, 2006, BLOOD, V108, P3271, DOI 10.1182/blood-2006-03-009142
   Gediya LK, 2005, J MED CHEM, V48, P5047, DOI 10.1021/jm058214k
   Hurtubise A, 2006, CANCER CHEMOTH PHARM, V58, P618, DOI 10.1007/s00280-006-0225-6
   Issa JPJ, 2007, CLIN CANCER RES, V13, P1634, DOI 10.1158/1078-0432.CCR-06-2076
   Issa JPJ, 2005, J CLIN ONCOL, V23, P3948, DOI 10.1200/JCO.2005.11.981
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   LEE JJ, SYNERGY SOFTWARE
   Leshchenko VV, 2010, BLOOD, V116, P1025, DOI 10.1182/blood-2009-12-257485
   Levine B, 2005, CELL, V120, P159, DOI 10.1016/j.cell.2005.01.005
   Li YF, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.08.030
   Lu KH, 2004, CLIN CANCER RES, V10, P3291, DOI 10.1158/1078-0432.CCR-03-0409
   Lu Z, 2006, CLIN CANCER RES, V12, P2404, DOI 10.1158/1078-0432.CCR-05-1036
   Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512
   MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163
   Menendez L, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-10
   Modesitt SC, 2008, GYNECOL ONCOL, V109, P182, DOI 10.1016/j.ygyno.2008.01.009
   Piekarz RL, 2007, CANCER J, V13, P30, DOI 10.1097/PPO.0b013e31803c73cc
   Rosen DG, 2004, CLIN CANCER RES, V10, P6559, DOI 10.1158/1078-0432.CCR-04-0698
   Santos FPS, 2010, EXPERT REV ANTICANC, V10, P9, DOI [10.1586/era.09.164, 10.1586/ERA.09.164]
   Sonnemann J, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-183
   Steele N, 2009, BRIT J CANCER, V100, P758, DOI 10.1038/sj.bjc.6604932
   Venturelli S, 2007, CANCER, V109, P2132, DOI 10.1002/cncr.22652
   Wijermans P, 2000, J CLIN ONCOL, V18, P956, DOI 10.1200/JCO.2000.18.5.956
   Yang H, 2005, LEUKEMIA RES, V29, P739, DOI 10.1016/j.leukres.2004.11.022
   Zhang CL, 2005, J INVEST DERMATOL, V125, P1045, DOI 10.1111/j.0022-202X.2005.23925.x
NR 40
TC 118
Z9 133
U1 0
U2 33
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD OCT 1
PY 2011
VL 117
IS 19
BP 4424
EP 4438
DI 10.1002/cncr.26073
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 824TN
UT WOS:000295225200014
PM 21491416
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Lima, SCS
   Hernandez-Vargas, H
   Simao, T
   Durand, G
   Kruel, CDP
   Le Calvez-Kelm, F
   Pinto, LFR
   Herceg, Z
AF Lima, Sheila C. S.
   Hernandez-Vargas, Hector
   Simao, Tatiana
   Durand, Geoffroy
   Pinto Kruel, Cleber Dario
   Le Calvez-Kelm, Florence
   Ribeiro Pinto, Luis Felipe
   Herceg, Zdenko
TI Identification of a DNA methylome signature of esophageal squamous cell
   carcinoma and potential epigenetic biomarkers
SO EPIGENETICS
LA English
DT Article
DE epigenomics; DNA methylation; esophageal squamous cell carcinoma (ESCC);
   cancer biomarkers
ID PROMOTER METHYLATION; BARRETTS-ESOPHAGUS; BREAST-CANCER; EXPRESSION;
   GENE; RISK; HYPERMETHYLATION; BCL-3; PS2; CARCINOGENESIS
AB Esophageal squamous cell carcinoma (ESCC) is believed to arise from esophageal mucosa through accumulation of both genetic and epigenetic changes. DNA methylation is a critical epigenetic mechanism involved in key cellular processes and its deregulation has been linked to many human cancers, including ESCC. The aim of this study is to examine the global deregulation of methylation states in ESCC and identify potential early biomarkers. With this purpose, we performed a bead array analysis of more than 800 cancer-related genes in ten ESCC samples, ten matched surrounding tissues and four esophageal mucosa from healthy individuals. Pyrosequencing was used for validation of DNA methylation changes in up to 106 cases and 27 controls. A total of 37 CpG sites were found to be differentially methylated between tumors and surrounding tissues. These CpG sites were significantly enriched in genes related to several pathways including IL-10 anti-inflammatory signaling pathway and cell communication pathway. In addition, by comparing with healthy esophageal mucosa, we identified TFF1 gene as a potential early marker of ESCC. This is the first study to address methylation changes in ESCC in a large set of genes. Methylome analysis is shown as a sensitive and powerful tool to identify molecular players in ESCC. These data should prove to be the reference for future studies identifying potential biomarkers and molecular targets in ESCC.
C1 [Lima, Sheila C. S.; Hernandez-Vargas, Hector; Durand, Geoffroy; Le Calvez-Kelm, Florence; Herceg, Zdenko] IARC, Epigenet Grp, Lyon, France.
   [Lima, Sheila C. S.; Simao, Tatiana; Ribeiro Pinto, Luis Felipe] Inst Nacl Canc, Div Genet, Rio De Janeiro, Brazil.
   [Simao, Tatiana; Ribeiro Pinto, Luis Felipe] Univ Estado Rio de Janeiro, Dept Bioquim, Inst Biol Roberto Alcantara Gomes, BR-20550011 Rio De Janeiro, Brazil.
   [Pinto Kruel, Cleber Dario] Hosp Clin Porto Alegre, Dept Cirurgia Gastrica, Fac Ciencias Med, Porto Alegre, RS, Brazil.
C3 World Health Organization; International Agency for Research on Cancer
   (IARC); National Cancer Institute (Inca); Universidade do Estado do Rio
   de Janeiro
RP Herceg, Z (通讯作者)，IARC, Epigenet Grp, Lyon, France.
EM herceg@iarc.fr
RI Lima, Sheila/A-9059-2015; Herceg, Zdenko/JOZ-6188-2023
OI Ribeiro Pinto, Luis Felipe/0000-0001-5509-1008; Le Calvez-Kelm,
   Florence/0000-0003-0063-5068; Hernandez-Vargas,
   Hector/0000-0001-6045-2103
FU l'Agence Nationale de Recherche Contre le Sida et Hepatites Virales
   (ANRS, France); l'Association pour la Recherche sur le Cancer (ARC),
   France; la Ligue Nationale (Francaise) Contre le Cancer, France
FX We thank John Daniel and Asiedua Asante for editing the manuscript. This
   work was supported by grants from l'Agence Nationale de Recherche Contre
   le Sida et Hepatites Virales (ANRS, France), l'Association pour la
   Recherche sur le Cancer (ARC), France; and la Ligue Nationale
   (Francaise) Contre le Cancer, France (to Z.H.). Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil), and Fundacao de
   Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ, Brazil). The
   funders had no role in study design, data collection and analysis,
   decision to publish or preparation of the manuscript.
CR Abdel-Latif MMM, 2009, CURR OPIN PHARMACOL, V9, P396, DOI 10.1016/j.coph.2009.06.010
   Allen JW, 1997, SURG ONCOL, V6, P193, DOI 10.1016/S0960-7404(98)00003-6
   Arai M, 2008, ONCOL REP, V20, P405, DOI 10.3892/or_00000022
   Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706
   Canoz O, 2004, MODERN PATHOL, V17, P911, DOI 10.1038/modpathol.3800140
   Carvalho R, 2002, LAB INVEST, V82, P1319, DOI 10.1097/01.LAB.0000029205.76632.A8
   Chidgey M, 2007, BRIT J CANCER, V96, P1783, DOI 10.1038/sj.bjc.6603808
   Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412
   Daskalos A, 2009, INT J CANCER, V124, P81, DOI 10.1002/ijc.23849
   DAWSEY SM, 1994, CANCER, V74, P1686, DOI 10.1002/1097-0142(19940915)74:6<1686::AID-CNCR2820740608>3.0.CO;2-V
   Dietrich D, 2009, J HISTOCHEM CYTOCHEM, V57, P477, DOI 10.1369/jhc.2009.953026
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Fox CA, 2005, NEOPLASIA, V7, P407, DOI 10.1593/neo.04715
   Gonda TA, 2009, CELL CYCLE, V8, P2005, DOI 10.4161/cc.8.13.8985
   Guo M, 2007, INT J CANCER, V121, P1219, DOI 10.1002/ijc.22828
   Guo MZ, 2006, CLIN CANCER RES, V12, P4515, DOI 10.1158/1078-0432.CCR-05-2858
   HENRY JA, 1991, BRIT J CANCER, V64, P677, DOI 10.1038/bjc.1991.380
   Herceg Z, 2007, MUTAGENESIS, V22, P91, DOI 10.1093/mutage/gel068
   Hernandez-Vargas H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009749
   Iacobuzio-Donahue CA, 2009, ANNU REV PATHOL-MECH, V4, P229, DOI 10.1146/annurev.pathol.3.121806.151442
   Islami F, 2009, INT J CANCER, V125, P491, DOI 10.1002/ijc.24445
   Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Karam SM, 2008, CELL PROLIFERAT, V41, P923, DOI 10.1111/j.1365-2184.2008.00562.x
   KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352
   Kim MS, 2006, CANCER RES, V66, P3409, DOI 10.1158/0008-5472.CAN-05-1608
   Kim YT, 2009, DIS ESOPHAGUS, V22, P143, DOI 10.1111/j.1442-2050.2008.00862.x
   Korn EL, 2007, STAT MED, V26, P4428, DOI 10.1002/sim.2865
   Lima SC, 2010, CURR OPIN MOL THER, V12, P316
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Mitas M, 2005, CLIN CANCER RES, V11, P2205, DOI 10.1158/1078-0432.CCR-04-1091
   Nie Y, 2002, CARCINOGENESIS, V23, P1713, DOI 10.1093/carcin/23.10.1713
   O'Neil BH, 2007, ONCOLOGY-BASEL, V72, P97, DOI 10.1159/000111116
   Oka D, 2009, CANCER-AM CANCER SOC, V115, P3412, DOI 10.1002/cncr.24394
   Ramírez N, 2008, EUR J CANCER, V44, P2689, DOI 10.1016/j.ejca.2008.09.004
   RIBIERAS S, 1998, BIOCHIM BIOPHYS ACTA, V1378, P61
   Rossini A, 2007, CARCINOGENESIS, V28, P2537, DOI 10.1093/carcin/bgm222
   Rossini A, 2010, MUTAT RES-GEN TOX EN, V696, P10, DOI 10.1016/j.mrgentox.2009.11.005
   Saadi A, 2010, P NATL ACAD SCI USA, V107, P2177, DOI 10.1073/pnas.0909797107
   Sabo E, 2008, CLIN CANCER RES, V14, P6440, DOI 10.1158/1078-0432.CCR-08-0302
   Shamma A, 2000, INT J ONCOL, V16, P261
   Soutto M, 2010, CANCER-AM CANCER SOC, V116, P4033, DOI 10.1002/cncr.25151
   Thornburg NJ, 2003, CANCER RES, V63, P8293
   Toh Y, 2010, INT J CLIN ONCOL, V15, P135, DOI 10.1007/s10147-010-0057-6
   TOMASETTO C, 1989, MOL ENDOCRINOL, V3, P1579, DOI 10.1210/mend-3-10-1579
   Vaissière T, 2009, EPIGENETICS-US, V4, P221, DOI 10.4161/epi.8833
   Vizcaino AP, 2002, INT J CANCER, V99, P860, DOI 10.1002/ijc.10427
   Wang JM, 2008, CANCER EPIDEM BIOMAR, V17, P118, DOI 10.1158/1055-9965.EPI-07-0733
   WELTER C, 1992, LAB INVEST, V66, P187
   Wong ML, 2006, INT J ONCOL, V28, P767
   Wright GW, 2003, BIOINFORMATICS, V19, P2448, DOI 10.1093/bioinformatics/btg345
   Yamaguchi S, 2005, DIS ESOPHAGUS, V18, P253, DOI 10.1111/j.1442-2050.2005.00501.x
   Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5
   YANG Y, 1992, PROSTATE, V21, P201, DOI 10.1002/pros.2990210304
   Zhang GY, 2010, J CANCER RES CLIN, V136, P587, DOI 10.1007/s00432-009-0693-2
   Zhang SQ, 2009, OMICS, V13, P307, DOI 10.1089/omi.2009.0030
NR 57
TC 48
Z9 53
U1 0
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD OCT
PY 2011
VL 6
IS 10
BP 1217
EP 1227
DI 10.4161/epi.6.10.17199
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 834PF
UT WOS:000295974000006
PM 21946330
OA Bronze
DA 2025-01-12
ER

PT J
AU Li, CT
   Hsiao, YM
   Wu, TC
   Lin, YW
   Yeh, KT
   Ko, JL
AF Li, Chien-Te
   Hsiao, Yi-Min
   Wu, Tzu-Chin
   Lin, Yu-Wen
   Yeh, Kun-Tu
   Ko, Jiunn-Liang
TI Vorinostat, SAHA, Represses Telomerase Activity via Epigenetic
   Regulation of Telomerase Reverse Transcriptase in Non-Small Cell Lung
   Cancer Cells
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE VORINOSTAT; LUNG CANCER; TELOMERASE ACTIVITY; HTERT; EPIGENETIC
   REGULATION
ID HISTONE DEACETYLASE INHIBITOR; SUBEROYLANILIDE HYDROXAMIC ACID; HTERT
   PROMOTER; DNA METHYLATION; TRICHOSTATIN-A; BREAST-CANCER; GENE;
   EXPRESSION; APOPTOSIS; TRIAL
AB Vorinostat (suberoylanilide hydroxamic acid), a class of histone deacetylase inhibitors, represents an emerging class of anticancer agents currently progressing in clinical trials. It causes cell growth inhibition, differentiation, and apoptosis of many tumor types in vitro and in vivo. Recently, it was reported that hTERT is one of the targets for cancer therapy in cancer cells. Telomerase repeat amplification protocol assay was used to analyze the expression of hTERT after vorinostat treatment in the A549 lung cancer cells. Vorinostat inhibited telomerase activity by reducing the expression of human telomerase reverse transcriptase (hTERT) in A549 human lung cancer cells. The epigenetic regulation mechanism is responsible for the repression of hTERT by vorinostat, analyzed through the methylation-specific PCR and bisulfite sequencing of the hTERT promoter. Vorinostat induced the demethylation of site-specific CpGs on the promoter region of hTERT, which was caused by the down-regulation of DNA methyltransferases. DNA methyltransferases (DNMT1 and DNMT3b) were also decreased in vorinostat-treated A549 cancer cells. Furthermore, chromatin immunoprecipitation analysis of the hTERT promoter revealed that vorinostat decreased the level of inactive chromatin markers dimethyl-H3K9, and the declined binding of DNMT1 and DNMT3b were associated. The novel insights showed that vorinostat down-regulated telomerase via epigenetic alteration in lung cancer to vorinostat-mediated cancer-specific therapies. J. Cell. Biochem. 112: 3044-3053, 2011. (C) 2011 Wiley-Liss, Inc.
C1 [Li, Chien-Te; Lin, Yu-Wen; Yeh, Kun-Tu; Ko, Jiunn-Liang] Chung Shan Med Univ, Inst Med, Taichung 40203, Taiwan.
   [Li, Chien-Te; Lin, Yu-Wen; Ko, Jiunn-Liang] Chung Shan Med Univ, Inst Med & Mol Toxicol, Taichung 40203, Taiwan.
   [Li, Chien-Te] Changhua Christian Hosp, Div Chest Med, Dept Internal Med, Changhua, Taiwan.
   [Hsiao, Yi-Min] Cent Taiwan Univ Sci & Technol, Dept Med Lab Sci & Biotechnol, Taichung, Taiwan.
   [Wu, Tzu-Chin; Ko, Jiunn-Liang] Chung Shan Med Univ Hosp, Dept Internal Med, Taichung, Taiwan.
   [Wu, Tzu-Chin] Chung Shan Med Univ, Sch Med, Taichung 40203, Taiwan.
   [Yeh, Kun-Tu] Changhua Christian Hosp, Dept Pathol, Changhua, Taiwan.
C3 Chung Shan Medical University; Chung Shan Medical University; Changhua
   Christian Hospital; Central Taiwan University Science & Technology;
   Chung Shan Medical University; Chung Shan Medical University Hospital;
   Chung Shan Medical University; Changhua Christian Hospital
RP Yeh, KT (通讯作者)，Chung Shan Med Univ, Inst Med, 110,Sec 1,Chien Kuo N Rd, Taichung 40203, Taiwan.
EM 10159@cch.org.tw; jlko@csmu.edu.tw
RI chen, yuying/JNS-9778-2023
OI Ko, Jiunn-Liang/0000-0001-6855-9239
FU National Science Council (NSC) Republic of China
   [NSC99-2314-B040-012-MY3]
FX Grant sponsor: National Science Council (NSC) Republic of China; Grant
   number: NSC99-2314-B040-012-MY3.
CR Abdul-Ghani R, 2000, MOL THER, V2, P539, DOI 10.1006/mthe.2000.0196
   Arnold NB, 2007, CLIN CANCER RES, V13, P18, DOI 10.1158/1078-0432.CCR-06-0914
   Bechter OE, 2002, EXP HEMATOL, V30, P26, DOI 10.1016/S0301-472X(01)00760-3
   Bouchain G, 2003, CURR MED CHEM, V10, P2359, DOI 10.2174/0929867033456585
   Choi JH, 2010, BIOCHEM BIOPH RES CO, V391, P449, DOI 10.1016/j.bbrc.2009.11.078
   Choi YH, 2005, INT J ONCOL, V27, P473
   Curtin M, 2003, CURR MED CHEM, V10, P2373, DOI 10.2174/0929867033456576
   Damiani LA, 2008, CANCER RES, V68, P9005, DOI 10.1158/0008-5472.CAN-08-1276
   Duvic M, 2007, BLOOD, V109, P31, DOI 10.1182/blood-2006-06-025999
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Fedier A, 2007, INT J ONCOL, V31, P633
   Ge Z, 2010, FASEB J, V24, P579, DOI 10.1096/fj.09-140087
   Guilleret I, 2003, EXP CELL RES, V289, P326, DOI 10.1016/S0014-4827(03)00281-7
   Guilleret I, 2002, INT J CANCER, V101, P335, DOI 10.1002/ijc.10593
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hou M, 2002, EXP CELL RES, V274, P25, DOI 10.1006/excr.2001.5462
   Hsin IL, 2010, MUTAT RES-FUND MOL M, V688, P72, DOI 10.1016/j.mrfmmm.2010.03.011
   Huang CH, 2007, BIOCHEM PHARMACOL, V73, P990, DOI 10.1016/j.bcp.2006.12.013
   Huang PH, 2011, MOL PHARMACOL, V79, P197, DOI 10.1124/mol.110.067702
   James SR, 2006, ONCOGENE, V25, P6975, DOI 10.1038/sj.onc.1209678
   Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6
   Kageyama Y, 1997, Int J Urol, V4, P407, DOI 10.1111/j.1442-2042.1997.tb00216.x
   Katiyar SK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021410
   Kitagawa Y, 2000, CLIN CANCER RES, V6, P2868
   Komata T, 2002, ONCOGENE, V21, P656, DOI 10.1038/sj.onc.1205072
   Komatsu N, 2006, ONCOL REP, V15, P187
   Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669
   Kyo S, 2008, CANCER SCI, V99, P1528, DOI 10.1111/j.1349-7006.2008.00878.x
   Landberg G, 1997, CANCER RES, V57, P549
   Lee EJ, 2008, INT J ONCOL, V33, P767, DOI 10.3892/ijo_00000063
   Li YY, 2009, INT J CANCER, V125, P286, DOI 10.1002/ijc.24398
   Lin SC, 2006, CANCER LETT, V236, P80, DOI 10.1016/j.canlet.2005.05.003
   Luu TH, 2008, CLIN CANCER RES, V14, P7138, DOI 10.1158/1078-0432.CCR-08-0122
   Marchetti A, 1999, CLIN CANCER RES, V5, P2077
   Marks PA, 2009, J CELL BIOCHEM, V107, P600, DOI 10.1002/jcb.22185
   Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079
   Meeran SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011457
   Munster PN, 2001, CANCER RES, V61, P8492
   Ou JN, 2007, BIOCHEM PHARMACOL, V73, P1297, DOI 10.1016/j.bcp.2006.12.032
   Owonikoko TK, 2010, INT J CANCER, V126, P743, DOI 10.1002/ijc.24759
   Renaud S, 2007, NUCLEIC ACIDS RES, V35, P1245, DOI 10.1093/nar/gkl1125
   Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906
   Wang SW, 2010, MOL BIOL CELL, V21, P821, DOI 10.1091/mbc.E09-06-0456
   Wilson PM, 2010, CANCER CHEMOTH PHARM, V65, P979, DOI 10.1007/s00280-009-1236-x
   Witta SE, 2009, ANN ONCOL, V20, P689, DOI 10.1093/annonc/mdn703
   Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200
   Wu TC, 2003, LUNG CANCER-J IASLC, V41, P163, DOI 10.1016/S0169-5002(03)00195-8
   Yan P, 1999, J PATHOL, V189, P207, DOI 10.1002/(SICI)1096-9896(199910)189:2<207::AID-PATH424>3.0.CO;2-H
   Zhu WG, 2001, CANCER RES, V61, P1327
   Zinn RL, 2007, CANCER RES, V67, P194, DOI 10.1158/0008-5472.CAN-06-3396
NR 50
TC 38
Z9 41
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD OCT
PY 2011
VL 112
IS 10
BP 3044
EP 3053
DI 10.1002/jcb.23229
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 829YP
UT WOS:000295623300041
PM 21678477
DA 2025-01-12
ER

PT J
AU Moelans, CB
   Verschuur-Maes, AHJ
   van Diest, PJ
AF Moelans, Cathy B.
   Verschuur-Maes, Anoek H. J.
   van Diest, Paul J.
TI Frequent promoter hypermethylation of <i>BRCA2</i>, <i>CDH13</i>,
   <i>MSH6</i>, <i>PAX5</i>, <i>PAX6</i> and <i>WT1</i> in ductal carcinoma
   <i>in situ</i> and invasive breast cancer
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE methylation; DCIS; breast cancer; MS-MLPA
ID SPORADIC BREAST; DNA METHYLATION; ABERRANT METHYLATION; GENE PROMOTER;
   CPG ISLAND; POOR-PROGNOSIS; COPY NUMBER; EXPRESSION; PROFILES; TUMORS
AB Epigenetic changes are considered to be a frequent event during tumour development. Hypermethylation of promoter CpG islands represents an alternative mechanism to inactivate tumour suppressor genes, DNA repair genes, cell cycle regulators and transcription factors. In search of epigenetic events related to progression, we used MS-MLPA (ME-0002-B1, MRC-Holland, Amsterdam, The Netherlands) to compare the methylation status of 25 breast cancer-related genes between laser-microdissected ductal carcinoma in situ (DCIS) and adjacent invasive ductal cancer (IDC) lesions in 33 breast cancer patients. Using absolute methylation percentages or, alternatively, a 15% cut-off for methylation, promoter methylation in DCIS and IDC was not significantly different for any of the genes studied. Aberrant methylation in at least 50% of both the DCIS and adjacent IDC lesions was observed for PAX6, BRCA2, PAX5, WT1, CDH13 and MSH6. Methylation of MSH6, however, was also frequent in normal breast tissue. In contrast, CDKN2A, CHFR, PYCARD and one of the two analysed RB1 CpG loci were rarely (<5%) methylated in both lesions. CDKN2A and GSTP1 showed significantly (p < 0.002) higher mean methylation levels in increasing grades (I, II, III) of DCIS (1% versus 4% versus 7% for CDKN2A and 6% versus 26% versus 28% for GSTP1). The mean number of methylated genes per sample increased with increasing grades of DCIS (p = 0.014) and IDC (p = 0.109). In contrast to the observations in DCIS, none of the analysed genes showed significantly higher methylation levels with increasing grades of IDC. In conclusion, there were no differences in promoter methylation between DCIS and IDC in the 25 analysed genes, suggesting that DCIS, at the epigenetic level, is as advanced as IDC. Promoter hypermethylation of PAX6, BRCA2, PAX5, WT1, CDH13 and MSH6 seems to be a frequent early event in breast cancer and methylation levels of GSTP1 (and CDKN2A, although still low) seem to increase with increasing DCIS grade. Copyright (C) 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
C1 [Moelans, Cathy B.; Verschuur-Maes, Anoek H. J.; van Diest, Paul J.] Univ Med Ctr Utrecht, Dept Pathol, NL-3508 GA Utrecht, Netherlands.
C3 Utrecht University; Utrecht University Medical Center
RP Moelans, CB (通讯作者)，Univ Med Ctr Utrecht, Dept Pathol H04 131, Heidelberglaan 100,POB 85500, NL-3508 GA Utrecht, Netherlands.
EM cmoelans@umcutrecht.nl
OI Moelans, Cathy/0000-0001-9992-8703
CR Allinen M, 2002, GENE CHROMOSOME CANC, V34, P384, DOI 10.1002/gcc.10079
   Arai T, 2006, BREAST CANCER RES TR, V100, P169, DOI 10.1007/s10549-006-9241-9
   Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604
   Bertolo C, 2008, AM J CLIN PATHOL, V130, P414, DOI 10.1309/J3QV9763DYPV338D
   Bol GM, 2010, HISTOPATHOLOGY, V57, P363, DOI 10.1111/j.1365-2559.2010.03642.x
   Brandes JC, 2007, ONCOGENE, V26, P6229, DOI 10.1038/sj.onc.1210433
   Brooks JD, 1998, CANCER EPIDEM BIOMAR, V7, P531
   Brooks J, 2009, CANCER CAUSE CONTROL, V20, P1539, DOI 10.1007/s10552-009-9415-y
   Buerger H, 2000, J CLIN PATHOL-MOL PA, V53, P118, DOI 10.1136/mp.53.3.118
   Buerger H, 2001, J PATHOL, V194, P165, DOI 10.1002/path.875
   Buyru N, 2009, CANCER INVEST, V27, P307, DOI 10.1080/07357900802350814
   Capel E, 2007, ONCOGENE, V26, P7596, DOI 10.1038/sj.onc.1210581
   Chen CM, 2003, AM J PATHOL, V163, P37, DOI 10.1016/S0002-9440(10)63628-0
   Chintamani, 2007, Int Semin Surg Oncol, V4, P5, DOI 10.1186/1477-7800-4-5
   Cimino D, 2008, INT J CANCER, V123, P1327, DOI 10.1002/ijc.23660
   Dejeux E, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-68
   Dikow N, 2007, MOL CELL PROBE, V21, P208, DOI 10.1016/j.mcp.2006.12.002
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Evron E, 2001, CANCER RES, V61, P2782
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Feng W, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1762
   Feng WW, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-378
   García JM, 2004, GENE CHROMOSOME CANC, V41, P117, DOI 10.1002/gcc.20062
   Gupta S., 2009, Indian Journal of Cancer, V46, P303, DOI 10.4103/0019-509X.55550
   Gylling A, 2007, GUT, V56, P926, DOI 10.1136/gut.2006.114876
   Heller G, 2007, BREAST CANCER RES TR, V103, P283, DOI 10.1007/s10549-006-9377-7
   Henken FE, 2007, BRIT J CANCER, V97, P1457, DOI 10.1038/sj.bjc.6604055
   HOLLAND R, 1994, SEMIN DIAGN PATHOL, V11, P167
   Holst CR, 2003, CANCER RES, V63, P1596
   Honorio S, 2003, ONCOGENE, V22, P147, DOI 10.1038/sj.onc.1206057
   Hoque MO, 2009, CANCER EPIDEM BIOMAR, V18, P2694, DOI 10.1158/1055-9965.EPI-08-0821
   Huang KT, 2010, BREAST CANCER RES TR, V124, P853, DOI 10.1007/s10549-010-1087-5
   Huggins GS, 2006, CANCER RES, V66, P1384, DOI 10.1158/0008-5472.CAN-05-2715
   Hwang ES, 2004, CLIN CANCER RES, V10, P5160, DOI 10.1158/1078-0432.CCR-04-0165
   Irvine T, 2007, EXPERT REV ANTICANC, V7, P135, DOI 10.1586/14737140.7.2.135
   Joensuu EI, 2008, CANCER RES, V68, P4597, DOI 10.1158/0008-5472.CAN-07-6645
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Khan S, 2004, INT J CANCER, V112, P407, DOI 10.1002/ijc.20447
   Lamy A, 2002, INT J CANCER, V100, P189, DOI 10.1002/ijc.10474
   Lasabova Z, 2010, NEOPLASMA, V57, P35, DOI 10.4149/neo_2010_01_035
   Laux DE, 1999, BREAST CANCER RES TR, V56, P35, DOI 10.1023/A:1006222803788
   Lee JS, 2008, CANCER BIOL THER, V7, P1400
   Lee JS, 2007, VIRCHOWS ARCH, V450, P637, DOI 10.1007/s00428-007-0421-8
   Leong KJ, 2011, BRIT J SURG, V98, P724, DOI 10.1002/bjs.7422
   Levenson VV, 2007, BBA-GEN SUBJECTS, V1770, P847, DOI 10.1016/j.bbagen.2007.01.017
   Loeb DM, 2001, CANCER RES, V61, P921
   Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8
   Matsukura S, 2001, ANN SURG ONCOL, V8, P807, DOI 10.1007/s10434-001-0807-9
   Mehrotra J, 2004, CLIN CANCER RES, V10, P3104, DOI 10.1158/1078-0432.CCR-03-0118
   Mirza S, 2007, LIFE SCI, V81, P280, DOI 10.1016/j.lfs.2007.05.012
   Moelans CB, 2010, ANAL CELL PATHOL, V33, P165, DOI [10.1155/2010/829358, 10.3233/ACP-CLO-2010-0546]
   Moelans CB, 2010, BREAST CANCER RES TR, V120, P1, DOI 10.1007/s10549-009-0539-2
   Moelans CB, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-4
   Mommers ECM, 2001, J PATHOL, V194, P327, DOI 10.1002/path.910
   Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466
   Nofech-Mozes S, 2005, ADV ANAT PATHOL, V12, P256, DOI 10.1097/01.pap.0000184177.65919.5e
   Nygren AOH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni127
   O'Connell P, 1998, JNCI-J NATL CANCER I, V90, P697, DOI 10.1093/jnci/90.9.697
   Palmisano WA, 2003, CANCER RES, V63, P4620
   Park SY, 2011, VIRCHOWS ARCH, V458, P73, DOI 10.1007/s00428-010-1013-6
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Parsons MJ, 2009, CANCER RES, V69, P1706, DOI 10.1158/0008-5472.CAN-08-2351
   Paulsson K, 2009, BRIT J HAEMATOL, V144, P838, DOI 10.1111/j.1365-2141.2008.07523.x
   Radpour R, 2010, MODERN PATHOL, V23, P763, DOI 10.1038/modpathol.2009.195
   Ramos EAS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-23
   Ronneberg JA, 2008, CANCER RES, V68, P5562, DOI 10.1158/0008-5472.CAN-07-5828
   Ronneberg JA, 2011, MOL ONCOL, V5, P61, DOI 10.1016/j.molonc.2010.11.004
   Sadeq V, 2011, MED ONCOL, V28, P420, DOI 10.1007/s12032-010-9473-8
   Schulmann K, 2005, ONCOGENE, V24, P4138, DOI 10.1038/sj.onc.1208598
   Seeber LMS, 2010, ENDOCR-RELAT CANCER, V17, P663, DOI 10.1677/ERC-10-0014
   Sharma G, 2009, CELL ONCOL, V31, P487, DOI 10.3233/CLO-2009-0507
   Suijkerbuijk KPM, 2008, ANN ONCOL, V19, P1870, DOI 10.1093/annonc/mdn409
   Suijkerbuijk KPM, 2010, ANAL CELL PATHOL, V33, P133, DOI [10.1155/2010/185219, 10.3233/ACP-CLO-2010-0542]
   Tokunaga E, 2006, BREAST CANCER RES TR, V97, P199, DOI 10.1007/s10549-005-9112-9
   Toyooka KO, 2001, CANCER RES, V61, P4556
   Treilleux I, 2007, HISTOPATHOLOGY, V51, P63, DOI 10.1111/j.1365-2559.2007.02726.x
   van Diest PJ, 2002, BMJ-BRIT MED J, V325, P648, DOI 10.1136/bmj.325.7365.648
   Vidal LJP, 2010, MOL CANCER RES, V8, P444, DOI 10.1158/1541-7786.MCR-09-0368
   Virmani A, 2003, INT J CANCER, V106, P198, DOI 10.1002/ijc.11206
   Vo QN, 2004, ONCOGENE, V23, P9432, DOI 10.1038/sj.onc.1208092
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Wen XZ, 2010, WORLD J GASTROENTERO, V16, P1201, DOI 10.3748/wjg.v16.i10.1201
   Zemlyakova V. V., 2003, Molekulyarnaya Biologiya (Moscow), V37, P696
   Zhuang Zhi-Gang, 2007, Zhonghua Yi Xue Za Zhi, V87, P81
NR 86
TC 109
Z9 130
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
EI 1096-9896
J9 J PATHOL
JI J. Pathol.
PD OCT
PY 2011
VL 225
IS 2
BP 222
EP 231
DI 10.1002/path.2930
PG 10
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA 826ZF
UT WOS:000295393400010
PM 21710692
DA 2025-01-12
ER

PT J
AU Luo, YL
   Li, J
   Liu, Y
   Lin, L
   Du, YT
   Li, ST
   Yang, HM
   Vajta, G
   Callesen, H
   Bolund, L
   Sorensen, CB
AF Luo, Yonglun
   Li, Juan
   Liu, Ying
   Lin, Lin
   Du, Yutao
   Li, Shengting
   Yang, Huanming
   Vajta, Gabor
   Callesen, Henrik
   Bolund, Lars
   Sorensen, Charlotte Brandt
TI High efficiency of BRCA1 knockout using rAAV-mediated gene targeting:
   developing a pig model for breast cancer
SO TRANSGENIC RESEARCH
LA English
DT Article
DE BRCA1; Breast cancer; rAAV; Gene targeting; Minipig
ID HANDMADE CLONING; NUCLEAR TRANSFER; VIRAL VECTORS; DNA-DAMAGE;
   CELL-CYCLE; MICE; SUSCEPTIBILITY; TUMORIGENESIS; MUTATIONS; PIGLETS
AB Germline inactivating mutations of the breast cancer associated gene 1 (BRCA1) predispose to breast cancer and account for most cases of familiar breast and/or ovarian cancer. The pig is an excellent model for medical research as well as testing of new methods and drugs for disease prevention and treatment. We have generated cloned BRCA1 knockout (KO) Yucatan miniature piglets by targeting exon 11 using recombinant adeno-associated virus (rAAV)-mediated gene targeting and somatic cell nuclear transfer by Handmade Cloning (HMC). We found a very high targeting rate of rAAV-mediated BRCA1 KO. Approximately 35% of the selected cells were BRCA1 targeted. One BRCA1 KO cell clone (5D1), identified by PCR and Southern blot, was used as nuclear donor for HMC. Reconstructed embryos were transferred to three recipient sows which gave birth to 8 piglets in total. Genotyping identified seven piglets as BRCA1 heterozygotes (BRCA1(+/Delta 11)), and one as wild type. The BRCA1 expression was decreased at the mRNA level in BRCA1(+/Delta 11) fibroblasts. However, all BRCA1(+/Delta 11) piglets died within 18 days after birth. The causes of perinatal mortality remain unclear. Possible explanations may include a combination of the BRCA1 haploinsufficiency, problems of epigenetic reprogramming, presence of the marker gene, single cell clone effects, and/or the special genetic background of the minipigs.
C1 [Luo, Yonglun; Bolund, Lars; Sorensen, Charlotte Brandt] Aarhus Univ, Dept Human Genet, DK-8000 Aarhus, Denmark.
   [Li, Juan; Liu, Ying; Lin, Lin; Vajta, Gabor; Callesen, Henrik] Aarhus Univ, Res Ctr Foulum, Dept Genet & Biotechnol, Sect Populat Genet & Embryol, DK-8830 Tjele, Denmark.
   [Luo, Yonglun; Lin, Lin; Du, Yutao; Yang, Huanming; Bolund, Lars] BGI Shenzhen HuaDa Shenzhen, Shenzhen 518083, Peoples R China.
   [Li, Shengting] Aarhus Univ, Bioinformat Res Ctr, DK-8000 Aarhus, Denmark.
C3 Aarhus University; Aarhus University; Beijing Genomics Institute (BGI);
   Aarhus University
RP Luo, YL (通讯作者)，Aarhus Univ, Dept Human Genet, Wilhelm Meyers 4, DK-8000 Aarhus, Denmark.
EM alun@humgen.au.dk
RI Wang, Yuhui/JTT-7711-2023; Luo, Yonglun/AAG-9253-2020; Vajta,
   Gabor/I-3672-2016; Liu, Ying/T-5064-2019; ying, liu/KEI-0478-2024; Yang,
   Huanming/C-6513-2013; Luo, Yonglun/C-4708-2013
OI Lin, Lin/0000-0002-7546-4948; Sorensen, Charlotte
   Brandt/0000-0002-4469-8696; Callesen, Henrik/0000-0002-0185-7300; Yang,
   Huanming/0000-0002-0858-3410; Luo, Yonglun/0000-0002-0007-7759
FU Danish National Advanced Technology Foundation; Danish Agency for
   Science, Technology and Innovation [274-05-0535]; DAGMAR; Sino-Danish
   Breast Cancer Research Centre of the Danish National Research
   Foundation; National Natural Science Foundation of China
FX We would like to thank Bert Vogelstein and Kenneth W. Kinzler, John
   Hopkins University, Baltimore, US, for kindly providing the pNeDaKO
   plasmid vector and Dr. R. Jude Samulski and the UNC Vector Core
   Facility, Chapel Hill, North Carolina, US for the rAAV packaging. We
   would also like to thank Lisbeth Dahl Schroder, Tina Hindkjaer, Anette
   Thomsen, Bodil Schmidt and Christian Knudsen for skilled technical
   assistance. The project was supported by grants from the "Pig and Health
   Platform" of the Danish National Advanced Technology Foundation
   (Hojteknologifonden), the Danish Agency for Science, Technology and
   Innovation (grant no. 274-05-0535), the DAnish Genetically Modified
   Animal Ressource (DAGMAR), and the "Sino-Danish Breast Cancer Research
   Centre" under the auspices of the Danish National Research Foundation
   (Grundforskningsfonden) and the National Natural Science Foundation of
   China.
CR Alberg Anthony J., 1999, Current Opinion in Oncology, V11, P435, DOI 10.1097/00001622-199911000-00003
   Bennett LM, 2000, MOL CARCINOGEN, V28, P174, DOI 10.1002/1098-2744(200007)28:3<174::AID-MC6>3.0.CO;2-C
   Bouwman P, 2008, CELL CYCLE, V7, P2647, DOI 10.4161/cc.7.17.6266
   BOYD M, 1995, NATURE, V375, P541, DOI 10.1038/375541b0
   Campbell KHS, 2005, REPROD DOMEST ANIM, V40, P256, DOI 10.1111/j.1439-0531.2005.00591.x
   Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2
   Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010
   Du Y, 2007, THERIOGENOLOGY, V68, P1104, DOI 10.1016/j.theriogenology.2007.07.021
   Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191
   Grieger JC, 2006, NAT PROTOC, V1, P1412, DOI 10.1038/nprot.2006.207
   Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1
   Jeng YM, 2007, ONCOGENE, V26, P6160, DOI 10.1038/sj.onc.1210451
   Kohli M, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh009
   Kragh PM, 2009, TRANSGENIC RES, V18, P545, DOI 10.1007/s11248-009-9245-4
   LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712
   Liu X, 2007, P NATL ACAD SCI USA, V104, P12111, DOI 10.1073/pnas.0702969104
   Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226
   Ludwig T, 2001, GENE DEV, V15, P1188, DOI 10.1101/gad.879201
   McCreath KJ, 2000, NATURE, V405, P1066, DOI 10.1038/35016604
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   Rogers CS, 2008, J CLIN INVEST, V118, P1571, DOI 10.1172/JCI34773
   Rosen EM, 2003, J CELL PHYSIOL, V196, P19, DOI 10.1002/jcp.10257
   Russell DW, 1998, NAT GENET, V18, P325, DOI 10.1038/ng0498-325
   Schmidt M, 2010, THERIOGENOLOGY, V74, P1233, DOI 10.1016/j.theriogenology.2010.05.026
   Szabo CI, 2004, CANCER BIOL THER, V3, P515, DOI 10.4161/cbt.3.6.841
   Tian XC, 2009, REPROD FERT DEVELOP, V21, P60, DOI 10.1071/RD08214
   Vajta G, 2000, MOL REPROD DEV, V55, P256, DOI 10.1002/(SICI)1098-2795(200003)55:3<256::AID-MRD3>3.0.CO;2-7
   Vajta G, 2007, TRENDS BIOTECHNOL, V25, P250, DOI 10.1016/j.tibtech.2007.04.004
   Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3
   Wernersson R, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-70
   Yoshida K, 2004, CANCER SCI, V95, P866, DOI 10.1111/j.1349-7006.2004.tb02195.x
   Yoshioka K, 2002, BIOL REPROD, V66, P112, DOI 10.1095/biolreprod66.1.112
   Young LE, 1998, REV REPROD, V3, P155, DOI 10.1530/revreprod/3.3.155
NR 34
TC 62
Z9 73
U1 1
U2 17
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0962-8819
J9 TRANSGENIC RES
JI Transgenic Res.
PD OCT
PY 2011
VL 20
IS 5
BP 975
EP 988
DI 10.1007/s11248-010-9472-8
PG 14
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 844XS
UT WOS:000296786900002
PM 21181439
DA 2025-01-12
ER

PT J
AU Kim, GE
   Lee, KH
   Choi, YD
   Lee, JS
   Lee, JH
   Nam, JH
   Choi, C
   Park, MH
   Yoon, JH
AF Kim, Ga-Eon
   Lee, Kyung Hwa
   Choi, Yoo Duk
   Lee, Ji Shin
   Lee, Jae Hyuk
   Nam, Jong Hee
   Choi, Chan
   Park, Min Ho
   Yoon, Jung Han
TI Detection of Slit2 promoter hypermethylation in tissue and serum samples
   from breast cancer patients
SO VIRCHOWS ARCHIV
LA English
DT Article
DE Breast cancer; Slit2; Methylation; Tissue; Serum; Biological marker
ID FREQUENT EPIGENETIC INACTIVATION; TUMOR DNA; ABERRANT METHYLATION; GENE;
   CARCINOMA; GUIDANCE; CHEMOTAXIS; RECEPTORS; MIGRATION; GROWTH
AB Promoter hypermethylation has been shown to be a common mechanism for inactivation of tumor suppressor genes in breast cancer. The aim of this study was to investigate the prevalence of Slit2 promoter hypermethylation in both the tumor and serum samples of breast cancer patients with ductal carcinoma in situ (DCIS) or invasive breast carcinoma (IBC). The methylation status of Slit2 was investigated in 210 tissue samples (15 breast with no pathological findings, 26 DCIS, and 169 IBC samples) and 123 corresponding serum samples (15 breast with no pathological findings, 26 DCIS, and 82 IBC samples) using methylation-specific polymerase chain reaction. Immunohistochemical staining for Slit2 was also performed using tissue microarray blocks to determine whether Slit2 promoter hypermethylation correlated with loss of Slit2 expression. Slit2 promoter hypermethylation was not detected in breast tissue and serum samples from patients with no pathological findings. DCIS or IBC showed a statistically higher frequency of Slit2 promoter hypermethylation compared to breast with no pathological findings in both the tissue and serum samples; however, there were no statistically significant differences between DCIS and IBC samples. Similar Slit2 promoter hypermethylation patterns were seen in the tissue samples and corresponding serum specimens (p < 0.001). Slit2 promoter hypermethylation was associated with loss of Slit2 expression. These results suggest that Slit2 promoter hypermethylation appears to be responsible for functionally silencing Slit2 expression. Slit2 promoter hypermethylation may be considered as a possible serum marker for early detection of breast cancer.
C1 [Lee, Ji Shin] Chonnam Natl Univ, Hwasun Hosp, Dept Pathol, Hwasun Gun 519809, Jeollanam Do, South Korea.
   [Kim, Ga-Eon; Lee, Kyung Hwa; Choi, Yoo Duk; Lee, Ji Shin; Lee, Jae Hyuk; Nam, Jong Hee; Choi, Chan] Chonnam Natl Univ, Sch Med, Dept Pathol, Kwangju, South Korea.
   [Kim, Ga-Eon; Lee, Kyung Hwa; Choi, Yoo Duk; Lee, Ji Shin; Lee, Jae Hyuk; Nam, Jong Hee; Choi, Chan; Park, Min Ho; Yoon, Jung Han] Res Inst Med Sci, Kwangju, South Korea.
   [Park, Min Ho; Yoon, Jung Han] Chonnam Natl Univ, Sch Med, Dept Surg, Kwangju, South Korea.
C3 Chonnam National University; Chonnam National University; Chonnam
   National University
RP Lee, JS (通讯作者)，Chonnam Natl Univ, Hwasun Hosp, Dept Pathol, 160 IIsim Ri, Hwasun Gun 519809, Jeollanam Do, South Korea.
EM jshinlee@hanmail.net
RI Kim, Suhnggwon/J-5407-2012; Choi, Youn/AAS-3301-2021
OI Kim, Ga-Eon/0000-0001-8539-6654
FU Chonnam National University Hospital Research Institute of Clinical
   Medicine [CRI10056-1]
FX This study was supported by a grant (CRI10056-1) from Chonnam National
   University Hospital Research Institute of Clinical Medicine.
CR a Tavassoli F., 2003, World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs, P63
   Alsayed Y, 2007, BLOOD, V109, P2708, DOI 10.1182/blood-2006-07-035857
   Anker P, 1999, CANCER METAST REV, V18, P65, DOI 10.1023/A:1006260319913
   Astuti D, 2004, BRIT J CANCER, V90, P515, DOI 10.1038/sj.bjc.6601447
   Baylin SB, 2005, COLD SH Q B, V70, P427, DOI 10.1101/sqb.2005.70.010
   Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Brooks JD, 1998, CANCER EPIDEM BIOMAR, V7, P531
   Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5
   Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182
   Dallol A, 2003, ONCOGENE, V22, P4611, DOI 10.1038/sj.onc.1206687
   Dallol A, 2003, CANCER RES, V63, P1054
   Dallol A, 2002, CANCER RES, V62, P5874
   Dickson BJ, 2006, ANNU REV CELL DEV BI, V22, P651, DOI 10.1146/annurev.cellbio.21.090704.151234
   Duffy MJ, 2009, EUR J CANCER, V45, P335, DOI 10.1016/j.ejca.2008.12.008
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Dunwell TL, 2009, EPIGENETICS-US, V4, P265, DOI 10.4161/epi.9137
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   Jin J, 2009, BIOCHEM BIOPH RES CO, V379, P86, DOI 10.1016/j.bbrc.2008.12.022
   Kim JH, 2010, GYNECOL ONCOL, V118, P176, DOI 10.1016/j.ygyno.2010.04.016
   Kim JH, 2010, GYNECOL ONCOL, V116, P99, DOI 10.1016/j.ygyno.2009.09.032
   Kim JH, 2009, VIRCHOWS ARCH, V455, P469, DOI 10.1007/s00428-009-0858-z
   Lamy A, 2002, INT J CANCER, V100, P189, DOI 10.1002/ijc.10474
   Lee JS, 2008, CANCER BIOL THER, V7, P1400
   Lee JS, 2007, CANCER BIOL THER, V6, P1114, DOI 10.4161/cbt.6.7.4331
   Lee JS, 2007, VIRCHOWS ARCH, V450, P637, DOI 10.1007/s00428-007-0421-8
   Marlow R, 2008, CANCER RES, V68, P7819, DOI 10.1158/0008-5472.CAN-08-1357
   Mirza S, 2007, LIFE SCI, V81, P280, DOI 10.1016/j.lfs.2007.05.012
   Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V
   Narayan G, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-16
   Prasad A, 2007, J LEUKOCYTE BIOL, V82, P465, DOI 10.1189/jlb.1106678
   Sharma G, 2007, LIFE SCI, V80, P1873, DOI 10.1016/j.lfs.2007.02.026
   Stein E, 2001, SCIENCE, V291, P1928, DOI 10.1126/science.1058445
   Wu JY, 2001, NATURE, V410, P948, DOI 10.1038/35073616
   Wu W, 1999, NATURE, V400, P331, DOI 10.1038/22477
   Yuan WL, 1999, DEV BIOL, V212, P290, DOI 10.1006/dbio.1999.9371
NR 36
TC 13
Z9 15
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0945-6317
EI 1432-2307
J9 VIRCHOWS ARCH
JI Virchows Arch.
PD OCT
PY 2011
VL 459
IS 4
BP 383
EP 390
DI 10.1007/s00428-011-1143-5
PG 8
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 828MN
UT WOS:000295505300005
PM 21894562
DA 2025-01-12
ER

PT J
AU Chiam, K
   Centenera, MM
   Butler, LM
   Tilley, WD
   Bianco-Miotto, T
AF Chiam, Karen
   Centenera, Margaret M.
   Butler, Lisa M.
   Tilley, Wayne D.
   Bianco-Miotto, Tina
TI GSTP1 DNA Methylation and Expression Status Is Indicative of
   5-aza-2′-Deoxycytidine Efficacy in Human Prostate Cancer Cells
SO PLOS ONE
LA English
DT Article
ID CPG ISLAND HYPERMETHYLATION; RISK MYELODYSPLASTIC SYNDROME; PROMOTER
   METHYLATION; BREAST-CANCER; GENE-EXPRESSION; PHASE-I; HYPOMETHYLATING
   AGENT; ANTINEOPLASTIC ACTION; L1210 LEUKEMIA; MOUSE MODEL
AB DNA methylation plays an important role in carcinogenesis and the reversibility of this epigenetic modification makes it a potential therapeutic target. To date, DNA methyltransferase inhibitors (DNMTi) have not demonstrated clinical efficacy in prostate cancer, with one of the major obstacles being the inability to monitor drug activity during the trial. Given the high frequency and specificity of GSTP1 DNA methylation in prostate cancer, we investigated whether GSTP1 is a useful marker of DNMTi treatment efficacy. LNCaP prostate cancer cells were treated with 5-aza-2'-deoxycytidine (5-aza-CdR) either with a single high dose (5-20 mu M), every alternate day (0.1-10 mu M) or daily (0.005-2.5 mu M). A daily treatment regimen with 5-aza-CdR was optimal, with significant suppression of cell proliferation achieved with doses of 0.05 mu M or greater (p<0.0001) and induction of cell death from 0.5 mu M (p<0.0001). In contrast, treatment with a single high dose of 20 mu M 5-aza-CdR inhibited cell proliferation but was not able to induce cell death. Demethylation of GSTP1 was observed with doses of 5-aza-CdR that induced significant suppression of cell proliferation (>= 0.05 mu M). Re-expression of the GSTP1 protein was observed only at doses of 5-aza-CdR (>= 0.5 mu M) associated with induction of cell death. Treatment of LNCaP cells with a more stable DNMTi, Zebularine required at least a 100-fold higher dose (>= 50 mu M) to inhibit proliferation and was less potent in inducing cell death, which corresponded to a lack of GSTP1 protein re-expression. We have shown that GSTP1 DNA methylation and protein expression status is correlated with DNMTi treatment response in prostate cancer cells. Since GSTP1 is methylated in nearly all prostate cancers, our results warrant its testing as a marker of epigenetic therapy response in future clinical trials. We conclude that the DNA methylation and protein expression status of GSTP1 are good indicators of DNMTi efficacy.
C1 [Chiam, Karen; Centenera, Margaret M.; Butler, Lisa M.; Tilley, Wayne D.; Bianco-Miotto, Tina] Univ Adelaide, Dame Roma Mitchell Canc Res Labs, Discipline Med, Hanson Inst, Adelaide, SA, Australia.
C3 University of Adelaide; Hanson Institute
RP Chiam, K (通讯作者)，Garvan Inst Med Res, Canc Res Program, Sydney, NSW, Australia.
EM tina.bianco@adelaide.edu.au
RI Butler, Lisa/AAP-9088-2020; Bianco-Miotto, Tina/C-4808-2008
OI centenera, margaret/0000-0002-2206-0632; Bianco-Miotto,
   Tina/0000-0002-8431-5338; Chiam, Karen/0000-0001-8154-6731; Tilley,
   Wayne/0000-0003-1893-2626; Butler, Lisa/0000-0003-2698-3220
FU National Health and Medical Research Council [627185]; U.S. Department
   of Defense [W81XWH-04-1-0017]; Cancer Australia/Prostate Cancer
   Foundation of Australia [627229]; Prostate Cancer Foundation of
   Australia [EG0809]; W. Bruce Hall Cancer Council of SA; Cancer Council
   SA
FX This work was supported by grants from the National Health and Medical
   Research Council (627185; WDT, LMB, TBM), the U.S. Department of Defense
   (W81XWH-04-1-0017; WDT, LMB), Cancer Australia/Prostate Cancer
   Foundation of Australia (627229; LMB, WDT), Prostate Cancer Foundation
   of Australia Equipment Grant (EG0809; WDT, LMB, TBM), W. Bruce Hall
   Cancer Council of SA Research Fellowship (TBM), and a Cancer Council SA
   Senior Research Fellowship (LMB). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Bastian PJ, 2005, CLIN CANCER RES, V11, P4037, DOI 10.1158/1078-0432.CCR-04-2446
   Bender CM, 1999, MOL CELL BIOL, V19, P6690
   Bender CM, 1998, CANCER RES, V58, P95
   Bianco-Miotto T, 2010, CANCER EPIDEM BIOMAR, V19, P2611, DOI 10.1158/1055-9965.EPI-10-0555
   Bott SRJ, 2005, PROSTATE CANCER P D, V8, P321, DOI 10.1038/sj.pcan.4500822
   Brothman AR, 2005, CANCER GENET CYTOGEN, V156, P31, DOI 10.1016/j.cancergencyto.2004.04.004
   Cheng JC, 2003, J NATL CANCER I, V95, P399, DOI 10.1093/jnci/95.5.399
   de Vos D, 2005, ANN HEMATOL, V84, P3, DOI 10.1007/s00277-005-0008-x
   Dowsett M, 2007, JNCI-J NATL CANCER I, V99, P167, DOI 10.1093/jnci/djk020
   Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260
   Festuccia C, 2008, INT J ONCOL, V33, P381, DOI 10.3892/ijo_00000019
   Flotho C, 2009, LEUKEMIA, V23, P1019, DOI 10.1038/leu.2008.397
   Hanson JA, 2006, JNCI-J NATL CANCER I, V98, P255, DOI 10.1093/jnci/djj051
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Huggins C, 1941, ARCH SURG-CHICAGO, V43, P209, DOI 10.1001/archsurg.1941.01210140043004
   Hurtubise A, 2004, ANTI-CANCER DRUG, V15, P161, DOI 10.1097/01.cad.0000113334.52071.97
   Hussain M, 2006, J CLIN ONCOL, V24, P3984, DOI 10.1200/JCO.2006.06.4246
   Issa JPJ, 2004, BLOOD, V103, P1635, DOI 10.1182/blood-2003-03-0687
   Jerónimo C, 2004, CLIN CANCER RES, V10, P8472, DOI 10.1158/1078-0432.CCR-04-0894
   JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8
   Jones RL, 2009, BREAST CANCER RES TR, V116, P53, DOI 10.1007/s10549-008-0081-7
   JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797
   Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1794, DOI 10.1002/cncr.21792
   Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751
   Lemaire M, 2005, ANTI-CANCER DRUG, V16, P301, DOI 10.1097/00001813-200503000-00009
   Lin XH, 2001, CANCER RES, V61, P8611
   Lin XH, 2001, AM J PATHOL, V159, P1815, DOI 10.1016/S0002-9440(10)63028-3
   Lübbert M, 2001, BRIT J HAEMATOL, V114, P349, DOI 10.1046/j.1365-2141.2001.02933.x
   Marrocco DL, 2007, MOL CANCER THER, V6, P51, DOI 10.1158/1535-7163.MCT-06-0144
   McCabe MT, 2006, CANCER RES, V66, P385, DOI 10.1158/0008-5472.CAN-05-2020
   MOMPARLER RL, 1985, PHARMACOL THERAPEUT, V30, P277, DOI 10.1016/0163-7258(85)90052-X
   Momparler RL, 2005, SEMIN HEMATOL, V42, pS9, DOI 10.1053/j.seminhematol.2005.05.002
   MOMPARLER RL, 1984, LEUKEMIA RES, V8, P1043, DOI 10.1016/0145-2126(84)90059-6
   Nakayama T, 2000, LAB INVEST, V80, P1789, DOI 10.1038/labinvest.3780190
   Patra SK, 2002, MOL CARCINOGEN, V33, P163, DOI 10.1002/mc.10033
   Patra SK, 2001, BIOCHEM BIOPH RES CO, V287, P705, DOI 10.1006/bbrc.2001.5639
   Perry AS, 2006, ENDOCR-RELAT CANCER, V13, P357, DOI 10.1677/erc.1.01184
   Pulukuri SMK, 2005, INT J ONCOL, V26, P863
   Richter E, 2007, EPIGENETICS-US, V2, P100, DOI 10.4161/epi.2.2.4611
   RIVARD GE, 1981, LEUKEMIA RES, V5, P453, DOI 10.1016/0145-2126(81)90116-8
   Santourlidis S, 1999, PROSTATE, V39, P166
   Shang DH, 2009, CANCER LETT, V278, P82, DOI 10.1016/j.canlet.2008.12.034
   Sigalotti L, 2007, J CELL PHYSIOL, V212, P330, DOI 10.1002/jcp.21066
   Singal R, 2001, CANCER RES, V61, P4820
   SORM F, 1968, NEOPLASMA, V15, P339
   Steiner MS, 2000, ONCOGENE, V19, P1297, DOI 10.1038/sj.onc.1203428
   Stewart DJ, 2009, CLIN CANCER RES, V15, P3881, DOI 10.1158/1078-0432.CCR-08-2196
   Tan LW, 2002, CARCINOGENESIS, V23, P231, DOI 10.1093/carcin/23.2.231
   Thibault A, 1998, TUMORI, V84, P87, DOI 10.1177/030089169808400120
   VANGROENINGEN CJ, 1986, CANCER RES, V46, P4831
   Walton TJ, 2008, PROSTATE, V68, P210, DOI 10.1002/pros.20673
   Wijermans P, 2000, J CLIN ONCOL, V18, P956, DOI 10.1200/JCO.2000.18.5.956
   XIANG N, 2008, CARCINOGENESIS
   Xiong JB, 2009, MOL CANCER THER, V8, P779, DOI 10.1158/1535-7163.MCT-08-0926
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Yang AS, 2006, CANCER RES, V66, P5495, DOI 10.1158/0008-5472.CAN-05-2385
   Yoo CB, 2004, BIOCHEM SOC T, V32, P910, DOI 10.1042/BST0320910
   Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498
   Zhang Q, 2005, MOL ENDOCRINOL, V19, P2390, DOI 10.1210/me.2005-0096
   Zorn CS, 2007, CLIN CANCER RES, V13, P2136, DOI 10.1158/1078-0432.CCR-06-2381
NR 60
TC 37
Z9 45
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 28
PY 2011
VL 6
IS 9
AR e25634
DI 10.1371/journal.pone.0025634
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 834CT
UT WOS:000295936900085
PM 21980513
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Matsukura, H
   Aisaki, K
   Igarashi, K
   Matsushima, Y
   Kanno, J
   Muramatsu, M
   Sudo, K
   Sato, N
AF Matsukura, Hiroshi
   Aisaki, Ken-ichi
   Igarashi, Katsuhide
   Matsushima, Yuko
   Kanno, Jun
   Muramatsu, Masaaki
   Sudo, Katsuko
   Sato, Noriko
TI Genistein promotes DNA demethylation of the steroidogenic factor 1
   (SF-1) promoter in endometrial stromal cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Genistein; DNA methylation; Ovariectomized mice; Primary culture;
   Steroidogenic factor 1; High-resolution melting analysis
ID BREAST-CANCER; STEM-CELLS; FACTOR-I; HYPERMETHYLATION; PHYTOESTROGENS;
   METHYLATION; THERAPY; UTERUS; GENE; SOY
AB It has recently been demonstrated that genistein (GEN), a phytoestrogen in soy products, is an epigenetic modulator in various types of cells; but its effect on endometrium has not yet been determined. We investigated the effects of GEN on mouse uterine cells, in vivo and in vitro. Oral administration of GEN for 1 week induced mild proliferation of the endometrium in ovariectomized (OVX) mice, which was accompanied by the induction of steroidogenic factor 1 (SF-1) gene expression. GEN administration induced demethylation of multiple CpG sites in the SF-1 promoter; these sites are extensively methylated and thus silenced in normal endometrium. The GEN-mediated promoter demethylation occurred predominantly on the luminal side, as opposed to myometrium side, indicating that the epigenetic change was mainly shown in regenerated cells. Primary cultures of endometrial stromal cell colonies were screened for GEN-mediated alterations of DNA methylation by a high-resolution melting (HRM) method. One out of 20 colony-forming cell clones showed GEN-induced demethylation of SF-1. This clone exhibited a high proliferation capacity with continuous colony formation activity through multiple serial clonings. We propose that only a portion of endometrial cells are capable of receiving epigenetic modulation by GEN. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Matsukura, Hiroshi; Muramatsu, Masaaki; Sudo, Katsuko; Sato, Noriko] Tokyo Med & Dent Univ, Dept Mol Epidemiol, Med Res Inst, Chiyoda Ku, Tokyo 1010062, Japan.
   [Aisaki, Ken-ichi; Igarashi, Katsuhide; Matsushima, Yuko; Kanno, Jun] Natl Inst Hlth Sci, Div Cellular & Mol Toxicol, Setagaya Ku, Tokyo 1588501, Japan.
   [Sudo, Katsuko] Tokyo Med Univ, Anim Res Ctr, Shinjuku Ku, Tokyo 1608402, Japan.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   National Institute of Health Sciences - Japan; Tokyo Medical University
RP Sato, N (通讯作者)，Tokyo Med & Dent Univ, Dept Mol Epidemiol, Med Res Inst, Chiyoda Ku, 2-3-10 Kanda Surugadai, Tokyo 1010062, Japan.
EM hmatsukura.epi@mri.tmd.ac.jp; nsato.epi@tmd.ac.jp
RI Sato, Noriko/Y-7693-2019
FU Grants-in-Aid for Scientific Research [22659070] Funding Source: KAKEN
CR Adlercreutz H, 2002, LANCET ONCOL, V3, P364, DOI 10.1016/S1470-2045(02)00777-5
   Beck VB, 2005, J STEROID BIOCHEM, V94, P499, DOI 10.1016/j.jsbmb.2004.12.038
   Bulun SE, 2009, MOL CELL ENDOCRINOL, V300, P104, DOI 10.1016/j.mce.2008.12.012
   Chan RWS, 2004, BIOL REPROD, V70, P1738, DOI 10.1095/biolreprod.103.024109
   Christensen BC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000602
   Diel P, 2006, J STEROID BIOCHEM, V102, P60, DOI 10.1016/j.jsbmb.2006.09.022
   Edmunds KM, 2005, REPROD NUTR DEV, V45, P709, DOI 10.1051/rnd:2005055
   Gargett CE, 2010, MOL HUM REPROD, V16, P818, DOI 10.1093/molehr/gaq061
   Gargett CE, 2009, BIOL REPROD, V80, P1136, DOI 10.1095/biolreprod.108.075226
   Guo SW, 2009, MOL HUM REPROD, V15, P587, DOI 10.1093/molehr/gap064
   Jha AK, 2010, FOLIA BIOL-PRAGUE, V56, P195
   Kanno J, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-64
   Kanno J, 2003, ENVIRON HEALTH PERSP, V111, P1530, DOI 10.1289/ehp.5780
   Klein CB, 2007, TOXICOL APPL PHARM, V224, P1, DOI 10.1016/j.taap.2007.06.022
   Kumaki Y, 2008, NUCLEIC ACIDS RES, V36, pW170, DOI 10.1093/nar/gkn294
   Li Y, 2010, CURR MED CHEM, V17, P2141, DOI 10.2174/092986710791299966
   Majid S, 2010, CANCER-AM CANCER SOC, V116, P66, DOI 10.1002/cncr.24662
   MCKAY JA, 2011, ACTA PHYSL OXF, P103
   Meeran SM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0011-5
   Messina M, 2006, JNCI-J NATL CANCER I, V98, P1275, DOI 10.1093/jnci/djj356
   MOROHASHI K, 1992, J BIOL CHEM, V267, P17913
   Pettersson K, 2001, ANNU REV PHYSIOL, V63, P165, DOI 10.1146/annurev.physiol.63.1.165
   Rimoldi G, 2007, ENVIRON HEALTH PERSP, V115, P62, DOI 10.1289/ehp.9367
   Sato N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019278
   Wu AH, 1998, AM J CLIN NUTR, V68, p1437S, DOI 10.1093/ajcn/68.6.1437S
   Wu Y, 2003, FERTIL STERIL, V79, P710, DOI 10.1016/S0015-0282(02)04821-5
   Xue Q, 2007, J CLIN ENDOCR METAB, V92, P3261, DOI 10.1210/jc.2007-0494
NR 27
TC 13
Z9 14
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD AUG 26
PY 2011
VL 412
IS 2
BP 366
EP 372
DI 10.1016/j.bbrc.2011.07.104
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 816JM
UT WOS:000294594500030
PM 21821006
DA 2025-01-12
ER

PT J
AU Taft, RJ
   Hawkins, PG
   Mattick, JS
   Morris, KV
AF Taft, Ryan J.
   Hawkins, Peter G.
   Mattick, John S.
   Morris, Kevin V.
TI The relationship between transcription initiation RNAs and CCCTC-binding
   factor (CTCF) localization
SO EPIGENETICS & CHROMATIN
LA English
DT Article
ID CYCLIN-DEPENDENT KINASES; UCSC GENOME BROWSER; BREAST-CANCER; NONCODING
   RNAS; RIBOSOMAL DNA; PROTEIN CTCF; HUMAN-CELLS; TINY RNAS; SITES; P21
AB Background: Transcription initiation RNAs (tiRNAs) are nuclear localized 18 nucleotide RNAs derived from sequences immediately downstream of RNA polymerase II (RNAPII) transcription start sites. Previous reports have shown that tiRNAs are intimately correlated with gene expression, RNA polymerase II binding and behaviors, and epigenetic marks associated with transcription initiation, but not elongation.
   Results: In the present work, we show that tiRNAs are commonly found at genomic CCCTC-binding factor (CTCF) binding sites in human and mouse, and that CTCF sites that colocalize with RNAPII are highly enriched for tiRNAs. To directly investigate the relationship between tiRNAs and CTCF we examined tiRNAs originating near the intronic CTCF binding site in the human tumor suppressor gene, p21 (cyclin-dependent kinase inhibitor 1A gene, also known as CDKN1A). Inhibition of CTCF-proximal tiRNAs resulted in increased CTCF localization and increased p21 expression, while overexpression of CTCF-proximal tiRNA mimics decreased CTCF localization and p21 expression. We also found that tiRNA-regulated CTCF binding influences the levels of trimethylated H3K27 at the alternate upstream p21 promoter, and affects the levels of alternate p21 (p21(alt)) transcripts. Extending these studies to another randomly selected locus with conserved CTCF binding we found that depletion of tiRNA alters nucleosome density proximal to sites of tiRNA biogenesis.
   Conclusions: Taken together, these data suggest that tiRNAs modulate local epigenetic structure, which in turn regulates CTCF localization.
C1 [Hawkins, Peter G.; Morris, Kevin V.] Scripps Res Inst, Dept Mol & Expt Med, Kellogg Sch Sci & Technol, La Jolla, CA 92037 USA.
   [Taft, Ryan J.; Mattick, John S.] Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia.
C3 Scripps Research Institute; University of Queensland
RP Morris, KV (通讯作者)，Scripps Res Inst, Dept Mol & Expt Med, Kellogg Sch Sci & Technol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.
EM kmorris@scripps.edu
RI Taft, Ryan/B-2945-2010; Mattick, John/ABH-6130-2020; morris,
   kevin/B-5481-2011; Mattick, John/I-7789-2012
OI Taft, Ryan/0000-0003-4538-3343; Hawkins, Peter/0000-0003-1100-9388;
   Mattick, John/0000-0002-7680-7527; Morris, Kevin/0000-0002-0157-0553
FU NIH [HL083473-02, AI084406-01A1]; University of Queensland; ARC [DP
   DP0988851]; ARC Federation [FF0561986]; Australian Research Council
   [DP0988851] Funding Source: Australian Research Council
FX This project was supported by NIH R01 grants HL083473-02 and
   AI084406-01A1 (KVM) a University of Queensland Postdoctoral Research
   Fellowship (RJT) and ARC Discovery Project Grant DP DP0988851 and ARC
   Federation Fellowship FF0561986 (JSM).
CR [Anonymous], 2009, NATURE, V457, P1028
   Chernukhin I, 2007, MOL CELL BIOL, V27, P1631, DOI 10.1128/MCB.01993-06
   De Biase I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007914
   Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079
   ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P
   Filippova GN, 2008, CURR TOP DEV BIOL, V80, P337, DOI 10.1016/S0070-2153(07)80009-3
   Fu YT, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000138
   Fujita PA, 2011, NUCLEIC ACIDS RES, V39, pD876, DOI 10.1093/nar/gkq963
   GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0
   Guerrero PA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016401
   Han J, 2007, P NATL ACAD SCI USA, V104, P12422, DOI 10.1073/pnas.0701635104
   HARPER JW, 1993, CELL, V75, P805
   Kanhere A, 2010, MOL CELL, V38, P675, DOI 10.1016/j.molcel.2010.03.019
   Kapranov P, 2007, NAT REV GENET, V8, P413, DOI 10.1038/nrg2083
   Kim TH, 2007, CELL, V128, P1231, DOI 10.1016/j.cell.2006.12.048
   Klenova EM, 2001, MOL CELL BIOL, V21, P2221, DOI 10.1128/MCB.21.6.2221-2234.2001
   Liao JY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010563
   Malecová B, 2010, CURR OPIN MOL THER, V12, P214
   Mattick JS, 2010, TRENDS GENET, V26, P21, DOI 10.1016/j.tig.2009.11.002
   Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521
   Mondal T, 2010, GENOME RES, V20, P899, DOI 10.1101/gr.103473.109
   Morris KV, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000258
   Myers RM, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001046
   Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6
   Pellikainen MJ, 2003, J CLIN PATHOL, V56, P214, DOI 10.1136/jcp.56.3.214
   Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001
   Pinto AE, 2005, PATHOLOGY, V37, P45, DOI 10.1080/00313020400011250
   Qi CF, 2003, P NATL ACAD SCI USA, V100, P633, DOI 10.1073/pnas.0237127100
   Radhakrishnan SK, 2006, ONCOGENE, V25, P1812, DOI 10.1038/sj.onc.1209195
   Rodríguez-Campos A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001182
   Rosenbloom KR, 2010, NUCLEIC ACIDS RES, V38, pD620, DOI 10.1093/nar/gkp961
   SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781
   Taft RJ, 2010, NAT STRUCT MOL BIOL, V17, P1030, DOI 10.1038/nsmb.1841
   Taft RJ, 2009, CELL CYCLE, V8, P2332, DOI 10.4161/cc.8.15.9154
   Taft RJ, 2009, NAT GENET, V41, P572, DOI 10.1038/ng.312
   Tiezzi DG, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-36
   Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002
   van de Nobelen S, 2010, EPIGENET CHROMATIN, V3, DOI 10.1186/1756-8935-3-19
   Wallace JA, 2007, CURR OPIN GENET DEV, V17, P400, DOI 10.1016/j.gde.2007.08.005
   Witcher M, 2009, MOL CELL, V34, P271, DOI 10.1016/j.molcel.2009.04.001
   XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572
   XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0
   Zentner GE, 2011, NUCLEIC ACIDS RES, V39, P4949, DOI 10.1093/nar/gkq1326
   Zhao J, 2010, MOL CELL, V40, P939, DOI 10.1016/j.molcel.2010.12.011
NR 44
TC 34
Z9 40
U1 0
U2 16
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-8935
J9 EPIGENET CHROMATIN
JI Epigenetics Chromatin
PD AUG 3
PY 2011
VL 4
AR 13
DI 10.1186/1756-8935-4-13
PG 13
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 819DH
UT WOS:000294805100001
PM 21813016
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Kim, JH
   Kang, HS
   Kim, TW
   Kim, SJ
AF Kim, Ju Hee
   Kang, Han-Sung
   Kim, Tae Woo
   Kim, Sun Jung
TI Differential methylation hybridization profiling identifies involvement
   of STAT1-mediated pathways in breast cancer
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE breast cancer; CpG island; differential methylation hybridization;
   methylation; STAT1
ID PROMOTER METHYLATION; TUMOR-SUPPRESSOR; DNA METHYLATION; CPG ISLAND;
   EXPRESSION; GENE; HYPOMETHYLATION; STAT1; SIGNATURE; CELLS
AB Many cancer-related genes are regulated by an epigenetic mechanism through modification of the methylation status of CpG sites at the promoter. This study was carried out at a genome-wide scale to mine genes in which the methylation of CpG sites is altered in breast cancer tissues. Differential methylation hybridization analysis was conducted using a chromosomal DNA mixture of ten normal and cancer tissue sets. A CpG microarray harboring 237,220 CpG sites of the whole genome was interrogated and the resulting methylation level differences, as well as the RNA expression differences, between the normal and cancer sets for selected genes were verified in breast cell lines by methylation-specific PCR and real-time PCR analyses. As a result, we identified and verified novel genes that were hypermethylated in breast cancer, such as NRN1, CA5B and RPIA. Pathway analysis of the genes with altered methylation patterns identified the involvement of a differentiation-related network of genes whose activity may be heavily regulated by STAT I in breast tumorigenesis. Our results suggest that epigenetic dysregulation of cellular processes relevant to STAT1-dependent cellular differentiation may be intimately involved in breast carcinogenesis. These findings lend credence to the possibility of using tumor-specific alterations in methylation patterns as biomarkers in estimating prognosis and assessing treatment options for breast cancer.
C1 [Kim, Ju Hee; Kim, Tae Woo; Kim, Sun Jung] Dongguk Univ, Dept Life Sci, Seoul 100715, South Korea.
   [Kang, Han-Sung] Natl Canc Ctr, Res Inst & Hosp, Gyeonggi Do 411764, South Korea.
C3 Dongguk University; National Cancer Center - Korea (NCC)
RP Kim, SJ (通讯作者)，Dongguk Univ, Dept Life Sci, Seoul 100715, South Korea.
EM rorerr@ncc.re.kr; sunjungk@dongguk.edu
RI Kim, Dokyun/IYJ-2278-2023; kang, han/KIC-4795-2024; kim, sun/T-1013-2019
FU National Research Foundation of Korea (NRF); Ministry of Education,
   Science and Technology [2010-0011481]; National Cancer Center, Korea
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Education, Science and Technology (2010-0011481). Dr Kang
   was supported by a grant provided by the National Cancer Center, Korea.
CR Ai LB, 2006, CANCER RES, V66, P7899, DOI 10.1158/0008-5472.CAN-06-0576
   Alarmo EL, 2007, BREAST CANCER RES TR, V103, P239, DOI 10.1007/s10549-006-9362-1
   Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985
   Cao YX, 2010, J BIOL CHEM, V285, P2152, DOI 10.1074/jbc.M109.039172
   Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630
   Deneberg S, 2010, LEUKEMIA, V24, P932, DOI 10.1038/leu.2010.41
   Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557
   Huang SY, 2002, ONCOGENE, V21, P2504, DOI 10.1038/sj.onc.1205341
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Ito Y, 2008, HUM MOL GENET, V17, P2633, DOI 10.1093/hmg/ddn163
   Kamalakaran S, 2011, MOL ONCOL, V5, P77, DOI 10.1016/j.molonc.2010.11.002
   Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556
   Kawaguchi-Ihara N, 2008, ANTICANCER RES, V28, P2701
   Kim HS, 2007, CELL SIGNAL, V19, P454, DOI 10.1016/j.cellsig.2006.09.003
   Kim SJ, 2011, CANCER LETT, V302, P47, DOI 10.1016/j.canlet.2010.12.010
   Kim TW, 2010, INT J ONCOL, V36, P1105, DOI 10.3892/ijo_00000592
   Lan LX, 2010, INT J CANCER, V126, P53, DOI 10.1002/ijc.24641
   Li LA, 2010, HUM MOL GENET, V19, P4273, DOI 10.1093/hmg/ddq351
   Liu B, 2010, SCIENCE, V330, P521, DOI 10.1126/science.1193787
   Loss LA, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-305
   Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544
   Lu SY, 2010, INT J CANCER, V126, P416, DOI 10.1002/ijc.24761
   Maegawa S, 2010, GENOME RES, V20, P332, DOI 10.1101/gr.096826.109
   Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8
   McCabe MT, 2009, CANCER RES, V69, P282, DOI 10.1158/0008-5472.CAN-08-3274
   Papageorgis P, 2010, CANCER RES, V70, P968, DOI 10.1158/0008-5472.CAN-09-1872
   Roman-Gomez J, 2005, ONCOGENE, V24, P7213, DOI 10.1038/sj.onc.1208866
   Roman-Gomez J, 2008, LEUKEMIA RES, V32, P487, DOI 10.1016/j.leukres.2007.07.021
   Ruike Y, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-137
   Sharma G, 2011, TUMOR BIOL, V32, P23, DOI 10.1007/s13277-010-0087-8
   Singh P, 2008, MOL CANCER RES, V6, P1710, DOI 10.1158/1541-7786.MCR-08-0269
   Teschendorff AE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008274
   Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233
   Widschwendter A, 2002, CLIN CANCER RES, V8, P3065
   Wolf I, 2006, CANCER RES, V66, P7818, DOI 10.1158/0008-5472.CAN-05-4368
   Xi SC, 2006, JNCI-J NATL CANCER I, V98, P181, DOI 10.1093/jnci/djj020
   Yan PS, 2003, CANCER RES, V63, P6178
   Yan PS, 2000, CLIN CANCER RES, V6, P1432
   Yan XH, 2011, BIOCHEM J, V434, P1, DOI 10.1042/BJ20101827
   Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275
   Yu JS, 2008, ONCOGENE, V27, P4657, DOI 10.1038/onc.2008.101
NR 41
TC 11
Z9 12
U1 0
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD OCT
PY 2011
VL 39
IS 4
BP 955
EP 963
DI 10.3892/ijo.2011.1075
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 815NU
UT WOS:000294533100023
PM 21674123
OA Bronze
DA 2025-01-12
ER

PT J
AU Kim, JH
   Kim, TW
   Kim, SJ
AF Kim, Ju Hee
   Kim, Tae Woo
   Kim, Sun Jung
TI Downregulation of ARFGEF1 and CAMK2B by promoter hypermethylation in
   breast cancer cells
SO BMB REPORTS
LA English
DT Article
DE ARFGEF1; Breast cancer; CAMK2B; Epigenetics; Methylation
ID TUMOR-SUPPRESSOR GENE; PROTEIN; HYPOMETHYLATION; METHYLATION;
   EXPRESSION; ISOFORMS; BIG1; BETA
AB To identify novel genes that are regulated by promoter methylation, a combinational approach involving in silico mining followed by molecular assay was performed. From the expression microarray dab registered in the European bioinformatics institute (FBI), genes showing downregulation in breast cancer cells were initially screened and then selected by e-Northem analysis using the Unigene database. A series of these in silico methods identified CAMK2B and ARFGEF1 as candidates, and the two genes were revealed to be hypermethylated in breast cancer cell lines and hypomethylated in normal breast cell lines. Additionally, cancer cell lines showed downregulated expression of these genes. Furthermore, treatment of the cancer cell lines with a demethylation agent, 5-Aza-2'-deoxycytidine, recovered expression of CAMK2B and ARFGEF1, implying that hypermethyaltion silenced gene activity in cancer cells. Taken together, promoter methylations of CAMK2B and ARFGEF1 are novel epigenetic markers identified in breast cancer cell lines and can be utilized for the application to clinical cancer tissues. [BMB reports 2011; 44(8): 523-528]
C1 [Kim, Ju Hee; Kim, Tae Woo; Kim, Sun Jung] Dongguk Univ Seoul, Dept Life Sci, Seoul 100715, South Korea.
C3 Dongguk University
RP Kim, SJ (通讯作者)，Dongguk Univ Seoul, Dept Life Sci, Seoul 100715, South Korea.
EM sunjun0gk@dongguk.edu
RI kim, sun/T-1013-2019
FU Ministry of Education, Science and Technology [2010-0011481]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Education, Science and Technology (2010-0011481).
CR Ai LB, 2006, CANCER RES, V66, P7899, DOI 10.1158/0008-5472.CAN-06-0576
   Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007
   Gaertner TR, 2004, J BIOL CHEM, V279, P12484, DOI 10.1074/jbc.M313597200
   Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191
   Ito Y, 2008, HUM MOL GENET, V17, P2633, DOI 10.1093/hmg/ddn163
   KULIS M, 2010, DNA METHYLATION CANC, V70, P27
   Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544
   Luedi PP, 2007, GENOME RES, V17, P1723, DOI 10.1101/gr.6584707
   Nabilsi NH, 2009, ONCOGENE, V28, P2046, DOI 10.1038/onc.2009.62
   Novak G, 2006, SYNAPSE, V59, P61, DOI 10.1002/syn.20211
   Pacheco-Rodriguez G, 2002, METHOD ENZYMOL, V345, P397
   Padilla PI, 2008, P NATL ACAD SCI USA, V105, P3357, DOI 10.1073/pnas.0712387105
   Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F
   Singh P, 2008, MOL CANCER RES, V6, P1710, DOI 10.1158/1541-7786.MCR-08-0269
   Takeuchi Y, 2004, J NEUROSCI RES, V75, P480, DOI 10.1002/jnr.20010
   Teschendorff AE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008274
   Thirlwell C, 2010, METHODS, V52, P248, DOI 10.1016/j.ymeth.2010.04.012
   Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233
   Van der Auwera I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012616
   Zeller C, 2003, ONCOGENE, V22, P2972, DOI 10.1038/sj.onc.1206474
NR 20
TC 17
Z9 20
U1 0
U2 3
PU KOREAN SOCIETY BIOCHEMISTRY & MOLECULAR BIOLOGY
PI SEOUL
PA KOREA SCIENCE & TECHNOLOGY CENTER, # 801,  635-4 , YEOKSAM-DONG,
   KANGNAM-KU, SEOUL, 135-703, SOUTH KOREA
SN 1976-6696
EI 1976-670X
J9 BMB REP
JI BMB Rep.
PD AUG 31
PY 2011
VL 44
IS 8
BP 523
EP 528
DI 10.5483/BMBRep.2011.44.8.523
PG 6
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 815GL
UT WOS:000294514000005
PM 21871176
OA gold
DA 2025-01-12
ER

PT J
AU Shu, Y
   Wang, B
   Wang, J
   Wang, JM
   Zou, SQ
AF Shu, Yi
   Wang, Bing
   Wang, Ji
   Wang, Jian-Ming
   Zou, Sheng-Quan
TI Identification of methylation profile of <i>HOX</i> genes in
   extrahepatic cholangiocarcinoma
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE DNA methylation; Epigenetic; Promoter microarray; Cholangiocarcinoma
ID CPG-ISLAND METHYLATION; EMBRYONIC STEM-CELLS; DNA-METHYLATION;
   BREAST-CANCER; PANCREATIC ADENOCARCINOMA; EPIGENETIC ALTERATIONS;
   OVARIAN-CANCER; LUNG-CANCER; GENOME; IMMUNOPRECIPITATION
AB AIM: To identify methylation profile and novel tumor marker of extrahepatic cholangiocarcinoma (CCA) with high throughout microarray.
   METHODS: Differential methylation profile was compared between normal bile duct epithelial cell lines and CCA cell lines by methyl-DNA immunoprecipitation (MeDIP) microarray. Bisulfite-polymerase chain reaction (BSP) was performed to identify the methylated allels of target genes. Expression of target genes was investigated before and after the treatment with DNA demethylating agent. Expression of candidate genes was also evaluated by immunofluorescence in 30 specimens of CCA tissues and 9 normal bile duct tissues.
   RESULTS: Methylation profile of CCA was identified with MeDIP microarray in the respects of different gene functions and signaling pathways. Interestingly, 97 genes with hypermethylated CpG islands in the promoter region were homeobox genes. The top 5 hypermethylated homeobox genes validated by BSP were HOXA2 (94.29%), HOXA5 (95.38%), HOXA11 (91.67%), HOXB4 (90.56%) and HOXD13 (94.38%). Expression of these genes was reactivated with 5'-aza-2'-deoxycytidine. Significant expression differences were found between normal bile duct and extrahepatic CCA tissues (66.67%-100% vs 3.33%-10%).
   CONCLUSION: HOXA2, HOXA5, HOXA11, HOXB4 and HOXD13 may work as differential epigenetic biomarkers between malignant and benign biliary tissues. (C) 2011 Baishideng. All rights reserved.
C1 [Shu, Yi; Wang, Bing; Wang, Ji; Wang, Jian-Ming; Zou, Sheng-Quan] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Gen Surg, Wuhan 430030, Hubei Province, Peoples R China.
C3 Huazhong University of Science & Technology
RP Zou, SQ (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Gen Surg, 1095 Jiefang Ave, Wuhan 430030, Hubei Province, Peoples R China.
EM sqzou05@yahoo.com.cn
RI Wang, Jingjing/ABD-5361-2021; wang, jiantao/GRS-9485-2022
FU Chinese Ministry of Science and Technology [2010DFA31870]
FX Supported by The grant for "Development of Novel Nano-Drug Delivery
   System Loaded with Traditional Chinese Anticancer Medicine for the
   Targeted Therapy of Malignant Tumors" issued by the Chinese Ministry of
   Science and Technology, Grant No. 2010DFA31870
CR Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907
   Bullinger L, 2010, BLOOD, V115, P636, DOI 10.1182/blood-2009-03-211003
   Calvanese V, 2009, AGEING RES REV, V8, P268, DOI 10.1016/j.arr.2009.03.004
   Cantile M, 2009, INT J CANCER, V125, P1532, DOI 10.1002/ijc.24438
   Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002
   Cao R, 2008, MOL CELL BIOL, V28, P1862, DOI 10.1128/MCB.01589-07
   Corn PG, 2008, CANCER BIOL THER, V7, P1157, DOI 10.4161/cbt.7.7.6616
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471
   Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909
   Fiegl H, 2008, INT J CANCER, V123, P725, DOI 10.1002/ijc.23563
   Gatto M, 2010, DIGEST LIVER DIS, V42, P253, DOI 10.1016/j.dld.2009.12.008
   Gordon-Keylock SAM, 2010, STEM CELLS DEV, V19, P1687, DOI 10.1089/scd.2009.0467
   Grier DG, 2005, J PATHOL, V205, P154, DOI 10.1002/path.1710
   Hartmann O, 2009, CLIN CANCER RES, V15, P315, DOI 10.1158/1078-0432.CCR-08-0166
   Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679
   Isomoto H, 2009, ONCOL REP, V22, P227, DOI 10.3892/or_00000428
   Jacinto FV, 2008, BIOTECHNIQUES, V44, P35, DOI 10.2144/000112708
   Jacinto FV, 2007, CANCER RES, V67, P11481, DOI 10.1158/0008-5472.CAN-07-2687
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kamihira T, 2005, HEPATOLOGY, V41, P151, DOI 10.1002/hep.20494
   Kim BH, 2007, ARCH PATHOL LAB MED, V131, P923
   Kim DS, 2009, MOL CARCINOGEN, V48, P1109, DOI 10.1002/mc.20561
   Lee S, 2002, AM J PATHOL, V161, P1015, DOI 10.1016/S0002-9440(10)64262-9
   Maeda K, 2005, INT J CANCER, V114, P436, DOI 10.1002/ijc.20706
   Marsit CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012334
   Mosconi S, 2009, CRIT REV ONCOL HEMAT, V69, P259, DOI 10.1016/j.critrevonc.2008.09.008
   Omura N, 2008, CANCER BIOL THER, V7, P1146, DOI 10.4161/cbt.7.7.6208
   Pälmke N, 2011, METHODS, V53, P175, DOI 10.1016/j.ymeth.2010.07.006
   Plowright L, 2009, BRIT J CANCER, V100, P470, DOI 10.1038/sj.bjc.6604857
   Rakyan VK, 2004, PLOS BIOL, V2, P2170, DOI 10.1371/journal.pbio.0020405
   Ruike Y, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-137
   Salsi V, 2009, MOL CELL BIOL, V29, P5775, DOI 10.1128/MCB.00509-09
   Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486
   Soshnikova N, 2009, EPIGENETICS-US, V4, P537, DOI 10.4161/epi.4.8.10132
   Tischoff I, 2006, J HEPATO-BILIARY-PAN, V13, P274, DOI 10.1007/s00534-005-1055-3
   Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233
   Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
   Weng YI, 2009, METHODS MOL BIOL, V590, P165, DOI 10.1007/978-1-60327-378-7_10
   Widschwendter M, 2009, INT J CANCER, V125, P2214, DOI 10.1002/ijc.24599
   Yang B, 2005, MODERN PATHOL, V18, P412, DOI 10.1038/modpathol.3800287
   Yasuda H, 2011, LUNG CANCER, V72, P32, DOI 10.1016/j.lungcan.2010.07.016
NR 42
TC 25
Z9 30
U1 0
U2 9
PU BAISHIDENG PUBL GRP CO LTD
PI BEIJING
PA RM 903, BLDG D, OCEAN INTERNATIONAL CTR, NO 62 DONGSIHUAN ZHONGLU,
   BEIJING, CHAOYANG DISTRICT 100025, PEOPLES R CHINA
SN 1007-9327
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD AUG 7
PY 2011
VL 17
IS 29
BP 3407
EP 3419
DI 10.3748/wjg.v17.i29.3407
PG 13
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 814IT
UT WOS:000294442600006
PM 21876633
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Lind, GE
   Danielsen, SA
   Ahlquist, T
   Merok, MA
   Andresen, K
   Skotheim, RI
   Hektoen, M
   Rognum, TO
   Meling, GI
   Hoff, G
   Bretthauer, M
   Thiis-Evensen, E
   Nesbakken, A
   Lothe, RA
AF Lind, Guro E.
   Danielsen, Stine A.
   Ahlquist, Terje
   Merok, Marianne A.
   Andresen, Kim
   Skotheim, Rolf I.
   Hektoen, Merete
   Rognum, Torleiv O.
   Meling, Gunn I.
   Hoff, Geir
   Bretthauer, Michael
   Thiis-Evensen, Espen
   Nesbakken, Arild
   Lothe, Ragnhild A.
TI Identification of an epigenetic biomarker panel with high sensitivity
   and specificity for colorectal cancer and adenomas
SO MOLECULAR CANCER
LA English
DT Article
DE Biomarker; CNRIP1; colorectal neoplasia; early detection; FBN1; INA;
   MAL; methylation; SNCA; SPG20
ID CPG-ISLAND METHYLATION; DNA METHYLATION; FECAL DNA; MICROSATELLITE
   INSTABILITY; PRECANCEROUS LESIONS; BREAST-CANCER; COLON-CANCER;
   CELL-LINES; GENES; MARKER
AB Background: The presence of cancer-specific DNA methylation patterns in epithelial colorectal cells in human feces provides the prospect of a simple, non-invasive screening test for colorectal cancer and its precursor, the adenoma. This study investigates a panel of epigenetic markers for the detection of colorectal cancer and adenomas.
   Methods: Candidate biomarkers were subjected to quantitative methylation analysis in test sets of tissue samples from colorectal cancers, adenomas, and normal colonic mucosa. All findings were verified in independent clinical validation series. A total of 523 human samples were included in the study. Receiver operating characteristic (ROC) curve analysis was used to evaluate the performance of the biomarker panel.
   Results: Promoter hypermethylation of the genes CNRIP1, FBN1, INA, MAL, SNCA, and SPG20 was frequent in both colorectal cancers (65-94%) and adenomas (35-91%), whereas normal mucosa samples were rarely (0-5%) methylated. The combined sensitivity of at least two positives among the six markers was 94% for colorectal cancers and 93% for adenoma samples, with a specificity of 98%. The resulting areas under the ROC curve were 0.984 for cancers and 0.968 for adenomas versus normal mucosa.
   Conclusions: The novel epigenetic marker panel shows very high sensitivity and specificity for both colorectal cancers and adenomas. Our findings suggest this biomarker panel to be highly suitable for early tumor detection.
C1 [Lind, Guro E.; Danielsen, Stine A.; Ahlquist, Terje; Merok, Marianne A.; Andresen, Kim; Skotheim, Rolf I.; Hektoen, Merete; Lothe, Ragnhild A.] Oslo Univ Hosp, Dept Canc Prevent, Radiumhosp, Inst Canc Res, Oslo, Norway.
   [Lind, Guro E.; Danielsen, Stine A.; Ahlquist, Terje; Merok, Marianne A.; Andresen, Kim; Skotheim, Rolf I.; Hektoen, Merete; Nesbakken, Arild; Lothe, Ragnhild A.] Univ Oslo, Ctr Canc Biomed, Fac Med, Oslo, Norway.
   [Merok, Marianne A.; Nesbakken, Arild] Oslo Univ Hosp, Dept Surg, Aker Hosp, Oslo, Norway.
   [Rognum, Torleiv O.; Meling, Gunn I.] Univ Oslo, Inst Forens Med, Oslo, Norway.
   [Hoff, Geir] Telemark Hosp, Dept Med, Div Gastroenterol, Skien, Norway.
   [Hoff, Geir; Bretthauer, Michael] Canc Registry Norway, Oslo, Norway.
   [Bretthauer, Michael] Oslo Univ Hosp, Dept Gastroenterol, Oslo, Norway.
   [Thiis-Evensen, Espen] Oslo Univ Hosp, Rikshosp, Dept Organ Transplantat Gastroenterol & Nephrol, Oslo, Norway.
   [Meling, Gunn I.] Akershus Univ Hosp, Res Ctr, Lorenskog, Norway.
C3 University of Oslo; University of Oslo; University of Oslo; University
   of Oslo; Telemark Hospital Trust; University of Oslo; University of
   Oslo; University of Oslo; National Hospital Norway; University of Oslo
RP Lothe, RA (通讯作者)，Oslo Univ Hosp, Dept Canc Prevent, Radiumhosp, Inst Canc Res, Oslo, Norway.
EM rlothe@rr-research.no
RI ; Skotheim, Rolf I./H-6192-2017
OI Lind, Guro Elisabeth/0000-0003-4643-9345; Lothe, Ragnhild
   A./0000-0002-1693-1032; Skotheim, Rolf I./0000-0002-5609-4048
FU Norwegian Cancer Society [PR-2008-0163, PR-2007-0166, PR-2006-0442,
   A95068]; Norwegian Research Council [163962/V50, 161448/V40]
FX Lind and Skotheim are senior research fellows (PR-2008-0163, and
   PR-2007-0166, respectively), Danielsen is a PhD student (PR-2006-0442,
   RAL), and Ahlquist a post doc (grant A95068, RAL) supported by the
   Norwegian Cancer Society. The study was also supported by grants from
   the Norwegian Research Council (163962/V50, RAL and 161448/V40, RAL).
CR Atkin WS, 2010, LANCET, V375, P1624, DOI 10.1016/S0140-6736(10)60551-X
   Ausch C, 2009, CLIN CHEM, V55, P1559, DOI 10.1373/clinchem.2008.122937
   Bretthauer M, 2010, BEST PRACT RES CL GA, V24, P417, DOI 10.1016/j.bpg.2010.06.005
   Bretthauer N, 2002, SCAND J GASTROENTERO, V37, P568, DOI 10.1080/00365520252903125
   Chan AOO, 2002, AM J PATHOL, V160, P1823, DOI 10.1016/S0002-9440(10)61128-5
   Chang E, 2010, HEPATO-GASTROENTEROL, V57, P720
   Chen WD, 2005, JNCI-J NATL CANCER I, V97, P1124, DOI 10.1093/jnci/dji204
   Chung W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002079
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Devos T., 2009, CLIN CHEM
   He QO, 2010, CANCER GENET CYTOGEN, V202, P1, DOI 10.1016/j.cancergencyto.2010.05.018
   Hellebrekers DMEI, 2007, CANCER RES, V67, P4138, DOI 10.1158/0008-5472.CAN-06-3032
   Herbst A, 2011, AM J GASTROENTEROL, V106, P1110, DOI 10.1038/ajg.2011.6
   Huang ZH, 2007, DIGEST DIS SCI, V52, P2287, DOI 10.1007/s10620-007-9755-y
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Jowaed A, 2010, J NEUROSCI, V30, P6355, DOI 10.1523/JNEUROSCI.6119-09.2010
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Kilpinen S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r139
   Kim MS, 2008, ONCOGENE, V27, P2045, DOI 10.1038/sj.onc.1210842
   Kim MS, 2010, CANCER METAST REV, V29, P181, DOI 10.1007/s10555-010-9207-6
   Kim MS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006555
   Kleivi K, 2004, CANCER GENET CYTOGEN, V155, P119, DOI 10.1016/j.cancergencyto.2004.03.014
   KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245
   LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0
   Levin B, 2008, GASTROENTEROLOGY, V134, P1570, DOI 10.1053/j.gastro.2008.02.002
   Lind GE, 2011, ONCOGENE, V30, P3967, DOI 10.1038/onc.2011.109
   Lind GE, 2009, EJC SUPPL, V7, P145, DOI 10.1016/S1359-6349(09)70494-X
   Lind GE, 2007, GASTROENTEROLOGY, V132, P1631, DOI 10.1053/j.gastro.2007.03.003
   Lind GE, 2006, CELL ONCOL, V28, P259
   Lind GE, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-13
   Lofton-Day C, 2008, CLIN CHEM, V54, P414, DOI 10.1373/clinchem.2007.095992
   LOTHE RA, 1993, CANCER RES, V53, P5849
   MELING GI, 1991, BRIT J CANCER, V64, P475, DOI 10.1038/bjc.1991.334
   Melki JR, 1999, CANCER RES, V59, P3730
   Müller HM, 2004, LANCET, V363, P1283, DOI 10.1016/S0140-6736(04)16002-9
   OBERWALDER M, 2007, INT J COLORECTAL DIS, P15
   OSTER B, 2011, INT J CANCER, P10
   Rashid A, 2001, AM J PATHOL, V159, P1129, DOI 10.1016/S0002-9440(10)61789-0
   Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Tänzer M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009061
   Tang D, 2011, CLIN INVEST MED, V34, pE88
   Thiis-Evensen E, 1999, SCAND J GASTROENTERO, V34, P414
   Thorstensen L, 2005, NEOPLASIA, V7, P99, DOI 10.1593/neo.04448
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   VAN DL, 2010, BEST PRACT RES CLIN, V24, P479
   Wang DR, 2008, WORLD J GASTROENTERO, V14, P524, DOI 10.3748/wjg.14.524
   Wang YP, 2005, NEOPLASIA, V7, P748, DOI 10.1593/neo.05289
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Yan PS, 2006, CLIN CANCER RES, V12, P6626, DOI 10.1158/1078-0432.CCR-06-0467
   Zhang WP, 2007, SCI CHINA SER G, V50, P1, DOI 10.1007/s11433-007-0010-5
   Zitt M, 2007, DIS MARKERS, V23, P51, DOI 10.1155/2007/891967
   Zou HZ, 2007, CANCER EPIDEM BIOMAR, V16, P2686, DOI 10.1158/1055-9965.EPI-07-0518
NR 55
TC 115
Z9 124
U1 0
U2 21
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD JUL 21
PY 2011
VL 10
AR 85
DI 10.1186/1476-4598-10-85
PG 15
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 815OT
UT WOS:000294535600001
PM 21777459
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Shargh, SA
   Mohaddes, SM
   Sakizli, M
   Gharesouran, J
   Karami, F
AF Shargh, Shohreh Alizadeh
   Mohaddes, Seyyed Mojtaba
   Sakizli, Meral
   Gharesouran, Jalal
   Karami, Fateme
TI Evaluation of methylation status. in glutation S-transferase P1(GSTP1)
   gene promoter in human breast cancer and it relation to tumor grade and
   stage
SO RESEARCH JOURNAL OF CHEMISTRY AND ENVIRONMENT
LA English
DT Article
DE GSTP1; promoter; methylation; pattern; breast cancer
ID DNA METHYLATION; HAPLOTYPES; MODULATION; CELLS
AB Glutation S-transferase P1 (GSTP1) gene methylation in promoter CpG islands has been described as a specific biomarker for many type of cancer including breast cancer as a tumor suppressor gene. In present study we found the GSTP1 gene promoter to be methylated in breast cancer tissues. To study the effect of sequence variation on hypermethylated GSTP1 promoter in cancer tissues and non methylated one in normal tissues, we analyzed the cytosine methylation status as epigenetic changes in 50 tumors from patient's with breast cancer and 50 normal breast tissues taken from the same breast tumor's adjacent region. In order to study the promoter methylation status for GSTP1 gene in breast cancer, 40 CpG sites [nucleotide(nt) 197,190,187,185,183,182,176,162,155,152,148,145,141, 132,127, 124,112,109,101,99,81,77,74,71,54,53,48, 47;43,42,40,38,23,22,15,14,13,11,8,4] were screened.
C1 [Shargh, Shohreh Alizadeh] Chalous Azad Univ, Hlth Inst, Dept Med Sci, Chalous, Iran.
   [Mohaddes, Seyyed Mojtaba; Gharesouran, Jalal; Karami, Fateme] Univ Med Sci, Fac Med, Dept Med Genet, Tabriz, Iran.
   [Shargh, Shohreh Alizadeh; Sakizli, Meral] 9 Eylul Univ, Hlth Inst, Dept Med Genet & Biol, Izmir, Turkey.
C3 Dokuz Eylul University
RP Shargh, SA (通讯作者)，Chalous Azad Univ, Hlth Inst, Dept Med Sci, Chalous, Iran.
EM shfatemi@ut.ac.ir
RI Gharesouran, Jalal/B-9393-2015
OI Gharesouran, Jalal/0000-0002-2613-3421
CR Bae Young Kyung, 2005, Cancer Res Treat, V37, P233, DOI 10.4143/crt.2005.37.4.233
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Chow HHS, 2007, CANCER EPIDEM BIOMAR, V16, P1662, DOI 10.1158/1055-9965.EPI-06-0830
   Christensen BC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001043
   Dejeux E, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-68
   Dietrich D, 2009, J HISTOCHEM CYTOCHEM, V57, P477, DOI 10.1369/jhc.2009.953026
   Esteller M, 2001, CANCER RES, V61, P3225
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fang MZ, 2007, J NUTR, V137, p223S, DOI 10.1093/jn/137.1.223S
   Gao P, 2009, CANCER, V115, P3222, DOI 10.1002/cncr.24369
   Holley SL, 2007, CARCINOGENESIS, V28, P2268, DOI 10.1093/carcin/bgm135
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   King-Batoon A, 2008, ENVIRON MOL MUTAGEN, V49, P36, DOI 10.1002/em.20363
   Klein EA, 2006, ANNU REV MED, V57, P49, DOI 10.1146/annurev.med.57.121304.131435
   Li M, 2008, BIOINFORMATICS, V24, P1745, DOI 10.1093/bioinformatics/btn256
   Maxwell A, 2009, LABMEDICINE, V40, P171, DOI 10.1309/LMMY5RHJL9UD6RGS
   Muggerud A.A., 2010, BREAST CANCER RES, V12, P1
   Paluszczak J, 2006, J APPL GENET, V47, P365, DOI 10.1007/BF03194647
   Poplawski T., 2008, Experimental Oncology, V30, P112
   Ronneberg JA, 2008, CANCER RES, V68, P5562, DOI 10.1158/0008-5472.CAN-07-5828
   Suzuki T, 2005, BIOCHEM J, V388, P65, DOI 10.1042/BJ20041860
   Tischoff I, 2008, WORLD J GASTROENTERO, V14, P1741, DOI 10.3748/wjg.14.1741
   Vaziri Gohar A., 2010, J BIOL SCI, V10, P373
   Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
   Wu YY, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-32
   Xiang N, 2008, CARCINOGENESIS, V29, P2175, DOI 10.1093/carcin/bgn179
NR 26
TC 0
Z9 0
U1 0
U2 4
PU DR JYOTI GARG
PI INDORE MP
PA SECTOR A/80 SCHEME NO 54, VIJAY NAGAR, A B ROAD, INDORE MP, 452 010,
   INDIA
SN 0972-0626
J9 RES J CHEM ENVIRON
JI Res. J. Chem. Environ.
PD JUN
PY 2011
VL 15
IS 2
BP 492
EP 497
PG 6
WC Chemistry, Multidisciplinary; Environmental Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Environmental Sciences & Ecology
GA 813NC
UT WOS:000294373200091
DA 2025-01-12
ER

PT J
AU Beltran, AS
   Russo, A
   Lara, H
   Fan, C
   Lizardi, PM
   Blancafort, P
AF Beltran, Adriana S.
   Russo, Angela
   Lara, Haydee
   Fan, Cheng
   Lizardi, Paul M.
   Blancafort, Pilar
TI Suppression of Breast Tumor Growth and Metastasis by an Engineered
   Transcription Factor
SO PLOS ONE
LA English
DT Article
ID PROSTATE-CANCER; GENE-EXPRESSION; MASPIN EXPRESSION;
   CLINICAL-SIGNIFICANCE; CARNOSINE; METHYLATION; CARCINOMA; PROTEIN;
   CELLS; LOCALIZATION
AB Maspin is a tumor and metastasis suppressor playing an essential role as gatekeeper of tumor progression. It is highly expressed in epithelial cells but is silenced in the onset of metastatic disease by epigenetic mechanisms. Reprogramming of Maspin epigenetic silencing offers a therapeutic potential to lock metastatic progression. Herein we have investigated the ability of the Artificial Transcription Factor 126 (ATF-126) designed to upregulate the Maspin promoter to inhibit tumor progression in pre-established breast tumors in immunodeficient mice. ATF-126 was transduced in the aggressive, mesenchymal-like and triple negative breast cancer line, MDA-MB-231. Induction of ATF expression in vivo by Doxycycline resulted in 50% reduction in tumor growth and totally abolished tumor cell colonization. Genome-wide transcriptional profiles of ATF-induced cells revealed a gene signature that was found over-represented in estrogen receptor positive (ER+) "Normal-like" intrinsic subtype of breast cancer and in poorly aggressive, ER+ luminal A breast cancer cell lines. The comparison transcriptional profiles of ATF-126 and Maspin cDNA defined an overlapping 19-gene signature, comprising novel targets downstream the Maspin signaling cascade. Our data suggest that Maspin up-regulates downstream tumor and metastasis suppressor genes that are silenced in breast cancers, and are normally expressed in the neural system, including CARNS1, SLC8A2 and DACT3. In addition, ATF-126 and Maspin cDNA induction led to the re-activation of tumor suppressive miRNAs also expressed in neural cells, such as miR-1 and miR-34, and to the down-regulation of potential oncogenic miRNAs, such as miR-10b, miR-124, and miR-363. As expected from its over-representation in ER+ tumors, the ATF-126-gene signature predicted favorable prognosis for breast cancer patients. Our results describe for the first time an ATF able to reduce tumor growth and metastatic colonization by epigenetic reactivation of a dormant, normal-like, and more differentiated gene program.
C1 [Beltran, Adriana S.; Lara, Haydee; Blancafort, Pilar] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27515 USA.
   [Fan, Cheng; Blancafort, Pilar] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Russo, Angela] Univ Illinois, Dept Pharmacol, Chicago, IL USA.
   [Lizardi, Paul M.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA.
   [Lara, Haydee] CICESE Res Inst, Dept Marine Biotechnol, Ensenada, Baja California, Mexico.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; Yale University; CICESE -
   Centro de Investigacion Cientifica y de Educacion Superior de Ensenada
RP Beltran, AS (通讯作者)，Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27515 USA.
EM pilar_blancafort@med.unc.edu
RI FAN, CHENG/KVY-9602-2024; Blancafort, Pilar/K-9029-2012
OI Blancafort, Pilar/0000-0002-3881-7396
FU National Cancer Institute/National Institutes of Health [1R01CA125273,
   3R01CA125273-03S1]; Department of Defense (DoD) [W81XWH-10-1-0265]
FX This work was supported from National Cancer Institute/National
   Institutes of Health grants 1R01CA125273, 3R01CA125273-03S1 and
   Department of Defense (DoD) W81XWH-10-1-0265 (PB). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Ambasudhan R, 2011, CELL STEM CELL, V9, P113, DOI 10.1016/j.stem.2011.07.002
   Bailey CM, 2006, J CELL PHYSIOL, V209, P617, DOI 10.1002/jcp.20782
   Bastian I, 2011, HISTOCHEM CELL BIOL, V135, P37, DOI 10.1007/s00418-010-0772-0
   Beltran A, 2007, ONCOGENE, V26, P2791, DOI 10.1038/sj.onc.1210072
   Beltran A, 2006, ASSAY DRUG DEV TECHN, V4, P317, DOI 10.1089/adt.2006.4.317
   Beltran AS, 2008, MOL CANCER THER, V7, P1080, DOI 10.1158/1535-7163.MCT-07-0526
   Beltran AS, 2010, METHODS MOL BIOL, V649, P163, DOI 10.1007/978-1-60761-753-2_10
   BELTRAN AS, 2011, EPIGENETICS, V6
   Cher ML, 2003, P NATL ACAD SCI USA, V100, P7847, DOI 10.1073/pnas.1331360100
   Damiano L, 2010, ONCOGENE, V29, P3677, DOI 10.1038/onc.2010.128
   Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Fan C, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-3
   Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886
   Ghosh T, 2008, NUCLEIC ACIDS RES, V36, P6318, DOI 10.1093/nar/gkn624
   Goulet B, 2011, LAB INVEST, V91, P1181, DOI 10.1038/labinvest.2011.66
   Guiotto A, 2005, CURR MED CHEM, V12, P2293, DOI 10.2174/0929867054864796
   Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441
   Hipkiss AR, 2007, J ALZHEIMERS DIS, V11, P229
   Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96
   Jaworski J, 2009, NEURON, V61, P85, DOI 10.1016/j.neuron.2008.11.013
   Jiang X, 2008, CANCER CELL, V13, P529, DOI 10.1016/j.ccr.2008.04.019
   Kalyanaraman S, 1998, GENOMICS, V49, P147, DOI 10.1006/geno.1998.5223
   LEONE V, 2011, J CLIN ENDOCRINOL ME
   Li XH, 2006, CANCER RES, V66, P9323, DOI 10.1158/0008-5472.CAN-06-1578
   Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Machtens S, 2001, INT J CANCER, V95, P337, DOI 10.1002/1097-0215(20010920)95:5<337::AID-IJC1059>3.0.CO;2-1
   Maina EN, 2005, ONCOGENE, V24, P4549, DOI 10.1038/sj.onc.1208649
   McKenzie S, 2008, ONCOGENE, V27, P7171, DOI 10.1038/onc.2008.321
   Nakagawa M, 2006, ANN SURG ONCOL, V13, P1517, DOI 10.1245/s10434-006-9030-z
   Nam E, 2010, CANCER RES TREAT, V42, P42, DOI 10.4143/crt.2010.42.1.42
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Nohata N, 2011, ONCOTARGET, V2, P29
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Qu M, 2010, NEUROPATH APPL NEURO, V36, P198, DOI 10.1111/j.1365-2990.2010.01070.x
   Renner C, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-2
   Renner C, 2010, NEUROL RES, V32, P101, DOI 10.1179/016164109X12518779082237
   Romani AA, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-255
   Sager R, 1997, ADV EXP MED BIOL, V425, P77
   Schaefer JS, 2006, EXPERT OPIN THER TAR, V10, P401, DOI 10.1517/14728222.10.3.401
   Seftor REB, 1998, CANCER RES, V58, P5681
   Sharma G, 2011, TUMOR BIOL, V32, P23, DOI 10.1007/s13277-010-0087-8
   Takebe N, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2876
   Tomomura M, 2007, NEUROSCIENCE, V148, P510, DOI 10.1016/j.neuroscience.2007.05.048
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Wozniak RJ, 2007, ONCOGENE, V26, P77, DOI 10.1038/sj.onc.1209763
   Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303
   Zhang M, 1997, CELL GROWTH DIFFER, V8, P179
NR 50
TC 43
Z9 48
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 13
PY 2011
VL 6
IS 9
AR e24595
DI 10.1371/journal.pone.0024595
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 825ZV
UT WOS:000295321800036
PM 21931769
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU de Beeck, KO
   Van Camp, G
   Thys, S
   Cools, N
   Callebaut, I
   Vrijens, K
   Van Nassauw, L
   Van Tendeloo, VF
   Timmermans, JP
   Van Laer, L
AF de Beeck, Ken Op
   Van Camp, Guy
   Thys, Sofie
   Cools, Nathalie
   Callebaut, Isabelle
   Vrijens, Karen
   Van Nassauw, Luc
   Van Tendeloo, Viggo Fi
   Timmermans, Jean Pierre
   Van Laer, Lut
TI The <i>DFNA5</i> gene, responsible for hearing loss and involved in
   cancer, encodes a novel apoptosis-inducing protein
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE tumor suppressor; hearing loss; apoptosis; dfna5; cancer; GSEA
ID HYDROPHOBIC CLUSTER-ANALYSIS; CHINESE FAMILY; IMPAIRMENT; EXPRESSION;
   MUTATION; CELLS; METHYLATION; SEQUENCES; ICERE-1; TRACT
AB DFNA5 was first identified as a gene causing autosomal dominant hearing loss (HL). Different mutations have been found, all exerting a highly specific gain-of-function effect, in which skipping of exon 8 causes the HL. Later reports revealed the involvement of the gene in different types of cancer. Epigenetic silencing of DFNA5 in a large percentage of gastric, colorectal and breast tumors and p53-dependent transcriptional activity have been reported, concluding that DFNA5 acts as a tumor suppressor gene in different frequent types of cancer. Despite these data, the molecular function of DFNA5 has not been investigated properly. Previous transfection studies with mutant DFNA5 in yeast and in mammalian cells showed a toxic effect of the mutant protein, which was not seen after transfection of the wild-type protein. Here, we demonstrate that DFNA5 is composed of two domains, separated by a hinge region. The first region induces apoptosis when transfected in HEK293T cells, the second region masks and probably regulates this apoptosis inducing capability. Moreover, the involvement of DFNA5 in apoptosis-related pathways in a physiological setting was demonstrated through gene expression microarray analysis using Dfna5 knockout mice. In view of its important role in carcinogenesis, this finding is expected to lead to new insights on the role of apoptosis in many types of cancer. In addition, it provides a new line of evidence supporting an important role for apoptosis in monogenic and complex forms of HL. European Journal of Human Genetics (2011) 19, 965-973; doi: 10.1038/ejhg.2011.63; published online 27 April 2011
C1 [de Beeck, Ken Op; Van Camp, Guy; Vrijens, Karen; Van Laer, Lut] Univ Antwerp, Dept Biomed Sci, Ctr Med Genet, B-2020 Antwerp, Belgium.
   [Thys, Sofie; Van Nassauw, Luc; Timmermans, Jean Pierre] Univ Antwerp, Dept Vet Sci, Cell Biol & Histol Lab, B-2020 Antwerp, Belgium.
   [Cools, Nathalie; Van Tendeloo, Viggo Fi] Univ Antwerp, Lab Expt Hematol, Vaccine & Infect Dis Inst, B-2020 Antwerp, Belgium.
   [Callebaut, Isabelle] Univ Paris 07, CNRS, Univ Paris 06, Dept Struct Biol,Inst Mineral & Phys Condensed Me, Paris, France.
   [Van Nassauw, Luc] Univ Antwerp, Fac Med, Lab Human Anat & Embryol, B-2020 Antwerp, Belgium.
C3 University of Antwerp; University of Antwerp; University of Antwerp;
   Universite Paris Cite; Centre National de la Recherche Scientifique
   (CNRS); Institut de Recherche pour le Developpement (IRD); Sorbonne
   Universite; University of Antwerp
RP Van Camp, G (通讯作者)，Univ Antwerp, Ctr Med Genet, Dept Biomed Sci, Univ Pl 1, B-2610 Antwerp, Belgium.
EM guy.vancamp@ua.ac.be
RI VanNassauw, Luc/A-6735-2015; Van Tendeloo, Viggo/A-1233-2010;
   Timmermans, Jean-Pierre/AFM-0481-2022; Cools, Nathalie/A-1211-2010; Op
   de Beeck, Ken/J-5248-2016; Van Camp, Guy/F-3386-2013
OI Op de Beeck, Ken/0000-0001-5527-6838; Timmermans,
   Jean-Pierre/0000-0003-2506-6252; Van Tendeloo,
   Viggo/0000-0003-3217-9917; Van Camp, Guy/0000-0001-5105-9000; Callebaut,
   Isabelle/0000-0003-3124-887X
FU European Community (Eurohear); 'Fonds voor Wetenschappelijk Onderzoek
   Vlaanderen' (FWO) [G.0245.10N]
FX This work was supported by grants of the European Community (Eurohear)
   and the 'Fonds voor Wetenschappelijk Onderzoek Vlaanderen' (FWO grant
   G.0245.10N). KODB holds a predoctoral research position with the
   'Instituut voor de Aanmoediging van Innovatie door Wetenschap en
   Technologie in Vlaanderen (IWT)'.
CR Akino K, 2007, CANCER SCI, V98, P88, DOI 10.1111/j.1349-7006.2006.00351.x
   Bischoff AMLC, 2004, AUDIOL NEURO-OTOL, V9, P34, DOI 10.1159/000074185
   Busch-Nentwich E, 2004, DEVELOPMENT, V131, P943, DOI 10.1242/dev.00961
   Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082
   Cheng J, 2007, CLIN GENET, V72, P471, DOI 10.1111/j.1399-0004.2007.00889.x
   Delmaghani S, 2006, NAT GENET, V38, P770, DOI 10.1038/ng1829
   Eudes R, 2007, BMC STRUCT BIOL, V7, DOI 10.1186/1472-6807-7-2
   Fujikane T, 2010, BREAST CANCER RES TR, V122, P699, DOI 10.1007/s10549-009-0600-1
   GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8
   Gregan J, 2003, BBA-MOL BASIS DIS, V1638, P179, DOI 10.1016/S0925-4439(03)00083-8
   Kim MS, 2008, ONCOGENE, V27, P3624, DOI 10.1038/sj.onc.1211021
   Kim MS, 2008, BIOCHEM BIOPH RES CO, V370, P38, DOI 10.1016/j.bbrc.2008.03.026
   Lage H, 2001, FEBS LETT, V494, P54, DOI 10.1016/S0014-5793(01)02304-3
   Masuda Yoshiko, 2006, J Hum Genet, V51, P652, DOI 10.1007/s10038-006-0004-6
   Park HJ, 2010, J HUM GENET, V55, P59, DOI 10.1038/jhg.2009.114
   Sha SH, 2009, HEARING RES, V254, P92, DOI 10.1016/j.heares.2009.04.019
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tamura M, 2007, GENOMICS, V89, P618, DOI 10.1016/j.ygeno.2007.01.003
   Thompson DA, 1998, EUR J BIOCHEM, V252, P169, DOI 10.1046/j.1432-1327.1998.2520169.x
   Van Laer L, 2005, NEUROBIOL DIS, V19, P386, DOI 10.1016/j.nbd.2005.01.019
   Van Laer L, 2004, J MED GENET, V41, P401, DOI 10.1136/jmg.2003.015073
   Van Laer L, 1998, NAT GENET, V20, P194
   Van Laer L, 2007, J HUM GENET, V52, P549, DOI 10.1007/s10038-007-0137-2
   Walsh T, 2010, AM J HUM GENET, V87, P101, DOI 10.1016/j.ajhg.2010.05.011
   Webb MS, 2007, J STEROID BIOCHEM, V107, P15, DOI 10.1016/j.jsbmb.2007.02.004
   WOODCOCK S, 1992, PROTEIN ENG, V5, P629, DOI 10.1093/protein/5.7.629
   Yu CA, 2003, GENOMICS, V82, P575, DOI 10.1016/S0888-7543(03)00175-7
NR 27
TC 99
Z9 110
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 1476-5438
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD SEP
PY 2011
VL 19
IS 9
BP 965
EP 973
DI 10.1038/ejhg.2011.63
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 808TZ
UT WOS:000294003100010
PM 21522185
OA Green Submitted, Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Gong, Y
   Li, YL
   Lu, Y
   Li, LL
   Abdolmaleky, H
   Blackburn, GL
   Zhou, JR
AF Gong, Yi
   Li, Yanli
   Lu, Yin
   Li, Linglin
   Abdolmaleky, Hamid
   Blackburn, George L.
   Zhou, Jin-Rong
TI Bioactive tanshinones in <i>Salvia Miltiorrhiza</i> inhibit the growth
   of prostate cancer cells <i>in vitro</i> and in mice
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE prostate cancer; tanshinones; Aurora A; angiogenesis; apoptosis;
   proliferation; chemoprevention
ID HUMAN BREAST-CANCER; AURORA-KINASE-A; SUPPRESSES TUMOR-GROWTH; HUMAN
   PANCREATIC-CANCER; OVER-EXPRESSION; APOPTOSIS; IIA; ANGIOGENESIS;
   PHOSPHORYLATION; CYTOTOXICITY
AB Searching for efficacious and safe agents for the chemoprevention and therapy of prostate cancer has become the top priority of research. The objective of this study was to determine the effects of a group of tanshinones from a Chinese herb Salvia Miltiorrhiza, cryptotanshinone (CT), tanshinone IIA (T2A) and tanshinone I (T1) on prostate cancer. The in vitro studies showed that these tanshinones inhibited the growth of human prostate cancer cell lines in a dose-dependent manner via cell cycle arrest and apoptosis induction. Among three compounds, T1 had the most potent activity with IC(50)s around 3-6 mu M. On the other hand, tanshinones had much less adverse effects on the growth of normal prostate epithelial cells. The epigenetic pathway focused array assay identified Aurora A kinase as a possible target of tanshinone actions. The expression of Aurora A was overexpressed in prostate cancer cell lines. Moreover, knockdown of Aurora A in prostate cancer cells significantly decreased cell growth. Tanshinones significantly downregulated the Aurora A expression, suggesting Aurora A may be a functional target of tanshinones. Tanshinones, especially T1, also showed potent anti-angiogenesis activity in vitro and in vivo. Furthermore, T1 inhibited the growth of DU145 prostate tumor in mice associated with induction of apoptosis, decrease of proliferation, inhibition of angiogenesis and downregulation of Aurora A, whereas it did not alter food intake or body weight. Our results support that T1 may be an efficacious and safe chemopreventive or therapeutic agent against prostate cancer progression.
C1 [Gong, Yi; Li, Yanli; Lu, Yin; Li, Linglin; Abdolmaleky, Hamid; Blackburn, George L.; Zhou, Jin-Rong] Harvard Univ, Dept Surg, Beth Israel Deaconess Med Ctr, Sch Med,Nutr Metab Lab, Boston, MA 02215 USA.
C3 Harvard University; Beth Israel Deaconess Medical Center; Harvard
   Medical School
RP Zhou, JR (通讯作者)，Harvard Univ, Dept Surg, Beth Israel Deaconess Med Ctr, Sch Med,Nutr Metab Lab, DA 881,330 Brookline Ave, Boston, MA 02215 USA.
EM jrzhou@bidmc.harvard.edu
RI li, yanli/AAT-2012-2021
OI Mostafavi Abdolmaleky, Hamid/0000-0002-8872-5174
FU Department of Defense [PC073988]; National Cancer Institute, NIH [R21
   CA133865]
FX Idea Award PC073988 (Department of Defense); R21 CA133865 (National
   Cancer Institute, NIH)
CR Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6
   Buschhorn HM, 2005, PROSTATE, V64, P341, DOI 10.1002/pros.20247
   Cao Y, 2010, EXP CELL RES, V316, P1304, DOI 10.1016/j.yexcr.2010.02.031
   Compérat E, 2008, UROLOGY, V72, P873, DOI 10.1016/j.urology.2007.12.026
   Dar AA, 2010, MOL CANCER THER, V9, P268, DOI 10.1158/1535-7163.MCT-09-0765
   de Castro I.Perez., 2008, CURR OPIN PHARMACOL, V8, P375
   Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569
   Görgün G, 2010, BLOOD, V115, P5202, DOI 10.1182/blood-2009-12-259523
   Gomella LG, 2005, CURR OPIN UROL, V15, P29, DOI 10.1097/00042307-200501000-00007
   Hata T, 2005, CANCER RES, V65, P2899, DOI 10.1158/0008-5472.CAN-04-3981
   Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1
   Huh JE, 2005, CARCINOGENESIS, V26, P1436, DOI 10.1093/carcin/bgi097
   Israels L G, 1999, Oncologist, V4, P332
   Kaestner P, 2009, MOL CANCER THER, V8, P2046, DOI 10.1158/1535-7163.MCT-09-0323
   Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487
   Kumano M, 2010, BJU INT, V106, P121, DOI 10.1111/j.1464-410X.2009.09047.x
   Lee CY, 2008, MOL CANCER THER, V7, P3527, DOI 10.1158/1535-7163.MCT-07-2288
   Lee ECY, 2006, CANCER RES, V66, P4996, DOI 10.1158/0008-5472.CAN-05-2796
   Lee WYW, 2008, FOOD CHEM TOXICOL, V46, P328, DOI 10.1016/j.fct.2007.08.013
   Lentini L, 2008, ONCOL RES, V17, P115, DOI 10.3727/096504008785055521
   Li DH, 2003, CLIN CANCER RES, V9, P991
   Lippman SM, 2009, JAMA-J AM MED ASSOC, V301, P39, DOI 10.1001/jama.2008.864
   Liu JJ, 2009, ONCOL REP, V21, P1075, DOI 10.3892/or_00000326
   Mai ZM, 2007, MOL CARCINOGEN, V46, P534, DOI 10.1002/mc.20300
   Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526
   Matarasso N, 2007, NEOPLASIA, V9, P707, DOI 10.1593/neo.07322
   Mosaddik MA, 2003, PHYTOMEDICINE, V10, P682, DOI 10.1078/0944-7113-00321
   Nizamutdinova IT, 2008, INT J ONCOL, V33, P485, DOI 10.3892/ijo_00000031
   PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P
   Qu Y, 2008, CANCER GENE THER, V15, P517, DOI 10.1038/cgt.2008.22
   Qu Yi, 2008, Sichuan Da Xue Xue Bao Yi Xue Ban, V39, P1
   Sasayama T, 2005, GENES CELLS, V10, P627, DOI 10.1111/j.1365-2443.2005.00870.x
   Singh AV, 2006, CANCER RES, V66, P1851, DOI 10.1158/0008-5472.CAN-05-1332
   Song Yi, 2005, Zhongguo Zhongyao Zazhi, V30, P207
   Su CC, 2008, INT J MOL MED, V22, P357, DOI 10.3892/ijmm_00000030
   Sung HJ, 1999, EXP MOL MED, V31, P174, DOI 10.1038/emm.1999.28
   Thompson IM, 2003, NEW ENGL J MED, V349, P215, DOI 10.1056/NEJMoa030660
   Vankayalapati H, 2003, MOL CANCER THER, V2, P283
   Wang J, 2007, J NEURO-ONCOL, V82, P11, DOI 10.1007/s11060-006-9242-x
   Wang X, 1996, Zhonghua Zhong Liu Za Zhi, V18, P412
   Wang X, 1996, Hua Xi Yi Ke Da Xue Xue Bao, V27, P388
   Wang XJ, 2005, INT J CANCER, V116, P799, DOI 10.1002/ijc.20880
   Yoon Y, 1999, J ETHNOPHARMACOL, V68, P121, DOI 10.1016/S0378-8741(99)00059-8
   Yuan S, 2002, HUA XI YI KE DA XUE, V33, P90
   Yuan SL, 2004, WORLD J GASTROENTERO, V10, P2024, DOI 10.3748/wjg.v10.i14.2024
   Yuan Shulan, 2002, Journal of West China University of Medical Sciences, V33, P84
   Zhang P, 1999, Zhongguo Zhong Xi Yi Jie He Za Zhi, V19, P103
   Zhou JR, 2004, INT J CANCER, V110, P800, DOI 10.1002/ijc.20206
   Zhou JR, 1998, CANCER RES, V58, P5231
   Zhou LM, 2005, J CLIN PHARMACOL, V45, P1345, DOI 10.1177/0091270005282630
NR 50
TC 116
Z9 125
U1 2
U2 33
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD SEP 1
PY 2011
VL 129
IS 5
BP 1042
EP 1052
DI 10.1002/ijc.25678
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 789IP
UT WOS:000292509400002
PM 20848589
OA Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Babu, E
   Ramachandran, S
   CoothanKandaswamy, V
   Elangovan, S
   Prasad, PD
   Ganapathy, V
   Thangaraju, M
AF Babu, E.
   Ramachandran, S.
   CoothanKandaswamy, V.
   Elangovan, S.
   Prasad, P. D.
   Ganapathy, V.
   Thangaraju, M.
TI Role of SLC5A8, a plasma membrane transporter and a tumor suppressor, in
   the antitumor activity of dichloroacetate
SO ONCOGENE
LA English
DT Article
DE SLC5A8; dichloroacetate; anticancer drug; Warburg effect; pyruvate
   dehydrogenase kinase; mitochondrial oxidation in cancer
ID NA+-COUPLED TRANSPORTER; CANCER-CELLS; COLON-CANCER; GENE SLC5A8;
   ELECTROGENIC TRANSPORT; PYRUVATE-DEHYDROGENASE; PERIPHERAL NEUROPATHY;
   IN-VITRO; APOPTOSIS; WARBURG
AB There has been growing interest among the public and scientists in dichloroacetate (DCA) as a potential anticancer drug. Credible evidence exists for the antitumor activity of this compound, but high concentrations are needed for significant therapeutic effect. Unfortunately, these high concentrations produce detrimental side effects involving the nervous system, thereby precluding its use for cancer treatment. The mechanistic basis of the compound's antitumor activity is its ability to activate the pyruvate dehydrogenase complex through inhibition of pyruvate dehydrogenase kinase. As the compound inhibits the kinase at micromolar concentrations, it is not known why therapeutically prohibitive high doses are needed for suppression of tumor growth. We hypothesized that lack of effective mechanisms for the entry of DCA into tumor cells may underlie this phenomenon. Here we show that SLC5A8 transports DCA very effectively with high affinity. This transporter is expressed in normal cells, but expression is silenced in tumor cells by epigenetic mechanisms. The lack of the transporter makes tumor cells resistant to the antitumor activity of DCA. However, if the transporter is expressed in tumor cells ectopically, the cells become sensitive to the drug at low concentrations. This is evident in breast cancer cells, colon cancer cells and prostate cancer cells. Normal cells, which constitutively express the transporter, are however not affected by the compound, indicating tumor cell-selective therapeutic activity. The mechanism of the compound's antitumor activity still remains its ability to inhibit pyruvate dehydrogenase kinase and force mitochondrial oxidation of pyruvate. As silencing of SLC5A8 in tumors involves DNA methylation and its expression can be induced by treatment with DNA methylation inhibitors, our findings suggest that combining DCA with a DNA methylation inhibitor would offer a means to reduce the doses of DCA to avoid detrimental effects associated with high doses but without compromising antitumor activity. Oncogene (2011) 30, 4026-4037; doi:10.1038/onc. 2011.113; published online 18 April 2011
C1 [Babu, E.; Ramachandran, S.; CoothanKandaswamy, V.; Elangovan, S.; Prasad, P. D.; Ganapathy, V.; Thangaraju, M.] Georgia Hlth Sci Univ, Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.
C3 University System of Georgia; Augusta University
RP Thangaraju, M (通讯作者)，Georgia Hlth Sci Univ, Med Coll Georgia, Dept Biochem & Mol Biol, 1459 Laney Walker Blvd,CB 2515, Augusta, GA 30912 USA.
EM mthangaraju@georgiahealth.edu
RI Elangovan, Selvakumar/ABB-9558-2021
OI S, Dr. Selvakumar/0000-0001-9795-3569; Elangovan,
   Selvakumar/0000-0001-9906-5477
FU National Institutes of Health [CA131402]
FX The work described here is supported in part by the National Institutes
   of Health Grant CA131402.
CR Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020
   Brahimi-Horn MC, 2007, CURR OPIN CELL BIOL, V19, P223, DOI 10.1016/j.ceb.2007.02.003
   Brandsma D, 2010, J NEUROL, V257, P2099, DOI 10.1007/s00415-010-5654-9
   Calcutt NA, 2009, J NEUROPATH EXP NEUR, V68, P985, DOI 10.1097/NEN.0b013e3181b40217
   Cao WG, 2008, PROSTATE, V68, P1223, DOI 10.1002/pros.20788
   Chen Z, 2007, J BIOENERG BIOMEMBR, V39, P267, DOI 10.1007/s10863-007-9086-x
   Coady MJ, 2004, J PHYSIOL-LONDON, V557, P719, DOI 10.1113/jphysiol.2004.063859
   COOPER RH, 1974, BIOCHEM J, V143, P625, DOI 10.1042/bj1430625
   Ganapathy V, 2005, BIOCHEM SOC T, V33, P237, DOI 10.1042/BST0330237
   Ganapathy V, 2009, PHARMACOL THERAPEUT, V121, P29, DOI 10.1016/j.pharmthera.2008.09.005
   Ganapathy V, 2008, AAPS J, V10, P193, DOI 10.1208/s12248-008-9022-y
   Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478
   Gopal E, 2005, BIOCHEM J, V388, P309, DOI 10.1042/BJ20041916
   Gopal E, 2004, J BIOL CHEM, V279, P44522, DOI 10.1074/jbc.M405365200
   Gupta N, 2006, LIFE SCI, V78, P2419, DOI 10.1016/j.lfs.2005.10.028
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Heshe D, 2011, CANCER CHEMOTH PHARM, V67, P647, DOI 10.1007/s00280-010-1361-6
   Hong CB, 2005, CANCER RES, V65, P3617, DOI 10.1158/0008-5472.CAN-05-0048
   Jackson VN, 1996, J BIOL CHEM, V271, P861, DOI 10.1074/jbc.271.2.861
   Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008-5472.CAN-06-1501
   Li H, 2003, P NATL ACAD SCI USA, V100, P8412, DOI 10.1073/pnas.1430846100
   Madhok BM, 2010, BRIT J CANCER, V102, P1746, DOI 10.1038/sj.bjc.6605701
   Martin PM, 2006, J NEUROCHEM, V98, P279, DOI 10.1111/j.1471-4159.2006.03878.x
   Mathupala SP, 2010, BBA-BIOENERGETICS, V1797, P1225, DOI 10.1016/j.bbabio.2010.03.025
   Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554
   Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677
   Miyauchi S, 2004, J BIOL CHEM, V279, P13293, DOI 10.1074/jbc.C400059200
   Miyauchi S, 2010, BBA-BIOMEMBRANES, V1798, P1164, DOI 10.1016/j.bbamem.2010.03.002
   Park JY, 2008, PANCREAS, V36, pE32, DOI 10.1097/MPA.0b013e3181630ffe
   Park JY, 2007, CANCER DETECT PREV, V31, P359, DOI 10.1016/j.cdp.2007.09.002
   Pearson H, 2007, NATURE, V446, P474, DOI 10.1038/446474a
   Porra V, 2005, J CLIN ENDOCR METAB, V90, P3028, DOI 10.1210/jc.2004-1394
   Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009
   Stacpoole PW, 1998, DRUG METAB REV, V30, P499, DOI 10.3109/03602539808996323
   Stacpoole PW, 2003, J CLIN PHARMACOL, V43, P683, DOI 10.1177/0091270003254637
   Stapoole PW, 2008, ADV DRUG DELIVER REV, V60, P1478, DOI 10.1016/j.addr.2008.02.014
   Stockwin LH, 2010, INT J CANCER, V127, P2510, DOI 10.1002/ijc.25499
   Sun RC, 2010, BREAST CANCER RES TR, V120, P253, DOI 10.1007/s10549-009-0435-9
   Thangaraju M, 2008, J GASTROINTEST SURG, V12, P1773, DOI 10.1007/s11605-008-0573-0
   Thangaraju M, 2006, CANCER RES, V66, P11560, DOI 10.1158/0008-5472.CAN-06-1950
   Thangaraju M, 2009, CANCER, V115, P4655, DOI 10.1002/cncr.24532
   Thangaraju M, 2009, BIOCHEM J, V417, P379, DOI 10.1042/BJ20081132
   Ueno M, 2004, TUMOR BIOL, V25, P134, DOI 10.1159/000079145
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Weimer LH, 2009, CURR NEUROL NEUROSCI, V9, P69, DOI 10.1007/s11910-009-0011-z
   WHITEHOUSE S, 1974, BIOCHEM J, V141, P761, DOI 10.1042/bj1410761
   Wong JYY, 2008, GYNECOL ONCOL, V109, P394, DOI 10.1016/j.ygyno.2008.01.038
   Xiao LL, 2010, MOL CELL BIOCHEM, V340, P31, DOI 10.1007/s11010-010-0397-6
NR 49
TC 70
Z9 81
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD SEP
PY 2011
VL 30
IS 38
BP 4026
EP 4037
DI 10.1038/onc.2011.113
PG 12
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 823KR
UT WOS:000295121600004
PM 21499304
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Meeran, SM
   Patel, SN
   Chan, TH
   Tollefsbol, TO
AF Meeran, Syed M.
   Patel, Shweta N.
   Chan, Tak-Hang
   Tollefsbol, Trygve O.
TI A Novel Prodrug of Epigallocatechin-3-gallate: Differential Epigenetic
   <i>hTERT</i> Repression in Human Breast Cancer Cells
SO CANCER PREVENTION RESEARCH
LA English
DT Article
ID GREEN TEA POLYPHENOL; TELOMERASE REVERSE-TRANSCRIPTASE; TUMOR-SUPPRESSOR
   GENES; HUMAN PROSTATE-CANCER; IN-VITRO; HISTONE ACETYLATION; ACTIVE
   CHROMATIN; DNA METHYLATION; APOPTOSIS; GROWTH
AB Epigallocatechin-3-gallate (EGCG), a major component of green tea polyphenols (GTP), has been reported to downregulate telomerase activity in breast cancer cells thereby increasing cellular apoptosis and inhibiting cellular proliferation. However, the major concerns with GTPs are their bioavailability and stability under physiologic conditions. In the present study, we show that treatments with EGCG and a novel prodrug of EGCG (pro-EGCG or pEGCG) dose-and time-dependently inhibited the proliferation of human breast cancer MCF-7 and MDA-MB-231 cells but not normal control MCF10A cells. Furthermore, both EGCG and pro-EGCG inhibited the transcription of hTERT (human telomerase reverse transcriptase), the catalytic subunit of telomerase, through epigenetic mechanisms in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 cells. The downregulation of hTERT expression was found to be because of hTERT promoter hypomethylation and histone deacetylations, mediated at least partially through inhibition of DNA methyltransferase and histone acetyltransferase activities, respectively. In addition, we also observed that EGCG and pEGCG can remodel chromatin structures of the hTERT promoter by decreasing the level of acetyl-H3, acetyl-H3K9, and acetyl-H4 to the hTERT promoter. EGCG and pEGCG induced chromatin alterations that facilitated the binding of many hTERT repressors such as MAD1 and E2F-1 to the hTERT regulatory region. Depletion of E2F-1 and MAD1 by using siRNA reversed the pEGCG downregulated hTERT expression and associated cellular apoptosis differently in ER-positive and ER-negative breast cancer cells. Collectively, our data provide new insights into breast cancer prevention through epigenetic modulation of telomerase by using pro-EGCG, a more stable form of EGCG, as a novel chemopreventive compound. Cancer Prev Res; 4(8); 1243-54. (C) 2011 AACR.
C1 [Meeran, Syed M.; Patel, Shweta N.; Tollefsbol, Trygve O.] Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Ctr Aging, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL 35294 USA.
   [Chan, Tak-Hang] McGill Univ, Dept Chem, Montreal, PQ, Canada.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham; McGill
   University
RP Meeran, SM (通讯作者)，Univ Alabama Birmingham, Dept Biol, 1300 Univ Blvd,Campbell Hall 175, Birmingham, AL 35294 USA.
EM musthapa@uab.edu
RI Meeran, Syed/AAG-2157-2020
FU National Cancer Institute, NIH [R01 CA129415]; National Science and
   Engineering Research Council of Canada
FX This work was supported by grant R01 CA129415 from the National Cancer
   Institute, NIH, and the National Science and Engineering Research
   Council of Canada (T. H. Chan).
CR Ahmad N, 1997, JNCI-J NATL CANCER I, V89, P1881, DOI 10.1093/jnci/89.24.1881
   Berletch JB, 2008, J CELL BIOCHEM, V103, P509, DOI 10.1002/jcb.21417
   Cheng ASL, 2006, MOL CELL, V21, P393, DOI 10.1016/j.molcel.2005.12.016
   Choi KC, 2009, CANCER RES, V69, P583, DOI 10.1158/0008-5472.CAN-08-2442
   Ciftci K, 2003, J PHARM PHARMACOL, V55, P1135, DOI 10.1211/002235703322277177
   Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200
   Crowe DL, 2001, NUCLEIC ACIDS RES, V29, P2789, DOI 10.1093/nar/29.13.2789
   Cunningham AP, 2006, CURR MED CHEM, V13, P2875, DOI 10.2174/092986706778521887
   Fang MZ, 2007, J NUTR, V137, p223S, DOI 10.1093/jn/137.1.223S
   Fang MZ, 2003, CANCER RES, V63, P7563
   Fassina G, 2004, CLIN CANCER RES, V10, P4865, DOI 10.1158/1078-0432.CCR-03-0672
   Ge Z, 2010, FASEB J, V24, P579, DOI 10.1096/fj.09-140087
   Golubovskaya VM, 2008, MOL CARCINOGEN, V47, P222, DOI 10.1002/mc.20380
   Green JE, 2000, ONCOGENE, V19, P1020, DOI 10.1038/sj.onc.1203280
   Gu B, 2009, ONCOL REP, V21, P635, DOI 10.3892/or_00000266
   Günes Ç, 2000, CANCER RES, V60, P2116
   Khan N, 2006, CANCER RES, V66, P2500, DOI 10.1158/0008-5472.CAN-05-3636
   Kikuno N, 2008, INT J CANCER, V123, P552, DOI 10.1002/ijc.23590
   Kyo S, 2008, CANCER SCI, V99, P1528, DOI 10.1111/j.1349-7006.2008.00878.x
   Lam WH, 2004, BIOORGAN MED CHEM, V12, P5587, DOI 10.1016/j.bmc.2004.08.002
   Lambert JD, 2006, DRUG METAB DISPOS, V34, P2111, DOI 10.1124/dmd.106.011460
   Landis-Piwowar KR, 2007, CANCER RES, V67, P4303, DOI 10.1158/0008-5472.CAN-06-4699
   Li YY, 2009, INT J CANCER, V125, P286, DOI 10.1002/ijc.24398
   Lin Jen-Kun, 2000, Proceedings of the National Science Council Republic of China Part B Life Sciences, V24, P1
   Liu L, 2004, GENE, V340, P1, DOI 10.1016/j.gene.2004.06.011
   Louie MC, 2010, MOL CANCER RES, V8, P343, DOI 10.1158/1541-7786.MCR-09-0395
   Majid S, 2008, CANCER RES, V68, P2736, DOI 10.1158/0008-5472.CAN-07-2290
   Meeran SM, 2008, TOXICOL APPL PHARM, V229, P33, DOI 10.1016/j.taap.2007.12.027
   Meeran SM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0011-5
   Meeran SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011457
   Misiti S, 2000, MOL CELL BIOL, V20, P3764, DOI 10.1128/MCB.20.11.3764-3771.2000
   Mittal A, 2004, INT J ONCOL, V24, P703
   Naasani I, 1998, BIOCHEM BIOPH RES CO, V249, P391, DOI 10.1006/bbrc.1998.9075
   Naasani I, 2003, CANCER RES, V63, P824
   Nanni S, 2002, J CLIN INVEST, V110, P219, DOI 10.1172/JCI200215552
   Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439
   Renaud S, 2007, NUCLEIC ACIDS RES, V35, P1245, DOI 10.1093/nar/gkl1125
   Rossi C, 2008, EUR J CANCER, V44, P2696, DOI 10.1016/j.ejca.2008.08.021
   ROYAM, 2005, MOL CANCER THER, V4, P81
   Sadava D, 2007, BIOCHEM BIOPH RES CO, V360, P233, DOI 10.1016/j.bbrc.2007.06.030
   Stender JD, 2007, MOL ENDOCRINOL, V21, P2112, DOI 10.1210/me.2006-0474
   Tran PLCHB, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-276
   Wang PW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010202
   Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198
   Yang HJ, 2010, CANCER LETT, V292, P48, DOI 10.1016/j.canlet.2009.11.006
   Zinn RL, 2007, CANCER RES, V67, P194, DOI 10.1158/0008-5472.CAN-06-3396
NR 46
TC 110
Z9 123
U1 0
U2 11
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
EI 1940-6215
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD AUG
PY 2011
VL 4
IS 8
BP 1243
EP 1254
DI 10.1158/1940-6207.CAPR-11-0009
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 802JJ
UT WOS:000293505700011
PM 21411498
OA Bronze, Green Accepted, Green Submitted
DA 2025-01-12
ER

PT J
AU Lund, E
AF Lund, Eiliv
TI An exposure driven functional model of carcinogenesis
SO MEDICAL HYPOTHESES
LA English
DT Article
ID BREAST-CANCER; MULTISTAGE MODELS; EPIDEMIOLOGY; MORTALITY; ASSOCIATION;
   SMOKING
AB The understanding of general models of carcinogenesis have not advanced substantially over the last years despite a rapidly increasing amount of detailed knowledge in molecular biology, genetics and epidemiology, and it has been difficult to come up with specific hypotheses in order to test existing models. Current multistage models consider mutations per se as the driving forces of carcinogenesis. In contrast, novel knowledge in epidemiology and basic research combined with upcoming large scale technologies of transcriptomics and epigenetics offers a new model - the exposure driven functional model. In this model exposures to carcinogenic substances are the determinants of the carcinogenesis leading to functional changes in gene regulation and to mutations. The diversity of exposures and functional changes could give not one, but many different cancer phenotypes. Under this novel model, cessation of exposure could arrest or reverse the carcinogenic process. To test hypotheses based on this novel model, studies with valid exposures measurements, biological material suitable for all "-omics" analyses, and a design that takes into account the time order principle of causality are a prerequisite. In epidemiology, such designs have been proposed, while in basic genetic research most designs only comply with some, but not all of these conditions. The strength of the exposure driven functional model is the potential for testing specific hypothesis of the effect of many exposures on different stages or mutations. An example of such design would be the testing of the effect of continuing or stopping exposures in relation to the last stage of carcinogenesis in a prospective or globolomic design. If successful the exposure driven carcinogenic model and the use of functional genomics could improve the understanding of carcinogenesis and concomitantly the assessment of causality as part of systems epidemiology. (C) 2011 Elsevier Ltd. All rights reserved.
C1 Univ Tromso, Inst Community Med, N-9037 Tromso, Norway.
C3 UiT The Arctic University of Tromso
RP Lund, E (通讯作者)，Univ Tromso, Inst Community Med, N-9037 Tromso, Norway.
EM eiliv.lund@uit.no
OI Lund, Eiliv/0000-0002-8071-8711
FU  [ERC-2008-AdG 232997-TICE]
FX Grant: ERC-2008-AdG 232997-TICE "Transcriptomics in cancer
   epidemiology".
CR [Anonymous], Cancer Registry of Norway Cervical Cancer Screening Programme
   ARMITAGE P, 1954, BRIT J CANCER, V8, P1, DOI 10.1038/bjc.1954.1
   ARMITAGE P, 1985, ENVIRON HEALTH PERSP, V63, P195, DOI 10.2307/3430046
   Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0
   Brody JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007053
   Chung CC, 2010, CARCINOGENESIS, V31, P111, DOI 10.1093/carcin/bgp273
   Croce CM, 2008, NEW ENGL J MED, V358, P502, DOI 10.1056/NEJMra072367
   DAY NE, 1980, JNCI-J NATL CANCER I, V64, P977
   DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192
   Doll R, 2004, BMJ-BRIT MED J, V328, P1519, DOI 10.1136/bmj.38142.554479.AE
   Dumeaux V, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1859
   Dumeaux V, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000873
   Felsher DW, 2008, CANCER RES, V68, P3081, DOI 10.1158/0008-5472.CAN-07-5832
   Goldstein DB, 2009, NEW ENGL J MED, V360, P1696, DOI 10.1056/NEJMp0806284
   Haddad H, 2004, BIOTECHNOL BIOENG, V87, P437, DOI 10.1002/bit.20166
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503
   Imaoka T, 2009, J RADIAT RES, V50, P281, DOI 10.1269/jrr.09027
   Klein G, 2009, P NATL ACAD SCI USA, V106, P859, DOI 10.1073/pnas.0811616106
   KREYBERG L, 1954, BRIT J CANCER, V8, P209, DOI 10.1038/bjc.1954.20
   LUND E, 1990, INT J EPIDEMIOL, V19, P527, DOI 10.1093/ije/19.3.527
   Lund E, 2008, CANCER EPIDEM BIOMAR, V17, P2954, DOI 10.1158/1055-9965.EPI-08-0519
   Lund E, 2010, INT J MOL EPIDEMIOL, V1, P124
   McDevitta MA, 2008, MOL CELL ENDOCRINOL, V290, P24, DOI 10.1016/j.mce.2008.04.003
   Meza R, 2008, CANCER CAUSE CONTROL, V19, P317, DOI 10.1007/s10552-007-9094-5
   MOOLGAVKAR SH, 1980, JNCI-J NATL CANCER I, V65, P559
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Potter JD, 2005, NAT CLIN PRACT ONCOL, V2, P625, DOI 10.1038/ncponc0359
   Preston DL, 2007, RADIAT RES, V168, P1, DOI 10.1667/RR0763.1
   Rosen JM, 2009, SCIENCE, V324, P1670, DOI 10.1126/science.1171837
   Rosenberg DW, 2009, CARCINOGENESIS, V30, P183, DOI 10.1093/carcin/bgn267
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943
   VINEIS P, 2009, ENV HLTH, V8, P1
   Vrieling A, 2010, INT J CANCER, V126, P2394, DOI 10.1002/ijc.24907
   Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293
NR 36
TC 5
Z9 5
U1 0
U2 5
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD AUG
PY 2011
VL 77
IS 2
BP 195
EP 198
DI 10.1016/j.mehy.2011.04.009
PG 4
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 809GF
UT WOS:000294039100011
PM 21550177
DA 2025-01-12
ER

PT J
AU Mian, OY
   Wang, SZ
   Zhu, SZ
   Gnanapragasam, MN
   Graham, L
   Bear, HD
   Ginder, GD
AF Mian, Omar Y.
   Wang, Shou Zhen
   Zhu, Sheng Zu
   Gnanapragasam, Merlin N.
   Graham, Laura
   Bear, Harry D.
   Ginder, Gordon D.
TI Methyl-Binding Domain Protein 2-Dependent Proliferation and Survival of
   Breast Cancer Cells
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID CARCINOMA IN-SITU; DNA METHYLATION; PROMOTER METHYLATION; CPG ISLANDS;
   GENE; MBD2; DECITABINE; INDUCTION; EPIGENETICS; DEFICIENCY
AB Methyl cytosine binding domain protein 2 (MBD2) has been shown to bind to and mediate repression of methylated tumor suppressor genes in cancer cells, where repatterning of CpG methylation and associated gene silencing is common. We have investigated the role of MBD2 in breast cancer cell growth and tumor suppressor gene expression. We show that stable short hairpin RNA (shRNA)-mediated knockdown of MBD2 leads to growth suppression of cultured human mammary epithelial cancer lines, SK-BR-3, MDA-MB-231, and MDA-MB-435. The peak antiproliferative occurs only after sustained, stable MBD2 knockdown. Once established, the growth inhibition persists over time and leads to a markedly decreased propensity for aggressive breast cancer cell lines to form in vivo xenograft tumors in Bagg Albino (BALB)/C nu/nu mice. The growth effects of MBD2 knockdown are accompanied by derepression of tumor suppressor genes, including DAPK1 and KLK10. Chromatin immunoprecipitation assays and bisulfite sequencing show MBD2 binding directly to the hyper methylated and CpG-rich promoters of both DAPK1 and KLK10. Remarkably, the promoter CpG island-associated methylation of these genes remained stable despite robust transcriptional activation in MBD2 knockdown cells. Expression of a shRNA-resistant MBD2 protein resulted in restoration of growth and resilencing of the MBD2-dependent tumor suppressor genes. Our data suggest that uncoupling CpG methylation from repressive chromatin remodeling and histone modifications by removing MBD2 is sufficient to initiate and maintain tumor suppressor gene transcription and suppress neoplastic cell growth. These results show a role for MBD2 in cancer progression and provide support for the prospect of targeting MBD2 therapeutically in aggressive breast cancers. Mol Cancer Res; 9(8); 1152-62. (C)2011 AACR.
C1 [Mian, Omar Y.; Wang, Shou Zhen; Zhu, Sheng Zu; Gnanapragasam, Merlin N.; Graham, Laura; Bear, Harry D.; Ginder, Gordon D.] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA.
   [Ginder, Gordon D.] Virginia Commonwealth Univ, Dept Internal Med, Div Hematol & Oncol, Richmond, VA 23298 USA.
   [Mian, Omar Y.; Bear, Harry D.; Ginder, Gordon D.] Virginia Commonwealth Univ, Dept Microbiol & Immunol, Richmond, VA 23298 USA.
   [Bear, Harry D.] Virginia Commonwealth Univ, Dept Surg, Div Surg Oncol, Richmond, VA 23298 USA.
   [Gnanapragasam, Merlin N.; Ginder, Gordon D.] Virginia Commonwealth Univ, Dept Human & Mol Genet, Richmond, VA 23298 USA.
C3 Virginia Commonwealth University; Virginia Commonwealth University;
   Virginia Commonwealth University; Virginia Commonwealth University;
   Virginia Commonwealth University
RP Ginder, GD (通讯作者)，Virginia Commonwealth Univ, Massey Canc Ctr, 401 Coll St,POB 980037, Richmond, VA 23298 USA.
EM gdginder@vcu.edu
OI Gnanapragasam, Merlin Nithya/0000-0002-2592-6315; Mian,
   Omar/0000-0002-8133-8120
FU NCI [RO1 CA87496]; Breeden-Adams Foundation; NCI (Biological
   Macromolecule Core, Flow Cytometry and Imaging Core) Massey Cancer
   Center) [P30 CA016059]
FX The work is financially supported by NCI RO1 CA87496, the Breeden-Adams
   Foundation (G. D. Ginder), and NCI P30 CA016059 (Biological
   Macromolecule Core, Flow Cytometry and Imaging Core) Massey Cancer
   Center.
CR Appleton K, 2007, J CLIN ONCOL, V25, P4603, DOI 10.1200/JCO.2007.10.8688
   Ballestar E, 2005, BIOCHEM CELL BIOL, V83, P374, DOI 10.1139/o05-035
   Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604
   Barrett DM, 2004, MOL CELL BIOL, V24, P6194, DOI 10.1128/MCB.24.14.6194-6204.2004
   Berger J, 2005, BIOCHEM SOC T, V33, P1537, DOI 10.1042/BST0331537
   Caballero IM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004315
   Choi JK, 2001, STEM CELLS, V19, P236, DOI 10.1634/stemcells.19-3-236
   CORN PG, 2009, CANC BIOL THER, V8
   Cui WW, 2007, NUCLEIC ACIDS RES, V35, pD805, DOI 10.1093/nar/gkl767
   Dumont N, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2457
   Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fraga MF, 2003, NUCLEIC ACIDS RES, V31, P1765, DOI 10.1093/nar/gkg249
   Futscher BW, 2004, NEOPLASIA, V6, P380, DOI 10.1593/neo.04115
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   GNANAPRAGASAM MN, 2011, P NATL ACAD SCI US
   Grant S, 2009, CLIN CANCER RES, V15, P7111, DOI 10.1158/1078-0432.CCR-09-2399
   Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538
   Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101
   Honorio S, 2003, ONCOGENE, V22, P147, DOI 10.1038/sj.onc.1206057
   Hoque MO, 2009, CANCER EPIDEM BIOMAR, V18, P2694, DOI 10.1158/1055-9965.EPI-08-0821
   Issa JP, 2010, HEMATOL ONCOL CLIN N, V24, P317, DOI 10.1016/j.hoc.2010.02.007
   Jabbour E, 2008, CANCER-AM CANCER SOC, V112, P2341, DOI 10.1002/cncr.23463
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Klerk CPW, 2007, BIOTECHNIQUES, V43, P7, DOI 10.2144/000112515
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   Kransdorf EP, 2006, BLOOD, V108, P2836, DOI 10.1182/blood-2006-04-016394
   Lopez-Serra L., 2008, ONCOGENE
   Lopez-Serra L, 2006, CANCER RES, V66, P8342, DOI 10.1158/0008-5472.CAN-06-1932
   Lustberg MB, 2009, DRUG NEWS PERSPECT, V22, P369, DOI 10.1358/dnp.2009.22.7.1405072
   Martin V, 2008, PATHOBIOLOGY, V75, P281, DOI 10.1159/000151708
   Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466
   Oki Y, 2006, REV RECENT CLIN TRIA, V1, P169, DOI 10.2174/157488706776876490
   Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]
   Prokhortchouk A, 2001, GENE DEV, V15, P1613, DOI 10.1101/gad.198501
   Pulukuri SM, 2006, ONCOGENE, V25, P4559, DOI 10.1038/sj.onc.1209462
   Rupon JW, 2006, P NATL ACAD SCI USA, V103, P6617, DOI 10.1073/pnas.0509322103
   Sansom OJ, 2005, ONCOGENE, V24, P2430, DOI 10.1038/sj.onc.1208166
   Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155
   Sansom OJ, 2007, NAT CLIN PRACT ONCOL, V4, P305, DOI 10.1038/ncponc0812
   SCARSDALE JN, 2011, NUCL ACIDS RES
   SCUDIERO DA, 1988, CANCER RES, V48, P4827
   Si J, 2010, CANCER RES, V70, P6968, DOI 10.1158/0008-5472.CAN-09-4474
   Sproul D, 2011, P NATL ACAD SCI USA, V108, P4364, DOI 10.1073/pnas.1013224108
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Taby R, 2010, CA-CANCER J CLIN, V60, P376, DOI 10.3322/caac.20085
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Tsai HC, 2011, CELL RES, V21, P502, DOI 10.1038/cr.2011.24
   Welch DR, 1997, CLIN EXP METASTAS, V15, P272, DOI 10.1023/A:1018477516367
   Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003
   Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924
NR 51
TC 39
Z9 46
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
EI 1557-3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD AUG
PY 2011
VL 9
IS 8
BP 1152
EP 1162
DI 10.1158/1541-7786.MCR-11-0252
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA 807GX
UT WOS:000293885600016
PM 21693597
OA Green Accepted, Green Submitted
DA 2025-01-12
ER

PT J
AU Yoshimura, T
   Nagahara, M
   Kuo, C
   Turner, RR
   Soon-Shiong, P
   Hoon, DSB
AF Yoshimura, Tetsunori
   Nagahara, Makoto
   Kuo, Christine
   Turner, Roderick R.
   Soon-Shiong, Patrick
   Hoon, Dave S. B.
TI Lymphovascular invasion of colorectal cancer is correlated to SPARC
   expression in the tumor stromal microenvironment
SO EPIGENETICS
LA English
DT Article
DE SPARC; methylation; lymphovascular; microenvironment; colorectal cancer
ID BREAST-CANCER; PROMOTER HYPERMETHYLATION; MATRICELLULAR PROTEIN;
   EXTRACELLULAR-MATRIX; PROGNOSTIC VALUE; GROWTH; MELANOMA; CELLS;
   ANGIOGENESIS; PROGRESSION
AB As an integral component of the microenvironment in colorectal cancer (CRC), stromal cells can influence tumor progression. Found in the extracellular matrix of CRC, secreted protein acidic and rich in cysteine (SPARC) is expressed in stromal and CRC cells. While SPARC's influence on CRC is not clear, we hypothesized that epigenetically regulated SPARC expression in the microenvironment stromal cells of CRC can affect primary CRC progression and is influenced by lymphovascular invasion (LVI). Quantitative immunohistochemistry (IHC) analysis of paraffin-embedded from 37 LVI-positive and 35 LVI-negative primary CRCs (n = 72) was performed. MassARRAY sequencing was performed to assess the methylation status of the promoter region in 22 LVI-positive and 20 LVI-negative CRC and to identify specific CpG island(s) regulating SPARC expression. SPARC in CRC cells was not correlated with LVI, whereas SPARC in the microenvironment stromal cells was inversely related to LVI (p < 0.0001). There was a direct relationship between LVI and 6 specific CpG site methylation in the SPARC promoter region of stromal cells (p = 0.017) but not in CRC cells. Stromal SPARC expression inversely correlated with VEGF-A expression in CRC (p = 0.003) and positively correlated with HSP27 expression (p = 0.009). The results suggested that the epigenetic regulation of SPARC expression in tumor cells versus stromal cells of CRC is significantly different. Stromal cell SPARC expression is epigenetically influenced by LVI of CRC tumors, and may play a significant role in primary CRC progression.
C1 [Yoshimura, Tetsunori; Nagahara, Makoto; Kuo, Christine; Hoon, Dave S. B.] John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA 90404 USA.
   [Turner, Roderick R.] St Johns Hlth Ctr, Dept Surg Pathol, Santa Monica, CA USA.
   [Soon-Shiong, Patrick] Abraxis Biosci, Los Angeles, CA USA.
C3 John Wayne Cancer Institute
RP Hoon, DSB (通讯作者)，John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA 90404 USA.
EM hoon@jwci.org
RI Hoon, Dave/C-7146-2018
OI Hoon, Dave/0000-0003-1915-3683
FU Leslie and Susan Gonda (Goldschmied) Foundation (Los Angeles, CA); Ruth
   and Martin H. Weil Fund (Los Angeles, CA)
FX The studies were supported by the Leslie and Susan Gonda (Goldschmied)
   Foundation (Los Angeles, CA) and Ruth and Martin H. Weil Fund (Los
   Angeles, CA). We thank Gwen Berry for editorial assistance, Xing Ye, MSc
   for biostatistical analysis, Kana Rivera and Linhda and Tung Nguyen for
   editorial support and technical support, Division of Surgical Pathology,
   Saint John's Health Center staff for histopathology support and
   Department of Molecular Oncology for technical support.
CR Ara T, 2009, CANCER RES, V69, P329, DOI 10.1158/0008-5472.CAN-08-0613
   Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939
   Brekken RA, 2003, J CLIN INVEST, V111, P487, DOI 10.1172/JCI16804
   Brekken Rolf A., 2001, Matrix Biology, V19, P816
   Briggs J, 2002, ONCOGENE, V21, P7077, DOI 10.1038/sj.onc.1205857
   Cheetham S, 2008, BRIT J CANCER, V98, P1810, DOI 10.1038/sj.bjc.6604377
   Chlenski A, 2006, INT J CANCER, V118, P310, DOI 10.1002/ijc.21357
   Chung YS, 1996, EUR J CANCER, V32A, P2501, DOI 10.1016/S0959-8049(96)00382-6
   de Maat MFG, 2008, J CLIN ONCOL, V26, P2327, DOI 10.1200/JCO.2007.14.0723
   de Maat MFG, 2007, J CLIN ONCOL, V25, P4887, DOI 10.1200/JCO.2006.09.8921
   de Maat MFG, 2010, AM J PATHOL, V177, P2347, DOI 10.2353/ajpath.2010.091103
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Golembieski WA, 2008, GLIA, V56, P1061, DOI 10.1002/glia.20679
   Gradishar WJ, 2005, J CLIN ONCOL, V23, P7794, DOI 10.1200/JCO.2005.04.937
   Infante JR, 2007, J CLIN ONCOL, V25, P319, DOI 10.1200/JCO.2006.07.8824
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kahn HJ, 2002, MODERN PATHOL, V15, P434, DOI 10.1038/modpathol.3880543
   Koukourakis MI, 2003, CANCER RES, V63, P5376
   Koyanagi K, 2005, J CLIN ONCOL, V23, P8057, DOI 10.1200/JCO.2005.02.0958
   Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635
   Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241
   Longatto A, 2008, VIRCHOWS ARCH, V452, P133, DOI 10.1007/s00428-007-0550-0
   Massi D, 1999, HUM PATHOL, V30, P339, DOI 10.1016/S0046-8177(99)90014-X
   Mesker WE, 2007, CELL ONCOL, V29, P387
   Mori T, 2006, CANCER RES, V66, P6692, DOI 10.1158/0008-5472.CAN-06-0801
   Nakagawa H, 2004, ONCOGENE, V23, P7366, DOI 10.1038/sj.onc.1208013
   Nozaki M, 2006, J CLIN INVEST, V116, P422, DOI 10.1172/JCI26316
   Podhajcer OL, 2008, CANCER METAST REV, V27, P523, DOI 10.1007/s10555-008-9135-x
   Robert G, 2006, CANCER RES, V66, P7516, DOI 10.1158/0008-5472.CAN-05-3189
   Royston D, 2009, J PATHOL, V217, P608, DOI 10.1002/path.2517
   Saad RS, 2006, MODERN PATHOL, V19, P1317, DOI 10.1038/modpathol.3800651
   SAGE H, 1989, J CELL BIOL, V109, P341, DOI 10.1083/jcb.109.1.341
   Sangaletti S, 2003, J EXP MED, V198, P1475, DOI 10.1084/jem.20030202
   Sato Y, 2009, CANCER MICROENVIRON, V2, pS205, DOI 10.1007/s12307-009-0022-y
   Schultz C, 2002, CANCER RES, V62, P6270
   Sun XF, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-43
   Sundlisxter E, 2007, INT J CANCER, V121, P1401, DOI 10.1002/ijc.22996
   Tai IT, 2008, DRUG RESIST UPDATE, V11, P231, DOI 10.1016/j.drup.2008.08.005
   Tanemura A, 2009, CLIN CANCER RES, V15, P1801, DOI 10.1158/1078-0432.CCR-08-1361
   Umetani N, 2005, ONCOGENE, V24, P4721, DOI 10.1038/sj.onc.1208538
   Watkins G, 2005, PROSTAG LEUKOTR ESS, V72, P267, DOI 10.1016/j.plefa.2004.12.003
   Witz IP, 2008, ADV CANCER RES, V100, P203, DOI 10.1016/S0065-230X(08)00007-9
   Witz IP, 2009, CANCER MICROENVIRON, V2, pS9, DOI 10.1007/s12307-009-0025-8
   Yamanaka M, 2001, J UROLOGY, V166, P2495, DOI 10.1016/S0022-5347(05)65623-6
   Yan Q, 1999, J HISTOCHEM CYTOCHEM, V47, P1495, DOI 10.1177/002215549904701201
   Yang EN, 2007, INT J CANCER, V121, P567, DOI 10.1002/ijc.22706
   Yu ZJ, 2010, MOL MED REP, V3, P953, DOI 10.3892/mmr.2010.372
   Yunker CK, 2008, INT J CANCER, V122, P2735, DOI 10.1002/ijc.23450
NR 48
TC 25
Z9 28
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD AUG
PY 2011
VL 6
IS 8
BP 1001
EP 1011
DI 10.4161/epi.6.8.16063
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 800FF
UT WOS:000293344500007
PM 21725199
OA Bronze
DA 2025-01-12
ER

PT J
AU Tost, J
   Hamzaoui, H
   Busato, F
   Neyret, A
   Mourah, S
   Dupont, JM
   Bouizar, Z
AF Tost, Joerg
   Hamzaoui, Hinda
   Busato, Florence
   Neyret, Aymeric
   Mourah, Samia
   Dupont, Jean-Michel
   Bouizar, Zhor
TI Methylation of specific CpG sites in the P2 promoter of <i>parathyroid
   hormone</i>-<i>related protein</i> determines the invasive potential of
   breast cancer cell lines
SO EPIGENETICS
LA English
DT Article
DE breast cancer; cell lines; parathyroid hormone related protein; DNA
   methylation; metastasis; azacytidine; trichostatin A
ID RNA SPLICING PATHWAYS; PTHRP GENE-EXPRESSION; SYNUCLEIN-GAMMA-GENE;
   GC-RICH PROMOTER; DNA METHYLATION; PEPTIDE GENE; EPITHELIAL-CELLS;
   CARCINOMA; METASTASIS; TUMORS
AB Parathyroid hormone-related protein (PTHrP) is upregulated in primary breast cancers and a major candidate for osteoclastic bone resorption present at sites of breast cancer to bone metastases. Using a human model of mammary epithelial cell lines differing in tumorigenicity and PTHrP expression, we investigated the role of epigenetic modifications for PTHrP expression. Quantitative analysis of the DNA methylation patterns at a total of 104 CpGs in the promoter region of PTHrP by pyrosequencing showed the absence of methylation in all analyzed cell lines in the large CpG island upstream of exon 1C. In the second intron of promoter 2 (P2) a region was identified containing 4 CpG nucleotides for which differential methylation correlated with the PTHrP expression level. The functional importance of this control mechanism was confirmed by the ability of the demethylating agent 5'-azacytidine to induce PTHrP mRNA and iPTHrP protein expression in previously non-expressing cell lines and increase their production by metastatic NS2T2A1 cells. In particular, transcription from P2 was activated in non-tumoral S1T3 cells upon treatment with 5'-azacytidine. Our findings support the hypothesis that the methylation status of specific CpG dinucleotides is the dominant mechanism involved in silencing of PTHrP expression rather than the overall methylation of the CpG island. Methylation of the PTHrP P2 is a potential marker of breast cancer progression and might be used to evaluate the metastatic potential of breast tumors.
C1 [Tost, Joerg; Busato, Florence] Ctr Natl Genotypage, Lab Epigenet, CEA Inst Genom, Evry, France.
   [Tost, Joerg] Fdn Jean Dausset CEPH, Lab Funct Genom, Paris, France.
   [Hamzaoui, Hinda; Neyret, Aymeric; Dupont, Jean-Michel] Inst Cochin Genet Mol, INSERM, U567, F-75014 Paris, France.
   [Hamzaoui, Hinda; Neyret, Aymeric; Dupont, Jean-Michel] Univ Paris 05, CNRS, UMR 8104, Paris, France.
   [Mourah, Samia] Hop St Louis, AP HP, Pharmacol Lab, INSERM,U716, Paris, France.
   [Dupont, Jean-Michel] Hop Cochin, Lab Cytogenet, F-75674 Paris, France.
   [Bouizar, Zhor] Hop Robert Debre, AP HP, INSERM, U676, F-75019 Paris, France.
   [Mourah, Samia; Bouizar, Zhor] Univ Paris Diderot, Paris, France.
C3 CEA; Universite Paris Saclay; Foundation Jean Dausset-CEPH; Universite
   Paris Cite; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS -
   National Institute for Biology (INSB); Universite Paris Cite; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Universite
   Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Saint-Louis - APHP; Assistance Publique Hopitaux Paris
   (APHP); Universite Paris Cite; Hopital Universitaire Cochin - APHP;
   Universite Paris Cite; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Robert-Debre - APHP; Universite Paris Cite
RP Tost, J (通讯作者)，Ctr Natl Genotypage, Lab Epigenet, CEA Inst Genom, Evry, France.
EM tost@cng.fr
RI Busato, Fabio/LIC-8043-2024; Tost, Jorg/H-7129-2019
OI DUPONT, Jean-Michel/0000-0002-9680-3662; Tost, Jorg/0000-0002-2683-0817
FU Association pour la Recherche contre le Cancer (ARC) [9689]; INSERM;
   Ministere Delegue a la Recherche et des Nouvelles Technologies of the
   French Government; EU [LSHG-CT-2004-512066]; Cancer & Solidarity
   Foundation; Fondation pour la Recherche Medicale (FRM)
FX The authors thank the Laboratoire de Biologie Endocrinienne, Hopital
   Lariboisiere (Paris, France) for the immunoradiometric measurement of
   the iPTHrP(1-84) peptide. This work was supported by grants 9689 from
   the Association pour la Recherche contre le Cancer (ARC), from INSERM,
   the Ministere Delegue a la Recherche et des Nouvelles Technologies of
   the French Government and the EU framework 6 integrated project MolPAGE
   (LSHG-CT-2004-512066). H. Hamzaoui was the recipient of fellowships from
   the Cancer & Solidarity Foundation, the Association pour la Recherche
   contre le Cancer (ARC) and the Fondation pour la Recherche Medicale
   (FRM). The use of the English language of the manuscript was edited by
   Dr. Owen Parkes.
CR Agrawal A, 2007, MODERN PATHOL, V20, P711, DOI 10.1038/modpathol.3800822
   Akino K, 1996, CANCER RES, V56, P77
   BERTHON P, 1992, INT J CANCER, V52, P92, DOI 10.1002/ijc.2910520117
   BOUIZAR Z, 1993, CANCER RES, V53, P5076
   Bouizar Z, 1999, J BONE MINER RES, V14, P406, DOI 10.1359/jbmr.1999.14.3.406
   BRANDT DW, 1992, BIOCHEM BIOPH RES CO, V189, P938, DOI 10.1016/0006-291X(92)92294-8
   BRANDT DW, 1994, CANCER RES, V54, P850
   BUNDRED NJ, 1992, EUR J CANCER, V28A, P690, DOI 10.1016/S0959-8049(05)80127-3
   CAMPOS RV, 1992, MOL ENDOCRINOL, V6, P1642, DOI 10.1210/me.6.10.1642
   Cataisson C, 2000, J BONE MINER RES, V15, P2129, DOI 10.1359/jbmr.2000.15.11.2129
   Cataisson C, 2003, MOL CELL ENDOCRINOL, V204, P155, DOI 10.1016/S0303-7207(02)00298-8
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Foley J, 2001, DEVELOPMENT, V128, P513
   Gallwitz WE, 2002, J CLIN INVEST, V110, P1559, DOI 10.1172/JCI200211936
   Ganderton RH, 1997, BBA-GENE STRUCT EXPR, V1352, P303, DOI 10.1016/S0167-4781(97)00031-6
   Ganderton RH, 2000, EUR J CANCER, V36, P2128, DOI 10.1016/S0959-8049(00)00294-X
   Gilmore JL, 2008, BREAST CANCER RES TR, V110, P493, DOI 10.1007/s10549-007-9748-8
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200
   Gupta A, 2003, CANCER RES, V63, P664
   Hamzaoui H, 2007, MOL CELL ENDOCRINOL, V268, P75, DOI 10.1016/j.mce.2007.01.014
   Henderson MA, 2006, CANCER RES, V66, P2250, DOI 10.1158/0008-5472.CAN-05-2814
   HOLT EH, 1993, J BIOL CHEM, V268, P20639
   JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Liao JH, 2006, CANCER METAST REV, V25, P559, DOI 10.1007/s10555-006-9033-z
   Linforth R, 2002, CLIN CANCER RES, V8, P3172
   Liu HY, 2005, CANCER RES, V65, P7635, DOI 10.1158/0008-5472.CAN-05-1089
   Liu Y, 2009, CLIN IMMUNOL, V130, P213, DOI 10.1016/j.clim.2008.08.009
   MANGIN M, 1990, MOL ENDOCRINOL, V4, P851, DOI 10.1210/mend-4-6-851
   MANGIN M, 1989, P NATL ACAD SCI USA, V86, P2408, DOI 10.1073/pnas.86.7.2408
   Murray TM, 2005, ENDOCR REV, V26, P78, DOI 10.1210/er.2003-0024
   Nadella MVP, 2007, LEUKEMIA, V21, P1752, DOI 10.1038/sj.leu.2404798
   Newell-Price J, 2001, MOL ENDOCRINOL, V15, P338, DOI 10.1210/me.15.2.338
   Ou JN, 2007, BIOCHEM PHARMACOL, V73, P1297, DOI 10.1016/j.bcp.2006.12.032
   Richard V, 2005, CRIT REV EUKAR GENE, V15, P115, DOI 10.1615/CritRevEukaryotGeneExpr.v15.i2.30
   Rizk-Rabin M, 2008, CANCER EPIDEM BIOMAR, V17, P2275, DOI 10.1158/1055-9965.EPI-07-2924
   Southby J, 1996, ENDOCRINOLOGY, V137, P1349, DOI 10.1210/en.137.4.1349
   SOUTHBY J, 1995, BRIT J CANCER, V72, P702, DOI 10.1038/bjc.1995.397
   Surowiak P, 2003, VIRCHOWS ARCH, V442, P245, DOI 10.1007/s00428-002-0743-5
   Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451
   Tost J, 2006, BIOTECHNIQUES, V40, P721, DOI 10.2144/000112190
   Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314
   Van Den Eynden GG, 2007, BONE, V40, P1166, DOI 10.1016/j.bone.2006.11.009
   VanHouten JN, 2006, J CLIN ENDOCR METAB, V91, P580, DOI 10.1210/jc.2005-2095
   VASAVADA RC, 1993, MOL ENDOCRINOL, V7, P273, DOI 10.1210/me.7.2.273
   Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   YASUDA T, 1989, J BIOL CHEM, V264, P7720
   Yoshida A, 2000, Breast Cancer, V7, P215, DOI 10.1007/BF02967463
NR 50
TC 6
Z9 7
U1 0
U2 2
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1559-2294
J9 EPIGENETICS-US
JI Epigenetics
PD AUG
PY 2011
VL 6
IS 8
BP 1035
EP 1046
DI 10.4161/epi.6.8.16077
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 800FF
UT WOS:000293344500011
PM 21775817
OA Bronze
DA 2025-01-12
ER

PT J
AU Cao, Q
   Mani, RS
   Ateeq, B
   Dhanasekaran, SM
   Asangani, IA
   Prensner, JR
   Kim, JH
   Brenner, JC
   Jing, XJ
   Cao, XH
   Wang, R
   Li, Y
   Dahiya, A
   Wang, L
   Pandhi, M
   Lonigro, RJ
   Wu, YM
   Tomlins, SA
   Palanisamy, N
   Qin, ZH
   Yu, JD
   Maher, CA
   Varambally, S
   Chinnaiyan, AM
AF Cao, Qi
   Mani, Ram-Shankar
   Ateeq, Bushra
   Dhanasekaran, Saravana M.
   Asangani, Irfan A.
   Prensner, John R.
   Kim, Jung H.
   Brenner, J. Chad
   Jing, Xiaojun
   Cao, Xuhong
   Wang, Rui
   Li, Yong
   Dahiya, Arun
   Wang, Lei
   Pandhi, Mithil
   Lonigro, Robert J.
   Wu, Yi-Mi
   Tomlins, Scott A.
   Palanisamy, Nallasivam
   Qin, Zhaohui
   Yu, Jindan
   Maher, Christopher A.
   Varambally, Sooryanarayana
   Chinnaiyan, Arul M.
TI Coordinated Regulation of Polycomb Group Complexes through microRNAs in
   Cancer
SO CANCER CELL
LA English
DT Article
ID GROUP PROTEIN EZH2; PROSTATE-CANCER; BREAST-CANCER; SELF-RENEWAL;
   STEM-CELLS; GENE-EXPRESSION; ZESTE HOMOLOG-2; DOWN-REGULATION;
   GASTRIC-CANCER; E-CADHERIN
AB Polycomb Repressive Complexes (PRC1 and PRC2)-mediated epigenetic regulation is critical for maintaining cellular homeostasis. Members of Polycomb Group (PcG) proteins including EZH2, a PRC2 component, are upregulated in various cancer types, implicating their role in tumorigenesis. Here, we have identified several microRNAs (miRNAs) that are repressed by EZH2. These miRNAs, in turn, regulate the expression of PRC1 proteins BMI1 and RING2. We found that ectopic overexpression of EZH2-regulated miRNAs attenuated cancer cell growth and invasiveness, and abrogated cancer stem cell properties. Importantly, expression analysis revealed an inverse correlation between miRNA and PRC protein levels in cell culture and prostate cancer tissues. Taken together, our data have uncovered a coordinate regulation of PRC1 and PRC2 activities that is mediated by miRNAs.
C1 [Cao, Qi; Mani, Ram-Shankar; Ateeq, Bushra; Dhanasekaran, Saravana M.; Asangani, Irfan A.; Prensner, John R.; Kim, Jung H.; Brenner, J. Chad; Jing, Xiaojun; Cao, Xuhong; Wang, Rui; Li, Yong; Dahiya, Arun; Wang, Lei; Pandhi, Mithil; Lonigro, Robert J.; Wu, Yi-Mi; Tomlins, Scott A.; Palanisamy, Nallasivam; Yu, Jindan; Maher, Christopher A.; Varambally, Sooryanarayana; Chinnaiyan, Arul M.] Univ Michigan, Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA.
   [Cao, Qi; Mani, Ram-Shankar; Ateeq, Bushra; Dhanasekaran, Saravana M.; Asangani, Irfan A.; Prensner, John R.; Kim, Jung H.; Brenner, J. Chad; Jing, Xiaojun; Wang, Rui; Li, Yong; Wang, Lei; Lonigro, Robert J.; Wu, Yi-Mi; Tomlins, Scott A.; Palanisamy, Nallasivam; Yu, Jindan; Maher, Christopher A.; Varambally, Sooryanarayana; Chinnaiyan, Arul M.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
   [Cao, Xuhong; Chinnaiyan, Arul M.] Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA.
   [Maher, Christopher A.] Univ Michigan, Ctr Computat Med & Bioinformat, Ann Arbor, MI 48109 USA.
   [Chinnaiyan, Arul M.] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA.
   [Palanisamy, Nallasivam; Varambally, Sooryanarayana; Chinnaiyan, Arul M.] Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
   [Qin, Zhaohui] Emory Univ, Ctr Comprehens Informat, Dept Biostat & Bioinformat, Atlanta, GA 30329 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; Howard Hughes Medical
   Institute; University of Michigan System; University of Michigan;
   University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan; Emory University
RP Chinnaiyan, AM (通讯作者)，Univ Michigan, Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA.
EM arul@umich.edu
RI Brenner, Chad/HLV-9645-2023; Cao, Qi/IUO-1776-2023; Chinnaiyan,
   Arul/LCE-5288-2024; wang, rui/JAC-6240-2023; Qin, Zhaohui/Q-3133-2019;
   Dahiya, Arun/G-8411-2012; Palanisamy, Nallasivam/ABC-8844-2020; Ateeq,
   Bushra/I-3967-2019; Cao, Qi/A-5517-2010; Qin, Zhaohui/E-8196-2011
OI Palanisamy, Nallasivam/0000-0002-0633-9772; asangani,
   irfan/0000-0001-5381-1702; Dhanasekaran, saravana
   mohan/0000-0002-0489-2224; Cao, Qi/0000-0002-5140-3681; Qin,
   Zhaohui/0000-0002-1583-146X; kim, julie/0000-0001-8300-6448; Ateeq,
   Bushra/0000-0003-4682-9773; Varambally,
   Sooryanarayana/0000-0002-2277-1127; Tomlins, Scott/0000-0001-8661-9821;
   Mani, Ram/0000-0003-3552-7905; Prensner, John/0000-0002-7024-636X
FU Early Detection Research Network [UO1 CA111275]; Prostate SPORE
   [P50CA69568, P50CA090386]; National Institutes of Health [R01CA132874,
   R01CA157845, 7R01HG005119-02, 5R00CA129565]; Doris Duke Charitable
   Foundation; Burroughs Welcome Foundation; Prostate Cancer Foundation
   (PCF); Howard Hughes Medical Institute; U.S. Department of Defense
   [PC094725, PC094290, BC083217, PC080665]; Genentech Foundation;
   Expedition Inspiration Fund for Breast Cancer Research; University of
   Michigan
FX We thank Xia Jiang, Javed Siddiqui, Wei Yan, Bo Han, Khalid Suleman,
   Rohit Mehra, Rupal Shastri, and Joy E. Tsai for technical assistance,
   Victor E. Marquez for providing DZNep, Michigan Center for hES Cell
   Research for H7 RNA and qPCR, the University of Michigan Vector Core for
   generating adenovirus and lentivirus, Kenneth J. Pienta, Xiaosong Wang,
   and Shanker Kalyana-Sundaram for discussions, and Jyoti Athanikar and
   Karen Giles for critically reading the manuscript and submission
   documents. This work is supported in part by the Early Detection
   Research Network UO1 CA111275, Prostate SPORE P50CA69568 and
   P50CA090386, and National Institutes of Health (R01CA132874,
   R01CA157845). A.M.C. is supported by the Doris Duke Charitable
   Foundation Clinical Scientist Award, Burroughs Welcome Foundation Award
   in Clinical Translational Research, the Prostate Cancer Foundation (PCF)
   and the Howard Hughes Medical Institute. A.M.C. is an American Cancer
   Society Research Professor. Q.C., J.R.P., and J.C.B. are supported by
   U.S. Department of Defense (PC094725 to Q.C.; PC094290 to J.R.P.;
   BC083217 to J.C.B.); R.-S.M., S.A.T., and C.A.M. are supported by Young
   Investigator Awards from the PCF; B.A. is supported by the Genentech
   Foundation Postdoctoral Fellowship and Young Investigator Award from the
   Expedition Inspiration Fund for Breast Cancer Research. N.P. is
   supported by the University of Michigan Prostate Cancer SPORE Career
   Development award. Z.Q. is supported by National Institutes of Health
   (7R01HG005119-02). J.Y. is supported by U.S. Department of Defense
   (PC080665) and National Institutes of Health (5R00CA129565); S.V. is
   supported by National Institutes of Health (R01CA157845) and Prostate
   Cancer SPORE Career Development award. Q.C. and A.M.C. designed the
   experiments. Q.C., R.-S.M., B.A., S.M.D., I.A.A., J.R.P., J.H.K.,
   J.C.B., X.J., X.C., R.W., Y.L., A.D., L.W., M.P., Y.-M.W., SAT., N.P.,
   J.Y., and S.V. performed the experimental work. R.J.L., Z.Q., and C.A.M.
   performed statistical analysis on miRNA and gene expression data. Q.C.
   and A.M.C. wrote the paper. All authors discussed the results and
   commented on the manuscript.
CR [Anonymous], CANC DISCOVERY
   Bock C, 2005, BIOINFORMATICS, V21, P4067, DOI 10.1093/bioinformatics/bti652
   Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880
   Bracken AP, 2009, NAT REV CANCER, V9, P773, DOI 10.1038/nrc2736
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Cao P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-108
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002
   Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200
   Chiang CW, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-35
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Ezhkova E, 2009, CELL, V136, P1122, DOI 10.1016/j.cell.2008.12.043
   Faber J, 2008, CANCER CELL, V13, P467, DOI 10.1016/j.ccr.2008.05.013
   Fasano CA, 2007, CELL STEM CELL, V1, P87, DOI 10.1016/j.stem.2007.04.001
   Friedman JM, 2009, CANCER RES, V69, P2623, DOI 10.1158/0008-5472.CAN-08-3114
   Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200
   Galmozzi E, 2006, CURR MED CHEM, V13, P603, DOI 10.2174/092986706776055661
   Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179
   Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Hurt EM, 2008, BRIT J CANCER, V98, P756, DOI 10.1038/sj.bjc.6604242
   Iliopoulos D, 2010, MOL CELL, V39, P761, DOI 10.1016/j.molcel.2010.08.013
   Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476
   Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678
   Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014
   Kaneko S, 2010, GENE DEV, V24, P2615, DOI 10.1101/gad.1983810
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Krützfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303
   Lawson DA, 2007, P NATL ACAD SCI USA, V104, P181, DOI 10.1073/pnas.0609684104
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lu JA, 2011, CANCER RES, V71, P225, DOI 10.1158/0008-5472.CAN-10-1850
   Lukacs RU, 2010, CELL STEM CELL, V7, P682, DOI 10.1016/j.stem.2010.11.013
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Matsukawa Y, 2006, CANCER SCI, V97, P484, DOI 10.1111/j.1349-7006.2006.00203.x
   Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100
   Palanisamy N, 2010, NAT MED, V16, P793, DOI 10.1038/nm.2166
   Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608
   Pereira CF, 2010, CELL STEM CELL, V6, P547, DOI 10.1016/j.stem.2010.04.013
   Pietersen AM, 2008, CURR BIOL, V18, P1094, DOI 10.1016/j.cub.2008.06.070
   Poliseno L, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000594
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Sánchez-Beato M, 2006, MODERN PATHOL, V19, P684, DOI 10.1038/modpathol.3800577
   Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011
   Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531
   Surface LE, 2010, CELL STEM CELL, V7, P288, DOI 10.1016/j.stem.2010.08.004
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679
   Tomlins SA, 2007, NATURE, V448, P595, DOI 10.1038/nature06024
   Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935
   Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005
   Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985
   Wang HJ, 2010, EUR J CANCER, V46, P2295, DOI 10.1016/j.ejca.2010.05.012
   Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998
   Wong CF, 2008, J BIOL CHEM, V283, P9836, DOI 10.1074/jbc.M709614200
   Yi R, 2008, NATURE, V452, P225, DOI 10.1038/nature06642
   Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054
   Yu J, 2010, ONCOGENE, V29, P5370, DOI 10.1038/onc.2010.269
   Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016
   Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498
NR 64
TC 178
Z9 193
U1 1
U2 26
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1535-6108
EI 1878-3686
J9 CANCER CELL
JI Cancer Cell
PD AUG 16
PY 2011
VL 20
IS 2
BP 187
EP 199
DI 10.1016/j.ccr.2011.06.016
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA 810BF
UT WOS:000294099700008
PM 21840484
OA Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Kosaka-Suzuki, N
   Suzuki, T
   Pugacheva, EM
   Vostrov, AA
   Morse, HC
   Loukinov, D
   Lobanenkov, V
AF Kosaka-Suzuki, Natsuki
   Suzuki, Teruhiko
   Pugacheva, Elena M.
   Vostrov, Alexander A.
   Morse, Herbert C., III
   Loukinov, Dmitri
   Lobanenkov, Victor
TI Transcription Factor BORIS (Brother of the Regulator of Imprinted Sites)
   Directly Induces Expression of a Cancer-Testis Antigen, TSP50, through
   Regulated Binding of BORIS to the Promoter
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID C-MYC GENE; CTCF-BINDING; EPIGENETIC REGULATION; ENHANCER-BLOCKING;
   CONTROL REGION; BREAST-CANCER; LUNG-CANCER; PROTEIN; CHROMATIN;
   INSULATOR
AB Cancer-testis antigens (CTAs) are normally expressed in testis but are aberrantly expressed in a variety of cancers with varying frequency. More than 100 proteins have been identified as CTA including testes-specific protease 50 (TSP50) and the testis-specific paralogue of CCCTC-binding factor, BORIS (brother of the regulator of imprinted sites). Because many CTAs are considered as excellent targets for tumor immunotherapy, understanding the regulatory mechanisms governing their expression is important. In this study we demonstrate that BORIS is directly responsible for the transcriptional activation of TSP50. We found two BORIS binding sites in the TSP50 promoter that are highly conserved between mouse and human. Mutations of the binding sites resulted in loss of BORIS binding and the ability of BORIS to activate the promoter. However, although expression of BORIS was essential, it was not sufficient for high expression of TSP50 in cancer cells. Further studies showed that binding of BORIS to the target sites was methylation-independent but was diminished by nucleosomal occupancy consistent with the findings that high expression of TSP50 was associated with increased DNase I sensitivity and high BORIS occupancy of the promoter. These findings indicate that BORIS-induced expression of TSP50 is governed by accessibility and binding of BORIS to the promoter. To our knowledge this is the first report of regulated expression of one CTA by another to be validated in a physiological context.
C1 [Lobanenkov, Victor] NIAID, Mol Pathol Sect, Immunopathol Lab, NIH, Rockville, MD 20852 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of
   Allergy & Infectious Diseases (NIAID)
RP Lobanenkov, V (通讯作者)，NIAID, Mol Pathol Sect, Immunopathol Lab, NIH, Twinbrook 1,Rm 1417,MSC-8152,5640 Fishers Lane, Rockville, MD 20852 USA.
EM vlobanenkov@niaid.nih.gov
RI Lobanenkov, Victor/ABD-5710-2021; Pugacheva, Elena M./GNH-1756-2022
OI Morse, Herbert/0000-0002-9331-3705; Pugacheva, Elena
   M./0000-0001-9693-9853; Lobanenkov, Victor/0000-0001-6665-3635
FU National Institutes of Health of the NIAID; Japan Society for the
   Promotion of Science Research at the National Institutes of Health
FX This work was supported, in whole or in part, by the National Institutes
   of Health Intramural Research Program of the NIAID. This work was also
   supported by the Japan Society for the Promotion of Science Research
   Fellowship for Japanese Biomedical and Behavioral Researchers at the
   National Institutes of Health (to T. S.).
CR Akers SN, 2010, FUTURE ONCOL, V6, P717, DOI 10.2217/FON.10.36
   Amelio AL, 2006, J VIROL, V80, P2358, DOI 10.1128/JVI.80.5.2358-2368.2006
   Brenet F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014524
   Caballero OL, 2009, CANCER SCI, V100, P2014, DOI 10.1111/j.1349-7006.2009.01303.x
   Chau CM, 2006, J VIROL, V80, P5723, DOI 10.1128/JVI.00025-06
   De la Rosa-Velázquez IA, 2007, CANCER RES, V67, P2577, DOI 10.1158/0008-5472.CAN-06-2024
   Dougherty CJ, 2008, BIOCHEM BIOPH RES CO, V370, P109, DOI 10.1016/j.bbrc.2008.03.040
   Filippova GN, 2002, CANCER RES, V62, P48
   Filippova GN, 1996, MOL CELL BIOL, V16, P2802
   Filippova GN, 2001, NAT GENET, V28, P335, DOI 10.1038/ng570
   Fu YT, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000138
   Han L, 2008, MOL CELL BIOL, V28, P1124, DOI 10.1128/MCB.01361-07
   Hong JA, 2005, CANCER RES, V65, P7763, DOI 10.1158/0008-5472.CAN-05-0823
   Huang Y, 2008, BIOCHEM BIOPH RES CO, V374, P658, DOI 10.1016/j.bbrc.2008.07.087
   Jäger E, 2006, P NATL ACAD SCI USA, V103, P14453, DOI 10.1073/pnas.0606512103
   Jin CY, 2009, NAT GENET, V41, P941, DOI 10.1038/ng.409
   Kanduri C, 2000, CURR BIOL, V10, P853, DOI 10.1016/S0960-9822(00)00597-2
   Kim TH, 2007, CELL, V128, P1231, DOI 10.1016/j.cell.2006.12.048
   Kirkin AF, 2002, CANCER INVEST, V20, P222, DOI 10.1081/CNV-120001150
   Klenova EA, 2002, SEMIN CANCER BIOL, V12, P399, DOI 10.1016/S1044-579X(02)00060-3
   KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612
   Kurukuti S, 2006, P NATL ACAD SCI USA, V103, P10684, DOI 10.1073/pnas.0600326103
   Lam FH, 2008, NATURE, V453, P246, DOI 10.1038/nature06867
   Li T, 2008, MOL CELL BIOL, V28, P6473, DOI 10.1128/MCB.00204-08
   Libby RT, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000257
   LOBANENKOV VV, 1990, ONCOGENE, V5, P1743
   Looijenga LHJ, 2006, CANCER RES, V66, P290, DOI 10.1158/0008-5472.CAN-05-2936
   Loukinov DI, 2002, P NATL ACAD SCI USA, V99, P6806, DOI 10.1073/pnas.092123699
   Loukinov D, 2006, J CELL BIOCHEM, V98, P1037, DOI 10.1002/jcb.20953
   Lu Qianjin, 2004, Methods Mol Biol, V287, P77
   Marchand M, 1999, INT J CANCER, V80, P219, DOI 10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.3.CO;2-J
   Mkrtichyan M, 2008, GENE THER, V15, P61, DOI 10.1038/sj.gt.3303044
   Moon H, 2005, EMBO REP, V6, P165, DOI 10.1038/sj.embor.7400334
   Nativio R, 2011, HUM MOL GENET, V20, P1363, DOI 10.1093/hmg/ddr018
   Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6
   Ohlsson R, 2010, BIOESSAYS, V32, P37, DOI 10.1002/bies.200900118
   Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001
   Renaud S, 2005, NUCLEIC ACIDS RES, V33, P6850, DOI 10.1093/nar/gki989
   Smith IM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004961
   Soto-Reyes E, 2010, ONCOGENE, V29, P2217, DOI 10.1038/onc.2009.509
   Stedman W, 2008, EMBO J, V27, P654, DOI 10.1038/emboj.2008.1
   Suzuki T, 2010, MOL CELL BIOL, V30, P2473, DOI 10.1128/MCB.01093-09
   Vatolin S, 2005, CANCER RES, V65, P7751, DOI 10.1158/0008-5472.CAN-05-0858
   Vostrov AA, 1997, J BIOL CHEM, V272, P33353, DOI 10.1074/jbc.272.52.33353
   Wang M, 2008, DNA CELL BIOL, V27, P307, DOI 10.1089/dna.2007.0692
   Woloszynska-Read A, 2011, CLIN CANCER RES, V17, P2170, DOI 10.1158/1078-0432.CCR-10-2315
   Xu HP, 2007, CANCER RES, V67, P1239, DOI 10.1158/0008-5472.CAN-06-3688
   Yang YX, 1999, J NEUROCHEM, V73, P2286, DOI 10.1046/j.1471-4159.1999.0732286.x
   Yuan LM, 1999, CANCER RES, V59, P3215
   Zhou LA, 2010, IUBMB LIFE, V62, P825, DOI 10.1002/iub.390
NR 50
TC 31
Z9 36
U1 0
U2 9
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 5
PY 2011
VL 286
IS 31
BP 27378
EP 27388
DI 10.1074/jbc.M111.243576
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 799EZ
UT WOS:000293268700033
PM 21659515
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Chimonidou, M
   Strati, A
   Tzitzira, A
   Sotiropoulou, G
   Malamos, N
   Georgoulias, V
   Lianidou, ES
AF Chimonidou, Maria
   Strati, Areti
   Tzitzira, Alexandra
   Sotiropoulou, Georgia
   Malamos, Nikos
   Georgoulias, Vasilis
   Lianidou, Evi S.
TI DNA Methylation of Tumor Suppressor and Metastasis Suppressor Genes in
   Circulating Tumor Cells
SO CLINICAL CHEMISTRY
LA English
DT Article
ID BREAST-CANCER METASTASIS; CYSTEINE PROTEINASE-INHIBITOR; RESISTANT
   PROSTATE-CANCER; RNA-POSITIVE CELLS; CYSTATIN-M; PERIPHERAL-BLOOD;
   MOLECULAR-DETECTION; PROGNOSTIC VALUE; PROGRESSION; SURVIVAL
AB BACKGROUND: Circulating tumor cells (CTCs) are associated with prognosis in a variety of human cancers and have been proposed as a liquid biopsy for follow-up examinations. We show that tumor suppressor and metastasis suppressor genes are epigenetically silenced in CTCs isolated from peripheral blood of breast cancer patients.
   METHODS: We obtained peripheral blood from 56 patients with operable breast cancer, 27 patients with verified metastasis, and 23 healthy individuals. We tested DNA extracted from the EpCAM-positive immuno-magnetically selected CTC fraction for the presence of methylated and unmethylated CST6, BRMS1, and SOX17 promoter sequences by methylation-specific PCR (MSP). All samples were checked for KRT19 (keratin 19, formerly CK-19) expression by reverse-transcription quantitative PCR.
   RESULTS: In CTCs of patients with operable breast cancer, promoter methylation of CST6 was observed in 17.9%, BRMS1 in 32.1%, and SOX17 in 53.6% of patients. In CTCs of patients with verified metastasis, promoter methylation of CST6 was observed in 37.0%, BRMS1 in 44.4%, and SOX17 in 74.1%. In healthy individuals, promoter methylation of CST6 was observed in 4.3%, BRMS1 in 8.7%, and SOX17 in 4.3%. DNA methylation of these genes for both operable and metastatic breast cancer was significantly different from that of the control population.
   CONCLUSIONS: DNA methylation of tumor suppressor and metastasis suppressor genes is a hallmark of CTCs and confirms their heterogeneity. Our findings add a new dimension to the molecular characterization of CTCs and may underlie the acquisition of malignant properties, including their stem-like phenotype. (C) 2011 American Association for Clinical Chemistry
C1 [Chimonidou, Maria; Strati, Areti; Tzitzira, Alexandra; Lianidou, Evi S.] Univ Athens, Dept Chem, Athens 15771, Greece.
   [Sotiropoulou, Georgia] Univ Patras, Sch Hlth Sci, Dept Pharm, GR-26110 Patras, Greece.
   [Malamos, Nikos] Elena Venizelou Hosp, Med Oncol Unit, Athens, Greece.
   [Georgoulias, Vasilis] Univ Crete, Sch Med, Tumor Cell Biol Lab, Iraklion, Greece.
C3 National & Kapodistrian University of Athens; University of Patras;
   University of Crete
RP Lianidou, ES (通讯作者)，Univ Athens, Dept Chem, Athens 15771, Greece.
EM lianidou@chem.uoa.gr
RI Strati, Areti/AIE-5421-2022
OI Lianidou, Evi/0000-0002-7796-5914
FU Greek General Secretariat of Research and Technology [PENED 2003]; Greek
   Ministry of Health
FX Research grant of the Greek General Secretariat of Research and
   Technology (PENED 2003) and Research Grant on Oncology from the Greek
   Ministry of Health.
CR Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256
   Ai LB, 2006, CANCER RES, V66, P7899, DOI 10.1158/0008-5472.CAN-06-0576
   Braun S, 2005, NEW ENGL J MED, V353, P793, DOI 10.1056/NEJMoa050434
   Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239
   Cristofanilli M, 2005, J CLIN ONCOL, V23, P1420, DOI 10.1200/JCO.2005.08.140
   Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766
   de Bono JS, 2008, CLIN CANCER RES, V14, P6302, DOI 10.1158/1078-0432.CCR-08-0872
   Du YC, 2009, GASTROENTEROLOGY, V137, P1346, DOI 10.1053/j.gastro.2009.06.041
   Fu DY, 2010, BREAST CANCER RES TR, V119, P601, DOI 10.1007/s10549-009-0339-8
   Hedley BD, 2008, CLIN EXP METASTAS, V25, P727, DOI 10.1007/s10585-008-9184-0
   Hicks DG, 2006, CLIN CANCER RES, V12, P6702, DOI 10.1158/1078-0432.CCR-06-0635
   Hurst DR, 2009, CANCER RES, V69, P1279, DOI 10.1158/0008-5472.CAN-08-3559
   Ignatiadis M, 2008, CLIN CANCER RES, V14, P2593, DOI 10.1158/1078-0432.CCR-07-4758
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025
   Kioulafa M, 2009, INT J CANCER, V125, P2887, DOI 10.1002/ijc.24686
   Klein CA, 2009, NAT REV CANCER, V9, P302, DOI 10.1038/nrc2627
   Lange AW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005711
   Leung CT, 2009, CELL, V139, P1226, DOI 10.1016/j.cell.2009.12.013
   Markou A, 2011, CLIN CHEM, V57, P421, DOI 10.1373/clinchem.2010.154328
   Metge BJ, 2008, CLIN EXP METASTAS, V25, P753, DOI 10.1007/s10585-008-9187-x
   Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949
   Morris MR, 2010, ONCOGENE, V29, P2104, DOI 10.1038/onc.2009.493
   Nagji AS, 2010, J PATHOL, V221, P229, DOI 10.1002/path.2707
   Pantel K, 2009, NAT REV CLIN ONCOL, V6, P339, DOI 10.1038/nrclinonc.2009.44
   Phadke PA, 2008, AM J PATHOL, V172, P809, DOI 10.2353/ajpath.2008.070772
   Pulukuri SM, 2009, ONCOGENE, V28, P2829, DOI 10.1038/onc.2009.134
   Radpour R, 2009, ONCOGENE, V28, P2969, DOI 10.1038/onc.2009.149
   Rivenbark AG, 2006, LAB INVEST, V86, P1233, DOI 10.1038/labinvest.3700485
   Rodenhiser DI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2121
   Scher HI, 2009, LANCET ONCOL, V10, P233, DOI 10.1016/S1470-2045(08)70340-1
   Shridhar R, 2004, ONCOGENE, V23, P2206, DOI 10.1038/sj.onc.1207340
   Sotiropoulou G, 1997, J BIOL CHEM, V272, P903, DOI 10.1074/jbc.272.2.903
   Stathopoulou A, 2002, J CLIN ONCOL, V20, P3404, DOI 10.1200/JCO.2002.08.135
   Stathopoulou A, 2006, INT J CANCER, V119, P1654, DOI 10.1002/ijc.22017
   Stenman G, 1997, CYTOGENET CELL GENET, V76, P45, DOI 10.1159/000134512
   Vaidya KS, 2008, J BIOL CHEM, V283, P28354, DOI 10.1074/jbc.M710068200
   Xenidis N, 2009, J CLIN ONCOL, V27, P2177, DOI 10.1200/JCO.2008.18.0497
   Xenidis N, 2006, J CLIN ONCOL, V24, P3756, DOI 10.1200/JCO.2005.04.5948
   Zhang W, 2008, CANCER RES, V68, P2764, DOI 10.1158/0008-5472.CAN-07-6349
NR 40
TC 129
Z9 140
U1 0
U2 17
PU AMER ASSOC CLINICAL CHEMISTRY
PI WASHINGTON
PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA
SN 0009-9147
J9 CLIN CHEM
JI Clin. Chem.
PD AUG
PY 2011
VL 57
IS 8
BP 1169
EP 1177
DI 10.1373/clinchem.2011.165902
PG 9
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA 798PN
UT WOS:000293222900014
PM 21700955
OA Bronze
DA 2025-01-12
ER

PT J
AU Cortés-Sempere, M
   Ibanez de Cáceres, I
AF Cortes-Sempere, Maria
   Ibanez de Caceres, Inmaculada
TI microRNAs as novel epigenetic biomarkers for human cancer
SO CLINICAL & TRANSLATIONAL ONCOLOGY
LA English
DT Article
DE MicroRNA expression profile; Epigenetics; Tumour suppressor genes
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; TUMOR-SUPPRESSIVE MICRORNAS; DNA
   METHYLTRANSFERASES 3A; REGULATES CELL-SURVIVAL; ACUTE MYELOID-LEUKEMIA;
   HUMAN BREAST-CANCER; COLORECTAL-CANCER; LUNG-CANCER; EXPRESSION
   PROFILES; GASTRIC-CANCER
AB MicroRNAs (miRNAs) are regulatory, non-coding RNAs that are approximately 22 nucleotides in length. Nearly 1000 unique miRNAs encoded in the human genome have been identified, shedding new light on the post-transcriptional regulation of more than one-third of human genes. These miRNAs are involved in numerous biological processes, including development, differentiation, apoptosis, homeostasis and stem cell biology. Aberrant miRNA expression patterns also play a substantial role in carcinogenesis. It is believed that genetic and epigenetic regulation is responsible for changes in miRNA expression in cancer development, however the exact mechanisms remain unclear. miRNAs are involved in almost all aspects of cancer biology such as apoptosis, invasion, metastasis and angiogenesis. Thanks to this wide range of biological functions, the analysis of changes in overall miRNA expression occurring within human tumours has helped identify miRNA signatures associated with diagnosis, staging, progression, prognosis and response to treatment. This positions miRNA-targeting therapeutics as a novel and promising tool for cancer treatment.
C1 [Ibanez de Caceres, Inmaculada] Univ Hosp La Paz, IdiPAZ, FIB, Biomarkers & Expt Therapeut Grp, ES-28046 Madrid, Spain.
   [Cortes-Sempere, Maria] Inst Invest Biomed CSIC UAM, IdiPAZ, Madrid, Spain.
C3 Hospital Universitario La Paz; Consejo Superior de Investigaciones
   Cientificas (CSIC)
RP Ibanez de Cáceres, I (通讯作者)，Univ Hosp La Paz, IdiPAZ, FIB, Biomarkers & Expt Therapeut Grp, Paseo Castellana 261, ES-28046 Madrid, Spain.
EM inma.ibanezca@salud.madrid.org
RI IBANEZ DE CACERES, INMACULADA/F-4653-2016
OI IBANEZ DE CACERES, INMACULADA/0000-0001-9805-8486
FU Fondo de Investigacion Sanitaria (ISCIII) [CP 08/000689, PI-717];
   FIS/ISCIII [CP08/00068, PS09/00472]
FX J. Siegfried is gratefully acknowledged for the English correction of
   the manuscript. Ibanez de Caceres was partially supported by the Fondo
   de Investigacion Sanitaria (ISCIII) through the 'Miguel Servet' program
   (CP 08/000689; PI-717). Note: Supported by Health Investigation funding
   (FIS/ISCIII), Project numbers CP08/00068 and PS09/00472.
CR Agirre X, 2009, CANCER RES, V69, P4443, DOI 10.1158/0008-5472.CAN-08-4025
   Akao Y, 2006, ONCOL REP, V16, P845
   Ando T, 2009, INT J CANCER, V125, P2595, DOI 10.1002/ijc.24666
   Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242
   Balaguer F, 2010, CANCER RES, V70, P6609, DOI 10.1158/0008-5472.CAN-10-0622
   Blower PE, 2007, MOL CANCER THER, V6, P1483, DOI 10.1158/1535-7163.MCT-07-0009
   Brodersen P, 2009, NAT REV MOL CELL BIO, V10, P141, DOI 10.1038/nrm2619
   Bueno MJ, 2008, CANCER CELL, V13, P496, DOI 10.1016/j.ccr.2008.04.018
   Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Ceppi P, 2010, MOL CANCER RES, V8, P1207, DOI 10.1158/1541-7786.MCR-10-0052
   Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137
   Chen YX, 2007, CANCER RES, V67, P976, DOI 10.1158/0008-5472.CAN-06-3667
   Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102
   Corcoran DL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005279
   Craig VJ, 2011, CANCER RES, V71, P3616, DOI 10.1158/0008-5472.CAN-10-3907
   Ding L, 2010, CELL RES, V20, P784, DOI 10.1038/cr.2010.79
   Duursma AM, 2008, RNA, V14, P872, DOI 10.1261/rna.972008
   Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104
   Fish JE, 2008, DEV CELL, V15, P272, DOI 10.1016/j.devcel.2008.07.008
   Franco-Zorrilla JM, 2007, NAT GENET, V39, P1033, DOI 10.1038/ng2079
   Furuta M, 2010, CARCINOGENESIS, V31, P766, DOI 10.1093/carcin/bgp250
   Garzon R, 2009, BLOOD, V113, P6411, DOI 10.1182/blood-2008-07-170589
   Giovannetti E, 2010, CANCER RES, V70, P4528, DOI 10.1158/0008-5472.CAN-09-4467
   Grady WM, 2008, ONCOGENE, V27, P3880, DOI 10.1038/onc.2008.10
   He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552
   Hildebrandt MAT, 2010, ONCOGENE, V29, P5724, DOI 10.1038/onc.2010.305
   Hutvágner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961
   Hutvágner G, 2002, CURR OPIN GENET DEV, V12, P225, DOI 10.1016/S0959-437X(02)00290-3
   Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868
   Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014
   Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632
   Kong W, 2010, J BIOL CHEM, V285, P17869, DOI 10.1074/jbc.M110.101055
   Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200
   Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194
   Kuhnert F, 2008, DEVELOPMENT, V135, P3989, DOI 10.1242/dev.029736
   Landi MT, 2010, CLIN CANCER RES, V16, P430, DOI 10.1158/1078-0432.CCR-09-1736
   Lawrie CH, 2008, LEUKEMIA, V22, P1440, DOI 10.1038/sj.leu.2405083
   Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Li A, 2010, CANCER RES, V70, P5226, DOI 10.1158/0008-5472.CAN-09-4227
   Lim LP, 2003, SCIENCE, V299, P1540, DOI 10.1126/science.1080372
   Liu HF, 2010, MOL CANCER THER, V9, P1080, DOI 10.1158/1535-7163.MCT-09-0965
   Liu M, 2009, CELL RES, V19, P828, DOI 10.1038/cr.2009.72
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   Markou A, 2008, CLIN CHEM, V54, P1696, DOI 10.1373/clinchem.2007.101741
   Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999
   Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022
   Michael MZ, 2003, MOL CANCER RES, V1, P882
   Ng EKO, 2009, BRIT J CANCER, V101, P699, DOI 10.1038/sj.bjc.6605195
   O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677
   Peng Y, 2011, CURR CANCER RES, P267, DOI 10.1007/978-1-61737-995-6_13
   Pigazzi M, 2009, CANCER RES, V69, P2471, DOI 10.1158/0008-5472.CAN-08-3404
   Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533
   Ranade AR, 2010, J THORAC ONCOL, V5, P1273, DOI 10.1097/JTO.0b013e3181dea6be
   Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704
   Roman-Gomez J, 2009, J CLIN ONCOL, V27, P1316, DOI 10.1200/JCO.2008.19.3441
   Roth C, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2766
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Saito Y, 2009, BIOCHEM BIOPH RES CO, V379, P726, DOI 10.1016/j.bbrc.2008.12.098
   Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083
   SIEUWERTS AM, 2011, CLIN CANC RES
   Simonini PDR, 2010, CANCER RES, V70, P9175, DOI 10.1158/0008-5472.CAN-10-1318
   Slaby O, 2007, ONCOLOGY-BASEL, V72, P397, DOI 10.1159/000113489
   Smalheiser NR, 2005, TRENDS GENET, V21, P322, DOI 10.1016/j.tig.2005.04.008
   Suh SO, 2011, CARCINOGENESIS, V32, P772, DOI 10.1093/carcin/bgr036
   Suzuki H, 2010, CARCINOGENESIS, V31, P2066, DOI 10.1093/carcin/bgq203
   Szczyrba J, 2010, MOL CANCER RES, V8, P529, DOI 10.1158/1541-7786.MCR-09-0443
   Taby R, 2010, CA-CANCER J CLIN, V60, P376, DOI 10.3322/caac.20085
   Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637
   Tellez CS, 2011, CANCER RES, V71, P3087, DOI 10.1158/0008-5472.CAN-10-3035
   Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325
   Tsukamoto Y, 2010, CANCER RES, V70, P2339, DOI 10.1158/0008-5472.CAN-09-2777
   Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037
   Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461
   Yi R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803
   Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103
NR 82
TC 30
Z9 33
U1 0
U2 7
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1699-048X
EI 1699-3055
J9 CLIN TRANSL ONCOL
JI Clin. Transl. Oncol.
PD JUN
PY 2011
VL 13
IS 6
BP 357
EP 362
DI 10.1007/s12094-011-0668-z
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 799PX
UT WOS:000293299700003
PM 21680295
DA 2025-01-12
ER

PT J
AU Yoshida, M
   Ishimura, A
   Terashima, M
   Enkhbaatar, Z
   Nozaki, N
   Satou, K
   Suzuki, T
AF Yoshida, Masakazu
   Ishimura, Akihiko
   Terashima, Minoru
   Enkhbaatar, Zanabazar
   Nozaki, Naohito
   Satou, Kenji
   Suzuki, Takeshi
TI PLU1 histone demethylase decreases the expression of KAT5 and enhances
   the invasive activity of the cells
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE cancer progression; cell invasion; histone demethylase; Jumonji C domain
   (JmjC domain); transcription
ID METASTASIS SUPPRESSOR GENE; GROUP PROTEIN EZH2; BREAST-CANCER; TIP60;
   METHYLATION; MARKER; KAI1; PROGRESSION; REPRESSION; GROWTH
AB PLU1 is a candidate oncogene that encodes H3K4 (Lys(4) of histone H3) demethylase. In the present study, we found that ectopic expression of PLU1 enhanced the invasive potential of the weakly invasive cells dependent on its demethylase activity. PLU1 was shown to repress the expression of the KAT5 gene through its H3K4 demethylation on the promoter. The regulation of KAT5 by PLU1 was suggested to be responsible for PLU1-induced cell invasion. First, knockdown of KAT5 similarly increased the invasive potential of the cells. Secondly, knockdown of PLU1 in the highly invasive cancer cells increased KAT5 expression and reduced the invasive activity. Thirdly, simultaneous knockdown of KAT5 partially relieved the suppression of cell invasion imposed by PLU1 knockdown. Finally, we found that CD82, which was transcriptionally regulated by KAT5, might be a candidate effector of cell invasion promoted by PLU1. The present study demonstrated a functional contribution of PLU1 overexpression with concomitant epigenetic dysregulation in cancer progression.
C1 [Yoshida, Masakazu; Ishimura, Akihiko; Terashima, Minoru; Enkhbaatar, Zanabazar; Suzuki, Takeshi] Kanazawa Univ, Div Funct Genom, Canc Res Inst, Kanazawa, Ishikawa 9201192, Japan.
   [Yoshida, Masakazu; Satou, Kenji] Kanazawa Univ, Div Elect Engn & Comp Sci, Grad Sch Nat Sci & Technol, Kanazawa, Ishikawa 9201192, Japan.
   [Nozaki, Naohito] Tokyo Inst Technol, Biofrontier Res Ctr, Kanagawa 2268503, Japan.
C3 Kanazawa University; Kanazawa University; Institute of Science Tokyo;
   Tokyo Institute of Technology
RP Suzuki, T (通讯作者)，Kanazawa Univ, Div Funct Genom, Canc Res Inst, Kanazawa, Ishikawa 9201192, Japan.
EM suzuki-t@staff.kanazawa-u.ac.jp
RI SUZUKI, Takeshi/D-8456-2015; ISHIMURA, Akihiko/D-8434-2015; Terashima,
   Minoru/D-8462-2015; Satou, Kenji/C-3316-2015
OI Suzuki, Takeshi/0000-0002-1737-0900; Satou, Kenji/0000-0001-5474-7087
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [21590303, 21022018]; Grants-in-Aid for Scientific Research [23790220,
   21590303, 21022018] Funding Source: KAKEN
FX This work was supported in part by Grants-in-Aid for Scientific Research
   C [grant number 21590303 (to T.S.)] and Science Research for Priority
   Areas [grant number 21022018 (to T.S.)] from the Ministry of Education,
   Culture, Sports, Science and Technology of Japan.
CR Barrett A, 2002, INT J CANCER, V101, P581, DOI 10.1002/ijc.10644
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001
   Bhaumik SR, 2007, NAT STRUCT MOL BIOL, V14, P1008, DOI 10.1038/nsmb1337
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Chen MW, 2010, CANCER RES, V70, P7830, DOI 10.1158/0008-5472.CAN-10-0833
   Christensen J, 2007, CELL, V128, P1063, DOI 10.1016/j.cell.2007.02.003
   Cloos PAC, 2008, GENE DEV, V22, P1115, DOI 10.1101/gad.1652908
   DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374
   Ellinger J, 2010, INT J CANCER, V127, P2360, DOI 10.1002/ijc.25250
   Gorrini C, 2007, NATURE, V448, P1063, DOI 10.1038/nature06055
   Hayami S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-59
   Ishimura A, 2009, BIOCHEM BIOPH RES CO, V389, P366, DOI 10.1016/j.bbrc.2009.08.155
   Iwase S, 2007, CELL, V128, P1077, DOI 10.1016/j.cell.2007.02.017
   Kim JH, 2005, NATURE, V434, P921, DOI 10.1038/nature03452
   Kimura H, 2008, CELL STRUCT FUNCT, V33, P61, DOI 10.1247/csf.07035
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Klose RJ, 2007, NAT REV MOL CELL BIO, V8, P307, DOI 10.1038/nrm2143
   Lim S, 2010, INT J CANCER, V127, P1991, DOI 10.1002/ijc.25538
   Lleonart ME, 2006, ONCOL REP, V16, P603
   Lu PJ, 1999, J BIOL CHEM, V274, P15633, DOI 10.1074/jbc.274.22.15633
   Miranti CK, 2009, CELL SIGNAL, V21, P196, DOI 10.1016/j.cellsig.2008.08.023
   Mosammaparast N, 2010, ANNU REV BIOCHEM, V79, P155, DOI 10.1146/annurev.biochem.78.070907.103946
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Sakuraba K, 2009, ANTICANCER RES, V29, P3953
   Scibetta AG, 2007, MOL CELL BIOL, V27, P7220, DOI 10.1128/MCB.00274-07
   Squatrito M, 2006, TRENDS CELL BIOL, V16, P433, DOI 10.1016/j.tcb.2006.07.007
   Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949
   Suzuki T, 2006, EMBO J, V25, P3422, DOI 10.1038/sj.emboj.7601215
   Terashima M, 2010, BIOCHEM BIOPH RES CO, V399, P238, DOI 10.1016/j.bbrc.2010.07.061
   Tsuchihara K, 2009, NUCLEIC ACIDS RES, V37, P2249, DOI 10.1093/nar/gkp066
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Xiang Y, 2007, P NATL ACAD SCI USA, V104, P19226, DOI 10.1073/pnas.0700735104
   Yamane K, 2007, MOL CELL, V25, P801, DOI 10.1016/j.molcel.2007.03.001
   Yang XH, 2000, CLIN CANCER RES, V6, P3424
   Yang XH, 1997, CANCER LETT, V119, P149, DOI 10.1016/S0304-3835(97)00273-5
NR 36
TC 21
Z9 25
U1 0
U2 6
PU PORTLAND PRESS LTD
PI LONDON
PA 5TH FLR, 90 HIGH HOLBORN, LONDON WC1V 6LJ, ENGLAND
SN 0264-6021
EI 1470-8728
J9 BIOCHEM J
JI Biochem. J.
PD AUG 1
PY 2011
VL 437
BP 555
EP 564
DI 10.1042/BJ20110343
PN 3
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 803VP
UT WOS:000293610400021
PM 21574959
DA 2025-01-12
ER

PT J
AU Kundakovic, M
   Champagne, FA
AF Kundakovic, Marija
   Champagne, Frances A.
TI Epigenetic perspective on the developmental effects of bisphenol A
SO BRAIN BEHAVIOR AND IMMUNITY
LA English
DT Article
DE Bisphenol A; DNA methylation; Gene expression; Epigenome; Estrogen
   receptor; Brain development; Behavior; Immune; Endocrine disruptor;
   Transgenerational
ID ESTROGEN-RECEPTOR-ALPHA; PERINATAL EXPOSURE; DNA METHYLATION;
   SEXUAL-DIFFERENTIATION; ENDOCRINE DISRUPTORS; TRANSGENERATIONAL ACTIONS;
   SOCIOSEXUAL BEHAVIOR; PRENATAL EXPOSURE; FETAL EXPOSURE; BREAST-CANCER
AB Bisphenol A (BPA) is an estrogenic environmental toxin widely used in the production of plastics and ubiquitous human exposure to this chemical has been proposed to be a potential risk to public health. Animal studies suggest that in utero and early postnatal exposure to this compound may produce a broad range of adverse effects, including impaired brain development, sexual differentiation, behavior, and immune function, which could extend to future generations. Molecular mechanisms that underlie the long-lasting effects of BPA continue to be elucidated, and likely involve disruption of epigenetic programming of gene expression during development. Several studies have provided evidence that maternal exposure to BPA results in postnatal changes in DNA methylation status and altered expression of specific genes in offspring. However, further studies are needed to extend these initial findings to other genes in different tissues, and to examine the correlations between BPA-induced epigenetic alterations, changes in gene expression, and various phenotypic outcomes. It will be also important to explore whether the epigenetic effects of BPA are related to its estrogenic activity, and to determine which downstream effector proteins could mediate changes in DNA methylation. In this review, we will highlight research indicating a consequence of prenatal BPA exposure for brain, behavior, and immune outcomes and discuss evidence for the role of epigenetic pathways in shaping these developmental effects. Based on this evidence, we will suggest future directions in the study of BPA-induced epigenetic effects and discuss the transgenerational implications of exposure to endocrine disrupting chemicals. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Kundakovic, Marija; Champagne, Frances A.] Columbia Univ, Dept Psychol, New York, NY 10027 USA.
C3 Columbia University
RP Champagne, FA (通讯作者)，Columbia Univ, Dept Psychol, 1190 Amsterdam Ave,Room 406,Schermerhorn Hall, New York, NY 10027 USA.
EM fac2105@columbia.edu
RI Kundakovic, Marija/GQH-6026-2022; Champagne, Frances Anne/Q-1220-2018
OI Champagne, Frances Anne/0000-0002-3922-084X; Kundakovic,
   Marija/0000-0002-6734-4217
FU National Institutes of Health [DP2OD001674]; NIEHS [5P01ES09600]; US EPA
   [RD834509]; Trustees of the Blanchette Hooker Rockefeller Fund; Gladys
   and Roland Harriman Foundation
FX This research was supported by Grant Number DP2OD001674 from the Office
   of the Director, National Institutes of Health and by the NIEHS (grant
   5P01ES09600), US EPA (grant RD834509), Trustees of the Blanchette Hooker
   Rockefeller Fund, and the Gladys and Roland Harriman Foundation.
CR Adriani W, 2003, ENVIRON HEALTH PERSP, V111, P395, DOI 10.1289/ehp.5856
   Alizadeh M, 2006, J MED INVESTIG, V53, P70, DOI 10.2152/jmi.53.70
   Alworth LC, 2002, TOXICOL APPL PHARM, V183, P10, DOI 10.1006/taap.2002.9459
   Andersen HR, 1999, ENVIRON HEALTH PERSP, V107, P89, DOI 10.2307/3434476
   Anway MD, 2006, ENDOCRINOLOGY, V147, P5515, DOI 10.1210/en.2006-0640
   Anway MD, 2006, ENDOCRINOLOGY, V147, pS43, DOI 10.1210/en.2005-1058
   Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190
   Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   Bernal AJ, 2010, BIRTH DEFECTS RES A, V88, P938, DOI 10.1002/bdra.20685
   Biddie SC, 2011, J NEUROENDOCRINOL, V23, P94, DOI 10.1111/j.1365-2826.2010.02079.x
   Biedermann S, 2010, ANAL BIOANAL CHEM, V398, P571, DOI 10.1007/s00216-010-3936-9
   Braun JM, 2009, ENVIRON HEALTH PERSP, V117, P1945, DOI 10.1289/ehp.0900979
   Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533
   Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391, DOI 10.1289/ehp.7534
   Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753
   Champagne FA, 2006, ENDOCRINOLOGY, V147, P2909, DOI 10.1210/en.2005-1119
   Champagne FA, 2008, CURR OPIN PHARMACOL, V8, P735, DOI 10.1016/j.coph.2008.06.018
   Chapin RE, 2008, BIRTH DEFECTS RES B, V83, P157, DOI 10.1002/bdrb.20147
   Clayton EMR, 2011, ENVIRON HEALTH PERSP, V119, P390, DOI 10.1289/ehp.1002883
   Cohn BA, 2007, ENVIRON HEALTH PERSP, V115, P1406, DOI 10.1289/ehp.10260
   Cooney CA, 2002, J NUTR, V132, p2393S
   Cox KH, 2010, HORM BEHAV, V58, P754, DOI 10.1016/j.yhbeh.2010.07.008
   Cummings AM, 1997, CRIT REV TOXICOL, V27, P367, DOI 10.3109/10408449709089899
   Dessì-Fulgheri F, 2002, ENVIRON HEALTH PERSP, V110, P403, DOI 10.1289/ehp.02110s3403
   Doherty Leo F., 2010, Hormones & Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9
   Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104
   Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700
   Farabollino F, 2002, ENVIRON HEALTH PERSP, V110, P409, DOI 10.1289/ehp.02110s3409
   Feng SH, 2010, SCIENCE, V330, P622, DOI 10.1126/science.1190614
   Fisher JS, 2004, REPRODUCTION, V127, P305, DOI 10.1530/rep.1.00025
   Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002
   Funabashi T, 2004, PSYCHONEUROENDOCRINO, V29, P475, DOI 10.1016/S0306-4530(03)00055-6
   Gioiosa L, 2007, HORM BEHAV, V52, P307, DOI 10.1016/j.yhbeh.2007.05.006
   Golebiewska A, 2009, STEM CELLS, V27, P1298, DOI 10.1002/stem.59
   Gore AC, 2008, FRONT NEUROENDOCRIN, V29, P358, DOI 10.1016/j.yfrne.2008.02.002
   Goto M, 2007, BIOSCI BIOTECH BIOCH, V71, P2136, DOI 10.1271/bbb.70004
   Gould JC, 1998, MOL CELL ENDOCRINOL, V142, P203, DOI 10.1016/S0303-7207(98)00084-7
   Guerrero-Bosagna C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013100
   Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516
   Igarashi A, 2006, BIOL PHARM BULL, V29, P2120, DOI 10.1248/bpb.29.2120
   Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839
   Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045
   Kavlock R, 2005, CRIT REV TOXICOL, V35, P721, DOI 10.1080/10408440591007377
   Kawai K, 2003, ENVIRON HEALTH PERSP, V111, P175, DOI 10.1289/ehp.5440
   Kawai K, 2007, REGUL TOXICOL PHARM, V47, P166, DOI 10.1016/j.yrtph.2006.04.002
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   Kubo K, 2003, NEUROSCI RES, V45, P345, DOI 10.1016/S0168-0102(02)00251-1
   Kubo K, 2001, NEUROSCI LETT, V304, P73, DOI 10.1016/S0304-3940(01)01760-8
   Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252
   Kwack SJ, 2009, J TOXICOL ENV HEAL A, V72, P1254, DOI 10.1080/15287390903212212
   Lange UC, 2010, BIOESSAYS, V32, P659, DOI 10.1002/bies.201000030
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Li SF, 1997, CANCER RES, V57, P4356
   Liu J, 2010, TRENDS NEUROSCI, V33, P193, DOI 10.1016/j.tins.2010.01.007
   McLachlan JA, 2001, ENDOCR REV, V22, P319, DOI 10.1210/er.22.3.319
   Métivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544
   Miao S, 2008, J TOXICOL ENV HEAL A, V71, P1000, DOI 10.1080/15287390801907467
   Miller FD, 2007, NEURON, V54, P357, DOI 10.1016/j.neuron.2007.04.019
   Mills PK, 2006, J ENVIRON HEALTH, V68, P15
   Nakamura K, 2007, NEUROSCI LETT, V420, P100, DOI 10.1016/j.neulet.2007.02.093
   Nakamura K, 2006, J NEUROSCI RES, V84, P1197, DOI 10.1002/jnr.21020
   Negishi T, 2004, ENVIRON HEALTH PERSP, V112, P1159, DOI 10.1289/ehp.6961
   Newbold RR, 2000, CARCINOGENESIS, V21, P1355, DOI 10.1093/carcin/21.7.1355
   Newbold RR, 1998, CARCINOGENESIS, V19, P1655, DOI 10.1093/carcin/19.9.1655
   Palanza P, 2002, ENVIRON HEALTH PERSP, V110, P415, DOI 10.1289/ehp.02110s3415
   Patisaul HB, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.010.2009
   Porrini S, 2005, BRAIN RES BULL, V65, P261, DOI 10.1016/j.brainresbull.2004.11.014
   Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443
   Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918
   Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004
   Rosenfeld CS, 2010, BIOL REPROD, V82, P473, DOI 10.1095/biolreprod.109.080952
   Rubin BS, 2006, ENDOCRINOLOGY, V147, P3681, DOI 10.1210/en.2006-0189
   Schönfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703, DOI 10.1289/ehp.021100703
   Smith CC, 2007, FASEB J, V21, P239, DOI 10.1096/fj.06-6635com
   Sohoni P, 1998, J ENDOCRINOL, V158, P327, DOI 10.1677/joe.0.1580327
   Stanisic V, 2010, PROG BRAIN RES, V181, P153, DOI 10.1016/S0079-6123(08)81009-6
   Takayanagi S, 2006, TOXICOL LETT, V167, P95, DOI 10.1016/j.toxlet.2006.08.012
   Tando S, 2007, BRAIN DEV-JPN, V29, P352, DOI 10.1016/j.braindev.2006.10.003
   Taylor JA, 2008, REPROD TOXICOL, V25, P169, DOI 10.1016/j.reprotox.2008.01.001
   Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716
   Veurink M, 2005, PHARM WORLD SCI, V27, P139, DOI 10.1007/s11096-005-3663-z
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   vom Saal FS, 2006, ENVIRON RES, V100, P50, DOI 10.1016/j.envres.2005.09.001
   vom Saal FS, 2005, ENVIRON HEALTH PERSP, V113, P926, DOI 10.1289/ehp.7713
   Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159
   Westberry JM, 2010, ENDOCRINOLOGY, V151, P731, DOI 10.1210/en.2009-0955
   Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010
   Xu LC, 2005, TOXICOLOGY, V216, P197, DOI 10.1016/j.tox.2005.08.006
   Xu XH, 2010, HORM BEHAV, V58, P326, DOI 10.1016/j.yhbeh.2010.02.012
   Yan HM, 2008, ENVIRON HEALTH PERSP, V116, P514, DOI 10.1289/ehp.10829
   Yaoi T, 2008, BIOCHEM BIOPH RES CO, V376, P563, DOI 10.1016/j.bbrc.2008.09.028
   Yoshino S, 2003, BRIT J PHARMACOL, V138, P1271, DOI 10.1038/sj.bjp.0705166
   Zhao ZR, 2010, P NATL ACAD SCI USA, V107, P5605, DOI 10.1073/pnas.0910578107
   Zhu ZY, 2009, ENVIRON HEALTH PERSP, V117, P928, DOI 10.1289/ehp.0800109
NR 94
TC 184
Z9 216
U1 0
U2 62
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0889-1591
EI 1090-2139
J9 BRAIN BEHAV IMMUN
JI Brain Behav. Immun.
PD AUG
PY 2011
VL 25
IS 6
BP 1084
EP 1093
DI 10.1016/j.bbi.2011.02.005
PG 10
WC Immunology; Neurosciences; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Neurosciences & Neurology; Psychiatry
GA 799SI
UT WOS:000293306000005
PM 21333735
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Martins, AT
   Monteiro, P
   Ramalho-Carvalho, J
   Costa, VL
   Dinis-Ribeiro, M
   Leal, C
   Henrique, R
   Jerónimo, C
AF Martins, Ana Teresa
   Monteiro, Paula
   Ramalho-Carvalho, Joao
   Costa, Vera L.
   Dinis-Ribeiro, Mario
   Leal, Conceicao
   Henrique, Rui
   Jeronimo, Carmen
TI High RASSF1A promoter methylation levels are predictive of poor
   prognosis in fine-needle aspirate washings of breast cancer lesions
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer; Quantitative DNA methylation; Epigenetic profile;
   Fine-needle aspirates; Prognosis
ID PROSTATE-CANCER; DNA METHYLATION; HYPERMETHYLATION; GENE; TUMOR;
   EPIGENOMICS; EPIGENETICS; BENIGN; MARKER; SERUM
AB Previously, we reported that the accuracy of cytological diagnosis of breast lesions could be augmented through the quantitative assessment of DNA methylation of fine-needle aspirate (FNA) washings. Herein, we aimed at the evaluation of the prognostic value of quantitative promoter methylation at three gene loci (APC, CCND2, and RASSF1A) in a large series of FNA washings from breast lesions. Methylation levels of three gene promoters were assessed by quantitative methylation-specific PCR in bisulfite-modified DNA from 211 FNA washings, comprising 178 carcinomas and 33 benign lesions, both histopathologically confirmed. Receiver operator characteristic (ROC) curve analysis was used to determine the diagnostic performance of the gene panel in distinguishing cancer from non-cancerous lesions. Relevant clinicopathologic data and time to progression and/or death from breast cancer were correlated with methylation findings. Log-rank test and Cox-regression model identified independent predictors of prognosis. APC, CCND2, and RASSF1A methylation levels differed significantly between malignant and benign lesions. ROC curve analysis confirmed the diagnostic performance of the gene panel. In univariate analysis, stage was significantly associated with overall, disease-specific and disease-free survival, whereas tumor grade was associated with disease-specific and disease-free survival. Remarkably, RASSF1A methylation was significantly and independently associated with worse disease-free survival in the final multivariate analysis. We confirmed that quantitative gene promoter methylation augments the diagnostic performance of cytopathology. Importantly, and in addition to standard clinicopathologic parameters, RASSF1A high-methylation levels are independent predictors of worse outcome in breast cancer. Thus, epigenetic biomarkers provide valuable tools for breast cancer patient management.
C1 [Ramalho-Carvalho, Joao; Costa, Vera L.; Jeronimo, Carmen] Portuguese Oncol Inst, Dept Genet, P-4200072 Oporto, Portugal.
   [Martins, Ana Teresa; Ramalho-Carvalho, Joao; Costa, Vera L.; Henrique, Rui; Jeronimo, Carmen] Portuguese Oncol Inst, Canc Epigenet Grp, Res Ctr, P-4200072 Oporto, Portugal.
   [Martins, Ana Teresa; Monteiro, Paula; Leal, Conceicao; Henrique, Rui] Portuguese Oncol Inst, Dept Pathol, P-4200072 Oporto, Portugal.
   [Dinis-Ribeiro, Mario] Portuguese Oncol Inst, Dept Gastroenterol, P-4200072 Oporto, Portugal.
   [Dinis-Ribeiro, Mario] Univ Porto, Dept Biostat & Med Informat, Fac Med, P-4100 Oporto, Portugal.
   [Henrique, Rui; Jeronimo, Carmen] Univ Porto, Dept Pathol & Mol Immunol, Inst Biomed Sci Abel Salazar ICBAS, P-4100 Oporto, Portugal.
C3 Portuguese Institute of Oncology; Portuguese Institute of Oncology;
   Portuguese Institute of Oncology; Portuguese Institute of Oncology;
   Universidade do Porto; Universidade do Porto
RP Jerónimo, C (通讯作者)，Portuguese Oncol Inst, Dept Genet, Rua Dr Antonio Bernardino de Almeida, P-4200072 Oporto, Portugal.
EM carmenjeronimo@ipoporto.min-saude.pt
RI Martins, Ana Teresa/JXN-9546-2024; Henrique, Rui/I-2757-2013;
   Dinis-Ribeiro, Mario/A-9248-2010; Jeronimo, Carmen/H-3284-2013; ,
   CINTESIS/C-6631-2014; Ramalho-Carvalho, Joao/U-2356-2017
OI Henrique, Rui/0000-0003-3171-4666; Dinis-Ribeiro,
   Mario/0000-0003-0121-6850; Jeronimo, Carmen/0000-0003-4186-5345; ,
   CINTESIS/0000-0001-7248-2086; Ramalho-Carvalho, Joao/0000-0001-6140-7363
FU Fundacao para a Ciencia e a Tecnologia [SFRH/BD/23374/2005]; Liga
   Portuguesa contra o Cancro-Nucleo Regional do Norte; Comissao de Fomento
   da Investigacao em Cuidados de Saude-Ministerio da Saude [21/2007];
   Fundação para a Ciência e a Tecnologia [SFRH/BD/23374/2005] Funding
   Source: FCT
FX V. L. C is supported by a grant from Fundacao para a Ciencia e a
   Tecnologia (SFRH/BD/23374/2005). This study was funded by grants from
   Liga Portuguesa contra o Cancro-Nucleo Regional do Norte and the
   Comissao de Fomento da Investigacao em Cuidados de Saude-Ministerio da
   Saude (Project no. 21/2007).
CR Bardou VJ, 2003, J CLIN ONCOL, V21, P1973, DOI 10.1200/JCO.2003.09.099
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Elston CW, 1998, ASSESSMENT HISTOLOGI, V3rd
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Euhus DM, 2008, CANCER EPIDEM BIOMAR, V17, P1051, DOI 10.1158/1055-9965.EPI-07-2582
   Ferlay J, 2010, EUR J CANCER, V46, P765, DOI 10.1016/j.ejca.2009.12.014
   Greene F., 2002, AJCC cancer staging handbook: From the AJCC cancer staging manual, V6th
   Hamill J, 2002, ACTA CYTOL, V46, P19, DOI 10.1159/000326710
   Henrique R, 2007, CLIN CANCER RES, V13, P6122, DOI 10.1158/1078-0432.CCR-07-1042
   Hinshelwood RA, 2008, J MOL MED, V86, P1315, DOI 10.1007/s00109-008-0386-3
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Jerónimo C, 2004, CLIN CANCER RES, V10, P4010, DOI 10.1158/1078-0432.CCR-03-0643
   Jerónimo C, 2003, CLIN CANCER RES, V9, P3413
   Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Liu JW, 2008, PROSTATE, V68, P418, DOI 10.1002/pros.20709
   Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879
   Müller HM, 2003, CANCER RES, V63, P7641
   Nemec CF, 2007, CLEV CLIN J MED, V74, P897, DOI 10.3949/ccjm.74.12.897
   Page DL, 1987, INFILTRATING CARCINO
   Pu RT, 2003, MODERN PATHOL, V16, P1095, DOI 10.1097/01.MP.0000095782.79895.E2
   Van der Auwera I, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-97
NR 26
TC 28
Z9 33
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD AUG
PY 2011
VL 129
IS 1
BP 1
EP 9
DI 10.1007/s10549-010-1160-0
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 794EQ
UT WOS:000292878700001
PM 20842524
DA 2025-01-12
ER

PT J
AU Weakley, SM
   Wang, H
   Yao, QZ
   Chen, CY
AF Weakley, Sarah M.
   Wang, Hao
   Yao, Qizhi
   Chen, Changyi
TI Expression and Function of a Large Non-coding RNA Gene XIST in Human
   Cancer
SO WORLD JOURNAL OF SURGERY
LA English
DT Article
ID INACTIVE X-CHROMOSOME; GERM-CELL TUMORS; BREAST-CANCER;
   KLINEFELTER-SYNDROME; OVARIAN-CANCER; SEX CHROMATIN; BRCA1;
   HETEROCHROMATIN; REPLICATION; METHYLATION
AB Background X inactive-specific transcript (XIST) RNA is involved in X chromosome silencing in female cells and allows X chromosome equilibration with males. X inactive-specific transcript expression has been found to be dysregulated in a variety of human cancers when compared to normal cells; meanwhile, the inactivated X chromosome has been noted to be conspicuously absent in human cancer specimens, whereas X chromosome duplications are widely noted. The specific pathways whereby changes in X chromosome status and XIST expression occur in cancer remain incompletely described. Nevertheless, a role for XIST in BRCA1-mediated epigenetic activity has been proposed.
   Methods Here we review the data regarding XIST expression and X chromosome status in a variety of female, male, and non-sex-related human cancers.
   Conclusions It is not yet known whether X chromosome duplication, XIST dysregulation, and over-expression of X-linked genes represent important factors in tumorgenesis or are simply a consequence of overall epigenetic instability in these cancers.
C1 [Weakley, Sarah M.; Wang, Hao; Yao, Qizhi; Chen, Changyi] Baylor Coll Med, Mol Surg Res Ctr, Michael E DeBakey Dept Surg, Houston, TX 77030 USA.
C3 Baylor College of Medicine
RP Chen, CY (通讯作者)，Baylor Coll Med, Mol Surg Res Ctr, Michael E DeBakey Dept Surg, 1 Baylor Plaza,Mail Stop BCM391, Houston, TX 77030 USA.
EM jchen@bcm.tmc.edu
RI Wang, Weiyi/GZN-0408-2022
FU St. Luke's Episcopal Hospital, Houston, Texas [09RDM006, 09RDM007]; Dan
   L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas
   [09-10]; National Institutes of Health [NIHR21CA140828, T32HL083774]
FX This work was supported in part by MacDonald General Research Fund
   Awards (09RDM006 and 09RDM007) from St. Luke's Episcopal Hospital,
   Houston, Texas; Duncan Inter and Intra Programmatic Pilot Project
   (#09-10) from the Dan L. Duncan Cancer Center, Baylor College of
   Medicine, Houston, Texas; and National Institutes of Health grant
   NIHR21CA140828 (Yao Q). S.M.W. was supported by NIH training grant
   T32HL083774.
CR Agrelo R, 2009, DEV CELL, V16, P507, DOI 10.1016/j.devcel.2009.03.006
   Ayoub N, 1997, CHROMOSOMA, V106, P1, DOI 10.1007/s004120050218
   BARR ML, 1949, NATURE, V163, P676, DOI 10.1038/163676a0
   Benoît MH, 2007, INT J ONCOL, V30, P5
   BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0
   Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8
   Ganesan S, 2004, PHILOS T R SOC B, V359, P123, DOI 10.1098/rstb.2003.1371
   Hall LL, 2002, P NATL ACAD SCI USA, V99, P8677, DOI 10.1073/pnas.132468999
   Huang KC, 2002, MOL CANCER THER, V1, P769
   Kawakami T, 2004, LANCET, V363, P40, DOI 10.1016/S0140-6736(03)15170-7
   Kawakami T, 2004, ONCOGENE, V23, P6163, DOI 10.1038/sj.onc.1207808
   Kawakami T, 2003, J UROLOGY, V169, P1546, DOI 10.1097/01.ju.0000044927.23323.5a
   KLEINHEINZ A, 1994, ANDROLOGIA, V26, P127
   Lassmann S, 2007, J MOL MED-JMM, V85, P289, DOI 10.1007/s00109-006-0126-5
   Looijenga LHJ, 1997, AM J PATHOL, V151, P581
   LYON MF, 1962, AM J HUM GENET, V14, P135
   LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0
   McCarrey JR, 2002, GENESIS, V34, P257, DOI 10.1002/gene.10163
   McDonald HL, 2000, GENE CHROMOSOME CANC, V28, P246, DOI 10.1002/1098-2264(200007)28:3<246::AID-GCC2>3.3.CO;2-S
   MOORE KL, 1957, BRIT J CANCER, V11, P384, DOI 10.1038/bjc.1957.45
   Nomura S, 2004, GASTROENTEROLOGY, V127, P582, DOI 10.1053/j.gastro.2004.05.029
   Pageau GJ, 2007, NAT REV CANCER, V7, P628, DOI 10.1038/nrc2172
   Pageau GJ, 2007, J CELL BIOCHEM, V100, P835, DOI 10.1002/jcb.21188
   Pageau GJ, 2006, J CELL BIOL, V175, P693, DOI 10.1083/jcb.200602055
   Perez DS, 2008, HUM MOL GENET, V17, P642, DOI 10.1093/hmg/ddm336
   RACK KA, 1994, HUM MOL GENET, V3, P1053, DOI 10.1093/hmg/3.7.1053
   Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013
   RICHLER C, 1992, NAT GENET, V2, P192, DOI 10.1038/ng1192-192
   Rudas M, 2000, CANCER GENET CYTOGEN, V121, P190, DOI 10.1016/S0165-4608(00)00254-5
   Shi ZQ, 2010, INT J CANCER, V127, P2334, DOI 10.1002/ijc.25222
   Silver DP, 2007, CELL, V128, P991, DOI 10.1016/j.cell.2007.02.025
   Sirchia SM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005559
   Sirchia SM, 2005, CANCER RES, V65, P2139, DOI 10.1158/0008-5472.CAN-04-3465
   Song MA, 2007, ELECTROPHORESIS, V28, P2379, DOI 10.1002/elps.200600852
   Spatz A, 2004, NAT REV CANCER, V4, P617, DOI 10.1038/nrc1413
   Swerdlow AJ, 2005, J NATL CANCER I, V97, P1204, DOI 10.1093/jnci/dji240
   Teixeira MR, 1998, GENE CHROMOSOME CANC, V23, P16, DOI 10.1002/(SICI)1098-2264(199809)23:1<16::AID-GCC3>3.0.CO;2-9
   Vincent-Salomon A, 2007, CANCER RES, V67, P5134, DOI 10.1158/0008-5472.CAN-07-0465
   Wu ZS, 2009, BJU INT, V103, P1721, DOI 10.1111/j.1464-410X.2008.08290.x
   Xiao CY, 2007, CELL, V128, P977, DOI 10.1016/j.cell.2007.01.034
   Zhang C, 2005, GENE CHROMOSOME CANC, V43, P104, DOI 10.1002/gcc.20160
NR 41
TC 122
Z9 139
U1 0
U2 16
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364-2313
EI 1432-2323
J9 WORLD J SURG
JI World J.Surg.
PD AUG
PY 2011
VL 35
IS 8
BP 1751
EP 1756
DI 10.1007/s00268-010-0951-0
PG 6
WC Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Surgery
GA 805CZ
UT WOS:000293705300008
PM 21212949
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Thomsen, R
   Christensen, DB
   Rosborg, S
   Linnet, TE
   Blechingberg, J
   Nielsen, AL
AF Thomsen, Rune
   Christensen, Dennis B.
   Rosborg, Sanne
   Linnet, Toke E.
   Blechingberg, Jenny
   Nielsen, Anders L.
TI Analysis of HP1α Regulation in Human Breast Cancer Cells
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE metastasis; heterochromatin; cell invasion; epigenetics; transcriptional
   regulation
ID HETEROCHROMATIN PROTEIN-1 HP1; HISTONE H3; CHROMATIN MODIFIERS;
   GENE-EXPRESSION; CYCLE; COMPLEX; PROLIFERATION; TRANSCRIPTION;
   METHYLATION; DISTINCT
AB The three mammalian HP1 proteins, HP1 alpha/CBX5, HP1 beta/CBX1, and HP gamma/CBX3, are involved in chromatin packing and gene regulation. The HP1 alpha protein is down-regulated in invasive compared to non-invasive breast cancer cells and HP1 alpha is a suppressor of cell migration and invasion. In this report, we examined the background for HP1 alpha protein down-regulation in invasive breast cancer cells. We identified a strict correlation between HP1 alpha down-regulation at the protein level and the mRNA level. The HP1 alpha mRNA down-regulation in invasive cancer cells was not caused by mRNA destabilization. Chromatin immunoprecipitation analysis of the HP1 alpha gene showed a decrease in the histone mark for transcriptional activity H3-K36 tri-methylation and RNA polymerase II in invasive breast cancer cells which correlated with a decreased abundance of basal transcription factors at the HP1 alpha promoter. E2F transcription factors regulate HP1 alpha transcription and we identified that E2F5 depletion increased HP1 alpha expression in invasive breast cancer cells. Finally, we have characterized two HP1 alpha mRNA isoforms and both HP1 alpha mRNA isoforms were down-regulated to a similar extend at the transcriptional level in invasive breast cancer cells. Collectively the presented results show that HP1 alpha down-regulation in invasive breast cancer cells is primary a transcriptional effect and demonstrates a novel set of mechanisms involved in HP1 alpha transcriptional regulation. The finding that HP1 alpha is down-regulated primarily at the transcriptional level provides a new insight for the further elucidation of the detailed molecular mechanisms causing the HP1 alpha down-regulation in invasive breast cancer cells. (C) 2011 Wiley-Liss, Inc.
C1 [Thomsen, Rune; Christensen, Dennis B.; Rosborg, Sanne; Linnet, Toke E.; Blechingberg, Jenny; Nielsen, Anders L.] Aarhus Univ, Dept Human Genet, DK-8000 Aarhus C, Denmark.
C3 Aarhus University
RP Nielsen, AL (通讯作者)，Aarhus Univ, Dept Human Genet, Bartholin Bldg, DK-8000 Aarhus C, Denmark.
RI ; Nielsen, Anders Lade/Q-9604-2016
OI Thomsen, Rune/0000-0002-9969-6567; Nielsen, Anders
   Lade/0000-0003-4372-9961
FU Danish National Research Council FSS; Foundation for the Progress of
   Medical Research; Lundbeck Foundation; Danish Cancer Society; Novo
   Nordisk Foundation; Carlsberg Foundation
FX We thank Tina Fuglsang for excellent technical assistance. This work was
   supported by the Danish National Research Council FSS, the Foundation
   for the Progress of Medical Research, the Lundbeck Foundation, the
   Danish Cancer Society, the Novo Nordisk Foundation, and the Carlsberg
   Foundation.
CR Ainsztein AM, 1998, J CELL BIOL, V143, P1763, DOI 10.1083/jcb.143.7.1763
   Auth T, 2006, EXP CELL RES, V312, P3349, DOI 10.1016/j.yexcr.2006.07.014
   Bannister AJ, 2005, J BIOL CHEM, V280, P17732, DOI 10.1074/jbc.M500796200
   Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138
   Berglund P, 2006, CELL CYCLE, V5, P606, DOI 10.4161/cc.5.6.2569
   Blais A, 2007, CURR OPIN CELL BIOL, V19, P658, DOI 10.1016/j.ceb.2007.10.003
   Blechingberg J, 2007, NUCLEIC ACIDS RES, V35, P7636, DOI 10.1093/nar/gkm931
   Daujat S, 2005, J BIOL CHEM, V280, P38090, DOI 10.1074/jbc.C500229200
   De Koning L, 2009, EMBO MOL MED, V1, P178, DOI 10.1002/emmm.200900022
   De Lange R, 2001, ANTICANCER RES, V21, P2329
   DeGregori J, 2006, CURR MOL MED, V6, P739
   Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613
   Dialynas GK, 2006, J BIOL CHEM, V281, P14350, DOI 10.1074/jbc.M600558200
   Dialynas GK, 2008, MUTAT RES-FUND MOL M, V647, P13, DOI 10.1016/j.mrfmmm.2008.09.007
   Fan JY, 2004, MOL CELL, V16, P655, DOI 10.1016/j.molcel.2004.10.023
   Ghosh T, 2008, NUCLEIC ACIDS RES, V36, P6318, DOI 10.1093/nar/gkn624
   Gilbert N, 2003, EMBO J, V22, P5540, DOI 10.1093/emboj/cdg520
   Grewal SIS, 2007, NAT REV GENET, V8, P35, DOI 10.1038/nrg2008
   Guenatri M, 2004, J CELL BIOL, V166, P493, DOI 10.1083/jcb.200403109
   Hiragami K, 2005, CELL MOL LIFE SCI, V62, P2711, DOI 10.1007/s00018-005-5287-9
   Kirschmann DA, 2000, CANCER RES, V60, P3359
   Lechner MS, 2005, BIOCHEM BIOPH RES CO, V331, P929, DOI 10.1016/j.bbrc.2005.04.016
   Li YH, 2002, P NATL ACAD SCI USA, V99, P16462, DOI 10.1073/pnas.162371699
   Lieberthal JG, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2329
   Litovchick L, 2007, MOL CELL, V26, P539, DOI 10.1016/j.molcel.2007.04.015
   Lomberk G, 2006, NAT CELL BIOL, V8, P407, DOI 10.1038/ncb1383
   Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578
   Maison C, 2004, NAT REV MOL CELL BIO, V5, P296, DOI 10.1038/nrm1355
   McClellan KA, 2007, CELL CYCLE, V6, P2917, DOI 10.4161/cc.6.23.4997
   Minc E, 1999, CHROMOSOMA, V108, P220, DOI 10.1007/s004120050372
   Muchardt C, 2002, EMBO REP, V3, P975, DOI 10.1093/embo-reports/kvf194
   Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385
   Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0
   Nielsen AL, 2002, EMBO J, V21, P5797, DOI 10.1093/emboj/cdf560
   Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620
   Norwood LE, 2006, J BIOL CHEM, V281, P18668, DOI 10.1074/jbc.M512454200
   Norwood LE, 2004, GENE, V336, P37, DOI 10.1016/j.gene.2004.04.003
   Oberley MJ, 2003, J BIOL CHEM, V278, P42466, DOI 10.1074/jbc.M307733200
   Obuse C, 2004, NAT CELL BIOL, V6, P1135, DOI 10.1038/ncb1187
   Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861
   Pilkinton M, 2007, ONCOGENE, V26, P7535, DOI 10.1038/sj.onc.1210562
   Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a
   Quivy JP, 2004, EMBO J, V23, P3516, DOI 10.1038/sj.emboj.7600362
   Rakha EA, 2004, J PATHOL, V203, P754, DOI 10.1002/path.1573
   Suárez Y, 2007, CIRC RES, V100, P1164, DOI 10.1161/01.RES.0000265065.26744.17
   Taddei A, 2005, EMBO REP, V6, P520, DOI 10.1038/sj.embor.7400441
   Thomsen Rune, 2010, J Bioinform Comput Biol, V8, P885, DOI 10.1142/S0219720010004963
   Umemura S, 2009, BRIT J CANCER, V100, P764, DOI 10.1038/sj.bjc.6604900
   Wasenius VM, 2003, CLIN CANCER RES, V9, P68
   Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102
   Xu XQ, 2007, GENOME RES, V17, P1550, DOI 10.1101/gr.6783507
   Zhou ZL, 2010, MOL BIOL REP, V37, P2407, DOI 10.1007/s11033-009-9751-8
NR 52
TC 15
Z9 19
U1 0
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
EI 1098-2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD AUG
PY 2011
VL 50
IS 8
BP 601
EP 613
DI 10.1002/mc.20755
PG 13
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 790PJ
UT WOS:000292601400004
PM 21374739
DA 2025-01-12
ER

PT J
AU Higashijima, J
   Kurita, N
   Miyatani, T
   Yoshikawa, K
   Morimoto, S
   Nishioka, M
   Iwata, T
   Shimada, M
AF Higashijima, Jun
   Kurita, Nobuhiro
   Miyatani, Tomohiko
   Yoshikawa, Kozo
   Morimoto, Shinya
   Nishioka, Masanori
   Iwata, Takashi
   Shimada, Mitsuo
TI Expression of histone deacetylase 1 and metastasis-associated protein 1
   as prognostic factors in colon cancer
SO ONCOLOGY REPORTS
LA English
DT Article
DE histone deacetylase 1; metastasis-associated protein 1; advanced colon
   cancer; epigenetic alteration; immunohistochemistry; survival rate;
   disease-free survival rate
ID MESSENGER-RNA EXPRESSION; GASTRIC-CANCER; BREAST-CANCER; MTA1 PROTEIN;
   IN-VITRO; OVEREXPRESSION; INHIBITORS; APOPTOSIS; GENE; CARCINOMA
AB Histone deacetylase 1 (HDAC1) and metastasis-associated protein 1 (MTA1) form the nucleosome remodeling and histone deacetylation (NuRD) complex and may possibly play a central role in cancer development. However, limited data has been reported regarding the expression of both HDAC1 and MTA1. The aim of the present study was to clarify the clinical role of HDAC1 and MTA1 expression in colon cancer. Seventy-four patients with colon cancer, who underwent colectomy at our institution, were enrolled in this study. Expression of HDAC1 and MTA1 was examined immunohistochemically. The patients were divided into four groups: HDAC1-positive group (n=58), HDAC1-negative group (n=16), MTA1-positive group (n=38) and MTA1-negative group (n=36). Clinicopathological factors and survival rates were compared between the groups. Regarding the clinicopathological factors, the depth of tumor invasion and stage correlated significantly with HDAC1 expression (p<0.05). Age, depth of tumor invasion and vascular invasion tended to correlate with MTA1 expression. The 5-year survival rate in the HDAC1-positive group (55.1%) was significantly worse compared to the HDAC1-negative group (86.5%) (p<0.05), and the 5-year survival rate of the MTA1-positive group (50.5%) was significantly worse than that of the MTA1-negative group (73.1%) (p=0.05). In patients with stages II-IV and curability A, B, the survival rate in those with HDAC1-positive expression was significantly worse than those with HDAC1-negative expression (p<0.05), and the survival rate of the MTA1-positive group tended to be worse than that of the MTA1-negative group (p=0.07). Overall survival in both the HDAC1 and MTA1-positive groups was significantly worse than overall survival of the other groups (p<0.05). Disease-free survival in both the HDAC1- and MTA1-positive groups, among patients with stages II-IV and curability A, B, was also significantly worse than that of the other groups (p<0.05). HDAC1 and MTA1 expression levels were significantly related to poorer prognosis. Therefore, HDAC1 and MTA1 expression levels are potential prognostic indicators for colon cancer.
C1 [Higashijima, Jun; Kurita, Nobuhiro; Miyatani, Tomohiko; Yoshikawa, Kozo; Morimoto, Shinya; Nishioka, Masanori; Iwata, Takashi; Shimada, Mitsuo] Univ Tokushima, Dept Surg, Inst Hlth Biosci, Tokushima 7708503, Japan.
C3 Tokushima University
RP Kurita, N (通讯作者)，Univ Tokushima, Dept Surg, Inst Hlth Biosci, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.
EM kurita@clin.med.tokushima-u.ac.jp
FU Research Support Foundation of the University of Tokushima; TAIHO
   Pharmaceutical Co., Ltd.; Grants-in-Aid for Scientific Research
   [23591935, 21591726, 23592010] Funding Source: KAKEN
FX This study was supported, in part, by a research grant from the Research
   Support Foundation of the University of Tokushima and the Cancer
   Research Project in cooperation with TAIHO Pharmaceutical Co., Ltd.
   (N.K.).
CR Aggarwal S, 2005, ONCOLOGY-NY, V19, P589
   [Anonymous], 2000, World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Digestive System
   [Anonymous], GEN RUL CLIN PATH ST
   Bartling B, 2005, LUNG CANCER-J IASLC, V49, P145, DOI 10.1016/j.lungcan.2005.02.006
   Bhalla KN, 2005, J CLIN ONCOL, V23, P3971, DOI 10.1200/JCO.2005.16.600
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010
   Choi JH, 2001, JPN J CANCER RES, V92, P1300, DOI 10.1111/j.1349-7006.2001.tb02153.x
   Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7
   Dales JP, 2005, INT J CANCER, V116, P734, DOI 10.1002/ijc.20984
   HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329
   Heerdt BG, 1997, CELL GROWTH DIFFER, V8, P523
   HEERDT BG, 1994, CANCER RES, V54, P3288
   Hofer MD, 2004, CANCER RES, V64, P825, DOI 10.1158/0008-5472.CAN-03-2755
   Jang KS, 2006, CANCER SCI, V97, P374, DOI 10.1111/j.1349-7006.2006.00186.x
   Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106
   Krusche CA, 2005, BREAST CANCER RES TR, V90, P15, DOI 10.1007/s10549-004-1668-2
   Kumar R, 2003, CELL, V113, P142, DOI 10.1016/S0092-8674(03)00274-5
   Kuwai T, 2003, INT J CANCER, V105, P176, DOI 10.1002/ijc.11068
   Lehmann A, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-395
   Mariadason JM, 2008, EPIGENETICS-US, V3, P28, DOI 10.4161/epi.3.1.5736
   Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272
   Marson CM, 2007, BIOORG MED CHEM LETT, V17, P136, DOI 10.1016/j.bmcl.2006.09.085
   Martin MD, 2006, BREAST CANCER RES TR, V95, P7, DOI 10.1007/s10549-005-9016-8
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Miyake K, 2008, PANCREAS, V36, pE1, DOI 10.1097/MPA.0b013e31815f2c2a
   Park JH, 2004, CLIN CANCER RES, V10, P5271, DOI 10.1158/1078-0432.CCR-03-0709
   Patra SK, 2001, BIOCHEM BIOPH RES CO, V287, P705, DOI 10.1006/bbrc.2001.5639
   Rasheed WK, 2007, EXPERT OPIN INV DRUG, V16, P659, DOI 10.1517/13543784.16.5.659
   Sasaki H, 2004, LUNG CANCER, V46, P171, DOI 10.1016/j.lungcan.2004.03.021
   Sasaki H, 2002, LUNG CANCER-J IASLC, V35, P149, DOI 10.1016/S0169-5002(01)00329-4
   Schwartz B, 1998, MOL CELL BIOCHEM, V188, P21, DOI 10.1023/A:1006831330340
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Song J, 2005, APMIS, V113, P264, DOI 10.1111/j.1600-0463.2005.apm_04.x
   Toh Y, 2000, J EXP CLIN CANC RES, V19, P105
   Toh Y, 1997, INT J CANCER, V74, P459, DOI 10.1002/(SICI)1097-0215(19970822)74:4<459::AID-IJC18>3.3.CO;2-H
   Toh Y, 1999, BRIT J CANCER, V79, P1723, DOI 10.1038/sj.bjc.6690274
   Toh Y, 2004, INT J CANCER, V110, P362, DOI 10.1002/ijc.20154
   Toh Y, 2003, ONCOL REP, V10, P333
   Waltregny D, 2004, EUR J HISTOCHEM, V48, P273
   Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990
   Weichert W, 2008, LANCET ONCOL, V9, P139, DOI 10.1016/S1470-2045(08)70004-4
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Yoo YG, 2006, EMBO J, V25, P1231, DOI 10.1038/sj.emboj.7601025
   Zhang ZH, 2005, BREAST CANCER RES TR, V94, P11, DOI 10.1007/s10549-005-6001-1
   Zhong H, 1999, CANCER RES, V59, P5830
NR 46
TC 48
Z9 53
U1 0
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD AUG
PY 2011
VL 26
IS 2
BP 343
EP 348
DI 10.3892/or.2011.1312
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 790IK
UT WOS:000292581500007
PM 21617866
OA Bronze
DA 2025-01-12
ER

PT J
AU Ge, MH
   Chen, C
   Xu, JJ
   Ling, ZQ
AF Ge, Ming-Hua
   Chen, Chao
   Xu, Jia-Jie
   Ling, Zhi-Qiang
TI Unfavorable clinical implications for hypermethylation of RUNX3 in
   patients with salivary gland adenoid cystic carcinoma
SO ONCOLOGY REPORTS
LA English
DT Article
DE human salivary gland adenoid cystic carcinoma; runt-related
   transcription factor-3; methylation; real-time methylation-specific PCR;
   Western blotting; disease-free survival
ID NONNEOPLASTIC GASTRIC EPITHELIA; CANCER CELL-LINES; PROMOTER
   HYPERMETHYLATION; DNA METHYLATION; PROTEIN MISLOCALIZATION; EPIGENETIC
   INACTIVATION; TUMOR-SUPPRESSOR; GENE-EXPRESSION; BREAST-CANCER;
   DAP-KINASE
AB To elucidate the potential etiological role of RUNX3 in the development of salivary gland adenoid cystic carcinoma (ACC), we analyzed the methylation status of RUNX3 in a series of 114 ACC tissues and 3 ACC cell lines. Results showed that the methylated rate of RUNX3 was 50.9 and 3.5% in the 114 ACC samples and the corresponding normal salivary glands, respectively, achieving a significant difference (P<0.001). There was a significant correlation between RUNX3 methylation and various clinicopathological parameters of ACCs, such as perineural invasion, lymph node involvement, T-stage and distant metastasis (P<0.001). RUNX3 methylation was a significant predictor of the 5-year disease-free survival in ACC patients after surgery. Partial methylation was found in all 3 ACC cell lines, and the reactivation and more potent expression of RUNX3 was induced by 5-triazole-2-deoxycytidine. Our findings indicate that RUNX3 methylation may occur as a common event in the development of ACC and that methylation may be a major mechanism for inactivation of RUNX3 in ACC.
C1 [Ling, Zhi-Qiang] Zhejiang Prov Canc Hosp, Zhejiang Canc Res Inst, Hangzhou 310022, Zhejiang, Peoples R China.
   [Ge, Ming-Hua; Chen, Chao; Xu, Jia-Jie] Zhejiang Prov Canc Hosp, Dept Surg Oncol, Hangzhou 310022, Zhejiang, Peoples R China.
C3 Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
RP Ling, ZQ (通讯作者)，Zhejiang Prov Canc Hosp, Zhejiang Canc Res Inst, Hangzhou 310022, Zhejiang, Peoples R China.
EM lingzq@hotmail.com
FU Natural Science Foundation of Zhejiang Province, China [Y2080660];
   Zhejiang Provincial Program for the Cultivation of High-level Innovative
   Health talents; Science and Technology General Project of Zhejiang
   Province [2009C33116]
FX This study was supported by a grant from the Natural Science Foundation
   of Zhejiang Province, China (no. Y2080660), a grant from the Zhejiang
   Provincial Program for the Cultivation of High-level Innovative Health
   talents, and a grant from the Science and Technology General Project of
   Zhejiang Province (no. 2009C33116).
CR [Anonymous], W CHIN J STOMATOL
   Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Chen WC, 2010, J GASTROEN HEPATOL, V25, P823, DOI 10.1111/j.1440-1746.2009.06191.x
   Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005
   Chuang LSH, 2010, ONCOGENE, V29, P2605, DOI 10.1038/onc.2010.88
   Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117
   Ehrlich M, 2005, BIOCHEMISTRY-MOSCOW+, V70, P568, DOI 10.1007/s10541-005-0150-z
   Fukamachi H, 2006, DEV GROWTH DIFFER, V48, P1, DOI 10.1111/j.1440-169x.2006.00832.x
   Fukamachi H, 2004, BIOCHEM BIOPH RES CO, V321, P58, DOI 10.1016/j.bbrc.2004.06.099
   Fukamachi H, 2004, ONCOGENE, V23, P4330, DOI 10.1038/sj.onc.1207121
   Gao F, 2009, J CANCER RES CLIN, V135, P739, DOI 10.1007/s00432-008-0508-x
   GARDEN AS, 1995, INT J RADIAT ONCOL, V32, P619, DOI 10.1016/0360-3016(95)00122-F
   GUAN XF, 1996, CHIN J STOMATOL, V3, P74
   He JF, 2008, CANCER SCI, V99, P1334, DOI 10.1111/j.1349-7006.2008.00826.x
   Homma N, 2006, CANCER SCI, V97, P51, DOI 10.1111/j.1349-7006.2005.00133.x
   Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743
   Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755
   Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8
   Jiang Y, 2008, PATHOBIOLOGY, V75, P244, DOI 10.1159/000132385
   KIM EJ, 2008, J UROLOGY, V180, P806
   Kim EJ, 2008, J UROLOGY, V180, P1141, DOI 10.1016/j.juro.2008.05.002
   KIM KH, 1994, ARCH OTOLARYNGOL, V120, P721
   Kim TY, 2004, ALIMENT PHARM THER, V20, P131, DOI 10.1111/j.1365-2036.2004.01984.x
   Kim WJ, 2005, CANCER RES, V65, P9347, DOI 10.1158/0008-5472.CAN-05-1647
   Ku JL, 2004, ONCOGENE, V23, P6736, DOI 10.1038/sj.onc.1207731
   Lau QC, 2006, CANCER RES, V66, P6512, DOI 10.1158/0008-5472.CAN-06-0369
   Li J, 2005, CANCER-AM CANCER SOC, V104, P771, DOI 10.1002/cncr.21215
   Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6
   Ling ZQ, 2007, CANCER GENET CYTOGEN, V175, P144, DOI 10.1016/j.cancergencyto.2007.02.011
   Maruya S, 2004, MODERN PATHOL, V17, P637, DOI 10.1038/modpathol.3800104
   Miyazono K, 2003, CANCER SCI, V94, P230, DOI 10.1111/j.1349-7006.2003.tb01425.x
   Mori T, 2005, LIVER INT, V25, P380, DOI 10.1111/j.1478-3231.2005.1059.x
   Nevadunsky NS, 2009, GYNECOL ONCOL, V112, P325, DOI 10.1016/j.ygyno.2008.09.006
   Noble JE, 2009, METHOD ENZYMOL, V463, P73, DOI 10.1016/S0076-6879(09)63008-1
   Nomoto S, 2008, BRIT J CANCER, V98, P1690, DOI 10.1038/sj.bjc.6604333
   Ogi K, 2002, CLIN CANCER RES, V8, P3164
   Park SR, 2003, EUR J IMMUNOL, V33, P3386, DOI 10.1002/eji.200324061
   Parsons JT, 1996, INT J RADIAT ONCOL, V35, P443, DOI 10.1016/S0360-3016(96)80005-8
   Pufulete M, 2005, BRIT J CANCER, V92, P838, DOI 10.1038/sj.bjc.6602439
   Rapidis AD, 2005, ORAL ONCOL, V41, P328, DOI 10.1016/j.oraloncology.2004.12.004
   Sakakura C, 2005, CLIN CANCER RES, V11, P6479, DOI 10.1158/1078-0432.CCR-05-0729
   Sato K, 2006, ONCOL REP, V15, P129
   So KJ, 2006, CANCER SCI, V97, P1155, DOI 10.1111/j.1349-7006.2006.00302.x
   SPIRO RH, 1974, AM J SURG, V128, P512, DOI 10.1016/0002-9610(74)90265-7
   SPIRO RH, 1979, AM J SURG, V138, P579, DOI 10.1016/0002-9610(79)90423-9
   Sung MW, 2003, ARCH OTOLARYNGOL, V129, P1193, DOI 10.1001/archotol.129.11.1193
   Suzuki M, 2005, BRIT J CANCER, V93, P1029, DOI 10.1038/sj.bjc.6602837
   Tamura G, 2009, PATHOL INT, V59, P895, DOI 10.1111/j.1440-1827.2009.02458.x
   Torquati A, 2004, SURGERY, V136, P310, DOI 10.1016/j.surg.2004.05.005
   Tozawa T, 2004, CANCER SCI, V95, P736, DOI 10.1111/j.1349-7006.2004.tb03254.x
   Tsunematsu T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005892
   Waki T, 2003, CANCER SCI, V94, P360, DOI 10.1111/j.1349-7006.2003.tb01447.x
   Wei DY, 2005, CANCER RES, V65, P4809, DOI 10.1158/0008-5472.CAN-04-3741
   Wittekind C, 2002, CANCER-AM CANCER SOC, V94, P2511, DOI 10.1002/cncr.10492.abs
   Yang QW, 2004, CLIN CANCER RES, V10, P8493, DOI 10.1158/1078-0432.CCR-04-1331
   Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499
   Zhang CY, 2007, CANCER-AM CANCER SOC, V110, P87, DOI 10.1002/cncr.22758
NR 58
TC 8
Z9 10
U1 0
U2 1
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
J9 ONCOL REP
JI Oncol. Rep.
PD AUG
PY 2011
VL 26
IS 2
BP 349
EP 357
DI 10.3892/or.2011.1282
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 790IK
UT WOS:000292581500008
PM 21567090
OA Bronze
DA 2025-01-12
ER

PT J
AU Talieri, M
   Alexopoulou, DK
   Scorilas, A
   Kypraios, D
   Arnogiannaki, N
   Devetzi, M
   Patsavela, M
   Xynopoulos, D
AF Talieri, Maroulio
   Alexopoulou, Dimitra K.
   Scorilas, Andreas
   Kypraios, Dimitris
   Arnogiannaki, Niki
   Devetzi, Marina
   Patsavela, Matina
   Xynopoulos, Dimitris
TI Expression analysis and clinical evaluation of kallikrein-related
   peptidase 10 (KLK10) in colorectal cancer
SO TUMOR BIOLOGY
LA English
DT Article
DE Cell lines; Colorectal cancer; Kallikrein-related peptidase 10; KLK10;
   Tumor markers
ID HUMAN TISSUE KALLIKREINS; DIFFERENTIAL EXPRESSION; BIOLOGICAL-FLUIDS;
   SERINE-PROTEASE; BREAST-CANCER; GENE; IDENTIFICATION; BIOMARKER;
   METHYLATION; PROMOTER
AB Kallikrein-related peptidases (KLKs) represent a serine protease family having 15 members. KLK10 is a secreted protease with a trypsin-like activity. The function of KLK10 is poorly understood, although it has been suggested that KLK10 may function as a tumor suppressor gene. In human cancer, KLK10 gene shows organ-specific up- or down-regulation. Since KLKs are promising tumor biomarkers, the examination of KLK10 mRNA expression and its association with colorectal cancer (CRC) progression was studied using semi-quantitative PCR. One hundred and nineteen primary CRC specimens were examined for which follow-up information was available for a median period of 29 months (range, 1-104 months). KLK10 expression was found to be significantly associated with TNM stage (p = 0.028). Cox proportional hazard regression model using univariate analysis revealed for the first time that high status KLK10 expression is a significant factor for disease-free survival (DFS; p = 0.002) and overall survival (OS; p = 0.026) of patients. Kaplan-Meier survival curves demonstrated that KLK10 expression of low status is significantly associated with longer DFS (p = 0.001) as well as OS (p = 0.021), suggesting that KLK10 gene expression may be used as a marker of unfavorable prognosis for CRC. As the epigenetics of cancer are unraveled, KLK10 may represent not only a novel biomarker, but also a promising future therapeutic target for the disease.
C1 [Talieri, Maroulio; Alexopoulou, Dimitra K.; Devetzi, Marina] St Savvas Canc Hosp, G Papanicolaou Res Ctr Oncol, Dept Cellular Physiol, Athens 11522, Greece.
   [Scorilas, Andreas] Univ Athens, Fac Biol, Dept Biochem & Mol Biol, Athens 15701, Greece.
   [Kypraios, Dimitris; Patsavela, Matina; Xynopoulos, Dimitris] St Savvas Hosp, Dept Gastroenterol, Athens 11522, Greece.
   [Arnogiannaki, Niki] St Savvas Hosp, Dept Pathol, Athens 11522, Greece.
C3 National & Kapodistrian University of Athens
RP Talieri, M (通讯作者)，St Savvas Canc Hosp, G Papanicolaou Res Ctr Oncol, Dept Cellular Physiol, 171 Alexandras Ave, Athens 11522, Greece.
EM talieri@agsavvas-hosp.gr
OI Devetzi, Marina/0000-0002-7123-7991; Talieri,
   Maroulio/0000-0002-7911-7150; Scorilas, Andreas/0000-0003-2427-4949
CR Avgeris M, 2010, BIOL CHEM, V391, P505, DOI 10.1515/BC.2010.056
   Benson AB, 2000, J CLIN ONCOL, V18, P3586, DOI 10.1200/JCO.2000.18.20.3586
   Borgoño CA, 2004, NAT REV CANCER, V4, P876, DOI 10.1038/nrc1474
   Christophi GP, 2004, J NEUROCHEM, V91, P1439, DOI 10.1111/j.1471-4159.2004.02826.x
   Dong Y, 2008, BIOL CHEM, V389, P99, DOI 10.1515/BC.2008.013
   Emami N, 2007, CLIN CHIM ACTA, V381, P78, DOI 10.1016/j.cca.2007.02.023
   Feng B, 2006, J GASTROEN HEPATOL, V21, P1596, DOI 10.1111/j.1440-1746.2006.04228.x
   Goyal J, 1998, CANCER RES, V58, P4782
   Hekim C, 2010, BIOL CHEM, V391, P475, DOI 10.1515/BC.2010.039
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kioulafa M, 2009, ANN ONCOL, V20, P1020, DOI 10.1093/annonc/mdn733
   Lawrence MG, 2010, ENDOCR REV, V31, P407, DOI 10.1210/er.2009-0034
   Li B, 2001, CANCER RES, V61, P8014
   Liu XL, 1996, CANCER RES, V56, P3371
   Luo LY, 2003, CLIN CHIM ACTA, V337, P115, DOI 10.1016/j.cccn.2003.07.008
   Luo LY, 1998, BIOCHEM BIOPH RES CO, V247, P580, DOI 10.1006/bbrc.1998.8793
   Luo LY, 2001, CLIN CHEM, V47, P237
   Paliouras M, 2007, CANCER LETT, V249, P61, DOI 10.1016/j.canlet.2006.12.018
   Pampalakis G, 2006, BIOL CHEM, V387, P795, DOI 10.1515/BC.2006.100
   Petraki CD, 2002, J HISTOCHEM CYTOCHEM, V50, P1247, DOI 10.1177/002215540205000912
   PREZAS P, 2006, BIOL CHEM, V387, P613
   Shaw JLV, 2007, CLIN CHEM, V53, P1423, DOI 10.1373/clinchem.2007.088104
   Sotiropoulou G, 2010, BIOL CHEM, V391, P321, DOI 10.1515/BC.2010.036
   Sotiropoulou G, 2009, J BIOL CHEM, V284, P32989, DOI 10.1074/jbc.R109.027946
   Talieri M, 2009, BRIT J CANCER, V100, P1659, DOI 10.1038/sj.bjc.6605033
   Talieri M, 2009, THROMB HAEMOSTASIS, V101, P741, DOI 10.1160/TH08-07-0471
   Tong Wei-Gang, 2010, Epigenetics, V5, P499
   Yousef GM, 2005, TUMOR BIOL, V26, P227, DOI 10.1159/000087377
   Zhang YW, 2010, CANCER SCI, V101, P934, DOI [10.1111/j.1349-7006.2009.01486.x, 10.1111/j.1349-7006.2010.01486.x]
NR 30
TC 33
Z9 40
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1010-4283
J9 TUMOR BIOL
JI Tumor Biol.
PD AUG
PY 2011
VL 32
IS 4
BP 737
EP 744
DI 10.1007/s13277-011-0175-4
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 789ZP
UT WOS:000292558600015
PM 21487810
DA 2025-01-12
ER

PT J
AU Wu, DL
   Wong, P
   Li, W
   Vogel, CF
   Matsumura, F
AF Wu, Dalei
   Wong, Patrick
   Li, Wen
   Vogel, Christoph F.
   Matsumura, Fumio
TI Suppression of <i>WIF</i>-1 through promoter hypermethylation causes
   accelerated proliferation of the aryl hydrocarbon receptor (AHR)
   overexpressing MCF10AT1 breast cancer cells
SO TOXICOLOGY
LA English
DT Article
DE WIF-1; DNA methylation; 5-Aza-2 '-deoxycytidine; MCF10AT1; AHR; ER alpha
ID ESTROGEN-RECEPTOR; DEPENDENT TRANSCRIPTION; ALPHA ER; EXPRESSION;
   INHIBITION; ACTIVATION; INACTIVATION; GENE
AB The cause for increased cell proliferation in AHR overexpressing breast cancer cells still remains unknown. Here we studied the molecular basis of aggressive cell proliferation of an AHR overexpressing and ER alpha functionally down-regulated MCF10AT1 cell line, designated as P20E, in comparison to a matched sub-line, P20C with normal AHR expression and ER alpha function. We found that a 4-day treatment of P2OE cells with 5-aza-2'-deoxycytidine (AZ) caused a significant suppression of cell proliferation. Such an effect of AZ was accompanied with the significant recovery of ER alpha function. Among diagnostic markers of AZ-induced cellular changes we found conspicuous up-regulation of mRNA expression of Wnt inhibitory factor-1 (WIF-1), particularly in P20E. The possibility of AZ-induced demethylation on the promoter of WIF-1 gene was confirmed through methylation specific PCR assay. Such AZ-induced changes in P2OE cells were also accompanied with the decrease in the binding of nuclear proteins to the (32)P labeled TRE (TCF response element) and the reduced accumulation of beta-catenin protein in the cell nucleus, indicating the importance of Wnt/beta-catenin pathway in maintaining the increased cell proliferation in P20E line over P20C line. The importance of WIF-1 in this regard has been validated by transfecting cells with siRNA against WIF-1, which caused an increase in cell proliferation. Moreover, artificial overexpression of ER alpha in both P2OE as well as MDA-MB-231 cells increased the mRNA expression of WIF-1. Together these results support our main conclusion that the aggressive cell proliferation of this AHR-overexpressing sub-type of transformed mammary epithelial cells is assisted by the epigenetic suppression of WIF-1 gene, which is caused by the loss of ER alpha. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Wu, Dalei; Wong, Patrick; Li, Wen; Vogel, Christoph F.; Matsumura, Fumio] Univ Calif Davis, Dept Environm Toxicol, Davis, CA 95616 USA.
C3 University of California System; University of California Davis
RP Matsumura, F (通讯作者)，Univ Calif Davis, Dept Environm Toxicol, 1 Shields Ave, Davis, CA 95616 USA.
EM fmatsumura@ucdavis.edu
RI Wu, Dalei/A-6884-2012
FU Susan G. Komen for the Cure [FAS0703859]
FX This study has been supported by Susan G. Komen for the Cure (Grant
   Number FAS0703859).
CR Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379
   Demircan B, 2009, GENE CHROMOSOME CANC, V48, P83, DOI 10.1002/gcc.20620
   FERGUSON AT, 1995, CANCER RES, V55, P2279
   MacPherson L, 2010, CANCER LETT, V299, P119, DOI 10.1016/j.canlet.2010.08.010
   Ohtake F, 2009, BIOCHEM PHARMACOL, V77, P474, DOI 10.1016/j.bcp.2008.08.034
   Park CH, 2005, BIOCHEM BIOPH RES CO, V328, P227, DOI 10.1016/j.bbrc.2004.12.151
   Safe S, 2003, CHEM RES TOXICOL, V16, P807, DOI 10.1021/tx034036r
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   Shin SR, 2006, CANCER RES, V66, P2570, DOI 10.1158/0008-5472.CAN-05-3056
   THOMSEN JS, 1994, CARCINOGENESIS, V15, P933, DOI 10.1093/carcin/15.5.933
   Trombino AF, 2000, BREAST CANCER RES TR, V63, P117, DOI 10.1023/A:1006443104670
   Urakami S, 2006, CLIN CANCER RES, V12, P383, DOI 10.1158/1078-0432.CCR-05-1344
   Wihlén B, 2009, MOL CANCER RES, V7, P977, DOI 10.1158/1541-7786.MCR-08-0396
   Wong PS, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-234
   Wong PSY, 2006, TOXICOL IN VITRO, V20, P382, DOI 10.1016/j.tiv.2005.08.016
   Yan L, 2003, CANCER BIOL THER, V2, P552, DOI 10.4161/cbt.2.5.469
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Yang XW, 2001, CANCER RES, V61, P7025
NR 18
TC 13
Z9 13
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0300-483X
J9 TOXICOLOGY
JI Toxicology
PD JUL 29
PY 2011
VL 285
IS 3
BP 97
EP 103
DI 10.1016/j.tox.2011.04.008
PG 7
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA 788WW
UT WOS:000292476100003
PM 21515334
DA 2025-01-12
ER

PT J
AU Ng, EKO
   Leung, CPH
   Shin, VY
   Wong, CLP
   Ma, ESK
   Jin, HC
   Chu, KM
   Kwong, A
AF Ng, Enders K. O.
   Leung, Candy P. H.
   Shin, Vivian Y.
   Wong, Chris L. P.
   Ma, Edmond S. K.
   Jin, Hong Chuan
   Chu, Kent-Man
   Kwong, Ava
TI Quantitative Analysis and Diagnostic Significance of Methylated SLC19A3
   DNA in the Plasma of Breast and Gastric Cancer Patients
SO PLOS ONE
LA English
DT Article
ID THIAMINE TRANSPORTER THTR2; PROMOTER HYPERMETHYLATION; GENE-EXPRESSION;
   CIRCULATING DNA; DOWN-REGULATION; SERUM; THERAPY; MARKER; FAMILY; TUMORS
AB Background: Previously, we have examined the methylation status of SLC19A3 (solute carrier family 19, member 3) promoter and found that SLC19A3 was epigenetically down-regulated in gastric cancer. Here, we aim to develop a new biomarker for cancer diagnosis using methylated SLC19A3 DNA in plasma.
   Methodology/Principal Findings: SLC19A3 gene expression was examined by RT-qPCR. Methylation status of SLC19A3 promoter was evaluated by methylation-specific qPCR. SLC19A3 expression was significantly down-regulated in 80% (12/15) of breast tumors (P<0.005). Breast tumors had significant increase in methylation percentage when compared to adjacent non-tumor tissues (P<0.005). A robust and simple methylation-sensitive restriction enzyme digestion and real-time quantitative PCR (MSRED-qPCR) was developed to quantify SLC19A3 DNA methylation in plasma. We validated this biomarker in an independent validation cohort of 165 case-control plasma including 60 breast cancer, 45 gastric cancer patients and 60 healthy subjects. Plasma SLC19A3 methylated DNA level was effective in differentiating both breast and gastric cancer from healthy subjects. We further validated this biomarker in another independent blinded cohort of 78 plasma including 38 breast cancer, 20 gastric cancer patients and 20 healthy subjects. The positive predictive values for breast and gastric cancer were 90% and 85%, respectively. The negative predictive value of this biomarker was 85%. Elevated level in plasma has been detected not only in advanced stages but also early stages of tumors. The positive predictive value for ductal carcinoma in situ (DCIS) cases was 100%.
   Conclusions: These results suggested that aberrant SLC19A3 promoter hypermethylation in plasma may be a novel biomarker for breast and gastric cancer diagnosis.
C1 [Ng, Enders K. O.; Leung, Candy P. H.; Shin, Vivian Y.; Chu, Kent-Man] Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China.
   [Ng, Enders K. O.; Wong, Chris L. P.; Ma, Edmond S. K.; Kwong, Ava] Hong Kong Sanat & Hosp, Dept Mol Pathol, Hong Kong, Hong Kong, Peoples R China.
   [Ng, Enders K. O.; Wong, Chris L. P.; Ma, Edmond S. K.; Kwong, Ava] Hong Kong Sanat & Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China.
   [Jin, Hong Chuan] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Biomed Res Ctr, Hangzhou 310003, Zhejiang, Peoples R China.
   [Wong, Chris L. P.; Ma, Edmond S. K.; Kwong, Ava] Hong Kong Hereditary Breast Canc Family Registry, Hong Kong, Hong Kong, Peoples R China.
   [Kwong, Ava] Stanford Univ, Sch Med, Dept Surg, Stanford, CA 94305 USA.
C3 University of Hong Kong; Zhejiang University; Stanford University
RP Ng, EKO (通讯作者)，Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China.
EM akwong@asiabreastregistry.com
RI Yu, Shi-Tong/H-3747-2018; Wong, Chris/JPX-1434-2023; NG,
   Enders/T-3881-2019; Jin, Hongchuan/C-3686-2009; Ma, Shiu Kwan
   Edmond/AAZ-7637-2021; Kwong, Ava/D-8005-2013
OI Wang, Xian/0000-0003-0041-7589; Ng, Enders Kai-on/0000-0002-5293-3529;
   Ng, Enders Kai-on/0000-0002-6955-0030; Jin,
   Hongchuan/0000-0002-6697-3097; Kwong, Ava/0000-0002-6968-9489; Shin,
   Vivian Yvonne/0000-0003-1282-7593; Ma, Edmond/0000-0002-1259-2205
FU University of Hong Kong [10400959]; Dr. Ellen Li Charitable Foundation
FX The University of Hong Kong Seed Fund for Basic Research 2009 (Ref #:
   10400959). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.We
   sincerely thank The Dr. Ellen Li Charitable Foundation for their
   support. We would also like to thank Dr. Dacita Suen, Dr. Catherine Choi
   and Ms. Wong Ling for helping in patient recruitment.
CR Chiu RWK, 2005, CLIN CHEM, V51, P2209, DOI 10.1373/clinchem.2005.056366
   Chiu RWK, 2003, CLIN CHEM, V49, P719, DOI 10.1373/49.5.719
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Eudy JD, 2000, MOL GENET METAB, V71, P581, DOI 10.1006/mgme.2000.3112
   Fiegl H, 2005, CANCER RES, V65, P1141, DOI 10.1158/0008-5472.CAN-04-2438
   Gal S, 2004, BRIT J CANCER, V90, P1211, DOI 10.1038/sj.bjc.6601609
   Ganapathy V, 2004, PFLUG ARCH EUR J PHY, V447, P641, DOI 10.1007/s00424-003-1068-1
   Lee BY, 2005, ONCOL REP, V14, P1589
   Liu SQ, 2004, MOL CANCER RES, V2, P477
   Liu SQ, 2003, MOL CANCER RES, V1, P665
   Liu X, 2009, TUMOR BIOL, V30, P242, DOI 10.1159/000243767
   Müller HM, 2003, CANCER RES, V63, P7641
   Ng EKO, 2009, GUT, V58, P1375, DOI 10.1136/gut.2008.167817
   Rajgopal A, 2001, BBA-MOL BASIS DIS, V1537, P175, DOI 10.1016/S0925-4439(01)00073-4
   Rashid A, 2004, GASTROENTEROLOGY, V127, P1578, DOI 10.1053/j.gastro.2004.09.007
   Reidling JC, 2010, GASTROENTEROLOGY, V138, P1802, DOI 10.1053/j.gastro.2009.10.042
   Wang YC, 2008, WORLD J GASTROENTERO, V14, P3074, DOI 10.3748/wjg.14.3074
   Widschwendter A, 2004, CLIN CANCER RES, V10, P565, DOI 10.1158/1078-0432.CCR-0825-03
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Widschwendter M, 2006, CLIN CANCER RES, V12, P7205, DOI 10.1158/1078-0432.CCR-06-2531
NR 21
TC 59
Z9 63
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 18
PY 2011
VL 6
IS 7
AR e22233
DI 10.1371/journal.pone.0022233
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 793HY
UT WOS:000292812400041
PM 21789241
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU van der Gun, BTF
   de Groote, ML
   Kazemier, HG
   Arendzen, AJ
   Terpstra, P
   Ruiters, MHJ
   McLaughlin, PMJ
   Rots, MG
AF van der Gun, B. T. F.
   de Groote, M. L.
   Kazemier, H. G.
   Arendzen, A. J.
   Terpstra, P.
   Ruiters, M. H. J.
   McLaughlin, P. M. J.
   Rots, M. G.
TI Transcription factors and molecular epigenetic marks underlying EpCAM
   overexpression in ovarian cancer
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE ovarian cancer; EpCAM; DNA methylation; histone modifications;
   transcription factors
ID CELL-ADHESION-MOLECULE; EP-CAM PROMOTER; DNA METHYLATION; BREAST-CANCER;
   HEPATOCELLULAR-CARCINOMA; POTENTIAL TARGET; GENE-THERAPY; TUMOR-CELLS;
   STEM-CELLS; EXPRESSION
AB BACKGROUND: The epithelial cell adhesion molecule (EpCAM) is overexpressed on carcinomas, and its downregulation inhibits the oncogenic potential of multiple tumour types. Here, we investigated underlying mechanisms of epcam overexpression in ovarian carcinoma.
   METHODS: Expression of EpCAM and DNA methylation (bisulphite sequencing) was determined for ovarian cancer cell lines. The association of histone modifications and 16 transcription factors with the epcam promoter was analysed by chromatin immunoprecipitation. Treatment with 5-Aza-2'-deoxycytidine (5-AZAC) was used to induce EpCAM expression.
   RESULTS: Expression of EpCAM was correlated with DNA methylation and histone modifications. Treatment with 5-AZAC induced EpCAM expression in negative cells. Ten transcription factors were associated with the epcam gene in EpCAM expressing cells, but not in EpCAM-negative cells. Methylation of an Sp1 probe inhibited the binding of nuclear extract proteins in electromobility shift assays; such DNA methylation sensitivity was not observed for an NF-kappa B probe.
   CONCLUSION: This study provides insights in transcriptional regulation of epcam in ovarian cancer. Epigenetic parameters associated with EpCAM overexpression are potentially reversible, allowing novel strategies for sustained silencing of EpCAM expression. British Journal of Cancer (2011) 105, 312-319. doi: 10.1038/bjc.2011.231 www.bjcancer.com Published online 21 June 2011 (C) 2011 Cancer Research UK
C1 [van der Gun, B. T. F.; de Groote, M. L.; Kazemier, H. G.; Arendzen, A. J.; Ruiters, M. H. J.; McLaughlin, P. M. J.; Rots, M. G.] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, NL-9713 GZ Groningen, Netherlands.
   [Terpstra, P.] Univ Groningen, Univ Med Ctr Groningen, Dept Genet Epidemiol & Bioinformat, NL-9713 GZ Groningen, Netherlands.
   [Ruiters, M. H. J.] Synvolux Therapeut Inc, NL-9713 GX Groningen, Netherlands.
C3 University of Groningen; University of Groningen
RP Rots, MG (通讯作者)，Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.
EM M.G.Rots@med.umcg.nl
OI van der Gun, Bernardina/0000-0001-5207-6814
FU EU [ProTuMa ET09008]
FX This study has been partially funded by the EU FP7 EuroTransBio: ProTuMa
   ET09008. We thank JM Dokter-Fokkens (UMCG) for culturing the cell lines.
CR Anttila MA, 2000, BRIT J CANCER, V82, P1974
   Balch C, 2009, ENDOCRINOLOGY, V150, P4003, DOI 10.1210/en.2009-0404
   Barton CA, 2008, GYNECOL ONCOL, V109, P129, DOI 10.1016/j.ygyno.2007.12.017
   Bellone S, 2009, INT J GYNECOL CANCER, V19, P860, DOI 10.1111/IGC.0b013e3181a8331f
   Bokemeyer C, 2010, EXPERT OPIN BIOL TH, V10, P1259, DOI 10.1517/14712598.2010.504706
   DU W, 2009, DIGEST DIS SCI, V55, P1033
   Gires O, 2001, CANCER, V92, P620, DOI 10.1002/1097-0142(20010801)92:3<620::AID-CNCR1362>3.0.CO;2-F
   Gommans WM, 2007, MOL CARCINOGEN, V46, P391, DOI 10.1002/mc.20289
   Hao M, 2009, J OBSTET GYNAECOL RE, V35, P918, DOI 10.1111/j.1447-0756.2009.01045.x
   Heinzelmann-Schwarz VA, 2004, CLIN CANCER RES, V10, P4427, DOI 10.1158/1078-0432.CCR-04-0073
   Honda H, 2007, CANCER BIOL THER, V6, P1733, DOI 10.4161/cbt.6.11.4832
   Ji JF, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-4
   Kim JH, 2003, CLIN CANCER RES, V9, P4782
   Klatte T, 2009, CLIN CANCER RES, V15, P1162, DOI 10.1158/1078-0432.CCR-08-1229
   Köbel M, 2008, PLOS MED, V5, P1749, DOI 10.1371/journal.pmed.0050232
   Kolfschoten GM, 2002, GYNECOL ONCOL, V84, P404, DOI 10.1006/gyno.2001.6537
   Li FY, 2007, NUCLEIC ACIDS RES, V35, P100, DOI 10.1093/nar/gkl1035
   LINNENBACH AJ, 1993, MOL CELL BIOL, V13, P1507, DOI 10.1128/MCB.13.3.1507
   Lu TY, 2010, J BIOL CHEM, V285, P8719, DOI 10.1074/jbc.M109.077081
   Maetzel D, 2009, NAT CELL BIOL, V11, P162, DOI 10.1038/ncb1824
   McLaughlin PMJ, 2004, CANCER GENE THER, V11, P603, DOI 10.1038/sj.cgt.7700725
   Morris KV, 2011, CLIN EPIGENETICS, V2, P433, DOI 10.1007/s13148-011-0034-6
   Oettgen P, 2010, J ONCOL, V2010, DOI 10.1155/2010/767384
   Osta WA, 2004, CANCER RES, V64, P5818, DOI 10.1158/0008-5472.CAN-04-0754
   Reimer D, 2007, CLIN CANCER RES, V13, P144, DOI 10.1158/1078-0432.CCR-06-0780
   Sankpal NV, 2009, CANCER RES, V69, P753, DOI 10.1158/0008-5472.CAN-08-2708
   Seligson DB, 2004, CLIN CANCER RES, V10, P2659, DOI 10.1158/1078-0432.CCR-1132-03
   Smith AE, 2008, J BIOL CHEM, V283, P9878, DOI 10.1074/jbc.M710393200
   Spizzo G, 2004, BREAST CANCER RES TR, V86, P207, DOI 10.1023/B:BREA.0000036787.59816.01
   Spizzo G, 2007, CANCER LETT, V246, P253, DOI 10.1016/j.canlet.2006.03.002
   Spizzo G, 2006, GYNECOL ONCOL, V103, P483, DOI 10.1016/j.ygyno.2006.03.035
   Spizzo G, 2011, J CLIN PATHOL, V64, P415, DOI 10.1136/jcp.2011.090274
   Strano S, 2007, ONCOGENE, V26, P2212, DOI 10.1038/sj.onc.1210296
   Tai KY, 2007, ONCOGENE, V26, P3989, DOI 10.1038/sj.onc.1210176
   van der Gun BTF, 2008, INT J CANCER, V123, P484, DOI 10.1002/ijc.23476
   van der Gun BTF, 2010, CARCINOGENESIS, V31, P1913, DOI 10.1093/carcin/bgq187
   van der Gun BTF, 2010, BIOCONJUGATE CHEM, V21, P1239, DOI 10.1021/bc1000388
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Wei YK, 2008, MOL CARCINOGEN, V47, P701, DOI 10.1002/mc.20413
   Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3
   Wimberger P, 2009, ANTICANCER RES, V29, P1787
   Xiang W, 2003, J CANCER RES CLIN, V129, P341, DOI 10.1007/s00432-003-0438-6
   Yamashita T, 2007, CANCER RES, V67, P10831, DOI 10.1158/0008-5472.CAN-07-0908
   Yamashita T, 2009, GASTROENTEROLOGY, V136, P1012, DOI 10.1053/j.gastro.2008.12.004
   Yanamoto S, 2007, ORAL ONCOL, V43, P869, DOI 10.1016/j.oraloncology.2006.10.010
   Yu GL, 2008, ONCOL REP, V20, P1061, DOI 10.3892/or_00000110
NR 46
TC 24
Z9 27
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD JUL 12
PY 2011
VL 105
IS 2
BP 312
EP 319
DI 10.1038/bjc.2011.231
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 791SE
UT WOS:000292684200017
PM 21694727
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Eades, G
   Yao, Y
   Yang, MH
   Zhang, YS
   Chumsri, S
   Zhou, Q
AF Eades, Gabriel
   Yao, Yuan
   Yang, Muhua
   Zhang, Yongshu
   Chumsri, Saranya
   Zhou, Qun
TI miR-200a Regulates SIRT1 Expression and Epithelial to Mesenchymal
   Transition (EMT)-like Transformation in Mammary Epithelial Cells
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID HUMAN CANCER-CELLS; DNA METHYLATION; DOWN-REGULATION; BREAST-CANCER;
   HISTONE DEACETYLASE; PROSTATE-CANCER; HUMAN GENES; MICRORNAS; FAMILY;
   GROWTH
AB Evidence supports a critical role for microRNAs (miRNAs) in regulation of tissue-specific differentiation and development. Signifying a disruption of these programs, expression profiling has revealed extensive miRNA dysregulation in tumors compared with healthy tissue. The miR-200 family has been established as a key regulator of epithelial phenotype and, as such, is deeply involved in epithelial to mesenchymal transition (EMT) processes in breast cancer. However, the effects of the miR-200 family on transformation of normal mammary epithelial cells have yet to be fully characterized. By examining a TGF-beta driven model of transformation of normal mammary epithelium, we demonstrate that the class III histone deacetylase silent information regulator 1 (SIRT1), a proposed oncogene in breast cancer, is overexpressed upon EMT-like transformation and that epigenetic silencing of miR-200a contributes at least in part to the overexpression of SIRT1. We have established the SIRT1 transcript as subject to regulation by miR-200a, through miR-200a targeting of SIRT1 3'-UTR. We also observed SIRT1 and miR-200a participation in a negative feedback regulatory loop. Restoration of miR-200a or the knockdown of SIRT1 prevented transformation of normal mammary epithelial cells evidenced by decreased anchorage-independent growth and decreased cell migration. Finally, we observed SIRT1 overexpression in association with decreased miR-200a in breast cancer patient samples. These observations provide further evidence for a critical tumor suppressive role of the miR-200 family in breast epithelium in addition to identifying a novel regulatory mechanism, which may contribute to SIRT1 up-regulation in breast cancer.
C1 [Eades, Gabriel; Yao, Yuan; Yang, Muhua; Zhang, Yongshu; Zhou, Qun] Univ Maryland Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA.
   [Chumsri, Saranya] Univ Maryland Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA.
C3 University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore
RP Zhou, Q (通讯作者)，Univ Maryland Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA.
EM qzhou@som.umaryland.edu
RI yao, yuan/AHB-5578-2022
FU Flight Attendants Medical Research Institute [FAMRI YCSA072084];
   Maryland Stem Cell Research Fund [2010-MSCRFE-0179-00]
FX This work was supported by Flight Attendants Medical Research Institute
   Grant FAMRI YCSA072084 (to Q. Z.) and the Maryland Stem Cell Research
   Fund Grant 2010-MSCRFE-0179-00 (to Q. Z.).
CR Abdelmohsen K, 2007, MOL CELL, V25, P543, DOI 10.1016/j.molcel.2007.01.011
   Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508
   Aoyagi S, 2008, MOL CELL BIOL, V28, P30, DOI 10.1128/MCB.01158-07
   Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942
   Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011
   Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105
   Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832
   Ford J, 2005, CANCER RES, V65, P10457, DOI 10.1158/0008-5472.CAN-05-1923
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952
   Häusler SFM, 2010, BRIT J CANCER, V103, P693, DOI 10.1038/sj.bjc.6605833
   Haigis MC, 2010, ANNU REV PATHOL-MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Huang ZH, 2010, INT J CANCER, V127, P118, DOI 10.1002/ijc.25007
   Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085
   Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622
   Jang KY, 2009, PATHOLOGY, V41, P366, DOI 10.1080/00313020902884451
   Kojima K, 2008, BIOCHEM BIOPH RES CO, V373, P423, DOI 10.1016/j.bbrc.2008.06.045
   Lawrie CH, 2008, BRIT J HAEMATOL, V141, P672, DOI 10.1111/j.1365-2141.2008.07077.x
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Liu T, 2009, CANCER RES, V69, P1702, DOI 10.1158/0008-5472.CAN-08-3365
   Lorincz MC, 2004, NAT STRUCT MOL BIOL, V11, P1068, DOI 10.1038/nsmb840
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017
   Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731
   Neugebauer RC, 2008, CURR PHARM DESIGN, V14, P562
   O'Hagan HM, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000155
   Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462
   Ota H, 2006, ONCOGENE, V25, P176, DOI 10.1038/sj.onc.1209049
   Peck B, 2010, MOL CANCER THER, V9, P844, DOI 10.1158/1535-7163.MCT-09-0971
   Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040
   Rane S, 2009, CIRC RES, V104, P879, DOI 10.1161/CIRCRESAHA.108.193102
   Rosenfeld N, 2008, NAT BIOTECHNOL, V26, P462, DOI 10.1038/nbt1392
   Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011
   Strum JC, 2009, MOL ENDOCRINOL, V23, P1876, DOI 10.1210/me.2009-0117
   Suzuki Y, 2001, GENOME RES, V11, P677, DOI 10.1101/gr.GR-1640R
   Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Uhlmann S, 2010, ONCOGENE, V29, P4297, DOI 10.1038/onc.2010.201
   Vandewalle C, 2005, NUCLEIC ACIDS RES, V33, P6566, DOI 10.1093/nar/gki965
   Vaquero A, 2007, NATURE, V450, P440, DOI 10.1038/nature06268
   Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037
   Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697
   Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228
   Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105
   Yao Y, 2010, CARCINOGENESIS, V31, P382, DOI 10.1093/carcin/bgp308
   Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103
   Zhang Y, 2009, ONCOGENE, V28, P445, DOI 10.1038/onc.2008.388
   Zillikens MC, 2009, DIABETES, V58, P2828, DOI 10.2337/db09-0536
NR 52
TC 229
Z9 257
U1 0
U2 24
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 22
PY 2011
VL 286
IS 29
BP 25992
EP 26002
DI 10.1074/jbc.M111.229401
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 796SS
UT WOS:000293073000058
PM 21596753
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU van Vlodrop, IJH
   Niessen, HEC
   Derks, S
   Baldewijns, MMLL
   van Criekinge, W
   Herman, JG
   van Engeland, M
AF van Vlodrop, Iris J. H.
   Niessen, Hanneke E. C.
   Derks, Sarah
   Baldewijns, Marcella M. L. L.
   van Criekinge, Wim
   Herman, James G.
   van Engeland, Manon
TI Analysis of Promoter CpG Island Hypermethylation in Cancer: Location,
   Location, Location!
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID UNSTABLE COLORECTAL-CANCER; METHYLATION-SPECIFIC PCR; TUMOR-SUPPRESSOR
   GENES; DE-NOVO METHYLATION; DNA METHYLATION; CELL-LINES; LUNG-CANCER;
   GASTRIC-CANCER; BREAST-CANCER; COLON-CANCER
AB The genetic and epigenetic alterations that underlie cancer pathogenesis are rapidly being identified. This provides novel insights in tumor biology as well as in potential cancer biomarkers. The somatic mutations in cancer genes that have been implemented in clinical practice are well defined and very specific. For epigenetic alterations, and more specifically aberrant methylation of promoter CpG islands, evidence is emerging that these markers could be used for the early detection of cancer as well as prediction of prognosis and response to therapy. However, the exact location of biologically and clinically relevant hypermethylation has not been identified for the majority of methylation markers. The most widely used approaches to analyze DNA methylation are based on primer- and probe-based assays that provide information for a limited number of CpG dinucleotides and thus for only part of the information available in a given CpG island. Validation of the current data and implementation of hypermethylation markers in clinical practice require a more comprehensive and critical evaluation of DNA methylation and limitations of the techniques currently used in methylation marker research. Here, we discuss the emerging evidence on the importance of the location of CpG dinucleotide hypermethylation in relation to gene expression and associations with clinicopathologic characteristics in cancer. Clin Cancer Res; 17(13); 4225-31. (C) 2011 AACR.
C1 [van Vlodrop, Iris J. H.; Niessen, Hanneke E. C.; Baldewijns, Marcella M. L. L.; van Engeland, Manon] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Dept Pathol, NL-6200 MD Maastricht, Netherlands.
   [Derks, Sarah] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Dept Internal Med, NL-6200 MD Maastricht, Netherlands.
   [van Criekinge, Wim] Univ Ghent, Dept Mol Biotechnol, B-9000 Ghent, Belgium.
   [Herman, James G.] Johns Hopkins Univ, Sch Med, Div Canc Biol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
C3 Maastricht University; Maastricht University; Ghent University; Johns
   Hopkins University; Johns Hopkins Medicine
RP van Engeland, M (通讯作者)，Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Dept Pathol, POB 616, NL-6200 MD Maastricht, Netherlands.
EM manon.van.engeland@mumc.nl
RI van Engeland, Manon/A-7479-2009; Niessen, Hanneke/B-7699-2009
OI Niessen, Hanneke/0000-0002-2639-0938; Derks, Sarah/0000-0002-4547-7457;
   Baldewijns, Marcella/0000-0002-0882-2944
FU Center for Translational Molecular Medicine [03O-101]
FX This work was supported by the Center for Translational Molecular
   Medicine (grant 03O-101).
CR Ahuja N, 1998, CANCER RES, V58, P5489
   Ahuja N, 2000, HISTOL HISTOPATHOL, V15, P835, DOI 10.14670/HH-15.835
   An Q, 2002, CANCER LETT, V188, P109, DOI 10.1016/S0304-3835(02)00496-2
   Bibikova M, 2009, EPIGENOMICS-UK, V1, P177, DOI 10.2217/EPI.09.14
   Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60
   BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0
   Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509
   Brock MV, 2008, NEW ENGL J MED, V358, P1118, DOI 10.1056/NEJMoa0706550
   Buffart TE, 2008, BRIT J CANCER, V99, P1802, DOI 10.1038/sj.bjc.6604777
   Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465
   Burgess-Beusse B, 2002, P NATL ACAD SCI USA, V99, P16433, DOI 10.1073/pnas.162342499
   Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451
   Christensen BC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000602
   Coolen MW, 2010, NAT CELL BIOL, V12, P235, DOI 10.1038/ncb2023
   Deng G, 2002, BRIT J CANCER, V86, P574, DOI 10.1038/sj.bjc.6600148
   Deng GR, 1999, CANCER RES, V59, P2029
   Derks S, 2004, CELL ONCOL, V26, P291
   Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173
   Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Ebert MPA, 2006, GASTROENTEROLOGY, V131, P1418, DOI 10.1053/j.gastro.2006.08.034
   Esteller M, 1999, CANCER RES, V59, P67
   Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Feltus FA, 2006, GENOMICS, V87, P572, DOI 10.1016/j.ygeno.2005.12.016
   Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100
   Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781
   Glöckner SC, 2009, CANCER RES, V69, P4691, DOI 10.1158/0008-5472.CAN-08-0142
   Gonzalgo ML, 1998, CANCER RES, V58, P1245
   Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322
   He HH., 2010, Nature Genetics, V42, P343
   Hegi ME, 2004, CLIN CANCER RES, V10, P1871, DOI 10.1158/1078-0432.CCR-03-0384
   Hellebrekers DMEI, 2009, CLIN CANCER RES, V15, P3990, DOI 10.1158/1078-0432.CCR-09-0055
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hitchins MP, 2007, CANCER RES, V67, P9107, DOI 10.1158/0008-5472.CAN-07-0869
   Homma N, 2006, CANCER SCI, V97, P51, DOI 10.1111/j.1349-7006.2005.00133.x
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Irvine RA, 2002, MOL CELL BIOL, V22, P6689, DOI 10.1128/MCB.22.19.6689-6696.2002
   Issa JPJ, 2001, CANCER RES, V61, P3573
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Jerónimo C, 2001, J NATL CANCER I, V93, P1747, DOI 10.1093/jnci/93.22.1747
   Jordà M, 2010, MUTAT RES-FUND MOL M, V693, P84, DOI 10.1016/j.mrfmmm.2010.06.010
   Kim MS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006555
   Ku M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000242
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lee PS, 2010, INT J CANCER, V126, P1378, DOI 10.1002/ijc.24797
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Lee TL, 2002, CLIN CANCER RES, V8, P1761
   Licchesi JDF, 2010, ONCOGENE, V29, P5923, DOI 10.1038/onc.2010.322
   Lin JC, 2007, CANCER CELL, V12, P432, DOI 10.1016/j.ccr.2007.10.014
   Lofton-Day C, 2008, CLIN CHEM, V54, P414, DOI 10.1373/clinchem.2007.095992
   MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282
   Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959
   Maunakea AK, 2010, NATURE, V466, P253, DOI 10.1038/nature09165
   McCabe MT, 2009, CANCER RES, V69, P282, DOI 10.1158/0008-5472.CAN-08-3274
   Melotte V, 2009, JNCI-J NATL CANCER I, V101, P916, DOI 10.1093/jnci/djp131
   Mohammad HP, 2009, CANCER RES, V69, P6322, DOI 10.1158/0008-5472.CAN-09-0065
   Mulero-Navarro S, 2008, CRIT REV ONCOL HEMAT, V68, P1, DOI 10.1016/j.critrevonc.2008.03.001
   Nagasaka T, 2004, J CLIN ONCOL, V22, P4584, DOI 10.1200/JCO.2004.02.154
   Nagasaka T, 2008, INT J CANCER, V122, P2429, DOI 10.1002/ijc.23398
   Nakagawa H, 2001, CANCER RES, V61, P6991
   Nestor C, 2010, BIOTECHNIQUES, V48, P317, DOI 10.2144/000113403
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Rauch TA, 2010, METHODS, V52, P213, DOI 10.1016/j.ymeth.2010.03.004
   Rodriguez J, 2008, P NATL ACAD SCI USA, V105, P19809, DOI 10.1073/pnas.0810133105
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Serre D, 2010, NUCLEIC ACIDS RES, V38, P391, DOI 10.1093/nar/gkp992
   Shu JM, 2006, CANCER RES, V66, P5077, DOI 10.1158/0008-5472.CAN-05-2629
   Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413
   Sohn BH, 2010, GASTROENTEROLOGY, V138, P1898, DOI 10.1053/j.gastro.2009.12.044
   Tiwari VK, 2008, PLOS BIOL, V6, P2911, DOI 10.1371/journal.pbio.0060306
   Uhlmann K, 2002, ELECTROPHORESIS, V23, P4072, DOI 10.1002/elps.200290023
   Unoki M, 2003, FEBS LETT, V554, P67, DOI 10.1016/S0014-5793(03)01092-5
   van Vlodrop IJH, 2010, AM J PATHOL, V176, P575, DOI 10.2353/ajpath.2010.090442
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Veeck J, 2010, J CLIN ONCOL, V28, pE563, DOI 10.1200/JCO.2010.30.1010
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Waki T, 2003, ONCOGENE, V22, P4128, DOI 10.1038/sj.onc.1206651
   Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Wong IHN, 1999, CANCER RES, V59, P71
   Yan PS, 2003, CANCER RES, V63, P6178
   Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/ng0501-29
   Zheng SC, 2000, CARCINOGENESIS, V21, P2057, DOI 10.1093/carcin/21.11.2057
   Zinn RL, 2007, CANCER RES, V67, P194, DOI 10.1158/0008-5472.CAN-06-3396
NR 87
TC 116
Z9 126
U1 0
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUL 1
PY 2011
VL 17
IS 13
BP 4225
EP 4231
DI 10.1158/1078-0432.CCR-10-3394
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 788LO
UT WOS:000292446600006
PM 21558408
OA Bronze
DA 2025-01-12
ER

PT J
AU Begum, S
   Brait, M
   Dasgupta, S
   Ostrow, KL
   Zahurak, M
   Carvalho, AL
   Califano, JA
   Goodman, SN
   Westra, WH
   Hoque, MO
   Sidransky, D
AF Begum, Shahnaz
   Brait, Mariana
   Dasgupta, Santanu
   Ostrow, Kimberly L.
   Zahurak, Marianna
   Carvalho, Andre L.
   Califano, Joseph A.
   Goodman, Steven N.
   Westra, William H.
   Hoque, Mohammad Obaidul
   Sidransky, David
TI An Epigenetic Marker Panel for Detection of Lung Cancer Using Cell-Free
   Serum DNA
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID ABERRANT PROMOTER METHYLATION; SPIRAL COMPUTED-TOMOGRAPHY; MULTIPLE
   GENES; PLASMA DNA; BREAST-CANCER; BRONCHOALVEOLAR LAVAGE; EARLY EVENT;
   HYPERMETHYLATION; TUMOR; SUPPRESSOR
AB Purpose: We investigated the feasibility of detecting aberrant DNA methylation of some novel and known genes in the serum of lung cancer patients.
   Experimental Design: To determine the analytic sensitivity, we examined the tumor and the matched serum DNA for aberrant methylation of 15 gene promoters from 10 patients with primary lung tumors by using quantitative methylation-specific PCR. We then tested this 15-gene set to identify the more useful DNA methylation changes in the serum of a limited number of lung cancer patients and controls. In an independent set, we tested the six most promising genes (APC, CDH1, MGMT, DCC, RASSF1A, and AIM1) for further elucidation of the diagnostic application of this panel of markers.
   Results: Promoter hypermethylation of at least one of the genes studied was detected in all 10 lung primary tumors. In majority of cases, aberrant methylation in serum DNA was accompanied by methylation in the matched tumor samples. In the independent set, using a single gene that had 100% specificity (DCC), 35.5% (95% CI: 25-47) of the 76 lung cancer patients were correctly identified. For patients without methylated DCC, addition of a logistic regression score that was based on the five remaining genes improved sensitivity from 35.5% to 75% (95% CI: 64-84) but decreased the specificity from 100% to 73% (95% CI: 54-88).
   Conclusion: This approach needs to be evaluated in a larger test set to determine the role of this gene set in early detection and surveillance of lung cancer. Clin Cancer Res; 17(13); 4494-503. (C) 2011 AACR.
C1 [Sidransky, David] Johns Hopkins Sch Med, Div Head & Neck Canc Res, Dept Otolaryngol & Head & Neck Surg, Baltimore, MD 21231 USA.
   [Zahurak, Marianna; Goodman, Steven N.] Johns Hopkins Sch Med, Div Biostat, Dept Oncol, Baltimore, MD 21231 USA.
   [Begum, Shahnaz; Westra, William H.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA.
   [Califano, Joseph A.] Greater Baltimore Med Ctr, Milton J Dance Head & Neck Ctr, Baltimore, MD USA.
   [Dasgupta, Santanu] Virginia Commonwealth Univ, Sch Med, Dept Human Mol Genet, VCU Inst Mol Med, Richmond, VA USA.
   [Carvalho, Andre L.] Barretos Canc Hosp, Dept Head & Neck Surg, Sao Paulo, Brazil.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Medicine; Johns Hopkins University; Johns
   Hopkins Medicine; Greater Baltimore Medical Center; Virginia
   Commonwealth University; Hospital de Cancer de Barretos
RP Sidransky, D (通讯作者)，Johns Hopkins Sch Med, Div Head & Neck Canc Res, Dept Otolaryngol & Head & Neck Surg, 1550 Orleans St 5N-03, Baltimore, MD 21231 USA.
EM dsidrans@jhmi.edu
RI Lopes Carvalho, Andre/S-7053-2016
OI Lopes Carvalho, Andre/0000-0001-7214-6402; Brait,
   Mariana/0000-0002-1652-8921; Hoque, Mohammad Obaidul/0000-0001-6701-9978
FU National Cancer Institute, Oncomethylome Sciences, SA [U01-CA84986];
   Flight Attendant Medical Research Institute; International Association
   for the Study of Lung Cancer
FX This work was supported by National Cancer Institute grant U01-CA84986,
   Oncomethylome Sciences, SA. S. Begum is supported by a Young Clinical
   Scientist award from the Flight Attendant Medical Research Institute and
   M.O. Hoque is supported by the Young Investigator Award from the
   International Association for the Study of Lung Cancer.
CR Ahrendt SA, 1999, JNCI-J NATL CANCER I, V91, P332, DOI 10.1093/jnci/91.4.332
   An Q, 2002, CANCER LETT, V188, P109, DOI 10.1016/S0304-3835(02)00496-2
   Baur AS, 1999, BLOOD, V94, P1773, DOI 10.1182/blood.V94.5.1773.417a12_1773_1781
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Belinsky SA, 2002, CANCER RES, V62, P2370
   Belinsky SA, 2006, CANCER RES, V66, P3338, DOI 10.1158/0008-5472.CAN-05-3408
   Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891
   BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I
   Brabender J, 2003, CLIN CANCER RES, V9, P223
   Cirincione R, 2006, INT J CANCER, V118, P1248, DOI 10.1002/ijc.21473
   Conway KE, 2000, CANCER RES, V60, P6236
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Ellis JRC, 2001, BRIT J RADIOL, V74, P478, DOI 10.1259/bjr.74.882.740478
   Esteller M, 2000, CANCER RES, V60, P4366
   Esteller M, 1999, CANCER RES, V59, P67
   Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178
   Esteller M, 2003, ADV EXP MED BIOL, V532, P39
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709
   Harden SV, 2003, CLIN CANCER RES, V9, P1370
   Henschke CI, 2000, CANCER, V89, P2474
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   Hoque MO, 2006, JNCI-J NATL CANCER I, V98, P996, DOI 10.1093/jnci/djj265
   Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Leonhardt H, 2000, J CELL BIOCHEM, P78
   LITTLE M, 1995, NAT MED, V1, P633, DOI 10.1038/nm0795-633
   Lo YMD, 2001, ANN NY ACAD SCI, V945, P1
   Lu C, 2004, J CLIN ONCOL, V22, P4575, DOI 10.1200/JCO.2004.01.091
   Marcus PM, 2001, J CLIN ONCOL, V19, p83S
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   Mulshine JL, 2005, NEW ENGL J MED, V352, P2714, DOI 10.1056/NEJMcp042630
   Ngan RKC, 2001, ANN NY ACAD SCI, V945, P73
   Ostrow KL, 2010, CLIN CANCER RES, V16, P3463, DOI 10.1158/1078-0432.CCR-09-3304
   Palmisano WA, 2000, CANCER RES, V60, P5954
   Sato M, 1998, HUM GENET, V103, P96, DOI 10.1007/s004390050790
   SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123
   Singhal S, 2005, CLIN CANCER RES, V11, P3974, DOI 10.1158/1078-0432.CCR-04-2661
   Swensen SJ, 2002, AM J RESP CRIT CARE, V165, P508, DOI 10.1164/ajrccm.165.4.2107006
   Topaloglu O, 2004, CLIN CANCER RES, V10, P2284, DOI 10.1158/1078-0432.CCR-1111-3
   Tsou JA, 2002, ONCOGENE, V21, P5450, DOI 10.1038/sj.onc.1205605
   Tsuda H, 2000, BRIT J CANCER, V82, P675
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Usadel H, 2002, CANCER RES, V62, P371
   Wardwell NR, 2005, SEMIN ONCOL, V32, P259, DOI 10.1053/j.seminoncol.2005.02.009
   Wingo PA, 1999, J NATL CANCER I, V91, P675, DOI 10.1093/jnci/91.8.675
   YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P249
   Zöchbauer-Müller S, 2002, ONCOLOGIST, V7, P451, DOI 10.1634/theoncologist.7-5-451
NR 50
TC 117
Z9 124
U1 1
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUL 1
PY 2011
VL 17
IS 13
BP 4494
EP 4503
DI 10.1158/1078-0432.CCR-10-3436
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 788LO
UT WOS:000292446600030
PM 21610147
OA Green Submitted, Green Accepted
DA 2025-01-12
ER

PT J
AU Xu, X
   Liu, RF
   Wan, BB
   Xing, WM
   Huang, J
   Han, ZG
AF Xu, Xiao
   Liu, Rui-Fang
   Wan, Bing-Bing
   Xing, Wen-Ming
   Huang, Jian
   Han, Ze-Guang
TI Expression of a novel gene FAM43B repressing cell proliferation is
   regulated by DNA methylation in hepatocellular carcinoma cell lines
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE FAM43B; Hepatocellular carcinoma; Methylation; Cell growth; RNA
   interference
ID FULL-LENGTH HUMAN; DOWN-REGULATION; PHARMACOLOGICAL UNMASKING; PROMOTER
   METHYLATION; BREAST-CANCER; E-CADHERIN; SFRP1
AB The epigenetic dysregulation of tumor suppressor genes plays an important role in many cancers, including hepatocellular carcinoma (HCC). In this study, we identified a new gene, family with sequence similarity 43, member B (FAM43B), based on a previous genome-wide approach. FAM43B was significantly downregulated in 60% (24/40) HCC specimens as compared to non-HCC livers. Enforced FAM43B overexpression could suppress cell growth and colony formation in vitro, and induce cell cycle delay, whereas FAM43B knockdown enhanced cell growth. The expression level of FAM43B was found related to the methylation level of FAM43B promoter in HCC cell lines and HCC specimens. The collective data suggest that the expression of FAM43B was regulated by methylation and the epigenetic silencing of FAM43B could contribute to HCC tumorigenesis by regulating cell proliferation.
C1 [Xu, Xiao; Liu, Rui-Fang; Wan, Bing-Bing; Xing, Wen-Ming; Huang, Jian; Han, Ze-Guang] Chinese Natl Human Genome Ctr, Shanghai MOST Key Lab Dis & Hlth Genom, Shanghai 201203, Peoples R China.
   [Xu, Xiao; Liu, Rui-Fang; Huang, Jian; Han, Ze-Guang] Shanghai Jiao Tong Univ, Natl Human Genome Ctr, Rui Jin Hosp, Sch Med, Shanghai 200025, Peoples R China.
C3 Shanghai Jiao Tong University
RP Han, ZG (通讯作者)，Chinese Natl Human Genome Ctr, Shanghai MOST Key Lab Dis & Hlth Genom, 351 Guo Shou Jing Rd, Shanghai 201203, Peoples R China.
EM hanzg@chgc.sh.cn
RI Zhu, Yuyan/ABE-4176-2021
OI Han, Ze-Guang/0000-0002-1018-1752; Wan, Bingbing/0000-0001-8629-0616
FU China National Key Projects for Infectious Disease [2008ZX10002-020,
   2008ZX10002-021]; National Basic Research Program of China
   [2010CB529204]; International Scientific Collaborative Project
   [20072901]; Shanghai Commission for Science and Technology
FX This study was supported by China National Key Projects for Infectious
   Disease (2008ZX10002-020 and 2008ZX10002-021), National Basic Research
   Program of China (2010CB529204), International Scientific Collaborative
   Project (20072901), and the Shanghai Commission for Science and
   Technology.
CR Cheung TH, 2004, GYNECOL ONCOL, V93, P621, DOI 10.1016/j.ygyno.2004.03.013
   Gregory SG, 2006, NATURE, V441, P315, DOI 10.1038/nature04727
   HERMAN JG, 1995, CANCER RES, V55, P4525
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Huang J, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-126
   Huang J, 2010, J CLIN INVEST, V120, P223, DOI 10.1172/JCI38012
   Kubo T, 2004, CANCER RES, V64, P5172, DOI 10.1158/0008-5472.CAN-03-3314
   Liu J, 2006, ONCOGENE, V25, P1008, DOI 10.1038/sj.onc.1209138
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996
   Matsuda Y, 1999, GASTROENTEROLOGY, V116, P394, DOI 10.1016/S0016-5085(99)70137-X
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   Ostrow KL, 2009, CLIN CANCER RES, V15, P1184, DOI 10.1158/1078-0432.CCR-08-1304
   Ota T, 2004, NAT GENET, V36, P40, DOI 10.1038/ng1285
   Shih YL, 2006, CANCER, V107, P579, DOI 10.1002/cncr.22023
   Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Wong CM, 2003, CANCER RES, V63, P7646
   Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5
NR 19
TC 9
Z9 10
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300-8177
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD AUG
PY 2011
VL 354
IS 1-2
BP 11
EP 20
DI 10.1007/s11010-011-0800-y
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 785GO
UT WOS:000292215600002
PM 21461611
DA 2025-01-12
ER

PT J
AU Mathews, HL
   Konley, T
   Kosik, KL
   Krukowski, K
   Eddy, J
   Albuquerque, K
   Janusek, LW
AF Mathews, Herbert L.
   Konley, Teresa
   Kosik, Kelly Loster
   Krukowski, Karen
   Eddy, Justin
   Albuquerque, Kevin
   Janusek, Linda Witek
TI Epigenetic patterns associated with the immune dysregulation that
   accompanies psychosocial distress
SO BRAIN BEHAVIOR AND IMMUNITY
LA English
DT Article
DE NK cell activity; Epigenetic; Histone acetylation and phosphorylation;
   Interferon gamma
ID NF-KAPPA-B; GYRUS GRANULE NEURONS; HISTONE H3 PHOSPHORYLATION;
   TUMOR-NECROSIS-FACTOR; NATURAL-KILLER-CELLS; QUALITY-OF-LIFE;
   GLUCOCORTICOID-RECEPTOR; CHRONIC STRESS; BREAST-CANCER; CYTOKINE
   DYSREGULATION
AB The molecular basis for psychosocial-distress mediated immune-dysregulation is not well understood. The purpose of this study was to determine whether peripheral blood mononuclear cell (PBMC) epigenetic pattern associates with this form of immune dysregulation. Women newly diagnosed with early stage breast cancer were enrolled into the study and psychosocial, immunological and epigenetic assessments were made at diagnosis and four months later, after completion of cancer treatment. At diagnosis women reported increased perceived stress, anxiety, and mood disturbance and the PBMC of these women exhibited reduced natural killer cell activity and reduced production of interferon gamma, which contrasted with results, obtained after completion of treatment. At the epigenetic level, a PBMC subset derived from women at diagnosis exhibited a distinct epigenetic pattern, with reduced nuclear acetylation of histone residues H4-K8 and H4-K12, as well as reduced phosphorylation of H3-S10, when compared to similar cells derived after the completion of treatment. Natural killer cell activity and interferon-gamma production were associated with nuclear acetylation and phosphorylation status of these histone residues. These findings demonstrate associations among nuclear epigenetic pattern and the immune dysregulation that accompanies psychosocial distress. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Mathews, Herbert L.; Konley, Teresa; Kosik, Kelly Loster; Krukowski, Karen; Eddy, Justin] Loyola Univ Chicago, Dept Microbiol & Immunol, Stritch Sch Med, Maywood, IL 60153 USA.
   [Albuquerque, Kevin] Loyola Univ Chicago, Dept Radiat Oncol, Stritch Sch Med, Maywood, IL 60153 USA.
   [Janusek, Linda Witek] Loyola Univ Chicago, Niehoff Sch Nursing, Maywood, IL 60153 USA.
C3 Loyola University Chicago; Loyola University Chicago; Loyola University
   Chicago
RP Mathews, HL (通讯作者)，Loyola Univ Chicago, Dept Microbiol & Immunol, Stritch Sch Med, 2160 S 1st Ave, Maywood, IL 60153 USA.
EM LJANUSE@luc.edu
FU National Cancer Institute [R21-CA-117261, R01-CA-134736]; Research
   Committee of the Council, Stritch School of Medicine
FX The study was supported in part by the National Cancer Institute
   R21-CA-117261, R01-CA-134736 and the Research Committee of the Council,
   Stritch School of Medicine. The authors gratefully acknowledge the
   expertise of Patricia Simms Loyola University Health Systems Flow
   Cytometry Facility and the assistance of Valerie Bednar, RN, MSN and
   Jennie Johnson, RN for recruitment of subjects and collection of
   clinical and psychological data. Importantly, the authors express
   sincere gratitude to those women with breast cancer who volunteered to
   participate in this study.
CR Andersen BL, 1998, JNCI-J NATL CANCER I, V90, P30, DOI 10.1093/jnci/90.1.30
   Andersen BL, 2004, J CLIN ONCOL, V22, P3570, DOI 10.1200/JCO.2004.06.030
   Arbibe L, 2007, NAT IMMUNOL, V8, P47, DOI 10.1038/ni1423
   Avni O, 2002, NAT IMMUNOL, V3, P643, DOI 10.1038/ni808
   Avraham R, 2007, PSYCHONEUROIMMUNOLOGY, VOLS I AND II, 4TH EDITION, P251
   Babichuk CK, 1996, J BIOL CHEM, V271, P16485, DOI 10.1074/jbc.271.28.16485
   Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557
   Barnes PJ, 1995, BIOCHEM SOC T, V23, P940, DOI 10.1042/bst0230940
   BENO DWA, 1995, J IMMUNOL, V154, P5273
   Bilang-Bleuel A, 2005, EUR J NEUROSCI, V22, P1691, DOI 10.1111/j.1460-9568.2005.04358.x
   Biondi M., 2001, Psychoneuroimmunology, V1, P189
   Bjornsson HT, 2004, TRENDS GENET, V20, P350, DOI 10.1016/j.tig.2004.06.009
   Chandramohan Y, 2008, EUR J NEUROSCI, V27, P2701, DOI 10.1111/j.1460-9568.2008.06230.x
   Chandramohan Y, 2007, J NEUROCHEM, V101, P815, DOI 10.1111/j.1471-4159.2006.04396.x
   Chrousos GP, 2000, ANN NY ACAD SCI, V917, P38, DOI 10.1111/j.1749-6632.2000.tb05371.x
   CHROUSOS GP, 1992, JAMA-J AM MED ASSOC, V267, P1244, DOI 10.1001/jama.267.9.1244
   CIPPITELLI M, 1995, J BIOL CHEM, V270, P12548, DOI 10.1074/jbc.270.21.12548
   COHEN S, 1988, CLAR SYMP, P31
   Cole SW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r189
   Cuddapah S, 2010, CURR OPIN IMMUNOL, V22, P341, DOI 10.1016/j.coi.2010.02.007
   Decker D, 1996, SURGERY, V119, P316, DOI 10.1016/S0039-6060(96)80118-8
   DIGHE AS, 1994, IMMUNITY, V1, P447, DOI 10.1016/1074-7613(94)90087-6
   EDGAR L, 1992, CANCER-AM CANCER SOC, V69, P817, DOI 10.1002/1097-0142(19920201)69:3<817::AID-CNCR2820690334>3.0.CO;2-S
   Espada J, 2007, CELL MOL LIFE SCI, V64, P449, DOI 10.1007/s00018-007-6358-x
   ESTERLING BA, 1994, HEALTH PSYCHOL, V13, P291, DOI 10.1037/0278-6133.13.4.291
   FAWZY FI, 1990, ARCH GEN PSYCHIAT, V47, P729
   Ganz PA, 1996, BREAST CANCER RES TR, V38, P183, DOI 10.1007/BF01806673
   Glaser R, 2005, NAT REV IMMUNOL, V5, P243, DOI 10.1038/nri1571
   GLASER R, 1986, BEHAV NEUROSCI, V100, P675, DOI 10.1037/0735-7044.100.5.675
   Govind CK, 2007, MOL CELL, V25, P31, DOI 10.1016/j.molcel.2006.11.020
   Henikoff S, 2005, ANNU REV CELL DEV BI, V21, P133, DOI 10.1146/annurev.cellbio.21.012704.133518
   Homburger JA, 2006, CURR OPIN ANESTHESIO, V19, P423, DOI 10.1097/01.aco.0000236143.61593.14
   Hunter RG, 2009, P NATL ACAD SCI USA, V106, P20912, DOI 10.1073/pnas.0911143106
   Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000
   Ito K, 2006, J EXP MED, V203, P7, DOI 10.1084/jem.20050466
   KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0
   Kagoshima M, 2003, BIOCHEM SOC T, V31, P60, DOI 10.1042/bst0310060
   Kagoshima M, 2001, EUR J PHARMACOL, V429, P327, DOI 10.1016/S0014-2999(01)01332-2
   Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556
   Kemeny ME, 2007, BRAIN BEHAV IMMUN, V21, P1009, DOI 10.1016/j.bbi.2007.07.010
   KIECOLTGLASER JK, 1987, PSYCHOSOM MED, V49, P523, DOI 10.1097/00006842-198709000-00008
   KiecoltGlaser JK, 1996, P NATL ACAD SCI USA, V93, P3043, DOI 10.1073/pnas.93.7.3043
   KIECOLTGLASER JK, 1991, PSYCHOSOM MED, V53, P345, DOI 10.1097/00006842-199107000-00001
   Kim HG, 2008, CANCER RES, V68, P2538, DOI 10.1158/0008-5472.CAN-07-6597
   Koda K, 1997, INT SURG, V82, P190
   Koltun WA, 1996, AM J SURG, V171, P68, DOI 10.1016/S0002-9610(99)80076-2
   KRUKOWSKI K, BRAIN BEHAV IN PRESS
   Kutza J, 1997, ANESTH ANALG, V85, P918, DOI 10.1097/00000539-199710000-00037
   Larson MR, 2000, J PSYCHOSOM RES, V48, P187, DOI 10.1016/S0022-3999(99)00110-5
   Lieb JD, 2005, CELL, V123, P1187, DOI 10.1016/j.cell.2005.12.010
   Lu QJ, 2003, J IMMUNOL, V170, P5124, DOI 10.4049/jimmunol.170.10.5124
   Lutgendorf SK, 2007, PSYCHONEUROIMMUNOLOGY, VOLS I AND II, 4TH EDITION, P869
   Maes M, 1999, BIOL PSYCHIAT, V45, P833, DOI 10.1016/S0006-3223(98)00131-0
   Marshall GD, 1998, BRAIN BEHAV IMMUN, V12, P297, DOI 10.1006/brbi.1998.0537
   Martino DJ, 2010, ALLERGY, V65, P7, DOI 10.1111/j.1398-9995.2009.02186.x
   Matthews JG, 2004, J ALLERGY CLIN IMMUN, V113, P1100, DOI 10.1016/j.jaci.2004.03.018
   McNair D.M., 1992, Revised Manual for the Profile of Mood States
   Miller GE, 2008, BIOL PSYCHIAT, V64, P266, DOI 10.1016/j.biopsych.2008.03.017
   Mishra N, 2001, P NATL ACAD SCI USA, V98, P2628, DOI 10.1073/pnas.051507098
   Mokart D, 2002, BRIT J SURG, V89, P1450, DOI 10.1046/j.1365-2168.2002.02218.x
   Monroe S., 1995, MEASURING STRESS, P122
   Muegge K, 2003, ANN NY ACAD SCI, V983, P55, DOI 10.1111/j.1749-6632.2003.tb05962.x
   Nagabhushan M, 2001, BRAIN BEHAV IMMUN, V15, P78, DOI 10.1006/brbi.2000.0589
   *NAT CANC I, 1997, CANC FACTS 1996
   Parra M, 2007, GENE DEV, V21, P638, DOI 10.1101/gad.1513107
   PLESKO MM, 1983, J BIOL CHEM, V258, P3738
   POLLOCK RE, 1991, ARCH SURG-CHICAGO, V126, P338
   Reinke H, 2003, MOL CELL, V11, P1599, DOI 10.1016/S1097-2765(03)00186-2
   Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748
   SACHS G, 1995, J NEUROIMMUNOL, V59, P83, DOI 10.1016/0165-5728(95)00029-2
   Schotta Gunnar, 2004, Novartis Found Symp, V259, P22
   Segerstrom SC, 2004, PSYCHOL BULL, V130, P601, DOI 10.1037/0033-2909.130.4.601
   Seki N, 2003, CANCER RES, V63, P207
   Shahbazian MD, 2007, ANNU REV BIOCHEM, V76, P75, DOI 10.1146/annurev.biochem.76.052705.162114
   Shakhar G, 2003, ANN SURG ONCOL, V10, P972, DOI 10.1245/ASO.2003.02.007
   Shapiro SL, 2001, J CLIN PSYCHOL, V57, P501, DOI 10.1002/jclp.1026
   Smyth MJ, 2005, J EXP MED, V201, P1973, DOI 10.1084/jem.20042280
   Smyth MJ, 1999, J IMMUNOL, V162, P6658
   Smyth MJ, 1998, J EXP MED, V188, P1611, DOI 10.1084/jem.188.9.1611
   SPIELBERGER CD, 1970, MANUAL STATE TRAIT A, P457
   Spies CD, 2004, ANESTHESIOLOGY, V100, P1088, DOI 10.1097/00000542-200405000-00010
   Street SEA, 2001, BLOOD, V97, P192, DOI 10.1182/blood.V97.1.192
   Thomas RM, 2005, J IMMUNOL, V174, P4639, DOI 10.4049/jimmunol.174.8.4639
   Thornton LM, 2007, BRAIN BEHAV IMMUN, V21, P185, DOI 10.1016/j.bbi.2006.06.007
   Tsankova NM, 2006, NAT NEUROSCI, V9, P519, DOI 10.1038/nn1659
   Tsaprouni LG, 2002, ANN NY ACAD SCI, V973, P481, DOI 10.1111/j.1749-6632.2002.tb04688.x
   vandenBroek MF, 1996, J EXP MED, V184, P1781, DOI 10.1084/jem.184.5.1781
   Wallace ME, 2005, SPRINGER SEMIN IMMUN, V27, P49, DOI 10.1007/s00281-004-0195-x
   Whelan RL, 2003, SURG ENDOSC, V17, P972, DOI 10.1007/s00464-001-8263-y
   Wichmann MW, 2003, DIS COLON RECTUM, V46, P875, DOI 10.1007/s10350-004-6677-z
   Wilkinson MB, 2009, J NEUROSCI, V29, P7820, DOI 10.1523/JNEUROSCI.0932-09.2009
   Witek-Janusek L, 2000, HANDBOOK OF STRESS, COPING AND HEALTH: IMPLICATIONS FOR NURSING RESEARCH, THEORY, AND PRACTICE, P47
   Witek-Janusek L, 1999, PEDIATR RES, V45, P224, DOI 10.1203/00006450-199902000-00011
   Witek-Janusek L, 2008, BRAIN BEHAV IMMUN, V22, P969, DOI 10.1016/j.bbi.2008.01.012
   Witek-Janusek L, 2007, PSYCHONEUROENDOCRINO, V32, P22, DOI 10.1016/j.psyneuen.2006.09.011
   Wrona D, 2006, J NEUROIMMUNOL, V172, P38, DOI 10.1016/j.jneuroim.2005.10.017
   YAMAMURA Y, 1995, CELL MOL BIOL, V41, pS121
   Zhang TY, 2010, ANNU REV PSYCHOL, V61, P439, DOI 10.1146/annurev.psych.60.110707.163625
NR 98
TC 17
Z9 24
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0889-1591
EI 1090-2139
J9 BRAIN BEHAV IMMUN
JI Brain Behav. Immun.
PD JUL
PY 2011
VL 25
IS 5
SI SI
BP 830
EP 839
DI 10.1016/j.bbi.2010.12.002
PG 10
WC Immunology; Neurosciences; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Neurosciences & Neurology; Psychiatry
GA 780EF
UT WOS:000291836600004
PM 21146603
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Selinger, CI
   Cooper, WA
   Al-Sohaily, S
   Mladenova, DN
   Pangon, L
   Kennedy, CW
   McCaughan, BC
   Stirzaker, C
   Kohonen-Corish, MRJ
AF Selinger, Christina I.
   Cooper, Wendy A.
   Al-Sohaily, Sam
   Mladenova, Dessislava N.
   Pangon, Laurent
   Kennedy, Catherine W.
   McCaughan, Brian C.
   Stirzaker, Clare
   Kohonen-Corish, Maija R. J.
TI Loss of Special AT-Rich Binding Protein 1 Expression is a Marker of Poor
   Survival in Lung Cancer
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Article
DE SATB1; Lung cancer; Prognostic; Biomarker
ID DOMAIN-MEDIATED DIMERIZATION; CIGARETTE-SMOKING; GENE-EXPRESSION;
   CHROMOSOME 3P; BRONCHIAL EPITHELIUM; HISTOLOGIC TYPE; RISK-ASSESSMENT;
   GASTRIC-CANCER; BREAST-CANCER; DNA-BINDING
AB Introduction: Lung cancer is the leading cause of cancer-related mortality and requires more effective molecular markers of prognosis and therapeutic responsiveness. Special AT-rich binding protein 1 (SATB1) is a global genome organizer that recruits chromatin remodeling proteins to epigenetically regulate hundreds of genes in a tissue-specific manner. Initial studies suggest that SATB1 overexpression is a predictor of poor prognosis in breast cancer, but the prognostic significance of SATB1 expression has not been evaluated in lung cancer.
   Methods: A cohort of 257 lung cancers was evaluated by immunohistochemistry. Epigenetic silencing of SATB1 was examined in cell lines by 5-Aza 2-deoxycytidine and trichostatin A treatment, and chromatin immunoprecipitation.
   Results: Significant loss of SATB1 expression was found in squamous preinvasive lesions (p < 0.04) and in non-small cell lung cancers (p < 0.001) compared with matched normal bronchial epithelium. Loss of SATB1 independently predicted poor cancer-specific survival in squamous cell carcinomas (SCCs; hazard ratio: 2.06, 95% confidence interval: 1.2-3.7, p = 0.016). Treatment of lung cancer cell lines with the histone deacetylase inhibitor trichostatin A resulted in up-regulation of SATB1. SATB1 was associated with a decrease in the active chromatin mark acetylated histone H3K9 and an increase in the repressive polycomb mark trimethylated H3K27 in a SCC cell line relative to a normal bronchial epithelial cell line.
   Conclusions: This is the first study showing that SATB1 expression is lost in early preinvasive squamous lesions and that loss of SATB1 is associated with poor prognosis in lung SCC. We hypothesize that the SATB1 gene is epigenetically silenced through histone modifications.
C1 [Selinger, Christina I.; Al-Sohaily, Sam; Mladenova, Dessislava N.; Pangon, Laurent; Stirzaker, Clare; Kohonen-Corish, Maija R. J.] Garvan Inst Med Res, Canc Res Program, Sydney, NSW, Australia.
   [Selinger, Christina I.; Cooper, Wendy A.] Royal Prince Alfred Hosp, Camperdown, NSW 2050, Australia.
   [Cooper, Wendy A.] Univ Western Sydney, Sch Med, Discipline Pathol, Sydney, NSW, Australia.
   [Kennedy, Catherine W.] Strathfield Private Hosp, Dept Surg, Sydney, NSW, Australia.
   [McCaughan, Brian C.] Royal Prince Alfred Hosp, Dept Cardiothorac Surg, Sydney, NSW, Australia.
   [Kohonen-Corish, Maija R. J.] Univ New S Wales, St Vincents Clin Sch, Fac Med, Sydney, NSW, Australia.
C3 Garvan Institute of Medical Research; NSW Health; Royal Prince Alfred
   Hospital; University of Sydney; Western Sydney University; NSW Health;
   Royal Prince Alfred Hospital; University of Sydney; University of New
   South Wales Sydney
RP Selinger, CI (通讯作者)，Royal Prince Alfred Hosp, Bldg 94,Missenden Rd, Camperdown, NSW 2050, Australia.
EM selinger.tina1@gmail.com
RI Kohonen-Corish, Maija/Q-9763-2019
OI Stirzaker, Clare/0000-0001-5601-3140; Kohonen-Corish,
   Maija/0000-0002-4073-1479
FU Cancer Institute NSW [09/RIG/1-18, 09/RIG/1-03, 07/CDF/1-19]; Australian
   Cancer Research Foundation; Garvan Research Foundation; RT Hall Trust
FX Supported by the Cancer Institute NSW (Grants 09/RIG/1-18 and
   09/RIG/1-03), Australian Cancer Research Foundation (2010), the Garvan
   Research Foundation and RT Hall Trust. M.R.J.K. is a Cancer Institute
   NSW Career Development Fellow (07/CDF/1-19).
CR Abrmofff MD., 2005, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1201/9781420005615.AX4
   Alvarez JD, 2000, GENE DEV, V14, P521
   AUERBACH O, 1979, NEW ENGL J MED, V300, P381, DOI 10.1056/NEJM197902223000801
   Baguma-Nibasheka M, 2007, HISTOL HISTOPATHOL, V22, P483, DOI 10.14670/HH-22.483
   Barbone F, 1997, CHEST, V112, P1474, DOI 10.1378/chest.112.6.1474
   Barlesi F, 2007, J CLIN ONCOL, V25, P4358, DOI 10.1200/JCO.2007.11.2599
   Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733
   Cai ST, 2003, NAT GENET, V34, P42, DOI 10.1038/ng1146
   Cheng C, 2010, APMIS, V118, P855, DOI 10.1111/j.1600-0463.2010.02673.x
   Crystal Ronald G, 2008, Proc Am Thorac Soc, V5, P772, DOI 10.1513/pats.200805-041HR
   de Belle I, 1998, J CELL BIOL, V141, P335, DOI 10.1083/jcb.141.2.335
   DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C
   Edge SB., 2010, AJCC Cancer Staging Manual, P253
   Elias AD, 1997, CHEST, V112, pS251, DOI 10.1378/chest.112.4_Supplement.251S
   Forbes S A, 2008, Curr Protoc Hum Genet, VChapter 10, DOI 10.1002/0471142905.hg1011s57
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Galande S, 2001, MOL CELL BIOL, V21, P5591, DOI 10.1128/MCB.21.16.5591-5604.2001
   GAZDAR AF, 1994, ANTICANCER RES, V14, P261
   Greenberg AK, 2002, RESPIR RES, V3, DOI 10.1186/rr170
   Han HJ, 2008, NATURE, V452, P187, DOI 10.1038/nature06781
   HANKER LC, BREAST IN PRESS, DOI DOI 10.1016/J.BREAST.2010.10.002
   Harvey BG, 2007, J MOL MED, V85, P39, DOI 10.1007/s00109-006-0103-z
   HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558
   Iorns E, 2010, JNCI-J NATL CANCER I, V102, P1284, DOI 10.1093/jnci/djq243
   Jeanmart M, 2003, CLIN CANCER RES, V9, P2195
   Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106
   Khuder SA, 2001, LUNG CANCER, V31, P139, DOI 10.1016/S0169-5002(00)00181-1
   Lantuéjoul S, 2009, HISTOPATHOLOGY, V54, P43, DOI 10.1111/j.1365-2559.2008.03182.x
   LI QQ, CANC SCI, V101, P80
   Liu ZY, 2008, LUNG CANCER, V62, P15, DOI 10.1016/j.lungcan.2008.02.005
   Lu XM, 2010, ONCOL REP, V24, P981, DOI 10.3892/or_00000945
   Patani N, 2009, CANCER CELL INT, V9, DOI 10.1186/1475-2867-9-18
   Pavan KP, 2006, MOL CELL, V22, P231, DOI 10.1016/j.molcel.2006.03.010
   Purbey PK, 2008, NUCLEIC ACIDS RES, V36, P2107, DOI 10.1093/nar/gkm1151
   Purbey PK, 2009, MOL CELL BIOL, V29, P1321, DOI 10.1128/MCB.00822-08
   Savarese F, 2009, GENE DEV, V23, P2625, DOI 10.1101/gad.1815709
   Seng TJ, 2008, BRIT J CANCER, V99, P375, DOI 10.1038/sj.bjc.6604452
   Shibuya K, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-37
   Sobin L.H., 2009, UICC: TNM classification of malignant tumors, V7th
   Sobue T, 2002, INT J CANCER, V99, P245, DOI 10.1002/ijc.10308
   Stearman RS, 2005, AM J PATHOL, V167, P1763, DOI 10.1016/S0002-9440(10)61257-6
   Tai ALS, 2006, CANCER RES, V66, P4133, DOI 10.1158/0008-5472.CAN-05-2775
   Talbot SG, 2005, CANCER RES, V65, P3063, DOI 10.1158/0008-5472.CAN-04-1985
   Van Den Broeck A, 2008, CLIN CANCER RES, V14, P7237, DOI 10.1158/1078-0432.CCR-08-0869
   Wistuba II, 2006, ANNU REV PATHOL-MECH, V1, P331, DOI 10.1146/annurev.pathol.1.110304.100103
   Wistuba II, 2000, CANCER RES, V60, P1949
   Wistuba II, 2005, CLIN CANCER RES, V11, P1358, DOI 10.1158/1078-0432.CCR-04-2156
   Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084
   Zhao XD, 2010, ORL-J OTO-RHIN-LARYN, V72, P1, DOI 10.1159/000264777
   Zhou Lai-Yong, 2009, Nan Fang Yi Ke Da Xue Xue Bao, V29, P534
NR 50
TC 71
Z9 75
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUL
PY 2011
VL 6
IS 7
BP 1179
EP 1189
DI 10.1097/JTO.0b013e31821b4ce0
PG 11
WC Oncology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Respiratory System
GA 778CY
UT WOS:000291678200005
PM 21597389
OA Bronze
DA 2025-01-12
ER

PT J
AU Kravchenko, J
   Akushevich, I
   Seewaldt, VL
   Abernethy, AP
   Lyerly, HK
AF Kravchenko, Julia
   Akushevich, Igor
   Seewaldt, Victoria L.
   Abernethy, Amy P.
   Lyerly, H. Kim
TI Breast cancer as heterogeneous disease: contributing factors and
   carcinogenesis mechanisms
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast lobular carcinoma; Breast ductal carcinoma; Age patterns; Grade;
   Estrogen receptor; Progesterone receptor; Carcinogenesis
ID CARCINOMA IN-SITU; GENE-EXPRESSION; DUCTAL CARCINOMA; FEMALE BREAST;
   CONSERVING THERAPY; HISTOLOGICAL GRADE; ESTROGEN-RECEPTOR;
   MAMMARY-CARCINOMA; LOCAL RECURRENCE; AGE DISTRIBUTION
AB The observed bimodal patterns of breast cancer incidence in the U.S. suggested that breast cancer may be viewed as more than one biological entity. We studied the factors potentially contributing to this phenomenon, specifically focusing on how disease heterogeneity could be linked to breast carcinogenesis mechanisms. Using empirical analyses and population-based biologically motivated modeling, age-specific patterns of incidence of ductal and lobular breast carcinomas from the SEER registry (1990-2003) were analyzed for heterogeneity and characteristics of carcinogenesis, stratified by race, stage, grade, and estrogen (ER)/progesterone (PR) receptor status. The heterogeneity of breast carcinoma age patterns decreased after stratification by grade, especially for grade I and III tumors. Stratification by ER/PR status further reduced the heterogeneity, especially for ER(+)/PR(-) and ER(-)/(-) tumors; however, the residual heterogeneity was still observed. The number of rate-limiting events of carcinogenesis and the latency of ductal and lobular carcinomas differed, decreasing from grade I to III, with poorly differentiated tumors associated with the least number of carcinogenesis stages and the shortest latency. Tumor grades play important role in bimodal incidence of breast carcinoma and have distinct mechanisms of carcinogenesis. Race and cancer subtype could play modifying role. ER/PR status contributes to the observed heterogeneity, but is subdominant to tumor grade. Further studies on sources of "remaining" heterogeneity of population with breast cancer (such as genetic/epigenetic characteristics) are necessary. The results of this study could suggest stratification rather than unification of breast cancer prevention strategies, risk assessment, and treatment.
C1 [Kravchenko, Julia; Abernethy, Amy P.; Lyerly, H. Kim] Duke Univ, Med Ctr DUMC, Duke Canc Inst, Durham, NC 27705 USA.
   [Akushevich, Igor] Duke Univ, Ctr Populat Hlth & Aging, Durham, NC 27705 USA.
   [Seewaldt, Victoria L.; Abernethy, Amy P.] Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC 27705 USA.
C3 Duke University; Duke University; Duke University
RP Kravchenko, J (通讯作者)，Duke Univ, Med Ctr DUMC, Duke Canc Inst, 2424 Erwin Rd,Box 2732,Hock Plaza,Suite G05, Durham, NC 27705 USA.
EM julia.krauchanka@duke.edu
RI Lyerly, Herbert/AAX-4925-2020; Lyerly, Herbert/B-6528-2014
OI Abernethy, Amy/0000-0001-6930-8722; Lyerly, Herbert/0000-0002-0063-4770
CR Althuis MD, 2004, CANCER EPIDEM BIOMAR, V13, P1558
   Anders CK, 2008, J CLIN ONCOL, V26, P3324, DOI 10.1200/JCO.2007.14.2471
   ANDERSON E, 1950, CANCER-AM CANCER SOC, V3, P410, DOI 10.1002/1097-0142(1950)3:3<410::AID-CNCR2820030303>3.0.CO;2-H
   Anderson WF, 2005, BREAST CANCER RES TR, V90, P127, DOI 10.1007/s10549-004-3777-3
   Anderson WF, 2002, BREAST CANCER RES TR, V76, P27, DOI 10.1023/A:1020299707510
   Anderson WF, 2007, J CLIN ONCOL, V25, P3923, DOI 10.1200/JCO.2007.11.6079
   Anderson WF, 2006, JNCI-J NATL CANCER I, V98, P948, DOI 10.1093/jnci/djj295
   ARMITAGE P, 1957, BRIT J CANCER, V11, P161, DOI 10.1038/bjc.1957.22
   Bijker N, 2001, BRIT J CANCER, V84, P539, DOI 10.1054/bjoc.2000.1618
   Boecker W, 2003, CELL PROLIFERAT, V36, P73, DOI 10.1046/j.1365-2184.36.s.1.7.x
   Boecker W, 2001, J PATHOL, V195, P415, DOI 10.1002/path.982
   Buerger H, 2000, AM J CLIN PATHOL, V114, P854, DOI 10.1309/XCPG-CR87-6U8D-B11K
   CLEMMESEN J, 1948, BRIT J RADIOL, V21, P583, DOI 10.1259/0007-1285-21-252-583
   Colditz GA, 2000, AM J EPIDEMIOL, V152, P950, DOI 10.1093/aje/152.10.950
   Colditz GA., 2006, Cancer epidemiology and prevention, V3rd
   Cserni G, 2002, J CLIN PATHOL, V55, P293, DOI 10.1136/jcp.55.4.293
   DEWAARD F, 1979, J NATL CANCER I, V63, P549, DOI 10.1093/jnci/63.3.549
   Elston C W, 2002, Histopathology, V41, P154
   Ferlicot S, 2004, EUR J CANCER, V40, P336, DOI 10.1016/j.ejca.2003.08.007
   Finn RS, 2006, J CLIN ONCOL, V24, p6S
   IGLEHART JD, 1995, BREAST CANCER RES TR, V34, P253, DOI 10.1007/BF00689717
   Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008-5472.CAN-05-4414
   Jones C, 2001, BRIT J CANCER, V85, P422, DOI 10.1054/bjoc.2001.1869
   Krüger S, 1999, INT J MOL MED, V4, P171
   Lacroix M, 2004, ENDOCR-RELAT CANCER, V11, P497, DOI 10.1677/erc.1.00758
   Li CI, 2003, JAMA-J AM MED ASSOC, V289, P1421, DOI 10.1001/jama.289.11.1421
   LILIENFELD AM, 1955, CANCER-AM CANCER SOC, V8, P875, DOI 10.1002/1097-0142(1955)8:5<875::AID-CNCR2820080504>3.0.CO;2-Z
   Manton K, 2009, CANC MORTALITY MORBI
   MANTON KG, 1980, JNCI-J NATL CANCER I, V64, P9
   Millis RR, 1998, EUR J CANCER, V34, P548, DOI 10.1016/S0959-8049(97)10072-7
   Mommers ECM, 2001, J PATHOL, V194, P327, DOI 10.1002/path.910
   Nguyen PL, 2008, J CLIN ONCOL, V26, P2373, DOI 10.1200/JCO.2007.14.4287
   Nunney L, 1999, P ROY SOC B-BIOL SCI, V266, P493, DOI 10.1098/rspb.1999.0664
   Parmigiani G, 1998, AM J HUM GENET, V62, P145, DOI 10.1086/301670
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   PIKE MC, 1983, NATURE, V303, P767, DOI 10.1038/303767a0
   Richard F, 2000, INT J CANCER, V89, P305
   Ringberg A, 2001, EUR J CANCER, V37, P1514, DOI 10.1016/S0959-8049(01)00165-4
   Roylance R, 1999, CANCER RES, V59, P1433
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-127
   Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052
   Visscher D, 2000, HUM PATHOL, V31, P201, DOI 10.1016/S0046-8177(00)80220-8
   Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087
   Wärnberg F, 2001, BRIT J CANCER, V85, P869, DOI 10.1054/bjoc.2001.1995
   Zafrani B, 2000, HISTOPATHOLOGY, V37, P536, DOI 10.1046/j.1365-2559.2000.01006.x
   Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786
NR 47
TC 34
Z9 42
U1 0
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JUL
PY 2011
VL 128
IS 2
BP 483
EP 493
DI 10.1007/s10549-011-1347-z
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 780OA
UT WOS:000291866300019
PM 21225455
DA 2025-01-12
ER

PT J
AU Wang, J
   Chen, H
   Fu, S
   Xu, ZM
   Sun, KL
   Fu, WN
AF Wang, Jin
   Chen, Hong
   Fu, Shuang
   Xu, Zhen-Ming
   Sun, Kai-Lai
   Fu, Wei-Neng
TI The involvement of <i>CHD5</i> hypermethylation in laryngeal squamous
   cell carcinoma
SO ORAL ONCOLOGY
LA English
DT Article
DE CHD5; Hypermethylation; Laryngeal squamous cell carcinoma;
   Immunohistochemistry; Sequencing; Apoptosis
ID TUMOR-SUPPRESSOR GENE; DNA METHYLATION; BREAST-CANCER; PROMOTER; HEAD;
   NEUROBLASTOMAS; EXPRESSION; 1P36.31
AB Chromodomain helicase DNA-binding protein 5 (CHD5) has been found to be a candidate tumor suppressor gene (TSG) in malignant neural tumors. In mice heterozygous for chd5 deficiency, the first tumor observed was pathological squamous cell carcinoma. More than 95% of primary laryngeal cancer is squamous cell carcinoma. Thus, we explored the expression of CHD5 in 65 patients with laryngeal squamous cell carcinoma (LSCC) using real-time PCR, immunohistochemistry and Western blotting. DNA methylation was detected using bisulfate-specific sequencing. The potential function of CHD5 was determined using MTT, apoptosis and transwell migration assays in CHD5-transfected Hep-2 cells. Our results revealed that the mRNA and protein expression levels of CHD5 in LSCC tissues were significantly lower than those in clear surgical margin tissues (p < 0.05), and there is a significant correlation between the mRNA and protein expression levels of CHD5 (p < 0.01). In addition, there were significant differences in CHD5 mRNA and protein levels with respect to the patient's clinical stage (p < 0.05). Aberrant methylation of the CHD5 promoter was frequently found in the Hep-2 cell line and LSCC tumor tissues, especially tumor tissues from advanced TNM (p < 0.05) or older patients (p < 0.05). Finally, ectopic expression of CHD5 in laryngeal cancer cells led to significant inhibition of growth and invasiveness. Our data suggest that CHD5 is a tumor suppressor gene that is epigenetically downregulated in LSCC. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Wang, Jin; Chen, Hong; Fu, Shuang; Sun, Kai-Lai; Fu, Wei-Neng] China Med Univ, Dept Med Genet, Shenyang 110001, Peoples R China.
   [Wang, Jin] China Med Univ, Shengjing Hosp, ENT Dept, Shenyang 110004, Peoples R China.
   [Xu, Zhen-Ming] 463 Hosp Chinese PLA, ENT Dept, Shenyang 110042, Peoples R China.
C3 China Medical University; China Medical University
RP Fu, WN (通讯作者)，China Med Univ, Dept Med Genet, 92 Beier Rd, Shenyang 110001, Peoples R China.
EM guoyan_1104@tom.com
RI Wang, Xuemei/GXF-3702-2022; Xu, Zhenming/J-5717-2017
FU National Nature Science Foundation of China [30700980]; National 863
   Project of China [2002BA711A08-18]; Natural Science Foundation of
   Liaoning Province [20092110]
FX The study was supported by the National Nature Science Foundation of
   China (30700980), the National 863 Project (2002BA711A08-18) of China,
   and the Natural Science Foundation of Liaoning Province (20092110). We
   thank Professor Garrett M. Brodeur, M.D. (The Children's Hospital of
   Philadelphia), for providing pcDNA3.1-CHD5.
CR [Anonymous], 2010, Cancer Facts Figures 2010
   Bagchi A, 2008, CANCER RES, V68, P2551, DOI 10.1158/0008-5472.CAN-07-2095
   Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052
   BECHHARDT RN, 1995, ARCH OTOLARYNGOL, V121, P1265
   BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1
   Calmon MF, 2009, NEOPLASIA, V11, P1329, DOI 10.1593/neo.91110
   Buim MEC, 2010, ORAL ONCOL, V46, P166, DOI 10.1016/j.oraloncology.2009.11.009
   Che XH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-306
   Cherrier T, 2009, ONCOGENE, V28, P3380, DOI 10.1038/onc.2009.193
   Diede SJ, 2010, P NATL ACAD SCI USA, V107, P234, DOI 10.1073/pnas.0907606106
   Dwivedi R. C., 2008, Indian Journal of Cancer, V45, P97
   Fujita T, 2008, JNCI-J NATL CANCER I, V100, P940, DOI 10.1093/jnci/djn176
   Futscher BW, 2004, NEOPLASIA, V6, P380, DOI 10.1593/neo.04115
   Gonzalo S, 2010, J APPL PHYSIOL, V109, P586, DOI 10.1152/japplphysiol.00238.2010
   Gorringe KL, 2008, NEOPLASIA, V10, P1253, DOI 10.1593/neo.08718
   [Greene FL. American Joint Commmittee on Cancer American Joint Commmittee on Cancer], 2002, AJCC CANC STAGING HD, P3
   Hall JA, 2007, BIOCHEM CELL BIOL, V85, P463, DOI 10.1139/O07-063
   KLIJANIENKO J, 1995, CANCER, V75, P1649, DOI 10.1002/1097-0142(19950401)75:7<1649::AID-CNCR2820750715>3.0.CO;2-E
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Liu J, 2010, ONCOL REP, V23, P1101, DOI 10.3892/or_00000738
   MICHALOWSKY LA, 1987, MOL CELL BIOL, V7, P3076, DOI 10.1128/MCB.7.9.3076
   Mulero-Navarro S, 2008, EPIGENETICS-US, V3, P210, DOI 10.4161/epi.3.4.6610
   Okawa ER, 2008, ONCOGENE, V27, P803, DOI 10.1038/sj.onc.1210675
   Schuster EF, 2002, MAMM GENOME, V13, P117, DOI 10.1007/s00335-001-3042-6
   Smith LT, 2006, P NATL ACAD SCI USA, V103, P982, DOI 10.1073/pnas.0510171102
   SPEICHER MR, 1995, CANCER RES, V55, P1010
   Wang X, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-95
   White PS, 2005, ONCOGENE, V24, P2684, DOI 10.1038/sj.onc.1208306
   YOSHIDA M, 1990, J BIOL CHEM, V265, P17174
   Zhang CJ, 2010, J HEPATOL, V53, P889, DOI 10.1016/j.jhep.2010.05.012
NR 30
TC 38
Z9 41
U1 0
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1368-8375
EI 1879-0593
J9 ORAL ONCOL
JI Oral Oncol.
PD JUL
PY 2011
VL 47
IS 7
BP 601
EP 608
DI 10.1016/j.oraloncology.2011.05.003
PG 8
WC Oncology; Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Dentistry, Oral Surgery & Medicine
GA 782QL
UT WOS:000292024500010
PM 21636313
DA 2025-01-12
ER

PT J
AU Lewis, SP
   Willis, AN
   Johnson, AE
   Resau, J
   Burnatowska-Hledin, MA
AF Lewis, Steven P.
   Willis, Angelica N.
   Johnson, Alyssa E.
   Resau, James
   Burnatowska-Hledin, Maria A.
TI Mutational analysis of VACM-1/cul5 exons in cancer cell lines
SO APMIS
LA English
DT Article
DE VACM-1; cul5
ID LINKED MENTAL-RETARDATION; UBIQUITIN LIGASE COMPLEX; BREAST-CANCER;
   CUL-5 GENE; NEDD8-ACTIVATING ENZYME; ENDOTHELIAL-CELLS; C-ELEGANS;
   EXPRESSION; NEDD8; DEGRADATION
AB VACM-1, a cul-5 gene product, functions via an E3 ligase complex and when overexpressed, has an antiproliferative effect in many cell types. Overexpression of VACM-/cul5 cDNA mutated at the PKA-specific phosphorylation site at Ser730 reversed this phenotype. These effects are associated with the appearance of larger M-r species subsequently identified as a Nedd8-modified VACM-1/cul5. Although decreased levels of VACM-1 mRNA detected in several cancers and cancer cell lines may explain the progression of cell growth, possible genetic and epigenetic changes in its sequence have not been analyzed. We hypothesized that in rapidly proliferating cells, VACM-1/cul5 may be mutated at either the PKA-specific phosphorylation site or the consensus neddylation site. We used RT-PCR and PCR, to amplify and to sequence mRNA and genomic DNA, respectively. To date we have sequenced all 19 coding exons of the VACM-1/cul5 gene in T47D breast cancer cells, U138MG glioma cells, ACHN renal cancer cells, and OVCAR-3 ovarian cancer cells. Our results indicate that in those cells VACM-1/cul5 is not mutated at the putative phosphorylation or the neddylation site. We have found one silent mutation in the genomic DNA isolated from U138MG, ACHN, and OVCAR-3 cell lines, but not from T47D cells. Our work suggests that in T47D breast cancer cells biologic activity of VACM-1/cul5 may be regulated by posttranslational modifications.
C1 [Burnatowska-Hledin, Maria A.] Hope Coll, Dept Biol, A Paul Schaap Sci Ctr, Holland, MI 49422 USA.
   [Lewis, Steven P.; Willis, Angelica N.; Johnson, Alyssa E.; Burnatowska-Hledin, Maria A.] Hope Coll, Dept Chem, Holland, MI 49422 USA.
   [Resau, James] Van Andel Res Ctr, Grand Rapids, MI USA.
C3 Hope College; Hope College; Van Andel Institute
RP Burnatowska-Hledin, MA (通讯作者)，Hope Coll, Dept Biol, A Paul Schaap Sci Ctr, Holland, MI 49422 USA.
EM hledin@hope.edu
FU NCI [R15CA104014]; Howard Hughes Medical Institute; National Science
   Foundation [DBI-0754293, CHE-851194]; Direct For Mathematical & Physical
   Scien; Division Of Chemistry [0851194] Funding Source: National Science
   Foundation; Div Of Biological Infrastructure; Direct For Biological
   Sciences [0754293] Funding Source: National Science Foundation
FX This work was supported by NCI (R15CA104014). This research was
   supported in part by a grant to Hope College from the Howard Hughes
   Medical Institute through the Undergraduate Science Education Program
   and by National Science Foundation-Research Experience for
   Undergraduates grants (DBI-0754293. CHE-851194). We thank the Van Andel
   Research Institute (Grand Rapids, MI) for providing DNA from cancer
   cells cataloged in the NCI60 cancer cell line database. This work was
   presented in part, at the National Organization for the Professional
   Advancement of Black Chemists and Chemical Engineers (NOBCChE) national
   meeting in Atlanta in 2010.
CR An P, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030019
   Badura-Stronka M, 2010, CLIN GENET, V77, P141, DOI 10.1111/j.1399-0004.2009.01331.x
   Bauer JA, 2003, J INTERF CYTOK RES, V23, P3, DOI 10.1089/10799900360520397
   Bradley SE, 2010, J BIOL CHEM, V285, P4883, DOI 10.1074/jbc.M109.085225
   Buchwalter A, 2008, MICROVASC RES, V75, P155, DOI 10.1016/j.mvr.2007.08.004
   Burnatowska-Hledin M, 2001, ENDOTHELIUM-J ENDOTH, V8, P49, DOI 10.3109/10623320109063157
   Burnatowska-Hledin MA, 2004, BIOCHEM BIOPH RES CO, V319, P817, DOI 10.1016/j.bbrc.2004.05.057
   BURNATOWSKAHLEDIN MA, 1995, AM J PHYSIOL-RENAL, V268, pF1198, DOI 10.1152/ajprenal.1995.268.6.F1198
   Byrd PJ, 1997, GENOME RES, V7, P71, DOI 10.1101/gr.7.1.71
   Chen C, 2006, MOL CANCER RES, V4, P695, DOI 10.1158/1541-7786.MCR-06-0182
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Fay Michael J, 2003, Mol Cancer, V2, P40, DOI 10.1186/1476-4598-2-40
   Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151
   Holbeck SL, 2010, MOL CANCER THER, V9, P1451, DOI 10.1158/1535-7163.MCT-10-0106
   Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093
   Huang DT, 2009, MOL CELL, V33, P483, DOI 10.1016/j.molcel.2009.01.011
   Huang KT, 2010, BREAST CANCER RES TR, V124, P853, DOI 10.1007/s10549-010-1087-5
   Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433
   Johnson AE, 2007, MOL CELL BIOCHEM, V301, P13, DOI 10.1007/s11010-006-9392-3
   Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557
   Kerzendorfer C, 2010, HUM MOL GENET, V19, P1324, DOI 10.1093/hmg/ddq008
   Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061
   Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2
   Laszlo GS, 2009, CURR BIOL, V19, P157, DOI 10.1016/j.cub.2008.12.007
   Lee Jennifer, 2010, Genes Cancer, V1, P690, DOI 10.1177/1947601910382899
   Lin JJ, 2010, CANCER RES, V70, P10310, DOI 10.1158/0008-5472.CAN-10-2062
   Lubbers J, 2011, CELL BIOL TOXICOL, V27, P95, DOI 10.1007/s10565-010-9173-3
   Mathias N, 1996, MOL CELL BIOL, V16, P6634
   Merlet J, 2009, CELL MOL LIFE SCI, V66, P1924, DOI 10.1007/s00018-009-8712-7
   Park SW, 2009, APMIS, V117, P880, DOI 10.1111/j.1600-0463.2009.02550.x
   Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547
   Pintard L, 2003, CURR BIOL, V13, P911, DOI 10.1016/S0960-9822(03)00336-1
   Saha A, 2008, MOL CELL, V32, P21, DOI 10.1016/j.molcel.2008.08.021
   Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884
   Sufan RI, 2006, NEOPLASIA, V8, P956, DOI 10.1593/neo.06520
   Swords RT, 2010, BLOOD, V115, P3796, DOI 10.1182/blood-2009-11-254862
   Van Dort C, 2003, AM J PHYSIOL-CELL PH, V285, pC1386, DOI 10.1152/ajpcell.00338.2002
   Wimuttisuk W, 2007, MOL BIOL CELL, V18, P899, DOI 10.1091/mbc.E06-06-0542
   Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591
   Zou YX, 2007, AM J HUM GENET, V80, P561, DOI 10.1086/512489
NR 40
TC 9
Z9 10
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0903-4641
EI 1600-0463
J9 APMIS
JI APMIS
PD JUL
PY 2011
VL 119
IS 7
BP 421
EP 430
DI 10.1111/j.1600-0463.2011.02747.x
PG 10
WC Immunology; Microbiology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Microbiology; Pathology
GA 772WI
UT WOS:000291268300003
PM 21635549
DA 2025-01-12
ER

PT J
AU Al-Moghrabi, N
   Al-Qasem, AJS
   Aboussekhra, A
AF Al-Moghrabi, Nisreen
   Al-Qasem, Abeer J. S.
   Aboussekhra, Abdelilah
TI Methylation-related mutations in the <i>BRCA1</i> promoter in peripheral
   blood cells from cancer-free women
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE breast cancer; breast cancer type 1 susceptibility gene; methylation;
   blood cells; methylation-related mutation
ID SPORADIC BREAST-CANCER; NONPOLYPOSIS COLORECTAL-CANCER; GENE-EXPRESSION
   PROFILES; OVARIAN-CANCER; DNA METHYLATION; SAUDI-ARABIA; TUMOR;
   HYPERMETHYLATION; REGION; INACTIVATION
AB Early-onset breast cancer is one of the most common malignancies and causes of death among young women, and its incidence is increasing. In the present study, we aimed to investigate the epigenetic modifications of the breast cancer type 1 susceptibility gene (BRCA1) in breast tissues and blood cells derived from women with breast cancer and women without breast cancer. BRCA1 promoter methylation was examined by methylation-specific PCR in 47 breast cancer tissues and in peripheral blood cells derived from 7 breast cancer patients and 73 healthy women. Subsequently, the methylation status of the BRCA1 promoter was confirmed and analyzed at high resolution by sodium bisulfite genomic sequencing. BRCA1 promoter methylation was detected in 13 primary sporadic breast cancer tissues (27.3%) and in 2 blood cell samples derived from breast cancer patients (28.5%). A strong association (p-value, 0.0038) was found between BRCA1 methylation and young age (<= 40 years) at diagnosis. The BRCA1 promoter was also methylated in blood cells from 8 women without breast cancer (10.9%) and 2 breast cancer patients (28%). The methylation pattern of the BRCA1 promoter CpG island was similar in the blood cells from healthy women as well as in women with breast cancer. Moreover, we report for the first time, the observation of methylation-related mutations leading to the formation of non-CpG methylation, as well as the formation of novel methylated CpG sites in the 5 regulatory region of the BRCA1 gene in the peripheral blood cells from cancer-free women. These results suggest the possible implication of BRCA1 promoter methylation in the early onset of breast cancer and propose the use of this epigenetic modification as a powerful molecular marker for detecting women potentially predisposed to cancer.
C1 [Al-Moghrabi, Nisreen; Al-Qasem, Abeer J. S.; Aboussekhra, Abdelilah] King Faisal Specialist Hosp & Res Ctr, Dept Biol & Med Res, DNA Repair & Apoptosis Sect, Riyadh 11211, Saudi Arabia.
C3 King Faisal Specialist Hospital & Research Center
RP Al-Moghrabi, N (通讯作者)，King Faisal Specialist Hosp & Res Ctr, Dept Biol & Med Res, DNA Repair & Apoptosis Sect, MBC 03,POB 3354, Riyadh 11211, Saudi Arabia.
EM nisreen@kfshrc.edu.sa
RI Aboussekhra, Abdelilah/JCD-8138-2023
OI Alqasem, Abeer/0000-0003-1710-0908
FU King Faisal Specialist Hospital and Research Center [2100 011]
FX We would like to thank the research center administration for its
   continuous encouragement and support. The King Faisal Specialist
   Hospital and Research Center supported this study under the RAC proposal
   no, 2100 011.
CR Arver B, 2000, SEMIN CANCER BIOL, V10, P271, DOI 10.1006/scbi.2000.0325
   Bianco T, 2000, CARCINOGENESIS, V21, P147, DOI 10.1093/carcin/21.2.147
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Brooks AR, 2004, J GENE MED, V6, P395, DOI 10.1002/jgm.516
   Butcher DT, 2007, EUR J CANCER, V43, P210, DOI 10.1016/j.ejca.2006.09.002
   Catteau A, 2002, SEMIN CANCER BIOL, V12, P359, DOI 10.1016/S1044-579X(02)00056-1
   Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509
   Chan TL, 2006, NAT GENET, V38, P1178, DOI 10.1038/ng1866
   Dobrovic A, 1997, CANCER RES, V57, P3347
   El-Harith EHA, 2002, SAUDI MED J, V23, P700
   Elkum N, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-222
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Esteller M, 2000, EUR J CANCER, V36, P2294, DOI 10.1016/S0959-8049(00)00303-8
   Fang JY, 2001, J VIROL, V75, P9753, DOI 10.1128/JVI.75.20.9753-9761.2001
   FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630
   Gazzoli I, 2002, CANCER RES, V62, P3925
   Hachana M, 2009, BREAST CANCER RES TR, V113, P43, DOI 10.1007/s10549-008-9901-z
   Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801
   Hitchins M, 2005, GASTROENTEROLOGY, V129, P1392, DOI 10.1053/j.gastro.2005.09.003
   Hitchins MP, 2007, NEW ENGL J MED, V356, P697, DOI 10.1056/NEJMoa064522
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kouidou S, 2005, LUNG CANCER-J IASLC, V50, P299, DOI 10.1016/j.lungcan.2005.06.012
   Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238
   LARSEN F, 1992, GENET ANAL-BIOMOL E, V9, P80, DOI 10.1016/1050-3862(92)90002-M
   Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630
   Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086
   Snell C, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1858
   THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Xu CF, 1997, HUM MOL GENET, V6, P1057, DOI 10.1093/hmg/6.7.1057
   Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994
NR 36
TC 30
Z9 30
U1 0
U2 11
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
J9 INT J ONCOL
JI Int. J. Oncol.
PD JUL
PY 2011
VL 39
IS 1
BP 129
EP 135
DI 10.3892/ijo.2011.1021
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 775ZS
UT WOS:000291504900014
PM 21537840
OA Bronze
DA 2025-01-12
ER

PT J
AU Sar, P
   Peter, R
   Rath, B
   Das Mohapatra, A
   Mishra, SK
AF Sar, Pranati
   Peter, Rosalima
   Rath, Bandita
   Das Mohapatra, Alok
   Mishra, Sandip K.
TI 3, 3′5 Triiodo L Thyronine Induces Apoptosis in Human Breast Cancer
   MCF-7cells, Repressing SMP30 Expression through Negative Thyroid
   Response Elements
SO PLOS ONE
LA English
DT Article
ID NUCLEAR RECEPTOR COREPRESSORS; MAMMARY EPITHELIAL-CELLS; MARKER
   PROTEIN-30 SMP30; HEP G2 CELLS; HORMONE RECEPTOR; HISTONE DEACETYLASE;
   ESTROGEN-RECEPTOR; IN-VIVO; KNOCKOUT MICE; TARGET GENE
AB Background: Thyroid hormones regulate cell proliferation, differentiation as well as apoptosis. However molecular mechanism underlying apoptosis as a result of thyroid hormone signaling is poorly understood. The antiapoptotic role of Senescence Marker Protein-30 (SMP30) has been characterized in response to varieties of stimuli as well as in knock out model. Our earlier data suggest that thyroid hormone 3, 395 Triiodo L Thyronine (T-3), represses SMP30 in rat liver.
   Methodology/Principal Findings: In highly metastatic MCF-7, human breast cancer cell line T3 treatment repressed SMP30 expression leading to enhanced apoptosis. Analysis by flow cytometry and other techniques revealed that overexpression and silencing of SMP30 in MCF-7 resulted in decelerated and accelerated apoptosis respectively. In order to identify the cis-acting elements involved in this regulation, we have analyzed hormone responsiveness of transiently transfected hSMP30 promoter deletion reporter vectors in MCF-7 cells. As opposed to the expected epigenetic outcome, thyroid hormone down regulated hSMP30 promoter activity despite enhanced recruitment of acetylated H3 on thyroid response elements (TREs). From the stand point of established epigenetic concept we have categorised these two TREs as negative response elements. Our attempt of siRNA mediated silencing of TR beta, reduced the fold of repression of SMP30 gene expression. In presence of thyroid hormone, Trichostatin-A (TSA), which is a Histone deacetylase (HDAC) inhibitor further inhibited SMP30 promoter activity. The above findings are in support of categorisation of both the thyroid response element as negative response elements as usually TSA should have reversed the repressions.
   Conclusion: This is the first report of novel mechanistic insights into the remarkable downregulation of SMP30 gene expression by thyroid hormone which in turn induces apoptosis in MCF-7 human breast cancer cells. We believe that our study represents a good ground for future effort to develop new therapeutic approaches to challenge the progression of breast cancer.
C1 [Sar, Pranati; Peter, Rosalima; Rath, Bandita; Mishra, Sandip K.] Inst Life Sci, Dept Gene Funct & Regulat, Canc Biol Lab, Bhubaneswar, Orissa, India.
   [Das Mohapatra, Alok] Inst Life Sci, Dept Infect Dis Biol, Vector Born Dis Lab, Bhubaneswar, Orissa, India.
C3 Department of Biotechnology (DBT) India; Institute of Life Sciences
   India (ILS); Department of Biotechnology (DBT) India; Institute of Life
   Sciences India (ILS)
RP Sar, P (通讯作者)，Inst Life Sci, Dept Gene Funct & Regulat, Canc Biol Lab, Bhubaneswar, Orissa, India.
EM sandipkmishra@hotmail.com
RI Sar, Pranati/AAE-5045-2022
OI Sar, Pranati/0000-0002-6233-8379; Mishra, Sandip/0000-0002-0776-6581
FU Department of Biotechnology, Goverment of India; University Grant
   Commission, Goverment of India, New Delhi
FX This study was supported by funds from the Department of Biotechnology,
   Goverment of India. PS is supported by a research fellowship from
   University Grant Commission, Goverment of India, New Delhi. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Ahmad N, 2011, CANCER LETT, V300, P1, DOI 10.1016/j.canlet.2010.09.008
   Alonso M, 2009, ENDOCRINOLOGY, V150, P3927, DOI 10.1210/en.2009-0093
   ALVARADOPISANI AR, 1986, ANTICANCER RES, V6, P1347
   Berghagen H, 2002, J BIOL CHEM, V277, P49517, DOI 10.1074/jbc.M209546200
   BURKE RE, 1978, CANCER RES, V38, P3769
   Cestari SH, 2009, ARQ BRAS ENDOCRINOL, V53, P859, DOI 10.1590/S0004-27302009000700010
   Chimenti F, 2009, J MED CHEM, V52, P530, DOI 10.1021/jm800885d
   CHOU CW, 2011, PLOS ONE, V6, P1
   Conde I, 2006, ANN ONCOL, V17, P60, DOI 10.1093/annonc/mdj040
   Denis LJ, 2000, SEMIN SURG ONCOL, V18, P52, DOI 10.1002/(SICI)1098-2388(200001/02)18:1<52::AID-SSU8>3.0.CO;2-6
   Diaz-Cruz ES, 2010, CANCER RES, V70, P3965, DOI 10.1158/0008-5472.CAN-09-3450
   Duan H, 2005, MOL CELL BIOL, V25, P1608, DOI 10.1128/MCB.25.5.1608-1619.2005
   Elsheikh SE, 2009, CANCER RES, V69, P3802, DOI 10.1158/0008-5472.CAN-08-3907
   FEI ZL, 1992, ENDOCRINOLOGY, V130, P1145
   FUJITA T, 1992, BIOCHIM BIOPHYS ACTA, V1116, P122, DOI 10.1016/0304-4165(92)90108-7
   Fujita T, 1998, BIOCHEM BIOPH RES CO, V250, P374, DOI 10.1006/bbrc.1998.9327
   Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610
   González-Sancho JM, 2002, MOL CARCINOGEN, V34, P25, DOI 10.1002/mc.10046
   GUIGON CJ, 2011, ONCOGENE, P1
   Handa S, 2009, BIOL PHARM BULL, V32, P1645, DOI 10.1248/bpb.32.1645
   Hara M, 2000, THYROID, V10, P1023, DOI 10.1089/thy.2000.10.1023
   Ishigami A, 2002, AM J PATHOL, V161, P1273, DOI 10.1016/S0002-9440(10)64404-5
   Ishii S, 2004, MOL ENDOCRINOL, V18, P1708, DOI 10.1210/me.2004-0067
   Jeong DH, 2008, J RADIAT RES, V49, P653, DOI 10.1269/jrr.08042
   KATZ RW, 1993, J BIOL CHEM, V268, P19392
   Kim JJ, 2010, SEMIN REPROD MED, V28, P81, DOI 10.1055/s-0029-1242998
   Kim SW, 2005, J BIOL CHEM, V280, P14545, DOI 10.1074/jbc.M411517200
   Lazar MA, 2003, J CLIN INVEST, V112, P497, DOI 10.1172/JCI200319479
   Lewis-Wambi JS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2255
   Liu Y, 2006, MOL ENDOCRINOL, V20, P483, DOI 10.1210/me.2005-0101
   LOPEZBARAHONA M, 1995, EMBO J, V14, P1145, DOI 10.1002/j.1460-2075.1995.tb07098.x
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   Martinez MB, 2000, CANCER CHEMOTH PHARM, V45, P93, DOI 10.1007/s002800050016
   Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532
   Mihara S, 1999, J CLIN ENDOCR METAB, V84, P1378, DOI 10.1210/jc.84.4.1378
   Mishra SK, 2004, ONCOGENE, V23, P4422, DOI 10.1038/sj.onc.1207569
   Mishra SK, 2003, J BIOL CHEM, V278, P19209, DOI 10.1074/jbc.M301968200
   NARAYANAN CH, 1986, EXP BRAIN RES, V62, P61
   Nicholson RI, 2005, BREAST CANCER RES TR, V93, pS3, DOI 10.1007/s10549-005-9036-4
   Nygård M, 2006, J MOL ENDOCRINOL, V36, P517, DOI 10.1677/jme.1.01874
   Ortiga-Carvalho TM, 2005, J CLIN INVEST, V115, P2517, DOI 10.1172/JCI24109
   Park SW, 2005, MOL CELL, V19, P643, DOI 10.1016/j.molcel.2005.08.008
   Porter P, 2008, NEW ENGL J MED, V358, P213, DOI 10.1056/NEJMp0708307
   Rath B, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-43
   SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L
   Santos GM, 2006, MOL PHARMACOL, V70, P793, DOI 10.1124/mol.106.025627
   Sar P, 2007, MOL CELL BIOCHEM, V303, P239, DOI 10.1007/s11010-007-9462-1
   Sasaki S, 1999, EMBO J, V18, P5389, DOI 10.1093/emboj/18.19.5389
   Shibusawa N, 2003, J CLIN INVEST, V112, P588, DOI 10.1172/JCI200318377
   Shibusawa N, 2003, J BIOL CHEM, V278, P732, DOI 10.1074/jbc.M207264200
   Silva JM, 2002, ONCOGENE, V21, P4307, DOI 10.1038/sj.onc.1205534
   SMALLRIDGE RC, 1980, CLIN RES, V28, pA421
   Smyth PPA, 1997, ANN MED, V29, P189, DOI 10.3109/07853899708999335
   Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642
   Tagami T, 1999, J BIOL CHEM, V274, P22345, DOI 10.1074/jbc.274.32.22345
   Tagami T, 1998, MOL ENDOCRINOL, V12, P1888, DOI 10.1210/me.12.12.1888
   TFAYLI A, 2010, J ONCOL, P1
   Turken O, 2003, BREAST CANCER RES, V5, pR110, DOI 10.1186/bcr609
   VONDERHAAR BK, 1979, ENDOCRINOLOGY, V104, P409, DOI 10.1210/endo-104-2-409
   WANG D, 2010, PLOS ONE, V5, P1
   Wang DQ, 2009, MOL ENDOCRINOL, V23, P600, DOI 10.1210/me.2008-0389
   WILLIAMS GR, BASIC CONCEPTS CLIN, P217
   Wilson MA, 2002, J BIOL CHEM, V277, P15171, DOI 10.1074/jbc.M200349200
   Yen PM, 2006, MOL CELL ENDOCRINOL, V246, P121, DOI 10.1016/j.mce.2005.11.030
   Yen PM, 2003, EMBO REP, V4, P581, DOI 10.1038/sj.embor.embor862
   Yokoe T, 1997, ANTICANCER RES, V17, P695
   LANCET, V374, P1567
NR 67
TC 34
Z9 39
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 7
PY 2011
VL 6
IS 6
AR e20861
DI 10.1371/journal.pone.0020861
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 777HR
UT WOS:000291607000024
PM 21687737
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Ungefroren, H
   Groth, S
   Sebens, S
   Lehnert, H
   Gieseler, F
   Fändrich, F
AF Ungefroren, Hendrik
   Groth, Stephanie
   Sebens, Susanne
   Lehnert, Hendrik
   Gieseler, Frank
   Faendrich, Fred
TI Differential roles of Smad2 and Smad3 in the regulation of
   TGF-β1-mediated growth inhibition and cell migration in pancreatic
   ductal adenocarcinoma cells: control by Rac1
SO MOLECULAR CANCER
LA English
DT Article
ID TGF-BETA RECEPTOR; ACTIVATED PROTEIN-KINASE; BIGLYCAN GENE-EXPRESSION;
   BREAST-CANCER CELLS; SIGNALING PATHWAY; NADPH OXIDASE; TUMOR-CELLS;
   PROGRESSION; INDUCTION; SUPPRESSION
AB Background: Progression of pancreatic ductal adenocarcinoma (PDAC) is largely the result of genetic and/or epigenetic alterations in the transforming growth factor-beta (TGF-beta)/Smad signalling pathway, eventually resulting in loss of TGF-beta-mediated growth arrest and an increase in cellular migration, invasion, and metastasis. These cellular responses to TGF-beta are mediated solely or partially through the canonical Smad signalling pathway which commences with activation of receptor-regulated Smads (R-Smads) Smad2 and Smad3 by the TGF-beta type I receptor. However, little is known on the relative contribution of each R-Smad, the possible existence of functional antagonism, or the crosstalk with other signalling pathways in the control of TGF-beta 1-induced growth inhibition and cell migration. Using genetic and pharmacologic approaches we have inhibited in PDAC cells endogenous Smad2 and Smad3, as well as a potential regulator, the small GTPase Rac1, and have analysed the consequences for TGF-beta 1-mediated growth inhibition and cell migration (chemokinesis).
   Results: SiRNA-mediated silencing of Smad3 in the TGF-beta responsive PDAC cell line PANC-1 reduced TGF-beta 1induced growth inhibition but increased the migratory response, while silencing of Smad2 enhanced growth inhibition but decreased chemokinesis. Interestingly, siRNA-mediated silencing of the small GTPase Rac1, or ectopic expression of a dominant-negative Rac1 mutant largely mimicked the effect of Smad2 silencing on both TGF-beta 1induced growth inhibition, via upregulation of the cdk inhibitor p21WAF1, and cell migration. Inhibition of Rac1 activation reduced both TGF-beta 1-induction of a Smad2-specific transcriptional reporter and Smad2 C-terminal phosphorylation in PDAC cells while Smad3-specific transcriptional activity and Smad3 C-terminal phosphorylation appeared increased. Disruption of autocrine TGF-beta signalling in PANC-1 cells rendered cells less susceptible to the growth-suppressive effect of Rac1 inhibition, suggesting that the decrease in " basal" proliferation upon Rac1 inhibition was caused by potentiation of autocrine TGF-beta growth inhibition.
   Conclusions: In malignant cells with a functional TGF-beta signalling pathway Rac1 antagonizes the TGF-beta 1 growth inhibitory response and enhances cell migration by antagonistically regulating Smad2 and Smad3 activation. This study reveals that Rac1 is prooncogenic in that it can alter TGF-beta signalling at the R-Smad level from a tumoursuppressive towards a tumour-promoting outcome. Hence, Rac1 might represent a viable target for therapeutic intervention to inhibit PDAC progression.
C1 [Ungefroren, Hendrik; Groth, Stephanie; Faendrich, Fred] Univ Hosp Schleswig Holstein UKSH, Clin Appl Cellular Med, D-24105 Kiel, Germany.
   [Sebens, Susanne] Univ Hosp Schleswig Holstein UKSH, Inst Expt Med, Lab Mol Gastroenterol & Hepatol, Dept Internal Med 1, D-24105 Kiel, Germany.
   [Ungefroren, Hendrik; Lehnert, Hendrik; Gieseler, Frank] Univ Hosp Schleswig Holstein UKSH, Dept Med 1, D-23538 Lubeck, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital; University
   of Kiel; Schleswig Holstein University Hospital; University of Kiel;
   Schleswig Holstein University Hospital
RP Ungefroren, H (通讯作者)，Univ Hosp Schleswig Holstein UKSH, Clin Appl Cellular Med, Campus Kiel, D-24105 Kiel, Germany.
EM hendrik.ungefroren@uk-sh.de
RI Sebens, Susanne/C-1222-2010; Goletz, Stephanie/K-1358-2014; Gieseler,
   Frank/E-8386-2012
OI Gieseler, Frank/0000-0001-6409-3822
FU Deutsche Forschungsgemeinschaft (DFG) [UN128/1-2, SE1831/2-1]
FX This work was supported in part by grants from the Deutsche
   Forschungsgemeinschaft (DFG) UN128/1-2 (HU) and SE1831/2-1 (SS). We
   thank S. Grammerstorf, D. Leisner and M. Grossmann for excellent
   technical assistance and G. M. Bokoch (San Diego), K. Giehl (Ulm), K.
   Miyazono (Tokyo, Japan), J. L. Wrana (Toronto, Canada), and S. Dooley
   (Mannheim, Germany) for generously providing plasmids.
CR Ammanamanchi S, 2004, CANCER RES, V64, P2509, DOI 10.1158/0008-5472.CAN-03-2654
   Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731
   Bakin AV, 2002, J CELL SCI, V115, P3193
   Bardeesy N, 2006, GENE DEV, V20, P3130, DOI 10.1101/gad.1478706
   Bokoch GM, 2002, BLOOD, V100, P2692, DOI 10.1182/blood-2002-04-1149
   Bosco EE, 2009, CELL MOL LIFE SCI, V66, P370, DOI 10.1007/s00018-008-8552-x
   Brown KA, 2007, J CELL BIOCHEM, V101, P9, DOI 10.1002/jcb.21255
   Chan AY, 2005, ONCOGENE, V24, P7821, DOI 10.1038/sj.onc.1208909
   Chen WB, 2002, J BIOL CHEM, V277, P36118, DOI 10.1074/jbc.M203709200
   Crnogorac-Jurcevic T, 2001, ONCOGENE, V20, P7437, DOI 10.1038/sj.onc.1204935
   Fensterer H, 2004, GENE CHROMOSOME CANC, V39, P224, DOI 10.1002/gcc.20000
   Fernandez-Zapico ME, 2005, CANCER CELL, V7, P39, DOI 10.1016/j.ccr.2004.11.024
   Geismann C, 2009, CANCER RES, V69, P4517, DOI 10.1158/0008-5472.CAN-08-3493
   Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973
   Giehl K, 2000, ONCOGENE, V19, P4531, DOI 10.1038/sj.onc.1203806
   Grau AM, 1997, CANCER RES, V57, P3929
   Groth S, 2005, J BIOL CHEM, V280, P33190, DOI 10.1074/jbc.M504249200
   Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936
   Hoot KE, 2008, J CLIN INVEST, V118, P2722, DOI 10.1172/JCI33713
   Hosokawa R, 2005, J INVEST DERMATOL, V125, P1302, DOI 10.1111/j.0022-202X.2005.23963.x
   Ijichi H, 2004, ONCOGENE, V23, P1043, DOI 10.1038/sj.onc.1207222
   Ijichi H, 2006, GENE DEV, V20, P3147, DOI 10.1101/gad.1475506
   Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649
   Jinnin M, 2006, MOL PHARMACOL, V69, P597, DOI 10.1124/mol.105.017483
   Kim SG, 2005, MOL BIOL CELL, V16, P4672, DOI 10.1091/mbc.E05-01-0054
   Kissil JL, 2007, CANCER RES, V67, P8089, DOI 10.1158/0008-5472.CAN-07-2300
   Knight-Krajewski S, 2004, ONCOGENE, V23, P5513, DOI 10.1038/sj.onc.1207708
   Kornmann M, 1999, INT J CANCER, V83, P247, DOI 10.1002/(SICI)1097-0215(19991008)83:2<247::AID-IJC17>3.0.CO;2-0
   Kretschmer A, 2003, ONCOGENE, V22, P6748, DOI 10.1038/sj.onc.1206791
   Maeda M, 2006, J BIOL CHEM, V281, P59, DOI 10.1074/jbc.M503304200
   Major MB, 2004, J BIOL CHEM, V279, P5278, DOI 10.1074/jbc.M311517200
   Massagué J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033
   Miyazono K, 2003, CANCER SCI, V94, P230, DOI 10.1111/j.1349-7006.2003.tb01425.x
   Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733
   Nicolás FJ, 2003, ONCOGENE, V22, P3698, DOI 10.1038/sj.onc.1206420
   Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199
   Parri M, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-23
   Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200
   Schniewind B, 2007, ONCOGENE, V26, P4850, DOI 10.1038/sj.onc.1210272
   Sekimoto G, 2007, CANCER RES, V67, P5090, DOI 10.1158/0008-5472.CAN-06-4629
   Song K, 2006, J BIOL CHEM, V281, P7765, DOI 10.1074/jbc.M511781200
   Sundberg LJ, 2003, J BIOL CHEM, V278, P29783, DOI 10.1074/jbc.M303771200
   Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643
   Ungefroren H, 2005, J BIOL CHEM, V280, P2644, DOI 10.1074/jbc.M411925200
   Ungefroren H, 2011, CURR CANCER DRUG TAR, V11, P524, DOI 10.2174/156800911795538075
   Voss M, 1999, INT J ONCOL, V14, P93
   Wang J, 2004, J BIOL CHEM, V279, P40237, DOI 10.1074/jbc.M401665200
   Wrighton KH, 2009, CELL RES, V19, P8, DOI 10.1038/cr.2008.327
   Yu J, 2008, J CELL PHYSIOL, V215, P422, DOI 10.1002/jcp.21325
NR 49
TC 95
Z9 109
U1 0
U2 18
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD MAY 30
PY 2011
VL 10
AR 67
DI 10.1186/1476-4598-10-67
PG 16
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 777GL
UT WOS:000291603800001
PM 21624123
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Dai, W
   Teodoridis, JM
   Zeller, C
   Graham, J
   Hersey, J
   Flanagan, JM
   Stronach, E
   Millan, DW
   Siddiqui, N
   Paul, J
   Brown, R
AF Dai, Wei
   Teodoridis, Jens M.
   Zeller, Constanze
   Graham, Janet
   Hersey, Jenny
   Flanagan, James M.
   Stronach, Euan
   Millan, David W.
   Siddiqui, Nadeem
   Paul, Jim
   Brown, Robert
TI Systematic CpG Islands Methylation Profiling of Genes in the Wnt Pathway
   in Epithelial Ovarian Cancer Identifies Biomarkers of Progression-Free
   Survival
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID GYNECOLOGIC-ONCOLOGY-GROUP; CATENIN SIGNALING PATHWAY; WNT/BETA-CATENIN;
   DNA METHYLATION; POOR SURVIVAL; PROGNOSTIC-SIGNIFICANCE; ANTAGONIST
   SFRP1; BREAST-CANCER; TUMOR-MARKER; RESISTANCE
AB Purpose: Wnt pathways control key biological processes that potentially impact on tumor progression and patient survival. We aimed to evaluate DNA methylation at promoter CpG islands (CGI) of Wnt pathway genes in ovarian tumors at presentation and identify biomarkers of patient progression-free survival (PFS).
   Experimental Design: Epithelial ovarian tumors (screening study n = 120, validation study n = 61), prospectively collected through a cohort study, were analyzed by differential methylation hybridization at 302 loci spanning 189 promoter CGIs at 137 genes in Wnt pathways. The association of methylation and PFS was examined by Cox proportional hazards model.
   Results: DNA methylation is associated with PFS at 20 of 302 loci (P < 0.05, n = 111), with 5 loci significant at false discovery rate (FDR) less than 10%. A total of 11 of 20 loci retain significance in an independent validation cohort (n = 48, P <= 0.05, FDR <= 10%), and 7 of these loci, at FZD4, DVL1, NFATC3, ROCK1, LRP5, AXIN1, and NKD1 genes, are independent from clinical parameters (adjusted P < 0.05). Increased methylation at these loci associates with increased hazard of disease progression. A multivariate Cox model incorporates only NKD1 and DVL1, identifying two groups differing in PFS [HR = 2.09; 95% CI (1.39-3.15); permutation test P < 0.005]. Methylation at DVL1 and NFATC3 show significant association with response. Consistent with their epigenetic regulation, reduced expression of FZD4, DVL1, and ROCK1 is an indicator of early-disease relapse in an independent ovarian tumor cohort (n = 311, adjusted P < 0.05).
   Conclusion: The data highlight the importance of epigenetic regulation of multiple promoter CGIs of Wnt pathway genes in ovarian cancer and identify methylation at NKD1 and DVL1 as independent predictors of PFS. Clin Cancer Res; 17(12); 4052-62. (C) 2011 AACR.
C1 [Brown, Robert] Univ London Imperial Coll Sci Technol & Med, Epigenet Unit, Ovarian Canc Ctr, Hammersmith Hosp, London W12 0NN, England.
   [Stronach, Euan] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Ovarian Canc Act Res Ctr, Hammersmith Hosp, London W12 0NN, England.
   [Millan, David W.] Glasgow Royal Infirm, Dept Pathol, Glasgow G4 0SF, Lanark, Scotland.
   [Siddiqui, Nadeem] Glasgow Royal Infirm, Dept Gynaecol, Glasgow G4 0SF, Lanark, Scotland.
   [Hersey, Jenny; Brown, Robert] Inst Canc Res, Med Sect, Sutton, Surrey, England.
   [Paul, Jim] Beatson W Scotland Canc Ctr, Canc Res UK Clin Trials Unit, Glasgow, Lanark, Scotland.
C3 Imperial College London; Imperial College London; University of Glasgow;
   University of Glasgow; University of London; Institute of Cancer
   Research - UK; Beatson Oncology Centre
RP Brown, R (通讯作者)，Univ London Imperial Coll Sci Technol & Med, Epigenet Unit, Ovarian Canc Ctr, Hammersmith Hosp, 4th Floor IRDB Bldg,Du Cane Rd, London W12 0NN, England.
EM b.brown@imperial.ac.uk
RI Siddiqui, Nadeem/KAL-7670-2024; Dai, Wei/T-8889-2019
OI Dai, Wei/0000-0002-5558-0685; Paul, James/0000-0001-7367-5816; Brown,
   Robert/0000-0001-7960-5755; Flanagan, James/0000-0003-4955-1383
FU Cancer Research UK; Ovarian Cancer Action
FX The study was financially supported by Cancer Research UK and Ovarian
   Cancer Action.
CR Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123
   AKIRA K, 2008, CANCER SCI, V99, P202
   Anastasi E, 2010, TUMOR BIOL, V31, P113, DOI 10.1007/s13277-009-0015-y
   Anglim PP, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-81
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bennett LB, 2010, EPIGENOMICS-UK, V2, P53, DOI 10.2217/EPI.09.43
   BERCHUCK A, 1990, CANCER RES, V50, P4087
   Bese T, 2010, J GYNECOL ONCOL, V21, P248, DOI 10.3802/jgo.2010.21.4.248
   Bock C, 2007, PLOS COMPUT BIOL, V3, P1055, DOI 10.1371/journal.pcbi.0030110
   Boyer A, 2010, TRENDS ENDOCRIN MET, V21, P25, DOI 10.1016/j.tem.2009.08.005
   Bristow RE, 2002, J CLIN ONCOL, V20, P1248, DOI 10.1200/JCO.20.5.1248
   Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842
   Cho KR, 2009, ANNU REV PATHOL-MECH, V4, P287, DOI 10.1146/annurev.pathol.4.110807.092246
   Chou JL, 2010, LAB INVEST, V90, P414, DOI 10.1038/labinvest.2009.138
   Cottrell SE, 2003, ANN NY ACAD SCI, V983, P120, DOI 10.1111/j.1749-6632.2003.tb05967.x
   Crijns APG, 2009, PLOS MED, V6, P181, DOI 10.1371/journal.pmed.1000024
   Dai W, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-337
   Deng Y, 2010, J CANCER RES CLIN, V136, P1161, DOI 10.1007/s00432-010-0763-5
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Gatcliffe TA, 2008, INT J GYNECOL CANCER, V18, P954, DOI 10.1111/j.1525-1438.2007.01127.x
   Gifford G, 2004, CLIN CANCER RES, V10, P4420, DOI 10.1158/1078-0432.CCR-03-0732
   Hastie T., 1999, Tech. Rep.
   Havrilesky L, 2003, J CLIN ONCOL, V21, P3814, DOI 10.1200/JCO.2003.11.052
   Havrilesky LJ, 2008, GYNECOL ONCOL, V110, P374, DOI 10.1016/j.ygyno.2008.04.041
   Illingworth RS, 2009, FEBS LETT, V583, P1713, DOI 10.1016/j.febslet.2009.04.012
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Kanehisa M, 2010, NUCLEIC ACIDS RES, V38, pD355, DOI 10.1093/nar/gkp896
   Klarmann GJ, 2008, EPIGENETICS-US, V3, P59, DOI 10.4161/epi.3.2.5899
   Konstantinopoulos PA, 2008, NAT CLIN PRACT ONCOL, V5, P577, DOI 10.1038/ncponc1178
   Kulasingam V, 2010, NAT REV CANCER, V10, P371, DOI 10.1038/nrc2831
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lee YN, 2008, CELL SIGNAL, V20, P443, DOI 10.1016/j.cellsig.2007.11.005
   Lee YK, 2009, GYNECOL ONCOL, V112, P475, DOI 10.1016/j.ygyno.2008.11.031
   Li M, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-34
   Luu HH, 2004, CURR CANCER DRUG TAR, V4, P653, DOI 10.2174/1568009043332709
   McDonald SL, 2009, BRIT J CANCER, V101, P209, DOI 10.1038/sj.bjc.6605174
   McShane LM, 2005, NAT CLIN PRACT ONCOL, V2, P416, DOI 10.1038/ncponc0252
   Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245
   Moore RG, 2010, GYNECOL ONCOL, V116, P240, DOI 10.1016/j.ygyno.2009.09.041
   Nouzova M, 2004, J PHARMACOL EXP THER, V311, P968, DOI 10.1124/jpet.104.072488
   Rhead B, 2010, NUCLEIC ACIDS RES, V38, pD613, DOI 10.1093/nar/gkp939
   Ricken A, 2002, ENDOCRINOLOGY, V143, P2741, DOI 10.1210/en.143.7.2741
   Rosen DG, 2009, FRONT BIOSCI-LANDMRK, V14, P2089, DOI 10.2741/3364
   Rustin GJS, 2010, LANCET, V376, P1155, DOI 10.1016/S0140-6736(10)61268-8
   Sparks AB, 1998, CANCER RES, V58, P1130
   Stewart FJ, 1998, BIOL CHEM, V379, P611
   Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540
   Su HY, 2010, INT J CANCER, V127, P555, DOI 10.1002/ijc.25083
   Sugiyama T, 2000, CANCER, V88, P2584, DOI 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5
   SUTHERLAND E, 1992, J MOL BIOL, V225, P327, DOI 10.1016/0022-2836(92)90925-A
   Takada T, 2004, CANCER SCI, V95, P741, DOI 10.1111/j.1349-7006.2004.tb03255.x
   THIGPEN T, 1993, CANCER-AM CANCER SOC, V71, P606
   Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196
   Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520
   Ueda M, 2001, BRIT J CANCER, V85, P64, DOI 10.1054/bjoc.2001.1863
   Valencia A, 2009, LEUKEMIA, V23, P1658, DOI 10.1038/leu.2009.86
   van Amerongen R, 2010, ONCOGENE, V29, P93, DOI 10.1038/onc.2009.310
   van Jaarsveld MTM, 2010, INT J BIOCHEM CELL B, V42, P1282, DOI 10.1016/j.biocel.2010.01.014
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Verri E, 2005, ONCOLOGY-BASEL, V68, P154, DOI 10.1159/000086958
   VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901
   Wang YQ, 2009, MOL CANCER THER, V8, P2103, DOI 10.1158/1535-7163.MCT-09-0282
   Wei SH, 2006, CLIN CANCER RES, V12, P2788, DOI 10.1158/1078-0432.CCR-05-1551
   Wu R, 2007, CANCER CELL, V11, P321, DOI 10.1016/j.ccr.2007.02.016
   Ying Y, 2009, EPIGENETICS-US, V4, P307, DOI 10.4161/epi.4.5.9371
   Yu J, 2009, CANCER-AM CANCER SOC, V115, P49, DOI 10.1002/cncr.23989
NR 66
TC 79
Z9 84
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUN 15
PY 2011
VL 17
IS 12
BP 4052
EP 4062
DI 10.1158/1078-0432.CCR-10-3021
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 777SG
UT WOS:000291644700021
PM 21459799
OA Green Submitted, Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Cuomo, A
   Moretti, S
   Minucci, S
   Bonaldi, T
AF Cuomo, Alessandro
   Moretti, Simona
   Minucci, Saverio
   Bonaldi, Tiziana
TI SILAC-based proteomic analysis to dissect the "histone modification
   signature" of human breast cancer cells
SO AMINO ACIDS
LA English
DT Article
DE Mass spectrometry; Quantitative proteomics; Epigenetic mark; Histones;
   Breast cancer
ID ELECTRON-CAPTURE DISSOCIATION; EMBRYONIC STEM-CELLS; MASS-SPECTROMETRY;
   POSTTRANSLATIONAL MODIFICATIONS; DNA METHYLATION; MODIFICATION PATTERNS;
   GENOME-WIDE; ACETYLATION; IDENTIFICATION; EXPRESSION
AB In living cells, the N-terminal tails of core histones, the proteinaceous component of nucleosomes, are subjected to a range of covalent post-translational modifications (PTMs), which have specific roles in modulating chromatin structure and function. A growing body of evidence suggests that deregulation of histone modification patterns, upstream or downstream of DNA methylation, is a critical event in cancer initiation and progression. However, a comprehensive description of how histone modifications, singly or in combination, is disrupted in transformed cells is missing; consequently the issue whether and how specific changes in histone PTMs patterns correlate to particular tumor features is still elusive. In the present study, we focused on human breast cancer and comprehensively analyzed PTMs on histone H3 and H4 from four cancer cell lines (MCF7, MDA-MB231, MDA-MB453 and T-47D), in comparison with normal epithelial breast cells. We performed high-resolution mass spectrometry analysis of histones, in combination with stable isotope labeling with amino acids in cell culture (SILAC), to quantitatively track the modification changes in cancer cells, as compared to their normal counterpart. Our investigation focuses on lysine acetylation and methylation on fourteen distinct sites in H3 and H4. We observed significant changes for several modifications in cancer cells: while in a few cases those modifications had been previously described as a hallmark of human tumors, we could identify novel modifications, whose abundance is significantly altered in breast cancer cells. Overall, these modifications may represent part of a "breast cancer-specific epigenetic signature", with implications in the characterization of histone-related biomarkers. This work demonstrates that SILAC-based proteomics is a powerful tool to study qualitatively and quantitatively histone PTMs patterns, contributing significantly to the comprehension of epigenetic phenomena in cancer biology.
C1 [Cuomo, Alessandro; Moretti, Simona; Minucci, Saverio; Bonaldi, Tiziana] European Inst Oncol, Dept Expt Oncol, I-20139 Milan, Italy.
   [Minucci, Saverio] Univ Milan, Dept Biomol Sci & Biotechnol, I-20133 Milan, Italy.
C3 IRCCS European Institute of Oncology (IEO); University of Milan
RP Bonaldi, T (通讯作者)，European Inst Oncol, Dept Expt Oncol, IFOM IEO Campus,Via Adamello 16, I-20139 Milan, Italy.
EM tiziana.bonaldi@ifom-ieo-campus.it
RI cuomo, alessandro/AAB-7372-2019; Minucci, Saverio/J-9669-2012; Bonaldi,
   Tiziana/K-5075-2016
OI Minucci, Saverio/0000-0001-5678-536X; Bonaldi,
   Tiziana/0000-0003-3556-1265; Cuomo, Alessandro/0000-0002-9778-7190
FU Giovanni Armenise-Harvard Foundation; Association of International
   Cancer Research (AICR); Associazione Italiana Ricerca sul Cancro (AIRC);
   Fondazione Cariplo; EEC (Epitron)
FX TB work is supported by grants from the Giovanni Armenise-Harvard
   Foundation Career Development Program, the Association of International
   Cancer Research (AICR), the Associazione Italiana Ricerca sul Cancro
   (AIRC) and the Fondazione Cariplo. Work in SMi lab is supported by EEC
   (Epitron) and AIRC. We would like to thank Pietro Spinelli for technical
   support in cell culture and David Cairns for critical reading of the
   manuscript.
CR Beck HC, 2010, METHODS MOL BIOL, V593, P263, DOI 10.1007/978-1-60327-194-3_13
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Burlingame AL, 2005, METHODS, V36, P383, DOI 10.1016/j.ymeth.2005.03.009
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Cosgrove MS, 2007, EXPERT REV PROTEOMIC, V4, P465, DOI 10.1586/14789450.4.4.465
   Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511
   Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895
   Elsheikh SE, 2009, CANCER RES, V69, P3802, DOI 10.1158/0008-5472.CAN-08-3907
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Feng WW, 2007, INT J CANCER, V120, P1664, DOI 10.1002/ijc.22474
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Freitas MA, 2004, J CELL BIOCHEM, V92, P691, DOI 10.1002/jcb.20106
   Garcia BA, 2007, CURR OPIN CHEM BIOL, V11, P66, DOI 10.1016/j.cbpa.2006.11.022
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Ikegami K, 2007, GENES CELLS, V12, P1, DOI 10.1111/j.1365-2443.2006.01029.x
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jung HR, 2010, MOL CELL PROTEOMICS, V9, P838, DOI 10.1074/mcp.M900489-MCP200
   Käll L, 2008, J PROTEOME RES, V7, P29, DOI 10.1021/pr700600n
   Kelleher RL, 1999, ANAL CHEM, V71, P4250, DOI 10.1021/ac990684x
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kovalchuk O, 2007, CELL CYCLE, V6, P2010, DOI 10.4161/cc.6.16.4549
   Loyola A, 2006, MOL CELL, V24, P309, DOI 10.1016/j.molcel.2006.08.019
   Mann M, 2006, NAT REV MOL CELL BIO, V7, P952, DOI 10.1038/nrm2067
   Medzihradszky KF, 2004, MOL CELL PROTEOMICS, V3, P872, DOI 10.1074/mcp.M400041-MCP200
   Olsen JV, 2005, MOL CELL PROTEOMICS, V4, P2010, DOI 10.1074/mcp.T500030-MCP200
   Ong SE, 2004, NAT METHODS, V1, P119, DOI 10.1038/NMETH715
   Pesavento JJ, 2004, J AM CHEM SOC, V126, P3386, DOI 10.1021/ja039748i
   Pfister S, 2008, INT J CANCER, V122, P1207, DOI 10.1002/ijc.23283
   Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026
   Rappsilber J, 2007, NAT PROTOC, V2, P1896, DOI 10.1038/nprot.2007.261
   Roth MJ, 2005, MOL CELL PROTEOMICS, V4, P1002, DOI 10.1074/mcp.M500064-MCP200
   Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672
   Siuti N, 2006, J PROTEOME RES, V5, P233, DOI 10.1021/pr050268v
   Su XD, 2007, EXPERT REV PROTEOMIC, V4, P211, DOI 10.1586/14789450.4.2.211
   Suzuki J, 2009, CLIN CANCER RES, V15, P3163, DOI 10.1158/1078-0432.CCR-08-2319
   Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200
   Taverna SD, 2007, P NATL ACAD SCI USA, V104, P2086, DOI 10.1073/pnas.0610993104
   Thomas CE, 2006, J PROTEOME RES, V5, P240, DOI 10.1021/pr050266a
   THORNE AW, 1990, EUR J BIOCHEM, V193, P701, DOI 10.1111/j.1432-1033.1990.tb19390.x
   Tryndyak VP, 2006, CANCER BIOL THER, V5, P65, DOI 10.4161/cbt.5.1.2288
   Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154
   Zhang KL, 2002, MOL CELL PROTEOMICS, V1, P500, DOI 10.1074/mcp.M200031-MCP200
NR 43
TC 56
Z9 59
U1 0
U2 20
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0939-4451
EI 1438-2199
J9 AMINO ACIDS
JI Amino Acids
PD JUL
PY 2011
VL 41
IS 2
BP 387
EP 399
DI 10.1007/s00726-010-0668-2
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 769QT
UT WOS:000291034000014
PM 20617350
DA 2025-01-12
ER

PT J
AU Abell, AN
   Jordan, NV
   Huang, WC
   Prat, A
   Midland, AA
   Johnson, NL
   Granger, DA
   Mieczkowski, PA
   Perou, CM
   Gomez, SM
   Li, LP
   Johnson, GL
AF Abell, Amy N.
   Jordan, Nicole Vincent
   Huang, Weichun
   Prat, Aleix
   Midland, Alicia A.
   Johnson, Nancy L.
   Granger, Deborah A.
   Mieczkowski, Piotr A.
   Perou, Charles M.
   Gomez, Shawn M.
   Li, Leping
   Johnson, Gary L.
TI MAP3K4/CBP-Regulated H2B Acetylation Controls Epithelial-Mesenchymal
   Transition in Trophoblast Stem Cells
SO CELL STEM CELL
LA English
DT Article
ID BREAST-CANCER; MOUSE EMBRYO; SELF-RENEWAL; MECHANISMS; DISEASE; KINASE;
   LINES
AB Epithelial stem cells self-renew while maintaining multipotency, but the dependence of stem cell properties on maintenance of the epithelial phenotype is unclear. We previously showed that trophoblast stem (TS) cells lacking the protein kinase MAP3K4 maintain properties of both sternness and epithelial-mesenchymal transition (EMT). Here, we show that MAP3K4 controls the activity of the histone acetyltransferase CBP, and that acetylation of histones H2A and H2B by CBP is required to maintain the epithelial phenotype. Combined loss of MAP3K4/CBP activity represses expression of epithelial genes and causes IS cells to undergo EMT while maintaining their self-renewal and multipotency properties. The expression profile of MAP3K4-deficient TS cells defines an H2B acetylation-regulated gene signature that closely overlaps with that of human breast cancer cells. Taken together, our data define an epigenetic switch that maintains the epithelial phenotype in TS cells and reveals previously unrecognized genes potentially contributing to breast cancer.
C1 [Abell, Amy N.; Jordan, Nicole Vincent; Johnson, Nancy L.; Granger, Deborah A.; Johnson, Gary L.] Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA.
   [Abell, Amy N.; Jordan, Nicole Vincent; Prat, Aleix; Johnson, Nancy L.; Granger, Deborah A.; Mieczkowski, Piotr A.; Perou, Charles M.; Johnson, Gary L.] Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Prat, Aleix; Mieczkowski, Piotr A.; Perou, Charles M.] Univ N Carolina, Sch Med, Dept Genet, Chapel Hill, NC 27599 USA.
   [Mieczkowski, Piotr A.] Univ N Carolina, Sch Med, Carolina Ctr Genome Sci, Chapel Hill, NC 27599 USA.
   [Midland, Alicia A.; Gomez, Shawn M.] Univ N Carolina, Sch Med, Dept Biomed Engn, Chapel Hill, NC 27599 USA.
   [Midland, Alicia A.; Gomez, Shawn M.] Univ N Carolina, Sch Med, Curriculum Bioinformat & Computat Biol, Chapel Hill, NC 27599 USA.
   [Huang, Weichun; Li, Leping] Natl Inst Environm Hlth Sci RTP, Biostat Branch, Res Triangle Pk, NC 27709 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine; University of North
   Carolina; University of North Carolina Chapel Hill; University of North
   Carolina School of Medicine; University of North Carolina School of
   Medicine; University of North Carolina; University of North Carolina
   Chapel Hill; University of North Carolina School of Medicine; University
   of North Carolina; University of North Carolina Chapel Hill; University
   of North Carolina School of Medicine; University of North Carolina;
   University of North Carolina Chapel Hill; University of North Carolina
   School of Medicine; University of North Carolina; University of North
   Carolina Chapel Hill
RP Abell, AN (通讯作者)，Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA.
EM amy_abell@med.unc.edu; gary_johnson@med.unc.edu
RI Li, Leping/F-6497-2019; Huang, Weichun/O-6474-2018; Prat,
   Aleix/P-8561-2014; Perou, Charles/H-9934-2014
OI Li, Leping/0000-0003-4208-0259; Prat, Aleix/0000-0003-2377-540X;
   Mieczkowski, Piotr/0000-0003-2418-0096; Gomez,
   Shawn/0000-0002-8251-4552; Perou, Charles/0000-0001-9827-2247
FU NIH [GM30324, DK37871, GM007040]; University Cancer Research Fund; NIH,
   NIEHS [ES-101765]
FX G.L.J. is supported by NIH grants GM30324 and DK37871 and the University
   Cancer Research Fund for support of the deep Sequencing Genomics
   Facility. N.V.J. is supported by NIH training grant GM007040. W.H. and
   L.L. are supported by the Intramural Research Program of NIH, NIEHS
   (ES-101765). The authors thank N. Sciaky for managing databases, K.
   Kluckman and the UNC Animal Models Core for production of chimeras, B.
   Clarke for graphical work, Z. Wang for ChIP-seq discussions, and T.-P.
   Yao (Duke University) for CBP/p300 constructs and helpful discussions.
   We thank T. Magnuson, B. Snider, B. Richardson, and J. Zawistowski for
   careful reading of the manuscript.
CR Abell AN, 2009, MOL CELL BIOL, V29, P2748, DOI 10.1128/MCB.01391-08
   Abell AN, 2005, MOL CELL BIOL, V25, P8948, DOI 10.1128/MCB.25.20.8948-8959.2005
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   He SH, 2009, ANNU REV CELL DEV BI, V25, P377, DOI 10.1146/annurev.cellbio.042308.113248
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Maupin KA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013002
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Niwa H, 2005, CELL, V123, P917, DOI 10.1016/j.cell.2005.08.040
   Norwitz ER, 2001, NEW ENGL J MED, V345, P1400, DOI 10.1056/NEJMra000763
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Ray ME, 1997, P NATL ACAD SCI USA, V94, P3229, DOI 10.1073/pnas.94.7.3229
   Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499
   Rugg-Gunn PJ, 2010, P NATL ACAD SCI USA, V107, P10783, DOI 10.1073/pnas.0914507107
   Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154
   Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009
NR 19
TC 102
Z9 118
U1 0
U2 17
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
J9 CELL STEM CELL
JI Cell Stem Cell
PD MAY 6
PY 2011
VL 8
IS 5
BP 525
EP 537
DI 10.1016/j.stem.2011.03.008
PG 13
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 768IN
UT WOS:000290927600013
PM 21549327
OA Green Accepted, Green Published
DA 2025-01-12
ER

PT J
AU Zhao, YZ
   Epstein, RJ
AF Zhao, Yongzhong
   Epstein, Richard J.
TI Unexpected functional similarities between gatekeeper tumour suppressor
   genes and proto-oncogenes revealed by systems biology
SO JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE adaptive evolution; carcinogenesis; molecular evolution
ID WILD-TYPE P53; 3' UNTRANSLATED REGION; DNA-REPAIR GENES; BREAST-CANCER;
   HEPATOCELLULAR-CARCINOMA; MUTATIONAL ASYMMETRY; RETINOBLASTOMA GENE;
   MISMATCH REPAIR; MESSENGER-RNA; UP-REGULATION
AB Familial tumor suppressor genes comprise two subgroups: caretaker genes (CTs) that repair DNA, and gatekeeper genes (GKs) that trigger cell death. Since GKs may also induce cell cycle delay and thus enhance cell survival by facilitating DNA repair, we hypothesized that the prosurvival phenotype of GKs could be selected during cancer progression, and we used a multivariable systems biology approach to test this. We performed multidimensional data analysis, non-negative matrix factorization and logistic regression to compare the features of GKs with those of their putative antagonists, the proto-oncogenes (POs), as well as with control groups of CTs and functionally unrelated congenital heart disease genes (HDs). GKs and POs closely resemble each other, but not CTs or HDs, in terms of gene structure (P < 0.001), expression level and breadth (P < 0.01), DNA methylation signature (P < 0.001) and evolutionary rate (P < 0.001). The similar selection pressures and epigenetic trajectories of GKs and POs so implied suggest a common functional attribute that is strongly negatively selected-that is, a shared phenotype that enhances cell survival. The counterintuitive finding of similar evolutionary pressures affecting GKs and POs raises an intriguing possibility: namely, that cancer microevolution is accelerated by an epistatic cascade in which upstream suppressor gene defects subvert the normal bifunctionality of wild-type GKs by constitutively shifting the phenotype away from apoptosis towards survival. If correct, this interpretation would explain the hitherto unexplained phenomenon of frequent wild-type GK (for example, p53) overexpression in tumors. Journal of Human Genetics (2011) 56, 369-376; doi: 10.1038/jhg.2011.21; published online 3 March 2011
C1 [Zhao, Yongzhong] Cleveland Clin Fdn, Dept Mol Genet, Lerner Res Inst, Cleveland, OH 44195 USA.
   [Epstein, Richard J.] Univ New S Wales, Garvan Inst Med Res, St Vincents Hosp, Darlinghurst, NSW, Australia.
   [Epstein, Richard J.] Univ New S Wales, Dept Oncol, St Vincents Hosp, Darlinghurst, NSW, Australia.
C3 Cleveland Clinic Foundation; University of New South Wales Sydney;
   Garvan Institute of Medical Research; NSW Health; St Vincents Hospital
   Sydney; NSW Health; St Vincents Hospital Sydney; University of New South
   Wales Sydney
RP Epstein, RJ (通讯作者)，St Vincents Hosp, Dept Oncol, Level 5,DeLacy Bldg,390 Victoria St, Sydney, NSW 2010, Australia.
EM repstein@stvincents.com.au
OI Epstein, Richard J./0000-0002-4640-0195
CR Acar M, 2008, NAT GENET, V40, P471, DOI 10.1038/ng.110
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bernichtein S, 2008, ENDOCRINOLOGY, V149, P651, DOI 10.1210/en.2007-0925
   Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309
   Brunet JP, 2004, P NATL ACAD SCI USA, V101, P4164, DOI 10.1073/pnas.0308531101
   Cao L, 2006, EMBO J, V25, P2167, DOI 10.1038/sj.emboj.7601115
   Chiaromonte F, 2003, GENOME RES, V13, P2602, DOI 10.1101/gr.1169203
   Chuang HY, 2010, ANNU REV CELL DEV BI, V26, P721, DOI 10.1146/annurev-cellbio-100109-104122
   Clarke AR, 2005, BIOCHEM SOC T, V33, P665, DOI 10.1042/BST0330665
   Cooper GM, 2004, GENOME RES, V14, P539, DOI 10.1101/gr.2034704
   Cordell HJ, 2002, HUM MOL GENET, V11, P2463, DOI 10.1093/hmg/11.20.2463
   Cybulski C, 2007, CANCER EPIDEM BIOMAR, V16, P572, DOI 10.1158/1055-9965.EPI-06-0566
   de Boer J, 2002, SCIENCE, V296, P1276, DOI 10.1126/science.1070174
   Devarajan K, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000029
   Doctor KS, 2003, CELL DEATH DIFFER, V10, P621, DOI 10.1038/sj.cdd.4401230
   Drummond DA, 2008, CELL, V134, P341, DOI 10.1016/j.cell.2008.05.042
   Ehrhart JC, 2003, PHOTOCH PHOTOBIO SCI, V2, P825, DOI 10.1039/b302281a
   Epstein RJ, 2009, CANCER INFORM, V7, P231
   Epstein RJ, 2000, GENE, V245, P291, DOI 10.1016/S0378-1119(00)00042-1
   EPSTEIN RJ, 1990, J BIOL CHEM, V265, P10746
   Feng QH, 2008, GYNECOL ONCOL, V111, P320, DOI 10.1016/j.ygyno.2008.07.036
   Freie BW, 2008, CANCER CELL, V14, P425, DOI 10.1016/j.ccr.2008.11.008
   Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299
   Geraldes A, 2006, GENET SEL EVOL, V38, P313, DOI 10.1051/gse:2006006
   Gordan JD, 2008, CANCER CELL, V14, P435, DOI 10.1016/j.ccr.2008.10.016
   Green P, 2003, NAT GENET, V33, P514, DOI 10.1038/ng1103
   Gueven N, 2007, CELL DEATH DIFFER, V14, P1149, DOI 10.1038/sj.cdd.4402116
   Helt CE, 2005, CELL CYCLE, V4, P529, DOI 10.4161/cc.4.4.1598
   Hinz JM, 2003, CARCINOGENESIS, V24, P249, DOI 10.1093/carcin/24.2.249
   Huang GC, 2002, BRIT J CANCER, V86, P1104, DOI 10.1038/sj/bjc/6600219
   ISOLA J, 1992, J NATL CANCER I, V84, P1109, DOI 10.1093/jnci/84.14.1109
   Jabbari K, 2004, GENE, V333, P143, DOI 10.1016/j.gene.2004.02.043
   Kaminski BC, 2006, EUR J CANCER PREV, V15, P274, DOI 10.1097/01.cej.0000199502.23195.29
   Kim E, 2009, BIOCHEM PHARMACOL, V77, P11, DOI 10.1016/j.bcp.2008.08.030
   Kim KM, 2002, AM J PATHOL, V160, P1503, DOI 10.1016/S0002-9440(10)62576-X
   KOBAYASHI M, 1995, ANTISENSE RES DEV, V5, P141, DOI 10.1089/ard.1995.5.141
   Lam MYJ, 2007, HUM MOL GENET, V16, P2233, DOI 10.1093/hmg/ddm175
   Lee DD, 1999, NATURE, V401, P788, DOI 10.1038/44565
   Lercher MJ, 2003, HUM MOL GENET, V12, P2411, DOI 10.1093/hmg/ddg251
   Levitt NC, 2002, TRENDS MOL MED, V8, P179, DOI 10.1016/S1471-4914(02)02298-0
   Li L, 2005, J CELL BIOCHEM, V94, P298, DOI 10.1002/jcb.20355
   Liao BY, 2006, MOL BIOL EVOL, V23, P2072, DOI 10.1093/molbev/msl076
   Lin K, 2003, J MOL EVOL, V57, P538, DOI 10.1007/s00239-003-2507-5
   Liu Y, 2008, ANTICANCER RES, V28, P2061
   Majewski J, 2003, AM J HUM GENET, V73, P688, DOI 10.1086/378134
   Marino S, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-91
   Martin RW, 2007, CANCER RES, V67, P9658, DOI 10.1158/0008-5472.CAN-07-0290
   Martinez SL, 2010, P NATL ACAD SCI USA, V107, P5070, DOI 10.1073/pnas.1000798107
   Massey A, 2003, DNA REPAIR, V2, P73, DOI 10.1016/S1568-7864(02)00187-8
   Mathieu O, 2007, CELL, V130, P851, DOI 10.1016/j.cell.2007.07.007
   Milde-Langosch K, 2001, BREAST CANCER RES TR, V67, P61, DOI 10.1023/A:1010623308275
   Morrish BC, 2002, MOL CELL BIOL, V22, P6089, DOI 10.1128/MCB.22.17.6089-6099.2002
   Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018
   Nowak MA, 2004, P NATL ACAD SCI USA, V101, P10635, DOI 10.1073/pnas.0400747101
   Payne SR, 2005, CARCINOGENESIS, V26, P2031, DOI 10.1093/carcin/bgi223
   Podsypanina K, 2008, P NATL ACAD SCI USA, V105, P5242, DOI 10.1073/pnas.0801197105
   Ponte I, 1996, J MOL EVOL, V43, P125, DOI 10.1007/BF02337357
   Porcedda P, 2006, DNA REPAIR, V5, P904, DOI 10.1016/j.dnarep.2006.05.002
   Qu XL, 2002, ARCH BIOCHEM BIOPHYS, V400, P233, DOI 10.1016/S0003-9861(02)00016-4
   Robles AI, 1999, ONCOGENE, V18, P4681, DOI 10.1038/sj.onc.1202862
   SAITO Y, 1995, ONCOGENE, V11, P1013
   Sathyan KM, 2007, MODERN PATHOL, V20, P1141, DOI 10.1038/modpathol.3800948
   Schiavone N, 2000, FASEB J, V14, P174, DOI 10.1096/fasebj.14.1.174
   Shi YZ, 2000, CLIN CANCER RES, V6, P4096
   Sijmons R H, 2001, Fam Cancer, V1, P51, DOI 10.1023/A:1011591403125
   Smith NGC, 1998, GENETICS, V150, P823
   Söreide K, 2006, BRIT J SURG, V93, P395, DOI 10.1002/bjs.5328
   Steen HB, 2000, CARCINOGENESIS, V21, P1773, DOI 10.1093/carcin/21.10.1773
   Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101
   Tang CS, 2006, GENOMICS, V88, P682, DOI 10.1016/j.ygeno.2006.06.017
   Tanguay RL, 1996, MOL CELL BIOL, V16, P146
   Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403
   Tomlinson JS, 2001, CANCER RES, V61, P5231
   Torbenson M, 2002, HUM PATHOL, V33, P871, DOI 10.1053/hupa.2002.128061
   *UICC, 2006, FAM CANC DAT
   Vanin K, 2002, J INVEST DERMATOL, V119, P1027, DOI 10.1046/j.1523-1747.2002.19513.x
   Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087
   Vogelstein B., 2002, The Genetic Basis of Human Cancer
   WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817
   Wang FY, 2008, HEPATO-GASTROENTEROL, V55, P62
   Wang YC, 2005, J CLIN ONCOL, V23, P154, DOI 10.1200/JCO.2005.03.139
   WANG YS, 1993, CELL GROWTH DIFFER, V4, P467
   WARNEFORD S, 1991, CELL GROWTH DIFFER, V2, P439
   Watt FM, 2008, NAT REV CANCER, V8, P234, DOI 10.1038/nrc2328
   Wee KB, 2006, BIOPHYS J, V91, P857, DOI 10.1529/biophysj.105.077693
   Wood RD, 2005, MUTAT RES-FUND MOL M, V577, P275, DOI 10.1016/j.mrfmmm.2005.03.007
   Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154
   Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555
   Zhao YZ, 2008, MOL BIOL EVOL, V25, P1737, DOI 10.1093/molbev/msn126
   Zhu GH, 1999, BIOCHEM PHARMACOL, V58, P193, DOI 10.1016/S0006-2952(99)00058-1
NR 90
TC 3
Z9 4
U1 0
U2 7
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1434-5161
EI 1435-232X
J9 J HUM GENET
JI J. Hum. Genet.
PD MAY
PY 2011
VL 56
IS 5
BP 369
EP 376
DI 10.1038/jhg.2011.21
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 768QF
UT WOS:000290950100008
PM 21368766
OA Bronze
DA 2025-01-12
ER

PT J
AU Gao, S
   Andreasen, PA
AF Gao, Shan
   Andreasen, Peter A.
TI DNA methylation profiles of protease nexin 1 (SERPINE2) gene in human
   cell lines
SO CHINESE JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE Protease nexin 1; SERPINE2; DNA methylation; Cancer
ID PLASMINOGEN-ACTIVATOR INHIBITOR-1; MASPIN GENE; CPG METHYLATION;
   EPIGENETIC ALTERATIONS; MESSENGER-RNA; BREAST-CANCER; RECEPTOR GENE;
   TUMOR-GROWTH; LUNG-CANCER; EXPRESSION
AB To investigated whether epigenetic mechanisms contribute to the variable expression of variable protease nexin1(PN-1) encoded by the SERPINE2 gene in different cell types.
   Working with 5 human cell lines, we determined the CpG methylation status within two CpG islands in the SERPINE2 gene by bisulphate sequencing and the PN-1 mRNA level by Q-RT PCR.
   A CpG island spanning the transcription initiation site showed little methylation in 3 of the cell lines and substantial methylation in 2 of the cell lines. A CpG island covering the translation starting site showed full methylation in all investigated cell lines. Methylation within the CpG island was not randomly distributed, but showed accumulation at specific sites. However, we were not able to distinguish any patterns which related the methylation frequency to the gene expression level. Inhibition of CpG methylation with 5-aza-2'-deoxycytidine led to a several fold increase in PN-1 mRNA levels, but based on the results on CpG methylation in the CpG island spanning the transcript, the effect is most likely indirect.
   We have carefully mapped the CpG methylation pattern in two CpG islands in the 5' part of the SERPINE2 gene without finding any obvious inverse correlation between methylation frequency and expression level.
C1 [Gao, Shan; Andreasen, Peter A.] Univ Aarhus, Dept Mol Biol, Danish Chinese Ctr Proteases & Canc, DK-8000 Aarhus C, Denmark.
C3 Aarhus University
RP Gao, S (通讯作者)，Univ Aarhus, Dept Mol Biol, Danish Chinese Ctr Proteases & Canc, DK-8000 Aarhus C, Denmark.
EM shg@mb.au.dk
FU Danish National Research Foundation [26-331-6]; Danish Cancer Society
   [DP 07043, DP 08001]; Grosserer Alfred Nielsen and Hustrus Fond
FX This work was supported by the Danish National Research Foundation
   (26-331-6); the Danish Cancer Society (DP 07043, DP 08001); Grosserer
   Alfred Nielsen and Hustrus Fond.
CR Akiyama Y, 2003, AM J PATHOL, V163, P1911, DOI 10.1016/S0002-9440(10)63549-3
   Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z
   Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497
   Buchholz M, 2003, CANCER RES, V63, P4945
   Candia BJ, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-16
   Chelbi ST, 2007, HYPERTENSION, V49, P76, DOI 10.1161/01.HYP.0000250831.52876.cb
   Cortese R, 2008, INT J BIOCHEM CELL B, V40, P1494, DOI 10.1016/j.biocel.2007.11.018
   Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5
   Duffy MJ, 2008, J PATHOL, V214, P283, DOI 10.1002/path.2282
   Duffy MJ, 2008, CLIN CHEM, V54, P1770, DOI 10.1373/clinchem.2008.110056
   Duffy MJ, 2004, CURR PHARM DESIGN, V10, P39, DOI 10.2174/1381612043453559
   Durand MK, 2004, THROMB HAEMOSTASIS, V91, P438, DOI 10.1160/TH03-12-0784
   Erno Henrik, 1993, Gene Expression, V3, P163
   Fong KM, 1996, CLIN CANCER RES, V2, P1369
   Fujisawa K, 2005, LAB INVEST, V85, P214, DOI 10.1038/labinvest.3700214
   Furuta T, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-39
   Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886
   Gao S, 2005, THROMB HAEMOSTASIS, V94, P651, DOI 10.1160/TH05-02-0114
   Gao S, 2008, ORAL ONCOL, V44, P309, DOI 10.1016/j.oraloncology.2007.02.009
   Gao S, 2010, GENE CHROMOSOME CANC, V49, P526, DOI 10.1002/gcc.20762
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Gopalan SM, 2006, J BIOL CHEM, V281, P1956, DOI 10.1074/jbc.M510935200
   Guttridge DC, 1996, J NEUROCHEM, V67, P498
   Harris L, 2007, J CLIN ONCOL, V25, P5287, DOI 10.1200/JCO.2007.14.2364
   Illemann M, 2004, AM J CLIN PATHOL, V122, P256, DOI 10.1309/F32XWQ20T568H8VP
   Kallakury BVS, 2001, CLIN CANCER RES, V7, P3113
   Law RHP, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-5-216
   Lindberg P, 2006, INT J CANCER, V118, P2948, DOI 10.1002/ijc.21568
   Miyajima A, 2009, DRUG METAB PHARMACOK, V24, P269, DOI 10.2133/dmpk.24.269
   Murakami J, 2004, ORAL ONCOL, V40, P597, DOI 10.1016/j.oraloncology.2003.12.008
   Nagahara A, 2010, BIOCHEM BIOPH RES CO, V391, P1641, DOI 10.1016/j.bbrc.2009.12.105
   Nakopoulou L, 2003, APMIS, V111, P1027, DOI 10.1111/j.1600-0463.2003.apm1111105.x
   Offersen BV, 2003, AM J PATHOL, V163, P1887, DOI 10.1016/S0002-9440(10)63547-X
   Ogasawara S, 2004, ONCOGENE, V23, P1117, DOI 10.1038/sj.onc.1207211
   Rose SL, 2006, GYNECOL ONCOL, V102, P319, DOI 10.1016/j.ygyno.2005.12.025
   Sato N, 2004, ONCOGENE, V23, P1531, DOI 10.1038/sj.onc.1207269
   Scrideli CA, 2010, LEUKEMIA RES, V34, P32, DOI 10.1016/j.leukres.2009.10.007
   Selzer-Plon J, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-201
   Shen LL, 2007, BIOTECHNIQUES, V42, P48, DOI 10.2144/000112312
   Usher PA, 2005, INT J CANCER, V113, P870, DOI 10.1002/ijc.20665
   Wong WK, 2003, J BIOL CHEM, V278, P36227, DOI 10.1074/jbc.M305549200
   Yang QW, 2004, CANCER RES, V64, P4531, DOI 10.1158/0008-5472.CAN-04-0956
   Yatabe Y, 2004, ONCOGENE, V23, P4041, DOI 10.1038/sj.onc.1207557
   Zhao H, 2005, CANCER-AM CANCER SOC, V104, P44, DOI 10.1002/cncr.21135
   Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003
   ZONG J, 1990, MOL CELL BIOL, V10, P5580, DOI 10.1128/MCB.10.10.5580
NR 46
TC 0
Z9 1
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1000-9604
J9 CHINESE J CANCER RES
JI Chin. J. Cancer Res.
PD JUN
PY 2011
VL 23
IS 2
BP 92
EP 98
DI 10.1007/s11670-011-0092-5
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 766RQ
UT WOS:000290804600002
PM 23482841
OA Green Published
DA 2025-01-12
ER

PT J
AU Parvani, JG
   Taylor, MA
   Schiemann, WP
AF Parvani, Jenny G.
   Taylor, Molly A.
   Schiemann, William P.
TI Noncanonical TGF-β Signaling During Mammary Tumorigenesis
SO JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
LA English
DT Article
DE Epithelial-mesenchymal transition; Metastasis; Signal transduction;
   Transforming growth factor-beta; Tumor microenvironment
ID GROWTH-FACTOR-BETA; EPITHELIAL-MESENCHYMAL TRANSITION; FACTOR-KAPPA-B;
   CANCER CELL-PROLIFERATION; ACTIVATED PROTEIN-KINASE; N-CADHERIN
   EXPRESSION; FYVE DOMAIN PROTEIN; BREAST-CANCER; LYSYL OXIDASE; DEPENDENT
   DEGRADATION
AB Breast cancer is a heterogeneous disease comprised of at least five major tumor subtypes that coalesce as the second leading cause of cancer death in women in the United States. Although metastasis clearly represents the most lethal characteristic of breast cancer, our understanding of the molecular mechanisms that govern this event remains inadequate. Clinically, similar to 30% of breast cancer patients diagnosed with early-stage disease undergo metastatic progression, an event that (a) severely limits treatment options, (b) typically results in chemoresistance and low response rates, and (c) greatly contributes to aggressive relapses and dismal survival rates. Transforming growth factor-beta (TGF-beta) is a pleiotropic cytokine that regulates all phases of postnatal mammary gland development, including branching morphogenesis, lactation, and involution. TGF-beta also plays a prominent role in suppressing mammary tumorigenesis by preventing mammary epithelial cell (MEC) proliferation, or by inducing MEC apoptosis. Genetic and epigenetic events that transpire during mammary tumorigenesis conspire to circumvent the tumor suppressing activities of TGF-beta, thereby permitting late-stage breast cancer cells to acquire invasive and metastatic phenotypes in response to TGF-beta. Metastatic progression stimulated by TGF-beta also relies on its ability to induce epithelial-mesenchymal transition (EMT) and the expansion of chemoresistant breast cancer stem cells. Precisely how this metamorphosis in TGF-beta function comes about remains incompletely understood; however, recent findings indicate that the initiation of oncogenic TGF-beta activity is contingent upon imbalances between its canonical and noncanonical signaling systems. Here we review the molecular and cellular contributions of noncanonical TGF-beta effectors to mammary tumorigenesis and metastatic progression.
C1 [Parvani, Jenny G.; Taylor, Molly A.; Schiemann, William P.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.
C3 University System of Ohio; Case Western Reserve University
RP Schiemann, WP (通讯作者)，Case Western Reserve Univ, Case Comprehens Canc Ctr, Wolstein Res Bldg,Room 2131,2103 Cornell Rd, Cleveland, OH 44106 USA.
EM William.Schiemann@case.edu
OI Taylor, Molly/0000-0002-7885-8395
FU National Institutes of Health [CA129359]; Komen Foundation
   [BCTR0706967]; Department of Defense [BC084651, BC093128]
FX W.P.S. was supported by grants from the National Institutes of Health
   (CA129359), the Komen Foundation (BCTR0706967), and the Department of
   Defense (BC084651), while M.A.T. was supported by the Department of
   Defense (BC093128).
CR Agiostratidou G, 2007, J MAMMARY GLAND BIOL, V12, P127, DOI 10.1007/s10911-007-9044-6
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Albini A, 2007, NAT REV CANCER, V7, P139, DOI 10.1038/nrc2067
   Allington TM, 2009, FASEB J, V23, P4231, DOI 10.1096/fj.09-138412
   [Anonymous], 2010, CANCER
   [Anonymous], CANC BREAST
   [Anonymous], BREAST CANC RES TREA
   [Anonymous], NEOPLASIA IN PRESS
   Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6
   ASLAKSON CJ, 1992, CANCER RES, V52, P1399
   Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429
   Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200
   Bakin AV, 2002, J CELL SCI, V115, P3193
   Bandyopadhyay A, 2006, CANCER RES, V66, P6714, DOI 10.1158/0008-5472.CAN-05-3565
   Barcellos-Hoff MH, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2224
   Barkan D, 2008, CANCER RES, V68, P6241, DOI 10.1158/0008-5472.CAN-07-6849
   Barkan D, 2010, CANCER RES, V70, P5706, DOI 10.1158/0008-5472.CAN-09-2356
   Barrios-Rodiles M, 2005, SCIENCE, V307, P1621, DOI 10.1126/science.1105776
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bennett CN, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2125
   Bhardwaj Arun, 2010, Mol Cell Pharmacol, V2, P213
   Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096
   Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922
   Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200
   Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27
   Bianchini G, 2010, J CLIN ONCOL, V28, P4316, DOI 10.1200/JCO.2009.27.2419
   Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926
   Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797
   Brown KA, 2007, J CELL BIOCHEM, V101, P9, DOI 10.1002/jcb.21255
   Butcher DT, 2009, NAT REV CANCER, V9, P108, DOI 10.1038/nrc2544
   Cabodi S, 2006, CANCER RES, V66, P4672, DOI 10.1158/0008-5472.CAN-05-2909
   Cabodi S, 2010, FASEB J, V24, P3796, DOI 10.1096/fj.10-157347
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276
   Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865
   Chandler EM, 2011, PHYS BIOL, V8, DOI 10.1088/1478-3975/8/1/015008
   Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003
   Chaudhury A, 2010, NAT CELL BIOL, V12, P286, DOI 10.1038/ncb2029
   Cheng N, 2005, ONCOGENE, V24, P5053, DOI 10.1038/sj.onc.1208685
   Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239
   Christofori G, 2003, EMBO J, V22, P2318, DOI 10.1093/emboj/cdg228
   Chua HL, 2007, ONCOGENE, V26, P711, DOI 10.1038/sj.onc.1209808
   Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117
   Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106
   Datta PK, 2000, MOL CELL BIOL, V20, P3157, DOI 10.1128/MCB.20.9.3157-3167.2000
   Datto MB, 1999, MOL CELL BIOL, V19, P2495
   Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086
   Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117
   Derynck R, 2007, NAT CELL BIOL, V9, P1000, DOI 10.1038/ncb434
   Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748
   Dupont S, 2009, CELL, V136, P123, DOI 10.1016/j.cell.2008.10.051
   Dzwonek J, 2009, MOL CANCER RES, V7, P1342, DOI 10.1158/1541-7786.MCR-08-0558
   Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079
   Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200
   Ebnet K, 2004, J CELL SCI, V117, P19, DOI 10.1242/jcs.00930
   Egeblad M, 2010, DEV CELL, V18, P884, DOI 10.1016/j.devcel.2010.05.012
   Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413
   Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664
   Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012
   Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695
   Faresse N, 2008, EMBO J, V27, P1804, DOI 10.1038/emboj.2008.109
   Farmer P, 2009, NAT MED, V15, P68, DOI 10.1038/nm.1908
   Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431
   Funaba M, 2002, J BIOL CHEM, V277, P41361, DOI 10.1074/jbc.M204597200
   Furuse M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002907
   Galliher AJ, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1524
   Galliher AJ, 2007, CANCER RES, V67, P3752, DOI 10.1158/0008-5472.CAN-06-3851
   Galliher-Beckley AJ, 2008, CARCINOGENESIS, V29, P244, DOI 10.1093/carcin/bgm245
   Gansler T, 2010, CA-CANCER J CLIN, V60, P1, DOI [10.3322/caac.20073, 10.3322/caac.20049]
   Garamszegi N, 2010, ONCOGENE, V29, P2368, DOI 10.1038/onc.2009.514
   Giampieri S, 2010, CANCER RES, V70, P3435, DOI 10.1158/0008-5472.CAN-10-0466
   Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973
   Grände M, 2002, J CELL SCI, V115, P4227, DOI 10.1242/jcs.00091
   Gravdal K, 2007, CLIN CANCER RES, V13, P7003, DOI 10.1158/1078-0432.CCR-07-1263
   Greber B, 2007, STEM CELLS, V25, P455, DOI 10.1634/stemcells.2006-0476
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Gumireddy K, 2008, ANGEW CHEM INT EDIT, V47, P7482, DOI 10.1002/anie.200801555
   Guo X, 2008, GENE DEV, V22, P106, DOI 10.1101/gad.1590908
   Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001
   Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010
   Hall A, 2005, BIOCHEM SOC T, V33, P891, DOI 10.1042/BST0330891
   Hall A, 2009, CANCER METAST REV, V28, P5, DOI 10.1007/s10555-008-9166-3
   Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7
   Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779
   He Y, 2011, ONCOGENE, V30, P1032, DOI 10.1038/onc.2010.477
   Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021
   Hocevar BA, 2005, J BIOL CHEM, V280, P25920, DOI 10.1074/jbc.M501150200
   Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789
   Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681
   Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358
   Hussey GS, 2011, MOL CELL, V41, P419, DOI 10.1016/j.molcel.2011.02.003
   Hutchison N, 2009, CELL SIGNAL, V21, P1522, DOI 10.1016/j.cellsig.2009.05.012
   Ibarrola N, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-2
   IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Itoh M, 2003, J MAMMARY GLAND BIOL, V8, P449, DOI 10.1023/B:JOMG.0000017431.45314.07
   Izzi L, 2004, ONCOGENE, V23, P2071, DOI 10.1038/sj.onc.1207412
   James D, 2005, DEVELOPMENT, V132, P1273, DOI 10.1242/dev.01706
   Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652
   Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kang JS, 2009, TRENDS CELL BIOL, V19, P385, DOI 10.1016/j.tcb.2009.05.008
   Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870
   Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9
   Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820
   Kim BG, 2006, NATURE, V441, P1015, DOI 10.1038/nature04846
   Kim KK, 2009, J CLIN INVEST, V119, P213, DOI 10.1172/JCI36940
   Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025
   Kim W, 2008, MOL BIOL CELL, V19, P2135, DOI 10.1091/mbc.E07-10-0991
   Kim Y, 2009, J CELL BIOL, V184, P309, DOI 10.1083/jcb.200806067
   Koinuma D, 2003, EMBO J, V22, P6458, DOI 10.1093/emboj/cdg632
   Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08
   Korpal M, 2009, NAT MED, V15, P960, DOI 10.1038/nm.1943
   Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021
   Kretschmer A, 2003, ONCOGENE, V22, P6748, DOI 10.1038/sj.onc.1206791
   Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804
   Krützfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303
   Kumar S, 2009, CANCER METAST REV, V28, P113, DOI 10.1007/s10555-008-9173-4
   Lacher MD, 2006, CANCER RES, V66, P1648, DOI 10.1158/0008-5472.CAN-05-2328
   Lamouille S, 2007, J CELL BIOL, V178, P437, DOI 10.1083/jcb.200611146
   Lee YH, 2008, CARCINOGENESIS, V29, P2243, DOI 10.1093/carcin/bgn199
   Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700
   Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027
   Li F, 2007, CELL RES, V17, P3, DOI 10.1038/sj.cr.7310118
   Li HX, 2010, J BIOL CHEM, V285, P17846, DOI 10.1074/jbc.M109.076992
   Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200
   Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044
   Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258
   Lu X, 2004, NEOPLASIA, V6, P603, DOI 10.1593/neo.04241
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Martin TA, 2009, BBA-BIOMEMBRANES, V1788, P872, DOI 10.1016/j.bbamem.2008.11.005
   Maschler S, 2005, ONCOGENE, V24, P2032, DOI 10.1038/sj.onc.1208423
   Massagué J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705
   Massagué J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753
   Massagué J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Massagué J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033
   McAllister SS, 2008, CELL, V133, P994, DOI 10.1016/j.cell.2008.04.045
   Micalizzi DS, 2010, J MAMMARY GLAND BIOL, V15, P117, DOI 10.1007/s10911-010-9178-9
   Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000
   Mizejewski GJ, 1999, P SOC EXP BIOL MED, V222, P124, DOI 10.1046/j.1525-1373.1999.d01-122.x
   Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554
   Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x
   Mu DZ, 2002, J CELL BIOL, V157, P493, DOI 10.1083/jcb.200109100
   Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0
   Murillo MM, 2005, ONCOGENE, V24, P4580, DOI 10.1038/sj.onc.1208664
   Murphy SJ, 2004, MOL BIOL CELL, V15, P2853, DOI 10.1091/mbc.E04-02-0097
   Mythreye K, 2009, P NATL ACAD SCI USA, V106, P8221, DOI 10.1073/pnas.0812879106
   Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369
   Neil JR, 2008, CARCINOGENESIS, V29, P2227, DOI 10.1093/carcin/bgn202
   Neil JR, 2008, CANCER RES, V68, P1462, DOI 10.1158/0008-5472.CAN-07-3094
   Neil JR, 2009, J BIOL CHEM, V284, P21209, DOI 10.1074/jbc.M109.018374
   Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101
   Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622
   Nishimura SL, 2009, AM J PATHOL, V175, P1362, DOI 10.2353/ajpath.2009.090393
   Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693
   Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807
   Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718
   Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046
   Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232
   Paszek MJ, 2004, J MAMMARY GLAND BIOL, V9, P325, DOI 10.1007/s10911-004-1404-x
   Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010
   Payne SL, 2007, J CELL BIOCHEM, V101, P1338, DOI 10.1002/jcb.21371
   Payne SL, 2006, J CELL BIOCHEM, V98, P827, DOI 10.1002/jcb.20792
   Penheiter SG, 2010, MOL BIOL CELL, V21, P4009, DOI 10.1091/mbc.E09-12-1019
   Pera MF, 2010, NATURE, V465, P713, DOI 10.1038/nature09228
   Petersen M, 2010, ONCOGENE, V29, P1351, DOI 10.1038/onc.2009.426
   Piek E, 1999, J CELL SCI, V112, P4557
   Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Qian BY, 2009, BREAST CANCER RES TR, V117, P131, DOI 10.1007/s10549-008-0219-7
   Rahimi RA, 2007, J CELL BIOCHEM, V102, P593, DOI 10.1002/jcb.21501
   RAK JW, 1992, BRIT J CANCER, V65, P641, DOI 10.1038/bjc.1992.138
   Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113
   Rifkin DB, 2005, J BIOL CHEM, V280, P7409, DOI 10.1074/jbc.R400029200
   Runyan CE, 2009, J BIOL CHEM, V284, P25181, DOI 10.1074/jbc.M109.032847
   Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273
   Scheel C, 2007, CANCER RES, V67, P11476, DOI 10.1158/0008-5472.CAN-07-1653
   Schiemann WP, 2007, EXPERT REV ANTICANC, V7, P609, DOI 10.1586/14737140.7.5.609
   Schneeberger EE, 2004, AM J PHYSIOL-CELL PH, V286, pC1213, DOI 10.1152/ajpcell.00558.2003
   Serra R, 2005, ENDOCR-RELAT CANCER, V12, P749, DOI 10.1677/erc.1.00936
   Serra Rosa, 2003, Breast Dis, V18, P61
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Shintani Y, 2006, MOL BIOL CELL, V17, P2963, DOI 10.1091/mbc.E05-12-1123
   Shintani Y, 2006, CANCER RES, V66, P11745, DOI 10.1158/0008-5472.CAN-06-2322
   Shiou SR, 2007, CANCER RES, V67, P1571, DOI 10.1158/0008-5472.CAN-06-1680
   Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013
   Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215
   Sloan EK, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1398
   Sorrentino A, 2008, NAT CELL BIOL, V10, P1199, DOI 10.1038/ncb1780
   Souchelnytskyi S, 1998, J BIOL CHEM, V273, P25364, DOI 10.1074/jbc.273.39.25364
   Sovak MA, 1999, CELL GROWTH DIFFER, V10, P537
   Stadtfeld M, 2010, GENE DEV, V24, P2239, DOI 10.1101/gad.1963910
   Sugahara KN, 2009, CANCER CELL, V16, P510, DOI 10.1016/j.ccr.2009.10.013
   Ta HQ, 2008, CANCER RES, V68, P8796, DOI 10.1158/0008-5472.CAN-08-2426
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Talmadge JE, 2007, CANCER RES, V67, P11471, DOI 10.1158/0008-5472.CAN-07-2496
   Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040
   Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899
   Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Taylor MA, 2010, J MAMMARY GLAND BIOL, V15, P169, DOI 10.1007/s10911-010-9181-1
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Tian F, 2004, CANCER RES, V64, P4523, DOI 10.1158/0008-5472.CAN-04-0030
   Tian F, 2003, CANCER RES, V63, P8284
   Tian M., 2010, Cell Signal
   Tian MZ, 2010, FASEB J, V24, P1105, DOI 10.1096/fj.09-141341
   Tian M, 2009, FUTURE ONCOL, V5, P259, DOI 10.2217/14796694.5.2.259
   Tian YC, 2002, AM J PATHOL, V160, P1619, DOI 10.1016/S0002-9440(10)61109-1
   Tomaskovic-Crook E, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2416
   Tomita K, 2000, CANCER RES, V60, P3650
   Tsuda N, 2006, CLIN CANCER RES, V12, P6557, DOI 10.1158/1078-0432.CCR-06-0588
   Tsuji T, 2008, CANCER RES, V68, P10377, DOI 10.1158/0008-5472.CAN-08-1444
   Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8
   Uttamsingh S, 2008, ONCOGENE, V27, P2626, DOI 10.1038/sj.onc.1210915
   Valastyan S, 2009, GENE DEV, V23, P2592, DOI 10.1101/gad.1832709
   Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047
   Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658
   van der Flier S, 2000, INT J CANCER, V89, P465, DOI 10.1002/1097-0215(20000920)89:5<465::AID-IJC11>3.0.CO;2-O
   Viloria-Petit AM, 2009, P NATL ACAD SCI USA, V106, P14028, DOI 10.1073/pnas.0906796106
   Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905
   Vogelmann R, 2005, J CELL SCI, V118, P4901, DOI 10.1242/jcs.02594
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Waddell DS, 2004, J BIOL CHEM, V279, P29236, DOI 10.1074/jbc.M400880200
   Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5
   Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3
   Weiler J, 2006, GENE THER, V13, P496, DOI 10.1038/sj.gt.3302654
   WEINSTATSASLOW D, 1994, FASEB J, V8, P401, DOI 10.1096/fasebj.8.6.7513289
   Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998
   Wels J, 2008, GENE DEV, V22, P559, DOI 10.1101/gad.1636908
   Wendt MK, 2010, ONCOGENE, V29, P6485, DOI 10.1038/onc.2010.377
   Wendt MK, 2009, J BIOL CHEM, V284, P34145, DOI 10.1074/jbc.M109.023614
   Wendt MK, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2360
   Wendt MK, 2009, FUTURE ONCOL, V5, P1145, DOI [10.2217/fon.09.90, 10.2217/FON.09.90]
   Wicks SJ, 2000, MOL CELL BIOL, V20, P8103, DOI 10.1128/MCB.20.21.8103-8111.2000
   Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2
   Wienke D, 2007, CANCER RES, V67, P10230, DOI 10.1158/0008-5472.CAN-06-3496
   Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5
   Yakmovych I, 2001, FASEB J, V15, P553
   Yakovich AJ, 2010, J CELL PHYSIOL, V224, P398, DOI 10.1002/jcp.22135
   Yamashita M, 2008, MOL CELL, V31, P918, DOI 10.1016/j.molcel.2008.09.002
   Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009
   Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004
   Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280
   You HJ, 2009, CARCINOGENESIS, V30, P1281, DOI 10.1093/carcin/bgp071
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zavadil J, 2007, CELLS TISSUES ORGANS, V185, P157, DOI 10.1159/000101316
   Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137
   Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24
   Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200
   Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4
   Zutter MM, 2007, ADV EXP MED BIOL, V608, P87
NR 254
TC 99
Z9 122
U1 0
U2 8
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1083-3021
EI 1573-7039
J9 J MAMMARY GLAND BIOL
JI J. Mammary Gland Biol. Neoplasia
PD JUN
PY 2011
VL 16
IS 2
BP 127
EP 146
DI 10.1007/s10911-011-9207-3
PG 20
WC Oncology; Endocrinology & Metabolism; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Endocrinology & Metabolism; Physiology
GA 765DL
UT WOS:000290683500008
PM 21448580
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Zhang, H
   Niu, BB
   Hu, JF
   Ge, SF
   Wang, HB
   Li, T
   Ling, JQ
   Steelman, BN
   Qian, GX
   Hoffman, AR
AF Zhang, He
   Niu, Beibei
   Hu, Ji-Fan
   Ge, Shengfang
   Wang, Haibo
   Li, Tao
   Ling, Jianqun
   Steelman, Brandon N.
   Qian, Guanxiang
   Hoffman, Andrew R.
TI Interruption of intrachromosomal looping by CCCTC binding factor decoy
   proteins abrogates genomic imprinting of human insulin-like growth
   factor II
SO JOURNAL OF CELL BIOLOGY
LA English
DT Article
ID ENHANCER-BLOCKING ACTIVITY; CTCF-BINDING; DIFFERENTIAL METHYLATION;
   REGION UPSTREAM; DNA METHYLATION; GENE-REGULATION; IGF2; H19;
   EXPRESSION; INSULATOR
AB Monoallelic expression of IGF2 is regulated by CCCTC binding factor (CTCF) binding to the imprinting control region (ICR) on the maternal allele, with subsequent formation of an intrachromosomal loop to the promoter region. The N-terminal domain of CTCF interacts with SUZ12, part of the polycomb repressive complex-2 (PRC2), to silence the maternal allele. We synthesized decoy CTCF proteins, fusing the CTCF deoxyribonucleic acid-binding zinc finger domain to CpG methyltransferase Sss1 or to enhanced green fluorescent protein. In normal human fibroblasts and breast cancer MCF7 cell lines, the CTCF decoy proteins bound to the unmethylated ICR and to the IGF2 promoter region but did not interact with SUZ12. EZH2, another part of PRC2, was unable to methylate histone H3-K27 in the IGF2 promoter region, resulting in reactivation of the imprinted allele. The intrachromosomal loop between the maternal ICR and the IGF2 promoters was not observed when IGF2 imprinting was lost. CTCF epigenetically governs allelic gene expression of IGF2 by orchestrating chromatin loop structures involving PRC2.
C1 [Zhang, He; Niu, Beibei; Hu, Ji-Fan; Wang, Haibo; Li, Tao; Ling, Jianqun; Steelman, Brandon N.; Hoffman, Andrew R.] Stanford Univ, Sch Med, Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA.
   [Zhang, He; Ge, Shengfang; Wang, Haibo; Qian, Guanxiang] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Biochem & Mol Biol, Shanghai 200025, Peoples R China.
C3 Stanford University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); VA Palo Alto Health Care System; Shanghai Jiao
   Tong University
RP Hu, JF (通讯作者)，Stanford Univ, Sch Med, Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA.
EM Jifan@stanford.edu; arhoffman@stanford.edu
RI Wang, Haibo/AAH-3749-2020
OI ZHANG, HE/0000-0001-9954-4451; HU, Jifan/0000-0002-2174-0361; Hoffman,
   Andrew/0000-0002-0145-1917
FU National Institutes of Health [1R43 CA103553-01]; Department of Defense
   [W81XWH-04-1-0597]; Medical Research Service of the Department of
   Veterans Affairs; National Key Program for Basic Research of China
   [2010CB529902]; National Natural Science Foundation of China [30973663];
   Shanghai Leading Academic Discipline Project [S30205]
FX This work was supported by a National Institutes of Health grant (1R43
   CA103553-01) and Department of Defense grant (W81XWH-04-1-0597) to J.-F.
   Hu, a Medical Merit Review from the Medical Research Service of the
   Department of Veterans Affairs to A. R. Hoffman, a National Key Program
   for Basic Research of China grant (2010CB529902) to G. Qian and S. Ge, a
   National Natural Science Foundation of China grant (30973663) to G.
   Qian, and a Shanghai Leading Academic Discipline Project grant (S30205)
   to S. Ge.
CR Arney KL, 2003, TRENDS GENET, V19, P17, DOI 10.1016/S0168-9525(02)00004-5
   Bartolomei MS, 2002, ADV EXP MED BIOL, V518, P239
   BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663
   Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4
   Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447
   Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100
   Chen HL, 2006, EMBO J, V25, P5329, DOI 10.1038/sj.emboj.7601399
   Cui HM, 2002, CANCER RES, V62, P6442
   Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799
   Donohoe ME, 2009, NATURE, V460, P128, DOI 10.1038/nature08098
   Dunn KL, 2003, BIOCHEM CELL BIOL, V81, P161, DOI 10.1139/o03-052
   Engel N, 2003, INT REV CYTOL, V232, P89, DOI 10.1016/S0074-7696(03)32003-0
   FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110
   Filippova GN, 2008, CURR TOP DEV BIOL, V80, P337, DOI 10.1016/S0070-2153(07)80009-3
   Fitzpatrick GV, 2007, MOL CELL BIOL, V27, P2636, DOI 10.1128/MCB.02036-06
   Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106
   Hu JF, 1996, J BIOL CHEM, V271, P18253, DOI 10.1074/jbc.271.30.18253
   Hu JF, 1997, J BIOL CHEM, V272, P20715, DOI 10.1074/jbc.272.33.20715
   Kanduri C, 2000, CURR BIOL, V10, P853, DOI 10.1016/S0960-9822(00)00597-2
   Kim TH, 2007, CELL, V128, P1231, DOI 10.1016/j.cell.2006.12.048
   Kurukuti S, 2006, P NATL ACAD SCI USA, V103, P10684, DOI 10.1073/pnas.0600326103
   Li T, 2008, MOL CELL BIOL, V28, P6473, DOI 10.1128/MCB.00204-08
   Ling JQ, 2006, SCIENCE, V312, P269, DOI 10.1126/science.1123191
   Mann JR, 2000, CRIT REV EUKAR GENE, V10, P241
   Moore T, 1997, P NATL ACAD SCI USA, V94, P12509, DOI 10.1073/pnas.94.23.12509
   Mukhopadhyay R, 2004, GENOME RES, V14, P1594, DOI 10.1101/gr.2408304
   Murrell A, 2004, NAT GENET, V36, P889, DOI 10.1038/ng1402
   Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6
   Ohlsson R, 2010, BIOESSAYS, V32, P37, DOI 10.1002/bies.200900118
   Pant V, 2004, MOL CELL BIOL, V24, P3497, DOI 10.1128/MCB.24.8.3497-3504.2004
   Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001
   Recillas-Targa F, 2006, J CELL MOL MED, V10, P554, DOI 10.1111/j.1582-4934.2006.tb00420.x
   Reik W, 2000, INT J DEV BIOL, V44, P145
   RENBAUM P, 1990, NUCLEIC ACIDS RES, V18, P1145, DOI 10.1093/nar/18.5.1145
   Sasaki H, 2000, J BIOCHEM, V127, P711, DOI 10.1093/oxfordjournals.jbchem.a022661
   Schoenherr CJ, 2003, NAT GENET, V33, P66, DOI 10.1038/ng1057
   Sparago A, 2004, NAT GENET, V36, P958, DOI 10.1038/ng1410
   Srivastava M, 2000, GENE DEV, V14, P1186
   Sullivan MJ, 1999, ONCOGENE, V18, P7527, DOI 10.1038/sj.onc.1203096
   Szabó PE, 2004, MOL CELL BIOL, V24, P4791, DOI 10.1128/MCB.24.11.4791-4800.2004
   Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693
   Ulaner GA, 2003, HUM MOL GENET, V12, P535, DOI 10.1093/hmg/ddg034
   Vu TH, 2010, HUM MOL GENET, V19, P901, DOI 10.1093/hmg/ddp558
   West AG, 2002, GENE DEV, V16, P271, DOI 10.1101/gad.954702
   Wolffe AP, 2000, CURR BIOL, V10, pR463, DOI 10.1016/S0960-9822(00)00534-0
   Xu GL, 1997, NAT GENET, V17, P376, DOI 10.1038/ng1297-376
   Yusufzai TM, 2004, MOL CELL, V13, P291, DOI 10.1016/S1097-2765(04)00029-2
NR 47
TC 65
Z9 69
U1 0
U2 15
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA
SN 0021-9525
EI 1540-8140
J9 J CELL BIOL
JI J. Cell Biol.
PD MAY 2
PY 2011
VL 193
IS 3
BP 475
EP 487
DI 10.1083/jcb.201101021
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 765AS
UT WOS:000290676400008
PM 21536749
OA hybrid, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Skytte, AB
   Waldstrom, M
   Rasmussen, AA
   Crüger, D
   Woodward, ER
   Kolvraa, S
AF Skytte, Anne-Bine
   Waldstrom, Marianne
   Rasmussen, Anders Aamann
   Cruger, Dorthe
   Woodward, Emma R.
   Kolvraa, Steen
TI Identification of <i>BRCA1</i>-deficient ovarian cancers
SO ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA
LA English
DT Article
DE ovarian cancer; BRCA1; BRCA1 immunohistochemistry; BRCA1 fluorescence in
   situ hybridization; methylation
ID BRCA2 MUTATIONS; SPORADIC OVARIAN; GENE-EXPRESSION; DNA METHYLATION;
   BREAST-TUMORS; CARCINOMAS; CARRIERS; SERIES; INSTABILITY; FAMILIES
AB Objective. It is believed that 24-40% of ovarian cancers have dysfunction in the BRCA1 or BRCA2 (BRCAness) genes, due to either inherited or somatic mutations or due to epigenetic inactivation. Demonstration of ovarian cancers with BRCAness is becoming important both due to the possibility of offering genetic counseling and due to beneficial effects of polyadenosine diphosphate ribose polymerase inhibitor treatment in this group. As DNA sequencing is expensive and time consuming, efforts have been devoted to develop more indirect methods for BRCA screening that can improve the selection of patients for sequence-based BRCA testing. Design. BRCA1 immunohistochemistry, fluorescence in situ hybridization (FISH) and methylation analyses were performed on formalin-fixed, paraffin-embedded ovarian cancer tissue. Sample. Fifty-four ovarian cancers; 15 BRCA1 cancers, four BRCA2 cancers, 10 cancers from patients with a family history but no mutation detected, and 25 ovarian cancers with unknown BRCA1 status. Results. Abnormal BRCA1 immunohistochemistry was found to indicate BRCA mutations with a sensitivity of 80%, a specificity of 93% and an estimated positive predictive value of 73%. The FISH analyses supported the diagnosis in most cases. Methylation analyses could indicate BRCA deficiency in combination with one of the other methods. Conclusions. BRCA1 immunohistochemistry is a promising screening method for BRCA1 mutation detection.
C1 [Skytte, Anne-Bine; Rasmussen, Anders Aamann; Cruger, Dorthe; Kolvraa, Steen] Vejle Hosp, Dept Clin Genet, DK-7100 Vejle, Denmark.
   [Skytte, Anne-Bine; Kolvraa, Steen] Univ So Denmark, Inst Reg Hlth Serv Res, Odense, Denmark.
   [Waldstrom, Marianne] Vejle Hosp, Dept Pathol, DK-7100 Vejle, Denmark.
   [Woodward, Emma R.] Univ Birmingham, Dept Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.
   [Woodward, Emma R.] Birmingham Womens Hosp, WestMidlands Reg Genet Serv, Birmingham, W Midlands, England.
C3 University of Southern Denmark; Lillebaelt Hospital; University of
   Southern Denmark; University of Southern Denmark; Lillebaelt Hospital;
   University of Birmingham; Birmingham Women's Hospital
RP Skytte, AB (通讯作者)，Vejle Hosp, Dept Clin Genet, Kabbeltoft 25, DK-7100 Vejle, Denmark.
EM anne-bine.skytte@slb.regionsyddanmark.dk
RI Woodward, Emma/U-1282-2019
OI Skytte, Anne-Bine/0000-0002-0067-9557; waldstroem,
   marianne/0000-0001-6272-7297
FU Max and Inger Worzners Fond; Aase and Ejner Danielsens Fond; National
   Institutes of Health Research (NIHR) [DHCS/06/06/013] Funding Source:
   National Institutes of Health Research (NIHR)
FX The work was supported by a grant from Max and Inger Worzners Fond and a
   grant from Aase and Ejner Danielsens Fond.
CR Al-Mulla F, 2005, J HISTOCHEM CYTOCHEM, V53, P621, DOI 10.1369/jhc.4A6544.2005
   Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Boyd J, 2000, JAMA-J AM MED ASSOC, V283, P2260, DOI 10.1001/jama.283.17.2260
   Catteau A, 2002, SEMIN CANCER BIOL, V12, P359, DOI 10.1016/S1044-579X(02)00056-1
   Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010
   Dworkin AM, 2009, FAM CANCER, V8, P339, DOI 10.1007/s10689-009-9240-1
   EASTON DF, 1993, AM J HUM GENET, V52, P678
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Fiegl H, 2004, CANCER EPIDEM BIOMAR, V13, P882
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   Kato H, 2004, EXP MOL PATHOL, V76, P138, DOI 10.1016/j.yexmp.2003.11.005
   Lakhani SR, 2004, CLIN CANCER RES, V10, P2473, DOI 10.1158/1078-0432.CCR-1029-3
   Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8
   Pal T, 2005, CANCER-AM CANCER SOC, V104, P2807, DOI 10.1002/cncr.21536
   Pharoah PDP, 1999, CANCER RES, V59, P868
   Press JZ, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-17
   Risch HA, 2001, AM J HUM GENET, V68, P700, DOI 10.1086/318787
   Shaw PA, 2002, INT J GYNECOL PATHOL, V21, P407, DOI 10.1097/00004347-200210000-00011
   Sogaard M, 2006, ACTA OBSTET GYN SCAN, V85, P93, DOI 10.1080/00016340500324621
   Staff S, 2000, GENE CHROMOSOME CANC, V28, P432, DOI 10.1002/1098-2264(200008)28:4<432::AID-GCC9>3.0.CO;2-J
   Swisher EM, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-48
   Thomassen M, 2008, ACTA ONCOL, V47, P772, DOI 10.1080/02841860802004974
   Thrall M, 2006, INT J GYNECOL CANCER, V16, P166, DOI 10.1111/j.1525-1438.2006.00504.x
   Wang C, 2004, J PATHOL, V202, P215, DOI 10.1002/path.1507
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987
   Werness BA, 2004, INT J GYNECOL PATHOL, V23, P29, DOI 10.1097/01.pgp.0000101083.35393.cd
NR 28
TC 15
Z9 15
U1 0
U2 14
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0001-6349
J9 ACTA OBSTET GYN SCAN
JI Acta Obstet. Gynecol. Scand.
PD JUN
PY 2011
VL 90
IS 6
BP 593
EP 599
DI 10.1111/j.1600-0412.2011.01121.x
PG 7
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Obstetrics & Gynecology
GA 775CB
UT WOS:000291433600006
PM 21371001
OA Bronze
DA 2025-01-12
ER

PT J
AU Rodriguez, BAT
   Weng, YI
   Liu, TM
   Zuo, T
   Hsu, PY
   Lin, CH
   Cheng, AL
   Cui, HM
   Yan, PS
   Huang, THM
AF Rodriguez, Benjamin A. T.
   Weng, Yu-I
   Liu, Ta-Ming
   Zuo, Tao
   Hsu, Pei-Yin
   Lin, Ching-Hung
   Cheng, Ann-Lii
   Cui, Hengmi
   Yan, Pearlly S.
   Huang, Tim H-M.
TI Estrogen-mediated epigenetic repression of the imprinted gene
   <i>cyclin</i>-<i>dependent kinase inhibitor 1C</i> in breast cancer
   cells
SO CARCINOGENESIS
LA English
DT Article
ID BECKWITH-WIEDEMANN-SYNDROME; SENSE-ANTISENSE TRANSCRIPTS; ABERRANT DNA
   METHYLATION; GENOME-WIDE ANALYSIS; CONTROL REGION; HISTONE ACETYLATION;
   CHROMOSOME 11P15.5; CDKN1C P57(KIP2); NONCODING RNAS; EXPRESSION
AB While tumor suppressor genes frequently undergo epigenetic silencing in cancer, how the instructions directing this transcriptional repression are transmitted in cancer cells remain largely unclear. Expression of cyclin-dependent kinase inhibitor 1C (CDKN1C), an imprinted gene on chromosomal band 11 p15.5, is reduced or lost in the majority of breast cancers. Here, we report that CDKN1C is suppressed by estrogen through epigenetic mechanisms involving the chromatin-interacting noncoding RNA KCNQ1OT1 and CCCTC-binding factor (CTCF). Activation of estrogen signaling reduced CDKN1C expression 3-fold (P < 0.001) and established repressive histone modifications at the 5' regulatory region of the locus. These events were concomitant with induction of KCNQ1OT1 expression as well as increased recruitment of CTCF to both the distal KCNQ1OT1 promoter-associated imprinting control region (ICR) and the CDKN1C locus. Transient depletion of CTCF by small interfering RNA increased CDKN1C expression and significantly reduced the estrogen-mediated repression of CDKN1C. Further studies in breast cancer cell lines indicated that the epigenetic silencing of CDKN1C occurs in part as the result of genetic loss of the inactive methylated 11p15.5 ICR allele (R(2) = 0.612, P < 0.001). We also found a novel cis-encoded antisense transcript, CDKN1C-AS, which is induced by estrogen signaling following pharmacologic inhibition of DNA methyltransferase and histone deacetylase activity. Forced expression of CDKN1C-AS was capable of repressing endogenous CDKN1C in vivo. Our findings suggest that in addition to promoter hypermethylation, epigenetic repression of tumor suppressor genes by CTCF and noncoding RNA transcripts could be more common and important than previously understood.
C1 [Huang, Tim H-M.] Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.
   [Lin, Ching-Hung; Cheng, Ann-Lii] Natl Taiwan Univ Hosp, Dept Internal Med & Oncol, Taipei 100, Taiwan.
   [Cui, Hengmi] Johns Hopkins Univ, Sch Med, Ctr Epigenet, Baltimore, MD 21205 USA.
   [Cui, Hengmi] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
C3 University System of Ohio; Ohio State University; James Cancer Hospital
   & Solove Research Institute; National Taiwan University; National Taiwan
   University Hospital; Johns Hopkins University; Johns Hopkins University
RP Huang, THM (通讯作者)，Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Dept Mol Virol Immunol & Med Genet, Room 814,460 W 12th Ave, Columbus, OH 43210 USA.
EM tim.huang@osumc.edu
RI Lin, Chih-Cheng/IQT-4912-2023; Yan, Pearlly/E-4339-2011; Cheng,
   Ann-Lii/ACM-0936-2022
OI Cheng, Ann-Lii/0000-0002-9152-6512; Zuo, Tao/0000-0002-2125-7548; LIN,
   CHING-HUNG/0000-0003-2403-4056; Zuo, Tao/0000-0001-8450-5281
FU National Institutes of Health; Ohio State University Comprehensive
   Cancer Center [U01ES015986, U54CA113001, R01CA069065, R01ES017594]
FX National Institutes of Health; Ohio State University Comprehensive
   Cancer Center (U01ES015986, U54CA113001, R01CA069065, R01ES017594).
CR ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Chen JJ, 2005, TRENDS GENET, V21, P326, DOI 10.1016/j.tig.2005.04.006
   Cheng ASL, 2008, CANCER RES, V68, P1786, DOI 10.1158/0008-5472.CAN-07-5547
   Chernukhin I, 2007, MOL CELL BIOL, V27, P1631, DOI 10.1128/MCB.01993-06
   Dallosso AR, 2007, RNA, V13, P2287, DOI 10.1261/rna.562907
   Diaz-Meyer N, 2003, J MED GENET, V40, P797, DOI 10.1136/jmg.40.11.797
   Du MJ, 2003, HUM MOL GENET, V12, P1927, DOI 10.1093/hmg/ddg194
   El Kharroubi A, 2001, J BIOL CHEM, V276, P8674, DOI 10.1074/jbc.M009392200
   Fitzpatrick GV, 2007, MOL CELL BIOL, V27, P2636, DOI 10.1128/MCB.02036-06
   Fitzpatrick GV, 2002, NAT GENET, V32, P426, DOI 10.1038/ng988
   Flanagan James M, 2007, Genome Biol, V8, P307, DOI 10.1186/gb-2007-8-6-307
   Foster JS, 2003, J BIOL CHEM, V278, P41355, DOI 10.1074/jbc.M302830200
   Foster JS, 2001, MOL CELL BIOL, V21, P794, DOI 10.1128/MCB.21.3.794-810.2001
   He YP, 2008, SCIENCE, V322, P1855, DOI 10.1126/science.1163853
   Hsu PY, 2010, GENOME RES, V20, P733, DOI 10.1101/gr.101923.109
   Hu JF, 2000, ENDOCRINOLOGY, V141, P4428, DOI 10.1210/en.141.12.4428
   Ito Y, 2008, HUM MOL GENET, V17, P2633, DOI 10.1093/hmg/ddn163
   Kapranov P, 2007, SCIENCE, V316, P1484, DOI 10.1126/science.1138341
   Kikuchi T, 2002, ONCOGENE, V21, P2741, DOI 10.1038/sj.onc.1205376
   Kiyosawa H, 2005, GENOME RES, V15, P463, DOI 10.1101/gr.3155905
   Kurukuti S, 2006, P NATL ACAD SCI USA, V103, P10684, DOI 10.1073/pnas.0600326103
   Lapidot M, 2006, EMBO REP, V7, P1216, DOI 10.1038/sj.embor.7400857
   Larson PS, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-68
   Lee MP, 1999, P NATL ACAD SCI USA, V96, P5203, DOI 10.1073/pnas.96.9.5203
   Li T, 2008, MOL CELL BIOL, V28, P6473, DOI 10.1128/MCB.00204-08
   Li YH, 2002, BLOOD, V100, P2572, DOI 10.1182/blood-2001-11-0026
   Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407
   Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018
   Mahmoudi S, 2009, MOL CELL, V33, P462, DOI 10.1016/j.molcel.2009.01.028
   Mancini-DiNardo D, 2006, GENE DEV, V20, P1268, DOI 10.1101/gad.1416906
   Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026
   Murakami K, 2007, J HUM GENET, V52, P926, DOI 10.1007/s10038-007-0196-4
   O'Neill MJ, 2005, HUM MOL GENET, V14, pR113, DOI 10.1093/hmg/ddi108
   Pandey RR, 2008, MOL CELL, V32, P232, DOI 10.1016/j.molcel.2008.08.022
   Pedone PV, 1999, FEBS LETT, V458, P45, DOI 10.1016/S0014-5793(99)01124-2
   Rossignol F, 2002, GENE, V299, P135, DOI 10.1016/S0378-1119(02)01049-1
   Sato N, 2005, CLIN CANCER RES, V11, P4681, DOI 10.1158/1078-0432.CCR-04-2471
   Scelfo RAM, 2002, ONCOGENE, V21, P2564, DOI 10.1038/sj.onc.1205336
   Schwienbacher C, 2000, P NATL ACAD SCI USA, V97, P5445, DOI 10.1073/pnas.090087497
   Shen LL, 2003, BLOOD, V101, P4131, DOI 10.1182/blood-2002-08-2466
   Shin JY, 2008, EMBO J, V27, P168, DOI 10.1038/sj.emboj.7601960
   Soejima H, 2004, ONCOGENE, V23, P4380, DOI 10.1038/sj.onc.1207576
   Vu TH, 2010, HUM MOL GENET, V19, P901, DOI 10.1093/hmg/ddp558
   Wan LB, 2008, ADV GENET, V61, P207, DOI 10.1016/S0065-2660(07)00007-7
   Weksberg R, 2003, HUM MOL GENET, V12, pR61, DOI 10.1093/hmg/ddg067
   Yang XJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005011
   Zupkovitz G, 2006, MOL CELL BIOL, V26, P7913, DOI 10.1128/MCB.01220-06
NR 48
TC 35
Z9 40
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD JUN
PY 2011
VL 32
IS 6
BP 812
EP 821
DI 10.1093/carcin/bgr017
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 782AG
UT WOS:000291979200004
PM 21304052
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Kim, K
   Lee, HC
   Park, JL
   Kim, M
   Kim, SY
   Noh, SM
   Song, KS
   Kim, JC
   Kim, YS
AF Kim, Kwoneel
   Lee, Han-Chul
   Park, Jong-Lyul
   Kim, Mirang
   Kim, Seon-Young
   Noh, Seung-Moo
   Song, Kyu-Sang
   Kim, Jin Cheon
   Kim, Yong Sung
TI Epigenetic regulation of <i>microRNA</i>-<i>10b</i> and targeting of
   oncogenic <i>MAPRE1</i> in gastric cancer
SO EPIGENETICS
LA English
DT Article
DE gastric cancer; miR-10b; CpG methylation; HOXD4; MAPRE1
ID TUMOR-SUPPRESSOR GENE; HUMAN SOLID TUMORS; DNA METHYLATION;
   BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; CELL-PROLIFERATION;
   DOWN-REGULATION; PROTEIN EB1; EXPRESSION; METASTASIS
AB MicroRNAs act as negative regulators of gene expression and the altered expression of microRNAs by epigenetic mechanisms is strongly implicated in carcinogenesis. Here we report that the microRNA-10b gene (miR-10b) was silenced in gastric cancer cells by promoter methylation. In this study, using a methylation array and bisulfate pyrosequencing analysis, we found that miR-10b promoter CpGs were heavily methylated in gastric cancers. Clinicopathologic data showed that miR-10b methylation increased with patient age and occurred significantly more frequently in intestinal-type (28/44, 64%) than in diffuse-type (22/56, 39%) gastric cancers (p = 0.016). In addition, miR-10b methylation was also associated with an increase in expression of the oncogene that encodes microtubule-associated protein, RP/EB family, member 1 (MAPRE1; p = 0.004), which was identified as a potential miR-10b target. After 5-aza-2'-deoxycytidine treatment of gastric cancer cells, miR-10b methylation was significantly decreased, and expression of miR-10b and HOXD4, which is 1 kb downstream of miR-10b, was greatly restored. Moreover, decreased MAPRE1 expression coincided with increased miR-10b expression, suggesting that miR-10b targets MAPRE1 transcription. We also found that transfection with precursor miR-10b into gastric cancer cells dramatically decreased MAPRE1 mRNA and protein, resulting in a significant decrease in colony formation and cell growth rates. Thus, we show a tumor-suppressive role for miR-10b in gastric carcinogenesis. miR-10b methylation may be a useful molecular biomarker for assessing the risk of gastric cancer development, and modulation of miR-10b may represent a therapeutic approach for treating gastric cancer.
C1 [Kim, Kwoneel; Lee, Han-Chul; Park, Jong-Lyul; Kim, Mirang; Kim, Seon-Young; Kim, Yong Sung] Korea Res Inst Biosci & Biotechnol KRIBB, Med Genom Res Ctr, Taejon, South Korea.
   [Noh, Seung-Moo] Chungnam Natl Univ, Coll Med, Dept Gen Surg, Taejon, South Korea.
   [Song, Kyu-Sang] Chungnam Natl Univ, Coll Med, Dept Pathol, Taejon, South Korea.
   [Kim, Jin Cheon] Univ Ulsan, Coll Med, Dept Surg, Seoul, South Korea.
C3 Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chungnam
   National University; Chungnam National University; University of Ulsan
RP Kim, YS (通讯作者)，Korea Res Inst Biosci & Biotechnol KRIBB, Med Genom Res Ctr, Taejon, South Korea.
EM yongsung@kribb.re.kr
RI Lee, Seung-Hyun/HKV-3475-2023; KIM, SEON HAHN/JTU-1415-2023; Park, Jun
   Won/KSM-8932-2024; Kim, Han/AAA-5787-2021; Kim, Sunghoon/AAE-8314-2020;
   Kim, Kwoneel/AAH-9178-2020
OI Kim, Kwoneel/0000-0002-4221-3421; Kim, Mirang/0000-0001-7415-0077
FU Ministry of Education, Science and Technology [NRF2010-0020590];
   Ministry of Health, Welfare and Family Affairs [A062254]; KRIBB
FX This work was supported by the future-based technology development
   program of the National Research Foundation of Korea (NRF2010-0020590)
   funded by the Ministry of Education, Science and Technology; by the
   Korea Health 21 R&D Project (A062254) funded by the Ministry of Health,
   Welfare and Family Affairs; and the KRIBB Research Initiative Grant.
CR Akao Y, 2006, BIOL PHARM BULL, V29, P903, DOI 10.1248/bpb.29.903
   Balaguer F, 2010, CANCER RES, V70, P6609, DOI 10.1158/0008-5472.CAN-10-0622
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Berrueta L, 1998, P NATL ACAD SCI USA, V95, P10596, DOI 10.1073/pnas.95.18.10596
   Bibikova M, 2006, GENOME RES, V16, P1075, DOI 10.1101/gr.5319906
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102
   El-Rifai W, 2001, INT J CANCER, V92, P832, DOI 10.1002/ijc.1264
   Fujii K, 2005, PROTEOMICS, V5, P1411, DOI 10.1002/pmic.200401004
   Garzon R, 2009, ANNU REV MED, V60, P167, DOI [10.1146/annurev.med.59.053006.104707, 10.1146/annurev.pathol.4.110807.092222]
   Gebeshuber CA, 2009, EMBO REP, V10, P400, DOI 10.1038/embor.2009.9
   Harfe BD, 2005, CURR OPIN GENET DEV, V15, P410, DOI 10.1016/j.gde.2005.06.012
   Hashimoto Y, 2010, CARCINOGENESIS, V31, P777, DOI 10.1093/carcin/bgq013
   Hiroki E, 2010, CANCER SCI, V101, P241, DOI 10.1111/j.1349-7006.2009.01385.x
   Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317
   Jin P, 2004, NAT CELL BIOL, V6, P1048, DOI 10.1038/ncb1104-1048
   Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014
   Kim M, 2008, CANCER RES, V68, P7147, DOI 10.1158/0008-5472.CAN-08-0667
   Kim M, 2008, CARCINOGENESIS, V29, P629, DOI 10.1093/carcin/bgm291
   Kim M, 2008, MOL CANCER RES, V6, P222, DOI 10.1158/1541-7786.MCR-07-0142
   Kim M, 2010, CARCINOGENESIS, V31, P1685, DOI 10.1093/carcin/bgq144
   Kim SK, 2008, CARCINOGENESIS, V29, P1623, DOI 10.1093/carcin/bgn110
   Kluiver J, 2005, J PATHOL, V207, P243, DOI 10.1002/path.1825
   Ladeiro Y, 2008, HEPATOLOGY, V47, P1955, DOI 10.1002/hep.22256
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957
   Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407
   Liu M, 2009, MOL CARCINOGEN, V48, P212, DOI 10.1002/mc.20471
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Ma L, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2720
   Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022
   Nishigaki R, 2005, PROTEOMICS, V5, P3205, DOI 10.1002/pmic.200401307
   Ohm JE, 2007, CELL CYCLE, V6, P1040, DOI 10.4161/cc.6.9.4210
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Pandey DP, 2009, MOL CELL BIOL, V29, P3783, DOI 10.1128/MCB.01875-08
   Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462
   Sasayama T, 2009, INT J CANCER, V125, P1407, DOI 10.1002/ijc.24522
   Shibuya K, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-37
   SU LK, 1995, CANCER RES, V55, P2972
   Suzuki H, 2010, CARCINOGENESIS, V31, P2066, DOI 10.1093/carcin/bgq203
   Tan YL, 2009, BMC MOL BIOL, V10, DOI 10.1186/1471-2199-10-12
   Tian YY, 2010, J BIOL CHEM, V285, P7986, DOI 10.1074/jbc.M109.062877
   Tirnauer JS, 2000, J CELL BIOL, V149, P761, DOI 10.1083/jcb.149.4.761
   Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Weber M, 2007, CURR OPIN CELL BIOL, V19, P273, DOI 10.1016/j.ceb.2007.04.011
   Xu H, 2009, CANCER RES, V69, P6275, DOI 10.1158/0008-5472.CAN-08-4517
   Yuasa Y, 2003, NAT REV CANCER, V3, P592, DOI 10.1038/nrc1141
   Zhang J, 2010, BRIT J CANCER, V103, P1215, DOI 10.1038/sj.bjc.6605895
   Zhou J, 1999, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, V16, P303
NR 55
TC 88
Z9 95
U1 0
U2 11
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1559-2294
J9 EPIGENETICS-US
JI Epigenetics
PD JUN
PY 2011
VL 6
IS 6
BP 740
EP 751
DI 10.4161/epi.6.6.15874
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 771HP
UT WOS:000291148100010
PM 21562367
OA Bronze
DA 2025-01-12
ER

PT J
AU Rajendran, P
   Delage, B
   Dashwood, WM
   Yu, TW
   Wuth, B
   Williams, DE
   Ho, E
   Dashwood, RH
AF Rajendran, Praveen
   Delage, Barbara
   Dashwood, W. Mohaiza
   Yu, Tian-Wei
   Wuth, Bradyn
   Williams, David E.
   Ho, Emily
   Dashwood, Roderick H.
TI Histone deacetylase turnover and recovery in sulforaphane-treated colon
   cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT
   corepressor complex dissociation/reassembly
SO MOLECULAR CANCER
LA English
DT Article
ID PROSTATE-CANCER; GENE-EXPRESSION; IN-VIVO; PHENETHYL ISOTHIOCYANATE;
   HDAC2 EXPRESSION; EPITHELIAL-CELLS; BREAST-CANCER; INHIBITORS;
   APOPTOSIS; PROTEASOME
AB Background: Histone deacetylase (HDAC) inhibitors are currently undergoing clinical evaluation as anti-cancer agents. Dietary constituents share certain properties of HDAC inhibitor drugs, including the ability to induce global histone acetylation, turn-on epigenetically-silenced genes, and trigger cell cycle arrest, apoptosis, or differentiation in cancer cells. One such example is sulforaphane (SFN), an isothiocyanate derived from the glucosinolate precursor glucoraphanin, which is abundant in broccoli. Here, we examined the time-course and reversibility of SFN-induced HDAC changes in human colon cancer cells.
   Results: Cells underwent progressive G(2)/M arrest over the period 6-72 h after SFN treatment, during which time HDAC activity increased in the vehicle-treated controls but not in SFN-treated cells. There was a time-dependent loss of class I and selected class II HDAC proteins, with HDAC3 depletion detected ahead of other HDACs. Mechanism studies revealed no apparent effect of calpain, proteasome, protease or caspase inhibitors, but HDAC3 was rescued by cycloheximide or actinomycin D treatment. Among the protein partners implicated in the HDAC3 turnover mechanism, silencing mediator for retinoid and thyroid hormone receptors (SMRT) was phosphorylated in the nucleus within 6 h of SFN treatment, as was HDAC3 itself. Co-immunoprecipitation assays revealed SFN-induced dissociation of HDAC3/SMRT complexes coinciding with increased binding of HDAC3 to 14-3-3 and peptidyl-prolyl cis/trans isomerase 1 (Pin1). Pin1 knockdown blocked the SFN-induced loss of HDAC3. Finally, SFN treatment for 6 or 24 h followed by SFN removal from the culture media led to complete recovery of HDAC activity and HDAC protein expression, during which time cells were released from G(2)/M arrest.
   Conclusion: The current investigation supports a model in which protein kinase CK2 phosphorylates SMRT and HDAC3 in the nucleus, resulting in dissociation of the corepressor complex and enhanced binding of HDAC3 to 14-3-3 or Pin1. In the cytoplasm, release of HDAC3 from 14-3-3 followed by nuclear import is postulated to compete with a Pin1 pathway that directs HDAC3 for degradation. The latter pathway predominates in colon cancer cells exposed continuously to SFN, whereas the former pathway is likely to be favored when SFN has been removed within 24 h, allowing recovery from cell cycle arrest.
C1 [Rajendran, Praveen; Delage, Barbara; Dashwood, W. Mohaiza; Yu, Tian-Wei; Wuth, Bradyn; Williams, David E.; Ho, Emily; Dashwood, Roderick H.] Oregon State Univ, Linus Pauling Inst, Corvallis, OR 97331 USA.
   [Ho, Emily] Oregon State Univ, Dept Nutr & Exercise Sci, Corvallis, OR 97331 USA.
   [Williams, David E.; Dashwood, Roderick H.] Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA.
C3 Oregon State University; Oregon State University; Oregon State
   University
RP Dashwood, RH (通讯作者)，Oregon State Univ, Linus Pauling Inst, Weniger 503, Corvallis, OR 97331 USA.
EM rod.dashwood@oregonstate.edu
RI Dashwood, Roderick/AAF-2025-2020; Rajendran, Praveen/AAK-9963-2021
OI Rajendran, Praveen/0000-0002-6221-7366; Dashwood,
   Roderick/0000-0003-0351-4034
FU NIH [CA090890, CA65525, CA122906, CA122959, CA80176]; National Institute
   of Environmental Health Sciences [T32 ES007060]
FX We thank Andrew Quest (Faculty of Medicine, University of Chile,
   Santiago, Chile) and Siva Kolluri (Department of Environmental and
   Molecular Toxicology, Oregon State University, Corvallis, OR) for useful
   discussions. Marty Mayo (The University of Virginia, Charlottesville,
   VA) provided phospho-SMRT antibody. Work supported by NIH grants
   CA090890, CA65525, CA122906, CA122959 and CA80176. Experiments in the
   Cell Imaging and Analysis Core were supported by Award T32 ES007060 from
   the National Institute of Environmental Health Sciences. The content of
   this report is solely the responsibility of the authors and does not
   necessarily represent the official views of NIH.
CR Ashktorab H, 2009, DIGEST DIS SCI, V54, P2109, DOI 10.1007/s10620-008-0601-7
   Bardai FH, 2011, J NEUROSCI, V31, P1746, DOI 10.1523/JNEUROSCI.5704-10.2011
   Buchwald M, 2009, CANCER LETT, V280, P160, DOI 10.1016/j.canlet.2009.02.028
   Buglio D, 2010, BRIT J HAEMATOL, V151, P387, DOI 10.1111/j.1365-2141.2010.08342.x
   Cheung KL, 2010, AAPS J, V12, P87, DOI 10.1208/s12248-009-9162-8
   Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876
   Clarke J.D., 2011, MOL NUTR FOOD RES
   Clarke JD, 2008, CANCER LETT, V269, P291, DOI 10.1016/j.canlet.2008.04.018
   Dashwood RH, 2006, CARCINOGENESIS, V27, P344, DOI 10.1093/carcin/bgi253
   Dashwood RH, 2007, SEMIN CANCER BIOL, V17, P363, DOI 10.1016/j.semcancer.2007.04.001
   Dasmahapatra G, 2010, BLOOD, V115, P4478, DOI 10.1182/blood-2009-12-257261
   Davis CD, 2007, NUTR REV, V65, P88, DOI 10.1301/nr.2007.feb.88-94
   Duenas-Gonzalez A, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-38
   Escaffit F, 2007, MOL CELL BIOL, V27, P554, DOI 10.1128/MCB.00869-06
   Fahey JW, 1997, P NATL ACAD SCI USA, V94, P10367, DOI 10.1073/pnas.94.19.10367
   Garske AL, 2010, NAT CHEM BIOL, V6, P283, DOI [10.1038/NCHEMBIO.319, 10.1038/nchembio.319]
   Gibbs A, 2009, P NATL ACAD SCI USA, V106, P16663, DOI 10.1073/pnas.0908908106
   Healy S, 2011, DISCOV MED, V11, P349
   Heider U, 2009, EUR J HAEMATOL, V82, P440, DOI 10.1111/j.1600-0609.2009.01239.x
   Herman-Antosiewicz A, 2007, MOL CANCER THER, V6, P1673, DOI 10.1158/1535-7163.MCT-06-0807
   Huang BH, 2005, CELL DEATH DIFFER, V12, P395, DOI 10.1038/sj.cdd.4401567
   Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a
   Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317
   Jagannath S, 2010, LEUKEMIA RES, V34, P1111, DOI 10.1016/j.leukres.2010.04.001
   Jeffery EH, 2008, MOL NUTR FOOD RES, V52, pS7, DOI 10.1002/mnfr.200700226
   Jonas BA, 2004, J BIOL CHEM, V279, P54676, DOI 10.1074/jbc.M410128200
   Kimura MT, 2001, J BIOL CHEM, V276, P17291, DOI 10.1074/jbc.M005453200
   Kwak MK, 2010, TOXICOL APPL PHARM, V244, P66, DOI 10.1016/j.taap.2009.08.028
   Lai RH, 2008, FOOD CHEM TOXICOL, V46, P195, DOI 10.1016/j.fct.2007.07.015
   Lane AA, 2009, J CLIN ONCOL, V27, P5459, DOI 10.1200/JCO.2009.22.1291
   Lin ZG, 2010, MUTAT RES-FUND MOL M, V690, P81, DOI 10.1016/j.mrfmmm.2010.06.007
   Ma H, 2005, ONCOGENE, V24, P3619, DOI 10.1038/sj.onc.1208433
   Ma XD, 2006, INT J ONCOL, V28, P1287
   Ma XJ, 2009, DRUGS, V69, P1911, DOI 10.2165/11315680-000000000-00000
   Matthias P, 2008, CELL CYCLE, V7, P7, DOI 10.4161/cc.7.1.5186
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Müller S, 2010, CURR CANCER DRUG TAR, V10, P210, DOI 10.2174/156800910791054149
   Myzak MC, 2006, CARCINOGENESIS, V27, P811, DOI 10.1093/carcin/bgi265
   Myzak MC, 2006, FASEB J, V20, P506, DOI 10.1096/fj.05-4785fje
   Myzak MC, 2006, CANCER LETT, V233, P208, DOI 10.1016/j.canlet.2005.02.033
   Myzak MC, 2004, CANCER RES, V64, P5767, DOI 10.1158/0008-5472.CAN-04-1326
   Nebbioso A, 2009, EMBO REP, V10, P776, DOI [10.1038/embor.2009.88, 10.15252/embr.202051028]
   Nian H, 2008, CARCINOGENESIS, V29, P1816, DOI 10.1093/carcin/bgn165
   Nian H, 2009, CARCINOGENESIS, V30, P1416, DOI 10.1093/carcin/bgp147
   Nishino TG, 2008, BIOCHEM BIOPH RES CO, V377, P852, DOI 10.1016/j.bbrc.2008.10.079
   Obsilová V, 2008, PHYSIOL RES, V57, pS11, DOI 10.33549/physiolres.931598
   Pappa G, 2007, MOL NUTR FOOD RES, V51, P977, DOI 10.1002/mnfr.200700115
   Pledgie-Tracy A, 2007, MOL CANCER THER, V6, P1013, DOI 10.1158/1535-7163.MCT-06-0494
   Poke FS, 2010, CURR MED CHEM, V17, P1246, DOI 10.2174/092986710790936329
   Rajendran P, 2011, CRIT REV BIOCHEM MOL, V46, P181, DOI 10.3109/10409238.2011.557713
   Scott FL, 2008, J BIOL CHEM, V283, P19499, DOI 10.1074/jbc.M800331200
   Senese S, 2007, MOL CELL BIOL, V27, P4784, DOI 10.1128/MCB.00494-07
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Simboeck E, 2010, J BIOL CHEM, V285, DOI 10.1074/jbc.M110.184481
   Singh AV, 2004, CARCINOGENESIS, V25, P83, DOI 10.1093/carcin/bgg178
   Spurling CC, 2008, MOL CARCINOGEN, V47, P137, DOI 10.1002/mc.20373
   Stanya KJ, 2008, J CELL BIOL, V183, P49, DOI 10.1083/jcb.200806172
   Telang U, 2009, EXP BIOL MED, V234, P287, DOI 10.3181/0808-RM-241
   Traka MH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-189
   Varlakhanova N, 2011, MOL CELL ENDOCRINOL, V332, P180, DOI 10.1016/j.mce.2010.10.010
   Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200
   Wilson AJ, 2008, MOL BIOL CELL, V19, P4062, DOI 10.1091/mbc.E08-02-0139
   Yamaguchi T, 2010, GENE DEV, V24, P455, DOI 10.1101/gad.552310
   Yang YL, 2007, CANCER RES, V67, P9472, DOI 10.1158/0008-5472.CAN-07-0568
   Zhang XH, 2005, GENE DEV, V19, P827, DOI 10.1101/gad.1286005
   Zhou JB, 2009, MOL CELL BIOL, V29, P4167, DOI 10.1128/MCB.01067-08
   Zhou YY, 2001, MOL CELL BIOCHEM, V220, P1, DOI 10.1023/A:1011087910699
   Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X
NR 68
TC 100
Z9 112
U1 0
U2 21
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD MAY 30
PY 2011
VL 10
AR 68
DI 10.1186/1476-4598-10-68
PG 18
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 786PS
UT WOS:000292321000001
PM 21624135
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Swift-Scanlan, T
   Vang, R
   Blackford, A
   Fackler, MJ
   Sukumar, S
AF Swift-Scanlan, Theresa
   Vang, Russell
   Blackford, Amanda
   Fackler, Mary Jo
   Sukumar, Saraswati
TI Methylated genes in breast cancer Associations with clinical and
   histopathological features in a familial breast cancer cohort
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE DNA methylation; breast cancer; familial; BRCA1; BRCA2; epigenetic;
   protective; risk; QM-MSP; methylation specific PCR
ID TUMOR-SUPPRESSOR GENE; ESTROGEN-RECEPTOR-ALPHA; PROMOTER
   HYPERMETHYLATION; DNA METHYLATION; E-CADHERIN; MESENCHYMAL TRANSITION;
   ABERRANT METHYLATION; TRANSCRIPTION FACTOR; PCR ASSAY; ER-ALPHA
AB Background: Hundreds of hypermethylated genes have been described in breast cancer, yet the nature and contribution of these genes in their methylated state to overall risk and prognosis is under-characterized in non-sporadic breast cancers. We therefore compared associations of DNA methylation with tumor stage, hormone/growth receptor status and clinical outcomes in a familial breast cancer cohort. Because few previous methylation studies have considered the oncogenic or tumor suppressor properties of their gene sets, this functional status was included as part of our correlative analysis.
   Results: We found methylation of oncogenes was associated with better prognostic indicators, whereas tumor suppressor gene methylation was associated with a more severe phenotype in women that were either ER2(+) or lymph node positive at diagnosis, and/or tended to recur or develop distant metastases. For example, the methylation of the tumor suppressor gene APC was strongly associated with a specific subset of tumors that were both ER+ and HER2(+), while methylation of the TWIST oncogene was associated with breast cancers that did not metastasize.
   Methods: This was a retrospective, hospital-based study of n = 99 archival breast tumors derived from women with a germline genetic BRCA1 or BRCA2 mutation and/or familial breast cancer history. DNA methylation was quantified from formalin fixed, paraffin embedded tumors using the established protocol of quantitative multiplex-methylation specific PCR (QM-MSP). Non-parametric statistics were used to analyze candidate gene methylation in association with clinical outcomes.
   Conclusion: We report several novel, positive associations between percent methylation of the AP C, RASSF1A, TWIST, ER alpha, CDH1 and Cyclin D2 genes and key variables such as tumor stage, hormone and growth receptor status, and a history of recurrent or metastatic disease. Our data suggest the potential utility of parsing gene methylation by functional status and breast tumor subtype.
C1 [Swift-Scanlan, Theresa] Univ N Carolina, Sch Nursing, Chapel Hill, NC 27515 USA.
   [Swift-Scanlan, Theresa; Vang, Russell; Blackford, Amanda; Fackler, Mary Jo; Sukumar, Saraswati] Sidney Kimmel Canc Ctr Johns Hopkins, Baltimore, MD USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   Johns Hopkins University; Johns Hopkins Medicine
RP Swift-Scanlan, T (通讯作者)，Univ N Carolina, Sch Nursing, Chapel Hill, NC 27515 USA.
EM tswift@unc.edu; saras@jhmi.edu
FU National Institutes of Health/National Cancer Institute (NIH/NCI)
   [P50CA88843, CA058823]; NIH/NINR [F31 NR008311-01A1]; American Cancer
   Society (ACS) [DSCN-04-162-01]; Susan G. Komen Foundation [KG090180];
   NIH/NCRR [1KL2RR025746-01]
FX We gratefully acknowledge the support of a National Institutes of
   Health/National Cancer Institute (NIH/NCI) Specialized Program of
   Research Excellence (SPORE) in Breast Cancer P50CA88843 to S. S. and an
   NIH/NINR F31 NR008311-01A1 and American Cancer Society (ACS)
   DSCN-04-162-01 to T. S. S. We are also thankful for the current support
   to T. S. S. of a Susan G. Komen Foundation KG090180 (Swift-Scanlan), an
   NIH/NCRR 1KL2RR025746-01, and an NIH/NCI Breast SPORE CA058823 (Earp).
CR Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088
   Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Alvarez S, 2005, CLIN CANCER RES, V11, P1146
   [Anonymous], 1989, Molecular Cloning, A Laboratory Manual
   Balogh GA, 2007, INT J ONCOL, V31, P253
   Barba M, 2006, CANCER CAUSE CONTROL, V17, P395, DOI 10.1007/s10552-005-0481-5
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Caldeira JRF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-48
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Dammann R, 2001, CANCER RES, V61, P3105
   Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105
   Edwards BK, 2005, JNCI-J NATL CANCER I, V97, P1407, DOI 10.1093/jnci/dji289
   Ehrlich M, 2006, CURR TOP MICROBIOL, V310, P251
   Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI [10.2217/epi.09.33, 10.2217/EPI.09.33]
   Esteller M, 2000, EUR J CANCER, V36, P2294, DOI 10.1016/S0959-8049(00)00303-8
   Evron E, 2001, CANCER RES, V61, P2782
   Fabianowska-Majewska K, 2006, NUCLEOS NUCLEOT NUCL, V25, P1025, DOI 10.1080/15257770600890640
   Fackler MJ, 2006, CLIN CANCER RES, V12, P3306, DOI 10.1158/1078-0432.CCR-05-2733
   Fackler MJ, 2009, CLIN CANCER RES, V15, P3802, DOI 10.1158/1078-0432.CCR-08-1981
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508
   Flanagan JM, 2010, AM J HUM GENET, V86, P420, DOI 10.1016/j.ajhg.2010.02.008
   Gort EH, 2008, CANCER EPIDEM BIOMAR, V17, P3325, DOI 10.1158/1055-9965.EPI-08-0472
   Hedenfalk I, 2003, P NATL ACAD SCI USA, V100, P2532, DOI 10.1073/pnas.0533805100
   Henrique R, 2006, J MOL MED, V84, P911, DOI 10.1007/s00109-006-0099-4
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Honrado E, 2007, MODERN PATHOL, V20, P1298, DOI 10.1038/modpathol.3800969
   Jin W, 2010, BREAST CANCER RES TR, V123, P359, DOI 10.1007/s10549-009-0652-2
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Kim SJ, 2004, INT J MOL MED, V14, P289
   Kinney SRM, 2008, MOL CANCER RES, V6, P1365, DOI 10.1158/1541-7786.MCR-08-0040
   Kontorovich T, 2009, BREAST CANCER RES TR, V116, P195, DOI 10.1007/s10549-008-0121-3
   Lee JS, 2008, CANCER BIOL THER, V7, P1400
   Lee MN, 2007, CLIN CANCER RES, V13, P832, DOI 10.1158/1078-0432.CCR-05-2694
   Lee MS, 1999, J CELL BIOCHEM, V75, P566, DOI 10.1002/(SICI)1097-4644(19991215)75:4<566::AID-JCB3>3.0.CO;2-0
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   Locke I, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1657
   Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996
   Loughrey M, 2008, PATHOLOGY, V40, P352, DOI 10.1080/00313020802035899
   Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207
   Martorell MR, 1997, CYTOGENET CELL GENET, V76, P123, DOI 10.1159/000134529
   Mirza S, 2007, LIFE SCI, V81, P280, DOI 10.1016/j.lfs.2007.05.012
   Müller HM, 2003, EXPERT REV MOL DIAGN, V3, P443, DOI 10.1586/14737159.3.4.443
   Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V
   Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465
   Okada T, 2010, GENE CHROMOSOME CANC, V49, P452, DOI 10.1002/gcc.20755
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Pinzone JJ, 2004, MOL CELL BIOL, V24, P4605, DOI 10.1128/MCB.24.11.4605-4612.2004
   Pu RT, 2003, MODERN PATHOL, V16, P1095, DOI 10.1097/01.MP.0000095782.79895.E2
   Rodriguez BAT, 2008, CARCINOGENESIS, V29, P1459, DOI 10.1093/carcin/bgn115
   Sarrió D, 2003, INT J CANCER, V106, P208, DOI 10.1002/ijc.11197
   Shigematsu H, 2005, INT J CANCER, V113, P600, DOI 10.1002/ijc.20622
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   Sirchia SM, 2002, CANCER RES, V62, P2455
   Sorlie T, 2004, EUR J CANCER, V40, P2667, DOI 10.1016/j.ejca.2004.08.021
   Suijkerbuijk KPM, 2008, ANN ONCOL, V19, P1870, DOI 10.1093/annonc/mdn409
   Sweeney KJ, 1997, ONCOGENE, V14, P1329, DOI 10.1038/sj.onc.1200951
   Swift-Scanlan T, 2006, BIOTECHNIQUES, V40, P210, DOI 10.2144/000112097
   Tapia T, 2008, EPIGENETICS-US, V3, P157, DOI 10.4161/epi.3.3.6387
   Trujillo KA, 2010, INT J CANC IN PRESS
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   Virmani AK, 2001, CLIN CANCER RES, V7, P1998
   Wei MJ, 2008, BREAST CANCER RES TR, V111, P113, DOI 10.1007/s10549-007-9766-6
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Yan PS, 2006, CLIN CANCER RES, V12, P6626, DOI 10.1158/1078-0432.CCR-06-0467
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
   Zinn RL, 2007, CANCER RES, V67, P194, DOI 10.1158/0008-5472.CAN-06-3396
NR 68
TC 38
Z9 39
U1 0
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD MAY 15
PY 2011
VL 11
IS 10
BP 853
EP 865
DI 10.4161/cbt.11.10.15177
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 764EX
UT WOS:000290612900001
PM 21383541
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Kachnic, LA
   Li, L
   Fournier, L
   Ferraiolo, N
   Dahm-Daphi, J
   Borgmann, K
   Willers, H
AF Kachnic, Lisa A.
   Li, Li
   Fournier, Loreen
   Ferraiolo, Natalie
   Dahm-Daphi, Jochen
   Borgmann, Kerstin
   Willers, Henning
TI FANCD2 but not FANCA promotes cellular resistance to type II
   topoisomerase poisons
SO CANCER LETTERS
LA English
DT Article
DE Fanconi Anemia; FANCD2; FANCA; Etoposide
ID MONOUBIQUITINATED FANCD2; ANEMIA/BRCA PATHWAY; REPAIR; COMPLEX; PROTEIN;
   BRCA1; GENE; FOCI; CELLS
AB Genetic or epigenetic inactivation of the pathway formed by the Fanconi Anemia (FA) and BRCA proteins occurs in several cancer types, including lung and breast cancer, rendering the affected tumors potentially hypersensitive to DNA crosslinking agents. However, the cytotoxicity of other commonly used cancer therapeutics in cells with FA/BRCA pathway defects remains to be defined. Building on earlier data that implicated BRCA1 and BRCA2 in the repair of DNA damage caused by the topoisomerase II poison etoposide, we studied the role of FANCD2 in mediating resistance to several topoisomerase II poisons. We establish that the loss of FANCD2 increases cell death in response to etoposide. FANCD2 promotes homologous recombination repair (HRR) and prevents DNA double-strand break formation and chromosomal aberrations in etoposide-treated cells. Strikingly, this function of FANCD2 is independent of FANCD2 foci formation and of FANCA, which is a member of the FA core complex upstream of FANCD2 mono-ubiquitination. Thus, FANCD2 appears to promote HRR in a mono-ubiquitination-independent manner in conjunction with BRCA1/2. These data add to an emerging body of evidence indicating that the FA pathway is not linear and that several protein subcomplexes with different functions exist. Our findings are potentially relevant for predicting the sensitivity of lung and breast cancers to etoposide and doxorubicin, respectively. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Kachnic, Lisa A.; Li, Li; Fournier, Loreen; Ferraiolo, Natalie; Willers, Henning] Massachusetts Gen Hosp, Ctr Canc, Dept Radiat Oncol, Lab Cellular & Mol Radiat Oncol, Charlestown, MA 02129 USA.
   [Kachnic, Lisa A.] Boston Med Ctr, Dept Radiat Oncol, Boston, MA 02118 USA.
   [Dahm-Daphi, Jochen; Borgmann, Kerstin] Univ Med Ctr Hamburg Eppendorf, Lab Radiobiol & Expt Radiat Oncol, D-20246 Hamburg, Germany.
C3 Harvard University; Massachusetts General Hospital; Boston Medical
   Center; University of Hamburg; University Medical Center
   Hamburg-Eppendorf
RP Willers, H (通讯作者)，Massachusetts Gen Hosp, Dept Radiat Oncol, Cox 3,55 Fruit St, Boston, MA 02114 USA.
EM hwillers@partners.org
FU Department of Defense [W81XWH-06-1-0309]; Susan G. Komen for the Cure of
   Breast Cancer [BCTR0504040]
FX The authors wish to thank Drs. Grover Bagby, Martin Brown, Alan
   D'Andrea, and Markus Grompe for their generous contribution of
   materials. The excellent technical assistance of Chake Tokadjian is
   acknowledged. This work was supported by the Department of Defense
   W81XWH-06-1-0309 (LAK, HW) and Susan G. Komen for the Cure of Breast
   Cancer BCTR0504040 (HW).
CR Adachi N, 2003, J BIOL CHEM, V278, P35897, DOI 10.1074/jbc.M306500200
   Bagby GC, 2006, SEMIN HEMATOL, V43, P147, DOI 10.1053/j.seminhematol.2006.04.005
   Borgmann K, 2007, RADIOTHER ONCOL, V83, P196, DOI 10.1016/j.radonc.2007.04.010
   Burkitt K, 2007, CANCER LETT, V253, P131, DOI 10.1016/j.canlet.2007.01.017
   de Oca RM, 2005, BLOOD, V105, P1003, DOI 10.1182/blood-2003-11-3997
   Digweed M, 2002, CARCINOGENESIS, V23, P1121, DOI 10.1093/carcin/23.7.1121
   Evans JW, 2008, CANCER RES, V68, P257, DOI 10.1158/0008-5472.CAN-06-4497
   Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3
   Gordon SM, 2005, J BIOL CHEM, V280, P36118, DOI 10.1074/jbc.M507758200
   Howlett NG, 2009, J BIOL CHEM, V284, P28935, DOI 10.1074/jbc.M109.016352
   Jakobs PM, 1996, SOMAT CELL MOLEC GEN, V22, P151, DOI 10.1007/BF02369905
   Kachnic LA, 2010, CANCER LETT, V292, P73, DOI 10.1016/j.canlet.2009.11.009
   Kennedy RD, 2005, GENE DEV, V19, P2925, DOI 10.1101/gad.1370505
   Kennedy RD, 2006, J CLIN ONCOL, V24, P3799, DOI 10.1200/JCO.2005.05.4171
   Kim JM, 2009, DEV CELL, V16, P314, DOI 10.1016/j.devcel.2009.01.001
   Kim Y, 2011, NAT GENET, V43, P142, DOI 10.1038/ng.750
   Kuhnert VM, 2009, INT J RADIAT BIOL, V85, P523, DOI 10.1080/09553000902883810
   Lyakhovich A, 2006, CANCER LETT, V232, P99, DOI 10.1016/j.canlet.2005.07.038
   Malik M, 2006, MOL CANCER THER, V5, P1405, DOI 10.1158/1535-7163.MCT-05-0263
   Mansour WY, 2008, NUCLEIC ACIDS RES, V36, P4088, DOI 10.1093/nar/gkn347
   Matsushita N, 2005, MOL CELL, V19, P841, DOI 10.1016/j.molcel.2005.08.018
   Medhurst AL, 2006, BLOOD, V108, P2072, DOI 10.1182/blood-2005-11-008151
   Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102
   Niedernhofer LJ, 2005, CELL, V123, P1191, DOI 10.1016/j.cell.2005.12.009
   Nitiss JL, 2009, NAT REV CANCER, V9, P327, DOI 10.1038/nrc2608
   Shi W, 2008, J BIOL CHEM, V283, P31608, DOI 10.1074/jbc.M801082200
   Smogorzewska A, 2007, CELL, V129, P289, DOI 10.1016/j.cell.2007.03.009
   Tebbs RS, 2005, DNA REPAIR, V4, P11, DOI 10.1016/j.dnarep.2004.06.013
   Thompson LH, 2009, MUTAT RES-FUND MOL M, V668, P54, DOI 10.1016/j.mrfmmm.2009.02.003
   Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1
   Treszezamsky AD, 2007, CANCER RES, V67, P7078, DOI 10.1158/0008-5472.CAN-07-0601
   Van der Heijden MS, 2004, CANCER BIOL THER, V3, P534, DOI 10.4161/cbt.3.6.844
   Vaz F, 2010, NAT GENET, V42, P406, DOI 10.1038/ng.570
   Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159
   Wang XZ, 2004, MOL CELL BIOL, V24, P5850, DOI 10.1128/MCB.24.13.5850-5862.2004
   Willers H, 2009, MOL CANCER RES, V7, P1304, DOI 10.1158/1541-7786.MCR-09-0149
   Willers H, 2008, J BIOMED BIOTECHNOL, DOI 10.1155/2008/821529
   Wilson JB, 2008, ONCOGENE, V27, P3641, DOI 10.1038/sj.onc.1211034
   Wilson JB, 2010, MUTAT RES-FUND MOL M, V689, P12, DOI 10.1016/j.mrfmmm.2010.04.003
   Zhi G, 2010, BRIT J HAEMATOL, V150, P88, DOI 10.1111/j.1365-2141.2010.08217.x
NR 40
TC 14
Z9 16
U1 0
U2 8
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD JUN 1
PY 2011
VL 305
IS 1
BP 86
EP 93
DI 10.1016/j.canlet.2011.02.030
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 758BD
UT WOS:000290133600010
PM 21414716
DA 2025-01-12
ER

PT J
AU Caffarelli, E
   Filetici, P
AF Caffarelli, Elisa
   Filetici, Patrizia
TI [Frontiers in Bioscience 16, 2682-2694, June 1, 2011] Epigenetic
   regulation in cancer development
SO FRONTIERS IN BIOSCIENCE-LANDMARK
LA English
DT Article
DE Epigenetic; Chromatin; Histone PTMs; DNA-Mehtylation; miRNA; Cancer;
   Differentiation; Proliferation; Review
ID BINDING PROTEIN MECP2; HUMAN MICRORNA GENES; DNA METHYLATION; HISTONE
   MODIFICATIONS; TRANSCRIPTIONAL REPRESSION; DOWN-REGULATION;
   BREAST-CANCER; EXPRESSION; GROWTH; RNA
AB From an operational definition of epigenetic, we move to provide the reader a general but comprehensive description of epigenetic phenomena that often lead to cell transformation. The last decade has, in fact, seen novel players involved in the regulation of gene expression. Not only protein factors but also a number of chromatin modifiers and remodelling proteins, which regulate the level of compaction of the genome through a variety of post-translational modifications deposed on histone tails or on DNA itself. Meanwhile, the discovery of tiny RNAs, of only 21-23 nucleotides in length, has brought to the attention their role as key regulators in the cell, being able to direct differentiation programs and function as oncogenes or oncosuppressors. In this general compendium, we aim to describe main cellular functions that through an epigenetic or epigenetic associated mechanism have been found to be directly implicated in cancerogenesis.
C1 [Filetici, Patrizia] Univ Roma La Sapienza, Ist Biol & Patol Mol, Ist Fis Gen, Lab Acidi Nucleici, I-00185 Rome, Italy.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e
   Patologia Molecolari (IBPM-CNR); Sapienza University Rome
RP Filetici, P (通讯作者)，Univ Roma La Sapienza, Ist Biol & Patol Mol, Ist Fis Gen, Lab Acidi Nucleici, P le A Moro 5, I-00185 Rome, Italy.
EM patrizia.filetici@uniroma1.it
OI filetici, patrizia/0000-0001-9459-7490
FU  [PRIN 20075h7a9_003]
FX We apologise for the Authors not cited in this review due to space
   limitations. This work was supported by PRIN 20075h7a9_003. European
   Union project SIROCCO (LSHG-CT-2006-037900) and Istituto Italiano di
   Tecnologia SEED-project.
CR Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003
   Allis CD, 2007, CELL, V131, P633, DOI 10.1016/j.cell.2007.10.039
   Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242
   Ball LJ, 1997, EMBO J, V16, P2473, DOI 10.1093/emboj/16.9.2473
   Bannister AJ, 2005, J BIOL CHEM, V280, P17732, DOI 10.1074/jbc.M500796200
   Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Benetti R, 2008, NAT STRUCT MOL BIOL, V15, P268, DOI 10.1038/nsmb.1399
   Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590
   Berezikov E, 2005, CELL, V120, P21, DOI 10.1016/j.cell.2004.12.031
   Berger SL, 2009, GENE DEV, V23, P781, DOI 10.1101/gad.1787609
   Braconi C, 2010, HEPATOLOGY, V51, P881, DOI 10.1002/hep.23381
   Brueckner B, 2007, CANCER RES, V67, P1419, DOI 10.1158/0008-5472.CAN-06-4074
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725
   Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634
   Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173
   Elsheikh SE, 2009, CANCER RES, V69, P3802, DOI 10.1158/0008-5472.CAN-08-3907
   Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832
   Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102
   Ferretti E, 2009, INT J CANCER, V124, P568, DOI 10.1002/ijc.23948
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Friedman JM, 2009, CANCER RES, V69, P2623, DOI 10.1158/0008-5472.CAN-08-3114
   Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200
   Garzon R, 2008, BLOOD, V111, P3183, DOI 10.1182/blood-2007-07-098749
   Gibney ER, 2010, HEREDITY, V105, P4, DOI 10.1038/hdy.2010.54
   Goll MG, 2002, GENE DEV, V16, P1739, DOI 10.1101/gad.1013902
   GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709
   He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552
   Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936
   Iorio MV, 2010, BBA-GENE REGUL MECH, V1799, P694, DOI 10.1016/j.bbagrm.2010.05.005
   Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kaneda M, 2004, NATURE, V429, P900, DOI 10.1038/nature02633
   Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106
   Khew-Goodall Y, 2010, NAT CELL BIOL, V12, P209, DOI 10.1038/ncb0310-209
   Kim YK, 2001, MET MATER-INT, V7, P437, DOI 10.1007/BF03027084
   Kitabayashi I, 2001, LEUKEMIA, V15, P89, DOI 10.1038/sj.leu.2401983
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253
   Laneve P, 2007, P NATL ACAD SCI USA, V104, P7957, DOI 10.1073/pnas.0700071104
   Latham JA, 2007, NAT STRUCT MOL BIOL, V14, P1017, DOI 10.1038/nsmb1307
   Lee YS, 2009, ANNU REV PATHOL-MECH, V4, P199, DOI 10.1146/annurev.pathol.4.110807.092222
   LEENDERS GJ, 2007, EUR UROL, V52, P455, DOI DOI 10.1016/J.EURURO.2006.11.020
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Li B, 2007, SCIENCE, V316, P1050, DOI 10.1126/science.1139004
   Long CZ, 2007, CANCER INVEST, V25, P685, DOI 10.1080/07357900701561131
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024
   Manuyakorn A, 2010, J CLIN ONCOL, V28, P1358, DOI 10.1200/JCO.2009.24.5639
   Nagano T, 2008, SCIENCE, V322, P1717, DOI 10.1126/science.1163802
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722
   Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789
   Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398
   Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202
   Rhodes DR, 2003, J NATL CANCER I, V95, P661, DOI 10.1093/jnci/95.9.661
   Roldo C, 2006, J CLIN ONCOL, V24, P4677, DOI 10.1200/JCO.2005.05.5194
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462
   Scott GK, 2006, CANCER RES, V66, P1277, DOI 10.1158/0008-5472.CAN-05-3632
   Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228
   Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Shi XB, 2007, P NATL ACAD SCI USA, V104, P19983, DOI 10.1073/pnas.0706641104
   Sinkkonen L, 2008, NAT STRUCT MOL BIOL, V15, P259, DOI 10.1038/nsmb.1391
   Sleutels F, 2002, NATURE, V415, P810, DOI 10.1038/415810a
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Szulwach KE, 2010, J CELL BIOL, V189, P127, DOI 10.1083/jcb.200908151
   Taverna SD, 2007, NAT STRUCT MOL BIOL, V14, P1025, DOI 10.1038/nsmb1338
   Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x
   Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325
   Tsai KW, 2009, EPIGENETICS-US, V4, P587, DOI 10.4161/epi.4.8.10230
   Tuddenham L, 2006, FEBS LETT, V580, P4214, DOI 10.1016/j.febslet.2006.06.080
   Villa R, 2007, CANCER CELL, V11, P513, DOI 10.1016/j.ccr.2007.04.009
   Visser HPJ, 2001, BRIT J HAEMATOL, V112, P950, DOI 10.1046/j.1365-2141.2001.02641.x
   Wang Y, 2004, BIOINFORMATICS, V20, P1170, DOI 10.1093/bioinformatics/bth059
   Weber B, 2007, CELL CYCLE, V6, P1001, DOI 10.4161/cc.6.9.4209
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007
   Yuan E, 2005, MOL CANCER RES, V3, P493, DOI 10.1158/1541-7786.MCR-05-0082
NR 90
TC 15
Z9 16
U1 0
U2 1
PU FRONTIERS IN BIOSCIENCE INC
PI IRVINE
PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA
SN 1093-9946
EI 1093-4715
J9 FRONT BIOSCI-LANDMRK
JI Front. Biosci.
PD JUN 1
PY 2011
VL 16
BP 2682
EP +
DI 10.2741/3880
PG 18
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 757OK
UT WOS:000290097400019
PM 21622203
OA Bronze
DA 2025-01-12
ER

PT J
AU Shi, L
   Sun, LY
   Li, Q
   Liang, J
   Yu, WH
   Yi, X
   Yang, XH
   Li, YY
   Han, X
   Zhang, Y
   Xuan, CH
   Yao, Z
   Shang, YF
AF Shi, Lei
   Sun, Luyang
   Li, Qian
   Liang, Jing
   Yu, Wenhua
   Yi, Xia
   Yang, Xiaohan
   Li, Yanyan
   Han, Xiao
   Zhang, Yu
   Xuan, Chenghao
   Yao, Zhi
   Shang, Yongfeng
TI Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and
   promotes hormonally responsive breast carcinogenesis
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE histone methylation; breast cancer
ID LYSINE METHYLATION; METHYLTRANSFERASE ACTIVITY; MAMMALIAN CHROMATIN;
   H3K4 TRIMETHYLATION; ANDROGEN RECEPTOR; GENE-EXPRESSION; X-CHROMOSOME;
   ESTROGEN; CANCER; HETEROCHROMATIN
AB It is well-documented that the methylation of histone H3 lysine 4 (H3K4) and of H3K9 are mutually exclusive, an epigenetic phenomenon conserved from yeast to humans. How this opposed methylation modification is accomplished and coordinated in mammalian cells is poorly understood. Here we report that the H3K9 trimethyl demethylase JMJD2B is an integral component of the H3K4-specific methyltransferase, the mixed-lineage leukemia (MLL) 2 complex. We show that the JMJD2B/MLL2 complex is copurified with estrogen receptor alpha (ER alpha) and is required for ER alpha-regulated transcription. We demonstrate that H3K9 demethylation and H3K4 methylation are coordinated in ER alpha-activated transcription such that H3K9 demethylation is a prerequisite for H3K4 methylation. Significantly, depletion of JMJD2B impairs the estrogen-induced G(1)/S transition of the cell cycle in vitro and inhibits breast tumorigenesis in vivo. Interestingly, JMJD2B itself is an ER alpha target gene, and forms a feed-forward regulatory loop in regulation of the hormone response. Our results provide a molecular basis for the coordinated H3K4 methylation/H3K9 demethylation in transcription activation, link the trimethyl demethylase JMJD2B to euchromatin functions, and provide a mechanism for JMJD2B in breast carcinogenesis.
C1 [Shi, Lei; Sun, Luyang; Li, Qian; Liang, Jing; Yu, Wenhua; Yi, Xia; Yang, Xiaohan; Li, Yanyan; Han, Xiao; Zhang, Yu; Xuan, Chenghao; Shang, Yongfeng] Peking Univ, Dept Biochem & Mol Biol, Hlth Sci Ctr, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100191, Peoples R China.
   [Yao, Zhi; Shang, Yongfeng] Tianjin Med Univ, Tianjin 300070, Peoples R China.
C3 Peking University; Tianjin Medical University
RP Shang, YF (通讯作者)，Peking Univ, Dept Biochem & Mol Biol, Hlth Sci Ctr, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100191, Peoples R China.
EM yshang@hsc.pku.edu.cn
RI YU, Wenhua/ABI-2704-2020; Liang, Jingyuan/CAH-2002-2022; Han,
   Xiao/A-1109-2017; Li, Qian/KIE-2130-2024
OI Li, Qian/0000-0003-0359-5604; Han, Xiao/0000-0002-6024-6286
FU National Natural Science Foundation of China [30830032, 30921062,
   81071673]; Ministry of Science and Technology of China [2011CB504204,
   2007-CB914503, 2009CB918903]
FX This work was supported by Grants 30830032 and 30921062 (to Y.S.) and
   81071673 (to L. Sun) from the National Natural Science Foundation of
   China and 973 Program Grants 2011CB504204 and 2007-CB914503 (to Y.S.)
   and 2009CB918903 (to Z.Y.) from the Ministry of Science and Technology
   of China.
CR Barrett A, 2007, INT J CANCER, V121, P265, DOI 10.1002/ijc.22673
   Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201
   Brinkman AB, 2006, EMBO REP, V7, P628, DOI 10.1038/sj.embor.7400686
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Cloos PAC, 2008, GENE DEV, V22, P1115, DOI 10.1101/gad.1652908
   Doisneau-Sixou SF, 2003, ENDOCR-RELAT CANCER, V10, P179, DOI 10.1677/erc.0.0100179
   Dou YL, 2006, NAT STRUCT MOL BIOL, V13, P713, DOI 10.1038/nsmb1128
   Dreijerink KMA, 2006, CANCER RES, V66, P4929, DOI 10.1158/0008-5472.CAN-05-4461
   Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9
   Fodor BD, 2006, GENE DEV, V20, P1557, DOI 10.1101/gad.388206
   Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038
   Issaeva I, 2007, MOL CELL BIOL, V27, P1889, DOI 10.1128/MCB.01506-06
   Janowski BA, 2007, NAT CHEM BIOL, V3, P166, DOI 10.1038/nchembio860
   Jin CY, 2007, GENE DEV, V21, P1519, DOI 10.1101/gad.1547707
   Katoh M, 2004, INT J ONCOL, V24, P1623
   Key TJ, 2001, LANCET ONCOL, V2, P133, DOI 10.1016/S1470-2045(00)00254-0
   Li F, 2008, CELL, V135, P272, DOI 10.1016/j.cell.2008.08.036
   Loyola A, 2003, METHODS, V31, P96, DOI 10.1016/S1046-2023(03)00093-8
   Luger K, 1999, METHOD ENZYMOL, V304, P3
   Luger K, 1997, J MOL BIOL, V272, P301, DOI 10.1006/jmbi.1997.1235
   Martens JHA, 2005, EMBO J, V24, P800, DOI 10.1038/sj.emboj.7600545
   Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761
   MESKO T W, 1990, Comprehensive Therapy, V16, P3
   Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4
   Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   Rougeulle C, 2004, MOL CELL BIOL, V24, P5475, DOI 10.1128/MCB.24.12.5475-5484.2004
   Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4
   Shang YF, 2006, NAT REV CANCER, V6, P360, DOI 10.1038/nrc1879
   Squazzo SL, 2006, GENOME RES, V16, P890, DOI 10.1101/gr.5306606
   Steward MM, 2006, NAT STRUCT MOL BIOL, V13, P852, DOI 10.1038/nsmb1131
   Vakoc CR, 2006, MOL CELL BIOL, V26, P9185, DOI 10.1128/MCB.01529-06
   Vakoc CR, 2005, MOL CELL, V19, P381, DOI 10.1016/j.molcel.2005.06.011
   Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050
   Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028
   Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546
   Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027
   Yoshioka H, 2009, BIOL REPROD, V80, P804, DOI 10.1095/biolreprod.108.072603
   Zhang H, 2004, GENE DEV, V18, P1753, DOI 10.1101/gad.1194704
NR 39
TC 207
Z9 234
U1 3
U2 58
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 3
PY 2011
VL 108
IS 18
BP 7541
EP 7546
DI 10.1073/pnas.1017374108
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 758YF
UT WOS:000290203100054
PM 21502505
OA Green Published
DA 2025-01-12
ER

PT J
AU Wang, YJ
   Meng, L
   Hu, HY
   Zhang, Y
   Zhao, CF
   Li, QQ
   Shi, FY
   Wang, XD
   Lin, AX
AF Wang, Yajuan
   Meng, Lu
   Hu, Hongyu
   Zhang, Ying
   Zhao, Chenfu
   Li, Qianqian
   Shi, Fangyu
   Wang, Xudong
   Lin, Aixing
TI Oct-4B isoform is differentially expressed in breast cancer cells:
   hypermethylation of regulatory elements of Oct-4A suggests an
   alternative promoter and transcriptional start site for Oct-4B
   transcription
SO BIOSCIENCE REPORTS
LA English
DT Article
DE alternative transcription; cis-regulatory element; DNA methylation;
   epigenetics; MCF-7 cells; Oct-4
ID EMBRYONIC STEM-CELLS; OCT4 EXPRESSION; SELF-RENEWAL; PLURIPOTENCY; GENE;
   PSEUDOGENES; METHYLATION; POU5F1; NANOG
AB The human Oct-4 gene has three isoforms, Oct-4A, Oct-4B and Oct-4B1, which are thought to be derived from alternative splicing. It remains controversial whether the Oct-4 gene is expressed in cancer cells. Expression of Oct-4A is regulated by two elements, the PE (proximal enhancer) and DE (distal enhancer), but the expression and regulation of Oct-4B are not well known. Here, we firstly report that Oct-4B is expressed at low levels in MCF-7 cells, while the Oct-4A gene is inactivated. By analysing the function of different promoter constructs and the DNA methylation status of three regulatory regions, we demonstrate that the Oct-4A gene in MCF-7 cells is repressed by epigenetic control rather than transcriptional control. In addition, we speculate that the transcription of Oct-4B in MCF-7 cells is differentially regulated by additional regulatory elements. This work will enhance the understanding of Oct-4 gone in differential regulation.
C1 [Wang, Yajuan; Meng, Lu; Hu, Hongyu; Zhang, Ying; Zhao, Chenfu; Li, Qianqian; Shi, Fangyu; Wang, Xudong; Lin, Aixing] China Agr Univ, Coll Biol Sci, State Key Lab Agrobiotechnol, Beijing 100193, Peoples R China.
C3 China Agricultural University
RP Lin, AX (通讯作者)，China Agr Univ, Coll Biol Sci, State Key Lab Agrobiotechnol, 2 Yuanmingyuan W Rd, Beijing 100193, Peoples R China.
EM linaix@cau.edu.cn
FU Stem Cell Research Center of Peking University Health Science Center;
   National Natural Science Foundation of China [30570947, 30370726];
   National High-Tech Research and Development Program of China (863
   Program) [2006AA02Z113]
FX We strongly acknowledge the support of the Stem Cell Research Center of
   Peking University Health Science Center, and thank Professor Chunyan
   Zhou (Peking University Health Center) for providing the MCF-7 cell
   line, Dr Li Wang (Stem Cell Research Center of Peking University Health
   Science Center) for providing the hES-H1 cell line, and Dr Lei Wang
   (Beijing Rehabilitation Hospital) for providing the breast adenofibroma
   tumour and adjacent normal tissue samples.This work was supported by the
   National Natural Science Foundation of China [grant numbers 30570947,
   30370726]; and partly supported by the National High-Tech Research and
   Development Program of China (863 Program) [grant number 2006AA02Z113].
CR Atlasi Y, 2008, STEM CELLS, V26, P3068, DOI 10.1634/stemcells.2008-0530
   Babaie Y, 2007, STEM CELLS, V25, P500, DOI 10.1634/stemcells.2006-0426
   Cantz T, 2008, STEM CELLS, V26, P692, DOI 10.1634/stemcells.2007-0657
   Cauffman G, 2006, STEM CELLS, V24, P2685, DOI 10.1634/stemcells.2005-0611
   Deb-Rinker P, 2005, J BIOL CHEM, V280, P6257, DOI 10.1074/jbc.C400479200
   Ezeh UI, 2005, CANCER-AM CANCER SOC, V104, P2255, DOI 10.1002/cncr.21432
   Freberg CT, 2007, MOL BIOL CELL, V18, P1543, DOI 10.1091/mbc.E07-01-0029
   Gu PL, 2005, MOL CELL BIOL, V25, P8507, DOI 10.1128/MCB.25.19.8507-8519.2005
   Gu PL, 2005, MOL CELL BIOL, V25, P3492, DOI 10.1128/MCB.25.9.3492-3505.2005
   Hattori N, 2004, J BIOL CHEM, V279, P17063, DOI 10.1074/jbc.M309002200
   Hu TS, 2008, CANCER RES, V68, P6533, DOI 10.1158/0008-5472.CAN-07-6642
   Kaltz N, 2008, STEM CELLS, V26, P2419, DOI 10.1634/stemcells.2008-0304
   Kotoula V, 2008, STEM CELLS, V26, P290, DOI 10.1634/stemcells.2007-0726
   Latham T, 2008, CELL TISSUE RES, V331, P31, DOI 10.1007/s00441-007-0537-9
   Liedtke S, 2008, BIOL CHEM, V389, P845, DOI 10.1515/BC.2008.098
   Liedtke S, 2007, CELL STEM CELL, V1, P364, DOI 10.1016/j.stem.2007.09.003
   Liu N, 2007, J CELL PHYSIOL, V211, P279, DOI 10.1002/jcp.20978
   Mallanna SK, 2008, MOL REPROD DEV, V75, P1247, DOI 10.1002/mrd.20871
   Nordhoff V, 2001, MAMM GENOME, V12, P309, DOI 10.1007/s003350010279
   Pan GJ, 2002, CELL RES, V12, P321, DOI 10.1038/sj.cr.7290134
   Papamichos SI, 2009, MOL HUM REPROD, V15, P269, DOI 10.1093/molehr/gap018
   Suo GL, 2005, BIOCHEM BIOPH RES CO, V337, P1047, DOI 10.1016/j.bbrc.2005.09.157
   Tai MH, 2005, CARCINOGENESIS, V26, P495, DOI 10.1093/carcin/bgh321
   TAKEDA J, 1992, NUCLEIC ACIDS RES, V20, P4613, DOI 10.1093/nar/20.17.4613
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Wang PX, 2003, BIOCHEM J, V375, P199, DOI 10.1042/BJ20030579
   Wang X, 2009, STEM CELLS, V27, P1265, DOI 10.1002/stem.58
   Zangrossi S, 2007, STEM CELLS, V25, P1675, DOI 10.1634/stemcells.2006-0611
   Zhang HJ, 2008, PLACENTA, V29, P549, DOI 10.1016/j.placenta.2008.03.003
   Zhang JQ, 2006, NAT CELL BIOL, V8, P1114, DOI 10.1038/ncb1481
   Zhang Y, 2009, PROG BIOCHEM BIOPHYS, V36, P1180, DOI 10.3724/SP.J.1206.2009.00128
NR 31
TC 7
Z9 9
U1 0
U2 8
PU PORTLAND PRESS LTD
PI LONDON
PA 5TH FLR, 90 HIGH HOLBORN, LONDON WC1V 6LJ, ENGLAND
SN 0144-8463
EI 1573-4935
J9 BIOSCIENCE REP
JI Biosci. Rep.
PD APR
PY 2011
VL 31
IS 2
BP 109
EP 115
DI 10.1042/BSR20100033
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 756IM
UT WOS:000290004900004
PM 20433421
DA 2025-01-12
ER

PT J
AU Shargh, SA
   Sakizli, M
   Farajnia, S
   Montazer-Saheb, S
AF Shargh, Shohreh A.
   Sakizli, Meral
   Farajnia, Safar
   Montazer-Saheb, Soheila
TI Evaluation of methylation pattern in promoter region of E-cadherin gene
   and its relation to tumor grade and stage in breast cancer
SO AFRICAN JOURNAL OF BIOTECHNOLOGY
LA English
DT Article
DE Breast cancer; E-cadherin; methylation pattern; tumor stage; tumor grade
ID SUPPRESSOR GENES; EXPRESSION; HYPERMETHYLATION; ASSOCIATION;
   PROGRESSION; MUTATIONS; CARCINOMA; DISEASE; RISK
AB The epithelial cadherin gene (CDH1) has been identified as a tumor suppressor gene located within the 16q22.1 region. The CDH1 gene encodes a transmembrane glycoprotein involved in cell to cell adhesion and loss of CDH1 expression contributes to increased proliferation, invasion and metastasis in breast carcinoma. No mutation in CDH1 have been identified in invasive ductal carcinoma (IDC), suggesting that, other inactivation mechanisms are responsible for IDC oncogenesis. In order to analyze the role of promoter methylation in CDH1 gene inactivation in breast cancer, the CpG methylation status of E-cadherin promoter region by bisulfite sequencing PCR (BSP) was investigated. 10 CpG sites [nucleotide (nt) 863, 865, 873, 879, 887, 892, 901, 918, 920 and 940] in the promoter region were screened for methylation. The CDH1 methylation was detected in 94% (47 to 50) of breast tumors which was associated with higher tumor grade (p = 0.035), tumor stage (p = 0.000) and tumor metastasis (p = 0.000). There was also a significant correlation between tumor stage, grade and metastatic status with sites of methylation (p = 0.000). The data indicate that CDH1 promoter methylation might be a potential mechanism for epigenetic silencing of CDH1 in primary breast cancer suggesting a valuable molecular marker for detection of breast cancer progression.
C1 [Farajnia, Safar] Tabriz Univ Med Sci, Biotechnol Res Ctr, Tabriz, Iran.
   [Farajnia, Safar; Montazer-Saheb, Soheila] Tabriz Univ Med Sci, Infect & Trop Dis Res Ctr, Tabriz, Iran.
   [Shargh, Shohreh A.; Sakizli, Meral] 9 Eylul Univ Izmir, Hlth Inst, Dept Med Genet & Biol, Izmir, Turkey.
   [Shargh, Shohreh A.] Chalous Azad Univ, Hlth Inst, Dept Med Sci, Chalous, Iran.
C3 Tabriz University of Medical Science; Tabriz University of Medical
   Science
RP Farajnia, S (通讯作者)，Tabriz Univ Med Sci, Biotechnol Res Ctr, Tabriz, Iran.
EM farajnia@gmail.com
OI Montazersaheb, Soheila/0000-0001-5010-7293; Farajnia,
   Safar/0000-0002-6087-9147
FU Health institute of 9 Eylul University, Izmir, Turkey; biotechnology
   research center of Tabriz university of Medical Sciences, Iran
FX This study was supported by the Health institute of 9 Eylul University,
   Izmir, Turkey and in part by biotechnology research center of Tabriz
   university of Medical Sciences, Iran.
CR Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309
   Berx G, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003129
   Bornman DM, 2001, AM J PATHOL, V159, P831, DOI 10.1016/S0002-9440(10)61758-0
   Brooks-Wilson AR, 2004, J MED GENET, V41, P508, DOI 10.1136/jmg.2004.018275
   Chan TA, 2008, PLOS MED, V5, P823, DOI 10.1371/journal.pmed.0050114
   Chao YL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-179
   Choi JY, 2009, CARCINOGENESIS, V30, P1889, DOI 10.1093/carcin/bgp143
   Conerly M, 2010, DIS MODEL MECH, V3, P290, DOI 10.1242/dmm.004812
   Duffy MJ, 2009, EUR J CANCER, V45, P335, DOI 10.1016/j.ejca.2008.12.008
   EHDAIE B, 2008, J UROLOGY, V24, P61
   Esteller M, 2005, J PATHOL, V205, P172, DOI 10.1002/path.1707
   Feng WW, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-378
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Goldstein NS, 2002, AM J CLIN PATHOL, V118, P425, DOI 10.1309/JMRD-W08Y-6K8M-7AD8
   Hiraki M, 2010, WORLD J GASTROENTERO, V16, P330, DOI 10.3748/wjg.v16.i3.330
   Hunter KW, 2009, CLIN EXP METASTAS, V26, P497, DOI 10.1007/s10585-009-9249-8
   Kim YH, 2006, GENE CHROMOSOME CANC, V45, P781, DOI 10.1002/gcc.20341
   Kordi-Tamandani DM, 2010, ARCH ORAL BIOL, V55, P809, DOI 10.1016/j.archoralbio.2010.06.017
   Lascombe I, 2006, CLIN CANCER RES, V12, P2780, DOI 10.1158/1078-0432.CCR-05-2387
   Li SY, 2006, CANCER LETT, V237, P272, DOI 10.1016/j.canlet.2005.06.011
   Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879
   Masciari S, 2007, J MED GENET, V44, P726, DOI 10.1136/jmg.2007.051268
   Nakata S, 2006, CANCER-AM CANCER SOC, V106, P2190, DOI 10.1002/cncr.21870
   Oyama T., 2009, CURR ENZYME INHIB, V5, P198, DOI 10.2174/157340809789630271
   Pourabbas R, 2009, AFR J BIOTECHNOL, V8, P5522
   Ribeiro LA, 2002, MOL CARCINOGEN, V34, P187, DOI 10.1002/mc.10064
   Rodenhiser D, 2006, CAN MED ASSOC J, V174, P341, DOI 10.1503/cmaj.050774
   Sahin AA, 2009, ARCH PATHOL LAB MED, V133, P869, DOI 10.1043/1543-2165-133.6.869
   Varshochi R, 2005, J BIOL CHEM, V280, P3185, DOI 10.1074/jbc.M408063200
   Vesuna F, 2008, BIOCHEM BIOPH RES CO, V367, P235, DOI 10.1016/j.bbrc.2007.11.151
   Zhang YY, 2008, WORLD J GASTROENTERO, V14, P1641, DOI 10.3748/wjg.14.1641
NR 31
TC 4
Z9 5
U1 0
U2 3
PU ACADEMIC JOURNALS
PI VICTORIA ISLAND
PA P O BOX 5170-00200 NAIROBI, VICTORIA ISLAND, LAGOS 73023, NIGERIA
SN 1684-5315
J9 AFR J BIOTECHNOL
JI Afr. J. Biotechnol.
PD MAR 7
PY 2011
VL 10
IS 10
BP 1745
EP 1751
PG 7
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology
GA 757NB
UT WOS:000290093000003
DA 2025-01-12
ER

PT J
AU So, AY
   Jung, JW
   Lee, S
   Kim, HS
   Kang, KS
AF So, Ah-Young
   Jung, Ji-Won
   Lee, Seunghee
   Kim, Hyung-Sik
   Kang, Kyung-Sun
TI DNA Methyltransferase Controls Stem Cell Aging by Regulating BMI1 and
   EZH2 through MicroRNAs
SO PLOS ONE
LA English
DT Article
ID HUMAN CANCER-CELLS; HISTONE DEACETYLASE; HUMAN FIBROBLASTS;
   PROSTATE-CANCER; BREAST-CANCER; LUNG-CANCER; IN-VITRO; GENE;
   DIFFERENTIATION; METHYLATION
AB Epigenetic regulation of gene expression is well known mechanism that regulates cellular senescence of cancer cells. Here we show that inhibition of DNA methyltransferases (DNMTs) with 5-azacytidine (5-AzaC) or with specific small interfering RNA (siRNA) against DNMT1 and 3b induced the cellular senescence of human umbilical cord blood-derived multipotent stem cells (hUCB-MSCs) and increased p16(INK4A) and p21(CIP1/WAF1) expression. DNMT inhibition changed histone marks into the active forms and decreased the methylation of CpG islands in the p16(INK4A) and p21(CIP1/WAF1) promoter regions. Enrichment of EZH2, the key factor that methylates histone H3 lysine 9 and 27 residues, was decreased on the p16(INK4A) and p21(CIP1/WAF1) promoter regions. We found that DNMT inhibition decreased expression levels of Polycomb-group (PcG) proteins and increased expression of microRNAs (miRNAs), which target PcG proteins. Decreased CpG island methylation and increased levels of active histone marks at genomic regions encoding miRNAs were observed after 5-AzaC treatment. Taken together, DNMTs have a critical role in regulating the cellular senescence of hUCB-MSCs through controlling not only the DNA methylation status but also active/inactive histone marks at genomic regions of PcG-targeting miRNAs and p16(INK4A) and p21(CIP1/WAF1) promoter regions.
C1 [So, Ah-Young; Lee, Seunghee; Kim, Hyung-Sik; Kang, Kyung-Sun] Seoul Natl Univ, Adult Stem Cell Res Ctr, Coll Vet Med, Seoul, South Korea.
   [So, Ah-Young; Lee, Seunghee; Kim, Hyung-Sik; Kang, Kyung-Sun] Seoul Natl Univ, Dept Vet Publ Hlth, Coll Vet Med, Seoul, South Korea.
   [So, Ah-Young; Lee, Seunghee; Kim, Hyung-Sik; Kang, Kyung-Sun] Seoul Natl Univ, Res Inst Vet Sci, Coll Vet Med, Seoul, South Korea.
   [Jung, Ji-Won] Korea Natl Inst Hlth, Div Intractable Dis, Ctr Biomed Sci, Chungbuk, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU); Korea Disease Control & Prevention Agency
   (KDCA); Korea National Institute of Health (KNIH); Korea CDC Center for
   Biomedical Science
RP So, AY (通讯作者)，Seoul Natl Univ, Adult Stem Cell Res Ctr, Coll Vet Med, Seoul, South Korea.
EM kangpub@snu.ac.kr
RI Kang, Kyung-Sun/G-6205-2013
OI Kang, Kyung-Sun/0000-0002-9322-741X
FU National Research Foundation of Korea (NRF) [2010-0020265]
FX This work was supported by the National Research Foundation of Korea
   (NRF) (MEST, 2010-0020265). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Ahluwalia A, 2001, GYNECOL ONCOL, V82, P299, DOI 10.1006/gyno.2001.6284
   Allan LA, 2000, MOL CELL BIOL, V20, P1291, DOI 10.1128/MCB.20.4.1291-1298.2000
   Balzer E, 2010, DEVELOPMENT, V137, P891, DOI 10.1242/dev.042895
   Banerjee S, 2010, EXP CELL RES, V316, P172, DOI 10.1016/j.yexcr.2009.08.011
   Barh D, 2010, CURR ONCOL, V17, P70
   Benetti R, 2008, NAT STRUCT MOL BIOL, V15, P268, DOI 10.1038/nsmb.1399
   Braconi C, 2010, HEPATOLOGY, V51, P881, DOI 10.1002/hep.23381
   Casillas MA, 2003, MOL CELL BIOCHEM, V252, P33, DOI 10.1023/A:1025548623524
   Chen Chun-ling, 2005, Zhonghua Fu Chan Ke Za Zhi, V40, P770
   Cheng H., 2010, MOL BIOL REP
   Datta J, 2003, J CELL BIOCHEM, V88, P855, DOI 10.1002/jcb.10457
   Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104
   Fabbri M, 2010, ADV GENET, V70, P87, DOI [10.1016/S0065-2660(10)70004-3, 10.1016/B978-0-12-380866-0.60004-6]
   Fandy TE, 2009, CURR MED CHEM, V16, P2075, DOI 10.2174/092986709788612738
   Fang JY, 2004, CHINESE MED J-PEKING, V117, P99
   Fang JY, 2002, WORLD J GASTROENTERO, V8, P400, DOI 10.3748/wjg.v8.i3.400
   Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995
   Hernández-Muñoz I, 2005, MOL CELL BIOL, V25, P11047, DOI 10.1128/MCB.25.24.11047-11058.2005
   Huang XP, 2010, CIRCULATION, V122, P2419, DOI 10.1161/CIRCULATIONAHA.110.955971
   HUPKES M, 2011, BIOCH BIOPHYS ACTA
   IMAM JS, ONCOGENE
   Jin BL, 2009, CANCER RES, V69, P7412, DOI 10.1158/0008-5472.CAN-09-0116
   Jori FP, 2005, J CELL BIOCHEM, V94, P645, DOI 10.1002/jcb.20315
   Jorl FP, 2005, CELL DEATH DIFFER, V12, P65, DOI 10.1038/sj.cdd.4401499
   Juan AH, 2009, MOL CELL, V36, P61, DOI 10.1016/j.molcel.2009.08.008
   Jung JW, 2010, CELL MOL LIFE SCI, V67, P1165, DOI 10.1007/s00018-009-0242-9
   Jung JW, 2005, CANCER LETT, V225, P199, DOI 10.1016/j.canlet.2004.11.029
   KOMASHKO VM, EPIGENETICS, V5
   Lee S, 2009, CELL PROLIFERAT, V42, P711, DOI 10.1111/j.1365-2184.2009.00633.x
   LEE S, CELL MOL LIFE SCI
   Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Li Y, 2010, CURR MED CHEM, V17, P2141, DOI 10.2174/092986710791299966
   Lin TS, 2005, CANCER LETT, V226, P77, DOI 10.1016/j.canlet.2004.12.031
   Lopatina N, 2002, J CELL BIOCHEM, V84, P324, DOI 10.1002/jcb.10015
   MAHPATRA S, ETHN DIS, V20
   Majumder S, 2002, J BIOL CHEM, V277, P16048, DOI 10.1074/jbc.M111662200
   Milutinovic S, 2000, J BIOL CHEM, V275, P6353, DOI 10.1074/jbc.275.9.6353
   Narita M, 2006, CELL, V126, P503, DOI 10.1016/j.cell.2006.05.052
   Noonan EJ, 2009, ONCOGENE, V28, P1714, DOI 10.1038/onc.2009.19
   Orciani M, 2011, J BIOL REG HOMEOS AG, V25, P115
   Park JR, 2008, CELL PROLIFERAT, V41, P859, DOI 10.1111/j.1365-2184.2008.00565.x
   Patra SK, 2002, MOL CARCINOGEN, V33, P163, DOI 10.1002/mc.10033
   Pignolo RJ, 2008, AGING CELL, V7, P23, DOI 10.1111/j.1474-9726.2007.00350.x
   Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068
   Rong QF, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-36
   ROSCA AM, 2011, STEM CELLS DEV
   Saito Y, 2006, CELL CYCLE, V5, P2220, DOI 10.4161/cc.5.19.3340
   Schneider-Stock R, 2007, IDRUGS, V10, P557
   Seo KW, 2009, BIOCHEM BIOPH RES CO, V384, P120, DOI 10.1016/j.bbrc.2009.04.094
   Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011
   Shin JY, 2000, CANCER RES, V60, P262
   Soleimani M, 2010, INT J DEV BIOL, V54, P1295, DOI 10.1387/ijdb.092999ms
   Spivakov M, 2007, NAT REV GENET, V8, P263, DOI 10.1038/nrg2046
   Su Yu, 2009, Yichuan, V31, P1087, DOI 10.3724/SP.J.1005.2009.01087
   Takeuchi S, 2010, CANCER RES, V70, P9381, DOI 10.1158/0008-5472.CAN-10-0801
   Urbich C, 2008, CARDIOVASC RES, V79, P581, DOI 10.1093/cvr/cvn156
   Valeri N, 2009, MAMM GENOME, V20, P573, DOI 10.1007/s00335-009-9206-5
   VINKEN M, TOXICOL IN VITRO, V24, P445
   VRBA L, PLOS ONE, V5, pE8697
   WAKITANI S, 1995, MUSCLE NERVE, V18, P1417, DOI 10.1002/mus.880181212
   Wang HJ, EUR J CANC, V46, P2295
   Woodbury D, 2002, J NEUROSCI RES, V69, P908, DOI 10.1002/jnr.10365
   XU C, EUR J CANC
   Xu WR, 2004, EXP BIOL MED, V229, P623, DOI 10.1177/153537020422900706
   Young JI, 2001, J BIOL CHEM, V276, P19610, DOI 10.1074/jbc.M009470200
   Yuan Yan, 2005, Zhonghua Xinxueguanbing Zazhi, V33, P170
   Zardo G, 2005, CELL RES, V15, P679, DOI 10.1038/sj.cr.7290337
   Zhou S, 2008, AGING CELL, V7, P335, DOI 10.1111/j.1474-9726.2008.00377.x
NR 69
TC 141
Z9 157
U1 2
U2 25
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 10
PY 2011
VL 6
IS 5
AR e19503
DI 10.1371/journal.pone.0019503
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 761YU
UT WOS:000290440200009
PM 21572997
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Atashrazm, F
   Zaker, F
   Aghaeipour, M
   Pazhakh, V
AF Atashrazm, Farzaneh
   Zaker, Farhad
   Aghaeipour, Mahnaz
   Pazhakh, Vahid
TI Polymorphisms of the Methylene Tetrahydrofolate Reductase and
   Susceptibility to Acute Lymphoblastic Leukemia in Children
SO LABMEDICINE
LA English
DT Article
DE MTHFR; polymorphism; acute lymphoblastic leukemia; pediatric
ID MTHFR GENETIC POLYMORPHISMS; METHYLENETETRAHYDROFOLATE REDUCTASE;
   5,10-METHYLENETETRAHYDROFOLATE REDUCTASE; CHINESE POPULATION;
   COLORECTAL-CANCER; DNA METHYLATION; BREAST-CANCER; RISK; MUTATION;
   FOLATE
AB Background: Correlation between epigenetic factors and their effects on hematopoietic cells has led to a study of 2 common functional polymorphisms (C677T and A1298C) of 5,10-methylene tetrahydrofolate reductase (MTHFR) enzyme. The aim of this study was to assess the individual and/or combined roles of these 2 polymorphisms in pediatric acute lymphoblastic leukemia (ALL).
   Methods: Using polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) analyses, we studied the frequencies of the C677T and A1298C MTHFR genotypes in 103 pediatric ALL patients and 160 age-sex matched controls. We calculated the odds ratio (OR) of MTHFR genotypes to determine if 1 or both of these polymorphisms may be associated with childhood ALL.
   Results: The T allele frequency for MTHFR 677C>T was 22.2% and 18.45% in controls and cases, respectively. The C allele frequency for MTHFR 1298 A>C was 40.65% and 40.72% in controls and cases, respectively. The OR for MTHFR 677CT was 1.08 (95%Cl 0.58-1.95) and OR for MTHFR 677TT was 0,25 (95%Cl 0.05-10.24). The OR for MTHFR 1298 AC was 0.57 (0.95% Cl 0.57-1.95) and for MTHFR CC was 0.96 (0.95% Cl 0.37-2.45). The OR for the combined heterozygous status (67701 and 1298AC) was 1.08 (95% CI 0.41-2.82).
   Conclusion: Our findings suggest that the MTHFR C677T and A1298C gene variants lack a major influence on the susceptibility for pediatric ALL. Another result was that the C allele frequency for MTHFR 1298 A>C was significantly higher than those reported for most Asian and European populations. The C677T prevalence seems to be similar to those reported in most Asian populations.
C1 [Zaker, Farhad] Univ Tehran Med Sci, Cellular & Mol Res Ctr, Tehran, Iran.
   [Zaker, Farhad] Univ Tehran Med Sci, Oncopathol Res Ctr, Tehran, Iran.
   [Atashrazm, Farzaneh; Pazhakh, Vahid] Iran Univ Med Sci, Cellular & Mol Res Ctr, Tehran, Iran.
   [Atashrazm, Farzaneh; Pazhakh, Vahid] Iran Univ Med Sci, Oncopathol Res Ctr, Tehran, Iran.
   [Aghaeipour, Mahnaz] Iranian Blood Transfus Org, Dept Flow Cytometry, Tehran, Iran.
C3 Tehran University of Medical Sciences; Tehran University of Medical
   Sciences; Iran University of Medical Sciences; Iran University of
   Medical Sciences
RP Zaker, F (通讯作者)，Univ Tehran Med Sci, Cellular & Mol Res Ctr, Tehran, Iran.
EM farhadz20@yahoo.co.uk
OI Atashrazm, Farzaneh/0000-0003-3471-8160
FU IUMS
FX We thank the patients and their clinicians for their participation in
   this study. We are also grateful to the Molecular Research Center of
   IUMS for establishing the molecular techniques and to the Flow Cytometry
   department staff of the IBTO for their contributions to sample
   collection. This research was financially supported by the research fund
   of IUMS.
CR Barbosa CG, 2008, GENET MOL BIOL, V31, P29, DOI 10.1590/S1415-47572008000100005
   Burnett AK, 2005, POSTGRADUATE HAEMATOLOGY, 5TH EDITION, P509, DOI 10.1002/9780470987056.ch31
   Chen J, 1996, CANCER RES, V56, P4862
   Chen J, 2005, CANCER RES, V65, P1606, DOI 10.1158/0008-5472.CAN-04-2630
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   de Jonge R, 2009, BLOOD, V113, P2284, DOI 10.1182/blood-2008-07-165928
   Franco RF, 2001, BRIT J HAEMATOL, V115, P616, DOI 10.1046/j.1365-2141.2001.03140.x
   Frosst P, 1996, MAMM GENOME, V7, P864, DOI 10.1007/s003359900255
   FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111
   Krajinovic M, 2004, BLOOD, V103, P252, DOI 10.1182/blood-2003-06-1794
   Levine AJ, 2000, CANCER EPIDEM BIOMAR, V9, P657
   Mc Carthy C, 2004, CLIN CHEM, V50, P2462, DOI 10.1373/clinchem.2004.041517
   PUI CH, 2005, WILLIAMS HEMATOLOGY, P1321
   Robien K, 2003, AM J EPIDEMIOL, V157, P571, DOI 10.1093/aje/kwg024
   Sabbagh AS, 2008, GENET TEST, V12, P75, DOI 10.1089/gte.2007.0064
   Sadananda AMN, 2010, INDIAN J CANCER, V47, P40, DOI 10.4103/0019-509X.58858
   Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, pA1
   Schnakenberg E, 2005, BMC MED GENET, V6, DOI 10.1186/1471-2350-6-23
   Sharp L, 2002, CANCER LETT, V181, P65, DOI 10.1016/S0304-3835(02)00030-7
   Sharp L, 2002, J NUTR, V132, p3542S
   Shen HB, 2001, INT J CANCER, V95, P332, DOI 10.1002/1097-0215(20010920)95:5<332::AID-IJC1058>3.0.CO;2-9
   Sibani S, 2000, HUM MUTAT, V15, P280, DOI 10.1002/(SICI)1098-1004(200003)15:3<280::AID-HUMU9>3.3.CO;2-9
   Skibola CF, 1999, P NATL ACAD SCI USA, V96, P12810, DOI 10.1073/pnas.96.22.12810
   Song CY, 2001, CANCER RES, V61, P3272
   Thirumaran RK, 2005, BLOOD, V106, P2590, DOI 10.1182/blood-2005-04-1719
   Ulrich CM, 1999, CANCER EPIDEM BIOMAR, V8, P659
   Wiemels JL, 2001, P NATL ACAD SCI USA, V98, P4004, DOI 10.1073/pnas.061408298
   Wilcken B, 2003, J MED GENET, V40, P619, DOI 10.1136/jmg.40.8.619
   Zanrosso CW, 2006, LEUKEMIA RES, V30, P477, DOI 10.1016/j.leukres.2005.08.008
   Zingg JM, 1997, CARCINOGENESIS, V18, P869, DOI 10.1093/carcin/18.5.869
NR 30
TC 5
Z9 5
U1 0
U2 0
PU AMER SOC CLINICAL PATHOLOGY
PI CHICAGO
PA 2100 W HARRISON ST, CHICAGO, IL 60612 USA
SN 0007-5027
J9 LABMEDICINE
JI Labmedicine
PD MAY
PY 2011
VL 42
IS 5
BP 275
EP 279
DI 10.1309/LM7BFTEZ98ZZMWPQ
PG 5
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA 754NM
UT WOS:000289861900003
DA 2025-01-12
ER

PT J
AU Lu, LG
   Katsaros, D
   Zhu, Y
   Hoffman, A
   Luca, S
   Marion, CE
   Mu, LN
   Risch, H
   Yu, H
AF Lu, Lingeng
   Katsaros, Dionyssios
   Zhu, Yong
   Hoffman, Aaron
   Luca, Scarampi
   Marion, Canuto Emilie
   Mu, Lina
   Risch, Harvey
   Yu, Herbert
TI Let-7a regulation of insulin-like growth factors in breast cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Let-7a-3 methylation; IGFs; Breast cancer; Epigenetics
ID EPITHELIAL OVARIAN-CANCER; MICRORNA EXPRESSION; LUNG-CANCER; FACTOR-II;
   PREDICTS SURVIVAL; IGF-II; CELLS; GENE; TARGETS; TRANSFORMATION
AB Expression of certain microRNA genes is regulated by DNA methylation, which in turn affects the activities of their downstream molecules. Our previous study showed that methylated let-7a-3 was associated with low IGF-II expression and favorable prognosis of ovarian cancer. The roles of let-7a-3 methylation in breast cancer and in regulation of IGF expression in the tumor are still unknown. Let-7a-3 methylation, IGF mRNAs, and peptides were analyzed in 348 breast cancer samples using quantitative methylation-specific PCR, qRT-PCR, and ELISA, respectively. The associations of let-7a-3 methylation with IGFs, disease features, and patient survivals were analyzed. In vitro experiments were performed using HeLa cells transfected with let-7a precursors to assess the effect of let-7a on IGF expression. Let-7a-3 methylation was detected frequently in breast cancer. An inverse correlation between let-7a-3 methylation and IGF expression was observed in breast cancer, which was similar to that seen in ovarian cancer. Our in vitro experiment showed that let-7a could increase IGF expression in cancer cells which had low endogenous let-7a. Let-7a-3 methylation was also found to be associated with high grade tumors and ER- or PR-negative cancer. However, let-7a-3 methylation was not associated with disease-free survival or overall survival of breast cancer patients. The study provides further evidence in support of the notion that epigenetic regulation of let-7a-3 may affect the actions of IGFs in cancer. Let-7a may up-regulate the expression of IGFs in cancer cells, which is different from its inhibitory effects on other oncogenes.
C1 [Lu, Lingeng; Zhu, Yong; Hoffman, Aaron; Risch, Harvey; Yu, Herbert] Yale Univ, Dept Epidemiol & Publ Hlth, Yale Canc Ctr, Sch Med, New Haven, CT 06520 USA.
   [Katsaros, Dionyssios; Luca, Scarampi; Marion, Canuto Emilie] Univ Turin, Dept Obstet & Gynecol, Gynecol Oncol & Breast Canc Unit, Turin, Italy.
   [Mu, Lina] SUNY Buffalo, Dept Social & Prevent Med, Sch Publ Hlth & Hlth Profess, Buffalo, NY 14214 USA.
C3 Yale University; University of Turin; State University of New York
   (SUNY) System; University at Buffalo, SUNY
RP Yu, H (通讯作者)，Yale Univ, Dept Epidemiol & Publ Hlth, Yale Canc Ctr, Sch Med, 60 Coll St, New Haven, CT 06520 USA.
EM herbert.yu@yale.edu
CR Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214
   Brueckner B, 2007, CANCER RES, V67, P1419, DOI 10.1158/0008-5472.CAN-06-4074
   Chin LJ, 2008, CANCER RES, V68, P8535, DOI 10.1158/0008-5472.CAN-08-2129
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Fabbri M, 2007, EXPERT OPIN BIOL TH, V7, P1009, DOI 10.1517/14712598.7.7.1009
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Inamura K, 2007, LUNG CANCER, V58, P392, DOI 10.1016/j.lungcan.2007.07.013
   Ioannidis P, 2005, J BIOL CHEM, V280, P20086, DOI 10.1074/jbc.M410036200
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083
   Kovalchuk O, 2007, CELL CYCLE, V6, P2010, DOI 10.4161/cc.6.16.4549
   Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003
   Landi MT, 2010, CLIN CANCER RES, V16, P430, DOI 10.1158/1078-0432.CCR-09-1736
   Lee EJ, 2008, RNA, V14, P35, DOI 10.1261/rna.804508
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Lu LG, 2006, CLIN CANCER RES, V12, P1208, DOI 10.1158/1078-0432.CCR-05-1801
   Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544
   Lu LG, 2006, GYNECOL ONCOL, V103, P990, DOI 10.1016/j.ygyno.2006.06.006
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999
   Miska EA, 2005, CURR OPIN GENET DEV, V15, P563, DOI 10.1016/j.gde.2005.08.005
   Mu L, 2009, BREAST CANCER RES TR, V115, P151, DOI 10.1007/s10549-008-0046-x
   Park SM, 2007, CELL CYCLE, V6, P2585, DOI 10.4161/cc.6.21.4845
   Ryan BM, 2010, NAT REV CANCER, V10, P389, DOI 10.1038/nrc2867
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637
   Trang P, 2010, ONCOGENE, V29, P1580, DOI 10.1038/onc.2009.445
   Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460
   Weber B, 2007, CELL CYCLE, V6, P1001, DOI 10.4161/cc.6.9.4209
   Weidhaas JB, 2007, CANCER RES, V67, P11111, DOI 10.1158/0008-5472.CAN-07-2858
   Yan PS, 2001, CANCER RES, V61, P8375
   Yu SL, 2008, CANCER CELL, V13, P48, DOI 10.1016/j.ccr.2007.12.008
NR 34
TC 23
Z9 24
U1 1
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD APR
PY 2011
VL 126
IS 3
BP 687
EP 694
DI 10.1007/s10549-010-1168-5
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 735VP
UT WOS:000288449000014
PM 20848182
DA 2025-01-12
ER

PT J
AU Berge, EO
   Knappskog, S
   Lillehaug, JR
   Lonning, PE
AF Berge, Elisabet Ognedal
   Knappskog, Stian
   Lillehaug, Johan Richard
   Lonning, Per Eystein
TI Alterations of the retinoblastoma gene in metastatic breast cancer
SO CLINICAL & EXPERIMENTAL METASTASIS
LA English
DT Article
DE Breast cancer; Chemoresistance; Metastasis; Driver; Passenger; RB1
ID HUMAN PROSTATE-CANCER; COLORECTAL CANCERS; ALLELIC IMBALANCE; FOLLOW-UP;
   TUMORS; MUTATION; RB1; HETEROZYGOSITY; INACTIVATION; METHYLATION
AB Germline mutations affecting the retinoblastoma gene (RB1) predispose to inherited retinoblastomas but also other malignancies, including breast cancer. While somatic RB1 mutations have been detected in different malignancies, information about the potential role of RB1 mutations in breast cancer is limited. Recently, we discovered RB1 mutations to be associated with resistance to anthracyclines/mitomycin in primary breast cancer. The present work is the first report evaluating RB1 mutation and epigenetic status in metastatic breast cancer. Among 148 breast cancer samples analyzed by MLPA, four samples harbored intragenic deletions/duplications: Thus, exons 1-2 were deleted in two tumors and exons 21-23 in one tumor, while one sample harbored duplication of exons 18-23. The entire RB1 gene was duplicated in two tumors and multiple amplifications were revealed in one sample. Reduced copy number was observed in 17 samples (11.5%). No point mutation or promoter hypermethylation was discovered (n = 38 and 114 tumors analyzed, respectively). Interestingly, among seven tumors expressing lack of response to epirubicin, two samples harbored alterations in RB1, contrasting none out of 16 tumors with stable disease or an objective response (P = 0.08). In summary, the frequency of RB1 alterations in metastatic lesions was not increased when compared to primary breast cancer, indicating that RB1 alterations do not play a major role in metastatic development. While a non-significant association suggesting RB1 alterations to be linked to therapy resistance was observed, our data do not suggest a major role for RB1 alterations explaining acquired drug resistance.
C1 [Berge, Elisabet Ognedal; Knappskog, Stian; Lonning, Per Eystein] Haukeland Hosp, Dept Oncol, N-5021 Bergen, Norway.
   [Berge, Elisabet Ognedal; Knappskog, Stian; Lonning, Per Eystein] Univ Bergen, Inst Med, Sect Oncol, Bergen, Norway.
   [Berge, Elisabet Ognedal; Knappskog, Stian; Lillehaug, Johan Richard] Univ Bergen, Dept Mol Biol, Bergen, Norway.
C3 University of Bergen; Haukeland University Hospital; University of
   Bergen; University of Bergen
RP Lonning, PE (通讯作者)，Haukeland Hosp, Dept Oncol, Jonas Lies Vei 26, N-5021 Bergen, Norway.
EM per.lonning@helse-bergen.no
OI Knappskog, Stian/0000-0002-4153-1655; Lonning, Per
   Eystein/0000-0002-8890-6303
FU Norwegian Cancer Society; Haukeland University Hospital; Western Norway
   Regional Health Authority
FX We thank Beryl Leirvaag, Linda Ramsevik and Hildegunn Helle for
   excellent technical assistance. This work was supported by grants from
   the Norwegian Cancer Society, Haukeland University Hospital Gene Therapy
   Program, and Western Norway Regional Health Authority. Parts of this
   work were performed at Mohn Cancer Research Laboratory, Haukeland
   University Hospital. The authors declare no competing financial
   interest.
CR Berge EO, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-173
   Bièche I, 2000, MOL CARCINOGEN, V29, P151, DOI 10.1002/1098-2744(200011)29:3<151::AID-MC4>3.0.CO;2-6
   Bissig H, 1999, AM J PATHOL, V155, P267, DOI 10.1016/S0002-9440(10)65120-6
   BORG A, 1992, CANCER RES, V52, P2991
   Ellsworth RE, 2005, MOL CANCER RES, V3, P71, DOI 10.1158/1541-7786.MCR-04-0180
   Gouyer V, 1998, AM J RESP CELL MOL, V18, P188, DOI 10.1165/ajrcmb.18.2.3008
   Greenberg PAC, 1996, J CLIN ONCOL, V14, P2197, DOI 10.1200/JCO.1996.14.8.2197
   Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610
   KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820
   Kubota Y, 1995, PROSTATE, V27, P314, DOI 10.1002/pros.2990270604
   Lonning PE, 2004, TRENDS MOL MED, V10, P113, DOI 10.1016/j.molmed.2004.01.005
   Maitra A, 1999, HUM PATHOL, V30, P1435, DOI 10.1016/S0046-8177(99)90165-X
   Marees T, 2008, J NATL CANCER I, V100, P1771, DOI 10.1093/jnci/djn394
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Pinyol M, 2007, BLOOD, V109, P5422, DOI 10.1182/blood-2006-11-057208
   Przybytkowski E, 2003, CANCER RES, V63, P4588
   Simpson DJ, 2000, CANCER RES, V60, P1211
   Sjöblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427
   Stirzaker C, 1997, CANCER RES, V57, P2229
   Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943
   TAMURA G, 1994, PATHOL INT, V44, P34, DOI 10.1111/j.1440-1827.1994.tb02583.x
   Ueda T, 1999, GENE CHROMOSOME CANC, V24, P183, DOI 10.1002/(SICI)1098-2264(199903)24:3<183::AID-GCC2>3.0.CO;2-J
   Valverde JR, 2005, BMC GENET, V6, DOI 10.1186/1471-2156-6-53
   WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Zemlyakova V. V., 2003, Molekulyarnaya Biologiya (Moscow), V37, P696
NR 26
TC 15
Z9 17
U1 0
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0262-0898
J9 CLIN EXP METASTAS
JI Clin. Exp. Metastasis
PD MAR
PY 2011
VL 28
IS 3
BP 319
EP 326
DI 10.1007/s10585-011-9375-y
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 753RK
UT WOS:000289797100007
PM 21253829
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Zhao, SP
   Sun, GX
   Tony, PW
   Ma, DH
   Zhao, CQ
AF Zhao, Shuping
   Sun, Guixia
   Tony, Parks W.
   Ma, Dehua
   Zhao, Chengquan
TI Expression and methylation status of the Syk gene in cervical carcinoma
SO ARCHIVES OF GYNECOLOGY AND OBSTETRICS
LA English
DT Article
DE Cervical cancer; Spleen tyrosine kinase; mRNA expression; Gene
   methylation; Cervical neoplasm; Gene; Suppressor; DNA methylation
ID PROTEIN-TYROSINE KINASE; HUMAN BREAST-CANCER; HUMAN
   HEPATOCELLULAR-CARCINOMA; DNA METHYLATION; PROMOTER HYPERMETHYLATION;
   EPITHELIAL-CELLS; TUMOR-SUPPRESSOR; MELANOMA-CELLS; GROWTH; EPIGENETICS
AB Objective Spleen tyrosine kinase (Syk), a non-receptor protein tyrosine kinase, has recently been recognized as a new candidate tumor suppressor. Decrease or loss of Syk expression has been associated with a malignant phenotype and poor prognosis in a variety of cancers. This study aimed to determine the precise role of Syk in cervical cancer.
   Methods Methylation-specific PCR (MSP) and RT-PCR were utilized to analyze the methylation status and Syk mRNA expression in tissue samples from 20 normal controls, 50 CIN patients and 60 cervical cancer patients.
   Results Syk expression was detected in all 20 normal cervical tissues, as well as in all 18 CIN1 samples. Syk expression was found in 18 of 32 (56%) of CIN2/3 samples.
   Conclusion The results indicate a potential link between the loss of Syk expression and cervical carcinogenesis.
C1 [Zhao, Shuping; Sun, Guixia; Ma, Dehua] Qingdao Univ, Coll Med, Dept Gynecol, Affiliated Hosp, Qingdao 266003, Peoples R China.
   [Tony, Parks W.; Zhao, Chengquan] Univ Pittsburgh, Med Ctr, Magee Womens Hosp, Dept Pathol, Pittsburgh, PA 15213 USA.
C3 Qingdao University; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh
RP Zhao, SP (通讯作者)，Univ Pittsburgh, Med Ctr, Magee Womens Hosp, Dept Gynecol, 300 Halket St, Pittsburgh, PA 15213 USA.
EM shuping.zhao@yahoo.com
OI Parks, W. Tony/0000-0001-7341-3277
FU Natural Science Foundation of Shandong Province, P. R. China [Y2008c139]
FX This research was supported in part by a grant to SP Zhao from the
   Natural Science Foundation of Shandong Province, P. R. China (Y2008c139,
   Syk). The author appreciated Ms. Xuebing Wang's art work and opinions on
   modifying figures (Department of Internal Medicine, University of
   Kentucky School of Medicine, Lexington, KY, USA) and Ms. Aihua Sui (Core
   Facility of the Affiliated Hospital, Qingdao University School of
   Medicine), we also appreciated Dr. John Ma's critical comments on this
   manuscript (George Washington University Medical School, Washington DC,
   USA).
CR Bailet O, 2009, CANCER RES, V69, P2748, DOI 10.1158/0008-5472.CAN-08-2690
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Calvisi DF, 2007, J CLIN INVEST, V117, P2713, DOI 10.1172/JCI31457
   Chu DH, 1998, IMMUNOL REV, V165, P167, DOI 10.1111/j.1600-065X.1998.tb01238.x
   Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086
   Ding Yong-bin, 2004, Zhonghua Yi Xue Za Zhi, V84, P290
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Feng QH, 2007, CANCER EPIDEM BIOMAR, V16, P1178, DOI 10.1158/1055-9965.EPI-06-0694
   Gokul G, 2007, EPIGENETICS-US, V2, P80, DOI 10.4161/epi.2.2.3692
   Hoeller C, 2005, J INVEST DERMATOL, V124, P1293, DOI 10.1111/j.0022-202X.2005.23685.x
   Inatome R, 2001, BIOCHEM BIOPH RES CO, V286, P195, DOI 10.1006/bbrc.2001.5355
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Katargin AN, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-30
   Ki KD, 2009, J GYNECOL ONCOL, V20, P117, DOI 10.3802/jgo.2009.20.2.117
   Kiefer F, 1998, MOL CELL BIOL, V18, P4209, DOI 10.1128/MCB.18.7.4209
   Kitkumthorn N, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-55
   Kurosaki T, 1997, CURR OPIN IMMUNOL, V9, P309, DOI 10.1016/S0952-7915(97)80075-1
   Lee S, 2003, AM J PATHOL, V163, P1371, DOI 10.1016/S0002-9440(10)63495-5
   Li J, 2005, INT J CANCER, V117, P14, DOI 10.1002/ijc.21074
   Lu J, 2006, J BIOL CHEM, V281, P8806, DOI 10.1074/jbc.M507305200
   Luangdilok S, 2007, CANCER RES, V67, P7907, DOI 10.1158/0008-5472.CAN-07-0331
   Magnusson PKE, 2000, MOL MED TODAY, V6, P145, DOI 10.1016/S1357-4310(00)01685-3
   Nakashima H, 2006, CANCER LETT, V236, P89, DOI 10.1016/j.canlet.2005.05.022
   Oikonomou P, 2007, EXP BIOL MED, V232, P881
   Ongenaert M, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-57
   Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440
   RUMBAUGH KM, 1997, J EXP MED, V186, P1965
   Sada K, 2001, J BIOCHEM-TOKYO, V130, P177, DOI 10.1093/oxfordjournals.jbchem.a002970
   Shivapurkar N, 2007, GYNECOL ONCOL, V107, P549, DOI 10.1016/j.ygyno.2007.08.057
   Stewart ZA, 2001, BREAST CANCER RES, V3, P5, DOI 10.1186/bcr261
   Sung YM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007445
   Suzuki K, 2006, CANCER CELL, V9, P199, DOI 10.1016/j.ccr.2006.02.016
   Toyama T, 2003, CANCER LETT, V189, P97, DOI 10.1016/S0304-3835(02)00463-9
   Tsujimura T, 2001, FEBS LETT, V489, P129, DOI 10.1016/S0014-5793(01)02097-X
   Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1
   Ulanova M, 2005, AM J PHYSIOL-LUNG C, V288, pL497, DOI 10.1152/ajplung.00246.2004
   Yamada T, 2001, J IMMUNOL, V166, P538, DOI 10.4049/jimmunol.166.1.538
   Yanagi S, 2001, BIOCHEM BIOPH RES CO, V288, P495, DOI 10.1006/bbrc.2001.5788
   YANG ZL, 2005, ZHONG HUA SHI YAN WA, V22, P68
   Yuan YF, 2001, CANCER RES, V61, P5558
   Yuan YF, 2006, CLIN CANCER RES, V12, P6687, DOI 10.1158/1078-0432.CCR-06-0921
   Zhang XY, 2009, MOL CANCER RES, V7, P634, DOI 10.1158/1541-7786.MCR-08-0371
   Zhao Xian-Lan, 2008, Ai Zheng, V27, P919
   Zhou F, 2006, MOL CELL BIOL, V26, P3478, DOI 10.1128/MCB.26.9.3478-3491.2006
   zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798
NR 46
TC 9
Z9 12
U1 0
U2 3
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0932-0067
EI 1432-0711
J9 ARCH GYNECOL OBSTET
JI Arch. Gynecol. Obstet.
PD MAY
PY 2011
VL 283
IS 5
BP 1113
EP 1119
DI 10.1007/s00404-010-1546-6
PG 7
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Obstetrics & Gynecology
GA 754ZO
UT WOS:000289896600032
PM 20563729
DA 2025-01-12
ER

PT J
AU Hayden, A
   Johnson, PWM
   Packham, G
   Crabb, SJ
AF Hayden, Annette
   Johnson, Peter W. M.
   Packham, Graham
   Crabb, Simon J.
TI S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A
   analogues induces anti-cancer effects in breast cancer cell lines and
   synergy with both histone deacetylase and HER2 inhibition
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE S-adenosylhomocysteine hydrolase; 3-Deazaneplanocin A; Histone
   deacetylase inhibitor; Breast cancer; Trastuzumab; Enhancer of zeste
   homolog 2
ID SUBEROYLANILIDE HYDROXAMIC ACID; GROUP PROTEIN EZH2; TRANSCRIPTIONAL
   REPRESSION; MOUSE DEVELOPMENT; DNA METHYLATION; GENES;
   METHYLTRANSFERASE; PROLIFERATION; ESTROGEN; TUMOR
AB Epigenetic abnormalities including abnormal histone methyltransferase activity contribute to breast cancer pathogenesis. An example is over expression of the polycomb repressive complex (PRC) 2 member enhancer of zeste homolog 2 (EZH2) which is linked to epigenetic silencing and poor prognosis. Recent evidence shows that S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors (AHI) such as 3-deazaneplanocin A (DZNep) modulate chromatin through indirect inhibition of histone methyltransferases including EZH2. We investigated the biological effects of AdoHcy hydrolase inhibition using DZNep and its structural analogues 3-deazaadenosine (DZA) and neplanocin A (Nep A) in breast cancer cells. EZH2 protein expression was decreased and dose dependent growth inhibition occurred with variable potencies in MCF7, MDA-MB-231 and SKBr3 breast cancer cells. Cellular proliferation was inhibited through G(2)/M cell cycle arrest and apoptosis. In addition breast cancer cells accumulated cytoplasmic lipid droplets in response to AdoHcy hydrolase inhibition consistent with a differentiating effect. Each analogue induced a similar pattern of biological activity against breast cancer cells but with differences in potency (DZA > DZNep > Nep A). Co-administration with the histone deacetylase (HDAC) inhibitor trichostatin A (TSA) induced synergistic inhibition of breast cancer cell proliferation. Furthermore, the relatively AHI resistant human epidermal growth factor receptor 2 (HER2) positive cell line SKBr3 underwent synergistic growth inhibition in response to co-treatment with the HER2 directed therapeutic antibody trastuzumab. In conclusion, AHI induce growth inhibition, cell cycle arrest, apoptosis and differentiation in breast cancer cells and synergise with HDAC and HER2 inhibition. Targeting histone methyltransferase activity might be of therapeutic value in breast cancer.
C1 [Hayden, Annette; Johnson, Peter W. M.; Packham, Graham; Crabb, Simon J.] Univ Southampton, Southampton Gen Hosp, Sch Med, Canc Res UK Ctr, Southampton SO16 6YD, Hants, England.
C3 University of Southampton; Cancer Research UK
RP Crabb, SJ (通讯作者)，Univ Southampton, Southampton Gen Hosp, Sch Med, Canc Res UK Ctr, Mailpoint 824,Tremona Rd, Southampton SO16 6YD, Hants, England.
EM s.j.crabb@southampton.ac.uk
RI Johnson, Peter/O-3529-2019; Johnson, Peter/L-2403-2018
OI Crabb, Simon/0000-0003-3521-9064; Packham, Graham/0000-0002-9232-5691;
   Johnson, Peter/0000-0003-2306-4974
FU Cancer Research UK; Wessex Medical Research
FX This work was supported by Cancer Research UK and Wessex Medical
   Research.
CR Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Bali P, 2005, CLIN CANCER RES, V11, P6382, DOI 10.1158/1078-0432.CCR-05-0344
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Crabb SJ, 2008, BIOCHEM PHARMACOL, V76, P463, DOI 10.1016/j.bcp.2008.06.004
   Crabb SJ, 2008, ONCOL REP, V19, P689
   De Clercq E, 2005, NUCLEOS NUCLEOT NUCL, V24, P1395, DOI 10.1080/15257770500265638
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fiskus W, 2009, BLOOD, V114, P2733, DOI 10.1182/blood-2009-03-213496
   Gonzalez ME, 2009, ONCOGENE, V28, P843, DOI 10.1038/onc.2008.433
   GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965
   Huang LL, 2000, MOL MED, V6, P849, DOI 10.1007/BF03401823
   Hwang C, 2008, BREAST CANCER RES TR, V107, P235, DOI 10.1007/s10549-007-9542-7
   Jiang X, 2008, CANCER CELL, V13, P529, DOI 10.1016/j.ccr.2008.04.019
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Laible G, 1997, EMBO J, V16, P3219, DOI 10.1093/emboj/16.11.3219
   Luu TH, 2008, CLIN CANCER RES, V14, P7138, DOI 10.1158/1078-0432.CCR-08-0122
   Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013
   Miremadi A, 2007, HUM MOL GENET, V16, pR28, DOI 10.1093/hmg/ddm021
   Munster P, 2009, CLIN CANCER RES, V15, P2488, DOI 10.1158/1078-0432.CCR-08-1930
   Munster PN, 2001, CANCER RES, V61, P8492
   Nolan L, 2008, BRIT J CANCER, V99, P689, DOI 10.1038/sj.bjc.6604557
   O'Carroll D, 2001, MOL CELL BIOL, V21, P4330, DOI 10.1128/MCB.21.13.4330-4336.2001
   Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807
   Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402
   Pietersen AM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2214
   Satijn DPE, 1999, BBA-GENE STRUCT EXPR, V1447, P1, DOI 10.1016/S0167-4781(99)00130-X
   Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07
   Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010
   Su I, 2005, CELL, V121, P425, DOI 10.1016/j.cell.2005.02.029
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Tonini T, 2004, ONCOGENE, V23, P4930, DOI 10.1038/sj.onc.1207608
   van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
NR 36
TC 89
Z9 99
U1 0
U2 15
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD MAY
PY 2011
VL 127
IS 1
BP 109
EP 119
DI 10.1007/s10549-010-0982-0
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 747DL
UT WOS:000289300400012
PM 20556507
DA 2025-01-12
ER

PT J
AU Calvo, V
   Beato, M
AF Calvo, Veronica
   Beato, Miguel
TI BRCA1 Counteracts Progesterone Action by Ubiquitination Leading to
   Progesterone Receptor Degradation and Epigenetic Silencing of Target
   Promoters
SO CANCER RESEARCH
LA English
DT Article
ID RNA-POLYMERASE-II; BREAST-CANCER CELLS; ESTROGEN-RECEPTOR;
   TRANSCRIPTIONAL REPRESSION; BRCA1/BARD1 HETERODIMER; POLYUBIQUITIN
   CHAINS; MUTATION CARRIERS; IN-VIVO; LIGASE; INHIBITION
AB Germ-line mutations in the BRCA1 gene increase the risk of breast cancer in women, but the precise mechanistic basis for this connection remains uncertain. One popular hypothesis to explain breast tissue specificity postulates a link between BRCA1 and the action of the ovarian hormones estrogen and progesterone. Given the relevance of progesterone for normal mammary development and breast cancer formation, we searched for a functional relationship between BRCA1 and progesterone receptor (PR) in the PR-positive breast cancer cell line T47D. Here, we report that BRCA1 inhibits the transcriptional activity of PR by at least 2 mechanisms involving the E3 ubiquitin ligase activity of BRCA1. First, BRCA1 has a direct effect on the cellular level of PR and, hence, on the extent of PR recruitment to target promoters through the promotion of its ligand-independent and -dependent degradation. Through in vitro and in vivo assays, we found that BRCA1/BARD1 may be the main E3 ubiquitin ligase responsible for ubiquitination and degradation of PR in the absence of hormone. Second, after hormone treatment of cells, the BRCA1/BARD1 complex is recruited via interaction with PR to the hormone-responsive regions of PR target genes, affecting local levels of monoubiquitinated histone H2A and contributing to epigenetic silencing of these promoters. The connections between BRCA1/BARD1 and PR activity suggested by our findings may help explain why host mutations in BRCA1 exert a tissue specificity in preferentially elevating the risk of breast cancer. Cancer Res; 71(9); 3422-31. (C) 2011 AACR.
C1 [Beato, Miguel] Univ Pompeu Fabra, Gene Regulat Program, CRG, E-08003 Barcelona, Spain.
C3 Barcelona Institute of Science & Technology; Pompeu Fabra University;
   Centre de Regulacio Genomica (CRG)
RP Beato, M (通讯作者)，Univ Pompeu Fabra, Gene Regulat Program, CRG, Dr Aiguader 88, E-08003 Barcelona, Spain.
EM miguel.beato@crg.es
RI Beato, Miguel/B-5564-2015
OI Beato, Miguel/0000-0002-2878-2222
FU Scientific Foundation of the Spanish Assotiation Against Cancer, the
   Spanish Ministry for Science and Innovation [BMC 200302902,
   CSD2006-00049]; Departament d'Innovacio Universitat i Empresa of the
   Generalitat de Catalunya; Carlos III Institute of Health, Spanish
   Ministry for Science and Innovation
FX This work was supported by Scientific Foundation of the Spanish
   Assotiation Against Cancer, the Spanish Ministry for Science and
   Innovation (BMC 200302902 and Consolider CSD2006-00049); Departament
   d'Innovacio Universitat i Empresa of the Generalitat de Catalunya;
   Carlos III Institute of Health, Spanish Ministry for Science and
   Innovation (V. Calvo).
CR Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6
   Brzovic PS, 2003, P NATL ACAD SCI USA, V100, P5646, DOI 10.1073/pnas.0836054100
   Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002
   Christensen DE, 2009, FEBS J, V276, P5381, DOI 10.1111/j.1742-4658.2009.07249.x
   Clarke RB, 1997, CANCER RES, V57, P4987
   Clemm DL, 2000, MOL ENDOCRINOL, V14, P52, DOI 10.1210/me.14.1.52
   Di Croce L, 1999, MOL CELL, V4, P45, DOI 10.1016/S1097-2765(00)80186-0
   DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475
   Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354
   Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073
   FRIEDMAN LS, 1994, CANCER RES, V54, P6374
   HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482
   Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200
   Hernández MP, 2002, J BIOL CHEM, V277, P11873, DOI 10.1074/jbc.M111445200
   Horwitz AA, 2007, P NATL ACAD SCI USA, V104, P6614, DOI 10.1073/pnas.0610481104
   Ismail PM, 2003, STEROIDS, V68, P779, DOI 10.1016/S0039-128X(03)00133-8
   KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x
   Katiyar P, 2009, MOL ENDOCRINOL, V23, P1135, DOI 10.1210/me.2008-0347
   KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015
   LaMarca HL, 2008, ENDOCRINOLOGY, V149, P4317, DOI 10.1210/en.2008-0450
   Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032
   Ma YX, 2006, MOL ENDOCRINOL, V20, P14, DOI 10.1210/me.2004-0488
   Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691
   Moore MR, 2006, J STEROID BIOCHEM, V98, P218, DOI 10.1016/j.jsbmb.2005.09.008
   PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U
   Poole AJ, 2006, SCIENCE, V314, P1467, DOI 10.1126/science.1130471
   Quiles I, 2009, MOL ENDOCRINOL, V23, P809, DOI 10.1210/me.2008-0454
   Rebbeck TR, 1999, JNCI-J NATL CANCER I, V91, P1475, DOI 10.1093/jnci/91.17.1475
   Shechter D, 2007, NAT PROTOC, V2, P1445, DOI 10.1038/nprot.2007.202
   Starita LM, 2005, J BIOL CHEM, V280, P24498, DOI 10.1074/jbc.M414020200
   Strutt H, 1999, METH MOL B, V119, P455
   Subtil-Rodríguez A, 2008, MOL CELL BIOL, V28, P3830, DOI 10.1128/MCB.01217-07
   Thakar A, 2010, J BIOMOL STRUCT DYN, V27, P399, DOI 10.1080/07391102.2010.10507326
   Thompson D, 2002, JNCI-J NATL CANCER I, V94, P1358, DOI 10.1093/jnci/94.18.1358
   TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x
   Vicent GP, 2004, MOL CELL, V16, P439, DOI 10.1016/j.molcel.2004.10.025
   Vicent GP, 2006, MOL CELL, V24, P367, DOI 10.1016/j.molcel.2006.10.011
   Wen J, 2009, ONCOGENE, V28, P575, DOI 10.1038/onc.2008.405
   Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003
   Wu-Baer F, 2003, J BIOL CHEM, V278, P34743, DOI 10.1074/jbc.C300249200
   Zhang PJ, 2007, EMBO J, V26, P1831, DOI 10.1038/sj.emboj.7601602
   Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298
   Zhou W, 2008, MOL CELL, V29, P69, DOI 10.1016/j.molcel.2007.11.002
NR 43
TC 44
Z9 49
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD MAY 1
PY 2011
VL 71
IS 9
BP 3422
EP 3431
DI 10.1158/0008-5472.CAN-10-3670
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 756NV
UT WOS:000290020400025
PM 21531767
OA Bronze
DA 2025-01-12
ER

PT J
AU Chase, A
   Cross, NCP
AF Chase, Andrew
   Cross, Nicholas C. P.
TI Aberrations of <i>EZH2</i> in Cancer
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID POLYCOMB-GROUP PROTEIN; METHYLTRANSFERASE GENE EZH2; HEMATOPOIETIC STEM;
   SOMATIC MUTATIONS; INCREASED EXPRESSION; DNA; CELLS; TRANSFORMATION;
   PROLIFERATION; OCCUPANCY
AB Control of gene expression is exerted at a number of different levels, one of which is the accessibility of genes and their controlling elements to the transcriptional machinery. Accessibility is dictated broadly by the degree of chromatin compaction, which is influenced in part by polycomb group proteins. EZH2, together with SUZ12 and EED, forms the polycomb repressive complex 2 (PRC2), which catalyzes trimethylation of histone H3 lysine 27 (H3K27me3). PRC2 may recruit other polycomb complexes, DNA methyltransferases, and histone deacetylases, resulting in additional transcriptional repressive marks and chromatin compaction at key developmental loci. Overexpression of EZH2 is a marker of advanced and metastatic disease in many solid tumors, including prostate and breast cancer. Mutation of EZH2 Y641 is described in lymphoma and results in enhanced activity, whereas inactivating mutations are seen in poor prognosis myeloid neoplasms. No histone demethylating agents are currently available for treatment of patients, but 3-deazaneplanocin (DZNep) reduces EZH2 levels and H3K27 trimethylation, resulting in reduced cell proliferation in breast and prostate cancer cells in vitro. Furthermore, synergistic effects are seen for combined treatment with DNA demethylating agents and histone deacetylation inhibitors, opening up the possibility of refined epigenetic treatments in the future. Clin Cancer Res; 17(9); 2613-8. (C)2011 AACR.
C1 [Chase, Andrew] Salisbury Dist Hosp, Wessex Reg Genet Lab, Salisbury SP2 8BJ, Wilts, England.
   Univ Southampton, Fac Med, Div Human Genet, Southampton SO9 5NH, Hants, England.
C3 Salisbury District Hospital; University of Southampton
RP Chase, A (通讯作者)，Salisbury Dist Hosp, Wessex Reg Genet Lab, Salisbury SP2 8BJ, Wilts, England.
EM achase@soton.ac.uk
RI Cross, Nicholas/B-4817-2009
OI Cross, Nicholas/0000-0001-5481-2555; Chase, Andrew/0000-0001-6617-9953
CR Arisan S, 2005, UROL INT, V75, P252, DOI 10.1159/000087804
   Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Cao P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-108
   Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621
   Garrick D, 2008, BLOOD, V112, P3889, DOI 10.1182/blood-2008-06-161901
   Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Koontz JI, 2001, P NATL ACAD SCI USA, V98, P6348, DOI 10.1073/pnas.101132598
   Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102
   Landeira D, 2011, TRENDS CELL BIOL, V21, P74, DOI 10.1016/j.tcb.2010.10.004
   Lessard J, 1999, GENE DEV, V13, P2691, DOI 10.1101/gad.13.20.2691
   Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143
   Majewski IJ, 2010, BLOOD, V116, P731, DOI 10.1182/blood-2009-12-260760
   Matsukawa Y, 2006, CANCER SCI, V97, P484, DOI 10.1111/j.1349-7006.2006.00203.x
   McGarvey KM, 2007, CANCER RES, V67, P5097, DOI 10.1158/0008-5472.CAN-06-2029
   Mohd-Sarip A, 2002, MOL CELL BIOL, V22, P7473, DOI 10.1128/MCB.22.21.7473-7483.2002
   Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518
   Nikoloski G, 2010, NAT GENET, V42, P665, DOI 10.1038/ng.620
   Oguro H, 2006, J EXP MED, V203, P2247, DOI 10.1084/jem.20052477
   Oguro H, 2010, CELL STEM CELL, V6, P279, DOI 10.1016/j.stem.2010.01.005
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Peng JC, 2009, CELL, V139, P1290, DOI 10.1016/j.cell.2009.12.002
   Raman JD, 2005, CLIN CANCER RES, V11, P8570, DOI 10.1158/1078-0432.CCR-05-1047
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Rush Margaret, 2009, Epigenetics, V4, P404
   Sarma K, 2008, MOL CELL BIOL, V28, P2718, DOI 10.1128/MCB.02017-07
   Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Shen XH, 2009, CELL, V139, P1303, DOI 10.1016/j.cell.2009.12.003
   Sneeringer CJ, 2010, P NATL ACAD SCI USA, V107, P20980, DOI 10.1073/pnas.1012525107
   Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531
   Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002
   van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602
   Van Dessel N, 2010, NUCLEIC ACIDS RES, V38, P7500, DOI 10.1093/nar/gkq643
   van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wang L, 2004, MOL CELL, V14, P637, DOI 10.1016/j.molcel.2004.05.009
   Watanabe H, 2008, CANCER CELL INT, V8, DOI 10.1186/1475-2867-8-15
   Weikert S, 2005, INT J MOL MED, V16, P349
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
NR 44
TC 451
Z9 513
U1 4
U2 62
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAY 1
PY 2011
VL 17
IS 9
BP 2613
EP 2618
DI 10.1158/1078-0432.CCR-10-2156
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 757NH
UT WOS:000290093600003
PM 21367748
OA Bronze
DA 2025-01-12
ER

PT J
AU Stefansson, OA
   Jonasson, JG
   Olafsdottir, K
   Hilmarsdottir, H
   Olafsdottir, G
   Esteller, M
   Johannsson, OT
   Eyfjord, JE
AF Stefansson, Olafur Andri
   Jonasson, Jon Gunnlaugur
   Olafsdottir, Kristrun
   Hilmarsdottir, Holmfridur
   Olafsdottir, Gudridur
   Esteller, Manel
   Johannsson, Oskar Thor
   Eyfjord, Jorunn Erla
TI CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring
   events in basal/triple-negative breast cancer
SO EPIGENETICS
LA English
DT Article
DE BRCA1; methylation; epigenetics; triple negative; breast cancer;
   retionblastoma tumor suppressor gene; pRb; p16
ID SPORADIC BREAST; PROMOTER METHYLATION; OVARIAN-CANCER; MUTATION; GENE;
   EXPRESSION; TUMORS; POPULATION; POLYMERASE; CANDIDATE
AB Triple-negative breast cancer (TNBC) occurs in approximately 15% of all breast cancer patients, and the incidence of TNBC is greatly increased in BRCA1 mutation carriers. This study aimed to assess the impact of BRCA1 promoter methylation with respect to breast cancer subtypes in sporadic disease. Tissue microarrays (TMAs) were constructed representing tumors from 303 patients previously screened for BRCA1 germline mutations, of which a subset of 111 sporadic tumors had previously been analyzed with respect to BRCA1 methylation. Additionally, a set of eight tumors from BRCA1 mutation carriers were included on the TMAs. Expression analysis was performed on TMAs by immunohistochemistry (IHC) for BRCA1, pRb, p16, p53, PTEN, ER, PR, HER2, CK5/6, CK8, CK18, EGFR, MUC1, and Ki-67. Data on BRCA1 aberrations and IHC expression was examined with respect to breast cancer-specific survival. The results demonstrate that CpG island hypermethylation of BRCA1 significantly associates with the basal/triple-negative subtype. Low expression of pRb, and high/intense p16, were associated with BRCA1 promoter hypermethylation, and the same effects were seen in BRCA1 mutated tumors. The expression patterns of BRCA1, pRb, p16 and PTEN were highly correlated, and define a subgroup of TNBCs characterized by BRCA1 aberrations, high Ki-67 (>= 40%) and favorable disease outcome. In conclusion, our findings demonstrate that epigenetic inactivation of the BRCA1 gene associates with RB/p16 dysfunction in promoting TNBCs. The clinical implications relate to the potential use of targeted treatment based on PARP inhibitors in sporadic TNBCs, wherein CpG island hypermethylation of BRCA1 represents a potential marker of therapeutic response.
C1 [Stefansson, Olafur Andri; Jonasson, Jon Gunnlaugur; Hilmarsdottir, Holmfridur; Eyfjord, Jorunn Erla] Univ Iceland, Fac Med, Canc Res Lab, IS-101 Reykjavik, Iceland.
   [Jonasson, Jon Gunnlaugur; Olafsdottir, Kristrun] Landspitali Univ Hosp, Dept Pathol, Hringbraut, Iceland.
   [Jonasson, Jon Gunnlaugur; Olafsdottir, Gudridur] Iceland Canc Registry, Reykjavik, Iceland.
   [Esteller, Manel] Bellvitge Biomed Res Inst, Canc Epigenet & Biol Program PEBC, Barcelona, Catalonia, Spain.
   [Esteller, Manel] ICREA, Barcelona, Catalonia, Spain.
C3 University of Iceland; Landspitali National University Hospital;
   Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); ICREA
RP Eyfjord, JE (通讯作者)，Univ Iceland, Fac Med, Canc Res Lab, IS-101 Reykjavik, Iceland.
EM jorunne@hi.is
RI ; Esteller, Manel/L-5956-2014
OI Hilmarsdottir, Holmfridur/0000-0003-1040-8125; Esteller,
   Manel/0000-0003-4490-6093; Jonasson, Jon G./0000-0002-2635-5032
FU Eimskipafelag University; Minningarsjodur Bergthoru Magnusdottur &
   Jakobs J Bjarnasonar; Gongum Saman; Icelandic Centre for Research
   RANNIS; University of Iceland; ICREA Funding Source: Custom
FX The authors would like to thank The Icelandic Cancer Registry for their
   support in providing data on clinical parameters and patient survival.
   This work was funded by Eimskipafelag University Fund (O.A.S.),
   Minningarsjodur Bergthoru Magnusdottur & Jakobs J Bjarnasonar (O.A.S.),
   Gongum Saman (O.A.S.), Icelandic Centre for Research RANNIS (O.A.S.,
   J.G.J., O.T.J., J.E.E.), The University of Iceland Research Fund
   (O.A.S., J.E.E.).
CR ANDERS CK, CLIN CANC RES, V16, P4702
   Annunziata CM, 2010, CLIN CANCER RES, V16, P4517, DOI 10.1158/1078-0432.CCR-10-0526
   Bergthorsson JT, 1998, HUM MUTAT, pS195
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509
   Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658
   Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082
   Chenevix-Trench G, 2006, CANCER RES, V66, P2019, DOI 10.1158/0008-5472.CAN-05-3546
   Colleoni M, 2004, CLIN CANCER RES, V10, P6622, DOI 10.1158/1078-0432.CCR-04-0380
   Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050
   FOULKES WD, N ENGL J MED, V363, P1938
   FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630
   Gauthier ML, 2007, CANCER CELL, V12, P479, DOI 10.1016/j.ccr.2007.10.017
   Gudmundsdottir K, 2006, ONCOGENE, V25, P5864, DOI 10.1038/sj.onc.1209874
   Herschkowitz JI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2142
   Holstege H, 2009, CANCER RES, V69, P3625, DOI 10.1158/0008-5472.CAN-08-3426
   Kassam F, 2009, CLIN BREAST CANCER, V9, P29, DOI 10.3816/CBC.2009.n.005
   Lakhani SR, 2005, CLIN CANCER RES, V11, P5175, DOI 10.1158/1078-0432.CCR-04-2424
   Liao CC, 2010, J BIOL CHEM, V285, P33134, DOI 10.1074/jbc.M110.143461
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8
   Melchor L, 2008, ONCOGENE, V27, P3165, DOI 10.1038/sj.onc.1210975
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220
   OSHAUGHNESSY J, N ENGL J MED, V364, P205
   PRAT A, BREAST CANC RES, V12, P68
   Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003
   Rakha EA, 2008, HUM PATHOL, V39, P857, DOI 10.1016/j.humpath.2007.10.011
   Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013
   Saal LH, 2008, NAT GENET, V40, P102, DOI 10.1038/ng.2007.39
   Schneider BP, 2008, CLIN CANCER RES, V14, P8010, DOI 10.1158/1078-0432.CCR-08-1208
   Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   STEFANSSON OA, 2009, BREAST CANCER RES, V11, P47
   Thorlacius S, 1997, AM J HUM GENET, V60, P1079
   Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117
   Tryggvadottir L, 2006, JNCI-J NATL CANCER I, V98, P116, DOI 10.1093/jnci/djj012
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457
   Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014
   van Beers EH, 2005, CANCER RES, V65, P822
   VEECK J, J CLIN ONCOL, V28, P563
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
NR 46
TC 82
Z9 101
U1 0
U2 14
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD MAY
PY 2011
VL 6
IS 5
BP 638
EP 649
DI 10.4161/epi.6.5.15667
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 758YH
UT WOS:000290203600014
PM 21593597
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Dvorak, HF
   Weaver, VM
   Tlsty, TD
   Bergers, G
AF Dvorak, Harold F.
   Weaver, Valerie M.
   Tlsty, Thea D.
   Bergers, Gabriele
TI Tumor Microenvironment and Progression
SO JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Article
DE angiogenesis; mechano-biology; patterning
ID HUMAN MAMMARY EPITHELIA; MESENCHYMAL TRANSITION; VESSEL FORMATION;
   BLOOD-VESSELS; GROWTH-FACTOR; VEGF-A; ANGIOGENESIS; CANCER; METHYLATION;
   INVASION
AB Tumor blood vessels are heterogeneous, of at least six distinct types, are induced primarily by vascular endothelial growth factor-A (VEGF-A), and provide a potentially useful therapeutic target. Breast cancer is characterized by changes in the microenvironment that result in altered tensional homeostasis. Also, breast cancers arise as the result of epigenetic as well as genetic changes. Tumor blood vessel pericytes result, in part, from bone marrow precursor cells, and VEGF is a negative regulator of glioblastoma tumor cell invasion. J. Surg. Oncol. 2011;103:468-474. (C) 2011 Wiley-Liss, Inc.
C1 [Dvorak, Harold F.] Harvard Univ, Dept Pathol, Sch Med, Ctr Vasc Biol Res,Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
   [Weaver, Valerie M.] Univ Calif San Francisco, Dept Surg & Anat, Ctr Bioengn & Tissue Regenerat, San Francisco, CA 94143 USA.
   [Tlsty, Thea D.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA USA.
   [Bergers, Gabriele] Univ Calif San Francisco, Dept Neurol Surg & Anat, San Francisco, CA 94143 USA.
C3 Harvard University; Harvard Medical School; Beth Israel Deaconess
   Medical Center; University of California System; University of
   California San Francisco; University of California System; University of
   California San Francisco; University of California System; University of
   California San Francisco
RP Dvorak, HF (通讯作者)，Harvard Univ, Dept Pathol, Sch Med, Ctr Vasc Biol Res,Beth Israel Deaconess Med Ctr, 330 Brookline Ave,RN227C, Boston, MA 02215 USA.
EM hdvorak@bidmc.harvard.edu
OI Bergers, Gabriele/0000-0003-3545-5171; Weaver, Valerie
   marie/0000-0003-4786-6752
FU U.S. Public Health Service [HL-64402, P01 CA92644]; National Foundation
   for Cancer Research; US Department of Defense [PSOC U54CA143836-01, DOD
   W81XWH-05-1-0330]; Susan G. Komen Foundation [PDF124906]; National
   Cancer Institute [T32 CA009043]; Department of Defense [BC023982];
   National Institutes of Health National Cancer Institute [CA097214,
   CA122024, PS-OC U54]; U.S. National Cancer Institute [R01 CA113382, R01
   CA109390]
FX Grant sponsor: U.S. Public Health Service; Grant numbers: HL-64402, P01
   CA92644; Grant sponsor: National Foundation for Cancer Research; Grant
   sponsor: US Department of Defense; Grant numbers: PSOC U54CA143836-01,
   DOD W81XWH-05-1-0330; Grant sponsor: Susan G. Komen Foundation
   Postdoctoral Award; Grant number: PDF124906; Grant sponsor: National
   Cancer Institute Institutional Training; Grant number: T32 CA009043;
   Grant sponsor: Department of Defense Breast Cancer Research Program
   Concept Award; Grant number: BC023982; Grant sponsor: National
   Institutes of Health National Cancer Institute; Grant numbers: CA097214,
   CA122024, PS-OC U54; Grant sponsor: U.S. National Cancer Institute;
   Grant numbers: R01 CA113382, R01 CA109390.
CR Berger M.S., 1999, GLIOMAS
   Bergers G, 2005, NEURO-ONCOLOGY, V7, P452, DOI 10.1215/S1152851705000232
   Blouw B, 2003, CANCER CELL, V4, P133, DOI 10.1016/S1535-6108(03)00194-6
   Brat DJ, 2004, CANCER RES, V64, P920, DOI 10.1158/0008-5472.CAN-03-2073
   Butcher DT, 2009, NAT REV CANCER, V9, P108, DOI 10.1038/nrc2544
   Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005
   Chang SH, 2009, CANCER RES, V69, P4537, DOI 10.1158/0008-5472.CAN-08-4539
   Crawford YG, 2004, CANCER CELL, V5, P263, DOI 10.1016/S1535-6108(04)00023-6
   Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034
   Du R, 2008, NEURO-ONCOLOGY, V10, P254, DOI 10.1215/15228517-2008-001
   Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105
   Dvorak H F., 2007, Endothelial Biomedicine, P1457
   Dvorak HF, 2003, AM J PATHOL, V162, P1747, DOI 10.1016/S0002-9440(10)64309-X
   Engler AJ, 2009, SCIENCE, V324, P208, DOI 10.1126/science.1170107
   Gerhardt H, 2003, CELL TISSUE RES, V314, P15, DOI 10.1007/s00441-003-0745-x
   Holash J, 2006, CANCER METAST REV, V25, P243, DOI 10.1007/s10555-006-8504-6
   Holst CR, 2003, CANCER RES, V63, P1596
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Jain RK, 2008, NAT REV CANCER, V8, P309, DOI 10.1038/nrc2346
   Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996
   Nagy JA, 2009, BRIT J CANCER, V100, P865, DOI 10.1038/sj.bjc.6604929
   Nagy JA, 2007, ANNU REV PATHOL-MECH, V2, P251, DOI 10.1146/annurev.pathol.2.010506.134925
   Pàez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027
   PAKU S, 1991, LAB INVEST, V65, P334
   Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010
   Pettersson A, 2000, LAB INVEST, V80, P99, DOI 10.1038/labinvest.3780013
   Reynolds PA, 2006, J BIOL CHEM, V281, P24790, DOI 10.1074/jbc.M604175200
   Shih SC, 2009, CANCER RES, V69, P3272, DOI 10.1158/0008-5472.CAN-08-4886
   Song S, 2005, NAT CELL BIOL, V7, P870, DOI 10.1038/ncb1288
   SWAYNE GTG, 1989, INT J MICROCIRC, V8, P25
   Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224
NR 31
TC 154
Z9 180
U1 2
U2 28
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0022-4790
J9 J SURG ONCOL
JI J. Surg. Oncol.
PD MAY 1
PY 2011
VL 103
IS 6
SI SI
BP 468
EP 474
DI 10.1002/jso.21709
PG 7
WC Oncology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Surgery
GA 749QD
UT WOS:000289482800003
PM 21480238
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Hoon, DSB
   Ferris, R
   Tanaka, R
   Chong, KK
   Alix-Panabières, C
   Pantel, K
AF Hoon, Dave S. B.
   Ferris, Robert
   Tanaka, Ryo
   Chong, Kelly K.
   Alix-Panabieres, Catherine
   Pantel, Klaus
TI Molecular Mechanisms of Metastasis
SO JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Article
DE chemokine receptor; CTC; methylation; microRNA
ID SQUAMOUS-CELL CARCINOMA; CIRCULATING TUMOR-CELLS; LYMPH-NODE METASTASIS;
   CHEMOKINE RECEPTOR CXCR4; BREAST-CANCER PATIENTS; ISLAND METHYLATOR
   PHENOTYPE; MALIGNANT-MELANOMA CELLS; NF-KAPPA-B; PROSTATE-CANCER;
   GASTRIC-CANCER
AB The mechanism of metastasis is a complex set of events that build upon each other to achieve successful growth in organ sites beyond the primary tumor. The cumulative events for metastasis of different cancers have both common and specific cancer specific events. This review discusses several key factors in different cancers that are responsible in metastasis, which includes epigenetic regulation of tumor suppressor genes, functional activity of tumor-related chemokine receptors, and circulating tumor cells. J. Surg. Oncol. 2011;103:508-517. (C) 2011 Wiley-Liss, Inc.
C1 [Hoon, Dave S. B.; Tanaka, Ryo; Chong, Kelly K.] John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA 90404 USA.
   [Ferris, Robert] Univ Pittsburgh, Dept Otolaryngol, Inst Canc, Pittsburgh, PA 15260 USA.
   [Ferris, Robert] Univ Pittsburgh, Inst Canc, Dept Immunol, Pittsburgh, PA USA.
   [Alix-Panabieres, Catherine] St Eloi Hosp, Univ Med Ctr, Inst Res Biotherapy, Lab Rare Human Circulating Cells Detect, Montpellier, France.
   [Alix-Panabieres, Catherine] Univ Inst Clin Res UM1 EA2415, Montpellier, France.
   [Pantel, Klaus] Univ Med Ctr Hamburg, Ctr Med Expt, Inst Tumor Biol, Hamburg, Germany.
C3 John Wayne Cancer Institute; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); University of Pittsburgh; Universite
   de Montpellier; CHU de Montpellier; Universite de Montpellier;
   University of Hamburg; University Medical Center Hamburg-Eppendorf
RP Hoon, DSB (通讯作者)，John Wayne Canc Inst, Dept Mol Oncol, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.
EM hoon@jwci.org
RI Chong, Kelly/JXN-8770-2024; ALIX-PANABIERES, Catherine/AAC-1773-2019;
   Hoon, Dave/C-7146-2018
OI Hoon, Dave/0000-0003-1915-3683; Alix-Panabieres, Prof
   Catherine/0000-0002-6401-2903
FU Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Grant
   sponsor: Melanoma Research Alliance [R01 115902, P01 CA029605]; National
   Institutes of Health, National Cancer Institute
FX Grant sponsor: Dr. Miriam and Sheldon G. Adelson Medical Research
   Foundation; Grant sponsor: Melanoma Research Alliance; Grant number: R01
   115902; Grant sponsor: National Institutes of Health, National Cancer
   Institute. These studies were supported by Dr. Miriam and Sheldon G.
   Adelson Medical Research Foundation [D.H.], the Melanoma Research
   Alliance [D.H.], and Award Number P01 CA029605 [D.H.] and R01 115902
   [R.F.] from the National Institutes of Health, National Cancer
   Institute. Figures 1-3 are reprinted with permission from Kitago et al.
   [30].
CR Alix-Panabières C, 2008, CLIN CANCER RES, V14, P5013, DOI 10.1158/1078-0432.CCR-07-5125
   Almofti A, 2004, INT J ONCOL, V25, P65
   Bachelder RE, 2002, CANCER RES, V62, P7203
   Balkwill F, 2004, SEMIN CANCER BIOL, V14, P171, DOI 10.1016/j.semcancer.2003.10.003
   Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388
   Bartels CL, 2009, CLIN CHEM, V55, P623, DOI 10.1373/clinchem.2008.112805
   Bemis LT, 2008, CANCER RES, V68, P1362, DOI 10.1158/0008-5472.CAN-07-2912
   Bidard FC, 2008, CLIN CANCER RES, V14, P3306, DOI 10.1158/1078-0432.CCR-07-4749
   Budd GT, 2006, CLIN CANCER RES, V12, P6403, DOI 10.1158/1078-0432.CCR-05-1769
   Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Caramuta S, 2010, J INVEST DERMATOL, V130, P2062, DOI 10.1038/jid.2010.63
   Chuang LSH, 2010, ONCOGENE, V29, P2605, DOI 10.1038/onc.2010.88
   Cohen SJ, 2008, J CLIN ONCOL, V26, P3213, DOI 10.1200/JCO.2007.15.8923
   Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766
   Davalos V, 2010, CURR OPIN ONCOL, V22, P35, DOI 10.1097/CCO.0b013e328333dcbb
   de Maat MFG, 2008, J CLIN ONCOL, V26, P2327, DOI 10.1200/JCO.2007.14.0723
   de Maat MFG, 2007, MOL CANCER RES, V5, P461, DOI 10.1158/1541-7786.MCR-06-0358
   Delilbasi CB, 2004, ORAL ONCOL, V40, P154, DOI 10.1016/S1368-8375(03)00144-1
   Dhawan P, 2002, J LEUKOCYTE BIOL, V72, P9
   Ding YZ, 2003, CLIN CANCER RES, V9, P3406
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   Fan T, 2009, GYNECOL ONCOL, V112, P185, DOI 10.1016/j.ygyno.2008.09.021
   Fordice J, 1999, ARCH OTOLARYNGOL, V125, P149, DOI 10.1001/archotol.125.2.149
   Garzon R, 2009, ANNU REV MED, V60, P167, DOI [10.1146/annurev.med.59.053006.104707, 10.1146/annurev.pathol.4.110807.092222]
   Gaur A, 2007, CANCER RES, V67, P2456, DOI 10.1158/0008-5472.CAN-06-2698
   Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112
   Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Humrich JY, 2006, IMMUNOLOGY, V117, P238, DOI 10.1111/j.1365-2567.2005.02292.x
   Igoucheva O, 2009, BIOCHEM BIOPH RES CO, V379, P790, DOI 10.1016/j.bbrc.2008.12.152
   Ishikawa T, 2006, INT J ONCOL, V28, P61
   Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755
   Ito Y, 2008, ADV CANCER RES, V99, P33, DOI 10.1016/S0065-230X(07)99002-8
   Javed A, 2005, P NATL ACAD SCI USA, V102, P1454, DOI 10.1073/pnas.0409121102
   Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025
   Kim WJ, 2005, CANCER RES, V65, P9347, DOI 10.1158/0008-5472.CAN-05-1647
   Kitago M, 2009, CLIN CANCER RES, V15, P2988, DOI 10.1158/1078-0432.CCR-08-3172
   Kulbe H, 2005, CANCER RES, V65, P10355, DOI 10.1158/0008-5472.CAN-05-0957
   Kusano M, 2006, CANCER-AM CANCER SOC, V106, P1467, DOI 10.1002/cncr.21789
   Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6
   Liotta LA, 2001, NATURE, V410, P24, DOI 10.1038/35065180
   Lu HT, 2006, MOL CANCER RES, V4, P221, DOI 10.1158/1541-7786.MCR-05-0261
   Lu J, 2010, INT J CANCER, V126, P669, DOI 10.1002/ijc.24814
   Ma ZH, 2009, J MOL DIAGN, V11, P420, DOI 10.2353/jmoldx.2009.090041
   Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Mashino K, 2002, CANCER RES, V62, P2937
   Mburu YK, 2006, IMMUNOL RES, V36, P61, DOI 10.1385/IR:36:1:61
   Miyazaki H, 2006, ORAL ONCOL, V42, P240, DOI 10.1016/j.oraloncology.2005.07.006
   Mori T, 2005, CANCER RES, V65, P1800, DOI 10.1158/0008-5472.CAN-04-3531
   Müller DW, 2008, ONCOGENE, V27, P6698, DOI 10.1038/onc.2008.282
   Mueller DW, 2009, BRIT J CANCER, V101, P551, DOI 10.1038/sj.bjc.6605204
   Mueller DW, 2009, J INVEST DERMATOL, V129, P1740, DOI 10.1038/jid.2008.452
   Muller A, 2006, INT J CANCER, V118, P2147, DOI 10.1002/ijc.21514
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Nagrath S, 2007, NATURE, V450, P1235, DOI 10.1038/nature06385
   Ohta M, 2002, INT J CANCER, V102, P220, DOI 10.1002/ijc.10705
   Onoue T, 2006, INT J ONCOL, V29, P1133
   PAGET S, 1989, CANCER METAST REV, V8, P98
   PANTEL K, AM ASS CANC RES 101, P179
   Pantel K, 2008, NAT REV CANCER, V8, P329, DOI 10.1038/nrc2375
   Pantel K, 2009, NAT REV CLIN ONCOL, V6, P339, DOI 10.1038/nrclinonc.2009.44
   Pinzani P, 2006, HUM PATHOL, V37, P711, DOI 10.1016/j.humpath.2006.01.026
   Poetsch M, 2003, MELANOMA RES, V13, P29, DOI 10.1097/00008390-200302000-00006
   Richmond A, 2002, NAT REV IMMUNOL, V2, P664, DOI 10.1038/nri887
   Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004
   Riethdorf S, 2010, CLIN CANCER RES, V16, P2634, DOI 10.1158/1078-0432.CCR-09-2042
   Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217
   Samara GJ, 2004, CANCER LETT, V214, P231, DOI 10.1016/j.canlet.2004.04.035
   Satzger I, 2010, INT J CANCER, V126, P2553, DOI 10.1002/ijc.24960
   Scher HI, 2009, LANCET ONCOL, V10, P233, DOI 10.1016/S1470-2045(08)70340-1
   Scher HI, 2009, J CLIN ONCOL, V27, P1531, DOI 10.1200/JCO.2008.21.2092
   Schioppa T, 2003, J EXP MED, V198, P1391, DOI 10.1084/jem.20030267
   Schultz J, 2008, CELL RES, V18, P549, DOI 10.1038/cr.2008.45
   Schwarzenbach H, 2007, INT J CANCER, V120, P1465, DOI 10.1002/ijc.22470
   Schwarzenbach H, 2009, CLIN CANCER RES, V15, P1032, DOI 10.1158/1078-0432.CCR-08-1910
   Segura MF, 2010, CLIN CANCER RES, V16, P1577, DOI 10.1158/1078-0432.CCR-09-2721
   Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106
   Shintani S, 2004, ONCOLOGY-BASEL, V66, P316, DOI 10.1159/000078333
   Soong R, 2009, BRIT J CANCER, V100, P676, DOI 10.1038/sj.bjc.6604899
   Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874
   Takeuchi H, 2004, CLIN CANCER RES, V10, P2351, DOI 10.1158/1078-0432.CCR-03-0195
   Talasaz AH, 2009, P NATL ACAD SCI USA, V106, P3970, DOI 10.1073/pnas.0813188106
   Tanemura A, 2009, CLIN CANCER RES, V15, P1801, DOI 10.1158/1078-0432.CCR-08-1361
   Toyota M, 1999, CANCER RES, V59, P5438
   Tsunematsu T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005892
   Tucker KL, 2001, NEURON, V30, P649, DOI 10.1016/S0896-6273(01)00325-7
   Uchida D, 2003, EXP CELL RES, V290, P289, DOI 10.1016/S0014-4827(03)00344-6
   Uchida D, 2007, MOL CANCER RES, V5, P685, DOI 10.1158/1541-7786.MCR-06-0368
   Uchida DE, 2004, LAB INVEST, V84, P1538, DOI 10.1038/labinvest.3700190
   Umetani N, 2004, CLIN CANCER RES, V10, P7475, DOI 10.1158/1078-0432.CCR-04-0689
   Vucic EA, 2008, PHARMACOGENOMICS, V9, P215, DOI 10.2217/14622416.9.2.215
   Wang J, 2005, ADV OTO-RHINO-LARYNG, V62, P121
   Wang J, 2005, ONCOGENE, V24, P5897, DOI 10.1038/sj.onc.1208740
   Wang J, 2004, CANCER RES, V64, P1861, DOI 10.1158/0008-5472.CAN-03-2968
   Wang J, 2008, JNCI-J NATL CANCER I, V100, P502, DOI 10.1093/jnci/djn059
   Watanabe H, 2002, ORAL ONCOL, V38, P670, DOI 10.1016/S1368-8375(02)00006-4
   Wei DY, 2005, CANCER RES, V65, P4809, DOI 10.1158/0008-5472.CAN-04-3741
   Wiley HE, 2001, J NATL CANCER I, V93, P1638, DOI 10.1093/jnci/93.21.1638
   Wilson JL, 2006, CANCER RES, V66, P11802, DOI 10.1158/0008-5472.CAN-06-1222
   Wong NS, 2006, BREAST CANCER RES TR, V99, P63, DOI 10.1007/s10549-006-9181-4
   Young DW, 2007, NATURE, V445, P442, DOI 10.1038/nature05473
   Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028
   Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103
   Zheng S, 2007, J CHROMATOGR A, V1162, P154, DOI 10.1016/j.chroma.2007.05.064
   Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X
NR 107
TC 33
Z9 36
U1 1
U2 20
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0022-4790
J9 J SURG ONCOL
JI J. Surg. Oncol.
PD MAY 1
PY 2011
VL 103
IS 6
SI SI
BP 508
EP 517
DI 10.1002/jso.21690
PG 10
WC Oncology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Surgery
GA 749QD
UT WOS:000289482800008
PM 21480243
DA 2025-01-12
ER

PT J
AU Hill, VK
   Ricketts, C
   Bieche, I
   Vacher, S
   Gentle, D
   Lewis, C
   Maher, ER
   Latif, F
AF Hill, Victoria K.
   Ricketts, Christopher
   Bieche, Ivan
   Vacher, Sophie
   Gentle, Dean
   Lewis, Cheryl
   Maher, Eamonn R.
   Latif, Farida
TI Genome-Wide DNA Methylation Profiling of CpG Islands in Breast Cancer
   Identifies Novel Genes Associated with Tumorigenicity
SO CANCER RESEARCH
LA English
DT Article
ID ABERRANT METHYLATION; FECAL DNA; RECK; HYPERMETHYLATION; INACTIVATION;
   CLAUDIN-6; MARKER
AB Epigenetic profiling of tumor DNAs may reveal important new theranostic targets to improve prognosis and treatment of advanced cancer patients. In this study, we performed a genome-wide profile of DNA methylation patterns in sporadic breast tumors by using the HumanMethylation27 BeadChips to assess relationships between DNA methylation changes and patient tumor characteristics. The arrays identified 264 hypermethylated loci/genes present in genomic CpG islands. Hierarchical clustering based on methylation levels divided the specimens into three distinct groups, within which certain clinical features also clustered. Statistically significant differences were determined between overall methylation levels of these clusters and estrogen receptor and progesterone receptor (ER/PR) status (P = 0.001), tumor relapse (P = 0.035), and lymph node metastasis (P = 0.042). We identified several individual methylated genes associated with clinical features, including six genes (RECK, SFRP2, UAP1L1, ACADL, ITR, and UGT3A1) that showed statistical significance between methylation and relapse-free survival. Notably, the RECK gene in this group has been associated in other cancers with poorest prognosis. Among the leading relapse-associated genes and the genes associated with ER/PR status, we sequenced an independent set of paired normal/tumor breast DNA samples to confirm tumor specificity of methylation. Further, we carried out quantitative real-time reverse transcriptase PCR to confirm reduced expression in methylated tumors. Our findings suggest the utility for the DNA methylation patterns in these genes as clinically useful surrogate markers in breast cancer, as well as new molecular pathways for further investigation as therapeutic targets. Cancer Res; 71(8); 2988-99. (C)2011 AACR.
C1 [Hill, Victoria K.; Ricketts, Christopher; Gentle, Dean; Maher, Eamonn R.; Latif, Farida] Univ Birmingham, Sch Clin & Expt Med, Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England.
   [Bieche, Ivan; Vacher, Sophie] Hop Rene Huguenin, Lab Oncogenet, Inst Curie, FNCLCC, St Cloud, France.
   [Lewis, Cheryl] Univ Texas SW Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA.
C3 University of Birmingham; Rene Huguenin Hospital; UNICANCER; Universite
   PSL; Institut Curie; University of Texas System; University of Texas
   Southwestern Medical Center Dallas
RP Latif, F (通讯作者)，Univ Birmingham, Sch Clin & Expt Med, Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England.
EM f.latif@bham.ac.uk
RI Ricketts, Christopher/AAV-9580-2020; MAHER, EAMONN/A-9507-2008; Bieche,
   Ivan/O-7399-2017
OI MAHER, EAMONN/0000-0002-6226-6918; VACHER, Sophie/0000-0002-0042-6023;
   Bieche, Ivan/0000-0002-2430-5429
FU Breast Cancer Campaign and Cancer Research UK
FX F. Latif's laboratory was funded by Breast Cancer Campaign and Cancer
   Research UK.
CR Anderton JA, 2008, NEURO-ONCOLOGY, V10, P981, DOI 10.1215/15228517-2008-048
   Chang HC, 2007, CANCER SCI, V98, P169, DOI 10.1111/j.1349-7006.2006.00367.x
   Christensen BC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001043
   Coughlin SS, 2009, CANCER EPIDEMIOL, V33, P315, DOI 10.1016/j.canep.2009.10.003
   Esteller M, 1998, CANCER RES, V58, P4515
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Evron E, 2001, CANCER RES, V61, P2782
   Gaudet MM, 2009, INT J CANCER, V124, P1716, DOI 10.1002/ijc.23919
   Griffiths EA, 2010, LEUKEMIA LYMPHOMA, V51, P1711, DOI 10.3109/10428194.2010.496505
   Hill VK, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-51
   Jang JY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-262
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Li LA, 2010, HUM MOL GENET, V19, P4273, DOI 10.1093/hmg/ddq351
   Long NK, 2008, ORAL ONCOL, V44, P1052, DOI 10.1016/j.oraloncology.2008.02.004
   Loss LA, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-305
   Mori K, 2009, INT J ONCOL, V34, P1593, DOI 10.3892/ijo_00000289
   Müller HM, 2004, LANCET, V363, P1283, DOI 10.1016/S0140-6736(04)16002-9
   Nagasaka T, 2009, JNCI-J NATL CANCER I, V101, P1244, DOI 10.1093/jnci/djp265
   Oberwalder M, 2008, INT J COLORECTAL DIS, V23, P15, DOI 10.1007/s00384-007-0355-2
   Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9
   Osanai M, 2007, CANCER SCI, V98, P1557, DOI 10.1111/j.1349-7006.2007.00569.x
   Ramaswamy B, 2009, MOL ENDOCRINOL, V23, P176, DOI 10.1210/me.2008-0211
   Shivapurkar N, 2004, INT J CANCER, V109, P786, DOI 10.1002/ijc.20041
   Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Veeck J, 2008, CARCINOGENESIS, V29, P991, DOI 10.1093/carcin/bgn076
   Veeck J, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-83
   Virmani AK, 2001, CLIN CANCER RES, V7, P1998
   Wu Q, 2010, EUR J CANCER PREV, V19, P186, DOI 10.1097/CEJ.0b013e328337210e
   Yanagitani A, 2004, HEPATOLOGY, V40, P366, DOI 10.1002/hep.20335
NR 30
TC 133
Z9 147
U1 0
U2 15
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
IS 8
BP 2988
EP 2999
DI 10.1158/0008-5472.CAN-10-4026
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 749YL
UT WOS:000289507800019
PM 21363912
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Dewdney, SB
   Rimel, BJ
   Thaker, PH
   Thompson, DM
   Schmidt, A
   Huettner, P
   Mutch, DG
   Gao, F
   Goodfellow, PJ
AF Dewdney, Summer B.
   Rimel, B. J.
   Thaker, Premal H.
   Thompson, Dominic M., Jr.
   Schmidt, Amy
   Huettner, Phyllis
   Mutch, David G.
   Gao, Feng
   Goodfellow, Paul J.
TI Aberrant Methylation of the X-Linked Ribosomal S6 Kinase <i>RPS6KA6</i>
   (<i>RSK4</i>) in Endometrial Cancers
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID BREAST-CANCER; MICROSATELLITE INSTABILITY; FGFR2 MUTATIONS; HUMAN
   TUMORS; CARCINOMAS; EXPRESSION; GENES; CELLS; INACTIVATION; ACTIVATION
AB Purpose: Effective treatments for advanced endometrial cancer are lacking. Novel therapies that target specific pathways hold promise for better treatment outcomes with less toxicity. Mutation activation of the FGFR2/RAS/ERK pathway is important in endometrial tumorigenesis. RPS6KA6 (RSK4) is a putative tumor suppressor gene and is a target of the ERK signaling pathway. We explored the role of RSK4 in endometrial cancer.
   Experimental Design: We showed that RSK4 is expressed in normal endometrial tissue and is absent or much reduced in endometrial cancer. On the basis of previous reports on methylation in other cancers, we hypothesized that the absence of RSK4 transcript is associated with epigenetic silencing rather than mutation. We determined the methylation and expression status of RSK4 in primary endometrial cancers and cell lines and the effects of treatment with a demethylating agent. The relationship between RSK4 methylation and clinicopathologic features was assessed.
   Results: RSK4 is frequently hypermethylated in endometrial cancer cells lines and in primary endometrial cancer compared with normal endometrial tissue. RSK4 methylation was significantly associated with tumor grade, with higher grade tumors having lower levels of methylation (P = 0.03). RSK4 methylation levels were not associated with other clinical variables. We did find that RSK4 methylation was significantly correlated with expression in primary endometrial tumors and in cell lines. Reactivation of RSK4 by 5-azacytidine was successfully performed showing 8- to more than 1,200-fold increases in transcript levels.
   Conclusion: RSK4 appears to be epigenetically silenced in endometrial cancer as evidenced by hypermethylation. Its role as a suppressor in endometrial cancer, however, remains uncertain. Clin Cancer Res; 17(8); 2120-9. (C) 2011 AACR.
C1 [Dewdney, Summer B.; Rimel, B. J.; Thaker, Premal H.; Mutch, David G.; Goodfellow, Paul J.] Washington Univ, Sch Med, Div Gynecol Oncol, Dept Obstet & Gynecol, St Louis, MO 63110 USA.
   [Thompson, Dominic M., Jr.; Schmidt, Amy; Goodfellow, Paul J.] Washington Univ, Sch Med, Dept Surg, Div Endocrine & Oncol Surg, St Louis, MO 63110 USA.
   [Huettner, Phyllis] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.
   [Gao, Feng] Washington Univ, Sch Med, Div Biostat, St Louis, MO 63110 USA.
   [Gao, Feng] Siteman Canc Ctr, St Louis, MO 63110 USA.
C3 Washington University (WUSTL); Washington University (WUSTL); Washington
   University (WUSTL); Washington University (WUSTL); Siteman Cancer Center
RP Dewdney, SB (通讯作者)，Washington Univ, Sch Med, Div Gynecol Oncol, Dept Obstet & Gynecol, 660 S Euclid,Campus Box 8064, St Louis, MO 63110 USA.
EM dewdneys@wudosis.wustl.edu
RI Gao, Feng/KLE-0680-2024
OI Gao, Feng/0000-0002-1425-1623
FU National Institutes of Health [NIH CAO71754]
FX Funding was supplied through National Institutes of Health grant NIH
   CAO71754.
CR Black D, 2006, J CLIN ONCOL, V24, P1745, DOI 10.1200/JCO.2005.04.1574
   Byron SA, 2008, CANCER RES, V68, P6902, DOI 10.1158/0008-5472.CAN-08-0770
   Byron SA, 2009, FUTURE ONCOL, V5, P27, DOI 10.2217/14796694.5.1.27
   Carrel L, 2005, NATURE, V434, P400, DOI 10.1038/nature03479
   Carriere A, 2008, FRONT BIOSCI-LANDMRK, V13, P4258, DOI 10.2741/3003
   Davies H, 2005, CANCER RES, V65, P7591, DOI 10.1158/0008-5472.CAN-05-1855
   DENG G, 1994, CANCER RES, V54, P499
   Dümmler BA, 2005, J BIOL CHEM, V280, P13304, DOI 10.1074/jbc.M408194200
   Dutt A, 2008, P NATL ACAD SCI USA, V105, P8713, DOI 10.1073/pnas.0803379105
   Frödin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1
   Hecht JL, 2006, J CLIN ONCOL, V24, P4783, DOI 10.1200/JCO.2006.06.7173
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Lleonart ME, 2006, ONCOL REP, V16, P603
   López-Vicente L, 2009, CLIN CANCER RES, V15, P4546, DOI 10.1158/1078-0432.CCR-08-3159
   Mackay HJ, 2010, EUR J CANCER, V46, P1365, DOI 10.1016/j.ejca.2010.02.031
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Mizumoto Y, 2007, CANCER SCI, V98, P652, DOI 10.1111/j.1349-7006.2007.00445.x
   Myers AP, 2004, MOL CELL BIOL, V24, P4255, DOI 10.1128/MCB.24.10.4255-4266.2004
   Niehof M, 2005, MOL PHARMACOL, V67, P604, DOI 10.1124/mol.104.008672
   Pollock PM, 2007, ONCOGENE, V26, P7158, DOI 10.1038/sj.onc.1210529
   Ray M, 2009, SEMIN ONCOL, V36, P145, DOI 10.1053/j.seminoncol.2008.12.006
   Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013
   Shabani N, 2007, EUR J CANCER, V43, P2434, DOI 10.1016/j.ejca.2007.08.014
   Thakur A, 2005, BREAST CANCER RES TR, V93, P135, DOI 10.1007/s10549-005-4516-0
   Thakur A, 2008, CLIN CANCER RES, V14, P4427, DOI 10.1158/1078-0432.CCR-08-0458
   Thakur A, 2007, MOL CANCER RES, V5, P171, DOI 10.1158/1541-7786.MCR-06-0071
   Vincent-Salomon A, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1666
   Whitcomb BP, 2003, CLIN CANCER RES, V9, P2277
   Whitehead TD, 2005, RADIAT RES, V164, P420, DOI 10.1667/RR3446.1
   Zighelboim I, 2007, J CLIN ONCOL, V25, P2042, DOI 10.1200/JCO.2006.08.2107
   Zighelboim I, 2007, CLIN CANCER RES, V13, P2882, DOI 10.1158/1078-0432.CCR-06-2367
NR 31
TC 36
Z9 44
U1 0
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD APR 15
PY 2011
VL 17
IS 8
BP 2120
EP 2129
DI 10.1158/1078-0432.CCR-10-2668
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 750NP
UT WOS:000289555500007
PM 21372219
OA Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Ba, Y
   Yu, H
   Liu, F
   Geng, X
   Zhu, C
   Zhu, Q
   Zheng, T
   Ma, S
   Wang, G
   Li, Z
   Zhang, Y
AF Ba, Y.
   Yu, H.
   Liu, F.
   Geng, X.
   Zhu, C.
   Zhu, Q.
   Zheng, T.
   Ma, S.
   Wang, G.
   Li, Z.
   Zhang, Y.
TI Relationship of folate, vitamin B<sub>12</sub> and methylation of
   insulin-like growth factor-II in maternal and cord blood
SO EUROPEAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE folate; vitamin B-12; methylation; IGF2; cord blood
ID INTRACYTOPLASMIC SPERM INJECTION; BECKWITH-WIEDEMANN-SYNDROME; IGF-II;
   BREAST-CANCER; FOLIC-ACID; TRANSCRIPTIONAL REGULATION; PROMOTER
   METHYLATION; GENE-EXPRESSION; ASSOCIATION; RECEPTOR
AB Background/Objective: One of the speculated mechanisms underlying fetal origin hypothesis of breast cancer is the possible influence of maternal environment on epigenetic regulation, such as changes in DNA methylation of the insulin-like growth factor-2 (IGF2) gene. The aim of the study is to investigate the relationship between folate, vitamin B-12 and methylation of the IGF2 gene in maternal and cord blood.
   Subjects/Methods: We conducted a cross-sectional study to measure methylation patterns of IGF2 in promoters 2 (P2) and promoters 3 (P3).
   Results: The percentage of methylation in IGF2 P3 was higher in maternal blood than in cord blood (P<0.0001), whereas the methylation in P2 was higher in cord blood than in maternal blood (P = 0.016). P3 methylation was correlated between maternal and cord blood (P<0.0001), but not P2 (P = 0.06). The multivariate linear regression model showed that methylation patterns of both promoters in cord blood were not associated with serum folate levels in either cord or maternal blood, whereas the P3 methylation patterns were associated with serum levels of vitamin B-12 in mother's blood (mean change (MC) = -0.22, P = 0.0014). Methylation patterns in P2 of maternal blood were associated with serum levels of vitamin B-12 in mother's blood (MC = -0.23, P = 0.012), exposure to passive smoking (MC = 0.46, P = 0.034) and mother's weight gain during pregnancy (MC = 0.23, P = 0.019).
   Conclusions: The study suggests that environment influences methylation patterns in maternal blood, and then the maternal patterns influence the methylation status and levels of folate and vitamin B-12 in cord blood. European Journal of Clinical Nutrition (2011) 65, 480-485; doi:10.1038/ejcn.2010.294; published online 19 January 2011
C1 [Zhang, Y.] Yale Univ, Div Environm Hlth Sci, Sch Publ Hlth, New Haven, CT 06520 USA.
   [Ba, Y.; Liu, F.; Wang, G.; Li, Z.] Zhengzhou Univ, Sch Publ Hlth, Zhengzhou, Peoples R China.
   [Geng, X.; Zhu, Q.] Houzhai Ctr Hosp, Zhengzhou, Peoples R China.
   [Zhu, C.] Sichuan Univ, Sch Publ Hlth, Chengdu 610064, Peoples R China.
C3 Yale University; Zhengzhou University; Sichuan University
RP Zhang, Y (通讯作者)，Yale Univ, Div Environm Hlth Sci, Sch Publ Hlth, 60 Coll St, New Haven, CT 06520 USA.
EM yawei.zhang@yale.edu
FU National Center for Research Resources (NCRR), NIH [UL1 RR024139]; NHL
   roadmap for medical Research; NIH [1D43TW008323-01, 1D43TW007864-01];
   Education Department of Henan Province, China [2009A330005]
FX We thank all the participants in this study and all the doctors and
   nurses of Houzhai Center Hospital. This publication was made possible by
   CTSA Grant number UL1 RR024139 from the National Center for Research
   Resources (NCRR), a component of the NIH and NHL roadmap for medical
   Research. Its contents are solely the responsibility of the authors and
   do not necessarily represent the official view of NCRR. This research is
   also supported by Fogarty training Grants 1D43TW008323-01 and
   1D43TW007864-01 from the NIH, and by the Grant 2009A330005 from the
   Education Department of Henan Province, China.
CR BATES P, 1995, BRIT J CANCER, V72, P1189, DOI 10.1038/bjc.1995.484
   Beeghly AC, 2007, J CANCER RES CLIN, V133, P713, DOI 10.1007/s00432-007-0211-3
   Cox GF, 2002, AM J HUM GENET, V71, P162, DOI 10.1086/341096
   DeBaun MR, 2003, AM J HUM GENET, V72, P156, DOI 10.1086/346031
   Engström W, 1998, CELL PROLIFERAT, V31, P173, DOI 10.1111/j.1365-2184.1998.tb01196.x
   HOLTHUIZEN P, 1993, MOL REPROD DEV, V35, P391, DOI 10.1002/mrd.1080350412
   Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757
   LEHTI KK, 1989, EUR J CLIN NUTR, V43, P505
   Lillycrop KA, 2005, J NUTR, V135, P1382, DOI 10.1093/jn/135.6.1382
   McCann AH, 1996, HUM MOL GENET, V5, P1123, DOI 10.1093/hmg/5.8.1123
   Michels KB, 2006, INT J CANCER, V119, P2007, DOI 10.1002/ijc.22004
   Movérare-Skrtic S, 2009, ENDOCRINE, V35, P204, DOI 10.1007/s12020-009-9153-7
   NIELSEN FC, 1992, J BIOL CHEM, V267, P19404
   NIELSEN FC, 1995, SCAND J CLIN LAB INV, V55, P37
   Ong K, 2000, J CLIN ENDOCR METAB, V85, P4266, DOI 10.1210/jc.85.11.4266
   Orstavik KH, 2003, AM J HUM GENET, V72, P218, DOI 10.1086/346030
   Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554
   Sun FL, 1997, NATURE, V389, P809, DOI 10.1038/39797
   Thoradeniya T, 2006, BRIT J NUTR, V95, P511, DOI 10.1079/BJN20051590
   TRICHOPOULOS D, 1990, LANCET, V335, P939, DOI 10.1016/0140-6736(90)91000-Z
   Van den Veyver IB, 2002, ANNU REV NUTR, V22, P255, DOI 10.1146/annurev.nutr.22.010402.102932
   van Roozendaal CEP, 1998, FEBS LETT, V437, P107, DOI 10.1016/S0014-5793(98)01211-3
   VANDIJK MA, 1991, MOL CELL ENDOCRINOL, V81, P81, DOI 10.1016/0303-7207(91)90207-9
   VOBECKY JS, 1985, INT J VITAM NUTR RES, V55, P205
   Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003
   Wolff GL, 1998, FASEB J, V12, P949, DOI 10.1096/fasebj.12.11.949
   Wu GY, 2004, J NUTR, V134, P2169, DOI 10.1093/jn/134.9.2169
   Wu HK, 1997, BIOCHEM BIOPH RES CO, V235, P123, DOI 10.1006/bbrc.1997.6744
NR 28
TC 77
Z9 90
U1 0
U2 24
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0954-3007
EI 1476-5640
J9 EUR J CLIN NUTR
JI Eur. J. Clin. Nutr.
PD APR
PY 2011
VL 65
IS 4
BP 480
EP 485
DI 10.1038/ejcn.2010.294
PG 6
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 745US
UT WOS:000289193400008
PM 21245875
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Xie, LQ
   Pelz, C
   Wang, WS
   Bashar, A
   Varlamova, O
   Shadle, S
   Impey, S
AF Xie, Liangqi
   Pelz, Carl
   Wang, Wensi
   Bashar, Amir
   Varlamova, Olga
   Shadle, Sean
   Impey, Soren
TI KDM5B regulates embryonic stem cell self-renewal and represses cryptic
   intragenic transcription
SO EMBO JOURNAL
LA English
DT Article
DE chromatin; epigenetics; histone demethylase; self-renewal;
   transcriptional elongation
ID GENOME-WIDE ANALYSIS; HISTONE H3; CHROMATIN-BINDING; H3K36 METHYLATION;
   BREAST-CANCER; ES CELLS; DEMETHYLASE; PLURIPOTENCY; COMPLEX; PROTEIN
AB Although regulation of histone methylation is believed to contribute to embryonic stem cell (ESC) self-renewal, the mechanisms remain obscure. We show here that the histone H3 trimethyl lysine 4 (H3K4me3) demethylase, KDM5B, is a downstream Nanog target and critical for ESC self-renewal. Although KDM5B is believed to function as a promoter-bound repressor, we find that it paradoxically functions as an activator of a gene network associated with self-renewal. ChIP-Seq reveals that KDM5B is predominantly targeted to intragenic regions and that it is recruited to H3K36me3 via an interaction with the chromodomain protein MRG15. Depletion of KDM5B or MRG15 increases intragenic H3K4me3, increases cryptic intragenic transcription, and inhibits transcriptional elongation of KDM5B target genes. We propose that KDM5B activates self-renewal-associated gene expression by repressing cryptic initiation and maintaining an H3K4me3 gradient important for productive transcriptional elongation. The EMBO Journal (2011) 30, 1473-1484. doi:10.1038/emboj.2011.91; Published online 29 March 2011 Subject Categories: chromatin & transcription; development
C1 [Xie, Liangqi; Pelz, Carl; Wang, Wensi; Bashar, Amir; Varlamova, Olga; Shadle, Sean; Impey, Soren] Oregon Hlth & Sci Univ, Oregon Stem Cell Ctr, Dept Pediat, Dept Cell & Dev Biol, Portland, OR 97239 USA.
C3 Oregon Health & Science University
RP Impey, S (通讯作者)，Oregon Hlth & Sci Univ, Oregon Stem Cell Ctr, Dept Pediat, Dept Cell & Dev Biol, 3181 SW Sam Jackson Pk Road,L321, Portland, OR 97239 USA.
EM impeys@ohsu.edu
CR Benevolenskaya EV, 2005, MOL CELL, V18, P623, DOI 10.1016/j.molcel.2005.05.012
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   Blackledge NP, 2010, MOL CELL, V38, P179, DOI 10.1016/j.molcel.2010.04.009
   Carrozza MJ, 2005, CELL, V123, P581, DOI 10.1016/j.cell.2005.10.023
   Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1
   Chan SW, 2001, J BIOL CHEM, V276, P28402, DOI 10.1074/jbc.M100313200
   Christensen J, 2007, CELL, V128, P1063, DOI 10.1016/j.cell.2007.02.003
   Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x
   Dehé PM, 2006, J BIOL CHEM, V281, P35404, DOI 10.1074/jbc.M603099200
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Dey BK, 2008, MOL CELL BIOL, V28, P5312, DOI 10.1128/MCB.00128-08
   Do JT, 2009, TRENDS PHARMACOL SCI, V30, P296, DOI 10.1016/j.tips.2009.03.003
   Fang R, 2010, MOL CELL, V39, P222, DOI 10.1016/j.molcel.2010.07.008
   Fejes AP, 2008, BIOINFORMATICS, V24, P1729, DOI 10.1093/bioinformatics/btn305
   Filion GJ, 2010, CELL, V143, P212, DOI 10.1016/j.cell.2010.09.009
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042
   Hayakawa T, 2007, GENES CELLS, V12, P811, DOI 10.1111/j.1365-2443.2007.01089.x
   Hayami S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-59
   Impey S, 2004, CELL, V119, P1041, DOI 10.1016/S0092-8674(04)01159-6
   Joshi AA, 2005, MOL CELL, V20, P971, DOI 10.1016/j.molcel.2005.11.021
   Keogh MC, 2005, CELL, V123, P593, DOI 10.1016/j.cell.2005.10.025
   Klose RJ, 2007, CELL, V128, P889, DOI 10.1016/j.cell.2007.02.013
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1
   Lee G, 2009, P NATL ACAD SCI USA, V106, P4701, DOI 10.1073/pnas.0900751106
   Lee JS, 2007, MUTAT RES-FUND MOL M, V618, P130, DOI 10.1016/j.mrfmmm.2006.08.014
   Lee N, 2007, NAT STRUCT MOL BIOL, V14, P341, DOI 10.1038/nsmb1216
   Lee N, 2009, MOL CELL BIOL, V29, P1401, DOI 10.1128/MCB.01643-08
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Liang J, 2008, NAT CELL BIOL, V10, P731, DOI 10.1038/ncb1736
   Lloret-Llinares M, 2008, NUCLEIC ACIDS RES, V36, P2852, DOI 10.1093/nar/gkn098
   Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760
   Lopez-Bigas N, 2008, MOL CELL, V31, P520, DOI 10.1016/j.molcel.2008.08.004
   Lu PJ, 1999, J BIOL CHEM, V274, P15633, DOI 10.1074/jbc.274.22.15633
   Luco RF, 2010, SCIENCE, V327, P996, DOI 10.1126/science.1184208
   Maherali N, 2007, CELL STEM CELL, V1, P55, DOI 10.1016/j.stem.2007.05.014
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3
   Moshkin YM, 2009, MOL CELL, V35, P782, DOI 10.1016/j.molcel.2009.07.020
   Nagalakshmi U, 2008, SCIENCE, V320, P1344, DOI 10.1126/science.1158441
   Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3
   Nicolas E, 2007, NAT STRUCT MOL BIOL, V14, P372, DOI 10.1038/nsmb1239
   NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0
   Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199
   Niwa H, 2007, GENE DEV, V21, P2071, DOI 10.1101/gad.1615707
   Niwa H, 2007, DEVELOPMENT, V134, P635, DOI 10.1242/dev.02787
   Pasini D, 2008, GENE DEV, V22, P1345, DOI 10.1101/gad.470008
   Pinskaya M, 2009, EMBO J, V28, P1697, DOI 10.1038/emboj.2009.108
   Rahl PB, 2010, CELL, V141, P432, DOI 10.1016/j.cell.2010.03.030
   Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020
   Secombe J, 2007, GENE DEV, V21, P537, DOI 10.1101/gad.1523007
   Shima N, 2007, NAT GENET, V39, P93, DOI 10.1038/ng1936
   Silva J, 2009, CELL, V138, P722, DOI 10.1016/j.cell.2009.07.039
   Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100
   USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P
   Vermeulen M, 2007, CELL, V131, P58, DOI 10.1016/j.cell.2007.08.016
   Vermeulen M, 2010, CELL, V142, P967, DOI 10.1016/j.cell.2010.08.020
   Vezzoli A, 2010, NAT STRUCT MOL BIOL, V17, P617, DOI 10.1038/nsmb.1797
   Wang GG, 2007, NAT CELL BIOL, V9, P804, DOI 10.1038/ncb1608
   Wang GG, 2009, NATURE, V459, P847, DOI 10.1038/nature08036
   Xiang Y, 2007, P NATL ACAD SCI USA, V104, P19226, DOI 10.1073/pnas.0700735104
   Yamane K, 2007, MOL CELL, V25, P801, DOI 10.1016/j.molcel.2007.03.001
   Zhang P, 2006, NUCLEIC ACIDS RES, V34, P6621, DOI 10.1093/nar/gkl989
NR 64
TC 128
Z9 155
U1 0
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
PD APR 20
PY 2011
VL 30
IS 8
BP 1473
EP 1484
DI 10.1038/emboj.2011.91
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 760EG
UT WOS:000290306300009
PM 21448134
OA Green Published
DA 2025-01-12
ER

PT J
AU Martinez-Outschoorn, UE
   Prisco, M
   Ertel, A
   Tsirigos, A
   Lin, Z
   Pavlides, S
   Wang, CW
   Flomenberg, N
   Knudsen, ES
   Howell, A
   Pestell, RG
   Sotgia, F
   Lisanti, MP
AF Martinez-Outschoorn, Ubaldo E.
   Prisco, Marco
   Ertel, Adam
   Tsirigos, Aristotelis
   Lin, Zhao
   Pavlides, Stephanos
   Wang, Chengwang
   Flomenberg, Neal
   Knudsen, Erik S.
   Howell, Anthony
   Pestell, Richard G.
   Sotgia, Federica
   Lisanti, Michael P.
TI Ketones and lactate increase cancer cell "stemness", driving recurrence,
   metastasis and poor clinical outcome in breast cancer
SO CELL CYCLE
LA English
DT Article
DE ketones; lactate; cancer stem cells; clinical outcome; recurrence;
   metastasis; personalized medicine; breast cancer; metformin; oxidative
   mitochondrial metabolism; metabologenomics
ID TUMOR-STROMA COEVOLUTION; LACTIC-ACIDOSIS; OXIDATIVE STRESS;
   GENE-EXPRESSION; ENERGY-METABOLISM; METFORMIN; FIBROBLASTS; AUTOPHAGY;
   HYPOXIA; MICROENVIRONMENT
AB Previously, we showed that high-energy metabolites (lactate and ketones) "fuel" tumor growth and experimental metastasis in an in vivo xenograft model, most likely by driving oxidative mitochondrial metabolism in breast cancer cells. To mechanistically understand how these metabolites affect tumor cell behavior, here we used genome-wide transcriptional profiling. Human breast cancer cells (MCF7) were cultured with lactate or ketones, and then subjected to transcriptional analysis (exon-array). Interestingly, our results show that treatment with these high-energy metabolites increases the transcriptional expression of gene profiles normally associated with "stemness", including genes upregulated in embryonic stem (ES) cells. Similarly, we observe that lactate and ketones promote the growth of bonafide ES cells, providing functional validation. The lactate-and ketone-induced "gene signatures" were able to predict poor clinical outcome (including recurrence and metastasis) in human breast cancer patients. Taken together, our results are consistent with the idea that lactate and ketone utilization in cancer cells promotes the "cancer stem cell" phenotype, resulting in significant decreases in patient survival. One possible mechanism by which high-energy metabolites might induce stemness is by increasing the pool of Acetyl-CoA, leading to increased histone acetylation and elevated gene expression. Thus, our results mechanistically imply that clinical outcome in breast cancer could simply be determined by epigenetics and energy metabolism, rather than by the accumulation of specific "classical" gene mutations. We also suggest that high-risk cancer patients (identified by the lactate/ketone gene signatures) could be treated with new therapeutics that target oxidative mitochondrial metabolism, such as the anti-oxidant and "mitochondrial poison" metformin. Finally, we propose that this new approach to personalized cancer medicine be termed "metabolo-genomics," which incorporates features of both (1) cell metabolism and (2) gene transcriptional profiling. This powerful new approach directly links cancer cell metabolism with clinical outcome, and suggests new therapeutic strategies for inhibiting the TCA cycle and mitochondrial oxidative phosphorylation in cancer cells.
C1 [Martinez-Outschoorn, Ubaldo E.; Prisco, Marco; Ertel, Adam; Lin, Zhao; Pavlides, Stephanos; Wang, Chengwang; Flomenberg, Neal; Knudsen, Erik S.; Pestell, Richard G.; Sotgia, Federica; Lisanti, Michael P.] Thomas Jefferson Univ, Jefferson Stem Cell Biol & Regenerat Med Ctr, Philadelphia, PA 19107 USA.
   [Martinez-Outschoorn, Ubaldo E.; Flomenberg, Neal; Knudsen, Erik S.; Pestell, Richard G.; Sotgia, Federica; Lisanti, Michael P.] Thomas Jefferson Univ, Dept Med Oncol, Philadelphia, PA 19107 USA.
   [Martinez-Outschoorn, Ubaldo E.; Prisco, Marco; Ertel, Adam; Lin, Zhao; Pavlides, Stephanos; Wang, Chengwang; Pestell, Richard G.; Sotgia, Federica; Lisanti, Michael P.] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA.
   [Tsirigos, Aristotelis] IBM Thomas J Watson Res Ctr, Computat Genom Grp, Yorktown Hts, NY USA.
   [Pavlides, Stephanos; Lisanti, Michael P.] Postgrad Res Inst Sci Technol Environm & Med, Limassol, Cyprus.
   [Howell, Anthony; Sotgia, Federica; Lisanti, Michael P.] Univ Manchester, Manchester Breast Ctr, Manchester, Lancs, England.
   [Howell, Anthony; Sotgia, Federica; Lisanti, Michael P.] Univ Manchester, Breakthrough Breast Canc Res Unit, Paterson Inst Canc Res, Sch Canc Enabling Sci & Technol,Manchester Acad H, Manchester, Lancs, England.
C3 Thomas Jefferson University; Thomas Jefferson University; Thomas
   Jefferson University; International Business Machines (IBM); University
   of Manchester; Paterson Institute for Cancer Research; University of
   Manchester
RP Lisanti, MP (通讯作者)，Thomas Jefferson Univ, Jefferson Stem Cell Biol & Regenerat Med Ctr, Philadelphia, PA 19107 USA.
EM federica.sotgia@jefferson.edu; michael.lisanti@kimmelcancercenter.org
RI Pavlides, Stephanos/F-9673-2011; Pestell, Richard/JQW-3484-2023;
   Lisanti, Michael/C-6866-2013; Martinet, Wim/I-7375-2015
OI Sotgia, Federica/0000-0003-2826-4529; Lisanti,
   Michael/0000-0003-2034-1382; Howell, Anthony/0000-0002-6233-719X;
   Tsirigos, Aristotelis/0000-0002-7512-8477; Martinez-Outschoorn,
   Ubaldo/0000-0003-1483-4551
FU NIH/NCI [R01-CA-080250, R01-CA-098779, R01-CA-120876, R01-AR-055660,
   R01-CA-70896, R01-CA-75503, R01-CA-86072, R01-CA-107382, P30-CA-56036];
   Susan G. Komen Breast Cancer Foundation; Breast Cancer Alliance (BCA);
   American Cancer Society (ACS); Dr. Ralph and Marian C. Falk Medical
   Research Trust; Pennsylvania Department of Health; Breakthrough Breast
   Cancer in the UK; European Research Council
FX M. P. L. and his laboratory were supported by grants from the NIH/NCI
   (R01-CA-080250; R01-CA-098779; R01-CA-120876; R01-AR-055660), and the
   Susan G. Komen Breast Cancer Foundation. F.S. was supported by grants
   from the Breast Cancer Alliance (BCA), and a Research Scholar Grant from
   the American Cancer Society (ACS). R. G. P. was supported by grants from
   the NIH/NCI (R01-CA-70896, R01-CA-75503, R01-CA-86072 and R01-CA-107382)
   and the Dr. Ralph and Marian C. Falk Medical Research Trust. The Kimmel
   Cancer Center was supported by the NIH/NCI Cancer Center Core grant
   P30-CA-56036 (to R.G.P.). Funds were also contributed by the Margaret Q.
   Landenberger Research Foundation (to M. P. L.). This project is funded,
   in part, under a grant with the Pennsylvania Department of Health (to M.
   P. L.). The Department specifically disclaims responsibility for any
   analyses, interpretations or conclusions. This work was also supported,
   in part, by a Centre grant in Manchester from Breakthrough Breast Cancer
   in the UK (to A.H.) and an Advanced ERC Grant from the European Research
   Council.
CR Authier S, 2008, MOL IMAGING BIOL, V10, P217, DOI 10.1007/s11307-008-0143-6
   Barrett T, 2007, NUCLEIC ACIDS RES, V35, pD760, DOI 10.1093/nar/gkl887
   Biradar V, 2010, CRIT CARE RESUSC, V12, P191
   Birket MJ, 2011, J CELL SCI, V124, P348, DOI 10.1242/jcs.072272
   Bonuccelli G, 2010, CELL CYCLE, V9, P3506, DOI 10.4161/cc.9.17.12731
   Brazma A, 2003, NUCLEIC ACIDS RES, V31, P68, DOI 10.1093/nar/gkg091
   Brizel DM, 2001, INT J RADIAT ONCOL, V51, P349, DOI 10.1016/S0360-3016(01)01630-3
   Chen EI, 2007, CANCER RES, V67, P1472, DOI 10.1158/0008-5472.CAN-06-3137
   Chen V, 2010, CELL CYCLE, V9, P4941, DOI 10.4161/cc.9.24.14230
   Cheng JC, 2004, J PEDIAT HEMATOL ONC, V26, P780, DOI 10.1097/00043426-200411000-00021
   Dykens JA, 2008, TOXICOL APPL PHARM, V233, P203, DOI 10.1016/j.taap.2008.08.013
   Ertel A, 2010, CELL CYCLE, V9, P4153, DOI 10.4161/cc.9.20.13454
   Ertel A, 2010, CANCER INFORM, V9, P11
   EVANS TRJ, 1992, CANCER, V69, P453, DOI 10.1002/1097-0142(19920115)69:2<453::AID-CNCR2820690230>3.0.CO;2-N
   FENSELAU A, 1976, CANCER RES, V36, P4429
   GORR TA, 2011, ACTA PHYSL IN PRESS
   HARVEY A, 2011, MITOCHONDRI IN PRESS
   Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008-5472.CAN-09-2994
   Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96
   KALLINOWSKI F, 1985, ADV EXP MED BIOL, V191, P763
   Kristiansen G, 2010, BRIT J CANCER, V102, P1736, DOI 10.1038/sj.bjc.6605702
   Lisanti MP, 2010, CANCER BIOL THER, V10, P537, DOI 10.4161/cbt.10.6.13370
   Magistretti PJ, 2006, J EXP BIOL, V209, P2304, DOI 10.1242/jeb.02208
   Magistretti PJ, 2009, AM J CLIN NUTR, V90, p875S, DOI 10.3945/ajcn.2009.27462CC
   Magistretti PJ, 1996, MOL PSYCHIATR, V1, P445
   MARKOWETZ F, 2010, PLOS COMPUT BIOL, V6
   Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P4297, DOI 10.4161/cc.9.21.13817
   Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P3515, DOI 10.4161/cc.9.17.12928
   Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P3256, DOI 10.4161/cc.9.16.12553
   Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P2423, DOI 10.4161/cc.9.12.12048
   MARTINEZOUTSCHO.UE, 2011, INT J BIOCH IN PRESS
   MCCONNELL AA, 1989, POSTGRAD MED J, V65, P120, DOI 10.1136/pgmj.65.760.120
   Memmott RM, 2010, CANCER PREV RES, V3, P1066, DOI 10.1158/1940-6207.CAPR-10-0055
   Moreaux J, 2005, BLOOD, V106, P1021, DOI 10.1182/blood-2004-11-4512
   Pavlides S, 2010, CELL CYCLE, V9, P3485, DOI 10.4161/cc.9.17.12721
   Pavlides S, 2010, CELL CYCLE, V9, P2201, DOI 10.4161/cc.9.11.11848
   Pavlides S, 2010, AGING-US, V2, P185, DOI 10.18632/aging.100134
   Pavlides S, 2009, CELL CYCLE, V8, P3984, DOI 10.4161/cc.8.23.10238
   Pollak M, 2010, CANCER PREV RES, V3, P1060, DOI 10.1158/1940-6207.CAPR-10-0175
   PRENEN GHM, 1990, APPL RADIAT ISOTOPES, V41, P1209
   SCULIER JP, 1983, EUR J CANCER CLIN ON, V19, P597, DOI 10.1016/0277-5379(83)90174-8
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   VARANASI UR, 1980, CANCER TREAT REP, V64, P1283
   Vazquez-Martin A, 2010, CURR MOL MED, V10, P674, DOI 10.2174/156652410792630625
   Vazquez-Martin A, 2010, CELL CYCLE, V9, P3807, DOI 10.4161/cc.9.18.13131
   Vazquez-Martin A, 2011, BREAST CANCER RES TR, V126, P355, DOI 10.1007/s10549-010-0924-x
   Walenta S, 2004, SEMIN RADIAT ONCOL, V14, P267, DOI 10.1016/j.semradonc.2004.04.004
   Walenta S, 2000, CANCER RES, V60, P916
   Walenta S, 1997, AM J PATHOL, V150, P409
   WARNER E, 1992, BREAST CANCER RES TR, V24, P75, DOI 10.1007/BF01832361
   Wohnsland S, 2010, NEUROCHEM RES, V35, P1635, DOI 10.1007/s11064-010-0224-1
   Xu HN, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3431714
NR 52
TC 273
Z9 314
U1 0
U2 42
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4101
EI 1551-4005
J9 CELL CYCLE
JI Cell Cycle
PD APR 15
PY 2011
VL 10
IS 8
BP 1271
EP 1286
DI 10.4161/cc.10.8.15330
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 758EV
UT WOS:000290145100023
PM 21512313
OA Green Published
DA 2025-01-12
ER

PT J
AU Oliveras-Ferraros, C
   Cufí, S
   Vazquez-Martin, A
   Torres-Garcia, VZ
   Del Barco, S
   Martin-Castillo, B
   Menendez, JA
AF Oliveras-Ferraros, Cristina
   Cufi, Slvia
   Vazquez-Martin, Alejandro
   Zenobia Torres-Garcia, Violeta
   Del Barco, Sonia
   Martin-Castillo, Begona
   Menendez, Javier A.
TI Micro(mi)RNA expression profile of breast cancer epithelial cells
   treated with the anti-diabetic drug metformin Induction of the tumor
   suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR
   miRNA-181a
SO CELL CYCLE
LA English
DT Article
DE metformin; microRNA; let-7; TGF beta; miRNA-181; miRNA-96; stem cells
ID MESENCHYMAL TRANSITION; STEM-CELLS; MICRORNAS; GROWTH; GENE;
   IDENTIFICATION; RESISTANCE; MIR-200; EMT
AB An unexplored molecular scenario that might explain the inhibitory impact of the anti-diabetic drug metformin on the genesis of breast cancer relates to metformin's ability to modulate the expression status of micro (mi)RNAs. We here report the first miRNA expression profiling of human epithelial breast cancer cells cultured in the presence of metformin. We conducted real-time transcription polymerase chain reaction (qRT-PCR) Arrays to quantitatively compare the expression profile of 88 cancer-related miRNA sequences before and after treatment of MCF-7 cells, which were used as well-differentiated, epithelioid cell controls, with graded concentrations of metformin. Metformin-treated MCF-7 cells notably exhibited up to 18-fold increases in miRNA lethal-7a (let-7a) expression compared with untreated control cells. We confirmed that MCF-7 cells undergoing epithelial-to-mesenchymal (EMT) transition in response to the cytokine TGF beta notably upregulated (similar to five-fold) miRNA-181a expression and exhibited better mammosphere-forming capabilities. We then explored the ability of metformin to impede TGF beta-enhanced propensity of breast cancer stem cells to form mammospheres in a miRNA-181a-related manner. Remarkably, TGF beta treatment failed to upregulate miRNA-181a expression in the presence of metformin, which was able to fully abrogate TGF beta-enhanced mammosphere-forming ability. In addition, metformin co-treatment fully prevented TGF beta-induced downregulation of the tumor suppressor miRNA-96 (similar to ten-fold). Metformin's molecular functioning to prevent invasive breast cancer can be explained in terms of its previously unrecognized ability to efficiently upregulate the tumor-suppressive miRNAs let-7a & miRNA-96 and inhibit the oncogenic miRNA-181a, thus epigenetically preserving the differentiated phenotype of mammary epithelium while preventing EMT-related cancer-initiating cell self-renewal.
C1 [Oliveras-Ferraros, Cristina; Cufi, Slvia; Vazquez-Martin, Alejandro; Zenobia Torres-Garcia, Violeta; Menendez, Javier A.] Catalan Inst Oncol Girona ICO Girona, Unit Translat Res, Girona, Catalonia, Spain.
   [Martin-Castillo, Begona] Catalan Inst Oncol Girona ICO Girona, Unit Clin Res, Girona, Catalonia, Spain.
   [Oliveras-Ferraros, Cristina; Cufi, Slvia; Vazquez-Martin, Alejandro; Zenobia Torres-Garcia, Violeta; Del Barco, Sonia; Martin-Castillo, Begona; Menendez, Javier A.] Hosp Girona Dr Josep Trueta, Girona Biomed Res Inst IdIBGi, Girona, Catalonia, Spain.
C3 Institut Catala d'Oncologia; Institut Catala d'Oncologia; Universitat de
   Girona; Girona University Hospital Dr. Josep Trueta; Institut
   d'Investigacio Biomedica de Girona (IDIBGI)
RP Menendez, JA (通讯作者)，Catalan Inst Oncol Girona ICO Girona, Unit Translat Res, Girona, Catalonia, Spain.
EM jmenendez@iconcologia.net
RI MENENDEZ MENENDEZ, JAVIER ABEL/C-6148-2016
OI MENENDEZ MENENDEZ, JAVIER ABEL/0000-0001-8733-4561; Martin-Castillo,
   Begona/0000-0001-8344-8174; Cufi, Silvia/0000-0002-2476-748X
FU Ministerio de Ciencia e Innovacion (MICINN, Spain) [SAF2009-11579];
   Ministerio de Sanidad y Consumo, Fondo de Investigacion Sanitaria-FIS-,
   Spain [CD08/00283]; Instituto de Salud Carlos III (Ministerio de Sanidad
   y Consumo, Fondo de Investigacion Sanitaria-FIS-, Spain) [CP05-00090,
   PI06-0778, RD06-0020-0028]; Fundacion Cientifica de la Asociacion
   Espanola Contrael Cancer (AECC, Spain)
FX Silvia Cufi is the recipient of a Research Fellowship (Formacion de
   Personal Investigador, FPI) by the Ministerio de Ciencia e Innovacion
   (MICINN, Spain). Alejandro Vazquez-Martin is the recipient of a "Sara
   Borrell" post-doctoral contract (CD08/00283, Ministerio de Sanidad y
   Consumo, Fondo de Investigacion Sanitaria-FIS-, Spain). Work at
   Menendez' Laboratory supported in part by the Instituto de Salud Carlos
   III (Ministerio de Sanidad y Consumo, Fondo de Investigacion
   Sanitaria-FIS-, Spain, Grants CP05-00090 and PI06-0778 and
   RD06-0020-0028), the Fundacion Cientifica de la Asociacion Espanola
   Contrael Cancer (AECC, Spain), and by the Ministerio de Ciencia e
   Innovacion (SAF2009-11579, Plan Nacional de I+D+I, MICINN, Spain).
CR Algire C, 2011, ONCOGENE, V30, P1174, DOI 10.1038/onc.2010.483
   Alimova IN, 2009, CELL CYCLE, V8, P909, DOI 10.4161/cc.8.6.7933
   Anisimov VN, 2010, AGING-US, V2, P760, DOI 10.18632/aging.100230
   Boyerinas B, 2008, CANCER RES, V68, P2587, DOI 10.1158/0008-5472.CAN-08-0264
   Boyerinas B, 2010, ENDOCR-RELAT CANCER, V17, pF19, DOI 10.1677/ERC-09-0184
   CAJA L, 2010, J CELL PHYS IN PRESS
   Cano A, 2008, TRENDS CELL BIOL, V18, P357, DOI 10.1016/j.tcb.2008.05.005
   Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741
   Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106
   Ding XC, 2008, CELL CYCLE, V7, P3083, DOI 10.4161/cc.7.19.6778
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Dowling RJO, 2007, CANCER RES, V67, P10804, DOI 10.1158/0008-5472.CAN-07-2310
   Esquela-Kerscher A, 2008, CELL CYCLE, V7, P759, DOI 10.4161/cc.7.6.5834
   Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008-5472.CAN-09-2994
   Huang SL, 2010, NUCLEIC ACIDS RES, V38, P7211, DOI 10.1093/nar/gkq564
   Ibarra I, 2007, GENE DEV, V21, P3238, DOI 10.1101/gad.1616307
   Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014
   Ji JF, 2009, HEPATOLOGY, V50, P472, DOI 10.1002/hep.22989
   Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083
   Li J, 2010, BMC EVOL BIOL, V10, DOI [10.1186/1471-2148-10-68, 10.1186/1471-2407-10-354]
   Li YW, 2009, CANCER RES, V69, P6704, DOI 10.1158/0008-5472.CAN-09-1298
   Liu BL, 2009, CELL CYCLE, V8, P2031, DOI 10.4161/cc.8.13.8814
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Martin-Castillo B, 2010, CELL CYCLE, V9, P1057, DOI 10.4161/cc.9.6.10994
   Mathonnet G, 2007, SCIENCE, V317, P1764, DOI 10.1126/science.1146067
   Mineno J, 2006, NUCLEIC ACIDS RES, V34, P1765, DOI 10.1093/nar/gkl096
   Park SM, 2007, CELL CYCLE, V6, P2585, DOI 10.4161/cc.6.21.4845
   Peter ME, 2009, CELL CYCLE, V8, P843, DOI 10.4161/cc.8.6.7907
   Pollak M, 2010, CANCER PREV RES, V3, P1060, DOI 10.1158/1940-6207.CAPR-10-0175
   Sarkar FH, 2010, DRUG RESIST UPDATE, V13, P57, DOI 10.1016/j.drup.2010.02.001
   Shell S, 2007, P NATL ACAD SCI USA, V104, P11400, DOI 10.1073/pnas.0704372104
   Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011
   Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Thomson JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.1444406
   Vazquez-Martin A, 2010, CURR MOL MED, V10, P674, DOI 10.2174/156652410792630625
   Vazquez-Martin A., 2010, BREAST CANC IN PRESS
   Vazquez-Martin A, 2011, ONCOL REP, V25, P135, DOI 10.3892/or_00001052
   Vazquez-Martin A, 2010, CELL CYCLE, V9, P3807, DOI 10.4161/cc.9.18.13131
   Vazquez-Martin A, 2009, CELL CYCLE, V8, P88, DOI 10.4161/cc.8.1.7499
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Wang B, 2010, ONCOGENE, V29, P1787, DOI 10.1038/onc.2009.468
   Wang Y., 2010, Oncogene
   Wang ZW, 2010, DRUG RESIST UPDATE, V13, P109, DOI 10.1016/j.drup.2010.07.001
   Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054
   Yu SN, 2010, CANCER RES, V70, P6015, DOI 10.1158/0008-5472.CAN-09-4531
   Zakikhani M, 2006, CANCER RES, V66, P10269, DOI 10.1158/0008-5472.CAN-06-1500
   Zavadil J, 2007, CELLS TISSUES ORGANS, V185, P157, DOI 10.1159/000101316
NR 49
TC 95
Z9 106
U1 0
U2 37
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4101
EI 1551-4005
J9 CELL CYCLE
JI Cell Cycle
PD APR 1
PY 2011
VL 10
IS 7
BP 1144
EP 1151
DI 10.4161/cc.10.7.15210
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 744JF
UT WOS:000289090000024
PM 21368581
OA Bronze
DA 2025-01-12
ER

PT J
AU Hernandez-Vargas, H
   Ouzounova, M
   Le Calvez-Kelm, F
   Lambert, MP
   McKay-Chopin, S
   Tavtigian, SV
   Puisieux, A
   Matar, C
   Herceg, Z
AF Hernandez-Vargas, Hector
   Ouzounova, Maria
   Le Calvez-Kelm, Florence
   Lambert, Marie-Pierre
   McKay-Chopin, Sandrine
   Tavtigian, Sean V.
   Puisieux, Alain
   Matar, Chantal
   Herceg, Zdenko
TI Methylome analysis reveals Jak-STAT pathway deregulation in putative
   breast cancer stem cells
SO EPIGENETICS
LA English
DT Article
DE DNA methylation; developmental pathways; Jak-STAT pathway; breast cancer
   stem cells; mammospheres; STAT3
ID EPITHELIAL-MESENCHYMAL TRANSITION; MAMMARY STEM/PROGENITOR CELLS; DNA
   METHYLATION PATTERNS; IN-VITRO PROPAGATION; GLAND DEVELOPMENT;
   SELF-RENEWAL; LUNG-CANCER; ACTIVATION; DIFFERENTIATION; INTERLEUKIN-6
AB Growing evidence supports the existence of a subpopulation of cancer cells with stem cell characteristics within breast tumors. In spite of its potential clinical implications, an understanding of the mechanisms responsible for retaining the stem cell characteristics in these cells is still lacking. Here, we used the mammosphere model combined with DNA methylation bead arrays and quantitative gene expression to characterize the epigenetic mechanisms involved in the regulation of developmental pathways in putative breast cancer stem cells. Our results revealed that MCF7-derived mammospheres exhibit distinct CpG promoter methylation profiles in a specific set of genes, including those involved in Jak-STAT signaling pathway. Hypomethylation of several gene components of the Jak-STAT pathway was correlated with an increased expression in mammospheres relative to parental cells. Remarkably, cell sorting of the cells with a putative cancer stem cell phenotype (CD44(+)/CD24 low) suggests a constitutive activation of Jak-STAT pathway in these cells. These results show that Jak-STAT activation may represent a characteristic of putative breast cancer stem cells. In addition, they favor the concept that the expression of cancer stem-like pathways and the establishment and maintenance of defining properties of cancer stem cells are orchestrated by epigenetic mechanisms.
C1 [Hernandez-Vargas, Hector; Ouzounova, Maria; Lambert, Marie-Pierre; Herceg, Zdenko] IARC, Epigenet Grp, Lyon, France.
   [Le Calvez-Kelm, Florence; McKay-Chopin, Sandrine; Tavtigian, Sean V.] IARC, Genet Canc Susceptibil Grp, Lyon, France.
   [Puisieux, Alain] Ctr Leon Berard, F-69373 Lyon, France.
   [Matar, Chantal] Univ Ottawa, Fac Hlth Sci, Ottawa, ON, Canada.
C3 World Health Organization; International Agency for Research on Cancer
   (IARC); World Health Organization; International Agency for Research on
   Cancer (IARC); UNICANCER; Centre Leon Berard; University of Ottawa
RP Herceg, Z (通讯作者)，IARC, Epigenet Grp, Lyon, France.
EM herceg@iarc.fr
RI Ouzounova, Maria/B-7189-2014; Herceg, Zdenko/JOZ-6188-2023
OI Ouzounova, Maria/0000-0001-8934-3461; Lambert,
   Marie-Pierre/0000-0002-4468-5203; Matar, Chantal/0000-0003-0346-4751;
   PUISIEUX, Alain/0000-0002-9938-3798; Le Calvez-Kelm,
   Florence/0000-0003-0063-5068; Hernandez-Vargas,
   Hector/0000-0001-6045-2103
FU la Ligue National (Francaise) Contre le Cancer; l'Association pour le
   Recherche Contre le Cancer (l'ARC)
FX We gratefully acknowledge Drs. E. Ballestar, R. Murr and D. Sarrio for
   critical reading of the manuscript. We also acknowledge G. Durand for
   assistance with the Illumina bead array assay. This work is supported by
   la Ligue National (Francaise) Contre le Cancer and l'Association pour le
   Recherche Contre le Cancer (l'ARC).
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Bachelot T, 2003, BRIT J CANCER, V88, P1721, DOI 10.1038/sj.bjc.6600956
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Bloushtain-Qimron N, 2008, P NATL ACAD SCI USA, V105, P14076, DOI 10.1073/pnas.0805206105
   Calvisi DF, 2007, J CLIN INVEST, V117, P2713, DOI 10.1172/JCI31457
   Daskalos A, 2009, INT J CANCER, V124, P81, DOI 10.1002/ijc.23849
   Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Farthing CR, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000116
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349
   Hao J, 2006, DEV BIOL, V290, P81, DOI 10.1016/j.ydbio.2005.11.011
   Hennighausen L, 2001, DEV CELL, V1, P467, DOI 10.1016/S1534-5807(01)00064-8
   Hernandez-Vargas H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009749
   Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Knüpfer H, 2007, BREAST CANCER RES TR, V102, P129, DOI 10.1007/s10549-006-9328-3
   Korkaya H, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000121
   Liao MJ, 2007, CANCER RES, V67, P8131, DOI 10.1158/0008-5472.CAN-06-4493
   Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261
   MONK M, 1987, DEVELOPMENT, V99, P371
   Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888
   Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048
   Niwa H, 2007, GENE DEV, V21, P2071, DOI 10.1101/gad.1615707
   Novak P, 2008, CANCER RES, V68, P8616, DOI 10.1158/0008-5472.CAN-08-1419
   Novak P, 2006, CANCER RES, V66, P10664, DOI 10.1158/0008-5472.CAN-06-2761
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Polyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295
   Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626
   Raz R, 1999, P NATL ACAD SCI USA, V96, P2846, DOI 10.1073/pnas.96.6.2846
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013
   Smalley MJ, 1999, CANCER METAST REV, V18, P215, DOI 10.1023/A:1006369223282
   Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496
   Stingl J, 2007, NAT REV CANCER, V7, P791, DOI 10.1038/nrc2212
   Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180
   Sultan AS, 2008, CANCER SCI, V99, P272, DOI 10.1111/j.1349-7006.2007.00685.x
   Suzuki K, 2006, CANCER CELL, V9, P199, DOI 10.1016/j.ccr.2006.02.016
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Vaissiere T, 2009, CANCER RES, V69, P243, DOI 10.1158/0008-5472.CAN-08-2489
   Vaissière T, 2008, MUTAT RES-REV MUTAT, V659, P40, DOI 10.1016/j.mrrev.2008.02.004
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Weber M, 2007, CURR OPIN CELL BIOL, V19, P273, DOI 10.1016/j.ceb.2007.04.011
   Weissman Irving L., 2005, V265, P35
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431
   Zhou JB, 2007, P NATL ACAD SCI USA, V104, P16158, DOI 10.1073/pnas.0702596104
NR 54
TC 60
Z9 73
U1 0
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD APR
PY 2011
VL 6
IS 4
BP 429
EP 440
DI 10.4161/epi.6.4.14515
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 744BG
UT WOS:000289066600006
PM 21266853
OA Bronze
DA 2025-01-12
ER

PT J
AU ten Haaf, A
   Franken, L
   Heymann, C
   von Serenyi, S
   Cornelissen, C
   de Hoon, JPJ
   Veeck, J
   Lüscher, B
   Knüchel, R
   Dahl, E
AF ten Haaf, Anette
   Franken, Laura
   Heymann, Caroline
   von Serenyi, Sonja
   Cornelissen, Christian
   de Hoon, Joep P. J.
   Veeck, Jurgen
   Luescher, Bernhard
   Knuechel, Ruth
   Dahl, Edgar
TI Paradox of sonic hedgehog (<i>SHH</i>) transcriptional regulation
   Alternative transcription initiation overrides the effect of downstream
   promoter DNA methylation
SO EPIGENETICS
LA English
DT Article
DE hedgehog; SHH; cancer; oncogene; methylation; expression
ID PANCREATIC-CANCER; GENE-EXPRESSION; GASTRIC-CANCER; BREAST-CANCER;
   CHROMOSOME-22; EPIGENETICS; ACTIVATION; MECHANISMS; TARGET; CELLS
AB Recently, DNA methylation has been suggested as a potential mechanism involved in the transcriptional regulation of SHH gene expression in cancer. However, detailed analyses on the underlying transcriptional mechanisms of SHH expression have not been presented so far and were therefore the focus of this study. We found that the genomic region of SHH contains two different transcriptional start sites and four CpG islands spread from the 5' promoter region to the 3' end of the SHH gene. Based on this CpG island topology we analyzed the influence of DNA methylation within the promoter region as well as in exon 2 and exon 3 on SHH mRNA expression in a large set (n = 14) of benign and malignant human cell lines, and further elucidated the functionality of the two identified SHH transcription initiation sites. Methylation-specific PCR (MSP) clearly showed that SHH is expressed independently of DNA methylation within exon 2 and exon 3 of its genomic region, while methylation of the promoter region is able to abrogate SHH expression. Most interesting, we found activation of the upstream SHH promoter in several breast cancer cell lines when the downstream SHH promoter is methylated. These observations lead us to propose a transcriptional model for the SHH gene, in which combined mechanisms of DNA methylation and alternative promoter usage coordinate the transcriptional activity of this important developmental gene.
C1 [ten Haaf, Anette; Franken, Laura; Heymann, Caroline; von Serenyi, Sonja; Knuechel, Ruth; Dahl, Edgar] Rhein Westfal TH Aachen, Fac Med, Inst Pathol, Mol Oncol Grp, Aachen, Germany.
   [Cornelissen, Christian; Luescher, Bernhard] Rhein Westfal TH Aachen, Fac Med, Inst Biochem & Mol Biol, Aachen, Germany.
   [de Hoon, Joep P. J.; Veeck, Jurgen] Maastricht Univ Med Ctr, Div Med Oncol, Dept Internal Med, GROW Sch Oncol & Dev Biol,Dept Pathol, Maastricht, Netherlands.
C3 RWTH Aachen University; RWTH Aachen University; Maastricht University;
   Maastricht University Medical Centre (MUMC)
RP Dahl, E (通讯作者)，Rhein Westfal TH Aachen, Fac Med, Inst Pathol, Mol Oncol Grp, Aachen, Germany.
EM edahl@ukaachen.de
RI Veeck, Jurgen/B-9256-2008; Luscher, Bernhard/A-7330-2011
OI Veeck, Jurgen/0000-0002-2952-6159; Luscher, Bernhard/0000-0002-9622-8709
FU German Ministry for Education and Research (BMBF); Deutsche
   Forschungsgemeinschaft [DA 329/3-1]
FX We thank Andrea Reinartz and Christina Klaus for comments on this
   manuscript, and Tim Calon for expert technical help. The study was
   supported by the German Ministry for Education and Research (BMBF) as a
   part of the German Human Genome Project (DHGP) to Edgar Dahl and by the
   Deutsche Forschungsgemeinschaft (project DA 329/3-1) to Edgar Dahl.
CR Bailey JM, 2009, ONCOGENE, V28, P3513, DOI 10.1038/onc.2009.220
   Cheng J, 2005, SCIENCE, V308, P1149, DOI 10.1126/science.1108625
   Cui W, 2010, CANCER SCI, V101, P927, DOI 10.1111/j.1349-7006.2010.01495.x
   Diede SJ, 2010, P NATL ACAD SCI USA, V107, P234, DOI 10.1073/pnas.0907606106
   Dorus S, 2006, HUM MOL GENET, V15, P2031, DOI 10.1093/hmg/ddl123
   Dumont N, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2457
   Esteller M, 2006, BRIT J CANCER, V94, P179, DOI 10.1038/sj.bjc.6602918
   Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327
   Fu XS, 2010, MOL CELL BIOCHEM, V337, P185, DOI 10.1007/s11010-009-0298-8
   Handel AE, 2010, TRENDS MOL MED, V16, P7, DOI 10.1016/j.molmed.2009.11.003
   Hellebrekers DMEI, 2007, BBA-REV CANCER, V1775, P76, DOI 10.1016/j.bbcan.2006.07.003
   Hemmatazad H, 2009, ARTHRITIS RHEUM-US, V60, P1519, DOI 10.1002/art.24494
   Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601
   Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9
   Kapranov P, 2005, GENOME RES, V15, P987, DOI 10.1101/gr.3455305
   Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597
   Katoh Y, 2009, CURR MOL MED, V9, P873, DOI 10.2174/156652409789105570
   Kawaji H, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-12-r118
   Kitazawa S, 1998, BBA-GENE STRUCT EXPR, V1443, P358, DOI 10.1016/S0167-4781(98)00243-7
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   Lambert MP, 2008, MOL ONCOL, V2, P33, DOI 10.1016/j.molonc.2008.03.005
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Mao L, 2009, CANCER SCI, V100, P1848, DOI 10.1111/j.1349-7006.2009.01262.x
   Marigo V, 1996, BIOCHEM SOC SYMP, P51
   Pan CC, 2010, UROL INT, V85, P347, DOI 10.1159/000318889
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   Satoh A, 2002, BRIT J CANCER, V86, P1817, DOI 10.1038/sj.bjc.6600319
   Schagdarsurengin U, 2009, EPIGENETICS-US, V4, P571, DOI 10.4161/epi.4.8.10056
   Shaw A, 2009, ONCOGENE, V28, P4480, DOI 10.1038/onc.2009.294
   Takahashi K, 2009, J IMMUNOL, V183, P6522, DOI 10.4049/jimmunol.0901271
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009
   Tost J, 2010, MOL BIOTECHNOL, V44, P71, DOI 10.1007/s12033-009-9216-2
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Wang LH, 2006, MODERN PATHOL, V19, P675, DOI 10.1038/modpathol.3800573
   Wang X, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-95
   Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598
   Yang L, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-112
   Yoshikawa K, 2009, J GASTROENTEROL, V44, P1113, DOI 10.1007/s00535-009-0110-2
   Zhang J, 2009, J INT MED RES, V37, P1842, DOI 10.1177/147323000903700620
NR 41
TC 11
Z9 12
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD APR
PY 2011
VL 6
IS 4
BP 466
EP 478
DI 10.4161/epi.6.4.14952
PG 13
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 744BG
UT WOS:000289066600009
PM 21372638
DA 2025-01-12
ER

PT J
AU Ye, WP
   Xu, PP
   Jen, R
   Feng, ER
   Zhong, SY
   Li, H
   Lin, SH
   Liu, JY
   Lin, YC
AF Ye, Weiping
   Xu, Pingping
   Jen, Robert
   Feng, Eric
   Zhong, Saiyi
   Li, Hong
   Lin, Shu-Hong
   Liu, Jie-Yu
   Lin, Young C.
TI Zeranol Down-Regulates p53 Expression in Primary Cultured Human Breast
   Cancer Epithelial Cells through Epigenetic Modification
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE breast cancer; growth promoter; zeranol; p53; DNMT1
ID MESSENGER-RNA EXPRESSION; GAMMA PTP-GAMMA; DNA METHYLATION; CPG ISLANDS;
   GENE; MUTATION; METHYLTRANSFERASE; OVEREXPRESSION; PROMOTER; GROWTH
AB Epidemiological studies have suggested that there are many risk factors associated with breast cancer. Silencing tumor suppressor genes through epigenetic alterations play critical roles in breast cancer initiation, promotion and progression. As a growth promoter, Zeranol (Z) has been approved by the FDA and is widely used to enhance the growth of beef cattle in the United States. However, the safety of Z use as a growth promoter is still under debate. In order to provide more evidence to clarify this critical health issue, the current study investigated the effect of Z on the proliferation of primary cultured human normal and cancerous breast epithelial cells (PCHNBECs and PCHBCECs, respectively) isolated from the same patient using MTS assay, RT-PCR and Western blot analysis. We also conducted an investigation regarding the mechanisms that might be involved. Our results show that Z is more potent to stimulate PCHBCEC growth than PCHNBEC growth. The stimulatory effects of Z on PCHBCECs and PCHBCECs may be mediated by its down-regulating expression of the tumor suppressor gene p53 at the mRNA and protein levels. Further investigation showed that the expression of DNA methylatransferase 1 mRNA and protein levels is up-regulated by treatment with Z in PCHBCECs as compared to PCHNBECs, which suggests a role of Z in epigenetic modification involved in the regulation of p53 gene expression in PCHBCECs. Our experimental results imply the potentially adverse health effect of Z in breast cancer development. Further study is continuing in our laboratory.
C1 [Ye, Weiping; Xu, Pingping; Jen, Robert; Feng, Eric; Zhong, Saiyi; Li, Hong; Lin, Shu-Hong; Liu, Jie-Yu; Lin, Young C.] Ohio State Univ, Coll Vet Med, Lab Reprod & Mol Endocrinol, Columbus, OH 43210 USA.
   [Lin, Young C.] Ohio State Univ, Ctr Comprehens Canc, Goss Lab 333, Columbus, OH 43210 USA.
C3 University System of Ohio; Ohio State University; James Cancer Hospital
   & Solove Research Institute; University System of Ohio; Ohio State
   University
RP Lin, YC (通讯作者)，Ohio State Univ, Coll Vet Med, Lab Reprod & Mol Endocrinol, Columbus, OH 43210 USA.
EM ye.44@osu.edu; xu.200@osu.edu; jenrt@mail.uc.edu; fanx40@gmail.com;
   zhong.66@osu.edu; li.801@osu.edu; lin.833@osu.edu; liu.1048@osu.edu;
   lin.15@osu.edu
RI Zhong, Sai-Yi/HMV-1578-2023; Xu, ping/KDN-1175-2024; Lin,
   Shu-Hong/AAT-3905-2020
OI LIN, SHU-HONG/0000-0002-4020-7714
FU National Institutes of Health, USA [RO1 ES 015212]
FX The authors thank Rikihisa's laboratory for providing
   photo-documentation equipment. This work was supported by the RO1 ES
   015212 (National Institutes of Health, USA)
CR Agoston AT, 2007, AM J PATHOL, V170, P1585, DOI 10.2353/ajpath.2007.060779
   Ahluwalia A, 2001, GYNECOL ONCOL, V82, P299, DOI 10.1006/gyno.2001.6284
   Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379
   AW TC, 1989, BRIT J IND MED, V46, P341
   Baker L, 2010, BRIT J CANCER, V102, P719, DOI 10.1038/sj.bjc.6605540
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   BESTOR TH, 1992, GENET ANAL-BIOMOL E, V9, P48, DOI 10.1016/1050-3862(92)90030-9
   Blaszyk H, 2000, INT J CANCER, V89, P32, DOI 10.1002/(SICI)1097-0215(20000120)89:1<32::AID-IJC6>3.0.CO;2-G
   Chetrite GS, 2000, J STEROID BIOCHEM, V72, P23, DOI 10.1016/S0960-0760(00)00040-6
   COE JE, 1992, P NATL ACAD SCI USA, V89, P1085, DOI 10.1073/pnas.89.3.1085
   Datta J, 2009, CANCER RES, V69, P4277, DOI 10.1158/0008-5472.CAN-08-3669
   Dinu I, 2009, BRIEF BIOINFORM, V10, P24, DOI 10.1093/bib/bbn042
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   Golubovskaya VM, 2009, INT J CANCER, V125, P1735, DOI 10.1002/ijc.24486
   Hartmann A, 1997, TRENDS GENET, V13, P27, DOI 10.1016/S0168-9525(96)10043-3
   Hassan NMM, 2008, CANCER LETT, V270, P108, DOI 10.1016/j.canlet.2008.04.052
   Haynes BP, 2010, CLIN CANCER RES, V16, P1790, DOI 10.1158/1078-0432.CCR-09-2481
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Kang JH, 2001, LAB INVEST, V81, P573, DOI 10.1038/labinvest.3780266
   Lai H, 2002, CANCER BIOL THER, V1, P31, DOI 10.4161/cbt.1.1.37
   LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1
   LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P
   Linos E, 2008, CANCER EPIDEM BIOMAR, V17, P2146, DOI 10.1158/1055-9965.EPI-08-0037
   Liu SL, 2002, ANTICANCER RES, V22, P3917
   Liu SL, 2002, BREAST CANCER RES TR, V71, P21, DOI 10.1023/A:1013343718942
   Liu Suling, 2004, Breast J, V10, P514, DOI 10.1111/j.1075-122X.2004.21410.x
   MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037
   Massart F, 2008, J PEDIATR-US, V152, P690, DOI 10.1016/j.jpeds.2007.10.020
   McGill G, 1999, J CLIN INVEST, V104, P223, DOI 10.1172/JCI7861
   Minervini F, 2005, TOXICOL LETT, V159, P272, DOI 10.1016/j.toxlet.2005.05.017
   Müller HM, 2003, CANCER RES, V63, P7641
   RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144
   Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905
   Rivenbark AG, 2006, EPIGENETICS-US, V1, P32, DOI 10.4161/epi.1.1.2358
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   Shu ST, 2010, ANTICANCER RES, V30, P1937
   Surani MA, 1998, CELL, V93, P309, DOI 10.1016/S0092-8674(00)81156-3
   Swan SH, 2007, HUM REPROD, V22, P1497, DOI 10.1093/humrep/dem068
   Takemura H, 2007, J STEROID BIOCHEM, V103, P170, DOI 10.1016/j.jsbmb.2006.08.008
   Ting AH, 2006, CANCER RES, V66, P729, DOI 10.1158/0008-5472.CAN-05-1537
   Toillon RA, 2002, BREAST CANCER RES TR, V71, P269, DOI 10.1023/A:1014422101452
   Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675
   Weiss RA, 2004, BRIT J CANCER, V91, P1981, DOI 10.1038/sj.bjc.6602318
   Xu PP, 2009, ANTICANCER RES, V29, P4621
   Xu XL, 2004, WORLD J GASTROENTERO, V10, P3441
   Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743
   Ye WP, 2010, EXP THER MED, V1, P963, DOI 10.3892/etm.2010.155
   Ye WP, 2011, INT J ONCOL, V38, P985, DOI 10.3892/ijo.2011.941
   Ye WP, 2009, ANTICANCER RES, V29, P5045
   Yuri T, 2006, ONCOL REP, V16, P1307
NR 53
TC 11
Z9 15
U1 0
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1661-6596
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR
PY 2011
VL 12
IS 3
BP 1519
EP 1532
DI 10.3390/ijms12031519
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 740HZ
UT WOS:000288784200007
PM 21673905
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Kapoor-Vazirani, P
   Kagey, JD
   Vertino, PM
AF Kapoor-Vazirani, Priya
   Kagey, Jacob D.
   Vertino, Paula M.
TI SUV420H2-Mediated H4K20 Trimethylation Enforces RNA Polymerase II
   Promoter-Proximal Pausing by Blocking hMOF-Dependent H4K16 Acetylation
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
ID BROMODOMAIN PROTEIN BRD4; TUMOR-SUPPRESSOR GENES; BREAST-CANCER CELLS;
   DNA METHYLATION; HISTONE H4; P-TEFB; CONSTITUTIVE HETEROCHROMATIN;
   TRANSCRIPTION INITIATION; PRODUCTIVE ELONGATION; MSL COMPLEX
AB Many human genes exhibit evidence of initiated RNA polymerase II (Pol II) at their promoters, despite a lack of significant full-length transcript. Such genes exhibit promoter-proximal "pausing," wherein initiated Pol II accumulates just downstream of the transcription start site due to a rate-limiting step mediating the transition to elongation. The mechanisms that regulate the escape of Pol II from pausing and the relationship to chromatin structure remain incompletely understood. Recently, we showed that CpG island hypermethylation and epigenetic silencing of TMS1/ASC in human breast cancers are accompanied by a local shift from histone H4 lysine 16 acetylation (H4K16Ac) to H4 lysine 20 trimethylation (H4K20me3). Here, we show that hMOF-mediated H4K16Ac and SUV420H2-mediated H4K20me3 play opposing roles in the regulation of Pol II pausing. We found that H4K16Ac promoted the release of Pol II from pausing through the recruitment of BRD4 and pTEFb. Aberrant methylation of CpG island DNA blocked Pol II recruitment to gene promoters. Whereas the inhibition of DNA methylation allowed for the reassociation and initiation of Pol II at the TMS1 promoter, Pol II remained paused in the presence of H4K20me3. Combined inhibition of H4K20me3 and DNA methylation resulted in the rerecruitment of hMOF and subsequent H4K16Ac, release of Pol II into active elongation, and synergistic reactivation of TMS1 expression. Marking by H4K20me3 was not restricted to TMS1 but also occurred at other genes independently of DNA methylation, where it similarly imposed a block to Pol II promoter escape through a mechanism that involved the local inhibition of H4K16Ac. These data indicate that H4K20me3 invokes gene repression by antagonizing hMOF-mediated H4K16Ac and suggest that overcoming Pol II pausing might be a rate-limiting step in achieving tumor suppressor gene reactivation in cancer therapy.
C1 Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA 30322 USA.
   Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA.
C3 Emory University; Emory University
RP Vertino, PM (通讯作者)，1365-C Clifton Rd NE,Room 4086, Atlanta, GA 30322 USA.
EM pvertin@emory.edu
OI Kagey, Jacob/0000-0002-6994-1795
FU Canadian Institute of Health Research; National Cancer Institute [2RO1
   CA-077337, CA-132065]
FX This work was supported by the Canadian Institute of Health Research
   Postdoctoral Fellowship to P.K.-V. and Public Health Service grants 2RO1
   CA-077337 and CA-132065 from the National Cancer Institute to P.M.V.
   P.M.V. is a Georgia Cancer Coalition Distinguished Cancer Scholar.
CR Adelman K, 2005, MOL CELL, V17, P103, DOI 10.1016/j.molcel.2004.11.028
   Benetti R, 2007, J CELL BIOL, V178, P925, DOI 10.1083/jcb.200703081
   Benetti R, 2007, NAT GENET, V39, P243, DOI 10.1038/ng1952
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Cai Y, 2010, J BIOL CHEM, V285, P4268, DOI 10.1074/jbc.C109.087981
   Chekhun VF, 2007, MOL CANCER THER, V6, P1089, DOI 10.1158/1535-7163.MCT-06-0663
   Cheng B, 2007, J BIOL CHEM, V282, P21901, DOI 10.1074/jbc.M702936200
   Collard RL, 2006, PROSTATE, V66, P687, DOI 10.1002/pros.20371
   Congdon LM, 2010, J CELL BIOCHEM, V110, P609, DOI 10.1002/jcb.22570
   Conway KE, 2000, CANCER RES, V60, P6236
   Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228
   Crawford NPS, 2008, P NATL ACAD SCI USA, V105, P6380, DOI 10.1073/pnas.0710331105
   Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100
   Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031
   Egger G, 2007, CANCER RES, V67, P346, DOI 10.1158/0008-5472.CAN-06-2845
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   French CA, 2001, AM J PATHOL, V159, P1987, DOI 10.1016/S0002-9440(10)63049-0
   Gilchrist DA, 2008, GENE DEV, V22, P1921, DOI 10.1101/gad.1643208
   Gilmour DS, 2009, CHROMOSOMA, V118, P1, DOI 10.1007/s00412-008-0182-4
   Gonzalo S, 2005, NAT CELL BIOL, V7, P420, DOI 10.1038/ncb1235
   Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322
   Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042
   Issa JPJ, 2007, CLIN CANCER RES, V13, P1634, DOI 10.1158/1078-0432.CCR-06-2076
   Jacinto FV, 2009, ONCOGENE, V28, P4212, DOI 10.1038/onc.2009.267
   Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027
   Jia D, 2007, NATURE, V449, P248, DOI 10.1038/nature06146
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Kagey JD, 2010, MOL CANCER RES, V8, P1048, DOI 10.1158/1541-7786.MCR-10-0189
   Kapoor-Vazirani P, 2008, CANCER RES, V68, P6810, DOI 10.1158/0008-5472.CAN-08-0141
   Kim D, 2010, NAT STRUCT MOL BIOL, V17, P1027, DOI 10.1038/nsmb.1856
   Levine JJ, 2003, ONCOGENE, V22, P3475, DOI 10.1038/sj.onc.1206430
   Li XZ, 2009, MOL CELL, V36, P290, DOI 10.1016/j.molcel.2009.07.031
   MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335
   Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835
   Matsui T, 2010, NATURE, V464, P927, DOI 10.1038/nature08858
   McCabe MT, 2009, CLIN CANCER RES, V15, P3927, DOI 10.1158/1078-0432.CCR-08-2784
   McConnell BB, 2004, APOPTOSIS, V9, P5, DOI 10.1023/B:APPT.0000012117.32430.0c
   McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481
   Mendjan S, 2006, MOL CELL, V21, P811, DOI 10.1016/j.molcel.2006.02.007
   Moore SA, 2010, J BIOL CHEM, V285, P40879, DOI 10.1074/jbc.M110.134312
   Muse GW, 2007, NAT GENET, V39, P1507, DOI 10.1038/ng.2007.21
   Nechaev S, 2008, CELL CYCLE, V7, P1539, DOI 10.4161/cc.7.11.6006
   Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Parsons MJ, 2006, ONCOGENE, V25, P6948, DOI 10.1038/sj.onc.1209684
   Parsons MJ, 2009, CANCER RES, V69, P1706, DOI 10.1158/0008-5472.CAN-08-2351
   Pesavento JJ, 2008, MOL CELL BIOL, V28, P468, DOI 10.1128/MCB.01517-07
   Pfister S, 2008, INT J CANCER, V122, P1207, DOI 10.1002/ijc.23283
   Pogribny IP, 2006, CARCINOGENESIS, V27, P1180, DOI 10.1093/carcin/bgi364
   Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704
   Schotta G, 2008, GENE DEV, V22, P2048, DOI 10.1101/gad.476008
   Smith ER, 2005, MOL CELL BIOL, V25, P9175, DOI 10.1128/MCB.25.21.9175-9188.2005
   Stimson KM, 2002, J BIOL CHEM, V277, P4951, DOI 10.1074/jbc.M109809200
   Stone AR, 2004, AM J PATHOL, V165, P1151, DOI 10.1016/S0002-9440(10)63376-7
   Sun JL, 2010, J BIOL CHEM, V285, P6443, DOI 10.1074/jbc.M109.084285
   Taipale M, 2005, MOL CELL BIOL, V25, P6798, DOI 10.1128/MCB.25.15.6798-6810.2005
   Takeshima H, 2009, GENOME RES, V19, P1974, DOI 10.1101/gr.093310.109
   Thomas MC, 2006, CRIT REV BIOCHEM MOL, V41, P105, DOI 10.1080/10409230600648736
   Van Den Broeck A, 2008, CLIN CANCER RES, V14, P7237, DOI 10.1158/1078-0432.CCR-08-0869
   Venters Bryan J, 2007, Genome Biol, V8, P319, DOI 10.1186/gb-2007-8-11-319
   Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395
   Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049
   Wu CH, 2003, GENE DEV, V17, P1402, DOI 10.1101/gad.1091403
   Yamada T, 2006, MOL CELL, V21, P227, DOI 10.1016/j.molcel.2005.11.024
   Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8
   Yang HB, 2008, J BIOL CHEM, V283, P12085, DOI 10.1074/jbc.M707974200
   Yang HB, 2009, BIOCHEM CELL BIOL, V87, P151, DOI 10.1139/O08-131
   Zeitlinger J, 2007, GENE DEV, V21, P385, DOI 10.1101/gad.1509607
   Zippo A, 2009, CELL, V138, P1122, DOI 10.1016/j.cell.2009.07.031
NR 69
TC 75
Z9 92
U1 0
U2 15
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD APR
PY 2011
VL 31
IS 8
BP 1594
EP 1609
DI 10.1128/MCB.00524-10
PG 16
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 741HZ
UT WOS:000288856100001
PM 21321083
OA Green Published
DA 2025-01-12
ER

PT J
AU Baird, AM
   Gray, SG
   O'Byrne, KJ
AF Baird, Anne-Marie
   Gray, Steven G.
   O'Byrne, Kenneth J.
TI Epigenetics Underpinning the Regulation of the CXC (ELR<SUP>+</SUP>)
   Chemokines in Non-Small Cell Lung Cancer
SO PLOS ONE
LA English
DT Article
ID DUFFY ANTIGEN RECEPTOR; GROWTH-FACTOR; TUMOR-GROWTH; OXIDATIVE STRESS;
   MELANOMA GROWTH; BREAST-CANCER; INTERLEUKIN-8; ANGIOGENESIS; EXPRESSION;
   CARCINOMA
AB Background: Angiogenesis may play a role in the pathogenesis of Non-Small Cell Lung cancer (NSCLC). The CXC (ELR+) chemokine family are powerful promoters of the angiogenic response.
   Methods: The expression of the CXC (ELR+) family members (CXCL1-3/GRO alpha-gamma, CXCL8/IL-8, CXCR1/2) was examined in a series of resected fresh frozen NSCLC tumours. Additionally, the expression and epigenetic regulation of these chemokines was examined in normal bronchial epithelial and NSCLC cell lines.
   Results: Overall, expression of the chemokine ligands (CXCL1, 2, 8) and their receptors (CXCR1/2) were down regulated in tumour samples compared with normal, with the exception of CXCL3. CXCL8 and CXCR1/2 were found to be epigenetically regulated by histone post-translational modifications. Recombinant CXCL8 did not stimulate cell growth in either a normal bronchial epithelial or a squamous carcinoma cell line (SKMES-1). However, an increase was observed at 72 hours post treatment in an adenocarcinoma cell line.
   Conclusions: CXC (ELR+) chemokines are dysregulated in NSCLC. The balance of these chemokines may be critical in the tumour microenvironment and requires further elucidation. It remains to be seen if epigenetic targeting of these pathways is a viable therapeutic option in lung cancer treatment.
C1 [Baird, Anne-Marie; Gray, Steven G.; O'Byrne, Kenneth J.] Trinity Coll Dublin, Inst Mol Med, Thorac Oncol Res Grp, Dublin, Ireland.
   [O'Byrne, Kenneth J.] St James Hosp, HOPE Directorate, Dublin 8, Ireland.
C3 Trinity College Dublin; Trinity College Dublin
RP Baird, AM (通讯作者)，Trinity Coll Dublin, Inst Mol Med, Thorac Oncol Res Grp, Dublin, Ireland.
EM kobyrne@stjames.ie
RI Gray, Steven/I-3081-2019
OI Gray, Steven/0000-0002-5850-6392; Baird, Anne-Marie/0000-0001-7501-1159;
   O'Byrne, Kenneth/0000-0002-6754-5633
FU Pfizer
FX This work was supported by an unrestricted educational grant from
   Pfizer. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038
   Acosta JC, 2009, CANCER RES, V69, P2167, DOI 10.1158/0008-5472.CAN-08-3772
   Addison CL, 2000, J IMMUNOL, V165, P5269, DOI 10.4049/jimmunol.165.9.5269
   Addison CL, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-28
   Anderson IC, 2000, CANCER RES, V60, P269
   Arenberg DA, 1997, J LEUKOCYTE BIOL, V62, P554, DOI 10.1002/jlb.62.5.554
   Arenberg DA, 1996, J CLIN INVEST, V97, P2792, DOI 10.1172/JCI118734
   Arenberg D, 2006, J THORAC ONCOL, V1, P287, DOI 10.1097/01243894-200605000-00003
   Atanackovic D, 2008, TUMOR BIOL, V29, P93, DOI 10.1159/000135689
   Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388
   Black JC, 2011, EPIGENETICS-US, V6, P13, DOI 10.4161/epi.6.1.13331
   Chavey C, 2008, MOL PHARMACOL, V74, P1359, DOI 10.1124/mol.108.047332
   Colasante A, 1997, AM J RESP CRIT CARE, V156, P968, DOI 10.1164/ajrccm.156.3.9701122
   Gabellini C, 2009, EUR J CANCER, V45, P2618, DOI 10.1016/j.ejca.2009.07.007
   Gilmour PS, 2003, AM J PHYSIOL-LUNG C, V284, pL533, DOI 10.1152/ajplung.00277.2002
   Heller G, 2010, CANCER METAST REV, V29, P95, DOI 10.1007/s10555-010-9203-x
   Horton LW, 2007, CANCER RES, V67, P9791, DOI 10.1158/0008-5472.CAN-07-0246
   Keane MP, 2004, J IMMUNOL, V172, P2853, DOI 10.4049/jimmunol.172.5.2853
   Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025
   Lawless MW, 2009, J CELL MOL MED, V13, P2800, DOI 10.1111/j.1582-4934.2009.00845.x
   Lazennec G, 2010, TRENDS MOL MED, V16, P133, DOI 10.1016/j.molmed.2010.01.003
   Luppi F, 2007, LUNG CANCER, V56, P25, DOI 10.1016/j.lungcan.2006.11.014
   Makki MS, 2008, NUCLEIC ACIDS RES, V36, P4067, DOI 10.1093/nar/gkn356
   Masuya D, 2001, CANCER, V92, P2628, DOI 10.1002/1097-0142(20011115)92:10<2628::AID-CNCR1616>3.0.CO;2-F
   Mestas J, 2005, J IMMUNOL, V175, P5351, DOI 10.4049/jimmunol.175.8.5351
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Murphy PM, 2001, NEW ENGL J MED, V345, P833, DOI 10.1056/NEJM200109133451113
   O'Byrne KJ, 2000, EUR J CANCER, V36, P151, DOI 10.1016/S0959-8049(99)00241-5
   Ohri CM, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-172
   Orditura M, 2002, J INTERF CYTOK RES, V22, P1129, DOI 10.1089/10799900260442557
   Owen JD, 1997, INT J CANCER, V73, P94, DOI 10.1002/(SICI)1097-0215(19970926)73:1<94::AID-IJC15>3.3.CO;2-#
   Pinskaya M, 2009, EPIGENETICS-US, V4, P302, DOI 10.4161/epi.4.5.9369
   Raman D, 2007, CANCER LETT, V256, P137, DOI 10.1016/j.canlet.2007.05.013
   Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703
   Seike M, 2007, JNCI-J NATL CANCER I, V99, P1257, DOI 10.1093/jnci/djm083
   Singh S, 2009, CANCER RES, V69, P411, DOI 10.1158/0008-5472.CAN-08-3378
   Slettenaar VIF, 2006, ADV DRUG DELIVER REV, V58, P962, DOI 10.1016/j.addr.2006.03.012
   Strieter RM, 2005, CYTOKINE GROWTH F R, V16, P593, DOI 10.1016/j.cytogfr.2005.04.007
   Strieter RM, 2004, ANN NY ACAD SCI, V1028, P351, DOI 10.1196/annals.1322.041
   Wang JY, 1996, J INTERF CYTOK RES, V16, P53, DOI 10.1089/jir.1996.16.53
   Wente MN, 2006, CANCER LETT, V241, P221, DOI 10.1016/j.canlet.2005.10.041
   White JR, 1998, J BIOL CHEM, V273, P10095, DOI 10.1074/jbc.273.17.10095
   Wislez M, 2004, INFLAMM RES, V53, P4, DOI 10.1007/s00011-003-1215-3
   Yanagawa J, 2009, CLIN CANCER RES, V15, P6820, DOI 10.1158/1078-0432.CCR-09-1558
   Zhou Q, 2009, BREAST CANCER RES TR, V117, P443, DOI 10.1007/s10549-008-0148-5
   Zhu YM, 2004, BRIT J CANCER, V91, P1970, DOI 10.1038/sj.bjc.6602227
   Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X
NR 47
TC 38
Z9 41
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 27
PY 2011
VL 6
IS 1
AR e14593
DI 10.1371/journal.pone.0014593
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 712JV
UT WOS:000286663900002
PM 21298036
OA gold, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Zhou, WJ
   Geng, ZH
   Chi, S
   Zhang, WL
   Niu, XF
   Lan, SJ
   Ma, L
   Yang, XS
   Wang, LJ
   Ding, YQ
   Geng, JG
AF Zhou, Wei-Jie
   Geng, Zhen H.
   Chi, Shan
   Zhang, Wenli
   Niu, Xiao-Feng
   Lan, Shu-Jue
   Ma, Li
   Yang, Xuesong
   Wang, Li-Jing
   Ding, Yan-Qing
   Geng, Jian-Guo
TI Slit-Robo signaling induces malignant transformation through
   Hakai-mediated E-cadherin degradation during colorectal epithelial cell
   carcinogenesis
SO CELL RESEARCH
LA English
DT Article
DE colorectal carcinogenesis; E-cadherin; Hakai; Robo; Slit
ID BREAST-CANCER CELLS; FREQUENT EPIGENETIC INACTIVATION; REPULSIVE AXON
   GUIDANCE; MESENCHYMAL TRANSITION; BETA-CATENIN; ROUNDABOUT RECEPTOR;
   TUMOR ANGIOGENESIS; DOWN-REGULATION; IN-VIVO; ADHESION
AB The Slit family of guidance cues binds to Roundabout (Robo) receptors and modulates cell migration. We report here that ectopic expression of Slit2 and Robo1 or recombinant Slit2 treatment of Robo1-expressing colorectal epithelial carcinoma cells recruited an ubiquitin ligase Hakai for E-cadherin (E-cad) ubiquitination and lysosomal degradation, epithelial-mesenchymal transition (EMT), and tumor growth and liver metastasis, which were rescued by knockdown of Hakai. In contrast, knockdown of endogenous Robo1 or specific blockade of Slit2 binding to Robo1 prevented E-cad degradation and reversed EMT, resulting in diminished tumor growth and liver metastasis. Ectopic expression of Robo1 also triggered a malignant transformation in Slit2-positive human embryonic kidney 293 cells. Importantly, the expression of Slit2 and Robo1 was significantly associated with an increased metastatic risk and poorer overall survival in colorectal carcinoma patients. We conclude that engagement of Robo1 by Slit2 induces malignant transformation through Hakai-mediated E-cad ubiquitination and lysosomal degradation during colorectal epithelial cell carcinogenesis.
C1 [Geng, Zhen H.; Ma, Li; Geng, Jian-Guo] Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA.
   [Zhou, Wei-Jie; Chi, Shan; Niu, Xiao-Feng; Lan, Shu-Jue] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, Shanghai 200031, Peoples R China.
   [Zhang, Wenli; Ding, Yan-Qing] So Med Univ, Dept Pathol, Nanfang Hosp, Guangzhou 510515, Guangdong, Peoples R China.
   [Zhang, Wenli; Ding, Yan-Qing] So Med Univ, Sch Basic Med Sci, Guangzhou 510515, Guangdong, Peoples R China.
   [Yang, Xuesong] Jinan Univ, Coll Med, Minist Educ, Key Lab Regenerat Med, Guangzhou 510632, Guangdong, Peoples R China.
   [Wang, Li-Jing; Geng, Jian-Guo] Guangdong Pharmaceut Univ, Vasc Biol Res Inst, Guangzhou 510006, Guangdong, Peoples R China.
C3 University of Michigan System; University of Michigan; Chinese Academy
   of Sciences; Center for Excellence in Molecular Cell Science, CAS;
   Southern Medical University - China; Southern Medical University -
   China; Jinan University; Guangdong Pharmaceutical University
RP Geng, JG (通讯作者)，Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA.
EM dyqsmu@sina.com; genglab@gmail.com
RI Xiao, Yang/B-5668-2012
OI Zhou, Weijie/0000-0002-0021-9454
FU Ministry of Science and Technology of China [2010CB529702,
   2010CB529403]; National Science Foundation of China [30871304]; National
   Institutes of Health [CA126897, AI064743]
FX We thank Biao Wang for preliminary studies and Michael J Franklin for
   editing the manuscript. We are grateful to Elaine Fuchs for the plasmid
   of the E-cadherin promoter luciferase reporter. This work was supported
   by grants from the Ministry of Science and Technology of China
   (2010CB529702 to XY and L-JW, 2010CB529403 to Y-QD), National Science
   Foundation of China (30871304 to L-JW) and National Institutes of Health
   (CA126897, AI064743 to J-GG).
CR Altay T, 2007, EXP NEUROL, V207, P186, DOI 10.1016/j.expneurol.2007.06.028
   Arima Y, 2008, CANCER RES, V68, P5104, DOI 10.1158/0008-5472.CAN-07-5680
   Astuti D, 2004, BRIT J CANCER, V90, P515, DOI 10.1038/sj.bjc.6601447
   Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1
   Battaglia S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004355
   Bedell VM, 2005, P NATL ACAD SCI USA, V102, P6373, DOI 10.1073/pnas.0408318102
   Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5
   Bryant DM, 2007, J CELL SCI, V120, P1818, DOI 10.1242/jcs.000653
   Dallol A, 2003, ONCOGENE, V22, P4611, DOI 10.1038/sj.onc.1206687
   Dallol A, 2003, CANCER RES, V63, P1054
   Dallol A, 2002, CANCER RES, V62, P5874
   Dammann R, 2005, EUR J CANCER, V41, P1223, DOI 10.1016/j.ejca.2005.02.020
   Dickson BJ, 2006, ANNU REV CELL DEV BI, V22, P651, DOI 10.1146/annurev.cellbio.21.090704.151234
   Dietrich D, 2009, J HISTOCHEM CYTOCHEM, V57, P477, DOI 10.1369/jhc.2009.953026
   Dunwell TL, 2009, EPIGENETICS-US, V4, P265, DOI 10.4161/epi.9137
   Fritz JL, 2000, DEVELOPMENT, V127, P1991
   Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758
   Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405
   Gregory PA, 2008, CELL CYCLE, V7, P3112, DOI 10.4161/cc.7.20.6851
   Gressner OA, 2008, J GASTROEN HEPATOL, V23, P1024, DOI 10.1111/j.1440-1746.2008.05345.x
   Gröne J, 2006, ONCOL REP, V15, P1437
   Grünert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175
   Guan HB, 2003, J IMMUNOL, V171, P6519, DOI 10.4049/jimmunol.171.12.6519
   Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699
   Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021
   Heuberger J, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002915
   Huminiecki L, 2002, GENOMICS, V79, P547, DOI 10.1006/geno.2002.6745
   Janda E, 2006, ONCOGENE, V25, P7117, DOI 10.1038/sj.onc.1209701
   Jin J, 2009, BIOCHEM BIOPH RES CO, V379, P86, DOI 10.1016/j.bbrc.2008.12.022
   Jones CA, 2008, NAT MED, V14, P448, DOI 10.1038/nm1742
   Jones CA, 2009, NAT CELL BIOL, V11, P1325, DOI 10.1038/ncb1976
   Kanellis J, 2004, AM J PATHOL, V165, P341, DOI 10.1016/S0002-9440(10)63301-9
   Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0
   Kobielak A, 2004, NAT REV MOL CELL BIO, V5, P614, DOI 10.1038/nrm1433
   Labbé E, 2007, CANCER RES, V67, P75, DOI 10.1158/0008-5472.CAN-06-2559
   Laffin B, 2008, MOL CELL BIOL, V28, P1936, DOI 10.1128/MCB.01701-07
   Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7
   Li LJ, 2003, J CELL SCI, V116, P3687, DOI 10.1242/jcs.00644
   Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0
   Ma SL, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2009.07.040
   MacMullin A, 2006, DEV BIOL, V293, P154, DOI 10.1016/j.ydbio.2006.01.027
   Maina F, 2001, MOL CELL, V7, P1293, DOI 10.1016/S1097-2765(01)00261-1
   Medioni C, 2008, J CELL BIOL, V182, P249, DOI 10.1083/jcb.200801100
   Mertsch S, 2008, J NEURO-ONCOL, V87, P1, DOI 10.1007/s11060-007-9484-2
   Narayan G, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-16
   Palacios F, 2005, MOL CELL BIOL, V25, P389, DOI 10.1128/MCB.25.1.389-402.2005
   Planas-Silva MD, 2007, J STEROID BIOCHEM, V104, P11, DOI 10.1016/j.jsbmb.2006.09.039
   Plump AS, 2002, NEURON, V33, P219, DOI 10.1016/S0896-6273(01)00586-4
   Pokutta S, 2007, ANNU REV CELL DEV BI, V23, P237, DOI 10.1146/annurev.cellbio.22.010305.104241
   Prasad A, 2008, J BIOL CHEM, V283, P26624, DOI 10.1074/jbc.M800679200
   Prasad A, 2007, J LEUKOCYTE BIOL, V82, P465, DOI 10.1189/jlb.1106678
   Qian L, 2005, CURR BIOL, V15, P2271, DOI 10.1016/j.cub.2005.10.037
   Radisky DC, 2005, J CELL SCI, V118, P4325, DOI 10.1242/jcs.02552
   Rhee J, 2002, NAT CELL BIOL, V4, P798, DOI 10.1038/ncb858
   Rhee J, 2007, NAT CELL BIOL, V9, P883, DOI 10.1038/ncb1614
   Santiago-Martínez E, 2008, J CELL BIOL, V182, P241, DOI 10.1083/jcb.200804120
   Santiago-Martínez E, 2006, P NATL ACAD SCI USA, V103, P12441, DOI 10.1073/pnas.0605284103
   Schmid BC, 2007, BREAST CANCER RES TR, V106, P333, DOI 10.1007/s10549-007-9504-0
   Sharma G, 2007, LIFE SCI, V80, P1873, DOI 10.1016/j.lfs.2007.02.026
   Sheldon H, 2009, FASEB J, V23, P513, DOI 10.1096/fj.07-098269
   Shen FH, 2009, AM J PATHOL, V175, P479, DOI 10.2353/ajpath.2009.090024
   Shen Y, 2008, J BIOL CHEM, V283, P5127, DOI 10.1074/jbc.M703300200
   Shimizu Y, 2003, ONCOGENE, V22, P884, DOI 10.1038/sj.onc.1206174
   Singh RK, 2007, HUM GENET, V122, P71, DOI 10.1007/s00439-007-0375-6
   Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835
   Tole S, 2009, J LEUKOCYTE BIOL, V86, P1403, DOI 10.1189/jlb.0609391
   Tseng RC, 2010, CANCER RES, V70, P543, DOI 10.1158/0008-5472.CAN-09-2084
   Urbich C, 2009, BLOOD, V113, P5669, DOI 10.1182/blood-2009-01-196485
   Wang B, 2003, CANCER CELL, V4, P19, DOI 10.1016/S1535-6108(03)00164-8
   WANG B, 2005, MED HYPOTHESES RES, V2, P315
   Wang HB, 2007, NAT IMMUNOL, V8, P882, DOI 10.1038/ni1491
   Wang LJ, 2008, CANCER SCI, V99, P510, DOI 10.1111/j.1349-7006.2007.00721.x
   Wheelock MJ, 2008, J CELL SCI, V121, P727, DOI 10.1242/jcs.000455
   Wong K, 2002, CURR OPIN GENET DEV, V12, P583, DOI 10.1016/S0959-437X(02)00343-X
   Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X
   Wu JY, 2001, NATURE, V410, P948, DOI 10.1038/35073616
   Xia YF, 2004, J IMMUNOL, V173, P4207, DOI 10.4049/jimmunol.173.6.4207
   Yang XM, 2010, BIOCHEM BIOPH RES CO, V396, P571, DOI 10.1016/j.bbrc.2010.04.152
   Yuasa-Kawada J, 2009, P NATL ACAD SCI USA, V106, P14530, DOI 10.1073/pnas.0801262106
   Zhang B, 2009, BLOOD, V114, P4300, DOI 10.1182/blood-2008-12-193326
NR 80
TC 111
Z9 133
U1 1
U2 43
PU INST BIOCHEMISTRY & CELL BIOLOGY
PI SHANGHAI
PA SIBS, CAS, 319 YUEYANG ROAD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1001-0602
EI 1748-7838
J9 CELL RES
JI Cell Res.
PD APR
PY 2011
VL 21
IS 4
BP 609
EP 626
DI 10.1038/cr.2011.17
PG 18
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 746GI
UT WOS:000289230800008
PM 21283129
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Sérandour, AA
   Avner, S
   Percevault, F
   Demay, F
   Bizot, M
   Lucchetti-Miganeh, C
   Barloy-Hubler, F
   Brown, M
   Lupien, M
   Métivier, R
   Salbert, G
   Eeckhoute, J
AF Serandour, Aurelien A.
   Avner, Stephane
   Percevault, Frederic
   Demay, Florence
   Bizot, Maud
   Lucchetti-Miganeh, Celine
   Barloy-Hubler, Frederique
   Brown, Myles
   Lupien, Mathieu
   Metivier, Raphael
   Salbert, Gilles
   Eeckhoute, Jerome
TI Epigenetic switch involved in activation of pioneer factor
   FOXA1-dependent enhancers
SO GENOME RESEARCH
LA English
DT Article
ID EMBRYONAL CARCINOMA-CELLS; FORKHEAD BOX A1; DNA METHYLATION;
   TRANSCRIPTION FACTORS; BREAST-CANCER; HUMAN GENOME; ANDROGEN RECEPTOR;
   NEURAL DIFFERENTIATION; HISTONE MODIFICATIONS; PROSTATE-CANCER
AB Transcription factors (TFs) bind specifically to discrete regions of mammalian genomes called cis-regulatory elements. Among those are enhancers, which play key roles in regulation of gene expression during development and differentiation. Despite the recognized central regulatory role exerted by chromatin in control of TF functions, much remains to be learned regarding the chromatin structure of enhancers and how it is established. Here, we have analyzed on a genomic-scale enhancers that recruit FOXA1, a pioneer transcription factor that triggers transcriptional competency of these cis-regulatory sites. Importantly, we found that FOXA1 binds to genomic regions showing local DNA hypomethylation and that its cell-type-specific recruitment to chromatin is linked to differential DNA methylation levels of its binding sites. Using neural differentiation as a model, we showed that induction of FOXA1 expression and its subsequent recruitment to enhancers is associated with DNA demethylation. Concomitantly, histone H3 lysine 4 methylation is induced at these enhancers. These epigenetic changes may both stabilize FOXA1 binding and allow for subsequent recruitment of transcriptional regulatory effectors. Interestingly, when cloned into reporter constructs, FOXA1-dependent enhancers were able to recapitulate their cell type specificity. However, their activities were inhibited by DNA methylation. Hence, these enhancers are intrinsic cell-type-specific regulatory regions of which activities have to be potentiated by FOXA1 through induction of an epigenetic switch that includes notably DNA demethylation.
C1 [Serandour, Aurelien A.; Avner, Stephane; Percevault, Frederic; Demay, Florence; Bizot, Maud; Lucchetti-Miganeh, Celine; Barloy-Hubler, Frederique; Metivier, Raphael; Salbert, Gilles; Eeckhoute, Jerome] Univ Rennes 1, F-35065 Rennes, France.
   [Serandour, Aurelien A.; Avner, Stephane; Percevault, Frederic; Bizot, Maud; Lucchetti-Miganeh, Celine; Barloy-Hubler, Frederique; Metivier, Raphael; Salbert, Gilles; Eeckhoute, Jerome] CNRS, Equipe SPARTE Labellise Ligue Natl Canc, UMR 6026, F-35042 Rennes, France.
   [Serandour, Aurelien A.; Avner, Stephane; Percevault, Frederic; Demay, Florence; Bizot, Maud; Lucchetti-Miganeh, Celine; Barloy-Hubler, Frederique; Metivier, Raphael; Salbert, Gilles; Eeckhoute, Jerome] Univ Europeenne Bretagne, F-35000 Rennes, France.
   [Demay, Florence] CNRS, Equipe RED, UMR 6026, F-35042 Rennes, France.
   [Brown, Myles] Dana Farber Canc Inst, Div Mol & Cellular Oncol, Dept Med Oncol, Boston, MA 02115 USA.
   [Lupien, Mathieu] Dartmouth Med Sch, Dept Genet, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA.
C3 Universite de Rennes; Centre National de la Recherche Scientifique
   (CNRS); Universite de Rennes; Universite de Bretagne Occidentale; Centre
   National de la Recherche Scientifique (CNRS); Universite de Rennes;
   Harvard University; Dana-Farber Cancer Institute; Norris Cotton Cancer
   Center; Dartmouth College
RP Salbert, G (通讯作者)，Univ Rennes 1, F-35065 Rennes, France.
EM gilles.salbert@univ-rennes1.fr; jerome.eeckhoute@inserm.fr
RI demay, florence/K-1881-2015; Brown, Myles/B-6906-2008; Serandour,
   Aurelien/AAG-7036-2019; percevault, frederic/K-1836-2015; Eeckhoute,
   Jerome/AAN-8219-2021; Salbert, Gilles/W-9196-2019; Lupien,
   Mathieu/KFB-6691-2024
OI Brown, Myles/0000-0002-8213-1658; Lupien, Mathieu/0000-0003-0929-9478;
   Eeckhoute, Jerome/0000-0002-7222-9264; Avner,
   Stephane/0000-0001-7413-1327; florence, DEMAY/0000-0002-4855-7241;
   Barloy-Hubler, Frederique/0000-0002-8277-6034
FU Centre National de la Recherche Scientifique (CNRS); Universite de
   Rennes 1; Region Bretagne [SAD 08HC315-02]; Rennes metropole [08.503];
   Ligue nationale contre le cancer; Agence Nationale de la Recherche;
   French Ministerede l'enseignement superieur et de la recherche
FX We are indebted to G. Palierne and C. Brigand for technical assistance
   and to Dr. C. Meyer and Dr. X. S. Liu (Dana-Farber Cancer Institute,
   Boston, MA) for advice regarding analyses of tiling array data. We also
   thank Dr. Patrick Descombes (University of Geneva, Switzerland) and Dr.
   Catherine Chevalier (OUEST-Genopole Microarray Core Facility, Nantes,
   France) for their advice and help with the DNA labeling and array
   hybridization protocols. We acknowledge Dr. M. Klug and Dr. M. Rehli
   (University Hospital, Regensburg, Germany) for their generous gift of
   the pCpGLCMV/EF1 vector and Dr. Z. Culig (Innsbruck Medical University,
   Austria) for providing us with the LNCaP-abl cells. This work was
   supported by funds from the Centre National de la Recherche Scientifique
   (CNRS), Universite de Rennes 1, Region Bretagne (SAD 08HC315-02), Rennes
   metropole (Allocation 08.503), Ligue nationale contre le cancer, and
   Agence Nationale de la Recherche. A. A. S. is a recipient of a
   fellowship from the French Ministerede l'enseignement superieur et de la
   recherche.
CR Aiba K, 2009, DNA RES, V16, P73, DOI 10.1093/dnares/dsn035
   Badve S, 2007, CLIN CANCER RES, V13, P4415, DOI 10.1158/1078-0432.CCR-07-0122
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Belikov S, 2009, MOL CELL BIOL, V29, P5413, DOI 10.1128/MCB.00368-09
   Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874
   Brandt-Bohne U, 2007, BIOCHEM J, V401, P447, DOI 10.1042/BJ20060691
   Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008
   Cecchini KR, 2009, SEMIN CELL DEV BIOL, V20, P842, DOI 10.1016/j.semcdb.2009.06.005
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Cheung E, 2010, ANNU REV PHYSIOL, V72, P191, DOI 10.1146/annurev-physiol-021909-135840
   Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8
   Crowe AJ, 1999, J BIOL CHEM, V274, P25113, DOI 10.1074/jbc.274.35.25113
   Culig Z, 1999, BRIT J CANCER, V81, P242, DOI 10.1038/sj.bjc.6690684
   Edwards JR, 2010, GENOME RES, V20, P972, DOI 10.1101/gr.101535.109
   Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746
   Eeckhoute J, 2006, GENE DEV, V20, P2513, DOI 10.1101/gad.1446006
   Eeckhoute J, 2009, J CELL SCI, V122, P4027, DOI 10.1242/jcs.054916
   Eeckhoute J, 2009, GENOME RES, V19, P372, DOI 10.1101/gr.084582.108
   Farnham PJ, 2009, NAT REV GENET, V10, P605, DOI 10.1038/nrg2636
   Friedman JR, 2006, CELL MOL LIFE SCI, V63, P2317, DOI 10.1007/s00018-006-6095-6
   Gao N, 2003, MOL ENDOCRINOL, V17, P1484, DOI 10.1210/me.2003-0020
   Hajkova P, 2008, NATURE, V452, P877, DOI 10.1038/nature06714
   He HSHS, 2010, NAT GENET, V42, P343, DOI 10.1038/ng.545
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Hoffman BG, 2010, GENOME RES, V20, P1037, DOI 10.1101/gr.104356.109
   Hua SJ, 2009, CELL, V137, P1259, DOI 10.1016/j.cell.2009.04.043
   Jacob A, 1997, EXP CELL RES, V234, P277, DOI 10.1006/excr.1997.3622
   Johnson WE, 2006, P NATL ACAD SCI USA, V103, P12457, DOI 10.1073/pnas.0601180103
   Jones PA, 2009, NAT REV GENET, V10, P805, DOI 10.1038/nrg2651
   JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   Klug M, 2006, EPIGENETICS-US, V1, P127, DOI 10.4161/epi.1.3.3327
   Lacroix M, 2004, MOL CELL ENDOCRINOL, V219, P1, DOI 10.1016/j.mce.2004.02.021
   Laganière J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102
   Lefterova MI, 2010, MOL CELL BIOL, V30, P2078, DOI 10.1128/MCB.01651-09
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018
   Malik S, 2010, MOL CELL BIOL, V30, P399, DOI 10.1128/MCB.00907-09
   Métivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6
   Métivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544
   Mirosevich J, 2006, PROSTATE, V66, P1013, DOI 10.1002/pros.20299
   Motallebipour M, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r129
   Nakshatri H, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001008
   Nucera C, 2009, CLIN CANCER RES, V15, P3680, DOI 10.1158/1078-0432.CCR-08-3155
   O'Geen H, 2006, BIOTECHNIQUES, V41, P577, DOI 10.2144/000112268
   Okitsu CY, 2007, MOL CELL BIOL, V27, P2746, DOI 10.1128/MCB.02291-06
   Ooi SKT, 2007, NATURE, V448, P714, DOI 10.1038/nature05987
   Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001
   Ruike Y, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-137
   Schmidl C, 2009, GENOME RES, V19, P1165, DOI 10.1101/gr.091470.109
   Sekiya T, 2009, GENE DEV, V23, P804, DOI 10.1101/gad.1775509
   Shin HJ, 2009, BIOINFORMATICS, V25, P2605, DOI 10.1093/bioinformatics/btp479
   Steger DJ, 2010, GENE DEV, V24, P1035, DOI 10.1101/gad.1907110
   Suganuma T, 2008, CELL, V135, P604, DOI 10.1016/j.cell.2008.10.036
   Tan YJ, 2010, STEM CELLS DEV, V19, P1365, DOI 10.1089/scd.2009.0386
   Thomson JP, 2010, NATURE, V464, P1082, DOI 10.1038/nature08924
   Thorat MA, 2008, J CLIN PATHOL, V61, P327, DOI 10.1136/jcp.2007.052431
   Visel A, 2009, NATURE, V461, P199, DOI 10.1038/nature08451
   Visel A, 2009, NATURE, V457, P854, DOI 10.1038/nature07730
   Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056
   Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598
   Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
   Xu J, 2009, GENE DEV, V23, P2824, DOI 10.1101/gad.1861209
   Yao J, 1998, DEV GROWTH DIFFER, V40, P133
   Zaret K, 1999, DEV BIOL, V209, P1, DOI 10.1006/dbio.1999.9228
   Zemach A, 2010, SCIENCE, V328, P916, DOI 10.1126/science.1186366
   Zilberman D, 2008, NATURE, V456, P125, DOI 10.1038/nature07324
NR 69
TC 174
Z9 209
U1 0
U2 31
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1088-9051
EI 1549-5469
J9 GENOME RES
JI Genome Res.
PD APR
PY 2011
VL 21
IS 4
BP 555
EP 565
DI 10.1101/gr.111534.110
PG 11
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 744BN
UT WOS:000289067800006
PM 21233399
OA Green Published, Green Submitted, hybrid
DA 2025-01-12
ER

PT J
AU Mao, XL
   Hou, TJ
   Cao, BY
   Wang, WJ
   Li, ZH
   Chen, SN
   Fei, M
   Hurren, R
   Gronda, M
   Wu, DP
   Trudel, S
   Schimmer, AD
AF Mao, Xinliang
   Hou, Tingjun
   Cao, Biyin
   Wang, Wenjie
   Li, Zhihua
   Chen, Suning
   Fei, Min
   Hurren, Rose
   Gronda, Marcela
   Wu, Depei
   Trudel, Suzanne
   Schimmer, Aaron D.
TI The Tricyclic Antidepressant Amitriptyline Inhibits D-Cyclin
   Transactivation and Induces Myeloma Cell Apoptosis by Inhibiting Histone
   Deacetylases: In Vitro and In Silico Evidence
SO MOLECULAR PHARMACOLOGY
LA English
DT Article
ID NF-KAPPA-B; MULTIPLE-MYELOMA; BREAST-CANCER; D DYSREGULATION; CRITICAL
   ROLES; T-CELL; TRANSCRIPTION; ACTIVATION; PROLIFERATION; PROGRESSION
AB Amitriptyline is a classic tricyclic antidepressant (TCA) and has been used to treat the depression and anxiety of patients with cancer, but its relevance to cancer cell apoptosis is not known. In the present study, we demonstrated that amitriptyline inhibited cyclin D2 transactivation and displayed potential antimyeloma activity by inhibiting histone deacetylases (HDACs). Amitriptyline markedly decreased cyclin D2 promoter-driven luciferase activity, reduced cyclin D2 expression, and arrested cells at the G(0)/G(1) phase of the cell cycle. Amitriptyline-induced apoptosis was confirmed by Annexin V staining, and cleavage of caspase-3 and poly(ADP-ribose) polymerase-1. D-Cyclin expression is reported to be epigenetically regulated by histone acetylation. Thus, we examined the effects of amitriptyline on histone 3 (H3) acetylation and demonstrated that amitriptyline increased acetylation of H3 and expression of p27 and p21. Further studies indicated that amitriptyline interfered with HDAC function by down-regulation of HDAC3, -6, -7, and -8, but not HDAC2, and by interacting with HDAC7. Molecular docking analysis and molecular dynamics simulations revealed that amitriptyline bound to HDAC7 and formed strong van der Waals interactions with five residues of HDAC7, including Phe162, His192, Phe221, Leu293, and His326, thus inhibiting HDAC activity. Therefore, we found that amitriptyline inhibited cyclin D2 transactivation and HDAC activity and could be a promising treatment for multiple myeloma.
C1 [Mao, Xinliang; Cao, Biyin; Wang, Wenjie; Chen, Suning; Fei, Min; Wu, Depei] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Cyrus Tang Hematol Ctr, Suzhou 215123, Jiangsu, Peoples R China.
   [Hou, Tingjun] Soochow Univ, Inst Funct Nano & Soft Mat FUNSOM, Suzhou 215123, Jiangsu, Peoples R China.
   [Hou, Tingjun] Soochow Univ, Jiangsu Key Lab Carbon Based Funct Mat & Devices, Suzhou 215123, Jiangsu, Peoples R China.
   [Mao, Xinliang; Li, Zhihua; Hurren, Rose; Gronda, Marcela; Trudel, Suzanne; Schimmer, Aaron D.] Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M4X 1K9, Canada.
C3 Soochow University - China; Soochow University - China; Soochow
   University - China; University of Toronto; University Health Network
   Toronto; Princess Margaret Cancer Centre
RP Mao, XL (通讯作者)，Soochow Univ, Cyrus Tang Hematol Ctr, Lab Targeted Antileukemia Drug Discovery, 199 Ren Ai Rd,Room 703-507,Suzhou Ind Pk, Suzhou 215123, Jiangsu, Peoples R China.
EM xinliangmao@suda.edu.cn
RI Li, ZhiHua/GYU-9914-2022; Hou, Tingjun/C-7492-2011
OI Schimmer, Aaron/0000-0003-4023-3899
FU Suzhou City Science and Technology Program Social Development Project
   [SS201033]; Program for the Development of Preponderant Disciplines of
   Jiangsu Universities: Blood Translational Medicine
FX This project was partially supported by Suzhou City Science and
   Technology Program Social Development Project [Grant SS201033] and by
   the Program for the Development of Preponderant Disciplines of Jiangsu
   Universities: Blood Translational Medicine (2010-2013).
CR Abdouh M, 2004, BRAIN BEHAV IMMUN, V18, P24, DOI 10.1016/S0889-1591(03)00088-6
   Amit B, 2009, EUR NEUROPSYCHOPHARM, V19, P726, DOI 10.1016/j.euroneuro.2009.06.003
   Argov M, 2009, CANCER LETT, V274, P118, DOI 10.1016/j.canlet.2008.09.005
   Arimochi H, 2006, EUR J PHARMACOL, V541, P17, DOI 10.1016/j.ejphar.2006.04.053
   BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004
   Bergsagel PL, 2005, BLOOD, V106, P296, DOI 10.1182/blood-2005-01-0034
   Bergsagel PL, 2003, IMMUNOL REV, V194, P96, DOI 10.1034/j.1600-065X.2003.00052.x
   Bhaskara S, 2008, MOL CELL, V30, P61, DOI 10.1016/j.molcel.2008.02.030
   Chang HC, 2008, TOXICOLOGY, V250, P9, DOI 10.1016/j.tox.2008.05.010
   Cloonan SM, 2011, INT J CANCER, V128, P1712, DOI 10.1002/ijc.25477
   Coogan PF, 2009, PHARMACOEPIDEM DR S, V18, P1111, DOI 10.1002/pds.1808
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Duan Y, 2003, J COMPUT CHEM, V24, P1999, DOI 10.1002/jcc.10349
   Fann JR, 2009, J GEN INTERN MED, V24, P417, DOI 10.1007/s11606-009-0999-4
   Gil-Ad I, 2008, INT J ONCOL, V33, P277, DOI 10.3892/ijo_00000007
   Gohlke H, 2003, J MOL BIOL, V330, P891, DOI 10.1016/S0022-2836(03)00610-7
   Higgins SC, 2010, ANTICANCER RES, V30, P391
   Hu J, 2005, MOL CANCER RES, V3, P100, DOI 10.1158/1541-7786.MCR-04-0070
   Huang WF, 2006, BIOCHEM BIOPH RES CO, V339, P165, DOI 10.1016/j.bbrc.2005.11.010
   Kamemura K, 2008, BIOCHEM BIOPH RES CO, V374, P84, DOI 10.1016/j.bbrc.2008.06.092
   Karagianni P, 2007, ONCOGENE, V26, P5439, DOI 10.1038/sj.onc.1210612
   Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200
   Kurup RK, 2003, PATHOL ONCOL RES, V9, P107, DOI 10.1007/BF03033754
   Lash TL, 2010, ACTA ONCOL, V49, P305, DOI 10.3109/02841860903575273
   Lawlor DA, 2003, J CLIN EPIDEMIOL, V56, P155
   Mao X, 2007, BLOOD, V110, P4047, DOI 10.1182/blood-2007-05-088666
   Meredith EJ, 2005, FASEB J, V19, P1187, DOI 10.1096/fj.04-3477fje
   Mishra S, 2008, AM J HOSP PALLIAT ME, V25, P447, DOI 10.1177/1049909108322288
   Onufriev A, 2004, PROTEINS, V55, P383, DOI 10.1002/prot.20033
   Pilkington GJ, 2008, SEMIN CANCER BIOL, V18, P226, DOI 10.1016/j.semcancer.2007.12.006
   Richardson PG, 2010, ONCOLOGY-NY, V24, P22
   Sharpe CR, 2002, BRIT J CANCER, V86, P92, DOI 10.1038/sj.bjc.6600013
   Stepulak A, 2008, CANCER BIOL THER, V7, P1685, DOI 10.4161/cbt.7.10.6664
   Tiedemann RE, 2008, J CLIN INVEST, V118, P1750, DOI 10.1172/JCI34149
   Wickström SA, 2010, EMBO J, V29, P131, DOI 10.1038/emboj.2009.317
   Xia ZL, 1999, J BIOCHEM MOL TOXIC, V13, P338, DOI 10.1002/(SICI)1099-0461(1999)13:6<338::AID-JBT8>3.3.CO;2-Z
NR 36
TC 57
Z9 61
U1 0
U2 14
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0026-895X
J9 MOL PHARMACOL
JI Mol. Pharmacol.
PD APR
PY 2011
VL 79
IS 4
BP 672
EP 680
DI 10.1124/mol.110.068122
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 737BA
UT WOS:000288541200005
PM 21220410
DA 2025-01-12
ER

PT J
AU Acosta, D
   Suzuki, M
   Connolly, D
   Thompson, RF
   Fazzari, MJ
   Greally, JM
   Montagna, C
AF Acosta, Deanna
   Suzuki, Masako
   Connolly, Diana
   Thompson, Reid F.
   Fazzari, Melissa J.
   Greally, John M.
   Montagna, Cristina
TI DNA methylation changes in murine breast adenocarcinomas allow the
   identification of candidate genes for human breast carcinogenesis
SO MAMMALIAN GENOME
LA English
DT Article
ID MAMMARY-GLAND ADENOCARCINOMAS; CENTROSOME AMPLIFICATION; CYTOSINE
   METHYLATION; MASS-SPECTROMETRY; TRANSGENIC MICE; HUMAN-DISEASES; CANCER
   MODEL; MOUSE; TUMORS; EXPRESSION
AB Epigenetic inactivation due to aberrant promoter methylation is a key process in breast tumorigenesis. Murine models for human breast cancer have been established for nearly every important human oncogene or tumor suppressor gene. Mouse-to-human comparative gene expression and cytogenetic profiling have been widely investigated for these models; however, little is known about the conservation of epigenetic alterations during tumorigenesis. To determine if this key process in human breast tumorigenesis is also mirrored in a murine breast cancer model, we mapped cytosine methylation changes in primary adenocarcinomas and paired lung metastases derived from the polyomavirus middle T antigen mouse model. Global changes in methylcytosine levels were observed in all tumors when compared to the normal mammary gland. Aberrant methylation and associated gene silencing was observed for Hoxa7, a gene that is differentially methylated in human breast tumors, and Gata2, a novel candidate gene. Analysis of HOXA7 and GATA2 expression in a bank of human primary tumors confirms that the expression of these genes is also reduced in human breast cancer. In addition, HOXA7 hypermethylation is observed in breast cancer tissues when compared to adjacent tumor-free tissue. Based on these studies, we present a model in which comparative epigenetic techniques can be used to identify novel candidate genes important for human breast tumorigenesis, in both primary and metastatic tumors.
C1 [Acosta, Deanna; Suzuki, Masako; Connolly, Diana; Thompson, Reid F.; Fazzari, Melissa J.; Greally, John M.; Montagna, Cristina] Yeshiva Univ, Albert Einstein Coll Med, Dept Genet, Bronx, NY 10461 USA.
   [Fazzari, Melissa J.] Yeshiva Univ, Dept Epidemiol & Populat Hlth, Albert Einstein Coll Med, Bronx, NY 10461 USA.
   [Montagna, Cristina] Yeshiva Univ, Dept Pathol, Albert Einstein Coll Med, Bronx, NY 10461 USA.
C3 Yeshiva University; Montefiore Medical Center; Albert Einstein College
   of Medicine; Yeshiva University; Montefiore Medical Center; Albert
   Einstein College of Medicine; Montefiore Medical Center; Albert Einstein
   College of Medicine; Yeshiva University
RP Montagna, C (通讯作者)，Yeshiva Univ, Albert Einstein Coll Med, Dept Genet, 1301 Morris Pk Ave, Bronx, NY 10461 USA.
EM cristina.montagna@einstein.yu.edu
RI Suzuki, Masako/ABF-6497-2020; Greally, John/AAF-9540-2019
OI Thompson, Reid/0000-0003-3661-5296; Greally, John/0000-0001-6069-7960;
   Fazzari, Melissa/0000-0002-5674-3589
CR Andrechek ER, 2003, CANCER RES, V63, P4920
   Antoniou AC, 2009, HUM MOL GENET, V18, P4442, DOI 10.1093/hmg/ddp372
   Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530
   Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001
   Bowen TJ, 2005, CANCER RES, V65, P8736, DOI 10.1158/0008-5472.CAN-05-1598
   Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779
   DAVISSON MT, 1994, GENE, V147, P157, DOI 10.1016/0378-1119(94)90060-4
   Demircan B, 2009, GENE CHROMOSOME CANC, V48, P83, DOI 10.1002/gcc.20620
   Dorritie K, 2004, EXPERT REV MOL DIAGN, V4, P663, DOI 10.1586/14737159.4.5.663
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Figueroa ME, 2010, CANCER CELL, V17, P13, DOI 10.1016/j.ccr.2009.11.020
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954
   Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76
   Hutchinson JN, 2000, ONCOGENE, V19, P6130, DOI 10.1038/sj.onc.1203970
   IHAKA R, 2008, R LANGUAGE ENV STAT
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Khulan B, 2006, GENOME RES, V16, P1046, DOI 10.1101/gr.5273806
   Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011
   Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7
   Makiyama K, 2005, ONCOL REP, V13, P673
   MCNEIL N, 2003, ATLAS GENET CYTOGENE, V7, P611
   Montagna C, 2003, CANCER RES, V63, P2179
   Montagna C, 2002, ONCOGENE, V21, P890, DOI 10.1038/sj.onc.1205146
   Novak P, 2008, CANCER RES, V68, P8616, DOI 10.1158/0008-5472.CAN-08-1419
   Novak P, 2006, CANCER RES, V66, P10664, DOI 10.1158/0008-5472.CAN-06-2761
   Oda M, 2009, NUCLEIC ACIDS RES, V37, P3829, DOI 10.1093/nar/gkp260
   Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266
   Ordway JM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001314
   Ried Thomas, 2004, Breast Dis, V19, P59
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Selzer RR, 2005, GENE CHROMOSOME CANC, V44, P305, DOI 10.1002/gcc.20243
   Thompson RF, 2009, BIOINFORMATICS, V25, P2164, DOI 10.1093/bioinformatics/btp382
   Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233
   Tsai AG, 2008, CELL, V135, P1130, DOI 10.1016/j.cell.2008.10.035
   Vu TH, 2006, CYTOGENET GENOME RES, V113, P202, DOI 10.1159/000090833
   Wang X, 2007, CELL DEATH DIFFER, V14, P924, DOI 10.1038/sj.cdd.4402105
   Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262
   Weaver Z, 2002, ONCOGENE, V21, P5097, DOI 10.1038/sj.onc.1205636
   Weaver ZA, 1999, GENE CHROMOSOME CANC, V25, P251, DOI 10.1002/(SICI)1098-2264(199907)25:3<251::AID-GCC7>3.3.CO;2-V
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007
   Ye Yumei, 2004, Breast Dis, V19, P69
NR 46
TC 11
Z9 15
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0938-8990
J9 MAMM GENOME
JI Mamm. Genome
PD APR
PY 2011
VL 22
IS 3-4
BP 249
EP 259
DI 10.1007/s00335-011-9318-6
PG 11
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 733KS
UT WOS:000288262200008
PM 21373886
DA 2025-01-12
ER

PT J
AU Paluszczak, J
   Krajka-Kuzniak, V
   Malecka, Z
   Jarmuz, M
   Kostrzewska-Poczekaj, M
   Grenman, R
   Baer-Dubowska, W
AF Paluszczak, Jaroslaw
   Krajka-Kuzniak, Violetta
   Malecka, Zuzanna
   Jarmuz, Malgorzata
   Kostrzewska-Poczekaj, Magdalena
   Grenman, Reidar
   Baer-Dubowska, Wanda
TI Frequent gene hypermethylation in laryngeal cancer cell lines and the
   resistance to demethylation induction by plant polyphenols
SO TOXICOLOGY IN VITRO
LA English
DT Article
DE Chemoprevention; DNA methylation; Epigenetics; Larynx cancer; Plant
   polyphenols
ID TUMOR-SUPPRESSOR GENES; DNA METHYLTRANSFERASE INHIBITORS; PROMOTER
   HYPERMETHYLATION; BREAST-CANCER; LUNG-CANCER; PROGNOSTIC-SIGNIFICANCE;
   METHYLATION STATUS; COLORECTAL-CANCER; PROSTATE-CANCER; MULTIPLE GENES
AB Promoter hypermethylation is one of the mechanisms in the transcriptional inactivation of certain carcinoma - associated genes. In laryngeal cancers hypermethylation of tumor suppressor genes is related to their major risk factors- cigarette smoking and drinking strong alcohols. Since DNA methylation is reversible, modulation of the activity of DNA methyltransferases is an established therapeutic strategy, which can be also applied in cancer chemoprevention. Here, using the MSP procedure, we evaluated the frequency of hypermethylation of RARbeta, RASSF1A, HIN-1, GSTP1, MGMT, VHL and DAPK genes in several laryngeal and other head and neck squamous cell carcinoma cell lines and the effect of various polyphenols on the methylation of RARbeta and MGMT genes in the UT-SCC 42B cell line. most of the cell lines tested were characterized by the hypermethylation of at least one of the genes analyzed. The most frequently hypermethylated genes were RARbeta and MGMT, while GSTP1 and VHL were not methylated in any of the cell lines. None of the tested compounds, including decitabine used as a reference compound, changed the methylation of RARbeta and MGMT genes. These findings suggest that although hypermethylation of RARbeta and MGMT may be considered as potential epigenetic biomarker, their application as therapeutic/chemopreventive targets requires further studies. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Paluszczak, Jaroslaw; Krajka-Kuzniak, Violetta; Malecka, Zuzanna; Baer-Dubowska, Wanda] Poznan Univ Med Sci, Dept Pharmaceut Biochem, PL-60781 Poznan, Poland.
   [Jarmuz, Malgorzata; Kostrzewska-Poczekaj, Magdalena] Polish Acad Sci, Inst Human Genet, Dept Mutagenesis, PL-60479 Poznan, Poland.
   [Grenman, Reidar] Turku Univ Cent Hosp, Dept Otorhinolaryngol Head & Neck Surg, Turku, Finland.
   [Grenman, Reidar] Turku Univ Cent Hosp, Dept Med Biochem, Turku, Finland.
   [Grenman, Reidar] Turku Univ, Turku, Finland.
C3 Poznan University of Medical Sciences; Polish Academy of Sciences;
   Institute of Human Genetics of the Polish Academy of Sciences;
   University of Turku; University of Turku; University of Turku
RP Baer-Dubowska, W (通讯作者)，Poznan Univ Med Sci, Dept Pharmaceut Biochem, Ul Swiecickiego 4, PL-60781 Poznan, Poland.
EM baerw@ump.edu.pl
RI Baer-Dubowska, Wanda/AGN-3671-2022; Paluszczak, Jaroslaw/IZE-4347-2023
OI Kostrzewska-Poczekaj, Magdalena/0000-0001-8099-3839; Jarmuz-Szymczak,
   Malgorzata/0000-0003-0437-5806; Baer-Dubowska,
   Wanda/0000-0002-6625-5343; Paluszczak, Jaroslaw/0000-0002-6187-7549;
   Krajka-Kuzniak, Violetta/0000-0001-7275-0298
CR Almadori G, 2004, EUR J CANCER, V40, P2383, DOI 10.1016/j.ejca.2004.04.023
   Almadori G, 2005, EUR J CANCER, V41, P683, DOI 10.1016/j.ejca.2004.10.031
   Alvarez S, 2007, INT J BIOCHEM CELL B, V39, P1406, DOI 10.1016/j.biocel.2007.02.010
   [Anonymous], 2005, CULTURE ANIMAL CELLS, DOI DOI 10.1002/9780471747598
   Azarschab P, 2003, ONCOL REP, V10, P501
   Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   Bazan V, 2002, J CELL PHYSIOL, V192, P286, DOI 10.1002/jcp.10138
   Belinsky SA, 2003, CANCER RES, V63, P7089
   Byun HM, 2008, CANCER LETT, V266, P238, DOI 10.1016/j.canlet.2008.02.069
   Chang HSW, 2004, CANCER-AM CANCER SOC, V101, P125, DOI 10.1002/cncr.20323
   Chuang JC, 2005, MOL CANCER THER, V4, P1515, DOI 10.1158/1535-7163.MCT-05-0172
   CIU Y, 2008, LIFE SCI, V82, P247
   De Stefani E, 2000, INT J CANCER, V87, P129, DOI 10.1002/1097-0215(20000701)87:1<129::AID-IJC19>3.0.CO;2-M
   Dikshit RP, 2007, CANCER-AM CANCER SOC, V110, P1745, DOI 10.1002/cncr.22975
   Dong SM, 2005, MODERN PATHOL, V18, P170, DOI 10.1038/modpathol.3800261
   Edefonti V, 2010, CANCER EPIDEM BIOMAR, V19, P18, DOI 10.1158/1055-9965.EPI-09-0900
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fang MZ, 2005, CLIN CANCER RES, V11, P7033, DOI 10.1158/1078-0432.CCR-05-0406
   Fang MZ, 2003, CANCER RES, V63, P7563
   Fini L, 2007, J NUTR, V137, P2622, DOI 10.1093/jn/137.12.2622
   Giefing M, 2008, CANCER GENET CYTOGEN, V184, P38, DOI 10.1016/j.cancergencyto.2008.03.004
   Hasegawa M, 2002, ONCOGENE, V21, P4231, DOI 10.1038/sj.onc.1205528
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hollenbach PW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009001
   Issa JP, 2008, CANCER PREV RES, V1, P219, DOI 10.1158/1940-6207.CAPR-08-0029
   Issa JPJ, 2009, CLIN CANCER RES, V15, P3938, DOI 10.1158/1078-0432.CCR-08-2783
   Jarmuz M, 2005, CANCER GENET CYTOGEN, V160, P82, DOI 10.1016/j.cancergencyto.2004.12.006
   Jarmuz M, 2002, EUR ARCH OTO-RHINO-L, V259, P269, DOI 10.1007/s00405-002-0450-5
   Kim H, 2004, J CLIN ONCOL, V22, P2363, DOI 10.1200/JCO.2004.10.077
   King-Batoon A, 2008, ENVIRON MOL MUTAGEN, V49, P36, DOI 10.1002/em.20363
   Kong WJ, 2005, LARYNGOSCOPE, V115, P1395, DOI 10.1097/01.MLG.0000166708.23673.3A
   Kopelovich L, 2003, JNCI-J NATL CANCER I, V95, P1747, DOI 10.1093/jnci/dig109
   Krop I, 2005, CANCER RES, V65, P9659, DOI 10.1158/0008-5472.CAN-05-1663
   Krop I, 2004, MOL CANCER RES, V2, P489
   Kulkarni V, 2004, ORAL ONCOL, V40, P145, DOI 10.1016/S1368-8375(03)00143-X
   Kwong J, 2002, CLIN CANCER RES, V8, P131
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lee WJ, 2006, CARCINOGENESIS, V27, P269, DOI 10.1093/carcin/bgi206
   Lee WJ, 2005, MOL PHARMACOL, V68, P1018, DOI 10.1124/mol.104.008367
   Liu ZF, 2009, J PHARMACOL EXP THER, V329, P505, DOI 10.1124/jpet.108.147934
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Majid S, 2008, CANCER RES, V68, P2736, DOI 10.1158/0008-5472.CAN-07-2290
   Majid S, 2009, CARCINOGENESIS, V30, P662, DOI 10.1093/carcin/bgp042
   Martone T, 2007, CLIN CANCER RES, V13, P5089, DOI 10.1158/1078-0432.CCR-07-0119
   Maruya SI, 2004, CLIN CANCER RES, V10, P3825, DOI 10.1158/1078-0432.CCR-03-0370
   McCabe MT, 2006, CANCER RES, V66, P385, DOI 10.1158/0008-5472.CAN-05-2020
   Ogi K, 2002, CLIN CANCER RES, V8, P3164
   Paluszczak J, 2006, J APPL GENET, V47, P365, DOI 10.1007/BF03194647
   Paluszczak J, 2010, TOXICOL LETT, V192, P119, DOI 10.1016/j.toxlet.2009.10.010
   Paz MF, 2003, CANCER RES, V63, P1114
   Perez-Ordoñez B, 2006, J CLIN PATHOL, V59, P445, DOI 10.1136/jcp.2003.007641
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Rubinstein JC, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-4
   Russo AL, 2005, CLIN CANCER RES, V11, P2466, DOI 10.1158/1078-0432.CCR-04-1962
   Sanchez-Cespedes M, 2000, CANCER RES, V60, P892
   Sasiadek MM, 2004, BRIT J CANCER, V90, P1594, DOI 10.1038/sj.bjc.6601679
   Stresemann C, 2006, CANCER RES, V66, P2794, DOI 10.1158/0008-5472.CAN-05-2821
   Stresemann C, 2008, INT J CANCER, V123, P8, DOI 10.1002/ijc.23607
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   van Engeland M, 2003, CANCER RES, V63, P3133
   Viswanathan M, 2003, INT J CANCER, V105, P41, DOI 10.1002/ijc.11028
   Vuillemenot BR, 2004, CARCINOGENESIS, V25, P623, DOI 10.1093/carcin/bgh038
   Yeh KT, 2003, ONCOL REP, V10, P659
   Yoo CB, 2008, CANCER PREV RES, V1, P233, DOI 10.1158/1940-6207.CAPR-07-0008
   Zhang Song, 2006, J Huazhong Univ Sci Technolog Med Sci, V26, P101
NR 65
TC 9
Z9 16
U1 0
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-2333
J9 TOXICOL IN VITRO
JI Toxicol. Vitro
PD FEB
PY 2011
VL 25
IS 1
BP 213
EP 221
DI 10.1016/j.tiv.2010.11.003
PG 9
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA 716YY
UT WOS:000287010600028
PM 21078381
DA 2025-01-12
ER

PT J
AU Paluszczak, J
   Misiak, P
   Wierzbicka, M
   Wozniak, A
   Baer-Dubowska, W
AF Paluszczak, Jaroslaw
   Misiak, Paulina
   Wierzbicka, Malgorzata
   Wozniak, Aldona
   Baer-Dubowska, Wanda
TI Frequent hypermethylation of <i>DAPK</i>, <i>RARbeta</i>, <i>MGMT</i>,
   <i>RASSF1A</i> and <i>FHIT</i> in laryngeal squamous cell carcinomas and
   adjacent normal mucosa
SO ORAL ONCOLOGY
LA English
DT Article
DE DNA methylation; Epigenetics; Field defect; Laryngeal squamous cell
   carcinoma; Head and neck cancer
ID PROMOTER HYPERMETHYLATION; RESECTION MARGINS; DNA METHYLATION;
   BREAST-CANCER; LUNG-CANCER; TUMOR; HEAD; FIELD; GENE; CARCINOGENESIS
AB Laryngeal cancers are the most frequent cancers of the head and neck region. While recent observations indicate the occurrence of an epigenetic field defect in head and neck cancer patients, a detailed exploration of the characteristic changes in the DNA methylation profile in laryngeal cancer patients was lacking. The aim of this study was to assess the methylation frequency of seven genes in a group of patients with primary laryngeal squamous cell carcinoma. Along tumor sections, matching samples of normal mucosa from epiglottis and trachea were analyzed. Gene methylation was assessed using the methylation-specific polymerase chain reaction. We found frequent gene hypermethylation in both the tumor and normal mucosa samples. The methylation of MGMT in tumor cells was associated with lymph node involvement. We report that laryngeal squamous cell carcinomas are characterized by frequent hypermethylation of DAPK, RARbeta, MGMT, RASSF1A and FHIT. Moreover, evidence is shown for the occurrence of a large epigenetically changed field of epithelial cells in laryngeal cancer patients. Our findings indicate the high prevalence of epigenetic abnormalities in laryngeal tumors. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Paluszczak, Jaroslaw; Misiak, Paulina; Baer-Dubowska, Wanda] Karol Marcinkowski Univ Med Sci, Dept Pharmaceut Biochem, PL-60781 Poznan, Poland.
   [Wierzbicka, Malgorzata] Karol Marcinkowski Univ Med Sci, Dept Otolaryngol & Laryngeal Oncol, PL-60781 Poznan, Poland.
   [Wozniak, Aldona] Karol Marcinkowski Univ Med Sci, Dept Clin Pathol, PL-60781 Poznan, Poland.
C3 Poznan University of Medical Sciences; Poznan University of Medical
   Sciences; Poznan University of Medical Sciences
RP Paluszczak, J (通讯作者)，Karol Marcinkowski Univ Med Sci, Dept Pharmaceut Biochem, Ul Swiecickiego 4, PL-60781 Poznan, Poland.
EM paluszcz@ump.edu.pl
RI Baer-Dubowska, Wanda/AGN-3671-2022; Paluszczak, Jaroslaw/IZE-4347-2023
OI Wierzbicka, Malgorzata/0000-0003-0006-6352; Paluszczak,
   Jaroslaw/0000-0002-6187-7549; Baer-Dubowska, Wanda/0000-0002-6625-5343
CR Almadori G, 2004, EUR J CANCER, V40, P2383, DOI 10.1016/j.ejca.2004.04.023
   Azarschab P, 2003, ONCOL REP, V10, P501
   Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   Balch C, 2007, BIOESSAYS, V29, P842, DOI 10.1002/bies.20619
   Bazan V, 2002, J CELL PHYSIOL, V192, P286, DOI 10.1002/jcp.10138
   Braakhuis BJM, 2010, ORAL ONCOL, V46, P485, DOI 10.1016/j.oraloncology.2010.01.019
   Chang HSW, 2004, CANCER-AM CANCER SOC, V101, P125, DOI 10.1002/cncr.20323
   Dikshit RP, 2007, CANCER-AM CANCER SOC, V110, P1745, DOI 10.1002/cncr.22975
   Dong SM, 2005, MODERN PATHOL, V18, P170, DOI 10.1038/modpathol.3800261
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Goldenberg D, 2004, ARCH OTOLARYNGOL, V130, P39, DOI 10.1001/archotol.130.1.39
   Guo MZ, 2004, CLIN CANCER RES, V10, P5131, DOI 10.1158/1078-0432.CCR-03-0763
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Kim H, 2004, J CLIN ONCOL, V22, P2363, DOI 10.1200/JCO.2004.10.077
   King-Batoon A, 2008, ENVIRON MOL MUTAGEN, V49, P36, DOI 10.1002/em.20363
   Kong WJ, 2005, LARYNGOSCOPE, V115, P1395, DOI 10.1097/01.MLG.0000166708.23673.3A
   Kulkarni V, 2004, ORAL ONCOL, V40, P145, DOI 10.1016/S1368-8375(03)00143-X
   Martone T, 2007, CLIN CANCER RES, V13, P5089, DOI 10.1158/1078-0432.CCR-07-0119
   Oka D, 2009, CANCER-AM CANCER SOC, V115, P3412, DOI 10.1002/cncr.24394
   Paluszczak J, 2006, J APPL GENET, V47, P365, DOI 10.1007/BF03194647
   Park SY, 2007, J KOREAN MED SCI, V22, P311, DOI 10.3346/jkms.2007.22.2.311
   Park TJ, 2001, CANCER, V92, P2760, DOI 10.1002/1097-0142(20011201)92:11<2760::AID-CNCR10123>3.0.CO;2-8
   Russo AL, 2005, CLIN CANCER RES, V11, P2466, DOI 10.1158/1078-0432.CCR-04-1962
   Sasiadek MM, 2004, BRIT J CANCER, V90, P1594, DOI 10.1038/sj.bjc.6601679
   Shaw RJ, 2007, BRIT J ORAL MAX SURG, V45, P617, DOI 10.1016/j.bjoms.2007.04.015
   SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q
   Szukala K, 2004, MED SCI MONITOR, V10, pCR233
   Tan HK, 2008, BRIT J CANCER, V99, P357, DOI 10.1038/sj.bjc.6604478
   Ushijima T, 2007, J BIOCHEM MOL BIOL, V40, P142
   van Engeland M, 2003, CANCER RES, V63, P3133
   Vuillemenot BR, 2004, CARCINOGENESIS, V25, P623, DOI 10.1093/carcin/bgh038
   Zhang Song, 2006, J Huazhong Univ Sci Technolog Med Sci, V26, P101
NR 32
TC 41
Z9 48
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1368-8375
J9 ORAL ONCOL
JI Oral Oncol.
PD FEB
PY 2011
VL 47
IS 2
BP 104
EP 107
DI 10.1016/j.oraloncology.2010.11.006
PG 4
WC Oncology; Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Dentistry, Oral Surgery & Medicine
GA 715XN
UT WOS:000286928800004
PM 21147548
DA 2025-01-12
ER

PT J
AU Roditi, LD
   Michor, F
AF Roditi, Laura De Vargas
   Michor, Franziska
TI Evolutionary dynamics of BRCA1 alterations in breast tumorigenesis
SO JOURNAL OF THEORETICAL BIOLOGY
LA English
DT Article
DE Stochastic modeling; Breast cancer; Moran model
ID TUMOR-SUPPRESSOR GENE; OVARIAN-CANCER; MUTATION; HYPOTHESIS
AB Cancer results from the accumulation of alterations in oncogenes and tumor suppressor genes. Tumor suppressors are classically defined as genes which contribute to tumorigenesis if their function is lost. Genetic or epigenetic alterations inactivating such genes may arise during somatic cell divisions or alternatively may be inherited from a parent. One notable exception to this rule is the BACA] tumor suppressor that predisposes to hereditary breast cancer when lost. Genetic alterations of this gene are hardly ever observed in sporadic breast cancer, while individuals harboring a germline mutation readily accumulate a second alteration inactivating the remaining allele a finding which represents a conundrum in cancer genetics. In this paper, we present a novel mathematical framework of sporadic and hereditary breast tumorigenesis. We study the dynamics of genetic alterations driving breast tumorigenesis and explore those scenarios which can explain the absence of somatic BRCA1 alterations while replicating all other disease statistics. Our results support the existence of a heterozygous phenotype of BRCA1 and suggest that the loss of one BRCA1 allele may suppress the fitness advantage caused by the inactivation of other tumor suppressor genes. This paper contributes to the mathematical investigation of breast tumorigenesis. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Michor, Franziska] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
   [Michor, Franziska] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
   [Roditi, Laura De Vargas] Mem Sloan Kettering Canc Ctr, Computat Biol Program, New York, NY 10065 USA.
   [Roditi, Laura De Vargas] Weill Cornell Med Coll, Tri Inst Training Program Computat Biol & Med, New York, NY 10065 USA.
C3 Harvard University; Dana-Farber Cancer Institute; Harvard University;
   Harvard T.H. Chan School of Public Health; Memorial Sloan Kettering
   Cancer Center; Cornell University; Weill Cornell Medicine
RP Michor, F (通讯作者)，Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
EM michor@jimmy.harvard.edu
FU NCI [U54CA143798]
FX The authors would like to thank the Michor laboratory for helpful
   comments and discussions. This work is supported by NCI Grant
   U54CA143798.
CR [Anonymous], 2009, CANC FACTS FIG 2009
   Ashkenazi R, 2007, STEM CELL REV, V3, P176, DOI 10.1007/s12015-007-0026-2
   Berry DA, 1997, J NATL CANCER I, V89, P227, DOI 10.1093/jnci/89.3.227
   Clare SE, 2000, BREAST CANCER RES, V2, P430, DOI 10.1186/bcr90
   David M.E., 2001, BREAST J, V7, P224
   Eliot M.R., 2003, J CELL PHYSIOL, V196, P19
   Elledge SJ, 2002, CANCER CELL, V1, P129, DOI 10.1016/S1535-6108(02)00041-7
   Fackenthal JD, 2007, NAT REV CANCER, V7, P937, DOI 10.1038/nrc2054
   FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399
   Gabriela D., 2003, CELL PROLIFERAT, V36, P59
   Gasco M, 2002, BREAST CANCER RES, V4, P70, DOI 10.1186/bcr426
   Hartman AR, 2002, NAT GENET, V32, P180, DOI 10.1038/ng953
   Jeng YM, 2007, ONCOGENE, V26, P6160, DOI 10.1038/sj.onc.1210451
   KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914
   Komarova NL, 2003, J THEOR BIOL, V223, P433, DOI 10.1016/S0022-5193(03)00120-6
   Kote-Jarai Z., 2005, BRIT J CANCER, V94, P308
   Kunkel TA, 2004, J BIOL CHEM, V279, P16895, DOI 10.1074/jbc.R400006200
   Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0
   Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292
   Meric-Bernstam F, 2007, ANN SURG ONCOL, V14, P2428, DOI 10.1245/s10434-007-9379-7
   Moran P.A.P, 1962, The Statistical Processes of Evolutionary Theory
   Nowak MA, 2004, P NATL ACAD SCI USA, V101, P10635, DOI 10.1073/pnas.0400747101
   Potemski P, 2005, ONCOLOGY-BASEL, V69, P478, DOI 10.1159/000090986
   RADFORD DM, 1995, CANCER RES, V55, P3399
   Saal LH, 2008, NAT GENET, V40, P102, DOI 10.1038/ng.2007.39
   Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000
   SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128
   Sorlie T, 1998, BREAST CANCER RES TR, V48, P259, DOI 10.1023/A:1005953519972
   SPEER JF, 1984, CANCER RES, V44, P4124
   Vogelstein B., 2002, The Genetic Basis of Human Cancer
   Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705
   Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743
   YASUO M, 2002, BREAST J, V8, P77
NR 33
TC 6
Z9 7
U1 0
U2 4
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-5193
EI 1095-8541
J9 J THEOR BIOL
JI J. Theor. Biol.
PD MAR 21
PY 2011
VL 273
IS 1
BP 207
EP 215
DI 10.1016/j.jtbi.2010.12.033
PG 9
WC Biology; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA 725XX
UT WOS:000287681300021
PM 21194536
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Syeed, N
   Husain, SA
   Sameer, AS
   Chowdhri, NA
   Siddiqi, MA
AF Syeed, Nidda
   Husain, Syed Akhtar
   Sameer, A. Syed
   Chowdhri, Nissar A.
   Siddiqi, Mushtaq A.
TI Mutational and promoter hypermethylation status of <i>FHIT</i> gene in
   breast cancer patients of Kashmir
SO MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
LA English
DT Article
DE FHIT; Breast cancer; Kashmir; Mutation; Hypermethylation
ID SQUAMOUS-CELL CARCINOMA; DNA METHYLATION; PROTEIN EXPRESSION;
   BLADDER-CANCER; SHORT ARM; PROFILE; 3P14.2; PROGRESSION; HETEROZYGOSITY;
   CHROMOSOME-3
AB Objective: Fragile histidine triad (FHIT) gene located at chromosome 3p14.2 is a putative tumor suppressor gene involved in the pathogenesis of breast cancer. Both genetic and epigenetic alterations in FHIT have been implicated in breast carcinoma. In the present study, our main aim was to study the impact of these two kinds of alterations of FHIT gene in breast cancer patients of Kashmir.
   Methods: We screened a total of 130 breast cancer patients of Kashmir by PCR-SSCP followed by direct sequencing and methylation specific PCR.
   Results: Mutational screening of FHIT gene revealed significant amount of mutations [40.7% (53/130)] in five hot spot exons (exon 5-9), FHIT promoter was found to be hypermethylated in 59 of 130 [45.3%] breast cancer patients in our population.
   Conclusion: In the present study we have shown a significant association between the mutational and hypermethylation profile of FHIT gene. Hence, we provide the first evidence to our knowledge that the significant association of FHIT mutation and hypermethylation leads to the complete inactivation of FHIT gene in patients with breast cancer. Silencing of the FHIT gene by promoter hypermethylation occurs in breast carcinomas, especially those with the significant amount of mutations. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Syeed, Nidda; Sameer, A. Syed; Siddiqi, Mushtaq A.] Sherikashmir Inst Med Sci, Dept Immunol & Mol Med, Srinagar 190011, Kashmir, India.
   [Chowdhri, Nissar A.] Sherikashmir Inst Med Sci, Dept Gen Surg, Srinagar 190011, Kashmir, India.
   [Syeed, Nidda; Husain, Syed Akhtar] Jamia Millia Islamia, Dept Biosci, New Delhi 110025, India.
C3 Sher-i-Kashmir Institute of Medical Sciences; Sher-i-Kashmir Institute
   of Medical Sciences; Jamia Millia Islamia
RP Siddiqi, MA (通讯作者)，Sherikashmir Inst Med Sci, Dept Immunol & Mol Med, Srinagar 190011, Kashmir, India.
EM siddiqimush@gmail.com
RI Syeed, Nidda/ABA-6243-2021; Sameer, Syed/Y-6158-2019
OI husain, syed akhtar/0000-0002-6513-7759; Sameer,
   Syed/0000-0002-8186-1149
FU Sher-I-Kashmir Institute of Medical Sciences, Kashmir; Department of
   General Surgery, Sher-I-Kashmir institute of Medical Sciences
FX The authors gratefully acknowledge the Sher-I-Kashmir Institute of
   Medical Sciences, Kashmir for providing funds for this research work.
   The present research was not funded by any funding agency. The
   collection of cancer samples used in this study was supported by the
   Department of General Surgery, Sher-I-Kashmir institute of Medical
   Sciences.
CR Ahuja N, 1998, CANCER RES, V58, P5489
   Arlt MF, 2003, CYTOGENET GENOME RES, V100, P92, DOI 10.1159/000072843
   Baffa R, 1998, CANCER RES, V58, P4708
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Beckmann MW, 1997, J MOL MED, V75, P429, DOI 10.1007/s001090050128
   Campiglio M, 1999, CANCER RES, V59, P3866
   CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H
   Çeçener G, 2007, TUMORI J, V93, P597
   Chang KW, 2002, J PATHOL, V196, P300, DOI 10.1002/path.1047
   CHEN LC, 1994, CANCER RES, V54, P3021
   Esteller M, 2001, CANCER RES, V61, P3225
   FERGUSON DJP, 1981, BRIT J CANCER, V44, P177, DOI 10.1038/bjc.1981.168
   Flanagan JM, 2010, AM J HUM GENET, V86, P420, DOI 10.1016/j.ajhg.2010.02.008
   Fong KM, 1997, CANCER RES, V57, P2256
   Gasser S, 2006, SEMIN CANCER BIOL, V16, P344, DOI 10.1016/j.semcancer.2006.07.004
   Gatalica Z, 2000, CANCER-AM CANCER SOC, V88, P1378, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1378::AID-CNCR15>3.0.CO;2-I
   Gemma A, 1997, CANCER RES, V57, P1435
   Gonzalgo ML, 1998, CANCER RES, V58, P1245
   Greenspan DL, 1997, CANCER RES, V57, P4692
   Guo ZY, 2000, PROSTATE, V43, P101
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hayashi S, 1997, CANCER RES, V57, P1981
   Huiping C, 2000, EUR J CANCER, V36, P1552, DOI 10.1016/S0959-8049(00)00143-X
   Ingvarsson S, 2001, CANCER DETECT PREV, V25, P292
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kaaks R, 2005, ENDOCR-RELAT CANCER, V12, P1071, DOI 10.1677/erc.1.01038
   Kisselev LL, 1998, FEBS LETT, V427, P157, DOI 10.1016/S0014-5793(98)00420-7
   KNUDSON AG, 1975, P NATL ACAD SCI USA, V72, P5116, DOI 10.1073/pnas.72.12.5116
   Lee JI, 2001, CANCER RES, V61, P837
   LONGACRE TA, 1986, AM J SURG PATHOL, V10, P382, DOI 10.1097/00000478-198606000-00003
   Maruyama R, 2001, CANCER RES, V61, P8659
   Maruyama R, 2002, CLIN CANCER RES, V8, P514
   MEYER JS, 1977, HUM PATHOL, V8, P67, DOI 10.1016/S0046-8177(77)80066-X
   Mir MM, 2005, INT J CANCER, V116, P62, DOI 10.1002/ijc.21002
   MORITA R, 1991, CANCER RES, V51, P820
   Nagata C, 1998, JNCI-J NATL CANCER I, V90, P1830, DOI 10.1093/jnci/90.23.1830
   Naqvi RA, 2008, DNA CELL BIOL, V27, P517, DOI 10.1089/dna.2007.0660
   Negrini M, 1996, CANCER RES, V56, P3173
   Nygren AOH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni127
   Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X
   Ordway JM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001314
   Otterson GA, 1998, J NATL CANCER I, V90, P426, DOI 10.1093/jnci/90.6.426
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   POTTER JD, 1995, CANCER EPIDEM BIOMAR, V4, P319
   Raish M, 2009, TRANSL ONCOL, V2, P264, DOI 10.1593/tlo.09148
   Roa JC, 2004, REV MED CHILE, V132, P1069
   RUSSO J, 1987, AM J CLIN PATHOL, V88, P123, DOI 10.1093/ajcp/88.2.123
   SATO T, 1991, CANCER RES, V51, P5794
   Sipetic Sandra, 2004, Med Pregl, V57, P467, DOI 10.2298/MPNS0410467S
   Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771
   Sozzi G, 1997, CANCER RES, V57, P5207
   Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8
   Tanaka H, 1998, CANCER RES, V58, P3429
   Tomlinson IPM, 1996, P NATL ACAD SCI USA, V93, P14800, DOI 10.1073/pnas.93.25.14800
   TSUCHIYA E, 1992, CANCER RES, V52, P2478
   Vartanian A, 1997, FEBS LETT, V415, P160, DOI 10.1016/S0014-5793(97)01086-7
   Virmani AK, 2001, CLIN CANCER RES, V7, P584
   Watson RE, 2002, TOXICOL SCI, V67, P11, DOI 10.1093/toxsci/67.1.11
   Xie GS, 2006, CHINESE MED J-PEKING, V119, P1469, DOI 10.1097/00029330-200609010-00011
   Yang QF, 2001, CLIN CANCER RES, V7, P3869
   YOKOTA J, 1989, CANCER RES, V49, P3598
   YOKOYAMA S, 1992, CANCER RES, V52, P873
   Yoshino K, 2000, INT J CANCER, V85, P6, DOI 10.1002/(SICI)1097-0215(20000101)85:1<6::AID-IJC2>3.3.CO;2-Y
   Yuan BZ, 2000, CANCER RES, V60, P1049
   Zou M, 1999, EUR J CANCER, V35, P467, DOI 10.1016/S0959-8049(98)00370-0
NR 66
TC 9
Z9 13
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1386-1964
EI 1873-135X
J9 MUTAT RES-FUND MOL M
JI Mutat. Res.-Fundam. Mol. Mech. Mutagen.
PD FEB 10
PY 2011
VL 707
IS 1-2
BP 1
EP 8
DI 10.1016/j.mrfmmm.2010.11.001
PG 8
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
GA 725AC
UT WOS:000287616600001
PM 21095196
DA 2025-01-12
ER

PT J
AU Englert, NA
   Spink, BC
   Spink, DC
AF Englert, Neal A.
   Spink, Barbara C.
   Spink, David C.
TI Persistent and non-persistent changes in gene expression result from
   long-term estrogen exposure of MCF-7 breast cancer cells
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article
DE Long-term estrogen exposure; AhR; STAT1; Gene expression; Breast cancer
ID MHC CLASS-I; RECEPTOR-ALPHA; TRANSCRIPTIONAL REGULATION; POSTMENOPAUSAL
   WOMEN; SIGNAL-TRANSDUCTION; PLUS PROGESTIN; GOOD PROGNOSIS; STAT1;
   INTERFERON; IDENTIFICATION
AB Life-long estrogen exposure is recognized as a major risk factor for the development of breast cancer. While the initial events in the regulation of gene expression by estrogen have been described in detail, far less is known of the role of estrogen in the long-term regulation of gene expression. In this study, we investigated the effects of long-term exposure of MCF-7 breast cancer cells to 1 nM 17 beta-estradiol on gene expression with the goal of distinguishing between gene expression that is continually reliant on estrogen receptor (ER) function as opposed to secondary and persistent effects that are downstream of ER. To assess the direct involvement of ER in the differential gene expression of long-term estrogen exposed (LTEE) cells in comparison with that of control cells, we exposed cultures to the selective estrogen receptor modulator raloxifene (RAL). cDNA microarray analysis showed that exposure to RAL inhibited expression of numerous characterized estrogen-regulated genes, including PGR,GREB1, and PDZK1. Genes that were increased in expression in LTEE cells yet were unaffected by RAL exposure included the aryl hydrocarbon receptor (AHR) and numerous other genes that were not previously reported to be regulated by estrogen. Epigenetic regulation was evident for the AHR gene; AhR transcript levels remained elevated for several cell passages after the removal of estrogen. Signal transducer and activator of transcription 1 (STAT1); STAT1-regulated genes including ISG15, IF127, and IFIT1; and MHC class I genes were also up-regulated in LTEE cells and were unaffected by RAL exposure. STAT1 is commonly overexpressed in breast and other cancers, and is associated with increased resistance to radiation and chemotherapy. This is the first study to relate estrogen exposure to increased STAT1 expression in breast cancer cells, an effect that may represent an additional role of estrogen in the pathogenesis of breast cancer. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Englert, Neal A.; Spink, Barbara C.; Spink, David C.] New York State Dept Hlth, Mol Toxicol Lab, Wadsworth Ctr, Albany, NY 12201 USA.
   [Englert, Neal A.; Spink, David C.] SUNY Albany, Sch Publ Hlth, Dept Environm Hlth Sci, Albany, NY 12201 USA.
C3 State University of New York (SUNY) System; Wadsworth Center; State
   University of New York (SUNY) System; University at Albany, SUNY
RP Spink, DC (通讯作者)，New York State Dept Hlth, Mol Toxicol Lab, Wadsworth Ctr, Albany, NY 12201 USA.
EM spink@wadsworth.org
CR Bhat-Nakshatri P, 2008, MOL CELL BIOL, V28, P7487, DOI 10.1128/MCB.00799-08
   Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527
   Bredfeldt TG, 2010, MOL ENDOCRINOL, V24, P993, DOI 10.1210/me.2009-0438
   Buettner R, 2002, CLIN CANCER RES, V8, P945
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Chang KCN, 2010, J STEROID BIOCHEM, V118, P117, DOI 10.1016/j.jsbmb.2009.11.003
   Cheon H, 2009, P NATL ACAD SCI USA, V106, P9373, DOI 10.1073/pnas.0903487106
   Chlebowski RT, 2010, JAMA-J AM MED ASSOC, V304, P1684, DOI 10.1001/jama.2010.1500
   Chlebowski RT, 2009, NEW ENGL J MED, V360, P573, DOI 10.1056/NEJMoa0807684
   Clamp A, 2002, LANCET ONCOL, V3, P611, DOI 10.1016/S1470-2045(02)00875-6
   Clemons M, 2001, NEW ENGL J MED, V344, P276, DOI 10.1056/NEJM200101253440407
   Cuzick J, 2007, JNCI-J NATL CANCER I, V99, P272, DOI 10.1093/jnci/djk049
   Doisneau-Sixou SF, 2003, ENDOCR-RELAT CANCER, V10, P179, DOI 10.1677/erc.0.0100179
   Dovhey SE, 2000, CANCER RES, V60, P5789
   Fisher B, 2005, JNCI-J NATL CANCER I, V97, P1652, DOI 10.1093/jnci/dji372
   Frasor J, 2009, CANCER RES, V69, P8918, DOI 10.1158/0008-5472.CAN-09-2608
   Fryknäs M, 2007, INT J CANCER, V120, P189, DOI 10.1002/ijc.22291
   Gobin SJP, 2000, HUM IMMUNOL, V61, P1102, DOI 10.1016/S0198-8859(00)00198-1
   Habib AA, 2003, MOL CANCER RES, V1, P219
   He F, 2005, NAT NEUROSCI, V8, P616, DOI 10.1038/nn1440
   He X, 2010, ANN SURG ONCOL, V17, P1459, DOI 10.1245/s10434-009-0891-9
   Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362
   Helleman J, 2008, CLIN CANCER RES, V14, P5555, DOI 10.1158/1078-0432.CCR-08-0555
   Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9
   Hui ZG, 2009, INT J RADIAT ONCOL, V73, P288, DOI 10.1016/j.ijrobp.2008.08.043
   Jordan VC, 2003, J MED CHEM, V46, P883, DOI 10.1021/jm020449y
   Khodarev NN, 2007, CANCER RES, V67, P9214, DOI 10.1158/0008-5472.CAN-07-1019
   Khodarev NN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005821
   Kimura A, 2008, P NATL ACAD SCI USA, V105, P9721, DOI 10.1073/pnas.0804231105
   Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0
   Kumle M, 2008, LANCET, V372, P608, DOI 10.1016/S0140-6736(08)61255-6
   Levenson AS, 2002, CANCER RES, V62, P4419
   Levin E.R., 2010, Mol. Endocrinol
   Lewis-Wambi JS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2255
   Li SF, 1997, CANCER RES, V57, P4356
   Lippman ME, 2001, J CLIN ONCOL, V19, P3111, DOI 10.1200/JCO.2001.19.12.3111
   Madak-Erdogan Z, 2011, MOL CELL BIOL, V31, P226, DOI 10.1128/MCB.00821-10
   Madjd Z, 2005, INT J CANCER, V117, P248, DOI 10.1002/ijc.21163
   MartinezLacaci I, 1996, J CELL PHYSIOL, V169, P497, DOI 10.1002/(SICI)1097-4652(199612)169:3<497::AID-JCP10>3.0.CO;2-3
   Ochsner SA, 2009, CANCER RES, V69, P23, DOI 10.1158/0008-5472.CAN-08-3492
   Pedersen MW, 2005, J CELL BIOCHEM, V96, P412, DOI 10.1002/jcb.20554
   PLARIASSILVA MD, 2007, CANCER CHEMOTH PHARM, V60, P535
   Remes K, 1996, LEUKEMIA LYMPHOMA, V21, P233, DOI 10.3109/10428199209067605
   Roberts D, 2005, BRIT J CANCER, V92, P1149, DOI 10.1038/sj.bjc.6602447
   Rodrik V, 2005, MOL CELL BIOL, V25, P7917, DOI 10.1128/MCB.25.17.7917-7925.2005
   Rouyez MC, 2005, J IMMUNOL, V174, P3948, DOI 10.4049/jimmunol.174.7.3948
   Simpson JAD, 2010, GUT, V59, P926, DOI 10.1136/gut.2009.194472
   Song RXD, 2006, ENDOCR-RELAT CANCER, V13, pS3, DOI 10.1677/erc.1.01322
   Span PN, 2004, J PATHOL, V202, P395, DOI 10.1002/path.1528
   Spink BC, 2009, TOXICOL APPL PHARM, V240, P355, DOI 10.1016/j.taap.2009.07.013
   Spink BC, 2006, CELL BIOL INT, V30, P227, DOI 10.1016/j.cellbi.2005.11.006
   Spink DC, 2003, CARCINOGENESIS, V24, P1941, DOI 10.1093/carcin/bgg162
   Strobl JS, 1995, GEN PHARMACOL, V26, P1643, DOI 10.1016/0306-3623(95)00062-3
   Tang WY, 2008, ENDOCRINOLOGY, V149, P5922, DOI 10.1210/en.2008-0682
   TEH M, 1989, J IMMUNOGENET, V16, P397
   Vogel VG, 2006, JAMA-J AM MED ASSOC, V295, P2727, DOI 10.1001/jama.295.23.joc60074
   Wang TL, 2009, MINI-REV MED CHEM, V9, P1191, DOI 10.2174/138955709789055207
   Wang X, 2008, CANCER RES, V68, P2259, DOI 10.1158/0008-5472.CAN-07-5544
   Weichselbaum RR, 2008, P NATL ACAD SCI USA, V105, P18490, DOI 10.1073/pnas.0809242105
   Xia L, 2002, J BIOL CHEM, V277, P30716, DOI 10.1074/jbc.M202823200
   Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734
   Zhang YG, 2004, CARCINOGENESIS, V25, P1165, DOI 10.1093/carcin/bgh115
NR 62
TC 16
Z9 18
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0760
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD FEB
PY 2011
VL 123
IS 3-5
BP 140
EP 150
DI 10.1016/j.jsbmb.2010.12.010
PG 11
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 722JC
UT WOS:000287427500008
PM 21185374
DA 2025-01-12
ER

PT J
AU Li, X
   Pan, YZ
   Seigel, GM
   Hu, ZH
   Huang, M
   Yu, AM
AF Li, Xin
   Pan, Yu-Zhuo
   Seigel, Gail M.
   Hu, Zi-Hua
   Huang, Min
   Yu, Ai-Ming
TI Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs
   (hsa-miR-328, -519c and -520h) and their differential expression in
   stem-like ABCG2+ cancer cells
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE miRNA; BCRP/ABCG2; Drug disposition; Gene regulation; Epigenetic;
   Multidrug resistance; Stem cell; Breast cancer; Retinoblastoma
ID MULTIDRUG-RESISTANCE; TARGET RECOGNITION; MESSENGER-RNAS; TRANSPORTER;
   GENE; HOECHST-33342; EFFLUX; DRUGS; LINES; SITES
AB Recent studies have shown that a number of microRNAs (miRNA or miR) may regulate human breast cancer resistance protein (BCRP/ABCG2), an important efflux transporter responsible for cellular drug disposition, whereas their effects on ABCG2 protein expression are not compared. In this study, we first identified a new proximal miRNA response element (MRE) for hsa-miR-519c within ABCG2 3'-untranslated region (3'UTR) through computational analyses. This miR-519c MRE site was confirmed using dual luciferase reporter assay and site-directed mutagenesis. Immunoblot analyses indicated that ABCG2 protein expression was significantly down-regulated in MCF-7/MX100 cells after transfection with hsa-miR-328- or -519c expression plasmids, and was markedly up-regulated in MCF-7 cells after transfection with miR-328 or -519c antagomir. However, ABCG2 protein expression was unchanged in MCF-7/MX100 cells after transfection with hsa-miR-520h expression plasmids, which was associated with undetectable miR-520h expression. Furthermore, ABCG2 mRNA degradation was accelerated dramatically in cells transfected with miR-519c expression plasmid, suggesting the involvement of mRNA degradation mechanism. Intervention of miR-328 or -519c signaling led to significant change in intracellular mitoxantrone accumulation, as determined by flow cytometry analyses. In addition, we separated RB143 human retinoblastoma cells into stem-like (ABCG2+) and non-stem-like (ABCG2) populations through immunomagnetic selection, and found that miR-328, -519c and -520h levels were 9-, 15- and 3-fold lower in the ABCG2+ cells, respectively. Our data suggest that miR-519c and -328 have greater impact on ABCG2 expression than miR-520h in MCF-7 human breast cancer cells, and the presence of proximal miR-519c MRE explains the action of miR-519c on shortened ABCG2 3'UTR. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Li, Xin; Pan, Yu-Zhuo; Yu, Ai-Ming] SUNY Buffalo, Dept Pharmaceut Sci, Buffalo, NY 14260 USA.
   [Li, Xin; Huang, Min] Sun Yat Sen Univ, Sch Pharmaceut Sci, Inst Clin Pharmacol, Guangzhou 510080, Guangdong, Peoples R China.
   [Seigel, Gail M.] SUNY Buffalo, Ctr Hearing & Deafness, Buffalo, NY 14260 USA.
   [Seigel, Gail M.] SUNY Buffalo, SUNY Eye Inst, Buffalo, NY 14260 USA.
   [Hu, Zi-Hua] SUNY Buffalo, Dept Ophthalmol, Buffalo, NY 14260 USA.
C3 State University of New York (SUNY) System; University at Buffalo, SUNY;
   Sun Yat Sen University; State University of New York (SUNY) System;
   University at Buffalo, SUNY; State University of New York (SUNY) System;
   University at Buffalo, SUNY; State University of New York (SUNY) System;
   University at Buffalo, SUNY
RP Yu, AM (通讯作者)，SUNY Buffalo, Dept Pharmaceut Sci, 541 Cooke Hall, Buffalo, NY 14260 USA.
EM huangmin@mail.sysu.edu.cn
OI Yu, Aiming/0000-0003-1441-4012
FU National Institute on Drug Abuse, National Institutes of Health (NIH)
   [R01DA021172]; University at Buffalo, The State University of New York;
   National Cancer Institute, NIH [R21CA127061, U54CA143876]; Sun Vat-Sen
   University; Science and Technology Ministry of China [2009ZX09304-003]
FX A.-M. Yu is supported by grant R01DA021172 from National Institute on
   Drug Abuse, National Institutes of Health (NIH), and by the
   Interdisciplinary Research Development Fund from University at Buffalo,
   The State University of New York. G.M. Seigel is supported by
   R21CA127061, Research to Prevent Blindness and U54CA143876 from the
   National Cancer Institute, NIH. Xin Li was supported by International
   Program of Project 985 at Sun Vat-Sen University and National Major
   Projects for science and technology development from Science and
   Technology Ministry of China, 2009ZX09304-003.
CR Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Apáti A, 2008, BBA-BIOMEMBRANES, V1778, P2700, DOI 10.1016/j.bbamem.2008.08.010
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178
   Choudhuri S, 2010, TOXICOL APPL PHARM, V245, P378, DOI 10.1016/j.taap.2010.03.022
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   García-Escarp M, 2004, CYTOM PART A, V62A, P129, DOI 10.1002/cyto.a.20072
   Gomez A, 2009, PHARMACOGENOMICS, V10, P1067, DOI 10.2217/PGS.09.56
   Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112
   Guo LL, 2010, EUR J CANCER, V46, P1692, DOI 10.1016/j.ejca.2010.02.043
   Ingelman-Sundberg M, 2007, PHARMACOL THERAPEUT, V116, P496, DOI 10.1016/j.pharmthera.2007.09.004
   Ji JL, 2009, FEBS LETT, V583, P759, DOI 10.1016/j.febslet.2009.01.034
   Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135
   Kim M, 2002, CLIN CANCER RES, V8, P22
   Knutsen T, 2000, GENE CHROMOSOME CANC, V27, P110, DOI 10.1002/(SICI)1098-2264(200001)27:1<110::AID-GCC14>3.3.CO;2-W
   Kovalchuk O, 2008, MOL CANCER THER, V7, P2152, DOI 10.1158/1535-7163.MCT-08-0021
   Krishnamurthy P, 2006, ANNU REV PHARMACOL, V46, P381, DOI 10.1146/annurev.pharmtox.46.120604.141238
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Liang ZX, 2010, BIOCHEM PHARMACOL, V79, P817, DOI 10.1016/j.bcp.2009.10.017
   Liao RX, 2008, J CELL BIOCHEM, V104, P805, DOI 10.1002/jcb.21668
   Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016
   Merino G, 2009, DRUG METAB DISPOS, V37, P5, DOI 10.1124/dmd.108.022715
   Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031
   Mohri T, 2010, BIOCHEM PHARMACOL, V79, P1045, DOI 10.1016/j.bcp.2009.11.015
   Monzani E, 2007, EUR J CANCER, V43, P935, DOI 10.1016/j.ejca.2007.01.017
   Pan YZ, 2009, DRUG METAB DISPOS, V37, P2112, DOI 10.1124/dmd.109.027680
   Pan YZ, 2009, MOL PHARMACOL, V75, P1374, DOI 10.1124/mol.108.054163
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Robey RW, 2001, BBA-BIOMEMBRANES, V1512, P171, DOI 10.1016/S0005-2736(01)00308-X
   Ross DD, 1999, J NATL CANCER I, V91, P429, DOI 10.1093/jnci/91.5.429
   Sandberg R, 2008, SCIENCE, V320, P1643, DOI 10.1126/science.1155390
   Scharenberg CW, 2002, BLOOD, V99, P507, DOI 10.1182/blood.V99.2.507
   Seigel GM, 2007, MOL VIS, V13, P823
   Takagi S, 2008, J BIOL CHEM, V283, P9674, DOI 10.1074/jbc.M709382200
   Takagi S, 2010, J BIOL CHEM, V285, P4415, DOI 10.1074/jbc.M109.085431
   To KKW, 2008, MOL CELL BIOL, V28, P5147, DOI 10.1128/MCB.00331-08
   To KKW, 2009, MOL CANCER THER, V8, P2959, DOI 10.1158/1535-7163.MCT-09-0292
   Tsuchiya Y, 2006, CANCER RES, V66, P9090, DOI 10.1158/0008-5472.CAN-06-1403
   van Herwaarden AE, 2006, TRENDS PHARMACOL SCI, V27, P10, DOI 10.1016/j.tips.2005.11.007
   Volk EL, 2002, CANCER RES, V62, P5035
   Wang F, 2010, BRIT J CANCER, V103, P567, DOI 10.1038/sj.bjc.6605724
   YOUNG IT, 1977, J HISTOCHEM CYTOCHEM, V25, P935, DOI 10.1177/25.7.894009
   Yu AM, 2007, CURR DRUG METAB, V8, P700, DOI 10.2174/138920007782109751
   Yu AM, 2009, EXPERT OPIN DRUG MET, V5, P1513, DOI 10.1517/17425250903307448
   Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028
   Zhou XF, 2005, DRUG METAB DISPOS, V33, P1220, DOI 10.1124/dmd.104.003558
   Zhu H, 2008, BIOCHEM PHARMACOL, V76, P582, DOI 10.1016/j.bcp.2008.06.007
NR 47
TC 98
Z9 126
U1 0
U2 24
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
EI 1873-2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD MAR 15
PY 2011
VL 81
IS 6
BP 783
EP 792
DI 10.1016/j.bcp.2010.12.018
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 730AX
UT WOS:000287996900010
PM 21219875
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Al-Dhaheri, M
   Wu, JC
   Skliris, GP
   Li, J
   Higashimato, K
   Wang, YD
   White, KP
   Lambert, P
   Zhu, YR
   Murphy, L
   Xu, W
AF Al-Dhaheri, Mariam
   Wu, Jiacai
   Skliris, Georgios P.
   Li, Jun
   Higashimato, Ken
   Wang, Yidan
   White, Kevin P.
   Lambert, Paul
   Zhu, Yuerong
   Murphy, Leigh
   Xu, Wei
TI CARM1 Is an Important Determinant of ERα-Dependent Breast Cancer Cell
   Differentiation and Proliferation in Breast Cancer Cells
SO CANCER RESEARCH
LA English
DT Article
ID ESTROGEN-RECEPTOR; ARGININE METHYLTRANSFERASE; GENE-EXPRESSION; CYCLE
   PROGRESSION; PPAR-GAMMA; METHYLATION; GROWTH; COMPLEX; TRANSCRIPTION;
   METASTASIS
AB Breast cancers with estrogen receptor alpha (ER alpha) expression are often more differentiated histologically than ER alpha-negative tumors, but the reasons for this difference are poorly understood. One possible explanation is that transcriptional cofactors associated with ER alpha determine the expression of genes which promote a more differentiated phenotype. In this study, we identify one such cofactor as coactivator-associated arginine methyltransferase 1 (CARM1), a unique coactivator of ER alpha that can simultaneously block cell proliferation and induce differentiation through global regulation of ER alpha-regulated genes. CARM1 was evidenced as an ER alpha coactivator in cell-based assays, gene expression microarrays, and mouse xenograft models. In human breast tumors, CARM1 expression positively correlated with ER alpha levels in ER-positive tumors but was inversely correlated with tumor grade. Our findings suggest that coexpression of CARM1 and ER alpha may provide a better biomarker of well-differentiated breast cancer. Furthermore, our findings define an important functional role of this histone arginine methyltransferase in reprogramming ER alpha-regulated cellular processes, implicating CARM1 as a putative epigenetic target in ER-positive breast cancers. Cancer Res; 71(6); 2118-28. (C) 2011 AACR.
C1 [Al-Dhaheri, Mariam; Wu, Jiacai; Li, Jun; Higashimato, Ken; Wang, Yidan; Lambert, Paul; Xu, Wei] Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA.
   [Zhu, Yuerong] BioInfoRx Inc, Madison, WI USA.
   [Skliris, Georgios P.; Murphy, Leigh] Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB, Canada.
   [White, Kevin P.] Univ Chicago, Cummings Life Sci Ctr, Dept Human Genet, Chicago, IL 60637 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Manitoba; University of Chicago
RP Xu, W (通讯作者)，Univ Wisconsin, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.
EM wxu@oncology.wisc.edu
RI wang, yidan/G-4566-2013
OI Murphy, Leigh C/0000-0002-7676-6032
FU NCI [CA125387]; Greater Milwaukee Foundation; Canadian Institutes of
   Health Research (CIHR); Canadian Breast Cancer Research Alliance
   (CBCRA); Uehara Memorial Foundation; Grants-in-Aid for Scientific
   Research [21790340] Funding Source: KAKEN
FX This work is supported by NCI grant CA125387 and Shaw Scientist Award
   from Greater Milwaukee Foundation to W. Xu and in part by grants to LCM
   from the Canadian Institutes of Health Research (CIHR) and the Canadian
   Breast Cancer Research Alliance (CBCRA). K. Higashimato is supported by
   Uehara Memorial Foundation.
CR Badve S, 2009, J CLIN PATHOL, V62, P6, DOI 10.1136/jcp.2008.059899
   Bauer UM, 2002, EMBO REP, V3, P39, DOI 10.1093/embo-reports/kvf013
   Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174
   Chen SL, 2002, J BIOL CHEM, V277, P4324, DOI 10.1074/jbc.M109835200
   Cheng DH, 2007, MOL CELL, V25, P71, DOI 10.1016/j.molcel.2006.11.019
   CLARK GM, 1984, J CLIN ONCOL, V2, P1102, DOI 10.1200/JCO.1984.2.10.1102
   Creighton CJ, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-4-r28
   de Jong JS, 1999, J CLIN PATHOL-MOL PA, V52, P78, DOI 10.1136/mp.52.2.78
   Deblois G, 2009, CANCER RES, V69, P6149, DOI 10.1158/0008-5472.CAN-09-1251
   Doisneau-Sixou SF, 2003, ENDOCR-RELAT CANCER, V10, P179, DOI 10.1677/erc.0.0100179
   Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397
   El Messaoudi S, 2006, P NATL ACAD SCI USA, V103, P13351, DOI 10.1073/pnas.0605692103
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   Feng Q, 2006, MOL CELL BIOL, V26, P7846, DOI 10.1128/MCB.00568-06
   Foster JS, 2001, MOL CELL BIOL, V21, P794, DOI 10.1128/MCB.21.3.794-810.2001
   Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567
   Frietze S, 2008, CANCER RES, V68, P301, DOI 10.1158/0008-5472.CAN-07-1983
   Ikeda K, 2004, ARCH HISTOL CYTOL, V67, P435, DOI 10.1679/aohc.67.435
   Karmakar S, 2009, ENDOCRINOLOGY, V150, P1588, DOI 10.1210/en.2008-1001
   Kim J, 2004, J BIOL CHEM, V279, P25339, DOI 10.1074/jbc.M402544200
   Kim YR, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-197
   Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011
   Kuhn F, 1999, MECH DEVELOP, V86, P193, DOI 10.1016/S0925-4773(99)00115-X
   Lupien M, 2009, MOL CELL BIOL, V29, P3413, DOI 10.1128/MCB.00020-09
   MCGUIRE WL, 1991, MOL ENDOCRINOL, V5, P1571, DOI 10.1210/mend-5-11-1571
   Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7
   O'Brien KB, 2010, DEVELOPMENT, V137, P2147, DOI 10.1242/dev.037150
   OSBORNE CK, 1980, CANCER-AM CANCER SOC, V46, P2884, DOI 10.1002/1097-0142(19801215)46:12+<2884::AID-CNCR2820461429>3.0.CO;2-U
   Page DL, 2001, AM J CLIN ONCOL-CANC, V24, P10, DOI 10.1097/00000421-200102000-00002
   Pang HY, 2004, BREAST CANCER RES, V6, pR239, DOI 10.1186/bcr780
   PARL FF, 1984, CANCER-AM CANCER SOC, V54, P2237, DOI 10.1002/1097-0142(19841115)54:10<2237::AID-CNCR2820541029>3.0.CO;2-V
   Skildum AJ, 2002, J BIOL CHEM, V277, P5145, DOI 10.1074/jbc.M109179200
   Skliris GP, 2006, BRIT J CANCER, V95, P616, DOI 10.1038/sj.bjc.6603295
   Snell L, 2006, METH MOLEC MED, V120, P3
   SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165
   Stein JL, 1996, INT J OBESITY, V20, pS84
   Stossi F, 2006, J BIOL CHEM, V281, P16272, DOI 10.1074/jbc.M513405200
   Vendrell JA, 2004, J MOL ENDOCRINOL, V32, P397, DOI 10.1677/jme.0.0320397
   Wainwright LJ, 2001, P NATL ACAD SCI USA, V98, P9396, DOI 10.1073/pnas.161288698
   Wang S, 2009, P NATL ACAD SCI USA, V106, P151, DOI 10.1073/pnas.0808703105
   Watson PH, 1996, CAN MED ASSOC J, V155, P281
   Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003
   Wu Q, 2009, STEM CELLS, V27, P2637, DOI 10.1002/stem.131
   Xu W, 2005, BIOCHEM CELL BIOL, V83, P418, DOI 10.1139/O05-057
   Xu W, 2004, GENE DEV, V18, P144, DOI 10.1101/gad.1141704
   Yadav N, 2003, P NATL ACAD SCI USA, V100, P6464, DOI 10.1073/pnas.1232272100
   Yadav N, 2008, EMBO REP, V9, P193, DOI 10.1038/sj.embor.7401151
   Zaytseva YY, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-90
NR 48
TC 78
Z9 112
U1 0
U2 12
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD MAR 15
PY 2011
VL 71
IS 6
BP 2118
EP 2128
DI 10.1158/0008-5472.CAN-10-2426
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 734YZ
UT WOS:000288381300012
PM 21282336
OA Green Accepted, Bronze, Green Submitted
DA 2025-01-12
ER

PT J
AU Wiklund, ED
   Bramsen, JB
   Hulf, T
   Dyrskjot, L
   Ramanathan, R
   Hansen, TB
   Villadsen, SB
   Gao, S
   Ostenfeld, MS
   Borre, M
   Peter, ME
   Orntoft, TF
   Kjems, J
   Clark, SJ
AF Wiklund, Erik D.
   Bramsen, Jesper B.
   Hulf, Toby
   Dyrskjot, Lars
   Ramanathan, Ramshanker
   Hansen, Thomas B.
   Villadsen, Sune B.
   Gao, Shan
   Ostenfeld, Marie S.
   Borre, Michael
   Peter, Marcus E.
   Orntoft, Torben F.
   Kjems, Jorgen
   Clark, Susan J.
TI Coordinated epigenetic repression of the miR-200 family and miR-205 in
   invasive bladder cancer
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE miR-200 family; miR-205; TWIST1; DNA methylation; epigenetics; bladder
   cancer; tumor invasion
ID EPITHELIAL-MESENCHYMAL TRANSITION; E-CADHERIN; BREAST-CANCER;
   TRANSCRIPTIONAL REPRESSOR; GENE-EXPRESSION; CELLS; ZEB1; MICRORNAS;
   METHYLATION; MICROARRAYS
AB MicroRNAs (miRNA) are small noncoding RNAs commonly deregulated in cancer. The miR-200 family (miR-200a, -200b, -200c, -141 and -429) and miR-205 are frequently silenced in advanced cancer and have been implicated in epithelial to mesenchymal transition (EMT) and tumor invasion by targeting the transcriptional repressors of E-cadherin, ZEB1 and ZEB2. ZEB1 is also known to repress miR-200c-141 transcription in a negative feedback loop, but otherwise little is known about the transcriptional regulation of the miR-200 family and miR-205. Recently, miR-200 silencing was also reported in cancer stem cells, implying that miR-200 deregulation is a key event in multiple levels of tumor biology. However, what prevents miR-200 expression remains largely unanswered. Here we report concerted transcriptional regulation of the miR-200 and miR-205 loci in bladder tumors and bladder cell lines. Using a combination of miRNA expression arrays, qPCR assays and mass spectrometry DNA methylation analyses, we show that the miR-200 and miR-205 loci are specifically silenced and gain promoter hypermethylation and repressive chromatin marks in muscle invasive bladder tumors and undifferentiated bladder cell lines. Moreover, we report that miR-200c expression is significantly correlated with early stage T1 bladder tumor progression, and propose miR-200 and miR-205 silencing and DNA hypermethylation as possible prognostic markers in bladder cancer. In addition, we observe that the mesoderm transcription factor TWIST1 and miR-200 expression are inversely correlated in bladder tumor samples and cell lines. TWIST1 associates directly with the miR-200 and miR-205 promoters, and may act as a repressor of miR-200 and miR-205 expression.
C1 [Wiklund, Erik D.; Bramsen, Jesper B.; Hansen, Thomas B.; Villadsen, Sune B.; Gao, Shan; Kjems, Jorgen] Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark.
   [Wiklund, Erik D.; Hulf, Toby; Clark, Susan J.] St Vincents Hosp, Garvan Inst Med Res, Canc Program, Darlinghurst, NSW 2010, Australia.
   [Dyrskjot, Lars; Ramanathan, Ramshanker; Ostenfeld, Marie S.; Orntoft, Torben F.] Aarhus Univ Hosp, Dept Mol Med, DK-8000 Aarhus N, Denmark.
   [Borre, Michael] Aarhus Univ Hosp, Dept Urol, DK-8000 Aarhus N, Denmark.
   [Peter, Marcus E.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
C3 Aarhus University; NSW Health; St Vincents Hospital Sydney; Garvan
   Institute of Medical Research; Aarhus University; Aarhus University; Ann
   & Robert H. Lurie Children's Hospital of Chicago; Northwestern
   University; Feinberg School of Medicine; Robert H. Lurie Comprehensive
   Cancer Center
RP Kjems, J (通讯作者)，Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark.
EM jk@mb.au.dk
RI Ostenfeld, Marie/D-2801-2017; Dyrskjot, Lars/H-4922-2012; Kjems,
   Jorgen/I-3490-2016; Clark, Susan/B-2272-2008
OI Hansen, Thomas/0000-0002-7573-9657; Peter, Marcus
   Ernst/0000-0003-3216-036X; Borre, Michael/0000-0002-1519-9185; Hulf,
   Toby/0009-0002-3814-9620; Kjems, Jorgen/0000-0003-4128-9317; Clark,
   Susan/0000-0001-5925-5030; Dyrskjot, Lars/0000-0001-7061-9851
FU European Community [FP7/2007-2011, 201663]; Australian National Health
   and Medical Research Council (NHMRC); Danish Natural Science Research
   Council (FNU); John and Birthe Meyer Foundation; Danish Cancer Society;
   Ministry of Technology and Science; Lundbeck Foundation
FX Grant sponsors: European Community's Seventh Framework programme
   SIROCCO, the Australian National Health and Medical Research Council
   (NH&MRC), The Danish Natural Science Research Council (FNU), the John
   and Birthe Meyer Foundation, the Danish Cancer Society, the Ministry of
   Technology and Science, the Lundbeck Foundation; Grant sponsor: European
   Community's Seventh Framework program FP7/2007-2011; Grant number:
   201663
CR Aaboe M, 2005, BRIT J CANCER, V93, P1182, DOI 10.1038/sj.bjc.6602813
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942
   Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Clark SJ, 2006, NAT PROTOC, V1, P2353, DOI 10.1038/nprot.2006.324
   Coolen MW, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm662
   Coolen MW, 2010, NAT CELL BIOL, V12, P235, DOI 10.1038/ncb2023
   Dyrskjot L, 2005, CLIN CANCER RES, V11, P4029, DOI 10.1158/1078-0432.CCR-04-2095
   Dyrskjot L, 2009, CANCER RES, V69, P4851, DOI 10.1158/0008-5472.CAN-08-4043
   Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Gottardo F, 2007, UROL ONCOL-SEMIN ORI, V25, P387, DOI 10.1016/j.urolonc.2007.01.019
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Hinshelwood RA, 2007, CANCER RES, V67, P11517, DOI 10.1158/0008-5472.CAN-07-1284
   Hurteau GJ, 2009, CELL CYCLE, V8, P2064, DOI 10.4161/cc.8.13.8883
   Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844
   Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608
   Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878
   Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2
   Schepeler T, 2008, CANCER RES, V68, P6416, DOI 10.1158/0008-5472.CAN-07-6110
   SHARMA S, CARCINOGENESIS, V31, P27
   Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011
   Vesuna F, 2008, BIOCHEM BIOPH RES CO, V367, P235, DOI 10.1016/j.bbrc.2007.11.151
   Weber B, 2007, CELL CYCLE, V6, P1001, DOI 10.4161/cc.6.9.4209
   Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998
   Wu ZJ, 2004, NAT BIOTECHNOL, V22, P656, DOI 10.1038/nbt0604-656b
NR 29
TC 312
Z9 337
U1 0
U2 38
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD MAR 15
PY 2011
VL 128
IS 6
BP 1327
EP 1334
DI 10.1002/ijc.25461
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 718XB
UT WOS:000287158700008
PM 20473948
DA 2025-01-12
ER

PT J
AU Loyo, M
   Brait, M
   Kim, MS
   Ostrow, KL
   Jie, CFC
   Chuang, AY
   Califano, JA
   Liégeois, NJ
   Begum, S
   Westra, WH
   Hoque, MO
   Tao, QA
   Sidransky, D
AF Loyo, Myriam
   Brait, Mariana
   Kim, Myoung S.
   Ostrow, Kimberly L.
   Jie, Chunfa C.
   Chuang, Alice Y.
   Califano, Joseph A.
   Liegeois, Nanette J.
   Begum, Shahnaz
   Westra, William H.
   Hoque, Mohammad O.
   Tao, Qian
   Sidransky, David
TI A survey of methylated candidate tumor suppressor genes in
   nasopharyngeal carcinoma
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE nasopharyngeal carcinoma; dna methylation; biomarker
ID EPSTEIN-BARR-VIRUS; SQUAMOUS-CELL CARCINOMA; PROMOTER HYPERMETHYLATION;
   QUANTITATIVE-ANALYSIS; BREAST-CANCER; DNA; PLASMA; ESOPHAGEAL; HEAD;
   LOCALIZATION
AB Nasopharyngeal carcinoma (NPC) is a rare malignancy with unique genetic, viral and environmental characteristic that distinguishes it from other head and neck carcinomas. The clinical management of NPC remains challenging largely due to the lack of early detection strategies for this tumor. In our study, we have sought to identify novel genes involved in the pathogenesis of NPC that might provide insight into this tumor's biology and could potentially be used as biomarkers. To identify these genes, we studied the epigenetics of NPC by characterizing a panel of methylation markers. Eighteen genes were evaluated by quantitative methylation-specific polymerase chain reaction (PCR) in cell lines as well as in tissue samples including 50 NPC tumors and 28 benign nasopharyngeal biopsies. Significance was evaluated using Fisher's exact test and quantitative values were optimized using cut off values derived from receiver-operator characteristic curves. The methylation status of AIM1, APC, CALCA, deleted in colorectal carcinomas (DCC), DLEC, deleted in liver cancer 1 (DLC1), estrogen receptor alpha (ESR), FHIT, KIF1A and PGP9.5 was significantly associated with NPC compared to controls. The sensitivity of the individual genes ranged from 26 to 66% and the specificity was above 92% for all genes except FHIT. The combination of PGP9.5, KIF1A and DLEC had a sensitivity of 84% and a specificity of 92%. Ectopic expression of DCC and DLC1 lead to decrease in colony formation and invasion properties. Our results indicate that methylation of novel biomarkers in NPC could be used to enhance early detection approaches. Additionally, our functional studies reveal previously unknown tumor suppressor roles in NPC.
C1 [Sidransky, David] Johns Hopkins Sch Med, Div Head & Neck Canc Res, Dept Dermatol, Baltimore, MD 21231 USA.
   [Loyo, Myriam; Brait, Mariana; Kim, Myoung S.; Ostrow, Kimberly L.; Chuang, Alice Y.; Califano, Joseph A.; Hoque, Mohammad O.; Sidransky, David] Greater Baltimore Med Ctr, Dept Otolaryngol Head & Neck Surg, Baltimore, MD USA.
   [Jie, Chunfa C.] Greater Baltimore Med Ctr, Inst Basic Biomed Sci, Baltimore, MD USA.
   [Califano, Joseph A.] Greater Baltimore Med Ctr, Milton J Dance Head & Neck Ctr, Baltimore, MD USA.
   [Liegeois, Nanette J.] Johns Hopkins Sch Med, Dept Surg, Baltimore, MD 21231 USA.
   [Begum, Shahnaz; Westra, William H.] Johns Hopkins Sch Med, Dept Pathol, Baltimore, MD 21231 USA.
   [Tao, Qian] Chinese Univ Hong Kong, Hong Kong Canc Inst, Dept Clin Oncol, Sir YK Pao Ctr Canc,Canc Epigenet Lab,State Key L, Shatin, Hong Kong, Peoples R China.
   [Tao, Qian] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China.
C3 Johns Hopkins University; Johns Hopkins Medicine; Greater Baltimore
   Medical Center; Greater Baltimore Medical Center; Greater Baltimore
   Medical Center; Johns Hopkins University; Johns Hopkins Medicine; Johns
   Hopkins University; Johns Hopkins Medicine; Chinese University of Hong
   Kong; Chinese University of Hong Kong
RP Sidransky, D (通讯作者)，Johns Hopkins Sch Med, Div Head & Neck Canc Res, Dept Dermatol, 1550 Orleans St 5N-03, Baltimore, MD 21231 USA.
EM dsidrans@jhmi.edu
RI KIM, JUSANG/AAB-3748-2019; Tao, Qian/T-4743-2018
OI Hoque, Mohammad Obaidul/0000-0001-6701-9978; Brait,
   Mariana/0000-0002-1652-8921; Tao, Qian/0000-0001-5383-4808; Liegeois,
   Nanette/0000-0001-5002-1799
FU National Institute of Dental and Craniofacial Reseach (NIDCR)
   [P50-DE019032]; National Institute of Health (NIH), National Cancer
   Institute (NCI), Early Detection Research Network (EDRN) [U01-CA084986]
FX Grant sponsor: National Institute of Dental and Craniofacial Reseach
   (NIDCR) [Specialized Program of Research Excellence (SPORE)]; Grant
   number: P50-DE019032; Grant sponsors: National Institute of Health
   (NIH), National Cancer Institute (NCI), Early Detection Research Network
   (EDRN); Grant number: U01-CA084986
CR ALTUN M, 1995, INT J RADIAT ONCOL, V32, P859, DOI 10.1016/0360-3016(95)00516-2
   August M, 2001, ORAL SURG ORAL MED O, V91, P205, DOI 10.1067/moe.2001.110698
   Bhattacharyya N, 2004, AM J OTOLARYNG, V25, P94, DOI 10.1016/j.amjoto.2003.11.005
   Brait M, 2008, CANCER EPIDEM BIOMAR, V17, P2786, DOI 10.1158/1055-9965.EPI-08-0192
   Carvalho AL, 2008, CLIN CANCER RES, V14, P97, DOI 10.1158/1078-0432.CCR-07-0722
   Carvalho AL, 2006, CANCER RES, V66, P9401, DOI 10.1158/0008-5472.CAN-06-1073
   Chang HW, 2003, CLIN CANCER RES, V9, P1033
   Cui Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002990
   Esteller M, 2001, CANCER RES, V61, P3225
   Fang Y, 2001, GENE CHROMOSOME CANC, V30, P254, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1086>3.0.CO;2-D
   Franklin WA, 1997, J CLIN INVEST, V100, P2133, DOI 10.1172/JCI119748
   Gallicchio L, 2006, INT J CANCER, V119, P1125, DOI 10.1002/ijc.21946
   Goodison S, 2005, CANCER RES, V65, P6042, DOI 10.1158/0008-5472.CAN-04-3043
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hoque MO, 2008, CANCER RES, V68, P2661, DOI 10.1158/0008-5472.CAN-07-5913
   Horii J, 2009, CANCER SCI, V100, P1005, DOI 10.1111/j.1349-7006.2009.01140.x
   HUANG DP, 1989, INT J CANCER, V43, P936, DOI 10.1002/ijc.2910430535
   Issa JPJ, 1996, CANCER RES, V56, P3655
   Kawai K, 2009, GENES CELLS, V14, P227, DOI 10.1111/j.1365-2443.2008.01265.x
   Kwong J, 2005, INT J CANCER, V113, P386, DOI 10.1002/ijc.20593
   Kwong J, 2007, GENE CHROMOSOME CANC, V46, P171, DOI 10.1002/gcc.20398
   Li Yu-Hong, 2003, Ai Zheng, V22, P645
   Lin JC, 2004, NEW ENGL J MED, V350, P2461, DOI 10.1056/NEJMoa032260
   Lo YMD, 1999, CANCER RES, V59, P1188
   Mandelker DL, 2005, CANCER RES, V65, P4963, DOI 10.1158/0008-5472.CAN-04-3923
   Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441
   MIYAKE S, 1994, CANCER RES, V54, P3007
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Ostrow KL, 2009, CLIN CANCER RES, V15, P1184, DOI 10.1158/1078-0432.CCR-08-1304
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Ray ME, 1997, P NATL ACAD SCI USA, V94, P3229, DOI 10.1073/pnas.94.7.3229
   Seng TJ, 2007, ONCOGENE, V26, P934, DOI 10.1038/sj.onc.1209839
   SHAM JST, 1990, INT J RADIAT ONCOL, V19, P929, DOI 10.1016/0360-3016(90)90014-B
   Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4
   SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q
   Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7
   Tao Qian, 2007, Expert Reviews in Molecular Medicine, V9, P1, DOI 10.1017/S1462399407000312
   Tokumaru Y, 2008, INT J CANCER, V123, P753, DOI 10.1002/ijc.23354
   Verri C, 2009, AM J RESP CRIT CARE, V179, P396, DOI 10.1164/rccm.200807-1153OC
   Waki T, 2003, ONCOGENE, V22, P4128, DOI 10.1038/sj.onc.1206651
   Wong TS, 2004, CLIN CANCER RES, V10, P2401, DOI 10.1158/1078-0432.CCR-03-0139
   Yonekawa Y, 1998, J CELL BIOL, V141, P431, DOI 10.1083/jcb.141.2.431
   Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452
   Yu KH, 2004, CLIN CANCER RES, V10, P1726, DOI 10.1158/1078-0432.CCR-0991-3
   Yuan BZ, 1998, CANCER RES, V58, P2196
   Yuan BZ, 1999, CYTOGENET CELL GENET, V87, P189, DOI 10.1159/000015462
   ZURHAUSE.H, 1970, NATURE, V228, P1056, DOI 10.1038/2281056a0
NR 47
TC 46
Z9 53
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD MAR 15
PY 2011
VL 128
IS 6
BP 1393
EP 1403
DI 10.1002/ijc.25443
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 718XB
UT WOS:000287158700015
PM 20473931
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Chen, Y
   Wang, DM
   Guo, Z
   Zhao, J
   Wu, B
   Deng, H
   Zhou, T
   Xiang, HJ
   Gao, F
   Yu, X
   Liao, JA
   Ward, T
   Xia, P
   Emenari, C
   Ding, X
   Thompson, W
   Ma, KL
   Zhu, JD
   Aikhionbare, F
   Dou, KF
   Cheng, SY
   Yao, XB
AF Chen, Yong
   Wang, Dongmei
   Guo, Zhen
   Zhao, Jun
   Wu, Bing
   Deng, Hui
   Zhou, Ti
   Xiang, Hongjun
   Gao, Fei
   Yu, Xue
   Liao, Jian
   Ward, Tarsha
   Xia, Peng
   Emenari, Chibuzo
   Ding, Xia
   Thompson, Winston
   Ma, Kelong
   Zhu, Jingde
   Aikhionbare, Felix
   Dou, Kefen
   Cheng, Shi-Yuan
   Yao, Xuebiao
TI Rho Kinase Phosphorylation Promotes Ezrin-Mediated Metastasis in
   Hepatocellular Carcinoma
SO CANCER RESEARCH
LA English
DT Article
ID BREAST-CANCER METASTASIS; ERM PROTEINS; ARF6; ACTIVATION; EXPRESSION
AB During progression of hepatocellular carcinoma, multiple genetic and epigenetic alterations act to posttranslationally modulate the function of proteins that promote cancer invasion and metastasis. To define such abnormalities that contribute to liver cancer metastasis, we carried out a proteomic comparison of primary hepatocellular carcinoma and samples of intravascular thrombi from the same patient. Mass spectrometric analyses of the liver cancer samples revealed a series of acidic phospho-isotypes associated with the intravascular thrombi samples. In particular, we found that Thr567 hyperphosphorylation of the cytoskeletal protein ezrin was tightly correlated to an invasive phenotype of clinical hepatocellular carcinomas and to poor outcomes in tumor xenograft assays. Using phospho-mimicking mutants, we showed that ezrin phosphorylation at Thr567 promoted in vitro invasion by hepatocarcinoma cells. Phospho-mimicking mutant ezrinT567D, but not the nonphosphorylatable mutant ezrinT567A, stimulated formation of membrane ruffles, suggesting that Thr567 phosphorylation promotes cytoskeletal-membrane remodeling. Importantly, inhibition of Rho kinase, either by Y27632 or RNA interference, resulted in inhibition of Thr567 phosphorylation and a blockade to cell invasion, implicating Rho kinase-ezrin signaling in hepatocellular carcinoma cell invasion. Our findings suggest a strategy to reduce liver tumor metastasis by blocking Rho kinase-mediated phosphorylation of ezrin. Cancer Res; 71( 5); 1721-9. (C)2011 AACR.
C1 [Wang, Dongmei; Guo, Zhen; Wu, Bing; Deng, Hui; Yu, Xue; Liao, Jian; Xia, Peng; Ma, Kelong; Zhu, Jingde; Yao, Xuebiao] Univ Sci & Technol China, Anhui Key Lab Cellular Dynam, Hefei 230027, Peoples R China.
   [Chen, Yong; Zhao, Jun; Zhou, Ti; Xiang, Hongjun; Gao, Fei; Dou, Kefen] Fourth Mil Med Univ, Xijing Hosp, Dept Hepatobiliary Surg, Xian 710032, Shanxi, Peoples R China.
   [Chen, Yong; Zhao, Jun; Zhou, Ti; Xiang, Hongjun; Gao, Fei; Dou, Kefen] Fourth Mil Med Univ, Xijing Hosp, Dept Pathol, Xian 710032, Shanxi, Peoples R China.
   [Ding, Xia] Beijing Univ Chinese Med, Dept Med, Beijing, Peoples R China.
   [Guo, Zhen; Deng, Hui; Liao, Jian; Ward, Tarsha; Emenari, Chibuzo; Thompson, Winston; Aikhionbare, Felix] Morehouse Sch Med, Dept Obstet & Gynecol, Canc Biol Program, Atlanta, GA 30310 USA.
   [Cheng, Shi-Yuan] Univ Pittsburgh, Dept Pathol, Inst Canc, Pittsburgh, PA USA.
C3 Chinese Academy of Sciences; University of Science & Technology of
   China, CAS; Air Force Military Medical University; Air Force Military
   Medical University; Beijing University of Chinese Medicine; Morehouse
   School of Medicine; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh
RP Yao, XB (通讯作者)，Univ Sci & Technol China, Anhui Key Lab Cellular Dynam, 96 Jinzhai Rd, Hefei 230027, Peoples R China.
EM yaoxb@ustc.edu.cn
RI Yao, Xuebiao/P-5771-2014; Cheng, Shiyuan/ISU-4685-2023; Guo,
   Zhen/AFV-1371-2022
OI Yao, Xuebiao/0000-0001-8982-5911; Xia, Peng/0000-0002-5419-7756
FU National Institutes of Health [DK-56292, CA118948, R01HD057235,
   CA102011, CA130966]; Clinical and Translational Science Award [UL1
   RR025008]; NCRR [G12RR03034]; Chinese Natural Science Foundation
   [30500183, 30870990, 90919024, 90508002, 90913016]; Chinese Academy of
   Science [KSCX1-YW-R-65, KSCX2-YW-H-10, KSCX2-YW-R- 195]; Chinese 973
   Project [2006CB943603, 2007CB914503, 2010CB912103, 2009CB825606,
   2009DFA31010, 2006BAI08B01-07]; China National Key Projects for
   Infectious Disease [2008ZX10002-021]; Anhui Province Project
   [08040102005, 11040606Q54]; NUIRP of China; K.C. Wong Education
   Foundation
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants DK-56292 and CA118948 (to X. Yao), R01HD057235 (to W.
   Thompson), CA102011 and CA130966 (to S. Cheng) and NCRR Grant UL1
   RR025008 from the Clinical and Translational Science Award Program, and
   NCRR Grant G12RR03034 (for use of facilities). This work was also
   supported by Chinese Natural Science Foundation Grants 30500183 and
   30870990 (to X. Ding), 90919024 (to J. Zhu) and 90508002 and 90913016
   (to X. Yao), Chinese Academy of Science Grants KSCX1-YW-R-65,
   KSCX2-YW-H-10, and KSCX2-YW-R- 195, Chinese 973 Project Grants
   2006CB943603, 2007CB914503, and 2010CB912103 (to X. Yao) and
   2009CB825606 (to J. Zhu), International Collaboration Grant 2009DFA31010
   (to X. Ding), and Technology Grant 2006BAI08B01-07 (to X. Ding). China
   National Key Projects for Infectious Disease Grant 2008ZX10002-021,
   Anhui Province Project Grant 08040102005 (to X. Yao) and 11040606Q54 (to
   Z. Guo), 2007 NUIRP of China (P. Xia), and K.C. Wong Education
   Foundation (Z. Guo). X. Yao is a GCC Eminent Scholar.
CR Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021
   Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882
   Bruix J, 2004, CANCER CELL, V5, P215, DOI 10.1016/S1535-6108(04)00058-3
   Coleman WB, 2003, CURR MOL MED, V3, P573, DOI 10.2174/1566524033479546
   Ding SJ, 2004, MOL CELL PROTEOMICS, V3, P73, DOI 10.1074/mcp.M300094-MCP200
   Fang ZY, 2006, MOL CELL PROTEOMICS, V5, P1437, DOI 10.1074/mcp.M600050-MCP200
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760
   Hashimoto S, 2004, P NATL ACAD SCI USA, V101, P6647, DOI 10.1073/pnas.0401753101
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6
   Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982
   Liu D, 2007, FEBS LETT, V581, P3563, DOI 10.1016/j.febslet.2007.06.071
   Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647
   Morishige M, 2008, NAT CELL BIOL, V10, P85, DOI 10.1038/ncb1672
   Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622
   Ren L, 2009, ONCOGENE, V28, P792, DOI 10.1038/onc.2008.437
   Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019
   Takamura M, 2001, HEPATOLOGY, V33, P577, DOI 10.1053/jhep.2001.22652
   Tamura A, 2005, J CELL BIOL, V169, P21, DOI 10.1083/jcb.200410083
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Yang HS, 2003, MOL CELL, V11, P1163, DOI 10.1016/S1097-2765(03)00135-7
   Yao XB, 2003, ANNU REV PHYSIOL, V65, P103, DOI 10.1146/annurev.physiol.65.072302.114200
   Yao XB, 1996, J BIOL CHEM, V271, P7224, DOI 10.1074/jbc.271.12.7224
   YAO XB, 1995, MOL BIOL CELL, V6, P541, DOI 10.1091/mbc.6.5.541
   Yeh CN, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-233
   Zhou RH, 2005, J CELL SCI, V118, P4381, DOI 10.1242/jcs.02559
   Zhou RH, 2003, J BIOL CHEM, V278, P35651, DOI 10.1074/jbc.M303416200
NR 27
TC 63
Z9 77
U1 2
U2 24
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD MAR 1
PY 2011
VL 71
IS 5
BP 1721
EP 1729
DI 10.1158/0008-5472.CAN-09-4683
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 728AH
UT WOS:000287845300023
PM 21363921
OA Green Accepted, Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Zuo, T
   Liu, TM
   Lan, X
   Weng, YI
   Shen, RL
   Gu, F
   Huang, YW
   Liyanarachchi, S
   Deatherage, DE
   Hsu, PY
   Taslim, C
   Ramaswamy, B
   Shapiro, CL
   Lin, HJL
   Cheng, ASL
   Jin, VX
   Huang, THM
AF Zuo, Tao
   Liu, Ta-Ming
   Lan, Xun
   Weng, Yu-I
   Shen, Rulong
   Gu, Fei
   Huang, Yi-Wen
   Liyanarachchi, Sandya
   Deatherage, Daniel E.
   Hsu, Pei-Yin
   Taslim, Cenny
   Ramaswamy, Bhuvaneswari
   Shapiro, Charles L.
   Lin, Huey-Jen L.
   Cheng, Alfred S. L.
   Jin, Victor X.
   Huang, Tim H. -M.
TI Epigenetic Silencing Mediated through Activated PI3K/AKT Signaling in
   Breast Cancer
SO CANCER RESEARCH
LA English
DT Article
ID DNA METHYLATION; DEVELOPMENTAL REGULATORS; POLYCOMB; PATHWAY; GENES;
   PATTERNS; EZH2; HYPERMETHYLATION; EPIGENOMICS; REPRESSION
AB Trimethylation of histone 3 lysine 27 (H3K27me3) is a critical epigenetic mark for the maintenance of gene silencing. Additional accumulation of DNA methylation in target loci is thought to cooperatively support this epigenetic silencing during tumorigenesis. However, molecular mechanisms underlying the complex interplay between the two marks remain to be explored. Here we show that activation of PI3K/AKT signaling can be a trigger of this epigenetic processing at many downstream target genes. We also find that DNA methylation can be acquired at the same loci in cancer cells, thereby reinforcing permanent repression in those losing the H3K27me3 mark. Because of a link between PI3K/AKT signaling and epigenetic alterations, we conducted epigenetic therapies in conjunction with the signaling-targeted treatment. These combined treatments synergistically relieve gene silencing and suppress cancer cell growth in vitro and in xenografts. The new finding has important implications for improving targeted cancer therapies in the future. Cancer Res; 71(5); 1752-62. (c) 2011 AACR.
C1 [Huang, Tim H. -M.] Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.
   [Lan, Xun; Gu, Fei; Taslim, Cenny; Jin, Victor X.] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA.
   [Shen, Rulong] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA.
   [Taslim, Cenny] Ohio State Univ, Dept Stat, Columbus, OH 43210 USA.
   [Ramaswamy, Bhuvaneswari; Shapiro, Charles L.] Ohio State Univ, Arthur G James Canc Hosp, Div Hematol & Oncol, Columbus, OH 43210 USA.
   [Ramaswamy, Bhuvaneswari; Shapiro, Charles L.] Ohio State Univ, Richard J Solove Res Inst, Columbus, OH 43210 USA.
   [Lin, Huey-Jen L.] Ohio State Univ, Sch Allied Med Profess, Med Technol Div, Columbus, OH 43210 USA.
   [Cheng, Alfred S. L.] Chinese Univ Hong Kong, Inst Digest Dis, Shatin, Hong Kong, Peoples R China.
   [Cheng, Alfred S. L.] Chinese Univ Hong Kong, Fac Med, Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China.
C3 James Cancer Hospital & Solove Research Institute; University System of
   Ohio; Ohio State University; University System of Ohio; Ohio State
   University; University System of Ohio; Ohio State University; University
   System of Ohio; Ohio State University; James Cancer Hospital & Solove
   Research Institute; University System of Ohio; Ohio State University;
   University System of Ohio; Ohio State University; James Cancer Hospital
   & Solove Research Institute; University System of Ohio; Ohio State
   University; Chinese University of Hong Kong; Chinese University of Hong
   Kong
RP Huang, THM (通讯作者)，Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Dept Mol Virol Immunol & Med Genet, 460 W 12th Ave,BRT 814, Columbus, OH 43210 USA.
EM tim.huang@osumc.edu
RI Ramaswamy, Bhuvaneswari/E-3919-2011; Lin, Huey-Jen/E-3514-2011; Huang,
   Yi-Wen/H-3989-2019; Shen, Rulong/E-4079-2011; Cheng, Alfred/C-3327-2014
OI Zuo, Tao/0000-0002-2125-7548; Lan, Xun/0000-0002-6523-046X; Gu,
   Fei/0000-0002-7725-3909; Cheng, Alfred/0000-0003-2345-6951; Zuo,
   Tao/0000-0001-8450-5281
FU Integrative Cancer Biology Program [U54 CA113001]; Gene and Environment
   Initiative [U01 ES015986]; U.S. National Institutes of Health
   [R01CA069065]; Department of Defense [BC073892]; Susan G. Komen Breast
   Cancer Foundation [KG081123]; Ohio State University Comprehensive Cancer
   Center
FX This work was supported by the Integrative Cancer Biology Program (U54
   CA113001), the Gene and Environment Initiative (U01 ES015986), and
   R01CA069065 at the U.S. National Institutes of Health, the Department of
   Defense grant BC073892, the Susan G. Komen Breast Cancer Foundation
   grant KG081123, and by the Ohio State University Comprehensive Cancer
   Center.
CR Bloushtain-Qimron N, 2009, CELL CYCLE, V8, P809, DOI 10.4161/cc.8.6.7938
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Bracken AP, 2009, NAT REV CANCER, V9, P773, DOI 10.1038/nrc2736
   Bredfeldt TG, 2010, MOL ENDOCRINOL, V24, P993, DOI 10.1210/me.2009-0438
   Brugge J, 2007, CANCER CELL, V12, P104, DOI 10.1016/j.ccr.2007.07.014
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947
   Chan M, 2008, NEOPLASIA, V10, P908, DOI 10.1593/neo.08540
   Cheng ASL, 2008, CANCER RES, V68, P1786, DOI 10.1158/0008-5472.CAN-07-5547
   Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Frietze S, 2010, J BIOL CHEM, V285, P1393, DOI 10.1074/jbc.M109.063032
   Gal-Yam EN, 2008, P NATL ACAD SCI USA, V105, P12979, DOI 10.1073/pnas.0806437105
   Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902
   Hinshelwood RA, 2007, CANCER RES, V67, P11517, DOI 10.1158/0008-5472.CAN-07-1284
   Hsu PY, 2009, CANCER RES, V69, P5936, DOI 10.1158/0008-5472.CAN-08-4914
   Issa JPJ, 2009, CLIN CANCER RES, V15, P3938, DOI 10.1158/1078-0432.CCR-08-2783
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jones PA, 2009, NAT REV GENET, V10, P805, DOI 10.1038/nrg2651
   Kagey JD, 2010, MOL CANCER RES, V8, P1048, DOI 10.1158/1541-7786.MCR-10-0189
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Lin HJL, 2008, CANCER RES, V68, P10257, DOI 10.1158/0008-5472.CAN-08-0288
   Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926
   Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Maroulakou IG, 2007, CANCER RES, V67, P167, DOI 10.1158/0008-5472.CAN-06-3782
   McCabe MT, 2009, CANCER RES, V69, P282, DOI 10.1158/0008-5472.CAN-08-3274
   McGarvey KM, 2007, CANCER RES, V67, P5097, DOI 10.1158/0008-5472.CAN-06-2029
   Mohn Fabio, 2009, V507, P55, DOI 10.1007/978-1-59745-522-0_5
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Oki Y, 2008, BLOOD, V111, P2382, DOI 10.1182/blood-2007-07-103960
   Oki Y, 2006, REV RECENT CLIN TRIA, V1, P169, DOI 10.2174/157488706776876490
   Pauler FM, 2009, GENOME RES, V19, P221, DOI 10.1101/gr.080861.108
   Robinson MD, 2010, GENOME RES, V20, P1719, DOI 10.1101/gr.110601.110
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Silverman LR, 2002, J CLIN ONCOL, V20, P2429, DOI 10.1200/JCO.2002.04.117
   Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Sun LD, 2007, CELL SIGNAL, V19, P2255, DOI 10.1016/j.cellsig.2007.06.014
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Xu JS, 2010, BIOMATERIALS, V31, P1716, DOI 10.1016/j.biomaterials.2009.11.052
NR 48
TC 50
Z9 62
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD MAR 1
PY 2011
VL 71
IS 5
BP 1752
EP 1762
DI 10.1158/0008-5472.CAN-10-3573
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 728AH
UT WOS:000287845300026
PM 21216892
OA Bronze, Green Accepted, Green Submitted
DA 2025-01-12
ER

PT J
AU Sabnis, GJ
   Goloubeva, O
   Chumsri, S
   Nguyen, N
   Sukumar, S
   Brodie, AMH
AF Sabnis, Gauri J.
   Goloubeva, Olga
   Chumsri, Saranya
   Nguyen, Nguyen
   Sukumar, Saraswati
   Brodie, Angela M. H.
TI Functional Activation of the Estrogen Receptor-α and Aromatase by the
   HDAC Inhibitor Entinostat Sensitizes ER-Negative Tumors to Letrozole
SO CANCER RESEARCH
LA English
DT Article
ID BREAST-CANCER CELLS; HISTONE DEACETYLASE INHIBITORS; REFRACTORY SOLID
   TUMORS; LONG-TERM; CHAPERONE FUNCTION; GENE-EXPRESSION; PHASE-I; MODEL;
   GROWTH; TAMOXIFEN
AB Approximately 25% of breast cancers do not express the estrogen receptor-alpha (ER alpha) and consequently do not respond to endocrine therapy. In these tumors, ER alpha repression is often due to epigenetic modifications such as methylation and histone deacetylation. For this reason, we investigated the ability of the histone deacetylase inhibitor entinostat (ENT) to trigger reexpression of ER alpha and aromatase in breast cancer cells, with the notion that this treatment would restore sensitivity to the aromatase inhibitor (AI) letrozole. ENT treatment of tumor cells increased expression of ER alpha and aromatase, along with the enzymatic activity of aromatase, in a dose-dependent manner both in vitro and in vivo. Notably, ER alpha and aromatase upregulation resulted in sensitization of breast cancer cells to estrogen and letrozole. Tumor growth rate was significantly lower in tumor xenografts following treatment with ENT alone and in combination with letrozole than in control tumors (P > 0.001). ENT plus letrozole also prevented lung colonization and growth of tumor cells, with a significant reduction (P > 0.03) in both visible and microscopic foci. Our results show that ENT treatment can be used to restore the letrozole responsiveness of ER-negative tumors. More generally, they provide a strong rationale for immediate clinical evaluation of combinations of histone deacetylase and aromatase inhibitors to treat ER-negative and endocrineresistant breast cancers. Cancer Res; 71(5); 1893-903. (c) 2011 AACR.
C1 [Sabnis, Gauri J.] Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, Hlth Sci Facil 1, Baltimore, MD 21201 USA.
   [Goloubeva, Olga] Univ Maryland, Sch Med, Div Biostat, Baltimore, MD 21201 USA.
   [Chumsri, Saranya] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA.
   Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA.
   [Nguyen, Nguyen; Sukumar, Saraswati] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.
C3 University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore; Johns
   Hopkins University
RP Sabnis, GJ (通讯作者)，Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, Hlth Sci Facil 1, Room 580G,685 W Baltimore St, Baltimore, MD 21201 USA.
EM abrodie@umaryland.edu
OI Sabnis, Gauri/0000-0001-8703-9394
FU NCI/NIH [CA-62483]; Susan G. Komen for the Cure [KG100037]; DOD-Center
   of Excellence USAMRMC [W81XWH-04-1-0595]
FX This work was supported by grants to A. Brodie (CA-62483 from NCI/NIH),
   to G Sabnis (KG100037 from Susan G. Komen for the Cure) and to A. Brodie
   and S. Sukumar (DOD-Center of Excellence USAMRMC W81XWH-04-1-0595; PI:
   S. Sukumar).
CR Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200
   Brodie A, 1998, BREAST CANCER RES TR, V49, pS23, DOI 10.1023/A:1006028202087
   Chen SA, 2010, P NATL ACAD SCI USA, V107, P11032, DOI 10.1073/pnas.1000917107
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   Fiskus W, 2007, CLIN CANCER RES, V13, P4882, DOI 10.1158/1078-0432.CCR-06-3093
   Giacinti L, 2006, ONCOLOGIST, V11, P1, DOI 10.1634/theoncologist.11-1-1
   Gore L, 2008, CLIN CANCER RES, V14, P4517, DOI 10.1158/1078-0432.CCR-07-1461
   Goss PE, 2008, CLIN BREAST CANCER, V8, P411, DOI 10.3816/CBC.2008.n.049
   Jelovac D, 2005, CANCER RES, V65, P5380, DOI 10.1158/0008-5472.CAN-04-4502
   Jelovac D, 2004, CLIN CANCER RES, V10, P7375, DOI 10.1158/1078-0432.CCR-04-0565
   Kawai H, 2003, INT J CANCER, V107, P353, DOI 10.1002/ijc.11403
   Kazi AA, 2005, MOL ENDOCRINOL, V19, P2006, DOI 10.1210/me.2004-0388
   Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021
   Kummar S, 2007, CLIN CANCER RES, V13, P5411, DOI 10.1158/1078-0432.CCR-07-0791
   Langston WC, 1935, ENDOCRINOLOGY, V19, P51, DOI 10.1210/endo-19-1-51
   Long BJ, 1998, J STEROID BIOCHEM, V67, P293, DOI 10.1016/S0960-0760(98)00122-8
   Long BJ, 2002, CLIN CANCER RES, V8, P2378
   Lu Q, 1998, BREAST CANCER RES TR, V50, P63, DOI 10.1023/A:1006004930930
   Macedo LF, 2008, CANCER RES, V68, P3516, DOI 10.1158/0008-5472.CAN-07-6807
   Núñez NP, 2004, CLIN CANCER RES, V10, P5375, DOI 10.1158/1078-0432.CCR-04-0261
   Oesterreich S, 2001, CANCER RES, V61, P5771
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Owens JW, 2002, CRIT REV TOXICOL, V32, P445, DOI 10.1080/20024091064291
   Pathiraja TN, 2010, J MAMMARY GLAND BIOL, V15, P35, DOI 10.1007/s10911-010-9166-0
   Prindull G, 2004, BLOOD, V103, P2892, DOI 10.1182/blood-2003-08-2807
   Sabnis G, 2007, CLIN CANCER RES, V13, P2751, DOI 10.1158/1078-0432.CCR-06-2466
   Sabnis G, 2010, MOL CANCER THER, V9, P46, DOI 10.1158/1535-7163.MCT-09-0696
   Sabnis G, 2009, CANCER RES, V69, P1416, DOI 10.1158/0008-5472.CAN-08-0857
   Sabnis GJ, 2008, J STEROID BIOCHEM, V108, P1, DOI 10.1016/j.jsbmb.2007.04.005
   Sabnis GJ, 2005, CANCER RES, V65, P3903, DOI 10.1158/0008-5472.CAN-04-4092
   Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   Stephens SM, 2009, AM J PHYSIOL-ENDOC M, V297, pE1235, DOI 10.1152/ajpendo.00575.2009
   Swain SM, 2005, NEW ENGL J MED, V353, P2807, DOI 10.1056/NEJMe058273
   WEIGEL RJ, 1993, CANCER RES, V53, P3472
   Yang XW, 2001, CANCER RES, V61, P7025
   Yang XW, 2000, CANCER RES, V60, P6890
NR 37
TC 133
Z9 147
U1 1
U2 16
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD MAR 1
PY 2011
VL 71
IS 5
BP 1893
EP 1903
DI 10.1158/0008-5472.CAN-10-2458
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 728AH
UT WOS:000287845300039
PM 21245100
OA Green Submitted, Green Accepted
DA 2025-01-12
ER

PT J
AU Muscarella, LA
   Barbano, R
   D'Angelo, V
   Copetti, M
   Coco, M
   Balsamo, T
   la Torre, A
   Notarangelo, A
   Troiano, M
   Parisi, S
   Icolaro, N
   Catapano, D
   Valori, VM
   Pellegrini, F
   Merla, G
   Carella, M
   Fazio, VM
   Parrella, P
AF Muscarella, Lucia Anna
   Barbano, Raffaela
   D'Angelo, Vincenzo
   Copetti, Massimiliano
   Coco, Michelina
   Balsamo, Teresa
   la Torre, Annamaria
   Notarangelo, Angelo
   Troiano, Michele
   Parisi, Salvatore
   Icolaro, Nadia
   Catapano, Domenico
   Valori, Vanna Maria
   Pellegrini, Fabio
   Merla, Giuseppe
   Carella, Massimo
   Fazio, Vito Michele
   Parrella, Paola
TI Regulation of <i>KEAP1</i> expression by promoter methylation in
   malignant gliomas and association with patient's outcome
SO EPIGENETICS
LA English
DT Article
DE glioma; KEAP1; NRF2; chemotherapy; radiotherapy; prognosis
ID DNA METHYLATION; LUNG-CANCER; GENE-EXPRESSION; BREAST-CANCER;
   GLIOBLASTOMA-MULTIFORME; NRF2; SURVIVAL; RESISTANCE; MUTATIONS; PATHWAY
AB In light with the view that KEAP1 loss of function may impact tumor behavior and modify response to chemotherapeutical agents, we sought to determine whether KEAP1 gene is epigenetically regulated in malignant gliomas. We developed a Quantitative Methylation Specific PC R (QMSP) assay to analyze 86 malignant gliomas and 20 normal brain tissues. The discriminatory power of the assay was assessed by Receiving Operating Characteristics (ROC) curve analysis. The AUC value of the curve was 0.823 (95% CI: 0.764-0.883) with an optimal cut off value of 0.133 yielding a 74% sensitivity (95% CI: 63%-82%) and an 85% specificity (95% CI: 64%-95%). Bisulfite sequencing analysis confirmed QMSP results and demonstrated a direct correlation between percentage of methylated CpGs and methylation levels (Spearman's Rho 0.929, p = 0.003). Remarkably, a strong inverse correlation was observed between methylation levels and KEAP1 mRNA transcript in tumor tissue (Spearman's Rho -0.656 p = 0.0001) and in a cell line before and after treatment with 2-deoxy-5-azacytidine (p = 0.003). RECPAM multivariate statistical analysis studying the interaction between MGMT and KEAP1 methylation in subjects treated with radiotherapy and temozolomide (n = 70), identified three prognostic classes of glioma patients at different risk to progress. While simultaneous methylation of MGMT and KEAP1 promoters was associated with the lowest risk to progress, patients showing only MGMT methylation were the subgroup at the higher risk (HR 5.54, 95% CI 1.35-22.74). Our results further suggest that KEAP1 expression is epigenetically regulated. In addition we demonstrated that KEAP1 is frequently methylated in malignant gliomas and a predictor of patient's outcome.
C1 [Muscarella, Lucia Anna; Barbano, Raffaela; Coco, Michelina; Balsamo, Teresa; la Torre, Annamaria; Fazio, Vito Michele; Parrella, Paola] IRCCS Casa Sollievo Sofferenza, Lab Oncol, San Giovanni Rotondo, FG, Italy.
   [D'Angelo, Vincenzo; Icolaro, Nadia; Catapano, Domenico] IRCCS Casa Sollievo Sofferenza, Dept Neurosurg, San Giovanni Rotondo, FG, Italy.
   [Copetti, Massimiliano; Pellegrini, Fabio] IRCCS Casa Sollievo Sofferenza, Biostat Unit, San Giovanni Rotondo, FG, Italy.
   [Notarangelo, Angelo; Merla, Giuseppe; Carella, Massimo] IRCCS Casa Sollievo Sofferenza, Med Genet Lab, San Giovanni Rotondo, FG, Italy.
   [Troiano, Michele; Parisi, Salvatore] IRCCS Casa Sollievo Sofferenza, Dept Radiotherapy, San Giovanni Rotondo, FG, Italy.
   [Valori, Vanna Maria] IRCCS Casa Sollievo Sofferenza, Dept Oncohaematol, San Giovanni Rotondo, FG, Italy.
   [Barbano, Raffaela] Univ Bari, Ctr Excellence Comparat Genom CEGBA, Dept Gen & Environm Physiol, Bari, Italy.
   [Pellegrini, Fabio] Consorzio Mario Negri Sud, Dept Clin Pharmacol & Epidemiol, Chieti, Italy.
   [Fazio, Vito Michele] Univ Campus BioMed, Mol Med & Biotechnol Lab, Rome, Italy.
C3 IRCCS Casa Sollievo Della Sofferenza; IRCCS Casa Sollievo Della
   Sofferenza; IRCCS Casa Sollievo Della Sofferenza; IRCCS Casa Sollievo
   Della Sofferenza; IRCCS Casa Sollievo Della Sofferenza; IRCCS Casa
   Sollievo Della Sofferenza; Universita degli Studi di Bari Aldo Moro;
   Consorzio Mario Negri Sud; University Campus Bio-Medico - Rome Italy
RP Fazio, VM (通讯作者)，IRCCS Casa Sollievo Sofferenza, Lab Oncol, San Giovanni Rotondo, FG, Italy.
EM fazio@unicampus.it; pparrella@operapadrepio.it
RI ; Barbano, Raffaela/H-3640-2016; Fazio, Vito Michele/H-3007-2016; la
   Torre, Annamaria/B-2717-2017; PARRELLA, PAOLA/D-8895-2011; Carella,
   Massimo/A-2804-2014; Muscarella, Lucia Anna/K-5979-2016; COPETTI,
   MASSIMILIANO/K-3186-2016
OI merla, giuseppe/0000-0001-5078-928X; Barbano,
   Raffaela/0000-0002-4533-4157; Fazio, Vito Michele/0000-0002-7751-1867;
   la Torre, Annamaria/0000-0003-4199-1077; la Torre,
   Annamaria/0000-0002-7017-0879; PARRELLA, PAOLA/0000-0001-6031-9636;
   Carella, Massimo/0000-0002-6830-6829; catapano,
   domenico/0000-0002-4301-9137; Muscarella, Lucia
   Anna/0000-0002-1866-8151; COPETTI, MASSIMILIANO/0000-0002-7960-5947;
   Notarangelo, Angelantonio/0000-0002-1540-8530
FU Ministero della Salute (Italian Ministry of Health) [IRCCS
   RC2009-RC2010]; Progetto Integrato Oncologia
FX This work is supported by Grants from the Ministero della Salute
   (Italian Ministry of Health) IRCCS RC2009-RC2010 and Progetto Integrato
   Oncologia 2006.
CR Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385
   Cho JM, 2008, CANCER LETT, V260, P96, DOI 10.1016/j.canlet.2007.10.022
   CIAMPI A, 1995, J CLIN EPIDEMIOL, V48, P675, DOI 10.1016/0895-4356(94)00164-L
   COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975
   De Berardis G, 2007, J UROLOGY, V177, P252, DOI 10.1016/j.juro.2006.08.102
   Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901
   Gerson SL, 2004, NAT REV CANCER, V4, P296, DOI 10.1038/nrc1319
   Hayes JD, 2009, TRENDS BIOCHEM SCI, V34, P176, DOI 10.1016/j.tibs.2008.12.008
   Hegi ME, 2008, J CLIN ONCOL, V26, P4189, DOI 10.1200/JCO.2007.11.5964
   Hunter SB, 2003, INT J ONCOL, V23, P857
   Jeong YI, 2010, COLLOID SURFACE B, V79, P149, DOI 10.1016/j.colsurfb.2010.03.037
   Jiang T, 2010, CANCER RES, V70, P5486, DOI 10.1158/0008-5472.CAN-10-0713
   Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046
   Kopp MU, 1997, EUR J BIOCHEM, V249, P489, DOI 10.1111/j.1432-1033.1997.00489.x
   Lau A, 2008, PHARMACOL RES, V58, P262, DOI 10.1016/j.phrs.2008.09.003
   Laws ER, 2003, J NEUROSURG, V99, P467, DOI 10.3171/jns.2003.99.3.0467
   Lo SC, 2006, J BIOL CHEM, V281, P37893, DOI 10.1074/jbc.M606539200
   Lu C, 2008, MOL CELL BIOCHEM, V312, P71, DOI 10.1007/s11010-008-9722-8
   MacLeod AK, 2009, CARCINOGENESIS, V30, P1571, DOI 10.1093/carcin/bgp176
   MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282
   Martinez R, 2010, NEUROBIOL DIS, V39, P40, DOI 10.1016/j.nbd.2009.12.030
   Martinez R, 2009, EPIGENETICS-US, V4, P255, DOI 10.4161/epi.9130
   Nioi P, 2007, BIOCHEM BIOPH RES CO, V362, P816, DOI 10.1016/j.bbrc.2007.08.051
   NOTARANGELO A, COMPREHENSIVE GENETI
   Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017
   Ohta T, 2008, CANCER RES, V68, P1303, DOI 10.1158/0008-5472.CAN-07-5003
   Padmanabhan B, 2006, MOL CELL, V21, P689, DOI 10.1016/j.molcel.2006.01.013
   Parrella P, 2001, CANCER RES, V61, P7623
   Parrella P, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/531692
   Plumb JA, 2000, CANCER RES, V60, P6039
   Prokhortchouk A, 2001, GENE DEV, V15, P1613, DOI 10.1101/gad.198501
   Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798
   Sarin H, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-77
   Savino M, 2009, CELL ONCOL, V31, P203, DOI 10.3233/CLO-2009-0468
   Scintu M, 2007, CANCER LETT, V254, P298, DOI 10.1016/j.canlet.2007.03.021
   Shen GX, 2009, BIOPHARM DRUG DISPOS, V30, P345, DOI 10.1002/bdd.680
   Shibata T, 2008, GASTROENTEROLOGY, V135, P1358, DOI 10.1053/j.gastro.2008.06.082
   Shim GS, 2009, FREE RADICAL BIO MED, V47, P1619, DOI 10.1016/j.freeradbiomed.2009.09.006
   Singh A, 2008, CANCER RES, V68, P7975, DOI 10.1158/0008-5472.CAN-08-1401
   Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420
   Solis LM, 2010, CLIN CANCER RES, V16, P3743, DOI 10.1158/1078-0432.CCR-09-3352
   Strachan GD, 2005, BIOCHEM BIOPH RES CO, V336, P490, DOI 10.1016/j.bbrc.2005.08.127
   Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7
   TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M
   Wang J, 2007, CELL MOL NEUROBIOL, V27, P831, DOI 10.1007/s10571-007-9188-3
   Wang KK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007538
   Wang R, 2008, BIOCHEM BIOPH RES CO, V373, P151, DOI 10.1016/j.bbrc.2008.06.004
   Zhang DD, 2006, DRUG METAB REV, V38, P769, DOI 10.1080/03602530600971974
NR 48
TC 85
Z9 100
U1 0
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD MAR
PY 2011
VL 6
IS 3
BP 317
EP 325
DI 10.4161/epi.6.3.14408
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 727ND
UT WOS:000287806600007
PM 21173573
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Henry, LA
   Johnson, DA
   Sarrió, D
   Lee, S
   Quinlan, PR
   Crook, T
   Thompson, AM
   Reis, JS
   Isacke, CM
AF Henry, L. A.
   Johnson, D. A.
   Sarrio, D.
   Lee, S.
   Quinlan, P. R.
   Crook, T.
   Thompson, A. M.
   Reis-Filho, J. S.
   Isacke, C. M.
TI Endoglin expression in breast tumor cells suppresses invasion and
   metastasis and correlates with improved clinical outcome
SO ONCOGENE
LA English
DT Article
DE endoglin; CD105; breast cancer; TGF-beta; MCF10A; ErbB2
ID GROWTH-FACTOR-BETA; MOUSE SKIN CARCINOGENESIS; TGF-BETA;
   ENDOTHELIAL-CELLS; TRANSFORMING GROWTH-FACTOR-BETA-1; RECEPTOR; CANCER;
   MIGRATION; PROLIFERATION; ACTIVATION
AB Tumor growth factor-beta (TGF-beta) signaling in cancer has been implicated in growth suppression of early lesions and enhancing tumor cell invasion and metastasis. However, the cellular mechanisms that determine this signaling output in individual tumors are still largely unknown. In endothelial cells, TGF-beta signaling is modulated by the TGF-beta co-receptor endoglin (CD105). Here we demonstrate that endoglin is expressed in a subset of invasive breast cancers and cell lines and is subject to epigenetic silencing by gene methylation. Endoglin downregulation in non-tumorigenic MCF10A breast cells leads to the formation of abnormal acini in 3D culture, but does not promote cell migration or transformation. In contrast, in the presence of activated ErbB2, endoglin downregulation in MCF10A cells leads to enhanced invasion into a 3D matrix. Consistent with these data, ectopic expression of endoglin in MDA-MB-231 cells blocks TGF-beta-enhanced cell motility and invasion and reduces lung colonization in an in vivo metastasis model. Unlike endothelial cells, endoglin does not modulate Smad-mediated TGF-beta signaling in breast cells but attenuates the cytoskeletal remodeling to impair cell migration and invasion. Importantly, in a large cohort of invasive breast cancers, lack of endoglin expression in the tumor cell compartment correlates with ENG gene methylation and poor clinical outcome. Oncogene (2011) 30, 1046-1058; doi:10.1038/onc.2010.488; published online 1 November 2010
C1 [Henry, L. A.; Johnson, D. A.; Sarrio, D.; Lee, S.; Crook, T.; Reis-Filho, J. S.; Isacke, C. M.] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England.
   [Quinlan, P. R.; Thompson, A. M.] Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland.
C3 University of London; Institute of Cancer Research - UK; Royal Marsden
   NHS Foundation Trust; University of Dundee
RP Isacke, CM (通讯作者)，Inst Canc Res, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.
EM clare.isacke@icr.ac.uk
RI SARRIO, DAVID/Y-8903-2019
OI Sarrio, David/0000-0003-4886-8290; Isacke, Clare/0000-0002-9222-3345;
   Quinlan, Philip/0000-0002-3012-6646
FU Breakthrough Breast Cancer; NHS; Marie Curie Intra-European Fellowship
   [PIEF-GA-2008-221083]; Breast Cancer Research Scotland; Tayside Tissue
   Bank
FX We thank Kay Savage and Suzanne Parry for immunohistochemical staining,
   Reshma Shah for help with the methylation analysis, Caterina Marchio for
   microdissection, Senthil Muthuswamy for the MCF10A.ErbB2 cells and Ariad
   Pharmaceuticals (www.ariad.com/regulationkits) for the AP1510 reagent.
   This project was funded by Breakthrough Breast Cancer and from NHS
   funding to the NIHR Biomedical Research Centre, a Marie Curie
   Intra-European Fellowship (PIEF-GA-2008-221083) and Breast Cancer
   Research Scotland with support from the Tayside Tissue Bank.
CR Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485
   Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584
   Bernabeu C, 2007, J CELL BIOCHEM, V102, P1375, DOI 10.1002/jcb.21594
   Bernabeu C, 2009, BBA-MOL BASIS DIS, V1792, P954, DOI 10.1016/j.bbadis.2009.07.003
   Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27
   CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027
   Conley BA, 2004, J BIOL CHEM, V279, P27440, DOI 10.1074/jbc.M312561200
   Craft CS, 2007, ONCOGENE, V26, P7240, DOI 10.1038/sj.onc.1210533
   Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695
   Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018
   Guerrero-Esteo M, 2002, J BIOL CHEM, V277, P29197, DOI 10.1074/jbc.M111991200
   Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433
   Illingworth RS, 2009, FEBS LETT, V583, P1713, DOI 10.1016/j.febslet.2009.04.012
   Ishibashi O, 2010, J CELL PHYSIOL, V222, P465, DOI 10.1002/jcp.21968
   Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189
   Klingbeil P, 2010, BREAST CANCER RES TR, V120, P95, DOI 10.1007/s10549-009-0380-7
   Lebrin F, 2004, EMBO J, V23, P4018, DOI 10.1038/sj.emboj.7600386
   Lee NY, 2007, J BIOL CHEM, V282, P21507, DOI 10.1074/jbc.M700176200
   Massagué J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345
   Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554
   Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785
   Mythreye K, 2009, P NATL ACAD SCI USA, V106, P8221, DOI 10.1073/pnas.0812879106
   Oxmann D, 2008, ONCOGENE, V27, P3567, DOI 10.1038/sj.onc.1211025
   Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718
   Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046
   Perez-Gomez E, 2007, CANCER RES, V67, P10268, DOI 10.1158/0008-5472.CAN-07-1348
   Quintanilla M, 2003, ONCOGENE, V22, P5976, DOI 10.1038/sj.onc.1206841
   Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100
   Rodríguez-Barbero A, 2006, CELL PHYSIOL BIOCHEM, V18, P135, DOI 10.1159/000095181
   Romero D, 2010, CARCINOGENESIS, V31, P359, DOI 10.1093/carcin/bgp217
   Sanz-Rodriguez F, 2004, J BIOL CHEM, V279, P32858, DOI 10.1074/jbc.M400843200
   Scharpfenecker M, 2007, J CELL SCI, V120, P964, DOI 10.1242/jcs.002949
   Scherner O, 2007, J BIOL CHEM, V282, P13934, DOI 10.1074/jbc.M611062200
   Seton-Rogers SE, 2004, P NATL ACAD SCI USA, V101, P1257, DOI 10.1073/pnas.0308090100
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X
   ten Dijke P, 2008, ANGIOGENESIS, V11, P79, DOI 10.1007/s10456-008-9101-9
   Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97
   Wong VCL, 2008, INT J CANCER, V123, P2816, DOI 10.1002/ijc.23882
   Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328
NR 40
TC 47
Z9 56
U1 1
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD MAR
PY 2011
VL 30
IS 9
BP 1046
EP 1058
DI 10.1038/onc.2010.488
PG 13
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 729PX
UT WOS:000287964100004
PM 21042283
DA 2025-01-12
ER

PT J
AU Lin, JQ
   Haffner, MC
   Zhang, YG
   Lee, BH
   Brennen, WN
   Britton, J
   Kachhap, SK
   Shim, JS
   Liu, JO
   Nelson, WG
   Yegnasubramanian, S
   Carducci, MA
AF Lin, Jianqing
   Haffner, Michael C.
   Zhang, Yonggang
   Lee, Byron H.
   Brennen, W. Nathaniel
   Britton, Justin
   Kachhap, Sushant K.
   Shim, Joong Sup
   Liu, Jun O.
   Nelson, William G.
   Yegnasubramanian, Srinivasan
   Carducci, Michael A.
TI Disulfiram Is a DNA Demethylating Agent and Inhibits Prostate Cancer
   Cell Growth
SO PROSTATE
LA English
DT Article
DE DNA methyltransferase inhibitor; DNA methylation; Prostate cancer;
   Disulfiram
ID CPG ISLAND HYPERMETHYLATION; IN-VITRO; METHYLTRANSFERASE INHIBITORS;
   PROTEASOME ACTIVITY; ANTIALCOHOLISM DRUG; BREAST-CANCER; TUMOR-CELLS;
   METHYLATION; THERAPY; EPIGENETICS
AB BACKGROUND. The clinical success of the nucleoside analogs 5-aza-cytidine (5-azaC) and 5-aza-2'deoxycytidine (5-aza-dC) as DNA methyltransferase (DNMT) inhibitors has spurred interest in the development of non-nucleoside inhibitors with improved pharmacologic and safety profiles. Because DNMT catalysis features attack of cytosine bases by an enzyme thiol group, we tested whether disulfiram (DSF), a thiol-reactive compound with known clinical safety, demonstrated DNMT inhibitory activity.
   METHODS. Inhibition of DNMT1 activity by DSF was assessed using methyltransferase activity assays with recombinant DNMT1. Next, prostate cancer cell lines were exposed to DSF and assessed for: i) reduction of global 5-methyl cytosine (C-5me) content using liquid chromatography/tandem mass spectrometry (LC-MS/MS); ii) gene-specific promoter demethylation by methylation-specific PCR (MSP); and iii) gene-reactivation by real-time RT-PCR. DSF was also tested for growth inhibition using prostate cancer cell lines propagated in vitro in cell culture and in vivo as xenografts in nude mice.
   RESULTS. Disulfiram showed a dose-dependent inhibition of DNMT1 activity on a hemimethylated DNA substrate. In prostate cancer cells in culture, DSF exposure led to reduction of global genomic C-5me content, increase in unmethylated APC and RARB gene promoters, and associated re-expression of these genes, but did not significantly alter prostate-specific antigen (PSA) expression. DSF significantly inhibited growth and clonogenic survival of prostate cancer cell lines in culture and showed a trend for reduced growth of prostate cancer xenografts.
   CONCLUSIONS. Disulfiram is a non-nucleoside DNMT1 inhibitor that can reduce global C-5me content, reactivate epigenetically silenced genes, and significantly inhibit growth in prostate cancer cell lines. Prostate 71: 333-343, 2011. (C) 2010 Wiley-Liss. Inc.
C1 [Lin, Jianqing; Haffner, Michael C.; Lee, Byron H.; Brennen, W. Nathaniel; Britton, Justin; Nelson, William G.; Yegnasubramanian, Srinivasan; Carducci, Michael A.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Sch Med, Prostate Canc Program, Baltimore, MD 21231 USA.
   [Lin, Jianqing; Kachhap, Sushant K.; Nelson, William G.; Carducci, Michael A.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Sch Med, Chem Therapeut Program, Baltimore, MD 21231 USA.
   [Zhang, Yonggang] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD 21231 USA.
   [Brennen, W. Nathaniel; Shim, Joong Sup; Liu, Jun O.; Nelson, William G.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21231 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Medicine; Johns Hopkins University; Johns
   Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine
RP Yegnasubramanian, S (通讯作者)，Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Sch Med, Prostate Canc Program, CRBI 1M59,1650 Orleans St, Baltimore, MD 21231 USA.
EM syegnasu@jhmi.edu; carducci@jhmi.edu
RI Carducci, Michael/R-8164-2019; Shim, Joong/O-2848-2016; Shim, Joong
   Sup/G-8383-2011
OI Lee, Byron/0000-0002-8755-9688; Shim, Joong Sup/0000-0003-0167-7307
FU NCI [P50-CA58236, 5T32CA009071-27, R01CA070196, 5P30CA006973]; Prostate
   Cancer Foundation; David Koch Foundation; Flight Attendant Medical
   Research Institute
FX Grant sponsor: NCI; Grant numbers: P50-CA58236, 5T32CA009071-27,
   R01CA070196, 5P30CA006973; Grant sponsor: Prostate Cancer Foundation;
   Grant sponsor: David Koch Foundation; Grant sponsor: Flight Attendant
   Medical Research Institute.
CR Agoston AT, 2005, J BIOL CHEM, V280, P18302, DOI 10.1074/jbc.M501675200
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   Brar SS, 2004, MOL CANCER THER, V3, P1049
   Brueckner B, 2004, TRENDS PHARMACOL SCI, V25, P551, DOI 10.1016/j.tips.2004.09.004
   Brueckner B, 2007, CANCER J, V13, P17, DOI 10.1097/PPO.0b013e31803c7245
   Butler LM, 2000, CANCER RES, V60, P5165
   Carducci MA, 2001, CLIN CANCER RES, V7, P3047
   Chen D, 2005, FRONT BIOSCI-LANDMRK, V10, P2932, DOI 10.2741/1749
   Chen D, 2006, CANCER RES, V66, P10425, DOI 10.1158/0008-5472.CAN-06-2126
   CHEN L, 1991, BIOCHEMISTRY-US, V30, P11018, DOI 10.1021/bi00110a002
   Chick J, 1999, DRUG SAFETY, V20, P427, DOI 10.2165/00002018-199920050-00003
   Cho HJ, 2007, J BIOCHEM MOL BIOL, V40, P1069
   Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   ENEANYA DI, 1981, ANNU REV PHARMACOL, V21, P575, DOI 10.1146/annurev.pa.21.040181.003043
   Esteller M, 2002, SCIENCE, V297, P1807
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Festuccia C, 2009, ENDOCR-RELAT CANCER, V16, P401, DOI 10.1677/ERC-08-0130
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Haffner MC, 2008, J BIOL CHEM, V283, P22089, DOI 10.1074/jbc.M801041200
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Iljin K, 2009, CLIN CANCER RES, V15, P6070, DOI 10.1158/1078-0432.CCR-09-1035
   Jeltsch A, 2002, CHEMBIOCHEM, V3, P275, DOI 10.1002/1439-7633(20020402)3:4<274::AID-CBIC274>3.0.CO;2-S
   JOHANSSON B, 1992, ACTA PSYCHIAT SCAND, V86, P15, DOI 10.1111/j.1600-0447.1992.tb03310.x
   Jones PA, 2009, NAT REV GENET, V10, P805, DOI 10.1038/nrg2651
   Jung Y, 2007, J MOL MED, V85, P1137, DOI 10.1007/s00109-007-0216-z
   Kaminskas E, 2005, CLIN CANCER RES, V11, P3604, DOI 10.1158/1078-0432.CCR-04-2135
   Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1794, DOI 10.1002/cncr.21792
   Lee BH, 2005, J BIOL CHEM, V280, P40749, DOI 10.1074/jbc.M505593200
   Li LC, 2005, JNCI-J NATL CANCER I, V97, P103, DOI 10.1093/jnci/dji010
   Lin XH, 2001, CANCER RES, V61, P8611
   Loo TW, 2000, JNCI-J NATL CANCER I, V92, P898, DOI 10.1093/jnci/92.11.898
   Lövborg H, 2006, INT J CANCER, V118, P1577, DOI 10.1002/ijc.21534
   Lyko F, 2005, JNCI-J NATL CANCER I, V97, P1498, DOI 10.1093/jnci/dji311
   Mack GS, 2006, J NATL CANCER I, V98, P1443, DOI 10.1093/jnci/djj447
   McCabe MT, 2006, CANCER RES, V66, P385, DOI 10.1158/0008-5472.CAN-05-2020
   Momparler RL, 1997, ANTI-CANCER DRUG, V8, P358, DOI 10.1097/00001813-199704000-00008
   Morey SR, 2006, CANCER RES, V66, P11659, DOI 10.1158/0008-5472.CAN-06-1937
   Müller CI, 2006, CURR PHARM BIOTECHNO, V7, P315, DOI 10.2174/138920106778521523
   Nelson WG, 2007, FRONT BIOSCI-LANDMRK, V12, P4254, DOI 10.2741/2385
   Nelson WG, 2009, ENDOCRINOLOGY, V150, P3991, DOI 10.1210/en.2009-0573
   OGara M, 1996, J MOL BIOL, V261, P634, DOI 10.1006/jmbi.1996.0489
   Patra SK, 2002, MOL CARCINOGEN, V33, P163, DOI 10.1002/mc.10033
   Pili R, 2001, CANCER RES, V61, P1477
   QUAGLIANA JM, 1977, CANCER TREAT REP, V61, P51
   Robertson KD, 2000, NUCLEIC ACIDS RES, V28, P2108, DOI 10.1093/nar/28.10.2108
   SAIKI JH, 1981, CANCER-AM CANCER SOC, V47, P1739, DOI 10.1002/1097-0142(19810401)47:7<1739::AID-CNCR2820470702>3.0.CO;2-2
   SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993
   SANTI DV, 1983, CELL, V33, P9, DOI 10.1016/0092-8674(83)90327-6
   Sauna ZE, 2005, MOL BIOSYST, V1, P127, DOI 10.1039/b504392a
   Scher HI, 2008, J CLIN ONCOL, V26, P1148, DOI 10.1200/JCO.2007.12.4487
   Shabbeer S, 2007, PROSTATE, V67, P1099, DOI 10.1002/pros.20587
   Shang DH, 2009, CANCER LETT, V278, P82, DOI 10.1016/j.canlet.2008.12.034
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Shiah SG, 2003, MOL PHARMACOL, V64, P1076, DOI 10.1124/mol.64.5.1076
   Sonpavde G, 2007, CLIN GENITOURIN CANC, V5, P457, DOI 10.3816/CGC.2007.n.036
   Veverka KA, 1997, BIOCHEM PHARMACOL, V53, P511, DOI 10.1016/S0006-2952(96)00767-8
   Walsh CP, 1999, GENE DEV, V13, P26, DOI 10.1101/gad.13.1.26
   Wang WG, 2003, INT J CANCER, V104, P504, DOI 10.1002/ijc.10972
   Wickström M, 2007, BIOCHEM PHARMACOL, V73, P25, DOI 10.1016/j.bcp.2006.08.016
   Yakisich JS, 2001, BIOCHEM BIOPH RES CO, V289, P586, DOI 10.1006/bbrc.2001.6027
   Yegnasubramanian S, 2004, CANCER RES, V64, P1975, DOI 10.1158/0008-5472.CAN-03-3972
   Yegnasubramanian S, 2008, CANCER RES, V68, P8954, DOI 10.1158/0008-5472.CAN-07-6088
NR 65
TC 142
Z9 163
U1 1
U2 35
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-4137
EI 1097-0045
J9 PROSTATE
JI Prostate
PD MAR 1
PY 2011
VL 71
IS 4
BP 333
EP 343
DI 10.1002/pros.21247
PG 11
WC Endocrinology & Metabolism; Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Urology & Nephrology
GA 728SE
UT WOS:000287894000001
PM 20809552
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Vogt, M
   Munding, J
   Grüner, M
   Liffers, ST
   Verdoodt, B
   Hauk, J
   Steinstraesser, L
   Tannapfel, A
   Hermeking, H
AF Vogt, Markus
   Munding, Johanna
   Gruener, Martha
   Liffers, Sven-Thorsten
   Verdoodt, Berlinda
   Hauk, Jennifer
   Steinstraesser, Lars
   Tannapfel, Andrea
   Hermeking, Heiko
TI Frequent concomitant inactivation of <i>miR-34a</i> and
   <i>miR-34b</i>/<i>c</i> by CpG methylation in colorectal, pancreatic,
   mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue
   sarcomas
SO VIRCHOWS ARCHIV
LA English
DT Article
DE CpG methylation; p53; miR-34a; miR-34b/c; miR-34 family; Cancer;
   Epigenetic inactivation
ID TUMOR-SUPPRESSOR; DOWN-REGULATION; LUNG-CANCER; P53; APOPTOSIS;
   MICRORNAS; GROWTH; ACTIVATION; EXPRESSION; MUTATION
AB The microRNA encoding genes miR-34a and miR-34b/c represent direct p53 target genes and possess tumor suppressive properties as they mediate apoptosis, cell cycle arrest, and senescence. We previously reported that the miR-34a gene is subject to epigenetic inactivation by CpG methylation of its promoter region in primary prostate cancer and melanomas, and in 110 different cancer cell lines of diverse origin. Here we analyzed the methylation status of miR-34a and miR-34b/c in additional primary tumors of divergent sites. We found methylation of miR34a or miR-34b/c in formalin-fixed, paraffin-embedded (FFPE) tumor samples from 178 patients with the following frequencies: colorectal cancer (74% miR-34a, 99% miR34b/c; n = 114), pancreatic cancer (64%, 100%; n = 11), mammary cancer (60%, 90%; n = 10), ovarian cancer (62%, 69%; n = 13), urothelial cancer (71%, 57%; n = 7), and renal cell cancer (58%, 100%; n = 12). Furthermore, soft tissue sarcomas showed methylation of miR-34 gene promoters in FFPE samples (64%, 45%; n = 11), in explanted, cultured cells (53%, 40%; n = 40), and in frozen tissue samples (75%, 75%, n = 8). In the colorectal cancer samples a statistically significant correlation of miR-34a methylation and the absence of p53 mutation was detected. With the exception of sarcoma cell lines, the inactivation of miR-34a and miR-34b/c was concomitant in most cases. These results show that miR-34 inactivation is a common event in tumor formation, and suggest that CpG methylation of miR-34a and miR-34-b/c may have diagnostic value. The mutual exclusiveness of miR-34a methylation and p53 mutation indicates that miR-34a inactivation may substitute for loss of p53 function in cancer.
C1 [Hermeking, Heiko] Univ Munich, Inst Pathol, D-80337 Munich, Germany.
   [Vogt, Markus; Munding, Johanna; Gruener, Martha; Liffers, Sven-Thorsten; Verdoodt, Berlinda; Tannapfel, Andrea; Hermeking, Heiko] Ruhr Univ Bochum, Inst Pathol, D-44789 Bochum, Germany.
   [Hauk, Jennifer; Steinstraesser, Lars] Ruhr Univ Bochum, BG Univ Hosp Bergmannsheil, Soft Tissue Tumour Reference Ctr, Dept Plast & Reconstruct Surg,Dept Hand Surg, D-44789 Bochum, Germany.
C3 University of Munich; Ruhr University Bochum; Ruhr University Bochum
RP Hermeking, H (通讯作者)，Univ Munich, Inst Pathol, Thalkirchner Str 36, D-80337 Munich, Germany.
EM heiko.hermeking@med.uni-muenchen.de
OI Hermeking, Heiko/0000-0001-6586-4406; Munding,
   Johanna/0000-0001-9699-8271
FU Deutsche Krebshilfe; Deutsche Forschungsgemeinschaft;
   Friedrich-Baur-Stiftung; Rudolf-Bartling-Stiftung;
   German-Israeli-Foundation for Scientific Research and Development (GIF).
FX Work in Heiko Hermeking's lab is supported by the Deutsche Krebshilfe,
   the Deutsche Forschungsgemeinschaft, the Friedrich-Baur-Stiftung, the
   Rudolf-Bartling-Stiftung, and the German-Israeli-Foundation for
   Scientific Research and Development (GIF).
CR Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068
   Cannell IG, 2010, P NATL ACAD SCI USA, V107, P5375, DOI 10.1073/pnas.0910015107
   Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010
   Chim CS, 2010, CARCINOGENESIS, V31, P745, DOI 10.1093/carcin/bgq033
   Christoffersen NR, 2010, CELL DEATH DIFFER, V17, P236, DOI 10.1038/cdd.2009.109
   Corney DC, 2007, CANCER RES, V67, P8433, DOI 10.1158/0008-5472.CAN-07-1585
   Corney DC, 2010, CLIN CANCER RES, V16, P1119, DOI 10.1158/1078-0432.CCR-09-2642
   Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634
   Gallardo E, 2009, CARCINOGENESIS, V30, P1903, DOI 10.1093/carcin/bgp219
   Garzon R, 2009, ANNU REV MED, V60, P167, DOI [10.1146/annurev.med.59.053006.104707, 10.1146/annurev.pathol.4.110807.092222]
   Hagman Z, 2010, INT J CANCER, V127, P2768, DOI 10.1002/ijc.25269
   Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735
   He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hermeking H, 2010, CELL DEATH DIFFER, V17, P193, DOI 10.1038/cdd.2009.56
   Hermeking H, 2007, CANCER CELL, V12, P414, DOI 10.1016/j.ccr.2007.10.028
   Hoff PM, 2005, J CLIN ONCOL, V23, P7395, DOI 10.1200/JCO.2005.07.021
   Iacopetta B, 2003, HUM MUTAT, V21, P271, DOI 10.1002/humu.10175
   Ji Q, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006816
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Li N, 2009, CANCER LETT, V275, P44, DOI 10.1016/j.canlet.2008.09.035
   Li YQ, 2009, CANCER RES, V69, P7569, DOI 10.1158/0008-5472.CAN-09-0529
   Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   Migliore C, 2008, CANCER RES, V68, P10128, DOI 10.1158/0008-5472.CAN-08-2148
   Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017
   Russo A, 2005, J CLIN ONCOL, V23, P7518, DOI 10.1200/JCO.2005.00.471
   Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436
   Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104
   Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325
   Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293
   Wiggins JF, 2010, CANCER RES, V70, P5923, DOI 10.1158/0008-5472.CAN-10-0655
   Wittekind C., 2002, TNM Klassifikation maligner Tumoren
NR 35
TC 266
Z9 297
U1 0
U2 28
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0945-6317
EI 1432-2307
J9 VIRCHOWS ARCH
JI Virchows Arch.
PD MAR
PY 2011
VL 458
IS 3
BP 313
EP 322
DI 10.1007/s00428-010-1030-5
PG 10
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 738YR
UT WOS:000288679000007
PM 21225432
DA 2025-01-12
ER

PT J
AU McGowan, PO
   Suderman, M
   Sasaki, A
   Huang, TCT
   Hallett, M
   Meaney, MJ
   Szyf, M
AF McGowan, Patrick O.
   Suderman, Matthew
   Sasaki, Aya
   Huang, Tony C. T.
   Hallett, Michael
   Meaney, Michael J.
   Szyf, Moshe
TI Broad Epigenetic Signature of Maternal Care in the Brain of Adult Rats
SO PLOS ONE
LA English
DT Article
ID RECEPTOR SUBUNIT EXPRESSION; LONG-TERM POTENTIATION; DE-NOVO
   METHYLATION; PROTOCADHERIN-ALPHA; DNA METHYLATION; ENVIRONMENTAL
   ENRICHMENT; GLUCOCORTICOID-RECEPTOR; STRESS RESPONSES; MESSENGER-RNA;
   BREAST-CANCER
AB Background: Maternal care is associated with long-term effects on behavior and epigenetic programming of the NR3C1 (GLUCOCORTICOID RECEPTOR) gene in the hippocampus of both rats and humans. In the rat, these effects are reversed by cross-fostering, demonstrating that they are defined by epigenetic rather than genetic processes. However, epigenetic changes at a single gene promoter are unlikely to account for the range of outcomes and the persistent change in expression of hundreds of additional genes in adult rats in response to differences in maternal care.
   Methodology/Principal Findings: We examine here using high-density oligonucleotide array the state of DNA methylation, histone acetylation and gene expression in a 7 million base pair region of chromosome 18 containing the NR3C1 gene in the hippocampus of adult rats. Natural variations in maternal care are associated with coordinate epigenetic changes spanning over a hundred kilobase pairs. The adult offspring of high compared to low maternal care mothers show epigenetic changes in promoters, exons, and gene ends associated with higher transcriptional activity across many genes within the locus examined. Other genes in this region remain unchanged, indicating a clustered yet specific and patterned response. Interestingly, the chromosomal region containing the protocadherin-alpha, -beta, and -gamma (Pcdh) gene families implicated in synaptogenesis show the highest differential response to maternal care.
   Conclusions/Significance: The results suggest for the first time that the epigenetic response to maternal care is coordinated in clusters across broad genomic areas. The data indicate that the epigenetic response to maternal care involves not only single candidate gene promoters but includes transcriptional and intragenic sequences, as well as those residing distantly from transcription start sites. These epigenetic and transcriptional profiles constitute the first tiling microarray data set exploring the relationship between epigenetic modifications and RNA expression in both protein coding and non-coding regions across a chromosomal locus in the mammalian brain.
C1 [McGowan, Patrick O.; Sasaki, Aya; Meaney, Michael J.] Douglas Mental Hlth Univ Inst, Montreal, PQ, Canada.
   [McGowan, Patrick O.; Suderman, Matthew; Sasaki, Aya; Meaney, Michael J.; Szyf, Moshe] McGill Univ, Sackler Program Epigenet & Dev Psychobiol, Montreal, PQ, Canada.
   [McGowan, Patrick O.; Sasaki, Aya] Univ Toronto, Ctr Neurobiol Stress, Toronto, ON, Canada.
   [Suderman, Matthew; Huang, Tony C. T.; Szyf, Moshe] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ, Canada.
   [Suderman, Matthew; Hallett, Michael] McGill Univ, McGill Ctr Bioinformat, Montreal, PQ, Canada.
   [Meaney, Michael J.] Singapore Inst Clin Sci, Singapore, Singapore.
   [Meaney, Michael J.; Szyf, Moshe] Canadian Inst Adv Res, Experience Based Brain & Biol Dev Program, Toronto, ON, Canada.
C3 McGill University; University of Toronto; McGill University; McGill
   University; Agency for Science Technology & Research (A*STAR); A*STAR -
   Singapore Institute for Clinical Sciences (SICS); Canadian Institute for
   Advanced Research (CIFAR)
RP McGowan, PO (通讯作者)，Douglas Mental Hlth Univ Inst, Montreal, PQ, Canada.
EM patrick.mcgowan@utoronto.ca; moshe.szyf@mcgill.ca
RI Meaney, Michael/N-5931-2019
OI Suderman, Matthew/0000-0002-2715-9930; Hallett,
   Michael/0000-0001-6738-6786
FU Canadian Institutes of Mental Health (CIHR); Sackler Foundation
FX This study was supported by grants from the Canadian Institutes of
   Mental Health (CIHR) and the Sackler Foundation to MJM and MS. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR [Anonymous], 2007, R: A Language and Environment for Statistical Computing
   Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
   Bredy TW, 2004, EUR J NEUROSCI, V20, P1355, DOI 10.1111/j.1460-9568.2004.03599.x
   Bredy TW, 2003, NEUROSCIENCE, V118, P571, DOI 10.1016/S0306-4522(02)00918-1
   Bredy TW, 2003, EUR J NEUROSCI, V18, P2903, DOI 10.1111/j.1460-9568.2003.02965.x
   Brown SE, 2008, CELL CYCLE, V7, P382, DOI 10.4161/cc.7.3.5283
   Caldji C, 2003, NEUROPSYCHOPHARMACOL, V28, P1950, DOI 10.1038/sj.npp.1300237
   Champagne DL, 2008, J NEUROSCI, V28, P6037, DOI 10.1523/JNEUROSCI.0526-08.2008
   Champagne FA, 2003, PHYSIOL BEHAV, V79, P359, DOI 10.1016/S0031-9384(03)00149-5
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Coldwell J, 2006, J CHILD PSYCHOL PSYC, V47, P1116, DOI 10.1111/j.1469-7610.2006.01655.x
   COOLEN MW, NAT CELL BIOL, V12, P235
   Crane-Robinson C, 1999, METHOD ENZYMOL, V304, P533
   Down TA, 2008, NAT BIOTECHNOL, V26, P779, DOI 10.1038/nbt1414
   Flanagan JM, 2009, HUM MOL GENET, V18, P1332, DOI 10.1093/hmg/ddp033
   Francis D, 1999, SCIENCE, V286, P1155, DOI 10.1126/science.286.5442.1155
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Junghans D, 2005, CURR OPIN CELL BIOL, V17, P446, DOI 10.1016/j.ceb.2005.08.008
   Kaplan N, 2009, NATURE, V458, P362, DOI 10.1038/nature07667
   Katori S, 2009, J NEUROSCI, V29, P9137, DOI 10.1523/JNEUROSCI.5478-08.2009
   Kawaguchi M, 2008, J BIOL CHEM, V283, P12064, DOI 10.1074/jbc.M709648200
   Kendler KS, 2002, AM J PSYCHIAT, V159, P1133, DOI 10.1176/appi.ajp.159.7.1133
   Keshet I, 2006, NAT GENET, V38, P149, DOI 10.1038/ng1719
   KOROSI A, DEV PSYCHOBIOL, V52, P661
   Liu D, 2000, NAT NEUROSCI, V3, P799, DOI 10.1038/77702
   McCormick JA, 2000, MOL ENDOCRINOL, V14, P506, DOI 10.1210/me.14.4.506
   McEwen BS, 2003, MENT RETARD DEV D R, V9, P149, DOI 10.1002/mrdd.10074
   McGowan PO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002085
   McGowan PO, 2009, NAT NEUROSCI, V12, P342, DOI 10.1038/nn.2270
   Meaney MJ, 2001, ANNU REV NEUROSCI, V24, P1161, DOI 10.1146/annurev.neuro.24.1.1161
   Menard JL, 2007, BEHAV BRAIN RES, V176, P302, DOI 10.1016/j.bbr.2006.10.014
   Nemeroff CB, 2004, J CLIN PSYCHIAT, V65, P18
   Nemeroff CB Charles B, 2004, Psychopharmacol Bull, V38, P14
   Nishida H, 2006, CHROMOSOME RES, V14, P203, DOI 10.1007/s10577-006-1036-7
   Novak P, 2008, CANCER RES, V68, P8616, DOI 10.1158/0008-5472.CAN-08-1419
   Ovtscharoff W, 2006, BRAIN RES, V1116, P58, DOI 10.1016/j.brainres.2006.07.106
   Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36
   Poeggel G, 2003, P NATL ACAD SCI USA, V100, P16137, DOI 10.1073/pnas.2434663100
   Rauch TA, 2009, P NATL ACAD SCI USA, V106, P671, DOI 10.1073/pnas.0812399106
   RIDEOUT WM, 1994, MOL CELL BIOL, V14, P6143, DOI 10.1128/MCB.14.9.6143
   Sadikovic B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002834
   Segal E, 2009, TRENDS GENET, V25, P335, DOI 10.1016/j.tig.2009.06.002
   Smith DT, 2009, GENET RES, V91, P237, DOI 10.1017/S0016672309000226
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Tang AC, 2002, HIPPOCAMPUS, V12, P398, DOI 10.1002/hipo.10017
   Tasic B, 2002, MOL CELL, V10, P21, DOI 10.1016/S1097-2765(02)00578-6
   Toki S, 2007, EUR J NEUROSCI, V25, P815, DOI 10.1111/j.1460-9568.2007.05288.x
   WAKSHLAK A, 1990, PHYSIOL BEHAV, V48, P289, DOI 10.1016/0031-9384(90)90315-U
   Weaver ICG, 2005, J NEUROSCI, V25, P11045, DOI 10.1523/JNEUROSCI.3652-05.2005
   Weaver ICG, 2006, P NATL ACAD SCI USA, V103, P3480, DOI 10.1073/pnas.0507526103
   Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276
   Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598
   WILSON DA, 1986, BEHAV BRAIN RES, V21, P223, DOI 10.1016/0166-4328(86)90240-8
   Wong DJ, 1999, MOL CELL BIOL, V19, P5642
   Yagi T, 2008, DEV GROWTH DIFFER, V50, pS131, DOI 10.1111/j.1440-169X.2008.00991.x
   Zou C, 2007, NEUROSCIENCE, V144, P579, DOI 10.1016/j.neuroscience.2006.10.011
NR 57
TC 297
Z9 327
U1 0
U2 61
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 28
PY 2011
VL 6
IS 2
AR e14739
DI 10.1371/journal.pone.0014739
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 729EM
UT WOS:000287931400004
PM 21386994
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Drini, M
   Wong, NC
   Scott, HS
   Craig, JM
   Dobrovic, A
   Hewitt, CA
   Dow, C
   Young, JP
   Jenkins, MA
   Saffery, R
   Macrae, FA
AF Drini, Musa
   Wong, Nicholas C.
   Scott, Hamish S.
   Craig, Jeffrey M.
   Dobrovic, Alexander
   Hewitt, Chelsee A.
   Dow, Christofer
   Young, Joanne P.
   Jenkins, Mark A.
   Saffery, Richard
   Macrae, Finlay A.
TI Investigating the Potential Role of Genetic and Epigenetic Variation of
   DNA Methyltransferase Genes in Hyperplastic Polyposis Syndrome
SO PLOS ONE
LA English
DT Article
ID ISLAND METHYLATOR PHENOTYPE; GENOME-WIDE ASSOCIATION; DE-NOVO
   METHYLATION; COLORECTAL-CANCER; SERRATED POLYPS;
   INITIAL-CHARACTERIZATION; KRAS MUTATIONS; BREAST-CANCER; BRAF MUTATION;
   DNMT3B
AB Background: Hyperplastic Polyposis Syndrome (HPS) is a condition associated with multiple serrated polyps, and an increased risk of colorectal cancer (CRC). At least half of CRCs arising in HPS show a CpG island methylator phenotype (CIMP), potentially linked to aberrant DNA methyltransferase (DNMT) activity. CIMP is associated with methylation of tumor suppressor genes including regulators of DNA mismatch repair (such as MLH1, MGMT), and negative regulators of Wnt signaling (such as WIF1). In this study, we investigated the potential for interaction of genetic and epigenetic variation in DNMT genes, in the aetiology of HPS.
   Methods: We utilized high resolution melting (HRM) analysis to screen 45 cases with HPS for novel sequence variants in DNMT1, DNMT3A, DNMT3B, and DNMT3L. 21 polyps from 13 patients were screened for BRAF and KRAS mutations, with assessment of promoter methylation in the DNMT1, DNMT3A, DNMT3B, DNMT3L MLH1, MGMT, and WIF1 gene promoters.
   Results: No pathologic germline mutations were observed in any DNA-methyltransferase gene. However, the T allele of rs62106244 (intron 10 of DNMT1 gene) was over-represented in cases with HPS (p<0.01) compared with population controls. The DNMT1, DNMT3A and DNMT3B promoters were unmethylated in all instances. Interestingly, the DNMT3L promoter showed low levels of methylation in polyps and normal colonic mucosa relative to matched disease free cells with methylation level negatively correlated to expression level in normal colonic tissue. DNMT3L promoter hypomethylation was more often found in polyps harbouring KRAS mutations (p = 0.0053). BRAF mutations were common (11 out of 21 polyps), whilst KRAS mutations were identified in 4 of 21 polyps.
   Conclusions: Genetic or epigenetic alterations in DNMT genes do not appear to be associated with HPS, but further investigation of genetic variation at rs62106244 is justified given the high frequency of the minor allele in this case series.
C1 [Drini, Musa; Macrae, Finlay A.] Univ Melbourne, Dept Med, Royal Melbourne Hosp, Parkville, Vic 3052, Australia.
   [Drini, Musa] Canberra Hosp, Dept Gastroenterol & Hepatol, Garran, ACT, Australia.
   [Wong, Nicholas C.; Craig, Jeffrey M.; Saffery, Richard] Univ Melbourne, Dept Paediat, Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia.
   [Scott, Hamish S.] Inst Med & Vet Sci, Adelaide, SA 5000, Australia.
   [Dobrovic, Alexander; Hewitt, Chelsee A.] Peter MacCallum Canc Ctr, Dept Pathol, Melbourne, Vic, Australia.
   [Dobrovic, Alexander] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia.
   [Young, Joanne P.] Queensland Inst Med Res, Herston, Qld 4006, Australia.
   [Jenkins, Mark A.] Univ Melbourne, Sch Populat Hlth, MEGA Epidemiol, Carlton, Vic 3053, Australia.
C3 Melbourne Health; Royal Melbourne Hospital; University of Melbourne;
   Australian National University; Canberra Hospital; Royal Children's
   Hospital Melbourne; University of Melbourne; Murdoch Children's Research
   Institute; Institute Medical & Veterinary Science Australia; Peter
   Maccallum Cancer Center; University of Melbourne; QIMR Berghofer Medical
   Research Institute; University of Melbourne
RP Drini, M (通讯作者)，Univ Melbourne, Dept Med, Royal Melbourne Hosp, Parkville, Vic 3052, Australia.
EM musa.drini@act.gov.au
RI Wong, Nick/AAF-8627-2021; Saffery, Richard/GLS-1976-2022; Young,
   Joanne/B-9981-2011; Craig, Jeffrey/B-3484-2012; Scott,
   Hamish/B-2122-2009; Jenkins, Mark/P-7803-2015
OI Hewitt, Chelsee/0000-0001-7472-6128; Dobrovic,
   Alexander/0000-0003-3414-112X; Craig, Jeffrey/0000-0003-3979-7849;
   Scott, Hamish/0000-0002-5813-631X; Saffery, Richard/0000-0002-9510-4181;
   Wong, Nicholas/0000-0003-4393-7541; Jenkins, Mark/0000-0002-8964-6160;
   Young, Joanne/0000-0002-1514-1522
FU Hicks Foundation
FX Hicks Foundation supported MD. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Aapola U, 2000, GENOMICS, V65, P293, DOI 10.1006/geno.2000.6168
   Aapola U, 2001, CYTOGENET CELL GENET, V92, P122, DOI 10.1159/000056881
   Amundadottir L, 2009, NAT GENET, V41, P986, DOI 10.1038/ng.429
   [Anonymous], HUM MOL GENET
   [Anonymous], GUT
   BENHATTAR J, 1993, GASTROENTEROLOGY, V104, P1044, DOI 10.1016/0016-5085(93)90272-E
   Bestor TH, 1998, AM J HUM GENET, V62, P1269, DOI 10.1086/301891
   Bock C, 2005, BIOINFORMATICS, V21, P4067, DOI 10.1093/bioinformatics/bti652
   BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0
   Bourc'his D, 2001, SCIENCE, V294, P2536, DOI 10.1126/science.1065848
   Carvajal-Carmona LG, 2007, J PATHOL, V212, P378, DOI 10.1002/path.2187
   Cebrian A, 2006, CARCINOGENESIS, V27, P1661, DOI 10.1093/carcin/bgi375
   Chan AOO, 2002, AM J PATHOL, V160, P529, DOI 10.1016/S0002-9440(10)64872-9
   Chan TL, 2003, CANCER RES, V63, P4878
   Chow E, 2006, GASTROENTEROLOGY, V131, P30, DOI 10.1053/j.gastro.2006.03.046
   Dodge JE, 2005, J BIOL CHEM, V280, P17986, DOI 10.1074/jbc.M413246200
   Ehrich M., 2006, INTRO EPITYPER QUANT
   Flynn J, 1996, BIOCHEMISTRY-US, V35, P7308, DOI 10.1021/bi9600512
   Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781
   Gokul G, 2007, EPIGENETICS-US, V2, P80, DOI 10.4161/epi.2.2.3692
   Gokul G, 2009, EPIGENETICS-US, V4, P322, DOI 10.4161/epi.4.5.9239
   Goldstein NS, 2006, AM J CLIN PATHOL, V125, P146, DOI 10.1309/87BD0C6UCGUG126J
   GRUENBAUM Y, 1982, NATURE, V295, P620, DOI 10.1038/295620a0
   Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   Issa JPJ, 2005, GASTROENTEROLOGY, V129, P1121, DOI 10.1053/j.gastro.2005.07.040
   Jass J R., 2000, WHO International Classification of Tumors (3rd edition): Pathology and genetics of tumors of the digestive system, P135
   Jass JR, 1999, J CLIN PATHOL, V52, P455, DOI 10.1136/jcp.52.6.455
   Jass JR, 2005, NAT CLIN PRACT ONCOL, V2, P398, DOI 10.1038/ncponc0248
   Jia D, 2007, NATURE, V449, P248, DOI 10.1038/nature06146
   Jin BL, 2008, HUM MOL GENET, V17, P690, DOI 10.1093/hmg/ddm341
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kambara T, 2004, GUT, V53, P1137, DOI 10.1136/gut.2003.037671
   Kanai Y, 1996, JPN J CANCER RES, V87, P1210, DOI 10.1111/j.1349-7006.1996.tb03135.x
   Kanai Y, 2007, CARCINOGENESIS, V28, P2434, DOI 10.1093/carcin/bgm206
   Kaneda M, 2004, NATURE, V429, P900, DOI 10.1038/nature02633
   Kato Y, 2007, HUM MOL GENET, V16, P2272, DOI 10.1093/hmg/ddm179
   Kelemen LE, 2008, CANCER RES, V68, P2498, DOI 10.1158/0008-5472.CAN-07-5165
   Kondo Y, 2004, CANCER METAST REV, V23, P29, DOI 10.1023/A:1025806911782
   Krypuy M, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-295
   Lee SJ, 2005, CARCINOGENESIS, V26, P403, DOI 10.1093/carcin/bgh307
   Lin RK, 2007, LUNG CANCER, V55, P205, DOI 10.1016/j.lungcan.2006.10.022
   Minoo P, 2006, GUT, V55, DOI 10.1136/gut.2005.082859
   Minoo P, 2007, J PATHOL, V212, P124, DOI 10.1002/path.2160
   Montgomery KG, 2004, BREAST CANCER RES, V6, pR390, DOI 10.1186/bcr807
   Nagasaka T, 2004, J CLIN ONCOL, V22, P4584, DOI 10.1200/JCO.2004.02.154
   Nosho K, 2009, CLIN CANCER RES, V15, P3663, DOI 10.1158/1078-0432.CCR-08-2383
   O'Brien MJ, 2004, AM J SURG PATHOL, V28, P423, DOI 10.1097/00000478-200404000-00001
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Okano M, 1998, NUCLEIC ACIDS RES, V26, P2536, DOI 10.1093/nar/26.11.2536
   Park BL, 2004, J HUM GENET, V49, P642, DOI 10.1007/s10038-004-0192-x
   Pertea M, 2001, NUCLEIC ACIDS RES, V29, P1185, DOI 10.1093/nar/29.5.1185
   Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15
   Sjöblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427
   Snover DC, 2005, AM J CLIN PATHOL, V124, P380, DOI 10.1309/V2EPTPLJRB3FGHJL
   STEGER G, 1994, NUCLEIC ACIDS RES, V22, P2760, DOI 10.1093/nar/22.14.2760
   Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710
   Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571
   van Rijnsoever M, 2002, GUT, V51, P797, DOI 10.1136/gut.51.6.797
   Webster KE, 2005, P NATL ACAD SCI USA, V102, P4068, DOI 10.1073/pnas.0500702102
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Wong NC, 2008, BIOTECHNIQUES, V45, P423, DOI 10.2144/000112945
   Xie SP, 1999, GENE, V236, P87, DOI 10.1016/S0378-1119(99)00252-8
   Yang S, 2004, AM J SURG PATHOL, V28, P1452, DOI 10.1097/01.pas.0000141404.56839.6a
NR 66
TC 8
Z9 8
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 10
PY 2011
VL 6
IS 2
AR e16831
DI 10.1371/journal.pone.0016831
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 721NZ
UT WOS:000287363000019
PM 21347319
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Hsu, CC
   Leu, YW
   Tseng, MJ
   Lee, KD
   Kuo, TY
   Yen, JY
   Lai, YL
   Hung, YC
   Sun, WS
   Chen, CM
   Chu, PY
   Yeh, KT
   Yan, PS
   Chang, YS
   Huang, THM
   Hsiao, SH
AF Hsu, Chia-Chen
   Leu, Yu-Wei
   Tseng, Min-Jen
   Lee, Kuan-Der
   Kuo, Tzen-Yu
   Yen, Jia-Yi
   Lai, Yen-Ling
   Hung, Yi-Chen
   Sun, Wei-Sheng
   Chen, Chien-Min
   Chu, Pei-Yi
   Yeh, Kun-Tu
   Yan, Pearlly S.
   Chang, Yu-Sun
   Huang, Tim H-M
   Hsiao, Shu-Huei
TI Functional characterization of <i>Trip10</i> in cancer cell growth and
   survival
SO JOURNAL OF BIOMEDICAL SCIENCE
LA English
DT Article
ID BREAST-CANCER; HUNTINGTONS-DISEASE; GENE-EXPRESSION; DNA METHYLATION;
   PROTEIN; CIP4; ENDOCYTOSIS; TRAFFICKING; ADIPOCYTES; ACTIN
AB Background: The Cdc42-interacting protein-4, Trip10 (also known as CIP4), is a multi-domain adaptor protein involved in diverse cellular processes, which functions in a tissue-specific and cell lineage-specific manner. We previously found that Trip10 is highly expressed in estrogen receptor-expressing (ER+) breast cancer cells. Estrogen receptor depletion reduced Trip10 expression by progressively increasing DNA methylation. We hypothesized that Trip10 functions as a tumor suppressor and may be involved in the malignancy of ER-negative (ER-) breast cancer. To test this hypothesis and evaluate whether Trip10 is epigenetically regulated by DNA methylation in other cancers, we evaluated DNA methylation of Trip10 in liver cancer, brain tumor, ovarian cancer, and breast cancer.
   Methods: We applied methylation-specific polymerase chain reaction and bisulfite sequencing to determine the DNA methylation of Trip10 in various cancer cell lines and tumor specimens. We also overexpressed Trip10 to observe its effect on colony formation and in vivo tumorigenesis.
   Results: We found that Trip10 is hypermethylated in brain tumor and breast cancer, but hypomethylated in liver cancer. Overexpressed Trip10 was associated with endogenous Cdc42 and huntingtin in IMR-32 brain tumor cells and CP70 ovarian cancer cells. However, overexpression of Trip10 promoted colony formation in IMR-32 cells and tumorigenesis in mice inoculated with IMR-32 cells, whereas overexpressed Trip10 substantially suppressed colony formation in CP70 cells and tumorigenesis in mice inoculated with CP70 cells.
   Conclusions: Trip10 regulates cancer cell growth and death in a cancer type-specific manner. Differential DNA methylation of Trip10 can either promote cell survival or cell death in a cell type-dependent manner.
C1 [Hsu, Chia-Chen; Leu, Yu-Wei; Tseng, Min-Jen; Kuo, Tzen-Yu; Yen, Jia-Yi; Lai, Yen-Ling; Hung, Yi-Chen; Sun, Wei-Sheng; Hsiao, Shu-Huei] Natl Chung Cheng Univ, Inst Mol Biol, Dept Life Sci, Human Epigenom Ctr, Chiayi, Taiwan.
   [Hsu, Chia-Chen; Leu, Yu-Wei; Tseng, Min-Jen; Kuo, Tzen-Yu; Yen, Jia-Yi; Lai, Yen-Ling; Hung, Yi-Chen; Sun, Wei-Sheng; Hsiao, Shu-Huei] Natl Chung Cheng Univ, Inst Biomed Sci, Chiayi, Taiwan.
   [Lee, Kuan-Der] Chang Gung Mem Hosp, Chiayi, Taiwan.
   [Chen, Chien-Min] ChangHua Christian Hosp, Div Neurosurg, Changhua, Taiwan.
   [Chu, Pei-Yi; Yeh, Kun-Tu] ChangHua Christian Hosp, Dept Pathol, Changhua, Taiwan.
   [Yan, Pearlly S.; Huang, Tim H-M] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Columbus, OH 43210 USA.
   [Yan, Pearlly S.; Huang, Tim H-M] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
   [Chang, Yu-Sun] Chang Gung Univ, Grad Inst Basic Med Sci, Tao Yuan, Taiwan.
C3 National Chung Cheng University; National Chung Cheng University; Chang
   Gung Memorial Hospital; Changhua Christian Hospital; Changhua Christian
   Hospital; University System of Ohio; Ohio State University; James Cancer
   Hospital & Solove Research Institute; University System of Ohio; Ohio
   State University; Chang Gung University
RP Hsiao, SH (通讯作者)，Natl Chung Cheng Univ, Inst Mol Biol, Dept Life Sci, Human Epigenom Ctr, Chiayi, Taiwan.
EM bioshh@ccu.edu.tw
RI Yan, Pearlly/E-4339-2011; chang, yu/KFB-2822-2024
OI Chu, Pei-Yi/0000-0001-7336-2465; Chang, Yu-Sun/0000-0002-6457-3890
FU NRPGM; NSC in Taiwan [NSC-98-3112-B-194-001, NSC-97 2320 B 194 003 MY3,
   NSC 96 2320 B 194 004, NSC 95 2320 B 194 003]
FX This work was supported by NRPGM and NSC (NSC-98-3112-B-194-001, NSC-97
   2320 B 194 003 MY3, NSC 96 2320 B 194 004, and NSC 95 2320 B 194 003) in
   Taiwan.
CR Banerjee PP, 2007, J EXP MED, V204, P2305, DOI 10.1084/jem.20061893
   Cahir-McFarland ED, 2004, J VIROL, V78, P4108, DOI 10.1128/JVI.78.8.4108-4119.2004
   Chang L, 2002, P NATL ACAD SCI USA, V99, P12835, DOI 10.1073/pnas.202495599
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385
   Colin E, 2005, EUR J NEUROSCI, V21, P1478, DOI 10.1111/j.1460-9568.2005.03985.x
   Feng YM, 2010, J BIOL CHEM, V285, P4348, DOI 10.1074/jbc.M109.041038
   Gonzalez E, 2009, CELL CYCLE, V8, P2502, DOI 10.4161/cc.8.16.9335
   Guil S, 2009, INT J BIOCHEM CELL B, V41, P87, DOI 10.1016/j.biocel.2008.09.005
   Hartig SM, 2009, J CELL SCI, V122, P2283, DOI 10.1242/jcs.041343
   Hirata T, 2007, BRAIN RES, V1130, P214, DOI 10.1016/j.brainres.2006.10.077
   Holbert S, 2003, P NATL ACAD SCI USA, V100, P2712, DOI 10.1073/pnas.0437967100
   Holliday R, 2006, EPIGENETICS-US, V1, P76, DOI 10.4161/epi.1.2.2762
   Hsiao SH, 2010, BIOCHEM BIOPH RES CO, V400, P305, DOI 10.1016/j.bbrc.2010.08.048
   Hu JH, 2009, CELL SIGNAL, V21, P1686, DOI 10.1016/j.cellsig.2009.07.007
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jin VX, 2004, NUCLEIC ACIDS RES, V32, P6627, DOI 10.1093/nar/gkh1005
   Lee KD, 2004, HEPATOLOGY, V40, P1275, DOI 10.1002/hep.20469
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926
   Lodhi IJ, 2007, CELL METAB, V5, P59, DOI 10.1016/j.cmet.2006.12.006
   Roignot J, 2010, CANCER LETT, V288, P116, DOI 10.1016/j.canlet.2009.06.030
   Tian L, 2000, J BIOL CHEM, V275, P7854, DOI 10.1074/jbc.275.11.7854
   Tsujita K, 2006, J CELL BIOL, V172, P269, DOI 10.1083/jcb.200508091
   Turner BM, 2007, NAT CELL BIOL, V9, P2, DOI 10.1038/ncb0107-2
   Yan PS, 2003, CANCER RES, V63, P6178
   Yuan RQ, 2001, CANCER RES, V61, P8022
   Zhang YQ, 2009, J BIOL CHEM, V284, P12956, DOI 10.1074/jbc.M807845200
NR 27
TC 22
Z9 22
U1 0
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1021-7770
EI 1423-0127
J9 J BIOMED SCI
JI J. Biomed. Sci.
PD FEB 7
PY 2011
VL 18
AR 12
DI 10.1186/1423-0127-18-12
PG 10
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 725PH
UT WOS:000287657300001
PM 21299869
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Tell, R
   Rivera, CA
   Eskra, J
   Taglia, LN
   Blunier, A
   Wang, QT
   Benya, RV
AF Tell, Robert
   Rivera, Claudio A.
   Eskra, Jillian
   Taglia, Lauren N.
   Blunier, Adam
   Wang, Q. Tian
   Benya, Richard V.
TI Gastrin-Releasing Peptide Signaling Alters Colon Cancer Invasiveness via
   Heterochromatin Protein 1<SUP>Hsβ</SUP>
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID FOCAL ADHESION KINASE; QUANTITATIVE IMMUNOHISTOCHEMISTRY; RECEPTOR
   ANTAGONIST; BREAST-CANCER; EXPRESSION; CELLS; BOMBESIN; HP1(HS-ALPHA);
   METASTASIS; ACTIVATION
AB Epithelial cells lining the adult colon do not normally express gastrin-releasing peptide (GRP) or its receptor (GRPR). In contrast, GRP/GRPR can be aberrantly expressed in colon cancer where they are associated with improved patient survival rates. However, the mechanism of action whereby these proteins mediate their beneficial effects is not known. Heterochromatin protein 1 is an epigenetic modifier of gene transcription for which three different isoforms exist in humans: HP1Hs alpha, HP1(Hs beta), and HP1(Hs gamma). In breast cancer and melanoma, respectively, HP1(Hs alpha) and HP1(Hs beta) have been shown to modulate the aggressiveness of tumor cells in vivo. In contrast, the role of HP1 in colon cancer has not been elucidated, and a mechanism of regulating the expression of any HP1 isoform in any context has not yet been identified. In this article we demonstrate that abrogating GRP/GRPR signaling specifically down-regulates HP1(Hs beta) expression and that inhibiting GRPR signaling, or ablating HP1(Hs beta) expression, increases colon cancer cell invasiveness in vitro. These findings identify for the first time a signaling pathway regulating heterochromatin protein expression and suggest a mechanism whereby aberrantly expressed GRPR might alter the outcome of patients with colorectal cancer. (Am J Pathol 2011, 178:672-678; DOI: 10.1016/j.ajpath.2010.10.017)
C1 [Benya, Richard V.] Univ Illinois, Dept Med, Chicago, IL 60612 USA.
   Univ Illinois, Dept Biol Sci, Chicago, IL 60612 USA.
   Univ Illinois, UIC Canc Ctr, Chicago, IL 60612 USA.
   Jessie Brown Vet Adm Med Ctr, Chicago, IL USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical
   Center
RP Benya, RV (通讯作者)，Univ Illinois, Dept Med, 840 S Wood St M-C 716, Chicago, IL 60612 USA.
EM rvbenya@uic.edu
RI Eskra, Jillian/U-9649-2019
FU Veterans Administration
FX Supported by a Veterans Administration Merit Review award (R.V.B.).
CR Berger JC, 2005, CANCER BIOL THER, V4, P805, DOI 10.4161/cbt.4.8.1865
   Carroll RE, 1999, PEPTIDES, V20, P229, DOI 10.1016/S0196-9781(98)00164-8
   Carroll RE, 1999, AM J PHYSIOL-GASTR L, V276, pG655, DOI 10.1152/ajpgi.1999.276.3.G655
   Carroll RE, 2002, MECH DEVELOP, V113, P121, DOI 10.1016/S0925-4773(02)00032-1
   Dialynas GK, 2008, MUTAT RES-FUND MOL M, V647, P13, DOI 10.1016/j.mrfmmm.2008.09.007
   Dillon N, 2004, BIOL CELL, V96, P631, DOI 10.1016/j.biolcel.2004.06.003
   Eissenberg JC, 2000, CURR OPIN GENET DEV, V10, P204, DOI 10.1016/S0959-437X(00)00058-7
   ERSPAMER V, 1972, BRIT J PHARMACOL, V45, P333, DOI 10.1111/j.1476-5381.1972.tb08087.x
   ERSPAMER V, 1988, ANN NY ACAD SCI, V547, P3, DOI 10.1111/j.1749-6632.1988.tb23870.x
   Grewal SIS, 2007, NAT REV GENET, V8, P35, DOI 10.1038/nrg2008
   Itoh F, 1996, CANCER, V77, P1717
   Jensen JAG, 2001, PEPTIDES, V22, P689, DOI 10.1016/S0196-9781(01)00380-1
   Jensen RT, 2008, PHARMACOL REV, V60, P1, DOI 10.1124/pr.107.07108
   Kirschmann DA, 2000, CANCER RES, V60, P3359
   Lomberk G, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-7-228
   Matkowskyj K., 2004, Microscopy Analysis, V18, P5
   Matkowskyj KA, 2003, J HISTOCHEM CYTOCHEM, V51, P1041, DOI 10.1177/002215540305100807
   Matkowskyj KA, 2003, J HISTOCHEM CYTOCHEM, V51, P205, DOI 10.1177/002215540305100209
   Matkowskyj KA, 2000, J HISTOCHEM CYTOCHEM, V48, P303, DOI 10.1177/002215540004800216
   Matkowskyj KA, 2006, QUANTITATIVE IMMUNOH, P279
   Moss TJ, 2007, MUTAT RES-FUND MOL M, V618, P163, DOI 10.1016/j.mrfmmm.2006.05.038
   Nishimura K, 2006, ANTICANCER RES, V26, P4349
   Norwood LE, 2006, J BIOL CHEM, V281, P18668, DOI 10.1074/jbc.M512454200
   Norwood LE, 2004, GENE, V336, P37, DOI 10.1016/j.gene.2004.04.003
   Olins DE, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-39
   Panteleeva I, 2007, EMBO J, V26, P3616, DOI 10.1038/sj.emboj.7601789
   PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263
   Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a
   QIN YF, 1994, CANCER RES, V54, P1035
   Rivera CA, 2009, CLIN EXP METASTAS, V26, P663, DOI 10.1007/s10585-009-9265-8
   Roesler R, 2004, EUR J PHARMACOL, V486, P35, DOI 10.1016/j.ejphar.2003.12.011
   Ruginis T, 2006, J PROTEOME RES, V5, P1460, DOI 10.1021/pr060005g
   Steeg Patricia S, 2003, Clin Breast Cancer, V4, P51, DOI 10.3816/CBC.2003.n.012
   Taglia L, 2008, CLIN EXP METASTAS, V25, P451, DOI 10.1007/s10585-008-9151-9
   Taglia L, 2007, AM J PHYSIOL-GASTR L, V292, pG182, DOI 10.1152/ajpgi.00201.2006
   Takanashi M, 2009, AM J PATHOL, V174, P309, DOI 10.2353/ajpath.2009.080148
   ToiScott M, 1996, LUNG CANCER-J IASLC, V15, P341, DOI 10.1016/0169-5002(95)00597-8
   Zhu XL, 2008, INT J COLORECTAL DIS, V23, P1041, DOI 10.1007/s00384-008-0520-2
NR 38
TC 19
Z9 24
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD FEB
PY 2011
VL 178
IS 2
BP 672
EP 678
DI 10.1016/j.ajpath.2010.10.017
PG 7
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 720EX
UT WOS:000287264400022
PM 21281799
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Brantley-Sieders, DM
   Dunaway, CM
   Rao, M
   Short, S
   Hwang, Y
   Gao, YD
   Li, DY
   Jiang, AX
   Shyr, Y
   Wu, JY
   Chen, J
AF Brantley-Sieders, Dana M.
   Dunaway, Charlene M.
   Rao, Meghana
   Short, Sarah
   Hwang, Yoonha
   Gao, Yandong
   Li, Deyu
   Jiang, Aixiang
   Shyr, Yu
   Wu, Jane Y.
   Chen, Jin
TI Angiocrine Factors Modulate Tumor Proliferation and Motility through
   EphA2 Repression of Slit2 Tumor Suppressor Function in Endothelium
SO CANCER RESEARCH
LA English
DT Article
ID BREAST-CANCER CELLS; FREQUENT EPIGENETIC INACTIVATION; GROWTH-FACTOR;
   METASTATIC PROGRESSION; SIGNALING PATHWAYS; IN-VIVO; ANGIOGENESIS; GENE;
   MIGRATION; EXPRESSION
AB It is well known that tumor-derived proangiogenic factors induce neovascularization to facilitate tumor growth and malignant progression. However, the concept of "angiocrine" signaling, in which signals produced by endothelial cells elicit tumor cell responses distinct from vessel function, has been proposed, yet remains underinvestigated. Here, we report that angiocrine factors secreted from endothelium regulate tumor growth and motility. We found that Slit2, which is negatively regulated by endothelial EphA2 receptor, is one such tumor suppressive angiocrine factor. Slit2 activity is elevated in EphA2-deficient endothelium. Blocking Slit activity restored angiocrine-induced tumor growth/motility, whereas elevated Slit2 impaired growth/motility. To translate our findings to human cancer, we analyzed EphA2 and Slit2 expression in human cancer. EphA2 expression inversely correlated with Slit2 in the vasculature of invasive human ductal carcinoma samples. Moreover, analysis of large breast tumor data sets revealed that Slit2 correlated positively with overall and recurrence-free survival, providing clinical validation for the tumor suppressor function for Slit2 in human breast cancer. Together, these data support a novel, clinically relevant mechanism through which EphA2 represses Slit2 expression in endothelium to facilitate angiocrine-mediated tumor growth and motility by blocking a tumor suppressive signal. Cancer Res; 71(3); 976-87. (C)2010 AACR.
C1 [Brantley-Sieders, Dana M.; Dunaway, Charlene M.; Hwang, Yoonha; Chen, Jin] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA.
   [Rao, Meghana; Short, Sarah; Jiang, Aixiang; Shyr, Yu; Chen, Jin] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA.
   [Gao, Yandong; Li, Deyu] Vanderbilt Univ, Dept Mech Engn, Nashville, TN 37232 USA.
   [Jiang, Aixiang; Shyr, Yu] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA.
   [Wu, Jane Y.] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
   [Wu, Jane Y.] Northwestern Univ, Feinberg Sch Med, Ctr Genet Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
   [Chen, Jin] Tennessee Valley Healthcare Syst, Vet Affairs Med Ctr, Nashville, TN USA.
   [Chen, Jin] Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA.
C3 Vanderbilt University; Vanderbilt University; Vanderbilt University;
   Vanderbilt University; Ann & Robert H. Lurie Children's Hospital of
   Chicago; Northwestern University; Feinberg School of Medicine; Robert H.
   Lurie Comprehensive Cancer Center; Robert H. Lurie Comprehensive Cancer
   Center; Northwestern University; Feinberg School of Medicine; Ann &
   Robert H. Lurie Children's Hospital of Chicago; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee
   Valley Healthcare System; Vanderbilt University
RP Chen, J (通讯作者)，Vanderbilt Univ, Sch Med, Dept Med, A-4323 MCN,1161 21st Ave S, Nashville, TN 37232 USA.
EM jin.chen@vanderbilt.edu
RI Shyr, Yu/KSM-5348-2024; Li, Deyu/D-2938-2012; Chen, Jin/KLE-0190-2024
OI Shyr, Yu/0000-0003-2086-9670; Li, Deyu/0000-0001-8364-0924; Jiang,
   Aixiang/0000-0002-6153-7595; Chen, Jin/0000-0002-5557-2079; Short,
   Sarah/0000-0001-9606-7370; Hwang, Yoonha/0000-0001-7420-4477
FU Department of Veterans Affairs through VA; NIH [CA95004, CA114301,
   CA1179151, CA114197, CA107193]; Department of Defense
   [W81XWH-10-1-0256]; Vanderbilt-Ingram Cancer Center Biostatistics Shared
   Resource NCI [P30 CA68485]; NSF [CBET0643583]; NCI [T32 CA09592-21, T32
   CA09592-22]; James S. McDonnell Foundation
FX This work was supported by the Department of Veterans Affairs through a
   VA Merit Award (J. Chen) and NIH grants CA95004 and CA114301 (J. Chen).
   D. M. Brantley-Sieders is supported by NIH grant CA1179151. M. Rao is
   supported by Department of Defense Breast Cancer Research Program Grant
   W81XWH-10-1-0256. Y. Shyr and A. Jiang are supported by the
   Vanderbilt-Ingram Cancer Center Biostatistics Shared Resource NCI Grant
   P30 CA68485. Y. Gao and D. Li are supported by NSF grant CBET0643583. S.
   Short is supported by NCI training grant T32 CA09592-21, 22 (L.
   Matrisian). J. Y. Wu is supported by NIH grants CA114197 and CA107193,
   and by the James S. McDonnell Foundation.
CR Ahmed Zubair, 2009, V467, P3, DOI 10.1007/978-1-59745-241-0_1
   Astuti D, 2004, BRIT J CANCER, V90, P515, DOI 10.1038/sj.bjc.6601447
   Barrett JM, 2006, PROSTATE, V66, P632, DOI 10.1002/pros.20370
   Barrett JM, 2005, PROSTATE, V64, P75, DOI 10.1002/pros.20206
   Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093
   Bin Fang W, 2008, J BIOL CHEM, V283, P16017, DOI 10.1074/jbc.M709934200
   Brantley DM, 2002, ONCOGENE, V21, P7011, DOI 10.1038/sj.onc.1205679
   Brantley-Sieders DM, 2008, J CLIN INVEST, V118, P64, DOI 10.1172/JCI33154
   Brantley-Sieders DM, 2006, CANCER RES, V66, P10315, DOI 10.1158/0008-5472.CAN-06-1560
   Brantley-Sieders Dana M., 2004, Angiogenesis, V7, P17, DOI 10.1023/B:AGEN.0000037340.33788.87
   Brantley-Sieders DM, 2005, FASEB J, V19, P1884, DOI 10.1096/fj.05-4038fje
   Brantley-Sieders DM, 2004, J CELL SCI, V117, P2037, DOI 10.1242/jcs.01061
   Butler JM, NAT REV CANC, V10, P138
   Cao Y, 2008, ADV CANCER RES, V100, P113, DOI 10.1016/S0065-230X(08)00004-3
   Chung AS, NAT REV CANC, V10, P505
   Dallol A, 2003, ONCOGENE, V22, P4611, DOI 10.1038/sj.onc.1206687
   Dallol A, 2002, CANCER RES, V62, P5874
   Dammann R, 2005, EUR J CANCER, V41, P1223, DOI 10.1016/j.ejca.2005.02.020
   De Bruyne E, 2006, LEUKEMIA, V20, P1870, DOI 10.1038/sj.leu.2404343
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   Dickson BJ, 2006, ANNU REV CELL DEV BI, V22, P651, DOI 10.1146/annurev.cellbio.21.090704.151234
   Dietrich D, 2009, J HISTOCHEM CYTOCHEM, V57, P477, DOI 10.1369/jhc.2009.953026
   Dunwell TL, 2009, EPIGENETICS-US, V4, P265, DOI 10.4161/epi.9137
   Fernandis A Z, 2001, Sci STKE, V2001, ppe1
   FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4
   Gasparini G, 2001, CRIT REV ONCOL HEMAT, V37, P97, DOI 10.1016/S1040-8428(00)00105-0
   Hatfield K, 2006, INT J CANCER, V119, P2313, DOI 10.1002/ijc.22180
   Hohenester E, 2008, BIOCHEM SOC T, V36, P251, DOI 10.1042/BST0360251
   Jones CA, 2008, NAT MED, V14, P448, DOI 10.1038/nm1742
   Killeen MT, 2008, DEV BIOL, V323, P143, DOI 10.1016/j.ydbio.2008.08.027
   Kim HK, 2008, NEOPLASIA, V10, P1411, DOI 10.1593/neo.08804
   Kuijper S, 2007, TRENDS CARDIOVAS MED, V17, P145, DOI 10.1016/j.tcm.2007.03.003
   Langley RR, 2003, CANCER RES, V63, P2971
   Legg JA, 2008, ANGIOGENESIS, V11, P13, DOI 10.1007/s10456-008-9100-x
   Marlow R, 2008, CANCER RES, V68, P7819, DOI 10.1158/0008-5472.CAN-08-1357
   Mertsch S, 2008, J NEURO-ONCOL, V87, P1, DOI 10.1007/s11060-007-9484-2
   Muraoka RS, 2003, MOL CELL BIOL, V23, P8691, DOI 10.1128/MCB.23.23.8691-8703.2003
   Narayan G, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-16
   Pasquale EB, NAT REV CANC, V10, P165
   Prasad A, 2004, J BIOL CHEM, V279, P9115, DOI 10.1074/jbc.M308083200
   Prasad A, 2008, J BIOL CHEM, V283, P26624, DOI 10.1074/jbc.M800679200
   Schmid BC, 2007, BREAST CANCER RES TR, V106, P333, DOI 10.1007/s10549-007-9504-0
   Sharma G, 2007, LIFE SCI, V80, P1873, DOI 10.1016/j.lfs.2007.02.026
   Shojaei F, 2008, DRUG RESIST UPDATE, V11, P219, DOI 10.1016/j.drup.2008.09.001
   Singh RK, 2007, HUM GENET, V122, P71, DOI 10.1007/s00439-007-0375-6
   Stella MC, 2009, MOL BIOL CELL, V20, P642, DOI 10.1091/mbc.E08-03-0321
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Wang LJ, 2008, CANCER SCI, V99, P510, DOI 10.1111/j.1349-7006.2007.00721.x
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   Weidner N, 1997, Surg Oncol Clin N Am, V6, P415
   Werbowetski-Ogilvie TE, 2006, ONCOGENE, V25, P5103, DOI 10.1038/sj.onc.1209524
   Wu JY, 2001, NATURE, V410, P948, DOI 10.1038/35073616
   Yang XM, BIOCH BIOPHYS RES CO, V396, P571
   Yiin JJ, 2009, NEURO-ONCOLOGY, V11, P779, DOI 10.1215/15228517-2008-017
   Yuasa-Kawada J, 2009, P NATL ACAD SCI USA, V106, P14530, DOI 10.1073/pnas.0801262106
NR 56
TC 54
Z9 71
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD FEB 1
PY 2011
VL 71
IS 3
BP 976
EP 987
DI 10.1158/0008-5472.CAN-10-3396
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 714SW
UT WOS:000286830300037
PM 21148069
OA Green Submitted, Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Moolmuang, B
   Tainsky, MA
AF Moolmuang, Benchamart
   Tainsky, Michael A.
TI CREG1 enhances p16<SUP>INK4a</SUP>-induced cellular senescence
SO CELL CYCLE
LA English
DT Article
DE CREG1; p16(INK4a); cellular immortalization; cellular senescence;
   Li-Fraumeni syndrome
ID BREAST-CANCER; E1A-STIMULATED GENES; DNA METHYLATION; GROWTH;
   EXPRESSION; CYCLE; P53; IMMORTALIZATION; INTERFERON; INDUCTION
AB Cellular senescence is an irreversible growth arrest that is activated in normal cells upon shortening of telomere and other cellular stresses. Bypassing cellular senescence is a necessary step for cells to become immortal during oncogenic transformation. During the spontaneous immortalization of Li-Fraumeni Syndrome (LFS) fibroblasts, we found that CREG1 (Cellular Repressor of E1A-stimulated Genes 1) expression was decreased during immortalization and increased in senescence. Moreover, we found that repression of CREG1 expression occurs via an epigenetic mechanism, promoter DNA methylation. Ectopic expression of CREG1 in the immortal LFS cell lines decreases cell proliferation but does not directly induce senescence. We confirmed this in osteosarcoma and fibrosarcoma cancer cell lines, cancers commonly seen in Li-Fraumeni Syndrome. In addition, we found that p16(INK4a) is also downregulated in immortal cells and that coexpression of CREG1 and p16(INK4a), an inhibitor of CDK4/6 and Rb phosphorylation, has a greater effect than either CREG1 and p16(INK4a) alone to reduce cell growth, induce cell cycle arrest and cellular senescence in immortal LFS fibroblasts, osteosarcoma and fibrosarcoma cell lines. Moreover, cooperation of CREG1 and p16(INK4a) inhibits the expression of cyclin A and cyclin B by inhibiting promoter activity, thereby decreasing mRNA and protein levels; these proteins are required for S-phase entry and G(2)/M transition. In conclusion, this is the first evidence to demonstrate that CREG1 enhances p16(INK4a)-induced senescence by transcriptional repression of cell cycle-regulated genes.
C1 [Moolmuang, Benchamart; Tainsky, Michael A.] Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Canc Biol Program, Detroit, MI 48202 USA.
   [Tainsky, Michael A.] Wayne State Univ, Sch Med, Dept Oncol, Program Mol Biol & Genet, Detroit, MI USA.
C3 Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne
   State University
RP Tainsky, MA (通讯作者)，Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Canc Biol Program, Detroit, MI 48202 USA.
EM tainskym@karmanos.org
OI Tainsky, Michael/0000-0002-0261-831X; Moolmuang,
   Benchamart/0000-0003-2008-4021
FU Barbara and Fred Erb Chair in Cancer Genetics; Genomics and Flow
   Cytometry Core laboratories of the KCI CCSG [P30-CA022453]; Royal Thai
   Government
FX This work was supported by the Barbara and Fred Erb Chair in Cancer
   Genetics to M. A. T. with support from the Genomics and Flow Cytometry
   Core laboratories of the KCI CCSG Grant P30-CA022453. B. M. was
   supported by a Predoctoral Fellowship from the Royal Thai Government. We
   thank Aviva Levine Fridman and Quanfang Li for the DNA samples used in
   analysis of CREG1 promoter and thank the Tainsky lab members for helpful
   comments and suggestions. We thank George Brush (Karmanos Cancer
   Institute) for expert comments on the manuscript, and Grace Gill (Tufts
   University) for her kind gift of CREG/pRC plasmid.
CR Ahmed-Choudhury J, 2005, CANCER RES, V65, P2690, DOI 10.1158/0008-5472.CAN-04-3593
   Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Bian ZY, 2009, J CELL MOL MED, V13, P1302, DOI 10.1111/j.1582-4934.2008.00633.x
   BISCHOFF FZ, 1990, CANCER RES, V50, P7979
   BISCHOFF FZ, 1991, ONCOGENE, V6, P183
   Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233
   Chompret A, 2002, BIOCHIMIE, V84, P75, DOI 10.1016/S0300-9084(01)01361-X
   Craig C, 1998, ONCOGENE, V16, P265, DOI 10.1038/sj.onc.1201493
   Dai CY, 2000, ONCOGENE, V19, P1613, DOI 10.1038/sj.onc.1203438
   Di Bacco A, 2003, ONCOGENE, V22, P5436, DOI 10.1038/sj.onc.1206670
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Doerksen LF, 1996, NUCLEIC ACIDS RES, V24, P2849, DOI 10.1093/nar/24.14.2849
   Fridman AL, 2006, J GERONTOL A-BIOL, V61, P879, DOI 10.1093/gerona/61.9.879
   HAAF T, 1995, PHARMACOL THERAPEUT, V65, P19, DOI 10.1016/0163-7258(94)00053-6
   Han YL, 2008, GENES CELLS, V13, P977, DOI 10.1111/j.1365-2443.2008.01221.x
   Han YL, 2008, J VASC SURG, V48, P201, DOI 10.1016/j.jvs.2008.01.061
   Han YL, 2008, CARDIOVASC RES, V78, P597, DOI 10.1093/cvr/cvn036
   Han YL, 2009, EXP CELL RES, V315, P3301, DOI 10.1016/j.yexcr.2009.09.013
   Hara E, 1996, MOL CELL BIOL, V16, P859
   HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9
   Helmbold H, 2009, ONCOGENE, V28, P3456, DOI 10.1038/onc.2009.222
   HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291
   Jackson JG, 2006, MOL CELL BIOL, V26, P2501, DOI 10.1128/MCB.26.7.2501-2510.2006
   Janderovd-Rossmeislová L, 2007, J STRUCT BIOL, V159, P56, DOI 10.1016/j.jsb.2007.02.008
   Kapic A, 2006, CELL DEATH DIFFER, V13, P324, DOI 10.1038/sj.cdd.4401756
   KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515
   Kulaeva OI, 2003, ONCOGENE, V22, P4118, DOI 10.1038/sj.onc.1206594
   Lacy S, 1997, ONCOGENE, V14, P2395, DOI 10.1038/sj.onc.1201085
   LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747
   Li QF, 2008, MOL CANCER RES, V6, P770, DOI 10.1158/1541-7786.MCR-07-0114
   MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757
   MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289
   Mitra J, 1999, MOL CELL BIOL, V19, P3916
   Paulson TG, 1998, MOL CELL BIOL, V18, P3089, DOI 10.1128/MCB.18.5.3089
   ROGAN EM, 1995, MOL CELL BIOL, V15, P4745
   Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339
   Sacher M, 2005, P NATL ACAD SCI USA, V102, P18326, DOI 10.1073/pnas.0505071102
   Schmittgen TD, 2000, ANAL BIOCHEM, V285, P194, DOI 10.1006/abio.2000.4753
   SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2
   Stein GH, 1999, MOL CELL BIOL, V19, P2109
   Veal E, 1998, MOL CELL BIOL, V18, P5032, DOI 10.1128/MCB.18.9.5032
   Veal E, 2000, ONCOGENE, V19, P2120, DOI 10.1038/sj.onc.1203529
   Vogt M, 1998, CELL GROWTH DIFFER, V9, P139
NR 44
TC 31
Z9 36
U1 1
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4101
EI 1551-4005
J9 CELL CYCLE
JI Cell Cycle
PD FEB 1
PY 2011
VL 10
IS 3
BP 518
EP 530
DI 10.4161/cc.10.3.14756
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 714RQ
UT WOS:000286827100029
PM 21263217
OA Green Published
DA 2025-01-12
ER

PT J
AU Al-Azzawi, H
   Yacqub-Usman, K
   Richardson, A
   Hofland, LJ
   Clayton, RN
   Farrell, WE
AF Al-Azzawi, Haneen
   Yacqub-Usman, Kiren
   Richardson, Alan
   Hofland, Leo J.
   Clayton, Richard N.
   Farrell, William E.
TI Reversal of Endogenous Dopamine Receptor Silencing in Pituitary Cells
   Augments Receptor-Mediated Apoptosis
SO ENDOCRINOLOGY
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITION; BREAST-CANCER CELLS; GENE-EXPRESSION;
   DNA METHYLTRANSFERASE; D2 RECEPTORS; IN-VITRO; DEMETHYLATION;
   EPIGENETICS; TUMORS; SOMATOSTATIN
AB Dopamine (DA)-agonist targeting of the DA D-2 receptor (D2R) in prolactinomas is the first-line treatment choice for suppression of prolactin and induction of tumor shrinkage. Resistance to DA agonists seems to be related to receptor number. Using the MMQ and GH3 pituitary cell lines, that either do or do not express D2R, respectively, we explored the epigenetic profile associated with the presence or absence of D2R in these cells lines. These studies led us to explore pharmacological strategies designed to restore receptor expression and thereby potentially augment DA agonist-mediated apoptosis. We show in GH3 cells that the D2R harbors increased CpG island-associated methylation and enrichment for histone H3K27me3. Conversely, MMQ cells and normal pituitaries show enrichment for H3K9Ac and barely detectable H3K27me3. Coculture of GH3 cells with the demethylating agent zebularine and the histone deacetylase inhibitor trichostatin A was responsible for a decrease in CpG island methylation and enrichment for the histone H3K9Ac mark. In addition, challenge of GH3 cells with zebularine alone or coculture with both agents led to expression of endogenous D2R in these cells. Induced expression D2R in GH3 cells was associated with a significant increase in apoptosis indices to challenge with either DA or bromocriptine. Specificity of a receptor-mediated response was established in coincubations with specific D2R antagonist and siRNA approaches in GH3 cell and D2R expressing MMQ cell lines. These studies point to the potential efficacy of combined treatment with epigenetic drugs and DA agonists for the medical management of different pituitary tumor subtypes, resistant to conventional therapies. (Endocrinology 152: 364-373, 2011)
C1 [Al-Azzawi, Haneen; Yacqub-Usman, Kiren; Richardson, Alan; Clayton, Richard N.; Farrell, William E.] Keele Univ, Sch Med, Human Dis & Genom Grp, Inst Sci & Technol Med, Stoke On Trent ST4 7QB, Staffs, England.
   [Hofland, Leo J.] Erasmus MC, Div Endocrinol, Dept Internal Med, NL-3015 Rotterdam, Netherlands.
C3 Keele University; Erasmus University Rotterdam; Erasmus MC
RP Al-Azzawi, H (通讯作者)，Keele Univ, Sch Med, Human Dis & Genom Grp, Inst Sci & Technol Med, Stoke On Trent ST4 7QB, Staffs, England.
RI ; Richardson, Alan/I-4631-2015
OI Yacqub-Usman, Kiren/0000-0003-4454-7027; Richardson,
   Alan/0000-0003-1825-3375; Hofland, Leo/0000-0002-4897-2197
CR An JJ, 2003, MOL CELL ENDOCRINOL, V206, P49, DOI 10.1016/S0303-7207(03)00236-3
   Bahar A, 2004, MOL ENDOCRINOL, V18, P1827, DOI 10.1210/me.2004-0087
   Balch C, 2005, FRONT BIOSCI-LANDMRK, V10, P1897, DOI 10.2741/1668
   BENJONATHAN N, 1985, ENDOCR REV, V6, P564, DOI 10.1210/edrv-6-4-564
   Bondioni S, 2008, EXP BIOL MED, V233, P439, DOI 10.3181/0704-RM-94
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Carew JS, 2008, CANCER LETT, V269, P7, DOI 10.1016/j.canlet.2008.03.037
   Cheng JC, 2003, J NATL CANCER I, V95, P399, DOI 10.1093/jnci/95.5.399
   Cheng JC, 2004, MOL CELL BIOL, V24, P1270, DOI 10.1128/MCB.24.3.1270-1278.2004
   Cheng JC, 2004, CANCER CELL, V6, P151, DOI 10.1016/j.ccr.2004.06.023
   Colao A, 2002, EXPERT OPIN INV DRUG, V11, P787, DOI 10.1517/13543784.11.6.787
   Colao A, 2009, REV ENDOCR METAB DIS, V10, P111, DOI 10.1007/s11154-008-9107-z
   Dudley KJ, 2009, J MOL ENDOCRINOL, V42, P461, DOI 10.1677/JME-09-0009
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Ezzat S, 2008, ENDOCR J, V55, P951, DOI 10.1507/endocrj.K08E-082
   Farrell WE, 2006, ENDOCR-RELAT CANCER, V13, P707, DOI 10.1677/erc.1.01131
   FERGUSON AT, 1995, CANCER RES, V55, P2279
   Ferone D, 2007, EUR J ENDOCRINOL, V156, pS37, DOI 10.1530/eje.1.02351
   Fink L, 1999, BIOTECHNIQUES, V26, P510, DOI 10.2144/99263rr02
   Flotho C, 2009, LEUKEMIA, V23, P1019, DOI 10.1038/leu.2008.397
   Garcia-Manero G, 2005, CANCER INVEST, V23, P635, DOI 10.1080/07357900500283119
   Gius D, 2004, CANCER CELL, V6, P361, DOI 10.1016/j.ccr.2004.08.029
   Gruszka A, 2007, ENDOCRINOLOGY, V148, P6107, DOI 10.1210/en.2007-0378
   Hofland LJ, 2010, MOL CELL ENDOCRINOL, V326, P89, DOI 10.1016/j.mce.2010.04.020
   Jaubert A, 2006, NEUROENDOCRINOLOGY, V83, P77, DOI 10.1159/000094044
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Kristensen LS, 2009, EUR J PHARMACOL, V625, P131, DOI 10.1016/j.ejphar.2009.10.011
   Martelle JL, 2008, CNS NEUROSCI THER, V14, P248, DOI 10.1111/j.1755-5949.2008.00047.x
   Martens JHA, 2010, CANCER CELL, V17, P173, DOI 10.1016/j.ccr.2009.12.042
   Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189
   Molitch Mark E, 2005, Pituitary, V8, P43, DOI 10.1007/s11102-005-5085-2
   Pathiraja TN, 2010, J MAMMARY GLAND BIOL, V15, P35, DOI 10.1007/s10911-010-9166-0
   Picetti R, 1997, CRIT REV NEUROBIOL, V11, P121, DOI 10.1615/CritRevNeurobiol.v11.i2-3.20
   Roh TY, 2006, P NATL ACAD SCI USA, V103, P15782, DOI 10.1073/pnas.0607617103
   Rowther FB, 2010, NEUROENDOCRINOLOGY, V91, P256, DOI 10.1159/000279753
   Scott SA, 2007, EXP HEMATOL, V35, P263, DOI 10.1016/j.exphem.2006.10.005
   Seeman P, 1988, Adv Exp Med Biol, V235, P55
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   SPADA A, 1983, J CLIN ENDOCR METAB, V56, P1
   Takai Daiya, 2003, In Silico Biology, V3, P235
   Tateno T, 2009, ENDOCR J, V56, P579, DOI 10.1507/endocrj.K08E-186
   Neto LV, 2009, J CLIN ENDOCR METAB, V94, P1931, DOI 10.1210/jc.2008-1826
   Yang XW, 2001, CANCER RES, V61, P7025
   Yang XW, 2000, CANCER RES, V60, P6890
NR 45
TC 26
Z9 27
U1 0
U2 3
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013-7227
EI 1945-7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD FEB
PY 2011
VL 152
IS 2
BP 364
EP 373
DI 10.1210/en.2010-0886
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 709FA
UT WOS:000286422100007
PM 21177832
DA 2025-01-12
ER

PT J
AU Png, KJ
   Yoshida, M
   Zhang, XHF
   Shu, WP
   Lee, H
   Rimner, A
   Chan, TA
   Comen, E
   Andrade, VP
   Kim, SW
   King, TA
   Hudis, CA
   Norton, L
   Hicks, J
   Massagué, J
   Tavazoie, SF
AF Png, Kim J.
   Yoshida, Mitsukuni
   Zhang, Xiang H. -F.
   Shu, Weiping
   Lee, Hyeseung
   Rimner, Andreas
   Chan, Timothy A.
   Comen, Elizabeth
   Andrade, Viktor P.
   Kim, Seok Won
   King, Tari A.
   Hudis, Clifford A.
   Norton, Larry
   Hicks, James
   Massague, Joan
   Tavazoie, Sohail F.
TI MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic
   and epigenetic mechanisms in human breast cancer
SO GENES & DEVELOPMENT
LA English
DT Article
DE miR-335; metastasis; genetic; tumor intiation; ovarian; epigenetic
ID METASTASIS; CARCINOMA; SURVIVAL; INVASION; CELLS
AB Post-transcriptional regulators have emerged as robust effectors of metastasis and display deregulated expression through unknown mechanisms. Here, we reveal that the human microRNA-335 locus undergoes genetic deletion and epigenetic promoter hypermethylation in every metastatic derivative obtained from independent patients' malignant cell populations. Genetic deletion of miR-335 is a common event in human breast cancer, is enriched for in breast cancer metastases, and also correlates with ovarian cancer recurrence. We furthermore identify miR-335 as a robust inhibitor of tumor reinitiation. We thus implicate the miR-335 locus on 7q32.2 as the first selective metastasis suppressor and tumor initiation suppressor locus in human breast cancer.
C1 [Png, Kim J.; Yoshida, Mitsukuni; Lee, Hyeseung; Tavazoie, Sohail F.] Rockefeller Univ, Lab Syst Canc Biol, New York, NY 10065 USA.
   [Zhang, Xiang H. -F.; Shu, Weiping; Massague, Joan] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10021 USA.
   [Rimner, Andreas; Chan, Timothy A.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA.
   [Comen, Elizabeth; Hudis, Clifford A.; Norton, Larry] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA.
   [Andrade, Viktor P.; Kim, Seok Won; King, Tari A.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA.
   [Hicks, James] Cold Spring Harbor Lab, Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA.
   [Massague, Joan] Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA.
C3 Rockefeller University; Memorial Sloan Kettering Cancer Center; Memorial
   Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center;
   Memorial Sloan Kettering Cancer Center; Cold Spring Harbor Laboratory;
   Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center
RP Tavazoie, SF (通讯作者)，Rockefeller Univ, Lab Syst Canc Biol, New York, NY 10065 USA.
EM stavazoie@mail.rockefeller.edu
RI Chan, Timothy/ABD-5850-2021; Massague, Joan/C-4216-2008; Andrade,
   Victor/K-6514-2012; Hudis, Clifford/AAW-9482-2021; Zhang,
   Xiang/B-1522-2008
OI Massague, Joan/0000-0001-9324-8408; Yoshida,
   Mitsukuni/0000-0002-2752-1231; Rimner, Andreas/0000-0002-1214-3856;
   Zhang, Xiang/0000-0002-5674-8670; Norton, Larry/0000-0003-3701-9250
FU Rita Allen; Anderson Cancer Center; Sidney Kimmel; ASCO; Meyer;
   Sinsheimer; Emerald foundations; Breast Cancer Alliance; Hess family;
   DOD; National Institutes of Health; Hearst Foundation; Kleberg
   Foundation
FX We thank Claudio Alarcon for comments on earlier versions of the
   manuscripts. We are grateful to Juan Li and Agnes Viale of the MSKCC
   genomics core facility for assistance with pyrosequencing. S.F.T was
   funded by the Rita Allen, Anderson Cancer Center, Sidney Kimmel, ASCO,
   Meyer, Sinsheimer, and Emerald foundations; the Breast Cancer Alliance;
   the Hess family; and the DOD Era of Hope Scholar award. J.M. was funded
   by a National Institutes of Health grant, and by grants of the Hearst
   Foundation and the Kleberg Foundation. J.M. is an Investigator of the
   Howard Hughes Medical Institute. S.F.T. conceptualized and designed the
   study. S.F.T. and J.M. supervised research. S.F.T. and K.J.P. wrote the
   manuscript. S.F.T. and J.M. edited the manuscript. K.J.P., M.Y., S.F.T.,
   H.L., and W.S. performed experiments. V.A., S.W.K., E.C., and T.K.
   assisted in clinical sample procurement and primary/matched tumor DNA
   extractions. X.H.Z. extracted DNA from cell lines for array-CGH. A.R.
   and T.C. assisted in MSP experiments. J.H, C.H., and L.N. collected
   clinical samples and provided ROMA data. J.H. conducted mir-335 copy
   number analysis in clinical tumor samples. All authors discussed the
   results and commented on the manuscript.
CR Balleine RL, 2008, CLIN CANCER RES, V14, P8244, DOI 10.1158/1078-0432.CCR-08-0939
   Calin GA, 2006, ONCOGENE, V25, P6202, DOI 10.1038/sj.onc.1209910
   Chen J, 2009, INT J ONCOL, V34, P1029, DOI 10.3892/ijo_00000228
   Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239
   Eccles SA, 2007, LANCET, V369, P1742, DOI 10.1016/S0140-6736(07)60781-8
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552
   He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939
   Hicks J, 2006, GENOME RES, V16, P1465, DOI 10.1101/gr.5460106
   Hoebeeck Jasmien, 2007, Methods Mol Biol, V353, P205
   Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681
   Kumar MS, 2008, P NATL ACAD SCI USA, V105, P3903, DOI 10.1073/pnas.0712321105
   Li T, 2002, J BIOL CHEM, V277, P13518, DOI 10.1074/jbc.M200458200
   Liao YL, 2008, ONCOGENE, V27, P5578, DOI 10.1038/onc.2008.168
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Nishita Y, 1996, GENOMICS, V36, P539, DOI 10.1006/geno.1996.0502
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Tost J, 2006, BIOTECHNIQUES, V40, P721, DOI 10.2144/000112190
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054
NR 21
TC 174
Z9 194
U1 0
U2 19
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 0890-9369
EI 1549-5477
J9 GENE DEV
JI Genes Dev.
PD FEB 1
PY 2011
VL 25
IS 3
BP 226
EP 231
DI 10.1101/gad.1974211
PG 6
WC Cell Biology; Developmental Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 715JL
UT WOS:000286880600004
PM 21289068
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Drew, Y
   Mulligan, EA
   Vong, WT
   Thomas, HD
   Kahn, S
   Kyle, S
   Mukhopadhyay, A
   Los, G
   Hostomsky, Z
   Plummer, ER
   Edmondson, RJ
   Curtin, NJ
AF Drew, Yvette
   Mulligan, Evan A.
   Vong, Wan-Tse
   Thomas, Huw D.
   Kahn, Samra
   Kyle, Suzanne
   Mukhopadhyay, Asima
   Los, Gerrit
   Hostomsky, Zdenek
   Plummer, Elizabeth R.
   Edmondson, Richard J.
   Curtin, Nicola J.
TI Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699
   in Human Cancers With Mutated or Methylated <i>BRCA1</i> or <i>BRCA2</i>
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID BREAST-CANCER; SPORADIC BREAST; DNA-DAMAGE; MAMMARY-TUMORS; HISTONE
   H2AX; IN-VIVO; REPAIR; MUTATIONS; COMBINATION; HYPERMETHYLATION
AB Background Mutations in BRCA1 and BRCA2 (BRCA1/2), components of the homologous recombination DNA repair (HRR) pathway, are associated with hereditary breast and ovarian cancers. Poly(ADP-ribose) polymerase (PARP) inhibitors are selectively cytotoxic to animal cells with defective HRR, but results in human cancer cells have been contradictory. We undertook, to our knowledge, the first comprehensive in vitro and in vivo investigations of the antitumor activity of the PARP inhibitor AG014699 in human cancer cells carrying mutated or epigenetically silenced BRCA1/2.
   Methods We used nine human cell lines, four with nonmutated BRCA1/2 (MCF7, MDA-MB-231, and HCC1937-BRCA1 [breast cancer] and OSEC-2 [ovarian surface epithelial]), two with mutated BRCA1 (MDA-MB-436 and HCC1937 [breast cancer]), one with mutated BRCA2 (CAPAN-1 [pancreatic cancer]), one that was heterozygous for BRCA2 (OSEC-1 [ovarian surface epithelial]), and one with epigenetically silenced BRCA1 (UACC3199 [breast cancer]), and two Chinese hamster ovary cell lines, parental AA8 and XRCC3 mutated IRS 1SF. We assessed cytotoxicity, DNA damage, and HRR function. Antitumor activity of AG014699 was determined by growth of xenograft tumors (five mice per treatment group). Long-term safety of AG014699 was assessed.
   Results AG014699 (<= 10 mu M) was cytotoxic to cells with mutated BRCA1/2 or XRCC3 and to UACC3199 cells with epigenetically silenced BRCA1 but not to cells without BRCA1/2 or XRCC3 mutations or that were heterozygous for BRCA2 mutation. AG014699 induced DNA double-strand breaks in all nine cell lines studied. HRR was observed only in cells with functional BRCA1/2 proteins. Growth of xenograft tumors with BRCA1/2 mutations or with epigenetically silenced BRCA1 was reduced by AG014699 treatment, and combination treatment with AG014699 plus carboplatin was more effective than either drug alone. AG014699 was not toxic in mice with nonmutated or heterozygous BRCA2.
   Conclusion Human cancer cells or xenograft tumors with mutated or epigenetically silenced BRCA1/2 were sensitive to AG014699 monotherapy, indicating a potential role for PARP inhibitors in sporadic human cancers.
C1 [Curtin, Nicola J.] Newcastle Univ, Sch Med, No Inst Canc Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Los, Gerrit; Hostomsky, Zdenek] Pfizer GRD, La Jolla, CA USA.
C3 Newcastle University - UK; Pfizer
RP Curtin, NJ (通讯作者)，Newcastle Univ, Sch Med, No Inst Canc Res, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM n.j.curtin@ncl.ac.uk
RI Edmondson, Richard/LZG-7604-2025; Hostomsky, Zdenek/G-3513-2011
OI Curtin, Nicola/0000-0003-1369-1843; Edmondson,
   Richard/0000-0003-2553-4423
FU Cancer Research UK [C9380/A7810]; Pfizer, Inc [140-N-1232663]
FX Cancer Research UK (C9380/A7810 to Y.D.) and Pfizer, Inc (140-N-1232663
   to E.A.M.).
CR Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8
   Baldwin RL, 2000, CANCER RES, V60, P5329
   Bogliolo M, 2000, ONCOGENE, V19, P5781, DOI 10.1038/sj.onc.1203951
   Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443
   Cleator S, 2007, LANCET ONCOL, V8, P235, DOI 10.1016/S1470-2045(07)70074-8
   Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423
   Dantzer F, 2006, METHOD ENZYMOL, V409, P493, DOI 10.1016/S0076-6879(05)09029-4
   Davies BR, 2003, EXP CELL RES, V288, P390, DOI 10.1016/S0014-4827(03)00218-0
   De Soto JA, 2006, INT J BIOL SCI, V2, P179
   Edwards SL, 2008, NATURE, V451, P1111, DOI 10.1038/nature06548
   Elstrodt F, 2006, CANCER RES, V66, P41, DOI 10.1158/0008-5472.CAN-05-2853
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4
   Gallmeier E, 2005, CANCER BIOL THER, V4, P703, DOI 10.4161/cbt.4.7.1909
   Goggins M, 1996, CANCER RES, V56, P5360
   Gudmundsdottir K, 2006, ONCOGENE, V25, P5864, DOI 10.1038/sj.onc.1209874
   Hay T, 2009, CANCER RES, V69, P3850, DOI 10.1158/0008-5472.CAN-08-2388
   Helleday T, 2007, DNA REPAIR, V6, P923, DOI 10.1016/j.dnarep.2007.02.006
   Hughes-Davies L, 2003, CELL, V115, P523, DOI 10.1016/S0092-8674(03)00930-9
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691
   King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759
   McCabe N, 2006, CANCER RES, V66, P8109, DOI 10.1158/0008-5472.CAN-06-0140
   O'Shaughnessy J., 2009, J CLIN ONCOL, V27, p18s
   Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2
   Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633
   Plummer R, 2008, CLIN CANCER RES, V14, P7917, DOI 10.1158/1078-0432.CCR-08-1223
   Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858
   Rottenberg S, 2008, P NATL ACAD SCI USA, V105, P17079, DOI 10.1073/pnas.0806092105
   ROWLATT C, 1976, Laboratory Animals (London), V10, P419, DOI 10.1258/002367776780956917
   Sakai W, 2008, NATURE, V451, P1116, DOI 10.1038/nature06633
   SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K
   SKEHAN P, 1990, JNCI-J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   Swisher EM, 2008, CANCER RES, V68, P2581, DOI 10.1158/0008-5472.CAN-08-0088
   Tassone P, 2003, BRIT J CANCER, V88, P1285, DOI 10.1038/sj.bjc.6600859
   Tomlinson GE, 1998, CANCER RES, V58, P3237
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457
   Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014
   Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6
   van der Heijden MS, 2005, CLIN CANCER RES, V11, P7508, DOI 10.1158/1078-0432.CCR-05-1048
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
NR 43
TC 212
Z9 226
U1 0
U2 23
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
EI 1460-2105
J9 JNCI-J NATL CANCER I
JI JNCI-J. Natl. Cancer Inst.
PD FEB
PY 2011
VL 103
IS 4
BP 334
EP 346
DI 10.1093/jnci/djq509
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 723HS
UT WOS:000287498000009
PM 21183737
OA Bronze
DA 2025-01-12
ER

PT J
AU Shetty, PJ
   Movva, S
   Pasupuleti, N
   Vedicherlla, B
   Vattam, KK
   Venkatasubramanian, S
   Ahuja, YR
   Hasan, Q
AF Shetty, Preetha J.
   Movva, Sireesha
   Pasupuleti, Nagarjuna
   Vedicherlla, Bhavani
   Vattam, Kiran K.
   Venkatasubramanian, Sambasivan
   Ahuja, Yog R.
   Hasan, Qurratulain
TI Regulation of IGF2 transcript and protein expression by altered
   methylation in breast cancer
SO JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
LA English
DT Article
DE Epigenetics; IGF2 methylation; Breast cancer; Loss of imprinting
ID GROWTH-FACTOR-II; EPITHELIAL OVARIAN-CANCER; COLORECTAL-CANCER;
   GENE-EXPRESSION; DNA METHYLATION; BRCA1 MUTATIONS; WILMS-TUMOR; RISK;
   H19; IMMUNOHISTOCHEMISTRY
AB Breast Cancer is one of the leading causes of cancer deaths among women worldwide. The role of epigenetics as a distinct mechanism to alter gene expression in a tissue-specific manner has emerged as an important mechanism in the pathophysiology of cancer. Present study was carried out to assess the role of methylation in regulating transcription and protein expression of Insulin-like growth factor 2 (IGF2), an oncogene with parental imprinting.
   Paraffin-embedded archival breast tumor and adjacent normal tissue samples were used for carrying out PCR-based methylation assay, genomic PCR, immunohistochemistry and Real-Time Reverse transcriptase PCR.
   A significant loss of methylation in exon 9 CpG cluster of IGF2 in breast tumor tissues was observed when compared to normal tissue (P < 0.0001). Expression of IGF2 by immunohistochemistry exhibited a mean twofold increase correlating with the hypomethylation of this specific CpG. Real-Time RT PCR showed increased transcripts in the tumor tissue supporting the IHC and methylation results. A total of 33% of tumor samples heterozygous for the ApaI IGF2 polymorphism exhibited biallelic IGF2 expression due to loss of imprinting; this was not seen in any of the normal breast tissues.
   Altered methylation of exonic CpG plays an important role in the enhanced transcription/expression of IGF2 in breast tumors. Methylation analysis of exon 9 CpG can be used as a biomarker for upregulation of IGF2 in breast tumor tissue and maybe developed as a diagnostic test in future.
C1 [Vattam, Kiran K.; Hasan, Qurratulain] Kamineni Hosp, Dept Genet & Mol Med, Hyderabad 500068, Andhra Pradesh, India.
   [Shetty, Preetha J.; Movva, Sireesha; Vedicherlla, Bhavani; Ahuja, Yog R.; Hasan, Qurratulain] Vasavi Med & Res Ctr, Dept Genet, Hyderabad 500004, Andhra Pradesh, India.
   [Pasupuleti, Nagarjuna] Kamineni Life Sci, Hyderabad 500040, Andhra Pradesh, India.
   [Venkatasubramanian, Sambasivan] Bhagwan Mahavir Med Res Ctr, Dept Genet, Hyderabad 500001, Andhra Pradesh, India.
RP Hasan, Q (通讯作者)，Kamineni Hosp, Dept Genet & Mol Med, Hyderabad 500068, Andhra Pradesh, India.
EM qhasan2000@yahoo.com
RI Shetty, Preetha/AAY-3646-2021
OI Shetty, Preetha J/0000-0002-1318-5863
FU Department of Science & Technology, Government of India
   [SR/WOS-A/LS-120/2007, SR/SO/HS-89/2004]; Council of Scientific and
   Industrial Research, Government of India [09/959(0001)/2009]
FX We would like to acknowledge the Pathology Department of Kamineni
   Hospitals, L.B.Nagar, Hyderabad, India, for providing the archival
   paraffin blocks. This work was supported by Department of Science &
   Technology, Government of India [Grant # SR/WOS-A/LS-120/2007 and Grant
   # SR/SO/HS-89/2004], and Fellowship from Council of Scientific and
   Industrial Research, Government of India to SM [09/959(0001)/2009].
CR Bhavani V, 2009, CANCER BIOMARK, V5, P207, DOI 10.3233/CBM-2009-0105
   Chen CL, 2000, CLIN CANCER RES, V6, P474
   Claus EB, 1996, CANCER, V77, P2318, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z
   CORREA P, 1975, AM J CLIN PATHOL, V64, P720
   Coughlin SS, 2009, CANCER EPIDEMIOL, V33, P315, DOI 10.1016/j.canep.2009.10.003
   Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902
   Cummings SR, 2009, JNCI-J NATL CANCER I, V101, P384, DOI 10.1093/jnci/djp018
   Dai YM, 2007, INT J MOL SCI, V8, P273, DOI 10.3390/i8040273
   Dobrovic A, 1997, CANCER RES, V57, P3347
   EASTON DF, 1993, AM J HUM GENET, V52, P678
   EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8
   Elzagheid A, 2006, DIAGN PATHOL, V1, DOI 10.1186/1746-1596-1-41
   FEIL R, 1994, NUCLEIC ACIDS RES, V22, P695, DOI 10.1093/nar/22.4.695
   FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630
   Giani C, 2002, INT J BIOL MARKER, V17, P90, DOI 10.1177/172460080201700203
   Ito Y, 2008, HUM MOL GENET, V17, P2633, DOI 10.1093/hmg/ddn163
   Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5
   Li Y, 2009, HUM PATHOL, V40, P1441, DOI 10.1016/j.humpath.2009.03.003
   Lu LG, 2006, CLIN CANCER RES, V12, P1208, DOI 10.1158/1078-0432.CCR-05-1801
   MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439
   Movva S, 2009, J DIABETES, V1, P118
   Murrell A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001849
   OGAWA O, 1993, NAT GENET, V5, P408, DOI 10.1038/ng1293-408
   Okonkwo QL, 2008, JNCI-J NATL CANCER I, V100, P1290, DOI 10.1093/jnci/djn292
   ROSEN N, 1991, BREAST CANCER RES TR, V18, pS55, DOI 10.1007/BF02633529
   Saxena Sunita, 2005, World J Surg Oncol, V3, P67, DOI 10.1186/1477-7819-3-67
   Soon PSH, 2009, ENDOCR-RELAT CANCER, V16, P573, DOI 10.1677/ERC-08-0237
   Soroceanu L, 2007, P NATL ACAD SCI USA, V104, P3466, DOI 10.1073/pnas.0611271104
   STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433
   Struewing JP, 1996, LANCET, V347, P1493, DOI 10.1016/S0140-6736(96)91732-8
   Takano Y, 2000, ONCOLOGY-BASEL, V59, P210, DOI 10.1159/000012163
   Toikkanen S, 1997, BRIT J CANCER, V76, P1234, DOI 10.1038/bjc.1997.540
   van Roozendaal CEP, 1998, FEBS LETT, V437, P107, DOI 10.1016/S0014-5793(98)01211-3
   Vasavi M, 2006, TUMORI J, V92, P155, DOI 10.1177/030089160609200212
   Yagi S, 2008, GENOME RES, V18, P1969, DOI 10.1101/gr.074070.107
   Yang XY, 2001, BIOSCIENCE REP, V21, P667, DOI 10.1023/A:1014725127189
   Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472
NR 37
TC 26
Z9 30
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171-5216
EI 1432-1335
J9 J CANCER RES CLIN
JI J. Cancer Res. Clin. Oncol.
PD FEB
PY 2011
VL 137
IS 2
BP 339
EP 345
DI 10.1007/s00432-010-0890-z
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 705CI
UT WOS:000286106000019
PM 20422427
DA 2025-01-12
ER

PT J
AU Dyer, LM
   Schooler, KP
   Ai, LB
   Klop, C
   Qiu, JX
   Robertson, KD
   Brown, KD
AF Dyer, Lisa M.
   Schooler, Kevin P.
   Ai, Lingbao
   Klop, Corinne
   Qiu, Jingxin
   Robertson, Keith D.
   Brown, Kevin D.
TI The transglutaminase 2 gene is aberrantly hypermethylated in glioma
SO JOURNAL OF NEURO-ONCOLOGY
LA English
DT Article
DE Glioma; Epigenetic silencing; Extra cellular matrix; Tumor invasiveness;
   Drug resistance
ID FACTOR-KAPPA-B; BREAST-CANCER CELLS; SWISS 3T3 FIBROBLASTS; TISSUE
   TRANSGLUTAMINASE; EXTRACELLULAR-MATRIX; BRAIN-TUMORS; DRUG-SENSITIVITY;
   ADULT PATIENTS; LUNG-CANCER; IN-VITRO
AB Transglutaminase 2 (TG2) is a ubiquitously expressed protein that catalyzes protein/protein crosslinking. Because extracellular TG2 crosslinks components of the extracellular matrix, TG2 is thought to function as a suppressor of cellular invasion. We have recently uncovered that the TG2 gene (TGM2) is a target for epigenetic silencing in breast cancer, highlighting a molecular mechanism that drives reduced TG2 expression, and this aberrant molecular event may contribute to invasiveness in this tumor type. Because tumor invasiveness is a primary determinant of brain tumor aggressiveness, we sought to determine if TGM2 is targeted for epigenetic silencing in glioma. Analysis of TGM2 gene methylation in a panel of cultured human glioma cells indicated that the 5' flanking region of the TGM2 gene is hypermethylated and that this feature is associated with reduced TG2 expression as judged by immunoblotting. Further, culturing glioma cells in the presence of the global DNA demethylating agent 5-aza-2'-deoxycytidine and the histone deacetylase inhibitor Trichostatin A resulted in re-expression of TG2 in these lines. In primary brain tumors we observed that the TGM2 promoter is commonly hypermethylated and that this feature is a cancer-associated phenomenon. Using publically available databases, TG2 expression in gliomas was found to vary widely, with many tumors showing overexpression or underexpression of this gene. Since overexpression of TG2 leads to resistance to doxorubicin through the ectopic activation of NF kappa B, we sought to examine the effects of recombinant TG2 expression in glioma cells treated with commonly used brain tumor therapeutics. We observed that in addition to doxorubicin, TG2 expression drove resistance to CCNU; however, TG2 expression did not alter sensitivity to other drugs tested. Finally, a catalytically null mutant of TG2 was also able to support doxorubicin resistance in glioma cells indicating that transglutaminase activity is not necessary for the resistance phenotype.
C1 [Dyer, Lisa M.; Ai, Lingbao; Robertson, Keith D.; Brown, Kevin D.] Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA.
   [Schooler, Kevin P.] Univ Florida, Coll Med, Dept Pediat, Gainesville, FL 32610 USA.
   [Qiu, Jingxin] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA.
   [Dyer, Lisa M.; Ai, Lingbao; Klop, Corinne; Qiu, Jingxin; Robertson, Keith D.; Brown, Kevin D.] Univ Florida, Coll Med, UF Shands Canc Ctr Program Genet Epigenet & Tumor, Gainesville, FL 32610 USA.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida; State University
   System of Florida; University of Florida; State University System of
   Florida; University of Florida
RP Brown, KD (通讯作者)，Univ Florida, Coll Med, Dept Biochem & Mol Biol, Box 100245, Gainesville, FL 32610 USA.
EM kdbrown1@ufl.edu
OI Ai, Lingbao/0009-0004-8907-8564; Robertson, Keith/0000-0002-7508-3328
FU  [RO1 CA102289]
FX The authors are grateful to Mr. Jonathan Green for technical expertise
   and the Florida Center for Brain Tumor Research (FCBTR) for providing
   access to clinical samples. Work was supported by a grant (RO1 CA102289)
   to KDB.
CR Aeschlimann D, 2000, CONNECT TISSUE RES, V41, P1, DOI 10.3109/03008200009005638
   Ai LB, 2008, CARCINOGENESIS, V29, P510, DOI 10.1093/carcin/bgm280
   Antonyak MA, 2001, J BIOL CHEM, V276, P33582, DOI 10.1074/jbc.M105318200
   Antonyak MA, 2009, J BIOL CHEM, V284, P17914, DOI 10.1074/jbc.M109.013037
   Balklava Z, 2002, J BIOL CHEM, V277, P16567, DOI 10.1074/jbc.M109836200
   Bellail AC, 2004, INT J BIOCHEM CELL B, V36, P1046, DOI 10.1016/j.biocel.2004.01.013
   BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I
   Boehm JE, 2002, J BIOL CHEM, V277, P20127, DOI 10.1074/jbc.C200147200
   Cao LY, 2008, CARCINOGENESIS, V29, P1893, DOI 10.1093/carcin/bgn158
   ChalmersRedman RME, 1997, NEUROSCIENCE, V76, P1121, DOI 10.1016/S0306-4522(96)00386-7
   Chen JSK, 2002, BREAST CANCER RES TR, V71, P237, DOI 10.1023/A:1014461832403
   Chhabra A, 2009, ANTICANCER RES, V29, P1909
   Demircan B, 2009, GENE CHROMOSOME CANC, V48, P83, DOI 10.1002/gcc.20620
   Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225
   Han JA, 1999, J CANCER RES CLIN, V125, P89, DOI 10.1007/s004320050247
   Haroon ZA, 1999, LAB INVEST, V79, P1679
   Herman JF, 2006, ONCOGENE, V25, P3049, DOI 10.1038/sj.onc.1209324
   Hunter SB, 2003, INT J ONCOL, V23, P857
   Jaworski DM, 1996, CANCER RES, V56, P2293
   JOHNSON TS, 1994, ONCOGENE, V9, P2935
   Jones RA, 2006, CELL DEATH DIFFER, V13, P1442, DOI 10.1038/sj.cdd.4401816
   Jones RA, 1997, J CELL SCI, V110, P2461
   Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780
   Kim DS, 2006, CANCER RES, V66, P10936, DOI 10.1158/0008-5472.CAN-06-1521
   KOOCHEKPOUR S, 1995, EUR J CANCER, V31A, P375, DOI 10.1016/0959-8049(94)00476-L
   KOOCHEKPOUR S, 1995, INT J CANCER, V63, P450, DOI 10.1002/ijc.2910630325
   Kotsakis P, 2007, AMINO ACIDS, V33, P373, DOI 10.1007/s00726-007-0516-1
   Lee JM, 2004, J BIOL CHEM, V279, P53725, DOI 10.1074/jbc.M407627200
   Levicar N, 2002, J NEURO-ONCOL, V58, P21, DOI 10.1023/A:1015892911420
   LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C
   LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602
   Mangala LS, 2007, ONCOGENE, V26, P2459, DOI 10.1038/sj.onc.1210035
   Mangala LS, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-33
   Mann AP, 2006, CANCER RES, V66, P8788, DOI 10.1158/0008-5472.CAN-06-1457
   MEHTA K, 1994, INT J CANCER, V58, P400, DOI 10.1002/ijc.2910580316
   Murthy SNP, 2002, P NATL ACAD SCI USA, V99, P2738, DOI 10.1073/pnas.052715799
   NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0
   Nagai S, 2002, J NEUROSURG, V96, P909, DOI 10.3171/jns.2002.96.5.0909
   Nakada M, 2007, CELL MOL LIFE SCI, V64, P458, DOI 10.1007/s00018-007-6342-5
   Nieder C, 2009, CLIN ONCOL-UK, V21, P515, DOI 10.1016/j.clon.2009.05.003
   Nieder C, 2006, CRIT REV ONCOL HEMAT, V60, P181, DOI 10.1016/j.critrevonc.2006.06.007
   Park KS, 2010, J CANCER RES CLIN, V136, P493, DOI 10.1007/s00432-009-0681-6
   Partap S, 2007, CURR OPIN PEDIATR, V19, P670, DOI 10.1097/MOP.0b013e3282f0eafa
   Paulus W, 1996, J NEUROPATH EXP NEUR, V55, P528, DOI 10.1097/00005072-199605000-00005
   PAULUS W, 1995, J NEURO-ONCOL, V24, P87, DOI 10.1007/BF01052664
   Qiu J, 2008, LAB INVEST, V88, P910, DOI 10.1038/labinvest.2008.66
   Satpathy N, 2007, CANCER RES, V67, P7194, DOI 10.1158/0008-5472.CAN-07-0307
   Telci D, 2006, FRONT BIOSCI-LANDMRK, V11, P867, DOI 10.2741/1843
   Verderio E, 1998, EXP CELL RES, V239, P119, DOI 10.1006/excr.1997.3874
   Verma A, 2007, DRUG RESIST UPDATE, V10, P144, DOI 10.1016/j.drup.2007.06.002
   Verma A, 2008, CLIN CANCER RES, V14, P2476, DOI 10.1158/1078-0432.CCR-07-4529
   Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400
   Wang HM, 2004, LAB INVEST, V84, P941, DOI 10.1038/labinvest.3700123
   Weinberg RA, 1996, SCI AM, V275, P62, DOI 10.1038/scientificamerican0996-62
   Wolffe AP, 2001, ONCOGENE, V20, P2988, DOI 10.1038/sj.onc.1204322
   Yuan L, 2007, ONCOGENE, V26, P2563, DOI 10.1038/sj.onc.1210048
   Yuan L, 2005, MOL CANCER THER, V4, P1293, DOI 10.1158/1535-7163.MCT-04-0328
   Zemskov EA, 2006, FRONT BIOSCI-LANDMRK, V11, P1057, DOI 10.2741/1863
NR 58
TC 27
Z9 28
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-594X
EI 1573-7373
J9 J NEURO-ONCOL
JI J. Neuro-Oncol.
PD FEB
PY 2011
VL 101
IS 3
BP 429
EP 440
DI 10.1007/s11060-010-0277-7
PG 12
WC Oncology; Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Neurosciences & Neurology
GA 709VI
UT WOS:000286469100008
PM 20596752
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Ronneberg, JA
   Fleischer, T
   Solvang, HK
   Nordgard, SH
   Edvardsen, H
   Potapenko, I
   Nebdal, D
   Daviaud, C
   Gut, I
   Bukholm, I
   Naume, B
   Borresen-Dale, AL
   Tost, J
   Kristensen, V
AF Ronneberg, Jo Anders
   Fleischer, Thomas
   Solvang, Hiroko Kato
   Nordgard, Silje H.
   Edvardsen, Hege
   Potapenko, Ivan
   Nebdal, Daniel
   Daviaud, Christian
   Gut, Ivo
   Bukholm, Ida
   Naume, Bjorn
   Borresen-Dale, Anne-Lise
   Tost, Joerg
   Kristensen, Vessela
TI Methylation profiling with a panel of cancer related genes: Association
   with estrogen receptor, TP53 mutation status and expression subtypes in
   sporadic breast cancer
SO MOLECULAR ONCOLOGY
LA English
DT Article
DE Breast cancer; DNA methylation; Homeobox genes; TP53; Epigenetics;
   Molecular classification; Gene expression
ID GENOME-WIDE ASSOCIATION; NF-KAPPA-B; BONE-MARROW; DNA HYPERMETHYLATION;
   MOLECULAR SUBTYPES; PROGNOSTIC-FACTORS; EPITHELIAL-CELLS; OSTEOPONTIN;
   EPIGENETICS; PROGRESSION
AB Breast cancer is a heterogeneous disease that can be divided in subtypes based on histology, gene expression profiles as well as differences in genomic aberrations. Distinct global DNA methylation profiles have been reported in normal breast epithelial cells as well as in breast tumors. However, the influence of the tumor methylome on the previously described subgroups of breast cancer is not fully understood. Here we report the DNA methylation profiles of 80 breast tumors using a panel of 807 cancer related genes interrogating 1505 CpG sites. We identified three major clusters based on the methylation profiles; one consisting of mainly tumors of myoepithelial origin and two other clusters with tumors of predominantly luminal epithelial origin. The clusters were different with respect to estrogen receptor status, TP53 status, ErbB2 status and grade. The most significantly differentially methylated genes including HDAC1, TFF1, OGG1, BMP3, FZD9 and HOXA11 were confirmed by pyrosequencing. Gene Ontology analysis revealed enrichment for genes involved in developmental processes including homeobox domain genes (HOXA9, HOXA11, PAX6, MYBL2, ISL1 and IPF1) and (ETS1, HDAC1, CREBBP, GAS7, SPI1 and TBX1). Extensive correlation to mRNA expression was observed. Pathway analyses identified a significant association with canonical (curated) pathways such as hepatic fibrosis including genes like EGF, NGFR and TNF, dendritic cell maturation and the NF-KB signaling pathway. Our results show that breast tumor expression subtypes harbor major epigenetic differences and tumors with similar gene expression profiles might belong to epigenetically different subtypes. Some of the transcription factors identified, with key roles in differentiation and development might play a role in inducing and maintaining the different phenotypes. (C) 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
C1 [Kristensen, Vessela] Dept Clin Mol Biol Epi Gen, Lorenskog, Norway.
   [Ronneberg, Jo Anders; Fleischer, Thomas; Solvang, Hiroko Kato; Nordgard, Silje H.; Edvardsen, Hege; Potapenko, Ivan; Nebdal, Daniel; Borresen-Dale, Anne-Lise; Kristensen, Vessela] Oslo Univ Hosp Radiumhosp, Inst Canc Res, Dept Genet, N-0310 Oslo, Norway.
   [Ronneberg, Jo Anders; Fleischer, Thomas; Borresen-Dale, Anne-Lise; Kristensen, Vessela] Univ Oslo, Fac Med, Inst Clin Med, N-0316 Oslo, Norway.
   [Daviaud, Christian; Gut, Ivo; Tost, Joerg] CEA, Inst Genom, Ctr Natl Genotypage, Lab Epigenet, F-91000 Evry, France.
   [Bukholm, Ida] Akershus Univ Hosp, Dept Surg, Nordbyhagen, Norway.
   [Kristensen, Vessela] Univ Oslo, Fac Med, Inst Clin Epidemiol & Mol Biol EpiGen, N-0316 Oslo, Norway.
   [Naume, Bjorn] Oslo Univ Hosp Radiumhosp, Canc Clin, N-0310 Oslo, Norway.
C3 University of Oslo; University of Oslo; Universite Paris Saclay; CEA;
   University of Oslo; University of Oslo; University of Oslo
RP Kristensen, V (通讯作者)，Dept Clin Mol Biol Epi Gen, Lorenskog, Norway.
EM vessela@ulrik.uio.no
RI Gut, Ivo/ABF-3188-2020; Potapenko, Ivan/IAR-9084-2023; Nord,
   Silje/R-5212-2016; Tost, Jorg/H-7129-2019; Fleischer, Thomas/T-8066-2017
OI Tost, Jorg/0000-0002-2683-0817; Nebdal, Daniel/0000-0002-9526-1662;
   Fleischer, Thomas/0000-0003-0985-8460; Potapenko,
   Ivan/0000-0002-7201-655X
FU Faculty Division the Norwegian Radium Hospital, University of Oslo;
   Norwegian Cancer Society (VNK) [D-03067]; Norwegian Research Council
   (NFR) [152004/150]; French-Norwegian cooperation program Aurora
   [15842WE]
FX JAR and TF are fellows of the Faculty Division the Norwegian Radium
   Hospital, University of Oslo. This work was supported by grant D-03067
   from The Norwegian Cancer Society (VNK), grant 152004/150 from The
   Functional Genomics Program (FUGE) of the Norwegian Research Council
   (NFR) (VNK) and the French-Norwegian cooperation program Aurora grant
   15842WE (JAR, JT, VNK). HE and SHN are postdoctoral fellows of the
   Norwegian Cancer association. Study design: VNK and JT. Expression
   analysis: HJ. Pyrosequencing analysis CD, Statistical analysis: JAR, SHN
   and HS. IPA analysis: HE. Writing of the manuscript: JAR, ALBD, JT and
   VNK.
CR Araki S, 2010, J CLIN INVEST, V120, P290, DOI 10.1172/JCI39194
   Barraclough DL, 2009, AM J PATHOL, V175, P1848, DOI 10.2353/ajpath.2009.090246
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Bloushtain-Qimron N, 2008, P NATL ACAD SCI USA, V105, P14076, DOI 10.1073/pnas.0805206105
   Borgen E, 1998, J PATHOL, V185, P427, DOI 10.1002/(SICI)1096-9896(199808)185:4<427::AID-PATH127>3.0.CO;2-7
   Bovelstad HM, 2007, BIOINFORMATICS, V23, P2080, DOI 10.1093/bioinformatics/btm305
   Caldeira JRF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-48
   Cao YX, 2003, J MAMMARY GLAND BIOL, V8, P215, DOI 10.1023/A:1025905008934
   Chow LWC, 2005, BIOMED PHARMACOTHER, V59, pS264, DOI 10.1016/S0753-3322(05)80042-3
   Dejeux E, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-68
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Elsheikh SE, 2009, CANCER RES, V69, P3802, DOI 10.1158/0008-5472.CAN-08-3907
   ENERLY E, 2010, MOL SYST BIOL UNPUB
   Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508
   Flanagan JM, 2010, AM J HUM GENET, V86, P420, DOI 10.1016/j.ajhg.2010.02.008
   Fleischer T, 2010, EJC SUPPL, V8, P221, DOI 10.1016/S1359-6349(10)71669-4
   Frasor J, 2009, CANCER RES, V69, P8918, DOI 10.1158/0008-5472.CAN-09-2608
   Hinshelwood RA, 2008, J MOL MED, V86, P1315, DOI 10.1007/s00109-008-0386-3
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Hunter DJ, 2007, NAT GENET, V39, P870, DOI 10.1038/ng2075
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   KAMALAKARAN S, 2010, MOL ONCOL UNPUB
   Kim H, 2005, BIOINFORMATICS, V21, P187, DOI 10.1093/bioinformatics/bth499
   Li SY, 2006, CANCER LETT, V237, P272, DOI 10.1016/j.canlet.2005.06.011
   Lu Shaolei, 2008, Endocrinology, V149, P4809, DOI 10.1210/en.2008-0035
   Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466
   Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629
   Naume B, 2007, MOL ONCOL, V1, P160, DOI 10.1016/j.molonc.2007.03.004
   Nordgard SH, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1784
   Park SY, 2010, CLIN CANCER RES, V16, P876, DOI 10.1158/1078-0432.CCR-09-1532
   Park SY, 2010, J CLIN INVEST, V120, P636, DOI 10.1172/JCI40724
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Ronneberg JA, 2008, CANCER RES, V68, P5562, DOI 10.1158/0008-5472.CAN-07-5828
   Rudland PS, 2002, CANCER RES, V62, P3417
   RUSSNES HG, 2010, SCI TRANSL UNPUB
   Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818
   Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23
   Soares J, 1999, CANCER, V85, P112, DOI 10.1002/(SICI)1097-0142(19990101)85:1<112::AID-CNCR16>3.0.CO;2-T
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sorlie T, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-127
   Stephens PJ, 2009, NATURE, V462, P1005, DOI 10.1038/nature08645
   Tao MH, 2009, BREAST CANCER RES TR, V114, P559, DOI 10.1007/s10549-008-0028-z
   Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   van Houwelingen HC, 2006, STAT MED, V25, P3201, DOI 10.1002/sim.2353
   Wai PY, 2008, CANCER METAST REV, V27, P103, DOI 10.1007/s10555-007-9104-9
   Weisz L, 2007, CANCER RES, V67, P2396, DOI 10.1158/0008-5472.CAN-06-2425
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Wiedswang G, 2003, J CLIN ONCOL, V21, P3469, DOI 10.1200/JCO.2003.02.009
NR 57
TC 99
Z9 117
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1574-7891
EI 1878-0261
J9 MOL ONCOL
JI Mol. Oncol.
PD FEB
PY 2011
VL 5
IS 1
BP 61
EP 76
DI 10.1016/j.molonc.2010.11.004
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 725AM
UT WOS:000287617600006
PM 21212030
OA Green Published
DA 2025-01-12
ER

PT J
AU Kamalakaran, S
   Varadan, V
   Russnes, HEG
   Levy, D
   Kendall, J
   Janevski, A
   Riggs, M
   Banerjee, N
   Synnestvedt, M
   Schlichting, E
   Kåresen, R
   Prasada, KS
   Rotti, H
   Rao, R
   Rao, L
   Tang, MHE
   Satyamoorthy, K
   Lucito, R
   Wigler, M
   Dimitrova, N
   Naume, B
   Borresen-Dale, AL
   Hicks, JB
AF Kamalakaran, Sitharthan
   Varadan, Vinay
   Russnes, Hege E. Giercksky
   Levy, Dan
   Kendall, Jude
   Janevski, Angel
   Riggs, Michael
   Banerjee, Nilanjana
   Synnestvedt, Marit
   Schlichting, Ellen
   Karesen, Rolf
   Prasada, K. Shama
   Rotti, Harish
   Rao, Ramachandra
   Rao, Laxmi
   Tang, Man-Hung Eric
   Satyamoorthy, K.
   Lucito, Robert
   Wigler, Michael
   Dimitrova, Nevenka
   Naume, Bjorn
   Borresen-Dale, Anne-Lise
   Hicks, James B.
TI DNA methylation patterns in luminal breast cancers differ from
   non-luminal subtypes and can identify relapse risk independent of other
   clinical variables
SO MOLECULAR ONCOLOGY
LA English
DT Article
DE Breast cancer; Subtypes; DNA methylation; MOMA; Survival; Epigenetics
ID EPIGENETIC INACTIVATION; ABERRANT METHYLATION; PROGNOSTIC MARKER; GENE;
   EXPRESSION; PROTEIN; NUMBER; MULTICENTER; VALIDATION; RECURRENCE
AB The diversity of breast cancers reflects variations in underlying biology and affects the clinical implications for patients. Gene expression studies have identified five major subtypes Luminal A, Luminal B, basal-like, ErbB2+ and Normal-Like. We set out to determine the role of DNA methylation in subtypes by performing genome-wide scans of CpG methylation in breast cancer samples with known expression-based subtypes. unsupervised hierarchical clustering using a set of most varying loci clustered the tumors into a Luminal A majority (82%) cluster, Basal-like/ErbB2+ majority (86%) cluster and a non-specific cluster with samples that were also inconclusive in their expression-based subtype correlations. Contributing methylation loci were both gene associated loci (30%) and non-gene associated (70%), suggesting subtype dependant genome-wide alterations in the methylation landscape. The methylation patterns of significant differentially methylated genes in luminal A tumors are similar to those identified in CD24 + luminal epithelial cells and the patterns in basal-like tumors similar to CD44 + breast progenitor cells. CpG islands in the HOXA cluster and other homeobox (IRX2, DLX2, NKX2-2) genes were significantly more methylated in Luminal A tumors. A significant number of genes (2853, p < 0.05) exhibited expression methylation correlation, implying possible functional effects of methylation on gene expression. Furthermore, analysis of these tumors by using follow-up survival data identified differential methylation of islands proximal to genes involved in Cell Cycle and Proliferation (Ki-67, UBE2C, KIF2C, HDAC4), angiogenesis (VEGF, BTG1, KLF5), cell fate commitment (SPRY1, OLIG2, LHX2 and LHX5) as having prognostic value independent of subtypes and other clinical factors. (C) 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
C1 [Kamalakaran, Sitharthan; Varadan, Vinay; Janevski, Angel; Banerjee, Nilanjana; Dimitrova, Nevenka] Philips Res N Amer, Biomed Informat, Briarcliff Manor, NY 10510 USA.
   [Russnes, Hege E. Giercksky; Synnestvedt, Marit; Naume, Bjorn] Norwegian Radium Hosp, Rikshosp Univ Hosp, Dept Oncol, Oslo, Norway.
   [Russnes, Hege E. Giercksky; Borresen-Dale, Anne-Lise] Norwegian Radium Hosp, Inst Canc Res, Dept Genet, Rikshosp Univ Hosp, Oslo, Norway.
   [Levy, Dan; Kendall, Jude; Riggs, Michael; Tang, Man-Hung Eric; Lucito, Robert; Wigler, Michael; Hicks, James B.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA.
   [Schlichting, Ellen; Karesen, Rolf] Oslo Univ Hosp, Dept Breast & Endocrine Surg, Oslo, Norway.
   [Prasada, K. Shama; Rotti, Harish; Rao, Ramachandra; Rao, Laxmi; Satyamoorthy, K.] Manipal Univ, Manipal, India.
   [Borresen-Dale, Anne-Lise] Norwegian Radium Hosp, Fac Med, Rikshosp Univ Hosp, Oslo, Norway.
C3 Philips; Philips Research; University of Oslo; National Hospital Norway;
   University of Oslo; National Hospital Norway; Cold Spring Harbor
   Laboratory; University of Oslo; Manipal Academy of Higher Education
   (MAHE); University of Oslo; National Hospital Norway
RP Kamalakaran, S (通讯作者)，Philips Res N Amer, Biomed Informat, Briarcliff Manor, NY 10510 USA.
EM sitharthk@philips.com; vinay.varadan@philips.com;
   hege_russnes@dfci.harvard.edu; levy@cshl.edu; kendall@cshl.edu;
   angel.janevski@philips.com; riggs@cshl.edu; nila.banerjee@philips.com;
   Ellen.Schlichting@ulleval.no; rolf.karesen@ulleval.no; mtang@cshl.edu;
   lucito@cshl.edu; wigler@cshl.edu; nevenka.dimitrova@philips.com;
   bjorn.naume@radiumhospitalet.no; alb@radium.uio.no; hicks@cshl.edu
RI kabekkodu, Shama/Q-2810-2018; Lucito, Robert/AID-7159-2022; Varadan,
   Vinay/AAC-2520-2020; Russnes, Hege G/N-6170-2015; Satyamoorthy,
   Kapaettu/H-3254-2015; Janevski, Angel/B-8098-2013
OI Satyamoorthy, Kapaettu/0000-0002-2368-5490; Kabekkodu,
   Shama/0000-0002-4158-3893; Janevski, Angel/0000-0003-2324-8976; Wigler,
   Michael/0000-0003-4396-1971; Tang, Man-Hung Eric/0000-0002-3483-0219
CR [Anonymous], BREAST CANC RES
   Beissbarth T, 2004, BIOINFORMATICS, V20, P1464, DOI 10.1093/bioinformatics/bth088
   Bergamaschi A, 2006, GENE CHROMOSOME CANC, V45, P1033, DOI 10.1002/gcc.20366
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Bloushtain-Qimron N, 2008, P NATL ACAD SCI USA, V105, P14076, DOI 10.1073/pnas.0805206105
   Burgess DJ, 2008, P NATL ACAD SCI USA, V105, P9053, DOI 10.1073/pnas.0803513105
   Caldeira JRF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-48
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   de Azambuja E, 2007, BRIT J CANCER, V96, P1504, DOI 10.1038/sj.bjc.6603756
   Flanagan JM, 2010, AM J HUM GENET, V86, P420, DOI 10.1016/j.ajhg.2010.02.008
   Harbeck N, 2008, J CLIN ONCOL, V26, P5036, DOI 10.1200/JCO.2007.14.1697
   Hartwell KA, 2006, P NATL ACAD SCI USA, V103, P18969, DOI 10.1073/pnas.0608636103
   Hinshelwood RA, 2008, J MOL MED, V86, P1315, DOI 10.1007/s00109-008-0386-3
   Hodges E, 2009, GENOME RES, V19, P1593, DOI 10.1101/gr.095190.109
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Irizarry RA, 2008, GENOME RES, V18, P780, DOI 10.1101/gr.7301508
   Ju H, 2005, INT J CANCER, V117, P957, DOI 10.1002/ijc.21281
   Kamalakaran S, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp413
   Khulan B, 2006, GENOME RES, V16, P1046, DOI 10.1101/gr.5273806
   Loussouarn D, 2009, BRIT J CANCER, V101, P166, DOI 10.1038/sj.bjc.6605122
   Lucito R, 2003, GENOME RES, V13, P2291, DOI 10.1101/gr.1349003
   Maier S, 2007, EUR J CANCER, V43, P1679, DOI 10.1016/j.ejca.2007.04.025
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   Naume B, 2007, MOL ONCOL, V1, P160, DOI 10.1016/j.molonc.2007.03.004
   Novak P, 2006, CANCER RES, V66, P10664, DOI 10.1158/0008-5472.CAN-06-2761
   Ordway JM, 2006, CARCINOGENESIS, V27, P2409, DOI 10.1093/carcin/bgl161
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086
   SCHAFFER JD, 2005, COMP INT BIOINF COMP
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Subramaniam MM, 2009, BREAST CANCER RES TR, V113, P113, DOI 10.1007/s10549-008-9917-4
   Sullivan A, 2007, BRIT J CANCER, V96, P196, DOI 10.1038/sj.bjc.6603525
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Taylor J, 2006, GENOME RES, V16, P1596, DOI 10.1101/gr.4537706
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Toyota M, 1999, CANCER RES, V59, P5438
   Wiedswang G, 2003, CYTOTHERAPY, V5, P40, DOI 10.1080/14653240310000065
NR 37
TC 105
Z9 124
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1574-7891
EI 1878-0261
J9 MOL ONCOL
JI Mol. Oncol.
PD FEB
PY 2011
VL 5
IS 1
BP 77
EP 92
DI 10.1016/j.molonc.2010.11.002
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 725AM
UT WOS:000287617600007
PM 21169070
OA Green Published
DA 2025-01-12
ER

PT J
AU Shin, JE
   Park, SH
   Jang, YK
AF Shin, Jung Eun
   Park, Su Hyung
   Jang, Yeun Kyu
TI Epigenetic up-regulation of leukemia inhibitory factor (LIF) gene during
   the progression to breast cancer
SO MOLECULES AND CELLS
LA English
DT Article
DE DNA methylation; histone methylation; isogenic MCF10 cell lines;
   leukemia inhibitory factor (LIF); MeCP2
ID TUMOR-SUPPRESSOR GENE; DNA METHYLATION; ONCOSTATIN-M; CELL-LINES;
   PROMOTER METHYLATION; EPITHELIAL-CELLS; CARCINOMA-CELLS; RECEPTOR
   EXPRESSION; PROSTATE-CANCER; MCF10 MODEL
AB The interleukin 6 family of cytokines including leukemia inhibitory factor (LIF) regulates the progression of several types of cancer. However, although LIF overexpression during breast cancer progression was observed in our previous report, the molecular mechanisms responsible for this deregulation remain largely unknown. Here we show that LIF expression is epigenetically up-regulated via DNA demethylation and changes in histone methylation status within its promoter region in the isogenic MCF10 model. Bisulfite sequencing revealed the CpG pairs within the promoter region are hypermethylated in normal breast epithelial cells, but extensively demethylated as breast cancer progresses. In agreement with the DNA methylation pattern, our chromatin immunoprecipitation showed that inactive epigenetic marks such as MeCP2 occupancy and histone H3-Lys9-dimethylation significantly decreased during the progression to breast cancer but an active histone mark was increased in an inverse manner. Also, the occupancy of the transcription factor Sp1, which has higher affinity for hypomethylated CpGs, increased. RNAimediated knockdown of LIF expression resulted in a significant reduction of cell growth and colony formation in breast cancer cells, suggesting the potential role of LIF-LIF receptor axis in autocrine stimulation of cancer cells. Collectively, our data suggest that the epigenetic up-regulation of the LIF gene likely play an important role in the development of breast cancer.
C1 [Shin, Jung Eun; Park, Su Hyung; Jang, Yeun Kyu] Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biol, Seoul 120749, South Korea.
   [Shin, Jung Eun; Park, Su Hyung; Jang, Yeun Kyu] Yonsei Univ, Yonsei Biomol Res Initiat, Seoul 120749, South Korea.
C3 Yonsei University; Yonsei University
RP Jang, YK (通讯作者)，Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biol, Seoul 120749, South Korea.
EM ykjang@yonsei.ac.kr
FU Korean Government Ministry of Education, Science and Technology
   [KRF-2007-313-C00525]; Ministry of Education, Science and Technology
   [R01-2007-000-20047-0, 2009-0083772]; Ministry for Health, Welfare and
   Family affairs, Republic of Korea [0920260]
FX We thank Fred Miller and S. J. Santner for providing human breast cell
   lines kindly. This work was supported by National Research Foundation of
   Korea Grant funded by the Korean Government Ministry of Education,
   Science and Technology (KRF-2007-313-C00525) and also by Mid-career
   Researcher Program through National Research Foundation of Korea grant
   funded by the Ministry of Education, Science and Technology (No.
   R01-2007-000-20047-0 (2007) or 2009-0083772). In addition, this study
   was in part supported by a grant from the National R& D Program for
   Cancer Control, Ministry for Health, Welfare and Family affairs,
   Republic of Korea (No. 0920260) to Y. K.
CR Abdollahi A, 2003, J BIOL CHEM, V278, P6041, DOI 10.1074/jbc.M210361200
   Ahmed H, 2007, BIOCHEM BIOPH RES CO, V358, P241, DOI 10.1016/j.bbrc.2007.04.114
   Ballestar E, 2008, ADV GENET, V61, P247, DOI 10.1016/S0065-2660(07)00009-0
   Baylin S.B., 2007, Epigenetics, P457
   Chernov AV, 2009, J BIOL CHEM, V284, P12727, DOI 10.1074/jbc.M900273200
   Chicoine É, 2002, BIOCHEM BIOPH RES CO, V297, P765, DOI 10.1016/S0006-291X(02)02283-0
   Clark SJ, 1997, GENE, V195, P67, DOI 10.1016/S0378-1119(97)00164-9
   COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975
   Crichton MB, 1996, MOL CELL ENDOCRINOL, V118, P215, DOI 10.1016/0303-7207(96)03761-6
   Demers M, 2009, BIOCHEM BIOPH RES CO, V387, P425, DOI 10.1016/j.bbrc.2009.07.015
   Dhingra K, 1998, BREAST CANCER RES TR, V48, P165, DOI 10.1023/A:1005942923757
   Douglas AM, 1998, INT J CANCER, V75, P64, DOI 10.1002/(SICI)1097-0215(19980105)75:1<64::AID-IJC11>3.0.CO;2-D
   Douglas AM, 1997, ONCOGENE, V14, P661, DOI 10.1038/sj.onc.1200882
   ESTROV Z, 1995, J INTERF CYTOK RES, V15, P905, DOI 10.1089/jir.1995.15.905
   Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332
   Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200
   García-Tuñón I, 2008, CANCER INVEST, V26, P222, DOI 10.1080/07357900701638491
   Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322
   Grant SL, 2001, GROWTH FACTORS, V19, P153, DOI 10.3109/08977190109001083
   Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200
   Honda H, 2006, J BIOL CHEM, V281, P21433, DOI 10.1074/jbc.M603767200
   Hurst DR, 2009, CLIN EXP METASTAS, V26, P89, DOI 10.1007/s10585-008-9216-9
   IGUCHIARIGA SM, 1998, GENE DEV, V3, P612
   Jorcyk CL, 2006, CYTOKINE, V33, P323, DOI 10.1016/j.cyto.2006.03.004
   Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298
   Kamohara H, 2007, INT J ONCOL, V30, P977
   KellokumpuLehtinen P, 1996, INT J CANCER, V66, P515, DOI 10.1002/(SICI)1097-0215(19960516)66:4<515::AID-IJC15>3.0.CO;2-6
   Kim JH, 2005, MOL CELLS, V19, P279
   Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492
   Liu JW, 1998, CYTOKINE, V10, P295, DOI 10.1006/cyto.1997.0283
   Mancini DN, 1999, ONCOGENE, V18, P4108, DOI 10.1038/sj.onc.1202764
   Marella NV, 2009, CANCER RES, V69, P5946, DOI 10.1158/0008-5472.CAN-09-0420
   McGough JM, 2008, MOL CANCER RES, V6, P1841, DOI 10.1158/1541-7786.MCR-08-0280
   Métivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544
   Motegi K, 2005, LAB INVEST, V85, P342, DOI 10.1038/labinvest.3700234
   Murayama A, 2006, EMBO J, V25, P1081, DOI 10.1038/sj.emboj.7601012
   Na YK, 2010, MOL CELLS, V30, P89, DOI 10.1007/s10059-010-0092-1
   Oh SH, 2009, MOL CELLS, V27, P635, DOI 10.1007/s10059-009-0084-1
   OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063
   Pakneshan P, 2004, J BIOL CHEM, V279, P31735, DOI 10.1074/jbc.M401669200
   Park HY, 2007, EXP MOL MED, V39, P195, DOI 10.1038/emm.2007.22
   Park WS, 2005, EXP MOL MED, V37, P276, DOI 10.1038/emm.2005.37
   Perrais M, 2001, J BIOL CHEM, V276, P15386, DOI 10.1074/jbc.M010534200
   Qu ZX, 2010, J BIOL CHEM, V285, P11786, DOI 10.1074/jbc.M109.086561
   Queen MM, 2005, CANCER RES, V65, P8896, DOI 10.1158/0008-5472.CAN-05-1734
   Rhee DK, 2008, GENOMICS, V92, P419, DOI 10.1016/j.ygeno.2008.08.005
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273
   Shvachko LP, 2009, CELL BIOL INT, V33, P904, DOI 10.1016/j.cellbi.2009.02.018
   Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727
   Suh ER, 2002, J BIOL CHEM, V277, P35795, DOI 10.1074/jbc.M205567200
   Tsujiuchi T, 2006, BIOCHEM BIOPH RES CO, V349, P1151, DOI 10.1016/j.bbrc.2006.08.159
   Vaissière T, 2008, MUTAT RES-REV MUTAT, V659, P40, DOI 10.1016/j.mrrev.2008.02.004
   Worsham MJ, 2006, BREAST CANCER RES TR, V96, P177, DOI 10.1007/s10549-005-9077-8
   Wysoczynski M, 2007, CANCER RES, V67, P2131, DOI 10.1158/0008-5472.CAN-06-1021
   Yu SE, 2010, MOL CELLS, V29, P217, DOI 10.1007/s10059-010-0052-9
   Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003
NR 57
TC 39
Z9 46
U1 0
U2 9
PU KOREAN SOC MOLECULAR & CELLULAR  BIOLOGY
PI SEOUL
PA 635-4, YUCKSAM-DONG, GANGNAM-GU, SEOUL 135-703, SOUTH KOREA
SN 1016-8478
EI 0219-1032
J9 MOL CELLS
JI Mol. Cells
PD FEB
PY 2011
VL 31
IS 2
BP 181
EP 189
DI 10.1007/s10059-011-0020-z
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 726VP
UT WOS:000287755000012
PM 21191816
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Pasquier, J
   Magal, P
   Boulangé-Lecomte, C
   Webb, G
   Le Foll, F
AF Pasquier, Jennifer
   Magal, Pierre
   Boulange-Lecomte, Celine
   Webb, Glenn
   Le Foll, Frank
TI Consequences of cell-to-cell P-glycoprotein transfer on acquired
   multidrug resistance in breast cancer: a cell population dynamics model
SO BIOLOGY DIRECT
LA English
DT Article
ID DRUG-RESISTANCE; INTERCELLULAR TRANSFER; TUMOR-CELLS; EXPRESSION;
   CHEMOTHERAPY; DOXORUBICIN; TRANSPORTERS; INDUCTION; ANTHRACYCLINES;
   MECHANISMS
AB Background: Cancer is a proliferation disease affecting a genetically unstable cell population, in which molecular alterations can be somatically inherited by genetic, epigenetic or extragenetic transmission processes, leading to a cooperation of neoplastic cells within tumoural tissue. The efflux protein P-glycoprotein (P-gp) is overexpressed in many cancer cells and has known capacity to confer multidrug resistance to cytotoxic therapies. Recently, cell-to-cell P-gp transfers have been shown. Herein, we combine experimental evidence and a mathematical model to examine the consequences of an intercellular P-gp trafficking in the extragenetic transfer of multidrug resistance from resistant to sensitive cell subpopulations.
   Methodology and Principal Findings: We report cell-to-cell transfers of functional P-gp in co-cultures of a P-gp overexpressing human breast cancer MCF-7 cell variant, selected for its resistance towards doxorubicin, with the parental sensitive cell line. We found that P-gp as well as efflux activity distribution are progressively reorganized over time in co-cultures analyzed by flow cytometry. A mathematical model based on a Boltzmann type integro-partial differential equation structured by a continuum variable corresponding to P-gp activity describes the cell populations in co-culture. The mathematical model elucidates the population elements in the experimental data, specifically, the initial proportions, the proliferative growth rates, and the transfer rates of P-gp in the sensitive and resistant subpopulations.
   Conclusions: We confirmed cell-to-cell transfer of functional P-gp. The transfer process depends on the gradient of P-gp expression in the donor-recipient cell interactions, as they evolve over time. Extragenetically acquired drug resistance is an additional aptitude of neoplastic cells which has implications in the diagnostic value of P-gp expression and in the design of chemotherapy regimens. Reviewers: This article was reviewed by Leonid Hanin, Anna Marciniak-Czochra and Marek Kimmel.
C1 [Pasquier, Jennifer; Boulange-Lecomte, Celine; Le Foll, Frank] Univ Le Havre, Lab Ecotoxicol, UPRES EA 3222, IFRMP 23, F-76058 Le Havre, France.
   [Magal, Pierre] Univ Bordeaux, CNRS, UMR 5251, IMB, F-33076 Bordeaux, France.
   [Magal, Pierre] Univ Bordeaux, INRIA Sudouest Anubis, F-33076 Bordeaux, France.
   [Webb, Glenn] Vanderbilt Univ, Dept Math, Nashville, TN 37240 USA.
C3 Universite de Reims Champagne-Ardenne; Universite Le Havre Normandie;
   Universite de Bordeaux; Centre National de la Recherche Scientifique
   (CNRS); CNRS - National Institute for Mathematical Sciences (INSMI);
   Universite de Bordeaux; Vanderbilt University
RP Le Foll, F (通讯作者)，Univ Le Havre, Lab Ecotoxicol, UPRES EA 3222, IFRMP 23, F-76058 Le Havre, France.
EM frank.lefoll@univ-lehavre.fr
RI Magal, Pierre/HLG-7279-2023; Boulangé-Lecomte, Céline/HNR-2154-2023;
   Webb, Glenn/AAW-7228-2021
OI Le Foll, Frank/0000-0002-9585-9250; magal, pierre/0000-0002-4776-0061;
   Pasquier, Jennifer/0000-0002-2465-7942; Boulange-Lecomte,
   Celine/0000-0002-2461-7473
FU Conseil Regional de Haute Normandie; SCiences Appliquees a
   L'Environnement [FED 4116]
FX This work was supported by grants of the federation FED 4116 SCALE
   (SCiences Appliquees a L'Environnement). Jennifer Pasquier was a
   recipient for a fellowship from the Conseil Regional de Haute Normandie
   The authors are indebted to Pr. Jean-Pierre Marie (Hotel Dieu, Paris,
   France) for providing MCF-7/Doxo and PSC833.
CR Allen JD, 2000, CANCER RES, V60, P5761
   Arnal M, 2000, BREAST CANCER RES TR, V61, P13, DOI 10.1023/A:1006449931921
   Axelrod R, 2006, P NATL ACAD SCI USA, V103, P13474, DOI 10.1073/pnas.0606053103
   Bebawy M, 2009, LEUKEMIA, V23, P1643, DOI 10.1038/leu.2009.76
   Beck WT, 1996, CANCER RES, V56, P3010
   Blagosklonny MV, 2005, CANCER BIOL THER, V4, P621, DOI 10.4161/cbt.4.6.1818
   Bonneterre J, 2004, BRIT J CANCER, V91, P1466, DOI 10.1038/sj.bjc.6602179
   Broxterman HJ, 2009, DRUG RESIST UPDATE, V12, P114, DOI 10.1016/j.drup.2009.07.001
   Broxterman HJ, 1996, BLOOD, V87, P4809, DOI 10.1182/blood.V87.11.4809.bloodjournal87114809
   Carlson Robert W, 2007, J Natl Compr Canc Netw, V5, P246
   CHAUDHARY PM, 1992, BLOOD, V80, P2735
   Coley HM, 2008, CANCER TREAT REV, V34, P378, DOI 10.1016/j.ctrv.2008.01.007
   DANO K, 1972, CANCER CHEMOTH REP 1, V56, P701
   Faneyte IF, 2001, INT J CANCER, V93, P114, DOI 10.1002/1097-0215(20010701)93:1<114::AID-IJC1309>3.3.CO;2-A
   Ferrand VL, 1996, CYTOMETRY, V23, P120, DOI 10.1002/(SICI)1097-0320(19960201)23:2<120::AID-CYTO5>3.0.CO;2-O
   FRANKFURT OS, 1991, CANCER RES, V51, P1190
   Greenberg PAC, 1996, J CLIN ONCOL, V14, P2197, DOI 10.1200/JCO.1996.14.8.2197
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hennessy M, 2007, PHARMACOL RES, V55, P1, DOI 10.1016/j.phrs.2006.10.007
   Hinow P, 2009, SIAM J APPL MATH, V70, P40, DOI 10.1137/080732420
   HU XF, 1995, BRIT J CANCER, V71, P931, DOI 10.1038/bjc.1995.180
   JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7
   Laginha KM, 2005, CLIN CANCER RES, V11, P6944, DOI 10.1158/1078-0432.CCR-05-0343
   Leonessa F, 2003, ENDOCR-RELAT CANCER, V10, P43, DOI 10.1677/erc.0.0100043
   Levchenko A, 2005, P NATL ACAD SCI USA, V102, P1933, DOI 10.1073/pnas.0401851102
   Li EX, 1999, CHINESE J CANCER RES, V11, P218
   LICHT T, 1991, INT J CANCER, V49, P630, DOI 10.1002/ijc.2910490427
   LINN SC, 1995, ANN ONCOL, V6, P679, DOI 10.1093/oxfordjournals.annonc.a059284
   Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706
   Luu KT, 2005, PHARM RES-DORDR, V22, P710, DOI 10.1007/s11095-005-2585-8
   Marin M, 2005, BIOCHEM BIOPH RES CO, V334, P1266, DOI 10.1016/j.bbrc.2005.07.010
   Meesungnoen J, 2002, CAN J PHYSIOL PHARM, V80, P1054, DOI 10.1139/Y02-132
   Molinari A, 2000, ANTICANCER RES, V20, P2691
   Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477
   Oleinikov VA, 2006, FEBS LETT, V580, P4953, DOI 10.1016/j.febslet.2006.07.069
   Pasquier J, 2010, WORKSH PROGR CELL IM
   Pesic M, 2006, J CHEMOTHERAPY, V18, P66, DOI 10.1179/joc.2006.18.1.66
   Rafii A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003894
   ROSSI C, 1987, CANCER TREAT REP, V71, P1221
   SANFILIPPO O, 1991, EUR J CANCER, V27, P155, DOI 10.1016/0277-5379(91)90476-T
   Sparreboom A, 2003, DRUG RESIST UPDATE, V6, P71, DOI 10.1016/S1368-7646(03)00005-0
   SPETH PAJ, 1987, CLIN PHARMACOL THER, V41, P661, DOI 10.1038/clpt.1987.92
   Trock BJ, 1997, J NATL CANCER I, V89, P917, DOI 10.1093/jnci/89.13.917
   Zhou Y, 1999, ARCH BIOCHEM BIOPHYS, V367, P74, DOI 10.1006/abbi.1999.1221
NR 44
TC 48
Z9 56
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1745-6150
J9 BIOL DIRECT
JI Biol. Direct
PD JAN 26
PY 2011
VL 6
AR 5
DI 10.1186/1745-6150-6-5
PG 18
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA 720VY
UT WOS:000287312000001
PM 21269489
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Iliopoulos, D
   Hirsch, HA
   Wang, GN
   Struhl, K
AF Iliopoulos, Dimitrios
   Hirsch, Heather A.
   Wang, Guannan
   Struhl, Kevin
TI Inducible formation of breast cancer stem cells and their dynamic
   equilibrium with non-stem cancer cells via IL6 secretion
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE cellular transformation; inflammation; cancer stem cells equilibrium
ID MIR-200 FAMILY; MESENCHYMAL TRANSITION; IDENTIFICATION; ZEB1;
   INFLAMMATION; REPRESSION; SIGNATURE
AB Tumors are often heterogeneous, being composed of multiple cell types with different phenotypic and molecular properties. Cancer stem-like cells (CSCs) are a highly tumorigenic cell type found in developmentally diverse tumors or cancer cell lines, and they are often resistant to standard chemotherapeutic drugs. The origins of CSCs and their relationships to nonstem cancer cells (NSCCs) are poorly understood. In an inducible breast oncogenesis model, CSCs are generated from nontransformed cells at a specific time during the transformation process, but CSC formation is not required for transformation. MicroRNA profiles indicate that CSCs and NSCCs are related, but different cell types arising from a common nontransformed population. Interestingly, medium from the transformed population stimulates NSCCs to become CSCs, and conversion of NSCCs to CSCs occurs in mouse xenografts. Furthermore, IL6 is sufficient to convert NSCCs to CSCs in genetically different breast cell lines, human breast tumors, and a prostate cell line. Thus, breast and prostate CSCs and NSCCs do not represent distinct epigenetic states, and these CSCs do not behave as or arise from classic stem cells. Instead, tumor heterogeneity involves a dynamic equilibrium between CSCs and NSCCs mediated by IL6 and activation of the inflammatory feedback loop required for oncogenesis. This dynamic equilibrium provides an additional rationale for combining conventional chemotherapy with metformin, which selectively inhibits CSCs.
C1 [Iliopoulos, Dimitrios; Hirsch, Heather A.; Wang, Guannan; Struhl, Kevin] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
C3 Harvard University; Harvard Medical School
RP Struhl, K (通讯作者)，Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
EM kevin@hms.harvard.edu
RI Wang, Guannan/AAV-2892-2020; Iliopoulos, Dimitrios/AAE-9106-2019
FU American Cancer Society; National Institutes of Health [CA 107486]
FX We thank Marianne Lindahl-Allen for help with the kinetic analysis of
   CSC formation and for useful comments on the work, and Philip N.
   Tsichlis for providing facilities for performing the xenograft
   experiments. This work was supported by a postdoctoral fellowship from
   the American Cancer Society (to H. A. H.) and National Institutes of
   Health research Grant CA 107486 (to K.S.).
CR Ailles LE, 2007, CURR OPIN BIOTECH, V18, P460, DOI 10.1016/j.copbio.2007.10.007
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Aziz N, 1999, MOL CELL BIOL, V19, P1101
   Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0
   Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942
   Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283
   Gotoh N, 2009, CURR STEM CELL RES T, V4, P9, DOI 10.2174/157488809787169048
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Grimshaw MJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2106
   Hirsch HA, 2010, CANCER CELL, V17, P348, DOI 10.1016/j.ccr.2010.01.022
   Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008-5472.CAN-09-2994
   Iliopoulos D, 2010, MOL CELL, V39, P761, DOI 10.1016/j.molcel.2010.08.013
   Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023
   Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356
   Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014
   Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200
   LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0
   Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030
   Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123
   Mlarotta LLC, 2009, CURR OPIN GENET DEV, V19, P44, DOI 10.1016/j.gde.2008.12.003
   Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104
   Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Rosen JM, 2009, SCIENCE, V324, P1670, DOI 10.1126/science.1171837
   Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489
   Shackleton M, 2009, CELL, V138, P822, DOI 10.1016/j.cell.2009.08.017
   Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011
   Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   SOULE HD, 1990, CANCER RES, V50, P6075
NR 37
TC 498
Z9 560
U1 1
U2 47
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JAN 25
PY 2011
VL 108
IS 4
BP 1397
EP 1402
DI 10.1073/pnas.1018898108
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 711MD
UT WOS:000286594800038
PM 21220315
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Radpour, R
   Barekati, Z
   Kohler, C
   Lv, Q
   Bürki, N
   Diesch, C
   Bitzer, J
   Zheng, H
   Schmid, S
   Zhong, XY
AF Radpour, Ramin
   Barekati, Zeinab
   Kohler, Corina
   Lv, Qing
   Buerki, Nicole
   Diesch, Claude
   Bitzer, Johannes
   Zheng, Hong
   Schmid, Seraina
   Zhong, Xiao Yan
TI Hypermethylation of Tumor Suppressor Genes Involved in Critical
   Regulatory Pathways for Developing a Blood-Based Test in Breast Cancer
SO PLOS ONE
LA English
DT Article
ID DNA METHYLATION; CLINICOPATHOLOGICAL FEATURES; PROMOTER
   HYPERMETHYLATION; PROGNOSTIC MARKER; MATERNAL PLASMA; MASS ARRAY; FETAL
   DNA; RAR-BETA; SERUM; PROFILE
AB Background: Aberrant DNA methylation patterns might be used as a biomarker for diagnosis and management of cancer patients.
   Methods and Findings: To achieve a gene panel for developing a breast cancer blood-based test we quantitatively assessed the DNA methylation proportion of 248 CpG sites per sample (total of 31,248 sites in all analyzed samples) on 10 candidate genes (APC, BIN1, BMP6, BRCA1, CST6, ESR-b, GSTP1, P16, P21 and TIMP3). The number of 126 samples consisting of two different cohorts was used (first cohort: plasma samples from breast cancer patients and normal controls; second cohort: triple matched samples including cancerous tissue, matched normal tissue and serum samples). In the first cohort, circulating cell free methylated DNA of the 8 tumor suppressor genes (TSGs) was significantly higher in patients with breast cancer compared to normal controls (P<0.01). In the second cohort containing triple matched samples, seven genes showed concordant hypermethylated profile in tumor tissue and serum samples compared to normal tissue (P<0.05). Using eight genes as a panel to develop a blood-based test for breast cancer, a sensitivity and specificity of more than 90% could be achieved in distinguishing between tumor and normal samples.
   Conclusions: Our study suggests that the selected TSG panel combined with the high-throughput technology might be a useful tool to develop epigenetic based predictive and prognostic biomarker for breast cancer relying on pathologic methylation changes in tumor tissue, as well as in circulation.
C1 [Radpour, Ramin; Barekati, Zeinab; Kohler, Corina; Zhong, Xiao Yan] Univ Basel, Womens Hosp, Dept Biomed, Lab Gynecol Oncol, Basel, Switzerland.
   [Lv, Qing] Sichuan Univ, W China Sch Med, W China Hosp, Dept Breast Surg, Chengdu 610064, Peoples R China.
   [Bitzer, Johannes; Schmid, Seraina] Univ Basel, Dept Obstet & Gynecol, Womens Hosp, Basel, Switzerland.
   [Buerki, Nicole; Diesch, Claude] Kantonsspital Liestal, Dept Obstet & Gynecol, CH-4410 Liestal, Switzerland.
   [Zheng, Hong] Sichuan Univ, W China Sch Med, W China Hosp, Lab Mol Diag Canc,Dept Oncol,State Key Lab Biothe, Chengdu 610064, Peoples R China.
C3 University of Basel; Sichuan University; University of Basel;
   Kantonsspital Baselland; Sichuan University
RP Radpour, R (通讯作者)，Univ Basel, Womens Hosp, Dept Biomed, Lab Gynecol Oncol, Basel, Switzerland.
EM sschmid@uhbs.ch; zhongx@uhbs.ch
RI Kohler, Corina/KTH-9502-2024; Radpour, PD Dr. Ramin/J-4949-2014
OI Radpour, PD Dr. Ramin/0000-0002-5632-7833; Buerki,
   Nicole/0000-0002-2625-7619
FU Swiss National Science Foundation [320000-119722/1, 320030_124958/1];
   Swiss National Science Foundation (SNF) [320030_124958] Funding Source:
   Swiss National Science Foundation (SNF)
FX This work was supported by Swiss National Science Foundation
   (320000-119722/1 and 320030_124958/1) (http://www.snf.ch). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR [Anonymous], 2006, SEER CANC STAT REV 1
   Barekati Z, 2010, HUM MOL GENET, V19, P2936, DOI 10.1093/hmg/ddq199
   Chan KCA, 2004, CLIN CHEM, V50, P88, DOI 10.1373/clinchem.2003.024893
   Diehl F, 2005, P NATL ACAD SCI USA, V102, P16368, DOI 10.1073/pnas.0507904102
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   Ehrich M, 2008, P NATL ACAD SCI USA, V105, P4844, DOI 10.1073/pnas.0712251105
   Etzioni R, 2003, NAT REV CANCER, V3, P243, DOI 10.1038/nrc1041
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Gautschi O, 2004, J CLIN ONCOL, V22, P4157, DOI 10.1200/JCO.2004.11.123
   Giacona MB, 1998, PANCREAS, V17, P89, DOI 10.1097/00006676-199807000-00012
   Jahr S, 2001, CANCER RES, V61, P1659
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   LEON SA, 1977, CANCER RES, V37, P646
   Li SY, 2006, CANCER LETT, V237, P272, DOI 10.1016/j.canlet.2005.06.011
   Li Y, 2004, CLIN CHEM, V50, P1002, DOI 10.1373/clinchem.2003.029835
   Müller HM, 2003, CANCER RES, V63, P7641
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Radpour R, 2009, ONCOGENE, V28, P2969, DOI 10.1038/onc.2009.149
   Radpour R, 2008, MOL CANCER RES, V6, P1702, DOI 10.1158/1541-7786.MCR-08-0262
   Radpour R, 2010, MODERN PATHOL, V23, P763, DOI 10.1038/modpathol.2009.195
   Radpour R, 2009, J PROTEOME RES, V8, P5264, DOI 10.1021/pr900591w
   Radpour R, 2009, GENET TEST MOL BIOMA, V13, P565, DOI 10.1089/gtmb.2009.0060
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   Shukla S, 2006, EPIGENETICS-US, V1, P88, DOI 10.4161/epi.1.2.2679
   SUNAMI EVA, 2009, ANAL METHYLATED CIRC, P349
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Tao MH, 2009, BREAST CANCER RES TR, V114, P559, DOI 10.1007/s10549-008-0028-z
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wong TS, 2004, CLIN CANCER RES, V10, P2401, DOI 10.1158/1078-0432.CCR-03-0139
   Zhong Xiao Yan, 2007, Archives of Gynecology and Obstetrics, V276, P327, DOI 10.1007/s00404-007-0345-1
NR 35
TC 109
Z9 132
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 24
PY 2011
VL 6
IS 1
AR e16080
DI 10.1371/journal.pone.0016080
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 710PJ
UT WOS:000286523400015
PM 21283676
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Zheng, YL
   Zhou, X
   Loffredo, CA
   Shields, PG
   Sun, B
AF Zheng, Yun-Ling
   Zhou, Xin
   Loffredo, Christopher A.
   Shields, Peter G.
   Sun, Bing
TI Telomere deficiencies on chromosomes 9p, 15p, 15q and Xp: potential
   biomarkers for breast cancer risk
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID EPIGENETIC REGULATION; IN-SITU; MAMMALIAN TELOMERES; SHORTENING OCCURS;
   BLOOD-CELLS; LENGTH; INSTABILITY; CARCINOMA; DNA; ABNORMALITIES
AB Although telomere dysfunction is a characteristic of breast cancer cells, the relationship between deficiency on individual chromosomal telomeres in normal somatic cells and breast cancer risk has not been characterized. A case-control study was conducted to examine the associations between individual lengths of 92 telomeres in the human genome and the risk of breast cancer in 204 newly diagnosed breast cancer patients and 236 healthy controls. Chromosome arm-specific telomere lengths were measured by telomere quantitative fluorescent in situ hybridization. Unconditional logistic regression was used to estimate the risk associations. This genome-wide screen identified that shorter telomere lengths on chromosomes Xp and 15p were associated with breast cancer risk in pre-menopausal women, with adjusted odds ratios (aORs) of 2.5 (95% CI = 1.3, 4.8) and 2.6 (1.3, 5.0), respectively. The study also revealed that greater length differences between homologous telomeres on chromosomes 9p, 15p and 15q were associated with breast cancer risk in pre-menopausal women, with aORs of 4.6 (2.3, 9.2), 3.1 (1.6, 6.0) and 2.8 (1.4, 5.4), respectively. When the subjects were categorized into quartiles, a dose-response relationship was observed for all of the above telomeres (P-for-trend < 0.005). This study revealed that telomere deficiencies on chromosomes 9p, 15p, 15q and Xp were associated with breast cancer risk in pre-menopausal women. If confirmed in future studies, chromosomal arm-specific telomeres are likely to be a useful panel of blood-based biomarkers for breast cancer risk assessment, given their strong associations with breast cancer risk.
C1 [Zheng, Yun-Ling; Zhou, Xin; Loffredo, Christopher A.; Shields, Peter G.] Georgetown Univ, Lombardi Comprehens Canc Ctr, Carcinogenesis Biomarkers & Epidemiol Program, Washington, DC 20057 USA.
   [Sun, Bing] BioMarkers, Rockville, MD USA.
C3 Georgetown University
RP Zheng, YL (通讯作者)，Georgetown Univ, Lombardi Comprehens Canc Ctr, Carcinogenesis Biomarkers & Epidemiol Program, 3800 Reservoir Rd NW,Box 571465, Washington, DC 20057 USA.
EM yz37@georgetown.edu
RI Shields, Peter/I-1644-2012
FU Susan G Komen for the Cure [BCTR 0600562, KG100283]; National Institutes
   of Health [P30 CA51008]; Department of Defense [DAMD17-03-1-0446]
FX This work was supported by grants from Susan G Komen for the Cure (BCTR
   0600562 and KG100283 to Y.-L.Z.); the National Institutes of Health (P30
   CA51008); Department of Defense grant (DAMD17-03-1-0446 to P.G.S.)
   supported the control recruitment.
CR Artandi SE, 2005, BIOCHEM BIOPH RES CO, V331, P881, DOI 10.1016/j.bbrc.2005.03.211
   Artandi SE, 2010, CARCINOGENESIS, V31, P9, DOI 10.1093/carcin/bgp268
   Barwell J, 2007, BRIT J CANCER, V97, P1696, DOI 10.1038/sj.bjc.6604085
   Benetti R, 2007, NAT GENET, V39, P243, DOI 10.1038/ng1952
   Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500
   Blasco MA, 2007, NAT REV GENET, V8, P299, DOI 10.1038/nrg2047
   Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271
   Capper R, 2007, GENE DEV, V21, P2495, DOI 10.1101/gad.439107
   Cesare AJ, 2004, MOL CELL BIOL, V24, P9948, DOI 10.1128/MCB.24.22.9948-9957.2004
   Cesare AJ, 2008, MECH AGEING DEV, V129, P99, DOI 10.1016/j.mad.2007.11.006
   Chin K, 2004, NAT GENET, V36, P984, DOI 10.1038/ng1409
   De Vivo I, 2009, CANCER EPIDEM BIOMAR, V18, P1152, DOI 10.1158/1055-9965.EPI-08-0998
   der-Sarkissian H, 2004, ONCOGENE, V23, P1221, DOI 10.1038/sj.onc.1207152
   Esteller M, 2001, CANCER RES, V61, P3225
   Fridlyand J, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-96
   García-Cao M, 2004, NAT GENET, V36, P94, DOI 10.1038/ng1278
   Gilson E, 2007, CELL CYCLE, V6, P2486, DOI 10.4161/cc.6.20.4798
   Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798
   Gorgoulis VG, 1998, MOL MED, V4, P807, DOI 10.1007/BF03401773
   Graakjaer J, 2003, MECH AGEING DEV, V124, P629, DOI 10.1016/S0047-6374(03)00081-2
   Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005
   Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615
   Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9
   Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058
   Hwang ES, 2004, CLIN CANCER RES, V10, P5160, DOI 10.1158/1078-0432.CCR-04-0165
   Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003
   Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685
   Meeker AK, 2004, CLIN CANCER RES, V10, P3317, DOI 10.1158/1078-0432.CCR-0984-03
   Meeker AK, 2004, J MAMMARY GLAND BIOL, V9, P285, DOI 10.1023/B:JOMG.0000048775.04140.92
   Meeker AK, 2004, AM J PATHOL, V164, P925, DOI 10.1016/S0002-9440(10)63180-X
   Meeker AK, 2002, CANCER RES, V62, P6405
   Murnane JP, 2006, DNA REPAIR, V5, P1082, DOI 10.1016/j.dnarep.2006.05.030
   OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7
   Pickett HA, 2009, EMBO J, V28, P799, DOI 10.1038/emboj.2009.42
   Pinkel D, 2005, NAT GENET, V37, pS11, DOI 10.1038/ng1569
   Schröder CP, 2001, BRIT J CANCER, V84, P1348, DOI 10.1054/bjoc.2001.1803
   Shen J, 2007, CANCER RES, V67, P5538, DOI 10.1158/0008-5472.CAN-06-3490
   Shen J, 2009, INT J CANCER, V124, P1637, DOI 10.1002/ijc.24105
   Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672
   Soler D, 2005, GENE CHROMOSOME CANC, V44, P339, DOI 10.1002/gcc.20244
   Subhawong AP, 2009, MODERN PATHOL, V22, p343A
   Svenson U, 2008, CANCER RES, V68, P3618, DOI 10.1158/0008-5472.CAN-07-6497
   Vera E, 2008, ONCOGENE, V27, P6817, DOI 10.1038/onc.2008.289
   Verdun RE, 2007, NATURE, V447, P924, DOI 10.1038/nature05976
   Xing JL, 2009, CANCER PREV RES, V2, P459, DOI 10.1158/1940-6207.CAPR-08-0227
   Zheng YL, 2005, CANCER RES, V65, P9566, DOI 10.1158/0008-5472.CAN-05-1003
   Zheng YL, 2010, BREAST CANCER RES TR, V120, P769, DOI 10.1007/s10549-009-0440-z
   Zheng YL, 2009, CARCINOGENESIS, V30, P1380, DOI 10.1093/carcin/bgp151
NR 48
TC 19
Z9 23
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JAN 15
PY 2011
VL 20
IS 2
BP 378
EP 386
DI 10.1093/hmg/ddq461
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 698XA
UT WOS:000285626900016
PM 20956286
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Allegrucci, C
   Rushton, MD
   Dixon, JE
   Sottile, V
   Shah, M
   Kumari, R
   Watson, S
   Alberio, R
   Johnson, AD
AF Allegrucci, Cinzia
   Rushton, Michael D.
   Dixon, James E.
   Sottile, Virginie
   Shah, Mansi
   Kumari, Rajendra
   Watson, Sue
   Alberio, Ramiro
   Johnson, Andrew D.
TI Epigenetic reprogramming of breast cancer cells with oocyte extracts
SO MOLECULAR CANCER
LA English
DT Article
ID EMBRYONIC STEM-CELLS; HUMAN SOMATIC-CELLS; DNA METHYLATION;
   MELANOMA-CELLS; URODELE AMPHIBIANS; GENOME; GENES; MICROENVIRONMENTS;
   DEMETHYLATION; SPECIFICATION
AB Background: Breast cancer is a disease characterised by both genetic and epigenetic alterations. Epigenetic silencing of tumour suppressor genes is an early event in breast carcinogenesis and reversion of gene silencing by epigenetic reprogramming can provide clues to the mechanisms responsible for tumour initiation and progression. In this study we apply the reprogramming capacity of oocytes to cancer cells in order to study breast oncogenesis.
   Results: We show that breast cancer cells can be directly reprogrammed by amphibian oocyte extracts. The reprogramming effect, after six hours of treatment, in the absence of DNA replication, includes DNA demethylation and removal of repressive histone marks at the promoters of tumour suppressor genes; also, expression of the silenced genes is re-activated in response to treatment. This activity is specific to oocytes as it is not elicited by extracts from ovulated eggs, and is present at very limited levels in extracts from mouse embryonic stem cells. Epigenetic reprogramming in oocyte extracts results in reduction of cancer cell growth under anchorage independent conditions and a reduction in tumour growth in mouse xenografts.
   Conclusions: This study presents a new method to investigate tumour reversion by epigenetic reprogramming. After testing extracts from different sources, we found that axolotl oocyte extracts possess superior reprogramming ability, which reverses epigenetic silencing of tumour suppressor genes and tumorigenicity of breast cancer cells in a mouse xenograft model. Therefore this system can be extremely valuable for dissecting the mechanisms involved in tumour suppressor gene silencing and identifying molecular activities capable of arresting tumour growth. These applications can ultimately shed light on the contribution of epigenetic alterations in breast cancer and advance the development of epigenetic therapies.
C1 [Allegrucci, Cinzia; Rushton, Michael D.; Dixon, James E.; Sottile, Virginie; Alberio, Ramiro; Johnson, Andrew D.] Univ Nottingham, Ctr Genet & Genom, Sch Biol, Queens Med Ctr, Nottingham NG2 2UH, England.
   [Allegrucci, Cinzia; Shah, Mansi] Univ Nottingham, Sch Vet Med & Sci, Loughborough LE12 5RD, Leics, England.
   [Sottile, Virginie] Univ Nottingham, Sch Clin Sci, Wolfson Ctr Stem Cells Tissue Engn & Modelling, Nottingham NG7 2RD, England.
   [Kumari, Rajendra; Watson, Sue] Univ Nottingham, Div Preclin Oncol, Sch Clin Sci, Nottingham NG2 2UH, England.
   [Alberio, Ramiro] Univ Nottingham, Sch Biosci, Loughborough LE12 5RD, Leics, England.
C3 University of Nottingham; University of Nottingham; University of
   Nottingham; University of Nottingham; University of Nottingham
RP Allegrucci, C (通讯作者)，Univ Nottingham, Ctr Genet & Genom, Sch Biol, Queens Med Ctr, Nottingham NG2 2UH, England.
EM cinzia.allegrucci@nottingham.ac.uk; andrew.d.johnson@nottingham.ac.uk
RI Allegrucci, Cinzia/A-6110-2009; Shah, Mansi/S-6774-2019; Alberio,
   Ramiro/G-5955-2011
OI Dixon, James/0000-0003-1225-3825; Shah, Mansi/0009-0006-6796-7664;
   Alberio, Ramiro/0000-0001-6560-3919; Chatfield,
   Jodie/0009-0005-8166-5083; Allegrucci, Cinzia/0000-0001-8517-2423;
   Johnson, Andrew/0000-0002-5183-2072
FU EvoCell Ltd., Nottingham, UK; Evocell Ltd.; MRC [G0700078, G1100025,
   G0900147] Funding Source: UKRI
FX We thank Jodie Chatfield and Ceri Allen for valuable technical support.
   We acknowledge Peter Brown for his assistance with histopathology. We
   thank Peter Andrews for donating the NTERA2 cells. This work was
   supported by EvoCell Ltd., Nottingham, UK.This work was funded by
   Evocell Ltd. RA and ADJ are share holders of Evocell Ltd.
CR Alberio R, 2005, EXP CELL RES, V307, P131, DOI 10.1016/j.yexcr.2005.02.028
   Alberio R, 2006, REPRODUCTION, V132, P709, DOI 10.1530/rep.1.01077
   Allegrucci C, 2007, HUM MOL GENET, V16, P1253, DOI 10.1093/hmg/ddm074
   Ayuzawa R, 2009, CANCER LETT, V280, P31, DOI 10.1016/j.canlet.2009.02.011
   Bachvarova RF, 2009, EVOL DEV, V11, P603, DOI 10.1111/j.1525-142X.2009.00366.x
   Bian YH, 2009, EPIGENETICS-US, V4, P194, DOI 10.4161/epi.4.3.8787
   Blelloch RH, 2004, P NATL ACAD SCI USA, V101, P13985, DOI 10.1073/pnas.0405015101
   BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0
   Bru T, 2008, EXP CELL RES, V314, P2634, DOI 10.1016/j.yexcr.2008.05.009
   Bui HT, 2008, DEVELOPMENT, V135, P3935, DOI 10.1242/dev.023747
   Clark SJ, 2007, HUM MOL GENET, V16, pR88, DOI 10.1093/hmg/ddm051
   Cucina A, 2006, APOPTOSIS, V11, P1617, DOI 10.1007/s10495-006-8895-4
   Díez-Torre A, 2009, INT J DEV BIOL, V53, P1563, DOI 10.1387/ijdb.093021ad
   Dixon JE, 2010, DEVELOPMENT, V137, P2973, DOI 10.1242/dev.049262
   Hajkova P, 2010, SCIENCE, V329, P78, DOI 10.1126/science.1187945
   Hansis C, 2004, CURR BIOL, V14, P1475, DOI 10.1016/j.cub.2004.08.031
   Hendrix MJC, 2007, NAT REV CANCER, V7, P246, DOI 10.1038/nrc2108
   Hinshelwood RA, 2008, J MOL MED, V86, P1315, DOI 10.1007/s00109-008-0386-3
   Hochedlinger K, 2004, GENE DEV, V18, P1875, DOI 10.1101/gad.1213504
   Jeter CR, 2009, STEM CELLS, V27, P993, DOI 10.1002/stem.29
   Johnson AD, 2003, EVOL DEV, V5, P414, DOI 10.1046/j.1525-142X.2003.03048.x
   Johnson AD, 2003, PHILOS T ROY SOC B, V358, P1371, DOI 10.1098/rstb.2003.1331
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Kulesa PM, 2006, P NATL ACAD SCI USA, V103, P3752, DOI 10.1073/pnas.0506977103
   Lee LMJ, 2005, DEV DYNAM, V233, P1560, DOI 10.1002/dvdy.20471
   Li L, 2003, CANCER RES, V63, P2733
   Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879
   McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481
   MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585
   Miyamoto K, 2009, BIOL REPROD, V80, P935, DOI 10.1095/biolreprod.108.073676
   Miyoshi N, 2010, P NATL ACAD SCI USA, V107, P40, DOI 10.1073/pnas.0912407107
   Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977
   Postovit LM, 2008, P NATL ACAD SCI USA, V105, P4329, DOI 10.1073/pnas.0800467105
   Sadikovic B, 2008, CURR GENOMICS, V9, P394, DOI 10.2174/138920208785699580
   Simonsson S, 2004, NAT CELL BIOL, V6, P984, DOI 10.1038/ncb1176
   Swiers G, 2010, DEV BIOL, V343, P138, DOI 10.1016/j.ydbio.2010.04.002
   Taranger CK, 2005, MOL BIOL CELL, V16, P5719, DOI 10.1091/mbc.e05-06-0572
   Telerman A, 2009, NAT REV CANCER, V9, P206, DOI 10.1038/nrc2589
   Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233
   Utikal J, 2009, J CELL SCI, V122, P3502, DOI 10.1242/jcs.054783
   Wierstra I, 2008, BIOCHEM BIOPH RES CO, V372, P1, DOI 10.1016/j.bbrc.2008.03.074
   Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0
NR 43
TC 50
Z9 58
U1 0
U2 19
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD JAN 13
PY 2011
VL 10
AR 7
DI 10.1186/1476-4598-10-7
PG 14
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 720RV
UT WOS:000287298800001
PM 21232089
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Carter, TC
   Pangilinan, F
   Troendle, JF
   Molloy, AM
   VanderMeer, J
   Mitchell, A
   Kirke, PN
   Conley, MR
   Shane, B
   Scott, JM
   Brody, LC
   Mills, JL
AF Carter, Tonia C.
   Pangilinan, Faith
   Troendle, James F.
   Molloy, Anne M.
   VanderMeer, Julia
   Mitchell, Adam
   Kirke, Peadar N.
   Conley, Mary R.
   Shane, Barry
   Scott, John M.
   Brody, Lawrence C.
   Mills, James L.
TI Evaluation of 64 Candidate Single Nucleotide Polymorphisms as Risk
   Factors for Neural Tube Defects in a Large Irish Study Population
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A
LA English
DT Article
DE congenital abnormalities; folic acid; neural tube defects; single
   nucleotide polymorphism; spina bifida
ID SPINA-BIFIDA MENINGOMYELOCELE; ALPHA-RECEPTOR; BREAST-CANCER; HUMAN T;
   ASSOCIATION; GENE; GENOTYPE; METABOLISM; PREVENTION; MUTATIONS
AB Individual studies of the genetics of neural tube defects (NTDs) contain results on a small number of genes in each report. To identify genetic risk factors for NTDs, we evaluated potentially functional single nucleotide polymorphisms (SNPs) that are biologically plausible risk factors for NTDs but that have never been investigated for an association with NTDs, examined SNPs that previously showed no association with NTDs in published studies, and tried to confirmpreviously reported associations in folate-related and non-folate-related genes. We investigated 64 SNPs in 34 genes for association with spina bifida in up to 558 case families (520 cases, 507 mothers, 457 fathers) and 994 controls in Ireland. Case-control and mother-control comparisons of genotype frequencies, tests of transmission disequilibrium, and log-linear regression models were used to calculate effect estimates. Spina bifida was associated with over-transmission of the LEPR (leptin receptor) rs1805134 minor C allele [genotype relative risk (GRR): 1.5; 95% confidence interval (CI): 1.0-2.1; P=0.0264] and the COMT (catechol-O-methyltransferase) rs737865 major T allele (GRR: 1.4; 95% CI: 1.1-2.0; P=0.0206). After correcting for multiple comparisons, these individual test P-values exceeded 0.05. Consistent with previous reports, spina bifida was associated with MTHFR 677C> T, T (Brachyury) rs3127334, LEPR K109R, and PDGFRA promoter haplotype combinations. The associations between LEPR SNPs and spina bifida suggest a possible mechanism for the finding that obesity is a NTD risk factor. The association between a variant in COMT and spina bifida implicates methylation and epigenetics in NTDs. (C) 2010 Wiley-Liss, Inc.
C1 [Carter, Tonia C.; Troendle, James F.; Conley, Mary R.; Mills, James L.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Epidemiol Stat & Prevent Res, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA.
   [Pangilinan, Faith; VanderMeer, Julia; Mitchell, Adam; Brody, Lawrence C.] NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA.
   [Molloy, Anne M.; Scott, John M.] Trinity Coll Dublin, Sch Immunol & Biochem, Dublin, Ireland.
   [Kirke, Peadar N.] Hlth Res Board Ireland, Child Hlth Epidemiol Unit, Dublin, Ireland.
   [Shane, Barry] Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA.
C3 National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver
   National Institute of Child Health & Human Development (NICHD); National
   Institutes of Health (NIH) - USA; NIH National Human Genome Research
   Institute (NHGRI); Trinity College Dublin; Health Research Board -
   Ireland; University of California System; University of California
   Berkeley
RP Carter, TC (通讯作者)，Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Epidemiol Stat & Prevent Res, NIH, Dept Hlth & Human Serv, 6100 Execut Blvd,Room 7B03C,MSC 7510, Bethesda, MD 20892 USA.
EM carterto@mail.nih.gov
OI Strel'nikova, Maria/0009-0007-2542-8280; Molloy,
   Anne/0000-0002-1688-9049; Mills, James/0000-0003-4496-332X
FU National Institutes of Health; Eunice Kennedy Shriver National Institute
   of Child Health and Human Development; National Human Genome Research
   Institute
FX Grant sponsor: Intramural Research Programs of the National Institutes
   of Health, Eunice Kennedy Shriver National Institute of Child Health and
   Human Development, and the National Human Genome Research Institute.
CR Au KS, 2005, AM J MED GENET A, V139A, P194, DOI 10.1002/ajmg.a.31002
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Brody LC, 1999, MOL GENET METAB, V67, P324, DOI 10.1006/mgme.1999.2881
   Chen ZS, 2003, CANCER RES, V63, P4048
   Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0
   CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602
   Davidson CM, 2008, REPROD SCI, V15, P51, DOI 10.1177/1933719107309590
   Deak KL, 2005, BIRTH DEFECTS RES A, V73, P868, DOI 10.1002/bdra.20183
   Feuchtbaum LB, 1999, GENET TEST, V3, P265, DOI 10.1089/109065799316572
   Goodman JE, 2001, CARCINOGENESIS, V22, P1661, DOI 10.1093/carcin/22.10.1661
   Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191
   HERRMANN BG, 1991, DEVELOPMENT, V113, P913
   Jensen LE, 2006, AM J MED GENET A, V140A, P1114, DOI 10.1002/ajmg.a.31212
   Jensen LE, 2005, BIRTH DEFECTS RES A, V73, P512, DOI 10.1002/bdra.20143
   Joosten PHLJ, 2001, NAT GENET, V27, P215, DOI 10.1038/84867
   King TM, 2007, ANN HUM GENET, V71, P719, DOI 10.1111/j.1469-1809.2007.00377.x
   KIRKE PN, 1993, Q J MED, V86, P703
   Kirke PN, 2004, BRIT MED J, V328, P1535, DOI 10.1136/bmj.38036.646030.EE
   Lavigne JA, 1997, CANCER RES, V57, P5493
   McDonnell RJ, 1999, J EPIDEMIOL COMMUN H, V53, P782, DOI 10.1136/jech.53.12.782
   MILLS JL, 1995, LANCET, V345, P149, DOI 10.1016/S0140-6736(95)90165-5
   Mitchell A, 2009, BIRTH DEFECTS RES A, V85, P156, DOI 10.1002/bdra.20520
   Morrison K, 1996, HUM MOL GENET, V5, P669, DOI 10.1093/hmg/5.5.669
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Olshan AF, 2005, AM J MED GENET A, V135A, P268, DOI 10.1002/ajmg.a.30713
   Pangilinan F, 2010, J MED GENET, V47, P677, DOI 10.1136/jmg.2009.073775
   Parle-McDermott A, 2003, J HUM GENET, V48, P190, DOI 10.1007/s10038-003-0008-4
   Richter B, 2002, J Med Genet, V39, pE14, DOI 10.1136/jmg.39.3.e14
   Roessler E, 2009, HUM MUTAT, V30, pE541, DOI 10.1002/humu.20982
   Sebold CD, 2005, GENET MED, V7, P64, DOI 10.1097/01.GIM.0000151158.09278.2B
   Shaw GM, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-49
   Shaw GM, 2000, TERATOLOGY, V61, P231, DOI 10.1002/(SICI)1096-9926(200003)61:3<231::AID-TERA11>3.0.CO;2-L
   Shields DC, 1999, AM J HUM GENET, V64, P1045, DOI 10.1086/302310
   Shields DC, 2000, AM J MED GENET, V92, P206
   Soriano P, 1997, DEVELOPMENT, V124, P2691
   Speer MC, 2002, AM J MED GENET, V110, P215, DOI 10.1002/ajmg.10436
   Toepoel M, 2009, BIRTH DEFECTS RES A, V85, P629, DOI 10.1002/bdra.20574
   Tunbridge EM, 2008, AM J MED GENET B, V147B, P996, DOI 10.1002/ajmg.b.30700
   WALD N, 1991, LANCET, V338, P131
   WALLER DK, 1994, AM J OBSTET GYNECOL, V170, P541, DOI 10.1016/S0002-9378(94)70224-1
   WINDHAM GC, 1982, AM J HUM GENET, V34, P988
   Zhu FP, 2004, MOL GENET METAB, V81, P127, DOI 10.1016/j.ymgme.2003.11.003
NR 42
TC 28
Z9 31
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4825
EI 1552-4833
J9 AM J MED GENET A
JI Am. J. Med. Genet. A
PD JAN
PY 2011
VL 155A
IS 1
BP 14
EP 21
DI 10.1002/ajmg.a.33755
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 702IZ
UT WOS:000285889100003
PM 21204206
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Chow, KHM
   Liu, J
   Sun, RWY
   Vanhoutte, PM
   Xu, AM
   Chen, J
   Che, CM
   Wang, Y
AF Chow, Kim Hei-Man
   Liu, Jing
   Sun, Raymond Wai-Yin
   Vanhoutte, Paul M.
   Xu, Aimin
   Chen, Jie
   Che, Chi-Ming
   Wang, Yu
TI The gold (III) porphyrin complex, gold-2a, suppresses <i>WNT1</i>
   expression in breast cancer cells by enhancing the promoter association
   of YY1
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Gold(III) porphyrin complex; anti-cancer drug; WNT1; YY1; breast cancer
AB The gold (III) porphyrin complex, gold-2a, elicits anti-tumor activity by targeting the Wnt/beta-catenin signaling pathway [Chow KH et al, Cancer Research 2010;70(1):329-37]. Here, the molecular mechanisms underlying the inhibitory effects of this compound on WNT1 gene expression were elucidated further. A response element to gold-2a was identified located within the -1290 to -1112 nt region of the WNT1 promoter, containing a binding site for the transcription regulator Yin Yang 1 (YY1). Gold-2a promoted the association of YY1 and suppressor of zeste 12 (Suz12; a component of the polycomb repressor complex 2) with the WNT1 promoter. Under normal culture conditions, the intracellular translocalization of YY1 was synchronized with cell cycle progression and WNT1 expression. Gold-2a promoted the nuclear accumulation and abolished the nuclear exportation of YY1, resulting in a persistent inhibition of WNT1 expression and a cell cycle arrest at G1/S phase. A dimorphic role of YY1 in regulating cell proliferation and division was revealed. Thus, the present study extends the understanding of the anti-tumor mechanism of gold-2a to the epigenetic level, which involves the modulation of the dynamic interactions between YY1 and a specific region of the WNT1 promoter.
C1 [Chow, Kim Hei-Man; Liu, Jing; Vanhoutte, Paul M.; Xu, Aimin; Chen, Jie; Wang, Yu] Univ Hong Kong, Dept Pharmacol & Pharm, Pokfulam, Hong Kong, Peoples R China.
   [Sun, Raymond Wai-Yin; Che, Chi-Ming; Wang, Yu] Univ Hong Kong, Dept Chem, Pokfulam, Hong Kong, Peoples R China.
   [Sun, Raymond Wai-Yin; Che, Chi-Ming; Wang, Yu] Univ Hong Kong, Inst Mol Technol Drug Discovery & Synth, Open Lab Chem Biol, Pokfulam, Hong Kong, Peoples R China.
C3 University of Hong Kong; University of Hong Kong; University of Hong
   Kong
RP Wang, Y (通讯作者)，Fac Med Bldg, Dept Pharmacol & Pharm, 21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.
EM cmche@hku.hk; yuwanghk@hku.hk
RI Wang, Yu/B-4534-2009; Sun, Raymond/D-3165-2009; Chow,
   Hei-Man/LFR-9773-2024
OI wang, yu/0000-0001-8697-2940; Chow, Hei-Man/0000-0003-1203-2096
FU Seed Funding for Basic Research of the HKU; Hong Kong Research Grant
   Council [HKU 777908M]; Area of Excellent Scheme under University Grants
   Committee, HKSAR [AoE/P-10-01]
FX This work was supported by the grants from Seed Funding for Basic
   Research of the HKU (Y. Wang), Hong Kong Research Grant Council grants
   HKU 777908M (Y. Wang), and the Area of Excellent Scheme (AoE/P-10-01)
   established under University Grants Committee, HKSAR (C.-M. Che).
CR Affar E, 2006, MOL CELL BIOL, V26, P3565, DOI 10.1128/MCB.26.9.3565-3581.2006
   Alberici P, 2006, GENOME DYN, V1, P149, DOI 10.1159/000092506
   Allouche A, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1851
   Aoki K, 2007, ONCOGENE, V26, P3511, DOI 10.1038/sj.onc.1210141
   Baritaki S, 2007, MOL CANCER THER, V6, P1387, DOI 10.1158/1535-7163.MCT-06-0521
   Bruijnincx PCA, 2008, CURR OPIN CHEM BIOL, V12, P197, DOI 10.1016/j.cbpa.2007.11.013
   Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473
   Casini A, 2008, J INORG BIOCHEM, V102, P564, DOI 10.1016/j.jinorgbio.2007.11.003
   Castellano G, 2009, CELL CYCLE, V8, P1367, DOI 10.4161/cc.8.9.8314
   Che CM, 2003, CHEM COMMUN, P1718, DOI 10.1039/b303294a
   Chen D, 2009, CURR PHARM DESIGN, V15, P777, DOI 10.2174/138161209787582183
   Chow KHM, 2010, CANCER RES, V70, P329, DOI 10.1158/0008-5472.CAN-09-3324
   Coronnello M, 2005, J MED CHEM, V48, P6761, DOI 10.1021/jm050493o
   Danielian PS, 1997, DEV BIOL, V192, P300, DOI 10.1006/dbio.1997.8762
   ECHELARD Y, 1994, DEVELOPMENT, V120, P2213
   Fenby BT, 2008, BBA-GENE REGUL MECH, V1779, P115, DOI 10.1016/j.bbagrm.2007.11.008
   Gordon S, 2006, ONCOGENE, V25, P1125, DOI 10.1038/sj.onc.1209080
   Hadjihannas MV, 2006, CELL CYCLE, V5, P2077, DOI 10.4161/cc.5.18.3282
   Hadjihannas MV, 2006, P NATL ACAD SCI USA, V103, P10747, DOI 10.1073/pnas.0604206103
   Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362
   ILER N, 1995, MECH DEVELOP, V53, P87, DOI 10.1016/0925-4773(95)00427-0
   Kaldis P, 2009, DEV CELL, V17, P749, DOI 10.1016/j.devcel.2009.12.001
   Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204
   Lagutin OV, 2003, GENE DEV, V17, P368, DOI 10.1101/gad.1059403
   Lieberthal JG, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2329
   Lucero OM, 2010, CURR ONCOL REP, V12, P314, DOI 10.1007/s11912-010-0114-3
   Lum CT, 2006, INT J CANCER, V118, P1527, DOI 10.1002/ijc.21484
   Matsumura N, 2009, MOL CANCER RES, V7, P210, DOI 10.1158/1541-7786.MCR-08-0255
   Milacic V, 2008, HISTOL HISTOPATHOL, V23, P101, DOI 10.14670/HH-23.101
   Nobili S, 2010, MED RES REV, V30, P550, DOI 10.1002/med.20168
   NUSSE R, 1990, MOL CELL BIOL, V10, P4170, DOI 10.1128/MCB.10.8.4170
   NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3
   Palko L, 2004, J CELL SCI, V117, P465, DOI 10.1242/jcs.00870
   Powe DG, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2461
   Rowitch DH, 1998, DEVELOPMENT, V125, P2735
   SCHUURING E, 1989, MOL CELL BIOL, V9, P1357, DOI 10.1128/MCB.9.3.1357
   Shaw CF, 1999, CHEM REV, V99, P2589, DOI 10.1021/cr980431o
   Squazzo SL, 2006, GENOME RES, V16, P890, DOI 10.1101/gr.5306606
   STARNAUD R, 1993, MOL CELL BIOL, V13, P1590, DOI 10.1128/MCB.13.3.1590
   Sun RWY, 2010, CHEM-EUR J, V16, P3097, DOI 10.1002/chem.200902741
   Tiekink E. R. T., 2008, Inflammopharmacology, V16, P138, DOI 10.1007/s10787-007-0018-5
   To YF, 2009, INT J CANCER, V124, P1971, DOI 10.1002/ijc.24130
   Vega MI, 2005, ONCOGENE, V24, P8114, DOI 10.1038/sj.onc.1208954
   Wang Y, 2005, CANCER RES, V65, P11553, DOI 10.1158/0008-5472.CAN-05-2867
   Wang Y, 2008, BIOCHEM PHARMACOL, V75, P1282, DOI 10.1016/j.bcp.2007.11.024
   Wang Y, 2006, CANCER RES, V66, P11462, DOI 10.1158/0008-5472.CAN-06-1969
   Wasserman WW, 2004, NAT REV GENET, V5, P276, DOI 10.1038/nrg1315
   Wilkinson FH, 2006, P NATL ACAD SCI USA, V103, P19296, DOI 10.1073/pnas.0603564103
   Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001
   Zaravinos A, 2010, CELL CYCLE, V9, P512, DOI 10.4161/cc.9.3.10588
   Zhang CX, 2003, CURR OPIN CHEM BIOL, V7, P481, DOI 10.1016/S1367-5931(03)00081-4
   Zhu ED, 2008, J BIOL CHEM, V283, P7361, DOI 10.1074/jbc.M703304200
NR 52
TC 5
Z9 6
U1 1
U2 4
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2011
VL 3
IS 5
BP 479
EP U120
PG 16
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA V28QI
UT WOS:000208694900007
PM 22046489
DA 2025-01-12
ER

PT J
AU Berner, C
   Aumüller, E
   Gnauck, A
   Nestelberger, M
   Just, A
   Haslberger, AG
AF Berner, Carolin
   Aumueller, Eva
   Gnauck, Anne
   Nestelberger, Manuela
   Just, A.
   Haslberger, Alexander G.
TI Epigenetic Control of Estrogen Receptor Expression and Tumor Suppressor
   Genes Is Modulated by Bioactive Food Compounds
SO ANNALS OF NUTRITION AND METABOLISM
LA English
DT Article
DE Estrogen receptor-alpha; Estrogen receptor-beta; p15; p16; DNA
   methylation; Resveratrol; Genistein; Folic acid;
   Epigallocatechin-3-gallate; Epigenetic mechanisms; Colon cancer
ID COLON-CANCER CELLS; DE-NOVO METHYLATION; DNA METHYLATION; CPG ISLAND;
   COLORECTAL-CANCER; DIETARY-FOLATE; ER-BETA; BREAST-CANCER; NEOPLASIA;
   GENISTEIN
AB Background: The tumor suppressor genes p15(INK4b) and p16(INK4a) as well as the estrogen receptor-alpha (ESR1) gene are abnormally methylated and expressed in colon cancer. The cancer-preventative abilities of several bioactive food components have been linked to their estrogenic and epigenetic activities. Methods: The effect of folic acid, zebularine, resveratrol, genistein and epigallocatechin-3-gallate (EGCG) on tumor cell growth, promoter methylation of ESR1, p15(INK4b) and p16(INK4a) and gene expression of ESR1 and ESR2 was analyzed in Caco-2 cells. Gene expression was measured using real-time PCR, and promoter CpG methylation was assessed using bisulfite conversion and methylation-specific PCR. Results: After exposure to a high concentration of folic acid (20 mu mol/l), enhanced cancer cell growth and concomitant increased methylation of the ESR1 (3.6-fold), p16(INK4a) and p15(INK4b) promoters was observed. A lower concentration of folic acid (2 mu mol/l) decreased cell growth. The phytoestrogens genistein and resveratrol enhanced expression of ESR1 (genistein 200 mu mol/l: 2.1-fold; resveratrol 50 mu mol/l: 6.3-fold) and ESR2 (2.6- and 3.6-fold, respectively). Genistein and resveratrol treatment increased promoter methylation of ESR1 (genistein 200 mu mol/l: 2.9-fold; resveratrol 50 mu mol/l: 1.4-fold). For p16(INK4a), increased methylation was found after exposure to 10 mu mol/l resveratrol, but for p15(INK4b), decreased methylation was found. Both components showed growth-inhibitory activities. For EGCG, growth inhibition at 100 mu mol/l and suppressed promoter methylation of tumor suppressor genes (p16(INK4a): 0.9-fold; p15(INK4b): 0.6-fold) was seen. Conclusions: Our results show that these food compounds regulate ESR and tumor suppressor gene expression by multiple mechanisms including epigenetic processes. An improved understanding of these epigenetic effects could therefore support specific dietary concepts of epigenetic cancer prevention and intervention. Copyright (C) 2010 S. Karger AG, Basel
C1 [Berner, Carolin; Aumueller, Eva; Gnauck, Anne; Nestelberger, Manuela; Haslberger, Alexander G.] Univ Vienna, Dept Nutr Sci, AT-1090 Vienna, Austria.
   [Just, A.] Med Univ Vienna, Dept Obstet & Gynecol, Vienna, Austria.
C3 University of Vienna; Medical University of Vienna
RP Haslberger, AG (通讯作者)，Univ Vienna, Dept Nutr Sci, Althanstr 14,UZAII,2D 541, AT-1090 Vienna, Austria.
EM alexander.haslberger@unvie.ac.at
RI Haslberger, Alexander/B-9120-2013
OI Haslberger, Alexander/0000-0001-9699-537X
CR Arai N, 2000, BIOCHEM BIOPH RES CO, V270, P425, DOI 10.1006/bbrc.2000.2444
   Auerkari EI, 2006, ORAL ONCOL, V42, P5, DOI 10.1016/j.oraloncology.2005.03.016
   Balestrieri ML, 2008, J BIOCHEM, V143, P179, DOI 10.1093/jb/mvm209
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Belshaw NJ, 2005, BIOCHEM SOC T, V33, P709, DOI 10.1042/BST0330709
   Berletch JB, 2008, J CELL BIOCHEM, V103, P509, DOI 10.1002/jcb.21417
   Butt MS, 2009, CRIT REV FOOD SCI, V49, P463, DOI 10.1080/10408390802145310
   Chen AC, 2004, J NUTR, V134, P1303, DOI 10.1093/jn/134.6.1303
   Choi KC, 2009, CANCER RES, V69, P583, DOI 10.1158/0008-5472.CAN-08-2442
   Cleveland AG, 2009, CARCINOGENESIS, V30, P1581, DOI 10.1093/carcin/bgp132
   Collins F, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-330
   Cui XL, 2010, CANCER PREV RES, V3, P549, DOI 10.1158/1940-6207.CAPR-09-0117
   Delcuve GP, 2009, J CELL PHYSIOL, V219, P243, DOI 10.1002/jcp.21678
   Fang MZ, 2007, J NUTR, V137, p223S, DOI 10.1093/jn/137.1.223S
   Fang MZ, 2005, CLIN CANCER RES, V11, P7033, DOI 10.1158/1078-0432.CCR-05-0406
   Feng Jing, 2009, Ai Zheng, V28, P436
   Foley EF, 2000, CANCER RES, V60, P245
   Goodin MG, 2002, TOXICOL SCI, V69, P354, DOI 10.1093/toxsci/69.2.354
   Goto T, 2009, ANTICANCER RES, V29, P275
   Herman JG, 1996, CANCER RES, V56, P722
   Hinshelwood RA, 2009, HUM MOL GENET, V18, P3098, DOI 10.1093/hmg/ddp251
   Ishiguro A, 2006, J GASTROEN HEPATOL, V21, P1334, DOI 10.1111/j.1440-1746.2006.04137.x
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Jefferson WN, 2002, BIOL REPROD, V67, P1285, DOI 10.1095/biolreprod67.4.1285
   Johnson IT, 2008, FOOD CHEM TOXICOL, V46, P1346, DOI 10.1016/j.fct.2007.09.101
   Kikuno N, 2008, INT J CANCER, V123, P552, DOI 10.1002/ijc.23590
   Kim YI, 1996, GUT, V39, P732, DOI 10.1136/gut.39.5.732
   Kressler D, 2002, J BIOL CHEM, V277, P13918, DOI 10.1074/jbc.M201134200
   Lamb J, 2000, MOL CELL BIOL, V20, P8667, DOI 10.1128/MCB.20.23.8667-8675.2000
   Lambert JD, 2006, DRUG METAB DISPOS, V34, P8, DOI 10.1124/dmd.104.003434
   Lee S, 2004, LAB INVEST, V84, P884, DOI 10.1038/labinvest.3700108
   Li YY, 2009, INT J CANCER, V125, P286, DOI 10.1002/ijc.24398
   Marquez VE, 2005, ANN NY ACAD SCI, V1058, P246, DOI 10.1196/annals.1359.037
   McCafferty MPJ, 2009, BREAST CANCER RES TR, V116, P425, DOI 10.1007/s10549-009-0429-7
   Ng MHL, 1997, BLOOD, V89, P2500, DOI 10.1182/blood.V89.7.2500
   Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465
   Qin Wenyi, 2005, Proceedings of the American Association for Cancer Research Annual Meeting, V46, P647
   Rody A, 2005, ENDOCR-RELAT CANCER, V12, P903, DOI 10.1677/erc.1.01088
   Ross SA, 2002, J NUTR, V132, p2329S, DOI 10.1093/jn/132.8.2329S
   Sambuy Y, 2005, CELL BIOL TOXICOL, V21, P1, DOI 10.1007/s10565-005-0085-6
   Schwartz B, 1998, MOL CELL BIOCHEM, V188, P21, DOI 10.1023/A:1006831330340
   Shen RL, 2009, INT J CLIN EXP PATHO, V2, P21
   Song J, 2000, CANCER RES, V60, P3191
   Stöger R, 2008, PHARMACOGENOMICS, V9, P1851, DOI 10.2217/14622416.9.12.1851
   Tanner KG, 2000, BIOCHEMISTRY-US, V39, P15652, DOI 10.1021/bi005121q
   Thompson LU, 2006, NUTR CANCER, V54, P184, DOI 10.1207/s15327914nc5402_5
   Trasler J, 2003, CARCINOGENESIS, V24, P39, DOI 10.1093/carcin/24.1.39
   Trincheri NF, 2007, CARCINOGENESIS, V28, P922, DOI 10.1093/carcin/bgl223
   Wakeling LA, 2009, AGE DORDR
   Weyant MJ, 2001, CANCER RES, V61, P2547
   Woodson K, 2005, CANCER EPIDEM BIOMAR, V14, P1219, DOI 10.1158/1055-9965.EPI-04-0726
NR 51
TC 50
Z9 53
U1 0
U2 12
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0250-6807
EI 1421-9697
J9 ANN NUTR METAB
JI Ann. Nutr. Metab.
PD JAN
PY 2011
VL 57
IS 3-4
BP 183
EP 189
DI 10.1159/000321514
PG 7
WC Endocrinology & Metabolism; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 709FI
UT WOS:000286422900005
PM 21088384
DA 2025-01-12
ER

PT J
AU Freiss, G
   Chalbos, D
AF Freiss, Gilles
   Chalbos, Dany
TI <i>PTPN13</i>/PTPL1: An Important Regulator of Tumor Aggressiveness
SO ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
LA English
DT Article
DE Cancer; Fas; Her2; Human papillomavirus 16; IRS-1; PTPN13; PTPL1; Src
ID PROTEIN-TYROSINE-PHOSPHATASE; FAS-MEDIATED APOPTOSIS; BREAST-CANCER
   CELLS; HUMAN HEPATOCELLULAR-CARCINOMA; ANCHORAGE-INDEPENDENT GROWTH;
   SUPPRESSOR GENE PTPN13/PTPL1; ZYXIN-RELATED PROTEIN; DOMAIN BINDING
   MOTIF; HUMAN OVARIAN-CANCER; KAPPA-B ACTIVATION
AB Protein tyrosine phosphorylation plays a major role in many cellular functions implicated in cancer development and progression, but only a few of the known protein tyrosine phosphatases have yet been clearly classified as oncogenes or tumor suppressors. PTPL1 interacts with tumor-associated proteins, suggesting a link between PTPL1, the PTPN13 gene product, and tumorigenesis or cancer progression. However, the impact of PTPL1 on cancer is divided between its capacity to counteract the activity of oncogenic tyrosine kinases and its inhibitory interaction with the death receptor, Fas. In this manuscript, we review the PTPL1-interacting proteins implicated in cancer. In addition, we examine the phenotypic arguments concerning both the PTPL1/Fas interaction and the ability of PTPL1 to inhibit signaling from growth factor receptors or oncogenes with tyrosine kinase activity. Finally, we compare the alterations in expression and the genetic and epigenetic arguments supporting an oncogenic or an anti-oncogenic impact of PTPL1.
C1 [Freiss, Gilles] IRCM, F-34298 Montpellier 5, France.
   Univ Montpellier 1, F-34298 Montpellier, France.
   INSERM, U896, F-34298 Montpellier, France.
   CRLC Val dAurelle Paul Lamarque, F-34298 Montpellier, France.
C3 Universite de Montpellier; UNICANCER; Institut Regional du Cancer
   Montpellier / Val d'Aurelle (ICM); Institut National de la Sante et de
   la Recherche Medicale (Inserm); Universite de Montpellier; Universite de
   Montpellier; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UNICANCER; Universite de Montpellier; Institut Regional du
   Cancer Montpellier / Val d'Aurelle (ICM)
RP Freiss, G (通讯作者)，IRCM, F-34298 Montpellier 5, France.
EM gilles.freiss@inserm.fr
RI Freiss, Gilles/T-2057-2019
OI Freiss, Gilles/0000-0002-1943-0735
CR Abaan OD, 2005, ONCOGENE, V24, P2715, DOI 10.1038/sj.onc.1208247
   Abaan OD, 2008, CANCER METAST REV, V27, P205, DOI 10.1007/s10555-008-9114-2
   Arai M, 1998, AIDS RES HUM RETROV, V14, P261, DOI 10.1089/aid.1998.14.261
   Bai CY, 2007, J CELL SCI, V120, P2828, DOI 10.1242/jcs.03477
   BANVILLE D, 1994, J BIOL CHEM, V269, P22320
   Bompard G, 2003, J CELL SCI, V116, P2519, DOI 10.1242/jcs.00448
   Bompard G, 2002, J BIOL CHEM, V277, P47861, DOI 10.1074/jbc.M208950200
   Boumber YA, 2007, CANCER RES, V67, P1997, DOI 10.1158/0008-5472.CAN-06-3093
   Broome HE, 1998, CELL DEATH DIFFER, V5, P200, DOI 10.1038/sj.cdd.4400329
   Chastre E, 2009, FASEB J, V23, P916, DOI 10.1096/fj.08-106344
   Chaudhry P, 2010, ONCOL RES, V18, P549, DOI 10.3727/096504010X12767359113884
   Christopherson KS, 1999, J BIOL CHEM, V274, P27467, DOI 10.1074/jbc.274.39.27467
   Cuppen E, 1999, J CELL SCI, V112, P3299
   Cuppen E, 2000, EUR J CELL BIOL, V79, P283, DOI 10.1078/S0171-9335(04)70031-X
   Cuppen E, 1997, J BIOL CHEM, V272, P30215, DOI 10.1074/jbc.272.48.30215
   Cuppen E, 1998, MOL BIOL CELL, V9, P671, DOI 10.1091/mbc.9.3.671
   Dromard M, 2007, CANCER RES, V67, P6806, DOI 10.1158/0008-5472.CAN-07-0513
   Elnemr A, 2001, INT J ONCOL, V18, P311
   Erdmann KS, 2000, ONCOGENE, V19, P3894, DOI 10.1038/sj.onc.1203725
   Erdmann KS, 2003, EUR J BIOCHEM, V270, P4789, DOI 10.1046/j.1432-1033.2003.03895.x
   Fan CG, 2002, J CELL SCI, V115, P4843, DOI 10.1242/jcs.00151
   Foehr ED, 2005, J NEURO-ONCOL, V74, P241, DOI 10.1007/s11060-004-7202-x
   FREISS G, 1994, MOL ENDOCRINOL, V8, P1389, DOI 10.1210/me.8.10.1389
   Freiss G, 1998, MOL ENDOCRINOL, V12, P568, DOI 10.1210/me.12.4.568
   Freiss G, 2005, J STEROID BIOCHEM, V94, P451, DOI 10.1016/j.jsbmb.2004.12.043
   Freiss G, 2004, B CANCER, V91, P325
   Glondu-Lassis M, 2010, CANCER RES, V70, P5116, DOI 10.1158/0008-5472.CAN-09-4368
   Glondu-Lassis M, 2009, INT J BIOCHEM CELL B, V41, P2173, DOI 10.1016/j.biocel.2009.04.004
   Gross C, 2001, FEBS LETT, V496, P101, DOI 10.1016/S0014-5793(01)02401-2
   Harris BZ, 2001, J CELL SCI, V114, P3219
   Hayakawa A, 2002, APOPTOSIS, V7, P107, DOI 10.1023/A:1014302212321
   Hayashi H, 1998, APOPTOSIS, V3, P431, DOI 10.1023/A:1009662619907
   Hedlund TE, 1998, PROSTATE, V36, P92, DOI 10.1002/(SICI)1097-0045(19980701)36:2<92::AID-PROS4>3.0.CO;2-G
   Heneberg P, 2009, CURR MED CHEM, V16, P706, DOI 10.2174/092986709787458407
   Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812
   Hogan A, 2004, J BIOL CHEM, V279, P53717, DOI 10.1074/jbc.M410654200
   Hoover AC, 2009, ONCOGENE, V28, P3960, DOI 10.1038/onc.2009.251
   Houghton JA, 1997, CLIN CANCER RES, V3, P2205
   Huang WQ, 2008, J BIOL CHEM, V283, P7921, DOI 10.1074/jbc.M706710200
   Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8
   Inazawa J, 1996, GENOMICS, V31, P240, DOI 10.1006/geno.1996.0039
   Irie S, 1999, FEBS LETT, V460, P191, DOI 10.1016/S0014-5793(99)01324-1
   Ivanov VN, 2006, J BIOL CHEM, V281, P1840, DOI 10.1074/jbc.M509866200
   Ivanov VN, 2003, MOL CELL BIOL, V23, P3623, DOI 10.1128/MCB.23.10.3623-3635.2003
   Jeong EG, 2008, PATHOLOGY, V40, P31, DOI 10.1080/00313020701716441
   Jou YS, 2004, CANCER RES, V64, P3030, DOI 10.1158/0008-5472.CAN-03-2320
   Juric D, 2005, P NATL ACAD SCI USA, V102, P17763, DOI 10.1073/pnas.0509082102
   Kaminski A, 2010, BIOSCIENCE REP, V30, P169, DOI 10.1042/BSR20090021
   Kawai H, 2002, MOL CELL BIOL, V22, P6079, DOI 10.1128/MCB.22.17.6079-6088.2002
   Kawano S, 2009, J BIOL CHEM, V284, P23793, DOI 10.1074/jbc.M109.025155
   Kim KM, 2000, EXP MOL MED, V32, P246, DOI 10.1038/emm.2000.41
   Kim S, 2003, CANCER RES, V63, P4792
   Kimber WA, 2003, BIOCHEM J, V376, P525, DOI 10.1042/BJ20031154
   Komada Y, 1997, BRIT J HAEMATOL, V99, P325, DOI 10.1046/j.1365-2141.1997.3903204.x
   Lai YJ, 2005, MOL CELL BIOL, V25, P5859, DOI 10.1128/MCB.25.14.5859-5868.2005
   Lai YJ, 2007, J BIOL CHEM, V282, P24381, DOI 10.1074/jbc.M701499200
   Lee HS, 2008, NAT CELL BIOL, V10, P979, DOI 10.1038/ncb1758
   Lee SH, 1999, APMIS, V107, P1101, DOI 10.1111/j.1699-0463.1999.tb01515.x
   Lee SH, 2001, HUM PATHOL, V32, P250, DOI 10.1053/hupa.2001.22769
   Li Y, 2000, INT J CANCER, V87, P473, DOI 10.1002/1097-0215(20000815)87:4<473::AID-IJC3>3.0.CO;2-1
   Lin D, 1999, J BIOL CHEM, V274, P3726, DOI 10.1074/jbc.274.6.3726
   Liu HQ, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-51
   Lorber B, 2005, EUR J NEUROSCI, V21, P2375, DOI 10.1111/j.1460-9568.2005.04065.x
   Lucci MA, 2010, CELL ONCOL, V32, P361, DOI 10.3233/CLO-2010-0520
   Maekawa K, 1999, BIOCHEM J, V337, P179, DOI 10.1042/0264-6021:3370179
   MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4
   Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5
   Meinhold-Heerlein I, 2001, AM J PATHOL, V158, P1335, DOI 10.1016/S0002-9440(10)64084-9
   Mita Y, 2010, J CANCER RES CLIN, V136, P249, DOI 10.1007/s00432-009-0656-7
   Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011
   Miyazaki T, 2006, J GASTROEN HEPATOL, V21, P84, DOI 10.1111/j.1440-1746.2005.04155.x
   Mori S, 1996, CANCER RES, V56, P1874
   Motiwala T, 2006, PROG NUCLEIC ACID RE, V81, P297, DOI 10.1016/S0079-6603(06)81008-1
   Murthy KK, 1999, J BIOL CHEM, V274, P20679, DOI 10.1074/jbc.274.29.20679
   Myagmar BE, 2005, BIOCHEM BIOPH RES CO, V329, P1046, DOI 10.1016/j.bbrc.2005.02.069
   Nakahira M, 2007, IMMUNITY, V26, P163, DOI 10.1016/j.immuni.2007.01.010
   Niu JG, 2009, CARCINOGENESIS, V30, P2053, DOI 10.1093/carcin/bgp265
   Östman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837
   Palmer A, 2002, MOL CELL, V9, P725, DOI 10.1016/S1097-2765(02)00488-4
   Révillion F, 2009, INT J CANCER, V124, P638, DOI 10.1002/ijc.23989
   Ripperger T, 2007, HAEMATOLOGICA, V92, P460, DOI 10.3324/haematol.10337
   Sabine VS, 2010, BREAST CANCER RES TR, V122, P419, DOI 10.1007/s10549-010-0928-6
   Saras J, 1997, J BIOL CHEM, V272, P24333, DOI 10.1074/jbc.272.39.24333
   Saras J, 1997, J BIOL CHEM, V272, P20979, DOI 10.1074/jbc.272.34.20979
   SARAS J, 1994, J BIOL CHEM, V269, P24082
   Sato S, 2002, J BIOL CHEM, V277, P39360, DOI 10.1074/jbc.M205141200
   SATO T, 1991, CANCER RES, V51, P5118
   SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343
   Schickel R, 2010, MOL CELL, V38, P908, DOI 10.1016/j.molcel.2010.05.018
   Schmidt A, 2007, EMBO J, V26, P1624, DOI 10.1038/sj.emboj.7601637
   Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1
   Spanos WC, 2008, J VIROL, V82, P2493, DOI 10.1128/JVI.02188-07
   Spanos WC, 2008, HEAD NECK-J SCI SPEC, V30, P139, DOI 10.1002/hed.20673
   Takizawa N, 2006, J CELL BIOL, V174, P447, DOI 10.1083/jcb.200512051
   Tillman DM, 1998, CELL DEATH DIFFER, V5, P450, DOI 10.1038/sj.cdd.4400369
   Tonks NK, 2006, NAT REV MOL CELL BIO, V7, P833, DOI 10.1038/nrm2039
   Ungefroren H, 2001, J CELL SCI, V114, P2735
   Ungefroren H, 1998, CANCER RES, V58, P1741
   van Ham M, 2003, GENES CELLS, V8, P631, DOI 10.1046/j.1365-2443.2003.00660.x
   VIGNON F, 1987, BIOCHEM BIOPH RES CO, V146, P1502, DOI 10.1016/0006-291X(87)90819-9
   Wang Y, 2003, BBA-MOL CELL RES, V1593, P115, DOI 10.1016/S0167-4889(02)00349-X
   Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096
   Wansink DG, 2004, PHYSIOL GENOMICS, V19, P50, DOI 10.1152/physiolgenomics.00079.2004
   Welters HJ, 2008, J ENDOCRINOL, V197, P543, DOI 10.1677/JOE-07-0262
   Wieckowski E, 2007, J CELL BIOCHEM, V100, P16, DOI 10.1002/jcb.20922
   Xiao ZY, 2010, WORLD J GASTROENTERO, V16, P112, DOI 10.3748/wjg.v16.i1.112
   Yamada Y, 1999, CANCER LETT, V147, P215, DOI 10.1016/S0304-3835(99)00313-4
   Yanagisawa J, 1997, J BIOL CHEM, V272, P8539, DOI 10.1074/jbc.272.13.8539
   Yao H, 2004, BRIT J CANCER, V91, P1718, DOI 10.1038/sj.bjc.6602136
   Yeh SH, 2006, CLIN CANCER RES, V12, P1097, DOI 10.1158/1078-0432.CCR-05-1383
   Yi JS, 2002, J BIOL CHEM, V277, P9580, DOI 10.1074/jbc.M106922200
   Ying J, 2006, LEUKEMIA, V20, P1173, DOI 10.1038/sj.leu.2404193
   ZHANG WD, 1990, JPN J CANCER RES, V81, P108, DOI 10.1111/j.1349-7006.1990.tb02534.x
   Zhang WY, 2007, AM J PHYSIOL-CELL PH, V292, pC1746, DOI 10.1152/ajpcell.00569.2006
   Zhang XH, 1997, J EXP MED, V185, P1837, DOI 10.1084/jem.185.10.1837
   Zhang YJ, 2009, J CELL BIOL, V184, P785, DOI 10.1083/jcb.200810155
   Zhu JH, 2008, ONCOGENE, V27, P2525, DOI 10.1038/sj.onc.1210922
NR 117
TC 44
Z9 47
U1 0
U2 9
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1871-5206
J9 ANTI-CANCER AGENT ME
JI Anti-Cancer Agents Med. Chem.
PD JAN
PY 2011
VL 11
IS 1
BP 78
EP 88
DI 10.2174/187152011794941262
PG 11
WC Oncology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 743BW
UT WOS:000288991900008
PM 21235435
OA Green Accepted, Green Submitted
DA 2025-01-12
ER

PT J
AU Qiu, HF
   Zhu, JZ
   Yu, JJ
   Pu, H
   Dong, RF
AF Qiu, Haifeng
   Zhu, Jiezhi
   Yu, Jinjin
   Pu, Hong
   Dong, Ruofan
TI SLIT2 is Epigenetically Silenced in Ovarian Cancers and Suppresses
   Growth when Activated
SO ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
LA English
DT Article
DE Ovarian cancer; tumor suppressor gene; hypermethylation
ID RENAL-CELL CARCINOMA; TUMOR-SUPPRESSOR; PROMOTER METHYLATION; AXON
   GUIDANCE; ABERRANT METHYLATION; GENE; INACTIVATION; HYPERMETHYLATION;
   PROGRESSION; NEUROBLASTOMA
AB Objectives: The SLIT2 gene is a novel tumor suppressor gene, whose hypermethylation has been detected in several malignances, including breast cancer, colorectal carcinoma and gliomas. In this study, we assessed the status of SLIT2 and its functions in ovarian cancers and cell lines. Methods: Methylation-specific PCR was used to investigate the methylated promoter of SLIT2; the functions of SLIT2 in ovarian cancer cells were measured by MTT, colony formation assay and flow cytometry. Results: SLIT2 promoter hypermethylation was detected in 56 of 66 (84.8%) ovarian cancer samples and downregulation of SLIT2 expression in 52 (78.8%). The decreased expression was signi.cantly correlated with SLIT2 promoter hypermethylation (p<0.01). Moreover, reversed expression of SLIT2 suppressed cell growth, migration, colony formation abilities and induced more apoptosis. Conclusions: These results suggest that SLIT2 is a tumor suppressor in ovarian cancer, and may be a novel target for ovarian cancer treatment.
C1 [Qiu, Haifeng; Yu, Jinjin; Pu, Hong; Dong, Ruofan] Suzhou Univ, Affiliated Hosp 4, Dept Obstet & Gynecol, Wuxi, Peoples R China.
   [Zhu, Jiezhi] Changzhi Med Coll, Heping Hosp, Dept Obstet & Gynecol, Changzhi, Peoples R China.
C3 Soochow University - China; Changzhi Medical College
RP Qiu, HF (通讯作者)，Suzhou Univ, Affiliated Hosp 4, Dept Obstet & Gynecol, Wuxi, Peoples R China.
EM haifengqiu120@hotmail.com
FU Wuxi medical management center [YGM1016]
FX Our project was supported by grants to Qiu Haifeng from Wuxi medical
   management center (No. YGM1016) The authors state no conflict of
   interest.
CR Astuti D, 2004, BRIT J CANCER, V90, P515, DOI 10.1038/sj.bjc.6601447
   Bol GM, 2010, HISTOPATHOLOGY, V57, P363, DOI 10.1111/j.1365-2559.2010.03642.x
   Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5
   Brose K, 2000, CURR OPIN NEUROBIOL, V10, P95, DOI 10.1016/S0959-4388(99)00066-5
   Chan KYK, 2002, CANCER RES, V62, P4151
   Chiang JW, 2006, GYNECOL ONCOL, V101, P403, DOI 10.1016/j.ygyno.2005.10.034
   Dallol A, 2003, ONCOGENE, V22, P4611, DOI 10.1038/sj.onc.1206687
   Dallol A, 2003, CANCER RES, V63, P1054
   Dallol A, 2002, CANCER RES, V62, P5874
   Dunwell TL, 2009, EPIGENETICS-US, V4, P265, DOI 10.4161/epi.9137
   Farnebo M, 2010, BIOCHEM BIOPH RES CO, V396, P85, DOI 10.1016/j.bbrc.2010.02.152
   Fukuhara H, 2002, JPN J CANCER RES, V93, P605, DOI 10.1111/j.1349-7006.2002.tb01297.x
   Georgas K, 1999, CYTOGENET CELL GENET, V86, P246, DOI 10.1159/000015351
   Hoebeeck J, 2009, CANCER LETT, V273, P336, DOI 10.1016/j.canlet.2008.08.019
   Jin J, 2009, BIOCHEM BIOPH RES CO, V379, P86, DOI 10.1016/j.bbrc.2008.12.022
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Kim HK, 2008, NEOPLASIA, V10, P1411, DOI 10.1593/neo.08804
   Liu D, 2006, CIRC RES, V98, P480, DOI 10.1161/01.RES.0000205764.85931.4b
   Maehama T, 2007, BIOL PHARM BULL, V30, P1624, DOI 10.1248/bpb.30.1624
   Marlow R, 2008, CANCER RES, V68, P7819, DOI 10.1158/0008-5472.CAN-08-1357
   Narayan G, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-16
   Qiu HF, 2010, CANCER SCI, V101, P1255, DOI 10.1111/j.1349-7006.2010.01497.x
   Schönorf T, 2004, CANCER LETT, V207, P215, DOI 10.1016/j.canlet.2003.10.028
   Sharma G, 2007, LIFE SCI, V80, P1873, DOI 10.1016/j.lfs.2007.02.026
   Simin K, 2004, PLOS BIOL, V2, P194, DOI 10.1371/journal.pbio.0020022
   Tseng RC, 2010, CANCER RES, V70, P543, DOI 10.1158/0008-5472.CAN-09-2084
   van Es JH, 2001, EXP CELL RES, V264, P126, DOI 10.1006/excr.2000.5142
   Wang KH, 1999, CELL, V96, P771, DOI 10.1016/S0092-8674(00)80588-7
   Zhang Q, 2007, CANCER LETT, V249, P220, DOI 10.1016/j.canlet.2006.08.019
NR 29
TC 25
Z9 28
U1 0
U2 6
PU ASIAN PACIFIC ORGANIZATION CANCER PREVENTION
PI GYEONGGI-DO
PA APJCP HEAD OFFICE, KOREAN NATL CANCER CENTER, 323 ILAN -RO,
   ILSANDONG-GU, GOYANG-SI, GYEONGGI-DO, 410-769, SOUTH KOREA
SN 1513-7368
J9 ASIAN PAC J CANCER P
JI Asian Pac. J. Cancer Prev.
PY 2011
VL 12
IS 3
BP 791
EP 795
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 798AR
UT WOS:000293173100039
PM 21627385
DA 2025-01-12
ER

PT J
AU Stefansson, OA
   Esteller, M
AF Andri Stefansson, Olafur
   Esteller, Manel
TI EZH2-mediated epigenetic repression of DNA repair in promoting breast
   tumor initiating cells
SO BREAST CANCER RESEARCH
LA English
DT Article
ID SPORADIC BREAST; POLYCOMB; CANCER; EZH2; HYPERMETHYLATION; ROLES
AB Members of the Polycomb-group (PcG) family of proteins, including EZH2 (enhancer of zeste homolog 2), are involved in establishing epigenetic silencing of developmental genes in adult and embryonic stem cells, and their deregulation has been implicated in cancer. In a recent report, EZH2-mediated epigenetic repression of DNA damage repair in breast tumor initiating cells (BTICs) was identified as a mechanism that could promote expansion of BTICs, and may contribute to cancer progression.
C1 [Andri Stefansson, Olafur; Esteller, Manel] Bellvitge Biomed Res Inst, Canc Epigenet & Biol Program PEBC, Barcelona 08908, Catalonia, Spain.
   [Esteller, Manel] Inst Catalana Recerca & Estudis Avancats, Barcelona 08010, Catalonia, Spain.
C3 Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); ICREA
RP Esteller, M (通讯作者)，Bellvitge Biomed Res Inst, Canc Epigenet & Biol Program PEBC, Barcelona 08908, Catalonia, Spain.
EM mesteller@idibell.cat
RI Esteller, Manel/L-5956-2014
OI Esteller, Manel/0000-0003-4490-6093
FU ICREA Funding Source: Custom
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Chang CJ, CANC CELL, V19, P86
   Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2000, EUR J CANCER, V36, P2294, DOI 10.1016/S0959-8049(00)00303-8
   Huang THM, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a004515
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   McCabe N, 2006, CANCER RES, V66, P8109, DOI 10.1158/0008-5472.CAN-06-0140
   MURPHY CG, CANC J, V16, P39
   Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858
   Pasini D, 2007, MOL CELL BIOL, V27, P3769, DOI 10.1128/MCB.01432-06
   Rajasekhar VK, 2007, STEM CELLS, V25, P2498, DOI 10.1634/stemcells.2006-0608
   Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010
   Zeidler M, 2005, NEOPLASIA, V7, P1011, DOI 10.1593/neo.05472
NR 17
TC 19
Z9 20
U1 0
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-5411
EI 1465-542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2011
VL 13
IS 3
AR 309
DI 10.1186/bcr2871
PG 2
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 832ID
UT WOS:000295797100034
PM 21672285
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Connolly, D
   Yang, ZX
   Castaldi, M
   Simmons, N
   Oktay, MH
   Coniglio, S
   Fazzari, MJ
   Verdier-Pinard, P
   Montagna, C
AF Connolly, Diana
   Yang, Zhixia
   Castaldi, Maria
   Simmons, Nichelle
   Oktay, Maja H.
   Coniglio, Salvatore
   Fazzari, Melissa J.
   Verdier-Pinard, Pascal
   Montagna, Cristina
TI Septin 9 isoform expression, localization and epigenetic changes during
   human and mouse breast cancer progression
SO BREAST CANCER RESEARCH
LA English
DT Article
DE Septin 9; breast cancer; oncogene; epigenetics; cytoskeleton
ID HIGH SEPT9-V1 EXPRESSION; SQUAMOUS-CELL CARCINOMA; ACUTE
   MYELOID-LEUKEMIA; COLORECTAL-CANCER; MAMMALIAN SEPTIN; DNA METHYLATION;
   MASS-SPECTROMETRY; GENE FAMILY; MSF-A; LINES
AB Introduction: Altered expression of Septin 9 (SEPT9), a septin coding for multiple isoform variants, has been observed in several carcinomas, including colorectal, head and neck, ovarian and breast, compared to normal tissues. The mechanisms regulating its expression during tumor initiation and progression in vivo and the oncogenic function of its different isoforms remain elusive.
   Methods: Using an integrative approach, we investigated SEPT9 at the genetic, epigenetic, mRNA and protein levels in breast cancer. We analyzed a panel of breast cancer cell lines, human primary tumors and corresponding tumor-free areas, normal breast tissues from reduction mammoplasty patients, as well as primary mammary gland adenocarcinomas derived from the polyoma virus middle T antigen, or PyMT, mouse model. MCF7 clones expressing individual GFP-tagged SEPT9 isoforms were used to determine their respective intracellular distributions and effects on cell migration.
   Results: An overall increase in gene amplification and altered expression of SEPT9 were observed during breast tumorigenesis. We identified an intragenic alternative promoter at which methylation regulates SEPT9_v3 expression. Transfection of specific GFP-SEPT9 isoforms in MCF7 cells indicates that these isoforms exhibit differential localization and affect migration rates. Additionally, the loss of an uncharacterized SEPT9 nucleolar localization is observed during tumorigenesis.
   Conclusions: In this study, we found conserved in vivo changes of SEPT9 gene amplification and overexpression during human and mouse breast tumorigenesis. We show that DNA methylation is a prominent mechanism responsible for regulating differential SEPT9 isoform expression and that breast tumor samples exhibit distinctive SEPT9 intracellular localization. Together, these findings support the significance of SEPT9 as a promising tool in breast cancer detection and further emphasize the importance of analyzing and targeting SEPT9 isoform-specific expression and function.
C1 [Connolly, Diana; Yang, Zhixia; Montagna, Cristina] Yeshiva Univ Albert Einstein Coll Med, Dept Genet, Bronx, NY 10461 USA.
   [Castaldi, Maria] Jacobi Med Ctr, Dept Surg, Bronx, NY 10461 USA.
   [Simmons, Nichelle] Jacobi Med Ctr, Dept Pathol, Bronx, NY 10461 USA.
   [Oktay, Maja H.; Montagna, Cristina] Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA.
   [Coniglio, Salvatore] Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA.
   [Fazzari, Melissa J.] Yeshiva Univ Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10461 USA.
   [Verdier-Pinard, Pascal] Ctr Rech Cancerol Marseille, INSERM, U891, F-13273 Marseille 09, France.
   [Verdier-Pinard, Pascal] Inst J Paoli I Calmettes, F-13009 Marseille, France.
   [Verdier-Pinard, Pascal] Aix Marseille Univ, F-13007 Marseille, France.
C3 Montefiore Medical Center; Albert Einstein College of Medicine; Yeshiva
   University; Jacobi Medical Center; Jacobi Medical Center; Yeshiva
   University; Montefiore Medical Center; Albert Einstein College of
   Medicine; Montefiore Medical Center; Albert Einstein College of
   Medicine; Yeshiva University; Yeshiva University; Montefiore Medical
   Center; Albert Einstein College of Medicine; Institut National de la
   Sante et de la Recherche Medicale (Inserm); Aix-Marseille Universite;
   UNICANCER; Institut Paoli-Calmette (IPC); Aix-Marseille Universite
RP Montagna, C (通讯作者)，Yeshiva Univ Albert Einstein Coll Med, Dept Genet, 1300 Morris Pk Ave, Bronx, NY 10461 USA.
EM cristina.montagna@einstein.yu.edu
OI Verdier-Pinard, Pascal/0000-0002-6149-6578; Fazzari,
   Melissa/0000-0002-5674-3589
FU Universite de la Mediterranee International Relations; ACS
   [RSG-11-021-01-CNE]
FX We thank the Shared Resources at Albert Einstein College of Medicine
   (AECOM): the Molecular Cytogenetic Facility, in particular Dr. Jidong
   Shan for her help with the FISH analysis, and the Genomics Core, in
   particular David Reynolds for his assistance with the methylation
   studies. We are grateful to Dr. Jeffrey Pollard (AECOM) for providing
   the PyMT mice and to Dr. Jeffrey Segall (AECOM) for providing insight
   and advice on the migration assays. We thank the Universite de la
   Mediterranee International Relations for financial support. We thank
   Jessie Brown, Priya Shivraj and Lauren Tal for their technical
   assistance. We thank Dr Elias Spiliotis for comments and scientific
   discussion. The work of the authors was supported by the grant from the
   ACS (ACS grant RSG-11-021-01-CNE to CM).
CR Amir S, 2006, CANCER RES, V66, P856, DOI 10.1158/0008-5472.CAN-05-2738
   Amir S, 2010, MOL CANCER RES, V8, P643, DOI 10.1158/1541-7786.MCR-09-0497
   [Anonymous], IMAGEJ SOFTWARE
   BATES D, 2008, R LANGUAGE ENV STAT
   Bennett KL, 2008, CANCER RES, V68, P4494, DOI 10.1158/0008-5472.CAN-07-6509
   Burdall SE, 2003, BREAST CANCER RES, V5, P89, DOI 10.1186/bcr577
   Burrows JF, 2003, J PATHOL, V201, P581, DOI 10.1002/path.1484
   deVos T, 2009, CLIN CHEM, V55, P1337, DOI 10.1373/clinchem.2008.115808
   Downing TE, 2010, CANCER GENET CYTOGEN, V198, P52, DOI 10.1016/j.cancergencyto.2009.12.007
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   Estey MP, 2010, J CELL BIOL, V191, P741, DOI 10.1083/jcb.201006031
   Feingold EA, 2004, SCIENCE, V306, P636, DOI 10.1126/science.1105136
   Gonzalez ME, 2007, CANCER RES, V67, P8554, DOI 10.1158/0008-5472.CAN-07-1474
   Gonzalez ME, 2009, CELL SIGNAL, V21, P477, DOI 10.1016/j.cellsig.2008.11.007
   Grützmann R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003759
   GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954
   Hall PA, 2005, CLIN CANCER RES, V11, P6780, DOI 10.1158/1078-0432.CCR-05-0997
   Hall PA, 2005, J PATHOL, V206, P269, DOI 10.1002/path.1789
   He QO, 2010, CANCER GENET CYTOGEN, V202, P1, DOI 10.1016/j.cancergencyto.2010.05.018
   HOLM S, 1979, SCAND J STAT, V6, P65
   Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146
   Kinoshita M, 2002, DEV CELL, V3, P791, DOI 10.1016/S1534-5807(02)00366-0
   Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003
   Kremer BE, 2007, CELL, V130, P837, DOI 10.1016/j.cell.2007.06.053
   Kuttler F, 2007, SEMIN CANCER BIOL, V17, P56, DOI 10.1016/j.semcancer.2006.10.007
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7
   Makhnevych T, 2007, J CELL BIOL, V177, P39, DOI 10.1083/jcb.200608066
   Maunakea AK, 2010, NATURE, V466, P253, DOI 10.1038/nature09165
   McDade SS, 2007, HUM MOL GENET, V16, P742, DOI 10.1093/hmg/ddm003
   McIlhatton MA, 2001, ONCOGENE, V20, P5930, DOI 10.1038/sj.onc.1204752
   Montagna C, 2003, CANCER RES, V63, P2179
   Nagata K, 2004, J BIOL CHEM, V279, P55895, DOI 10.1074/jbc.M406153200
   Nagata K, 2003, J BIOL CHEM, V278, P18538, DOI 10.1074/jbc.M205246200
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428
   Pizarro-Cerdá J, 2002, CELL MICROBIOL, V4, P101, DOI 10.1046/j.1462-5822.2002.00169.x
   Robertson C, 2004, J PATHOL, V203, P519, DOI 10.1002/path.1551
   Roohi J, 2008, CYTOGENET GENOME RES, V121, P7, DOI 10.1159/000124374
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Scott M, 2006, INT J CANCER, V118, P1325, DOI 10.1002/ijc.21486
   Shankar J, 2010, CANCER RES, V70, P3780, DOI 10.1158/0008-5472.CAN-09-4439
   Sorensen AB, 2000, J VIROL, V74, P2161, DOI 10.1128/JVI.74.5.2161-2168.2000
   Spiliotis ET, 2006, J CELL SCI, V119, P4, DOI 10.1242/jcs.02746
   Stanbery L, 2010, TRANSL ONCOL, V3, P239, DOI 10.1593/tlo.10109
   Surka MC, 2002, MOL BIOL CELL, V13, P3532, DOI 10.1091/mbc.E02-01-0042
   Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949
   Tachibana T, 2010, HYBRIDOMA, V29, P169, DOI 10.1089/hyb.2009.0092
   Taki T, 1999, CANCER RES, V59, P4261
   Thompson RF, 2009, BIOINFORMATICS, V25, P2164, DOI 10.1093/bioinformatics/btp382
   Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001
NR 51
TC 86
Z9 102
U1 0
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1465-542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2011
VL 13
IS 4
AR R76
DI 10.1186/bcr2924
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 850BP
UT WOS:000297169700006
PM 21831286
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Sebova, K
   Zmetakova, I
   Bella, V
   Kajo, K
   Stankovicova, I
   Kajabova, V
   Krivulcik, T
   Lasabova, Z
   Tomka, M
   Galbavy, S
   Fridrichova, I
AF Sebova, Katarina
   Zmetakova, Iveta
   Bella, Vladimir
   Kajo, Karol
   Stankovicova, Iveta
   Kajabova, Viera
   Krivulcik, Tomas
   Lasabova, Zora
   Tomka, Miroslav
   Galbavy, Stefan
   Fridrichova, Ivana
TI <i>RASSF1A</i> and <i>CDH1</i> hypermethylation as potential epimarkers
   in breast cancer
SO CANCER BIOMARKERS
LA English
DT Article
DE Breast cancer; DNA hypermethylation; quantitative assay; RASSF1A
   methylation; CDH1 methylation; epigenetic biomarkers
ID CADHERIN PROTEIN EXPRESSION; CPG ISLAND METHYLATION; TUMOR-SUPPRESSOR
   GENE; DNA METHYLATION; PROMOTER HYPERMETHYLATION; EPIGENETIC
   ALTERATIONS; LOBULAR CARCINOMA; EPITHELIAL-CELLS; PATTERNS; PROFILES
AB Breast cancer is the most common cancer in women worldwide, representing 28.2% of all female malignancies. In addition to genetic changes, epigenetic events, as aberrant DNA methylation and histone modification, are responsible for cancer development. Many tumour suppressor genes are inactivated by DNA hypermethylation, which could be utilized for identification of new epigenetic biomarkers. To investigate the relation between DNA methylation level and breast cancer progression, we analysed DNA methylation in RASSF1A and CDH1 promoters using quantitative multiplex methylation-specific PCR in paraffin-embedded tumour tissues and blood samples from 92 breast cancer patients and 50 controls, respectively. The associations between RASSF1A and CDH1 methylation levels and clinico-pathological parameters were tested by Kruskal-Wallis and van der Waerden ANOVA tests. Out of 92 breast cancer patients, 76 (82.6%) manifested various levels of RASSF1A (range from 1.20 to 92.63%) and 20 (21.7%) of CDH1 (range from 1.20 to 79.62%) methylation. However, no methylation was found in 50 controls. Increasing trends in RASSF1A methylation were observed in tumour size, lymph node status and TNM stage, but only CDH1 methylation levels showed statistically significant differences between the patient subgroups in lymph node status and IHC subtype. Overall, stable relatively high RASSF1A methylation could be utilised as universal tumour marker and the less frequent but highly methylated CDH1 promoter can serve for identification of potentially metastasising tumours.
C1 [Sebova, Katarina; Zmetakova, Iveta; Kajabova, Viera; Krivulcik, Tomas; Tomka, Miroslav; Fridrichova, Ivana] Slovak Acad Sci, Canc Res Inst, Canc Genet Lab, Bratislava 83391, Slovakia.
   [Bella, Vladimir] St Elizabeth Canc Inst, Dept Mammol, Bratislava, Slovakia.
   [Kajo, Karol] Comenius Univ & Fac Hosp, Jessenius Fac Med, Dept Pathol, Martin, Slovakia.
   [Stankovicova, Iveta] Comenius Univ, Fac Management, Dept Informat Syst, Bratislava, Slovakia.
   [Lasabova, Zora] Comenius Univ & Fac Hosp, Jessenius Fac Med, Dept Mol Biol, Martin, Slovakia.
   [Galbavy, Stefan] St Elizabeth Univ, Coll Hlth & Social Work, Bratislava, Slovakia.
   [Galbavy, Stefan] St Elizabeth Canc Inst, Dept Pathol, Bratislava, Slovakia.
   [Galbavy, Stefan] Comenius Univ, Fac Med, Inst Forens Med, Bratislava, Slovakia.
C3 Slovak Academy of Sciences; Comenius University Bratislava; Comenius
   University Bratislava; Comenius University Bratislava; Comenius
   University Bratislava; Slovak Academy of Sciences
RP Fridrichova, I (通讯作者)，Slovak Acad Sci, Canc Res Inst, Canc Genet Lab, Vlarska 7, Bratislava 83391, Slovakia.
EM Ivana.Fridrichova@savba.sk
RI Kajo, Karol/HJZ-4538-2023; Stefan, Galbavy/AAA-2201-2021; Stankovičová,
   Iveta/ABC-1763-2020; Fridrichova, Ivana/AAF-3485-2019; Horvathova
   Kajabova, Viera/HNQ-4239-2023; Lasabova, Zora/X-8254-2018
OI Fridrichova, Ivana/0000-0001-7581-1770; Kajo, Karol/0000-0002-8178-1093;
   galbavy, stefan/0000-0001-9503-0971; Horvathova Kajabova,
   Viera/0000-0002-7081-0602; Lasabova, Zora/0000-0003-2530-3991
FU ERDF [26240220058]; Slovak Grant Agency VEGA [2/0065/10]; League Against
   Cancer Slovakia
FX We thank to Mrs. Gabriela Gasajova for excellent technical assistance.
   This publication is the result of the implementation of projects: no.
   26240220058, Research and Development Operational Programme funded by
   the ERDF (30%), no. 2/0065/10 supported by the Slovak Grant Agency VEGA
   (50%), and the League Against Cancer Slovakia (20%).
CR Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088
   [Anonymous], TNM CLASSIFICATION M
   Bertucci F, 2008, ONCOGENE, V27, P5359, DOI 10.1038/onc.2008.158
   Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309
   Caldeira JRF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-48
   Cavusoglu AC, 2010, NEOPLASMA, V57, P465, DOI 10.4149/neo_2010_05_465
   Dammann R, 2001, CANCER RES, V61, P3105
   Dammann R, 2005, HISTOL HISTOPATHOL, V20, P645, DOI 10.14670/HH-20.645
   Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389
   Duffy MJ, 2009, EUR J CANCER, V45, P335, DOI 10.1016/j.ejca.2008.12.008
   Ellis IO., 2003, Pathology and genetics of tumours of the breast and female genital organs, P13
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   Euhus DM, 2008, CANCER EPIDEM BIOMAR, V17, P1051, DOI 10.1158/1055-9965.EPI-07-2582
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Feng W, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1762
   Feng WW, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-378
   Ferlay J, 2010, EUR J CANCER, V46, P765, DOI 10.1016/j.ejca.2009.12.014
   Fraga MF, 2007, TRENDS GENET, V23, P413, DOI 10.1016/j.tig.2007.05.008
   Fucito A, 2008, INT J BIOCHEM CELL B, V40, P565, DOI 10.1016/j.biocel.2007.10.018
   Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727
   Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322
   Harigopal Malini, 2005, World J Surg Oncol, V3, P73, DOI 10.1186/1477-7819-3-73
   Hinshelwood RA, 2008, J MOL MED, V86, P1315, DOI 10.1007/s00109-008-0386-3
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Lee JS, 2010, CANCER BIOL THER, V9, P1017, DOI 10.4161/cbt.9.12.11804
   Pan ZG, 2005, CANCER BIOL THER, V4, P1116, DOI 10.4161/cbt.4.10.2023
   Pasquali L, 2007, CANCER LETT, V257, P136, DOI 10.1016/j.canlet.2007.07.010
   Prasad CP, 2008, LIFE SCI, V83, P318, DOI 10.1016/j.lfs.2008.06.019
   Rakha EA, 2010, AM J SURG PATHOL, V34, P1472, DOI 10.1097/PAS.0b013e3181f01916
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100
   Sunami E, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2098
   Swift-Scanlan T, 2006, BIOTECHNIQUES, V40, P210, DOI 10.2144/000112097
   Tao MH, 2009, BREAST CANCER RES TR, V114, P559, DOI 10.1007/s10549-008-0028-z
   Van der Auwera I, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-97
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wo JY, 2011, J CLIN ONCOL, V29, P2619, DOI 10.1200/JCO.2010.29.5907
   Wong CM, 2010, EPIGENETICS-US, V5, P645, DOI 10.4161/epi.5.7.12961
   Yan PS, 2003, CANCER RES, V63, P6178
   Yoder BJ, 2007, BREAST J, V13, P172, DOI 10.1111/j.1524-4741.2007.00393.x
   Zou DH, 2009, J PATHOL, V218, P265, DOI 10.1002/path.2541
NR 41
TC 41
Z9 42
U1 0
U2 9
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1574-0153
EI 1875-8592
J9 CANCER BIOMARK
JI Cancer Biomark.
PY 2011
VL 10
IS 1
BP 13
EP 26
DI 10.3233/CBM-2012-0230
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 894AF
UT WOS:000300398500003
PM 22297548
DA 2025-01-12
ER

PT J
AU Srivastava, S
   Grizzle, WE
AF Srivastava, Sudhir
   Grizzle, William E.
TI Biomarkers and the genetics of early neoplastic lesions
SO CANCER BIOMARKERS
LA English
DT Article
DE Intraepithelial neoplasia; dysplasia; methylation; microsatellite
   instability; mutations; insertions; deletions; oncogenes; suppressor
   genes; aneuploidy; translocations; caretakers; gatekeepers; landscapers;
   mismatch repair genes; LOCDIR; epigenetics; immunoregulation; tumor
   associated fibroblasts; exosomes; angiogenesis; clonal selection; viral
   insertions; biomarkers; validation
ID ENDOTHELIAL GROWTH-FACTOR; TUMOR-SUPPRESSOR GENES; DNA METHYLATION;
   BREAST-CANCER; MICROSATELLITE INSTABILITY; INTRAEPITHELIAL NEOPLASIA;
   ANALYTICAL VALIDATION; TRANSCRIPTION FACTORS; UNIPARENTAL DISOMY;
   PANCREATIC-CANCER
AB It has become increasingly evident that the study of DNA is inadequate to explain many, if not most, aspects of the development and progression of neoplastic lesions from pre-invasive lesions to metastasis. Thus, the term "genetic" can no longer refer to just the study of the genome. Much of the action in genetic research now shifts to the methods by which the pre-mRNA from one gene is processed to yield multiple different proteins, different quantities of the same protein as well as other forms of regulating RNA. Thus, the age of post-transcriptional processing and epigenetic control of the transfer of information from the genome has arrived. The mechanisms of post-transcriptional processing and epigenetic control that must be characterized in greater detail including alternate splicing, regulation of mRNA degradation, RNA regulatory factors including those factors which extensively edit mRNAs, control of translation, and control of protein stability and degradation. This chapter reviews many of the processes that control information from the genome to proteins and how these factors lead from less than 40,000 genes to more than an order of magnitude increase more proteins which actually control the phenotypes of cells - normal or neoplastic. It is usually the products of genes (e. g., mRNA, microRNA and proteins) that are the molecular markers that will control translational research and ultimately, individualized (personal) medical approaches to disease. This chapter emphasizes how the process of neoplasia "hijacks" the normal processes of cellular operations, especially those processes that are important in the normal development of the organisms - including proliferation, cellular death, angiogenesis, cellular mobility and invasion, and immunoregulation to ensure neoplastic development, survival and progression. This chapter reviews the wide range of processes controlling the information that flows from the genome to proteins and emphasizes how molecular steps in pure processes can be used as biomarkers to study prevention, treatment and/or management of diseases.
C1 [Srivastava, Sudhir] NCI, NIH, Bethesda, MD 20892 USA.
   [Grizzle, William E.] Univ Alabama Birmingham, Div Anat Pathol, Dept Pathol, Birmingham, AL USA.
C3 National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); University of Alabama System; University of Alabama Birmingham
RP Srivastava, S (通讯作者)，NCI, NIH, Bethesda, MD 20892 USA.
EM ss1a@nih.gov
FU Early Detection Research Network (EDRN) [5U24 CA86359]; Department of
   Defense [PC093309]; SPORES at UAB [5P50CA089019, 2P50CA101955]; Susan G.
   Komen Breast Cancer Foundation [BCTR0600484]; Skin Disease Research
   Center at UAB [5P30AR50948]
FX Supported in part by the Early Detection Research Network (EDRN) (5U24
   CA86359), Department of Defense, "Biomarkers in the Detection of
   Prostate Cancer in African-Americans" (PC093309), the Breast
   (5P50CA089019) and Pancreatic (2P50CA101955) SPORES at UAB, the Susan G.
   Komen Breast Cancer Foundation (BCTR0600484), and the Skin Disease
   Research Center at UAB (5P30AR50948).
CR Aarnio M, 1999, INT J CANCER, V81, P214, DOI 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.0.CO;2-L
   Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703
   Ahrendt S A, 1999, Surg Oncol Clin N Am, V8, P641
   Al-Sarireh B, 2000, J ROY COLL SURG EDIN, V45, P1
   Albain KS, 2010, LANCET ONCOL, V11, P55, DOI 10.1016/S1470-2045(09)70314-6
   Aldulaimi D, 1999, DIS ESOPHAGUS, V12, P177, DOI 10.1046/j.1442-2050.1999.00043.x
   Ali MH, 1999, AM J PHYSIOL-LUNG C, V277, pL1057, DOI 10.1152/ajplung.1999.277.5.L1057
   Andersen CL, 2007, CARCINOGENESIS, V28, P38, DOI 10.1093/carcin/bgl086
   Anderson IC, 2000, CANCER RES, V60, P269
   Arndt GM, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-374
   Asad J, 2008, AM J SURG, V196, P527, DOI 10.1016/j.amjsurg.2008.06.021
   Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891
   Belinsky SA, 2008, NUTR REV, V66, pS24, DOI 10.1111/j.1753-4887.2008.00061.x
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059
   Blume SW, 2003, EXP CELL RES, V288, P131, DOI 10.1016/S0014-4827(03)00182-4
   Bobrovnikova-Marjon EV, 2004, CANCER RES, V64, P4858, DOI 10.1158/0008-5472.CAN-04-0682
   Boland CR, 1999, P NATL ACAD SCI USA, V96, P14675, DOI 10.1073/pnas.96.26.14675
   Boland CR, 1998, CANCER RES, V58, P5248
   BOONE CW, 1992, CANCER RES, V52, P1651
   Borg TK, 2004, AM J PATHOL, V164, P1141, DOI 10.1016/S0002-9440(10)63201-4
   Bornstein S, 2009, J CLIN INVEST, V119, P3408, DOI 10.1172/JCI38854
   Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310
   Brooks J, 2009, CANCER CAUSE CONTROL, V20, P1539, DOI 10.1007/s10552-009-9415-y
   Burke HB, 2004, J NATL CANCER I, V96, P1408, DOI 10.1093/jnci/djh293
   Caldas C, 1998, BRIT MED J, V316, P1360, DOI 10.1136/bmj.316.7141.1360
   Callagy GM, 2006, CLIN CANCER RES, V12, P2468, DOI 10.1158/1078-0432.CCR-05-2719
   CAMPBELL C, 1993, J INVEST DERMATOL, V100, P746, DOI 10.1111/1523-1747.ep12475717
   Campisi J, 2005, MECH AGEING DEV, V126, P51, DOI 10.1016/j.mad.2004.09.024
   Charalambous C, 2005, CANCER RES, V65, P10347, DOI 10.1158/0008-5472.CAN-05-0949
   Chen JJ, 1999, CANCER RES, V59, p1752S
   Chen JJW, 2003, CLIN CANCER RES, V9, P729
   Chen K, 2007, NAT REV GENET, V8, P93, DOI 10.1038/nrg1990
   Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822
   Choi H, 2008, J CELL BIOCHEM, V105, P1092, DOI 10.1002/jcb.21909
   Chow M, 2000, CANCER RES, V60, P6510
   Coughlin SS, 1999, AM J PREV MED, V16, P91, DOI 10.1016/S0749-3797(98)00136-6
   Cronin M, 2007, CLIN CHEM, V53, P1084, DOI 10.1373/clinchem.2006.076497
   Cunha GR, 1996, ACTA ANAT, V155, P63
   DECACERES II, 2007, CLIN TRANSL ONCOL, V9, P429, DOI DOI 10.1007/S12094-007-0081-9
   Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057
   Dietmaier W, 1997, CANCER RES, V57, P4749
   DOERFLER W, 1995, ADV CANCER RES, V66, P313, DOI 10.1016/S0065-230X(08)60259-6
   Dulaimi E, 2004, CLIN CANCER RES, V10, P3972, DOI 10.1158/1078-0432.CCR-04-0175
   Eulalio A, 2009, RNA, V15, P21, DOI 10.1261/rna.1399509
   FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Ferrando I, 1998, REV ESP ENFERM DIG, V90, P436
   Feunteun J, 1998, MOL MED TODAY, V4, P263, DOI 10.1016/S1357-4310(98)01262-3
   Fitzgerald RC, 1998, DIGEST DIS, V16, P63, DOI 10.1159/000016850
   FOLKMAN J, 1995, MOL MED, V1, P120, DOI 10.1007/BF03401559
   Frank SA, 2003, CURR BIOL, V13, pR261, DOI 10.1016/S0960-9822(03)00195-7
   Gamazon ER, 2010, BIOINFORMATICS, V26, P259, DOI 10.1093/bioinformatics/btp644
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Goggins M, 1996, CANCER RES, V56, P5360
   Goswami S, 2005, CANCER RES, V65, P5278, DOI 10.1158/0008-5472.CAN-04-1853
   Grizzle WE, 1999, MOLECULAR PATHOLOGY OF EARLY CANCER, P135
   Grizzle WE, 2002, INT J CANCER, V101, P270, DOI 10.1002/ijc.10606
   Grizzle WE, 2005, CANCER INFORM, V1, P86
   Grizzle WE, 2011, CANCER BIOMARK, V9, P21, DOI 10.3233/CBM-2011-0172
   Grizzle WE, 2011, CANCER BIOMARK, V9, P7, DOI 10.3233/CBM-2011-0159
   Gu J, 2005, CARCINOGENESIS, V26, P1741, DOI 10.1093/carcin/bgi126
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hayward SW, 1998, INT J ONCOL, V13, P35
   Henson Donald Earl, 1999, Current Opinion in Oncology, V11, P419, DOI 10.1097/00001622-199909000-00018
   Herbst RS, 2005, J CLIN ONCOL, V23, P3243, DOI 10.1200/JCO.2005.18.853
   HERMAN JG, 1995, CANCER RES, V55, P4525
   HOLLINGSWORTH RE, 1991, J NATL CANCER I, V83, P91, DOI 10.1093/jnci/83.2.91
   Holmes K, 2007, CELL SIGNAL, V19, P2003, DOI 10.1016/j.cellsig.2007.05.013
   Holowaty P, 1999, JNCI-J NATL CANCER I, V91, P252, DOI 10.1093/jnci/91.3.252
   Hong W K, 1995, J Natl Cancer Inst Monogr, P49
   HONNAVARA N, 1997, NAT MED, V3, P510
   Iero M, 2008, CELL DEATH DIFFER, V15, P80, DOI 10.1038/sj.cdd.4402237
   IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0
   Ito K, 2008, CANCER CELL, V14, P226, DOI 10.1016/j.ccr.2008.08.004
   Jhala N, 2006, AM J CLIN PATHOL, V126, P572, DOI 10.1309/CEV30BE088CBDQD9
   Johnstone RM, 2006, BLOOD CELL MOL DIS, V36, P315, DOI 10.1016/j.bcmd.2005.12.001
   Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025
   Jones JM, 1999, CELL GROWTH DIFFER, V10, P213
   Jones PA, 1997, P NATL ACAD SCI USA, V94, P2103, DOI 10.1073/pnas.94.6.2103
   Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9
   Jones PL, 1999, SEMIN CANCER BIOL, V9, P339, DOI 10.1006/scbi.1999.0134
   KALEBIC T, 1988, CLIN EXP METASTAS, V6, P301, DOI 10.1007/BF01753577
   KALEBIC T, 1983, SCIENCE, V221, P281, DOI 10.1126/science.6190230
   Katkoori VR, 2009, CLIN CANCER RES, V15, P2406, DOI 10.1158/1078-0432.CCR-08-1719
   Kim MS, 2006, LAB INVEST, V86, P175, DOI 10.1038/labinvest.3700378
   Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0
   Korc M, 2009, J CLIN INVEST, V119, P3208, DOI 10.1172/JCI41230
   Koshiba T, 2000, CLIN CANCER RES, V6, P3530
   KOSS LG, 1979, LG KOSSS DIAGNOSTIC, P285
   Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101
   KVINNSLAND S, 1991, SCAND J CLIN LAB INV, V51, P6, DOI 10.3109/00365519109107720
   Lawler J, 2001, AM J PATHOL, V159, P1949, DOI 10.1016/S0002-9440(10)63042-8
   Lee S, 2007, P NATL ACAD SCI USA, V104, P13732, DOI 10.1073/pnas.0701771104
   Levitt NC, 2002, TRENDS MOL MED, V8, P179, DOI 10.1016/S1471-4914(02)02298-0
   Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005
   Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369
   Lin MC, 1998, AM J PATHOL, V152, P1313
   Lindberg JÖ, 1999, BRIT J SURG, V86, P947, DOI 10.1046/j.1365-2168.1999.01133.x
   Ling G, 2001, AM J PATHOL, V159, P1247, DOI 10.1016/S0002-9440(10)62511-4
   LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C
   Lippman S M, 1995, Cancer Treat Res, V74, P89
   LIPPMAN SM, 1992, JNCI-J NATL CANCER I, V13, P111
   LITTLEPAGE LE, MOL BASIS CANC, P229
   Liu CR, 2006, J IMMUNOL, V176, P1375, DOI 10.4049/jimmunol.176.3.1375
   Loeb LA, 2001, CANCER RES, V61, P3230
   Loeb LA, 1997, SCIENCE, V277, P1449, DOI 10.1126/science.277.5331.1449
   LOEB LA, 1974, CANCER RES, V34, P2311
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Macaluso M, 2003, ONCOGENE, V22, P6472, DOI 10.1038/sj.onc.1206955
   MACEOD K, 2000, CURRENT OPINION GENE, V10, P81
   Manne U, 2000, INT J CANCER, V89, P423, DOI 10.1002/1097-0215(20000920)89:5<423::AID-IJC5>3.0.CO;2-T
   Mao L, 1996, NAT MED, V2, P682, DOI 10.1038/nm0696-682
   Masramon L, 2006, J CELL SCI, V119, P1477, DOI 10.1242/jcs.02871
   McLerran D, 2008, CLIN CHEM, V54, P44, DOI 10.1373/clinchem.2007.091470
   Meng Z, 2008, J CELL PHYSIOL, V217, P172, DOI 10.1002/jcp.21486
   MICALE MA, 1994, HUM PATHOL, V25, P29, DOI 10.1016/0046-8177(94)90167-8
   Michor F, 2004, NAT REV CANCER, V4, P197, DOI 10.1038/nrc1295
   MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585
   Montironi R, 1997, J CLIN PATHOL, V50, P775, DOI 10.1136/jcp.50.9.775
   Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950
   MORTON NE, 1995, ELECTROPHORESIS, V16, P1670, DOI 10.1002/elps.11501601277
   MYERS RB, 1994, PROSTATE, V25, P243, DOI 10.1002/pros.2990250504
   MYERS RB, 1994, J UROLOGY, V152, P243, DOI 10.1016/S0022-5347(17)32870-7
   Nam RK, 2007, BRIT J CANCER, V97, P1690, DOI 10.1038/sj.bjc.6604054
   Nguyen-Ba G, 1999, ONCOL REP, V6, P925
   Nowak MA, 2002, P NATL ACAD SCI USA, V99, P16226, DOI 10.1073/pnas.202617399
   NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840
   Ohuchida K, 2004, CANCER RES, V64, P3215, DOI 10.1158/0008-5472.CAN-03-2464
   Olumi AF, 1999, CANCER RES, V59, P5002
   OPTENBERG SA, 1990, UROL CLIN N AM, V17, P719
   PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798
   Patan S, 2000, J NEURO-ONCOL, V50, P1, DOI 10.1023/A:1006493130855
   Pepe MS, 2001, J NATL CANCER I, V93, P1054, DOI 10.1093/jnci/93.14.1054
   PERERA FP, 1988, IARC SCI PUBL, V89, P451
   Pistoia V, 2009, J CLIN ONCOL, V27, P4809, DOI 10.1200/JCO.2008.21.3579
   Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533
   Potapova A, 2008, CANCER RES, V68, P998, DOI 10.1158/0008-5472.CAN-07-2418
   Qu ZC, 2008, CANCER RES, V68, P6232, DOI 10.1158/0008-5472.CAN-07-5654
   Quintas-Cardama A., 2008, MOL BASIS CANC, P371
   Ravaioli A, 2008, ANN ONCOL, V19, P660, DOI 10.1093/annonc/mdm547
   Rebbeck TR, 1999, AM J HUM GENET, V64, P1371, DOI 10.1086/302366
   Reimann J.D.R., 2008, MOL BASIS CANC, P471
   Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555
   Roy HK, 2008, GASTROENTEROLOGY, V135, P1069, DOI 10.1053/j.gastro.2008.06.046
   Roy HK, 2008, DIS COLON RECTUM, V51, P1381, DOI 10.1007/s10350-008-9384-3
   Roy HK, 2009, CANCER RES, V69, P4476, DOI 10.1158/0008-5472.CAN-08-4780
   Rydén L, 2005, BREAST CANCER RES TR, V89, P135, DOI 10.1007/s10549-004-1655-7
   SANDGREN EP, 2005, PANCREATIC CANC, P87
   Sato E, 2007, BRIT J CANCER, V96, P1735, DOI 10.1038/sj.bjc.6603790
   Schafer BW, 1998, GEN PHYSIOL BIOPHYS, V17, P211
   Schraufstatter IU, 2001, AM J PHYSIOL-LUNG C, V280, pL1094, DOI 10.1152/ajplung.2001.280.6.L1094
   Schwertfeger KL, 2006, CANCER RES, V66, P5676, DOI 10.1158/0008-5472.CAN-05-3781
   Shanmugam C, 2008, J HISTOCHEM CYTOCHEM, V56, P305, DOI 10.1369/jhc.7A7362.2007
   Sidransky D, 1997, SCIENCE, V278, P1054, DOI 10.1126/science.278.5340.1054
   SINGH S, 2004, LAB INVEST, P1
   Slack FJ, 2008, NEW ENGL J MED, V359, P2720, DOI 10.1056/NEJMe0808667
   SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q
   Smith JM, 2005, AM J PHYSIOL-GASTR L, V288, pG316, DOI 10.1152/ajpgi.00208.2004
   Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945
   SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167
   Srivastava S, 1995, Cancer Treat Res, V72, P91
   Srivastava S, 1996, INT J CANCER, V69, P35, DOI 10.1002/(SICI)1097-0215(19960220)69:1<35::AID-IJC8>3.0.CO;2-X
   Steg A, 2006, J MOL DIAGN, V8, P76, DOI 10.2353/jmoldx.2006.040402
   Steg A, 2007, DIAGN MOL PATHOL, V16, P229, DOI 10.1097/PDM.0b013e31811edc7e
   STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x
   Subramanian H, 2009, CANCER RES, V69, P5357, DOI 10.1158/0008-5472.CAN-08-3895
   Tamm M, 1998, AM J RESP CELL MOL, V19, P653, DOI 10.1165/ajrcmb.19.4.3058
   TERRANOVA VP, 1983, P NATL ACAD SCI-BIOL, V80, P444, DOI 10.1073/pnas.80.2.444
   Tessema M, 2009, CARCINOGENESIS, V30, P1132, DOI 10.1093/carcin/bgp114
   THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122
   Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679
   Tomlinson I, 1999, NAT MED, V5, P11, DOI 10.1038/4687
   TONON G, 2008, MOL BASIS CANC, P351
   van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049
   van Heemst D, 2007, EUR J CANCER, V43, P2144, DOI 10.1016/j.ejca.2007.07.011
   Walsh CS, 2008, CLIN CANCER RES, V14, P7645, DOI 10.1158/1078-0432.CCR-08-1291
   Wang DZ, 2006, J EXP MED, V203, P941, DOI 10.1084/jem.20052124
   Wang GJ, 2008, J IMMUNOL, V181, P5242, DOI 10.4049/jimmunol.181.8.5242
   Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252
   Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231
   Weinberg R.A., 2008, The Molecular Basis of Cancer, P3
   Weinberg RA, 1996, SCI AM, V275, P62, DOI 10.1038/scientificamerican0996-62
   Williams AE, 2008, CELL MOL LIFE SCI, V65, P545, DOI 10.1007/s00018-007-7355-9
   Zhang HG, 2003, IMMUNOL ALLERGY CLIN, V23, P83, DOI 10.1016/S0889-8561(02)00085-1
   Zhang HG, 2006, J IMMUNOL, V176, P7385, DOI 10.4049/jimmunol.176.12.7385
   Zhang HG, 2011, CLIN CANCER RES, V17, P959, DOI 10.1158/1078-0432.CCR-10-1489
NR 189
TC 10
Z9 11
U1 0
U2 4
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1574-0153
EI 1875-8592
J9 CANCER BIOMARK
JI Cancer Biomark.
PY 2011
VL 9
IS 1-6
BP 41
EP 64
DI 10.3233/CBM-2011-0204
PG 24
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 856ZB
UT WOS:000297682300004
PM 22112469
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Carmona, FJ
   Esteller, M
AF Javier Carmona, F.
   Esteller, Manel
TI DNA methylation in early neoplasia
SO CANCER BIOMARKERS
LA English
DT Article
DE DNA methylation; cancer; biomarker; early detection; screening
ID CELL LUNG-CANCER; ABERRANT PROMOTER METHYLATION; CPG ISLAND
   HYPERMETHYLATION; TUMOR-SUPPRESSOR MICRORNAS; COLORECTAL-CANCER;
   MULTIPLE GENES; FECAL DNA; BREAST-CANCER; EPIGENETIC INACTIVATION;
   POTENTIAL BIOMARKER
AB Life expectancy rises steeply when a tumor is diagnosed at an early stage. Therefore, diagnosing cancer before it turns into an aggressive, barely curable disease is one of the main goals of oncological research in the 21st century. This is of vital importance for certain types of cancer for which survival rates drastically drop as primary tumors are detected by currently available screening procedures. Aberrant DNA methylation is a common hallmark of human cancer. This epigenetic mark is altered in instructive ways in the distinct stages of multistep tumorigenesis from the early onset of malignant transformation. Therefore, the possibility of detecting precise methylation signatures associated with particular cancers and the development of methodologies increasingly sensitive at detecting them, makes DNA methylation biomarkers attractive predictors for the development of effective diagnostic tests for the early detection of human neoplasia.
C1 [Javier Carmona, F.; Esteller, Manel] Bellvitge Inst Biomed Res IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona 08907, Catalonia, Spain.
C3 Institut d'Investigacio Biomedica de Bellvitge (IDIBELL)
RP Esteller, M (通讯作者)，Bellvitge Inst Biomed Res IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona 08907, Catalonia, Spain.
EM mesteller@iconcologia.net
RI ; Esteller, Manel/L-5956-2014
OI Carmona Sanz, F Javier/0000-0001-7904-8493; Esteller,
   Manel/0000-0003-4490-6093
CR Ahlquist DA, 2009, GASTROENTEROLOGY, V136, P2068, DOI 10.1053/j.gastro.2009.04.025
   Ahrendt SA, 1999, JNCI-J NATL CANCER I, V91, P332, DOI 10.1093/jnci/91.4.332
   Anglim P.P., 2008, MOL CANC, V7
   Anglim PP, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-81
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Beck S, 2008, TRENDS GENET, V24, P231, DOI 10.1016/j.tig.2008.01.006
   Belinsky SA, 2007, BRIT J CANCER, V96, P1278, DOI 10.1038/sj.bjc.6603721
   Belinsky SA, 2002, CANCER RES, V62, P2370
   Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Brabender J, 2001, ONCOGENE, V20, P3528, DOI 10.1038/sj.onc.1204455
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Chung W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002079
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469
   deVos T, 2009, CLIN CHEM, V55, P1337, DOI 10.1373/clinchem.2008.115808
   Dong SM, 2005, MODERN PATHOL, V18, P170, DOI 10.1038/modpathol.3800261
   Eguchi K, 1997, CANCER RES, V57, P4913
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Esteller M, 1999, CANCER RES, V59, P67
   Esteller M, 2001, CANCER RES, V61, P3225
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Fraga ME, 2002, BIOTECHNIQUES, V33, P632, DOI 10.2144/02333rv01
   Garcia P, 2009, MOL CARCINOGEN, V48, P79, DOI 10.1002/mc.20457
   Grady WM, 2001, CANCER RES, V61, P900
   Grote HJ, 2004, INT J CANCER, V110, P751, DOI 10.1002/ijc.20196
   Grützmann R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003759
   Hanoun N, 2010, CLIN CHEM, V56, P1107, DOI 10.1373/clinchem.2010.144709
   Henrique Rui, 2007, Critical Reviews in Oncogenesis, V13, P265
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hiltunen MO, 1997, INT J CANCER, V70, P644, DOI 10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.3.CO;2-2
   Hirsch FR, 2001, CLIN CANCER RES, V7, P5
   Honorio S, 2003, ONCOGENE, V22, P147, DOI 10.1038/sj.onc.1206057
   Huang ZH, 2007, WORLD J GASTROENTERO, V13, P950, DOI 10.3748/wjg.v13.i6.950
   Illingworth R, 2008, PLOS BIOL, V6, P37, DOI 10.1371/journal.pbio.0060022
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jerónimo C, 2003, CLIN CANCER RES, V9, P3413
   Jie G, 2007, INT J CLIN PRACT, V61, P1523, DOI 10.1111/j.1742-1241.2006.01033.x
   Kaneda A, 2005, CANCER RES, V65, P11236, DOI 10.1158/0008-5472.CAN-05-2959
   Kawasaki T, 2008, MODERN PATHOL, V21, P245, DOI 10.1038/modpathol.3800982
   Koga Y, 2009, GENOME RES, V19, P1462, DOI 10.1101/gr.091447.109
   Kondo Y, 2004, CANCER METAST REV, V23, P29, DOI 10.1023/A:1025806911782
   Krassenstein R, 2004, CLIN CANCER RES, V10, P28, DOI 10.1158/1078-0432.CCR-0410-3
   Krtolica K, 2007, WORLD J GASTROENTERO, V13, P1187, DOI 10.3748/wjg.v13.i8.1187
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lee BB, 2009, CLIN CANCER RES, V15, P6185, DOI 10.1158/1078-0432.CCR-09-0111
   Lee S, 2004, LAB INVEST, V84, P884, DOI 10.1038/labinvest.3700108
   Levenson VV, 2007, BBA-GEN SUBJECTS, V1770, P847, DOI 10.1016/j.bbagen.2007.01.017
   LIGGETT T, CANCER, V116, P1674
   Lofton-Day C, 2008, CLIN CHEM, V54, P414, DOI 10.1373/clinchem.2007.095992
   LOYO M, INT J CANC
   Lujambio A, 2007, CELL CYCLE, V6, P1455
   Melotte V, 2009, JNCI-J NATL CANCER I, V101, P916, DOI 10.1093/jnci/djp131
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   Mittag F, 2006, CANCER LETT, V240, P69, DOI 10.1016/j.canlet.2005.08.034
   Miyamoto K, 2005, INT J CANCER, V116, P407, DOI 10.1002/ijc.21054
   Moriyama T, 2007, DIS COLON RECTUM, V50, P1384, DOI 10.1007/10350-007-0302-x
   Müller HM, 2004, LANCET, V363, P1283, DOI 10.1016/S0140-6736(04)16002-9
   Mulshine JL, 2005, CLIN CANCER RES, V11, p4993S, DOI 10.1158/1078-0432.CCR-05-9011
   Nagasaka T, 2009, JNCI-J NATL CANCER I, V101, P1244, DOI 10.1093/jnci/djp265
   Nakayama H, 2002, CANCER LETT, V188, P115, DOI 10.1016/S0304-3835(01)00839-4
   Oberwalder M, 2008, INT J COLORECTAL DIS, V23, P15, DOI 10.1007/s00384-007-0355-2
   Onay H, 2009, UROL INT, V83, P107, DOI 10.1159/000224878
   Ordway JM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001314
   Rauch T, 2007, P NATL ACAD SCI USA, V104, P5527, DOI 10.1073/pnas.0701059104
   Saito Y, 2006, CELL CYCLE, V5, P2220, DOI 10.4161/cc.5.19.3340
   Sakatani T, 2005, SCIENCE, V307, P1976, DOI 10.1126/science.1108080
   Sato F, 2002, CANCER RES, V62, P1148
   Sato N, 2003, CANCER RES, V63, P3735
   Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486
   Shaw RJ, 2006, BRIT J CANCER, V94, P561, DOI 10.1038/sj.bjc.6602972
   Shen LL, 2005, JNCI-J NATL CANCER I, V97, P1330, DOI 10.1093/jnci/dji275
   Shivapurkar N, 2007, CANCER LETT, V247, P56, DOI 10.1016/j.canlet.2006.03.020
   Soria JC, 2002, CANCER RES, V62, P351
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Tessema M, 2009, CARCINOGENESIS, V30, P1132, DOI 10.1093/carcin/bgp114
   Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233
   Toyooka KO, 2001, CANCER RES, V61, P4556
   Toyooka S, 2001, MOL CANCER THER, V1, P61
   Trinh BN, 2001, METHODS, V25, P456, DOI 10.1006/meth.2001.1268
   Tsou JA, 2002, ONCOGENE, V21, P5450, DOI 10.1038/sj.onc.1205605
   Tsou JA, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-70
   Veeck J, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-83
   Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303
   Wang DR, 2008, WORLD J GASTROENTERO, V14, P524, DOI 10.3748/wjg.14.524
   Wistuba II, 2006, ANNU REV PATHOL-MECH, V1, P331, DOI 10.1146/annurev.pathol.1.110304.100103
   Wong DJ, 1999, MOL CELL BIOL, V19, P5642
   Wong JJL, 2007, GUT, V56, P140, DOI 10.1136/gut.2005.088799
   Woodson K, 2004, JNCI-J NATL CANCER I, V96, P407, DOI 10.1093/jnci/djh042
   WORSHAM MJ, OTOLARYNGOL HEAD NEC, V143, P121
   WORSHAM MJ, OTOLARYNGOL HEAD NEC, V143, pE1
   WORSHAM MJ, OTOLARYNGOL HEAD NEC, V143, P116
   Yamaguchi S, 2003, CANCER LETT, V194, P99, DOI 10.1016/S0304-3835(03)00055-7
   Yanagawa N, 2003, CANCER SCI, V94, P589, DOI 10.1111/j.1349-7006.2003.tb01487.x
   Yoshino M, 2009, INT J ONCOL, V35, P1201, DOI 10.3892/ijo_00000437
   Zhu JD, 2009, INT J BIOCHEM CELL B, V41, P147, DOI 10.1016/j.biocel.2008.09.003
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P249
   Zöchbauer-Müller S, 2003, INT J CANCER, V107, P612, DOI 10.1002/ijc.11458
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P3581
   Zou HZ, 2002, CLIN CANCER RES, V8, P188
NR 107
TC 18
Z9 22
U1 1
U2 10
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1574-0153
EI 1875-8592
J9 CANCER BIOMARK
JI Cancer Biomark.
PY 2011
VL 9
IS 1-6
BP 101
EP 111
DI 10.3233/CBM-2011-0184
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 856ZB
UT WOS:000297682300006
PM 22112471
DA 2025-01-12
ER

PT J
AU Issa, JPJ
   Garber, JE
AF Issa, Jean-Pierre J.
   Garber, Judy E.
TI Time to Think Outside the (Genetic) Box
SO CANCER PREVENTION RESEARCH
LA English
DT Article
ID BREAST-CANCER; PROMOTER METHYLATION; DNA METHYLATION; LYNCH SYNDROME;
   COLORECTAL-CANCER; RISK; INDIVIDUALS; PATHOLOGY; CARRIERS; BRCA1
AB Many patients develop cancers that have clinical features of inherited syndromes (e. g., young age of onset and unique pathology) but lack mutations in the genes characteristic of the disease. In this issue of the journal, Wong et al. report that somatic epigenetic inactivation could explain some such cases in the setting of BRCA1-associated breast cancer. Here, we discuss the implications of this work in terms of the etiology, risk, and potential prevention of cancer. Cancer Prev Res; 4(1); 6-8. (C) 2011 AACR.
C1 [Issa, Jean-Pierre J.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.
   [Garber, Judy E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; Harvard
   University; Dana-Farber Cancer Institute
RP Issa, JPJ (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Leukemia, 1515 Holcombe Blvd,Box 428, Houston, TX 77030 USA.
EM jpissa@mdanderson.org; judy_garber@dfci.harvard.edu
OI Issa, Jean-Pierre/0000-0003-2258-5030
CR Candiloro ILM, 2009, CANCER PREV RES, V2, P862, DOI 10.1158/1940-6207.CAPR-09-0056
   Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902
   Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104
   Ebbing M, 2009, JAMA-J AM MED ASSOC, V302, P2119, DOI 10.1001/jama.2009.1622
   Estécio MRH, 2009, GENOME MED, V1, DOI 10.1186/gm106
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   Hampel H, 2011, CANCER PREV RES, V4, P1, DOI 10.1158/1940-6207.CAPR-10-0345
   Hampel H, 2008, J CLIN ONCOL, V26, P5783, DOI 10.1200/JCO.2008.17.5950
   Hesson LB, 2010, CURR OPIN GENET DEV, V20, P290, DOI 10.1016/j.gde.2010.02.005
   Hitchins MP, 2009, CANCER PREV RES, V2, P847, DOI 10.1158/1940-6207.CAPR-09-0178
   Issa JP, 2008, CANCER PREV RES, V1, P219, DOI 10.1158/1940-6207.CAPR-08-0029
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Katari S, 2009, HUM MOL GENET, V18, P3769, DOI 10.1093/hmg/ddp319
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Kwon JS, 2010, J CLIN ONCOL, V28, P4214, DOI 10.1200/JCO.2010.28.0719
   Lee JS, 2010, CANCER BIOL THER, V9, P1017, DOI 10.4161/cbt.9.12.11804
   Ligtenberg MJL, 2009, NAT GENET, V41, P112, DOI 10.1038/ng.283
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Tassone P, 2003, BRIT J CANCER, V88, P1285, DOI 10.1038/sj.bjc.6600859
   Tung N, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2478
   Vargas AC, 2010, FAM CANCER, V9, P545, DOI 10.1007/s10689-010-9362-5
   Wallace K, 2010, CANCER PREV RES, V3, P1552, DOI 10.1158/1940-6207.CAPR-10-0047
   Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003
   Wei MJ, 2008, BREAST CANCER RES TR, V111, P113, DOI 10.1007/s10549-007-9766-6
   Weitzel JN, 2007, JAMA-J AM MED ASSOC, V297, P2587, DOI 10.1001/jama.297.23.2587
   Wong EM, 2011, CANCER PREV RES, V4, P23, DOI 10.1158/1940-6207.CAPR-10-0212
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
NR 27
TC 9
Z9 9
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD JAN
PY 2011
VL 4
IS 1
BP 6
EP 8
DI 10.1158/1940-6207.CAPR-10-0348
PG 3
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 702BS
UT WOS:000285870200002
PM 21205738
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Mkrtichyan, M
   Ghochikyan, A
   Davtyan, H
   Movsesyan, N
   Loukinov, D
   Lobanenkov, V
   Cribbs, DH
   Laust, AK
   Nelson, EL
   Agadjanyan, MG
AF Mkrtichyan, Mikayel
   Ghochikyan, Anahit
   Davtyan, Hayk
   Movsesyan, Nina
   Loukinov, Dmitry
   Lobanenkov, Victor
   Cribbs, David H.
   Laust, Amanda K.
   Nelson, Edward L.
   Agadjanyan, Michael G.
TI Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells
   is extremely effective against a very aggressive and highly metastatic
   mouse mammary carcinoma
SO CELLULAR IMMUNOLOGY
LA English
DT Article
DE Immunotherapy of breast cancer; Myeloid derived suppressor cells (MDSC);
   Cancer-testis antigen (CTA); Dendritic cell (DC)-based vaccine; Brother
   of regulator of imprinted sites (BORIS); Tumor promoting transcription
   factor; 4T1 mammary carcinoma
ID COMPLEX CLASS-II; SUPPRESSOR-CELLS; BREAST-CANCER; ANTITUMOR IMMUNITY;
   TRANSCRIPTION FACTOR; TUMOR; IMMUNOTHERAPY; PROTEIN; GENE; CTCF
AB Here, we analyze for the first time the immunological and therapeutic efficacy of a dendritic cell (DC) vaccine based on a cancer-testis antigen, Brother of regulator of imprinted sites (BORIS), an epigenetically acting tumor-promoting transcription factor. Vaccination of mice with DC loaded with truncated form of BORIS (DC/mBORIS) after 4T1 mammary tumor implantation induced strong anti-cancer immunity, inhibited tumor growth (18.75% of mice remained tumor-free), and dramatically lowered the number of spontaneous clonogenic metastases (50% of mice remained metastases-free). Higher numbers of immune effector CD4 and CD8 T cells infiltrated the tumors of vaccinated mice vs. control animals. Vaccination significantly decreased the number of myeloid-derived suppressor cells (MDSCs) infiltrating the tumor sites, but not MDSCs in the spleens of vaccinated animals. These data suggest that DC-based mBORIS vaccination strategies have significant anti-tumor activity in a therapeutic setting and will be more effective when combined with agents to attenuate tumor-associated immune suppression. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Mkrtichyan, Mikayel; Ghochikyan, Anahit; Davtyan, Hayk; Agadjanyan, Michael G.] Inst Mol Med, Dept Mol Immunol, Huntington Beach, CA 92647 USA.
   [Movsesyan, Nina; Cribbs, David H.; Agadjanyan, Michael G.] Univ Calif Irvine, Inst Memory Impairments & Neurol Disorders, Irvine, CA 92697 USA.
   [Loukinov, Dmitry; Lobanenkov, Victor] NIAID, Immunopathol Lab, NIH, Rockville, MD 20852 USA.
   [Cribbs, David H.] Univ Calif Irvine, Dept Neurol, Irvine, CA 92697 USA.
   [Laust, Amanda K.; Nelson, Edward L.] Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.
   [Nelson, Edward L.] Univ Calif Irvine, Div Hematol & Oncol, Dept Med, Irvine, CA 92697 USA.
C3 University of California System; University of California Irvine;
   National Institutes of Health (NIH) - USA; NIH National Institute of
   Allergy & Infectious Diseases (NIAID); University of California System;
   University of California Irvine; University of California System;
   University of California Irvine; University of California System;
   University of California Irvine
RP Agadjanyan, MG (通讯作者)，Inst Mol Med, Dept Mol Immunol, 16371 Gothard St,Suite H, Huntington Beach, CA 92647 USA.
EM mikayel.mkrtichyan@nih.gov; aghochikya-n@immed.org;
   hayk.davtyan@immed.org; nmovse-sy@uci.edu; DLOUKINOV@niaid.nih.gov;
   VLOBANENKOV@niaid.nih.gov; cribbs@uci.edu; alaust@uci.edu;
   enelson@uci.edu; magadjanyan@imme-d.org
RI Lobanenkov, Victor/ABD-5710-2021
OI Ghochikyan, Anahit/0000-0001-5436-0616; Nelson,
   Edward/0000-0001-7887-032X; Lobanenkov, Victor/0000-0001-6665-3635
FU Susan Komen Foundation [BCTR0707720]; NIH [AG-20241]; National Institute
   of Allergy and Infectious Diseases, NIH [NS-50895, NS57395]; National
   Cancer Institute [T32CA009054] Funding Source: NIH RePORTER
FX We would like to thank students Mr. M. Shugay, Mr. J. Khlghatyan, Mr.
   Tiraturyan, Ms. A. Davtyan, and Ms. A. Hovakimyan for technical help and
   Dr. I. Petrushina for valuable comments. This work was supported by
   Susan Komen Foundation BCTR0707720 for ELN and NIH AG-20241 for DHC and
   MGA; NS-50895 for DHC and MGA; NS57395 for MGA grants and in part by
   Intramural Research Program of the National Institute of Allergy and
   Infectious Diseases, NIH.
CR Anderson KS, 2009, CANCER INVEST, V27, P361, DOI 10.1080/07357900802574421
   Audia S, 2007, CLIN EXP IMMUNOL, V150, P523, DOI 10.1111/j.1365-2249.2007.03521.x
   Bertucci Francois, 2009, Journal of Biology (London), V8, P28, DOI 10.1186/jbiol128
   Bunt SK, 2006, J IMMUNOL, V176, P284, DOI 10.4049/jimmunol.176.1.284
   Cheever MA, 2009, CLIN CANCER RES, V15, P5323, DOI 10.1158/1078-0432.CCR-09-0737
   Chen L, 2007, MOL THER, V15, P2194, DOI 10.1038/sj.mt.6300310
   Cheng Fengdong, 2004, Breast Dis, V20, P93
   COLIGAN JE, 2004, CURRENT PROTOCOLS IM, P20
   Cunto-Amesty G, 2003, INT J PARASITOL, V33, P597, DOI 10.1016/S0020-7519(03)00054-7
   D'Arcy V, 2008, BRIT J CANCER, V98, P571, DOI 10.1038/sj.bjc.6604181
   Dannull J, 2005, J CLIN INVEST, V115, P3623, DOI 10.1172/JCI25947
   Darrasse-Jèze G, 2009, J CLIN INVEST, V119, P2648, DOI 10.1172/JCI36628
   Davis ID, 2004, P NATL ACAD SCI USA, V101, P10697, DOI 10.1073/pnas.0403572101
   Diaz-Montero CM, 2009, CANCER IMMUNOL IMMUN, V58, P49, DOI 10.1007/s00262-008-0523-4
   Dougherty CJ, 2008, BIOCHEM BIOPH RES CO, V370, P109, DOI 10.1016/j.bbrc.2008.03.040
   Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506
   Ghochikyan A, 2007, J IMMUNOL, V178, P566, DOI 10.4049/jimmunol.178.1.566
   Ghosh I, 2009, J PEDIAT HEMATOL ONC, V31, P539, DOI 10.1097/MPH.0b013e3181979494
   Hoechst B, 2008, GASTROENTEROLOGY, V135, P234, DOI 10.1053/j.gastro.2008.03.020
   Hong JA, 2005, CANCER RES, V65, P7763, DOI 10.1158/0008-5472.CAN-05-0823
   Hortobagyi GN, 1998, NEW ENGL J MED, V339, P974, DOI 10.1056/NEJM199810013391407
   Kaplan JM, 1999, J IMMUNOL, V163, P699
   Kim SH, 2008, BRIT J CANCER, V99, P741, DOI 10.1038/sj.bjc.6604526
   Klenova EA, 2002, SEMIN CANCER BIOL, V12, P399, DOI 10.1016/S1044-579X(02)00060-3
   Ko JS, 2009, CLIN CANCER RES, V15, P2148, DOI 10.1158/1078-0432.CCR-08-1332
   Kouprina N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000359
   Loukinov DI, 2002, P NATL ACAD SCI USA, V99, P6806, DOI 10.1073/pnas.092123699
   Loukinov D, 2006, J CELL BIOCHEM, V98, P1037, DOI 10.1002/jcb.20953
   Makki Amira, 2002, Cancer Immun, V2, P4
   Marchand M, 1999, INT J CANCER, V80, P219, DOI 10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.3.CO;2-J
   Marigo I, 2008, IMMUNOL REV, V222, P162, DOI 10.1111/j.1600-065X.2008.00602.x
   Melief CJM, 2008, IMMUNITY, V29, P372, DOI 10.1016/j.immuni.2008.08.004
   MILLER BE, 1983, CANCER RES, V43, P4102
   Mkrtichyan M, 2008, GENE THER, V15, P61, DOI 10.1038/sj.gt.3303044
   Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444
   Ostrand-Rosenberg S, 2002, J IMMUNOL, V169, P5796, DOI 10.4049/jimmunol.169.10.5796
   Ostrand-Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740
   Overwijk WW, 2005, CURR OPIN IMMUNOL, V17, P187, DOI 10.1016/j.coi.2005.01.011
   Ozao-Choy J, 2009, CANCER RES, V69, P2514, DOI 10.1158/0008-5472.CAN-08-4709
   Palucka K, 2009, ANN NY ACAD SCI, V1174, P88, DOI 10.1111/j.1749-6632.2009.05000.x
   Peranzoni E, 2010, CURR OPIN IMMUNOL, V22, P238, DOI 10.1016/j.coi.2010.01.021
   Pulaski BA, 2000, CANCER RES, V60, P2710
   Pulaski BA, 1998, CANCER RES, V58, P1486
   Ribas Antoni, 2007, Update Cancer Ther, V2, P133, DOI 10.1016/j.uct.2007.09.001
   Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100
   RUTGERS EJT, 1989, BRIT J SURG, V76, P187, DOI 10.1002/bjs.1800760227
   Scanlan Matthew J, 2004, Cancer Immun, V4, P1
   Schadendorf D, 2009, ANN ONCOL, V20, P41, DOI 10.1093/annonc/mdp253
   Schreurs MWJ, 2000, CANCER RES, V60, P6995
   Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669
   Smith FO, 2008, CLIN CANCER RES, V14, P5610, DOI 10.1158/1078-0432.CCR-08-0116
   Smyth MJ, 2001, NAT IMMUNOL, V2, P293, DOI 10.1038/86297
   Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175
   Stewart TJ, 2009, J CELL MOL MED, V13, P3939, DOI 10.1111/j.1582-4934.2009.00685.x
   Sun HX, 2009, VACCINE, V27, P1787, DOI 10.1016/j.vaccine.2009.01.091
   TOMIN R, 1987, J CLIN ONCOL, V5, P62, DOI 10.1200/JCO.1987.5.1.62
   Vatolin S, 2005, CANCER RES, V65, P7751, DOI 10.1158/0008-5472.CAN-05-0858
   Waeckerle-Men Y, 2006, CANCER IMMUNOL IMMUN, V55, P1524, DOI 10.1007/s00262-006-0157-3
   Waldmann TA, 2006, ANNU REV MED, V57, P65, DOI 10.1146/annurev.med.56.082103.104549
   Wang HY, 2002, J CLIN INVEST, V109, P1463, DOI 10.1172/JCI200215399
   *WHO, 2006, 297 WHO
   Woloszynska-Read Anna, 2007, Cancer Immun, V7, P21
   Xiang XY, 2009, INT J CANCER, V124, P2621, DOI 10.1002/ijc.24249
NR 63
TC 27
Z9 32
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0008-8749
EI 1090-2163
J9 CELL IMMUNOL
JI Cell. Immunol.
PY 2011
VL 270
IS 2
BP 188
EP 197
DI 10.1016/j.cellimm.2011.05.007
PG 10
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA 812UV
UT WOS:000294319300011
PM 21641588
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Zhu, Y
   Stevens, RG
   Hoffman, AE
   Tjonneland, A
   Vogel, UB
   Zheng, TZ
   Hansen, J
AF Zhu, Yong
   Stevens, Richard G.
   Hoffman, Aaron E.
   Tjonneland, Anne
   Vogel, Ulla B.
   Zheng, Tongzhang
   Hansen, Johnni
TI Epigenetic Impact of Long-Term Shiftwork: Pilot Evidence From Circadian
   Genes and Whole-Genome Methylation Analysis
SO CHRONOBIOLOGY INTERNATIONAL
LA English
DT Article
DE Cancer; Circadian genes; Genome-wide methylation; Shiftwork
ID BREAST-CANCER RISK; PROMOTER METHYLATION; DNA METHYLATION;
   ELECTRIC-POWER; EXPRESSION; DENMARK; WOMEN; WORK
AB Epigenetic association studies have demonstrated differential promoter methylation in the core circadian genes in breast cancer cases relative to cancer-free controls. The current pilot study aims to investigate whether epigenetic changes affecting breast cancer risk could be caused by circadian disruption through exposure to light at night. Archived DNA samples extracted from whole blood of 117 female subjects from a prospective cohort conducted in Denmark were included in this study. A polymerase chain reaction (PCR)-based method was used for detection of gene-promoter methylation, whereas genome-wide methylation analysis was performed using the Illumina Infinium Methylation Chip. Long-term shiftwork resulted in the same promoter hypomethylation of CLOCK and hypermethylation of CRY2, as was previously observed in breast cancer case-control studies. Genome-wide methylation analysis further discovered widespread methylation alterations in shiftworkers, including changes in many methylation-and cancer-relevant genes. Pathway analysis of the genes with altered methylation patterns revealed several cancer-related pathways. One of the top three networks generated was designated as "DNA replication, recombination, and repair, gene expression, behavior" with ESR1 (estrogen receptor a) featured most prominently in the network, underscoring the potential breast cancer relevance of the genes differentially methylated in long-term shiftworkers. These results, although exploratory, demonstrate the first evidence of the cancer-relevant epigenetic effects of night shiftwork, which warrant further investigation. Considering there are millions of shiftworkers worldwide, understanding the effects of this exposure may lead to novel strategies for cancer prevention and new policies regulating shiftwork. (Author correspondence: yong.zhu@yale.edu)
C1 [Zhu, Yong; Hoffman, Aaron E.; Zheng, Tongzhang] Yale Univ, Dept Epidemiol & Publ Hlth, Sch Med, New Haven, CT 06520 USA.
   [Stevens, Richard G.] Univ Connecticut, Ctr Hlth, Farmington, CT USA.
   [Tjonneland, Anne; Hansen, Johnni] Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark.
   [Vogel, Ulla B.] Natl Res Ctr Working Environm, Copenhagen, Denmark.
C3 Yale University; University of Connecticut; Danish Cancer Society;
   National Research Centre for the Working Environment
RP Zhu, Y (通讯作者)，Yale Univ, Dept Epidemiol & Publ Hlth, Sch Med, New Haven, CT 06520 USA.
EM yong.zhu@yale.edu
RI Vogel, Ulla/ABC-2212-2020; Tjonneland, Anne/AGU-0320-2022; Vogel,
   Ulla/I-5048-2012
OI Hansen, Johnni/0000-0002-9342-2725; Tjonneland,
   Anne/0000-0003-4385-2097; Vogel, Ulla/0000-0001-6807-1524
FU National Institutes of Environmental Health Sciences (NIEHS) [ES018915];
   Yale University; Danish Cancer Society
FX This work was supported by the National Institutes of Environmental
   Health Sciences (NIEHS) grant ES018915 and funds from Yale University.
   The Diet, Cancer and Health cohort was funded by the Danish Cancer
   Society.
CR Bai ZL, 2009, ARCH PHARM, V342, P133, DOI 10.1002/ardp.200800174
   Bollati V, 2010, CHRONOBIOL INT, V27, P1093, DOI 10.3109/07420528.2010.490065
   Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985
   Cavusoglu AC, 2010, NEOPLASMA, V57, P465, DOI 10.4149/neo_2010_05_465
   Hansen J, 2010, J EPIDEMIOL COMMUN H, V64, P1025, DOI 10.1136/jech.2009.101691
   Hoffman AE, 2010, CANCER PREV RES, V3, P539, DOI 10.1158/1940-6207.CAPR-09-0127
   Hoffman AE, 2010, CANCER RES, V70, P1459, DOI 10.1158/0008-5472.CAN-09-3798
   Kang TH, 2010, P NATL ACAD SCI USA, V107, P4890, DOI 10.1073/pnas.0915085107
   Kim YI, 2004, CANCER EPIDEM BIOMAR, V13, P511
   Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544
   OVERVAD K, 1991, INT J EPIDEMIOL, V20, P900, DOI 10.1093/ije/20.4.900
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Portaluppi F, 2010, CHRONOBIOL INT, V27, P1911, DOI 10.3109/07420528.2010.516381
   Ruike Y, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-137
   STEVENS RG, 1992, FASEB J, V6, P853, DOI 10.1096/fasebj.6.3.1740235
   STEVENS RG, 1987, AM J EPIDEMIOL, V125, P556, DOI 10.1093/oxfordjournals.aje.a114569
   Stevens RG, 2009, MUTAT RES-REV MUTAT, V682, P1, DOI 10.1016/j.mrrev.2009.01.003
   Straif K, 2007, LANCET ONCOL, V8, P1065, DOI 10.1016/S1470-2045(07)70373-X
   Suzuki J, 2009, CLIN CANCER RES, V15, P3163, DOI 10.1158/1078-0432.CCR-08-2319
   Tjonneland A, 2007, SCAND J PUBLIC HEALT, V35, P432, DOI 10.1080/14034940601047986
   Widschwendter M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002656
   Zhu Y, 2005, BREAST CANCER RES, V7, pR745, DOI 10.1186/bcr1283
NR 22
TC 122
Z9 137
U1 0
U2 26
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0742-0528
J9 CHRONOBIOL INT
JI Chronobiol. Int.
PY 2011
VL 28
IS 10
BP 852
EP 861
DI 10.3109/07420528.2011.618896
PG 10
WC Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Physiology
GA 847NP
UT WOS:000296979900002
PM 22080730
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Sappok, A
   Mahlknecht, U
AF Sappok, Anne
   Mahlknecht, Ulrich
TI Ribavirin restores ESR1 gene expression and tamoxifen sensitivity in
   ESR1 negative breast cancer cell lines
SO CLINICAL EPIGENETICS
LA English
DT Article
DE epigenetic; estrogen receptor alpha; HDAC; methylation; ribavirin; SAHA
AB Tumor growth is estrogen independent in approximately one-third of all breast cancers, which makes these patients unresponsive to hormonal treatment. This unresponsiveness to hormonal treatment may be explained through the absence of the estrogen receptor alpha (ESR1). The ESR1 gene re-expression through epigenetic modulators such as DNA methyltransferase inhibitors and/or histone deacetylase inhibitors restores tamoxifen sensitivity in ESR1 negative breast cancer cell lines and opens new treatment horizons in patients who were previously associated with a poor prognosis.
   In the study presented herein, we tested the ability of ribavirin, which shares some structural similarities with the DNA-methyltransferase inhibitor 5-azacytidine and which is widely known as an anti-viral agent in the treatment of hepatitis C, to restore ESR1 gene re-expression in ESR1 negative breast cancer cell lines.
   In our study we identified ribavirin to restore ESR1 gene re-expression alone and even more in combination with suberoylanilide hydroxamic acid (SAHA - up to 276 fold induction).
   Ribavirin and analogs could pave the way to novel translational research projects that aim to restore ESR1 gene re-expression and thus the susceptibility to tamoxifen-based endocrine treatment strategies.
C1 [Sappok, Anne; Mahlknecht, Ulrich] Univ Saarland, Med Ctr, Dept Internal Med, Div Immunotherapy & Gene Therapy, Homburg, Germany.
C3 Saarland University
RP Mahlknecht, U (通讯作者)，Univ Saarland, Med Ctr, Dept Internal Med, Div Immunotherapy & Gene Therapy, Homburg, Germany.
EM ulrich.mahlknecht@uks.eu
FU Deutsche Jose Carreras Leukamie-Stiftung e. V. [DJCLS R 09/20]
FX This work was supported by grants from the Deutsche Jose Carreras
   Leukamie-Stiftung e. V. (DJCLS R 09/20) to U.M.
CR Bovenzi V, 2001, CANCER CHEMOTH PHARM, V48, P71, DOI 10.1007/s002800100294
   Brinkman JA, 2009, J MAMMARY GLAND BIOL, V14, P67, DOI 10.1007/s10911-009-9113-0
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346
   CLARK GM, 1983, BREAST CANCER RES TR, V3, pS69, DOI 10.1007/BF01855130
   DECABO SF, 1994, EXPERIENTIA, V50, P658
   FABIANOWSKAMAJEWSKA K, 1994, BIOCHEM PHARMACOL, V48, P897, DOI 10.1016/0006-2952(94)90360-3
   Fan J, 2008, J CANCER RES CLIN, V134, P883, DOI 10.1007/s00432-008-0354-x
   FERGUSON AT, 1995, CANCER RES, V55, P2279
   Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260
   GABBARA S, 1995, BIOCHEM J, V307, P87, DOI 10.1042/bj3070087
   Glue P, 1999, SEMIN LIVER DIS, V19, P17
   Hortobagyi GN, 1998, NEW ENGL J MED, V339, P974, DOI 10.1056/NEJM199810013391407
   JOHNSTON SRD, 1992, ANN ONCOL, V3, P503, DOI 10.1093/oxfordjournals.annonc.a058251
   KNIGHT WA, 1977, CANCER RES, V37, P4669
   Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889
   Mei SP, 2004, INT J ONCOL, V25, P1509
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Platet N, 2004, CRIT REV ONCOL HEMAT, V51, P55, DOI 10.1016/j.critrevonc.2004.02.001
   ROODI N, 1995, JNCI-J NATL CANCER I, V87, P446, DOI 10.1093/jnci/87.6.446
   SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993
   Scott LJ, 2002, DRUGS, V62, P507, DOI 10.2165/00003495-200262030-00009
   Voelter-Mahlknecht S, 2005, CLIN EPIGENETICS, V1, P71
   Wei MJ, 2008, BREAST CANCER RES TR, V111, P113, DOI 10.1007/s10549-007-9766-6
   Yang XW, 2001, CANCER RES, V61, P7025
   Yang XW, 2000, CANCER RES, V60, P6890
   Zhou Q, 2008, MOL CANCER RES, V6, P873, DOI 10.1158/1541-7786.MCR-07-0330
   Zhu Wei-Guo, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P187, DOI 10.2174/1568011033482440
NR 29
TC 18
Z9 18
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PY 2011
VL 3
AR 8
DI 10.1186/1868-7083-3-8
PG 9
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA V30QP
UT WOS:000208830800008
PM 22414275
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Oing, C
   Jost, E
   Dahl, E
   Wilop, S
   Brümmendorf, TH
   Galm, O
AF Oing, Christoph
   Jost, Edgar
   Dahl, Edgar
   Wilop, Stefan
   Bruemmendorf, Tim H.
   Galm, Oliver
TI Aberrant DNA hypermethylation of the ITIH5 tumor suppressor gene in
   acute myeloid leukemia
SO CLINICAL EPIGENETICS
LA English
DT Article
DE DNA hypermethylation; Epigenetics; Acute myeloid leukemia;
   Inter-alpha-trypsine inhibitor; Tumor suppressor gene
ID ALPHA-TRYPSIN INHIBITOR; EXTRACELLULAR-MATRIX; CANCER; EPIGENETICS;
   FAMILY; PROTEINS; BINDING; CHAINS
AB Epigenetic mechanisms such as DNA hypermethylation and modifications of histone amino acids are known to play an important role in the control of gene expression both in normal human development and tumorigenesis. Hypermethylation of CpG islands within promoter regions of tumor suppressor genes is associated with transcriptional inactivation and represents, in addition to genetic aberrations, an important mechanism of gene silencing in the pathogenesis of human cancer. Inter-alpha-trypsine inhibitors (ITIs) are a family of serine protease inhibitors consisting of one light chain (bikunin) and two heavy chains (ITI heavy chains, ITIHs). ITIHs stabilize the extracellular matrix (ECM) by interacting with hyaluronic acid, which is a major ECM component. Hypermethylation in the upstream region of the promoter-associated CpG island of ITIH5, the most recently described member of the ITIH family, has been previously detected in breast cancer and was associated with an adverse outcome. In this study, we determined the DNA methylation status of the promoter region near the transcription start site of the ITIH5 tumor suppressor gene in leukemia cell lines and primary samples from patients with acute myeloid leukemia (AML) as well as the potential use of demethylating agents to restore a demethylated state of the promoter. Aberrant ITIH5 promoter hypermethylation occurred in 15 of 104 (14.4%) diagnostic AML samples. There were no statistically significant correlations between the ITIH5 methylation status and clinical prognostic parameters. Our results indicate that aberrant ITIH5 promoter hypermethylation is a novel epigenetic event in AML.
C1 [Oing, Christoph; Jost, Edgar; Wilop, Stefan; Bruemmendorf, Tim H.; Galm, Oliver] Rhein Westfal TH Aachen, Univ Klinikum Aachen, Klin Onkol Hamatol & Stammzelltransplantat, Pauwelsstr 30, D-52074 Aachen, Germany.
   [Dahl, Edgar] Rhein Westfal TH Aachen, Univ Klinikum Aachen, Inst Pathol, D-52074 Aachen, Germany.
C3 RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen
   University; RWTH Aachen University Hospital
RP Galm, O (通讯作者)，Rhein Westfal TH Aachen, Univ Klinikum Aachen, Klin Onkol Hamatol & Stammzelltransplantat, Pauwelsstr 30, D-52074 Aachen, Germany.
EM ogalm@ukaachen.de
RI Oing, Christoph/Y-4937-2019
OI Oing, Christoph/0000-0001-5578-3418
CR BHATIA R, 1995, BLOOD, V85, P3636, DOI 10.1182/blood.V85.12.3636.bloodjournal85123636
   Bost F, 1998, EUR J BIOCHEM, V252, P339, DOI 10.1046/j.1432-1327.1998.2520339.x
   Bourguignon J, 1999, J HISTOCHEM CYTOCHEM, V47, P1625, DOI 10.1177/002215549904701214
   CHEN L, 1994, J BIOL CHEM, V269, P28282
   ENGHILD JJ, 1991, J BIOL CHEM, V266, P747
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Figueroa ME, 2010, CANCER CELL, V17, P13, DOI 10.1016/j.ccr.2009.11.020
   Galm O, 2006, BLOOD REV, V20, P1, DOI 10.1016/j.blre.2005.01.006
   Gilbert J, 2004, CLIN CANCER RES, V10, P4589, DOI 10.1158/1078-0432.CCR-03-0297
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Himmelfarb M, 2004, CANCER LETT, V204, P69, DOI 10.1016/j.canlet.2003.09.011
   Huntly BJP, 2005, NAT REV CANCER, V5, P311, DOI 10.1038/nrc1592
   Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1794, DOI 10.1002/cncr.21792
   KOBAYASHI H, 1995, J BIOL CHEM, V270, P8361, DOI 10.1074/jbc.270.14.8361
   Löwenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407
   Mayani H, 1996, LEUKEMIA, V10, P1041
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Sundström G, 2005, MED ONCOL, V22, P71, DOI 10.1385/MO:22:1:071
   Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989
   Veeck J, 2008, ONCOGENE, V27, P865, DOI 10.1038/sj.onc.1210669
   Zhuo LS, 2004, J BIOL CHEM, V279, P38079, DOI 10.1074/jbc.R300039200
NR 23
TC 21
Z9 22
U1 0
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PY 2011
VL 2
BP 419
EP 423
DI 10.1007/s13148-011-0043-5
PG 5
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA V42ST
UT WOS:000209634200031
PM 22704354
OA Green Accepted, gold
DA 2025-01-12
ER

PT J
AU Paterson, S
   Sin, KL
   Tiang, JM
   Minchin, RF
   Butcher, NJ
AF Paterson, Scott
   Sin, Kok L.
   Tiang, Jacky M.
   Minchin, Rodney F.
   Butcher, Neville J.
TI Histone Deacetylase Inhibitors Increase Human Arylamine
   <i>N</i>-Acetyltransferase-1 Expression in Human Tumor Cells
SO DRUG METABOLISM AND DISPOSITION
LA English
DT Article
ID ACETYLTRANSFERASE TYPE-I; BREAST-CANCER CELLS; N-ACETYLTRANSFERASE; SP1
   SITE; PROMOTER; GENE; ACETYLATION; NAT1; IDENTIFICATION; POLYMORPHISMS
AB Arylamine N-acetyltransferase-1 (NAT1) has been associated with disorders involving folate metabolism, such as spina bifida, as well as numerous human cancers. As a result, the transcriptional and post-transcriptional regulation of NAT1 activity has been extensively studied. However, little work has been reported on the epigenetic control of NAT1 expression. Here, we demonstrate that the histone deacetylase inhibitor trichostatin A (TSA) increases NAT1 activity in human cancer cells by increasing transcription from the proximal promoter NATb. A specific Sp1 binding site was identified as essential for optimal induction of NAT1 by TSA. However, TSA did not increase the expression of Sp1 in HeLa cells. Instead, TSA increased the acetylation of histones associated with the NATb promoter. This allowed recruitment of Sp1 to the promoter along with acetylated histones. We propose that NAT1 transcription is partially repressed by the local chromatin condensation in the vicinity of NATb and that histone deacetylase inhibition leads to up-regulation of NAT1 expression via a direct change in chromatin conformation.
C1 [Paterson, Scott; Sin, Kok L.; Tiang, Jacky M.; Minchin, Rodney F.; Butcher, Neville J.] Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia.
C3 University of Queensland
RP Butcher, NJ (通讯作者)，Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia.
EM n.butcher@uq.edu.au
OI Minchin, Rodney/0000-0002-3178-4835; Butcher,
   Neville/0000-0002-0709-5589
CR Adam PJ, 2003, MOL CANCER RES, V1, P826
   Barker DF, 2006, PHARMACOGENET GENOM, V16, P515, DOI 10.1097/01.fpc.0000215066.29342.26
   Boukouvala S, 2005, BASIC CLIN PHARMACOL, V96, P343, DOI 10.1111/j.1742-7843.2005.pto_02.x
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Butcher N. J., 2002, Pharmacogenomics Journal, V2, P30, DOI 10.1038/sj.tpj.6500053
   Butcher NJ, 2008, CURR DRUG METAB, V9, P498, DOI 10.2174/138920008784892128
   Butcher NJ, 2007, CANCER RES, V67, P85, DOI 10.1158/0008-5472.CAN-06-2635
   Butcher NJ, 2010, CARCINOGENESIS, V31, P820, DOI 10.1093/carcin/bgq042
   Butcher NJ, 2005, BIOCHEM J, V387, P119, DOI 10.1042/BJ20040903
   Butcher NJ, 2000, MOL PHARMACOL, V57, P468, DOI 10.1124/mol.57.3.468
   Cornish VA, 2003, PHARMACOGENOMICS J, V3, P169, DOI 10.1038/sj.tpj.6500170
   Erickson RP, 2008, MOL REPROD DEV, V75, P1071, DOI 10.1002/mrd.20852
   Fishel ML, 2005, J PHARMACOL EXP THER, V312, P206, DOI 10.1124/jpet.104.073924
   Gray SG, 1998, BIOCHEM BIOPH RES CO, V245, P423, DOI 10.1006/bbrc.1998.8449
   Hatta M, 2007, J BIOL CHEM, V282, P35583, DOI 10.1074/jbc.M704735200
   HEIN DW, 1993, CARCINOGENESIS, V14, P1633, DOI 10.1093/carcin/14.8.1633
   Hein DW, 2000, CANCER EPIDEM BIOMAR, V9, P29
   Hickman D, 1998, GUT, V42, P402, DOI 10.1136/gut.42.3.402
   Husain A, 2007, DRUG METAB DISPOS, V35, P1649, DOI 10.1124/dmd.107.016485
   Jensen LE, 2006, HUM GENET, V120, P52, DOI 10.1007/s00439-006-0181-6
   Kim SJ, 2008, ONCOL REP, V19, P663
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lomberk G, 2005, BIOCHEM J, V392, P1, DOI 10.1042/BJ20051234
   López-Soto A, 2009, ONCOGENE, V28, P2370, DOI 10.1038/onc.2009.117
   MINCHIN RF, 1995, BIOCHEM J, V307, P1
   MINCHIN RF, 1992, BIOCHEM BIOPH RES CO, V185, P839, DOI 10.1016/0006-291X(92)91703-S
   Minchin RF, 2007, INT J BIOCHEM CELL B, V39, P1999, DOI 10.1016/j.biocel.2006.12.006
   Ragunathan N, 2008, MOL PHARMACOL, V73, P1761, DOI 10.1124/mol.108.045328
   Schroer K, 2002, CIRCULATION, V105, P2760, DOI 10.1161/01.CIR.0000018127.10968.34
   Senese S, 2007, MOL CELL BIOL, V27, P4784, DOI 10.1128/MCB.00494-07
   SIM E, 1995, HUM EXP TOXICOL, V14, P696, DOI 10.1177/096032719501400812
   Singh P, 2010, NUCLEIC ACIDS RES, V38, P7974, DOI 10.1093/nar/gkq680
   Smith KT, 2009, INT J BIOCHEM CELL B, V41, P21, DOI 10.1016/j.biocel.2008.09.008
   Spange S, 2009, INT J BIOCHEM CELL B, V41, P185, DOI 10.1016/j.biocel.2008.08.027
   Sugamori KS, 2003, MOL PHARMACOL, V64, P170, DOI 10.1124/mol.64.1.170
   Tiang JM, 2010, BIOCHEM BIOPH RES CO, V393, P95, DOI 10.1016/j.bbrc.2010.01.087
   Wakefield L, 2010, GENE, V452, P16, DOI 10.1016/j.gene.2009.12.002
   Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200
   Yokota T, 2004, ONCOGENE, V23, P5340, DOI 10.1038/sj.onc.1207689
   Zhao SJ, 2003, CANCER RES, V63, P2624
NR 40
TC 14
Z9 16
U1 0
U2 1
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0090-9556
EI 1521-009X
J9 DRUG METAB DISPOS
JI Drug Metab. Dispos.
PD JAN
PY 2011
VL 39
IS 1
BP 77
EP 82
DI 10.1124/dmd.110.036202
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 694WR
UT WOS:000285332100012
PM 20870783
DA 2025-01-12
ER

PT J
AU Wu, HC
   John, EM
   Ferris, JS
   Keegan, TH
   Chung, WK
   Andrulis, I
   Delgado-Cruzata, L
   Kappil, M
   Gonzalez, K
   Santella, RM
   Terry, MB
AF Wu, Hui-Chen
   John, Esther M.
   Ferris, Jennifer S.
   Keegan, Theresa H.
   Chung, Wendy K.
   Andrulis, Irene
   Delgado-Cruzata, Lissette
   Kappil, Maya
   Gonzalez, Karina
   Santella, Regina M.
   Terry, Mary Beth
TI Global DNA methylation levels in girls with and without a family history
   of breast cancer
SO EPIGENETICS
LA English
DT Article
DE Alu; DNA global methylation; early life exposure; epigenetics; LINE1;
   methylight; pyrosequencing; Sat2
ID GENOMIC DNA; EXPOSURE; RISK; HYPOMETHYLATION; EPIDEMIOLOGY; BIOMARKER
AB Lower levels of global DNA methylation in white blood cell (WBC) DNA have been associated with adult cancers. It is unknown whether individuals with a family history of cancer also have lower levels of global DNA methylation early in life. We examined global DNA methylation in WBC (measured in three repetitive elements, LINE1, Sat2 and Alu, by MethyLight and in LINE1 by pyrosequencing) in 51 girls aged 6-17 years. Compared to girls without a family history of breast cancer, methylation levels were lower for all assays in girls with a family history of breast cancer and statistically significantly lower for Alu and LINE1 pyrosequencing. After adjusting for age, body mass index (BMI) and Tanner stage, only methylation in Alu was associated with family history of breast cancer. If these findings are replicated in larger studies, they suggest that lower levels of global WBC DNA methylation observed later in life in adults with cancer may also be present early in life in children with a family history of cancer.
C1 [Wu, Hui-Chen; Ferris, Jennifer S.; Terry, Mary Beth] Columbia Univ, Med Ctr, Dept Epidemiol, New York, NY 10027 USA.
   [Wu, Hui-Chen; Delgado-Cruzata, Lissette; Kappil, Maya; Gonzalez, Karina; Santella, Regina M.] Columbia Univ, Med Ctr, Dept Environm Hlth Sci, Mailman Sch Publ Hlth, New York, NY USA.
   [Terry, Mary Beth] Columbia Univ, Med Ctr, Imprints Ctr, New York, NY USA.
   [Santella, Regina M.; Terry, Mary Beth] Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY USA.
   [Chung, Wendy K.] Columbia Univ, Med Ctr, Dept Pediat, New York, NY USA.
   [Chung, Wendy K.] Columbia Univ, Med Ctr, Dept Med, New York, NY USA.
   [John, Esther M.; Keegan, Theresa H.] Canc Prevent Inst Calif, Fremont, CA USA.
   [John, Esther M.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
   [John, Esther M.] Stanford Canc Ctr, Stanford, CA USA.
   [Andrulis, Irene] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada.
   [Andrulis, Irene] Mt Sinai Hosp & Canc Care Ontario, Samuel Lunenfeld Res Inst, Toronto, ON, Canada.
C3 Columbia University; Columbia University; Columbia University; Columbia
   University; Columbia University; Columbia University; Cancer Prevention
   Institute of California; Stanford University; Stanford University;
   Stanford Medicine; Stanford Cancer Institute; University of Toronto;
   Cancer Care Ontario; University of Toronto; Sinai Health System Toronto;
   Lunenfeld Tanenbaum Research Institute
RP Terry, MB (通讯作者)，Columbia Univ, Med Ctr, Dept Epidemiol, New York, NY 10027 USA.
EM mt146@columbia.edu
RI Wu, Lisa/JPA-4139-2023; Andrulis, Irene/E-7267-2013
OI Deyssenroth, Maya/0000-0003-2913-2392; Terry, Mary
   Beth/0000-0002-4106-5033; Delgado-Cruzata, Lissette/0000-0002-2884-0234;
   John, Esther/0000-0003-3259-8003
FU Breast Cancer Research Foundation; NIH [U01 CA69398, P30 CA13696, P30
   ES009089, R03 CA141528]; Stanford Cancer Center Development grant;
   National Cancer Institute; National Institutes of Health under RFA
   [CA-06-503]
FX This work was supported by an award from the Breast Cancer Research
   Foundation and NIH grants U01 CA69398, P30 CA13696 and P30 ES009089. The
   recruitment of girls in California was supported by a Stanford Cancer
   Center Development grant and NIH grant R03 CA141528. This work was also
   supported by the National Cancer Institute, National Institutes of
   Health under RFA # CA-06-503 and through cooperative agreements with
   members of the Breast Cancer Family Registry (BCFR) and Principal
   Investigators. The content of this manuscript does not necessarily
   reflect the views or policies of the National Cancer Institute or any of
   the collaborating centers in the BCFR, nor does mention of trade names,
   commercial products or organizations imply endorsement by the US
   Government or the BCFR.
CR Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877
   Bollati V, 2007, CANCER RES, V67, P876, DOI 10.1158/0008-5472.CAN-06-2995
   Breton CV, 2009, AM J RESP CRIT CARE, V180, P462, DOI 10.1164/rccm.200901-0135OC
   Choi JY, 2009, CARCINOGENESIS, V30, P1889, DOI 10.1093/carcin/bgp143
   Deininger PL, 2003, CURR OPIN GENET DEV, V13, P651, DOI 10.1016/j.gde.2003.10.013
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Gluckman PD, 2008, NEW ENGL J MED, V359, P61, DOI 10.1056/NEJMra0708473
   Hsiung DT, 2007, CANCER EPIDEM BIOMAR, V16, P108, DOI 10.1158/1055-9965.EPI-06-0636
   John EM, 2004, BREAST CANCER RES, V6, pR375, DOI 10.1186/bcr801
   Michels KB, 2006, INT J CANCER, V119, P2007, DOI 10.1002/ijc.22004
   Moore LE, 2008, LANCET ONCOL, V9, P359, DOI 10.1016/S1470-2045(08)70038-X
   Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109
   Pavanello S, 2009, INT J CANCER, V125, P1692, DOI 10.1002/ijc.24492
   Rampersaud GC, 2000, AM J CLIN NUTR, V72, P998
   Sato K, 2006, ENDOCR J, V53, P331, DOI 10.1507/endocrj.K06-009
   Terry MB, 2008, CANCER EPIDEM BIOMAR, V17, P2306, DOI 10.1158/1055-9965.EPI-08-0312
   Titus-Ernstoff L, 2002, CANCER EPIDEM BIOMAR, V11, P207
   Tobi EW, 2009, HUM MOL GENET, V18, P4046, DOI 10.1093/hmg/ddp353
   TRICHOPOULOS D, 1990, LANCET, V335, P939, DOI 10.1016/0140-6736(90)91000-Z
   Waterland RA, 2007, ANNU REV NUTR, V27, P363, DOI 10.1146/annurev.nutr.27.061406.093705
   Weiner AM, 2002, CURR OPIN CELL BIOL, V14, P343, DOI 10.1016/S0955-0674(02)00338-1
   Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987
NR 24
TC 27
Z9 34
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD JAN
PY 2011
VL 6
IS 1
BP 29
EP 33
DI 10.4161/epi.6.1.13393
PG 5
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 701OG
UT WOS:000285828700005
PM 20930546
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Wu, HC
   Delgado-Cruzata, L
   Flom, JD
   Kappil, M
   Ferris, JS
   Liao, YY
   Santella, RM
   Terry, MB
AF Wu, Hui-Chen
   Delgado-Cruzata, Lissette
   Flom, Julie D.
   Kappil, Maya
   Ferris, Jennifer S.
   Liao, Yuyan
   Santella, Regina M.
   Terry, Mary Beth
TI Global methylation profiles in DNA from different blood cell types
SO EPIGENETICS
LA English
DT Article
DE [H-3]-methyl acceptance assay; Alu; DNA demethylation; epigenetics;
   LINE1; LUMA; methylight; Sat2
ID GENE-EXPRESSION; CHROMOSOMAL INSTABILITY; GENOME EVOLUTION; MOBILE
   ELEMENTS; BREAST-CANCER; LEUKOCYTE DNA; HYPOMETHYLATION; FOLATE;
   PATTERNS; WOMEN
AB DNA methylation measured in white blood cell DNA is increasingly being used in studies of cancer susceptibility. However, little is known about the correlation between different assays to measure global methylation and whether the source of DNA matters when examining methylation profiles in different blood cell types. Using information from 620 women, 217 and 403 women with DNA available from granulocytes (Gran) and total white blood cells (WBC), respectively, and 48 women with DNA available from four different sources [WBC, Gran, mononuclear (MN) and lymphoblastoid cell lines (LCL)], we compared DNA methylation for three repetitive elements (LINE1, Sat2, Alu) by MethyLight, luminometric methylation assay (LUMA) and [H-3]-methyl acceptance assay. For four of the five assays, DNA methylation levels measured in Gran were not correlated with methylation in LCL, MN or WBC; the exception was Sat2. DNA methylation in LCL was correlated with methylation in MN and WBC for the [H-3]-methyl acceptance, LINE1 and Alu assays. Methylation in MN was correlated with methylation in WBC for the [H-3]-methyl acceptance and LUMA assays. When we compared the five assays to each other by source of DNA, we observed statistically significant correlations ranging from 0.3-0.7 for each cell type with one exception (Sat2 and Alu in MN). Among the 620 women stratified by DNA source, correlations among assays were highest for the three repetitive elements (range 0.39-0.64). Results from the LUMA assay were modestly correlated with LINE1 (0.18-0.20). These results suggest that both assay and source of DNA are critical components in the interpretation of global DNA methylation patterns from WBC.
C1 [Wu, Hui-Chen; Flom, Julie D.; Ferris, Jennifer S.; Liao, Yuyan; Terry, Mary Beth] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10027 USA.
   [Wu, Hui-Chen; Delgado-Cruzata, Lissette; Kappil, Maya; Santella, Regina M.] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY USA.
   [Santella, Regina M.; Terry, Mary Beth] Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY USA.
C3 Columbia University; Columbia University; Columbia University
RP Terry, MB (通讯作者)，Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10027 USA.
EM mt146@columbia.edu
RI Wu, Lisa/JPA-4139-2023
OI Terry, Mary Beth/0000-0002-4106-5033; Delgado-Cruzata,
   Lissette/0000-0002-2884-0234; Deyssenroth, Maya/0000-0003-2913-2392
FU Breast Cancer Research Foundation; NIH [U01 CA69398, P30 CA13696, P30
   ES009089]; National Cancer Institute, National Institutes of Health
   [CA-06-503]
FX This work was supported by an award from the Breast Cancer Research
   Foundation and NIH grants U01 CA69398, P30 CA13696 and P30 ES009089.
   This work was also supported by the National Cancer Institute, National
   Institutes of Health under RFA # CA-06-503 and through cooperative
   agreements with members of the Breast Cancer Family Registry (CFR) and
   Principal Investigators. The content of this manuscript does not
   necessarily reflect the views or policies of the National Cancer
   Institute or any of the collaborating centers in the CFR, nor does
   mention of trade names, commercial products or organizations imply
   endorsement by the US Government or the CFR.
CR Axume J, 2007, EPIGENETICS-US, V2, P66, DOI 10.4161/epi.2.1.4066
   Axume J, 2007, NUTR RES, V27, P13, DOI 10.1016/j.nutres.2006.12.006
   BALAGHI M, 1993, BIOCHEM BIOPH RES CO, V193, P1184, DOI 10.1006/bbrc.1993.1750
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877
   Brennan EP, 2009, EPIGENETICS-US, V4, P159, DOI 10.4161/epi.4.3.8793
   Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779
   Cho NY, 2007, J PATHOL, V211, P269, DOI 10.1002/path.2106
   Dahl C, 2003, BIOGERONTOLOGY, V4, P233, DOI 10.1023/A:1025103319328
   Deininger PL, 2003, CURR OPIN GENET DEV, V13, P651, DOI 10.1016/j.gde.2003.10.013
   Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Florl AL, 2004, BRIT J CANCER, V91, P985, DOI 10.1038/sj.bjc.6602030
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435
   Hsiung DT, 2007, CANCER EPIDEM BIOMAR, V16, P108, DOI 10.1158/1055-9965.EPI-06-0636
   Irizarry RA, 2008, GENOME RES, V18, P780, DOI 10.1101/gr.7301508
   JACOB RA, 1995, J NUTR, V125, P1495
   Jacob RA, 1998, J NUTR, V128, P1204, DOI 10.1093/jn/128.7.1204
   JEANPIERRE M, 1994, ANN GENET-PARIS, V37, P163
   Johanning GL, 2002, J NUTR, V132, p3814S, DOI 10.1093/jn/132.12.3814S
   John EM, 2004, BREAST CANCER RES, V6, pR375, DOI 10.1186/bcr801
   Jordan IK, 2003, TRENDS GENET, V19, P68, DOI 10.1016/S0168-9525(02)00006-9
   Karimi M, 2006, EXP CELL RES, V312, P1989, DOI 10.1016/j.yexcr.2006.03.006
   Kazazian HH, 2004, SCIENCE, V303, P1626, DOI 10.1126/science.1089670
   Kenneth PN, 2008, METHOD MOL BIOL, V507, P35
   LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Moore LE, 2008, LANCET ONCOL, V9, P359, DOI 10.1016/S1470-2045(08)70038-X
   Oakeley EJ, 1999, PHARMACOL THERAPEUT, V84, P389, DOI 10.1016/S0163-7258(99)00043-1
   Pilsner JR, 2007, AM J CLIN NUTR, V86, P1179, DOI 10.1093/ajcn/86.4.1179
   Quinlivan EP, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn534
   RAIZIS AM, 1995, ANAL BIOCHEM, V226, P161, DOI 10.1006/abio.1995.1204
   Rodriguez J, 2006, CANCER RES, V66, P8462, DOI 10.1158/0008-5472.CAN-06-0293
   Römermann D, 2008, LEUKEMIA, V22, P1954, DOI 10.1038/leu.2008.76
   Sharma P, 2005, BREAST CANCER RES, V7, pR634, DOI 10.1186/bcr1203
   Shen LL, 2007, CURR OPIN CLIN NUTR, V10, P576, DOI 10.1097/MCO.0b013e3282bf6f43
   Subrahmanyam YVBK, 2001, BLOOD, V97, P2457, DOI 10.1182/blood.V97.8.2457
   Suzuki K, 2006, CANCER CELL, V9, P199, DOI 10.1016/j.ccr.2006.02.016
   Terry MB, 2008, CANCER EPIDEM BIOMAR, V17, P2306, DOI 10.1158/1055-9965.EPI-08-0312
   Weiner AM, 2002, CURR OPIN CELL BIOL, V14, P343, DOI 10.1016/S0955-0674(02)00338-1
   Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987
   Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481
   Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032
   Zhang XQ, 2004, J LEUKOCYTE BIOL, V75, P358, DOI 10.1189/jlb.0903412
NR 46
TC 123
Z9 132
U1 0
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD JAN
PY 2011
VL 6
IS 1
BP 76
EP 85
DI 10.4161/epi.6.1.13391
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 701OG
UT WOS:000285828700010
PM 20890131
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Vähäkangas, K
AF Vahakangas, Kirsi
TI Chemical exposure as etiology in developmental origin of adult onset
   human cancer
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE transplacental carcinogenesis; fetal exposure; epigenetic modifications;
   environmental chemicals; endocrine disruptors
ID ENDOCRINE DISRUPTOR VINCLOZOLIN; MAMMARY-GLAND; TRANSPLACENTAL TRANSFER;
   BREAST-CANCER; GENE-EXPRESSION; HUMAN PLACENTA; CRITICAL WINDOWS;
   LUNG-CANCER; DNA; DIETHYLSTILBESTROL
AB Chemical exposures are in principle preventable causes of cancer. People are exposed to chemicals already during fetal period and the possibility of disturbances in human development by chemical compounds leading to cancer later in life has been proven by diethylstilbestrol. The mechanisms most probably include epigenetic modifications of promoter regions of key genes. The world-wide increases in cancer incidence and concurrent increase in the number and quantity of chemicals in the environment raises concerns about a link between these two. Developmental origin and related mechanisms in chemically induced human cancer are worth pursuing.
C1 [Vahakangas, Kirsi] Univ Eastern Finland, Sch Pharm, FL-70211 Kuopio, Finland.
C3 University of Eastern Finland
RP Vähäkangas, K (通讯作者)，Univ Eastern Finland, Fac Hlth Sci, POB 1627, FL-70211 Kuopio, Finland.
EM kirsi.vahakangas@uef.fi
CR Anderson LM, 2000, ENVIRON HEALTH PERSP, V108, P573, DOI 10.2307/3454549
   Annola K, 2009, PLACENTA, V30, P277, DOI 10.1016/j.placenta.2008.12.012
   Annola K, 2008, TOXICOL LETT, V182, P50, DOI 10.1016/j.toxlet.2008.08.006
   [Anonymous], 1986, IARC Monographs on the Evaluation of Carcinogenic Risks to Human, V38
   Anway MD, 2008, PROSTATE, V68, P517, DOI 10.1002/pros.20724
   Anway MD, 2006, ENDOCRINOLOGY, V147, P5515, DOI 10.1210/en.2006-0640
   Barekati Z, 2010, HUM MOL GENET, V19, P2936, DOI 10.1093/hmg/ddq199
   Barr DB, 2007, REPROD TOXICOL, V23, P260, DOI 10.1016/j.reprotox.2007.03.003
   Bergonzi R, 2009, CHEMOSPHERE, V76, P747, DOI 10.1016/j.chemosphere.2009.05.026
   Birnbaum LS, 2003, ENVIRON HEALTH PERSP, V111, P389, DOI 10.1289/ehp.5686
   Brody JG, 2011, ENVIRON HEALTH PERSP, V119, pA326, DOI 10.1289/ehp.1104077
   Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533
   Collins LL, 2009, REPROD TOXICOL, V28, P11, DOI 10.1016/j.reprotox.2009.02.013
   Costa Lucio G, 2008, Acta Biomed, V79, P172
   Doherty Leo F., 2010, Hormones & Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Esteller M, 1999, CANCER RES, V59, P67
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fenton SE, 2002, TOXICOL SCI, V67, P63, DOI 10.1093/toxsci/67.1.63
   HSIEH LL, 1993, CANCER RES, V53, P1278
   Hsu PY, 2009, CANCER RES, V69, P5936, DOI 10.1158/0008-5472.CAN-08-4914
   Hu YC, 2009, TOXICOL LETT, V190, P23, DOI 10.1016/j.toxlet.2009.06.860
   Jorgensen ED, 2004, CELL CYCLE, V3, P1154
   Karttunen V, 2010, TOXICOL LETT, V197, P75, DOI 10.1016/j.toxlet.2010.04.028
   Launay JM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007959
   Lew BJ, 2009, TOXICOL SCI, V111, P151, DOI 10.1093/toxsci/kfp125
   Liu F, 2010, ONCOGENE, V29, P3650, DOI 10.1038/onc.2010.129
   LOEB LA, 1984, CANCER RES, V44, P5940
   Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033
   Makris SL, 2011, ENVIRON HEALTH PERSP, V119, P1047, DOI 10.1289/ehp.1002676
   MANCHESTER DK, 1988, P NATL ACAD SCI USA, V85, P9243, DOI 10.1073/pnas.85.23.9243
   Martin-Villalba A, 2008, BRAIN PATHOL, V18, P455, DOI 10.1111/j.1750-3639.2008.00136.x
   Mathiesen L, 2009, BASIC CLIN PHARMACOL, V105, P181, DOI 10.1111/j.1742-7843.2009.00431.x
   Mazdai A, 2003, ENVIRON HEALTH PERSP, V111, P1249, DOI 10.1289/ehp.6146
   Mose T, 2007, INT J TOXICOL, V26, P221, DOI 10.1080/10915810701352721
   Newbold RR, 2007, MOL CARCINOGEN, V46, P783, DOI 10.1002/mc.20308
   Newbold RR, 2006, ENDOCRINOLOGY, V147, pS11, DOI 10.1210/en.2005-1164
   Olesen IA, 2007, BEST PRACT RES CL EN, V21, P462, DOI 10.1016/j.beem.2007.04.002
   Partanen HA, 2010, TOXICOL SCI, V113, P216, DOI 10.1093/toxsci/kfp257
   Pfeifer GP, 2009, SEMIN CANCER BIOL, V19, P181, DOI 10.1016/j.semcancer.2009.02.008
   Reamon-Buettner SM, 2008, MUTAT RES-REV MUTAT, V659, P158, DOI 10.1016/j.mrrev.2008.01.003
   Rudel RA, 2011, ENVIRON HEALTH PERSP, V119, P1053, DOI 10.1289/ehp.1002864
   Rybaczyk LA, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-134
   Savarese TM, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1674
   Skinner MK, 2007, PEDIATR RES, V61, p48R, DOI 10.1203/pdr.0b013e3180457671
   Smith CC, 2007, FASEB J, V21, P239, DOI 10.1096/fj.06-6635com
   Sörgel F, 2002, CHEMOTHERAPY, V48, P267, DOI 10.1159/000069715
   Soto AM, 2008, BASIC CLIN PHARMACOL, V102, P125, DOI 10.1111/j.1742-7843.2007.00165.x
   Topinka J, 2009, MUTAT RES-FUND MOL M, V669, P13, DOI 10.1016/j.mrfmmm.2009.04.011
   TRICHOPOULOS D, 1990, LANCET, V335, P939, DOI 10.1016/0140-6736(90)91000-Z
   Tysnes BB, 2007, BBA-REV CANCER, V1775, P283, DOI 10.1016/j.bbcan.2007.01.001
   Vähäkangas KH, 2001, CANCER RES, V61, P4350
   Vähäkangas K, 2009, BRIT J PHARMACOL, V158, P665, DOI 10.1111/j.1476-5381.2009.00336.x
   Veurink M, 2005, PHARM WORLD SCI, V27, P139, DOI 10.1007/s11096-005-3663-z
   Vorderstrasse BA, 2004, TOXICOL SCI, V78, P248, DOI 10.1093/toxsci/kfh062
   White SS, 2011, ENVIRON HEALTH PERSP, V119, P1070, DOI 10.1289/ehp.1002741
   Wild CP, 2009, CANCER LETT, V286, P22, DOI 10.1016/j.canlet.2009.02.053
   WOGAN GN, 1992, CANCER RES, V52, pS2114
   Xue F, 2007, LANCET ONCOL, V8, P1088, DOI 10.1016/S1470-2045(07)70377-7
   Zama AM, 2009, ENDOCRINOLOGY, V150, P4681, DOI 10.1210/en.2009-0499
NR 60
TC 8
Z9 10
U1 1
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PY 2011
VL 2
AR 62
DI 10.3389/fphar.2011.00062
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA V35XB
UT WOS:000209177400062
PM 22203803
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Taylor, MA
   Lee, YH
   Schiemann, WP
AF Taylor, Molly A.
   Lee, Yong-Hun
   Schiemann, William P.
TI Role of TGF-β and the Tumor Microenvironment During Mammary
   Tumorigenesis
SO GENE EXPRESSION
LA English
DT Article
DE Mammary tumorigenesis; Metastasis; Microenvironment; Transforming growth
   factor-beta (TGF-beta)
ID GROWTH-FACTOR-BETA; EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER
   PROGRESSION; TRANSFORMING GROWTH-FACTOR-BETA-1 TRANSGENE; KAPPA-B
   ACTIVATION; IMMUNE-RESPONSE; ENDOTHELIAL-CELLS; LYSYL OXIDASE; II
   RECEPTOR; STROMAL FIBROBLASTS
AB Transforming growth factor-beta (TGF-beta) is a multifunctional cytokine that functions to inhibit mammary tumorigenesis by directly inducing mammary epithelial cells (MECs) to undergo cell cycle arrest or apoptosis, and to secrete a variety of cytokines, growth factors, and extracellular matrix proteins that maintain cell and tissue homeostasis. Genetic and epigenetic events that transpire during mammary tumorigenesis typically inactivate the tumor suppressing activities of TGF-beta and ultimately confer this cytokine with tumor promoting activities, including the ability to stimulate breast cancer invasion, metastasis, angiogenesis, and evasion from the immune system. This dramatic conversion in TGF-beta function is known as the "TGF-beta paradox" and reflects a variety of dynamic alterations that occur not only within the developing mammary carcinoma, but also within the cellular and structural composition of its accompanying tumor microenvironment. Recent studies have begun to elucidate the critical importance of mammary tumor microenvironments in manifesting the TGF-beta paradox and influencing the response of developing mammary carcinomas to TGF-beta. Here we highlight recent findings demonstrating the essential function of tumor microenvironments in regulating the oncogenic activities of TGF-beta and its stimulation of metastatic progression during mammary tumorigenesis.
C1 [Taylor, Molly A.; Lee, Yong-Hun; Schiemann, William P.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Div Gen Med Sci Oncol, Cleveland, OH 44106 USA.
C3 University System of Ohio; Case Western Reserve University
RP Schiemann, WP (通讯作者)，Case Western Reserve Univ, Case Comprehens Canc Ctr, Div Gen Med Sci Oncol, Wolstein Res Bldg,2103 Cornell Rd, Cleveland, OH 44106 USA.
EM william.schiemann@case.edu
OI Taylor, Molly/0000-0002-7885-8395
FU National Institutes of Health [CA 129359]; Komen Foundation
   [BCTR0706967]; Department of Defense [BC084651, BC093128]; Case
   Comprehensive Cancer Center; University Hospitals Seidman Cancer Center
FX We thank members of the Schiemann Laboratory for critical comments and
   reading of the manuscript. W.P.S. was supported by grants from the
   National Institutes of Health (CA 129359), the Komen Foundation
   (BCTR0706967), the Department of Defense (BC084651); and Case
   Comprehensive Cancer Center and the University Hospitals Seidman Cancer
   Center. M.A.T. was supported by the Department of Defense (BC093128).
CR Ahmadzadeh M, 2005, J IMMUNOL, V174, P5215, DOI 10.4049/jimmunol.174.9.5215
   Albig Allan R, 2005, Future Oncol, V1, P23, DOI 10.1517/14796694.1.1.23
   Bazzoni G, 2004, PHYSIOL REV, V84, P869, DOI 10.1152/physrev.00035.2003
   BELLONE G, 1995, J IMMUNOL, V155, P1066
   Bergers G, 2005, NEURO-ONCOLOGY, V7, P452, DOI 10.1215/S1152851705000232
   Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096
   Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003
   Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922
   Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27
   Bierie B, 2008, CANCER RES, V68, P1809, DOI 10.1158/0008-5472.CAN-07-5597
   Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926
   Bierie B, 2010, CYTOKINE GROWTH F R, V21, P49, DOI 10.1016/j.cytogfr.2009.11.008
   Bierie B, 2009, J CLIN INVEST, V119, P1571, DOI 10.1172/JCI37480
   Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807
   Bobik A, 2006, ARTERIOSCL THROM VAS, V26, P1712, DOI 10.1161/01.ATV.0000225287.20034.2c
   Bönig H, 1999, SCAND J IMMUNOL, V50, P612
   Bose R, 2006, CURR OPIN CELL BIOL, V18, P206, DOI 10.1016/j.ceb.2006.02.005
   Brown KA, 2007, J CELL BIOCHEM, V101, P9, DOI 10.1002/jcb.21255
   Butcher DT, 2009, NAT REV CANCER, V9, P108, DOI 10.1038/nrc2544
   Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003
   Cheng N, 2005, ONCOGENE, V24, P5053, DOI 10.1038/sj.onc.1208685
   Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Cunha SI, 2010, J EXP MED, V207, P85, DOI 10.1084/jem.20091309
   Dejana E, 2009, CELL TISSUE RES, V335, P17, DOI 10.1007/s00441-008-0694-5
   DICKSON MC, 1995, DEVELOPMENT, V121, P1845
   Dünker N, 2000, EUR J BIOCHEM, V267, P6982, DOI 10.1046/j.1432-1327.2000.01825.x
   Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133
   ENENSTEIN J, 1992, EXP CELL RES, V203, P499, DOI 10.1016/0014-4827(92)90028-7
   Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012
   Erler JT, 2009, CLIN EXP METASTAS, V26, P35, DOI 10.1007/s10585-008-9209-8
   Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695
   Fang WB, 2011, CLIN EXP METASTAS, V28, P351, DOI 10.1007/s10585-011-9373-0
   Faure E, 2000, CELL TISSUE RES, V300, P89, DOI 10.1007/s004410000183
   Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018
   FONTANA A, 1992, INT ARCH ALLERGY IMM, V99, P1, DOI 10.1159/000236328
   Forrester E, 2005, CANCER RES, V65, P2296, DOI 10.1158/0008-5472.CAN-04-3272
   Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506
   Gatza CE, 2010, CELL SIGNAL, V22, P1163, DOI 10.1016/j.cellsig.2010.01.016
   Geissmann F, 1999, J IMMUNOL, V162, P4567
   Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047
   González-Mariscal L, 2008, BBA-BIOMEMBRANES, V1778, P729, DOI 10.1016/j.bbamem.2007.08.018
   Gorelik L, 2001, NAT MED, V7, P1118, DOI 10.1038/nm1001-1118
   Gorska AE, 1998, CELL GROWTH DIFFER, V9, P229
   Gorska AE, 2003, AM J PATHOL, V163, P1539, DOI 10.1016/S0002-9440(10)63510-9
   Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743
   Goumans MJ, 2000, INT J DEV BIOL, V44, P253
   Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1
   HAAKFRENDSCHO M, 1990, CLIN EXP IMMUNOL, V82, P404
   Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hawinkels LJAC, 2010, CANCER RES, V70, P4141, DOI 10.1158/0008-5472.CAN-09-4466
   Holderfield MT, 2008, CIRC RES, V102, P637, DOI 10.1161/CIRCRESAHA.107.167171
   JHAPPAN C, 1993, EMBO J, V12, P1835, DOI 10.1002/j.1460-2075.1993.tb05832.x
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kang JS, 2009, TRENDS CELL BIOL, V19, P385, DOI 10.1016/j.tcb.2009.05.008
   Kang Y., P NATL ACAD SCI US, V102, P13909
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6
   Kontani K, 2006, CANCER IMMUNOL IMMUN, V55, P579, DOI 10.1007/s00262-005-0044-3
   KULKARNI AB, 1993, AM J PATHOL, V143, P3
   KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770
   Labelle M, 2008, CANCER RES, V68, P1388, DOI 10.1158/0008-5472.CAN-07-2706
   Larsson J, 2001, EMBO J, V20, P1663, DOI 10.1093/emboj/20.7.1663
   Lebrin F, 2005, CARDIOVASC RES, V65, P599, DOI 10.1016/j.cardiores.2004.10.036
   Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027
   Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534
   Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737
   Lin EY, 2006, CANCER RES, V66, P11238, DOI 10.1158/0008-5472.CAN-06-1278
   López M, 2006, IMMUNOBIOLOGY, V211, P127, DOI 10.1016/j.imbio.2005.11.003
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Mantovani A, 2006, CANCER METAST REV, V25, P315, DOI 10.1007/s10555-006-9001-7
   Massagué J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Massagué J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033
   Mempel TR, 2006, IMMUNITY, V25, P129, DOI 10.1016/j.immuni.2006.04.015
   MERWIN JR, 1990, J CELL PHYSIOL, V142, P117, DOI 10.1002/jcp.1041420115
   Micke P, 2004, LUNG CANCER, V45, pS163, DOI 10.1016/j.lungcan.2004.07.977
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320
   Mitchell D, 2010, MOL CANCER THER, V9, P379, DOI 10.1158/1535-7163.MCT-09-0650
   Moretta A, 2000, IMMUNOL TODAY, V21, P228, DOI 10.1016/S0167-5699(00)01596-6
   Muraoka RS, 2003, MOL CELL BIOL, V23, P8691, DOI 10.1128/MCB.23.23.8691-8703.2003
   Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234
   Muraoka-Cook RS, 2004, CANCER RES, V64, P9002, DOI 10.1158/0008-5472.CAN-04-2111
   Nam JS, 2008, CANCER RES, V68, P3915, DOI 10.1158/0008-5472.CAN-08-0206
   Neil JR, 2008, CARCINOGENESIS, V29, P2227, DOI 10.1093/carcin/bgn202
   Neil JR, 2008, CANCER RES, V68, P1462, DOI 10.1158/0008-5472.CAN-07-3094
   Neil JR, 2009, J BIOL CHEM, V284, P21209, DOI 10.1074/jbc.M109.018374
   Niessen CM, 2007, J INVEST DERMATOL, V127, P2525, DOI 10.1038/sj.jid.5700865
   Nishiyama K, 2005, CIRCULATION, V112, P2840, DOI 10.1161/CIRCULATIONAHA.104.516898
   Nyqvist D, 2008, EMBO REP, V9, P742, DOI 10.1038/embor.2008.123
   Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626
   Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259
   Ota T, 2002, J CELL PHYSIOL, V193, P299, DOI 10.1002/jcp.10170
   Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718
   Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046
   Pardali E, 2010, TRENDS CELL BIOL, V20, P556, DOI 10.1016/j.tcb.2010.06.006
   Parvani JG, 2011, J MAMMARY GLAND BIOL, V16, P127, DOI 10.1007/s10911-011-9207-3
   Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010
   Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2
   Petersen M, 2010, ONCOGENE, V29, P1351, DOI 10.1038/onc.2009.426
   PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254
   Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256
   Pollard JW, 2001, BREAST CANCER RES, V3, P230, DOI 10.1186/bcr301
   Radisky Derek C, 2008, Proc Am Thorac Soc, V5, P316, DOI 10.1513/pats.200711-166DR
   Raza A, 2010, AM J HEMATOL, V85, P593, DOI 10.1002/ajh.21745
   REIBMAN J, 1991, P NATL ACAD SCI USA, V88, P6805, DOI 10.1073/pnas.88.15.6805
   RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7
   Rizki A, 2004, CANCER CELL, V6, P1, DOI 10.1016/j.ccr.2004.06.019
   ROBINSON SD, 1991, DEVELOPMENT, V113, P867
   ROOK AH, 1986, J IMMUNOL, V136, P3916
   Rudini N, 2008, EMBO J, V27, P993, DOI 10.1038/emboj.2008.46
   Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029
   Schürch W, 1999, CURR TOPICS PATHOL, V93, P135
   Serra Rosa, 2003, Breast Dis, V18, P61
   Serratì S, 2009, BIOCHEM PHARMACOL, V77, P813, DOI 10.1016/j.bcp.2008.10.036
   Shen WY, 2011, EUR J CELL BIOL, V90, P323, DOI 10.1016/j.ejcb.2010.10.013
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X
   Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013
   Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100
   Singer CF, 2008, BREAST CANCER RES TR, V110, P273, DOI 10.1007/s10549-007-9725-2
   Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289
   Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047
   Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107
   Taylor MA, 2011, NEOPLASIA, V13, P406, DOI 10.1593/neo.101086
   Taylor MA, 2010, J MAMMARY GLAND BIOL, V15, P169, DOI 10.1007/s10911-010-9181-1
   Teicher BA, 2007, CLIN CANCER RES, V13, P6247, DOI 10.1158/1078-0432.CCR-07-1654
   ten Dijke P, 2008, ANGIOGENESIS, V11, P79, DOI 10.1007/s10456-008-9101-9
   ten Dijke P, 2007, NAT REV MOL CELL BIO, V8, P857, DOI 10.1038/nrm2262
   Thomas DA, 2005, CANCER CELL, V8, P369, DOI 10.1016/j.ccr.2005.10.012
   Tian MZ, 2011, CELL SIGNAL, V23, P951, DOI 10.1016/j.cellsig.2010.10.015
   Tian MZ, 2010, FASEB J, V24, P1105, DOI 10.1096/fj.09-141341
   Tian M, 2009, FUTURE ONCOL, V5, P259, DOI 10.2217/14796694.5.2.259
   Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224
   TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486
   Townsend TA, 2008, J BIOL CHEM, V283, P13834, DOI 10.1074/jbc.M710607200
   Venkatesha S, 2006, NAT MED, V12, P642, DOI 10.1038/nm1429
   Wang JH, 2001, J BIOL CHEM, V276, P49236, DOI 10.1074/jbc.M108523200
   Wendt MK, 2010, ONCOGENE, V29, P6485, DOI 10.1038/onc.2010.377
   Wendt MK, 2011, MOL BIOL CELL, V22, P2423, DOI 10.1091/mbc.E11-04-0306
   Wendt MK, 2009, FUTURE ONCOL, V5, P1145, DOI [10.2217/fon.09.90, 10.2217/FON.09.90]
   Wrzesinski SH, 2007, CLIN CANCER RES, V13, P5262, DOI 10.1158/1078-0432.CCR-07-1157
   Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004
   Yang L, 2010, TRENDS IMMUNOL, V31, P220, DOI 10.1016/j.it.2010.04.002
   Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280
   Yang YA, 2002, J CLIN INVEST, V109, P1607, DOI 10.1172/JCI200215333
   Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017
NR 146
TC 79
Z9 96
U1 1
U2 8
PU COGNIZANT COMMUNICATION CORP
PI PUTNAM VALLEY
PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA
SN 1052-2166
EI 1555-3884
J9 GENE EXPRESSION
JI Gene Expr.
PY 2011
VL 15
IS 3
SI SI
BP 117
EP 132
DI 10.3727/105221611X13176664479322
PG 16
WC Biotechnology & Applied Microbiology; Gastroenterology & Hepatology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Gastroenterology & Hepatology;
   Genetics & Heredity
GA 862BQ
UT WOS:000298065200003
PM 22268294
OA Green Published
DA 2025-01-12
ER

PT J
AU Matsumura, N
   Huang, ZQ
   Mori, S
   Baba, T
   Fujii, S
   Konishi, I
   Iversen, ES
   Berchuck, A
   Murphy, SK
AF Matsumura, Noriomi
   Huang, Zhiqing
   Mori, Seiichi
   Baba, Tsukasa
   Fujii, Shingo
   Konishi, Ikuo
   Iversen, Edwin S.
   Berchuck, Andrew
   Murphy, Susan K.
TI Epigenetic suppression of the TGF-beta pathway revealed by transcriptome
   profiling in ovarian cancer
SO GENOME RESEARCH
LA English
DT Article
ID GROWTH-FACTOR-BETA; DNA METHYLATION CHANGES; HUMAN BREAST-CANCER;
   GENE-EXPRESSION; TRANSFORMING GROWTH-FACTOR-BETA-1; MESENCHYMAL
   TRANSITION; MUTATIONAL ANALYSIS; GASTRIC-CANCER; SILENCED GENES;
   RECEPTOR GENE
AB Epithelial ovarian cancer is the leading cause of death among gynecologic malignancies. Diagnosis usually occurs after metastatic spread, largely reflecting vague symptoms of early disease combined with lack of an effective screening strategy. Epigenetic mechanisms of gene regulation, including DNA methylation, are fundamental to normal cellular function and also play a major role in carcinogenesis. To elucidate the biological and clinical relevance of DNA methylation in ovarian cancer, we conducted expression microarray analysis of 39 cell lines and 17 primary culture specimens grown in the presence or absence of DNA methyltransferase (DNMT) inhibitors. Two parameters, induction of expression and standard deviation among untreated samples, identified 378 candidate methylated genes, many relevant to TGF-beta signaling. We analyzed 43 of these genes and they all exhibited methylation. Treatment with DNMT inhibitors increased TGF-beta pathway activity. Hierarchical clustering of ovarian cancers using the 378 genes reproducibly generated a distinct gene cluster strongly correlated with TGF-beta pathway activity that discriminates patients based on age. These data suggest that accumulation of age-related epigenetic modifications leads to suppression of TGF-beta signaling and contributes to ovarian carcinogenesis.
C1 [Matsumura, Noriomi; Huang, Zhiqing; Baba, Tsukasa; Berchuck, Andrew; Murphy, Susan K.] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Durham, NC 27710 USA.
   [Mori, Seiichi] Duke Univ, Inst Genome Sci & Policy, Durham, NC 27710 USA.
   [Matsumura, Noriomi; Baba, Tsukasa; Konishi, Ikuo] Kyoto Univ, Dept Gynecol & Obstet, Kyoto 6068507, Japan.
   [Fujii, Shingo] Natl Hosp Org Kyoto Med Ctr, Kyoto 6128555, Japan.
   [Iversen, Edwin S.] Duke Univ, Dept Stat Sci, Durham, NC 27708 USA.
   [Murphy, Susan K.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.
C3 Duke University; Duke University; Kyoto University; Duke University;
   Duke University
RP Murphy, SK (通讯作者)，Duke Univ, Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Durham, NC 27710 USA.
EM murph035@mc.duke.edu
RI Murphy, Susan/R-3903-2019
OI BABA, Tsukasa/0000-0003-0066-3747; Matsumura,
   Noriomi/0000-0002-4512-7975; Murphy, Susan/0000-0001-8298-7272
FU Department of Defense CDMRP [W81XWH-05-1-0053]; Japan Society for the
   Promotion of Science [21791551]; Grants-in-Aid for Scientific Research
   [21791551, 22659300, 21390452] Funding Source: KAKEN
FX We thank Regina S. Whitaker, Lauren R. Simel, Tiffany Perry, Darby
   Kroyer, Carole Grenier, Cara E. Davis, and Kerone Walker for their
   technical contributions. This research was supported by grant
   W81XWH-05-1-0053 to S.K.M. from the Department of Defense CDMRP Ovarian
   Cancer Research Program and by grant 21791551 to N.M. from the Japan
   Society for the Promotion of Science.
CR Ahuja N, 1998, CANCER RES, V58, P5489
   Alvi AJ, 2001, J CLIN PATHOL-MOL PA, V54, P240, DOI 10.1136/mp.54.4.240
   Andrechek ER, 2008, DEVELOPMENT, V135, P2403, DOI 10.1242/dev.019018
   Antequera F, 2003, CELL MOL LIFE SCI, V60, P1647, DOI 10.1007/s00018-003-3088-6
   Baba T, 2009, ONCOGENE, V28, P209, DOI 10.1038/onc.2008.374
   Badgwell D, 2007, DIS MARKERS, V23, P397, DOI 10.1155/2007/309382
   Barton CA, 2008, GYNECOL ONCOL, V109, P129, DOI 10.1016/j.ygyno.2007.12.017
   Berchuck A, 2005, CLIN CANCER RES, V11, P3686, DOI 10.1158/1078-0432.CCR-04-2398
   Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296
   Cairns Paul, 2009, V507, P165, DOI 10.1007/978-1-59745-522-0_13
   Chang JT, 2006, BIOINFORMATICS, V22, P2926, DOI 10.1093/bioinformatics/btl483
   Chen HY, 2007, NEW ENGL J MED, V356, P11, DOI 10.1056/NEJMoa060096
   Chen SJ, 2006, J BIOL CHEM, V281, P21183, DOI 10.1074/jbc.M603270200
   Ding W, 2005, CANCER RES, V65, P6526, DOI 10.1158/0008-5472.CAN-04-4385
   Do TV, 2008, MOL CANCER RES, V6, P695, DOI 10.1158/1541-7786.MCR-07-0294
   Dunfield LD, 2002, ENDOCRINOLOGY, V143, P1174, DOI 10.1210/en.143.4.1174
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Francis-Thickpenny KM, 2001, BRIT J CANCER, V85, P687, DOI 10.1054/bjoc.2001.1950
   Furuta J, 2006, CANCER RES, V66, P6080, DOI 10.1158/0008-5472.CAN-06-0157
   Goh L, 2007, BIOINFORMATICS, V23, P281, DOI 10.1093/bioinformatics/btl620
   HAVRILESKY LJ, 1995, CANCER RES, V55, P944
   Herfs M, 2008, AM J PATHOL, V172, P1391, DOI 10.2353/ajpath.2008.071004
   Hirashima Y, 2003, J BIOL CHEM, V278, P26793, DOI 10.1074/jbc.M212187200
   Hoque MO, 2008, CANCER RES, V68, P2661, DOI 10.1158/0008-5472.CAN-07-5913
   Huang ZQ, 2006, NUCLEIC ACIDS RES, V34, P555, DOI 10.1093/nar/gkj468
   Ibanez de Caceres I, 2006, CANCER RES, V66, P5021, DOI 10.1158/0008-5472.CAN-05-3365
   Ihn H, 2002, CURR OPIN RHEUMATOL, V14, P681, DOI 10.1097/00002281-200211000-00009
   Kang SH, 1999, ONCOGENE, V18, P7280, DOI 10.1038/sj.onc.1203146
   Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007
   Keen JC, 2004, CANCER BIOL THER, V3, P1304, DOI 10.4161/cbt.3.12.1458
   Kondoh E, 2010, INT J CANCER, V126, P2448, DOI 10.1002/ijc.24919
   Kwabi-Addo B, 2007, CLIN CANCER RES, V13, P3796, DOI 10.1158/1078-0432.CCR-07-0085
   Li Q, 1999, ONCOGENE, V18, P3284, DOI 10.1038/sj.onc.1202663
   Liang G, 2002, CANCER RES, V62, P961
   LOUNIS H, 1994, EXP CELL RES, V215, P303, DOI 10.1006/excr.1994.1346
   Lynch MA, 1998, CANCER RES, V58, P4227
   Ma C, 2008, GENE DEV, V22, P308, DOI 10.1101/gad.1632008
   Massagué J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Medici D, 2008, MOL BIOL CELL, V19, P4875, DOI 10.1091/mbc.E08-05-0506
   Mund C, 2006, EPIGENETICS-US, V1, P7
   Muthusamy V, 2006, CANCER RES, V66, P11187, DOI 10.1158/0008-5472.CAN-06-1274
   Nilsson Eric E, 2002, Reprod Biomed Online, V5, P254
   Onwuegbusi BA, 2006, GUT, V55, P764, DOI 10.1136/gut.2005.076430
   Renzoni EA, 2004, RESP RES, V5, DOI 10.1186/1465-9921-5-24
   Rodriguez GC, 2001, GYNECOL ONCOL, V80, P245, DOI 10.1006/gyno.2000.6042
   Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196
   Ueki T, 2002, ONCOGENE, V21, P2114, DOI 10.1038/sj.onc.1205275
   Umetani N, 2005, ONCOGENE, V24, P4721, DOI 10.1038/sj.onc.1208538
   Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571
   Wen XZ, 2006, ONCOGENE, V25, P2666, DOI 10.1038/sj.onc.1209297
   West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998
   Yamashita S, 2006, CANCER SCI, V97, P64, DOI 10.1111/j.1349-7006.2006.00136.x
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Yu HY, 2008, FASEB J, V22, P1778, DOI 10.1096/fj.07-083857
   Zhao H, 2005, CANCER-AM CANCER SOC, V104, P44, DOI 10.1002/cncr.21135
NR 58
TC 75
Z9 88
U1 0
U2 8
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1088-9051
EI 1549-5469
J9 GENOME RES
JI Genome Res.
PD JAN
PY 2011
VL 21
IS 1
BP 74
EP 82
DI 10.1101/gr.108803.110
PG 9
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 702BC
UT WOS:000285868300008
PM 21156726
OA Green Published, Green Submitted, hybrid
DA 2025-01-12
ER

PT J
AU Mukherjee, N
   Bhattacharya, N
   Sinha, S
   Alam, N
   Chakravarti, R
   Roychoudhury, S
   Panda, CK
AF Mukherjee, Nupur
   Bhattacharya, Nilanjana
   Sinha, Satyabrata
   Alam, Neyaz
   Chakravarti, Runu
   Roychoudhury, Susanta
   Panda, Chinmay Kumar
TI Association of <i>APC</i> and <i>MCC</i> polymorphisms with increased
   breast cancer risk in an Indian population
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS
LA English
DT Article
DE APC; MCC; Wnt/beta-catenin; Breast cancer
ID COLORECTAL-CANCER; GENE-MUTATIONS; EARLY-ONSET; SUSCEPTIBILITY; LOCI
AB The adenomatous polyposis coli (APC) and mutated in colorectal cancer (MCC) genes are key regulatory genes of the Wnt/beta-catenin signaling pathway, which are independently involved in maintaining low levels of-catenin in the cell. In addition to genetic and epigenetic alterations, some genetic polymorphisms in the genes associated with the Wnt signaling pathway have been reported to be associated with an increased risk of cancer, including breast cancer. In the present study we analyzed the association of genotype and haplotype status of two single nucleotide polymorphisms (SNPs), rs2229992 and rs11283943, in the APC and MCC genes, respectively, with an increased risk of breast carcinogenesis in a breast cancer and control population from eastern India. We observed a significant association of the rs11283943 SNP with increased breast cancer risk. Two specific haplotypes involving the minor allele of rs11283943 were found to be associated with an increased breast cancer risk. Kaplan-Meier curves showed a significant association of the 2-2 genotype (genotype homozygous for the rs11283943 minor allele) with decreased survival (p=0.045) of the breast cancer patients in our study, in particular patients with early-onset BC.
C1 [Mukherjee, Nupur; Bhattacharya, Nilanjana; Panda, Chinmay Kumar] Chittaranjan Natl Canc Inst, Dept Oncogene Regulat, Kolkata 700026, India.
   [Sinha, Satyabrata] WVU Eye Inst, Morgantown, WV USA.
   [Alam, Neyaz] Chittaranjan Natl Canc Inst, Dept Surg Oncol, Kolkata 700026, India.
   [Chakravarti, Runu] ID & BG Hosp Campus, ICMR Virus Unit Kolkata, Kolkata, India.
   [Roychoudhury, Susanta] Indian Inst Chem Biol, Mol & Human Genet Div, Kolkata, India.
C3 Indian Council of Medical Research (ICMR); ICMR - National Institute of
   Cholera & Enteric Diseases (NICED); ICMR - Virus Unit, Kolkata; Council
   of Scientific & Industrial Research (CSIR) - India; CSIR - Indian
   Institute of Chemical Biology (IICB)
RP Panda, CK (通讯作者)，Chittaranjan Natl Canc Inst, Dept Oncogene Regulat, Kolkata 700026, India.
EM ckpanda.cnci@gmail.com
RI Sinha, Satyabrata/K-9095-2016; Roychoudhury, Susanta/AAD-7946-2021
OI Sinha, Satyabrata/0000-0003-0514-8613
FU CSIR [60(0077)/06/EMR-II]; Chittaranjan National Cancer Institute,
   Kolkata, India
FX Financial support was provided by CSIR grant no. 60(0077)/06/EMR-II to
   Dr C. K. Panda and institutional funding provided by the Director,
   Chittaranjan National Cancer Institute, Kolkata, India.
CR [Anonymous], 2010, Cancer Facts and Figures 2010
   Bradbury AR, 2007, REV ENDOCR METAB DIS, V8, P255, DOI 10.1007/s11154-007-9038-0
   Chen SP, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-83
   Dasgupta S, 2002, ORAL ONCOL, V38, P6, DOI 10.1016/S1368-8375(00)00131-7
   Dumitrescu RG, 2005, J CELL MOL MED, V9, P208, DOI 10.1111/j.1582-4934.2005.tb00350.x
   Fukuyama R, 2008, ONCOGENE, V27, P6044, DOI 10.1038/onc.2008.204
   HORII A, 1992, CANCER RES, V52, P3231
   HORII A, 1992, CANCER RES, V52, P6696
   Jones KA, 2008, GENE DEV, V22, P3077, DOI 10.1101/gad.1741008
   Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316
   McCartney BM, 2008, CURR OPIN CELL BIOL, V20, P186, DOI 10.1016/j.ceb.2008.02.001
   Nathanson KL, 2001, HUM MOL GENET, V10, P715, DOI 10.1093/hmg/10.7.715
   Nkondjock A, 2005, M S-MED SCI, V21, P175, DOI 10.1051/medsci/2005212175
   Peto J, 1999, J NATL CANCER I, V91, P943, DOI 10.1093/jnci/91.11.943
   POWELL SM, 1994, GASTROENTEROLOGY, V107, P1759, DOI 10.1016/0016-5085(94)90818-4
   Sikdar N, 2003, J ORAL PATHOL MED, V32, P450, DOI 10.1034/j.1600-0714.2003.00132.x
   Sinha S, 2008, ANN SURG ONCOL, V15, P1070, DOI 10.1245/s10434-007-9790-0
   Tranah GJ, 2005, CANCER EPIDEM BIOMAR, V14, P863, DOI 10.1158/1055-9965.EPI-04-0687
   Wang XS, 2008, CANCER EPIDEM BIOMAR, V17, P2101, DOI 10.1158/1055-9965.EPI-08-0134
   Weber BL, 2000, EUR J CANCER, V36, P1193, DOI 10.1016/S0959-8049(00)00082-4
NR 20
TC 4
Z9 5
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0393-6155
EI 1724-6008
J9 INT J BIOL MARKER
JI Int. J. Biol. Markers
PD JAN-MAR
PY 2011
VL 26
IS 1
BP 43
EP 49
DI 10.5301/JBM.2011.6266
PG 7
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA 768CQ
UT WOS:000290909500006
PM 21279955
DA 2025-01-12
ER

PT J
AU Cabello, MJ
   Grau, L
   Franco, N
   Orenes, E
   Alvarez, M
   Blanca, A
   Heredero, O
   Palacios, A
   Urrutia, M
   Fernández, JM
   López-Beltrán, A
   Sánchez-Carbayo, M
AF Jose Cabello, Maria
   Grau, Laura
   Franco, Noreli
   Orenes, Esteban
   Alvarez, Miguel
   Blanca, Ana
   Heredero, Oscar
   Palacios, Alberto
   Urrutia, Manuel
   Maria Fernandez, Jesus
   Lopez-Beltran, Antonio
   Sanchez-Carbayo, Marta
TI Multiplexed Methylation Profiles of Tumor Suppressor Genes in Bladder
   Cancer
SO JOURNAL OF MOLECULAR DIAGNOSTICS
LA English
DT Article
ID DEPENDENT PROBE AMPLIFICATION; SQUAMOUS-CELL CARCINOMA; MS-MLPA;
   PROMOTER HYPERMETHYLATION; EPIGENETIC EVENTS; DNA METHYLATION; URINE
   SEDIMENTS; BREAST-CANCER; MICROARRAYS; DIAGNOSIS
AB Changes in DNA methylation of tumor suppressors can occur early in carcinogenesis and are potentially important early indicators of cancer. The objective of this study was to assess the methylation of 25 tumor suppressor genes in bladder cancer using a methylation-specific (MS) multiplex ligation-dependent probe amplification assay (MLPA). Initial analyses in bladder cancer cell lines (n = 14) and fresh-fro:ten primary bladder tumor specimens (n = 31) supported the panel of genes selected being altered in bladder cancer. The process of MS-MLPA was optimized for its application in body fluids using two independent training and validation sets of urinary specimens (n = 146), including patients with bladder cancer (n = 96) and controls (n = 50). BRCA1 (71.0%), WT1 (38.7%), and RARB (38.7%) were the most frequently methylated genes in bladder tumors, with WT1 methylation being significantly associated with tumor stage (P = 0.011). WT1 and PAX5A were identified as methylated tumor suppressors. In addition, BRCA1, WT1, and RARB were the most frequently methylated genes in urinary specimens. Receiver operating characteristic curve analyses revealed significant diagnostic accuracies in both urinary sets for BRCA1, RARB, and WT1. The novelty of this report relates to applying MS-MLPA, a multiplexed methylation technique., for tumor suppressors in bladder cancer and body fluids. Methylation profiles of tumor suppressor genes were clinically relevant for histopathological stratification of bladder tumors and offered a noninvasive diagnostic strategy for the clinical management of patients affected with uroepithelial neoplasias. (J Mol Diagn 2011, 13:29-40; DOI: 10.1016/j.moldx.2010.11.008)
C1 [Jose Cabello, Maria; Grau, Laura; Franco, Noreli; Orenes, Esteban; Sanchez-Carbayo, Marta] Spanish Natl Canc Ctr, Tumor Markers Grp, Mol Pathol Program, Madrid, Spain.
   [Alvarez, Miguel; Maria Fernandez, Jesus] Univ Oviedo, Hosp Cent Asturias, Dept Urol, E-33080 Oviedo, Spain.
   [Blanca, Ana; Lopez-Beltran, Antonio] Hosp Reina Sofia, Dept Pathol, Cordoba, Spain.
   [Heredero, Oscar; Palacios, Alberto; Urrutia, Manuel] Hosp Univ Salamanca, Dept Urol, Salamanca, Spain.
C3 Centro Nacional de Investigaciones Oncologicas (CNIO); Central
   University Hospital Asturias; University of Oviedo; Hospital
   Universitario Reina Sofia - Cordoba; University of Salamanca
RP Sánchez-Carbayo, M (通讯作者)，Spanish Natl Canc Res Ctr, Tumor Markers Grp, 310A,Melchor Fernandez Almagro 3, E-28029 Madrid, Spain.
EM mscarbayo@cnio.es
RI López-Beltrán, António/AAK-7326-2020; Orenes-Piñero,
   Esteban/AAG-8752-2019; Blanca, Ana/F-6841-2016; Fernandez Gomez, Jesus
   M./AAS-8587-2021
OI Blanca, Ana/0000-0002-4360-4352; Orenes-Pinero,
   Esteban/0000-0003-3979-6678; Lopez-Beltran, Antonio/0000-0002-0724-1267;
   Fernandez Gomez, Jesus M./0000-0001-9344-2980
FU Spanish Ministry of Science and Innovation [SAF2009-13035]
FX Supported by the Spanish Ministry of Science and Innovation grant
   SAF2009-13035 (M.S.-C.).
CR Aleman A, 2008, BRIT J CANCER, V98, P466, DOI 10.1038/sj.bjc.6604143
   Baffa R, 2006, J EXP CLIN CANC RES, V25, P145
   Berkhout M, 2007, MODERN PATHOL, V20, P1253, DOI 10.1038/modpathol.3800952
   Buyru N, 2009, CANCER INVEST, V27, P307, DOI 10.1080/07357900802350814
   Chan MWY, 2002, CLIN CANCER RES, V8, P464
   Chen KM, 2007, ARCH OTOLARYNGOL, V133, P1131, DOI 10.1001/archotol.133.11.1131
   Ching TT, 2005, NAT GENET, V37, P645, DOI 10.1038/ng1563
   Cordon-Cardo C, 2000, SCAND J UROL NEPHROL, V34, P82, DOI 10.1080/003655900750169338
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Dulaimi E, 2004, CLIN CANCER RES, V10, P1887, DOI 10.1158/1078-0432.CCR-03-0127
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X
   Ewald C, 2008, J NEURO-ONCOL, V90, P267, DOI 10.1007/s11060-008-9672-8
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Friedrich MG, 2004, CLIN CANCER RES, V10, P7457, DOI 10.1158/1078-0432.CCR-04-0930
   Gonzalgo ML, 2007, UROL ONCOL-SEMIN ORI, V25, P228, DOI 10.1016/j.urolonc.2006.07.020
   Gylling A, 2009, INT J CANCER, V124, P2333, DOI 10.1002/ijc.24230
   Henken FE, 2007, BRIT J CANCER, V97, P1457, DOI 10.1038/sj.bjc.6604055
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hess CJ, 2008, LEUKEMIA LYMPHOMA, V49, P1132, DOI 10.1080/10428190802035990
   Hoque MO, 2006, JNCI-J NATL CANCER I, V98, P996, DOI 10.1093/jnci/djj265
   Hu YC, 2002, ONCOGENE, V21, P7289, DOI 10.1038/sj.onc.1205805
   Huster W J, 1992, J Biopharm Stat, V2, P219, DOI 10.1080/10543409208835041
   Jeuken JW, 2007, LAB INVEST, V87, P1055, DOI 10.1038/labinvest.3700664
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kim WJ, 2005, J CELL BIOCHEM, V95, P24, DOI 10.1002/jcb.20412
   Kirkali Z, 2005, UROLOGY, V66, P4, DOI 10.1016/j.urology.2005.07.062
   Nygren AOH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni127
   Phé V, 2009, BJU INT, V104, P896, DOI 10.1111/j.1464-410X.2009.08696.x
   Pu RT, 2006, ACTA CYTOL, V50, P499, DOI 10.1159/000326003
   Sanchez-Carbayo M, 2006, J CLIN ONCOL, V24, P778, DOI 10.1200/JCO.2005.03.2375
   Sanchez-Carbayo M, 2002, CANCER RES, V62, P6973
   Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056
   Scott RH, 2008, J MED GENET, V45, P106, DOI 10.1136/jmg.2007.053207
   Wolff EM, 2005, NAT CLIN PRACT UROL, V2, P502, DOI 10.1038/ncpuro0318
   Worsham MJ, 2006, ARCH OTOLARYNGOL, V132, P668, DOI 10.1001/archotol.132.6.668
   Yan PS, 2000, CLIN CANCER RES, V6, P1432
   Yates DR, 2006, ONCOGENE, V25, P1984, DOI 10.1038/sj.onc.1209209
   Yu J, 2007, CLIN CANCER RES, V13, P7296, DOI 10.1158/1078-0432.CCR-07-0861
   Zhang ZW, 2006, UROL ONCOL-SEMIN ORI, V24, P152, DOI 10.1016/j.urolonc.2005.11.004
NR 40
TC 38
Z9 44
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1525-1578
EI 1943-7811
J9 J MOL DIAGN
JI J. Mol. Diagn.
PD JAN
PY 2011
VL 13
IS 1
BP 29
EP 40
DI 10.1016/j.jmoldx.2010.11.008
PG 12
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 707LE
UT WOS:000286287200006
PM 21227392
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Monroy, CM
   Cortes, AC
   Lopez, MS
   D'Amelio, AM
   Etzel, CJ
   Younes, A
   Strom, SS
   El-Zein, RA
AF Monroy, Claudia M.
   Cortes, Andrea C.
   Lopez, Mirtha S.
   D'Amelio, Anthony M., Jr.
   Etzel, Carol J.
   Younes, Anas
   Strom, Sara S.
   El-Zein, Randa A.
TI Hodgkin Disease Risk: Role of Genetic Polymorphisms and Gene-Gene
   Interactions in Inflammation Pathway Genes
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE Hodgkin disease; inflammation genes; cytokine polymorphisms
ID B-CELL LYMPHOMA; REGULATORY T-CELLS; BREAST-CANCER; EXPRESSION;
   INTERLEUKIN-10; CYTOKINES; LYMPHOCYTES; RECEPTORS; CARCINOMA; SURVIVAL
AB Inflammation is a critical component of cancer development. The clinical and pathological features of Hodgkin disease (HD) reflect an abnormal immunity that results from cytokines secreted by Reed-Sternberg cells and the surrounding tumor. Numerous studies have reported the association between genetic polymorphisms in cytokine genes and the susceptibility to different hematologic cancers. However, the effects of such SNPs on modulating HD risk have not yet been investigated. We hypothesized that gene-gene interactions between candidate genes in the anti-and pro-inflammatory pathways carrying suspicious polymorphisms may contribute to susceptibility to HD. To test this hypothesis, we conducted a study on 200 HD cases and 220 controls to assess associations between HD risk and 38 functional SNPs in inflammatory genes. We evaluated potential gene-gene interactions using a multi-analytic strategy combining logistic regression, multi-factor dimensionality reduction, and classification and regression tree (CART) approaches. We observed that, in combination, allelic variants in the COX2, IL18, ILR4, and IL10 genes modify the risk for developing HD. Moreover, the cumulative genetic risk score (CGRS) revealed a significant trend where the risk for developing HD increases as the number of adverse alleles in the cytokine genes increase. These findings support the notion that epigenetic-interactions between these cytokines may influence pathogenesis of HD modulating the proliferation of regulatory T cells. In this way, the innate and adaptative immune responses may be altered and defy their usual functions in the host anti-tumor response. Our study is the first to report the association between polymorphisms in inflammation genes and HD susceptibility risk. (C) 2010 Wiley-Liss, Inc.
C1 [Monroy, Claudia M.; Cortes, Andrea C.; Lopez, Mirtha S.; D'Amelio, Anthony M., Jr.; Etzel, Carol J.; Strom, Sara S.; El-Zein, Randa A.] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA.
   [Younes, Anas] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center
RP El-Zein, RA (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, POB 301439, Houston, TX 77030 USA.
CR AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705
   BREIMAN L, 1984, CLASSIFICATION REGRE, P15
   Brenner AV, 2007, CARCINOGENESIS, V28, P2543, DOI 10.1093/carcin/bgm210
   Bushley AW, 2004, GYNECOL ONCOL, V95, P672, DOI 10.1016/j.ygyno.2004.08.024
   Carpagnano GE, 2007, ONCOL RES, V16, P375
   Cerhan JR, 2007, BLOOD, V110, P4455, DOI 10.1182/blood-2007-05-088682
   Chang HD, 2007, EUR J IMMUNOL, V37, P807, DOI 10.1002/eji.200636385
   CHERNICK MR, 1999, BOOTSTRAP METHODS PR, P45
   Clària J, 2003, CURR PHARM DESIGN, V9, P2177, DOI 10.2174/1381612033454054
   Cohen MC, 1996, AM J CLIN PATHOL, V105, P589
   Diakowska D., 2006, Experimental Oncology, V28, P319
   Ebrahimi B, 2004, CANCER-AM CANCER SOC, V101, P2727, DOI 10.1002/cncr.20672
   Fujii A, 2004, INT J ONCOL, V24, P529
   Gao LB, 2009, CARCINOGENESIS, V30, P295, DOI 10.1093/carcin/bgn281
   Germano G, 2008, CYTOKINE, V43, P374, DOI 10.1016/j.cyto.2008.07.014
   Habermann TM, 2008, BLOOD, V112, P2694, DOI 10.1182/blood-2007-09-111658
   Hedi H, 2004, CELL IMMUNOL, V228, P99, DOI 10.1016/j.cellimm.2004.04.003
   Herling M, 2003, CLIN CANCER RES, V9, P2114
   Hoeft B, 2008, CANCER CAUSE CONTROL, V19, P163, DOI 10.1007/s10552-007-9082-9
   HOHAUS S, 2009, LEUKEMIA RES, V6, P1352
   Hsia CY, 2007, EJSO-EUR J SURG ONC, V33, P208, DOI 10.1016/j.ejso.2006.10.036
   KHRIPKO OP, 2008, MEDIAT INFLAMM, V2, P1
   Küppers R, 2009, NAT REV CANCER, V9, P15, DOI 10.1038/nrc2542
   Lan Q, 2006, BLOOD, V107, P4101, DOI 10.1182/blood-2005-10-4160
   Lech-Maranda E, 2004, BLOOD, V103, P3529, DOI 10.1182/blood-2003-06-1850
   Lee HJ, 2000, J EXP MED, V192, P105, DOI 10.1084/jem.192.1.105
   Loktionov A, 2004, CANCER LETT, V208, P1, DOI 10.1016/j.canlet.2004.02.009
   Marshall NA, 2004, BLOOD, V103, P1755, DOI 10.1182/blood-2003-07-2594
   Messi M, 2003, NAT IMMUNOL, V4, P78, DOI 10.1038/ni872
   Mettler L, 2004, Clin Exp Obstet Gynecol, V31, P20
   Munro LR, 2003, LEUKEMIA LYMPHOMA, V44, P2083, DOI 10.1080/1042819031000119316
   Muste A, 2009, CYTOKINE, V45, P8, DOI 10.1016/j.cyto.2008.10.019
   Nieters A, 2006, GENES IMMUN, V7, P615, DOI 10.1038/sj.gene.6364337
   Niiro H, 1998, BIOCHEM BIOPH RES CO, V250, P200, DOI 10.1006/bbrc.1998.9287
   Otto SP, 2002, ADV GENET, V46, P451
   Park S, 2007, CELL MOL IMMUNOL, V4, P329
   Pockaj BA, 2004, ANN SURG ONCOL, V11, P328, DOI 10.1245/ASO.2004.05.027
   Reyes-Gibby CC, 2008, LANCET ONCOL, V9, P777, DOI 10.1016/S1470-2045(08)70197-9
   Rhein P, 2007, LEUKEMIA, V21, P897, DOI 10.1038/sj.leu.2404613
   Ritchie MD, 2001, AM J HUM GENET, V69, P138, DOI 10.1086/321276
   Schoof N, 2009, ANN ONCOL, V20, P1548, DOI 10.1093/annonc/mdp110
   Shattuck-Brandt RL, 2000, GASTROENTEROLOGY, V118, P337, DOI 10.1016/S0016-5085(00)70216-2
   Skapenko A, 2005, J IMMUNOL, V175, P6107, DOI 10.4049/jimmunol.175.9.6107
   Takubo T, 2000, ACTA HAEMATOL-BASEL, V104, P220, DOI 10.1159/000046520
   Talar-Wojnarowska R, 2009, DIGEST DIS SCI, V54, P683, DOI 10.1007/s10620-008-0390-z
   Taniguchi M, 1997, J IMMUNOL METHODS, V206, P107, DOI 10.1016/S0022-1759(97)00094-X
   Ueda T, 2005, ANTICANCER RES, V25, P4595
   Wang SS, 2006, CANCER RES, V66, P9771, DOI 10.1158/0008-5472.CAN-06-0324
   Zha S, 2004, CANCER LETT, V215, P1, DOI 10.1016/j.canlet.2004.06.014
   Zhu JF, 2006, CELL RES, V16, P3, DOI 10.1038/sj.cr.7310002
NR 50
TC 32
Z9 33
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
EI 1098-2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD JAN
PY 2011
VL 50
IS 1
BP 36
EP 46
DI 10.1002/mc.20688
PG 11
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 696FU
UT WOS:000285428100005
PM 21061265
DA 2025-01-12
ER

PT J
AU Meng, J
   Xing, JM
   Wang, YZ
   Lu, J
   Zhao, YL
   Gao, XY
   Wang, PC
   Jia, L
   Liang, XJ
AF Meng, Jie
   Xing, Jianmin
   Wang, Yingze
   Lu, Juan
   Zhao, Yuliang
   Gao, Xueyun
   Wang, Paul C.
   Jia, Lee
   Liang, Xingjie
TI Epigenetic modulation of human breast cancer by metallofullerenol
   nanoparticles: <i>in vivo</i> treatment and <i>in vitro</i> analysis
SO NANOSCALE
LA English
DT Article
ID CATHEPSIN-S; ENDOTHELIAL-CELLS; GROWTH; CISPLATIN; ANGIOGENESIS;
   INHIBITION; EXPRESSION; APOPTOSIS; TOXICITY; MODEL
AB Multi-hydroxylated endohedral metallofullerenol [Gd@C(82)(OH)(22)](n) nanoparticles possess the general physico-chemical characteristics of most nanoparticles. They also exhibit uniquely low toxicity and antineoplastic efficacy. In the current study, the molecular mechanisms and epigenetic characteristics of the antineoplastic action of these nanoparticles are explored. Human breast cancer MCF-7 and human umbilical vein endothelial ECV304 cell lines were used. Cell viability assay, cell hierarchical cluster analysis by cDNA microarray, semi-quantitative reverse transcription-polymerase chain reaction and Western blot analysis were conducted to investigate the changes in molecular and cellular signaling pathways caused by [Gd@C(82)(OH)(22)](n). The results demonstrated the high antitumor activity and low cytotoxicity of [Gd@C(82)(OH)(22)](n) nanoparticles both in vivo and in vitro. Their possible anti-tumor mechanisms were also discussed. The present study may provide new insight into the mechanism of action of these nanoparticles.
C1 [Meng, Jie; Wang, Yingze; Lu, Juan; Zhao, Yuliang; Jia, Lee; Liang, Xingjie] Natl Ctr Nanosci & Technol China, Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100190, Peoples R China.
   [Zhao, Yuliang; Gao, Xueyun] Chinese Acad Sci, Inst High Energy Phys, Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100049, Peoples R China.
   [Xing, Jianmin] Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing 100029, Peoples R China.
   [Wang, Paul C.] Howard Univ, Dept Radiol, Lab Mol Imaging, Washington, DC 20060 USA.
C3 Chinese Academy of Sciences; National Center for Nanoscience &
   Technology, CAS; Chinese Academy of Sciences; Institute of High Energy
   Physics, CAS; Beijing University of Chinese Medicine; Howard University
RP Liang, XJ (通讯作者)，Natl Ctr Nanosci & Technol China, Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100190, Peoples R China.
EM liangxj@nanoctr.cn
RI yingze, wang/H-4974-2018; Liang, Xing-Jie/U-7657-2019
OI Gao, Xueyun/0000-0002-2267-9945; JIA, LEE/0000-0001-6839-5545; yingze,
   wang/0000-0003-2775-5166
FU MOST [2009CB930200, 2011CB933403]; National Natural Science Foundation
   of China [Y0361111JJ, 30970784]
FX This work was financially supported by the National Key Basic Research
   Program of China (MOST 973 projects 2009CB930200 and 2011CB933403), and
   the National Natural Science Foundation of China (Program No: Y0361111JJ
   and 30970784).
CR Brown SB, 2004, LANCET ONCOL, V5, P497, DOI 10.1016/S1470-2045(04)01529-3
   Chen CY, 2005, NANO LETT, V5, P2050, DOI 10.1021/nl051624b
   Daugaard M, 2005, CELL CYCLE, V4, P877, DOI 10.4161/cc.4.7.1838
   Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088
   Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011
   Flannery T, 2003, AM J PATHOL, V163, P175, DOI 10.1016/S0002-9440(10)63641-3
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   Hashizume H, 2000, AM J PATHOL, V156, P1363, DOI 10.1016/S0002-9440(10)65006-7
   Kitada S, 2008, BLOOD, V111, P3211, DOI 10.1182/blood-2007-09-113647
   KRATSCHMER W, 1990, NATURE, V347, P354, DOI 10.1038/347354a0
   Liang XJ, 2010, P NATL ACAD SCI USA, V107, P7449, DOI 10.1073/pnas.0909707107
   Liu Y, 2009, BIOMATERIALS, V30, P3934, DOI 10.1016/j.biomaterials.2009.04.001
   Ma Xiaowei, 2010, AAPS J, V12, P272, DOI 10.1208/s12248-010-9187-z
   Meng H, 2010, ACS NANO, V4, P2773, DOI 10.1021/nn100448z
   Meng J, 2010, J NANOSCI NANOTECHNO, V10, P8610, DOI 10.1166/jnn.2010.2691
   Mroz P, 2007, FREE RADICAL BIO MED, V43, P711, DOI 10.1016/j.freeradbiomed.2007.05.005
   Nishiyama N, 2003, CANCER RES, V63, P8977
   Palermo C, 2008, TRENDS PHARMACOL SCI, V29, P22, DOI 10.1016/j.tips.2007.10.011
   Petanceska S, 1996, J BIOL CHEM, V271, P4403
   Rohde M, 2005, GENE DEV, V19, P570, DOI 10.1101/gad.305405
   Ryschich E, 2006, CANCER RES, V66, P198, DOI 10.1158/0008-5472.CAN-05-1636
   Sun BY, 2002, CARBON, V40, P1591, DOI 10.1016/S0008-6223(02)00021-0
   Wang B, 2006, J BIOL CHEM, V281, P6020, DOI 10.1074/jbc.M509134200
   Wang YZ, 2010, CURR DRUG METAB, V11, P507, DOI 10.2174/138920010791636149
   Xing GM, 2004, J PHYS CHEM B, V108, P11473, DOI 10.1021/jp0487962
   Yang Y, 2005, WORLD J GASTROENTERO, V11, P2491, DOI 10.3748/wjg.v11.i16.2491
   Yang YX, 2010, J PROTEOME RES, V9, P4767, DOI 10.1021/pr100492x
   Yin JJ, 2009, BIOMATERIALS, V30, P611, DOI 10.1016/j.biomaterials.2008.09.061
   Zhao YL, 2004, J AM CHEM SOC, V126, P11134, DOI 10.1021/ja048232b
NR 29
TC 25
Z9 28
U1 1
U2 64
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040-3364
J9 NANOSCALE
JI Nanoscale
PY 2011
VL 3
IS 11
BP 4713
EP 4719
DI 10.1039/c1nr10898k
PG 7
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 843FZ
UT WOS:000296659000033
PM 21971916
DA 2025-01-12
ER

PT J
AU Jung, S
   Yi, L
   Jeong, D
   Kim, J
   An, S
   Oh, TJ
   Kim, CH
   Kim, CJ
   Yang, Y
   Kim, KI
   Lim, JS
   Lee, MS
AF Jung, Samil
   Yi, Lisha
   Jeong, Dongjun
   Kim, Jinsun
   An, Sungwhan
   Oh, Tae-Jeong
   Kim, Chang-Hwan
   Kim, Chang-Jin
   Yang, Young
   Kim, Keun Il
   Lim, Jong-Seok
   Lee, Myeong-Sok
TI The role of ADCYAP1, adenylate cyclase activating polypeptide 1, as a
   methylation biomarker for the early detection of cervical cancer
SO ONCOLOGY REPORTS
LA English
DT Article
DE methylation biomarker; epigenetic gene regulation; cervical cancer;
   ADCYAP1
ID HUMAN-PAPILLOMAVIRUS; BREAST-CANCER; EXPRESSION; PACAP; DNA; NEOPLASIA;
   PEPTIDE; VIP
AB The ADCYAP1 gene encodes an adenylate cyclase activating polypeptide 1. ADCYAP1 has been known to be involved in various biological processes. Multiple cytosine guanine dinucleotides (CpG island) are found in the ADCYAP1 promoter region. Transcriptional silencing by promoter hypermethylation is an important regulatory mechanism in tumorigenesis in many cancers. Therefore, the methylation level of the ADCYAP1 promoter was investigated in eight cervical cancer cell lines and human tissue samples with a distinctive degree of malignant transformation. While multiple CpG sites in the ADCYAP1 promoter were highly methylated in CIN III and invasive carcinoma cells as well as seven cervical cancer cell lines, they were rarely methylated in normal cells. Importantly, methylation in the ADCYAP1 promoter seems to start from CIN 1, relatively early stage of multistep carcinogenesis. This fact suggest that ADCYAP1 can be used as an effective and sensitive methylation biomarker for the early diagnosis of cervical cancer. Moreover, our data imply that the level of the ADCYAP1 promoter hypermethylation is correlated with cervical cancer development. We also show that ADCYAP1 gene expression was reactivated by the treatment of a DNA methyltransferase inhibitor of 5'-aza-2'deoxycytidine and/or a histone deacetylase inhibitor of trichostain A in cervical cancer cells suggesting that hypermethylation in the ADCYAP1 promoter is responsible for the transcriptional silencing of the ADCYAP1 gene in cervical cancer cells.
C1 [Jung, Samil; Yi, Lisha; Kim, Jinsun; Yang, Young; Kim, Keun Il; Lim, Jong-Seok; Lee, Myeong-Sok] Sookmyung Womens Univ, Div Biol Sci, Seoul 140742, South Korea.
   [Jung, Samil; Yi, Lisha; Kim, Jinsun; Yang, Young; Kim, Keun Il; Lim, Jong-Seok; Lee, Myeong-Sok] Sookmyung Womens Univ, Res Ctr Womens Dis, Seoul 140742, South Korea.
   [Jeong, Dongjun; Kim, Chang-Hwan; Kim, Chang-Jin] Soonchunhyang Univ, Dept Pathol, Coll Med, Cheonan 330090, South Korea.
   [An, Sungwhan; Oh, Tae-Jeong] Genomictree Inc, Taejon 305811, South Korea.
C3 Sookmyung Women's University; Sookmyung Women's University;
   Soonchunhyang University
RP Lee, MS (通讯作者)，Sookmyung Womens Univ, Div Biol Sci, Seoul 140742, South Korea.
EM mslee@sookmyung.ac.kr
RI JEONG, DONGJUN/HTL-8968-2023; Kim, Seung-Hyung/AAA-4707-2020; KIM,
   KEUN/D-2959-2011
OI Yang, Young/0000-0003-4239-0804; Lim, Jong-Seok/0000-0003-4024-6868
FU Korea Research Foundation; Sookmyung Women's University
FX This study was supported by the Korea Research Foundation and Sookmyung
   Women's University (2009).
CR Agorastos T, 2005, EUR J OBSTET GYN R B, V121, P99, DOI 10.1016/j.ejogrb.2004.11.024
   Asakawa S, 2001, BIOCHEM BIOPH RES CO, V286, P863, DOI 10.1006/bbrc.2001.5490
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796
   Castorina A, 2008, BRAIN RES, V1241, P29, DOI 10.1016/j.brainres.2008.09.035
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   DURST M, 1992, VIROLOGY, V189, P132, DOI 10.1016/0042-6822(92)90688-L
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Esteller M, 2001, CANCER RES, V61, P3225
   García-Fernández MO, 2004, CANCER LETT, V205, P189, DOI 10.1016/j.canlet.2003.10.008
   García-Fernández MO, 2002, REGUL PEPTIDES, V110, P9, DOI 10.1016/S0167-0115(02)00108-8
   Germano PM, 2009, J MOL NEUROSCI, V39, P391, DOI 10.1007/s12031-009-9283-7
   Hayez N, 2004, J NEUROIMMUNOL, V149, P167, DOI 10.1016/j.jneuroim.2003.12.008
   Isobe K, 2004, REGUL PEPTIDES, V123, P29, DOI 10.1016/j.regpep.2004.05.011
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   Jones P A, 1990, Adv Cancer Res, V54, P1, DOI 10.1016/S0065-230X(08)60806-4
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Li M, 2006, CANCER RES, V66, P8796, DOI 10.1158/0008-5472.CAN-05-2809
   Monaghan TK, 2008, J MOL NEUROSCI, V36, P45, DOI 10.1007/s12031-008-9082-6
   Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1<18::AID-IJC5>3.0.CO;2-M
   SOLOMON D, 1989, JAMA-J AM MED ASSOC, V262, P931
   Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
   Wolman SR, 1997, FASEB J, V11, P535, DOI 10.1096/fasebj.11.7.9212077
   zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798
NR 27
TC 26
Z9 26
U1 0
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD JAN
PY 2011
VL 25
IS 1
BP 245
EP 252
DI 10.3892/or_00001067
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 707RN
UT WOS:000286303800033
PM 21109983
OA Bronze
DA 2025-01-12
ER

PT J
AU Missaoui, N
   Hmissa, S
   Trabelsi, A
   Traoré, C
   Mokni, M
   Dante, R
   Frappart, L
AF Missaoui, Nabiha
   Hmissa, Sihem
   Trabelsi, Amel
   Traore, Cheick
   Mokni, Moncef
   Dante, Robert
   Frappart, Lucien
TI Promoter hypermethylation of <i>CDH13</i>, <i>DAPK1</i> and
   <i>TWIST1</i> genes in precancerous and cancerous lesions of the uterine
   cervix
SO PATHOLOGY RESEARCH AND PRACTICE
LA English
DT Article
DE Uterine cervix; Cancer; Diagnosis; Biomarker; DNA hypermethylation
ID ABERRANT DNA METHYLATION; TUMOR-SUPPRESSOR GENES; INTRAEPITHELIAL
   NEOPLASIA; CELL CARCINOMA; BREAST-CANCER; CPG ISLAND; PROGRESSION;
   EXPRESSION; MARKER; SERUM
AB Aberrant DNA methylation is an early event in carcinogenesis and could serve as an additional molecular marker for the early diagnosis. The study was performed to investigate the promoter methylation of DAPK1,CDH13, and TWIST1 genes in uterine cervix lesions in an effort to examine whether this epigenetic event is involved in the process of cervical carcinogenesis, and whether it might be used as a molecular marker of cervical lesions.
   We conducted a retrospective study of 60 uterine cervix specimens, including 8 normal tissue samples, 10 benign lesions, 28 precancerous lesions (CIN1-3), and 14 squamous cell carcinomas (SCC). DNA hypermethylation was investigated using methylation-specific PCR. Immunohistochemistry was used to find p16(INK4A) overexpression.
   No hypermethylated promoters were detected in normal tissues and benign lesions. However, promoter hypermethylation of CDH13, TWIST1, and DAPK1 increased progressively from CIN1 to cancer, reaching values higher than 50% for cancer. DAPK1 and CDH13 displayed a significantly increased frequency of promoter methylation with progressively more severe cervical neoplasia (p < 0.05). A statistically significant association was observed between p16(INK4A) expression and hypermethylation of DAPK1,TWIST1, and CDH13 (p < 0.0001).
   Hypermethylation of CDH13, DAPK1, and TWIST1 promoters is an early event in the initiation and progression of cervix neoplasia. CDH13, DAPK1, and TWIST1 genes are potential biomarkers of cervical cancer risk. (C) 2010 Elsevier GmbH. All rights reserved.
C1 [Missaoui, Nabiha; Hmissa, Sihem] Fac Med, Canc Epidemiol & Cytopathol Tunisian Ctr, Res Unit UR 08 13 03, Sousse, Tunisia.
   [Missaoui, Nabiha; Dante, Robert; Frappart, Lucien] Ctr Leon Berard, UMR INSERM Oncogenese & Progress Tumorale 590, F-69373 Lyon, France.
   [Missaoui, Nabiha; Hmissa, Sihem; Trabelsi, Amel; Mokni, Moncef] Farhat Hached Univ Hosp, Dept Pathol, Sousse, Tunisia.
   [Traore, Cheick; Frappart, Lucien] Edouard Herriot Univ Hosp, Dept Pathol, Lyon, France.
C3 Universite de Sousse; UNICANCER; Centre Leon Berard; Institut National
   de la Sante et de la Recherche Medicale (Inserm); Universite de Sousse;
   Hopital Farhat Hached; CHU Lyon
RP Missaoui, N (通讯作者)，CHU, Lab Anat & Cytol Pathol, Rue Ibn Eljazzar, Sousse 4000, Tunisia.
EM missaouinabiha@live.fr
RI NABIHA, MISSAOUI/HGB-5945-2022
OI NABIHA, MISSAOUI/0000-0001-6964-075X
FU Agence Universitaire de la Francophonie (AUF); Association pour la
   Recherche sur le Cancer (ARC), France; Ministry of Higher Education,
   Scientific Research and Technology; Ministry of Public Health in
   Tunisia; Ligue Contre le Cancer de la Loire, France
FX Nabiha Missaoui is a recipient of a fellowship from the Agence
   Universitaire de la Francophonie (AUF) and the Association pour la
   Recherche sur le Cancer (ARC), France. This work was supported by the
   Ministry of Higher Education, Scientific Research and Technology, and
   the Ministry of Public Health in Tunisia, and the Ligue Contre le Cancer
   de la Loire, France.
CR [Anonymous], 2003, PATHOLOGY GENETICS T
   [Anonymous], 2007, IARC Scientific Publications
   Benedet JL, 2000, INT J GYNECOL OBSTET, V70, P135, DOI 10.1016/S0020-7292(00)00232-0
   Catto JWF, 2005, J CLIN ONCOL, V23, P2903, DOI 10.1200/JCO.2005.03.163
   Christofori G, 2003, EMBO J, V22, P2318, DOI 10.1093/emboj/cdg228
   Dell C, 2001, CELL MOL LIFE SCI, V58, P1923, DOI 10.1007/PL00000827
   Dong SM, 2001, CLIN CANCER RES, V7, P1982
   DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024
   Feng QH, 2005, JNCI-J NATL CANCER I, V97, P273, DOI 10.1093/jnci/dji041
   Feng QH, 2007, CANCER EPIDEM BIOMAR, V16, P1178, DOI 10.1158/1055-9965.EPI-06-0694
   Florl AL, 2004, BRIT J CANCER, V91, P985, DOI 10.1038/sj.bjc.6602030
   Henken FE, 2007, BRIT J CANCER, V97, P1457, DOI 10.1038/sj.bjc.6604055
   Hiraga J, 2006, INT J HEMATOL, V84, P248, DOI 10.1532/IJH97.06087
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   Hüsemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003
   Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599
   Jeong DH, 2006, INT J GYNECOL CANCER, V16, P1234, DOI 10.1111/j.1525-1438.2006.00522.x
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kahn SL, 2008, CANCER CYTOPATHOL, V114, P57, DOI 10.1002/cncr.23258
   Kang S, 2006, INT J CANCER, V118, P2168, DOI 10.1002/ijc.21609
   Kang S, 2005, GYNECOL ONCOL, V96, P173, DOI 10.1016/j.ygyno.2004.09.031
   Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207
   Magdinier F, 2000, FASEB J, V14, P1585, DOI 10.1096/fj.14.11.1585
   Mironchik Y, 2005, CANCER RES, V65, P10801, DOI 10.1158/0008-5472.CAN-05-0712
   Missaoui N, 2010, PATHOL RES PRACT, V206, P550, DOI 10.1016/j.prp.2010.02.014
   Müller HM, 2004, ANN NY ACAD SCI, V1022, P44, DOI 10.1196/annals.1318.008
   Narayan Gopeshwar, 2003, Mol Cancer, V2, P24, DOI 10.1186/1476-4598-2-24
   Oikonomou P, 2007, EXP BIOL MED, V232, P881
   OSTOR AG, 1993, INT J GYNECOL PATHOL, V12, P186
   Perrin D, 2007, ONCOGENE, V26, P2518, DOI 10.1038/sj.onc.1210039
   Reesink-Peters N, 2004, MOL CANCER RES, V2, P289
   Shivapurkar N, 2007, GYNECOL ONCOL, V107, P549, DOI 10.1016/j.ygyno.2007.08.057
   SNIJDERS PJF, 1990, J GEN VIROL, V71, P173, DOI 10.1099/0022-1317-71-1-173
   Terra APS, 2007, TUMORI J, V93, P572
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Tost J, 2010, MOL BIOTECHNOL, V44, P71, DOI 10.1007/s12033-009-9216-2
   Toyooka KO, 2001, CANCER RES, V61, P4556
   van Doorn R, 2005, J CLIN ONCOL, V23, P3886, DOI 10.1200/JCO.2005.11.353
   Virmani AK, 2001, CLIN CANCER RES, V7, P584
   Wentzensen N, 2009, GYNECOL ONCOL, V112, P293, DOI 10.1016/j.ygyno.2008.10.012
   Widschwendter A, 2004, INT J CANCER, V109, P163, DOI 10.1002/ijc.11706
   Widschwendter A, 2004, CLIN CANCER RES, V10, P3396, DOI 10.1158/1078-0432.CCR-03-0143
   Widschwendter A, 2004, CLIN CANCER RES, V10, P565, DOI 10.1158/1078-0432.CCR-0825-03
   Wisman GBA, 2006, INT J CANCER, V119, P1908, DOI 10.1002/ijc.22060
   Yang HJ, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-212
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
   zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798
NR 49
TC 33
Z9 40
U1 0
U2 8
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0344-0338
J9 PATHOL RES PRACT
JI Pathol. Res. Pract.
PY 2011
VL 207
IS 1
BP 37
EP 42
DI 10.1016/j.prp.2010.11.001
PG 6
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 715VJ
UT WOS:000286917600006
PM 21129853
DA 2025-01-12
ER

PT J
AU Bennett, KL
   Mester, J
   Eng, C
AF Bennett, Kristi L.
   Mester, Jessica
   Eng, Charis
TI Germline Epigenetic Regulation of <i>KILLIN</i> in Cowden and
   Cowden-like Syndrome
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID HAMARTOMA-TUMOR-SYNDROME; PTEN; MUTATIONS; CANCER; DISEASE;
   INACTIVATION; BREAST; GENES; DNA
AB Context Germline loss-of-function phosphatase and tensin homolog gene (PTEN) mutations cause 80% of Cowden syndrome, a rare autosomal-dominant disorder (1 in 200 000 live births), characterized by high risks of breast, thyroid, and other cancers. A large heterogeneous group of individuals with Cowden-like syndrome, who have various combinations of Cowden syndrome features but who do not meet Cowden syndrome diagnostic criteria, have PTEN mutations less than 10% of the time, making molecular diagnosis, prediction, genetic counseling, and risk management challenging. Other mechanisms of loss of function such as hypermethylation, which should result in underexpression of PTEN or of KILLIN, a novel tumor suppressor transcribed in the opposite direction, may account for the remainder of Cowden syndrome and Cowden-like syndrome.
   Objective To determine whether germline methylation is found in Cowden syndrome or Cowden-like syndrome in individuals lacking germline PTEN mutations.
   Design, Setting, and Participants Nucleic acids from prospective nested series of 123 patients with Cowden syndrome or Cowden-like syndrome and 50 unaffected individuals without PTEN variants were analyzed for germline methylation and expression of PTEN and KILLIN at the Cleveland Clinic, August 2008-June 2010. Prevalence of component cancers between groups was compared using the Fisher exact test.
   Main Outcome Measures Frequency of germline methylation in PTEN mutation-negative Cowden syndrome and Cowden syndrome-like individuals. Prevalence of component cancers in methylation-positive and PTEN mutation-positive individuals.
   Results Of 123 patients with Cowden syndrome or Cowden-like syndrome, 45 (37%; 95% confidence interval [CI], 29%-45%) showed hypermethylation upstream of PTEN but no transcriptional repression. The germline methylation was found to transcriptionally down-regulate KILLIN by 250-fold (95% CI, 45-14 286; P=.007) and exclusively disrupted TP53 activation of KILLIN by 30% (95% CI, 7%-45%; P=.008). Demethylation treatment increased only KILLIN expression 4.88-fold (95% CI, 1.4-18.1; P=.05). Individuals with KILLIN-promoter methylation had a 3-fold increased prevalence of breast cancer (35/42 vs 24/64; P<.0001) and a greater than 2-fold increase of kidney cancer (4/45 vs 6/155; P=.004) over individuals with germline PTEN mutations.
   Conclusions Germline KILLIN methylation is common among patients with Cowden syndrome or Cowden-like syndrome and is associated with increased risks of breast and renal cancer over PTEN mutation-positive individuals. These observations need to be replicated. JAMA. 2010;304(24):2724-2732 www.jama.com
C1 [Bennett, Kristi L.; Mester, Jessica; Eng, Charis] Cleveland Clin, Genom Med Inst, Cleveland, OH 44195 USA.
   [Eng, Charis] Cleveland Clin, Taussig Canc Inst, Lerner Res Inst, Cleveland, OH 44195 USA.
   [Eng, Charis] Cleveland Clin, Stanley Shalom Zielony Nursing Inst, Cleveland, OH 44195 USA.
   [Eng, Charis] Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA.
   [Eng, Charis] Case Western Reserve Univ, Sch Med, CASE Comprehens Canc Ctr, Cleveland, OH 44106 USA.
C3 Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland
   Clinic Foundation; University System of Ohio; Case Western Reserve
   University; University System of Ohio; Case Western Reserve University
RP Eng, C (通讯作者)，Cleveland Clin, Genom Med Inst, 9500 Euclid Ave,NE-50, Cleveland, OH 44195 USA.
EM engc@ccf.org
OI Eng, Charis/0000-0002-3693-5145
FU Breast Cancer Research Foundation; William Randolph Hearst Foundations;
   National Cancer Institute [P01CA124570]; FM Kirby Foundation
FX Dr Eng reports receipt of funding for this study, in part, by the Breast
   Cancer Research Foundation, the William Randolph Hearst Foundations, and
   the National Cancer Institute (P01CA124570). Dr Eng is the Sondra J. and
   Stephen R. Hardis Chair of Cancer Genomic Medicine at the Cleveland
   Clinic, was a Doris Duke Distinguished Clinical Scientist, and is an
   American Cancer Society Clinical Research Professor, which is funded, in
   part, by the FM Kirby Foundation.
CR Bennett KL, 2007, CANCER RES, V67, P4657, DOI 10.1158/0008-5472.CAN-06-4793
   Cho YJ, 2008, P NATL ACAD SCI USA, V105, P5396, DOI 10.1073/pnas.0705410105
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435
   Hitchins M, 2005, GASTROENTEROLOGY, V129, P1392, DOI 10.1053/j.gastro.2005.09.003
   Hitchins MP, 2007, NEW ENGL J MED, V356, P697, DOI 10.1056/NEJMoa064522
   Hobert JA, 2009, GENET MED, V11, P687, DOI 10.1097/GIM.0b013e3181ac9aea
   Kikuno N, 2008, INT J CANCER, V123, P552, DOI 10.1002/ijc.23590
   Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64
   Marsh DJ, 1998, J MED GENET, V35, P881, DOI 10.1136/jmg.35.11.881
   Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114
   Ni Y, 2008, AM J HUM GENET, V83, P261, DOI 10.1016/j.ajhg.2008.07.011
   Pilarski R, 2004, J MED GENET, V41, P323, DOI 10.1136/jmg.2004.018036
   Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013
   Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8
   Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9
   STARINK TM, 1986, CLIN GENET, V29, P222
   Tada T, 2006, JNCI-J NATL CANCER I, V98, P396, DOI 10.1093/jnci/djj093
   Teresi RE, 2007, AM J HUM GENET, V81, P756, DOI 10.1086/521051
   Yu L, 2004, GENOMICS, V84, P647, DOI 10.1016/j.ygeno.2004.06.010
   Zhou XP, 2003, AM J HUM GENET, V73, P1191, DOI 10.1086/379382
NR 23
TC 111
Z9 120
U1 0
U2 10
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD DEC 22
PY 2010
VL 304
IS 24
BP 2724
EP 2731
DI 10.1001/jama.2010.1877
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 697MP
UT WOS:000285518000017
PM 21177507
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Riis, MLH
   Lüders, T
   Nesbakken, AJ
   Vollan, HS
   Kristensen, V
   Bukholm, IRK
AF Riis, Margit L. H.
   Luders, Torben
   Nesbakken, Anne-Jorunn
   Vollan, Hilde S.
   Kristensen, Vessela
   Bukholm, Ida R. K.
TI Expression of BMI-1 and Mel-18 in breast tissue - a diagnostic marker in
   patients with breast cancer
SO BMC CANCER
LA English
DT Article
ID OVEREXPRESSION; PROTEIN; ONCOPROTEIN; SENESCENCE; LYMPHOMA; CELLS
AB Background: Polycomb Group (PcG) proteins are epigenetic silencers involved in maintaining cellular identity, and their deregulation can result in cancer. Expression of Mel-18 and Bmi-1 has been studied in tumor tissue, but not in adjacent non-cancerous breast epithelium. Our study compares the expression of the two genes in normal breast epithelium of cancer patients and relates it to the level of expression in the corresponding tumors as well as in breast epithelium of healthy women.
   Methods: A total of 79 tumors, of which 71 malignant tumors of the breast, 6 fibroadenomas, and 2 DCIS were studied and compared to the reduction mammoplastic specimens of 11 healthy women. In addition there was available adjacent cancer free tissue for 23 of the malignant tumors. The tissue samples were stored in RNAlater, RNA was isolated to create expression microarray profile. These two genes were then studied more closely first on mRNA transcription level by microarrays (Agilent 44 K) and quantitative RT-PCR (TaqMan) and then on protein expression level using immunohistochemistry.
   Results: Bmi-1 mRNA is significantly up-regulated in adjacent normal breast tissue in breast cancer patients compared to normal breast tissue from noncancerous patients. Conversely, mRNA transcription level of Mel-18 is lower in normal breast from patients operated for breast cancer compared to breast tissue from mammoplasty. When protein expression of these two genes was evaluated, we observed that most of the epithelial cells were positive for Bmi-1 in both groups of tissue samples, although the expression intensity was stronger in normal tissue from cancer patients compared to mammoplasty tissue samples. Protein expression of Mel-18 showed inversely stronger intensity in tissue samples from mammoplasty compared to normal breast tissue from patients operated for breast cancer.
   Conclusion: Bmi-1 mRNA level is consistently increased and Mel-18 mRNA level is consistently decreased in adjacent normal breast tissue of cancer patients as compared to normal breast tissue in women having had reduction mammoplasties. Bmi-1/Mel-18 ratio can be potentially used as a tool for stratifying women at risk of developing malignancy.
C1 [Riis, Margit L. H.; Luders, Torben; Vollan, Hilde S.; Kristensen, Vessela] Univ Oslo, Akershus Univ Hosp, Inst Clin Med, Dept Clin Mol Biol EpiGen, Lorenskog, Norway.
   [Riis, Margit L. H.; Bukholm, Ida R. K.] Akershus Univ Hosp, Dept Surg, Lorenskog, Norway.
   [Nesbakken, Anne-Jorunn] Akershus Univ Hosp, Dept Pathol, Lorenskog, Norway.
   [Bukholm, Ida R. K.] Univ Oslo, Inst Clin Med, Lorenskog, Norway.
C3 University of Oslo; University of Oslo; University of Oslo; University
   of Oslo
RP Kristensen, V (通讯作者)，Univ Oslo, Akershus Univ Hosp, Inst Clin Med, Dept Clin Mol Biol EpiGen, Lorenskog, Norway.
EM vessela.kristensen@medisin.uio.no
RI Riis, Margit/AAY-7926-2020
OI Luders, Torben/0000-0001-5176-7808; Gjerdrum, Hilde Synnove
   Vollan/0000-0001-9488-5265
FU Helse Sor-Ost [2789119]; Akershus University Hospital [2689023]
FX We thank our surgical colleagues, Dr. S. Tronnes, Dr. B. Gravdehaug, and
   Dr. E. Kjaestad at the Surgical Department, Akershus University Hospital
   and colleagues at the Radiology Department same hospital for helping us
   collect the samples from cancer patients. Likewise we would like to
   thank colleagues at the Collosseum Clinic, Oslo, for providing samples
   from mammoplasties. We are grateful to T. Sonerud, Department for
   Clinical Molecular Biology (EpiGen), for help with performing the qPCR
   experiments. MR is a fellow of the Faculty of Medicine, University of
   Oslo, this work was supported by grant number 2789119 from Helse Sor-Ost
   and internal grants from Akershus University Hospital, grant number
   2689023.
CR Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262
   Beà S, 2001, CANCER RES, V61, P2409
   BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43
   Chen DT, 2010, BREAST CANCER RES TR, V119, P335, DOI 10.1007/s10549-009-0344-y
   Dimri GP, 2002, CANCER RES, V62, P4736
   Dimri GP, 2005, CANCER CELL, V7, P505, DOI 10.1016/j.ccr.2005.05.025
   Dukers DF, 2004, AM J PATHOL, V164, P873, DOI 10.1016/S0002-9440(10)63175-6
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Guo WJ, 2007, CANCER RES, V67, P5083, DOI 10.1158/0008-5472.CAN-06-4368
   Guo WJ, 2007, MOL BIOL CELL, V18, P536, DOI 10.1091/mbc.E06-05-0447
   Itahana K, 2003, MOL CELL BIOL, V23, P389, DOI 10.1128/MCB.23.1.389-401.2003
   Kim JH, 2004, BREAST, V13, P383, DOI 10.1016/j.breast.2004.02.010
   Lindström MS, 2001, ONCOGENE, V20, P2171, DOI 10.1038/sj.onc.1204303
   Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054
   McNeill RE, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-107
   Paajanen H, 2006, AM SURGEON, V72, P167
   Park IK, 2004, J CLIN INVEST, V113, P175, DOI 10.1172/JCI200420800
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Saeki M, 2009, INT J ONCOL, V35, P511, DOI 10.3892/ijo_00000362
   Silva J, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1760
   Song LB, 2006, CANCER RES, V66, P6225, DOI 10.1158/0008-5472.CAN-06-0094
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   TAGAWA M, 1990, J BIOL CHEM, V265, P20021
   Tripathi A, 2008, INT J CANCER, V122, P1557, DOI 10.1002/ijc.23267
   van Kemenade FJ, 2001, BLOOD, V97, P3896, DOI 10.1182/blood.V97.12.3896
   Vonlanthen S, 2001, BRIT J CANCER, V84, P1372, DOI 10.1054/bjoc.2001.1791
   Wei J., 2002, DNA microarrays a Mol. clonging Man, P110
   Weigel S, 2009, ROFO-FORTSCHR RONTG, V181, P1144, DOI 10.1055/s-0028-1109831
NR 29
TC 24
Z9 27
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD DEC 16
PY 2010
VL 10
AR 686
DI 10.1186/1471-2407-10-686
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 701BE
UT WOS:000285788500001
PM 21162745
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Orta, ML
   Domínguez, I
   Pastor, N
   Cortés, F
   Mateos, S
AF Luis Orta, Manuel
   Dominguez, Inmaculada
   Pastor, Nuria
   Cortes, Felipe
   Mateos, Santiago
TI The role of the DNA hypermethylating agent Budesonide in the
   decatenating activity of DNA topoisomerase II
SO MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
LA English
DT Article
DE Topoisomerase II; Hypermethylation of DNA; Chromosome segregation;
   Endoreduplication
ID MESSENGER-RNA EXPRESSION; MOUSE LUNG-TUMORS; BREAST-CANCER; PROMOTER
   HYPERMETHYLATION; INDUCED ENDOREDUPLICATION; CHROMATIN MODIFICATION;
   CLEAVAGE SITES; CHO-CELLS; METHYLATION; HYPOMETHYLATION
AB Catenations between sister chromatids result from DNA replication and must be resolved to ensure proper chromatid segregation in mitosis Functionally active Topoisomerase II (Topo II) through its mechanism of concerted breaking and rejoining of double stranded DNA is required to carry out this fundamental process In previous studies we have shown that modifications in DNA sequence by halogenated pyrimidines and by the demethylating agent 5-azacytidine leads to malfunction of Topo II that results in an Increased yield of endorreduplicated cells as a result of segregation failure In the present work we have evaluated the possible influence of the methylating agent Budesonide to modify the frequency of endoreduplicated cells in AA8 Chinese hamster cell population Our results seem to indicate that when Budesonide was administered for two consecutive cell cycles did induce an increase in the yield of endoreduplicated cells as previously observed for the hypomethylating agent 5-azaC We have also examined the possible relationship between extensive hypermethylation induced by Budesonide in DNA and stabilization of cleavable complexes by m-AMSA Taken as a whole our results show that the degree of methylation in DNA correlates with the effectiveness of m-AMSA to stabilize the Topo II-DNA complexes and to Induce DNA cleavage These findings evidence for the first time the functional Importance of DNA hyper- and hypomethylation changes as epigenetic factors able to modulate Topo II activity for proper chromosome segregation (C) 2010 Elsevier B V All rights reserved
C1 [Luis Orta, Manuel; Dominguez, Inmaculada; Pastor, Nuria; Cortes, Felipe; Mateos, Santiago] Univ Seville, Fac Biol, Dept Cell Biol, E-41012 Seville, Spain.
C3 University of Sevilla
RP Mateos, S (通讯作者)，Univ Seville, Fac Biol, Dept Cell Biol, Avda Reina Mercedes 6, E-41012 Seville, Spain.
RI García-Domínguez, Irene/J-8352-2018; Orta Vazquez, Manuel
   Luis/L-4141-2014; Mateos, Santiago/K-3777-2014; Pastor,
   Nuria/K-7885-2014; Dominguez Garcia, Inmaculada/K-4377-2014
OI Orta Vazquez, Manuel Luis/0000-0003-1007-4145; Mateos,
   Santiago/0000-0002-6442-6372; Pastor, Nuria/0000-0001-5052-357X;
   Dominguez Garcia, Inmaculada/0000-0002-5629-0604
FU Spanish Ministry of Education and Science [BFU 2007-61301]; Junta de
   Andalucia [BIO-120]; Ministry of Education and Science
FX This work has been partly funded by Grants from Spanish Ministry of
   Education and Science (BFU 2007-61301) and Junta de Andalucia (BIO-120)
   Spain One of the authors (Manuel Luis Orta) was the recipient of a
   fellowship from the Ministry of Education and Science (F P U)
CR Agrawal A, 2007, MODERN PATHOL, V20, P711, DOI 10.1038/modpathol.3800822
   Andoh T, 1998, BBA-GENE STRUCT EXPR, V1400, P155, DOI 10.1016/S0167-4781(98)00133-X
   [Anonymous], 1996, ANNU REV BIOCHEM, V65, P635
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Brena RM, 2007, HUM MOL GENET, V16, pR96, DOI 10.1093/hmg/ddm073
   BUCHENAU P, 1993, J CELL SCI, V104, P1175
   Cantero G, 2006, MUTAT RES-FUND MOL M, V599, P160, DOI 10.1016/j.mrfmmm.2006.02.006
   Cantero G, 2006, DNA REPAIR, V5, P667, DOI 10.1016/j.dnarep.2005.11.008
   Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369
   Cortés F, 2004, LIFE SCI, V76, P121, DOI 10.1016/j.lfs.2004.08.006
   Cortés F, 2003, DNA REPAIR, V2, P719, DOI 10.1016/S1568-7864(03)00044-2
   Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285
   DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616
   Downes CS, 1991, P NATL ACAD SCI USA, V88, P2616
   DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Esteller M, 2001, CANCER RES, V61, P3225
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   GIMENEZABIAN JF, 1995, J CELL BIOL, V131, P7, DOI 10.1083/jcb.131.1.7
   Gonzalgo ML, 1997, MUTAT RES-REV MUTAT, V386, P107, DOI 10.1016/S1383-5742(96)00047-6
   HEARTLEIN MW, 1987, EXP CELL RES, V169, P245
   Hoffmann MJ, 2005, BIOCHEM CELL BIOL, V83, P296, DOI 10.1139/o05-036
   Hu XC, 2003, ONCOL REP, V10, P1811
   ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jones PA, 1997, P NATL ACAD SCI USA, V94, P2103, DOI 10.1073/pnas.94.6.2103
   Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   KIRCHNER S, 1995, TOXICOL IN VITRO, V9, P519, DOI 10.1016/0887-2333(95)00044-9
   Kuzmin L, 2001, INT ARCH BLOSCI, P1047
   LEE MP, 1989, J BIOL CHEM, V264, P21779
   Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887
   Li LC, 2007, FRONT BIOSCI-LANDMRK, V12, P3377, DOI 10.2741/2320
   Li XR, 2004, ONCOGENE, V23, P1474, DOI 10.1038/sj.onc.1207249
   LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031
   Mateos S, 2005, MUTAT RES-FUND MOL M, V578, P33, DOI 10.1016/j.mrfmmm.2005.02.001
   Mateos S, 2008, MUTAT RES-FUND MOL M, V644, P24, DOI 10.1016/j.mrfmmm.2008.06.007
   Miremadi A, 2007, HUM MOL GENET, V16, pR28, DOI 10.1093/hmg/ddm021
   Murata H, 2005, CANCER LETT, V223, P143, DOI 10.1016/j.canlet.2004.09.039
   Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0
   Osanai T, 2005, JPN J CLIN ONCOL, V35, P121, DOI 10.1093/jjco/hyi036
   Pastor N, 2002, MUTAT RES-GEN TOX EN, V516, P113, DOI 10.1016/S1383-5718(02)00029-3
   Pereira MA, 2002, CARCINOGENESIS, V23, P1185, DOI 10.1093/carcin/23.7.1185
   Pogribny I, 1999, BIOCHEM BIOPH RES CO, V262, P624, DOI 10.1006/bbrc.1999.1187
   POMMIER Y, 1992, CANCER RES, V52, P3125
   POMMIER Y, 1993, CANCER CHEMOTH PHARM, V32, P103, DOI 10.1007/BF00685611
   POMMIER Y, 1991, J MOL BIOL, V222, P909, DOI 10.1016/0022-2836(91)90585-T
   Rauch TA, 2008, P NATL ACAD SCI USA, V105, P252, DOI 10.1073/pnas.0710735105
   Rodenhiser D, 2006, CAN MED ASSOC J, V174, P341, DOI 10.1503/cmaj.050774
   SANDER M, 1987, J MOL BIOL, V194, P219, DOI 10.1016/0022-2836(87)90370-6
   SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921
   Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727
   SPITZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533, DOI 10.1093/nar/16.12.5533
   SUMNER AT, 1995, EXP CELL RES, V217, P440, DOI 10.1006/excr.1995.1107
   Sumner AT, 1998, CHROMOSOMA, V107, P486, DOI 10.1007/s004120050333
   Takahashi Y, 2005, CLIN CANCER RES, V11, P1380, DOI 10.1158/1078-0432.CCR-04-1773
   Tao LH, 2002, MOL CARCINOGEN, V35, P93, DOI 10.1002/mc.10078
   Uemura T, 1987, CELL, V50, P817
   Umetani N, 2005, ONCOGENE, V24, P4721, DOI 10.1038/sj.onc.1208538
   Veeck J, 2008, ONCOGENE, V27, P865, DOI 10.1038/sj.onc.1210669
   Wachsman JT, 1997, MUTAT RES-FUND MOL M, V375, P1, DOI 10.1016/S0027-5107(97)00003-1
   Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007
   Yang DF, 2007, CANCER RES, V67, P3301, DOI 10.1158/0008-5472.CAN-06-4068
NR 64
TC 7
Z9 7
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0027-5107
EI 1873-135X
J9 MUTAT RES-FUND MOL M
JI Mutat. Res.-Fundam. Mol. Mech. Mutagen.
PD DEC 10
PY 2010
VL 694
IS 1-2
BP 45
EP 52
DI 10.1016/j.mrfmmm.2010.09.004
PG 8
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
GA 699MQ
UT WOS:000285667900007
PM 20883705
DA 2025-01-12
ER

PT J
AU Fortunati, N
   Catalano, MG
   Marano, F
   Mugoni, V
   Pugliese, M
   Bosco, O
   Mainini, F
   Boccuzzi, G
AF Fortunati, N.
   Catalano, M. G.
   Marano, F.
   Mugoni, V.
   Pugliese, M.
   Bosco, O.
   Mainini, F.
   Boccuzzi, G.
TI The pan-DAC inhibitor LBH589 is a multi-functional agent in breast
   cancer cells: cytotoxic drug and inducer of sodium-iodide symporter
   (NIS)
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE DAC inhibitors; Breast cancer; NIS; Targeted therapy; Epigenetic
ID HISTONE DEACETYLASE INHIBITORS; SODIUM/IODIDE-SYMPORTER; RETINOIC ACID;
   NA+/I-SYMPORTER; RADIOIODIDE UPTAKE; GENE-EXPRESSION; VALPROIC ACID;
   THERAPY; DEXAMETHASONE; STIMULATION
AB New drugs with anti-tumor activity, also able to modify the expression of selected molecules, are under evaluation in breast cancer which is becoming resistant to conventional treatment, or in metastatic disease. The sodium-iodide symporter (NIS), which mediates iodide uptake into thyroid cells, and is the molecular basis of radioiodine imaging and therapy in thyroid cancer, is also expressed in a large portion of breast tumors. Since MS expression in breast cancer is not sufficient for a significant iodide uptake, drugs able to induce its expression and correct function are under evaluation. In the present study, we report for the first time that the pan-deacetylase (DAC) inhibitor LBH589 (panobinostat) significantly induced NIS, both as mRNA and as protein, through the increase of MS promoter activity, with the final consequence of obtaining a significant up-take of iodide in MCF7, T47D, and MDA-MB231 breast cancer cells. Moreover, we observed that LBH589 causes a significant reduction in cell viability of estrogen-sensitive and -insensitive breast cancer cells within nanomolar range. The anti-tumor effect of LBH589 is sustained by apoptosis induction and cell cycle arrest in G(2)/M. In conclusion, our data suggest that LBH589 might be a powerful tool in the management of breast cancer due to its multiple effects and support a potential application of LBH589 in the diagnosis and treatment of this disease.
C1 [Catalano, M. G.; Pugliese, M.; Bosco, O.; Boccuzzi, G.] Univ Turin, Dept Clin Pathophysiol, I-10126 Turin, Italy.
   [Fortunati, N.; Marano, F.; Mugoni, V.; Boccuzzi, G.] Univ Turin, AOU San Giovanni Battista, I-10126 Turin, Italy.
   [Mainini, F.] Novartis Farma SpA, Origgio, VA, Italy.
C3 University of Turin; University of Turin; A.O.U. Citta della Salute e
   della Scienza di Torino; AOU San Giovanni Battista-Molinette; Novartis
RP Boccuzzi, G (通讯作者)，Univ Turin, Dept Clin Pathophysiol, Via Genova 3, I-10126 Turin, Italy.
EM giuseppe.boccuzzi@unito.it
RI Bosco, Ornella/AAB-2105-2019; boccuzzi, giuseppe/A-6707-2012; CATALANO,
   Maria Graziella/J-4320-2016; Fortunati, Nicoletta/K-3081-2016
OI CATALANO, Maria Graziella/0000-0002-1170-8245; Fortunati,
   Nicoletta/0000-0001-8069-9621
FU Fondazione CRT, Torino; Compagnia San Paolo, Torino; MIUR; Regione
   Piemonte
FX We thank Novartis Pharma AG, Basel, Switzerland for providing us LBH589;
   Giuseppe Damante, Dipartimento di Scienze e Tecnologie Biomediche,
   Policlinico Universitario di Udine, Udine, Italy, for providing us with
   the luc-NIS construct; Daniela Taverna and Alessandra Solero,
   Dipartimento di Scienze Oncologiche, Universita di Torino and M. B. C.,
   Torino, Italy, for helping us with luciferase experiments. This study
   was supported by the Project "Alfieri 2007", Fondazione CRT, Torino, the
   Special Project "Oncology", Compagnia San Paolo, Torino, by MIUR and by
   Regione Piemonte to Giuseppe Boccuzzi.
CR Arturi F, 2005, J CLIN ENDOCR METAB, V90, P2321, DOI 10.1210/jc.2004-1562
   Atadja P, 2009, CANCER LETT, V280, P233, DOI 10.1016/j.canlet.2009.02.019
   Behr M, 1998, BIOCHEM J, V331, P359, DOI 10.1042/bj3310359
   Berry DA, 2005, NEW ENGL J MED, V353, P1784, DOI 10.1056/NEJMoa050518
   Beyer SJ, 2009, BREAST CANCER RES TR, V115, P205, DOI 10.1007/s10549-008-0059-5
   Boelaert K, 2003, LANCET, V361, P796, DOI 10.1016/S0140-6736(03)12720-1
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Botrugno OA, 2009, CANCER LETT, V280, P134, DOI 10.1016/j.canlet.2009.02.027
   Cardoso F, 2009, JNCI-J NATL CANCER I, V101, P1174, DOI 10.1093/jnci/djp235
   Cho JY, 2000, J CLIN ENDOCR METAB, V85, P2936, DOI 10.1210/jc.85.8.2936
   Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0
   Dohán O, 2006, MOL ENDOCRINOL, V20, P1121, DOI 10.1210/me.2005-0376
   Dohán O, 2003, ENDOCR REV, V24, P48, DOI 10.1210/er.2001-0029
   Fiskus W, 2007, CLIN CANCER RES, V13, P4882, DOI 10.1158/1078-0432.CCR-06-3093
   Fortunati N, 2004, J CLIN ENDOCR METAB, V89, P1006, DOI 10.1210/jc.2003-031407
   Fortunati N, 2008, CANCER LETT, V259, P156, DOI 10.1016/j.canlet.2007.10.006
   Furuya F, 2004, ENDOCRINOLOGY, V145, P2865, DOI 10.1210/en.2003-1258
   Giles F, 2006, CLIN CANCER RES, V12, P4628, DOI 10.1158/1078-0432.CCR-06-0511
   Gonzalez-Angulo AM, 2007, ADV EXP MED BIOL, V608, P1
   Kim IA, 2009, RADIOTHER ONCOL, V92, P125, DOI 10.1016/j.radonc.2009.03.008
   Kitazono M, 2001, J CLIN ENDOCR METAB, V86, P3430, DOI 10.1210/jc.86.7.3430
   Knostman KAB, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-137
   Kogai T, 2005, ENDOCRINOLOGY, V146, P3059, DOI 10.1210/en.2004-1334
   Kogai T, 2004, CANCER RES, V64, P415, DOI 10.1158/0008-5472.CAN-03-2285
   Kogai T, 2008, J CLIN ENDOCR METAB, V93, P1884, DOI 10.1210/jc.2007-1627
   Lee MJ, 2008, CURR OPIN ONCOL, V20, P639, DOI 10.1097/CCO.0b013e3283127095
   Moon DH, 2001, NUCL MED BIOL, V28, P829
   Ohashi E, 2009, CANCER RES, V69, P3443, DOI 10.1158/0008-5472.CAN-08-3234
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Puppin C, 2005, ENDOCRINOLOGY, V146, P3967, DOI 10.1210/en.2005-0128
   Reiners C, 2008, BEST PRACT RES CL EN, V22, P989, DOI 10.1016/j.beem.2008.09.013
   Tanosaki S, 2003, BREAST CANCER RES TR, V79, P335, DOI 10.1023/A:1024064424855
   Tazebay UH, 2000, NAT MED, V6, P871, DOI 10.1038/78630
   Unterholzner S, 2006, J CLIN ENDOCR METAB, V91, P69, DOI 10.1210/jc.2005-0779
   Wapnir IL, 2004, CLIN CANCER RES, V10, P4294, DOI 10.1158/1078-0432.CCR-04-0074
   Wapnir IL, 2003, J CLIN ENDOCR METAB, V88, P1880, DOI 10.1210/jc.2002-021544
   Willhauck MJ, 2008, BREAST CANCER RES TR, V109, P263, DOI 10.1007/s10549-007-9646-0
   Zarnegar R, 2002, SURGERY, V132, P984, DOI 10.1067/msy.2002.128690
   Zhou Q, 2007, CANCER BIOL THER, V6, P64, DOI 10.4161/cbt.6.1.3549
NR 39
TC 22
Z9 25
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD DEC
PY 2010
VL 124
IS 3
BP 667
EP 675
DI 10.1007/s10549-010-0789-z
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 683WJ
UT WOS:000284508300008
PM 20213084
DA 2025-01-12
ER

PT J
AU Huang, KT
   Dobrovic, A
   Fox, SB
AF Huang, Katie T.
   Dobrovic, Alexander
   Fox, Stephen B.
TI No evidence for DNA methylation of von Hippel-Lindau ubiquitin ligase
   complex genes in breast cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE VHL ubiquitin ligase complex; DNA methylation; Breast cancer; Hypoxia
ID TUMOR-SUPPRESSOR GENE; HYPOXIA; EXPRESSION; CARCINOMA
AB pVHL is the central component of an ubiquitin ligase complex that targets hypoxia-inducible factor 1 alpha (HIF-1 alpha) for proteasomal degradation. This complex includes four other genes, Cullin 2 (CUL2), elongin C (TCEB1), elongin B (TCEB2) and ring-box 1 (RBX1). VHL has previously been reported to be methylated in sporadic renal cell carcinoma. Since HIF-1 alpha is frequently expressed in breast carcinomas, we evaluated DNA methylation as a possible mechanism of silencing one or more of the VHL complex genes. Methylation-specific high resolution melting (MS-HRM) was used to screen the proximal promoter CpG islands for methylation of the VHL ubiquitin ligase complex genes. We were unable to identify methylation of any of the five genes in 84 breast carcinoma samples or in a range of cancer cell lines including 13 breast cancer cell lines of various subtypes. We were able, however, to identify VHL methylation in control renal cell carcinoma samples. Epigenetic silencing by promoter DNA methylation for VHL and the complex genes, CUL2, elongin C (TCEB1), elongin B (TCEB2) and RBX1, is unlikely to play a role in HIF-1 alpha upregulation in breast carcinomas.
C1 [Huang, Katie T.; Dobrovic, Alexander; Fox, Stephen B.] Peter MacCallum Canc Ctr, Dept Pathol, Melbourne, Vic 3002, Australia.
   [Huang, Katie T.; Dobrovic, Alexander; Fox, Stephen B.] Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia.
C3 Peter Maccallum Cancer Center; University of Melbourne
RP Fox, SB (通讯作者)，Peter MacCallum Canc Ctr, Dept Pathol, Melbourne, Vic 3002, Australia.
EM Katie.Huang@petermac.org; Alexander.Dobrovic@petermac.org;
   Stephen.Fox@petermac.org
RI ; Fox, Stephen/G-9719-2016
OI Dobrovic, Alexander/0000-0003-3414-112X; Fox,
   Stephen/0000-0002-7648-8896
FU Victorian Breast Cancer Research Consortium, Australia; Cancer Council
   of Victoria; National Breast Cancer Foundation
FX This work is supported by the Victorian Breast Cancer Research
   Consortium, Australia, the Cancer Council of Victoria and the National
   Breast Cancer Foundation. We would like to thank Professor Adrian L.
   Harris, University of Oxford, UK for the kind donation of breast tumour
   DNA.
CR Banks RE, 2006, CANCER RES, V66, P2000, DOI 10.1158/0008-5472.CAN-05-3074
   Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200
   Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704
   Hatzimichael E, 2009, CLIN LYMPHOMA MYELOM, V9, P239, DOI 10.3816/CLM.2009.n.047
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   Park SW, 2009, APMIS, V117, P880, DOI 10.1111/j.1600-0463.2009.02550.x
   Patard JJ, 2009, BRIT J CANCER, V101, P1417, DOI 10.1038/sj.bjc.6605298
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Sourvinos G, 2001, TUMOR BIOL, V22, P131, DOI 10.1159/000050607
   Wojdacz TK, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm013
   Zia MK, 2007, INT J MOL MED, V20, P605
NR 11
TC 2
Z9 4
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD DEC
PY 2010
VL 124
IS 3
BP 853
EP 856
DI 10.1007/s10549-010-1087-5
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 683WJ
UT WOS:000284508300031
PM 20680678
DA 2025-01-12
ER

PT J
AU Pirouzpanah, S
   Taleban, FA
   Atri, M
   Abadi, AR
   Mehdipour, P
AF Pirouzpanah, Saeed
   Taleban, Forough A.
   Atri, Morteza
   Abadi, Ali-Reza
   Mehdipour, Parvin
TI The effect of modifiable potentials on hypermethylation status of
   <i>retinoic acid receptor</i>-<i>beta2</i> and <i>estrogen
   receptor</i>-<i>alpha</i> genes in primary breast cancer
SO CANCER CAUSES & CONTROL
LA English
DT Article
DE Breast cancer; ERalpha; RARbeta2; Hypermethylation; Environment
ID CPG-ISLAND METHYLATION; GENOMIC DNA METHYLATION; RETINOIC ACID RECEPTOR;
   CELL LUNG-CANCER; PROMOTER METHYLATION; COLORECTAL-CANCER; ABERRANT
   METHYLATION; FOLATE STATUS; RAR-BETA; RISK
AB Epigenetic silencing of retinoic acid receptor-beta2 (RARbeta2) and estrogen receptor-alpha (ERalpha) expressions have been revealed to be important in the development of approaches for diagnosis and therapy of breast cancer. We aimed to explore the correlation of some potential factors with the hypermethylation status of RARbeta2 and ERalpha genes among Iranian breast cancer patients. The hypermethylation status was investigated in 137 dissected tissues from primary breast cancer patients through methylation-specific PCR. Overall, the methylation frequencies of RARbeta2 and ERalpha genes were observed in 36.5 and 51.1% of participants, respectively. The hypermethylated RARbeta2 was associated with younger age at diagnosis and negative family history of breast cancer. The hypermethylation of ERalpha was correlated positively with smoking, duration of estradiol exposure, ER-negativity in tumors and body mass index (at 5 years ago). The plasma levels of folate and vitamin B(12) were inversely related to the hypermethylation status of ERalpha, after controlling for covariates. The risk of ERalpha hypermethylation was increased with high plasma level of total homocysteine. In conclusion, our data provide new insights into the possible effect of some lifestyle-related factors on the aberrant methylation drift of ERalpha and RARbeta2 genes in breast cancer.
C1 [Pirouzpanah, Saeed; Taleban, Forough A.] Shahid Beheshti Univ MC, Fac Nutr Sci & Food Technol, Natl Nutr & Food Technol Res Inst, Dept Human Nutr, Tehran 193954741, Iran.
   [Atri, Morteza] Univ Tehran Med Sci, Day Gen Hosp, Inst Canc, Tehran 1417613151, Iran.
   [Abadi, Ali-Reza] Shahid Beheshti Univ MC, Sch Med, Dept Community & Hlth, Tehran 193954741, Iran.
   [Mehdipour, Parvin] Univ Tehran Med Sci, Sch Med, Dept Med Genet, Tehran 1417613151, Iran.
C3 Shahid Beheshti University Medical Sciences; Tehran University of
   Medical Sciences; Shahid Beheshti University Medical Sciences; Tehran
   University of Medical Sciences
RP Pirouzpanah, S (通讯作者)，Shahid Beheshti Univ MC, Fac Nutr Sci & Food Technol, Natl Nutr & Food Technol Res Inst, Dept Human Nutr, Tehran 193954741, Iran.
EM pirouzpanah@gmail.com; mehdipor@tums.ac.ir
RI abadi, alireza/AAY-2615-2021; Pirouzpanah, Saeed/J-6262-2015
OI Pirouzpanah, Saeed/0000-0001-5461-2115; Abadi,
   Ashraf/0000-0002-7433-261X
FU National Nutrition & Food Technology Research Institute, Shaheed
   Beheshti University of Medical Sciences, Iran
FX We are thankful to all participating patients and our valued colleagues
   in Day General Hospital. We are also grateful to researches affaire of
   National Nutrition & Food Technology Research Institute, Shaheed
   Beheshti University of Medical Sciences, Iran, for providing financial
   support to conduct this study. The authors are grateful to Dr. Sonia
   Ijadi-Maghsoudi and Dr. Mohammad-Amin Tabatabaifar for their valuable
   reading of this manuscript.
CR Atri M, 2003, Fam Cancer, V2, P117, DOI 10.1023/A:1025765910106
   Baldwin RL, 2000, CANCER RES, V60, P5329
   Bean GR, 2007, CANCER EPIDEM BIOMAR, V16, P50, DOI 10.1158/1055-9965.EPI-06-0598
   Brait M, 2009, CANCER EPIDEM BIOMAR, V18, P2984, DOI 10.1158/1055-9965.EPI-08-1245
   Chan AOO, 2002, AM J PATHOL, V160, P529, DOI 10.1016/S0002-9440(10)64872-9
   Chen Y, 2006, GENET TEST, V10, P281, DOI 10.1089/gte.2006.10.281
   Cote S, 1998, ANTI-CANCER DRUG, V9, P743
   Davis CD, 2004, EXP BIOL MED, V229, P988, DOI 10.1177/153537020422901002
   Eckel RH, 1998, CIRCULATION, V97, P2099, DOI 10.1161/01.CIR.97.21.2099
   Euhus DM, 2008, CANCER EPIDEM BIOMAR, V17, P1051, DOI 10.1158/1055-9965.EPI-07-2582
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Friso S, 2002, P NATL ACAD SCI USA, V99, P5606, DOI 10.1073/pnas.062066299
   Friso S, 2007, BRIT J NUTR, V97, P617, DOI 10.1017/S0007114507433013
   Gabriel HE, 2006, AM J CLIN NUTR, V83, P835, DOI 10.1093/ajcn/83.4.835
   Gunter MJ, 2006, J NUTR BIOCHEM, V17, P145, DOI 10.1016/j.jnutbio.2005.06.011
   Herceg Z, 2007, MUTAGENESIS, V22, P91, DOI 10.1093/mutage/gel068
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Issa JP, 2000, CURR TOP MICROBIOL, V249, P101
   Johnson IT, 2008, FOOD CHEM TOXICOL, V46, P1346, DOI 10.1016/j.fct.2007.09.101
   Kim DH, 2003, CANCER RES, V63, P3743
   Kim YI, 2004, CANCER EPIDEM BIOMAR, V13, P511
   Lai JC, 2005, INT J CANCER, V117, P974, DOI 10.1002/ijc.21278
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   Li SY, 2006, CANCER LETT, V237, P272, DOI 10.1016/j.canlet.2005.06.011
   Lin RK, 2010, J CLIN INVEST, V120, P521, DOI 10.1172/JCI40706
   McCourt CK, 2007, GYNECOL ONCOL, V104, P535, DOI 10.1016/j.ygyno.2006.09.019
   Nass SJ, 2000, CANCER RES, V60, P4346
   Nkhata KJ, 2009, BREAST CANCER RES TR, V114, P71, DOI 10.1007/s10549-008-9991-7
   Pappas JJ, 2008, GENE CHROMOSOME CANC, V47, P978, DOI 10.1002/gcc.20603
   Rousseau C, 2003, J STEROID BIOCHEM, V86, P1, DOI 10.1016/S0960-0760(03)00255-3
   Shukla S, 2006, EPIGENETICS-US, V1, P88, DOI 10.4161/epi.1.2.2679
   Swafford DS, 1997, MOL CELL BIOL, V17, P1366, DOI 10.1128/MCB.17.3.1366
   van Engeland M, 2003, CANCER RES, V63, P3133
   Wei MJ, 2008, BREAST CANCER RES TR, V111, P113, DOI 10.1007/s10549-007-9766-6
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Youssef EM, 2004, CLIN CANCER RES, V10, P1733, DOI 10.1158/1078-0432.CCR-0989-3
   Zhang SM, 2005, CANCER EPIDEM BIOMAR, V14, P2004, DOI 10.1158/1055-9965.EPI-05-0083
NR 38
TC 28
Z9 31
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957-5243
J9 CANCER CAUSE CONTROL
JI Cancer Causes Control
PD DEC
PY 2010
VL 21
IS 12
SI SI
BP 2101
EP 2111
DI 10.1007/s10552-010-9629-z
PG 11
WC Oncology; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Public, Environmental & Occupational Health
GA 737ZR
UT WOS:000288609600017
PM 20711807
DA 2025-01-12
ER

PT J
AU López-Lago, MA
   Thodima, VJ
   Guttapalli, A
   Chan, T
   Heguy, A
   Molina, AM
   Reuter, VE
   Motzer, RJ
   Chaganti, RSK
AF Lopez-Lago, Miguel A.
   Thodima, Venkata J.
   Guttapalli, Asha
   Chan, Timothy
   Heguy, Adriana
   Molina, Ana M.
   Reuter, Victor E.
   Motzer, Robert J.
   Chaganti, Raju S. K.
TI Genomic Deregulation during Metastasis of Renal Cell Carcinoma
   Implements a Myofibroblast-Like Program of Gene Expression
SO CANCER RESEARCH
LA English
DT Article
ID BREAST-CANCER METASTASIS; EPITHELIAL-MESENCHYMAL TRANSITION; DNA
   METHYLATION; NUDE-MICE; TUMOR; FIBROBLASTS; FIBROSIS; TISSUE; LUNG;
   HYPOMETHYLATION
AB Clear cell renal cell carcinoma (RCC) is the most common and invasive adult kidney cancer. The genetic and biological mechanisms that drive metastatic spread of RCC remain largely unknown. We have investigated the molecular signatures and underlying genomic aberrations associated with RCC metastasis, using an approach that combines a human xenograft model; expression profiling of RNA, DNA, and microRNA (miRNA); functional verification; and clinical validation. We show that increased metastatic activity is associated with acquisition of a myofibroblast-like signature in both tumor cell lines and in metastatic tumor biopsies. Our results also show that the mesenchymal trait did not provide an invasive advantage to the metastatic tumor cells. We further show that some of the constituents of the mesenchymal signature, including the expression of the well-characterized myofibroblastic marker S100A4, are functionally relevant. Epigenetic silencing and miRNA-induced expression changes accounted for the change in expression of a significant number of genes, including S100A4, in the myofibroblastic signature; however, DNA copy number variation did not affect the same set of genes. These findings provide evidence that widespread genetic and epigenetic alterations can lead directly to global deregulation of gene expression and contribute to the development or progression of RCC metastasis culminating in a highly malignant myofibroblast-like cell. Cancer Res; 70(23); 9682-92. (C) 2010 AACR.
C1 [Reuter, Victor E.; Chaganti, Raju S. K.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA.
   [Lopez-Lago, Miguel A.; Thodima, Venkata J.; Guttapalli, Asha; Chaganti, Raju S. K.] Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA.
   [Chan, Timothy; Heguy, Adriana] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA.
   [Molina, Ana M.; Motzer, Robert J.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA.
C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer
   Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering
   Cancer Center
RP Chaganti, RSK (通讯作者)，Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA.
EM chagantr@mskcc.org
RI Heguy, Adriana/GPP-3907-2022; Chan, Timothy/ABD-5850-2021
OI Motzer, Robert/0000-0001-6925-2327
FU V-Foundation; Pfizer, Inc.; NIH [CA-121327]
FX This study was supported by grants from the V-Foundation, a Syms kidney
   cancer award, Pfizer, Inc., and the NIH (CA-121327).
CR Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010
   Andrews J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008665
   Banks RE, 2006, CANCER RES, V66, P2000, DOI 10.1158/0008-5472.CAN-05-3074
   Bestor TH, 2003, ANN NY ACAD SCI, V983, P22, DOI 10.1111/j.1749-6632.2003.tb05959.x
   Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Chambers RC, 2003, AM J PATHOL, V162, P533, DOI 10.1016/S0002-9440(10)63847-3
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009
   Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172
   Desmoulière A, 2005, WOUND REPAIR REGEN, V13, P7, DOI 10.1111/j.1067-1927.2005.130102.x
   Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927
   GABBIANI G, 1971, EXPERIENTIA, V27, P549, DOI 10.1007/BF02147594
   Grum-Schwensen B, 2005, CANCER RES, V65, P3772, DOI 10.1158/0008-5472.CAN-04-4510
   Hüsemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003
   Hwang RF, 2008, CANCER RES, V68, P918, DOI 10.1158/0008-5472.CAN-07-5714
   Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518
   Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Mann J, 2007, CELL DEATH DIFFER, V14, P275, DOI 10.1038/sj.cdd.4401979
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Morris MR, 2010, ONCOGENE, V29, P2104, DOI 10.1038/onc.2009.493
   Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
   NAITO S, 1989, CLIN EXP METASTAS, V7, P381, DOI 10.1007/BF01753659
   NAITO S, 1986, CANCER RES, V46, P4109
   Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101
   Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622
   O'Hara AJ, 2009, BLOOD, V113, P5938, DOI 10.1182/blood-2008-09-179168
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   PAGET S, 1989, CANCER METAST REV, V8, P98
   Podsypanina K, 2008, SCIENCE, V321, P1841, DOI 10.1126/science.1161621
   Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999
   Psaila B, 2009, NAT REV CANCER, V9, P285, DOI 10.1038/nrc2621
   Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060
   Rogers MA, 1998, J BIOL CHEM, V273, P26683, DOI 10.1074/jbc.273.41.26683
   Rosty C, 2002, AM J PATHOL, V160, P45, DOI 10.1016/S0002-9440(10)64347-7
   Roxburgh SA, 2006, NEPHRON PHYSIOL, V103, P139, DOI 10.1159/000092453
   Sadikovic B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002834
   Schneider M, 2008, J MOL MED, V86, P507, DOI 10.1007/s00109-007-0301-3
   Selman Moises, 2006, Proc Am Thorac Soc, V3, P364, DOI 10.1513/pats.200601-003TK
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637
   Taylor RC, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000166
   van Vlodrop IJH, 2010, AM J PATHOL, V176, P575, DOI 10.2353/ajpath.2010.090442
   van 't Veer LJ, 2008, NATURE, V452, P564, DOI 10.1038/nature06915
   Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009
NR 48
TC 28
Z9 32
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 1
PY 2010
VL 70
IS 23
BP 9682
EP 9692
DI 10.1158/0008-5472.CAN-10-2279
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 690YJ
UT WOS:000285045900018
PM 20952505
OA Green Submitted, Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Roarty, K
   Rosen, JM
AF Roarty, Kevin
   Rosen, Jeffrey M.
TI Wnt and mammary stem cells: hormones cannot fly wingless
SO CURRENT OPINION IN PHARMACOLOGY
LA English
DT Article
ID MEDIATES RADIATION-RESISTANCE; GLAND DEVELOPMENT; PROGENITOR CELLS;
   BREAST-CANCER; EPIGENETIC INACTIVATION; PROGESTERONE-RECEPTOR;
   SELF-RENEWAL; EXPRESSION; GENE; TUMORIGENESIS
AB The mammary stem cell and its local microenvironment are central for the maintenance of proper tissue homeostasis during normal development Defining the hierarchical organization of the epithelial subtypes in the mammary gland and the molecular pathways guiding their development has begun to provide a framework for understanding how cancer stem cells sustain the progression and heterogeneity of breast cancers The Wnt pathway plays a fundamental role in multiple adult stem cells, as well as in orchestrating proper mammary gland development and maintenance These processes are intricately guided by the influence of systemic hormones and local factors Alterations in Wnt signaling can skew the homeostatic balance of the mammary epithelium to drive malignant progression, however, complexities of Wnt pathway components present a challenge in understanding their physiological function
C1 [Roarty, Kevin; Rosen, Jeffrey M.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
C3 Baylor College of Medicine
RP Rosen, JM (通讯作者)，Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
RI Roarty, Kevin/HTS-2935-2023
FU NIH, National Cancer Institute [R37 CA16303]; Department of Defense
   (DOD) [BC093440]
FX JMR is supported by NIH grant R37 CA16303 from the National Cancer
   Institute KR is supported by Department of Defense (DOD) Breast Cancer
   Research Program (BCRP) Postdoctoral Fellowship BC093440
CR Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717
   Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027
   Badders NM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006594
   Beleut M, 2010, P NATL ACAD SCI USA, V107, P2989, DOI 10.1073/pnas.0915148107
   Booth BW, 2010, EXP CELL RES, V316, P422, DOI 10.1016/j.yexcr.2009.11.006
   BRADBURY JM, 1995, DEV BIOL, V170, P553, DOI 10.1006/dbio.1995.1236
   Brisken C, 1998, P NATL ACAD SCI USA, V95, P5076, DOI 10.1073/pnas.95.9.5076
   Brisken C, 2000, GENE DEV, V14, P650
   Brisken C, 2007, STEM CELL REV, V3, P147, DOI 10.1007/s12015-007-0019-1
   BUHLER TA, 1993, DEV BIOL, V155, P87, DOI 10.1006/dbio.1993.1009
   Chen MS, 2007, J CELL SCI, V120, P468, DOI 10.1242/jcs.03348
   Ciarloni L, 2007, P NATL ACAD SCI USA, V104, P5455, DOI 10.1073/pnas.0611647104
   Clarke RB, 1997, CANCER RES, V57, P4987
   Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106
   DEOME KB, 1959, CANCER RES, V19, P515
   Dimeo TA, 2009, CANCER RES, V69, P5364, DOI 10.1158/0008-5472.CAN-08-4135
   GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418
   Gu BN, 2009, J CELL BIOL, V185, P811, DOI 10.1083/jcb.200810133
   HALL SJW, 1994, DIFFERENTIATION, V57, P205
   Hiremath M, 2007, DEVELOPMENT, V134, P3703, DOI 10.1242/dev.006585
   Hsu W, 2001, J CELL BIOL, V155, P1055, DOI 10.1083/jcb.200107066
   Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555
   Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091
   Kendrick H, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-591
   Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125
   Kouros-Mehr H, 2006, DEV DYNAM, V235, P3404, DOI 10.1002/dvdy.20978
   LaMarca HL, 2008, ENDOCRINOLOGY, V149, P4317, DOI 10.1210/en.2008-0450
   Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100
   Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560
   Lindvall C, 2006, J BIOL CHEM, V281, P35081, DOI 10.1074/jbc.M607571200
   Lindvall C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005813
   Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101
   Liu CC, 2010, P NATL ACAD SCI USA, V107, P5136, DOI 10.1073/pnas.0911220107
   MILLER RK, DEV DYN, V239, P77
   Roarty K, 2007, DEVELOPMENT, V134, P3929, DOI 10.1242/dev.008250
   Robinson GW, 2000, GENE DEV, V14, P889
   Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Tanos Tamara, 2008, Breast Dis, V29, P69
   Teissedre B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004537
   Tepera SB, 2003, J CELL SCI, V116, P1137, DOI 10.1242/jcs.00334
   Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706
   Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949
   van Amerongen R, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.135re9
   Veeck J, 2008, CARCINOGENESIS, V29, P991, DOI 10.1093/carcin/bgn076
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509
   Watson CJ, 2008, DEVELOPMENT, V135, P995, DOI 10.1242/dev.005439
   Woodward WA, 2007, P NATL ACAD SCI USA, V104, P618, DOI 10.1073/pnas.0606599104
   Zeng YA, 2010, CELL STEM CELL, V6, P568, DOI 10.1016/j.stem.2010.03.020
NR 50
TC 68
Z9 78
U1 0
U2 12
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4892
J9 CURR OPIN PHARMACOL
JI Curr. Opin. Pharmacol.
PD DEC
PY 2010
VL 10
IS 6
BP 643
EP 649
DI 10.1016/j.coph.2010.07.004
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 687BS
UT WOS:000284749400006
PM 20810315
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Denis, GV
AF Denis, Gerald V.
TI Bromodomain Coactivators in Cancer, Obesity, Type 2 Diabetes, and
   Inflammation
SO DISCOVERY MEDICINE
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; CREB-BINDING-PROTEIN; B-CELL LYMPHOMA; P300
   HISTONE ACETYLTRANSFERASES; SARCOMA-ASSOCIATED HERPESVIRUS;
   SYSTEMIC-LUPUS-ERYTHEMATOSUS; EFFECT HOMEOTIC GENE; INSULIN-RESISTANCE;
   TRANSCRIPTIONAL REGULATION; BREAST-CANCER
AB Double bromodomain proteins bind to acetylated lysines in histones, bringing associated histone modification and nucleosome remodeling activity to chromatin. The ability of bromodomain regulators to alter chromatin status and control gene expression has long been appreciated to be important in the development of certain human cancers. However, bromodomain proteins have now been found also to be critical, non-redundant players in diverse, non-malignant phenotypes, directing transcriptional programs that control adipogenesis, energy metabolism and inflammation. The fact that such different processes are functionally linked by the same molecular machinery suggests a common epigenetic basis to understand and interpret the origins of several important co-morbidities, such as asthma or cancer that occurs in obesity, and complex inflammatory diseases like cardiovascular disease, systemic lupus erythematosus, rheumatoid arthritis and insulin resistance that may be built on a common pro-inflammatory foundation. [Discovery Medicine 10(55):489-499, december 2010]
C1 [Denis, Gerald V.] Boston Univ, Sch Med, Boston Nutr Obes Res Ctr, Boston, MA 02118 USA.
   [Denis, Gerald V.] Boston Univ, Sch Med, Immunol Training Program, Boston, MA 02118 USA.
C3 Boston University; Boston University
RP Denis, GV (通讯作者)，Boston Univ, Sch Med, Boston Nutr Obes Res Ctr, 72 E Concord St,K520, Boston, MA 02118 USA.
EM gdenis@bu.edu
OI Denis, Gerald/0000-0001-9886-0401
FU NIH [R03 CA128006, P30 DK057521]; American Cancer Society
   [RSG-05-072-01]; Leukemia and Lymphoma Society Translational Award
   [6023-09]
FX This work was supported by NIH grants R03 CA128006 (Denis), P30 DK057521
   (Joseph Avruch), American Cancer Society grant RSG-05-072-01 (Denis),
   and Leukemia and Lymphoma Society Translational Award 6023-09 (Denis). I
   thank Anna Belkina, Barbara Nikolajczyk, Maureen Scully, and John
   Trowsdale for helpful comments and suggestions. Space constraints do not
   permit comprehensive citation of many excellent studies on bromodomain
   function and malignancy, transcription, chromatin status, and other
   mechanisms of action. Any errors or omissions in the present review are
   of course the responsibility of the author alone.
CR Alkemade FE, 2010, AM J PATHOL, V176, P542, DOI 10.2353/ajpath.2010.090031
   Allende-Vega N, 2007, ONCOGENE, V26, P4234, DOI 10.1038/sj.onc.1210209
   Bao JJ, 2010, CELL MOL LIFE SCI, V67, P3073, DOI 10.1007/s00018-010-0402-y
   Bastard JP, 2006, EUR CYTOKINE NETW, V17, P4
   Bea S, 2005, BLOOD, V106, P3183, DOI 10.1182/blood-2005-04-1399
   Beck S, 1992, DNA Seq, V2, P203, DOI 10.3109/10425179209020804
   Bedford DC, 2010, EPIGENETICS-US, V5, P9, DOI 10.4161/epi.5.1.10449
   Belkina AC, 2010, OBESITY, V18, pS58
   Belkina AC, 2010, CURR OPIN ENDOCRINOL, V17, P472, DOI 10.1097/MED.0b013e32833c5c48
   Bonora E, 1998, DIABETES CARE, V21, P221, DOI 10.2337/diacare.21.2.221
   Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33
   Boyer LA, 2000, J BIOL CHEM, V275, P18864, DOI 10.1074/jbc.M002810200
   BROIDE DH, 1992, ALLERGY CLIN IMMUNOL, V89, P958
   Burrows AE, 2010, P NATL ACAD SCI USA, V107, P14280, DOI 10.1073/pnas.1009559107
   Cang SD, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-22
   Caron C, 2010, ONCOGENE, V29, P5171, DOI 10.1038/onc.2010.259
   Chang YL, 2007, MOL CELL BIOL, V27, P5486, DOI 10.1128/MCB.00692-07
   Chen L, 2010, NUCLEIC ACIDS RES, V38, P4011, DOI 10.1093/nar/gkq112
   Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876
   CHUA P, 1995, MOL CELL BIOL, V15, P3685
   Ciró M, 2009, CANCER RES, V69, P8491, DOI 10.1158/0008-5472.CAN-09-2131
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Crawford NPS, 2008, P NATL ACAD SCI USA, V105, P6380, DOI 10.1073/pnas.0710331105
   Cucca F, 2001, HUM MOL GENET, V10, P2025, DOI 10.1093/hmg/10.19.2025
   de Bakker PIW, 2006, NAT GENET, V38, P1166, DOI 10.1038/ng1885
   Denis GV, 2010, FEBS LETT, V584, P3260, DOI 10.1016/j.febslet.2010.05.030
   Denis GV, 2006, J PROTEOME RES, V5, P502, DOI 10.1021/pr050430u
   Denis GV, 2000, CELL GROWTH DIFFER, V11, P417
   Denis GV, 2001, FRONT BIOSCI, V6, pD1065
   Denis GV, 2001, FRONT BIOSCI, V6, pD849, DOI 10.2741/Denis
   Dey A, 2000, MOL CELL BIOL, V20, P6537, DOI 10.1128/MCB.20.17.6537-6549.2000
   Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100
   Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974
   DiBenedetto AJ, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-39
   DIGAN ME, 1986, DEV BIOL, V114, P161, DOI 10.1016/0012-1606(86)90392-1
   Drost J, 2010, NAT CELL BIOL, V12, P380, DOI 10.1038/ncb2038
   DUNHAM LJ, 1972, CANCER RES, V32, P1359
   Eberharter A, 2004, J CELL SCI, V117, P3707, DOI 10.1242/jcs.01175
   EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715
   Elisha B, 2010, DIABETES METAB, V36, P319, DOI 10.1016/j.diabet.2010.03.004
   Figueroa ME, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001882
   FILIPPAKOPOULOS P, 2010, NATURE
   French CA, 2001, AM J PATHOL, V159, P1987, DOI 10.1016/S0002-9440(10)63049-0
   French CA, 2010, CANCER GENET CYTOGEN, V203, P16, DOI 10.1016/j.cancergencyto.2010.06.007
   Garbati MR, 2010, CANCER LETT, V291, P237, DOI 10.1016/j.canlet.2009.10.018
   GLEESON MH, 1972, GUT, V13, P438, DOI 10.1136/gut.13.6.438
   Graham RR, 2002, AM J HUM GENET, V71, P543, DOI 10.1086/342290
   Greenwald RJ, 2004, BLOOD, V103, P1475, DOI 10.1182/blood-2003-06-2116
   GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102
   Guo N, 2000, J CELL SCI, V113, P3085
   Gyuris A, 2009, BBA-GENE REGUL MECH, V1789, P413, DOI 10.1016/j.bbagrm.2009.03.005
   Harte MT, 2010, CANCER RES, V70, P2538, DOI 10.1158/0008-5472.CAN-09-2089
   HAYNES SR, 1989, DEV BIOL, V134, P246, DOI 10.1016/0012-1606(89)90094-8
   HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603
   Higashi M, 2010, EXP CELL RES, V316, P2707, DOI 10.1016/j.yexcr.2010.05.028
   HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183
   Houzelstein D, 2002, MOL CELL BIOL, V22, P3794, DOI 10.1128/MCB.22.11.3794-3802.2002
   Hursting SD, 2010, J CLIN ONCOL, V28, P4058, DOI 10.1200/JCO.2010.27.9935
   Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422
   Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027
   Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6
   Johnston RA, 2007, AM J RESP CRIT CARE, V176, P650, DOI 10.1164/rccm.200702-323OC
   Kabesch M, 2010, EUR RESPIR J, V36, P950, DOI 10.1183/09031936.00019310
   Kahn SE, 2006, DIABETES, V55, P2357, DOI 10.2337/db06-0116
   Kampranis SC, 2009, ADV CANCER RES, V102, P103, DOI 10.1016/S0065-230X(09)02004-1
   Karelis AD, 2005, J CLIN ENDOCR METAB, V90, P4145, DOI 10.1210/jc.2005-0482
   Kasahara M, 1996, P NATL ACAD SCI USA, V93, P9096, DOI 10.1073/pnas.93.17.9096
   Kim CS, 2006, INT J OBESITY, V30, P1347, DOI 10.1038/sj.ijo.0803259
   Kitabayashi I, 2001, LEUKEMIA, V15, P89, DOI 10.1038/sj.leu.2401983
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655
   Lenburg ME, 2007, J BIOL CHEM, V282, P4803, DOI 10.1074/jbc.M605870200
   Leroy G, 2008, MOL CELL, V30, P51, DOI 10.1016/j.molcel.2008.01.018
   Lessard JA, 2010, ANNU REV CELL DEV BI, V26, P503, DOI 10.1146/annurev-cellbio-051809-102012
   Li X, 2010, J ALLERGY CLIN IMMUN, V125
   Liedman D, 2001, CURR OPIN HEMATOL, V8, P218, DOI 10.1097/00062752-200107000-00007
   Lim CT, 2010, J MOL ENDOCRINOL, V44, P87, DOI 10.1677/JME-09-0063
   Liu Y, 2008, BIOCHEMISTRY-US, V47, P6403, DOI 10.1021/bi8001659
   Longe HO, 2009, INT J CANCER, V124, P473, DOI 10.1002/ijc.23946
   Mahdi H, 2009, NAT GENET, V41, P1319, DOI 10.1038/ng.480
   Mangge H., 2010, Current Medicinal Chemistry
   Martens JHA, 2010, CANCER CELL, V17, P173, DOI 10.1016/j.ccr.2009.12.042
   McPhillips MG, 2005, J VIROL, V79, P8920, DOI 10.1128/JVI.79.14.8920-8932.2005
   Mertens F., Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer
   Mogal A, 2006, MOL CELL PROBE, V20, P81, DOI 10.1016/j.mcp.2005.09.008
   Moss TJ, 2007, MUTAT RES-FUND MOL M, V618, P163, DOI 10.1016/j.mrfmmm.2006.05.038
   MOZER BA, 1989, P NATL ACAD SCI USA, V86, P3738, DOI 10.1073/pnas.86.10.3738
   Mujtaba S, 2004, MOL CELL, V13, P251, DOI 10.1016/S1097-2765(03)00528-8
   Nagl NG, 2006, CANCER RES, V66, P1289, DOI 10.1158/0008-5472.CAN-05-3427
   Nagl NG, 2007, EMBO J, V26, P752, DOI 10.1038/sj.emboj.7601541
   Nakamura Y, 2007, J BIOL CHEM, V282, P4193, DOI 10.1074/jbc.M605971200
   Nalbandian A, 2009, CLIN EXP IMMUNOL, V157, P209, DOI 10.1111/j.1365-2249.2009.03944.x
   Nicodeme E, 2010, NATURE
   Ozaki K, 2002, NAT GENET, V32, P650, DOI 10.1038/ng1047
   Ozgen M, 2010, ARCH MED RES, V41, P457, DOI 10.1016/j.arcmed.2010.08.012
   Pan W, 2010, J IMMUNOL, V184, P6773, DOI 10.4049/jimmunol.0904060
   Panagopoulos I, 2001, HUM MOL GENET, V10, P395, DOI 10.1093/hmg/10.4.395
   Pieringer H, 2010, QJM
   Redner RL, 1999, BLOOD, V94, P417, DOI 10.1182/blood.V94.2.417.414k49_417_428
   Romano M, 2003, J CLIN ENDOCR METAB, V88, P5321, DOI 10.1210/jc.2003-030508
   Romesser PB, 2009, AM J PATHOL, V175, P25, DOI 10.2353/ajpath.2009.080707
   RUDERMAN NB, 1981, AM J CLIN NUTR, V34, P1617, DOI 10.1093/ajcn/34.8.1617
   Sanchez R, 2009, CURR OPIN DRUG DISC, V12, P659
   Schwartz YB, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000805
   Sebova K, 2010, ANTI-CANCER DRUG, V21, P565, DOI 10.1097/CAD.0b013e32833a4352
   Serravalle S, 2010, LEUKEMIA RES, V34, pE292, DOI 10.1016/j.leukres.2010.05.026
   Shang EY, 2009, DEV DYNAM, V238, P908, DOI 10.1002/dvdy.21911
   Shen W, 2010, NEUROCHEM RES, V35, P940, DOI 10.1007/s11064-009-0091-9
   Shen WQ, 2007, BIOCHEMISTRY-US, V46, P2100, DOI 10.1021/bi0611208
   Shigeno K, 2004, CANCER LETT, V213, P11, DOI 10.1016/S0304-3835(03)00442-7
   Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1016/j.febslet.2007.11.057
   Sinha A, 2005, BIOCHEM J, V387, P257, DOI 10.1042/BJ20041793
   Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732
   Srivastava N, 2009, MUTAT RES-REV MUTAT, V681, P180, DOI 10.1016/j.mrrev.2008.08.003
   Stattin P, 2004, INT J CANCER, V109, P149, DOI 10.1002/ijc.11668
   Succurro E, 2008, OBESITY, V16, P1881, DOI 10.1038/oby.2008.308
   Suganami T, 2010, J LEUKOCYTE BIOL, V88, P33, DOI 10.1189/jlb.0210072
   Sun YL, 2010, CELL CYCLE, V9, P930, DOI 10.4161/cc.9.5.10931
   TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E
   Taverna SD, 2007, NAT STRUCT MOL BIOL, V14, P1025, DOI 10.1038/nsmb1338
   Thomson CA, 2009, FUTURE ONCOL, V5, P1257, DOI [10.2217/fon.09.86, 10.2217/FON.09.86]
   Thorpe KL, 1997, GENE, V200, P177, DOI 10.1016/S0378-1119(97)00415-0
   Tian YF, 2007, ENDOCR-RELAT CANCER, V14, P669, DOI 10.1677/ERC-06-0089
   TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0
   Trenkmann M, 2010, CLIN REV ALLERG IMMU, V39, P10, DOI 10.1007/s12016-009-8166-6
   Verma SC, 2003, FEMS MICROBIOL LETT, V222, P155, DOI 10.1016/S0378-1097(03)00261-1
   Vermeulen L, 2009, TRENDS BIOCHEM SCI, V34, P311, DOI 10.1016/j.tibs.2009.02.007
   Vona-Davis L, 2009, J WOMENS HEALTH, V18, P883, DOI 10.1089/jwh.2008.1127
   Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658
   Wang FN, 2010, BIOCHEM J, V425, P71, DOI 10.1042/BJ20090928
   Wei EK, 2005, JNCI-J NATL CANCER I, V97, P1688, DOI 10.1093/jnci/dji376
   Westlake SL, 2010, RHEUMATOLOGY OXFORD
   Wildman RP, 2008, ARCH INTERN MED, V168, P1617, DOI 10.1001/archinte.168.15.1617
   Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593
   Wu SY, 2007, J BIOL CHEM, V282, P13141, DOI 10.1074/jbc.R700001200
   Yang XJ, 2004, BIOESSAYS, V26, P1076, DOI 10.1002/bies.20104
   Yang ZY, 2005, MOL CELL, V19, P535, DOI 10.1016/j.molcel.2005.06.029
   You JX, 2006, J VIROL, V80, P8909, DOI 10.1128/JVI.00502-06
   Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9
NR 140
TC 56
Z9 107
U1 0
U2 11
PU DISCOVERY MEDICINE
PI TIMONIUM
PA 10 GERARD AVE, STE 201, TIMONIUM, MD 21093 USA
SN 1539-6509
EI 1944-7930
J9 DISCOV MED
JI Discov. Med.
PD DEC
PY 2010
VL 10
IS 55
BP 489
EP 499
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA V27UV
UT WOS:000208639000002
PM 21189220
DA 2025-01-12
ER

PT J
AU Wei, J
   Xie, L
   Taron, M
   Rose, R
   Liu, BR
AF Wei, Jia
   Xie, Li
   Taron, Miguel
   Rose, Rafael
   Liu, Baorui
TI EPIGENETIC ALTERATIONS OF TUMOR MARKER MICRORNAs: TOWARDS NEW CANCER
   THERAPIES
SO DRUG NEWS & PERSPECTIVES
LA English
DT Article
ID HUMAN LUNG CANCERS; EXPRESSION PROFILES; DOWN-REGULATION; BREAST-CANCER;
   PROMOTES TRANSFORMATION; CIRCULATING MICRORNAS; CELL-PROLIFERATION;
   PREDICTS SURVIVAL; DNA METHYLATION; SUPPRESSOR GENE
AB MicroRNAs (miRNAs) are a class of short noncoding RNAs that participate in mastering the balance of gene-regulating networks. By targeting and controlling expression of messenger RNA, miRNAs can control highly complex signal transduction pathways and other biological pathways. Unique aberrant expression of miRNA at each stage of cancer development suggests that miRNA could play a novel role in cancer diagnosis and therapeutic strategies. Accumulated information on epigenetic modification of miRNA suggests a promising platform for miRNA in cancer therapy. Clinical applications exploiting the understanding of miRNA's function will be the next great challenge in cancer research.
C1 [Liu, Baorui] Nanjing Univ, Sch Med, Clin Canc Inst, Dept Oncol,Drum Tower Hosp, Nanjing 210008, Peoples R China.
   [Taron, Miguel; Rose, Rafael] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain.
C3 Nanjing University; Institut Catala d'Oncologia; Hospital Germans Trias
   i Pujol
RP Liu, BR (通讯作者)，Nanjing Univ, Sch Med, Clin Canc Inst, Dept Oncol,Drum Tower Hosp, Zhongshan Rd 321, Nanjing 210008, Peoples R China.
EM baoruiliu@nju.edu.cn
CR Agirre X, 2009, CANCER RES, V69, P4443, DOI 10.1158/0008-5472.CAN-08-4025
   Bandres E, 2009, INT J CANCER, V125, P2737, DOI 10.1002/ijc.24638
   Bandres E, 2009, CLIN CANCER RES, V15, P2281, DOI 10.1158/1078-0432.CCR-08-1818
   Benetti R, 2008, NAT STRUCT MOL BIOL, V15, P268, DOI 10.1038/nsmb.1399
   Bloomston M, 2007, JAMA-J AM MED ASSOC, V297, P1901, DOI 10.1001/jama.297.17.1901
   Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068
   BONI V, 2010, PHARMACOGENOMI UNPUB
   Budhu A, 2008, HEPATOLOGY, V47, P897, DOI 10.1002/hep.22160
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995
   Camps C, 2008, CLIN CANCER RES, V14, P1340, DOI 10.1158/1078-0432.CCR-07-1755
   Chang KW, 2008, J DENT RES, V87, P1063, DOI 10.1177/154405910808701116
   Chen X, 2008, CELL RES, V18, P997, DOI 10.1038/cr.2008.282
   Chen YX, 2007, CANCER RES, V67, P976, DOI 10.1158/0008-5472.CAN-06-3667
   Childs G, 2009, AM J PATHOL, V174, P736, DOI 10.2353/ajpath.2009.080731
   Christensen BC, 2009, CARCINOGENESIS, V30, P1003, DOI 10.1093/carcin/bgp099
   Díaz R, 2008, GENE CHROMOSOME CANC, V47, P794, DOI 10.1002/gcc.20580
   Duursma AM, 2008, RNA, V14, P872, DOI 10.1261/rna.972008
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104
   Fazi F, 2007, CANCER CELL, V12, P457, DOI 10.1016/j.ccr.2007.09.020
   Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Garzon R, 2008, BLOOD, V111, P3183, DOI 10.1182/blood-2007-07-098749
   Grady WM, 2008, ONCOGENE, V27, P3880, DOI 10.1038/onc.2008.10
   Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952
   Guo Y, 2008, CANCER RES, V68, P26, DOI 10.1158/0008-5472.CAN-06-4418
   Han L, 2007, CANCER BIOL THER, V6, P1284
   Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352
   He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552
   Hermeking H, 2007, CANCER CELL, V12, P414, DOI 10.1016/j.ccr.2007.10.028
   Hu ZB, 2008, J CLIN INVEST, V118, P2600, DOI 10.1172/JCI34934
   Hu ZB, 2010, J CLIN ONCOL, V28, P1721, DOI 10.1200/JCO.2009.24.9342
   Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681
   Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023
   Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936
   Jazdzewski K, 2008, P NATL ACAD SCI USA, V105, P7269, DOI 10.1073/pnas.0802682105
   Jiang J, 2008, CLIN CANCER RES, V14, P419, DOI 10.1158/1078-0432.CCR-07-0523
   Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083
   Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014
   Kong W, 2010, J BIOL CHEM, V285, P17869, DOI 10.1074/jbc.M110.101055
   Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194
   Lawrie CH, 2008, BRIT J HAEMATOL, V141, P672, DOI 10.1111/j.1365-2141.2008.07077.x
   Lebanony D, 2009, J CLIN ONCOL, V27, P2030, DOI 10.1200/JCO.2008.19.4134
   Lee I, 2009, GENOME RES, V19, P1175, DOI 10.1101/gr.089367.108
   Lee KH, 2009, PANCREATOLOGY, V9, P293, DOI 10.1159/000186051
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li WX, 2008, INT J CANCER, V123, P1616, DOI 10.1002/ijc.23693
   Link A, 2010, CANCER EPIDEM BIOMAR, V19, P1766, DOI 10.1158/1055-9965.EPI-10-0027
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544
   Lu YJ, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkn1053
   Lytle JR, 2007, P NATL ACAD SCI USA, V104, P9667, DOI 10.1073/pnas.0703820104
   Mack GS, 2006, J NATL CANCER I, V98, P1443, DOI 10.1093/jnci/djj447
   Malumbres R, 2009, BLOOD, V113, P3754, DOI 10.1182/blood-2008-10-184077
   Markou A, 2008, CLIN CHEM, V54, P1696, DOI 10.1373/clinchem.2007.101741
   Mascaux C, 2009, EUR RESPIR J, V33, P352, DOI 10.1183/09031936.00084108
   Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999
   Meng F, 2008, ONCOGENE, V27, P378, DOI 10.1038/sj.onc.1210648
   Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022
   Mishra PJ, 2009, PHARMACOGENOMICS, V10, P399, DOI 10.2217/14622416.10.3.399
   Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105
   Motoyama K, 2009, INT J ONCOL, V34, P1069, DOI 10.3892/ijo_00000233
   Murakami Y, 2006, ONCOGENE, V25, P2537, DOI 10.1038/sj.onc.1209283
   Nam EJ, 2008, CLIN CANCER RES, V14, P2690, DOI 10.1158/1078-0432.CCR-07-1731
   Noonan EJ, 2009, ONCOGENE, V28, P1714, DOI 10.1038/onc.2009.19
   O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677
   Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013
   Qian BY, 2009, BREAST CANCER RES TR, V117, P131, DOI 10.1007/s10549-008-0219-7
   Qin WM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009429
   Roldo C, 2006, J CLIN ONCOL, V24, P4677, DOI 10.1200/JCO.2005.05.5194
   Roman-Gomez J, 2009, J CLIN ONCOL, V27, P1316, DOI 10.1200/JCO.2008.19.3441
   Rosenfeld N, 2008, NAT BIOTECHNOL, V26, P462, DOI 10.1038/nbt1392
   Saito Y, 2009, ONCOGENE, V28, P2738, DOI 10.1038/onc.2009.140
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425
   Scott GK, 2006, CANCER RES, V66, P1277, DOI 10.1158/0008-5472.CAN-05-3632
   Shen J, 2008, CARCINOGENESIS, V29, P1963, DOI 10.1093/carcin/bgn172
   Slaby O, 2007, ONCOLOGY-BASEL, V72, P397, DOI 10.1159/000113489
   Szafranska AE, 2008, J MOL DIAGN, V10, P415, DOI 10.2353/jmoldx.2008.080018
   Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Tili Esmerina, 2007, Future Oncol, V3, P521, DOI 10.2217/14796694.3.5.521
   Tong AW, 2009, CANCER GENE THER, V16, P206, DOI 10.1038/cgt.2008.77
   Tsujiura M, 2010, BRIT J CANCER, V102, P1174, DOI 10.1038/sj.bjc.6605608
   Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460
   Visone R, 2008, GASTROENTEROLOGY, V135, P1866, DOI 10.1053/j.gastro.2008.10.074
   Visone R, 2009, AM J PATHOL, V174, P1131, DOI 10.2353/ajpath.2009.080794
   Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Wang CJ, 2009, DIS MARKERS, V26, P27, DOI [10.3233/DMA-2009-0601, 10.1155/2009/921907]
   Wang YC, 2010, CARCINOGENESIS, V31, P1516, DOI 10.1093/carcin/bgq107
   Wu W, 2010, DRUGS R&D, V10, P1, DOI 10.2165/11537800-000000000-00000
   Xi YG, 2006, BIOMARK INSIGHTS, V1, P113
   Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441
   YAN HJ, 2010, HUM GENE THER UNPUB
   Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808
   Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025
   Yu SL, 2008, CANCER CELL, V13, P48, DOI 10.1016/j.ccr.2007.12.008
   Zhang BH, 2008, J CELL MOL MED, V12, P3, DOI 10.1111/j.1582-4934.2007.00196.x
   Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200
NR 104
TC 6
Z9 6
U1 0
U2 5
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 0214-0934
EI 2013-0139
J9 DRUG NEWS PERSPECT
JI Drug News Perspect.
PD DEC
PY 2010
VL 23
IS 10
BP 655
EP 661
DI 10.1358/dnp.2010.23.10.1560143
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 754QV
UT WOS:000289872600005
PM 21180651
DA 2025-01-12
ER

PT J
AU Lagger, S
   Meunier, D
   Mikula, M
   Brunmeir, R
   Schlederer, M
   Artaker, M
   Pusch, O
   Egger, G
   Hagelkruys, A
   Mikulits, W
   Weitzer, G
   Muellner, EW
   Susani, M
   Kenner, L
   Seiser, C
AF Lagger, Sabine
   Meunier, Dominique
   Mikula, Mario
   Brunmeir, Reinhard
   Schlederer, Michaela
   Artaker, Matthias
   Pusch, Oliver
   Egger, Gerda
   Hagelkruys, Astrid
   Mikulits, Wolfgang
   Weitzer, Georg
   Muellner, Ernst W.
   Susani, Martin
   Kenner, Lukas
   Seiser, Christian
TI Crucial function of histone deacetylase 1 for differentiation of
   teratomas in mice and humans
SO EMBO JOURNAL
LA English
DT Article
DE cancer treatment; chromatin; epigenetics; HDAC inhibitors; histone
   modifications
ID BREAST-CANCER PROGRESSION; E-CADHERIN REPRESSION; CLASS-I;
   DOWN-REGULATION; COLON-CANCER; CELL-DIFFERENTIATION; TRANSCRIPTION
   FACTOR; NEGATIVE REGULATION; EXPRESSION PROFILE; PANCREATIC-CANCER
AB Histone deacetylase (HDAC) inhibitors induce cell cycle arrest, differentiation or apoptosis in tumour cells and are, therefore, promising anti-cancer reagents. However, the specific HDAC isoforms that mediate these effects are not yet identified. To explore the role of HDAC1 in tumourigenesis and tumour proliferation, we established an experimental teratoma model using wild-type and HDAC1-deficient embryonic stem cells. HDAC1-deficient teratomas showed no significant difference in size compared with wild-type teratomas. Surprisingly, loss of HDAC1 was not only linked to increased apoptosis, but also to significantly enhanced proliferation. Epithelial structures showed reduced differentiation as monitored by Oct3/4 expression and changed E-cadherin localization and displayed up-regulated expression of SNAIL1, a regulator of epithelial cell plasticity. Increased levels of the transcriptional regulator SNAIL1 are crucial for enhanced proliferation and reduced differentiation of HDAC1-deficient teratoma. Importantly, the analysis of human teratomas revealed a similar link between loss of HDAC1 and enhanced tumour malignancy. These findings reveal a novel role for HDAC1 in the control of tumour proliferation and identify HDAC1 as potential marker for benign teratomas. The EMBO Journal (2010) 29, 3992-4007. doi:10.1038/emboj.2010.264; Published online 22 October 2010
C1 [Schlederer, Michaela; Egger, Gerda; Susani, Martin; Kenner, Lukas] Med Univ Vienna, Clin Inst Pathol, A-1090 Vienna, Austria.
   [Lagger, Sabine; Meunier, Dominique; Brunmeir, Reinhard; Artaker, Matthias; Hagelkruys, Astrid; Weitzer, Georg; Muellner, Ernst W.; Seiser, Christian] Med Univ Vienna, Dept Med Biochem, Max F Perutz Labs, Vienna Bioctr, A-1030 Vienna, Austria.
   [Mikula, Mario; Mikulits, Wolfgang] Med Univ Vienna, Inst Canc Res, A-1030 Vienna, Austria.
   [Kenner, Lukas] Med Univ Vienna, Clin Inst Pathol, A-1030 Vienna, Austria.
   [Pusch, Oliver] Med Univ Vienna, Ctr Anat & Cell Biol, A-1030 Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna; University
   of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL);
   Medical University of Vienna; Medical University of Vienna; Medical
   University of Vienna
RP Kenner, L (通讯作者)，Med Univ Vienna, Clin Inst Pathol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM lukas.kenner@meduniwien.ac.at; christian.seiser@meduniwien.ac.at
RI Lagger, Sabine/GQP-6676-2022; Weitzer, Georg/LKK-4340-2024; Mikulits,
   Wolfgang/AAH-4043-2021; Egger, Gerda/B-7177-2013
OI Mikulits, Wolfgang/0000-0003-4612-7106; Mikula,
   Mario/0000-0001-5782-0681; Egger, Gerda/0000-0003-2489-155X; Seiser,
   Christian/0000-0002-7046-9352; Kenner, Lukas/0000-0003-2184-1338;
   Weitzer, Georg/0000-0002-6831-6429; Lagger, Sabine/0000-0002-3032-9910;
   Brunmeir, Reinhard/0000-0001-7545-2819; Pusch,
   Oliver/0000-0001-7166-2800
FU Austrian Science Fund (FWF) [P18746, P16443]; Austrian Ministry of
   Science and Research (BM:WF); WWTF (Vienna Science and Technology Fund)
   [LS09-031]; FWF; Schering PhD fellowship; Austrian Science Fund (FWF)
   [P16443, P18746] Funding Source: Austrian Science Fund (FWF)
FX We thank Andreas Eger for many fruitful scientific discussions and the
   ZEB1 antibody and the Manuela Baccarini laboratory for providing
   antibodies. Furthermore, we are grateful to Gordin Zupkovitz, Mircea
   Winter, Anna Sawicka, Magdalena Rennmayr, Mirjam Moser, Laura Bayer, and
   Evelyn Pineda for providing excellent technical assistance. We also
   thank Ingrid Mudrak for generously providing the F9 cell line. The work
   in the laboratory of CS was supported by the Austrian Science Fund (FWF
   P18746 and P16443), the GEN-AU project 'Epigenetic Plasticity of the
   Mammalian Genome' (Austrian Ministry of Science and Research (BM:WF))
   and the WWTF ((Vienna Science and Technology Fund) project LS09-031. SL
   was a fellow of the Vienna Biocenter International PhD program supported
   by the FWF, AH is a fellow of the International PhD program 'Molecular
   mechanism of Cell Signaling' supported by the FWF and RB was funded by a
   Schering PhD fellowship.
CR ALONSO A, 1991, International Journal of Developmental Biology, V35, P389
   Alves CC, 2007, J PATHOL, V211, P507, DOI 10.1002/path.2138
   Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001
   Andrews PW, 2002, PHILOS T R SOC B, V357, P405, DOI 10.1098/rstb.2002.1058
   Balasubramanian S, 2009, CANCER LETT, V280, P211, DOI 10.1016/j.canlet.2009.02.013
   Bandyopadhyay D, 2004, CANCER RES, V64, P7706, DOI 10.1158/0008-5472.CAN-03-3897
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Brunmeir R, 2009, INT J DEV BIOL, V53, P275, DOI 10.1387/ijdb.082649rb
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Choi JH, 2001, JPN J CANCER RES, V92, P1300, DOI 10.1111/j.1349-7006.2001.tb02153.x
   Dovey OM, 2010, P NATL ACAD SCI USA, V107, P8242, DOI 10.1073/pnas.1000478107
   Elloul S, 2005, CANCER-AM CANCER SOC, V103, P1631, DOI 10.1002/cncr.20946
   Giannini R, 2005, ANTICANCER RES, V25, P4287
   Glaser KB, 2003, BIOCHEM BIOPH RES CO, V310, P529, DOI 10.1016/j.bbrc.2003.09.043
   Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610
   Gotzmann J, 2004, MUTAT RES-REV MUTAT, V566, P9, DOI 10.1016/S1383-5742(03)00033-4
   Gotzmann J, 2002, J CELL SCI, V115, P1189
   Grausenburger R, 2010, J IMMUNOL, V185, P3489, DOI 10.4049/jimmunol.0903610
   Guarino M, 2007, INT J BIOCHEM CELL B, V39, P2153, DOI 10.1016/j.biocel.2007.07.011
   Haberland M, 2009, P NATL ACAD SCI USA, V106, P7751, DOI 10.1073/pnas.0903139106
   Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485
   Halkidou K, 2004, PROSTATE, V59, P177, DOI 10.1002/pros.20022
   Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519
   Hauser C, 2002, MOL CELL BIOL, V22, P7820, DOI 10.1128/MCB.22.22.7820-7830.2002
   Hayashi A, 2010, INT J CANCER, V127, P1332, DOI 10.1002/ijc.25151
   Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08
   Huang BH, 2005, CELL DEATH DIFFER, V12, P395, DOI 10.1038/sj.cdd.4401567
   Ishihama K, 2007, J CLIN PATHOL, V60, P1205, DOI 10.1136/jcp.2005.029165
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jin Ke Long, 2008, J Gynecol Oncol, V19, P185, DOI 10.3802/jgo.2008.19.3.185
   Jones TD, 2006, CLIN CANCER RES, V12, P5377, DOI 10.1158/1078-0432.CCR-06-0444
   Kato T, 2009, CANCER RES, V69, P3597, DOI 10.1158/0008-5472.CAN-08-4368
   Kawai H, 2003, INT J CANCER, V107, P353, DOI 10.1002/ijc.11403
   Kim JH, 2004, J GASTROEN HEPATOL, V19, P218, DOI 10.1111/j.1440-1746.2004.03336.x
   Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507
   Krusche CA, 2005, BREAST CANCER RES TR, V90, P15, DOI 10.1007/s10549-004-1668-2
   Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672
   Lee YS, 2008, CANCER RES, V68, P7561, DOI 10.1158/0008-5472.CAN-08-0188
   Lin HY, 2006, MED RES REV, V26, P397, DOI 10.1002/med.20056
   Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247
   Mariadason JM, 2008, EPIGENETICS-US, V3, P28, DOI 10.4161/epi.3.1.5736
   Marks PA, 2009, J CELL BIOCHEM, V107, P600, DOI 10.1002/jcb.22185
   Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4
   Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040
   Montgomery RL, 2007, GENE DEV, V21, P1790, DOI 10.1101/gad.1563807
   Montgomery RL, 2009, P NATL ACAD SCI USA, V106, P7876, DOI 10.1073/pnas.0902750106
   Nakagawa M, 2007, ONCOL REP, V18, P769
   Olmeda D, 2007, ONCOGENE, V26, P1862, DOI 10.1038/sj.onc.1209997
   Özdag H, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-90
   Patra SK, 2001, BIOCHEM BIOPH RES CO, V287, P705, DOI 10.1006/bbrc.2001.5639
   Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004
   Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131
   Peiró S, 2006, NUCLEIC ACIDS RES, V34, P2077, DOI 10.1093/nar/gkl141
   Rikimaru T, 2007, ONCOLOGY-BASEL, V72, P69, DOI 10.1159/000111106
   Senese S, 2007, MOL CELL BIOL, V27, P4784, DOI 10.1128/MCB.00494-07
   Spange S, 2009, INT J BIOCHEM CELL B, V41, P185, DOI 10.1016/j.biocel.2008.08.027
   Suzuki J, 2009, CLIN CANCER RES, V15, P3163, DOI 10.1158/1078-0432.CCR-08-2319
   Taplick J, 2001, J MOL BIOL, V308, P27, DOI 10.1006/jmbi.2001.4569
   Thangaraju M, 2009, BIOCHEM J, V417, P379, DOI 10.1042/BJ20081132
   Trivedi CM, 2007, NAT MED, V13, P324, DOI 10.1038/nm1552
   von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004
   Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693
   Wang W, 2009, ONCOL REP, V21, P1439, DOI 10.3892/or_00000372
   Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154
   Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199
   Weichert W, 2008, NEOPLASIA, V10, P1021, DOI 10.1593/neo.08474
   Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990
   Weichert W, 2009, CANCER LETT, V280, P168, DOI 10.1016/j.canlet.2008.10.047
   Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200
   Wilting RH, 2010, EMBO J, V29, P2586, DOI 10.1038/emboj.2010.136
   Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016
   Yamaguchi T, 2010, GENE DEV, V24, P455, DOI 10.1101/gad.552310
   Zhou XB, 2000, P NATL ACAD SCI USA, V97, P1056, DOI 10.1073/pnas.97.3.1056
   Zimmermann S, 2007, CANCER RES, V67, P9047, DOI 10.1158/0008-5472.CAN-07-0312
   Zupkovitz G, 2006, MOL CELL BIOL, V26, P7913, DOI 10.1128/MCB.01220-06
   Zupkovitz G, 2010, MOL CELL BIOL, V30, P1171, DOI 10.1128/MCB.01500-09
NR 76
TC 34
Z9 38
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0261-4189
J9 EMBO J
JI Embo J.
PD DEC 1
PY 2010
VL 29
IS 23
BP 3992
EP 4007
DI 10.1038/emboj.2010.264
PG 16
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 695SE
UT WOS:000285392100011
PM 20967026
OA Green Published
DA 2025-01-12
ER

PT J
AU Robinson, MD
   Stirzaker, C
   Statham, AL
   Coolen, MW
   Song, JZ
   Nair, SS
   Strbenac, D
   Speed, TP
   Clark, SJ
AF Robinson, Mark D.
   Stirzaker, Clare
   Statham, Aaron L.
   Coolen, Marcel W.
   Song, Jenny Z.
   Nair, Shalima S.
   Strbenac, Dario
   Speed, Terence P.
   Clark, Susan J.
TI Evaluation of affinity-based genome-wide DNA methylation data: Effects
   of CpG density, amplification bias, and copy number variation
SO GENOME RESEARCH
LA English
DT Article
ID GENE-EXPRESSION; PROSTATE-CANCER; DIFFERENTIATED CELLS; SINGLE-MOLECULE;
   BREAST-CANCER; LUNG-CANCER; CHIP-CHIP; HYPERMETHYLATION; RESOLUTION;
   ABERRATIONS
AB DNA methylation is an essential epigenetic modification that plays a key role associated with the regulation of gene expression during differentiation, but in disease states such as cancer, the DNA methylation landscape is often deregulated. There are now numerous technologies available to interrogate the DNA methylation status of CpG sites in a targeted or genome-wide fashion, but each method, due to intrinsic biases, potentially interrogates different fractions of the genome. In this study, we compare the affinity-purification of methylated DNA between two popular genome-wide techniques, methylated DNA immunoprecipitation (MeDIP) and methyl-CpG binding domain-based capture (MBDCap), and show that each technique operates in a different domain of the CpG density landscape. We explored the effect of whole-genome amplification and illustrate that it can reduce sensitivity for detecting DNA methylation in GC-rich regions of the genome. By using MBDCap, we compare and contrast microarray- and sequencing-based readouts and highlight the impact that copy number variation (CNV) can make in differential comparisons of methylomes. These studies reveal that the analysis of DNA methylation data and genome coverage is highly dependent on the method employed, and consideration must be made in light of the GC content, the extent of DNA amplification, and the copy number.
C1 [Robinson, Mark D.; Stirzaker, Clare; Statham, Aaron L.; Coolen, Marcel W.; Song, Jenny Z.; Nair, Shalima S.; Strbenac, Dario; Clark, Susan J.] Garvan Inst Med Res, Canc Res Program, Epigenet Lab, Sydney, NSW 2010, Australia.
   [Robinson, Mark D.; Speed, Terence P.] Walter & Eliza Hall Inst Med Res, Bioinformat Div, Parkville, Vic 3052, Australia.
   [Coolen, Marcel W.] Radboud Univ Nijmegen, Nijmegen Ctr Mol Life Sci, Fac Sci, Dept Mol Biol, NL-6500 HB Nijmegen, Netherlands.
   [Clark, Susan J.] Univ New S Wales, St Vincents Clin Sch, Sydney, NSW 2010, Australia.
C3 Garvan Institute of Medical Research; Walter & Eliza Hall Institute;
   Radboud University Nijmegen; University of New South Wales Sydney
RP Clark, SJ (通讯作者)，Garvan Inst Med Res, Canc Res Program, Epigenet Lab, Sydney, NSW 2010, Australia.
EM s.clark@garvan.org.au
RI Speed, Terence/B-8085-2009; Clark, Susan/B-2272-2008; Robinson,
   Mark/A-6432-2015
OI Stirzaker, Clare/0000-0001-5601-3140; Clark, Susan/0000-0001-5925-5030;
   Robinson, Mark/0000-0002-3048-5518; Coolen, Marcel/0000-0002-8188-8480
FU National Health and Medical Research Council (NHMRC) [427614, 481347];
   Cancer Institute NSW; NBCF; ACRF
FX We thank Kate Patterson for help with preparation of the figures and
   critical reading of the manuscript and Oleg Mayba for mappability
   calculation code. This work is supported by National Health and Medical
   Research Council (NH&MRC) project (427614, 481347) (M.D.R., C.S., D.S.)
   and Fellowship (S.J.C.), Cancer Institute NSW grants (CINSW: S.J.C.,
   A.L.S.), and NBCF Program Grant (S.J.C.) and ACRF. We also thank the
   Ramaciotti Centre, University of New South Wales (Sydney, Australia) for
   array hybridizations and Illumina GAII sequencing of MBDCap DNA.
CR Bengtsson H., 2008, aroma. affymetrix: A generic framework in R for analyzing small to very large Affymetrix data sets in bounded memory
   Bredel M, 2005, J MOL DIAGN, V7, P171, DOI 10.1016/S1525-1578(10)60543-0
   Clarke J, 2009, NAT NANOTECHNOL, V4, P265, DOI [10.1038/nnano.2009.12, 10.1038/NNANO.2009.12]
   Coolen MW, 2010, NAT CELL BIOL, V12, P235, DOI 10.1038/ncb2023
   Flusberg BA, 2010, NAT METHODS, V7, P461, DOI [10.1038/NMETH.1459, 10.1038/nmeth.1459]
   Gal-Yam EN, 2008, P NATL ACAD SCI USA, V105, P12979, DOI 10.1073/pnas.0806437105
   Gu H, 2010, NAT METHODS, V7, P133, DOI 10.1038/nmeth.1414
   Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015
   Irizarry RA, 2008, GENOME RES, V18, P780, DOI 10.1101/gr.7301508
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jeddeloh JA, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-8-231
   Johnson DS, 2008, GENOME RES, V18, P393, DOI 10.1101/gr.7080508
   Johnson WE, 2006, P NATL ACAD SCI USA, V103, P12457, DOI 10.1073/pnas.0601180103
   Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kaminsky ZA, 2009, NAT GENET, V41, P240, DOI 10.1038/ng.286
   Laird PW, 2010, NAT REV GENET, V11, P191, DOI 10.1038/nrg2732
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   LI N, 2010, METHODS IN PRESS, DOI DOI 10.1016/J.YMETH.2010.04.009
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   MATSUO K, 1994, NUCLEIC ACIDS RES, V22, P5354, DOI 10.1093/nar/22.24.5354
   Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107
   Nakayama M, 2004, J CELL BIOCHEM, V91, P540, DOI 10.1002/jcb.10740
   Novak P, 2008, CANCER RES, V68, P8616, DOI 10.1158/0008-5472.CAN-08-1419
   Oda M, 2009, NUCLEIC ACIDS RES, V37, P3829, DOI 10.1093/nar/gkp260
   Paris PL, 2009, METHODS MOL BIOL, V556, P89, DOI 10.1007/978-1-60327-192-9_7
   Pelizzola M, 2008, GENOME RES, V18, P1652, DOI 10.1101/gr.080721.108
   Ponzielli R, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn735
   Pugh TJ, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn378
   Rauch T, 2006, CANCER RES, V66, P7939, DOI 10.1158/0008-5472.CAN-06-1888
   Rauch TA, 2008, P NATL ACAD SCI USA, V105, P252, DOI 10.1073/pnas.0710735105
   Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Ruike Y, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-137
   Serre D, 2010, NUCLEIC ACIDS RES, V38, P391, DOI 10.1093/nar/gkp992
   Song JZ, 2002, ONCOGENE, V21, P1048, DOI 10.1038/sj.onc.1205153
   Sorensen AL, 2010, MOL BIOL CELL, V21, P2066, DOI 10.1091/mbc.E10-01-0018
   Statham AL, 2010, BIOINFORMATICS, V26, P1662, DOI 10.1093/bioinformatics/btq247
   Stranger BE, 2007, SCIENCE, V315, P848, DOI 10.1126/science.1136678
   Teo YY, 2008, NAT METHODS, V5, P279, DOI 10.1038/nmeth0408-279
   Teytelman L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006700
   Vega VB, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005241
   Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598
   Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
   Wei HR, 2008, NUCLEIC ACIDS RES, V36, P2926, DOI 10.1093/nar/gkn133
   Weng YI, 2009, METHODS MOL BIOL, V590, P165, DOI 10.1007/978-1-60327-378-7_10
   Xie C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-80
   Zhang ZZ, 2009, BIOTECHNIQUES, V47, P775, DOI 10.2144/000113203
NR 49
TC 95
Z9 118
U1 0
U2 6
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1088-9051
EI 1549-5469
J9 GENOME RES
JI Genome Res.
PD DEC
PY 2010
VL 20
IS 12
BP 1719
EP 1729
DI 10.1101/gr.110601.110
PG 11
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 688FK
UT WOS:000284835000011
PM 21045081
OA Green Submitted, hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Giraldi, T
   Giovannelli, P
   Di Donato, M
   Castoria, G
   Migliaccio, A
   Auricchio, F
AF Giraldi, Tiziana
   Giovannelli, Pia
   Di Donato, Marzia
   Castoria, Gabriella
   Migliaccio, Antimo
   Auricchio, Ferdinando
TI Steroid signaling activation and intracellular localization of sex
   steroid receptors
SO JOURNAL OF CELL COMMUNICATION AND SIGNALING
LA English
DT Article
DE Steroid action; Signaling activation; Sex steroid receptor localization
AB In addition to stimulating gene transcription, sex steroids trigger rapid, non-genomic responses in the extranuclear compartment of target cells. These events take place within seconds or minutes after hormone administration and do not require transcriptional activity of sex steroid receptors. Depending on cell systems, activation of extra-nuclear signaling pathways by sex steroids fosters cell cycle progression, prevents apoptosis, leads to epigenetic modifications and increases cell migration through cytoskeleton changes. These findings have raised the question of intracellular localization of sex steroid receptors mediating these responses. During the past years, increasing evidence has shown that classical sex steroid receptors localized in the extra-nuclear compartment or close to membranes of target cells induce these events. The emerging picture is that a process of bidirectional control between signaling activation and sex steroid receptor localization regulates the outcome of hormonal responses in target cells. This mechanism ensures cell cycle progression in estradiol-treated breast cancer cells, and its derangement might occur in progression of human proliferative diseases. These findings will be reviewed here together with unexpected examples of the relationship between sex steroid receptor localization, signaling activation and biological responses in target cells. We apologize to scientists whose reports are not mentioned or extensively discussed owing to space limitations.
C1 [Giraldi, Tiziana; Giovannelli, Pia; Di Donato, Marzia; Castoria, Gabriella; Migliaccio, Antimo; Auricchio, Ferdinando] Univ Naples 2, Dept Gen Pathol, I-80138 Naples, Italy.
C3 Universita della Campania Vanvitelli
RP Castoria, G (通讯作者)，Univ Naples 2, Dept Gen Pathol, Via L de Crecchio 7, I-80138 Naples, Italy.
EM gabriella.castoria@unina2.it
RI Castoria, Gabriella/I-3349-2019; Di Donato, Marzia/M-3114-2018;
   Migliaccio, Antimo/AAB-3376-2019; Giovannelli, Pia/J-7931-2019
OI Di Donato, Marzia/0000-0001-7207-826X; Migliaccio,
   Antimo/0000-0002-4197-2055; Castoria, Gabriella/0000-0002-0576-4494;
   Giovannelli, Pia/0000-0002-2488-917X
FU Associazione Italiana per la Ricerca sul Cancro; AIRC
FX This work was supported by grants from Associazione Italiana per la
   Ricerca sul Cancro.M. Di Donato is an AIRC fellowship recipient.
CR Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0
   Acconcia F, 2005, MOL BIOL CELL, V16, P231, DOI 10.1091/mbc.e04-07-0547
   Ballaré C, 2003, MOL CELL BIOL, V23, P1994, DOI 10.1128/MCB.23.6.1994-2008.2003
   Bedolla RG, 2009, CLIN CANCER RES, V15, P788, DOI 10.1158/1078-0432.CCR-08-1402
   Black BE, 2001, CURR BIOL, V11, P1749, DOI 10.1016/S0960-9822(01)00537-1
   Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5
   Boonyaratanakornkit V, 2007, MOL ENDOCRINOL, V21, P359, DOI 10.1210/me.2006-0337
   Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050
   Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500
   Castoria G, 2003, J CELL BIOL, V161, P547, DOI 10.1083/jcb.200211099
   Castoria G, 2010, PLOSONE IN PRESS
   Castoria G, 2008, FRONT BIOSCI-LANDMRK, V13, P1318, DOI 10.2741/2764
   Chambliss KL, 2002, ENDOCR REV, V23, P665, DOI 10.1210/er.2001-0045
   Cinar B, 2007, J BIOL CHEM, V282, P29584, DOI 10.1074/jbc.M703310200
   Damdimopoulos AE, 2008, ENDOCRINOLOGY, V149, P339, DOI 10.1210/en.2007-0198
   DAUVOIS S, 1993, J CELL SCI, V106, P1377
   Faivre EJ, 2007, MOL CELL BIOL, V27, P466, DOI 10.1128/MCB.01539-06
   Fizazi K, 2010, BJU INT, V105, P748, DOI 10.1111/j.1464-410X.2010.09236.x
   Fu XD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002790
   Galluzzo P, 2007, ENDOCR-RELAT CANCER, V14, P153, DOI 10.1677/ERC-06-0020
   Gioeli D, 2006, MOL ENDOCRINOL, V20, P503, DOI 10.1210/me.2005-0351
   Giretti MS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002238
   GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4
   Hammes SR, 2007, ENDOCR REV, V28, P726, DOI 10.1210/er.2007-0022
   Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825
   Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189
   Karteris E, 2006, MOL ENDOCRINOL, V20, P1519, DOI 10.1210/me.2005-0243
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9
   Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889
   Le Romancer M, 2008, MOL CELL, V31, P212, DOI 10.1016/j.molcel.2008.05.025
   Liu JM, 2000, MOL ENDOCRINOL, V14, P40, DOI 10.1210/me.14.1.40
   Lombardi M, 2008, J CELL BIOL, V182, P327, DOI 10.1083/jcb.200712125
   Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200
   Marcelli M, 2006, J CELL BIOCHEM, V98, P770, DOI 10.1002/jcb.20593
   Maruvada P, 2003, J BIOL CHEM, V278, P12425, DOI 10.1074/jbc.M202752200
   McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4
   Migliaccio A, 2007, ONCOGENE, V26, P6619, DOI 10.1038/sj.onc.1210487
   Migliaccio A, 2005, CANCER RES, V65, P10585, DOI 10.1158/0008-5472.CAN-05-0912
   Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406
   Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008
   Migliaccio A, 2010, PROTEINS CELL REGUL, V8, P365, DOI 10.1007/978-90-481-3303-1_15
   Morelli C, 2010, MOL CELL BIOL, V30, P857, DOI 10.1128/MCB.00824-09
   Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000
   Ozanne DM, 2000, MOL ENDOCRINOL, V14, P1618, DOI 10.1210/me.14.10.1618
   Papakonstanti EA, 2003, MOL ENDOCRINOL, V17, P870, DOI 10.1210/me.2002-0253
   Pedram A, 2007, J BIOL CHEM, V282, P22278, DOI 10.1074/jbc.M611877200
   Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x
   Peterziel H, 1999, ONCOGENE, V18, P6322, DOI 10.1038/sj.onc.1203032
   Picard N, 2008, MOL ENDOCRINOL, V22, P317, DOI 10.1210/me.2007-0281
   Prescott J, 2006, CANCER LETT, V231, P12, DOI 10.1016/j.canlet.2004.12.037
   Price D, 2006, J UROLOGY, V176, P965, DOI 10.1016/j.juro.2006.04.011
   Qiu M, 2003, MOL ENDOCRINOL, V17, P628, DOI 10.1210/me.2002-0378
   Razandi M, 2010, MOL CELL BIOL, V30, P3249, DOI 10.1128/MCB.01354-09
   Risbridger GP, 2010, NAT REV CANCER, V10, P205, DOI 10.1038/nrc2795
   Saitoh M, 2005, ENDOCRINOLOGY, V146, P4917, DOI 10.1210/en.2004-1535
   Saporita AJ, 2003, J BIOL CHEM, V278, P41998, DOI 10.1074/jbc.M302460200
   Savory JGA, 1999, MOL CELL BIOL, V19, P1025
   Schuur ER, 2001, J BIOL CHEM, V276, P33554, DOI 10.1074/jbc.M105555200
   Shank LC, 2008, J BIOL CHEM, V283, P10568, DOI 10.1074/jbc.M800810200
   Simoncini T, 2006, MOL ENDOCRINOL, V20, P1756, DOI 10.1210/me.2005-0259
   Song RX, 2004, P NATL ACAD SCI USA, V101, P2076, DOI 10.1073/pnas.0308334100
   Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116
   Stenoien DL, 2001, MOL CELL BIOL, V21, P4404, DOI 10.1128/MCB.21.13.4404-4412.2001
   Tyagi RK, 1998, MOL ENDOCRINOL, V12, P1684, DOI 10.1210/me.12.11.1684
   Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162
   Vallejo G, 2005, MOL ENDOCRINOL, V19, P3023, DOI 10.1210/me.2005-0016
   van der Heide LP, 2004, BIOCHEM J, V380, P297, DOI 10.1042/BJ20040167
   Vicent GP, 2006, MOL CELL, V24, P367, DOI 10.1016/j.molcel.2006.10.011
   Vicent GP, 2010, MOL ENDOCRINOL, V24, P2088, DOI 10.1210/me.2010-0027
   Zhang LQ, 2003, CANCER RES, V63, P4552
   Zhao HH, 2001, J BIOL CHEM, V276, P27907, DOI 10.1074/jbc.M104278200
   Zheng FHF, 2005, MOL CELL BIOL, V25, P8273, DOI 10.1128/MCB.25.18.8273-8284.2005
   Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2231, DOI 10.1073/pnas.0336132100
   Zou YY, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1872
NR 74
TC 18
Z9 21
U1 1
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1873-9601
EI 1873-961X
J9 J CELL COMMUN SIGNAL
JI J. Cell Commun. Signal
PD DEC
PY 2010
VL 4
IS 4
BP 161
EP 172
DI 10.1007/s12079-010-0103-1
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA V39OG
UT WOS:000209419700002
PM 21234121
OA Green Published
DA 2025-01-12
ER

PT J
AU Reins, J
   Mossner, M
   Neumann, M
   Platzbecker, U
   Schumann, C
   Thiel, E
   Hofmann, WK
AF Reins, Jana
   Mossner, Maximilian
   Neumann, Martin
   Platzbecker, Uwe
   Schumann, Christiane
   Thiel, Eckhard
   Hofmann, Wolf-Karsten
TI Transcriptional down-regulation of the Wnt antagonist <i>SFRP1</i> in
   haematopoietic cells of patients with different risk types of MDS
SO LEUKEMIA RESEARCH
LA English
DT Article
DE MDS; Acute leukaemia; SFRP; Wnt signalling; Promoter methylation;
   Pyrosequencing
ID ACUTE MYELOID-LEUKEMIA; CHRONIC LYMPHOCYTIC-LEUKEMIA; FRIZZLED-RELATED
   PROTEIN-1; SIGNALING PATHWAY; MYELODYSPLASTIC SYNDROMES; EPIGENETIC
   INACTIVATION; PROMOTER METHYLATION; ABERRANT EXPRESSION;
   GENE-EXPRESSION; BREAST-CANCER
AB Secreted frizzled related protein 1 (SFRP1) is an extracellular antagonist of the Wnt signalling pathway that plays an important role in the pathogenesis of solid tumours and haematopoietic malignancies. SFRP1 has been observed to be transcriptionally down-regulated due to hypermethylation in acute and chronic leukaemia, but so far not in myelodysplastic syndrome (MDS). Moreover, it has been shown that the epigenetic inactivation of SFRP1 correlates with an overexpression of the Wnt receptor Frizzled 3 (Fzd3) in acute leukaemia. Using real-time quantitative reverse transcription polymerase chain reaction (RT-PCR) we examined mRNA expression of SFRP1 and Fzd3 in bone marrow cells derived from 121 patients with different risk types of MDS, acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL). We employed pyrosequencing to quantify promoter DNA methylation in MDS and acute leukaemia. We detected significant lower mRNA transcription of SFRP1 in MDS compared to healthy individuals. However, DNA sequence mutations or frequent elevated DNA methylation levels of the SFRP1 promoter could not be observed in MDS but in AML and ALL as previously reported. The expression levels of Fzd3 were up-regulated in both acute leukaemia and MDS. Our data show a significant transcriptional down-regulation of SFRP1 as a common event in AML, ALL and - as demonstrated for the first time - in MDS. An inactivation of SFRP1 and the transcriptional up-regulation of Fzd3 seem to be associated with an activation of the Wnt signalling pathway in these haematopoietic diseases. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Reins, Jana] Charite Campus Benjamin Franklin, Dept Hematol & Oncol, Med Clin 3, D-12203 Berlin, Germany.
   [Platzbecker, Uwe] Univ Hosp Dresden, Dept Hematol & Oncol, Dresden, Germany.
   [Schumann, Christiane; Hofmann, Wolf-Karsten] Univ Hosp Mannheim, Dept Hematol & Oncol, Mannheim, Germany.
C3 Berlin Institute of Health; Free University of Berlin; Humboldt
   University of Berlin; Charite Universitatsmedizin Berlin; Technische
   Universitat Dresden; Carl Gustav Carus University Hospital; Ruprecht
   Karls University Heidelberg
RP Reins, J (通讯作者)，Charite Campus Benjamin Franklin, Dept Hematol & Oncol, Med Clin 3, Hindenburgdamm 30, D-12203 Berlin, Germany.
EM jana.reins@charite.de
RI Platzbecker, Uwe/AEH-0224-2022; Mossner, Maximilian/D-2292-2018
OI Mossner, Maximilian/0000-0001-9751-3803
FU Gutermuth- and the Jose Carreras Leukaemia Foundation
FX We thank Ouidad Benlasfer and Anke Kmetsch for their technical support.
   Furthermore, we thank Dr. Martin Meixner for his assistance with the
   primer design for the pyrosequencing analysis. Research in our
   laboratory was funded by the Gutermuth- and the Jose Carreras Leukaemia
   Foundation.
CR Armes JE, 2004, ONCOGENE, V23, P5697, DOI 10.1038/sj.onc.1207740
   Austin TW, 1997, BLOOD, V89, P3624, DOI 10.1182/blood.V89.10.3624.3624_3624_3635
   Awakura Y, 2008, ONCOL REP, V20, P1257, DOI 10.3892/or_00000138
   Brandon C, 2000, BLOOD, V96, P4132, DOI 10.1182/blood.V96.13.4132.h8004132_4132_4141
   Bu XM, 2008, WORLD J GASTROENTERO, V14, P3421, DOI 10.3748/wjg.14.3421
   Dahl E, 2007, ONCOGENE, V26, P5680, DOI 10.1038/sj.onc.1210345
   Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079
   He J, 2006, J BIOL CHEM, V281, P35598, DOI 10.1074/jbc.C600200200
   Hofmann WK, 2002, BLOOD, V100, P3553, DOI 10.1182/blood.V100.10.3553
   Huang J, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-126
   Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258
   Janssens N, 2006, INVEST NEW DRUG, V24, P263, DOI 10.1007/s10637-005-5199-4
   Jost E, 2008, BRIT J HAEMATOL, V142, P745, DOI 10.1111/j.1365-2141.2008.07242.x
   Katoh Y, 2006, INT J MOL MED, V17, P171
   Katoh Y, 2006, INT J MOL MED, V18, P1019
   Khan NI, 2006, HISTOL HISTOPATHOL, V21, P761, DOI 10.14670/HH-21.761
   Kirikoshi H, 2001, INT J MOL MED, V8, P651
   Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784
   Liu TH, 2006, CANCER RES, V66, P653, DOI 10.1158/0008-5472.CAN-05-3712
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lo PK, 2006, CANCER BIOL THER, V5, P281, DOI 10.4161/cbt.5.3.2384
   Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100
   Mikesch JH, 2007, LEUKEMIA, V21, P1638, DOI 10.1038/sj.leu.2404732
   Mills KI, 2009, BLOOD, V114, P1063, DOI 10.1182/blood-2008-10-187203
   Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787
   Pehlivan M, 2009, LEUKEMIA RES, V33, P1062, DOI 10.1016/j.leukres.2008.11.013
   Polakis P, 2000, GENE DEV, V14, P1837
   Reya T, 2003, RECENT PROG HORM RES, V58, P283, DOI 10.1210/rp.58.1.283
   Román-Gómez J, 2007, BLOOD, V109, P3462, DOI 10.1182/blood-2006-09-047043
   Shi Y, 2007, ACTA PHARMACOL SIN, V28, P1499, DOI 10.1111/j.1745-7254.2007.00692.x
   Simon M, 2005, ONCOGENE, V24, P2410, DOI 10.1038/sj.onc.1208431
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Suzuki Hiromu, 2005, Nihon Rinsho, V63, P707
   TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6
   Uchida T, 1997, BLOOD, V90, P1403, DOI 10.1182/blood.V90.4.1403.1403_1403_1409
   Zhao CH, 2007, WORLD J GASTROENTERO, V13, P2214, DOI 10.3748/wjg.v13.i15.2214
NR 36
TC 31
Z9 35
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0145-2126
EI 1873-5835
J9 LEUKEMIA RES
JI Leuk. Res.
PD DEC
PY 2010
VL 34
IS 12
BP 1610
EP 1616
DI 10.1016/j.leukres.2010.04.013
PG 7
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Hematology
GA 675QQ
UT WOS:000283845900025
PM 20471677
DA 2025-01-12
ER

PT J
AU Joseph, R
   Orlov, YL
   Huss, M
   Sun, WJ
   Kong, SL
   Ukil, L
   Pan, YF
   Li, GL
   Lim, M
   Thomsen, JS
   Ruan, YJ
   Clarke, ND
   Prabhakar, S
   Cheung, E
   Liu, ET
AF Joseph, Roy
   Orlov, Yuriy L.
   Huss, Mikael
   Sun, Wenjie
   Kong, Say Li
   Ukil, Leena
   Pan, You Fu
   Li, Guoliang
   Lim, Michael
   Thomsen, Jane S.
   Ruan, Yijun
   Clarke, Neil D.
   Prabhakar, Shyam
   Cheung, Edwin
   Liu, Edison T.
TI Integrative model of genomic factors for determining binding site
   selection by estrogen receptor-α
SO MOLECULAR SYSTEMS BIOLOGY
LA English
DT Article
DE chromatin; DNA binding; modeling; recognition motifs; transcription
   factor
ID TRANSCRIPTION FACTOR-BINDING; EMBRYONIC STEM-CELLS; HUMAN BREAST-CANCER;
   GENE-EXPRESSION; HISTONE MODIFICATIONS; NUCLEOSOME OCCUPANCY; SIGNALING
   PATHWAYS; HUMAN CHROMATIN; PROTEIN; SIGNATURES
AB A major question in transcription factor (TF) biology is why a TF binds to only a small fraction of motif eligible binding sites in the genome. Using the estrogen receptor-alpha as a model system, we sought to explicitly define parameters that determine TF-binding site selection. By examining 12 genetic and epigenetic parameters, we find that an energetically favorable estrogen response element (ERE) motif sequence, co-occupancy by the TF FOXA1, the presence of the H3K4me1 mark and an open chromatin configuration in the pre-ligand state provide specificity for ER binding. These factors can model estrogen-induced ER binding with high accuracy (ROC-AUC=0.95 and 0.88 using different genomic backgrounds). Moreover, when assessed in another estrogen-responsive cell line, this model was highly predictive for ER alpha binding (ROC-AUC=0.86). Variance in binding site selection between MCF-7 and T47D resides in sites with suboptimal ERE motifs, but modulated by the chromatin configuration. These results suggest a definable interplay between sequence motifs and local chromatin in selecting TF binding. Molecular Systems Biology 6: 456; published online 21 December 2010; doi:10.1038/msb.2010.109
C1 [Joseph, Roy; Orlov, Yuriy L.; Huss, Mikael; Sun, Wenjie; Kong, Say Li; Ukil, Leena; Pan, You Fu; Li, Guoliang; Lim, Michael; Thomsen, Jane S.; Ruan, Yijun; Clarke, Neil D.; Prabhakar, Shyam; Cheung, Edwin; Liu, Edison T.] Agcy Sci Technol & Res, Genome Inst Singapore, Singapore 138672, Singapore.
C3 Agency for Science Technology & Research (A*STAR); A*STAR - Genome
   Institute of Singapore (GIS)
RP Liu, ET (通讯作者)，Agcy Sci Technol & Res, Genome Inst Singapore, 60 Biopolis, Singapore 138672, Singapore.
EM liue@gis.a-star.edu.sg
RI Li, Guoliang/D-8014-2012; Clarke, Neil/D-9613-2014; Joseph,
   Roy/AAS-8769-2020; Li, Guoliang/I-1494-2015; Orlov, Yuriy/F-1520-2013
OI Li, Guoliang/0000-0003-1601-6640; Pan, You-Fu/0000-0002-9996-8892;
   Orlov, Yuriy/0000-0003-0587-1609; Huss, Mikael/0000-0003-0839-2451
FU A*STAR of Singapore; European Community [FP6-018652]
FX We thank Kartiki V Desai, Vinsensius B Vega., Sebastian Pott, Vipin
   Narang, Haixia Li, Han Xu, Yew Kok Lee, Tze Howe Charn, and RKM Karuturi
   for technical assistance, advice and science discussion. This research
   was supported by A*STAR of Singapore funds and also in part by the 6th
   European Community Framework Program grant CRESCENDO (FP6-018652) to
   ETL.
CR Ali S, 2000, J MAMMARY GLAND BIOL, V5, P271, DOI 10.1023/A:1009594727358
   Bailey TL, 2009, NUCLEIC ACIDS RES, V37, pW202, DOI 10.1093/nar/gkp335
   Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138
   Bernstein BE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r62
   Cairns BR, 2007, NAT STRUCT MOL BIOL, V14, P989, DOI 10.1038/nsmb1333
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008
   Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043
   Cheng ASL, 2006, MOL CELL, V21, P393, DOI 10.1016/j.molcel.2005.12.016
   Cheng Y, 2009, GENOME RES, V19, P2172, DOI 10.1101/gr.098921.109
   De Santa F, 2009, EMBO J, V28, P3341, DOI 10.1038/emboj.2009.271
   Ernst J, 2010, GENOME RES, V20, P526, DOI 10.1101/gr.096305.109
   Farnham PJ, 2009, NAT REV GENET, V10, P605, DOI 10.1038/nrg2636
   Foat BC, 2006, BIOINFORMATICS, V22, pE141, DOI 10.1093/bioinformatics/btl223
   Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497
   Giresi PG, 2007, GENOME RES, V17, P877, DOI 10.1101/gr.5533506
   Gregory PD, 1998, EUR J BIOCHEM, V251, P9, DOI 10.1046/j.1432-1327.1998.2510009.x
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Hurtado A, 2008, NATURE, V456, P663, DOI 10.1038/nature07483
   KRISHNAN V, 1994, J BIOL CHEM, V269, P15912
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Lee W, 2007, NAT GENET, V39, P1235, DOI 10.1038/ng2117
   Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087
   Liu XS, 2002, NAT BIOTECHNOL, V20, P835, DOI 10.1038/nbt717
   Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018
   McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4
   Morse RH, 2003, BIOCHEM CELL BIOL, V81, P101, DOI 10.1139/o03-039
   Pan YF, 2008, J BIOL CHEM, V283, P32977, DOI 10.1074/jbc.M802024200
   Petesch SJ, 2008, CELL, V134, P74, DOI 10.1016/j.cell.2008.05.029
   Rando OJ, 2007, CURR OPIN CELL BIOL, V19, P250, DOI 10.1016/j.ceb.2007.04.006
   Robertson AG, 2008, GENOME RES, V18, P1906, DOI 10.1101/gr.078519.108
   Roh TY, 2006, P NATL ACAD SCI USA, V103, P15782, DOI 10.1073/pnas.0607617103
   Safe S, 2008, J MOL ENDOCRINOL, V41, P263, DOI 10.1677/JME-08-0103
   Schones DE, 2008, CELL, V132, P887, DOI 10.1016/j.cell.2008.02.022
   Shadeo A, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1370
   Sing T, 2005, BIOINFORMATICS, V21, P3940, DOI 10.1093/bioinformatics/bti623
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Vega VB, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-9-r82
   Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88
   Zhao Y, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000590
NR 40
TC 127
Z9 165
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1744-4292
J9 MOL SYST BIOL
JI Mol. Syst. Biol.
PD DEC
PY 2010
VL 6
AR 456
DI 10.1038/msb.2010.109
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 702XY
UT WOS:000285930400009
PM 21179027
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Yu, J
   Ma, X
   Cheung, KF
   Li, X
   Tian, L
   Wang, S
   Wu, CW
   Wu, WKK
   He, M
   Wang, M
   Ng, SSM
   Sung, JJY
AF Yu, J.
   Ma, X.
   Cheung, K. F.
   Li, X.
   Tian, L.
   Wang, S.
   Wu, C. W.
   Wu, W. K. K.
   He, M.
   Wang, M.
   Ng, S. S. M.
   Sung, J. J. Y.
TI Epigenetic inactivation of <i>T</i>-<i>box transcription factor 5</i>, a
   novel tumor suppressor gene, is associated with colon cancer
SO ONCOGENE
LA English
DT Article
DE T-box transcription factor 5; colon cancer; tumor suppressor gene;
   epigenetic alteration; prognosis
ID SYNUCLEIN-GAMMA-GENE; COLORECTAL-CANCER; GASTRIC-CANCER; BREAST-CANCER;
   DNA METHYLATION; CPG ISLAND; APOPTOSIS; METASTASIS; EXPRESSION; SURVIVAL
AB T-box transcription factor 5 (TBX5) is a member of a phylogenetically conserved family of genes involved in the regulation of developmental processes. The function of TBX5 in cancer development is largely unclear. We identified that TBX5 was preferentially methylated in cancer using methylation-sensitive arbitrarily primed PCR. We aim to clarify the epigenetic inactivation, biological function and clinical significance of TBX5 in colon cancer. Promoter methylation was evaluated by combined bisulfite restriction analysis and bisulfite genomic sequencing. Cell proliferation was examined by cell viability assay and colony formation assay, apoptosis by flow cytometry and cell migration by wound-healing assay. TBX5 target genes were identified by cDNA microarray analysis. Cox regression model and log-rank test were used to identify independent predictors of prognosis. TBX5 was silenced or downregulated in 88% (7/8) colon cancer cell lines, but was expressed in normal colon tissues. Loss of gene expression was associated with promoter methylation. The biological function of TBX5 in human colon cancer cells was examined. Re-expression of TBX5 in silenced colon cancer cell lines suppressed colony formation (P<0.001), proliferation (P<0.001), migration and induced apoptosis (P<0.01). Induction of apoptosis was mediated through cross-talk of extrinsic apoptosis pathway, apoptotic BCL2-associated X protein and Granzyme A signaling cascades. TBX5 suppressed tumor cell proliferation and metastasis through the upregulation of cyclin-dependent kinase inhibitor 2A, metastasis suppressor 1 and downregulation of synuclein gamma and metastasis-associated protein 1 family member 2. TBX5 methylation was detected in 68% (71/105) of primary colon tumors. Multivariate analysis showed that patients with TBX5 methylation had a significantly poor overall survival (P=0.0007). In conclusion, we identified a novel functional tumor suppressor gene TBX5 inactivated by promoter methylation in colon cancer. Detection of methylated TBX5 may serve as a potential biomarker for the prognosis of this malignancy. Oncogene (2010) 29, 6464-6474; doi:10.1038/onc.2010.370; published online 30 August 2010
C1 [Yu, J.; Ma, X.; Cheung, K. F.; Li, X.; Wang, S.; Wu, C. W.; Wu, W. K. K.; Sung, J. J. Y.] Chinese Univ Hong Kong, Dept Med & Therapeut, Inst Digest Dis, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China.
   [Yu, J.; Ma, X.; Cheung, K. F.; Li, X.; Wang, S.; Wu, C. W.; Wu, W. K. K.; Sung, J. J. Y.] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China.
   [Ma, X.; Wang, M.] Hebei Med Univ, Dept Neurol, Hosp 1, Shijiazhuang, Peoples R China.
   [He, M.] Chinese Univ Hong Kong, Sch Publ Hlth & Primary Care, Stanley Ho Ctr Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China.
   [Ng, S. S. M.] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Prince of Wales Hospital; Chinese
   University of Hong Kong; Hebei Medical University; Chinese University of
   Hong Kong; Chinese University of Hong Kong
RP Yu, J (通讯作者)，Chinese Univ Hong Kong, Dept Med & Therapeut, Inst Digest Dis, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.
EM junyu@cuhk.edu.hk
RI HE, Ming-Liang/AFK-4738-2022; Ng, Simon/M-1219-2018; SUNG, Joseph J
   Y/R-3203-2018; Li, Xiaoxing/B-9114-2008; Jun, Yu/D-8569-2015; Wu,
   William K.K./A-3277-2009; Tian, Linwei/A-9736-2009
OI Tian, Linwei/0000-0003-2240-8886; SUNG, Joseph J Y/0000-0003-3125-5199;
   He, Ming-Liang/0000-0002-4317-2836; Li, Xiaoxing/0000-0001-8791-7505;
   Jun, Yu/0000-0001-5008-2153; HE, Mingliang/0000-0002-9942-9151; Wu,
   William K.K./0000-0002-5662-5240; Tian, Linwei/0000-0002-4739-1534
FU Council Competitive Earmarked Research Grant CUHK [473008]
FX This work was supported by research grant of Council Competitive
   Earmarked Research Grant CUHK (473008).
CR Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628
   Barton CA, 2008, GYNECOL ONCOL, V109, P129, DOI 10.1016/j.ygyno.2007.12.017
   Cai CL, 2005, DEVELOPMENT, V132, P2475, DOI 10.1242/dev.01832
   Chowdhury D, 2008, ANNU REV IMMUNOL, V26, P389, DOI 10.1146/annurev.immunol.26.021607.090404
   Cullen SP, 2010, CELL DEATH DIFFER, V17, P616, DOI 10.1038/cdd.2009.206
   Finotto Susetta, 2008, V94, P83, DOI 10.1159/000154869
   Grady WM, 2008, GASTROENTEROLOGY, V135, P1079, DOI 10.1053/j.gastro.2008.07.076
   Greene FL., 2002, TNM classification of malignant tumors, V6th
   Gupta A, 2003, ONCOGENE, V22, P7593, DOI 10.1038/sj.onc.1206880
   Gupta A, 2003, CANCER RES, V63, P664
   He ML, 2002, BIOCHEM BIOPH RES CO, V297, P185, DOI 10.1016/S0006-291X(02)02142-3
   Hicks DG, 2006, CLIN CANCER RES, V12, P6702, DOI 10.1158/1078-0432.CCR-06-0635
   Holoch PA, 2009, EUR J PHARMACOL, V625, P63, DOI 10.1016/j.ejphar.2009.06.066
   Hu H, 2009, CLIN CANCER RES, V15, P5485, DOI 10.1158/1078-0432.CCR-08-2491
   Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465
   Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003
   Liu HY, 2005, CANCER RES, V65, P7635, DOI 10.1158/0008-5472.CAN-05-1089
   Liu YE, 2007, ONCOGENE, V26, P2115, DOI 10.1038/sj.onc.1210000
   Maitra M, 2009, DEV BIOL, V326, P368, DOI 10.1016/j.ydbio.2008.11.004
   Mori AD, 2006, DEV BIOL, V297, P566, DOI 10.1016/j.ydbio.2006.05.023
   Nemer M, 2008, CARDIOVASC PATHOL, V17, P48, DOI 10.1016/j.carpath.2007.06.005
   NewburyEcob RA, 1996, J MED GENET, V33, P300, DOI 10.1136/jmg.33.4.300
   Pan ZZ, 2002, J BIOL CHEM, V277, P35050, DOI 10.1074/jbc.M201650200
   Papaioannou VE, 1998, BIOESSAYS, V20, P9, DOI 10.1002/(SICI)1521-1878(199801)20:1<9::AID-BIES4>3.0.CO;2-Q
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Parr C, 2009, EUR J CANCER, V45, P1673, DOI 10.1016/j.ejca.2009.02.019
   Plageman TF, 2006, DEV DYNAM, V235, P2868, DOI 10.1002/dvdy.20923
   Schütze S, 2008, NAT REV MOL CELL BIO, V9, P655, DOI 10.1038/nrm2430
   Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312
   Toh Y, 2009, CLIN EXP METASTAS, V26, P215, DOI 10.1007/s10585-008-9233-8
   Yanagawa N, 2004, CLIN CANCER RES, V10, P2447, DOI 10.1158/1078-0432.CCR-03-0107
   Yu J, 2009, CANCER-AM CANCER SOC, V115, P49, DOI 10.1002/cncr.23989
   Yu J, 2009, GASTROENTEROLOGY, V136, P640, DOI 10.1053/j.gastro.2008.10.050
   Zitt M, 2007, DIS MARKERS, V23, P51, DOI 10.1155/2007/891967
NR 34
TC 74
Z9 82
U1 0
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD DEC
PY 2010
VL 29
IS 49
BP 6464
EP 6474
DI 10.1038/onc.2010.370
PG 11
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 692FP
UT WOS:000285138900006
PM 20802524
DA 2025-01-12
ER

PT J
AU Reed, K
   Hembruff, SL
   Sprowl, JA
   Parissenti, AM
AF Reed, K.
   Hembruff, S. L.
   Sprowl, J. A.
   Parissenti, A. M.
TI The temporal relationship between <i>ABCB1</i> promoter hypomethylation,
   <i>ABCB1</i> expression and acquisition of drug resistance
SO PHARMACOGENOMICS JOURNAL
LA English
DT Article
DE ABCB1; promoter hypomethylation; drug resistance; breast cancer;
   epirubicin; paclitaxel
ID HUMAN MDR1 GENE; P-GLYCOPROTEIN EXPRESSION; CANCER-CELL-LINES;
   MULTIDRUG-RESISTANCE; TRANSCRIPTIONAL ACTIVATION; CHROMATIN-STRUCTURE;
   DNA METHYLATION; HEAT-SHOCK; AMPLIFICATION; REGION
AB Induced expression of the Abcb1 drug transporter often occurs in tumors in response to chemotherapy. The role that epigenetic modifications within the ABCB1 promoter play in Abcb1 expression remains unclear. We selected MCF-7 cells for survival in increasing doses of chemotherapy drugs, and assessed the methylation status of 66 CpG sites within the ABCB1 promoter preceding, accompanying and following the onset of drug resistance. Increased ABCB1 transcript expression coincident with acquisition of resistance to epirubicin or paclitaxel was temporally associated with hypomethylation of the ABCB1 downstream promoter in the absence of gene amplifications or changes in mRNA stability. Treatment of control MCF-7 cells with demethylating and/or acetylating agents increased ABCB1 transcript expression. In addition to broad promoter hypomethylation, dramatic reductions in the methylation of specific CpG sites within the promoter were observed, suggesting that these sites may play a predominant role in transcriptional activation through promoter hypomethylation. Furthermore, our data suggest that allele-specific reductions in ABCB1 promoter methylation regulate promoter usage within paclitaxel-resistant cells. This study provides strong evidence that changes in ABCB1 promoter methylation, ABCB1 promoter usage and ABCB1 transcript expression can be temporally and causally correlated with the acquisition of drug resistance in breast tumor cells. The Pharmacogenomics Journal (2010) 10, 489-504; doi:10.1038/tpj.2010.1; published online 2 February 2010
C1 [Reed, K.; Sprowl, J. A.; Parissenti, A. M.] Laurentian Univ, Program Biomol Sci, Sudbury, ON P3E 5J1, Canada.
   [Reed, K.; Hembruff, S. L.; Sprowl, J. A.; Parissenti, A. M.] Sudbury Reg Hosp, Tumour Biol Res Program, Sudbury, ON, Canada.
   [Parissenti, A. M.] No Ontario Sch Med, Div Med Sci, Sudbury, ON, Canada.
C3 Laurentian University; Health Sciences North; NOSM University
RP Parissenti, AM (通讯作者)，Laurentian Univ, Program Biomol Sci, Reg Canc Program, Sudbury Reg Hosp, 41 Ramsey Lake Rd, Sudbury, ON P3E 5J1, Canada.
EM aparissenti@hrsrh.on.ca
OI Sprowl, Jason/0000-0003-2573-2518
FU Canadian Breast Cancer Foundation-Ontario Region; Canadian Institutes of
   Health Research [MOP-89993]; Northern Cancer Research Foundation; Cancer
   Care Ontario
FX We thank Matthew L Poulin and Liying Yan of EpigenDx (Worchester, MA,
   USA) for primer design and performing pyrosequencing experiments
   assessing ABCB1 promoter methylation in clonal isolates of
   MCF-7<INF>CC</INF> and MCF-7<INF>TAX-2</INF> cells. We also thank Dr
   Gilbert Cote, Bernice Suitor and Anne McBain of the Sudbury Regional
   Hospital for providing technical support for the FISH experiments.
   Funding: This project was funded by the Canadian Breast Cancer
   Foundation-Ontario Region. This work was also supported, in part, by
   funds from the Canadian Institutes of Health Research (Grant MOP-89993),
   the Northern Cancer Research Foundation and core support funds from
   Cancer Care Ontario.
CR Baker EK, 2003, EXP CELL RES, V290, P177, DOI 10.1016/S0014-4827(03)00342-2
   Baker EK, 2005, ONCOGENE, V24, P8061, DOI 10.1038/sj.onc.1208955
   BORELLINI F, 1990, MOL CELL BIOL, V10, P5541, DOI 10.1128/MCB.10.10.5541
   Chekhun VF, 2006, CANCER LETT, V231, P87, DOI 10.1016/j.canlet.2005.01.038
   Chen GK, 2002, GENE CHROMOSOME CANC, V34, P372, DOI 10.1002/gcc.10067
   Chen KG, 2005, CANCER RES, V65, P9388, DOI 10.1158/0008-5472.CAN-04-4133
   CHIN KV, 1990, J BIOL CHEM, V265, P221
   COMBATES NJ, 1994, J BIOL CHEM, V269, P29715
   CORNWELL MM, 1993, J BIOL CHEM, V268, P19505
   David GL, 2004, CANCER BIOL THER, V3, P540, DOI 10.4161/cbt.3.6.845
   Desiderato L, 1997, SOMAT CELL MOLEC GEN, V23, P391, DOI 10.1007/BF02673749
   El-Osta A, 2002, MOL CELL BIOL, V22, P1844, DOI 10.1128/MCB.22.6.1844-1857.2002
   ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033
   Fujita T, 2005, CLIN CANCER RES, V11, P8837, DOI 10.1158/1078-0432.CCR-05-0945
   GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856
   Gómez-Martínez A, 2007, MOL CANCER RES, V5, P641, DOI 10.1158/1541-7786.MCR-06-0177
   Gottesman MM, 2001, J BIOENERG BIOMEMBR, V33, P453, DOI 10.1023/A:1012866803188
   Guo BQ, 2004, BREAST CANCER RES TR, V85, P31, DOI 10.1023/B:BREA.0000021046.29834.12
   Hembruff SL, 2005, ANAL BIOCHEM, V345, P237, DOI 10.1016/j.ab.2005.07.014
   Hembruff SL, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-318
   Hu Z, 2000, J BIOL CHEM, V275, P2979, DOI 10.1074/jbc.275.4.2979
   Ince TA, 1996, CANCER RES, V56, P2021
   Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200
   Kantharidis P, 1997, CLIN CANCER RES, V3, P2025
   Kitada K, 2007, CANCER GENET CYTOGEN, V178, P120, DOI 10.1016/j.cancergencyto.2007.06.014
   Kusaba H, 1999, EUR J BIOCHEM, V262, P924, DOI 10.1046/j.1432-1327.1999.00469.x
   Lehnert M, 1996, EUR J CANCER, V32A, P912, DOI 10.1016/0959-8049(96)00069-X
   Liscovitch M, 2007, CANCER LETT, V245, P350, DOI 10.1016/j.canlet.2006.01.013
   MADDEN MJ, 1993, J BIOL CHEM, V268, P8290
   Mickley LA, 1998, BLOOD, V91, P1749, DOI 10.1182/blood.V91.5.1749.1749_1749_1756
   Milani L, 2009, GENOME RES, V19, P1, DOI 10.1101/gr.083931.108
   MIYAZAKI M, 1992, BIOCHEM BIOPH RES CO, V187, P677, DOI 10.1016/0006-291X(92)91248-O
   Ogretmen B, 2000, BIOCHEMISTRY-US, V39, P194, DOI 10.1021/bi991943f
   Ogretmen B, 1999, BIOCHEMISTRY-US, V38, P2189, DOI 10.1021/bi982236+
   OGURA M, 1991, JPN J CANCER RES, V82, P1151, DOI 10.1111/j.1349-7006.1991.tb01770.x
   Palii SS, 2008, MOL CELL BIOL, V28, P752, DOI 10.1128/MCB.01799-07
   Plass C, 2002, HUM MOL GENET, V11, P2479, DOI 10.1093/hmg/11.20.2479
   Reed K, 2008, EPIGENETICS-US, V3, P270, DOI 10.4161/epi.3.5.6868
   Reed K, 2010, ANAL BIOCHEM, V397, P96, DOI 10.1016/j.ab.2009.10.021
   Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200
   Scotto KW, 1998, CYTOTECHNOLOGY, V27, P257, DOI 10.1023/A:1008032716628
   Scotto KW, 2003, ONCOGENE, V22, P7496, DOI 10.1038/sj.onc.1206950
   Tada Y, 2000, CLIN CANCER RES, V6, P4618
   Takeda M, 2007, PROSTATE, V67, P955, DOI 10.1002/pros.20581
   UEDA K, 1987, J BIOL CHEM, V262, P17432
   Veitch ZW, 2009, PHARMACOGENET GENOM, V19, P477, DOI 10.1097/FPC.0b013e32832c484b
   Wang YC, 2006, GENE CHROMOSOME CANC, V45, P365, DOI 10.1002/gcc.20300
   Yabuki N, 2007, CANCER GENET CYTOGEN, V173, P1, DOI 10.1016/j.cancergencyto.2006.07.020
   Yagüe E, 2003, J BIOL CHEM, V278, P10344, DOI 10.1074/jbc.M211093200
NR 49
TC 41
Z9 50
U1 2
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1470-269X
EI 1473-1150
J9 PHARMACOGENOMICS J
JI Pharmacogenomics J.
PD DEC
PY 2010
VL 10
IS 6
BP 489
EP 504
DI 10.1038/tpj.2010.1
PG 16
WC Genetics & Heredity; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Pharmacology & Pharmacy
GA 688FQ
UT WOS:000284835600003
PM 20125118
DA 2025-01-12
ER

PT J
AU Jeong, J
   Li, L
   Liu, YL
   Nephew, KP
   Huang, THM
   Shen, CY
AF Jeong, Jaesik
   Li, Lang
   Liu, Yunlong
   Nephew, Kenneth P.
   Huang, Tim Hui-Ming
   Shen, Changyu
TI An empirical Bayes model for gene expression and methylation profiles in
   antiestrogen resistant breast cancer
SO BMC MEDICAL GENOMICS
LA English
DT Article
ID DNA METHYLATION; HISTONE H3; CHROMATIN; HYPERMETHYLATION; EPIGENETICS;
   CELLS; TUMORIGENESIS; TRANSCRIPTION; FULVESTRANT; PATTERNS
AB Background: The nuclear transcription factor estrogen receptor alpha (ER-alpha) is the target of several antiestrogen therapeutic agents for breast cancer. However, many ER-alpha positive patients do not respond to these treatments from the beginning, or stop responding after being treated for a period of time. Because of the association of gene transcription alteration and drug resistance and the emerging evidence on the role of DNA methylation on transcription regulation, understanding of these relationships can facilitate development of approaches to re-sensitize breast cancer cells to treatment by restoring DNA methylation patterns.
   Methods: We constructed a hierarchical empirical Bayes model to investigate the simultaneous change of gene expression and promoter DNA methylation profiles among wild type (WT) and OHT/ICI resistant MCF7 breast cancer cell lines.
   Results: We found that compared with the WT cell lines, almost all of the genes in OHT or ICI resistant cell lines either do not show methylation change or hypomethylated. Moreover, the correlations between gene expression and methylation are quite heterogeneous across genes, suggesting the involvement of other factors in regulating transcription. Analysis of our results in combination with H3K4me2 data on OHT resistant cell lines suggests a clear interplay between DNA methylation and H3K4me2 in the regulation of gene expression. For hypomethylated genes with alteration of gene expression, most (similar to 80%) are up-regulated, consistent with current view on the relationship between promoter methylation and gene expression.
   Conclusions: We developed an empirical Bayes model to study the association between DNA methylation in the promoter region and gene expression. Our approach generates both global (across all genes) and local (individual gene) views of the interplay. It provides important insight on future effort to develop therapeutic agent to re-sensitize breast cancer cells to treatment.
C1 [Jeong, Jaesik; Shen, Changyu] Indiana Univ, Dept Med, Div Biostat, Indianapolis, IN 46204 USA.
   [Li, Lang; Liu, Yunlong] Indiana Univ, Dept Med & Mol Genet, Indianapolis, IN 46204 USA.
   [Nephew, Kenneth P.] Indiana Univ, Dept Med Sci, Simon Canc Ctr, Bloomington, IN USA.
   [Huang, Tim Hui-Ming] Ohio State Univ, Dept Mol Virol Immunol & Med Genet Human Canc Gen, Columbus, OH 43210 USA.
C3 Indiana University System; Indiana University Indianapolis; Indiana
   University System; Indiana University Indianapolis; Indiana University
   System; Indiana University Bloomington; University System of Ohio; Ohio
   State University
RP Shen, CY (通讯作者)，Indiana Univ, Dept Med, Div Biostat, Indianapolis, IN 46204 USA.
EM chashen@iupui.edu
RI Shen, Changyu/E-7519-2016
FU National Institutes of Health [U54 CA113001-06]; Department of Defense
   [BC030400]
FX This study was supported by National Institutes of Health [U54
   CA113001-06] and Department of Defense [BC030400].
CR Anderson E, 2002, BREAST CANCER RES, V4, P197, DOI 10.1186/bcr452
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Clouaire T, 2008, CELL MOL LIFE SCI, V65, P1509, DOI 10.1007/s00018-008-7324-y
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x
   Dwivedi Rama S., 2003, Proceedings of the Indian National Science Academy Part B Biological Sciences, V69, P111
   Fan MY, 2006, CANCER RES, V66, P11954, DOI 10.1158/0008-5472.CAN-06-1666
   Feng W, 2008, BMC GENOMICS, V9, pS2
   Herman JG, 1999, SEMIN CANCER BIOL, V9, P359, DOI 10.1006/scbi.1999.0138
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hinshelwood RA, 2008, J MOL MED, V86, P1315, DOI 10.1007/s00109-008-0386-3
   Howell A, 2005, CANCER TREAT REV, V31, pS3, DOI 10.1016/j.ctrv.2005.08.010
   IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612
   Ji HK, 2010, NAT BIOTECHNOL, V28, P337, DOI 10.1038/nbt.1619
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Lee MG, 2007, SCIENCE, V318, P447, DOI 10.1126/science.1149042
   Lee TI, 2006, NAT PROTOC, V1, P729, DOI 10.1038/nprot.2006.98
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Li M, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-34
   McLachlan G.J., 2007, EM ALGORITHM EXTENSI
   MOLLOY PL, 1990, PHILOS T R SOC B, V326, P267, DOI 10.1098/rstb.1990.0010
   Newton MA, 2004, BIOSTATISTICS, V5, P155, DOI 10.1093/biostatistics/5.2.155
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506
   RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983
   SMITH AFM, 1973, J ROY STAT SOC B, V35, P67
   Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967
   WANG CS, 1994, GENET SEL EVOL, V26, P91, DOI 10.1051/gse:19940202
   Yuan GC, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-8-r70
   Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301
NR 34
TC 14
Z9 16
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1755-8794
J9 BMC MED GENOMICS
JI BMC Med. Genomics
PD NOV 25
PY 2010
VL 3
AR 55
DI 10.1186/1755-8794-3-55
PG 9
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 696FG
UT WOS:000285426700001
PM 21108837
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU D'Anello, L
   Sansone, P
   Storci, G
   Mitrugno, V
   D'Uva, G
   Chieco, P
   Bonafé, M
AF D'Anello, Laura
   Sansone, Pasquale
   Storci, Gianluca
   Mitrugno, Valentina
   D'Uva, Gabriele
   Chieco, Pasquale
   Bonafe, Massimiliano
TI Epigenetic control of the basal-like gene expression profile via
   Interleukin-6 in breast cancer cells
SO MOLECULAR CANCER
LA English
DT Article
ID ESTROGEN-RECEPTOR-ALPHA; DNA METHYLATION; PROMOTER; GROWTH; P53;
   CARCINOMA; CD133; IDENTIFICATION; INVOLVEMENT; PROTEINS
AB Background: Basal-like carcinoma are aggressive breast cancers that frequently carry p53 inactivating mutations, lack estrogen receptor-a (ER alpha) and express the cancer stem cell markers CD133 and CD44. These tumors also over-express Interleukin 6 (IL-6), a pro-inflammatory cytokine that stimulates the growth of breast cancer stem/progenitor cells.
   Results: Here we show that p53 deficiency in breast cancer cells induces a loss of methylation at IL-6 proximal promoter region, which is maintained by an IL-6 autocrine loop. IL-6 also elicits the loss of methylation at the CD133 promoter region 1 and of CD44 proximal promoter, enhancing CD133 and CD44 gene transcription. In parallel, IL-6 induces the methylation of estrogen receptor (ERa) promoter and the loss of ERa mRNA expression. Finally, IL-6 induces the methylation of IL-6 distal promoter and of CD133 promoter region 2, which harbour putative repressor regions.
   Conclusion: We conclude that IL-6, whose methylation-dependent autocrine loop is triggered by the inactivation of p53, induces an epigenetic reprogramming that drives breast carcinoma cells towards a basal-like/stem cell-like gene expression profile.
C1 [D'Anello, Laura; Sansone, Pasquale; Storci, Gianluca; Mitrugno, Valentina; D'Uva, Gabriele; Chieco, Pasquale; Bonafe, Massimiliano] St Orsola Malpighi Univ Hosp, Ctr Appl Biomed Res, I-40138 Bologna, Italy.
   [D'Anello, Laura; Storci, Gianluca; Bonafe, Massimiliano] Univ Bologna, Dept Expt Pathol, I-40126 Bologna, Italy.
   [Sansone, Pasquale; D'Uva, Gabriele] Univ Bologna, Dept Pharmacol & Toxicol, I-40126 Bologna, Italy.
C3 IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of
   Bologna; University of Bologna
RP Bonafé, M (通讯作者)，St Orsola Malpighi Univ Hosp, Ctr Appl Biomed Res, Via Massarenti 9, I-40138 Bologna, Italy.
EM massimiliano.bonafe@unibo.it
RI Bonafe, Massimiliano/K-5416-2016; D'Uva, Gabriele/A-6252-2015; STORCI,
   GIANLUCA/AED-6195-2022
OI D'Uva, Gabriele/0000-0001-9622-9288; STORCI,
   GIANLUCA/0000-0001-5145-3091; Chieco, Pasquale/0000-0002-8933-0684
FU Fondazione Banca del Monte di Bologna e Ravenna to P. Chieco; University
   of Bologna RFO funds-ex; Cornelia Pallotti and Roberto Pallotti
   Foundation; PRIN 2008 "Clinical, diagnostic and therapeutics
   implications of studies of breast cancer stem cell"; Fondazione Cassa di
   Risparmio in Bologna
FX This work has been supported by Fondazione Banca del Monte di Bologna e
   Ravenna to P. Chieco, and by University of Bologna RFO funds-ex 60%,
   Cornelia Pallotti and Roberto Pallotti Foundation and PRIN 2008
   "Clinical, diagnostic and therapeutics implications of studies of breast
   cancer stem cell" to M. Bonafe. We also thank Fondazione Cassa di
   Risparmio in Bologna for supporting the Center of Applied Biomedical
   Research. We thank W. L. Farrar (Cytokine Molecular Section, Laboratory
   of Molecular Immunoregulation, NCI-Frederick Cancer Research and
   Development Center) for IL-6 Promoter-Luc, T. Taniguchi (Department of
   Immunology, Graduate School of Medicine and Faculty of Medicine,
   University of Tokyo) for pCAG-IRF1 and pCAG-IRF2, K. Tabu (Department of
   Stem Cell Regulation, Medical Research Institute, Tokyo Medical and
   Dental University) for CD133promoters-Luc.
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Angelo LS, 2002, CANCER RES, V62, P932
   Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Bertheau P, 2007, PLOS MED, V4, P585, DOI 10.1371/journal.pmed.0040090
   Bertucci F, 2009, INT J CANCER, V124, P1338, DOI 10.1002/ijc.24055
   Cariati M, 2008, INT J CANCER, V122, P298, DOI 10.1002/ijc.23103
   Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254
   Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048
   Cleator S, 2007, LANCET ONCOL, V8, P235, DOI 10.1016/S1470-2045(07)70074-8
   Dandrea M, 2009, NUCLEIC ACIDS RES, V37, P6681, DOI 10.1093/nar/gkp723
   Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105
   Estève PO, 2005, P NATL ACAD SCI USA, V102, P1000, DOI 10.1073/pnas.0407729102
   Foran E, 2010, MOL CANCER RES, V8, P471, DOI 10.1158/1541-7786.MCR-09-0496
   Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006
   Gonzalgo ML, 1997, MUTAT RES-REV MUTAT, V386, P107, DOI 10.1016/S1383-5742(96)00047-6
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108
   Horwitzt KB, 2008, P NATL ACAD SCI USA, V105, P5774, DOI 10.1073/pnas.0706216105
   Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014
   Kemper K, 2010, CANCER RES, V70, P719, DOI 10.1158/0008-5472.CAN-09-1820
   Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123
   Liu G, 2009, ONCOGENE, V28, P4491, DOI 10.1038/onc.2009.297
   Macaluso M, 2007, CANCER RES, V67, P7731, DOI 10.1158/0008-5472.CAN-07-1476
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Müller I, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-297
   Ndlovu MN, 2009, MOL CELL BIOL, V29, P5488, DOI 10.1128/MCB.01657-08
   Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007
   Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495
   Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15
   Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533
   Schmutte C, 1998, BIOL CHEM, V379, P377
   SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581
   Storci G, 2008, J PATHOL, V214, P25, DOI 10.1002/path.2254
   Storci G, 2010, J CELL PHYSIOL, V225, P682, DOI 10.1002/jcp.22264
   Stuelten CH, 2010, STEM CELLS, V28, P649, DOI 10.1002/stem.324
   Tabu K, 2008, CELL RES, V18, P1037, DOI 10.1038/cr.2008.270
   Tanaka N, 2000, SEMIN CANCER BIOL, V10, P73, DOI 10.1006/scbi.2000.0310
   Wehbe H, 2006, CANCER RES, V66, P10517, DOI 10.1158/0008-5472.CAN-06-2130
   Woodfield GW, 2009, CLIN CANCER RES, V15, P3672, DOI 10.1158/1078-0432.CCR-08-2343
   Wright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855
   Xiao WH, 2004, PROSTATE, V61, P354, DOI 10.1002/pros.20113
   You HN, 2010, HEPATOLOGY, V51, P1635, DOI 10.1002/hep.23544
NR 43
TC 50
Z9 53
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD NOV 23
PY 2010
VL 9
AR 300
DI 10.1186/1476-4598-9-300
PG 13
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 695HT
UT WOS:000285361900001
PM 21092249
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Pal, R
   Srivastava, N
   Chopra, R
   Gochhait, S
   Gupta, P
   Prakash, N
   Agarwal, G
   Bamezai, RNK
AF Pal, Ranjana
   Srivastava, Niloo
   Chopra, Rupali
   Gochhait, Sailesh
   Gupta, Pawan
   Prakash, Neeraj
   Agarwal, Gaurav
   Bamezai, Rameshwar N. K.
TI Investigation of DNA damage response and apoptotic gene methylation
   pattern in sporadic breast tumors using high throughput quantitative DNA
   methylation analysis technology
SO MOLECULAR CANCER
LA English
DT Article
ID CANCER-CELLS; CPG METHYLATION; APO2 LIGAND/TRAIL; ESOPHAGEAL CANCER;
   BINDING-SITE; MASS ARRAY; P53; PROMOTER; DEATH; TRAIL
AB Background-: Sporadic breast cancer like many other cancers is proposed to be a manifestation of abnormal genetic and epigenetic changes. For the past decade our laboratory has identified genes involved in DNA damage response (DDR), apoptosis and immunesurvelliance pathways to influence sporadic breast cancer risk in north Indian population. Further to enhance our knowledge at the epigenetic level, we performed DNA methylation study involving 17 gene promoter regions belonging to DNA damage response (DDR) and death receptor apoptotic pathway in 162 paired normal and cancerous breast tissues from 81 sporadic breast cancer patients, using a high throughput quantitative DNA methylation analysis technology.
   Results-: The study identified five genes with statistically significant difference between normal and tumor tissues. Hypermethylation of DR5 (P = 0.001), DCR1 (P = 0.00001), DCR2 (P = 0.0000000005) and BRCA2 (P = 0.007) and hypomethylation of DR4 (P = 0.011) in sporadic breast tumor tissues suggested a weak/aberrant activation of the DDR/apoptotic pathway in breast tumorigenesis. Negative correlation was observed between methylation status and transcript expression levels for TRAIL, DR4, CASP8, ATM, CHEK2, BRCA1 and BRCA2 CpG sites. Categorization of the gene methylation with respect to the clinicopathological parameters showed an increase in aberrant methylation pattern in advanced tumors. These uncharacteristic methylation patterns corresponded with decreased death receptor apoptosis (P = 0.047) and DNA damage repair potential (P = 0.004) in advanced tumors. The observation of BRCA2 -26 G/A 5 ' UTR polymorphism concomitant with the presence of methylation in the promoter region was novel and emerged as a strong candidate for susceptibility to sporadic breast tumors.
   Conclusion-: Our study indicates that methylation of DDR-apoptotic gene promoters in sporadic breast cancer is not a random phenomenon. Progressive epigenetic alterations in advancing tumors result in aberrant DDR-apoptotic pathway thereby promoting tumor development. We propose, since pathological epigenetic changes of the DDR-apoptotic genes are reversible modifications, these could further be targeted for therapeutic interventions.
C1 [Pal, Ranjana; Srivastava, Niloo; Chopra, Rupali; Gochhait, Sailesh; Bamezai, Rameshwar N. K.] Jawaharlal Nehru Univ, Sch Life Sci, Natl Ctr Appl Human Genet, New Delhi 110067, India.
   [Gupta, Pawan] Dharamshila Canc Hosp & Res Ctr, Delhi 96, India.
   [Prakash, Neeraj] Rajiv Gandhi Canc Inst & Res Ctr, Sector 5, New Delhi 110085, India.
   [Agarwal, Gaurav] Sanjay Gandhi Postgrad Inst Med Sci, Lucknow 226014, Uttar Pradesh, India.
C3 Jawaharlal Nehru University, New Delhi; Sanjay Gandhi Postgraduate
   Institute of Medical Sciences
RP Bamezai, RNK (通讯作者)，Jawaharlal Nehru Univ, Sch Life Sci, Natl Ctr Appl Human Genet, Aruna Asafali Rd, New Delhi 110067, India.
EM bamezai@hotmail.com
RI Agarwal, Gaurav/K-2998-2013
OI Agarwal, Gaurav/0000-0003-4194-2670; Pal, Ranjana/0000-0002-9824-6337
FU Council of Scientific and Industrial Research, New Delhi, India;
   University Grants Commission; Department of Biotechnology (DBT), New
   Delhi
FX The authors thank the patient and control subjects for their
   participation. Ranjana Pal is grateful to the Council of Scientific and
   Industrial Research, New Delhi, India, for the pre-doctoral fellowship.
   Rameshwar N. K. Bamezai was supported by a research grant from the
   University Grants Commission to the National Centre of Applied Human
   Genetics, the University with Potential of Excellence project and the
   High-Throughput project from Department of Biotechnology (DBT), New
   Delhi.
CR Ashkenazi A, 2008, NAT REV DRUG DISCOV, V7, P1001, DOI 10.1038/nrd2637
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Cotter TG, 2009, NAT REV CANCER, V9, P501, DOI 10.1038/nrc2663
   Cucer N, 2008, J GENET, V87, P155, DOI 10.1007/s12041-008-0023-5
   Darvishi K, 2007, CANCER LETT, V249, P249, DOI 10.1016/j.canlet.2006.09.005
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   Ehrich M, 2008, P NATL ACAD SCI USA, V105, P4844, DOI 10.1073/pnas.0712251105
   Ehrich M, 2006, CANCER RES, V66, P10911, DOI 10.1158/0008-5472.CAN-06-0400
   Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213
   Falschlehner C, 2007, INT J BIOCHEM CELL B, V39, P1462, DOI 10.1016/j.biocel.2007.02.007
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Fernández Y, 2002, INT J CANCER, V101, P317, DOI 10.1002/ijc.10628
   Flanagan JM, 2010, AM J HUM GENET, V86, P420, DOI 10.1016/j.ajhg.2010.02.008
   Fukazawa T, 2001, ONCOGENE, V20, P5225, DOI 10.1038/sj.onc.1204673
   Gochhait S, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1780
   Gochhait S, 2008, INT J CANCER, V123, P2580, DOI 10.1002/ijc.23817
   Gochhait S, 2009, CANCER LETT, V273, P305, DOI 10.1016/j.canlet.2008.08.009
   Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465
   Kalari S, 2010, ADV GENET, V70, P277, DOI [10.1016/B978-0-12-380866-0.60010-1, 10.1016/S0065-2660(10)70010-9]
   Kang JH, 2001, LAB INVEST, V81, P573, DOI 10.1038/labinvest.3780266
   Kelley RF, 2005, J BIOL CHEM, V280, P2205, DOI 10.1074/jbc.M410660200
   Kuribayashi K, 2008, CANCER BIOL THER, V7, P2034, DOI 10.4161/cbt.7.12.7460
   Laird PW, 2010, NAT REV GENET, V11, P191, DOI 10.1038/nrg2732
   Li D, 2008, NUCLEIC ACIDS RES, V36, P330, DOI 10.1093/nar/gkm1028
   Liu XG, 2004, CANCER RES, V64, P5078, DOI 10.1158/0008-5472.CAN-04-1195
   McShane LM, 2005, NAT CLIN PRACT ONCOL, V2, P416, DOI 10.1038/ncponc0252
   Meek DW, 2009, NAT REV CANCER, V9, P714, DOI 10.1038/nrc2716
   O'Driscoll M, 2006, NAT REV GENET, V7, P45, DOI 10.1038/nrg1746
   Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412
   Oldenburg RA, 2007, CRIT REV ONCOL HEMAT, V63, P125, DOI 10.1016/j.critrevonc.2006.12.004
   Ordway JM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001314
   PAL R, 2010, BREAST CANC RES TREA
   Radpour R, 2009, ONCOGENE, V28, P2969, DOI 10.1038/onc.2009.149
   Radpour R, 2008, MOL CANCER RES, V6, P1702, DOI 10.1158/1541-7786.MCR-08-0262
   Ramchandani S, 1999, P NATL ACAD SCI USA, V96, P6107, DOI 10.1073/pnas.96.11.6107
   Ravi R, 2002, CANCER RES, V62, P4180
   Ray S, 2007, MOL CANCER THER, V6, P1368, DOI 10.1158/1535-7163.MCT-05-0414
   RUSSO J, 1998, FRONT BIOSCI, V3, P944, DOI DOI 10.2741/A335
   Saha A, 2005, IMMUNOGENETICS, V57, P165, DOI 10.1007/s00251-005-0783-5
   Saha A, 2004, EUR J IMMUNOGENET, V31, P37, DOI 10.1111/j.1365-2370.2004.00442.x
   Saha A, 2003, EUR J IMMUNOGENET, V30, P397, DOI 10.1111/j.1365-2370.2003.00423.x
   Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723
   Shivapurkar N, 2004, INT J CANCER, V109, P786, DOI 10.1002/ijc.20041
   Solier S, 2009, CELL CYCLE, V8, P1853, DOI 10.4161/cc.8.12.8865
   Solier S, 2009, MOL CELL BIOL, V29, P68, DOI 10.1128/MCB.00581-08
   Srivastava N, 2008, CANCER GENET CYTOGEN, V180, P121, DOI 10.1016/j.cancergencyto.2007.09.024
   Stanssens P, 2004, GENOME RES, V14, P126
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026
   Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489
   Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312
   Ushijima T, 2005, CANCER RES, V65, P11
   van Noesel MM, 2002, CANCER RES, V62, P2157
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   Wu JX, 1996, ANTICANCER RES, V16, P2233
   Xu XR, 2009, BREAST CANCER RES TR, V115, P397, DOI 10.1007/s10549-008-0075-5
   Yang QW, 2007, CLIN CANCER RES, V13, P3191, DOI 10.1158/1078-0432.CCR-06-2846
   Zelko IN, 2010, FREE RADICAL BIO MED, V48, P895, DOI 10.1016/j.freeradbiomed.2010.01.007
   Zhivotovsky B, 2004, NAT REV MOL CELL BIO, V5, P752, DOI 10.1038/nrm1443
NR 62
TC 28
Z9 32
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD NOV 23
PY 2010
VL 9
AR 303
DI 10.1186/1476-4598-9-303
PG 16
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 696UW
UT WOS:000285467900001
PM 21092294
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Blish, KR
   Clausen, KA
   Hawkins, GA
   Garvin, AJ
   Willingham, MC
   Turner, JC
   Torti, FM
   Torti, SV
AF Blish, Kimberly R.
   Clausen, Kathryn A.
   Hawkins, Gregory A.
   Garvin, A. Julian
   Willingham, Mark C.
   Turner, Julie C.
   Torti, Frank M.
   Torti, Suzy V.
TI Loss of heterozygosity and <i>SOSTDC1</i> in adult and pediatric renal
   tumors
SO JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
LA English
DT Article
ID MORPHOGENETIC PROTEIN ANTAGONIST; CELL-CARCINOMA; WILMS-TUMOR;
   HOMOZYGOUS DELETION; GENE-EXPRESSION; GENOME BROWSER; BREAST-CANCER;
   BETA-CATENIN; KIDNEY; BMP
AB Background: Deletions within the short arm of chromosome 7 are observed in approximately 25% of adult and 10% of Wilms pediatric renal tumors. Within Wilms tumors, the region of interest has been delineated to a 2-Mb minimal region that includes ten known genes. Two of these ten candidate genes, SOSTDC1 and MEOX2, are particularly relevant to tumor development and maintenance. This finding, coupled with evidence that SOSTDC1 is frequently downregulated in adult renal cancer and regulates both Wingless-Int (Wnt)-and bone morphogenetic protein (BMP)-induced signaling, points to a role for SOSTDC1 as a potential tumor suppressor.
   Methods: To investigate this hypothesis, we interrogated the Oncomine database to examine the SOSTDC1 levels in adult renal clear cell tumors and pediatric Wilms tumors. We then performed single nucleotide polymorphism (SNP) and sequencing analyses of SOSTDC1 in 25 pediatric and 36 adult renal tumors. Immunohistochemical staining of patient samples was utilized to examine the impact of SOSTDC1 genetic aberrations on SOSTDC1 protein levels and signaling.
   Results: Within the Oncomine database, we found that SOSTDC1 levels were reduced in adult renal clear cell tumors and pediatric Wilms tumors. Through SNP and sequencing analyses of 25 Wilms tumors, we identified four with loss of heterozygosity (LOH) at 7p and three that affected SOSTDC1. Of 36 adult renal cancers, we found five with LOH at 7p, two of which affected SOSTDC1. Immunohistochemical analysis of SOSTDC1 protein levels within these tumors did not reveal a relationship between these instances of SOSTDC1 LOH and SOSTDC1 protein levels. Moreover, we could not discern any impact of these genetic alterations on Wnt signaling as measured by altered beta-catenin levels or localization.
   Conclusions: This study shows that genetic aberrations near SOSTDC1 are not uncommon in renal cancer, and occur in adult as well as pediatric renal tumors. These observations of SOSTDC1 LOH, however, did not correspond with changes in SOSTDC1 protein levels or signaling regulation. Although our conclusions are limited by sample size, we suggest that an alternative mechanism such as epigenetic silencing of SOSTDC1 may be a key contributor to the reduced SOSTDC1 mRNA and protein levels observed in renal cancer.
C1 [Clausen, Kathryn A.; Turner, Julie C.; Torti, Frank M.] Wake Forest Univ, Dept Canc Biol, Sch Med, Winston Salem, NC 27157 USA.
   [Blish, Kimberly R.] Wake Forest Univ, Dept Mol Med, Sch Med, Winston Salem, NC 27157 USA.
   [Hawkins, Gregory A.] Wake Forest Univ, Ctr Genom & Personalized Med Res, Sch Med, Winston Salem, NC 27157 USA.
   [Garvin, A. Julian; Willingham, Mark C.] Wake Forest Univ, Dept Pathol, Sch Med, Winston Salem, NC 27157 USA.
   [Garvin, A. Julian; Willingham, Mark C.; Torti, Frank M.; Torti, Suzy V.] Wake Forest Univ, Comprehens Canc Ctr, Sch Med, Winston Salem, NC 27157 USA.
   [Torti, Suzy V.] Wake Forest Univ, Dept Biochem, Sch Med, Winston Salem, NC 27157 USA.
C3 Wake Forest University; Wake Forest University; Wake Forest University;
   Wake Forest University; Wake Forest University; Wake Forest University
RP Clausen, KA (通讯作者)，Wake Forest Univ, Dept Canc Biol, Sch Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM kclausen@wfubmc.edu
FU NIH [R21CA119181]; National Cancer Institute [T32CA079448]
FX This project was supported in part by grant NIH R21CA119181 (ST). KC
   acknowledges support from the T32CA079448 training grant from the
   National Cancer Institute. The authors also acknowledge generous support
   for this work from the Ben Mynatt family. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Cancer Institute or the National
   Institutes of Health.
CR AUNE GJ, 2008, PEDIAT REV, V29, P143
   Aune Gregory J, 2008, Pediatr Rev, V29, P142, DOI 10.1542/pir.29-4-142
   Baudry D, 2000, CLIN CANCER RES, V6, P3957
   Beroukhim R, 2009, CANCER RES, V69, P4674, DOI 10.1158/0008-5472.CAN-09-0146
   Blish KR, 2008, MOL BIOL CELL, V19, P457, DOI 10.1091/mbc.E07-05-0433
   Cerrato F, 2008, HUM MOL GENET, V17, P1427, DOI 10.1093/hmg/ddn031
   Chen Y, 2007, J BIOL CHEM, V282, P507, DOI 10.1074/jbc.M606604200
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Cutcliffe C, 2005, CLIN CANCER RES, V11, P7986, DOI 10.1158/1078-0432.CCR-05-1354
   Dome JS, 2002, CURR OPIN PEDIATR, V14, P5, DOI 10.1097/00008480-200202000-00002
   GESSLER M, 1994, HUM MUTAT, V3, P212, DOI 10.1002/humu.1380030307
   Grundy RG, 1998, BRIT J CANCER, V78, P1181, DOI 10.1038/bjc.1998.651
   Guillén-Ahlers H, 2008, CURR DRUG TARGETS, V9, P591, DOI 10.2174/138945008784911813
   Gumz ML, 2007, CLIN CANCER RES, V13, P4740, DOI 10.1158/1078-0432.CCR-07-0143
   Hardwick JC, 2008, NAT REV CANCER, V8, P806, DOI 10.1038/nrc2467
   Haruta M, 2008, GENE CHROMOSOME CANC, V47, P712, DOI 10.1002/gcc.20572
   Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561
   Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416
   Jiang F, 1998, AM J PATHOL, V153, P1467, DOI 10.1016/S0002-9440(10)65734-3
   Karolchik D, 2008, NUCLEIC ACIDS RES, V36, pD773, DOI 10.1093/nar/gkm966
   Katsuno Y, 2008, ONCOGENE, V27, P6322, DOI 10.1038/onc.2008.232
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Kim IY, 2003, CLIN CANCER RES, V9, P6046
   Koesters R, 1999, CANCER RES, V59, P3880
   KURODA N, PATHOL INT, V60, P9
   Lai TH, 2008, PROSTATE, V68, P1341, DOI 10.1002/pros.20799
   Laurikkala J, 2003, DEV BIOL, V264, P91, DOI 10.1016/j.ydbio.2003.08.011
   Lenburg ME, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-31
   Linehan WM, 2004, CANCER CELL, V6, P223, DOI 10.1016/j.ccr.2004.09.006
   Lintern KB, 2009, J BIOL CHEM, V284, P23159, DOI 10.1074/jbc.M109.025478
   Maiti S, 2000, CANCER RES, V60, P6288
   Namimatsu S, 2005, J HISTOCHEM CYTOCHEM, V53, P3, DOI 10.1369/jhc.4C6466.2005
   Ohshima J, 2009, GENE CHROMOSOME CANC, V48, P1037, DOI 10.1002/gcc.20705
   Pavlovich CP, 2003, GENE CHROMOSOME CANC, V37, P252, DOI 10.1002/gcc.10209
   Powlesland RM, 2000, BRIT J CANCER, V82, P323, DOI 10.1054/bjoc.1999.0922
   Rauta J, 2006, BREAST CANCER RES TR, V95, P257, DOI 10.1007/s10549-005-9017-7
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   Rubin BP, 2000, AM J SURG PATHOL, V24, P1663, DOI 10.1097/00000478-200012000-00011
   Sossey-Alaoui K, 2003, GENE CHROMOSOME CANC, V36, P1, DOI 10.1002/gcc.10133
   Varan A, 2008, NEPHRON CLIN PRACT, V108, pC83, DOI 10.1159/000113012
   Waldert M, 2008, BJU INT, V102, P1381, DOI 10.1111/j.1464-410X.2008.07999.x
   Yanagita M, 2005, CYTOKINE GROWTH F R, V16, P309, DOI 10.1016/j.cytogfr.2005.02.007
   Yanagita M, 2004, BIOCHEM BIOPH RES CO, V316, P490, DOI 10.1016/j.bbrc.2004.02.075
   Yusenko MV, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-152
NR 45
TC 15
Z9 17
U1 0
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-9966
J9 J EXP CLIN CANC RES
JI J. Exp. Clin. Cancer Res.
PD NOV 16
PY 2010
VL 29
AR 147
DI 10.1186/1756-9966-29-147
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 694QK
UT WOS:000285312500001
PM 21080955
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Simonini, PDR
   Breiling, A
   Gupta, N
   Malekpour, M
   Youns, M
   Omranipour, R
   Malekpour, F
   Volinia, S
   Croce, CM
   Najmabadi, H
   Diederichs, S
   Sahin, Ö
   Mayer, D
   Lyko, F
   Hoheisel, JD
   Riazalhosseini, Y
AF Simonini, Pedro de Souza Rocha
   Breiling, Achim
   Gupta, Nibedita
   Malekpour, Mahdi
   Youns, Mahmoud
   Omranipour, Ramesh
   Malekpour, Fatemeh
   Volinia, Stefano
   Croce, Carlo M.
   Najmabadi, Hossein
   Diederichs, Sven
   Sahin, Oezguer
   Mayer, Doris
   Lyko, Frank
   Hoheisel, Joerg D.
   Riazalhosseini, Yasser
TI Epigenetically Deregulated microRNA-375 Is Involved in a Positive
   Feedback Loop with Estrogen Receptor α in Breast Cancer Cells
SO CANCER RESEARCH
LA English
DT Article
ID TRANSCRIPTIONAL REPRESSOR; EXPRESSION; PROTEIN; PROLIFERATION;
   METHYLATION; SIGNATURE; CTCF; RESISTANCE; CARCINOMA; INVASION
AB Estrogen receptor alpha (ER alpha) upregulation causes abnormal cell proliferation in about two thirds of breast cancers, yet understanding of the underlying mechanisms remains incomplete. Here, we show that high expression of the microRNA miR-375 in ER alpha-positive breast cell lines is a key driver of their proliferation. miR-375 overexpression was caused by loss of epigenetic marks including H3K9me2 and local DNA hypo-methylation, dissociation of the transcriptional repressor CTCF from the miR-375 promoter, and interactions of ER alpha with regulatory regions of miR-375. Inhibiting miR-375 in ER alpha-positive MCF-7 cells resulted in reduced ERa activation and cell proliferation. A combination of expression profiling from tumor samples and miRNA target prediction identified RASD1 as a potential miR-375 target. Mechanistic investigations revealed that miR-375 regulates RASD1 by targeting the 3' untranslated region in RASD1 mRNA. Additionally, we found that RASD1 negatively regulates ER alpha expression. Our findings define a forward feedback pathway in control of ER alpha expression, highlighting new strategies to treat ER alpha-positive invasive breast tumors. Cancer Res; 70(22); 9175-84. (C) 2010 AACR.
C1 [Riazalhosseini, Yasser] German Canc Res Ctr, Div Funct Genome Anal, INF 580, D-69120 Heidelberg, Germany.
   [Simonini, Pedro de Souza Rocha; Diederichs, Sven] German Canc Res Ctr, Helmholtz Univ Young Investigator Grp Mol RNA Bio, D-69120 Heidelberg, Germany.
   [Simonini, Pedro de Souza Rocha; Diederichs, Sven] Heidelberg Univ, Inst Pathol, D-6900 Heidelberg, Germany.
   [Breiling, Achim; Lyko, Frank] DKFZ ZMBH Alliance, Div Epigenet, Heidelberg, Germany.
   [Gupta, Nibedita; Mayer, Doris] German Canc Res Ctr, Hormones & Signal Transduct Grp, D-69120 Heidelberg, Germany.
   [Sahin, Oezguer] German Canc Res Ctr, Div Mol Genome Anal, D-69120 Heidelberg, Germany.
   [Malekpour, Mahdi; Omranipour, Ramesh] Univ Tehran Med Sci, Imam Khomeini Hosp, Inst Canc, Tehran, Iran.
   [Malekpour, Fatemeh] Shahid Beheshti Univ Med Sci, Shohada Tajrish Hosp, Tehran, Iran.
   [Najmabadi, Hossein] Univ Social Welf & Rehabil, Genet Res Ctr, Tehran, Iran.
   [Youns, Mahmoud] Helwan Univ, Fac Pharm, Dept Biochem & Mol Biol, Cairo, Egypt.
   [Volinia, Stefano] Univ Ferrara, Dept Morphol & Embryol, I-44100 Ferrara, Italy.
   [Croce, Carlo M.] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Ctr Comprehens Canc, Columbus, OH 43210 USA.
C3 Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz
   Association; German Cancer Research Center (DKFZ); Ruprecht Karls
   University Heidelberg; Helmholtz Association; German Cancer Research
   Center (DKFZ); Helmholtz Association; German Cancer Research Center
   (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ);
   Tehran University of Medical Sciences; Shahid Beheshti University
   Medical Sciences; Egyptian Knowledge Bank (EKB); Helwan University;
   University of Ferrara; James Cancer Hospital & Solove Research
   Institute; University System of Ohio; Ohio State University
RP Riazalhosseini, Y (通讯作者)，German Canc Res Ctr, Div Funct Genome Anal, INF 580, D-69120 Heidelberg, Germany.
EM y.riazalhosseini@dkfz.de
RI omranipour, ramesh/D-4871-2018; Najmabadi, Hossein/P-8182-2017; Gupta,
   N./C-8317-2009; Malekpour, Mahdi/B-6174-2009; Sahin, Ozgur/F-4403-2014;
   Volinia, Stefano/A-3029-2010; Diederichs, Sven/J-6237-2012
OI Sahin, Ozgur/0000-0002-8033-7089; Volinia, Stefano/0000-0003-0910-3893;
   Najmabadi, Hossein/0000-0002-6084-7778; Gupta,
   Vishal/0000-0002-5004-8024; Diederichs, Sven/0000-0001-7901-4752;
   Breiling, Achim/0000-0002-7928-299X; Youns, Mahmoud/0000-0001-8754-9634
FU Federal Ministry of Education and Research (BMBF); Helmholtz Association
   [VH-NG-504]
FX Federal Ministry of Education and Research (BMBF) as part of the NGFN
   program and the Helmholtz Association (VH-NG-504).
CR Adams BD, 2007, MOL ENDOCRINOL, V21, P1132, DOI 10.1210/me.2007-0022
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Avnit-Sagi T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005033
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bhat-Nakshatri P, 2009, NUCLEIC ACIDS RES, V37, P4850, DOI 10.1093/nar/gkp500
   Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214
   Bock C, 2005, BIOINFORMATICS, V21, P4067, DOI 10.1093/bioinformatics/bti652
   Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Castellano L, 2009, P NATL ACAD SCI USA, V106, P15732, DOI 10.1073/pnas.0906947106
   Chan CS, 2008, CANCER RES, V68, P9041, DOI 10.1158/0008-5472.CAN-08-2632
   D'Arcy V, 2008, BRIT J CANCER, V98, P571, DOI 10.1038/sj.bjc.6604181
   Docquier F, 2005, CANCER RES, V65, P5112, DOI 10.1158/0008-5472.CAN-03-3498
   Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429
   Filippova GN, 2008, CURR TOP DEV BIOL, V80, P337, DOI 10.1016/S0070-2153(07)80009-3
   Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hossain A, 2006, MOL CELL BIOL, V26, P8191, DOI 10.1128/MCB.00242-06
   Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Liu WH, 2009, GASTROENTEROLOGY, V136, P683, DOI 10.1053/j.gastro.2008.10.029
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   Mathé EA, 2009, CLIN CANCER RES, V15, P6192, DOI 10.1158/1078-0432.CCR-09-1467
   McCafferty MPJ, 2009, BREAST CANCER RES TR, V116, P425, DOI 10.1007/s10549-009-0429-7
   Medunjanin S, 2005, J BIOL CHEM, V280, P33006, DOI 10.1074/jbc.M506758200
   Nguyen P, 2008, CANCER RES, V68, P5546, DOI 10.1158/0008-5472.CAN-08-1005
   Pandey DP, 2009, MOL CELL BIOL, V29, P3783, DOI 10.1128/MCB.01875-08
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001
   Poy MN, 2009, P NATL ACAD SCI USA, V106, P5813, DOI 10.1073/pnas.0810550106
   Pscherer A, 2006, FASEB J, V20, P1188, DOI 10.1096/fj.05-4854fje
   Sahin Ö, 2007, P NATL ACAD SCI USA, V104, P6579, DOI 10.1073/pnas.0606827104
   Schmitt M, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp581
   Sempere LF, 2007, CANCER RES, V67, P11612, DOI 10.1158/0008-5472.CAN-07-5019
   Sessa L, 2007, RNA, V13, P223, DOI 10.1261/rna.266707
   Shoker BS, 1999, AM J PATHOL, V155, P1811, DOI 10.1016/S0002-9440(10)65498-3
   Spaderna S, 2008, CANCER RES, V68, P537, DOI 10.1158/0008-5472.CAN-07-5682
   Tsukamoto Y, 2010, CANCER RES, V70, P2339, DOI 10.1158/0008-5472.CAN-09-2777
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Uhlmann S, 2010, ONCOGENE, V29, P4297, DOI 10.1038/onc.2010.201
   Vaidyanathan G, 2004, ONCOGENE, V23, P5858, DOI 10.1038/sj.onc.1207774
   Vargo-Gogola T, 2007, NAT REV CANCER, V7, P659, DOI 10.1038/nrc2193
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Weber B, 2007, CELL CYCLE, V6, P1001, DOI 10.4161/cc.6.9.4209
   Werner T, 2000, Methods Mol Biol, V132, P337
   Zhao JJ, 2008, J BIOL CHEM, V283, P31079, DOI 10.1074/jbc.M806041200
NR 46
TC 188
Z9 208
U1 0
U2 17
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD NOV 15
PY 2010
VL 70
IS 22
BP 9175
EP 9184
DI 10.1158/0008-5472.CAN-10-1318
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 680DT
UT WOS:000284213300023
PM 20978187
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Ellinger, J
   Kahl, P
   Mertens, C
   Rogenhofer, S
   Hauser, S
   Hartmann, W
   Bastian, PJ
   Büttner, R
   Müller, SC
   von Ruecker, A
AF Ellinger, Joerg
   Kahl, Philip
   Mertens, Claudia
   Rogenhofer, Sebastian
   Hauser, Stefan
   Hartmann, Wolfgang
   Bastian, Patrick J.
   Buettner, Reinhard
   Mueller, Stefan C.
   von Ruecker, Alexander
TI Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in
   renal cell carcinoma
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE histone; methylation; H3K4; renal cell carcinoma; prognosis
ID MODIFICATIONS PREDICT PROGNOSIS; CANCER RECURRENCE; DNA-METHYLATION;
   BREAST-CANCER; ACETYLATION; PATTERN
AB Epigenetic alterations play an important role in carcinogenesis. Recent studies suggested that global histone modifications are predictors of cancer recurrence in various tumor entities. Our study was performed to evaluate histone H3 lysine 4 monomethyl (H3K4me1), -di-methyl (H3K4me2) and -trimethyl (H3K4me3) patterns in renal cell carcinoma (RCC) using a tissue microarray with 193 RCC (including 142 clear cell, 31 papillary, 10 chromophobe and 10 sarcomatoid RCC) and 10 oncocytoma specimens: H3K4me3 staining was more intense in papillary RCC, whereas H3K4me1 and H3K4me2 were similar in the diverse RCC subtypes. H3K4me2 and H3K4me3 levels were increased in oncocytoma. H3K4me1-3 levels were inversely correlated with Fuhrman grading, pT stage, lymph node involvement and distant metastasis. Progression-free survival and cancer-specific survival were shorter in patients with low levels of H3K4me1-3 in the univariate analysis, but we did not observe a significant correlation of a single modification in a multivariate model, which also included the established prognostic parameters TNM-stage and Fuhrman grade. In comparison, the H3K4me score, which combined staining levels of the H3K4 modifications, was an independent predictor of RCC progression-free survival. Our study on H3K4 methylation supports the concept of global histone modifications as potential cancer prognosis markers.
C1 [Ellinger, Joerg; Mertens, Claudia; Rogenhofer, Sebastian; Hauser, Stefan; Mueller, Stefan C.] Univ Klinikum Bonn, Klin & Poliklin Urol, D-53105 Bonn, Germany.
   [Kahl, Philip; Hartmann, Wolfgang; Buettner, Reinhard; von Ruecker, Alexander] Univ Klinikum Bonn, Inst Pathol, D-53105 Bonn, Germany.
   [Bastian, Patrick J.] Klinikum Univ Munchen Grosshadern, Urol Klin & Poliklin, D-81377 Munich, Germany.
C3 University of Bonn; University of Bonn; University of Munich
RP Ellinger, J (通讯作者)，Univ Klinikum Bonn, Klin & Poliklin Urol, Sigmund Freud Str 25, D-53105 Bonn, Germany.
EM joerg.ellinger@ukb.uni-bonn.de
RI Ellinger, Jorg/D-8389-2011; Hartmann, Wolfgang/G-1893-2017
OI Ellinger, Jorg/0000-0002-7526-0857; Hartmann,
   Wolfgang/0000-0002-7609-5021
FU North-Rhine Westphalian Association of Urology
FX Grant sponsor: North-Rhine Westphalian Association of Urology
CR Barlesi F, 2007, J CLIN ONCOL, V25, P4358, DOI 10.1200/JCO.2007.11.2599
   Ellinger J, 2010, PROSTATE, V70, P61, DOI 10.1002/pros.21038
   Elsheikh SE, 2009, CANCER RES, V69, P3802, DOI 10.1158/0008-5472.CAN-08-3907
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Gonzalgo ML, 2004, CLIN CANCER RES, V10, P7276, DOI 10.1158/1078-0432.CCR-03-0692
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Kanao K, 2008, J UROLOGY, V180, P1131, DOI 10.1016/j.juro.2008.04.136
   Kawamoto K, 2008, INT J CANCER, V123, P535, DOI 10.1002/ijc.23514
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kurdistani SK, 2007, BRIT J CANCER, V97, P1, DOI 10.1038/sj.bjc.6603844
   Minardi D, 2009, J CELL MOL MED, V13, P2115, DOI 10.1111/j.1582-4934.2008.00482.x
   Orr JA, 2007, ANAL QUANT CYTOL, V29, P17
   Park YS, 2008, ANN SURG ONCOL, V15, P1968, DOI 10.1245/s10434-008-9927-9
   Patard JJ, 2005, J CLIN ONCOL, V23, P2763, DOI 10.1200/JCO.2005.07.055
   REMMELE W, 1987, PATHOLOGE, V8, P138
   Richards KL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004941
   Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735
   Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874
   Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672
   Shi Y, 2007, NAT REV GENET, V8, P829, DOI 10.1038/nrg2218
   Waldert M, 2008, BJU INT, V102, P1381, DOI 10.1111/j.1464-410X.2008.07999.x
   Xia XB, 2009, P NATL ACAD SCI USA, V106, P4260, DOI 10.1073/pnas.0810067106
NR 23
TC 86
Z9 98
U1 0
U2 9
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD NOV 15
PY 2010
VL 127
IS 10
BP 2360
EP 2366
DI 10.1002/ijc.25250
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 672DT
UT WOS:000283563900012
PM 20162570
DA 2025-01-12
ER

PT J
AU Xiong, JH
   Liu, JA
   Rayner, S
   Tian, Z
   Li, YH
   Chen, SG
AF Xiong, Jianghui
   Liu, Juan
   Rayner, Simon
   Tian, Ze
   Li, Yinghui
   Chen, Shanguang
TI Pre-Clinical Drug Prioritization via Prognosis-Guided Genetic
   Interaction Networks
SO PLOS ONE
LA English
DT Article
ID CELL LUNG-CANCER; BREAST-CANCER; TARGETED THERAPIES; IDENTIFICATION;
   PHARMACOLOGY; GEMCITABINE; ROBUSTNESS; MODULARITY; INHIBITORS;
   SIGNATURES
AB The high rates of failure in oncology drug clinical trials highlight the problems of using pre-clinical data to predict the clinical effects of drugs. Patient population heterogeneity and unpredictable physiology complicate pre-clinical cancer modeling efforts. We hypothesize that gene networks associated with cancer outcome in heterogeneous patient populations could serve as a reference for identifying drug effects. Here we propose a novel in vivo genetic interaction which we call 'synergistic outcome determination' (SOD), a concept similar to 'Synthetic Lethality'. SOD is defined as the synergy of a gene pair with respect to cancer patients' outcome, whose correlation with outcome is due to cooperative, rather than independent, contributions of genes. The method combines microarray gene expression data with cancer prognostic information to identify synergistic gene-gene interactions that are then used to construct interaction networks based on gene modules (a group of genes which share similar function). In this way, we identified a cluster of important epigenetically regulated gene modules. By projecting drug sensitivity-associated genes on to the cancer-specific intermodule network, we defined a perturbation index for each drug based upon its characteristic perturbation pattern on the inter-module network. Finally, by calculating this index for compounds in the NCI Standard Agent Database, we significantly discriminated successful drugs from a broad set of test compounds, and further revealed the mechanisms of drug combinations. Thus, prognosis-guided synergistic gene-gene interaction networks could serve as an efficient in silico tool for pre-clinical drug prioritization and rational design of combinatorial therapies.
C1 [Xiong, Jianghui; Liu, Juan] Wuhan Univ, Sch Comp Sci, Wuhan 430072, Peoples R China.
   [Xiong, Jianghui; Li, Yinghui; Chen, Shanguang] China Astronaut Res & Training Ctr, State Key Lab Space Med Fundamentals & Applicat, Bioinformat Syst Biol & Translat Med Grp, Beijing, Peoples R China.
   [Rayner, Simon] Chinese Acad Sci, Wuhan Inst Virol, State Key Lab Virol, Bioinformat Grp, Wuhan, Peoples R China.
   [Tian, Ze] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
C3 Wuhan University; Chinese Academy of Sciences; Wuhan Institute of
   Virology, CAS; Harvard University; Dana-Farber Cancer Institute; Harvard
   Medical School
RP Xiong, JH (通讯作者)，Wuhan Univ, Sch Comp Sci, Wuhan 430072, Peoples R China.
EM laserxiong@gmail.com; liujuan@whu.edu.cn
RI tian, ze/HDM-4308-2022; XIONG, JIANGHUI/B-3621-2010; rayner,
   simon/N-7715-2013
OI XIONG, JIANGHUI/0000-0002-3198-5303; rayner, simon/0000-0001-8703-9140
FU National Natural Science Foundation of China [30600759, 60773010,
   60970063]; State Key Lab of Space Medicine Fundamentals and Application
   [SMFA09A07]; Advanced Space Medico-Engineering Research Project of China
   [01105015, 01104099]
FX This work was partly supported by the National Natural Science
   Foundation of China to J.X. (30600759) and J.L. (60773010 and 60970063),
   grant from State Key Lab of Space Medicine Fundamentals and Application
   to J.X. (SMFA09A07), and Advanced Space Medico-Engineering Research
   Project of China to J.X. (01105015, 01104099). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Anastassiou D, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100124
   Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894
   Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296
   Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874
   Brock A, 2009, NAT REV GENET, V10, P336, DOI 10.1038/nrg2556
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385
   Chuang HY, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100180
   Clegg A, 2002, THORAX, V57, P20, DOI 10.1136/thorax.57.1.20
   Csermely P, 2005, TRENDS PHARMACOL SCI, V26, P178, DOI 10.1016/j.tips.2005.02.007
   Davies AM, 2009, J THORAC ONCOL, V4, P87, DOI 10.1097/JTO.0b013e3181915052
   DEVITA VT, 1989, CANC PRINCIPLES PRAC, V1
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   FONG PC, 2009, N ENGL J MED
   Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706
   Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952
   Hoeller D, 2009, NATURE, V458, P438, DOI 10.1038/nature07960
   Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718
   Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118
   Jänne PA, 2009, NAT REV DRUG DISCOV, V8, P709, DOI 10.1038/nrd2871
   Jones D, 2009, NAT BIOTECHNOL, V27, P108, DOI 10.1038/nbt0209-108
   Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691
   Kamat AM, 2004, MOL CANCER THER, V3, P279
   Kamb A, 2005, NAT REV DRUG DISCOV, V4, P161, DOI 10.1038/nrd1635
   Kemper C, 2007, NAT REV IMMUNOL, V7, P9, DOI 10.1038/nri1994
   Kitano H, 2004, NAT REV GENET, V5, P826, DOI 10.1038/nrg1471
   Kitano H, 2007, NAT REV DRUG DISCOV, V6, P202, DOI 10.1038/nrd2195
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Lauss M, 2008, BRIT J CANCER, V98, P816, DOI 10.1038/sj.bjc.6604219
   Markiewski MM, 2008, NAT IMMUNOL, V9, P1225, DOI 10.1038/ni.1655
   Metzeler KH, 2008, BLOOD, V112, P4193, DOI 10.1182/blood-2008-02-134411
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Nalepa G, 2006, NAT REV DRUG DISCOV, V5, P596, DOI 10.1038/nrd2056
   Newman MEJ, 2006, P NATL ACAD SCI USA, V103, P8577, DOI 10.1073/pnas.0601602103
   Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306
   Potti A, 2006, NEW ENGL J MED, V355, P570, DOI 10.1056/NEJMoa060467
   Provencio M, 2010, CLIN LUNG CANCER, V11, P91, DOI 10.3816/CLC.2010.n.012
   Radiloff Daniel R, 2008, Drug Discov Today Dis Models, V4, P83
   Ruepp A, 2008, NUCLEIC ACIDS RES, V36, pD646, DOI 10.1093/nar/gkm936
   Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439
   Shoemaker RH, 2006, NAT REV CANCER, V6, P813, DOI 10.1038/nrc1951
   Suh MR, 2004, DEV BIOL, V270, P488, DOI 10.1016/j.ydbio.2004.02.019
   Taylor IW, 2009, NAT BIOTECHNOL, V27, P199, DOI 10.1038/nbt.1522
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   Watkinson J, 2008, BMC SYST BIOL, V2, DOI 10.1186/1752-0509-2-10
   Whitehurst AW, 2007, NATURE, V446, P815, DOI 10.1038/nature05697
   Wu M, 2009, P NATL ACAD SCI USA, V106, P7022, DOI 10.1073/pnas.0811785106
   Yildirim MA, 2007, NAT BIOTECHNOL, V25, P1119, DOI 10.1038/nbt1338
NR 49
TC 6
Z9 11
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 10
PY 2010
VL 5
IS 11
AR e13937
DI 10.1371/journal.pone.0013937
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 677ZN
UT WOS:000284036800024
PM 21085674
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Ables, ET
   Drummond-Barbosa, D
AF Ables, Elizabeth T.
   Drummond-Barbosa, Daniela
TI The Steroid Hormone Ecdysone Functions with Intrinsic Chromatin
   Remodeling Factors to Control Female Germline Stem Cells in
   <i>Drosophila</i>
SO CELL STEM CELL
LA English
DT Article
ID BREAST-CANCER; NUCLEAR RECEPTORS; BROAD-COMPLEX; INSULIN; GENE;
   METAMORPHOSIS; TRANSCRIPTION; MELANOGASTER; MAINTENANCE; OOGENESIS
AB Steroid hormones are known systemic regulators of multiple normal and cancerous tissues; however, whether or how they impact the fate and function of adult stem cells is unclear. In the Drosophila ovary, insulin signals modulate the proliferation and self-renewal of germline stem cells (GSCs), yet despite evidence that additional systemic factors control GSC activity, these have remained largely unknown. Here, we report that ecdysone, a steroid hormone structurally related to mammalian sex steroids, directly regulates adult GSC proliferation and self-renewal independently of insulin signaling. Ecdysone controls GSCs through a functional interaction with the chromatin remodeling factors ISWI, an intrinsic epigenetic factor required for GSC fate and activity, and Nurf301, the largest subunit of the ISWI-containing NURF chromatin remodeling complex. Our findings support a link between systemic steroid hormones and the intrinsic chromatin remodeling machinery as a potential mechanism to promote broad transcriptional programs required for adult stem cell self-renewal.
C1 [Ables, Elizabeth T.; Drummond-Barbosa, Daniela] Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN 37232 USA.
   [Ables, Elizabeth T.; Drummond-Barbosa, Daniela] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA.
   [Ables, Elizabeth T.; Drummond-Barbosa, Daniela] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Div Reprod Biol, Baltimore, MD 21205 USA.
   [Drummond-Barbosa, Daniela] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA.
C3 Vanderbilt University; Johns Hopkins University; Johns Hopkins Bloomberg
   School of Public Health; Johns Hopkins University; Johns Hopkins
   Bloomberg School of Public Health; Johns Hopkins University; Johns
   Hopkins Bloomberg School of Public Health
RP Drummond-Barbosa, D (通讯作者)，Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN 37232 USA.
EM dbarbosa@jhsph.edu
OI Ables, Elizabeth/0000-0002-6934-9302
FU National Institutes of Health [R01 GM069875, T32 DK007563, F32
   GM086031]; American Cancer Society [RSG-DDC-112316]
FX We wish to thank M. Bender, E. Hafen, T. Lee, E. Matunis, C. Cherry, D.
   Montell, J. Truman, J. Tamkun, J. Maines, W.-M. Deng, T. Nystul, A.
   Spradling, the Bloomington Stock Center, and the Developmental Studies
   Hybridoma Bank for reagents; the Vanderbilt and Johns Hopkins Microscopy
   Facilities; and V. Culotta, B. Zirkin, H.-J. Hsu, and L. LaFever for
   critical reading of this manuscript. E.T.A. and D.D.-B. designed
   experiments, interpreted results, and wrote the manuscript. E.T.A.
   performed all experiments. This work was supported by National
   Institutes of Health R01 GM069875 and American Cancer Society
   RSG-DDC-112316. E.T.A. was supported by training grant T32 DK007563 and
   National Research Service Award F32 GM086031 from the National
   Institutes of Health.
CR Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027
   Badenhorst P, 2005, GENE DEV, V19, P2540, DOI 10.1101/gad.1342605
   Bai JW, 2000, CELL, V103, P1047, DOI 10.1016/S0092-8674(00)00208-7
   Bialecki M, 2002, DEV CELL, V3, P209, DOI 10.1016/S1534-5807(02)00204-6
   Britt K, 2007, ENDOCR-RELAT CANCER, V14, P907, DOI 10.1677/ERC-07-0137
   Britt KL, 2004, BIOL REPROD, V71, P1712, DOI 10.1095/biolreprod.104.028175
   Buszczak M, 1999, DEVELOPMENT, V126, P4581
   Carney GE, 2000, GENETICS, V154, P1203
   Clarke MF, 2006, CELL, V124, P1111, DOI 10.1016/j.cell.2006.03.011
   Colombani J, 2005, SCIENCE, V310, P667, DOI 10.1126/science.1119432
   D'Errico I, 2008, CELL MOL LIFE SCI, V65, P1523, DOI 10.1007/s00018-008-7552-1
   de Cuevas M, 1998, DEVELOPMENT, V125, P2781
   Deng WM, 1997, DEVELOPMENT, V124, P4639
   Deuring R, 2000, MOL CELL, V5, P355, DOI 10.1016/S1097-2765(00)80430-X
   Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9
   DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000
   Drummond-Barbosa D, 2001, DEV BIOL, V231, P265, DOI 10.1006/dbio.2000.0135
   Drummond-Barbosa D, 2008, GENETICS, V180, P1787, DOI 10.1534/genetics.108.098244
   Eliassen AH, 2008, ADV EXP MED BIOL, V630, P148
   Fair Alecia Malin, 2009, V472, P57, DOI 10.1007/978-1-60327-492-0_3
   Flajollet S, 2007, MOL CELL ENDOCRINOL, V270, P23, DOI 10.1016/j.mce.2007.02.004
   FLETCHER JC, 1995, GENETICS, V141, P1025
   FLETCHER JC, 1995, DEVELOPMENT, V121, P1455
   GAREN A, 1977, P NATL ACAD SCI USA, V74, P5099, DOI 10.1073/pnas.74.11.5099
   Ghbeish N, 2001, P NATL ACAD SCI USA, V98, P3867, DOI 10.1073/pnas.061437798
   Hsu HJ, 2009, P NATL ACAD SCI USA, V106, P1117, DOI 10.1073/pnas.0809144106
   Hsu HJ, 2008, DEV BIOL, V313, P700, DOI 10.1016/j.ydbio.2007.11.006
   Huang X, 2008, J GENET GENOMICS, V35, P1, DOI 10.1016/S1673-8527(08)60001-6
   IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868
   Jang ACC, 2009, NAT CELL BIOL, V11, P569, DOI 10.1038/ncb1863
   Jeong Y, 2009, EXP MOL MED, V41, P525, DOI 10.3858/emm.2009.41.8.091
   Kai TS, 2003, P NATL ACAD SCI USA, V100, P4633, DOI 10.1073/pnas.0830856100
   Kirilly D, 2007, CELL RES, V17, P15, DOI 10.1038/sj.cr.7310123
   LaFever L, 2005, SCIENCE, V309, P1071, DOI 10.1126/science.1111410
   Lanzino M, 2008, CURR CANCER DRUG TAR, V8, P597, DOI 10.2174/156800908786241104
   Lee T, 2000, NEURON, V28, P807, DOI 10.1016/S0896-6273(00)00155-0
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   MARGOLIS J, 1995, DEVELOPMENT, V121, P3797
   Marvin KA, 2009, BIOCHEMISTRY-US, V48, P7056, DOI 10.1021/bi900697c
   Mendez P, 2006, FRONT NEUROENDOCRIN, V27, P391, DOI 10.1016/j.yfrne.2006.09.001
   Ninov N, 2009, PLOS BIOL, V7, P892, DOI 10.1371/journal.pbio.1000079
   Pawluski JL, 2009, FRONT NEUROENDOCRIN, V30, P343, DOI 10.1016/j.yfrne.2009.03.007
   Privalsky ML, 2004, ANNU REV PHYSIOL, V66, P315, DOI 10.1146/annurev.physiol.66.032802.155556
   Ray R, 2008, MOL MED, V14, P493, DOI 10.2119/2008-00004.Ray
   Riddiford L M, 2000, Vitam Horm, V60, P1, DOI 10.1016/S0083-6729(00)60016-X
   Riehle MA, 1999, INSECT BIOCHEM MOLEC, V29, P855, DOI 10.1016/S0965-1748(99)00084-3
   Schubiger M, 2005, DEVELOPMENT, V132, P5239, DOI 10.1242/dev.02093
   SCHWARTZ MB, 1985, J INSECT PHYSIOL, V31, P947, DOI 10.1016/0022-1910(85)90029-0
   Spradling Allan C., 1993, P1
   Thorne JL, 2009, INT J BIOCHEM CELL B, V41, P164, DOI 10.1016/j.biocel.2008.08.029
   Tsai CC, 1999, MOL CELL, V4, P175, DOI 10.1016/S1097-2765(00)80365-2
   Tu MP, 2002, AGING CELL, V1, P158, DOI 10.1046/j.1474-9728.2002.00016.x
   Wolf IM, 2008, J CELL BIOCHEM, V104, P1580, DOI 10.1002/jcb.21755
   Xi RW, 2005, SCIENCE, V310, P1487, DOI 10.1126/science.1120140
   Xiao H, 2001, MOL CELL, V8, P531, DOI 10.1016/S1097-2765(01)00345-8
   Xie T, 1998, CELL, V94, P251, DOI 10.1016/S0092-8674(00)81424-5
   XU T, 1993, DEVELOPMENT, V117, P1223
   Xu W, 2005, BIOCHEM CELL BIOL, V83, P418, DOI 10.1139/O05-057
NR 58
TC 121
Z9 152
U1 1
U2 32
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1934-5909
EI 1875-9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD NOV 5
PY 2010
VL 7
IS 5
BP 581
EP 592
DI 10.1016/j.stem.2010.10.001
PG 12
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 682GX
UT WOS:000284390500010
PM 21040900
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Loo, WTY
   Jin, LJ
   Cheung, MNB
   Wang, M
   Chow, LWC
AF Loo, Wings T. Y.
   Jin, Lijian
   Cheung, Mary N. B.
   Wang, Min
   Chow, Louis W. C.
TI Epigenetic change in E-Cardherin and COX-2 to predict chronic
   periodontitis
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
ID CPG ISLAND METHYLATION; GENDER-DIFFERENCES; TOOTH LOSS; E-CADHERIN;
   CANCER; GENE; DISEASE; HEALTH; BREAST; RISK
AB Background: DNA methylation of certain genes frequently occurs in neoplastic cells. Although the cause remains unknown, many genes have been identified with such atypical methylation in neoplastic cells. The hypermethylation of E-Cadherin and Cyclooxygenase 2 (COX-2) in chronic inflammation such as chronic periodontitis may demonstrate mild lesion/mutation epigenetic level. This study compares the hypermethylation status of E-Cadherin and COX-2 genes which are often found in breast cancer patients with that in chronic periodontitis.
   Methods: Total DNA was extracted from the blood samples of 108 systemically healthy non-periodontitis subjects, and the gingival tissues and blood samples of 110 chronic periodontitis patient as well as neoplastic tissues of 106 breast cancer patients. Methylation-specific PCR for E-Cadherin and COX-2 was performed on these samples and the PCR products were analyzed on 2% agarose gel.
   Results: Hypermethylation of E-Cadherin and COX-2 was observed in 38% and 35% of the breast cancer samples, respectively. In chronic periodontitis patients the detection rate was 25% and 19% respectively, and none was found in the systemically healthy non-periodontitis control subjects. The hypermethylation status was shown to be correlated among the three groups with statistical significance (p < 0.0001). The methylation of CpG islands in E-Cadherin and COX-2 genes in periodontitis patients occurs more frequently in periodontitis patients than in the control subjects, but occurs less frequently than in the breast cancer patients.
   Conclusions: This set of data shows that the epigenetic change in E-Cadherin and Cyclooxygenase-2 is associated with chronic periodontitis. The epigenetic changes presented in chronic inflammation patients might demonstrate an irreversible destruction in the tissues or organs similar to the effects of cancer. Chronic periodontitis to some extent might be associated with DNA hypermethylation which is related to cancer risk factors.
C1 [Loo, Wings T. Y.; Jin, Lijian] Univ Hong Kong, Fac Dent, Hong Kong, Hong Kong, Peoples R China.
   [Cheung, Mary N. B.] Keenlink Dent Clin, Hong Kong, Hong Kong, Peoples R China.
   [Wang, Min] Sichuan Univ, W China Coll Stomatol, Dept Prosthodont, Chengdu, Peoples R China.
   [Wang, Min] Sichuan Univ, W China Coll Stomatol, State Key Lab Oral Dis, Chengdu, Peoples R China.
   [Chow, Louis W. C.] UNIMED Med Inst, Hong Kong, Hong Kong, Peoples R China.
   [Chow, Louis W. C.] Org Oncol & Translat Res Hong Kong, Hong Kong, Hong Kong, Peoples R China.
C3 University of Hong Kong; Sichuan University; Sichuan University
RP Loo, WTY (通讯作者)，Univ Hong Kong, Fac Dent, Hong Kong, Hong Kong, Peoples R China.
EM wtyloo@gmail.com
RI Jin, Lijian/B-2148-2009; Loo, Wings Tjing Yung/AHD-4884-2022
OI Jin, Lijian/0000-0003-4305-1337
FU Science and Technology Department of Sichuan province, China
   [2007SGY028]; Department of Sichuan province, China [2007SGY028]
FX This study was supported by Scientific Support Project of Science and
   Technology Department of Sichuan province, China (2007SGY028).
CR Armitage GC, 2009, J AM DENT ASSOC, V140, p36S, DOI 10.14219/jada.archive.2009.0356
   Bock C, 2006, PLOS GENET, V2, P243, DOI 10.1371/journal.pgen.0020026
   Chow LWC, 2005, BIOMED PHARMACOTHER, V59, pS264, DOI 10.1016/S0753-3322(05)80042-3
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   DAVID HR, 2005, CANCER RES, V65, P4673
   de Heens GLT, 2009, CYTOKINE, V47, P157, DOI 10.1016/j.cyto.2009.05.006
   Desvarieux M, 2004, STROKE, V35, P2029, DOI 10.1161/01.STR.0000136767.71518.36
   Gabay C, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1917
   Irwin Chris, 2008, Dent Update, V35, P92
   Issa JPJ, 2001, CANCER RES, V61, P3573
   JEANPIERRE IJ, 2001, CANCER RES, V63, P3573
   Kang GH, 2003, AM J PATHOL, V163, P1551, DOI 10.1016/S0002-9440(10)63511-0
   Kowalski PJ, 2003, BREAST CANCER RES, V5, pR217, DOI 10.1186/bcr651
   LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733
   Lui ELH, 2005, BIOMED PHARMACOTHER, V59, pS363, DOI 10.1016/S0753-3322(05)80079-4
   MAIRI MH, 2009, CURRENT OPINION PHAR, V9, P370
   MICHALOWICZ BS, 1991, J PERIODONTOL, V62, P293, DOI 10.1902/jop.1991.62.5.293
   Michaud DS, 2008, LANCET ONCOL, V9, P550, DOI 10.1016/S1470-2045(08)70106-2
   Michaud DS, 2007, JNCI-J NATL CANCER I, V99, P171, DOI 10.1093/jnci/djk021
   Nagarakanti S, 2007, J PERIODONTOL, V78, P2197, DOI 10.1902/jop.2007.070070
   Nakajima T, 2010, J PERIODONTAL RES, V45, P116, DOI 10.1111/j.1600-0765.2009.01209.x
   Nephew KP, 2003, CANCER LETT, V190, P125, DOI 10.1016/S0304-3835(02)00511-6
   Nibali L, 2009, J MED MICROBIOL, V58, P1269, DOI 10.1099/jmm.0.012021-0
   Pihlstrom BL, 2001, PERIODONTOL 2000, V25, P37, DOI 10.1034/j.1600-0757.2001.22250104.x
   Pinho Márcia de Noronha, 2008, Braz. Dent. J., V19, P323, DOI 10.1590/S0103-64402008000400007
   Reichert S, 2002, ORAL MICROBIOL IMMUN, V17, P360, DOI 10.1034/j.1399-302X.2002.170605.x
   Rosania AE, 2009, J PERIODONTOL, V80, P260, DOI [10.1902/jop.2009.080334, 10.1902/jop.2009.080334 ]
   Sminia P, 2005, BIOMED PHARMACOTHER, V59, pS272, DOI 10.1016/S0753-3322(05)80044-7
   Timmerman M F, 2006, Int J Dent Hyg, V4, P2
   Tycko B, 2000, J CLIN INVEST, V105, P401, DOI 10.1172/JCI9462
   Van der Stelt P F, 1993, Adv Dent Res, V7, P158
   Van Dyke Thomas E, 2005, J Int Acad Periodontol, V7, P3
   Watts TLP, 1998, BMJ-BRIT MED J, V316, P993, DOI 10.1136/bmj.316.7136.993
   Wu YL, 2005, BIOMED PHARMACOTHER, V59, pS289, DOI 10.1016/S0753-3322(05)80048-4
NR 34
TC 50
Z9 59
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD NOV 4
PY 2010
VL 8
AR 110
DI 10.1186/1479-5876-8-110
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 692IO
UT WOS:000285146700001
PM 21047437
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Du, ZW
   Song, J
   Wang, Y
   Zhao, YQ
   Guda, K
   Yang, SM
   Kao, HY
   Xu, Y
   Willis, J
   Markowitz, SD
   Sedwick, D
   Ewing, RM
   Wang, ZH
AF Du, Zhanwen
   Song, Jing
   Wang, Yong
   Zhao, Yiqing
   Guda, Kishore
   Yang, Shuming
   Kao, Hung-Ying
   Xu, Yan
   Willis, Joseph
   Markowitz, Sanford D.
   Sedwick, David
   Ewing, Robert M.
   Wang, Zhenghe
TI DNMT1 Stability Is Regulated by Proteins Coordinating Deubiquitination
   and Acetylation-Driven Ubiquitination
SO SCIENCE SIGNALING
LA English
DT Article
ID DNA METHYLTRANSFERASE-1; GENE-EXPRESSION; BREAST-CANCER; CELLS; COMPLEX;
   HAUSP; METHYLATION; EPIGENETICS; ICBP90; TARGET
AB DNA methyltransferase 1 (DNMT1) is the primary enzyme that maintains DNA methylation. We describe a previously unknown mode of regulation of DNMT1 protein stability through the coordinated action of an array of DNMT1-associated proteins. DNMT1 was destabilized by acetylation by the acetyltransferase Tip60, which triggered ubiquitination by the E3 ligase UHRF1, thereby targeting DNMT1 for proteasomal degradation. In contrast, DNMT1 was stabilized by histone deacetylase 1 (HDAC1) and the deubiquitinase HAUSP (herpes virus-associated ubiquitin-specific protease). Analysis of the abundance of DNMT1 and Tip60, as well as the association between HAUSP and DNMT1, suggested that during the cell cycle the initiation of DNMT1 degradation was coordinated with the end of DNA replication and the need for DNMT activity. In human colon cancers, the abundance of DNMT1 correlated with that of HAUSP. HAUSP knockdown rendered colon cancer cells more sensitive to killing by HDAC inhibitors both in tissue culture and in tumor xenograft models. Thus, these studies provide a mechanism-based rationale for the development of HDAC and HAUSP inhibitors for combined use in cancer therapy.
C1 [Du, Zhanwen; Wang, Yong; Zhao, Yiqing; Ewing, Robert M.; Wang, Zhenghe] Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA.
   [Du, Zhanwen; Wang, Yong; Zhao, Yiqing; Guda, Kishore; Willis, Joseph; Markowitz, Sanford D.; Sedwick, David; Wang, Zhenghe] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.
   [Song, Jing; Ewing, Robert M.] Case Western Reserve Univ, Case Ctr Prote & Bioinformat, Cleveland, OH 44106 USA.
   [Guda, Kishore; Markowitz, Sanford D.; Sedwick, David] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA.
   [Guda, Kishore; Markowitz, Sanford D.] Howard Hughes Med Inst, Cleveland, OH 44106 USA.
   [Yang, Shuming; Xu, Yan] Case Western Reserve Univ, Canc Pharmacol Core Facil, Cleveland, OH 44106 USA.
   [Kao, Hung-Ying] Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA.
   [Xu, Yan] Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA.
   [Willis, Joseph] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA.
   [Wang, Zhenghe] Cleveland Clin Fdn, Genom Med Inst, Cleveland, OH 44195 USA.
C3 University System of Ohio; Case Western Reserve University; University
   System of Ohio; Case Western Reserve University; University System of
   Ohio; Case Western Reserve University; University System of Ohio; Case
   Western Reserve University; Howard Hughes Medical Institute; University
   System of Ohio; Case Western Reserve University; University System of
   Ohio; Case Western Reserve University; University System of Ohio;
   Cleveland State University; University System of Ohio; Case Western
   Reserve University; Cleveland Clinic Foundation
RP Wang, ZH (通讯作者)，Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA.
EM zhenghe.wang@case.edu
RI Song, Jing/F-7567-2014; Xu, Yan/AAW-4085-2021; Zhao,
   Yiqing/KXQ-4238-2024; Du, Zhanwen/H-9903-2016
OI Ewing, Rob/0000-0001-6510-4001; Kao, Hung-Ying/0000-0003-4535-0314
FU NIH [R01-CA127590, R01-HG004722, HG004722-02S1]; V foundation
   [R01-CA101983, DK078965, HL093269]; Case Comprehensive Cancer Center
   [P30 CA43703]
FX We thank B. Vogelstein for providing an HCT116 HAUSP knockout clone; M.
   Miyagi, C.-Y. Bao, and A. Polinkovsky for technical assistance; Y.
   Zhang, H. Lou, A. Ting, and M. Veigl for helpful discussions and
   critical reading of the manuscript; and X. Zhu for advice on statistical
   analyses. Funding: This research was supported by the NIH (grants
   R01-CA127590, R01-HG004722, and HG004722-02S1) and the V foundation (to
   Z.W.); R01-CA101983 (to D.S.); DK078965 and HL093269 (to H.-Y.K.); and
   the core facilities of the Case Comprehensive Cancer Center (P30
   CA43703). Author contributions: Z.W., Z.D., R. M. E., Y. X., D. S., S.
   D. M., and H.-Y.K. designed the experiments. Z.D., J.S., Y.W., Y.Z.,
   K.G., and S.Y. performed the experiments. D.S. and J.W. provided
   essential reagents. Z.D., Z.W., R.M.E., J.S., and Y.X. analyzed the
   data. Z.W., D.S., Z.D., S.D.M., and R.M.E. wrote the manuscript.
   Competing interests: The authors declare that they have no competing
   interests. A materials transfer agreement (MTA) is required by Case
   Western Reserve University for DNMT1, DNMT3B, Tip60 3xFlag knock-in cell
   lines, the HAUSP knockout cell line, the HDAC1-inducible knockdown
   cells, and the plasmids generated for this study.
CR Achour M, 2008, ONCOGENE, V27, P2187, DOI 10.1038/sj.onc.1210855
   Achour M, 2009, BIOCHEM BIOPH RES CO, V390, P523, DOI 10.1016/j.bbrc.2009.09.131
   Agoston AT, 2005, J BIOL CHEM, V280, P18302, DOI 10.1074/jbc.M501675200
   Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913
   Bostick M, 2007, SCIENCE, V317, P1760, DOI 10.1126/science.1147939
   Bots M, 2009, CLIN CANCER RES, V15, P3970, DOI 10.1158/1078-0432.CCR-08-2786
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371
   Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996
   Citterio E, 2004, MOL CELL BIOL, V24, P2526, DOI 10.1128/MCB.24.6.2526-2535.2004
   Cummins JM, 2004, NATURE, V428, DOI 10.1038/nature02501
   De Marzo AM, 1999, CANCER RES, V59, P3855
   Faustrup H, 2009, J CELL BIOL, V184, P13, DOI 10.1083/jcb.200807137
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   Holm TM, 2005, CANCER CELL, V8, P275, DOI 10.1016/j.ccr.2005.09.007
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Karagianni P, 2008, MOL CELL BIOL, V28, P705, DOI 10.1128/MCB.01598-07
   Karberg S, 2009, CELL, V139, P1029, DOI 10.1016/j.cell.2009.11.038
   Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026
   Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1
   Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124
   Robertson KD, 2000, NUCLEIC ACIDS RES, V28, P2108, DOI 10.1093/nar/28.10.2108
   Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023
   Sharif J, 2007, NATURE, V450, P908, DOI 10.1038/nature06397
   Song MS, 2008, NATURE, V455, P813, DOI 10.1038/nature07290
   SZYF M, 1991, J BIOL CHEM, V266, P10027
   Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906
   van der Horst A, 2006, NAT CELL BIOL, V8, P1064, DOI 10.1038/ncb1469
   Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003
   WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891
   Zhang XD, 2008, NAT METHODS, V5, P163, DOI 10.1038/NMETH1170
   Zhao YQ, 2010, P NATL ACAD SCI USA, V107, P2592, DOI 10.1073/pnas.0914884107
   Zhou Q, 2008, MOL CANCER RES, V6, P873, DOI 10.1158/1541-7786.MCR-07-0330
NR 33
TC 266
Z9 313
U1 1
U2 37
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1945-0877
EI 1937-9145
J9 SCI SIGNAL
JI Sci. Signal.
PD NOV 2
PY 2010
VL 3
IS 146
AR ra80
DI 10.1126/scisignal.2001462
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 674IT
UT WOS:000283734500005
PM 21045206
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Stein, T
   Cosimo, E
   Yu, XZ
   Smith, PR
   Simon, R
   Cottrel, L
   Pringle, MA
   Bell, AK
   Lattanzio, L
   Sauter, G
   Lo Nigro, C
   Crook, T
   Machesky, LM
   Gusterson, BA
AF Stein, Torsten
   Cosimo, Emilio
   Yu, Xinzi
   Smith, Paul R.
   Simon, Ronald
   Cottrel, Lorna
   Pringle, Marie-Anne
   Bell, Alexandra K.
   Lattanzio, Laura
   Sauter, Guido
   Lo Nigro, Cristiana
   Crook, Timothy
   Machesky, Laura M.
   Gusterson, Barry A.
TI Loss of Reelin Expression in Breast Cancer Is Epigenetically Controlled
   and Associated with Poor Prognosis
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID APOE RECEPTOR 2; NEURONAL MIGRATION; BRAIN-DEVELOPMENT; TYROSINE
   PHOSPHORYLATION; ALPHA-3-BETA-1 INTEGRIN; VLDL RECEPTOR; DISABLED-1;
   MOUSE; GENE; PROTEIN
AB Reelin is a secreted, signaling protein associated with neuronal cell positioning and migration. Recently, reelin was found to be epigenetically silenced in gastric and pancreatic cancers in which down-regulation was associated with increased migratory ability and reduced survival. Here we analyzed reelin expression by immunohistochemistry in 17 normal breast tissue samples from reduction mammoplasties and in two independent tissue microarrays of 136 and more than 2000 breast cancer biopsy samples, respectively. Results were analyzed with regard to clinical parameters, including BRE (Bloom, Richardson, Elston) grade, nodal status, estrogen receptor and HER2 status, and overall survival. Reelin was expressed in the luminal epithelium and myoepithelium of the normal human breast but not in cancerous breasts. Loss of reelin protein expression correlated significantly with decreased survival (P = 0.01) and positive lymph node status (P < 0.001). By measuring reelin expression and promoter methylation status in 39 primary breast tumors, as well as in breast cancer-derived cell lines before and after decitabine treatment, we established that reelin expression levels correlated inversely with promoter methylation status, whereas demethylation increased reelin mRNA expression in vitro. Reelin overexpression in MDA-MB231 cells, as well as incubation with recombinant reelin, suppressed cell migration, invadopodia formation, and invasiveness in vitro. We conclude that reelin may play an important role in controlling invasiveness and metastatic potential of breast cancer cells and that its expression is controlled by promoter methylation. (Am J Pathol 2010 177:2323-2333; DOI: 10.2353/ajpath.2010.100209)
C1 [Stein, Torsten; Cosimo, Emilio; Pringle, Marie-Anne; Bell, Alexandra K.; Gusterson, Barry A.] Univ Glasgow, Inst Canc Sci, Coll Med Vet & Life Sci, Glasgow G11 6NT, Lanark, Scotland.
   [Cottrel, Lorna] Univ Glasgow, Western Infirm, Dept Pathol, Glasgow G11 6NT, Lanark, Scotland.
   [Yu, Xinzi; Machesky, Laura M.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland.
   [Smith, Paul R.; Crook, Timothy] Inst Canc Res, Breakthrongh Breast Canc Ctr, London SW3 6JB, England.
   [Simon, Ronald; Sauter, Guido] Univ Med Ctr Hamburg Eppendorf, Dept Pathol, Hamburg, Germany.
   [Lattanzio, Laura; Lo Nigro, Cristiana] S Croce Gen Hosp, Lab Oncol Translaz, Cuneo, Italy.
C3 University of Glasgow; University of Glasgow; Beatson Institute;
   University of London; Institute of Cancer Research - UK; Royal Marsden
   NHS Foundation Trust; University of Hamburg; University Medical Center
   Hamburg-Eppendorf
RP Stein, T (通讯作者)，Univ Glasgow, Inst Canc Sci, Coll Med Vet & Life Sci, Glasgow G11 6NT, Lanark, Scotland.
EM torsten.stein@glasgow.ac.uk
RI Machesky, Laura/Z-4554-2019; Cosimo, Emilio/ISB-1891-2023; Stein,
   Torsten/G-1147-2012
OI Lo Nigro, Cristiana/0000-0002-3615-2431; Machesky,
   Laura/0000-0002-7592-9856; Cosimo, Emilio/0000-0002-7294-222X; PRINGLE,
   MARIE ANNE/0000-0002-1358-4610; Stein, Torsten/0000-0002-9946-1549;
   Simon, Ronald/0000-0003-0158-4258
FU Breakthrough Breast Cancer; International Breast Cancer Study Group;
   Medical Research Council UK [G117/569]; MRC [G117/569] Funding Source:
   UKRI
FX Supported by Breakthrough Breast Cancer (project grant to T.S. and
   B.A.G.) and by the International Breast Cancer Study Group for
   production of the Trial V tissue array (BAG.). L.M.M. is funded by a
   Medical Research Council UK Senior Fellowship (G117/569).
CR Al-Kuraya K, 2005, MODERN PATHOL, V18, P891, DOI 10.1038/modpathol.3800408
   Arnaud L, 2003, CURR BIOL, V13, P9, DOI 10.1016/S0960-9822(02)01397-0
   Assadi AH, 2003, NAT GENET, V35, P270, DOI 10.1038/ng1257
   Ballif BA, 2003, MOL BRAIN RES, V117, P152, DOI 10.1016/S0169-328X(03)00295-X
   Beffert U, 2002, J BIOL CHEM, V277, P49958, DOI 10.1074/jbc.M209205200
   Chen Y, 2002, NUCLEIC ACIDS RES, V30, P2930, DOI 10.1093/nar/gkf401
   D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0
   DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0
   DArcangelo G, 1997, J NEUROSCI, V17, P23, DOI 10.1523/JNEUROSCI.17-01-00023.1997
   deBergeyck V, 1997, MOL BRAIN RES, V50, P85, DOI 10.1016/S0169-328X(97)00166-6
   DOHI O, INT J ONCOL, V36, P85
   Dulabon L, 2000, NEURON, V27, P33, DOI 10.1016/S0896-6273(00)00007-6
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   FALCONER DS, 1951, J GENET, V50, P192, DOI 10.1007/BF02996215
   Förster E, 2002, P NATL ACAD SCI USA, V99, P13178, DOI 10.1073/pnas.202035899
   Frotscher M, 1998, CURR OPIN NEUROBIOL, V8, P570, DOI 10.1016/S0959-4388(98)80082-2
   GOLDHIRSCH A, 1988, NEW ENGL J MED, V319, P677
   Goldowitz D, 1997, J NEUROSCI, V17, P8767
   Grayson DR, 2006, PHARMACOL THERAPEUT, V111, P272, DOI 10.1016/j.pharmthera.2005.01.007
   Grayson DR, 2005, P NATL ACAD SCI USA, V102, P9341, DOI 10.1073/pnas.0503736102
   Hack I, 2007, DEVELOPMENT, V134, P3883, DOI 10.1242/dev.005447
   HENNIGAN RF, 1994, ONCOGENE, V9, P3591
   Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2
   Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607
   Ikeda Y, 1997, DEV DYNAM, V210, P157, DOI 10.1002/(SICI)1097-0177(199710)210:2<157::AID-AJA8>3.0.CO;2-F
   Jossin Y, 2004, MOL NEUROBIOL, V30, P225, DOI 10.1385/MN:30:3:225
   Keshvara L, 2001, J BIOL CHEM, V276, P16008, DOI 10.1074/jbc.M101422200
   Kundakovic M, 2007, MOL PHARMACOL, V71, P644, DOI 10.1124/mol.106.030635
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Morini M, 2000, INT J CANCER, V87, P336, DOI 10.1002/1097-0215(20000801)87:3<336::AID-IJC5>3.0.CO;2-3
   Perrone G, 2007, MODERN PATHOL, V20, P344, DOI 10.1038/modpathol.3800743
   Ruiz C, 2006, INT J CANCER, V118, P2190, DOI 10.1002/ijc.21581
   Sato N, 2006, GASTROENTEROLOGY, V130, P548, DOI 10.1053/j.gastro.2005.11.008
   Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601
   Smalheiser NR, 2000, P NATL ACAD SCI USA, V97, P1281, DOI 10.1073/pnas.97.3.1281
   Stein T, 2005, CLIN CANCER RES, V11, P6872, DOI 10.1158/1078-0432.CCR-05-0547
   Suetsugu S, 2004, BIOCHEM J, V384, P1, DOI 10.1042/BJ20041103
   Tissir F, 2003, NAT REV NEUROSCI, V4, P496, DOI 10.1038/nrn1113
   Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5
NR 39
TC 55
Z9 60
U1 0
U2 3
PU AMER SOC INVESTIGATIVE PATHOLOGY, INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3993 USA
SN 0002-9440
J9 AM J PATHOL
JI Am. J. Pathol.
PD NOV
PY 2010
VL 177
IS 5
BP 2323
EP 2333
DI 10.2353/ajpath.2010.100209
PG 11
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 679TE
UT WOS:000284182900020
PM 20847288
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Yang, ZQ
   Liu, G
   Bollig-Fischer, A
   Giroux, CN
   Ethier, SP
AF Yang, Zeng-Quan
   Liu, Gang
   Bollig-Fischer, Aliccia
   Giroux, Craig N.
   Ethier, Stephen P.
TI Transforming Properties of 8p11-12 Amplified Genes in Human Breast
   Cancer
SO CANCER RESEARCH
LA English
DT Article
ID CELL-LINES; THERAPEUTIC TARGET; PWWP DOMAIN; AMPLICON; AMPLIFICATION;
   METHYLATION; ONCOGENE; PATHWAYS; PROTEIN; ABERRATIONS
AB Amplification of the 8p11-12 region has been found in about 15% of human breast cancers and is associated with poor prognosis. Earlier, we used genomic analysis of copy number and gene expression to perform a detailed analysis of the 8p11-12 amplicon to identify candidate oncogenes in breast cancer. We identified 21 candidate genes and provided evidence that three genes, namely, LSM-1, TC-1, and BAG4, have transforming properties when overexpressed. In the present study, we systematically investigated the transforming properties of 13 newly identified 8p11-12 candidate oncogenes in vitro. WHSC1L1, DDHD2, and ERLIN2 were most potently transforming oncogenes based on the number of altered phenotypes expressed by the cells. WHSC1L1 contains a PWWP-domain that is a methyl-lysine recognition motif involved in histone code modification and epigenetic regulation of gene expression. Knockdown of WHSC1L1 in 8p11-12-amplified breast cancer cells resulted in profound loss of growth and survival of these cells. Further, we identified several WHSC1L1 target genes, one of which is iroquois homeobox 3 gene (IRX3), a member of the Iroquois homeobox transcription factor family. Cancer Res; 70(21); 8487-97. (C)2010 AACR.
C1 [Yang, Zeng-Quan; Liu, Gang; Bollig-Fischer, Aliccia; Ethier, Stephen P.] Wayne State Univ, Karmanos Canc Inst, Breast Canc Program, Detroit, MI 48201 USA.
C3 Wayne State University; Barbara Ann Karmanos Cancer Institute
RP Yang, ZQ (通讯作者)，Wayne State Univ, Karmanos Canc Inst, Breast Canc Program, 4100 John R HWCRC 815, Detroit, MI 48201 USA.
EM yangz@karmanos.org
RI LIU, GANG/AAR-4584-2021
OI Bollig-Fischer, Aliccia/0000-0003-4832-9457
FU Karmanos Cancer Institute [P30-CA022453-29]; Department of Defense
   [BC083945]; National Institutes of Health [RO1 CA100724]
FX We thank Michele L. Dziubinski and Katie L. Streicher for technical
   assistance on the cell culture and three-dimensional morphogenesis
   assays. The expression profiling was preformed by the Genomics Core of
   the Karmanos Cancer Institute that is supported by grant number
   P30-CA022453-29. The array CGH work was facilitated by the Microarray
   and Bioinformatics Core Facility of the Wayne State University
   Environmental Health Sciences Center, NIEHS P30 ES06639.Department of
   Defense Breast Cancer Program (BC083945) to Z-Q. Yang and a grant from
   the National Institutes of Health (RO1 CA100724) to S. P. Ethier.
CR Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215
   Albertson DG, 2006, TRENDS GENET, V22, P447, DOI 10.1016/j.tig.2006.06.007
   Angrand PO, 2001, GENOMICS, V74, P79, DOI 10.1006/geno.2001.6524
   Arteaga CL, 2002, SEMIN ONCOL, V29, P4, DOI 10.1053/sonc.2002.34047
   Badache A, 2006, J MAMMARY GLAND BIOL, V11, P13, DOI 10.1007/s10911-006-9009-1
   Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465
   Bergemann AD, 2005, TRENDS GENET, V21, P188, DOI 10.1016/j.tig.2005.01.008
   Bernard-Pierrot I, 2008, CANCER RES, V68, P7165, DOI 10.1158/0008-5472.CAN-08-1360
   Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822
   Chen M, 2009, NAT REV MOL CELL BIO, V10, P741, DOI 10.1038/nrm2777
   Chen TP, 2004, MOL CELL BIOL, V24, P9048, DOI 10.1128/MCB.24.20.9048-9058.2004
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009
   Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   Ferrell CM, 2005, STEM CELLS, V23, P644, DOI 10.1634/stemcells.2004-0198
   Forozan F, 1999, BRIT J CANCER, V81, P1328, DOI 10.1038/sj.bjc.6695007
   Garcia MJ, 2005, ONCOGENE, V24, P5235, DOI 10.1038/sj.onc.1208741
   Gelsi-Boyer W, 2005, MOL CANCER RES, V3, P655, DOI 10.1158/1541-7786.MCR-05-0128
   Guffanti A, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-163
   Haverty PM, 2008, GENE CHROMOSOME CANC, V47, P530, DOI 10.1002/gcc.20558
   Lüscher-Firzlaff J, 2008, CANCER RES, V68, P749, DOI 10.1158/0008-5472.CAN-07-3158
   Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477
   Pole JCM, 2006, ONCOGENE, V25, P5693, DOI 10.1038/sj.onc.1209570
   Rahman N, 2005, CURR OPIN GENET DEV, V15, P227, DOI 10.1016/j.gde.2005.04.007
   Ray ME, 2004, CANCER RES, V64, P40, DOI 10.1158/0008-5472.CAN-03-1022
   Rosati R, 2002, BLOOD, V99, P3857, DOI 10.1182/blood.V99.10.3857
   Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014
   Stec I, 2001, GENOMICS, V76, P5, DOI 10.1006/geno.2001.6581
   Streicher KL, 2007, ONCOGENE, V26, P2104, DOI 10.1038/sj.onc.1210002
   Taverna SD, 2007, NAT STRUCT MOL BIOL, V14, P1025, DOI 10.1038/nsmb1338
   Tonon G, 2005, P NATL ACAD SCI USA, V102, P9625, DOI 10.1073/pnas.0504126102
   Turner N, 2010, CANCER RES, V70, P2085, DOI 10.1158/0008-5472.CAN-09-3746
   Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087
   Wang Y, 2009, MOL CELL, V33, P428, DOI 10.1016/j.molcel.2009.02.002
   Yang ZQ, 2006, CANCER RES, V66, P11632, DOI 10.1158/0008-5472.CAN-06-2946
   Yang ZQ, 2007, INT J CANCER, V121, P1265, DOI 10.1002/ijc.22831
   Yang ZQ, 2009, INT J CANCER, V125, P1613, DOI 10.1002/ijc.24518
   Yang ZQ, 2004, CANCER GENET CYTOGEN, V155, P57, DOI 10.1016/j.cancergencyto.2004.03.013
   Yang ZQ, 2000, CANCER RES, V60, P4735
   Zhang JQ, 2009, J CLIN INVEST, V119, P2171, DOI 10.1172/JCI37622
   Zhang Y, 2009, CANCER RES, V69, P37, DOI 10.1158/0008-5472.CAN-08-1648
NR 41
TC 75
Z9 85
U1 1
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD NOV 1
PY 2010
VL 70
IS 21
BP 8487
EP 8497
DI 10.1158/0008-5472.CAN-10-1013
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 673MJ
UT WOS:000283667300027
PM 20940404
OA Green Accepted, Bronze, Green Submitted
DA 2025-01-12
ER

PT J
AU Yamamoto, M
   Ito, T
   Shimizu, T
   Ishida, T
   Semba, K
   Watanabe, S
   Yamaguchi, N
   Inoue, J
AF Yamamoto, Mizuki
   Ito, Taku
   Shimizu, Takafumi
   Ishida, Takaomi
   Semba, Kentaro
   Watanabe, Shinya
   Yamaguchi, Noritaka
   Inoue, Jun-ichiro
TI Epigenetic alteration of the NF-κB-inducing kinase (<i>NIK</i>) gene is
   involved in enhanced NIK expression in basal-like breast cancer
SO CANCER SCIENCE
LA English
DT Article
ID ALPHA-DEPENDENT APOPTOSIS; CELL-LINES; ACTIVATION; METHYLATION;
   PROLIFERATION; TRANSCRIPTION; PROGRESSION; MUTATIONS; SUBTYPES; PATHWAY
AB Basal-like breast cancers are triple-negative (estrogen receptor negative, progesterone receptor negative, erythroblastic leukemia viral oncogene homolog 2 (ERBB2) negative) tumors with an aggressive clinical behavior that lacks effective molecular targets for therapy. We reported previously that the basal-like subtype cell lines display high constitutive nuclear factor (NF)-kappa B activation, whose inhibition in the basal-like subtypes suppressed their proliferation. Moreover, NF-kappa B-inducing kinase (NIK) is involved in the constitutive NF-kappa B activation. Here, we report that enhanced NIK expression, which is exclusively observed in the basal-like subtype rather than the luminal-like subtype or non-tumorigenic mammary epithelial cells, is caused by epigenetic alteration of the NIK gene. The stability of NIK mRNA and transcriptional activity driven by the NIK promoter are similar in the basal-like and luminal-like subtypes. However, histone H3 acetylation levels were up-regulated in the basal-like subtype. Furthermore, treatment of the luminal-like subtype with a histone deacetylase inhibitor, valproic acid, significantly increased NIK expression. Although DNA methylation of the NIK locus was not detected, NIK expression also increased when the luminal-like subtype was treated with 5-azacytidine, which inhibits histone H3-Lys-9 dimethylation in addition to DNA methylation. Taken together, these results suggest that the closed chromatin structure mediated by histone H3 methylation and deacetylation suppresses NIK expression in the luminal-like subtype, whereas disruption of these suppression mechanisms leads to enhanced NIK expression and the constitutive NF-kappa B activation in the basal-like subtype. Thus, NIK and genes induced by the NIK-mediated constitutive NF-kappa B activation could be therapeutic targets of basal-like breast cancer. (Cancer Sci 2010; 101: 2391-2397).
C1 [Yamamoto, Mizuki; Ito, Taku; Yamaguchi, Noritaka; Inoue, Jun-ichiro] Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Cellular & Mol Biol,Minato Ku, Tokyo, Japan.
   [Shimizu, Takafumi] Univ Tokyo, Inst Med Sci, Lab Stem Cell Therapy, Minato Ku, Tokyo, Japan.
   [Ishida, Takaomi; Semba, Kentaro] Waseda Univ, Dept Life Sci & Med Biosci, Shinjuku Ku, Tokyo, Japan.
   [Watanabe, Shinya] Fukushima Med Univ, Translat Res Ctr, Dept Clin Genom, Tokyo Branch,Shibuya Ku, Tokyo, Japan.
C3 University of Tokyo; University of Tokyo; Waseda University
RP Inoue, J (通讯作者)，Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Cellular & Mol Biol,Minato Ku, Tokyo, Japan.
EM jun-i@ims.u-tokyo.ac.jp
RI Yamaguchi, Noritaka/HKN-7206-2023; Yamamoto, Mizuki/AAW-1688-2020
OI Yamamoto, Mizuki/0000-0003-3731-1702
FU Ministry of Education, Culture, Sports, Science and Technology, Japan;
   Waseda University; New Energy and Industrial Technology Development
   Organization; Princess Takamatsu Cancer Research Fund; Kanzawa Medical
   Research Foundation
FX This study was supported by: Grants-in-aid for Scientific Research on
   Priority Areas (J.I.) and Young Scientists B (N.Y.), "Establishment of
   Consolidated Research Institute for Advanced Science and Medical Care"
   Project (N.Y., K.S.) and High-Tech Research Center; a Project for
   Private Universities: matching fund subsidy (K.S.) from the Ministry of
   Education, Culture, Sports, Science and Technology, Japan; a Waseda
   University Grant for Special Research Projects (N.Y., K.S.); the
   "Translational Research Program" from the New Energy and Industrial
   Technology Development Organization (S.W.); and research grants from the
   Princess Takamatsu Cancer Research Fund (J.I.) and Kanzawa Medical
   Research Foundation (N.Y.). M.Y. is a research fellow of the Japan
   Society for the Promotion of Science.
CR Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Dambacher S, 2010, HEREDITY, V105, P24, DOI 10.1038/hdy.2010.49
   Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Inoue J, 2007, CANCER SCI, V98, P268, DOI 10.1111/j.1349-7006.2007.00389.x
   Ito E, 2007, FEBS LETT, V581, P3909, DOI 10.1016/j.febslet.2007.07.016
   Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870
   Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003
   Lee SH, 2009, ONCOGENE, V28, P184, DOI 10.1038/onc.2008.377
   Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Rakha EA, 2008, J CLIN ONCOL, V26, P2568, DOI 10.1200/JCO.2007.13.1748
   Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81
   Saitoh Y, 2008, BLOOD, V111, P5118, DOI 10.1182/blood-2007-09-110635
   Schmitz ML, 2004, CHEMBIOCHEM, V5, P1348, DOI 10.1002/cbic.200400144
   Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   SOULE HD, 1990, CANCER RES, V50, P6075
   Tachibana M, 2005, GENE DEV, V19, P815, DOI 10.1101/gad.1284005
   Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030
   Vargo-Gogola T, 2007, NAT REV CANCER, V7, P659, DOI 10.1038/nrc2193
   Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037
   Yamaguchi N, 2008, CANCER RES, V68, P1881, DOI 10.1158/0008-5472.CAN-07-1597
   Yamaguchi N, 2009, CANCER SCI, V100, P1668, DOI 10.1111/j.1349-7006.2009.01228.x
   Zarnegar BJ, 2008, NAT IMMUNOL, V9, P1371, DOI 10.1038/ni.1676
NR 27
TC 33
Z9 45
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD NOV
PY 2010
VL 101
IS 11
BP 2391
EP 2397
DI 10.1111/j.1349-7006.2010.01685.x
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 666YG
UT WOS:000283158300014
PM 20735436
OA hybrid
DA 2025-01-12
ER

PT J
AU Bapat, SA
   Jin, V
   Berry, N
   Balch, C
   Sharma, N
   Kurrey, N
   Zhang, S
   Fang, F
   Lan, X
   Li, M
   Kennedy, B
   Bigsby, RM
   Huang, THM
   Nephew, KP
AF Bapat, Sharmila A.
   Jin, Victor
   Berry, Nicholas
   Balch, Curt
   Sharma, Neeti
   Kurrey, Nawneet
   Zhang, Shu
   Fang, Fang
   Lan, Xun
   Li, Meng
   Kennedy, Brian
   Bigsby, Robert M.
   Huang, Tim H. M.
   Nephew, Kenneth P.
TI Multivalent epigenetic marks confer microenvironment-responsive
   epigenetic plasticity to ovarian cancer cells
SO EPIGENETICS
LA English
DT Article
DE histone modifications; gene expression; chromatin remodeling; ovarian
   cancer; epigenetic plasticity; tumor microenvironment; bivalent histone
   mark
ID EMBRYONIC STEM-CELLS; EPITHELIAL-MESENCHYMAL TRANSITION;
   TUMOR-SUPPRESSOR GENES; DNA METHYLATION; BREAST-CANCER; PHENOTYPIC
   PLASTICITY; SURFACE EPITHELIUM; CHROMATIN PATTERN; MIR-200 FAMILY;
   MAMMARY-GLAND
AB "Epigenetic plasticity" refers to the capability of mammalian cells to alter their differentiation status via chromatin remodeling-associated alterations in gene expression. While epigenetic plasticity has been best associated with lineage commitment of embryonic stem cells, recent studies have demonstrated chromatin remodeling even in terminally differentiated normal cells and advanced-stage melanoma and breast cancer cells, in context-dependent responses to alterations in their microenvironment. In the current study, we extend this attribute of epigenetic plasticity to aggressive ovarian cancer cells, by using an integrative approach to associate cellular phenotypes with chromatin modifications ("ChIP-chip") and mRNA and microRNA expression. While we identified numerous gene promoters possessing the well-known "bivalent mark" of H3K27me3/H3K4me2, we also report 14 distinct, lesser known bi-, tri- and tetravalent combinations of activating and repressive chromatin modifications, in platinum-resistant CP70 ovarian cancer cells. The vast majority (>90%) of all the histone marks studied localized to regions within 2,000 bp of transcription start sites, supporting a role in gene regulation. Upon a simple alteration in the microenvironment, transition from two-to three-dimensional culture, an increase (17-38%) in repressive-only marked promoters was observed, concomitant with a decrease (31-21%) in multivalent (i.e., juxtaposed permissive and repressive histone marked) promoters. Like embryonic/tissue stem and other (non-ovarian) carcinoma cells, ovarian cancer cell epigenetic plasticity reflects an inherent transcriptional flexibility for context-responsive alterations in phenotype. It is possible that this plasticity could be therapeutically exploited for the management of this lethal gynecologic malignancy.
C1 [Berry, Nicholas; Balch, Curt; Zhang, Shu; Fang, Fang; Li, Meng; Nephew, Kenneth P.] Indiana Univ, Sch Med, Bloomington, IN 47405 USA.
   [Balch, Curt; Nephew, Kenneth P.] Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN USA.
   [Bigsby, Robert M.; Nephew, Kenneth P.] Indiana Univ, Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA.
   [Balch, Curt; Bigsby, Robert M.; Nephew, Kenneth P.] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA.
   [Bapat, Sharmila A.; Berry, Nicholas; Sharma, Neeti; Kurrey, Nawneet] Natl Ctr Cell Sci, Pune, Maharashtra, India.
   [Jin, Victor; Lan, Xun; Kennedy, Brian] Ohio State Univ, Ctr Comprehens Canc, Dept Biomed Informat, Columbus, OH 43210 USA.
   [Huang, Tim H. M.] Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Columbus, OH 43210 USA.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Indianapolis; Indiana University
   System; Indiana University Indianapolis; Indiana University System;
   Indiana University Indianapolis; Department of Biotechnology (DBT)
   India; National Centre for Cell Science, Pune (NCCS); James Cancer
   Hospital & Solove Research Institute; University System of Ohio; Ohio
   State University; University System of Ohio; Ohio State University;
   James Cancer Hospital & Solove Research Institute
RP Nephew, KP (通讯作者)，Indiana Univ, Sch Med, Bloomington, IN 47405 USA.
EM sabapat@nccs.res.in; knephew@indiana.edu
RI Sharma, Neeti/L-6282-2019; Bapat, Sharmila/AGU-4130-2022; Kurrey,
   Nawneet/M-1557-2013
OI Kurrey, Nawneet/0000-0001-7550-6549; Lan, Xun/0000-0002-6523-046X;
   Sharma, Neeti/0000-0002-4457-5717; Bapat, Sharmila/0000-0002-9557-2233
FU National Cancer Institute [CA113001, CA085289]; NCCS; Department of
   Biotechnology, Govt. of India; Council of Scientific & Industrial
   Research, India; Indiana University; Andrea Caperell; Indiana Genomics
   Initiative of Indiana University, INGEN; Lilly Endowment, Inc.
FX The authors thank Henry Paik for bioinformatics assistance. This work
   was funded by National Cancer Institute awards CA113001 (to T.H.-M.H.)
   and CA085289 (to K.P.N.) and an NCCS Institutional Grant (to S. A. B.).
   S. A. B. received a Short-Term Overseas Fellowship from the Department
   of Biotechnology, Govt. of India. N.S. and N.K. receive a Senior
   Research Fellowship from the Council of Scientific & Industrial
   Research, India. N.B. received a postdoctoral Bridge Fellowship from
   Indiana University. The authors also wish to thank Andrea Caperell-Grant
   (Indiana University Department of Obstetrics and Gynecology) for
   establishment of normal ovarian surface epithelial (nOSE) cell primary
   cultures used in the study. The microarray studies were performed at the
   Center for Medical Genomics, Indiana University School of Medicine (Dr.
   H.J. Edenberg, Director), supported in part by the Indiana Genomics
   Initiative of Indiana University, INGEN, which is supported in part by
   the Lilly Endowment, Inc. All analyzed data sets can be obtained from
   www.broad.mit.edu/seq_platform/chip/.
CR Abbosh PH, 2006, CANCER RES, V66, P5582, DOI 10.1158/0008-5472.CAN-05-3575
   Ahluwalia A, 2001, GYNECOL ONCOL, V82, P299, DOI 10.1006/gyno.2001.6284
   Ahmed N, 2007, J CELL PHYSIOL, V213, P581, DOI 10.1002/jcp.21240
   Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255
   Balch C, 2007, BIOESSAYS, V29, P842, DOI 10.1002/bies.20619
   Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931
   Bendoraite A, 2010, GYNECOL ONCOL, V116, P117, DOI 10.1016/j.ygyno.2009.08.009
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096
   Bissell MJ, 2005, CANCER CELL, V7, P17, DOI 10.1016/j.ccr.2004.12.013
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Bryant RJ, 2007, PROSTATE, V67, P547, DOI 10.1002/pros.20550
   Campos EI, 2009, ANNU REV GENET, V43, P559, DOI 10.1146/annurev.genet.032608.103928
   Cicero SA, 2009, P NATL ACAD SCI USA, V106, P6685, DOI 10.1073/pnas.0901596106
   Corney DC, 2008, HISTOL HISTOPATHOL, V23, P1161, DOI 10.14670/HH-23.1161
   Corney DC, 2007, CANCER RES, V67, P8433, DOI 10.1158/0008-5472.CAN-07-1585
   Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854
   Huangfu DW, 2008, NAT BIOTECHNOL, V26, P1269, DOI 10.1038/nbt.1502
   Dreesen O, 2007, STEM CELL REV, V3, P7, DOI 10.1007/s12015-007-0004-8
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Ekins S, 2007, METH MOL B, V356, P319
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fan MY, 2006, CANCER RES, V66, P11954, DOI 10.1158/0008-5472.CAN-06-1666
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   Giannakakis A, 2007, EXPERT OPIN BIOL TH, V7, P1375, DOI 10.1517/14712598.7.9.1375
   Gillis AJM, 2007, J PATHOL, V213, P319, DOI 10.1002/path.2230
   Golmohammadi MG, 2008, STEM CELLS, V26, P979, DOI 10.1634/stemcells.2007-0919
   Graf T, 2009, NATURE, V462, P587, DOI 10.1038/nature08533
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Hendrix MJC, 2007, NAT REV CANCER, V7, P246, DOI 10.1038/nrc2108
   Hochedlinger K, 2009, DEVELOPMENT, V136, P509, DOI 10.1242/dev.020867
   Hudson LG, 2008, CLIN EXP METASTAS, V25, P643, DOI 10.1007/s10585-008-9171-5
   Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jin VX, 2006, GENOME RES, V16, P1585, DOI 10.1101/gr.5520206
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jordan CT, 2009, CELL STEM CELL, V4, P203, DOI 10.1016/j.stem.2009.02.003
   Katz E, 2009, CLIN CANCER RES, V15, P70, DOI 10.1158/1078-0432.CCR-08-1233
   Ke XS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004687
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200
   Kudo-Saito C, 2009, CANCER CELL, V15, P195, DOI 10.1016/j.ccr.2009.01.023
   Kusumbe AP, 2009, STEM CELLS, V27, P498, DOI 10.1634/stemcells.2008-0868
   L'Espérance S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-99
   Li L, 2010, J CELL SCI, V123, P853, DOI 10.1242/jcs.061598
   Li M, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-34
   Liao MJ, 2007, CANCER RES, V67, P8131, DOI 10.1158/0008-5472.CAN-06-4493
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Maherali N, 2007, CELL STEM CELL, V1, P55, DOI 10.1016/j.stem.2007.05.014
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Marson A, 2008, CELL, V134, P521, DOI 10.1016/j.cell.2008.07.020
   McGarvey KM, 2008, CANCER RES, V68, P5753, DOI 10.1158/0008-5472.CAN-08-0700
   Mohn F, 2008, MOL CELL, V30, P755, DOI 10.1016/j.molcel.2008.05.007
   Morroni M, 2004, P NATL ACAD SCI USA, V101, P16801, DOI 10.1073/pnas.0407647101
   Moss NM, 2009, CANCER RES, V69, P7121, DOI 10.1158/0008-5472.CAN-08-4151
   Nam S, 2009, NUCLEIC ACIDS RES, V37, pW356, DOI 10.1093/nar/gkp294
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Pan GJ, 2007, CELL STEM CELL, V1, P299, DOI 10.1016/j.stem.2007.08.003
   Papageorgis P, 2010, CANCER RES, V70, P968, DOI 10.1158/0008-5472.CAN-09-1872
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Postovit LM, 2008, P NATL ACAD SCI USA, V105, P4329, DOI 10.1073/pnas.0800467105
   Qin HX, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-73
   Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918
   Rice JC, 2001, NATURE, V414, P258, DOI 10.1038/35104721
   Rodriguez J, 2008, P NATL ACAD SCI USA, V105, P19809, DOI 10.1073/pnas.0810133105
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157
   Shell S, 2007, P NATL ACAD SCI USA, V104, P11400, DOI 10.1073/pnas.0704372104
   Shen CN, 2000, NAT CELL BIOL, V2, P879, DOI 10.1038/35046522
   Shield K, 2009, GYNECOL ONCOL, V113, P143, DOI 10.1016/j.ygyno.2008.11.032
   Sood AK, 2001, AM J PATHOL, V158, P1279, DOI 10.1016/S0002-9440(10)64079-5
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Suvà ML, 2009, CANCER RES, V69, P9211, DOI 10.1158/0008-5472.CAN-09-1622
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103
   Thomson JM, 2004, NAT METHODS, V1, P47, DOI 10.1038/NMETH704
   Tsuda N, 2005, INT J ONCOL, V27, P1299
   Weishaupt H, 2010, BLOOD, V115, P247, DOI 10.1182/blood-2009-07-235176
   Wernig M, 2008, NAT BIOTECHNOL, V26, P916, DOI 10.1038/nbt1483
   Xin FX, 2009, BIOINFORMATICS, V25, P430, DOI 10.1093/bioinformatics/btn646
   Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103
   Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364
NR 85
TC 39
Z9 44
U1 1
U2 13
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD NOV-DEC
PY 2010
VL 5
IS 8
BP 716
EP 729
DI 10.4161/epi.5.8.13014
PG 14
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 680VH
UT WOS:000284263500007
PM 20676026
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Richter, AM
   Schagdarsurengin, U
   Rastetter, M
   Steinmann, K
   Dammann, RH
AF Richter, Antje M.
   Schagdarsurengin, Undraga
   Rastetter, Matthias
   Steinmann, Katrin
   Dammann, Reinhard H.
TI Protein kinase A-mediated phosphorylation of the RASSF1A tumour
   suppressor at Serine 203 and regulation of RASSF1A function
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE RASSF1A; Tumour suppressor PKA; Phosphorylation; Apoptosis
ID PROMOTES APOPTOSIS; CELL-PROLIFERATION; FAMILY PROTEIN; BREAST-CANCER;
   AURORA-A; HIPPO; RAS; IDENTIFICATION; DROSOPHILA; 3P21.3
AB Epigenetic inactivation of the Ras Association Domain Family 1A (RASSF1A) gene is one of the most frequent alterations detected in cancer The tumour suppressor function of RASSF1A contributes to cell cycle progression microtubule stabilisation and apoptotic signalling Here we investigated the putative phosphorylation sites of RASSF1A and the functional consequences RASSF1A is mainly phosphorylated at Serine 203 within its Ras association domain Phosphorylation at this site is accomplished by protein kinase A (PKA) and is reduced and elevated by PKA specific inhibitors and activators respectively Functionally an alanine substitution of Serine 203 (S203A) slightly affected the microtubule stability mediated by RASSF1A (p <0 05) Interestingly the inhibition of PICA and the S203A substitution of RASSF1A resulted in a reduced rate of apoptotic cells induced by RASSF1A More over RASSF1A mediated upregulation of p21 and BAX was observed This induction was reduced when the S203A substitution was present or when PICA activity was inhibited In summary our data show that RASSF1A is phosphorylated by PKA and this phosphorylation may affect apoptotic signalling of RASSF1A Thus epigenetic silencing of RASSF1A may counteract its proapoptotic function in cancer (C) 2010 Elsevier Ltd All rights reserved
C1 [Richter, Antje M.; Schagdarsurengin, Undraga; Rastetter, Matthias; Steinmann, Katrin; Dammann, Reinhard H.] Univ Giessen, Inst Genet, D-35392 Giessen, Germany.
C3 Justus Liebig University Giessen
RP Dammann, RH (通讯作者)，Univ Giessen, Inst Genet, Heinrich Buff Ring 58 62, D-35392 Giessen, Germany.
RI Schagdarsurengin, Undraga/AAH-4312-2020
OI Schagdarsurengin, Undraga/0000-0003-0127-4938
FU German Research Council (DFG) [DA552]
FX This work was supported by a Grant DA552 from the German Research
   Council (DFG) to Reinhard H Dammann This organisation had no involvement
   in the study design, in the acquisition, analysis and interpretation of
   data in the writing of the manuscript and in the decision to submit the
   manuscript for publication
CR Collins SP, 2000, BIOCHEM J, V345, P673, DOI 10.1042/0264-6021:3450673
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   De Laurenzi V, 2000, ANN NY ACAD SCI, V926, P90
   Downward J, 2008, MOL CELL, V32, P749, DOI 10.1016/j.molcel.2008.12.002
   Gao BN, 2008, CANCER RES, V68, P22, DOI 10.1158/0008-5472.CAN-07-5183
   Hamilton G, 2009, CURR BIOL, V19, P2020, DOI 10.1016/j.cub.2009.10.040
   Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9
   Hay BA, 2003, DEV CELL, V5, P361, DOI 10.1016/S1534-5807(03)00270-3
   Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538
   Lerman MI, 2000, CANCER RES, V60, P6116
   Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035
   Liu L, 2008, ONCOGENE, V27, P6175, DOI 10.1038/onc.2008.220
   Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984
   Matallanas D, 2007, MOL CELL, V27, P962, DOI 10.1016/j.molcel.2007.08.008
   NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6
   Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584
   Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8
   Praskova M, 2004, BIOCHEM J, V381, P453, DOI 10.1042/BJ20040025
   Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004
   Rong R, 2007, ONCOGENE, V26, P7700, DOI 10.1038/sj.onc.1210575
   Schagdarsurengin U, 2005, INT J ONCOL, V27, P185
   Scheel H, 2003, CURR BIOL, V13, pR899, DOI 10.1016/j.cub.2003.11.007
   Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858
   Song SJ, 2009, CANCER RES, V69, P8540, DOI 10.1158/0008-5472.CAN-09-1554
   Song SJ, 2009, CANCER RES, V69, P2314, DOI 10.1158/0008-5472.CAN-08-3984
   TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2
   Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3
   Thaler S, 2009, CANCER RES, V69, P1748, DOI 10.1158/0008-5472.CAN-08-1377
   The I, 1997, SCIENCE, V276, P791, DOI 10.1126/science.276.5313.791
   Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747
   Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439
   Verma SK, 2008, FEBS LETT, V582, P2270, DOI 10.1016/j.febslet.2008.05.028
   Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X
   Ye KQ, 2007, CELL ADHES MIGR, V1, P196, DOI 10.4161/cam.1.4.5192
   Ye Y, 1996, EMBO J, V15, P5606, DOI 10.1002/j.1460-2075.1996.tb00945.x
   Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011
NR 36
TC 14
Z9 16
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
EI 1879-0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD NOV
PY 2010
VL 46
IS 16
BP 2986
EP 2995
DI 10.1016/j.ejca.2010.06.128
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 689ZA
UT WOS:000284968400022
PM 20655196
DA 2025-01-12
ER

PT J
AU Tsai, KW
   Hu, LY
   Wu, CW
   Li, SC
   Lai, CH
   Kao, HW
   Fang, WL
   Lin, WC
AF Tsai, Kuo-Wang
   Hu, Ling-Yueh
   Wu, Chew-Wun
   Li, Sung-Chou
   Lai, Chun-Hung
   Kao, Hsiao-Wei
   Fang, Wen-Liang
   Lin, Wen-chang
TI Epigenetic Regulation of miR-196b Expression in Gastric Cancer
SO GENES CHROMOSOMES & CANCER
LA English
DT Article
ID DNA METHYLATION; MICRORNA EXPRESSION; COLORECTAL-CANCER;
   GENE-EXPRESSION; BREAST-CANCER; MESSENGER-RNA; IN-VITRO; BINDING;
   PROTEINS; PROMOTER
AB MicroRNAs (miRNAs) are short noncoding RNAs that play important roles in cellular processes and disease pathogenesis via the control of specific targeted gene expression. The miR-196s miRNA is encoded at three paralogous loci in three HOX clusters and acts as an oncogenic miRNA in cancer progression. Recent studies have demonstrated that the expression of miR-196b increases cell proliferation and survival in leukemic cells. Here, we used a sequential methylation analysis to reveal that the methylation status correlated well with miR-196b expression in different cell lines. Treatment with the demethylating drug 5-Aza-dC reactivated miR-196b transcription in methylation-silenced cells. Using in vitro methylation approach, we further provide evidences that promoter hypermethylation represses miR-196b transcriptional activation tightly in human cancer cell lines. We also demonstrate that the expression of miR-196b is significantly elevated in gastric cancer and that hypomethylation status of miR-196b CpG islands frequently is observed in primary gastric tumors. Our results provide important information on miR-196s regulation and demonstrate that abnormal DNA hypomethylation induces overexpression of miR-196b in gastric cancer. (C) 2010 Wiley-Liss, Inc.
C1 [Tsai, Kuo-Wang; Hu, Ling-Yueh; Li, Sung-Chou; Lai, Chun-Hung; Kao, Hsiao-Wei; Lin, Wen-chang] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan.
   [Wu, Chew-Wun; Fang, Wen-Liang] Vet Gen Hosp, Dept Surg, Taipei 11217, Taiwan.
   [Li, Sung-Chou; Lin, Wen-chang] Natl Yang Ming Univ, Inst Biomed Informat, Taipei 112, Taiwan.
   [Li, Sung-Chou] Acad Sinica, Taiwan Int Grad Program, Bioinformat Program, Taipei 115, Taiwan.
C3 Academia Sinica - Taiwan; National Yang Ming Chiao Tung University;
   Academia Sinica - Taiwan
RP Lin, WC (通讯作者)，Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan.
EM wenlin@ibms.sinica.edu.tw
RI Lin, Wen-chang/ABH-7976-2020; Lin, Wen-chang/B-3100-2011; Li,
   Sung-Chou/AGZ-8626-2022; Tsai, Kuo-Wang/AFS-8885-2022
OI Lin, Wen-chang/0000-0003-0194-1745; Li, Sung-Chou/0000-0002-3016-9718;
   Tsai, Kuo-Wang/0000-0002-9028-9834
FU Academia Sinica; National Science Council, Taiwan
FX Supported by: Academia Sinica and National Science Council, Taiwan.
CR Balch C, 2009, ENDOCRINOLOGY, V150, P4003, DOI 10.1210/en.2009-0404
   Bandres E, 2009, INT J CANCER, V125, P2737, DOI 10.1002/ijc.24638
   Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159
   Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406
   Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178
   Choi YS, 2004, BIOCHEM BIOPH RES CO, V314, P118, DOI 10.1016/j.bbrc.2003.12.065
   Cierpicki T, 2010, NAT STRUCT MOL BIOL, V17, P62, DOI 10.1038/nsmb.1714
   Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256
   Cui L, 2008, CLIN CANCER RES, V14, P7674, DOI 10.1158/1078-0432.CCR-08-0420
   Erfurth FE, 2008, P NATL ACAD SCI USA, V105, P7517, DOI 10.1073/pnas.0800090105
   GASTON K, 1995, NUCLEIC ACIDS RES, V23, P901, DOI 10.1093/nar/23.6.901
   Grady WM, 2008, ONCOGENE, V27, P3880, DOI 10.1038/onc.2008.10
   Hoffman AE, 2009, CANCER RES, V69, P5970, DOI 10.1158/0008-5472.CAN-09-0236
   Hornstein E, 2005, NATURE, V438, P671, DOI 10.1038/nature04138
   Huang YW, 2009, CANCER RES, V69, P9038, DOI 10.1158/0008-5472.CAN-09-1499
   Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317
   Januchowski Radoslaw, 2004, Journal of Applied Genetics, V45, P237
   Jun HJ, 2009, CANCER RES, V69, P2180, DOI 10.1158/0008-5472.CAN-08-3351
   Kim TY, 2004, ALIMENT PHARM THER, V20, P131, DOI 10.1111/j.1365-2036.2004.01984.x
   Kim VN, 2005, MOL CELLS, V19, P1
   Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194
   KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Lewis A, 2004, NAT GENET, V36, P1291, DOI 10.1038/ng1468
   Liang Y, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-166
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   Luthra R, 2008, ONCOGENE, V27, P6667, DOI 10.1038/onc.2008.256
   Mansfield JH, 2004, NAT GENET, V36, P1079, DOI 10.1038/ng1421
   Maru DM, 2009, AM J PATHOL, V174, P1940, DOI 10.2353/ajpath.2009.080718
   McGlinn E, 2009, P NATL ACAD SCI USA, V106, P18610, DOI 10.1073/pnas.0910374106
   Meola Nicola, 2009, Pathogenetics, V2, P7, DOI 10.1186/1755-8417-2-7
   Momparler RL, 2005, SEMIN ONCOL, V32, P443, DOI 10.1053/j.seminoncol.2005.07.008
   Oue N, 2001, ONCOL REP, V8, P1085
   Popovic R, 2009, BLOOD, V113, P3314, DOI 10.1182/blood-2008-04-154310
   Rabbani SA, 2008, NEOPLASIA, V10, P266, DOI 10.1593/neo.07947
   Rountree MR, 1997, GENE DEV, V11, P2383, DOI 10.1101/gad.11.18.2383
   Saini HK, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-564
   Schimanski CC, 2009, WORLD J GASTROENTERO, V15, P2089, DOI 10.3748/wjg.15.2089
   Shukeir N, 2006, CANCER RES, V66, P9202, DOI 10.1158/0008-5472.CAN-06-1954
   Sunahori K, 2009, J IMMUNOL, V182, P1500, DOI 10.4049/jimmunol.182.3.1500
   TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M
   Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434
   Zhou XF, 2007, PLOS COMPUT BIOL, V3, P412, DOI 10.1371/journal.pcbi.0030037
NR 44
TC 88
Z9 100
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1045-2257
EI 1098-2264
J9 GENE CHROMOSOME CANC
JI Gene Chromosomes Cancer
PD NOV
PY 2010
VL 49
IS 11
BP 969
EP 980
DI 10.1002/gcc.20804
PG 12
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA 654SG
UT WOS:000282188000001
PM 20662076
DA 2025-01-12
ER

PT J
AU Polo, SE
   Theocharis, SE
   Grandin, L
   Gambotti, L
   Antoni, G
   Savignoni, A
   Asselain, B
   Patsouris, E
   Almouzni, G
AF Polo, Sophie E.
   Theocharis, Stamatios E.
   Grandin, Laure
   Gambotti, Laetitia
   Antoni, Guillemette
   Savignoni, Alexia
   Asselain, Bernard
   Patsouris, Efstratios
   Almouzni, Genevieve
TI Clinical significance and prognostic value of chromatin assembly
   factor-1 overexpression in human solid tumours
SO HISTOPATHOLOGY
LA English
DT Article
DE carcinoma; chromatin assembly; marker; prognosis; proliferation
ID DNA-REPLICATION INVITRO; HUMAN-CELLS; EPIGENETIC CHANGES; STRAND BREAKS;
   CANCER; REPAIR; CAF-1; PROLIFERATION; BEHAVIOR; MARKERS
AB Aims: Chromatin assembly factor-1 (CAF-1), whose function is critical for maintaining chromatin stability during DNA replication and repair, has been identified as a proliferation marker in breast cancer. The aim was to investigate CAF-1 as a proliferation marker in a wide variety of solid tumours, and to assess its potential value in predicting clinical outcome.
   Methods and results: Using immunocytochemistry on paraffin-embedded tissue sections, the CAF-1 labelling index was compared with known proliferation markers Ki-67 and minichromosome maintenance (MCM), and its association with clinicopathological data and patients' outcome analysed. CAF-1 expression showed a strong positive correlation with Ki-67, used routinely to detect proliferating cells, while it generally displayed weaker correlations with MCM markers, known to label cells with replicative potential. CAF-1 expression was associated significantly with histological grade in breast, cervical, endometrial and renal cell carcinomas, and with disease stage in endometrial and renal carcinomas. Furthermore, high expression of CAF-1 was an independent predictor of adverse clinical outcome in renal, endometrial and cervical carcinomas.
   Conclusions: CAF-1 is a proliferation marker in various malignant tumours with prognostic value in renal, endometrial and cervical carcinomas, which supports the value of CAF-1 as a clinical marker of cancer progression.
C1 [Polo, Sophie E.; Almouzni, Genevieve] Inst Curie, CNRS, Curie UMR218, F-75248 Paris 5, France.
   [Grandin, Laure; Gambotti, Laetitia; Antoni, Guillemette; Savignoni, Alexia; Asselain, Bernard] Inst Curie, Dept Biostat, F-75248 Paris 5, France.
   [Patsouris, Efstratios] Univ Athens, Sch Med, Dept Pathol 1, GR-11527 Athens, Greece.
   [Theocharis, Stamatios E.] Univ Athens, Sch Med, Dept Forens Med & Toxicol, GR-11527 Athens, Greece.
C3 Universite PSL; UNICANCER; Institut Curie; Centre National de la
   Recherche Scientifique (CNRS); UNICANCER; Universite PSL; Institut
   Curie; National & Kapodistrian University of Athens; Athens Medical
   School; Athens Medical School; National & Kapodistrian University of
   Athens
RP Almouzni, G (通讯作者)，Inst Curie, CNRS, UMR218, 26 Rue Ulm, F-75248 Paris 5, France.
EM genevieve.almouzni@curie.fr
RI Almouzni, Genevieve/ABG-1029-2021
OI Polo, Sophie/0000-0003-4821-9354
FU la Ligue Nationale contre le Cancer (Equipe labellisee la Ligue);
   European Commission Network of Excellence [LSHG-CT-2004-503433]; RTN
   [HPRN-CT-2002-00238]; ACI-DRAB [04393]; Curie Institute; CEA; Human
   Frontier Science Program Organization; ACI-2007-Canceropole IdF 'Breast
   Cancer and Epigenetics'
FX This work was supported by la Ligue Nationale contre le Cancer (Equipe
   labellisee la Ligue), ACI-2007-Canceropole IdF 'Breast Cancer and
   Epigenetics', the European Commission Network of Excellence Epigenome
   (LSHG-CT-2004-503433), contract RTN (HPRN-CT-2002-00238), ACI-DRAB (no.
   04393) and a collaborative programme 'Parametres Epigenetiques' between
   the Curie Institute and the CEA. S.E.P. was supported by an ARC
   fellowship followed by a postdoctoral fellowship from Human Frontier
   Science Program Organization. We thank Faculty Members of the Medical
   School of the University of Athens (E. Agapitos, S. Tseleni, A. Kyroudi,
   G. Kouraklis, D. Mytropoulos) for samples and clinical data collection.
CR Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096
   BROWN DC, 1990, HISTOPATHOLOGY, V17, P489, DOI 10.1111/j.1365-2559.1990.tb00788.x
   Corpet A, 2009, TRENDS CELL BIOL, V19, P29, DOI 10.1016/j.tcb.2008.10.002
   De Koning L, 2007, NAT STRUCT MOL BIOL, V14, P997, DOI 10.1038/nsmb1318
   Esteller M, 2006, BRIT J CANCER, V94, P179, DOI 10.1038/sj.bjc.6602918
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Freeman A, 1999, CLIN CANCER RES, V5, P2121
   Gaillard PHL, 1996, CELL, V86, P887, DOI 10.1016/S0092-8674(00)80164-6
   Gonzalez MA, 2005, NAT REV CANCER, V5, P135, DOI 10.1038/nrc1548
   Green CM, 2003, EMBO J, V22, P5163, DOI 10.1093/emboj/cdg478
   Groth A, 2007, CELL, V128, P721, DOI 10.1016/j.cell.2007.01.030
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hoek M, 2003, P NATL ACAD SCI USA, V100, P12183, DOI 10.1073/pnas.1635158100
   Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596
   Iacobuzio-Donahue CA, 2009, ANNU REV PATHOL-MECH, V4, P229, DOI 10.1146/annurev.pathol.3.121806.151442
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7
   KORNBERG RD, 1977, ANNU REV BIOCHEM, V46, P931, DOI 10.1146/annurev.bi.46.070177.004435
   Kurdistani SK, 2007, BRIT J CANCER, V97, P1, DOI 10.1038/sj.bjc.6603844
   Lan L, 2004, P NATL ACAD SCI USA, V101, P13738, DOI 10.1073/pnas.0406048101
   Liontos M, 2007, CANCER RES, V67, P10899, DOI 10.1158/0008-5472.CAN-07-2837
   Martini E, 1998, J CELL BIOL, V143, P563, DOI 10.1083/jcb.143.3.563
   Nabatiyan A, 2004, MOL CELL BIOL, V24, P2853, DOI 10.1128/MCB.24.7.2853-2862.2004
   Nabatiyan A, 2006, MOL CELL BIOL, V26, P1839, DOI 10.1128/MCB.26.5.1839-1849.2006
   Okano S, 2003, MOL CELL BIOL, V23, P3974, DOI 10.1128/MCB.23.11.3974-3981.2003
   Özdag H, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-90
   Polo SE, 2006, CURR OPIN GENET DEV, V16, P104, DOI 10.1016/j.gde.2006.02.011
   Polo SE, 2004, CANCER RES, V64, P2371, DOI 10.1158/0008-5472.CAN-03-2893
   Polo SE, 2006, CELL, V127, P481, DOI 10.1016/j.cell.2006.08.049
   Qiu W, 2008, NAT GENET, V40, P650, DOI 10.1038/ng.117
   Sawyers CL, 2008, NATURE, V452, P548, DOI 10.1038/nature06913
   SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X
   Staibano S, 2007, HISTOPATHOLOGY, V50, P911, DOI 10.1111/j.1365-2559.2007.02698.x
   Staibano S, 2009, HISTOPATHOLOGY, V54, P580, DOI 10.1111/j.1365-2559.2009.03266.x
   STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4
   Stoeber K, 2001, J CELL SCI, V114, P2027
   Tachibana KEK, 2005, J PATHOL, V205, P123, DOI 10.1002/path.1708
   Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4
   Ward RJ, 2007, ANNU REV PATHOL-MECH, V2, P175, DOI 10.1146/annurev.pathol.2.010506.091847
   Whitfield ML, 2006, NAT REV CANCER, V6, P99, DOI 10.1038/nrc1802
   Ye XF, 2003, MOL CELL, V11, P341, DOI 10.1016/S1097-2765(03)00037-6
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
NR 46
TC 42
Z9 50
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0309-0167
EI 1365-2559
J9 HISTOPATHOLOGY
JI Histopathology
PD NOV
PY 2010
VL 57
IS 5
BP 716
EP 724
DI 10.1111/j.1365-2559.2010.03681.x
PG 9
WC Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Pathology
GA 681MQ
UT WOS:000284320300007
PM 21083601
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Li, LA
   Lee, KM
   Han, W
   Choi, JY
   Lee, JY
   Kang, GH
   Park, SK
   Noh, DY
   Yoo, KY
   Kang, D
AF Li, Lian
   Lee, Kyoung-Mu
   Han, Wonshik
   Choi, Ji-Yeob
   Lee, Ji-Young
   Kang, Gyeong Hoon
   Park, Sue Kyung
   Noh, Dong-Young
   Yoo, Keun-Young
   Kang, Daehee
TI Estrogen and progesterone receptor status affect genome-wide DNA
   methylation profile in breast cancer
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID RISK-FACTORS; EXPRESSION; GENES; TUMORS
AB DNA methylation is the main epigenetic modification that occurs at the early stages of carcinogenesis. We performed a genome-wide DNA methylation profiling to evaluate whether the DNA methylation state is different in the estrogen receptor (ER) and progesterone receptor (PR) status of breast cancer. Twelve ER+/PR+ and 12 ER-/PR- breast cancer tissues were selected from the biorepository of the Seoul Breast Cancer Study for Infinium Methylation Assay. The difference of the DNA methylation state of 27 578 methylation sites in 14 000 genes between two groups was evaluated by Student's t-test. False discovery rate (FDR) was estimated to evaluate the probability of false positive associations. Of the 27 578 sites, 148 sites (0.54%) were significantly different between ER+/PR+ and ER-/PR- breast cancers (P < 0.001); 93 hypermethylated and 55 hypomethylated. Five genes, FAM124B (P = 7.26 x 10(-7)), MANEAL (P = 3.38 x 10(-7)), ST6GALNAC1 (P = 2.85 x 10(-6)), NAV1 (P = 5.94 x 10(-6)) and PER1 (P = 6.45 x 10(-6)) remained significant after correction for multiple tests (FDR < 0.05). In a subsequent replication study for five genes, four of the five genes were validated; FAM124B and ST6GALNAC1 were significantly hypermethylated, and NAV1 and PER1 were significantly hypomethylated in ER+/PR+ breast cancers (P < 0.05). In the first genome-wide DNA methylation profiling according to the receptor status of breast cancer, we found that ER/PR status affects the DNA methylation state of FAM124B, ST6GALNAC1, NAV1 and PER1 in breast cancer.
C1 [Kang, Daehee] Seoul Natl Univ, Coll Med, Dept Prevent Med, Mol & Genet Epidemiol Lab, Seoul 110799, South Korea.
   [Li, Lian; Han, Wonshik; Kang, Gyeong Hoon; Park, Sue Kyung; Noh, Dong-Young; Kang, Daehee] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 110799, South Korea.
   [Han, Wonshik; Noh, Dong-Young] Seoul Natl Univ, Coll Med, Dept Surg, Seoul 110799, South Korea.
   [Kang, Gyeong Hoon] Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 110799, South Korea.
   [Lee, Kyoung-Mu] Seoul Natl Univ Hosp, Clin Res Inst, Seoul 110744, South Korea.
   [Choi, Ji-Yeob] Inje Univ, Coll Med, Pharmacogenom Res Ctr, Pusan, South Korea.
   [Kang, Daehee] Seoul Natl Univ, Coll Med, Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Sci, Seoul 110799, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU); Seoul National University Hospital; Inje
   University; Seoul National University (SNU)
RP Kang, D (通讯作者)，Seoul Natl Univ, Coll Med, Dept Prevent Med, Mol & Genet Epidemiol Lab, 28 Yongon Dong, Seoul 110799, South Korea.
EM dhkang@snu.ac.kr
RI Park, Sue/J-2757-2012; Yoo, Keun-Young/J-5548-2012; Noh,
   Dong-Young/G-5531-2011; Choi, Ji-Yeob/J-2796-2012; Lee,
   Hyo-Suk/J-5618-2012; Kang, Dae/E-8631-2012; Han, Wonshik/B-3699-2008;
   Kang, Gyeong Hoon/F-1051-2010
OI Kang, Gyeong Hoon/0000-0003-2380-6675; Kang, Daehee/0000-0003-4031-5878
FU Ministry of Education, Science and Technology [2009-0089141]
FX This work was supported by the Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education, Science and Technology (2009-0089141).
CR Althuis MD, 2004, CANCER EPIDEM BIOMAR, V13, P1558
   Andre F, 2006, NAT CLIN PRACT ONCOL, V3, P621, DOI 10.1038/ncponc0636
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706
   Colditz GA, 2004, JNCI-J NATL CANCER I, V96, P218, DOI 10.1093/jnci/djh025
   Creighton CJ, 2009, BREAST CANCER RES TR, V114, P287, DOI 10.1007/s10549-008-0017-2
   Feng W, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1762
   Han W, 2008, GENE CHROMOSOME CANC, V47, P490, DOI 10.1002/gcc.20550
   KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3
   Kuo SJ, 2009, VIRCHOWS ARCH, V454, P467, DOI 10.1007/s00428-009-0761-7
   Setiawan VW, 2009, AM J EPIDEMIOL, V169, P1251, DOI 10.1093/aje/kwp036
   Sewell R, 2006, J BIOL CHEM, V281, P3586, DOI 10.1074/jbc.M511826200
   Sunami E, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2098
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Winter SL, 2007, NEOPLASIA, V9, P797, DOI 10.1593/neo.07595
NR 16
TC 74
Z9 80
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD NOV 1
PY 2010
VL 19
IS 21
BP 4273
EP 4277
DI 10.1093/hmg/ddq351
PG 5
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 661TR
UT WOS:000282751500014
PM 20724461
DA 2025-01-12
ER

PT J
AU Katoh, H
   Zheng, P
   Liu, Y
AF Katoh, Hiroto
   Zheng, Pan
   Liu, Yang
TI Signalling through FOXP3 as an X-linked tumor suppressor
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE FOXP3; Epithelial cell; X-linked tumor suppressor gene; Breast cancer;
   Prostate cancer
ID REGULATORY T-CELLS; TRANSCRIPTION FACTOR FOXP3; BREAST-CANCER;
   EXPRESSION; REPRESSOR; GENE; ONCOGENE; LOCUS; P21
AB The FOXP3 (forkhead box P3) gene is a member of forkhead winged helix family transcription factors and functions as both a transcriptional activator and a repressor. FOXP3 dysfunction is responsible for an X-linked autoimmune syndrome: immune dysregulation, polyendopathy, enterophathy. X-linked syndrome. In addition to its role as an essential transcription factor in regulatory T cells, the FOXP3 gene is an epithelial cell-intrinsic tumor suppressor for breast and prostate cancers. We will focus on the FOXP3 signalling pathway in epithelial cells and discuss how genetic and/or epigenetic inactivation of the FOXP3 contributes to the malignant transformation of cells. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Katoh, Hiroto; Zheng, Pan; Liu, Yang] Univ Michigan, Sch Med, Dept Surg, Div Immunotherapy, Ann Arbor, MI 48109 USA.
   [Zheng, Pan] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.
   [Liu, Yang] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA.
   [Katoh, Hiroto; Zheng, Pan; Liu, Yang] Ctr Canc, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan
RP Zheng, P (通讯作者)，Univ Michigan, Sch Med, Dept Surg, Div Immunotherapy, Ann Arbor, MI 48109 USA.
EM panz@umich.edu; yangl@umich.edu
RI Katoh, Hiroto/ADO-8117-2022; Liu, Yang/HNJ-6693-2023; Zheng,
   Pan/E-8691-2011
OI Liu, Yang/0000-0002-9442-700X; Zheng, Pan/0000-0003-2598-3544
FU National Institute of Health; Department of Defense, the United States
   of America
FX We apologize to any authors whose work could not be referenced due to
   strict limitation in citation numbers. We thank Drs. Lizhong Wang and
   Runhua Liu for valuable discussions about this manuscript, and Ms.
   Chun-Shu Wong for editorial assistance. This work was supported by
   grants from National Institute of Health and Department of Defense, the
   United States of America.
CR Abukhdeir Abde M., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000744
   Bettelli E, 2005, P NATL ACAD SCI USA, V102, P5138, DOI 10.1073/pnas.0501675102
   Chang X, 2005, J EXP MED, V202, P1141, DOI 10.1084/jem.20050157
   Chen GY, 2008, J IMMUNOL, V180, P5163, DOI 10.4049/jimmunol.180.8.5163
   Ebert LM, 2008, CANCER RES, V68, P3001, DOI 10.1158/0008-5472.CAN-07-5664
   Fontenot JD, 2005, NAT IMMUNOL, V6, P331, DOI 10.1038/ni1179
   Hinz S, 2007, CANCER RES, V67, P8344, DOI 10.1158/0008-5472.CAN-06-3304
   Holmes D, 2008, IMMUNOL RES, V41, P248, DOI 10.1007/s12026-008-8037-x
   Jung DJ, 2010, J BIOL CHEM, V285, P7995, DOI 10.1074/jbc.M109.047985
   Krejsgaard T, 2008, LEUKEMIA, V22, P2230, DOI 10.1038/leu.2008.224
   Lal G, 2009, BLOOD, V114, P3727, DOI 10.1182/blood-2009-05-219584
   Lee SM, 2008, BLOOD, V111, P3599, DOI 10.1182/blood-2007-09-115014
   Li B, 2007, P NATL ACAD SCI USA, V104, P4571, DOI 10.1073/pnas.0700298104
   Liu RH, 2009, CANCER RES, V69, P2252, DOI 10.1158/0008-5472.CAN-08-3717
   Liu Y, 2009, CANCER RES, V69, P5954, DOI 10.1158/0008-5472.CAN-09-0778
   Liu Y, 2010, TRENDS GENET, V26, P260, DOI 10.1016/j.tig.2010.03.004
   Lopes JE, 2006, J IMMUNOL, V177, P3133, DOI 10.4049/jimmunol.177.5.3133
   Merlo A, 2009, J CLIN ONCOL, V27, P1746, DOI 10.1200/JCO.2008.17.9036
   Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881
   Ono M, 2007, NATURE, V446, P685, DOI 10.1038/nature05673
   Pan F, 2009, SCIENCE, V325, P1142, DOI 10.1126/science.1176077
   Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904
   Ruan QG, 2009, IMMUNITY, V31, P932, DOI 10.1016/j.immuni.2009.10.006
   Spector NL, 2009, J CLIN ONCOL, V27, P5838, DOI 10.1200/JCO.2009.22.1507
   Tone Y, 2008, NAT IMMUNOL, V9, P194, DOI 10.1038/ni1549
   Wang LZ, 2009, CANCER CELL, V16, P336, DOI 10.1016/j.ccr.2009.08.016
   WU V, 2006, NFAT Cell, V126, P375
   Zhang HY, 2010, CANCER LETT, V287, P91, DOI 10.1016/j.canlet.2009.06.001
   Zheng Y, 2007, NATURE, V445, P936, DOI 10.1038/nature05563
   Zuo T, 2007, J CLIN INVEST, V117, P3765, DOI 10.1172/JCI32538
   Zuo T, 2007, CELL, V129, P1275, DOI 10.1016/j.cell.2007.04.034
NR 31
TC 23
Z9 29
U1 0
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357-2725
EI 1878-5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD NOV
PY 2010
VL 42
IS 11
BP 1784
EP 1787
DI 10.1016/j.biocel.2010.07.015
PG 4
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 673YA
UT WOS:000283698900008
PM 20678582
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Malchenko, S
   Galat, V
   Seftor, EA
   Vanin, EF
   Costa, FF
   Seftor, REB
   Soares, MB
   Hendrix, MJC
AF Malchenko, Sergey
   Galat, Vasiliy
   Seftor, Elisabeth A.
   Vanin, Elio F.
   Costa, Fabricio F.
   Seftor, Richard E. B.
   Soares, Marcelo B.
   Hendrix, Mary J. C.
TI Cancer Hallmarks in Induced Pluripotent Cells: New Insights
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID EMBRYONIC STEM-CELLS; BREAST-CANCER; EXPRESSION; GENES; LINES
AB Studies are beginning to emerge that demonstrate intriguing differences between human-induced pluripotent stem cells (hiPSCs) and human embryonic stem cells (hESCs). Here, we investigated the expression of key members of the Nodal embryonic signaling pathway, critical to the maintenance of pluripotency in hESCs. Western blot and real-time RT-PCR analyses reveal slightly lower levels of Nodal (a TGF-beta family member) and Cripto-1 (Nodal's co-receptor) and a dramatic decrease in Lefty (Nodal's inhibitor and TGF-beta family member) in hiPSCs compared with hESCs. The noteworthy drop in hiPSC's Lefty expression correlated with an increase in the methylation of Lefty B CpG island. Based on these findings, we addressed a more fundamental question related to the consequences of epigenetically reprogramming hiPSCs, especially with respect to maintaining a stable ESC phenotype. A global comparative analysis of 365 microRNAs (miRs) in two hiPSC versus four hESC lines ultimately identified 10 highly expressed miRs in hiPCSs with >10-fold difference, which have been shown to be cancer related. These data demonstrate cancer hallmarks expressed by hiPSCs, which will require further assessment for their impact on future therapies. J. Cell. Physiol. 225: 390-393, 2010. (C) 2010 Wiley-Liss, Inc.
C1 [Malchenko, Sergey; Seftor, Elisabeth A.; Vanin, Elio F.; Costa, Fabricio F.; Seftor, Richard E. B.; Soares, Marcelo B.; Hendrix, Mary J. C.] Northwestern Univ, Feinberg Sch Med, Childrens Mem Res Ctr, Canc Biol & Epigenom Program, Chicago, IL 60614 USA.
   [Galat, Vasiliy] Northwestern Univ, Feinberg Sch Med, Childrens Mem Res Ctr, Dev Biol Program, Chicago, IL 60614 USA.
C3 Northwestern University; Feinberg School of Medicine; Northwestern
   University; Feinberg School of Medicine
RP Hendrix, MJC (通讯作者)，Northwestern Univ, Feinberg Sch Med, Childrens Mem Res Ctr, Canc Biol & Epigenom Program, 2430 N Halsted St, Chicago, IL 60614 USA.
EM m-hendrix@northwestern.edu
RI Costa, Fabricio/M-5309-2017
OI Galat, Vasiliy/0000-0003-3612-098X
FU NCI [CA121205, CA143869, NHLBI10279457]; Maeve McNicholas Memorial
   Foundation; Medical Research Institute Council
FX The authors wish to thank Dr. Victor Ambrose and Dr. Todd Golub for
   critical reading of the manuscript. Research was supported by NCI
   CA121205 and CA143869 (MJCH), NHLB110279457 (VG), the Maeve McNicholas
   Memorial Foundation (FFC), and the Medical Research Institute Council.
CR Chin MH, 2009, CELL STEM CELL, V5, P111, DOI 10.1016/j.stem.2009.06.008
   Costa FF, 2009, EPIGENOMICS-UK, V1, P387, DOI [10.2217/epi.09.25, 10.2217/EPI.09.25]
   Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471
   Feng Q, 2010, STEM CELLS, V28, P704, DOI 10.1002/stem.321
   Gibcus JH, 2009, NEOPLASIA, V11, P167, DOI 10.1593/neo.08980
   Greither T, 2010, INT J CANCER, V126, P73, DOI 10.1002/ijc.24687
   Knoepfler PS, 2009, STEM CELLS, V27, P1050, DOI 10.1002/stem.37
   Laurent LC, 2010, NAT METHODS, V7, P6, DOI 10.1038/nmeth0110-06
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mertens-Talcott SU, 2007, CANCER RES, V67, P11001, DOI 10.1158/0008-5472.CAN-07-2416
   Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934
   Pichiorri F, 2008, P NATL ACAD SCI USA, V105, P12885, DOI 10.1073/pnas.0806202105
   Postovit LM, 2008, P NATL ACAD SCI USA, V105, P4329, DOI 10.1073/pnas.0800467105
   Schier AF, 2003, ANNU REV CELL DEV BI, V19, P589, DOI 10.1146/annurev.cellbio.19.041603.094522
   Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tong AW, 2009, CANCER GENE THER, V16, P206, DOI 10.1038/cgt.2008.77
   Wernig M, 2008, CELL STEM CELL, V2, P10, DOI 10.1016/j.stem.2007.12.001
   Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
NR 20
TC 38
Z9 45
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD NOV
PY 2010
VL 225
IS 2
BP 390
EP 393
DI 10.1002/jcp.22280
PG 4
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA 664ZS
UT WOS:000283003400016
PM 20568225
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Revenko, AS
   Kalashnikova, EV
   Gemo, AT
   Zou, JX
   Chen, HW
AF Revenko, Alexey S.
   Kalashnikova, Ekaterina V.
   Gemo, Abigael T.
   Zou, June X.
   Chen, Hong-Wu
TI Chromatin Loading of E2F-MLL Complex by Cancer-Associated Coregulator
   ANCCA via Reading a Specific Histone Mark
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
ID BROMODOMAIN PROTEIN BRD4; CELL-CYCLE CONTROL; RNA-POLYMERASE-II;
   GENE-EXPRESSION; BREAST-CANCER; MLL FAMILY; TRANSCRIPTIONAL ACTIVATION;
   DEPENDENT TRANSCRIPTION; COACTIVATOR COMPLEX; BINDING MODULES
AB Histone modifications are regarded as the carrier of epigenetic memory through cell divisions. How the marks facilitate cell cycle-dependent gene expression is poorly understood. The evolutionarily conserved AAA ATPase ANCCA (AAA nuclear coregulator cancer-associated protein)/ATAD2 was identified as a direct target of oncogene AIB1/ACTR/SRC-3 and a transcriptional coregulator for estrogen and androgen receptors and is strongly implicated in tumorigenesis. We report here that ANCCA directly interacts with E2F1 to E2F3 and that its N terminus interacts with both the N and C termini of E2F1. ANCCA preferentially associates via its bromodomain with H3 acetylated at lysine 14 (H3K14ac) and is required for key cell cycle gene expression and cancer cell proliferation. ANCCA associates with chromosomes at late mitosis, and its occupancy at E2F targets peaks at the G(1)-to-S transition. Strikingly, ANCCA is required for recruitment of specific E2Fs to their targets and chromatin assembly of the host cell factor 1 (HCF-1)-MLL histone methyltransferase complex. ANCCA depletion results in a marked decrease of the gene activation-linked H3K4me3 mark. Bromodomain mutations disable ANCCA function as an E2F coactivator and its ability to promote cancer cell proliferation, while ANCCA overexpression in tumors correlates with tumor growth. Together, these results suggest that ANCCA acts as a pioneer factor in E2F-dependent gene activation and that a novel mechanism involving ANCCA bromodomain may contribute to cancer cell proliferation.
C1 [Chen, Hong-Wu] Univ Calif Davis, Sch Med, UCD Canc Ctr Basic Sci, Dept Biochem & Mol Med, Sacramento, CA 95817 USA.
   [Zou, June X.] Univ Calif Davis, Sch Med, Dept Internal Med, Sacramento, CA 95817 USA.
C3 University of California System; University of California Davis;
   University of California System; University of California Davis
RP Chen, HW (通讯作者)，Univ Calif Davis, Sch Med, UCD Canc Ctr Basic Sci, Dept Biochem & Mol Med, UCDMC Res 3,Room 1400B,4645 2nd Ave, Sacramento, CA 95817 USA.
EM hwzchen@ucdavis.edu
RI Zou, June/LDF-4772-2024
FU NIH [R01-CA113860, R01-CA134766, R01-DK060019]; DoD [W81XWH-0810689]
FX This work was supported by grants from the NIH (R01-CA113860,
   R01-CA134766, and R01-DK060019) to H.-W.C. E.V.K. is a recipient of a
   DoD BCRP predoctoral fellowship award (W81XWH-0810689).
CR Acevedo ML, 2003, MOL CELL BIOL, V23, P335, DOI 10.1128/MCB.23.1.335-348.2003
   Bhat-Nakshatri P, 2008, MOL CELL BIOL, V28, P7487, DOI 10.1128/MCB.00799-08
   Blais A, 2007, CURR OPIN CELL BIOL, V19, P658, DOI 10.1016/j.ceb.2007.10.003
   Blobel GA, 2009, MOL CELL, V36, P970, DOI 10.1016/j.molcel.2009.12.001
   Bosco EE, 2007, J CLIN INVEST, V117, P218, DOI 10.1172/JCI28803
   Caldon CE, 2009, MOL CELL BIOL, V29, P4623, DOI 10.1128/MCB.00269-09
   Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696
   Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9
   Ciró M, 2009, CANCER RES, V69, P8491, DOI 10.1158/0008-5472.CAN-09-2131
   Delcuve GP, 2008, J CELL BIOCHEM, V105, P1, DOI 10.1002/jcb.21806
   Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100
   Dey A, 2009, MOL BIOL CELL, V20, P4899, DOI 10.1091/mbc.E09-05-0380
   Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031
   Erzberger JP, 2006, ANNU REV BIOPH BIOM, V35, P93, DOI 10.1146/annurev.biophys.35.040405.101933
   Hanson PI, 2005, NAT REV MOL CELL BIO, V6, P519, DOI 10.1038/nrm1684
   Hargreaves DC, 2009, CELL, V138, P129, DOI 10.1016/j.cell.2009.05.047
   Hsia EYC, 2010, MOL CANCER RES, V8, P183, DOI 10.1158/1541-7786.MCR-09-0095
   Indiani C, 2006, NAT REV MOL CELL BIO, V7, P751, DOI 10.1038/nrm2022
   Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027
   Jeong KW, 2009, J BIOL CHEM, V284, P29298, DOI 10.1074/jbc.M109.037010
   Johnsson A, 2009, EMBO REP, V10, P1009, DOI 10.1038/embor.2009.127
   Kalashnikova EV, 2010, CANCER RES, V70, P9402, DOI 10.1158/0008-5472.CAN-10-1199
   Kanno T, 2004, MOL CELL, V13, P33, DOI 10.1016/S1097-2765(03)00482-9
   Kasten M, 2004, EMBO J, V23, P1348, DOI 10.1038/sj.emboj.7600143
   Kininis M, 2009, MOL CELL BIOL, V29, P1123, DOI 10.1128/MCB.00841-08
   Kouskouti A, 2005, EMBO J, V24, P347, DOI 10.1038/sj.emboj.7600516
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Ladurner AG, 2003, MOL CELL, V11, P365, DOI 10.1016/S1097-2765(03)00035-2
   Lang SE, 2001, J BIOL CHEM, V276, P32627, DOI 10.1074/jbc.M102067200
   Lee YH, 2005, P NATL ACAD SCI USA, V102, P3611, DOI 10.1073/pnas.0407159102
   Leroy G, 2008, MOL CELL, V30, P51, DOI 10.1016/j.molcel.2008.01.018
   Leung JY, 2008, ONCOGENE, V27, P4172, DOI 10.1038/onc.2008.55
   Lim JH, 2005, EMBO J, V24, P3038, DOI 10.1038/sj.emboj.7600768
   Liu H, 2007, GENE DEV, V21, P2385, DOI 10.1101/gad.1574507
   Loomis RJ, 2009, MOL CELL, V33, P450, DOI 10.1016/j.molcel.2009.02.003
   Louie MC, 2006, MOL CELL BIOL, V26, P3810, DOI 10.1128/MCB.26.10.3810-3823.2006
   Louie MC, 2004, MOL CELL BIOL, V24, P5157, DOI 10.1128/MCB.24.12.5157-5171.2004
   Louie MC, 2003, P NATL ACAD SCI USA, V100, P2226, DOI 10.1073/pnas.0437824100
   McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8
   Mochizuki K, 2008, J BIOL CHEM, V283, P9040, DOI 10.1074/jbc.M707603200
   Mujtaba S, 2007, ONCOGENE, V26, P5521, DOI 10.1038/sj.onc.1210618
   Müller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201
   Nagl NG, 2007, EMBO J, V26, P752, DOI 10.1038/sj.emboj.7601541
   Nagy Z, 2007, ONCOGENE, V26, P5341, DOI 10.1038/sj.onc.1210604
   Narayanan A, 2007, P NATL ACAD SCI USA, V104, P10835, DOI 10.1073/pnas.0704351104
   Vicent GP, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000567
   Rabinovich A, 2008, GENOME RES, V18, P1763, DOI 10.1101/gr.080622.108
   Ruthenburg AJ, 2007, NAT REV MOL CELL BIO, V8, P983, DOI 10.1038/nrm2298
   Sarge KD, 2009, CELL CYCLE, V8, P818, DOI 10.4161/cc.8.6.7849
   Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189
   Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076
   Shahbazian MD, 2007, ANNU REV BIOCHEM, V76, P75, DOI 10.1146/annurev.biochem.76.052705.162114
   Sims RJ, 2007, MOL CELL, V28, P665, DOI 10.1016/j.molcel.2007.11.010
   Stender JD, 2007, MOL ENDOCRINOL, V21, P2112, DOI 10.1210/me.2006-0474
   Tackett AJ, 2005, J CELL BIOL, V169, P35, DOI 10.1083/jcb.200502104
   Takahashi Y, 2000, GENE DEV, V14, P804
   Takeda S, 2006, GENE DEV, V20, P2397, DOI 10.1101/gad.1449406
   Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004
   Taverna SD, 2007, NAT STRUCT MOL BIOL, V14, P1025, DOI 10.1038/nsmb1338
   Truscott M, 2008, MOL CELL BIOL, V28, P3127, DOI 10.1128/MCB.02089-07
   Tseng RJ, 2007, MOL GENET GENOMICS, V278, P507, DOI 10.1007/s00438-007-0265-6
   Tyagi S, 2007, MOL CELL, V27, P107, DOI 10.1016/j.molcel.2007.05.030
   Tyagi S, 2009, EMBO J, V28, P3185, DOI 10.1038/emboj.2009.258
   Valls E, 2005, J BIOL CHEM, V280, P42592, DOI 10.1074/jbc.M507407200
   VanDemark AP, 2007, MOL CELL, V27, P817, DOI 10.1016/j.molcel.2007.08.018
   Vermeulen M, 2007, CELL, V131, P58, DOI 10.1016/j.cell.2007.08.016
   Wade HE, 2010, MOL CELL BIOL, V30, P1866, DOI 10.1128/MCB.01060-09
   Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000
   Wu SY, 2006, GENE DEV, V20, P2383, DOI 10.1101/gad.1448206
   Xu W, 2004, GENE DEV, V18, P144, DOI 10.1101/gad.1141704
   Yang XJ, 2007, ONCOGENE, V26, P5310, DOI 10.1038/sj.onc.1210599
   Yang ZY, 2008, MOL CELL BIOL, V28, P967, DOI 10.1128/MCB.01020-07
   Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004
   Zeng L, 2008, STRUCTURE, V16, P643, DOI 10.1016/j.str.2008.01.010
   Zippo A, 2009, CELL, V138, P1122, DOI 10.1016/j.cell.2009.07.031
   Zou JX, 2007, P NATL ACAD SCI USA, V104, P18067, DOI 10.1073/pnas.0705814104
   Zou JX, 2009, CANCER RES, V69, P3339, DOI 10.1158/0008-5472.CAN-08-3440
NR 77
TC 103
Z9 118
U1 0
U2 13
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD NOV
PY 2010
VL 30
IS 22
BP 5260
EP 5272
DI 10.1128/MCB.00484-10
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 673JX
UT WOS:000283656700001
PM 20855524
OA Green Published
DA 2025-01-12
ER

PT J
AU Reeves, ME
   Baldwin, SW
   Baldwin, ML
   Chen, ST
   Moretz, JM
   Aragon, RJ
   Li, XM
   Strong, DD
   Mohan, S
   Amaar, YG
AF Reeves, Mark E.
   Baldwin, Scott W.
   Baldwin, Melissa L.
   Chen, Shin-Tai
   Moretz, Jeremy M.
   Aragon, Robert J.
   Li, Xinmin
   Strong, Donna D.
   Mohan, Subburaman
   Amaar, Yousef G.
TI Ras-association domain family 1C protein promotes breast cancer cell
   migration and attenuates apoptosis
SO BMC CANCER
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; HUMAN-CHROMOSOME 3P21.3; EPIGENETIC INACTIVATION;
   CPG ISLAND; IN-VITRO; RASSF1A; GROWTH; EXPRESSION; LUNG; IGFBP-5
AB Background: The Ras association domain family 1 (RASSF1) gene is a Ras effector encoding two major mRNA forms, RASSF1A and RASSF1C, derived by alternative promoter selection and alternative mRNA splicing. RASSF1A is a tumor suppressor gene. However, very little is known about the function of RASSF1C both in normal and transformed cells.
   Methods: Gene silencing and over-expression techniques were used to modulate RASSF1C expression in human breast cancer cells. Affymetrix-microarray analysis was performed using T47D cells over-expressing RASSF1C to identify RASSF1C target genes. RT-PCR and western blot techniques were used to validate target gene expression. Cell invasion and apoptosis assays were also performed.
   Results: In this article, we report the effects of altering RASSF1C expression in human breast cancer cells. We found that silencing RASSF1C mRNA in breast cancer cell lines (MDA-MB231 and T47D) caused a small but significant decrease in cell proliferation. Conversely, inducible over-expression of RASSF1C in breast cancer cells (MDA-MB231 and T47D) resulted in a small increase in cell proliferation. We also report on the identification of novel RASSF1C target genes. RASSF1C down-regulates several pro-apoptotic and tumor suppressor genes and up-regulates several growth promoting genes in breast cancer cells. We further show that down-regulation of caspase 3 via overexpression of RASSF1C reduces breast cancer cells' sensitivity to the apoptosis inducing agent, etoposide. Furthermore, we found that RASSF1C over-expression enhances T47D cell invasion/migration in vitro.
   Conclusion: Together, our findings suggest that RASSF1C, unlike RASSF1A, is not a tumor suppressor, but instead may play a role in stimulating metastasis and survival in breast cancer cells.
C1 [Reeves, Mark E.; Baldwin, Scott W.; Baldwin, Melissa L.; Moretz, Jeremy M.; Aragon, Robert J.; Strong, Donna D.; Mohan, Subburaman; Amaar, Yousef G.] Loma Linda VA Med Ctr, Surg Oncol Lab, Loma Linda, CA 92350 USA.
   [Chen, Shin-Tai] Loma Linda VA Med Ctr, Musculoskeletal Dis Ctr, Loma Linda, CA 92350 USA.
   [Reeves, Mark E.; Baldwin, Scott W.; Aragon, Robert J.; Amaar, Yousef G.] Loma Linda Univ, Dept Surg, Loma Linda, CA 92350 USA.
   [Li, Xinmin] Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90095 USA.
C3 Loma Linda University; Loma Linda University; Loma Linda University;
   University of California System; University of California Los Angeles
RP Amaar, YG (通讯作者)，Loma Linda VA Med Ctr, Surg Oncol Lab, 11201 Benton St 151, Loma Linda, CA 92350 USA.
EM yousef.amaar@va.gov
FU Department of Surgery, Loma Linda University School of Medicine
FX This work was supported by a grant from the Department of Surgery, Loma
   Linda University School of Medicine.
CR Afonja O, 2002, ONCOGENE, V21, P7850, DOI 10.1038/sj.onc.1205985
   Agathanggelou A, 2003, CANCER RES, V63, P5344
   Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Ai LB, 2008, CARCINOGENESIS, V29, P510, DOI 10.1093/carcin/bgm280
   Amaar YG, 2005, J BONE MINER RES, V20, P1430, DOI 10.1359/JBMR.050311
   Amaar YG, 2002, J BIOL CHEM, V277, P12053, DOI 10.1074/jbc.M110872200
   Amaar YG, 2006, AM J PHYSIOL-LUNG C, V291, pL1185, DOI 10.1152/ajplung.00072.2006
   Beattie J, 2006, BIOCHEM J, V395, P1, DOI 10.1042/BJ20060086
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182
   Butt AJ, 2003, J BIOL CHEM, V278, P29676, DOI 10.1074/jbc.M301965200
   Chen YC, 2005, CANCER RES, V65, P331
   Chow LSN, 2006, ONCOGENE, V25, P310, DOI 10.1038/sj.onc.1209001
   Dallol A, 2005, CANCER RES, V65, P7653, DOI 10.1158/0008-5472.CAN-05-0247
   Dammann R, 2001, CANCER RES, V61, P3105
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469
   Di Benedetto M, 2006, GENE, V380, P127, DOI 10.1016/j.gene.2006.05.021
   Divisova J, 2006, BREAST CANCER RES TR, V98, P315, DOI 10.1007/s10549-006-9168-1
   Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298
   Du JL, 2001, CANCER LETT, V165, P211, DOI 10.1016/S0304-3835(01)00409-8
   Estrabaud E, 2007, CANCER RES, V67, P1054, DOI 10.1158/0008-5472.CAN-06-2530
   Iglesias D, 2006, CANCER GENET CYTOGEN, V167, P138, DOI 10.1016/j.cancergencyto.2005.12.002
   Ji L, 2002, CANCER RES, V62, P2715
   Ji L, 1999, CANCER RES, V59, P3333
   Jiang Y, 2008, ONCOGENE, V27, P1865, DOI 10.1038/sj.onc.1210829
   Kitagawa D, 2006, EMBO J, V25, P3286, DOI 10.1038/sj.emboj.7601212
   Kuzmin I, 2002, CANCER RES, V62, P3498
   Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098
   Li JF, 2004, ONCOGENE, V23, P5941, DOI 10.1038/sj.onc.1207789
   Liu L, 2000, ONCOGENE, V21, P6835
   Liu QY, 2008, MOL NEURODEGENER, V3, DOI 10.1186/1750-1326-3-4
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lo KW, 2001, CANCER RES, V61, P3877
   Marlow R, 2008, CANCER RES, V68, P7819, DOI 10.1158/0008-5472.CAN-08-1357
   McIlroy D, 1999, ONCOGENE, V18, P4401, DOI 10.1038/sj.onc.1202868
   Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192
   Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002
   Smith MCP, 2004, CANCER RES, V64, P8604, DOI 10.1158/0008-5472.CAN-04-1844
   Subramanian A, 2007, ANTICANCER RES, V27, P3513
   Tambe Y, 2007, CARCINOGENESIS, V28, P777, DOI 10.1093/carcin/bgl211
   Tommasi S, 2005, CANCER RES, V65, P92
   Vos MD, 2006, J BIOL CHEM, V281, P4557, DOI 10.1074/jbc.M512128200
   Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339
   Wang HT, 2003, WORLD J GASTROENTERO, V9, P392, DOI 10.3748/wjg.v9.i3.392
   Ward KR, 2004, ONCOGENE, V23, P1187, DOI 10.1038/sj.onc.1207226
   Yu J, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-29
   Zendman AJW, 2003, GENE, V309, P125, DOI 10.1016/S0378-1119(03)00497-9
   Zhang X, 2003, J BIOL CHEM, V278, P7580, DOI 10.1074/jbc.M212050200
NR 49
TC 32
Z9 36
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD OCT 18
PY 2010
VL 10
AR 562
DI 10.1186/1471-2407-10-562
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 671YR
UT WOS:000283550700001
PM 20955597
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Hu, S
   Yu, LL
   Li, ZM
   Shen, Y
   Wang, J
   Cai, J
   Xiao, L
   Wang, ZH
AF Hu, Sha
   Yu, Lili
   Li, Zhimin
   Shen, Yi
   Wang, Jing
   Cai, Jing
   Xiao, Lan
   Wang, Zehua
TI Overexpression of EZH2 contributes to acquired cisplatin resistance in
   ovarian cancer cells in vitro and in vivo
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE EZH2; acquired cisplatin resistance; epigenetics; ovarian cancer; H3K27
   methylation; cell proliferation; cell cycle
ID AGGRESSIVE BREAST-CANCER; GROUP PROTEIN EZH2; HISTONE METHYLTRANSFERASE;
   ZESTE HOMOLOG-2; DNA METHYLATION; PROSTATE-CANCER; CHROMATIN-STRUCTURE;
   GASTRIC-CANCER; EXPRESSION; PROLIFERATION
AB Enhancer of Zeste Homologue 2 (EZH2), a specific histone 3 lysine 27 (H3K27) methyltransferase, plays a critical role in tumorigenesis and cancer progression through epigenetic gene silencing and chromatin remodeling. However, the role of EZH2 in chemotherapy resistance is unknown. In this study, we found that EZH2 was overexpressed in cisplatin-resistant ovarian cancer cells compared with cisplatin-sensitive cells. Knockdown of EZH2 by RNA interference (RNAi) resensitized drug-resistant ovarian cancer A2780/DDP cells to cisplatin and decreased the level of H3K27 trimethylation (H3K27me3). Moreover, EZH2 downregulation suppressed cell proliferation and caused G(2)/M cell cycle arrest in A2780/DDP cells. Loss of EZH2 also enhanced sensibility of tumor xenografts to cisplatin and inhibited tumor growth in vivo. Our results indicate that EZH2 is essential for chemotherapy resistance in cisplatin-resistant cancer cells in vitro and in vivo, which is probably through H3K27 methylation as well as regulation of cell proliferation. EZH2 could be a potential novel epigenetic target to overcome drug resistance.
C1 [Hu, Sha; Yu, Lili; Li, Zhimin; Shen, Yi; Wang, Jing; Cai, Jing; Wang, Zehua] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Obstet & Gynecol, Wuhan 430074, Peoples R China.
   [Xiao, Lan] An Hui Med Coll, Affiliated Hosp 1, Dept Obstet & Gynecol, Hefei, Peoples R China.
C3 Huazhong University of Science & Technology
RP Wang, ZH (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Obstet & Gynecol, Wuhan 430074, Peoples R China.
EM zehuawang@163.net
RI wang, jing/GVT-8700-2022; Shen, Yi/GRS-3602-2022
FU National Natural Science Foundation of China [30901585]
FX This work was supported by grant NO. 30901585 from the National Natural
   Science Foundation of China. We sincerely thank our colleagues Jianfeng
   Guo, Huijuan Tang and Ting Cao for their valuable help."
CR Abbosh PH, 2006, CANCER RES, V66, P5582, DOI 10.1158/0008-5472.CAN-05-3575
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Batch C, 2004, AM J OBSTET GYNECOL, V191, P1552, DOI 10.1016/j.agoj.2004.05.025
   BEHRENS BC, 1987, CANCER RES, V47, P414
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Bryant RJ, 2007, PROSTATE, V67, P547, DOI 10.1002/pros.20550
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   CARMICHAEL J, 1987, CANCER RES, V47, P936
   Chekhun VF, 2006, CANCER LETT, V231, P87, DOI 10.1016/j.canlet.2005.01.038
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Dukers DF, 2004, AM J PATHOL, V164, P873, DOI 10.1016/S0002-9440(10)63175-6
   Fujii S, 2008, CANCER SCI, V99, P738, DOI 10.1111/j.1349-7006.2008.00743.x
   Gelato KA, 2008, BIOL CHEM, V389, P353, DOI 10.1515/BC.2008.048
   Gonzalez ME, 2009, ONCOGENE, V28, P843, DOI 10.1038/onc.2008.433
   Hinz S, 2009, J UROLOGY, V182, P2920, DOI 10.1016/j.juro.2009.08.014
   Hoffmann MJ, 2007, CANCER BIOL THER, V6, P1403, DOI 10.4161/cbt.6.9.4542
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kidani K, 2009, ORAL ONCOL, V45, P39, DOI 10.1016/j.oraloncology.2008.03.016
   Kim MS, 2003, CANCER RES, V63, P7291
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504
   Marchion DC, 2005, CANCER RES, V65, P3815, DOI 10.1158/0008-5472.CAN-04-2478
   Matsukawa Y, 2006, CANCER SCI, V97, P484, DOI 10.1111/j.1349-7006.2006.00203.x
   Moss C, 2002, EUR J CANCER, V38, P1701, DOI 10.1016/S0959-8049(02)00161-2
   Nephew KP, 2003, CANCER LETT, V190, P125, DOI 10.1016/S0304-3835(02)00511-6
   Ougolkov AV, 2008, CLIN CANCER RES, V14, P6790, DOI 10.1158/1078-0432.CCR-08-1013
   Raman JD, 2005, CLIN CANCER RES, V11, P8570, DOI 10.1158/1078-0432.CCR-05-1047
   Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010
   Steele N, 2009, BRIT J CANCER, V100, P758, DOI 10.1038/sj.bjc.6604932
   Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531
   Szakács G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984
   Tang XH, 2004, ONCOGENE, V23, P5759, DOI 10.1038/sj.onc.1207706
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wagener N, 2008, INT J CANCER, V123, P1545, DOI 10.1002/ijc.23683
   Weikert S, 2005, INT J MOL MED, V16, P349
   Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481
   Yonemitsu Y, 2009, HUM PATHOL, V40, P1304, DOI 10.1016/j.humpath.2009.01.017
NR 39
TC 122
Z9 145
U1 2
U2 34
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD OCT 15
PY 2010
VL 10
IS 8
BP 788
EP 795
DI 10.4161/cbt.10.8.12913
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 665PB
UT WOS:000283046800008
PM 20686362
DA 2025-01-12
ER

PT J
AU Weng, YI
   Hsu, PY
   Liyanarachchi, S
   Liu, J
   Deatherage, DE
   Huang, YW
   Zuo, T
   Rodriguez, B
   Lin, CH
   Cheng, AL
   Huang, THM
AF Weng, Yu-I
   Hsu, Pei-Yin
   Liyanarachchi, Sandya
   Liu, Joseph
   Deatherage, Daniel E.
   Huang, Yi-Wen
   Zuo, Tao
   Rodriguez, Benjamin
   Lin, Ching-Hung
   Cheng, Ann-Lii
   Huang, Tim H. -M.
TI Epigenetic influences of low-dose bisphenol A in primary human breast
   epithelial cells
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE Bisphenol A; Estrogen; DNA methylation; Epigenetics; Breast cancer
ID ESTROGEN-RECEPTOR; MAMMARY-GLAND; DNA METHYLATION; CANCER; EXPOSURE;
   EPIGENOMICS; MECHANISMS; MIGRATION; PROSTATE; ALTERS
AB Substantial evidence indicates that exposure to bisphenol A (BPA) during early development may increase breast cancer risk later in life. The changes may persist into puberty and adulthood, suggesting an epigenetic process being imposed in differentiated breast epithelial cells. The molecular mechanisms by which early memory of BPA exposure is imprinted in breast progenitor cells and then passed onto their epithelial progeny are not well understood. The aim of this study was to examine epigenetic changes in breast epithelial cells treated with low-dose BPA. We also investigated the effect of BPA on the ER alpha signaling pathway and global gene expression profiles. Compared to control cells, nuclear internalization of ER alpha was observed in epithelial cells preexposed to BPA. We identified 170 genes with similar expression changes in response to BPA. Functional analysis confirms that gene suppression was mediated in part through an ER alpha-dependent pathway. As a result of exposure to BPA or other estrogen-like chemicals, the expression of lysosomal-associated membrane protein 3 (LAMP3) became epigenetically silenced in breast epithelial cells. Furthermore, increased DNA methylation in the LAMP3 CpG island was this repressive mark preferentially occurred in ER alpha-positive breast tumors. These results suggest that the in vitro system developed in our laboratory is a valuable tool for exposure studies of BPA and other xenoestrogens in human cells. Individual and geographical differences may contribute to altered patterns of gene expression and DNA methylation in susceptible loci. Combination of our exposure model with epigenetic analysis and other biochemical assays can give insight into the heritable effect of low-dose BPA in human cells. Published by Elsevier Inc.
C1 [Weng, Yu-I; Hsu, Pei-Yin; Liyanarachchi, Sandya; Liu, Joseph; Deatherage, Daniel E.; Huang, Yi-Wen; Zuo, Tao; Rodriguez, Benjamin; Huang, Tim H. -M.] Ohio State Univ, Human Canc Genet Program, Columbus, OH 43210 USA.
   [Lin, Ching-Hung; Cheng, Ann-Lii] Natl Taiwan Univ Hosp, Dept Internal Med & Oncol, Taipei, Taiwan.
C3 University System of Ohio; Ohio State University; National Taiwan
   University; National Taiwan University Hospital
RP Huang, THM (通讯作者)，Ohio State Univ, Human Canc Genet Program, Room 814,Biomed Res Tower,460 W 12th Ave, Columbus, OH 43210 USA.
EM Tim.Huang@osumc.edu
RI Cheng, Ann-Lii/ACM-0936-2022; Lin, Chih-Cheng/IQT-4912-2023; Huang,
   Yiwen/KPB-2034-2024
OI Zuo, Tao/0000-0002-2125-7548; LIN, CHING-HUNG/0000-0003-2403-4056; Zuo,
   Tao/0000-0001-8450-5281; Cheng, Ann-Lii/0000-0002-9152-6512
FU National Institutes of Health [U01 ES015986, R01 CA069065, R01 ES017594]
FX This work was supported by the National Institutes of Health [U01
   ES015986, R01 CA069065, and R01 ES017594 to T.H.-M.H]. We thank Jeff
   Apostolos for his technical assistance.
CR Akamine R, 2007, J BIOCHEM BIOPH METH, V70, P481, DOI 10.1016/j.jbbm.2006.11.008
   Björnström L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486
   Buteau-Lozano H, 2008, J ENDOCRINOL, V196, P399, DOI 10.1677/JOE-07-0198
   Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753
   *CDC, 2009, 4 CDC CDCP NAT CTR E
   Cheng ASL, 2008, CANCER RES, V68, P1786, DOI 10.1158/0008-5472.CAN-07-5547
   Dairkee SH, 2008, CANCER RES, V68, P2076, DOI 10.1158/0008-5472.CAN-07-6526
   Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104
   Dontu G, 2004, TRENDS ENDOCRIN MET, V15, P193, DOI 10.1016/j.tem.2004.05.011
   Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282
   Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Goodson A, 2004, FOOD ADDIT CONTAM A, V21, P1015, DOI 10.1080/02652030400011387
   Harréus UA, 2002, INT J ENVIRON AN CH, V82, P395, DOI 10.1080/0306731021000015047
   Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516
   Hsu PY, 2009, CANCER RES, V69, P5936, DOI 10.1158/0008-5472.CAN-08-4914
   Huang YW, 2009, CANCER RES, V69, P9038, DOI 10.1158/0008-5472.CAN-09-1499
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kanao H, 2005, CANCER RES, V65, P8640, DOI 10.1158/0008-5472.CAN-04-4112
   Kang JH, 2003, J FOOD PROTECT, V66, P1444, DOI 10.4315/0362-028X-66.8.1444
   Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1
   Lin CH, 2009, CANCER EPIDEM BIOMAR, V18, P1807, DOI 10.1158/1055-9965.EPI-09-0096
   Markey CM, 2001, BIOL REPROD, V65, P1215, DOI 10.1093/biolreprod/65.4.1215
   Mlarotta LLC, 2009, CURR OPIN GENET DEV, V19, P44, DOI 10.1016/j.gde.2008.12.003
   Mountfort KA, 1997, FOOD ADDIT CONTAM, V14, P737, DOI 10.1080/02652039709374584
   Muñoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340
   Murphy LC, 2009, J STEROID BIOCHEM, V114, P90, DOI 10.1016/j.jsbmb.2009.01.017
   Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Nikaido Y, 2004, REPROD TOXICOL, V18, P803, DOI 10.1016/j.reprotox.2004.05.002
   Ohm JE, 2007, CELL CYCLE, V6, P1040, DOI 10.4161/cc.6.9.4210
   Okada H, 2008, ENVIRON HEALTH PERSP, V116, P32, DOI 10.1289/ehp.10587
   Prins Gail S, 2008, Fertil Steril, V89, pe41, DOI 10.1016/j.fertnstert.2007.12.023
   Richter CA, 2007, REPROD TOXICOL, V24, P199, DOI 10.1016/j.reprotox.2007.06.004
   Röhrdanz E, 2002, J NUTR, V132, P370, DOI 10.1093/jn/132.3.370
   Soto AM, 2006, BEST PRACT RES CL EN, V20, P15, DOI 10.1016/j.beem.2005.09.001
   Timms BG, 2005, P NATL ACAD SCI USA, V102, P7014, DOI 10.1073/pnas.0502544102
   Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314
   Tyl RW, 2009, ENVIRON HEALTH PERSP, V117, P1644, DOI 10.1289/ehp.0900893
   Vaissière T, 2008, MUTAT RES-REV MUTAT, V659, P40, DOI 10.1016/j.mrrev.2008.02.004
   Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021
   Vogel Sarah A, 2009, Am J Public Health, V99 Suppl 3, pS559, DOI 10.2105/AJPH.2008.159228
   Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Yaoi T, 2008, BIOCHEM BIOPH RES CO, V376, P563, DOI 10.1016/j.bbrc.2008.09.028
NR 47
TC 88
Z9 100
U1 1
U2 32
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0041-008X
EI 1096-0333
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD OCT 15
PY 2010
VL 248
IS 2
BP 111
EP 121
DI 10.1016/j.taap.2010.07.014
PG 11
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA 663BG
UT WOS:000282857400004
PM 20678512
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Li, YY
   Yuan, YY
   Meeran, SM
   Tollefsbol, TO
AF Li, Yuanyuan
   Yuan, Yih-Ying
   Meeran, Syed M.
   Tollefsbol, Trygve O.
TI Synergistic epigenetic reactivation of estrogen receptor-α (ERα) by
   combined green tea polyphenol and histone deacetylase inhibitor in
   ERα-negative breast cancer cells
SO MOLECULAR CANCER
LA English
DT Article
ID DNA METHYLATION; EPIGALLOCATECHIN GALLATE; IN-VITRO; TAMOXIFEN;
   ACTIVATION; MECHANISMS; EXPRESSION; METHYLTRANSFERASE; CHEMOPREVENTION;
   TRANSCRIPTION
AB Background: The status of estrogen receptor-alpha (ER alpha) is critical to the clinical prognosis and therapeutic approach in breast cancer. ER alpha-negative breast cancer is clinically aggressive and has a poor prognosis because of the lack of hormone target-directed therapies. Previous studies have shown that epigenetic regulation plays a major role in ER alpha silencing in human breast cancer cells. Dietary green tea polyphenol, (-)-epigallocatechin-3-gallate (EGCG), is believed to be an anticancer agent in part through its regulation of epigenetic processes.
   Results: In our current studies, we found that EGCG can reactivate ER alpha expression in ER alpha-negative MDA-MB-231 breast cancer cells. Combination studies using EGCG with the histone deacetylase (HDAC) inhibitor, trichostatin A (TSA), revealed a synergistic effect of reactivation of ER alpha expression in ER alpha-negative breast cancer cells. Reactivation of ER alpha expression by EGCG and TSA treatment was found to sensitize ER alpha-dependent cellular responses to activator 17 beta-estradiol (E-2) and antagonist tamoxifen in ER alpha-negative breast cancer cells. We also found that EGCG can lead to remodeling of the chromatin structure of the ER alpha promoter by altering histone acetylation and methylation status thereby resulting in ER alpha reactivation. A decreased binding of the transcription repressor complex, Rb/p130-E2F4/5-HDAC1-SUV39H1-DNMT1, in the regulatory region of the ER alpha promoter also contributes to ER alpha transcriptional activation through treatment with EGCG and/or TSA.
   Conclusions: Collectively, these studies show that green tea EGCG can restore ER alpha expression by regulating epigenetic mechanisms, and this effect is enhanced when combined with an HDAC inhibitor. This study will facilitate more effective uses of combination approaches in breast cancer therapy and will help to explore more effective chemotherapeutic strategies toward hormone-resistant breast cancer.
C1 [Li, Yuanyuan; Yuan, Yih-Ying; Meeran, Syed M.; Tollefsbol, Trygve O.] Univ Alabama, Dept Biol, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama, Ctr Aging, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama, Nutr Obes Res Ctr, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Tollefsbol, TO (通讯作者)，Univ Alabama, Dept Biol, 1300 Univ Blvd, Birmingham, AL 35294 USA.
EM trygve@uab.edu
RI Meeran, Syed/AAG-2157-2020
FU National Cancer Institute [RO1 CA129415]; Susan G. Komen for the Cure;
   Glenn Foundation for Medical Research
FX This work was supported by grants from the National Cancer Institute
   (RO1 CA129415), Susan G. Komen for the Cure, and the Glenn Foundation
   for Medical Research. We would like to thank Dr. Asim Kumar Bej
   (Department of Biology, University of Alabama at Birmingham) and Dr.
   Santosh K. Katiyar (Department of Dermatology, University of Alabama at
   Birmingham) for providing assistance with facilities in this study.
CR Belguise K, 2007, CANCER RES, V67, P5763, DOI 10.1158/0008-5472.CAN-06-4327
   Berletch JB, 2008, J CELL BIOCHEM, V103, P509, DOI 10.1002/jcb.21417
   BOVENZI V, 2001, CANC CHEMOTHER PHARM, V48
   Bushman JL, 1998, NUTR CANCER, V31, P151, DOI 10.1080/01635589809514697
   Chisholm K, 2004, ANTI-CANCER DRUG, V15, P889, DOI 10.1097/00001813-200410000-00010
   Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937
   Fang MZ, 2007, J NUTR, V137, p223S, DOI 10.1093/jn/137.1.223S
   Fang MZ, 2003, CANCER RES, V63, P7563
   Gadducci A, 2005, GYNECOL ENDOCRINOL, V20, P343, DOI 10.1080/09513590500128492
   Goodin MG, 2002, TOXICOL SCI, V69, P354, DOI 10.1093/toxsci/69.2.354
   Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664
   Jang ER, 2004, ONCOGENE, V23, P1724, DOI 10.1038/sj.onc.1207315
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Juge N, 2007, CELL MOL LIFE SCI, V64, P1105, DOI 10.1007/s00018-007-6484-5
   Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905
   Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Li Y, 2010, CURR MED CHEM, V17, P2141, DOI 10.2174/092986710791299966
   Li YY, 2010, FASEB J, V24, P1442, DOI 10.1096/fj.09-149328
   Li YY, 2009, INT J CANCER, V125, P286, DOI 10.1002/ijc.24398
   Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578
   Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881
   McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884
   Nakachi K, 1998, JPN J CANCER RES, V89, P254, DOI 10.1111/j.1349-7006.1998.tb00556.x
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   ROODI N, 1995, JNCI-J NATL CANCER I, V87, P446, DOI 10.1093/jnci/87.6.446
   Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402
   Thangapazham RL, 2007, CANCER LETT, V245, P232, DOI 10.1016/j.canlet.2006.01.027
   Vasanthi HR, 2009, MINI-REV MED CHEM, V9, P749, DOI 10.2174/138955709788452685
   Vaute O, 2002, NUCLEIC ACIDS RES, V30, P475, DOI 10.1093/nar/30.2.475
   Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381
   Yang XW, 2001, CANCER RES, V61, P7025
   Yang XW, 2000, CANCER RES, V60, P6890
NR 34
TC 141
Z9 167
U1 0
U2 23
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD OCT 14
PY 2010
VL 9
AR 274
DI 10.1186/1476-4598-9-274
PG 12
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 674IA
UT WOS:000283730600001
PM 20946668
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU King, JA
   Tan, F
   Mbeunkui, F
   Chambers, Z
   Cantrell, S
   Chen, HR
   Alvarez, D
   Shevde, LA
   Ofori-Acquah, SF
AF King, Judy A.
   Tan, Fang
   Mbeunkui, Flaubert
   Chambers, Zachariah
   Cantrell, Sarah
   Chen, Hairu
   Alvarez, Diego
   Shevde, Lalita A.
   Ofori-Acquah, Solomon F.
TI Mechanisms of transcriptional regulation and prognostic significance of
   activated leukocyte cell adhesion molecule in cancer
SO MOLECULAR CANCER
LA English
DT Article
ID BREAST-CANCER; IMMUNOGLOBULIN SUPERFAMILY; DM-GRASP; SURFACE
   GLYCOPROTEIN; CD6 LIGAND; EXPRESSION; ALCAM; ALCAM/CD166; METASTASIS;
   MELANOMA
AB Background: Activated leukocyte cell adhesion molecule ( ALCAM) is implicated in the prognosis of multiple cancers with low level expression associated with metastasis and early death in breast cancer. Despite this significance, mechanisms that regulate ALCAM gene expression and ALCAM's role in adhesion of pre-metastatic circulating tumor cells have not been defined. We studied ALCAM expression in 20 tumor cell lines by real-time PCR, western blot and immunochemistry. Epigenetic alterations of the ALCAM promoter were assessed using methylation-specific PCR and bisulfite sequencing. ALCAM's role in adhesion of tumor cells to the vascular wall was studied in isolated perfused lungs.
   Results: A common site for transcription initiation of the ALCAM gene was identified and the ALCAM promoter sequenced. The promoter contains multiple cis-active elements including a functional p65 NF-kappa B motif, and it harbors an extensive array of CpG residues highly methylated exclusively in ALCAM-negative tumor cells. These CpG residues were modestly demethylated after 5-aza-2-deoxycytidine treatment. Restoration of high-level ALCAM expression using an ALCAM cDNA increased clustering of MDA-MB-435 tumor cells perfused through the pulmonary vasculature of ventilated rat lungs. Anti-ALCAM antibodies reduced the number of intravascular tumor cell clusters.
   Conclusion: Our data suggests that loss of ALCAM expression, due in part to DNA methylation of extensive segments of the promoter, significantly impairs the ability of circulating tumor cells to adhere to each other, and may therefore promote metastasis. These findings offer insight into the mechanisms for down-regulation of ALCAM gene expression in tumor cells, and for the positive prognostic value of high-level ALCAM in breast cancer.
C1 [King, Judy A.; Mbeunkui, Flaubert; Ofori-Acquah, Solomon F.] Univ S Alabama, Ctr Excellence Healthy Communities, Mobile, AL 36688 USA.
   [King, Judy A.; Chambers, Zachariah; Cantrell, Sarah; Chen, Hairu; Alvarez, Diego] Univ S Alabama, Ctr Lung Biol, Mobile, AL 36688 USA.
   [Tan, Fang; Ofori-Acquah, Solomon F.] Emory Univ, Sch Med, Aflac Canc Ctr, Atlanta, GA 30322 USA.
   [Tan, Fang; Ofori-Acquah, Solomon F.] Emory Univ, Sch Med, Blood Disorders Serv, Dept Pediat, Atlanta, GA 30322 USA.
   [Shevde, Lalita A.] Univ S Alabama, Mitchell Canc Inst, Mobile, AL 36604 USA.
C3 University of South Alabama; University of South Alabama; Emory
   University; Emory University; University of South Alabama
RP Ofori-Acquah, SF (通讯作者)，Univ S Alabama, Ctr Excellence Healthy Communities, 307 N Univ Blvd, Mobile, AL 36688 USA.
EM soforia@emory.edu
RI Alvarez, Diego/KSM-5349-2024
OI Alvarez, Diego/0000-0001-8244-629X; Ofori-Acquah,
   Solomon/0000-0001-5000-3048
FU NIH [R01HL077769, P20MD002314-030001]; AHA [0655377B]; American Heart
   Association (AHA) [0655377B] Funding Source: American Heart Association
   (AHA)
FX This work was supported by NIH grants R01HL077769 and P20MD002314-030001
   awarded to S.F Ofori-Acquah and AHA grant 0655377B (J.A. King).
CR Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429
   Alvarez DF, 2006, CIRC RES, V99, P988, DOI 10.1161/01.RES.0000247065.11756.19
   Begg CB, 2005, JNCI-J NATL CANCER I, V97, P1507, DOI 10.1093/jnci/dji312
   Borner C, 1999, MELANOMA RES, V9, P347, DOI 10.1097/00008390-199908000-00002
   BOWEN MA, 1995, J EXP MED, V181, P2213, DOI 10.1084/jem.181.6.2213
   Bruder SP, 1998, J BONE MINER RES, V13, P655, DOI 10.1359/jbmr.1998.13.4.655
   Burkhardt M, 2006, J CLIN PATHOL, V59, P403, DOI 10.1136/jcp.2005.028209
   BURNS FR, 1991, NEURON, V7, P209, DOI 10.1016/0896-6273(91)90259-3
   Çelebi JT, 2000, J MED GENET, V37, P653, DOI 10.1136/jmg.37.9.653
   Chetham PM, 1999, AM J PHYSIOL-LUNG C, V276, pL41, DOI 10.1152/ajplung.1999.276.1.L41
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Davies S, 2010, ANTICANCER RES, V30, P1163
   Davies SR, 2008, ONCOL REP, V19, P555
   Degen WGJ, 1998, AM J PATHOL, V152, P805
   DeLeeuw WJF, 1997, J PATHOL, V183, P404, DOI 10.1002/(SICI)1096-9896(199712)183:4<404::AID-PATH1148>3.0.CO;2-9
   Fillmore RA, 2009, INT J CANCER, V125, P556, DOI 10.1002/ijc.24276
   GLAVES D, 1988, BRIT J CANCER, V57, P32, DOI 10.1038/bjc.1988.4
   Ihnen M, 2008, BREAST CANCER RES TR, V112, P419, DOI 10.1007/s10549-007-9879-y
   IHNEN M, 2010, BR J CANC
   Ikeda K, 2004, J BIOL CHEM, V279, P55315, DOI 10.1074/jbc.M407776200
   Issa JPJ, 2004, BLOOD, V103, P1635, DOI 10.1182/blood-2003-03-0687
   Jansen CF., 2003, UROONCOLOGY, V3, P121, DOI DOI 10.1080/15610950310001632322
   Jezierska A, 2006, MED SCI MONITOR, V12, pBR263
   Jezierska A, 2006, MED SCI MONITOR, V12, pBR245
   Kahlert C, 2009, BRIT J CANCER, V101, P457, DOI 10.1038/sj.bjc.6605136
   KANKI JP, 1994, J NEUROBIOL, V25, P831, DOI 10.1002/neu.480250708
   Kilic E, 2008, Pathologe, V29 Suppl 2, P347, DOI 10.1007/s00292-008-1080-5
   King JA, 2004, BREAST CANCER RES, V6, pR478, DOI 10.1186/bcr815
   Konno A, 2001, J LEUKOCYTE BIOL, V69, P944
   Kristiansen G, 2003, PROSTATE, V54, P34, DOI 10.1002/pros.10161
   Kulasingam V, 2009, INT J CANCER, V125, P9, DOI 10.1002/ijc.24292
   LAESSING U, 1994, DIFFERENTIATION, V56, P21, DOI 10.1007/s002580050017
   Masedunskas A, 2006, FEBS LETT, V580, P2637, DOI 10.1016/j.febslet.2006.04.013
   Mitra A, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1874
   Ofori-Acquah SF, 2008, TRANSL RES, V151, P122, DOI 10.1016/j.trsl.2007.09.006
   PASCHKE KA, 1992, J CELL BIOL, V117, P863, DOI 10.1083/jcb.117.4.863
   PEDUZZI JD, 1994, BRAIN RES, V640, P296, DOI 10.1016/0006-8993(94)91885-6
   POURQUIE O, 1992, P NATL ACAD SCI USA, V89, P5261, DOI 10.1073/pnas.89.12.5261
   PRINCE JT, 1992, DEV BRAIN RES, V68, P193, DOI 10.1016/0165-3806(92)90061-Z
   Samant RS, 2001, CLIN EXP METASTAS, V18, P683, DOI 10.1023/A:1013124725690
   Senior K, 2009, LANCET INFECT DIS, V9, P80, DOI 10.1016/S1473-3099(09)70008-8
   Shevde LA, 2006, CLIN EXP METASTAS, V23, P123, DOI 10.1007/s10585-006-9013-2
   Stephan JP, 1999, DEV BIOL, V212, P264, DOI 10.1006/dbio.1999.9348
   TANAKA H, 1991, NEURON, V7, P535, DOI 10.1016/0896-6273(91)90366-8
   van Kempen LCLT, 2001, J BIOL CHEM, V276, P25783, DOI 10.1074/jbc.M011272200
   van Kempen LCLT, 2000, AM J PATHOL, V156, P769, DOI 10.1016/S0002-9440(10)64943-7
   Verma A, 2005, ONCOLOGY-BASEL, V68, P462, DOI 10.1159/000086989
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Weichert W, 2004, J CLIN PATHOL, V57, P1160, DOI 10.1136/jcp.2004.016238
   Wong CW, 2002, AM J PATHOL, V161, P749, DOI 10.1016/S0002-9440(10)64233-2
   ZHANG GQ, 1995, MOL CELL BIOL, V15, P1806
   Zheng Xiangyi, 2004, Zhonghua Nan Ke Xue, V10, P265
NR 52
TC 25
Z9 30
U1 0
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD OCT 7
PY 2010
VL 9
AR 266
DI 10.1186/1476-4598-9-266
PG 16
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 668IJ
UT WOS:000283261500001
PM 20929568
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Ramachandran, K
   Miller, H
   Gordian, E
   Rocha-Lima, C
   Singal, R
AF Ramachandran, Kavitha
   Miller, Heather
   Gordian, Edna
   Rocha-Lima, Caio
   Singal, Rakesh
TI Methylation-mediated Silencing of <i>TMS1</i> in Pancreatic Cancer and
   its Potential Contribution to Chemosensitivity
SO ANTICANCER RESEARCH
LA English
DT Article
DE Epigenetics; pancreatic cancer; DNA methylation; chemotherapy
ID RECRUITMENT DOMAIN PROTEIN; BREAST-CANCER; PHASE-II; EPIGENETIC
   ALTERATIONS; OVARIAN-CANCER; CELLS; EXPRESSION; DOCETAXEL; APOPTOSIS;
   DEATH
AB Background: Resistance to chemotherapeutic agents, resulting in part from epigenetic silencing of proapoptotic genes, is one of the causes of treatment failure of pancreatic cancer. We examined whether epigenetic silencing of target of methylation induced silencing 1 (TMS1) contributes to resistance to chemotherapy in pancreatic cancer. Materials and Methods: Methylation analysis was performed by methylation-specific PCR (MS-PCR) and gene expression was analyzed by quantitative reverse transcriptase PCR (qRT-PCR). MIA PaCa-2 cells were transfected with pCMV6-XL5/TMS1 plasmid and the effect of TMS1 expression on sensitivity to gemcitabine and docetaxel was determined. Cell viability was measured using Cell Titer Blue assay. Results: TMS1 expression was repressed in MIA PaCa-2 cells by DNA methylation. Up-regulation of TMS1 by recombinant gene expression in MIA PaCa-2 cells or by pretreatment of these cells with 5-azacytidine resulted in enhanced sensitivity to gemcitabine and docetaxel. Conclusion: Our results suggest that TMS1 is a potential therapeutic target in pancreatic cancer.
C1 [Ramachandran, Kavitha; Miller, Heather; Gordian, Edna; Rocha-Lima, Caio; Singal, Rakesh] Univ Miami, Sylvester Canc Ctr, Miami, FL 33136 USA.
C3 University of Miami
RP Singal, R (通讯作者)，1550 NW 10th Ave,PAP 219 M877, Miami, FL 33136 USA.
EM rsingal@med.miami.edu
CR Akahira J, 2004, CANCER SCI, V95, P40, DOI 10.1111/j.1349-7006.2004.tb03168.x
   Androulakis N, 1999, J CLIN ONCOL, V17, P1779, DOI 10.1200/JCO.1999.17.6.1779
   [Anonymous], CA CANC J CLIN
   Carmichael J, 1996, BRIT J CANCER, V73, P101, DOI 10.1038/bjc.1996.18
   Conway KE, 2000, CANCER RES, V60, P6236
   Das PM, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-28
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Fabbri F, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-6
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Gordian E, 2009, ANTICANCER RES, V29, P3207
   Haldar S, 1996, CANCER RES, V56, P1253
   Hasegawa M, 2007, ONCOGENE, V26, P1748, DOI 10.1038/sj.onc.1209965
   Jiang PH, 2006, WORLD J GASTROENTERO, V12, P1597, DOI 10.3748/wjg.v12.i10.1597
   Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602
   Levine JJ, 2003, ONCOGENE, V22, P3475, DOI 10.1038/sj.onc.1206430
   Masumoto J, 2003, BIOCHEM BIOPH RES CO, V303, P69, DOI 10.1016/S0006-291X(03)00309-7
   McConnell BB, 2000, CANCER RES, V60, P6243
   McConnell BB, 2004, APOPTOSIS, V9, P5, DOI 10.1023/B:APPT.0000012117.32430.0c
   Meggiato T, 2003, PANCREAS, V26, P65, DOI 10.1097/00006676-200301000-00011
   Omura N, 2009, INT J CLIN EXP PATHO, V2, P310
   Parsons MJ, 2006, ONCOGENE, V25, P6948, DOI 10.1038/sj.onc.1209684
   Parsons MJ, 2009, CANCER RES, V69, P1706, DOI 10.1158/0008-5472.CAN-08-2351
   Ramachandran K, 2009, CANCER RES, V69, P1527, DOI 10.1158/0008-5472.CAN-08-3609
   Rougier P, 2000, EUR J CANCER, V36, P1016, DOI 10.1016/S0959-8049(00)00072-1
   Sato N, 2006, J HEPATO-BILIARY-PAN, V13, P286, DOI 10.1007/s00534-005-1057-1
   Singal R, 1997, P NATL ACAD SCI USA, V94, P13724, DOI 10.1073/pnas.94.25.13724
   Terasawa K, 2004, CLIN CANCER RES, V10, P2000, DOI 10.1158/1078-0432.CCR-0932-03
   Virmani A, 2003, INT J CANCER, V106, P198, DOI 10.1002/ijc.11206
   Wang LG, 1999, CANCER CHEMOTH PHARM, V44, P355, DOI 10.1007/s002800050989
NR 30
TC 23
Z9 24
U1 0
U2 3
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
J9 ANTICANCER RES
JI Anticancer Res.
PD OCT
PY 2010
VL 30
IS 10
BP 3919
EP 3925
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 676LZ
UT WOS:000283914400008
PM 21036703
DA 2025-01-12
ER

PT J
AU Bianco-Miotto, T
   Chiam, K
   Buchanan, G
   Jindal, S
   Day, TK
   Thomas, M
   Pickering, MA
   O'Loughlin, MA
   Ryan, NK
   Raymond, WA
   Horvath, LG
   Kench, JG
   Stricker, PD
   Marshall, VR
   Sutherland, RL
   Henshall, SM
   Gerald, WL
   Scher, HI
   Risbridger, GP
   Clements, JA
   Butler, LM
   Tilley, WD
   Horsfall, DJ
   Ricciardelli, C
AF Bianco-Miotto, Tina
   Chiam, Karen
   Buchanan, Grant
   Jindal, Shalini
   Day, Tanya K.
   Thomas, Mervyn
   Pickering, Marie A.
   O'Loughlin, Melissa A.
   Ryan, Natalie K.
   Raymond, Wendy A.
   Horvath, Lisa G.
   Kench, James G.
   Stricker, Phillip D.
   Marshall, Villis R.
   Sutherland, Robert L.
   Henshall, Susan M.
   Gerald, William L.
   Scher, Howard I.
   Risbridger, Gail P.
   Clements, Judith A.
   Butler, Lisa M.
   Tilley, Wayne D.
   Horsfall, David J.
   Ricciardelli, Carmela
CA Australian Prostate Canc BioResour
TI Global Levels of Specific Histone Modifications and an Epigenetic Gene
   Signature Predict Prostate Cancer Progression and Development
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID VIDEO IMAGE-ANALYSIS; ANDROGEN RECEPTOR; DNA METHYLATION; BREAST-CANCER;
   RADICAL PROSTATECTOMY; ABERRANT EXPRESSION; TRIMETHYLATION; RECURRENCE;
   METHYLTRANSFERASE; COACTIVATOR
AB Background: Epigenetic alterations are common in prostate cancer, yet how these modifications contribute to carcinogenesis is poorly understood. We investigated whether specific histone modifications are prognostic for prostate cancer relapse, and whether the expression of epigenetic genes is altered in prostate tumorigenesis.
   Methods: Global levels of histone H3 lysine-18 acetylation (H3K18Ac) and histone H3 lysine-4 dimethylation (H3K4diMe) were assessed immunohistochemically in a prostate cancer cohort of 279 cases. Epigenetic gene expression was investigated in silico by analysis of microarray data from 23 primary prostate cancers (8 with biochemical recurrence and 15 without) and 7 metastatic lesions.
   Results: H3K18Ac and H3K4diMe are independent predictors of relapse-free survival, with high global levels associated with a 1.71-fold (P < 0.0001) and 1.80-fold (P = 0.006) increased risk of tumor recurrence, respectively. High levels of both histone modifications were associated with a 3-fold increased risk of relapse (P < 0.0001). Epigenetic gene expression profiling identified a candidate gene signature (DNMT3A, MBD4, MLL2, MLL3, NSD1, and SRCAP), which significantly discriminated nonmalignant from prostate tumor tissue (P = 0.0063) in an independent cohort.
   Conclusions: This study has established the importance of histone modifications in predicting prostate cancer relapse and has identified an epigenetic gene signature associated with prostate tumorigenesis.
   Impact: Our findings suggest that targeting the epigenetic enzymes specifically involved in a particular solid tumor may be a more effective approach. Moreover, testing for aberrant expression of epigenetic genes such as those identified in this study may be beneficial in predicting individual patient response to epigenetic therapies. Cancer Epidemiol Biomarkers Prev; 19(10); 2611-22. (C) 2010 AACR.
C1 [Ricciardelli, Carmela] Univ Adelaide, Discipline Obstet & Gynaecol, Sch Paediat & Reprod Hlth, Res Ctr Reprod Hlth,Robinson Inst, Adelaide, SA 5005, Australia.
   [Bianco-Miotto, Tina; Chiam, Karen; Buchanan, Grant; Jindal, Shalini; Day, Tanya K.; Pickering, Marie A.; O'Loughlin, Melissa A.; Ryan, Natalie K.; Butler, Lisa M.; Tilley, Wayne D.; Horsfall, David J.; Ricciardelli, Carmela] Univ Adelaide, Discipline Med, Dame Roma Mitchell Canc Res Labs, Brisbane, Qld, Australia.
   [Buchanan, Grant; O'Loughlin, Melissa A.] Univ Adelaide, Discipline Med, Freemasons Fdn Ctr Mens Hlth, Mol Ageing Lab, Brisbane, Qld, Australia.
   Hanson Inst, Brisbane, Qld, Australia.
   [Thomas, Mervyn] Emphron Informat, Brisbane, Qld, Australia.
   [Raymond, Wendy A.] Flinders Med Ctr, Bedford Pk, SA, Australia.
   [Raymond, Wendy A.] Gribbles Pathol, Bedford Pk, SA, Australia.
   [Horvath, Lisa G.; Kench, James G.; Sutherland, Robert L.; Henshall, Susan M.] St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia.
   [Stricker, Phillip D.] St Vincents Hosp, Dept Urol, Sydney, NSW 2010, Australia.
   [Stricker, Phillip D.; Sutherland, Robert L.; Henshall, Susan M.] Univ New S Wales, Fac Med, St Vincents Clin Sch, Kensington, NSW 2033, Australia.
   [Marshall, Villis R.] Royal Adelaide Hosp, Surg Serv, New York, NY USA.
   [Marshall, Villis R.] Royal Adelaide Hosp, Specialty Serv, New York, NY USA.
   [Gerald, William L.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA.
   [Scher, Howard I.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA.
   [Risbridger, Gail P.] Monash Univ, Dept Anat & Dev Biol, Prostate & Breast Canc Res Grp, Clayton, Vic, Australia.
   [Clements, Judith A.] Queensland Univ Technol, Australian Prostate Canc Res Centre Queensland, Discipline Mol Biosci, Kelvin Grove, Qld, Australia.
   [Clements, Judith A.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Kelvin Grove, Qld, Australia.
C3 University of Adelaide; Robinson Research Institute; University of
   Adelaide; University of Adelaide; Hanson Institute; Flinders Medical
   Centre; Garvan Institute of Medical Research; NSW Health; St Vincents
   Hospital Sydney; NSW Health; St Vincents Hospital Sydney; University of
   New South Wales Sydney; Memorial Sloan Kettering Cancer Center; Memorial
   Sloan Kettering Cancer Center; Monash University; Queensland University
   of Technology (QUT); Queensland University of Technology (QUT)
RP Ricciardelli, C (通讯作者)，Univ Adelaide, Discipline Obstet & Gynaecol, Sch Paediat & Reprod Hlth, Res Ctr Reprod Hlth,Robinson Inst, Adelaide, SA 5005, Australia.
EM carmela.ricciardelli@adelaide.edu.au
RI Day, Tanya/J-2187-2012; Butler, Lisa/AAP-9088-2020; Sutherland,
   Robert/A-8378-2008; Ryan, Natalie/H-1539-2011; Pickering,
   Marie/JPQ-5395-2023; Ricciardelli, Carmela/K-2212-2015; Bianco-Miotto,
   Tina/C-4808-2008; Risbridger, Gail/B-8655-2008
OI Horvath, Lisa/0000-0001-6842-9223; Butler, Lisa/0000-0003-2698-3220;
   Pickering, Marie/0009-0004-1351-4622; Thomas,
   Mervyn/0000-0003-2024-0688; Ricciardelli, Carmela/0000-0001-7415-1854;
   Kench, James Geoffrey/0000-0001-8687-4988; Stricker,
   Phillip/0000-0002-0934-0656; Clements, Judith/0000-0001-6026-1964;
   Bianco-Miotto, Tina/0000-0002-8431-5338; Tilley,
   Wayne/0000-0003-1893-2626; Chiam, Karen/0000-0001-8154-6731; Risbridger,
   Gail/0000-0003-3089-4028
FU Cancer Council of SA; National Health and Medical Research Council;
   University of Adelaide Medical Endowment Funds; University of Adelaide;
   National Health and Medical Research Council (NHMRC) [349457, 453662,
   627185, 290456]; U.S. Department of Defense [W81XWH-04-1-0017]; Prostate
   Cancer Foundation of Australia [YI02]; Cancer Institute NSW RT Hall
   Trust
FX Cancer Council of SA (Fellowship to T. Bianco-Miotto and L. M. Butler);
   National Health and Medical Research Council (Career Development Award,
   G. Buchanan); University of Adelaide Medical Endowment Funds (Hilda
   Farmer Research Fellowship, C. Ricciardelli); University of Adelaide
   (Postgraduate International Scholarship, K. Chiam); the National Health
   and Medical Research Council (NHMRC, Project Grant No. 349457, D.J.
   Horsfall, C. Ricciardelli, V. R. Marshall, and W. D. Tilley; no. 453662,
   W. D. Tilley, L. M. Butler, and V. R. Marshall; no. 627185, W. D.
   Tilley, L. M. Butler, H. I. Scher, and T. Bianco-Miotto); NHMRC
   (Enabling Grant No. 290456 to the Australian Prostate Cancer
   BioResource-J.A. Clements, G. P. Risbridger, R. L. Sutherland, and W. D.
   Tilley); the U.S. Department of Defense (W81XWH-04-1-0017, W. D.
   Tilley); the Prostate Cancer Foundation of Australia (G. Buchanan; ID
   no. YI02), Cancer Institute NSW & RT Hall Trust.
CR Barlesi F, 2007, J CLIN ONCOL, V25, P4358, DOI 10.1200/JCO.2007.11.2599
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bryant RJ, 2007, PROSTATE, V67, P547, DOI 10.1002/pros.20550
   Buchanan G, 2007, CANCER RES, V67, P10087, DOI 10.1158/0008-5472.CAN-07-1646
   Comuzzi B, 2004, J PATHOL, V204, P159, DOI 10.1002/path.1609
   Debes JD, 2003, CANCER RES, V63, P7638
   Dobosy JR, 2007, J UROLOGY, V177, P822, DOI 10.1016/j.juro.2006.10.063
   Ellinger J, 2010, PROSTATE, V70, P61, DOI 10.1002/pros.21038
   Elsheikh SE, 2009, CANCER RES, V69, P3802, DOI 10.1158/0008-5472.CAN-08-3907
   Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Fu MF, 2003, MOL CELL BIOL, V23, P8563, DOI 10.1128/MCB.23.23.8563-8575.2003
   Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200
   Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575
   Halkidou K, 2004, EUR UROL, V45, P382, DOI 10.1016/j.eururo.2003.10.005
   Halkidou K, 2004, PROSTATE, V59, P177, DOI 10.1002/pros.20022
   Henshall SM, 2006, J NATL CANCER I, V98, P1420, DOI 10.1093/jnci/djj378
   Hermanek P, 1992, Langenbecks Arch Chir Suppl Kongressbd, P40
   Hoffmann MJ, 2007, CANCER BIOL THER, V6, P1403, DOI 10.4161/cbt.6.9.4542
   Holzbeierlein J, 2004, AM J PATHOL, V164, P217, DOI 10.1016/S0002-9440(10)63112-4
   Hong H, 2004, CANCER-AM CANCER SOC, V101, P83, DOI 10.1002/cncr.20327
   HORSFALL DJ, 1989, BRIT J CANCER, V59, P129, DOI 10.1038/bjc.1989.26
   Horvath LG, 2005, INT J CANCER, V113, P415, DOI 10.1002/ijc.20599
   Isharwal S, 2008, PROSTATE, V68, P1097, DOI 10.1002/pros.20772
   Ke XS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004687
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lockwood CA, 1999, INT J CANCER, V84, P203, DOI 10.1002/(SICI)1097-0215(19990621)84:3<203::AID-IJC1>3.0.CO;2-U
   Miremadi A, 2007, HUM MOL GENET, V16, pR28, DOI 10.1093/hmg/ddm021
   Miyamoto K, 2005, JPN J CLIN ONCOL, V35, P293, DOI 10.1093/jjco/hyi088
   Mohamed MA, 2007, BJU INT, V99, P908, DOI 10.1111/j.1464-410X.2006.06704.x
   Özdag H, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-90
   Pang ST, 2006, PROSTATE, V66, P157, DOI 10.1002/pros.20328
   Park YS, 2008, ANN SURG ONCOL, V15, P1968, DOI 10.1245/s10434-008-9927-9
   Patra SK, 2002, MOL CARCINOGEN, V33, P163, DOI 10.1002/mc.10033
   Patra SK, 2001, BIOCHEM BIOPH RES CO, V287, P705, DOI 10.1006/bbrc.2001.5639
   Pritchard C, 2009, CANCER RES, V69, P1739, DOI 10.1158/0008-5472.CAN-07-6817
   Rhodes DR, 2003, J NATL CANCER I, V95, P661, DOI 10.1093/jnci/95.9.661
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   Ricciardelli C, 2005, PROSTATE, V63, P19, DOI 10.1002/pros.20154
   Ricciardelli C, 2008, PROSTATE, V68, P830, DOI 10.1002/pros.20747
   Ricciardelli C, 2009, PROSTATE, V69, P761, DOI 10.1002/pros.20926
   Sakko AJ, 2008, CANCER EPIDEM BIOMAR, V17, P2488, DOI 10.1158/1055-9965.EPI-08-0204
   Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874
   Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672
   Spin JM, 2004, PHYSIOL GENOMICS, V19, P292, DOI 10.1152/physiolgenomics.00148.2004
   Szyf M, 2005, BIOCHEMISTRY-MOSCOW+, V70, P533, DOI 10.1007/s10541-005-0147-7
   Szyf M, 2004, CANCER LETT, V211, P133, DOI 10.1016/j.canlet.2004.04.009
   TILLEY WD, 1994, CANCER RES, V54, P4096
   Tryndyak VP, 2006, CANCER BIOL THER, V5, P65, DOI 10.4161/cbt.5.1.2288
   Tzao C, 2009, MODERN PATHOL, V22, P252, DOI 10.1038/modpathol.2008.172
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Wei YK, 2008, MOL CARCINOGEN, V47, P701, DOI 10.1002/mc.20413
   Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199
   Yegnasubramanian S, 2008, CANCER RES, V68, P8954, DOI 10.1158/0008-5472.CAN-07-6088
NR 57
TC 114
Z9 134
U1 0
U2 11
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD OCT
PY 2010
VL 19
IS 10
BP 2611
EP 2622
DI 10.1158/1055-9965.EPI-10-0555
PG 12
WC Oncology; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Public, Environmental & Occupational Health
GA 659TT
UT WOS:000282590500024
PM 20841388
OA Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Gao, XA
   Fu, ZK
   Chen, SA
   Zhang, J
   Zhang, H
   Jiang, W
   Pang, D
   Li, DJ
AF Gao Xiang
   Fu Zhenkun
   Chen Shuang
   Zhang Jie
   Zhang Hua
   Jiang Wei
   Pang Da
   Li Dianjun
TI Association of <i>DNMT1</i> Gene Polymorphisms in Exons With Sporadic
   Infiltrating Ductal Breast Carcinoma Among Chinese Han Women in the
   Heilongjiang Province
SO CLINICAL BREAST CANCER
LA English
DT Article
DE DNA-methyltransferase 1; Haplotype; Infiltrating ductal carcinoma;
   Single nucleotide polymorphism
ID DNA-METHYLTRANSFERASE; CANCER; METHYLATION; EXPRESSION; MUTATION;
   OVEREXPRESSION; PROGNOSIS; TAMOXIFEN; C-ERBB-2; CLONING
AB Background: Infiltrating ductal carcinoma (IDC) is the most common malignant breast cancer in women, and genetic factors appear to play a significant role in the susceptibility to IDC. Alteration of DNA methylation is an epigenetic change in human cancers, including breast cancer. DNA-methyltransferase 1 (DNMT1) is a major enzyme that determines genomic methylation patterns. In order to clarify the association of DNMT1 polymorphisms with IDC, a case-control study was conducted in women from the Heilongjiang Province, in the northeast of China. Patients and Methods: We scrutinized the 2 genetic polymorphisms in exons of DNMT1 that may influence the activity of DNMT1. Our research subjects consisted of 305 patients with IDC and 314 age-matched healthy controls. Genotypes were determined by polymerase chain reaction restriction fragment length polymorphism. Data were analyzed using the chi(2) test by SPSS, version 13.0, and Haploview, version 4.1. The association between DNMT1 polymorphisms and the clinical features of IDC was analyzed. Results: In rs16999593, the frequency of CT genotype and C allele were lower in patients than in controls (P = .028 and P = .017, respectively). Also, rs2228611 AG genotype was higher in patients than in controls (P = .015). The frequency of haplotype CA was lower in patients than in controls (P = .034). Significant association was shown between the 2 single nucleotide polymorphisms of the DNMT1 gene and progesterone receptor (PgR) and p53 status. No association was found between DNMT1 gene polymorphisms and tumor size or estrogen receptor status. Conclusion: Our results was a previous study, which suggested that DNMT1 gene polymorphisms in exons may provide valuable information for predicting the sporadic IDC risk and may be associated with prognosis factors such as PgR and p53 status in Chinese Han women in the Heilongjiang Province.
C1 [Gao Xiang; Fu Zhenkun; Chen Shuang; Zhang Jie; Zhang Hua; Li Dianjun] Harbin Med Coll, Dept Immunol, Harbin 150086, Heilongjiang Pr, Peoples R China.
   [Pang Da] Harbin Med Coll, Affiliated Hosp 3, Dept Breast Surg, Harbin 150081, Heilongjiang Pr, Peoples R China.
   [Gao Xiang; Pang Da; Li Dianjun] Harbin Med Coll, Inst Canc Prevent & Treatment, Harbin 150081, Heilongjiang Pr, Peoples R China.
   [Jiang Wei] Harbin Med Coll, Coll Bioinformat, Harbin 150081, Heilongjiang Pr, Peoples R China.
C3 Harbin Medical University; Harbin Medical University; Harbin Medical
   University; Harbin Medical University
RP Li, DJ (通讯作者)，Harbin Med Coll, Dept Immunol, Baojian St, Harbin 150086, Heilongjiang Pr, Peoples R China.
EM pangdasir@163.com; dianjunli@163.com
RI 陈, 文杰·/HHN-5495-2022
FU National Natural Science Foundation of China [31070780]; Foundation of
   Health Department, Heilongjiang Province Graduate Student [2009-212];
   Innovative Fund of Heilongjiang Province Graduate Student
   [YJSCX2009-220HLJ]
FX This study was supported by a grant from the National Natural Science
   Foundation of China (31070780), the Foundation of Health Department,
   Heilongjiang Province Graduate Student (2009-212) and the Innovative
   Fund of Heilongjiang Province Graduate Student (YJSCX2009-220HLJ). We
   thank all patients and healthy volunteers for providing blood samples.
   We are grateful for the collaboration received from the participating
   hospitals and their staff.
CR Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618
   Beenken SW, 2001, ANN SURG, V233, P630, DOI 10.1097/00000658-200105000-00006
   BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   Chen TP, 2007, NAT GENET, V39, P391, DOI 10.1038/ng1982
   Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887
   Elledge RM, 2000, INT J CANCER, V89, P111, DOI 10.1002/(SICI)1097-0215(20000320)89:2<111::AID-IJC2>3.0.CO;2-W
   Feng W, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1762
   Hermann A, 2004, J BIOL CHEM, V279, P48350, DOI 10.1074/jbc.M403427200
   Howell CY, 2001, CELL, V104, P829, DOI 10.1016/S0092-8674(01)00280-X
   Jones JS, 2006, CANCER EPIDEM BIOMAR, V15, P886, DOI 10.1158/1055-9965.EPI-05-0644
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Kanai Y, 2003, CANCER LETT, V192, P75, DOI 10.1016/S0304-3835(02)00689-4
   Kimchi-Sarfaty C, 2007, SCIENCE, V315, P525, DOI 10.1126/science.1135308
   Lee SJ, 2005, CARCINOGENESIS, V26, P403, DOI 10.1093/carcin/bgh307
   Leng SG, 2008, CARCINOGENESIS, V29, P1380, DOI 10.1093/carcin/bgn121
   LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F
   Milutinovic S, 2004, J BIOL CHEM, V279, P27915, DOI 10.1074/jbc.M312823200
   Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890
   Park BL, 2004, J HUM GENET, V49, P642, DOI 10.1007/s10038-004-0192-x
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341
   Rudolph P, 2001, HUM PATHOL, V32, P311, DOI 10.1053/hupa.2001.22748
   Stendahl M, 2006, CLIN CANCER RES, V12, P4614, DOI 10.1158/1078-0432.CCR-06-0248
   Taylor J, 2009, MOL REPROD DEV, V76, P501, DOI 10.1002/mrd.20968
   Wjst M, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-92
NR 26
TC 22
Z9 28
U1 0
U2 6
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 1526-8209
J9 CLIN BREAST CANCER
JI Clin. Breast Cancer
PD OCT
PY 2010
VL 10
IS 5
BP 373
EP 377
DI 10.3816/CBC.2010.n.049
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 656OR
UT WOS:000282346600006
PM 20920981
DA 2025-01-12
ER

PT J
AU Villanueva, A
   Hoshida, Y
   Toffanin, S
   Lachenmayer, A
   Alsinet, C
   Savic, R
   Cornella, H
   Llovet, JM
AF Villanueva, Augusto
   Hoshida, Yujin
   Toffanin, Sara
   Lachenmayer, Anja
   Alsinet, Clara
   Savic, Radoslav
   Cornella, Helena
   Llovet, Josep M.
TI New Strategies in Hepatocellular Carcinoma: Genomic Prognostic Markers
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID MICRORNA EXPRESSION PATTERNS; ACUTE MYELOID-LEUKEMIA; GENE-EXPRESSION;
   MOLECULAR CLASSIFICATION; DNA METHYLATION; LIVER-CANCER; HEPATITIS-B;
   BREAST-CANCER; SURVIVAL; SIGNATURE
AB Accurate prognosis prediction in oncology is critical. In patients with hepatocellular carcinoma (HCC), unlike most solid tumors, the coexistence of two life-threatening conditions, cancer and cirrhosis, makes prognostic assessments difficult. Despite the usefulness of clinical staging systems for HCC in routine clinical decision making (e.g., Barcelona-Clinic Liver Cancer algorithm), there is still a need to refine and complement outcome predictions. Recent data suggest the ability of gene signatures from the tumor (e.g., EpCAM signature) and adjacent tissue (e.g., poor-survival signature) to predict outcome in HCC (either recurrence or overall survival), although independent external validation is still required. In addition, novel information is being produced by alternative genomic sources such as microRNA (miRNA; e.g., miR-26a) or epigenomics, areas in which promising preliminary data are thoroughly explored. Prognostic models need to contemplate the impact of liver dysfunction and risk of subsequent de novo tumors in a patient's life expectancy. The challenge for the future is to precisely depict genomic predictors (e.g., gene signatures, miRNA, or epigenetic biomarkers) at each stage of the disease and their specific influence to determine patient prognosis. Clin Cancer Res; 16(19); 4688-94. (C) 2010 AACR.
C1 [Toffanin, Sara; Lachenmayer, Anja; Savic, Radoslav; Llovet, Josep M.] Mt Sinai Sch Med, Div Liver Dis, Liver Canc Program, New York, NY 10029 USA.
   [Villanueva, Augusto; Alsinet, Clara; Cornella, Helena; Llovet, Josep M.] Hosp Clin Barcelona, IDIBAPS, Liver Unit, HCC Translat Res Lab,Barcelona Clin Liver Canc Gr, Barcelona, Spain.
   [Villanueva, Augusto; Alsinet, Clara; Cornella, Helena; Llovet, Josep M.] Inst Salud Carlos III, CIBEREHD, Madrid, Spain.
   [Hoshida, Yujin] Broad Inst Harvard & MIT, Canc Program, Cambridge, MA USA.
   [Toffanin, Sara] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Gastrointestinal Surg, Milan, Italy.
   [Toffanin, Sara] Fdn IRCCS Ist Nazl Tumori, Liver Transplantat Unit, Milan, Italy.
   [Llovet, Josep M.] Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain.
C3 Icahn School of Medicine at Mount Sinai; University of Barcelona;
   Hospital Clinic de Barcelona; IDIBAPS; Instituto de Salud Carlos III;
   CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; Harvard
   University; Massachusetts Institute of Technology (MIT); Broad
   Institute; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione
   IRCCS Istituto Nazionale Tumori Milan; ICREA
RP Llovet, JM (通讯作者)，Mt Sinai Sch Med, Div Liver Dis, Liver Canc Program, Madison Ave 1425,11F-70 Box 1123, New York, NY 10029 USA.
EM Josep.Llovet@mssm.edu
RI Augusto, Villanueva/F-9378-2012; Llovet, Josep M/ABB-6264-2021;
   Lachenmayer, Anja/CAH-3461-2022; Hoshida, Yujin/R-7513-2019; Llovet,
   Josep M/D-4340-2014
OI Savic, Radoslav/0000-0002-2670-3674; Villanueva,
   Augusto/0000-0003-3585-3727; Lachenmayer, Anja/0000-0002-5879-5737;
   Llovet, Josep M/0000-0003-0547-2667
FU European Association for the Study of the Liver; German Research
   Foundation (DFG); Istituto Nazionale dei Tumori, Fondazione IRCCS, Milan
   (Italy); Spanish National Health Institute [SAF-2007-61898]; Instituto
   de Salud Carlos III; NIH -NIDDK [1R01DK076986-01]; National Institutes
   of Health (Spain) [SAF-2007-61898]; Samuel Waxman Cancer Research
   Foundation; Bayer; Bristol-Myers Squibb; Johnson Johnson; Exelixis;
   ICREA Funding Source: Custom
FX A. Villanueva is a recipient of a Sheila Sherlock fellowship (European
   Association for the Study of the Liver). A. Lachenmayer is the recipient
   of a postdoctoral fellowship grant from the German Research Foundation
   (DFG). S. Toffanin is supported by a fellowship from Istituto Nazionale
   dei Tumori, Fondazione IRCCS, Milan (Italy). H. Cornella is supported by
   a grant from the Spanish National Health Institute (SAF-2007-61898). C.
   Alsinet is supported by a grant of Instituto de Salud Carlos III. J.M.
   Llovet has grants from NIH -NIDDK 1R01DK076986-01, National Institutes
   of Health (Spain) grant I+D Program (SAF-2007-61898), and Samuel Waxman
   Cancer Research Foundation.J.M. Llovet, research support, Bayer,
   Bristol-Myers Squibb, Johnson & Johnson, Exelixis; consultant, Bayer,
   Bristol Myers Squibb, Novartis, Biocompatibles. The other authors
   disclosed no potential conflicts of interest.
CR Andersen JB, 2010, HEPATOLOGY, V51, P1401, DOI 10.1002/hep.23488
   Bloomston M, 2007, JAMA-J AM MED ASSOC, V297, P1901, DOI 10.1001/jama.297.17.1901
   Boyault S, 2007, HEPATOLOGY, V45, P42, DOI 10.1002/hep.21467
   Budhu A, 2008, HEPATOLOGY, V47, P897, DOI 10.1002/hep.22160
   Budhu A, 2006, CANCER CELL, V10, P99, DOI 10.1016/j.ccr.2006.06.016
   Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995
   Calvisi DF, 2006, GASTROENTEROLOGY, V130, P1117, DOI 10.1053/j.gastro.2006.01.006
   Calvisi DF, 2007, J CLIN INVEST, V117, P2713, DOI 10.1172/JCI31457
   Chang MH, 2009, JNCI-J NATL CANCER I, V101, P1348, DOI 10.1093/jnci/djp288
   Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602
   Chiang DY, 2008, CANCER RES, V68, P6779, DOI 10.1158/0008-5472.CAN-08-0742
   Coulouarn C, 2009, ONCOGENE, V28, P3526, DOI 10.1038/onc.2009.211
   El-Serag HB, 2004, GASTROENTEROLOGY, V127, pS27, DOI 10.1053/j.gastro.2004.09.013
   Esteller M, 2001, CANCER RES, V61, P3225
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fan JB, 2004, GENOME RES, V14, P878, DOI 10.1101/gr.2167504
   FDA, GUID IND CL IN PRESS
   Foekens JA, 2008, P NATL ACAD SCI USA, V105, P13021, DOI 10.1073/pnas.0803304105
   Gao W, 2008, CARCINOGENESIS, V29, P1901, DOI 10.1093/carcin/bgn170
   Gramantieri L, 2009, CLIN CANCER RES, V15, P5073, DOI 10.1158/1078-0432.CCR-09-0092
   Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331
   Hoshida Y, 2008, NEW ENGL J MED, V359, P1995, DOI 10.1056/NEJMoa0804525
   Hoshida Y, 2010, SEMIN LIVER DIS, V30, P35, DOI 10.1055/s-0030-1247131
   Hoshida Y, 2009, HEPATOLOGY, V50, p312A
   Hoshida Yujin, 2009, Expert Rev Gastroenterol Hepatol, V3, P101, DOI 10.1586/egh.09.5
   Ji JF, 2009, NEW ENGL J MED, V361, P1437, DOI 10.1056/NEJMoa0901282
   Jiang J, 2008, CLIN CANCER RES, V14, P419, DOI 10.1158/1078-0432.CCR-07-0523
   Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021
   Krützfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303
   Kwon GY, 2005, J KOREAN MED SCI, V20, P242, DOI 10.3346/jkms.2005.20.2.242
   Lee JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377
   Lee JS, 2004, HEPATOLOGY, V40, P667, DOI 10.1002/hep.20375
   Lee S, 2003, AM J PATHOL, V163, P1371, DOI 10.1016/S0002-9440(10)63495-5
   Li WX, 2008, INT J CANCER, V123, P1616, DOI 10.1002/ijc.23693
   Liaw YF, 2004, NEW ENGL J MED, V351, P1521, DOI 10.1056/NEJMoa033364
   Lin CH, 2001, CANCER RES, V61, P4238
   Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Llovet JM, 2008, JNCI-J NATL CANCER I, V100, P698, DOI 10.1093/jnci/djn134
   Lou C, 2009, CANCER SCI, V100, P996, DOI 10.1111/j.1349-7006.2009.01138.x
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   McShane LM, 2005, JNCI-J NATL CANCER I, V97, P1180, DOI 10.1093/jnci/dji237
   Mi SL, 2007, P NATL ACAD SCI USA, V104, P19971, DOI 10.1073/pnas.0709313104
   Michiels S, 2005, LANCET, V365, P488, DOI 10.1016/S0140-6736(05)17866-0
   Murakami Y, 2006, ONCOGENE, V25, P2537, DOI 10.1038/sj.onc.1209283
   Ntzani EE, 2003, LANCET, V362, P1439, DOI 10.1016/S0140-6736(03)14686-7
   Oh BK, 2007, INT J MOL MED, V20, P65
   Payton JE, 2009, J CLIN INVEST, V119, P1714, DOI 10.1172/JCI38248
   Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060
   Rimsza LM, 2008, BLOOD, V112, P3425, DOI 10.1182/blood-2008-02-137372
   Saito Y, 2003, INT J CANCER, V105, P527, DOI 10.1002/ijc.11127
   Sangiovanni A, 2004, GASTROENTEROLOGY, V126, P1005, DOI 10.1053/j.gastro.2003.12.049
   Schepeler T, 2008, CANCER RES, V68, P6416, DOI 10.1158/0008-5472.CAN-07-6110
   Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425
   Sherman M, 2008, NEW ENGL J MED, V359, P2045, DOI 10.1056/NEJMe0807581
   Shi LM, 2006, NAT BIOTECHNOL, V24, P1151, DOI 10.1038/nbt1239
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Toffanin Sara, 2010, Gastroenterology, V138, P1202, DOI 10.1053/j.gastro.2010.01.024
   Villanueva A, 2008, CURR OPIN ONCOL, V20, P444, DOI 10.1097/CCO.0b013e328302c9e9
   Villanueva A, 2010, ANNU REV MED, V61, P317, DOI 10.1146/annurev.med.080608.100623
   Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392
   Yamashita T, 2008, CANCER RES, V68, P1451, DOI 10.1158/0008-5472.CAN-07-6013
   Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
NR 65
TC 104
Z9 115
U1 0
U2 12
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD OCT 1
PY 2010
VL 16
IS 19
BP 4688
EP 4694
DI 10.1158/1078-0432.CCR-09-1811
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 660MO
UT WOS:000282647900002
PM 20713493
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Wang, LZ
   Liu, RH
   Ribick, M
   Zheng, P
   Liu, Y
AF Wang, Lizhong
   Liu, Runhua
   Ribick, Mark
   Zheng, Pan
   Liu, Yang
TI FOXP3 as an X-linked Tumor Suppressor
SO DISCOVERY MEDICINE
LA English
DT Article
ID TRANSCRIPTION FACTOR FOXP3; HUMAN OVARIAN-CANCER; PROSTATE-CANCER;
   BREAST-CANCER; SUSCEPTIBILITY LOCUS; CARCINOMA CELLS; ACTIVE-X;
   CHROMOSOME; EXPRESSION; HETEROZYGOSITY
AB The FOXP3 gene was initially identified because its mutation caused lethal autoimmune diseases in mice and humans. Mice with heterozygous mutations of FoxP3 (mouse version of the FOXP3 gene) succumb to mammary tumors spontaneously, while those with prostate-specific deletions develop prostate intraepithelial neoplasia. Somatic mutations, deletion, and epigenetic inactivation of FOXP3 are widespread among human breast and prostate cancers. Unlike autosomal tumor suppressor genes that are usually inactivated by mutations in both alleles, X-linked FOXP3 mutations in cancer samples are usually heterozygous, with the wildtype allele selectively inactivated in cancer. This skewed X-inactivation suggests a new approach to reactivation of FOXP3 for cancer therapy. [Discovery Medicine 10(53):322-328, october 2010]
C1 [Wang, Lizhong; Liu, Runhua; Ribick, Mark; Liu, Yang] Univ Michigan, Sch Med, Dept Surg, Div Immunotherapy, Ann Arbor, MI 48109 USA.
   [Wang, Lizhong; Liu, Runhua; Ribick, Mark; Zheng, Pan; Liu, Yang] Univ Michigan, Ctr Canc, Ann Arbor, MI 48109 USA.
   [Zheng, Pan] Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48109 USA.
   [Zheng, Pan] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.
   [Liu, Yang] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan; University of Michigan System; University of
   Michigan; University of Michigan System; University of Michigan
RP Wang, LZ (通讯作者)，Univ Michigan, Sch Med, Dept Surg, Div Immunotherapy, Ann Arbor, MI 48109 USA.
EM lizhongw@umich.edu
RI LIU, Yani/ISB-3249-2023; Liu, Runhua/K-2388-2019; Wang,
   Lizhong/J-4268-2019; Zheng, Pan/E-8691-2011
OI Zheng, Pan/0000-0003-2598-3544
FU U.S. National Institutes of Health; U.S. Department of Defense
FX This work was supported by funding from the U.S. National Institutes of
   Health and the U.S. Department of Defense.
CR Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713
   Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784
   Buekers TE, 2000, GYNECOL ONCOL, V76, P418, DOI 10.1006/gyno.1999.5713
   Carrel L, 2005, NATURE, V434, P400, DOI 10.1038/nature03479
   Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679
   Chen GY, 2008, J IMMUNOL, V180, P5163, DOI 10.4049/jimmunol.180.8.5163
   ChenevixTrench G, 1997, GENE CHROMOSOME CANC, V18, P75, DOI 10.1002/(SICI)1098-2264(199702)18:2<75::AID-GCC1>3.0.CO;2-Y
   Cheng PC, 1996, J NATL CANCER I, V88, P510, DOI 10.1093/jnci/88.8.510
   Choi C, 1997, GENE CHROMOSOME CANC, V20, P234
   Crockford GP, 2006, HUM MOL GENET, V15, P443, DOI 10.1093/hmg/ddi459
   DODSON MK, 1993, CANCER RES, V53, P4456
   Ebert LM, 2008, CANCER RES, V68, P3001, DOI 10.1158/0008-5472.CAN-07-5664
   Edelson MI, 1998, ONCOGENE, V16, P197, DOI 10.1038/sj.onc.1201479
   Gudmundsson J, 2008, NAT GENET, V40, P281, DOI 10.1038/ng.89
   Hinz S, 2007, CANCER RES, V67, P8344, DOI 10.1158/0008-5472.CAN-06-3304
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   Karanikas V, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-19
   Katoh H, 2010, INT J BIOCHEM CELL B, V42, P1784, DOI 10.1016/j.biocel.2010.07.015
   Krejsgaard T, 2008, LEUKEMIA, V22, P2230, DOI 10.1038/leu.2008.224
   Ladoire S, 2010, BREAST CANC RES TREA
   Lange EM, 1999, CLIN CANCER RES, V5, P4013
   Liu RH, 2009, CANCER RES, V69, P2252, DOI 10.1158/0008-5472.CAN-08-3717
   Liu Y, 2010, TRENDS GENET, V26, P260, DOI 10.1016/j.tig.2010.03.004
   Martin F, 2010, ONCOGENE, V29, P4121, DOI 10.1038/onc.2010.174
   Merlo A, 2009, J CLIN ONCOL, V27, P1746, DOI 10.1200/JCO.2008.17.9036
   OSBORNE RJ, 1994, BRIT J CANCER, V69, P429, DOI 10.1038/bjc.1994.79
   Peters MA, 2000, HUM HERED, V51, P107, DOI 10.1159/000022965
   Rapley EA, 2000, NAT GENET, V24, P197, DOI 10.1038/72877
   Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013
   Rivera MN, 2007, SCIENCE, V315, P642, DOI 10.1126/science.1137509
   Sirchia SM, 2005, CANCER RES, V65, P2139, DOI 10.1158/0008-5472.CAN-04-3465
   Stephan DA, 2002, GENOMICS, V79, P41, DOI 10.1006/geno.2001.6681
   Wang LZ, 2009, CANCER CELL, V16, P336, DOI 10.1016/j.ccr.2009.08.016
   WANG N, 1990, CANCER GENET CYTOGEN, V46, P271, DOI 10.1016/0165-4608(90)90112-N
   Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707
   Woo YL, 2008, J CLIN PATHOL, V61, P969, DOI 10.1136/jcp.2008.056200
   Xu JF, 1998, NAT GENET, V20, P175, DOI 10.1038/2477
   YANGFENG TL, 1992, INT J CANCER, V52, P575, DOI 10.1002/ijc.2910520414
   YANGFENG TL, 1993, INT J CANCER, V54, P546, DOI 10.1002/ijc.2910540405
   Yaspan BL, 2008, HUM GENET, V123, P379, DOI 10.1007/s00439-008-0486-8
   Zhang HY, 2010, CANCER LETT, V287, P91, DOI 10.1016/j.canlet.2009.06.001
   Zuo T, 2007, J CLIN INVEST, V117, P3765, DOI 10.1172/JCI32538
   Zuo T, 2007, CELL, V129, P1275, DOI 10.1016/j.cell.2007.04.034
NR 43
TC 21
Z9 23
U1 0
U2 3
PU DISCOVERY MEDICINE
PI TIMONIUM
PA 10 GERARD AVE, STE 201, TIMONIUM, MD 21093 USA
SN 1539-6509
EI 1944-7930
J9 DISCOV MED
JI Discov. Med.
PD OCT
PY 2010
VL 10
IS 53
BP 322
EP 328
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA V27UT
UT WOS:000208638800005
PM 21034673
DA 2025-01-12
ER

PT J
AU Ko, FCF
   Chan, LK
   Tung, EKK
   Lowe, SW
   Ng, IOL
   Yam, JWP
AF Ko, Frankie Chi Fat
   Chan, Lo-Kong
   Tung, Edmund Kwok-Kwan
   Lowe, Scott W.
   Ng, Irene Oi-Lin
   Yam, Judy Wai Ping
TI Akt Phosphorylation of Deleted in Liver Cancer 1 Abrogates Its
   Suppression of Liver Cancer Tumorigenesis and Metastasis
SO GASTROENTEROLOGY
LA English
DT Article
DE Deleted in Liver Cancer 1; Akt; Phosphorylation; Hepatocellular
   Carcinoma
ID GTPASE-ACTIVATING PROTEIN; HUMAN HEPATOCELLULAR-CARCINOMA;
   TUMOR-SUPPRESSOR; SIGNALING PATHWAY; BREAST-CANCER; CELL-PROLIFERATION;
   DLC-1 GENE; RHO; MIGRATION; GROWTH
AB BACKGROUND & AIMS: Deleted in liver cancer 1 (DLC1), which encodes a Rho GTPase activating protein, is a bona fide tumor suppressor in hepatocellular carcinoma. Underexpression of DLC1 in cancer has been attributed to genomic deletion and epigenetic silencing. However, the regulatory mechanism of the tumor suppressive activity of DLC1 remains elusive. In this study, we elucidated a novel post-translational modification by which the activity of DLC1 is functionally regulated. METHODS: Molecular and biochemical approaches were employed to study Akt phosphorylation of DLC1. In vitro and in vivo functional assays were performed to elucidate the functional significance of Akt phosphorylation of DLC1. RESULTS: Phosphorylation of ectopically expressed and endogenous DLC1 was enhanced upon insulin induction or with Akt expression in liver cancer cell lines. Conversely, addition of a phosphatidylinositol 3-kinase/Akt pathway inhibitor or silencing of Akt attenuated the phosphorylation level of DLC1. Site-directed mutagenesis was employed to replace the serine residue of the consensus Akt substrate motifs of DLC1 with alanine. S567 of DLC1 was identified as the only target of Akt phosphorylation. S567 is well conserved in all DLC family members. DLC2 was phosphorylated by Akt at the corresponding residue. Functional assays demonstrated that the S567D phosphomimetic DLC1 mutant lost its inhibitory activities in tumorigenesis and metastasis of oncogenically transformed hepatoblasts in a mouse model. CONCLUSIONS: This study has revealed a novel post-translational modification that functionally deregulates the biologic activities of DLC1. Phosphorylation of DLC1 and DLC2 by Akt at the conserved residue points to a common regulatory mechanism of the DLC tumor suppressor family.
C1 [Ko, Frankie Chi Fat; Chan, Lo-Kong; Tung, Edmund Kwok-Kwan; Ng, Irene Oi-Lin; Yam, Judy Wai Ping] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.
   [Ko, Frankie Chi Fat; Chan, Lo-Kong; Tung, Edmund Kwok-Kwan; Ng, Irene Oi-Lin; Yam, Judy Wai Ping] Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Hong Kong, Peoples R China.
   [Ko, Frankie Chi Fat; Chan, Lo-Kong; Tung, Edmund Kwok-Kwan; Ng, Irene Oi-Lin; Yam, Judy Wai Ping] Univ Hong Kong, Li Ka Shing Fac Med, Ctr Canc Res, Hong Kong, Hong Kong, Peoples R China.
   [Lowe, Scott W.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA.
   [Lowe, Scott W.] Howard Hughes Med Inst, New York, NY USA.
C3 University of Hong Kong; University of Hong Kong; University of Hong
   Kong; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute
RP Yam, JWP (通讯作者)，Univ Hong Kong, Dept Pathol, Queen Mary Hosp, Univ Pathology Bldg, Hong Kong, Hong Kong, Peoples R China.
EM iolng@hku.hk; judyyam@pathology.hku.hk
RI Kong, Chan/AAI-9300-2020; Ko, Frankie Chi Fat/C-4759-2009; Yam, Judy Wai
   Ping/C-4454-2009
OI Ng, Irene Oi-lin/0000-0001-7532-2029; Ko, Frankie Chi
   Fat/0000-0002-0393-9668; Yam, Judy Wai Ping/0000-0002-5637-121X; CHAN,
   LO KONG/0000-0003-3082-1013
FU Hong Kong Research Grants Council [HKU7798/07M]; RGC [HKU 1/06C];
   University of Hong Kong
FX Supported by the Hong Kong Research Grants Council (HKU7798/07M), RGC
   collaborative research grants (HKU 1/06C), and the University of Hong
   Kong Seed Funding Programme for Basic Research and Outstanding Young
   Researcher Award (to J.W.P. Yam).
CR Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085
   Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933
   Chan LK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005572
   Durkin ME, 2007, ONCOGENE, V26, P4580, DOI 10.1038/sj.onc.1210244
   Durkin ME, 2007, J CELL MOL MED, V11, P1185, DOI 10.1111/j.1582-4934.2007.00098.x
   Goodison S, 2005, CANCER RES, V65, P6042, DOI 10.1158/0008-5472.CAN-04-3043
   Guan M, 2006, CLIN CANCER RES, V12, P1412, DOI 10.1158/1078-0432.CCR-05-1906
   Healy KD, 2008, MOL CARCINOGEN, V47, P326, DOI 10.1002/mc.20389
   Heering J, 2009, EXP CELL RES, V315, P2505, DOI 10.1016/j.yexcr.2009.05.022
   Hers I, 2006, J BIOL CHEM, V281, P4762, DOI 10.1074/jbc.M511008200
   Holeiter G, 2008, CANCER RES, V68, P8743, DOI 10.1158/0008-5472.CAN-08-0984
   Kim TY, 2008, J BIOL CHEM, V283, P32762, DOI 10.1074/jbc.M800617200
   Kim TY, 2007, BIOCHEM BIOPH RES CO, V355, P72, DOI 10.1016/j.bbrc.2007.01.121
   Ko FCF, 2010, LIVER INT, V30, P139, DOI 10.1111/j.1478-3231.2009.02133.x
   Lahoz A, 2008, GENE DEV, V22, P1724, DOI 10.1101/gad.1691408
   Liao YC, 2008, CANCER RES, V68, P7718, DOI 10.1158/0008-5472.CAN-08-2042
   Liao YC, 2007, J CELL BIOL, V176, P43, DOI 10.1083/jcb.200608015
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Ng IOL, 2000, CANCER RES, V60, P6581
   Plaumann M, 2003, J CANCER RES CLIN, V129, P349, DOI 10.1007/s00432-003-0440-z
   Qian XL, 2007, P NATL ACAD SCI USA, V104, P9012, DOI 10.1073/pnas.0703033104
   Schmitz KJ, 2008, J HEPATOL, V48, P83, DOI 10.1016/j.jhep.2007.08.018
   Scholz RP, 2009, J CELL SCI, V122, P92, DOI 10.1242/jcs.036251
   Seng TJ, 2007, ONCOGENE, V26, P934, DOI 10.1038/sj.onc.1209839
   Wong CCL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002779
   Wong CM, 2003, CANCER RES, V63, P7646
   Wong CM, 2005, CANCER RES, V65, P8861, DOI 10.1158/0008-5472.CAN-05-1318
   Xue W, 2008, GENE DEV, V22, P1439, DOI 10.1101/gad.1672608
   Yam JWP, 2006, HEPATOLOGY, V44, P881, DOI 10.1002/hep.21339
   Yam JWP, 2006, CANCER RES, V66, P8367, DOI 10.1158/0008-5472.CAN-05-2850
   Yuan BZ, 1998, CANCER RES, V58, P2196
   Yuan BZ, 2003, CANCER GENET CYTOGEN, V140, P113, DOI 10.1016/S0165-4608(02)00674-X
   Yuan BZ, 2004, ONCOGENE, V23, P1405, DOI 10.1038/sj.onc.1207291
   Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030
   Zhou XL, 2004, ONCOGENE, V23, P1308, DOI 10.1038/sj.onc.1207246
NR 35
TC 33
Z9 39
U1 0
U2 5
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD OCT
PY 2010
VL 139
IS 4
BP 1397
EP +
DI 10.1053/j.gastro.2010.06.051
PG 17
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 656WV
UT WOS:000282372700049
PM 20600027
OA Bronze
DA 2025-01-12
ER

PT J
AU Dong, WJ
   Chen, XB
   Xie, J
   Sun, PH
   Wu, YL
AF Dong, Wenjie
   Chen, Xiaobing
   Xie, Jing
   Sun, Pinghu
   Wu, Yunlin
TI Epigenetic inactivation and tumor suppressor activity of
   <i>HAI</i>-<i>2</i>/<i>SPINT2</i> in gastric cancer
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE gastric cancer; methylation; HAI-2/SPINT2
ID HEPATOCYTE GROWTH-FACTOR; FACTOR ACTIVATOR INHIBITOR; RENAL-CELL
   CARCINOMA; HUMAN BREAST-CANCER; C-MET; OVARIAN-CANCER; PROTEASE
   INHIBITOR; BIKUNIN HAI-2/PB; MOUSE MODEL; EXPRESSION
AB Hepatocyte growth factor (HGF) activator inhibitor type 2 (HAI-2/SPINT2) encodes Kunitz-type protease inhibitor that regulates HGF activity. Inspection of the human HAI-2/SPINT2 locus uncovered a large and dense CpG island within the 5' region of this gene. Analysis of cultured human gastric tumor lines indicated that HAI-2/SPINT2 expression is either undetectable or in low abundance in several lines; however, enhanced gene expression was measured in cells cultured on the DNA demethylating agent 5-aza-2'-deoxycytidine. Bisulfite DNA sequencing confirmed the densely methylated HAI-2/SPINT2 promoter region. Forced expression of HAI-2/SPINT2 induced cell apoptosis, suppressed anchorage independent growth in vitro and tumor growth in vivo. We investigated HAI-2/SPINT2 aberrant methylation in patients with gastric cancer. The HAI-2/SPINT2 methylation was found preferentially in cancerous tissues (30 of 40, 75%) compared with nontumor tissues (no methylation was detected), indicating that this aberrant characteristic is common in gastric malignancies. In conclusion, epigenetic inactivation of HAI-2/SPINT2 is a common event contributing to gastric carcinogenesis and may be a potential biomarker for gastric cancer.
C1 [Wu, Yunlin] Shanghai Jiao Tong Univ, Sch Med, Rui Jin Hosp, Dept Gastroenterol, Shanghai 200025, Peoples R China.
   [Chen, Xiaobing] Henan Tumor Hosp, Dept Med Oncol, Zhengzhou, Peoples R China.
   [Xie, Jing] Shanghai Jiao Tong Univ, Dept Pathol, Rui Jin Hosp, Shanghai 200025, Peoples R China.
C3 Shanghai Jiao Tong University; Zhengzhou University; Shanghai Jiao Tong
   University
RP Wu, YL (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Rui Jin Hosp, Dept Gastroenterol, 197 Rui Jin Rd 2, Shanghai 200025, Peoples R China.
EM wuyunlin195136@126.com
CR Abounader R, 2005, NEURO-ONCOLOGY, V7, P436, DOI 10.1215/S1152851705000050
   Cassinelli G, 2006, MOL CANCER THER, V5, P2388, DOI 10.1158/1535-7163.MCT-06-0245
   Cheng YY, 2007, BRIT J CANCER, V97, P895, DOI 10.1038/sj.bjc.6603968
   Finegold David N., 2008, Lymphatic Research and Biology, V6, P65, DOI 10.1089/lrb.2008.1524
   Fukai K, 2003, CANCER RES, V63, P8674
   Hamasuna R, 2001, INT J CANCER, V93, P339, DOI 10.1002/ijc.1349.abs
   Heideman DAM, 2004, J GENE MED, V6, P317, DOI 10.1002/jgm.523
   Heideman DAM, 2001, J PATHOL, V194, P428, DOI 10.1002/path.934
   Jeffers M, 1996, ONCOGENE, V13, P853
   Kaji M, 1996, CANCER GENE THER, V3, P393
   Kataoka H, 1998, CANCER LETT, V128, P219, DOI 10.1016/S0304-3835(98)00067-6
   Kawaguchi T, 1997, J BIOL CHEM, V272, P27558, DOI 10.1074/jbc.272.44.27558
   Knudsen BS, 2008, CURR OPIN GENET DEV, V18, P87, DOI 10.1016/j.gde.2008.02.001
   Kobayashi H, 2004, INT J CANCER, V110, P134, DOI 10.1002/ijc.20082
   Kobayashi H, 2004, CANCER-AM CANCER SOC, V100, P869, DOI 10.1002/cncr.20034
   Kobayashi H, 2003, J BIOL CHEM, V278, P7790, DOI 10.1074/jbc.M210407200
   Kongkham PN, 2008, CANCER RES, V68, P9945, DOI 10.1158/0008-5472.CAN-08-2169
   KUNIYASU H, 1992, BIOCHEM BIOPH RES CO, V189, P227, DOI 10.1016/0006-291X(92)91548-5
   Leung WK, 2006, CLIN CANCER RES, V12, P3216, DOI 10.1158/1078-0432.CCR-05-2442
   Maier JAM, 1996, ONCOGENE, V13, P1009
   Maruyama R, 2008, CARCINOGENESIS, V29, P1312, DOI 10.1093/carcin/bgn060
   Mitsuno M, 2007, J GASTROENTEROL, V42, P866, DOI 10.1007/s00535-007-2113-1
   MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024
   Morris MR, 2008, BRIT J CANCER, V98, P496, DOI 10.1038/sj.bjc.6604180
   Morris MR, 2005, CANCER RES, V65, P4598, DOI 10.1158/0008-5472.CAN-04-3371
   Parr C, 2004, CLIN CANCER RES, V10, P202, DOI 10.1158/1078-0432.CCR-0553-3
   Parr C, 2006, INT J CANCER, V119, P1176, DOI 10.1002/ijc.21881
   Sato K, 2001, BRIT J CANCER, V85, P199, DOI 10.1054/bjoc.2001.1888
   Sattler Martin, 2007, Curr Oncol Rep, V9, P102, DOI 10.1007/s11912-007-0005-4
   Schuster JM, 2003, J NEURO-ONCOL, V64, P219, DOI 10.1023/A:1025674227750
   SERUCA R, 1995, CANCER GENET CYTOGEN, V82, P140, DOI 10.1016/0165-4608(95)00033-L
   Stuart KA, 2000, INT J EXP PATHOL, V81, P17, DOI 10.1046/j.1365-2613.2000.00138.x
   Suzuki H, 1999, INT J CANCER, V83, P309, DOI 10.1002/(SICI)1097-0215(19991029)83:3<309::AID-IJC4>3.0.CO;2-Z
   Suzuki M, 2003, INT J CANCER, V104, P289, DOI 10.1002/ijc.10950
   Takei Y, 2005, INT J CANCER, V113, P54, DOI 10.1002/ijc.20548
   Tanaka Y, 2004, INT J CANCER, V109, P336, DOI 10.1002/ijc.11700
   Wang SY, 2004, J HEPATOL, V41, P267, DOI 10.1016/j.jhep.2004.04.013
   Yagyu T, 2006, INT J CANCER, V118, P2322, DOI 10.1002/ijc.21293
   Yu J, 2003, BRIT J CANCER, V88, P1560, DOI 10.1038/sj.bjc.6600940
   Zou B, 2006, GASTROENTEROLOGY, V131, P1835, DOI 10.1053/j.gastro.2006.09.050
NR 40
TC 40
Z9 48
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD OCT 1
PY 2010
VL 127
IS 7
BP 1526
EP 1534
DI 10.1002/ijc.25161
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 643ZM
UT WOS:000281340200004
PM 20063316
OA Bronze
DA 2025-01-12
ER

PT J
AU Marzese, DM
   Gago, FE
   Vargas-Roig, LM
   Roqué, M
AF Marzese, Diego M.
   Gago, Francisco E.
   Vargas-Roig, Laura M.
   Roque, Maria
TI Simultaneous analysis of the methylation profile of 26 cancer related
   regions in invasive breast carcinomas by MS-MLPA and drMS-MLPA
SO MOLECULAR AND CELLULAR PROBES
LA English
DT Article
DE Epigenetic signature; DNA methylation; Invasive breast tumor;
   Circulating tumor DNA
ID PROMOTER METHYLATION; DNA METHYLATION; CELLS
AB Genetic and epigenetic events play a critical role in the tumorigenic process of breast cancer. The more genes are studied, the more accurate the epigenetic "signature" can be established. The aim of our work has been to apply the technique Methylation-Specific Multiplex Ligation dependent Probe Amplification (MS-MLPA) to study the methylation profile of 26 cancer related gene regions in breast cancers. Secondly, we aimed to establish if the epigenetic "signature" could serve to detect circulating tumor DNA (ctDNA) in breast cancer patients. The MS-MLPA was successfully setup and allowed to establish which regions were preferentially associated with the tumor process. The analysis permitted also to detect significant concurrent methylation between some genes. The detection of ctDNA could be performed by a "double-round" MS-MLPA (drMS-MLPA) approach and nested-Methyl Specific PCR (Nested-MSP). This development is an important novelty and served to detect a small amount of tumor DNA shaded into the blood stream of breast cancer patients. We conclude that MS-MLPA is an excellent assay to analyze the methylation profile of a tumor. The 82 studied samples presented a specific methylation "mark". These studies serve to enhance the knowledge of the role of epigenetic alterations in breast tumors and can contribute to the development of personalized diagnosis, surveillance and treatment strategies. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Marzese, Diego M.; Roque, Maria] Natl Univ Cuyo, Sch Med Sci, IHEM CCT CONICET, Cellular & Mol Lab, RA-5500 Mendoza, Argentina.
   [Gago, Francisco E.] Gineco Mamario Inst Mendoza, RA-5500 Mendoza, Argentina.
   [Vargas-Roig, Laura M.] Natl Univ Cuyo, Inst Med & Expt Biol Cuyo, CCT CONICET Mendoza, RA-5500 Mendoza, Argentina.
C3 University Nacional Cuyo Mendoza; Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET); University Nacional Cuyo Mendoza;
   Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)
RP Roqué, M (通讯作者)，Natl Univ Cuyo, Sch Med Sci, IHEM CCT CONICET, Cellular & Mol Lab, Parque Gen San Martin S-N, RA-5500 Mendoza, Argentina.
EM marzese.diego@fcm.uncu.edu.ar; edugago@arlinkbbt.com.ar;
   vargasl@lab.cricyt.edu.ar; mroque@fcm.uncu.edu.ar
RI Marzese, Diego/AAA-3547-2022
OI Roque, Maria/0000-0002-9564-1032; Marzese, Diego/0000-0002-3258-8852
FU Vrije Universiteit of Amsterdam, The Netherlands; MRC-Holland BV,
   Amsterdam, The Netherlands
FX We would like to thank Dr J Orozco, Dr O Tello, Dr B Mendiondo and Dr F
   Real for their collaboration during the breast surgeries. We also would
   like to thank Dr Gerard Pals and Dr Jan Schouten from the Vrije
   Universiteit of Amsterdam, The Netherlands and MRC-Holland BV,
   Amsterdam, The Netherlands for their support and KJ and DH for their
   carefully revision of the English language.
CR Ballestar E, 2002, CARCINOGENESIS, V23, P1103, DOI 10.1093/carcin/23.7.1103
   Dolezel J, 2003, CYTOM PART A, V51A, P127, DOI 10.1002/cyto.a.10013
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Ghossein RA, 2000, EUR J CANCER, V36, P1681, DOI 10.1016/S0959-8049(00)00152-0
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hatada I, 2002, J HUM GENET, V47, P448, DOI 10.1007/s100380200063
   Henken FE, 2007, BRIT J CANCER, V97, P1457, DOI 10.1038/sj.bjc.6604055
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Li JD, 2005, GYNECOL ONCOL, V96, P150, DOI 10.1016/j.ygyno.2004.08.050
   Nygren AOH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni127
   Racila E, 1998, P NATL ACAD SCI USA, V95, P4589, DOI 10.1073/pnas.95.8.4589
   Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Yan PS, 2001, CANCER RES, V61, P8375
NR 14
TC 17
Z9 17
U1 2
U2 9
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0890-8508
J9 MOL CELL PROBE
JI Mol. Cell. Probes
PD OCT
PY 2010
VL 24
IS 5
BP 271
EP 280
DI 10.1016/j.mcp.2010.05.002
PG 10
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Biotechnology & Applied Microbiology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Cell Biology
GA 647DM
UT WOS:000281596400006
PM 20561583
DA 2025-01-12
ER

PT J
AU Beedanagari, SR
   Taylor, RT
   Bui, P
   Wang, F
   Nickerson, DW
   Hankinson, O
AF Beedanagari, Sudheer R.
   Taylor, Robert T.
   Bui, Peter
   Wang, Feng
   Nickerson, Derek W.
   Hankinson, Oliver
TI Role of Epigenetic Mechanisms in Differential Regulation of the
   Dioxin-Inducible Human <i>CYP1A1</i> and <i>CYP1B1</i> Genes
SO MOLECULAR PHARMACOLOGY
LA English
DT Article
ID ARYL-HYDROCARBON RECEPTOR; HUMAN BREAST-CANCER; DNA METHYLATION;
   PROSTATE-CANCER; AH RECEPTOR; CHROMATIN; TRANSCRIPTION; RECRUITMENT;
   PROMOTER; COMPLEX
AB The aryl hydrocarbon receptor (AhR) mediates induction of CYP1A1 and CYP1B1 by 2,3,7,8-tetrachlorodibenzo-rho-dioxin (dioxin) via binding to xenobiotic-responsive elements (XREs) in their enhancer regions. CYP1A1 and CYP1B1 were both inducible by dioxin in human MCF-7 cells. However, only CYP1A1 was inducible in human HepG2 cells. Further experiments focused on providing an explanation for this last observation. Dioxin induced the recruitment of AHR and the transcriptional coactivators p300 and p300/cAMP response element-binding protein binding protein-associated factor (PCAF) to the CYP1B1 enhancer in HepG2 cells but failed to induce recruitment of RNA polymerase II (poIII) or the TATA binding protein (TBP) and acetylations of histones 3 and 4 or methylation of histone 3 at the promoter. Because p300 was required for dioxin induction of the aforementioned histone modifications at the CYP1B1 promoter and for induction of CYP1B1 transcription (in MCF-7 cells), the recruitments of p300 and AhR, although necessary, are not sufficient for eliciting the above responses to dioxin. Cytosine residues within CpG dinucleotides at the enhancer, including those within the XREs, were partially methylated, whereas those at the promoter were fully methylated. Treatment of HepG2 cells with 5-aza-2'-deoxycytidine led to partial demethylation of the promoter, restored poIII and TBP binding, and CYP1B1 inducibility. Thus, the deficiency of CYP1B1 induction in HepG2 cells is ascribable to cytosine methylation at the promoter, which prevents recruitment of TBP and poIII. It is noteworthy that our data indicate that stable recruitment of p300 and PCAF to the CYP1B1 gene does not require their tethering to the promoter and to the enhancer.
C1 [Hankinson, Oliver] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Interdept Mol Toxicol Program, Los Angeles, CA 90095 USA.
   [Hankinson, Oliver] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
   [Hankinson, Oliver] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA.
   [Nickerson, Derek W.] Univ Calif Los Angeles, Dept Pediat Hematol & Oncol, Los Angeles, CA 90095 USA.
   [Taylor, Robert T.] Roche Pharmaceut, Nutley, NJ USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; UCLA Jonsson Comprehensive Cancer Center;
   University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   Roche Holding
RP Hankinson, O (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Interdept Mol Toxicol Program, 650 Charles Young Dr, Los Angeles, CA 90095 USA.
EM ohank@mednet.ucla.edu
FU National Institutes of Health National Cancer Institute [R01-CA28868];
   National Institutes of Health National Institute of Environmental Health
   Sciences [T32-ES015457]; National Institute of Environmental Health
   Sciences [T32ES015457] Funding Source: NIH RePORTER
FX This research was supported by the National Institutes of Health
   National Cancer Institute [Grant R01-CA28868]; and by the National
   Institutes of Health National Institute of Environmental Health Sciences
   [Grant T32-ES015457].
CR Beedanagari SR, 2010, TOXICOL LETT, V194, P26, DOI 10.1016/j.toxlet.2010.01.019
   Beedanagari SR, 2009, TOXICOL SCI, V110, P61, DOI 10.1093/toxsci/kfp079
   Bieche I, 2007, PHARMACOGENET GENOM, V17, P731, DOI 10.1097/FPC.0b013e32810f2e58
   Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200
   Habano W, 2009, INT J ONCOL, V34, P1085, DOI 10.3892/ijo_00000235
   Han WG, 2006, ANAL BIOCHEM, V355, P50, DOI 10.1016/j.ab.2006.05.010
   HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307
   Hestermann EV, 2003, MOL CELL BIOL, V23, P7920, DOI 10.1128/MCB.23.21.7920-7925.2003
   Hsu EL, 2007, TOXICOL SCI, V98, P436, DOI 10.1093/toxsci/kfm125
   HUFF J, 1994, ANNU REV PHARMACOL, V34, P343
   Kang GH, 2008, LAB INVEST, V88, P161, DOI 10.1038/labinvest.3700707
   Kornberg RD, 2007, P NATL ACAD SCI USA, V104, P12955, DOI 10.1073/pnas.0704138104
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   MacPherson L, 2009, BIOCHEM BIOPH RES CO, V385, P263, DOI 10.1016/j.bbrc.2009.05.060
   Mandal PK, 2005, J COMP PHYSIOL B, V175, P221, DOI 10.1007/s00360-005-0483-3
   Matthews J, 2007, BIOCHEM J, V406, P343, DOI 10.1042/BJ20070585
   Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978
   NEBERT DW, 1993, ANN NY ACAD SCI, V685, P624, DOI 10.1111/j.1749-6632.1993.tb35928.x
   O'Malley BW, 2007, MOL ENDOCRINOL, V21, P1009, DOI 10.1210/me.2007-0012
   Okino ST, 2006, CANCER RES, V66, P7420, DOI 10.1158/0008-5472.CAN-06-0504
   POLLENZ RS, 1994, MOL PHARMACOL, V45, P428
   REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193
   Schnekenburger M, 2007, MOL CELL BIOL, V27, P7089, DOI 10.1128/MCB.00838-07
   Shehin SE, 2000, J BIOL CHEM, V275, P6770, DOI 10.1074/jbc.275.10.6770
   SHEN ES, 1989, J BIOL CHEM, V264, P17754
   Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059
   Szyf M, 2009, ANNU REV PHARMACOL, V49, P243, DOI 10.1146/annurev-pharmtox-061008-103102
   Tang WM, 1996, J BIOL CHEM, V271, P28324, DOI 10.1074/jbc.271.45.28324
   Taylor RT, 2009, TOXICOL SCI, V107, P1, DOI 10.1093/toxsci/kfn217
   Tokizane T, 2005, CLIN CANCER RES, V11, P5793, DOI 10.1158/1078-0432.CCR-04-2545
   Tsuchiya Y, 2003, J BIOCHEM, V133, P583, DOI 10.1093/jb/mvg075
   Wihlén B, 2009, MOL CANCER RES, V7, P977, DOI 10.1158/1541-7786.MCR-08-0396
   Wo YYP, 1997, J BIOL CHEM, V272, P26702, DOI 10.1074/jbc.272.42.26702
   Yang XH, 2008, J CELL BIOCHEM, V104, P402, DOI 10.1002/jcb.21630
NR 35
TC 66
Z9 87
U1 0
U2 11
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0026-895X
EI 1521-0111
J9 MOL PHARMACOL
JI Mol. Pharmacol.
PD OCT
PY 2010
VL 78
IS 4
BP 608
EP 616
DI 10.1124/mol.110.064899
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 651FE
UT WOS:000281910200009
PM 20631054
OA Green Published
DA 2025-01-12
ER

PT J
AU Hildebrandt, MAT
   Gu, J
   Lin, J
   Ye, Y
   Tan, W
   Tamboli, P
   Wood, CG
   Wu, X
AF Hildebrandt, M. A. T.
   Gu, J.
   Lin, J.
   Ye, Y.
   Tan, W.
   Tamboli, P.
   Wood, C. G.
   Wu, X.
TI Hsa-miR-9 methylation status is associated with cancer development and
   metastatic recurrence in patients with clear cell renal cell carcinoma
SO ONCOGENE
LA English
DT Article
DE renal cell carcinoma; microRNA; methylation; metastasis; miR-9
ID HUMAN BREAST-CANCER; MICRORNAS; EXPRESSION; MIR-9
AB The long-term prognosis for clear cell renal cell carcinoma (ccRCC) is dramatically altered by the development of metastatic recurrence. However, there are very few indicators that can predict which patient will develop a recurrence. MicroRNAs regulate many cellular processes and have been shown to be associated with cancer development and recurrence. More recently it has been shown that microRNA genes can be epigenetically modified in cancer, resulting in aberrant silencing of microRNA genes with tumor suppressor functions. In this study, we show that two genes encoding for hsa-miR-9 are significantly hypermethylated in ccRCC tumors compared with adjacent normal tissues (P-value <0.001 for both miR-9-1 and miR-9-3) resulting in decreased expression, and that the methylation of these genes was more significant in DNA obtained from the primary tumor for patients who developed a recurrence (P-value: 0.012 and 0.009 for miR-9-1 and miR-9-3, respectively) than in tumors from nonrecurrent patients. Furthermore, methylation of miR-9-3 was significantly associated with an increased risk of recurrence (hazard ratio: 5.85, 95% confidence intervals: 1.30-26.35) and high methylation levels of either miR-9-1 or miR-9-3 resulted in a significant, nearly 30-month decrease in recurrence-free survival time (P-value: 0.034 and 0.007 for miR-9-1 and miR-9-3, respectively). Our results demonstrate that hsa-miR-9 is involved in the development of ccRCC while also having a role in the development of metastatic recurrence. Oncogene (2010) 29, 5724-5728; doi:10.1038/onc.2010.305; published online 2 August 2010
C1 [Wu, X.] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Unit 1340, Houston, TX 77030 USA.
   [Tamboli, P.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
   [Wood, C. G.] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; University of Texas System;
   UTMD Anderson Cancer Center
RP Wu, X (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Unit 1340, 1155 Pressler Blvd, Houston, TX 77030 USA.
EM xwu@mdanderson.org
RI Gu, Jian/Q-4780-2018
OI Gu, Jian/0000-0003-3499-0973
FU National Institute of Health [R01 CA098897]
FX Supported, in part, by National Institute of Health Grant R01 CA098897.
CR Bandres E, 2009, INT J CANCER, V125, P2737, DOI 10.1002/ijc.24638
   Budhu A, 2008, HEPATOLOGY, V47, P897, DOI 10.1002/hep.22160
   Garzon R, 2009, ANNU REV MED, V60, P167, DOI [10.1146/annurev.med.59.053006.104707, 10.1146/annurev.pathol.4.110807.092222]
   Hsu PY, 2009, CANCER RES, V69, P5936, DOI 10.1158/0008-5472.CAN-08-4914
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Laios A, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-35
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   Lujambio A, 2007, CELL CYCLE, V6, P1455
   Luo HC, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-82
   Omura N, 2008, CANCER BIOL THER, V7, P1146, DOI 10.4161/cbt.7.7.6208
   Pantuck AJ, 2001, J UROLOGY, V166, P1611, DOI 10.1016/S0022-5347(05)65640-6
   Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025
NR 15
TC 183
Z9 208
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD OCT
PY 2010
VL 29
IS 42
BP 5724
EP 5728
DI 10.1038/onc.2010.305
PG 5
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 668IT
UT WOS:000283262500008
PM 20676129
DA 2025-01-12
ER

PT J
AU Qian, T
   Lee, JY
   Park, JH
   Kim, HJ
   Kong, G
AF Qian, T.
   Lee, J-Y
   Park, J-H
   Kim, H-J
   Kong, G.
TI Id1 enhances RING1b E3 ubiquitin ligase activity through the
   Mel-18/Bmi-1 polycomb group complex
SO ONCOGENE
LA English
DT Article
DE Id1; polycomb group proteins; E3 ubiquitin ligase
ID CELL-CYCLE PROGRESSION; ESOPHAGEAL CANCER-CELLS; NF-KAPPA-B;
   BREAST-CANCER; PROTEASOME PATHWAY; STEM-CELLS; TRANSCRIPTIONAL
   REPRESSION; H2A UBIQUITYLATION; SIGNALING PATHWAY; DEPENDENT MANNER
AB The helix-loop-helix inhibitor of differentiation and DNA binding (Id1) is well known as an oncogene in various tumors. Although it has been reported that Id1 promotes several oncogenic processes, it is still unclear whether Id1 functions through epigenetic transcriptional regulation. In this study, we examined the effect of Id1 on polycomb group (PcG) proteins, which are crucial epigenetic gene silencers, and found that Id1 regulated the expression of Mel-18 and Bmi-1, both of which belong to polycomb repressive complex 1. We also confirmed that Id1 induced Mel-18 downregulation, which was mediated by the Akt pathway, and consequently upregulated the transcription of its target gene, c-Myc. Using a promoter-reporter, we demonstrated that Id1 regulated Bmi-1 transcription through c-Myc binding to its E-box in the promoter. Finally, we examined the activity of E3 ligase RING1b, whose catalytic activity is increased by binding with the RING finger protein Bmi-1, and found that Id1 overexpression enhanced RING1b E3 ligase activity leading to accumulation of H2A ubiquitination and ubiquitin/proteasome-mediated degradation of geminin. Taken together, our study provided a novel link between Id1 and PcG proteins and suggested that Id1 may contribute to tumor development through PcG-mediated epigenetic regulation. Oncogene (2010) 29, 5818-5827; doi: 10.1038/onc.2010.317; published online 9 August 2010
C1 [Qian, T.; Park, J-H; Kim, H-J; Kong, G.] Hanyang Univ, Dept Pathol, Coll Med, Seoul 133791, South Korea.
   [Lee, J-Y; Kong, G.] Hanyang Univ, Inst Bioengn & Biopharmaceut Res, Seoul 133791, South Korea.
C3 Hanyang University; Hanyang University
RP Kong, G (通讯作者)，Hanyang Univ, Dept Pathol, Coll Med, 17 Haengdang Dong, Seoul 133791, South Korea.
EM gkong@hanyang.ac.kr
FU Korean Government (MOEHRD) [KRF-2007-314-E00041]; Korean government
   (MEST) [20090081874]
FX This work was supported by a Korea Research Foundation Grant
   (KRF-2007-314-E00041) funded by the Korean Government (MOEHRD, Basic
   Research Promotion Fund) and a Korea Science and Engineering Foundation
   grant funded by the Korean government (MEST) (No. 20090081874).
CR Bernardi R, 2000, ONCOGENE, V19, P2447, DOI 10.1038/sj.onc.1203564
   Buchwald G, 2006, EMBO J, V25, P2465, DOI 10.1038/sj.emboj.7601144
   Calsés C, 2008, MOL CELL BIOL, V28, P1018, DOI 10.1128/MCB.01136-07
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002
   Choi YS, 2005, MOL CELLS, V20, P241
   Elderkin S, 2007, MOL CELL, V28, P107, DOI 10.1016/j.molcel.2007.08.009
   Gao HD, 2007, MOL CELL BIOCHEM, V305, P35, DOI 10.1007/s11010-007-9525-3
   Geng H, 2010, CANCER RES, V70, P3239, DOI 10.1158/0008-5472.CAN-09-3186
   Guo WJ, 2007, MOL BIOL CELL, V18, P536, DOI 10.1091/mbc.E06-05-0447
   Hattori T, 2003, GENES CELLS, V8, P889, DOI 10.1046/j.1365-2443.2003.00684.x
   Jang KS, 2006, CANCER LETT, V244, P203, DOI 10.1016/j.canlet.2005.12.016
   KANNO M, 1995, EMBO J, V14, P5672, DOI 10.1002/j.1460-2075.1995.tb00254.x
   Kim H, 2008, BREAST CANCER RES TR, V112, P287, DOI 10.1007/s10549-007-9871-6
   Kim HJ, 2007, MOL CANCER RES, V5, P321, DOI 10.1158/1541-7786.MCR-06-0218
   Kroll KL, 2007, FRONT BIOSCI, V12, P1395, DOI 10.2741/2156
   Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504
   Lee JY, 2009, ONCOGENE, V28, P824, DOI 10.1038/onc.2008.451
   Lee JY, 2008, CANCER RES, V68, P4201, DOI 10.1158/0008-5472.CAN-07-2570
   Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572
   Levine SS, 2004, TRENDS BIOCHEM SCI, V29, P478, DOI 10.1016/j.tibs.2004.07.007
   Li B, 2007, CARCINOGENESIS, V28, P2313, DOI 10.1093/carcin/bgm152
   Li B, 2009, INT J CANCER, V125, P2576, DOI 10.1002/ijc.24675
   Li ZZ, 2006, J BIOL CHEM, V281, P20643, DOI 10.1074/jbc.M602461200
   Lin JZ, 2010, CLIN CANCER RES, V16, P77, DOI 10.1158/1078-0432.CCR-08-2362
   Ling MT, 2006, DIFFERENTIATION, V74, P481, DOI 10.1111/j.1432-0436.2006.00083.x
   Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054
   Lund AH, 2004, CURR OPIN CELL BIOL, V16, P239, DOI 10.1016/j.ceb.2004.03.010
   Matsuo Fumie, 2002, Breast Cancer, V9, P33, DOI 10.1007/BF02967544
   McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X
   Ohtsubo M, 2008, P NATL ACAD SCI USA, V105, P10396, DOI 10.1073/pnas.0800672105
   Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587
   Saxena S, 2005, MUTAT RES-FUND MOL M, V569, P111, DOI 10.1016/j.mrfmmm.2004.05.026
   Seo S, 2005, GENE DEV, V19, P1723, DOI 10.1101/gad.1319105
   Singh J, 2002, ONCOGENE, V21, P1812, DOI 10.1038/sj.onc.1205252
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Swarbrick A, 2005, ONCOGENE, V24, P381, DOI 10.1038/sj.onc.1208188
   Tang XL, 2007, NAT CELL BIOL, V9, P1199, DOI 10.1038/ncb1641
   Van Damme N, 2008, CELL HOST MICROBE, V3, P245, DOI 10.1016/j.chom.2008.03.001
   Voncken JW, 2003, P NATL ACAD SCI USA, V100, P2468, DOI 10.1073/pnas.0434312100
   Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985
   Wei JH, 2006, J BIOL CHEM, V281, P22537, DOI 10.1074/jbc.M600826200
   Zaaroor-Regev D, 2010, P NATL ACAD SCI USA, V107, P6788, DOI 10.1073/pnas.1003108107
   Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103
   Zhao J, 2000, J CELL SCI, V113, P4363
   Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973
NR 46
TC 16
Z9 17
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD OCT
PY 2010
VL 29
IS 43
BP 5818
EP 5827
DI 10.1038/onc.2010.317
PG 10
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 672LY
UT WOS:000283586200007
PM 20697353
DA 2025-01-12
ER

PT J
AU Chang, JW
   Hsu, HS
   Ni, HJ
   Chuang, CT
   Hsiung, CH
   Huang, TH
   Wang, YC
AF Chang, Jer-Wei
   Hsu, Han-Shui
   Ni, Huey-Juin
   Chuang, Ching-Ting
   Hsiung, Chi-Hui
   Huang, Tim H.
   Wang, Yi-Ching
TI Distinct Epigenetic Domains Separated by a CTCF Bound Insulator between
   the Tandem Genes, <i>BLU</i> and <i>RASSF1A</i>
SO PLOS ONE
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; CELL LUNG-CANCER; DNA METHYLATION; NASOPHARYNGEAL
   CARCINOMA; MOLECULAR PATHOGENESIS; REGULATORY ELEMENTS; BREAST-CANCER;
   PROTEIN CTCF; ALLELE LOSS; INACTIVATION
AB Background: Tumor suppressor gene (TSG) RASSF1A and candidate TSG BLU are two tandem head-to-tail genes located at 3p21.3. We hypothesized that there may be a concordance on their gene expression and promoter methylation status. If not, then there may be an insulator located between RASSF1A and BLU genes that provides a barrier activity.
   Methodology/Principal Findings: We first identified potential transcriptionally important CpG sites using the methylation-specific oligonucleotide array in relation to mRNA expression of RASSF1A and BLU genes in primary lung tumors. We demonstrated that E2F1 bound to the potential transcriptionally important CpG sites in RASSF1A gene of a normal lung cell line expressing RASSF1A transcripts, whereas loss of E2F1 binding to RASSF1A in A549 cancer cell line was the result of DNA methylation. Both RASSF1A and BLU genes had their own potential transcriptionally important CpG regions. However, there was no correlation of methylation status between RASSF1A and BLU. Using gel shift assay and chromatin immunoprecipitation-PCR (ChIP-PCR), we found that CCCTC-binding factor (CTCF) bound to insulator sequences located between these two genes. Bisulfite sequencing and ChIP-PCR revealed distinct methylation and chromatin boundaries separated by the CTCF binding domains in normal cells, whereas such distinct epigenetic domains were not observed in cancer cells. Note that demethylation reagent and histone deacetylase inhibitor treatments led to CTCF binding and recovery of barrier effect for RASSF1A and BLU genes in cancer cells.
   Conclusions/Significance: Our study dissects the potential transcriptionally important CpG sites for RASSF1A and BLU genes at the sequence level and demonstrates that CTCF binding to the insulator of BLU gene provides a barrier activity within separate epigenetic domains of the juxtaposed BLU and RASSF1A loci in the 3p21.3 gene cluster region.
C1 [Chang, Jer-Wei; Hsiung, Chi-Hui; Wang, Yi-Ching] Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan.
   [Hsu, Han-Shui] Natl Yang Ming Univ, Inst Emergency & Crit Care Med, Taipei Vet Gen Hosp, Div Thorac Surg, Taipei 112, Taiwan.
   [Ni, Huey-Juin; Chuang, Ching-Ting] Natl Taiwan Normal Univ, Dept Life Sci, Taipei, Taiwan.
   [Huang, Tim H.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.
C3 National Cheng Kung University; National Yang Ming Chiao Tung
   University; Taipei Veterans General Hospital; National Taiwan Normal
   University; University System of Ohio; Ohio State University; James
   Cancer Hospital & Solove Research Institute
RP Chang, JW (通讯作者)，Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan.
EM ycw5798@mail.ncku.edu.tw
RI Wang, Yi-Ching/J-8702-2019
OI Wang, Yi-Ching/0000-0002-7694-2067
FU National Science Council [NSC96-2628-B-006-048-MY3]; Department of
   Health (The Executive Yuan, Republic of China) [DOH98-TD-G-111-024]
FX This work was supported in part by grant NSC96-2628-B-006-048-MY3 from
   the National Science Council and grant DOH98-TD-G-111-024 from the
   Department of Health (The Executive Yuan, Republic of China). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Agathanggelou A, 2003, ONCOGENE, V22, P1580, DOI 10.1038/sj.onc.1206243
   Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088
   Antes TJ, 2001, BIOCHEMISTRY-US, V40, P6731, DOI 10.1021/bi0100743
   Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697
   Dallol A, 2005, CANCER RES, V65, P7653, DOI 10.1158/0008-5472.CAN-05-0247
   Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389
   Filippova GN, 2008, CURR TOP DEV BIOL, V80, P337, DOI 10.1016/S0070-2153(07)80009-3
   Fong KM, 1999, J THORAC CARDIOV SUR, V118, P1136, DOI 10.1016/S0022-5223(99)70121-2
   Gaszner M, 2006, NAT REV GENET, V7, P703, DOI 10.1038/nrg1925
   Gitan RS, 2002, GENOME RES, V12, P158, DOI 10.1101/gr.202801
   Hesson L, 2004, ONCOGENE, V23, P2408, DOI 10.1038/sj.onc.1207407
   Hesson LB, 2007, ONCOGENE, V26, P7283, DOI 10.1038/sj.onc.1210547
   Kim DH, 2003, CANCER RES, V63, P3743
   Liu L, 2007, CELL CYCLE, V6, P1663, DOI 10.4161/cc.6.13.4435
   Marsit CJ, 2005, INT J CANCER, V114, P219, DOI 10.1002/ijc.20714
   Martinez A, 2001, J CLIN PATHOL-MOL PA, V54, P300, DOI 10.1136/mp.54.5.300
   Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333
   Mukhopadhyay R, 2004, GENOME RES, V14, P1594, DOI 10.1101/gr.2408304
   Müller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5
   Mund C, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni072
   Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192
   Palakurthy RK, 2009, MOL CELL, V36, P219, DOI 10.1016/j.molcel.2009.10.009
   Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632
   Rabizadeh S, 2004, J BIOL CHEM, V279, P29247, DOI 10.1074/jbc.M401699200
   Riquelme E, 2007, CANCER LETT, V250, P100, DOI 10.1016/j.canlet.2006.09.019
   Sekido Y, 1998, BBA-REV CANCER, V1378, pF21, DOI 10.1016/S0304-419X(98)00010-9
   Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091
   Strunnikova M, 2005, MOL CELL BIOL, V25, P3923, DOI 10.1128/MCB.25.10.3923-3933.2005
   Thiagalingam S, 2002, CURR OPIN ONCOL, V14, P65, DOI 10.1097/00001622-200201000-00012
   Tischoff I, 2005, INT J CANCER, V115, P684, DOI 10.1002/ijc.20944
   Tseng RC, 2005, INT J CANCER, V117, P241, DOI 10.1002/ijc.21178
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Vos MD, 2006, J BIOL CHEM, V281, P4557, DOI 10.1074/jbc.M512128200
   Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339
   Wang YC, 1998, CANCER RES, V58, P328
   Witcher M, 2009, MOL CELL, V34, P271, DOI 10.1016/j.molcel.2009.04.001
   Yan Pearlly S, 2004, Methods Mol Biol, V287, P251
   Yan PS, 2003, CANCER RES, V63, P6178
   Yau WL, 2006, INT J CANCER, V119, P2821, DOI 10.1002/ijc.22232
   Zhang B, 2009, ONCOGENE, V28, P651, DOI 10.1038/onc.2008.419
   Zhang DD, 2006, ANAL BIOCHEM, V355, P117, DOI 10.1016/j.ab.2006.04.048
NR 43
TC 12
Z9 15
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 20
PY 2010
VL 5
IS 9
AR e12847
DI 10.1371/journal.pone.0012847
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 651YH
UT WOS:000281963200016
PM 20877461
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Rauhala, HE
   Jalava, SE
   Isotalo, J
   Bracken, H
   Lehmusvaara, S
   Tammela, TLJ
   Oja, H
   Visakorpi, T
AF Rauhala, Hanna E.
   Jalava, Sanni E.
   Isotalo, Jarkko
   Bracken, Hazel
   Lehmusvaara, Saara
   Tammela, Teuvo L. J.
   Oja, Hannu
   Visakorpi, Tapio
TI miR-193b is an epigenetically regulated putative tumor suppressor in
   prostate cancer
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE prostatic carcinoma; neoplasia; CpG; methylation; miRNA
ID DOWN-REGULATION; BREAST-CANCER; MICRORNA; EXPRESSION; CELLS;
   CARCINOGENESIS; IDENTIFICATION; METHYLATION; PROGRESSION; SIGNATURE
AB miRNAs have proven to be key regulators of gene expression and are differentially expressed in various diseases, including cancer. Our aim was to identify epigenetically dysregulated genes in prostate cancer. We performed miRNA expression profiling after relieving epigenetic modifications in 6 prostate cancer cell lines and nonmalignant prostate epithelial cells. Thirty-eight miRNAs showed increased expression in any prostate cancer cell line after 5-aza-2 '-deoxycytidine (5azadC) and trichostatin A (TSA) treatments. Six of these also had decreased expression in clinical prostate cancer samples compared to benign prostatic hyperplasia. Among these, miR-193b was methylated in 22Rv1 cell line at a CpG island similar to 1 kb upstream of the miRNA locus. Expressing miR-193b in 22Rv1 cells using pre-miR-193b oligonucleotides caused a significant growth reduction (p < 0.001) resulting from a decrease of cells in S-phase of the cell cycle (p < 0.01). In addition, the anchorage independent growth was partially inhibited in transiently miR-193b-expressing 22Rv1 cells (p < 0.01). Altogether, our data suggest that miR-193b is an epigenetically silenced putative tumor suppressor in prostate cancer.
C1 [Rauhala, Hanna E.; Jalava, Sanni E.; Isotalo, Jarkko; Bracken, Hazel; Lehmusvaara, Saara; Visakorpi, Tapio] Univ Tampere, Inst Med Technol, FIN-33014 Tampere, Finland.
   [Rauhala, Hanna E.; Jalava, Sanni E.; Isotalo, Jarkko; Bracken, Hazel; Lehmusvaara, Saara; Tammela, Teuvo L. J.; Visakorpi, Tapio] Tampere Univ Hosp, Tampere, Finland.
   [Tammela, Teuvo L. J.] Univ Tampere, Dept Urol, FIN-33014 Tampere, Finland.
   [Oja, Hannu] Univ Tampere, Tampere Sch Publ Hlth, FIN-33014 Tampere, Finland.
C3 Tampere University; Tampere University; Tampere University Hospital;
   Tampere University; Tampere University
RP Visakorpi, T (通讯作者)，Univ Tampere, Inst Med Technol, FIN-33014 Tampere, Finland.
EM tapio.visakorpi@uta.fi
OI Rauhala, Hanna/0000-0001-7796-9117; Lehmusvaara,
   Saara/0000-0002-6608-0256; Visakorpi, Tapio/0000-0002-5004-0364
FU European Community [FP7/2007-2013, HEALTH-F2-2007-201438]; Academy of
   Finland; Cancer Society of Finland; Reino Lahtikari Foundation; Sigrid
   Juselius Foundation; Pirkanmaa Hospital District; Finnish Cultural
   Foundation
FX Grant sponsor: European Community's Seventh Framework Programme; Grant
   numbers: FP7/2007-2013, HEALTH-F2-2007-201438; Grant sponsors: Academy
   of Finland, Cancer Society of Finland, Reino Lahtikari Foundation,
   Sigrid Juselius Foundation, Competitive Research Funding of the
   Pirkanmaa Hospital District, Finnish Cultural Foundation
CR Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995
   Faller M, 2008, BBA-GENE REGUL MECH, V1779, P663, DOI 10.1016/j.bbagrm.2008.08.005
   Farré D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605
   Helenius MA, 2006, BJU INT, V97, P404, DOI 10.1111/j.1464-410X.2005.05912.x
   Ke XS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004687
   Kogan I, 2006, CANCER RES, V66, P3531, DOI 10.1158/0008-5472.CAN-05-2183
   KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188
   Kumano M, 2009, UROL ONCOL-SEMIN ORI, V27, P180, DOI 10.1016/j.urolonc.2008.01.012
   Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921
   Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329
   Leivonen SK, 2009, ONCOGENE, V28, P3926, DOI 10.1038/onc.2009.241
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Li XF, 2009, ONCOGENE, V28, P3937, DOI 10.1038/onc.2009.245
   Linja MJ, 2003, PROSTATE, V55, P180, DOI 10.1002/pros.10242
   Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079
   Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333
   Noonan EJ, 2009, ONCOGENE, V28, P1714, DOI 10.1038/onc.2009.19
   Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533
   Saini HK, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-564
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395
   Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103
   Zhou XF, 2007, PLOS COMPUT BIOL, V3, P412, DOI 10.1371/journal.pcbi.0030037
NR 27
TC 110
Z9 125
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD SEP 15
PY 2010
VL 127
IS 6
BP 1363
EP 1372
DI 10.1002/ijc.25162
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 643ZL
UT WOS:000281340100011
PM 20073067
DA 2025-01-12
ER

PT J
AU Dexter, TJ
   Sims, D
   Mitsopoulos, C
   Mackay, A
   Grigoriadis, A
   Ahmad, AS
   Zvelebil, M
AF Dexter, Tim J.
   Sims, David
   Mitsopoulos, Costas
   Mackay, Alan
   Grigoriadis, Anita
   Ahmad, Amar S.
   Zvelebil, Marketa
TI Genomic distance entrained clustering and regression modelling
   highlights interacting genomic regions contributing to proliferation in
   breast cancer
SO BMC SYSTEMS BIOLOGY
LA English
DT Article
ID COPY NUMBER ALTERATION; GENE-EXPRESSION; HISTOLOGIC GRADE;
   TUMOR-SUPPRESSOR; MOLECULAR-BASIS; CELL-CYCLE; SIGNATURE; ABERRATIONS;
   PROGRESSION; CARCINOMAS
AB Background: Genomic copy number changes and regional alterations in epigenetic states have been linked to grade in breast cancer. However, the relative contribution of specific alterations to the pathology of different breast cancer subtypes remains unclear. The heterogeneity and interplay of genomic and epigenetic variations means that large datasets and statistical data mining methods are required to uncover recurrent patterns that are likely to be important in cancer progression.
   Results: We employed ridge regression to model the relationship between regional changes in gene expression and proliferation. Regional features were extracted from tumour gene expression data using a novel clustering method, called genomic distance entrained agglomerative (GDEC) clustering. Using gene expression data in this way provides a simple means of integrating the phenotypic effects of both copy number aberrations and alterations in chromatin state. We show that regional metagenes derived from GDEC clustering are representative of recurrent regions of epigenetic regulation or copy number aberrations in breast cancer. Furthermore, detected patterns of genomic alterations are conserved across independent oestrogen receptor positive breast cancer datasets. Sequential competitive metagene selection was used to reveal the relative importance of genomic regions in predicting proliferation rate. The predictive model suggested additive interactions between the most informative regions such as 8p22-12 and 8q13-22.
   Conclusions: Data-mining of large-scale microarray gene expression datasets can reveal regional clusters of coordinate gene expression, independent of cause. By correlating these clusters with tumour proliferation we have identified a number of genomic regions that act together to promote proliferation in ER+ breast cancer. Identification of such regions should enable prioritisation of genomic regions for combinatorial functional studies to pinpoint the key genes and interactions contributing to tumourigenicity.
C1 [Dexter, Tim J.; Sims, David; Mitsopoulos, Costas; Mackay, Alan; Grigoriadis, Anita; Ahmad, Amar S.; Zvelebil, Marketa] Inst Canc Res, Chester Beatty Labs, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England.
C3 Royal Marsden NHS Foundation Trust; University of London; Institute of
   Cancer Research - UK
RP Dexter, TJ (通讯作者)，Inst Canc Res, Chester Beatty Labs, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.
EM tim.dexter@icr.ac.uk
OI Mitsopoulos, Costas/0000-0002-9116-5921; Grigoriadis,
   Anita/0000-0003-3434-201X; Sims, David/0000-0001-8960-8335; Zvelebil,
   Marketa/0000-0001-8018-5591
FU Breakthrough Breast Cancer; NHS
FX The authors would like to thank Prof. Alan Ashworth of the Institute for
   comments on the manuscript. We acknowledge funding from Breakthrough
   Breast Cancer and NHS funding to the NIHR Biomedical Research Centre.
CR [Anonymous], [No title captured]
   Bergamaschi A, 2006, GENE CHROMOSOME CANC, V45, P1033, DOI 10.1002/gcc.20366
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
   Brunet JP, 2004, P NATL ACAD SCI USA, V101, P4164, DOI 10.1073/pnas.0308531101
   Chen HX, 2004, MOL CELL BIOL, V24, P924, DOI 10.1128/MCB.24.2.924-935.2004
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009
   Dai HY, 2005, CANCER RES, V65, P4059, DOI 10.1158/0008-5472.CAN-04-3953
   Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Hicks J, 2006, GENOME RES, V16, P1465, DOI 10.1101/gr.5460106
   Huang E, 2003, NAT GENET, V34, P226, DOI 10.1038/ng1167
   Ignatiadis M, 2008, PATHOBIOLOGY, V75, P104, DOI 10.1159/000123848
   Jansen MPHM, 2007, J CLIN ONCOL, V25, P662, DOI 10.1200/JCO.2006.07.3676
   Korsching E, 2004, BRIT J CANCER, V90, P1422, DOI 10.1038/sj.bjc.6601658
   LANCE GN, 1967, COMPUT J, V9, P373, DOI 10.1093/comjnl/9.4.373
   Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522
   Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102
   Novak P, 2008, CANCER RES, V68, P8616, DOI 10.1158/0008-5472.CAN-08-1419
   Novak P, 2006, CANCER RES, V66, P10664, DOI 10.1158/0008-5472.CAN-06-2761
   Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008
   Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325
   Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999
   Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125
   Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002
   Simpson PT, 2005, J PATHOL, V205, P248, DOI 10.1002/path.1691
   SIMS D, BREAST CANC RES TREA
   Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   Whitfield ML, 2006, NAT REV CANCER, V6, P99, DOI 10.1038/nrc1802
   Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030
   Witcher M, 2009, MOL CELL, V34, P271, DOI 10.1016/j.molcel.2009.04.001
NR 31
TC 8
Z9 8
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1752-0509
J9 BMC SYST BIOL
JI BMC Syst. Biol.
PD SEP 8
PY 2010
VL 4
AR 127
DI 10.1186/1752-0509-4-127
PG 14
WC Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mathematical & Computational Biology
GA 655PC
UT WOS:000282260900001
PM 20825665
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Liang, CY
   Wang, LJ
   Chen, CP
   Chen, LF
   Chen, YH
   Chen, HW
AF Liang, Ching-Yeu
   Wang, Liang-Jie
   Chen, Chie-Pein
   Chen, Liang-Fu
   Chen, Yee-Hsiung
   Chen, Hungwen
TI GCM1 Regulation of the Expression of Syncytin 2 and Its Cognate Receptor
   MFSD2A in Human Placenta
SO BIOLOGY OF REPRODUCTION
LA English
DT Article
DE DNA methylation; female reproductive tract; GCM1; MFSDA2; placenta;
   pregnancy; syncytin 2; syncytiotrophoblast; trophoblast
ID MEMBRANE-PROTEIN SYNCYTIN; DNA DEMETHYLATION; HERV-W;
   FUNCTIONAL-CHARACTERIZATION; TRANSCRIPTIONAL ACTIVITY; ENVELOPE
   GLYCOPROTEIN; METHYLATION; GENE; PREECLAMPSIA; DIFFERENTIATION
AB Syncytin 2 is a newly identified placental membrane protein with fusogenic and immunosuppressive activities. Major facilitator superfamily domain containing 2A (MFSD2A) is the cognate receptor for syncytin 2-mediated cell-cell fusion. Both syncytin 2 and MFSD2A are highly expressed in placenta. In this study to understand the regulation of syncytin 2 and MFSD2A expression in placenta, we found that syncytin 2 gene is epigenetically silenced in nonplacental cells by cytosine-phosphate-guanine (CpG) dinucleotide methylation and that expression of syncytin 2 and MFSD2A genes are regulated by the placental transcription factor GCM1 in placental cells. Functional GCM1-binding sites were identified in syncytin 2 and MFSD2A promoters based on electrophoretic mobility shift assay and chromatin immunoprecipitation assay. Because GCM1 activity is decreased in hypoxic placental cells, we further confirmed that expression of MFSD2A is downregulated in hypoxic BeWo choriocarcinoma cells. Interestingly, ectopic expression of GCM1 activated syncytin 2 and MFSD2A expression in MCF-7 breast cancer cells and facilitated MCF-7 cell fusion. The expression of syncytin 2 in MCF-7 cells was partly attributed to CpG demethylation in the syncytin 2 promoter in the presence of GCM1. Our results suggest that GCM1 is a critical factor in controlling placental cell fusion through transcriptional regulation of syncytin 2 and MFSD2A gene expression in placenta. In addition, GCM1 may also play an important role in the epigenetic regulation of syncytin 2 gene expression.
C1 [Chen, Hungwen] Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan.
   [Chen, Chie-Pein] Mackay Mem Hosp, Div High Risk Pregnancy, Taipei, Taiwan.
   [Liang, Ching-Yeu; Wang, Liang-Jie; Chen, Liang-Fu; Chen, Yee-Hsiung; Chen, Hungwen] Natl Taiwan Univ, Grad Inst Biochem Sci, Taipei 10764, Taiwan.
C3 Academia Sinica - Taiwan; Mackay Memorial Hospital; National Taiwan
   University
RP Chen, HW (通讯作者)，Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan.
EM hwchen@gate.sinica.edu.tw
RI Chen, Hung-Wen/A-9312-2013
OI Liang, Ching-Yeu/0000-0002-9027-1853
FU National Science Council [96-2311-B-001-034]; Academia Sinica, Taiwan
FX Supported by grants (to H.C.) from the National Science Council
   (96-2311-B-001-034) and Academia Sinica, Taiwan.
CR Angers M, 2008, BIOCHEM J, V416, P347, DOI 10.1042/BJ20080165
   Barreto G, 2007, NATURE, V445, P671, DOI 10.1038/nature05515
   Bhutani N, 2010, NATURE, V463, P1042, DOI 10.1038/nature08752
   Blaise S, 2003, P NATL ACAD SCI USA, V100, P13013, DOI 10.1073/pnas.2132646100
   Blond JL, 2000, J VIROL, V74, P3321, DOI 10.1128/JVI.74.7.3321-3329.2000
   Blond JL, 1999, J VIROL, V73, P1175, DOI 10.1128/JVI.73.2.1175-1185.1999
   Cariappa R, 2003, PLACENTA, V24, P713, DOI 10.1016/S0143-4004(03)00085-7
   Chang C, 2004, BIOL REPROD, V71, P1956, DOI 10.1095/biolreprod.104.033340
   Chang CW, 2005, MOL CELL BIOL, V25, P8401, DOI 10.1128/MCB.25.19.8401-8414.2005
   Chen CP, 2008, BIOL REPROD, V79, P815, DOI 10.1095/biolreprod.108.069765
   Chen CP, 2006, BJOG-INT J OBSTET GY, V113, P152, DOI 10.1111/j.1471-0528.2005.00843.x
   Chen CP, 2004, PLACENTA, V25, P413, DOI 10.1016/j.placenta.2003.10.014
   Chiang MH, 2009, J BIOL CHEM, V284, P17411, DOI 10.1074/jbc.M109.016170
   Dupressoir A, 2005, P NATL ACAD SCI USA, V102, P725, DOI 10.1073/pnas.0406509102
   Dupressoir A, 2009, P NATL ACAD SCI USA, V106, P12127, DOI 10.1073/pnas.0902925106
   Esnault C, 2008, P NATL ACAD SCI USA, V105, P17532, DOI 10.1073/pnas.0807413105
   Frendo JL, 2003, MOL CELL BIOL, V23, P3566, DOI 10.1128/MCB.23.10.3566-3574.2003
   Gimenez J, 2009, DNA RES, V16, P195, DOI 10.1093/dnares/dsp011
   Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640
   Kekuda R, 1996, J BIOL CHEM, V271, P18657, DOI 10.1074/jbc.271.31.18657
   Kim MS, 2009, NATURE, V461, P1007, DOI 10.1038/nature08456
   KLIMAN HJ, 1986, ENDOCRINOLOGY, V118, P1567, DOI 10.1210/endo-118-4-1567
   Lavillette D, 2002, J VIROL, V76, P6442, DOI 10.1128/JVI.76.13.6442-6452.2002
   Mangeney M, 2007, P NATL ACAD SCI USA, V104, P20534, DOI 10.1073/pnas.0707873105
   Matousková M, 2006, EXP CELL RES, V312, P1011, DOI 10.1016/j.yexcr.2005.12.010
   Métivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544
   Mi S, 2000, NATURE, V403, P785, DOI 10.1038/35001608
   Niehrs C, 2009, DIFFERENTIATION, V77, P1, DOI 10.1016/j.diff.2008.09.004
   Simmons DG, 2008, DEVELOPMENT, V135, P2083, DOI 10.1242/dev.020099
   Um S, 1998, J BIOL CHEM, V273, P20728, DOI 10.1074/jbc.273.33.20728
   Yu CC, 2002, J BIOL CHEM, V277, P50062, DOI 10.1074/jbc.M209316200
   2000, AM J OBSTET GYNEC S1, V183, pS1
NR 32
TC 90
Z9 96
U1 0
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0006-3363
EI 1529-7268
J9 BIOL REPROD
JI Biol. Reprod.
PD SEP
PY 2010
VL 83
IS 3
BP 387
EP 395
DI 10.1095/biolreprod.110.083915
PG 9
WC Reproductive Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Reproductive Biology
GA 641TY
UT WOS:000281153800010
PM 20484742
OA Bronze, Green Submitted
DA 2025-01-12
ER

PT J
AU Jin, W
   Chen, L
   Chen, Y
   Xu, SG
   Di, GH
   Yin, WJ
   Wu, JO
   Shao, ZM
AF Jin, Wei
   Chen, Li
   Chen, Ying
   Xu, Si-guang
   Di, Gen-hong
   Yin, Wen-jin
   Wu, Jiong
   Shao, Zhi-ming
TI UHRF1 is associated with epigenetic silencing of BRCA1 in sporadic
   breast cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE UHRF1; BRCA1 promoter; DNA methylation; Histone modification
ID HISTONE H3 ACETYLATION; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION;
   MAMMALIAN-CELLS; DNA METHYLATION; BINDING-PROTEIN; SRA DOMAIN; ICBP90;
   PROMOTER; P300
AB BRCA1 is closely related to the pathogenesis of breast cancer, BRCA1 mRNA is reduced in sporadic breast cancer cells despite the lack of mutations. In the present report, we found that overexpression of UHRF1 (ubiquitin-like, containing PHD and RING finger domains 1) was closely related to DNA methylation, deacetylation, and methylation of histones, recruitment of an inhibiting transcriptional complex on the BRCA1 promoter in sporadic breast cancer. Overexpression of UHRF1 induced deacetylation of histones H3 and H4, which was facilitated by recruitment of histone deacetylase1 (HDAC1) to the BRCA1 promoter. Loss of acetylation was accompanied by loss of binding of the key transcription factors MyoD, CBP, and p300. UHRF1 also recruited histone lysine methyltransferase G9a to the BRCA1 promoter and histone 3 lysine 4 (H3K4) was demethylated, and histone 3 lysine 9 (H3K9) was methylated. Finally, overexpression of UHRF1 leaded to methylation of BRCA1 promoter by recruitment of DNMT1 to the BRCA1 promoter, locking in marked suppression of BRCA1. It is the first to describe that UHRF1 is responsible for regulating BRCA1 transcription by inducing DNA methylation, histone modifications, and recruitment of transcriptional complex on the BRCA1 promoter, UHRF1 is a new bio-marker in sporadic breast cancer.
C1 [Jin, Wei; Chen, Li; Chen, Ying; Xu, Si-guang; Di, Gen-hong; Yin, Wen-jin; Wu, Jiong; Shao, Zhi-ming] Fudan Univ, Shanghai Med Coll, Inst Biomed Sci,Dept Breast Surg, Breast Canc Inst,Canc Hosp,Canc Inst,Dept Oncol, Shanghai 200032, Peoples R China.
C3 Fudan University
RP Jin, W (通讯作者)，Fudan Univ, Shanghai Med Coll, Inst Biomed Sci,Dept Breast Surg, Breast Canc Inst,Canc Hosp,Canc Inst,Dept Oncol, 270 Dong An Rd, Shanghai 200032, Peoples R China.
EM jinwei7207@163.com; shaozhiming@yahoo.com
RI Yin, Wenjin/L-6020-2019; Wu, Jiong/LFT-4903-2024
OI Xu, Siguang/0000-0002-2010-1111; Di, Genhong/0000-0003-1171-7907
FU Shanghai Pujiang Program [2008]; Natural Science Foundation of Shanghai
   [09ZR1406900]; National Basic Research Program of China [2006CB910501];
   National Natural Science Foundation of China [30371580, 30572109];
   Scientific Research Foundation for the Returned Overseas Chinese
   Scholars, State Education Ministry and Innovation Program of Shanghai
   Municipal Education Commission [09ZZ04]
FX The authors thank the studied women for their willingness to cooperate
   with our study. The work was supported by the grants from Shanghai
   Pujiang Program (2008); the Natural Science Foundation of Shanghai (No.
   09ZR1406900); the National Basic Research Program of China
   (2006CB910501), National Natural Science Foundation of China (30371580,
   30572109); the Scientific Research Foundation for the Returned Overseas
   Chinese Scholars, State Education Ministry and Innovation Program of
   Shanghai Municipal Education Commission (No. 09ZZ04).
CR Achour M, 2008, ONCOGENE, V27, P2187, DOI 10.1038/sj.onc.1210855
   Atlas E, 2001, ONCOGENE, V20, P7110, DOI 10.1038/sj.onc.1204890
   Bae I, 2004, CANCER RES, V64, P7893, DOI 10.1158/0008-5472.CAN-04-1119
   Baldassarre G, 2003, MOL CELL BIOL, V23, P2225, DOI 10.1128/MCB.23.7.2225-2238.2003
   Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0
   Beger C, 2001, P NATL ACAD SCI USA, V98, P130, DOI 10.1073/pnas.98.1.130
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   Blobel GA, 2002, J LEUKOCYTE BIOL, V71, P545
   Bostick M, 2007, SCIENCE, V317, P1760, DOI 10.1126/science.1147939
   Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996
   Hashimoto H, 2009, EPIGENETICS-US, V4, P8, DOI 10.4161/epi.4.1.7370
   Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519
   Hopfner R, 2000, CANCER RES, V60, P121
   Huang Y, 2006, SCIENCE, V312, P748, DOI 10.1126/science.1125162
   Jeffy BD, 2005, NEOPLASIA, V7, P873, DOI 10.1593/neo.05256
   Kim JK, 2009, NUCLEIC ACIDS RES, V37, P493, DOI 10.1093/nar/gkn961
   LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P
   Liang GN, 2004, P NATL ACAD SCI USA, V101, P7357, DOI 10.1073/pnas.0401866101
   MacLachlan TK, 2000, J BIOL CHEM, V275, P31869, DOI 10.1074/jbc.M003338200
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Mousli M, 2003, BRIT J CANCER, V89, P120, DOI 10.1038/sj.bjc.6601068
   Mueller CR, 2003, BREAST CANCER RES, V5, P45, DOI 10.1186/bcr557
   Nightingale KP, 2007, J BIOL CHEM, V282, P4408, DOI 10.1074/jbc.M606773200
   Oberley MJ, 2003, J BIOL CHEM, V278, P42466, DOI 10.1074/jbc.M307733200
   Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2
   Rauch T, 2005, CELL CYCLE, V4, P1078
   Sharif J, 2007, NATURE, V450, P908, DOI 10.1038/nature06397
   Spillman MA, 1996, ONCOGENE, V13, P1639
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457
   Unoki M, 2004, ONCOGENE, V23, P7601, DOI 10.1038/sj.onc.1208053
   Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200
   Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029
NR 34
TC 86
Z9 103
U1 1
U2 15
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD SEP
PY 2010
VL 123
IS 2
BP 359
EP 373
DI 10.1007/s10549-009-0652-2
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 637HK
UT WOS:000280807900005
PM 19943104
DA 2025-01-12
ER

PT J
AU Xiang, TX
   Li, LL
   Fan, YC
   Jiang, YY
   Ying, Y
   Putti, TC
   Tao, QA
   Ren, GS
AF Xiang, Tingxiu
   Li, Lili
   Fan, Yichao
   Jiang, Yanyan
   Ying, Ying
   Putti, Thomas C.
   Tao, Qian
   Ren, Guosheng
TI PLCD1 is a functional tumor suppressor inducing G<sub>2</sub>/M arrest
   and frequently methylated in breast cancer
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE PLCD1; breast cancer; methylation; tumor suppressor gene
ID STRESS-RESPONSIVE GENE; PROMOTER HYPERMETHYLATION; PHOSPHOLIPASE
   C-DELTA-1; CHROMOSOME 3P; CELL GROWTH; 3P21.3; CYCLE; BLU
AB Chromosome 3p harbors multiple tumor-suppressor genes. PLCD1, located at 3p22, encodes an enzyme that mediates regulatory signaling of energy metabolism, calcium homeostasis and intracellular movement. We investigated the epigenetic alterations of PLCD1 and its tumor suppressor function in breast cancer. Frequent downregulation/silencing of PLCD1 was shown in most breast cancer cell lines by using semi-quantitative PCR. Promoter methylation of PLCD1 was detected in 78% (7/9) of cell lines and 52% (13/25) of primary tumors by Methylation-specific PCR (MSP), but not in any tumor adjacent breast tissues and normal breast tissues, which was further confirmed by bisulfite genomic sequencing (BGS). The silencing of PLCD1 could be reversed by pharmacological demethylation, indicating a methylation-mediated mechanism. Ectopic expression of PLCD1 in silenced breast cancer cells significantly inhibited their colony formation. In addition, PLCD1 inhibited tumor cell migration and induced cell cycle G(2)/M arrest. Thus, this study for the first time demonstrates the frequent inactivation of PLCD1 by promoter methylation and its tumor inhibitory function in breast cancer. Tumor-specific methylation of PLCD1 might serve as a biomarker for possible early detection and prognosis prediction of breast cancer.
C1 [Xiang, Tingxiu; Jiang, Yanyan; Tao, Qian; Ren, Guosheng] Chongqing Med Univ, Affiliated Hosp 1, Mol Oncol & Epigenet Lab, Chongqing, Peoples R China.
   [Li, Lili; Fan, Yichao; Ying, Ying; Tao, Qian] Chinese Univ Hong Kong, State Key Lab Oncol S China, Hong Kong Canc Inst,Canc Epigenet Lab, Sir YK Pao Ctr Canc,Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China.
   [Putti, Thomas C.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pathol, Singapore 117595, Singapore.
C3 Chongqing Medical University; Chinese University of Hong Kong; National
   University of Singapore
RP Tao, QA (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Mol Oncol & Epigenet Lab, Chongqing, Peoples R China.
EM qtao@clo.cuhk.edu.hk; rgs726@163.com
RI Xiang, Tingxiu/E-6157-2016; Tao, Qian/T-4743-2018; Li, Lili/Q-5750-2018
OI Tao, Qian/0000-0001-5383-4808; Li, Lili/0000-0002-0292-5889
FU Chinese University of Hong Kong; Chongqing science & technology
   commission; Chongqing Health Bureau
FX This study was supported by the Chinese University of Hong Kong,
   Chongqing science & technology commission and Chongqing Health Bureau
   grant. We thank Dr. Xin-Yuan Guan (Department of Clinical Oncology,
   University of Hong Kong) for the PLCD1 cDNA plasmid.
CR Agathanggelou A, 2003, ONCOGENE, V22, P1580, DOI 10.1038/sj.onc.1206243
   Ahmed S, 2009, NAT GENET, V41, P585, DOI 10.1038/ng.354
   CORN PG, 2009, CANC BIOL THER, V8
   Cui Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002990
   Drin G, 2007, CELL SIGNAL, V19, P1383, DOI 10.1016/j.cellsig.2007.04.006
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Fu L, 2007, CANCER RES, V67, P10720, DOI 10.1158/0008-5472.CAN-07-2411
   Hesson LB, 2007, ONCOGENE, V26, P7283, DOI 10.1038/sj.onc.1210547
   Hu XT, 2009, ONCOGENE, V28, P2466, DOI 10.1038/onc.2009.92
   Janetopoulos C, 2006, J CELL BIOL, V174, P485, DOI 10.1083/jcb.200603156
   Jin HC, 2007, P NATL ACAD SCI USA, V104, P12353, DOI 10.1073/pnas.0700153104
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kaproth-Joslin KA, 2008, BIOCHEM J, V415, P439, DOI 10.1042/BJ20080233
   McCracken M, 2007, CA-CANCER J CLIN, V57, P190, DOI 10.3322/canjclin.57.4.190
   Paz MF, 2003, HUM MOL GENET, V12, P2209, DOI 10.1093/hmg/ddg226
   Qin YR, 2008, INT J CANCER, V123, P826, DOI 10.1002/ijc.23577
   Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632
   Qiu GH, 2008, J HEPATOL, V48, P433, DOI 10.1016/j.jhep.2007.11.015
   Rebecchi MJ, 2009, ADV ENZYME REGUL, V49, P59, DOI 10.1016/j.advenzreg.2009.01.009
   Sidhu RS, 2005, J BIOL CHEM, V280, P21933, DOI 10.1074/jbc.M412966200
   Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413
   Stallings JD, 2005, J BIOL CHEM, V280, P22060, DOI 10.1074/jbc.M413813200
   Suh PG, 2008, BMB REP, V41, P415, DOI 10.5483/BMBRep.2008.41.6.415
   Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7
   Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091
   Wang Y, 2009, CANCER RES, V69, P5194, DOI 10.1158/0008-5472.CAN-08-3694
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Yang QF, 2002, J HUM GENET, V47, P453, DOI 10.1007/s100380200064
   Ying J, 2007, BLOOD, V110, P4130, DOI 10.1182/blood-2007-06-094870
   Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267
   Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835
NR 33
TC 49
Z9 59
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD SEP 1
PY 2010
VL 10
IS 5
DI 10.4161/cbt.10.5.12726
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 651EZ
UT WOS:000281909400016
PM 20657189
DA 2025-01-12
ER

PT J
AU Kim, M
   Jang, HR
   Haam, K
   Kang, TW
   Kim, JH
   Kim, SY
   Noh, SM
   Song, KS
   Cho, JS
   Jeong, HY
   Kim, JC
   Yoo, HS
   Kim, YS
AF Kim, Mirang
   Jang, Hay-Ran
   Haam, Keeok
   Kang, Tae-Wook
   Kim, Jeong-Hwan
   Kim, Seon-Young
   Noh, Seung-Moo
   Song, Kyu-Sang
   Cho, June-Sik
   Jeong, Hyun-Yong
   Kim, Jin Cheon
   Yoo, Hyang-Sook
   Kim, Yong Sung
TI Frequent silencing of <i>popeye domain-containing</i> genes, <i>BVES</i>
   and <i>POPDC3</i>, is associated with promoter hypermethylation in
   gastric cancer
SO CARCINOGENESIS
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITIONS; DNA METHYLATION; CELL-MIGRATION;
   TUMOR PROGRESSION; SKELETAL-MUSCLE; BREAST-CANCER; EXPRESSION; INVASION;
   PATTERNS; EGF
AB The Popeye domain-containing (POPDC) genes BVES, POPDC2 and POPDC3 encode proteins that regulate cell-cell adhesion and cell migration during development. Herein, we report the frequent downregulation of BVES and POPDC3 by promoter hypermethylation in gastric cancer. POPDC expression in 11 gastric cancer cell lines and 96 paired gastric tumor and normal adjacent tissues was analyzed with quantitative reverse transcription-polymerase chain reaction. The methylation status of BVES and POPDC3 was analyzed with methylated DNA immunoprecipitation sequencing, bisulfite sequencing and pyrosequencing. Expression of BVES and POPDC3 was downregulated in 73% of the gastric cancer cell lines and in 69% (BVES) and 87% (POPDC3) of the gastric cancer tissues. The BVES and POPDC3 promoter regions were hypermethylated in the gastric cancer cell lines in which they were silenced. Combined treatment with a DNA methylation inhibitor and a histone deacetylase inhibitor strongly induced BVES and POPDC3 expression. BVES and POPDC3 were hypermethylated in 69% (BVES) and 64% (POPDC3) of the gastric cancer tissues. We knocked down POPDC3 expression with short hairpin RNAs and examined the consequences on cell migration and invasion. Knockdown of POPDC3 in SNU-216 cells caused increased cell migration and invasion. Thus, epigenetic inactivation of BVES and POPDC3 occurs frequently in gastric tumors and may promote gastric cancer cell migration and invasion.
C1 [Kim, Mirang; Jang, Hay-Ran; Haam, Keeok; Kang, Tae-Wook; Kim, Jeong-Hwan; Kim, Seon-Young; Yoo, Hyang-Sook; Kim, Yong Sung] Korea Res Inst Biosci & Biotechnol, Med Genom Res Ctr, Taejon 305806, South Korea.
   [Haam, Keeok; Kim, Yong Sung] Univ Sci & Technol, Dept Funct Genom, Taejon 305333, South Korea.
   [Noh, Seung-Moo] Chungnam Natl Univ, Coll Med, Dept Gen Surg, Taejon 301747, South Korea.
   [Song, Kyu-Sang] Chungnam Natl Univ, Coll Med, Dept Pathol, Taejon 301747, South Korea.
   [Cho, June-Sik] Chungnam Natl Univ, Coll Med, Dept Diagnost Radiol, Taejon 301747, South Korea.
   [Jeong, Hyun-Yong] Chungnam Natl Univ, Coll Med, Dept Internal Med, Taejon 301747, South Korea.
   [Kim, Jin Cheon] Univ Ulsan, Coll Med, Dept Surg, Seoul 138736, South Korea.
C3 Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chungnam
   National University; Chungnam National University; Chungnam National
   University; Chungnam National University; University of Ulsan
RP Kim, YS (通讯作者)，Korea Res Inst Biosci & Biotechnol, Med Genom Res Ctr, Taejon 305806, South Korea.
EM yongsung@kribb.re.kr
RI Kim, Jin Young/AAB-6510-2020; Kim, Jong/C-9615-2011; Kim,
   Sunghoon/AAE-8314-2020; Kim, Han/AAA-5787-2021; Kim, Jin/Q-6322-2018;
   Kan, Tae Wook/CAI-4750-2022
OI Kang, Tae-Wook/0000-0002-1121-1562; Haam, Keeok/0000-0002-9933-7433;
   Jeong, Hyun Yong/0000-0001-8783-0506; Kim, Mirang/0000-0001-7415-0077
FU Ministry of Science and Technology [FG09-11-01]; Ministry of Health &
   Welfare of Korea [A062254]
FX 21C Frontier Functional Human Genome Project from the Ministry of
   Science and Technology (FG09-11-01); Korea Health 21 R&D Project
   (A062254) from the Ministry of Health & Welfare of Korea.
CR Andrée B, 2000, DEV BIOL, V223, P371, DOI 10.1006/dbio.2000.9751
   Andrée B, 2002, MOL CELL BIOL, V22, P1504, DOI 10.1128/MCB.22.5.1504-1512.2002
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Feng QH, 2008, CANCER EPIDEM BIOMAR, V17, P645, DOI 10.1158/1055-9965.EPI-07-2518
   Hager HA, 2009, HISTOL HISTOPATHOL, V24, P777, DOI 10.14670/HH-24.777
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   Hitz MP, 2002, MECH DEVELOP, V115, P123, DOI 10.1016/S0925-4773(02)00085-0
   Itoh RE, 2008, J CELL SCI, V121, P2635, DOI 10.1242/jcs.028647
   Johnson MR, 2000, ANAL BIOCHEM, V278, P175, DOI 10.1006/abio.1999.4461
   JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8
   Katoh M, 2005, INT J ONCOL, V27, P1677
   Katz M, 2007, NAT CELL BIOL, V9, P961, DOI 10.1038/ncb1622
   Kim Jeong-Hwan, 2006, Genomics & Informatics, V4, P1
   Kim M, 2008, CANCER RES, V68, P7147, DOI 10.1158/0008-5472.CAN-08-0667
   Kim M, 2008, CARCINOGENESIS, V29, P629, DOI 10.1093/carcin/bgm291
   Kim M, 2008, MOL CANCER RES, V6, P222, DOI 10.1158/1541-7786.MCR-07-0142
   Kim SK, 2008, CARCINOGENESIS, V29, P1623, DOI 10.1093/carcin/bgn110
   Kim SK, 2006, BIOCHEM BIOPH RES CO, V349, P1032, DOI 10.1016/j.bbrc.2006.08.128
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lee MY, 2008, CLIN CANCER RES, V14, P4743, DOI 10.1158/1078-0432.CCR-08-0234
   Lin S, 2007, INT J DEV BIOL, V51, P37, DOI 10.1387/ijdb.052108sl
   Marcoux N, 2003, ONCOGENE, V22, P6100, DOI 10.1038/sj.onc.1206712
   Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757
   Ohm JE, 2007, CELL CYCLE, V6, P1040, DOI 10.4161/cc.6.9.4210
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Osler ME, 2005, J CELL SCI, V118, P4667, DOI 10.1242/jcs.02588
   Pantel K, 2003, CLIN CANCER RES, V9, P6326
   Parnes D, 2007, BBA-GENE STRUCT EXPR, V1769, P586, DOI 10.1016/j.bbaexp.2007.06.001
   Ray RM, 2007, CELL MOTIL CYTOSKEL, V64, P143, DOI 10.1002/cm.20172
   Sahai E, 2005, CURR OPIN GENET DEV, V15, P87, DOI 10.1016/j.gde.2004.12.002
   Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822
   Shibuya K, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-37
   Smith TK, 2008, P NATL ACAD SCI USA, V105, P8298, DOI 10.1073/pnas.0802345105
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Wada AM, 2001, DEVELOPMENT, V128, P2085
   Weber M, 2007, CURR OPIN CELL BIOL, V19, P273, DOI 10.1016/j.ceb.2007.04.011
   Yasui Wataru, 2005, Gastric Cancer, V8, P86, DOI 10.1007/s10120-005-0320-0
   YOSHIDA M, 1990, J BIOL CHEM, V265, P17174
   Yuasa Y, 2003, NAT REV CANCER, V3, P592, DOI 10.1038/nrc1141
   Zardo G, 2002, NAT GENET, V32, P453, DOI 10.1038/ng1007
NR 42
TC 49
Z9 56
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD SEP
PY 2010
VL 31
IS 9
BP 1685
EP 1693
DI 10.1093/carcin/bgq144
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 646HP
UT WOS:000281530400024
PM 20627872
OA Bronze
DA 2025-01-12
ER

PT J
AU Huang, THM
   Esteller, M
AF Huang, Tim H. -M.
   Esteller, Manel
TI Chromatin Remodeling in Mammary Gland Differentiation and Breast
   Tumorigenesis
SO COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY
LA English
DT Article
ID DNA METHYLATION PATTERNS; CPG ISLAND; EPITHELIAL-CELLS; ABERRANT
   EXPRESSION; ESTROGEN-RECEPTOR; CANCER-CELLS; GENE-EXPRESSION; HISTONE
   H4; GENOME; WIDE
AB DNA methylation and histone modifications have essential roles in remodeling chromatin structure of genes necessary for multi-lineage differentiation of mammary stem/progenitor cells. The role of this well-defined epigenetic programming is to heritably maintain transcriptional plasticity of these loci over multiple cell divisions in the differentiated progeny. Epigenetic events can be deregulated in progenitor cells chronically exposed to xenoestrogen or inflammatory microenvironment. In addition, epigenetically mediated silencing of genes associated with tumor suppression can take place, resulting in clonal proliferation of undifferentiated or semidifferentiated cells. Alternatively, microRNAs that negatively regulate the expression of their protein-coding targets may become epigenetically repressed, leading to oncogenic expression of these genes. Here we further discuss interactions between DNA methylation and histone modifications that have significant contributions to the differentiation of mammary stem/progenitor cells and to tumor initiation and progression.
C1 [Huang, Tim H. -M.] Ohio State Univ, Human Canc Genet Program, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43220 USA.
   [Esteller, Manel] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona, Catalonia, Spain.
C3 University System of Ohio; Ohio State University; Institut
   d'Investigacio Biomedica de Bellvitge (IDIBELL)
RP Huang, THM (通讯作者)，Ohio State Univ, Human Canc Genet Program, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43220 USA.
EM tim.huang@osumc.edu
RI Esteller, Manel/L-5956-2014
OI Esteller, Manel/0000-0003-4490-6093
FU National Institutes of Health [U01ES015986, U54CA113001, R01CA069065,
   R01ES017594]; Ohio State University Comprehensive Cancer Center; Health
   Department of the Catalan Government; Spanish Association Against
   Cancer; Fondo de Investigaciones Sanitarias [PI08-1345, MEC09-05.]
FX The authors wish to thank Drs. Yi-Wen Huang and Gregory Singer for
   technical assistance. This work was supported by the National Institutes
   of Health grants (U01ES015986, U54CA113001, R01CA069065, and
   R01ES017594), the Ohio State University Comprehensive Cancer Center, the
   Health Department of the Catalan Government, the Spanish Association
   Against Cancer, and the grants by Fondo de Investigaciones Sanitarias
   PI08-1345 and Consolider MEC09-05.
CR ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995
   Antequera F, 1999, CURR BIOL, V9, pR661, DOI 10.1016/S0960-9822(99)80418-7
   Balch C, 2005, FRONT BIOSCI-LANDMRK, V10, P1897, DOI 10.2741/1668
   Balch C, 2007, BIOESSAYS, V29, P842, DOI 10.1002/bies.20619
   Balch Curt, 2008, P197
   Ballestar E, 2005, PROG MOLEC, V38, P169
   Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Batty N, 2009, CANCER LETT, V280, P192, DOI 10.1016/j.canlet.2009.03.013
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Bloushtain-Qimron N, 2008, P NATL ACAD SCI USA, V105, P14076, DOI 10.1073/pnas.0805206105
   Bloushtain-Qimron N, 2009, CELL CYCLE, V8, P809, DOI 10.4161/cc.8.6.7938
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Brena RM, 2006, NAT GENET, V38, P1359, DOI 10.1038/ng1206-1359
   Brena RM, 2006, J MOL MED, V84, P365, DOI 10.1007/s00109-005-0034-0
   Cairns BR, 2009, NATURE, V461, P193, DOI 10.1038/nature08450
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Chan MWY, 2005, CLIN CANCER RES, V11, P7376, DOI 10.1158/1078-0432.CCR-05-1100
   Chang JW, 2008, PHARMACOGENOMICS, V9, P1869, DOI 10.2217/14622416.9.12.1869
   Cheng ASL, 2008, CANCER RES, V68, P1786, DOI 10.1158/0008-5472.CAN-07-5547
   Cho BS, 2003, BIOCHEM BIOPH RES CO, V307, P52, DOI 10.1016/S0006-291X(03)01121-5
   Crawford GE, 2006, GENOME RES, V16, P123, DOI 10.1101/gr.4074106
   Davalos V, 2010, CURR OPIN ONCOL, V22, P35, DOI 10.1097/CCO.0b013e328333dcbb
   De Smet C, 2004, MOL CELL BIOL, V24, P4781, DOI 10.1128/MCB.24.11.4781-4790.2004
   Dimri GP, 2002, CANCER RES, V62, P4736
   Dontu G, 2004, TRENDS ENDOCRIN MET, V15, P193, DOI 10.1016/j.tem.2004.05.011
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Dontu G, 2005, STEM CELL REV, V1, P207, DOI 10.1385/SCR:1:3:207
   Ehrlich M, 2006, CURR TOP MICROBIOL, V310, P251
   Ehrlich M, 2002, J NUTR, V132, p2424S, DOI 10.1093/jn/132.8.2424S
   Esteller M, 2006, E SCHERING RES FDN W, V57, P115
   Fan MY, 2006, CANCER RES, V66, P11954, DOI 10.1158/0008-5472.CAN-06-1666
   Feinberg AP, 2008, JAMA-J AM MED ASSOC, V299, P1345, DOI 10.1001/jama.299.11.1345
   Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886
   Gal-Yam EN, 2008, P NATL ACAD SCI USA, V105, P12979, DOI 10.1073/pnas.0806437105
   Gilbert N, 2004, CELL, V118, P555, DOI 10.1016/j.cell.2004.08.011
   Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727
   Gudjonsson T, 2002, GENE DEV, V16, P693, DOI 10.1101/gad.952602
   Guil S, 2009, INT J BIOCHEM CELL B, V41, P87, DOI 10.1016/j.biocel.2008.09.005
   Gupta A, 2003, CANCER RES, V63, P664
   HERMAN JG, 1995, CANCER RES, V55, P4525
   Hinshelwood RA, 2007, CANCER RES, V67, P11517, DOI 10.1158/0008-5472.CAN-07-1284
   Hinshelwood RA, 2009, HUM MOL GENET, V18, P3098, DOI 10.1093/hmg/ddp251
   Hinshelwood RA, 2008, J MOL MED, V86, P1315, DOI 10.1007/s00109-008-0386-3
   Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516
   Hsu PY, 2009, CANCER RES, V69, P5936, DOI 10.1158/0008-5472.CAN-08-4914
   Huang YW, 2009, CANCER RES, V69, P9038, DOI 10.1158/0008-5472.CAN-09-1499
   Huschtscha LI, 1998, CANCER RES, V58, P3508
   Issa JP, 2003, CLIN IMMUNOL, V109, P103, DOI 10.1016/S1521-6616(03)00203-1
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jensen EV, 2003, CLIN CANCER RES, V9, P1980
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jones PA, 2009, NAT REV GENET, V10, P805, DOI 10.1038/nrg2651
   KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634
   Kaneda A, 2005, CANCER RES, V65, P11236, DOI 10.1158/0008-5472.CAN-05-2959
   Kim MS, 2009, NATURE, V461, P1007, DOI 10.1038/nature08456
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Ko CY, 2008, J BIOL CHEM, V283, P30919, DOI 10.1074/jbc.M804029200
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Lin HJL, 2008, CANCER RES, V68, P10257, DOI 10.1158/0008-5472.CAN-08-0288
   Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033
   McGarvey KM, 2007, CANCER RES, V67, P5097, DOI 10.1158/0008-5472.CAN-06-2029
   Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107
   Meric-Bernstam F, 2007, ANN SURG ONCOL, V14, P2428, DOI 10.1245/s10434-007-9379-7
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431
   Nephew KP, 2003, CANCER LETT, V190, P125, DOI 10.1016/S0304-3835(02)00511-6
   Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977
   Ohgane J, 2004, METH MOL B, V289, P371
   Pakneshan P, 2004, J BIOL CHEM, V279, P31735, DOI 10.1074/jbc.M401669200
   Pasini D, 2007, MOL CELL BIOL, V27, P3769, DOI 10.1128/MCB.01432-06
   Péchoux C, 1999, DEV BIOL, V206, P88, DOI 10.1006/dbio.1998.9133
   Reynolds PA, 2006, J BIOL CHEM, V281, P24790, DOI 10.1074/jbc.M604175200
   Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302
   Shen L, 2007, PLOS GENET, V3, P2023, DOI 10.1371/journal.pgen.0030181
   Soares J, 1999, CANCER, V85, P112, DOI 10.1002/(SICI)1097-0142(19990101)85:1<112::AID-CNCR16>3.0.CO;2-T
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Tlsty TD, 2001, J MAMMARY GLAND BIOL, V6, P235, DOI 10.1023/A:1011369026168
   Tryndyak VP, 2006, CANCER BIOL THER, V5, P65, DOI 10.4161/cbt.5.1.2288
   Villadsen R, 2007, J CELL BIOL, V177, P87, DOI 10.1083/jcb.200611114
   Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154
   Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049
   Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598
   Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
   Weil MR, 2004, GENOME RES, V14, P1374, DOI 10.1101/gr.1396104
   Wu JJ, 2006, CANCER RES, V66, P6899, DOI 10.1158/0008-5472.CAN-06-0276
   Xu XR, 2009, BREAST CANCER RES TR, V115, P397, DOI 10.1007/s10549-008-0075-5
   Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776
   Yan PS, 2006, CLIN CANCER RES, V12, P6626, DOI 10.1158/1078-0432.CCR-06-0467
   Yan PS, 2003, CANCER RES, V63, P6178
   Yen PS, 2000, BRIT J CANCER, V82, P514, DOI 10.1054/bjoc.1999.0955
   Zhu JK, 2009, ANNU REV GENET, V43, P143, DOI 10.1146/annurev-genet-102108-134205
   Zuo T, 2009, EPIGENOMICS-UK, V1, P331, DOI 10.2217/epi.09.31
NR 110
TC 24
Z9 27
U1 0
U2 3
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1943-0264
J9 CSH PERSPECT BIOL
JI Cold Spring Harbor Perspect. Biol.
PD SEP
PY 2010
VL 2
IS 9
AR a004515
DI 10.1101/cshperspect.a004515
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 646WS
UT WOS:000281575800012
PM 20610549
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Huang, KT
   Mikeska, T
   Dobrovic, A
   Fox, SB
AF Huang, Katie T.
   Mikeska, Thomas
   Dobrovic, Alexander
   Fox, Stephen B.
TI DNA methylation analysis of the HIF-1α prolyl hydroxylase domain genes
   <i>PHD1</i>, <i>PHD2</i>, <i>PHD3</i> and the factor inhibiting HIF gene
   <i>FIH</i> in invasive breast carcinomas
SO HISTOPATHOLOGY
LA English
DT Article
DE breast cancer; DNA methylation; factor inhibiting HIF; hypoxia; prolyl
   hydroxylase domain
ID HYPOXIA-INDUCIBLE FACTOR; CYTOPLASMIC LOCATION; HIGH-THROUGHPUT; CANCER;
   FACTOR-1-ALPHA; OVEREXPRESSION; ERYTHROCYTOSIS; EXPRESSION; PROGNOSIS;
   PROTEIN-2
AB Aims:
   Hypoxia-inducible factor-1 (HIF-1) activity is regulated by prolyl hydroxylase (PHD1, PHD2, PHD3) and factor inhibiting HIF-1 (FIH) that target the alpha subunit of HIF-1 (HIF-1 alpha) for proteosomal degradation. We hypothesised that the elevated HIF-1 alpha level is due in some tumours to epigenetic silencing by DNA hypermethylation of the promoter region of one or more of the PHDs and FIH genes. The aims were to define the presence or absence of promoter methylation of PHDs and FIH in cell lines of various sources and breast carcinomas and, if present, determine its effect on mRNA and protein expression.
   Methods and results:
   Tumour cell lines (n = 20) and primary invasive breast carcinomas (n = 168) were examined for promoter region DNA methylation using methylation-sensitive high-resolution melting. There was evidence of PHD3 but not of PHD1, PHD2 or FIH DNA methylation in breast cancer (SkBr3) and leukaemic (HL60 and CCRF-CEM) cell lines, but there was no evidence of methylation in any of 168 breast cancers. Only the high-level PHD3 methylation seen in leukaemic cell lines correlated with absent mRNA and protein expression.
   Conclusions:
   Methylation-induced epigenetic silencing of PHD1, PHD2, PHD3 and FIH is unlikely to underlie up-regulated HIF-1 alpha expression in human breast cancer but may play a role in other tumour types.
C1 [Huang, Katie T.; Mikeska, Thomas; Dobrovic, Alexander; Fox, Stephen B.] Peter MacCallum Canc Inst, Dept Pathol, Mol Pathol Res & Dev Lab, Melbourne, Vic 3000, Australia.
   [Huang, Katie T.; Mikeska, Thomas; Dobrovic, Alexander; Fox, Stephen B.] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia.
C3 Peter Maccallum Cancer Center; University of Melbourne
RP Fox, SB (通讯作者)，St Andrews Pl, Melbourne, Vic 3002, Australia.
EM stephen.fox@petermac.org
RI ; Fox, Stephen/G-9719-2016; Mikeska, Thomas/B-4876-2008
OI Dobrovic, Alexander/0000-0003-3414-112X; Fox,
   Stephen/0000-0002-7648-8896; Mikeska, Thomas/0000-0003-1318-0859
FU Victorian Breast Cancer Research Consortium of Australia; National
   Breast Cancer Foundation of Australia
FX We thank Elena Takano for her advice in immunohistochemistry work. We
   would also like to thank Professor Adrian Harris for supplying us with
   the sample DNA and the Molecular Pathology Research and Development
   group in Peter MacCallum Cancer Centre for their help and support. This
   work was funded by a grant from the Victorian Breast Cancer Research
   Consortium of Australia to SF and a grant from the National Breast
   Cancer Foundation of Australia to AD.
CR Al-Sheikh M, 2008, BLOOD CELL MOL DIS, V40, P160, DOI 10.1016/j.bcmd.2007.07.017
   Bos R, 2001, JNCI-J NATL CANCER I, V93, P309, DOI 10.1093/jnci/93.4.309
   Candiloro ILM, 2008, EPIGENET CHROMATIN, V1, DOI 10.1186/1756-8935-1-7
   Cervera AM, 2006, CANCER LETT, V233, P131, DOI 10.1016/j.canlet.2005.03.004
   Dales JP, 2005, INT J CANCER, V116, P734, DOI 10.1002/ijc.20984
   Erez N, 2003, CANCER RES, V63, P8777
   Fong GH, 2008, CELL DEATH DIFFER, V15, P635, DOI 10.1038/cdd.2008.10
   Fox SB, 2004, CANCER RES, V64, P6075, DOI 10.1158/0008-5472.CAN-04-0708
   FOX SB, 2007, BREAST CANCER RES, V9, P11
   Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704
   Kato H, 2006, INT J CANCER, V118, P1144, DOI 10.1002/ijc.21488
   Kimbro KS, 2006, ENDOCR-RELAT CANCER, V13, P739, DOI 10.1677/erc.1.00728
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Kristensen LS, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn113
   Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402
   Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015
   Lundgren K, 2007, CELL MOL LIFE SCI, V64, P3233, DOI 10.1007/s00018-007-7390-6
   Morris MR, 2004, J CLIN PATHOL, V57, P706, DOI 10.1136/jcp.2003.011767
   Nolan T, 2006, NAT PROTOC, V1, P1559, DOI 10.1038/nprot.2006.236
   Patiar S, 2006, ENDOCR-RELAT CANCER, V13, pS61, DOI 10.1677/erc.1.01290
   Percy MJ, 2007, BLOOD, V110, P2193, DOI 10.1182/blood-2007-04-084434
   Percy MJ, 2006, P NATL ACAD SCI USA, V103, P654, DOI 10.1073/pnas.0508423103
   Rasmussen R., 2001, Rapid cycle realtime PCR, methods and applications, P21, DOI [10.1007/978-3-642-59524-03, DOI 10.1007/978-3-642-59524-0_3, 10.1007/978-3-642-59524-0_3]
   Schindl M, 2002, CLIN CANCER RES, V8, P1831
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Shah R, 2009, BRIT J CANCER, V100, P1687, DOI 10.1038/sj.bjc.6605042
   Soilleux EJ, 2005, HISTOPATHOLOGY, V47, P602, DOI 10.1111/j.1365-2559.2005.02280.x
   Stolze IP, 2004, J BIOL CHEM, V279, P42719, DOI 10.1074/jbc.M406713200
   Tan EY, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1838
   Trastour C, 2007, INT J CANCER, V120, P1451, DOI 10.1002/ijc.22436
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Wojdacz TK, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm013
   Wojdacz Tomasz K, 2008, BMC Res Notes, V1, P54, DOI 10.1186/1756-0500-1-54
   Yamamoto Y, 2008, BREAST CANCER RES TR, V110, P465, DOI 10.1007/s10549-007-9742-1
   Zhong H, 1999, CANCER RES, V59, P5830
NR 35
TC 15
Z9 18
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0309-0167
EI 1365-2559
J9 HISTOPATHOLOGY
JI Histopathology
PD SEP
PY 2010
VL 57
IS 3
BP 451
EP 460
DI 10.1111/j.1365-2559.2010.03633.x
PG 10
WC Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Pathology
GA 650LN
UT WOS:000281851100013
PM 20727020
DA 2025-01-12
ER

PT J
AU Papoutsis, AJ
   Lamore, SD
   Wondrak, GT
   Selmin, OI
   Romagnolo, DF
AF Papoutsis, Andreas J.
   Lamore, Sarah D.
   Wondrak, Georg T.
   Selmin, Ornella I.
   Romagnolo, Donato F.
TI Resveratrol Prevents Epigenetic Silencing of BRCA-1 by the Aromatic
   Hydrocarbon Receptor in Human Breast Cancer Cells
SO JOURNAL OF NUTRITION
LA English
DT Article
ID 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; TRANSCRIPTIONAL REPRESSION;
   POLYPHENOLIC COMPOUND; DNA METHYLTRANSFERASE; P21(WAF1) EXPRESSION;
   HISTONE ACETYLATION; DIOXIN EXPOSURE; IN-VIVO; ACTIVATION; CHROMATIN
AB The BRCA-1 protein is a tumor suppressor involved in repair of DNA damage. Epigenetic mechanisms contribute to its reduced expression in sporadic breast tumors. Through diet, humans are exposed to a complex mixture of xenobiotics and natural ligands of the aromatic hydrocarbon receptor (AhR), which contributes to the etiology of various types of cancers. The AhR binds xenobiotics, endogenous ligands, and many natural dietary bioactive compounds, including the phytoalexin resveratrol (Res). In estrogen receptor-alpha (ER alpha)-positive and BRCA-1 wild-type MCF-7 breast cancer cells, we investigated the influence of AhR activation with the agonist 2,3,7,8 tetrachlorobenzo(p)dioxin (TCDD) on epigenetic regulation of the BRCA-1 gene and the preventative effects of Res. We report that activation and recruitment of the AhR to the BRCA-1 promoter hampers 17 beta-estradiol (E2)-dependent stimulation of BRCA-1 transcription and protein levels. These inhibitory effects are paralleled by reduced occupancy of ER alpha, acetylated histone (AcH)-4, and AcH3K9. Conversely, the treatment with TCDD increases the association of mono-methylated-H3K9, DNA-methyltransferase-1 (DNMT1), and methyl-binding domain protein-2 with the BRCA-1 promoter and stimulates the accumulation of DNA strand breaks. The AhR-dependent repression of BRCA-1 expression is reversed by small interference for the AhR and DNMT1 or pretreatment with Res, which reduces TCDD-induced DNA strand breaks. These results support the hypothesis that epigenetic silencing of the BRCA-1 gene by the AhR is preventable with Res and provide the molecular basis for the development of dietary strategies based on natural AhR antagonists. J. Nutr. 140: 1607-1614, 2010.
C1 [Papoutsis, Andreas J.; Selmin, Ornella I.; Romagnolo, Donato F.] Univ Arizona, Dept Nutr Sci, Tucson, AZ 85721 USA.
   [Lamore, Sarah D.; Wondrak, Georg T.] Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.
C3 University of Arizona; University of Arizona
RP Romagnolo, DF (通讯作者)，Univ Arizona, Dept Nutr Sci, Tucson, AZ 85721 USA.
EM donato@u.arizona.edu
RI Selmin, Ornella/ABC-8971-2020
FU Arizona Biomedical Research Commission [10819]; Susan G. Komen Breast
   Cancer Foundation [BCTR0707643]; Arizona Cancer Center [P30CA23074];
   SWEHSC [ES006694]; NCI [64 CFR 72090, 64 CFR 28205]
FX Supported by grants from the Arizona Biomedical Research Commission
   10819, D.F.R.), Susan G. Komen Breast Cancer Foundation (BCTR0707643,
   D.F.R.), Arizona Cancer Center Support grant P30CA23074, and SWEHSC
   grant ES006694. TCDD was supplied by the National Cancer Institute,
   Division of Cancer Biology, Chemical and Physical Carcinogenesis Branch
   and distributed by Midwest Research Institute under a contract to NCI
   (64 CFR 72090, 64 CFR 28205).
CR Abdelrahim M, 2003, MOL PHARMACOL, V63, P1373, DOI 10.1124/mol.63.6.1373
   Banerjee S, 2002, CANCER RES, V62, P4945
   Beedanagari SR, 2009, TOXICOL SCI, V110, P61, DOI 10.1093/toxsci/kfp079
   Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Boocock DJ, 2007, CANCER EPIDEM BIOMAR, V16, P1246, DOI 10.1158/1055-9965.EPI-07-0022
   Butcher DT, 2007, EUR J CANCER, V43, P210, DOI 10.1016/j.ejca.2006.09.002
   Casper RF, 1999, MOL PHARMACOL, V56, P784
   Chan CYY, 2004, TOXICOL SCI, V81, P133, DOI 10.1093/toxsci/kfh200
   Chen YX, 2004, WORLD J GASTROENTERO, V10, P2643, DOI 10.3748/wjg.v10.i18.2643
   Connor KT, 2008, J EXPO SCI ENV EPID, V18, P369, DOI 10.1038/sj.jes.7500607
   de Medina P, 2005, J MED CHEM, V48, P287, DOI 10.1021/jm0498194
   Degner SC, 2007, NUTR CANCER, V59, P248, DOI 10.1080/01635580701485585
   Degner SC, 2009, J NUTR, V139, P26, DOI 10.3945/jn.108.099259
   Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828
   Dragan YP, 2000, FOOD ADDIT CONTAM A, V17, P289, DOI 10.1080/026520300283360
   Ellis L, 2009, MOL CANCER THER, V8, P1409, DOI 10.1158/1535-7163.MCT-08-0860
   Erdelyi I, 2009, J NUTR, V139, P2072, DOI 10.3945/jn.108.104125
   Fang MZ, 2003, CANCER RES, V63, P7563
   Fustier P, 2003, BRIT J CANCER, V89, P168, DOI 10.1038/sj.bjc.6600983
   Gehm BD, 1997, P NATL ACAD SCI USA, V94, P14138, DOI 10.1073/pnas.94.25.14138
   GUDAS JM, 1995, CANCER RES, V55, P4561
   Guil S, 2009, INT J BIOCHEM CELL B, V41, P87, DOI 10.1016/j.biocel.2008.09.005
   Hockings JK, 2006, CANCER RES, V66, P2224, DOI 10.1158/0008-5472.CAN-05-1619
   Hooper K, 1998, ENVIRON HEALTH PERSP, V106, P797, DOI 10.2307/3434123
   Jeffy BD, 2005, NEOPLASIA, V7, P873, DOI 10.1593/neo.05256
   Jeffy BD, 2002, CANCER RES, V62, P113
   Jenkins S, 2007, REPROD TOXICOL, V23, P391, DOI 10.1016/j.reprotox.2006.10.004
   JIN W, BREAST CANC RES TREA
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kawajiri K, 2009, P NATL ACAD SCI USA, V106, P13481, DOI 10.1073/pnas.0902132106
   Knerr S, 2006, MOL NUTR FOOD RES, V50, P897, DOI 10.1002/mnfr.200600006
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lamore SD, 2010, CELL STRESS CHAPERON, V15, P309, DOI 10.1007/s12192-009-0145-6
   Le Corre L, 2004, CLIN CHIM ACTA, V344, P115, DOI 10.1016/j.cccn.2004.02.024
   Lin PH, 2007, TOXICOL LETT, V172, P146, DOI 10.1016/j.toxlet.2007.06.003
   Lu R, 2008, EPIGENETICS-US, V3, P330, DOI 10.4161/epi.3.6.7125
   Ma XD, 2006, INT J ONCOL, V28, P1287
   Martinez J, 2000, BIOCHEM PHARMACOL, V59, P865, DOI 10.1016/S0006-2952(99)00380-9
   Medjakovic S, 2008, J STEROID BIOCHEM, V108, P171, DOI 10.1016/j.jsbmb.2007.10.001
   Miyamoto K, 2002, JPN J CLIN ONCOL, V32, P79, DOI 10.1093/jjco/hyf020
   Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6
   Myzak MC, 2006, FASEB J, V20, P506, DOI 10.1096/fj.05-4785fje
   Myzak MC, 2007, EXP BIOL MED, V232, P227
   Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118
   Peng DF, 2006, CARCINOGENESIS, V27, P1160, DOI 10.1093/carcin/bgi361
   PISKORSKAPLISZCZYNSKA J, 1986, TOXICOL LETT, V34, P67, DOI 10.1016/0378-4274(86)90146-3
   Ray SS, 2004, J BIOL CHEM, V279, P27187, DOI 10.1074/jbc.M402771200
   Reid G, 2009, INT J BIOCHEM CELL B, V41, P155, DOI 10.1016/j.biocel.2008.08.028
   Revich B, 2001, CHEMOSPHERE, V43, P951, DOI 10.1016/S0045-6535(00)00456-2
   Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233
   Ross SA, 2008, NUTR REV, V66, pS1, DOI 10.1111/j.1753-4887.2008.00055.x
   Russo J, 2002, ENVIRON MOL MUTAGEN, V39, P254, DOI 10.1002/em.10052
   Schlezinger JJ, 2006, BIOL CHEM, V387, P1175, DOI 10.1515/BC.2006.145
   Weiss J, 2003, ACTA PAEDIATR, V92, P467, DOI 10.1111/j.1651-2227.2003.tb00580.x
   Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029
   Zhao J, 2006, ACTA PHARMACOL SIN, V27, P1459, DOI 10.1111/j.1745-7254.2006.00433.x
NR 57
TC 111
Z9 123
U1 0
U2 16
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0022-3166
EI 1541-6100
J9 J NUTR
JI J. Nutr.
PD SEP
PY 2010
VL 140
IS 9
BP 1607
EP 1614
DI 10.3945/jn.110.123422
PG 8
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 642KE
UT WOS:000281210800012
PM 20631324
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Griffiths, EA
   Gore, SD
   Hooker, CM
   McDevitt, MA
   Karp, JE
   Smith, BD
   Mohammad, HP
   Ye, Y
   Herman, JG
   Carraway, HE
AF Griffiths, Elizabeth A.
   Gore, Steven D.
   Hooker, Craig M.
   McDevitt, Michael A.
   Karp, Judith E.
   Smith, B. Douglas
   Mohammad, Helai P.
   Ye, Ying
   Herman, James G.
   Carraway, Hetty E.
TI Acute myeloid leukemia is characterized by Wnt pathway inhibitor
   promoter hypermethylation
SO LEUKEMIA & LYMPHOMA
LA English
DT Article
DE Cytogenetics; DNA methylation; epigenetics; leukemia; Wnt pathway
ID ACUTE MYELOGENOUS LEUKEMIA; FRIZZLED-RELATED PROTEINS; BETA-CATENIN;
   SIGNALING PATHWAY; EPIGENETIC INACTIVATION; CYTOSINE-ARABINOSIDE; DNA
   METHYLATION; BREAST-CANCER; STEM-CELLS; PHASE-II
AB Nuclear localization of non-phosphorylated, active beta-catenin is a measure of Wnt pathway activation and is associated with adverse outcome in patients with acute myeloid leukemia (AML). While genetic alterations of the Wnt pathway are infrequent in AML, inhibitors of this pathway are silenced by promoter methylation in other malignanices. Leukemia cell lines were examined for Wnt pathway inhibitor methylation and total beta-catenin levels, and had frequent methylation of Wnt inhibitors and upregulated beta-catenin by Western blot and immunofluorescence. One hundred sixty-nine AML samples were examined for methylation of Wnt inhibitor genes. Diagnostic samples from 72 patients with normal cytogenetics who received standard high-dose induction chemotherapy were evaluated for associations between methylation and event-free or overall survival. Extensive methylation of Wnt pathway inhibitor genes was observed in cell lines, and 89% of primary AML samples had at least one methylated gene: DKK1 (16%), DKK3 (8%), RUNX3 (27%), sFRP1 (34%), sFRP2 (66%), sFRP4 (9%), sFRP5 (54%), SOX17 (29%), and WIF1 (32%). In contrast to epithelial tumors, methylation of APC (2%) and RASSF1A (0%) was rare. In patients with AML with normal cytogenetics, sFRP2 and sFRP5 methylation at the time of diagnosis was associated with an increased risk of relapse, and sFRP2 methylation was associated with an increased risk for death. In patients with AML: (a) there is a high frequency of Wnt pathway inhibitor methylation; (b) Wnt pathway inhibitor methylation is distinct from that observed in epithelial malignancies; and (c) methylation of sFRP2 and sFRP5 may predict adverse clinical outcome in patients with normal karyotype AML.
C1 [Griffiths, Elizabeth A.; Gore, Steven D.; Hooker, Craig M.; Karp, Judith E.; Smith, B. Douglas; Mohammad, Helai P.; Ye, Ying; Herman, James G.; Carraway, Hetty E.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21231 USA.
   [McDevitt, Michael A.] Johns Hopkins Univ, Sch Med, Dept Med, Div Hematol, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University
RP Carraway, HE (通讯作者)，Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, 1650 Orleans St,Canc Res Bldg 1,Room 290, Baltimore, MD 21231 USA.
EM hcarraw1@jhmi.edu
RI Carraway, Hetty/AAR-4977-2020
FU Flight Attendant Medical Research Institute (FAMRI) [032053]; NCI Cancer
   Center [CA06793]; OncoMethylome Sciences
FX This work was supported by The Flight Attendant Medical Research
   Institute (FAMRI), grant number 032053. This work was also supported by
   a NCI Cancer Center Support Grant (CA06793), which helped the Specimen
   Acquisition Core (SAC) Laboratory with sample collection and storage.Dr.
   James Herman is a consultant to and receives research support from
   OncoMethylome Sciences. The terms of this arrangement are being managed
   by the Johns Hopkins University in accordance with its conflict of
   interest policies.
CR Bolaños-Meade J, 2003, LEUKEMIA RES, V27, P313, DOI 10.1016/S0145-2126(02)00177-7
   Bovolenta P, 2008, J CELL SCI, V121, P737, DOI 10.1242/jcs.026096
   Carraway HE, 2009, BREAST CANCER RES TR, V114, P315, DOI 10.1007/s10549-008-0004-7
   Chung EJ, 2002, BLOOD, V100, P982, DOI 10.1182/blood.V100.3.982
   Dhir M, 2008, J GASTROINTEST SURG, V12, P1745, DOI 10.1007/s11605-008-0633-5
   Easwaran HP, 2004, EMBO REP, V5, P1181, DOI 10.1038/sj.embor.7400295
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Figueroa ME, 2009, BLOOD, V114, P3448, DOI 10.1182/blood-2009-01-200519
   GELLER RB, 1989, BLOOD, V74, P1499
   Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Jaffe E.S., 2009, American Society of Hematology. Education Program, P523
   Jost E, 2008, BRIT J HAEMATOL, V142, P745, DOI 10.1111/j.1365-2141.2008.07242.x
   Karp JE, 2007, CLIN CANCER RES, V13, P4467, DOI 10.1158/1078-0432.CCR-07-0381
   Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316
   Khan NI, 2006, HISTOL HISTOPATHOL, V21, P761, DOI 10.14670/HH-21.761
   Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045
   Klarmann GJ, 2008, EPIGENETICS-US, V3, P59, DOI 10.4161/epi.3.2.5899
   Licchesi JDF, 2008, CARCINOGENESIS, V29, P895, DOI 10.1093/carcin/bgn017
   Linker CA, 2000, BIOL BLOOD MARROW TR, V6, P50, DOI 10.1016/S1083-8791(00)70052-8
   Majetl R, 2009, P NATL ACAD SCI USA, V106, P3396, DOI 10.1073/pnas.0900089106
   Martín V, 2010, CANCER SCI, V101, P425, DOI 10.1111/j.1349-7006.2009.01413.x
   Minke KS, 2009, EUR J HAEMATOL, V82, P165, DOI 10.1111/j.1600-0609.2008.01188.x
   Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549
   Moore MAS, 2005, EXP HEMATOL, V33, P719, DOI 10.1016/j.exphem.2005.04.011
   Paz MF, 2002, CANCER RES, V62, P4519
   Renneville A, 2008, LEUKEMIA, V22, P915, DOI 10.1038/leu.2008.19
   Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   Schlenk RF, 2008, NEW ENGL J MED, V358, P1909, DOI 10.1056/NEJMoa074306
   Scholl C, 2008, SEMIN ONCOL, V35, P336, DOI 10.1053/j.seminoncol.2008.04.004
   Serinsöz E, 2004, BRIT J HAEMATOL, V126, P313, DOI 10.1111/j.1365-2141.2004.05049.x
   Simon M, 2005, ONCOGENE, V24, P2410, DOI 10.1038/sj.onc.1208431
   Steffen B, 2005, CRIT REV ONCOL HEMAT, V56, P195, DOI 10.1016/j.critrevonc.2004.10.012
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Tickenbrock L, 2005, BLOOD, V105, P3699, DOI 10.1182/blood-2004-07-2924
   Tolwinski NS, 2004, PLOS BIOL, V2, P486, DOI 10.1371/journal.pbio.0020095
   Valencia A, 2009, LEUKEMIA, V23, P1658, DOI 10.1038/leu.2009.86
   Xu J, 2008, BRIT J HAEMATOL, V140, P394, DOI 10.1111/j.1365-2141.2007.06914.x
   Ysebaert L, 2006, LEUKEMIA, V20, P1211, DOI 10.1038/sj.leu.2404239
NR 39
TC 66
Z9 79
U1 0
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1042-8194
EI 1029-2403
J9 LEUKEMIA LYMPHOMA
JI Leuk. Lymphoma
PD SEP
PY 2010
VL 51
IS 9
BP 1711
EP 1719
DI 10.3109/10428194.2010.496505
PG 9
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Hematology
GA 655FO
UT WOS:000282233200019
PM 20795789
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Luo, J
   Feng, J
   Lu, J
   Wang, YP
   Tang, XB
   Xie, F
   Li, WB
AF Luo, Jie
   Feng, Jing
   Lu, Jun
   Wang, Yuping
   Tang, Xuanbin
   Xie, Fei
   Li, Wenbin
TI Aberrant methylation profile of 14-3-3 sigma and its reduced
   transcription/expression levels in Chinese sporadic female breast
   carcinogenesis
SO MEDICAL ONCOLOGY
LA English
DT Article
DE Sporadic breast cancer; DNA methylation; Carcinogenesis; 14-3-3 sigma
ID CANCER; HYPERMETHYLATION; EVENT; BRCA1; DNA
AB To study the relation of 14-3-3 sigma gene promoter hypermethylation and its transcription expression levels in sporadic breast carcinogenesis. Methylation of 14-3-3 sigma gene was detected by sensitive MSP assay in carcinous, non-cancerous, and normal tissue, and its mRNA was also detected by real time PCR based on SYBR Green 1 as well, and protein was detected by west blotting assay. The methylation frequencies of 14-3-3 sigma were 90% in 68 cases of sporadic breast cancer patients. Methylation was presented in portions (2/13, 18%) of hyperplastic samples, and no hypermethylation was presented in normal tissue. The methylation change of 14-3-3 sigma gene was markedly related with various types, grades, and lymph node metastases (P < 0.05), and no significant differences in methylation frequencies were seen between premenopause and postmenopause (P > 0.05). The methylation of 14-3-3 sigma shows reverse relation with its mRNA transcription and expression level (P < 0.05). Only was lymph node metastases strongly associated with poor outcome (P = 0.02). Whether 14-3-3 sigma promoter methylation or not did not affect the 5 years survival rate of sporadic breast cancer patients (P > 0.05). Epigenetics alterations of the 14-3-3 sigma can contribute to reducing or losing expression of 14-3-3 sigma protein, which play an important role in the development of sporadic breast carcinomas and involved in various types, grades, and lymph node metastases. Otherwise, node metastases of breast carcinogenesis patients are strongly associated with poor outcome.
C1 [Feng, Jing; Lu, Jun; Wang, Yuping; Tang, Xuanbin; Xie, Fei; Li, Wenbin] Taihe Hosp, Yunyang Med Coll, Ctr Lab Med, Shiyan 442000, Hubei, Peoples R China.
   [Luo, Jie] Taihe Hosp, Yunyang Med Coll, Dept Neurosurg, Shiyan 442000, Hubei, Peoples R China.
RP Feng, J (通讯作者)，Taihe Hosp, Yunyang Med Coll, Ctr Lab Med, Shiyan 442000, Hubei, Peoples R China.
EM fengjinggood@hotmail.com
RI Wang, Yuping/AAW-2930-2021; Li, Wen-Bin/AGR-0005-2022
OI Wang, Yuping/0000-0003-0087-4771
CR Al-Mulla F, 2005, J HISTOCHEM CYTOCHEM, V53, P621, DOI 10.1369/jhc.4A6544.2005
   Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188
   COUCH FJ, 2001, METABOLIC MOL BASIS, P999
   Deng CX, 2000, BIOESSAYS, V22, P728
   DONG ES, 2006, KOREAN J PATHOL, V40, P9
   FENG J, 2005, CHINA ONCOL, V25, P442
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Henrique R, 2005, DNA CELL BIOL, V24, P264, DOI 10.1089/dna.2005.24.264
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7
   HUILING Y, 2006, CANCER RES, V66, P3097
   KISHOR B, 2003, CANCER EPIDEM BIOMAR, V12, P165
   Leitch A M, 1999, Surg Oncol Clin N Am, V8, P657
   Lodygin D, 2005, CELL RES, V15, P237, DOI 10.1038/sj.cr.7290292
   Moreira JMA, 2005, MOL CELL PROTEOMICS, V4, P555, DOI 10.1074/mcp.M400205-MCP200
   Morrison TB, 1998, BIOTECHNIQUES, V24, P954
   NORIKAZU H, 2000, ONCOGENE, V19, P5298
   Ramirez JL, 2005, J CLIN ONCOL, V23, P9105, DOI 10.1200/JCO.2005.02.2905
   Sambrook J, 2001, Molecular Cloning: a Laboratory Manual, Vthird
   TOMOSHIGE K, 2000, J BIOL CHEM, V275, P23106
   ULRICH L, 2002, AM J PATHOL, V160, P605
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
NR 22
TC 16
Z9 20
U1 0
U2 6
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1357-0560
EI 1559-131X
J9 MED ONCOL
JI Med. Oncol.
PD SEP
PY 2010
VL 27
IS 3
BP 791
EP 797
DI 10.1007/s12032-009-9287-8
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 646FG
UT WOS:000281522400036
PM 19685192
DA 2025-01-12
ER

PT J
AU Salvatico, J
   Kim, JH
   Chung, IK
   Muller, MT
AF Salvatico, Jose
   Kim, Joo Hee
   Chung, In Kwon
   Muller, Mark T.
TI Differentiation linked regulation of telomerase activity by Makorin-1
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Makorin-1; hTERT; Ubiquitin; Ubiquitin ligase; Telomerase; Proteasome
ID BREAST-CANCER CELLS; REVERSE-TRANSCRIPTASE; LEUKEMIA-CELLS;
   CELLULAR-DIFFERENTIATION; EPIGENETIC REGULATION; ACTIVATES TELOMERASE;
   HTERT GENE; PROTEIN; EXPRESSION; MECHANISMS
AB To understand telomere homeostasis, a significant aspect of cancer and growth control, it is important to examine telomerase induction as well as mechanisms of regulated elimination. Makorin-1 (MKRN1) was previously shown to be an E3 ubiquitin ligase that targets the telomerase catalytic subunit (hTERT) for proteasome processing (Kim et al., Genes Dev 19:776-781, 2005). In this study we examined expression and regulation of endogenous MKRN1 during the cell cycle and terminal differentiation. When WI-38 cells transition from active growth into a resting G1 state, basal levels of MKRN1 were found to increase by sixfold. In contrast, cancer cells typically contained low or in some cases undetectable levels of MKRN1 protein. HL-60 cells growing exponentially in culture contain no detectable MKRN1; however, following terminal differentiation, MKRN1 mRNA and protein levels are strongly up-regulated while hTERT mRNA, hTERC, and telomerase are shut down. The initial decrease in telomerase activity is due to a gradual reduction in transcription of the hTERT gene that occurs during the first 12 h of terminal differentiation. MKRN1 protein appears between 12 and 24 h and is attended by a more rapid loss of telomerase activity. As more MKRN1 protein accumulates, significantly less telomerase activity is seen. Addition of the proteasome inhibitor, MG132, reverses the loss of telomerase activity; therefore, reductions in telomerase activity are dynamic, ongoing, and correlated with robust up-regulation of MKRN1 as the cells terminally differentiate. The data are consistent with the idea that MKRN1 represents a telomerase elimination pathway to rapidly draw down the activity during differentiation or cell cycle arrest when telomerase action at chromosome ends is no longer necessary.
C1 [Salvatico, Jose; Kim, Joo Hee; Muller, Mark T.] Univ Cent Florida, Coll Med, Dept Mol & Microbiol, Orlando, FL 32826 USA.
   [Chung, In Kwon] Yonsei Univ, Dept Biol, Seoul 120749, South Korea.
   [Chung, In Kwon] Yonsei Univ, Mol Aging Res Ctr, Seoul 120749, South Korea.
C3 State University System of Florida; University of Central Florida;
   Yonsei University; Yonsei University
RP Muller, MT (通讯作者)，Univ Cent Florida, Coll Med, Dept Mol & Microbiol, 12722 Res Pkwy, Orlando, FL 32826 USA.
EM mtmuller@mail.ucf.edu
FU NIH [CA127416]
FX We thank Dr. W. E. Wright for valuable discussion and input on this
   study. We wish to acknowledge comments on the article from Dr. Bongyong
   Lee, Dr. Gun Eui Lee, and Rhea Manjooran. This was supported in part by
   NIH Grant CA127416.
CR Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5
   Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4
   Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349
   BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082
   Cech T R, 1997, Ciba Found Symp, V211, P20
   CECH TR, 1997, CIBA F SYMP, V211, P28
   Choi JH, 2007, BIOCHEM BIOPH RES CO, V361, P615, DOI 10.1016/j.bbrc.2007.07.051
   COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315
   COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x
   de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005
   Forsyth NR, 2002, DIFFERENTIATION, V69, P188, DOI 10.1046/j.1432-0436.2002.690412.x
   Forsythe HL, 2001, J BIOL CHEM, V276, P15571, DOI 10.1074/jbc.C100055200
   Gray TA, 2000, GENOMICS, V66, P76, DOI 10.1006/geno.2000.6199
   Guilleret I, 2003, EXP CELL RES, V289, P326, DOI 10.1016/S0014-4827(03)00281-7
   Her YR, 2009, J BIOL CHEM, V284, P8557, DOI 10.1074/jbc.M806702200
   Holt SE, 1996, MOL CELL BIOL, V16, P2932
   Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817
   Igarashi H, 1997, BLOOD, V89, P1299, DOI 10.1182/blood.V89.4.1299
   Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085
   Kim JH, 2005, GENE DEV, V19, P776, DOI 10.1101/gad.1289405
   Koyanagi Y, 2000, ANTICANCER RES, V20, P773
   Kyo S, 1999, CANCER RES, V59, P5917
   Lee EW, 2009, EMBO J, V28, P2100, DOI 10.1038/emboj.2009.164
   Lee GE, 2004, J BIOL CHEM, V279, P34750, DOI 10.1074/jbc.M401843200
   Lee JH, 2010, CANCER LETT, V290, P76, DOI 10.1016/j.canlet.2009.08.026
   Li H, 1998, J BIOL CHEM, V273, P33436, DOI 10.1074/jbc.273.50.33436
   Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729
   LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310
   Liu JP, 1999, FASEB J, V13, P2091, DOI 10.1096/fasebj.13.15.2091
   Liu KB, 2001, J IMMUNOL, V166, P4826, DOI 10.4049/jimmunol.166.8.4826
   Liu L, 2004, GENE, V340, P1, DOI 10.1016/j.gene.2004.06.011
   Liu L, 2004, MOL CANCER THER, V3, P1003
   Liu L, 2004, GENE CHROMOSOME CANC, V41, P26, DOI 10.1002/gcc.20058
   Lopatina NG, 2003, BIOCHEM BIOPH RES CO, V306, P650, DOI 10.1016/S0006-291X(03)01033-7
   Love WK, 2008, INT J ONCOL, V32, P625
   Marcotte R, 2002, J GERONTOL A-BIOL, V57, pB257, DOI 10.1093/gerona/57.7.B257
   Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6
   Miller WH, 1998, CANCER, V83, P1471, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1471::AID-CNCR1>3.0.CO;2-6
   Nakatake M, 2007, CELL CYCLE, V6, P1496
   Palm W, 2008, ANNU REV GENET, V42, P301, DOI 10.1146/annurev.genet.41.110306.130350
   Possemato R, 2008, MOL CANCER RES, V6, P1582, DOI 10.1158/1541-7786.MCR-08-0070
   Renaud S, 2007, NUCLEIC ACIDS RES, V35, P1245, DOI 10.1093/nar/gkl1125
   Renaud S, 2005, NUCLEIC ACIDS RES, V33, P6850, DOI 10.1093/nar/gki989
   Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2
   Tsiftsoglou AS, 2003, PHARMACOL THERAPEUT, V100, P257, DOI 10.1016/j.pharmthera.2003.09.002
   Ulaner GA, 1998, CANCER RES, V58, P4168
   Ulaner GA, 2001, INT J CANCER, V91, P644, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1103>3.3.CO;2-M
   Venteicher AS, 2008, CELL, V132, P945, DOI 10.1016/j.cell.2008.01.019
   Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769
   Wright WE, 1999, EXP CELL RES, V251, P492, DOI 10.1006/excr.1999.4602
   Yamada O, 1998, LEUKEMIA RES, V22, P711, DOI 10.1016/S0145-2126(98)00065-4
   Yamada O, 2008, J LEUKOCYTE BIOL, V83, P1240, DOI 10.1189/jlb.1207848
   Zhao Y, 2009, CELL, V138, P463, DOI 10.1016/j.cell.2009.05.026
   Zhou XZ, 2001, CELL, V107, P347, DOI 10.1016/S0092-8674(01)00538-4
NR 54
TC 17
Z9 22
U1 1
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300-8177
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD SEP
PY 2010
VL 342
IS 1-2
BP 241
EP 250
DI 10.1007/s11010-010-0490-x
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 640ME
UT WOS:000281054900028
PM 20473778
DA 2025-01-12
ER

PT J
AU Kumar, R
   Srinivasan, S
   Pahari, P
   Rohr, J
   Damodaran, C
AF Kumar, Raj
   Srinivasan, Sowmyalakshmi
   Pahari, Pallab
   Rohr, Juergen
   Damodaran, Chendil
TI Activating Stress-Activated Protein Kinase-Mediated Cell Death and
   Inhibiting Epidermal Growth Factor Receptor Signaling: A Promising
   Therapeutic Strategy for Prostate Cancer
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID JNK ACTIVATION; BREAST-CANCER; APOPTOSIS; EXPRESSION; PROGRESSION; EGF;
   PATHWAYS; CHEMOTHERAPY; CHECKPOINT; TARGET
AB Epidermal growth factor receptor (EGFR) activation is an important event that regulates mitogenic signaling, such as the Raf, mitogen-activated protein kinase (MAPK), and extracellular signal-regulated kinase 1/2 cascades. EGFR activation has been implicated in the transition of prostate cancer from androgen dependence to independence. Therefore, inhibition of EGFR may effectively suppress prostate cancer growth and progression. The goal of this study was to determine whether the natural compound psoralidin alters EGFR-mediated signaling resulting in the inhibition of prostate cancer growth. Results suggest that inhibition of EGFR alone (by serum deprivation) fails to induce stress-mediated protein kinases (SAPK), namely, Jun NH2-terminal kinase/c-Jun signaling, in androgen-independent prostate cancer (AIPC) cells. Treatment with psoralidin, however, inhibited both constitutive and EGF-induced EGFR activation and simultaneously triggered SAPK signaling, resulting in the induction of apoptosis in AIPC cells. In addition, psoralidin downregulated EGFR-regulated MAPK signaling and inhibited cell proliferation in AIPC cells. Oral administration of psoralidin effectively suppressed PC-3 xenograft tumors in nude mice. Compared with control tumors, inhibition of pEGFR expression and an increase in the phosphorylation, activation, and nuclear translocation of c-Jun were observed in psoralidin-treated tumor sections. Our studies suggest that psoralidin may be a potent therapeutic agent that modulates EGFR-mediated key epigenetic events in AIPC. Mol Cancer Ther; 9(9); 2488-96. (C) 2010 AACR.
C1 [Kumar, Raj; Srinivasan, Sowmyalakshmi; Damodaran, Chendil] Univ Kentucky, Dept Clin Lab Sci, Coll Hlth Sci, Lexington, KY 40536 USA.
   [Pahari, Pallab; Rohr, Juergen] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   [Damodaran, Chendil] Univ Kentucky, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA.
C3 University of Kentucky; University of Kentucky; University of Kentucky
RP Damodaran, C (通讯作者)，Univ Kentucky, Dept Clin Sci, Coll Hlth Sci, Room 124E,900 S Limestone St, Lexington, KY 40536 USA.
EM dchen2@uky.edu
RI Rohr, Jurgen/G-5375-2014; Kumar, Raj/M-3662-2014; Pahari,
   Pallab/AAF-5664-2019
OI Pahari, Pallab/0000-0003-3662-2015
FU NIHR01 [AT002890]
FX NIHR01 (AT002890).
CR Anderson MW, 2008, CARCINOGENESIS, V29, P1594, DOI 10.1093/carcin/bgn129
   Chendil D, 2004, ONCOGENE, V23, P1599, DOI 10.1038/sj.onc.1207284
   Chun JY, 2009, CLIN CANCER RES, V15, P4815, DOI 10.1158/1078-0432.CCR-09-0640
   Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301
   Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013
   Fan MY, 2001, DRUG RESIST UPDATE, V4, P253, DOI 10.1054/drup.2001.0214
   Festuccia C, 2005, THROMB HAEMOSTASIS, V93, P964, DOI 10.1160/TH04-09-0637
   Gioeli D, 1999, CANCER RES, V59, P279
   Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0
   Hu R, 2004, NUTRITION, V20, P83, DOI 10.1016/j.nut.2003.09.015
   Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x
   Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289
   Kumar R, 2009, CANCER PREV RES, V2, P234, DOI 10.1158/1940-6207.CAPR-08-0129
   LAX I, 1990, CELL REGUL, V1, P173, DOI 10.1091/mbc.1.2.173
   Lee SY, 2006, LUNG CANCER, V51, P297, DOI 10.1016/j.lungcan.2005.10.010
   Lee TL, 2006, MOL CANCER THER, V5, P8, DOI 10.1158/1535-7163.MCT-05-0069
   LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601
   Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141
   Li LC, 2005, JNCI-J NATL CANCER I, V97, P103, DOI 10.1093/jnci/dji010
   Liu J, 2005, CELL RES, V15, P36, DOI 10.1038/sj.cr.7290262
   Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021
   Marks RA, 2008, PROSTATE, V68, P919, DOI 10.1002/pros.20715
   Oh HY, 2007, PROSTATE, V67, P1061, DOI 10.1002/pros.20593
   Pham NA, 2004, MOL CANCER THER, V3, P1239
   PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655
   Putz T, 1999, CANCER RES, V59, P227
   Ravindran J, 2009, AAPS J, V11, P495, DOI 10.1208/s12248-009-9128-x
   Sastry KSR, 2006, J BIOL CHEM, V281, P27367, DOI 10.1074/jbc.M511485200
   Sato K, 2000, GENES CELLS, V5, P749, DOI 10.1046/j.1365-2443.2000.00358.x
   Sowmyalakshmi S, 2005, PLANTA, V220, P910, DOI 10.1007/s00425-004-1405-4
   Srikanth S, 1999, MOL CELL BIOCHEM, V199, P169, DOI 10.1023/A:1006980326855
   Srinivasan S, 2007, CANCER RES, V67, P246, DOI 10.1158/0008-5472.CAN-06-2430
   Srinivasan S, 2010, APOPTOSIS, V15, P153, DOI 10.1007/s10495-009-0416-9
   Srinivasan S, 2009, INT J CANCER, V125, P961, DOI 10.1002/ijc.24419
   Syed S, 2003, CANCER, V98, P2088, DOI 10.1002/cncr.11788
   Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568
   TILLOTSON JK, 1991, CANCER LETT, V60, P109, DOI 10.1016/0304-3835(91)90216-5
   Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870
   Uzgare AR, 2003, PROSTATE, V55, P128, DOI 10.1002/pros.10212
   Xu CJ, 2006, CARCINOGENESIS, V27, P437, DOI 10.1093/carcin/bgi251
NR 40
TC 24
Z9 26
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD SEP
PY 2010
VL 9
IS 9
BP 2488
EP 2496
DI 10.1158/1535-7163.MCT-10-0180
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 648HN
UT WOS:000281683000006
PM 20736346
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Das, PM
   Thor, AD
   Edgerton, SM
   Barry, SK
   Chen, DF
   Jones, FE
AF Das, P. M.
   Thor, A. D.
   Edgerton, S. M.
   Barry, S. K.
   Chen, D. F.
   Jones, F. E.
TI Reactivation of epigenetically silenced <i>HER4</i>/<i>ERBB4</i> results
   in apoptosis of breast tumor cells
SO ONCOGENE
LA English
DT Article
DE breast cancer; EGFR-family; epigenetics; apoptosis; heregulin
ID INTRACELLULAR DOMAIN 4ICD; ESTROGEN-RECEPTOR; BH3-ONLY PROTEIN;
   GENE-EXPRESSION; MAMMARY-GLAND; CANCER; ERBB4; METHYLATION; HER4;
   DIFFERENTIATION
AB Experimental and clinical data support a growth inhibitory role for HER4 in breast cancer. Clinically HER4 expression is extinguished during breast tumorigenesis supporting a tumor suppressor function for HER4, however, a molecular mechanism to explain the selective loss of HER4 expression has remained elusive. Epigenetic mechanisms, for example, aberrant gene promoter hypermethylation, have been shown to ablate tumor suppressor gene expression in breast carcinomas. We identified a CpG island within the HER4 promoter and show by pyrosequencing of bisulfite-treated DNA an inverse correlation between HER4 expression and the extent of promoter methylation. Treatment of the HER4-negative BT20 cell line with the DNA demethylating agent 5-aza-2'-deoxycytidine (DAC)-enhanced HER4 expression, confirming a role for DNA methylation in suppressed HER4 expression. DAC treatment to reactive HER4 expression in combination with the HER4 ligand heregulin-beta 1 (HRG) resulted in apoptosis of BT20 cells providing a novel therapeutic strategy for triple-negative tumors. The BT20 cells were rescued from apoptosis when preincubated with HER4 small interfering RNA, thereby confirming a role for HER4 in DAC/HRG-induced apoptosis. We verified HER4 promoter methylation in primary breast carcinomas and detected a significant increase in HER4 promoter methylation in HER4-negative breast tumors (P < 0.001). Furthermore, increased levels of HER4 promoter methylation were significantly associated with worse patient prognosis (P = 0.0234). Taken together, our data support a tumor suppressor function for HER4, which is epigenetically suppressed in breast tumors through promoter hypermethylation. Oncogene (2010) 29, 5214-5219; doi:10.1038/onc.2010.271; published online 5 July 2010
C1 [Das, P. M.; Jones, F. E.] Tulane Univ, Dept Cell & Mol Biol, New Orleans, LA 70118 USA.
   [Thor, A. D.; Edgerton, S. M.] Univ Colorado Denver, Dept Pathol, Aurora, CO USA.
   [Barry, S. K.; Chen, D. F.] Tulane Univ, Sch Med, New Orleans, LA 70112 USA.
C3 Tulane University; Children's Hospital Colorado; University of Colorado
   System; University of Colorado Anschutz Medical Campus; Tulane
   University
RP Jones, FE (通讯作者)，Tulane Univ, Dept Cell & Mol Biol, 6400 Freret St, New Orleans, LA 70118 USA.
EM fjones3@tulane.edu
RI Das, Partha/C-6898-2012
FU National Cancer Institute/National Institutes of Health [RO1CA95783,
   RO1CA96717]
FX We thank June Allison for excellent lab management and other members of
   the Jones lab for valuable input. This work is dedicated to the loving
   memory of June Allison who will no longer be subjected to the hardships
   of breast cancer. This work was supported by National Cancer
   Institute/National Institutes of Health Grants RO1CA95783 (FEJ) and
   RO1CA96717 (FEJ).
CR Chua YL, 2009, ONCOGENE, V28, P4041, DOI 10.1038/onc.2009.259
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fernandez SV, 2010, MUTAT RES-FUND MOL M, V688, P28, DOI 10.1016/j.mrfmmm.2010.02.007
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hoadley KA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-258
   Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77
   Jones FE, 2008, J MAMMARY GLAND BIOL, V13, P247, DOI 10.1007/s10911-008-9076-6
   KREIKE B, 2009, BREAST CANC RES TREA
   Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715
   Muraoka-Cook RS, 2006, MOL BIOL CELL, V17, P4118, DOI 10.1091/mbc.E06-02-0101
   Muraoka-Cook RS, 2006, MOL CELL BIOL, V26, P6412, DOI 10.1128/MCB.01950-05
   Muraoka-Cook RS, 2009, MOL CELL BIOL, V29, P4935, DOI 10.1128/MCB.01705-08
   Naresh A, 2008, CANCER RES, V68, P6387, DOI 10.1158/0008-5472.CAN-08-0538
   Naresh A, 2006, CANCER RES, V66, P6412, DOI 10.1158/0008-5472.CAN-05-2368
   Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Rokavec M, 2007, CLIN CANCER RES, V13, P7506, DOI 10.1158/1078-0432.CCR-07-0457
   Sassen A, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2339
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Soung YH, 2006, INT J CANCER, V118, P1426, DOI 10.1002/ijc.21507
   Strathdee G, 2004, CARCINOGENESIS, V25, P693, DOI 10.1093/carcin/bgh066
   Strohecker AM, 2008, J BIOL CHEM, V283, P18269, DOI 10.1074/jbc.M802156200
   Sundvall M, 2008, J MAMMARY GLAND BIOL, V13, P259, DOI 10.1007/s10911-008-9079-3
   Thor AD, 2009, AM J PATHOL, V175, P1802, DOI 10.2353/ajpath.2009.090204
   Tvorogov D, 2009, J BIOL CHEM, V284, P5582, DOI 10.1074/jbc.M805438200
   Vidal GA, 2007, ONCOGENE, V26, P462, DOI 10.1038/sj.onc.1209794
   Vidal GA, 2005, J BIOL CHEM, V280, P19777, DOI 10.1074/jbc.M412457200
   Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155
   Zhu Y, 2006, CANCER RES, V66, P7991, DOI 10.1158/0008-5472.CAN-05-4397
NR 29
TC 37
Z9 40
U1 1
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD SEP
PY 2010
VL 29
IS 37
BP 5214
EP 5219
DI 10.1038/onc.2010.271
PG 6
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 650QZ
UT WOS:000281867200010
PM 20603612
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Liu, BB
   Zheng, D
   Liu, YK
   Kang, XN
   Sun, L
   Guo, K
   Sun, RX
   Chen, J
   Zhao, Y
AF Liu, Bin-Bin
   Zheng, Dan
   Liu, Yin-Kun
   Kang, Xiao-Nan
   Sun, Lu
   Guo, Kun
   Sun, Rui-Xia
   Chen, Jie
   Zhao, Yan
TI Array-based profiling of the differential methylation status of CpG
   islands in hepatocellular carcinoma cell lines
SO ONCOLOGY LETTERS
LA English
DT Article
DE hepatocellular carcinoma; methylation; CpG island; microarray;
   methylation-specific PCR
ID TYROSINE KINASE EPHB4; DNA METHYLATION; SLIT-ROBO; MOLECULAR
   PATHOGENESIS; EPIGENETIC ALTERATIONS; TUMOR ANGIOGENESIS; BREAST-CANCER;
   GROWTH; HEPATOCARCINOGENESIS; ACTIVATION
AB Alterations in the DNA methylation status particularly in CpG islands are involved in the initiation and progression of many types of human cancer. A number of DNA methylation alterations have been reported in hepatocellular carcinoma (HCC). However, a systematic analysis is required to elucidate the relationship between differential DNA methylation status and the characteristics and progression of HCC. In the present study, a global analysis of DNA methylation using a human CpG-island 12K array was performed on a number of HCC cell lines of different origin and metastatic potential. Based on a standard methylation alteration ratio of >= 2 or <= 0.5, 58 CpG island sites and 66 tumor-related genes upstream, downstream or within were identified. This study showed a series of CpG island methylation alterations in the HCC cell lines. The expression of various oncogenes, tumor suppressor genes and other key genes were up- or downregulated, respectively, resulting in CpG island hypomethylation or hypermethylation accordingly. To conclude, a foundation has been provided for screening CpG island methylation profiles as HOC biological markers.
C1 [Liu, Bin-Bin; Zheng, Dan; Liu, Yin-Kun; Kang, Xiao-Nan; Sun, Lu; Guo, Kun; Sun, Rui-Xia; Chen, Jie; Zhao, Yan] Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Shanghai 200032, Peoples R China.
C3 Fudan University
RP Liu, YK (通讯作者)，Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Shanghai 200032, Peoples R China.
EM liu.yinkun@zs-hospital.sh.cn
RI Liu, Zhiying/IWV-2966-2023
OI , LIU/0000-0002-3458-4046
FU National Nature Science Foundation of China [30500484]; Shanghai Nature
   Science Foundation [04ZR14025]
FX This study was supported by a grant from the National Nature Science
   Foundation of China (no. 30500484) and Shanghai Nature Science
   Foundation (no. 04ZR14025).
CR Banno K, 2006, ONCOL REP, V16, P1189
   Bashaw GJ, 1999, CELL, V97, P917, DOI 10.1016/S0092-8674(00)80803-X
   Berclaz G, 2003, ANN ONCOL, V14, P220, DOI 10.1093/annonc/mdg072
   CALVISI DF, 2006, AACR M, pA763
   Calvisi DF, 2007, J CLIN INVEST, V117, P2713, DOI 10.1172/JCI31457
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Gollob JA, 2006, SEMIN ONCOL, V33, P392, DOI 10.1053/j.seminoncol.2006.04.002
   Herath NI, 2006, J GASTROEN HEPATOL, V21, P15, DOI 10.1111/j.1440-1746.2005.04043.x
   Hohenester E, 2008, BIOCHEM SOC T, V36, P251, DOI 10.1042/BST0360251
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Humeniuk R, 2009, CURR PHARM BIOTECHNO, V10, P161, DOI 10.2174/138920109787315123
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kumar SR, 2006, AM J PATHOL, V169, P279, DOI 10.2353/ajpath.2006.050889
   Liu ZJ, 2003, CANCER CELL, V4, P1, DOI 10.1016/S1535-6108(03)00166-1
   Marlow R, 2008, CANCER RES, V68, P7819, DOI 10.1158/0008-5472.CAN-08-1357
   Noren NK, 2004, P NATL ACAD SCI USA, V101, P5583, DOI 10.1073/pnas.0401381101
   Pang RWC, 2007, ONCOLOGY-BASEL, V72, P30, DOI 10.1159/000111705
   Park IY, 2007, GASTROENTEROLOGY, V132, P1476, DOI 10.1053/j.gastro.2007.01.034
   Pei YF, 2009, ACTA BIOCH BIOPH SIN, V41, P1, DOI 10.1093/abbs/gmn001
   Pfister S, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm094
   Prasad CP, 2008, LIFE SCI, V83, P318, DOI 10.1016/j.lfs.2008.06.019
   Scarano MI, 2005, J CELL PHYSIOL, V204, P21, DOI 10.1002/jcp.20280
   Schneider-Stock R, 2007, IDRUGS, V10, P557
   Shen L, 2007, CLIN CANCER RES, V13, P6093, DOI 10.1158/1078-0432.CCR-07-1011
   Stella MC, 2009, MOL BIOL CELL, V20, P642, DOI 10.1091/mbc.E08-03-0321
   Supic G, 2009, ORAL ONCOL, V45, P1051, DOI 10.1016/j.oraloncology.2009.07.007
   Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339
   Tommasi S, 2007, CURR PHARM DESIGN, V13, P3279, DOI 10.2174/138161207782360663
   Wang B, 2003, CANCER CELL, V4, P19, DOI 10.1016/S1535-6108(03)00164-8
   Wang L, 2007, HEPATOL RES, V37, P389, DOI 10.1111/j.1872-034X.2007.00042.x
   Yan Pearlly S., 2009, V507, P89, DOI 10.1007/978-1-59745-522-0_8
NR 33
TC 3
Z9 3
U1 0
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD SEP-OCT
PY 2010
VL 1
IS 5
BP 815
EP 820
DI 10.3892/ol_00000143
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 687TJ
UT WOS:000284800500008
PM 22966386
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Iliopoulos, D
   Jaeger, SA
   Hirsch, HA
   Bulyk, ML
   Struhl, K
AF Iliopoulos, Dimitrios
   Jaeger, Savina A.
   Hirsch, Heather A.
   Bulyk, Martha L.
   Struhl, Kevin
TI STAT3 Activation of miR-21 and miR-181b-1 via PTEN and CYLD Are Part of
   the Epigenetic Switch Linking Inflammation to Cancer
SO MOLECULAR CELL
LA English
DT Article
ID NF-KAPPA-B; EMBRYONIC STEM-CELLS; BREAST-CANCER; MICRORNA MIR-21;
   EXPRESSION; BINDING; TARGET; LET-7; IDENTIFICATION; TRANSFORMATION
AB A transient inflammatory signal can initiate an epigenetic switch from nontransformed to cancer cells via a positive feedback loop involving NF-kappa B, Lin28, let-7, and IL-6. We identify differentially regulated nnicroRNAs important for this switch and putative transcription factor binding sites in their promoters. STAT3, a transcription factor activated by IL-6, directly activates miR-21 and miR-181b-1. Remarkably, transient expression of either microRNA induces the epigenetic switch. MiR-21 and miR-181b-1, respectively, inhibit PTEN and CYLD tumor suppressors, leading to increased NF-kappa B activity required to maintain the transformed state. These STAT3-mediated regulatory circuits are required for the transformed state in diverse cell lines and tumor growth in xenografts, and their transcriptional signatures are observed in colon adenocarcinomas. Thus, STAT3 is not only a downstream target of IL-6 but, with miR-21, miR-181b-1, PTEN, and CYLD, is part of the positive feedback loop that underlies the epigenetic switch that links inflammation to cancer.
C1 [Iliopoulos, Dimitrios; Hirsch, Heather A.; Struhl, Kevin] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
   [Bulyk, Martha L.] Harvard Univ, Sch Med, Harvard Mit Div Hlth Sci & Technol HST, Boston, MA 02115 USA.
   [Jaeger, Savina A.; Bulyk, Martha L.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Genet,Dept Med, Boston, MA 02115 USA.
   [Bulyk, Martha L.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
C3 Harvard University; Harvard Medical School; Harvard University; Harvard
   Medical School; Harvard University; Brigham & Women's Hospital; Harvard
   Medical School; Harvard University; Brigham & Women's Hospital; Harvard
   Medical School
RP Struhl, K (通讯作者)，Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
EM kevin@hms.harvard.edu
RI Bulyk, Martha/LTD-8833-2024; Iliopoulos, Dimitrios/AAE-9106-2019
FU National Institutes of Health [HG 3985, CA 107486]
FX We thank Philip N. Tsichlis for providing facilities for performing the
   xenograft experiments and George Q. Daley for Lin28B expression vector.
   This work was supported by grants from the National Institutes of Health
   to M.L.B. (HG 3985) and K.S. (CA 107486).
CR Badis G, 2009, SCIENCE, V324, P1720, DOI 10.1126/science.1162327
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Berger MF, 2008, CELL, V133, P1266, DOI 10.1016/j.cell.2008.05.024
   Berger MF, 2006, NAT BIOTECHNOL, V24, P1429, DOI 10.1038/nbt1246
   Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5
   Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811
   Cervigne NK, 2009, HUM MOL GENET, V18, P4818, DOI 10.1093/hmg/ddp446
   Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30
   Conti A, 2009, J NEURO-ONCOL, V93, P325, DOI 10.1007/s11060-009-9797-4
   Frank DA, 2007, CANCER LETT, V251, P199, DOI 10.1016/j.canlet.2006.10.017
   Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200
   García MG, 2009, LEUKEMIA RES, V33, P288, DOI 10.1016/j.leukres.2008.06.010
   Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001
   Guigon CJ, 2009, ONCOGENE, V28, P509, DOI 10.1038/onc.2008.407
   Hagan JP, 2009, NAT STRUCT MOL BIOL, V16, P1021, DOI 10.1038/nsmb.1676
   Hirsch HA, 2010, CANCER CELL, V17, P348, DOI 10.1016/j.ccr.2010.01.022
   Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014
   Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014
   Lin CH, 2009, EMBO J, V28, P3157, DOI 10.1038/emboj.2009.254
   Löffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood-2007-03-081133
   Marson A, 2008, CELL, V134, P521, DOI 10.1016/j.cell.2008.07.020
   Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999
   Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022
   O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677
   Ozsolak F, 2008, GENE DEV, V22, P3172, DOI 10.1101/gad.1706508
   Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425
   Shi L, 2008, BRAIN RES, V1236, P185, DOI 10.1016/j.brainres.2008.07.085
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803
   Warner JB, 2008, NAT METHODS, V5, P347, DOI [10.1038/NMETH.1188, 10.1038/nmeth.1188]
   Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808
   Yang A, 2006, MOL CELL, V24, P593, DOI 10.1016/j.molcel.2006.10.018
   Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734
   Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245
   Zhang Z, 2009, CELL CYCLE, V8, P2756, DOI 10.4161/cc.8.17.9387
NR 35
TC 712
Z9 811
U1 3
U2 110
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1097-2765
EI 1097-4164
J9 MOL CELL
JI Mol. Cell
PD AUG 27
PY 2010
VL 39
IS 4
BP 493
EP 506
DI 10.1016/j.molcel.2010.07.023
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 644ZQ
UT WOS:000281421100004
PM 20797623
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Saladi, SV
   Marathe, H
   de la Serna, IL
AF Saladi, Srinivas Vinod
   Marathe, Himangi
   de la Serna, Ivana L.
TI SWItching on the transcriptional circuitry in melanoma
SO EPIGENETICS
LA English
DT Article
DE melanoma; micropththalmia-associated transcription factor; SWI/SNF
   chromatin remodeling enzymes; gene expression; oncogenes; signaling
   pathways
ID CHROMATIN REMODELING COMPLEXES; CELL-CYCLE ARREST; SWI-SNF COMPLEX;
   MALIGNANT-MELANOMA; TUMOR-SUPPRESSOR; LINEAGE-SURVIVAL; SWI/SNF COMPLEX;
   ONCOGENIC TRANSFORMATION; BREAST-CANCER; BETA-CATENIN
AB Melanoma is an aggressive malignancy that is resistant to current therapy, and is the most lethal of all human skin cancers. It is characterized by genetic alterations that trigger disruptions in the normal transcriptional circuitry, leading to changes in gene expression and tumorigenesis. Transformation and tumor progression are thought to be promoted by a complex interplay between the accumulation of genetic alterations and epigenetic changes. In this review, we discuss recent studies that have implicated SWI/SNF chromatin remodeling enzymes as epigenetic regulators of a transcriptional circuit that operates within the context of the genetic alterations that frequently occur in melanoma.
C1 [Saladi, Srinivas Vinod; Marathe, Himangi; de la Serna, Ivana L.] Univ Toledo, Coll Med, Dept Biochem & Canc Biol, Toledo, OH 43606 USA.
C3 University System of Ohio; University of Toledo
RP de la Serna, IL (通讯作者)，Univ Toledo, Coll Med, Dept Biochem & Canc Biol, 2801 W Bancroft St, Toledo, OH 43606 USA.
EM ivana.delaserna@utoledo.edu
RI Saladi, SrinivasVinod/AAM-3146-2020
FU National Institute of Environmental Health Sciences [5K22ES12981];
   American Cancer Society, Ohio Division
FX I.L.D. was supported by the National Institute of Environmental Health
   Sciences; Grant number: 5K22ES12981, Ohio Cancer Research Associates,
   American Cancer Society, Ohio Division.
CR Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935
   Bartkova J, 1996, CANCER RES, V56, P5475
   Becker TM, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-4
   Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412
   BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996
   Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706
   Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1
   Bourachot B, 2003, EMBO J, V22, P6505, DOI 10.1093/emboj/cdg621
   Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1
   Bultman SJ, 2008, ONCOGENE, V27, P460, DOI 10.1038/sj.onc.1210664
   Carreira S, 2005, NATURE, V433, P764, DOI 10.1038/nature03269
   Carreira S, 1998, MOL CELL BIOL, V18, P5099, DOI 10.1128/MCB.18.9.5099
   Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406
   Chai JJ, 2005, CANCER RES, V65, P10192, DOI 10.1158/0008-5472.CAN-05-1896
   Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811
   Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   de la Serna IL, 2005, MOL CELL BIOL, V25, P3997, DOI 10.1128/MCB.25.10.3997-4009.2005
   de la Serna IL, 2006, NAT REV GENET, V7, P461, DOI 10.1038/nrg1882
   DELASERNA IL, 2006, J BIOL CHEM
   Delmas V, 2007, GENE DEV, V21, P2923, DOI 10.1101/gad.450107
   Doan DN, 2004, ONCOGENE, V23, P3462, DOI 10.1038/sj.onc.1207472
   Du JY, 2004, CANCER CELL, V6, P565, DOI 10.1016/j.ccr.2004.10.014
   DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7
   Dynek JN, 2008, CANCER RES, V68, P3124, DOI 10.1158/0008-5472.CAN-07-6622
   Flowers S., 2009, J Biol Chem
   Foster KSJ, 2006, ONCOGENE, V25, P4605, DOI 10.1038/sj.onc.1209496
   Galibert MD, 2001, EMBO J, V20, P5022, DOI 10.1093/emboj/20.17.5022
   Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664
   Garraway LA, 2006, NAT REV CANCER, V6, P593, DOI 10.1038/nrc1947
   Glaros S, 2007, ONCOGENE, V26, P7058, DOI 10.1038/sj.onc.1210514
   Goldstein AM, 2006, CANCER RES, V66, P9818, DOI 10.1158/0008-5472.CAN-06-0494
   Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001
   Hingorani SR, 2003, CANCER RES, V63, P5198
   Ho LN, 2009, P NATL ACAD SCI USA, V106, P5187, DOI 10.1073/pnas.0812888106
   Hsiao PW, 2003, MOL CELL BIOL, V23, P6210, DOI 10.1128/MCB.23.17.6210-6220.2003
   Isakoff MS, 2005, P NATL ACAD SCI USA, V102, P17745, DOI 10.1073/pnas.0509014102
   Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200
   Jhappan C, 2003, ONCOGENE, V22, P3099, DOI 10.1038/sj.onc.1206450
   Jiao ZX, 2004, PIGM CELL RES, V17, P352, DOI 10.1111/j.1600-0749.2004.00154.x
   Kadam S, 2003, MOL CELL, V11, P377, DOI 10.1016/S1097-2765(03)00034-0
   KEENEN B, ONCOGENE, V29, P81
   Keenen B, 2009, J CELL PHYSIOL, V219, P1, DOI 10.1002/jcp.21654
   Kia SK, 2008, MOL CELL BIOL, V28, P3457, DOI 10.1128/MCB.02019-07
   Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339
   Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129
   Lang D, 2005, NATURE, V433, P884, DOI 10.1038/nature03292
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Lin H, 2009, CLIN CANCER RES, V15, P6404, DOI 10.1158/1078-0432.CCR-09-1135
   Link KA, 2005, MOL CELL BIOL, V25, P2200, DOI 10.1128/MCB.25.6.2200-2215.2005
   Liu R, 2001, CELL, V106, P309, DOI 10.1016/S0092-8674(01)00446-9
   Loercher AE, 2005, J CELL BIOL, V168, P35, DOI 10.1083/jcb.200410115
   McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6
   Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890
   Muchardt C, 1998, EMBO J, V17, P223, DOI 10.1093/emboj/17.1.223
   Nagl NG, 2007, EMBO J, V26, P752, DOI 10.1038/sj.emboj.7601541
   Naidu S.R., 2009, ONCOGENE
   Park J, 2002, MOL CELL BIOL, V22, P1307, DOI 10.1128/MCB.22.5.1307-1316.2002
   Park JH, 2009, DNA REPAIR, V8, P29, DOI 10.1016/j.dnarep.2008.08.011
   Passeron T, 2007, P NATL ACAD SCI USA, V104, P13984, DOI 10.1073/pnas.0705117104
   Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9
   Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054
   Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4
   Reisman DN, 2005, APPL IMMUNOHISTO M M, V13, P66, DOI 10.1097/00129039-200503000-00011
   Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979
   Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697
   Rothhammer T, 2007, PIGM CELL RES, V20, P92, DOI 10.1111/j.1600-0749.2007.00367.x
   Ryme J, 2009, J CELL BIOCHEM, V108, P565, DOI 10.1002/jcb.22288
   Sentani K, 2001, PATHOBIOLOGY, V69, P315, DOI 10.1159/000064638
   Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423
   Steingrímsson E, 2004, ANNU REV GENET, V38, P365, DOI 10.1146/annurev.genet.38.072902.092717
   Sun A, 2007, PROSTATE, V67, P203, DOI 10.1002/pros.20521
   Tachibana M, 1996, NAT GENET, V14, P50, DOI 10.1038/ng0996-50
   Urnov FD, 2001, ONCOGENE, V20, P2991, DOI 10.1038/sj.onc.1204323
   VACHTENHEIM J, BIOCH BIOPHYS RES CO, V392, P454
   Vance KW, 2005, CANCER RES, V65, P2260, DOI 10.1158/0008-5472.CAN-04-3045
   Varga-Weisz P, 2001, ONCOGENE, V20, P3076, DOI 10.1038/sj.onc.1204332
   Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212
   Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032
   Walker GJ, 1998, GENE CHROMOSOME CANC, V22, P157, DOI 10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N
   Wang X, 2009, CANCER RES, V69, P8094, DOI 10.1158/0008-5472.CAN-09-0733
   Wong AKC, 2000, CANCER RES, V60, P6171
   Wu JI, 2009, CELL, V136, P200, DOI 10.1016/j.cell.2009.01.009
   Xia W, 2008, CANCER RES, V68, P1667, DOI 10.1158/0008-5472.CAN-07-5276
   Xu Y, 2007, J BIOL CHEM, V282, P37429, DOI 10.1074/jbc.M706039200
   Xue YT, 2000, P NATL ACAD SCI USA, V97, P13015, DOI 10.1073/pnas.240208597
   Yang Y, 2006, EMBO J, V25, P2107, DOI 10.1038/sj.emboj.7601114
NR 87
TC 1
Z9 1
U1 0
U2 1
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1559-2294
J9 EPIGENETICS-US
JI Epigenetics
PD AUG 16
PY 2010
VL 5
IS 6
DI 10.4161/epi.5.6.12315
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 639ED
UT WOS:000280952700003
OA Green Published
DA 2025-01-12
ER

PT J
AU Yang, J
   Jubb, AM
   Pike, L
   Buffa, FM
   Turley, H
   Baban, D
   Leek, R
   Gatter, KC
   Ragoussis, J
   Harris, AL
AF Yang, Jun
   Jubb, Adrian M.
   Pike, Luke
   Buffa, Francesca M.
   Turley, Helen
   Baban, Dilair
   Leek, Russell
   Gatter, Kevin C.
   Ragoussis, Jiannis
   Harris, Adrian L. f
TI The Histone Demethylase JMJD2B Is Regulated by Estrogen Receptor α and
   Hypoxia, and Is a Key Mediator of Estrogen Induced Growth
SO CANCER RESEARCH
LA English
DT Article
ID SET ENRICHMENT ANALYSIS; GENE-EXPRESSION; BREAST-CANCER; INDUCIBLE
   FACTOR-1; BINDING-SITES; HIF; DISEASE; METHYLATION; HOMEOSTASIS;
   PROGNOSIS
AB Estrogen receptor alpha (ER alpha) plays an important role in breast cancer. Upregulation of HIF-1 alpha in ER alpha-positive cancers suggests that HIF-1 alpha may cooperate with ER alpha to promote breast cancer progression and consequently affect breast cancer treatment. Here, we show the histone demethylase JMJD2B is regulated by both ER alpha and HIF-1 alpha, drives breast cancer cell proliferation in normoxia and hypoxia, and epigenetically regulates the expression of cell cycle genes such as CCND1, CCNA1, and WEE1. We also show that JMJD2B and the hypoxia marker CA9 together stratify a subclass of breast cancer patients and predict a worse outcome of these breast cancers. Our findings provide a biological rationale to support the therapeutic targeting of histone demethylases in breast cancer patients. Cancer Res; 70(16); 6456-66. (C)2010 AACR.
C1 [Yang, Jun; Pike, Luke; Buffa, Francesca M.; Harris, Adrian L. f] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Growth Factor Grp,Canc Res UK,Mol Oncol Labs, Headington, England.
   [Jubb, Adrian M.; Turley, Helen; Leek, Russell; Gatter, Kevin C.] Univ Oxford, Canc Res UK Tumour Pathol Grp, Nuffield Dept Clin Lab Sci, Oxford OX3 9DS, England.
   [Baban, Dilair; Ragoussis, Jiannis] Univ Oxford, Genom Grp, Wellcome Trust Ctr Human Genet, Oxford OX3 9DS, England.
C3 Cancer Research UK; University of Oxford; University of Oxford;
   University of Oxford; Wellcome Centre for Human Genetics
RP Harris, AL (通讯作者)，Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Canc Res UK, Oxford OX3 9DS, England.
EM aharris.lab@imm.ox.ac.uk
RI Ragoussis, Ioannis/AAD-9790-2022; Yang, Jun/N-2309-2018; Buffa,
   Francesca M./D-2574-2013; Harris, Adrian/ABA-3343-2020
OI Leek, Russell/0000-0002-8038-8660; Buffa, Francesca
   M./0000-0003-0409-406X; Ragoussis, Ioannis/0000-0002-8515-0934; Harris,
   Adrian/0000-0003-1376-8409
FU Cancer Research UK; Oxford NHS Biomedical Research Centre; Pathological
   Society of Great Britain and Ireland; Experimental Cancer Medicine
   Centre
FX J. Yang was supported by a Cancer Research UK postdoctoral fellowship.
   Pathology analysis was supported by the Oxford NHS Biomedical Research
   Centre and the Experimental Cancer Medicine Centre. A.M. Jubb is funded
   by a career development fellowship from the Pathological Society of
   Great Britain and Ireland.
CR Beyer S, 2008, J BIOL CHEM, V283, P36542, DOI 10.1074/jbc.M804578200
   Bos R, 2001, JNCI-J NATL CANCER I, V93, P309, DOI 10.1093/jnci/93.4.309
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Carroll JS, 2006, MOL ENDOCRINOL, V20, P1707, DOI 10.1210/me.2005-0334
   Cho J, 2006, J STEROID BIOCHEM, V100, P18, DOI 10.1016/j.jsbmb.2006.03.002
   Cloos PAC, 2008, GENE DEV, V22, P1115, DOI 10.1101/gad.1652908
   Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837
   Dressing GE, 2009, ENDOCR-RELAT CANCER, V16, P351, DOI 10.1677/ERC-08-0281
   Elvidge GP, 2006, J BIOL CHEM, V281, P15215, DOI 10.1074/jbc.M511408200
   Enmark E, 1999, J INTERN MED, V246, P133, DOI 10.1046/j.1365-2796.1999.00545.x
   Generali D, 2009, J CLIN ONCOL, V27, P227, DOI 10.1200/JCO.2007.13.7083
   Gordan JD, 2007, CURR OPIN GENET DEV, V17, P71, DOI 10.1016/j.gde.2006.12.006
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hirota K, 2006, CRIT REV ONCOL HEMAT, V59, P15, DOI 10.1016/j.critrevonc.2005.12.003
   Johnson AB, 2008, MUTAT RES-FUND MOL M, V640, P174, DOI 10.1016/j.mrfmmm.2008.01.001
   Kaelin WG, 2005, BIOCHEM BIOPH RES CO, V338, P627, DOI 10.1016/j.bbrc.2005.08.165
   Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009
   Lee DS, 2009, J AM COLL SURGEONS, V208, P1077, DOI 10.1016/j.jamcollsurg.2009.01.050
   Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087
   Loncaster JA, 2001, CANCER RES, V61, P6394
   McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884
   Ng SS, 2007, NATURE, V448, P87, DOI 10.1038/nature05971
   Northcott PA, 2009, NAT GENET, V41, P465, DOI 10.1038/ng.336
   PASTOREKOVA S, 1992, VIROLOGY, V187, P620, DOI 10.1016/0042-6822(92)90464-Z
   Pollard PJ, 2008, BIOCHEM J, V416, P387, DOI 10.1042/BJ20081238
   Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500
   Seifeddine R, 2007, J STEROID BIOCHEM, V104, P169, DOI 10.1016/j.jsbmb.2007.03.025
   Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672
   Shi Y, 2007, NAT REV GENET, V8, P829, DOI 10.1038/nrg2218
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Subramanian A, 2007, BIOINFORMATICS, V23, P3251, DOI 10.1093/bioinformatics/btm369
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Wigfield SM, 2008, BRIT J CANCER, V98, P1975, DOI 10.1038/sj.bjc.6604356
   Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546
   Xia XB, 2009, P NATL ACAD SCI USA, V106, P4260, DOI 10.1073/pnas.0810067106
   Yang J, 2009, ANN NY ACAD SCI, V1177, P185, DOI 10.1111/j.1749-6632.2009.05027.x
   Yi JM, 2009, BIOCHEM BIOPH RES CO, V378, P842, DOI 10.1016/j.bbrc.2008.11.142
NR 39
TC 148
Z9 174
U1 1
U2 15
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD AUG 15
PY 2010
VL 70
IS 16
BP 6456
EP 6466
DI 10.1158/0008-5472.CAN-10-0413
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 638IK
UT WOS:000280887000008
PM 20682797
OA Green Accepted, Green Submitted
DA 2025-01-12
ER

PT J
AU Wang, XH
   Zhang, LH
   Zhong, XY
   Xing, XF
   Liu, YQ
   Niu, ZJ
   Peng, Y
   Du, H
   Zhang, GG
   Hu, Y
   Liu, N
   Zhu, YB
   Ge, SH
   Zhao, W
   Lu, AP
   Li, JY
   Ji, JF
AF Wang, Xiao-Hong
   Zhang, Lian-Hai
   Zhong, Xi-Yao
   Xing, Xiao-Fang
   Liu, Yi-Qiang
   Niu, Zhao-Jian
   Peng, Yong
   Du, Hong
   Zhang, Gui-Guo
   Hu, Ying
   Liu, Ni
   Zhu, Yu-Bing
   Ge, Shao-Hua
   Zhao, Wei
   Lu, Ai-Ping
   Li, Ji-You
   Ji, Jia-Fu
TI S100A6 Overexpression Is Associated with Poor Prognosis and Is
   Epigenetically Up-Regulated in Gastric Cancer
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID GENE-EXPRESSION PATTERNS; CALCIUM-BINDING PROTEIN; CELL-LINES;
   DIFFERENTIAL EXPRESSION; TISSUE MICROARRAYS; CALCYCLIN S100A6;
   TUMOR-SUPPRESSOR; PROSTATE-CANCER; BREAST-CANCER; MARKER
AB S100A6 has been implicated in a variety of biological functions as well as tumorigenesis. In this study, we investigated the expression status of S100A6 in relation to the clinicopathological features and prognosis of patients with gastric cancer and further explored a possible association of its expression with epigenetic regulation. S100A6 expression was remarkably increased in 67.5% of gastric cancer tissues as compared with matched noncancerous tissues. Statistical analysis demonstrated a clear correlation between high S100A6 expression and various clinicopathological features, such as depth of wall invasion, positive lymph node involvement, liver metastasis, vascular invasion, and tumor-node metastasis stage (P < 0.05 in all cases), as well as revealed that S100A6 is an independent prognostic predictor (P = 0.026) significantly related to poor prognosis (P = 0.0004). Further exploration found an inverse relationship between S100A6 expression and the methylation status of the seventh and eighth CpG sites in the promoter/first exon and the second to fifth sites in the second exon/second intron. In addition, the level of histone H3 acetylation was found to be significantly higher in S100A6-expressing cancer cells. After 5-azacytidine or trichostatin A treatment, S100A6 expression was clearly increased in S100A6 low-expressing cells. In conclusion, our results suggested that S100A6 plays an important role in the progression of gastric cancer, affecting patient prognosis, and is up-regulated by epigenetic regulation. (Am J Pathol 2010, 177:586-597; DOL. 10.2353/ajpath.2010.091217)
C1 [Wang, Xiao-Hong; Zhang, Lian-Hai; Zhong, Xi-Yao; Xing, Xiao-Fang; Peng, Yong; Liu, Ni; Zhu, Yu-Bing; Ge, Shao-Hua; Ji, Jia-Fu] Peking Univ, Sch Oncol, Dept Surg,Minist Educ, Beijing Canc Hosp & Inst,Key Lab Carcinogenesis &, Beijing 100142, Peoples R China.
   [Liu, Yi-Qiang; Lu, Ai-Ping; Li, Ji-You] Peking Univ, Sch Oncol, Dept Pathol,Minist Educ, Beijing Canc Hosp & Inst,Key Lab Carcinogenesis &, Beijing 100142, Peoples R China.
   [Du, Hong; Zhang, Gui-Guo; Hu, Ying] Peking Univ, Sch Oncol, Tissue Bank,Minist Educ, Beijing Canc Hosp & Inst,Key Lab Carcinogenesis &, Beijing 100142, Peoples R China.
   [Zhao, Wei] Peking Univ, Sch Oncol, Clin Res Lab,Minist Educ, Beijing Canc Hosp & Inst,Key Lab Carcinogenesis &, Beijing 100142, Peoples R China.
   [Niu, Zhao-Jian] Shandong Univ, Dept Gen Surg, Qilu Hosp, Jinan 250100, Shandong, Peoples R China.
C3 Peking University; Peking University; Peking University; Peking
   University; Shandong University
RP Ji, JF (通讯作者)，Peking Univ, Sch Oncol, Dept Surg,Minist Educ, Beijing Canc Hosp & Inst,Key Lab Carcinogenesis &, Beijing 100142, Peoples R China.
EM jiafuj@gmail.com
RI Hu, Ying/GQZ-8100-2022; LU, Aiping/JDX-0577-2023; Liu,
   Yongyu/AAL-5429-2021; Wang, Xiaohong/S-4334-2019; Zhang,
   Hongyang/IAR-1565-2023
OI JI, JIAFU/0000-0001-6878-5543; Zhang, Lianhai/0000-0001-9464-0233
FU National Natural Science Foundation of China [30471677]; Foundation of
   Beijing Municipal Committee of Science Technology [D0905001040631]
FX Supported by National Natural Science Foundation of China (No. 30471677)
   and Foundation of Beijing Municipal Committee of Science & Technology
   (No. D0905001040631).
CR Bender J, 2004, CURR OPIN PLANT BIOL, V7, P521, DOI 10.1016/j.pbi.2004.07.003
   Breen EC, 2003, J CELL BIOCHEM, V88, P848, DOI 10.1002/jcb.10398
   Brown LM, 2006, MOL CARCINOGEN, V45, P613, DOI 10.1002/mc.20193
   CALABRETTA B, 1986, J BIOL CHEM, V261, P2628
   CALABRETTA B, 1985, P NATL ACAD SCI USA, V82, P4463, DOI 10.1073/pnas.82.13.4463
   Cross SS, 2005, HISTOPATHOLOGY, V46, P256, DOI 10.1111/j.1365-2559.2005.02097.x
   De Petris L, 2009, LUNG CANCER, V63, P410, DOI 10.1016/j.lungcan.2008.06.003
   Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2
   Emberley ED, 2004, BIOCHEM CELL BIOL, V82, P508, DOI 10.1139/O04-052
   Feng G, 2001, CANCER RES, V61, P7999
   FERRARI S, 1987, J BIOL CHEM, V262, P8325
   Filipek Anna, 1993, Acta Biochimica Polonica, V40, P321
   Frederick L.G., 2002, AJCC cancer staging manual, V6th, P99
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Golitsina NL, 1996, BIOCHEM BIOPH RES CO, V220, P360, DOI 10.1006/bbrc.1996.0410
   Guo Y, 2006, LEUKEMIA, V20, P115, DOI 10.1038/sj.leu.2404019
   Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v
   Ito T, 2007, J BIOCHEM, V141, P609, DOI 10.1093/jb/mvm091
   Ji JF, 2002, ONCOGENE, V21, P6549, DOI 10.1038/sj.onc.1205829
   Kill IR, 1996, J CELL SCI, V109, P1253
   Kim JW, 2002, HEPATOL RES, V23, P274, DOI 10.1016/S1386-6346(02)00008-6
   Kleinjan DA, 2005, AM J HUM GENET, V76, P8, DOI 10.1086/426833
   Komatsu K, 2000, BRIT J CANCER, V83, P769, DOI 10.1054/bjoc.2000.1356
   Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0
   Lesniak W, 2000, ACTA NEUROBIOL EXP, V60, P569, DOI 10.55782/ane-2000-1377
   Lesniak W, 2007, J INVEST DERMATOL, V127, P2307, DOI 10.1038/sj.jid.5700879
   Maelandsmo GM, 1997, INT J CANCER, V74, P464, DOI 10.1002/(SICI)1097-0215(19970822)74:4<464::AID-IJC19>3.3.CO;2-G
   MANI RS, 1992, BIOCHEMISTRY-US, V31, P11896, DOI 10.1021/bi00162a031
   Nakamura N, 1998, CLIN EXP METASTAS, V16, P471
   Nedjadi T, 2009, BRIT J CANCER, V101, P1145, DOI 10.1038/sj.bjc.6605289
   Ohuchida K, 2005, CLIN CANCER RES, V11, P7785, DOI 10.1158/1078-0432.CCR-05-0714
   Packeisen J, 2002, J CLIN PATHOL, V55, P613, DOI 10.1136/jcp.55.8.613
   PEDROCCHI M, 1994, INT J CANCER, V57, P684, DOI 10.1002/ijc.2910570513
   Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212
   Rehman I, 2005, PROSTATE, V65, P322, DOI 10.1002/pros.20302
   Rehman I, 2004, BRIT J CANCER, V91, P739, DOI 10.1038/sj.bjc.6602034
   Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432
   Rosty C, 2002, AM J PATHOL, V160, P45, DOI 10.1016/S0002-9440(10)64347-7
   Rothenburg S, 2001, IMMUNOGENETICS, V52, P231
   Sandberg R, 2005, P NATL ACAD SCI USA, V102, P2052, DOI 10.1073/pnas.0408105102
   Sato N, 2004, ONCOGENE, V23, P1531, DOI 10.1038/sj.onc.1207269
   Shekouh AR, 2003, PROTEOMICS, V3, P1988, DOI 10.1002/pmic.200300466
   Slomnicki LP, 2009, INT J BIOCHEM CELL B, V41, P784, DOI 10.1016/j.biocel.2008.08.007
   Splechowicz M, 2007, BIOCHEM BIOPH RES CO, V357, P1148, DOI 10.1016/j.bbrc.2007.04.073
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Stulík J, 2000, EUR J CANCER, V36, P1050, DOI 10.1016/S0959-8049(00)00043-5
   Tsoporis JN, 2008, J BIOL CHEM, V283, P30174, DOI 10.1074/jbc.M805318200
   Vimalachandran D, 2005, CANCER RES, V65, P3218, DOI 10.1158/0008-5472.CAN-04-4311
   WETERMAN MAJ, 1992, CANCER RES, V52, P1291
   Wicki R, 1997, CELL CALCIUM, V22, P243, DOI 10.1016/S0143-4160(97)90063-4
   Yang YQ, 2007, J DIGEST DIS, V8, P186, DOI 10.1111/j.1751-2980.2007.00311.x
NR 51
TC 68
Z9 79
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD AUG
PY 2010
VL 177
IS 2
BP 586
EP 597
DI 10.2353/ajpath.2010.091217
PG 12
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 638KU
UT WOS:000280894600011
PM 20581057
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Fujikane, T
   Nishikawa, N
   Toyota, M
   Suzuki, H
   Nojima, M
   Maruyama, R
   Ashida, M
   Ohe-Toyota, M
   Kai, M
   Nishidate, T
   Sasaki, Y
   Ohmura, T
   Hirata, K
   Tokino, T
AF Fujikane, Tomoko
   Nishikawa, Noriko
   Toyota, Minoru
   Suzuki, Hiromu
   Nojima, Masanori
   Maruyama, Reo
   Ashida, Masami
   Ohe-Toyota, Mutsumi
   Kai, Masahiro
   Nishidate, Toshihiko
   Sasaki, Yasushi
   Ohmura, Tousei
   Hirata, Koichi
   Tokino, Takashi
TI Genomic screening for genes upregulated by demethylation revealed novel
   targets of epigenetic silencing in breast cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE DNA methylation; Epigenetics; Gene expression
ID TUMOR-SUPPRESSOR GENE; DNA METHYLATION; FAMILY GENES; SFRP GENES; CPG
   ISLAND; INACTIVATION; HYPERMETHYLATION; EXPRESSION; PROSTATE; FREQUENT
AB Breast cancer arises through the accumulation of multiple genetic alterations and epigenetic changes such as methylation, which silences gene expression in a variety of cancers. In the present study, we applied genomic screening to identify genes upregulated by the demethylating agent 5-aza-2'-deoxycytidine (DAC) in a human breast cancer cell line (MCF7). We identified 288 genes upregulated and 29 genes downregulated more than fivefold after treatment with DAC, and gene ontology analyses revealed the genes to be involved in immune responses, apoptosis, and cell differentiation. In addition, real-time PCR analysis of ten genes silenced in MCF7 cells confirmed that they are upregulated by DAC, while bisulfite-pyrosequencing analysis confirmed that nine of those genes were silenced by methylation. We also found that treating MCF7 cells with DAC restored induction of DFNA5 by p53, as well as by two other p53 family genes, p63 gamma and p73 beta. Introduction of NTN4 into MCF7 cells suppressed cell growth, indicating that NTN4 has tumor suppressive activity. In primary breast cancers, we detected cancer-specific methylation of NTN4, PGP9.5, and DKK3, suggesting that methylation of these genes could be useful markers for diagnosis of breast cancer. Thus, DNA methylation appears to be a common event in breast cancer, and the genes silenced by methylation could be useful targets for both diagnosis and therapy.
C1 [Toyota, Minoru; Ashida, Masami; Kai, Masahiro] Sapporo Med Univ, Dept Biochem, Chuo Ku, Sapporo, Hokkaido 0608556, Japan.
   [Fujikane, Tomoko; Toyota, Minoru; Suzuki, Hiromu; Maruyama, Reo; Ohe-Toyota, Mutsumi; Sasaki, Yasushi; Tokino, Takashi] Sapporo Med Univ, Canc Res Inst, Dept Mol Biol, Sapporo, Hokkaido 0608556, Japan.
   [Fujikane, Tomoko; Nishikawa, Noriko; Nishidate, Toshihiko; Ohmura, Tousei; Hirata, Koichi] Sapporo Med Univ, Dept Surg 1, Sapporo, Hokkaido 0608556, Japan.
   [Toyota, Minoru; Suzuki, Hiromu; Maruyama, Reo] Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 0608556, Japan.
   [Nojima, Masanori] Sapporo Med Univ, Dept Publ Hlth, Sapporo, Hokkaido 0608556, Japan.
C3 Sapporo Medical University; Sapporo Medical University; Sapporo Medical
   University; Sapporo Medical University; Sapporo Medical University
RP Toyota, M (通讯作者)，Sapporo Med Univ, Dept Biochem, Chuo Ku, South 1,West 17, Sapporo, Hokkaido 0608556, Japan.
EM mtoyota@sapmed.ac.jp
RI Tokino, Takashi/AAI-9887-2021; Nojima, Masanori/ABE-2237-2020; Sasaki,
   Yasushi/AAA-3079-2019
OI Nojima, Masanori/0000-0002-8788-2522; Sasaki,
   Yasushi/0000-0002-3500-8059
FU Ministry of Education, Culture, Sports, Science, and Technology; Japan
   Society for Promotion of Science; Third-term Comprehensive 10-year
   Strategy for Cancer Control; Ministry of Health, Labor, and Welfare,
   Japan
FX The authors thank Dr. William F. Goldman for editing the manuscript.
   This study was supported in part by Grants-inAid for Scientific Research
   on Priority Areas from the Ministry of Education, Culture, Sports,
   Science, and Technology (K. I., T. T., and M. T.), Grants-in-Aid for
   Scientific Research (S) from Japan Society for Promotion of Science (K.
   I.), a Grant-in-Aid for the Third-term Comprehensive 10-year Strategy
   for Cancer Control, and Grant-in-Aid for Cancer Research from the
   Ministry of Health, Labor, and Welfare, Japan (M. T.).
CR Akino K, 2007, CANCER SCI, V98, P88, DOI 10.1111/j.1349-7006.2006.00351.x
   Arakawa H, 2004, NAT REV CANCER, V4, P978, DOI 10.1038/nrc1504
   Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032
   BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I
   Chung W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002079
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Conway KE, 2000, CANCER RES, V60, P6236
   Crackower MA, 2003, SCIENCE, V300, P1291, DOI 10.1126/science.1083022
   Dammann R, 2001, CANCER RES, V61, P3105
   Douglas DB, 2004, CANCER RES, V64, P1611, DOI 10.1158/0008-5472.CAN-0318-2
   Esseghir S, 2007, CLIN CANCER RES, V13, P3164, DOI 10.1158/1078-0432.CCR-07-0224
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   GRAFF JR, 1995, CANCER RES, V55, P5195
   HERMAN JG, 1995, CANCER RES, V55, P4525
   Issa JPJ, 2001, CANCER RES, V61, P3573
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007
   Kim MS, 2008, BIOCHEM BIOPH RES CO, V370, P38, DOI 10.1016/j.bbrc.2008.03.026
   Krop IE, 2001, P NATL ACAD SCI USA, V98, P9796, DOI 10.1073/pnas.171138398
   Kwabi-Addo B, 2007, CLIN CANCER RES, V13, P3796, DOI 10.1158/1078-0432.CCR-07-0085
   Lage H, 2001, FEBS LETT, V494, P54, DOI 10.1016/S0014-5793(01)02304-3
   Lehto M, 2008, J CELL SCI, V121, P695, DOI 10.1242/jcs.016964
   Lejmi E, 2008, P NATL ACAD SCI USA, V105, P12491, DOI 10.1073/pnas.0804008105
   Mandelker DL, 2005, CANCER RES, V65, P4963, DOI 10.1158/0008-5472.CAN-04-3923
   Marchesani M, 2003, JNCI-J NATL CANCER I, V95, P812, DOI 10.1093/jnci/95.11.812
   Masuda Yoshiko, 2006, J Hum Genet, V51, P652, DOI 10.1007/s10038-006-0004-6
   Meng X, 1998, GENOMICS, V52, P130, DOI 10.1006/geno.1998.5412
   Micale L, 2008, EUR J HUM GENET, V16, P1038, DOI 10.1038/ejhg.2008.68
   Nojima M, 2007, ONCOGENE, V26, P4699, DOI 10.1038/sj.onc.1210259
   Ostrow KL, 2009, CLIN CANCER RES, V15, P1184, DOI 10.1158/1078-0432.CCR-08-1304
   Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859
   Rodriguez BAT, 2008, CARCINOGENESIS, V29, P1459, DOI 10.1093/carcin/bgn115
   Sasaki Y, 2001, GENE THER, V8, P1401, DOI 10.1038/sj.gt.3301538
   Sasaki Y, 2009, J BIOL CHEM, V284, P872, DOI 10.1074/jbc.M807185200
   Sato H, 2007, CARCINOGENESIS, V28, P2459, DOI 10.1093/carcin/bgm178
   Schlosshauer PW, 2000, CARCINOGENESIS, V21, P1453, DOI 10.1093/carcin/21.7.1453
   Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157
   Shen LL, 2007, P NATL ACAD SCI USA, V104, P18654, DOI 10.1073/pnas.0704652104
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Suzuki H, 2010, CARCINOGENESIS, V31, P342, DOI 10.1093/carcin/bgp179
   Thompson DA, 1998, EUR J BIOCHEM, V252, P169, DOI 10.1046/j.1432-1327.1998.2520169.x
   Tokumaru Y, 2008, INT J CANCER, V123, P753, DOI 10.1002/ijc.23354
   Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233
   Toyota M, 2009, CANCER SCI, V100, P787, DOI 10.1111/j.1349-7006.2009.01095.x
   Van Laer L, 1998, NAT GENET, V20, P194
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Veeck J, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2151
   Watanabe Y, 2007, CLIN CANCER RES, V13, P4786, DOI 10.1158/1078-0432.CCR-07-0305
   Wu GJ, 2007, CANCER RES, V67, P4123, DOI 10.1158/0008-5472.CAN-07-0012
   Yamashita K, 2006, CANCER RES, V66, P3921, DOI 10.1158/0008-5472.CAN-05-1511
   Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032
NR 54
TC 77
Z9 80
U1 0
U2 12
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD AUG
PY 2010
VL 122
IS 3
BP 699
EP 710
DI 10.1007/s10549-009-0600-1
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 627SK
UT WOS:000280062600009
PM 19859801
DA 2025-01-12
ER

PT J
AU Kutanzi, KR
   Koturbash, I
   Kovalchuk, O
AF Kutanzi, Kristy R.
   Koturbash, Igor
   Kovalchuk, Olga
TI Reversibility of pre-malignant estrogen-induced epigenetic changes
SO CELL CYCLE
LA English
DT Article
DE estrogen; breast carcinogenesis; epigenetics; DNA methylation; histones
ID BREAST-CANCER-CELLS; DNA METHYLATION; GENE-EXPRESSION; MAMMARY
   CARCINOGENESIS; HISTONE ACETYLATION; PROGRESSION; RAT; MECHANISMS;
   TAMOXIFEN; METHYLTRANSFERASE
AB The development of early detection and prevention strategies of breast cancer relies on defining molecular and cellular events that characterize progressive alterations underlying preneoplastic changes in the mammary epithelium. Studies have shown that estrogen exerts its carcinogenic effects through both genetic and epigenetic pathways to promote imbalances in proliferation and apoptosis, genomic instability and cancer.
   The purpose of this study was to identify the earliest epigenetic changes that could be detected in response to estrogen treatment. More importantly, having detected these early pre-malignant epigenetic changes, a follow-up study was designed to address the potential to reverse these estrogen-induced alterations. Using a well-established ACI rat model, morphological and epigenetic changes were identified in the mammary gland tissue as early as 2 days after exposure to constitutively elevated estrogen levels produced by continuous release estrogen mini-pellets.
   Progressive hyperproliferative changes were paralleled by epigenetic disturbances, including the upregulation of DNA methyltransferases and hyperacetylation of histone residues. These changes could be detected early, and they continued to persist if estrogen was maintained within a high physiological range. Epigenetic features of short-term estrogen exposure were strikingly similar to hallmarks of cancer promotion and progression. Yet, importantly, these changes exhibited a degree of reversibility if a source of elevated levels of estrogen was removed.
   Knowing that operational reversibility during the promotion stage of carcinogenesis provides a window for intervention, the potential to reverse the effects of elevated levels of estrogen prior to tumor development may prove to be a promising avenue to explore.
C1 [Kutanzi, Kristy R.; Koturbash, Igor; Kovalchuk, Olga] Univ Lethbridge, Dept Biol Sci, Lethbridge, AB T1K 3M4, Canada.
C3 University of Lethbridge
RP Kovalchuk, O (通讯作者)，Univ Lethbridge, Dept Biol Sci, Lethbridge, AB T1K 3M4, Canada.
EM olga.kovalchuk@uleth.ca
FU Canadian Breast Cancer Foundation; Vanier Canada Graduate Scholarship;
   National Science and Engineering Research Council; Queen Elizabeth II
   Graduate Scholarship; Alberta Heritage for Medical Research Scholarship
FX Work was supported by the Canadian Breast Cancer Foundation Operating
   grant to Olga Kovalchuk. Kristy Kutanzi is a recipient of the Vanier
   Canada Graduate Scholarship, National Science and Engineering Research
   Council Graduate Scholarship, Queen Elizabeth II Graduate Scholarship
   and the Alberta Heritage for Medical Research Scholarship. We are
   thankful to Dr. Roderick Bronson for help with histopathological
   evaluations, to Rocio Rodriguez-Juarez for technical assistance and to
   Dr. Valentina Titova for careful proofreading of this manuscript.
CR Arens N, 2005, Verh Dtsch Ges Pathol, V89, P191
   Ariazi JL, 2005, MOL CARCINOGEN, V43, P155, DOI 10.1002/mc.20104
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045
   Bernardino T, 1997, CANCER GENET CYTOGEN, V97, P83, DOI 10.1016/S0165-4608(96)00385-8
   BRUNNER N, 1989, CANCER RES, V49, P1515
   Cheng ASL, 2008, CANCER RES, V68, P1786, DOI 10.1158/0008-5472.CAN-07-5547
   CLARKE R, 1994, BREAST CANCER RES TR, V31, P237, DOI 10.1007/BF00666157
   Clemons M, 2001, NEW ENGL J MED, V344, P276, DOI 10.1056/NEJM200101253440407
   FEHER T, 1982, ENDOKRINOLOGIE, V80, P173
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Ferguson A. T., 2000, Current Genomics, V1, P41, DOI 10.2174/1389202003351652
   Groth A, 2009, BIOCHEM CELL BIOL, V87, P51, DOI 10.1139/O08-102
   Gunin AG, 2005, J ENDOCRINOL, V185, P539, DOI 10.1677/joe.1.06118
   HENDERSON BE, 1982, CANCER RES, V42, P3232
   Hikita H, 1999, TOXICOL SCI, V52, P17, DOI 10.1093/toxsci/52.2.17
   JENSEN EV, PHYSL BEHAV, V99, P151
   Kimura H, 2003, J BIOL CHEM, V278, P4806, DOI 10.1074/jbc.M209923200
   King MC, 2001, JAMA-J AM MED ASSOC, V286, P2251, DOI 10.1001/jama.286.18.2251
   Kininis M, 2007, MOL CELL BIOL, V27, P5090, DOI 10.1128/MCB.00083-07
   Kovalchuk O, 2007, CELL CYCLE, V6, P2010, DOI 10.4161/cc.6.16.4549
   Kristensen LS, 2009, CLIN CHEM, V55, P1471, DOI 10.1373/clinchem.2008.121962
   LOIDL P, 1988, FEBS LETT, V227, P91, DOI 10.1016/0014-5793(88)80874-3
   Medina D, 2003, CANCER RES, V63, P1067
   Mense SM, 2008, TOXICOL APPL PHARM, V232, P78, DOI 10.1016/j.taap.2008.06.007
   Narod SA, 2000, LANCET, V356, P1876, DOI 10.1016/S0140-6736(00)03258-X
   Okobia M N, 2006, Afr J Reprod Health, V10, P13
   Pedram A, 2009, MOL BIOL CELL, V20, P3374, DOI 10.1091/mbc.E09-01-0085
   PITOT HC, 1991, FASEB J, V5, P2280, DOI 10.1096/fasebj.5.9.1860619
   Plachot C, 2004, EXP CELL RES, V298, P122, DOI 10.1016/j.yexcr.2004.04.024
   Pogribny I. P., 2005, Ukrainskii Biokhimicheskii Zhurnal, V77, P114
   Pogribny IP, 2009, CELL MOL LIFE SCI, V66, P2249, DOI 10.1007/s00018-009-0015-5
   Prall OWJ, 1998, J STEROID BIOCHEM, V65, P169, DOI 10.1016/S0960-0760(98)00021-1
   Rajkumar L, 2001, P NATL ACAD SCI USA, V98, P11755, DOI 10.1073/pnas.201393798
   Russo J, 2006, J STEROID BIOCHEM, V102, P89, DOI 10.1016/j.jsbmb.2006.09.004
   Russo J, 2005, BREAST CANCER RES, V7, P131, DOI 10.1186/bcr1029
   Russo J, 1982, Breast Cancer Res Treat, V2, P5, DOI 10.1007/BF01805718
   Santen R, 2009, ANN NY ACAD SCI, V1155, P132, DOI 10.1111/j.1749-6632.2008.03685.x
   Schedin P, 2000, J MAMMARY GLAND BIOL, V5, P211, DOI 10.1023/A:1026447506666
   SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237
   TATEMATSU M, 1983, CANCER RES, V43, P5049
   Terasaka S, 2004, ENVIRON HEALTH PERSP, V112, P773, DOI 10.1289/ehp.6753
   *US DEP HHS CDCP N, 2002, 1999 NAT HLTH INT SU, P1
   Wang CG, 2001, FRONT BIOSCI-LANDMRK, V6, pD610, DOI 10.2741/1wang1
   Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776
   Yoder JA, 1997, J MOL BIOL, V270, P385, DOI 10.1006/jmbi.1997.1125
   Yoshidome K, 2000, CANCER RES, V60, P6901
   Zhang F, 2001, CHEM RES TOXICOL, V14, P1654, DOI 10.1021/tx010158c
NR 49
TC 13
Z9 19
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4101
EI 1551-4005
J9 CELL CYCLE
JI Cell Cycle
PD AUG 1
PY 2010
VL 9
IS 15
BP 3078
EP 3084
DI 10.4161/cc.9.15.12516
PG 7
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 642JD
UT WOS:000281206300037
PM 20699652
OA Bronze
DA 2025-01-12
ER

PT J
AU Zhang, G
   Wang, Q
   Xu, R
AF Zhang, G.
   Wang, Q.
   Xu, R.
TI Therapeutics Based on microRNA: A New Approach for Liver Cancer
SO CURRENT GENOMICS
LA English
DT Article
DE Hepatocellular carcinoma; gene therapy; microRNA; hepatitis; hepatic
   fibrosis; tumor suppressor genes; hepatic targeting vector
ID HEPATITIS-C-VIRUS; HUMAN HEPATOCELLULAR-CARCINOMA; TUMOR-SUPPRESSOR
   MICRORNA; HUMAN BREAST-CANCER; PHASE-II TRIAL; B-VIRUS; GENE-EXPRESSION;
   VIRAL-HEPATITIS; IN-VIVO; TRANSGENE EXPRESSION
AB Hepatocellular carcinoma (HCC) is a serious public health hazard. Polygenes involvement, accumulation of genetic and epigenetic changes and immune response of viral vector during gene therapy have resulted in the high mortality rate without marked change. To provide a safeguard for gene therapy and the feasibility for a clinical application, efforts have been focused predominantly upon constructing liver-targeted vector recently. MicroRNAs (miRNAs), a class of short endogenous RNAs, regulate the gene expression at the post-transcriptional level through imperfect base pairing with the 3'-untranslated region of target mRNAs. miRNAs, especially the liver-specific miRNA: miR-122, have multiple functions in liver development and abnormal expression of miRNAs could lead to liver diseases. Altered miRNA expressions have been observed in HCCs, viral hepatitis and hepatic fibrosis. The different expression profiles of miRNAs in HCC suggest that miRNAs may serve as either novel potential targets acting directly as oncogenes or therapeutic molecules working as tumor suppressor genes. Moreover, the abundance in general and liver specificity in particular, all together make them attractive to be considered as elements for hepatic specific targeting viral vector. This review describes recent progress in miRNA investigation on liver associated for better understanding the relationship between miRNA and liver cancer in order to raise prospects for therapy.
C1 [Xu, R.] Huaqiao Univ, Minist Educ, Engn Res Ctr Mol Med, Inst Mol Med, Quanzhou 362021, Fujian, Peoples R China.
C3 Huaqiao University
RP Xu, R (通讯作者)，Huaqiao Univ, Minist Educ, Engn Res Ctr Mol Med, Inst Mol Med, 518-519 Shengjun Bldg,Main Campus, Quanzhou 362021, Fujian, Peoples R China.
EM ruianxu@hqu.edu.cn
RI wang, qizhao/T-1690-2017
FU National High-Tech Research and Development Plan of China
   [2008AA02Z135]; National Natural Science Foundation of China [30900822];
   Fujian Provincial Government
FX This work is supported by the National High-Tech Research and
   Development Plan of China (to Diao Y. and R. A. XU, No. 2008AA02Z135),
   National Natural Science Foundation of China (No. 30900822) and Fujian
   Provincial Government Funding to R.A. XU.
CR Aravalli RN, 2008, HEPATOLOGY, V48, P2047, DOI 10.1002/hep.22580
   Arbuthnot P, 2001, INT J EXP PATHOL, V82, P77, DOI 10.1111/j.1365-2613.2001.iep178.x
   Bai SM, 2009, J BIOL CHEM, V284, P32015, DOI 10.1074/jbc.M109.016774
   Barber GN, 2005, ONCOGENE, V24, P7710, DOI 10.1038/sj.onc.1209042
   Bazan-Peregrino M, 2007, CANCER GENE THER, V14, P117, DOI 10.1038/sj.cgt.7701001
   Bell JC, 2008, NAT BIOTECHNOL, V26, P1346, DOI 10.1038/nbt1208-1346
   Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214
   Blum HE, 2005, WORLD J GASTROENTERO, V11, P7391
   Bosch FX, 1999, SEMIN LIVER DIS, V19, P271, DOI 10.1055/s-2007-1007117
   Brown BD, 2007, BLOOD, V110, P4144, DOI 10.1182/blood-2007-03-078493
   Brown BD, 2007, NAT BIOTECHNOL, V25, P1457, DOI 10.1038/nbt1372
   Brown BD, 2006, NAT MED, V12, P585, DOI 10.1038/nm1398
   Bruix J, 2004, CANCER CELL, V5, P215, DOI 10.1016/S1535-6108(04)00058-3
   Budhu A, 2008, HEPATOLOGY, V47, P897, DOI 10.1002/hep.22160
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Cawood R, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000440
   Chang Jinhong, 2004, RNA Biol, V1, P106, DOI 10.4161/rna.1.2.1066
   Chen C, 2008, IN VITRO CELL DEV-AN, V44, pS2
   CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562
   Connolly E, 2008, AM J PATHOL, V173, P856, DOI 10.2353/ajpath.2008.080096
   Corney DC, 2007, CANCER RES, V67, P8433, DOI 10.1158/0008-5472.CAN-07-1585
   Coulouarn C, 2009, ONCOGENE, V28, P3526, DOI 10.1038/onc.2009.211
   Cramp ME, 1999, GUT, V45, P168, DOI 10.1136/gut.45.2.168
   Daniels Danni, 2009, Morbidity and Mortality Weekly Report, V58, P1
   De Geest BR, 2003, BLOOD, V101, P2551, DOI 10.1182/blood-2002-07-2146
   Dogantekin E, 2009, EXPERT SYST APPL, V36, P11282, DOI 10.1016/j.eswa.2009.03.021
   Donato F, 2002, AM J EPIDEMIOL, V155, P323, DOI 10.1093/aje/155.4.323
   Edge RE, 2008, MOL THER, V16, P1437, DOI 10.1038/mt.2008.130
   Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102
   El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061
   Ely A, 2008, MOL THER, V16, P1105, DOI 10.1038/mt.2008.82
   Esau C, 2006, CELL METAB, V3, P87, DOI 10.1016/j.cmet.2006.01.005
   Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934
   Fornari F, 2008, ONCOGENE, V27, P5651, DOI 10.1038/onc.2008.178
   Fornari F, 2009, CANCER RES, V69, P5761, DOI 10.1158/0008-5472.CAN-08-4797
   Friedman SL, 2008, GASTROENTEROLOGY, V134, P1655, DOI 10.1053/j.gastro.2008.03.003
   Friedman SL, 2006, HEPATOLOGY, V43, pS82, DOI 10.1002/hep.20974
   Gamble C, 2009, BIOORG MED CHEM LETT, V19, P3581, DOI 10.1016/j.bmcl.2009.04.139
   Gao YF, 2008, WORLD J GASTROENTERO, V14, P4684, DOI 10.3748/wjg.14.4684
   Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014
   Gentner B, 2009, NAT METHODS, V6, P63, DOI [10.1038/nmeth.1277, 10.1038/NMETH.1277]
   Girard M, 2008, J HEPATOL, V48, P648, DOI 10.1016/j.jhep.2008.01.019
   Araújo FMG, 2009, J MED VIROL, V81, P1212, DOI 10.1002/jmv.21507
   Gramantieri L, 2007, CANCER RES, V67, P6092, DOI 10.1158/0008-5472.CAN-06-4607
   Gramantieri L, 2009, CLIN CANCER RES, V15, P5073, DOI 10.1158/1078-0432.CCR-09-0092
   Guo YH, 2009, J MED VIROL, V81, P1177, DOI 10.1002/jmv.21525
   Haraguchi T, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp040
   Hashimoto E, 2004, ALCOHOL CLIN EXP RES, V28, p164S, DOI 10.1097/01.ALC.0000133547.70803.83
   He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102
   He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552
   He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939
   Hellerbrand C, 2003, CLIN GASTROENTEROL H, V1, P279, DOI 10.1016/S1542-3565(03)00132-0
   Henke JI, 2008, EMBO J, V27, P3300, DOI 10.1038/emboj.2008.244
   Heo I, 2009, CELL, V138, P696, DOI 10.1016/j.cell.2009.08.002
   Herath NI, 2006, J GASTROEN HEPATOL, V21, P15, DOI 10.1111/j.1440-1746.2005.04043.x
   Huang XH, 2009, HEPATOL RES, V39, P786, DOI 10.1111/j.1872-034X.2009.00502.x
   Huang YS, 2008, J GASTROEN HEPATOL, V23, P87, DOI 10.1111/j.1440-1746.2007.05223.x
   Hunt DR, 2009, AM J GASTROENTEROL, V104, P1024, DOI 10.1038/ajg.2008.143
   Ilves H, 2006, ANN NY ACAD SCI, V1082, P52, DOI 10.1196/annals.1348.060
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Jacob JR, 2004, HEPATOLOGY, V39, P1008, DOI 10.1002/hep.20106
   Ji JL, 2009, FEBS LETT, V583, P759, DOI 10.1016/j.febslet.2009.01.034
   Ji JF, 2009, NEW ENGL J MED, V361, P1437, DOI 10.1056/NEJMoa0901282
   Jiang J, 2008, CLIN CANCER RES, V14, P419, DOI 10.1158/1078-0432.CCR-07-0523
   Jin WB, 2007, COMPUT BIOL CHEM, V31, P124, DOI 10.1016/j.compbiolchem.2007.01.005
   Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014
   Jopling CL, 2008, CELL HOST MICROBE, V4, P77, DOI 10.1016/j.chom.2008.05.013
   Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329
   Kanda T, 2007, J VIROL, V81, P669, DOI 10.1128/JVI.01496-06
   Kato M, 2009, NAT CELL BIOL, V11, P881, DOI 10.1038/ncb1897
   Kim VN, 2006, TRENDS GENET, V22, P165, DOI 10.1016/j.tig.2006.01.003
   Kloosterman WP, 2006, DEV CELL, V11, P441, DOI 10.1016/j.devcel.2006.09.009
   Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021
   Kremsdorf D, 2006, ONCOGENE, V25, P3823, DOI 10.1038/sj.onc.1209559
   Krützfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303
   Kutay H, 2006, J CELL BIOCHEM, V99, P671, DOI 10.1002/jcb.20982
   KWIECINSKI M, 2008, HEPATOLOGY, V48, pS110
   Ladeiro Y, 2008, HEPATOLOGY, V47, P1955, DOI 10.1002/hep.22256
   Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6
   Laurent-Puig P, 2006, ONCOGENE, V25, P3778, DOI 10.1038/sj.onc.1209547
   Lavanchy D, 2004, J VIRAL HEPATITIS, V11, P97, DOI 10.1046/j.1365-2893.2003.00487.x
   Le MTN, 2009, GENE DEV, V23, P862, DOI 10.1101/gad.1767609
   Lee CYF, 2009, CLIN CANCER RES, V15, P5126, DOI 10.1158/1078-0432.CCR-09-0051
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407
   Lemmer ER, 2006, SEMIN LIVER DIS, V26, P373, DOI 10.1055/s-2006-951604
   Li S, 2009, HEPATOLOGY, V49, P1194, DOI 10.1002/hep.22757
   Lin AY, 2005, CANCER, V103, P119, DOI 10.1002/cncr.20732
   Lin CJF, 2008, BIOCHEM BIOPH RES CO, V375, P315, DOI 10.1016/j.bbrc.2008.07.154
   Liu Z, 2009, J VIROL, V83, P6554, DOI 10.1128/JVI.02550-08
   Llovet JM, 2000, HEPATOLOGY, V31, P54, DOI 10.1002/hep.510310111
   Love TM, 2008, J ALLERGY CLIN IMMUN, V121, P309, DOI 10.1016/j.jaci.2007.12.1167
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lunn RM, 1997, CANCER RES, V57, P3471
   MA L, 2010, CANC BIOL THER, V9
   Maheshwari S, 2007, J HEPATOL, V47, P506, DOI 10.1016/j.jhep.2007.03.015
   Malka D, 2007, J CLIN ONCOL, V25
   Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999
   Medina R, 2008, CANCER RES, V68, P2773, DOI 10.1158/0008-5472.CAN-07-6754
   Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022
   Merle P, 2005, J HEPATOL, V43, P854, DOI 10.1016/j.jhep.2005.05.018
   Michael MZ, 2003, MOL CANCER RES, V1, P882
   Murakami Y, 2006, ONCOGENE, V25, P2537, DOI 10.1038/sj.onc.1209283
   Murakami Y, 2009, J HEPATOL, V50, P453, DOI 10.1016/j.jhep.2008.06.010
   Nagai H, 2002, CANCER LETT, V186, P59, DOI 10.1016/S0304-3835(02)00244-6
   Pan QW, 2009, J MOL MED, V87, P713, DOI 10.1007/s00109-009-0470-3
   Pang R, 2006, CANCER LETT, V240, P157, DOI 10.1016/j.canlet.2005.08.031
   Panteva M, 2003, VIRUS RES, V92, P131, DOI 10.1016/S0168-1702(02)00356-8
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Patt YZ, 2005, CANCER, V103, P749, DOI 10.1002/cncr.20821
   Patt YZ, 2003, J CLIN ONCOL, V21, P421, DOI 10.1200/JCO.2003.10.103
   Philip PA, 2005, J CLIN ONCOL, V23, P6657, DOI 10.1200/JCO.2005.14.696
   PINEAU P, 2010, P NATL ACAD SCI US
   Roberts LR, 2005, SEMIN LIVER DIS, V25, P212, DOI 10.1055/s-2005-871200
   Scherr M, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm971
   Seki E, 2007, NAT MED, V13, P1324, DOI 10.1038/nm1663
   Shan Y, 2007, GASTROENTEROLOGY, V133, P1166, DOI 10.1053/j.gastro.2007.08.002
   Sieghart W, 2006, J HEPATOL, V44, P151, DOI 10.1016/j.jhep.2005.09.010
   Soini Y, 1996, CARCINOGENESIS, V17, P1007, DOI 10.1093/carcin/17.5.1007
   Song B, 2008, CLIN CANCER RES, V14, P8080, DOI 10.1158/1078-0432.CCR-08-1422
   Su H, 2008, MUTAT RES-FUND MOL M, V641, P27, DOI 10.1016/j.mrfmmm.2008.02.005
   Su H, 2009, CANCER RES, V69, P1135, DOI 10.1158/0008-5472.CAN-08-2886
   Sun BS, 2008, HEPATOLOGY, V48, P1834, DOI 10.1002/hep.22531
   SUN XY, 2008, MOL GENE MED, P433
   Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199
   Suzuki T, 2008, MOL THER, V16, P1719, DOI 10.1038/mt.2008.159
   Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637
   Takashima M, 2009, J GASTROENTEROL, V44, P847, DOI 10.1007/s00535-009-0073-3
   Takwi A, 2009, CURR GENOMICS, V10, P194, DOI 10.2174/138920209788185270
   Tanaka S, 2009, CANCER SCI, V100, P1, DOI 10.1111/j.1349-7006.2008.01006.x
   Terris B, 1999, ONCOGENE, V18, P6583, DOI 10.1038/sj.onc.1203051
   Thomas CE, 2003, NAT REV GENET, V4, P346, DOI 10.1038/nrg1066
   Thomas MB, 2007, CANCER-AM CANCER SOC, V110, P1059, DOI 10.1002/cncr.22886
   Tsai WC, 2009, HEPATOLOGY, V49, P1571, DOI 10.1002/hep.22806
   Uprichard SL, 2005, P NATL ACAD SCI USA, V102, P773, DOI 10.1073/pnas.0409028102
   Ura S, 2009, HEPATOLOGY, V49, P1098, DOI 10.1002/hep.22749
   Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040
   Vivekanandan P, 2008, CLIN INFECT DIS, V46, P1227, DOI 10.1086/529437
   Waehler R, 2007, NAT REV GENET, V8, P573, DOI 10.1038/nrg2141
   Wang QZ, 2009, CURR CANCER DRUG TAR, V9, P572, DOI 10.2174/156800909788486731
   Weiss U, 2005, NATURE, V436, P929, DOI 10.1038/436929a
   Wolff LJ, 2009, HUM GENE THER, V20, P374, DOI 10.1089/hum.2008.088
   Wong QWL, 2008, GASTROENTEROLOGY, V135, P257, DOI 10.1053/j.gastro.2008.04.003
   XU RA, 2009, Patent No. 101532024
   Yasuda E, 2005, BIOCHEM BIOPH RES CO, V337, P337, DOI 10.1016/j.bbrc.2005.08.273
   Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843
   Ylösmäki E, 2008, J VIROL, V82, P11009, DOI 10.1128/JVI.01608-08
   Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/ng0501-29
   Zhang XY, 2009, HEPATOLOGY, V50, P490, DOI 10.1002/hep.23008
   Zhao LJ, 2005, EXP CELL RES, V305, P23, DOI 10.1016/j.yexcr.2004.12.024
   Zhu AX, 2007, J CLIN ONCOL, V25
   Zhu AX, 2005, ONCOLOGIST, V10, P392, DOI 10.1634/theoncologist.10-6-392
   Zhu ZW, 2008, HEPATOLOGY, V48, P1430, DOI 10.1002/hep.22491
NR 155
TC 33
Z9 39
U1 0
U2 10
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-2029
EI 1875-5488
J9 CURR GENOMICS
JI Curr. Genomics
PD AUG
PY 2010
VL 11
IS 5
BP 311
EP 325
DI 10.2174/138920210791616671
PG 15
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 632XV
UT WOS:000280463800002
PM 21286309
OA Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Kim, JH
   Shin, MH
   Kweon, SS
   Park, MH
   Yoon, JH
   Lee, JS
   Choi, C
   Fackler, MJ
   Sukumar, S
AF Kim, Jo-Heon
   Shin, Min-Ho
   Kweon, Sun-Seog
   Park, Min Ho
   Yoon, Jung Han
   Lee, Ji Shin
   Choi, Chan
   Fackler, Mary Jo
   Sukumar, Saraswati
TI Evaluation of promoter hypermethylation detection in serum as a
   diagnostic tool for breast carcinoma in Korean women
SO GYNECOLOGIC ONCOLOGY
LA English
DT Article
DE Breast; Invasive ductal carcinoma; Ductal carcinoma in situ;
   Methylation; Quantitation; Serum; Diagnosis
ID TUMOR DNA; METHYLATION; GENE; P16(INK4A)
AB Objective. We have noted that quantitative multiplex-methylation specific PCR (QM-MSP) analysis of a key panel of genes may be useful as an ancillary tool for ductal carcinoma in situ (DCIS) detection in breast tissue. In this study, we investigated aberrant promoter hypermethylation of four genes as a means to detect epigenetic alterations specific to breast carcinoma in the serum of patients with DCIS and invasive ductal carcinoma (IDC).
   Methods. Two hundred forty-three serum samples from 89 patients with IDC, 30 patients with DCIS, and 125 age-matched healthy controls were examined. After DNA extraction and sodium bisulfite treatment, QM-MSP was performed for HIN-1, RASSF1A, RAR-beta?,, and Twist.
   Results. Overall significant differences in rnethylation levels were observed for HIN-1 (p = 0.006), RAR-beta (p<0.001), RASSF1A (p = 0.004), and Twist (p<0.001). All four genes showed significantly higher methylation frequencies in DCIS or IDC than in control subjects (p<0.001 for all comparisons). However, methylation frequencies were not significantly different between DCIS and IDC. In receiver-operating characteristic analysis, the two-gene combination (RAR-beta/RASSF1A) showed the best performance in distinguishing DCIS/IDC from control samples. The estimated specificity of this two-gene panel for detecting DCIS/IDC was 88.8%, and its sensitivity was 94.1%.
   Conclusions. The quantitative detection of aberrant DNA methylation in serum samples may be a promising high throughput approach for the diagnosis of breast cancer including DCIS. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Kim, Jo-Heon] Jeju Natl Univ, Sch Med, Dept Pathol, Jejusi, South Korea.
   [Shin, Min-Ho] Chonnam Natl Univ, Sch Med, Dept Prevent Med, Kwangju, South Korea.
   [Shin, Min-Ho; Park, Min Ho; Yoon, Jung Han; Lee, Ji Shin; Choi, Chan] Res Inst Med Sci, Kwangju, South Korea.
   [Kweon, Sun-Seog] Chonnam Natl Univ, Hwasun Hosp, Jeonnam Reg Canc Ctr, Jeollanamdo, South Korea.
   [Park, Min Ho; Yoon, Jung Han] Chonnam Natl Univ, Sch Med, Dept Surg, Kwangju, South Korea.
   [Lee, Ji Shin; Choi, Chan] Chonnam Natl Univ, Sch Med, Dept Pathol, Kwangju, South Korea.
   [Fackler, Mary Jo; Sukumar, Saraswati] Johns Hopkins Univ, Sch Med, Dept Oncol, Breast Canc Program, Baltimore, MD 21205 USA.
C3 Jeju National University; Chonnam National University; Chonnam National
   University; Chonnam National University; Chonnam National University;
   Johns Hopkins University
RP Lee, JS (通讯作者)，Chonnam Natl Univ, Hwasun Hosp, Dept Pathol, 160 Ilsim Ri, Hwasun Gun 519809, Jeollanam Do, South Korea.
EM jshinlee@hanmail.net
RI Kim, Seong/J-5408-2012; Kweon, Sun-Seog/AAZ-4732-2021
OI Shin, Min-Ho/0000-0002-2217-5624; KWEON, SUNSEOG/0000-0003-2378-8550
FU Korean Government [KRF-2007-313-E00099]
FX This study was supported by a grant of the Korean Government (MOEHRD,
   Basic Research Promotion Fund) (KRF-2007-313-E00099).
CR a Tavassoli F., 2003, World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs, P63
   ALAGARATNAM TT, 1985, CLIN RADIOL, V36, P175, DOI 10.1016/S0009-9260(85)80104-5
   Anker P, 1999, CANCER METAST REV, V18, P65, DOI 10.1023/A:1006260319913
   Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Brooks JD, 1998, CANCER EPIDEM BIOMAR, V7, P531
   Carvalho AL, 2008, CLIN CANCER RES, V14, P97, DOI 10.1158/1078-0432.CCR-07-0722
   Cottrell SE, 2003, ANN NY ACAD SCI, V983, P120, DOI 10.1111/j.1749-6632.2003.tb05967.x
   Duffy MJ, 2009, EUR J CANCER, V45, P335, DOI 10.1016/j.ejca.2008.12.008
   Elmore G, 1998, NEW ENGL J MED, V338, P1089, DOI 10.1056/NEJM199804163381601
   Ernster VL, 2002, JNCI-J NATL CANCER I, V94, P1546
   Esteller M, 2000, CANCER RES, V60, P4366
   Fackler MJ, 2006, CLIN CANCER RES, V12, P3306, DOI 10.1158/1078-0432.CCR-05-2733
   HOGUE MO, 2006, CLIN ONCOL, V24, P4262
   Jerónimo C, 2001, J NATL CANCER I, V93, P1747, DOI 10.1093/jnci/93.22.1747
   Jing F, 2008, ONCOLOGY-BASEL, V75, P60, DOI 10.1159/000155145
   Kim HN, 2008, BRIT J HAEMATOL, V140, P287, DOI 10.1111/j.1365-2141.2007.06893.x
   Ko SS, 2008, J SURG ONCOL, V98, P318, DOI 10.1002/jso.21110
   Kwabi-Addo B, 2007, CLIN CANCER RES, V13, P3796, DOI 10.1158/1078-0432.CCR-07-0085
   Lamy A, 2002, INT J CANCER, V100, P189, DOI 10.1002/ijc.10474
   Lee JS, 2008, CANCER BIOL THER, V7, P1400
   Martínez-Galán J, 2008, CANCER BIOL THER, V7, P962, DOI 10.4161/cbt.7.6.5966
   Mirza S, 2007, LIFE SCI, V81, P280, DOI 10.1016/j.lfs.2007.05.012
   MULLER HM, 2004, CLIN CANCER RES, V10, P6189
   Sharma G, 2007, LIFE SCI, V80, P1873, DOI 10.1016/j.lfs.2007.02.026
   Shukla S, 2006, EPIGENETICS-US, V1, P88, DOI 10.4161/epi.1.2.2679
   Silva JM, 1999, BRIT J CANCER, V80, P1262, DOI 10.1038/sj.bjc.6690495
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
NR 27
TC 27
Z9 33
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0090-8258
EI 1095-6859
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD AUG 1
PY 2010
VL 118
IS 2
BP 176
EP 181
DI 10.1016/j.ygyno.2010.04.016
PG 6
WC Oncology; Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Obstetrics & Gynecology
GA 627LB
UT WOS:000280039900015
PM 20466412
DA 2025-01-12
ER

PT J
AU Barekati, Z
   Radpour, R
   Kohler, C
   Zhang, B
   Toniolo, P
   Lenner, P
   Lv, Q
   Zheng, H
   Zhong, XY
AF Barekati, Zeinab
   Radpour, Ramin
   Kohler, Corina
   Zhang, Bei
   Toniolo, Paolo
   Lenner, Per
   Lv, Qing
   Zheng, Hong
   Zhong, Xiao Yan
TI Methylation profile of <i>TP53</i> regulatory pathway and mtDNA
   alterations in breast cancer patients lacking <i>TP53</i> mutations
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID GENE PROMOTER HYPERMETHYLATION; MITOCHONDRIAL-DNA DEPLETION; WILD-TYPE
   P53; TUMOR-SUPPRESSOR; SOMATIC MUTATIONS; LUNG-CANCER; NUCLEAR-DNA;
   SERUM DNA; PTEN; MDM2
AB The present study investigated promoter hypermethylation of TP53 regulatory pathways providing a potential link between epigenetic changes and mitochondrial DNA (mtDNA) alterations in breast cancer patients lacking a TP53 mutation. The possibility of using the cancer-specific alterations in serum samples as a blood-based test was also explored. Triple-matched samples (cancerous tissues, matched adjacent normal tissues and serum samples) from breast cancer patients were screened for TP53 mutations, and the promoter methylation profile of P14(ARF), MDM2, TP53 and PTEN genes was analyzed as well as mtDNA alterations, including D-loop mutations and mtDNA content. In the studied cohort, no mutation was found in TP53 (DNA-binding domain). Comparison of P14(ARF) and PTEN methylation patterns showed significant hypermethylation levels in tumor tissues (P < 0.05 and < 0.01, respectively) whereas the TP53 tumor suppressor gene was not hypermethylated (P < 0.511). The proportion of PTEN methylation was significantly higher in serum than in the normal tissues and it has a significant correlation to tumor tissues (P < 0.05). mtDNA analysis revealed 36.36% somatic and 90.91% germline mutations in the D-loop region and also significant mtDNA depletion in tumor tissues (P < 0.01). In addition, the mtDNA content in matched serum was significantly lower than in the normal tissues (P < 0.05). These data can provide an insight into the management of a therapeutic approach based on the reversal of epigenetic silencing of the crucial genes involved in regulatory pathways of the tumor suppressor TP53. Additionally, release of significant aberrant methylated PTEN in matched serum samples might represent a promising biomarker for breast cancer.
C1 [Barekati, Zeinab; Radpour, Ramin; Kohler, Corina; Zheng, Hong; Zhong, Xiao Yan] Univ Basel, Womens Hosp, Dept Biomed, Lab Gynecol Oncol, CH-4003 Basel, Switzerland.
   [Toniolo, Paolo] NYU, Sch Med, Dept Obstet & Gynecol, New York, NY USA.
   [Toniolo, Paolo] CHUV, Inst Univ Med Sociale & Prevent, Lausanne, Switzerland.
   [Lenner, Per] Umea Univ Hosp, Dept Oncol, S-90185 Umea, Sweden.
   [Lv, Qing] Sichuan Univ, Dept Breast Surg, Chengdu 610064, Peoples R China.
   [Zheng, Hong] Sichuan Univ, Dept Oncol, State Key Lab Biotherapy & Canc Ctr, Chengdu 610064, Peoples R China.
   [Zheng, Hong] Sichuan Univ, W China Hosp, W China Sch Med, Lab Mol Diag Canc, Chengdu 610064, Peoples R China.
C3 University of Basel; New York University; University of Lausanne; Centre
   Hospitalier Universitaire Vaudois (CHUV); Umea University; Sichuan
   University; Sichuan University; Sichuan University
RP Zheng, H (通讯作者)，Univ Basel, Womens Hosp, Dept Biomed, Lab Gynecol Oncol, CH-4003 Basel, Switzerland.
EM zhongx@uhbs.ch
RI Kohler, Corina/KTH-9502-2024; Radpour, PD Dr. Ramin/J-4949-2014
OI Radpour, PD Dr. Ramin/0000-0002-5632-7833
FU Swiss National Science Foundation [320000-119722/1, 320030_124958/1];
   Swiss Cancer League, Krebsliga Beider Basel [OCS 01993-02-2007]; Swiss
   National Science Foundation (SNF) [320030_124958] Funding Source: Swiss
   National Science Foundation (SNF)
FX This work was supported in part by Swiss National Science Foundation
   (320000-119722/1 and 320030_124958/1) and Swiss Cancer League, Krebsliga
   Beider Basel (OCS 01993-02-2007), Dr Hans Altschueler Stiftung,
   SwissLife and Freiwillige Akademische Gesellschaft (FAK) in Basel.
CR Achanta G, 2005, EMBO J, V24, P3482, DOI 10.1038/sj.emboj.7600819
   ALMOG N, 1997, BIOCHIM BIOPHYS ACTA, V1333, P1
   Chang SC, 2009, INT J COLORECTAL DIS, V24, P623, DOI 10.1007/s00384-009-0663-9
   Chen DX, 2006, CANCER RES, V66, P3485, DOI 10.1158/0008-5472.CAN-05-4103
   Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004
   Deb SP, 2003, MOL CANCER RES, V1, P1009
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   Esteller M, 1999, CANCER RES, V59, P67
   Fan AXC, 2009, J CANCER RES CLIN, V135, P983, DOI 10.1007/s00432-008-0533-9
   Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7
   Fujiwara K, 2005, CLIN CANCER RES, V11, P1219
   Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482
   García JM, 2004, GENE CHROMOSOME CANC, V41, P117, DOI 10.1002/gcc.20062
   Gochhait S, 2008, INT J CANCER, V123, P2580, DOI 10.1002/ijc.23817
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Heyne K, 2004, FEBS LETT, V578, P198, DOI 10.1016/j.febslet.2004.10.099
   Hibi K, 1998, CANCER RES, V58, P1405
   Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292
   KERN SE, 1991, ONCOGENE, V6, P131
   Khan S, 2004, INT J CANCER, V112, P407, DOI 10.1002/ijc.20447
   Kohler C, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-105
   Lebedeva MA, 2009, BBA-BIOENERGETICS, V1787, P328, DOI 10.1016/j.bbabio.2009.01.004
   LEON SA, 1977, CANCER RES, V37, P646
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298
   Liu VWS, 2001, CANCER RES, V61, P5998
   Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200
   Moll UM, 2003, MOL CANCER RES, V1, P1001
   Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466
   Müller HM, 2003, CANCER RES, V63, P7641
   Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4
   Onel K, 2004, MOL CANCER RES, V2, P1
   Pharoah PDP, 1999, BRIT J CANCER, V80, P1968, DOI 10.1038/sj.bjc.6690628
   Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108
   QUESNEL B, 1994, EUR J CANCER, V30A, P982, DOI 10.1016/0959-8049(94)90128-7
   Radpour R, 2009, ONCOGENE, V28, P2969, DOI 10.1038/onc.2009.149
   Radpour R, 2010, MODERN PATHOL, V23, P763, DOI 10.1038/modpathol.2009.195
   Radpour R, 2009, J PROTEOME RES, V8, P5264, DOI 10.1021/pr900591w
   Rogounovitch TI, 2002, CANCER RES, V62, P7031
   Sanchez-Cespedes M, 2000, CANCER RES, V60, P892
   Schwartz D, 1997, ONCOGENE, V15, P2597, DOI 10.1038/sj.onc.1201436
   Sharma G, 2007, LIFE SCI, V80, P1873, DOI 10.1016/j.lfs.2007.02.026
   Silva J, 2003, J PATHOL, V199, P289, DOI 10.1002/path.1297
   Silva J, 2001, ONCOGENE, V20, P4586, DOI 10.1038/sj.onc.1204617
   Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648
   Trimboli AJ, 2009, NATURE, V461, P1084, DOI 10.1038/nature08486
   Trotman LC, 2003, CANCER CELL, V3, P97, DOI 10.1016/S1535-6108(03)00022-9
   Tseng LM, 2006, GENE CHROMOSOME CANC, V45, P629, DOI 10.1002/gcc.20326
   Ueda K, 1998, JPN J CANCER RES, V89, P17, DOI 10.1111/j.1349-7006.1998.tb00473.x
   Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864
   Xia P, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-454
   Xia P, 2009, GENET MOL BIOL, V32, P20, DOI 10.1590/S1415-47572009000100003
   Xie CH, 2007, BIOCHEM BIOPH RES CO, V364, P656, DOI 10.1016/j.bbrc.2007.10.047
   Zhong Xiao Yan, 2007, Archives of Gynecology and Obstetrics, V276, P327, DOI 10.1007/s00404-007-0345-1
   Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973
NR 56
TC 36
Z9 38
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD AUG 1
PY 2010
VL 19
IS 15
BP 2936
EP 2946
DI 10.1093/hmg/ddq199
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 633HA
UT WOS:000280491200002
PM 20466735
OA Green Published
DA 2025-01-12
ER

PT J
AU Hannigan, A
   Smith, P
   Kalna, G
   Lo Nigro, C
   Orange, C
   O'Brien, DI
   Shah, R
   Syed, N
   Spender, LC
   Herrera, B
   Thurlow, JK
   Lattanzio, L
   Monteverde, M
   Maurer, ME
   Buffa, FM
   Mann, J
   Chu, DCK
   West, CML
   Patridge, M
   Oien, KA
   Cooper, JA
   Frame, MC
   Harris, AL
   Hiller, L
   Nicholson, LJ
   Gasco, M
   Crook, T
   Inman, GJ
AF Hannigan, Adele
   Smith, Paul
   Kalna, Gabriela
   Lo Nigro, Cristiana
   Orange, Clare
   O'Brien, Darren I.
   Shah, Reshma
   Syed, Nelofer
   Spender, Lindsay C.
   Herrera, Blanca
   Thurlow, Johanna K.
   Lattanzio, Laura
   Monteverde, Martino
   Maurer, Meghan E.
   Buffa, Francesca M.
   Mann, Jelena
   Chu, David C. K.
   West, Catharine M. L.
   Patridge, Max
   Oien, Karin A.
   Cooper, Jonathan A.
   Frame, Margaret C.
   Harris, Adrian L.
   Hiller, Louise
   Nicholson, Linda J.
   Gasco, Milena
   Crook, Tim
   Inman, Gareth J.
TI Epigenetic downregulation of human disabled homolog 2 switches TGF-β
   from a tumor suppressor to a tumor promoter
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID GROWTH-FACTOR-BETA; CHEMICALLY TRANSFORMED-CELLS; BREAST-CANCER; ADAPTER
   PROTEIN; DAB2; GENE; METASTASIS; EXPRESSION; RECEPTORS; PATHWAY
AB The cytokine TGF-beta acts as a tumor suppressor in normal epithelial cells and during the early stages of tumorigenesis. During malignant progression, cancer cells can switch their response to TGF-beta and use this cytokine as a potent oncogenic factor; however, the mechanistic basis for this is poorly understood. Here we demonstrate that downregulation of disabled homolog 2 (DAB2) gene expression via promoter methylation frequently occurs in human squamous cell carcinomas (SCCs) and acts as an independent predictor of metastasis and poor prognosis. Retrospective microarray analysis in an independent data set indicated that low levels of DAB2 and high levels of TGFB2 expression correlate with poor prognosis. Immunohistochemistry, reexpression, genetic knockout, and RNAi silencing studies demonstrated that downregulation of DAB2 expression modulated the TGF-beta/Smad pathway. Simultaneously, DAB2 down-regulation abrogated TGF-beta tumor suppressor function, while enabling TGF-beta tumor-promoting activities. Downregulation of DAB2 blocked TGF-beta-mediated inhibition of cell proliferation and migration and enabled TGF-beta to promote cell motility, anchorage-independent growth, and tumor growth in vivo. Our data indicate that DAB2 acts as a tumor suppressor by dictating tumor cell TGF-beta responses, identify a biomarker for SCC progression, and suggest a means to stratify patients with advanced SCC who may benefit clinically from anti-TGF-beta therapies.
C1 [Hannigan, Adele; Kalna, Gabriela; O'Brien, Darren I.; Spender, Lindsay C.; Herrera, Blanca; Thurlow, Johanna K.; Inman, Gareth J.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland.
   [Smith, Paul; Shah, Reshma; Syed, Nelofer; Crook, Tim] Inst Canc Res, Canc Genet & Epigenet Lab, London SW3 6JB, England.
   [Lo Nigro, Cristiana; Lattanzio, Laura; Monteverde, Martino; Gasco, Milena] Osped Santa Croce & Carle, Dept Med Oncol, Cuneo, Italy.
   [Orange, Clare; Oien, Karin A.] Univ Glasgow, Fac Med, Div Canc Sci & Mol Pathol, Glasgow, Lanark, Scotland.
   [Maurer, Meghan E.; Cooper, Jonathan A.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
   [Buffa, Francesca M.; Harris, Adrian L.] Univ Oxford, Weatherall Inst Mol Med, CRUK Mol Oncol Labs, Oxford, England.
   [Mann, Jelena] Newcastle Univ, Fac Med Sci, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   [Chu, David C. K.] Univ Georgia, Coll Pharm, Athens, GA 30602 USA.
   [West, Catharine M. L.] Christie Hosp NHS Trust, Sch Canc & Enabling Sci, Manchester M20 4BX, Lancs, England.
   [Patridge, Max] Guys Hosp, Univ London Kings Coll, Dept Oral & Maxillofacial Surg, London SE1 9RT, England.
   [Patridge, Max] Kings Hosp, Univ London Kings Coll, Dept Oral & Maxillofacial Surg, London, England.
   [Patridge, Max] St Thomas Hosp, Univ London Kings Coll, Dept Oral & Maxillofacial Surg, London, England.
   [Frame, Margaret C.] Western Gen Hosp, Inst Genet & Mol Med, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland.
   [Hiller, Louise] Univ Warwick, Warwick Med Sch, Clin Trials Unit, Coventry CV4 7AL, W Midlands, England.
   [Nicholson, Linda J.] St Thomas Hosp, Univ London Kings Coll, Sch Med, Canc Studies Div,Rayne Inst, London, England.
C3 Beatson Institute; University of London; Institute of Cancer Research -
   UK; Royal Marsden NHS Foundation Trust; University of Glasgow; Fred
   Hutchinson Cancer Center; University of Oxford; Newcastle University -
   UK; University System of Georgia; University of Georgia; Christie NHS
   Foundation Trust; Christie Hospital; Guy's & St Thomas' NHS Foundation
   Trust; University of London; King's College London; University of
   London; King's College London; King's College Hospital NHS Foundation
   Trust; King's College Hospital; Guy's & St Thomas' NHS Foundation Trust;
   University of London; King's College London; University of Edinburgh;
   University of Warwick; Guy's & St Thomas' NHS Foundation Trust;
   University of London; King's College London
RP Inman, GJ (通讯作者)，Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Inst, Level 5, Dundee DD1 9SY, Scotland.
EM g.j.inman@dundee.ac.uk
RI Oien, Karin/AAH-3849-2019; Herrera, Blanca/K-1803-2014; Orange,
   Clare/GWC-5914-2022; Buffa, Francesca M./D-2574-2013; Harris,
   Adrian/ABA-3343-2020; West, Catharine Mary Louise/J-4152-2012
OI Monteverde, Martino/0000-0003-2623-414X; Buffa, Francesca
   M./0000-0003-0409-406X; Hiller, Louise/0000-0001-8538-9163; Inman,
   Gareth/0000-0002-6264-4253; Lo Nigro, Cristiana/0000-0002-3615-2431;
   Harris, Adrian/0000-0003-1376-8409; Spender, Lindsay
   Claire/0009-0005-2936-6828; Frame, Margaret/0000-0001-5882-1942; West,
   Catharine Mary Louise/0000-0002-0839-3449
FU AICR; CRUK; Breakthrough Breast Cancer; Institute of Cancer Research;
   Associazione Italiana Ricerca Cancro; US Public Health Service
   [GM066257]
FX We thank Philip Howe for reagents, Tom Hamilton for invaluable help with
   xenograft experiments, Colin Nixon for immunohistochemistry expertise,
   and Kevin Ryan and Clare Isacke for helpful discussions and critically
   reading the manuscript. G.J. Inman is an Association for International
   Cancer Research (AICR) fellow. G.J. Inman and L.C. Spender are supported
   by AICR and CRUK. A. Hannigan, D.I. O'Brien, B. Herrera, and M.C. Frame
   were supported by CRUK. T. Crook is a clinical research fellow of CRUK.
   Work in T. Crook's laboratory is supported by CRUK, Breakthrough Breast
   Cancer, and the Institute of Cancer Research. C.L. Nigro, L. Lattanzio,
   M. Monteverde, and M. Gasco were partially supported by the Associazione
   Italiana Ricerca Cancro. J.A. Cooper was supported by the US Public
   Health Service grant GM066257.
CR Anupam K, 2006, WORLD J GASTROENTERO, V12, P6041, DOI 10.3748/wjg.v12.i37.6041
   Arteaga CL, 2006, CURR OPIN GENET DEV, V16, P30, DOI 10.1016/j.gde.2005.12.009
   Atalay A, 2002, BIOCHEM BIOPH RES CO, V299, P839, DOI 10.1016/S0006-291X(02)02751-1
   Bagadi SAR, 2007, BREAST CANCER RES TR, V104, P277, DOI 10.1007/s10549-006-9422-6
   Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   Bierie B, 2006, CYTOKINE GROWTH F R, V17, P29, DOI 10.1016/j.cytogfr.2005.09.006
   Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023
   Calvisi DF, 2007, J CLIN INVEST, V117, P2713, DOI 10.1172/JCI31457
   Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006
   Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649
   Guasch G, 2007, CANCER CELL, V12, P313, DOI 10.1016/j.ccr.2007.08.020
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hocevar BA, 2005, J BIOL CHEM, V280, P25920, DOI 10.1074/jbc.M501150200
   Hocevar BA, 2003, EMBO J, V22, P3084, DOI 10.1093/emboj/cdg286
   Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789
   Hunter KD, 2006, CANCER RES, V66, P7405, DOI 10.1158/0008-5472.CAN-06-0186
   Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3
   Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65
   Jazag A, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni130
   Jenssen TK, 2002, HUM GENET, V111, P411, DOI 10.1007/s00439-002-0804-5
   Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145
   Kalna G, 2008, INT J COMPUT MATH, V85, P475, DOI 10.1080/00207160701210158
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6
   Karam JA, 2007, CLIN CANCER RES, V13, P4400, DOI 10.1158/1078-0432.CCR-07-0287
   Koizumi K, 2007, CANCER SCI, V98, P1652, DOI 10.1111/j.1349-7006.2007.00606.x
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lin HK, 2004, NATURE, V431, P205, DOI 10.1038/nature02783
   Massagué J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705
   Massagué J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Maurer ME, 2006, J CELL SCI, V119, P4235, DOI 10.1242/jcs.03217
   Mishra L, 2006, CYTOKINE GROWTH F R, V17, P75, DOI 10.1016/j.cytogfr.2005.09.001
   Mishra SK, 2002, EMBO J, V21, P4915, DOI 10.1093/emboj/cdf487
   Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769
   Morris SM, 2002, EMBO J, V21, P1555, DOI 10.1093/emboj/21.7.1555
   MOSES HL, 1981, CANCER RES, V41, P2842
   Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807
   Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316
   Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004
   Prunier C, 2005, J BIOL CHEM, V280, P17540, DOI 10.1074/jbc.M500974200
   ROBERTS AB, 1980, P NATL ACAD SCI-BIOL, V77, P3494, DOI 10.1073/pnas.77.6.3494
   Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100
   Saunier EF, 2006, CURR CANCER DRUG TAR, V6, P565, DOI 10.2174/156800906778742460
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X
   Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208
   Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Teckchandani A, 2009, J CELL BIOL, V186, P98, DOI 10.1083/jcb.200812160
   Thurlow JK, 2010, J CLIN ONCOL, V28, P2881, DOI 10.1200/JCO.2009.24.8724
   Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8
   VANNETTEN JP, 1987, EUR J CANCER CLIN ON, V23, P1337, DOI 10.1016/0277-5379(87)90117-9
   von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320
   Wakefield LM, 2007, CANCER CELL, V12, P293, DOI 10.1016/j.ccr.2007.10.002
   Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3
   Winter SC, 2007, CANCER RES, V67, P3441, DOI 10.1158/0008-5472.CAN-06-3322
   Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678
   Yang DH, 2006, AM J PATHOL, V169, P258, DOI 10.2353/ajpath.2006.060036
   Zhou J, 2003, J BIOL CHEM, V278, P6936, DOI 10.1074/jbc.M210628200
   Zhu QW, 2005, MOL CELL BIOL, V25, P10731, DOI 10.1128/MCB.25.24.10731-10744.2005
NR 58
TC 75
Z9 84
U1 0
U2 6
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD AUG
PY 2010
VL 120
IS 8
BP 2842
EP 2857
DI 10.1172/JCI36125
PG 16
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 633HI
UT WOS:000280492100020
PM 20592473
OA Green Accepted, Green Submitted, Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Dar, AA
   Majid, S
   Nosrati, M
   de Semir, D
   Federman, S
   Kashani-Sabet, M
AF Dar, Altaf A.
   Majid, Shahana
   Nosrati, Mehdi
   de Semir, David
   Federman, Scot
   Kashani-Sabet, Mohammed
TI Functional Modulation of IGF-Binding Protein-3 Expression in Melanoma
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Article
ID BREAST-CANCER CELLS; ABERRANT PROMOTER METHYLATION; MALIGNANT-MELANOMA;
   EPIGENETIC INACTIVATION; DNA HYPERMETHYLATION; CUTANEOUS MELANOMA;
   GROWTH-INHIBITION; RETINOIC ACID; RENAL-CANCER; LUNG-CANCER
AB IGF-binding protein-3 (IGFBP3) is a member of the IGFBP family, which regulates mitogenic and antiapoptotic effects of IGFs. In this report we evaluated the role of IGFBP3 in melanoma. Quantitative real-time PCR (qRT-PCR), western blot, and ELISA analyses indicated a significant downregulation of IGFBP3 expression in melanoma cell lines as compared with a normal melanocyte cell line. Melanoma cell lines treated with the demethylating agent 5-AZA-2'-deoxycytidine reexpressed IGFBP3 at the mRNA and protein levels. Chromatin immunoprecipitation assays revealed enrichment of acetylated histones H3 and H4, and H3 di- and tri-methylated lysine 4 on the unmethylated IGFBP3 promoter. The IGFBP3 promoter region was highly methylated in human melanoma samples as compared with normal nevi. Overexpression of IGFBP3 in melanoma cells in vitro suppressed tumor cell survival, induced apoptosis, reduced colony formation and invasion, and induced expression of the proapoptotic genes p21, PUMA, and BAX. IGFBP3 overexpression also resulted in cleavage of caspase 3 and reduced expression of phosphorylated AKT. Stable overexpression of IGFBP3 suppressed tumor cell growth in vivo. Our study results indicate that silencing of IGFBP3 in melanoma is due to the methylation of its promoter, and that overexpression of IGFBP3 induces apoptosis and suppresses cell survival and growth.
C1 [Dar, Altaf A.; Nosrati, Mehdi; de Semir, David; Federman, Scot; Kashani-Sabet, Mohammed] Univ Calif San Francisco, Ctr Comprehens Canc, Melanoma Ctr, Auerback Melanoma Res Lab, San Francisco, CA 94143 USA.
   [Majid, Shahana] Vet Affairs Med Ctr, Dept Urol, San Francisco, CA 94121 USA.
C3 University of California System; University of California San Francisco;
   UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer
   Center; US Department of Veterans Affairs; Veterans Health
   Administration (VHA)
RP Kashani-Sabet, M (通讯作者)，Calif Pacific Med Ctr, Res Inst, Ctr Melanoma Res & Treatment, 475 Brannan St, San Francisco, CA 94107 USA.
EM kashani@cpmcri.org
FU Herschel and Diana Zackheim Endowment Fund; National Institutes of
   Health [CA114337, CA122947]
FX This work was supported by the Herschel and Diana Zackheim Endowment
   Fund and the National Institutes of Health (CA114337 and CA122947).
CR Archer SY, 1999, CURR OPIN GENET DEV, V9, P171, DOI 10.1016/S0959-437X(99)80026-4
   Balch CM, 2001, J CLIN ONCOL, V19, P3635, DOI 10.1200/JCO.2001.19.16.3635
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Behrmann I, 2003, AM J PATHOL, V163, P683, DOI 10.1016/S0002-9440(10)63695-4
   Bender CM, 1999, MOL CELL BIOL, V19, P6690
   Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115
   BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0
   Chang YS, 2002, CLIN CANCER RES, V8, P3669
   Chin L, 2003, NAT REV CANCER, V3, P559, DOI 10.1038/nrc1145
   Christoph F, 2006, INT J CANCER, V119, P1396, DOI 10.1002/ijc.21971
   Dar AA, 2008, CANCER-AM CANCER SOC, V112, P1688, DOI 10.1002/cncr.23371
   DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6
   Furuta J, 2004, CANCER SCI, V95, P962, DOI 10.1111/j.1349-7006.2004.tb03184.x
   Gonzalgo ML, 1997, CANCER RES, V57, P5336
   Guan X, 2003, INT J CANCER, V107, P202, DOI 10.1002/ijc.11376
   Gucev ZS, 1996, CANCER RES, V56, P1545
   Gütgemann A, 2001, ARCH DERMATOL RES, V293, P283, DOI 10.1007/s004030100232
   Hanafusa T, 2002, CANCER LETT, V176, P149, DOI 10.1016/S0304-3835(01)00736-4
   Haqq C, 2005, P NATL ACAD SCI USA, V102, P6092, DOI 10.1073/pnas.0501564102
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hoon DSB, 2004, ONCOGENE, V23, P4014, DOI 10.1038/sj.onc.1207505
   Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761
   Ibanez de Caceres I, 2006, CANCER RES, V66, P5021, DOI 10.1158/0008-5472.CAN-05-3365
   Kane MF, 1997, CANCER RES, V57, P808
   Kristeleit Rebecca, 2004, Expert Opin Emerg Drugs, V9, P135, DOI 10.1517/14728214.9.1.135
   Kusano M, 2006, CANCER-AM CANCER SOC, V106, P1467, DOI 10.1002/cncr.21789
   Laird PW, 2005, HUM MOL GENET, V14, pR65, DOI 10.1093/hmg/ddi113
   Le Marchand L, 2005, CANCER EPIDEM BIOMAR, V14, P1319, DOI 10.1158/1055-9965.EPI-04-0847
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Majid S, 2009, CARCINOGENESIS, V30, P662, DOI 10.1093/carcin/bgp042
   MARTIN JL, 1995, ENDOCRINOLOGY, V136, P1219, DOI 10.1210/en.136.3.1219
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   Mirmohammadsadegh A, 2006, CANCER RES, V66, P6546, DOI 10.1158/0008-5472.CAN-06-0384
   Moon JW, 2006, INT J CANCER, V118, P353, DOI 10.1002/ijc.21339
   Nakagawa T, 2005, J UROLOGY, V173, P1767, DOI 10.1097/01.ju.0000154632.11824.4d
   Nosrati M, 2004, CLIN CANCER RES, V10, P4983, DOI 10.1158/1078-0432.CCR-04-0134
   Oh JS, 2002, NEOPLASIA, V4, P204, DOI 10.1038/sj.neo.7900229
   OH YM, 1993, J BIOL CHEM, V268, P14964
   Oy GF, 2010, INT J CANCER, V126, P350, DOI 10.1002/ijc.24727
   Paz MF, 2003, CANCER RES, V63, P1114
   Spugnardi M, 2003, CANCER RES, V63, P1639
   Tomii K, 2007, INT J CANCER, V120, P566, DOI 10.1002/ijc.22341
   Tucker MA, 2003, ONCOGENE, V22, P3042, DOI 10.1038/sj.onc.1206444
   VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361
   Wargo JA, 2009, HEMATOL ONCOL CLIN N, V23, P565, DOI 10.1016/j.hoc.2009.03.002
   Wiley A, 2006, CANCER-AM CANCER SOC, V107, P299, DOI 10.1002/cncr.21992
   Worm J, 2000, ONCOGENE, V19, P5111, DOI 10.1038/sj.onc.1203891
   Worm J, 2004, ONCOGENE, V23, P5215, DOI 10.1038/sj.onc.1207647
   Xi YG, 2006, MOL CANCER THER, V5, P3078, DOI 10.1158/1535-7163.MCT-06-0424
   Yu JZ, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-70
   Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5
NR 51
TC 28
Z9 33
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD AUG
PY 2010
VL 130
IS 8
BP 2071
EP 2079
DI 10.1038/jid.2010.70
PG 9
WC Dermatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Dermatology
GA 626RG
UT WOS:000279984000016
PM 20357812
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Souter, LH
   Andrews, JD
   Zhang, GH
   Cook, AC
   Postenka, CO
   Al-Katib, W
   Leong, HS
   Rodenhiser, DI
   Chambers, AF
   Tuck, AB
AF Souter, Lesley H.
   Andrews, Joseph D.
   Zhang, Guihua
   Cook, Amy C.
   Postenka, Carl O.
   Al-Katib, Waleed
   Leong, Hon S.
   Rodenhiser, David I.
   Chambers, Ann F.
   Tuck, Alan B.
TI Human 21T breast epithelial cell lines mimic breast cancer progression
   <i>in vivo</i> and <i>in vitro</i> and show stage-specific gene
   expression patterns
SO LABORATORY INVESTIGATION
LA English
DT Article
DE breast cancer; tumor progression; expression microarray; atypical ductal
   hyperplasia; ductal carcinoma in situ; invasive mammary carcinoma
ID HEPATOCYTE GROWTH-FACTOR; PROPHYLACTIC MASTECTOMY; TUMOR PROGRESSION;
   FOLLOW-UP; MODEL; METASTASIS; SITU; CULTURE; LESIONS; MICRODISSECTION
AB Early breast cancer progression involves advancement through specific morphological stages including atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS) and invasive mammary carcinoma (IMC), although not necessarily always in a linear fashion. Observational studies have examined genetic, epigenetic and gene expression differences in breast tissues representing these stages of progression, but model systems which would allow for experimental testing of specific factors influencing transition through these stages are scarce. The 21T series cell lines, all originally derived from the same patient with metastatic breast cancer, have been proposed to represent a mammary tumor progression series. We report here that three of the 21T cell lines indeed mimic specific stages of human breast cancer progression (21PT-derived cells, ADH; 21NT-derived cells, DCIS; 21MT-1 cells, IMC) when grown in the mammary fat pad of nude mice, albeit after a year. To develop a more rapid, readily manipulatable in vitro assay for examining the biological differences between these cell lines, we have used a 3D Matrigel system. When the three cell lines were grown in 3D Matrigel, they showed characteristic morphologies, in which quantifiable aspects of stage-specific in vivo behaviors (ie, differences in acinar structure formation, cell polarization, colony morphology, cell proliferation, cell invasion) were recapitulated in a reproducible fashion. Gene expression profiling revealed a characteristic pattern for each of the three cell lines. Interestingly, Wnt pathway alterations are particularly predominant in the early transition from 21PTci (ADH) to 21NTci (DCIS), whereas alterations in expression of genes associated with control of cell motility and invasion phenomena are more prominent in the later transition of 21NTci (DCIS) to 21MT-1 (IMC). This system thus reveals potential therapeutic targets and will provide a means of testing the influences of identified genes on transitions between these stages of pre-malignant to malignant growth. Laboratory Investigation (2010) 90, 1247-1258; doi:10.1038/labinvest.2010.97; published online 10 May 2010
C1 [Tuck, Alan B.] Univ Hosp, London Hlth Sci Ctr, Dept Pathol, London Reg Canc Program, London, ON N6A 5A5, Canada.
   [Souter, Lesley H.; Cook, Amy C.; Chambers, Ann F.; Tuck, Alan B.] Univ Western Ontario, Dept Pathol, London, ON, Canada.
   [Rodenhiser, David I.] Univ Western Ontario, Dept Biochem, London, ON, Canada.
   [Rodenhiser, David I.] Univ Western Ontario, Dept Paediat, London, ON, Canada.
   [Rodenhiser, David I.] Childrens Hlth Res Inst, London, ON, Canada.
   [Chambers, Ann F.; Tuck, Alan B.] Univ Western Ontario, Dept Oncol, London, ON, Canada.
C3 London Health Sciences Centre; Western University (University of Western
   Ontario); Western University (University of Western Ontario); Western
   University (University of Western Ontario); Western University
   (University of Western Ontario); Western University (University of
   Western Ontario)
RP Tuck, AB (通讯作者)，Univ Hosp, London Hlth Sci Ctr, Dept Pathol, London Reg Canc Program, 339 Windermere Rd, London, ON N6A 5A5, Canada.
EM atuck@uwo.ca
RI zhang, guihua/GVU-4494-2022; Chambers, Ann/L-6285-2015
OI Leong, Hon/0000-0001-7801-1402; Chambers, Ann/0000-0002-9509-5123
FU Canadian Institute for Health Research [42511]; Canadian Breast Cancer
   Research Alliance [016506]; Canadian Breast Cancer Foundation; Cancer
   Research Society; London Regional Cancer Program; Canada Research Chairs
   Program
FX We thank David Dales for technical assistance and Larry Stitt for
   statistical advice. This research was funded by Grant no. 42511 from the
   Canadian Institute for Health Research and Grant no. 016506 from the
   Canadian Breast Cancer Research Alliance with special funding support
   from the Canadian Breast Cancer Foundation and the Cancer Research
   Society. LHS is the recipient of a Translational Breast Cancer
   Studentship from the London Regional Cancer Program. HSL is the
   recipient of a Canadian Breast Cancer Foundation Post Doctoral
   Fellowship award. AFC is a Cancer Research Chair in Oncology and
   receives salary support from the Canada Research Chairs Program.
CR Abba MC, 2004, BREAST CANCER RES, V6, pR499, DOI 10.1186/bcr899
   Allred DC, 2008, CLIN CANCER RES, V14, P370, DOI 10.1158/1078-0432.CCR-07-1127
   Allred DC, 2001, ENDOCR-RELAT CANCER, V8, P47, DOI 10.1677/erc.0.0080047
   Arpino G, 2005, ANN INTERN MED, V143, P446, DOI 10.7326/0003-4819-143-6-200509200-00009
   Asaka SI, 2006, SURG TODAY, V36, P793, DOI 10.1007/s00595-006-3261-2
   Ball EMA, 2001, DEV BIOL, V238, P1, DOI 10.1006/dbio.2001.0399
   BAND V, 1990, CANCER RES, V50, P7351
   Benton G, 2009, FASEB J, V23, P3884, DOI 10.1096/fj.08-128702
   Biswas DK, 1998, MOL MED, V4, P454, DOI 10.1007/BF03401751
   Biswas DK, 2001, MOL MED, V7, P59, DOI 10.1007/BF03401839
   Boughey JC, 2007, ONCOLOGIST, V12, P1276, DOI 10.1634/theoncologist.12-11-1276
   Briand P, 2001, BREAST CANCER RES TR, V65, P179, DOI 10.1023/A:1006434503061
   Cardiff RD, 2000, J MAMMARY GLAND BIOL, V5, P421, DOI 10.1023/A:1009534129331
   Cook AC, 2005, MOL CARCINOGEN, V43, P225, DOI 10.1002/mc.20105
   Dawson PJ, 1996, AM J PATHOL, V148, P313
   Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695
   Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2
   Dimeo TA, 2009, CANCER RES, V69, P5364, DOI 10.1158/0008-5472.CAN-08-4135
   Duffy SW, 2005, BREAST CANCER RES, V7, P258, DOI 10.1186/bcr1354
   El-Sayed ME, 2008, HISTOPATHOLOGY, V53, P650, DOI 10.1111/j.1365-2559.2008.03158.x
   Fauquette W, 1997, BIOL CELL, V89, P453, DOI 10.1016/S0248-4900(97)89316-1
   Furger KA, 2003, MOL CANCER RES, V1, P810
   Hebner C, 2008, ANNU REV PATHOL-MECH, V3, P313, DOI 10.1146/annurev.pathmechdis.3.121806.151526
   Hirai Y, 1998, J CELL BIOL, V140, P159, DOI 10.1083/jcb.140.1.159
   Isern AE, 2008, EJSO-EUR J SURG ONC, V34, P1148, DOI 10.1016/j.ejso.2008.03.002
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6
   Kauff ND, 2003, CANCER-AM CANCER SOC, V97, P1601, DOI 10.1002/cncr.11225
   Kikuchi A, 2008, CANCER SCI, V99, P202, DOI 10.1111/j.1349-7006.2007.00675.x
   LAKHANI SR, 1995, J CLIN PATHOL, V48, P611, DOI 10.1136/jcp.48.7.611
   Li Zongkai, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P901
   Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3
   Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100
   Medina D, 2000, J MAMMARY GLAND BIOL, V5, P393, DOI 10.1023/A:1009529928422
   Meiners S, 1998, ONCOGENE, V16, P9, DOI 10.1038/sj.onc.1201486
   Miller FR, 2000, J MAMMARY GLAND BIOL, V5, P379, DOI 10.1023/A:1009577811584
   Milovanovic T, 2004, INT J ONCOL, V25, P1337
   Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320
   Mohinta S, 2007, FRONT BIOSCI-LANDMRK, V12, P4020, DOI 10.2741/2368
   Niemann C, 2000, ADV EXP MED BIOL, V480, P9
   Nishidate T, 2004, INT J ONCOL, V25, P797
   O'Brien N, 2007, TUMOR BIOL, V28, P312, DOI 10.1159/000115527
   PAGE DL, 1985, CANCER-AM CANCER SOC, V55, P2698, DOI 10.1002/1097-0142(19850601)55:11<2698::AID-CNCR2820551127>3.0.CO;2-A
   PAGE DL, 1993, BREAST CANCER RES TR, V28, P157, DOI 10.1007/BF00666428
   Polyak K, 2008, CLIN CANCER RES, V14, P339, DOI 10.1158/1078-0432.CCR-07-2188
   Provenzano E, 2009, PATHOLOGY, V41, P3, DOI 10.1080/00313020802563478
   Rizki A, 2008, CANCER RES, V68, P1378, DOI 10.1158/0008-5472.CAN-07-2225
   Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273
   Schuetz CS, 2006, CANCER RES, V66, P5278, DOI 10.1158/0008-5472.CAN-05-4610
   Sgroi DC, 1999, CANCER RES, V59, P5656
   Shaw KRM, 2004, J MAMMARY GLAND BIOL, V9, P297, DOI 10.1007/s10911-004-1402-z
   Shen RL, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-94
   Simian M, 2001, DEVELOPMENT, V128, P3117
   Simpson JF, 2009, PATHOLOGY, V41, P36, DOI 10.1080/00313020802568097
   Soriano JV, 1998, J MAMMARY GLAND BIOL, V3, P133, DOI 10.1023/A:1018790705727
   Stampfer MR, 2000, J MAMMARY GLAND BIOL, V5, P365, DOI 10.1023/A:1009525827514
   Tuck AB, 1999, ONCOGENE, V18, P4237, DOI 10.1038/sj.onc.1202799
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821
   Wang XL, 2009, TISSUE ENG PT A, V15, P3087, DOI [10.1089/ten.tea.2008.0670, 10.1089/ten.TEA.2008.0670]
   Wang YQ, 2009, MOL CANCER THER, V8, P2103, DOI 10.1158/1535-7163.MCT-09-0282
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   WEAVER VM, 1995, SEMIN CANCER BIOL, V6, P175, DOI 10.1006/scbi.1995.0021
   Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231
   Worsham MJ, 2002, CYTOMETRY, V47, P56, DOI 10.1002/cyto.10040
NR 64
TC 28
Z9 36
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD AUG
PY 2010
VL 90
IS 8
BP 1247
EP 1258
DI 10.1038/labinvest.2010.97
PG 12
WC Medicine, Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pathology
GA 634AL
UT WOS:000280549600011
PM 20458274
OA Bronze
DA 2025-01-12
ER

PT J
AU Rui, W
   You-Wei, Z
   Long-Bang, C
AF Rui, Wang
   You-Wei, Zhang
   Long-Bang, Chen
TI Aberrant promoter methylation of FBLN-3 gene and clinicopathological
   significance in non-small cell lung carcinoma
SO LUNG CANCER
LA English
DT Article
DE FBLN-3; Methylation-specific PCR; Promoter methylation; Non-small cell
   lung carcinoma; Immunohistochemical stainning; Biomarker
ID DNA METHYLATION; BREAST-CANCER; HYPERMETHYLATION; ANGIOGENESIS;
   FIBULINS; EPIGENETICS; MECHANISMS; EXPRESSION; FAMILY; EFEMP1
AB FBLN-3 has been identified as an antagonist of angiogenesis which modulates cell morphology, growth, adhesion, and motility. In the present study, we investigated the promoter methylation status of FBLN-3 gene in non-small cell lung carcinoma (NSCLC) by methylation-specific PCR and analyzed its correlation with clinicopathological factors. The methylation of FBLN-3 gene promoter was detected in 28 of 65 (43.1%) NSCLC tissue samples and 6 of 65 (9.2%) corresponding non-tumor tissue samples (P < 0.05). The methylation of FBLN-3 gene promoter led to the loss of FBLN-3 gene expression in NSCLC. Additionally, FBLN-3 promoter methylation was observed to be correlated with relative poor differentiation, advanced pathological stage and lymph node metastasis of NSCLC patients (P = 0.017, 0.0057 or 0.002, respectively), but not with gender, age, histological type, and smoking condition (P > 0.05). These results indicated that the loss of FBLN-3 gene induced by promoter methylation might play important roles in the progression of NSCLC and FBLN-3 promoter methylation might be a promising biomarker for early detection of NSCLC. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
C1 [Rui, Wang; You-Wei, Zhang; Long-Bang, Chen] Nanjing Univ, Sch Med, Jinling Hosp, Dept Med Oncol, Nanjing 210002, Peoples R China.
C3 Nanjing University
RP Long-Bang, C (通讯作者)，Nanjing Univ, Sch Med, Jinling Hosp, Dept Med Oncol, Nanjing 210002, Peoples R China.
EM chenlb_nanjing@yahoo.com.cn
RI rui, WANG/KCY-0880-2024
CR Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Baylin SB, 2002, SEMIN CANCER BIOL, V12, P331, DOI 10.1016/S1044-579X(02)00053-6
   Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432
   Belinsky SA, 2005, CARCINOGENESIS, V26, P1481, DOI 10.1093/carcin/bgi020
   Cheng YY, 2008, BRIT J CANCER, V99, P2083, DOI 10.1038/sj.bjc.6604760
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   de Vega S, 2009, CELL MOL LIFE SCI, V66, P1890, DOI 10.1007/s00018-009-8632-6
   Fidler IJ, 2000, CANCER J, V6, pS134
   Folkman J, 1992, Semin Cancer Biol, V3, P65
   FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27
   Gallagher WM, 2005, TRENDS MOL MED, V11, P336, DOI 10.1016/j.molmed.2005.06.001
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217
   LECKACZERNIK B, 1995, MOL CELL BIOL, V15, P120, DOI 10.1128/MCB.15.1.120
   Lopez J, 2009, BRIT J CANCER, V100, P571, DOI 10.1038/sj.bjc.6604930
   Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2
   Sadr-Nabavi A, 2009, INT J CANCER, V124, P1727, DOI 10.1002/ijc.24108
   Timpl R, 2003, NAT REV MOL CELL BIO, V4, P479, DOI 10.1038/nrm1130
   Tsou JA, 2002, ONCOGENE, V21, P5450, DOI 10.1038/sj.onc.1205605
   Wlazlinski A, 2007, PROSTATE, V67, P1770, DOI 10.1002/pros.20667
   Yi CH, 2007, AM J PATHOL, V170, P1535, DOI 10.2353/ajpath.2007.060478
   Yue W, 2007, CLIN CANCER RES, V13, P4336, DOI 10.1158/1078-0432.CCR-07-0015
NR 25
TC 24
Z9 24
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0169-5002
EI 1872-8332
J9 LUNG CANCER
JI Lung Cancer
PD AUG
PY 2010
VL 69
IS 2
BP 239
EP 244
DI 10.1016/j.lungcan.2009.10.009
PG 6
WC Oncology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Respiratory System
GA 627ZE
UT WOS:000280082700017
PM 19913326
DA 2025-01-12
ER

PT J
AU Grinberg-Rashi, H
   Cytron, S
   Gelman-Kohan, Z
   Litmanovitch, T
   Avivi, L
AF Grinberg-Rashi, Helena
   Cytron, Samuel
   Gelman-Kohan, Zully
   Litmanovitch, Talia
   Avivi, Lydia
TI Replication Timing Aberrations and Aneuploidy in Peripheral Blood
   Lymphocytes of Breast Cancer Patients
SO NEOPLASIA
LA English
DT Article
ID ALLELE-SPECIFIC REPLICATION; ASYNCHRONOUS REPLICATION; DNA-REPLICATION;
   LOCI; GENE; CELLS; EXPRESSION; METHYLATION; EPIGENETICS; THERAPY
AB BACKGROUND: Peripheral blood lymphocytes of patients with hematological malignancies or solid tumors, such as renal cell carcinoma or prostate cancer, display epigenetic aberrations (loss of synchronous replication of allelic counterparts) and genetic changes (aneuploidy) characteristic of the cancerous phenotype. This study sought to determine whether such alterations could differentiate breast cancer patients from cancer-free subjects. METHODS: The HER2 locus-an oncogene assigned to chromosome 17 whose amplification is associated with breast cancer (BCA)-and the pericentromeric satellite sequence of chromosome 17 (CEN17) were used for replication timing assessments. Aneuploidy was monitored by enumerating the copy numbers of chromosome 17. Replication timing and aneuploidy were detected cytogenetically using fluorescence in situ hybridization technology applied to phytohemagglutinin- stimulated lymphocytes of 20 women with BCA and 10 control subjects. RESULTS: We showed that both the HER2 and CEN17 loci in the stimulated BCA lymphocytes altered their characteristic pattern of synchronous replication and exhibited asynchronicity. In addition, there was an increase in chromosome 17 aneuploidy. The frequency of cells displaying asynchronous replication in the patients' samples was significantly higher (P < 10(-12) for HER2 and P < 10(-6) for CEN17) than the corresponding values in the control samples. Similarly, aneuploidy in patients' cells was significantly higher (P < 10(-9)) than that in the controls. CONCLUSIONS: The HER2 and CEN17 aberrant replication differentiated clearly between BCA patients and control subjects. Thus, monitoring the replication of these genes offers potential blood markers for the detection and monitoring of breast cancer. Neoplasia (2010) 12, 668-674
C1 [Grinberg-Rashi, Helena; Gelman-Kohan, Zully; Litmanovitch, Talia; Avivi, Lydia] Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, IL-699788 Tel Aviv, Israel.
   [Cytron, Samuel] Ben Gurion Univ Negev, Fac Hlth Sci, Dept Urol, Barzilai Med Ctr, Askelon, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Ben Gurion University;
   Barzilai Medical Center
RP Avivi, L (通讯作者)，Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, IL-699788 Tel Aviv, Israel.
EM lydia@post.tau.ac.il
CR Amiel A, 1998, GENE CHROMOSOME CANC, V22, P225, DOI 10.1002/(SICI)1098-2264(199807)22:3<225::AID-GCC8>3.0.CO;2-Y
   Bergman Y, 2004, NAT REV IMMUNOL, V4, P753, DOI 10.1038/nri1458
   Boggs BA, 1997, METHODS, V13, P259, DOI 10.1006/meth.1997.0525
   CHAMBERLAIN JS, 1993, AM J HUM GENET, V52, P792
   Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260
   Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902
   Dotan ZA, 2004, INT J CANCER, V111, P60, DOI 10.1002/ijc.20237
   Dotan ZA, 2000, GENE CHROMOSOME CANC, V27, P270, DOI 10.1002/(SICI)1098-2264(200003)27:3<270::AID-GCC7>3.0.CO;2-7
   Dotan ZA, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-390
   Ensminger AW, 2004, HUM MOL GENET, V13, P651, DOI 10.1093/hmg/ddh062
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781
   Gilbert DM, 2002, CURR OPIN CELL BIOL, V14, P377, DOI 10.1016/S0955-0674(02)00326-5
   Gimelbrant AA, 2005, J BIOL CHEM, V280, P1354, DOI 10.1074/jbc.M411283200
   Goldmit M, 2004, IMMUNOL REV, V200, P197, DOI 10.1111/j.0105-2896.2004.00158.x
   Gopalakrishnan S, 2009, HUM MOL GENET, V18, P3178, DOI 10.1093/hmg/ddp256
   Goren A, 2003, NAT REV MOL CELL BIO, V4, P25, DOI 10.1038/nrm1008
   Gribnau J, 2003, GENE DEV, V17, P759, DOI 10.1101/gad.1059603
   GUNARATNE PH, 1995, GENE DEV, V9, P808, DOI 10.1101/gad.9.7.808
   KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0
   KNOLL JHM, 1994, NAT GENET, V6, P41, DOI 10.1038/ng0194-41
   Korenstein-Ilan A, 2002, CANCER GENET CYTOGEN, V139, P97, DOI 10.1016/S0165-4608(02)00610-6
   LASALLE JM, 1995, NAT GENET, V9, P386, DOI 10.1038/ng0495-386
   Litmanovitch T, 1998, CYTOGENET CELL GENET, V81, P26, DOI 10.1159/000015003
   McNairn AJ, 2003, BIOESSAYS, V25, P647, DOI 10.1002/bies.10305
   Meyer R, 2009, CLIN CANCER RES, V15, P2703, DOI 10.1158/1078-0432.CCR-08-2454
   MORISHIMA A, 1962, P NATL ACAD SCI USA, V48, P756, DOI 10.1073/pnas.48.5.756
   Nagler A, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-230
   PRIEST JH, 1967, J CELL BIOL, V35, P483, DOI 10.1083/jcb.35.2.483
   Ross JS, 2009, ONCOLOGIST, V14, P320, DOI 10.1634/theoncologist.2008-0230
   Ross JS, 2004, MOL CELL PROTEOMICS, V3, P379, DOI 10.1074/mcp.R400001-MCP200
   SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x
   Simon I, 1999, NATURE, V401, P929, DOI 10.1038/44866
   STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615
   Vorsanova SG, 2001, BRAIN DEV-JPN, V23, pS191, DOI 10.1016/S0387-7604(01)00364-3
   White LM, 1996, AM J HUM GENET, V59, P423
   Woodfine K, 2004, HUM MOL GENET, V13, P191, DOI 10.1093/hmg/ddh016
   Yeshaya J, 1999, HUM GENET, V105, P86, DOI 10.1007/s004390051068
   You FL, 2008, J HEMATOL ONCOL, V1, DOI 10.1186/1756-8722-1-2
NR 39
TC 19
Z9 21
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1476-5586
J9 NEOPLASIA
JI Neoplasia
PD AUG
PY 2010
VL 12
IS 8
BP 668
EP 674
DI 10.1593/neo.10568
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 634VJ
UT WOS:000280613500008
PM 20689761
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Noetzel, E
   Rose, M
   Sevinc, E
   Hilgers, RD
   Hartmann, A
   Naami, A
   Knüchel, R
   Dahl, E
AF Noetzel, E.
   Rose, M.
   Sevinc, E.
   Hilgers, R-D
   Hartmann, A.
   Naami, A.
   Knuechel, R.
   Dahl, E.
TI Intermediate filament dynamics and breast cancer: Aberrant promoter
   methylation of the <i>Synemin</i> gene is associated with early tumor
   relapse
SO ONCOGENE
LA English
DT Article
DE tumor suppressor gene; SYNM; promoter methylation; epigenetics;
   recurrence-free survival; pyrosequencing
ID PROTEIN SYNEMIN; VIMENTIN FILAMENTS; MYOEPITHELIAL CELL; DNA
   METHYLATION; EXPRESSION; HYPERMETHYLATION; IDENTIFICATION; MARKER;
   DISEASE
AB Synemin (SYNM) is a type IV intermediate filament that has recently been shown to interact with the LIM domain protein zyxin, thereby possibly modulating cell adhesion and cell motility. Owing to this multiplicity of potential functions relevant to cancer development, we initiated a study to decipher SYNM expression and regulation in benign human breast tissue and breast cancer. Dot blot array analysis showed significant SYNM mRNA downregulation in 86% (n = 100, P < 0.001) of breast cancers compared with their normal tissue counterparts, a result that was confirmed by real-time PCR analysis (n = 36, P < 0.0001). Immunohistochemistry analysis showed abundant SYNM protein expression in healthy myoepithelial breast cells, whereas SYNM expression loss was evident in 57% (n = 37, P < 0.001) of breast cancer specimens. Next, we analyzed methylation of the SYNM promoter to clarify whether the SYNM gene can be silenced by epigenetic means. Indeed, methylation-specific PCR analysis showed tumor-specific SYNM promoter methylation in 27% (n = 195) of breast cancers. As expected, SYNM promoter methylation was tightly associated (P < 0.0001) with SYNM expression loss. In-depth analysis of the SYNM promoter by pyrosequencing showed extensive CpG methylation of DNA elements supposed to regulate gene transcription. Demethylating treatment of SYNM methylated breast cancer cell lines with 5-aza-2-deoxycytidine clearly reestablished the SYNM expression. Statistical analysis of the patient cohort showed a close association between SYNM promoter methylation and unfavorable recurrence-free survival (hazard ratio = 2.941, P = 0.0282). Furthermore, SYNM methylation positively correlated with lymph node metastases (P = 0.0177) and advanced tumor grade (P = 0.0275), suggesting that SYNM methylation is associated with aggressive forms of breast cancer. This is the first study on the epigenetic regulation of the SYNM gene in a cancer entity. We provide first hints that SYNM could represent a novel putative breast tumor suppressor gene that is prone to epigenetic silencing. SYNM promoter methylation may become a useful predictive biomarker to stratify breast cancer patients' risk for tumor relapse. Oncogene (2010) 29, 4814-4825; doi:10.1038/onc.2010.229; published online 14 June 2010
C1 [Noetzel, E.; Rose, M.; Sevinc, E.; Naami, A.; Knuechel, R.; Dahl, E.] Rhein Westfal TH Aachen, Fac Med, Mol Oncol Grp, Inst Pathol, Aachen, Germany.
   [Hilgers, R-D] Rhein Westfal TH Aachen, Dept Med Stat, Aachen, Germany.
   [Hartmann, A.] Univ Erlangen Nurnberg, Dept Pathol, Erlangen, Germany.
C3 RWTH Aachen University; RWTH Aachen University; University of Erlangen
   Nuremberg
RP Dahl, E (通讯作者)，Rhein Westfal TH Aachen, Univ Hosp, Mol Oncol Grp, Inst Pathol, Pauwelsstr 30, D-52074 Aachen, Germany.
EM edahl@ukaachen.de
RI Noetzel-Reiss, Erik/GYV-0999-2022; Hilgers, Ralf-Dieter/C-7090-2013
OI Noetzel-Reiss, Erik/0000-0003-3163-6848; Hilgers,
   Ralf-Dieter/0000-0002-5945-1119
FU BMBF [01KW0401]
FX We thank Sonja von Serenyi and Sevim Alkaya for excellent technical
   assistance and Monika Klinkhammer-Schalke, as well as Armin Pauer from
   the Tumor Registry Regensburg for continuous help in obtaining clinical
   follow-up data. We are thankful to Professor Matthias Durst
   (Friedrich-Schiller University Jena, Germany) for kindly providing
   patient samples and follow-up data. This work is a research project
   within the German Human Genome Project and has been supported by the
   BMBF Grants 01KW0401 to ED.
CR BECKERLE MC, 1986, J CELL BIOL, V103, P1679, DOI 10.1083/jcb.103.5.1679
   Bellin RM, 1999, J BIOL CHEM, V274, P29493, DOI 10.1074/jbc.274.41.29493
   Bellin RM, 2001, J BIOL CHEM, V276, P32330, DOI 10.1074/jbc.M104005200
   Bharadwaj S, 2005, ONCOGENE, V24, P8291, DOI 10.1038/sj.onc.1208993
   Bilak SR, 1998, ARCH BIOCHEM BIOPHYS, V355, P63, DOI 10.1006/abbi.1998.0702
   Blake DJ, 2002, TRENDS CARDIOVAS MED, V12, P224, DOI 10.1016/S1050-1738(02)00166-4
   Brandes JC, 2007, ONCOGENE, V26, P6229, DOI 10.1038/sj.onc.1210433
   Caldeira JRF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-48
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Dahl E, 2005, J PATHOL, V205, P21, DOI 10.1002/path.1687
   Dahl E, 2006, CLIN CANCER RES, V12, P3950, DOI 10.1158/1078-0432.CCR-05-2090
   Deugnier MA, 2002, BREAST CANCER RES, V4, P224, DOI 10.1186/bcr459
   Dobrovic A, 1997, CANCER RES, V57, P3347
   ELSTON CW, 1993, J CLIN PATHOL, V46, P189
   ETIENNE J, 1990, ANN BIOL CLIN-PARIS, V48, P681
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   GRANGER BL, 1980, CELL, V22, P727, DOI 10.1016/0092-8674(80)90549-8
   Guarino M, 2007, INT J BIOCHEM CELL B, V39, P2153, DOI 10.1016/j.biocel.2007.07.011
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Herrmann H, 2007, NAT REV MOL CELL BIO, V8, P562, DOI 10.1038/nrm2197
   Hirako Y, 2003, CELL TISSUE RES, V313, P195, DOI 10.1007/s00441-003-0732-2
   Hoque MO, 2008, CANCER RES, V68, P2661, DOI 10.1158/0008-5472.CAN-07-5913
   Kristensen LS, 2009, EUR J PHARMACOL, V625, P131, DOI 10.1016/j.ejphar.2009.10.011
   Lakhani SR, 2001, BREAST CANCER RES, V3, P1, DOI 10.1186/bcr260
   Lüscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7
   Mizuno Y, 2001, P NATL ACAD SCI USA, V98, P6156, DOI 10.1073/pnas.111153298
   Mook S, 2009, BREAST CANCER RES TR, V116, P295, DOI 10.1007/s10549-008-0130-2
   Nguyen M, 2000, ONCOGENE, V19, P3449, DOI 10.1038/sj.onc.1203677
   Noetzel E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-154
   Omary MB, 2004, NEW ENGL J MED, V351, P2087, DOI 10.1056/NEJMra040319
   Pan YH, 2008, FASEB J, V22, P3196, DOI 10.1096/fj.08-106187
   REMMELE W, 1987, PATHOLOGE, V8, P138
   Schmitt-Graeff A, 2006, HUM PATHOL, V37, P1200, DOI 10.1016/j.humpath.2006.04.017
   Sobin LH, 1997, TNM CLASSIFICATION M
   Sun N, 2010, EXP CELL RES, V316, P491, DOI 10.1016/j.yexcr.2009.10.015
   Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511
   Tawk M, 2003, EXP NEUROL, V183, P499, DOI 10.1016/S0014-4886(03)00240-1
   Titeux M, 2001, EUR J BIOCHEM, V268, P6435, DOI 10.1046/j.0014-2956.2001.02594.x
   Van Rossen E, 2009, HISTOCHEM CELL BIOL, V131, P313, DOI 10.1007/s00418-008-0544-2
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Veeck J, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-83
   Whipple RA, 2008, CANCER RES, V68, P5678, DOI 10.1158/0008-5472.CAN-07-6589
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wiesmann F, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2319
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
NR 46
TC 43
Z9 45
U1 5
U2 18
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD AUG
PY 2010
VL 29
IS 34
BP 4814
EP 4825
DI 10.1038/onc.2010.229
PG 12
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 643VB
UT WOS:000281326400007
PM 20543860
DA 2025-01-12
ER

PT J
AU Feng, J
   Wang, YP
   Chen, Y
   Luo, J
   Lu, J
   Tang, XB
   Hu, LH
AF Feng Jing
   Wang Yuping
   Chen Yong
   Luo Jie
   Lu Jun
   Tang Xuanbing
   Hu Lihua
TI CpG island methylator phenotype of multigene in serum of sporadic breast
   carcinoma
SO TUMOR BIOLOGY
LA English
DT Article
DE CpG island methylator phenotype; Sporadic breast cancer; Methylation
   profile
ID DNA METHYLATION; PROMOTER HYPERMETHYLATION; ABERRANT METHYLATION;
   CANCER-PATIENTS; LUNG-CANCER; EPIGENETIC INACTIVATION; MULTIPLE GENES;
   COLON-CANCER; EARLY EVENT; TUMOR
AB CpG island methylator phenotype (CIMP) involves methylation targeted toward the promoters of multiple genes. We determined a methylation profile of tumor-related genes in serum of sporadic breast cancer (SBC). The multigene methylation was examined by methylation-specific polymerase chain reaction assay in serum of 50 SBCs and 50 paired nontumors, and CIMP+ was defined as having three genes that are concordantly methylated. The methylation frequency of ten genes in serum of 50 SBCs varied from 10% in FHIT to 74% in RASSF1A. The methylation status of RASSF1A, BRCA1, p16, CDH1, ER, RAR beta 2, APC, and DAPK was significantly correlated with SBC and nontumor serum (P<0.05). Methylation of at least one gene was found in 92% SBC; CIMP was more frequent in SBC than nontumor serum (P<0.001). There was a significant association between CIMP and methylation of RASSF1A, BRCA1, p16, CDH1, ER, RAR beta 2, APC, and DAPK (P<0.05); the methylation link profile of CDH1, RASSF1A, BRCA1, and RAR beta 2 as breast cancer marker may contribute high sensitivity (90%) and specificity (88%). ER and RAR beta 2 methylation was associated with elevated serum CA153 levels in 39 SBC samples with CIMP+ (P<0.05). Multivariate analysis showed that living area of patients was found to provide independent prognostic information associated with a relative risk of tumor recurrence of 5.3. Multigene-specific methylation profile in serum was association with the recurrence risk of rural SBC, and positive correlation of CIMP can serve as a promising molecular marker of SBC.
C1 [Feng Jing; Hu Lihua] Huazhong Univ Sci & Technol, Dept Lab Med, Union Hosp, Tongji Med Coll, Wuhan 430074, Peoples R China.
   [Feng Jing; Wang Yuping] So Med Univ, Fengxian Hosp, Shanghai, Peoples R China.
   [Chen Yong; Luo Jie; Lu Jun; Tang Xuanbing] Taihe Hosp, Yunyang Med Coll, Shiyan, Peoples R China.
C3 Huazhong University of Science & Technology; Southern Medical University
   - China
RP Hu, LH (通讯作者)，Huazhong Univ Sci & Technol, Dept Lab Med, Union Hosp, Tongji Med Coll, Wuhan 430074, Peoples R China.
EM fengjinggood@hotmail.com
RI Wang, Yuping/AAW-2930-2021; Hu, Lihua/AGG-8893-2022
OI Wang, Yuping/0000-0003-0087-4771
FU Science Funds for Distinguished Young Scholar of Hubei Province
   [2008154]; Natural Science Foundation of Hubei Province [2007ABA371];
   Hubei Provincial Department of Education [Q20082407]; Innovation
   Foundation for Young Scholars of Yunyang Medical College [CXX200805]
FX Grants provided by Science Funds for Distinguished Young Scholar of
   Hubei Province (2008154), Natural Science Foundation of Hubei Province
   (2007ABA371), Science Funds from Hubei Provincial Department of
   Education (Q20082407), and Innovation Foundation for Young Scholars of
   Yunyang Medical College (CXX200805).
CR Abe O, 1998, LANCET, V352, P930
   ANDERS R, 2008, CANCER RES, V68, P5562
   Barault L, 2008, CANCER RES, V68, P8541, DOI 10.1158/0008-5472.CAN-08-1171
   Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Clarke M, 1998, LANCET, V351, P1451
   Corn PG, 2000, CLIN CANCER RES, V6, P4243
   COUCH FJ, 2001, METABOLIC MOL BASIS, P999
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Eads CA, 2001, CANCER RES, V61, P3410
   Esteller M, 2000, CANCER RES, V60, P4366
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Euhus DM, 2008, CANCER EPIDEM BIOMAR, V17, P1051, DOI 10.1158/1055-9965.EPI-07-2582
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Evron E, 2001, CANCER RES, V61, P2782
   Goldhirsch A, 2001, J CLIN ONCOL, V19, P3817, DOI 10.1200/JCO.2001.19.18.3817
   Grunau C, 2001, NUCLEIC ACIDS RES, V29, P270, DOI 10.1093/nar/29.1.270
   Hawkins N, 2002, GASTROENTEROLOGY, V122, P1376, DOI 10.1053/gast.2002.32997
   Hayes DF, 2001, J MAMMARY GLAND BIOL, V6, P375, DOI 10.1023/A:1014778713034
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hoque MO, 2004, CANCER RES, V64, P5511, DOI 10.1158/0008-5472.CAN-04-0799
   Hu XC, 2003, ONCOL REP, V10, P1811
   Jerónimo C, 2003, CLIN CANCER RES, V9, P3413
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353
   Kawakami K, 2000, J NATL CANCER I, V92, P1805, DOI 10.1093/jnci/92.22.1805
   Leitch A M, 1999, Surg Oncol Clin N Am, V8, P657
   Lo YMD, 2001, BIOMED PHARMACOTHER, V55, P362, DOI 10.1016/S0753-3322(01)00083-X
   MAHMOOD A, 2001, CANCER RES, V61, P2399
   MAIKE W, 2006, CLIN CANCER RES, V12, P7347
   Misawa K, 2008, CLIN CANCER RES, V14, P7604, DOI 10.1158/1078-0432.CCR-07-4673
   Mori T, 2006, CANCER RES, V66, P6692, DOI 10.1158/0008-5472.CAN-06-0801
   Müller HM, 2003, CANCER RES, V63, P7641
   Müller HM, 2004, ANN NY ACAD SCI, V1022, P44, DOI 10.1196/annals.1318.008
   Ngan RKC, 2001, ANN NY ACAD SCI, V945, P73
   Ogino S, 2006, GUT, V55, P1000, DOI 10.1136/gut.2005.082933
   Oue N, 2006, CANCER-AM CANCER SOC, V106, P1250, DOI 10.1002/cncr.21754
   SABINE ZM, 2001, CANCER RES, V61, P3581
   Sambrook J, 2001, Molecular Cloning: a Laboratory Manual, Vthird
   Samowitz WS, 2005, GASTROENTEROLOGY, V129, P837, DOI 10.1053/j.gastro.2005.06.020
   SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123
   Topaloglu O, 2004, CLIN CANCER RES, V10, P2284, DOI 10.1158/1078-0432.CCR-1111-3
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Toyota M, 1999, CANCER RES, V59, P5438
   Tsou JA, 2002, ONCOGENE, V21, P5450, DOI 10.1038/sj.onc.1205605
   Ulivi P, 2006, J CELL PHYSIOL, V206, P611, DOI 10.1002/jcp.20503
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Usadel H, 2002, CANCER RES, V62, P371
   Van der Auwera I, 2009, BRIT J CANCER, V100, P1277, DOI 10.1038/sj.bjc.6605013
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Yamashita K, 2003, CANCER CELL, V4, P121, DOI 10.1016/S1535-6108(03)00190-9
   Yang HJ, 2004, GYNECOL ONCOL, V93, P435, DOI 10.1016/j.ygyno.2004.01.039
   Zhang CS, 2007, CLIN CANCER RES, V13, P944, DOI 10.1158/1078-0432.CCR-06-2268
NR 54
TC 36
Z9 40
U1 0
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD AUG
PY 2010
VL 31
IS 4
BP 321
EP 331
DI 10.1007/s13277-010-0040-x
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 670PE
UT WOS:000283439000011
PM 20490964
DA 2025-01-12
ER

PT J
AU Zhou, ZL
   Thomsen, R
   Kahns, S
   Nielsen, AL
AF Zhou, Zhangle
   Thomsen, Rune
   Kahns, Soren
   Nielsen, Anders Lade
TI The NSD3L histone methyltransferase regulates cell cycle and cell
   invasion in breast cancer cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE NSD3; WHSC1L1; Histone methyltransferase; Epigenetics; Cell cycle;
   Carcinogenesis; Metastasis
ID GENE; PROTEIN; PROLIFERATION; DISTINCT; MAPS; E2F
AB NSD3/WHSC1L1 histone methyltransferase gene aberrations are observed in leukemia and in breast and lung carcinomas, suggesting that NSD3 is implicated in carcinogenesis. In this study we examined in human breast cancer cells the NSD3L isoform which contains the catalytic histone methyltransferase SET-domain. siRNA directed depletion of NSD3L followed by genome-wide microarray analysis identified NSD3L regulated genes which could be functionally linked to cellular signaling pathways such as cell growth, cell cycle, cell motility, transcription, and apoptosis. Notably up-regulated genes are the cell cycle regulators E2F2 and Arl2. In accordance with a function of NSD3L in cell cycle regulation NSD3L depletion resulted in an increase in the number of cells in the S and G2/M cell cycle phases. Moreover, NSD3L depletion increased the invasiveness of MDA-MB-231 breast cancer cells indicating that NSD3L normally restrain cellular metastatic potential. Together the presented data indicates that NSD3L is a candidate tumor suppressor. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Zhou, Zhangle; Thomsen, Rune; Kahns, Soren; Nielsen, Anders Lade] Aarhus Univ, Dept Human Genet, DK-8000 Aarhus C, Denmark.
C3 Aarhus University
RP Nielsen, AL (通讯作者)，Aarhus Univ, Dept Human Genet, Bartholin Bldg, DK-8000 Aarhus C, Denmark.
EM aln@humgen.au.dk
RI ; Nielsen, Anders Lade/Q-9604-2016
OI Thomsen, Rune/0000-0002-9969-6567; Kahns, Soren/0009-0006-9330-8734;
   Nielsen, Anders Lade/0000-0003-4372-9961
FU Medical Faculty, University of Aarhus, Denmark; Novo Nordisk Foundation;
   The Lundbeck Foundation; Danish Research Council FSS; Danish Cancer
   Society
FX We thank Yonglun Luo for assistance with microarray data analysis and
   Soren Pedersen and Hanne Jacobsen for assistance with FACS analysis. ZZ
   and RT are supported by PhD fellowships from the Medical Faculty,
   University of Aarhus, Denmark. ALN is supported by a Hallas-Moller
   Fellowship from the Novo Nordisk Foundation. This work was supported by
   grants from The Novo Nordisk Foundation, The Lundbeck Foundation, the
   Danish Research Council FSS, and the Danish Cancer Society.
CR Angrand PO, 2001, GENOMICS, V74, P79, DOI 10.1006/geno.2001.6524
   Bernard-Pierrot I, 2008, CANCER RES, V68, P7165, DOI 10.1158/0008-5472.CAN-08-1360
   Chaussepied M, 2005, CELL CYCLE, V4, P392, DOI 10.4161/cc.4.3.1556
   DeGregori J, 2006, CURR MOL MED, V6, P739
   Douglas J, 2005, EUR J HUM GENET, V13, P150, DOI 10.1038/sj.ejhg.5201298
   Draghici S, 2003, GENOMICS, V81, P98, DOI 10.1016/S0888-7543(02)00021-6
   Golias CH, 2004, INT J CLIN PRACT, V58, P1134, DOI 10.1111/j.1742-1241.2004.00284.x
   Guffanti A, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-163
   Hosack DA, 2003, GENOME BIOL, V4, P4, DOI DOI 10.1186/GB-2003-4-6-P4
   Huang NW, 1998, EMBO J, V17, P3398, DOI 10.1093/emboj/17.12.3398
   Kamath L, 2001, CANCER RES, V61, P5933
   Kedrin D, 2007, J MAMMARY GLAND BIOL, V12, P143, DOI 10.1007/s10911-007-9046-4
   Kim SM, 2006, BIOCHEM BIOPH RES CO, V345, P318, DOI 10.1016/j.bbrc.2006.04.095
   Kim SM, 2007, EXP CELL RES, V313, P975, DOI 10.1016/j.yexcr.2006.12.007
   Rosati R, 2002, BLOOD, V99, P3857, DOI 10.1182/blood.V99.10.3857
   Stec I, 2001, GENOMICS, V76, P5, DOI 10.1006/geno.2001.6581
   Taketani T, 2009, CANCER GENET CYTOGEN, V190, P108, DOI 10.1016/j.cancergencyto.2008.12.008
   Tonon G, 2005, P NATL ACAD SCI USA, V102, P9625, DOI 10.1073/pnas.0504126102
   VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503
NR 19
TC 31
Z9 42
U1 0
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUL 30
PY 2010
VL 398
IS 3
BP 565
EP 570
DI 10.1016/j.bbrc.2010.06.119
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 638CB
UT WOS:000280867400040
PM 20599755
DA 2025-01-12
ER

PT J
AU Sharma, G
   Mirza, S
   Parshad, R
   Srivastava, A
   Gupta, SD
   Pandya, P
   Ralhan, R
AF Sharma, Gayatri
   Mirza, Sameer
   Parshad, Rajinder
   Srivastava, Anurag
   Gupta, Siddartha Datta
   Pandya, Pranav
   Ralhan, Ranju
TI Clinical significance of promoter hypermethylation of DNA repair genes
   in tumor and serum DNA in invasive ductal breast carcinoma patients
SO LIFE SCIENCES
LA English
DT Article
DE Breast cancer; DNA methylation; BRCA1; GSTP1; MGMT; Gene silencing
ID CANCER-PATIENTS; SPORADIC BREAST; OVARIAN-TUMORS; MULTIPLE GENES;
   METHYLATION; BRCA1; EXPRESSION; RISK; EPIGENETICS; METASTASIS
AB Aims: The clinical relevance of frequent methylation of CpG islands of key cancer genes in breast cancer is being increasingly recognized. Our study aimed to evaluate the promoter methylation status of DNA repair genes-BRCA1 MGMT and GSTP1 in tumor and circulating DNA of invasive ductal breast carcinoma patients.
   Main methods: Methylation-specific PCR was carried out to investigate the promoter methylation status of genes in tumor and circulating DNA of 100 breast cancer patients in a prospective study. The effect of promoter methylation on protein expression was evaluated by immunohistochemistry.
   Key findings: The frequency of tumor hypermethylation was 27% in BRCA1, 32% in MGMT and 25% in GSTP1 and correlated with methylation of these genes in paired serum DNA Immunohistochemical analysis showed no detectable expression of BRCA1 and MGMT in 51/89 (57%) and 35/89 (39%) tumors, respectively. MGMT promoter methylation mediated gene silencing was associated with loss of its protein expression (p = 0.002, O.R. = 4.5, 95% C.I. = 1.7-12.0). BRCA1 promoter methylation was not associated with loss of its protein expression, indicating that methylation is not the sole mechanism accounting for the loss/reduced BRCA1 protein expression. Importantly, GSTP1 and BRCA1 hypermethylation were found to be independent of other prognostic factors in predicting disease recurrence (p = 0.02, HR = 7.6, 95% C.I. = 1.4-44.1: p = 0.04, HR = 6.2, 95% C.I. = 1.1-35.7).
   Significance: Our study underscores the potential utility of DNA methylation of these genes in serum as a promising biomarker and can serve as a surrogate for tumor DNA methylation for diagnosis and prognosis of breast cancer. (c) 2010 Elsevier Inc. All rights reserved.
C1 [Ralhan, Ranju] Mt Sinai Hosp, Joseph & Mildred Sonshine Family Ctr Head & Neck, Toronto, ON M5G 1X5, Canada.
   [Sharma, Gayatri; Mirza, Sameer; Ralhan, Ranju] All India Inst Med Sci, Dept Biochem, New Delhi 110029, India.
   [Parshad, Rajinder; Srivastava, Anurag] All India Inst Med Sci, Dept Surg, New Delhi 110029, India.
   [Gupta, Siddartha Datta] All India Inst Med Sci, Dept Pathol, New Delhi 110029, India.
   [Sharma, Gayatri; Pandya, Pranav] Dev Sanskriti Vishwa Vidyalaya, Hardwar, India.
   [Ralhan, Ranju] Univ Toronto, Dept Otolaryngol Head & Neck Surg, Toronto, ON M5S 1A1, Canada.
   [Ralhan, Ranju] Mt Sinai Hosp, Dept Otolaryngol Head & Neck Surg, Toronto, ON M5G 1X5, Canada.
   [Ralhan, Ranju] Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada.
C3 University of Toronto; Sinai Health System Toronto; All India Institute
   of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical
   Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences
   (AIIMS) New Delhi; Dev Sanskriti Vishwavidyalaya; University of Toronto;
   University of Toronto; Sinai Health System Toronto; Lunenfeld Tanenbaum
   Research Institute; University of Toronto; Sinai Health System Toronto;
   Lunenfeld Tanenbaum Research Institute
RP Ralhan, R (通讯作者)，Mt Sinai Hosp, Joseph & Mildred Sonshine Family Ctr Head & Neck, Joseph & Wolf Lebovic Hlth Complex,600 Univ Ave,R, Toronto, ON M5G 1X5, Canada.
EM rralhan@mtsinai.on.ca
FU All India Institute of Medical Sciences; UGC
FX We are grateful to All India Institute of Medical Sciences for providing
   financial support to conduct this study. SM is grateful to UGC for
   providing Senior Research Fellowship.
CR Ahuja N, 2000, HISTOL HISTOPATHOL, V15, P835, DOI 10.14670/HH-15.835
   Arai T, 2006, BREAST CANCER RES TR, V100, P169, DOI 10.1007/s10549-006-9241-9
   Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Belinsky SA, 2006, CANCER RES, V66, P3338, DOI 10.1158/0008-5472.CAN-05-3408
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Catteau A, 2002, SEMIN CANCER BIOL, V12, P359, DOI 10.1016/S1044-579X(02)00056-1
   Coles BF, 2003, BIOFACTORS, V17, P115, DOI 10.1002/biof.5520170112
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Danam RP, 2005, MOL CANCER THER, V4, P61
   Daniels DS, 2004, NAT STRUCT MOL BIOL, V11, P714, DOI 10.1038/nsmb791
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2000, EUR J CANCER, V36, P2294, DOI 10.1016/S0959-8049(00)00303-8
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Euhus DM, 2007, CANCER EPIDEM BIOMAR, V16, P1812, DOI 10.1158/1055-9965.EPI-06-1034
   Fiegl H, 2005, CANCER RES, V65, P1141, DOI 10.1158/0008-5472.CAN-04-2438
   Fraga MF, 2004, CANCER RES, V64, P5527, DOI 10.1158/0008-5472.CAN-03-4061
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   García JM, 2004, GENE CHROMOSOME CANC, V41, P117, DOI 10.1002/gcc.20062
   Gonzalgo ML, 2003, CLIN CANCER RES, V9, P2673
   Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232
   Jacinto FV, 2007, MUTAGENESIS, V22, P247, DOI 10.1093/mutage/gem009
   Jeong DH, 2006, INT J GYNECOL CANCER, V16, P1234, DOI 10.1111/j.1525-1438.2006.00522.x
   Jing F, 2008, ONCOLOGY-BASEL, V75, P60, DOI 10.1159/000155145
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   Lopez J, 2009, BRIT J CANCER, V100, P571, DOI 10.1038/sj.bjc.6604930
   Mehrotra J, 2004, CLIN CANCER RES, V10, P3104, DOI 10.1158/1078-0432.CCR-03-0118
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Mirza S, 2007, LIFE SCI, V81, P280, DOI 10.1016/j.lfs.2007.05.012
   Miyoshi Y, 2008, INT J CLIN ONCOL, V13, P395, DOI 10.1007/s10147-008-0831-x
   Müller HM, 2003, CANCER RES, V63, P7641
   Osanai T, 2005, JPN J CLIN ONCOL, V35, P121, DOI 10.1093/jjco/hyi036
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   PERTSCHUK LP, 1990, CANCER-AM CANCER SOC, V66, P1663, DOI 10.1002/1097-0142(19901015)66:8<1663::AID-CNCR2820660802>3.0.CO;2-C
   Qi J, 2005, WORLD J GASTROENTERO, V11, P2022
   Ralhan R, 2007, CANCER LETT, V248, P1, DOI 10.1016/j.canlet.2006.06.004
   Rhodes A, 2002, AM J CLIN PATHOL, V118, P408
   Ronneberg JA, 2008, CANCER RES, V68, P5562, DOI 10.1158/0008-5472.CAN-07-5828
   Sharma G, 2007, LIFE SCI, V80, P1873, DOI 10.1016/j.lfs.2007.02.026
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   Shukla S, 2006, EPIGENETICS-US, V1, P88, DOI 10.4161/epi.1.2.2679
   Soejima H, 2005, BIOCHEM CELL BIOL, V83, P429, DOI 10.1139/O05-140
   Suijkerbuijk KPM, 2008, PATHOBIOLOGY, V75, P149, DOI 10.1159/000123853
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Taback B, 2006, ANN NY ACAD SCI, V1075, P211, DOI 10.1196/annals.1368.029
   Tao MH, 2009, BREAST CANCER RES TR, V114, P559, DOI 10.1007/s10549-008-0028-z
   Tapia T, 2008, EPIGENETICS-US, V3, P157, DOI 10.4161/epi.3.3.6387
   Van der Auwera I, 2009, BRIT J CANCER, V100, P1277, DOI 10.1038/sj.bjc.6605013
   Wiley A, 2006, CANCER-AM CANCER SOC, V107, P299, DOI 10.1002/cncr.21992
NR 52
TC 72
Z9 79
U1 0
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD JUL 17
PY 2010
VL 87
IS 3-4
BP 83
EP 91
DI 10.1016/j.lfs.2010.05.001
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 626OL
UT WOS:000279975200002
PM 20470789
DA 2025-01-12
ER

PT J
AU Lo, PK
   Lee, JS
   Liang, XH
   Han, LF
   Mori, T
   Fackler, MJ
   Sadik, H
   Argani, P
   Pandita, TK
   Sukumar, S
AF Lo, Pang-Kuo
   Lee, Ji Shin
   Liang, Xiaohui
   Han, Liangfeng
   Mori, Tsuyoshi
   Fackler, Mary Jo
   Sadik, Helen
   Argani, Pedram
   Pandita, Tej K.
   Sukumar, Saraswati
TI Epigenetic Inactivation of the Potential Tumor Suppressor Gene
   <i>FOXF1</i> in Breast Cancer
SO CANCER RESEARCH
LA English
DT Article
ID MAMMARY EPITHELIAL-CELLS; PROSTATE-CANCER; DNA-REPLICATION;
   RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTORS; EXPRESSION PATTERNS;
   LUNG; ADENOCARCINOMA; CARCINOMAS; REVEALS
AB The expression of several members of the FOX gene family is known to be altered in a variety of cancers. We show that in breast cancer, FOXF1 gene is a target of epigenetic inactivation and that its gene product exhibits tumor-suppressive properties. Loss or downregulation of FOXF1 expression is associated with FOXF1 promoter hypermethylation in breast cancer cell lines and in invasive ductal carcinomas. Methylation of FOXF1 in invasive ductal carcinoma (37.6% of 117 cases) correlated with high tumor grade. Pharmacologic unmasking of epigenetic silencing in breast cancer cells restored FOXF1 expression. Re-expression of FOXF1 in breast cancer cells with epigenetically silenced FOXF1 genes led to G(1) arrest concurrent with or without apoptosis to suppress both in vitro cell growth and in vivo tumor formation. FOXF1-induced G(1) arrest resulted from a blockage at G(1)-S transition of the cell cycle through inhibition of the CDK2-RB-E2F cascade. Small interfering RNA-mediated depletion of FOXF1 in breast cancer cells led to increased DNA re-replication, suggesting that FOXF1 is required for maintaining the stringency of DNA replication and genomic stability. Furthermore, expression profiling of cell cycle regulatory genes showed that abrogation of FOXF1 function resulted in increased expression of E2F-induced genes involved in promoting the progression of S and G(2) phases. Therefore, our studies have identified FOXF1 as a potential tumor suppressor gene that is epigenetically silenced in breast cancer, which plays an essential role in regulating cell cycle progression to maintain genomic stability. Cancer Res; 70(14); 6047-58. (C) 2010 AACR.
C1 [Lo, Pang-Kuo; Lee, Ji Shin; Liang, Xiaohui; Han, Liangfeng; Mori, Tsuyoshi; Fackler, Mary Jo; Sadik, Helen; Argani, Pedram; Sukumar, Saraswati] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.
   [Argani, Pedram] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   [Pandita, Tej K.] Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA.
C3 Johns Hopkins University; Johns Hopkins University; University of Texas
   System; University of Texas Southwestern Medical Center Dallas
RP Sukumar, S (通讯作者)，Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, 1650 Orleans St,CRB 1,Room 143, Baltimore, MD 21231 USA.
EM saras@jhmi.edu
RI Pandita, Tej/AAM-9188-2020
FU NIH [P50 CA088843-08, W81XWH-04-1-0595]; Avon Research Foundation
FX NIH Specialized Programs of Research Excellence-1 P50 CA088843-08, DOD
   Center of Excellence W81XWH-04-1-0595, and the Avon Research Foundation
   (S. Sukumar).
CR Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493
   Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733
   BERGSTRAESSER LM, 1993, CANCER RES, V53, P2644
   Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998
   Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663
   Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780
   Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008
   *COMP BIOSC INC, 2008, ONC 4 3 RES ED DAT I
   Dyrskjot L, 2004, CANCER RES, V64, P4040, DOI 10.1158/0008-5472.CAN-03-3620
   FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x
   Goodyear S, 2007, EXP MOL PATHOL, V82, P25, DOI 10.1016/j.yexmp.2006.09.002
   Hellqvist M, 1996, J BIOL CHEM, V271, P4482
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614
   Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001
   Jiang YY, 2004, J BIOL CHEM, V279, P40511, DOI 10.1074/jbc.M404496200
   Kalinichenko VV, 2003, HEPATOLOGY, V37, P107, DOI 10.1053/jhep.2003.50005
   Kalinichenko VV, 2002, J BIOL CHEM, V277, P12369, DOI 10.1074/jbc.M112162200
   Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704
   Katoh M, 2004, INT J ONCOL, V25, P1495
   Kearsey SE, 2003, MOL CELL, V12, P1067, DOI 10.1016/S1097-2765(03)00441-6
   LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421
   Lancaster JM, 2004, J SOC GYNECOL INVEST, V11, P51, DOI 10.1016/j.jsgi.2003.07.004
   Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101
   Lee KY, 1997, J BIOL CHEM, V272, P5622, DOI 10.1074/jbc.272.9.5622
   Lo PK, 2006, CANCER BIOL THER, V5, P281, DOI 10.4161/cbt.5.3.2384
   Lucas JJ, 2004, MOL CANCER RES, V2, P105
   Mahlapuu M, 2001, DEVELOPMENT, V128, P2397
   Mahlapuu M, 2001, DEVELOPMENT, V128, P155
   Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104
   Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223
   Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881
   Nishitani H, 2004, FRONT BIOSCI-LANDMRK, V9, P2115
   PLON SE, 1993, P NATL ACAD SCI USA, V90, P10484, DOI 10.1073/pnas.90.22.10484
   Powell CA, 2003, AM J RESP CELL MOL, V29, P157, DOI 10.1165/rcmb.2002-0183RC
   Sanchez-Carbayo M, 2006, J CLIN ONCOL, V24, P778, DOI 10.1200/JCO.2005.03.2375
   SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544
   Stearman RS, 2005, AM J PATHOL, V167, P1763, DOI 10.1016/S0002-9440(10)61257-6
   Sumara I, 2007, DEV CELL, V12, P887, DOI 10.1016/j.devcel.2007.03.019
   Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014
   *U SO CAL KECK SCH, 2004, CPG ISL SEARCH AN TO
   van der Horst A, 2007, NAT REV MOL CELL BIO, V8, P440, DOI 10.1038/nrm2190
   Vanaja DK, 2003, CANCER RES, V63, P3877
   Wachi S, 2005, BIOINFORMATICS, V21, P4205, DOI 10.1093/bioinformatics/bti688
   Wang XJ, 2000, J BIOL CHEM, V275, P31763, DOI 10.1074/jbc.M004358200
   Watson JEV, 2004, ONCOGENE, V23, P3487, DOI 10.1038/sj.onc.1207474
   Welsh JB, 2001, CANCER RES, V61, P5974
   Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158
   Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786
NR 49
TC 68
Z9 74
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUL 15
PY 2010
VL 70
IS 14
BP 6047
EP 6058
DI 10.1158/0008-5472.CAN-10-1576
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 626GV
UT WOS:000279955300040
PM 20587515
OA Green Accepted, Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Prencipe, M
   McGoldrick, A
   Perry, AS
   O'Grady, A
   Phelan, S
   McGrogan, B
   Fitzpatrick, P
   Watson, JA
   Furlong, F
   Brennan, DJ
   Lawler, M
   Kay, E
   McCann, A
AF Prencipe, Maria
   McGoldrick, Aloysius
   Perry, Antoinette S.
   O'Grady, Anthony
   Phelan, Sine
   McGrogan, Barbara
   Fitzpatrick, Patricia
   Watson, Jenny A.
   Furlong, Fiona
   Brennan, Donal J.
   Lawler, Mark
   Kay, Elaine
   McCann, Amanda
TI MAD2 downregulation in hypoxia is independent of promoter
   hypermethylation
SO CELL CYCLE
LA English
DT Article
DE MAD2; Hypoxia; promoter methylation; ovarian cancer; epigenetic
   regulation
ID INDUCIBLE FACTOR 1-ALPHA; MITOTIC CHECKPOINT CONTROL; SQUAMOUS-CELL
   CARCINOMA; CARBONIC-ANHYDRASE-IX; BREAST-CANCER; TUMOR HYPOXIA;
   UNFAVORABLE PROGNOSIS; RADIATION-RESISTANCE; GENETIC INSTABILITY;
   ANGIOGENIC PATHWAYS
AB Aberrant expression of the MAD2 protein has been linked to chromosomal instability, malignant transformation and chemoresistance. Although reduced MAD2 expression is well recognised in human cancer cell lines, the mechanism(s) underlying its downregulation remain elusive.
   The objective of this study was to establish the impact of hypoxia on MAD2 expression and to investigate the potential role of aberrant promoter methylation as a possible mechanism of MAD2 downregulation. For this purpose, three ovarian cancer cell lines, displaying differing levels of MAD2, were treated with chromatin modifying drugs, pre and post-hypoxia exposure and a DHPLC analysis of DNA promoter methylation carried out. We show that hypoxia induces downregulation of MAD2 expression, independently of MAD2 promoter methylation. We also show no evidence of MAD2 promoter methylation in breast and prostate cancer cells or in breast cancer clinical material. While our findings provide no evidence for MAD2 promoter methylation, we show a concomitant upregulation of p21 with downregulation of MAD2 in hypoxia. Our in vitro results were also confirmed in an ovarian cancer tissue microarray (TMA), where a reciprocal staining of MAD2 and CAIX was found in 21/60 (35%) of tumours.
   In summary, MAD2 downregulation may be a crucial mechanism by which hypoxic cells become chemorefractory. This stems from our previous work where we demonstrated that MAD2 downregulation induces cellular senescence, a viable cellular fate, with resultant cellular resistance to paclitaxel. Moreover, MAD2 downregulation could play a central role in the induction of chemoresistance in hypoxia, a key tumour microenvironment associated with chemoresistance.
C1 [Prencipe, Maria; McGoldrick, Aloysius; Phelan, Sine; McGrogan, Barbara; Watson, Jenny A.; Furlong, Fiona; McCann, Amanda] Univ Coll Dublin, UCD Sch Med & Med Sci SMMS, Dublin 2, Ireland.
   [Perry, Antoinette S.; Lawler, Mark] Univ Dublin Trinity Coll, Inst Mol Med, Prostate Canc Res Grp, Dublin 2, Ireland.
   [O'Grady, Anthony; Kay, Elaine] Beaumont Hosp, Dept Pathol, RCSI Educ & Res Ctr, Dublin 9, Ireland.
   [Fitzpatrick, Patricia] Univ Coll Dublin, UCD Sch Publ Hlth & Populat Sci, Dublin 2, Ireland.
   [Brennan, Donal J.] Natl Matern Hosp, Dept Obstet & Ginecol, Dublin 2, Ireland.
C3 University College Dublin; Trinity College Dublin; Royal College of
   Surgeons - Ireland; University College Dublin; National Maternity
   Hospital, Dublin
RP Prencipe, M (通讯作者)，Univ Coll Dublin, UCD Sch Med & Med Sci SMMS, Dublin 2, Ireland.
EM maria.prencipe@ucd.ie
RI Fitzpatrick, Patricia/Y-6017-2019; Kay, Elaine/D-8539-2013
OI McCann, Amanda/0000-0003-1911-3307; Perry,
   Antoinette/0000-0002-6108-512X; Lawler, Mark/0000-0002-3930-8470;
   Fitzpatrick, Patricia/0000-0003-2524-3677; Prencipe,
   Maria/0000-0002-8864-1560; Furlong, Fiona/0000-0002-9206-2297
FU Irish Research Council for Science, Engineering and Technology (IRCSET);
   College of Life Science (CLS) Epigenetics Research Group UCD (CERGU);
   University College Dublin, Belfield, Dublin Ireland; Irish Cancer
   Society [CRF08FUR]; Eccles Breast Health Research Fund Mater
   Misericordiae Hospital, Dublin, Ireland
FX This work was supported by the Irish Research Council for Science,
   Engineering and Technology (IRCSET), the College of Life Science (CLS)
   Epigenetics Research Group UCD (CERGU), University College Dublin,
   Belfield, Dublin Ireland and the Irish Cancer Society (CRF08FUR) and the
   Eccles Breast Health Research Fund Mater Misericordiae Hospital, Dublin,
   Ireland.
CR Aebersold DM, 2001, CANCER RES, V61, P2911
   Ashida S, 2002, J CANCER RES CLIN, V128, P561, DOI 10.1007/s00432-002-0374-x
   Birner P, 2000, CANCER RES, V60, P4693
   Birner P, 2001, CLIN CANCER RES, V7, P1661
   Birner P, 2001, CANCER, V92, P165, DOI 10.1002/1097-0142(20010701)92:1<165::AID-CNCR1305>3.0.CO;2-F
   Bos R, 2001, JNCI-J NATL CANCER I, V93, P309, DOI 10.1093/jnci/93.4.309
   Brennan DJ, 2006, CLIN CANCER RES, V12, P6421, DOI 10.1158/1078-0432.CCR-06-0480
   Brennana DJ, 2009, EUR J CANCER, V45, P1510, DOI 10.1016/j.ejca.2009.01.028
   Brown JM, 2007, METHOD ENZYMOL, V435, P297, DOI 10.1016/S0076-6879(07)35015-5
   Brown JM, 1999, CANCER RES, V59, P5863
   Cahill DP, 1999, GENOMICS, V58, P181, DOI 10.1006/geno.1999.5831
   Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291
   Cho M, 2001, BRIT J CANCER, V85, P563, DOI 10.1054/bjoc.2001.1951
   Cho M, 2000, MOL CARCINOGEN, V27, P184, DOI 10.1002/(SICI)1098-2744(200003)27:3<184::AID-MC5>3.0.CO;2-P
   Comerford KM, 2002, CANCER RES, V62, P3387
   Fung MKL, 2007, BBA-MOL CELL RES, V1773, P821, DOI 10.1016/j.bbamcr.2007.03.014
   Gemma A, 2001, LUNG CANCER-J IASLC, V32, P289, DOI 10.1016/S0169-5002(00)00223-3
   Giatromanolaki A, 2001, CANCER RES, V61, P7992
   Goda N, 2003, MOL CELL BIOL, V23, P359, DOI 10.1128/MCB.23.1.359-369.2003
   Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0
   Haapasalo JA, 2006, CLIN CANCER RES, V12, P473, DOI 10.1158/1078-0432.CCR-05-0848
   Hernando E, 2001, INT J CANCER, V95, P223, DOI 10.1002/1097-0215(20010720)95:4<223::AID-IJC1038>3.0.CO;2-L
   Höckel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266
   Imai Y, 1999, JPN J CANCER RES, V90, P837, DOI 10.1111/j.1349-7006.1999.tb00824.x
   Jeong SJ, 2004, CANCER RES, V64, P8666, DOI 10.1158/0008-5472.CAN-03-3455
   Koshiji M, 2005, MOL CELL, V17, P793, DOI 10.1016/j.molcel.2005.02.015
   Kurokawa T, 2003, BRIT J CANCER, V89, P1042, DOI 10.1038/sj.bjc.6601186
   Le QT, 2004, CANCER METAST REV, V23, P293, DOI 10.1023/B:CANC.0000031768.89246.d7
   Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246
   Loncaster JA, 2001, CANCER RES, V61, P6394
   Overgaard J, 2007, J CLIN ONCOL, V25, P4066, DOI 10.1200/JCO.2007.12.7878
   Paliwal S, 2007, CANCER RES, V67, P9322, DOI 10.1158/0008-5472.CAN-07-1743
   Park S, 2008, ACTA HAEMATOL-BASEL, V120, P217, DOI 10.1159/000195698
   Percy MJ, 2000, GENE CHROMOSOME CANC, V29, P356, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1044>3.0.CO;2-N
   Perry Antoinette S, 2007, Epigenetics, V2, P43
   Prencipe M, 2009, BRIT J CANCER, V101, P1900, DOI 10.1038/sj.bjc.6605419
   Reynolds TY, 1996, CANCER RES, V56, P5754
   Rofstad EK, 2000, BRIT J CANCER, V83, P354, DOI 10.1054/bjoc.2000.1266
   Schindl M, 2002, CLIN CANCER RES, V8, P1831
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Sivridis E, 2002, CANCER-AM CANCER SOC, V95, P1055, DOI 10.1002/cncr.10774
   Sudo T, 2004, CANCER RES, V64, P2502, DOI 10.1158/0008-5472.CAN-03-2013
   Swinson DEB, 2003, J CLIN ONCOL, V21, P473, DOI 10.1200/JCO.2003.11.132
   Sze KMF, 2004, J BIOMED SCI, V11, P920, DOI 10.1159/000081839
   Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807
   To-Ho KW, 2008, ONCOGENE, V27, P347, DOI 10.1038/sj.onc.1210633
   Vaughan-Jones RD, 2002, BIOCHEM CELL BIOL, V80, P579, DOI 10.1139/O02-157
   Walsh S, 2009, INT J CANCER, V124, P1871, DOI 10.1002/ijc.24145
   Wang XH, 2002, CANCER RES, V62, P1662
   Wang XH, 2000, CARCINOGENESIS, V21, P2293, DOI 10.1093/carcin/21.12.2293
   Wartenberg M, 2003, FASEB J, V17, P503, DOI 10.1096/fj.02-0358fje
   Watson JA, 2009, HUM MOL GENET, V18, P3594, DOI 10.1093/hmg/ddp307
   Wykoff CC, 2000, CANCER RES, V60, P7075
   Yoon DS, 2002, AM J PATHOL, V161, P391, DOI 10.1016/S0002-9440(10)64194-6
   Yun M, 2009, MOL CANCER RES, V7, P371, DOI 10.1158/1541-7786.MCR-08-0056
   Zhang QH, 2006, P NATL ACAD SCI USA, V103, P9029, DOI 10.1073/pnas.0603269103
NR 56
TC 12
Z9 12
U1 0
U2 8
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD JUL 15
PY 2010
VL 9
IS 14
BP 2856
EP 2865
DI 10.4161/cc.9.14.12362
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 642IY
UT WOS:000281205500035
PM 20676051
OA Bronze
DA 2025-01-12
ER

PT J
AU Guo, X
   Liu, W
   Pan, Y
   Ni, P
   Ji, J
   Guo, L
   Zhang, J
   Wu, J
   Jiang, J
   Chen, X
   Cai, Q
   Li, J
   Zhang, J
   Gu, Q
   Liu, B
   Zhu, Z
   Yu, Y
AF Guo, X.
   Liu, W.
   Pan, Y.
   Ni, P.
   Ji, J.
   Guo, L.
   Zhang, J.
   Wu, J.
   Jiang, J.
   Chen, X.
   Cai, Q.
   Li, J.
   Zhang, J.
   Gu, Q.
   Liu, B.
   Zhu, Z.
   Yu, Y.
TI Homeobox gene <i>IRX1</i> is a tumor suppressor gene in gastric
   carcinoma
SO ONCOGENE
LA English
DT Article
DE epigenetic; gastric carcinoma; homeobox genes; IRX1; tumor suppressor
ID SQUAMOUS-CELL CARCINOMA; PROTEOMICS TECHNOLOGY; EPIGENETIC THERAPY;
   ENDOTHELIAL-CELLS; LUNG DEVELOPMENT; DNA METHYLATION; IROQUOIS GENES;
   BREAST-CANCER; EXPRESSION; IDENTIFICATION
AB The IRX1 tumor suppressor gene is located on 5p15.33, a cancer susceptibility locus. Loss of heterozygosity of 5p15.33 in gastric cancer was identified in our previous work. In this study, we analyzed the molecular features and function of IRX1. We found that IRX1 expression was lost or reduced in gastric cancer. However, no mutations were identified in IRX1-encoding regions. IRX1 transcription was suppressed by hypermethylation, and the expression of IRX1 mRNA was partially restored in gastric cancer cells after 5-Aza-dC treatment. Restoring IRX1 expression in SGC-7901 and NCI-N87 gastric cancer cells inhibited growth, invasion and tumorigenesis in vitro and in vivo. We identified a number of target genes by global microarray analysis after IRX1 transfection combined with real-time PCR and chromatin immunoprecipitation assay. BDKRB2, an angiogenesis-related gene, HIST2H2BE and FGF7, cell proliferation and invasion-related genes, were identified as direct IRX1 target genes. The hypermethylation of IRX1 was not only detected in primary gastric cancer tissues but also in the peripheral blood of gastric cancer patients, suggesting IRX1 could potentially serve as a biomarker for gastric cancer. Oncogene (2010) 29, 3908-3920; doi:10.1038/onc.2010.143; published online 3 May 2010
C1 [Guo, X.; Liu, W.; Pan, Y.; Ji, J.; Guo, L.; Zhang, J.; Wu, J.; Jiang, J.; Chen, X.; Cai, Q.; Li, J.; Zhang, J.; Gu, Q.; Liu, B.; Zhu, Z.; Yu, Y.] Shanghai Ruijin Hosp, Dept Surg, Shanghai, Peoples R China.
   [Guo, X.; Liu, W.; Pan, Y.; Ji, J.; Guo, L.; Zhang, J.; Wu, J.; Jiang, J.; Chen, X.; Cai, Q.; Li, J.; Zhang, J.; Gu, Q.; Liu, B.; Zhu, Z.; Yu, Y.] Shanghai Inst Digest Surg, Shanghai, Peoples R China.
   [Ni, P.] Shanghai Jiao Tong Univ, Sch Med, Dept Clin Biochem, Shanghai 200025, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Yu, Y (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Surg, Ruijin Er Rd 197, Shanghai 200025, Peoples R China.
EM surgeryzhu@yahoo.com.cn; yingyan3y@yahoo.com.cn
RI Liu, Bingya/GMW-5655-2022; yu, yingying/GRR-7851-2022
OI Yu, Yingyan/0000-0002-3585-3252
FU National Natural Science Foundation of China [30572127, 30770961,
   30973486]; Chinese National High Tech Program [863-2006AA02A402,
   2006AA02A301]; Shanghai Pu Jiang Project [PJ200700367]; Shanghai Science
   and Technology Commission [09DZ1950101, 09JC1409600]; Shanghai Charity
   Foundation for Cancer Research
FX This work was supported, in part by grants from the National Natural
   Science Foundation of China (30572127, 30770961 and 30973486), the
   Chinese National High Tech Program (863-2006AA02A402, 2006AA02A301), the
   Shanghai Pu Jiang Project (PJ200700367), Key Research Project from
   Shanghai Science and Technology Commission (09DZ1950101 and
   09JC1409600), and Shanghai Charity Foundation for Cancer Research.
CR Alarcón P, 2008, DEVELOPMENT, V135, P3197, DOI 10.1242/dev.023697
   Asaka SI, 2006, SURG TODAY, V36, P793, DOI 10.1007/s00595-006-3261-2
   Becker MB, 2001, MECH DEVELOP, V106, P155, DOI 10.1016/S0925-4773(01)00412-9
   Bennett KL, 2008, CANCER RES, V68, P4494, DOI 10.1158/0008-5472.CAN-07-6509
   Bergman Y, 1998, BIOL CHEM, V379, P401
   Cairns Paul, 2009, V507, P165, DOI 10.1007/978-1-59745-522-0_13
   Choi IS, 2005, CELL RES, V15, P247, DOI 10.1038/sj.cr.7290293
   Do Jee C, 2009, EUR J CANCER, V45, P1282, DOI 10.1016/j.ejca.2008.12.027
   Duffy MJ, 2009, EUR J CANCER, V45, P335, DOI 10.1016/j.ejca.2008.12.008
   Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434
   Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018
   Ferguson CA, 1998, GENE DEV, V12, P2636, DOI 10.1101/gad.12.16.2636
   Garinis GA, 2002, HUM GENET, V111, P115, DOI 10.1007/s00439-002-0783-6
   Hao Y, 2008, J PROTEOME RES, V7, P3668, DOI 10.1021/pr700638k
   Hellebrekers DMEI, 2007, CANCER RES, V67, P4138, DOI 10.1158/0008-5472.CAN-06-3032
   Huang QJ, 2008, J CANCER RES CLIN, V134, P1219, DOI 10.1007/s00432-008-0398-y
   Hurtubise A, 2008, CANCER CELL INT, V8, DOI 10.1186/1475-2867-8-16
   Ikeda Y, 2004, CANCER RES, V64, P5178, DOI 10.1158/0008-5472.CAN-03-3589
   Iorns E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005120
   Ishihara K, 2002, INT IMMUNOPHARMACOL, V2, P499, DOI 10.1016/S1567-5769(01)00193-X
   Ishihara K, 2001, JPN J PHARMACOL, V87, P318, DOI 10.1254/jjp.87.318
   Jin GF, 2009, CARCINOGENESIS, V30, P987, DOI 10.1093/carcin/bgp090
   KAMEI M, 1992, BIOTHERAPY, V4, P17, DOI 10.1007/BF02171705
   Kawakami K, 2000, J NATL CANCER I, V92, P1805, DOI 10.1093/jnci/92.22.1805
   Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031
   Knudson AG, 1996, J CANCER RES CLIN, V122, P135, DOI 10.1007/BF01366952
   Kuga D, 2008, NEURO-ONCOLOGY, V10, P995, DOI 10.1215/15228517-2008-064
   Lai IR, 2002, HEPATO-GASTROENTEROL, V49, P1157
   Lemaire M, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-128
   Lewis MT, 1999, CELL TISSUE RES, V296, P549, DOI 10.1007/s004410051316
   Lu Y, 2005, CANCER LETT, V224, P329, DOI 10.1016/j.canlet.2004.11.057
   McKay JD, 2008, NAT GENET, V40, P1404, DOI 10.1038/ng.254
   Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774
   Perez-Diez A, 2007, ADV EXP MED BIOL, V593, P74
   Plendl J, 2000, BIOL CHEM, V381, P1103, DOI 10.1515/BC.2000.135
   Quackenbush J, 2006, NEW ENGL J MED, V354, P2463, DOI 10.1056/NEJMra042342
   Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461
   Ropiquet F, 1999, INT J CANCER, V82, P237, DOI 10.1002/(SICI)1097-0215(19990719)82:2<237::AID-IJC14>3.0.CO;2-Q
   Schneider-Stock R, 2007, IDRUGS, V10, P557
   Shaker S, 2004, ONCOL REP, V11, P1253
   Shaoul R, 2006, BIOCHEM BIOPH RES CO, V350, P825, DOI 10.1016/j.bbrc.2006.08.198
   Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614
   Tamura M, 1999, CANCER RES, V59, P442
   TELFORD JL, 1994, TRENDS BIOTECHNOL, V12, P420, DOI 10.1016/0167-7799(94)90031-0
   Tocchi A, 1998, J CANCER RES CLIN, V124, P450, DOI 10.1007/s004320050198
   Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233
   Toyota M, 2005, SEMIN ONCOL, V32, P521, DOI 10.1053/j.seminoncol.2005.07.003
   Tycko B, 2000, J CLIN INVEST, V105, P401, DOI 10.1172/JCI9462
   Ushijima T, 2006, J GASTROENTEROL, V41, P401, DOI 10.1007/s00535-006-1846-6
   van Tuyl M, 2006, AM J PHYSIOL-LUNG C, V290, pL777, DOI 10.1152/ajplung.00293.2005
   Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5
   Ychou M, 2000, DIS MARKERS, V16, P105, DOI 10.1155/2000/595492
   Yu Ying-yan, 2006, Zhonghua Zhongliu Zazhi, V28, P84
   Zhao HJ, 2005, PROSTATE, V63, P187, DOI 10.1002/pros.20158
NR 54
TC 75
Z9 87
U1 3
U2 21
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD JUL 8
PY 2010
VL 29
IS 27
BP 3908
EP 3920
DI 10.1038/onc.2010.143
PG 13
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 621SL
UT WOS:000279603200004
PM 20440264
DA 2025-01-12
ER

PT J
AU Chao, YL
   Shepard, CR
   Wells, A
AF Chao, Yvonne L.
   Shepard, Christopher R.
   Wells, Alan
TI Breast carcinoma cells re-express E-cadherin during mesenchymal to
   epithelial reverting transition
SO MOLECULAR CANCER
LA English
DT Article
ID 5' CPG ISLAND; CANCER METASTASIS; TUMOR PROGRESSION; BETA-CATENIN;
   IN-VITRO; ADHESION; GROWTH; METHYLATION; INVASION; BINDING
AB Background: Epithelial to mesenchymal transition (EMT), implicated as a mechanism for tumor dissemination, is marked by loss of E-cadherin, disruption of cell adhesion, and induction of cell motility and invasion. In most intraductal breast carcinomas E-cadherin is regulated epigenetically via methylation of the promoter. E-cadherin expression is therefore dynamic and open to modulation by the microenvironment. In addition, it has been observed that metastatic foci commonly appear more differentiated than the primary tumor, suggesting that cancer cells may further undergo a mesenchymal to epithelial reverting transition (MErT) in the secondary organ environment following the EMT that allows for escape.
   Results: We first examined E-cadherin expression in primary breast tumors and their corresponding metastases to liver, lung and brain and discovered that 62% (10/16) of cases showed increased E-cadherin expression in the metastases compared to the primaries. These observations led to the question of whether the positive metastatic foci arose from expansion of E-cadherin-positive cells or from MErT of originally E-cadherin-negative disseminated cells. Thus, we aimed to determine whether it was possible for the mesenchymal-like MDA-MB-231 breast cancer cells to undergo an MErT through the re-expression of E-cadherin, either through exogenous introduction or induction by the microenvironment. Ectopic expression of full-length E-cadherin in MDA-MB-231 cells resulted in a morphological and functional reversion of the epithelial phenotype, with even just the cytosolic domain of E-cadherin yielding a partial phenotype. Introduction of MDA-MB-231 cells or primary explants into a secondary organ environment simulated by a hepatocyte coculture system induced E-cadherin re-expression through passive loss of methylation of the promoter. Furthermore, detection of E-cadherin-positive metastatic foci following the spontaneous metastasis of MDA-MB-231 cells injected into the mammary fat pad of mice suggests that this re-expression is functional.
   Conclusions: Our clinical observations and experimental data indicate that the secondary organ microenvironment can induce the re-expression of E-cadherin and consequently MErT. This phenotypic change is reflected in altered cell behavior and thus may be a critical step in cell survival at metastatic sites.
C1 [Wells, Alan] Pittsburgh VAMC, Dept Pathol, Pittsburgh, PA 15213 USA.
   Univ Pittsburgh, Pittsburgh, PA 15213 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh
RP Wells, A (通讯作者)，Pittsburgh VAMC, Dept Pathol, Pittsburgh, PA 15213 USA.
EM wellsa@upmc.edu
RI Shepard, Christopher/B-5832-2014
OI Wells, Alan/0000-0002-1637-8150
FU DoD CDMRP on Breast Carcinoma Cancer
FX We thank Ioannis Vizirianakis for the H-2kd-Ecad construct and Steve
   Strom, William Bowen, and Liang Kang for providing hepatocytes. These
   studies were supported by grants from the DoD CDMRP on Breast Carcinoma
   Cancer and the VA Merit Award Program.
CR Benton G, 2009, FASEB J, V23, P3884, DOI 10.1096/fj.08-128702
   Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498
   BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0
   Bukholm IK, 2000, J PATHOL, V190, P15
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Chaffer CL, 2006, CANCER RES, V66, P11271, DOI 10.1158/0008-5472.CAN-06-2044
   Chambers AF, 1995, CANCER METAST REV, V14, P279, DOI 10.1007/BF00690599
   Chu K, 2008, MOL CANCER RES, V6, P1259, DOI 10.1158/1541-7786.MCR-08-0077
   Corn PG, 2000, CLIN CANCER RES, V6, P4243
   Fedor-Chaiken M, 2003, J BIOL CHEM, V278, P52371, DOI 10.1074/jbc.M310576200
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   Gassmann P, 2008, CLIN EXP METASTAS, V25, P171, DOI 10.1007/s10585-007-9130-6
   Glinskii OV, 2005, NEOPLASIA, V7, P522, DOI 10.1593/neo.04646
   Goldstein NS, 2002, AM J CLIN PATHOL, V118, P425, DOI 10.1309/JMRD-W08Y-6K8M-7AD8
   Gotzmann J, 2004, MUTAT RES-REV MUTAT, V566, P9, DOI 10.1016/S1383-5742(03)00033-4
   Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Green SK, 2004, MOL CANCER THER, V3, P149
   Hajra KM, 2002, CANCER RES, V62, P1613
   HIRANO S, 1987, J CELL BIOL, V105, P2501, DOI 10.1083/jcb.105.6.2501
   HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127
   Hudson LG, 2008, CLIN EXP METASTAS, V25, P643, DOI 10.1007/s10585-008-9171-5
   Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223
   Kallakury BVS, 2001, CANCER, V92, P2786, DOI 10.1002/1097-0142(20011201)92:11<2786::AID-CNCR10128>3.0.CO;2-I
   Kienast Y, 2010, NAT MED, V16, P116, DOI 10.1038/nm.2072
   Kokkinos MI, 2007, CELLS TISSUES ORGANS, V185, P191, DOI 10.1159/000101320
   KOOP S, 1995, CANCER RES, V55, P2520
   Kowalski PJ, 2003, BREAST CANCER RES, V5, pR217, DOI 10.1186/bcr651
   Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018
   Li M, 2010, J BIOL CHEM, V285, P6285, DOI 10.1074/jbc.M109.057943
   Lu X, 2007, J MAMMARY GLAND BIOL, V12, P153, DOI 10.1007/s10911-007-9047-3
   Lucifero D, 2002, GENOMICS, V79, P530, DOI 10.1006/geno.2002.6732
   Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3
   Matsuo K, 1998, EMBO J, V17, P1446, DOI 10.1093/emboj/17.5.1446
   Nam JS, 2004, CLIN EXP METASTAS, V21, P49, DOI 10.1023/B:CLIN.0000017180.19881.c1
   Ochs RL, 2003, IN VITRO CELL DEV-AN, V39, P63
   Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938
   Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200
   Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp
   Perrais M, 2007, MOL BIOL CELL, V18, P2013, DOI 10.1091/mbc.E06-04-0348
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Punglia RS, 2007, NEW ENGL J MED, V356, P2399, DOI 10.1056/NEJMra065241
   Rae JM, 2004, CLIN EXP METASTAS, V21, P543, DOI 10.1007/s10585-004-3759-1
   Sanders DSA, 1999, J CLIN PATHOL-MOL PA, V52, P151, DOI 10.1136/mp.52.3.151
   Sarrió D, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-74
   Shiraishi K, 2005, J IMMUNOL, V175, P1014, DOI 10.4049/jimmunol.175.2.1014
   SILKE J, 1995, FEBS LETT, V370, P170, DOI 10.1016/0014-5793(95)00830-3
   Silye R, 1998, J PATHOL, V186, P350, DOI 10.1002/(SICI)1096-9896(199812)186:4<350::AID-PATH181>3.0.CO;2-K
   St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557
   St Croix Brad, 1997, Current Opinion in Oncology, V9, P549
   TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419
   Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P
   Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148
   Tse JC, 2007, J CELL BIOCHEM, V101, P816, DOI 10.1002/jcb.21215
   Vizirianakis IS, 2002, INT J ONCOL, V21, P135
   Wang LY, 2009, ARCH BIOCHEM BIOPHYS, V481, P116, DOI 10.1016/j.abb.2008.10.021
   Wells A, 2008, CLIN EXP METASTAS, V25, P621, DOI 10.1007/s10585-008-9167-1
   Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033
   Yates CC, 2007, BRIT J CANCER, V96, P1246, DOI 10.1038/sj.bjc.6603700
   Zhou W, 2006, BRIT J CANCER, V95, P164, DOI 10.1038/sj.bjc.6603234
NR 60
TC 319
Z9 389
U1 1
U2 22
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD JUL 7
PY 2010
VL 9
AR 179
DI 10.1186/1476-4598-9-179
PG 18
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 629IM
UT WOS:000280189300001
PM 20609236
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Meeran, SM
   Patel, SN
   Tollefsbol, TO
AF Meeran, Syed M.
   Patel, Shweta N.
   Tollefsbol, Trygve O.
TI Sulforaphane Causes Epigenetic Repression of <i>hTERT</i> Expression in
   Human Breast Cancer Cell Lines
SO PLOS ONE
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITOR; TELOMERASE REVERSE-TRANSCRIPTASE;
   GENE-EXPRESSION; DNA METHYLATION; APOPTOSIS; PROMOTER; GROWTH;
   TRICHOSTATIN; ACETYLATION; MODULATION
AB Background: Sulforaphane (SFN), an isothiocyanate found in cruciferous vegetables, is a common dietary component that has histone deacetylase inhibition activity and exciting potential in cancer prevention. The mechanisms by which SFN imparts its chemopreventive properties are of considerable interest and little is known of its preventive potential for breast cancer.
   Principal Findings: We found that SFN significantly inhibits the viability and proliferation of breast cancer cells in vitro while it has negligible effects on normal breast cells. Inhibition of telomerase has received considerable attention because of its high expression in cancer cells and extremely low level of expression in normal cells. SFN treatment dose-and time-dependently inhibited human telomerase reverse transcriptase (hTERT), the catalytic regulatory subunit of telomerase, in both MCF-7 and MDA-MB-231 human breast cancer cells. DNA methyltransferases (DNMTs), especially DNMT1 and DNMT3a, were also decreased in SFN-treated breast cancer cells suggesting that SFN may repress hTERT by impacting epigenetic pathways. Down-regulation of DNMTs in response to SFN induced site-specific CpG demethylation occurring primarily in the first exon of the hTERT gene thereby facilitating CTCF binding associated with hTERT repression. Chromatin immunoprecipitation (ChIP) analysis of the hTERT promoter revealed that SFN increased the level of active chromatin markers acetyl-H3, acetyl-H3K9 and acetyl-H4, whereas the trimethyl-H3K9 and trimethyl-H3K27 inactive chromatin markers were decreased in a dose-dependent manner. SFN-induced hyperacetylation facilitated the binding of many hTERT repressor proteins such as MAD1 and CTCF to the hTERT regulatory region. Depletion of CTCF using siRNA reduced the SFN-induced down-regulation of hTERT mRNA transcription in these breast cancer cells. In addition, down-regulation of hTERT expression facilitated the induction of cellular apoptosis in human breast cancer cells.
   Significance: Collectively, our results provide novel insights into SFN-mediated epigenetic down-regulation of telomerase in breast cancer prevention and may open new avenues for approaches to SFN-mediated cancer prevention.
C1 [Meeran, Syed M.; Patel, Shweta N.; Tollefsbol, Trygve O.] Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Ctr Aging, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Meeran, SM (通讯作者)，Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA.
EM trygve@uab.edu
RI Meeran, Syed/AAG-2157-2020
FU National Cancer Institute [R01 CA129415]
FX R01 CA129415 National Cancer Institute (http://www.cancer.gov/). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Ahmed A, 2003, J ANTI-AGING MED, V6, P315, DOI 10.1089/109454503323028911
   Anderson CJ, 2006, ONCOGENE, V25, P61, DOI 10.1038/sj.onc.1209011
   Berletch JB, 2008, J CELL BIOCHEM, V103, P509, DOI 10.1002/jcb.21417
   Bhamre S, 2009, PROSTATE, V69, P181, DOI 10.1002/pros.20869
   Choi JH, 2010, BIOCHEM BIOPH RES CO, V391, P449, DOI 10.1016/j.bbrc.2009.11.078
   Choi KC, 2009, CANCER RES, V69, P583, DOI 10.1158/0008-5472.CAN-08-2442
   Chu WF, 2009, ORAL ONCOL, V45, P998, DOI 10.1016/j.oraloncology.2009.05.641
   Ciftci K, 2003, J PHARM PHARMACOL, V55, P1135, DOI 10.1211/002235703322277177
   Cornblatt BS, 2007, CARCINOGENESIS, V28, P1485, DOI 10.1093/carcin/bgm049
   Dashwood RH, 2008, NUTR REV, V66, pS36, DOI 10.1111/j.1753-4887.2008.00065.x
   Fahey JW, 1997, P NATL ACAD SCI USA, V94, P10367, DOI 10.1073/pnas.94.19.10367
   Golubovskaya VM, 2008, MOL CARCINOGEN, V47, P222, DOI 10.1002/mc.20380
   Guilleret I, 2002, INT J CANCER, V101, P335, DOI 10.1002/ijc.10593
   Ho E, 2009, J NUTR, V139, P2393, DOI 10.3945/jn.109.113332
   Hou M, 2002, EXP CELL RES, V274, P25, DOI 10.1006/excr.2001.5462
   Jacinto FV, 2007, CANCER RES, V67, P11481, DOI 10.1158/0008-5472.CAN-07-2687
   Jew S, 2009, J MED FOOD, V12, P925, DOI 10.1089/jmf.2008.0268
   Kyo S, 2008, CANCER SCI, V99, P1528, DOI 10.1111/j.1349-7006.2008.00878.x
   Li YY, 2009, INT J CANCER, V125, P286, DOI 10.1002/ijc.24398
   Liu L, 2004, GENE, V340, P1, DOI 10.1016/j.gene.2004.06.011
   Liu L, 2004, MOL CANCER THER, V3, P1003
   Meeran SM, 2007, EXP DERMATOL, V16, P405, DOI 10.1111/j.1600-0625.2007.00542.x
   Munster P, 2009, CLIN CANCER RES, V15, P2488, DOI 10.1158/1078-0432.CCR-08-1930
   Murakami J, 2005, CANCER CHEMOTH PHARM, V56, P22, DOI 10.1007/s00280-004-0976-x
   Myzak MC, 2006, FASEB J, V20, P506, DOI 10.1096/fj.05-4785fje
   Myzak MC, 2004, CANCER RES, V64, P5767, DOI 10.1158/0008-5472.CAN-04-1326
   Myzak MC, 2007, EXP BIOL MED, V232, P227
   Naasani I, 2003, CANCER RES, V63, P824
   Nian H, 2009, ENVIRON MOL MUTAGEN, V50, P213, DOI 10.1002/em.20454
   Patil BS, 2009, J AGR FOOD CHEM, V57, P8142, DOI 10.1021/jf9000132
   Pledgie-Tracy A, 2007, MOL CANCER THER, V6, P1013, DOI 10.1158/1535-7163.MCT-06-0494
   Renaud S, 2007, NUCLEIC ACIDS RES, V35, P1245, DOI 10.1093/nar/gkl1125
   Renaud S, 2005, NUCLEIC ACIDS RES, V33, P6850, DOI 10.1093/nar/gki989
   Schwab M, 2008, IMMUNOLOGY, V125, P241, DOI 10.1111/j.1365-2567.2008.02834.x
   Shun MC, 2004, NUTR CANCER, V48, P95, DOI 10.1207/s15327914nc4801_13
   Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599
   Suenaga M, 2002, INT J CANCER, V97, P621, DOI 10.1002/ijc.10082
   Takakura M, 2001, NUCLEIC ACIDS RES, V29, P3006, DOI 10.1093/nar/29.14.3006
   Telang U, 2009, EXP BIOL MED, V234, P287, DOI 10.3181/0808-RM-241
   Wei N, 2009, FASEB J, V23
   Woo HJ, 2007, EXP MOL PATHOL, V82, P77, DOI 10.1016/j.yexmp.2006.02.004
   Xiao D, 2009, PHARM RES-DORDR, V26, P1729, DOI 10.1007/s11095-009-9883-5
   Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198
   Zinn RL, 2007, CANCER RES, V67, P194, DOI 10.1158/0008-5472.CAN-06-3396
NR 44
TC 269
Z9 301
U1 1
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 6
PY 2010
VL 5
IS 7
AR e11457
DI 10.1371/journal.pone.0011457
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 620TI
UT WOS:000279522500022
PM 20625516
OA gold, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Yoon, SO
   Zhang, X
   Freedman, AS
   Zahrieh, D
   Lossos, IS
   Li, L
   Choi, YS
AF Yoon, Sun-Ok
   Zhang, Xin
   Freedman, Arnold S.
   Zahrieh, David
   Lossos, Izidore S.
   Li, Li
   Choi, Yong Sung
TI Down-Regulation of CD9 Expression and its Correlation to Tumor
   Progression in B Lymphomas
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID FOLLICULAR DENDRITIC CELLS; MULTIPLE-MYELOMA CELLS; COLON-CARCINOMA
   CELLS; HUMAN BREAST-CANCER; PROTEIN-1 MRP-1/CD9; GENE-EXPRESSION;
   LUNG-CANCER; MONOCLONAL-ANTIBODY; TETRASPANIN CD9; DECREASED EXPRESSION
AB Histological transformation, a pivotal event in the natural history of cancers including lymphomas, is typically associated with more aggressive clinical behavior. L3055, a B lymphoma cell line of germinal center (GC) origin, is dependent on follicular dendritic cells (FDCs) for survival and proliferation, similar to GC-B cells. However, L3055 cells become less FDC-dependent after prolonged culture, which is analogous to transformation in vivo. Comparison of two L3055 subclones (i.e., the FDC-dependent indolent clone 12 and the FDC-independent aggressive clone 33) by DNA microarray revealed that CD9 was the most differentially expressed gene (P = 0.05). L3055-12 expresses high levels of CD9 while L3055-33 does not. Reduced levels or loss of CD9 expression is also observed in other CD9-positive B lymphoma cell lines. The resultant CD9-negative cells grow faster than CD9-positive cells due to their greater resistance to apoptosis. Furthermore CD9-negative cells are less dependent on FDCs for their survival and growth compared with CD9-positive cells. CD9 down-regulation in B lymphomas appears to be controlled epigenetically, mainly through histone modifications. These findings imply that CD9 is inversely correlated with B lymphoma progression, and CD9 inactivation may play an important role in B lymphoma transformation. (Am J Pathol 2010, 177:377-386; DOI: 10.2353/ajpath.2010.100048)
C1 [Yoon, Sun-Ok; Zhang, Xin; Li, Li; Choi, Yong Sung] Ochsner Clin Fdn, Cellular Immunol Lab, New Orleans, LA 70121 USA.
   [Freedman, Arnold S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Zahrieh, David] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA.
   [Zahrieh, David] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Computat Biol, Boston, MA 02115 USA.
   [Lossos, Izidore S.] Univ Miami, Dept Med, Div Hematol Oncol, Miami, FL USA.
   [Lossos, Izidore S.] Univ Miami, Dept Mol & Cellular Pharmacol, Miami, FL USA.
C3 Ochsner Health System; Harvard University; Dana-Farber Cancer Institute;
   Harvard Medical School; Harvard University; Dana-Farber Cancer
   Institute; Harvard Medical School; Harvard University; Harvard Medical
   School; Dana-Farber Cancer Institute; University of Miami; University of
   Miami
RP Choi, YS (通讯作者)，Ochsner Clin Fdn, Cellular Immunol Lab, 1514 Jefferson Highway, New Orleans, LA 70121 USA.
EM ychoi@ochsner.org
RI Li, Li/K-2372-2013; Choi, Yong-Sung/ABG-7840-2020
FU National Institutes of Health [R01CA121039]; Norman Hirshfield
   Foundation
FX Supported by National Institutes of Health grant R01CA121039 to Y.S.C.
   and Norman Hirshfield Foundation to A.S.F.
CR ACKER B, 1983, J CLIN ONCOL, V1, P11, DOI 10.1200/JCO.1983.1.1.11
   Adachi M, 1996, CANCER RES, V56, P1751
   ATKINSON B, 1984, CANCER RES, V44, P2577
   ATKINSON B, 1985, HYBRIDOMA, V4, P243, DOI 10.1089/hyb.1985.4.243
   Barreiro O, 2005, BLOOD, V105, P2852, DOI 10.1182/blood-2004-09-3606
   Barrena S, 2005, LEUKEMIA, V19, P1376, DOI 10.1038/sj.leu.2403822
   Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933
   Cajot JF, 1997, CANCER RES, V57, P2593
   Chao CH, 2006, CANCER RES, V66, P6579, DOI 10.1158/0008-5472.CAN-05-2415
   Choe J, 2000, J IMMUNOL, V164, P56, DOI 10.4049/jimmunol.164.1.56
   Choi YS, 1997, IMMUNOL RES, V16, P161, DOI 10.1007/BF02786360
   De Bruyne E, 2006, LEUKEMIA, V20, P1870, DOI 10.1038/sj.leu.2404343
   De Bruyne E, 2008, CLIN CANCER RES, V14, P2918, DOI 10.1158/1078-0432.CCR-07-4489
   Freedman Arnold S, 2005, Hematology Am Soc Hematol Educ Program, P314
   Guo XZ, 1996, CANCER RES, V56, P4876
   Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736
   HIGASHIYAMA M, 1995, CANCER RES, V55, P6040
   Higashiyama M, 1997, INT J CANCER, V74, P205, DOI 10.1002/(SICI)1097-0215(19970422)74:2<205::AID-IJC12>3.0.CO;2-C
   HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929
   Houle CD, 2002, GYNECOL ONCOL, V86, P69, DOI 10.1006/gyno.2002.6729
   Huang CI, 1998, AM J PATHOL, V153, P973, DOI 10.1016/S0002-9440(10)65639-8
   Kagami Y, 2001, LEUKEMIA, V15, P148, DOI 10.1038/sj.leu.2402002
   KIM HS, 1994, J IMMUNOL, V153, P2951
   Kimoto H, 1997, EUR J IMMUNOL, V27, P268, DOI 10.1002/eji.1830270140
   Ko EM, 2006, MOL CELLS, V22, P70
   KONDOH M, 1993, MELANOMA RES, V3, P241
   KoscoVilbois MH, 1995, CURR TOP MICROBIOL, V201, P69
   Küppers R, 1999, NEW ENGL J MED, V341, P1520
   Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098
   Li L, 2004, BLOOD, V104, P815, DOI 10.1182/blood-2004-01-0292
   Liton PB, 2005, INVEST OPHTH VIS SCI, V46, P183, DOI 10.1167/iovs.04-0330
   Lombardi DP, 1999, CANCER RES, V59, P5724
   Longo N, 2001, BLOOD, V98, P3717, DOI 10.1182/blood.V98.13.3717
   Lossos IS, 2002, P NATL ACAD SCI USA, V99, P8886, DOI 10.1073/pnas.132253599
   Lung HL, 2006, CANCER RES, V66, P9385, DOI 10.1158/0008-5472.CAN-06-0590
   Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523
   MASELLISSMITH A, 1994, J IMMUNOL, V152, P2768
   MIYAKE M, 1995, CANCER RES, V55, P4127
   Miyake M, 1996, CANCER RES, V56, P1244
   Montoto S, 2007, J CLIN ONCOL, V25, P2426, DOI 10.1200/JCO.2006.09.3260
   Mori M, 1998, CLIN CANCER RES, V4, P1507
   Mutter GL, 2001, GYNECOL ONCOL, V83, P177, DOI 10.1006/gyno.2001.6352
   Nakamura K, 2000, J BIOL CHEM, V275, P18284, DOI 10.1074/jbc.M907971199
   Ovalle S, 2007, INT J CANCER, V121, P2140, DOI 10.1002/ijc.22902
   PASCUAL V, 1994, J EXP MED, V180, P329, DOI 10.1084/jem.180.1.329
   PETRASCH S, 1992, BRIT J HAEMATOL, V80, P21, DOI 10.1111/j.1365-2141.1992.tb06395.x
   Shi GX, 2002, J IMMUNOL, V169, P2507, DOI 10.4049/jimmunol.169.5.2507
   Shiozawa E, 2003, PATHOL RES PRACT, V199, P293, DOI 10.1078/0344-0338-00421
   Sincock PM, 1997, J HISTOCHEM CYTOCHEM, V45, P515, DOI 10.1177/002215549704500404
   Stevenson F, 1998, IMMUNOL REV, V162, P247, DOI 10.1111/j.1600-065X.1998.tb01446.x
   Sun HG, 2005, CANCER RES, V65, P4442, DOI 10.1158/0008-5472.CAN-04-4200
   Takeda T, 2007, CANCER RES, V67, P1744, DOI 10.1158/0008-5472.CAN-06-3090
   VanRiet J, 1997, LEUKEMIA, V11, P284, DOI 10.1038/sj.leu.2400564
   Wang JC, 2007, CLIN CANCER RES, V13, P2354, DOI 10.1158/1078-0432.CCR-06-1692
   Won WJ, 2002, J IMMUNOL, V168, P5605, DOI 10.4049/jimmunol.168.11.5605
   Yang XH, 2000, CLIN CANCER RES, V6, P3424
   Yau JC, 1998, ONCOL REP, V5, P1507
   Zhong S, 2007, ONCOGENE, V26, P2621, DOI 10.1038/sj.onc.1210041
   Zöller M, 2009, NAT REV CANCER, V9, P40, DOI 10.1038/nrc2543
   Zvereff V, 2007, BRIT J CANCER, V97, P941, DOI 10.1038/sj.bjc.6603964
NR 60
TC 16
Z9 18
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD JUL
PY 2010
VL 177
IS 1
BP 377
EP 386
DI 10.2353/ajpath.2010.100048
PG 10
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 624GM
UT WOS:000279805100039
PM 20566742
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Nishio, M
   Sakakura, C
   Nagata, T
   Komiyama, S
   Miyashita, A
   Hamada, T
   Kuryu, Y
   Ikoma, H
   Kubota, T
   Kimura, A
   Nakanishi, M
   Ichikawa, D
   Fujiwara, H
   Okamoto, K
   Ochiai, T
   Kokuba, Y
   Sonoyama, T
   Ida, H
   Ito, K
   Chiba, T
   Ito, Y
   Otsuji, E
AF Nishio, Minoru
   Sakakura, Chouhei
   Nagata, Tomoyuki
   Komiyama, Sosuke
   Miyashita, Atsushi
   Hamada, Takuo
   Kuryu, Yoshiaki
   Ikoma, Hisashi
   Kubota, Takeshi
   Kimura, Akio
   Nakanishi, Masayoshi
   Ichikawa, Daisuke
   Fujiwara, Hitoshi
   Okamoto, Kazuma
   Ochiai, Toshiya
   Kokuba, Yukihito
   Sonoyama, Teruhisa
   Ida, Hiroshia
   Ito, Kosei
   Chiba, Tsutomu
   Ito, Yoshiaki
   Otsuji, Eigo
TI RUNX3 Promoter Methylation in Colorectal Cancer: Its Relationship with
   Microsatellite Instability and its Suitability as a Novel Serum Tumor
   Marker
SO ANTICANCER RESEARCH
LA English
DT Article
DE RUNX3; MSI; methylation; colorectal cancer
ID GASTRIC-CANCER; CELL-LINES; PANCREATIC-CANCER; BREAST-CANCER; EPIGENETIC
   INACTIVATION; ADVERSE PROGNOSIS; SUPPRESSOR GENES; DNA METHYLATION;
   COLON CANCERS; EXPRESSION
AB Background/Aim: RUNX3 is a novel gastric cancer tumor suppressor. RUNX3 promoter hypermethylation is associated with many types of cancer, including colorectal cancer. Furthermore, the RUNX3 promotor is one of the CpG island methylator phenotype (CIMP)-specific promotors. CIMP is a distinct phenotype associated with microsatellite instability (MSI) in colorectal cancer. In this study, the suitability of the quantitative analysis of RUNX3 promoter hypermethylation as a novel serum tumor marker was investigated. Moreover, we investigated the relationship between RUNX3 promoter methylation and MSI in colorectal cancer. Patients and Methods: A RUNX3 real-time quantitative methylation -specific PCR (RTQ-MSP) technique we developed was used to analyze the CpG sites in the RUNX3 promoter of 119 colorectal tumors and 344 sera from colorectal cancer patients. MSI analysis of 119 colorectal tumors was performed with five microsatellite markers (BAT25, BAT26, D5S346. D2S123, and D17S250). Results: Proximal colon tumors exhibited significantly higher RUNX3 methylation than their paired normal tissues (p=0.0438). Analysis of the clinicopathological parameters revealed that a proximal location (p=0.0054), lymphatic invasion (p<0.0001), and an advanced pathological stage (p=0.0018) were associated with significantly higher RUNX3 methylation. Assessment of the relationship between RUNX3 methylation and tumor MSI revealed 11 out of 13 tumors with high-frequency MSI (85%) were positive for RUNX3 hypermethylation, significantly more than the tumors with low-frequency MSI or which were microsatellite stable (34%, p=0.0070). In preoperative sera from 344 colorectal cancer patients, significantly higher RUNX3 methylation was associated with lymphatic invasion (p=0.0487) and an advanced pathological stage (p=0.0466). Post-operative follow-up data revealed that recurrence cases exhibited significantly higher preoperative serum RUNX3 methylation than non-recurrence cases (p=0.0003). Concomitant analysis of carcinoembryonic antigen (CEA) levels in the preoperative sera showed that 17.7% (61/344) were CEA-negative but RUNX3 methylation-positive, which means assessing both serum RUNX3 methylation and CEA should improve diagnosis of colorectal carcinoma. Conclusion: RTQ-MSP-based quantification of serum RUNX3 methylation is useful for the detection and monitoring of colorectal cancer.
C1 [Nishio, Minoru; Sakakura, Chouhei; Nagata, Tomoyuki; Komiyama, Sosuke; Miyashita, Atsushi; Hamada, Takuo; Kuryu, Yoshiaki; Ikoma, Hisashi; Kubota, Takeshi; Kimura, Akio; Nakanishi, Masayoshi; Ichikawa, Daisuke; Fujiwara, Hitoshi; Okamoto, Kazuma; Ochiai, Toshiya; Kokuba, Yukihito; Sonoyama, Teruhisa; Otsuji, Eigo] Kyoto Prefectural Univ Med, Dept Surg, Div Digest Surg, Grad Sch Med Sci,Kamigyo Ku, Kyoto 6028566, Japan.
   [Ida, Hiroshia; Chiba, Tsutomu] Kyoto Univ, Grad Sch Internal Med, Div Gastroenterol & Hepatol, Sakyo Ku, Kyoto 6068507, Japan.
   [Ito, Kosei] Nagasaki Univ, Grad Sch Biomed Sci, Nagasaki 8528588, Japan.
   [Ito, Yoshiaki] Proteos, Inst Mol & Cell Biol, Singapore 138673, Singapore.
C3 Kyoto Prefectural University of Medicine; Kyoto University; Nagasaki
   University; Agency for Science Technology & Research (A*STAR); A*STAR -
   Institute of Molecular & Cell Biology (IMCB)
RP Sakakura, C (通讯作者)，Kyoto Prefectural Univ Med, Dept Surg, Div Digest Surg, Grad Sch Med Sci,Kamigyo Ku, Kyoto 6028566, Japan.
EM sakakura@koto.kpu-m.ac.jp
RI Ochiai, Toshiya/AFO-6491-2022
OI Nagata, Tomoyuki/0000-0002-1461-2601
CR Araki K, 2005, CANCER SCI, V96, P227, DOI 10.1111/j.1349-7006.2005.00033.x
   Boland CR, 1998, CANCER RES, V58, P5248
   Bubb VJ, 1996, ONCOGENE, V12, P2641
   Cottrell SE, 2003, ANN NY ACAD SCI, V983, P120, DOI 10.1111/j.1749-6632.2003.tb05967.x
   Cunningham JM, 1998, CANCER RES, V58, P3455
   Esteller M, 1999, CANCER RES, V59, P67
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Feeley KM, 1999, J PATHOL, V188, P14, DOI 10.1002/(SICI)1096-9896(199905)188:1<14::AID-PATH323>3.0.CO;2-Q
   Gafà R, 2000, CANCER, V89, P2025, DOI 10.1002/1097-0142(20001115)89:10<2025::AID-CNCR1>3.0.CO;2-S
   Goebel G, 2005, DIS MARKERS, V21, P105, DOI 10.1155/2005/218759
   Goel A, 2004, INT J CANCER, V112, P754, DOI 10.1002/ijc.20472
   Goel A, 2001, GASTROENTEROLOGY, V121, P1497, DOI 10.1053/gast.2001.29978
   Grady WM, 2007, GUT, V56, P1498, DOI 10.1136/gut.2007.125732
   Graziano F, 2003, ANN ONCOL, V14, P1705, DOI 10.1093/annonc/mdg486
   Gryfe R, 2001, SURGERY, V130, P17, DOI 10.1067/msy.2001.112738
   Hanai A, 1998, JPN J CLIN ONCOL, V28, P450, DOI 10.1093/jjco/28.7.450
   Hasegawa K, 2007, CANCER SCI, V98, P838, DOI 10.1111/j.1349-7006.2007.00460.x
   Herfarth KKF, 1997, GENE CHROMOSOME CANC, V18, P42, DOI 10.1002/(SICI)1098-2264(199701)18:1<42::AID-GCC5>3.0.CO;2-1
   Hiramatsu T, 2005, PATHOBIOLOGY, V72, P316, DOI 10.1159/000091329
   Hsu PI, 2009, ANN SURG ONCOL, V16, P1686, DOI 10.1245/s10434-009-0428-2
   HUANG F, 1994, ONCOGENE, V9, P3701
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   Ito K, 2008, CANCER CELL, V14, P226, DOI 10.1016/j.ccr.2008.08.004
   Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755
   Jass JR, 1999, INT J COLORECTAL DIS, V14, P194, DOI 10.1007/s003840050211
   Jiang Y, 2008, PATHOBIOLOGY, V75, P244, DOI 10.1159/000132385
   Ku JL, 2004, ONCOGENE, V23, P6736, DOI 10.1038/sj.onc.1207731
   Lee S, 2008, PATHOL INT, V58, P104, DOI 10.1111/j.1440-1827.2007.02197.x
   Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6
   Miyagawa K, 2006, ANTICANCER RES, V26, P3633
   Mulcahy HE, 1998, CLIN CANCER RES, V4, P271
   Nomoto S, 2008, BRIT J CANCER, V98, P1690, DOI 10.1038/sj.bjc.6604333
   Ogino S, 2007, J MOL DIAGN, V9, P305, DOI 10.2353/jmoldx.2007.060170
   PISANI P, 1993, INT J CANCER, V55, P891, DOI 10.1002/ijc.2910550604
   Sakakura C, 2007, ONCOGENE, V26, P5927, DOI 10.1038/sj.onc.1210403
   Sakakura C, 2005, CLIN CANCER RES, V11, P6479, DOI 10.1158/1078-0432.CCR-05-0729
   Sakakura C, 2009, ANTICANCER RES, V29, P2619
   Salahshor S, 1999, BRIT J CANCER, V81, P190, DOI 10.1038/sj.bjc.6690676
   Shi H, 2007, EXPERT REV MOL DIAGN, V7, P519, DOI 10.1586/14737159.7.5.519
   Silva JM, 1999, CANCER RES, V59, P3251
   Soong R, 2009, BRIT J CANCER, V100, P676, DOI 10.1038/sj.bjc.6604899
   Tan SH, 2007, ONCOL REP, V18, P1225
   Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Ushijima T, 2006, J GASTROENTEROL, V41, P401, DOI 10.1007/s00535-006-1846-6
   VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901
   Wada M, 2004, ONCOGENE, V23, P2401, DOI 10.1038/sj.onc.1207395
   Wei DY, 2005, CANCER RES, V65, P4809, DOI 10.1158/0008-5472.CAN-04-3741
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Wong JJL, 2007, GUT, V56, P140, DOI 10.1136/gut.2005.088799
   Wright CM, 2000, BRIT J SURG, V87, P1197, DOI 10.1046/j.1365-2168.2000.01508.x
   Yamamoto H, 2001, Gan To Kagaku Ryoho, V28, P1299
   Yanada M, 2005, ONCOL REP, V14, P817
   Yashiro M, 2001, CANCER RES, V61, P2676
   ZAMCHECK N, 1975, HUM PATHOL, V6, P31, DOI 10.1016/S0046-8177(75)80108-0
NR 55
TC 36
Z9 45
U1 0
U2 3
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD JUL
PY 2010
VL 30
IS 7
BP 2673
EP 2682
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 637DQ
UT WOS:000280796400026
PM 20682997
DA 2025-01-12
ER

PT J
AU Licata, LA
   Hostetter, CL
   Crismale, J
   Sheth, A
   Keen, JC
AF Licata, Lauren A.
   Hostetter, Christine L.
   Crismale, James
   Sheth, Anjali
   Keen, Judith Clancy
TI The RNA-binding protein HuR regulates GATA3 mRNA stability in human
   breast cancer cell lines
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE HuR; GATA-3; MCF7; mRNA stability; BT474; ELAV1; 3 ' UTR
ID ESTROGEN-RECEPTOR-ALPHA; HISTONE DEACETYLASE INHIBITION;
   GENE-EXPRESSION; DNA METHYLTRANSFERASE; TAMOXIFEN RESISTANCE;
   MAMMARY-GLAND; ER-ALPHA; DIFFERENTIATION; ACTIVATION; DEMETHYLATION
AB Meta-analyses of microarray data indicate that GATA3 is co-expressed with estrogen receptor alpha (ER) in breast cancer cells. While the significance of this remains unclear, it is thought that GATA3 may serve as a prognostic indicator in breast tumors and may play a role in ER signaling. Recently, reciprocal regulation of GATA3 and ER transcription was demonstrated, suggesting that control of their expression is intertwined. We sought to determine whether GATA3 and ER expression was also coordinately regulated at other levels. Unlike ER, GATA3 was not under epigenetic control and was not re-expressed in the presence of DNMT or HDAC inhibitors in ER/GATA3-negative cells. However, like ER, these inhibitors decreased GATA3 expression in ER/GATA3-positive cell lines. We have previously reported that ER mRNA stability is increased through binding of the RNA-binding protein HuR/ELAV1 to the 3'untranslated region (UTR) and that DNMT and HDAC inhibitors reduce ER expression by altering this interaction. Biotin pull-down assays using a biotinylated GATA3 RNA probe confirmed that HuR also binds to the GATA3 3'UTR. Inhibition of HuR using siRNA probes decreased GATA3 mRNA, mRNA stability and protein expression, indicating that HuR plays a role in regulating GATA3 expression. Inhibition of either HuR or GATA3 reduced cell growth of MCF7 cells. Based on our findings, it is clear that coordinate regulation of ER and GATA3 occurs, however differences do exist. These findings may aid in identification of new targets that control cell growth of breast cancer cells.
C1 [Licata, Lauren A.; Hostetter, Christine L.; Crismale, James; Sheth, Anjali; Keen, Judith Clancy] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, Camden, NJ 08106 USA.
   [Licata, Lauren A.] Cooper Univ Hosp, Dept Surg, Camden, NJ USA.
C3 Rutgers University System; Rutgers University New Brunswick; Rutgers
   University Biomedical & Health Sciences; Cooper University Hospital
RP Keen, JC (通讯作者)，Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, Rm 170 E&R Bldg,401 Haddon Ave, Camden, NJ 08106 USA.
EM keenjc@umdnj.edu
OI Keen, Judith/0000-0002-2894-130X
CR Adams BD, 2007, MOL ENDOCRINOL, V21, P1132, DOI 10.1210/me.2007-0022
   Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530
   Bertucci F, 2000, HUM MOL GENET, V9, P2981, DOI 10.1093/hmg/9.20.2981
   Ciocca V, 2009, HUM PATHOL, V40, P489, DOI 10.1016/j.humpath.2008.09.010
   Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746
   FERGUSON AT, 1995, CANCER RES, V55, P2279
   Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260
   Hinman MN, 2008, CELL MOL LIFE SCI, V65, P3168, DOI 10.1007/s00018-008-8252-6
   Hoch RV, 1999, INT J CANCER, V84, P122
   Hostetter C, 2008, CANCER BIOL THER, V7, P1498, DOI 10.4161/cbt.7.9.6490
   Ing NH, 2008, J BIOL CHEM, V283, P1764, DOI 10.1074/jbc.M704745200
   Keen JC, 2003, CANCER-AM CANCER SOC, V97, P825, DOI 10.1002/cncr.11126
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   Keen JC, 2001, AM J RESP CELL MOL, V24, P58, DOI 10.1165/ajrcmb.24.1.3870
   Kenealy MR, 1996, BIOCHEM SOC T, V24, pS107, DOI 10.1042/bst024107s
   Kenealy MR, 2000, ENDOCRINOLOGY, V141, P2805, DOI 10.1210/en.141.8.2805
   Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011
   Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Liu WH, 2009, GASTROENTEROLOGY, V136, P683, DOI 10.1053/j.gastro.2008.10.029
   Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578
   Macaluso M, 2007, CANCER RES, V67, P7731, DOI 10.1158/0008-5472.CAN-07-1476
   Mehra R, 2005, CANCER RES, V65, P11259, DOI 10.1158/0008-5472.CAN-05-2495
   Miller TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200
   Pryzbylkowski P, 2008, BREAST CANCER RES TR, V111, P15, DOI 10.1007/s10549-007-9751-0
   Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   Shen DJ, 2005, BIOCHEM BIOPH RES CO, V326, P218, DOI 10.1016/j.bbrc.2004.10.214
   Usary J, 2004, ONCOGENE, V23, P7669, DOI 10.1038/sj.onc.1207966
   Wilson BJ, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-49
   Yan L, 2003, CANCER BIOL THER, V2, P552, DOI 10.4161/cbt.2.5.469
   Yang XW, 2001, CANCER RES, V61, P7025
   Yang XW, 2000, CANCER RES, V60, P6890
   Zhao JJ, 2008, J BIOL CHEM, V283, P31079, DOI 10.1074/jbc.M806041200
NR 34
TC 19
Z9 22
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JUL
PY 2010
VL 122
IS 1
BP 55
EP 63
DI 10.1007/s10549-009-0517-8
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 608WD
UT WOS:000278615800007
PM 19728080
DA 2025-01-12
ER

PT J
AU Feng, YM
   Li, XQ
   Sun, BC
   Wang, YL
   Zhang, LN
   Pan, XH
   Chen, XH
   Wang, XY
   Wang, JF
   Hao, XS
AF Feng, Yumei
   Li, Xiaoqing
   Sun, Baocun
   Wang, Yuli
   Zhang, Lina
   Pan, Xiuhua
   Chen, Xiaohui
   Wang, Xiaoyan
   Wang, Jinfeng
   Hao, Xishan
TI Evidence for a transcriptional signature of breast cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer; Gene expression profiling; Diagnosis
ID DIFFERENTIALLY EXPRESSED GENES; CDNA; MICRODISSECTION; IDENTIFICATION;
   CARCINOMAS; SINGLE; RNA
AB Cancer arises from a step-wise accumulation of genetic and epigenetic changes in oncogenes and tumor suppressor genes, followed by changes in transcription and protein profiles. To identify the intrinsic transcriptional features of breast cancer and to explore in more detail the molecular basis of breast carcinogenesis, genes differentially expressed between cancers and their paired normal breast samples in nine breast cancer patients were screened using microarray. Nine normal breast tissues and 49 breast cancer tissue samples were then clustered based on the set of differentially expressed genes. A transcriptional signature of breast cancer consisting of 188 differentially expressed genes was identified. This signature allowed the normal breast tissues to be distinguished from all of the breast cancer samples, and primary breast cancers could be classified into two phenotype-associated subgroups with different ER status and clinical outcome. Furthermore, the classification accuracy of the set of differentially expressed genes was validated in publically available breast microarray data. Moreover, the differentially expressed genes could be grouped into five subclusters involved in different biological processes of carcinogenesis. Most genes in a given subcluster interacted within an independent subnetwork, and subnetworks could cross-talk through a set of signal molecules. Thus, the transcriptional signature identified here may be an intrinsic feature of breast cancer, and it may constitute to the molecular basis of breast carcinogenesis and different phenotypes of breast cancer.
C1 [Feng, Yumei; Wang, Jinfeng] Tianjin Univ, Sch Pharmaceut Sci & Technol, Tianjin 300072, Peoples R China.
   [Feng, Yumei; Li, Xiaoqing; Wang, Yuli; Zhang, Lina; Pan, Xiuhua; Chen, Xiaohui; Wang, Xiaoyan] Tianjin Med Univ Canc Inst & Hosp, Dept Biochem & Mol Biol, Tianjin 300060, Peoples R China.
   [Feng, Yumei; Li, Xiaoqing; Sun, Baocun; Hao, Xishan] Tianjin Med Univ Canc Inst & Hosp, Minist Educ, Breast Canc Prevent & Treatment Key Lab, Tianjin 300060, Peoples R China.
   [Sun, Baocun] Tianjin Med Univ Canc Inst & Hosp, Dept Pathol, Tianjin 300060, Peoples R China.
C3 Tianjin University; Tianjin Medical University; Tianjin Medical
   University; Tianjin Medical University
RP Wang, JF (通讯作者)，Tianjin Univ, Sch Pharmaceut Sci & Technol, Tianjin 300072, Peoples R China.
EM jinfwang@hotmail.com; ymfeng@tijmu.edu.cn
RI Wang, Yuli/AGJ-1891-2022; Li, Xiao-Qing/HKO-4048-2023; Zhang,
   Li-Na/T-8909-2018; Zhao, Xiaoshan/GPF-7929-2022
OI Li, Xiao-Qing/0000-0002-9815-6040
FU Tianjin Major Program of Science and Technology [013182311]; National
   High-Tech Research Development Plan of China [2002AA2Z2011]; Program for
   Changjiang Scholars and Innovative Research Team in University
   [URT0743]; Science and Technology Commission Foundation of Tianjin
   [06YFJMJC1290]; TaiJi Co., China
FX This research was supported by the Tianjin Major Program of Science and
   Technology (013182311), the National High-Tech Research Development Plan
   of China (2002AA2Z2011), the Program for Changjiang Scholars and
   Innovative Research Team in University (URT0743), the Applied Basic
   Research Programs of Science and Technology Commission Foundation of
   Tianjin (06YFJMJC1290) and a donation from TaiJi Co., China.
CR Feng YM, 2007, BREAST CANCER RES TR, V103, P319, DOI 10.1007/s10549-006-9385-7
   Gomes LI, 2003, ANAL BIOCHEM, V321, P244, DOI 10.1016/S0003-2697(03)00466-4
   Guo Y, 2005, J VIROL, V79, P14392, DOI 10.1128/JVI.79.22.14392-14403.2005
   Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902
   Lee EJ, 2005, INT J GYNECOL CANCER, V15, P146, DOI 10.1111/j.1048-891x.2005.15016.x
   Nindl I, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-30
   Nishidate T, 2004, INT J ONCOL, V25, P797
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Smith L, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng009
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052
   TAYLORPAPADIMITRIOU J, 1989, J CELL SCI, V94, P403
   Turashvili G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-55
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15
   Zeeberg BR, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r28
NR 19
TC 13
Z9 14
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JUL
PY 2010
VL 122
IS 1
BP 65
EP 75
DI 10.1007/s10549-009-0505-z
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 608WD
UT WOS:000278615800008
PM 19728083
DA 2025-01-12
ER

PT J
AU Marik, R
   Fackler, M
   Gabrielson, E
   Zeiger, MA
   Sukumar, S
   Stearns, V
   Umbricht, CB
AF Marik, Radharani
   Fackler, MaryJo
   Gabrielson, Edward
   Zeiger, Martha A.
   Sukumar, Saraswati
   Stearns, Vered
   Umbricht, Christopher B.
TI DNA methylation-related vitamin D receptor insensitivity in breast
   cancer
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE VDR; DNA methylation; breast cancer; splice variants
ID DRUG-INDUCED OSTEOMALACIA; N-TERMINAL VARIANT; MESSENGER-RNA;
   CELL-LINES; 25-HYDROXYVITAMIN D-1-ALPHA-HYDROXYLASE; SPLICE VARIANTS;
   EXPRESSION; GENE; D-3; CYP3A4
AB Calcitriol (1 alpha, 25(OH)(2)-Vitamin D3) binds to the vitamin D receptor (VDR) and regulates differentiation of the normal mammary gland, and may therefore be useful in breast cancer treatment or prevention. Many breast cancer cells are, however, resistant to Calcitriol. In this study, we investigated the resistance mechanism and the role of epigenetic silencing of VDR by promoter hypermethylation. Bisulfite sequencing of the VDR promoter region revealed methylated CpG islands at -700 base pairs (bp) upstream and near the transcription start site. VDR CpG islands were demethylated by 5'deoxy-azacytidine treatment, and this was accompanied by a parallel increase in VDR mRNA levels in breast cancer cell lines. Quantitative methylation-specific PCR analyses confirmed hypermethylation of these CpG islands in primary tumors, and its absence in normal breast tissue. VDR transcripts detected in breast cancers were predominantly 5-truncated, while normal breast tissue expressed full-length transcripts. Consistent with this observation, genes containing the VDR-responsive element (VDRE), such as cytochrome p450 hydroxylases, p21 or C/EBP were underexpressed in breast cancers compared to normal breast samples. Expression of the active longer transcripts of VDR was restored with 5'deoxy-Azacytidine (AZA) treatment, with a concurrent increase in expression of VDRE-containing genes. Thus, promoter methylation-mediated silencing of expression of the functional variants of VDR may contribute to reduced expression of downstream effectors of the VDR pathway and subsequent Calcitriol insensitivity in breast cancer. These data suggest that pharmacological reversal of VDR methylation may re-establish breast cancer cell susceptibility to differentiation therapy using Calcitriol.
C1 [Marik, Radharani; Zeiger, Martha A.; Umbricht, Christopher B.] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA.
   [Gabrielson, Edward; Sukumar, Saraswati; Umbricht, Christopher B.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   [Fackler, MaryJo; Zeiger, Martha A.; Sukumar, Saraswati; Stearns, Vered; Umbricht, Christopher B.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   University
RP Umbricht, CB (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA.
EM cumbrich@jhmi.edu
FU Susan G. Komen Foundation; Department of Defense [DAMD17-03-1-0547]; NCI
   [P50 CA088843-06A1]; Breast Cancer Research Foundation
FX Susan G. Komen Foundation and Department of Defense DAMD17-03-1-0547
   (C.B.U.), NCI P50 CA088843-06A1 (S.S., C.B.U., VS.), Breast Cancer
   Research Foundation (V.S.).
CR Anderson MG, 2006, CANCER CHEMOTH PHARM, V57, P234, DOI 10.1007/s00280-005-0059-7
   Anttila MA, 1999, BRIT J CANCER, V79, P1870, DOI 10.1038/sj.bjc.6690298
   Bais AJ, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-22
   BAND V, 1990, CANCER RES, V50, P7351
   Banwell CM, 2003, RECENT RESULTS CANC, V164, P83
   BERGSTRAESSER LM, 1993, CANCER RES, V53, P2644
   Chung I, 2007, J BIOL CHEM
   COLSTON K, 1981, ENDOCRINOLOGY, V108, P1083, DOI 10.1210/endo-108-3-1083
   Colston KW, 2002, ENDOCR-RELAT CANCER, V9, P45, DOI 10.1677/erc.0.0090045
   Crofts LA, 1998, P NATL ACAD SCI USA, V95, P10529, DOI 10.1073/pnas.95.18.10529
   Ellis PA, 1997, BRIT J CANCER, V76, P480, DOI 10.1038/bjc.1997.413
   Esteban LM, 2005, BIOCHEM BIOPH RES CO, V334, P9, DOI 10.1016/j.bbrc.2005.06.054
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Fischer D, 2009, ANTICANCER RES, V29, P3627
   Gardiner EM, 2004, J STEROID BIOCHEM, V89-90, P233, DOI 10.1016/j.jsbmb.2004.03.078
   Grant WB, 2002, CANCER-AM CANCER SOC, V94, P1867, DOI 10.1002/cncr.10427
   Gupta RP, 2005, J CLIN ENDOCR METAB, V90, P1210, DOI 10.1210/jc.2004-0966
   Halsall JA, 2007, J STEROID BIOCHEM, V103, P352, DOI 10.1016/j.jsbmb.2006.12.046
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Kapucuoglu N, 2003, CANCER LETT, V202, P17, DOI 10.1016/j.canlet.2003.08.015
   Kemmis CM, 2008, J CELL BIOCHEM, V105, P980, DOI 10.1002/jcb.21896
   Lechner D, 2007, MOL CELL ENDOCRINOL, V263, P55, DOI 10.1016/j.mce.2006.08.009
   Lin YS, 2002, MOL PHARMACOL, V62, P162, DOI 10.1124/mol.62.1.162
   McCarthy K, 2009, ANTICANCER RES, V29, P155
   Miller CW, 1997, MOL CARCINOGEN, V19, P254, DOI 10.1002/(SICI)1098-2744(199708)19:4<254::AID-MC6>3.0.CO;2-C
   Miyamoto K, 1997, MOL ENDOCRINOL, V11, P1165, DOI 10.1210/me.11.8.1165
   Norman AW, 1998, AM J CLIN NUTR, V67, P1108, DOI 10.1093/ajcn/67.6.1108
   Plante BJ, 2009, REPROD BIOL ENDOCRIN, V7, DOI 10.1186/1477-7827-7-15
   Pospechova K, 2009, MOL CELL ENDOCRINOL, V299, P178, DOI 10.1016/j.mce.2008.12.003
   Qi XM, 2002, J BIOL CHEM, V277, P25884, DOI 10.1074/jbc.M203039200
   Raimondi S, 2009, CARCINOGENESIS, V30, P1170, DOI 10.1093/carcin/bgp103
   Rebbaa A, 2006, CELL DEATH DIFFER, V13, P1960, DOI 10.1038/sj.cdd.4401895
   Saramäki A, 2009, J BIOL CHEM, V284, P8073, DOI 10.1074/jbc.M808090200
   Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157
   Schwartz GG, 2004, CARCINOGENESIS, V25, P1015, DOI 10.1093/carcin/bgh086
   Smirnoff P, 1999, ONCOL RES, V11, P255
   Suman G, 2009, CANCER BIOMARK, V5, P33, DOI 10.3233/CBM-2009-0569
   Sunn KL, 2001, MOL ENDOCRINOL, V15, P1599, DOI 10.1210/me.15.9.1599
   Sunn KL, 2005, BIOCHEM J, V388, P509, DOI 10.1042/BJ20042040
   Takai Daiya, 2003, In Silico Biology, V3, P235
   Theodoropoulos C, 2003, CLIN ENDOCRINOL, V58, P489, DOI 10.1046/j.1365-2265.2003.01743.x
   Townsend K, 2005, CLIN CANCER RES, V11, P3579, DOI 10.1158/1078-0432.CCR-04-2359
   van den Bemd GJCM, 2002, CURR DRUG TARGETS, V3, P85, DOI 10.2174/1389450023348064
   Whitcomb BP, 2003, CLIN CANCER RES, V9, P2277
   Wietzke JA, 2005, MOL CELL ENDOCRINOL, V230, P59, DOI 10.1016/j.mce.2004.11.001
   Wietzke JA, 2003, J STEROID BIOCHEM, V84, P149, DOI 10.1016/S0960-0760(03)00024-4
   Wu S, 2007, ENDOCRINOLOGY, V148, P3410, DOI 10.1210/en.2006-1388
   Xie ZJ, 2002, J BIOL CHEM, V277, P36987, DOI 10.1074/jbc.M201404200
   Xu Y, 2006, MOL PHARMACOL, V69, P56, DOI 10.1124/mol.105.017392
   Yabushita H, 1996, J Obstet Gynaecol Res, V22, P529
   Zhou CC, 2006, J CLIN INVEST, V116, P1703, DOI 10.1172/JCI27793
   Zinser G, 2002, DEVELOPMENT, V129, P3067
NR 52
TC 79
Z9 93
U1 0
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD JUL 1
PY 2010
VL 10
IS 1
BP 44
EP 53
DI 10.4161/cbt.10.1.11994
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 621PS
UT WOS:000279593900008
PM 20431345
OA Green Published
DA 2025-01-12
ER

PT J
AU Zhang, SY
   Lu, JA
   Zhao, XY
   Wu, WT
   Wang, HB
   Lu, J
   Wu, QH
   Chen, X
   Fan, WW
   Chen, HY
   Wang, F
   Hu, ZB
   Jin, L
   Wei, QY
   Shen, HB
   Huang, W
   Lu, DR
AF Zhang, Shuyu
   Lu, Juan
   Zhao, Xueying
   Wu, Wenting
   Wang, Huibo
   Lu, Jun
   Wu, Qihan
   Chen, Xin
   Fan, Weiwei
   Chen, Hongyan
   Wang, Feng
   Hu, Zhibin
   Jin, Li
   Wei, Qingyi
   Shen, Hongbing
   Huang, Wei
   Lu, Daru
TI A variant in the <i>CHEK2</i> promoter at a methylation site relieves
   transcriptional repression and confers reduced risk of lung cancer
SO CARCINOGENESIS
LA English
DT Article
ID BREAST-CANCER; DNA-DAMAGE; CIGARETTE-SMOKING; CHK2; MUTATIONS; GENE;
   SUSCEPTIBILITY; EXPRESSION; SP1; CHEK2-ASTERISK-1100DELC
AB Checkpoint kinase (CHEK) 2, a tumor suppressor gene, plays an essential role in the DNA damage checkpoint response cascade. We first investigated two polymorphisms in the proximal promoter of the CHEK2 gene and evaluated their associations with the risk of lung cancer in a case-control study using 500 incident lung cancer cases and 517 cancer-free controls. We found that CHEK2 rs2236141 -48 G > A was significantly associated with lung cancer risk (P = 0.0018). Similar results were obtained in a follow-up replication study in 575 lung cancer patients and 589 controls (P = 0.042). Quantitative polymerase chain reaction showed that individuals with the G allele had lower levels of CHEK2 transcripts in peripheral blood mononuclear cells and normal lung tissues. The -48 G -> A variant eliminated a methylation site and thereby relieve the transcriptional repression of CHEK2. Therefore, this polymorphism affected downstream transcription through genetic and epigenetic modifications. Luciferase reporter assays demonstrated that the major G allele significantly attenuated reporter gene expression when methylated. Electrophoretic Mobility shift assays and surface plasmon resonance revealed that the methylated G allele increased transcription factor accessibility. We used in vivo chromatin immunoprecipitation to confirm that the relevant transcription factor was Sp1. Using lung tissue heterozygous for the G/A single-nucleotide polymorphism, we found that Sp1 acted as a repressor and had a stronger binding affinity for the G allele. These results support our hypothesis that the CHEK2 rs2236141 variant modifies lung cancer susceptibility in the Chinese population by affecting CHEK2 expression.
C1 [Zhang, Shuyu; Lu, Juan; Zhao, Xueying; Wu, Wenting; Wang, Huibo; Fan, Weiwei; Chen, Hongyan; Wang, Feng; Jin, Li; Lu, Daru] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200433, Peoples R China.
   [Zhang, Shuyu; Lu, Juan; Zhao, Xueying; Wu, Wenting; Wang, Huibo; Fan, Weiwei; Chen, Hongyan; Wang, Feng; Jin, Li; Lu, Daru] Fudan Univ, Sch Life Sci, MOE Key Lab Contemporary Anthropol, Shanghai 200433, Peoples R China.
   [Lu, Jun] Fuzhou Gen Hosp, Organ Transplant Inst, Fuzhou 350025, Peoples R China.
   [Wu, Qihan; Chen, Xin] E China Normal Univ, Sch Life Sci, Dept Biomed, Shanghai 200062, Peoples R China.
   [Hu, Zhibin; Shen, Hongbing] Nanjing Med Univ, Canc Res Ctr, Dept Epidemiol & Biostat, Nanjing 210029, Peoples R China.
   [Wei, Qingyi] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA.
   [Huang, Wei] Chinese Natl Human Genome Ctr Shanghai, Dept Genet, Shanghai 201203, Peoples R China.
C3 Fudan University; Fudan University; East China Normal University;
   Nanjing Medical University; University of Texas System; UTMD Anderson
   Cancer Center
RP Lu, DR (通讯作者)，Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200433, Peoples R China.
EM drlu@fudan.edu.cn
RI Wei, Yingying/HLW-6638-2023; Chen, Hongyan/R-8238-2019; Frank,
   Viki/GXZ-9902-2022; Wang, Huibo/KRQ-8650-2024; Jin, Li/M-5063-2019;
   shen, hong/HTQ-6147-2023; wu, wenting/Q-4979-2016; Wang,
   Feng/G-4847-2015; Zhao, Xueying/KXR-5029-2024
OI Jin, Li/0000-0001-9201-2321
FU Shanghai Science and Technology Key Project [09JC1402200]; Shanghai
   International Cooperation Programme [10410709100]; Doctoral Candidate
   Innovation Research Support Program by Science & Technology Review
   [kjdb200902-2]; National Natural Science Foundation [30800622]
FX Shanghai Science and Technology Key Project (09JC1402200); Shanghai
   International Cooperation Programme (10410709100); Doctoral Candidate
   Innovation Research Support Program by Science & Technology Review
   (kjdb200902-2); and National Natural Science Foundation (30800622).
CR Ahn J, 2004, DNA REPAIR, V3, P1039, DOI 10.1016/j.dnarep.2004.03.033
   Bahassi EM, 2007, MUTAT RES-FUND MOL M, V616, P201, DOI 10.1016/j.mrfmmm.2006.11.025
   Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7
   Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528
   Brennan P, 2007, HUM MOL GENET, V16, P1794, DOI 10.1093/hmg/ddm127
   Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925
   Cybulski C, 2004, AM J HUM GENET, V75, P1131, DOI 10.1086/426403
   Cybulski C, 2008, CARCINOGENESIS, V29, P762, DOI 10.1093/carcin/bgn044
   Dong XY, 2003, AM J HUM GENET, V72, P270, DOI 10.1086/346094
   Driver KE, 2008, CARCINOGENESIS, V29, P333, DOI 10.1093/carcin/bgm284
   Estève PO, 2007, J BIOL CHEM, V282, P2615, DOI 10.1074/jbc.M606203200
   Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124
   Florescu A, 2009, THER DRUG MONIT, V31, P14, DOI 10.1097/FTD.0b013e3181957a3b
   Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65
   Hangaishi A, 2002, BLOOD, V99, P3075, DOI 10.1182/blood.V99.8.3075
   Henderson B, 2008, ATHEROSCLEROSIS, V201, P298, DOI 10.1016/j.atherosclerosis.2008.02.022
   Hoeijmakers JHJ, 2007, MECH AGEING DEV, V128, P460, DOI 10.1016/j.mad.2007.05.002
   Hofmann WK, 2001, LEUKEMIA RES, V25, P333, DOI 10.1016/S0145-2126(00)00130-2
   Hu ZB, 2007, HUM MUTAT, V28, P431, DOI 10.1002/humu.20462
   Kilpivaara O, 2004, INT J CANCER, V111, P543, DOI 10.1002/ijc.20299
   Kim DS, 2009, LUNG CANCER, V65, P247, DOI 10.1016/j.lungcan.2009.03.011
   Kleibl Z, 2009, EUR J CANCER, V45, P618, DOI 10.1016/j.ejca.2008.09.022
   Li RG, 1996, J BIOL CHEM, V271, P18925, DOI 10.1074/jbc.271.31.18925
   Lipton L, 2003, CANCER LETT, V200, P149, DOI 10.1016/S0304-3835(03)00391-4
   Matsuoka S, 2001, CANCER RES, V61, P5362
   Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879
   Miller CW, 2002, GENE CHROMOSOME CANC, V33, P17, DOI 10.1002/gcc.1207
   Ogra Y, 2001, J BIOL CHEM, V276, P16534, DOI 10.1074/jbc.M100570200
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Raveendran M, 2005, FEBS LETT, V579, P733, DOI 10.1016/j.febslet.2004.12.052
   SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419
   Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011
   Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974
   Su YC, 1998, AM J RESP CELL MOL, V19, P819, DOI 10.1165/ajrcmb.19.5.3091
   Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943
   Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6
   Walsh T, 2006, JAMA-J AM MED ASSOC, V295, P1379, DOI 10.1001/jama.295.12.1379
   Wang HW, 2010, LIFE SCI, V86, P185, DOI 10.1016/j.lfs.2009.11.023
   Williams LH, 2006, CLIN CANCER RES, V12, P6967, DOI 10.1158/1078-0432.CCR-06-1770
   Won JJ, 2002, FASEB J, V16, P1943, DOI 10.1096/fj.02-0311fje
   Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869
   Zaid A, 2001, EUR J BIOCHEM, V268, P5497, DOI 10.1046/j.1432-1033.2001.02453.x
   Zhang PL, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-14
   Zienolddiny S, 2006, CARCINOGENESIS, V27, P560, DOI 10.1093/carcin/bgi232
NR 44
TC 24
Z9 28
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD JUL
PY 2010
VL 31
IS 7
BP 1251
EP 1258
DI 10.1093/carcin/bgq089
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 620BD
UT WOS:000279473100011
PM 20462940
OA Bronze
DA 2025-01-12
ER

PT J
AU Healey, MA
   Deaton, SL
   Alder, JK
   Winnepenninckx, V
   Casero, RA
   Herman, JG
AF Healey, Megan A.
   Deaton, Staci L.
   Alder, Jonathan K.
   Winnepenninckx, Veronique
   Casero, Robert A., Jr.
   Herman, James G.
TI Id1 overexpression is independent of repression and epigenetic silencing
   of tumor suppressor genes in melanoma
SO EPIGENETICS
LA English
DT Article
DE Id1; thrombospondin; melanoma; DNA methylation; oncogene
ID CPG ISLAND METHYLATION; DNA HYPERMETHYLATION; CELLULAR SENESCENCE;
   METHYLTRANSFERASE RECRUITMENT; TRANSCRIPTIONAL REPRESSION;
   THROMBOSPONDIN-1 GENE; TARGET PROMOTERS; PROGENITOR CELLS; LUNG
   METASTASIS; BREAST-CANCER
AB The full molecular consequences of oncogene activation during tumorigenesis are not well understood, but several studies have recently linked oncogene activation to epigenetic silencing of specific genes.(1,2) Transcriptional repressor Id1 is overexpressed in many malignancies including melanoma, and Id1 targets include tumor suppressor genes TSP1, CDKN2A (p16) and CDKN1A (p21), which are frequently epigenetically silenced in cancer. We confirmed that both TSP1 and CDKN2A have abnormal promoter region DNA methylation in primary melanoma, but the mechanism by which this silencing occurs remains unknown. Here we explore the effects of stable lentiviral Id1 overexpression on the expression of these Id1 target genes in human melanoma cell lines. Overexpressed Id1 was functional and bound transcriptional activator E2A, but did not sequester E2A from gene promoters and repress gene expression. Therefore, these Id1 target genes were resistant to Id1-mediated gene silencing. Our results suggest that Id1 activation may need to occur at discrete stages in cooperation with additional gene dysregulation to repress and induce epigenetic silencing of tumor suppressor genes during melanoma progression.
C1 [Healey, Megan A.; Casero, Robert A., Jr.; Herman, James G.] Johns Hopkins Univ, Sch Med, Canc Biol Program, Baltimore, MD 21218 USA.
   [Deaton, Staci L.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.
   [Deaton, Staci L.] Johns Hopkins Univ, Sch Med, Dept Pharmacol, Baltimore, MD 21205 USA.
   [Alder, Jonathan K.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Div Immunol, Baltimore, MD 21205 USA.
   [Alder, Jonathan K.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Div Hematopoiesis, Baltimore, MD 21205 USA.
   [Winnepenninckx, Veronique] Maastricht Univ, GROW Sch Oncol & Dev Biol, Dept Pathol, Maastricht, Netherlands.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   University; Johns Hopkins University; Johns Hopkins Medicine; Johns
   Hopkins University; Johns Hopkins Medicine; Maastricht University
RP Herman, JG (通讯作者)，Johns Hopkins Univ, Sch Med, Canc Biol Program, Baltimore, MD 21218 USA.
EM hermanji@jhmi.edu
RI Alder, Jonathan/AAF-3540-2020
OI Casero, Robert/0000-0001-5653-3306; Alder, Jonathan/0000-0003-3741-6512
FU NIH [CA127055]
FX We thank R. Alani, C. Civin and X.-B. Yu for technical advice and
   reagents. We thank B. Ryu for BRAF sequencing data. This work was
   supported entirely by NIH grant CA127055 James G. Herman, MD.
CR Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398
   Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509
   Connerney J, 2008, DEV BIOL, V318, P323, DOI 10.1016/j.ydbio.2008.03.037
   Cummings SD, 2008, MOL CARCINOGEN, V47, P653, DOI 10.1002/mc.20422
   Darby S, 2008, J PATHOL, V214, P394, DOI 10.1002/path.2292
   Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173
   Fahrner JA, 2002, CANCER RES, V62, P7213
   FRAMSON P, 1993, J BIOL CHEM, V268, P4989
   Gao DC, 2008, SCIENCE, V319, P195, DOI 10.1126/science.1150224
   Gazin C, 2007, NATURE, V449, P1073, DOI 10.1038/nature06251
   Gonzalgo ML, 1997, CANCER RES, V57, P5336
   Gupta GP, 2007, P NATL ACAD SCI USA, V104, P19506, DOI 10.1073/pnas.0709185104
   Lee CH, 2005, CANCER GENE THER, V12, P175, DOI 10.1038/sj.cgt.7700777
   Li Q, 1999, ONCOGENE, V18, P3284, DOI 10.1038/sj.onc.1202663
   Markovic SN, 2007, AM J CLIN ONCOL-CANC, V30, P303, DOI 10.1097/01.coc.0000256104.80089.35
   Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131
   Opavsky R, 2007, PLOS GENET, V3, P1757, DOI 10.1371/journal.pgen.0030167
   Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673
   Perk J, 2006, CANCER RES, V66, P10870, DOI 10.1158/0008-5472.CAN-06-2643
   Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888
   Puto LA, 2008, GENE DEV, V22, P998, DOI 10.1101/gad.1632208
   Rofstad EK, 2003, CANCER RES, V63, P4055
   Roman-Gomez J, 2002, BLOOD, V99, P2291, DOI 10.1182/blood.V99.7.2291
   Ryu B, 2007, INT J CANCER, V121, P1705, DOI 10.1002/ijc.22875
   Salomon R, 2009, J HISTOCHEM CYTOCHEM, V57, P599, DOI 10.1369/jhc.2009.953182
   Schoppmann SF, 2003, INT J CANCER, V104, P677, DOI 10.1002/ijc.11009
   Straume O, 2005, BRIT J CANCER, V93, P933, DOI 10.1038/sj.bjc.6602792
   Sun RJ, 2009, BIOCHEM J, V419, P457, DOI 10.1042/BJ20080515
   Swarbrick A, 2008, P NATL ACAD SCI USA, V105, P5402, DOI 10.1073/pnas.0801505105
   Takahashi E, 2004, BIOCHEM BIOPH RES CO, V325, P1136, DOI 10.1016/j.bbrc.2004.10.148
   Tanaka K, 1998, J BIOL CHEM, V273, P25922, DOI 10.1074/jbc.273.40.25922
   Tellez CS, 2009, MELANOMA RES, V19, P146, DOI 10.1097/CMR.0b013e32832b274e
   Tiwari VK, 2008, PLOS BIOL, V6, P2911, DOI 10.1371/journal.pbio.0060306
   Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087
   Volpert OV, 2002, CANCER CELL, V2, P473, DOI 10.1016/S1535-6108(02)00209-X
   Winnepenninckx VR, 2006, JNCI-J NATL CANCER I, V98, P472, DOI 10.1093/jnci/djj103
   Yang QW, 2003, CANCER RES, V63, P6299
   Yu XB, 2003, MOL THER, V7, P827, DOI 10.1016/S1525-0016(03)00104-7
   Zinn RL, 2007, CANCER RES, V67, P194, DOI 10.1158/0008-5472.CAN-06-3396
NR 39
TC 7
Z9 12
U1 0
U2 4
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1559-2294
J9 EPIGENETICS-US
JI Epigenetics
PD JUL 1
PY 2010
VL 5
IS 5
BP 410
EP 421
DI 10.4161/epi.5.5.11929
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 629OQ
UT WOS:000280209900009
PM 20484992
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Albergaria, A
   Ribeiro, AS
   Pinho, S
   Milanezi, F
   Carneiro, V
   Sousa, B
   Sousa, S
   Oliveira, C
   Machado, JC
   Seruca, R
   Paredes, J
   Schmitt, F
AF Albergaria, Andre
   Ribeiro, Ana Sofia
   Pinho, Sandra
   Milanezi, Fernanda
   Carneiro, Vitor
   Sousa, Barbara
   Sousa, Sonia
   Oliveira, Carla
   Machado, Jose Carlos
   Seruca, Raquel
   Paredes, Joana
   Schmitt, Fernando
TI ICI 182,780 induces P-cadherin overexpression in breast cancer cells
   through chromatin remodelling at the promoter level: a role for C/EBPβ
   in <i>CDH3</i> gene activation
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID ESTROGEN-RECEPTOR MODULATORS; BINDING-PROTEIN BETA; HUMAN GENOME;
   PROGNOSTIC-SIGNIFICANCE; TRANSCRIPTION FACTOR; ADHESION MOLECULES;
   EPITHELIAL-CELLS; MAMMARY-GLAND; IN-SITU; EXPRESSION
AB CDH3/P-cadherin is a classical cadherin. Overexpression of which has been associated with proliferative lesions of high histological grade, decreased cell polarity and poor survival of patients with breast cancer. In vitro studies showed that it can be up-regulated by ICI 182,780, suggesting that the lack of ER alpha signalling is responsible for the aberrant P-cadherin overexpression and for its role in inducing breast cancer cell invasion and migration. However, the mechanism by which ER-signalling inhibition leads to P-cadherin expression is still unknown. The aim of this study was to explore the molecular mechanism linking the ER alpha-signalling and P-cadherin-regulated expression in breast cancer cell lines. This study showed that ICI 182,780 is able to increase CDH3 promoter activity, inducing high levels of the active chromatin mark H3 lysine 4 dimethylation. We also observed, for the first time, that the transcription factor C/EBP beta is able to up-regulate CDH3 promoter activity in breast cancer cells. Moreover, we showed that the expression of P-cadherin and C/EBP beta are highly associated in human breast carcinomas and linked with a worse prognosis of breast cancer patients. This study demonstrates the existence of an epigenetic regulation by which ICI 182,780 up-regulates P-cadherin expression in MCF-7/AZ breast cancer cells through chromatin remodelling at CDH3 promoter, bringing forward the growing evidence that ER alpha signalling-abrogation by anti-oestrogens is able to induce the expression of ER alpha-repressed genes which, in the appropriate cell biology context, may contribute to a breast cancer cell invasion phenotype.
   CDH3 GenBank accession no. NT_010498.
C1 [Albergaria, Andre; Ribeiro, Ana Sofia; Milanezi, Fernanda; Sousa, Barbara; Sousa, Sonia; Oliveira, Carla; Machado, Jose Carlos; Seruca, Raquel; Paredes, Joana; Schmitt, Fernando] Porto Univ IPATIMUP, Inst Mol Pathol & Immunol, Canc Genet Grp, P-4200465 Oporto, Portugal.
   [Albergaria, Andre] Univ Minho, Sch Hlth Sci, Inst Life & Hlth Sci ICVS, P-4710057 Braga, Portugal.
   [Pinho, Sandra] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, London W12 0NN, England.
   [Carneiro, Vitor] Hosp Divino Espirito Santo, Dept Pathol, P-9500370 Ponta Delgada, Portugal.
   [Machado, Jose Carlos; Schmitt, Fernando] Univ Porto, Fac Med, Dept Pathol, P-4200319 Oporto, Portugal.
C3 Universidade do Porto; Universidade do Minho; Imperial College London;
   Universidade do Porto
RP Schmitt, F (通讯作者)，Porto Univ IPATIMUP, Inst Mol Pathol & Immunol, Canc Genet Grp, Rua Dr Roberto Frias S-N, P-4200465 Oporto, Portugal.
EM fschmitt@ipatimup.pt
RI seruca, raquel/F-8187-2011; Pinho, Sandra/GWC-8029-2022; Paredes,
   Joana/F-8224-2011; Oliveira, Carla/F-8188-2011; Sousa,
   Barbara/K-8854-2014; Pais Ribeiro, Ana Sofia/J-7334-2013; Schmitt,
   Fernando/A-5270-2008; Albergaria, Andre/J-6162-2013; Machado, Jose
   Carlos/C-5907-2009
OI Schmitt, Fernando/0000-0003-1006-6946; Paredes,
   Joana/0000-0002-1076-1343; Oliveira, Carla/0000-0001-8340-2264; Sousa,
   Barbara/0000-0002-0990-022X; Pais Ribeiro, Ana
   Sofia/0000-0002-9698-9233; Pinho, Sandra/0000-0002-5241-7364; Schmitt,
   Fernando/0000-0002-3711-8681; Seruca, Raquel/0000-0002-8851-4166;
   Albergaria, Andre/0000-0002-2315-2360; Machado, Jose
   Carlos/0000-0003-4741-8415
FU FCT-Portuguese Foundation for Science and Technology
   [SFRH/BD/15316/2005, SFRH/BD/36096/2007]; FCT [POCI/BIA-BCM/59252/2004];
   Fundação para a Ciência e a Tecnologia [POCI/BIA-BCM/59252/2004,
   SFRH/BD/15316/2005, SFRH/BD/36096/2007] Funding Source: FCT
FX This work was supported by research grants from FCT-Portuguese
   Foundation for Science and Technology [grant numbers SFRH/BD/15316/2005
   to A. A. and SFRH/BD/36096/2007 to A. S. R.]. The work was mainly
   supported by a scientific project (POCI/BIA-BCM/59252/2004) funded by
   FCT. IPATIMUP is an Associate Laboratory of the Portuguese Ministry of
   Science, Technology and Higher Education and is partially supported by
   FCT.
CR Albergaria A, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2327
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Baxter J, 2004, EMBO J, V23, P4462, DOI 10.1038/sj.emboj.7600414
   Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874
   Borley AC, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2206
   Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429
   Cowell LN, 2006, ONCOGENE, V25, P7597, DOI 10.1038/sj.onc.1209747
   Faraldo MM, 2007, FEBS LETT, V581, P831, DOI 10.1016/j.febslet.2007.01.053
   Frasor J, 2006, CANCER RES, V66, P7334, DOI 10.1158/0008-5472.CAN-05-4269
   Gamallo C, 2001, MODERN PATHOL, V14, P650, DOI 10.1038/modpathol.3880367
   Gee JMW, 2006, ENDOCR-RELAT CANCER, V13, pS77, DOI 10.1677/erc.1.01274
   Goodwin M, 2004, J MOL HISTOL, V35, P839, DOI 10.1007/s10735-004-1833-2
   Howell A, 2000, EUR J CANCER, V36, pS87
   Hutcheson IR, 2006, ENDOCR-RELAT CANCER, V13, pS89, DOI 10.1677/erc.1.01279
   Jones HE, 2006, ENDOCR-RELAT CANCER, V13, pS45, DOI 10.1677/erc.1.01275
   Koch CM, 2007, GENOME RES, V17, P691, DOI 10.1101/gr.5704207
   Matos I, 2005, VIRCHOWS ARCH, V447, P688, DOI 10.1007/s00428-005-0010-7
   McKenna N, 2000, NAT MED, V6, P960, DOI 10.1038/79637
   McKenna NJ, 2001, ANN NY ACAD SCI, V949, P3
   Mello MLS, 2007, MUTAT RES-FUND MOL M, V617, P1, DOI 10.1016/j.mrfmmm.2006.08.013
   Milde-Langosch K, 2003, BREAST CANCER RES TR, V79, P175, DOI 10.1023/A:1023929504884
   Milicic A, 2008, CANCER RES, V68, P7760, DOI 10.1158/0008-5472.CAN-08-0020
   Nicholson RI, 2005, ENDOCR-RELAT CANCER, V12, pS29, DOI 10.1677/erc.1.00991
   Paredes J, 2008, J CLIN PATHOL, V61, P856, DOI 10.1136/jcp.2007.052704
   Paredes J, 2005, CLIN CANCER RES, V11, P5869, DOI 10.1158/1078-0432.CCR-05-0059
   Paredes J, 2004, CANCER RES, V64, P8309, DOI 10.1158/0008-5472.CAN-04-0795
   Paredes J, 2002, VIRCHOWS ARCH, V440, P16, DOI 10.1007/s004280100487
   Paredes J, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1774
   Paredes J, 2007, VIRCHOWS ARCH, V450, P73, DOI 10.1007/s00428-006-0334-y
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Pinskaya M, 2009, EPIGENETICS-US, V4, P302, DOI 10.4161/epi.4.5.9369
   Ribeiro AS, 2010, ONCOGENE, V29, P392, DOI 10.1038/onc.2009.338
   Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907
   Sato N, 2003, CANCER RES, V63, P4158
   Sato N, 2003, CANCER RES, V63, P3735
   Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917
   Shimomura Y, 2008, DEVELOPMENT, V135, P743, DOI 10.1242/dev.006718
   Soler AP, 1999, CANCER-AM CANCER SOC, V86, P1263, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1263::AID-CNCR23>3.3.CO;2-U
   Tsutsumida A, 2004, INT J ONCOL, V25, P1415
   Varshochi R, 2005, J BIOL CHEM, V280, P3185, DOI 10.1074/jbc.M408063200
   Visram H, 2006, CANCER BIOL THER, V5, P1677, DOI 10.4161/cbt.5.12.3378
   Wheelock MJ, 2001, J MAMMARY GLAND BIOL, V6, P275, DOI 10.1023/A:1011319507155
   Zahnow CA, 2002, BREAST CANCER RES, V4, P109, DOI 10.1186/bcr428
   Zahnow CA, 1997, J NATL CANCER I, V89, P1887, DOI 10.1093/jnci/89.24.1887
   Zahnow CA, 2001, CANCER RES, V61, P261
   Zahnow CA, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001033
NR 46
TC 16
Z9 21
U1 0
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JUL 1
PY 2010
VL 19
IS 13
BP 2554
EP 2566
DI 10.1093/hmg/ddq134
PG 13
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 622OX
UT WOS:000279674200002
PM 20385540
OA Bronze
DA 2025-01-12
ER

PT J
AU Vardi, A
   Bosviel, R
   Rabiau, N
   Adjakly, M
   Satih, S
   Dechelotte, P
   Boiteux, JP
   Fontana, L
   Bignon, YJ
   Guy, L
   Bernard-Gallon, DJ
AF Vardi, Adam
   Bosviel, Remy
   Rabiau, Nadege
   Adjakly, Mawussi
   Satih, Samir
   Dechelotte, Pierre
   Boiteux, Jean-Paul
   Fontana, Luc
   Bignon, Yves-Jean
   Guy, Laurent
   Bernard-Gallon, Dominique J.
TI Soy Phytoestrogens Modify DNA Methylation of <i>GSTP1</i>,
   <i>RASSF1A</i>, <i>EPH2</i> and <i>BRCA1</i> Promoter in Prostate Cancer
   Cells
SO IN VIVO
LA English
DT Article
DE 5-Azacytidine; daidzein; genistein; immunohistochemistry;
   methylation-specific-PCR; prostate cancer; GSTP1; EPHB2; RASSF1A; BRCA1
ID GENE; HYPERMETHYLATION; GENISTEIN; REACTIVATION; EXPRESSION; REVERSAL;
   MUTATION; GROWTH
AB Background: The aim of this study was to determine the effects of soy phytoestrogens on the methylation of promoter genes in prostate tumors. The incidence of prostate cancer in Asia is thirty percent lower than in Western countries. Since soy phytoestrogens represent a large portion of the Asian diet, evidence suggests their protective effect against prostate cancer. Materials and Methods: In three human prostate cancer cell lines, methylation-specific-PCR was used to determine the effect of soy isoflavones (genistein and daidzein), compared to known demethylating agent 5-azacytidine as control in the promoter regions of glutathione S-transferase PI (GSTP1), Ras association domain family 1 (RASSF1A), ephrin B2 (EPHB2) and breast cancer 1 (BRCA1) genes. In parallel, immunohistochemistry was used to assess the effects of genistein, daidzein and 5-azacytidine treatment on the corresponding protein expression. Results: All studied promoters, with the exception of that for BRCA1, were strongly methylated without treatment. After treatment by phytoestrogens, demethylation of GSTP1 and EPHB2 promoter regions was observed and an increase in their protein expression was demonstrated by immunohistochemistry. Conclusion: Epigenetic modifications of DNA, such as the promoter CpG island demethylation of tumor suppressor genes, might be related to the protective effect of soy on prostate cancer.
C1 [Vardi, Adam; Bosviel, Remy; Rabiau, Nadege; Adjakly, Mawussi; Satih, Samir; Bignon, Yves-Jean; Bernard-Gallon, Dominique J.] CBRV, EA 4233, Dept Oncogenet, Ctr Jean Perrin, F-63001 Clermont Ferrand, France.
   [Vardi, Adam; Boiteux, Jean-Paul; Guy, Laurent] CHU, Dept Urol, F-63001 Clermont Ferrand, France.
   [Rabiau, Nadege] Soluscience SA, Biopole Clermont Limagne, F-63360 St Beauzire, France.
   [Dechelotte, Pierre] Hosp Estaing, Dept Pathol, F-63003 Clermont Ferrand, France.
   [Dechelotte, Pierre; Boiteux, Jean-Paul; Fontana, Luc; Bignon, Yves-Jean; Guy, Laurent] Univ Auvergne, F-63000 Clermont Ferrand, France.
   [Fontana, Luc] CHU, Inst Occupat Hlth, F-63001 Clermont Ferrand, France.
C3 UNICANCER; Centre Jean Perrin; CHU Clermont Ferrand; CHU Clermont
   Ferrand; Universite Clermont Auvergne (UCA); CHU Clermont Ferrand
RP Bignon, YJ (通讯作者)，Ctr Jean Perrin, Dept Oncogenet, 58 Rue Montalembert,BP 392, F-63011 Clermont Ferrand 01, France.
EM Yves-Jean.BIGNON@cjp.fr
RI FONTANA, LUC/AAK-2701-2020; Bernard-Gallon, Dominique/L-6079-2015
OI FONTANA, LUC/0000-0003-1870-3671
FU l'Association Francaise d'Urologie; Credits du Conseil Regional
   D'Auvergne/Axe Nutrition et Cancer; Soluscience S.A.; Clermont-Ferrand,
   France
FX A.Vardi was a recipient of a grant from l'Association Francaise
   d'Urologie. R. Bosviel is a recipient of a grant CPER, Credits du
   Conseil Regional D'Auvergne/Axe Nutrition et Cancer. N. Rabiau is a
   recipient of a grant CIFRE from Soluscience S.A., Clermont-Ferrand,
   France. We thank Timothy H. Gunnels for assisting with the English
   translation of this study.
CR Colonna M, 2008, EUR J CANCER, V44, P115, DOI 10.1016/j.ejca.2007.10.022
   COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975
   Fang MZ, 2007, J NUTR, V137, p223S, DOI 10.1093/jn/137.1.223S
   Fang MZ, 2005, CLIN CANCER RES, V11, P7033, DOI 10.1158/1078-0432.CCR-05-0406
   Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721
   Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575
   Hedlund TE, 2003, PROSTATE, V54, P68, DOI 10.1002/pros.10137
   Horsburgh S, 2005, PROSTATE, V65, P124, DOI 10.1002/pros.20278
   JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8
   Kawamoto K, 2007, CLIN CANCER RES, V13, P2541, DOI 10.1158/1078-0432.CCR-06-2225
   Kittles RA, 2006, J MED GENET, V43, P507, DOI 10.1136/jmg.2005.035790
   Kuzmin I, 2002, CANCER RES, V62, P3498
   LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733
   Li YW, 2005, CANCER RES, V65, P6934, DOI 10.1158/0008-5472.CAN-04-4604
   Lin XH, 2001, CANCER RES, V61, P8611
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Nakamura Y, 2000, J AOAC INT, V83, P635
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   RABIAU N, CANC EPIDEMIOL, V34, P200
   RABIAU N, 2008, GENETIC PREDISPOSITI, P293
   Rabiau N, 2009, IN VIVO, V23, P387
   Rabiau N, 2009, IN VIVO, V23, P203
   Reibenwein J, 2007, PROSTATE, V67, P427, DOI 10.1002/pros.20533
   Shen WJ, 2008, WORLD J GASTROENTERO, V14, P595, DOI 10.3748/wjg.14.595
   Soulié M, 2001, PROG UROL, V11, P49
   Wang J, 2002, CANCER LETT, V186, P11, DOI 10.1016/S0304-3835(01)00811-4
   Wang YP, 2005, NEOPLASIA, V7, P748, DOI 10.1593/neo.05289
   Wu QH, 2007, EPIGENETICS-US, V2, P237, DOI 10.4161/epi.2.4.5406
NR 28
TC 92
Z9 99
U1 0
U2 8
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0258-851X
EI 1791-7549
J9 IN VIVO
JI In Vivo
PD JUL-AUG
PY 2010
VL 24
IS 4
BP 393
EP 400
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 638JH
UT WOS:000280890000003
PM 20668305
DA 2025-01-12
ER

PT J
AU Fischer, AH
   Zhao, C
   Li, QK
   Gustafson, KS
   Eltoum, IE
   Tambouret, R
   Benstein, B
   Savaloja, LC
   Kulesza, P
AF Fischer, Andrew H.
   Zhao, Chengquan
   Li, Qing Kay
   Gustafson, Karen S.
   Eltoum, Isam-Eldin
   Tambouret, Rosemary
   Benstein, Barbara
   Savaloja, Lynnette C.
   Kulesza, Peter
TI The Cytologic Criteria of Malignancy
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE CANCER CELL STRUCTURE; DIAGNOSIS; CRITERIA OF MALIGNANCY
ID PAPILLARY THYROID-CARCINOMA; BREAST-CANCER PROGRESSION; NUCLEAR-MEMBRANE
   PROTEIN; IN-SITU HYBRIDIZATION; GRANULOSA-CELL TUMORS; RHABDOID TUMORS;
   IMAGE-ANALYSIS; PROLIFERATIVE ACTIVITY; MAMMARY TUMORIGENESIS;
   SIDEROBLASTIC ANEMIA
AB Cytology and cell biology are two separate fields that share a focus on cancer. Cancer is still diagnosed based on morphology, and surprisingly little is known about the molecular basis of the defining structural features. Cytology uses the smallest possible biopsy for diagnosis by reducing morphologic "criteria of malignancy" to the smallest scale. To begin to develop common ground, members of the American Society of Cytopathology Cell Biology Liaison Working Group classify some of the "criteria of malignancy" and review their relation to current cell biology concepts. The criteria of malignancy are extremely varied, apparently reflecting many different pathophysiologies in specific microenvironments. Criteria in Group 1 comprise tissue-level alterations that appear to relate to resistance to anoikis, alterations in cell adhesion molecules, and loss of apical-basal polarity. Criteria in Group 2 reflect genetic instability, including chromosomal and possibly epigenetic instability. Criteria in Groups 3 are subcellular structural changes involving cytoplasmic components, nuclear lamina, chromatin and nucleoli that cannot be accounted for by genetic instability. Some distinct criteria in Group 3 are known to be induced by cancer genes. but their precise structural basis remains obscure. The criteria of malignancy are not closely related to the histogenetic classification of cancers, and they appear to provide an alternative, biologically relevant framework for establishing common ground between cytologists and cell biologists. To understand the criteria of malignancy at a molecular level would improve diagnosis, and likely point to novel cell physiologies that are not encompassed by current cell biology concepts. J. Cell. Biochem. 110: 795-811, 2010. (C) 2010 Wiley-Liss. Inc.
C1 [Fischer, Andrew H.] Univ Massachusetts, Dept Pathol, Worcester, MA 01605 USA.
   [Zhao, Chengquan] Univ Pittsburgh, Magee Womens Hosp, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA.
   [Li, Qing Kay] Dept Pathol, Baltimore, MD USA.
   [Gustafson, Karen S.] Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA.
   [Eltoum, Isam-Eldin] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA.
   [Tambouret, Rosemary] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
   [Benstein, Barbara] Univ Tennessee, Ctr Hlth Sci, Dept Clin Lab Serv, Memphis, TN 38163 USA.
   [Savaloja, Lynnette C.] Reg Hosp, St Paul, MN USA.
   Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA.
C3 University of Massachusetts System; University of Massachusetts
   Worcester; Pennsylvania Commonwealth System of Higher Education (PCSHE);
   University of Pittsburgh; Fox Chase Cancer Center; University of Alabama
   System; University of Alabama Birmingham; Harvard University;
   Massachusetts General Hospital; University of Tennessee System;
   University of Tennessee Health Science Center; Northwestern University;
   Feinberg School of Medicine
RP Fischer, AH (通讯作者)，Univ Massachusetts, Dept Pathol, Rm 213 Biotech 3,1 Innovat Dr, Worcester, MA 01605 USA.
EM andrew.fischer@umassmemorial.org
OI Fischer, Andrew/0000-0002-5944-4621
CR Abzhanov A, 2004, SCIENCE, V305, P1462, DOI 10.1126/science.1098095
   Adler PN, 2001, CURR OPIN CELL BIOL, V13, P635, DOI 10.1016/S0955-0674(00)00263-5
   [Anonymous], CELL HLTH DIS EVALUA
   Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485
   Bártová E, 2005, J CELL SCI, V118, P5035, DOI 10.1242/jcs.02621
   BASERGA R, 1965, CANCER RES, V25, P581
   Bibbo M., 2008, Comprehensive Cytopathology, V3rd
   Biesterfeld S, 2003, ANTICANCER RES, V23, P4269
   Bignold LP, 2002, CELL MOL LIFE SCI, V59, P950, DOI 10.1007/s00018-002-8482-y
   Borrello MG, 2005, P NATL ACAD SCI USA, V102, P14825, DOI 10.1073/pnas.0503039102
   Brankley SM, 2006, J MOL DIAGN, V8, P260, DOI 10.2353/jmoldx.2006.050118
   Broers JLV, 2004, HUM MOL GENET, V13, P2567, DOI 10.1093/hmg/ddh295
   Broers JLV, 1997, HISTOCHEM CELL BIOL, V107, P505, DOI 10.1007/s004180050138
   Bronner MP, 2008, AM J PATHOL, V173, P1853, DOI 10.2353/ajpath.2008.080250
   Bubendorf L, 2001, AM J CLIN PATHOL, V116, P79
   Burke B, 2009, DEV CELL, V17, P587, DOI 10.1016/j.devcel.2009.10.018
   Burridge K, 2001, CURR OPIN CELL BIOL, V13, P525, DOI 10.1016/S0955-0674(00)00246-5
   Bussolati G, 2008, ROM J MORPHOL EMBRYO, V49, P435
   Bussolati G, 2008, J CELL MOL MED, V12, P209, DOI 10.1111/j.1582-4934.2007.00176.x
   Cameselle-Teijeiro J, 2006, INT J SURG PATHOL, V14, P79, DOI 10.1177/106689690601400116
   Capo-Chichi CD, 2009, MOL CELL BIOL, V29, P4766, DOI 10.1128/MCB.00087-09
   Caramel J, 2008, ONCOGENE, V27, P2035, DOI 10.1038/sj.onc.1210847
   CASPERSSON T, 1943, ACTA RADIOL, V25, P113
   Cho KR, 2009, ARCH PATHOL LAB MED, V133, P1775, DOI 10.1043/1543-2165-133.11.1775
   Cho YM, 2006, PATHOL INT, V56, P702, DOI 10.1111/j.1440-1827.2006.02033.x
   Chuang CH, 2006, CURR BIOL, V16, P825, DOI 10.1016/j.cub.2006.03.059
   Cibas EdmundS., 2009, Cytology: Diagnostic Principle and Clinical Correlates, Vthird
   Cibas ES, 2005, AM J CLIN PATHOL, V124, P58, DOI 10.1309/23WU42WYHV8YAJYU
   Contreras A, 2009, ARCH PATHOL LAB MED, V133, P1116, DOI 10.1043/1543-2165-133.7.1116
   Cremer M, 2004, EUR J HISTOCHEM, V48, P15
   Dauer WT, 2009, DEV CELL, V17, P626, DOI 10.1016/j.devcel.2009.10.016
   de Capoa A, 1998, CYTOMETRY, V31, P85, DOI 10.1002/(SICI)1097-0320(19980201)31:2<85::AID-CYTO3>3.3.CO;2-8
   De Capoa A, 2004, ANTICANCER RES, V24, P1495
   Debnath J, 2002, CELL, V111, P757, DOI 10.1016/S0092-8674(02)01163-7
   Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2
   DeMay R.M., 1996, The Art and Science of Cytopathology: Exfoliative Cytology/Aspiration Cytology
   DEY P, 2010, DIAGNOSTIC IN PRESS
   DOORBAR J, 1991, NATURE, V352, P824, DOI 10.1038/352824a0
   EVANS MP, 1995, CANCER, V75, P2295, DOI 10.1002/1097-0142(19950501)75:9<2295::AID-CNCR2820750918>3.0.CO;2-C
   Favreau C, 2003, EXP CELL RES, V282, P14, DOI 10.1006/excr.2002.5669
   Feigin ME, 2009, CURR OPIN CELL BIOL, V21, P694, DOI 10.1016/j.ceb.2009.07.003
   Fischer AH, 2004, J CELL BIOCHEM, V93, P28, DOI 10.1002/jcb.20105
   Fischer AH, 2004, J CELL BIOCHEM, V91, P170, DOI 10.1002/jcb.10735
   Fischer AH, 1998, J CELL BIOCHEM, V70, P130, DOI 10.1002/(SICI)1097-4644(19980701)70:1<130::AID-JCB13>3.3.CO;2-8
   Fischer AH, 2003, AM J PATHOL, V163, P1091, DOI 10.1016/S0002-9440(10)63468-2
   Fischer AH, 1998, AM J PATHOL, V153, P1443, DOI 10.1016/S0002-9440(10)65731-8
   Fischer AH, 2001, HISTOL HISTOPATHOL, V16, P1, DOI 10.14670/HH-16.1
   FISCHER AH, 2000, COLD SPRING HARB S D
   Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9
   Fuller CE, 2001, HUM PATHOL, V32, P1102, DOI 10.1053/hupa.2001.28252
   Galusca B, 2005, VIRCHOWS ARCH, V447, P18, DOI 10.1007/s00428-005-1268-5
   Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011
   Gattermann N, 2000, LEUKEMIA RES, V24, P141, DOI 10.1016/S0145-2126(99)00160-5
   Gilmore AP, 2009, CURR OPIN CELL BIOL, V21, P654, DOI 10.1016/j.ceb.2009.05.009
   Gomes ER, 2005, CELL, V121, P451, DOI 10.1016/j.cell.2005.02.022
   Gruenbaum Y, 2005, NAT REV MOL CELL BIO, V6, P21, DOI 10.1038/nrm1550
   Halling KC, 2000, J UROLOGY, V164, P1768, DOI 10.1016/S0022-5347(05)67104-2
   Hameed O, 2009, MODERN PATHOL, V22, P1236, DOI 10.1038/modpathol.2009.91
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hiraoka Y, 2009, DEV CELL, V17, P598, DOI 10.1016/j.devcel.2009.10.014
   Hoffmann K, 2002, NAT GENET, V31, P410, DOI 10.1038/ng925
   Houwerzijl EJ, 2009, LEUKEMIA, V23, P886, DOI 10.1038/leu.2008.389
   Huang Y, 2001, P NATL ACAD SCI USA, V98, P15044, DOI 10.1073/pnas.251547398
   JOHANNESSEN JV, 1978, HUM PATHOL, V9, P385, DOI 10.1016/S0046-8177(78)80025-2
   JOHANNESSEN JV, 1983, AM J CLIN PATHOL, V79, P166, DOI 10.1093/ajcp/79.2.166
   KAMEI H, 1994, CELL STRUCT FUNCT, V19, P123, DOI 10.1247/csf.19.123
   Knauf JA, 2005, CANCER RES, V65, P4238, DOI 10.1158/0008-5472.CAN-05-0047
   Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836
   Lammerding J, 2005, J CELL BIOL, V170, P781, DOI 10.1083/jcb.200502148
   Lammerding J, 2004, J CLIN INVEST, V113, P370, DOI 10.1172/JCI200419670
   Lempiäinen H, 2009, CURR OPIN CELL BIOL, V21, P855, DOI 10.1016/j.ceb.2009.09.002
   MELLO MLS, 1994, ANAL QUANT CYTOL, V16, P113
   Mercurio AM, 2001, CURR OPIN CELL BIOL, V13, P541, DOI 10.1016/S0955-0674(00)00249-0
   Michaloglou C, 2008, ONCOGENE, V27, P877, DOI 10.1038/sj.onc.1210704
   Münger K, 2004, J VIROL, V78, P11451, DOI 10.1128/JVI.78.21.11451-11460.2004
   Mutter GL, 2007, INT J GYNECOL PATHOL, V26, P103, DOI 10.1097/PGP.0b013e31802e4696
   Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000
   Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X
   Nikiforov YE, 2008, MODERN PATHOL, V21, pS37, DOI 10.1038/modpathol.2008.10
   OYAMA T, 1989, VIRCHOWS ARCH A, V414, P91, DOI 10.1007/BF00718588
   Pageau GJ, 2007, NAT REV CANCER, V7, P628, DOI 10.1038/nrc2172
   Papotti M, 2004, VIRCHOWS ARCH, V444, P350, DOI 10.1007/s00428-003-0962-4
   Pearson GW, 2007, J CELL BIOL, V179, P1555, DOI 10.1083/jcb.200706099
   Pihan GA, 2003, CANCER RES, V63, P1398
   Pratap J, 2009, CANCER RES, V69, P6807, DOI 10.1158/0008-5472.CAN-09-1471
   PUROLA E, 1977, ACTA CYTOL, V21, P26
   Rao XT, 2008, MUTAT RES-FUND MOL M, V646, P41, DOI 10.1016/j.mrfmmm.2008.09.004
   Ravid K, 2002, J CELL PHYSIOL, V190, P7, DOI 10.1002/jcp.10035
   Rezk S, 2004, ENDOCR PATHOL, V15, P329, DOI 10.1385/EP:15:4:329
   Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697
   Roberts S, 2003, J VIROL, V77, P673, DOI 10.1128/JVI.77.1.673-684.2003
   Rosai J., 1992, TUMORS THYROID GLAND
   Roux KJ, 2009, P NATL ACAD SCI USA, V106, P2194, DOI 10.1073/pnas.0808602106
   Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015
   Schirmer EC, 2003, SCIENCE, V301, P1380, DOI 10.1126/science.1088176
   Schirmer EC, 2001, J CELL BIOL, V153, P479, DOI 10.1083/jcb.153.3.479
   SCHULTE EKW, 1995, ANAL CELL PATHOL, V9, P257
   Shah SP, 2009, NEW ENGL J MED, V360, P2719, DOI 10.1056/NEJMoa0902542
   Sheftel AD, 2009, ACTA HAEMATOL-BASEL, V122, P120, DOI 10.1159/000243796
   Shimizu N, 1998, J CELL BIOL, V140, P1307, DOI 10.1083/jcb.140.6.1307
   Shimizu N, 2007, GENE CHROMOSOME CANC, V46, P865, DOI 10.1002/gcc.20473
   Shiratsuchi H, 2002, MODERN PATHOL, V15, P146, DOI 10.1038/modpathol.3880506
   Solovei I, 2009, CELL, V137, P356, DOI 10.1016/j.cell.2009.01.052
   Speeckaert MM, 2009, ACTA HAEMATOL-BASEL, V121, P202, DOI 10.1159/000220333
   Starr DA, 2003, J CELL SCI, V116, P211, DOI 10.1242/jcs.00248
   Stein GS, 2009, ANN NY ACAD SCI, V1155, P4, DOI 10.1111/j.1749-6632.2009.03697.x
   Stoler MH, 2000, INT J GYNECOL PATHOL, V19, P16, DOI 10.1097/00004347-200001000-00004
   Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276
   Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459
   TAKESHITA H, 1985, Journal of the Japanese Orthopaedic Association, V59, P763
   TANNOCK I, 1978, CANCER TREAT REP, V62, P1117
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Tomasini R, 2008, TRENDS CELL BIOL, V18, P244, DOI 10.1016/j.tcb.2008.03.003
   Tóth KF, 2004, J CELL SCI, V117, P4277, DOI 10.1242/jcs.01293
   Ulbert S, 2006, FEBS LETT, V580, P6435, DOI 10.1016/j.febslet.2006.10.060
   Wang Q, 2009, J VIROL, V83, P3668, DOI 10.1128/JVI.02063-08
   Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7
   Weaver VM, 1996, BIOCHEM CELL BIOL, V74, P833, DOI 10.1139/o96-089
   Wilkie GS, 2006, MOL CELL PROTEOMICS, V5, P1865, DOI 10.1074/mcp.R600003-MCP200
   Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431
   Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006
   Yoshida A, 1999, SURG TODAY, V29, P204
   Yoshida Y, 2009, LEUKEMIA RES, V33, P614, DOI 10.1016/j.leukres.2008.09.014
   Young DW, 2007, NATURE, V445, P442, DOI 10.1038/nature05473
   Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045
   Zink D, 2004, NAT REV CANCER, V4, P677, DOI 10.1038/nrc1430
   Zinner R, 2006, HISTOCHEM CELL BIOL, V125, P3, DOI 10.1007/s00418-005-0049-1
   ZITTOUN R, 1984, CANCER-AM CANCER SOC, V53, P1526, DOI 10.1002/1097-0142(19840401)53:7<1526::AID-CNCR2820530718>3.0.CO;2-2
NR 128
TC 34
Z9 38
U1 0
U2 10
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JUL 1
PY 2010
VL 110
IS 4
BP 795
EP 811
DI 10.1002/jcb.22585
PG 17
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 619OS
UT WOS:000279440100001
PM 20564180
DA 2025-01-12
ER

PT J
AU Watanabe, M
   Nakahata, S
   Hamasaki, M
   Saito, Y
   Kawano, Y
   Hidaka, T
   Yamashita, K
   Umeki, K
   Taki, T
   Taniwaki, M
   Okayama, A
   Morishita, K
AF Watanabe, Masaaki
   Nakahata, Shingo
   Hamasaki, Makoto
   Saito, Yusuke
   Kawano, Yohei
   Hidaka, Tomonori
   Yamashita, Kiyoshi
   Umeki, Kazumi
   Taki, Tomohiko
   Taniwaki, Masafumi
   Okayama, Akihiko
   Morishita, Kazuhiro
TI Downregulation of CDKN1A in Adult T-Cell Leukemia/Lymphoma despite
   Overexpression of CDKN1A in Human T-Lymphotropic Virus 1-Infected Cell
   Lines
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID LEUKEMIA-VIRUS; BREAST-CANCER; POOR-PROGNOSIS; TYPE-1 TAX; IN-VIVO;
   EXPRESSION; GENE; P27(KIP1); PHOSPHORYLATION; TRANSCRIPTION
AB Human T-lymphotropic virus 1 (HTLV-1) causes an aggressive malignancy of T lymphocytes called adult T-cell leukemia/lymphoma (ATLL), and expression of HTLV-1 Tax influences cell survival, proliferation, and genomic stability in the infected T lymphocytes. Cyclin-dependent kinase inhibitor 1A (CDKN1A/p21(waf1/Cip1)) is upregulated by Tax, without perturbation of cell cycle control. During an analysis of the gene expression profiles of ATLL cells, we found very low expression of CDKN1A in ATLL-derived cell lines and ATLL cells from patient samples, and epigenetic abnormalities including promoter methylation are one of the mechanisms for the low CDKN1A expression in ATLL cells. Three HTLV-1-infected cell lines showed high levels of expression of both CDKN1A and Tax, but expression of CDKN1A was detected in only two of six ATLL-derived cell lines. In both the HTLV-1-infected and ATLL cell lines, we found that activated Akt phosphorylates CDKN1A at threonine 145 (T145), leading to cytoplasmic localization of CDKNIA. In HTLV-1-infected cell lines, cytoplasmic CDKN1A did not inhibit the cell cycle after UV irradiation; however, following treatment with LY294002, a PI3K inhibitor, CDKN1A was dephosphorylated and relocalized to the nucleus, resulting in suppression of the cell cycle. In the ATLL cell lines, treatment with LY294002 did not inhibit the cell cycle but induced apoptosis with the cytoplasmic localization. Therefore, the low CDKN1A expression in ATLL cells may be a key player in ATLL leukemogenesis, and the abnormal genomic methylation may influence the expression of not only HTLV-1 Tax but also CDKN1A during long-term development of ATLL from the HTLV-1-infected T lymphocytes.
C1 [Watanabe, Masaaki; Nakahata, Shingo; Hamasaki, Makoto; Saito, Yusuke; Kawano, Yohei; Morishita, Kazuhiro] Miyazaki Univ, Div Tumor & Cellular Biochem, Dept Med Sci, Fac Med, Miyazaki, Japan.
   [Hidaka, Tomonori; Yamashita, Kiyoshi] Miyazaki Univ, Fac Med, Dept Internal Med, Miyazaki, Japan.
   [Umeki, Kazumi; Okayama, Akihiko] Miyazaki Univ, Fac Med, Dept Internal Med Rheumatol Infect Dis & Lab Med, Miyazaki, Japan.
   [Taki, Tomohiko; Taniwaki, Masafumi] Kyoto Prefectural Univ Med, Dept Hematol & Oncol, Kyoto, Japan.
C3 University of Miyazaki; University of Miyazaki; University of Miyazaki;
   Kyoto Prefectural University of Medicine
RP Morishita, K (通讯作者)，Miyazaki Univ, Div Tumor & Cellular Biochem, Dept Med Sci, Fac Med, Miyazaki, Japan.
EM kmorishi@med.miyazaki-u.ac.jp
RI Hamasaki, Makoto/AAO-2229-2020
FU Ministry of Education, Culture, Sports, Science and Technology of Japan;
   JST; Grants-in-Aid for Scientific Research [21390098] Funding Source:
   KAKEN
FX This work was supported in part by Grants-in-Aid for Scientific Research
   of Priority Area from the Ministry of Education, Culture, Sports,
   Science and Technology of Japan, and by a research fund from the
   Miyazaki Prefecture Collaboration of Regional Entities for the
   Advancement of Technological Excellence, JST.
CR AKAGI T, 1995, BLOOD, V86, P4243, DOI 10.1182/blood.V86.11.4243.bloodjournal86114243
   Cereseto A, 1999, ONCOGENE, V18, P2441, DOI 10.1038/sj.onc.1202567
   Claus R, 2003, ONCOGENE, V22, P6489, DOI 10.1038/sj.onc.1206814
   De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000
   De la Fuente C, 2000, AIDS RES HUM RETROV, V16, P1695, DOI 10.1089/08892220050193164
   Dewan MZ, 2008, J VIROL, V82, P11958, DOI 10.1128/JVI.01149-08
   Fang JY, 2002, WORLD J GASTROENTERO, V8, P400, DOI 10.3748/wjg.v8.i3.400
   Fukuda R, 2009, J BIOL CHEM, V284, P2680, DOI 10.1074/jbc.M806325200
   Harhaj EW, 1999, ONCOGENE, V18, P1341, DOI 10.1038/sj.onc.1202405
   Hidaka T, 2008, BLOOD, V112, P383, DOI 10.1182/blood-2008-01-131185
   Jiemjit A, 2008, ONCOGENE, V27, P3615, DOI 10.1038/sj.onc.1211018
   KATRIN S, 2007, SIGNAL TRANSDUCT, V7, P34
   Kehn Kylene, 2004, Retrovirology, V1, P6, DOI 10.1186/1742-4690-1-6
   Koiwa T, 2002, J VIROL, V76, P9389, DOI 10.1128/JVI.76.18.9389-9397.2002
   Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761
   Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038/nrc2111
   Peloponese JM, 2006, J BIOL CHEM, V281, P8927, DOI 10.1074/jbc.M510598200
   Pise-Masison CA, 2002, CANCER RES, V62, P3562
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   Proietti FA, 2005, ONCOGENE, V24, P6058, DOI 10.1038/sj.onc.1208968
   RAIZIS AM, 1995, ANAL BIOCHEM, V226, P161, DOI 10.1006/abio.1995.1204
   Roman-Gomez J, 2002, BLOOD, V99, P2291, DOI 10.1182/blood.V99.7.2291
   Sasaki H, 2005, BLOOD, V105, P1204, DOI 10.1182/blood-2004-03-1222
   SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618
   Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759
   Shin JY, 2000, CANCER RES, V60, P262
   Siegel R S, 2001, Curr Treat Options Oncol, V2, P291, DOI 10.1007/s11864-001-0022-8
   TAJIMA K, 1990, INT J CANCER, V45, P237, DOI 10.1002/ijc.2910450206
   Takeda S, 2004, INT J CANCER, V109, P559, DOI 10.1002/ijc.20007
   Tanaka G, 2005, J INFECT DIS, V191, P1140, DOI 10.1086/428625
   Taniguchi Y, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-64
   Tripp A, 2005, J VIROL, V79, P14069, DOI 10.1128/JVI.79.22.14069-14078.2005
   Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762
   Winters ZE, 2003, BREAST CANCER RES, V5, pR242, DOI 10.1186/bcr654
   Xia WY, 2004, CLIN CANCER RES, V10, P3815, DOI 10.1158/1078-0432.CCR-03-0527
   Yamada Y, 2001, BRIT J HAEMATOL, V113, P375, DOI 10.1046/j.1365-2141.2001.02737.x
   YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031
   Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032
   Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003
NR 39
TC 31
Z9 34
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD JUL
PY 2010
VL 84
IS 14
BP 6966
EP 6977
DI 10.1128/JVI.00073-10
PG 12
WC Virology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Virology
GA 612WF
UT WOS:000278935700007
PM 20444901
OA Green Published
DA 2025-01-12
ER

PT J
AU Xu, M
   Gao, J
   Du, YQ
   Gao, DJ
   Zhang, YQ
   Li, ZS
   Zhang, YL
   Gong, YF
   Xu, P
AF Xu, Min
   Gao, Jun
   Du, Yi Qi
   Gao, Dao-Jian
   Zhang, Yu Qi
   Li, Zhao Shen
   Zhang, You Li
   Gong, Yan Fang
   Xu, Ping
TI Reduction of pancreatic cancer cell viability and induction of apoptosis
   mediated by siRNA targeting DNMT1 through suppression of total DNA
   methyltransferase activity
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE DNA methylation; DNA methytransferase 1; small interfering RNA;
   pancreatic cancer
ID BREAST-CANCER; CPG METHYLATION; CYTOSINE-DNA; EXPRESSION; INHIBITION;
   3B; 3A; HYPERMETHYLATION; TUMORIGENESIS; CONSEQUENCES
AB Aberrant methylation leads to epigenetic changes in human genes that may cause carcinogenesis. DNA methyltransferase 1 (DNMT1) plays an important role in maintaining DNA methylation patterns during genomic DNA replication. To understand the role of this protein in pancreatic cancer cell growth and apoptosis, small interfering RNA (siRNA) oligonucleotides were used to knockdown DNMT1 expression in pancreatic cancer PaTu8988 cells. We found that the DNMT1 siRNA markedly decreased DNMT1 expression and total DNA methyltransferase activity in the cells. Upon the inhibition of DNMT1 expression, the proliferation of the tumor cells was inhibited. Tumor cell growth was arrested in the S-phase of the cell cycle and cells underwent apoptosis. The expression of p21 was up-regulated and the ratio of Bax/Bcl-2 expression was increased after DNMT1 knockdown in PaTu8988 cells. Furthermore. DNMT1 siRNA caused demethylation of the tumor suppressor gene hMLH1, resulting in its re-expression in PaTu8988 cells. The results of this study suggest that DNMT1 siRNA oligonucleotides are candidates for further evaluation as therapeutic tools for the clinical control of pancreatic cancer.
C1 [Xu, Min; Gao, Jun; Du, Yi Qi; Gao, Dao-Jian; Zhang, Yu Qi; Li, Zhao Shen; Gong, Yan Fang] Second Mil Med Univ, Changhai Hosp, Dept Gastroenterol, Shanghai 200433, Peoples R China.
   [Zhang, You Li; Xu, Ping] Jiangsu Univ Affiliated Hosp, Dept Gastroenterol, Zhenjiang 212001, Jiangsu, Peoples R China.
C3 Naval Medical University
RP Li, ZS (通讯作者)，Second Mil Med Univ, Changhai Hosp, Dept Gastroenterol, Shanghai 200433, Peoples R China.
EM lizhaoshen111@gmail.com
RI Zhu, Wusheng/JXN-2944-2024
OI , Jun/0000-0002-0506-632X
FU Chinese National Key Technology RD Program [2006BAI02A12]; Natural
   Science Foundation of Jiangsu Province [BK2009210]; Jiangsu Province's
   Health Department Program [H200836]
FX This work was partially supported by the Chinese National Key Technology
   R&D Program (Grant No. 2006BAI02A12), the Natural Science Foundation of
   Jiangsu Province (Grant No. BK2009210), and Jiangsu Province's Health
   Department Program (Grant No. H200836).
CR Agoston AT, 2005, J BIOL CHEM, V280, P18302, DOI 10.1074/jbc.M501675200
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   Bigey P, 1999, J BIOL CHEM, V274, P4594, DOI 10.1074/jbc.274.8.4594
   Chen TP, 2004, CURR TOP DEV BIOL, V60, P55
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235
   Knox JD, 2000, J BIOL CHEM, V275, P17986, DOI 10.1074/jbc.C900894199
   Li SF, 2003, GYNECOL ONCOL, V90, P123, DOI 10.1016/S0090-8258(03)00194-X
   MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037
   Milutinovic S, 2003, J BIOL CHEM, V278, P14985, DOI 10.1074/jbc.M213219200
   Milutinovic S, 2000, J BIOL CHEM, V275, P6353, DOI 10.1074/jbc.275.9.6353
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684
   Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068
   Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   Sowinska A, 2007, CANCER LETT, V255, P153, DOI 10.1016/j.canlet.2007.04.004
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   SZYF M, 1994, TRENDS PHARMACOL SCI, V15, P233, DOI 10.1016/0165-6147(94)90317-4
   Ting AH, 2005, NAT GENET, V37, P906, DOI 10.1038/ng1611
   Ting AH, 2004, NAT GENET, V36, P582, DOI 10.1038/ng1365
   Xiong YN, 2005, GYNECOL ONCOL, V96, P601, DOI 10.1016/j.ygyno.2004.11.047
NR 27
TC 18
Z9 20
U1 0
U2 10
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD JUL-AUG
PY 2010
VL 3
IS 4
BP 699
EP 704
DI 10.3892/mmr_00000320
PG 6
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA 616KA
UT WOS:000279207000026
PM 21472302
OA Bronze
DA 2025-01-12
ER

PT J
AU Osaki, M
   Inaba, A
   Nishikawa, K
   Sugimoto, Y
   Shomori, K
   Inoue, T
   Oshimura, M
   Ito, H
AF Osaki, Mitsuhiko
   Inaba, Aiko
   Nishikawa, Kei
   Sugimoto, Yui
   Shomori, Kohei
   Inoue, Toshiaki
   Oshimura, Mitsuo
   Ito, Hisao
TI Cysteine-rich protein 61 suppresses cell invasion via down-regulation of
   matrix metalloproteinase-7 expression in the human gastric carcinoma
   cell line MKN-45
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE cysteine-rich protein 61; gastric carcinoma; cell invasion; matrix
   metalloproteinase-7
ID IMMEDIATE-EARLY GENE; CANCER-CELLS; CCN FAMILY; TUMOR PROGRESSION; MMP-7
   EXPRESSION; BREAST-CANCER; LUNG-CANCER; CYR61; GROWTH; HYPERMETHYLATION
AB Cysteine-rich protein 61 (CYR61) is a member of the CCN (CYR61/CTGF/NOV) family, which is associated with progression in a variety of human cancers. Our previous study confirmed that the expression levels of CYR61 protein were decreased in gastric carcinoma compared to non-tumoral mucosa as determined by proteome analysis. Histological research also showed that the reduction in CYR61 expression was significantly correlated with cellular invasiveness and inversely correlated with matrix metalloproteinase-7 (MMP-7/ matrilysin) expression in human gastric carcinoma. We examined the cause of CYR61 down-regulation in a human gastric carcinoma cell line, MKN-45. Lower expression of CYR61, but no genetic or epigenetic alterations of the gene, were observed. We then examined the correlation between CYR61 protein and MMP-7 expression and cellular invasiveness in MKN-45 cells. CYR61 was secreted from CYR61 expression-vector-transfected 293T cells, and the supernatant was added to MKN-45 cells. The expression level of MMP-7 was reduced by treatment of the supernatant, including CYR61, in a dose-dependent manner. An invasion assay showed that the cellular invasiveness of MKN-45 was significantly suppressed by the transfection of CYR61 expression vector compared to transfection with a control vector. Taken together, these results raise the possibility that CYR61 suppresses cell invasion at least partly via the downregulation of MMP-7 expression in human gastric carcinoma cells.
C1 [Osaki, Mitsuhiko; Nishikawa, Kei; Sugimoto, Yui; Oshimura, Mitsuo] Tottori Univ, Div Mol Genet & Biofunct, Dept Biomed Sci, Grad Sch Med Sci, Tottori 6838503, Japan.
   [Osaki, Mitsuhiko; Oshimura, Mitsuo] Tottori Univ, Chromosome Engn Res Ctr, Fac Med, Tottori 6838503, Japan.
   [Inaba, Aiko; Shomori, Kohei; Ito, Hisao] Tottori Univ, Div Organ Pathol, Fac Med, Tottori 6838503, Japan.
   [Inoue, Toshiaki] Tottori Univ, Div Human Genome Sci, Fac Med, Tottori 6838503, Japan.
C3 Tottori University; Tottori University; Tottori University; Tottori
   University
RP Osaki, M (通讯作者)，Tottori Univ, Div Mol Genet & Biofunct, Dept Biomed Sci, Grad Sch Med Sci, 86 Nishi Cho, Tottori 6838503, Japan.
EM osamitsu@med.tottori-u.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [19790260]; Grants-in-Aid for Scientific Research [19790260] Funding
   Source: KAKEN
FX This study was supported, in part, by a Grant-in-Aid for Scientific
   Research from the Ministry of Education, Culture, Sports, Science and
   Technology of Japan (grant no. 19790260).
CR Aihara R, 2006, J SURG ONCOL, V93, P491, DOI 10.1002/jso.20439
   Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355
   Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189
   Chen JQ, 2004, WORLD J GASTROENTERO, V10, P776
   Chien WW, 2004, J BIOL CHEM, V279, P53087, DOI 10.1074/jbc.M410254200
   Endoh Y, 2000, AM J PATHOL, V157, P717, DOI 10.1016/S0002-9440(10)64584-1
   FUCHS CS, 1995, NEW ENGL J MED, V333, P32, DOI 10.1056/NEJM199507063330107
   Grzeszkiewicz TM, 2002, ENDOCRINOLOGY, V143, P1441, DOI 10.1210/en.143.4.1441
   Holloway SE, 2005, J AM COLL SURGEONS, V200, P371, DOI 10.1016/j.jamcollsurg.2004.10.005
   Honda M, 1996, GUT, V39, P444, DOI 10.1136/gut.39.3.444
   Honda T, 2002, JPN J CANCER RES, V93, P857, DOI 10.1111/j.1349-7006.2002.tb01329.x
   Hou P, 2005, BIOCHEM GENET, V43, P1, DOI 10.1007/s10528-005-1062-8
   Huachuan Zheng, 2003, Chin Med Sci J, V18, P80
   Kireeva ML, 1996, MOL CELL BIOL, V16, P1326
   Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548
   Kitoh T, 2004, J GASTROENTEROL, V39, P434, DOI 10.1007/s00535-003-1316-3
   Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456
   Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6
   Lin MT, 2007, J BIOL CHEM, V282, P34594, DOI 10.1074/jbc.M706600200
   Lin MT, 2005, CLIN CANCER RES, V11, P5809, DOI 10.1158/1078-0432.CCR-04-2639
   Maeta N, 2007, ONCOLOGY-BASEL, V73, P118, DOI 10.1159/000121000
   Menéndez JA, 2003, ENDOCR-RELAT CANCER, V10, P141, DOI 10.1677/erc.0.0100141
   *MIN SECR STAT INF, 2000, VIT STAT 1998 JAP, V1, P284
   Mitra Aparna, 2003, Journal of Environmental Pathology Toxicology and Oncology, V22, P167, DOI 10.1615/JEnvPathToxOncol.v22.i3.20
   Mori M, 2002, SURGERY, V131, pS39, DOI 10.1067/msy.2002.119292
   Nishigaki R, 2005, PROTEOMICS, V5, P3205, DOI 10.1002/pmic.200401307
   Nomura H, 1996, INT J CANCER, V69, P9, DOI 10.1002/(SICI)1097-0215(19960220)69:1<9::AID-IJC3>3.0.CO;2-8
   OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569
   Parsons SL, 1997, BRIT J SURG, V84, P160, DOI 10.1046/j.1365-2168.1997.02719.x
   Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57
   Pilarsky CP, 1998, PROSTATE, V36, P85
   Sier CFM, 1996, BRIT J CANCER, V74, P413, DOI 10.1038/bjc.1996.374
   Soon LL, 2003, J BIOL CHEM, V278, P11465, DOI 10.1074/jbc.M210945200
   Tong XJ, 2001, J BIOL CHEM, V276, P47709, DOI 10.1074/jbc.M107878200
   Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682
   Tsai MS, 2002, ONCOGENE, V21, P964, DOI 10.1038/sj.onc.1205131
   Waki T, 2003, CANCER SCI, V94, P360, DOI 10.1111/j.1349-7006.2003.tb01447.x
   Xie D, 2004, CANCER RES, V64, P1987, DOI 10.1158/0008-5472.CAN-03-0666
   Yamamoto H, 2004, CARCINOGENESIS, V25, P325, DOI 10.1093/carcin/bgh011
   Yamashita K, 1998, INT J CANCER, V79, P187
   Zheng HC, 2003, PATHOL INT, V53, P659, DOI 10.1046/j.1440-1827.2003.01542.x
NR 41
TC 5
Z9 5
U1 0
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD JUL-AUG
PY 2010
VL 3
IS 4
BP 711
EP 715
DI 10.3892/mmr_00000322
PG 5
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA 616KA
UT WOS:000279207000028
PM 21472304
OA Bronze
DA 2025-01-12
ER

PT J
AU Tysnes, BB
AF Tysnes, Berit Bolge
TI Tumor-Initiating and -Propagatin Cells: Cells That We Would Like to
   Identify and Control
SO NEOPLASIA
LA English
DT Article
ID CANCER STEM-CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTIONAL
   REGULATORY CIRCUITRY; ACUTE MYELOID-LEUKEMIA; BREAST-CANCER; MICRORNA
   EXPRESSION; COLORECTAL-CANCER; DNA METHYLATION; DRUG-RESISTANCE;
   EPIGENETIC REGULATION
AB Identification of the cell types capable of initiating and sustaining growth of the neoplastic clone in vivo is a fundamental problem in cancer research. It is likely that tumor growth can be sustained both by rare cancer stem-like cells and selected aggressive clones and that the nature of the mutations, the cell of origin, and its environment will contribute to tumor propagation. Genomic instability, suggested as a driving force in tumorigenesis, may be induced by genetic and epigenetic changes. The feature of self-renewal in stem cells is shared with tumor cells, and deviant function of the stem cell regulatory networks may, in complex ways, contribute to malignant transformation and the establishment of a cancer stem cell-like phenotype. Understanding the nature of the more quiescent cancer stem-like cells and their niches has the potential to develop novel cancer therapeutic protocols including pharmacological targeting of self-renewal pathways. Drugs that target cancer-related inflammation may have the potential to reeducate a tumor-promoting microenvironment. Because most epigenetic modifications may be reversible, DNA methylation and histone deacetylase inhibitors can be used to induce reexpression of genes that have been silenced epigenetically. Design of therapies that eliminate cancer stem-like cells without eliminating normal stem cells will be important. Further insight into the mechanisms by which pluripotency transcription factors (e. g., OCT4, SOX2, and Nanog), polycomb repressive complexes and microRNAs balance self-renewal and differentiation will be essential for our understanding of both embryonic differentiation and human carcinogenesis and for the development of new treatment strategies.
C1 Univ Bergen, Dept Biomed, N-5009 Bergen, Norway.
C3 University of Bergen
RP Tysnes, BB (通讯作者)，Univ Bergen, Dept Biomed, Jonas Lies Vei 91, N-5009 Bergen, Norway.
EM berit.tysnes@biomed.uib.no
FU Norwegian Cancer Society; Norwegian Research Council; Helse Vest;
   Haukeland University Hospital
FX This work was supported by the Norwegian Cancer Society, the Norwegian
   Research Council, Helse Vest, Haukeland University Hospital, The Bergen
   Translational Research Program, CRP-Sante Luxembourg, and the European
   Commission 6th framework program, contract no. 504743.
CR Adams JM, 2008, CANCER RES, V68, P4018, DOI 10.1158/0008-5472.CAN-07-6334
   Al-Hajj M, 2004, CURR OPIN GENET DEV, V14, P43, DOI 10.1016/j.gde.2003.11.007
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Baccarelli A, 2009, CURR OPIN PEDIATR, V21, P243, DOI 10.1097/MOP.0b013e32832925cc
   Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013
   Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0
   Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Baumann M, 2008, NAT REV CANCER, V8, P545, DOI 10.1038/nrc2419
   Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180
   Belinsky SA, 2003, CANCER RES, V63, P7089
   Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604
   Bjerkvig R, 2005, NAT REV CANCER, V5, P899, DOI 10.1038/nrc1740
   Blum B, 2008, ADV CANCER RES, V100, P133, DOI 10.1016/S0065-230X(08)00005-5
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020
   Bracken AP, 2009, NAT REV CANCER, V9, P773, DOI 10.1038/nrc2736
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Card DAG, 2008, MOL CELL BIOL, V28, P6426, DOI 10.1128/MCB.00359-08
   Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741
   Chen CZ, 2005, NEW ENGL J MED, V353, P1768, DOI 10.1056/NEJMp058190
   Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048
   Clark PA, 2007, DEV DYNAM, V236, P3297, DOI 10.1002/dvdy.21381
   Collins AT, 2006, EUR J CANCER, V42, P1213, DOI 10.1016/j.ejca.2006.01.037
   Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906
   Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106
   Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819
   Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590
   Dean M, 2009, J MAMMARY GLAND BIOL, V14, P3, DOI 10.1007/s10911-009-9109-9
   Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1
   Dontu G, 2003, CELL PROLIFERAT, V36, P59, DOI 10.1046/j.1365-2184.36.s.1.6.x
   Douville J, 2009, STEM CELLS DEV, V18, P17, DOI 10.1089/scd.2008.0055
   Du L, 2008, CLIN CANCER RES, V14, P6751, DOI 10.1158/1078-0432.CCR-08-1034
   Eaves CJ, 2008, NATURE, V456, P581, DOI 10.1038/456581a
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Eyler CE, 2008, J CLIN ONCOL, V26, P2839, DOI 10.1200/JCO.2007.15.1829
   Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343
   Frank NY, 2010, J CLIN INVEST, V120, P41, DOI 10.1172/JCI41004
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364
   Gibbs CP, 2005, NEOPLASIA, V7, P967, DOI 10.1593/neo.05394
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397
   Giraldez AJ, 2005, SCIENCE, V308, P833, DOI 10.1126/science.1109020
   Godlewski J, 2010, CELL DEATH DIFFER, V17, P221, DOI 10.1038/cdd.2009.71
   Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017
   Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
   Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010
   Guzman ML, 2007, BLOOD, V110, P4436, DOI 10.1182/blood-2007-05-088815
   Guzman ML, 2007, BLOOD, V110, P4427, DOI 10.1182/blood-2007-05-090621
   Hatfield S, 2008, CELL TISSUE RES, V331, P57, DOI 10.1007/s00441-007-0530-3
   He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   Houghton J, 2007, SEMIN CANCER BIOL, V17, P191, DOI 10.1016/j.semcancer.2006.04.003
   Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003
   Huang EH, 2009, CANCER RES, V69, P3382, DOI 10.1158/0008-5472.CAN-08-4418
   Ishikawa F, 2007, NAT BIOTECHNOL, V25, P1315, DOI 10.1038/nbt1350
   Issa JPJ, 2009, CLIN CANCER RES, V15, P3938, DOI 10.1158/1078-0432.CCR-08-2783
   Iwasaki H, 2009, CANCER SCI, V100, P1166, DOI 10.1111/j.1349-7006.2009.01177.x
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Johannessen TCA, 2009, NEUROPATH APPL NEURO, V35, P380, DOI [10.1111/j.1365-2990.2009.01008.x, 10.1111/j.1365-2990.2008.01008.x]
   Johannessen TCA, 2008, CANCER TREAT REV, V34, P558, DOI 10.1016/j.ctrv.2008.03.125
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Joo KM, 2008, LAB INVEST, V88, P808, DOI 10.1038/labinvest.2008.57
   Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703
   Kashyap V, 2009, STEM CELLS DEV, V18, P1093, DOI 10.1089/scd.2009.0113
   Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596
   Kim CF, 2008, CELL STEM CELL, V3, P147, DOI 10.1016/j.stem.2008.07.012
   Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032
   Klisovic MI, 2003, LEUKEMIA, V17, P350, DOI 10.1038/sj.leu.2402776
   Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021
   LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0
   Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030
   Li LH, 2006, CANCER RES, V66, P4553, DOI 10.1158/0008-5472.CAN-05-3986
   Li QQ, 2009, CLIN CANCER RES, V15, P2657, DOI 10.1158/1078-0432.CCR-08-2372
   Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123
   Lin SL, 2008, RNA, V14, P2115, DOI 10.1261/rna.1162708
   Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154
   Lotem J, 2006, ONCOGENE, V25, P7663, DOI 10.1038/sj.onc.1209816
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Ma S, 2007, GASTROENTEROLOGY, V132, P2542, DOI 10.1053/j.gastro.2007.04.025
   Ma XJ, 2009, DRUGS, V69, P1911, DOI 10.2165/11315680-000000000-00000
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Mantovani A, 2008, ADV EXP MED BIOL, V610, P112
   Marson A, 2008, CELL, V134, P521, DOI 10.1016/j.cell.2008.07.020
   Molofsky AV, 2004, CURR OPIN CELL BIOL, V16, P700, DOI 10.1016/j.ceb.2004.09.004
   Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888
   Nickoloff BJ, 2003, ONCOGENE, V22, P6598, DOI 10.1038/sj.onc.1206758
   NOWELL PC, 1989, CANCER CELL-MON REV, V1, P29
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Ogden AT, 2008, NEUROSURGERY, V62, P505, DOI 10.1227/01.neu.0000316019.28421.95
   Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232
   Passegué E, 2009, NAT MED, V15, P612, DOI [10.1038/nm0609-612, 10.1038/nm0109-23]
   Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349
   Pierce G B, 1967, Curr Top Dev Biol, V2, P223
   Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104
   Prokhorova TA, 2009, STEM CELLS DEV, V18, P47, DOI 10.1089/scd.2007.0266
   Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907
   RUIZ IAA, 2004, CANC LETT, V204, P145
   Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533
   Schatton T, 2009, BIOESSAYS, V31, P1038, DOI 10.1002/bies.200900058
   Schuebel K, 2006, NAT GENET, V38, P738, DOI 10.1038/ng0706-738
   Sell S, 2004, CRIT REV ONCOL HEMAT, V51, P1, DOI 10.1016/j.critrevonc.2004.04.007
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011
   Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401
   Sieber O, 2005, SEMIN CANCER BIOL, V15, P61, DOI 10.1016/j.semcancer.2004.09.005
   Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170
   Singh SK, 2008, NATURE, V453, P223, DOI 10.1038/nature06863
   Singh SK, 2003, CANCER RES, V63, P5821
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160
   Suh MR, 2004, DEV BIOL, V270, P488, DOI 10.1016/j.ydbio.2004.02.019
   Tay Y, 2008, NATURE, V455, P1124, DOI 10.1038/nature07299
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892
   Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001
   Tomasson MH, 2009, J CELL BIOCHEM, V106, P745, DOI 10.1002/jcb.22050
   Tysnes BB, 2007, BBA-REV CANCER, V1775, P283, DOI 10.1016/j.bbcan.2007.01.001
   Vaissière T, 2008, MUTAT RES-REV MUTAT, V659, P40, DOI 10.1016/j.mrrev.2008.02.004
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Vlashi E, 2009, JNCI-J NATL CANCER I, V101, P350, DOI 10.1093/jnci/djn509
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Wang JL, 2010, STEM CELLS, V28, P17, DOI 10.1002/stem.261
   Wang J, 2008, INT J CANCER, V122, P761, DOI 10.1002/ijc.23130
   Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Wienholds E, 2005, SCIENCE, V309, P310, DOI 10.1126/science.1114519
   Wilson KD, 2009, STEM CELLS DEV, V18, P749, DOI 10.1089/scd.2008.0247
   Winquist RJ, 2009, BIOCHEM PHARMACOL, V78, P326, DOI 10.1016/j.bcp.2009.03.020
   Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038
   Yang AD, 2006, CLIN CANCER RES, V12, P4147, DOI 10.1158/1078-0432.CCR-06-0038
   Yilmaz ÖH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703
   You JS, 2009, CANCER RES, V69, P5716, DOI 10.1158/0008-5472.CAN-08-4953
   Zhang BH, 2007, J CELL PHYSIOL, V210, P279, DOI 10.1002/jcp.20869
   Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747
   Zhang M, 2010, P NATL ACAD SCI USA, V107, P3522, DOI 10.1073/pnas.0910179107
   Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137
NR 152
TC 71
Z9 85
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1476-5586
J9 NEOPLASIA
JI Neoplasia
PD JUL
PY 2010
VL 12
IS 7
BP 506
EP 515
DI 10.1593/neo.10290
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 634VE
UT WOS:000280612900001
PM 20651980
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Farias, EF
   Petrie, K
   Leibovitch, B
   Murtagh, J
   Chornet, MB
   Schenk, T
   Zelent, A
   Waxman, S
AF Farias, Eduardo F.
   Petrie, Kevin
   Leibovitch, Boris
   Murtagh, Janice
   Chornet, Manuel Boix
   Schenk, Tino
   Zelent, Arthur
   Waxman, Samuel
TI Interference with Sin3 function induces epigenetic reprogramming and
   differentiation in breast cancer cells
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE E-cadherin; estrogen receptor; triple-negative; Sin3 interaction domain
ID TO-MESENCHYMAL TRANSITION; TRANSCRIPTIONAL REPRESSION; E-CADHERIN;
   HISTONE DEACETYLASES; GENE-EXPRESSION; DOMAIN; MAD; METHYLATION;
   PROTEINS; FAMILY
AB Sin3A/B is a master transcriptional scaffold and corepressor that plays an essential role in the regulation of gene transcription and maintenance of chromatin structure, and its inappropriate recruitment has been associated with aberrant gene silencing in cancer. Sin3A/B are highly related, large, multidomian proteins that interact with a wide variety of transcription factors and corepressor components, and we examined whether disruption of the function of a specific domain could lead to epigenetic reprogramming and derepression of specific subsets of genes. To this end, we selected the Sin3A/B-paired amphipathic alpha-helices (PAH2) domain based on its established role in mediating the effects of a relatively small number of transcription factors containing a PAH2-binding motif known as the Sin3 interaction domain (SID). Here, we show that in both human and mouse breast cancer cells, the targeted disruption of Sin3 function by introduction of a SID decoy that interferes with PAH2 binding to SID-containing partner proteins reverted the silencing of genes involved in cell growth and differentiation. In particular, the SID decoy led to epigenetic reprogramming and reexpression of the important breast cancer-associated silenced genes encoding E-cadherin, estrogen receptor alpha, and retinoic acid receptor beta and impaired tumor growth in vivo. Interestingly, the SID decoy was effective in the triple-negative M. D. Anderson-Metastatic Breast-231 (MDA-MB-231) breast cancer cell line, restoring sensitivity to 17 beta-estradiol, tamoxifen, and retinoids. Therefore, the development of small molecules that can block interactions between PAH2 and SID-containing proteins offers a targeted epigenetic approach for treating this type of breast cancer that may also have wider therapeutic implications.
C1 [Farias, Eduardo F.; Leibovitch, Boris; Murtagh, Janice; Waxman, Samuel] Mt Sinai Sch Med, Tisch Canc Ctr, Div Hematol & Oncol, Dept Med, New York, NY 10029 USA.
   [Petrie, Kevin; Chornet, Manuel Boix; Schenk, Tino; Zelent, Arthur] Inst Canc Res, Sect Haematooncol, Sutton SM2 5NG, Surrey, England.
C3 Icahn School of Medicine at Mount Sinai; University of London; Institute
   of Cancer Research - UK
RP Waxman, S (通讯作者)，Mt Sinai Sch Med, Tisch Canc Ctr, Div Hematol & Oncol, Dept Med, New York, NY 10029 USA.
EM Samuel.Waxman@mssm.edu
RI Zelent, Arthur/B-3532-2009; Schenk, Tino/P-4381-2019; Petrie,
   Kevin/I-7115-2015
OI Petrie, Kevin/0000-0002-9805-9152; Leibovitch,
   Boris/0000-0001-6771-5906; Zelent, Arthur/0000-0002-7968-9888
FU Samuel Waxman Cancer Research Foundation; Chemotherapy Foundation;
   National Institutes of Health-National Cancer Institute
   [5R24-CA095823-04]; National Science Foundation [DBI-972404]; National
   Institutes of Health [1S10-RR0-9145-01]; Leukaemia and Lymphoma
   Research, UK
FX We thank Dr. T.-C. He (University of Chicago Medical Center, Chicago,
   IL) for pTHE and pTRE plasmids. This work was supported by the Samuel
   Waxman Cancer Research Foundation, the Chemotherapy Foundation, National
   Institutes of Health-National Cancer Institute Shared Resources Grant
   5R24-CA095823-04, National Science Foundation Major Research
   Instrumentation Grant DBI-972404, and National Institutes of Health
   Shared Instrumentation Grant 1S10-RR0-9145-01 to Mount Sinai School of
   Medicine's Microscopy Shared Resources Facility. K. P., T. S., and A.Z
   were also supported by a Program Grant from Leukaemia and Lymphoma
   Research, UK.
CR Ayer DE, 1996, MOL CELL BIOL, V16, P5772
   AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0
   Barrett A, 2002, INT J CANCER, V101, P581, DOI 10.1002/ijc.10644
   Barrett A, 2007, INT J CANCER, V121, P265, DOI 10.1002/ijc.22673
   Binda O, 2008, ONCOGENE, V27, P3384, DOI 10.1038/sj.onc.1211014
   Cardarelli F, 2008, TRAFFIC, V9, P528, DOI 10.1111/j.1600-0854.2007.00696.x
   Cerchietti LC, 2009, BLOOD, V113, P3397, DOI 10.1182/blood-2008-07-168773
   Cowin P, 2005, CURR OPIN CELL BIOL, V17, P499, DOI 10.1016/j.ceb.2005.08.014
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007
   Farias EF, 2005, ONCOGENE, V24, P1598, DOI 10.1038/sj.onc.1208347
   Farias EF, 2005, J NATL CANCER I, V97, P21, DOI 10.1093/jnci/dji004
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781
   Hu J, 2009, P NATL ACAD SCI USA, V106, P3342, DOI 10.1073/pnas.0813280106
   Jiang W, 2001, J BIOL CHEM, V276, P45168, DOI 10.1074/jbc.M106924200
   KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914
   Kuppumbatti YS, 2000, J NATL CANCER I, V92, P475, DOI 10.1093/jnci/92.6.475
   Le Guezennec X, 2004, J BIOL CHEM, V279, P25823, DOI 10.1074/jbc.M313860200
   Leong KG, 2007, J EXP MED, V204, P2935, DOI 10.1084/jem.20071082
   Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996
   Moshkin YM, 2009, MOL CELL, V35, P782, DOI 10.1016/j.molcel.2009.07.020
   Okitsu CY, 2007, MOL CELL BIOL, V27, P2746, DOI 10.1128/MCB.02291-06
   Ooi SKT, 2007, NATURE, V448, P714, DOI 10.1038/nature05987
   Petrie K, 2009, CURR OPIN HEMATOL, V16, P84, DOI 10.1097/MOH.0b013e3283257aee
   Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040
   SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9
   Secombe J, 2007, CELL CYCLE, V6, P1324, DOI 10.4161/cc.6.11.4269
   Silverstein RA, 2005, CURR GENET, V47, P1, DOI 10.1007/s00294-004-0541-5
   Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906
   van Ingen H, 2004, BIOCHEMISTRY-US, V43, P46, DOI 10.1021/bi0355645
   van Oevelen C, 2008, MOL CELL, V32, P359, DOI 10.1016/j.molcel.2008.10.015
   Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033
   Yamane K, 2007, MOL CELL, V25, P801, DOI 10.1016/j.molcel.2007.03.001
   Zelent A, 2008, CANCER RES, V68, P4967, DOI 10.1158/0008-5472.CAN-07-6779
NR 35
TC 55
Z9 63
U1 0
U2 10
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 29
PY 2010
VL 107
IS 26
BP 11811
EP 11816
DI 10.1073/pnas.1006737107
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 618DT
UT WOS:000279332300030
PM 20547842
OA Green Published
DA 2025-01-12
ER

PT J
AU Müller, I
   Wischnewski, F
   Pantel, K
   Schwarzenbach, H
AF Mueller, Imke
   Wischnewski, Frank
   Pantel, Klaus
   Schwarzenbach, Heidi
TI Promoter- and cell-specific epigenetic regulation of CD44, Cyclin D2,
   GLIPR1 and PTEN by Methyl-CpG binding proteins and histone modifications
SO BMC CANCER
LA English
DT Article
ID DNA METHYLATION; GENE; CANCER; HYPERMETHYLATION; EXPRESSION; RTVP-1;
   DOMAIN; IDENTIFICATION; P16(INK4A); HYALURONAN
AB Background : The aim of the current study was to analyze the involvement of methyl-CpG binding proteins (MBDs) and histone modifications on the regulation of CD44, Cyclin D2, GLIPR1 and PTEN in different cellular contexts such as the prostate cancer cells DU145 and LNCaP, and the breast cancer cells MCF-7. Since global chromatin changes have been shown to occur in tumours and regions of tumour-associated genes are affected by epigenetic modifications, these may constitute important regulatory mechanisms for the pathogenesis of malignant transformation.
   Methods : In DU145, LNCaP and MCF-7 cells mRNA expression levels of CD44, Cyclin D2, GLIPR1 and PTEN were determined by quantitative RT-PCR at the basal status as well as after treatment with demethylating agent 5-aza-2'deoxycytidine and/ or histone deacetylase inhibitor Trichostatin A. Furthermore, genomic DNA was bisulfite-converted and sequenced. Chromatin immunoprecipitation was performed with the stimulated and unstimulated cells using antibodies for MBD1, MBD2 and MeCP2 as well as 17 different histone antibodies.
   Results : Comparison of the different promoters showed that MeCP2 and MBD2a repressed promoter-specifically Cyclin D2 in all cell lines, whereas in MCF-7 cells MeCP2 repressed cell-specifically all methylated promoters. Chromatin immunoprecipitation showed that all methylated promoters associated with at least one MBD. Treatment of the cells by the demethylating agent 5-aza-2'-deoxycytidine (5-aza-CdR) caused dissociation of the MBDs from the promoters. Only MBD1v1 bound and repressed methylation-independently all promoters. Real-time amplification of DNA immunoprecipitated by 17 different antibodies showed a preferential enrichment for methylated lysine of histone H3 (H3K4me1, H3K4me2 and H3K4me3) at the particular promoters. Notably, the silent promoters were associated with unmodified histones which were acetylated following treatment by 5-aza-CdR.
   Conclusions : This study is one of the first to reveal the histone code and MBD profile at the promoters of CD44, Cyclin D2, GLIPR1 and PTEN in different tumour cells and associated changes after stimulation with methylation inhibitor 5aza-CdR.
C1 [Mueller, Imke; Wischnewski, Frank; Pantel, Klaus; Schwarzenbach, Heidi] Univ Med Ctr Hamburg Eppendorf, Dept Tumour Biol, D-20246 Hamburg, Germany.
C3 University of Hamburg; University Medical Center Hamburg-Eppendorf
RP Schwarzenbach, H (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Dept Tumour Biol, Martinistr 52, D-20246 Hamburg, Germany.
EM hschwarz@uke.uni-hamburg.de
FU European Commission [LSHCCT-2005-018911]
FX We thank Bettina Steinbach for her excellent technical assistance and
   Dirk Kemming for his support in setting up the real-time PCR
   experiments. We also like to thank Dr. Olaf Friese for providing the
   MBD1 knock out mouse. We are grateful to Lena Herich (Institute for
   Medical Biometrics and Epidemiology, UKE Hamburg, Germany) for
   assistance with the statistical evaluation of the data. This work was
   supported by the European Commission; grant number LSHCCT-2005-018911.
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Blanco-Aparicio C, 2007, CARCINOGENESIS, V28, P1379, DOI 10.1093/carcin/bgm052
   Dahl JA, 2007, STEM CELLS, V25, P1037, DOI 10.1634/stemcells.2006-0430
   Dillon RL, 2007, ONCOGENE, V26, P1338, DOI 10.1038/sj.onc.1210202
   El-Osta A, 2002, MOL CELL BIOL, V22, P1844, DOI 10.1128/MCB.22.6.1844-1857.2002
   Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024
   Fujita H, 2003, MOL CELL BIOL, V23, P2645, DOI 10.1128/MCB.23.8.2645-2657.2003
   Garcia-Segura LM, 2008, J NEUROENDOCRINOL, V20, P705, DOI 10.1111/j.1365-2826.2008.01713.x
   Götte M, 2006, CANCER RES, V66, P10233, DOI 10.1158/0008-5472.CAN-06-1464
   Hendrich B, 2003, TRENDS GENET, V19, P269, DOI 10.1016/S0168-9525(03)00080-5
   Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538
   Henrique R, 2006, J MOL MED, V84, P911, DOI 10.1007/s00109-006-0099-4
   Hirsch CL, 2004, FEBS LETT, V570, P37, DOI 10.1016/j.febslet.2004.06.018
   Isacke CM, 2002, INT J BIOCHEM CELL B, V34, P718, DOI 10.1016/S1357-2725(01)00166-2
   Jorgensen HF, 2004, MOL CELL BIOL, V24, P3387, DOI 10.1128/MCB.24.8.3387-3395.2004
   Kito H, 2001, PROSTATE, V49, P110, DOI 10.1002/pros.1124
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   Kondo E, 2005, MOL CELL BIOL, V25, P4388, DOI 10.1128/MCB.25.11.4388-4396.2005
   Krishnan M, 2010, ONCOGENE, V29, P305, DOI 10.1038/onc.2009.324
   Lopez-Serra L, 2006, CANCER RES, V66, P8342, DOI 10.1158/0008-5472.CAN-06-1932
   Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096
   Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659
   Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598
   Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370
   Peng ST, 2007, INT J ONCOL, V31, P1119
   Pryzbylkowski P, 2008, BREAST CANCER RES TR, V111, P15, DOI 10.1007/s10549-007-9751-0
   Radhakrishnan P, 2008, INT J BIOCHEM CELL B, V40, P1944, DOI 10.1016/j.biocel.2008.02.014
   Ren CZ, 2004, CANCER RES, V64, P969, DOI 10.1158/0008-5472.CAN-03-2592
   Rich T, 1996, GENE, V180, P125, DOI 10.1016/S0378-1119(96)00431-3
   Rosenzweig T, 2006, CANCER RES, V66, P4139, DOI 10.1158/0008-5472.CAN-05-2851
   Sawa H, 2001, Brain Tumor Pathol, V18, P109, DOI 10.1007/BF02479423
   Sharma G, 2007, LIFE SCI, V80, P1873, DOI 10.1016/j.lfs.2007.02.026
   Squazzo SL, 2006, GENOME RES, V16, P890, DOI 10.1101/gr.5306606
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Verkaik NS, 2000, LAB INVEST, V80, P1291, DOI 10.1038/labinvest.3780137
   Wischnewski F, 2007, MOL CANCER RES, V5, P749, DOI 10.1158/1541-7786.MCR-06-0364
   Yu F, 2001, NUCLEIC ACIDS RES, V29, P4493, DOI 10.1093/nar/29.21.4493
   Zheng YG, 2008, MED RES REV, V28, P645, DOI 10.1002/med.20120
NR 40
TC 24
Z9 32
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JUN 17
PY 2010
VL 10
AR 297
DI 10.1186/1471-2407-10-297
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 660RZ
UT WOS:000282662900001
PM 20565761
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Lee, JS
   Fackler, MJ
   Lee, JH
   Choi, C
   Park, MH
   Yoon, JH
   Zhang, Z
   Sukumar, S
AF Lee, Ji Shin
   Fackler, Mary Jo
   Lee, Jae Hyuk
   Choi, Chan
   Park, Min Ho
   Yoon, Jung Han
   Zhang, Zhe
   Sukumar, Saraswati
TI Basal-like breast cancer displays distinct patterns of promoter
   methylation
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE breast cancer; basal-like; luminal; HER2; methylation; quantitation
ID SPORADIC BREAST; DNA METHYLATION; TUMOR SUBTYPES; GENE; EXPRESSION;
   HYPERMETHYLATION; BRCA1; CLASSIFICATION; PROFILES; CARCINOMAS
AB Recent microarray profiling studies on breast cancer have identified distinct subtypes that are associated with different clinical outcomes. Promoter hypermethylation of several known or putative tumor suppressor genes occurs frequently during the pathogenesis of breast cancer. We proposed that immunohistopathologic subtypes of breast cancer are likely to contain distinct promoter methylation patterns. A panel of ten gene promoters was assessed by quantitative multiplex methylation-specific PCR in 114 invasive ductal carcinomas from Korea representing the three major subtypes [57 luminal, 24 human epidermal growth factor 2 (HER2), and 33 basal-like] based on immunohistochemical findings of estrogen receptor, progesterone receptor, HER2, cytokeratin 5/6 and epidermal growth factor receptor. The median methylation levels of HIN1, RASSF1A and TWIST, and the average methylation ratio were significantly lower in basal-like subtype compared to luminal or HER2 subtypes. In contrast, BRCA1 methylation level was significantly higher in basal-like subtype than in luminal subtype. The methylation status of a panel of four genes (APC1, CDH, BRCA1 and RAR-beta) in luminal and HER2 subtypes were dissimilar, where HER2 tumors showed a significantly higher level of methylation compared to luminal tumors. These results suggest that gene methylation in breast cancer can potentially serve as epigenetic biomarkers and may contribute further to current breast cancer classification.
C1 [Fackler, Mary Jo; Sukumar, Saraswati] Johns Hopkins Univ, Sch Med, Dept Biol, Breast Canc Program, Baltimore, MD 21218 USA.
   [Lee, Ji Shin; Lee, Jae Hyuk; Choi, Chan] Chonnam Natl Univ, Sch Med, Dept Pathol, Kwangju, South Korea.
   [Park, Min Ho; Yoon, Jung Han] Chonnam Natl Univ, Sch Med, Dept Surg, Kwangju, South Korea.
   [Park, Min Ho; Yoon, Jung Han] Res Inst Med Sci, Kwangju, South Korea.
   [Zhang, Zhe] Johns Hopkins Univ, Sch Med, Div Biostat, Dept Oncol, Baltimore, MD USA.
C3 Johns Hopkins University; Chonnam National University; Chonnam National
   University; Johns Hopkins University
RP Sukumar, S (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Biol, Breast Canc Program, Baltimore, MD 21218 USA.
EM saras@jhmi.edu
FU NIH [P50 CA88843]; DOD-COE [W81XWH-04-1-0595]; Korean Government
   (MOEHRD) [KRF-2007-313-E00099]
FX This work was supported by NIH SPORE P50 CA88843 and DOD-COE
   W81XWH-04-1-0595 to S. S. and the Korea Research Foundation Grant funded
   by the Korean Government (MOEHRD, Basic Research Promotion Fund)
   (KRF-2007-313-E00099) to Ji Shin Lee.
CR Alizadeh AA, 2001, J PATHOL, V195, P41, DOI 10.1002/path.889
   Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   Baylin SB, 2005, COLD SH Q B, V70, P427, DOI 10.1101/sqb.2005.70.010
   Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Bertolo C, 2008, AM J CLIN PATHOL, V130, P414, DOI 10.1309/J3QV9763DYPV338D
   Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509
   Chang YS, 2004, YONSEI MED J, V45, P435, DOI 10.3349/ymj.2004.45.3.435
   Costa VL, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-133
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Fackler MJ, 2006, CLIN CANCER RES, V12, P3306, DOI 10.1158/1078-0432.CCR-05-2733
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Gonzalgo ML, 2004, CLIN CANCER RES, V10, P7276, DOI 10.1158/1078-0432.CCR-03-0692
   Huang P, 2005, BIOMETRICS, V61, P532, DOI 10.1111/j.1541-0420.2005.00322.x
   Huang P, 2008, STAT MED, V27, P3084, DOI 10.1002/sim.3182
   Kern SE., 2001, MOL BASIS CANC, P41
   Ko SS, 2008, J SURG ONCOL, V98, P318, DOI 10.1002/jso.21110
   Lee JS, 2008, CANCER BIOL THER, V7, P1400
   Lehmann U, 2002, CANCER RES, V62, P6634
   Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248
   Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8
   Motoshita J, 2005, CANCER SCI, V96, P474, DOI 10.1111/j.1349-7006.2005.00074.x
   Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220
   Pal SK, 2009, MATURITAS, V63, P269, DOI 10.1016/j.maturitas.2009.06.010
   Rakha EA, 2008, J CLIN ONCOL, V26, P2568, DOI 10.1200/JCO.2007.13.1748
   Reis JS, 2008, J PATHOL, V216, P394, DOI 10.1002/path.2419
   Risinger JI, 2003, ANN NY ACAD SCI, V983, P208, DOI 10.1111/j.1749-6632.2003.tb05975.x
   Simpson PT, 2005, J PATHOL, V205, P248, DOI 10.1002/path.1691
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100
   Suijkerbuijk KPM, 2008, ANN ONCOL, V19, P1870, DOI 10.1093/annonc/mdn409
   Tisserand P, 2003, CANCER BIOL THER, V2, P559, DOI 10.4161/cbt.2.5.511
   Toyooka S, 2003, INT J CANCER, V103, P153, DOI 10.1002/ijc.10787
   Turner N, 2005, CURR OPIN PHARMACOL, V5, P388, DOI 10.1016/j.coph.2005.03.006
   Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
NR 38
TC 28
Z9 33
U1 1
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD JUN 15
PY 2010
VL 9
IS 12
BP 1017
EP 1024
DI 10.4161/cbt.9.12.11804
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 662TV
UT WOS:000282836700012
PM 20505321
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Bapat, SA
   Krishnan, A
   Ghanate, AD
   Kusumbe, AP
   Kalra, RS
AF Bapat, Sharmila A.
   Krishnan, Anagha
   Ghanate, Avinash D.
   Kusumbe, Anjali P.
   Kalra, Rajkumar S.
TI Gene Expression: Protein Interaction Systems Network Modeling Identifies
   Transformation-Associated Molecules and Pathways in Ovarian Cancer
SO CANCER RESEARCH
LA English
DT Article
ID LONG-RANGE INTERACTION; COPY NUMBER GAIN; THERAPEUTIC TARGET;
   COLORECTAL-CANCER; BREAST-CANCER; STEM-CELLS; CARCINOMA; BIOMARKER;
   PROMOTER; 8Q24
AB Multiple, dissimilar genetic defects in cancers of the same origin contribute to heterogeneity in tumor phenotypes and therapeutic responses of patients, yet the associated molecular mechanisms remain elusive. Here, we show at the systems level that serous ovarian carcinoma is marked by the activation of interconnected modules associated with a specific gene set that was derived from three independent tumor-specific gene expression data sets. Network prediction algorithms combined with preestablished protein interaction networks and known functionalities affirmed the importance of genes associated with ovarian cancer as predictive biomarkers, besides "discovering" novel ones purely on the basis of interconnectivity, whose precise involvement remains to be investigated. Copy number alterations and aberrant epigenetic regulation were identified and validated as significant influences on gene expression. More importantly, three functional modules centering on c-Myc activation, altered retinoblastoma signaling, and p53/cell cycle/DNA damage repair pathways have been identified for their involvement in transformation-associated events. Further studies will assign significance to and aid the design of a panel of specific markers predictive of individual-and tumor-specific pathways. In the parlance of this emerging field, such networks of gene-hub interactions may define personalized therapeutic decisions. Cancer Res; 70( 12); 4809-19. (C)2010 AACR.
C1 [Bapat, Sharmila A.; Kusumbe, Anjali P.; Kalra, Rajkumar S.] Natl Ctr Cell Sci, Pune 411007, Maharashtra, India.
   [Krishnan, Anagha; Ghanate, Avinash D.] Pune Univ, Inst Bioinformat & Biotechnol, Pune, Maharashtra, India.
C3 Department of Biotechnology (DBT) India; National Centre for Cell
   Science, Pune (NCCS); Savitribai Phule Pune University
RP Bapat, SA (通讯作者)，Natl Ctr Cell Sci, NCCS Complex, Pune 411007, Maharashtra, India.
EM sabapat@nccs.res.in
RI Ghanate, Avinash/JVO-1306-2024; Bapat, Sharmila/AGU-4130-2022; Kalra,
   Rajkumar/L-6944-2018
OI Bapat, Sharmila/0000-0002-9557-2233; Kalra,
   Rajkumar/0000-0002-8181-457X; Ghanate, Avinash/0000-0002-6284-7667
FU Department of Biotechnology, Government of India, New Delhi
   [BT/PR11465/Med/30/145/2008]; Council of Scientific and Industrial
   Research, New Delhi
FX Department of Biotechnology, Government of India, New Delhi, grant no.
   BT/PR11465/Med/30/145/2008 ( S. A. Bapat). A. P. Kusumbe and R. S. Kalra
   receive a research fellowship from the Council of Scientific and
   Industrial Research, New Delhi.
CR Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931
   Berchuck A, 2009, CLIN CANCER RES, V15, P2448, DOI 10.1158/1078-0432.CCR-08-2430
   Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296
   Biswas S, 2008, GENE CHROMOSOME CANC, V47, P95, DOI 10.1002/gcc.20511
   Chan TA, 2008, PLOS MED, V5, P823, DOI 10.1371/journal.pmed.0050114
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385
   Dekel B, 2006, CANCER RES, V66, P6040, DOI 10.1158/0008-5472.CAN-05-4528
   Fejzo MS, 2008, GENE CHROMOSOME CANC, V47, P873, DOI 10.1002/gcc.20592
   Frigola J, 2005, ONCOGENE, V24, P7320, DOI 10.1038/sj.onc.1208883
   Ghoussaini M, 2008, JNCI-J NATL CANCER I, V100, P962, DOI 10.1093/jnci/djn190
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Ishikawa N, 2007, CANCER RES, V67, P11601, DOI 10.1158/0008-5472.CAN-07-3243
   Kilpinen S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r139
   Köbel M, 2008, PLOS MED, V5, P1749, DOI 10.1371/journal.pmed.0050232
   Kulkarni AA, 2009, CLIN CANCER RES, V15, P2417, DOI 10.1158/1078-0432.CCR-08-1276
   Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154
   Kusumbe AP, 2009, CANCER RES, V69, P9245, DOI 10.1158/0008-5472.CAN-09-2802
   Kusumbe AP, 2009, STEM CELLS, V27, P498, DOI 10.1634/stemcells.2008-0868
   Lawrenson K, 2009, PLOS MED, V6, P126, DOI 10.1371/journal.pmed.1000025
   LEE PS, 2009, INT J CANCER, V26, P1378
   Li Y, 2008, EXP MOL PATHOL, V84, P234, DOI 10.1016/j.yexmp.2008.03.013
   Lin MT, 2009, INT J CANCER, V125, P603, DOI 10.1002/ijc.24346
   Margolin LG, 2006, J TURBUL, V7, P1, DOI 10.1080/14685240500331595
   Nakanishi H, 2004, ONCOL REP, V12, P1273
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Peiró G, 2002, AM J CLIN PATHOL, V118, P922, DOI 10.1092/JU8YP7MJK2WDT1FY
   Pomerantz MM, 2009, NAT GENET, V41, P882, DOI 10.1038/ng.403
   Pontén F, 2008, J PATHOL, V216, P387, DOI 10.1002/path.2440
   Sadr-Nabavi A, 2009, INT J CANCER, V124, P1727, DOI 10.1002/ijc.24108
   Scotto L, 2008, GENE CHROMOSOME CANC, V47, P755, DOI 10.1002/gcc.20577
   Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289
   Staebler A, 2006, GENE CHROMOSOME CANC, V45, P905, DOI 10.1002/gcc.20356
   Swanton C, 2009, BRIT J CANCER, V100, P1517, DOI 10.1038/sj.bjc.6605031
   Takano M, 2001, Hum Cell, V14, P267
   Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403
   Vucic EA, 2008, PHARMACOGENOMICS, V9, P215, DOI 10.2217/14622416.9.2.215
   Wang YP, 2005, ANN NY ACAD SCI, V1058, P162, DOI 10.1196/annals.1359.024
   Wani AA, 2006, ONCOGENE, V25, P6336, DOI 10.1038/sj.onc.1209649
   Wu JM, 2009, NAT METHODS, V6, P75, DOI [10.1038/NMETH.1282, 10.1038/nmeth.1282]
   Yamamoto A, 2006, BIOCHEM BIOPH RES CO, V346, P1324, DOI 10.1016/j.bbrc.2006.06.057
   Yan T, 2001, CANCER RES, V61, P8290
   Yasui DH, 2007, P NATL ACAD SCI USA, V104, P19416, DOI 10.1073/pnas.0707442104
   Zhou ZX, 2006, CANCER RES, V66, P7889, DOI 10.1158/0008-5472.CAN-06-0486
NR 43
TC 37
Z9 42
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD JUN 15
PY 2010
VL 70
IS 12
BP 4809
EP 4819
DI 10.1158/0008-5472.CAN-10-0447
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 610QP
UT WOS:000278749600004
PM 20530682
OA Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Chen, SA
   Ye, JJ
   Kijima, I
   Evans, D
AF Chen, Shiuan
   Ye, Jingjing
   Kijima, Ikuko
   Evans, Dean
TI The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of
   aromatase gene expression
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITOR; TISSUE-SPECIFIC EXONS-1; BREAST-CANCER;
   ESTROGEN BIOSYNTHESIS; RANDOMIZED-TRIAL; ALTERNATIVE USE; MESSENGER-RNA;
   DNA; PROTEIN; PROMOTERS
AB Aromatase converts androgens to estrogens. Although third-generation aromatase inhibitors (AIs) are important drugs in hormonal therapy for breast cancer in postmenopausal women, there are concerns about the side effects associated with the estrogen deprivation achieved with AIs. Expression of aromatase in breast cancer tissue is driven by different promoters than those in noncancer tissues; thus, suppression of aromatase expression in cancer tissues through the down-regulation of breast tumor-specific promoters would reduce the side effects associated with whole-body suppression of estrogen biosynthesis by AIs. We report that histone deacetylase inhibitor LBH589 (panobinostat) is a potent inhibitor of aromatase expression (with an IC50 value < 25 nM). LBH589 selectively suppresses human aromatase gene promoters I.3/II, which are preferentially used in breast cancer tissue. Furthermore, using the H295R cell culture model, we found that achieving the same degree of inhibition of aromatase activity required only one-fifth as much letrozole (an AI) in the presence of 25 nM LBH589 as in the absence of LBH589. We also used an H295R/MCF7 coculture model to demonstrate the synergistic interaction of LBH589 + letrozole in suppressing the proliferation of hormone-responsive breast cancer cells. Finally, our results also indicate that LBH589 down-regulates the activity of promoters I.3/II in an epigenetic fashion. LBH589 reduces the levels of C/EBP delta, decreases the binding of C/EBP delta, and increases the levels and binding of acetyl-histones to the promoters I.3/II. These findings provide an important basis for future clinical evaluations of LBH589 in hormone-dependent breast cancer.
C1 [Chen, Shiuan; Ye, Jingjing; Kijima, Ikuko] City Hope Natl Med Ctr, Beckman Res Inst, Div Tumor Cell Biol, Duarte, CA 91010 USA.
   [Evans, Dean] Novartis Pharma Ag, Novartis Inst Biomed Res, Oncol Res, CH-4002 Basel, Switzerland.
C3 City of Hope; Beckman Research Institute of City of Hope; Novartis
RP Chen, SA (通讯作者)，City Hope Natl Med Ctr, Beckman Res Inst, Div Tumor Cell Biol, Duarte, CA 91010 USA.
EM schen@coh.org
RI Flicek, Paul/JOZ-9351-2023
FU Susan G. Komen [KG080161]; National Institutes of Health [CA44735]
FX We thank Dr. Dujin Zhou for her help in the Western blot analysis of ER
   alpha and ER beta expression in H295R cells before and after LBH589
   treatment. This research was supported by Susan G. Komen for the Cure
   Grant KG080161 and National Institutes of Health Grant CA44735.
CR ACKERMAN GE, 1981, J CLIN ENDOCR METAB, V53, P412, DOI 10.1210/jcem-53-2-412
   Agarwal VR, 1996, J CLIN ENDOCR METAB, V81, P3843, DOI 10.1210/jc.81.11.3843
   Atadja P, 2009, CANCER LETT, V280, P233, DOI 10.1016/j.canlet.2009.02.019
   Banerji U, 2009, CLIN CANCER RES, V15, P9, DOI 10.1158/1078-0432.CCR-08-0132
   Bots M, 2009, CLIN CANCER RES, V15, P3970, DOI 10.1158/1078-0432.CCR-08-2786
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   *BREAST CANC ACT, 2008, SID EFF REV WOM EXP
   BULUN SE, 1993, J CLIN ENDOCR METAB, V77, P1622, DOI 10.1210/jc.77.6.1622
   Bulun SE, 2003, J STEROID BIOCHEM, V86, P219, DOI 10.1016/S0960-0760(03)00359-5
   Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299
   CHEN SU, 1988, DNA-J MOLEC CELL BIO, V7, P27, DOI 10.1089/dna.1988.7.27
   Chinnaiyan P, 2006, INT J CANCER, V118, P1041, DOI 10.1002/ijc.21465
   Coombes RC, 2004, NEW ENGL J MED, V350, P1081, DOI 10.1056/NEJMoa040331
   COOMBES RC, 2004, NEW ENGL J MED, V355, P1746
   Dokmanovic M, 2007, MOL CANCER RES, V5, P981, DOI 10.1158/1541-7786.MCR-07-0324
   Edwards A, 2007, MOL CANCER THER, V6, P2515, DOI 10.1158/1535-7163.MCT-06-0761
   Ellis L, 2008, CLIN CANCER RES, V14, P4500, DOI 10.1158/1078-0432.CCR-07-4262
   Ellis L, 2009, BLOOD, V114, P380, DOI 10.1182/blood-2008-10-182758
   Elsheikh SE, 2009, CANCER RES, V69, P3802, DOI 10.1158/0008-5472.CAN-08-3907
   Fantin VR, 2007, CLIN CANCER RES, V13, P7237, DOI 10.1158/1078-0432.CCR-07-2114
   Fiskus W, 2007, CLIN CANCER RES, V13, P4882, DOI 10.1158/1078-0432.CCR-06-3093
   Fiskus W, 2006, MOL CANCER THER, V5, P3096, DOI 10.1158/1535-7163.MCT-06-0418
   Foster PA, 2008, CLIN CANCER RES, V14, P6469, DOI 10.1158/1078-0432.CCR-08-1027
   Goss PE, 2005, JNCI-J NATL CANCER I, V97, P1262, DOI 10.1093/jnci/dji250
   Harada N, 1997, J STEROID BIOCHEM, V61, P175
   HARADA N, 1992, BIOCHEM BIOPH RES CO, V189, P1001, DOI 10.1016/0006-291X(92)92303-F
   HARADA N, 1993, P NATL ACAD SCI USA, V90, P11312, DOI 10.1073/pnas.90.23.11312
   Hauswald S, 2009, CLIN CANCER RES, V15, P3705, DOI 10.1158/1078-0432.CCR-08-2048
   Howell A, 2005, LANCET, V365, P60, DOI 10.1016/s0140-6736(04)17666-6
   JAMES V H T, 1987, Steroids, V50, P269, DOI 10.1016/0039-128X(83)90077-6
   Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5
   Kijima I, 2008, CANCER RES, V68, P4455, DOI 10.1158/0008-5472.CAN-07-3249
   Kijima I, 2006, CANCER RES, V66, P5960, DOI 10.1158/0008-5472.CAN-06-0053
   LaBonte MJ, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-67
   Lee YS, 2008, CANCER RES, V68, P7561, DOI 10.1158/0008-5472.CAN-08-0188
   Lester J, 2005, BRIT J CANCER, V93, pS16, DOI 10.1038/sj.bjc.6602691
   Maiso P, 2009, LEUKEMIA, V23, P2265, DOI 10.1038/leu.2009.182
   Maiso P, 2006, CANCER RES, V66, P5781, DOI 10.1158/0008-5472.CAN-05-4186
   Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272
   Nicol MR, 2009, MOL CELL ENDOCRINOL, V300, P115, DOI 10.1016/j.mce.2008.10.032
   Okubo T, 2001, CANCER RES, V61, P1338
   Qiao LP, 2006, ENDOCRINOLOGY, V147, P865, DOI 10.1210/en.2005-1030
   Schrump DS, 2009, CLIN CANCER RES, V15, P3947, DOI 10.1158/1078-0432.CCR-08-2787
   Scuto A, 2008, BLOOD, V111, P5093, DOI 10.1182/blood-2007-10-117762
   Shan B, 2008, J BIOL CHEM, V283, P21065, DOI 10.1074/jbc.M802786200
   Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200
   Sun XZ, 1997, J STEROID BIOCHEM, V63, P29, DOI 10.1016/S0960-0760(97)00068-X
   Utsumi T, 1996, J CLIN ENDOCR METAB, V81, P2344, DOI 10.1210/jc.81.6.2344
   Wang X, 2006, CANCER RES, V66, P10281, DOI 10.1158/0008-5472.CAN-06-2134
   Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620
   Xu WS, 2006, P NATL ACAD SCI USA, V103, P15540, DOI 10.1073/pnas.0607518103
   Yang C, 1998, CANCER RES, V58, P5695
   Yang C, 2002, ONCOGENE, V21, P2854, DOI 10.1038/sj.onc.1205386
   Zhou CB, 1996, J STEROID BIOCHEM, V59, P163, DOI 10.1016/S0960-0760(96)00100-8
   ZHOU D, 1990, CANCER RES, V50, P6949
   Zhou DJ, 1999, ARCH BIOCHEM BIOPHYS, V371, P179, DOI 10.1006/abbi.1999.1454
   Zhou Q, 2008, MOL CANCER RES, V6, P873, DOI 10.1158/1541-7786.MCR-07-0330
   Zhou Q, 2007, CANCER BIOL THER, V6, P64, DOI 10.4161/cbt.6.1.3549
NR 58
TC 40
Z9 44
U1 0
U2 7
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 15
PY 2010
VL 107
IS 24
BP 11032
EP 11037
DI 10.1073/pnas.1000917107
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 611IC
UT WOS:000278807400047
PM 20534486
OA Green Published
DA 2025-01-12
ER

PT J
AU Knower, KC
   To, SQ
   Simpson, ER
   Clyne, CD
AF Knower, Kevin C.
   To, Sarah Q.
   Simpson, Evan R.
   Clyne, Colin D.
TI Epigenetic mechanisms regulating CYP19 transcription in human breast
   adipose fibroblasts
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE Breast cancer; Epigenetics; Aromatase; Breast adipose fibroblasts;
   Estrogen biosynthesis
ID AROMATASE CYTOCHROME-P450 TRANSCRIPTS; POLYMERASE-CHAIN-REACTION; DNA
   METHYLATION; GENE-EXPRESSION; STROMAL CELLS; ALTERNATIVE PROMOTERS;
   ABERRANT EXPRESSION; SODIUM-BUTYRATE; BINDING-SITE; CANCER-CELLS
AB Cytochrome aromatase p450, encoded by the gene CYP19, catalyzes the synthesis of estrogens from androgens. In post-menopausal women, adipose becomes the major site for estrogen production, where basal CYP19 transcription is driven by distal promoter I 4 In breast adipose fibroblasts (BAFs). CYP19 expression is elevated in the presence of tumour-derived factors through use of promoters 13 and 11 We show for the first time that DNA methylation contributes to CYP19 regulation in BAFs and breast cell lines Promoter I 4 and I 3/II-derived mRNA were not dependent on the CpG methylation status within respective promoters However, inhibition of DNA methylation with 5-aza-2'-deoxycytidine resulted in a significant similar to 40-fold induction in CYP19 mRNA expression in BAFs and breast cell lines These studies uncover a new layer of complexity in the regulation of aromatase where CYP19 appears to be inhibited by DNA methylation and evokes the possibility that disruption to this epigenetic regulation may give rise to an increase in aromatase levels in the breast. Published by Elsevier Ireland Ltd
C1 [Knower, Kevin C.; To, Sarah Q.; Simpson, Evan R.; Clyne, Colin D.] Prince Henrys Inst Med Res, Clayton, Vic 3168, Australia.
   [To, Sarah Q.; Simpson, Evan R.; Clyne, Colin D.] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia.
C3 Prince Henry's Institute of Medical Research; Monash University
RP Knower, KC (通讯作者)，Prince Henrys Inst Med Res, POB 5152, Clayton, Vic 3168, Australia.
RI Knower, Kevin/C-2869-2014
OI To, Sarah Quynh Giao/0000-0002-7198-484X
FU National Health & Medical Research Council of Australia (CDC) [338518];
   Victorian Breast Cancer Research Consortium Inc.; U.S. Department of
   Defense [W81XWH-08-BCRP-POSTDOC]
FX This work was supported by the National Health & Medical Research
   Council of Australia (CDC, 338518) and the Victorian Breast Cancer
   Research Consortium Inc. K.C.K. supported by a U.S. Department of
   Defense Post-doctoral Training Award (W81XWH-08-BCRP-POSTDOC).
CR ACKERMAN GE, 1981, J CLIN ENDOCR METAB, V53, P412, DOI 10.1210/jcem-53-2-412
   Agarwal VR, 1996, J CLIN ENDOCR METAB, V81, P3843, DOI 10.1210/jc.81.11.3843
   Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010
   Bock C, 2005, BIOINFORMATICS, V21, P4067, DOI 10.1093/bioinformatics/bti652
   Brena RM, 2006, NAT GENET, V38, P1359, DOI 10.1038/ng1206-1359
   Brueggemeier RW, 1999, CANCER LETT, V140, P27, DOI 10.1016/S0304-3835(99)00050-6
   Bulun SE, 2004, SEMIN REPROD MED, V22, P5
   BULUN SE, 1993, J CLIN ENDOCR METAB, V77, P1622, DOI 10.1210/jc.77.6.1622
   BULUN SE, 1994, BREAST CANCER RES TR, V30, P19, DOI 10.1007/BF00682738
   BULUN SE, 1994, J CLIN ENDOCR METAB, V78, P428, DOI 10.1210/jc.78.2.428
   Carlini P, 2007, EXPERT OPIN INV DRUG, V16, P1023, DOI 10.1517/13543784.16.7.1023
   Chandrasekhar K, 1997, MOL REPROD DEV, V48, P421
   CLELAND WH, 1985, J CLIN ENDOCR METAB, V60, P174, DOI 10.1210/jcem-60-1-174
   Clyne CD, 2002, J BIOL CHEM, V277, P20591, DOI 10.1074/jbc.M201117200
   Dannenberg LO, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-181
   Deb S, 2006, J BIOL CHEM, V281, P2585, DOI 10.1074/jbc.M508498200
   Demura M, 2008, MOL CELL ENDOCRINOL, V283, P127, DOI 10.1016/j.mce.2007.12.003
   Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909
   Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024
   Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508
   Flotho C, 2009, LEUKEMIA, V23, P1019, DOI 10.1038/leu.2008.397
   Fürbass R, 2008, MOL REPROD DEV, V75, P1, DOI 10.1002/mrd.20756
   Fujii G, 2006, BIOCHEM J, V395, P203, DOI 10.1042/BJ20051802
   Fürbass R, 2001, EUR J BIOCHEM, V268, P1222, DOI 10.1046/j.1432-1327.2001.01988.x
   Harada N, 1997, J STEROID BIOCHEM, V61, P175
   HARADA N, 1993, P NATL ACAD SCI USA, V90, P11312, DOI 10.1073/pnas.90.23.11312
   HINSHELWOOD RA, 2008, J MOL MED
   Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596
   Imir AG, 2007, J CLIN ENDOCR METAB, V92, P1979, DOI 10.1210/jc.2006-2482
   Irahara N, 2006, INT J CANCER, V118, P1915, DOI 10.1002/ijc.21562
   Izawa M, 2008, FERTIL STERIL, V89, P1390, DOI 10.1016/j.fertnstert.2007.03.078
   Jones B, 2006, EMBO J, V25, P2443, DOI 10.1038/sj.emboj.7601148
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kijima I, 2008, CANCER RES, V68, P4455, DOI 10.1158/0008-5472.CAN-07-3249
   LESHIN M, 1985, P NATL ACAD SCI USA, V82, P3005, DOI 10.1073/pnas.82.9.3005
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   MAHENDROO MS, 1993, J BIOL CHEM, V268, P19463
   Qiu W, 2008, NAT GENET, V40, P650, DOI 10.1038/ng.117
   Rink JD, 1996, J CLIN ENDOCR METAB, V81, P2443, DOI 10.1210/jc.81.7.2443
   Rohde C, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn083
   Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011
   SCHREY MP, 1995, BRIT J CANCER, V72, P1412, DOI 10.1038/bjc.1995.523
   Shann YJ, 2008, GENOME RES, V18, P791, DOI 10.1101/gr.070961.107
   Simpson ER, 2004, SEMIN REPROD MED, V22, P11
   Simpson ER, 1997, RECENT PROG HORM RES, V52, P185
   Sofi M, 2003, BREAST CANCER RES TR, V79, P399, DOI 10.1023/A:1024038632570
   Sullivan KE, 2007, MOL CELL BIOL, V27, P5147, DOI 10.1128/MCB.02429-06
   Tao LH, 2000, CANCER LETT, V158, P185, DOI 10.1016/S0304-3835(00)00518-8
   THORSEN T, 1982, EUR J CANCER CLIN ON, V18, P333, DOI 10.1016/0277-5379(82)90002-5
   Vanselow J, 2005, MOL CELL ENDOCRINOL, V233, P57, DOI 10.1016/j.mce.2005.01.007
   VANSELOW J, 2008, EXP CLIN ENDOCRINOL
   Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007
   ZHAO Y, 1995, MOL ENDOCRINOL, V9, P340, DOI 10.1210/me.9.3.340
   ZHAO Y, 1995, J BIOL CHEM, V270, P16449, DOI 10.1074/jbc.270.27.16449
   Zhao Y, 1996, ENDOCRINOLOGY, V137, P5739, DOI 10.1210/en.137.12.5739
   Zhao Y, 1996, MOL ENDOCRINOL, V10, P1350, DOI 10.1210/me.10.11.1350
   Zhou DJ, 1997, J STEROID BIOCHEM, V61, P273
   Zilberman D, 2007, DEVELOPMENT, V134, P3959, DOI 10.1242/dev.001131
NR 58
TC 34
Z9 37
U1 0
U2 9
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303-7207
EI 1872-8057
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD JUN 10
PY 2010
VL 321
IS 2
BP 123
EP 130
DI 10.1016/j.mce.2010.02.035
PG 8
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA 599ND
UT WOS:000277919000003
PM 20211687
DA 2025-01-12
ER

PT J
AU Loss, LA
   Sadanandam, A
   Durinck, S
   Nautiyal, S
   Flaucher, D
   Carlton, VEH
   Moorhead, M
   Lu, YT
   Gray, JW
   Faham, M
   Spellman, P
   Parvin, B
AF Loss, Leandro A.
   Sadanandam, Anguraj
   Durinck, Steffen
   Nautiyal, Shivani
   Flaucher, Diane
   Carlton, Victoria E. H.
   Moorhead, Martin
   Lu, Yontao
   Gray, Joe W.
   Faham, Malek
   Spellman, Paul
   Parvin, Bahram
TI Prediction of epigenetically regulated genes in breast cancer cell lines
SO BMC BIOINFORMATICS
LA English
DT Article
ID DNA METHYLATION; ESTROGEN-RECEPTOR; EXPRESSION; HYPERMETHYLATION;
   PROTEIN; PROGRESSION; MICROARRAY; SITE
AB Background: Methylation of CpG islands within the DNA promoter regions is one mechanism that leads to aberrant gene expression in cancer. In particular, the abnormal methylation of CpG islands may silence associated genes. Therefore, using high-throughput microarrays to measure CpG island methylation will lead to better understanding of tumor pathobiology and progression, while revealing potentially new biomarkers. We have examined a recently developed high-throughput technology for measuring genome-wide methylation patterns called mTACL. Here, we propose a computational pipeline for integrating gene expression and CpG island methylation profles to identify epigenetically regulated genes for a panel of 45 breast cancer cell lines, which is widely used in the Integrative Cancer Biology Program (ICBP). The pipeline (i) reduces the dimensionality of the methylation data, (ii) associates the reduced methylation data with gene expression data, and (iii) ranks methylation-expression associations according to their epigenetic regulation. Dimensionality reduction is performed in two steps: (i) methylation sites are grouped across the genome to identify regions of interest, and (ii) methylation profles are clustered within each region. Associations between the clustered methylation and the gene expression data sets generate candidate matches within a fxed neighborhood around each gene. Finally, the methylation-expression associations are ranked through a logistic regression, and their significance is quantified through permutation analysis.
   Results: Our two-step dimensionality reduction compressed 90% of the original data, reducing 137,688 methylation sites to 14,505 clusters. Methylation-expression associations produced 18,312 correspondences, which were used to further analyze epigenetic regulation. Logistic regression was used to identify 58 genes from these correspondences that showed a statistically signifcant negative correlation between methylation profles and gene expression in the panel of breast cancer cell lines. Subnetwork enrichment of these genes has identifed 35 common regulators with 6 or more predicted markers. In addition to identifying epigenetically regulated genes, we show evidence of differentially expressed methylation patterns between the basal and luminal subtypes.
   Conclusions: Our results indicate that the proposed computational protocol is a viable platform for identifying epigenetically regulated genes. Our protocol has generated a list of predictors including COL1A2, TOP2A, TFF1, and VAV3, genes whose key roles in epigenetic regulation is documented in the literature. Subnetwork enrichment of these predicted markers further suggests that epigenetic regulation of individual genes occurs in a coordinated fashion and through common regulators.
C1 [Loss, Leandro A.; Sadanandam, Anguraj; Durinck, Steffen; Gray, Joe W.; Spellman, Paul; Parvin, Bahram] Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA.
   [Nautiyal, Shivani; Flaucher, Diane; Carlton, Victoria E. H.; Moorhead, Martin; Lu, Yontao; Faham, Malek] Affymetrix Inc, Santa Clara, CA USA.
C3 United States Department of Energy (DOE); Lawrence Berkeley National
   Laboratory; University of California System; University of California
   Berkeley; Affymetrix
RP Loss, LA (通讯作者)，Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA.
EM laloss@lbl.gov; B_Parvin@lbl.gov
RI Gray, Joe/AAX-9549-2020
OI Sadanandam, Anguraj/0000-0001-8485-5150
FU Office of Science, Office of Biological & Environmental Research, of the
   U.S. Department of Energy [DE-AC02-05CH11231]; National Institutes of
   Health, National Cancer Institute [P50 CA 58207, U54 CA 112970]
FX This work was supported by the Director, Office of Science, Office of
   Biological & Environmental Research, of the U.S. Department of Energy
   under Contract No. DE-AC02-05CH11231, and by the National Institutes of
   Health, National Cancer Institute grants P50 CA 58207, and the U54 CA
   112970.
CR Anderton JA, 2008, NEURO-ONCOLOGY, V10, P981, DOI 10.1215/15228517-2008-048
   [Anonymous], 2015, Adaptive Control Processes-A Guided Tour, DOI DOI 10.1515/9781400874668
   [Anonymous], 1996, EPIGENETIC MECH GENE
   Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103
   Bock C, 2008, BIOINFORMATICS, V24, P1, DOI 10.1093/bioinformatics/btm546
   Borg Å, 2000, J NATL CANCER I, V92, P1260, DOI 10.1093/jnci/92.15.1260
   BRASEL JC, 2010, CLIN CANC RES, V16
   Chiba T, 2005, EUR J CANCER, V41, P1185, DOI 10.1016/j.ejca.2005.02.014
   Chung R. K. F., 1997, Spectral Graph Theory
   DAVIDSON B, 2010, J CELL MOL MED
   Dietrich D, 2009, J HISTOCHEM CYTOCHEM, V57, P477, DOI 10.1369/jhc.2009.953026
   Dillon N, 2006, CHROMOSOME RES, V14, P117, DOI 10.1007/s10577-006-1027-8
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Hartigan J. A., 1979, Applied Statistics, V28, P100, DOI 10.2307/2346830
   Hui AM, 2000, CANCER LETT, V154, P93, DOI 10.1016/S0304-3835(00)00385-2
   Jain A. K., 1988, Algorithms for Clustering Data, V6
   Johnson N, 2008, BREAST CANCER RES TR, V111, P55, DOI 10.1007/s10549-007-9758-6
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lee KW, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-158
   Martin V, 1997, J CELL BIOCHEM, V65, P95, DOI 10.1002/(SICI)1097-4644(199704)65:1<95::AID-JCB10>3.0.CO;2-G
   NAUTIYAL S, PNAS IN PRESS
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Ng AY, 2002, ADV NEUR IN, V14, P849
   NGUYEN A, 2010, FJ EXPRESS, DOI DOI 10.1096/FJ.FJ.10-154484
   Rody A, 2009, BREAST CANCER RES TR, V113, P457, DOI 10.1007/s10549-008-9964-x
   Sengupta PK, 2003, CANCER RES, V63, P1789
   Shi JB, 2000, IEEE T PATTERN ANAL, V22, P888, DOI 10.1109/34.868688
   Sjahputera O, 2007, IEEE ACM T COMPUT BI, V4, P176, DOI 10.1109/TCBB.2007.070205
   Wicki R, 1997, CELL CALCIUM, V22, P243, DOI 10.1016/S0143-4160(97)90063-4
   Widschwendter M, 2004, CANCER RES, V64, P4472, DOI 10.1158/0008-5472.CAN-04-0238
NR 32
TC 33
Z9 39
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PD JUN 4
PY 2010
VL 11
AR 305
DI 10.1186/1471-2105-11-305
PG 14
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
GA 631FB
UT WOS:000280330900001
PM 20525369
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Shu, ST
   Sugimoto, Y
   Liu, SL
   Chang, HL
   Ye, WP
   Wang, LS
   Huang, YW
   Yan, P
   Lin, YC
AF Shu, Sherry T.
   Sugimoto, Yasuro
   Liu, Suling
   Chang, Hsiang-Lin
   Ye, Weiping
   Wang, Li-Shu
   Huang, Yi-Wen
   Yan, Pearlly
   Lin, Young C.
TI Function and Regulatory Mechanisms of the Candidate Tumor Suppressor
   Receptor Protein Tyrosine Phosphatase Gamma (PTPRG) in Breast Cancer
   Cells
SO ANTICANCER RESEARCH
LA English
DT Article
DE PTPG; breast cancer; tumor suppressor; cell cycle regulators
ID HUMAN LUNG-CANCER; ETA SUPPRESSES; EXPRESSION; GENE; ACTIVATION;
   DEGRADATION; INHIBITORS; P27(KIP1); KINASES; PATHWAY
AB Background: Protein phosphotylation is one of the essential steps in cell signaling, and aberrant phosphorylation is a common event in human cancer. The expression of receptor type protein tyrosine phosphatase gamma (PTPRG) in normal breast is found to be similar to 50-60% higher than that of breast tumor tissue. Overexpression of PTPRG inhibits anchorage-independent growth and proliferation of breast cancer cells. To understand the tumor suppression characteristics of PTPRG, we studied its tumor suppressive function in an athymic mouse model and evaluated factors that can potentially regulate its expression in breast cancer cells. Materials and Methods: To investigate the function of PTPRG in vivo, athymic nude mice were implanted with MCF-7 cells overexpressing PTPRG. For in vitro study, protein levels of cell cycle regulators, cell cycle re-entry, and the phosphorylation levels of extracellular signal-regulated protein kinases 112 (ERKI/2) were examined. In addition, methylation assays were conducted to investigate the epigenetic modification on the promoter of PTPRG. Results: Athymic nude mice bearing MCF-7 cells overexpressing PTPRG showed a reduction in tumor burden in comparison to animals implanted with MCF-7 cells transfected with vector alone. When these two cell lines were studied in an in vitro system, elevated mRNA and protein levels of cell cycle regulators, p21(cip) and p27(kip) were detected in MCF-7 cells overexpressing PTPRG compared to cells transfected with vector alone. Similarly, overexpression of PTPRG also delayed the re-entry of breast cancer cells into the cell cycle after serum starvation, and reduced the phosphorylation levels ERK1/2 in MCF-7 cells. In addition, methylation assays in PTPRG promoter in breast cancer cell lines (including SK-Br-3) revealed an aberrant methylation pattern. When SK-Br-3 and MCF-7 cells were treated with deoxy-5-azacytidine (DAC) and trichostatin A (TSA), these compounds reactivated the expression of PTPRG, suggesting an epigenetic control on its expression. Conclusion: Our results indicated that PTPRG inhibited breast tumor formation in vivo; PTPRG may up-regulate p21(cip) and p27(kip) proteins through the ERK1/2 pathway. This study also showed methylation-mediated silencing of PTPRG in breast cancer cell lines. These data indicate that PTPRG exhibits the characteristics of a breast tumor suppressor.
C1 [Shu, Sherry T.; Sugimoto, Yasuro; Liu, Suling; Chang, Hsiang-Lin; Ye, Weiping; Wang, Li-Shu; Huang, Yi-Wen; Lin, Young C.] Ohio State Univ, Coll Vet Med, Dept Vet Biosci, Lab Reprod & Mol Endocrinol, Columbus, OH 43210 USA.
   [Sugimoto, Yasuro; Yan, Pearlly; Lin, Young C.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
   [Yan, Pearlly] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.
C3 University System of Ohio; Ohio State University; James Cancer Hospital
   & Solove Research Institute; University System of Ohio; Ohio State
   University; University System of Ohio; Ohio State University
RP Lin, YC (通讯作者)，1925 Coffey Rd, Columbus, OH 43210 USA.
EM Young.Lin@cvm.osu.edu
RI Huang, Yi-Wen/H-3989-2019; Yan, Pearlly/E-4339-2011; Sugimoto,
   Yasuro/AAR-1423-2021; Liu, Suling/N-2796-2013
OI liu, suling/0000-0002-0475-0242; Sugimoto, Yasuro/0000-0002-5094-4347
FU The Ohio State University Hospital, Department of Defense [DAMD 8140];
   National Institutes of Health [CA94718, R01 ES015212]
FX We thank Dr. Tim Huang (The Ohio State University) for providing
   assistance in the COBRA assays. We also thank Dr. Petra Schomalbrock
   (The Ohio State University) for performing MRI and data analysis,
   Chieh-Ti Kuo for figure preparation, and Dr. Donna Kusewitt (The Ohio
   State University) for histopathological examination. This project was
   supported by the Cooperative Human Tissue Network of The Ohio State
   University Hospital, Department of Defense Breast Cancer Research
   Program Grant (DAMD 8140), and National Institutes of Health Grants
   (CA94718 and R01 ES015212).
CR Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018
   Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001
   Brady H, 2002, CANCER RES, V62, P1439
   Florio T, 2001, MOL ENDOCRINOL, V15, P1838, DOI 10.1210/me.15.10.1838
   Ghoshal K, 2005, MOL CELL BIOL, V25, P4727, DOI 10.1128/MCB.25.11.4727-4741.2005
   Harris DL, 2007, MOL VIS, V13, P785
   Iuliano R, 2003, CANCER RES, V63, P882
   Jiang ZX, 2008, CANCER METAST REV, V27, P263, DOI 10.1007/s10555-008-9113-3
   Kantarjian HM, 2007, BLOOD, V110, P3540, DOI 10.1182/blood-2007-03-080689
   Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228
   Khoury JD, 2004, BLOOD, V104, P1580, DOI 10.1182/blood-2004-03-1151
   Lamprianou S, 2006, MOL CELL BIOL, V26, P5106, DOI 10.1128/MCB.00101-06
   Lissandrini D, 2006, BLOOD, V108, P4223, DOI 10.1182/blood-2006-05-024257
   Liu SL, 2004, ONCOGENE, V23, P1256, DOI 10.1038/sj.onc.1207235
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   LUBINSKI J, 1994, CANCER RES, V54, P3710
   Marzocchini R, 2008, INT J CANCER, V122, P1675, DOI 10.1002/ijc.23266
   Mei SP, 2004, INT J ONCOL, V25, P1509
   Modi S, 2005, BREAST CANCER RES TR, V90, P157, DOI 10.1007/s10549-004-3974-0
   Motiwala T, 2004, P NATL ACAD SCI USA, V101, P13844, DOI 10.1073/pnas.0405451101
   Mustelin T, 2003, BIOCHEM J, V371, P15, DOI 10.1042/BJ20021637
   Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337
   Shintani T, 2001, DEV NEUROSCI-BASEL, V23, P55, DOI 10.1159/000048696
   Sorio C, 1997, BLOOD, V90, P49
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Trapasso F, 2000, MOL CELL BIOL, V20, P9236, DOI 10.1128/MCB.20.24.9236-9246.2000
   TSUKAMOTO T, 1992, CANCER RES, V52, P3506
   van Niekerk CC, 1999, CANCER LETT, V137, P61, DOI 10.1016/S0304-3835(98)00344-9
   Vezzalini M, 2007, HISTOPATHOLOGY, V50, P615, DOI 10.1111/j.1365-2559.2007.02661.x
   Zhang SH, 1999, J BIOL CHEM, V274, P17806, DOI 10.1074/jbc.274.25.17806
   Zheng J, 2000, ANTICANCER RES, V20, P11
NR 31
TC 27
Z9 30
U1 0
U2 3
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD JUN
PY 2010
VL 30
IS 6
BP 1937
EP 1946
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 629WE
UT WOS:000280230300009
PM 20651337
DA 2025-01-12
ER

PT J
AU Xu, XR
   Gammon, MD
   Zhang, YJ
   Cho, YH
   Wetmur, JG
   Bradshaw, PT
   Garbowski, G
   Hibshoosh, H
   Teitelbaum, SL
   Neugut, AI
   Santella, RM
   Chen, J
AF Xu, Xinran
   Gammon, Marilie D.
   Zhang, Yujing
   Cho, Yoon Hee
   Wetmur, James G.
   Bradshaw, Patrick T.
   Garbowski, Gail
   Hibshoosh, Hanina
   Teitelbaum, Susan L.
   Neugut, Alfred I.
   Santella, Regina M.
   Chen, Jia
TI Gene promoter methylation is associated with increased mortality among
   women with breast cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Methylation; Epigenetics; Mortality; Breast cancer
ID CPG ISLAND HYPERMETHYLATION; DNA METHYLATION; BRCA1 GENE; LONG-ISLAND;
   EXPRESSION; SURVIVAL; MARKER; APC
AB To better understand breast cancer etiology and progression, we explored the association between promoter methylation status of three breast cancer-related genes (BRCA1, APC, and p16) and survival in a large cohort of women with breast cancer. About 800 archived tumor tissues were collected from women diagnosed with a first primary invasive or in situ breast cancer in 1996-1997. The vital status of the participants was followed through the end of year 2005 with a mean follow-up time of 8.0 years. Promoter methylation was assessed by methylation-specific PCR (for BRCA1) and MethyLight (for APC and p16). The association of promoter methylation and breast cancer mortality was evaluated by Cox-proportional hazards models. Methylated promoters were found in 59.0, 48.4, and 3.6% of the tumor samples for BRCA1, APC, and p16, respectively. Breast cancer-specific mortality was strongly associated with promoter methylation of p16 [HR and 95% CI: 3.53 (1.83-6.78)], whereas the associations with of BRCA1 and APC were less pronounced [HR and 95% CI: 1.81 (1.18-2.78) and 1.46 (0.98-2.17), respectively]. Similar associations were observed with all-cause mortality. As the number of methylated genes increased, the risk of breast cancer-specific mortality also increased in a dose-dependent manner (P, trend = 0.01). Importantly, even with our results stratified by hormone receptor status, promoter methylation of the three genes remained predictive of mortality. Our results suggest that promoter methylation could be promising epigenetic markers to be considered for breast cancer survival.
C1 [Xu, Xinran; Teitelbaum, Susan L.; Chen, Jia] Mt Sinai Sch Med, Dept Prevent Med, New York, NY 10029 USA.
   [Wetmur, James G.] Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA.
   [Wetmur, James G.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA.
   [Chen, Jia] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA.
   [Chen, Jia] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA.
   [Gammon, Marilie D.; Bradshaw, Patrick T.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA.
   [Zhang, Yujing; Cho, Yoon Hee; Garbowski, Gail; Santella, Regina M.] Columbia Univ, Dept Environm Hlth Sci, New York, NY USA.
   [Hibshoosh, Hanina] Columbia Univ, Dept Pathol, New York, NY USA.
   [Neugut, Alfred I.] Columbia Univ, Dept Epidemiol, New York, NY USA.
   [Neugut, Alfred I.] Columbia Univ, Dept Med, New York, NY USA.
C3 Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at
   Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of
   Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai;
   University of North Carolina; University of North Carolina Chapel Hill;
   Columbia University; Columbia University; Columbia University; Columbia
   University
RP Chen, J (通讯作者)，Mt Sinai Sch Med, Dept Prevent Med, Box 1057,1 Gustave L Levy Pl, New York, NY 10029 USA.
EM jia.chen@mssm.edu
RI Zhang, Yujing/ABB-3590-2021; Cho, Yoon/AAN-6560-2021; Bradshaw,
   Patrick/AAJ-7529-2021
OI Cho, Yoon Hee/0000-0002-4290-7140; Xu, Xinran/0000-0001-6435-8181
FU National Institutes of Health [CA109753, UO1CA/ES66572, UO1CA66572,
   P30CA013696, P30ES009089, P30ES10126]; Department of Defense [BC031746,
   W81XWH-06-1-0298]
FX This work was supported by grants from the National Institutes of Health
   (CA109753) and in part by grants from Department of Defense (BC031746),
   National Institutes of Health (UO1CA/ES66572, UO1CA66572, P30CA013696,
   P30ES009089, and P30ES10126). Xu, X. is a recipient of the Predoctoral
   Traineeship Award (W81XWH-06-1-0298) of Department of Defense Breast
   Cancer Research Program.
CR Al-Mulla F, 2005, J HISTOCHEM CYTOCHEM, V53, P621, DOI 10.1369/jhc.4A6544.2005
   [Anonymous], 2009, Modern Epidemiology
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Cleveland RJ, 2007, CANCER EPIDEM BIOMAR, V16, P1803, DOI 10.1158/1055-9965.EPI-06-0889
   Eads CA, 1999, CANCER RES, V59, P2302
   Eads CA, 2000, CANCER RES, V60, P5021
   Gammon MD, 2002, BREAST CANCER RES TR, V74, P235, DOI 10.1023/A:1016387020854
   Gammon MD, 2002, CANCER EPIDEM BIOMAR, V11, P677
   Gralow J, 2008, J CLIN ONCOL, V26, P313, DOI 10.1200/JCO.2007.15.4088
   Herman JG, 1999, SEMIN CANCER BIOL, V9, P359, DOI 10.1006/scbi.1999.0138
   Hopper JL, 2001, SEMIN CANCER BIOL, V11, P367, DOI 10.1006/scbi.2001.0392
   Hosmer DW., 1999, Applied survival analysis: regression modeling of time to event data
   Klarmann GJ, 2008, EPIGENETICS-US, V3, P59, DOI 10.4161/epi.3.2.5899
   Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8
   Liebens FP, 2007, EUR J CANCER, V43, P238, DOI 10.1016/j.ejca.2006.07.019
   Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   McShane LM, 2006, BREAST CANCER RES TR, V100, P229, DOI 10.1007/s10549-006-9242-8
   Moller P, 2007, INT J CANCER, V121, P1017, DOI 10.1002/ijc.22789
   Müller HM, 2003, CANCER RES, V63, P7641
   Osborne CK, 1998, BREAST CANCER RES TR, V51, P227, DOI 10.1023/A:1006132427948
   POLAKIS P, 1997, BIOCHIM BIOPHYS ACTA, V1332, P127
   Ralhan R, 2007, CANCER LETT, V248, P1, DOI 10.1016/j.canlet.2006.06.004
   RICHEDWARDS JW, 1994, AM J EPIDEMIOL, V140, P1016, DOI 10.1093/oxfordjournals.aje.a117191
   Richiardi L, 2009, J CLIN ONCOL, V27, P3161, DOI 10.1200/JCO.2008.18.2485
   Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149
   Rosen EM, 2003, J CELL PHYSIOL, V196, P19, DOI 10.1002/jcp.10257
   Rosner B., 2000, FUNDAMENTALS BIOSTAT, V5th
   SILVESTRINI R, 1995, J CLIN ONCOL, V13, P697, DOI 10.1200/JCO.1995.13.3.697
   Sington JD, 2002, J CLIN PATHOL, V55, P499, DOI 10.1136/jcp.55.7.499
   Sunami E, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2098
   Tao MH, 2009, BREAST CANCER RES TR, V114, P559, DOI 10.1007/s10549-008-0028-z
   Van der Auwera I, 2008, BRIT J CANCER, V99, P1735, DOI 10.1038/sj.bjc.6604705
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029
   Xu XR, 2008, CANCER EPIDEM BIOMAR, V17, P2109, DOI 10.1158/1055-9965.EPI-07-2900
   Xu XR, 2009, BREAST CANCER RES TR, V115, P397, DOI 10.1007/s10549-008-0075-5
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   2003, CANC MED
NR 39
TC 30
Z9 33
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JUN
PY 2010
VL 121
IS 3
BP 685
EP 692
DI 10.1007/s10549-009-0628-2
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 595TM
UT WOS:000277636000016
PM 19921426
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Ye, CZ
   Beeghly-Fadiel, A
   Lu, W
   Long, JR
   Shu, XO
   Gao, YT
   Zheng, W
   Cai, QY
AF Ye, Chuanzhong
   Beeghly-Fadiel, Alicia
   Lu, Wei
   Long, Jirong
   Shu, Xiao Ou
   Gao, Yu-Tang
   Zheng, Wei
   Cai, Qiuyin
TI Two-stage case-control study of DNMT-1 and DNMT-3B gene variants and
   breast cancer risk
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer; SNPs; DNMT-1; DNMT-3B; Risk
ID SQUAMOUS-CELL CARCINOMA; PROMOTER POLYMORPHISMS; ASSOCIATION;
   EXPRESSION; DISEASE; NECK; HEAD; 3B
AB Aberrant DNA methylation of CpG islands is a common epigenetic alteration found in cancers. DNA methylation is typically mediated by DNA methyltransferases (DNMTs). Only two studies have evaluated DNMT-1 and/or DNMT-3B gene polymorphisms in relation to breast cancer risk, and results have been inconsistent. We comprehensively evaluated genetic variations in the DNMT-1 and DNMT-3B genes with breast cancer risk among the participants of the Shanghai Breast Cancer Study, a large-scale, two-stage, case-control study. Of the 25 SNPs in the DNMT-1 and DNMT-3B genes analyzed, only one (rs8101866) reached a normal significance level (P = 0.042). This association, however, was no longer statistically significant after adjustment for multiple comparisons. Our data suggest that there is no apparent association of common DNMT-1 and DNMT-3B polymorphisms with the risk of breast cancer among Chinese women.
C1 [Ye, Chuanzhong; Beeghly-Fadiel, Alicia; Long, Jirong; Shu, Xiao Ou; Zheng, Wei; Cai, Qiuyin] Vanderbilt Univ, Div Epidemiol, Dept Med,Sch Med, Vanderbilt Epidemiol Ctr,Vanderbilt Ingram Canc C, Nashville, TN 37232 USA.
   [Lu, Wei] Shanghai Ctr Dis Control & Prevent, Shanghai, Peoples R China.
   [Gao, Yu-Tang] Shanghai Canc Inst, Dept Epidemiol, Shanghai, Peoples R China.
C3 Vanderbilt University; Shanghai Center for Disease Control & Prevention;
   Shanghai Jiao Tong University
RP Cai, QY (通讯作者)，Vanderbilt Univ, Div Epidemiol, Dept Med,Sch Med, Vanderbilt Epidemiol Ctr,Vanderbilt Ingram Canc C, B-2104,Med Ctr N,1161 21st Ave S, Nashville, TN 37232 USA.
EM qiuyin.cai@vanderbilt.edu
RI Shu, Xiao'Ou/KPA-5613-2024; Zheng, Wei/O-3351-2013
OI Ye, Chuanzhong/0000-0002-3584-1075; Long, Jirong/0000-0002-7433-9766
FU Vanderbilt-Ingram Cancer Center [P30 CA68485]; National Cancer Institute
   [R01 CA064277, R01 CA090899, R01 CA122756]
FX We thank the participants and research staff of the Shanghai Breast
   Cancer Study for their contributions and commitment to this project,
   Regina Courtney and Qing Wang for laboratory assistance, and Bethanie
   Hull for her assistance in the preparation of this manuscript.
   Genotyping assays were conducted at the Vanderbilt Microarray Shared
   Resource and the Survey and Biospecimen Shared Resource; both are
   supported in part by the Vanderbilt-Ingram Cancer Center (P30
   CA68485).This research was supported by National Cancer Institute grants
   R01 CA064277, R01 CA090899, and R01 CA122756.
CR Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   Cebrian A, 2006, CARCINOGENESIS, V27, P1661, DOI 10.1093/carcin/bgi375
   Chang KP, 2007, ORAL ONCOL, V43, P345, DOI 10.1016/j.oraloncology.2006.04.006
   de Bakker PIW, 2006, NAT GENET, V38, P1166, DOI 10.1038/ng1885
   Fan H, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-24
   Gao YT, 2000, INT J CANCER, V87, P295, DOI 10.1002/1097-0215(20000715)87:2<295::AID-IJC23>3.0.CO;2-7
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   Hardenbol P, 2005, GENOME RES, V15, P269, DOI 10.1101/gr.3185605
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Lee SJ, 2005, CARCINOGENESIS, V26, P403, DOI 10.1093/carcin/bgh307
   Liu ZS, 2008, CANCER LETT, V268, P158, DOI 10.1016/j.canlet.2008.03.034
   Montgomery KG, 2004, BREAST CANCER RES, V6, pR390, DOI 10.1186/bcr807
   Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068
   Saito Y, 2003, INT J CANCER, V105, P527, DOI 10.1002/ijc.11127
   Shen HB, 2002, CANCER RES, V62, P4992
   Singal R, 2005, ONCOL REP, V14, P569
   Wang Luo, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P863
   Zheng W, 2009, NAT GENET, V41, P324, DOI 10.1038/ng.318
NR 18
TC 12
Z9 15
U1 1
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JUN
PY 2010
VL 121
IS 3
BP 765
EP 769
DI 10.1007/s10549-009-0569-9
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 595TM
UT WOS:000277636000025
PM 19798569
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Ahmed, IA
   Pusch, CM
   Hamed, T
   Rashad, H
   Idris, A
   Abou El-Fadle, A
   Blin, N
AF Ahmed, Inas A.
   Pusch, Carsten M.
   Hamed, Thanaa
   Rashad, Hamed
   Idris, Amal
   Abou El-Fadle, Amal
   Blin, Nikolaus
TI Epigenetic alterations by methylation of <i>RASSF1A</i> and <i>DAPK1</i>
   promoter sequences in mammary carcinoma detected in extracellular tumor
   DNA
SO CANCER GENETICS AND CYTOGENETICS
LA English
DT Article
ID BREAST-CANCER PATIENTS; COLORECTAL-CANCER; PLASMA DNA; MICROSATELLITE
   ALTERATIONS; CPG METHYLATION; SERUM DNA; GENE; HYPERMETHYLATION;
   DIAGNOSIS; EXPRESSION
AB Novel strategies for early detection of breast cancer, the most common and second most lethal cancer in women, are urgently needed. Silencing tumor suppressor genes via DNA methylation has established hypermethylation as one of the most frequent molecular alterations that may initiate and drive many types of human neoplasia including breast cancer. Detecting such epigenetic changes in DNA derived not only from tumor tissue, but also from bodily fluids, may be a promising target for the molecular analysis of cancer. In this study we examined serum, a readily accessible bodily fluid known to contain neoplastie DNA, from individuals with breast carcinoma. Using sensitive methylation-specific polymerase chain reaction, we searched for aberrant promoter hypermethylation of two normally nonmethylated genes: RAS association domain family member 1A (RASSF1A) and death-associated protein kinase 1 (DAPK1) in 26 patients with breast cancer, 16 patients with benign breast diseases, and 12 age-matched healthy controls. Hypermethylation of at least one gene was detected in 25/26 (96%) cancer patients, in 7/16 (43%) cases with benign breast diseases, and only 1/12 (8%) control subjects. Furthermore, methylation of both genes was found to be associated with ductal type of breast carcinoma. RASSF1A was hypermethylated in 18/26 cases (69%) and DAPK1 in 23/26 (88%). However, DAPK I promoter methylation was more pronounced, as 12/23 DAPK1 methylated cases (52%) were strongly methylated (>75%) compared to the weaker methylation of RASSF1A (none of the cases with methylation at the level of > 75%). These findings, if confirmed in studies of extended cohorts, may lead to useful clinical application in early diagnosis of breast cancer and better management of the neoplastic disease. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Pusch, Carsten M.; Blin, Nikolaus] Univ Tubingen, Div Mol Genet, Inst Human Genet, D-72074 Tubingen, Germany.
   [Ahmed, Inas A.; Hamed, Thanaa; Abou El-Fadle, Amal] Benha Univ, Fac Med, Dept Biochem, Al Qalyubiyah, Egypt.
   [Rashad, Hamed] Benha Univ, Dept Gen Surg, Al Qalyubiyah, Egypt.
   [Idris, Amal] Benha Univ, Fac Med, Mol Biol Unit, Al Qalyubiyah, Egypt.
C3 Eberhard Karls University of Tubingen; Egyptian Knowledge Bank (EKB);
   Benha University; Egyptian Knowledge Bank (EKB); Benha University;
   Egyptian Knowledge Bank (EKB); Benha University
RP Blin, N (通讯作者)，Univ Tubingen, Div Mol Genet, Inst Human Genet, Wilhelmstr 27, D-72074 Tubingen, Germany.
EM blin@uni-tuebingen.de
RI Ahmed, Inas/LXB-2548-2024
OI Ahmed, Inas/0000-0001-8518-3827
CR Agrawal A, 2007, MODERN PATHOL, V20, P711, DOI 10.1038/modpathol.3800822
   Anker P, 1999, CANCER METAST REV, V18, P65, DOI 10.1023/A:1006260319913
   Azarschab P, 2002, GENE CHROMOSOME CANC, V35, P121, DOI 10.1002/gcc.10101
   Carvalho R, 2002, LAB INVEST, V82, P1319, DOI 10.1097/01.LAB.0000029205.76632.A8
   Chan AKC, 2003, ANN CLIN BIOCHEM, V40, P122, DOI 10.1258/000456303763046030
   Chan AOO, 2002, AM J PATHOL, V160, P529, DOI 10.1016/S0002-9440(10)64872-9
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Esteller M, 1999, CANCER RES, V59, P67
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Evron E, 2001, CANCER RES, V61, P2782
   Fackler MJ, 2009, CLIN CANCER RES, V15, P3802, DOI 10.1158/1078-0432.CCR-08-1981
   Feng W, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1762
   Flanagan JM, 2009, HUM MOL GENET, V18, P1332, DOI 10.1093/hmg/ddp033
   Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781
   Goessl C, 1998, CANCER RES, V58, P4728
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   HOLZMANN K, 1993, INT J ONCOL, V3, P261
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   Karpinski P, 2008, MOL CANCER RES, V6, P585, DOI 10.1158/1541-7786.MCR-07-2158
   Kawakami K, 2000, J NATL CANCER I, V92, P1805, DOI 10.1093/jnci/92.22.1805
   Lo YMD, 1998, AM J HUM GENET, V62, P768, DOI 10.1086/301800
   Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774
   Nawroz H, 1996, NAT MED, V2, P1035, DOI 10.1038/nm0996-1035
   Nicoll G, 2001, BRIT J CANCER, V85, P1878, DOI 10.1054/bjoc.2001.2163
   Papadopoulou E, 2006, ANN NY ACAD SCI, V1075, P235, DOI 10.1196/annals.1368.032
   Sanchez-Cespedes M, 2000, CANCER RES, V60, P892
   SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123
   Silva JM, 1999, CANCER RES, V59, P3251
   Sozzi G, 1999, CLIN CANCER RES, V5, P2689
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Tsou JA, 2002, ONCOGENE, V21, P5450, DOI 10.1038/sj.onc.1205605
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Wong IHN, 1999, CANCER RES, V59, P71
   Yano M, 2005, INT J CANCER, V113, P59, DOI 10.1002/ijc.20531
   Yeo W, 2005, LIVER INT, V25, P266, DOI 10.1111/j.1478-3231.2005.01084.x
NR 35
TC 22
Z9 26
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0165-4608
J9 CANCER GENET CYTOGEN
JI Cancer Genet. Cytogenet.
PD JUN
PY 2010
VL 199
IS 2
BP 96
EP 100
DI 10.1016/j.cancergencyto.2010.02.007
PG 5
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA 602RI
UT WOS:000278156100005
PM 20471512
DA 2025-01-12
ER

PT J
AU Hsu, PY
   Hsu, HK
   Singer, GAC
   Yan, PS
   Rodriguez, BAT
   Liu, JC
   Weng, YI
   Deatherage, DE
   Chen, Z
   Pereira, JS
   Lopez, R
   Russo, J
   Wang, QB
   Lamartiniere, CA
   Nephew, KP
   Huang, THM
AF Hsu, Pei-Yin
   Hsu, Hang-Kai
   Singer, Gregory A. C.
   Yan, Pearlly S.
   Rodriguez, Benjamin A. T.
   Liu, Joseph C.
   Weng, Yu-I
   Deatherage, Daniel E.
   Chen, Zhong
   Pereira, Julia S.
   Lopez, Ricardo
   Russo, Jose
   Wang, Qianben
   Lamartiniere, Coral A.
   Nephew, Kenneth P.
   Huang, Tim H. -M.
TI Estrogen-mediated epigenetic repression of large chromosomal regions
   through DNA looping
SO GENOME RESEARCH
LA English
DT Article
ID CPG-ISLAND METHYLATION; CHROMATIN IMMUNOPRECIPITATION; GENE; RECEPTOR;
   CANCER; WIDE; MODEL; HYPERMETHYLATION; SUSCEPTIBILITY; LYSINE-27
AB The current concept of epigenetic repression is based on one repressor unit corresponding to one silent gene. This notion, however, cannot adequately explain concurrent silencing of multiple loci observed in large chromosome regions. The long-range epigenetic silencing (LRES) can be a frequent occurrence throughout the human genome. To comprehensively characterize the influence of estrogen signaling on LRES, we analyzed transcriptome, methylome, and estrogen receptor alpha (ESR1)-binding datasets from normal breast epithelia and breast cancer cells. This "omics" approach uncovered 11 large repressive zones (range, 0.35 similar to 5.98 megabases), including a 14-gene cluster located on 16p11.2. In normal cells, estrogen signaling induced transient formation of multiple DNA loops in the 16p11.2 region by bringing 14 distant loci to focal ESR1-docking sites for coordinate repression. However, the plasticity of this free DNA movement was reduced in breast cancer cells. Together with the acquisition of DNA methylation and repressive chromatin modifications at the 16p11.2 loci, an inflexible DNA scaffold may be a novel determinant used by breast cancer cells to reinforce estrogen-mediated repression.
C1 [Hsu, Pei-Yin; Hsu, Hang-Kai; Singer, Gregory A. C.; Yan, Pearlly S.; Rodriguez, Benjamin A. T.; Liu, Joseph C.; Weng, Yu-I; Deatherage, Daniel E.; Huang, Tim H. -M.] Ohio State Univ, Human Canc Genet Program, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.
   [Chen, Zhong; Wang, Qianben] Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA.
   [Pereira, Julia S.; Lopez, Ricardo; Russo, Jose] Fox Chase Canc Ctr, Breast Canc Res Lab, Philadelphia, PA 19111 USA.
   [Lamartiniere, Coral A.] Univ Alabama Birmingham, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA.
   Indiana Univ, Sch Med, Bloomington, IN 47405 USA.
C3 University System of Ohio; Ohio State University; University System of
   Ohio; Ohio State University; Fox Chase Cancer Center; University of
   Alabama System; University of Alabama Birmingham; Indiana University
   System; Indiana University Bloomington
RP Huang, THM (通讯作者)，Ohio State Univ, Human Canc Genet Program, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.
EM tim.huang@osumc.edu
RI Wang, Qianben/E-4267-2011; Yan, Pearlly/E-4339-2011; Chen,
   Zhong/E-2776-2018
OI Chen, Zhong/0000-0002-9644-1737
FU Gene and Environment Initiative [U01ES015986, U01ES016003]; U.S.
   National Institutes of Health [U54CA113001, R01CA069065, R01 ES017594];
   Ohio State University Comprehensive Cancer Center
FX This work was supported by the Gene and Environment Initiative
   (U01ES015986 to T.H.-M.H and U01ES016003 to C. A. L.), the Integrative
   Cancer Biology Program (U54CA113001 to T.H.-M.H. and K.P.N.),
   R01CA069065 (T.H.-M.H.), and R01 ES017594 (T.H.-M.H.) at the U.S.
   National Institutes of Health and by The Ohio State University
   Comprehensive Cancer Center (Q. W. and T.H.-M.H.).
CR Bock C, 2006, PLOS GENET, V2, P243, DOI 10.1371/journal.pgen.0020026
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008
   Cheng ASL, 2008, CANCER RES, V68, P1786, DOI 10.1158/0008-5472.CAN-07-5547
   Clark SJ, 2007, HUM MOL GENET, V16, pR88, DOI 10.1093/hmg/ddm051
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Dolinoy DC, 2007, REPROD TOXICOL, V23, P297, DOI 10.1016/j.reprotox.2006.08.012
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Eisenberg E, 2003, TRENDS GENET, V19, P362, DOI 10.1016/S0168-9525(03)00140-9
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Feltus FA, 2006, GENOMICS, V87, P572, DOI 10.1016/j.ygeno.2005.12.016
   Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131
   Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781
   Göndör A, 2009, NATURE, V461, P212, DOI 10.1038/nature08453
   Hagège H, 2007, NAT PROTOC, V2, P1722, DOI 10.1038/nprot.2007.243
   Hansen KH, 2008, NAT CELL BIOL, V10, P1291, DOI 10.1038/ncb1787
   Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516
   Hsu PY, 2009, CANCER RES, V69, P5936, DOI 10.1158/0008-5472.CAN-08-4914
   Hu X, 2009, P NATL ACAD SCI USA, V106, P10141, DOI 10.1073/pnas.0900437106
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Jensen EV, 2003, CLIN CANCER RES, V9, P1980
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Karolchik D, 2008, NUCLEIC ACIDS RES, V36, pD773, DOI 10.1093/nar/gkm966
   Kleinjan DA, 2008, ADV GENET, V61, P339, DOI 10.1016/S0065-2660(07)00013-2
   Lee TI, 2006, NAT PROTOC, V1, P729, DOI 10.1038/nprot.2006.98
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Lorincz MC, 2004, NAT STRUCT MOL BIOL, V11, P1068, DOI 10.1038/nsmb840
   Lorincz MC, 2002, MOL CELL BIOL, V22, P7572, DOI 10.1128/MCB.22.21.7572-7580.2002
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Newbold RR, 2006, ENDOCRINOLOGY, V147, pS11, DOI 10.1210/en.2005-1164
   Nie Y, 2001, CARCINOGENESIS, V22, P1615, DOI 10.1093/carcin/22.10.1615
   Novak P, 2006, CANCER RES, V66, P10664, DOI 10.1158/0008-5472.CAN-06-2761
   Perissi V, 2005, NAT REV MOL CELL BIO, V6, P542, DOI 10.1038/nrm1680
   Pruitt KD, 2007, NUCLEIC ACIDS RES, V35, pD61, DOI 10.1093/nar/gkl842
   Roberti A, 2006, J CELL PHYSIOL, V207, P571, DOI 10.1002/jcp.20515
   Robertson G, 2007, NAT METHODS, V4, P651, DOI 10.1038/NMETH1068
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Rodriguez BAT, 2008, CARCINOGENESIS, V29, P1459, DOI 10.1093/carcin/bgn115
   Schaffer BS, 2006, CANCER RES, V66, P7793, DOI 10.1158/0008-5472.CAN-06-0143
   Smith LT, 2006, P NATL ACAD SCI USA, V103, P982, DOI 10.1073/pnas.0510171102
   Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515
   van Noesel MM, 2003, GENE CHROMOSOME CANC, V38, P226, DOI 10.1002/gcc.10278
   Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598
   West AG, 2005, HUM MOL GENET, V14, pR101, DOI 10.1093/hmg/ddi104
NR 46
TC 77
Z9 90
U1 0
U2 5
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1088-9051
EI 1549-5469
J9 GENOME RES
JI Genome Res.
PD JUN
PY 2010
VL 20
IS 6
BP 733
EP 744
DI 10.1101/gr.101923.109
PG 12
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 604HF
UT WOS:000278269400004
PM 20442245
OA hybrid, Green Submitted, Green Accepted, Green Published
DA 2025-01-12
ER

PT J
AU Peláez, IM
   Kalogeropoulou, M
   Ferraro, A
   Voulgari, A
   Pankotai, T
   Boros, I
   Pintzas, A
AF Pelaez, Ignacio Mazon
   Kalogeropoulou, Margarita
   Ferraro, Angelo
   Voulgari, Angeliki
   Pankotai, Tibor
   Boros, Imre
   Pintzas, Alexander
TI Oncogenic RAS alters the global and gene-specific histone modification
   pattern during epithelial-mesenchymal transition in colorectal carcinoma
   cells
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE Histone modifications; RAS; EMT; Colon cancer; MSK1
ID E-CADHERIN EXPRESSION; BREAST-CANCER; BINDING PROTEIN; STEM-CELLS; H3;
   D1; PHOSPHORYLATION; TRANSFORMATION; ACTIVATION; EZH2
AB The presence of different forms of histone covalent modifications, such as phosphorylation, acetylation and methylation in localized promoter regions are markers for chromatin packing and transcription. Activation of RAS signalling pathways through oncogenic RAS mutations is a hallmark of colorectal cancer Overexpression of Harvey-Ras oncogene induces epithelial-mesenchymal transition (EMT) in Caco-2 cells. We focused on the role of epigenetic modifications of histone H3 and its dependence on RAS signal transduction pathways and oncogenic transformation Using cell lines stably overexpressing oncogenic Harvey-RAS with EMT phenotype, we studied the acquired changes in the H3 histone modification patterns Two genes show Inverse protein expression patterns after Ha-RAS overexpression Cyclin D1, a cell cycle-related gene, and the EMT marker-gene E-cadherin We report that these two genes demonstrate matching inverse histone repression patterns on their promoter, while histone markers associated with an active state of genes were affected by the RAS-activated signalling pathway MEK-ERK-MSK1 Furthermore, we show that though the level of methyltransferases enzymes was increased, the status of H3 three-methylation at lysine 27 (H3K27me(3)), associated with gene repression on the promoter of Cyclin D1, was lower Together, these results suggest that histone covalent modifications can be affected by oncogenic RAS pathways to regulate the expression of target genes like Cycl in D1 or E-caclherin and that the dynamic balance of opposing histone-modifying enzymes is critical for the regulation of cell proliferation (C) 2010 Elsevier Ltd All rights reserved.
C1 [Pelaez, Ignacio Mazon; Kalogeropoulou, Margarita; Ferraro, Angelo; Voulgari, Angeliki; Pintzas, Alexander] Natl Hellen Res Fdn, Inst Biol Res & Biotechnol, Lab Signal Mediated Gene Express, Athens 11635, Greece.
   [Pankotai, Tibor] IGBMC, Dept Canc Biol Nucl Architecture & Chromatin Stru, F-67404 Strasbourg, France.
   [Pankotai, Tibor] Genome Integr Grp, F-67404 Strasbourg, France.
   [Boros, Imre] Univ Szeged, Dept Biochem & Mol Biol, Has Chromatin Res Grp, Szeged, Hungary.
C3 National Hellenic Research Foundation; Institut National de la Sante et
   de la Recherche Medicale (Inserm); Szeged University
RP Pintzas, A (通讯作者)，Natl Hellen Res Fdn, Inst Biol Res & Biotechnol, Lab Signal Mediated Gene Express, 48 Vas Constantinou Ave, Athens 11635, Greece.
RI Boros, Ildikó/H-6721-2012; Ferraro, Angelo/H-3193-2019; Pankotai,
   Tibor/A-5942-2015; Ferraro, Angelo/A-4172-2014
OI Pankotai, Tibor/0000-0001-9810-5465; Boros, Imre/0000-0001-8504-9687;
   Ferraro, Angelo/0000-0002-2044-7569
FU EU [MRTN-CT-2004-504228]
FX I.M P. and T.P. are Marie Curie Fellows supported by the EU Marie Curie
   Research Training Network "TAF-Chromatin". Grant MRTN-CT-2004-504228 is
   provided to A.P. and I B. We would like to thank Prof. A. Fusco for his
   support.
CR Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186
   Andreolas C, 2008, INT J CANCER, V122, P1745, DOI 10.1002/ijc.23309
   Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4
   Bolós V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224
   Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947
   Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914
   CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745
   Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X
   Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162
   Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173
   Drobic B, 2004, CANCER RES, V64, P9076, DOI 10.1158/0008-5472.CAN-04-2369
   Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105
   Dyson MH, 2005, J CELL SCI, V118, P2247, DOI 10.1242/jcs.02373
   Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X
   FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   HERBER, 1994, ONCOGENE, V9, P2105
   Hilton TL, 2005, MOL CELL BIOL, V25, P4321, DOI 10.1128/MCB.25.10.4321-4332.2005
   Hong SH, 2007, P NATL ACAD SCI USA, V104, P18439, DOI 10.1073/pnas.0707292104
   Hulit J, 2004, MOL CELL BIOL, V24, P7598, DOI 10.1128/MCB.24.17.7598-7611.2004
   Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245
   Kimura H, 2004, MOL CELL BIOL, V24, P5710, DOI 10.1128/MCB.24.13.5710-5720.2004
   Kirmizis A, 2003, MOL CANCER THER, V2, P113
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341
   Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9
   Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996
   Margueron R, 2008, MOL CELL, V32, P503, DOI 10.1016/j.molcel.2008.11.004
   Martin C, 2006, J BIOL CHEM, V281, P8365, DOI 10.1074/jbc.M513425200
   Meshorer E, 2006, NAT REV MOL CELL BIO, V7, P540, DOI 10.1038/nrm1938
   Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888
   Nagata D, 2001, J BIOL CHEM, V276, P662, DOI 10.1074/jbc.M005522200
   Nakamura N, 1998, CLIN EXP METASTAS, V16, P471
   Oikonomou E, 2009, NEOPLASIA, V11, P1116, DOI 10.1593/neo.09514
   Özdag H, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-90
   Park H, 2008, INT J MOL MED, V21, P325
   Park YS, 2008, ANN SURG ONCOL, V15, P1968, DOI 10.1245/s10434-008-9927-9
   Roberts ML, 2006, INT J CANCER, V118, P616, DOI 10.1002/ijc.21386
   Sakatani T, 2005, SCIENCE, V307, P1976, DOI 10.1126/science.1108080
   Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672
   Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383
   Shen Q, 2008, ONCOGENE, V27, P366, DOI 10.1038/sj.onc.1210643
   Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273
   Spurling CC, 2008, MOL CARCINOGEN, V47, P137, DOI 10.1002/mc.20373
   Suter CM, 2004, INT J COLORECTAL DIS, V19, P95, DOI 10.1007/s00384-003-0539-3
   Sutter T, 1997, J MED, V28, P285
   Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835
   Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Voulgari A, 2008, MOL CANCER RES, V6, P1071, DOI 10.1158/1541-7786.MCR-07-0375
   Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154
   Wei YK, 2008, MOL CARCINOGEN, V47, P701, DOI 10.1002/mc.20413
   Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200
   Zhang XH, 2004, MOL CELL BIOL, V24, P5106, DOI 10.1128/MCB.24.12.5106-5118.2004
   Zhu P, 2004, CELL CYCLE, V3, P1240, DOI 10.4161/cc.3.10.1195
NR 57
TC 31
Z9 38
U1 0
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357-2725
EI 1878-5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD JUN
PY 2010
VL 42
IS 6
BP 911
EP 920
DI 10.1016/j.biocel.2010.01.024
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 606IO
UT WOS:000278417700019
PM 20109579
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Pandey, M
   Shukla, S
   Gupta, S
AF Pandey, Mitali
   Shukla, Sanjeev
   Gupta, Sanjay
TI Promoter demethylation and chromatin remodeling by green tea polyphenols
   leads to re-expression of GSTP1 in human prostate cancer cells
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE prostate cancer; GSTP1; chemoprevention; DNA methylation; histone
   modification; epigenetics
ID GLUTATHIONE-S-TRANSFERASE; CPG ISLAND HYPERMETHYLATION;
   METHYLATION-SILENCED GENES; DNA METHYLTRANSFERASE; CARCINOMA-CELLS;
   BREAST-CANCER; HYPOMETHYLATION; EXPRESSION;
   (-)-EPIGALLOCATECHIN-3-GALLATE; INHIBITION
AB Epigenetic silencing of gluthathione-S-transferase pi (GSTP1) is recognized as being a molecular hallmark of human prostate cancer. We investigated the effects of green tea polyphenols (GTPs) on GSTP1 re-expression and further elucidated its mechanism of action and long-term safety, compared with nucleoside-analog inhibitor of DNA methyltransferase (DNMT), 5-aza-2'-deoxycitidine. Exposure of human prostate cancer LNCaP cells to 1-10 mu g/ml of GTP for 1-7 days caused a concentration- and time-dependent re-expression of GSTP1, which correlated with DNMT1 inhibition. Methyl-specific-PCR and sequencing revealed extensive demethylation in the proximal GSTP1 promoter and regions distal to the transcription factor binding sites. GTP exposure in a time-dependent fashion diminished the mRNA and protein levels of MBD1, MBD4 and MeCP2; HDAC 1-3 and increased the levels of acetylated histone H3 (LysH9/18) and H4. Chromatin immunoprecipitation assays demonstrated that cells treated with GTP have reduced MBD2 association with accessible Sp1 binding sites leading to increased binding and transcriptional activation of the GSTP1 gene. Exposure of cells to GTP did not result in global hypomethylation, as demonstrated by methyl-specific PCR for LINE-1 promoter; rather GTP promotes maintenance of genomic integrity. Furthermore, exposure of cells to GIP did not cause activation of the prometaststic gene S100P, a reverse response noted after exposure of cells to 5-aza-2'deoxycitidine. Our results, for the first time, demonstrate that GTP has dual potential to alter DNA methylation and chromatin modeling, the 2 global epigenetic mechanisms of gene regulation and their lack of toxicity makes them excellent candidates for the chemoprevention of prostate cancer.
C1 [Pandey, Mitali; Shukla, Sanjeev; Gupta, Sanjay] Case Western Reserve Univ, Dept Urol, James & Eilleen Dicke Res Lab, Cleveland, OH 44106 USA.
   [Pandey, Mitali; Shukla, Sanjeev; Gupta, Sanjay] Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA.
   [Shukla, Sanjeev; Gupta, Sanjay] Case Western Reserve Univ, Dept Nutr, James & Eilleen Dicke Res Lab, Cleveland, OH 44106 USA.
   [Gupta, Sanjay] Case Comprehens Canc Ctr, Div Gen Med Sci, James & Eilleen Dicke Res Lab, Cleveland, OH USA.
C3 University System of Ohio; Case Western Reserve University; University
   System of Ohio; Case Western Reserve University; Case Western Reserve
   University Hospital; University System of Ohio; Case Western Reserve
   University; University System of Ohio; Case Western Reserve University
RP Gupta, S (通讯作者)，Case Western Reserve Univ, Dept Urol, James & Eilleen Dicke Res Lab, 10900 Euclid Ave, Cleveland, OH 44106 USA.
EM sanjay.gupta@case.edu
OI Gupta, Sanjay/0000-0002-9492-3249
FU United States Public Health Services [RO1 CA115491, R21 CA109424]
FX Grant sponsor: United States Public Health Services;Grant numbers: RO1
   CA115491, R21 CA109424
CR Bakker J, 2002, J BIOL CHEM, V277, P22573, DOI 10.1074/jbc.M203009200
   Brothman AR, 2005, CANCER GENET CYTOGEN, V156, P31, DOI 10.1016/j.cancergencyto.2004.04.004
   Chen CL, 2001, HUM PATHOL, V32, P1240, DOI 10.1053/hupa.2001.28950
   Chen D, 2008, HISTOL HISTOPATHOL, V23, P487, DOI 10.14670/HH-23.487
   Cho NY, 2007, J PATHOL, V211, P269, DOI 10.1002/path.2106
   Cullen KJ, 2003, CANCER RES, V63, P8097
   Fang MZ, 2003, CANCER RES, V63, P7563
   Florl AL, 2004, BRIT J CANCER, V91, P985, DOI 10.1038/sj.bjc.6602030
   Gsur A, 2001, INT J CANCER, V95, P152, DOI 10.1002/1097-0215(20010520)95:3<152::AID-IJC1026>3.0.CO;2-S
   Gupta S, 2000, TOXICOL APPL PHARM, V164, P82, DOI 10.1006/taap.1999.8885
   Gupta S, 2001, P NATL ACAD SCI USA, V98, P10350, DOI 10.1073/pnas.171326098
   Henderson CJ, 1998, CHEM-BIOL INTERACT, V112, P69, DOI 10.1016/S0009-2797(97)00176-2
   Henderson CJ, 1998, P NATL ACAD SCI USA, V95, P5275, DOI 10.1073/pnas.95.9.5275
   Hopkins TG, 2007, UROLOGY, V69, P11, DOI 10.1016/j.urology.2006.10.008
   JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797
   Karpf AR, 2007, CURR OPIN MOL THER, V9, P231
   Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602
   Khan N, 2006, CANCER RES, V66, P2500, DOI 10.1158/0008-5472.CAN-05-3636
   Kopelovich L, 2003, JNCI-J NATL CANCER I, V95, P1747, DOI 10.1093/jnci/dig109
   Kurahashi N, 2008, AM J EPIDEMIOL, V167, P71, DOI 10.1093/aje/kwm249
   Kuzuhara T, 2006, J BIOL CHEM, V281, P17446, DOI 10.1074/jbc.M601196200
   Larsson SC, 2005, ARCH INTERN MED, V165, P2683, DOI 10.1001/archinte.165.22.2683
   Li LC, 2005, JNCI-J NATL CANCER I, V97, P103, DOI 10.1093/jnci/dji010
   Lin XH, 2003, CANCER RES, V63, P498
   Lin XH, 2001, AM J PATHOL, V159, P1815, DOI 10.1016/S0002-9440(10)63028-3
   Lyko F, 2005, JNCI-J NATL CANCER I, V97, P1498, DOI 10.1093/jnci/dji311
   McCabe MT, 2006, CANCER RES, V66, P385, DOI 10.1158/0008-5472.CAN-05-2020
   Millar DS, 2000, J BIOL CHEM, V275, P24893, DOI 10.1074/jbc.M906538199
   Millar DS, 1999, ONCOGENE, V18, P1313, DOI 10.1038/sj.onc.1202415
   Moffat GJ, 1996, J BIOL CHEM, V271, P1054, DOI 10.1074/jbc.271.2.1054
   Morey SR, 2006, CANCER RES, V66, P11659, DOI 10.1158/0008-5472.CAN-06-1937
   Nakayama M, 2004, J CELL BIOCHEM, V91, P540, DOI 10.1002/jcb.10740
   Nakayama M, 2003, AM J PATHOL, V163, P923, DOI 10.1016/S0002-9440(10)63452-9
   Nelson WG, 2007, FRONT BIOSCI-LANDMRK, V12, P4254, DOI 10.2741/2385
   Okino ST, 2007, MOL CARCINOGEN, V46, P839, DOI 10.1002/mc.20313
   Pakneshan P, 2003, FASEB J, V17, P1081, DOI 10.1096/fj.02-0973com
   Patra SK, 2001, BIOCHEM BIOPH RES CO, V287, P705, DOI 10.1006/bbrc.2001.5639
   Prokhortchouk E, 2002, ONCOGENE, V21, P5394, DOI 10.1038/sj.onc.1205631
   Ptak C, 2008, ANNU REV PHARMACOL, V48, P257, DOI 10.1146/annurev.pharmtox.48.113006.094731
   Rehman I, 2007, PROSTATE, V67, P341, DOI 10.1002/pros.20401
   Roman-Gomez J, 2005, ONCOGENE, V24, P7213, DOI 10.1038/sj.onc.1208866
   Schwartsmann G, 2000, INVEST NEW DRUG, V18, P83, DOI 10.1023/A:1006388031954
   Siedlecki P, 2006, ACTA BIOCHIM POL, V53, P245
   Singal R, 2001, CANCER RES, V61, P4820
   Strange RC, 2001, MUTAT RES-FUND MOL M, V482, P21, DOI 10.1016/S0027-5107(01)00206-8
   Vidanes GM, 2002, PROSTATE, V51, P225, DOI 10.1002/pros.10093
   Wang Q, 2007, ONCOGENE, V26, P6560, DOI 10.1038/sj.onc.1210472
   Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007
   Zhang M, 2007, CARCINOGENESIS, V28, P1074, DOI 10.1093/carcin/bgl252
   Zhou L, 2002, J MOL BIOL, V321, P591, DOI 10.1016/S0022-2836(02)00676-9
NR 50
TC 156
Z9 170
U1 1
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD JUN 1
PY 2010
VL 126
IS 11
BP 2520
EP 2533
DI 10.1002/ijc.24988
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 592AV
UT WOS:000277347900002
PM 19856314
OA Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Tryndyak, VP
   Beland, FA
   Pogribny, IP
AF Tryndyak, Volodymyr P.
   Beland, Frederick A.
   Pogribny, Igor P.
TI E-cadherin transcriptional down-regulation by epigenetic and
   microRNA-200 family alterations is related to mesenchymal and
   drug-resistant phenotypes in human breast cancer cells
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE breast cancer; E-cadherin; promoter methylation; histone; acetylation;
   microRNA miR-200
ID MIR-200 FAMILY; DNA METHYLATION; REPRESSORS ZEB1; PROMOTES EMT;
   TRANSITION; SIRT1; INHIBITION; GROWTH; DOXORUBICIN; GENES
AB The conversion of early stage tumors into invasive malignancies with an aggressive phenotype has been associated with the irreversible loss of E-cadherin expression. The loss of E-cadherin expression in human tumors, including breast cancer, has been attributed to promoter CpG island hypermethylation and direct inhibition by transcriptional repressors. Recent evidence demonstrates that up-regulation of E-cadherin by microRNA-200b (miR-200b) and miR-200c through direct targeting of transcriptional repressors of E-cadherin, ZEB1, and ZEB2, inhibits epithelial-to-mesenchymal transition (EMT), a crucial process in the tumor progression. We demonstrate that microRNA miR-200 family-mediated transcriptional up-regulation of E-cadherin in mesenchymal MDA-MB-231 and BT-549 cells is associated directly with translational repression of ZEB1 and indirectly with increased acetylation of histone H3 at the E-cadherin promoter. The increase in histone H3 acetylation may be attributed to the disruption of repressive complexes between ZEB1 and histone deacetylases and to the inhibition of SIRT1, a class Ill histone deacetylase. These events inhibit EMT and reactivate a less aggressive epithelial phenotype in cancer cells. Additionally, disruption of ZEB1-histone deacetylase repressor complexes and down-regulation of SIRT1 histone deacetylase up-regulate proapoptotic genes in the p53 apoptotic pathway resulting in the increased sensitivity of cancer cells to the chemotherapeutic agent doxorubicin.
C1 [Tryndyak, Volodymyr P.; Beland, Frederick A.; Pogribny, Igor P.] Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA.
C3 US Food & Drug Administration (FDA)
RP Pogribny, IP (通讯作者)，Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA.
EM igor.pogribny@fda.hhs.gov
OI Beland, Frederick/0000-0002-2113-6260; Tryndyak,
   Volodymyr/0000-0002-8319-2954
CR Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74
   Chang CJ, 2009, BIOCHEM BIOPH RES CO, V380, P236, DOI 10.1016/j.bbrc.2009.01.040
   Coley HM, 2008, CANCER TREAT REV, V34, P378, DOI 10.1016/j.ctrv.2008.01.007
   Cowin P, 2005, CURR OPIN CELL BIOL, V17, P499, DOI 10.1016/j.ceb.2005.08.014
   Dai JM, 2007, J CELL PHYSIOL, V210, P161, DOI 10.1002/jcp.20831
   De Wever O, 2008, HISTOCHEM CELL BIOL, V130, P481, DOI 10.1007/s00418-008-0464-1
   Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105
   Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429
   Fontemaggi G, 2005, ONCOGENE, V24, P7273, DOI 10.1038/sj.onc.1208891
   Gonzalez-Angulo AM, 2007, ADV EXP MED BIOL, V608, P1
   Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322
   Gregory PA, 2008, CELL CYCLE, V7, P3112, DOI 10.4161/cc.7.20.6851
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hiscox S, 2006, INT J CANCER, V118, P290, DOI 10.1002/ijc.21355
   Ho LH, 2008, ONCOGENE, V27, P3393, DOI 10.1038/sj.onc.1211005
   Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011
   Kojima K, 2008, BIOCHEM BIOPH RES CO, V373, P423, DOI 10.1016/j.bbrc.2008.06.045
   Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200
   Lim YB, 2008, J BIOL CHEM, V283, P33110, DOI 10.1074/jbc.M804255200
   Liu T, 2009, CANCER RES, V69, P1702, DOI 10.1158/0008-5472.CAN-08-3365
   Liu YQ, 2008, CANCER INVEST, V26, P575, DOI 10.1080/07357900701837168
   Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996
   Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706
   Mauro L, 2007, CANCER RES, V67, P3412, DOI 10.1158/0008-5472.CAN-06-2890
   Milner J, 2009, CURR PHARM DESIGN, V15, P39, DOI 10.2174/138161209787185841
   O'Driscoll L, 2006, CURR CANCER DRUG TAR, V6, P365, DOI 10.2174/156800906777723958
   Ohira T, 2003, P NATL ACAD SCI USA, V100, P10429, DOI 10.1073/pnas.1734137100
   Osmak M, 1998, NEOPLASMA, V45, P223
   Park SJ, 2004, ANTICANCER RES, V24, P123
   Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608
   Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040
   Raguz S, 2008, BRIT J CANCER, V99, P387, DOI 10.1038/sj.bjc.6604510
   Sabbah M, 2008, DRUG RESIST UPDATE, V11, P123, DOI 10.1016/j.drup.2008.07.001
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Scott GK, 2006, CANCER RES, V66, P1277, DOI 10.1158/0008-5472.CAN-05-3632
   Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148
   Vandewalle C, 2005, NUCLEIC ACIDS RES, V33, P6566, DOI 10.1093/nar/gki965
   Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X
   von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004
   Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598
   Witta SE, 2006, CANCER RES, V66, P944, DOI 10.1158/0008-5472.CAN-05-1988
   Yang AD, 2006, CLIN CANCER RES, V12, P4147, DOI 10.1158/1078-0432.CCR-06-0038
   Yang C, 2009, APOPTOSIS, V14, P124, DOI 10.1007/s10495-008-0282-x
   Yang L, 2007, CANCER RES, V67, P5587, DOI 10.1158/0008-5472.CAN-06-2287
   Yoshikawa M, 2007, J AM SOC NEPHROL, V18, P58, DOI 10.1681/ASN.2005111187
NR 49
TC 199
Z9 231
U1 0
U2 25
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD JUN 1
PY 2010
VL 126
IS 11
BP 2575
EP 2583
DI 10.1002/ijc.24972
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 592AV
UT WOS:000277347900007
PM 19839049
DA 2025-01-12
ER

PT J
AU Götze, S
   Wolter, M
   Reifenberger, G
   Müller, O
   Sievers, S
AF Goetze, Silke
   Wolter, Marietta
   Reifenberger, Guido
   Mueller, Oliver
   Sievers, Sonja
TI Frequent promoter hypermethylation of Wnt pathway inhibitor genes in
   malignant astrocytic gliomas
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE glioma; DNA hypermethylation; Wnt inhibitor; NKD
ID HISTONE DEACETYLASE INHIBITION; BETA-CATENIN; EPIGENETIC INACTIVATION;
   SIGNALING PATHWAY; ABERRANT METHYLATION; DOWN-REGULATION; BREAST-CANCER;
   RAT GLIOMAS; SFRP GENES; ACTIVATION
AB Aberrant activation of wingless (Wnt) signaling is involved in the pathogenesis of various cancers. Recent studies suggested a role of Wnt signaling in gliomas, the most common primary brain tumors. We investigated 70 gliomas of different malignancy grades for promoter hypermethylation in 8 genes encoding members of the secreted frizzled-related protein (SFRP1, SFRP2, SFRP4, SFRP5), dickkopf (DKK1, DKK3) and naked (NKD1, NKD2) families of Wnt pathway inhibitors. All tumors were additionally analyzed for mutations in exon 3 of the beta-catenin gene (CTNNB1). While none of the tumors carried CTNNB1 mutations, we found frequent promoter hypermethylation of Wnt pathway inhibitor genes, with at least one of these genes being hypermethylated in 6 of 16 diffuse astrocytomas (38%), 4 of 14 anaplastic astrocytomas (29%), 7 of 10 secondary glioblastomas (70%) and 23 of 30 primary glioblastomas (77%). Glioblastomas often demonstrated hypermethylation of 2 or more analyzed genes. Hypermethylation of SFRP1, SFRP2 and NKD2 each occurred in more than 40% of the primary glioblastomas, while DKK1 hypermethylation was found in 50% of secondary glioblastomas. Treatment of SFRP1-, SFRP5-, DKK1-, DKK3-, NKD1- and NKD2-hypermethylated U87-MG glioblastoma cells with 5-aza-2'-deoxycytidine and trichostatin A resulted in increased expression of each gene. Furthermore, SFRP1-hypermethylated gliomas showed significantly lower expression of the respective transcripts when compared with unmethylated tumors. Taken together, our results suggest an important role of epigenetic silencing of Wnt pathway inhibitor genes in astrocytic gliomas, in particular, in glioblastomas, with distinct patterns of hypermethylated genes distinguishing primary from secondary glioblastomas.
C1 [Goetze, Silke; Sievers, Sonja] Max Planck Inst Mol Physiol, Dept Biol Struct, D-44227 Dortmund, Germany.
   [Wolter, Marietta; Reifenberger, Guido] Univ Dusseldorf, Dept Neuropathol, Dusseldorf, Germany.
   [Mueller, Oliver] Univ Appl Sci Kaiserslautern, Dept Mol Oncol, Zweibrucken, Germany.
C3 Max Planck Society; Heinrich Heine University Dusseldorf; University of
   Kaiserslautern
RP Götze, S (通讯作者)，Max Planck Inst Mol Physiol, Dept Biol Struct, Otto Hahn Str 11, D-44227 Dortmund, Germany.
EM silke.goetze@mpi-dortmund.mpg.de
RI Reifenberger, Guido/AAE-3599-2019
FU Hans Bockler Foundation [346895]
FX Grant sponsor: Hans Bockler Foundation; Grant number: 346895
CR Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Chan CC, 2008, DEV BIOL, V318, P17, DOI 10.1016/j.ydbio.2008.02.050
   Chan CC, 2007, DEV BIOL, V311, P538, DOI 10.1016/j.ydbio.2007.09.002
   Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018
   Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331
   Hegi ME, 2008, J CLIN ONCOL, V26, P4189, DOI 10.1200/JCO.2007.11.5964
   Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316
   Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389
   Kleihues P, 1999, Neuro Oncol, V1, P44, DOI 10.1093/neuonc/1.1.44
   Krex D, 2007, BRAIN, V130, P2596, DOI 10.1093/brain/awm204
   Kunitz A, 2007, BRAIN PATHOL, V17, P363, DOI 10.1111/j.1750-3639.2007.00083.x
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Louis DN., 2007, WHO CLASSIFICATION T
   Mizobuchi Y, 2008, NEURO-ONCOLOGY, V10, P244, DOI 10.1215/15228517-2008-016
   Moon Randall T, 2004, Nat Rev Genet, V5, P691, DOI 10.1038/nrg1427
   Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787
   Mueller W, 2005, ACTA NEUROPATHOL, V109, P314, DOI 10.1007/s00401-004-0969-1
   Mulero-Navarro S, 2008, CRIT REV ONCOL HEMAT, V68, P1, DOI 10.1016/j.critrevonc.2008.03.001
   Nikuseva-Martic T, 2007, PATHOL RES PRACT, V203, P779, DOI 10.1016/j.prp.2007.07.009
   Nojima M, 2007, ONCOGENE, V26, P4699, DOI 10.1038/sj.onc.1210259
   Ohgaki H, 2005, J NEUROPATH EXP NEUR, V64, P479, DOI 10.1093/jnen/64.6.479
   Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011
   Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3
   Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007
   Preusser M, 2008, BRAIN PATHOL, V18, P520, DOI 10.1111/j.1750-3639.2008.00153.x
   Pu P, 2009, CANCER GENE THER, V16, P351, DOI 10.1038/cgt.2008.78
   Roman-Gomez J, 2004, BRIT J CANCER, V91, P707, DOI 10.1038/sj.bjc.6602008
   Rousset R, 2001, GENE DEV, V15, P658, DOI 10.1101/gad.869201
   Sareddy GR, 2009, NEUROCHEM RES, V34, P1278, DOI 10.1007/s11064-008-9906-3
   Schumann H, 2000, CARDIOVASC RES, V45, P720, DOI 10.1016/S0008-6363(99)00376-4
   Shou J, 2002, ONCOGENE, V21, P878, DOI 10.1038/sj.onc.1205138
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Tepel M, 2008, INT J CANCER, V123, P2080, DOI 10.1002/ijc.23705
   Utsuki S, 2002, J NEURO-ONCOL, V57, P187, DOI 10.1023/A:1015720220602
   van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Wang J, 2000, ONCOGENE, V19, P1843, DOI 10.1038/sj.onc.1203503
   Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710
   Yang XW, 2001, CANCER RES, V61, P7025
   Yano H, 2000, NEUROL RES, V22, P527
   Yu JM, 2007, CANCER LETT, V257, P172, DOI 10.1016/j.canlet.2007.07.011
   Zhang S, 2007, MOL CELL BIOL, V27, P4454, DOI 10.1128/MCB.00133-07
   Zou HZ, 2005, INT J CANCER, V116, P584, DOI 10.1002/ijc.21045
NR 45
TC 116
Z9 129
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD JUN 1
PY 2010
VL 126
IS 11
BP 2584
EP 2593
DI 10.1002/ijc.24981
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 592AV
UT WOS:000277347900008
PM 19847810
OA Bronze
DA 2025-01-12
ER

PT J
AU Dumitrescu, RG
   Marian, C
   Krishnan, SS
   Spear, SL
   Kallakury, BVS
   Perry, DJ
   Convit, JR
   Seillier-Moiseiwitsch, F
   Yang, Y
   Freudenheim, JL
   Shields, PG
AF Dumitrescu, R. G.
   Marian, C.
   Krishnan, S. S.
   Spear, S. L.
   Kallakury, B. V. S.
   Perry, D. J.
   Convit, J. R.
   Seillier-Moiseiwitsch, F.
   Yang, Y.
   Freudenheim, J. L.
   Shields, P. G.
TI Familial and racial determinants of tumour suppressor genes promoter
   hypermethylation in breast tissues from healthy women
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE p16(INK4); BRCA1; ER alpha CpG islands hypermethylation; breast biology;
   family history of cancer
AB To determine the hypermethylation status of the promoter regions of tumour suppressor genes in breast tissues from healthy women and identify the determinants of these epigenetic changes. Questionnaires and breast tissues were collected from healthy women without a history of cancer and undergoing reduction mammoplasty (N = 141). Methylation for p16(INK4), BRCA1, ER alpha and RAR-beta promoter regions from breast tissues were determined by methylation specific PCR. Associations were examined with chi-square and Fisher's exact test as well as logistic regression. All statistical tests were two-sided. p16INK4, BRCA1, ER alpha and RAR-beta hypermethylation were identified in 31%, 17%, 9% and 0% of the women, respectively. Women with BRCA1 hypermethylation had an eight-fold increase in the risk of ER alpha hypermethylation (P = 0.007). p16(INK4) hypermethylation was present in 28% of African-Americans, but 65% in European-Americans (P = 0.02). There was an increased likelihood of p16(INK4) or BRCA1 hypermethylation for women with family history of cancer (OR 2.3; 95% CI: 1.05-4.85 and OR 5.0; 95% CI: 1.55-15.81, respectively). ER alpha hypermethylation was associated with family history of breast cancer (OR 6.6; 95% CI: 1.58-27.71). After stratification by race, p16(INK4) in European-Americans and BRCA1 hypermethylation in African-Americans were associated with family history of cancer (OR 3.8; 95% CI: 1.21-12.03 and OR 6.5; 95% CI: 1.33-31.32, respectively). Gene promoter hypermethylation was commonly found in healthy breast tissues from women without cancer, indicating that these events are frequent and early lesions. Race and family history of cancer increase the likelihood of these early events.
C1 [Dumitrescu, R. G.; Marian, C.; Krishnan, S. S.; Spear, S. L.; Kallakury, B. V. S.; Perry, D. J.; Seillier-Moiseiwitsch, F.; Yang, Y.; Shields, P. G.] Georgetown Univ, Lombardi Comprehens Canc Ctr, Med Ctr, Washington, DC 20057 USA.
   [Freudenheim, J. L.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Buffalo, NY 14260 USA.
   [Perry, D. J.; Convit, J. R.] Washington Hosp Ctr, Washington, DC 20010 USA.
C3 Georgetown University; State University of New York (SUNY) System;
   University at Buffalo, SUNY; MedStar Washington Hospital Center
RP Dumitrescu, RG (通讯作者)，Georgetown Univ, Lombardi Comprehens Canc Ctr, Med Ctr, 3800 Reservoir Rd NW,LL S Level,Room 116A, Washington, DC 20057 USA.
EM rgd2@georgetown.edu
RI Shields, Peter/I-1644-2012; Marian, Catalin/KHU-8477-2024; Marian,
   Catalin/P-2885-2019
OI Marian, Catalin/0000-0002-7749-1384; Freudenheim, Jo/0000-0002-9301-0499
FU Department of Defense, Alcohol Center of Excellence [DOD BC022346]
FX We would like to thank Drs. Robert Dickson (in memoriam) and Michael
   Johnson for their support and helpful discussions. We would also like to
   acknowledge Leonidas Leondaridis and David Goerlitz together with our
   repository team for providing tissue samples and creating and
   maintaining the laboratory database. Department of Defense, Alcohol
   Center of Excellence grant (DOD BC022346) supported this work.
CR Alvarez S, 2005, CLIN CANCER RES, V11, P1146
   Anderson E, 2002, BREAST CANCER RES, V4, P197, DOI 10.1186/bcr452
   [Anonymous], J NATL CANC I MONOGR
   [Anonymous], CANC FACTS FIG 2008
   Baldwin RL, 2000, CANCER RES, V60, P5329
   Barba M, 2006, CANCER CAUSE CONTROL, V17, P395, DOI 10.1007/s10552-005-0481-5
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Bean GR, 2007, CLIN CANCER RES, V13, P6834, DOI 10.1158/1078-0432.CCR-07-0407
   Bean GR, 2007, CANCER EPIDEM BIOMAR, V16, P50, DOI 10.1158/1055-9965.EPI-06-0598
   Bianco T, 2000, CARCINOGENESIS, V21, P147, DOI 10.1093/carcin/21.2.147
   Boice JD, 2000, PLAST RECONSTR SURG, V106, P755, DOI 10.1097/00006534-200009040-00001
   BRINTON LA, 2001, CANCER, V3, P478
   Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2001, CANCER RES, V61, P3225
   ESTELLER M, 2005, ANN REV PHARM TOXICO, P629
   FACKLER MJ, 2003, J CANC, V6, P970
   Farias EF, 2002, CELL GROWTH DIFFER, V13, P335
   Holst CR, 2003, CANCER RES, V63, P1596
   *IARC, 2004, CANC INC MORT PREV W
   Jacinto FV, 2007, MUTAGENESIS, V22, P247, DOI 10.1093/mutage/gem009
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kusano AS, 2006, INT J CANCER, V118, P2031, DOI 10.1002/ijc.21588
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   Locke I, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1657
   Mehrotra J, 2004, CLIN CANCER RES, V10, P2052, DOI 10.1158/1078-0432.CCR-03-0514
   Nass SJ, 2000, CANCER RES, V60, P4346
   O'Hagan HM, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000155
   Palmieri B, 2006, BREAST, V15, P476, DOI 10.1016/j.breast.2005.09.011
   Palmisano WA, 2000, CANCER RES, V60, P5954
   Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Tao MH, 2009, BREAST CANCER RES TR, V114, P559, DOI 10.1007/s10549-008-0028-z
   Teixeira MR, 2002, GENE CHROMOSOME CANC, V33, P1, DOI 10.1002/gcc.1206
   Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710
   Trichopoulos D, 2008, INT J CANCER, V122, P481, DOI 10.1002/ijc.23303
   Tsou JA, 2002, ONCOGENE, V21, P5450, DOI 10.1038/sj.onc.1205605
   Weiss HA, 1997, EPIDEMIOLOGY, V8, P181, DOI 10.1097/00001648-199703000-00010
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wong DJ, 1999, MOL CELL BIOL, V19, P5642
   Woodcock DM, 1999, BRIT J CANCER, V79, P251, DOI 10.1038/sj.bjc.6690041
   Zöchbauer-Müller S, 2002, ONCOLOGIST, V7, P451, DOI 10.1634/theoncologist.7-5-451
NR 45
TC 34
Z9 38
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-1838
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD JUN
PY 2010
VL 14
IS 6B
BP 1468
EP 1475
DI 10.1111/j.1582-4934.2009.00924.x
PG 8
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 782QA
UT WOS:000292023100009
PM 19799643
OA Green Accepted, hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Jawaid, K
   Crane, SR
   Nowers, JL
   Lacey, M
   Whitehead, SA
AF Jawaid, Kiran
   Crane, Smiley R.
   Nowers, Jennifer L.
   Lacey, Michael
   Whitehead, Saffron A.
TI Long-term genistein treatment of MCF-7 cells decreases acetylated
   histone 3 expression and alters growth responses to mitogens and histone
   deacetylase inhibitors
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article
DE Histone deacetylase inhibitors; Histone 3; Epigenetics; Breast cancer
   cells; Growth; Cyclin D1; Genistein; Pro-caspase 9
ID BREAST-CANCER CELLS; ANTINEOPLASTIC ACTION; GENE-EXPRESSION; CARCINOMA
   CELLS; VALPROIC ACID; APOPTOSIS; TRICHOSTATIN; PATHWAY; RISK;
   5-AZA-2'-DEOXYCYTIDINE
AB Defects in epigenetic regulation of gene transcription play an important role in carcinogenesis of the breast and other tissues. The two most widely studied epigenetic changes are DNA methylation and acetylation of histone proteins and inhibition of these processes inhibits growth in breast cancer cell lines. These data coupled with the evidence that fetal and neonatal exposure to oestrogenic substances may lead to epigenetic changes that predispose or protect against the development of breast cancer in later life formed the basis for this study.
   Three histone deacetylases, valproic acid (VPA), trichostatin A (TCA) and apicidin dose-dependently inhibited basal growth in MCF-7 and MDA-MB-231 as well as the growth promoting effects of oestradiol (E-2) and epidermal growth factor (EGF) in MCF-7 cells. The growth inhibitory responses to the DNA methyl transferase inhibitor, 5-aza-2'deoxycytidine (decitabine) were weak. HDACi's reduced the protein levels of pro-caspase 9 and cyclin D1, whereas decitabine had no effect.
   Long-term genistein treatment (LTGT) of MCF-7 cells markedly reduced the basal expression of acetylated histone 3 (H3) and the effects of HDACi's on increasing the levels of acetylated H3 protein. However, this was not correlated with a reduced expression of total H3 except after a high dose of VPA. LTGT inhibited growth of MCF-7 cells and the mitogenic responses to E-2 and EGF. The growth inhibitory responses to HDACI's in the presence of E-2 and EGF was significantly reduced in LTGT cells compared to control MCF-7 cells and there was evidence that LTGT maintained the protein levels of pro-caspase 9 in the presence of HDACi's. This study provides further evidence that oestrogenic substances can induce significant epigenetic changes to alter the dynamics of growth in breast cancer cell lines. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Jawaid, Kiran; Crane, Smiley R.; Nowers, Jennifer L.; Lacey, Michael; Whitehead, Saffron A.] St Georges Univ London, Div Basic Med Sci, London SW17 0RE, England.
C3 City St Georges, University of London; St Georges University London
RP Whitehead, SA (通讯作者)，St Georges Univ London, Div Basic Med Sci, London SW17 0RE, England.
EM saffron@sgul.ac.uk
CR Alao JP, 2004, CLIN CANCER RES, V10, P8094, DOI 10.1158/1078-0432.CCR-04-1023
   ANASTASIUS N, 2009, MOL BIOL, V116, P50
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Billam M, 2010, BREAST CANCER RES TR, V120, P581, DOI 10.1007/s10549-009-0420-3
   Bovenzi V, 2001, CANCER CHEMOTH PHARM, V48, P71, DOI 10.1007/s002800100294
   Chiam K, 2009, BBA-REV CANCER, V1795, P104, DOI 10.1016/j.bbcan.2008.12.001
   Choi EJ, 2009, J CLIN BIOCHEM NUTR, V44, P260, DOI 10.3164/jcbn.08-230
   Day JK, 2002, J NUTR, V132, p2419S, DOI 10.1093/jn/132.8.2419S
   Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700
   Ehrlich M, 2006, CURR TOP MICROBIOL, V310, P251
   Fortunati N, 2008, CANCER LETT, V259, P156, DOI 10.1016/j.canlet.2007.10.006
   Hodges-Gallagher L, 2007, BREAST CANCER RES TR, V105, P297, DOI 10.1007/s10549-006-9459-6
   Hsu YL, 2009, J AGR FOOD CHEM, V57, P8688, DOI 10.1021/jf901053x
   Hurtubise A, 2006, CANCER CHEMOTH PHARM, V58, P618, DOI 10.1007/s00280-006-0225-6
   Im JY, 2008, CHEM-BIOL INTERACT, V172, P235, DOI 10.1016/j.cbi.2008.01.007
   Jin S, 2010, ANN ONCOL, V21, P263, DOI 10.1093/annonc/mdp499
   Kikuno N, 2008, INT J CANCER, V123, P552, DOI 10.1002/ijc.23590
   Kim MS, 2000, CANCER LETT, V157, P23, DOI 10.1016/S0304-3835(00)00465-1
   Krusche CA, 2005, BREAST CANCER RES TR, V90, P15, DOI 10.1007/s10549-004-1668-2
   Lin YJ, 2009, BIOCHEM BIOPH RES CO, V378, P683, DOI 10.1016/j.bbrc.2008.10.178
   Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879
   Lopez J, 2009, BRIT J CANCER, V100, P571, DOI 10.1038/sj.bjc.6604930
   Margueron R, 2003, J ENDOCRINOL, V179, P41, DOI 10.1677/joe.0.1790041
   Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079
   Min KN, 2004, ARCH PHARM RES, V27, P554, DOI 10.1007/BF02980131
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Momparler RL, 2005, SEMIN ONCOL, V32, P443, DOI 10.1053/j.seminoncol.2005.07.008
   Nakagawa M, 2007, ONCOL REP, V18, P769
   Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6
   Noh EL, 2009, BIOCHEM BIOPH RES CO, V378, P326, DOI 10.1016/j.bbrc.2008.11.057
   Olsen CM, 2004, MOL CELL ENDOCRINOL, V213, P173, DOI 10.1016/j.mce.2003.10.032
   Park JH, 2004, CLIN CANCER RES, V10, P5271, DOI 10.1158/1078-0432.CCR-03-0709
   Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200
   Rabbani SA, 2008, NEOPLASIA, V10, P266, DOI 10.1593/neo.07947
   Roy PG, 2006, BREAST, V15, P718, DOI 10.1016/j.breast.2006.02.005
   Trock BJ, 2006, JNCI-J NATL CANCER I, V98, P459, DOI 10.1093/jnci/djj102
   Warri A, 2008, BRIT J CANCER, V98, P1485, DOI 10.1038/sj.bjc.6604321
   Wu AH, 2008, BRIT J CANCER, V98, P9, DOI 10.1038/sj.bjc.6604145
   Zhang ZH, 2005, BREAST CANCER RES TR, V94, P11, DOI 10.1007/s10549-005-6001-1
NR 39
TC 29
Z9 33
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0760
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD JUN
PY 2010
VL 120
IS 4-5
BP 164
EP 171
DI 10.1016/j.jsbmb.2010.04.007
PG 8
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 621HK
UT WOS:000279566400003
PM 20399854
DA 2025-01-12
ER

PT J
AU Kim, GE
   Kim, JH
   Kim, YH
   Choi, C
   Lee, JS
AF Kim, Ga-Eon
   Kim, Jo-Heon
   Kim, Yeong-Hui
   Choi, Chan
   Lee, Ji Shin
TI Utility of Promoter Hypermethylation for Differentiating Malignant and
   Benign Effusions in Liquid-Based Cytology Specimens
SO KOREAN JOURNAL OF PATHOLOGY
LA English
DT Article
DE Liquid based cytology; Malignancy; Body fluids; Methylation; Polymerase
   chain reaction
ID DNA METHYLATION; MULTIPLE GENES; LUNG-CANCER; PLEURAL EFFUSIONS; SEROUS
   EFFUSIONS; DIAGNOSTIC-VALUE; BREAST-CANCER; FLUID; SPUTUM
AB Background : Making the cytologic differentiation between benign and malignant effusions can be difficult. Because promoter hypermethylation of tumor suppressor genes is a frequent epigenetic event in many human cancers, it could serve as a marker for the diagnosis of cancer. The aim of this study was to investigate the feasibility of detecting promoter hypermethylation as a diagnostic tool with using liquid-based cytology samples for differentiating between malignant and benign effusions. Methods : A multiplex, nested, methylation-specific polymerase chain reaction analysis was used to examine promoter methylation of 4 genes (retinoic acid receptor-beta, [RAR-beta], adenomatous polyposis coli [APC], Twist and high in normal-1 [HIN-1]) in malignant (n = 85) and benign (n = 31) liquid-based cytology samples. Results : The frequencies of hypermethylation of RAR-beta, APC, Twist and HIN-1 were significantly higher in the malignant effusions than in the benign effusions (p < 0.001 for each). On the receiver-operating characteristic analysis, the area under the curve (AUC) for APC was the greatest. The AUC for the best two-gene combination (APC/HIN-1) was not statistically different from the AUC for the best individual tumor suppressor gene (APC). Conclusions : This study suggests that promoter methylation analysis on residual liquid-based effusion samples may be a feasible approach to detect malignant effusions, and that APC is the best marker for differentiating between malignant and benign effusions.
C1 [Kim, Ga-Eon; Kim, Yeong-Hui; Choi, Chan; Lee, Ji Shin] Chonnam Natl Univ, Sch Med, Dept Pathol, Kwangju, South Korea.
   [Kim, Ga-Eon; Kim, Yeong-Hui; Choi, Chan; Lee, Ji Shin] Res Inst Med Sci, Kwangju, South Korea.
   [Kim, Jo-Heon] Jeju Natl Univ, Sch Med, Dept Pathol, Cheju, South Korea.
C3 Chonnam National University; Jeju National University
RP Lee, JS (通讯作者)，Chonnam Natl Univ, Dept Pathol, Hwasun Hosp, 160 Ilsim Ri, Hwasun Eup 519809, Hwasun, South Korea.
EM jshinlee@hanmail.net
RI Kim, Seong/J-5408-2012; Kim, Suhnggwon/J-5407-2012
OI Kim, Ga-Eon/0000-0001-8539-6654
FU Korean Society for Cytopathology; Ministry of Health & Welfare, Republic
   of Korea [A080075]
FX This work was supported by a grant from the 2008 Korean Society for
   Cytopathology and a grant of the Korea Healthcare technology R&D
   Project, Ministry of Health & Welfare, Republic of Korea (A080075) to Ji
   Shin Lee.
CR Belinsky SA, 2006, CANCER RES, V66, P3338, DOI 10.1158/0008-5472.CAN-05-3408
   Benlloch S, 2006, CANCER-AM CANCER SOC, V107, P1859, DOI 10.1002/cncr.22190
   Brock MV, 2005, ANN THORAC SURG, V80, P1241, DOI 10.1016/j.athoracsur.2005.05.088
   Cairns P, 2007, NAT REV CANCER, V7, P531, DOI 10.1038/nrc2170
   Chen ML, 2007, KAOHSIUNG J MED SCI, V23, P498, DOI 10.1016/S1607-551X(08)70007-X
   CHERNOW B, 1977, AM J MED, V63, P695, DOI 10.1016/0002-9343(77)90154-1
   Esteller M, 2000, CANCER RES, V60, P4366
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   FENTON KN, 1995, AM J SURG, V170, P69, DOI 10.1016/S0002-9610(99)80257-8
   Gabriel C, 2004, ACTA CYTOL, V48, P825, DOI 10.1159/000326453
   Gustafson KS, 2004, CANCER CYTOPATHOL, V102, P259, DOI 10.1002/cncr.20425
   House MG, 2003, CARCINOGENESIS, V24, P193, DOI 10.1093/carcin/24.2.193
   Ibanez de Caceres I, 2004, CANCER RES, V64, P6476
   Katayama H, 2007, INT J CANCER, V120, P2191, DOI 10.1002/ijc.22576
   Lee JS, 2007, CANCER BIOL THER, V6, P1114, DOI 10.4161/cbt.6.7.4331
   Lee JS, 1997, ACTA CYTOL, V41, P1719
   Mohanty SK, 2003, POSTGRAD MED J, V79, P569, DOI 10.1136/pmj.79.936.569
   Palmisano WA, 2000, CANCER RES, V60, P5954
   Pereira TC, 2006, ADV ANAT PATHOL, V13, P174, DOI 10.1097/00125480-200607000-00004
   SONG JS, 2008, KOREAN J CYTOPATHOL, V19, P126
   Toyooka S, 2003, INT J CANCER, V103, P153, DOI 10.1002/ijc.10787
   Tsou JA, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-70
   VANDEMOLENGRAFT FJJM, 1989, ACTA CYTOL, V33, P911
   Wajed SA, 2001, ANN SURG, V234, P10, DOI 10.1097/00000658-200107000-00003
   Wisman GBA, 2006, INT J CANCER, V119, P1908, DOI 10.1002/ijc.22060
NR 26
TC 1
Z9 1
U1 0
U2 2
PU KOREAN SOCIETY PATHOLOGISTS
PI SEOUL
PA ROOM 702 KOREAN MED ASSOC BLDG, 302-75 ICHON, 1 DONG, YOUNGSAN-GU,
   SEOUL, 140-721, SOUTH KOREA
SN 1738-1843
J9 KOREAN J PATHOL
JI Korean J. Pathol.
PD JUN
PY 2010
VL 44
IS 3
BP 315
EP 321
DI 10.4132/KoreanJPathol.2010.44.3.315
PG 7
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 618VQ
UT WOS:000279384500012
OA Bronze
DA 2025-01-12
ER

PT J
AU Zhou, ZL
   Kahns, S
   Nielsen, AL
AF Zhou, Zhangle
   Kahns, Soren
   Nielsen, Anders Lade
TI Identification of a novel vimentin promoter and mRNA isoform
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Intermediate filaments; Gene regulation; Epigenetics; Metastasis; Cell
   invasion
ID HUMAN BREAST-CANCER; FIBRILLARY ACIDIC PROTEIN; INTERMEDIATE-FILAMENTS;
   ANTISILENCER ELEMENT; EXPRESSION; GENE; GFAP; TRANSCRIPTION; DISTINCT;
   CELLS
AB The intermediate filament protein vimentin is involved in a variety of cellular functions both during the normal developmental processes and in human malignancies. We here describe the identification of an alternative vimentin transcript initiating upstream for the canonical vimentin gene promoter and spliced using the vimentin promoter sequence as an intron. Expression analysis showed that the alternative vimentin promoter had the same expression profile as the canonical vimentin gene promoter. The presented data suggest that alternative promoter usage and alternative splicing could be regulatory mechanisms participating in vimentin gene regulation.
C1 [Zhou, Zhangle; Kahns, Soren; Nielsen, Anders Lade] Univ Aarhus, Dept Human Genet, Aarhus, Denmark.
C3 Aarhus University
RP Nielsen, AL (通讯作者)，Univ Aarhus, Dept Human Genet, Aarhus, Denmark.
EM aln@humgen.au.dk
RI ; Nielsen, Anders Lade/Q-9604-2016
OI Kahns, Soren/0009-0006-9330-8734; Nielsen, Anders
   Lade/0000-0003-4372-9961
FU The Danish Cancer Society; The Danish Medical Research Foundation;
   Fonden til Laegevidenskabens Fremme; Christinan X's Foundation; The
   Lundbeck Foundation; The NovoNordisk Foundation
FX This project was supported by funding from The Danish Cancer Society,
   The Danish Medical Research Foundation, Fonden til Laegevidenskabens
   Fremme, Christinan X's Foundation, The Lundbeck Foundation, and The
   NovoNordisk Foundation.
CR Aparicio Oscar, 2005, Curr Protoc Mol Biol, VChapter 21, DOI 10.1002/0471142727.mb2103s69
   Benazzouz A, 1999, DIFFERENTIATION, V65, P171, DOI 10.1046/j.1432-0436.1999.6530171.x
   Blechingberg J, 2007, NUCLEIC ACIDS RES, V35, P7636, DOI 10.1093/nar/gkm931
   Butler R, 2000, FEBS LETT, V470, P198, DOI 10.1016/S0014-5793(00)01316-8
   Carninci P, 2006, NAT GENET, V38, P626, DOI 10.1038/ng1789
   Condorelli DF, 1999, J NEUROSCI RES, V56, P219, DOI 10.1002/(SICI)1097-4547(19990501)56:3<219::AID-JNR1>3.0.CO;2-2
   Condorelli DF, 1999, NEUROCHEM RES, V24, P709, DOI 10.1023/A:1021016828704
   DUPREY P, 1995, INT J DEV BIOL, V39, P443
   Evans RM, 1998, BIOESSAYS, V20, P79, DOI 10.1002/(SICI)1521-1878(199801)20:1<79::AID-BIES11>3.0.CO;2-5
   Gilles C, 1999, J CELL SCI, V112, P4615
   Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042
   HEDBERG KK, 1986, EXP CELL RES, V163, P509, DOI 10.1016/0014-4827(86)90081-9
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Hendrix MJC, 1997, AM J PATHOL, V150, P483
   Herrmann H, 2004, ANNU REV BIOCHEM, V73, P749, DOI 10.1146/annurev.biochem.73.011303.073823
   Hol EM, 2003, MOL PSYCHIATR, V8, P786, DOI 10.1038/sj.mp.4001379
   Ivaska J, 2007, EXP CELL RES, V313, P2050, DOI 10.1016/j.yexcr.2007.03.040
   Izmailova ES, 1999, GENE, V235, P69, DOI 10.1016/S0378-1119(99)00209-7
   Izmailova ES, 1999, GENE, V230, P111, DOI 10.1016/S0378-1119(99)00046-3
   Kimura K, 2006, GENOME RES, V16, P55, DOI 10.1101/gr.4039406
   Kokkinos MI, 2007, CELLS TISSUES ORGANS, V185, P191, DOI 10.1159/000101320
   Kragh PM, 2009, TRANSGENIC RES, V18, P545, DOI 10.1007/s11248-009-9245-4
   Kryszke MH, 1998, PATHOL BIOL, V46, P39
   Martianov I, 2007, NATURE, V445, P666, DOI 10.1038/nature05519
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   MouraNeto V, 1996, GENE, V168, P261, DOI 10.1016/0378-1119(95)00789-X
   Nielsen AL, 2002, J BIOL CHEM, V277, P29983, DOI 10.1074/jbc.M112121200
   Parry DAD, 1999, Q REV BIOPHYS, V32, P99, DOI 10.1017/S0033583500003516
   PERREAU J, 1988, GENE, V62, P7, DOI 10.1016/0378-1119(88)90575-6
   PIEPER FR, 1992, EUR J BIOCHEM, V210, P509, DOI 10.1111/j.1432-1033.1992.tb17449.x
   RITTLING SR, 1987, MOL CELL BIOL, V7, P3908, DOI 10.1128/MCB.7.11.3908
   SARRIA AJ, 1994, J CELL SCI, V107, P1593
   SAX CM, 1988, NUCLEIC ACIDS RES, V16, P8057, DOI 10.1093/nar/16.16.8057
   SOMMERS CL, 1994, CELL GROWTH DIFFER, V5, P839
   STOVER DM, 1994, CANCER RES, V54, P3092
   Wang N, 2002, J MUSCLE RES CELL M, V23, P535, DOI 10.1023/A:1023470709071
   Wu YZ, 2007, GENES CELLS, V12, P905, DOI 10.1111/j.1365-2443.2007.01104.x
   Wu YZ, 2004, ONCOGENE, V23, P168, DOI 10.1038/sj.onc.1207003
   Yamamichi-Nishina M, 2003, J BIOL CHEM, V278, P7422, DOI 10.1074/jbc.M208458200
   Zhang XP, 2009, MOL CANCER THER, V8, P499, DOI 10.1158/1535-7163.MCT-08-0544
NR 40
TC 13
Z9 13
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD JUN
PY 2010
VL 37
IS 5
BP 2407
EP 2413
DI 10.1007/s11033-009-9751-8
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 617UW
UT WOS:000279308400036
PM 19690979
DA 2025-01-12
ER

PT J
AU Yamamura, S
   Kawakami, K
   Hirata, H
   Ueno, K
   Saini, S
   Majid, S
   Dahiya, R
AF Yamamura, Soichiro
   Kawakami, Kazumori
   Hirata, Hiroshi
   Ueno, Koji
   Saini, Sharanjot
   Majid, Shahana
   Dahiya, Rajvir
TI Oncogenic Functions of Secreted Frizzled-Related Protein 2 in Human
   Renal Cancer
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID FREQUENT EPIGENETIC INACTIVATION; COLORECTAL-CANCER; BETA-CATENIN;
   BREAST-CANCER; WNT PROTEINS; BCL2 FAMILY; SFRP2 GENE; FECAL DNA;
   CYCLIN-E; APOPTOSIS
AB The secreted Frizzled-related proteins (sFRP) are modulators of the Wnt signaling pathway, which is involved in embryonic development and tumor progression. The functions of sFRP2 have not been studied in renal cancer. Transient transfection of sFRP2 promoted cell growth in renal carcinoma cells, whereby the largest effect was observed in A498 cells. To further study the functions of sFRP2 gene in renal carcinoma cells, we established A498 renal cancer cell lines, which stably expressed sFRP2. Stably expressed sFRP2 significantly promoted cell proliferation in vitro and in vivo tumor growth. The stably expressed sFRP2 cells were also found to have reduced UV-induced apoptosis and increased G(2) phase of the cell cycle. The phosphorylation level at Ser(33/37)/Thr(41) of beta-catenin was lower in the stable sFRP2 cell lines compared with the control cell line. sFRP2 significantly activated T-cell factor/lymphoid enhancer factor transcriptional activity. In the stable sFRP2 cell line, expression of c-Fos, Bcl2, Bcl-w, cyclin B2, and cyclin E2 genes was significantly increased and p53 expression was decreased. This is the first report documenting that sFRP2 activates the canonical Wnt pathway and promotes cell growth by evoking diverse signaling cascades in renal cancer cells. This study may provide better strategies for the management of renal cancer through regulation of sFRP2 pathways. Mol Cancer Ther; 9(6); 1680-7. (C)2010 AACR.
C1 San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA.
   Univ Calif San Francisco, San Francisco, CA 94143 USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   San Francisco VA Medical Center; University of California System;
   University of California San Francisco
RP Dahiya, R (通讯作者)，Vet Affairs Med Ctr, Urol Res Ctr 112F, 4150 Clement St, San Francisco, CA 94121 USA.
EM rdahiya@urology.ucsf.edu
FU NIH [RO1CA130860, T32DK007790]; Veterans Affairs Research Enhancement
   Award Program; Veterans Affairs Merit Review
FX Grant SupportNIH grants RO1CA130860 (S. Yamamura, K. Kawakami, H.
   Hirata, K. Ueno, and R. Dahiya) and T32DK007790 (S. Saini, S. Majid, and
   R. Dahiya), Veterans Affairs Research Enhancement Award Program (R.
   Dahiya), and Veterans Affairs Merit Review (R. Dahiya).
CR Bänziger C, 2006, CELL, V125, P509, DOI 10.1016/j.cell.2006.02.049
   Bartscherer K, 2006, CELL, V125, P523, DOI 10.1016/j.cell.2006.04.009
   Cheng YY, 2007, BRIT J CANCER, V97, P895, DOI 10.1038/sj.bjc.6603968
   Chung MT, 2009, GYNECOL ONCOL, V112, P646, DOI 10.1016/j.ygyno.2008.10.026
   Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883
   Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200
   Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899
   Huang ZH, 2007, DIGEST DIS SCI, V52, P2287, DOI 10.1007/s10620-007-9755-y
   Hwang HC, 2005, ONCOGENE, V24, P2776, DOI 10.1038/sj.onc.1208613
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Kirkin V, 2004, BBA-MOL CELL RES, V1644, P229, DOI 10.1016/j.bbamcr.2003.08.009
   Kress E, 2009, J BIOL CHEM, V284, P1234, DOI 10.1074/jbc.M806548200
   Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881
   Lee JL, 2006, BREAST CANCER RES TR, V100, P49, DOI 10.1007/s10549-006-9233-9
   Lee JL, 2004, J BIOL CHEM, V279, P14602, DOI 10.1074/jbc.M309008200
   Lisovsky M, 2002, CURR BIOL, V12, P53, DOI 10.1016/S0960-9822(01)00628-5
   Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636
   MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4
   MULLER R, 1983, NATURE, V304, P454, DOI 10.1038/304454a0
   Nusse R, 2008, COLD SH Q B, V73, P59, DOI 10.1101/sqb.2008.73.035
   Oberwalder M, 2008, INT J COLORECTAL DIS, V23, P15, DOI 10.1007/s00384-007-0355-2
   Park SH, 2007, CLIN CANCER RES, V13, P858, DOI 10.1158/1078-0432.CCR-06-1461
   Paul S, 2008, NEOPLASMA, V55, P165
   Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783
   Sarafan-Vasseur N, 2002, ONCOGENE, V21, P2051, DOI 10.1038/sj.onc.1205257
   Soria JC, 2000, CANCER RES, V60, P4000
   Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Taurin S, 2006, J BIOL CHEM, V281, P9971, DOI 10.1074/jbc.M508778200
   Thomadaki H, 2006, CRIT REV CL LAB SCI, V43, P1, DOI 10.1080/10408360500295626
   Veeck J, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-83
   Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037
   Wang DR, 2008, WORLD J GASTROENTERO, V14, P524, DOI 10.3748/wjg.14.524
   Wang L, 2009, CANCER INVEST, V27, P816, DOI 10.1080/07357900802672753
   Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443
NR 37
TC 39
Z9 46
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD JUN
PY 2010
VL 9
IS 6
BP 1680
EP 1687
DI 10.1158/1535-7163.MCT-10-0012
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 608FS
UT WOS:000278569200020
PM 20501806
OA Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Ambrosino, C
   Tarallo, R
   Bamundo, A
   Cuomo, D
   Franci, G
   Nassa, G
   Paris, O
   Ravo, M
   Giovane, A
   Zambrano, N
   Lepikhova, T
   Jänne, OA
   Baumann, M
   Nyman, TA
   Cicatiello, L
   Weisz, A
AF Ambrosino, Concetta
   Tarallo, Roberta
   Bamundo, Angela
   Cuomo, Danila
   Franci, Gianluigi
   Nassa, Giovanni
   Paris, Ornella
   Ravo, Maria
   Giovane, Alfonso
   Zambrano, Nicola
   Lepikhova, Tatiana
   Janne, Olli A.
   Baumann, Marc
   Nyman, Tuula A.
   Cicatiello, Luigi
   Weisz, Alessandro
TI Identification of a Hormone-regulated Dynamic Nuclear Actin Network
   Associated with Estrogen Receptor α in Human Breast Cancer Cell Nuclei
SO MOLECULAR & CELLULAR PROTEOMICS
LA English
DT Article
ID RNA-POLYMERASE-II; GENE-EXPRESSION; RIBOSOMAL-PROTEINS; POSTMENOPAUSAL
   WOMEN; STRUCTURAL BASIS; POTENTIAL ROLE; FLIGHTLESS-I; CYCLIN D1;
   MYOSIN-I; ER-ALPHA
AB Estrogen receptor alpha (ER alpha) is a modular protein of the steroid/nuclear receptor family of transcriptional regulators that upon binding to the hormone undergoes structural changes, resulting in its nuclear translocation and docking to specific chromatin sites. In the nucleus, ER alpha assembles in multiprotein complexes that act as final effectors of estrogen signaling to the genome through chromatin remodeling and epigenetic modifications, leading to dynamic and coordinated regulation of hormone-responsive genes. Identification of the molecular partners of ER alpha and understanding their combinatory interactions within functional complexes is a prerequisite to define the molecular basis of estrogen control of cell functions. To this end, affinity purification was applied to map and characterize the ER alpha interactome in hormone-responsive human breast cancer cell nuclei. MCF-7 cell clones expressing human ER alpha fused to a tandem affinity purification tag were generated and used to purify native nuclear ER-containing complexes by IgG-Sepharose affinity chromatography and glycerol gradient centrifugation. Purified complexes were analyzed by two-dimensional DIGE and mass spectrometry, leading to the identification of a ligand-dependent multiprotein complex comprising beta-actin, myosins, and several proteins involved in actin filament organization and dynamics and/or known to participate in actin-mediated regulation of gene transcription, chromatin dynamics, and ribosome biogenesis. Time course analyses indicated that complexes containing ER alpha and actin are assembled in the nucleus early after receptor activation by ligands, and gene knockdown experiments showed that gelsolin and the nuclear isoform of myosin 1c are key determinants for assembly and/or stability of these complexes. Based on these results, we propose that the actin network plays a role in nuclear ER alpha actions in breast cancer cells, including coordinated regulation of target gene activity, spatial and functional reorganization of chromatin, and ribosome biogenesis. Molecular & Cellular Proteomics 9:1352-1367, 2010.
C1 [Ambrosino, Concetta; Tarallo, Roberta; Bamundo, Angela; Cuomo, Danila; Franci, Gianluigi; Nassa, Giovanni; Paris, Ornella; Ravo, Maria; Cicatiello, Luigi; Weisz, Alessandro] Univ Naples 2, Dipartimento Patol Gen, I-80138 Naples, Italy.
   [Giovane, Alfonso] Univ Naples 2, Dept Biochem & Biophys F Cedrangolo, I-80138 Naples, Italy.
   [Ambrosino, Concetta] Univ Sannio, Dept Biol & Environm Sci, I-82100 Benevento, Italy.
   [Paris, Ornella; Cicatiello, Luigi; Weisz, Alessandro] AIRC, Naples Oncogenom Ctr, I-80145 Naples, Italy.
   [Zambrano, Nicola] Univ Naples Federico 2, CEINGE Biotecnol Avanzate, I-80145 Naples, Italy.
   [Zambrano, Nicola] Univ Naples Federico 2, Dept Biochem & Med Biotechnol, I-80145 Naples, Italy.
   [Lepikhova, Tatiana; Janne, Olli A.] Univ Helsinki, Biomedicum Helsinki, Inst Biomed Physiol, FIN-00290 Helsinki, Finland.
   [Baumann, Marc] Univ Helsinki, Biomedicum Helsinki, Prot Chem Unit, FIN-00290 Helsinki, Finland.
   [Nyman, Tuula A.] Univ Helsinki, Inst Biotechnol, Prot Chem Res Grp, Helsinki 00790, Finland.
   [Weisz, Alessandro] Univ Salerno, Fac Med & Surg, Mol Med Lab, I-84081 Baronissi, Italy.
C3 Universita della Campania Vanvitelli; Universita della Campania
   Vanvitelli; University of Sannio; University of Naples Federico II;
   CEINGE Biotecnologie Avanzate; University of Naples Federico II;
   University of Helsinki; University of Helsinki; University of Helsinki;
   University of Salerno
RP Weisz, A (通讯作者)，Univ Naples 2, Dipartimento Patol Gen, Vico L De Crecchio 7, I-80138 Naples, Italy.
EM alessandro.weisz@unina2.it
RI Nyman, Tuula/A-8992-2016; ambrosino, concetta/AAB-3452-2019; Nassa,
   Giovanni/AAB-2059-2022; Cuomo, Danila/AAS-8567-2021; Franci,
   Gianluigi/AAC-6841-2022; Tarallo, Roberta/C-2600-2014; Weisz,
   Alessandro/A-1317-2014; Zambrano, Nicola/B-9352-2014
OI Tarallo, Roberta/0000-0001-9668-3632; Weisz,
   Alessandro/0000-0003-0455-2083; Baumann, Marc/0000-0002-2991-889X;
   Nyman, Tuula/0000-0001-8787-5886; Giovane, Alfonso/0000-0002-2508-2597;
   Franci, Gianluigi/0000-0003-3321-4331; Ravo, Maria/0000-0003-1003-2922;
   Zambrano, Nicola/0000-0001-9395-3481; Cuomo, Danila/0000-0003-4752-5819
FU European Union [LSHM-CT2005-018652]; Associazione Italiana per la
   Ricerca sul Cancro [IG-8586]; Regione Campania and Ministero
   dell'Istruzione, dell'Universitae della Ricerca [PRIN 2008CJ4SYW_004];
   Second University of Naples; University of Cagliari
FX This work was supported in part by European Union CRESCENDO Integrated
   Project Contract LSHM-CT2005-018652, Associazione Italiana per la
   Ricerca sul Cancro Grant IG-8586, Regione Campania and Ministero
   dell'Istruzione, dell'Universitae della Ricerca Grant PRIN
   2008CJ4SYW_004, and the Ph.D. programs "Design and Use of Biomolecules
   of Biotechnological Interest" (to A. B.) and "Pathology of Cell Signal
   Transduction" (to G. N.) of the Second University of Naples and
   "Toxicology, Oncology and Molecular Pathology" of the University of
   Cagliari (to M. R.).
CR Andrin C, 2004, J BIOL CHEM, V279, P25017, DOI 10.1074/jbc.M401805200
   Archer SK, 2004, BIOCHEM SOC T, V32, P940, DOI 10.1042/BST0320940
   Balaguer P, 1999, SCI TOTAL ENVIRON, V233, P47, DOI 10.1016/S0048-9697(99)00178-3
   Barrett-Connor E, 2006, NEW ENGL J MED, V355, P125, DOI 10.1056/NEJMoa062462
   Belandia B, 2003, CELL, V114, P277, DOI 10.1016/S0092-8674(03)00599-3
   Berghöfer-Hochheimer Y, 1998, J CELL BIOCHEM, V69, P1, DOI 10.1002/(SICI)1097-4644(19980401)69:1<1::AID-JCB1>3.0.CO;2-X
   Brogna S, 2002, MOL CELL, V10, P93, DOI 10.1016/S1097-2765(02)00565-8
   Chaurasia G, 2009, NUCLEIC ACIDS RES, V37, pD657, DOI 10.1093/nar/gkn841
   Chen MM, 2007, CURR OPIN CELL BIOL, V19, P326, DOI 10.1016/j.ceb.2007.04.009
   Cheng PC, 2010, MOL CELL PROTEOMICS, V9, P209, DOI 10.1074/mcp.M900183-MCP200
   Cheskis BJ, 2007, J CELL PHYSIOL, V213, P610, DOI 10.1002/jcp.21253
   Cicatiello L, 2004, MOL CELL BIOL, V24, P7260, DOI 10.1128/MCB.24.16.7260-7274.2004
   CICATIELLO L, 2010, AM J PATHOL IN PRESS
   Cimino D, 2008, INT J CANCER, V123, P1327, DOI 10.1002/ijc.23660
   Ciocca DR, 1997, TRENDS ENDOCRIN MET, V8, P313, DOI 10.1016/S1043-2760(97)00122-7
   Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301
   Ellmann S, 2009, CELL MOL LIFE SCI, V66, P2405, DOI 10.1007/s00018-009-0017-3
   Endoh H, 1999, MOL CELL BIOL, V19, P5363
   Frehlick LJ, 2007, BIOESSAYS, V29, P49, DOI 10.1002/bies.20512
   Gieni RS, 2009, BIOCHEM CELL BIOL, V87, P283, DOI 10.1139/O08-133
   Giretti MS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002238
   Grummt I, 2006, CURR OPIN GENET DEV, V16, P191, DOI 10.1016/j.gde.2006.02.001
   HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0
   Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006
   Hofmann WA, 2004, NAT CELL BIOL, V6, P1094, DOI 10.1038/ncb1182
   Hofmann WA, 2006, J CELL BIOCHEM, V99, P1001, DOI 10.1002/jcb.21035
   Hofmann WA, 2009, INT REV CEL MOL BIO, V273, P219, DOI 10.1016/S1937-6448(08)01806-6
   Hu Q, 2008, P NATL ACAD SCI USA, V105, P19199, DOI 10.1073/pnas.0810634105
   Kojetin DJ, 2008, ENDOCR-RELAT CANCER, V15, P851, DOI 10.1677/ERC-07-0281
   Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863
   Kuiper GGJM, 1998, FRONT NEUROENDOCRIN, V19, P253, DOI 10.1006/frne.1998.0170
   Kukalev A, 2005, NAT STRUCT MOL BIOL, V12, P238, DOI 10.1038/nsmb904
   Kyselá K, 2005, HISTOCHEM CELL BIOL, V124, P347, DOI 10.1007/s00418-005-0042-8
   Lahusen T, 2009, BREAST CANCER RES TR, V116, P225, DOI 10.1007/s10549-009-0405-2
   Lee YH, 2004, MOL CELL BIOL, V24, P2103, DOI 10.1128/MCB.24.5.2103-2117.2004
   Levin ER, 2008, BREAST CANCER RES TR, V108, P351, DOI 10.1007/s10549-007-9618-4
   Lindström MS, 2009, BIOCHEM BIOPH RES CO, V379, P167, DOI 10.1016/j.bbrc.2008.12.083
   Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2
   Louvet E, 2009, INT REV CEL MOL BIO, V272, P107, DOI 10.1016/S1937-6448(08)01603-1
   Ma CX, 2009, ONCOLOGY-NY, V23, P133
   Manavathi B, 2006, J CELL PHYSIOL, V207, P594, DOI 10.1002/jcp.20551
   McKenna NJ, 2009, MOL ENDOCRINOL, V23, P740, DOI 10.1210/me.2009-0135
   McKenna NJ, 2002, ENDOCRINOLOGY, V143, P2461, DOI 10.1210/en.143.7.2461
   Métivier R, 2004, EMBO J, V23, P3653, DOI 10.1038/sj.emboj.7600377
   Métivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6
   Métivier R, 2008, ADV EXP MED BIOL, V617, P129, DOI 10.1007/978-0-387-69080-3_12
   Mutarelli M, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-S2-S12
   O'Malley BW, 2007, MOL ENDOCRINOL, V21, P1009, DOI 10.1210/me.2007-0012
   Ogawa S, 2005, GENES CELLS, V10, P1095, DOI 10.1111/j.1365-2443.2005.00904.x
   Ondrej V, 2008, MOL CELLS, V26, P356
   Ou K, 2008, J PROTEOME RES, V7, P1518, DOI 10.1021/pr700820g
   Ou K, 2006, J PROTEOME RES, V5, P2194, DOI 10.1021/pr060115n
   Pacilio C, 1998, CANCER RES, V58, P871
   Percipalle P, 2009, CELL MOL LIFE SCI, V66, P2151, DOI 10.1007/s00018-009-0012-8
   Prossnitz ER, 2009, MOL CELL ENDOCRINOL, V308, P32, DOI 10.1016/j.mce.2009.03.026
   Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X
   Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732
   Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806
   Russo J, 2008, ADV EXP MED BIOL, V630, P52
   Sabbah M, 1998, BIOCHEM J, V336, P639, DOI 10.1042/bj3360639
   SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034
   Scafoglio C, 2006, J CELL BIOCHEM, V98, P1163, DOI 10.1002/jcb.20820
   Sebastian T, 2002, J CELL BIOCHEM, V84, P227, DOI 10.1002/jcb.1280
   Shiau AK, 2002, NAT STRUCT BIOL, V9, P359, DOI 10.1038/nsb787
   Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1
   Silva CM, 2007, MOL ENDOCRINOL, V21, P1499, DOI 10.1210/me.2007-0109
   Solakidi S, 2005, BBA-MOL CELL RES, V1745, P382, DOI 10.1016/j.bbamcr.2005.05.010
   Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9
   Spears M, 2009, EXPERT OPIN THER TAR, V13, P665, DOI 10.1517/14728220902911509
   Spiegelman BM, 2004, CELL, V119, P157, DOI 10.1016/j.cell.2004.09.037
   Syed FA, 2007, ENDOCRINOLOGY, V148, P1902, DOI 10.1210/en.2006-1165
   Taddei A, 2007, CURR OPIN CELL BIOL, V19, P305, DOI 10.1016/j.ceb.2007.04.012
   Tokunaga K, 2006, GENES CELLS, V11, P305, DOI 10.1111/j.1365-2443.2006.00936.x
   Voss TC, 2005, MOL CELL ENDOCRINOL, V231, P33, DOI 10.1016/j.mce.2004.12.003
   Warner JR, 2009, MOL CELL, V34, P3, DOI 10.1016/j.molcel.2009.03.006
   Watson CS, 2007, MOL CELL ENDOCRINOL, V274, P1, DOI 10.1016/j.mce.2007.05.011
   WHELLY SM, 1986, BIOCHIM BIOPHYS ACTA, V880, P179, DOI 10.1016/0304-4165(86)90078-4
   WHELLY SM, 1985, BIOL REPROD, V33, P1, DOI 10.1095/biolreprod33.1.1
   Wilson DN, 2005, CRIT REV BIOCHEM MOL, V40, P243, DOI 10.1080/10409230500256523
   Wu SY, 1999, J BIOL CHEM, V274, P23480, DOI 10.1074/jbc.274.33.23480
   Wu YL, 2005, MOL CELL, V18, P413, DOI 10.1016/j.molcel.2005.04.014
   Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5
   Zheng B, 2009, FEBS J, V276, P2669, DOI 10.1111/j.1742-4658.2009.06986.x
   Zhu XJ, 2004, BIOCHEM BIOPH RES CO, V321, P623, DOI 10.1016/j.bbrc.2004.05.229
NR 84
TC 51
Z9 55
U1 0
U2 10
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 1535-9476
EI 1535-9484
J9 MOL CELL PROTEOMICS
JI Mol. Cell. Proteomics
PD JUN
PY 2010
VL 9
IS 6
BP 1352
EP 1367
DI 10.1074/mcp.M900519-MCP200
PG 16
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 618ZZ
UT WOS:000279396900024
PM 20308691
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Fernandez, SV
   Snider, KE
   Wu, YZ
   Russo, IH
   Plass, C
   Russo, J
AF Fernandez, Sandra V.
   Snider, Kara E.
   Wu, Yue-Zhong
   Russo, Irma H.
   Plass, Christoph
   Russo, Jose
TI DNA methylation changes in a human cell model of breast cancer
   progression
SO MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
LA English
DT Article
DE Epigenetic changes; Breast cancer; DNA methylation; Neuregulin; Cell
   transformation
ID HISTONE-DEACETYLASE INHIBITORS; EPITHELIAL-CELLS; MESENCHYMAL
   TRANSITION; HEREGULIN; RECEPTOR; LINES; DIFFERENTIATION; TRANSFORMATION;
   NEUREGULINS; EXPRESSION
AB Epigenetic inactivation of genes by DNA hypermethylation plays an important role in carcinogenesis An in vitro model of human breast epithelial cell transformation was used to study epigenetic changes induced by estradiol during the neoplastic process Different stages of tumor initiation and progression are represented in this model being MCF-10F the normal stage; trMCF cells, the transformed stage, bsMCF cells, the invasive stage and, caMCF cells, the tumor stage Global methylation studies by restriction landmark genomic scanning (RLGS) showed an increased DNA methylation during the in the invasive and tumor stages Expression studies showed that NRG1 (neuregulin 1), CSS3 (chondroitin sulfate synthase 3) and SNIP (SNAP-25-interacting protein) were downregulated in the invasive and tumor cells. The transformed cells showed low expression of STXBP6(amysin)compared to the parental cells MCF-10F The treatment of these cells with the demethylating agent 5-aza-dC alone or in combination with the histone deacetylase inhibitor trichostatin increased the expression of NRG1, STXBP6, CSS3 and SNIP confirming that DNA methylation plays an Important role in the regulation of the expression of these genes The NRG1 exon 1 has a region located between -136 and +79 (considering +1, the translational initiation site) rich in CpG sites that was analyzed by methylation specific PCR (MSP) NRG1 exon 1 showed progressive changes in the methylation pattern associated with the progression of the neoplastic process in this model; NRG1 exon 1 was unmethylated in MCF-10F and trMCF cells, becoming hypermethylated in the invasive (bsMCF) and tumor (caMCF) stages Studies of human breast tissue samples showed that NRG1 exon 1 was partially methylated in 14 out of 17 (82.4%) invasive carcinomas although it was unmethylated in normal tissues (8 out of 10 normal breast tissue samples) Furthermore, NRG1 exon 1 was partially methylated in 9 out of 14(64.3%) morphologically normal tissue samples adjacent to invasive carcinomas. (C) 2010 Elsevier B V. All rights reserved
C1 [Fernandez, Sandra V.; Snider, Kara E.; Russo, Irma H.; Russo, Jose] Fox Chase Canc Ctr, Breast Canc Res Lab, Philadelphia, PA 19111 USA.
   [Wu, Yue-Zhong; Plass, Christoph] Ohio State Univ, Dept Med Microbiol & Immunol, Div Human Canc Genet, Columbus, OH 43210 USA.
   [Plass, Christoph] German Canc Res Ctr, Div Epigenom & Canc Risk Factors, D-6900 Heidelberg, Germany.
C3 Fox Chase Cancer Center; University System of Ohio; Ohio State
   University; Helmholtz Association; German Cancer Research Center (DKFZ)
RP Fernandez, SV (通讯作者)，Fox Chase Canc Ctr, Breast Canc Res Lab, 333 Cottman Ave, Philadelphia, PA 19111 USA.
RI Plass, Christoph/H-7192-2014; Fernandez, Sandra/A-8031-2010
FU National Institute of Environmental Health Sciences [R21 ESO15148]; NIH
   [UO1ES/CA1271]
FX This work was supported by grant R21 ESO15148 from the National
   Institute of Environmental Health Sciences and partially covered by
   UO1ES/CA1271 from NIH. The quantifications of the Western blots were
   done in collaboration with Dr Xin-Ming Li from the Proteomic Facility at
   FCCC.
CR Bender CM, 1998, PHARM RES-DORDR, V15, P175, DOI 10.1023/A:1011946030404
   Beral Valerie, 2003, Lancet, V362, P419
   BERNSTEIN L, 1993, EPIDEMIOL REV, V15, P48, DOI 10.1093/oxfordjournals.epirev.a036116
   Birnbaum D, 2003, LANCET ONCOL, V4, P639, DOI 10.1016/S1470-2045(03)01225-7
   Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254
   Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243
   CHUA Y, 2006, BREAST CANC RES S2, V8, P5
   Chuang CC, 2008, INT J FUZZY SYST, V10, P11
   Di Stefano P, 2007, EMBO J, V26, P2843, DOI 10.1038/sj.emboj.7601724
   Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7
   Fernandez SV, 2010, TOXICOL PATHOL, V38, P110, DOI 10.1177/0192623309354108
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Grunau C, 2001, NUCLEIC ACIDS RES, V29, P270, DOI 10.1093/nar/29.1.270
   Hayes NVL, 2008, J MAMMARY GLAND BIOL, V13, P205, DOI 10.1007/s10911-008-9078-4
   HENDERSON BE, 1991, SCIENCE, V254, P1131, DOI 10.1126/science.1957166
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hirai Y, 1998, J CELL BIOL, V140, P159, DOI 10.1083/jcb.140.1.159
   Huang HE, 2004, CANCER RES, V64, P6840, DOI 10.1158/0008-5472.CAN-04-1762
   Huang Y, 2007, CANCER RES, V67, P11147, DOI 10.1158/0008-5472.CAN-07-1371
   Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772
   JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004
   Kondo Y, 2004, P NATL ACAD SCI USA, V101, P7398, DOI 10.1073/pnas.0306641101
   Li CI, 2003, JAMA-J AM MED ASSOC, V289, P3254, DOI 10.1001/jama.289.24.3254
   Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   O'Connell P, 2003, BREAST CANCER RES TR, V78, P347, DOI 10.1023/A:1023037925950
   Offterdinger M, 2003, J CELL PHYSIOL, V195, P260, DOI 10.1002/jcp.10237
   Pole JCM, 2006, ONCOGENE, V25, P5693, DOI 10.1038/sj.onc.1209570
   Raj EH, 2001, BREAST, V10, P41, DOI 10.1054/brst.2000.0182
   RIESE DJ, 1995, MOL CELL BIOL, V15, P5770
   Russo J, 2006, FASEB J, V20, P1622, DOI 10.1096/fj.05-5399com
   Schwartz NB, 2002, GLYCOBIOLOGY, V12, p57R, DOI 10.1093/glycob/12.4.57R
   SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661
   Smiraglia DJ, 2002, ONCOGENE, V21, P5414, DOI 10.1038/sj.onc.1205608
   Stein RA, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-79
   Steinthorsdottir V, 2004, GENE, V342, P97, DOI 10.1016/j.gene.2004.07.029
   Tiezzi DG, 2007, INT J ONCOL, V31, P823
   TZAHAR E, 1994, J BIOL CHEM, V269, P25226
   Weinstein EJ, 1998, ONCOGENE, V17, P2107, DOI 10.1038/sj.onc.1202428
NR 41
TC 27
Z9 30
U1 0
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1386-1964
EI 1873-135X
J9 MUTAT RES-FUND MOL M
JI Mutat. Res.-Fundam. Mol. Mech. Mutagen.
PD JUN 1
PY 2010
VL 688
IS 1-2
BP 28
EP 35
DI 10.1016/j.mrfmmm.2010.02.007
PG 8
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
GA 609BX
UT WOS:000278631100005
PM 20193695
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Nihal, M
   Roelke, CT
   Wood, GS
AF Nihal, Minakshi
   Roelke, Craig T.
   Wood, Gary S.
TI Anti-Melanoma Effects of Vorinostat in Combination with Polyphenolic
   Antioxidant (-)-Epigallocatechin-3-Gallate (EGCG)
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE chemoprevention; EGCG; green tea; melanoma; vorinostat
ID HISTONE DEACETYLASE INHIBITORS; T-CELL LYMPHOMA; SUBEROYLANILIDE
   HYDROXAMIC ACID; FACTOR-KAPPA-B; PHASE-I TRIAL; MALIGNANT-MELANOMA;
   SYNERGISTIC INTERACTION; DNA METHYLTRANSFERASE; P21(WAF1) EXPRESSION;
   BREAST-CANCER
AB Melanoma is an aggressive neoplasm with a propensity for metastases and resistance to therapy. Previously, we showed that (-)-epigallocatechin-3-gallate (EGCG), the major polyphenolic antioxidant present in green tea, resulted in a significant decrease in the viability and growth of melanoma and induction of apoptosis via modulation of the cki-cdk-cyclin network and Bcl2 family proteins. Epigenetic regulation of gene transcription by histone deacetylase (HDAC) inhibitors is gaining momentum as a novel cancer therapy. SAHA-suberoylanilidine hydroxamic acid ZolinzaA (R) (vorinostat) is the first HDAC inhibitor approved by the U.S. FDA. In this study, we determined if vorinostat alone or in combination with EGCG imparts anti-proliferative effects against human melanoma cells.
   Employing human melanoma cell lines A-375, Hs-294T and G-361, we determined the effect of vorinostat and/or EGCG on 1) growth/viability and colony formation, 2) apoptosis, and 3) the critical molecules involved in cell cycle and apoptosis regulation.
   Our data demonstrated that the anti-proliferative effects of vorinostat were greater than or similar to those of EGCG among the cell lines tested. Furthermore, relative to monotherapy, the combination treatment resulted in significantly greater inhibition of cell proliferation, increased apoptosis, activation of p21, p27 and caspases (3, 7 and 9) and Bax as well as down-regulation of cdk2, cdk4, cyclin A, NF-kappa B protein p65/RelA and Bcl2 protein and transcript.
   Our preclinical findings suggest that combination therapy with EGCG and vorinostat may be beneficial for the management of human melanoma.
C1 [Wood, Gary S.] Wm S Middleton VA Med Ctr, Madison, WI USA.
   [Nihal, Minakshi; Roelke, Craig T.; Wood, Gary S.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Dermatol, Madison, WI 53706 USA.
C3 University of Wisconsin System; University of Wisconsin Madison
RP Wood, GS (通讯作者)，Wm S Middleton VA Med Ctr, Madison, WI USA.
EM gwood@dermatology.wisc.edu
FU Department of Veterans Affairs and Merck & Co, Boston, Massachusetts,
   USA
FX Supported by Merit Review funding from the Department of Veterans
   Affairs and Merck & Co, Boston, Massachusetts, USA.
CR Amiri KI, 2005, CANCER METAST REV, V24, P301, DOI 10.1007/s10555-005-1579-7
   Boyle GM, 2005, PIGM CELL RES, V18, P160, DOI 10.1111/j.1600-0749.2005.00228.x
   Callagy GM, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-153
   Cerimele F, 2005, P NATL ACAD SCI USA, V102, P175, DOI 10.1073/pnas.0408381102
   Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206
   Choi KC, 2009, CANCER RES, V69, P583, DOI 10.1158/0008-5472.CAN-08-2442
   Crump M, 2008, ANN ONCOL, V19, P964, DOI 10.1093/annonc/mdn031
   Demierre MF, 2006, CURR OPIN ONCOL, V18, P180, DOI 10.1097/01.cco.0000208792.22442.d2
   Demierre MF, 2003, J CLIN ONCOL, V21, P158, DOI 10.1200/JCO.2003.07.173
   Duvic M, 2007, DRUG TODAY, V43, P585, DOI 10.1358/dot.2007.43.9.1112980
   Emanuele S, 2007, APOPTOSIS, V12, P1327, DOI 10.1007/s10495-007-0063-y
   Facchetti F, 2004, APOPTOSIS, V9, P573, DOI 10.1023/B:APPT.0000038036.31271.50
   Fang MZ, 2003, CANCER RES, V63, P7563
   Fried L, 2008, PIGM CELL MELANOMA R, V21, P117, DOI 10.1111/j.1755-148X.2008.00451.x
   Glaser KB, 2007, BIOCHEM PHARMACOL, V74, P659, DOI 10.1016/j.bcp.2007.04.007
   Heider U, 2008, EUR J HAEMATOL, V80, P133, DOI 10.1111/j.1600-0609.2007.00995.x
   Heider U, 2009, EUR J HAEMATOL, V82, P440, DOI 10.1111/j.1600-0609.2009.01239.x
   Ju R, 2003, CANCER RES, V63, P2891
   Kadekaro AL, 2006, FRONT BIOSCI-LANDMRK, V11, P2157, DOI 10.2741/1958
   Kato Y, 2007, MOL CANCER THER, V6, P70, DOI 10.1158/1535-7163.MCT-06-0125
   Khan N, 2008, ANTIOXID REDOX SIGN, V10, P475, DOI 10.1089/ars.2007.1740
   Krajewski S, 1999, ENDOCR-RELAT CANCER, V6, P29, DOI 10.1677/erc.0.0060029
   Lao CD, 2006, EXPERT REV ANTICANC, V6, P1559, DOI 10.1586/14737140.6.11.1559
   Lee MJ, 2008, CURR OPIN ONCOL, V20, P639, DOI 10.1097/CCO.0b013e3283127095
   Lillehammer T, 2007, J GENE MED, V9, P440, DOI 10.1002/jgm.1036
   Marchion D, 2007, EXPERT REV ANTICANC, V7, P583, DOI 10.1586/14737140.7.4.583
   Masuoka Yuhta, 2008, V66
   Meyskens FL, 1999, CLIN CANCER RES, V5, P1197
   Modesitt SC, 2008, GYNECOL ONCOL, V109, P182, DOI 10.1016/j.ygyno.2008.01.009
   Munshi A, 2006, MOL CANCER THER, V5, P1967, DOI 10.1158/1535-7163.MCT-06-0022
   Munster PN, 2009, BRIT J CANCER, V101, P1044, DOI 10.1038/sj.bjc.6605293
   Nihal M, 2005, INT J CANCER, V114, P513, DOI 10.1002/ijc.20785
   Nolan L, 2008, BRIT J CANCER, V99, P689, DOI 10.1038/sj.bjc.6604557
   Olsen EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200/JCO.2006.10.2434
   Richardson P, 2008, LEUKEMIA LYMPHOMA, V49, P502, DOI 10.1080/10428190701817258
   Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197
   Schaefer EW, 2009, HAEMATOL-HEMATOL J, V94, P1375, DOI 10.3324/haematol.2009.009217
   Schmit TL, 2009, CELL CYCLE, V8, P2697, DOI 10.4161/cc.8.17.9413
   Stresemann C, 2006, CANCER RES, V66, P2794, DOI 10.1158/0008-5472.CAN-05-2821
   Zhang CL, 2005, J INVEST DERMATOL, V125, P1045, DOI 10.1111/j.0022-202X.2005.23925.x
NR 40
TC 50
Z9 61
U1 0
U2 17
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD JUN
PY 2010
VL 27
IS 6
BP 1103
EP 1114
DI 10.1007/s11095-010-0054-5
PG 12
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 597VW
UT WOS:000277791300017
PM 20232120
DA 2025-01-12
ER

PT J
AU Hsia, DA
   Tepper, CG
   Pochampalli, MR
   Hsia, EYC
   Izumiya, C
   Huerta, SB
   Wright, ME
   Chen, HW
   Kung, HJ
   Izumiya, Y
AF Hsia, Datsun A.
   Tepper, Clifford G.
   Pochampalli, Mamata R.
   Hsia, Elaine Y. C.
   Izumiya, Chie
   Huerta, Steve B.
   Wright, Michael E.
   Chen, Hong-Wu
   Kung, Hsing-Jien
   Izumiya, Yoshihiro
TI KDM8, a H3K36me2 histone demethylase that acts in the cyclin A1 coding
   region to regulate cancer cell proliferation
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE breast cancer; epigenetics; JmjC; cell cycle; transcription
ID TRANSCRIPTION; FAMILY; MICE; DEACETYLATION; METHYLATION; LYSINE-36;
   PROTEINS; H3
AB Localized chromatin modifications of histone tails play an important role in regulating gene transcription, and aberration of these processes leads to carcinogenesis. Methylated histone lysine residues, a key player in chromatin remodeling, are demethylated by the JmjC class of enzymes. Here we show that JMJD5 (now renamed KDM8), a JmjC family member, demethylates H3K36me2 and is required for cell cycle progression. Chromatin immunoprecipitation assays applied to human genome tiling arrays in conjunction with RNA microarray revealed that KDM8 occupies the coding region of cyclin A1 and directly regulates transcription. Mechanistic analyses showed that KDM8 functioned as a transcriptional activator by inhibiting HDAC recruitment via demethylation of H3K36me2, an epigenetic repressive mark. Tumor array experiments revealed KDM8 is overexpressed in several types of cancer. In addition, loss-of-function studies in MCF7 cells leads to cell cycle arrest. These studies identified KDM8 as an important cell cycle regulator.
C1 [Hsia, Datsun A.; Tepper, Clifford G.; Pochampalli, Mamata R.; Hsia, Elaine Y. C.; Izumiya, Chie; Huerta, Steve B.; Chen, Hong-Wu; Kung, Hsing-Jien; Izumiya, Yoshihiro] Univ Calif Davis, Sch Med, Dept Biochem & Mol Med, Univ Calif Davis Canc Ctr, Sacramento, CA 95817 USA.
   [Wright, Michael E.] Univ Iowa, Dept Mol Physiol & Biophys, Iowa City, IA 52242 USA.
   [Izumiya, Yoshihiro] Univ Calif Davis, Sch Med, Dept Dermatol, Univ Calif Davis Canc Ctr, Sacramento, CA 95817 USA.
C3 University of California System; University of California Davis;
   University of Iowa; University of California System; University of
   California Davis
RP Kung, HJ (通讯作者)，Univ Calif Davis, Sch Med, Dept Biochem & Mol Med, Univ Calif Davis Canc Ctr, Sacramento, CA 95817 USA.
EM hkung@ucdavis.edu; yizumiya@ucdavis.edu
RI Kung, Hsing-Jien/C-7651-2013; Tepper, Clifford/H-6527-2011
OI Izumiya, Yoshihiro/0000-0002-9184-2603; Wright,
   Michael/0000-0002-4243-2931
FU Auburn Cancer Endowment Fund; Cancer Center Support Grant [2 P30
   CA93373]; University of California Davis Health Science; National
   Institutes of Health [DK52659, CA114575, CA150179]; Department of
   Defense (DoD) [PC093350]
FX We thank Tony Martinez, Harryl Martinez, and Ryan R. Davis for their
   expert technical assistance and consultation for experiments; Dr.
   William Jewell at the University of California Davis Campus MS facility
   for assistance; Dr. Ming-Daw Tsai and Dr. Pang-Hung Hsu for the initial
   phase of substrate analysis; Mel Campbell for revising the manuscript;
   and Dr. Xin-bin Chen (University of California School of Veterinary
   Medicine) for the TR7-MCF7 cell line. This work was supported by the
   Auburn Cancer Endowment Fund and contributions from the University of
   California Davis Cancer Center Genomics and Expression Resource
   (supported by Cancer Center Support Grant 2 P30 CA93373; principal
   investigator, Ralph de Vere White). This work was also supported by a
   University of California Davis Health Science grant (to Y.I.), National
   Institutes of Health Grants DK52659, CA114575, and CA150179; Department
   of Defense (DoD) Idea Award PC093350 (to H.-J.K.); and a DoD
   postdoctoral training award (to M. R. P.).
CR Bannister AJ, 2005, J BIOL CHEM, V280, P17732, DOI 10.1074/jbc.M500796200
   Carrozza MJ, 2005, CELL, V123, P581, DOI 10.1016/j.cell.2005.10.023
   Iwase S, 2007, CELL, V128, P1077, DOI 10.1016/j.cell.2007.02.017
   Joshi AA, 2005, MOL CELL, V20, P971, DOI 10.1016/j.molcel.2005.11.021
   Klose RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945
   Klose RJ, 2006, NATURE, V442, P312, DOI 10.1038/nature04853
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Liu D, 2000, DEV BIOL, V224, P388, DOI 10.1006/dbio.2000.9776
   Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010
   Suzuki T, 2006, EMBO J, V25, P3422, DOI 10.1038/sj.emboj.7601215
   Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028
   Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546
   Yang R, 1999, MOL CELL BIOL, V19, P2400
   Yang XJ, 2008, NAT REV MOL CELL BIO, V9, P206, DOI 10.1038/nrm2346
NR 14
TC 147
Z9 167
U1 2
U2 18
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 25
PY 2010
VL 107
IS 21
BP 9671
EP 9676
DI 10.1073/pnas.1000401107
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 601JP
UT WOS:000278054700037
PM 20457893
OA Green Published
DA 2025-01-12
ER

PT J
AU Lee, J
   Jeong, DJ
   Kim, J
   Lee, S
   Park, JH
   Chang, B
   Jung, SI
   Yi, L
   Han, Y
   Yang, Y
   Kim, KI
   Lim, JS
   Yang, I
   Jeon, S
   Bae, DH
   Kim, CJ
   Lee, MS
AF Lee, Jaehyouk
   Jeong, Dong-Jun
   Kim, Jinsun
   Lee, Soonduck
   Park, Jin-Hwa
   Chang, Boogi
   Jung, Sam-Il
   Yi, Lisha
   Han, Youngsoo
   Yang, Young
   Kim, Keun Il
   Lim, Jong-Seok
   Yang, Inchul
   Jeon, Seob
   Bae, Dong Han
   Kim, Chang-Jin
   Lee, Myeong-Sok
TI The anti-aging gene <i>KLOTHO</i> is a novel target for epigenetic
   silencing in human cervical carcinoma
SO MOLECULAR CANCER
LA English
DT Article
ID COLORECTAL-CANCER; BREAST-CANCER; BETA-CATENIN; SFRP GENES; CELL-LINES;
   WNT; INACTIVATION; FREQUENT; PATHWAY; ACTIVATION
AB Background: Klotho was originally characterized as an anti-aging gene that predisposed Klotho-deficient mice to a premature aging-like syndrome. Recently, KLOTHO was reported to function as a secreted Wnt antagonist and as a tumor suppressor. Epigenetic gene silencing of secreted Wnt antagonists is considered a common event in a wide range of human malignancies. Abnormal activation of the canonical Wnt pathway due to epigenetic deregulation of Wnt antagonists is thought to play a crucial role in cervical tumorigenesis. In this study, we examined epigenetic silencing of KLOTHO in human cervical carcinoma.
   Results: Loss of KLOTHO mRNA was observed in several cervical cancer cell lines and in invasive carcinoma samples, but not during the early, preinvasive phase of primary cervical tumorigenesis. KLOTHO mRNA was restored after treatment with either the DNA demethylating agent 2'-deoxy-5-azacytidine or histone deacetylase inhibitor trichostatin A. Methylation-specific PCR and bisulfite genomic sequencing analysis of the promoter region of KLOTHO revealed CpG hypermethylation in non-KLOTHO-expressing cervical cancer cell lines and in 41% (9/22) of invasive carcinoma cases. Histone deacetylation was also found to be the major epigenetic silencing mechanism for KLOTHO in the SiHa cell line. Ectopic expression of the secreted form of KLOTHO restored anti-Wnt signaling and anti-clonogenic activity in the CaSki cell line including decreased active beta-catenin levels, suppression of T-cell factor/beta-catenin target genes, such as c-MYC and CCND1, and inhibition of colony growth.
   Conclusions: Epigenetic silencing of KLOTHO may occur during the late phase of cervical tumorigenesis, and consequent functional loss of KLOTHO as the secreted Wnt antagonist may contribute to aberrant activation of the canonical Wnt pathway in cervical carcinoma.
C1 [Lee, Jaehyouk; Kim, Jinsun; Lee, Soonduck; Park, Jin-Hwa; Chang, Boogi; Jung, Sam-Il; Yi, Lisha; Han, Youngsoo; Yang, Young; Kim, Keun Il; Lim, Jong-Seok; Lee, Myeong-Sok] Sookmyung Womens Univ, Res Ctr Womens Dis, Seoul 140742, South Korea.
   [Lee, Jaehyouk; Kim, Jinsun; Lee, Soonduck; Park, Jin-Hwa; Chang, Boogi; Jung, Sam-Il; Yi, Lisha; Han, Youngsoo; Yang, Young; Kim, Keun Il; Lim, Jong-Seok; Lee, Myeong-Sok] Sookmyung Womens Univ, Div Biol Sci, Seoul 140742, South Korea.
   [Jeong, Dong-Jun; Kim, Chang-Jin] Soonchunhyang Univ, Coll Med, Dept Pathol, Cheonan 330090, South Korea.
   [Yang, Inchul] Korea Res Inst Stand & Sci, Hlth Metrol Grp, Taejon 305333, South Korea.
   [Jeon, Seob; Bae, Dong Han] Soonchunhyang Univ, Cheonan Hosp, Dept Obstet & Gynecol, Cheonan 330721, South Korea.
C3 Sookmyung Women's University; Sookmyung Women's University;
   Soonchunhyang University; Korea Research Institute of Standards &
   Science (KRISS); Soonchunhyang University
RP Lee, MS (通讯作者)，Sookmyung Womens Univ, Res Ctr Womens Dis, Seoul 140742, South Korea.
EM mslee@sm.ac.kr
RI Kim, Seung-Hyung/AAA-4707-2020; KIM, KEUN/D-2959-2011; JEONG,
   DONGJUN/HTL-8968-2023
OI Lim, Jong-Seok/0000-0003-4024-6868; Yang, Young/0000-0003-4239-0804
FU Sookmyung Women's University; Research Center for Women's Diseases at
   the Korea Research Foundation
FX This work was supported by the Research Center for Women's Diseases at
   the Korea Research Foundation and by a grant from Sookmyung Women's
   University (2008).
CR Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Chung MT, 2009, GYNECOL ONCOL, V112, P301, DOI 10.1016/j.ygyno.2008.10.004
   Duenas-Gonzalez A, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-38
   Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389
   Ku JL, 1997, INT J CANCER, V72, P313, DOI 10.1002/(SICI)1097-0215(19970717)72:2<313::AID-IJC19>3.0.CO;2-G
   Kuro-O M, 2008, BIOL CHEM, V389, P233, DOI 10.1515/BC.2008.028
   Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285
   Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766
   Lee EJ, 2009, INT J CANCER, V124, P287, DOI 10.1002/ijc.23913
   Lee J, 2008, GYNECOL ONCOL, V109, P270, DOI 10.1016/j.ygyno.2008.01.034
   Liu HJ, 2007, SCIENCE, V317, P803, DOI 10.1126/science.1143578
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Matsumura Y, 1998, BIOCHEM BIOPH RES CO, V242, P626, DOI 10.1006/bbrc.1997.8019
   Nojima M, 2007, ONCOGENE, V26, P4699, DOI 10.1038/sj.onc.1210259
   Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440
   Perez-Plasencia Carlos, 2008, Int Arch Med, V1, P10, DOI 10.1186/1755-7682-1-10
   RIOU GF, 1990, ANTICANCER RES, V10, P1225
   Shinohara A, 2001, GYNECOL ONCOL, V82, P450, DOI 10.1006/gyno.2001.6298
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Urakami S, 2006, CLIN CANCER RES, V12, P2109, DOI 10.1158/1078-0432.CCR-05-2468
   Üren A, 2005, CANCER RES, V65, P6199, DOI 10.1158/0008-5472.CAN-05-0455
   Wolf I, 2008, ONCOGENE, V27, P7094, DOI 10.1038/onc.2008.292
   zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798
NR 25
TC 117
Z9 128
U1 0
U2 20
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD MAY 18
PY 2010
VL 9
AR 109
DI 10.1186/1476-4598-9-109
PG 10
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 617IY
UT WOS:000279275500001
PM 20482749
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Holloway, KR
   Calhoun, TN
   Saxena, M
   Metoyer, CF
   Kandler, EF
   Rivera, CA
   Pruitt, K
AF Holloway, Kimberly R.
   Calhoun, Tara N.
   Saxena, Madhurima
   Metoyer, Cheynita F.
   Kandler, Ethan F.
   Rivera, Chantal A.
   Pruitt, Kevin
TI SIRT1 regulates Dishevelled proteins and promotes transient and
   constitutive Wnt signaling
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE breast cancer; colon cancer; cambinol; beta-catenin; sirtuin 2
ID BONE MORPHOGENETIC PROTEIN-4; BETA-CATENIN; CANCER-CELLS;
   COLORECTAL-CANCER; PATHWAY ACTIVATION; PROSTATE-CANCER; COLON-CANCER;
   LUNG-CANCER; DNA-DAMAGE; CYCLIN D1
AB Sirtuin 1 (SIRT1) is a class III histone deacetylase that deacetylates histone and nonhistone proteins to regulate gene transcription and protein function. Because SIRT1 regulates very diverse responses such as apoptosis, insulin sensitivity, autophagy, differentiation, and stem cell pluripotency, it has been a challenge to reconcile how it orchestrates such pleiotropic effects. Here we show that SIRT1 serves as an important regulator of Wnt signaling. We demonstrate that SIRT1 loss of function leads to a significant decrease in the levels of all three Dishevelled (Dvl) proteins. Furthermore, we demonstrate that SIRT1 and Dvl proteins complex in vivo and that inhibition of SIRT1 leads to changes in gene expression of Wnt target genes. Finally, we demonstrate that Wnt-stimulated cell migration is inhibited by a SIRT1 inhibitor. Because the three mammalian Dvl proteins serve as key messengers for as many as 19 Wnt ligands, SIRT1-mediated regulation of Dvl proteins may explain the diverse physiological responses observed in different cellular contexts. Previously, SIRT1 had only been shown to mediate the epigenetic silencing of Wnt antagonists. In contrast, here we report that SIRT1 regulates Dvl protein levels and Wnt signaling in several cellular contexts. These findings demonstrate that SIRT1 is a regulator of transient and constitutive Wnt signaling.
C1 [Holloway, Kimberly R.; Calhoun, Tara N.; Saxena, Madhurima; Kandler, Ethan F.; Rivera, Chantal A.; Pruitt, Kevin] Louisiana State Univ, Hlth Sci Ctr, Dept Mol & Cellular Physiol, Shreveport, LA 71130 USA.
   [Holloway, Kimberly R.; Calhoun, Tara N.; Saxena, Madhurima; Metoyer, Cheynita F.; Kandler, Ethan F.; Rivera, Chantal A.; Pruitt, Kevin] Louisiana State Univ, Hlth Sci Ctr, Sch Med, Shreveport, LA 71130 USA.
   [Pruitt, Kevin] Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA.
C3 Louisiana State University System; Louisiana State University Health
   Sciences Center at Shreveport; Louisiana State University System;
   Louisiana State University Health Sciences Center at Shreveport;
   Louisiana State University System; Louisiana State University Health
   Sciences Center at Shreveport
RP Pruitt, K (通讯作者)，Louisiana State Univ, Hlth Sci Ctr, Dept Mol & Cellular Physiol, Shreveport, LA 71130 USA.
EM kpruit@lsuhsc.edu
OI Holloway, Katy/0000-0001-5064-6350; Saxena, Maddie/0000-0003-0094-8566
FU Feist-Weiller Cancer Center
FX Our research was supported by an intramural grant to K.P. from the
   Feist-Weiller Cancer Center.
CR Angers S, 2006, NAT CELL BIOL, V8, P348, DOI 10.1038/ncb1381
   Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717
   Barker N, 2006, NAT REV DRUG DISCOV, V5, P997, DOI 10.1038/nrd2154
   Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011
   Chien AJ, 2009, P NATL ACAD SCI USA, V106, P1193, DOI 10.1073/pnas.0811902106
   Cong F, 2004, MOL CELL BIOL, V24, P2000, DOI 10.1128/MCB.24.5.2000-2011.2004
   Coussens M, 2008, PLOS ONE, V3, DOI [10.1371/journal.pone.0001571, 10.1371/journal.pone.0002640]
   Creyghton MP, 2005, GENE DEV, V19, P376, DOI 10.1101/gad.328905
   Deng HY, 2007, EXP CELL RES, V313, P1033, DOI 10.1016/j.yexcr.2006.12.020
   Esufali S, 2007, CANCER RES, V67, P2469, DOI 10.1158/0008-5472.CAN-06-2843
   Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020
   Gan XQ, 2008, J CELL BIOL, V180, P1087, DOI 10.1083/jcb.200710050
   Heltweg B, 2006, CANCER RES, V66, P4368, DOI 10.1158/0008-5472.CAN-05-3617
   Houlston RS, 2008, NAT GENET, V40, P1426, DOI 10.1038/ng.262
   Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085
   Hussain M, 2009, CANCER RES, V69, P3570, DOI 10.1158/0008-5472.CAN-08-2807
   Itoh Keiji, 2005, J Biol, V4, P3, DOI 10.1186/jbiol20
   Jin QH, 2007, J CELL PHYSIOL, V213, P88, DOI 10.1002/jcp.21091
   Kang H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006611
   Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316
   Kim JS, 2002, CANCER RES, V62, P2744
   Kojima K, 2008, BIOCHEM BIOPH RES CO, V373, P423, DOI 10.1016/j.bbrc.2008.06.045
   Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105
   Lee YN, 2008, CELL SIGNAL, V20, P443, DOI 10.1016/j.cellsig.2007.11.005
   Liang XJ, 2008, MOL CANCER RES, V6, P1499, DOI 10.1158/1541-7786.MCR-07-2130
   Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4
   Ma PP, 2006, MOL REPROD DEV, V73, P774, DOI 10.1002/mrd.20468
   McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38-54.2003
   Miyazaki K, 2004, J BIOL CHEM, V279, P11327, DOI 10.1074/jbc.M312389200
   Najdi R, 2009, ONCOGENE, V28, P4133, DOI 10.1038/onc.2009.271
   Nosho K, 2009, MODERN PATHOL, V22, P922, DOI 10.1038/modpathol.2009.49
   Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583
   Prasad CP, 2007, ONCOLOGY-BASEL, V73, P112, DOI 10.1159/000120999
   Prestwich TC, 2007, CURR OPIN CELL BIOL, V19, P612, DOI 10.1016/j.ceb.2007.09.014
   Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040
   Qiang L, 2007, MOL CELL BIOL, V27, P4698, DOI 10.1128/MCB.02279-06
   Rodgers JT, 2008, FEBS LETT, V582, P46, DOI 10.1016/j.febslet.2007.11.034
   Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950
   Samarzija I, 2009, BIOCHEM BIOPH RES CO, V386, P449, DOI 10.1016/j.bbrc.2009.06.033
   Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674
   Shimazu T, 2007, J BIOL CHEM, V282, P4470, DOI 10.1074/jbc.M609745200
   Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522
   Tanno M, 2007, J BIOL CHEM, V282, P6823, DOI 10.1074/jbc.M609554200
   Tapia JC, 2006, P NATL ACAD SCI USA, V103, P15079, DOI 10.1073/pnas.0606845103
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Uematsu K, 2003, ONCOGENE, V22, P7218, DOI 10.1038/sj.onc.1206817
   Uematsu K, 2003, CANCER RES, V63, P4547
   Wang LD, 2009, CANCER CELL, V15, P207, DOI 10.1016/j.ccr.2009.01.018
   Wang S, 2006, CURR BIOL, V16, P2239, DOI 10.1016/j.cub.2006.09.034
   Wharton KA, 2003, DEV BIOL, V253, P1, DOI 10.1006/dbio.2002.0869
   Willert K, 2006, GENE DEV, V20, P1394, DOI 10.1101/gad.1424006
   You L, 2004, CANCER RES, V64, P5385, DOI 10.1158/0008-5472.CAN-04-1227
   Zhang Y, 2009, ONCOGENE, V28, P445, DOI 10.1038/onc.2008.388
   Zschoernig B, 2009, BIOCHEM BIOPH RES CO, V381, P372, DOI 10.1016/j.bbrc.2009.02.085
NR 54
TC 95
Z9 103
U1 0
U2 18
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 18
PY 2010
VL 107
IS 20
BP 9216
EP 9221
DI 10.1073/pnas.0911325107
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 598GH
UT WOS:000277822600037
PM 20439735
OA Green Published
DA 2025-01-12
ER

PT J
AU Chari, R
   Coe, BP
   Vucic, EA
   Lockwood, WW
   Lam, WL
AF Chari, Raj
   Coe, Bradley P.
   Vucic, Emily A.
   Lockwood, William W.
   Lam, Wan L.
TI An integrative multi-dimensional genetic and epigenetic strategy to
   identify aberrant genes and pathways in cancer
SO BMC SYSTEMS BIOLOGY
LA English
DT Article
ID COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER ALTERATIONS;
   BREAST-CANCER; EXPRESSION PATTERNS; MOLECULAR PORTRAITS; MICROARRAY
   ANALYSIS; DNA AMPLIFICATION; CGH; CELL; ONCOGENE
AB Background: Genomics has substantially changed our approach to cancer research. Gene expression profiling, for example, has been utilized to delineate subtypes of cancer, and facilitated derivation of predictive and prognostic signatures. The emergence of technologies for the high resolution and genome-wide description of genetic and epigenetic features has enabled the identification of a multitude of causal DNA events in tumors. This has afforded the potential for large scale integration of genome and transcriptome data generated from a variety of technology platforms to acquire a better understanding of cancer.
   Results: Here we show how multi-dimensional genomics data analysis would enable the deciphering of mechanisms that disrupt regulatory/signaling cascades and downstream effects. Since not all gene expression changes observed in a tumor are causal to cancer development, we demonstrate an approach based on multiple concerted disruption (MCD) analysis of genes that facilitates the rational deduction of aberrant genes and pathways, which otherwise would be overlooked in single genomic dimension investigations.
   Conclusions: Notably, this is the first comprehensive study of breast cancer cells by parallel integrative genome wide analyses of DNA copy number, LOH, and DNA methylation status to interpret changes in gene expression pattern. Our findings demonstrate the power of a multi-dimensional approach to elucidate events which would escape conventional single dimensional analysis and as such, reduce the cohort sample size for cancer gene discovery.
C1 [Chari, Raj; Coe, Bradley P.; Vucic, Emily A.; Lockwood, William W.; Lam, Wan L.] BC Canc Res Ctr, Dept Integrat Oncol, Vancouver, BC, Canada.
C3 British Columbia Cancer Agency
RP Chari, R (通讯作者)，BC Canc Res Ctr, Dept Integrat Oncol, Vancouver, BC, Canada.
EM rchari@bccrc.ca
RI Chari, Raj/G-3285-2019; Lockwood, William/A-2879-2009; Coe,
   Bradley/A-2878-2009
OI Vucic, Emily/0000-0002-2728-8708; Coe, Bradley/0000-0001-8471-4016
FU Canadian Institutes for Health Research (CIHR); Michael Smith Foundation
   for Heath Research; Canadian Breast Cancer Research Alliance IDEA;
   Canadian Institutes for Health Research
FX We would like to thank Dr. Adi F. Gazdar and Ian M. Wilson for critical
   reading of the manuscript. RC is supported by scholarships from the
   Canadian Institutes for Health Research (CIHR); RC and WWL are supported
   by scholarships from the Michael Smith Foundation for Heath Research.
   This work was supported by grants from the Canadian Breast Cancer
   Research Alliance IDEA and Canadian Institutes for Health Research.
CR Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985
   Andre F, 2009, CLIN CANCER RES, V15, P441, DOI 10.1158/1078-0432.CCR-08-1791
   Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994
   Bertucci F, 2008, INT J CANCER, V123, P236, DOI 10.1002/ijc.23518
   Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706
   BOVA GS, 1993, CANCER RES, V53, P3869
   Carvalho B, 2007, BIOSTATISTICS, V8, P485, DOI 10.1093/biostatistics/kxl042
   Chang JC, 2003, LANCET, V362, P362, DOI 10.1016/S0140-6736(03)14023-8
   Chang JT, 2006, BIOINFORMATICS, V22, P2926, DOI 10.1093/bioinformatics/btl483
   Chari R, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-324
   Chari R, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-422
   Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385
   Chin SF, 2007, ONCOGENE, V26, P1959, DOI 10.1038/sj.onc.1209985
   Chin SF, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r215
   Chinen K, 1996, CYTOGENET CELL GENET, V75, P190, DOI 10.1159/000134480
   Coe BP, 2006, BRIT J CANCER, V94, P1927, DOI 10.1038/sj.bjc.6603167
   Coe BP, 2008, J CELL PHYSIOL, V217, P590, DOI 10.1002/jcp.21554
   Cooke SL, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-288
   Fridlyand J, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-96
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502
   Gluz O, 2009, ANN ONCOL, V20, P1913, DOI 10.1093/annonc/mdp492
   Han W, 2008, GENE CHROMOSOME CANC, V47, P490, DOI 10.1002/gcc.20550
   He J, 2007, CANCER BIOL THER, V6, P76, DOI 10.4161/cbt.6.1.3551
   Hyman E, 2002, CANCER RES, V62, P6240
   Ishkanian AS, 2004, NAT GENET, V36, P299, DOI 10.1038/ng1307
   Jain AN, 2001, P NATL ACAD SCI USA, V98, P7952, DOI 10.1073/pnas.151241198
   Jee CD, 2005, INT J ONCOL, V26, P1265
   Johnson N, 2008, BREAST CANCER RES TR, V111, P55, DOI 10.1007/s10549-007-9758-6
   Jong K, 2004, BIOINFORMATICS, V20, P3636, DOI 10.1093/bioinformatics/bth355
   Karolchik D, 2008, NUCLEIC ACIDS RES, V36, pD773, DOI 10.1093/nar/gkm966
   Khojasteh M, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-274
   Kreike B, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1771
   Lin M, 2004, BIOINFORMATICS, V20, P1233, DOI 10.1093/bioinformatics/bth069
   Lockwood WW, 2008, ONCOGENE, V27, P4615, DOI 10.1038/onc.2008.98
   Lockwood WW, 2007, INT J CANCER, V120, P436, DOI 10.1002/ijc.22335
   Naylor TL, 2005, BREAST CANCER RES, V7, pR1186, DOI 10.1186/bcr1356
   Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Pils D, 2005, CANCER-AM CANCER SOC, V104, P2417, DOI 10.1002/cncr.21538
   Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999
   Rakha EA, 2007, CANCER-AM CANCER SOC, V109, P25, DOI 10.1002/cncr.22381
   Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060
   Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329
   Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112
   Shadeo A, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1370
   Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486
   SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152
   Soh J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007464
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x
   Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854
   Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520
   Tuna M, 2009, TRENDS MOL MED, V15, P120, DOI 10.1016/j.molmed.2009.01.005
   Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489
   Ueki T, 2001, INT J CANCER, V91, P673, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1113>3.0.CO;2-U
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Wang E, 2007, CELL MOL LIFE SCI, V64, P1752, DOI 10.1007/s00018-007-7054-6
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   Yan H, 2002, SCIENCE, V297, P1143, DOI 10.1126/science.1072545
   YAREMKO ML, 1995, GENE CHROMOSOME CANC, V13, P186, DOI 10.1002/gcc.2870130308
NR 65
TC 47
Z9 53
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1752-0509
J9 BMC SYST BIOL
JI BMC Syst. Biol.
PD MAY 17
PY 2010
VL 4
AR 67
DI 10.1186/1752-0509-4-67
PG 14
WC Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mathematical & Computational Biology
GA 604EE
UT WOS:000278259300001
PM 20478067
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Härmä, V
   Virtanen, J
   Mäkelä, R
   Happonen, A
   Mpindi, JP
   Knuuttila, M
   Kohonen, P
   Lötjönen, J
   Kallioniemi, O
   Nees, M
AF Harma, Ville
   Virtanen, Johannes
   Makela, Rami
   Happonen, Antti
   Mpindi, John-Patrick
   Knuuttila, Matias
   Kohonen, Pekka
   Lotjonen, Jyrki
   Kallioniemi, Olli
   Nees, Matthias
TI A Comprehensive Panel of Three-Dimensional Models for Studies of
   Prostate Cancer Growth, Invasion and Drug Responses
SO PLOS ONE
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; GENE-EXPRESSION SIGNATURE; TUMOR-CELL
   INVASION; STEM-CELLS; BREAST-CANCER; MAMMARY EPITHELIA; CULTURE MODEL;
   METASTASIS; LINES; DIFFERENTIATION
AB Prostate epithelial cells from both normal and cancer tissues, grown in three-dimensional (3D) culture as spheroids, represent promising in vitro models for the study of normal and cancer-relevant patterns of epithelial differentiation. We have developed the most comprehensive panel of miniaturized prostate cell culture models in 3D to date (n = 29), including many non-transformed and most currently available classic prostate cancer (PrCa) cell lines. The purpose of this study was to analyze morphogenetic properties of PrCa models in 3D, to compare phenotypes, gene expression and metabolism between 2D and 3D cultures, and to evaluate their relevance for pre-clinical drug discovery, disease modeling and basic research. Primary and non-transformed prostate epithelial cells, but also several PrCa lines, formed well-differentiated round spheroids. These showed strong cell-cell contacts, epithelial polarization, a hollow lumen and were covered by a complete basal lamina (BL). Most PrCa lines, however, formed large, poorly differentiated spheroids, or aggressively invading structures. In PC-3 and PC-3M cells, well-differentiated spheroids formed, which were then spontaneously transformed into highly invasive cells. These cell lines may have previously undergone an epithelial-to-mesenchymal transition (EMT), which is temporarily suppressed in favor of epithelial maturation by signals from the extracellular matrix (ECM). The induction of lipid and steroid metabolism, epigenetic reprogramming, and ECM remodeling represents a general adaptation to 3D culture, regardless of transformation and phenotype. In contrast, PI3-Kinase, AKT, STAT/interferon and integrin signaling pathways were particularly activated in invasive cells. Specific small molecule inhibitors targeted against PI3-Kinase blocked invasive cell growth more effectively in 3D than in 2D monolayer culture, or the growth of normal cells. Our panel of cell models, spanning a wide spectrum of phenotypic plasticity, supports the investigation of different modes of cell migration and tumor morphologies, and will be useful for predictive testing of anti-cancer and anti-metastatic compounds.
C1 [Harma, Ville; Makela, Rami; Nees, Matthias] VTT Tech Res Ctr Finland, Med Biotechnol Knowledge Ctr, Turku, Finland.
   [Happonen, Antti; Lotjonen, Jyrki] VTT Tech Res Ctr Finland, Knowledge Intens Serv, Turku, Finland.
   [Virtanen, Johannes; Mpindi, John-Patrick; Knuuttila, Matias; Kohonen, Pekka] Univ Turku, Ctr Biotechnol, Turku, Finland.
   [Kallioniemi, Olli] Univ Helsinki, FIMM, Helsinki, Finland.
C3 VTT Technical Research Center Finland; VTT Technical Research Center
   Finland; University of Turku; University of Helsinki
RP Härmä, V (通讯作者)，VTT Tech Res Ctr Finland, Med Biotechnol Knowledge Ctr, Turku, Finland.
EM matthias.nees@vtt.fi
RI Kallioniemi, Olli/H-5111-2011; Happonen, Antti/M-7644-2014; Kohonen,
   Pekka/F-9596-2011; Kallioniemi, Olli/H-4738-2012; Nees,
   Matthias/W-6596-2018
OI Harma, Ville/0000-0001-5767-5226; Kohonen, Pekka/0000-0002-7845-3611;
   Knuuttila, Matias/0000-0002-9953-5755; Kallioniemi,
   Olli/0000-0002-3231-0332; Nees, Matthias/0000-0002-9034-301X
FU Finnish Academy [111597]; European commission; Academy of Finland (AKA)
   [111597] Funding Source: Academy of Finland (AKA)
FX This study was supported by a grant of the Finnish Academy to MN (No.
   111597). Additional funding to OK and JV was provided by FP6 and FP7
   Integrated Projects PRIMA and EPITRON of the European commission. The
   funding agencies had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Alcaraz J, 2008, EMBO J, V27, P2829, DOI 10.1038/emboj.2008.206
   Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Birnie R, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-5-r83
   Bissell Mina, 2009, J Cell Biol, V185, P374, DOI 10.1083/jcb.1853pi
   Bisson I, 2009, CELL RES, V19, P683, DOI 10.1038/cr.2009.43
   Björkman M, 2008, INT J CANCER, V123, P2774, DOI 10.1002/ijc.23885
   Brekhman V, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-415
   Carmona-Fontaine C, 2008, CELL ADHES MIGR, V2, P240, DOI 10.4161/cam.2.4.6747
   Carmona-Fontaine C, 2008, NATURE, V456, P957, DOI 10.1038/nature07441
   Chu JH, 2009, PROSTATE, V69, P428, DOI 10.1002/pros.20897
   Diehn M, 2006, J NATL CANCER I, V98, P1755, DOI 10.1093/jnci/djj505
   Dontu G, 2003, CELL PROLIFERAT, V36, P59, DOI 10.1046/j.1365-2184.36.s.1.6.x
   Dubrovska A, 2009, P NATL ACAD SCI USA, V106, P268, DOI 10.1073/pnas.0810956106
   Fata JE, 2004, BREAST CANCER RES, V6, P1, DOI 10.1186/bcr634
   Fournier MV, 2006, CANCER RES, V66, P7095, DOI 10.1158/0008-5472.CAN-06-0515
   Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075
   Friedl P, 2008, CANCER RES, V68, P7247, DOI 10.1158/0008-5472.CAN-08-0784
   Friedl P, 2010, J CELL BIOL, V188, P11, DOI 10.1083/jcb.200909003
   Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658
   Gudjonsson T, 2005, J MAMMARY GLAND BIOL, V10, P261, DOI 10.1007/s10911-005-9586-4
   Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010
   Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
   Guzmán-Ramírez N, 2009, PROSTATE, V69, P1683, DOI 10.1002/pros.21018
   Han J, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000684
   Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014
   Isaacs JT, 2004, NAT MED, V10, P26, DOI 10.1038/nm0104-26
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kawano Y, 2009, BRIT J CANCER, V100, P1165, DOI 10.1038/sj.bjc.6604976
   Ke XS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003368
   Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004
   Kenny PA, 2007, FRONT BIOSCI-LANDMRK, V12, P3468, DOI 10.2741/2327
   Kilpinen S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r139
   Klarmann GJ, 2009, CLIN EXP METASTAS, V26, P433, DOI 10.1007/s10585-009-9242-2
   Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154
   Kurrey NK, 2005, GYNECOL ONCOL, V97, P155, DOI 10.1016/j.ygyno.2004.12.043
   Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015
   Leivonen SK, 2009, ONCOGENE, V28, P3926, DOI 10.1038/onc.2009.241
   Liao MJ, 2007, CANCER RES, V67, P8131, DOI 10.1158/0008-5472.CAN-06-4493
   Litvinov IV, 2006, CANCER RES, V66, P8598, DOI 10.1158/0008-5472.CAN-06-1228
   Liu H, 2006, P NATL ACAD SCI USA, V103, P4134, DOI 10.1073/pnas.0511342103
   Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Martin KJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002994
   Medjkane S, 2009, NAT CELL BIOL, V11, P257, DOI 10.1038/ncb1833
   Miki J, 2007, CANCER RES, V67, P3153, DOI 10.1158/0008-5472.CAN-06-4429
   Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938
   Rizki A, 2008, CANCER RES, V68, P1378, DOI 10.1158/0008-5472.CAN-07-2225
   Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043
   Shah GV, 2009, J BIOL CHEM, V284, P1018, DOI 10.1074/jbc.M807823200
   Simian M, 2001, DEVELOPMENT, V128, P3117
   Spencer VA, 2010, J MAMMARY GLAND BIOL, V15, P65, DOI 10.1007/s10911-010-9163-3
   STREULI CH, 1995, J CELL BIOL, V129, P591, DOI 10.1083/jcb.129.3.591
   STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383
   Suzuki K, 2006, UROLOGY, V67, P647, DOI 10.1016/j.urology.2005.10.013
   Turley EA, 2008, NAT CLIN PRACT ONCOL, V5, P280, DOI 10.1038/ncponc1089
   van Bokhoven A, 2003, PROSTATE, V57, P205, DOI 10.1002/pros.10290
   Wallerand H, 2010, UROL ONCOL-SEMIN ORI, V28, P473, DOI 10.1016/j.urolonc.2008.12.018
   Wang HH, 2007, CANCER RES, V67, P2922, DOI 10.1158/0008-5472.CAN-06-3598
   Wang SY, 2009, METHODS MOL BIOL, V568, P151, DOI 10.1007/978-1-59745-280-9_9
   Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4
   Weigelt B, 2010, BREAST CANCER RES TR, V122, P35, DOI 10.1007/s10549-009-0502-2
   Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006
   Wolf K, 2009, SEMIN CELL DEV BIOL, V20, P931, DOI 10.1016/j.semcdb.2009.08.005
   Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009
   Yang J, 2006, CANCER RES, V66, P4549, DOI 10.1158/0008-5472.CAN-05-3850
NR 65
TC 276
Z9 320
U1 0
U2 62
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 3
PY 2010
VL 5
IS 5
AR e10431
DI 10.1371/journal.pone.0010431
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 590PW
UT WOS:000277240300008
PM 20454659
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Hasen, NS
   O'Leary, KA
   Auger, AP
   Schuler, LA
AF Hasen, Nina S.
   O'Leary, Kathleen A.
   Auger, Anthony P.
   Schuler, Linda A.
TI Social Isolation Reduces Mammary Development, Tumor Incidence, and
   Expression of Epigenetic Regulators in Wild-type and p53-Heterozygotic
   Mice
SO CANCER PREVENTION RESEARCH
LA English
DT Article
ID ESTROGEN-RECEPTOR-ALPHA; MESSENGER-RNA EXPRESSION; GLAND DEVELOPMENT;
   DNA METHYLATION; MOUSE MODEL; FEMALE RAT; GENDER-DIFFERENCES;
   ANIMAL-MODELS; CANCER; STRESS
AB Chronic stress is associated with more rapid tumor progression, and recent evidence suggests that stress may contribute to social and ethnic disparities in the incidence and mortality of breast cancer. We evaluated the p53(+/-) FVB/N mouse as a model to investigate effects of chronic social stress on mammary gland development, gene expression, and tumorigenesis. We individually housed (IH) wild- type and p53(+/-) female FVB/N mice, starting at weaning. At 14 weeks of age, both wild- type and p53(+/-) IH mice showed strikingly reduced mammary development compared with group-housed (GH) controls, with IH mice having significantly fewer preterminal end buds. This morphologic difference was not reflected in levels of mammary transcripts for estrogen receptor-alpha or progestin receptor. However, IH increased levels of mRNA for the kisspeptin receptor in the medial preoptic area of the hypothalamus, associated with reduced duration of estrous cycles. Furthermore, IH altered mammary transcripts of genes associated with DNA methylation; transcripts for methyl-binding protein 2 and DNA methyltransferase 3b (DNMT3b), but not DNMT1 and DNMT3a, were reduced in IH compared with GH females. Interestingly, the glands of p53(+/-) females showed reduced expression of all these mediators compared with wild- type females. However, contrary to our initial hypothesis, IH did not increase mammary tumorigenesis. Rather, p53(+/-) GH females developed significantly more mammary tumors than IH mice. Together, these data suggest that social isolation initiated at puberty might confound studies of tumorigenesis by altering mammary development in mouse models. Cancer Prev Res; 3(5); 620-9. (C) 2010 AACR.
C1 [Hasen, Nina S.; O'Leary, Kathleen A.; Schuler, Linda A.] Univ Wisconsin, Dept Comparat Biosci, Madison, WI 53706 USA.
   [Hasen, Nina S.; Auger, Anthony P.; Schuler, Linda A.] Univ Wisconsin, Ctr Womens Hlth Res, Madison, WI 53706 USA.
   [Auger, Anthony P.] Univ Wisconsin, Dept Psychol, Madison, WI 53706 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison
RP Schuler, LA (通讯作者)，Univ Wisconsin, Dept Comparat Biosci, Madison, WI 53706 USA.
EM schulerl@svm.vetmed.wisc.edu
FU Congressionally Directed Medical Research Programs [W81XWH-08-1-0504,
   T32 HD049302, R01 MH072956]
FX Congressionally Directed Medical Research Programs W81XWH-08-1-0504 (L.
   A. Schuler), T32 HD049302 (N. S. Hasen), and R01 MH072956 (A. P. Auger).
CR Allain DC, 2008, J MOL DIAGN, V10, P383, DOI 10.2353/jmoldx.2008.070161
   Antoni MH, 2006, NAT REV CANCER, V6, P240, DOI 10.1038/nrc1820
   Bennett CN, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2125
   Brower V, 2008, J NATL CANCER I, V100, P1126, DOI 10.1093/jnci/djn302
   Champagne FA, 2006, ENDOCRINOLOGY, V147, P2909, DOI 10.1210/en.2005-1119
   Charbonneau AM, 2009, J YOUTH ADOLESCENCE, V38, P1050, DOI 10.1007/s10964-009-9398-8
   Conneely OM, 2003, J MAMMARY GLAND BIOL, V8, P205, DOI 10.1023/A:1025952924864
   Dobosy JR, 2007, J UROLOGY, V177, P822, DOI 10.1016/j.juro.2006.10.063
   Dodge JE, 2005, J BIOL CHEM, V280, P17986, DOI 10.1074/jbc.M413246200
   Duijts SFA, 2003, INT J CANCER, V107, P1023, DOI 10.1002/ijc.11504
   Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024
   Goldman JM, 2007, BIRTH DEFECTS RES B, V80, P84, DOI 10.1002/bdrb.20106
   Green JE, 2000, ONCOGENE, V19, P1020, DOI 10.1038/sj.onc.1203280
   Harms JF, 2003, CLIN EXP METASTAS, V20, P11, DOI 10.1023/A:1022530100931
   Henn FA, 2005, NEUROSCI BIOBEHAV R, V29, P799, DOI 10.1016/j.neubiorev.2005.03.019
   Hermes GL, 2008, DEV PSYCHOBIOL, V50, P353, DOI 10.1002/dev.20295
   Hermes GL, 2009, P NATL ACAD SCI USA, V106, P22393, DOI 10.1073/pnas.0910753106
   Horn HF, 2007, ONCOGENE, V26, P1306, DOI 10.1038/sj.onc.1210263
   Ibarguen-Vargas Y, 2008, PSYCHONEUROENDOCRINO, V33, P1357, DOI 10.1016/j.psyneuen.2008.07.010
   IMAGAWA W, 1990, ENDOCR REV, V11, P494, DOI 10.1210/edrv-11-4-494
   JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6
   Joslyn SA, 2005, BREAST CANCER RES TR, V92, P97, DOI 10.1007/s10549-005-2112-y
   Kinsey-Jones JS, 2009, J NEUROENDOCRINOL, V21, P20, DOI 10.1111/j.1365-2826.2008.01807.x
   Knox AMI, 2009, J NEUROENDOCRINOL, V21, P683, DOI 10.1111/j.1365-2826.2009.01885.x
   Koolhaas JM, 2008, BRAIN BEHAV IMMUN, V22, P662, DOI 10.1016/j.bbi.2007.11.006
   Kurian JR, 2007, EPIGENETICS, V2, P173, DOI 10.4161/epi.2.3.4841
   LaMarca HL, 2008, ENDOCRINOLOGY, V149, P4317, DOI 10.1210/en.2008-0450
   Lozano G, 2005, J PATHOL, V205, P206, DOI 10.1002/path.1704
   Mallepell S, 2006, P NATL ACAD SCI USA, V103, P2196, DOI 10.1073/pnas.0510974103
   McBride WJ, 2009, PHARMACOL BIOCHEM BE, V92, P304, DOI 10.1016/j.pbb.2008.12.019
   Medina D, 2003, CANCER RES, V63, P1067
   Murphy KG, 2005, J NEUROENDOCRINOL, V17, P519, DOI 10.1111/j.1365-2826.2005.01328.x
   Palanza P, 2001, NEUROSCI BIOBEHAV R, V25, P219, DOI 10.1016/S0149-7634(01)00010-0
   Palanza P, 2001, PHYSIOL BEHAV, V73, P411, DOI 10.1016/S0031-9384(01)00494-2
   Paul K, 2008, J NATL MED ASSOC, V100, P540, DOI 10.1016/S0027-9684(15)31300-6
   Paxinos G., 2001, MOUSE BRAIN STERIOTA, VSecond
   Pierce BL, 2009, J CLIN ONCOL, V27, P3437, DOI 10.1200/JCO.2008.18.9068
   Plachot C, 2004, EXP CELL RES, V298, P122, DOI 10.1016/j.yexcr.2004.04.024
   Roa J, 2006, ENDOCRINOLOGY, V147, P2864, DOI 10.1210/en.2005-1463
   Rose-Hellekant TA, 2003, ONCOGENE, V22, P4664, DOI 10.1038/sj.onc.1206619
   Royds JA, 2006, CELL DEATH DIFFER, V13, P1017, DOI 10.1038/sj.cdd.4401913
   Sansom OJ, 2007, NAT CLIN PRACT ONCOL, V4, P305, DOI 10.1038/ncponc0812
   Sephton SE, 2009, BRAIN BEHAV IMMUN, V23, P1148, DOI 10.1016/j.bbi.2009.07.007
   Shepherd T, 2001, J MAMMARY GLAND BIOL, V6, P129, DOI 10.1023/A:1009576801226
   Spiegel D, 2003, BIOL PSYCHIAT, V54, P269, DOI 10.1016/S0006-3223(03)00566-3
   TAYLOR SM, 2006, CELLSCIENCE REV, V2, P82
   Taylor TR, 2007, AM J EPIDEMIOL, V166, P46, DOI 10.1093/aje/kwm056
   Tena-Sempere M, 2010, MOL CELL ENDOCRINOL, V314, P164, DOI 10.1016/j.mce.2009.05.004
   Thaker PH, 2006, NAT MED, V12, P939, DOI 10.1038/nm1447
   Tsellou E, 2008, EPIGENETICS-US, V3, P143, DOI 10.4161/epi.3.3.6371
   Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675
   Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276
   Westberry JM, 2008, NEUROSCIENCE, V152, P982, DOI 10.1016/j.neuroscience.2008.01.048
   WHITTEN WK, 1956, J ENDOCRINOL, V13, P399, DOI 10.1677/joe.0.0130399
   WHITTEN WK, 1959, J ENDOCRINOL, V18, P102, DOI 10.1677/joe.0.0180102
   Williams JB, 2009, CANCER PREV RES, V2, P850, DOI 10.1158/1940-6207.CAPR-08-0238
   Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007
NR 57
TC 24
Z9 26
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
EI 1940-6215
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD MAY
PY 2010
VL 3
IS 5
BP 620
EP 629
DI 10.1158/1940-6207.CAPR-09-0225
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 591IP
UT WOS:000277294000008
PM 20424136
OA Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Wu, ZL
   Zheng, SS
   Li, ZM
   Qiao, YY
   Aau, MY
   Yu, Q
AF Wu, Z. L.
   Zheng, S. S.
   Li, Z. M.
   Qiao, Y. Y.
   Aau, M. Y.
   Yu, Q.
TI Polycomb protein EZH2 regulates E2F1-dependent apoptosis through
   epigenetically modulating Bim expression
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Article
DE EZH2; E2F1; apoptosis; epigenetics; Bim
ID EMBRYONIC STEM-CELLS; CANCER-CELLS; EPITHELIAL-CELLS; BREAST-CANCER;
   DIRECT TARGET; HISTONE H3; GENE; E2F; PATHWAY; DEATH
AB Deregulation of the pRB/E2F pathway, which occurs frequently in human malignancy, is often associated with inappropriate proliferation and/or apoptosis. While the role of E2F1 in apoptosis induction has been well-established, it remains unclear how this pro-apoptotic activity is regulated in cancer. Here we describe EZH2, an oncogenic polycomb histone methyltransferase and an E2F1 target, as an important regulator of E2F1-dependent apoptosis. We show that E2F1 induces EZH2 expression, which in turn antagonizes the induction of E2F1 pro-apoptotic target Bim expression. RNAi-mediated gene depletion of EZH2 enhances E2F1-dependent Bim expression, thereby promoting the pro-apoptotic activity of E2F1. Hence, the concomitant induction of EZH2 and Bim by E2F1 constitutes a fail-safe mechanism to allow tumor cells with aberrant E2F1 activity to evade apoptosis. These findings reveal a novel mechanism by which the apoptotic activity of E2F1 is restrained in human cancer and also provide the first evidence that EZH2 directly regulates apoptotic process in cancer cells. Cell Death and Differentiation (2010) 17, 801-810; doi:10.1038/cdd.2009.162; published online 6 November 2009
C1 [Wu, Z. L.; Zheng, S. S.; Li, Z. M.; Qiao, Y. Y.; Aau, M. Y.; Yu, Q.] ASTAR, Genome Inst Singapore, Singapore 138672, Singapore.
   [Qiao, Y. Y.; Yu, Q.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117595, Singapore.
C3 Agency for Science Technology & Research (A*STAR); A*STAR - Genome
   Institute of Singapore (GIS); National University of Singapore
RP Yu, Q (通讯作者)，ASTAR, Genome Inst Singapore, 60 Biopolis St 0201, Singapore 138672, Singapore.
EM yuq@gis.a-star.edu.sg
RI Qiao, Yuanyuan/AAB-9230-2020
OI Yu, Qiang/0000-0003-2132-8278; Qiao, Yuanyuan/0000-0002-1178-3480
FU Agency for Science, Technology and Research of Singapore
FX We thank Dr Kristian Helin (European Institute of Oncology, Milan) for
   the ER-E2F1 plasmids and Dr Claudio Brancolini for providing the
   IMR90/E1A cells. This work was supported by the Agency for Science,
   Technology and Research of Singapore.
CR Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Cowling VH, 2007, MOL CELL BIOL, V27, P5135, DOI 10.1128/MCB.02282-06
   David J., 2000, Clin. Appl. Immunol. Rev, V1, P105
   Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101
   Esteller M, 2006, BRIT J CANCER, V94, P179, DOI 10.1038/sj.bjc.6602918
   Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200
   Gazin C, 2007, NATURE, V449, P1073, DOI 10.1038/nature06251
   Hallstrom TC, 2003, P NATL ACAD SCI USA, V100, P10848, DOI 10.1073/pnas.1831408100
   Hallstrom TC, 2008, CANCER CELL, V13, P11, DOI 10.1016/j.ccr.2007.11.031
   Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200
   Iaquinta PJ, 2007, CURR OPIN CELL BIOL, V19, P649, DOI 10.1016/j.ceb.2007.10.006
   Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614
   Jiang X, 2008, CANCER CELL, V13, P529, DOI 10.1016/j.ccr.2008.04.019
   Johnson L, 2002, CANCER CELL, V1, P325, DOI 10.1016/S1535-6108(02)00060-0
   Kawabe S, 2002, MOL THER, V6, P637, DOI 10.1006/mthe.2002.0714
   Kitagawa M, 2008, ONCOGENE, V27, P5303, DOI 10.1038/onc.2008.164
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194
   Loughran O, 2000, MOL CELL BIOL, V20, P2186, DOI 10.1128/MCB.20.6.2186-2197.2000
   Lynch JL, 1999, EUR J PHARMACOL, V364, P141, DOI 10.1016/S0014-2999(98)00840-1
   Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527
   Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868
   Pan GJ, 2007, CELL STEM CELL, V1, P299, DOI 10.1016/j.stem.2007.08.003
   Polager S, 2008, TRENDS CELL BIOL, V18, P528, DOI 10.1016/j.tcb.2008.08.003
   Pützer BM, 2007, J CELL MOL MED, V11, P239, DOI 10.1111/j.1582-4934.2007.00030.x
   Sander S, 2008, BLOOD, V112, P4202, DOI 10.1182/blood-2008-03-147645
   Semizarov D, 2004, NUCLEIC ACIDS RES, V32, P3836, DOI 10.1093/nar/gkh714
   Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617
   Tan J, 2006, J BIOL CHEM, V281, P10508, DOI 10.1074/jbc.M512719200
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Vigo E, 1999, MOL CELL BIOL, V19, P6379
   Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072
   Yang XJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005011
   Zhao XD, 2007, CELL STEM CELL, V1, P286, DOI 10.1016/j.stem.2007.08.004
   Zhao Y, 2005, P NATL ACAD SCI USA, V102, P16090, DOI 10.1073/pnas.0505585102
NR 43
TC 99
Z9 111
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1350-9047
J9 CELL DEATH DIFFER
JI Cell Death Differ.
PD MAY
PY 2010
VL 17
IS 5
BP 801
EP 810
DI 10.1038/cdd.2009.162
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 581HU
UT WOS:000276513600009
PM 19893569
OA Bronze
DA 2025-01-12
ER

PT J
AU Kim, TW
   Kim, YJ
   Lee, HJ
   Min, SY
   Kang, HS
   Kim, SJ
AF Kim, Tae Woo
   Kim, Yo Jung
   Lee, Hyun Ji
   Min, Sun Young
   Kang, Han-Sung
   Kim, Sun Jung
TI Hs.137007 is a novel epigenetic marker hypermethylated and up-regulated
   in breast cancer
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE digital differential display; unigene; Hs 137007; methylation; breast
   cancer
ID DNA METHYLATION; TUMOR-SUPPRESSOR; HUMAN HOMOLOG; MOUSE-BRAIN; CPG
   ISLANDS; CELL-LINES; GENE; HYPOMETHYLATION; RECEPTOR; CARCINOGENESIS
AB This study was conducted to mine novel breast-specific unigenes and analyze their epigenetic regulation in breast cancer. Differential digital display and methylation analysis identified the Hs 137007 acne containing a Ketch domain as a candidate novel epigenetic marker. In 50 pairs of breast cancer tissues and nearby normal tissues the methylation level of the 14 CpG sites at the promoter region (-778 to -485) of the gene was higher in cancer tissues (72-93%) than in normal tissues (31-83%). with a high correlation rate (p<0.05). End-point RT-PCR and real-time RT-PCR revealed that Hs. 137007 was up-regulated in cancer tissues A clear relationship between high methylation levels and up-regulated expression was also observed in the cultured breast cell lines. The MCF7 (90-100%) and MDAMB468 (100%) cancer cell lines that showed higher methylation than the BT549 (20-90%) and 184B5 (10-100%) at the 14 CpGs also showed elevated gene expression. Taken together. these results indicate that the Hs. 137007 gene is a novel gene specifically expressed in the breast that can be utilized as an epigenetic marker of breast cancer.
C1 [Kim, Tae Woo; Kim, Yo Jung; Lee, Hyun Ji; Kim, Sun Jung] Dongguk Univ, Dept Life Sci, Seoul 100715, South Korea.
   [Min, Sun Young; Kang, Han-Sung] Natl Canc Ctr, Res Inst Hosp, Goyang 411769, Gyeonggi, South Korea.
C3 Dongguk University; National Cancer Center - Korea (NCC)
RP Kim, SJ (通讯作者)，Dongguk Univ, Dept Life Sci, Seoul 100715, South Korea.
RI Kim, Ju/D-6357-2011; kim, sun/T-1013-2019; Min, Sun/AAK-3757-2020; Kim,
   Dokyun/IYJ-2278-2023; kang, han/KIC-4795-2024
FU Yonsei University
FX The authors thank Dr K.H Han and Dr W I Yang at Yonsei University for
   their kind support of the histological analysis of tissues.
CR Adams JC, 2002, GENE, V297, P69, DOI 10.1016/S0378-1119(02)00887-9
   Ai LB, 2006, CANCER RES, V66, P7899, DOI 10.1158/0008-5472.CAN-06-0576
   Arapshian A, 2000, ONCOGENE, V19, P4066, DOI 10.1038/sj.onc.1203734
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Blelloch R, 2006, STEM CELLS, V24, P2007, DOI 10.1634/stemcells.2006-0050
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Cox GS, 1998, BBA-GENE STRUCT EXPR, V1396, P67, DOI 10.1016/S0167-4781(97)00175-9
   Ding XF, 2009, J CELL BIOCHEM, V106, P285, DOI 10.1002/jcb.22002
   Fazzari MJ, 2004, NAT REV GENET, V5, P446, DOI 10.1038/nrg1349
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Ito Y, 2008, HUM MOL GENET, V17, P2633, DOI 10.1093/hmg/ddn163
   Ji JW, 2006, BIOCHEM BIOPH RES CO, V346, P1254, DOI 10.1016/j.bbrc.2006.06.029
   Kang JH, 2001, J MOL MED-JMM, V79, P648, DOI 10.1007/s001090100269
   KITADAI Y, 1993, CELL GROWTH DIFFER, V4, P291
   Lai F, 2000, GENOMICS, V66, P65, DOI 10.1006/geno.2000.6181
   Miyamoto K, 2005, INT J CANCER, V116, P407, DOI 10.1002/ijc.21054
   Morrione A, 1995, CELL PROLIFERAT, V28, P659, DOI 10.1111/j.1365-2184.1995.tb00052.x
   Nabilsi NH, 2009, ONCOGENE, V28, P2046, DOI 10.1038/onc.2009.62
   Ohmachi M, 1999, GENES CELLS, V4, P325, DOI 10.1046/j.1365-2443.1999.00264.x
   Rivenbark AG, 2006, EPIGENETICS-US, V1, P32, DOI 10.4161/epi.1.1.2358
   Rodenhiser DI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2121
   Schones DE, 2008, NAT REV GENET, V9, P179, DOI 10.1038/nrg2270
   Schumacher A, 2006, NUCLEIC ACIDS RES, V34, P528, DOI 10.1093/nar/gkj461
   Shaw RJ, 2006, BRIT J CANCER, V94, P561, DOI 10.1038/sj.bjc.6602972
   Singh P, 2008, MOL CANCER RES, V6, P1710, DOI 10.1158/1541-7786.MCR-08-0269
   Wang YP, 2005, NEOPLASIA, V7, P748, DOI 10.1593/neo.05289
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Witcher M, 2009, MOL CELL, V34, P271, DOI 10.1016/j.molcel.2009.04.001
   Wolf I, 2006, CANCER RES, V66, P7818, DOI 10.1158/0008-5472.CAN-05-4368
   Wu HJ, 2005, NATURE, V438, P981, DOI 10.1038/nature04225
   XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9
   Yang HL, 2007, GENE, V395, P144, DOI 10.1016/j.gene.2007.03.005
   Yu JS, 2008, ONCOGENE, V27, P4657, DOI 10.1038/onc.2008.101
   Zighelboim I, 2007, CLIN CANCER RES, V13, P2882, DOI 10.1158/1078-0432.CCR-06-2367
NR 34
TC 16
Z9 16
U1 0
U2 0
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
J9 INT J ONCOL
JI Int. J. Oncol.
PD MAY
PY 2010
VL 36
IS 5
BP 1105
EP 1111
DI 10.3892/ijo_00000592
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 589EQ
UT WOS:000277129600008
PM 20372783
OA Bronze
DA 2025-01-12
ER

PT J
AU Kastl, L
   Brown, I
   Schofield, AC
AF Kastl, Lena
   Brown, Iain
   Schofield, Andrew C.
TI Altered DNA methylation is associated with docetaxel resistance in human
   breast cancer cells
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE breast cancer; chemotherapy; DNA methylation; drug resistance
ID MESSENGER-RNA EXPRESSION; METHYLTRANSFERASES DNMT3A; HISTONE
   DEACETYLASE; ESTROGEN-RECEPTOR; OVARIAN-CANCER; BETA-TUBULIN; GENE;
   HYPERMETHYLATION; HYPOMETHYLATION; DEMETHYLATION
AB Docetaxel is an effective chemotherapy drug to treat breast cancer but the underlying molecular mechanisms of drug resistance are not fully understood DNA methylation is an epigenetic event, involved in the control of gene expression. which is known to play an important role in cancer and chemotherapy drug resistance. To investigate the role of DNA methylation in docetaxel resistance in breast cancer we used two human breast cancer cell lines (MCF-7 and MDA-MB-231) that were made resistant to docetaxel Docetaxel-resistant sub-lines were treated with different concentrations of decitabine Global methylation and DNA methyltransferase (DNMT) activity was measured using an ELISA-based assay Quantitative real-time PCR was used to study DNMT acne expression Cell viability was studied by MTT assay Global methylation was increased in MCF-7 but not significantly changed in MDA-MB-231 docetaxel-resistant cells Decreased DNMT activity and decreased DNMT1 and DNMT3b mRNA expression was associated with docetaxel resistance in both cell lines. To investigate how the components of the DNA methylation machinery may contribute towards docetaxel resistance. decitabine (5-aza-2'-deoxycytidine). an inhibitor of DNA methylation, was used Decitabine treatment decreased global methylation. DNMT activity and DNMT1, DNMT3a and DNMT3b mRNA expression in MDA-MB-23 I docetaxel-resistant cells In contrast. decitabine-treated MCF-7 docetaxel-resistant cells showed increased DNMT1, DNMT3a and DNMT3b mRNA expression indicating a cell line specific effect of decitabine Decitabine treatment increased resistance in MCF-7 docetaxel-resistant cells and in the parental MCF-7 and MDA-MB231 docetaxel-sensitive cell lines, however. it did not alter response to docetaxel in MDA-MB-231 docetaxel-resistant cells This study demonstrates that changes in the DNA methylation machinery are associated with resistance to docetaxel in breast cancer cells. The use of epigenetic therapies. as a strategy to overcome drug resistance, needs to be investigated more fully to determine their effectiveness in different cancers and for different chemotherapy drugs.
C1 [Kastl, Lena; Brown, Iain; Schofield, Andrew C.] Univ Aberdeen, Sch Med, Coll Life Sci & Med, Sch Med & Dent, Aberdeen AB25 2ZD, Scotland.
C3 University of Aberdeen
RP Schofield, AC (通讯作者)，Univ Aberdeen, Sch Med, Coll Life Sci & Med, Sch Med & Dent, Foresterhill, Aberdeen AB25 2ZD, Scotland.
FU Fraserburah Moonlight Prowl Fund
FX The authors especially thank Dr Alun Hughes for his help and support
   with performing and analysing the quantitative PCR studies This study
   was supported by a Dr James Alexander Mearns studentship and the
   Fraserburah Moonlight Prowl Fund.
CR Brown I, 2004, BREAST CANCER RES, V6, pR601, DOI 10.1186/bcr918
   Chekhun VF, 2006, CANCER LETT, V231, P87, DOI 10.1016/j.canlet.2005.01.038
   Feng W, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1762
   Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750
   Goffin J, 2002, ANN ONCOL, V13, P1699, DOI 10.1093/annonc/mdf314
   Hostetter CL, 2009, CANCER LETT, V275, P178, DOI 10.1016/j.canlet.2008.10.005
   Ishida C, 2003, GENE, V310, P151, DOI 10.1016/S0378-1119(03)00545-6
   Izutsu N, 2008, INT J ONCOL, V32, P1227
   Jones SE, 2005, J CLIN ONCOL, V23, P5542, DOI 10.1200/JCO.2005.02.027
   KASTL L, MOL CELL PR IN PRESS
   McDonald SL, 2005, EUR J CANCER, V41, P1086, DOI 10.1016/j.ejca.2005.01.018
   Miyoshi Yasuo, 2005, Breast Cancer, V12, P11, DOI 10.2325/jbcs.12.11
   Modok S, 2006, CURR OPIN PHARMACOL, V6, P350, DOI 10.1016/j.coph.2006.01.009
   Nakayama M, 1998, BLOOD, V92, P4296, DOI 10.1182/blood.V92.11.4296.423k25_4296_4307
   Noguchi S, 2006, CANCER SCI, V97, P813, DOI 10.1111/j.1349-7006.2006.00265.x
   Oka M, 2005, ONCOGENE, V24, P3091, DOI 10.1038/sj.onc.1208540
   Plumb JA, 2000, CANCER RES, V60, P6039
   Pulukuri SMK, 2005, INT J ONCOL, V26, P863
   QUI YY, 2002, CANC DETECT REV, V26, P444
   Robertson KD, 2000, NUCLEIC ACIDS RES, V28, P2108, DOI 10.1093/nar/28.10.2108
   Schneider-Stock R, 2007, IDRUGS, V10, P557
   Segura-Pacheco B, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-32
   Shalli K, 2005, FASEB J, V19, P1299, DOI 10.1096/fj.04-3178fje
   Shang D, 2007, UROLOGY, V69, P1007, DOI 10.1016/j.urology.2007.02.026
   Slack A, 1999, EUR J BIOCHEM, V264, P191, DOI 10.1046/j.1432-1327.1999.00603.x
   Smith IC, 2002, J CLIN ONCOL, V20, P1456, DOI 10.1200/JCO.20.6.1456
   Staub J, 2007, ONCOGENE, V26, P4969, DOI 10.1038/sj.onc.1210300
   Steele N, 2009, BRIT J CANCER, V100, P758, DOI 10.1038/sj.bjc.6604932
   Sunami E, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2098
   Weisenberger DJ, 2004, MOL CANCER RES, V2, P62
   Yanagisawa Y, 2002, BBA-GENE STRUCT EXPR, V1577, P457, DOI 10.1016/S0167-4781(02)00482-7
   Yanokura M, 2007, ONCOL REP, V17, P41
   Zhang XT, 2006, ONCOL REP, V16, P563
NR 33
TC 51
Z9 57
U1 0
U2 9
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD MAY
PY 2010
VL 36
IS 5
BP 1235
EP 1241
DI 10.3892/ijo_00000607
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 589EQ
UT WOS:000277129600023
PM 20372798
OA Bronze
DA 2025-01-12
ER

PT J
AU Wang, H
   Wang, XQ
   Xu, XP
   Lin, GW
AF Wang, Hong
   Wang, Xiao-Qin
   Xu, Xiao-Ping
   Lin, Guo-Wei
TI ID4 methylation predicts high risk of leukemic transformation in
   patients with myelodysplastic syndrome
SO LEUKEMIA RESEARCH
LA English
DT Article
DE ID4 methylation; MDS; Leukemic transformation; Prognosis
ID ACUTE MYELOID-LEUKEMIA; LOOP-HELIX PROTEINS; DNA METHYLATION; PROMOTER
   HYPERMETHYLATION; BREAST-CANCER; GENE-EXPRESSION; ADENOCARCINOMA;
   SUPPRESSOR; PROGNOSIS; DISEASE
AB Epigenetic gene silencing due to promoter methylation is observed in human cancers like acute myeloid leukemia (AML). Little is known about aberrant methylation in myelodysplastic syndrome (MDS), a heterogeneous clonal stem cell disorder with a similar to 30% risk of transformation into secondary AML. Recent evidence demonstrated that ID4, a negative regulator of transcription, may act as a tumor-suppressor gene. To clarify the role of ID4 in MDS, we employed methylation-specific PCR (MSP) to examine the methylation status of ID4 in 144 adult de novo MDS patients. We found that ID4 methylation was present in 35.4% (n = 51) of these MDS patients and methylaiton was correlated significantly with World Health Organization (WHO) subtypes and International Prognostic Scoring System (IPSS) risk groups. Patients with advanced stages of WHO subtypes (45.8% vs. 21.3%, P=0.002) and higher risk IPSS subgroups (45.7% vs. 26.0%, P=0.014) exhibited a significantly higher frequency of ID4 methylation. The median survival of patients with ID4 methylation was shorter than patients without ID4 methylation (12.2 months vs. 26.9 months, P=0.005). Multivariate analysis indicated that ID4 methylation status was the independent factor that impacted leukemia-free survival (LFS). Disease in patients with ID4 methylation progressed more rapidly than those without ID4 methylation (P=0.047, HR=2.11). Our results suggest that ID4 may be a therapeutic target in MDS. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Wang, Hong; Wang, Xiao-Qin; Xu, Xiao-Ping; Lin, Guo-Wei] Fudan Univ, Huashan Hosp, Dept Haematol, Shanghai 200040, Peoples R China.
C3 Fudan University
RP Wang, XQ (通讯作者)，Fudan Univ, Huashan Hosp, Dept Haematol, 12 Wulumuqi Rd Cent, Shanghai 200040, Peoples R China.
EM wang_xiaoqin@hotmail.com
FU Shanghai Leukemia Cooperative Group
FX This study was supported by Shanghai Leukemia Cooperative Group. We
   would like to thank the patients and the physicians from eight hospitals
   of Shanghai Leukemia Cooperative Group who participated in the study.
   Participating hospitals included Huashan Hospital, Zhongshan Hospital of
   Fudan University; Xinhua Hospital, No. 1 People's Hospital, No. 6
   People's Hospital, No. 9 People's Hospital of Jiaotong University;
   Changzheng Hospital and Changhai Hospital of Second Military Medical
   College.
CR Aggerholm A, 2006, EUR J HAEMATOL, V76, P23, DOI 10.1111/j.1600-0609.2005.00559.x
   Arnold JM, 2001, BRIT J CANCER, V84, P352, DOI 10.1054/bjoc.2000.1620
   Asirvatham AJ, 2006, PROSTATE, V66, P921, DOI 10.1002/pros.20366
   Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160
   Brakensiek K, 2005, BRIT J HAEMATOL, V130, P209, DOI 10.1111/j.1365-2141.2005.05590.x
   Chan ASW, 2003, ONCOGENE, V22, P6946, DOI 10.1038/sj.onc.1206799
   Dahl C, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm984
   Deleu S, 2002, EXP CELL RES, V279, P62, DOI 10.1006/excr.2002.5589
   Desprez PY, 2003, J MAMMARY GLAND BIOL, V8, P225, DOI 10.1023/A:1025957025773
   Esteller M, 2005, J PATHOL, V205, P172, DOI 10.1002/path.1707
   Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024
   Germing U, 2000, LEUKEMIA RES, V24, P983, DOI 10.1016/S0145-2126(00)00088-6
   Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079
   Hagiwara K, 2007, J CLIN EXP HEMATOP, V47, P15, DOI 10.3960/jslrt.47.15
   Heaney ML, 1999, NEW ENGL J MED, V340, P1649, DOI 10.1056/NEJM199905273402107
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Holtan SG, 2008, AM J HEMATOL, V83, P708, DOI 10.1002/ajh.21245
   Iwai M, 2005, LEUKEMIA, V19, P1367, DOI 10.1038/sj.leu.2403805
   Jaffe E.S., 2001, PATHOLOGY GENETICS T, V3
   Jen Y, 1996, DEV DYNAM, V207, P235
   Jen Y, 1997, DEV DYNAM, V208, P92, DOI 10.1002/(SICI)1097-0177(199701)208:1<92::AID-AJA9>3.0.CO;2-X
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597
   Kee Y, 2001, MECH DEVELOP, V109, P341, DOI 10.1016/S0925-4773(01)00576-7
   Kleeff J, 1998, CANCER RES, V58, P3769
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093
   Lee JH, 2003, LEUKEMIA, V17, P305, DOI 10.1038/sj.leu.2402798
   Lehmann U, 2004, ANN HEMATOL, V83, P137, DOI 10.1007/s00277-003-0798-7
   Lowenthal RM, 1997, INT J HEMATOL, V65, P319
   Malcovati L, 2005, J CLIN ONCOL, V23, P7594, DOI 10.1200/JCO.2005.01.7038
   Matsuda A, 2005, BLOOD, V106, P2633, DOI 10.1182/blood-2005-01-0040
   Mitelman F, 1995, INT SYSTEM HUMAN CYT
   Noetzel E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-154
   OGUMA S, 1995, LEUKEMIA RES, V19, P219, DOI 10.1016/0145-2126(94)00135-W
   Pozdnyakova O, 2008, CANCER-AM CANCER SOC, V113, P3331, DOI 10.1002/cncr.23977
   Rivera R, 2001, ONCOGENE, V20, P8308, DOI 10.1038/sj.onc.1205091
   Roman-Gomez J, 2004, BLOOD, V104, P2492, DOI 10.1182/blood-2004-03-0954
   Roman-Gomez J, 2003, J CLIN ONCOL, V21, P1472, DOI 10.1200/JCO.2003.08.166
   Rüter B, 2004, INT J HEMATOL, V80, P128, DOI 10.1532/IJH97.04094
   Smith E, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-75
   Tennant GB, 2004, BRIT J HAEMATOL, V124, P840, DOI 10.1111/j.1365-2141.2004.04860.x
   Tien HF, 2001, BRIT J HAEMATOL, V112, P148, DOI 10.1046/j.1365-2141.2001.02496.x
   Umetani N, 2004, CLIN CANCER RES, V10, P7475, DOI 10.1158/1078-0432.CCR-04-0689
   Umetani N, 2005, ONCOGENE, V24, P4721, DOI 10.1038/sj.onc.1208538
   Vandeputte DAA, 2002, GLIA, V38, P329, DOI 10.1002/glia.10076
   Verma M, 2002, LANCET ONCOL, V3, P755, DOI 10.1016/S1470-2045(02)00932-4
   Voso MT, 2004, BLOOD, V103, P698, DOI 10.1182/blood-2003-07-2249
   Wilson JW, 2001, CANCER RES, V61, P8803
   Yu L, 2005, NAT GENET, V37, P265, DOI 10.1038/ng1521
   Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092
   Zhao MM, 2006, ACTA PHARMACOL SIN, V27, P298
NR 52
TC 23
Z9 31
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0145-2126
J9 LEUKEMIA RES
JI Leuk. Res.
PD MAY
PY 2010
VL 34
IS 5
BP 598
EP 604
DI 10.1016/j.leukres.2009.09.031
PG 7
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Hematology
GA 586WI
UT WOS:000276945300010
PM 19853913
DA 2025-01-12
ER

PT J
AU Bredfeldt, TG
   Greathouse, KL
   Safe, SH
   Hung, MC
   Bedford, MT
   Walker, CL
AF Bredfeldt, Tiffany G.
   Greathouse, K. Leigh
   Safe, Stephen H.
   Hung, Mien-Chie
   Bedford, Mark T.
   Walker, Cheryl L.
TI Xenoestrogen-Induced Regulation of EZH2 and Histone Methylation via
   Estrogen Receptor Signaling to PI3K/AKT
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID CONTROLS DNA METHYLATION; NITRIC-OXIDE SYNTHASE; BREAST-CANCER CELLS;
   DEVELOPMENTAL EXPOSURE; DIETHYLSTILBESTROL DES; LYSINE METHYLATION;
   TARGET GENES; IN-VITRO; H3 METHYLTRANSFERASE; NONGENOMIC ACTIONS
AB Although rapid, membrane-activated estrogen receptor (ER) signaling is no longer controversial, the biological function of this nongenomic signaling is not fully characterized. We found that rapid signaling from membrane-associated ER regulates the histone methyltransferase enhancer of Zeste homolog 2 (EZH2). In response to both 17 beta-estradiol (E2) and the xenoestrogen diethylstilbestrol, ER signaling via phosphatidylinositol 3-kinase/protein kinase B phosphorylates EZH2 at S21, reducing levels of trimethylation of lysine 27 on histone H3 in hormone-responsive cells. During windows of uterine development that are susceptible to developmental reprogramming, activation of this ER signaling pathway by diethylstilbestrol resulted in phosphorylation of EZH2 and reduced levels of trimethylation of lysine 27 on histone H3 in chromatin of the developing uterus. Furthermore, activation of nongenomic signaling reprogrammed the expression profile of estrogen-responsive genes in uterine myometrial cells, suggesting this as a potential mechanism for developmental reprogramming caused by early-life exposure to xenoestrogens. These data demonstrate that rapid ER signaling provides a direct linkage between xenoestrogen-induced nuclear hormone receptor signaling and modulation of the epigenetic machinery during tissue development. (Molecular Endocrinology 24: 993-1006, 2010)
C1 [Bredfeldt, Tiffany G.; Greathouse, K. Leigh; Bedford, Mark T.; Walker, Cheryl L.] Univ Texas MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA.
   [Greathouse, K. Leigh; Hung, Mien-Chie; Bedford, Mark T.; Walker, Cheryl L.] Univ Texas Hlth Sci Ctr, Grad Sch Biomed Sci, Houston, TX 77225 USA.
   [Hung, Mien-Chie] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.
   [Safe, Stephen H.] Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; University of Texas Health Science Center Houston;
   University of Texas System; UTMD Anderson Cancer Center; Texas A&M
   University System; Texas A&M University College Station
RP Walker, CL (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, 1808 Pk Rd 1C,POB 389, Smithville, TX 78957 USA.
EM cwalker@wotan.mdacc.tmc.edu
RI Greathouse, Leigh/S-6612-2018; Hung, Mien-Chie/ABD-5911-2021; Bedford,
   Mark/E-7856-2011
OI Hung, Mien-Chie/0000-0003-4317-4740
FU National Institute of Environmental Health Sciences [ES008263,
   P30-ES007784, F32-ES016509]; National Cancer Institute [P30-CA016672]
FX This work was supported by grants from the National Institute of
   Environmental Health Sciences (ES008263 and P30-ES007784) and National
   Cancer Institute (P30-CA016672). T.B. is supported by a grant from the
   National Institute of Environmental Health Sciences (F32-ES016509).
CR Acconcia F, 2006, CANCER LETT, V238, P1, DOI 10.1016/j.canlet.2005.06.018
   Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138
   Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5
   Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Björnström L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947
   Chen JR, 2005, J BIOL CHEM, V280, P4632, DOI 10.1074/jbc.M411530200
   Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347
   COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890
   Cook JD, 2005, P NATL ACAD SCI USA, V102, P8644, DOI 10.1073/pnas.0503218102
   Cook JD, 2007, REPROD SCI, V14, P121, DOI 10.1177/1933719106298401
   Couse JF, 2004, TOXICOLOGY, V205, P55, DOI 10.1016/j.tox.2004.06.046
   DEGEN GH, 1987, ARCH TOXICOL, P264
   deGraffenried LA, 2003, ANN ONCOL, V14, P1051, DOI 10.1093/annonc/mdg291
   Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987
   Estève PO, 2006, GENE DEV, V20, P3089, DOI 10.1101/gad.1463706
   Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200
   Glidewell-Kenney C, 2007, P NATL ACAD SCI USA, V104, P8173, DOI 10.1073/pnas.0611514104
   Greathouse KL, 2008, REPROD SCI, V15, P765, DOI 10.1177/1933719108322440
   Gruber CJ, 2002, NEW ENGL J MED, V346, P340, DOI 10.1056/NEJMra000471
   Hall JM, 2005, MOL INTERV, V5, P343, DOI 10.1124/mi.5.6.7
   Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200
   Hansen KH, 2008, NAT CELL BIOL, V10, P1291, DOI 10.1038/ncb1787
   Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0
   Hermenegildo C, 2000, HUM REPROD UPDATE, V6, P237, DOI 10.1093/humupd/6.3.237
   Hewitt SC, 2003, REPRODUCTION, V125, P143, DOI 10.1530/rep.0.1250143
   Higashimoto K, 2007, P NATL ACAD SCI USA, V104, P12318, DOI 10.1073/pnas.0610792104
   Hodges LC, 2002, MOL CELL ENDOCRINOL, V196, P11, DOI 10.1016/S0303-7207(02)00230-7
   HOWE SR, 1995, ENDOCRINOLOGY, V136, P4996, DOI 10.1210/en.136.11.4996
   HOWE SR, 1995, ANN NY ACAD SCI, V761, P373, DOI 10.1111/j.1749-6632.1995.tb31396.x
   Inoue A, 2002, J MOL ENDOCRINOL, V29, P175, DOI 10.1677/jme.0.0290175
   Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731
   Jenuwein T, 2006, FEBS J, V273, P3121, DOI 10.1111/j.1742-4658.2006.05343.x
   Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Kondo Y, 2007, HEPATOL RES, V37, P974, DOI 10.1111/j.1872-034X.2007.00141.x
   KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022
   Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935
   Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132
   Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493
   Le Romancer M, 2008, MOL CELL, V31, P212, DOI 10.1016/j.molcel.2008.05.025
   Lee DY, 2005, ENDOCR REV, V26, P147, DOI 10.1210/er.2004-0008
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Levin ER, 2002, STEROIDS, V67, P471, DOI 10.1016/S0039-128X(01)00179-9
   Levin ER, 2001, J APPL PHYSIOL, V91, P1860, DOI 10.1152/jappl.2001.91.4.1860
   Li SF, 2003, MOL CARCINOGEN, V38, P78, DOI 10.1002/mc.10147
   Li XR, 2006, J STEROID BIOCHEM, V98, P122, DOI 10.1016/j.jsbmb.2005.08.018
   LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162
   Margueron R, 2008, MOL CELL, V32, P503, DOI 10.1016/j.molcel.2008.11.004
   Marino M, 2006, CURR GENOMICS, V7, P497, DOI 10.2174/138920206779315737
   Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761
   Martin C, 2007, CURR OPIN CELL BIOL, V19, P266, DOI 10.1016/j.ceb.2007.04.002
   McDevitt MA, 2007, ENDOCRINOLOGY, V148, P5288, DOI 10.1210/en.2007-0673
   McLachlan JA, 2001, TOXICOL LETT, V120, P161, DOI 10.1016/S0378-4274(01)00295-8
   Métivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Nagel SC, 1999, J STEROID BIOCHEM, V69, P343, DOI 10.1016/S0960-0760(99)00078-3
   Newbold RR, 2007, MOL CARCINOGEN, V46, P783, DOI 10.1002/mc.20308
   Newbold RR, 2004, REPROD TOXICOL, V18, P399, DOI 10.1016/j.reprotox.2004.01.007
   Newbold RR, 2002, TOXICOL PATHOL, V30, P611, DOI 10.1080/01926230290105839
   Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535
   Numakawa Y, 2007, ENDOCRINOLOGY, V148, P627, DOI 10.1210/en.2006-1210
   Pietras RJ, 2005, SCIENCE, V310, P51, DOI 10.1126/science.310.5745.51
   Plotkin LI, 2005, J BIOL CHEM, V280, P7317, DOI 10.1074/jbc.M412817200
   Prins GS, 2006, ANN NY ACAD SCI, V1089, P1, DOI 10.1196/annals.1386.009
   Raz L, 2008, NEUROSIGNALS, V16, P140, DOI 10.1159/000111559
   Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907
   Safe S, 2008, J MOL ENDOCRINOL, V41, P263, DOI 10.1677/JME-08-0103
   Sarraf SA, 2004, MOL CELL, V15, P595, DOI 10.1016/j.molcel.2004.06.043
   Shaul PW, 1999, STEROIDS, V64, P28, DOI 10.1016/S0039-128X(98)00105-6
   SHEEHAN DM, 1979, ENDOCRINOLOGY, V104, P1442, DOI 10.1210/endo-104-5-1442
   Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016
   Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131
   Smallwood A, 2007, GENE DEV, V21, P1169, DOI 10.1101/gad.1536807
   SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519
   Soto AM, 2008, INT J ANDROL, V31, P288, DOI 10.1111/j.1365-2605.2007.00834.x
   Soulez M, 2001, J MOL ENDOCRINOL, V27, P259, DOI 10.1677/jme.0.0270259
   Stevis PE, 1999, ENDOCRINOLOGY, V140, P5455, DOI 10.1210/en.140.11.5455
   Takada I, 2007, NAT CELL BIOL, V9, P1273, DOI 10.1038/ncb1647
   Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wu TW, 2005, NEUROSCIENCE, V135, P59, DOI 10.1016/j.neuroscience.2004.12.027
   Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301
   Zhao Q, 2009, NAT STRUCT MOL BIOL, V16, P304, DOI 10.1038/nsmb.1568
NR 88
TC 132
Z9 145
U1 0
U2 11
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0888-8809
EI 1944-9917
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD MAY
PY 2010
VL 24
IS 5
BP 993
EP 1006
DI 10.1210/me.2009-0438
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 588LH
UT WOS:000277071100011
PM 20351197
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Lamprecht, B
   Walter, K
   Kreher, S
   Kumar, R
   Hummel, M
   Lenze, D
   Köchert, K
   Bouhlel, MA
   Richter, J
   Soler, E
   Stadhouders, R
   Jöhrens, K
   Wurster, KD
   Callen, DF
   Harte, MF
   Giefing, M
   Barlow, R
   Stein, H
   Anagnostopoulos, I
   Janz, M
   Cockerill, PN
   Siebert, R
   Dörken, B
   Bonifer, C
   Mathas, S
AF Lamprecht, Bjoern
   Walter, Korden
   Kreher, Stephan
   Kumar, Raman
   Hummel, Michael
   Lenze, Dido
   Koechert, Karl
   Bouhlel, Mohamed Amine
   Richter, Julia
   Soler, Eric
   Stadhouders, Ralph
   Joehrens, Korinna
   Wurster, Kathrin D.
   Callen, David F.
   Harte, Michael F.
   Giefing, Maciej
   Barlow, Rachael
   Stein, Harald
   Anagnostopoulos, Ioannis
   Janz, Martin
   Cockerill, Peter N.
   Siebert, Reiner
   Doerken, Bernd
   Bonifer, Constanze
   Mathas, Stephan
TI Derepression of an endogenous long terminal repeat activates the
   <i>CSF1R</i> proto-oncogene in human lymphoma
SO NATURE MEDICINE
LA English
DT Article
ID REED-STERNBERG CELLS; STIMULATING FACTOR-I; HODGKIN LYMPHOMA;
   DIFFERENTIAL TRANSCRIPTION; DNA HYPOMETHYLATION; BREAST-CANCER; B-CELLS;
   KAPPA-B; GENE; RECEPTOR
AB Mammalian genomes contain many repetitive elements, including long terminal repeats (LTRs), which have long been suspected to have a role in tumorigenesis. Here we present evidence that aberrant LTR activation contributes to lineage-inappropriate gene expression in transformed human cells and that such gene expression is central for tumor cell survival. We show that B cell-derived Hodgkin's lymphoma cells depend on the activity of the non-B, myeloid-specific proto-oncogene colony-stimulating factor 1 receptor (CSF1R). In these cells, CSF1R transcription initiates at an aberrantly activated endogenous LTR of the MaLR family (THE1B). Derepression of the THE1 subfamily of MaLR LTRs is widespread in the genome of Hodgkin's lymphoma cells and is associated with impaired epigenetic control due to loss of expression of the corepressor CBFA2T3. Furthermore, we detect LTR-driven CSF1R transcripts in anaplastic large cell lymphoma, in which CSF1R is known to be expressed aberrantly. We conclude that LTR derepression is involved in the pathogenesis of human lymphomas, a finding that might have diagnostic, prognostic and therapeutic implications.
C1 [Lamprecht, Bjoern; Kreher, Stephan; Koechert, Karl; Wurster, Kathrin D.; Janz, Martin; Doerken, Bernd; Mathas, Stephan] Max Delbruck Ctr Mol Med, Berlin, Germany.
   [Lamprecht, Bjoern; Kreher, Stephan; Koechert, Karl; Wurster, Kathrin D.; Janz, Martin; Doerken, Bernd; Mathas, Stephan] Charite, CVK, D-13353 Berlin, Germany.
   [Walter, Korden; Bouhlel, Mohamed Amine; Barlow, Rachael; Cockerill, Peter N.; Bonifer, Constanze] Univ Leeds, St Jamess Univ Hosp, Sect Expt Haematol, Leeds Inst Mol Med, Leeds, W Yorkshire, England.
   [Kumar, Raman; Callen, David F.] Univ Adelaide, Breast Canc Genet Grp, Discipline Med, Adelaide, SA 5005, Australia.
   [Hummel, Michael; Lenze, Dido; Joehrens, Korinna; Stein, Harald; Anagnostopoulos, Ioannis] Charite, Inst Pathol, CBF, D-13353 Berlin, Germany.
   [Richter, Julia; Giefing, Maciej; Siebert, Reiner] Univ Kiel, Inst Human Genet, Kiel, Germany.
   [Richter, Julia; Giefing, Maciej; Siebert, Reiner] Univ Hosp Schleswig Holstein, Kiel, Germany.
   [Soler, Eric; Stadhouders, Ralph] Erasmus MC, Univ Med Ctr, Dept Cell Biol, Rotterdam, Netherlands.
   [Harte, Michael F.] Cytopia Res Pty Ltd, Richmond, Vic, Australia.
   [Giefing, Maciej] Polish Acad Sci, Inst Human Genet, PL-60479 Poznan, Poland.
C3 Helmholtz Association; Max Delbruck Center for Molecular Medicine;
   Berlin Institute of Health; Free University of Berlin; Humboldt
   University of Berlin; Charite Universitatsmedizin Berlin; University of
   Leeds; Saint James's University Hospital; University of Adelaide; Berlin
   Institute of Health; Free University of Berlin; Humboldt University of
   Berlin; Charite Universitatsmedizin Berlin; University of Kiel;
   University of Kiel; Schleswig Holstein University Hospital; Erasmus
   University Rotterdam; Erasmus MC; Polish Academy of Sciences; Institute
   of Human Genetics of the Polish Academy of Sciences
RP Mathas, S (通讯作者)，Max Delbruck Ctr Mol Med, Berlin, Germany.
EM c.bonifer@leeds.ac.uk; stephan.mathas@charite.de
RI Bonifer, Constanze/B-3000-2009; Giefing, Maciej/D-2568-2009; Kumar,
   Raman/AHE-0538-2022; Soler, Eric/ABE-9723-2021; Mathas,
   Stephan/I-5589-2015; Siebert, Reiner/A-8049-2010; Callen,
   David/G-1975-2012; Stadhouders, Ralph/J-8663-2015
OI Hummel, Michael/0000-0001-6717-605X; Soler, Eric/0000-0003-0521-7463;
   Sharma, Raman/0000-0001-7976-8386; Kochert, Karl/0000-0002-5548-2022;
   Giefing, Maciej/0000-0002-4760-8246; Janz, Martin/0000-0002-1127-0044;
   Bonifer, Constanze/0000-0002-4267-0825; Stadhouders,
   Ralph/0000-0002-1060-5607; Callen, David/0000-0002-6189-9991; Cockerill,
   Peter/0000-0002-4410-8174
FU Federation of European Biochemical Societies; Deutsche
   Forschungsgemeinschaft [SFB/TRR54]; Wilhelm Sander-Stiftung; Deutsche
   Krebshilfe; KinderKrebsInitiative Buchholz/Holm-Seppensen; Susan G.
   Komen for the Cure; Leukaemia and Lymphoma Research; Cancer Research UK;
   Yorkshire Cancer Research
FX We thank F. Hummel, S. Kressmann, S. Meier, C. Cieluch, B. Wollert-Wulf
   and R. Zuhlke-Jenisch for outstanding technical assistance, H. Tagoh for
   help with experiments, P. Rahn for cell sorting and K. Rajewsky for
   helpful discussion and critical reading of the manuscript. M. G. is
   funded by the Federation of European Biochemical Societies. This work
   was supported in part by grants from the Deutsche Forschungsgemeinschaft
   (SFB/TRR54), the Wilhelm Sander-Stiftung, the Deutsche Krebshilfe, the
   KinderKrebsInitiative Buchholz/Holm-Seppensen, Susan G. Komen for the
   Cure, Leukaemia and Lymphoma Research, Cancer Research UK and Yorkshire
   Cancer Research. We also thank V. Diehl (University Cologne) for cell
   lines L1236 and L591, A. Engert (University Cologne) for L540Cy cells,
   P. Krammer (German Cancer Research Center Heidelberg) for BJAB cells, L.
   Staudt (US National Cancer Institute) for OCI-Ly3 and OCI-Ly10 cells, M.
   Falk (Helmholtz Zentrum Munchen) for BL-60 cells and S. Rosen
   (Northwestern University) for MM1.S cells.
CR Bonifer C, 2008, FRONT BIOSCI-LANDMRK, V13, P549, DOI 10.2741/2700
   Borowitz MJ., 2008, WHO CLASSIFICATION T, P149
   Burns CJ, 2009, BIOORG MED CHEM LETT, V19, P1206, DOI 10.1016/j.bmcl.2008.12.073
   Chambers SK, 1997, CLIN CANCER RES, V3, P999
   Chyla BJ, 2008, MOL CELL BIOL, V28, P6234, DOI 10.1128/MCB.00404-08
   Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309
   Druker R, 2004, J INHERIT METAB DIS, V27, P319, DOI 10.1023/B:BOLI.0000031096.81518.66
   Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557
   Ehlers A, 2008, LEUKEMIA, V22, P835, DOI 10.1038/leu.2008.12
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Fan T, 2008, EPIGENETICS-US, V3, P134, DOI 10.4161/epi.3.3.6252
   Faulkner GJ, 2009, NAT GENET, V41, P563, DOI 10.1038/ng.368
   Feldman AL, 2008, BLOOD, V111, P5433, DOI 10.1182/blood-2007-11-124792
   Follows GA, 2003, NUCLEIC ACIDS RES, V31, P5805, DOI 10.1093/nar/gkg804
   Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037
   Goardon N, 2006, EMBO J, V25, P357, DOI 10.1038/sj.emboj.7600934
   Howard G, 2008, ONCOGENE, V27, P404, DOI 10.1038/sj.onc.1210631
   Huang JQ, 2004, NUCLEIC ACIDS RES, V32, P5019, DOI 10.1093/nar/gkh821
   Hug BA, 2004, ONCOGENE, V23, P4270, DOI 10.1038/sj.onc.1207674
   Irvine KM, 2006, FASEB J, V20, P1921, DOI 10.1096/fj.06-5848fje
   Janz M, 2006, CELL CYCLE, V5, P1057, DOI 10.4161/cc.5.10.2737
   Jern P, 2008, ANNU REV GENET, V42, P709, DOI 10.1146/annurev.genet.42.110807.091501
   Joos S, 2002, BLOOD, V99, P1381, DOI 10.1182/blood.V99.4.1381
   Jundt F, 2002, BLOOD, V99, P3060, DOI 10.1182/blood.V99.8.3060
   KACINSKI BM, 1995, ANN MED, V27, P79, DOI 10.3109/07853899509031941
   Kluger HM, 2004, CLIN CANCER RES, V10, P173, DOI 10.1158/1078-0432.CCR-0699-3
   Küppers R, 2009, NAT REV CANCER, V9, P15, DOI 10.1038/nrc2542
   Kumar R, 2008, J BIOL CHEM, V283, P19026, DOI 10.1074/jbc.M709136200
   Küppers R, 2003, J CLIN INVEST, V111, P529, DOI 10.1172/JC1200316624
   Maksakova IA, 2008, CELL MOL LIFE SCI, V65, P3329, DOI 10.1007/s00018-008-8494-3
   Mathas S, 2006, NAT IMMUNOL, V7, P207, DOI 10.1038/ni1285
   Mathas S, 2002, EMBO J, V21, P4104, DOI 10.1093/emboj/cdf389
   Mathas S, 2009, P NATL ACAD SCI USA, V106, P5831, DOI 10.1073/pnas.0900912106
   MOREAU A, 1992, LEUKEMIA, V6, P126
   Ohshima K, 2001, INT J CANCER, V92, P678, DOI 10.1002/1097-0215(20010601)92:5<678::AID-IJC1259>3.0.CO;2-R
   Pixley FJ, 2004, TRENDS CELL BIOL, V14, P628, DOI 10.1016/j.tcb.2004.09.016
   SMIT AFA, 1993, NUCLEIC ACIDS RES, V21, P1863, DOI 10.1093/nar/21.8.1863
   VISVADER J, 1989, MOL CELL BIOL, V9, P1336, DOI 10.1128/MCB.9.3.1336
   Walter K, 2008, BLOOD, V112, P1673, DOI 10.1182/blood-2008-02-142786
NR 39
TC 272
Z9 297
U1 0
U2 16
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
J9 NAT MED
JI Nat. Med.
PD MAY
PY 2010
VL 16
IS 5
BP 571
EP 579
DI 10.1038/nm.2129
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 592QP
UT WOS:000277394700036
PM 20436485
DA 2025-01-12
ER

PT J
AU Shasthree, T
   Mallaiah, B
AF Shasthree, T.
   Mallaiah, B.
TI Somaclonal Variations in an Endangered and Medicinally Important
   Cucurbit, <i>Citrullus Colosynthis</i> (<i>L</i>.) Schrad
SO RESEARCH JOURNAL OF BIOTECHNOLOGY
LA English
DT Article
DE Somaclonal variations; Citrullus colocynthis; Cucurbit; Androecious;
   Gynoecious; Gamma rays; Ro plants; Genomic instability and Epigenetic
   changes
ID TRANSFORMATION; REGENERATION; CULTURE; PLANTS; SALT
AB Somaclonal variations were studied in in vitro regenerated plants of an endangered cucurbit, Citrullus colosynthis (L.) commonly known as 'bitter apple'. It is a medicinally important plant used as a antirheumatic, anthelminthic and its exractive 'colosynth' is a very strong laxative. Roots are used in urinary diseases, mamma litis and opt halmia. Its exract cucurbitacin glucosides inhibit growth of human breast cancer.
   During in vitro mutagenesis and regeneration studies, a number of somaclones have been isolated and characterized. Regenerated plants from R-0 are scored for the identification of variant plants in R-1 and R-2 generation. During these studies a number of variations in habit, leaf and tendrillar character, floral somaclones like androecious, gynoecious, andro monoecious and andro gynoecious were isolated. Variation in fruit number, sizes, colours and seed coat colours were also screened.
C1 [Shasthree, T.; Mallaiah, B.] Kakatiya Univ, Biotechnol Lab, Dept Bot, Warangal 506009, Andhra Pradesh, India.
C3 Kakatiya University
RP Shasthree, T (通讯作者)，Kakatiya Univ, Biotechnol Lab, Dept Bot, Warangal 506009, Andhra Pradesh, India.
EM tadurishastri@rediffmail.com
RI Shasthree, Taduri/AAG-9374-2021
CR ARCIONI S, 1990, BIOTECHNOLOGY AGR FO, V10, P197
   ARNHOLDTSCHMITT B, 1996, J PLANT NUTR SOIL SC, V159, P317
   BAYLISS MW, 1985, INT REV CYTOL, V1, P113
   Bhojwani S.S., 1996, BOTANICA, V46, P1
   BROWN DCW, 1995, WORLD J MICROB BIOT, V11, P409, DOI 10.1007/BF00364616
   CHATURVEDI HC, 2000, INDIAN J EXPT BIOL, V39, P1080
   CHOI PS, 1994, PLANT CELL REP, V13, P344, DOI 10.1007/BF00232634
   DEJONG J, 1986, EUPHYTICA, V35, P137, DOI 10.1007/BF00028551
   DEKLERK GJ, 1990, ACTA BOT NEERL, V39, P145, DOI 10.1111/j.1438-8677.1990.tb01482.x
   Evans D A., 1988, Handbook of Plant Cell Culture. Volume, V4, P97
   FUCHS M, 1995, BIO-TECHNOL, V13, P1466, DOI 10.1038/nbt1295-1466
   Fuchs Marc, 2004, Environmental Biosafety Research, V3, P17, DOI 10.1051/ebr:2004004
   Gonzalo S, 2005, NAT CELL BIOL, V7, P420, DOI 10.1038/ncb1235
   GREEN CE, 1977, HORTSCIENCE, V12, P131
   Hartwell L., 2008, Genetics: from genes to genomes
   Hirochika H, 1996, P NATL ACAD SCI USA, V93, P7783, DOI 10.1073/pnas.93.15.7783
   Kaeppler SM, 2000, PLANT MOL BIOL, V43, P179, DOI 10.1023/A:1006423110134
   Karp A., 1985, Oxford Surveys of Plant Molecular and Cell Biology, V2, P199
   Kathiravan K, 2006, PLANT CELL TISS ORG, V85, P285, DOI 10.1007/s11240-006-9079-1
   KUMAR N, 1999, NAT S ROL PLANT TISS, P60
   LARKIN PJ, 1987, IOWA STATE J RES, V61, P393
   LARKIN PJ, 1981, THEOR APPL GENET, V60, P197, DOI 10.1007/BF02342540
   Maraschin M, 2002, BRAZ J MED BIOL RES, V35, P633, DOI 10.1590/S0100-879X2002000600002
   MORENO V, 1990, BIOTECHNOLOGY AGR FO, V2, P435
   MULLER E, 1990, THEOR APPL GENET, V80, P673, DOI 10.1007/BF00224228
   Navarro JM, 2001, J PLANT PHYSIOL, V158, P375, DOI 10.1078/0176-1617-00147
   NIRMALA BN, 1997, THESIS KAKATIYA U WA
   ORTON TJ, 1980, THEOR APPL GENET, V56, P101, DOI 10.1007/BF00265080
   REDDY VD, 1987, IN VITRO SEED UNPUB
   SCOWCROFT WR, 1984, P INT C GEN GEN FRON, P35
   SHEPARD JF, 1980, SCIENCE, V208, P17, DOI 10.1126/science.208.4439.17
   Singh M. N., 1996, Phytomorphology, V46, P395
   Skirvin R. M., 1993, Acta Horticulturae, P333
   SMITH SM, 1974, ANN BOT-LONDON, V38, P223, DOI 10.1093/oxfordjournals.aob.a084807
   TEPFER D, 1984, CELL, V37, P959, DOI 10.1016/0092-8674(84)90430-6
   Vázquez AM, 2001, PLANT BIOSYST, V135, P57, DOI 10.1080/11263500112331350650
   VENKATESHWARLU M, 1999, THESIS KAKATIYA U WA
   Zhu JK, 2002, ANNU REV PLANT BIOL, V53, P247, DOI 10.1146/annurev.arplant.53.091401.143329
NR 38
TC 0
Z9 0
U1 0
U2 1
PU RESEARCH JOURNAL BIOTECHNOLOGY
PI INDORE
PA SECTOR A-80, SCHEME NO 54, VIJAY NAGAR, A B ROAD, INDORE, 452 010 MP,
   INDIA
SN 2278-4535
J9 RES J BIOTECHNOL
JI Res. J. Biotechnol.
PD MAY
PY 2010
VL 5
IS 2
BP 56
EP 60
PG 5
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology
GA 603TJ
UT WOS:000278230700011
DA 2025-01-12
ER

PT J
AU Qu, ZX
   Fu, J
   Yan, PR
   Hu, J
   Cheng, SY
   Xiao, GT
AF Qu, Zhaoxia
   Fu, Jing
   Yan, Pengrong
   Hu, Jing
   Cheng, Shi-Yuan
   Xiao, Gutian
TI Epigenetic Repression of PDZ-LIM Domain-containing Protein 2
   <i>IMPLICATIONS FOR THE BIOLOGY AND TREATMENT OF BREAST CANCER</i>
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID NF-KAPPA-B; DNA METHYLATION; INDEPENDENT GROWTH; KINASE NIK;
   DEGRADATION; ACTIVATION; AUTOPHAGY; TAX; DEREGULATION; TERMINATION
AB The NF-kappa B transcription factor plays a pivotal role in breast cancer progression and therapy resistance. However, the mechanisms by which the tightly regulated NF-kappa B becomes constitutively activated during breast cancer pathogenesis remain obscure. Here, we report that PDZ-LIM domain-containing protein 2 (PDLIM2), an essential terminator of NF-kappa B activation, is repressed in both estrogen receptor-positive and estrogen receptor-negative breast cancer cells, suggesting one important mechanism for the constitutive activation of NF-kappa B. Indeed, PDLIM2 reexpression inhibited constitutive NF-kappa B activation and expression of NF-kappa B-targeted genes in those breast cancer cells. Importantly, PDLIM2, but not its mutants defective in NF-kappa B termination, could suppress in vitro anchorage-independent growth and in vivo tumor formation of those malignant breast cells. In addition, we have shown that PDLIM2 repression involves promoter methylation. Accordingly, treatment of the breast cancer cells with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine reverses the methylation of the PDLIM2 promoter, restored PDLIM2 expression, and suppressed tumorigenicities of human breast cancer cells both in vitro and in vivo. These studies thus provide important mechanistic insights into breast cancer pathogenesis. These studies also suggest a tumor suppression function of PDLIM2 and a therapeutic strategy for breast cancer.
C1 [Qu, Zhaoxia; Fu, Jing; Yan, Pengrong; Hu, Jing; Cheng, Shi-Yuan; Xiao, Gutian] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA.
   [Qu, Zhaoxia; Fu, Jing; Yan, Pengrong; Xiao, Gutian] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA 15213 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh
RP Xiao, GT (通讯作者)，Hillman Canc Ctr Res Pavil,5117 Ctr Ave, Pittsburgh, PA 15213 USA.
EM xiaog2@upmc.edu
RI Cheng, Shiyuan/ISU-4685-2023; Yan, Pengrong/H-1150-2012; Hu,
   Jing/M-3130-2014; Fu, Jing/C-7921-2016
OI Fu, Jing/0000-0002-3894-722X; Yan, Pengrong/0000-0003-0021-6461
FU NCI/National Institutes of Health [R01 CA116616, R01 CA102011, R01
   CA130966]; American Cancer Society [RSG-06-066-01-MGO, RSG-CSM-107144];
   Pennsylvania Department of Health; Hillman Innovative Research Scholar;
   Hillman Innovative Cancer Research Award
FX This study was supported, in whole or in part, by NCI/National
   Institutes of Health Grants R01 CA116616, R01 CA102011, and R01
   CA130966. This work was also supported by American Cancer Society Grants
   RSG-06-066-01-MGO and RSG-CSM-107144, grants from the Pennsylvania
   Department of Health, and a Hillman Innovative Research Scholar and a
   Hillman Innovative Cancer Research Award (to G. X. and S. Y. C.).
CR Biswas DK, 2006, J CELL PHYSIOL, V209, P645, DOI 10.1002/jcp.20785
   Cao YX, 2003, J MAMMARY GLAND BIOL, V8, P215, DOI 10.1023/A:1025905008934
   Cvijic ME, 2003, J IMMUNOL METHODS, V278, P293, DOI 10.1016/S0022-1759(03)00191-1
   Garcia-Manero G, 2008, CURR OPIN ONCOL, V20, P705, DOI 10.1097/CCO.0b013e328313699c
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879
   Loughran G, 2005, MOL BIOL CELL, V16, P1811, DOI 10.1091/mbc.E04-12-1052
   Luczak MW, 2006, FOLIA HISTOCHEM CYTO, V44, P143
   Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629
   Pratt MAC, 2009, ONCOGENE, V28, P2710, DOI 10.1038/onc.2009.131
   Qing GL, 2005, J BIOL CHEM, V280, P18, DOI 10.1074/jbc.M406619200
   Qing GL, 2005, J BIOL CHEM, V280, P40578, DOI 10.1074/jbc.M508776200
   Qing GL, 2007, CELL RES, V17, P520, DOI 10.1038/cr.2007.47
   Qing GL, 2007, P NATL ACAD SCI USA, V104, P5324, DOI 10.1073/pnas.0609914104
   Qing GL, 2006, CELL RES, V16, P895, DOI 10.1038/sj.cr.7310109
   Qu ZX, 2010, CANCER RES, V70, P1766, DOI 10.1158/0008-5472.CAN-09-3263
   Qu ZX, 2004, J BIOL CHEM, V279, P44563, DOI 10.1074/jbc.M403689200
   Saccani S, 2004, J EXP MED, V200, P107, DOI 10.1084/jem.20040196
   Samlowski WE, 2005, J CLIN ONCOL, V23, P3897, DOI 10.1200/JCO.2005.06.118
   Sun SC, 2003, CANCER METAST REV, V22, P405, DOI 10.1023/A:1023733231406
   Tanaka T, 2005, IMMUNITY, V22, P729, DOI 10.1016/j.immuni.2005.04.008
   Tanaka T, 2007, NAT IMMUNOL, V8, P584, DOI 10.1038/ni1464
   Torrado M, 2004, INVEST OPHTH VIS SCI, V45, P3955, DOI 10.1167/iovs.04-0721
   Wu JT, 2005, J SURG RES, V123, P158, DOI 10.1016/j.jss.2004.06.006
   Xiao GT, 2007, CYTOKINE GROWTH F R, V18, P233, DOI 10.1016/j.cytogfr.2007.04.006
   Xiao GT, 2006, CYTOKINE GROWTH F R, V17, P281, DOI 10.1016/j.cytogfr.2006.04.005
   Yan PR, 2009, NEOPLASIA, V11, P1036, DOI 10.1593/neo.09752
   Yan PR, 2009, BLOOD, V113, P4370, DOI 10.1182/blood-2008-10-185660
NR 28
TC 50
Z9 53
U1 0
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 16
PY 2010
VL 285
IS 16
BP 11786
EP 11792
DI 10.1074/jbc.M109.086561
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 584XI
UT WOS:000276787100005
PM 20185823
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Al Sarakbi, W
   Reefy, S
   Jiang, WG
   Roberts, T
   Newbold, RF
   Mokbel, K
AF Al Sarakbi, W.
   Reefy, S.
   Jiang, W. G.
   Roberts, T.
   Newbold, R. F.
   Mokbel, K.
TI Evidence of a Tumour Suppressor Function for DLEC1 in Human Breast
   Cancer
SO ANTICANCER RESEARCH
LA English
DT Article
DE Breast; DLEC1
ID EPIGENETIC INACTIVATION; GENE; EXPRESSION; MLH1; ARM; 3P
AB DLEC1 (deleted in lung and oesophageal cancer), located on 3p22.3, is a candidate tumour suppressor gene in lung, esophageal, and renal cancer. The aim of this study was determine whether the mRNA expression levels of DLEC1 were consistent with a tumour suppressive function. Materials and Methods: A total of 153 samples were analysed. The levels of transcription of DLEC1 were determined using quantitative PCR and normalised against (CK19). Transcript levels within breast cancer specimens were compared to normal background tissues. Results: Levels of transcription were higher in tumour samples compared to adjacent non cancerous tissue (ANCT) samples but this was not statistically significant (median 0.167 vs. 0.03; p=0.138). DLEC1 expression levels were significantly lower in samples from patients who developed metastasis, local recurrence, or died of breast cancer when compared to those who were disease free for >10 years (p=0.041). Discussion: These findings are consistent with a possible tumour suppressor function of DLEC I in breast cancer.
C1 [Reefy, S.; Mokbel, K.] Princess Grace Hosp, London Breast Inst, London W1U 5NY, England.
   [Al Sarakbi, W.; Mokbel, K.] St Georges Univ London, London SW17 OQT, England.
   [Jiang, W. G.; Mokbel, K.] Cardiff Univ, Wales Coll Med, Univ Dept Surg, Cardiff CF14 4XN, S Glam, Wales.
   [Roberts, T.; Newbold, R. F.] Brunel Univ, Inst Canc Genet & Pharmacogenom, Uxbridge UB8 3PH, Middx, England.
C3 City St Georges, University of London; St Georges University London;
   Cardiff University; Brunel University
RP Mokbel, K (通讯作者)，Princess Grace Hosp, London Breast Inst, 45 Nottingham Pl, London W1U 5NY, England.
EM kefahmokbel@hotmail.com
RI Roberts, Terry/A-8211-2014; Jiang, Wen/AAF-1876-2020; Newbold,
   Robert/JDN-0280-2023; Jiang, Wen G./B-1293-2010
OI Jiang, Wen G./0000-0002-3283-1111; Mokbel, Kefah/0000-0001-7255-7850
CR Al Sarakbi W, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-290
   BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402
   Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#
   Daigo Y, 1999, CANCER RES, V59, P1966
   Fullwood P, 1999, CANCER RES, V59, P4662
   Hitchins MP, 2007, CANCER RES, V67, P9107, DOI 10.1158/0008-5472.CAN-07-0869
   Ishikawa S, 1997, DNA Res, V4, P35, DOI 10.1093/dnares/4.1.35
   Jiang WG, 2004, ENDOCR-RELAT CANCER, V11, P781, DOI 10.1677/erc.1.00825
   Jiang WG, 2003, CLIN CANCER RES, V9, P6432
   Jiang WG, 2003, INT J CANCER, V106, P752, DOI 10.1002/ijc.11302
   Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2
   Kwong J, 2006, NEOPLASIA, V8, P268, DOI 10.1593/neo.05502
   Kwong J, 2007, GENE CHROMOSOME CANC, V46, P171, DOI 10.1002/gcc.20398
   Martinelli M, 2001, J OPT A-PURE APPL OP, V3, P300, DOI 10.1088/1464-4258/3/4/312
   Mau S, 1996, CANCER RES, V56, P5484
   Seng TJ, 2008, BRIT J CANCER, V99, P375, DOI 10.1038/sj.bjc.6604452
   Wistuba II, 1999, ONCOGENE, V18, P643, DOI 10.1038/sj.onc.1202349
NR 17
TC 7
Z9 8
U1 0
U2 0
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD APR
PY 2010
VL 30
IS 4
BP 1079
EP 1082
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 609VS
UT WOS:000278686600006
PM 20530412
DA 2025-01-12
ER

PT J
AU Bellido, ML
   Radpour, R
   Lapaire, O
   De Bie, I
   Hösli, I
   Bitzer, J
   Hmadcha, A
   Zhong, XY
   Holzgreve, W
AF Luz Bellido, Maria
   Radpour, Ramin
   Lapaire, Olav
   De Bie, Isabelle
   Hoesli, Irene
   Bitzer, Johannes
   Hmadcha, Abdelkrim
   Zhong, Xiao Yan
   Holzgreve, Wolfgang
TI MALDI-TOF Mass Array Analysis of <i>RASSF1A</i> and <i>SERPINB5</i>
   Methylation Patterns in Human Placenta and Plasma
SO BIOLOGY OF REPRODUCTION
LA English
DT Article
DE DNA methylation; MALDI-TOF; mass spectrometry; placenta; preeclampsia;
   pregnancy
ID NONINVASIVE PRENATAL-DIAGNOSIS; MATERNAL PLASMA; FETAL DNA;
   HYPERMETHYLATED RASSF1A; BREAST-CANCER; NUCLEIC-ACIDS; GENE; INHIBITOR;
   CLEAVAGE; MASPIN
AB Differences in DNA methylation patterns between placenta and blood cells of pregnant women have been suggested as potential biomarkers for noninvasive prenatal diagnostic strategies, including for common obstetrical complications, such as preeclampsia. New findings in epigenetic origins of fetal or placental disorders may improve our ability for optimal management of these conditions. Using a novel high-throughput mass spectrometry on matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass array, we compared the quantitative methylation changes of RASSF1 and SERPINB5 (also known as MASPIN) genes in placenta and plasma samples. We analyzed the methylation status of a total of 3569 CpG dinucleotides on these two genes in 83 different samples: 50 plasma samples (20 from pregnant women and 30 from nonpregnant women) and 33 placenta tissue samples (25 from normal pregnancies and eight from preeclamptic pregnancies). The aim of this study was to assess the utility of epigenetic changes as biomarkers for noninvasive prenatal diagnostic procedures. Using a two-way hierarchical cluster analysis, significantly different methylation levels of the RASSF1 gene were found between placenta (normal and preeclamptic) and plasma samples of pregnant women. Although the SERPINB5 gene was hypomethylated in placenta DNA more than in plasma DNA, it did not demonstrate significant differences between studied groups. The MALDI-TOF mass spectrometry analysis of placenta and plasma DNA methylation patterns may serve as a tool for the study of gender-independent biomarkers in noninvasive prenatal diagnosis.
C1 [Radpour, Ramin; De Bie, Isabelle; Zhong, Xiao Yan] Univ Basel, Lab Prenatal Med & Gynecol Oncol, Womens Hosp, Dept Biomed, CH-4031 Basel, Switzerland.
   [Luz Bellido, Maria; Hmadcha, Abdelkrim] Andalusian Ctr Mol Biol & Regenerat Med CABIMER, Dept Cell Therapy & Regenerat Med, Seville, Spain.
   [Lapaire, Olav; Hoesli, Irene; Bitzer, Johannes] Univ Basel Hosp, Dept Obstet & Gynecol, CH-4031 Basel, Switzerland.
   [Holzgreve, Wolfgang] Univ Med Ctr Freiburg, Freiburg, Germany.
C3 University of Basel; Consejo Superior de Investigaciones Cientificas
   (CSIC); Universidad Pablo de Olavide; University of Sevilla; CSIC -
   Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER);
   University of Basel; University of Freiburg
RP Zhong, XY (通讯作者)，Univ Basel, Lab Prenatal Med & Gynecol Oncol, Womens Hosp, Dept Biomed, Hebelstr 20,Room 420, CH-4031 Basel, Switzerland.
EM xzhong@uhbs.ch
RI De Bie, Isabelle/M-1793-2019; Hmadcha, Abdelkrim/T-1173-2019; Radpour,
   PD Dr. Ramin/J-4949-2014; Hmadcha, Abdelkrim/F-2407-2011
OI Radpour, PD Dr. Ramin/0000-0002-5632-7833; BELLIDO DIAZ, MARIA
   LUZ/0000-0002-9330-9132; Hmadcha, Abdelkrim/0000-0002-4105-3702
FU Swiss National Science Foundation [320000-119722/1]; Swiss Cancer
   League, Krebsliga Beider Basel; Spanish Ministry of Health [CM06/00183];
   Foundation Progreso y Salud
FX Supported in part by Swiss National Science Foundation grant
   320000-119722/1, the Swiss Cancer League, Krebsliga Beider Basel, and
   Dr. Hans Altschueler Stiftung. M. L. B. is a Fund for Health Research
   (FIS) researcher supported by the Spanish Ministry of Health (the Carlos
   III Health Institute; grant CM06/00183) and the Foundation Progreso y
   Salud.
CR Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088
   Alberry M, 2007, PRENATAL DIAG, V27, P415, DOI 10.1002/pd.1700
   Bianchi DW, 2005, OBSTET GYNECOL, V106, P841, DOI 10.1097/01.AOG.0000179477.59385.93
   Chan KCA, 2006, CLIN CHEM, V52, P2211, DOI 10.1373/clinchem.2006.074997
   Chan KCA, 2004, CLIN CHEM, V50, P88, DOI 10.1373/clinchem.2003.024893
   Chim SSC, 2005, P NATL ACAD SCI USA, V102, P14753, DOI 10.1073/pnas.0503335102
   Chiu RWK, 2001, CLIN CHEM, V47, P1607
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   Ehrich M, 2008, P NATL ACAD SCI USA, V105, P4844, DOI 10.1073/pnas.0712251105
   Hahn S, 2008, CURR OPIN OBSTET GYN, V20, P146, DOI 10.1097/GCO.0b013e3282f73349
   Hesson LB, 2007, DIS MARKERS, V23, P73, DOI 10.1155/2007/291538
   Hultén MA, 2003, REPRODUCTION, V126, P279, DOI 10.1530/reprod/126.3.279
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lo YMD, 2007, NAT REV GENET, V8, P71, DOI 10.1038/nrg1982
   Lo YMD, 1998, AM J HUM GENET, V62, P768, DOI 10.1086/301800
   Lo YMD, 1997, LANCET, V350, P485, DOI 10.1016/S0140-6736(97)02174-0
   Lo YMD, 1998, NEW ENGL J MED, V339, P1734, DOI 10.1056/NEJM199812103392402
   Poon LLM, 2002, CLIN CHEM, V48, P35
   Radpour R, 2009, ONCOGENE, V28, P2969, DOI 10.1038/onc.2009.149
   Radpour R, 2008, MOL CANCER RES, V6, P1702, DOI 10.1158/1541-7786.MCR-08-0262
   Stanssens P, 2004, GENOME RES, V14, P126
   Sternlicht MD, 1996, LAB INVEST, V74, P781
   Tsui DWY, 2007, PRENATAL DIAG, V27, P1212, DOI 10.1002/pd.1897
   Wright CF, 2009, HUM REPROD UPDATE, V15, P139, DOI 10.1093/humupd/dmn047
   Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303
   Zimmermann B, 2005, CLIN CHEM, V51, P1598, DOI 10.1373/clinchem.2005.051235
NR 26
TC 37
Z9 45
U1 1
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0006-3363
EI 1529-7268
J9 BIOL REPROD
JI Biol. Reprod.
PD APR
PY 2010
VL 82
IS 4
BP 745
EP 750
DI 10.1095/biolreprod.109.082271
PG 6
WC Reproductive Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Reproductive Biology
GA 572GA
UT WOS:000275814400012
PM 20075396
OA Bronze
DA 2025-01-12
ER

PT J
AU Przybylski, M
   Kozlowska, A
   Pietkiewicz, PP
   Lutkowska, A
   Lianeri, M
   Jagodzinski, PP
AF Przybylski, M.
   Kozlowska, A.
   Pietkiewicz, P. P.
   Lutkowska, A.
   Lianeri, M.
   Jagodzinski, P. P.
TI Increased CXCR4 expression in AsPC1 pancreatic carcinoma cells with RNA
   interference-mediated knockdown of DNMT1 and DNMT3B
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE CXCR4; Pancreatic cancer; DNA methyltransferases
ID CHEMOKINE RECEPTOR CXCR4; EPIGENETIC UP-REGULATION; HUMAN CANCER-CELLS;
   CXCL12 EXPRESSION; DNA METHYLATION; BREAST-CANCER; PROSTATE-CANCER;
   MELANOMA-CELLS; METASTASIS; GENE
AB The effect of DNA methylation on CXCR4 expression has been demonstrated in pancreatic cancer and melanoma cells, but little is known about the effect of DNA methyltransferases 1 and 3 (DNMT1 and DNMT3B) on CXCR4 expression. Employing lentiviral vectors, we created stable RNA interference-mediated knockdown of DNMT1 and DNMT3B in AsPC1 pancreatic cancer cells. Using reverse transcription real-time quantitative PCR and flow cytometric analysis, we evaluated the increase in the expression of CXCR4 transcript and protein levels in these cells. Bisulfite sequencing analysis showed that the level of promoter demethylation appeared more effective in cells with knockdown of DNMT1 than in those with DNMT3B knockdown. Furthermore, the combined RNA interference knockdown of both DNMT1 and DNMT3B increased promoter demethylation, leading to a slight increase in CXCR4 expression. However, the demethylating agent 5-Aza-2'-deoxycytidine exhibited the strongest effect on promoter demethylation, which correlated with the highest production of CXCR4 transcript and protein in AsPC1 cells. Our results indicate that DNMT1 plays the main role in maintenance of methylation of CXCR4 promoter, while DNMT3B may function as an accessory DNA methyltransferase to modulate CXCR4 expression in AsPC1 cells. (C) 2009 Elsevier Masson SAS. All rights reserved.
C1 [Przybylski, M.; Kozlowska, A.; Pietkiewicz, P. P.; Lutkowska, A.; Lianeri, M.; Jagodzinski, P. P.] Poznan Univ Med Sci, Dept Biochem & Mol Biol, PL-60781 Poznan, Poland.
   [Przybylski, M.] Poznan Univ Med Sci, Div Gynecol Oncol, Dept Gynecol Obstet & Gynecol Oncol, PL-60781 Poznan, Poland.
C3 Poznan University of Medical Sciences; Poznan University of Medical
   Sciences
RP Jagodzinski, PP (通讯作者)，Poznan Univ Med Sci, Dept Biochem & Mol Biol, 6 Swiecickiego St, PL-60781 Poznan, Poland.
EM pjagodzi@am.poznan.pl
RI Kozlowska, Anna/P-1620-2015; Przybylski, Marcin/GZL-7794-2022;
   Jagodzinski, Pawel/KWV-0637-2024; Pietkiewicz, Pawel/J-6074-2012
OI Przybylski, Marcin/0000-0002-9679-0822; Jagodzinski,
   Pawel/0000-0002-9046-6802; Kozlowska, Anna Karolina/0000-0003-2465-217X;
   Pietkiewicz, Pawel/0000-0001-7262-2456
FU Poznan University of Medical Sciences [502-01-01124182-07474]
FX We would like to acknowledge Anna Sowinska for technical assistance.
   Supported by Poznan University of Medical Sciences grant No
   502-01-01124182-07474.
CR Akashi T, 2008, CANCER SCI, V99, P539, DOI 10.1111/j.1349-7006.2007.00712.x
   Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0
   Bogani C, 2008, STEM CELLS, V26, P1920, DOI 10.1634/stemcells.2008-0377
   Broxmeyer HE, 2008, CURR OPIN HEMATOL, V15, P49, DOI 10.1097/MOH.0b013e3282f29012
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   FEDERSPPIEL B, 1993, GENOMICS, V16, P707, DOI 10.1006/geno.1993.1251
   Feng Q, 2001, GENE DEV, V15, P827
   Kajiyama H, 2008, INT J CANCER, V122, P91, DOI 10.1002/ijc.23083
   Kijima T, 2002, CANCER RES, V62, P6304
   Kim J, 2006, ANN SURG, V244, P113, DOI 10.1097/01.sla.0000217690.65909.9c
   Koshiba T, 2000, CLIN CANCER RES, V6, P3530
   Kubarek L, 2007, FEBS LETT, V581, P1441, DOI 10.1016/j.febslet.2007.02.070
   Lee HJ, 2009, INT J ONCOL, V34, P473, DOI 10.3892/ijo_00000172
   Luczak MW, 2006, FOLIA HISTOCHEM CYTO, V44, P143
   Maréchal R, 2009, BRIT J CANCER, V100, P1444, DOI 10.1038/sj.bjc.6605020
   Mori T, 2005, CANCER RES, V65, P1800, DOI 10.1158/0008-5472.CAN-04-3531
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   Robledo MM, 2001, J BIOL CHEM, V276, P45098, DOI 10.1074/jbc.M106912200
   Sato N, 2005, CANCER BIOL THER, V4, P70, DOI 10.4161/cbt.4.1.1378
   Scotton CJ, 2002, CANCER RES, V62, P5930
   Sehgal A, 1998, J SURG ONCOL, V69, P239, DOI 10.1002/(SICI)1096-9098(199812)69:4<239::AID-JSO9>3.0.CO;2-U
   Shi HD, 2003, CANCER RES, V63, P2164
   Sowinska A, 2007, CANCER LETT, V255, P153, DOI 10.1016/j.canlet.2007.04.004
   Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874
   Taichman RS, 2002, CANCER RES, V62, P1832
   Weisenberger DJ, 2004, MOL CANCER RES, V2, P62
   Wendt MK, 2006, ONCOGENE, V25, P4986, DOI 10.1038/sj.onc.1209505
   Yasuoka H, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-340
   Zlotnik A, 2008, J PATHOL, V215, P211, DOI 10.1002/path.2350
   Zlotnik A, 2006, INT J CANCER, V119, P2026, DOI 10.1002/ijc.22024
   Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871
NR 35
TC 10
Z9 12
U1 0
U2 7
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD APR
PY 2010
VL 64
IS 4
BP 254
EP 258
DI 10.1016/j.biopha.2009.06.008
PG 5
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 602PF
UT WOS:000278150600004
PM 19932585
DA 2025-01-12
ER

PT J
AU Billam, M
   Sobolewski, MD
   Davidson, NE
AF Billam, Madhavi
   Sobolewski, Michele D.
   Davidson, Nancy E.
TI Effects of a novel DNA methyltransferase inhibitor zebularine on human
   breast cancer cells
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE DNA methyltransferase; Zebularine; Breast cancer; Epigenetic; Estrogen
   receptor
ID ESTROGEN-RECEPTOR-ALPHA; CYTOSINE-ARABINOSIDE; MECHANISM; GENE;
   5-AZA-2-DEOXYCYTIDINE; DEMETHYLATION; ACTIVATION; EXPRESSION;
   REACTIVATION; METHYLATION
AB Because DNA methyltransferase (DNMT) inhibitors like azacytidine and decitabine are known to be effective in the clinic for diseases like myelodysplastic syndromes that may result in part from transcriptional dysregulation due to epigenetic changes, there is interest in developing novel DNMT inhibitors that would be more effective and less toxic. The effects of one such agent, zebularine, which inhibits DNMT and cytidine deaminase, were assessed in two human breast cancer cell lines, MDA-MB-231 and MCF-7. Zebularine treatment inhibited cell growth in a dose and time dependent manner with an IC-50 of similar to 100 mu M and 150 mu M in MDA-MB-231 and MCF-7 cells, respectively, on 96 h exposure. This was associated with increased expression of p21, decreased expression of cyclin-D, and induction of S-phase arrest. At high doses zebularine induced changes in apoptotic proteins in a cell line specific manner manifested by alteration in caspase-3, Bax, Bcl2 and PARP cleavage. Like other DNMT inhibitors, zebularine decreased expression of DNMTs post-transcriptionally as well as expression of other epigenetic regulators like methyl CpG binding proteins and global acetyl H3 and H4 protein levels. Its capacity to reexpress epigenetically silenced genes in human breast cancer cells at low doses was confirmed by its ability to induce expression of estrogen and progesterone receptor mRNA in association with changes suggestive of active chromatin at the ER promoter as evidenced by ChIP. Finally, its effect in combination with other DNMT or HDAC inhibitors like decitabine or vorinostat was explored. The combination of 50 mu M zebularine with decitabine or vorinostat significantly inhibited cell proliferation and colony formation in MDA-MB-231 cells compared with either drug alone. These findings suggest that zebularine is an effective DNMT inhibitor and demethylating agent in human breast cancer cell lines and potentiates the effects of other epigenetic therapeutics like decitabine and vorinostat.
C1 [Davidson, Nancy E.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15232 USA.
   [Sobolewski, Michele D.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
   [Billam, Madhavi] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Roswell Park Comprehensive Cancer Center; Johns Hopkins
   University; Johns Hopkins Medicine
RP Davidson, NE (通讯作者)，Univ Pittsburgh, Inst Canc, 5150 Ctr Ave,Suite 500, Pittsburgh, PA 15232 USA.
EM madhumukhi@gmail.com; davidsonne@upmc.edu
FU National Institutes of Health [NIH CA 88843]; Breast Cancer Research
   Foundation
FX This study was supported by grants from the National Institutes of
   Health (NIH CA 88843) and the Breast Cancer Research Foundation.
CR Agoston AT, 2005, J BIOL CHEM, V280, P18302, DOI 10.1074/jbc.M501675200
   BARCHI JJ, 1992, J ORG CHEM, V57, P536, DOI 10.1021/jo00028a026
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   BEISLER JA, 1978, J MED CHEM, V21, P204, DOI 10.1021/jm00200a012
   Ben-Kasus T, 2005, BIOCHEM PHARMACOL, V70, P121, DOI 10.1016/j.bcp.2005.04.010
   Cheng JC, 2003, J NATL CANCER I, V95, P399, DOI 10.1093/jnci/95.5.399
   Cheng JC, 2004, MOL CELL BIOL, V24, P1270, DOI 10.1128/MCB.24.3.1270-1278.2004
   Cheng JC, 2004, CANCER CELL, V6, P151, DOI 10.1016/j.ccr.2004.06.023
   CONSTANTINIDES PG, 1977, NATURE, V267, P364, DOI 10.1038/267364a0
   CONSTANTINIDES PG, 1978, DEV BIOL, V66, P57, DOI 10.1016/0012-1606(78)90273-7
   Eliopoulos N, 1998, CANCER CHEMOTH PHARM, V42, P373, DOI 10.1007/s002800050832
   FERGUSON AT, 1995, CANCER RES, V55, P2279
   Flotho C, 2009, LEUKEMIA, V23, P1019, DOI 10.1038/leu.2008.397
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339
   GABBARA S, 1995, BIOCHEM J, V307, P87, DOI 10.1042/bj3070087
   Hahm HA, 2001, CLIN CANCER RES, V7, P391
   Hurd PJ, 1999, J MOL BIOL, V286, P389, DOI 10.1006/jmbi.1998.2491
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   KIM CH, 1986, J MED CHEM, V29, P1374, DOI 10.1021/jm00158a009
   LALIBERTE J, 1992, CANCER CHEMOTH PHARM, V30, P7, DOI 10.1007/BF00686478
   Lemaire M, 2005, ANTI-CANCER DRUG, V16, P301, DOI 10.1097/00001813-200503000-00009
   Margueron R, 2003, J ENDOCRINOL, V179, P41, DOI 10.1677/joe.0.1790041
   MARQUEZ VE, 1980, J MED CHEM, V23, P713, DOI 10.1021/jm00181a001
   Marquez VE, 2005, NUCLEOS NUCLEOT NUCL, V24, P305, DOI 10.1081/NCN-200059765
   Milutinovic S, 2003, J BIOL CHEM, V278, P14985, DOI 10.1074/jbc.M213219200
   MOMPARLER RL, 1979, CANCER RES, V39, P3822
   Nelson DM, 2002, MOL CELL BIOL, V22, P7459, DOI 10.1128/MCB.22.21.7459-7472.2002
   Neureiter D, 2007, SCAND J GASTROENTERO, V42, P103, DOI 10.1080/00365520600874198
   Pledgie-Tracy A, 2007, MOL CANCER THER, V6, P1013, DOI 10.1158/1535-7163.MCT-06-0494
   Rao SP, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-3
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993
   Scott SA, 2007, EXP HEMATOL, V35, P263, DOI 10.1016/j.exphem.2006.10.005
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   SHEIKH MS, 1994, J CELL BIOCHEM, V54, P289, DOI 10.1002/jcb.240540305
   Tamm I, 2005, ANN HEMATOL, V84, P47, DOI 10.1007/s00277-005-0013-0
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Yang XW, 2000, CANCER RES, V60, P6890
   Ye XF, 2003, MOL CELL, V11, P341, DOI 10.1016/S1097-2765(03)00037-6
   Yoo CB, 2004, BIOCHEM SOC T, V32, P910, DOI 10.1042/BST0320910
   Yoo CB, 2008, CANCER PREV RES, V1, P233, DOI 10.1158/1940-6207.CAPR-07-0008
NR 42
TC 104
Z9 124
U1 3
U2 21
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD APR
PY 2010
VL 120
IS 3
BP 581
EP 592
DI 10.1007/s10549-009-0420-3
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 571LH
UT WOS:000275752800006
PM 19459041
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Blackburn, EH
   Tlsty, TD
   Lippman, SM
AF Blackburn, Elizabeth H.
   Tlsty, Thea D.
   Lippman, Scott M.
TI Unprecedented Opportunities and Promise for Cancer Prevention Research
SO CANCER PREVENTION RESEARCH
LA English
DT Article
ID MAMMARY EPITHELIAL-CELLS; SPORADIC COLORECTAL ADENOMAS; BREAST-CANCER;
   TELOMERE LENGTH; GENE-EXPRESSION; PROSTATE-CANCER;
   HEPATOCELLULAR-CARCINOMA; DYSKERATOSIS-CONGENITA; HUMAN-PAPILLOMAVIRUS;
   SOCIAL-ISOLATION
AB Cancer prevention encompasses a wide range of highly developed science and clinical impact. Enunciating these two aspects in the same breath highlights the crucial link between them. The breadth and excitement of current opportunities in the science of cancer prevention have never been greater. Major avenues of such research include the extent and effect of premalignancy, the molecular underpinnings of carcinogenesis and related prevention targets, in vitro model systems of the progression of normal human epithelial cells to tumorigenesis, molecular risk stratification and pharmacogenomic approaches, and many more. We describe the clinical impacts of cancer prevention (with examples in the areas of molecular targeting, vaccines, epidemiology, and behavioral science) and the stage-setting science that facilitated them. In addition, discussed are new prevention opportunities such as interactions between stromal and micro-environmental factors, the control of premalignant stem cell phenotypes through epigenetic reprogramming, and neoplastic cells and various stress responses including those involving telomere biology. The promise of this science, particularly integrative, interdisciplinary research, is to hasten the ability of clinical prevention to reduce the burden of cancer. Cancer Prev Res; 3(4); 394-402. (C)2010 AACR.
C1 [Blackburn, Elizabeth H.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.
   [Tlsty, Thea D.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA.
   [Lippman, Scott M.] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA.
C3 University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   University of Texas System; UTMD Anderson Cancer Center
RP Blackburn, EH (通讯作者)，Univ Calif San Francisco, Dept Biochem & Biophys, Box 2200,Genentech Hall S312F, San Francisco, CA 94143 USA.
EM Elizabeth.Blackburn@ucsf.edu
CR ALPERS CE, 1985, HUM PATHOL, V16, P796, DOI 10.1016/S0046-8177(85)80251-3
   ANDRIOLE GL, 2009, ANN M AM UR ASS CHIC
   Artandi SE, 2010, CARCINOGENESIS, V31, P9, DOI 10.1093/carcin/bgp268
   AUERBACH O, 1957, NEW ENGL J MED, V256, P97, DOI 10.1056/NEJM195701172560301
   BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249
   Baron JA, 2003, NEW ENGL J MED, V348, P891, DOI 10.1056/NEJMoa021735
   Beane J, 2008, CANCER PREV RES, V1, P56, DOI 10.1158/1940-6207.CAPR-08-0011
   Beatty PL, 2010, CANCER PREV RES, V3, P438, DOI 10.1158/1940-6207.CAPR-09-0194
   BERMAN HK, 2010, CANC PREV R IN PRESS
   Bertagnolli MM, 2006, NEW ENGL J MED, V355, P873, DOI 10.1056/NEJMoa061355
   Blackburn EH, 2006, NAT MED, V12, P1133, DOI 10.1038/nm1006-1133
   Blaser MJ, 2008, CANCER PREV RES, V1, P15, DOI 10.1158/1940-6207.CAPR-08-0024
   BLUMBERG BS, 1976, AM J CLIN PATHOL, V65, P848
   BLUMBERG BS, 1967, ANN INTERN MED, V66, P924, DOI 10.7326/0003-4819-66-5-924
   Boyle JO, 2010, CANCER PREV RES, V3, P266, DOI 10.1158/1940-6207.CAPR-09-0192
   Brouilette SW, 2007, LANCET, V369, P107, DOI 10.1016/S0140-6736(07)60071-3
   CARMELLI D, 1992, NEW ENGL J MED, V327, P829, DOI 10.1056/NEJM199209173271201
   Cerny EH, 2009, HUM VACCINES, V5, P200, DOI 10.4161/hv.5.4.7310
   Chan AT, 2007, NEW ENGL J MED, V356, P2131, DOI 10.1056/NEJMoa067208
   Chan AT, 2009, GASTROENTEROLOGY, V136, P2127, DOI 10.1053/j.gastro.2009.02.045
   Chang MH, 2009, JNCI-J NATL CANCER I, V101, P1348, DOI 10.1093/jnci/djp288
   Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602
   Crawford YG, 2004, CANCER CELL, V5, P263, DOI 10.1016/S1535-6108(04)00023-6
   D'Souza G, 2007, NEW ENGL J MED, V356, P1944, DOI 10.1056/NEJMoa065497
   Disis ML, 2010, CANCER PREV RES, V3, P406, DOI 10.1158/1940-6207.CAPR-10-0043
   DOLL R, 1950, BRIT MED J, V2, P739, DOI 10.1136/bmj.2.4682.739
   Duffield-Lillico AJ, 2009, CANCER PREV RES, V2, P322, DOI 10.1158/1940-6207.CAPR-09-0005
   DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812
   EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1
   Eng C, 2009, CANCER RES, V69, P6759, DOI 10.1158/0008-5472.CAN-09-0985
   Epel ES, 2006, PSYCHONEUROENDOCRINO, V31, P277, DOI 10.1016/j.psyneuen.2005.08.011
   Epel ES, 2004, P NATL ACAD SCI USA, V101, P17312, DOI 10.1073/pnas.0407162101
   FENG H, 2008, SCIENCE, V22, P1319
   Feng HC, 2008, SCIENCE, V319, P1096, DOI 10.1126/science.1152586
   Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371
   Flossmann E, 2007, LANCET, V369, P1603, DOI 10.1016/S0140-6736(07)60747-8
   FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0
   Fordyce C, 2010, CANCER PREV RES, V3, P190, DOI 10.1158/1940-6207.CAPR-09-0229
   Fukase K, 2008, LANCET, V372, P392, DOI 10.1016/S0140-6736(08)61159-9
   Gandhi L, 2009, CANCER PREV RES, V2, P330, DOI 10.1158/1940-6207.CAPR-08-0213
   Gauthier ML, 2007, CANCER CELL, V12, P479, DOI 10.1016/j.ccr.2007.10.017
   Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780
   HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435
   Hermes GL, 2009, P NATL ACAD SCI USA, V106, P22393, DOI 10.1073/pnas.0910753106
   Holla VR, 2008, CANCER PREV RES, V1, P93, DOI 10.1158/1940-6207.CAPR-07-0009
   Hou LF, 2009, CANCER EPIDEM BIOMAR, V18, P3103, DOI 10.1158/1055-9965.EPI-09-0347
   Huggins C, 1941, CANCER RES, V1, P293
   Hursting SD, 2009, CANCER PREV RES, V2, P295, DOI 10.1158/1940-6207.CAPR-09-0040
   Issa JP, 2008, CANCER PREV RES, V1, P219, DOI 10.1158/1940-6207.CAPR-08-0029
   JORDAN VC, 1974, J STEROID BIOCHEM, V5, P354, DOI 10.1016/0022-4731(74)90388-4
   Kenter GG, 2009, NEW ENGL J MED, V361, P1838, DOI 10.1056/NEJMoa0810097
   Koutsky L, 2009, ANN EPIDEMIOL, V19, P239, DOI 10.1016/j.annepidem.2009.01.023
   LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1
   Lathrop A E, 1916, J Cancer Res, V1, P1
   LI Y, 2010, LANCET ONCO IN PRESS
   LIPKIN SM, 2010, CANC PREV R IN PRESS
   Lippman SM, 2009, JAMA-J AM MED ASSOC, V301, P39, DOI 10.1001/jama.2008.864
   Lippman SM, 1999, JNCI-J NATL CANCER I, V91, P1809, DOI 10.1093/jnci/91.21.1809
   LYNCH HT, 1977, ANN SURG, V185, P435, DOI 10.1097/00000658-197704000-00011
   Marrone A, 2007, HAEMATOLOGICA, V92, P1013, DOI 10.3324/haematol.11407
   MARSHALL BJ, 1984, LANCET, V1, P1311
   Martínez ME, 2003, P NATL ACAD SCI USA, V100, P7859, DOI 10.1073/pnas.1332465100
   McClintock MK, 2005, J GERONTOL B-PSYCHOL, V60, P32, DOI 10.1093/geronb/60.Special_Issue_1.32
   Meyskens FL, 2008, CANCER PREV RES, V1, P32, DOI 10.1158/1940-6207.CAPR-08-0042
   NIELSEN M, 1987, BRIT J CANCER, V56, P814, DOI 10.1038/bjc.1987.296
   Olumi AF, 1999, CANCER RES, V59, P5002
   Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1
   PENNEY KL, 2010, CANC PREV R IN PRESS
   Pollak M, 2009, CANCER PREV RES, V2, P698, DOI 10.1158/1940-6207.CAPR-09-0134
   Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158
   Redman MW, 2008, CANCER PREV RES, V1, P174, DOI 10.1158/1940-6207.CAPR-08-0092
   Risques RA, 2007, CANCER EPIDEM BIOMAR, V16, P2649, DOI 10.1158/1055-9965.EPI-07-0624
   Roblyer D, 2009, CANCER PREV RES, V2, P423, DOI 10.1158/1940-6207.CAPR-08-0229
   Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579
   RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69
   Schembri F, 2009, P NATL ACAD SCI USA, V106, P2319, DOI 10.1073/pnas.0806383106
   Schiffman M, 2009, NEW ENGL J MED, V360, P1453, DOI 10.1056/NEJMe0901167
   Schmeler KM, 2006, NEW ENGL J MED, V354, P261, DOI 10.1056/NEJMoa052627
   Seager CM, 2009, CANCER PREV RES, V2, P1008, DOI 10.1158/1940-6207.CAPR-09-0169
   Settle K, 2009, CANCER PREV RES, V2, P776, DOI 10.1158/1940-6207.CAPR-09-0149
   Shureiqi I, 2003, P NATL ACAD SCI USA, V100, P9968, DOI 10.1073/pnas.1631086100
   Spira A, 2004, P NATL ACAD SCI USA, V101, P10143, DOI 10.1073/pnas.0401422101
   SPORN MB, 1980, NATURE, V287, P107, DOI 10.1038/287107a0
   Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603
   TANNENBAUM A, 1943, CANCER RES, V3, P749
   Thompson IM, 2003, NEW ENGL J MED, V349, P215, DOI 10.1056/NEJMoa030660
   Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224
   TOFT D, 1966, P NATL ACAD SCI USA, V55, P1574, DOI 10.1073/pnas.55.6.1574
   Valdes AM, 2005, LANCET, V366, P662, DOI 10.1016/S0140-6736(05)66630-5
   Varella-Garcia M, 2010, CANCER PREV RES, V3, P447, DOI 10.1158/1940-6207.CAPR-09-0165
   Villa LL, 2007, NEW ENGL J MED, V356, P1915, DOI 10.1056/NEJMoa061741
   Vogel VG, 2006, JAMA-J AM MED ASSOC, V295, P2727, DOI 10.1001/jama.295.23.joc60074
   Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585
   Vulliamy TJ, 2006, BLOOD, V107, P2680, DOI 10.1182/blood-2005-07-2622
   Wacholder S, 2010, NEW ENGL J MED, V362, P986, DOI 10.1056/NEJMoa0907727
   WALEN KH, 1989, CANCER GENET CYTOGEN, V37, P249, DOI 10.1016/0165-4608(89)90056-3
   Waters EA, 2010, CANCER EPIDEM BIOMAR, V19, P443, DOI 10.1158/1055-9965.EPI-09-0930
   Weiner LM, 2010, CANCER PREV RES, V3, P410, DOI 10.1158/1940-6207.CAPR-10-0040
   Williams JB, 2009, CANCER PREV RES, V2, P850, DOI 10.1158/1940-6207.CAPR-08-0238
   WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701
   Wong KK, 2010, CANCER PREV RES, V3, P403, DOI 10.1158/1940-6207.CAPR-10-0042
   Wu XF, 2009, CANCER PREV RES, V2, P617, DOI 10.1158/1940-6207.CAPR-09-0025
   WYNDER EL, 1950, JAMA-J AM MED ASSOC, V143, P329, DOI 10.1001/jama.1950.02910390001001
   ZHANG LF, 2010, NATURE IN PRESS
   zur Hausen H, 1974, Int J Cancer, V13, P650
NR 105
TC 15
Z9 18
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD APR
PY 2010
VL 3
IS 4
BP 394
EP 402
DI 10.1158/1940-6207.CAPR-10-0051
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 577ZS
UT WOS:000276263600002
PM 20354163
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Hoffman, AE
   Zheng, TZ
   Yi, CH
   Stevens, RG
   Ba, Y
   Zhang, YW
   Leaderer, D
   Holford, T
   Hansen, J
   Zhu, Y
AF Hoffman, Aaron E.
   Zheng, Tongzhang
   Yi, Chun-Hui
   Stevens, Richard G.
   Ba, Yue
   Zhang, Yawei
   Leaderer, Derek
   Holford, Theodore
   Hansen, Johnni
   Zhu, Yong
TI The Core Circadian Gene <i>Cryptochrome 2</i> Influences Breast Cancer
   Risk, Possibly by Mediating Hormone Signaling
SO CANCER PREVENTION RESEARCH
LA English
DT Article
ID POLYCHLORINATED-BIPHENYLS; DOWN-REGULATION; CLOCK; EXPRESSION; ESTROGEN;
   CRY2; ASSOCIATION; RHYTHMS; PER2; PROTEINS
AB As transcriptional regulators, circadian genes have the potential to influence a variety of biological pathways, including many cancer-related processes. Cryptochrome 2 (CRY2) is essential for proper circadian timing and is a key component of the circadian regulatory feedback loop. Here, we report findings from genetic, epigenetic, loss-of-function, and transcriptional profiling analyses of CRY2 in breast cancer. Six single-nucleotide polymorphisms in CRY2 were identified for genotyping in a case-control population (n = 441 cases and n = 479 controls), and three single-nucleotide polymorphisms (rs11038689, rs7123390, and rs1401417) were significantly associated with postmenopausal breast cancer risk, with significant effect modification by menopausal status [ dominant model for rs11038689: odds ratio (OR), 0.71; 95% confidence interval (95% CI), 0.51-0.99; P for trend = 0.028; homozygous variants for rs7123390: OR, 0.44; 95% CI, 0.22-0.86; P for trend = 0.028; and rs1401417: OR, 0.44; 95% CI, 0.21-0.92; P for trend = 0.017]. Interestingly, this association was only evident in women with estrogen and progesterone receptor (ER/PR)-negative breast tumors but not with ER/PR-positive tumors. Breast cancer patients also had significantly higher levels of CRY2 promoter methylation relative to controls, which is consistent with tissue array data showing lower levels of CRY2 expression in tumor tissue relative to adjacent normal tissue. Furthermore, in vitro analyses identified several breast cancer-relevant genes that displayed altered expression following CRY2 knockdown. These findings suggest a role for CRY2 in breast tumorigenesis and provide further evidence that the circadian system may be an important modulator of hormone-related cancer susceptibility. Cancer Prev Res; 3(4); 539-48. (C)2010 AACR.
C1 [Hoffman, Aaron E.; Zheng, Tongzhang; Yi, Chun-Hui; Ba, Yue; Zhang, Yawei; Leaderer, Derek; Holford, Theodore; Zhu, Yong] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA.
   [Stevens, Richard G.] Univ Connecticut, Ctr Hlth, Dept Community Med & Hlth Care, Farmington, CT USA.
   [Hansen, Johnni] Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark.
C3 Yale University; University of Connecticut; Danish Cancer Society
RP Zhu, Y (通讯作者)，Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, 333 Cedar St, New Haven, CT 06520 USA.
EM yong.zhu@yale.edu
OI Hansen, Johnni/0000-0002-9342-2725
FU NIH [CA122676, CA110937]
FX NIH grants CA122676 and CA110937.
CR BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bossenmeyer-Pourié C, 2002, J CELL BIOL, V157, P761, DOI 10.1083/jcb200108056
   Cheng ASL, 2008, CANCER RES, V68, P1786, DOI 10.1158/0008-5472.CAN-07-5547
   Chu LW, 2008, PROSTATE CANCER P D, V11, P342, DOI 10.1038/sj.pcan.4501024
   Cui YM, 2004, MOL CANCER RES, V2, P225
   de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669
   Duffield GE, 2002, CURR BIOL, V12, P551, DOI 10.1016/S0960-9822(02)00765-0
   Gauger MA, 2005, CANCER RES, V65, P6828, DOI 10.1158/0008-5472.CAN-05-1119
   Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768
   Hoffman AE, 2009, CANCER RES, V69, P3605, DOI 10.1158/0008-5472.CAN-08-4572
   Hunter DJ, 2007, NAT GENET, V39, P870, DOI 10.1038/ng2075
   Kondratov RV, 2007, CURR TOP DEV BIOL, V78, P173, DOI 10.1016/S0070-2153(06)78005-X
   Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4
   Lamont EW, 2007, SLEEP MED, V8, P547, DOI 10.1016/j.sleep.2006.11.002
   Langmesser S, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-41
   Le Minh N, 2001, EMBO J, V20, P7128, DOI 10.1093/emboj/20.24.7128
   Lin YM, 2008, MOL CARCINOGEN, V47, P925, DOI 10.1002/mc.20446
   Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544
   Matsuo T, 2003, SCIENCE, V302, P255, DOI 10.1126/science.1086271
   MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716
   Mostafaie N, 2009, MOL CARCINOGEN, V48, P642, DOI 10.1002/mc.20510
   Nakamura TJ, 2008, AM J PHYSIOL-ENDOC M, V295, pE1025, DOI 10.1152/ajpendo.90392.2008
   Nakamura TJ, 2001, NEUROSCI RES, V41, P251, DOI 10.1016/S0168-0102(01)00285-1
   Navara KJ, 2007, J PINEAL RES, V43, P215, DOI 10.1111/j.1600-079X.2007.00473.x
   Oster H, 2006, GENES BRAIN BEHAV, V5, P73, DOI 10.1111/j.1601-183X.2006.00226.x
   Parkinson H, 2009, NUCLEIC ACIDS RES, V37, pD868, DOI 10.1093/nar/gkn889
   Perry JK, 2008, TRENDS ENDOCRIN MET, V19, P74, DOI 10.1016/j.tem.2007.10.003
   Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647
   Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965
   RUDER AM, 1989, CANCER-AM CANCER SOC, V64, P196, DOI 10.1002/1097-0142(19890701)64:1<196::AID-CNCR2820640134>3.0.CO;2-3
   Sancar A, 2000, ANNU REV BIOCHEM, V69, P31, DOI 10.1146/annurev.biochem.69.1.31
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Stevens RG, 2007, ENVIRON HEALTH PERSP, V115, P1357, DOI 10.1289/ehp.10200
   Storch KF, 2002, NATURE, V417, P78, DOI 10.1038/nature744
   Straif K, 2007, LANCET ONCOL, V8, P1065, DOI 10.1016/S1470-2045(07)70373-X
   Ünsal-Kaçmaz K, 2005, MOL CELL BIOL, V25, P3109, DOI 10.1128/MCB.25.8.3109-3116.2005
   van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323
   Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114
   Widschwendter M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002656
   Yang MY, 2006, CANCER SCI, V97, P1298, DOI 10.1111/j.1349-7006.2006.00331.x
   Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576
   Yu WJ, 2002, BIOCHEM BIOPH RES CO, V290, P933, DOI 10.1006/bbrc.2001.6300
   Zheng T, 2000, AM J EPIDEMIOL, V152, P50, DOI 10.1093/aje/152.1.50
   Zheng TZ, 2000, CANCER EPIDEM BIOMAR, V9, P167
   Zhu Y, 2005, CANCER EPIDEM BIOMAR, V14, P268
   Zhu Y, 2008, BREAST CANCER RES TR, V107, P421, DOI 10.1007/s10549-007-9565-0
NR 46
TC 83
Z9 94
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD APR
PY 2010
VL 3
IS 4
BP 539
EP 548
DI 10.1158/1940-6207.CAPR-09-0127
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 577ZS
UT WOS:000276263600019
PM 20233903
OA Green Accepted, Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Zhang, YW
   Song, HZ
   Miao, YF
   Wang, R
   Chen, LB
AF Zhang, Youwei
   Song, Haizhu
   Miao, Yufeng
   Wang, Rui
   Chen, Longbang
TI Frequent transcriptional inactivation of Kallikrein 10 gene by CpG
   island hypermethylation in non-small cell lung cancer
SO CANCER SCIENCE
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; GASTRIC-CANCER; BREAST-CANCER; PROMOTER
   HYPERMETHYLATION; COLORECTAL-CANCER; SERINE-PROTEASE; DOWN-REGULATION;
   EXPRESSION; KLK10; DNA
AB The role of Kallikrein 10 gene (KLK10) in non-small cell lung cancer (NSCLC) remains largely unknown. We determined the frequency and functional significance of KLK10 hypermethylation in NSCLC. The mRNA expression and methylation status of KLK10 in 78 pairs NSCLC specimens was explored. The biological effects of KLK10 were analyzed by transfection. The results showed that, KLK10 was significantly downregulated in NSCLC (57.7%, 45/78) as compared to non-cancer samples (P = 0.010). CpG island hypermethylation of KLK10 was detected in 46.2% (36/78) NSCLC tissues and was closely correlated with loss of transcript (P < 0.001). KLK10 methylation was associated with advanced stage (P = 0.013) and lymph metastasis (P = 0.015). Furthermore, demethylation treatment restored the expression of KLK10 in two lung adencarcinoma cell lines (A549, SPC-A1). Forced expression of KLK10 in A549 and SPC-A1 remarkably suppressed cells proliferation, migration in vitro and oncogenicity in vivo. Additionally, methylated KLK10 was detected in 38.7% (30/78) of plasma samples from cancer patients but rare in cancer-free controls (P < 0.001). In conclusion, KLK10 acts as a functional tumor suppressor gene in NSCLC, epigenetic inactivation of KLK10 is a common event contributing to NSCLC pathogenesis and may be used as a potential biomarker. (Cancer Sci 2010; 101: 934-940)
C1 [Zhang, Youwei; Song, Haizhu; Miao, Yufeng; Wang, Rui; Chen, Longbang] Nanjing Univ, Dept Med Oncol, Jinling Hosp, Sch Med, Nanjing 210008, Peoples R China.
C3 Nanjing University
RP Chen, LB (通讯作者)，Nanjing Univ, Dept Med Oncol, Jinling Hosp, Sch Med, Nanjing 210008, Peoples R China.
EM chenlongbang@yeah.net
RI Wang, Rui/AAP-7243-2021; miao, yufeng/GXH-5812-2022
FU Departments of Cardiothoracic Surgery of Jinling Hospital
FX Our study would not have been possible without the participation of the
   patients and healthy donors. The valuable help from Departments of
   Cardiothoracic Surgery of Jinling Hospital is great granted.
CR Anglim PP, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-81
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Belinsky SA, 2005, CARCINOGENESIS, V26, P1481, DOI 10.1093/carcin/bgi020
   Borgoño CA, 2004, NAT REV CANCER, V4, P876, DOI 10.1038/nrc1474
   Cheng C, 2009, CANCER SCI, V100, P303, DOI 10.1111/j.1349-7006.2008.01021.x
   Diamandis EP, 2000, TRENDS ENDOCRIN MET, V11, P54, DOI 10.1016/S1043-2760(99)00225-8
   Feng B, 2006, J GASTROEN HEPATOL, V21, P1596, DOI 10.1111/j.1440-1746.2006.04228.x
   Goyal J, 1998, CANCER RES, V58, P4782
   Hsu HS, 2007, CANCER-AM CANCER SOC, V110, P2019, DOI 10.1002/cncr.23001
   Huang W, 2008, WORLD J GASTROENTERO, V14, P5810, DOI 10.3748/wjg.14.5810
   Huang W, 2007, CANCER LETT, V251, P78, DOI 10.1016/j.canlet.2006.11.006
   Jahr S, 2001, CANCER RES, V61, P1659
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Kioulafa M, 2009, ANN ONCOL, V20, P1020, DOI 10.1093/annonc/mdn733
   Li B, 2001, CANCER RES, V61, P8014
   Liu XL, 1996, CANCER RES, V56, P3371
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu CY, 2009, GENE CHROMOSOME CANC, V48, P1057, DOI 10.1002/gcc.20708
   Luo LY, 2003, CLIN CHIM ACTA, V337, P115, DOI 10.1016/j.cccn.2003.07.008
   Luo LY, 2001, BRIT J CANCER, V85, P220, DOI 10.1054/bjoc.2001.1870
   Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2
   Pampalakis G, 2009, CANCER RES, V69, P3779, DOI 10.1158/0008-5472.CAN-08-1976
   Petraki CD, 2002, J HISTOCHEM CYTOCHEM, V50, P1247, DOI 10.1177/002215540205000912
   Pettus JR, 2009, HISTOL HISTOPATHOL, V24, P197, DOI 10.14670/HH-24.197
   Planque C, 2008, CLIN CANCER RES, V14, P1355, DOI 10.1158/1078-0432.CCR-07-4117
   Planque C, 2006, BIOL CHEM, V387, P783, DOI 10.1515/BC.2006.098
   Roman-Gomez J, 2004, LEUKEMIA, V18, P362, DOI 10.1038/sj.leu.2403223
   Rückert F, 2008, BRIT J CANCER, V99, P1484, DOI 10.1038/sj.bjc.6604717
   Santin AD, 2006, AM J OBSTET GYNECOL, V194, P1296, DOI 10.1016/j.ajog.2005.10.794
   Shvartsman HS, 2003, GYNECOL ONCOL, V90, P44, DOI 10.1016/S0090-8258(03)00257-9
   Sidiropoulos M, 2005, TUMOR BIOL, V26, P324, DOI 10.1159/000089290
   Sotiropoulou G, 2009, J BIOL CHEM, V284, P32989, DOI 10.1074/jbc.R109.027946
   Talieri M, 2009, BRIT J CANCER, V100, P1659, DOI 10.1038/sj.bjc.6605033
   Wang YC, 2007, LUNG CANCER, V56, P289, DOI 10.1016/j.lungcan.2006.12.007
   Yanagawa N, 2003, CANCER SCI, V94, P589, DOI 10.1111/j.1349-7006.2003.tb01487.x
NR 35
TC 34
Z9 39
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1349-7006
J9 CANCER SCI
JI Cancer Sci.
PD APR
PY 2010
VL 101
IS 4
BP 934
EP 940
DI 10.1111/j.1349-7006.2010.01486.x
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 571CK
UT WOS:000275728200016
PM 20180809
OA Bronze
DA 2025-01-12
ER

PT J
AU Ho, CM
   Lai, HC
   Huang, SH
   Chien, TY
   Lin, MC
   Chang, SF
AF Ho, Chih-Ming
   Lai, Hung-Cheng
   Huang, Shih-Hung
   Chien, Tsai-Yen
   Lin, Ming-Chieh
   Chang, Shwu-Fen
TI Promoter methylation of sFRP5 in patients with ovarian clear cell
   adenocarcinoma
SO EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
DE MS-PCR; ovarian clear cell adenocarcinoma; promoter methylation
ID WNT ANTAGONIST SFRP1; HISTOLOGIC-TYPE; EXPRESSION; CARCINOMA; GENE;
   HYPERMETHYLATION; CHEMOTHERAPY; PROGRESSION; SURVIVAL; MARKER
AB P>Background
   Specific tumour suppressor genes with promoter methylation in ovarian clear cell adenocarcinoma (OCCA) can be one important epigenetic mark distinguishing OCCA from ovarian serous adenocarcinoma (OSA), benign endometriotic cysts and normal ovarian epitheliums.
   Materials and methods
   Five OCCA cell lines, 63 cancer tissues (48 OCCA and 15 OSA), 10 benign endometriotic cysts and five normal ovarian epitheliums were analysed by methylation-specific PCR using pooled DNAs to determine the methylation status of the promoter of the target genes, including genes for secreted frizzled-related proteins (sFRP1 to 5), adenomatous polyposis coli (APC), retinoblastoma protein 1 (Rb1), breast cancer 1 gene (BRCA1), p14ARF, p15INK4b, p16INK4a and survivin. Methylation frequencies of identified targets were further analysed with individual DNA samples.
   Results
   The sFRP5 promoter was significantly methylated in all OCCA cell lines, with 64 center dot 6% in OCCA tissues compared with 13 center dot 3% in OSA, and 0% in benign endometriotic cysts and normal ovarian epitheliums (P < 0 center dot 0001). With a median follow-up of 44 months, the expected 5-year overall survival (OS) for patients with methylated sFRP5 promoter were significantly worse than for those with unmethylated sFRP5 (52% vs. 88%, P = 0 center dot 03). After adjusting for age, stage, and residual disease after primary surgery, patients with unmethylated sFRP5 promoter had an independent good prognostic factor in OS (P = 0 center dot 017).
   Conclusion
   The high percentage of promoter methylation in the sFRP5 gene in OCCA indicates its importance in the development of OCCA and is a potential useful marker for prognoses and target for treatment of OCCA.
C1 [Chang, Shwu-Fen] Taipei Med Univ, Grad Inst Med Sci, Taipei 110, Taiwan.
   [Ho, Chih-Ming; Huang, Shih-Hung; Chien, Tsai-Yen] Cathay Gen Hosp, Taipei, Taiwan.
   [Ho, Chih-Ming] Fu Jen Catholic Univ, Hsinchuang, Taipei Hsien, Taiwan.
   [Lai, Hung-Cheng] Triserv Gen Hosp, Taipei, Taiwan.
   [Lin, Ming-Chieh] Natl Taiwan Univ Hosp, Taipei, Taiwan.
C3 Taipei Medical University; Cathay General Hospital; Fu Jen Catholic
   University; Tri-Service General Hospital; National Taiwan University;
   National Taiwan University Hospital
RP Chang, SF (通讯作者)，Taipei Med Univ, Grad Inst Med Sci, 250 Wu Hsing St, Taipei 110, Taiwan.
EM cmbsfc21@tmu.edu.tw
RI Lai, Hung/F-6426-2012
FU National Science Council, Taiwan [93WHK0705006, NSC 94-2314-B-281-005,
   NSC 96-2320-B-038-028]; Cathay General Hospital, Taipei, Taiwan
   [93CGH-TMU-11, 95CGH-TMU-05, 97CGH-TMU-1, 98CGH-TMU-09-2]
FX This work has been supported by a research grant from the National
   Science Council, Taiwan (93WHK0705006; NSC 94-2314-B-281-005; NSC
   96-2320-B-038-028) and research funds from Cathay General Hospital,
   Taipei, Taiwan (93CGH-TMU-11; 95CGH-TMU-05; 97CGH-TMU-1;
   98CGH-TMU-09-2).
CR Bovolenta P, 2006, DEVELOPMENT, V133, P4399, DOI 10.1242/dev.02592
   Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Gray JW, 2003, GYNECOL ONCOL, V88, pS16, DOI 10.1006/gyno.2002.6677
   Gumz ML, 2007, CLIN CANCER RES, V13, P4740, DOI 10.1158/1078-0432.CCR-07-0143
   Ho CM, 2009, GYNECOL ONCOL, V112, P307, DOI 10.1016/j.ygyno.2008.09.040
   Ho CM, 2004, GYNECOL ONCOL, V94, P197, DOI 10.1016/j.ygyno.2004.04.004
   Ho CM, 2003, GYNECOL ONCOL, V88, P394, DOI 10.1016/S0090-8258(02)00156-7
   Ibanez de Caceres I, 2004, CANCER RES, V64, P6476
   Kaneuchi M, 2005, CANCER-AM CANCER SOC, V104, P1924, DOI 10.1002/cncr.21397
   KENNEDY AW, 1989, GYNECOL ONCOL, V32, P342, DOI 10.1016/0090-8258(89)90637-9
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Okada S, 2002, JPN J CANCER RES, V93, P798, DOI 10.1111/j.1349-7006.2002.tb01322.x
   Qi J, 2006, WORLD J GASTROENTERO, V12, P7113, DOI 10.3748/wjg.v12.i44.7113
   Serov SF., 1973, INT CLASSIFICATION S, P37
   Shedden KA, 2005, CLIN CANCER RES, V11, P2123, DOI 10.1158/1078-0432.CCR-04-2061
   Shih YL, 2006, CANCER, V107, P579, DOI 10.1002/cncr.22023
   Shimizu M, 1999, CANCER, V85, P669, DOI 10.1002/(SICI)1097-0142(19990201)85:3<669::AID-CNCR17>3.0.CO;2-F
   Stoehr R, 2004, LAB INVEST, V84, P465, DOI 10.1038/labinvest.3700068
   Su HY, 2009, INT J CANCER, V124, P387, DOI 10.1002/ijc.23957
   Sugiyama T, 2000, CANCER, V88, P2584, DOI 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5
   Takada T, 2004, CANCER SCI, V95, P741, DOI 10.1111/j.1349-7006.2004.tb03255.x
   Tsuchiya A, 2003, AM J PATHOL, V163, P2503, DOI 10.1016/S0002-9440(10)63605-X
   Wu R, 2001, CANCER RES, V61, P8247
   Yoshida H, 2001, INT J ONCOL, V19, P537
NR 26
TC 20
Z9 22
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2972
EI 1365-2362
J9 EUR J CLIN INVEST
JI Eur. J. Clin. Invest.
PD APR
PY 2010
VL 40
IS 4
BP 310
EP 318
DI 10.1111/j.1365-2362.2010.02266.x
PG 9
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA 571CO
UT WOS:000275728900005
PM 20486992
OA Bronze
DA 2025-01-12
ER

PT J
AU Zhou, XL
   Yang, XY
   Popescu, NC
AF Zhou, Xiaoling
   Yang, Xu-Yu
   Popescu, Nicholas C.
TI Synergistic antineoplastic effect of DLC1 tumor suppressor protein and
   histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA),
   on prostate and liver cancer cells: Perspectives for therapeutics
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE DLC1; tumor suppressor gene; SAHA; apoptosis; cell proliferation;
   tumorigenicity; prostate cancer cells; liver cancer cells
ID HUMAN BREAST-CANCER; PROMOTER HYPERMETHYLATION;
   HEPATOCELLULAR-CARCINOMA; MULTIPLE-MYELOMA; IN-VIVO; GENE; THERAPY;
   TUMORIGENICITY; EXPRESSION; GROWTH
AB Inactivation of tumor suppressor genes is a major contributing alteration in the initiation or progression of cancer. The human tumor suppressor gene DLC1 (deleted in liver cancer 1) is frequently downregulated or silenced in multiple cancers, predominantly by epigenetic mechanisms. With the Current considerable interest and progress in epigenetic therapy, a number of promising antineoplastic agents, particularly histone deacetylase (HDAC) inhibitors, have been developed and Used Successfully in clinical trials. Both DLC1 and HDAC inhibitors exert antineoplastic functions, and their combined action Could be exploited for a more effective cancer therapy. To evaluate the potential benefits of this approach, we examined the antineoplastic effects of adenoviral (Ad)-DLC1-mediated transduction and exposure to suberoylanilide hydroxamic acid (SAHA), a powerful HDAC inhibitor, in two human cancer cell lines that lack intrinsic DLC1 expression, 22Rv1 prostate cancer cells and 7703K human hepatocellular carcinoma cells. Consistent with the oncosuppressive function of DLC1 in several cancers. including prostate and liver cancer. transduction of 22Rv1 and 7703K cells with all Ad-DLC1 expression vector resulted in alterations of cell morphology, induction of apoptosis, and inhibition of cell proliferation, migration, and anchorage-independent growth. A low concentration of SAHA (5 IN) efficiently restored the expression of DLC1 in 22Rv1 cells that lack DLC1 expression due to historic deacetylation but had a minimal effect in 7703K cells in which silencing of the DLC1 gene is due mainly to promoter hypermethylation. Regardless of the epigenetic mechanism of DLC1 inactivation, SAHA treatment of DLC1-transduced cells had a synergistic inhibitory effect on tumor, cell proliferation and tumorigenesis in both cell lines. In 22Rv1 cells, this combination regimen nearly abolished the formation of colonies in semisolid media as a measure of tumorigenicity in vitro. Current in vitro results validate this protocol as a potentially new therapeutic option in certain cancers.
C1 [Zhou, Xiaoling; Yang, Xu-Yu; Popescu, Nicholas C.] NCI, Expt Carcinogenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI)
RP Popescu, NC (通讯作者)，NCI, Expt Carcinogenesis Lab, Ctr Canc Res, NIH, 37 Convent Dr,MSC 4262, Bethesda, MD 20892 USA.
EM popescun@mail.nih.gov
RI yang, xuyu/D-1414-2012
FU National Cancer Institute, NIH
FX This work was Supported by the Intramural Research Program of the
   National Cancer Institute, NIH. We Would like to thank Drs Yung-Jue Bang
   and Tai Young Kim for providing the DLC1 promotor-luciferase construct
   and Dr Victoria Richon for helpful suggestions.
CR Batty N, 2009, CANCER LETT, V280, P192, DOI 10.1016/j.canlet.2009.03.013
   BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204
   Botrugno OA, 2009, CANCER LETT, V280, P134, DOI 10.1016/j.canlet.2009.02.027
   Butler LM, 2000, CANCER RES, V60, P5165
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Carew JS, 2008, CANCER LETT, V269, P7, DOI 10.1016/j.canlet.2008.03.037
   Cheng JC, 2004, CANCER CELL, V6, P151, DOI 10.1016/j.ccr.2004.06.023
   Durkin ME, 2007, J CELL MOL MED, V11, P1185, DOI 10.1111/j.1582-4934.2007.00098.x
   Goodison S, 2005, CANCER RES, V65, P6042, DOI 10.1158/0008-5472.CAN-04-3043
   Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080
   Guan M, 2008, CANCER GENE THER, V15, P371, DOI 10.1038/cgt.2008.13
   Guan M, 2006, CLIN CANCER RES, V12, P1412, DOI 10.1158/1078-0432.CCR-05-1906
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Herman JG, 1999, SEMIN CANCER BIOL, V9, P359, DOI 10.1006/scbi.1999.0138
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6
   Kim TY, 2008, EXP MOL MED, V40, P639, DOI 10.3858/emm.2008.40.6.639
   Kim TY, 2003, ONCOGENE, V22, P3943, DOI 10.1038/sj.onc.1206573
   Lahoz A, 2008, GENE DEV, V22, P1724, DOI 10.1101/gad.1691408
   Liao YC, 2008, CANCER RES, V68, P7718, DOI 10.1158/0008-5472.CAN-08-2042
   Maass N, 2002, BIOCHEM BIOPH RES CO, V297, P125, DOI 10.1016/S0006-291X(02)02136-8
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Nolan L, 2008, BRIT J CANCER, V99, P689, DOI 10.1038/sj.bjc.6604557
   Palii SS, 2007, CRIT REV EUKAR GENE, V17, P295
   PALMIERI D, CLIN CANC R IN PRESS
   Pihur V, 2008, GENOMICS, V92, P400, DOI 10.1016/j.ygeno.2008.05.003
   Richon VM, 2009, CANCER LETT, V280, P201, DOI 10.1016/j.canlet.2009.01.002
   Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725
   Song YF, 2006, J CLIN PATHOL, V59, P947, DOI 10.1136/jcp.2005.031377
   Ullmannova-Benson V, 2009, LEUKEMIA, V23, P383, DOI 10.1038/leu.2008.285
   Xu WS, 2006, P NATL ACAD SCI USA, V103, P15540, DOI 10.1073/pnas.0607518103
   Xue W, 2008, GENE DEV, V22, P1439, DOI 10.1101/gad.1672608
   Yoo CB, 2004, BIOCHEM SOC T, V32, P910, DOI 10.1042/BST0320910
   Yuan BZ, 1998, CANCER RES, V58, P2196
   Yuan BZ, 2003, CANCER GENET CYTOGEN, V140, P113, DOI 10.1016/S0165-4608(02)00674-X
   Yuan BZ, 2004, ONCOGENE, V23, P1405, DOI 10.1038/sj.onc.1207291
   Yuan BZ, 2003, ONCOGENE, V22, P445, DOI 10.1038/sj.onc.1206064
   Zhou XL, 2004, ONCOGENE, V23, P1308, DOI 10.1038/sj.onc.1207246
NR 39
TC 12
Z9 13
U1 0
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD APR
PY 2010
VL 36
IS 4
BP 999
EP 1005
DI 10.3892/ijo_00000580
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 571ZD
UT WOS:000275794300031
PM 20198346
DA 2025-01-12
ER

PT J
AU Archer, KJ
   Mas, VR
   Maluf, DG
   Fisher, RA
AF Archer, Kellie J.
   Mas, Valeria R.
   Maluf, Daniel G.
   Fisher, Robert A.
TI High-throughput assessment of CpG site methylation for distinguishing
   between HCV-cirrhosis and HCV-associated hepatocellular carcinoma
SO MOLECULAR GENETICS AND GENOMICS
LA English
DT Article
DE Liver neoplasms; Gene silencing; Epigenesis genetic; Gene expression;
   Gene expression profiling
ID GENE-EXPRESSION; DNA METHYLATION; PROMOTER METHYLATION; ABERRANT
   METHYLATION; BREAST-CANCER; CHRONIC HEPATITIS; PREDICT SURVIVAL;
   SIGNATURE; TUMOR; LIVER
AB Methylation of promoter CpG islands has been associated with gene silencing and demonstrated to lead to chromosomal instability. Therefore, some postulate that aberrantly methylated CpG regions may be important biomarkers indicative of cancer development. In this study we used the Illumina GoldenGate Methylation BeadArray Cancer Panel I for simultaneously profiling methylation of 1,505 CpG sites in order to identify methylation differences in 76 liver tissues ranging from normal to pre-neoplastic and neoplastic states. CpG sites for ESR1, GSTM2, and MME were significantly differentially methylated when comparing the pre-neoplastic tissues from patients with concomitant hepatocellular carcinoma (HCC) to the pre-neoplastic tissues from patients without HCC. When comparing paired HCC tissues to their corresponding pre-neoplastic non-tumorous tissues, eight CpG sites, including one CpG site that was hypermethylated (APC) and seven (NOTCH4, EMR3, HDAC9, DCL1, HLA-DOA, HLA-DPA1, and ERN1) that were hypomethylated in HCC, were identified. Our study demonstrates that high-throughput methylation technologies may be used to identify differentially methylated CpG sites that may prove to be important molecular events involved in carcinogenesis.
C1 [Archer, Kellie J.] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA 23298 USA.
   [Archer, Kellie J.; Mas, Valeria R.; Maluf, Daniel G.; Fisher, Robert A.] Virginia Commonwealth Univ, Dept Surg, Div Transplantat, Richmond, VA 23298 USA.
   [Mas, Valeria R.] Virginia Commonwealth Univ, Dept Pathol, Richmond, VA 23298 USA.
C3 Virginia Commonwealth University; Virginia Commonwealth University;
   Virginia Commonwealth University
RP Archer, KJ (通讯作者)，Virginia Commonwealth Univ, Dept Biostat, 730 E Broad St,POB 980032, Richmond, VA 23298 USA.
EM kjarcher@vcu.edu
RI Mas, Valeria/AEN-9503-2022; Fisher, Robert/H-6779-2019; Maluf,
   Daniel/KAM-2337-2024
OI Archer, Kellie/0000-0003-1555-5781
FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
   [RO1DK069859]
FX This project was supported by a National Institute of Diabetes and
   Digestive and Kidney Diseases (NIDDK) grant, RO1DK069859.
CR [Anonymous], 2007, R LANG ENV STAT COMP
   Barrett T, 2005, NUCLEIC ACIDS RES, V33, pD562
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Baylin SB, 2000, J NATL CANCER I, V92, P1460, DOI 10.1093/jnci/92.18.1460
   Beale G, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-200
   Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733
   Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706
   Bibikova M, 2006, GENOME RES, V16, P1075, DOI 10.1101/gr.5319906
   But DYK, 2008, WORLD J GASTROENTERO, V14, P1652, DOI 10.3748/wjg.14.1652
   Calvisi DF, 2007, J CLIN INVEST, V117, P2713, DOI 10.1172/JCI31457
   Csepregi A, 2008, J CANCER RES CLIN, V134, P579, DOI 10.1007/s00432-007-0321-y
   Dunning MJ, 2007, BIOINFORMATICS, V23, P2183, DOI 10.1093/bioinformatics/btm311
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Fan JB, 2003, COLD SPRING HARB SYM, V68, P69, DOI 10.1101/sqb.2003.68.69
   Fox BP, 2006, BIOCHEM BIOPH RES CO, V342, P1263, DOI 10.1016/j.bbrc.2006.02.099
   Gao W, 2008, CARCINOGENESIS, V29, P1901, DOI 10.1093/carcin/bgn170
   Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531
   Iizuka N, 2004, LANCET, V364, P1837, DOI 10.1016/S0140-6736(04)17455-2
   Itano O, 2000, ONCOGENE, V19, P1676, DOI 10.1038/sj.onc.1203459
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Kondo Y, 2000, HEPATOLOGY, V32, P970, DOI 10.1053/jhep.2000.19797
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Llovet JM, 2006, GASTROENTEROLOGY, V131, P1758, DOI 10.1053/j.gastro.2006.09.014
   Mas VR, 2006, MOL MED, V12, P97, DOI 10.2119/2006-00032.Mas
   McCaughan GW, 2002, INTERN MED J, V32, P394, DOI 10.1046/j.1445-5994.2002.00227.x
   Moinzadeh P, 2005, BRIT J CANCER, V92, P935, DOI 10.1038/sj.bjc.6602448
   Nam SW, 2005, HEPATOLOGY, V42, P809, DOI 10.1002/hep.20878
   Nishida N, 2008, HEPATOLOGY, V47, P908, DOI 10.1002/hep.22110
   Poon TCW, 2006, GASTROENTEROLOGY, V131, P1262, DOI 10.1053/j.gastro.2006.08.014
   Qiu GH, 2007, J HEPATOL, V46, P655, DOI 10.1016/j.jhep.2006.11.012
   Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914
   Sherman Morris, 2007, Clin Liver Dis, V11, P817, DOI 10.1016/j.cld.2007.08.011
   Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100
   Trevisani F, 2007, AM J GASTROENTEROL, V102, P2448, DOI 10.1111/j.1572-0241.2007.01395.x
   Trinh BN, 2001, METHODS, V25, P456, DOI 10.1006/meth.2001.1268
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van 't Veer LJ, 2003, BREAST CANCER RES, V5, P57, DOI 10.1186/bcr562
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Wong IHN, 2000, CLIN CHEM, V46, P1420
   Wong IHN, 2000, CLIN CANCER RES, V6, P3516
   Wong W, 1999, PC WEEK, V16, P73
   Wurmbach E, 2007, HEPATOLOGY, V45, P938, DOI 10.1002/hep.21622
   Yu J, 2003, CELL RES, V13, P319, DOI 10.1038/sj.cr.7290177
   Yuan GC, 2005, SCIENCE, V309, P626, DOI 10.1126/science.1112178
   Zhang JC, 2006, MOL CARCINOGEN, V45, P530, DOI 10.1002/mc.20188
NR 46
TC 50
Z9 60
U1 1
U2 5
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1617-4615
EI 1617-4623
J9 MOL GENET GENOMICS
JI Mol. Genet. Genomics
PD APR
PY 2010
VL 283
IS 4
BP 341
EP 349
DI 10.1007/s00438-010-0522-y
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 570UG
UT WOS:000275703000004
PM 20165882
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Zhang, W
   Zeng, X
   Briggs, KJ
   Beaty, R
   Simons, B
   Yen, RWC
   Tyler, MA
   Tsai, HC
   Ye, Y
   Gesell, GS
   Herman, JG
   Baylin, SB
   Watkins, DN
AF Zhang, W.
   Zeng, X.
   Briggs, K. J.
   Beaty, R.
   Simons, B.
   Yen, R-W Chiu
   Tyler, M. A.
   Tsai, H-C
   Ye, Y.
   Gesell, G. S.
   Herman, J. G.
   Baylin, S. B.
   Watkins, D. N.
TI A potential tumor suppressor role for Hic1 in breast cancer through
   transcriptional repression of <i>ephrin</i>-<i>A1</i>
SO ONCOGENE
LA English
DT Article
DE Hic1; ephrin-A1; EphA2; EphA4
ID MILLER-DIEKER-SYNDROME; EPHA2 RECEPTOR; CELL-MIGRATION;
   COLORECTAL-CANCER; GENE; EXPRESSION; LIGAND; MICE;
   HYPERMETHYLATED-IN-CANCER-1; PROGRESSION
AB The tumor suppressor gene hypermethylated in cancer 1 (HIC1), which encodes a transcriptional repressor, is epigenetically inactivated in various human cancers. In this study, we show that HIC1 is a direct transcriptional repressor of the gene encoding ephrin-A1, a cell surface ligand implicated in the pathogenesis of epithelial cancers. We also show that mouse embryos lacking both Hic1 alleles manifest developmental defects spatially associated with the misexpression of ephrin-A1, and that overexpression of ephrin-A1 is a feature of tumors arising in Hic1 heterozygous mice in which the remaining wild-type allele is epigenetically silenced. In breast cancer, we find that ephrin-A1 expression is common in vivo, but that in cell culture, expression of the EphA receptors is predominant. Restoration of HIC1 function in breast cancer cells leads to a reduction in tumor growth in vivo, an effect that can be partially rescued by co-overexpression of ephrin-A1. Interestingly, overexpression of ephrin-A1 in vitro triggers downregulation of EphA2 and EphA4 levels, resulting in an expression pattern similar to that seen in vivo. We conclude that Hic1 spatially restricts ephrin-A1 expression in development, and that upregulated expression of ephrin-A1 resulting from epigenetic silencing of HIC1 in cancer cells may be an important mechanism in epithelial malignancy. Oncogene (2010) 29, 2467-2476; doi:10.1038/onc.2010.12; published online 15 February 2010
C1 [Zhang, W.; Zeng, X.; Briggs, K. J.; Beaty, R.; Simons, B.; Yen, R-W Chiu; Tyler, M. A.; Tsai, H-C; Ye, Y.; Gesell, G. S.; Herman, J. G.; Baylin, S. B.; Watkins, D. N.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA.
   [Zhang, W.; Zeng, X.; Briggs, K. J.; Beaty, R.; Simons, B.; Yen, R-W Chiu; Tyler, M. A.; Tsai, H-C; Ye, Y.; Gesell, G. S.; Herman, J. G.; Baylin, S. B.; Watkins, D. N.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21231 USA.
   [Zeng, X.; Briggs, K. J.; Tsai, H-C] Johns Hopkins Univ, Sch Med, Grad Training Program Cellular & Mol Med, Baltimore, MD 21231 USA.
   [Watkins, D. N.] Monash Univ, Ctr Canc Res, Monash Inst Med Res, Clayton, Vic, Australia.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins University; Monash University; Monash
   Institute of Medical Research
RP Watkins, DN (通讯作者)，Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, 1650 Orleans St,CRB I 541, Baltimore, MD 21231 USA.
EM sbaylin@jhmi.edu; neil.watkins@med.monash.edu.au
RI Watkins, David/I-6113-2013; zhang, wei/A-7015-2011; Tsai,
   Hsing-Chen/AAE-7530-2021; Simons, Brian/G-7352-2015
OI Tsai, Hsing-Chen/0000-0002-7057-9084; Simons, Brian/0000-0003-0644-211X;
   Watkins, Neil/0000-0001-8218-4920
FU National Cancer Institute [R01 CA43318]; American Cancer Society
FX This work was supported by the National Cancer Institute Grant R01
   CA43318 (SB Baylin) and an American Cancer Society Postdoctoral
   Fellowship (W Zhang). We thank Craig D Peacock, Leslie Meszler and
   Lillian Dasko-Vincent for technical assistance, Leander Van Neste for
   biostatistical support and Kathy Bender for the preparation and
   submission of this paper.
CR Arvanitis D, 2008, GENE DEV, V22, P416, DOI 10.1101/gad.1630408
   Brantley-Sieders DM, 2006, CANCER RES, V66, P10315, DOI 10.1158/0008-5472.CAN-06-1560
   Brantley-Sieders DM, 2004, J CELL SCI, V117, P2037, DOI 10.1242/jcs.01061
   Briggs KJ, 2008, GENE DEV, V22, P770, DOI 10.1101/gad.1640908
   Carter MG, 2000, HUM MOL GENET, V9, P413, DOI 10.1093/hmg/9.3.413
   Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011
   Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077
   Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030
   Chong SS, 1997, HUM MOL GENET, V6, P147, DOI 10.1093/hmg/6.2.147
   Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831
   Deltour S, 2002, MOL CELL BIOL, V22, P4890, DOI 10.1128/MCB.22.13.4890-4901.2002
   Deltour S, 1998, BBA-GENE STRUCT EXPR, V1443, P230, DOI 10.1016/S0167-4781(98)00219-X
   Easty DJ, 1999, INT J CANCER, V84, P494, DOI 10.1002/(SICI)1097-0215(19991022)84:5<494::AID-IJC8>3.0.CO;2-O
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976
   Guo H, 2006, CANCER RES, V66, P7050, DOI 10.1158/0008-5472.CAN-06-0004
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   Herath NI, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-144
   Hirotsune S, 1997, GENOME RES, V7, P625, DOI 10.1101/gr.7.6.625
   Holder N, 1999, DEVELOPMENT, V126, P2033
   Iida H, 2005, GUT, V54, P843, DOI 10.1136/gut.2004.049486
   Jenal M, 2009, MOL CANCER RES, V7, P916, DOI 10.1158/1541-7786.MCR-08-0359
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1
   Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856
   Macrae M, 2005, CANCER CELL, V8, P111, DOI 10.1016/j.ccr.2005.07.005
   Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604
   Miao H, 2009, CANCER CELL, V16, P9, DOI 10.1016/j.ccr.2009.04.009
   Nakamura R, 2005, CANCER SCI, V96, P42, DOI 10.1111/j.1349-7006.2005.00007.x
   Ogawa K, 2000, ONCOGENE, V19, P6043, DOI 10.1038/sj.onc.1204004
   Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662
   Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011
   Poliakov A, 2004, DEV CELL, V7, P465, DOI 10.1016/j.devcel.2004.09.006
   Potla L, 2002, CANCER LETT, V175, P187, DOI 10.1016/S0304-3835(01)00613-9
   Shi L, 2008, ONCOGENE, V27, P3265, DOI 10.1038/sj.onc.1210992
   Takai N, 2001, ONCOL REP, V8, P567
   Tang XX, 1999, CLIN CANCER RES, V5, P1491
   Van Rechem C, 2009, J BIOL CHEM, V284, P20927, DOI 10.1074/jbc.M109.022350
   WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570
   Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316
   Wykosky J, 2008, ONCOGENE, V27, P7260, DOI 10.1038/onc.2008.328
   Wykosky J, 2008, MOL CANCER RES, V6, P1795, DOI 10.1158/1541-7786.MCR-08-0244
   Zhang W, 2008, CANCER RES, V68, P2764, DOI 10.1158/0008-5472.CAN-07-6349
NR 44
TC 36
Z9 44
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD APR
PY 2010
VL 29
IS 17
BP 2467
EP 2476
DI 10.1038/onc.2010.12
PG 10
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 589RB
UT WOS:000277169400002
PM 20154726
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Huang, RS
   Dolan, ME
AF Huang, R. Stephanie
   Dolan, M. Eileen
TI Approaches to the discovery of pharmacogenomic markers in oncology:
   2000-2010-2020
SO PHARMACOGENOMICS
LA English
DT Article
DE cancer; chemotherapy; genome-wide association study; pharmacogenomics
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; CISPLATIN-INDUCED CYTOTOXICITY;
   BREAST-CANCER; LUNG-CANCER; GENOME; EXPRESSION; THERAPY; GENES; MAP
AB Pharmacogenomics is emerging as an important component both in facilitating new drug development and in improving the utility of existing chemotherapeutic agents. Both candidate gene and genome-wide approaches have been used to identify genetic markers associated with chemotherapeutic response and/or toxicity. New molecular targeted agents have been designed based on a sophisticated understanding of the molecular alterations defining cancers. Over the next decade, the translation of these findings into clinical practice, as well as functional studies of genetic variants, is likely to take center stage. More comprehensive evaluation of the human genome, including the examination of rare SNPs, copy number variations, tandem repeats and epigenetic effects, will further improve our understanding of the relationship between genetics and drug response.
C1 [Dolan, M. Eileen] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA.
C3 University of Chicago
RP Dolan, ME (通讯作者)，Univ Chicago, Dept Med, Hematol Oncol Sect, 900 E 57th St,Room 7100, Chicago, IL 60637 USA.
EM edolan@medicine.bsd.uchicago.edu
OI Huang, R. Stephanie/0000-0002-9862-0368
FU NIH/NIGMS through the Pharmacogenetics of Anticancer Agents Research
   Group [U01GM61393]; University of Chicago Breast Cancer SPORE [P50
   CA125183]; University of Chicago Cancer Center [P30 CA14599]; NCI [RO1
   CA 136765, R21 CA139278]
FX The authors are supported through the Pharmacogenetics of Anticancer
   Agents Research Group by the NIH/NIGMS grant U01GM61393, University of
   Chicago Breast Cancer SPORE grant P50 CA125183, and Career Development
   Award, University of Chicago Cancer Center Support Grant (#P30 CA14599),
   NCI RO1 CA 136765 and R21 CA139278. The authors have no other relevant
   affiliations or financial involvement with any organization or entity
   with a financial interest in or financial conflict with the subject
   matter or materials discussed in the manuscript apart from those
   disclosed.
CR Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385
   Dolan ME, 2004, CANCER RES, V64, P4353, DOI 10.1158/0008-5472.CAN-04-0340
   Druker BJ, 2008, BLOOD, V112, P4808, DOI 10.1182/blood-2008-07-077958
   Duan S, 2008, AM J HUM GENET, V82, P1101, DOI 10.1016/j.ajhg.2008.03.006
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Goetz MP, 2005, J CLIN ONCOL, V23, P9312, DOI 10.1200/JCO.2005.03.3266
   Holleman A, 2006, BLOOD, V107, P769, DOI 10.1182/blood-2005-07-2930
   Holleman A, 2004, NEW ENGL J MED, V351, P533, DOI 10.1056/NEJMoa033513
   Hoskins JM, 2007, J NATL CANCER I, V99, P1290, DOI 10.1093/jnci/djm115
   Huang RS, 2007, AM J HUM GENET, V81, P427, DOI 10.1086/519850
   Huang YT, 2009, J CLIN ONCOL, V27, P2660, DOI 10.1200/JCO.2008.18.7906
   Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403
   Lane AA, 2009, J CLIN ONCOL, V27, P5459, DOI 10.1200/JCO.2009.22.1291
   LENNARD L, 1990, LANCET, V336, P225, DOI 10.1016/0140-6736(90)91745-V
   McPherson JD, 2001, NATURE, V409, P934, DOI 10.1038/35057157
   Morris SR, 2007, CURR OPIN ONCOL, V19, P547, DOI 10.1097/CCO.0b013e3282f0ada3
   Potti A, 2006, NAT MED, V12, P1294, DOI 10.1038/nm1491
   Ritter CA, 2003, SEMIN ONCOL, V30, P3, DOI 10.1053/sonc.2003.50027
   Thomas RK, 2006, CLIN CANCER RES, V12, p4384S, DOI 10.1158/1078-0432.CCR-06-0098
   Watters JW, 2004, P NATL ACAD SCI USA, V101, P11809, DOI 10.1073/pnas.0404580101
   Weiner LM, 1999, SEMIN ONCOL, V26, P41
   Yang JJ, 2008, BLOOD, V112, P4178, DOI 10.1182/blood-2008-06-165027
   Zhang Y, 2009, CANCER RES, V69, P3795, DOI 10.1158/0008-5472.CAN-08-4596
NR 23
TC 9
Z9 10
U1 0
U2 1
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1462-2416
EI 1744-8042
J9 PHARMACOGENOMICS
JI Pharmacogenomics
PD APR
PY 2010
VL 11
IS 4
SI SI
BP 471
EP 474
DI 10.2217/PGS.10.11
PG 4
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 584RD
UT WOS:000276769300002
PM 20350124
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Huang, YW
   Huang, THM
   Wang, LS
AF Huang, Yi-Wen
   Huang, Tim H. -M.
   Wang, Li-Shu
TI Profiling DNA Methylomes from Microarray to Genome-Scale Sequencing
SO TECHNOLOGY IN CANCER RESEARCH & TREATMENT
LA English
DT Article
DE DNA methylation; Microarray; Next-generation sequencing
ID CPG ISLAND METHYLATION; CYTOSINE METHYLATION; COLORECTAL-CANCER;
   BREAST-CANCER; HUMAN-CELLS; RESOLUTION; MAPS; WIDE; HYPERMETHYLATION;
   DIFFERENTIATION
AB DNA cytosine methylation is a central epigenetic modification which plays critical roles in cellular processes including genome regulation, development and disease. Here, we review current and emerging microarray and next-generation sequencing based technologies that enhance our knowledge of DNA methylation profiling. Each methodology has limitations and their unique applications, and combinations of several modalities may help build the entire methylome. With advances on next-generation sequencing technologies, it is now possible to globally map the DNA cytosine methylation at single-base resolution, providing new insights into the regulation and dynamics of DNA methylation in genomes.
C1 [Huang, Yi-Wen; Huang, Tim H. -M.; Wang, Li-Shu] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
C3 James Cancer Hospital & Solove Research Institute; University System of
   Ohio; Ohio State University
RP Huang, YW (通讯作者)，Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
EM Yi-wen.huang@osumc.edu; Li-shu.wang@osumc.edu
RI Huang, Yi-Wen/H-3989-2019
FU NIH [U54 CA113001, R01 CA148818]
FX The authors thank supports from the NIH grants, U54 CA113001 and R01
   CA148818, and Pearlly Yan and Claire Seguin for critical reading of the
   manuscript.
CR Adorján P, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.5.e21
   Aihara T, 2003, ONCOLOGY-BASEL, V64, P124, DOI 10.1159/000067771
   Ammerpohl O, 2009, BBA-GEN SUBJECTS, V1790, P847, DOI 10.1016/j.bbagen.2009.02.001
   Ansorge WJ, 2009, NEW BIOTECHNOL, V25, P195, DOI 10.1016/j.nbt.2008.12.009
   Ball MP, 2009, NAT BIOTECHNOL, V27, P361, DOI 10.1038/nbt.1533
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Brunner AL, 2009, GENOME RES, V19, P1044, DOI 10.1101/gr.088773.108
   Chang JW, 2008, PHARMACOGENOMICS, V9, P1869, DOI 10.2217/14622416.9.12.1869
   Cokus SJ, 2008, NATURE, V452, P215, DOI 10.1038/nature06745
   Deatherage DE, 2009, METHODS MOL BIOL, V556, P117, DOI 10.1007/978-1-60327-192-9_9
   Deng J, 2009, NAT BIOTECHNOL, V27, P353, DOI 10.1038/nbt.1530
   Down TA, 2008, NAT BIOTECHNOL, V26, P779, DOI 10.1038/nbt1414
   Estécio MRH, 2007, GENOME RES, V17, P1529, DOI 10.1101/gr.6417007
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fukasawa M, 2006, J HUM GENET, V51, P368, DOI 10.1007/s10038-005-0355-4
   Gitan RS, 2002, GENOME RES, V12, P158, DOI 10.1101/gr.202801
   Hatada I, 2002, J HUM GENET, V47, P448, DOI 10.1007/s100380200063
   HOTCHKISS RD, 1948, J BIOL CHEM, V175, P315
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Ibrahim AEK, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl551
   Irizarry RA, 2008, GENOME RES, V18, P780, DOI 10.1101/gr.7301508
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7
   Khulan B, 2006, GENOME RES, V16, P1046, DOI 10.1101/gr.5273806
   Killian JK, 2009, CANCER RES, V69, P758, DOI 10.1158/0008-5472.CAN-08-2984
   Kimura N, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni046
   Kreil DP, 2006, METHOD ENZYMOL, V410, P73, DOI 10.1016/S0076-6879(06)10004-X
   LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0
   Lippman Z, 2004, NATURE, V430, P471, DOI 10.1038/nature02651
   Lister R, 2008, CELL, V133, P523, DOI 10.1016/j.cell.2008.03.029
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Lister R, 2009, GENOME RES, V19, P959, DOI 10.1101/gr.083451.108
   Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107
   Metzker ML, 2010, NAT REV GENET, V11, P31, DOI 10.1038/nrg2626
   Miller MB, 2009, CLIN MICROBIOL REV, V22, P611, DOI 10.1128/CMR.00019-09
   Nouzova M, 2004, J PHARMACOL EXP THER, V311, P968, DOI 10.1124/jpet.104.072488
   Oda M, 2009, NUCLEIC ACIDS RES, V37, P3829, DOI 10.1093/nar/gkp260
   Park PJ, 2009, NAT REV GENET, V10, P669, DOI 10.1038/nrg2641
   Rauch T, 2005, LAB INVEST, V85, P1172, DOI 10.1038/labinvest.3700311
   Rauch T, 2006, CANCER RES, V66, P7939, DOI 10.1158/0008-5472.CAN-06-1888
   Rauch TA, 2009, P NATL ACAD SCI USA, V106, P671, DOI 10.1073/pnas.0812399106
   RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315
   Taylor KH, 2007, CANCER RES, V67, P8511, DOI 10.1158/0008-5472.CAN-07-1016
   Toyota M, 1999, CANCER RES, V59, P2307
   Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598
NR 47
TC 45
Z9 52
U1 0
U2 3
PU ADENINE PRESS
PI SCHENECTADY
PA 2066 CENTRAL AVE, SCHENECTADY, NY 12304 USA
SN 1533-0346
J9 TECHNOL CANCER RES T
JI Technol. Cancer Res. Treat.
PD APR
PY 2010
VL 9
IS 2
BP 139
EP 147
DI 10.1177/153303461000900203
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 576HP
UT WOS:000276135400003
PM 20218736
OA Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Dejeux, E
   Ronneberg, JA
   Solvang, H
   Bukholm, I
   Geisler, S
   Aas, T
   Gut, IG
   Borresen-Dale, AL
   Lonning, PE
   Kristensen, VN
   Tost, J
AF Dejeux, Emelyne
   Ronneberg, Jo Anders
   Solvang, Hiroko
   Bukholm, Ida
   Geisler, Stephanie
   Aas, Turid
   Gut, Ivo G.
   Borresen-Dale, Anne-Lise
   Lonning, Per Eystein
   Kristensen, Vessela N.
   Tost, Joerg
TI DNA methylation profiling in doxorubicin treated primary locally
   advanced breast tumours identifies novel genes associated with survival
   and treatment response
SO MOLECULAR CANCER
LA English
DT Article
ID HORMONE-RECEPTOR STATUS; PROMOTER METHYLATION; DRUG-RESISTANCE; MDR1
   PROMOTER; CANCER; EXPRESSION; PATTERNS; CELL; HYPERMETHYLATION;
   OVEREXPRESSION
AB Background: Breast cancer is the most frequent cancer in women and consists of a heterogeneous collection of diseases with distinct histopathological, genetic and epigenetic characteristics. In this study, we aimed to identify DNA methylation based biomarkers to distinguish patients with locally advanced breast cancer who may benefit from neoadjuvant doxorubicin treatment.
   Results: We investigated quantitatively the methylation patterns in the promoter regions of 14 genes (ABCB1, ATM, BRCA1, CDH3, CDKN2A, CXCR4, ESR1, FBXW7, FOXC1, GSTP1, IGF2, HMLH1, PPP2R2B, and PTEN) in 75 well-described pretreatment samples from locally advanced breast cancer and correlated the results to the available clinical and molecular parameters. Six normal breast tissues were used as controls and 163 unselected breast cancer cases were used to validate associations with histopathological and clinical parameters.
   Aberrant methylation was detected in 9 out of the 14 genes including the discovery of methylation at the FOXC1 promoter. Absence of methylation at the ABCB1 promoter correlated with progressive disease during doxorubicin treatment. Most importantly, the DNA methylation status at the promoters of GSTP1, FOXC1 and ABCB1 correlated with survival, whereby the combination of methylated genes improved the subdivision with respect to the survival of the patients. In multivariate analysis GSTP1 and FOXC1 methylation status proved to be independent prognostic markers associated with survival.
   Conclusions: Quantitative DNA methylation profiling is a powerful tool to identify molecular changes associated with specific phenotypes. Methylation at the ABCB1 or GSTP1 promoter improved overall survival probably due to prolonged availability and activity of the drug in the cell while FOXC1 methylation might be a protective factor against tumour invasiveness. FOXC1 proved to be general prognostic factor, while ABCB1 and GSTP1 might be predictive factors for the response to and efficacy of doxorubicin treatment. Pharmacoepigenetic effects such as the reported associations in this study provide molecular explanations for differential responses to chemotherapy and it might prove valuable to take the methylation status of selected genes into account for patient management and treatment decisions.
C1 [Dejeux, Emelyne; Gut, Ivo G.; Tost, Joerg] CEA, Lab Epigenet, Ctr Natl Genotypage, Inst Genom, Evry, France.
   [Ronneberg, Jo Anders; Borresen-Dale, Anne-Lise; Kristensen, Vessela N.] Univ Hosp Montebello, Rikshosp, Norwegian Radium Hosp, Dept Genet,Inst Canc Res, Oslo, Norway.
   [Ronneberg, Jo Anders; Solvang, Hiroko; Bukholm, Ida; Borresen-Dale, Anne-Lise; Kristensen, Vessela N.] Univ Oslo, Fac Med, N-0316 Oslo, Norway.
   [Solvang, Hiroko] Univ Oslo, Inst Med Stat, N-0316 Oslo, Norway.
   [Bukholm, Ida] Akershus Univ Hosp, Dept Surg, Lorenskog, Norway.
   [Geisler, Stephanie; Lonning, Per Eystein] Haukeland Hosp, Dept Oncol, N-5021 Bergen, Norway.
   [Aas, Turid] Haukeland Hosp, Dept Surg, N-5021 Bergen, Norway.
   [Lonning, Per Eystein] Univ Bergen, Inst Med, Sect Oncol, N-5020 Bergen, Norway.
C3 Universite Paris Saclay; CEA; University of Oslo; National Hospital
   Norway; University of Oslo; University of Oslo; University of Oslo;
   University of Bergen; Haukeland University Hospital; University of
   Bergen; Haukeland University Hospital; University of Bergen
RP Tost, J (通讯作者)，CEA, Lab Epigenet, Ctr Natl Genotypage, Inst Genom, Evry, France.
EM tost@cng.fr
RI Gut, Ivo/ABF-3188-2020; Tost, Jorg/H-7129-2019
OI Tost, Jorg/0000-0002-2683-0817; Lonning, Per Eystein/0000-0002-8890-6303
FU EU [LSHG-CT-2004-512066]; Norwegian Cancer Society [D-03067]; Norwegian
   Research Council [152004/150]; French-Norwegian cooperation program
   Aurora [15842WE]
FX We thank Grethe I. Grenaker Alnaes for performing the TaqMan assays.
   This work was supported by the EU framework 6 integrated project MolPAGE
   (LSHG-CT-2004-512066) (JT, IGG), grant D-03067 from The Norwegian Cancer
   Society (VNK), grant 152004/150 from The Functional Genomics Program
   (FUGE) of the Norwegian Research Council (NFR) (VNK), the
   French-Norwegian cooperation program Aurora grant 15842WE (JAR, JT,
   VNK). JAR is a fellow at the Faculty Division The Norwegian Radium
   Hospital, University of Oslo.
CR Akaike H., 1973, 2 INT S INFORM THEOR, P267, DOI DOI 10.1007/978-1-4612-1694-0_15
   Akhoondi S, 2007, CANCER RES, V67, P9006, DOI 10.1158/0008-5472.CAN-07-1320
   Bergamaschi A, 2006, GENE CHROMOSOME CANC, V45, P1033, DOI 10.1002/gcc.20366
   Bloushtain-Qimron N, 2008, P NATL ACAD SCI USA, V105, P14076, DOI 10.1073/pnas.0805206105
   Chanock SJ, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1637
   Coon JS, 2002, CLIN CANCER RES, V8, P1061
   David GL, 2004, CANCER BIOL THER, V3, P540, DOI 10.4161/cbt.3.6.845
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Esteller M, 1998, CANCER RES, V58, P4515
   Esteller M, 2001, CANCER RES, V61, P3225
   Feng W, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1762
   Fontanière S, 2006, ENDOCR-RELAT CANCER, V13, P1223, DOI 10.1677/erc.1.01294
   García JM, 2004, GENE CHROMOSOME CANC, V41, P117, DOI 10.1002/gcc.20062
   Geisler S, 2001, CANCER RES, V61, P2505
   GILBERT L, 1993, J CLIN ONCOL, V11, P49, DOI 10.1200/JCO.1993.11.1.49
   Harris LN, 2007, CLIN CANCER RES, V13, P1198, DOI 10.1158/1078-0432.CCR-06-1304
   Huang JX, 2003, MODERN PATHOL, V16, P558, DOI 10.1097/01.MP.0000071842.83169.5A
   Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757
   Jain AN, 2001, P NATL ACAD SCI USA, V98, P7952, DOI 10.1073/pnas.151241198
   Johannsdottir HK, 2006, INT J CANCER, V119, P1052, DOI 10.1002/ijc.21934
   Kalinina EV, 2007, B EXP BIOL MED+, V143, P328, DOI 10.1007/s10517-007-0102-2
   Kantharidis P, 1997, CLIN CANCER RES, V3, P2025
   Keen JC, 2004, CANCER BIOL THER, V3, P1304, DOI 10.4161/cbt.3.12.1458
   Korshunova Y, 2008, GENOME RES, V18, P19, DOI 10.1101/gr.6883307
   Laird PW, 2005, HUM MOL GENET, V14, pR65, DOI 10.1093/hmg/ddi113
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Leonessa F, 2003, ENDOCR-RELAT CANCER, V10, P43, DOI 10.1677/erc.0.0100043
   Lonning PE, 2007, ANN ONCOL, V18, P3, DOI 10.1093/annonc/mdm260
   Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104
   Misra S, 2005, J BIOL CHEM, V280, P20310, DOI 10.1074/jbc.M500737200
   Mori T, 2005, CANCER RES, V65, P1800, DOI 10.1158/0008-5472.CAN-04-3531
   Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223
   Nordgard SH, 2007, PHARMACOGENET GENOM, V17, P127, DOI 10.1097/FPC.0b013e328011abaa
   Ordway JM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001314
   Pajic M, 2009, CANCER RES, V69, P6396, DOI 10.1158/0008-5472.CAN-09-0041
   Paredes J, 2005, CLIN CANCER RES, V11, P5869, DOI 10.1158/1078-0432.CCR-05-0059
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Raguz S, 2004, CLIN CANCER RES, V10, P2776, DOI 10.1158/1078-0432.CCR-03-0517
   Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15
   Ronneberg JA, 2008, CANCER RES, V68, P5562, DOI 10.1158/0008-5472.CAN-07-5828
   Shen F, 2008, J PHARMACOL EXP THER, V324, P95, DOI 10.1124/jpet.107.127704
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   SORLIE T, 2004, METH MOL B, V291, P207
   Staalesen V, 2006, CLIN CANCER RES, V12, P6000, DOI 10.1158/1078-0432.CCR-05-2822
   Tanner M, 2006, J CLIN ONCOL, V24, P2428, DOI 10.1200/JCO.2005.02.9264
   Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314
   Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014
   Vargo-Gogola T, 2007, NAT REV CANCER, V7, P659, DOI 10.1038/nrc2193
   Vo QN, 2004, ONCOGENE, V23, P9432, DOI 10.1038/sj.onc.1208092
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yan PS, 2000, CLIN CANCER RES, V6, P1432
NR 52
TC 107
Z9 115
U1 0
U2 16
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD MAR 25
PY 2010
VL 9
AR 68
DI 10.1186/1476-4598-9-68
PG 13
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 589IS
UT WOS:000277141100001
PM 20338046
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Lehmann, U
   Streichert, T
   Otto, B
   Albat, C
   Hasemeier, B
   Christgen, H
   Schipper, E
   Hille, U
   Kreipe, HH
   Länger, F
AF Lehmann, Ulrich
   Streichert, Thomas
   Otto, Benjamin
   Albat, Cord
   Hasemeier, Britta
   Christgen, Henriette
   Schipper, Elisa
   Hille, Ursula
   Kreipe, Hans H.
   Laenger, Florian
TI Identification of differentially expressed microRNAs in human male
   breast cancer
SO BMC CANCER
LA English
DT Article
ID MIR-21; GENE; TARGET; PDCD4; RNA
AB Background: The discovery of small non-coding RNAs and the subsequent analysis of microRNA expression patterns in human cancer specimens have provided completely new insights into cancer biology. Genetic and epigenetic data indicate oncogenic or tumor suppressor function of these pleiotropic regulators. Therefore, many studies analyzed the expression and function of microRNA in human breast cancer, the most frequent malignancy in females. However, nothing is known so far about microRNA expression in male breast cancer, accounting for approximately 1% of all breast cancer cases.
   Methods: The expression of 319 microRNAs was analyzed in 9 primary human male breast tumors and in epithelial cells from 15 male gynecomastia specimens using fluorescence-labeled bead technology. For identification of differentially expressed microRNAs data were analyzed by cluster analysis and selected statistical methods. Expression levels were validated for the most up-or down-regulated microRNAs in this training cohort using real-time PCR methodology as well as in an independent test cohort comprising 12 cases of human male breast cancer.
   Results: Unsupervised cluster analysis separated very well male breast cancer samples and control specimens according to their microRNA expression pattern indicating cancer-specific alterations of microRNA expression in human male breast cancer. miR-21, miR519d, miR-183, miR-197, and miR-493-5p were identified as most prominently up-regulated, miR-145 and miR-497 as most prominently down-regulated in male breast cancer.
   Conclusions: Male breast cancer displays several differentially expressed microRNAs. Not all of them are shared with breast cancer biopsies from female patients indicating male breast cancer specific alterations of microRNA expression.
C1 [Lehmann, Ulrich; Albat, Cord; Hasemeier, Britta; Christgen, Henriette; Schipper, Elisa; Kreipe, Hans H.; Laenger, Florian] Hannover Med Sch, Inst Pathol, D-30625 Hannover, Germany.
   [Streichert, Thomas; Otto, Benjamin] Univ Klinikum Hamburg Eppendorf, Cent Labs, Dept Clin Chem, D-20246 Hamburg, Germany.
   [Hille, Ursula] Hannover Med Sch, Dept Gynecol, D-30625 Hannover, Germany.
C3 Hannover Medical School; University of Hamburg; University Medical
   Center Hamburg-Eppendorf; Hannover Medical School
RP Lehmann, U (通讯作者)，Hannover Med Sch, Inst Pathol, D-30625 Hannover, Germany.
EM Lehmann.Ulrich@MH-Hannover.de
OI Laenger, Florian/0000-0003-1191-4855
FU Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe
FX The work of UL and HK is supported by grants from the "Deutsche
   Forschungsgemeinschaft" and "Deutsche Krebshilfe".
CR Anderson WF, 2004, BREAST CANCER RES TR, V83, P77, DOI 10.1023/B:BREA.0000010701.08825.2d
   Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214
   Bock O, 2001, ANAL BIOCHEM, V295, P116, DOI 10.1006/abio.2001.5188
   Braunstein GD, 2007, NEW ENGL J MED, V357, P1229, DOI 10.1056/NEJMcp070677
   Cho WCS, 2009, EUR J CANCER, V45, P2197, DOI 10.1016/j.ejca.2009.04.039
   Chow TFF, 2008, BIOL CHEM, V389, P731, DOI 10.1515/BC.2008.071
   Christgen M, 2009, J PATHOL, V217, P620, DOI 10.1002/path.2495
   Ciocca V, 2006, HISTOPATHOLOGY, V49, P365, DOI 10.1111/j.1365-2559.2006.02519.x
   Dixon-McIver A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002141
   Du LQ, 2009, MOL CANCER RES, V7, P1234, DOI 10.1158/1541-7786.MCR-08-0507
   Elcheva I, 2009, MOL CELL, V35, P240, DOI 10.1016/j.molcel.2009.06.007
   Fassan M, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2348
   Fentiman IS, 2006, LANCET, V367, P595, DOI 10.1016/S0140-6736(06)68226-3
   Fisher SE, 2009, TRENDS GENET, V25, P166, DOI 10.1016/j.tig.2009.03.002
   Flavin RJ, 2009, MODERN PATHOL, V22, P197, DOI 10.1038/modpathol.2008.135
   Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200
   Garzon R, 2009, ANNU REV MED, V60, P167, DOI [10.1146/annurev.med.59.053006.104707, 10.1146/annurev.pathol.4.110807.092222]
   Godlewski J, 2008, CANCER RES, V68, P9125, DOI 10.1158/0008-5472.CAN-08-2629
   Hasemeier B, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-90
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Khoshnaw SM, 2009, J CLIN PATHOL, V62, P422, DOI 10.1136/jcp.2008.060681
   Motoyama K, 2009, INT J ONCOL, V34, P1069, DOI 10.3892/ijo_00000233
   Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106
   Schaefer A, 2010, INT J CANCER, V126, P1166, DOI 10.1002/ijc.24827
   Selcuklu SD, 2009, BIOCHEM SOC T, V37, P918, DOI 10.1042/BST0370918
   Talotta F, 2009, ONCOGENE, V28, P73, DOI 10.1038/onc.2008.370
   Tessema M, 2003, LEUKEMIA, V17, P910, DOI 10.1038/sj.leu.2402891
   von Wasielewski R, 2002, AM J CLIN PATHOL, V118, P675
   Weber F, 2006, J CLIN ENDOCR METAB, V91, P3584, DOI 10.1210/jc.2006-0693
   Xiao FF, 2009, NUCLEIC ACIDS RES, V37, pD105, DOI 10.1093/nar/gkn851
   Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808
NR 31
TC 111
Z9 125
U1 1
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD MAR 23
PY 2010
VL 10
AR 109
DI 10.1186/1471-2407-10-109
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 581BD
UT WOS:000276494300001
PM 20331864
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Hines, WC
   Bazarov, AV
   Mukhopadhyay, R
   Yaswen, P
AF Hines, William C.
   Bazarov, Alexey V.
   Mukhopadhyay, Rituparna
   Yaswen, Paul
TI <i>BORIS</i> (<i>CTCFL</i>) Is Not Expressed in Most Human Breast Cell
   Lines and High Grade Breast Carcinomas
SO PLOS ONE
LA English
DT Article
ID COMPARATIVE GENOMIC HYBRIDIZATION; CANCER-TESTIS GENE; FREQUENT
   AMPLIFICATION; METHYLATION; EPIGENETICS; DEREPRESSION; CTCFL/BORIS;
   REGULATOR; MELANOMA; MAGE-A1
AB BORIS (CTCFL) is the only known paralog of the versatile regulatory protein CTCF, a multifunctional DNA binding protein that mediates distinct gene regulatory functions involved in cell growth, differentiation, and apoptosis. Unlike CTCF, the expression of BORIS is normally restricted to specific cells in testes (the only cells where CTCF is not expressed), where it may play a role in reprogramming the methylation pattern of male germ line DNA. Frequent amplification of the 20q13.2 region, which contains the BORIS gene, and expression of BORIS transcripts in diverse human tumors and cell lines have led to the hypothesis that aberrant expression of BORIS may play a role in tumorigenesis by interfering with CTCF functions. However, recent studies using more quantitative methods indicate low frequency of BORIS expression in melanoma, ovarian, prostate, and bladder carcinomas. To investigate the relationship between chromosome 20q13 amplification and BORIS mRNA levels within breast cancer cell lines and tissues, we developed a quantitative RT-PCR assay to measure the levels of BORIS mRNA. Endpoint RT-PCR assays were also used to investigate the possible expression of alternatively spliced variants. Using multiple primer sets and controls, we found that neither mature BORIS transcripts nor spliced variants are commonly expressed at detectable levels in malignant breast cells or tissues, although endogenous BORIS transcripts can be induced in MCF-7 cells following 5-aza-29-deoxycytidine treatment. In conclusion, in most breast cancer cells, endogenous BORIS is unlikely to be expressed at sufficient levels to interfere with CTCF functions. Thus it is improbable that aberrant BORIS expression plays a role in most human breast cancers.
C1 [Hines, William C.; Mukhopadhyay, Rituparna; Yaswen, Paul] Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA.
   [Bazarov, Alexey V.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.
C3 University of California System; University of California Berkeley;
   United States Department of Energy (DOE); Lawrence Berkeley National
   Laboratory; University of California System; University of California
   San Francisco
RP Hines, WC (通讯作者)，Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA.
EM P_Yaswen@lbl.gov
OI Hines, William/0000-0002-0707-3160
FU California Breast Cancer Research Program [9WB-0193]; Department of
   Defense Breast Cancer Research Program [W81XWH-04-1-0283]; Office of
   Health and Environmental Research, Health Effects Division, United
   States Department of Energy [DE-AC02-05CH11231]; Komen Foundation
   [PDF0707408, BCTR0707231]; Flight Attendant Medical Research Institute
   [032122]
FX This work was funded by grants from the California Breast Cancer
   Research Program (9WB-0193), the Department of Defense Breast Cancer
   Research Program (W81XWH-04-1-0283), and by the Office of Health and
   Environmental Research, Health Effects Division, United States
   Department of Energy (contract no. DE-AC02-05CH11231). W. C. Hines and
   A. Bazarov received support from the Komen Foundation (fellowship
   PDF0707408 & grant BCTR0707231) and the Flight Attendant Medical
   Research Institute (032122). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010
   D'Arcy V, 2008, BRIT J CANCER, V98, P571, DOI 10.1038/sj.bjc.6604181
   Darcy V, 2006, CLIN CANCER RES, V12, P5978, DOI 10.1158/1078-0432.CCR-05-2731
   Dougherty CJ, 2008, BIOCHEM BIOPH RES CO, V370, P109, DOI 10.1016/j.bbrc.2008.03.040
   Filippova GN, 2008, CURR TOP DEV BIOL, V80, P337, DOI 10.1016/S0070-2153(07)80009-3
   Hoffmann MJ, 2006, BIOCHEM PHARMACOL, V72, P1577, DOI 10.1016/j.bcp.2006.06.020
   Hong JA, 2005, CANCER RES, V65, P7763, DOI 10.1158/0008-5472.CAN-05-0823
   Hore TA, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000169
   KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156
   Kholmanskikh O, 2008, INT J CANCER, V122, P777, DOI 10.1002/ijc.23140
   Klenova EA, 2002, SEMIN CANCER BIOL, V12, P399, DOI 10.1016/S1044-579X(02)00060-3
   Looijenga LHJ, 2006, CANCER RES, V66, P290, DOI 10.1158/0008-5472.CAN-05-2936
   Loukinov DI, 2002, P NATL ACAD SCI USA, V99, P6806, DOI 10.1073/pnas.092123699
   Mahlamäki EH, 2002, GENE CHROMOSOME CANC, V35, P353, DOI 10.1002/gcc.10122
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6
   Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001
   Rae JM, 2007, BREAST CANCER RES TR, V104, P13, DOI 10.1007/s10549-006-9392-8
   Renaud S, 2007, NUCLEIC ACIDS RES, V35, P7372, DOI 10.1093/nar/gkm896
   Risinger JI, 2007, CLIN CANCER RES, V13, P1713, DOI 10.1158/1078-0432.CCR-05-2569
   Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432
   Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669
   Sun LC, 2008, CANCER RES, V68, P2726, DOI 10.1158/0008-5472.CAN-07-6654
   Tanner MM, 1995, CLIN CANCER RES, V1, P1455
   Tanner MM, 2000, CLIN CANCER RES, V6, P1833
   Ulaner GA, 2003, HUM MOL GENET, V12, P535, DOI 10.1093/hmg/ddg034
   Vatolin S, 2005, CANCER RES, V65, P7751, DOI 10.1158/0008-5472.CAN-05-0858
   Woloszynska-Read Anna, 2007, Cancer Immun, V7, P21
   Yao J, 2006, CANCER RES, V66, P4065, DOI 10.1158/0008-5472.CAN-05-4083
NR 29
TC 17
Z9 17
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 17
PY 2010
VL 5
IS 3
AR e9738
DI 10.1371/journal.pone.0009738
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 572EG
UT WOS:000275809600010
PM 20305816
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Li, ZD
   Chen, B
   Wu, YQ
   Jin, F
   Xia, YJ
   Liu, XJ
AF Li, Zidong
   Chen, Bo
   Wu, Yiqing
   Jin, Feng
   Xia, Yongjing
   Liu, Xiangjun
TI Genetic and epigenetic silencing of the <i>beclin 1</i> gene in sporadic
   breast tumors
SO BMC CANCER
LA English
DT Article
ID INDUCED APOPTOSIS; DNA METHYLATION; SUPPRESSOR GENE; BRCA1; CANCER;
   AUTOPHAGY; MUTATIONS; PROMOTER; HYPERMETHYLATION; HETEROZYGOSITY
AB Background: Beclin 1, an important autophagy-related protein in human cells, is involved in cell death and cell survival. Beclin 1 mapped to human chromosome 17q21. It is widely expressed in normal mammary epithelial cells. Although down-regulated expression with mono-allelic deletions of beclin 1 gene was frequently observed in breast tumors, whether there was other regulatory mechanism of beclin 1 was to be investigated. We studied the expression of beclin 1 and explored the possible regulatory mechanisms on its expression in breast tumors.
   Methods: 20 pairs of tumors and adjacent normal tissues from patients with sporadic breast invasive ductal cancer (IDCs) were collected. The mRNA expression of beclin 1 was detected by real-time quantitative RT-PCR. Loss of heterozygosity (LOH) was determined by real-time quantitative PCR and microsatellite methods. The protein expression of beclin 1, p53, BRCA1 and BRCA2 was assessed by immunohistochemistry. CpG islands in 5' genomic region of beclin 1 gene were identified using MethylPrimer Program. Sodium bisulfite sequencing was used in examining the methylation status of each CpG island.
   Results: Decreased beclin 1 mRNA expression was detected in 70% of the breast tumors, and the protein levels were co-related to the mRNA levels. Expression of beclin 1 mRNA was demonstrated to be much higher in the BRCA1 positive tumors than that in the BRCA1 negative ones. Loss of heterozygosity was detected in more than 45% of the breast tumors, and a dense cluster of CpG islands was found from the 5' end to the intron 2 of the beclin 1 gene. Methylation analysis showed that the promoter and the intron 2 of beclin 1 were aberrantly methylated in the tumors with decreased expression.
   Conclusions: These data indicated that LOH and aberrant DNA methylation might be the possible reasons of the decreased expression of beclin 1 in the breast tumors. The findings here shed some new light on the regulatory mechanisms of beclin 1 in breast cancer.
C1 [Li, Zidong; Wu, Yiqing; Xia, Yongjing; Liu, Xiangjun] Tsinghua Univ, Sch Med, Inst Biomed Informat, Beijing 100084, Peoples R China.
   [Li, Zidong; Wu, Yiqing; Xia, Yongjing; Liu, Xiangjun] Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China.
   [Li, Zidong; Wu, Yiqing; Xia, Yongjing; Liu, Xiangjun] Tsinghua Univ, Minist Educ, Key Lab Bioinformat, Beijing 100084, Peoples R China.
   [Chen, Bo; Jin, Feng] China Med Univ, Affiliated Hosp 1, Dept Surg Oncol, Shenyang, Peoples R China.
C3 Tsinghua University; Tsinghua University; Tsinghua University; China
   Medical University
RP Xia, YJ (通讯作者)，Tsinghua Univ, Sch Med, Inst Biomed Informat, Beijing 100084, Peoples R China.
EM yjxia@mail.tsinghua.edu.cn
RI LIU, XIANGJUN/HJJ-0673-2023; Chen, Bo/IUN-5898-2023; Li,
   Zidong/AAK-8957-2020
FU Tsinghua-Yue-Yuen Medical Sciences Fund; Foundation for the Mainstay
   Talents of Tsinghua University; National Natural Science Foundation of
   China (NSFC) [30670851]; Wu Shunde Medical Science Research Fund; Key
   Project of Chinese Ministry of Education [03180]; Foundation of Science
   and Technology Bureau of Liaoning Province of China [20061038];
   Foundation of Educational Commission of Liaoning Province of China
   [2008762]
FX This project is supported by Tsinghua-Yue-Yuen Medical Sciences Fund,
   Foundation for the Mainstay Talents of Tsinghua University, National
   Natural Science Foundation of China (NSFC) Grants 30670851, Wu Shunde
   Medical Science Research Fund and the Key Project of Chinese Ministry of
   Education (No. 03180), Foundation of Science and Technology Bureau of
   Liaoning Province of China (No. 20061038), Foundation of Educational
   Commission of Liaoning Province of China (No. 2008762).
CR Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Cheng CK, 2005, CANCER RES, V65, P8646, DOI 10.1158/0008-5472.CAN-04-4243
   COLES C, 1992, CANCER RES, V52, P5291
   Daniel F, 2006, WORLD J GASTROENTERO, V12, P2895, DOI 10.3748/wjg.v12.i18.2895
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Douglas DB, 2004, CANCER RES, V64, P1611, DOI 10.1158/0008-5472.CAN-0318-2
   ECCLES DM, 1992, ONCOGENE, V7, P2069
   Edinger AL, 2003, CANCER CELL, V4, P422, DOI 10.1016/S1535-6108(03)00306-4
   Esteller M, 2001, CANCER RES, V61, P3225
   Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100
   Furuya D, 2005, EXP CELL RES, V307, P26, DOI 10.1016/j.yexcr.2005.02.023
   FUTREAL PA, 1992, CANCER RES, V52, P2624
   GAO X, 1995, CANCER RES, V55, P1002
   Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009
   Greenblatt MS, 2001, CANCER RES, V61, P4092
   HEDENFALK I, 2001, NEW ENGL J MED, V344, P344
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Lakhani SR, 1998, JNCI-J NATL CANCER I, V90, P1138, DOI 10.1093/jnci/90.15.1138
   Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liang XH, 2001, CANCER RES, V61, P3443
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Miremadi A, 2007, HUM MOL GENET, V16, pR28, DOI 10.1093/hmg/ddm021
   Mueller CR, 2003, BREAST CANCER RES, V5, P45, DOI 10.1186/bcr557
   O'Connell P, 1998, JNCI-J NATL CANCER I, V90, P697, DOI 10.1093/jnci/90.9.697
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086
   Roessler M, 2006, MOL CELL PROTEOMICS, V5, P2092, DOI 10.1074/mcp.M600118-MCP200
   SATO T, 1991, CANCER RES, V51, P5118
   THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845
   Unoki M, 2003, FEBS LETT, V554, P67, DOI 10.1016/S0014-5793(03)01092-5
   Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001
   Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7
   Widschwendter M, 2002, CLIN CANCER RES, V8, P17
   Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029
   Wilson FH, 2003, P NATL ACAD SCI USA, V100, P680, DOI 10.1073/pnas.242735399
   XL X, 1999, NAT GENET, V22, P37
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zhang Q, 2003, GENE, V318, P45, DOI 10.1016/S0378-1119(03)00753-4
NR 45
TC 105
Z9 127
U1 0
U2 19
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD MAR 16
PY 2010
VL 10
AR 98
DI 10.1186/1471-2407-10-98
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 587PY
UT WOS:000277006100001
PM 20230646
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Koprowska, K
   Czyz, M
AF Koprowska, Kamila
   Czyz, Malgorzata
TI Molecular mechanisms of parthenolide's action: Old drug with a new face
SO POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ
LA Croatian
DT Article
DE parthenolid; NF-kappa B; STAT; p53; DNMT2; HDAC1; reactive oxygen
   species; GSH; B anticancer activity; anti-arteriosclerotic activity;
   anti-inflammatory activity cancer
ID NF-KAPPA-B; SESQUITERPENE LACTONE PARTHENOLIDE; BREAST-CANCER CELLS;
   ENDOPLASMIC-RETICULUM STRESS; MYELOGENOUS LEUKEMIA STEM; INDUCED
   APOPTOSIS; IN-VITRO; OXIDATIVE STRESS; TANACETUM-PARTHENIUM;
   TRANSCRIPTION FACTOR
AB Parthenolide, a sesquiterpene lactone derived from the leaves of feverfew (Tanacetum parthenium parthenium),), is considered a main bioactive component of this herb. Feverfew has been used orally or as an infusion for the treatment of migraine, arthritis, fever, and stomachache. Besides its anti-inflammatory and anti-migraine properties, parthenolide also shows anticancer activities in a variety of cell lines. It contains an alpha-methylene-gamma-lactone ring and an epoxide moiety which are able to interact with nucleophilic sites of biologically important molecules. Parthenolide modulates multiple tar targets, thereby contributing to its various in vitro and in vivo effects. Inhibition of NF-kappa B activity, B constitutive in many types of cancers, via either interaction with IKK or more directly with the p65 subunit of NF-kappa B, is considered one of the main mechanisms of its action. In addition, B, inhibition of STAT and MAP kinase activities and the induction of sustained JNK activity as well as p53 activity via influencing MDM2 and HDAC1 levels lead to an increased susceptibility of can cancer cells to chemo-and radiotherapy. At the epigenetic level, parthenolide reduces HDAC1 level and, by inhibiting DNMT2 activity, induces global hypomethylation of DNA, which can restore the expressions of some suppressor genes. Moreover, this compound reduces the cellular level of GSH in cancer cells, followed by ROS accumulation and apoptosis. A unique property of par parthenolide is its ability to induce cell death mainly in cancer cells, while sparing healthy ones and it also protects normal cells from UVB and oxidative stress. More remarkably, it seems to have the potential to target some cancer stem cells. Its wide array of biological activity and low toxicity make parthenolide a very promising drug with multi-pharmacological potential, largely de dependent on the cellular context.
C1 [Koprowska, Kamila; Czyz, Malgorzata] Wydzial Lekarski Uniwersytetu Med, Zaklad Biol Mol Nowotworow, Lodzi, Poland.
RP Koprowska, K (通讯作者)，Wydzial Lekarski Uniwersytetu Med, Zaklad Biol Mol Nowotworow, Lodzi, Poland.
RI Koprowska, Kamila/J-8550-2012; Czyz, Malgorzata/AAD-1869-2020
OI Czyz, Malgorzata/0000-0002-8279-4742
CR Anderson KN, 2008, J PHARMACOL SCI, V106, P318, DOI 10.1254/jphs.SC0060164
   Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x
   Awang DVC, 1997, CAN MED ASSOC J, V157, P510
   Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991
   Banno T, 2005, J BIOL CHEM, V280, P18973, DOI 10.1074/jbc.M411758200
   Bedoya LM, 2008, CURR SIGNAL TRANSD T, V3, P82, DOI 10.2174/157436208784223134
   Bilska Anna, 2007, Postepy Hig Med Dosw (Online), V61, P438
   Bork PM, 1997, FEBS LETT, V402, P85, DOI 10.1016/S0014-5793(96)01502-5
   Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527
   Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476
   Criswell T, 2003, ONCOGENE, V22, P5813, DOI 10.1038/sj.onc.1206680
   Curry EA, 2004, INVEST NEW DRUG, V22, P299, DOI 10.1023/B:DRUG.0000026256.38560.be
   De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560
   Duechler M, 2008, CANCER CHEMOTH PHARM, V61, P727, DOI 10.1007/s00280-007-0527-3
   Fiebich BL, 2002, J NEUROIMMUNOL, V132, P18, DOI 10.1016/S0165-5728(02)00279-5
   Fojo T, 2003, ONCOGENE, V22, P7512, DOI 10.1038/sj.onc.1206951
   Fonrose X, 2007, CANCER RES, V67, P3371, DOI 10.1158/0008-5472.CAN-06-3732
   Francescato HDC, 2007, TOXICOLOGY, V230, P64, DOI 10.1016/j.tox.2006.10.025
   García-Piñeres AJ, 2001, J BIOL CHEM, V276, P39713, DOI 10.1074/jbc.M101985200
   Gilmore TD, 2006, ONCOGENE, V25, P6887, DOI 10.1038/sj.onc.1209982
   Gómez-Hernández A, 2006, ATHEROSCLEROSIS, V187, P139, DOI 10.1016/j.atherosclerosis.2005.08.035
   Gopal YNV, 2009, MOL CANCER THER, V8, P552, DOI 10.1158/1535-7163.MCT-08-0661
   Gopal YV, 2007, CHEM BIOL, V14, P813, DOI 10.1016/j.chembiol.2007.06.007
   Guzman ML, 2005, BLOOD, V105, P4163, DOI 10.1182/blood-2004-10-4135
   Guzman ML, 2007, BLOOD, V110, P4427, DOI 10.1182/blood-2007-05-090621
   Hashizume M, 2008, RHEUMATOLOGY, V47, P1635, DOI 10.1093/rheumatology/ken363
   Hehner SP, 1999, J IMMUNOL, V163, P5617
   Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288
   Herrera F, 2005, BIOCHEM BIOPH RES CO, V332, P321, DOI 10.1016/j.bbrc.2005.04.131
   Hobbs C., 1989, HERBAL GRAM, V20, P267
   Hwang D, 1996, BIOCHEM BIOPH RES CO, V226, P810, DOI 10.1006/bbrc.1996.1433
   Hwang DR, 2006, BIOORGAN MED CHEM, V14, P83, DOI 10.1016/j.bmc.2005.07.055
   Idris AI, 2009, MOL CANCER THER, V8, P2339, DOI 10.1158/1535-7163.MCT-09-0133
   Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616
   Izumi E, 2008, EXP PARASITOL, V118, P324, DOI 10.1016/j.exppara.2007.08.015
   Jeong WS, 2005, J BIOCHEM MOL BIOL, V38, P167
   Jin P, 2007, AAPS PHARMSCITECH, V8, DOI 10.1208/pt0804105
   JOHNSON ES, 1985, BMJ-BRIT MED J, V291, P569, DOI 10.1136/bmj.291.6495.569
   Jung M, 2001, SEMIN RADIAT ONCOL, V11, P346, DOI 10.1053/srao.2001.26034
   Kang BY, 2001, IMMUNOL LETT, V77, P159, DOI 10.1016/S0165-2478(01)00211-5
   Kang SN, 2002, BRIT J PHARMACOL, V135, P1235, DOI 10.1038/sj.bjp.0704573
   Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780
   Kawasaki BT, 2009, PROSTATE, V69, P827, DOI 10.1002/pros.20931
   Kim HJ, 2006, CELL DEATH DIFFER, V13, P738, DOI 10.1038/sj.cdd.4401877
   Kim JH, 2005, CANCER RES, V65, P6312, DOI 10.1158/0008-5472.CAN-04-4193
   Kim R, 1999, ANTICANCER RES, V19, P1779
   Kishida Y, 2007, CLIN CANCER RES, V13, P59, DOI 10.1158/1078-0432.CCR-06-1559
   KNIGHT DW, 1995, NAT PROD REP, V12, P271, DOI 10.1039/np9951200271
   Kurdi M, 2007, J CELL PHYSIOL, V212, P424, DOI 10.1002/jcp.21033
   Kurdi M, 2007, FREE RADICAL BIO MED, V42, P474, DOI 10.1016/j.freeradbiomed.2006.11.012
   Kwok BHB, 2001, CHEM BIOL, V8, P759, DOI 10.1016/S1074-5521(01)00049-7
   Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672
   Legendre F, 2003, J BIOL CHEM, V278, P2903, DOI 10.1074/jbc.M110773200
   Lesiak K, 2010, MELANOMA RES, V20, P21, DOI 10.1097/CMR.0b013e328333bbe4
   Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909
   Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362
   Li XM, 2006, CYTOKINE, V33, P299, DOI 10.1016/j.cyto.2006.03.002
   Li-Weber M, 2002, EUR J IMMUNOL, V32, P3587, DOI 10.1002/1521-4141(200212)32:12<3587::AID-IMMU3587>3.0.CO;2-E
   Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204
   Lindenmeyer MT, 2007, LIFE SCI, V80, P1608, DOI 10.1016/j.lfs.2007.01.036
   Lindenmeyer MT, 2006, BIOORGAN MED CHEM, V14, P2487, DOI 10.1016/j.bmc.2005.11.027
   Liu L, 1999, MOL CELL BIOL, V19, P1202
   Liu Y, 2009, CELL DEATH DIFFER, V16, P847, DOI 10.1038/cdd.2009.14
   Liu Y, 2008, J CONTROL RELEASE, V129, P18, DOI 10.1016/j.jconrel.2008.03.022
   Liu ZF, 2009, J PHARMACOL EXP THER, V329, P505, DOI 10.1124/jpet.108.147934
   López-Franco O, 2006, ARTERIOSCL THROM VAS, V26, P1864, DOI 10.1161/01.ATV.0000229659.94020.53
   Lovat PE, 2003, CANCER LETT, V197, P157, DOI 10.1016/S0304-3835(03)00098-3
   Mendonca MS, 2007, RADIAT RES, V168, P689, DOI 10.1667/RR1128.1
   Miglietta A, 2004, CHEM-BIOL INTERACT, V149, P165, DOI 10.1016/j.cbi.2004.07.005
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Miyata N, 2008, INT IMMUNOPHARMACOL, V8, P874, DOI 10.1016/j.intimp.2008.02.002
   MURPHY JJ, 1988, LANCET, V2, P189
   Nakshatri H, 2004, ONCOGENE, V23, P7330, DOI 10.1038/sj.onc.1207995
   Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629
   Nozaki S, 2001, ONCOGENE, V20, P2178, DOI 10.1038/sj.onc.1204292
   Onozato T, 2009, PHYTOTHER RES, V23, P791, DOI 10.1002/ptr.2638
   Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373
   Pajak B, 2008, FOLIA HISTOCHEM CYTO, V46, P129, DOI 10.2478/v10042-008-0019-2
   Parada-Turska J, 2007, PHARMACOL REP, V59, P233
   Patel NM, 2000, ONCOGENE, V19, P4159, DOI 10.1038/sj.onc.1203768
   PATTRICK M, 1989, ANN RHEUM DIS, V48, P547, DOI 10.1136/ard.48.7.547
   POWIS G, 1994, CANCER CHEMOTH PHARM, V34, P344, DOI 10.1007/BF00686043
   Pozarowski P, 2003, CYTOM PART A, V54A, P118, DOI 10.1002/cyto.a.10057
   Pozarowski P, 2003, CELL CYCLE, V2, P377, DOI 10.4161/cc.2.4.420
   Ralstin MC, 2006, MOL CANCER RES, V4, P387, DOI 10.1158/1541-7786.MCR-05-0157
   Rayburn E, 2005, CURR CANCER DRUG TAR, V5, P27, DOI 10.2174/1568009053332636
   Riggins RB, 2005, MOL CANCER THER, V4, P33
   Saadane A, 2007, AM J RESP CELL MOL, V36, P728, DOI 10.1165/rcmb.2006-0323OC
   SABURI Y, 1989, CANCER RES, V49, P7020
   Schmidt TJ, 1999, CURR ORG CHEM, V3, P577
   Schmidt TJ, 1997, BIOORGAN MED CHEM, V5, P645, DOI 10.1016/S0968-0896(97)00003-5
   Schnyder B, 2002, BIOCHEM BIOPH RES CO, V292, P841, DOI 10.1006/bbrc.2002.6754
   Sheehan M, 2002, MOL PHARMACOL, V61, P953, DOI 10.1124/mol.61.5.953
   Sobota R, 2000, BIOCHEM BIOPH RES CO, V267, P329, DOI 10.1006/bbrc.1999.1948
   Steele AJ, 2006, LEUKEMIA, V20, P1073, DOI 10.1038/sj.leu.2404230
   Stepulak Andrzej, 2005, Postepy Hig Med Dosw (Online), V59, P68
   Sun Y, 2007, MOL CANCER THER, V6, P2477, DOI 10.1158/1535-7163.MCT-07-0186
   Suvannasankha A, 2008, CLIN CANCER RES, V14, P1814, DOI 10.1158/1078-0432.CCR-07-1359
   Sweeney C, 2004, CLIN CANCER RES, V10, P5501, DOI 10.1158/1078-0432.CCR-0571-03
   Tanaka K, 2005, J PHARMACOL EXP THER, V315, P624, DOI 10.1124/jpet.105.088674
   Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568
   Tassorelli C, 2005, CEPHALALGIA, V25, P612, DOI 10.1111/j.1468-2982.2005.00915.x
   Thieu VT, 2007, J LEUKOCYTE BIOL, V82, P370, DOI 10.1189/jlb.1106707
   Tian ZJ, 2004, ACTA PHARMACOL SIN, V25, P1157
   Tiuman TS, 2005, ANTIMICROB AGENTS CH, V49, P176, DOI 10.1128/AAC.49.11.176-182.2005
   Uchi H, 2002, J ALLERGY CLIN IMMUN, V110, P269, DOI 10.1067/mai.2002.126381
   Umemura K, 2008, BIOCHEM BIOPH RES CO, V368, P948, DOI 10.1016/j.bbrc.2008.02.018
   Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472
   Vogler BK, 1998, CEPHALALGIA, V18, P704, DOI 10.1046/j.1468-2982.1998.1810704.x
   Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037
   Wang W, 2006, APOPTOSIS, V11, P2225, DOI 10.1007/s10495-006-0287-2
   Wang WX, 1999, CLIN CANCER RES, V5, P119
   Watson C, 2009, RADIAT RES, V171, P389, DOI 10.1667/RR1394.1
   Wen J, 2002, J BIOL CHEM, V277, P38954, DOI 10.1074/jbc.M203842200
   Wider B, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002286.pub3
   WIEDHOPF RM, 1973, J PHARM SCI, V62, P345, DOI 10.1002/jps.2600620244
   WOYNAROWSKI JM, 1981, MOL PHARMACOL, V19, P97
   Yang JY, 2006, MOL CELL BIOL, V26, P7269, DOI 10.1128/MCB.00172-06
   Yao HP, 2007, CELL RES, V17, P565, DOI 10.1038/cr.2007.6
   Yip KHM, 2004, J BONE MINER RES, V19, P1905, DOI 10.1359/JBMR.040919
   Yip-Schneider MT, 2005, MOL CANCER THER, V4, P587, DOI 10.1158/1535-7163.MCT-04-0215
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Zhang DL, 2009, MOL CANCER RES, V7, P1139, DOI 10.1158/1541-7786.MCR-08-0410
   Zhang K, 1998, INT J ONCOL, V12, P871
   Zhang S, 2004, CANCER LETT, V208, P143, DOI 10.1016/j.canlet.2003.11.028
   Zhang Siyuan, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P239, DOI 10.2174/1568011053765976
   Zhang SY, 2004, CARCINOGENESIS, V25, P2191, DOI 10.1093/carcin/bgh234
   Zhou JB, 2008, BREAST CANCER RES TR, V111, P419, DOI 10.1007/s10549-007-9798-y
   Zhou YM, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-59
   Zilfou JT, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001883
   Zingarelli B, 2002, SHOCK, V17, P127, DOI 10.1097/00024382-200202000-00008
   Zunino SJ, 2007, CANCER LETT, V254, P119, DOI 10.1016/j.canlet.2007.03.002
NR 132
TC 27
Z9 30
U1 0
U2 15
PU POLISH ACAD SCIENCES, INST IMMUNOL & EXP THERAPY
PI WROCLAW
PA RUDOLF WEIGL 12, WROCLAW, 53-114, POLAND
SN 0032-5449
EI 1732-2693
J9 POSTEP HIG MED DOSW
JI Postep. Hig. Med. Dosw.
PD MAR 16
PY 2010
VL 64
BP 100
EP 114
PG 15
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 569ZQ
UT WOS:000275641800001
PM 20354259
DA 2025-01-12
ER

PT J
AU Lee, PS
   Teaberry, VS
   Bland, AE
   Huang, ZQ
   Whitaker, RS
   Baba, T
   Fujii, S
   Secord, AA
   Berchuck, A
   Murphy, SK
AF Lee, Paula S.
   Teaberry, Vanessa S.
   Bland, Amy E.
   Huang, Zhiqing
   Whitaker, Regina S.
   Baba, Tsukasa
   Fujii, Shingo
   Secord, Angeles Alvarez
   Berchuck, Andrew
   Murphy, Susan K.
TI Elevated <i>MAL</i> expression is accompanied by promoter
   hypomethylation and platinum resistance in epithelial ovarian cancer
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE MAL; ovarian cancer; epigenetic; methylation; chemoresistance
ID GLYCOLIPID-ENRICHED MEMBRANES; TRANSCRIPTION FACTOR USF; T-CELL
   DIFFERENTIATION; DARBY CANINE KIDNEY; GENE-EXPRESSION; DNA-METHYLATION;
   SIGNALING PATHWAYS; CDNA MICROARRAY; PROSTATE-CANCER; BREAST-CANCER
AB We previously found that the gene encoding the Myelin and Lymphocyte protein, MAL, was among the most highly expressed genes in serous ovarian cancers from short-term survivors (<3 years) relative to those of long-term survivors (>7 years). In the present study, we have found that this difference in expression is partially attributable to differences in DNA methylation at a specific region within the MAL promoter CpG island. While MAL was largely unmethylated at the transcription start site (Region 1; -48 to +73 bp) in primary serous ovarian cancers, methylation of an upstream region (Region 2; -452 to -266 bp) was inversely correlated with MAL transcription in the primary cancers (R = -0.463) and ovarian cancer cell lines (R = -0.444). Following treatment of the OVCA432 cell line with 5-azacytidine, methylation of Region 2 decreased from 73.3% to 34.7% (p = 0.007) while Region 1 was unaffected. This was accompanied by a 10-fold increase in MAL expression. Since MAL transcripts are elevated in tumors from short-term survivors, all of whom were treated with platinum-based therapy, MAL may have a role in cisplatin response. We therefore determined the 50% growth inhibitory dose of cisplatin in 30 ovarian cancer cell lines and compared this to MAL expression. MAL transcript levels were higher in the resistant ovarian cell lines (p = 0.04). MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum-based drugs in ovarian cancer.
C1 [Lee, Paula S.; Teaberry, Vanessa S.; Bland, Amy E.; Huang, Zhiqing; Whitaker, Regina S.; Baba, Tsukasa; Secord, Angeles Alvarez; Berchuck, Andrew; Murphy, Susan K.] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Durham, NC 27708 USA.
   [Baba, Tsukasa; Fujii, Shingo] Kyoto Univ, Dept Gynecol & Obstet, Kyoto, Japan.
   [Berchuck, Andrew; Murphy, Susan K.] Duke Univ, Duke Inst Genome Sci & Policy, Durham, NC 27708 USA.
   [Murphy, Susan K.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27708 USA.
C3 Duke University; Kyoto University; Duke University; Duke University
RP Murphy, SK (通讯作者)，Duke Univ, Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Box 91012, Durham, NC 27708 USA.
EM murph035@mc.duke.edu
RI Murphy, Susan/R-3903-2019
OI Murphy, Susan/0000-0001-8298-7272; BABA, Tsukasa/0000-0003-0066-3747
FU Translational Research in Oncology Training; Duke Comprehensive Cancer
   Center; Gail Parkins Ovarian Cancer Research Fund
FX This research was supported by a T32 award to PSL from the Translational
   Research in Oncology Training Grant program of the Duke Comprehensive
   Cancer Center and by the Gail Parkins Ovarian Cancer Research Fund.
CR Ahluwalia A, 2001, GYNECOL ONCOL, V82, P299, DOI 10.1006/gyno.2001.6284
   ALONSO MA, 1987, P NATL ACAD SCI USA, V84, P1997, DOI 10.1073/pnas.84.7.1997
   ALONSO MA, 1988, IMMUNOGENETICS, V27, P91, DOI 10.1007/BF00351081
   BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380
   Berchuck A, 2005, CLIN CANCER RES, V11, P3686, DOI 10.1158/1078-0432.CCR-04-2398
   Berchuck A, 2009, CLIN CANCER RES, V15, P2448, DOI 10.1158/1078-0432.CCR-08-2430
   Blaveri E, 2005, CLIN CANCER RES, V11, P4044, DOI 10.1158/1078-0432.CCR-04-2409
   Cheong KH, 1999, P NATL ACAD SCI USA, V96, P6241, DOI 10.1073/pnas.96.11.6241
   Copie-Bergman C, 2002, MODERN PATHOL, V15, P1172, DOI 10.1097/01.MP.0000032534.81894.B3
   Copie-Bergman R, 1999, BLOOD, V94, P3567, DOI 10.1182/blood.V94.10.3567.422k06_3567_3575
   Crum CP, 2007, CLIN MED RES, V5, P35, DOI 10.3121/cmr.2007.702
   Czekierdowski A, 2006, NEUROENDOCRINOL LETT, V27, P381
   Di Vizio D, 2008, TUMORI J, V94, P633
   Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104
   Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700
   Furey TS, 2000, BIOINFORMATICS, V16, P906, DOI 10.1093/bioinformatics/16.10.906
   GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730
   Gupta A, 2003, CANCER RES, V63, P664
   Hatta M, 2004, J OBSTET GYNAECOL RE, V30, P53, DOI 10.1111/j.1341-8076.2004.00156.x
   Horne HN, 2009, MOL CANCER RES, V7, P199, DOI 10.1158/1541-7786.MCR-08-0314
   Hsi ED, 2006, AM J CLIN PATHOL, V125, P776, DOI 10.1309/98KLHRDAM5CMDHE2
   Huang ZQ, 2006, NUCLEIC ACIDS RES, V34, P555, DOI 10.1093/nar/gkj468
   Hughes S, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-91
   Ismail RS, 2000, CANCER RES, V60, P6744
   Ito Y, 2008, HUM MOL GENET, V17, P2633, DOI 10.1093/hmg/ddn163
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Kim SJ, 2008, ONCOL REP, V19, P663
   Lage Hermann, 2007, V176, P51
   Lancaster JM, 2004, J SOC GYNECOL INVEST, V11, P51, DOI 10.1016/j.jsgi.2003.07.004
   Li M, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-34
   Lind GE, 2007, GASTROENTEROLOGY, V132, P1631, DOI 10.1053/j.gastro.2007.03.003
   Lind GE, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-13
   Llorente A, 2004, J CELL SCI, V117, P5343, DOI 10.1242/jcs.01420
   Ma DWL, 2007, APPL PHYSIOL NUTR ME, V32, P341, DOI 10.1139/H07-036
   Marazuela M, 2004, HISTOL HISTOPATHOL, V19, P925, DOI 10.14670/HH-19.925
   Martín-Belmonte F, 2003, J CELL BIOL, V163, P155, DOI 10.1083/jcb.200304053
   Martín-Belmonte F, 1998, ENDOCRINOLOGY, V139, P2077, DOI 10.1210/en.139.4.2077
   Martín-Belmonte F, 2000, MOL BIOL CELL, V11, P2033, DOI 10.1091/mbc.11.6.2033
   Martín-Belmonte F, 2009, INT REV CEL MOL BIO, V274, P129, DOI 10.1016/S1937-6448(08)02003-0
   Martoglio AM, 2000, MOL MED, V6, P750, DOI 10.1007/BF03402191
   Michel V, 2007, BIOL CELL, V99, P129, DOI 10.1042/BC20060051
   Milicic A, 2008, CANCER RES, V68, P7760, DOI 10.1158/0008-5472.CAN-08-0020
   Mimori K, 2003, ONCOGENE, V22, P3463, DOI 10.1038/sj.onc.1206378
   Mimori K, 2007, ANN SURG ONCOL, V14, P1670, DOI 10.1245/s10434-006-9064-2
   Mori Y, 2006, GASTROENTEROLOGY, V131, P797, DOI 10.1053/j.gastro.2006.06.006
   Murphy SK, 2003, HUM MUTAT, V22, P92, DOI 10.1002/humu.10237
   Ono K, 2000, CANCER RES, V60, P5007
   Paquette J, 2007, ENDOCRINOLOGY, V148, P6007, DOI 10.1210/en.2006-1729
   Patra SK, 2008, FEBS J, V275, P5217, DOI 10.1111/j.1742-4658.2008.06658.x
   Patra SK, 2007, ONCOL REP, V17, P1279
   Patra SK, 2008, BBA-REV CANCER, V1785, P182, DOI 10.1016/j.bbcan.2007.11.002
   Patra SK, 2008, CANCER METAST REV, V27, P315, DOI 10.1007/s10555-008-9118-y
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Puertollano R, 1999, BIOCHEM BIOPH RES CO, V254, P689, DOI 10.1006/bbrc.1998.0122
   RANCANO C, 1994, J BIOL CHEM, V269, P8159
   Sawiris GP, 2002, CANCER RES, V62, P2923
   Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439
   Schoenenberger C A, 1991, Trends Cell Biol, V1, P87, DOI 10.1016/0962-8924(91)90035-8
   Schug J., 1997, TESS TRANSCRIPTION E
   Schummer M, 1999, GENE, V238, P375, DOI 10.1016/S0378-1119(99)00342-X
   Shridhar V, 2001, CANCER RES, V61, P5895
   SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427
   Spentzos D, 2004, J CLIN ONCOL, V22, P4700, DOI 10.1200/JCO.2004.04.070
   Spentzos D, 2005, J CLIN ONCOL, V23, P7911, DOI 10.1200/JCO.2005.02.9363
   Strathdee G, 2001, AM J PATHOL, V158, P1121, DOI 10.1016/S0002-9440(10)64059-X
   Tada T, 2006, JNCI-J NATL CANCER I, V98, P396, DOI 10.1093/jnci/djj093
   Tracey L, 2002, AM J PATHOL, V161, P1825, DOI 10.1016/S0002-9440(10)64459-8
   Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405
   Wang K, 1999, GENE, V229, P101, DOI 10.1016/S0378-1119(99)00035-9
   Waterland RA, 2006, HUM MOL GENET, V15, P705, DOI 10.1093/hmg/ddi484
   Waterland RA, 2006, GENESIS, V44, P401, DOI 10.1002/dvg.20230
   Wei SH, 2002, CLIN CANCER RES, V8, P2246
   Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176
   Wong KK, 2001, BIOTECHNIQUES, V30, P670, DOI 10.2144/01303dd05
   Xu Zhixiong, 1999, Zhonghua Zhongliu Zazhi, V21, P250
NR 77
TC 44
Z9 49
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD MAR 15
PY 2010
VL 126
IS 6
BP 1378
EP 1389
DI 10.1002/ijc.24797
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 567GU
UT WOS:000275434100009
PM 19642140
OA Bronze
DA 2025-01-12
ER

PT J
AU Flanagan, JM
   Cocciardi, S
   Waddell, N
   Johnstone, CN
   Marsh, A
   Henderson, S
   Simpson, P
   da Silva, L
   Khanna, K
   Lakhani, S
   Boshoff, C
   Chenevix-Trench, G
AF Flanagan, James M.
   Cocciardi, Sibylle
   Waddell, Nic
   Johnstone, Cameron N.
   Marsh, Anna
   Henderson, Stephen
   Simpson, Peter
   da Silva, Leonard
   Khanna, Kumkum
   Lakhani, Sunil
   Boshoff, Chris
   Chenevix-Trench, Georgia
CA kConFab Investigators
TI DNA Methylome of Familial Breast Cancer Identifies Distinct Profiles
   Defined by Mutation Status
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID ESTROGEN-RECEPTOR; METHYLATION PATTERNS; COLORECTAL-CANCER; PROMOTER
   DNA; BRCA1; GENE; CARCINOGENESIS; EXPRESSION; GENOME; SGK1
AB It is now understood that epigenetic alterations occur frequently in sporadic breast carcinogenesis, but little is known about the epigenetic alterations associated with familial breast tumors. We performed genome-wide DNA-methylation profiling on familial breast cancers (n = 33) to identify patterns of methylation specific to the different mutation groups (BRCA1, BRCA2, and BRCAx) or intrinsic subtypes of breast cancer (basal, luminal A, luminal B, HER2-amplified, and normal-like). We used methylated DNA immunoprecipitation (MeDIP) on Affymetrix promoter chips to interrogate methylation profiles across 25,500 distinct transcripts. Using a support vector machine classification algorithm, we demonstrated that genome-wide methylation profiles predicted tumor mutation status with estimated error rates of 19016 (BRCA1), 31% (BRCA2), and 36% (BRCAx) but did not accurately predict the intrinsic subtypes defined by gene expression. Furthermore, using unsupervised hierarchical Clustering, we identified a distinct subgroup of BRCAx tumors defined by methylation profiles. We validated these findings in the 33 tumors in the test set, as well as in an independent validation set of 47 formalin-fixed, paraffin-embedded familial breast tumors, by pyrosequencing and Epityper. Finally, gene-expression profiling and SNP CGH array previously performed on the same samples allowed full integration of methylation, gene-expression, and copy-number data sets, revealing frequent hypermethylation of genes that also displayed loss of heterozygosity, as well as of genes that show copy-number gains, providing a potential mechanism for expression dosage compensation. Together, these data show that methylation profiles for familial breast cancers are defined by the mutation status and are distinct from the intrinsic subtypes.
C1 [Flanagan, James M.; Henderson, Stephen; Boshoff, Chris] UCL, Inst Canc, CRUK Viral Oncol Grp, London WC1E 6BT, England.
   [Cocciardi, Sibylle; Waddell, Nic; Johnstone, Cameron N.; Marsh, Anna; Chenevix-Trench, Georgia] Queensland Inst Med Res, Div Genet & Populat Hlth, Brisbane, Qld 4006, Australia.
   [Simpson, Peter; da Silva, Leonard; Lakhani, Sunil] Univ Queensland, Clin Res Ctr, Brisbane, Qld 4029, Australia.
   [kConFab Investigators] Peter MacCallum Canc Ctr, Melbourne, Vic 3002, Australia.
   [Khanna, Kumkum] Queensland Inst Med Res, Div Canc & Cell Biol, Brisbane, Qld 4006, Australia.
C3 University of London; University College London; QIMR Berghofer Medical
   Research Institute; University of Queensland; Peter Maccallum Cancer
   Center; QIMR Berghofer Medical Research Institute
RP Flanagan, JM (通讯作者)，UCL, Inst Canc, CRUK Viral Oncol Grp, Mortimer St, London WC1E 6BT, England.
EM j.flanagan@imperial.ac.uk
RI Waddell, Nicola/H-4929-2015; Da Silva, Leonard/F-6584-2010;
   Chenevix-Trench, Georgia/AAV-2014-2020; Khanna, Kum/I-1747-2013;
   Simpson, Peter/F-1225-2010; Da Silva, Leonard/C-4562-2017; Lakhani,
   Sunil/I-1970-2018
OI Simpson, Peter/0000-0002-4816-8289; Chenevix-Trench,
   Georgia/0000-0002-1878-2587; Waddell, Nicola/0000-0002-3950-2476; Da
   Silva, Leonard/0000-0001-6751-6819; Flanagan, James/0000-0003-4955-1383;
   Thorne, Heather/0000-0003-3610-2511; Lakhani, Sunil/0000-0003-4067-2760;
   Henderson, Stephen/0000-0002-9032-3828
FU NHMRC [145684, 288704, 454508]; Queensland Cancer Fund; Cancer Councils
   of New South Wales, Victoria, Tasmania and South Australia; Cancer
   Foundation of Western Australia; Susan Komen Foundation; Cancer Research
   UK [C536/A6689]; University College London Hospital Charities
FX The authors would like to acknowledge Lynne Reid, Patricia Keith, and
   Jeremy Arnold for their assistance. We would also like to acknowledge
   the Wolfson Institute for Biomedical Research and the UCL Cancer
   Institute Scientific Support Services for performing the microarray
   hybridizations, in particular Jacob Raby and Catherine King. We wish to
   thank Heather Thorne, Eveline Niedermayr, all of the kConFab research
   nurses and staff, the heads and staff of the Family Cancer Clinics, and
   the Clinical Follow Up Study (funded by NHMRC grants 145684, 288704, and
   454508) for their contributions to this resource, as well as the many
   families who contribute to kConFab. kConFab is supported by grants from
   the National Breast Cancer Foundation, funded by the National Health and
   Medical Research Council (NHMRC), and by the Queensland Cancer Fund, the
   Cancer Councils of New South Wales, Victoria, Tasmania and South
   Australia, and the Cancer Foundation of Western Australia. This work was
   funded by a Susan Komen Foundation grant to G.C.T. J.M.F. was funded in
   part by Cancer Research UK to C.B. and University College London
   Hospital Charities to J.M.F.J.M.F. is a Breast Cancer Campaign Fellow
   and is partly funded by Cancer Research UK program C536/A6689; G.C.T.
   and K.K. are NHMRC Research Fellows.
CR [Anonymous], BREAST CANC RES TREA
   Archey WB, 2002, ONCOGENE, V21, P7034, DOI 10.1038/sj.onc.1205844
   Armes JE, 1998, CANCER-AM CANCER SOC, V83, P2335, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2335::AID-CNCR13>3.0.CO;2-N
   Barreto G, 2007, NATURE, V445, P671, DOI 10.1038/nature05515
   Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2
   Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1
   Boletta A, 2003, TRENDS CELL BIOL, V13, P484, DOI 10.1016/S0962-8924(03)00169-7
   Clark SJ, 2007, HUM MOL GENET, V16, pR88, DOI 10.1093/hmg/ddm051
   Easton DF, 2007, AM J HUM GENET, V81, P873, DOI 10.1086/521032
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Flanagan JM, 2009, HUM MOL GENET, V18, P1332, DOI 10.1093/hmg/ddp033
   Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781
   Hedenfalk I, 2003, P NATL ACAD SCI USA, V100, P2532, DOI 10.1073/pnas.0533805100
   Hong F, 2008, MOL CELL, V30, P701, DOI 10.1016/j.molcel.2008.04.027
   Hosey AM, 2007, J NATL CANCER I, V99, P1683, DOI 10.1093/jnci/djm207
   Hudelist G, 2009, J CANCER RES CLIN, V135, P191, DOI 10.1007/s00432-008-0458-3
   Ito Y, 2008, HUM MOL GENET, V17, P2633, DOI 10.1093/hmg/ddn163
   Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10
   Johnson WE, 2006, P NATL ACAD SCI USA, V103, P12457, DOI 10.1073/pnas.0601180103
   Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640
   Knudson AG, 1996, J CANCER RES CLIN, V122, P135, DOI 10.1007/BF01366952
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Krop I, 2003, CANCER RES, V63, P2024
   Kuijper TM, 2009, MOL CELL ENDOCRINOL, V302, P58, DOI 10.1016/j.mce.2008.12.016
   Lakhani SR, 2005, CLIN CANCER RES, V11, P5175, DOI 10.1158/1078-0432.CCR-04-2424
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Mann GJ, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1377
   Martinez-Rumayor A, 2008, AM J CARDIOL, V101, p3A, DOI 10.1016/j.amjcard.2007.11.012
   Métivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Novak P, 2008, CANCER RES, V68, P8616, DOI 10.1158/0008-5472.CAN-08-1419
   Ordway JM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001314
   Rai K, 2008, CELL, V135, P1201, DOI 10.1016/j.cell.2008.11.042
   Robson ME, 2004, BREAST CANCER RES, V6, pR8, DOI 10.1186/bcr658
   Rodenhiser DI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2121
   Royo JL, 2007, NAT PROTOC, V2, P1734, DOI 10.1038/nprot.2007.244
   Smith P, 2006, GENE CHROMOSOME CANC, V45, P646, DOI 10.1002/gcc.20330
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Suijkerbuijk KPM, 2008, ANN ONCOL, V19, P1870, DOI 10.1093/annonc/mdn409
   Suzuki R, 2006, BIOINFORMATICS, V22, P1540, DOI 10.1093/bioinformatics/btl117
   Tangir J, 2004, CLIN EXP METASTAS, V21, P477, DOI 10.1007/s10585-004-4226-8
   Vasilatos SN, 2009, CANCER EPIDEM BIOMAR, V18, P901, DOI 10.1158/1055-9965.EPI-08-0875
   Waddell N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000080
   Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
   Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983
   You H, 2004, P NATL ACAD SCI USA, V101, P14057, DOI 10.1073/pnas.0406286101
   Zhang Y, 2005, MOL CELL BIOL, V25, P7929, DOI 10.1128/MCB.25.18.7929-7939.2005
   Zheng WX, 2000, GYNECOL ONCOL, V76, P294, DOI 10.1006/gyno.1999.5664
NR 49
TC 69
Z9 79
U1 0
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD MAR 12
PY 2010
VL 86
IS 3
BP 420
EP 433
DI 10.1016/j.ajhg.2010.02.008
PG 14
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 570LG
UT WOS:000275678800013
PM 20206335
OA Green Accepted, Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Chatagnon, A
   Ballestar, E
   Esteller, M
   Dante, R
AF Chatagnon, Amandine
   Ballestar, Esteban
   Esteller, Manel
   Dante, Robert
TI A Role for Methyl-CpG Binding Domain Protein 2 in the Modulation of the
   Estrogen Response of <i>pS2</i>/<i>TFF1</i> Gene
SO PLOS ONE
LA English
DT Article
ID CANCER-CELL-LINES; DNA METHYLATION; BREAST-CANCER; PS2 GENE;
   CHROMATIN-STRUCTURE; EPIGENETIC REGULATION; ACTIVE CHROMATIN; PROMOTER
   DNA; EXPRESSION; TRANSCRIPTION
AB Background: In human Estrogen Receptor alpha (ER alpha)-positive breast cancers, 59 end dense methylation of the estrogen-regulated pS2/TFF1 gene correlates with its transcriptional inhibition. However, in some ER alpha-rich biopsies, pS2 expression is observed despite the methylation of its TATA-box region. Herein, we investigated the methylation-dependent mechanism of pS2 regulation.
   Methodology/Principal Findings: We observed interplay between Methyl-CpG Binding Domain protein 2 (MBD2) transcriptional repressor and ER alpha transactivator: (i) the pS2 gene is poised for transcription upon demethylation limited to the enhancer region containing the estrogen responsive element (ERE); (ii) MBD2-binding sites overlapped with the methylation status of the pS2 59 end; (iii) MBD2 depletion elevated pS2 expression and ectopic expression of ER alpha partially overcame the inhibitory effect of MBD2 when the ERE is unmethylated. Furthermore, serial chromatin immunoprecipitation assays indicated that MBD2 and ER alpha could simultaneously occupy the same pS2 DNA molecule; (iv) concomitant ectopic ER alpha expression and MBD2 depletion resulted in synergistic transcriptional stimulation, while the pS2 promoter remains methylated.
   Conclusions/Significance: MBD2 and ER alpha drive opposite effects on pS2 expression, which are associated with specific steady state levels of histone H3 acetylation and methylation marks. Thus, epigenetic silencing of pS2 could be dependent on balance of the relative intracellular concentrations of ER alpha and MBD2.
C1 [Chatagnon, Amandine; Dante, Robert] INSERM, U590, F-69008 Lyon, France.
   [Ballestar, Esteban; Esteller, Manel] ICO IDIBELL, PEBC, Barcelona, Spain.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Institut d'Investigacio Biomedica de Bellvitge (IDIBELL)
RP Chatagnon, A (通讯作者)，INSERM, U590, F-69008 Lyon, France.
EM dante@univ-lyon1.f
RI Ballestar, Esteban/ABG-8561-2020; Esteller, Manel/L-5956-2014
OI Ballestar, Esteban/0000-0002-1400-2440; Esteller,
   Manel/0000-0003-4490-6093
FU Ligue Nationale contre le Cancer (Comite du Rhene and Comite de la
   Loire); Institut National contre le Cancer (EpiPro and CircBio)
FX The present work was supported by the Ligue Nationale contre le Cancer
   (Comite du Rhene and Comite de la Loire), the Institut National contre
   le Cancer (EpiPro and CircBio). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Amiry N, 2009, ENDOCRINOLOGY, V150, P4473, DOI 10.1210/en.2009-0066
   Auriol E, 2005, NUCLEIC ACIDS RES, V33, P4243, DOI 10.1093/nar/gki729
   Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604
   Barr H, 2007, MOL CELL BIOL, V27, P3750, DOI 10.1128/MCB.02204-06
   Barreto G, 2007, NATURE, V445, P671, DOI 10.1038/nature05515
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Billard LM, 2002, ONCOGENE, V21, P2704, DOI 10.1038/sj/onc/1205357
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x
   BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344
   CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5
   Chen WG, 2003, SCIENCE, V302, P885, DOI 10.1126/science.1086446
   Curradi M, 2002, MOL CELL BIOL, V22, P3157, DOI 10.1128/MCB.22.9.3157-3173.2002
   Delaval K, 2004, CURR OPIN GENET DEV, V14, P188, DOI 10.1016/j.gde.2004.01.005
   Dietrich D, 2009, J HISTOCHEM CYTOCHEM, V57, P477, DOI 10.1369/jhc.2009.953026
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fatemi M, 2006, J CELL SCI, V119, P3033, DOI 10.1242/jcs.03099
   Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038
   Giamarchi C, 1999, ONCOGENE, V18, P533, DOI 10.1038/sj.onc.1202317
   Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538
   Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843
   HUANG LH, 1984, NATURE, V308, P293, DOI 10.1038/308293a0
   Hutchins AS, 2002, MOL CELL, V10, P81, DOI 10.1016/S1097-2765(02)00564-6
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jin SG, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000013
   Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640
   KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   Lopez-Serra L, 2006, CANCER RES, V66, P8342, DOI 10.1158/0008-5472.CAN-06-1932
   Lorincz MC, 2004, NAT STRUCT MOL BIOL, V11, P1068, DOI 10.1038/nsmb840
   Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298
   Martin V, 1998, BIOL CHEM, V379, P409, DOI 10.1515/bchm.1998.379.4-5.409
   Martin V, 1997, J CELL BIOCHEM, V65, P95, DOI 10.1002/(SICI)1097-4644(199704)65:1<95::AID-JCB10>3.0.CO;2-G
   Martinowich K, 2003, SCIENCE, V302, P890, DOI 10.1126/science.1090842
   MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895
   MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3
   Métivier R, 2004, EMBO J, V23, P3653, DOI 10.1038/sj.emboj.7600377
   Métivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6
   Métivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544
   METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579
   Morgan HD, 2005, HUM MOL GENET, V14, pR47, DOI 10.1093/hmg/ddi114
   Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598
   NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x
   Ooi SKT, 2008, CELL, V133, P1145, DOI 10.1016/j.cell.2008.06.009
   Pao MM, 2001, HUM MOL GENET, V10, P903, DOI 10.1093/hmg/10.9.903
   Perrin D, 2007, ONCOGENE, V26, P2518, DOI 10.1038/sj.onc.1210039
   Perry JK, 2008, TRENDS ENDOCRIN MET, V19, P74, DOI 10.1016/j.tem.2007.10.003
   Probst AV, 2009, NAT REV MOL CELL BIO, V10, P192, DOI 10.1038/nrm2640
   Renaud S, 2007, NUCLEIC ACIDS RES, V35, P1245, DOI 10.1093/nar/gkl1125
   RIO MC, 1987, P NATL ACAD SCI USA, V84, P9243, DOI 10.1073/pnas.84.24.9243
   Sahar S, 2007, CELL CYCLE, V6, P1329, DOI 10.4161/cc.6.11.4295
   Saito M, 2002, J BIOL CHEM, V277, P35434, DOI 10.1074/jbc.M203455200
   Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664
   Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924
   Zinn RL, 2007, CANCER RES, V67, P194, DOI 10.1158/0008-5472.CAN-06-3396
NR 56
TC 10
Z9 10
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 12
PY 2010
VL 5
IS 3
AR e9665
DI 10.1371/journal.pone.0009665
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 569SL
UT WOS:000275620900005
PM 20300195
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Poage, GM
   Christensen, BC
   Houseman, EA
   McClean, MD
   Wiencke, JK
   Posner, MR
   Clark, JR
   Nelson, HH
   Marsit, CJ
   Kelsey, KT
AF Poage, Graham M.
   Christensen, Brock C.
   Houseman, E. Andres
   McClean, Michael D.
   Wiencke, John K.
   Posner, Marshall R.
   Clark, John R.
   Nelson, Heather H.
   Marsit, Carmen J.
   Kelsey, Karl T.
TI Genetic and Epigenetic Somatic Alterations in Head and Neck Squamous
   Cell Carcinomas Are Globally Coordinated but Not Locally Targeted
SO PLOS ONE
LA English
DT Article
ID COMPARATIVE GENOMIC HYBRIDIZATION; DNA METHYLATION; COPY NUMBER;
   PROMOTER METHYLATION; HIGH-RESOLUTION; CANCER PATIENTS; POOR-PROGNOSIS;
   BREAST-CANCER; SURVIVAL; ARRAY
AB Background: Solid tumors, including head and neck squamous cell carcinomas (HNSCC), arise as a result of genetic and epigenetic alterations in a sustained stress environment. Little work has been done that simultaneously examines the spectrum of both types of changes in human tumors on a genome-wide scale and results so far have been limited and mixed. Since it has been hypothesized that epigenetic alterations may act by providing the second carcinogenic hit in gene silencing, we sought to identify genome-wide DNA copy number alterations and CpG dinucleotide methylation events and examine the global/local relationships between these types of alterations in HNSCC.
   Methodology/Principal Findings: We have extended a prior analysis of 1,413 cancer-associated loci for epigenetic changes in HNSCC by integrating DNA copy number alterations, measured at 500,000 polymorphic loci, in a case series of 19 primary HNSCC tumors. We have previously demonstrated that local copy number does not bias methylation measurements in this array platform. Importantly, we found that the global pattern of copy number alterations in these tumors was significantly associated with tumor methylation profiles (p<0.002). However at the local level, gene promoter regions did not exhibit a correlation between copy number and methylation (lowest q = 0.3), and the spectrum of genes affected by each type of alteration was unique.
   Conclusion/Significance: This work, using a novel and robust statistical approach demonstrates that, although a "second hit'' mechanism is not likely the predominant mode of action for epigenetic dysregulation in cancer, the patterns of methylation events are associated with the patterns of allele loss. Our work further highlights the utility of integrative genomics approaches in exploring the driving somatic alterations in solid tumors.
C1 [Poage, Graham M.; Kelsey, Karl T.] Brown Univ, Dept Mol Pharmacol, Providence, RI 02912 USA.
   [Poage, Graham M.; Kelsey, Karl T.] Brown Univ, Dept Physiol, Providence, RI 02912 USA.
   [Christensen, Brock C.; Marsit, Carmen J.; Kelsey, Karl T.] Brown Univ, Dept Pathol, Providence, RI 02912 USA.
   [Christensen, Brock C.; Marsit, Carmen J.; Kelsey, Karl T.] Brown Univ, Dept Lab Med, Providence, RI 02912 USA.
   [Christensen, Brock C.; Houseman, E. Andres; Kelsey, Karl T.] Brown Univ, Dept Community Hlth, Ctr Environm Hlth & Technol, Providence, RI 02912 USA.
   [Houseman, E. Andres] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
   [McClean, Michael D.] Boston Univ, Dept Environm Hlth, Boston, MA 02215 USA.
   [Wiencke, John K.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
   [Posner, Marshall R.] Dana Farber Canc Inst, Dept Med Oncol Solid Tumor Oncol, Boston, MA 02115 USA.
   [Clark, John R.] Massachusetts Gen Hosp, Dept Med Hematol Oncol, Boston, MA 02114 USA.
   [Nelson, Heather H.] Univ Minnesota, Mason Canc Ctr, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
C3 Brown University; Brown University; Brown University; Brown University;
   Brown University; Harvard University; Harvard T.H. Chan School of Public
   Health; Boston University; University of California System; University
   of California San Francisco; Harvard University; Dana-Farber Cancer
   Institute; Harvard University; Massachusetts General Hospital;
   University of Minnesota System; University of Minnesota Twin Cities
RP Poage, GM (通讯作者)，Brown Univ, Dept Mol Pharmacol, Providence, RI 02912 USA.
EM Karl_Kelsey@Brown.edu
RI Kelsey, Karl/I-1252-2014; Christensen, Brock/B-8460-2009; McClean,
   Michael/J-2934-2015; Houseman, Eugene Andres/LXW-8656-2024
OI Marsit, Carmen/0000-0003-4566-150X; Houseman, Eugene
   Andres/0000-0003-0703-1830; Nelson, Heather/0000-0003-1901-9513;
   McClean, Michael/0000-0002-3902-8823
FU Flight Attendant Medical Research Institute; National Institutes of
   Health [5R01CA078609-10, 2R01CA100679-06A1, 5RO1ES006717-13]
FX This work was supported by Flight Attendant Medical Research Institute
   (C. M. and M. M.), and the National Institutes of Health
   (5R01CA078609-10, 2R01CA100679-06A1, 5RO1ES006717-13) (K.K. and J.W.).
   The funders had no role in study design, data collection, decision to
   publish, or preparation of the manuscript.
CR Adélaide J, 2007, CANCER RES, V67, P11565, DOI 10.1158/0008-5472.CAN-07-2536
   Andrews J, PLOS ONE, V5, pe8665
   Arnold CN, 2004, CANCER BIOL THER, V3, P960, DOI 10.4161/cbt.3.10.1113
   Ashman JNE, 2003, BRIT J CANCER, V89, P864, DOI 10.1038/sj.bjc.6601199
   Bauer VL, 2008, J MOL MED, V86, P1353, DOI 10.1007/s00109-008-0397-0
   Bérgamo NA, 2005, CLIN CANCER RES, V11, P621
   Bockmühl U, 2000, AM J PATHOL, V157, P369, DOI 10.1016/S0002-9440(10)64549-X
   Bockmühl U, 2001, OTOLARYNG HEAD NECK, V124, P451, DOI 10.1067/mhn.2001.114794
   Bollati V, 2007, CANCER RES, V67, P876, DOI 10.1158/0008-5472.CAN-06-2995
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385
   Christensen BC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000602
   Christensen BC, 2009, CANCER RES, V69, P227, DOI 10.1158/0008-5472.CAN-08-2586
   Costello Joseph F., 2009, V507, P131, DOI 10.1007/978-1-59745-522-0_11
   Dikshit RP, 2007, CANCER-AM CANCER SOC, V110, P1745, DOI 10.1002/cncr.22975
   Ell SR, 2002, LARYNGOSCOPE, V112, P1094, DOI 10.1097/00005537-200206000-00029
   Furniss CS, 2007, INT J CANCER, V120, P2386, DOI 10.1002/ijc.22633
   Garnis C, 2004, ONCOGENE, V23, P2582, DOI 10.1038/sj.onc.1207367
   Gollin SM, 2001, HEAD NECK-J SCI SPEC, V23, P238, DOI 10.1002/1097-0347(200103)23:3<238::AID-HED1025>3.0.CO;2-H
   Ha PK, 2006, LANCET ONCOL, V7, P77, DOI 10.1016/S1470-2045(05)70540-4
   Hasegawa M, 2002, ONCOGENE, V21, P4231, DOI 10.1038/sj.onc.1205528
   Hassan KMA, 2001, HUM GENET, V109, P452
   Hogg RP, 2002, EUR J CANCER, V38, P1585, DOI 10.1016/S0959-8049(01)00422-1
   Houseman EA, 2009, BIOINFORMATICS, V25, P1999, DOI 10.1093/bioinformatics/btp364
   Houseman EA, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-365
   Huang Jing, 2004, Human Genomics, V1, P287
   Irizarry RA, 2008, GENOME RES, V18, P780, DOI 10.1101/gr.7301508
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Jin C, 2002, CANCER GENET CYTOGEN, V132, P85, DOI 10.1016/S0165-4608(01)00535-0
   Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368
   Jun P, 2009, NEURO-ONCOLOGY, V11, P414, DOI 10.1215/15228517-2008-096
   KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820
   Li XH, 2008, CANCER PREV RES, V1, P413, DOI 10.1158/1940-6207.CAPR-08-0121
   Lin LJ, 2008, ONCOLOGY-BASEL, V75, P102, DOI 10.1159/000155813
   Marsit CJ, 2008, CANCER-AM CANCER SOC, V113, P1566, DOI 10.1002/cncr.23770
   Marsit CJ, 2006, INT J CANCER, V119, P1761, DOI 10.1002/ijc.22051
   Marsit CJ, 2009, CARCINOGENESIS, V30, P416, DOI 10.1093/carcin/bgp006
   Matsuzaki K, 2005, CLIN CANCER RES, V11, P8564, DOI 10.1158/1078-0432.CCR-05-0859
   Miracca EC, 1999, BRIT J CANCER, V81, P677, DOI 10.1038/sj.bjc.6690747
   Modrek B, 2009, MOL CANCER RES, V7, P1244, DOI 10.1158/1541-7786.MCR-08-0532
   Oda M, 2009, NUCLEIC ACIDS RES, V37, P3829, DOI 10.1093/nar/gkp260
   Ohta S, 2009, ORAL SURG ORAL MED O, V107, P81, DOI 10.1016/j.tripleo.2008.08.027
   Park JJ, 2008, GENE, V407, P139, DOI 10.1016/j.gene.2007.10.011
   Pfister S, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm094
   Richards KL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004941
   Sadikovic B, 2009, HUM MOL GENET, V18, P1962, DOI 10.1093/hmg/ddp117
   Sellick GS, 2007, BLOOD, V110, P3326, DOI 10.1182/blood-2007-05-091561
   Singh B, 2001, CANCER RES, V61, P4506
   Wang YP, 2005, NEOPLASIA, V7, P748, DOI 10.1593/neo.05289
   Welm AL, 2007, P NATL ACAD SCI USA, V104, P7570, DOI 10.1073/pnas.0702095104
   Wolff E, 1998, ORAL ONCOL, V34, P186, DOI 10.1016/S1368-8375(97)00079-1
   Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052
   Yang QF, 2002, CLIN CANCER RES, V8, P2890
   Yuan E, 2006, CANCER RES, V66, P3443, DOI 10.1158/0008-5472.CAN-05-3739
NR 53
TC 32
Z9 36
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 11
PY 2010
VL 5
IS 3
AR e9651
DI 10.1371/journal.pone.0009651
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 569SJ
UT WOS:000275620600007
PM 20300172
OA gold, Green Accepted, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Hill, VK
   Hesson, LB
   Dansranjavin, T
   Dallol, A
   Bieche, I
   Vacher, S
   Tommasi, S
   Dobbins, T
   Gentle, D
   Euhus, D
   Lewis, C
   Dammann, R
   Ward, RL
   Minna, J
   Maher, ER
   Pfeifer, GP
   Latif, F
AF Hill, Victoria K.
   Hesson, Luke B.
   Dansranjavin, Temuujin
   Dallol, Ashraf
   Bieche, Ivan
   Vacher, Sophie
   Tommasi, Stella
   Dobbins, Timothy
   Gentle, Dean
   Euhus, David
   Lewis, Cheryl
   Dammann, Reinhard
   Ward, Robyn L.
   Minna, John
   Maher, Eammon R.
   Pfeifer, Gerd P.
   Latif, Farida
TI Identification of 5 novel genes methylated in breast and other
   epithelial cancers
SO MOLECULAR CANCER
LA English
DT Article
ID TUMOR-SUPPRESSOR REGION; SQUAMOUS-CELL CARCINOMA; DNA METHYLATION;
   BLADDER-CANCER; CHROMOSOME 3P; ALLELIC LOSS; HETEROZYGOSITY; EXPRESSION;
   DBCCR1; HYPERMETHYLATION
AB Background: There are several high throughput approaches to identify methylated genes in cancer. We utilized one such recently developed approach, MIRA (methylated-CpG island recovery assay) combined with CpG island arrays to identify novel genes that are epigenetically inactivated in breast cancer.
   Results: Using this approach we identified numerous CpG islands that demonstrated aberrant DNA methylation in breast cancer cell lines. Using a combination of COBRA and sequencing of bisulphite modified DNA, we confirmed 5 novel genes frequently methylated in breast tumours; EMILIN2, SALL1, DBC1, FBLN2 and CIDE-A. Methylation frequencies ranged from between 25% and 63% in primary breast tumours, whilst matched normal breast tissue DNA was either unmethylated or demonstrated a much lower frequency of methylation compared to malignant breast tissue DNA. Furthermore expression of the above 5 genes was shown to be restored following treatment with a demethylating agent in methylated breast cancer cell lines. We have expanded this analysis across three other common epithelial cancers (lung, colorectal, prostate). We demonstrate that the above genes show varying levels of methylation in these cancers. Lastly and most importantly methylation of EMILIN2 was associated with poorer clinical outcome in breast cancer and was strongly associated with estrogen receptor as well as progesterone receptor positive breast cancers.
   Conclusion: The combination of the MIRA assay with CpG island arrays is a very useful technique for identifying epigenetically inactivated genes in cancer genomes and can provide molecular markers for early cancer diagnosis, prognosis and epigenetic therapy.
C1 [Hill, Victoria K.; Hesson, Luke B.; Dallol, Ashraf; Gentle, Dean; Maher, Eammon R.; Latif, Farida] Univ Birmingham, Coll Med & Dent Sci, Sch Clin & Expt Med, Dept Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.
   [Hesson, Luke B.; Dobbins, Timothy; Ward, Robyn L.] Univ New S Wales, Fac Med, Prince Wales Clin Sch, Sydney, NSW 2052, Australia.
   [Hesson, Luke B.; Dobbins, Timothy; Ward, Robyn L.] Univ New S Wales, Fac Med, Lowy Canc Res Ctr, Adult Canc Program, Sydney, NSW 2052, Australia.
   [Dansranjavin, Temuujin; Dammann, Reinhard] Univ Giessen, Inst Genet, D-35392 Giessen, Germany.
   [Bieche, Ivan; Vacher, Sophie] Ctr Rene Huguenin, INSERM, U735, Oncogenet Lab, St Cloud, France.
   [Tommasi, Stella; Pfeifer, Gerd P.] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA.
   [Euhus, David; Lewis, Cheryl] Univ Texas SW Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA.
   [Minna, John] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA.
C3 University of Birmingham; University of New South Wales Sydney;
   University of New South Wales Sydney; Justus Liebig University Giessen;
   Rene Huguenin Hospital; Institut National de la Sante et de la Recherche
   Medicale (Inserm); City of Hope; Beckman Research Institute of City of
   Hope; University of Texas System; University of Texas Southwestern
   Medical Center Dallas; University of Texas System; University of Texas
   Southwestern Medical Center Dallas
RP Latif, F (通讯作者)，Univ Birmingham, Coll Med & Dent Sci, Sch Clin & Expt Med, Dept Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.
EM f.latif@bham.ac.uk
RI Dobbins, Timothy/AAS-1422-2020; Minna, John/AAB-1036-2022; MAHER,
   EAMONN/A-9507-2008; Hesson, Luke/HDM-0311-2022; Ward, Robyn
   Lynne/I-2313-2013; Dobbins, Timothy/I-5819-2013; Dallol,
   Ashraf/H-8661-2012; Bieche, Ivan/O-7399-2017
OI Ward, Robyn Lynne/0000-0002-6877-8906; VACHER,
   Sophie/0000-0002-0042-6023; Dobbins, Timothy/0000-0003-1841-9056;
   Dallol, Ashraf/0000-0002-8803-228X; Tommasi, Stella/0000-0001-6897-4985;
   Bieche, Ivan/0000-0002-2430-5429
FU Breast Cancer Campaign; CRUK; Komen foundation; DOD
FX F Latif laboratory is partly funded by Breast Cancer Campaign and CRUK.
   J Minna funded by Komen foundation and DOD. We thank Tapio Visakorpi for
   providing DNA from prostate tumour cell lines.
CR Argos M, 2008, CANCER GENET CYTOGEN, V182, P69, DOI 10.1016/j.cancergencyto.2008.01.001
   Braga E, 2002, INT J CANCER, V100, P534, DOI 10.1002/ijc.10511
   Chan TA, 2008, PLOS MED, V5, P823, DOI 10.1371/journal.pmed.0050114
   Chin SF, 2007, ONCOGENE, V26, P1959, DOI 10.1038/sj.onc.1209985
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Dunwell TL, 2009, EPIGENETICS-US, V4, P185, DOI 10.4161/epi.4.3.8752
   Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007
   Gao S, 2004, BRIT J CANCER, V91, P760, DOI 10.1038/sj.bjc.6601980
   Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L
   Habuchi T, 1998, GENOMICS, V48, P277, DOI 10.1006/geno.1997.5165
   Habuchi T, 2001, ONCOGENE, V20, P531, DOI 10.1038/sj.onc.1204122
   Hesson L, 2004, ONCOGENE, V23, P2408, DOI 10.1038/sj.onc.1207407
   Hesson LB, 2007, DIS MARKERS, V23, P73, DOI 10.1155/2007/291538
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526
   Izumi H, 2005, HUM MOL GENET, V14, P997, DOI 10.1093/hmg/ddi092
   JOSEFNERIZ FS, 2006, BRIT J HAEMATOL, V134, P137
   Karkera JD, 2000, CLIN CANCER RES, V6, P3565
   Kittiniyom K, 2001, BREAST CANCER RES, V3, P192, DOI 10.1186/bcr294
   Kohlhase J, 1998, NAT GENET, V18, P81, DOI 10.1038/ng0198-81
   Kuang SQ, 2008, LEUKEMIA, V22, P1529, DOI 10.1038/leu.2008.130
   Lewis CM, 2006, BREAST CANCER RES TR, V99, P103, DOI 10.1007/s10549-006-9189-9
   Li D, 2008, NUCLEIC ACIDS RES, V36, P330, DOI 10.1093/nar/gkm1028
   Maitra A, 2001, AM J PATHOL, V159, P119, DOI 10.1016/S0002-9440(10)61679-3
   Mongiat M, 2007, MOL CELL BIOL, V27, P7176, DOI 10.1128/MCB.00696-07
   Nishinakamura R, 2005, KIDNEY INT, V68, P1948, DOI 10.1111/j.1523-1755.2005.00626.x
   Nishiyama H, 2001, ONCOGENE, V20, P2956, DOI 10.1038/sj.onc.1204432
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Rauch T, 2007, P NATL ACAD SCI USA, V104, P5527, DOI 10.1073/pnas.0701059104
   Rauch T, 2006, CANCER RES, V66, P7939, DOI 10.1158/0008-5472.CAN-06-1888
   Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004
   Sadr-Nabavi A, 2009, INT J CANCER, V124, P1727, DOI 10.1002/ijc.24108
   Toziu-Kara S, 2007, J MOL ENDOCRINOL, V39, P305, DOI 10.1677/JME-07-0001
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yi CH, 2007, AM J PATHOL, V170, P1535, DOI 10.2353/ajpath.2007.060478
   Zhou ZH, 2003, NAT GENET, V35, P49, DOI 10.1038/ng1225
NR 36
TC 67
Z9 71
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD MAR 5
PY 2010
VL 9
AR 51
DI 10.1186/1476-4598-9-51
PG 13
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 571FQ
UT WOS:000275737500001
PM 20205715
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Suzuki, H
   Igarashi, S
   Nojima, M
   Maruyama, R
   Yamamoto, E
   Kai, M
   Akashi, H
   Watanabe, Y
   Yamamoto, H
   Sasaki, Y
   Itoh, F
   Imai, K
   Sugai, T
   Shen, LL
   Issa, JPJ
   Shinomura, Y
   Tokino, T
   Toyota, M
AF Suzuki, Hiromu
   Igarashi, Shinichi
   Nojima, Masanori
   Maruyama, Reo
   Yamamoto, Eiichiro
   Kai, Masahiro
   Akashi, Hirofumi
   Watanabe, Yoshiyuki
   Yamamoto, Hiroyuki
   Sasaki, Yasushi
   Itoh, Fumio
   Imai, Kohzoh
   Sugai, Tamotsu
   Shen, Lanlan
   Issa, Jean-Pierre J.
   Shinomura, Yasuhisa
   Tokino, Takashi
   Toyota, Minoru
TI IGFBP7 is a p53-responsive gene specifically silenced in colorectal
   cancer with CpG island methylator phenotype
SO CARCINOGENESIS
LA English
DT Article
ID PROTEIN-RELATED PROTEIN-1; TUMOR-SUPPRESSIVE ACTIVITY; COLON-CANCER;
   P53-REGULATED GENES; SECRETED PROTEIN; PROSTATE-CANCER; DOWN-REGULATION;
   GASTRIC-CANCER; BREAST-CANCER; DIRECT TARGET
AB A subset of colorectal cancers (CRCs) show simultaneous methylation of multiple genes; these tumors have the CpG island methylator phenotype (CIMP). CRCs with CIMP show a specific pattern of genetic alterations, including a high frequency of BRAF mutations and a low frequency of p53 mutations. We therefore hypothesized that genes inactivated by DNA methylation are involved in the BRAF- and p53-signaling pathways. Among those, we examined the epigenetic inactivation of insulin-like growth factor-binding protein 7 (IGFBP7) expression in CRCs. We found that in CRC cell lines, the silencing of IGFBP7 expression was correlated with high levels of DNA methylation and low levels of histone H3K4 methylation. Luciferase and chromatin immunoprecipitation assays in unmethylated cells revealed that p53 induces expression of IGFBP7 upon binding to a p53 response element within intron 1 of the gene. Treating methylated CRC cell lines with 5-aza-2'-deoxycytidine restored p53-induced IGFBP7 expression. Levels of IGFBP7 methylation were also significantly higher in primary CRC specimens than in normal colonic tissue (P < 0.001). Methylation of IGFBP7 was correlated with BRAF mutations, an absence of p53 mutations and the presence of CIMP. Thus, epigenetic inactivation of IGFBP7 appears to play a key role in tumorigenesis of CRCs with CIMP by enabling escape from p53-induced senescence.
C1 [Suzuki, Hiromu; Kai, Masahiro; Toyota, Minoru] Sapporo Med Univ, Dept Biochem, Chuo Ku, Sapporo, Hokkaido 0608556, Japan.
   [Suzuki, Hiromu; Igarashi, Shinichi; Maruyama, Reo; Yamamoto, Eiichiro; Yamamoto, Hiroyuki; Imai, Kohzoh; Shinomura, Yasuhisa] Sapporo Med Univ, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido 0608556, Japan.
   [Suzuki, Hiromu; Sasaki, Yasushi; Tokino, Takashi] Sapporo Med Univ, Dept Mol Biol, Inst Canc Res, Chuo Ku, Sapporo, Hokkaido 0608556, Japan.
   [Nojima, Masanori] Sapporo Med Univ, Dept Publ Hlth, Chuo Ku, Sapporo, Hokkaido 0608556, Japan.
   [Akashi, Hirofumi] Sapporo Med Univ, Ctr Bioinformat, Chuo Ku, Sapporo, Hokkaido 0608556, Japan.
   [Watanabe, Yoshiyuki; Itoh, Fumio] St Marianna Univ, Sch Med, Dept Gastroenterol & Hepatol, Kawasaki, Kanagawa 2168511, Japan.
   [Sugai, Tamotsu] Iwate Med Univ, Dept Pathol, Div Diagnost Mol Pathol, Morioka, Iwate 0208505, Japan.
   [Shen, Lanlan; Issa, Jean-Pierre J.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.
   [Shen, Lanlan; Issa, Jean-Pierre J.] Univ Texas MD Anderson Canc Ctr, Epigenet Ctr, Houston, TX 77030 USA.
C3 Sapporo Medical University; Sapporo Medical University; Sapporo Medical
   University; Sapporo Medical University; Sapporo Medical University;
   Saint Marianna University; Iwate Medical University; University of Texas
   System; UTMD Anderson Cancer Center; University of Texas System; UTMD
   Anderson Cancer Center
RP Toyota, M (通讯作者)，Sapporo Med Univ, Dept Biochem, Chuo Ku, South 1,West 17, Sapporo, Hokkaido 0608556, Japan.
EM shinomura@sapmed.ac.jp; mtoyota@sapmed.ac.jp
RI Nojima, Masanori/ABE-2237-2020; Tokino, Takashi/AAI-9887-2021; Sasaki,
   Yasushi/AAA-3079-2019
OI Shen, Lanlan/0000-0002-1532-5807; Nojima, Masanori/0000-0002-8788-2522;
   Sasaki, Yasushi/0000-0002-3500-8059; Issa,
   Jean-Pierre/0000-0003-2258-5030
FU Ministry of Education, Culture, Sports, Science and Technology, Japan;
   Japan Society for Promotion of Science, Japan; Ministry of Health,
   Labor, and Welfare, Japan
FX Grants-in-Aid for Scientific Research on Priority Areas from the
   Ministry of Education, Culture, Sports, Science and Technology ( K. I.,
   T. T. and M. T.); Grants-in-Aid for Scientific Research ( S) from Japan
   Society for Promotion of Science ( K. I.); Grant-in-Aid for the
   Third-term Comprehensive 10 year Strategy for Cancer Control;
   Grant-in-Aid for Cancer Research from the Ministry of Health, Labor, and
   Welfare, Japan ( M. T.).
CR Adachi K, 2004, ONCOGENE, V23, P7791, DOI 10.1038/sj.onc.1208067
   AKAOGI K, 1994, BIOCHEM BIOPH RES CO, V198, P1046, DOI 10.1006/bbrc.1994.1149
   Akino K, 2005, GASTROENTEROLOGY, V129, P156, DOI 10.1053/j.gastro.2005.03.051
   Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0
   Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497
   Burger AM, 1998, ONCOGENE, V16, P2459, DOI 10.1038/sj.onc.1201772
   CHEN JY, 1993, ONCOGENE, V8, P2159
   Chen Y, 2007, J PATHOL, V211, P431, DOI 10.1002/path.2132
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Egger G, 2006, P NATL ACAD SCI USA, V103, P14080, DOI 10.1073/pnas.0604602103
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097
   Gazin C, 2007, NATURE, V449, P1073, DOI 10.1038/nature06251
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kanai Y, 2007, CARCINOGENESIS, V28, P2434, DOI 10.1093/carcin/bgm206
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1
   Kortlever RM, 2006, NAT CELL BIOL, V8, P877, DOI 10.1038/ncb1448
   Landberg G, 2001, ONCOGENE, V20, P3497, DOI 10.1038/sj.onc.1204471
   Lin J, 2007, J PATHOL, V212, P83, DOI 10.1002/path.2144
   Lin J, 2008, CANCER BIOL THER, V7, P1896, DOI 10.4161/cbt.7.12.6937
   Maruyama R, 2006, CANCER RES, V66, P4574, DOI 10.1158/0008-5472.CAN-05-2562
   Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890
   Minoo P, 2006, J PATHOL, V210, P137, DOI 10.1002/path.2047
   Minoo P, 2007, MODERN PATHOL, V20, P331, DOI 10.1038/modpathol.3800740
   Mutaguchi K, 2003, CANCER RES, V63, P7717
   Nojima M, 2007, ONCOGENE, V26, P4699, DOI 10.1038/sj.onc.1210259
   Qian YJ, 2008, J BIOL CHEM, V283, P2896, DOI 10.1074/jbc.M708624200
   Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395
   Sasaki Y, 2003, CANCER RES, V63, P8145
   Sato J, 1999, J CELL BIOCHEM, V75, P187, DOI 10.1002/(SICI)1097-4644(19991101)75:2<187::AID-JCB1>3.3.CO;2-I
   Sato Y, 2007, CANCER SCI, V98, P1055, DOI 10.1111/j.1349-7006.2007.00502.x
   Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9
   Shen LL, 2007, P NATL ACAD SCI USA, V104, P18654, DOI 10.1073/pnas.0704652104
   Sprenger CC, 2002, ONCOGENE, V21, P140, DOI 10.1038/sj.onc.1205021
   Suzuki H, 2000, CANCER RES, V60, P4353
   Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325
   Ushijima T, 2005, CANCER SCI, V96, P206, DOI 10.1111/j.1349-7006.2005.00035.x
   Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032
   WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Wilson HMP, 2002, CELL GROWTH DIFFER, V13, P205
   Yamashita S, 2006, CANCER SCI, V97, P64, DOI 10.1111/j.1349-7006.2006.00136.x
   Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517
   Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997
NR 51
TC 87
Z9 96
U1 0
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD MAR
PY 2010
VL 31
IS 3
BP 342
EP 349
DI 10.1093/carcin/bgp179
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 564VE
UT WOS:000275245200003
PM 19638426
OA Bronze
DA 2025-01-12
ER

PT J
AU Starlard-Davenport, A
   Tryndyak, VP
   James, SR
   Karpf, AR
   Latendresse, JR
   Beland, FA
   Pogribny, IP
AF Starlard-Davenport, Athena
   Tryndyak, Volodymyr P.
   James, Smitha R.
   Karpf, Adam R.
   Latendresse, John R.
   Beland, Frederick A.
   Pogribny, Igor P.
TI Mechanisms of epigenetic silencing of the <i>Rassf1a</i> gene during
   estrogen-induced breast carcinogenesis in ACI rats
SO CARCINOGENESIS
LA English
DT Article
ID DNA METHYLATION; CPG ISLAND; CANCER STATISTICS; TUMOR-SUPPRESSOR;
   CELL-LINES; HYPERMETHYLATION; HEPATOCARCINOGENESIS; METHYLTRANSFERASES;
   ASSOCIATION; REPRESSION
AB Breast cancer, the most common malignancy in women, emerges through a multistep process, encompassing the progressive sequential evolution of morphologically distinct stages from a normal cell to hyperplasia (with and without atypia), carcinoma in situ, invasive carcinoma and metastasis. The success of treatment of breast cancer could be greatly improved by the detection at early stages of cancer. In the present study, we investigated the underlying molecular mechanisms involved in breast carcinogenesis in Augustus and Copenhagen-Irish female rats, a cross between the ACI strains, induced by continuous exposure to 17 beta-estradiol. The results of our study demonstrate that early stages of estrogen-induced breast carcinogenesis are characterized by altered global DNA methylation, aberrant expression of proteins responsible for the proper maintenance of DNA methylation pattern and epigenetic silencing of the critical Rassf1a (Ras-association domain family 1, isoform A) tumor suppressor gene. Interestingly, transcriptional repression of the Rassf1a gene in mammary glands during early stages of breast carcinogenesis was associated with an increase in trimethylation of histones H3 lysine 9 and H3 lysine 27 and de novo CpG island methylation and at the Rassf1a promoter and first exon. In conclusion, we demonstrate that epigenetic alterations precede formation of preneoplastic lesions indicating the significance of epigenetic events in induction of oncogenic pathways in early stages of carcinogenesis.
C1 [Starlard-Davenport, Athena; Tryndyak, Volodymyr P.; Beland, Frederick A.; Pogribny, Igor P.] Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA.
   [James, Smitha R.; Karpf, Adam R.] Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA.
   [Latendresse, John R.] Toxicol Pathol Associates, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA.
C3 US Food & Drug Administration (FDA); Roswell Park Comprehensive Cancer
   Center; US Food & Drug Administration (FDA)
RP Pogribny, IP (通讯作者)，Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA.
EM igor.pogribny@fda.hhs.gov
RI Latendresse, John/A-9215-2009; Starlard-Davenport, Athena/Q-3866-2017
OI Karpf, Adam/0000-0002-0866-0666; Beland, Frederick/0000-0002-2113-6260;
   Tryndyak, Volodymyr/0000-0002-8319-2954; Starlard-Davenport,
   Athena/0000-0002-8938-237X
FU DA-National Center for Toxicological Research
FX Intramural Research Program, FDA-National Center for Toxicological
   Research.
CR Asada K, 2006, ONCOL REP, V15, P1241
   Bagnyukova TV, 2008, CELL CYCLE, V7, P3202, DOI 10.4161/cc.7.20.6816
   Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2
   Dammann R, 2001, CANCER RES, V61, P3105
   Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Glass AG, 2007, JNCI-J NATL CANCER I, V99, P1152, DOI 10.1093/jnci/djm059
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hesson LB, 2007, DIS MARKERS, V23, P73, DOI 10.1155/2007/291538
   Hinshelwood RA, 2009, HUM MOL GENET, V18, P3098, DOI 10.1093/hmg/ddp251
   Hinshelwood RA, 2008, J MOL MED, V86, P1315, DOI 10.1007/s00109-008-0386-3
   Hublitz P, 2009, INT J DEV BIOL, V53, P335, DOI 10.1387/ijdb.082717ph
   JEMAL A, 2007, BREAST CANCER RES, V9, P108
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kioulafa M, 2009, CLIN BIOCHEM, V42, P970, DOI 10.1016/j.clinbiochem.2009.04.003
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Li JJ, 2003, ADV EXP MED BIOL, V532, P195
   Liang GG, 2002, MOL CELL BIOL, V22, P480, DOI 10.1128/MCB.22.2.480-491.2002
   Majumder S, 2006, J BIOL CHEM, V281, P22062, DOI 10.1074/jbc.M601155200
   Medina D, 2002, BBA-REV CANCER, V1603, P1, DOI 10.1016/S0304-419X(02)00053-7
   Moss TJ, 2007, MUTAT RES-FUND MOL M, V618, P163, DOI 10.1016/j.mrfmmm.2006.05.038
   Polyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295
   Ravoori S, 2007, INT J ONCOL, V31, P113
   Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004
   Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Shimizu K, 2007, CANCER SCI, V98, P1318, DOI 10.1111/j.1349-7006.2007.00564.x
   Simpson PT, 2005, J PATHOL, V205, P248, DOI 10.1002/path.1691
   Snowden AW, 2002, CURR BIOL, V12, P2159, DOI 10.1016/S0960-9822(02)01391-X
   Song LG, 2005, ANAL CHEM, V77, P504, DOI 10.1021/ac0489420
   Tryndyak VP, 2006, CARCINOGENESIS, V27, P1713, DOI 10.1093/carcin/bgl050
   Ushijima T, 2005, CANCER SCI, V96, P206, DOI 10.1111/j.1349-7006.2005.00035.x
   VANDERWEYDEN L, 2007, BIOCHIM BIOPHYS ACTA, V1766, P58
   Vichalkovski A, 2008, CURR BIOL, V18, P1889, DOI 10.1016/j.cub.2008.10.060
   Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wu M, 2009, P NATL ACAD SCI USA, V106, P7022, DOI 10.1073/pnas.0811785106
   Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776
   Yan PS, 2003, CANCER RES, V63, P6178
   Ye Yumei, 2004, Breast Dis, V19, P69
   Yu Q, 2008, EPIGENETICS, V3, P315, DOI 10.4161/epi.3.6.7202
NR 44
TC 21
Z9 22
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD MAR
PY 2010
VL 31
IS 3
BP 376
EP 381
DI 10.1093/carcin/bgp304
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 564VE
UT WOS:000275245200007
PM 20008439
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Lim, S
   Janzer, A
   Becker, A
   Zimmer, A
   Schüle, R
   Buettner, R
   Kirfel, J
AF Lim, Soyoung
   Janzer, Andreas
   Becker, Astrid
   Zimmer, Andreas
   Schuele, Roland
   Buettner, Reinhard
   Kirfel, Jutta
TI Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative
   breast cancers and a biomarker predicting aggressive biology
SO CARCINOGENESIS
LA English
DT Article
ID CYCLIN-A EXPRESSION; ANDROGEN-RECEPTOR; HISTONE DEMETHYLATION; GENE;
   TRIMETHYLATION; TRANSCRIPTION; METHYLATION; ACTIVATION; PROTEIN-2;
   TARGET
AB Breast carcinogenesis is a multistep process involving both genetic and epigenetic changes. Since epigenetic changes like histone modifications are potentially reversible processes, much effort has been directed toward understanding this mechanism with the goal of finding novel therapies as well as more refined diagnostic and prognostic tools in breast cancer. Lysine-specific demethylase 1 (LSD1) plays a key role in the regulation of gene expression by removing the methyl groups from methylated lysine 4 of histone H3 and lysine 9 of histone H3. LSD1 is essential for mammalian development and involved in many biological processes. Considering recent evidence that LSD1 is involved in carcinogenesis, we investigated the role of LSD1 in breast cancer. Therefore, we developed an enzyme-linked immunosorbent assay to determine LSD1 protein levels in tissue specimens of breast cancer and measured very high LSD1 levels in estrogen receptor (ER)-negative tumors. Pharmacological LSD1 inhibition resulted in growth inhibition of breast cancer cells. Knockdown of LSD1 using small interfering RNA approach induced regulation of several proliferation-associated genes like p21, ERBB2 and CCNA2. Additionally, we found that LSD1 is recruited to the promoters of these genes. In summary, our data indicate that LSD1 may provide a predictive marker for aggressive biology and a novel attractive therapeutic target for treatment of ER-negative breast cancers.
C1 [Lim, Soyoung; Janzer, Andreas; Buettner, Reinhard; Kirfel, Jutta] Univ Bonn, Inst Pathol, D-53127 Bonn, Germany.
   [Becker, Astrid; Zimmer, Andreas] Univ Bonn, Inst Mol Psychiat, D-53127 Bonn, Germany.
   [Schuele, Roland] Univ Freiburg, Med Ctr, Clin Res Ctr, D-79106 Freiburg, Germany.
C3 University of Bonn; University of Bonn; University of Freiburg
RP Kirfel, J (通讯作者)，Univ Bonn, Inst Pathol, Sigmund Freud Str 25, D-53127 Bonn, Germany.
EM jutta.kirfel@ukb.uni-bonn.de
RI Schüle, Rebecca/B-5763-2019; Zimmer, Andreas/B-8357-2009
FU Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe
FX Grants from the Deutsche Forschungsgemeinschaft to R. B. and J.K. and by
   a grant from the Deutsche Krebshilfe to support the Center of Integrated
   Oncology (CIO Koln/Bonn).
CR Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657
   Bradley C, 2007, CARCINOGENESIS, V28, P2184, DOI 10.1093/carcin/bgm100
   Chen Q, 2004, DEV NEUROSCI-BASEL, V26, P435, DOI 10.1159/000082285
   Cui XJ, 2005, J CLIN ONCOL, V23, P7721, DOI 10.1200/JCO.2005.09.004
   Ding L, 2006, CANCER RES, V66, P9352, DOI 10.1158/0008-5472.CAN-06-2384
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Forneris F, 2008, TRENDS BIOCHEM SCI, V33, P181, DOI 10.1016/j.tibs.2008.01.003
   Fraczek M, 2008, ACTA OTO-LARYNGOL, V128, P329, DOI 10.1080/00016480701487742
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   GARCIABASSETS I, 2007, NUCL RECEPTORS, V128, P505
   Gartenhaus RB, 1996, P NATL ACAD SCI USA, V93, P265, DOI 10.1073/pnas.93.1.265
   Goidin D, 2001, ANAL BIOCHEM, V295, P17, DOI 10.1006/abio.2001.5171
   HARPER JW, 1993, CELL, V75, P805
   Huang Y, 2007, P NATL ACAD SCI USA, V104, P8023, DOI 10.1073/pnas.0700720104
   Husdal A, 2006, CELL ONCOL, V28, P107
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570
   Klose RJ, 2006, NATURE, V442, P312, DOI 10.1038/nature04853
   Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493
   Lee MG, 2006, CHEM BIOL, V13, P563, DOI 10.1016/j.chembiol.2006.05.004
   Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879
   Mann BS, 2007, CLIN CANCER RES, V13, P2318, DOI 10.1158/1078-0432.CCR-06-2672
   Marchiò C, 2008, J PATHOL, V216, P399, DOI 10.1002/path.2423
   McIntyre E, 2009, BREAST CANC RES TREA
   Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   O'Brien SL, 2007, INT J CANCER, V120, P1434, DOI 10.1002/ijc.22413
   Osthus RC, 2005, CANCER RES, V65, P5620, DOI 10.1158/0008-5472.CAN-05-0536
   Patel RS, 2007, HISTOPATHOLOGY, V51, P21, DOI 10.1111/j.1365-2559.2007.02729.x
   Pellikainen JM, 2007, INT J CANCER, V120, P2061, DOI 10.1002/ijc.22648
   Ramachandran C, 2005, ANTICANCER RES, V25, P3293
   REMMELE W, 1986, VIRCHOWS ARCH A, V409, P127, DOI 10.1007/BF00708323
   SANTISTEBAN M, 2009, BREAST CANC RES TREA, pK167
   Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735
   Scoumanne A, 2007, J BIOL CHEM, V282, P15471, DOI 10.1074/jbc.M701023200
   Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   STREBHARDT K, 2006, NAT REV CANCER, V330, P1
   SUNAMI E, 2008, BREAST CANCER RES, V46, P2
   Traub F, 2006, BREAST CANCER RES TR, V99, P185, DOI 10.1007/s10549-006-9202-3
   Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433
   Wang JX, 2007, NATURE, V446, P882, DOI 10.1038/nature05671
   Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268
   Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028
   Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546
   Worku D, 2008, ANTICANCER RES, V28, P2135
   Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027
NR 46
TC 381
Z9 494
U1 3
U2 62
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD MAR
PY 2010
VL 31
IS 3
BP 512
EP 520
DI 10.1093/carcin/bgp324
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 564VE
UT WOS:000275245200026
PM 20042638
DA 2025-01-12
ER

PT J
AU Cecener, G
   Tunca, B
   Egeli, U
   Bekar, A
   Guler, G
   Tolunay, S
   Aksoy, K
AF Cecener, Gulsah
   Tunca, Berrin
   Egeli, Unal
   Bekar, Ahmet
   Guler, Gulnur
   Tolunay, Sahsine
   Aksoy, Kaya
TI FHIT Gene Sequence Variants and Reduced Fhit Protein Expression in
   Glioblastoma Multiforme
SO CELLULAR AND MOLECULAR NEUROBIOLOGY
LA English
DT Article
DE Glioblastoma multiforme; FHIT gene; Sequence alterations; SSCP; IHC
ID COMMON FRAGILE SITES; CELL LUNG-CANCER; TUMOR-SUPPRESSOR GENE;
   BRAIN-TUMORS; BREAST-CANCER; TURKISH PATIENTS; PREDISPOSITION;
   MUTATIONS; 3P14.2; CARCINOMA
AB Molecular studies have an important role in the elucidation of the mechanisms involved in Glioblastoma multiforme (GBM) development. The occurrence of FHIT gene alterations, which has an important role in different cancers, has not yet been studied well in GBM. We aimed to investigate the occurrence of alterations of FHIT gene sequence and protein expression in the GBMs. Sequence alterations in exons 5-9 of the FHIT gene were screened in 63 GBMs using the single-strand conformational polymorphism method, followed by DNA sequencing. Additionally, the level of Fhit protein expression in tissues of 48 tumors was assessed by immunohistochemistry (IHC). In our investigation, FHIT gene alterations in the coding region were detected in 11 of the 63 GBM cases (17.5%). Two different sequence variants were determined: one novel missense variant (G -> C transition at codon 49) and one previously described silent alteration (C -> T transition at codon 88). Using web-based programs, such as SIFT and ESEfinder, it was determined that both alterations might have caused significant modification on protein function. In addition, we identified a previously reported an intronic polymorphism (T -> A transition at IVS8-17) in 47.5% of cases as a similar rate (45%) in the control group. Moreover, it was observed that Fhit protein expression was reduced in 87.5% of tumors. In conclusion, the reduction or loss of Fhit protein expression by genetic alterations or epigenetic mechanisms in GBM might be associated with brain tumorigenesis.
C1 [Cecener, Gulsah; Tunca, Berrin; Egeli, Unal] Uludag Univ, Dept Med Biol, Sch Med, Bursa, Turkey.
   [Bekar, Ahmet] Uludag Univ, Dept Neurosurg, Sch Med, Bursa, Turkey.
   [Guler, Gulnur] Hacettepe Univ, Sch Med, Dept Pathol, Ankara, Turkey.
   [Tolunay, Sahsine] Uludag Univ, Dept Pathol, Sch Med, Bursa, Turkey.
   [Aksoy, Kaya] Acibadem Hosp, Dept Neurosurg, Bursa, Turkey.
C3 Uludag University; Uludag University; Hacettepe University; Uludag
   University; Acibadem Hastaneleri
RP Cecener, G (通讯作者)，Uludag Univ, Dept Med Biol, Sch Med, Bursa, Turkey.
EM gcecener@uludag.edu.tr
RI GULER, GULNUR/I-9887-2013; Cecener, Gulsah/AAP-9988-2020; Tolunay,
   Sahsine/AAI-1612-2021; Egeli, Unal/AAH-1420-2021; Tunca,
   Berrin/ABI-6078-2020
OI Egeli, Unal/0000-0001-7904-883X; Cecener, Gulsah/0000-0002-3820-424X
CR Ahmadian M, 1997, CANCER RES, V57, P3664
   Barker FG, 1996, J NEUROSURG, V84, P442, DOI 10.3171/jns.1996.84.3.0442
   Batchelor TT, 2004, CLIN CANCER RES, V10, P228, DOI 10.1158/1078-0432.CCR-0841-3
   Bekar A, 2007, TUMORI J, V93, P604
   Çeçener G, 1998, TERATOGEN CARCIN MUT, V18, P279, DOI 10.1002/(SICI)1520-6866(1998)18:6<279::AID-TCM2>3.0.CO;2-U
   Çeçener G, 2007, TUMORI J, V93, P597
   Collins VP, 2004, J NEUROL NEUROSUR PS, V75, P2, DOI 10.1136/jnnp.2004.040337
   CURRAN WJ, 1993, J NATL CANCER I, V85, P704, DOI 10.1093/jnci/85.9.704
   Druck T, 1997, CANCER RES, V57, P504
   Egeli U, 1997, CANCER GENET CYTOGEN, V95, P153, DOI 10.1016/S0165-4608(96)00215-4
   Egeli Ü, 2000, HEAD NECK-J SCI SPEC, V22, P591, DOI 10.1002/1097-0347(200009)22:6<591::AID-HED8>3.0.CO;2-C
   Fong KM, 1997, CANCER RES, V57, P2256
   Frank S, 1997, CANCER RES, V57, P2638
   Gemma A, 1997, CANCER RES, V57, P1435
   Guler G, 2004, CANCER, V100, P1605, DOI 10.1002/cncr.20137
   Hill C, 2003, ADV ANAT PATHOL, V10, P212, DOI 10.1097/00125480-200307000-00004
   Huebner K, 2001, NAT REV CANCER, V1, P214, DOI 10.1038/35106058
   Ichimura K, 2004, J NEURO-ONCOL, V70, P137, DOI 10.1007/s11060-004-2747-2
   Iliopoulos D, 2006, CANCER LETT, V232, P27, DOI 10.1016/j.canlet.2005.06.048
   Jansen M, 2004, BRAIN RES REV, V45, P143, DOI 10.1016/j.brainresrev.2004.03.001
   Kannan K, 2000, INT J ONCOL, V17, P1031
   Karadag M, 2002, TERATOGEN CARCIN MUT, V22, P31, DOI 10.1002/tcm.1036
   KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x
   Le Beau MM, 1998, GENE CHROMOSOME CANC, V21, P281, DOI 10.1002/(SICI)1098-2264(199804)21:4<281::AID-GCC1>3.0.CO;2-V
   Mathe E, 2006, NUCLEIC ACIDS RES, V34, P1317, DOI 10.1093/nar/gkj518
   Ohgaki H, 2005, J NEUROPATH EXP NEUR, V64, P479, DOI 10.1093/jnen/64.6.479
   Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337
   Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X
   Pekarsky Y, 2002, LANCET ONCOL, V3, P748, DOI 10.1016/S1470-2045(02)00931-2
   Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8
   Tsai TC, 1999, ONCOL REP, V6, P345
   Tunca B, 2000, CANCER GENET CYTOGEN, V119, P139, DOI 10.1016/S0165-4608(99)00228-9
   Tunca B, 2002, TERATOGEN CARCIN MUT, V22, P205, DOI 10.1002/tcm.10014
   Tunca B, 2007, J NEURO-ONCOL, V82, P263, DOI 10.1007/s11060-006-9293-z
   Wang JH, 2005, NUCLEIC ACIDS RES, V33, P5053, DOI 10.1093/nar/gki810
   WATSON JD, 1987, MOL BIOL GENE, P444
   Yoshino K, 1998, INT J CANCER, V76, P176, DOI 10.1002/(SICI)1097-0215(19980413)76:2<176::AID-IJC2>3.0.CO;2-U
   Zhao Xi-Rong, 2003, Ai Zheng, V22, P50
NR 38
TC 6
Z9 8
U1 0
U2 5
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0272-4340
EI 1573-6830
J9 CELL MOL NEUROBIOL
JI Cell. Mol. Neurobiol.
PD MAR
PY 2010
VL 30
IS 2
BP 301
EP 307
DI 10.1007/s10571-009-9452-9
PG 7
WC Cell Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Neurosciences & Neurology
GA 570UW
UT WOS:000275704800014
PM 19760177
DA 2025-01-12
ER

PT J
AU Sharma, G
   Mirza, S
   Parshad, R
   Srivastava, A
   Gupta, SD
   Pandya, P
   Ralhan, R
AF Sharma, Gayatri
   Mirza, Sameer
   Parshad, Rajinder
   Srivastava, Anurag
   Gupta, Siddartha Datta
   Pandya, Pranav
   Ralhan, Ranju
TI CpG hypomethylation of <i>MDR1</i> gene in tumor and serum of invasive
   ductal breast carcinoma patients
SO CLINICAL BIOCHEMISTRY
LA English
DT Article
DE CpG Hypomethylation; MDR1; Breast cancer; Prognosis; Invasive ductal
   carcinoma
ID PROMOTER HYPERMETHYLATION; MULTIDRUG-RESISTANCE; CANCER PATIENTS;
   DRUG-RESISTANCE; P-GLYCOPROTEIN; INDUCTION CHEMOTHERAPY; DNA
   METHYLATION; CELL-LINES; EXPRESSION; MARKER
AB Objectives: Multidrug resistance 1 (MDR1) gene encodes P-glycoprotein (P-gp), a transmembrane calcium-dependent efflux pump, implicated in drug resistance. In this prospective Study, methylation status of MDR1 promoter and its correlation with clinicopathological parameters were evaluated in tumor and serum of breast cancer patients.
   Design and methods: Methylation-specific PCR was carried out to investigate the promoter methylation status of MDR1 in tumor and serum of 100 patients with invasive ductal carcinomas of breast (IDCs). The effect of promoter methylation oil protein expression was evaluated by immunohistochemistry.
   Results: MDR1 was hypomethylated in 47% tumors and 44% paired sera of IDC patients and correlated significantly with increased tumor size and advanced tumor stage. Promoter hypomethylation of MDR1 in serum DNA showed 98% specificity and 50% sensitivity.
   Conclusions: Hypomethylation of MDR1 promoter in IDCs accounted for P-gp overexpression and aggressive biologic behavior in a subset of patients. Detection of these epigenetic changes in circulating DNA may not only enhance insight into the biological behavior of the primary tumor of an individual but may also provide valuable information regarding prognosis that call be readily monitored throughout the disease course. (C) 2009 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
C1 [Sharma, Gayatri; Mirza, Sameer; Ralhan, Ranju] All India Inst Med Sci, Dept Biochem, New Delhi 110029, India.
   [Parshad, Rajinder; Srivastava, Anurag] All India Inst Med Sci, Dept Surg, New Delhi 110029, India.
   [Gupta, Siddartha Datta] All India Inst Med Sci, Dept Pathol, New Delhi 110029, India.
   [Sharma, Gayatri; Pandya, Pranav] Dev Sanskriti Vishwavidyalaya, Hardwar, India.
C3 All India Institute of Medical Sciences (AIIMS) New Delhi; All India
   Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of
   Medical Sciences (AIIMS) New Delhi; Dev Sanskriti Vishwavidyalaya
RP Ralhan, R (通讯作者)，Mt Sinai Hosp, Joseph & Mildred Sunshine Family Ctr Head & Neck, Joseph & Wolf Lebovic Hlth Complex,600 Univ Ave,R, Toronto, ON M5G 1X5, Canada.
EM ralhanr@mail.com
CR Baker EK, 2005, ONCOGENE, V24, P8061, DOI 10.1038/sj.onc.1208955
   CHINTAMANI SJP, 2005, WORLD J SURG ONCOL, V3, P61
   Choi JH, 2002, BRIT J CANCER, V86, P1578, DOI 10.1038/sj.bjc.6600305
   Chopra R, 2001, J CLIN ONCOL, V19, p106S
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Eifel P, 2001, JNCI-J NATL CANCER I, V93, P979
   El-Osta A, 2002, MOL CELL BIOL, V22, P1844, DOI 10.1128/MCB.22.6.1844-1857.2002
   Enokida H, 2004, CANCER RES, V64, P5956, DOI 10.1158/0008-5472.CAN-04-0081
   Fenaux Pierre, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS36, DOI 10.1038/ncponc0351
   Fiegl H, 2008, CLIN CANCER RES, V14, P3494, DOI 10.1158/1078-0432.CCR-07-4557
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377
   Kanda T, 2005, ONCOL REP, V14, P975
   Kantharidis P, 1997, CLIN CANCER RES, V3, P2025
   Labialle S, 2002, BIOCHEM PHARMACOL, V64, P943, DOI 10.1016/S0006-2952(02)01156-5
   Lage H, 2003, INT J ANTIMICROB AG, V22, P188, DOI 10.1016/S0924-8579(03)00203-6
   Leonessa F, 2003, ENDOCR-RELAT CANCER, V10, P43, DOI 10.1677/erc.0.0100043
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   LINN SC, 1995, ANN ONCOL, V6, P679, DOI 10.1093/oxfordjournals.annonc.a059284
   Materna V, 2004, GYNECOL ONCOL, V94, P152, DOI 10.1016/j.ygyno.2004.03.035
   Mirza S, 2007, LIFE SCI, V81, P280, DOI 10.1016/j.lfs.2007.05.012
   Mori I, 2002, PATHOL INT, V52, P186, DOI 10.1046/j.1440-1827.2002.01335.x
   Müller HM, 2003, CANCER RES, V63, P7641
   Nakayama M, 1998, BLOOD, V92, P4296, DOI 10.1182/blood.V92.11.4296.423k25_4296_4307
   PERTSCHUK LP, 1990, CANCER-AM CANCER SOC, V66, P1663, DOI 10.1002/1097-0142(19901015)66:8<1663::AID-CNCR2820660802>3.0.CO;2-C
   Rhodes A, 2002, AM J CLIN PATHOL, V118, P408
   Rybárová S, 2006, NEOPLASMA, V53, P128
   Saxena Sunita, 2005, World J Surg Oncol, V3, P67, DOI 10.1186/1477-7819-3-67
   Schneider J, 2001, BREAST CANCER RES, V3, P183, DOI 10.1186/bcr293
   Schneider J, 2000, ANTICANCER RES, V20, P4373
   Sharma D, 2004, CANCER BIOL THER, V3, P549, DOI 10.4161/cbt.3.6.1041
   Sharma G, 2007, LIFE SCI, V80, P1873, DOI 10.1016/j.lfs.2007.02.026
   Shervington A, 2008, OLIGONUCLEOTIDES, V18, P365, DOI 10.1089/oli.2008.0128
   Steele N, 2009, BRIT J CANCER, V100, P758, DOI 10.1038/sj.bjc.6604932
   Sun SS, 2000, CANCER LETT, V153, P95, DOI 10.1016/S0304-3835(00)00356-6
   Surowiak P, 2005, BREAST CANCER RES, V7, pR862, DOI 10.1186/bcr1313
NR 38
TC 52
Z9 67
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-9120
EI 1873-2933
J9 CLIN BIOCHEM
JI Clin. Biochem.
PD MAR
PY 2010
VL 43
IS 4-5
BP 373
EP 379
DI 10.1016/j.clinbiochem.2009.10.009
PG 7
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA 564MQ
UT WOS:000275219400004
PM 19879256
DA 2025-01-12
ER

PT J
AU Khaenam, P
   Jearanaikoon, P
   Pairojkul, C
   Bhudhisawasdi, V
   Lempaiboon, T
AF Khaenam, Prasong
   Jearanaikoon, Patcharee
   Pairojkul, Chawalit
   Bhudhisawasdi, Vajarabhongsa
   Lempaiboon, Temduang
TI Genetic and epigenetic alterations of <i>RIZ1</i> and the correlation to
   clinicopathological parameters in liver fluke-related cholangiocarcinoma
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE retinoblastoma interacting zinc finger; cholangiocarcinoma; promoter
   hypermethylation; frameshift mutation; loss of heterozygosity
ID TUMOR-SUPPRESSOR GENE; BONE-MINERAL DENSITY; PROMOTER HYPERMETHYLATION;
   MICROSATELLITE ALTERATIONS; DELETION POLYMORPHISM; FRAMESHIFT MUTATIONS;
   DNA METHYLATION; BREAST-CANCER; INACTIVATION; EXPRESSION
AB The retinoblastoma interacting zinc finger (RIZ1) gene is adjacent to D1S228 where microsatellite instability has been associated with poor patient survival in liver fluke-associated cholangiocarcinoma (CCA). An understanding of the molecular mechanisms underlying the carcinogenesis and pathogenesis of CCA is necessary to improve patient survival. Therefore; we determined the genetic and epigenetic alterations of RIZ1 in 81 CCA samples and 69 matched non-tumor tissues. Methylation was found in 31 of 81 (38%) tumor samples and in 5 of 69 (7%) matched non-tumor tissues. Frameshift mutations (2 of 81) and loss of heterozygosity (LOH) (14 of 81) were not common. Statistical analysis found no significant correlation between RIZ1 alterations and clinicopathological features, but RIZPro704 LOH was associated with patient survival in the multivariate analysis. RIZ1 hypermethylation may be one of the crucial molecular events contributing to cholangiocarcinogenesis, and RIZPro704 LOH may adversely impact patient survival. The biological function of RIZ1 in CCA should be further investigated in order to verify its potential role in regulating this cancer.
C1 [Khaenam, Prasong; Jearanaikoon, Patcharee; Lempaiboon, Temduang] Khon Kaen Univ, Fac Associated Med Sci, Ctr Res & Dev, Med Diagnost Labs, Khon Kaen 40002, Thailand.
   [Khaenam, Prasong] Khon Kaen Univ, Grad Sch, Dept Biomed Sci, Khon Kaen 40002, Thailand.
   [Pairojkul, Chawalit] Khon Kaen Univ, Fac Med, Dept Pathol, Khon Kaen 40002, Thailand.
   [Bhudhisawasdi, Vajarabhongsa] Khon Kaen Univ, Fac Med, Dept Surg, Khon Kaen 40002, Thailand.
   [Khaenam, Prasong; Jearanaikoon, Patcharee; Pairojkul, Chawalit; Bhudhisawasdi, Vajarabhongsa; Lempaiboon, Temduang] Khon Kaen Univ, Fac Med, Liver Fluke & Cholangiocarcinoma Res Ctr, Khon Kaen 40002, Thailand.
C3 Khon Kaen University; Khon Kaen University; Khon Kaen University; Khon
   Kaen University; Khon Kaen University
RP Lempaiboon, T (通讯作者)，Khon Kaen Univ, Fac Associated Med Sci, Ctr Res & Dev, Med Diagnost Labs, Khon Kaen 40002, Thailand.
EM temduang@kku.ac.th
FU Thailand Research Fund [PHD/0084/2546]; Centre for Research and
   Development of the Medical Diagnostic Laboratories, Faculty of
   Associated Medical Sciences, Khon Kaen University, Thailand
FX This study was supported by the Thailand Research Fund through The Royal
   Golden Jubilee PhD Program, grant no. PHD/0084/2546 to P. Khaenam and T.
   Limpaiboon, and by the Centre for Research and Development of the
   Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences,
   Khon Kaen University, Thailand.
CR Abbondanza C, 2000, P NATL ACAD SCI USA, V97, P3130, DOI 10.1073/pnas.050015697
   Akahira JI, 2007, PATHOL INT, V57, P725, DOI 10.1111/j.1440-1827.2007.02169.x
   Alvaro D, 2006, AM J PATHOL, V169, P877, DOI 10.2353/ajpath.2006.050464
   Buyse IM, 1996, GENOMICS, V34, P119, DOI 10.1006/geno.1996.0249
   Carling T, 2004, MOL CELL BIOL, V24, P7032, DOI 10.1128/MCB.24.16.7032-7042.2004
   Carling T, 2003, SURGERY, V134, P932, DOI 10.1016/S0039-6060(03)00422-7
   Chadwick RB, 2000, P NATL ACAD SCI USA, V97, P2662, DOI 10.1073/pnas.040579497
   Du Y, 2001, CANCER RES, V61, P8094
   Fang W, 2000, GENE CHROMOSOME CANC, V28, P269, DOI 10.1002/1098-2264(200007)28:3<269::AID-GCC4>3.0.CO;2-K
   Gazzerro P, 2006, EXP CELL RES, V312, P340, DOI 10.1016/j.yexcr.2005.11.002
   Grundberg E, 2004, J CLIN ENDOCR METAB, V89, P6173, DOI 10.1210/jc.2004-0403
   Hasegawa Y, 2007, CANCER SCI, V98, P32, DOI 10.1111/j.1349-7006.2006.00338.x
   He LS, 1998, CANCER RES, V58, P4238
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Jiang GL, 2001, CANCER RES, V61, P1796
   Jiang GL, 1999, INT J CANCER, V83, P541, DOI 10.1002/(SICI)1097-0215(19991112)83:4<541::AID-IJC17>3.0.CO;2-F
   Kahlert S, 2000, J BIOL CHEM, V275, P18447, DOI 10.1074/jbc.M910345199
   Limpaiboon T, 2005, CANCER LETT, V217, P213, DOI 10.1016/j.canlet.2004.06.020
   Limpaiboon T, 2002, CANCER LETT, V181, P215, DOI 10.1016/S0304-3835(02)00052-6
   Limpaiboon T, 2006, WORLD J GASTROENTERO, V12, P4377, DOI 10.3748/wjg.v12.i27.4377
   Liu LB, 1997, J BIOL CHEM, V272, P1997, DOI 10.1074/jbc.272.3.1997
   Oshimo Y, 2004, INT J CANCER, V110, P212, DOI 10.1002/ijc.20090
   Pastural E, 2007, ONCOGENE, V26, P1586, DOI 10.1038/sj.onc.1209959
   Piao Z, 2000, CANCER RES, V60, P4701
   Poetsch M, 2002, ONCOGENE, V21, P3038, DOI 10.1038/sj.onc.1205457
   Sripa B, 2008, CURR OPIN GASTROEN, V24, P349, DOI 10.1097/MOG.0b013e3282fbf9b3
   Sripa B, 2007, PLOS MED, V4, P1148, DOI 10.1371/journal.pmed.0040201
   Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101
   Stolk L, 2008, BONE, V42, P286, DOI 10.1016/j.bone.2007.10.008
   Tokumaru Y, 2003, ONCOGENE, V22, P6954, DOI 10.1038/sj.onc.1206403
   Xie M, 1997, J BIOL CHEM, V272, P26360, DOI 10.1074/jbc.272.42.26360
   Yamamoto H, 1997, CANCER RES, V57, P4420
NR 32
TC 5
Z9 6
U1 0
U2 1
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
EI 1792-1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD MAR-APR
PY 2010
VL 1
IS 2
BP 385
EP 390
DI 10.3892/etm_00000060
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 687XM
UT WOS:000284811700025
PM 22993552
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Hu, L
   Chen, G
   Yu, HP
   Qiu, XQ
AF Hu, Lang
   Chen, Gang
   Yu, Hongping
   Qiu, Xiaoqiang
TI Clinicopathological significance of RASSF1A reduced expression and
   hypermethylation in hepatocellular carcinoma
SO HEPATOLOGY INTERNATIONAL
LA English
DT Article
DE RASSF1A; Hepatocellular carcinoma; Immunohistochemistry; Promoter
   hypermethylation; Tissue microarrays (TMAs); DNA
ID TUMOR-SUPPRESSOR GENE; PROMOTER HYPERMETHYLATION; EPIGENETIC
   INACTIVATION; BREAST-CANCER; ASSOCIATION; METHYLATION; SERUM; DNA;
   PROTEIN; PLASMA
AB Protein downregulation and hypermethylation of Ras association domain family 1A (RASSF1A) has been recognized as an important early event in different classes of carcinogenesis, but clinicopathological significance of RASSF1A protein expression and methylation in hepatocellular carcinoma (HCC) remains largely unknown. The aim of the study was to investigate the expression of RASSF1A protein and methylation in HCC and their clinical significance.
   Immunohistochemistry was employed to detect the expression of RASSF1A proteins in liver tissue microarrays. Aberrant promoter hypermethylation of RASSF1A was investigated in DNA from HCC, matching noncancerous tissues and serum of 35 HCC patients by methylation-specific PCR.
   RASSF1A protein expression in HCC was significantly lower than that in noncancerous (p = 0.015) and paracancerous tissues (p = 0.017). In addition, reduced RASSF1A protein expression is related to TNM stage, metastasis, alpha-fetoprotein, portal vein embolus, capsular infiltration, and multiple tumor nodes. Furthermore, RASSF1A promoter methylation in HCC was significantly higher than that in noncancerous liver tissues (p < 0.05). Meanwhile, RASSF1A promoter hypermethylation was detected in 14 in the serum DNA from HCC patients, whereas no hypermethylation was detected in the normal controls. Hypermethylation of RASSF1A in HCC serum and tissues was negatively correlated with the expression of RASSF1A protein expression (p < 0.05).
   The loss or abnormal protein downregulation and the promoter hypermethylation of RASSF1A could play important roles in the tumorigenesis development and metastases of HCC. The detection of the promoter hypermethylation of RASSF1A in serum DNA could be a valuable biomarker for early-stage diagnosis in populations at high risk of HCC.
C1 [Hu, Lang; Yu, Hongping; Qiu, Xiaoqiang] Guangxi Med Univ, Dept Epidemiol, Nanning 530021, Guangxi Zhuang, Peoples R China.
   [Chen, Gang] Guangxi Med Univ, Dept Pathol, Nanning 530021, Guangxi Zhuang, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University
RP Qiu, XQ (通讯作者)，Guangxi Med Univ, Dept Epidemiol, Nanning 530021, Guangxi Zhuang, Peoples R China.
EM hulang2000060@sina.com; chen_gang_triones@163.com; YHP268@163.com;
   starsstars1204@hotmail.com
RI Yu, Hongping/F-3710-2011
FU Medical Major Scientific Research Foundation of Guangxi [Zhong200513]
FX This work was performed in People's Republic of China. The study was
   supported by Medical Major Scientific Research Foundation of Guangxi
   (Zhong200513). The authors thank Dr. Ping Li for her immunodetection
   work and Meinhart Francois from Belgium for his useful suggestions in
   the manuscript preparation.
CR Bolondi L, 2003, J HEPATOL, V39, P1076, DOI 10.1016/S0168-8278(03)00349-0
   Brennan Donal J., 2007, Cancer Genomics & Proteomics, V4, P121
   Chan MWY, 2003, INT J CANCER, V104, P611, DOI 10.1002/ijc.10971
   Chen YJ, 2005, WORLD J GASTROENTERO, V11, P1333, DOI 10.3748/wjg.v11.i9.1333
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Di Gioia S, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-89
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Ghosh S, 2008, INT J CANCER, V123, P2594, DOI 10.1002/ijc.23834
   Hsu HS, 2007, CANCER-AM CANCER SOC, V110, P2019, DOI 10.1002/cncr.23001
   Hu JT, 2008, J HUAZHONG U SCI-MED, V28, P182, DOI 10.1007/s11596-008-0217-3
   Jagadeesh S, 2007, BIOCHEM BIOPH RES CO, V362, P212, DOI 10.1016/j.bbrc.2007.08.005
   Kee SK, 2007, MOL CELLS, V24, P364
   Ko SS, 2007, INT J SURG PATHOL, V15, P98, DOI 10.1177/1066896906299124
   Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844
   Kwong J, 2002, CLIN CANCER RES, V8, P131
   Lee JS, 2008, CANCER BIOL THER, V7, P1400
   Lemmer ER, 2006, SEMIN LIVER DIS, V26, P373, DOI 10.1055/s-2006-951604
   Li YM, 2008, ONCOL REP, V19, P1149
   Lo PHY, 2007, CANCER LETT, V257, P199, DOI 10.1016/j.canlet.2007.07.018
   Nagai H, 2008, RECENT PAT ANTI-CANC, V3, P220, DOI 10.2174/157489208786242296
   Orito E, 2007, HEPATOL RES, V37, pS33, DOI 10.1111/j.1872-034X.2007.00101.x
   Pallarés J, 2008, MODERN PATHOL, V21, P691, DOI 10.1038/modpathol.2008.38
   Peters I, 2007, CANCER EPIDEM BIOMAR, V16, P2526, DOI 10.1158/1055-9965.EPI-07-0203
   Schagdarsurengin U, 2003, ONCOGENE, V22, P1866, DOI 10.1038/sj.onc.1206338
   Sherman M, 2001, J HEPATOL, V34, P603, DOI 10.1016/S0168-8278(01)00025-3
   Shukla S, 2006, EPIGENETICS-US, V1, P88, DOI 10.4161/epi.1.2.2679
   Sung JS, 2008, LUNG CANCER, V61, P301, DOI 10.1016/j.lungcan.2008.01.012
   Tezval Hossein, 2008, BMC Urol, V8, P12, DOI 10.1186/1471-2490-8-12
   Tischoff I, 2005, INT J CANCER, V115, P684, DOI 10.1002/ijc.20944
   Wang YC, 2008, WORLD J GASTROENTERO, V14, P3074, DOI 10.3748/wjg.14.3074
   Wong TS, 2004, CLIN CANCER RES, V10, P2401, DOI 10.1158/1078-0432.CCR-03-0139
   Xue WJ, 2008, J GASTROEN HEPATOL, V23, P1448, DOI 10.1111/j.1440-1746.2007.05067.x
   Ye M, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-120
   Yeo W, 2005, LIVER INT, V25, P266, DOI 10.1111/j.1478-3231.2005.01084.x
   Zhang CS, 2007, CLIN CANCER RES, V13, P944, DOI 10.1158/1078-0432.CCR-06-2268
   Zhang YJ, 2007, CLIN CANCER RES, V13, P2378, DOI 10.1158/1078-0432.CCR-06-1900
NR 36
TC 52
Z9 59
U1 0
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1936-0533
EI 1936-0541
J9 HEPATOL INT
JI Hepatol. Int.
PD MAR
PY 2010
VL 4
IS 1
BP 423
EP 432
DI 10.1007/s12072-010-9164-8
PG 10
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 567OL
UT WOS:000275456400007
PM 20305761
OA Green Published
DA 2025-01-12
ER

PT J
AU Luo, XG
   Zou, JN
   Wang, SZ
   Zhang, TC
   Xi, T
AF Luo, Xue-Gang
   Zou, Jia-Ning
   Wang, Shu-Zhen
   Zhang, Tong-Cun
   Xi, Tao
TI Novobiocin Decreases SMYD3 Expression and Inhibits the Migration of
   MDA-MB-231 Human Breast Cancer Cells
SO IUBMB LIFE
LA English
DT Article
DE Novobiocin; SMYD3; shRNA; migration; breast cancer
ID HUMAN-DISEASE; HISTONE; EPIGENETICS; CHROMATIN; GROWTH; DOMAIN
AB SET and MYND domain-containing protein 3 (SMYD3) is a histone methyltransferase that plays an important role in transcriptional regulation in human carcinogenesis, and heat-shock protein HSP90A has been shown to increase the activity of SMYD3. We previously reported that overexpression of SMYD3 stimulated the migration of cells. In this study, we further found that novobiocin, a HSP90 inhibitor, could decrease the expression of SMYD3 and dose dependently inhibit the proliferation and migration of MDA-MB-231 human breast cancer cells. As a control, the short hairpin RNA (shRNA) targeting SMYD3 gene also showed similar effects with novobicin. This study is the first to show that novobiocin can inhibit the migration of breast cancer cells and such event may involve the downregulation of SMYD3. These findings might throw light on the development of novel therapeutic approaches to human cancers, and lend further understanding to the potential role of SMYD3 in human carcinogenesis. (C) 2009 IUBMB IUBMB Life, 62(3): 194-199, 2010
C1 [Luo, Xue-Gang; Zou, Jia-Ning; Wang, Shu-Zhen; Xi, Tao] China Pharmaceut Univ, Key Lab Carcinogenesis & Invervent, Sch Life Sci & Technol, Nanjing 210009, Jiangsu, Peoples R China.
   [Luo, Xue-Gang; Zhang, Tong-Cun] Tianjin Univ Sci & Technol, Key Lab Ind Microbiol, Minist Educ, Coll Biotechnol, Tianjin, Peoples R China.
   [Luo, Xue-Gang; Zhang, Tong-Cun] Tianjin Univ Sci & Technol, Tianjin Key Lab Ind Microbiol, Coll Biotechnol, Tianjin, Peoples R China.
C3 China Pharmaceutical University; Tianjin University Science &
   Technology; Tianjin University Science & Technology
RP Xi, T (通讯作者)，China Pharmaceut Univ, Key Lab Carcinogenesis & Invervent, Sch Life Sci & Technol, Tone Jiang Xiang 29, Nanjing 210009, Jiangsu, Peoples R China.
EM xitaocpu@yahoo.com.cn
RI Wang, Shuzhen/L-2895-2016; Zheng, Lufeng/ABJ-3416-2022
OI Xi, Tao/0000-0001-8065-2639
FU National Basic Research Program of China (973 Program) [0199805119,
   2009CB825504]; Tianjin University of Science and Technology [20080414]
FX This study was financially supported by the National Basic Research
   Program of China (973 Program) (NO. 0199805119 and NO. 2009CB825504) and
   the Scientific Research Launch Fund for Introduction of Talents into
   Tianjin University of Science and Technology (No. 20080414).
CR Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Gibbons RJ, 2005, HUM MOL GENET, V14, pR85, DOI 10.1093/hmg/ddi106
   Grad W, 2007, MOL CELL ENDOCRINOL, V275, P2, DOI 10.1016/j.mce.2007.05.018
   Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151
   Hamamoto R, 2006, CANCER SCI, V97, P113, DOI 10.1111/j.1349-7006.2006.00146.x
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Laganière J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102
   Luo XG, 2007, J BIOSCI BIOENG, V103, P444, DOI 10.1263/jbb.103.444
   Marcu MG, 2000, JNCI-J NATL CANCER I, V92, P242, DOI 10.1093/jnci/92.3.242
   Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131
   Rodenhiser D, 2006, CAN MED ASSOC J, V174, P341, DOI 10.1503/cmaj.050774
   Ruden DM, 2005, HUM MOL GENET, V14, pR149, DOI 10.1093/hmg/ddi103
   SCANLON EF, 1991, CA-CANCER J CLIN, V41, P301, DOI 10.3322/canjclin.41.5.301
   Schneider R, 2002, TRENDS BIOCHEM SCI, V27, P396, DOI 10.1016/S0968-0004(02)02141-2
   Sims RJ, 2004, NAT CELL BIOL, V6, P685, DOI 10.1038/ncb0804-685
   Walchli S, 2008, FRONT BIOSCI, V13, P3488
   Wang SZ, 2008, BMB REP, V41, P294, DOI 10.5483/BMBRep.2008.41.4.294
NR 18
TC 31
Z9 37
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1521-6543
EI 1521-6551
J9 IUBMB LIFE
JI IUBMB Life
PD MAR
PY 2010
VL 62
IS 3
BP 194
EP 199
DI 10.1002/iub.288
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 582GR
UT WOS:000276585200005
PM 20039369
OA Bronze
DA 2025-01-12
ER

PT J
AU Hao, JM
   Chen, JZ
   Sui, HM
   Si-Ma, XQ
   Li, GQ
   Liu, C
   Li, JL
   Ding, YQ
   Li, JM
AF Hao, Jun-Mei
   Chen, Juan-Zhi
   Sui, Hong-Mei
   Si-Ma, Xue-Qing
   Li, Guang-Qiu
   Liu, Chao
   Li, Ji-Liang
   Ding, Yan-Qing
   Li, Jian-Ming
TI A five-gene signature as a potential predictor of metastasis and
   survival in colorectal cancer
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE single cell-derived progenies; gene signature; prognosis; metastasis;
   colorectal cancer
ID HUMAN-COLON-CANCER; ANTAGONIST DICKKOPF-1 GENE; SMALL INTERFERING RNA;
   BREAST-CANCER; PROSTATE-CANCER; LYN KINASE; CYCLOOXYGENASE-2 EXPRESSION;
   EPIGENETIC INACTIVATION; PANCREATIC-CANCER; LIVER METASTASIS
AB To understand the molecular mechanisms of metastasis and prognosis of colorectal cancer (CRC), we isolated single cell-derived progenies (SCPs) from SW480 cells in vitro and compared their metastatic potential in an orthotopic CRC tumour model in vivo. Two groups of SCPs with the capability of high and low metastasis, respectively, were obtained. By analysing the gene expression profiles of high (SCP51), low (SCP58) metastatic SCPs, and their parental cell line (SW480/EGFP), we demonstrated that 143 genes were differentially expressed either between SCP51 and SCP58 or between SCP58 and SW480/EGFP. Gene-annotation enrichment analysis of DAVID revealed 80 genes in the top ten clusters of the analysis (gene enrichment score >1). Of the 80-gene set, 32 genes are potentially involved in metastasis, as revealed by Geneclip. Five putative metastatic genes (LYN, SDCBP, MAP4K4, DKK1, and MID1) were selected for further validations. Immunohistochemical analysis in a cohort of 181 CRC clinical samples showed that the individual expression of LYN, MAP4K4, and MID1, as well as the five-gene signature, was closely correlated with lymph node metastasis in CRC patients. More importantly, the individual expression of LYN, MAP4K4, SDCBP, and MID1, as well as the five-gene signature, was significantly correlated with overall survival in CRC patients. Thus, our five-gene signature may be able to predict metastasis and survival of CRC in the clinic, and opens new perspectives on the biology of CRC. Copyright (C) 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
C1 [Hao, Jun-Mei; Sui, Hong-Mei; Si-Ma, Xue-Qing; Li, Guang-Qiu; Liu, Chao; Ding, Yan-Qing; Li, Jian-Ming] So Med Univ, Dept Pathol, Sch Basic Med Sci, Guangzhou 510515, Guangdong, Peoples R China.
   [Hao, Jun-Mei; Chen, Juan-Zhi; Ding, Yan-Qing; Li, Jian-Ming] So Med Univ, Dept Pathol, Nanfang Hosp, Guangzhou 510515, Guangdong, Peoples R China.
   [Hao, Jun-Mei; Chen, Juan-Zhi; Ding, Yan-Qing; Li, Jian-Ming] Guangdong Prov Key Lab Mol Tumour Pathol, Guangzhou 510515, Guangdong, Peoples R China.
   [Li, Ji-Liang] So Med Univ, Sch Biotechnol, Guangzhou 510515, Guangdong, Peoples R China.
   [Li, Ji-Liang] Univ Oxford, Canc Res UK Mol Oncol Labs, Weatherall Inst Mol Med, John Radcliffe Hosp, Oxford OX3 9DS, England.
C3 Southern Medical University - China; Southern Medical University -
   China; Southern Medical University - China; University of Oxford
RP Li, JM (通讯作者)，So Med Univ, Dept Pathol, Sch Basic Med Sci, Guangzhou 510515, Guangdong, Peoples R China.
EM dyq@fimmu.com; lixinyue@fimmu.com
FU National Nature Science Foundation of China [30670968, 30670967,
   30971361]; Distinguished Young Scientists of Southern Medical
   University; Municipal Programs of Guangzhou for Science and Technology
   Development [2007Z3-E4011]
FX We would like to thank Dinah Gorelik for critical reading of the
   manuscript. This work was funded by the National Nature Science
   Foundation of China (grant Nos 30670968, 30670967, and 30971361). This
   work was also supported by Fostering Funds for Distinguished Young
   Scientists of Southern Medical University and Municipal Programs of
   Guangzhou for Science and Technology Development (No.2007Z3-E4011).
CR Acharya CR, 2008, JAMA-J AM MED ASSOC, V299, P1574, DOI 10.1001/jama.299.13.1574
   Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439
   Aguilera O, 2007, CARCINOGENESIS, V28, P1877, DOI 10.1093/carcin/bgm094
   Bates RC, 2001, CANCER RES, V61, P5275
   Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021
   Boukerche H, 2008, P NATL ACAD SCI USA, V105, P15914, DOI 10.1073/pnas.0808171105
   Brooks DJ, 1996, BRIT J CANCER, V74, P1518, DOI 10.1038/bjc.1996.583
   Chen WS, 1999, INT J CANCER, V83, P579, DOI 10.1002/(SICI)1097-0215(19991126)83:5<579::AID-IJC1>3.0.CO;2-R
   Collins CS, 2006, P NATL ACAD SCI USA, V103, P3775, DOI 10.1073/pnas.0600040103
   Evans SRT, 1998, CLIN CANCER RES, V4, P1591
   Fu YG, 2006, INT J ONCOL, V29, P1453
   García-Escudero R, 2008, MOL CARCINOGEN, V47, P573, DOI 10.1002/mc.20430
   Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032
   Goldenberg-Furmanov M, 2004, CANCER RES, V64, P1058, DOI 10.1158/0008-5472.CAN-03-2420
   Gonzálex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303
   Helmke BM, 2004, ONCOL REP, V12, P221
   Huang ZX, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-308
   Kallioniemi A, 2002, NEW ENGL J MED, V347, P2067, DOI 10.1056/NEJMe020152
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6
   Khan K, 2006, BRIT J CANCER, V95, P1367, DOI 10.1038/sj.bjc.6603453
   Ki DH, 2007, INT J CANCER, V121, P2005, DOI 10.1002/ijc.22975
   Koo TH, 2002, ONCOGENE, V21, P4080, DOI 10.1038/sj.onc.1205514
   Li T, 2009, BIOCHEM BIOPH RES CO, V383, P280, DOI 10.1016/j.bbrc.2009.03.077
   Masunaga R, 2000, CLIN CANCER RES, V6, P4064
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Munshi N, 1999, J BIOL CHEM, V274, P31863, DOI 10.1074/jbc.274.45.31863
   Nguyen QD, 2006, MOL CANCER THER, V5, P2070, DOI 10.1158/1535-7163.MCT-06-0044
   Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060
   Rashid A, 2001, AM J PATHOL, V159, P1129, DOI 10.1016/S0002-9440(10)61789-0
   Rashidi B, 2000, CLIN CANCER RES, V6, P2556
   Sagiv E, 2008, CANCER RES, V68, P2803, DOI 10.1158/0008-5472.CAN-07-6463
   Sagiv E, 2006, GASTROENTEROLOGY, V131, P630, DOI 10.1053/j.gastro.2006.04.028
   Sato H, 2007, CARCINOGENESIS, V28, P2459, DOI 10.1093/carcin/bgm178
   Soumaoro LT, 2004, CLIN CANCER RES, V10, P8465, DOI 10.1158/1078-0432.CCR-04-0653
   Swanton C, 2009, BRIT J CANCER, V100, P1517, DOI 10.1038/sj.bjc.6605031
   Tao H, 2008, BIOCHEMISTRY-US, V47, P2450, DOI 10.1021/bi7018496
   Tilman G, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-80
   Urzúa U, 2006, J CELL PHYSIOL, V206, P594, DOI 10.1002/jcp.20522
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Vider BZ, 1997, BIOCHEM BIOPH RES CO, V232, P742, DOI 10.1006/bbrc.1997.6364
   Wang S, 2009, J PATHOL, V219, P114, DOI 10.1002/path.2575
   Wang T, 2007, BIOCHEM BIOPH RES CO, V352, P203, DOI 10.1016/j.bbrc.2006.11.006
   Winter J, 2004, HUM GENET, V114, P541, DOI 10.1007/s00439-004-1114-x
NR 44
TC 72
Z9 83
U1 0
U2 25
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
EI 1096-9896
J9 J PATHOL
JI J. Pathol.
PD MAR
PY 2010
VL 220
IS 4
BP 475
EP 489
DI 10.1002/path.2668
PG 15
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA 560TA
UT WOS:000274924600008
PM 20077526
DA 2025-01-12
ER

PT J
AU Mittal, MK
   Myers, JN
   Bailey, CK
   Misra, S
   Chaudhuri, G
AF Mittal, Mukul K.
   Myers, Jeremy N.
   Bailey, Charvann K.
   Misra, Smita
   Chaudhuri, Gautam
TI Mode of action of the retrogene product SNAI1P, a SNAIL homolog, in
   human breast cancer cells
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE SNAI1P; SNAIL; Claudin 7; E2-box; Transcriptional repression; CtBP1;
   HDAC1
ID TRANSCRIPTIONAL REPRESSOR SNAIL; TUMOR RECURRENCE; EXPRESSION; PROTEIN;
   GENE; SLUG; CARCINOMA; INVASION; PROGRESSION; PROMOTER
AB SNAI1P, a protein coded by a retrogene, is a member of the SNAI family of E2-box binding transcriptional repressors. To evaluate whether the mode of action of SNAI1P is similar to those of the other predominant members of the SNAI family, we studied its action on human claudin 7 (CLDN7) gene promoter which has seven E2-boxes. We over-expressed FLAG-tagged SNAI1P in MCF7 and MDA-MB-468 cells. SNAI1P inhibited the expression of CLDN7 in these recombinant cells. SNAI1P also inhibited cloned CLDN7 gene promoter activity in human breast cancer cells. ChIP assays revealed that SNAI1P is recruited on the CLDN7 gene promoter along with the co-repressor CtBP1 and the effector HDAC1. Treatment of the cells with trichostatin A, an inhibitor of HDAC1, abrogated the repressor activity of SNAI1P. These data suggest that SNAI1P inhibits CLDN7 gene promoter epigenetically in breast cancer cells through chromatin remodeling.
C1 [Mittal, Mukul K.; Myers, Jeremy N.; Bailey, Charvann K.; Misra, Smita; Chaudhuri, Gautam] Meharry Med Coll, Dept Microbial Pathogenesis & Immune Response, Nashville, TN 37208 USA.
C3 Meharry Medical College
RP Chaudhuri, G (通讯作者)，Meharry Med Coll, Dept Microbial Pathogenesis & Immune Response, 1005 DB Todd,Jr Blvd, Nashville, TN 37208 USA.
EM gchaudhuri@mmc.edu
OI Mittal, Mukul/0000-0002-9795-7372
FU DOD-CDMRP IDEA [W81XWH-06-1-0466]; NIH [U54NS041071-06, G12RR03032-19,
   U54CA91408, U54RR019192-04]
FX This work was supported by the DOD-CDMRP IDEA Grant # W81XWH-06-1-0466
   to GC. Immunofluorescence analysis-was performed in the MMC Morphology
   Core facility (supported by NIH grants U54NS041071-06, G12RR03032-19,
   U54CA91408, and U54RR019192-04).
CR Ayyanathan K, 2007, CANCER RES, V67, P9097, DOI 10.1158/0008-5472.CAN-07-2987
   Bailey CK, 2007, BIOCHEM BIOPH RES CO, V353, P661, DOI 10.1016/j.bbrc.2006.12.097
   Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907
   Bennett RD, 2007, J BIOL CHEM, V282, P3205, DOI 10.1074/jbc.M607174200
   Chiba H, 2008, BBA-BIOMEMBRANES, V1778, P588, DOI 10.1016/j.bbamem.2007.08.017
   Côme C, 2006, CLIN CANCER RES, V12, P5395, DOI 10.1158/1078-0432.CCR-06-0478
   Davidson NE, 2005, CANCER CELL, V8, P173, DOI 10.1016/j.ccr.2005.08.006
   De Craene B, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1521
   Dhasarathy A, 2007, MOL ENDOCRINOL, V21, P2907, DOI 10.1210/me.2007-0293
   Hou ZY, 2008, MOL CELL BIOL, V28, P3198, DOI 10.1128/MCB.01435-07
   Ko H, 2007, CELLS TISSUES ORGANS, V185, P66, DOI 10.1159/000101305
   Kominsky SL, 2003, ONCOGENE, V22, P2021, DOI 10.1038/sj.onc.1206199
   Krause G, 2008, BBA-BIOMEMBRANES, V1778, P631, DOI 10.1016/j.bbamem.2007.10.018
   Kwon YS, 2007, P NATL ACAD SCI USA, V104, P4852, DOI 10.1073/pnas.0700715104
   Lioni M, 2007, AM J PATHOL, V170, P709, DOI 10.2353/ajpath.2007.060343
   Locascio A, 2002, J BIOL CHEM, V277, P38803, DOI 10.1074/jbc.M205358200
   Martin TA, 2005, ANN SURG ONCOL, V12, P488, DOI 10.1245/ASO.2005.04.010
   Martínez-Estrada OM, 2006, BIOCHEM J, V394, P449, DOI 10.1042/BJ20050591
   Mittal MK, 2008, BIOCHEM BIOPH RES CO, V372, P30, DOI 10.1016/j.bbrc.2008.04.187
   Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009
   Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346
   Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757
   Okubo T, 2001, CANCER RES, V61, P1338
   Oshima T, 2008, ONCOL REP, V19, P953
   Paznekas WA, 1999, GENOMICS, V62, P42, DOI 10.1006/geno.1999.6010
   Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131
   Tripathi MK, 2005, J BIOL CHEM, V280, P17163, DOI 10.1074/jbc.M501375200
   Twigg SRF, 1999, HUM GENET, V105, P320, DOI 10.1007/s004390051108
   Xia Y, 2002, J BIOL CHEM, V277, P24601, DOI 10.1074/jbc.M201369200
   Yamasaki H, 2005, GENES CELLS, V10, P455, DOI 10.1111/j.1365-2443.2005.00850.x
   Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508
NR 31
TC 7
Z9 7
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD MAR
PY 2010
VL 37
IS 3
BP 1221
EP 1227
DI 10.1007/s11033-009-9492-8
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 551MA
UT WOS:000274212500010
PM 19277896
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Pozharny, Y
   Lambertini, L
   Clunie, G
   Ferrara, L
   Lee, MJ
AF Pozharny, Yevgeniya
   Lambertini, Luca
   Clunie, Garfield
   Ferrara, Lauren
   Lee, Men-Jean
TI Epigenetics in Women's Health Care
SO MOUNT SINAI JOURNAL OF MEDICINE
LA English
DT Article
DE epigenetics; imprinted genes; placenta
ID INTRAUTERINE GROWTH-RETARDATION; PRIMORDIAL GERM-CELLS; RECEPTOR CPG
   ISLAND; NEURAL-TUBE DEFECTS; DNA METHYLATION; GENE-EXPRESSION; MAMMALIAN
   DEVELOPMENT; BREAST-CANCER; FOLIC-ACID; DEVELOPMENTAL ORIGINS
AB Epigenetics refers to structural modifications to genes that do not change the nucleotide sequence itself but instead control and regulate gene expression. DNA methylation, histone modification, and RNA regulation are some of the mechanisms involved in epigenetic modification. Epigenetic changes are believed to be a result of changes in an organism's environment that result in fixed and permanent changes in most differentiated cells. Some environmental changes that have been linked to epigenetic changes include starvation, folic acid, and various chemical exposures. There are periods in an organism's life cycle in which the organism is particularly susceptible to epigenetic influences; these include fertilization, gametogenesis, and early embryo development. These are also windows of opportunity for interventions during the reproductive life cycle of women to improve maternal-child health. New data suggest that epigenetic influences might be involved in the regulation of fetal development and the pathophysiology of adult diseases such as cancer, diabetes, obesity, and neurodevelopmental disorders. Various epigenetic mechanisms may also be involved in the pathogenesis of preeclampsia and intrauterine growth restriction. Additionally, environmental exposures are being held responsible for causing epigenetic changes that lead to a disease process. Exposure to heavy metals, bioflavinoids, and endocrine disruptors, such as bisphenol A and phthalates, has been shown to affect the epigenetic memory of all organism. Their long-term effects are unclear at this point, but many ongoing studies are attempting to elucidate the pathophysiological effects of such gene-environment interactions. Mt Sinai J Med 77:225-235, 2010. (C) 2010 Mount Sinai School of Medicine
C1 [Pozharny, Yevgeniya; Lambertini, Luca; Clunie, Garfield; Ferrara, Lauren; Lee, Men-Jean] Mt Sinai Sch Med, New York, NY 10029 USA.
C3 Icahn School of Medicine at Mount Sinai
RP Lee, MJ (通讯作者)，Mt Sinai Sch Med, New York, NY 10029 USA.
EM menjean.lee@mssm.edu
OI Lambertini, Luca/0000-0003-3326-219X
CR Badcock C, 2006, J EVOLUTION BIOL, V19, P1007, DOI 10.1111/j.1420-9101.2006.01091.x
   BARKER DJP, 1986, LANCET, V1, P1077
   Beaujean N, 2004, BIOL REPROD, V71, P185, DOI 10.1095/biolreprod.103.026559
   Beaujean N, 2005, M S-MED SCI, V21, P412, DOI 10.1051/medsci/2005214412
   Bell AW, 1999, J REPROD FERTIL, P401
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Bogdarina I, 2007, CIRC RES, V100, P520, DOI 10.1161/01.RES.0000258855.60637.58
   Burdge GC, 2008, BRIT J NUTR, V99, P540, DOI 10.1017/S0007114507815819
   Chelbi ST, 2008, MOL CELL ENDOCRINOL, V282, P120, DOI 10.1016/j.mce.2007.11.022
   Chen HB, 2006, MOL CELL BIOL, V26, P3728, DOI 10.1128/MCB.26.10.3728-3737.2006
   Cheng RYS, 2004, MOL CARCINOGEN, V40, P1, DOI 10.1002/mc.20022
   Constância M, 2002, NATURE, V417, P945, DOI 10.1038/nature00819
   Cooper C, 1997, ANN RHEUM DIS, V56, P17, DOI 10.1136/ard.56.1.17
   COUTURE LA, 1990, TERATOLOGY, V42, P619, DOI 10.1002/tera.1420420606
   D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249
   Dabelea D, 2000, DIABETES, V49, P2208, DOI 10.2337/diabetes.49.12.2208
   Dean W, 2001, CURR BIOL, V11, pR527, DOI 10.1016/S0960-9822(01)00311-6
   DEKKER GA, 1995, AM J OBSTET GYNECOL, V173, P1042, DOI 10.1016/0002-9378(95)91324-6
   Desaulniers D, 2005, TOXICOL SCI, V86, P175, DOI 10.1093/toxsci/kfi178
   Dolinoy DC, 2007, REPROD TOXICOL, V23, P297, DOI 10.1016/j.reprotox.2006.08.012
   Edwards TM, 2007, ENVIRON HEALTH PERSP, V115, P1264, DOI 10.1289/ehp.9951
   Elsheikh A, 2001, ARCH GYNECOL OBSTET, V264, P182, DOI 10.1007/s004040000104
   Feil R, 2006, MUTAT RES-FUND MOL M, V600, P46, DOI 10.1016/j.mrfmmm.2006.05.029
   Foster PMD, 2006, INT J ANDROL, V29, P140, DOI 10.1111/j.1365-2605.2005.00563.x
   Fowden AL, 2006, HORM RES, V65, P50, DOI 10.1159/000091506
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332
   Geyer PK, 1997, CURR OPIN GENET DEV, V7, P242, DOI 10.1016/S0959-437X(97)80134-7
   GINSBURG M, 1990, DEVELOPMENT, V110, P521
   Gluckman PD, 2004, TRENDS ENDOCRIN MET, V15, P183, DOI 10.1016/j.tem.2004.03.002
   Gluckman PD, 2004, SCIENCE, V305, P1733, DOI 10.1126/science.1095292
   Gluckman PD, 2007, P NATL ACAD SCI USA, V104, P12796, DOI 10.1073/pnas.0705667104
   GoddijnWessel TAW, 1996, EUR J OBSTET GYN R B, V66, P23, DOI 10.1016/0301-2115(96)02383-4
   Godfrey KM, 2007, PEDIATR RES, V61, p5R, DOI 10.1203/pdr.0b013e318045bedb
   Granger JP, 2002, MICROCIRCULATION, V9, P147, DOI 10.1038/sj.mn.7800137
   Gupta S, 2005, OBSTET GYNECOL SURV, V60, P807, DOI 10.1097/01.ogx.0000193879.79268.59
   Hajkova P, 2002, MECH DEVELOP, V117, P15, DOI 10.1016/S0925-4773(02)00181-8
   HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1093/ije/dyt133
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045
   Kaati G, 2002, EUR J HUM GENET, V10, P682, DOI 10.1038/sj.ejhg.5200859
   Kanayama N, 2002, MOL HUM REPROD, V8, P1129, DOI 10.1093/molehr/8.12.1129
   Kensara OA, 2005, AM J CLIN NUTR, V82, P980
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   Knox KS, 2007, MOL HUM REPROD, V13, P251, DOI 10.1093/molehr/gal116
   Knudtson EJ, 2004, AM J OBSTET GYNECOL, V191, P537, DOI 10.1016/j.ajog.2003.12.005
   Lane N, 2003, GENESIS, V35, P88, DOI 10.1002/gene.10168
   LAURENCE KM, 1986, J ROY SOC HEALTH, V106, P153, DOI 10.1177/146642408610600501
   LAURIN J, 1987, OBSTET GYNECOL, V69, P895
   Lillycrop KA, 2005, J NUTR, V135, P1382, DOI 10.1093/jn/135.6.1382
   Lillycrop KA, 2007, BRIT J NUTR, V97, P1064, DOI 10.1017/S000711450769196X
   Maloney CA, 2005, REPRODUCTION, V130, P401, DOI 10.1530/rep.1.00523
   McKay JA, 2004, BIOCHEM SOC T, V32, P1006, DOI 10.1042/BST0321006
   McLachlan JA, 2006, BEST PRACT RES CL EN, V20, P63, DOI 10.1016/j.beem.2005.09.009
   Menon M K, 1966, J Obstet Gynaecol Br Commonw, V73, P49
   MILLER JW, 1994, BIOCHEM J, V298, P415, DOI 10.1042/bj2980415
   Morgan HD, 2005, HUM MOL GENET, V14, pR47, DOI 10.1093/hmg/ddi114
   Morgan HD, 1999, NAT GENET, V23, P314, DOI 10.1038/15490
   Myatt L, 2006, J PHYSIOL-LONDON, V572, P25, DOI 10.1113/jphysiol.2006.104968
   Nafee TM, 2008, BJOG-INT J OBSTET GY, V115, P158, DOI 10.1111/j.1471-0528.2007.01528.x
   NYLUND L, 1983, BRIT J OBSTET GYNAEC, V90, P16, DOI 10.1111/j.1471-0528.1983.tb06739.x
   OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519
   Quina AS, 2006, BIOCHEM PHARMACOL, V72, P1563, DOI 10.1016/j.bcp.2006.06.016
   Randhawa R, 2005, MOL GENET METAB, V86, P84, DOI 10.1016/j.ymgme.2005.07.028
   Redman CWG, 2000, PLACENTA, V21, P597, DOI 10.1053/plac.2000.0560
   Redman CWG, 2004, SEMIN NEPHROL, V24, P565, DOI 10.1016/j.semnephrol.2004.07.005
   Reichard JF, 2007, BIOCHEM BIOPH RES CO, V352, P188, DOI 10.1016/j.bbrc.2006.11.001
   Reik W, 1998, CURR OPIN GENET DEV, V8, P154, DOI 10.1016/S0959-437X(98)80136-6
   Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443
   Richardson B, 2003, AGEING RES REV, V2, P245, DOI 10.1016/S1568-1637(03)00010-2
   Roberts JM, 2005, HYPERTENSION, V46, P1243, DOI 10.1161/01.HYP.0000188408.49896.c5
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   SALNIKOW K, 2000, J ENVIRON PATHOL TOX, V18, P307
   Santos F, 2002, DEV BIOL, V241, P172, DOI 10.1006/dbio.2001.0501
   Sato S, 2003, MOL REPROD DEV, V65, P41, DOI 10.1002/mrd.10264
   Scholl TO, 2000, AM J CLIN NUTR, V71, p1295S, DOI 10.1093/ajcn/71.5.1295s
   Seki Y, 2005, DEV BIOL, V278, P440, DOI 10.1016/j.ydbio.2004.11.025
   Shaw GM, 2004, PUBLIC HEALTH REP, V119, P170, DOI 10.1177/003335490411900210
   Shiao YH, 2005, TOXICOL APPL PHARM, V205, P290, DOI 10.1016/j.taap.2004.10.017
   Sinclair KD, 2007, P NATL ACAD SCI USA, V104, P19351, DOI 10.1073/pnas.0707258104
   Singh SM, 2003, CLIN GENET, V64, P451, DOI 10.1046/j.1399-0004.2003.00190.x
   SMITHELLS RW, 1982, PEDIATRICS, V69, P498
   Stolzenberg-Solomon RZ, 2006, AM J CLIN NUTR, V83, P895, DOI 10.1093/ajcn/83.4.895
   Surani MA, 2001, NATURE, V414, P122, DOI 10.1038/35102186
   Takiguchi M, 2003, EXP CELL RES, V286, P355, DOI 10.1016/S0014-4827(03)00062-4
   Tao LH, 2005, TOXICOL SCI, V87, P344, DOI 10.1093/toxsci/kfi257
   Tilghman SM, 1999, CELL, V96, P185, DOI 10.1016/S0092-8674(00)80559-0
   Toyota M, 2000, ELECTROPHORESIS, V21, P329, DOI 10.1002/(SICI)1522-2683(20000101)21:2<329::AID-ELPS329>3.0.CO;2-9
   Trasler JM, 2006, REPROD FERT DEVELOP, V18, P63, DOI 10.1071/RD05118
   Vickers MH, 2005, ENDOCRINOLOGY, V146, P4211, DOI 10.1210/en.2005-0581
   Wang JX, 2002, LANCET, V359, P673, DOI 10.1016/S0140-6736(02)07804-2
   Waterland RA, 2004, NUTRITION, V20, P63, DOI 10.1016/j.nut.2003.09.011
   Waterland RA, 1999, AM J CLIN NUTR, V69, P179
   Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276
   WOUTERS MGAJ, 1993, FERTIL STERIL, V60, P820
   Wyrwoll CS, 2006, ENDOCRINOLOGY, V147, P599, DOI 10.1210/en.2005-0748
   Xu XR, 2009, J GENET GENOMICS, V36, P203, DOI 10.1016/S1673-8527(08)60108-3
   Yenbutr P, 1998, MECH AGEING DEV, V106, P93, DOI 10.1016/S0047-6374(98)00093-1
   Zhang SM, 1999, JAMA-J AM MED ASSOC, V281, P1632, DOI 10.1001/jama.281.17.1632
NR 100
TC 31
Z9 36
U1 0
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0027-2507
EI 1931-7581
J9 MT SINAI J MED
JI Mt. Sinai J. Med.
PD MAR-APR
PY 2010
VL 77
IS 2
BP 225
EP 235
DI 10.1002/msj.20176
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 580GW
UT WOS:000276437000011
PM 20309920
DA 2025-01-12
ER

PT J
AU Coolen, MW
   Stirzaker, C
   Song, JZ
   Statham, AL
   Kassir, Z
   Moreno, CS
   Young, AN
   Varma, V
   Speed, TP
   Cowley, M
   Lacaze, P
   Kaplan, W
   Robinson, MD
   Clark, SJ
AF Coolen, Marcel W.
   Stirzaker, Clare
   Song, Jenny Z.
   Statham, Aaron L.
   Kassir, Zena
   Moreno, Carlos S.
   Young, Andrew N.
   Varma, Vijay
   Speed, Terence P.
   Cowley, Mark
   Lacaze, Paul
   Kaplan, Warren
   Robinson, Mark D.
   Clark, Susan J.
TI Consolidation of the cancer genome into domains of repressive chromatin
   by long-range epigenetic silencing (LRES) reduces transcriptional
   plasticity
SO NATURE CELL BIOLOGY
LA English
DT Article
ID CANDIDATE TUMOR-SUPPRESSOR; POLYCOMB GROUP PROTEIN; HUMAN
   PROSTATE-CANCER; EMBRYONIC STEM-CELLS; GENE-EXPRESSION; DNA
   HYPERMETHYLATION; PROMOTER METHYLATION; COLORECTAL-CANCER; ABERRANT
   METHYLATION; BREAST-CANCER
AB Silencing of individual genes can occur by genetic and epigenetic processes during carcinogenesis, but the underlying mechanisms remain unclear. By creating an integrated prostate cancer epigenome map using tiling arrays, we show that contiguous regions of gene suppression commonly occur through long-range epigenetic silencing (LRES). We identified 47 LRES regions in prostate cancer, typically spanning about 2 Mb and harbouring approximately 12 genes, with a prevalence of tumour suppressor and miRNA genes. Our data reveal that LRES is associated with regional histone deacetylation combined with subdomains of different epigenetic remodelling patterns, which include re-enforcement, gain or exchange of repressive histone, and DNA methylation marks. The transcriptional and epigenetic state of genes in normal prostate epithelial and human embryonic stem cells can play a critical part in defining the mode of cancer-associated epigenetic remodelling. We propose that consolidation or effective reduction of the cancer genome commonly occurs in domains through a combination of LRES and LOH or genomic deletion, resulting in reduced transcriptional plasticity within these regions.
C1 [Coolen, Marcel W.; Stirzaker, Clare; Song, Jenny Z.; Statham, Aaron L.; Kassir, Zena; Robinson, Mark D.; Clark, Susan J.] Garvan Inst Med Res, Canc Program, Epigenet Lab, Sydney, NSW 2010, Australia.
   [Moreno, Carlos S.; Young, Andrew N.; Varma, Vijay] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA.
   [Varma, Vijay] Atlanta VA Med Ctr, Atlanta, GA USA.
   [Speed, Terence P.; Robinson, Mark D.] Walter & Eliza Hall Inst Med Res, Bioinformat Div, Melbourne, Vic 3052, Australia.
   [Cowley, Mark; Lacaze, Paul; Kaplan, Warren] Garvan Inst Med Res, Peter Wills Bioinformat Ctr, Sydney, NSW 2010, Australia.
   [Clark, Susan J.] Univ NSW, St Vincents Clin Sch, Sydney, NSW, Australia.
C3 Garvan Institute of Medical Research; Emory University; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA
   Medical Center; Atlanta VA Health Care System; Walter & Eliza Hall
   Institute; Garvan Institute of Medical Research; University of New South
   Wales Sydney
RP Clark, SJ (通讯作者)，Garvan Inst Med Res, Canc Program, Epigenet Lab, Sydney, NSW 2010, Australia.
EM s.clark@garvan.org.au
RI Speed, Terence/B-8085-2009; Cowley, Mark/K-8731-2019; Moreno,
   Carlos/B-3863-2009; Robinson, Mark/A-6432-2015; Clark, Susan/B-2272-2008
OI Stirzaker, Clare/0000-0001-5601-3140; Robinson,
   Mark/0000-0002-3048-5518; Clark, Susan/0000-0001-5925-5030; Coolen,
   Marcel/0000-0002-8188-8480; Moreno, Carlos/0000-0002-5582-0028; Cowley,
   Mark/0000-0002-9519-5714; Lacaze, Paul/0000-0002-0902-6798
FU Cancer Institute NSW (CINSW); National Health and Medical Research
   Council (NHMRC) [427614, 481347]; NBCF
FX We thank K. Patterson, P. Molloy and T. Hulf for reviewing the
   manuscript. We thank the Ramaciotti Centre, University of NSW (Sydney,
   Australia) for array hybridizations. This work is supported by Cancer
   Institute NSW (CINSW) program (S. J. C.), CINSW Fellowship (M. W. C.)
   and CINSW Student (A. L. S.) grants and National Health and Medical
   Research Council (NH&MRC) project (427614, 481347) and Fellowship grants
   (S. J. C. and T. S.) and NBCF program grant.
CR Bachmann N, 2008, CANCER GENET CYTOGEN, V182, P103, DOI 10.1016/j.cancergencyto.2008.01.006
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Chêne L, 2004, INT J CANCER, V111, P798, DOI 10.1002/ijc.20337
   Cher ML, 1996, CANCER RES, V56, P3091
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Coolen MW, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm662
   Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585
   Dhanasekaran SM, 2004, FASEB J, V18, P243, DOI 10.1096/fj.04-2415fje
   Dumur CI, 2003, GENOMICS, V81, P260, DOI 10.1016/S0888-7543(03)00020-X
   Engström PG, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-2-r34
   Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   Feltus FA, 2006, GENOMICS, V87, P572, DOI 10.1016/j.ygeno.2005.12.016
   Friedman JM, 2009, CANCER RES, V69, P2623, DOI 10.1158/0008-5472.CAN-08-3114
   Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781
   Gal-Yam EN, 2008, P NATL ACAD SCI USA, V105, P12979, DOI 10.1073/pnas.0806437105
   Gandellini P, 2009, CANCER RES, V69, P2287, DOI 10.1158/0008-5472.CAN-08-2894
   Guan M, 2006, CLIN CANCER RES, V12, P1412, DOI 10.1158/1078-0432.CCR-05-1906
   Guelen L, 2008, NATURE, V453, P948, DOI 10.1038/nature06947
   Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010
   Henrique R, 2007, CLIN CANCER RES, V13, P6122, DOI 10.1158/1078-0432.CCR-07-1042
   Hitchins MP, 2007, CANCER RES, V67, P9107, DOI 10.1158/0008-5472.CAN-07-0869
   Hong ZH, 2008, NUCLEIC ACIDS RES, V36, P2939, DOI 10.1093/nar/gkn146
   Johnson WE, 2006, P NATL ACAD SCI USA, V103, P12457, DOI 10.1073/pnas.0601180103
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Ke XS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004687
   Khalili A, 2007, CANCER INFORM, V3, P43
   Kim H, 2005, CANCER RES, V65, P8118, DOI 10.1158/0008-5472.CAN-04-4562
   Kohonen-Corish MRJ, 2007, ONCOGENE, V26, P4435, DOI 10.1038/sj.onc.1210210
   Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101
   Latil A, 1995, CLIN CANCER RES, V1, P1385
   Liu PB, 2006, CANCER RES, V66, P4011, DOI 10.1158/0008-5472.CAN-05-3055
   Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504
   Luo J, 2001, CANCER RES, V61, P4683
   Nie Y, 2001, CARCINOGENESIS, V22, P1615, DOI 10.1093/carcin/22.10.1615
   Novak P, 2008, CANCER RES, V68, P8616, DOI 10.1158/0008-5472.CAN-08-1419
   Novak P, 2006, CANCER RES, V66, P10664, DOI 10.1158/0008-5472.CAN-06-2761
   O'Hagan HM, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000155
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Pajerowski JD, 2007, P NATL ACAD SCI USA, V104, P15619, DOI 10.1073/pnas.0702576104
   Palmisano WA, 2003, CANCER RES, V63, P4620
   Pauler FM, 2009, GENOME RES, V19, P221, DOI 10.1101/gr.080861.108
   Santos-Rebouças CB, 2007, EUR J HUM GENET, V15, P10, DOI 10.1038/sj.ejhg.5201727
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Schotta G, 2008, GENE DEV, V22, P2048, DOI 10.1101/gad.476008
   Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2
   Smith JS, 2006, NAT GENET, V38, P504, DOI 10.1038/ng0506-504
   Song JZ, 2002, ONCOGENE, V21, P1048, DOI 10.1038/sj.onc.1205153
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Spivakov M, 2007, NAT REV GENET, V8, P263, DOI 10.1038/nrg2046
   Stransky N, 2006, NAT GENET, V38, P1386, DOI 10.1038/ng1923
   Tatarelli C, 2000, GENOMICS, V68, P1, DOI 10.1006/geno.2000.6272
   Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906
   Tobias ES, 2001, ONCOGENE, V20, P2844, DOI 10.1038/sj.onc.1204433
   Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935
   van Noesel MM, 2003, GENE CHROMOSOME CANC, V38, P226, DOI 10.1002/gcc.10278
   Vanaja DK, 2003, CANCER RES, V63, P3877
   Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001
   Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395
   Welsh JB, 2001, CANCER RES, V61, P5974
   Wen B, 2009, NAT GENET, V41, P246, DOI 10.1038/ng.297
   Wiblin AE, 2005, J CELL SCI, V118, P3861, DOI 10.1242/jcs.02500
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158
NR 69
TC 133
Z9 158
U1 0
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-7392
EI 1476-4679
J9 NAT CELL BIOL
JI Nat. Cell Biol.
PD MAR
PY 2010
VL 12
IS 3
BP 235
EP U37
DI 10.1038/ncb2023
PG 20
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 562MD
UT WOS:000275054200009
PM 20173741
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Yamaguchi, K
   Mandai, M
   Oura, T
   Matsumura, N
   Hamanishi, J
   Baba, T
   Matsui, S
   Murphy, SK
   Konishi, I
AF Yamaguchi, K.
   Mandai, M.
   Oura, T.
   Matsumura, N.
   Hamanishi, J.
   Baba, T.
   Matsui, S.
   Murphy, S. K.
   Konishi, I.
TI Identification of an ovarian clear cell carcinoma gene signature that
   reflects inherent disease biology and the carcinogenic processes
SO ONCOGENE
LA English
DT Article
DE ovarian clear cell carcinoma; microarray; carcinogenesis; signature
ID EXPRESSION PROFILES; POOR-PROGNOSIS; CANCER-CELLS; MOLECULAR MARKER;
   BREAST-CANCER; CHEMORESISTANCE; METHYLATION; PATTERNS;
   HYPOXIA-INDUCIBLE-FACTOR-1-ALPHA; ENDOMETRIOSIS
AB Ovarian clear cell carcinoma (OCCC) shows unique clinical features including an association with endometriosis and poor prognosis. We previously reported that the contents of endometriotic cysts, especially high concentrations of free iron, are a possible cause of OCCC carcinogenesis through iron-induced persistent oxidative stress. In this study, we conducted gene expression microarray analysis using 38 ovarian cancer cell lines and identified genes commonly expressed in both OCCC cell lines and clinical samples, which comprise an OCCC gene signature. The OCCC signature reproducibly predicts OCCC specimens in other microarray data sets, suggesting that this gene profile reflects the inherent biological characteristics of OCCC. The OCCC signature contains known markers of OCCC, such as hepatocyte nuclear factor-1 beta (HNF-1 beta) and versican (VCAN), and other genes that reflect oxidative stress. Expression of OCCC signature genes was induced by treatment of immortalized ovarian surface epithelial cells with the contents of endometriotic cysts, indicating that the OCCC signature is largely dependent on the tumor microenvironment. Induction of OCCC signature genes is at least in part epigenetically regulated, as we found hypomethylation of HNF-1 beta and VCAN in OCCC cell lines. This genome-wide study indicates that the tumor microenvironment induces specific gene expression profiles that contribute to the development of distinct cancer subtypes. Oncogene (2010) 29, 1741-1752; doi:10.1038/onc.2009.470; published online 11 January 2010
C1 [Yamaguchi, K.; Mandai, M.; Matsumura, N.; Hamanishi, J.; Baba, T.; Konishi, I.] Kyoto Univ, Grad Sch Med, Dept Gynecol & Obstet, Sakyo Ku, Kyoto 6068507, Japan.
   [Yamaguchi, K.; Murphy, S. K.] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Durham, NC 27710 USA.
   [Oura, T.] Kyoto Univ, Grad Sch Publ Hlth, Dept Biostat, Sakyo Ku, Kyoto 6068507, Japan.
   [Matsui, S.] Inst Stat Math, Dept Data Sci, Res Org Informat & Syst, Tokyo, Japan.
C3 Kyoto University; Duke University; Kyoto University; Research
   Organization of Information & Systems (ROIS); Institute of Statistical
   Mathematics (ISM) - Japan
RP Mandai, M (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Gynecol & Obstet, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.
EM mandai@kuhp.kyoto-u.ac.jp
RI Murphy, Susan/R-3903-2019; Mandai, Michiko/E-7986-2011; Hamanishi,
   Junzo/AAX-3318-2020; Yamaguchi, Ken/Y-6633-2018
OI Yamaguchi, Ken/0000-0002-7669-1405; Matsumura,
   Noriomi/0000-0002-4512-7975; Murphy, Susan/0000-0001-8298-7272; BABA,
   Tsukasa/0000-0003-0066-3747; Hamanishi, Junzo/0000-0002-7750-0623
CR Aggarwal BB, 2009, ANN NY ACAD SCI, V1171, P59, DOI 10.1111/j.1749-6632.2009.04911.x
   Aggarwal BB, 2009, CLIN CANCER RES, V15, P425, DOI 10.1158/1078-0432.CCR-08-0149
   Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296
   Bonome T, 2008, CANCER RES, V68, P5478, DOI 10.1158/0008-5472.CAN-07-6595
   Brinton LA, 1997, AM J OBSTET GYNECOL, V176, P572, DOI 10.1016/S0002-9378(97)70550-7
   Cattaruzza Sabrina, 2004, FASEB J, V18, P779
   Chan JK, 2008, GYNECOL ONCOL, V109, P370, DOI 10.1016/j.ygyno.2008.02.006
   Cheng WJ, 2005, NAT MED, V11, P531, DOI 10.1038/nm1230
   Dinulescu DM, 2005, NAT MED, V11, P63, DOI 10.1038/nm1173
   García-Escudero R, 2008, MOL CARCINOGEN, V47, P573, DOI 10.1002/mc.20430
   Gibson G, 2008, NAT REV GENET, V9, P575, DOI 10.1038/nrg2383
   Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704
   Hawthorne VS, 2009, MOL CANCER RES, V7, P592, DOI 10.1158/1541-7786.MCR-08-0316
   Horikawa Y, 1997, NAT GENET, V17, P384, DOI 10.1038/ng1297-384
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Issa JPJ, 2001, CANCER RES, V61, P3573
   Itamochi H, 2008, CANCER SCI, V99, P653, DOI 10.1111/j.1349-7006.2008.00747.x
   Ito M, 2007, J UROLOGY, V178, P1073, DOI 10.1016/j.juro.2007.05.012
   Kato N, 2008, HISTOPATHOLOGY, V52, P682, DOI 10.1111/j.1365-2559.2008.03006.x
   Lau CK, 2009, CLIN CANCER RES, V15, P3462, DOI 10.1158/1078-0432.CCR-08-2127
   Lee S, 2007, GYNECOL ONCOL, V106, P311, DOI 10.1016/j.ygyno.2007.03.041
   Maeda T, 2005, BRIT J CANCER, V93, P116, DOI 10.1038/sj.bjc.6602662
   Marquez RT, 2005, CLIN CANCER RES, V11, P6116, DOI 10.1158/1078-0432.CCR-04-2509
   Newton MA, 2007, ANN APPL STAT, V1, P85, DOI 10.1214/07-AOAS104
   Osada R, 2007, HUM PATHOL, V38, P1310, DOI 10.1016/j.humpath.2007.02.010
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Pyeon D, 2007, CANCER RES, V67, P4605, DOI 10.1158/0008-5472.CAN-06-3619
   Ramaswamy S, 2002, J CLIN ONCOL, V20, P1932, DOI 10.1200/JCO.2002.20.7.1932
   Sandberg R, 2005, P NATL ACAD SCI USA, V102, P2052, DOI 10.1073/pnas.0408105102
   Schaner ME, 2003, MOL BIOL CELL, V14, P4376, DOI 10.1091/mbc.E03-05-0279
   Schwartz DR, 2002, CANCER RES, V62, P4722
   Shimizu M, 1999, CANCER, V85, P669, DOI 10.1002/(SICI)1097-0142(19990201)85:3<669::AID-CNCR17>3.0.CO;2-F
   Skírnisdóttir I, 2005, INT J ONCOL, V26, P177
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sugiyama T, 2000, CANCER, V88, P2584, DOI 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5
   Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490
   Takano M, 2006, BRIT J CANCER, V94, P1369, DOI 10.1038/sj.bjc.6603116
   Takemoto Y, 2004, CLIN CANCER RES, V10, P7418, DOI 10.1158/1078-0432.CCR-04-0279
   Tsuchiya A, 2003, AM J PATHOL, V163, P2503, DOI 10.1016/S0002-9440(10)63605-X
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Yamaguchi K, 2008, CLIN CANCER RES, V14, P32, DOI 10.1158/1078-0432.CCR-07-1614
   Zaffanello M, 2008, MED SCI MONITOR, V14, pRA78
   Zorn KK, 2005, CLIN CANCER RES, V11, P6422, DOI 10.1158/1078-0432.CCR-05-0508
NR 46
TC 138
Z9 150
U1 1
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD MAR
PY 2010
VL 29
IS 12
BP 1741
EP 1752
DI 10.1038/onc.2009.470
PG 12
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 574VR
UT WOS:000276022800004
PM 20062075
DA 2025-01-12
ER

PT J
AU Davies, GF
   Ross, AR
   Arnason, TG
   Juurlink, BHJ
   Harkness, TAA
AF Davies, G. F.
   Ross, A. R.
   Arnason, T. G.
   Juurlink, B. H. J.
   Harkness, T. A. A.
TI Troglitazone inhibits histone deacetylase activity in breast cancer
   cells
SO CANCER LETTERS
LA English
DT Article
DE Troglitazone; Breast cancer; Histone post-translational modifications;
   Cell killing; PI3K/AKT inhibition
ID ACTIVATED-RECEPTOR-GAMMA; DOUBLE-STRAND BREAKS; ANALOG ALPHA-TEA;
   PPAR-GAMMA; PROTEIN-KINASE; COLON-CANCER; IN-VITRO; TRICHOSTATIN-A;
   PHASE-II; LIGAND TROGLITAZONE
AB We previously demonstrated that the PPAR gamma agonist Troglitazone (TRG), a potent antiproliferative agent, in combination with the anthracycline antibiotic Doxorubicin (DOX), is an effective killer of multiple drug resistant (MDR) human cancer cells. Cell killing was accompanied by increased global histone H3 acetylation. Presently, we investigated the epigenetic and cell killing effects of TRG in estrogen receptor (ER) positive MCF7 breast cancer cells. MCF7 cells were treated with the Thiazolidinediones (TZDs) TRG and Ciglitazone (CIG), the non-TZD PPAR gamma agonist 15PGJ2, and the histone deacetylase inhibitors (HDACi's) Trichostatin A (TSA), sodium butyrate and PXD101. Using MTT cell viability assays, Western analyzes and mass spectrometry, we showed a dose-dependent increase in cell killing in TRG and HDACi treated cells, that was associated with increased H3 lysine 9 (H3K9) and H3K23 acetylation, H2AX and H3S10 phosphorylation, and H3K79 monoand di-methylation. These effects were mediated through an ER independent pathway. Using HDAC activity assays, TRG inhibited HDAC activity in cells and in cell lysates, similar to that observed with TSA. Furthermore, TRG and TSA induced a slower migrating HDAC1 species that was refractory to HDAC2 associations. Lastly, TRG and the HDACi's decreased total and phosphorylated AKT levels. These findings suggest that TRG's mode of killing may involve downregulation of PI3K signaling through HDAC inhibition, leading to increased global histone post-translational modifications. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
C1 [Davies, G. F.; Juurlink, B. H. J.; Harkness, T. A. A.] Univ Saskatchewan, Dept Anat & Cell Biol, Saskatoon, SK S7N 5E5, Canada.
   [Ross, A. R.] Natl Res Council Canada, Inst Plant Biotechnol, Saskatoon, SK S7N 0W9, Canada.
   [Arnason, T. G.] Univ Saskatchewan, Dept Med, Saskatoon, SK S7N 0W8, Canada.
C3 University of Saskatchewan; National Research Council Canada; University
   of Saskatchewan
RP Harkness, TAA (通讯作者)，B313 Hlth Sci Bldg,107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.
EM troy.harkness@usask.ca
OI Harkness, Troy/0000-0002-8271-7229
CR Ajiro K, 2000, J BIOL CHEM, V275, P439, DOI 10.1074/jbc.275.1.439
   Alao JP, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-40
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Burstein HJ, 2003, BREAST CANCER RES TR, V79, P391, DOI 10.1023/A:1024038127156
   Butler KV, 2008, CURR PHARM DESIGN, V14, P505
   Campbell SE, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-25
   Camphausen K, 2007, J CLIN ONCOL, V25, P4051, DOI 10.1200/JCO.2007.11.6202
   Chen CS, 2005, J BIOL CHEM, V280, P38879, DOI 10.1074/jbc.M505733200
   Cheung WL, 2003, CELL, V113, P507, DOI 10.1016/S0092-8674(03)00355-6
   Copland JA, 2006, ONCOGENE, V25, P2304, DOI 10.1038/sj.onc.1209267
   Dashwood RH, 2007, SEMIN CANCER BIOL, V17, P363, DOI 10.1016/j.semcancer.2007.04.001
   Davies GF, 2009, DRUG DES DEV THER, V3, P79
   Davies GF, 2005, LEUKEMIA LYMPHOMA, V46, P1199, DOI 10.1080/10428190500102555
   Davies GF, 2001, BIOCHEM PHARMACOL, V62, P1071, DOI 10.1016/S0006-2952(01)00764-X
   Dayon L, 2006, J PROTEOME RES, V5, P793, DOI 10.1021/pr050365o
   Demetri GD, 1999, P NATL ACAD SCI USA, V96, P3951, DOI 10.1073/pnas.96.7.3951
   Duvic M, 2007, EXPERT OPIN INV DRUG, V16, P1111, DOI 10.1517/13543784.16.7.1111
   Fediuc S, 2008, J CELL PHYSIOL, V215, P392, DOI 10.1002/jcp.21321
   Feng R, 2007, BRIT J HAEMATOL, V139, P385, DOI 10.1111/j.1365-2141.2007.06772.x
   Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024
   Fernandez-Capetillo O, 2004, J EXP MED, V199, P1671, DOI 10.1084/jem.20032247
   Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710
   Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200
   Galli A, 2006, EXPERT OPIN INV DRUG, V15, P1039, DOI 10.1517/13543784.15.9.1039
   Gimsing P, 2008, EUR J HAEMATOL, V81, P170, DOI 10.1111/j.1600-0609.2008.01102.x
   Glaser KB, 2007, BIOCHEM PHARMACOL, V74, P659, DOI 10.1016/j.bcp.2007.04.007
   Govindarajan R, 2007, J CLIN ONCOL, V25, P1476, DOI 10.1200/JCO.2006.07.2777
   Gu CH, 2006, LEUKEMIA RES, V30, P1447, DOI 10.1016/j.leukres.2006.03.029
   Hess-Stumpp H, 2007, INT J BIOCHEM CELL B, V39, P1388, DOI 10.1016/j.biocel.2007.02.009
   Hosokawa M, 2004, BBA-GEN SUBJECTS, V1675, P113, DOI 10.1016/j.bbagen.2004.08.012
   HUTTTAYLOR SR, 1988, BLOOD, V71, P209
   Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114
   Isley William L, 2003, Expert Opin Drug Saf, V2, P581, DOI 10.1517/14740338.2.6.581
   Jarrar MH, 2007, J CELL MOL MED, V11, P71, DOI 10.1111/j.1582-4934.2007.00003.x
   Kikuchi H, 2005, GENE, V347, P83, DOI 10.1016/j.gene.2004.12.007
   KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x
   Kodani M, 2005, ONCOL REP, V13, P477
   Koga H, 2001, HEPATOLOGY, V33, P1087, DOI 10.1053/jhep.2001.24024
   Kulke MH, 2002, CANCER J, V8, P395, DOI 10.1097/00130404-200209000-00010
   Li A, 2005, BIOCHEM CELL BIOL, V83, P505, DOI 10.1139/O05-114
   Loi CM, 1999, J CLIN PHARMACOL, V39, P920, DOI 10.1177/00912709922008533
   Loi CM, 1997, J CLIN PHARMACOL, V37, P1114, DOI 10.1002/j.1552-4604.1997.tb04295.x
   Marchion D, 2007, EXPERT REV ANTICANC, V7, P583, DOI 10.1586/14737140.7.4.583
   MEEKSWAGNER D, 1986, CELL, V44, P43, DOI 10.1016/0092-8674(86)90483-6
   Monami M, 2008, DIABETES CARE, V31, P1455, DOI 10.2337/dc07-2308
   Mueller E, 2000, P NATL ACAD SCI USA, V97, P10990, DOI 10.1073/pnas.180329197
   MULDER GJ, 1983, ENVIRON HEALTH PERSP, V49, P27, DOI 10.2307/3429577
   Neuzil J, 2001, FASEB J, V15, P403, DOI 10.1096/fj.00-0251com
   Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502
   Nian H, 2009, ENVIRON MOL MUTAGEN, V50, P213, DOI 10.1002/em.20454
   Ocker M, 2007, INT J BIOCHEM CELL B, V39, P1367, DOI 10.1016/j.biocel.2007.03.001
   Odegard VH, 2005, IMMUNITY, V23, P101, DOI 10.1016/j.immuni.2005.05.007
   Okura T, 2000, EUR J PHARMACOL, V407, P227, DOI 10.1016/S0014-2999(00)00758-5
   Qiu L, 1999, BRIT J CANCER, V80, P1252, DOI 10.1038/sj.bjc.6690493
   Ramalingam SS, 2009, J THORAC ONCOL, V4, P97, DOI 10.1097/JTO.0b013e318191520c
   Ray DM, 2006, J IMMUNOL, V177, P5068, DOI 10.4049/jimmunol.177.8.5068
   Ricciarelli R, 1998, BIOCHEM J, V334, P243, DOI 10.1042/bj3340243
   Ross ARS, 2002, PROTEOMICS, V2, P928, DOI 10.1002/1615-9861(200207)2:7<928::AID-PROT928>3.0.CO;2-P
   Scheen AJ, 1999, DIABETES CARE, V22, P1568, DOI 10.2337/diacare.22.9.1568
   Sekhavat A, 2007, BIOCHEM CELL BIOL, V85, P751, DOI 10.1139/O07-145
   Shun MC, 2004, NUTR CANCER, V48, P95, DOI 10.1207/s15327914nc4801_13
   Sluss HK, 2006, MOL CELL, V23, P152, DOI 10.1016/j.molcel.2006.07.001
   Snyder RM, 2008, NUTR CANCER, V60, P401, DOI 10.1080/01635580701759716
   Somoza JR, 2004, STRUCTURE, V12, P1325, DOI 10.1016/j.str.2004.04.012
   Stafford JM, 2007, VASC HEALTH RISK MAN, V3, P503
   Sugimura A, 1999, BIOCHEM BIOPH RES CO, V261, P833, DOI 10.1006/bbrc.1999.1049
   Suzuki T, 2005, CURR MED CHEM, V12, P2867, DOI 10.2174/092986705774454706
   Tafazoli S, 2005, CHEM RES TOXICOL, V18, P1567, DOI 10.1021/tx0500575
   Tanaka T, 2006, CELL CYCLE, V5, P1940, DOI 10.4161/cc.5.17.3191
   Taylor RT, 2009, TOXICOL SCI, V107, P1, DOI 10.1093/toxsci/kfn217
   Thiriet C, 2005, MOL CELL, V18, P617, DOI 10.1016/j.molcel.2005.05.008
   To KKW, 2008, MOL CANCER RES, V6, P151, DOI 10.1158/1541-7786.MCR-07-0175
   Tumber A, 2007, CANCER CHEMOTH PHARM, V60, P275, DOI 10.1007/s00280-006-0374-7
   Turturro F, 2007, AM J PHYSIOL-CELL PH, V292, pC1137, DOI 10.1152/AJPCELL.00396.2006
   van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6
   Vannini A, 2004, P NATL ACAD SCI USA, V101, P15064, DOI 10.1073/pnas.0404603101
   Voutsadakis IA, 2007, J CANCER RES CLIN, V133, P917, DOI 10.1007/s00432-007-0277-y
   Wang DF, 2005, J MED CHEM, V48, P6936, DOI 10.1021/jm0505011
   Wang X, 2007, LIFE SCI, V81, P160, DOI 10.1016/j.lfs.2007.04.034
   Willermain F, 2006, PROSTAG OTH LIPID M, V80, P136, DOI 10.1016/j.prostaglandins.2006.06.001
   Yamazaki H, 2000, XENOBIOTICA, V30, P61
   Yang CC, 2007, CANCER RES, V67, P3229, DOI 10.1158/0008-5472.CAN-06-2759
   Yao CJ, 2006, INT J CANCER, V118, P773, DOI 10.1002/ijc.21361
   YOSHIDA M, 1987, CANCER RES, V47, P3688
   YOSHIDA M, 1990, J BIOL CHEM, V265, P17174
   Yu WP, 2008, MOL NUTR FOOD RES, V52, P447, DOI 10.1002/mnfr.200700254
   Yurek-George A, 2007, J MED CHEM, V50, P5720, DOI 10.1021/jm0703800
   Zhou H, 2006, BIOCHEMISTRY-US, V45, P2852, DOI 10.1021/bi0521083
NR 88
TC 20
Z9 20
U1 0
U2 14
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD FEB 28
PY 2010
VL 288
IS 2
BP 236
EP 250
DI 10.1016/j.canlet.2009.07.011
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 563RJ
UT WOS:000275150800013
PM 19699029
DA 2025-01-12
ER

PT J
AU Hoffman, AE
   Yi, CH
   Zheng, TZ
   Stevens, RG
   Leaderer, D
   Zhang, YW
   Holford, TR
   Hansen, J
   Paulson, J
   Zhu, Y
AF Hoffman, Aaron E.
   Yi, Chun-Hui
   Zheng, Tongzhang
   Stevens, Richard G.
   Leaderer, Derek
   Zhang, Yawei
   Holford, Theodore R.
   Hansen, Johnni
   Paulson, Jennifer
   Zhu, Yong
TI <i>CLOCK</i> in Breast Tumorigenesis: Genetic, Epigenetic, and
   Transcriptional Profiling Analyses
SO CANCER RESEARCH
LA English
DT Article
ID CIRCADIAN CLOCK; CANCER RISK; EXPRESSION; DISRUPTION; PROTEINS;
   RECEPTOR; LIGHT; WOMEN; NIGHT; POWER
AB The transcription factors responsible for maintaining circadian rhythm influence a variety of biological processes. Recently, it has been suggested that the core circadian genes may play a role in breast tumorigenesis, possibly by influencing hormone regulation or other pathways relevant to cancer. To evaluate this hypothesis, we conducted a genetic and epigenetic association study, as well as a transcriptional profiling array and a pathway-based network analysis. We report significant correlations between single nucleotide polymorphisms associated with the central circadian regulator CLOCK and breast cancer risk, with apparent effect modification by estrogen receptor/progesterone receptor status. We also found that hypermethylation in the CLOCK promoter reduced the risk of breast cancer, and lower levels of CLOCK expression were documented in healthy controls relative to normal or tumor tissue from patients with breast cancer. Finally, we silenced CLOCK in vitro and performed a whole-genome expression microarray and pathway analysis, which identified a cancer-relevant network of transcripts with altered expression following CLOCK gene knockdown. Our findings support the hypothesis that circadian genes influence tumorigenesis, and identify a set of circadian gene variants as candidate breast cancer susceptibility biomarkers. Cancer Res; 70(4); 1459-68. (C) 2010 AACR.
C1 [Hoffman, Aaron E.; Yi, Chun-Hui; Zheng, Tongzhang; Leaderer, Derek; Zhang, Yawei; Holford, Theodore R.; Paulson, Jennifer; Zhu, Yong] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA.
   [Stevens, Richard G.] Univ Connecticut, Ctr Hlth, Dept Community Med & Hlth Care, Farmington, CT USA.
   [Hansen, Johnni] Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark.
C3 Yale University; University of Connecticut; Danish Cancer Society
RP Zhu, Y (通讯作者)，Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA.
EM yong.zhu@yale.edu
OI Hansen, Johnni/0000-0002-9342-2725
FU NIH [CA122676, CA110937]
FX Grant Support NIH grants (CA122676, and CA110937).
CR Antoch MP, 2008, CELL CYCLE, V7, P1197, DOI 10.4161/cc.7.9.5886
   Azenshtein E, 2002, CANCER RES, V62, P1093
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bjarnason GA, 1999, AM J PATHOL, V154, P613, DOI 10.1016/S0002-9440(10)65306-0
   Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985
   Cao Y, 2008, APPL IMMUNOHISTO M M, V16, P530, DOI 10.1097/PAI.0b013e31817432c3
   Cheng ASL, 2008, CANCER RES, V68, P1786, DOI 10.1158/0008-5472.CAN-07-5547
   Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902
   Davis S, 2001, JNCI-J NATL CANCER I, V93, P1557, DOI 10.1093/jnci/93.20.1557
   de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669
   Doi M, 2006, CELL, V125, P497, DOI 10.1016/j.cell.2006.03.033
   Fu LN, 2003, NAT REV CANCER, V3, P350, DOI 10.1038/nrc1072
   Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564
   Greco S, 2004, J CELL PHYSIOL, V201, P84, DOI 10.1002/jcp.20052
   Hansen J, 2001, EPIDEMIOLOGY, V12, P74, DOI 10.1097/00001648-200101000-00013
   Kondratov RV, 2007, COLD SPRING HARB SYM, V72, P477, DOI 10.1101/sqb.2007.72.050
   Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544
   Matsuo T, 2003, SCIENCE, V302, P255, DOI 10.1126/science.1086271
   MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716
   Miller BH, 2007, P NATL ACAD SCI USA, V104, P3342, DOI 10.1073/pnas.0611724104
   Parkinson H, 2009, NUCLEIC ACIDS RES, V37, pD868, DOI 10.1093/nar/gkn889
   Schernhammer ES, 2001, J NATL CANCER I, V93, P1563, DOI 10.1093/jnci/93.20.1563
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Stevens RG, 2005, EPIDEMIOLOGY, V16, P254, DOI 10.1097/01.ede.0000152525.21924.54
   Stevens RG, 2001, CANCER CAUSE CONTROL, V12, P279, DOI 10.1023/A:1011237000609
   STEVENS RG, 1987, AM J EPIDEMIOL, V125, P556, DOI 10.1093/oxfordjournals.aje.a114569
   Storch KF, 2002, NATURE, V417, P78, DOI 10.1038/nature744
   Uray IP, 2004, CANCER LETT, V207, P101, DOI 10.1016/j.canlet.2003.10.021
   Wang GZ, 2006, CANCER RES, V66, P1199, DOI 10.1158/0008-5472.CAN-05-2605
   Widschwendter M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002656
   Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576
   Zheng TZ, 2000, CANCER EPIDEM BIOMAR, V9, P167
   Zhu Y, 2005, CANCER EPIDEM BIOMAR, V14, P268
   Zhu Y, 2008, BREAST CANCER RES TR, V107, P421, DOI 10.1007/s10549-007-9565-0
NR 35
TC 147
Z9 163
U1 0
U2 13
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD FEB 15
PY 2010
VL 70
IS 4
BP 1459
EP 1468
DI 10.1158/0008-5472.CAN-09-3798
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 607FY
UT WOS:000278485700020
PM 20124474
OA Green Accepted, Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Wakefield, L
   Boukouvala, S
   Sim, E
AF Wakefield, Larissa
   Boukouvala, Sotiria
   Sim, Edith
TI Characterisation of CpG methylation in the upstream control region of
   mouse <i>Nat2</i>: Evidence for a gene-environment interaction in a
   polymorphic gene implicated in folate metabolism
SO GENE
LA English
DT Article
DE Arylamine N-acetyltransferase; Mouse Nat2 gene; Epigenetic gene control;
   Folate; DNA methylation; Cancer
ID ARYLAMINE N-ACETYLTRANSFERASES; ONE-CARBON METABOLISM; BREAST-CANCER;
   N-ACETYLTRANSFERASE-1 GENE; P-AMINOBENZOYLGLUTAMATE; DNA
   HYPOMETHYLATION; PROSTATE-CANCER; MAJOR PROMOTER; EXPRESSION; MICE
AB Human arylamine N-acetyltransferase I (NAT1), a polymorphic xenobiotic metabolising enzyme, has been investigated in relation to susceptibility and prognosis in certain types of cancer. Both human NAT1 and its murine equivalent NAT2 have previously been shown to play roles in the catabolism of folate, which is required for the synthesis of S-adenosylmethionine, the methyl donor for cellular methylation reactions. We have tested whether the expression of mouse Nat2 is subject to epigenetic regulation, specifically CpG methylation in the promoter region, by determining levels of 5-methylcytosine by bisulphite sequencing and methylation-specific PCR. Under normal conditions, methylation levels of the Nat2 promoter were low, and varied in different tissues. However, CpG methylation was significantly increased by dietary folate supplementation, and increased methylation corresponded to decreased use of the core promoter. Functional deletion of the Nat2 gene gave rise to a significant increase in Nat2 methylation, extending our previous observations that folate catabolism is decreased in Nat2 null mice. Mouse NAT2 is likely to influence epigenetic gene control, particularly of its own locus, and this is consistent with recent evidence associating aberrant mouse Nat2/human NAT1 gene expression with certain developmental malformations and cancers. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Wakefield, Larissa; Sim, Edith] Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England.
   [Boukouvala, Sotiria] Democritus Univ Thrace, Dept Mol Biol & Genet, Alexandroupolis 68100, Greece.
C3 University of Oxford; Democritus University of Thrace
RP Sim, E (通讯作者)，Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.
EM edith.sim@pharm.ox.ac.uk
RI Boukouvala, Sotiria/JGL-8032-2023
FU Wellcome Trust; EPA Cephalosporin Fund; John Fell Fund
FX The authors thank Nathan Lack for critical reading of the manuscript,
   Hilary Long and Rachel Cough for technical assistance, and Lindsay
   Johnson for her help preparing the manuscript. This work was funded by
   the Wellcome Trust, the EPA Cephalosporin Fund and the John Fell Fund.
CR Adam PJ, 2003, MOL CANCER RES, V1, P826
   Barker DF, 2006, PHARMACOGENET GENOM, V16, P515, DOI 10.1097/01.fpc.0000215066.29342.26
   Bièche I, 2004, BREAST CANCER RES, V6, pR252, DOI 10.1186/bcr784
   Boukouvala S, 2005, DRUG METAB REV, V37, P511, DOI 10.1080/03602530500251204
   Boukouvala S, 2005, BASIC CLIN PHARMACOL, V96, P343, DOI 10.1111/j.1742-7843.2005.pto_02.x
   Boukouvala S, 2003, BIOCHEM J, V375, P593, DOI 10.1042/BJ20030812
   Boukouvala S, 2002, PHARMACOGENETICS, V12, P385, DOI 10.1097/00008571-200207000-00006
   Butcher NJ, 2008, CURR DRUG METAB, V9, P498, DOI 10.2174/138920008784892128
   Butcher NJ, 2007, CANCER RES, V67, P85, DOI 10.1158/0008-5472.CAN-06-2635
   Butcher NJ, 2005, BIOCHEM J, V387, P119, DOI 10.1042/BJ20040903
   Cornish VA, 2003, PHARMACOGENOMICS J, V3, P169, DOI 10.1038/sj.tpj.6500170
   Curtin K, 2007, CARCINOGENESIS, V28, P1672, DOI 10.1093/carcin/bgm089
   Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104
   Ehrlich M, 2006, CURR TOP MICROBIOL, V310, P251
   Erickson RP, 2008, MOL REPROD DEV, V75, P1071, DOI 10.1002/mrd.20852
   Estrada-Rodgers L, 1998, GENE EXPRESSION, V7, P13
   Fakis G, 2000, CYTOGENET CELL GENET, V90, P134, DOI 10.1159/000015648
   Hirsch S, 2008, NUTRITION, V24, P1103, DOI 10.1016/j.nut.2008.05.018
   Husain A, 2004, PHARMACOGENETICS, V14, P397, DOI 10.1097/01.fpc.0000114755.08559.6e
   Husain A, 2007, DRUG METAB DISPOS, V35, P1649, DOI 10.1124/dmd.107.016485
   Kawamura A, 2008, BIOCHEM PHARMACOL, V75, P1550, DOI 10.1016/j.bcp.2007.12.012
   Kim SJ, 2008, ONCOL REP, V19, P663
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Laird PW, 2005, HUM MOL GENET, V14, pR65, DOI 10.1093/hmg/ddi113
   Larsson SC, 2006, GASTROENTEROLOGY, V131, P1271, DOI 10.1053/j.gastro.2006.08.010
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Loehle JA, 2006, J PHARMACOL EXP THER, V319, P724, DOI 10.1124/jpet.106.108662
   Marchal C, 2008, EJSO-EUR J SURG ONC, V34, P805, DOI 10.1016/j.ejso.2007.09.008
   MINCHIN RF, 1995, BIOCHEM J, V307, P1
   Minchin RF, 2007, INT J BIOCHEM CELL B, V39, P1999, DOI 10.1016/j.biocel.2006.12.006
   Payton M, 1999, BIOCHEM PHARMACOL, V58, P779, DOI 10.1016/S0006-2952(99)00171-9
   Robien K, 2005, PHARMACOGENOMICS, V6, P673, DOI 10.2217/14622416.6.7.673
   Shields DC, 1999, AM J HUM GENET, V64, P1045, DOI 10.1086/302310
   Sim E, 2008, DRUG METAB REV, V40, P479, DOI [10.1080/03602530802186603, 10.1080/03602530802186603 ]
   Sim E, 2007, EXPERT OPIN DRUG MET, V3, P169, DOI 10.1517/17425255.3.2.169
   Smelt VA, 2000, HUM MOL GENET, V9, P1101, DOI 10.1093/hmg/9.7.1101
   Song J, 2000, CANCER RES, V60, P5434
   Srour N, 2008, PATHOBIOLOGY, V75, P112, DOI 10.1159/000123849
   Suzuki T, 2008, CARCINOGENESIS, V29, P356, DOI 10.1093/carcin/bgm295
   Upton A, 2000, BBA-GEN SUBJECTS, V1524, P143, DOI 10.1016/S0304-4165(00)00149-5
   Vucic EA, 2008, PHARMACOGENOMICS, V9, P215, DOI 10.2217/14622416.9.2.215
   Wakefield L, 2008, BIOMARKERS, V13, P106, DOI 10.1080/13547500701673529
   Wakefield L, 2007, BIOCHEM BIOPH RES CO, V364, P556, DOI 10.1016/j.bbrc.2007.10.026
   WARD A, 1995, BIOCHEM PHARMACOL, V49, P1759, DOI 10.1016/0006-2952(95)00087-G
NR 44
TC 31
Z9 32
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD FEB 15
PY 2010
VL 452
IS 1
BP 16
EP 21
DI 10.1016/j.gene.2009.12.002
PG 6
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 558WF
UT WOS:000274778500003
PM 20026257
DA 2025-01-12
ER

PT J
AU Wang, JK
   Tsai, MC
   Poulin, G
   Adler, AS
   Chen, SZ
   Liu, HL
   Shi, Y
   Chang, HY
AF Wang, Jordon K.
   Tsai, Miao-Chih
   Poulin, Gino
   Adler, Adam S.
   Chen, Shuzhen
   Liu, Helen
   Shi, Yang
   Chang, Howard Y.
TI The histone demethylase UTX enables RB-dependent cell fate control
SO GENES & DEVELOPMENT
LA English
DT Article
DE Gene regulation; epigenetics; chromatin; histone demethylation; cancer
ID CAENORHABDITIS-ELEGANS; TRANSCRIPTIONAL REPRESSOR; RETINOBLASTOMA GENE;
   VULVAL DEVELOPMENT; H3K27 DEMETHYLASE; JMJD3 CONTRIBUTES; INK4A-ARF
   LOCUS; BREAST-CANCER; SYNMUV GENES; TARGET GENES
AB Trimethylation of histone H3 on Lys 27 (H3K27me3) is key for cell fate regulation. The H3K27me3 demethylase UTX functions in development and tumor suppression with undefined mechanisms. Here, genome-wide chromatin occupancy analysis of UTX and associated histone modifications reveals distinct classes of UTX target genes, including genes encoding Retinoblastoma (RB)-binding proteins. UTX removes H3K27me3 and maintains expression of several RB-binding proteins, enabling cell cycle arrest. Genetic interactions in mammalian cells and Caenorhabditis elegans show that UTX regulates cell fates via RB-dependent pathways. Thus, UTX defines an evolutionarily conserved mechanism to enable coordinate transcription of a RB network in cell fate control.
C1 [Wang, Jordon K.; Tsai, Miao-Chih; Adler, Adam S.; Liu, Helen; Chang, Howard Y.] Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA.
   [Wang, Jordon K.; Tsai, Miao-Chih; Adler, Adam S.; Liu, Helen; Chang, Howard Y.] Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA.
   [Poulin, Gino] Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England.
   [Chen, Shuzhen; Shi, Yang] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
   [Chen, Shuzhen; Shi, Yang] Childrens Hosp, Dept Med, Div Newborn Med, Boston, MA 02115 USA.
C3 Stanford University; Howard Hughes Medical Institute; Stanford
   University; University of Manchester; Harvard University; Harvard
   Medical School; Harvard University; Boston Children's Hospital
RP Chang, HY (通讯作者)，Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA.
EM howchang@stanford.edu
RI Cheng, Shuqun/HTS-9930-2023
OI Adler, Adam/0000-0001-9301-0037; Poulin, Gino/0000-0003-1016-348X; Tsai,
   Miao-Chih/0000-0003-4471-4825; Wang, Jordon/0000-0003-1108-2534
FU California Institute for Regenerative Medicine [RN1-00529-1]; National
   Cancer Institute [R01-CA118487, R01-CA118750]; American Cancer Society
   [RSG 07-084-01-MGO]; MRC [G0600127] Funding Source: UKRI
FX We thank E. Canaani for the gift of anti-UTX antibody; J. Sage and D.
   Burkhart for TKO MEFs; A. Bergmann for communicating unpublished
   information; and J. Sage, P. Khavari, and Seung Kim for input. This work
   was supported by grants from the California Institute for Regenerative
   Medicine (RN1-00529-1), the National Cancer Institute (R01-CA118487 to
   Y. S. and R01-CA118750 to H. Y. C.), and the American Cancer Society
   (RSG 07-084-01-MGO). H. Y. C. is an Early Career Scientist of the Howard
   Hughes Medical Institute.
CR Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145
   Agger K, 2009, GENE DEV, V23, P1171, DOI 10.1101/gad.510809
   Barradas M, 2009, GENE DEV, V23, P1177, DOI 10.1101/gad.511109
   Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399
   Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985
   Ceol CJ, 2004, DEV CELL, V6, P563, DOI 10.1016/S1534-5807(04)00065-6
   Fay DS, 2007, DEV BIOL, V306, P1, DOI 10.1016/j.ydbio.2007.03.016
   FERGUSON EL, 1989, GENETICS, V123, P109
   Issaeva I, 2007, MOL CELL BIOL, V27, P1889, DOI 10.1128/MCB.01506-06
   Jepsen K, 2007, NATURE, V450, P415, DOI 10.1038/nature06270
   Johnson DS, 2008, GENOME RES, V18, P393, DOI 10.1101/gr.7080508
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kotake Y, 2007, GENE DEV, V21, P49, DOI 10.1101/gad.1499407
   Lan F, 2007, NATURE, V449, P689, DOI 10.1038/nature06192
   Lee MG, 2007, SCIENCE, V318, P447, DOI 10.1126/science.1149042
   Liu H, 2007, PLOS GENET, V3, P996, DOI 10.1371/journal.pgen.0030091
   Morishita H, 2007, CURR OPIN CELL BIOL, V19, P584, DOI 10.1016/j.ceb.2007.09.006
   Olender Tsviya, 2008, Human Genomics, V3, P87
   Paulson KE, 2007, CANCER RES, V67, P6136, DOI 10.1158/0008-5472.CAN-07-0567
   Rando OJ, 2009, ANNU REV BIOCHEM, V78, P245, DOI 10.1146/annurev.biochem.78.071107.134639
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014
   Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764
   Segal E, 2004, NAT GENET, V36, P1090, DOI 10.1038/ng1434
   Sen GL, 2008, GENE DEV, V22, P1865, DOI 10.1101/gad.1673508
   Shaw T, 2009, EMBO REP, V10, P881, DOI 10.1038/embor.2009.102
   Solari F, 2000, CURR BIOL, V10, P223, DOI 10.1016/S0960-9822(00)00343-2
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383
   van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
NR 35
TC 119
Z9 151
U1 1
U2 5
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 0890-9369
EI 1549-5477
J9 GENE DEV
JI Genes Dev.
PD FEB 15
PY 2010
VL 24
IS 4
BP 327
EP 332
DI 10.1101/gad.1882610
PG 6
WC Cell Biology; Developmental Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 556GD
UT WOS:000274577100001
PM 20123895
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Wu, YY
   Alvarez, M
   Slamon, DJ
   Koeffler, P
   Vadgama, JV
AF Wu, Yanyuan
   Alvarez, Monica
   Slamon, Dennis J.
   Koeffler, Phillip
   Vadgama, Jaydutt V.
TI Caspase 8 and maspin are downregulated in breast cancer cells due to CpG
   site promoter methylation
SO BMC CANCER
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITION; DNA METHYLATION; GENE; HYPERMETHYLATION;
   EXPRESSION; APOPTOSIS; PROTEIN; GLIOBLASTOMA; ASSOCIATION; ACTIVATION
AB Background: Epigenetic changes associated with promoter DNA methylation results in silencing of several tumor suppressor genes that lead to increased risk for tumor formation and for progression of the cancer.
   Methods: Methylation specific PCR (MSP) and bisulfite sequencing were used for determination of proapoptotic gene Caspase 8 (CASP8) and the tumor suppressor gene maspin promoter methylation in four breast cancer and two non-tumorigenic breast cell lines. Involvement of histone H3 methylation in those cell lines were examined by CHIP assay.
   Results: The CpG sites in the promoter region of CASP8 and maspin were methylated in all four breast cancer cell lines but not in two non-tumorigenic breast cell lines. Demethylation agent 5-aza-2'-deoxycytidine (5-aza-dc) selectively inhibits DNA methyltransferases, DNMT3a and DNMT3b, and restored CASP8 and maspin gene expression in breast cancer cells. 5-aza-dc also reduced histone H3k9me2 occupancy on CASP8 promoter in SKBR3cells, but not in MCF-7 cells. Combination of histone deacetylase inhibitor Trichostatin A (TSA) and 5-aza-dc significant decrease in nuclear expression of Di- methyl histone H3-Lys27 and slight increase in acetyl histone H3-Lys9 in MCF-7 cells. CASP8 mRNA and protein level in MCF-7 cells were increased by the 5-aza-dc in combination with TSA. Data from our study also demonstrated that treatment with 5-FU caused a significant increase in unmethylated CASP8 and in CASP8 mRNA in all 3 cancer lines.
   Conclusions: CASP8 and maspin expression were reduced in breast cancer cells due to promoter methylation. Selective application of demethylating agents could offer novel therapeutic opportunities in breast cancer.
C1 [Wu, Yanyuan; Alvarez, Monica; Vadgama, Jaydutt V.] Charles R Drew Univ Med & Sci, Dept Internal Med, Div Canc Res & Training, Los Angeles, CA 90059 USA.
   [Wu, Yanyuan; Slamon, Dennis J.; Koeffler, Phillip; Vadgama, Jaydutt V.] David Geffen UCLA Sch Med, Dept Internal Med, Div Hematol Oncol, Los Angeles, CA 90095 USA.
   [Koeffler, Phillip] Cedars Sinai Med Ctr, Dept Internal Med, Div Hematol Oncol, Los Angeles, CA 90048 USA.
C3 Charles R. Drew University of Medicine & Science; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA; Cedars Sinai Medical Center
RP Vadgama, JV (通讯作者)，Charles R Drew Univ Med & Sci, Dept Internal Med, Div Canc Res & Training, 1731 E 120th St, Los Angeles, CA 90059 USA.
EM javadgam@cdrewu.edu
FU NIH/NCI [U54 CA14393-01, U56 CA101599-01, CA15083-25S3]; NIH/NIDDK [R25
   DK067015-01]; Department of Defense (BCRP) [BC043180]; MBRS NIH [SO6
   GM0685-10-01]
FX This work received financial support from the following sources: NIH/NCI
   U54 CA14393-01 (JVV); U56 CA101599-01 ( JVV), CA15083-25S3 (JVV),
   NIH/NIDDK R25 DK067015-01 ( JVV), Department of Defense (BCRP) BC043180
   ( JVV), and MBRS NIH SO6 GM0685-10-01 (YW).
CR Bachman KE, 1999, CANCER RES, V59, P798
   Bailey CM, 2006, J CELL PHYSIOL, V209, P617, DOI 10.1002/jcp.20782
   Barton CA, 2008, GYNECOL ONCOL, V109, P129, DOI 10.1016/j.ygyno.2007.12.017
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812
   Chen KM, 2007, ARCH OTOLARYNGOL, V133, P1131, DOI 10.1001/archotol.133.11.1131
   Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346
   Dobosy JR, 2007, J UROLOGY, V177, P822, DOI 10.1016/j.juro.2006.10.063
   Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5
   Ehrhardt H, 2008, ONCOGENE, V27, P783, DOI 10.1038/sj.onc.1210666
   Ellinger J, 2008, J UROLOGY, V179, P346, DOI 10.1016/j.juro.2007.08.091
   Eramo A, 2005, CANCER RES, V65, P11469, DOI 10.1158/0008-5472.CAN-05-1724
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508
   Fulda S, 2002, ONCOGENE, V21, P2295, DOI 10.1038/sj.onc.1205255
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Harada K, 2002, CANCER RES, V62, P5897
   Henken FE, 2007, BRIT J CANCER, V97, P1457, DOI 10.1038/sj.bjc.6604055
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Khalkhali-Ellis Z, 2006, CLIN CANCER RES, V12, P7279, DOI 10.1158/1078-0432.CCR-06-1589
   Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879
   Lan F, 2007, NATURE, V449, P689, DOI 10.1038/nature06192
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Liedtke C, 2003, J BIOL CHEM, V278, P27593, DOI 10.1074/jbc.M304077200
   Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485
   Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298
   Martinez R, 2007, CARCINOGENESIS, V28, P1264, DOI 10.1093/carcin/bgm014
   Miyakura Y, 2001, GASTROENTEROLOGY, V121, P1300, DOI 10.1053/gast.2001.29616
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Odero-Marah VA, 2003, CANCER BIOL THER, V2, P398, DOI 10.4161/cbt.2.4.471
   Park DY, 2007, AM J PATHOL, V171, P1509, DOI 10.2353/ajpath.2007.070331
   Pingoud-Meier C, 2003, CLIN CANCER RES, V9, P6401
   Press JZ, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-17
   Qi W, 2007, EMBO J, V26, P65, DOI 10.1038/sj.emboj.7601483
   REED JC, 1999, CURR OPIN ONCOL, V11, P58
   Ricciardiello L, 2003, CANCER RES, V63, P787
   Rinkenberger JL, 1997, CURR OPIN GENET DEV, V7, P589, DOI 10.1016/S0959-437X(97)80004-4
   Salvesen GS, 1999, STRUCT FOLD DES, V7, pR225, DOI 10.1016/S0969-2126(00)80048-9
   Sheng SJ, 2004, FRONT BIOSCI-LANDMRK, V9, P2733, DOI 10.2741/1432
   Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007
   Trojer P, 2006, CELL, V125, P213, DOI 10.1016/j.cell.2006.04.003
   Wei MJ, 2008, BREAST CANCER RES TR, V111, P113, DOI 10.1007/s10549-007-9766-6
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yang QW, 2007, CLIN CANCER RES, V13, P3191, DOI 10.1158/1078-0432.CCR-06-2846
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Yang XW, 2001, CANCER RES, V61, P7025
   Yuan JH, 2003, CANCER RES, V63, P4174
   Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303
   Zhang W.G., 2005, BMC CANC, V5
   Zoli W, 2005, BREAST CANCER RES, V7, pR681, DOI 10.1186/bcr1274
NR 52
TC 55
Z9 60
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD FEB 4
PY 2010
VL 10
AR 32
DI 10.1186/1471-2407-10-32
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 564JB
UT WOS:000275208000001
PM 20132554
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Cheng, CW
   Yu, JC
   Wang, HW
   Huang, CS
   Shieh, JC
   Fu, YP
   Chang, CW
   Wu, PE
   Shen, CY
AF Cheng, Chun-Wen
   Yu, Jyh-Cherng
   Wang, Hsiao-Wei
   Huang, Chiun-Sheng
   Shieh, Jia-Ching
   Fu, Yi-Ping
   Chang, Chia-Wei
   Wu, Pei-Ei
   Shen, Chen-Yang
TI The clinical implications of MMP-11 and CK-20 expression in human breast
   cancer
SO CLINICA CHIMICA ACTA
LA English
DT Article
DE Breast cancer; MMP-11; CK-20; qRT-PCR; Lymph node metastasis
ID MESSENGER-RNA EXPRESSION; STROMELYSIN-3 EXPRESSION; PERIPHERAL-BLOOD;
   CYTOKERATIN 20; CELL; CARCINOMA; METASTASIS; GROWTH; METALLOPROTEINASES;
   POLYMORPHISM
AB Background: Tumor invasiveness and metastasis in cancer progression is manifested by epigenetic abnormality. However, it remains unknown whether transcription regulation of matrix metalloproteinase-11 (MMP-11) and cytoskeleton-20 (CK-20) genes for the homoeostasis of epithelial/connective interface that can enhance cell dissemination and invasion may act as alternative mutators to tumor clinicopathology.
   Methods: Paired cancerous and tumor-adjacent normal tissues from 72 breast cancer patients were assayed for the expression of MMP-11 and CK-20 by using real-time RT-PCR. The expression profiles were evaluated for the association with clinicopathological factors.
   Results: Breast tumor tissues displayed higher expression levels of MMP-11 and CK-20 than those of the adjacent non-cancerous tissues. Overexpression of either MMP-11 or CK-20 correlated with patients having poorly differentiated tumors (PMMP-11 = 0.01 and PCK-20= 0.05) and lymph node metastasis (LNM) (PMMP-11 = 0.04 and PCK-20= 0.001). A synergistic effect between MMP-11 and CK-20 on risk elevation was significant in patients with advanced tumor stage (OR = 2.03, 95%CI = 1.10-3.77) and LNM (OR = 2.83. 95%CI = 1.20-4.71). Additionally. patients lacking progesterone receptor exhibited high expression of MMP-11 and CK-20.
   Conclusion: We demonstrate that MMP-11 and CK-20 are probable prognostic markers whose expression reflects the stages of tumor differentiation and LNM of breast cancer. (c) 2009 Elsevier B.V. All rights reserved.
C1 [Cheng, Chun-Wen; Chang, Chia-Wei] Chung Shan Med Univ, Inst Biochem & Biotechnol, Taichung 402, Taiwan.
   [Cheng, Chun-Wen; Wang, Hsiao-Wei; Wu, Pei-Ei; Shen, Chen-Yang] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan.
   [Cheng, Chun-Wen] Chung Shan Med Univ Hosp, Clin Lab, Taichung, Taiwan.
   [Yu, Jyh-Cherng] Natl Def Med Ctr, Tri Serv Gen Hosp, Dept Surg, Taipei, Taiwan.
   [Huang, Chiun-Sheng] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan.
   [Shieh, Jia-Ching] Chung Shan Med Univ, Dept Biomed Sci, Taichung, Taiwan.
   [Fu, Yi-Ping] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol, Sch Publ Hlth, Houston, TX USA.
   [Shen, Chen-Yang] China Med Univ, Inst Environm Sci, Taichung, Taiwan.
C3 Chung Shan Medical University; Academia Sinica - Taiwan; Chung Shan
   Medical University; Chung Shan Medical University Hospital; National
   Defense Medical Center; Tri-Service General Hospital; National Taiwan
   University; National Taiwan University Hospital; Chung Shan Medical
   University; University of Texas System; University of Texas Health
   Science Center Houston; University of Texas School Public Health;
   University of Texas Health Science Center at San Antonio; China Medical
   University Taiwan
RP Cheng, CW (通讯作者)，Chung Shan Med Univ, Inst Biochem & Biotechnol, 110,Sec 1,Chien Kuo N Rd, Taichung 402, Taiwan.
EM cwcheng@csmu.edu.tw; bmcys@ibms.sinica.edu.tw
RI Chen, Wei-Yu/ABH-4523-2020; SHEN, CHEN-YANG/F-6271-2010
OI Huang, Chiun-Sheng/0000-0002-6557-211X; SHEN,
   CHEN-YANG/0000-0001-5555-9950
FU National Science Council (Taipei, Taiwan, ROC) [NSC
   95-2314-B-040-030-MY2]
FX We thank Ms. Show-Lin Yang for assistance in organizing our study
   specimens. We are also grateful to all of the study participants for
   their collaboration. This study was supported by the research grants NSC
   95-2314-B-040-030-MY2 from the National Science Council (Taipei, Taiwan,
   ROC).
CR Agnantis NJ, 2004, IN VIVO, V18, P481
   Ananth CV, 1997, INT J EPIDEMIOL, V26, P1323, DOI 10.1093/ije/26.6.1323
   Arora S, 2005, CLIN CANCER RES, V11, P2272, DOI 10.1158/1078-0432.CCR-04-0572
   Bae JW, 2000, J KOREAN MED SCI, V15, P194, DOI 10.3346/jkms.2000.15.2.194
   Basset P, 1997, CRIT REV ONCOL HEMAT, V26, P43, DOI 10.1016/S1040-8428(97)00010-3
   Bosserhoff AK, 2006, CLIN CHIM ACTA, V367, P28, DOI 10.1016/j.cca.2005.10.029
   Bostick PJ, 1998, J CLIN ONCOL, V16, P2632, DOI 10.1200/JCO.1998.16.8.2632
   Chausovsky G, 1999, CANCER, V86, P2398, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2398::AID-CNCR30>3.0.CO;2-5
   Cheng CW, 2008, BREAST CANCER RES TR, V111, P145, DOI 10.1007/s10549-007-9754-x
   Cheng TC, 2005, INT J CANCER, V113, P345, DOI 10.1002/ijc.20630
   Christoph F, 2004, UROLOGY, V64, P157, DOI 10.1016/j.urology.2004.02.020
   Conzen SD, 2008, MOL ENDOCRINOL, V22, P2215, DOI 10.1210/me.2007-0421
   Delany AM, 2001, ENDOCRINOLOGY, V142, P1561, DOI 10.1210/en.142.4.1561
   Delebecq TJ, 2000, CLIN CANCER RES, V6, P1086
   Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65
   Giribaldi G, 2006, J MOL DIAGN, V8, P105, DOI 10.2353/jmoldx.2006.050054
   Hegedüs L, 2008, J CELL PHYSIOL, V216, P480, DOI 10.1002/jcp.21417
   Kim J, 2005, BIOMED PHARMACOTHER, V59, pS380, DOI 10.1016/S0753-3322(05)80083-6
   Kim JH, 2001, MOL CELLS, V12, P32
   Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535
   MIETTINEN M, 1995, MODERN PATHOL, V8, P384
   MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7
   MOLL R, 1993, DIFFERENTIATION, V53, P75, DOI 10.1111/j.1432-0436.1993.tb00648.x
   MOLL R, 1992, AM J PATHOL, V140, P427
   Mueller J, 2000, VIRCHOWS ARCH, V437, P618, DOI 10.1007/s004280000261
   Munck-Wikland E, 1998, INT J ONCOL, V12, P859
   Obokata A, 2007, ANTICANCER RES, V27, P95
   Okada A, 1997, GENE, V185, P187, DOI 10.1016/S0378-1119(96)00615-4
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Rio MC, 2005, BIOCHIMIE, V87, P299, DOI 10.1016/j.biochi.2004.11.016
   Schedin P, 2004, BREAST CANCER RES, V6, P93, DOI 10.1186/bcr772
   Selvey S, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-40
   Soeth E, 2005, J CANCER RES CLIN, V131, P669, DOI 10.1007/s00432-005-0008-1
   Soni S, 2003, INT J CANCER, V107, P309, DOI 10.1002/ijc.11366
   Stojic J, 2008, NEUROSCI RES, V60, P40, DOI 10.1016/j.neures.2007.09.009
   Studebaker AW, 2008, CANCER RES, V68, P9087, DOI 10.1158/0008-5472.CAN-08-0400
   Tlsty TD, 2001, SEMIN CANCER BIOL, V11, P97, DOI 10.1006/scbi.2000.0361
   Vazquez-Ortiz G, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-68
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   Yu JC, 2009, CARCINOGENESIS, V30, P1562, DOI 10.1093/carcin/bgp173
   Zangani D, 1999, DIFFERENTIATION, V64, P91, DOI 10.1046/j.1432-0436.1999.6420091.x
NR 43
TC 49
Z9 61
U1 0
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0009-8981
EI 1873-3492
J9 CLIN CHIM ACTA
JI Clin. Chim. Acta
PD FEB 2
PY 2010
VL 411
IS 3-4
BP 234
EP 241
DI 10.1016/j.cca.2009.11.009
PG 8
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA 550BS
UT WOS:000274102700019
PM 19914229
DA 2025-01-12
ER

PT J
AU Galizia, E
   Giorgetti, G
   Piccinini, G
   Santinelli, A
   Loretelli, C
   Bianchi, F
   Gagliardini, D
   Carbonari, G
   Pisa, E
   Belvederesi, L
   Bracci, R
   Ferretti, C
   Corradini, F
   Cellerino, R
AF Galizia, Eva
   Giorgetti, Gessica
   Piccinini, Gina
   Santinelli, Alfredo
   Loretelli, Cristian
   Bianchi, Francesca
   Gagliardini, Daniela
   Carbonari, Giovanna
   Pisa, Eleonora
   Belvederesi, Laura
   Bracci, Raffaella
   Ferretti, Concetta
   Corradini, Fabio
   Cellerino, Riccardo
TI <i>BRCA1</i> Expression in Triple Negative Sporadic Breast Cancers
SO ANALYTICAL AND QUANTITATIVE CYTOLOGY AND HISTOLOGY
LA English
DT Article
DE BRCA1; breast cancer; somatic inactivation
ID PROMOTER HYPERMETHYLATION; DNA METHYLATION; MECHANISMS; DISEASE; REGION
AB OBJECTIVE: To study how to identify patients with "triple negative" sporadic breast cancers (BCs) having BRCA1 silenced or down-regulated due to epigenetic BRCA1 inactivation.
   STUDY DESIGN: We selected, from our database, patients diagnosed with BC between 1995 and 2001 with tumors exhibiting the "triple negative" phenotype. "Triple positive" tumors were used as controls. BRCA1 protein expression was determined by immunohistochemistry. Methylation specific polymerase chain reaction (PCR) and bisulfite sequencing on genomic DNA were used to assess BRCA1 promoter methylation. BRCA1 m-RNA expression analysis was conducted by real-time PCR.
   RESULTS: Forty-four triple negative and 68 controls (triple positive) were eligible for our analysis. BRCA1 promoter methylation was present in 31.8% of triple negative and in 20.6% of triple positive cases. BRCA1 was inactivated (absent BRCA1 m-RNA expression and lack of BRCA1 protein) in 21.4% of tumors with BRCA1 promoter methylation, as compared with 6% of non-methylated ones (p=0.0453).
   CONCLUSION: BRCA1 inactivation due to promoter methylation could play an important role in some sporadic BC cases. Patients with this signature could represent the basis for prospective studies aiming to compare clinical response to different drugs. (Anal Quant Cytol Histol 2010;32:24-29)
C1 [Galizia, Eva; Giorgetti, Gessica; Piccinini, Gina; Loretelli, Cristian; Bianchi, Francesca; Gagliardini, Daniela; Belvederesi, Laura; Bracci, Raffaella; Ferretti, Concetta; Corradini, Fabio; Cellerino, Riccardo] Univ Politecn Marche, Osped Riuniti, Reg Ctr Genet Oncol, I-60020 Ancona, Italy.
   [Santinelli, Alfredo; Pisa, Eleonora] Univ Politecn Marche, Osped Riuniti, Dept Anat & Histol Pathol, I-60020 Ancona, Italy.
   [Bracci, Raffaella] Univ Politecn Marche, Osped Riuniti, Clin Med Oncol, I-60020 Ancona, Italy.
   [Carbonari, Giovanna] Osped Senigallia, Senigallia, Italy.
C3 Marche Polytechnic University; Marche Polytechnic University; Marche
   Polytechnic University
RP Cellerino, R (通讯作者)，Univ Politecn Marche, Osped Riuniti, Reg Ctr Genet Oncol, Via Tronto, I-60020 Ancona, Italy.
EM r.cellerino@univpm.it
RI Pisa, Eleonora/AAP-9814-2020; Bracci, Raffaella/AGY-2243-2022;
   Loretelli, Cristian/AAO-7678-2020
OI Corradini, Fabio/0009-0000-5805-7323; Loretelli,
   Cristian/0000-0002-7583-8540
FU Ministero della Salute, Rome, Italy
FX Supported by Ministero della Salute, Rome, Italy.
CR Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509
   Cleator S, 2007, LANCET ONCOL, V8, P235, DOI 10.1016/S1470-2045(07)70074-8
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Honrado E, 2005, MODERN PATHOL, V18, P1305, DOI 10.1038/modpathol.3800453
   Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602
   Kennedy RD, 2004, JNCI-J NATL CANCER I, V96, P1659, DOI 10.1093/jnci/djh312
   Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031
   Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8
   Miyamoto K, 2002, JPN J CLIN ONCOL, V32, P79, DOI 10.1093/jjco/hyf020
   Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431
   Niwa Y, 2000, JPN J CANCER RES, V91, P519, DOI 10.1111/j.1349-7006.2000.tb00976.x
   Sobin L.H., 2009, UICC: TNM classification of malignant tumors, V7th
   Tassone P, 2005, INT J ONCOL, V26, P1257
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457
   Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014
   Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029
   WILSON CA, 1996, NAT GENET, V12, P303
NR 21
TC 16
Z9 18
U1 0
U2 2
PU SCI PRINTERS & PUBL INC
PI ST LOUIS
PA PO DRAWER 12425 8342 OLIVE BLVD, ST LOUIS, MO 63132 USA
SN 0884-6812
J9 ANAL QUANT CYTOL
JI Anal. Quant. Cytol. Histol.
PD FEB
PY 2010
VL 32
IS 1
BP 24
EP 29
PG 6
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 740BJ
UT WOS:000288766300003
PM 20701084
DA 2025-01-12
ER

PT J
AU Murphy, SK
AF Murphy, Susan K.
TI Targeting Ovarian Cancer-Initiating Cells
SO ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
LA English
DT Article
DE Ovarian cancer; Cancer-initiating cells; Cancer stem cells; Spheroids;
   Epigenetics; Dormancy; Quiescence
ID ENGINEERED TRANSCRIPTION FACTORS; SURFACE EPITHELIAL-CELLS; EMBRYONIC
   STEM-CELLS; BREAST-CANCER; GENE-EXPRESSION; DNA METHYLATION; SUPPRESSOR
   GENE; FALLOPIAN-TUBES; SIDE POPULATION; PREMENOPAUSAL WOMEN
AB Evidence supports that a variety of cancers are sparked by the growth of cells that exhibit characteristics of stem cells. Such cancer-initiating cells are capable of populating a tumor with a heterogeneous group of daughter cells while still maintaining the ability to self-renew. Several groups have recently reported the identification of cancer-initiating cells in ovarian cancer, the most lethal gynecologic malignancy. Epithelial ovarian cancer comprises 90% of cancers of the ovary and consists of four major histologic types, each bearing some resemblance to different tissues in the peritoneal cavity. Although epithelial ovarian cancer has traditionally been thought to originate from the single layer of cells surrounding each ovary, new findings suggest that many of these cancers derive from Mullerian epithelium. This raises questions about the origin of ovarian cancer-initiating cells, and if there may be more than one source. Despite the initial effectiveness of primary therapy against advanced stage ovarian cancer, most of these cases recur, months to years following diagnosis. The cause of disease recurrence is unknown, but may involve cancer-initiating cells that survive chemotherapy and enter a period of dormancy while residing in as-yet undefined niches within the body before being triggered to initiate renewed growth. Herein the nature of these cells is explored as well as novel approaches for therapeutic targeting.
C1 [Murphy, Susan K.] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Durham, NC 27710 USA.
   [Murphy, Susan K.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.
C3 Duke University; Duke University
RP Murphy, SK (通讯作者)，Box 91012, Durham, NC 27708 USA.
EM murph035@mc.duke.edu
RI Murphy, Susan/R-3903-2019
OI Murphy, Susan/0000-0001-8298-7272
FU Ovarian Cancer Research Fund; Department of Defense Ovarian Cancer
   Research [W81XWH-05-1-0053]; Gail Parkins Memorial Ovarian Cancer
   Awareness Fund
FX Supported by a Liz Tilberis Scholar Award from the Ovarian Cancer
   Research Fund, grant W81XWH-05-1-0053 from the Department of Defense
   Ovarian Cancer Research Program and the Gail Parkins Memorial Ovarian
   Cancer Awareness Fund.
CR Alvero AB, 2009, CELL CYCLE, V8, P158, DOI 10.4161/cc.8.1.7533
   Atkinson SP, 2008, STEM CELLS, V26, P1174, DOI 10.1634/stemcells.2007-0497
   AUERSPERG N, 2004, OVARY, P579
   Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403
   Baba T, 2009, ONCOGENE, V28, P209, DOI 10.1038/onc.2008.374
   Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931
   Beier D, 2008, CANCER RES, V68, P5706, DOI 10.1158/0008-5472.CAN-07-6878
   BERCHUCK A, 1994, AM J OBSTET GYNECOL, V170, P246
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Berry NB, 2008, J OVARIAN RES, V1, DOI 10.1186/1757-2215-1-8
   Boren T, 2009, GYNECOL ONCOL, V113, P249, DOI 10.1016/j.ygyno.2009.01.014
   Carcangiu ML, 2004, INT J GYNECOL PATHOL, V23, P35, DOI 10.1097/01.pgp.0000101082.35393.84
   Cheng WJ, 2005, NAT MED, V11, P531, DOI 10.1038/nm1230
   Choi EJ, 2007, LIFE SCI, V80, P1403, DOI 10.1016/j.lfs.2006.12.031
   Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126
   CURLEY MD, 2009, STEM CELLS, V8, P8
   DELIGDISCH L, 1995, CANCER, V76, P1027, DOI 10.1002/1097-0142(19950915)76:6<1027::AID-CNCR2820760617>3.0.CO;2-6
   Deng S, 2008, CELL CYCLE, V7, P2643, DOI 10.4161/cc.7.17.6597
   Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471
   Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104
   Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700
   Du HL, 2004, ANN NY ACAD SCI, V1034, P152, DOI 10.1196/annals.1335.018
   Dubeau L, 1999, GYNECOL ONCOL, V72, P437, DOI 10.1006/gyno.1998.5275
   Dubeau L, 2008, LANCET ONCOL, V9, P1191, DOI 10.1016/S1470-2045(08)70308-5
   Fang MZ, 2005, CLIN CANCER RES, V11, P7033, DOI 10.1158/1078-0432.CCR-05-0406
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Ferrandina G, 2008, INT J GYNECOL CANCER, V18, P506, DOI 10.1111/j.1525-1438.2007.01056.x
   Fiegl H, 2008, INT J CANCER, V123, P725, DOI 10.1002/ijc.23563
   Folkins AK, 2008, GYNECOL ONCOL, V109, P168, DOI 10.1016/j.ygyno.2008.01.012
   Gao QL, 2009, ULTRASTRUCT PATHOL, V33, P175, DOI 10.1080/01913120903086072
   Gossner G, 2007, GYNECOL ONCOL, V105, P23, DOI 10.1016/j.ygyno.2006.11.009
   GREEN JM, 2009, CANCER BIOL THER, V8, P18
   Guerrero-Bosagna Carlos M., 2008, BMC Physiology, V8, P17, DOI 10.1186/1472-6793-8-17
   Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
   HAMBURGER AW, 1977, SCIENCE, V197, P461, DOI 10.1126/science.560061
   Hedley BD, 2009, ADV CANCER RES, V102, P67, DOI 10.1016/S0065-230X(09)02003-X
   Hibi K, 2009, ANTICANCER RES, V29, P2235
   Hsu EL, 2009, J ONCOL, V2009, DOI 10.1155/2009/491985
   Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936
   Ji Q, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006816
   Jin S, 2010, ANN ONCOL, V21, P263, DOI 10.1093/annonc/mdp499
   Jouvenot Y, 2003, GENE THER, V10, P513, DOI 10.1038/sj.gt.3301930
   King-Batoon A, 2008, ENVIRON MOL MUTAGEN, V49, P36, DOI 10.1002/em.20363
   KONDOH E, 2009, INT J CANC
   Kwek JW, 2006, AM J ROENTGENOL, V187, P99, DOI 10.2214/AJR.05.0004
   Lee Y, 2007, J PATHOL, V211, P26, DOI 10.1002/path.2091
   Levanon K, 2008, J CLIN ONCOL, V26, P5284, DOI 10.1200/JCO.2008.18.1107
   Levina V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003077
   Li CS, 2009, AAPS J, V11, P747, DOI 10.1208/s12248-009-9145-9
   Lou W, 1999, CANCER RES, V59, P2329
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   MAJID S, 2010, CANCER, V3, P116
   Majid S, 2009, CARCINOGENESIS, V30, P662, DOI 10.1093/carcin/bgp042
   Mandell JG, 2006, NUCLEIC ACIDS RES, V34, pW516, DOI 10.1093/nar/gkl209
   Marquez RT, 2005, CLIN CANCER RES, V11, P6116, DOI 10.1158/1078-0432.CCR-04-2509
   Mathews LA, 2009, DIFFERENTIATION, V78, P1, DOI 10.1016/j.diff.2009.04.002
   Mok SC, 2007, DIS MARKERS, V23, P367, DOI 10.1155/2007/474320
   Moserle L, 2008, CANCER RES, V68, P5658, DOI 10.1158/0008-5472.CAN-07-6341
   Murdoch WJ, 2005, BIOL REPROD, V73, P586, DOI 10.1095/biolreprod.105.042622
   Murdoch WJ, 2001, BIOL REPROD, V65, P1417, DOI 10.1095/biolreprod65.5.1417
   Murdoch WJ, 2004, EXP BIOL MED, V229, P546, DOI 10.1177/153537020422900613
   Naora H, 2005, CELL CYCLE, V4, P1033, DOI 10.4161/cc.4.8.1906
   Nezhat F, 2008, FERTIL STERIL, V90, P1559, DOI 10.1016/j.fertnstert.2008.08.007
   Novak P, 2006, CANCER RES, V66, P10664, DOI 10.1158/0008-5472.CAN-06-2761
   Ouyang GL, 2009, CELL BIOL INT, V33, P1237, DOI 10.1016/j.cellbi.2009.08.011
   OVARIAN C, 2008, LANCET, V371, P303
   Ozols RF, 2006, SEMIN ONCOL, V33, pS3, DOI 10.1053/j.seminoncol.2006.03.011
   Pantel K, 2009, NAT REV CLIN ONCOL, V6, P339, DOI 10.1038/nrclinonc.2009.44
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Piek JMJ, 2001, J PATHOL, V195, P451, DOI 10.1002/path.1000
   Pleshkan VV, 2008, BBA-GENE REGUL MECH, V1779, P599, DOI 10.1016/j.bbagrm.2008.06.002
   Qin WY, 2009, NUTR CANCER, V61, P238, DOI 10.1080/01635580802404196
   Rebar EJ, 2002, NAT MED, V8, P1427, DOI 10.1038/nm795
   Sato S, 1999, JPN J CANCER RES, V90, P485, DOI 10.1111/j.1349-7006.1999.tb00773.x
   Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439
   SCULLY RE, 1995, INT J GYNECOL OBSTET, V49, pS9, DOI 10.1016/0020-7292(95)02404-Z
   Scully RE, 1995, J CELL BIOCHEM, P208
   Segal DJ, 2002, METHODS, V26, P76, DOI 10.1016/S1046-2023(02)00009-9
   Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011
   Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14
   Smith A, 2006, NATURE, V441, P1060, DOI 10.1038/nature04954
   Smith LH, 2005, CANCER, V104, P1398, DOI 10.1002/cncr.21310
   Snowden AW, 2003, CANCER RES, V63, P8968
   Solomon LA, 2008, J OVARIAN RES, V1, DOI 10.1186/1757-2215-1-9
   Somjen D, 2008, J STEROID BIOCHEM, V110, P144, DOI 10.1016/j.jsbmb.2008.03.033
   Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103
   Tabu K, 2008, CELL RES, V18, P1037, DOI 10.1038/cr.2008.270
   Thasni KAA, 2008, EUR J PHARMACOL, V588, P158, DOI 10.1016/j.ejphar.2008.04.041
   THOR AD, 1991, HUM PATHOL, V22, P856, DOI 10.1016/0046-8177(91)90174-N
   Trumpp A, 2008, NAT CLIN PRACT ONCOL, V5, P337, DOI 10.1038/ncponc1110
   Verschure PJ, 2006, ADV GENET, V56, P163, DOI 10.1016/S0065-2660(06)56005-5
   Vessella Robert L, 2007, Cancer Biol Ther, V6, P1496
   Visser AE, 2006, ADV GENET, V56, P131, DOI 10.1016/S0065-2660(06)56004-3
   VLAHOS NF, 2009, GYNECOL ENDOCRINOL, V28, P1
   Widschwendter M, 2009, INT J CANCER, V125, P2214, DOI 10.1002/ijc.24599
   Winquist RJ, 2009, BIOCHEM PHARMACOL, V78, P326, DOI 10.1016/j.bcp.2009.03.020
   Wu Q, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-45
   Wyman SK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005311
   Yan P, 2003, GENE CHROMOSOME CANC, V36, P129, DOI 10.1002/gcc.10150
   Yi JM, 2008, CANCER RES, V68, P8094, DOI 10.1158/0008-5472.CAN-07-6208
   Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200
   Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364
   Zhou JB, 2008, BREAST CANCER RES TR, V111, P419, DOI 10.1007/s10549-007-9798-y
   Zhou JB, 2009, BREAST CANCER RES TR, V115, P269, DOI 10.1007/s10549-008-0072-8
NR 104
TC 26
Z9 26
U1 3
U2 33
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1871-5206
EI 1875-5992
J9 ANTI-CANCER AGENT ME
JI Anti-Cancer Agents Med. Chem.
PD FEB
PY 2010
VL 10
IS 2
BP 157
EP 163
DI 10.2174/187152010790909272
PG 7
WC Oncology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 568HD
UT WOS:000275512200009
PM 20184540
DA 2025-01-12
ER

PT J
AU Fu, DY
   Wang, ZM
   Chen, L
   Wang, BL
   Shen, ZZ
   Huang, W
   Shao, ZM
AF Fu, De-Yuan
   Wang, Zhi-Min
   Chen, Li
   Wang, Bei-Lan
   Shen, Zhen-Zhou
   Huang, Wei
   Shao, Zhi-Ming
TI Sox17, the canonical Wnt antagonist, is epigenetically inactivated by
   promoter methylation in human breast cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer; Sox17; DNA methylation; Wnt signaling
ID BETA-CATENIN; SIGNALING PATHWAY; DNA METHYLATION; STEM-CELLS;
   UNFAVORABLE PROGNOSIS; TRANSCRIPTION FACTOR; EXPRESSION; GENES;
   DIFFERENTIATION; ENDODERM
AB SRY-box 17 (Sox17) is a transcription factor which involved in a variety of developmental processes and can act as an antagonist of canonical Wnt/beta-catenin signaling pathway. However, the relationship between Sox17 gene expression, methylation status, and beta-catenin in breast cancer has not been established. Here we report that the expression level of Sox17 mRNA was dramatically decreased in five different breast cancer cell lines and 23 of 31 primary breast tumor samples, which significantly correlated with its methylation status. After treated with 5-aza-2'-deoxycytidine (5-aza-dC, a demethylation agent), the expression levels of Sox17 mRNA and protein were obviously increased. Restored expression of Sox17 by 5-aza-dC treatment decreased the expression level of beta-catenin in breast cancer cell lines. Furthermore, small interfering RNA (siRNA)-mediated knockdown of Sox17 in SKBR-3 and Bacp-37 cells enhanced beta-catenin expression. In 31 paired tissue samples, a significant difference between the expression level of Sox17 and beta-catenin was also observed (P < 0.001). Clinically, Sox17 methylation was detected in 74.3% breast tumors (84/113) and 31.9% (36/113) paired normal tissues, respectively (P < 0.0001). Sox17 methylation was also associated with tumor stage (P = 0.028) and lymph node metastasis (P = 0.013). These findings indicate that silencing of Sox17 due to promoter hypermethylation is a frequent event and may contribute to aberrant activation of Wnt signaling in breast cancer. Sox17 may be a valuable biomarker for the study of breast cancer carcinogenesis and progression.
C1 [Wang, Zhi-Min; Wang, Bei-Lan; Huang, Wei] Chinese Natl Human Genome Ctr Shanghai, Shanghai 201203, Peoples R China.
   [Fu, De-Yuan; Chen, Li; Shen, Zhen-Zhou; Shao, Zhi-Ming] Fudan Univ, Dept Breast Surg, Breast Canc Inst, Canc Hosp,Canc Inst, Shanghai 200032, Peoples R China.
C3 Fudan University
RP Huang, W (通讯作者)，Chinese Natl Human Genome Ctr Shanghai, 250 Bi Bo Rd, Shanghai 201203, Peoples R China.
EM huangwei@chgc.sh.cn; zhimingshao@yahoo.com
RI Huang, Wei/L-7090-2019
FU National Basic Research Program of China [2006CB910501, 2004CB518605];
   National Natural Science Foundation of China [30371580, 30572109];
   Chinese National Natural Science Fund for Distinguished Young Scholars
   [30625019]; Shanghai Science and Technology Committee [03J14019,
   06DJ14004, 06DZ19504]
FX The authors thank the studied patients for their willingness to
   cooperate with our study. This research was supported in part by the
   grants from the National Basic Research Program of China (2006CB910501,
   2004CB518605), National Natural Science Foundation of China (30371580,
   30572109); Chinese National Natural Science Fund for Distinguished Young
   Scholars (30625019); Shanghai Science and Technology Committee
   (03J14019, 06DJ14004, 06DZ19504).
CR Agrawal A, 2007, MODERN PATHOL, V20, P711, DOI 10.1038/modpathol.3800822
   Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379
   Akiyama H, 2004, GENE DEV, V18, P1072, DOI 10.1101/gad.1171104
   Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027
   Candidus S, 1996, CANCER RES, V56, P49
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   de Jong J, 2008, J PATHOL, V215, P21, DOI 10.1002/path.2332
   Dolled-Filhart M, 2006, CANCER RES, V66, P5487, DOI 10.1158/0008-5472.CAN-06-0100
   Dong C, 2004, CYTOGENET GENOME RES, V105, P442, DOI 10.1159/000078217
   Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561
   Jang YY, 2007, CELL, V130, P403, DOI 10.1016/j.cell.2007.07.027
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1
   Kanai-Azuma M, 2002, DEVELOPMENT, V129, P2367
   Karim RZ, 2004, PATHOLOGY, V36, P120, DOI 10.1080/00313020410001671957
   Katoh M, 2002, INT J MOL MED, V9, P153
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Kiefer JC, 2007, DEV DYNAM, V236, P2356, DOI 10.1002/dvdy.21218
   Kim I, 2007, CELL, V130, P470, DOI 10.1016/j.cell.2007.06.011
   Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055
   Lefebvre V, 2007, INT J BIOCHEM CELL B, V39, P2195, DOI 10.1016/j.biocel.2007.05.019
   Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100
   Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397
   Liu Y, 2007, P NATL ACAD SCI USA, V104, P3859, DOI 10.1073/pnas.0609100104
   Lo PK, 2006, CANCER BIOL THER, V5, P281, DOI 10.4161/cbt.5.3.2384
   Matsui T, 2006, J CELL SCI, V119, P3513, DOI 10.1242/jcs.03081
   Morin Patrice J, 2003, Cancer Treat Res, V115, P169
   Park KS, 2006, DEV BIOL, V294, P192, DOI 10.1016/j.ydbio.2006.02.038
   Shimoda M, 2007, J CELL SCI, V120, P3859, DOI 10.1242/jcs.007856
   Sinner D, 2004, DEVELOPMENT, V131, P3069, DOI 10.1242/dev.01176
   Sinner D, 2007, MOL CELL BIOL, V27, P7802, DOI 10.1128/MCB.02179-06
   Sohn J, 2006, J NEUROSCI, V26, P9722, DOI 10.1523/JNEUROSCI.1716-06.2006
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Takash W, 2001, NUCLEIC ACIDS RES, V29, P4274, DOI 10.1093/nar/29.21.4274
   Turashvili G, 2006, PATHOBIOLOGY, V73, P213, DOI 10.1159/000098207
   Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Veeck J, 2008, CARCINOGENESIS, V29, P991, DOI 10.1093/carcin/bgn076
   Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409
   Zhang W, 2008, CANCER RES, V68, P2764, DOI 10.1158/0008-5472.CAN-07-6349
   Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2
NR 45
TC 73
Z9 89
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD FEB
PY 2010
VL 119
IS 3
BP 601
EP 612
DI 10.1007/s10549-009-0339-8
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 544AZ
UT WOS:000273624900009
PM 19301122
DA 2025-01-12
ER

PT J
AU Papageorgis, P
   Lambert, AW
   Ozturk, S
   Gao, FM
   Pan, HJ
   Manne, U
   Alekseyev, YO
   Thiagalingam, A
   Abdolmaleky, HM
   Lenburg, M
   Thiagalingam, S
AF Papageorgis, Panagiotis
   Lambert, Arthur W.
   Ozturk, Sait
   Gao, Fangming
   Pan, Hongjie
   Manne, Upender
   Alekseyev, Yuriy O.
   Thiagalingam, Arunthathi
   Abdolmaleky, Hamid M.
   Lenburg, Marc
   Thiagalingam, Sam
TI Smad Signaling Is Required to Maintain Epigenetic Silencing during
   Breast Cancer Progression
SO CANCER RESEARCH
LA English
DT Article
ID GROWTH-FACTOR-BETA; EPITHELIAL-MESENCHYMAL TRANSITION; CELL-LINES;
   TUMOR-SUPPRESSOR; DNA METHYLATION; ENHANCES TUMORIGENESIS; CPG
   METHYLATION; BONE METASTASIS; RECEPTOR; PATHWAY
AB Breast cancer progression is associated with aberrant DNA methylation and expression of genes that control the epithelial-mesenchymal transition (EMT), a critical step in malignant conversion. Although the genes affected have been studied, there is little understanding of how aberrant activation of the DNA methylation machinery itself occurs. Using a breast cancer cell-based model system, we found that cells that underwent EMT exhibited overactive transforming growth factor beta (TGF beta) signaling and loss of expression of the CDH1, CGN, CLDN4, and KLK10 genes as a result of hypermethylation of their corresponding promoter regions. Based on these observations, we hypothesized that activated TGF beta-Smad signaling provides an "epigenetic memory" to maintain silencing of critical genes. In support of this hypothesis, disrupting Smad signaling in mesenchymal breast cancer cells resulted in DNA demethylation and reexpression of the genes identified. This epigenetic reversal was accompanied by an acquisition of epithelial morphology and a suppression of invasive properties. Notably, disrupting TGF beta signaling decreased the DNA binding activity of DNA methyltransferase DNMT1, suggesting that failure to maintain methylation of newly synthesized DNA was the likely cause of DNA demethylation. Together, our findings reveal a hyperactive TGF beta-TGF beta R-Smad2 signaling axis needed to maintain epigenetic silencing of critical EMT genes and breast cancer progression. Cancer Res; 70(3); 968-78. (C)2010 AACR.
C1 [Papageorgis, Panagiotis; Lambert, Arthur W.; Ozturk, Sait; Gao, Fangming; Pan, Hongjie; Thiagalingam, Arunthathi; Abdolmaleky, Hamid M.; Lenburg, Marc; Thiagalingam, Sam] Boston Univ, Sch Med, Dept Med, Genet & Mol Med Programs, Boston, MA 02118 USA.
   [Papageorgis, Panagiotis; Lambert, Arthur W.; Ozturk, Sait; Gao, Fangming; Pan, Hongjie; Thiagalingam, Arunthathi; Abdolmaleky, Hamid M.; Lenburg, Marc; Thiagalingam, Sam] Boston Univ, Sch Med, Canc Res Ctr, Boston, MA 02118 USA.
   [Papageorgis, Panagiotis; Gao, Fangming; Pan, Hongjie; Alekseyev, Yuriy O.; Abdolmaleky, Hamid M.; Lenburg, Marc; Thiagalingam, Sam] Boston Univ, Sch Med, Dept Genet & Genom, Boston, MA 02118 USA.
   [Gao, Fangming; Alekseyev, Yuriy O.; Lenburg, Marc; Thiagalingam, Sam] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA.
   [Manne, Upender] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA.
C3 Boston University; Boston University; Boston University; Boston
   University; University of Alabama System; University of Alabama
   Birmingham
RP Thiagalingam, S (通讯作者)，Boston Univ, Sch Med, Dept Med, Genet & Mol Med Programs, 72 E Concord St, Boston, MA 02118 USA.
EM samthia@bu.edu
RI Papageorgis, Panagiotis/J-5711-2019; Lenburg, Marc/B-8027-2008
OI Thiagalingam, Sam/0000-0001-5211-266X; Papageorgis,
   Panagiotis/0000-0002-7595-5616; Alekseyev, Yuriy/0000-0001-6105-8861;
   Mostafavi Abdolmaleky, Hamid/0000-0002-8872-5174; Lenburg,
   Marc/0000-0002-5760-4708
FU Cure Investigator-Initiated Research Award [KG081435]; NIH [CA101773]
FX Susan G. Komen for the Cure Investigator-Initiated Research Award
   KG081435 and NIH grant CA101773 (S. Thiagalingam).
CR Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678
   Agrawal A, 2007, MODERN PATHOL, V20, P711, DOI 10.1038/modpathol.3800822
   Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229
   [Anonymous], [No title captured]
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6
   Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560
   Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105
   Gao FM, 2009, CANCER BIOL THER, V8, P627, DOI 10.4161/cbt.8.7.7928
   Gazin C, 2007, NATURE, V449, P1073, DOI 10.1038/nature06251
   Gehring M, 2009, TRENDS GENET, V25, P82, DOI 10.1016/j.tig.2008.12.001
   Goyal J, 1998, CANCER RES, V58, P4782
   Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001
   Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Itoh S, 2003, J BIOL CHEM, V278, P3751, DOI 10.1074/jbc.M208258200
   Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343
   Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102
   Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996
   Massagué J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807
   Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462
   Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7
   Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938
   Ooi SKT, 2008, CELL, V133, P1145, DOI 10.1016/j.cell.2008.06.009
   Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068
   Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273
   Sarrió D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017
   Strickland LB, 2000, BREAST CANCER RES TR, V64, P235, DOI 10.1023/A:1026562720218
   Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Tian F, 2004, CANCER RES, V64, P4523, DOI 10.1158/0008-5472.CAN-04-0030
   Tian F, 2003, CANCER RES, V63, P8284
   Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598
   Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009
   YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416
   Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366
   Zhou SB, 1998, P NATL ACAD SCI USA, V95, P2412, DOI 10.1073/pnas.95.5.2412
NR 40
TC 147
Z9 172
U1 1
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD FEB 1
PY 2010
VL 70
IS 3
BP 968
EP 978
DI 10.1158/0008-5472.CAN-09-1872
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 607FX
UT WOS:000278485600014
PM 20086175
OA Green Submitted, Green Accepted
DA 2025-01-12
ER

PT J
AU Yamaguchi, J
   Sasaki, M
   Sato, Y
   Itatsu, K
   Harada, K
   Zen, Y
   Ikeda, H
   Nimura, Y
   Nagino, M
   Nakanuma, Y
AF Yamaguchi, Junpei
   Sasaki, Motoko
   Sato, Yasunori
   Itatsu, Keita
   Harada, Kenichi
   Zen, Yoh
   Ikeda, Hiroko
   Nimura, Yuji
   Nagino, Masato
   Nakanuma, Yasuni
TI Histone deacetylase inhibitor (SAHA) and repression of EZH2
   synergistically inhibit proliferation of gallbladder carcinoma
SO CANCER SCIENCE
LA English
DT Article
ID GROUP PROTEIN EZH2; AGGRESSIVE BREAST-CANCER; ZESTE HOMOLOG-2 EZH2;
   CELL-PROLIFERATION; PROSTATE-CANCER; EXPRESSION; ENHANCER; THERAPY;
   METHYLATION; EPIGENETICS
AB Polycomb group protein EZH2, frequently overexpressed in malignant tumors, is the catalytic subunit of polycomb repressive complex 2 (PRC2). PRC2 interacts with HDACs in transcriptional silencing and relates to tumor suppressor loss. We examined the expression of HDAC isoforms (HDAC 1 and 2) and EZH2, and evaluated the possible use of HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) and EZH2 repressor for gallbladder carcinoma. We used 48 surgically resected gallbladders and cultures of human gallbladder epithelial cells (HGECs), gallbladder carcinoma (TGBC2TKB), and cholangiocarcinoma (HuCCT-1 and TFK-1) cell lines for examination. Immunohistochemically, EZH2 was overexpressed in gallbladder carcinoma, especially poorly differentiated carcinoma, but not in normal epithelium. In contrast, HDAC1/2 were expressed in both carcinoma and normal epithelium in vivo. This pattern was verified in cultured cells; EZH2 was highly expressed only in TGBC2TKB, whereas HDAC1/2 were expressed in HGECs and TGBC2TKB. Interestingly, SAHA treatment caused significant cell number decline in three carcinoma cells, and this effect was synergized with EZH2 siRNA treatment; however, HGECs were resistant to SAHA. In TGBC2TKB cells, the expression of EZH2 and HDAC1/2 were decreased by SAHA treatment, and p16INK4a, E-cadherin, and p21were simultaneously activated; however, no such findings were obtained in HGECs, suggesting that the effect of SAHA depends on the EZH2-mediated tumor suppressor loss. In conclusion, this study suggests a possible mechanism by which carcinoma cells but not normal cells are sensitive to SAHA and indicates the efficacy of this new anticancer agent in combination with EZH2 repression in gallbladder carcinoma. (Cancer Sci 2010; 101: 355-362)
C1 [Yamaguchi, Junpei; Sasaki, Motoko; Sato, Yasunori; Harada, Kenichi; Ikeda, Hiroko; Nakanuma, Yasuni] Kanazawa Univ, Grad Sch Med, Dept Human Pathol, Kanazawa, Ishikawa, Japan.
   [Itatsu, Keita; Nagino, Masato] Nagoya Univ, Grad Sch Med, Dept Surg Oncol, Nagoya, Aichi 4648601, Japan.
   [Zen, Yoh] Kanazawa Univ Hosp, Dept Diagnost Pathol, Kanazawa, Ishikawa, Japan.
   [Nimura, Yuji] Aichi Canc Ctr Hosp, Dept Surg Gastroenterol, Aichi, Japan.
C3 Kanazawa University; Nagoya University; Kanazawa University; Aichi
   Cancer Center
RP Nakanuma, Y (通讯作者)，Kanazawa Univ, Grad Sch Med, Dept Human Pathol, Kanazawa, Ishikawa, Japan.
EM pbcpsc@kenroku.kanazawa-u.ac.jp
RI YAMAGUCHI, Junpei/E-4440-2015; Nagino, Masato/I-7342-2014; Sasaki,
   Motoko/K-5913-2015
CR ALBORESSAAVEDRA J, 2000, WHO CLASSIFICATION T
   Bhalla KN, 2005, J CLIN ONCOL, V23, P3971, DOI 10.1200/JCO.2005.16.600
   Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Burgess A, 2004, ONCOGENE, V23, P6693, DOI 10.1038/sj.onc.1207893
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Croonquist PA, 2005, ONCOGENE, V24, P6269, DOI 10.1038/sj.onc.1208771
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Fiskus W, 2006, MOL CANCER THER, V5, P3096, DOI 10.1158/1535-7163.MCT-06-0418
   Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200
   Garcia P, 2009, MOL CARCINOGEN, V48, P79, DOI 10.1002/mc.20457
   Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100
   Harada K, 2004, HEPATOLOGY, V40, P925, DOI 10.1002/hep.20379
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kotake Y, 2007, GENE DEV, V21, P49, DOI 10.1101/gad.1499407
   Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902
   Lehrmann H, 2002, ADV CANCER RES, V86, P41, DOI 10.1016/S0065-230X(02)86002-X
   Lin ZH, 2009, CLIN CANCER RES, V15, P570, DOI 10.1158/1078-0432.CCR-08-1813
   Mai A, 2005, MED RES REV, V25, P261, DOI 10.1002/med.20024
   Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272
   Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506
   Rhodes DR, 2003, J NATL CANCER I, V95, P661, DOI 10.1093/jnci/95.9.661
   Sasaki M, 2008, J PATHOL, V215, P175, DOI 10.1002/path.2345
   Sasaki M, 1999, PATHOL INT, V49, P38, DOI 10.1046/j.1440-1827.1999.00822.x
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Takahashi T, 2004, CLIN CANCER RES, V10, P6126, DOI 10.1158/1078-0432.CCR-04-0579
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Ungerstedt JS, 2005, P NATL ACAD SCI USA, V102, P673, DOI 10.1073/pnas.0408732102
   Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005
   van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Weichert W, 2008, NEOPLASIA, V10, P1021, DOI 10.1593/neo.08474
   Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990
   Xu LN, 2008, WORLD J GASTROENTERO, V14, P2578, DOI 10.3748/wjg.14.2578
   Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620
   Yamaguchi J, 2009, LAB INVEST, V89, P1018, DOI 10.1038/labinvest.2009.65
   Yamato T, 1999, J PATHOL, V188, P30, DOI 10.1002/(SICI)1096-9896(199905)188:1<30::AID-PATH291>3.0.CO;2-Q
NR 38
TC 49
Z9 65
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1349-7006
J9 CANCER SCI
JI Cancer Sci.
PD FEB
PY 2010
VL 101
IS 2
BP 355
EP 362
DI 10.1111/j.1349-7006.2009.01387.x
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 550UR
UT WOS:000274156400010
PM 19860841
OA Green Published
DA 2025-01-12
ER

PT J
AU Lv, J
   Su, JZ
   Wang, F
   Qi, YF
   Liu, HB
   Zhang, Y
AF Lv, Jie
   Su, Jianzhong
   Wang, Fang
   Qi, Yunfeng
   Liu, Hongbo
   Zhang, Yan
TI Detecting novel hypermethylated genes in Breast cancer benefiting from
   feature selection
SO COMPUTERS IN BIOLOGY AND MEDICINE
LA English
DT Article
DE Hypermethylation; Breast cancer; Genomic features; Feature selection;
   Weka
ID CPG-ISLAND METHYLATION; DNA METHYLATION; CLASSIFICATION; EPIGENETICS;
   PROMOTERS; PATTERNS; DATABASE; DISEASE
AB The aberrant hypermethylation of CpG islands in promoter regions of genes plays an important role in the onset and progression of Breast cancer. Meanwhile, it is highly associated with human genomic features. Two feature selection algorithms: t-test and CfsSubsetEval were used to obtain efficient feature subsets. We discovered 14 significant feature subsets by CfsSubsetEval, which can distinguish hypermethylated genes from control genes. As a result, 393 unconfirmed hypermethylated genes in Breast cancer were prioritized. These genes were assigned the hypermethylated scores and were supported by literature and Gene Ontology enrichment. This paper suggests that the feature subsets could be served as discriminating genomic markers to infer novel hypermethylated genes in cancer potentially. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Lv, Jie; Su, Jianzhong; Wang, Fang; Qi, Yunfeng; Liu, Hongbo; Zhang, Yan] Harbin Med Coll, Coll Bioinformat Sci & Technol, Harbin 150081, Peoples R China.
C3 Harbin Medical University
RP Zhang, Y (通讯作者)，Harbin Med Coll, Coll Bioinformat Sci & Technol, Harbin 150081, Peoples R China.
EM yanyou1225@yahoo.com.cn
RI Lyu, Jie/AAP-4077-2020; Liu, Hongbo/M-2162-2015
OI Liu, Hongbo/0000-0002-0733-8616; Lyu, Jie/0000-0002-6530-5257
FU Natural Science Foundation of Heilongjiang Province [D2007-35];
   Heilongjiang Province Department of Education Outstanding Overseas
   Scientist [1152hq28]; Innovation and Technology special Fund for
   researchers of Harbin [RC2007LX003004]
FX We thank anonymous reviewers who provided comments and suggestions that
   help significantly improve the quality of the paper. This work was
   supported in part by the Natural Science Foundation of Heilongjiang
   Province (Grant no. D2007-35), the Heilongjiang Province Department of
   Education Outstanding Overseas Scientist grant (Grant no. 1152hq28), and
   the Innovation and Technology special Fund for researchers of Harbin
   (Grant no. RC2007LX003004).
CR Antequera F, 2003, CELL MOL LIFE SCI, V60, P1647, DOI 10.1007/s00018-003-3088-6
   Bird AP, 1996, CANCER SURV, V28, P87
   Bock C, 2008, BIOINFORMATICS, V24, P1, DOI 10.1093/bioinformatics/btm546
   Bock C, 2006, PLOS GENET, V2, P243, DOI 10.1371/journal.pgen.0020026
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Das R, 2006, P NATL ACAD SCI USA, V103, P10713, DOI 10.1073/pnas.0602949103
   Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832
   Fang YC, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-22
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Frank E, 2004, BIOINFORMATICS, V20, P2479, DOI 10.1093/bioinformatics/bth261
   Gal-Yam EN, 2008, ANNU REV MED, V59, P267, DOI 10.1146/annurev.med.59.061606.095816
   Gambin A, 2009, COMPUT BIOL MED, V39, P460, DOI 10.1016/j.compbiomed.2009.03.006
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Giardine B, 2005, GENOME RES, V15, P1451, DOI 10.1101/gr.4086505
   Goh L, 2007, BIOINFORMATICS, V23, P281, DOI 10.1093/bioinformatics/btl620
   Hall M.A., 2000, COMPUTER SCI WORKING
   Heris HK, 2009, COMPUT BIOL MED, V39, P860, DOI 10.1016/j.compbiomed.2009.06.014
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Huang DS, 2006, BIOINFORMATICS, V22, P1855, DOI 10.1093/bioinformatics/btl190
   Illingworth RS, 2009, FEBS LETT, V583, P1713, DOI 10.1016/j.febslet.2009.04.012
   Jiang WG, 2005, EUR J CANCER, V41, P1628, DOI 10.1016/j.ejca.2005.03.023
   Karolchik D, 2008, NUCLEIC ACIDS RES, V36, pD773, DOI 10.1093/nar/gkm966
   Khandoker AH, 2009, COMPUT BIOL MED, V39, P88, DOI 10.1016/j.compbiomed.2008.11.003
   Liu YH, 2009, COMPUT BIOL MED, V39, P818, DOI 10.1016/j.compbiomed.2009.06.012
   Marinakis Y, 2009, COMPUT BIOL MED, V39, P69, DOI 10.1016/j.compbiomed.2008.11.006
   Morales DA, 2008, COMPUT BIOL MED, V38, P1177, DOI 10.1016/j.compbiomed.2008.09.002
   Oehme I, 2009, CLIN CANCER RES, V15, P91, DOI 10.1158/1078-0432.CCR-08-0684
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Rollins RA, 2006, GENOME RES, V16, P157, DOI 10.1101/gr.4262006
   Saxonov S, 2006, P NATL ACAD SCI USA, V103, P1412, DOI 10.1073/pnas.0510310103
   Sherman BT, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-426
   Wee S, 2008, P NATL ACAD SCI USA, V105, P13057, DOI 10.1073/pnas.0802655105
   Zhou N, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-484
NR 33
TC 7
Z9 8
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0010-4825
EI 1879-0534
J9 COMPUT BIOL MED
JI Comput. Biol. Med.
PD FEB
PY 2010
VL 40
IS 2
BP 159
EP 167
DI 10.1016/j.compbiomed.2009.11.012
PG 9
WC Biology; Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Computer Science;
   Engineering; Mathematical & Computational Biology
GA 568KW
UT WOS:000275522200005
PM 20044084
DA 2025-01-12
ER

PT J
AU Westberry, JM
   Trout, AL
   Wilson, ME
AF Westberry, Jenne M.
   Trout, Amanda L.
   Wilson, Melinda E.
TI Epigenetic Regulation of Estrogen Receptor α Gene Expression in the
   Mouse Cortex during Early Postnatal Development
SO ENDOCRINOLOGY
LA English
DT Article
ID DNA METHYLTRANSFERASES DNMT3A; HUMAN BREAST-CANCER;
   SEXUAL-DIFFERENTIATION; CEREBRAL-CORTEX; NERVOUS-SYSTEM; RAT-BRAIN;
   MESSENGER-RNA; PREOPTIC AREA; CELL-DEATH; METHYLATION
AB Estrogens play a critical role in brain development by acting on areas that express estrogen receptors. In the rodent cortex, estrogen receptor alpha (ER alpha) mRNA expression is high early in postnatal development but declines starting at postnatal day (PND) 10 and is virtually absent in the adult cortex. The mechanisms controlling this regulation are largely unknown. Methylation is important for gene silencing during development in many tissues, including the brain. In the present study, we examined the methylation status of ER alpha 5' untranslated exons during early postnatal development in male and female mice using methylation-specific PCR and pyrosequencing. Several regions of ER alpha promoter displayed a significant increase in methylation at PND 18 and 25 compared with PND 4. DNA methyltransferases (DNMT) are important for the initiation and maintenance of methylation. Real-time PCR showed that DNMT3A, the de novo DNMT peaked at PND 10 and was decreased by PND 25. DNMT1, which is important for maintenance of methylation, increased across development and stayed high in adult cortex. The methyl-CpG-binding protein 2 (MeCP2) is also important for stabilization of methylation. A chromatin immunoprecipitation assay showed a correlation between association of MeCP2 with ER alpha promoter and the increase in methylation and decrease in ER alpha expression after PND 10. In mice containing a mutant MeCP2 protein, ER alpha mRNA expression and promoter methylation patterns across development were different compared with wild-type mice. These data suggest that methylation of ER alpha promoters regulates ER alpha mRNA expression in the cortex during postnatal development in a MeCP2-dependent fashion. (Endocrinology 151: 731-740, 2010)
C1 [Westberry, Jenne M.; Trout, Amanda L.; Wilson, Melinda E.] Univ Kentucky, Coll Med, Dept Physiol, Lexington, KY 40536 USA.
C3 University of Kentucky
RP Wilson, ME (通讯作者)，Univ Kentucky, Coll Med, Dept Physiol, MS 508,800 Rose St, Lexington, KY 40536 USA.
EM melinda.wilson@uky.edu
FU National Institutes of Health National Center for Research Resources
   [P20 RR 15592]; National Science Foundation [IOS-0919944]
FX This work was supported by National Institutes of Health National Center
   for Research Resources Grant P20 RR 15592 and National Science
   Foundation IOS-0919944.
CR Alvarez S, 2005, CLIN CANCER RES, V11, P1146
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   Boulware MI, 2005, DRUG NEWS PERSPECT, V18, P631, DOI 10.1358/dnp.2005.18.10.959577
   Champagne FA, 2006, ENDOCRINOLOGY, V147, P2909, DOI 10.1210/en.2005-1119
   Chung WCJ, 2000, J NEUROBIOL, V43, P234, DOI 10.1002/(SICI)1097-4695(20000605)43:3<234::AID-NEU2>3.0.CO;2-3
   De Vries GJ, 2002, J NEUROSCI, V22, P9005
   Dubal DB, 1999, J NEUROSCI, V19, P6385
   Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012
   Dubal DB, 2006, ENDOCRINOLOGY, V147, P3076, DOI 10.1210/en.2005-1177
   Dunn BK, 2003, ANN NY ACAD SCI, V983, P28, DOI 10.1111/j.1749-6632.2003.tb05960.x
   Feng J, 2005, J NEUROSCI RES, V79, P734, DOI 10.1002/jnr.20404
   Forger NG, 2006, NEUROSCIENCE, V138, P929, DOI 10.1016/j.neuroscience.2005.07.006
   Hayashi SI, 2003, ENDOCR-RELAT CANCER, V10, P193, DOI 10.1677/erc.0.0100193
   Hill RA, 2009, SEMIN REPROD MED, V27, P218, DOI 10.1055/s-0029-1216275
   Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3
   JURASKA JM, 1991, PSYCHONEUROENDOCRINO, V16, P105, DOI 10.1016/0306-4530(91)90073-3
   Kanai Y, 2001, INT J CANCER, V91, P205, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1040>3.0.CO;2-2
   Kurian JR, 2007, EPIGENETICS, V2, P173, DOI 10.4161/epi.2.3.4841
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Li L, 2009, PAIN, V143, P37, DOI 10.1016/j.pain.2009.01.005
   MIRANDA RC, 1992, CEREB CORTEX, V2, P1, DOI 10.1093/cercor/2.1.1
   Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172
   Mong JA, 2001, J COMP NEUROL, V432, P259, DOI 10.1002/cne.1101
   Müller HM, 2003, BRIT J CANCER, V89, P1934, DOI 10.1038/sj.bjc.6601392
   Nan XH, 2001, BRAIN DEV-JPN, V23, pS32, DOI 10.1016/S0387-7604(01)00333-3
   Nishino K, 2004, J BIOL CHEM, V279, P22306, DOI 10.1074/jbc.M309513200
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Park IY, 2005, J CELL BIOCHEM, V94, P585, DOI 10.1002/jcb.20263
   Prewitt AK, 2007, BRAIN RES, V1134, P62, DOI 10.1016/j.brainres.2006.11.069
   REID SNM, 1992, J COMP NEUROL, V321, P442, DOI 10.1002/cne.903210310
   Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068
   Rusa R, 1999, STROKE, V30, P1665, DOI 10.1161/01.STR.30.8.1665
   Sanoja R, 2010, AUTON NEUROSCI-BASIC, V153, P84, DOI 10.1016/j.autneu.2009.07.001
   Sarkar SN, 2008, P NATL ACAD SCI USA, V105, P15148, DOI 10.1073/pnas.0802379105
   Semeralul MO, 2006, J NEUROBIOL, V66, P1646, DOI 10.1002/neu.20302
   Shahbazian MD, 2002, NEURON, V35, P243, DOI 10.1016/S0896-6273(02)00768-7
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   SHUGHRUE PJ, 1990, ENDOCRINOLOGY, V126, P1112, DOI 10.1210/endo-126-2-1112
   Simerly RB, 2002, ANNU REV NEUROSCI, V25, P507, DOI 10.1146/annurev.neuro.25.112701.142745
   Söderström I, 2009, EUR J NEUROSCI, V29, P1215, DOI 10.1111/j.1460-9568.2009.06662.x
   STUMPF WE, 1976, J STEROID BIOCHEM, V7, P1163, DOI 10.1016/0022-4731(76)90050-9
   Ting AH, 2004, CELL CYCLE, V3, P1024
   TORANALLERAND CD, 1976, BRAIN RES, V106, P407
   TORANALLERAND CD, 1976, BRAIN RES, V118, P293, DOI 10.1016/0006-8993(76)90713-7
   TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315
   Welboren WJ, 2009, ENDOCR-RELAT CANCER, V16, P1073, DOI 10.1677/ERC-09-0086
   Westberry JM, 2008, NEUROSCIENCE, V152, P982, DOI 10.1016/j.neuroscience.2008.01.048
   Xie SP, 1999, GENE, V236, P87, DOI 10.1016/S0378-1119(99)00252-8
   Yokochi T, 2002, J BIOL CHEM, V277, P11735, DOI 10.1074/jbc.M106590200
NR 50
TC 97
Z9 106
U1 0
U2 6
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013-7227
EI 1945-7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD FEB
PY 2010
VL 151
IS 2
BP 731
EP 740
DI 10.1210/en.2009-0955
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 548GR
UT WOS:000273948600032
PM 19966177
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Tardiff, RG
   Gargas, ML
   Kirman, CR
   Carson, ML
   Sweeney, LM
AF Tardiff, Robert G.
   Gargas, Michael L.
   Kirman, Christopher R.
   Carson, M. Leigh
   Sweeney, Lisa M.
TI Estimation of safe dietary intake levels of acrylamide for humans
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
DE Acrylamide; Glycidamide; Food safety; Neurotoxicity; Cancer; Dietary
   intake
ID BREAST-CANCER RISK; DOSE-RESPONSE; PROSPECTIVE COHORT; MORTALITY
   PATTERNS; RENAL-CELL; IN-VITRO; COLORECTAL-CANCER; EXPOSURE;
   GLYCIDAMIDE; MOUSE
AB Acrylamide (AA), a human neurotoxicant and rat tumorigen, is produced in starchy foods when cooked AA is also an industrial chemical used in polyacrylamide production A safety evaluation of ingested AA by humans was conducted using a newly developed, state-of-the-art physiologically-based toxicokinetic (PBPK or PBTK) model to compare internal doses of AA and its metabolite glycidamide (CA) in humans and rats Based on modes of action (MoA), a nonlinear dose-response approach was applied for neurotoxicity (non-genotoxicity) and carcinogenicity (mixed: genotoxicity and epigenetic MoA). Tolerable daily intake (TDI) for neurotoxicity from AA was estimated to be 40 mu g/kg-day: TDIs for cancer were estimated to be 2.6 and 16 mu g/kg-day based on AA or CA, respectively. Margins of exposure (MoE) were calculated for average AA consumers to be 300 and 500 based on AA and GA, respectively, for cancer, the MoE for average AA consumers was estimated to be 200 and 1200 based on AA and GA, respectively. For high consumers of AA, MoEs were somewhat less. (C) 2009 Elsevier Ltd All rights reserved
C1 [Tardiff, Robert G.] Sapphire Grp Inc, Bethesda Metro Ctr 3, Bethesda, MD 20814 USA.
RP Tardiff, RG (通讯作者)，Sapphire Grp Inc, Bethesda Metro Ctr 3, Suite 830, Bethesda, MD 20814 USA.
RI Sweeney, Lisa/K-5114-2012
OI Sweeney, Lisa/0000-0002-4672-7358
FU Grocery Manufacturers Association, Washington, DC
FX The authors are grateful for the financial support for this work
   provided by the Grocery Manufacturers Association, Washington, DC. The
   authors also appreciate the encouragement, support. and insights
   provided by Dr. Nancy Rachman in this enterprise.
CR AGRAWAL AK, 1981, PHARMACOL BIOCHEM BE, V14, P527, DOI 10.1016/0091-3057(81)90312-9
   [Anonymous], HUM HLTH RISK ASS PR
   [Anonymous], 1983, Risk Assessment in the Federal Government: Managing the Process
   [Anonymous], 2005, Groundwater Sampling and Monitoring with Direct Push Technologies, P1
   Asano N, 2006, MUTAGENESIS, V21, P15, DOI 10.1093/mutage/gei068
   Barlow S, 2006, FOOD CHEM TOXICOL, V44, P1636, DOI 10.1016/j.fct.2006.06.020
   Baum M, 2008, J AGR FOOD CHEM, V56, P5989, DOI 10.1021/jf703741a
   Bowyer JF, 2008, TOXICOL APPL PHARM, V232, P498, DOI 10.1016/j.taap.2008.07.021
   Bowyer JF, 2008, TOXICOL APPL PHARM, V230, P208, DOI 10.1016/j.taap.2008.02.028
   CALLEMAN CJ, 1994, TOXICOL APPL PHARM, V126, P361, DOI 10.1006/taap.1994.1127
   Carere Angelo, 2006, Ann Ist Super Sanita, V42, P144
   CARLSON GP, 1985, TOXICOL APPL PHARM, V79, P307, DOI 10.1016/0041-008X(85)90352-7
   CARLSON GP, 1986, ENVIRON HEALTH PERSP, V68, P53, DOI 10.2307/3430248
   COLLINS JJ, 1989, J OCCUP ENVIRON MED, V31, P614, DOI 10.1097/00043764-198907000-00013
   DiNovi M., 2006, The 2006 exposure assessment for acrylamide
   Doak SH, 2007, CANCER RES, V67, P3904, DOI 10.1158/0008-5472.CAN-06-4061
   Dourson M, 2008, REGUL TOXICOL PHARM, V52, P264, DOI 10.1016/j.yrtph.2008.08.004
   Dybing E, 2003, TOXICOL SCI, V75, P7, DOI 10.1093/toxsci/kfg165
   *EFSA, 2009, RES MON ACR LEV FOOD, V285, P1
   Erdreich LS, 2004, REGUL TOXICOL PHARM, V39, P150, DOI 10.1016/j.yrtph.2003.12.004
   Farris GM, 1996, MUTAGENESIS, V11, P455, DOI 10.1093/mutage/11.5.455
   Favor J, 1998, MUTAT RES-FUND MOL M, V405, P221, DOI 10.1016/S0027-5107(98)00139-0
   FRIEDMAN MA, 1995, FUND APPL TOXICOL, V27, P95, DOI 10.1006/faat.1995.1112
   Friedman MA, 2008, J AGR FOOD CHEM, V56, P6024, DOI 10.1021/jf703746f
   Galesa K, 2008, J AGR FOOD CHEM, V56, P8720, DOI 10.1021/jf800965y
   Gargas ML, 2009, FOOD CHEM TOXICOL, V47, P760, DOI 10.1016/j.fct.2008.12.032
   GILBERT SG, 1982, J TOXICOL ENV HEALTH, V10, P31, DOI 10.1080/15287398209530228
   GUTTENPLAN JB, 1990, MUTAT RES, V233, P177, DOI 10.1016/0027-5107(90)90161-V
   Haber LT, 2009, REGUL TOXICOL PHARM, V53, P134, DOI 10.1016/j.yrtph.2008.12.008
   Hagmar L, 2001, SCAND J WORK ENV HEA, V27, P219, DOI 10.5271/sjweh.608
   HASHIMOTO K, 1981, ARCH TOXICOL, V47, P179, DOI 10.1007/BF00368678
   Hogervorst JG, 2008, AM J CLIN NUTR, V87, P1428, DOI 10.1093/ajcn/87.5.1428
   Hogervorst JG, 2007, CANCER EPIDEM BIOMAR, V16, P2304, DOI 10.1158/1055-9965.EPI-07-0581
   Hogervorst JGF, 2008, J NUTR, V138, P2229, DOI 10.3945/jn.108.092957
   Hogervorst JGF, 2009, JNCI-J NATL CANCER I, V101, P651, DOI 10.1093/jnci/djp077
   Hogervorst JGF, 2009, CANCER EPIDEM BIOMAR, V18, P1663, DOI 10.1158/1055-9965.EPI-08-1133
   *JECFA, 2002, HLTH IMPL ACR FOOD
   JEFCA (Joint FAO/WHO Expert Committee on Food Additives), 2005, JOINT FAO WHO EXP CO
   Johnson GE, 2009, MUTAT RES-GEN TOX EN, V678, P95, DOI 10.1016/j.mrgentox.2009.05.009
   JOHNSON KA, 1986, TOXICOL APPL PHARM, V85, P154, DOI 10.1016/0041-008X(86)90109-2
   KEEFE RT, 1991, 28 DAY SUBCHRONIC TO
   LARSSON SC, 2009, BIOMARKERS PREV, V18, P994
   Larsson SC, 2009, CANCER EPIDEM BIOMAR, V18, P1939, DOI 10.1158/1055-9965.EPI-09-0280
   Larsson SC, 2009, EUR J CANCER, V45, P513, DOI 10.1016/j.ejca.2008.12.001
   Larsson SC, 2009, INT J CANCER, V124, P1196, DOI 10.1002/ijc.24002
   Larsson SC, 2009, AM J EPIDEMIOL, V169, P376, DOI 10.1093/aje/kwn319
   LoPachin RM, 2004, NEUROTOXICOLOGY, V25, P617, DOI 10.1016/j.neuro.2004.01.004
   *LUNDS U, 2007, HEATOX PROJ HEAT GEN
   MAEKAWA A, 1984, GANN, V75, P117
   Marsh GM, 2007, J OCCUP ENVIRON MED, V49, P82, DOI 10.1097/JOM.0b013e31802db536
   Marsh GM, 1999, OCCUP ENVIRON MED, V56, P181, DOI 10.1136/oem.56.3.181
   MARTENSON CH, 1995, TOXICOL APPL PHARM, V133, P73, DOI 10.1006/taap.1995.1128
   MAURISSEN JPJ, 1990, FUND APPL TOXICOL, V15, P93, DOI 10.1016/0272-0590(90)90166-H
   MAURISSEN JPJ, 1983, TOXICOL APPL PHARM, V71, P266, DOI 10.1016/0041-008X(83)90343-5
   Meek ME, 2003, CRIT REV TOXICOL, V33, P591, DOI 10.1080/713608373
   Mei N, 2008, FOOD CHEM TOXICOL, V46, P628, DOI 10.1016/j.fct.2007.09.093
   MOORE MM, 1987, ENVIRON MUTAGEN, V9, P261, DOI 10.1002/em.2860090305
   Mucci LA, 2003, BRIT J CANCER, V88, P84, DOI 10.1038/sj.bjc.6600726
   Mucci LA, 2006, INT J CANCER, V118, P169, DOI 10.1002/ijc.21309
   Mucci LA, 2005, JAMA-J AM MED ASSOC, V293, P1326, DOI 10.1001/jama.293.11.1326
   Mucci LA, 2004, INT J CANCER, V109, P774, DOI 10.1002/ijc.20011
   Mucci LA, 2008, J AGR FOOD CHEM, V56, P6013, DOI 10.1021/jf703747b
   Mucci LA, 2009, JNCI-J NATL CANCER I, V101, P618, DOI 10.1093/jnci/djp080
   Muri SD, 2009, FOOD CHEM TOXICOL, V47, P2906, DOI 10.1016/j.fct.2009.08.002
   *OEHHA, 2006, NO SIGN RISK LEV NSR
   Parry JM, 2000, MUTAT RES-GEN TOX EN, V464, P53, DOI 10.1016/S1383-5718(99)00166-7
   Paulsson B, 2005, ADV EXP MED BIOL, V561, P127
   Paulsson B, 2005, MUTAT RES-GEN TOX EN, V580, P53, DOI 10.1016/j.mrgentox.2004.11.006
   Pelucchi C, 2003, INT J CANCER, V105, P558, DOI 10.1002/ijc.11118
   Pelucchi C, 2006, INT J CANCER, V118, P467, DOI 10.1002/ijc.21336
   Pelucchi C, 2007, INT J CANCER, V120, P1376, DOI 10.1002/ijc.22457
   Phelps KK, 1999, BIOCHEMISTRY-US, V38, P10750, DOI 10.1021/bi990706+
   POST EJ, 1977, J NEUROL SCI, V33, P353, DOI 10.1016/0022-510X(77)90133-2
   Renwick A, 2010, FOOD CHEM TOXICOL, V48, pS75, DOI 10.1016/j.fct.2009.09.025
   RENWICK GA, 2008, FOOD CHEM TOXICOL, V88, pS81
   Rozman KK, 2006, TARG ORG T, P195
   SATCHELL PM, 1981, J NEUROL NEUROSUR PS, V44, P906, DOI 10.1136/jnnp.44.10.906
   Schulz MR, 2001, OCCUP ENVIRON MED, V58, P609, DOI 10.1136/oem.58.9.609
   Shipp A, 2006, CRIT REV TOXICOL, V36, P481, DOI 10.1080/10408440600851377
   Sickles DW, 1996, J NEUROSCI RES, V46, P7, DOI 10.1002/(SICI)1097-4547(19961001)46:1<7::AID-JNR2>3.0.CO;2-P
   Swaen GMH, 2007, OCCUP ENVIRON MED, V64, P396, DOI 10.1136/oem.2006.030130
   SWEENEY LM, 2010, FOOD CHEM T IN PRESS
   Swenberg JA, 2008, CHEM RES TOXICOL, V21, P253, DOI 10.1021/tx700408t
   Tareke E, 2002, J AGR FOOD CHEM, V50, P4998, DOI 10.1021/jf020302f
   *USEPA, 2002, EPA630P021002F
   USEPA, 1994, EPA/ 600/890/066F.
   *USEPA, 1991, INT RISK INF SYST AC
   Waddell WJ, 2006, HUM EXP TOXICOL, V25, P413, DOI 10.1191/0960327106ht633oa
   *WHO, 1985, ENV HLTH CRIT, V49
   WHO, 2016, Guidelines for drinking water quality
   WHO/IPCS, 2005, Chemical-Specific Adjustment Factors for Interspecies Differences and Human Variability: Guidance Document for Use of Data in Dose/ConcentrationResponse Assessment
   Wilson KM, 2009, AM J EPIDEMIOL, V169, P954, DOI 10.1093/aje/kwn421
   Zeiger E, 2009, TOXICOL SCI, V107, P247, DOI 10.1093/toxsci/kfn214
NR 93
TC 94
Z9 109
U1 6
U2 85
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278-6915
EI 1873-6351
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD FEB
PY 2010
VL 48
IS 2
BP 658
EP 667
DI 10.1016/j.fct.2009.11.048
PG 10
WC Food Science & Technology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Toxicology
GA 561VK
UT WOS:000275007700032
PM 19948203
DA 2025-01-12
ER

PT J
AU Karray-Chouayekh, S
   Trifa, F
   Khabir, A
   Boujelbane, N
   Sellami-Boudawara, T
   Daoud, J
   Frikha, M
   Jlidi, R
   Gargouri, A
   Mokdad-Gargouri, R
AF Karray-Chouayekh, Sondes
   Trifa, Fatma
   Khabir, Abdelmajid
   Boujelbane, Nouredine
   Sellami-Boudawara, Tahia
   Daoud, Jamel
   Frikha, Mounir
   Jlidi, Rachid
   Gargouri, Ali
   Mokdad-Gargouri, Raja
TI Aberrant methylation of RASSF1A is associated with poor survival in
   Tunisian breast cancer patients
SO JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
LA English
DT Article
DE Promoter methylation; Methylation-specific PCR; Tumor suppressor genes;
   Breast cancer; Disease-free survival
ID TUMOR-SUPPRESSOR GENE; FREQUENT EPIGENETIC INACTIVATION; PROMOTER
   HYPERMETHYLATION; DNA METHYLATION; MULTIPLE GENES; ESTROGEN-RECEPTOR;
   CPG ISLAND; RAR-BETA; 3P21.3; SERUM
AB Epigenetic gene silencing is one of the major causes of inactivation of tumor-suppressor genes in many human cancers.
   The aim of the present study was to determine the methylation status of the promoter region CpG islands of four cancer-related genes RASSF1A, RAR beta 2, CDH1, and p16 (INK4a) in 78 breast cancer specimens and to evaluate whether the methylation status is associated with estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2/neu) together with the major clinico-pathological parameters.
   We showed that the methylation frequencies ranged from 19.6% (p16 (INK4a) ) to 87% (RASSF1A) in primary breast tumors of Tunisian patients. Aberrant methylation of RAR beta 2 was observed in 66.6% of cases and associated with age at diagnosis (P = 0.043), while CDH1 was methylated in 47.4% of tumors and was correlated with tumor size (P = 0.013). RASSF1A presented the highest percentage of methylation (87%) and was strongly associated with poor survival (P = 0.014), with age (P = 0.048), and tumor stage (P = 0.033). Loss of ER and PR was strongly associated with GIII tumors (P = 0.000 and 0.037 respectively) while HER2/neu was associated with lymph node involvement (P = 0.026) and 5-year survival rate (P = 0.028).
   Our preliminary findings suggested that aberrant methylation of RASSF1A and RAR beta 2 occurs frequently in Tunisian breast cancer patients compared with others. Furthermore, RASSF1A hypermethylation could be used as a potential marker of poor prognosis.
C1 [Karray-Chouayekh, Sondes; Trifa, Fatma; Gargouri, Ali; Mokdad-Gargouri, Raja] Ctr Biotechnol, Unite Rech Genet Canc & Prod Prot Therapeut, Sfax, Tunisia.
   [Khabir, Abdelmajid; Boujelbane, Nouredine; Sellami-Boudawara, Tahia; Daoud, Jamel; Frikha, Mounir] Univ Habib Bourguiba, Ctr Hosp, Sfax, Tunisia.
   [Jlidi, Rachid] Lab Prive Anatomopathol, Sfax, Tunisia.
C3 Centre de Biotechnologie de Sfax; Universite de Sfax; Centre de
   Biotechnologie de Borj Cedria; Universite de Sfax; Hopital Habib
   Bourguiba
RP Mokdad-Gargouri, R (通讯作者)，Ctr Biotechnol, Unite Rech Genet Canc & Prod Prot Therapeut, BP 1177, Sfax, Tunisia.
EM raja.gargouri@cbs.rnrt.tn
OI ABDELMAJID, KHABIR/0000-0003-0031-2242
FU Ministere de l'Enseignement Superieur et de la Recherche Scientifique
   Tunisien
FX This work was supported by a grant of the Ministere de l'Enseignement
   Superieur et de la Recherche Scientifique Tunisien.
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   [Anonymous], IARC SCI PUBL LYON F
   Asch BB, 2001, J MAMMARY GLAND BIOL, V6, P151, DOI 10.1023/A:1011306222533
   Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   Bagadi SAR, 2008, LIFE SCI, V82, P1288, DOI 10.1016/j.lfs.2008.04.020
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Brock MV, 2003, CLIN CANCER RES, V9, P2912
   Byun DS, 2001, CANCER RES, V61, P7034
   Caldeira JRF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-48
   Dammann R, 2001, CANCER RES, V61, P3105
   Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298
   Duffy MJ, 2006, CRIT REV CL LAB SCI, V43, P325, DOI 10.1080/10408360600739218
   ELSTON CW, 1998, BREAST SYSTEMIC PATH, V13, P385
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Esteller M, 2001, CANCER RES, V61, P3225
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   FENDRI A, 2008, CANC BIOL THER
   FENG W, 2007, BREAST CANCER RES, V9, P1, DOI DOI 10.1186/BCR1762
   FEUER EJ, 1993, J NATL CANCER I, V85, P892, DOI 10.1093/jnci/85.11.892
   Francis G, 2006, PATHOLOGY, V38, P391, DOI 10.1080/00313020600922488
   Hachana M, 2009, BREAST CANCER RES TR, V113, P43, DOI 10.1007/s10549-008-9901-z
   HERMAN JG, 1995, CANCER RES, V55, P4525
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Issa JPJ, 2003, CLIN CANCER RES, V9, P2879
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Lee JS, 2007, CANCER BIOL THER, V6, P1114, DOI 10.4161/cbt.6.7.4331
   Lee MG, 2001, CANCER RES, V61, P6688
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Li SY, 2006, CANCER LETT, V237, P272, DOI 10.1016/j.canlet.2005.06.011
   Mehrotra J, 2004, CLIN CANCER RES, V10, P2052, DOI 10.1158/1078-0432.CCR-03-0514
   MOURALI N, 1980, CANCER-AM CANCER SOC, V46, P2741, DOI 10.1002/1097-0142(19801215)46:12<2741::AID-CNCR2820461234>3.0.CO;2-W
   Nass SJ, 2000, CANCER RES, V60, P4346
   Nielsen NH, 2001, CANCER LETT, V163, P59, DOI 10.1016/S0304-3835(00)00674-1
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Rusiecki JA, 2005, CANCER DETECT PREV, V29, P419, DOI 10.1016/j.cdp.2005.07.004
   Sambrook J, 2001, Molecular Cloning: a Laboratory Manual, Vthird
   Sharma G, 2007, LIFE SCI, V80, P1873, DOI 10.1016/j.lfs.2007.02.026
   Shukla S, 2006, EPIGENETICS-US, V1, P88, DOI 10.4161/epi.1.2.2679
   Sobin LH, 1997, INT UNION CANC TNM C, P25
   Sunami E, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2098
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yang QF, 2001, AM J PATHOL, V158, P299, DOI 10.1016/S0002-9440(10)63969-7
NR 45
TC 32
Z9 38
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171-5216
EI 1432-1335
J9 J CANCER RES CLIN
JI J. Cancer Res. Clin. Oncol.
PD FEB
PY 2010
VL 136
IS 2
BP 203
EP 210
DI 10.1007/s00432-009-0649-6
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 536GO
UT WOS:000273033100004
PM 19657672
DA 2025-01-12
ER

PT J
AU Jung, JK
   Park, SH
   Jang, KL
AF Jung, Jin Kyu
   Park, Sun-Hye
   Jang, Kyung Lib
TI Hepatitis B virus X protein overcomes the growth-inhibitory potential of
   retinoic acid by downregulating retinoic acid receptor-β<sub>2</sub>
   expression via DNA methylation
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID CPG ISLAND HYPERMETHYLATION; BREAST-CANCER CELLS;
   HEPATOCELLULAR-CARCINOMA; TRANSGENIC MICE; UP-REGULATION; LUNG-CANCER;
   HBX PROTEIN; BETA; GENE; ACTIVATION
AB Aberrant promoter methylation of retinoic acid receptor-beta(2) (RAR-beta(2)) is frequently detected in hepatitis B virus (HBV)-positive hepatocellular carcinoma (HCC); however, the mechanism of methylation and its biological significance are unknown. This study showed that HBx, the principal oncogene product of HBV, induced promoter hypermethylation of RAR-beta(2) via upregulation of DNA methyltransferases 1 and 3a, resulting in downregulation of its expression in human HCC cells. In addition, HBx abolished the potential of retinoic acid (RA) to downregulate levels of IS,checkpoint regulators including p16, p21 and p27, resulting in activation of E2F1 in the presence of RA. As a consequence, HBx-expressing cells were less susceptible to RA-induced cell growth inhibition compared with control cells. These effects almost completely disappeared when levels of RAR-beta(2) in HBx-expressing cells were restored by treatment with a universal DNA methylation inhibitor, 5-aza-2'-deoxycytidine. As RAR-beta(2) is a major executor of the anti-tumour potential of RA, its epigenetic downregulation by HBx is likely to be an important step during HBV-mediated tumongenesis.
C1 [Jung, Jin Kyu; Park, Sun-Hye; Jang, Kyung Lib] Pusan Natl Univ, Coll Nat Sci, Dept Microbiol, Pusan 609735, South Korea.
C3 Pusan National University
RP Jang, KL (通讯作者)，Pusan Natl Univ, Coll Nat Sci, Dept Microbiol, Pusan 609735, South Korea.
EM kljang@pusan.ac.kr
FU Korean Government [KRF-2008-313-C00661]
FX This work was supported by the Korea Research Foundation Grant funded by
   the Korean Government (KRF-2008-313-C00661).
CR Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996
   Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176
   DE LUCA LM, 1991, FASEB J, V5, P2924
   Dietze EC, 2002, MICROSC RES TECHNIQ, V59, P23, DOI 10.1002/jemt.10174
   GEBERT JF, 1991, ONCOGENE, V6, P1859
   Hansen LA, 2000, CARCINOGENESIS, V21, P1271, DOI 10.1093/carcin/21.7.1271
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hoffman AD, 1996, CLIN CANCER RES, V2, P1077
   HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985
   HU L, 1991, CANCER RES, V51, P3972
   Jung JK, 2007, CANCER RES, V67, P5771, DOI 10.1158/0008-5472.CAN-07-0529
   KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0
   Kim GD, 2002, EMBO J, V21, P4183, DOI 10.1093/emboj/cdf401
   Kwun HJ, 2004, NUCLEIC ACIDS RES, V32, P2202, DOI 10.1093/nar/gkh553
   Lee JO, 2005, ONCOGENE, V24, P6617, DOI 10.1038/sj.onc.1208827
   Lee S, 2003, AM J PATHOL, V163, P1371, DOI 10.1016/S0002-9440(10)63495-5
   Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510
   Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723
   Liu Y, 1996, MOL CELL BIOL, V16, P1138
   LOTAN R, 1995, J NATL CANCER I, V87, P1655, DOI 10.1093/jnci/87.22.1655
   MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531
   Matsushima-Nishiwaki R, 2001, CANCER RES, V61, P7675
   MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372
   Palii SS, 2007, CRIT REV EUKAR GENE, V17, P295
   Park IY, 2007, GASTROENTEROLOGY, V132, P1476, DOI 10.1053/j.gastro.2007.01.034
   Park SG, 2006, J BIOL CHEM, V281, P31770, DOI 10.1074/jbc.M603194200
   PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208
   QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003
   Ren MQ, 2005, MOL CELL BIOL, V25, P10591, DOI 10.1128/MCB.25.23.10591-10603.2005
   Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068
   Saito Y, 2003, INT J CANCER, V105, P527, DOI 10.1002/ijc.11127
   SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077
   Seo SY, 2008, CANCER LETT, V270, P66, DOI 10.1016/j.canlet.2008.04.043
   Shih WL, 2000, J BIOL CHEM, V275, P25858, DOI 10.1074/jbc.M003578200
   Si SP, 1996, EXP CELL RES, V223, P102, DOI 10.1006/excr.1996.0062
   Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J
   Soprano KJ, 2006, ONCOGENE, V25, P5315, DOI 10.1038/sj.onc.1209679
   Sun SY, 2000, J BIOL CHEM, V275, P17149, DOI 10.1074/jbc.M000527200
   Tang H, 2006, CANCER SCI, V97, P977, DOI 10.1111/j.1349-7006.2006.00299.x
   Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850
   Ting AH, 2004, NAT GENET, V36, P582, DOI 10.1038/ng1365
   Tischoff I, 2008, WORLD J GASTROENTERO, V14, P1741, DOI 10.3748/wjg.14.1741
   Tsai CN, 2002, P NATL ACAD SCI USA, V99, P10084, DOI 10.1073/pnas.152059399
   Wang AX, 2008, ONCOL RES, V17, P175, DOI 10.3727/096504008785114129
   XU XC, 1994, CANCER RES, V54, P3580
   Xu XC, 2007, CANCER LETT, V253, P14, DOI 10.1016/j.canlet.2006.11.019
   Yang B, 2003, AM J PATHOL, V163, P1101, DOI 10.1016/S0002-9440(10)63469-4
   Zancai P, 1998, ONCOGENE, V17, P1827, DOI 10.1038/sj.onc.1202089
   Zheng DL, 2009, J HEPATOL, V50, P377, DOI 10.1016/j.jhep.2008.10.019
NR 49
TC 38
Z9 42
U1 0
U2 4
PU SOC GENERAL MICROBIOLOGY
PI READING
PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
   BERKS, ENGLAND
SN 0022-1317
J9 J GEN VIROL
JI J. Gen. Virol.
PD FEB
PY 2010
VL 91
BP 493
EP 500
DI 10.1099/vir.0.015149-0
PN 2
PG 8
WC Biotechnology & Applied Microbiology; Virology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Virology
GA 559FA
UT WOS:000274806600020
PM 19828754
OA Bronze
DA 2025-01-12
ER

PT J
AU Zhai, RL
   Wang, GB
   Cai, KL
   Tao, KX
   Xu, F
   Zhang, WL
   Wang, ZY
AF Zhai, Ronglin
   Wang, Guobin
   Cai, Kailin
   Tao, Kaixiong
   Xu, Fei
   Zhang, Wanli
   Wang, Zhiyong
TI Epigenetic regulation of the ERβ gene on the estrogen signal
   transfection pathway in colon cancer cells
SO JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL
   SCIENCES
LA English
DT Article
DE estrogen receptor beta; signal transfection; methylation; colon cancer;
   epigenetics
ID HORMONE REPLACEMENT THERAPY; COLORECTAL-CANCER; RECEPTOR-ALPHA;
   BREAST-CANCER; EXPRESSION; RISK; IDENTIFICATION; METAANALYSIS
AB We studied the regulatory effects of the estragen receptor beta (ER beta) gene on the downstream estrogen signal transfection pathway in colon cancer cells and the possible mechanisms involved. A human ER beta gene recombinant expression plasmid, pEGFP-C1-ER beta, was constructed and transfected into the Caco-2 colon cancer cell line, a line with low ER beta gene expression. The expression of ER beta mRNA and protein was detected 72 h after transfection. RT-PCR was used to examine the expression levels of the progesterone recepror (PR) gene containing the classic estrogen response element (ERE), the C-fos oncogene containing the AP-1 site (a non-classical ER binding site), the epigenetic modifying genes, such as Dnmt1, Dnmt3a, Dnmt3b, and histone methyltransferase (HMT), and the human mismatch repair gene hMLH1. Methylation-specific PCR was used to detect the changes in the methylated sites of the CpG islands in the promoters of the ER beta, PR, and C-fos genes. The results indicated that the human ER beta gene recombinant expression plasmid pEGFP-C1-ER beta was successfully constructed and transfected into Caco-2 cells. As compared with the control group, the mRNA and protein expression of ER beta gene was increased significantly 72 h after the transfection of pEGFP-C1-ER beta into the Caco-2 cells. As compared with the control group, the mRNA expression of the PR, C-fos, Dnmt3a and Dnmt3b genes was increased significantly 72 h after the transfection of pEGFP-C1-ER beta into the Caco-2 cells, but the mRNA expression of the Dnmt1, HMT, and hMLH1 genes decreased significantly (P < 0.05). As compared with the control group, different degrees of demethylation occurred in the promoters of the ER beta, progesterone receptor (PR), and C-fos oncogene 72 h after the transfection of pEGFP-C1-ER beta into the Caco-2 cells. The methylation index of the estrogen signal transfection pathway in Caco-2 cells was decreased significantly following the expression restoration of ER beta gene (P < 0.05). It is concluded that the restoration or up-regulation of the ER beta gene in Caco-2 cells may significantly activate the expression of the related target genes in the downstream estrogen signal transfection pathway and may result in the demethylation changes of the pathway. During the process, the expression level and activity of the epigenetic modifying genes and the human mismatch repair gene have changed simultaneously. The regulatory effect of the ER beta gene on the estrogen signal transfection pathway to a certain extent partly involves demethylation.
C1 [Zhai, Ronglin; Wang, Guobin; Cai, Kailin; Tao, Kaixiong; Xu, Fei; Zhang, Wanli; Wang, Zhiyong] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Gen Surg, Wuhan 430022, Peoples R China.
C3 Huazhong University of Science & Technology
RP Wang, GB (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Gen Surg, Wuhan 430022, Peoples R China.
EM zhaironglin@yahoo.com.cn
RI Wanli, Zhang/AAO-4066-2020; XU, FEI/KVY-3201-2024; cai,
   kailin/KIA-9950-2024
FU National Natural Sciences Foundation of China [30500488]
FX This project was supported by a grant from the National Natural Sciences
   Foundation of China (No. 30500488).
CR Bai ZL, 2009, ARCH PHARM, V342, P133, DOI 10.1002/ardp.200800174
   Bardin A, 2004, ENDOCR-RELAT CANCER, V11, P537, DOI 10.1677/erc.1.00800
   Crandall CJ, 1999, J WOMEN HEALTH GEN-B, V8, P1155, DOI 10.1089/jwh.1.1999.8.1155
   Dardes RC, 2000, BRIT MED BULL, V56, P773, DOI 10.1258/0007142001903355
   Fiorelli G, 1999, BIOCHEM BIOPH RES CO, V261, P521, DOI 10.1006/bbrc.1999.1062
   Franceschi S, 2000, BRIT J CANCER, V82, P1860, DOI 10.1054/bjoc.1999.1084
   GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802
   Grodstein F, 1999, AM J MED, V106, P574, DOI 10.1016/S0002-9343(99)00063-7
   Henderson BE, 2000, CARCINOGENESIS, V21, P427, DOI 10.1093/carcin/21.3.427
   Hilakivi-Clarke L, 2000, CANCER RES, V60, P4993
   HSU HH, 2006, CHIN J PHYSL, V49, P167
   Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905
   Konstantinopoulos PA, 2003, EUR J CANCER, V39, P1251, DOI 10.1016/S0959-8049(03)00239-9
   Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Métivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6
   Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X
   Murff HJ, 2007, CANCER DETECT PREV, V31, P161, DOI 10.1016/j.cdp.2007.03.002
   Nanda K, 1999, OBSTET GYNECOL, V93, P880, DOI 10.1016/S0029-7844(98)00424-4
   Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535
   PARL FF, 2009, ANN NY ACAD SCI, P1155
   Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Sayeed A, 2007, CANCER RES, V67, P7746, DOI 10.1158/0008-5472.CAN-06-3724
   Scobie GA, 2002, STEROIDS, V67, P985, DOI 10.1016/S0039-128X(02)00047-8
   Slattery ML, 2005, CANCER EPIDEM BIOMAR, V14, P2936, DOI 10.1158/1055-9965.EPI-05-0514
   Takeyama J, 2001, J CLIN ENDOCR METAB, V86, P2258, DOI 10.1210/jc.86.5.2258
   Wong NACS, 2005, J PATHOL, V207, P53, DOI 10.1002/path.1807
NR 27
TC 5
Z9 6
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1672-0733
J9 J HUAZHONG U SCI-MED
JI J. Huazhong Univ. Sci. Tech.-Med.
PD FEB
PY 2010
VL 30
IS 1
BP 69
EP 74
DI 10.1007/s11596-010-0112-6
PG 6
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 554UY
UT WOS:000274461900012
PM 20155458
DA 2025-01-12
ER

EF